{"meta":{"query_hash":"c064095007dd","filters":{"venue":"Annals of Oncology"},"cohort_total":2693,"direct_labels_cover":15,"predictions_cover":2693,"exported":2693,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c064095007dd","api":"https://metacan.xera.ac/api/v1/cohort?venue=Annals+of+Oncology"},"results":[{"id":"W1532269447","doi":"10.1093/annonc/mdu349.91","title":"The Relationship Between Egfr and Kras Mutation Status and Overall Survival (Os) in the Ncic Ctg Br.26 Randomized Trial of Dacomitinib (D) Versus Placebo (P) in Patients with Previously Treated Non Small Cell Lung Cancer (Nsclc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; KRAS; Internal medicine; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology; Colorectal cancer; Alternative medicine","score_opus":0.04690554964151951,"score_gpt":0.37916275750292766,"score_spread":0.33225720786140817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1532269447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357724,0.0004138701,0.0000147984565,0.001080393,0.00008593922,0.0026922345,0.000019658912,0.000005900914,0.0021099465],"genre_scores_gemma":[0.99919105,0.00028743973,0.00005428627,0.0000833644,0.000043236625,0.00020789933,0.000065866996,0.000013548455,0.000053308544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983126,0.0006869065,0.0004516152,0.00017631087,0.00016096173,0.0002116008],"domain_scores_gemma":[0.9941821,0.0051524392,0.00033822143,0.00014729057,0.0001261177,0.00005383914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010564495,0.0001269209,0.0005618777,0.00010212183,0.000063186235,0.000009775778,0.00005297109,0.00009941149,0.0000040519917],"category_scores_gemma":[0.00051454693,0.000071299735,0.00004567472,0.00013915225,0.00016702608,0.00005717927,0.000015188412,0.00014742489,2.7196725e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35722542,0.00026530388,0.63514113,0.0000566894,0.00015090487,0.0000016655306,0.0028207945,0.000030929787,0.0000025041088,0.0001465006,0.00005131375,0.0041068196],"study_design_scores_gemma":[0.4757669,0.0024594755,0.5208524,0.00006764315,0.00036110953,2.370995e-7,0.00014653997,0.000070593465,0.000018997536,0.000087246604,0.00012203029,0.000046829657],"about_ca_topic_score_codex":0.0023081892,"about_ca_topic_score_gemma":0.0024310155,"teacher_disagreement_score":0.11854146,"about_ca_system_score_codex":0.000075480486,"about_ca_system_score_gemma":0.000259251,"threshold_uncertainty_score":0.3489307},"labels":[],"label_agreement":null},{"id":"W1549851394","doi":"10.1093/annonc/mdu364","title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Trastuzumab; Adjuvant; Breast cancer; Cohort; Oncology; Cohort study; Cancer; Internal medicine; Surgery","score_opus":0.08889308378065346,"score_gpt":0.4284548250882904,"score_spread":0.33956174130763694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549851394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284184,0.00013720056,0.00010814331,0.0007838055,0.000250302,0.0048056524,0.00077343767,0.0000031617308,0.0002964577],"genre_scores_gemma":[0.99766445,0.00047307808,0.000060233964,0.00007184857,0.00007270865,0.0014190145,0.00019439575,0.000011496873,0.00003279187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765766,0.00045813815,0.00075882446,0.00027273913,0.000615191,0.00023747972],"domain_scores_gemma":[0.9944857,0.0033624775,0.0005055424,0.00024304689,0.0013587401,0.00004451854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012291775,0.0001577179,0.0010149309,0.00026430513,0.00005397333,0.000007529909,0.00029809962,0.00007900529,0.00010925176],"category_scores_gemma":[0.0003189492,0.00008916546,0.00037777412,0.00028094073,0.0002863037,0.000036682468,0.000038804985,0.0000926748,4.708755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26062867,0.010711808,0.48225695,0.00005970883,0.006847928,0.0000029328041,0.00555265,0.00036190578,0.000029120809,0.00013147395,0.00022192982,0.23319493],"study_design_scores_gemma":[0.1264936,0.045134537,0.82243377,0.00006678082,0.0024924972,0.000002110908,0.000675975,0.0016783958,0.00027647082,0.00010229487,0.00055272464,0.00009081732],"about_ca_topic_score_codex":0.0061716195,"about_ca_topic_score_gemma":0.003988155,"teacher_disagreement_score":0.34017682,"about_ca_system_score_codex":0.00020871626,"about_ca_system_score_gemma":0.00032571983,"threshold_uncertainty_score":0.9329683},"labels":[],"label_agreement":null},{"id":"W1775323748","doi":"10.1093/annonc/mdv483","title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; Eli Lilly Japan; Lilly Oncology; Academy of Nutrition and Dietetics; Cancer Research UK; Amgen","keywords":"Medicine; Biliary tract cancer; Oncology; Internal medicine; Cancer; Biliary tract; Overall survival; Gemcitabine","score_opus":0.23276027427737012,"score_gpt":0.487441968741263,"score_spread":0.2546816944638929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1775323748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006665957,0.9885113,7.3283877e-7,0.0008875567,0.00045831662,0.002402799,0.0002768938,0.000019780291,0.0007766367],"genre_scores_gemma":[0.0015515466,0.99684054,0.00016252797,0.00011844038,0.0002173623,0.0007977558,0.000120831195,0.00004612204,0.00014487699],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981977,0.000117059004,0.0006430393,0.0004429883,0.00021572152,0.00038353697],"domain_scores_gemma":[0.9979385,0.0008987087,0.00041991193,0.00031231917,0.00027404953,0.00015652386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004314,0.00036035504,0.0028303708,0.00022790223,0.00002819066,0.000004988245,0.00016438306,0.00037313864,0.0000139589565],"category_scores_gemma":[0.0007961952,0.00024701862,0.0003205175,0.00016849228,0.00015155222,0.000060754974,0.00013347389,0.0003143727,7.5364096e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020103686,0.0003499304,0.017833272,0.012475276,0.0002657155,0.000045365003,0.0003230657,1.2598412e-7,6.296505e-7,0.000020296407,0.006492613,0.9619927],"study_design_scores_gemma":[0.0020512359,0.0028562907,0.016908677,0.007034929,0.00070805114,0.000025159094,0.000095954776,9.857486e-7,0.0000022154873,0.0001522502,0.9699338,0.00023045692],"about_ca_topic_score_codex":0.000098569246,"about_ca_topic_score_gemma":0.00025413014,"teacher_disagreement_score":0.9634412,"about_ca_system_score_codex":0.00012136846,"about_ca_system_score_gemma":0.0013181921,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W1816850522","doi":"10.1093/annonc/mdu330.27","title":"The Herby Study: a Phase 2 Open-Label, Randomized, Multicenter Study of Bevacizumab-Based Therapy in Pediatric Patients with Newly Diagnosed High-Grade Glioma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Bevacizumab; Glioma; Open label; Randomized controlled trial; Oncology; Internal medicine; Chemotherapy","score_opus":0.05287409813008815,"score_gpt":0.38182818516985884,"score_spread":0.3289540870397707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1816850522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009943,0.00037170577,0.0000034678712,0.0016001639,0.00012457569,0.007707047,0.000011088867,0.000012485882,0.00007001916],"genre_scores_gemma":[0.99801266,0.00017952081,0.000109463675,0.00043944144,0.00004727756,0.0011571943,0.000019042616,0.000030647316,0.000004721725],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967536,0.0012083778,0.0008626172,0.00038728985,0.0004367273,0.0003514363],"domain_scores_gemma":[0.9957685,0.0024983236,0.00062036625,0.00057260203,0.00041446043,0.00012575423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012447992,0.00027244329,0.0014333269,0.0002886436,0.00008683014,0.000020588142,0.00034091316,0.00008942564,0.0000234654],"category_scores_gemma":[0.00041229196,0.00014798055,0.00008638321,0.000479147,0.00014423707,0.00007436883,0.00008487571,0.00014803091,0.000003835832],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17720816,0.23176847,0.5408827,0.000024861318,0.00074887456,0.00018551046,0.0016910364,0.000044515647,0.0000440241,0.000019388504,0.000526455,0.04685602],"study_design_scores_gemma":[0.70183146,0.062402003,0.23399733,0.000027954737,0.00034132937,4.851112e-7,0.00045605953,0.00009245322,0.00048998283,0.000017879463,0.00023628204,0.00010676707],"about_ca_topic_score_codex":0.0012603798,"about_ca_topic_score_gemma":0.0015430818,"teacher_disagreement_score":0.52462333,"about_ca_system_score_codex":0.00004347768,"about_ca_system_score_gemma":0.00014609676,"threshold_uncertainty_score":0.6034472},"labels":[],"label_agreement":null},{"id":"W1851335480","doi":"10.1093/annonc/mdv262.06","title":"LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Placebo; Gastroenterology; Refractory (planetary science); Population; Adverse effect; Phases of clinical research; Ramucirumab; Progression-free survival; Regorafenib; Cancer; Randomized controlled trial; Surgery; Clinical trial; Overall survival; Colorectal cancer; Pathology","score_opus":0.18170627398145425,"score_gpt":0.45104667703990203,"score_spread":0.26934040305844775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1851335480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826794,0.003768909,0.000006036336,0.0024004695,0.00015868641,0.010049327,0.00009196145,0.00002264174,0.00082252896],"genre_scores_gemma":[0.99664414,0.000521681,0.000097509095,0.00010856956,0.000116166244,0.0016380568,0.000036173496,0.00002573455,0.0008119429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943428,0.0017982324,0.0021839915,0.00063178444,0.00053688104,0.0005063049],"domain_scores_gemma":[0.99495846,0.002272968,0.0015528651,0.00039382747,0.0005930657,0.00022881449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0059354464,0.0004736529,0.0041158716,0.0003763381,0.000119583085,0.000016353659,0.0002083694,0.00011832524,0.000029821358],"category_scores_gemma":[0.0026603944,0.00027548755,0.0003001364,0.00044259176,0.0004084551,0.00014786779,0.00015200913,0.00048402094,9.107495e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9485655,0.020549206,0.0034400458,0.000027754451,0.0014137613,0.00024548153,0.008249393,0.000029323759,0.000420173,0.000011143515,0.0034021633,0.01364605],"study_design_scores_gemma":[0.8848064,0.098644525,0.0027038269,0.00016075409,0.0011004616,0.00006210392,0.011491352,0.00006350068,0.00011112598,0.000049970768,0.0006453293,0.00016062631],"about_ca_topic_score_codex":0.004693314,"about_ca_topic_score_gemma":0.005856265,"teacher_disagreement_score":0.07809532,"about_ca_system_score_codex":0.00022895615,"about_ca_system_score_gemma":0.0005387632,"threshold_uncertainty_score":0.9999697},"labels":[],"label_agreement":null},{"id":"W1867872577","doi":"10.1093/annonc/mdu334.76","title":"Regional Subanalysis of the Phase III Mpact Trial: Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients (Pts) with Metastatic Pancreatic Cancer (Pc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Nab-paclitaxel; Oncology; Paclitaxel; Internal medicine; Pancreatic cancer; Cancer","score_opus":0.12571041764461283,"score_gpt":0.44594145697464377,"score_spread":0.32023103933003094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1867872577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98491085,0.0005278077,0.0009526696,0.009097604,0.00013738209,0.0026251508,0.00012827372,0.000018559353,0.001601712],"genre_scores_gemma":[0.9932897,0.0006383526,0.0014989101,0.0016907576,0.00021044188,0.00058770645,0.00010848422,0.000044789198,0.0019308663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99636906,0.00061132223,0.0011249747,0.00046540244,0.0007398768,0.0006893611],"domain_scores_gemma":[0.99447274,0.0021612565,0.0010099491,0.00075326697,0.0013118975,0.00029086208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018371643,0.00032512454,0.0025605655,0.00030862598,0.0001506085,0.0000075265416,0.0003672544,0.00021387487,0.00033626895],"category_scores_gemma":[0.0017914884,0.00019729181,0.00047981547,0.0005787823,0.0008181365,0.00009759591,0.00008568703,0.0002960653,0.000006968145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5860901,0.019930698,0.21757036,0.002373836,0.016428726,0.000055755307,0.0037963863,0.00023003014,0.0018330934,0.0024073997,0.08484029,0.064443335],"study_design_scores_gemma":[0.67268366,0.13445638,0.09302409,0.0009488845,0.015645292,0.00007792721,0.0010564511,0.011922424,0.002529669,0.0030851904,0.06369554,0.00087448943],"about_ca_topic_score_codex":0.0012733112,"about_ca_topic_score_gemma":0.00051787624,"teacher_disagreement_score":0.12454627,"about_ca_system_score_codex":0.0002129114,"about_ca_system_score_gemma":0.0014469281,"threshold_uncertainty_score":0.80453265},"labels":[],"label_agreement":null},{"id":"W1898108800","doi":"10.1093/annonc/mdu325.4","title":"Mir Profiling Identifies Cdk6 Down-Regulation As a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small Cell Lung Carcinoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cisplatin; Cancer research; Carcinoma; Mechanism (biology); Acquired resistance; Small Cell Lung Carcinoma; Oncology; Internal medicine; Small-cell carcinoma; Chemotherapy; Cancer","score_opus":0.015241751334297398,"score_gpt":0.2841056917758501,"score_spread":0.2688639404415527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1898108800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993416,0.0005116115,0.0032779698,0.00016510049,0.00013115692,0.00035582512,0.000014589264,0.000005283066,0.0021224592],"genre_scores_gemma":[0.99739623,0.000029752333,0.0019677598,0.00007613031,0.000094628325,0.000025883788,0.00013443803,0.000018181598,0.00025701034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986566,0.00017694099,0.0004894531,0.00032026912,0.00012932208,0.0002274326],"domain_scores_gemma":[0.9989293,0.000028828188,0.00041861567,0.00032220298,0.00024925062,0.000051762054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046080133,0.00013995533,0.00028141684,0.000121695884,0.000032802156,0.0000066543057,0.00018305847,0.0002736209,0.00002236168],"category_scores_gemma":[0.000100631165,0.00015435554,0.00011323192,0.00011002894,0.00008395476,0.00000871301,0.00009692246,0.00003776368,0.0000033982326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003692102,0.0001241599,0.0012540494,0.00019632884,0.000023351848,0.0000033005515,0.00011703452,0.00025571196,0.9960234,0.0008533339,0.00039100388,0.0003890925],"study_design_scores_gemma":[0.0009101922,0.00036110356,0.034048904,0.000040164643,0.000027085902,0.0000029232071,0.0000579284,0.0011473426,0.9605322,0.0023964802,0.0003390522,0.00013661374],"about_ca_topic_score_codex":0.000054331493,"about_ca_topic_score_gemma":0.00018640465,"teacher_disagreement_score":0.035491213,"about_ca_system_score_codex":0.000018281096,"about_ca_system_score_gemma":0.0001418292,"threshold_uncertainty_score":0.6294436},"labels":[],"label_agreement":null},{"id":"W1899647126","doi":"10.1093/annonc/mdv242","title":"Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"Imperial Experimental Cancer Medicine Centre; NIHR Imperial Biomedical Research Centre; Cancer Research UK; Government of Ontario; Pfizer","keywords":"Exemestane; Medicine; Tamoxifen; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Population; Cohort; Breast cancer; Cancer","score_opus":0.03392842988816233,"score_gpt":0.31727501803888214,"score_spread":0.2833465881507198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1899647126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946586,0.0034664497,0.000012944226,0.00057890225,0.000053387426,0.00039176524,0.000046824767,0.0000026659893,0.00078844547],"genre_scores_gemma":[0.9989797,0.00070449593,0.00008998879,0.00009680727,0.000041525003,0.000021449141,0.00004496182,0.000006838547,0.000014228285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989625,0.0003115573,0.00027676186,0.0002229743,0.00009441648,0.00013179779],"domain_scores_gemma":[0.9993339,0.00019622523,0.00014473243,0.0001770591,0.000097372664,0.00005068641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069402944,0.000104152976,0.00022970876,0.00004326415,0.000022575789,0.0000050501076,0.00012127233,0.00017028069,3.6179566e-7],"category_scores_gemma":[0.0004316354,0.00007125256,0.000026881673,0.00007152244,0.00023959269,0.000004640924,0.00012979694,0.00011910395,3.5491988e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027065158,0.009346485,0.6975689,0.00021213452,0.0022452017,0.0006006126,0.09555657,0.0003908781,0.102578364,0.00080275035,0.016260112,0.04737283],"study_design_scores_gemma":[0.016098069,0.10876188,0.7589784,0.00026559964,0.00038219985,0.00014986919,0.03571625,0.0006143088,0.06499491,0.0027569355,0.010707536,0.00057400746],"about_ca_topic_score_codex":0.00019741488,"about_ca_topic_score_gemma":0.00011846827,"teacher_disagreement_score":0.09941539,"about_ca_system_score_codex":0.0000039013394,"about_ca_system_score_gemma":0.000059091028,"threshold_uncertainty_score":0.2905595},"labels":[],"label_agreement":null},{"id":"W1908203980","doi":"10.1093/annonc/mdu336.54","title":"A Prospective, Multinational Observational Study of Men with Later-Stage Prostate Cancer, a New Global Study to Examine Patterns of Care and Outcomes","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Observational study; Prostate cancer; Stage (stratigraphy); Multinational corporation; Oncology; Prospective cohort study; Cancer; Gerontology; Family medicine; Internal medicine","score_opus":0.12135896974923743,"score_gpt":0.45308857348550974,"score_spread":0.3317296037362723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1908203980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953578,0.0001422187,0.0000058453693,0.0015341786,0.000019834504,0.0022724492,0.00016645622,0.0000074094287,0.00049379334],"genre_scores_gemma":[0.99832106,0.000036847337,0.00023167174,0.00008991456,0.000024661958,0.00014244848,0.000024501769,0.000008928772,0.0011199506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881405,0.00008573882,0.0003108548,0.000242901,0.00037842576,0.0001680112],"domain_scores_gemma":[0.99871194,0.00010325154,0.00017852518,0.00015137225,0.0007455824,0.00010935417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019575098,0.00012332262,0.0005327942,0.00008960102,0.000026967984,0.0000032473724,0.00007383632,0.00003205933,0.000030601754],"category_scores_gemma":[0.000070000155,0.000082747654,0.000027851107,0.00017927124,0.000057795216,0.00005096149,0.00008327337,0.0000625924,3.260774e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002836345,0.0031457462,0.971139,0.00016989006,0.00046230527,0.000014959287,0.01193057,0.000041666106,0.00014045174,0.00005266637,0.00011396904,0.009952409],"study_design_scores_gemma":[0.011516026,0.036737505,0.94283533,0.00006177445,0.0000755453,0.0000016348561,0.0077331015,0.00001884046,0.00070945284,0.000021795178,0.00022481344,0.000064203006],"about_ca_topic_score_codex":0.0029290754,"about_ca_topic_score_gemma":0.004701163,"teacher_disagreement_score":0.03359176,"about_ca_system_score_codex":0.00008025605,"about_ca_system_score_gemma":0.00037543217,"threshold_uncertainty_score":0.44279054},"labels":[],"label_agreement":null},{"id":"W1916004087","doi":"10.1093/annonc/mdv220","title":"A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Ottawa","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Oncology; Population; Hazard ratio; Neutropenia; Lung cancer; Adenocarcinoma; Cancer; Gastroenterology; Surgery; Chemotherapy; Confidence interval","score_opus":0.044982263876036516,"score_gpt":0.383263850186563,"score_spread":0.3382815863105265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916004087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926876,0.002127259,0.000048587408,0.00029176337,0.000030051495,0.004385654,0.000018530676,0.0000032611576,0.0004072902],"genre_scores_gemma":[0.99808455,0.0003586918,0.00032287772,0.000061713115,0.000030460238,0.00093844265,0.000028175784,0.000024219846,0.00015088511],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976047,0.0006531704,0.00078372116,0.00036358825,0.00026191236,0.00033290376],"domain_scores_gemma":[0.9985932,0.00006235382,0.00027373788,0.00033583073,0.0006365225,0.00009835649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016113461,0.00019924698,0.00093051593,0.000260508,0.000018440716,0.0000030654871,0.00024163353,0.00022108342,0.000024876446],"category_scores_gemma":[0.00018879348,0.00016432873,0.00007626342,0.0003445175,0.00016165104,0.000012049866,0.00012780547,0.00020860715,2.4124665e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.118452966,0.008018574,0.0025915331,0.00014543033,0.00011146854,0.000016386806,0.0018581606,0.00079760887,0.8622492,0.000003516376,0.00009248173,0.0056626988],"study_design_scores_gemma":[0.26069993,0.032866023,0.00024429028,0.0000778021,0.000007286659,0.0000014798469,0.00043772318,0.0004057196,0.704776,0.000025547803,0.00033024943,0.00012794307],"about_ca_topic_score_codex":0.0010282192,"about_ca_topic_score_gemma":0.003145806,"teacher_disagreement_score":0.15747316,"about_ca_system_score_codex":0.000044688215,"about_ca_system_score_gemma":0.0009664207,"threshold_uncertainty_score":0.6701131},"labels":[],"label_agreement":null},{"id":"W1917893066","doi":"10.1093/annonc/mdu336.34","title":"The Impact of the Derived Neutrophil to Lymphocyte Ratio and Duration of Initial Androgen Deprivation Therapy (Adt) on Survival of Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Receiving First-Line Chemotherapy: Data from Two Randomized Phase III Trials","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Neutrophil to lymphocyte ratio; Internal medicine; Chemotherapy; Overall survival; Androgen; Cancer; Hormone","score_opus":0.12359717501087145,"score_gpt":0.44455332624592964,"score_spread":0.32095615123505816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1917893066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936916,0.000538756,0.00034679356,0.0023655964,0.00005923601,0.0025708457,0.00035198155,0.000006697554,0.00006847619],"genre_scores_gemma":[0.99737936,0.0017393683,0.00038954275,0.00014142692,0.00008270742,0.00012403977,0.00011960372,0.000020089105,0.000003834932],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99659044,0.0014148231,0.0012485149,0.0002557228,0.00032890827,0.00016158127],"domain_scores_gemma":[0.99452794,0.0025728617,0.0017045696,0.0005749912,0.0005487268,0.00007094034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036772527,0.00019160933,0.0012326331,0.00008991733,0.00009320193,0.00001217053,0.00021711476,0.00005943951,0.000035215668],"category_scores_gemma":[0.001521536,0.000098879274,0.0001612401,0.0002016801,0.00037441647,0.0001120691,0.000049062095,0.000063669286,1.278425e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6634681,0.0005163407,0.003534511,0.00008054716,0.003101229,0.0000026891487,0.0017190459,0.0006307562,0.2732253,0.00006400927,0.00015824009,0.053499214],"study_design_scores_gemma":[0.36813712,0.0051322877,0.035528433,0.00039287165,0.000864826,0.0000041673284,0.00022794255,0.00930213,0.5796,0.00049395295,0.0001320144,0.000184284],"about_ca_topic_score_codex":0.0013158349,"about_ca_topic_score_gemma":0.000674107,"teacher_disagreement_score":0.30637467,"about_ca_system_score_codex":0.000053693235,"about_ca_system_score_gemma":0.00073791604,"threshold_uncertainty_score":0.40321797},"labels":[],"label_agreement":null},{"id":"W1922595793","doi":"10.1093/annonc/mdg290","title":"Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer","year":2003,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Window of opportunity; Breast cancer; Endocrine system; Downregulation and upregulation; Oncology; Oestrogen receptor; Cancer; Internal medicine; Gynecology; Hormone","score_opus":0.11426934589530409,"score_gpt":0.44596606783263115,"score_spread":0.3316967219373271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1922595793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018657492,0.97922134,0.0000075211483,0.00018297801,0.00019815161,0.0011885896,0.00027001018,0.0000042305337,0.0002696841],"genre_scores_gemma":[0.0021925052,0.99639577,0.00020429672,0.00012082124,0.00017248522,0.0003173881,0.00044020358,0.00003983409,0.00011668755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981445,0.0004970831,0.0006104924,0.00034819686,0.00009202384,0.00030768127],"domain_scores_gemma":[0.9985228,0.000098206896,0.0006730285,0.00041185893,0.00019830624,0.000095760086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053039583,0.00028305373,0.0010050494,0.00009373911,0.000047131743,0.000003924054,0.00031619883,0.00047385052,0.00004408176],"category_scores_gemma":[0.000052667852,0.00019014839,0.00040024848,0.00016918642,0.00015810979,0.0000067205588,0.000046369016,0.00020583838,6.782885e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025362798,0.00023111046,0.00003520142,0.0005583239,0.00028868843,0.0000023649181,0.000017417635,0.000022207332,0.004576069,0.00010581035,0.00048342202,0.9934258],"study_design_scores_gemma":[0.00086005626,0.0022236512,0.0000795012,0.0005045967,0.00008341601,0.00007947362,0.000023224648,0.0000017722085,0.0051749013,0.000045596273,0.99071676,0.0002070317],"about_ca_topic_score_codex":0.000023990753,"about_ca_topic_score_gemma":0.000014514613,"teacher_disagreement_score":0.9932187,"about_ca_system_score_codex":0.000024223886,"about_ca_system_score_gemma":0.0007978881,"threshold_uncertainty_score":0.77540267},"labels":[],"label_agreement":null},{"id":"W1929365128","doi":"10.1093/annonc/mdu337.6","title":"Brain Metastases in Male Germ Cell Tumors (Gct): a Large Retrospective Analysis on Behalf of the Swenoteca and the G3 Consortium","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Germ cell; Germ cell tumors; Oncology; Internal medicine; Genetics; Chemotherapy","score_opus":0.01980334238059176,"score_gpt":0.3306538310347342,"score_spread":0.31085048865414244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1929365128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897598,0.0010838078,0.00001529066,0.0057864664,0.0000228506,0.00033183387,0.00009007208,0.000004794139,0.0029051022],"genre_scores_gemma":[0.99804693,0.00006865693,0.00004359378,0.0016180683,0.000015095922,0.000019665405,0.000010478396,0.000006991407,0.00017053168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988213,0.00037613563,0.0002788282,0.0001867115,0.00016279206,0.00017421518],"domain_scores_gemma":[0.9985896,0.000603949,0.00031596379,0.0003346311,0.000097047196,0.000058847643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060254964,0.00010562299,0.0005976556,0.000120508514,0.00003863238,0.000003011994,0.000082054605,0.00005530917,0.00008869382],"category_scores_gemma":[0.0006953103,0.000055611887,0.00024387451,0.00033785254,0.00029871773,0.000016690181,0.00005653625,0.00010750705,0.0000024704923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010914318,0.002329291,0.98218596,0.000069002584,0.0012085488,0.00008062961,0.00053195434,0.000045595087,0.00030919505,0.007039658,0.00078318326,0.004325538],"study_design_scores_gemma":[0.0050426763,0.0016894225,0.98674345,0.00003587111,0.0014152216,0.000014828351,0.00016606602,0.00023433796,0.0025400848,0.0008003405,0.0012601584,0.00005751328],"about_ca_topic_score_codex":0.0003674438,"about_ca_topic_score_gemma":0.00036751552,"teacher_disagreement_score":0.0082871355,"about_ca_system_score_codex":0.000020732396,"about_ca_system_score_gemma":0.00008854984,"threshold_uncertainty_score":0.22677869},"labels":[],"label_agreement":null},{"id":"W1931431191","doi":"10.1023/a:1008394827806","title":"Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut du Savoir Montfort","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Methotrexate; Relative risk; Central nervous system; Lymphoma; Logistic regression; Risk factor; Gastroenterology; Cohort; Surgery; Confidence interval","score_opus":0.020452847945330702,"score_gpt":0.28467767074417344,"score_spread":0.26422482279884274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1931431191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968337,0.00052005646,8.0510193e-7,0.000070322625,0.00012695756,0.0017652574,0.00007292662,0.00004391907,0.0005660798],"genre_scores_gemma":[0.99886787,0.00085709884,0.000045818226,0.000037522223,0.000033800286,0.000091098664,0.00002136051,0.000027522301,0.0000179173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689627,0.000505221,0.00097539305,0.0005896579,0.00041598294,0.0006175008],"domain_scores_gemma":[0.997788,0.0004448536,0.00081649213,0.00034201774,0.00029081493,0.00031783187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035992658,0.0003876975,0.0013167511,0.0002546748,0.000102414335,0.000015040387,0.00014030002,0.00033739838,0.000010706309],"category_scores_gemma":[0.00032967338,0.00027740304,0.00011628027,0.00031990337,0.00024558144,0.000096422125,0.00007025686,0.00018758187,0.0000028155794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001953278,0.004357876,0.7815758,0.0002123703,0.00025710714,0.0011775249,0.0032491845,0.000035318433,0.000029012208,0.00002297492,0.000049005026,0.20708056],"study_design_scores_gemma":[0.006727527,0.029559301,0.9587058,0.0010109372,0.00024841324,0.00014918449,0.0026836565,0.00021732236,0.00044160782,0.0000033781014,0.000055110693,0.00019775731],"about_ca_topic_score_codex":0.0045981114,"about_ca_topic_score_gemma":0.00042856456,"teacher_disagreement_score":0.2068828,"about_ca_system_score_codex":0.0008537053,"about_ca_system_score_gemma":0.00027039053,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W1932317695","doi":"10.1023/a:1012258723075","title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Center for Research Resources; McGill University","keywords":"Medicine; Docetaxel; Prostate cancer; Toxicity; Internal medicine; Clinical endpoint; Analgesic; Cancer; Oncology; Surgery; Anesthesia; Clinical trial","score_opus":0.10827415176359521,"score_gpt":0.465925237781815,"score_spread":0.35765108601821977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932317695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990425,0.002112599,4.833978e-7,0.0036995811,0.0000750645,0.0012575495,0.000018833978,0.000012249075,0.0023986744],"genre_scores_gemma":[0.9945366,0.003242435,0.000017216806,0.0001669123,0.000036468464,0.00017895835,0.000010854218,0.00001352241,0.0017970713],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99852633,0.00010535075,0.0004848568,0.0002260597,0.0003127796,0.0003445978],"domain_scores_gemma":[0.9991662,0.00006152554,0.00018327672,0.00022835378,0.00024337479,0.000117281095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039422448,0.00012730462,0.00060455356,0.00027500163,0.000037127895,0.0000024587684,0.00010308615,0.000086451415,0.00023119568],"category_scores_gemma":[0.000039294577,0.00009614128,0.000066222914,0.00036754145,0.000105740866,0.00006326698,0.00007558505,0.00015986162,0.000005183554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011724408,0.0695538,0.4594156,0.000436931,0.0010496875,0.0019816624,0.015462132,0.000044288932,0.010478361,0.000045704484,0.0032876402,0.42651978],"study_design_scores_gemma":[0.24027283,0.40695375,0.22538981,0.0010783552,0.0006821867,0.00033411678,0.01720055,0.0008780689,0.07339635,0.0009879745,0.032129075,0.0006969409],"about_ca_topic_score_codex":0.0007826402,"about_ca_topic_score_gemma":0.00067244994,"teacher_disagreement_score":0.42582282,"about_ca_system_score_codex":0.00008976061,"about_ca_system_score_gemma":0.0004590668,"threshold_uncertainty_score":0.39205277},"labels":[],"label_agreement":null},{"id":"W1934264093","doi":"10.1093/annonc/mdv245","title":"Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Hazard ratio; Androgen deprivation therapy; Tolerability; Clinical endpoint; Cancer; Chemotherapy; Confidence interval; Clinical trial; Adverse effect","score_opus":0.21872978042644023,"score_gpt":0.4953311044673172,"score_spread":0.276601324040877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934264093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018731647,0.9841457,0.0000033339688,0.0006275512,0.00005700277,0.0066783424,0.0061766664,0.000009799628,0.0004284403],"genre_scores_gemma":[0.0015775764,0.9958536,0.00040161537,0.00009008971,0.000046541394,0.0007864675,0.00095089443,0.000052114676,0.00024111957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980968,0.00014547435,0.00056935276,0.00037537175,0.00041935346,0.00039362774],"domain_scores_gemma":[0.99591494,0.0002702475,0.0006300512,0.00021912248,0.0027558063,0.00020982217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003505794,0.0003372286,0.0033891143,0.0002046938,0.000040300987,0.0000060685443,0.00008048824,0.00020038767,0.000005549191],"category_scores_gemma":[0.0001163791,0.00019858334,0.00020823396,0.00018892532,0.00041856442,0.00005597573,0.00005352818,0.00023902098,3.7467663e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009781149,0.0003128694,0.0001392141,0.031867888,0.0020698956,0.00005143553,0.0012917082,2.7511163e-7,8.204145e-7,0.00003547834,0.0036294856,0.9508198],"study_design_scores_gemma":[0.008757359,0.039739486,0.0000659003,0.0052517354,0.0030748895,0.0000109669645,0.00047311813,8.632655e-7,0.0000727828,0.000037555983,0.9423167,0.00019864173],"about_ca_topic_score_codex":0.00007283168,"about_ca_topic_score_gemma":0.0000792307,"teacher_disagreement_score":0.9506211,"about_ca_system_score_codex":0.00021547775,"about_ca_system_score_gemma":0.0033219121,"threshold_uncertainty_score":0.8097993},"labels":[],"label_agreement":null},{"id":"W1934904577","doi":"10.1023/a:1011609401132","title":"Targeted intra-operative radiotherapy (Targit): An innovative method of treatment for early breast cancer","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University College London; Ryerson University","keywords":"Medicine; Radiation therapy; Breast cancer; Quadrant (abdomen); Occult; Mastectomy; External beam radiotherapy; Breast-conserving surgery; Radiology; Wide local excision; Surgery; Cancer; Brachytherapy; Internal medicine; Pathology","score_opus":0.05596525435526641,"score_gpt":0.43092045076814406,"score_spread":0.37495519641287767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934904577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874837,0.0020244503,0.0049255635,0.003395287,0.00014804988,0.0005912656,0.00087785465,0.00000995747,0.0005438676],"genre_scores_gemma":[0.9846817,0.0029645339,0.010634545,0.00076602894,0.0002818966,0.00034879634,0.00014620897,0.000028506542,0.00014777505],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988905,0.00014603561,0.00030804693,0.0003337115,0.000059035003,0.00026263553],"domain_scores_gemma":[0.998674,0.000057526475,0.00024102221,0.00022291222,0.0007482371,0.0000562981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015200512,0.00020718883,0.0004887035,0.00006949907,0.000054443375,0.0000034538145,0.00012406897,0.00015841227,0.00005961341],"category_scores_gemma":[0.00001997295,0.00016704397,0.00010926312,0.00019300742,0.0001790746,0.0000094566285,0.00002512195,0.00003728543,4.1519013e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073489845,0.0017269974,0.028555375,0.000022933598,0.0033923713,0.0000063156713,0.003907726,0.0002690911,0.42676044,0.00047806455,0.0018835516,0.5256481],"study_design_scores_gemma":[0.0078093973,0.0238241,0.09526526,0.000025999592,0.00012163205,0.00006933713,0.00055139593,0.00007339013,0.77546316,0.00023940275,0.096145056,0.00041184938],"about_ca_topic_score_codex":0.0011012654,"about_ca_topic_score_gemma":0.00046610917,"teacher_disagreement_score":0.5252363,"about_ca_system_score_codex":0.00007831265,"about_ca_system_score_gemma":0.00033886096,"threshold_uncertainty_score":0.68118554},"labels":[],"label_agreement":null},{"id":"W1935950879","doi":"10.1023/a:1026579400806","title":"A phase I-II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: An NCIC Clinical Trials Group study","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University; Queen's University","funders":"","keywords":"Medicine; Tolerability; Renal cell carcinoma; Internal medicine; Regimen; Retinoid; Pharmacokinetics; Phases of clinical research; Pharmacology; Toxicity; Gastroenterology; Dosing; Oncology; Clinical trial; Retinoic acid; Adverse effect","score_opus":0.06741899109355771,"score_gpt":0.41606202469884823,"score_spread":0.34864303360529053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1935950879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979209,0.00053271337,0.000011111001,0.000021524213,0.00005904593,0.0010339173,0.000016600085,0.0000051504135,0.00039905516],"genre_scores_gemma":[0.99932,0.00018702648,0.00012957567,0.000084475614,0.00006588385,0.000058595404,0.00006710315,0.000022563529,0.00006477636],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9963254,0.0014171586,0.0012146352,0.0005934922,0.00018313646,0.00026619798],"domain_scores_gemma":[0.9985731,0.000098073215,0.00052187924,0.00048234078,0.00021242833,0.000112124355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021938896,0.00022528965,0.0009083322,0.00008754851,0.000049155533,0.000006095646,0.00027658138,0.00022784469,0.00003992022],"category_scores_gemma":[0.00024096681,0.00017952995,0.00008527469,0.0001469543,0.0001947863,0.000014442231,0.00012564573,0.00019758634,7.689445e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054024395,0.11038091,0.38928598,0.0001257583,0.00033504618,0.00006441012,0.003489524,0.00003981984,0.07295266,0.0000022792804,0.0003685146,0.3689307],"study_design_scores_gemma":[0.06061876,0.7564707,0.06797311,0.000034792014,0.00018337359,0.0000050627723,0.0026850777,0.00001474682,0.10990458,0.000024966583,0.0016753238,0.00040954526],"about_ca_topic_score_codex":0.000043496108,"about_ca_topic_score_gemma":0.00014619352,"teacher_disagreement_score":0.6460898,"about_ca_system_score_codex":0.000010308177,"about_ca_system_score_gemma":0.00013066136,"threshold_uncertainty_score":0.73210186},"labels":[],"label_agreement":null},{"id":"W1937737154","doi":"10.1093/annonc/mdu326.12","title":"Generation of a Plasma Microrna (Mirna) Signature Predicting Response to Metronomic Chemotherapy (Mc) for Advanced Breast Cancer (Abc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Ottawa Regional Cancer Foundation; Ottawa Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"MiRBase; Medicine; microRNA; Oncology; Breast cancer; Internal medicine; Cyclophosphamide; Cancer; Teniposide; Chemotherapy; Pharmacology; Cancer research; Gene; Biology","score_opus":0.030293502833830265,"score_gpt":0.3406865754365081,"score_spread":0.31039307260267784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1937737154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314976,0.0003247841,0.00284127,0.0028456452,0.00014877165,0.00041670597,0.00020772679,0.00000651396,0.000058842637],"genre_scores_gemma":[0.99467033,0.000076018325,0.0039275954,0.0007064687,0.00032590498,0.00008384213,0.00008668093,0.000025568055,0.000097608696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999003,0.0001360969,0.00030466754,0.00028870432,0.00006784771,0.00019971255],"domain_scores_gemma":[0.9990035,0.00006565023,0.00030376067,0.00024083945,0.00031177423,0.000074439144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047507256,0.00012754968,0.00025161984,0.000082322505,0.000038868035,0.00000411542,0.00015241581,0.00021800895,0.000019213558],"category_scores_gemma":[0.00018071005,0.00013155433,0.00011849309,0.00007611275,0.000055589368,0.0000062366366,0.00003890369,0.00004587106,8.830809e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004588078,0.00008840286,0.00034483385,0.000029528417,0.00009258986,1.06752964e-7,0.00006359626,0.0023304904,0.94280815,0.000020173084,0.0037435468,0.045890477],"study_design_scores_gemma":[0.0014994766,0.0013479622,0.0058358945,0.00002164214,0.000021685199,0.000004475976,0.000019265783,0.0011371906,0.934912,0.000022095008,0.05505858,0.00011970136],"about_ca_topic_score_codex":0.000013724548,"about_ca_topic_score_gemma":0.000051529045,"teacher_disagreement_score":0.051315032,"about_ca_system_score_codex":0.00003286573,"about_ca_system_score_gemma":0.0001892148,"threshold_uncertainty_score":0.536463},"labels":[],"label_agreement":null},{"id":"W1943008665","doi":"10.1093/annonc/mdu337.25","title":"Pancreatic Metastases from Renal Cell Carcinoma: Incidence and Prognostic Impact","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Incidence (geometry); Oncology; Internal medicine; Carcinoma","score_opus":0.05595619436937144,"score_gpt":0.34725560715614423,"score_spread":0.2912994127867728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1943008665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906605,0.0032378465,0.00005752656,0.0007174026,0.000039348597,0.00033240783,0.00003311577,0.000018139306,0.0049037305],"genre_scores_gemma":[0.99757314,0.00013591418,0.001567818,0.0004227292,0.00010470439,0.000025442267,0.00005549164,0.000017339104,0.0000974279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986601,0.00022021848,0.0003373647,0.00029744417,0.00019622211,0.00028865054],"domain_scores_gemma":[0.9982141,0.0008610099,0.00020160711,0.00031606873,0.00016265083,0.00024452017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003173879,0.00019029807,0.0006862157,0.000112286034,0.0000346874,0.000007006119,0.000079454556,0.00010501825,0.00014913433],"category_scores_gemma":[0.00035749207,0.00013714677,0.00013443085,0.000106826934,0.0001724883,0.000059665752,0.000065166874,0.00012944886,0.000028871633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001135345,0.00097211293,0.89463353,0.00019944337,0.00032162806,0.0005744826,0.0005600187,0.000014435271,0.0625459,0.00009056256,0.004360576,0.034591958],"study_design_scores_gemma":[0.0017982128,0.012164191,0.89529175,0.000059071575,0.00055444863,0.0001520935,0.00005632916,0.00014298112,0.08769806,0.0005716064,0.0013857426,0.00012552121],"about_ca_topic_score_codex":0.0013939788,"about_ca_topic_score_gemma":0.00004381586,"teacher_disagreement_score":0.034466434,"about_ca_system_score_codex":0.000048012742,"about_ca_system_score_gemma":0.00021547635,"threshold_uncertainty_score":0.5592683},"labels":[],"label_agreement":null},{"id":"W1944579984","doi":"10.1093/annonc/mdu342.3","title":"Phase I Study of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Pneumonitis; Internal medicine; Adverse effect; Melanoma; Common Terminology Criteria for Adverse Events; Oncology; Gastroenterology; Cancer; Immunotherapy; Cancer research; Lung","score_opus":0.058387123618302054,"score_gpt":0.37296636802090927,"score_spread":0.3145792444026072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944579984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967714,0.00020051697,0.000019994586,0.000576796,0.000038101956,0.0004907631,0.0000026361954,0.000004132051,0.0018956857],"genre_scores_gemma":[0.99951357,0.000028005119,0.00011493659,0.00022688508,0.000008050847,0.000023720528,0.000008315244,0.0000088944125,0.00006762919],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988764,0.0002194048,0.0004392388,0.00015490224,0.00015605809,0.0001539814],"domain_scores_gemma":[0.9993269,0.00012801331,0.00022197326,0.00018112011,0.00011104306,0.000030940453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064832286,0.000089389956,0.0004714667,0.00028512662,0.000010128865,0.0000013703464,0.000070302216,0.00004887912,0.000039044706],"category_scores_gemma":[0.000031344414,0.00007327309,0.000039539027,0.0003077502,0.00008981374,0.00004350785,0.000013563528,0.00010908851,9.6988e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10382765,0.119593054,0.2062301,0.0007473016,0.00045441237,0.00039798315,0.02082129,0.00008593666,0.14374949,0.00015198589,0.0024224191,0.40151837],"study_design_scores_gemma":[0.20559831,0.2478912,0.4761208,0.00016530449,0.00014303208,0.000036660447,0.0050243116,0.000590166,0.06114808,0.00018706957,0.002875636,0.00021944054],"about_ca_topic_score_codex":0.00141568,"about_ca_topic_score_gemma":0.0018178,"teacher_disagreement_score":0.4012989,"about_ca_system_score_codex":0.00004971686,"about_ca_system_score_gemma":0.00016804847,"threshold_uncertainty_score":0.29879898},"labels":[],"label_agreement":null},{"id":"W1948155544","doi":"10.1093/annonc/mdu326.14","title":"Genome-Wide Association Study (Gwas) Identifies Candidate Neurotoxicity Markers in Platinum-Taxane Treated Ovarian Cancer Patients in Icon7","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Genome-wide association study; Oncology; Internal medicine; Hazard ratio; Taxane; Genetic model; Carboplatin; Odds ratio; Confidence interval; Cancer; Single-nucleotide polymorphism; Breast cancer; Genetics; Genotype; Biology; Chemotherapy","score_opus":0.038762503880015134,"score_gpt":0.3719917841676429,"score_spread":0.33322928028762777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948155544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933705,0.00005274153,5.1601586e-7,0.0023378183,0.0003168548,0.0011801734,0.000033266675,0.000017098659,0.0026910433],"genre_scores_gemma":[0.9972498,0.00023279563,0.0000055887303,0.001447328,0.00007958152,0.00020415148,0.000071865,0.000016301445,0.00069260853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811596,0.00047247502,0.00055452134,0.0003040843,0.00019228258,0.00036065676],"domain_scores_gemma":[0.99873835,0.0004791235,0.0003875168,0.00014634166,0.00016309063,0.00008556135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006291065,0.00016717652,0.0006522668,0.00032292766,0.000031544274,0.00000617199,0.00009005898,0.00016535906,0.00036301126],"category_scores_gemma":[0.00036326965,0.00015995603,0.00006542834,0.00034111997,0.000040716437,0.00008068049,0.00004338594,0.0002241727,0.000010695477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017461983,0.0030752635,0.9866695,0.000029136994,0.00019866234,0.000050747705,0.00112273,0.00004609807,0.0011691711,0.0000013814945,0.0017850653,0.0041060797],"study_design_scores_gemma":[0.010899216,0.0048060953,0.97950095,0.000025170895,0.00010034372,5.866184e-7,0.00011991752,0.00004425594,0.0014228896,0.00003074821,0.0029412291,0.00010861683],"about_ca_topic_score_codex":0.012197133,"about_ca_topic_score_gemma":0.03469372,"teacher_disagreement_score":0.022496589,"about_ca_system_score_codex":0.0004492564,"about_ca_system_score_gemma":0.00015647223,"threshold_uncertainty_score":0.9943807},"labels":[],"label_agreement":null},{"id":"W1953192109","doi":"10.1093/annonc/mdv378","title":"Designs of preoperative biomarkers trials in oncology: a systematic review of the literature","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Surrogate endpoint; Surgery; Oncology; Protocol (science); Pathology; Alternative medicine","score_opus":0.325932852202509,"score_gpt":0.5127602736362655,"score_spread":0.18682742143375652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1953192109","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012099675,0.98133075,8.729644e-7,0.001971281,0.00019137477,0.0065255333,0.00008179989,0.0000056217705,0.009880684],"genre_scores_gemma":[0.000021483616,0.9975268,0.00011594796,0.0011478434,0.000056720568,0.00032442328,0.000043264394,0.000025244874,0.000738276],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9818218,0.012940447,0.0042400323,0.00029855056,0.00044579414,0.00025338677],"domain_scores_gemma":[0.98403347,0.010428859,0.0037908652,0.0007507524,0.0008699526,0.00012607887],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.018051952,0.000394917,0.023239348,0.0003469959,0.000012380995,0.0000032903395,0.00037488123,0.0008787631,0.000045705507],"category_scores_gemma":[0.018856775,0.00018830346,0.0038807995,0.0010126842,0.00030587846,0.000035997607,0.00008597159,0.00045976977,0.0000064997034],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015718382,0.00034371964,0.000018414503,0.9408204,0.0018111443,0.00012872813,0.000430401,5.8698774e-8,0.0000016368572,0.00048155626,0.003566217,0.05224057],"study_design_scores_gemma":[0.0005270453,0.0011092626,0.000008888302,0.52455574,0.0045866286,0.00027415346,0.00004695122,1.1247461e-7,0.000007376228,0.000014038889,0.46877956,0.00009025591],"about_ca_topic_score_codex":0.000012321462,"about_ca_topic_score_gemma":0.0000052086884,"teacher_disagreement_score":0.46521333,"about_ca_system_score_codex":0.00015645835,"about_ca_system_score_gemma":0.0031406109,"threshold_uncertainty_score":0.99126166},"labels":[],"label_agreement":null},{"id":"W1955490869","doi":"10.1093/annonc/mdu340.9","title":"Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) in Patients with Head &amp; Neck Squamos Cell Carcinoma (Hn-Scc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada)","funders":"","keywords":"Medicine; Head and neck; Sine; Nuclear export signal; Cancer research; Pharmacology; Surgery; Cell nucleus; Nucleus","score_opus":0.02755906852539221,"score_gpt":0.3115242311421473,"score_spread":0.2839651626167551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1955490869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982195,0.00001889061,0.000023962033,0.0001667692,0.00019382228,0.00021364365,0.000016252308,0.0000029470004,0.0011442086],"genre_scores_gemma":[0.99899864,0.00001123915,0.00042991943,0.00035825957,0.00011988249,0.000002598099,0.000017920464,0.00001920976,0.00004232208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987613,0.00025924068,0.00040185408,0.00026577912,0.00013213784,0.00017969175],"domain_scores_gemma":[0.998808,0.000035198627,0.00042356353,0.00034979224,0.0003349091,0.00004848821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031403382,0.00012979789,0.00038309884,0.00004098788,0.000026067613,0.0000017809422,0.0001610519,0.00028676848,0.00001413183],"category_scores_gemma":[0.00012691935,0.00009289591,0.00012748191,0.00013118767,0.00021716784,0.00000688701,0.00010176752,0.00017961221,0.0000018151892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004222101,0.0014630142,0.86820424,0.00006988678,0.000070771806,5.596776e-7,0.00019078539,0.000039922463,0.10210446,0.000029166933,0.0065786336,0.017026456],"study_design_scores_gemma":[0.0020681466,0.007326125,0.88234645,0.000012751677,0.00002554918,0.0000012277505,0.00002275899,0.000018460556,0.077524595,0.00003048563,0.030514048,0.00010939021],"about_ca_topic_score_codex":0.000120342826,"about_ca_topic_score_gemma":0.0003005994,"teacher_disagreement_score":0.024579866,"about_ca_system_score_codex":0.00000999646,"about_ca_system_score_gemma":0.00012874529,"threshold_uncertainty_score":0.37881854},"labels":[],"label_agreement":null},{"id":"W1958187625","doi":"10.1093/annonc/mdv267","title":"Treatment of mCRPC in the AR-axis-targeted therapy-resistant state","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Clinical trial; Oncology; Intensive care medicine; Internal medicine; Androgen receptor; Cancer","score_opus":0.3831027820635907,"score_gpt":0.5307939155282516,"score_spread":0.1476911334646609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958187625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001302103,0.9887557,1.8582003e-7,0.0012085404,0.00008841025,0.0019911607,0.00018530017,0.0000081956205,0.0064604087],"genre_scores_gemma":[0.0006332289,0.99735916,0.000027419346,0.00009364822,0.000079943486,0.00030201187,0.00024119503,0.00003041899,0.0012329791],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975667,0.0006056534,0.0007771844,0.00028596018,0.00036642322,0.00039810422],"domain_scores_gemma":[0.9982265,0.0003967781,0.00046152686,0.00051325664,0.0002930414,0.000108877015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006756812,0.0003176682,0.0025348484,0.000323429,0.000021560189,0.000004242838,0.00023335029,0.00026330273,0.00007538163],"category_scores_gemma":[0.00004554534,0.00014953985,0.00047739496,0.0004452847,0.0002526886,0.000023677565,0.000027003476,0.00021558617,0.000016317503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010718642,0.0018335901,0.000073451556,0.0020553095,0.0007403827,0.00040272062,0.0010100286,1.4849888e-7,0.0000068780614,0.00003185909,0.0028181246,0.98995566],"study_design_scores_gemma":[0.002838942,0.01656318,0.00009747494,0.0011518064,0.00024184221,0.00005312964,0.00010485537,5.952404e-7,0.00008259893,0.00019085697,0.9785705,0.000104174454],"about_ca_topic_score_codex":0.0002715591,"about_ca_topic_score_gemma":0.00006568585,"teacher_disagreement_score":0.9898515,"about_ca_system_score_codex":0.00026192798,"about_ca_system_score_gemma":0.0024145746,"threshold_uncertainty_score":0.6098058},"labels":[],"label_agreement":null},{"id":"W1966051563","doi":"10.1093/annonc/mdu165.112","title":"Standard Clinical Practice of Folfirinox in Advanced/Metastatic Pancreatic Cancer (Pc) Patients: A Canadian Registry","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; Sunnybrook Health Science Centre; Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Regimen; Internal medicine; Population; Performance status; Pancreatic cancer; Surgery; Cancer; Irinotecan","score_opus":0.06692371531196874,"score_gpt":0.4597018881989226,"score_spread":0.3927781728869539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966051563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97173744,0.002205025,0.00030522494,0.010674815,0.00037456205,0.0006259355,0.00012332769,0.000016665508,0.013936974],"genre_scores_gemma":[0.98428315,0.0011004743,0.0090355035,0.0052474122,0.00009342885,0.000061742445,0.00001636571,0.000028410961,0.00013349747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776816,0.0003084601,0.00093637087,0.00029858074,0.00027627722,0.00041212948],"domain_scores_gemma":[0.9967637,0.0010002445,0.00069117855,0.00042952842,0.00083913474,0.00027622143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092860224,0.00016243232,0.0009900978,0.00020205959,0.000023172144,0.0000022421323,0.00014848306,0.0001339113,0.00011935008],"category_scores_gemma":[0.0036443085,0.00015011558,0.000112554706,0.0002775623,0.00031097172,0.00016152106,0.000030409703,0.00029885775,0.0000054456054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048144525,0.0007269983,0.22266549,0.00028520654,0.00028324605,0.000059840684,0.0004670216,0.00012635555,0.00010096646,0.0006139491,0.0015000615,0.7683564],"study_design_scores_gemma":[0.0096394615,0.009873881,0.22552782,0.0006734664,0.00022417816,0.000040856496,0.00065076636,0.00004685585,0.0008325824,0.0016363114,0.75061977,0.00023405832],"about_ca_topic_score_codex":0.01661333,"about_ca_topic_score_gemma":0.030338628,"teacher_disagreement_score":0.7681224,"about_ca_system_score_codex":0.00022745469,"about_ca_system_score_gemma":0.0014930243,"threshold_uncertainty_score":0.9899351},"labels":[],"label_agreement":null},{"id":"W1971745560","doi":"10.1093/annonc/mdr033","title":"Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta; Princess Margaret Cancer Centre; Saint John Regional Hospital; Dalhousie University","funders":"National Cancer Institute; Alberta Cancer Foundation; GlaxoSmithKline; Ligue Contre le Cancer; U.S. Public Health Service; Les Laboratories Pierre Fabre; Sanofi","keywords":"Medicine; Vinorelbine; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Lung cancer; Cancer; Predictive marker; Clinical trial; Cisplatin; Confidence interval","score_opus":0.1547743045193898,"score_gpt":0.5033060809807542,"score_spread":0.34853177646136446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971745560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21240264,0.77019274,0.0001268198,0.00012052804,0.00022487403,0.013942716,0.0020837707,0.000011675479,0.00089422986],"genre_scores_gemma":[0.038972728,0.9545585,0.0002873494,0.000065162414,0.00011921633,0.004039064,0.0013827403,0.00005617092,0.0005190829],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99463785,0.0008810105,0.0033267415,0.0005931717,0.00027838236,0.00028285905],"domain_scores_gemma":[0.9899906,0.003834837,0.004322978,0.00053492753,0.0012174656,0.00009920892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029897909,0.00042940804,0.011971552,0.0010808989,0.000033907017,0.0000066777593,0.00023186256,0.0005620245,0.0005584721],"category_scores_gemma":[0.00062197493,0.0003042918,0.0020042367,0.00095423625,0.00013559124,0.000056369023,0.00004595398,0.00021961793,6.608164e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20788063,0.0077535636,0.004326599,0.0064174975,0.13489203,0.000022346718,0.0071632904,0.00020413147,0.00003709357,0.000025801284,0.0004605117,0.6308165],"study_design_scores_gemma":[0.59475434,0.015071909,0.010429508,0.008043436,0.3132027,0.0000028545678,0.00073918275,0.0009059613,0.00086690456,0.00016882858,0.05519996,0.0006144135],"about_ca_topic_score_codex":0.01035617,"about_ca_topic_score_gemma":0.0015983195,"teacher_disagreement_score":0.6302021,"about_ca_system_score_codex":0.00024992545,"about_ca_system_score_gemma":0.0017037445,"threshold_uncertainty_score":0.99994093},"labels":[],"label_agreement":null},{"id":"W1978163074","doi":"10.1093/annonc/mdt203.161","title":"A Canadian Registry of Folfirinox in Advanced/Metastatic Pancreatic Cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRINOX; Irinotecan; Clinical trial; Cancer registry; Regimen; Pancreatic cancer; Tolerability; Internal medicine; Adverse effect; Colorectal cancer; Oncology; Cancer","score_opus":0.09604996683701543,"score_gpt":0.4386897262548128,"score_spread":0.34263975941779734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978163074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9461151,0.0015991647,0.0000072922394,0.0103019215,0.000053549233,0.00062806514,0.0000194549,0.0000059973922,0.041269455],"genre_scores_gemma":[0.9925527,0.001752558,0.0017305199,0.0011834686,0.000029532024,0.00022006575,0.000009096956,0.00001345915,0.0025086252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984597,0.00012991352,0.0005415221,0.00019748161,0.0001812263,0.00049016316],"domain_scores_gemma":[0.99841034,0.00037035623,0.00019884652,0.000335854,0.00036956806,0.00031501372],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039150348,0.00011893488,0.0009404681,0.0003574795,0.000021361282,0.000002124741,0.00015324038,0.00014579236,0.0015608113],"category_scores_gemma":[0.00054340356,0.00010226506,0.0000808171,0.0003200853,0.0002574892,0.000066887675,0.000030672934,0.00022394785,0.00004867206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028070988,0.00046319608,0.90559596,0.00043212462,0.00024948633,0.00019442984,0.0005370005,0.000014209435,0.0030486188,0.0004692402,0.013178948,0.075536065],"study_design_scores_gemma":[0.0034175145,0.0037782427,0.97249365,0.00045054825,0.00015047984,0.00008865663,0.0008436297,0.00042040722,0.0018408109,0.0028519144,0.013508682,0.00015544743],"about_ca_topic_score_codex":0.2670344,"about_ca_topic_score_gemma":0.108046554,"teacher_disagreement_score":0.15898785,"about_ca_system_score_codex":0.00018886762,"about_ca_system_score_gemma":0.0029172532,"threshold_uncertainty_score":0.9993519},"labels":[],"label_agreement":null},{"id":"W1979444467","doi":"10.1093/annonc/mdh657","title":"Intensive radiologic surveillance: a focus on the psychological issues","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Worry; Mammography; Anxiety; Population; Cancer; Distress; Depression (economics); Oncology; Gynecology; Internal medicine; Psychiatry; Clinical psychology; Environmental health","score_opus":0.08491979761567622,"score_gpt":0.4134086298727709,"score_spread":0.3284888322570947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979444467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92917013,0.0016884087,0.00014045372,0.059615236,0.00028617575,0.00018308336,0.00001794044,0.00001096711,0.008887627],"genre_scores_gemma":[0.9881868,0.0015819916,0.00035383186,0.009447776,0.00025107843,0.00004385427,0.000016842838,0.000009814553,0.000108016306],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990333,0.00017072301,0.00020589952,0.00028566504,0.000090770125,0.00021367185],"domain_scores_gemma":[0.9990131,0.00009529991,0.00012306166,0.00037659984,0.00035629002,0.00003561359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038392982,0.00011691768,0.00019961174,0.00003118825,0.000054232652,0.000004742813,0.00028078683,0.00025022717,0.00007489821],"category_scores_gemma":[0.00076555,0.000075785254,0.00010385713,0.00009949829,0.00035408352,0.0000013279728,0.00007049245,0.00013861149,0.00003586367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022636675,0.0013380985,0.0037651632,0.00002435287,0.00067053246,0.00009214619,0.001144336,0.0028510082,0.33716458,0.04473061,0.48149326,0.12446225],"study_design_scores_gemma":[0.0021258518,0.019669503,0.02751954,0.000026782775,0.000016618487,0.00020836345,0.0010245027,0.0000060552275,0.50369126,0.0538167,0.39144707,0.00044774878],"about_ca_topic_score_codex":0.000023592263,"about_ca_topic_score_gemma":0.000055111803,"teacher_disagreement_score":0.16652669,"about_ca_system_score_codex":0.000025567937,"about_ca_system_score_gemma":0.00013299959,"threshold_uncertainty_score":0.3090433},"labels":[],"label_agreement":null},{"id":"W1982148917","doi":"10.1093/annonc/mdj011","title":"Chemotherapy-induced amenorrhea in early breast cancer","year":2005,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Chemotherapy; Docetaxel; Gynecology; Cancer; Amenorrhea; Cyclophosphamide","score_opus":0.08963379391860817,"score_gpt":0.4085803626262904,"score_spread":0.31894656870768223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982148917","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28265962,0.00061035337,4.948575e-7,0.71138597,0.0003502004,0.00031126427,0.00011937768,0.000018332374,0.0045444085],"genre_scores_gemma":[0.1791074,0.0032909245,0.000030557552,0.8099544,0.0053127464,0.000066947825,0.000059240403,0.00006943382,0.0021083616],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983241,0.00006183479,0.0005000806,0.0003704724,0.00024713273,0.0004964083],"domain_scores_gemma":[0.9990024,0.00007715437,0.00031769433,0.0003461263,0.00017400333,0.000082631945],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015121257,0.0002756948,0.0010980925,0.000323443,0.0000151870945,0.000005566359,0.0001633688,0.001164726,0.0013704344],"category_scores_gemma":[0.000010005185,0.0002436558,0.00021748661,0.0002040732,0.00010018048,0.000045124998,0.000028443334,0.0014735191,0.000032463882],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035720313,0.0001619348,0.008098507,0.00010381867,0.00015594908,0.00026500522,0.00040660036,8.24817e-7,0.0003784608,0.0000021651344,0.78605837,0.20401119],"study_design_scores_gemma":[0.0016311976,0.001072944,0.097602874,0.00020122791,0.0000504659,0.00007381219,0.0000129769505,0.0000027305582,0.000454423,0.000021344737,0.89868075,0.00019526725],"about_ca_topic_score_codex":0.009839151,"about_ca_topic_score_gemma":0.0010041549,"teacher_disagreement_score":0.2038159,"about_ca_system_score_codex":0.00023822272,"about_ca_system_score_gemma":0.0007487737,"threshold_uncertainty_score":0.9995425},"labels":[],"label_agreement":null},{"id":"W1986666594","doi":"10.1093/annonc/mdp396","title":"Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1–2pN0 disease?","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Proportional hazards model; Mastectomy; Adjuvant; Cancer","score_opus":0.013255681557688201,"score_gpt":0.3132021243879798,"score_spread":0.2999464428302916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986666594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141353,0.00036172377,0.000007900288,0.0071055708,0.000031509815,0.00039901346,0.0006080919,0.000008318538,0.000064360785],"genre_scores_gemma":[0.9977363,0.00040831813,0.0001331024,0.0011383326,0.00007471907,0.00021531834,0.0002268385,0.000014369179,0.0000527534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989156,0.000044208038,0.00021506425,0.00035151967,0.000101037374,0.00037256692],"domain_scores_gemma":[0.99915224,0.000026860314,0.0001560335,0.00016719673,0.0003935564,0.0001041267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042202384,0.000199687,0.00028493922,0.000059972223,0.000045212604,0.000005934468,0.00011239966,0.00010521054,0.000013084769],"category_scores_gemma":[0.000024391586,0.00012420591,0.000067508714,0.000118795484,0.00015786823,0.000010972751,0.000032705368,0.000050883657,8.884786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003941835,0.00073390506,0.9786681,0.00003028961,0.00016065,0.0000074628592,0.00008102202,0.00017229248,0.0017435708,0.00002827479,0.002024705,0.012407899],"study_design_scores_gemma":[0.003047852,0.0014155362,0.97862166,0.000057908885,0.00003775989,0.0000024073854,0.000046539346,0.0000041636545,0.0056574754,0.00012699835,0.010806878,0.00017482156],"about_ca_topic_score_codex":0.00030543245,"about_ca_topic_score_gemma":0.0010884476,"teacher_disagreement_score":0.012233077,"about_ca_system_score_codex":0.000035155463,"about_ca_system_score_gemma":0.00023438035,"threshold_uncertainty_score":0.506497},"labels":[],"label_agreement":null},{"id":"W1988884001","doi":"10.1093/annonc/mdt358","title":"Equipoise abandoned? Randomization and clinical trials","year":2013,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Randomized controlled trial; Medicine; Randomization; Clinical equipoise; Clinical trial; Psychotherapist; Family medicine; Psychology; Surgery; Internal medicine","score_opus":0.8798660536227575,"score_gpt":0.7276655212249659,"score_spread":0.15220053239779163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988884001","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042359945,0.0016446584,0.00011720635,0.9737636,0.00087552716,0.0016841282,0.000031994976,0.000028131288,0.017618777],"genre_scores_gemma":[0.0029801582,0.049363855,0.00084833876,0.9241241,0.008252433,0.000098215554,0.0002293369,0.00006738712,0.0140361795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9892263,0.0052926694,0.0034120078,0.0006527309,0.0009150567,0.0005012433],"domain_scores_gemma":[0.78431267,0.2098292,0.0019912084,0.00095792726,0.0025511738,0.00035783573],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.050509773,0.00025700452,0.0037414224,0.0002774757,0.000042181477,0.00002078589,0.00027924887,0.006221706,0.0010198051],"category_scores_gemma":[0.22492829,0.00018916029,0.0007627294,0.00013289726,0.0012068009,0.000056404828,0.00025327498,0.007912989,0.00013925563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028277745,0.00023473373,0.00050984236,0.00061514275,0.0006289544,0.00025622928,0.000028592169,1.08927374e-7,0.000027299235,0.00029836842,0.93654346,0.058029488],"study_design_scores_gemma":[0.017974708,0.005961862,0.00071488385,0.00046925835,0.0004994591,0.000043140495,0.000009368211,0.0000403476,0.00009398886,0.018954024,0.95506006,0.00017887226],"about_ca_topic_score_codex":0.000104666615,"about_ca_topic_score_gemma":0.000026455387,"teacher_disagreement_score":0.20491363,"about_ca_system_score_codex":0.000029832368,"about_ca_system_score_gemma":0.001467918,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W1997784642","doi":"10.1093/annonc/mdf246","title":"Critical appraisal of the Minimal Clinical Recommendations (MCR) of the European Society for Medical Oncology (ESMO): challenges for a European framework for the development of clinical practice guidelines","year":2002,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Critical appraisal; Clinical Practice; Clinical Oncology; Medical physics; Family medicine; Alternative medicine; Internal medicine; Pathology; Cancer","score_opus":0.7222495314363488,"score_gpt":0.6651006144408299,"score_spread":0.05714891699551894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997784642","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005339495,0.00088840775,0.035104882,0.95309097,0.0052371537,0.0030132418,0.0004330532,0.000018807923,0.0016795471],"genre_scores_gemma":[0.003774024,0.0053911502,0.5231084,0.45409828,0.012720536,0.00032687577,0.0002478844,0.00017153219,0.00016128723],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97902465,0.0059389398,0.012368146,0.0008695798,0.0011322908,0.00066637184],"domain_scores_gemma":[0.67152977,0.31039372,0.00801782,0.001395255,0.008473085,0.00019031609],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.0515215,0.00044254604,0.0023473487,0.00007602204,0.00025370857,0.000008997327,0.0015642133,0.0017427981,0.00013385012],"category_scores_gemma":[0.5508985,0.00025710152,0.0030040313,0.00022428489,0.0023304836,0.00011183839,0.00076949777,0.0030067987,0.0000036267786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010559906,0.0018602461,0.00010120429,0.00058841455,0.0013688037,0.0000037994068,0.00056143384,0.0000016082975,0.000003737494,0.00077640935,0.62248784,0.37119052],"study_design_scores_gemma":[0.0048390934,0.005772981,0.0024984444,0.000666125,0.0024907864,0.00005999922,0.0023070495,0.0005876498,0.00003660854,0.00047381766,0.98005515,0.0002122951],"about_ca_topic_score_codex":0.000013755399,"about_ca_topic_score_gemma":0.00007208201,"teacher_disagreement_score":0.49937698,"about_ca_system_score_codex":0.00005545901,"about_ca_system_score_gemma":0.0037522397,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2003014459","doi":"10.1093/annonc/mdt048.4","title":"A Phase 1B Study of Brivanib in Combination with 5FU/LV and FOLFIRI in Patients with Advanced or Metastatic Gastro-Intestinal Malignancies","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; FOLFIRI; Internal medicine; Nausea; Mucositis; Vomiting; Gastroenterology; Regimen; Neutropenia; Oncology; Irinotecan; Surgery; Colorectal cancer; Adverse effect; Cancer; Chemotherapy","score_opus":0.049274607013160804,"score_gpt":0.3593437677843544,"score_spread":0.3100691607711936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003014459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976743,0.000027877388,0.00006064603,0.00068830175,0.000015282534,0.0013412824,0.000002035222,0.000005808624,0.00018450807],"genre_scores_gemma":[0.9980318,0.000018935867,0.00156383,0.00021213252,0.0000031571635,0.00007323159,0.000008140632,0.000008373254,0.00008039387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999084,0.000056185436,0.00033330603,0.00016347764,0.00018563385,0.00017738836],"domain_scores_gemma":[0.9992825,0.0001103306,0.00022664394,0.00011759371,0.00021956344,0.00004339139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015251349,0.000108044915,0.0004831659,0.00025784702,0.000009897071,0.0000035885726,0.000051657113,0.000017337163,0.000033679353],"category_scores_gemma":[0.00009072787,0.00007139907,0.00001373804,0.00030606726,0.00007965282,0.00012888064,0.000032022195,0.00007095339,7.153747e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004505537,0.011342255,0.9293137,0.00012035624,0.00008052344,0.000060070794,0.001133164,0.000014579309,0.000045312543,0.00003261223,0.00017920433,0.05317265],"study_design_scores_gemma":[0.050358664,0.07745941,0.8695586,0.00015116429,0.000067842215,0.000005959648,0.0020741988,0.000050032886,0.0000714105,0.000037643207,0.0001055768,0.0000595181],"about_ca_topic_score_codex":0.0003852175,"about_ca_topic_score_gemma":0.0010671136,"teacher_disagreement_score":0.06611715,"about_ca_system_score_codex":0.000026983284,"about_ca_system_score_gemma":0.00006722089,"threshold_uncertainty_score":0.29115695},"labels":[],"label_agreement":null},{"id":"W2003534034","doi":"10.1093/annonc/mdt203.213","title":"Adjuvant Chemotherapy (AC) Outcomes in Young (YP) and Elderly Patients (EP) with High Risk Stage II Colon Cancer (CC)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Perineural invasion; Lymphovascular invasion; Stage (stratigraphy); Proportional hazards model; Perforation; Cancer; Chemotherapy; Adjuvant therapy; Oncology; Surgery; Metastasis","score_opus":0.02688545980674069,"score_gpt":0.34113910375462897,"score_spread":0.3142536439478883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003534034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910274,0.00086969894,6.932657e-7,0.0052490705,0.000112380396,0.000701928,0.000056743578,0.000013456779,0.0019686406],"genre_scores_gemma":[0.99359614,0.0037939698,0.0001288249,0.0008992405,0.000024426508,0.00021013078,0.000008772123,0.00001522318,0.0013232885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907404,0.000040863026,0.0002529352,0.00022901199,0.00014308325,0.00026005728],"domain_scores_gemma":[0.9993269,0.000076034354,0.0001865722,0.00012651454,0.00020813232,0.000075837364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076503835,0.00016423625,0.0006504827,0.000085320484,0.00006922954,0.0000047731696,0.000045704077,0.00008896066,0.00017746563],"category_scores_gemma":[0.000029445004,0.00010613807,0.00004282679,0.00010092727,0.00014006032,0.00007143651,0.000042933272,0.00012245135,0.0000026992295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008442813,0.001509991,0.8844337,0.000029321876,0.00031784578,0.000011752299,0.0016624326,0.0000012516207,0.000043185242,0.000014504704,0.001286434,0.109845325],"study_design_scores_gemma":[0.011516023,0.01725997,0.9651632,0.00004505265,0.00006056062,0.0000018262389,0.00030152404,0.0000075505777,0.00044606614,0.00006745546,0.0050267763,0.00010404836],"about_ca_topic_score_codex":0.020180741,"about_ca_topic_score_gemma":0.016061218,"teacher_disagreement_score":0.10974128,"about_ca_system_score_codex":0.00008904048,"about_ca_system_score_gemma":0.0000942447,"threshold_uncertainty_score":0.986344},"labels":[],"label_agreement":null},{"id":"W2004959870","doi":"10.1093/annonc/mdi818","title":"ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine","score_opus":0.2574790015634335,"score_gpt":0.4988641872042931,"score_spread":0.2413851856408596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004959870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966013,0.0007713277,0.000028769917,0.030977458,0.0001320179,0.0009576012,0.00018910864,0.000017763092,0.0009129168],"genre_scores_gemma":[0.98476744,0.0055162883,0.0078940615,0.0005436812,0.00015695501,0.00031910665,0.00014595258,0.000014351379,0.00064216234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987027,0.0001132014,0.0005719993,0.00024157895,0.00009446854,0.00027605443],"domain_scores_gemma":[0.99719596,0.0019092849,0.0001917197,0.00022632522,0.00025055656,0.00022617825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035158862,0.0001261804,0.00061216176,0.000118806594,0.00005057834,0.000002714044,0.000059074915,0.00015235745,0.000097225464],"category_scores_gemma":[0.0008511758,0.00009840236,0.00022706548,0.00007394519,0.00017516065,0.00005210821,0.000036269368,0.00006857682,0.000010309465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018364842,0.0026985947,0.29180062,0.000039223443,0.0005316384,0.000007682954,0.00019367918,4.22809e-7,0.00016391656,0.0000778252,0.025305979,0.67734396],"study_design_scores_gemma":[0.028480893,0.0253335,0.2369483,0.00007657739,0.00023349693,0.000022957309,0.00018745309,0.00057187147,0.02213084,0.0001245365,0.6857676,0.000121982],"about_ca_topic_score_codex":0.00013754667,"about_ca_topic_score_gemma":0.00044764325,"teacher_disagreement_score":0.67722195,"about_ca_system_score_codex":0.000044750614,"about_ca_system_score_gemma":0.0002099707,"threshold_uncertainty_score":0.40127316},"labels":[],"label_agreement":null},{"id":"W2007557005","doi":"10.1093/annonc/mdm290","title":"Response evaluation: beyond RECIST","year":2007,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Medical physics; Nuclear medicine; Oncology; Internal medicine; Chemotherapy; Progressive disease","score_opus":0.4820481525410028,"score_gpt":0.6090247866017172,"score_spread":0.1269766340607144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007557005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000057845828,0.943398,0.00016764464,0.01111023,0.00010826393,0.0012053072,0.000022782358,0.000053581007,0.04392843],"genre_scores_gemma":[0.000005156993,0.9874717,0.0074682427,0.0024474964,0.00022434269,0.00025141385,0.00016892595,0.000028786144,0.0019339557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781466,0.00041259298,0.0008364024,0.00029738355,0.00040563845,0.00023331457],"domain_scores_gemma":[0.9971603,0.0010294007,0.00047601227,0.00061990315,0.00052173133,0.00019260774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052966126,0.00019203311,0.0015477835,0.00028877656,0.00003367078,0.0000033294941,0.00020101487,0.00052310416,0.00073817617],"category_scores_gemma":[0.0014816385,0.0001487196,0.00039033807,0.00039667357,0.00024847226,0.000016180746,0.00006761689,0.0004606727,0.00010376675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007709897,0.0001662828,2.517692e-7,0.001133303,0.000063543965,0.00002476918,0.000009295156,4.7577426e-9,0.0000025753056,0.00039307776,0.19440357,0.8037262],"study_design_scores_gemma":[0.00024821825,0.0008760066,0.0000033435033,0.0029120485,0.00072959193,0.000259162,0.0000040046557,0.000005564997,0.000017459546,0.00044864652,0.9943892,0.00010680396],"about_ca_topic_score_codex":0.000008997874,"about_ca_topic_score_gemma":0.0000012178796,"teacher_disagreement_score":0.80361944,"about_ca_system_score_codex":0.00009993706,"about_ca_system_score_gemma":0.0017593551,"threshold_uncertainty_score":0.80825114},"labels":[],"label_agreement":null},{"id":"W2011441939","doi":"10.1093/annonc/mdv095.7","title":"Identifying ATMic non-small cell lung cancer cell lines: Implications for designing clinical trials","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.6213517073570092,"score_gpt":0.602548487235175,"score_spread":0.01880322012183422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011441939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7771961,0.020379804,0.14662185,0.028789911,0.0035126214,0.0051443353,0.00029422477,0.0001518166,0.01790934],"genre_scores_gemma":[0.95284456,0.0061813807,0.028151417,0.007770341,0.0024310714,0.0011828202,0.00007563141,0.00007208068,0.0012907254],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972861,0.00043204633,0.0014519655,0.00035995673,0.00012361362,0.0003463522],"domain_scores_gemma":[0.9953185,0.0021245268,0.00093693426,0.00036360027,0.00096282054,0.0002936406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005346893,0.00016371011,0.0010485167,0.000097257194,0.00006371044,0.000010345876,0.00017723754,0.00031341196,0.00008900639],"category_scores_gemma":[0.0008218569,0.00015055414,0.00039206663,0.00015769481,0.00011098073,0.00008739945,0.00003909351,0.00020437971,0.000014033385],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037812376,0.0021900972,0.05714513,0.0009080767,0.00061322836,0.000013342096,0.0027213146,0.00025934487,0.27480432,0.00029182585,0.5880852,0.069186874],"study_design_scores_gemma":[0.049033638,0.010714643,0.016057368,0.0008217625,0.0017322234,0.000052073,0.0021517766,0.001806854,0.6246307,0.0059706056,0.28614053,0.00088783266],"about_ca_topic_score_codex":0.00014663722,"about_ca_topic_score_gemma":0.000063630694,"teacher_disagreement_score":0.34982637,"about_ca_system_score_codex":0.00016139972,"about_ca_system_score_gemma":0.0016325052,"threshold_uncertainty_score":0.61394197},"labels":[],"label_agreement":null},{"id":"W2012386044","doi":"10.1093/annonc/mdn753","title":"Stopping a trial early in oncology: for patients or for industry?","year":2009,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gemcitabine; Clinical trial; Randomized controlled trial; Internal medicine; Oncology; Tamoxifen; Breast cancer; Cancer; Letrozole; Pancreatic cancer","score_opus":0.8599858372397515,"score_gpt":0.6777961142334386,"score_spread":0.18218972300631298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012386044","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012145887,0.000054645698,0.016627995,0.9320898,0.008544333,0.021986365,0.0030157533,0.000121828925,0.005413398],"genre_scores_gemma":[0.000138124,0.000045691435,0.6306098,0.35815114,0.007669879,0.001782917,0.00007384017,0.000121098936,0.0014075148],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932014,0.0018731026,0.0029176841,0.00072988635,0.00036435726,0.00091356685],"domain_scores_gemma":[0.829951,0.16694795,0.0018701042,0.00046964118,0.00066160935,0.00009970599],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00615876,0.0004428959,0.0033617683,0.00036211434,0.0000536583,0.000017183687,0.00068262307,0.007148854,0.00013405985],"category_scores_gemma":[0.23861878,0.00037049848,0.0005892772,0.00023243339,0.0002567397,0.000055838398,0.00010971444,0.0027568955,0.0000053636227],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03387437,0.0013372593,0.000015905565,0.00039671367,0.00016707338,0.00005149846,0.00009872539,2.1627935e-7,0.0000011786393,0.0016809365,0.7924257,0.16995046],"study_design_scores_gemma":[0.03590877,0.031364586,0.00003237096,0.0001661227,0.00014398596,0.0000011410278,0.000008786929,0.0000063263747,0.00001873028,0.40806612,0.5240419,0.00024115249],"about_ca_topic_score_codex":0.000017030914,"about_ca_topic_score_gemma":0.000024112918,"teacher_disagreement_score":0.6139818,"about_ca_system_score_codex":0.00021282831,"about_ca_system_score_gemma":0.0010356097,"threshold_uncertainty_score":0.9998747},"labels":[],"label_agreement":null},{"id":"W2014504782","doi":"10.1093/annonc/mdt482","title":"The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Radiation therapy; Diffuse large B-cell lymphoma; Chemotherapy; Surgery; Retrospective cohort study; Gastroenterology; Adverse effect; Anthracycline; Lymphoma; Chemotherapy regimen; Cancer","score_opus":0.014917543905354658,"score_gpt":0.3113641136041908,"score_spread":0.29644656969883615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014504782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583834,0.001335373,5.216549e-7,0.0009899717,0.000058434212,0.0013462866,0.000011251756,0.0000028430127,0.00041699756],"genre_scores_gemma":[0.998202,0.0009722763,0.0002233116,0.0004275185,0.000008580942,0.000100637706,0.0000055249466,0.0000068233844,0.000053297732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987827,0.00022390576,0.0004633892,0.00016038155,0.00018631794,0.00018329722],"domain_scores_gemma":[0.99814105,0.0010140651,0.00038305315,0.0002608861,0.0001527799,0.00004813716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002196146,0.00011863133,0.0005181842,0.00003992278,0.000024958576,0.0000026976204,0.000092671966,0.000117214215,0.000005046125],"category_scores_gemma":[0.0002984091,0.000050366652,0.00009633264,0.00007769,0.00037737357,0.000030195648,0.00013407628,0.00006404913,6.4397636e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011502499,0.02056057,0.95067984,0.00030455564,0.00016940564,0.000038462338,0.00032983004,2.5882656e-7,0.000057849407,0.0001462217,0.0010884999,0.025474261],"study_design_scores_gemma":[0.018456979,0.005818515,0.9705527,0.00026382567,0.000146768,0.0000047762405,0.00012744169,0.0000027388446,0.003763633,0.00008078738,0.00073993363,0.000041940137],"about_ca_topic_score_codex":0.000062905245,"about_ca_topic_score_gemma":0.000060587325,"teacher_disagreement_score":0.02543232,"about_ca_system_score_codex":0.000013091307,"about_ca_system_score_gemma":0.000036894267,"threshold_uncertainty_score":0.20538925},"labels":[],"label_agreement":null},{"id":"W2016044915","doi":"10.1093/annonc/mdm210","title":"The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Pancreatic cancer; Erlotinib; Cancer; Chemoradiotherapy; Oncology; Internal medicine; Intensive care medicine","score_opus":0.14044446229117685,"score_gpt":0.4749154249668576,"score_spread":0.33447096267568077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016044915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8796773,0.026483351,0.00033696595,0.08160742,0.0010683835,0.0013274403,0.00014347908,0.000020556747,0.009335084],"genre_scores_gemma":[0.8396642,0.15236452,0.0031928124,0.002259031,0.0005314653,0.0003630428,0.000075775846,0.000027390608,0.001521731],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99856013,0.00018261083,0.0004625285,0.00020744164,0.00023648965,0.00035081487],"domain_scores_gemma":[0.99706084,0.0020328464,0.00026634193,0.0002771621,0.00024477113,0.00011802923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088088715,0.0001310263,0.0004453608,0.00007392542,0.00017634142,0.0000059217914,0.00017858857,0.00004243726,0.00023749424],"category_scores_gemma":[0.000097933116,0.00007693355,0.000061674196,0.00017280858,0.0005343501,0.000024371391,0.00009488298,0.00025296703,0.0000034525904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022524402,0.000618174,0.31048024,0.00011580332,0.00067010196,0.000025748304,0.00051097677,0.000004350536,0.0007673991,0.002022549,0.0775479,0.60498434],"study_design_scores_gemma":[0.0026193308,0.001828543,0.75892174,0.0018534772,0.0001806927,0.000020119234,0.0016036821,0.00023070007,0.0014772186,0.00048789856,0.23066428,0.00011232614],"about_ca_topic_score_codex":0.002107577,"about_ca_topic_score_gemma":0.0022078308,"teacher_disagreement_score":0.604872,"about_ca_system_score_codex":0.00008503055,"about_ca_system_score_gemma":0.00025350356,"threshold_uncertainty_score":0.318604},"labels":[],"label_agreement":null},{"id":"W2018799735","doi":"10.1093/annonc/mdh275","title":"Quality of cancer care","year":2004,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Intensive care medicine; Quality (philosophy); Cancer; Clinical trial; Disease; Evidence-based medicine; Cancer treatment; Alternative medicine; Family medicine; Internal medicine; Pathology","score_opus":0.8451968459680101,"score_gpt":0.6566788518688672,"score_spread":0.18851799409914294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018799735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009829602,0.9806161,0.00003905576,0.0032417406,0.000848909,0.0008991684,0.002505648,0.000016520244,0.0117345825],"genre_scores_gemma":[0.00022571205,0.9965681,0.0005006275,0.0017657335,0.00030923914,0.00021926523,0.00012684427,0.000047448113,0.00023704232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9878227,0.00085331826,0.01021906,0.00059601996,0.00009818302,0.00041069725],"domain_scores_gemma":[0.9837434,0.0017112653,0.013383507,0.00073245366,0.00028410935,0.00014524814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011887743,0.0003257444,0.0075292336,0.00050872884,0.000052851647,0.000008011254,0.0005608919,0.00077083113,0.00065706426],"category_scores_gemma":[0.0026057279,0.00038112237,0.00088944036,0.00027263458,0.00019550447,0.00012580637,0.00009777347,0.00031665375,0.0004834454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001503899,0.00028974898,0.0007240675,0.18429087,0.0007934512,0.0000017497721,0.0020685422,0.00003492508,4.170253e-8,0.132377,0.012906295,0.66649824],"study_design_scores_gemma":[0.00032775724,0.00024965697,0.00022044557,0.0041742,0.00004090866,0.000001660237,0.0002543397,7.971665e-7,5.5677117e-7,0.004145108,0.9902899,0.00029461653],"about_ca_topic_score_codex":0.006022307,"about_ca_topic_score_gemma":0.00082851545,"teacher_disagreement_score":0.9773837,"about_ca_system_score_codex":0.0007816939,"about_ca_system_score_gemma":0.0025410787,"threshold_uncertainty_score":0.99986404},"labels":[],"label_agreement":null},{"id":"W2025531309","doi":"10.1093/annonc/mdv048.05","title":"Effect of Comorbidity on Surgery and Survival Among Lung Cancer Patients in England","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Comorbidity; Lung cancer; Hazard ratio; Proportional hazards model; Internal medicine; Odds ratio; Cancer; Surgery; Confidence interval","score_opus":0.15812391004533566,"score_gpt":0.4428322901216427,"score_spread":0.28470838007630705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025531309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672383,0.00044660273,6.562308e-7,0.00030473212,0.00023807828,0.00016423884,0.000010855648,0.0000043624686,0.002106629],"genre_scores_gemma":[0.9993909,0.00030825337,0.000004945452,0.00020487417,0.00005644993,0.000009434409,0.00000838492,0.0000047560857,0.000012023645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907565,0.00021205617,0.00024051199,0.000120917386,0.00019567553,0.0001551894],"domain_scores_gemma":[0.99893653,0.0005622282,0.00013676005,0.00008907708,0.00017341001,0.000102017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011932014,0.000076732234,0.0005126749,0.000093906696,0.000008258395,0.000001276953,0.000036222365,0.00009298794,0.00001272798],"category_scores_gemma":[0.00062929315,0.00006089137,0.00004365413,0.00010970134,0.00009862002,0.000046457484,0.00002779391,0.00010859578,5.3278796e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017096961,0.00009432523,0.96883416,0.000093508905,0.000025402633,0.000026261694,0.00026220252,0.000013612675,0.000023566063,0.0000059805766,0.0029574363,0.025953863],"study_design_scores_gemma":[0.0022901546,0.0045178817,0.9881631,0.00022686676,0.000027710985,0.0000018711194,0.000026608446,0.000063390304,0.003064493,0.000012568051,0.0015535678,0.000051793115],"about_ca_topic_score_codex":0.0044245725,"about_ca_topic_score_gemma":0.0016121933,"teacher_disagreement_score":0.025902068,"about_ca_system_score_codex":0.000043530184,"about_ca_system_score_gemma":0.000140562,"threshold_uncertainty_score":0.6688659},"labels":[],"label_agreement":null},{"id":"W2026001276","doi":"10.1093/annonc/mdj088","title":"Reply to the Letter to the Editor on ‘Cost-opportunity analysis in clinical oncology: from the “wild far-west” to a correct integration of the disciplines, avoiding the “war of the worlds”’, by D. Tassinari et al. (Ann Oncol 2006; 17: 876)","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical Oncology; Oncology; Library science; Family medicine; Internal medicine; Cancer","score_opus":0.4971506705477903,"score_gpt":0.590347943849948,"score_spread":0.09319727330215777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026001276","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07640996,0.000078004785,0.012839089,0.90015984,0.004512352,0.0037428017,0.0009565239,0.00002234977,0.0012790535],"genre_scores_gemma":[0.36503288,0.00022090427,0.027315121,0.59958595,0.006017439,0.0007834583,0.000018705587,0.00008015602,0.0009453516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97696817,0.017095003,0.0035989233,0.0007373021,0.0010250785,0.00057552406],"domain_scores_gemma":[0.8343685,0.16001825,0.002179343,0.0026409053,0.0005864241,0.00020653564],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03726709,0.00040740336,0.0017657522,0.00013434132,0.0004063551,0.000039118684,0.002926026,0.0004266712,0.0002109229],"category_scores_gemma":[0.1868005,0.00015084393,0.0009031081,0.0019880785,0.0009011688,0.000075538315,0.0011135078,0.0022699512,0.000028090906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089082855,0.0010831167,0.0015591305,0.0000055154733,0.00043156728,0.0000016778823,0.002977951,0.00067457586,0.00020706253,0.0011250941,0.9263959,0.06464756],"study_design_scores_gemma":[0.00084292475,0.0020246308,0.025733162,0.00020461141,0.0008356696,0.0000019458048,0.0019158093,0.0007095809,0.00113921,0.012600215,0.9537453,0.0002469158],"about_ca_topic_score_codex":0.0009559023,"about_ca_topic_score_gemma":0.014866234,"teacher_disagreement_score":0.3005739,"about_ca_system_score_codex":0.00020524205,"about_ca_system_score_gemma":0.0006837864,"threshold_uncertainty_score":0.9913361},"labels":[],"label_agreement":null},{"id":"W2028529479","doi":"10.1093/annonc/mdt201.30","title":"Results According to Age in Avex, a Randomized Phase 3 Trial of Bevacizumab with Capecitabine for Elderly Patients with Mcrc","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Capecitabine; Bevacizumab; Hazard ratio; Internal medicine; Confidence interval; Clinical endpoint; Population; Colorectal cancer; Randomized controlled trial; Oncology; Cancer; Surgery; Chemotherapy","score_opus":0.0542663344520244,"score_gpt":0.3840398754555675,"score_spread":0.3297735410035431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028529479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887147,0.000071301496,0.00003830628,0.0028636015,0.00007491288,0.0048964377,0.00004949566,0.000007642844,0.00328358],"genre_scores_gemma":[0.9972287,0.00004313273,0.0012130026,0.000260735,0.000051345723,0.00097347324,0.000040322564,0.000013116605,0.00017620932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987681,0.00006654017,0.0005346982,0.00022123657,0.0001704387,0.00023897454],"domain_scores_gemma":[0.9984767,0.00053606555,0.0002727089,0.00015593164,0.0004796085,0.000079031124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029448478,0.00014593662,0.0012648765,0.00016902387,0.00002595495,0.0000035769149,0.00005551581,0.00006215249,0.000018652026],"category_scores_gemma":[0.0004942447,0.0000857479,0.00010216096,0.0001836727,0.000115767856,0.00005607739,0.000024828923,0.00006218487,0.0000013785414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9085798,0.0022435493,0.0007410984,0.00004168537,0.0004006494,0.000016637385,0.0011654376,0.00000356393,0.000099526944,0.000017211809,0.00088089483,0.085809894],"study_design_scores_gemma":[0.90318394,0.089584984,0.0040880665,0.0001221999,0.00016451471,0.0000016528976,0.00038078247,0.000009967964,0.0005294944,0.00006607791,0.0017798704,0.00008847077],"about_ca_topic_score_codex":0.0005354036,"about_ca_topic_score_gemma":0.00079822756,"teacher_disagreement_score":0.08734143,"about_ca_system_score_codex":0.00005299599,"about_ca_system_score_gemma":0.00014757938,"threshold_uncertainty_score":0.34966978},"labels":[],"label_agreement":null},{"id":"W2029031776","doi":"10.1093/annonc/mdv094.3","title":"Control of cell fate by the mammalian target of rapamycin (mTOR) under stress depends on eIF2α serine 51 phosphorylation","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"mTORC2; mTORC1; PI3K/AKT/mTOR pathway; P70-S6 Kinase 1; Protein kinase B; Ribosomal s6 kinase; Cell biology; Ribosomal protein s6; Mechanistic target of rapamycin; Unfolded protein response; EIF-2 kinase; Protein kinase R; Phosphorylation; Kinase; Biology; Protein kinase A; Endoplasmic reticulum; Signal transduction; Mitogen-activated protein kinase kinase; Cyclin-dependent kinase 2","score_opus":0.031438570828671866,"score_gpt":0.31275228953493145,"score_spread":0.2813137187062596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029031776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047875,0.0014652403,0.002049098,0.001527744,0.00008676242,0.00019657369,0.00038739928,0.0000032516969,0.003805168],"genre_scores_gemma":[0.9983868,0.00016560352,0.0001752336,0.0004901119,0.00006764791,0.000020558362,0.00016532643,0.000010633635,0.0005180745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918544,0.00010239075,0.00029489913,0.00015771153,0.0001087742,0.00015079317],"domain_scores_gemma":[0.99908566,0.00003478538,0.00030070436,0.00030942107,0.00020718374,0.00006224833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028336933,0.00010135,0.00023880853,0.000028914817,0.000020311281,0.0000019295794,0.00021309787,0.00013284716,0.000018911946],"category_scores_gemma":[0.00003986935,0.000077632736,0.000074049516,0.00007630115,0.0001325224,0.0000032077457,0.00004425423,0.000059572085,0.0000030806848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003568611,0.00045212073,0.001492635,0.000018284409,0.00006224831,3.781429e-7,0.00005673626,0.0005845336,0.98139787,0.0008571234,0.011072724,0.0036485016],"study_design_scores_gemma":[0.0010742786,0.00094350363,0.0026559057,0.0000029901807,0.000021907663,0.0000011557887,0.000098799224,0.00003817352,0.91502047,0.00028724744,0.07978767,0.0000679053],"about_ca_topic_score_codex":0.00009943413,"about_ca_topic_score_gemma":0.000027221311,"teacher_disagreement_score":0.06871495,"about_ca_system_score_codex":0.0000039770694,"about_ca_system_score_gemma":0.00009975704,"threshold_uncertainty_score":0.3165771},"labels":[],"label_agreement":null},{"id":"W2029746624","doi":"10.1093/annonc/mdt459.78","title":"Clinical Trial Using Cancer/Testis Antigen- and/or VEGFR1/2-Derived Peptide-Vaccine Cocktails","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Peptide vaccine; Clinical endpoint; Adverse effect; Internal medicine; Vaccination; Adjuvant; Clinical trial; ELISPOT; Cancer; Oncology; Antigen; Immunology; Epitope","score_opus":0.17028549287460995,"score_gpt":0.4426726818134175,"score_spread":0.27238718893880753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029746624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97911155,0.016205054,0.000044683402,0.0020154992,0.0015427128,0.0006958814,0.000019560675,0.00004299887,0.00032206584],"genre_scores_gemma":[0.9797306,0.016057359,0.00037807162,0.0016626739,0.00015582304,0.000068667185,0.000018641364,0.000029691422,0.0018984765],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970437,0.0009951822,0.0010251871,0.00036464512,0.00003916859,0.0005321048],"domain_scores_gemma":[0.99755156,0.0012436592,0.0005268885,0.00034683576,0.00028630707,0.0000447496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008124015,0.00024710377,0.000982779,0.00015301521,0.00019152586,0.000014670196,0.00028613987,0.0006065113,0.0029826255],"category_scores_gemma":[0.00061239745,0.00019351246,0.00019846328,0.00015785593,0.0005248554,0.00018661984,0.000135206,0.00039319,0.00015798476],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06266546,0.00089102105,0.0074721132,0.000028102986,0.0008842887,0.000015551243,0.00041022472,0.0000035071657,0.63871586,0.00007774816,0.015945913,0.2728902],"study_design_scores_gemma":[0.10085751,0.028635131,0.15927936,0.00022852045,0.00016407199,0.00037482436,0.00065201987,0.00004135453,0.17232119,0.000348152,0.53629965,0.0007982332],"about_ca_topic_score_codex":0.0016205534,"about_ca_topic_score_gemma":0.0000734747,"teacher_disagreement_score":0.52035373,"about_ca_system_score_codex":0.000021650738,"about_ca_system_score_gemma":0.00048431946,"threshold_uncertainty_score":0.9979288},"labels":[],"label_agreement":null},{"id":"W2029984468","doi":"10.1093/annonc/mdu165.210","title":"Efficacy, Safety and Patient-Reported Outcomes of Oxaliplatin-Based Chemotherapy in Elderly Patients with Colorectal Cancer (CRC): A Post-Hoc Analysis of the Glutox Study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Regional Municipality of Durham; Sanofi (Canada); Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Notre-Dame; Hôtel-Dieu de Québec; London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Cégep de Rimouski; Hôpital Maisonneuve-Rosemont; Hôpital Saint-Luc","funders":"","keywords":"Medicine; Oxaliplatin; Colorectal cancer; Oncology; Post-hoc analysis; Internal medicine; Post hoc; Chemotherapy; Cancer","score_opus":0.02181064666228554,"score_gpt":0.33847126582789,"score_spread":0.31666061916560445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029984468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972432,0.00013780726,0.0000010040175,0.0012803465,0.00004413761,0.0009650476,0.0000560079,0.0000057271554,0.00026671487],"genre_scores_gemma":[0.9994132,0.000043712884,0.00003869751,0.00042542923,0.000004144276,0.00004071547,0.000013219387,0.000010273793,0.000010629418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985943,0.00013172392,0.0005986517,0.00022809439,0.0002801941,0.00016704915],"domain_scores_gemma":[0.99833554,0.00033726648,0.0005945015,0.00021732229,0.00047174943,0.00004359936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017321797,0.00016109861,0.0011199199,0.00020580688,0.0000373445,0.0000015417033,0.00006742734,0.00006791861,0.000033195007],"category_scores_gemma":[0.00012413067,0.00009082064,0.00014819475,0.0005953541,0.00021286232,0.0000193723,0.000035885736,0.00007967526,6.526429e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013769245,0.0032771772,0.91876566,0.000020280493,0.0035166927,0.0000026725938,0.0027001034,0.00011116768,0.00014300176,0.0000037975904,0.000014641603,0.057675567],"study_design_scores_gemma":[0.0119823,0.031289034,0.9544122,0.000035648856,0.0010086682,3.1928406e-7,0.0004183637,0.00007968769,0.00051137176,0.0000022957236,0.0001852844,0.00007482073],"about_ca_topic_score_codex":0.0017451581,"about_ca_topic_score_gemma":0.008797979,"teacher_disagreement_score":0.057600744,"about_ca_system_score_codex":0.000052425363,"about_ca_system_score_gemma":0.0001722619,"threshold_uncertainty_score":0.4909479},"labels":[],"label_agreement":null},{"id":"W2030957507","doi":"10.1093/annonc/mdp035","title":"Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy","year":2009,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Chemotherapy; Oncology; Enterocolitis; Internal medicine; Chemotherapy regimen","score_opus":0.06922443339293845,"score_gpt":0.38405517838271824,"score_spread":0.3148307449897798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030957507","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01699087,0.0016324504,0.000006612801,0.9395788,0.00035522095,0.00069757807,0.000038530135,0.000045428602,0.040654518],"genre_scores_gemma":[0.013248778,0.007632115,0.000117030904,0.96972924,0.0026424932,0.00007153419,0.00009021091,0.00004942037,0.006419169],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984276,0.00009352133,0.0004507506,0.00040420913,0.00019262372,0.0004312911],"domain_scores_gemma":[0.99890685,0.00008304876,0.00029860888,0.0003910397,0.00020914488,0.00011128513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000121223704,0.0002850403,0.0010891493,0.00021461805,0.000050271177,0.000013506213,0.00013817468,0.0007323636,0.0005281278],"category_scores_gemma":[0.000015382766,0.0002496619,0.00025234,0.00012038477,0.00020099143,0.00005622603,0.000041303127,0.0011219969,0.00003826449],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018381063,0.00014099876,0.00029976334,0.00013630922,0.000200419,0.0005141269,0.00005777216,1.5268937e-7,0.0005775583,0.00004645238,0.9055044,0.09233824],"study_design_scores_gemma":[0.0021011364,0.0053111296,0.0071799755,0.00014733437,0.00015853652,0.0009317499,0.000007770048,6.7464987e-7,0.0012922978,0.00032961246,0.98235774,0.00018204225],"about_ca_topic_score_codex":0.00012522179,"about_ca_topic_score_gemma":0.000019916954,"teacher_disagreement_score":0.0921562,"about_ca_system_score_codex":0.00005647681,"about_ca_system_score_gemma":0.00030843998,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W2030957668","doi":"10.1093/annonc/mdn686","title":"A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Lynch syndrome; MLH1; Pedigree chart; Medicine; Proband; Family history; MSH6; Mutation; Penetrance; Cancer; Colorectal cancer; Endometrial cancer; MSH2; Genetics; Internal medicine; Oncology; DNA mismatch repair; Biology","score_opus":0.16757994155456443,"score_gpt":0.45272742324093523,"score_spread":0.28514748168637083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030957668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997235,0.00045505346,0.00044307386,0.003928475,0.00011331705,0.00037378928,0.000013339867,0.000014941706,0.004685645],"genre_scores_gemma":[0.99709314,0.000037826496,0.0017636975,0.0009946323,0.000038881244,0.000010037035,0.0000071007057,0.000007480186,0.000047207915],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990617,0.00004930986,0.00035097921,0.00017149348,0.00019564078,0.00017089989],"domain_scores_gemma":[0.9992222,0.000103456034,0.00014577752,0.00015563445,0.0002302152,0.00014271171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019318103,0.00009217953,0.0004939509,0.00012686235,0.000016308575,0.0000018052465,0.00006172804,0.00013791061,0.00003434024],"category_scores_gemma":[0.00016092557,0.000086148706,0.00004877613,0.00014560825,0.00009815048,0.000033601933,0.000020897272,0.00009661672,0.000001405745],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068982886,0.0019722946,0.11539952,0.0004276681,0.00048765345,0.00006662904,0.04094483,0.016162135,0.25508353,0.0012297361,0.053605698,0.507722],"study_design_scores_gemma":[0.0070322775,0.09199801,0.35079235,0.00031422905,0.00036839908,0.00010355888,0.0027580715,0.018590106,0.5023911,0.008522871,0.016664395,0.00046463287],"about_ca_topic_score_codex":0.000054244403,"about_ca_topic_score_gemma":0.000053521286,"teacher_disagreement_score":0.5072574,"about_ca_system_score_codex":0.000036634097,"about_ca_system_score_gemma":0.00019530799,"threshold_uncertainty_score":0.3513042},"labels":[],"label_agreement":null},{"id":"W2035885090","doi":"10.1093/annonc/mdv104","title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemoradiotherapy; Internal medicine; Placebo; Clinical endpoint; Oncology; Subgroup analysis; Biomarker; Lung cancer; Surrogate endpoint; Stage (stratigraphy); Phases of clinical research; Cancer; Gastroenterology; Clinical trial; Pathology; Confidence interval","score_opus":0.22608756890889636,"score_gpt":0.5120381683515557,"score_spread":0.2859505994426593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035885090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164433,0.0033427877,0.000009330102,0.004498216,0.00011249991,0.0014311755,0.00004462785,0.000012305522,0.008904734],"genre_scores_gemma":[0.9970121,0.0012172428,0.000028648405,0.0005346722,0.00005687463,0.00014336812,0.00001930046,0.000017778453,0.0009700112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975846,0.0005257555,0.00051612273,0.00036837067,0.00045346338,0.00055172073],"domain_scores_gemma":[0.9986161,0.00035132776,0.00016154659,0.00035658025,0.00035769073,0.00015675972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002456047,0.00020138903,0.00083484384,0.00039503982,0.0000553901,0.000015452551,0.00022446773,0.000095143114,0.00011613266],"category_scores_gemma":[0.00023089041,0.00013744152,0.000053562733,0.0006822832,0.00022857437,0.000112149515,0.00023134827,0.00035133166,0.0000016747844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01586887,0.008767365,0.8534012,0.00041444413,0.0014529416,0.0018193561,0.018677527,0.00029847556,0.01696622,0.00003170039,0.07443731,0.007864619],"study_design_scores_gemma":[0.15923198,0.020090314,0.7156545,0.00038016,0.0005853918,0.000022096161,0.059473768,0.0058032824,0.009031785,0.00013049821,0.028850906,0.0007453162],"about_ca_topic_score_codex":0.030896997,"about_ca_topic_score_gemma":0.030711412,"teacher_disagreement_score":0.1433631,"about_ca_system_score_codex":0.00020364558,"about_ca_system_score_gemma":0.00087179826,"threshold_uncertainty_score":0.98697555},"labels":[],"label_agreement":null},{"id":"W2049086053","doi":"10.1093/annonc/mdv050.12","title":"Afatinib (A) Vs Erlotinib (E) as Second-Line Treatment of Patients (PTS) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (LL8), a Phase Iii Global Trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Lung cancer; Erlotinib; Oncology; Progression-free survival; Chemotherapy regimen; Surrogate endpoint; Chemotherapy; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.04037316368819774,"score_gpt":0.3937972074679882,"score_spread":0.3534240437797904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049086053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022496,0.0007305922,0.00006464435,0.0011776796,0.0003980774,0.0028267237,0.00033173565,0.000022176973,0.0042234194],"genre_scores_gemma":[0.99787945,0.000020567066,0.0006879029,0.0005104758,0.00010925913,0.0001658716,0.0002196499,0.000034776684,0.00037204448],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796045,0.00010532192,0.0008138412,0.00035341617,0.00042047194,0.000346507],"domain_scores_gemma":[0.9977167,0.00021762,0.0008681559,0.00047500405,0.00051653385,0.0002059346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017107159,0.00032913033,0.0011009912,0.00008848985,0.00007246829,0.0000042563956,0.00014614321,0.00016185436,0.00011735172],"category_scores_gemma":[0.0000977642,0.00020289213,0.00037266943,0.0003261001,0.00014701734,0.00007866636,0.000026256042,0.00008580214,0.0000014939965],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57036465,0.07228645,0.23432536,0.0009601548,0.0033088806,0.000255604,0.015784925,0.0035898844,0.0015408675,0.00012137516,0.0052487166,0.092213124],"study_design_scores_gemma":[0.77045506,0.15132546,0.010822136,0.00018437633,0.0020257551,0.000009556445,0.00061772024,0.0011001815,0.053381328,0.000049531547,0.009701005,0.000327859],"about_ca_topic_score_codex":0.00044310954,"about_ca_topic_score_gemma":0.00028995378,"teacher_disagreement_score":0.22350323,"about_ca_system_score_codex":0.00039365608,"about_ca_system_score_gemma":0.0016386388,"threshold_uncertainty_score":0.8273701},"labels":[],"label_agreement":null},{"id":"W2049734392","doi":"10.1093/annonc/mdt042.18","title":"Winther: A Study to Select Rational Therapeutics Based On the Analysis of Tumor and Matched Normal Tissue Biopsies in Subjects with Advanced Malignancies","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Cancer; Colorectal cancer; Oncology; Clinical trial; Personalized medicine; Internal medicine; Clinical endpoint; Biopsy; Progression-free survival; Precision medicine; Overall survival; Bioinformatics; Pathology; Biology","score_opus":0.021927682623834804,"score_gpt":0.3086624931115533,"score_spread":0.2867348104877185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049734392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977,0.00014964977,0.00007674992,0.0014558242,0.000014273427,0.00039584353,0.000025801264,0.0000015274658,0.00018034212],"genre_scores_gemma":[0.99749327,0.000066437984,0.00036815926,0.0019520336,0.000014724334,0.00006726608,0.000014186132,0.000007661801,0.000016258311],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993445,0.000073838186,0.00019399145,0.00016835635,0.000083721796,0.00013559013],"domain_scores_gemma":[0.999329,0.00015677743,0.00010935986,0.0001857247,0.00018909402,0.00003007549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019279127,0.00009532935,0.00024671477,0.000114003844,0.000023071527,0.000007559915,0.000102028775,0.000036864436,0.000023707162],"category_scores_gemma":[0.0000633119,0.00006648265,0.00003229435,0.00028248792,0.000084267056,0.0000027369717,0.000036792655,0.000038739665,7.956093e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017292603,0.0014915459,0.12850025,0.000020945516,0.0010138447,0.000008400026,0.0016908185,0.022829944,0.8315658,0.00017594712,0.0004114314,0.010561834],"study_design_scores_gemma":[0.0012381952,0.014153806,0.45059198,0.000014772974,0.00018697849,0.0000023331147,0.0017623205,0.00094658544,0.528851,0.00005330084,0.0019980907,0.00020064204],"about_ca_topic_score_codex":0.0001936393,"about_ca_topic_score_gemma":0.0018101636,"teacher_disagreement_score":0.32209173,"about_ca_system_score_codex":0.0000070767,"about_ca_system_score_gemma":0.00013115938,"threshold_uncertainty_score":0.2711084},"labels":[],"label_agreement":null},{"id":"W2051712211","doi":"10.1093/annonc/mdr052","title":"2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Seminoma; Positron emission tomography; Nuclear medicine; Radiology; Retrospective cohort study; Chemotherapy; Internal medicine","score_opus":0.08301514578194344,"score_gpt":0.36923653323102523,"score_spread":0.28622138744908177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051712211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953258,0.0011514437,0.000018788634,0.0010104182,0.00015872023,0.0014458708,0.000089310444,0.000021667342,0.0007779565],"genre_scores_gemma":[0.9975338,0.00021944378,0.0015338208,0.00033108055,0.00010941928,0.000074675445,0.00005198358,0.000020988185,0.00012477749],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881846,0.00012272067,0.00038904016,0.0002496035,0.00021283158,0.00020732923],"domain_scores_gemma":[0.99858123,0.00014866384,0.00042510757,0.0003599912,0.00037815043,0.000106841886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025365164,0.00015150222,0.0004377765,0.00010948979,0.000072232004,0.0000029743185,0.00012148435,0.00013130209,0.000066640205],"category_scores_gemma":[0.00032029764,0.0001012132,0.00037459444,0.00020311544,0.00012989533,0.000053447264,0.000038091654,0.000087952365,0.0000012883964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23378325,0.01923968,0.43096545,0.00046735286,0.0031001614,0.00012915574,0.003982483,0.0000015277718,0.22085877,0.001900721,0.017602349,0.06796911],"study_design_scores_gemma":[0.03107819,0.019255444,0.3938682,0.0002024864,0.0005334561,0.000047029247,0.00018946991,0.0000071046684,0.5511036,0.0028549726,0.0007366407,0.00012342108],"about_ca_topic_score_codex":0.00011448644,"about_ca_topic_score_gemma":0.000007061597,"teacher_disagreement_score":0.3302448,"about_ca_system_score_codex":0.00004371466,"about_ca_system_score_gemma":0.0002739595,"threshold_uncertainty_score":0.41273546},"labels":[],"label_agreement":null},{"id":"W2056274073","doi":"10.1093/annonc/mdt081.2","title":"Trastuzumab Beyond Progression for Metastatic HER2+ Breast Cancer (MBC): Survival Outcomes in a Canadian Population","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Cohort; Oncology; Population; Cancer; Hazard ratio; Breast cancer; Surgery; Confidence interval","score_opus":0.13781537271264574,"score_gpt":0.5099880635076068,"score_spread":0.37217269079496107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056274073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392728,0.00031644816,0.000010317582,0.056108885,0.00028682462,0.0019419363,0.00018543543,0.00001509924,0.0018622023],"genre_scores_gemma":[0.99667746,0.00009818201,0.00085501873,0.0010229979,0.00008676503,0.00076498865,0.00006435664,0.000028330818,0.0004018974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822956,0.00014571415,0.00043532668,0.00025008526,0.00029135268,0.0006479299],"domain_scores_gemma":[0.99869186,0.00022674733,0.00012230998,0.00020125299,0.00039117204,0.0003666859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070807216,0.00013710238,0.0006260101,0.00035900698,0.000044641794,0.000010169118,0.0001223644,0.00013330962,0.0008062524],"category_scores_gemma":[0.00022929032,0.000110830246,0.000096580625,0.00025091344,0.00008540083,0.00010830013,0.000023297947,0.00019065564,0.00001840646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022912378,0.000412165,0.60862046,0.0002526905,0.00011230183,0.000029522402,0.0003251796,0.000016036638,0.00046590628,0.00020667756,0.007292745,0.3820372],"study_design_scores_gemma":[0.0019369867,0.0016748897,0.9811994,0.00012510158,0.0000335499,0.000023602124,0.000200883,0.0004365274,0.00034954917,0.00081837206,0.013080142,0.000120990415],"about_ca_topic_score_codex":0.660821,"about_ca_topic_score_gemma":0.6807251,"teacher_disagreement_score":0.3819162,"about_ca_system_score_codex":0.00055061525,"about_ca_system_score_gemma":0.0017080464,"threshold_uncertainty_score":0.88278985},"labels":[],"label_agreement":null},{"id":"W2057634318","doi":"10.1093/annonc/mdt211","title":"Spin and bias: the tip of the iceberg","year":2013,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Selection bias; Scopus; Perspective (graphical); End point; Publication bias; Point (geometry); Clinical trial; MEDLINE; Internal medicine; Meta-analysis; Pathology; Law; Computer science","score_opus":0.8134681196420586,"score_gpt":0.622572782676002,"score_spread":0.19089533696605654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057634318","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024247814,0.00031115618,0.0005113199,0.9790701,0.0013593781,0.00094040757,0.00016562136,0.000015308817,0.015201913],"genre_scores_gemma":[0.00090698135,0.00065948436,0.14503822,0.8456531,0.003503851,0.00011506305,0.0000030647802,0.00008522109,0.004035006],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99482286,0.002978685,0.0012664292,0.00027637658,0.00035538644,0.0003002521],"domain_scores_gemma":[0.8838527,0.11352817,0.0014201015,0.00086078746,0.00030269005,0.000035526835],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003996783,0.00022191985,0.0012939721,0.00004894023,0.000045782042,0.000010062471,0.00079164247,0.0011056628,0.0005048346],"category_scores_gemma":[0.08948043,0.0001079567,0.00028875296,0.00013101354,0.0011993985,0.000018640767,0.0003695491,0.0013620434,0.000022251867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017786246,0.00006035,0.00003058434,0.0003002088,0.00019220727,0.00000778921,0.00007616791,6.7703006e-8,0.000019530107,0.013161103,0.961922,0.024212217],"study_design_scores_gemma":[0.00019512096,0.00036468348,0.00022798662,0.000101951424,0.0001389527,0.0000070415817,0.000012034923,0.0000042673078,0.00032424636,0.55280143,0.44574454,0.00007771565],"about_ca_topic_score_codex":0.00006198646,"about_ca_topic_score_gemma":0.000008894255,"teacher_disagreement_score":0.53964037,"about_ca_system_score_codex":0.000011131078,"about_ca_system_score_gemma":0.0001486863,"threshold_uncertainty_score":0.9181893},"labels":[],"label_agreement":null},{"id":"W2060465654","doi":"10.1093/annonc/mdt382","title":"A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Biomarker; Population; Normalization (sociology); Kinetics; Oncology; Computational biology; Bioinformatics; Biology","score_opus":0.27143280157762306,"score_gpt":0.4356279254394577,"score_spread":0.16419512386183466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060465654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029294126,0.99667305,0.000044129298,0.00041986688,0.00015592267,0.001154223,0.0002485424,0.0000020704176,0.0010092816],"genre_scores_gemma":[0.0006478468,0.9977903,0.0005434556,0.0002697988,0.00021670933,0.00031128144,0.00011738909,0.000037559606,0.00006566359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826676,0.00015497275,0.00083719013,0.00035968283,0.000095443924,0.0002859266],"domain_scores_gemma":[0.99827635,0.0003382833,0.00051232264,0.0005443706,0.00024868044,0.00007997769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002407646,0.0002807683,0.0013662521,0.000046109402,0.00003715954,0.0000069237535,0.00029827398,0.00030854272,0.000020551535],"category_scores_gemma":[0.0014182104,0.00018687556,0.00097380456,0.0001101035,0.0002512277,0.0000015059792,0.0001904432,0.00008611908,0.0000017236786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022321654,0.000446413,0.000007752957,0.0702689,0.00055300846,0.0000035073901,0.000008115427,0.0000026986934,0.00032195105,0.0007203686,0.002862625,0.92478234],"study_design_scores_gemma":[0.00022307738,0.0010390502,0.00001624574,0.0077752843,0.0008568327,0.00006170398,0.0000058684577,0.000021513335,0.0006545587,0.000055670647,0.98910123,0.00018894642],"about_ca_topic_score_codex":0.000009731611,"about_ca_topic_score_gemma":0.000004926043,"teacher_disagreement_score":0.9862386,"about_ca_system_score_codex":0.000047583762,"about_ca_system_score_gemma":0.0004973609,"threshold_uncertainty_score":0.76205647},"labels":[],"label_agreement":null},{"id":"W2061415759","doi":"10.1093/annonc/mdt459.53","title":"Phase III Study of Crizotinib vs. Chemotherapy in Advanced ALK+ NSCLC: Patient-Reported Symptoms and Quality of Life","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Crizotinib; Docetaxel; Internal medicine; Lung cancer; Quality of life (healthcare); Pemetrexed; Chemotherapy; ALK inhibitor; Phases of clinical research; Randomization; Performance status; Oncology; non-small cell lung cancer (NSCLC); Clinical trial; Cisplatin","score_opus":0.0706192058174058,"score_gpt":0.46268956407546463,"score_spread":0.3920703582580588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061415759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955098,0.00034014662,0.000005444833,0.0011975117,0.000054000597,0.0011150739,0.000010085952,0.000007790055,0.001760135],"genre_scores_gemma":[0.99886495,0.00014087032,0.00013930432,0.0006822319,0.000011094314,0.00008306907,0.000013088153,0.000009033802,0.000056330693],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987005,0.00008154988,0.0007727283,0.00017187165,0.00014049606,0.00013287154],"domain_scores_gemma":[0.99871165,0.0001216598,0.00053716404,0.00021313323,0.00033208137,0.00008430409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001659044,0.000095664334,0.00066526385,0.000109309425,0.000013322261,0.0000012109399,0.000038586695,0.0000662325,0.000107613174],"category_scores_gemma":[0.00013557162,0.000076959695,0.000048119975,0.00014383609,0.000096971235,0.00006625591,0.000017964567,0.000059213195,6.711972e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069953064,0.038630784,0.3472819,0.00022574737,0.0015618827,0.000017930102,0.020174937,0.000014627563,0.025517413,0.00013262143,0.0009251838,0.5585217],"study_design_scores_gemma":[0.095616885,0.053101264,0.82972175,0.00011342586,0.0001990849,0.0000056851313,0.0074460814,0.000030479687,0.011535833,0.00015936086,0.0019177594,0.0001524051],"about_ca_topic_score_codex":0.0020104803,"about_ca_topic_score_gemma":0.00012868924,"teacher_disagreement_score":0.5583693,"about_ca_system_score_codex":0.000020393281,"about_ca_system_score_gemma":0.00020153043,"threshold_uncertainty_score":0.31383252},"labels":[],"label_agreement":null},{"id":"W2064341535","doi":"10.1093/annonc/mdt202.33","title":"The Canadian Colorectal Cancer Consortium: the First Large-Scale Molecular Based Approach to Translational Cancer Care in Canada","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Terry Fox Research Institute; Jewish General Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Cancer; Translational research; Biobank; Oncology; Clinical trial; Biopsy; Internal medicine; Bioinformatics; Pathology","score_opus":0.028724484630604945,"score_gpt":0.31788264694052965,"score_spread":0.2891581623099247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064341535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8586689,0.0063602095,0.0000038771723,0.11462649,0.00020919678,0.001230556,0.0002459715,0.0000050101535,0.018649789],"genre_scores_gemma":[0.9890013,0.00018911908,0.000044836066,0.009295468,0.000041922944,0.0013317395,0.000021490192,0.000011245879,0.00006289613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998869,0.000051521372,0.00023620452,0.00019633085,0.00021942361,0.0004274962],"domain_scores_gemma":[0.9991565,0.00013834782,0.000060178958,0.00013551199,0.0003416542,0.0001678515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010788396,0.00013095183,0.0003019182,0.00005484036,0.00026887597,0.000009295988,0.0001299228,0.0000646688,0.000143112],"category_scores_gemma":[0.000025297695,0.00007736437,0.000065348846,0.00023069848,0.00011206954,0.000019271027,0.000017965307,0.00014707258,0.0000024705632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011251736,0.0003233023,0.8306447,0.00012329937,0.00069467723,0.0000744485,0.009843539,0.008146668,0.00012472931,0.0004855154,0.077609554,0.07080438],"study_design_scores_gemma":[0.0013468727,0.00049988326,0.7193197,0.000032370383,0.00005912308,0.0000037766804,0.0026293036,0.0010247678,0.00061022886,0.000022913633,0.27432486,0.00012622848],"about_ca_topic_score_codex":0.9949398,"about_ca_topic_score_gemma":0.99996156,"teacher_disagreement_score":0.1967153,"about_ca_system_score_codex":0.00094483315,"about_ca_system_score_gemma":0.008570264,"threshold_uncertainty_score":0.9970502},"labels":[],"label_agreement":null},{"id":"W2066669741","doi":"10.1093/annonc/mdt084.6","title":"Evaluation of Breast Cancer Test-Treatment Strategies Using Decision-Analytic Modeling – Preliminary Results for the 21-Gene Assay Recurrence Score","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Cost effectiveness; Personalized medicine; Cohort; Cost-effectiveness analysis; Test (biology); Quality-adjusted life year; Medical physics; Oncology; Internal medicine; Cancer; Risk analysis (engineering); Bioinformatics","score_opus":0.7347792538062464,"score_gpt":0.5536954516783067,"score_spread":0.18108380212793973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066669741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94145995,0.008614598,0.0140179,0.030330934,0.00060034945,0.0025766343,0.0015858106,0.000013077197,0.0008007451],"genre_scores_gemma":[0.9944587,0.00095018686,0.0033337632,0.0005602121,0.00019559916,0.00042955027,0.000024385305,0.000016819895,0.000030802883],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954195,0.00036972092,0.0032816443,0.0004272501,0.00018798771,0.00031389392],"domain_scores_gemma":[0.9898456,0.0054542543,0.0027326057,0.00050868286,0.0013769659,0.00008190816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024334084,0.00016670779,0.0008847392,0.00021844749,0.0001488483,0.00003265814,0.00027511205,0.00015961488,0.00014665289],"category_scores_gemma":[0.0062257587,0.00014927854,0.00016971023,0.00017599741,0.00010371575,0.0004262846,0.000042259526,0.000077257806,0.0000383939],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048855506,0.00089925324,0.008330008,0.00028798656,0.000774348,2.8353023e-7,0.003525442,0.8717498,0.0001361481,0.0046867356,0.009403361,0.09971805],"study_design_scores_gemma":[0.0011964366,0.0009362804,0.013676146,0.00013368395,0.00010744367,0.000005644936,0.0012439635,0.950029,0.00006113656,0.03201424,0.00044561212,0.0001504219],"about_ca_topic_score_codex":0.0060063284,"about_ca_topic_score_gemma":0.00053194433,"teacher_disagreement_score":0.09956763,"about_ca_system_score_codex":0.0005300731,"about_ca_system_score_gemma":0.0013947397,"threshold_uncertainty_score":0.90798116},"labels":[],"label_agreement":null},{"id":"W2066875072","doi":"10.1093/annonc/mdu336.49","title":"Prosper: a Phase 3 Study of Enzalutamide in Non-Metastatic (M0) Castration-Resistant Prostate Cancer (Crpc) Patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Placebo; Oncology; Androgen receptor; Cancer; Pathology; Alternative medicine","score_opus":0.08478641429722598,"score_gpt":0.45563239507221664,"score_spread":0.37084598077499065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066875072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958962,0.00023908366,0.0000017794447,0.0007535061,0.00007529141,0.0019652494,0.00005993683,0.000007364664,0.0010015487],"genre_scores_gemma":[0.99881333,0.0002460393,0.000092960974,0.00014885238,0.000028444863,0.00029950772,0.000038208087,0.000016655451,0.0003159961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832284,0.00015900006,0.00058878266,0.00026158747,0.00033683368,0.00033098],"domain_scores_gemma":[0.9987935,0.00012528681,0.0002578327,0.00023214538,0.00047727258,0.00011397371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045258825,0.0001449981,0.0006127378,0.00023917435,0.000031899133,0.0000044661015,0.00009026824,0.00005563086,0.00006878314],"category_scores_gemma":[0.00014162349,0.00010945421,0.000059217244,0.00031434023,0.00013130717,0.00007540556,0.000038902785,0.0001523754,0.00000468698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014801529,0.03349618,0.7335884,0.00079494563,0.00054067705,0.00018644135,0.012253328,0.00008859684,0.02680438,0.00005220923,0.0012922647,0.17610101],"study_design_scores_gemma":[0.07237364,0.10474326,0.77958727,0.00043877718,0.00024066262,0.000005200865,0.0021955192,0.00044849396,0.036250982,0.00026886206,0.0031703757,0.00027693235],"about_ca_topic_score_codex":0.0013109115,"about_ca_topic_score_gemma":0.0012652082,"teacher_disagreement_score":0.17582409,"about_ca_system_score_codex":0.00009268367,"about_ca_system_score_gemma":0.00041866128,"threshold_uncertainty_score":0.4463413},"labels":[],"label_agreement":null},{"id":"W2070763870","doi":"10.1093/annonc/mdv048.21","title":"Role of Treatment in International Differences in One-Year Mortality From Early Stage Non-Small Cell Lung Cancer: a Tentative Answer From the International Cancer Benchmarking Partnership Study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Benchmarking; Lung cancer; Stage (stratigraphy); Oncology; General partnership; Cancer; Internal medicine","score_opus":0.15202475012584318,"score_gpt":0.4490947623995554,"score_spread":0.2970700122737122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070763870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925291,0.0006640057,0.0000042605316,0.0012899657,0.00029172108,0.0006980715,0.00051961304,0.0000045639667,0.0039987257],"genre_scores_gemma":[0.9983644,0.0004990534,0.00012755998,0.00019722301,0.0001770853,0.0003456081,0.000109694025,0.000008569107,0.00017078902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988201,0.00011672789,0.0003939029,0.00026218352,0.00025364343,0.00015343312],"domain_scores_gemma":[0.9990876,0.00021775183,0.00026484468,0.00015389398,0.0002095285,0.00006643665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001798847,0.00013071799,0.00039956585,0.000100069745,0.000015783378,0.000010007609,0.00018291743,0.000063828025,0.00029209795],"category_scores_gemma":[0.000027363425,0.00009174931,0.00006292001,0.00011338158,0.000069915426,0.00007987038,0.00005328386,0.000110749264,0.0000011143577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048806285,0.0019924536,0.9476661,0.0000041774033,0.00096846075,0.000017054841,0.04390903,0.00010860761,0.00034984463,0.00001860294,0.00009984597,0.004377773],"study_design_scores_gemma":[0.0050912085,0.00137126,0.97380894,0.00009913366,0.00020790123,9.0297114e-8,0.01711453,0.0004935541,0.0011394438,0.00015852774,0.00044376444,0.000071665854],"about_ca_topic_score_codex":0.29715413,"about_ca_topic_score_gemma":0.11761516,"teacher_disagreement_score":0.17953897,"about_ca_system_score_codex":0.0005336241,"about_ca_system_score_gemma":0.0008467442,"threshold_uncertainty_score":0.8984861},"labels":[],"label_agreement":null},{"id":"W2082415536","doi":"10.1093/annonc/mdt312","title":"Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Genetic counseling; Medicine; Worry; Genetic testing; Recall; Family medicine; Clinical psychology; Internal medicine; Psychiatry; Psychology; Anxiety; Genetics","score_opus":0.04425346226296378,"score_gpt":0.36991073885133996,"score_spread":0.3256572765883762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082415536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975992,0.00034861037,0.00032958676,0.00024156464,0.00006297518,0.00022162791,0.0000151861095,0.000003099394,0.0011781811],"genre_scores_gemma":[0.9970729,0.00075441925,0.0018298564,0.00012778294,0.000062142906,0.000034253004,0.000016184835,0.000009960059,0.000092536146],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99914473,0.000139986,0.0002823349,0.00021571518,0.00006964838,0.00014759385],"domain_scores_gemma":[0.99919254,0.000081030834,0.00023995563,0.00017595914,0.00027427138,0.000036252077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036819352,0.00009168501,0.00017781416,0.00007046934,0.000024325322,0.000004759932,0.00008828681,0.00014561105,0.00006943471],"category_scores_gemma":[0.00028295227,0.00008516169,0.00004359378,0.00012557559,0.00011030394,0.0000063624457,0.000027731578,0.00008140803,0.0000050599933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025408238,0.00047760992,0.07182647,0.00004752931,0.00010912664,0.000001440778,0.0005714123,0.0048790774,0.68533313,0.00004600985,0.0065068523,0.22994724],"study_design_scores_gemma":[0.0011104731,0.005649423,0.9473913,0.000080840146,0.000025681378,0.000013515076,0.0003006762,0.0011117466,0.038381092,0.002490502,0.0032363997,0.00020840623],"about_ca_topic_score_codex":0.0003580566,"about_ca_topic_score_gemma":0.00008964578,"teacher_disagreement_score":0.87556475,"about_ca_system_score_codex":0.000029611301,"about_ca_system_score_gemma":0.00025599182,"threshold_uncertainty_score":0.3472793},"labels":[],"label_agreement":null},{"id":"W2083404329","doi":"10.1093/annonc/mdq773","title":"A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; GiST; Sunitinib; Imatinib; Internal medicine; Stromal tumor; Adjuvant therapy; Imatinib mesylate; Oncology; Tyrosine-kinase inhibitor; Targeted therapy; Demographics; Stromal cell; Cancer; Demography","score_opus":0.23203998356276784,"score_gpt":0.43573434927332305,"score_spread":0.20369436571055521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083404329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965274,0.00012876405,0.0000015756782,0.0014224674,0.0000053909316,0.00027167422,0.00003979015,0.0000058028822,0.0015971544],"genre_scores_gemma":[0.9956631,0.00010532504,0.004028554,0.00013095952,0.000020417556,0.000011361588,0.00001268193,0.000007211238,0.000020360008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986779,0.00039536075,0.00030192442,0.00016009409,0.00019767825,0.00026704214],"domain_scores_gemma":[0.9974876,0.0011797727,0.0007385237,0.0001704459,0.0002491552,0.00017449055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064987777,0.0001282164,0.0004534738,0.00013646207,0.000036629135,0.0000036655113,0.00010810192,0.000046644716,0.000043510183],"category_scores_gemma":[0.0042653484,0.0001027525,0.000024079745,0.000096090334,0.00047288512,0.00015686132,0.00015227096,0.00061130826,0.0000023249856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015256567,0.0011283823,0.9924773,0.0001681192,0.00005648859,0.00014952573,0.0005036364,1.9402275e-8,0.0017428943,0.000046382604,0.000035304154,0.0021662994],"study_design_scores_gemma":[0.0018942644,0.02622288,0.96819407,0.0004997932,0.00008877156,0.00063580024,0.0007353852,0.000004676142,0.0014521952,0.00018194014,0.000035785648,0.000054432527],"about_ca_topic_score_codex":0.0038231756,"about_ca_topic_score_gemma":0.00035964677,"teacher_disagreement_score":0.025094498,"about_ca_system_score_codex":0.000027812157,"about_ca_system_score_gemma":0.00017569738,"threshold_uncertainty_score":0.5779523},"labels":[],"label_agreement":null},{"id":"W2088911092","doi":"10.1093/annonc/mdv097.3","title":"Comparison of Human Nucleoside Transporter Interactions with BCR-ABL Kinase Inhibitors","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dasatinib; Bosutinib; Nilotinib; Imatinib; Pharmacology; Medicine; Cladribine; Nucleoside transporter; Imatinib mesylate; Cancer research; Myeloid leukemia; Chemistry; Biochemistry; Internal medicine; Transporter","score_opus":0.1699478740717183,"score_gpt":0.4530179599606671,"score_spread":0.28307008588894883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088911092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749472,0.00019606446,0.000020741509,0.0020369457,0.00012384333,0.00024844776,0.000010910121,0.000024229459,0.022391587],"genre_scores_gemma":[0.99841666,0.000013544443,0.0007112226,0.00030454504,0.000087538465,0.000015225801,0.00004738399,0.000019196237,0.0003846934],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988865,0.000050121685,0.00048266086,0.00017884902,0.00020238949,0.00019946361],"domain_scores_gemma":[0.99890065,0.00006851649,0.0002892949,0.00027263942,0.0002873748,0.00018152641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015170335,0.00013121353,0.00062372786,0.0001415564,0.000024595995,0.0000017385793,0.00007257903,0.00009998665,0.00023857581],"category_scores_gemma":[0.00003430291,0.00010395197,0.00009379391,0.00013863931,0.00019782918,0.0000741808,0.00001647229,0.00018561407,0.00002007482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048432127,0.012095388,0.7023426,0.00041818674,0.0016860346,0.00064707553,0.016117765,0.00014944386,0.070030995,0.0011086093,0.11139279,0.07916785],"study_design_scores_gemma":[0.025769494,0.051520534,0.14788674,0.00089314894,0.0010948575,0.0003236759,0.005769947,0.00018209158,0.5206642,0.00045925126,0.24494638,0.0004896576],"about_ca_topic_score_codex":0.0005443195,"about_ca_topic_score_gemma":0.000671193,"teacher_disagreement_score":0.55445594,"about_ca_system_score_codex":0.00018634502,"about_ca_system_score_gemma":0.0004843499,"threshold_uncertainty_score":0.42390382},"labels":[],"label_agreement":null},{"id":"W2090405189","doi":"10.1093/annonc/mdq726","title":"Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"Pfizer Foundation; Ministerul Cercetării, Inovării şi Digitalizării","keywords":"Medicine; Minimal clinically important difference; Quality of life (healthcare); Physical therapy; Clinical trial; Cancer; Cognition; Clinical psychology; Randomized controlled trial; Psychiatry; Internal medicine","score_opus":0.17280766439273162,"score_gpt":0.41988452489372985,"score_spread":0.24707686050099822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090405189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873484,0.001242165,0.00002017675,0.006700192,0.0005354159,0.0004902887,0.000056339977,0.000012795229,0.0035942227],"genre_scores_gemma":[0.9935292,0.0012684606,0.0001078122,0.0045606387,0.00016903252,0.00014284633,0.000010017243,0.000015339714,0.0001966468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986049,0.000109934284,0.0005320977,0.00028344826,0.00016465127,0.0003049905],"domain_scores_gemma":[0.9981841,0.0010156448,0.00023537691,0.00019059084,0.00026334685,0.000110926114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006155784,0.0001456142,0.00053251704,0.000077955876,0.000049481456,0.0000054296147,0.00016326495,0.00019120751,0.00012771791],"category_scores_gemma":[0.0004603524,0.00009797983,0.00012290866,0.00011305434,0.00034078347,0.000050055936,0.00007358552,0.0001825911,0.0000019659328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020217174,0.00043682742,0.84040356,0.00009014214,0.000107551554,0.000007682881,0.004740586,1.5996854e-7,0.000067812165,0.00043348075,0.0045701647,0.14712031],"study_design_scores_gemma":[0.0020370418,0.005334678,0.9733806,0.00010015555,0.0000725171,0.0000030592225,0.0011478722,0.000032415144,0.00031774328,0.0009036448,0.016546873,0.00012340056],"about_ca_topic_score_codex":0.0023194873,"about_ca_topic_score_gemma":0.025327893,"teacher_disagreement_score":0.14699692,"about_ca_system_score_codex":0.000022847402,"about_ca_system_score_gemma":0.000188764,"threshold_uncertainty_score":0.99245733},"labels":[],"label_agreement":null},{"id":"W2091569809","doi":"10.1093/annonc/mdt082.1","title":"Genomic Analysis of Drug Resistant Triple Negative Breast Cancers: A Translational Biopsy Study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Université de Montréal; Royal Victoria Hospital; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Medicine; Chemotherapy; Breast cancer; Comparative genomic hybridization; Biopsy; Cancer research; PTEN; Somatic evolution in cancer; Gene expression profiling; Triple-negative breast cancer; Oncology; Pathology; Cancer; Internal medicine; Gene; Gene expression; Chromosome; Biology; Genetics","score_opus":0.026081551458349672,"score_gpt":0.3218725377677426,"score_spread":0.29579098630939293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091569809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966395,0.0006276738,0.00008211943,0.0006226495,0.00007829932,0.00033875604,0.00046369337,0.0000024372646,0.0011449035],"genre_scores_gemma":[0.998786,0.00030015243,0.00037055326,0.00020677621,0.00007501146,0.000046460133,0.00010330637,0.000010512992,0.00010127041],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989572,0.0000884258,0.00041262177,0.0002599057,0.000103517326,0.00017829279],"domain_scores_gemma":[0.9989628,0.000082595754,0.00026480123,0.00026254304,0.0003582247,0.00006899549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021385308,0.000116255134,0.00039382282,0.00016278056,0.000032655724,0.000006435613,0.00017570872,0.000087043,0.00016944822],"category_scores_gemma":[0.000050970528,0.00011359411,0.00019568678,0.0003021084,0.00012965155,0.000003845741,0.00005255335,0.000050339106,0.0000030629365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027850321,0.002680852,0.12831241,0.000054834767,0.010461256,0.00001322444,0.0042000455,0.006728132,0.79451203,0.0006229004,0.018439332,0.031189926],"study_design_scores_gemma":[0.0030044306,0.0036957317,0.94444853,0.000010417137,0.00097049435,0.000007725389,0.0025234357,0.00060714706,0.03630646,0.0006597828,0.007393491,0.00037234763],"about_ca_topic_score_codex":0.004266725,"about_ca_topic_score_gemma":0.0038294792,"teacher_disagreement_score":0.8161361,"about_ca_system_score_codex":0.000023041053,"about_ca_system_score_gemma":0.0003898422,"threshold_uncertainty_score":0.64500403},"labels":[],"label_agreement":null},{"id":"W2095838797","doi":"10.1093/annonc/mds075","title":"mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Exemestane; Medicine; Everolimus; Aromatase; Breast cancer; Oncology; PI3K/AKT/mTOR pathway; Guideline; Internal medicine; Hormone receptor; Cancer; Pharmacology; Pathology; Signal transduction","score_opus":0.07041783749388918,"score_gpt":0.39008392546317244,"score_spread":0.31966608796928325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095838797","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010289685,0.9946509,0.0000010591922,0.002413569,0.00047581672,0.00059705495,0.00022418318,0.000003066422,0.0006054073],"genre_scores_gemma":[0.004625527,0.9936817,0.000051712657,0.00019242067,0.0010529913,0.00027094627,0.000042085478,0.000022231809,0.00006037051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984246,0.00041337046,0.00045921886,0.0003026497,0.00014517011,0.00025502333],"domain_scores_gemma":[0.9987721,0.00015123168,0.0005076898,0.00038782452,0.00013883336,0.000042338197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078133243,0.00024295469,0.000628565,0.000060420203,0.00006178088,0.0000077519935,0.00041791776,0.0003763748,0.000016211789],"category_scores_gemma":[0.000013587976,0.00014537523,0.00019993965,0.00026430868,0.00027690703,0.0000068893073,0.00017730087,0.00026893427,0.000002147487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058709924,0.00013436764,0.00004797807,0.0011682005,0.00047609519,0.0000029334,0.00020214982,0.0000013630278,0.0002113445,0.00008035848,0.009021581,0.9885949],"study_design_scores_gemma":[0.000111645044,0.00042619547,0.00064478186,0.0015593839,0.00038896324,0.000044498414,0.000121667086,1.3256432e-7,0.00016651674,0.000008072401,0.9963824,0.00014574754],"about_ca_topic_score_codex":0.00013978106,"about_ca_topic_score_gemma":0.00007140324,"teacher_disagreement_score":0.98844916,"about_ca_system_score_codex":0.000042212945,"about_ca_system_score_gemma":0.00019149433,"threshold_uncertainty_score":0.59282297},"labels":[],"label_agreement":null},{"id":"W2095861620","doi":"10.1093/annonc/mdt182","title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1274,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Roche","keywords":"Medicine; Epirubicin; Pertuzumab; Trastuzumab; Breast cancer; Internal medicine; Anthracycline; Docetaxel; Neoadjuvant therapy; Chemotherapy; Oncology; Tolerability; Ejection fraction; Carboplatin; Surgery; Adverse effect; Cancer; Heart failure; Cisplatin","score_opus":0.013261540795153877,"score_gpt":0.31523711260238363,"score_spread":0.3019755718072297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095861620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98749673,0.00026888237,0.00011377511,0.0064923465,0.000064875836,0.0051582204,0.00012881853,0.000030320234,0.00024601512],"genre_scores_gemma":[0.997848,0.0007445812,0.0002600014,0.0006133512,0.000059181286,0.00032302996,0.00007392509,0.00004985813,0.00002810598],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972645,0.00048977236,0.00078942836,0.0005321964,0.0004899935,0.00043411792],"domain_scores_gemma":[0.99793667,0.00037433105,0.00049044885,0.00035612826,0.00068457524,0.0001578633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009309876,0.0003592433,0.0020654453,0.00032721405,0.00012034372,0.000020065121,0.00010449505,0.00021521818,0.000039530772],"category_scores_gemma":[0.00009636182,0.00027347705,0.00012725759,0.00038900244,0.00042472623,0.00036130386,0.00004685312,0.0004133836,5.0350195e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6153925,0.0102020595,0.14862658,0.00008786964,0.0014542805,0.00010908205,0.036741503,0.000103472696,0.0026106492,0.000049585888,0.00012424764,0.18449815],"study_design_scores_gemma":[0.53881377,0.0351124,0.41720402,0.00050721865,0.00016816682,0.000026032252,0.003193611,0.000283164,0.004284387,0.00006870154,0.000044087363,0.00029447218],"about_ca_topic_score_codex":0.0034562794,"about_ca_topic_score_gemma":0.00061532506,"teacher_disagreement_score":0.26857743,"about_ca_system_score_codex":0.000543995,"about_ca_system_score_gemma":0.00052078377,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W2095891194","doi":"10.1093/annonc/mdq418","title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Roche","keywords":"Rituximab; Medicine; CHOP; Internal medicine; Diffuse large B-cell lymphoma; Lymphoma; International Prognostic Index; Chemotherapy; Oncology; Surgery; Gastroenterology","score_opus":0.037411170413930356,"score_gpt":0.33787127636633907,"score_spread":0.3004601059524087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095891194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878707,0.000034762088,0.0000034546395,0.0028382186,0.00028738513,0.0016110009,0.000041393367,0.000023896395,0.0072891833],"genre_scores_gemma":[0.9968753,0.00008077255,0.0007379634,0.0011523793,0.00023490479,0.00015237073,0.000033389417,0.00003083772,0.00070208247],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982591,0.00011745181,0.00052057864,0.00035708718,0.0005055399,0.0002402012],"domain_scores_gemma":[0.9982547,0.00025576973,0.0005401392,0.00049007905,0.00035195675,0.00010731644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038834426,0.00024355228,0.00076710817,0.000107138796,0.000050439852,0.000008913683,0.00025533093,0.00013945288,0.00011416784],"category_scores_gemma":[0.000050975163,0.0001140831,0.0001159049,0.0002140793,0.0003276204,0.00006358328,0.000047441372,0.0001337517,0.000004560705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55304563,0.06254861,0.2820769,0.000042984928,0.0014090277,0.0002731215,0.0015828386,0.0000010859586,0.0025774138,0.000025654417,0.0022842716,0.09413248],"study_design_scores_gemma":[0.50530934,0.054819703,0.41562325,0.000093526156,0.0003329,0.00024251579,0.0003015557,0.000019442437,0.009112107,0.0000070305846,0.013975556,0.00016303427],"about_ca_topic_score_codex":0.0004789832,"about_ca_topic_score_gemma":0.0008677324,"teacher_disagreement_score":0.13354637,"about_ca_system_score_codex":0.00007728506,"about_ca_system_score_gemma":0.0006184458,"threshold_uncertainty_score":0.46521738},"labels":[],"label_agreement":null},{"id":"W2096005250","doi":"10.1093/annonc/mdu287","title":"Pancreatic cancer risk after treatment of Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"National Cancer Institute; Kræftens Bekæmpelse; University of Texas MD Anderson Cancer Center; National Institute of Environmental Health Sciences; Suomen Syöpärekisteri; University of Iowa; National Institute of Allergy and Infectious Diseases; Karolinska Institutet","keywords":"Medicine; Pancreatic cancer; Internal medicine; Chemotherapy; Gastroenterology; Odds ratio; Radiation therapy; Cyclophosphamide; Cancer; Oncology; Procarbazine; Pancreatic disease; Surgery; Vincristine; Pancreas","score_opus":0.08003235757065993,"score_gpt":0.4301087726005485,"score_spread":0.3500764150298885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096005250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97375435,0.0020717,0.000082186474,0.0020886143,0.00008243685,0.00034928173,0.00003850396,0.000013209929,0.021519728],"genre_scores_gemma":[0.98818743,0.008344067,0.0010717615,0.0004524875,0.00017127465,0.00018414635,0.000008226636,0.000015395686,0.0015651926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985164,0.00030017082,0.00044169617,0.00021323864,0.0001968965,0.00033161446],"domain_scores_gemma":[0.99831855,0.00063712295,0.00025676508,0.00035563417,0.00026989798,0.00016202318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043980536,0.00014345188,0.0010970044,0.00014985605,0.00002920524,0.0000014560195,0.00007189266,0.00020201321,0.00080907036],"category_scores_gemma":[0.0002777988,0.000103559396,0.00017503763,0.00014192781,0.00034842436,0.000025214038,0.000027197084,0.00005836071,0.000040687348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019560093,0.0013767586,0.688061,0.000094022645,0.0005465128,0.00003537062,0.0005867824,0.0000015624473,0.00066754344,0.00017311383,0.0014983581,0.305003],"study_design_scores_gemma":[0.0054166517,0.021424847,0.880358,0.00009457022,0.0006958909,0.000037226342,0.000100852885,0.00041389075,0.006558323,0.00069502386,0.08409838,0.000106339074],"about_ca_topic_score_codex":0.0017850142,"about_ca_topic_score_gemma":0.0002212292,"teacher_disagreement_score":0.30489665,"about_ca_system_score_codex":0.000100031735,"about_ca_system_score_gemma":0.0005279916,"threshold_uncertainty_score":0.8858753},"labels":[],"label_agreement":null},{"id":"W2096047333","doi":"10.1093/annonc/mdp432","title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; Vincristine; Internal medicine; CHOP; Diffuse large B-cell lymphoma; Hazard ratio; Population; Cyclophosphamide; Prednisone; Oncology; Lymphoma; Chemotherapy; Gastroenterology; Surgery; Confidence interval","score_opus":0.014081428593435396,"score_gpt":0.2987387082526246,"score_spread":0.2846572796591892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096047333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804574,0.00014877968,0.000006467907,0.00042100583,0.000028344904,0.0009939382,0.0002824557,0.0000044417557,0.0000688139],"genre_scores_gemma":[0.9995516,0.00016800383,0.000058540205,0.00015222684,0.000013331638,0.000026050046,0.00001685894,0.0000085091415,0.0000048884913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991477,0.000073700125,0.00028955485,0.00014120138,0.00013692136,0.00021088301],"domain_scores_gemma":[0.9990054,0.00022505289,0.00032553228,0.00023365347,0.00014547289,0.00006489846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014482826,0.000120447185,0.00043698627,0.00006085157,0.00003588621,0.0000024260173,0.00008112747,0.0000763481,0.000004794203],"category_scores_gemma":[0.00007876859,0.00005705603,0.00012823698,0.00014516289,0.000058659836,0.00003508631,0.000016952943,0.00003780775,2.51044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026028713,0.015399923,0.9483071,0.000055718996,0.00014176467,0.0000032323119,0.0017674163,0.000016011341,0.0001093106,0.000058148114,0.00093706726,0.030601425],"study_design_scores_gemma":[0.022251362,0.008376587,0.96559,0.00014070865,0.000076576755,0.0000033996089,0.0002152507,0.000038019647,0.0031420258,0.0000244109,0.000093386414,0.00004828474],"about_ca_topic_score_codex":0.0008520551,"about_ca_topic_score_gemma":0.00011147081,"teacher_disagreement_score":0.03055314,"about_ca_system_score_codex":0.00014405457,"about_ca_system_score_gemma":0.0001261697,"threshold_uncertainty_score":0.23266774},"labels":[],"label_agreement":null},{"id":"W2096262742","doi":"10.1093/annonc/mds527","title":"Early development of the metabolic syndrome after chemotherapy for testicular cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"KWF Kankerbestrijding","keywords":"Medicine; Metabolic syndrome; Internal medicine; Odds ratio; Overweight; Chemotherapy; Testicular cancer; Confidence interval; Gastroenterology; Body mass index; Obesity","score_opus":0.07706447644904496,"score_gpt":0.3960272651008577,"score_spread":0.3189627886518127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096262742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925709,0.004645403,0.00006087089,0.0019349513,0.00023519043,0.00033136088,0.000014976357,0.000004529691,0.00020183354],"genre_scores_gemma":[0.9967455,0.00027323866,0.0010548052,0.0015028734,0.0000835187,0.00012774351,0.0000011967454,0.0000116980045,0.00019938499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938315,0.000015064566,0.00022274989,0.00007540821,0.00010239657,0.00020125647],"domain_scores_gemma":[0.9994982,0.00004656238,0.0001255839,0.00014220696,0.00012413753,0.000063350424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018507395,0.00007315155,0.00033330897,0.000036565303,0.000018743249,8.803257e-7,0.00006178046,0.000073042116,0.00016415282],"category_scores_gemma":[0.00003029914,0.00004522336,0.00011021729,0.00008579381,0.00007373043,0.000029045072,0.00001905564,0.00005380677,0.000002172033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096442946,0.00094145804,0.6463417,0.000200522,0.0008304369,0.000003366767,0.0066931313,0.0000024824878,0.012578024,0.00028440123,0.003140834,0.32801923],"study_design_scores_gemma":[0.00060710567,0.00024008068,0.69895345,0.0000289829,0.00005257473,0.0000080398395,0.000020069156,9.549176e-7,0.028830057,0.000023446251,0.2711972,0.000038066253],"about_ca_topic_score_codex":0.00014147701,"about_ca_topic_score_gemma":0.000030480081,"teacher_disagreement_score":0.32798114,"about_ca_system_score_codex":0.000021209682,"about_ca_system_score_gemma":0.00026750634,"threshold_uncertainty_score":0.18441552},"labels":[],"label_agreement":null},{"id":"W2096424270","doi":"10.1093/annonc/mdh130","title":"Glycemic index, glycemic load and risk of gastric cancer","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Cancer; Odds ratio; Glycemic index; Quartile; Internal medicine; Glycemic load; Confidence interval; Body mass index; Glycemic; Insulin; Gastroenterology; Endocrinology; Oncology","score_opus":0.023390583821348728,"score_gpt":0.3229544524529805,"score_spread":0.29956386863163176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096424270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8181892,0.1805524,0.00009099626,0.000074551084,0.00015504779,0.00008755148,0.00006450111,0.0000035583828,0.0007822031],"genre_scores_gemma":[0.74575883,0.2535159,0.0001212641,0.00039089526,0.00014331444,0.000016159402,0.000009327387,0.000010662862,0.000033639895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990253,0.00005381354,0.00028664505,0.0002573971,0.00011855587,0.00025830147],"domain_scores_gemma":[0.9991551,0.000017764696,0.0002846289,0.00023579155,0.00022284455,0.000083862025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016598188,0.00013164312,0.000330869,0.000056825724,0.00002726394,0.0000027110952,0.0001519426,0.00023103935,0.000044200166],"category_scores_gemma":[0.00009374959,0.00012366977,0.00008972344,0.00011388734,0.00022614145,0.000004206478,0.00008064151,0.000107500106,0.0000023009684],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048930477,0.00040094784,0.02593381,0.00013864873,0.000640072,0.000005828213,0.00033630218,0.00084742147,0.17988898,0.00026677942,0.0044147507,0.7822334],"study_design_scores_gemma":[0.008198247,0.0058069476,0.0122814225,0.0000600555,0.00018973021,0.00002652249,0.00013897833,0.000013044299,0.43242204,0.0022255282,0.53825533,0.0003821561],"about_ca_topic_score_codex":0.0007548842,"about_ca_topic_score_gemma":0.0003953302,"teacher_disagreement_score":0.78185123,"about_ca_system_score_codex":0.000019286555,"about_ca_system_score_gemma":0.0005471788,"threshold_uncertainty_score":0.50431067},"labels":[],"label_agreement":null},{"id":"W2096764404","doi":"10.1093/annonc/mdq626","title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":393,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Medicine; Lenalidomide; Refractory (planetary science); Lymphoma; Aggressive lymphoma; Oncology; Internal medicine; Multiple myeloma; Rituximab","score_opus":0.17223423508747657,"score_gpt":0.42186340011588325,"score_spread":0.24962916502840668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096764404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886269,0.00017171474,0.000047564237,0.00068496796,0.0008510967,0.0009578976,0.000111682944,0.000016166952,0.008532036],"genre_scores_gemma":[0.9951552,0.0004791241,0.002576718,0.00074720994,0.0002980969,0.00020148125,0.00010672358,0.000023568766,0.0004118621],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984919,0.00008126237,0.0006657912,0.0002989002,0.00021811604,0.00024404099],"domain_scores_gemma":[0.9977791,0.00029303876,0.000936819,0.00035281046,0.00047331103,0.00016495895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032530396,0.00017841655,0.0006626317,0.00017769323,0.000048659615,0.0000033850731,0.00018792688,0.00020150292,0.0003623164],"category_scores_gemma":[0.00030303805,0.00013145093,0.00027035223,0.00007163384,0.00013914576,0.00012027863,0.000050419283,0.00004133928,0.0000073224755],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41119823,0.11884099,0.000772447,0.000103924256,0.0009780686,0.00056305726,0.0028574532,0.0000013197572,0.03162555,0.00025887223,0.012600824,0.42019928],"study_design_scores_gemma":[0.3575714,0.23499104,0.0025678682,0.00016223213,0.0003789019,0.00006362687,0.0002732817,0.00005707345,0.3319942,0.00017918178,0.07158569,0.00017551082],"about_ca_topic_score_codex":0.00013599418,"about_ca_topic_score_gemma":0.000024814186,"teacher_disagreement_score":0.42002377,"about_ca_system_score_codex":0.0001468328,"about_ca_system_score_gemma":0.0005403058,"threshold_uncertainty_score":0.5360413},"labels":[],"label_agreement":null},{"id":"W2097086646","doi":"10.1093/annonc/mdp552","title":"Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Randomized controlled trial; Clinical trial; Internal medicine; Adjuvant; Absolute risk reduction; Clinical endpoint; Oncology; Metastatic breast cancer; Cancer; Surgery; Confidence interval","score_opus":0.7966786870764,"score_gpt":0.7264287769357396,"score_spread":0.0702499101406604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097086646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8725109,0.0028546718,0.000021604334,0.12296591,0.00015862168,0.00076476764,0.000098272736,0.0000068378654,0.00061838754],"genre_scores_gemma":[0.9664992,0.028906405,0.00035223138,0.0037072776,0.00038433308,0.000054136726,0.0000064592873,0.000009074888,0.000080852784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962423,0.0006033621,0.0019123163,0.00029077593,0.0006455239,0.00030576033],"domain_scores_gemma":[0.9658424,0.032550998,0.0004551939,0.0001750676,0.00069972384,0.00027661258],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.034417495,0.000102746446,0.0015588392,0.00013349688,0.000020991885,0.0000030934157,0.00020433508,0.0009600532,0.0002770964],"category_scores_gemma":[0.03944707,0.00007727644,0.00022849925,0.00014599305,0.00074015144,0.000032578235,0.00006570397,0.00090771524,8.312513e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015081598,0.0026520097,0.004786618,0.00011657292,0.00020542332,0.000020881966,0.00038066044,0.000001129411,0.0008604391,0.010709057,0.002198747,0.9629869],"study_design_scores_gemma":[0.11795175,0.091054566,0.68252,0.0021871973,0.00031110627,0.00015255548,0.00063635176,0.0012175259,0.007355356,0.07710659,0.019105764,0.00040122966],"about_ca_topic_score_codex":0.00015311026,"about_ca_topic_score_gemma":0.0010183546,"teacher_disagreement_score":0.9625856,"about_ca_system_score_codex":0.000018423902,"about_ca_system_score_gemma":0.0014607697,"threshold_uncertainty_score":0.9942704},"labels":[],"label_agreement":null},{"id":"W2097111905","doi":"10.1093/annonc/mdu438.2","title":"Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Trastuzumab; Hazard ratio; Adjuvant; Oncology; Clinical endpoint; Breast cancer; Surgery; Cancer; Clinical trial; Confidence interval","score_opus":0.1481050724017683,"score_gpt":0.4505014088418088,"score_spread":0.3023963364400405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097111905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95865476,0.0011680132,0.0000018355573,0.035066653,0.00022397359,0.0021095853,0.00075570797,0.0000048314214,0.0020146207],"genre_scores_gemma":[0.99623,0.002152321,0.000013268309,0.0007122364,0.00043499738,0.00028613684,0.000026519163,0.000018528128,0.00012599856],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959451,0.0016750251,0.00084855413,0.00036561504,0.00073041196,0.00043526932],"domain_scores_gemma":[0.9965192,0.0017378085,0.00042532073,0.00089928624,0.00029447075,0.00012390915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00249781,0.00021857012,0.00092231744,0.00010377901,0.00005548109,0.000008632347,0.00053188857,0.00014177639,0.000033846347],"category_scores_gemma":[0.00062758365,0.00011140251,0.00016999777,0.00042367596,0.00068652123,0.000046475685,0.00010019518,0.00029573843,0.0000013783604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44041944,0.021968009,0.05110054,0.00036744447,0.00061256124,0.00028857746,0.046404835,0.00004895809,0.0036511174,0.0007248222,0.009448688,0.42496502],"study_design_scores_gemma":[0.2511022,0.029993506,0.6975762,0.00073030696,0.0002560871,0.00003644375,0.0033803978,0.00013033072,0.0054779523,0.0008494824,0.010226102,0.00024093121],"about_ca_topic_score_codex":0.0125769405,"about_ca_topic_score_gemma":0.011839604,"teacher_disagreement_score":0.64647573,"about_ca_system_score_codex":0.00012106251,"about_ca_system_score_gemma":0.0007855762,"threshold_uncertainty_score":0.9939984},"labels":[],"label_agreement":null},{"id":"W2097244998","doi":"10.1023/a:1011116626590","title":"A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program; Baker Hughes (Canada); University of Calgary; Princess Margaret Cancer Centre; University of Toronto","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Internal medicine; Prednisone; Palliative care; Prostate cancer; Oncology; Mitoxantrone; Proportional hazards model; Randomized controlled trial; Cancer; Survival analysis; Urology; Chemotherapy","score_opus":0.0921645997882064,"score_gpt":0.40340858439290395,"score_spread":0.31124398460469754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097244998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985706,0.0026267462,9.678946e-7,0.007103425,0.00009883134,0.00409655,0.00031418004,0.0000041369235,0.000049190032],"genre_scores_gemma":[0.99533004,0.002437577,0.000012569969,0.00008504583,0.000029775973,0.001999622,0.00002549547,0.000011371545,0.000068505426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980135,0.00075635803,0.000551781,0.00024199816,0.00013543086,0.00030095415],"domain_scores_gemma":[0.9962544,0.002968683,0.0003786848,0.00017818829,0.0001114728,0.0001086092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017083803,0.00015246744,0.00152178,0.0005974383,0.000044325196,0.000004267228,0.000049797094,0.00012570345,0.00000468221],"category_scores_gemma":[0.0011166226,0.00010179421,0.0002788788,0.00074958557,0.000095246876,0.000038268037,0.000012812815,0.00008576941,1.2150495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17480773,0.00018278926,0.8174477,0.000031193405,0.0017624008,0.00002339039,0.004521255,0.000021799564,0.000025373274,0.000039816397,0.0000072501857,0.0011292972],"study_design_scores_gemma":[0.25667736,0.0026792139,0.7382596,0.00021770103,0.0014142584,5.446895e-7,0.00036731263,0.00008182386,0.00004943302,0.00013259906,0.000061266684,0.000058888596],"about_ca_topic_score_codex":0.09353667,"about_ca_topic_score_gemma":0.5219113,"teacher_disagreement_score":0.42837465,"about_ca_system_score_codex":0.0013473736,"about_ca_system_score_gemma":0.0010597609,"threshold_uncertainty_score":0.91249955},"labels":[],"label_agreement":null},{"id":"W2097262030","doi":"10.1093/annonc/mdt380","title":"Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Head and neck squamous-cell carcinoma; microRNA; Oncology; Internal medicine; Head and neck cancer; Mutation; Survival rate; Cancer; Cancer research; Gene; Biology; Genetics","score_opus":0.04064207019135942,"score_gpt":0.34910536174437484,"score_spread":0.30846329155301544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097262030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985943,0.00033051026,0.0000067889564,0.00012388872,0.000085955835,0.00031387742,0.000032577944,0.0000032238809,0.00050890644],"genre_scores_gemma":[0.9992733,0.000036888476,0.00022314626,0.00019185808,0.000027933605,0.000015299349,0.00017244676,0.000011713537,0.00004742044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866533,0.0002026679,0.000638833,0.00023281887,0.00008746415,0.00017286961],"domain_scores_gemma":[0.9990078,0.00006909066,0.00040499077,0.00017971678,0.0002581121,0.00008029466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022180437,0.00010308878,0.00027743084,0.00006067197,0.000016641181,0.0000031920763,0.00010203978,0.00030238146,0.000023312545],"category_scores_gemma":[0.00035527284,0.00009996109,0.00007639455,0.000057857873,0.00011174193,0.000006824436,0.0000957268,0.00007282965,0.0000034567545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115391595,0.0007479513,0.78487253,0.00004270615,0.000007817759,0.0000017563239,0.00005565775,0.0000145208105,0.21015792,0.0000020341968,0.0022178888,0.0017638211],"study_design_scores_gemma":[0.0021448932,0.0015151673,0.83343345,0.000012564478,0.0000094180305,7.566765e-7,0.000019424613,0.000034914166,0.16215919,0.00004909646,0.0005464473,0.00007467874],"about_ca_topic_score_codex":0.00014342251,"about_ca_topic_score_gemma":0.00004915487,"teacher_disagreement_score":0.04856091,"about_ca_system_score_codex":0.000011599678,"about_ca_system_score_gemma":0.00008173952,"threshold_uncertainty_score":0.4076295},"labels":[],"label_agreement":null},{"id":"W2097370514","doi":"10.1093/annonc/mdu245","title":"Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9–15, 2014)","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary","funders":"","keywords":"Medicine; Multidisciplinary approach; Oncology; Internal medicine; Position paper; Annals; Medical education; Family medicine; Pathology","score_opus":0.059436053886158545,"score_gpt":0.4236584266451373,"score_spread":0.3642223727589788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097370514","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028716017,0.00050893443,0.0013513397,0.9622176,0.0013915789,0.003646422,0.00071931013,0.000018487795,0.0014302923],"genre_scores_gemma":[0.028144587,0.0012077729,0.0018103785,0.96472603,0.0023546773,0.0005238172,0.00051962957,0.00007729244,0.0006357981],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99631983,0.00067318586,0.0012647861,0.0006138585,0.00043933297,0.00068900984],"domain_scores_gemma":[0.98857754,0.007826306,0.0012829509,0.0010986816,0.0010698284,0.00014471792],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016409488,0.00049686583,0.0018993182,0.00029503426,0.00016712924,0.0000040189016,0.00080209493,0.0014530679,0.00033092612],"category_scores_gemma":[0.00051252684,0.0002971431,0.00055719126,0.00021262211,0.00080013886,0.000071468006,0.00023373966,0.0013711082,0.000029531122],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00724397,0.0015940273,0.00085988437,0.00024827005,0.0009309008,0.000028574674,0.0014115144,0.00019256973,0.00014851926,0.00035813963,0.92264384,0.0643398],"study_design_scores_gemma":[0.0023613528,0.047010273,0.009347825,0.00028770076,0.00029547518,0.000019417295,0.000093180046,0.000034291617,0.0011303528,0.0014576545,0.9377022,0.00026028085],"about_ca_topic_score_codex":0.00012417737,"about_ca_topic_score_gemma":0.0002959378,"teacher_disagreement_score":0.064079516,"about_ca_system_score_codex":0.00020716616,"about_ca_system_score_gemma":0.00019952681,"threshold_uncertainty_score":0.9999481},"labels":[],"label_agreement":null},{"id":"W2097608507","doi":"10.1093/annonc/mdn731","title":"Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Lung; Osteosarcoma; Chemotherapy; Surgery; Population; Survival analysis; Internal medicine; Oncology; Pathology","score_opus":0.03871459704018074,"score_gpt":0.36443907353196275,"score_spread":0.32572447649178204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097608507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99162644,0.00471662,0.0000066261987,0.0029675507,0.00000978975,0.00023297133,0.000011038744,0.000008454723,0.00042051502],"genre_scores_gemma":[0.9977611,0.0009332338,0.00040236895,0.000850833,0.000014337415,0.0000101872365,0.000014634349,0.0000054021766,0.00000795202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991632,0.00008367638,0.00021958626,0.00022843317,0.00012252011,0.00018259768],"domain_scores_gemma":[0.99952024,0.000054674605,0.000093946364,0.00014308908,0.00008004273,0.00010798789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001757402,0.00012045087,0.00063017,0.00025566516,0.00001836144,0.0000050046174,0.000029548224,0.00005899002,0.000010206921],"category_scores_gemma":[0.00003440734,0.00008482857,0.000054024862,0.0002985117,0.000084795975,0.00004440277,0.000017740653,0.00007129084,5.458553e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010196653,0.0011067047,0.9137373,0.000036642075,0.00044938616,0.00015005127,0.00015999223,0.0000018289959,0.00002825772,0.00006769224,0.000042593863,0.08319987],"study_design_scores_gemma":[0.004312209,0.0033531021,0.99018824,0.00017846863,0.00080941204,0.000048626094,0.00021817174,0.000085963446,0.00043778395,0.000029463377,0.00026381327,0.00007475695],"about_ca_topic_score_codex":0.00025986723,"about_ca_topic_score_gemma":0.00086404616,"teacher_disagreement_score":0.083125114,"about_ca_system_score_codex":0.00001544157,"about_ca_system_score_gemma":0.000039298833,"threshold_uncertainty_score":0.34592086},"labels":[],"label_agreement":null},{"id":"W2097680149","doi":"10.1093/annonc/mdf295","title":"Trastuzumab therapy for the metastatic patient: does the primary match?","year":2002,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Primary tumor; Internal medicine; Cancer; Metastasis","score_opus":0.21853642125591463,"score_gpt":0.4468525590948695,"score_spread":0.22831613783895485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097680149","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015902711,0.010191252,0.00004962144,0.9770558,0.0007232878,0.0033311152,0.0002536491,0.000026205402,0.006778787],"genre_scores_gemma":[0.0035929598,0.014760607,0.00036769552,0.97106105,0.0026456043,0.0014199412,0.00015065282,0.00011544468,0.0058860458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970088,0.0004739745,0.00064579106,0.0003994431,0.0007656544,0.00070631196],"domain_scores_gemma":[0.99390095,0.004198653,0.00040132765,0.00093988015,0.0004950178,0.000064195236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009818736,0.00031606146,0.000990473,0.00014850766,0.00014853025,0.00002087446,0.0006637393,0.00047425006,0.0012036521],"category_scores_gemma":[0.00025567712,0.00013234712,0.00046953757,0.00020048341,0.0006466639,0.00003337278,0.000087914304,0.0017120882,0.000047034555],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028367917,0.00017420923,0.000022161841,0.00033987765,0.0006216678,0.00011582158,0.0007083317,0.0000010708476,0.00003440968,0.00001328407,0.7179891,0.2796964],"study_design_scores_gemma":[0.0011606794,0.006172489,0.00027664157,0.000098250704,0.00017361266,0.000091047856,0.00015861512,0.000021619997,0.00045584174,0.0007291753,0.9905227,0.00013932312],"about_ca_topic_score_codex":0.0001413313,"about_ca_topic_score_gemma":0.000020035173,"teacher_disagreement_score":0.27955708,"about_ca_system_score_codex":0.0001467913,"about_ca_system_score_gemma":0.0007756318,"threshold_uncertainty_score":0.99970937},"labels":[],"label_agreement":null},{"id":"W2097683816","doi":"10.1093/annonc/mdq033","title":"Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Choriocarcinoma; Quartile; Confidence interval; Internal medicine; Methotrexate; Human chorionic gonadotropin; Population; Antifolate; Proportional hazards model; Univariate analysis; Gynecology; Gastroenterology; Multivariate analysis; Antimetabolite; Hormone","score_opus":0.029562019345993687,"score_gpt":0.3595174108239785,"score_spread":0.3299553914779848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097683816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936126,0.00040501598,0.0014117489,0.0005806272,0.00022921925,0.00052826374,0.00092537794,0.000010112242,0.00229704],"genre_scores_gemma":[0.9734735,0.0005158493,0.025616547,0.000062331485,0.00007786672,0.00007334282,0.000020979349,0.000018172212,0.00014143782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983183,0.00018045721,0.00069728633,0.00026364895,0.00031011898,0.00023019506],"domain_scores_gemma":[0.99480516,0.0029535065,0.0008046944,0.00020006935,0.0011530876,0.00008350786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061651994,0.00014666896,0.00069179095,0.00021627502,0.000036702066,0.000001289831,0.00010683814,0.00011540665,0.000038019098],"category_scores_gemma":[0.006369171,0.00013389911,0.00016126229,0.000237974,0.00059632666,0.000055977827,0.00003092656,0.00024581756,0.0000029732578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28926983,0.016168728,0.44488743,0.010258421,0.0068821358,0.00021448733,0.024738468,0.022746878,0.08886703,0.046367113,0.023270728,0.026328739],"study_design_scores_gemma":[0.0032573934,0.003070252,0.9618514,0.00025316028,0.00026863866,0.000003087758,0.00038885546,0.0008718089,0.00593462,0.02338928,0.00061745587,0.00009401448],"about_ca_topic_score_codex":0.00006290877,"about_ca_topic_score_gemma":0.00030139447,"teacher_disagreement_score":0.516964,"about_ca_system_score_codex":0.000020840309,"about_ca_system_score_gemma":0.0004739306,"threshold_uncertainty_score":0.7624953},"labels":[],"label_agreement":null},{"id":"W2097934619","doi":"10.1093/annonc/mdp447","title":"Activity of fulvestrant in HER2-overexpressing advanced breast cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Trastuzumab; Cancer; Breast cancer; Metastatic breast cancer; Population; Hormone receptor; Endocrine system; Tamoxifen; Gynecology; Hormone","score_opus":0.13496576755862585,"score_gpt":0.5092962090046241,"score_spread":0.37433044144599825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097934619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97140265,0.0006282416,0.000013763814,0.016710378,0.00006891441,0.00025011264,0.00003714003,0.0000107184405,0.010878099],"genre_scores_gemma":[0.9976879,0.001013467,0.0003555953,0.0007316576,0.00007463384,0.000013600564,0.0000016977074,0.000009995622,0.000111500056],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875444,0.000110662935,0.0003094552,0.00021001103,0.00027174273,0.0003436897],"domain_scores_gemma":[0.9991727,0.00009711091,0.00015540881,0.00024768413,0.00021707849,0.00011001077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039213314,0.00010172448,0.0005393804,0.0001525458,0.000014219569,0.0000020618502,0.00011899547,0.0001440501,0.00028483963],"category_scores_gemma":[0.000093132796,0.00009256497,0.000077321034,0.00026551585,0.00015943017,0.000087807566,0.00002707079,0.00029413844,0.000002756274],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017075952,0.00076229195,0.011045927,0.00013690224,0.000024469518,0.00006429188,0.00024400263,0.00007140642,0.28674364,0.000063907675,0.0010105625,0.698125],"study_design_scores_gemma":[0.0025158243,0.0031603007,0.783827,0.00070146477,0.000015456035,0.00006374935,0.000090609414,0.00010288599,0.20054366,0.0004183899,0.008443929,0.00011669708],"about_ca_topic_score_codex":0.0008697531,"about_ca_topic_score_gemma":0.00023285532,"teacher_disagreement_score":0.77278113,"about_ca_system_score_codex":0.0001084065,"about_ca_system_score_gemma":0.0007617713,"threshold_uncertainty_score":0.377469},"labels":[],"label_agreement":null},{"id":"W2098158939","doi":"10.1093/annonc/mdi126","title":"Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital","funders":"Centre hospitalier régional universitaire de Lille; Centre Hospitalier Universitaire de Nice; Eli Lilly and Company","keywords":"Medicine; Vinorelbine; Docetaxel; Gemcitabine; Internal medicine; Neutropenia; Hazard ratio; Lung cancer; Febrile neutropenia; Phases of clinical research; Chemotherapy; Gastroenterology; Progression-free survival; Cisplatin; Oncology; Confidence interval; Surgery","score_opus":0.15369913740941848,"score_gpt":0.5084618124912188,"score_spread":0.3547626750818003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098158939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744994,0.0021084577,0.00029450338,0.004394644,0.00025478416,0.0036539577,0.0001261889,0.000021153537,0.0016963419],"genre_scores_gemma":[0.9924773,0.00022848032,0.0041186437,0.00076304626,0.00015925957,0.0013052294,0.000045060347,0.000035339162,0.00086763146],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828535,0.00009377971,0.0006851978,0.00035643042,0.00014788774,0.00043136938],"domain_scores_gemma":[0.99804217,0.0008269189,0.00038620393,0.00033644127,0.00028174312,0.00012652937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041185273,0.0002428732,0.00072102033,0.00018456038,0.00016314146,0.00001280656,0.00012471735,0.000072766336,0.00017818254],"category_scores_gemma":[0.0001709119,0.00015802521,0.00012870948,0.0003548787,0.00008176386,0.00013044012,0.00004633508,0.00019442271,0.0000027228994],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041608732,0.019501306,0.004529182,0.00081963406,0.0028684055,0.005013819,0.025096927,0.0054375683,0.0027889197,0.00011583978,0.009290506,0.88292915],"study_design_scores_gemma":[0.71150386,0.08463067,0.0063897213,0.0010343256,0.013243958,0.0013265194,0.04665241,0.07602853,0.010477176,0.000097572905,0.047248438,0.0013667896],"about_ca_topic_score_codex":0.0008639726,"about_ca_topic_score_gemma":0.0076829214,"teacher_disagreement_score":0.88156235,"about_ca_system_score_codex":0.00020747932,"about_ca_system_score_gemma":0.00082261674,"threshold_uncertainty_score":0.6444081},"labels":[],"label_agreement":null},{"id":"W2098391039","doi":"10.1093/annonc/mds577","title":"Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Magnesium in Health and Disease","field":"Nursing","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; Moncton Hospital; Toronto East General Hospital; St. Joseph's Hospital; Queen's University","funders":"","keywords":"Medicine; Hypomagnesemia; Internal medicine; Cetuximab; Randomized controlled trial; Rash; Hazard ratio; Colorectal cancer; Gastroenterology; Cancer; Confidence interval","score_opus":0.06059893155297664,"score_gpt":0.4186906865314862,"score_spread":0.3580917549785096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098391039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870281,0.0014883005,0.0000026658802,0.00039336775,0.00089804135,0.0029337993,0.00044476448,0.000022294382,0.0067886505],"genre_scores_gemma":[0.9989503,0.00002846226,0.0000506561,0.00013073714,0.00015835921,0.00028488212,0.00026653128,0.000037192007,0.00009287931],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994946,0.0014168003,0.0016604885,0.00040742222,0.00069613906,0.00087316294],"domain_scores_gemma":[0.99329764,0.0019723596,0.0021179344,0.00042150108,0.0017954947,0.00039505123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015040269,0.0003657323,0.002361389,0.0004130357,0.00009348711,0.000009120731,0.000249112,0.0003574515,0.0002619652],"category_scores_gemma":[0.0019747682,0.00033395263,0.0002278949,0.00048266852,0.00030947194,0.0003189643,0.00007312434,0.00033510645,0.000008703859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6279438,0.009786597,0.273095,0.0013465442,0.00022550959,0.00007906844,0.080274634,0.00004710945,0.00032804706,0.000013094622,0.0008394585,0.0060210964],"study_design_scores_gemma":[0.72506696,0.048119627,0.0516411,0.00011915904,0.0017491367,0.0000055958394,0.1665215,0.000040458708,0.0056942124,0.00001736479,0.00044973896,0.00057514454],"about_ca_topic_score_codex":0.00639972,"about_ca_topic_score_gemma":0.0058792173,"teacher_disagreement_score":0.2214539,"about_ca_system_score_codex":0.0005369119,"about_ca_system_score_gemma":0.0011518906,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W2098427446","doi":"10.1093/annonc/mdq383","title":"Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"BC Cancer Agency; Eli Lilly Canada","keywords":"Medicine; Serous fluid; Ovarian cancer; Radiation therapy; Stage (stratigraphy); Oncology; Cohort; Internal medicine; Population; Disease; Adjuvant therapy; Debulking; Adjuvant; Chemotherapy; Cancer; Surgery","score_opus":0.05624276589817073,"score_gpt":0.3594123704605975,"score_spread":0.30316960456242675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098427446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9145411,0.0027861602,0.00015622935,0.06907822,0.0011342068,0.00088631635,0.0000822675,0.000011584664,0.011323881],"genre_scores_gemma":[0.9970976,0.00093459786,0.0004158525,0.0011853899,0.00017763296,0.000036585297,0.0000061313895,0.000010196477,0.00013598563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917233,0.000087324406,0.0002961242,0.00013554166,0.00016491223,0.00014378643],"domain_scores_gemma":[0.9987828,0.00024096483,0.00031559347,0.00037542506,0.00023887442,0.000046313366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033609572,0.000090251866,0.0003701258,0.000040732608,0.000041534473,0.0000016252767,0.00014478032,0.00009608313,0.00044687852],"category_scores_gemma":[0.00005619278,0.00004719697,0.000125348,0.00012140037,0.0004705141,0.000025640818,0.00002062147,0.00016510532,0.000001188451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068752426,0.0045424304,0.042375647,0.0003141093,0.0065737856,0.000112359085,0.022815384,0.00041673472,0.13957755,0.0694999,0.17181085,0.535086],"study_design_scores_gemma":[0.005154053,0.009913027,0.285098,0.00007895094,0.00047712287,0.000065163826,0.00041417437,0.00020236381,0.053997956,0.0011805937,0.64329785,0.000120753604],"about_ca_topic_score_codex":0.0057853106,"about_ca_topic_score_gemma":0.00079772447,"teacher_disagreement_score":0.5349652,"about_ca_system_score_codex":0.00004448806,"about_ca_system_score_gemma":0.0006502577,"threshold_uncertainty_score":0.8745697},"labels":[],"label_agreement":null},{"id":"W2098480747","doi":"10.1093/annonc/mdr050","title":"Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Anal cancer; Chemoradiotherapy; Internal medicine; Cancer; Population; Confidence interval; Gastroenterology; Prospective cohort study; Surgery","score_opus":0.10009979474598425,"score_gpt":0.370105966912556,"score_spread":0.27000617216657175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098480747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952612,0.00058200007,0.0000039625006,0.0010012607,0.00013267086,0.0004355823,0.000047321493,0.000009010724,0.0025269752],"genre_scores_gemma":[0.9979965,0.00028160604,0.00017466077,0.001050437,0.000083423874,0.00008977612,0.000021864254,0.000011970084,0.00028974036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926007,0.0000302759,0.00023168189,0.00016676872,0.000097076874,0.00021412995],"domain_scores_gemma":[0.99946105,0.00004691157,0.000117909294,0.00009671686,0.00020578803,0.000071634095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001235539,0.00009436812,0.00037275872,0.00009419746,0.000018846898,0.0000012008245,0.000064855696,0.000112341,0.00028751596],"category_scores_gemma":[0.000030480036,0.0000731881,0.000079645026,0.00009329986,0.000063757405,0.00003802548,0.000017739781,0.0000897444,0.0000025231845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007867526,0.0024172587,0.9193849,0.0002680654,0.000058639955,0.000040930787,0.0031748477,0.000002234984,0.02802131,0.000038542217,0.017338885,0.021386862],"study_design_scores_gemma":[0.0049578855,0.0071130316,0.78395164,0.00007460492,0.000038649778,0.0000035985574,0.00011478263,0.000107798944,0.18451133,0.00017327695,0.01883177,0.00012160505],"about_ca_topic_score_codex":0.00029626075,"about_ca_topic_score_gemma":0.00036406252,"teacher_disagreement_score":0.15649003,"about_ca_system_score_codex":0.000043195934,"about_ca_system_score_gemma":0.00016620973,"threshold_uncertainty_score":0.3148098},"labels":[],"label_agreement":null},{"id":"W2098675401","doi":"10.1093/annonc/mdr173","title":"VII. The role of the microenvironment in lymphoid cancers","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cyclin D1; Lymphoma; Cancer research; Follicular lymphoma; Mantle cell lymphoma; Cancer cell; Medicine; Cyclin; Cell cycle; Cancer; Biology; Cell biology; Immunology; Internal medicine","score_opus":0.0543061739795201,"score_gpt":0.31094950381304787,"score_spread":0.2566433298335278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098675401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629423,0.0020114058,1.2989302e-7,0.0029930146,0.00006500707,0.00022195044,0.0000067844953,0.000001895562,0.031757537],"genre_scores_gemma":[0.99718565,0.0010670805,0.000044384313,0.001549838,0.000016624512,0.00003817569,9.0225825e-7,0.000004602827,0.000092721595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994487,0.000054119646,0.00019226098,0.00009018879,0.00008510534,0.00012962948],"domain_scores_gemma":[0.9995403,0.00005514548,0.00011682284,0.00024035314,0.000019877518,0.000027453441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001249338,0.000061688486,0.00020379946,0.000024419105,0.000016777893,4.5543135e-7,0.00010405322,0.00005005805,0.00017936963],"category_scores_gemma":[0.000015706479,0.000030746447,0.00008645457,0.00006003571,0.00017056025,0.0000110537285,0.000048942835,0.000034901746,0.000008651782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030985475,0.0015311105,0.8595318,0.000015028548,0.00017402411,0.000020875055,0.0029760497,0.000007392545,0.0073195864,0.00095762237,0.0017805509,0.12537606],"study_design_scores_gemma":[0.0011812054,0.0008893284,0.70873636,0.000031558724,0.000045310182,0.000023888275,0.00045897244,0.0000054024276,0.23840013,0.00038048727,0.04981889,0.000028475664],"about_ca_topic_score_codex":0.0023451846,"about_ca_topic_score_gemma":0.00031465126,"teacher_disagreement_score":0.23108055,"about_ca_system_score_codex":0.00012903707,"about_ca_system_score_gemma":0.00018311467,"threshold_uncertainty_score":0.3545233},"labels":[],"label_agreement":null},{"id":"W2099019973","doi":"10.1093/annonc/mdu331.5","title":"Dose-Escalation Study of Sonidegib (Lde225) Plus Buparlisib (Bkm120) in Patients (Pts) with Advanced Solid Tumors","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; De-escalation; Internal medicine; Oncology","score_opus":0.03187013370945412,"score_gpt":0.3378268854350654,"score_spread":0.30595675172561126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099019973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998058,0.00008692285,0.00011424313,0.000096622025,0.000077844954,0.00041584333,0.0000075269104,0.000007059828,0.0011359261],"genre_scores_gemma":[0.9994107,0.00003406863,0.00023190996,0.0001466017,0.00005144157,0.000037172565,0.000030795247,0.000020336838,0.00003700122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984984,0.00020692116,0.0005008556,0.00033930037,0.0001791894,0.0002753767],"domain_scores_gemma":[0.9988422,0.000056456225,0.0003668082,0.00031285046,0.00036797795,0.000053731663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003992201,0.0001694756,0.0005042186,0.00010509124,0.00003668015,0.0000029952362,0.00018509431,0.00013474854,0.000004192318],"category_scores_gemma":[0.00026805172,0.00014854725,0.00005264875,0.00014891358,0.00012710207,0.00000686285,0.00011382268,0.000094340474,0.0000024226733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065191444,0.008907527,0.68941283,0.00020580033,0.00062053796,0.000018906407,0.0057724817,0.02042699,0.14133671,0.00012885217,0.0014318955,0.12521832],"study_design_scores_gemma":[0.013865742,0.06376544,0.76737493,0.0001145078,0.000055867265,0.0000029411615,0.0020437413,0.00024788716,0.1469285,0.0001177538,0.00497953,0.00050318346],"about_ca_topic_score_codex":0.000073934345,"about_ca_topic_score_gemma":0.0004991382,"teacher_disagreement_score":0.124715135,"about_ca_system_score_codex":0.0000193471,"about_ca_system_score_gemma":0.00011362867,"threshold_uncertainty_score":0.6057581},"labels":[],"label_agreement":null},{"id":"W2099105421","doi":"10.1093/annonc/mdn035","title":"Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Ovarian cancer; Debulking; Kallikrein; Oncology; Paclitaxel; Internal medicine; Ovarian carcinoma; Biomarker; Cancer; Survival analysis; Pathology; Biology; Enzyme","score_opus":0.2511979292167753,"score_gpt":0.46694948593184477,"score_spread":0.21575155671506946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099105421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438244,0.0006076809,0.052926477,0.0007778473,0.000062543804,0.0011889159,0.00003346425,0.000015505937,0.0005631368],"genre_scores_gemma":[0.77284884,0.000007912169,0.22670697,0.00014467083,0.0000362277,0.000055140972,0.000024618377,0.000022701783,0.00015290848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840903,0.00008561544,0.00069807057,0.0003233461,0.00017700861,0.0003069306],"domain_scores_gemma":[0.9985255,0.00026163372,0.00047674144,0.00023201486,0.00041385472,0.00009024951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005384926,0.00018030837,0.000771483,0.00031296062,0.00007732177,0.0000019585937,0.00010269296,0.0002114896,0.000033142947],"category_scores_gemma":[0.00035939302,0.00016946011,0.00014347826,0.00029671908,0.00017099474,0.000121051955,0.000049728533,0.00009698223,6.816969e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012214707,0.0009524309,0.0023147056,0.00017478986,0.000054431286,0.000017101698,0.002319019,0.00006818675,0.98467,0.002641572,0.000072147384,0.005494163],"study_design_scores_gemma":[0.008076797,0.0037167,0.1016678,0.0004491627,0.000052116444,0.000088265544,0.0005360244,0.0016528697,0.8802626,0.0006434104,0.0026438446,0.00021037253],"about_ca_topic_score_codex":0.00071463874,"about_ca_topic_score_gemma":0.000159995,"teacher_disagreement_score":0.17378049,"about_ca_system_score_codex":0.000044891854,"about_ca_system_score_gemma":0.00031631143,"threshold_uncertainty_score":0.69103825},"labels":[],"label_agreement":null},{"id":"W2099259685","doi":"10.1093/annonc/mdi310","title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":301,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Toxicity; Adverse effect; Kinase; Internal medicine; Bay; Pharmacology; Refractory (planetary science); Tyrosine-kinase inhibitor; Cancer; Gastroenterology; Oncology","score_opus":0.03243005053116366,"score_gpt":0.3398462573339467,"score_spread":0.30741620680278303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099259685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760365,0.00018175533,0.00003998737,0.0005757836,0.000090042835,0.0010773616,0.00021752619,0.0000023404139,0.00021156723],"genre_scores_gemma":[0.99838024,0.00008721308,0.00029101103,0.0010078553,0.0001003409,0.000036415964,0.000027391992,0.000017865785,0.000051651765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988721,0.00009139609,0.00039434424,0.00030322804,0.00011581203,0.00022310209],"domain_scores_gemma":[0.99910855,0.00009369328,0.0002445798,0.000322197,0.00014645586,0.00008452741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029123967,0.00017087274,0.00031710937,0.000048147976,0.000059225422,0.000004622375,0.00018538891,0.000075771284,0.0000031386896],"category_scores_gemma":[0.00014346807,0.00010741306,0.00004265171,0.0000705299,0.00014736726,0.00000685259,0.00016063021,0.00009227706,2.5139613e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025258213,0.0144018065,0.017148338,0.0001390934,0.00021001232,0.000010953485,0.002436272,0.00024426277,0.6419104,0.0000510268,0.0013819481,0.2968077],"study_design_scores_gemma":[0.036748946,0.097478256,0.08194674,0.0001263192,0.00011454284,0.000013826391,0.0008243746,0.00014636866,0.6124875,0.00001223736,0.16963176,0.0004691409],"about_ca_topic_score_codex":0.0000034871189,"about_ca_topic_score_gemma":0.00012136799,"teacher_disagreement_score":0.2963386,"about_ca_system_score_codex":0.000010197402,"about_ca_system_score_gemma":0.00009299443,"threshold_uncertainty_score":0.43801776},"labels":[],"label_agreement":null},{"id":"W2099333150","doi":"10.1023/a:1008304128577","title":"Dietary glycemic load and colorectal cancer risk","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":240,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Glycemic load; Colorectal cancer; Glycemic index; Internal medicine; Overweight; Cancer; Odds ratio; Glycemic; Body mass index; Rectum; Insulin resistance; Gastroenterology; Endocrinology; Oncology; Insulin","score_opus":0.03328704373829819,"score_gpt":0.34115885124368306,"score_spread":0.3078718075053849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099333150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77184,0.22477295,0.0000057650036,0.00015295901,0.00021251118,0.00007335981,0.000041323383,0.000004895839,0.0028962414],"genre_scores_gemma":[0.6439457,0.3546778,0.000052509142,0.0008996826,0.00025746383,0.000022440696,0.000013752275,0.000009049736,0.00012159696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991384,0.00007621463,0.00018746709,0.00025521513,0.000086575994,0.0002561227],"domain_scores_gemma":[0.99945676,0.000021378075,0.00013676815,0.00014929754,0.00014828937,0.00008749003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017764524,0.00011741554,0.00024755433,0.000026626847,0.000043396332,0.000004100342,0.000113870046,0.00019342607,0.00011501701],"category_scores_gemma":[0.00007368216,0.000108886845,0.00007310659,0.00006352023,0.00017691952,0.0000036927418,0.000074668096,0.00008998788,0.0000054066936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012711595,0.00011594453,0.015068688,0.000016984508,0.000167255,0.0000067182996,0.00011621637,0.000021440652,0.0783544,0.00001985051,0.016452141,0.88838917],"study_design_scores_gemma":[0.0009764135,0.0016203565,0.011203629,0.0000071443733,0.000041865245,0.000013831162,0.000046165187,0.000017206263,0.08800754,0.00026394182,0.89765227,0.00014966371],"about_ca_topic_score_codex":0.00034271466,"about_ca_topic_score_gemma":0.0006403223,"teacher_disagreement_score":0.88823956,"about_ca_system_score_codex":0.000010123755,"about_ca_system_score_gemma":0.0002105267,"threshold_uncertainty_score":0.44402766},"labels":[],"label_agreement":null},{"id":"W2099386389","doi":"10.1093/annonc/mdh172","title":"Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience","year":2004,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Fluorouracil; Chemotherapy; Internal medicine; Biliary tract; Biliary tract cancer; Gastroenterology; Toxicity; Adenocarcinoma; Progressive disease; Surgery; Cancer; Oncology","score_opus":0.06541495423101631,"score_gpt":0.4016542816104351,"score_spread":0.33623932737941875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099386389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024449702,0.9919368,0.0000014327142,0.0016745845,0.00039664694,0.0021973276,0.00008749945,0.000011024526,0.0012496961],"genre_scores_gemma":[0.0046028043,0.99382204,0.0000812835,0.00072417175,0.00008238163,0.0005436174,0.00004400167,0.000029065668,0.00007063454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736905,0.00017219235,0.0011533659,0.00047646518,0.0004588636,0.00037006428],"domain_scores_gemma":[0.9974855,0.00021406141,0.0011761348,0.00053201884,0.0004983276,0.00009392254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031436732,0.0004181247,0.0034049673,0.00012454565,0.000035286226,0.0000026972698,0.00040070672,0.00020119981,0.0000957125],"category_scores_gemma":[0.00029192914,0.00023745325,0.0005061869,0.0006183779,0.0005965865,0.00007157139,0.0002609429,0.00050683,0.0000020138489],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009710901,0.00038614083,0.0024310884,0.10024953,0.00028725193,0.0001145988,0.0007478708,7.9118416e-7,8.1664245e-7,0.00007792352,0.0012511238,0.8943558],"study_design_scores_gemma":[0.0013431151,0.002506649,0.004030721,0.24639587,0.00045985795,0.0001294662,0.0001662298,1.4061492e-7,0.0000119348215,0.00000826688,0.7447111,0.0002366705],"about_ca_topic_score_codex":0.00025716642,"about_ca_topic_score_gemma":0.00020591359,"teacher_disagreement_score":0.8941191,"about_ca_system_score_codex":0.00036986766,"about_ca_system_score_gemma":0.0035928122,"threshold_uncertainty_score":0.96830624},"labels":[],"label_agreement":null},{"id":"W2099465542","doi":"10.1093/annonc/mdp251","title":"Biomarkers in melanoma","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Melanoma; Tissue microarray; Biomarker; Biomarker discovery; Oncology; DNA microarray; Bioinformatics; Internal medicine; Computational biology; Cancer; Proteomics; Cancer research; Biology; Genetics","score_opus":0.14281690891575236,"score_gpt":0.43745723784661444,"score_spread":0.2946403289308621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099465542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019997673,0.90340203,0.000002343228,0.00075908867,0.00023243259,0.0006819891,0.000004797929,0.00002432092,0.09487301],"genre_scores_gemma":[0.00005554222,0.9974686,0.00012592346,0.00071152137,0.00009911208,0.000030627023,0.000033517892,0.00001998769,0.0014551532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855196,0.0001434467,0.0006700687,0.00026658038,0.0001254368,0.0002425063],"domain_scores_gemma":[0.9991194,0.000114948416,0.00032402738,0.00029887143,0.00005125186,0.00009151012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035091338,0.00021164089,0.0018958407,0.00065730815,0.000011044478,0.000002916572,0.00011373388,0.00039011167,0.000232732],"category_scores_gemma":[0.00008657828,0.00017430908,0.00041416698,0.00036108046,0.000055073368,0.00001340887,0.000042947388,0.0002495911,0.00010992027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006119635,0.00025809073,0.0000026657085,0.003498877,0.00032512684,0.00080675504,0.000014308994,5.4974844e-8,6.0614184e-7,0.00012126535,0.013033448,0.9818776],"study_design_scores_gemma":[0.00037473257,0.0023248917,0.000027518325,0.0028771714,0.00033425228,0.0007838593,0.000015486867,0.0000010032372,0.0000025855106,0.00004694182,0.993089,0.00012255061],"about_ca_topic_score_codex":0.00003627377,"about_ca_topic_score_gemma":0.000047148482,"teacher_disagreement_score":0.9817551,"about_ca_system_score_codex":0.000098718396,"about_ca_system_score_gemma":0.00030816928,"threshold_uncertainty_score":0.7108118},"labels":[],"label_agreement":null},{"id":"W2099516399","doi":"10.1093/annonc/mdm340","title":"Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Intraocular lymphoma; Primary central nervous system lymphoma; Primary (astronomy); Lymphoma; Central nervous system; Internal medicine","score_opus":0.028685198676324634,"score_gpt":0.3397442184537616,"score_spread":0.311059019777437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099516399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404898,0.0010171491,0.0001930341,0.0014984686,0.0010265016,0.0006624011,0.0000568817,0.00010514562,0.05495057],"genre_scores_gemma":[0.9932873,0.00043730918,0.002526953,0.002157292,0.0005773321,0.00006053484,0.0007486633,0.00004046091,0.00016412129],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972549,0.000120731784,0.00096417684,0.0005377774,0.0005419341,0.0005804923],"domain_scores_gemma":[0.99764925,0.00019612667,0.0005543974,0.00053635566,0.00066697336,0.00039689394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008706952,0.00028867237,0.0008702939,0.00026254385,0.00008290089,0.000019246181,0.00021145627,0.00029805195,0.000047161622],"category_scores_gemma":[0.00009765139,0.00025597203,0.0002282592,0.00032982274,0.00020853018,0.00023363568,0.00010253465,0.000063393585,0.000019019502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026372736,0.008060457,0.09950221,0.00021110423,0.0011770424,0.025573287,0.0006216272,0.000007736502,0.0028362751,0.0043896614,0.0046081003,0.85037524],"study_design_scores_gemma":[0.0048041,0.0031319489,0.87089896,0.00011857023,0.00017067148,0.0046037603,0.00050796283,0.00002092868,0.0054319953,0.000035062767,0.11008144,0.00019462033],"about_ca_topic_score_codex":0.0003563294,"about_ca_topic_score_gemma":0.00009154499,"teacher_disagreement_score":0.8501806,"about_ca_system_score_codex":0.0014186421,"about_ca_system_score_gemma":0.0010491072,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W2099634017","doi":"10.1093/annonc/mds171","title":"Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case–control studies","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; European Commission; European Regional Development Fund; University of California, San Francisco; Fondation de France; Bundesamt für Strahlenschutz; American Institute for Cancer Research; Canadian Institutes of Health Research; Associazione Italiana per la Ricerca sul Cancro; Leukaemia and Lymphoma Research; Compagnia di San Paolo; Blood Cancer UK","keywords":"Medicine; Odds ratio; Follicular lymphoma; Lymphoma; Confidence interval; Logistic regression; Hormonal contraception; Internal medicine; Gynecology; Family planning; Oncology; Population; Obstetrics; Environmental health; Research methodology","score_opus":0.16836939034375875,"score_gpt":0.44764995307566674,"score_spread":0.279280562731908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099634017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31580463,0.68294686,0.000008306682,0.000100629855,0.000050826948,0.0005320444,0.00053108134,0.0000045602355,0.000021082235],"genre_scores_gemma":[0.43385398,0.56590766,0.000037173966,0.000023849783,0.00005204193,0.000032541087,0.00006621321,0.000012081097,0.000014495942],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812967,0.00026036266,0.0008078402,0.0003961646,0.00016172661,0.00024425235],"domain_scores_gemma":[0.9972779,0.0009200429,0.0010914372,0.00022837485,0.0003874891,0.000094761046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000637402,0.00029872404,0.0038495476,0.0007290384,0.00003392027,0.0000066884395,0.000040062278,0.00031447734,0.000012232904],"category_scores_gemma":[0.00031375673,0.0002016827,0.00027615036,0.00054075575,0.00031316193,0.00012120085,0.000040063678,0.00016021967,1.8564823e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029958223,0.0003419036,0.05913082,0.0011117673,0.025178924,0.00011108444,0.0027194954,8.637975e-7,0.0000062529616,0.000027191314,0.00007590525,0.9109962],"study_design_scores_gemma":[0.006133162,0.0068928786,0.7865461,0.002841378,0.11343457,0.0008771487,0.0035004057,0.0000270701,0.000011811381,0.000018538429,0.079130106,0.00058683584],"about_ca_topic_score_codex":0.0016298913,"about_ca_topic_score_gemma":0.0028708943,"teacher_disagreement_score":0.9104094,"about_ca_system_score_codex":0.00023147144,"about_ca_system_score_gemma":0.00031927857,"threshold_uncertainty_score":0.8224382},"labels":[],"label_agreement":null},{"id":"W2099712757","doi":"10.1093/annonc/mdr063","title":"Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Temsirolimus; Carboplatin; Medicine; Tolerability; Paclitaxel; Adverse effect; Neutropenia; Nausea; Chemotherapy; Internal medicine; Toxicity; Common Terminology Criteria for Adverse Events; Pharmacology; Oncology; Urology; Cisplatin","score_opus":0.1238114440220481,"score_gpt":0.438953404819226,"score_spread":0.31514196079717793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099712757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520266,0.00009950316,0.0000032674288,0.00031907516,0.000043370015,0.002356917,0.000010101347,0.000010220797,0.0019548587],"genre_scores_gemma":[0.9990917,0.00003169894,0.0002622555,0.00029326836,0.0000133061585,0.00019886049,0.00004849349,0.000018245326,0.00004219553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987277,0.00015299798,0.0004109713,0.00030696674,0.00015109695,0.00025029652],"domain_scores_gemma":[0.99921745,0.000086167034,0.0002709051,0.00015155708,0.000182149,0.00009176622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025905328,0.00017114141,0.0006069479,0.0002700852,0.000028286637,0.0000052251407,0.00007919175,0.00008808596,0.000037554877],"category_scores_gemma":[0.000029186032,0.00013262131,0.000011537544,0.00030176862,0.000105326944,0.00021564575,0.000049630744,0.00016896492,0.0000014327998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033529647,0.04501739,0.8543566,0.00004336826,0.00014590449,0.00016528655,0.006863927,0.0000069277444,0.000536404,0.00004469021,0.00007120976,0.059218638],"study_design_scores_gemma":[0.10655104,0.098369844,0.7929897,0.000096605036,0.00008370245,0.0000071188356,0.00076755846,0.00008823171,0.00073091773,0.000119409684,0.00007176368,0.00012411518],"about_ca_topic_score_codex":0.0009007268,"about_ca_topic_score_gemma":0.002621074,"teacher_disagreement_score":0.0730214,"about_ca_system_score_codex":0.000092782786,"about_ca_system_score_gemma":0.0001924173,"threshold_uncertainty_score":0.540814},"labels":[],"label_agreement":null},{"id":"W2099818449","doi":"10.1093/annonc/mdq430","title":"First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Bevacizumab; Taxane; Metastatic breast cancer; Internal medicine; Docetaxel; Oncology; Clinical endpoint; Neutropenia; Chemotherapy; Breast cancer; Population; Surgery; Cancer; Clinical trial","score_opus":0.13956061855920757,"score_gpt":0.48037675997332335,"score_spread":0.34081614141411576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099818449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98647106,0.00014960628,0.000012077839,0.0088367555,0.0002820626,0.0039676023,0.00021979985,0.0000104953,0.00005057163],"genre_scores_gemma":[0.9962267,0.00048908126,0.0005342645,0.0019974571,0.00006987234,0.0004940614,0.00009995386,0.000026813015,0.00006179724],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984361,0.00013162165,0.0005772617,0.00039492195,0.00012587191,0.00033425572],"domain_scores_gemma":[0.9987355,0.00040951036,0.00024639058,0.00021468574,0.00023859937,0.00015532934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047958508,0.000210373,0.0008741768,0.00020125625,0.000045909466,0.000008845242,0.000192343,0.00011204331,0.00028502214],"category_scores_gemma":[0.00006965525,0.00016523545,0.000031489646,0.0002448815,0.000114236354,0.00009262899,0.00005572503,0.0002458855,0.0000011211098],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1452561,0.07870491,0.096899,0.00021357533,0.00030535876,0.000096612195,0.0020599035,0.00012367213,0.0004936392,0.000018958572,0.00090455246,0.6749237],"study_design_scores_gemma":[0.34309596,0.105112076,0.5311501,0.00016458349,0.0003067877,0.000021882497,0.00020021049,0.0033705973,0.00055953884,0.00005165404,0.015629085,0.00033752294],"about_ca_topic_score_codex":0.0013342286,"about_ca_topic_score_gemma":0.057286344,"teacher_disagreement_score":0.6745862,"about_ca_system_score_codex":0.00016415572,"about_ca_system_score_gemma":0.0008343812,"threshold_uncertainty_score":0.9599157},"labels":[],"label_agreement":null},{"id":"W2099968714","doi":"10.1093/annonc/mdp394","title":"Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canadian Blood Services; University of Toronto","funders":"","keywords":"Medicine; Menopause; Chemotherapy; Quality of life (healthcare); Breast cancer; Prospective cohort study; Surgical Menopause; Internal medicine; Premature Menopause; Gynecology; Cancer","score_opus":0.03937500721189139,"score_gpt":0.3935273905509959,"score_spread":0.3541523833391045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099968714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877715,0.0008990206,5.265037e-7,0.005653888,0.000091726135,0.0026661383,0.000002171561,0.00003299385,0.0028820452],"genre_scores_gemma":[0.9946395,0.00025234345,0.000054519394,0.0046368837,0.00005663334,0.00011500931,0.0000024272451,0.000018643153,0.00022404655],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980421,0.00018104487,0.00058440876,0.00035930626,0.00023861649,0.00059450767],"domain_scores_gemma":[0.9988396,0.0002597005,0.0002645217,0.00022521161,0.00014516352,0.00026581218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071167777,0.00024210924,0.0012137935,0.00025775458,0.000063605534,0.000011338254,0.00006955937,0.0001308487,0.000061356135],"category_scores_gemma":[0.00019694093,0.00018028762,0.000010843914,0.0002428867,0.000051169387,0.00010464426,0.00002313079,0.00026137516,0.0000048244365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17402285,0.040269163,0.1267791,0.0004677895,0.0059718615,0.002633998,0.048985,0.0000048871743,0.29833114,0.0017295834,0.00091039453,0.29989424],"study_design_scores_gemma":[0.13395765,0.2500415,0.6111805,0.00012145495,0.0001388596,0.00009540905,0.0013368661,0.000019935855,0.0014474131,0.0011909469,0.00025626377,0.00021320955],"about_ca_topic_score_codex":0.00012009944,"about_ca_topic_score_gemma":0.00014647996,"teacher_disagreement_score":0.4844014,"about_ca_system_score_codex":0.00032430456,"about_ca_system_score_gemma":0.00043411975,"threshold_uncertainty_score":0.7351916},"labels":[],"label_agreement":null},{"id":"W2100067358","doi":"10.1093/annonc/mdt026","title":"Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"SABR volatility model; Medicine; Propensity score matching; VATS lobectomy; Radiosurgery; Surgery; Video-assisted thoracoscopic surgery; Lung cancer; Pneumonectomy; Radiation therapy; Retrospective cohort study; Internal medicine","score_opus":0.10737862020604397,"score_gpt":0.39846594845136274,"score_spread":0.2910873282453188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100067358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398595,0.0018936693,0.000097048076,0.0019161919,0.0001045326,0.0016645499,0.00007666026,0.000041581505,0.00021979671],"genre_scores_gemma":[0.9951909,0.0014327281,0.00052398955,0.0010243763,0.000032288164,0.00025843436,0.000035934234,0.00005971762,0.0014416126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975886,0.00027730773,0.00086961035,0.000506035,0.0002881183,0.00047032547],"domain_scores_gemma":[0.9970182,0.000633351,0.000996774,0.000521041,0.00063699414,0.00019360568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034343507,0.00037770963,0.0023863546,0.00033153075,0.000077989236,0.000017594532,0.000128629,0.0002260858,0.0012057781],"category_scores_gemma":[0.000055131582,0.0002487851,0.00047519404,0.00094994763,0.00016903428,0.00017126431,0.000056234247,0.00016233386,0.0000024929075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009412842,0.0026175494,0.9659408,0.00038204974,0.011883226,0.0000636465,0.00088730257,0.000059663955,0.010521704,8.020059e-7,0.003061061,0.0036409216],"study_design_scores_gemma":[0.003896453,0.002016482,0.9375442,0.00030546213,0.003898332,0.00000561309,0.0001512435,0.0009976886,0.05040211,0.0000020988612,0.00050786685,0.00027240542],"about_ca_topic_score_codex":0.025314359,"about_ca_topic_score_gemma":0.0020219742,"teacher_disagreement_score":0.039880402,"about_ca_system_score_codex":0.00054964266,"about_ca_system_score_gemma":0.00082862907,"threshold_uncertainty_score":0.9999964},"labels":[],"label_agreement":null},{"id":"W2100072610","doi":"10.1093/annonc/mdt190","title":"Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi Pasteur; University of Texas MD Anderson Cancer Center; U.S. Public Health Service; National Institutes of Health","keywords":"Medicine; Oncology; Breast cancer; Transcription factor; Internal medicine; Stage (stratigraphy); Cancer research; Cancer; Genetics; Gene","score_opus":0.08215057838743603,"score_gpt":0.3446324223793106,"score_spread":0.2624818439918746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100072610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133754,0.0022322224,0.0000035899282,0.0038073994,0.00018880106,0.0007731736,0.00019341592,0.000008633127,0.0014552565],"genre_scores_gemma":[0.9981138,0.0007388486,0.000036256155,0.0006741449,0.00003836671,0.00011201685,0.0000049998175,0.000013163486,0.00026838647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998626,0.00018430738,0.00046038628,0.00020088333,0.00025507555,0.00027337045],"domain_scores_gemma":[0.99910706,0.000106748295,0.0002018354,0.00024660022,0.00024870486,0.000089071975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023837844,0.0001426123,0.00061568426,0.00013027947,0.000029602545,0.000003917324,0.0001299975,0.00011075972,0.0003281117],"category_scores_gemma":[0.00009226199,0.00009186735,0.00017242842,0.00029995615,0.0001675467,0.00007954202,0.000042311724,0.00019199058,0.000009149166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032340048,0.0009960035,0.9108728,0.00043698124,0.000320459,0.00011044055,0.0021469938,0.000008898655,0.031149412,0.00033870531,0.0031646192,0.050131246],"study_design_scores_gemma":[0.0011859391,0.0010691863,0.9944124,0.00012683854,0.00008819463,0.00007794688,0.00037432354,0.00003670783,0.0011321804,0.00005315968,0.0013679067,0.00007520688],"about_ca_topic_score_codex":0.00399588,"about_ca_topic_score_gemma":0.00017440508,"teacher_disagreement_score":0.08353957,"about_ca_system_score_codex":0.000036667905,"about_ca_system_score_gemma":0.00022312987,"threshold_uncertainty_score":0.60406023},"labels":[],"label_agreement":null},{"id":"W2100471642","doi":"10.1093/annonc/mdn288","title":"Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mitoxantrone; Docetaxel; Medicine; Oncology; Prostate cancer; Internal medicine; Crossover study; Chemotherapy; Cancer; Pathology","score_opus":0.09394859648610601,"score_gpt":0.42496393803982735,"score_spread":0.33101534155372137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100471642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944528,0.00024979783,4.6848083e-7,0.0037426709,0.000067909605,0.001013077,0.00006142929,0.0000034444859,0.00040845724],"genre_scores_gemma":[0.9975382,0.00050522014,0.00003092049,0.0006893755,0.00003366108,0.00007642678,0.0000061402693,0.000009084742,0.0011109379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984436,0.00047833528,0.0002932898,0.00020797086,0.000317992,0.00025883445],"domain_scores_gemma":[0.99872524,0.00060528493,0.00008830739,0.00023254863,0.00026318213,0.00008543591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007608737,0.0001089103,0.0004410652,0.00015972776,0.00004183485,0.0000035452165,0.00010251968,0.00007937705,0.00009268863],"category_scores_gemma":[0.00038414606,0.00006350823,0.00004200766,0.0003031416,0.00022110766,0.000053524083,0.00006836081,0.00013917599,0.000005639908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1561634,0.0036318786,0.8109442,0.000047063284,0.0001824924,0.00062947196,0.017309127,0.0000013060322,0.0009331132,0.0000023580897,0.0075693037,0.002586294],"study_design_scores_gemma":[0.009081628,0.01702586,0.9615637,0.00003671037,0.000030476856,0.0000063675047,0.0015598234,0.0000018084065,0.0013354326,0.000006492411,0.009292591,0.000059075453],"about_ca_topic_score_codex":0.000474611,"about_ca_topic_score_gemma":0.0006475532,"teacher_disagreement_score":0.15061954,"about_ca_system_score_codex":0.0000485912,"about_ca_system_score_gemma":0.00030673755,"threshold_uncertainty_score":0.25897908},"labels":[],"label_agreement":null},{"id":"W2100672365","doi":"10.1093/annonc/mdu090","title":"Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Breast cancer; Cumulative incidence; Oncology; Internal medicine; Radiation therapy; Grading (engineering); Tumor hypoxia; Breast-conserving surgery; Biomarker; Randomized controlled trial; Pathology; Cancer; Mastectomy; Cohort","score_opus":0.02911776360710796,"score_gpt":0.34932847197736455,"score_spread":0.3202107083702566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100672365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561775,0.0005590136,0.00028648943,0.0023665265,0.00023237157,0.00068114087,0.000035455807,0.000007405828,0.00021383165],"genre_scores_gemma":[0.99842393,0.0002094913,0.00022784925,0.00087228836,0.000088516594,0.00012283398,0.000016364274,0.00001628627,0.000022410859],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805593,0.0009566967,0.0004248033,0.0002535489,0.000112350324,0.00019669329],"domain_scores_gemma":[0.9985421,0.0008077243,0.0002558361,0.0001999137,0.00014282527,0.000051632112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001179485,0.00015682376,0.00079118053,0.00014209848,0.000030537616,0.0000027675499,0.00012915095,0.00011506193,0.000014760782],"category_scores_gemma":[0.00080135185,0.00012865796,0.0002634278,0.00013914803,0.00013124834,0.0000062782324,0.000040693914,0.00005929892,5.2189307e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9017201,0.0003918066,0.0034163434,0.000004125418,0.00061088585,0.0000027452563,0.0004904985,0.00006997183,0.0882364,0.000015857755,0.00026380154,0.00477748],"study_design_scores_gemma":[0.8254409,0.006854199,0.06376626,0.000050645118,0.00004433338,0.000015383192,0.0003311712,0.00004527075,0.09489923,0.00015141103,0.008179318,0.0002219176],"about_ca_topic_score_codex":0.0003420626,"about_ca_topic_score_gemma":0.0000486476,"teacher_disagreement_score":0.07627922,"about_ca_system_score_codex":0.00003066284,"about_ca_system_score_gemma":0.00018106725,"threshold_uncertainty_score":0.52465194},"labels":[],"label_agreement":null},{"id":"W2101838543","doi":"10.1093/annonc/mdv198","title":"Agenda science: turning nothing into something: a response to the editorial by Oldenburg et al. and its featured article by Vidal et al.","year":2015,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Nothing; Medicine; Epistemology; Philosophy","score_opus":0.05578521941221469,"score_gpt":0.416357461090749,"score_spread":0.3605722416785343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101838543","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.116518974,0.004694251,0.000009733984,0.87342703,0.004600517,0.0005109974,0.00012190515,0.0000328608,0.00008370358],"genre_scores_gemma":[0.046196103,0.00014381377,0.000295038,0.9489055,0.0037007942,0.00005513379,0.000120157856,0.00004187123,0.0005415539],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971031,0.00051902764,0.00032808533,0.000573581,0.0009766426,0.00049958966],"domain_scores_gemma":[0.9975983,0.000889677,0.0002829791,0.00037846982,0.0005460148,0.00030456553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029044158,0.0002787944,0.0005749159,0.00019978471,0.00016449815,0.000075072996,0.00027936185,0.00040319495,0.000017830975],"category_scores_gemma":[0.0048784968,0.00019480703,0.00011392628,0.00031999985,0.0002461427,0.00015931156,0.0002448351,0.0012086481,0.000017884193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011555467,0.00017468871,0.00005240622,0.000024030836,0.00015239611,0.00032406536,0.0025710405,0.0000025576312,0.030226866,0.000001998727,0.9633765,0.0019378586],"study_design_scores_gemma":[0.0018599825,0.0023453953,0.00027643473,0.00012891127,0.00016391372,0.000060183338,0.00009911111,0.000023997374,0.0020829348,0.000043207503,0.99274504,0.00017086715],"about_ca_topic_score_codex":0.00015749576,"about_ca_topic_score_gemma":0.0000052730493,"teacher_disagreement_score":0.07547848,"about_ca_system_score_codex":0.00013509455,"about_ca_system_score_gemma":0.0014017989,"threshold_uncertainty_score":0.7944},"labels":[],"label_agreement":null},{"id":"W2101858167","doi":"10.1093/annonc/mdt078.6","title":"A Majority of Breast Cancer Specimens with 1-9 % ER Positivity Behave Like Hormone Receptor Negative Tumors","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Estrogen receptor; Breast cancer; Internal medicine; Oncology; Immunohistochemistry; Estrogen; Cancer; Pathology","score_opus":0.01334170656271378,"score_gpt":0.2896460671020374,"score_spread":0.2763043605393236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101858167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942988,0.0009040376,0.00001635776,0.0012583424,0.00007325602,0.00033400304,0.000121595935,0.0000068114136,0.002986807],"genre_scores_gemma":[0.99795604,0.0006624036,0.0005018196,0.00029341978,0.00011560601,0.000050344403,0.000038574646,0.000019123921,0.00036269493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989478,0.00013986569,0.00024162521,0.00027099386,0.00011857683,0.0002811216],"domain_scores_gemma":[0.9989625,0.000039805796,0.00025735653,0.00023005524,0.00039356813,0.00011671682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013896487,0.00017008156,0.00035246444,0.000047824917,0.000038056452,0.000004351094,0.00013563411,0.00026940898,0.00012085664],"category_scores_gemma":[0.00001901174,0.00013203002,0.000106182,0.00011444418,0.0003301566,0.00000924717,0.00008532074,0.0001634816,0.000016523756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087915815,0.00051691354,0.0045839734,0.000020876209,0.00037044697,0.000010283517,0.00015107093,0.000014961921,0.97196484,0.000050113722,0.014566928,0.0068704286],"study_design_scores_gemma":[0.0014609633,0.0069433087,0.15088281,0.00004815844,0.000070081755,0.00008544184,0.00015165747,0.000013812749,0.83745605,0.000080230704,0.0025432312,0.00026426977],"about_ca_topic_score_codex":0.0009211449,"about_ca_topic_score_gemma":0.00006808195,"teacher_disagreement_score":0.14629884,"about_ca_system_score_codex":0.00001620487,"about_ca_system_score_gemma":0.00019254128,"threshold_uncertainty_score":0.5384028},"labels":[],"label_agreement":null},{"id":"W2102068733","doi":"10.1093/annonc/mdm566","title":"Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Letrozole; Medicine; Placebo; Breast cancer; Hazard ratio; Tamoxifen; Randomization; Internal medicine; Confidence interval; Surgery; Randomized controlled trial; Oncology; Cancer","score_opus":0.04168575060205764,"score_gpt":0.3507932049311994,"score_spread":0.3091074543291418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102068733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945347,0.0012613192,0.000027759921,0.0022061502,0.00014423444,0.0011806668,0.00031820513,0.000002932413,0.00032406772],"genre_scores_gemma":[0.9969574,0.0017593838,0.000064414475,0.0003605195,0.00008666363,0.0005259556,0.000022027447,0.000013367036,0.00021025084],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998616,0.00015149028,0.0005389107,0.00029098662,0.00014250368,0.00026015472],"domain_scores_gemma":[0.9987033,0.0001078509,0.00041895104,0.00036699197,0.00035891525,0.000043986074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023899789,0.00017907328,0.0010058479,0.00018799664,0.00004458494,0.0000014113089,0.0002619629,0.00014527976,0.000020529784],"category_scores_gemma":[0.0000793995,0.00012236515,0.00055112515,0.00036258926,0.00022510918,0.00000384969,0.00008554779,0.000054607848,3.1299868e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78710705,0.0026660606,0.0740718,0.000032839187,0.0069938716,0.000005197593,0.0012554897,0.0007607259,0.085995294,0.000043198528,0.0035523411,0.037516136],"study_design_scores_gemma":[0.28209424,0.00837905,0.5711493,0.000040565097,0.0009665348,0.000011111749,0.00024449595,0.00005129479,0.1345281,0.000052484767,0.0022084024,0.00027440808],"about_ca_topic_score_codex":0.0011759299,"about_ca_topic_score_gemma":0.0013956542,"teacher_disagreement_score":0.5050128,"about_ca_system_score_codex":0.000034778983,"about_ca_system_score_gemma":0.00025106786,"threshold_uncertainty_score":0.4989906},"labels":[],"label_agreement":null},{"id":"W2102120311","doi":"10.1093/annonc/mdl060","title":"Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Barbara Ann Karmanos Cancer Institute; National Cancer Institute; National Institutes of Health; University of Chicago; University of California, San Francisco; Memorial Sloan-Kettering Cancer Center; University of Pennsylvania","keywords":"Peritoneal mesothelioma; Medicine; Mesothelioma; Peritoneal carcinomatosis; Oncology; Pathology; Internal medicine; Cancer","score_opus":0.07153174082721413,"score_gpt":0.36591394848095227,"score_spread":0.2943822076537381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102120311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867246,0.006487734,0.0000036661627,0.0030863252,0.00009491747,0.00023241929,0.00025827144,0.0000070343463,0.0031050285],"genre_scores_gemma":[0.99782366,0.0016369179,0.00021036543,0.00008228846,0.00007158102,0.000022470223,0.00005078841,0.000008151531,0.00009379633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991115,0.00007345884,0.0003784144,0.00017159793,0.00010826189,0.00015680354],"domain_scores_gemma":[0.99933887,0.00013261067,0.00022940965,0.00016613392,0.00007916054,0.000053822256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009680487,0.00012376769,0.00039380448,0.00008339415,0.00006375028,0.0000014804795,0.00007570626,0.00008201237,0.00007676619],"category_scores_gemma":[0.000026143642,0.0000824734,0.00013840698,0.00009656775,0.00064641534,0.000027724405,0.00007024297,0.000052312196,0.0000018591812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008930363,0.0038544945,0.89729726,0.0003147158,0.00022405166,0.000007807495,0.00045081275,0.000056196946,0.055905167,0.009279337,0.0015192011,0.030197896],"study_design_scores_gemma":[0.0015558841,0.0030888673,0.9242575,0.0001734823,0.00019238921,0.000038875387,0.00018064285,0.0001151576,0.033020195,0.0009207335,0.036348797,0.000107437765],"about_ca_topic_score_codex":0.0006354465,"about_ca_topic_score_gemma":0.00015683749,"teacher_disagreement_score":0.034829598,"about_ca_system_score_codex":0.00003499264,"about_ca_system_score_gemma":0.0001271089,"threshold_uncertainty_score":0.33631676},"labels":[],"label_agreement":null},{"id":"W2102763015","doi":"10.1093/annonc/mdl268","title":"New targets and non-cytotoxics in ovarian cancer","year":2006,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Cancer; Internal medicine","score_opus":0.1266691729296048,"score_gpt":0.4571530828931772,"score_spread":0.33048390996357235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102763015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019113271,0.9882794,0.0000086154205,0.0026560156,0.00024381986,0.00086198514,0.00006584934,0.0000065826407,0.007858596],"genre_scores_gemma":[0.000118515505,0.997096,0.00071636477,0.00053555664,0.00040821676,0.00019482973,0.000072006995,0.000036416517,0.00082210125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984985,0.00006943415,0.0006319007,0.00037571968,0.0001211115,0.00030334978],"domain_scores_gemma":[0.99899906,0.0001562281,0.00035850948,0.0002598027,0.00006291384,0.0001634631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001853562,0.00029364665,0.002433903,0.00025261237,0.000015629907,0.000005262321,0.00008152546,0.00048191534,0.00022098038],"category_scores_gemma":[0.000024386882,0.00022835794,0.00024834168,0.00023818167,0.000055023636,0.00002707983,0.00005225099,0.00027014257,0.000012899025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025766314,0.00032355625,0.0006219967,0.00393963,0.0002946838,0.00025759902,0.00003629666,4.4123198e-7,3.513896e-7,0.00011560402,0.040258106,0.95412594],"study_design_scores_gemma":[0.0014580595,0.0010312169,0.0027082358,0.0059985244,0.0006741429,0.000049921553,0.0000027570873,6.0755025e-7,0.000013160342,0.000093317205,0.98781514,0.00015492717],"about_ca_topic_score_codex":0.0029660035,"about_ca_topic_score_gemma":0.0010248882,"teacher_disagreement_score":0.953971,"about_ca_system_score_codex":0.00018294848,"about_ca_system_score_gemma":0.002083432,"threshold_uncertainty_score":0.9312166},"labels":[],"label_agreement":null},{"id":"W2103252719","doi":"10.1093/annonc/mdh408","title":"Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems","year":2004,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Quarter (Canadian coin); Pediatrics; Leukemia; Internal medicine; Oncology","score_opus":0.02125600361656128,"score_gpt":0.3464367489054979,"score_spread":0.32518074528893665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103252719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928369,0.006422436,0.0000062364975,0.000086747146,0.062477656,0.0020290448,0.00011267775,0.00003133879,0.00046489405],"genre_scores_gemma":[0.9539713,0.00096421,0.00009937507,0.000039697836,0.04431142,0.00022938263,0.00023673457,0.000090742855,0.00005711249],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958465,0.0002574344,0.0010982649,0.0006987826,0.0012850773,0.0008139031],"domain_scores_gemma":[0.9967794,0.0007976768,0.0007427754,0.00049157423,0.0009696507,0.00021892494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008085269,0.00044963934,0.0018403663,0.0007262149,0.00002862943,0.00004301493,0.0002225093,0.0011218973,0.00002573996],"category_scores_gemma":[0.00043608886,0.0003606181,0.00012692202,0.00043686322,0.0004917472,0.00018203042,0.00017367263,0.00077017274,0.0000038095802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.047350924,0.004660441,0.09106295,0.10894386,0.005940013,0.006358023,0.008547711,0.0025402082,0.00027213345,0.0000744159,0.66396314,0.06028619],"study_design_scores_gemma":[0.41667598,0.08432301,0.046836138,0.066964604,0.0020360986,0.00024650164,0.0014384157,0.006079228,0.0007871411,0.00007043267,0.37170354,0.0028389299],"about_ca_topic_score_codex":0.0051763724,"about_ca_topic_score_gemma":0.0002276704,"teacher_disagreement_score":0.36932504,"about_ca_system_score_codex":0.058893066,"about_ca_system_score_gemma":0.11349794,"threshold_uncertainty_score":0.9998846},"labels":[],"label_agreement":null},{"id":"W2103455702","doi":"10.1093/annonc/mdv071","title":"Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Trabectedin; Medicine; Oncology; Ovarian cancer; Internal medicine; Phases of clinical research; Chemotherapy; Cancer; BRCA mutation; Clinical trial; Pathology; Sarcoma","score_opus":0.046515431706351196,"score_gpt":0.40140119112359324,"score_spread":0.35488575941724204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103455702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662954,0.00026407387,7.1971505e-7,0.0014240782,0.000040511695,0.0014717969,0.0001188576,0.0000052468604,0.00004520827],"genre_scores_gemma":[0.9995165,0.00006930231,0.00003965361,0.00010340847,0.0000076316965,0.00022624352,0.000015280923,0.000010666552,0.000011298558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985298,0.0004986769,0.00035849228,0.00026387334,0.0002029555,0.00014621373],"domain_scores_gemma":[0.99869126,0.00045840762,0.00022948172,0.00026170255,0.00022368996,0.00013543315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041453962,0.0001625498,0.00082633155,0.00039709755,0.000023784802,0.0000024225674,0.00004457319,0.00005828567,0.000013454652],"category_scores_gemma":[0.00015034337,0.000093976574,0.00006228703,0.00081699423,0.00009551615,0.00003963227,0.00002137184,0.00005872648,2.1742864e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057416163,0.008995933,0.8124234,0.000027282116,0.0026211333,0.000036582886,0.009351276,0.00066903816,0.00069324975,0.0000058419796,0.000035407353,0.1077247],"study_design_scores_gemma":[0.033848293,0.12815532,0.8236333,0.000084728475,0.0017698348,7.647552e-7,0.0005680533,0.000036856098,0.011727677,0.0000022029326,0.00010923733,0.00006370889],"about_ca_topic_score_codex":0.00064899906,"about_ca_topic_score_gemma":0.0014313597,"teacher_disagreement_score":0.11915939,"about_ca_system_score_codex":0.00016617164,"about_ca_system_score_gemma":0.00026789284,"threshold_uncertainty_score":0.38322535},"labels":[],"label_agreement":null},{"id":"W2103580773","doi":"10.1093/annonc/mdl385","title":"Suicide and cancer: a gender-comparative study","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Suicide and Self-Harm Studies","field":"Psychology","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Cancer; Lung cancer; Demography; Population; Epidemiology; Oncology; Environmental health","score_opus":0.2622333478223887,"score_gpt":0.48664032979407296,"score_spread":0.22440698197168424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103580773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8965513,0.008753974,0.000006568461,0.0009752945,0.00024041347,0.0002821996,0.000013568754,0.00002663663,0.09315006],"genre_scores_gemma":[0.9979362,0.00022807195,0.000039340393,0.0006879054,0.00014725537,0.00011350973,0.0000025155368,0.000008938458,0.0008362773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987789,0.00021942347,0.00032601962,0.00028107053,0.00009639309,0.0002981844],"domain_scores_gemma":[0.9991847,0.0003002885,0.00015868804,0.00017451591,0.00014016284,0.000041644515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026731563,0.00013843237,0.000501936,0.00010422576,0.000076104065,0.000004907105,0.000109878485,0.00008611651,0.00039372093],"category_scores_gemma":[0.00001222617,0.00012146208,0.000053164047,0.00013494692,0.00016012207,0.000038278664,0.00006123112,0.00011554701,0.00004256206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057904795,0.0025407362,0.843463,0.000014882635,0.00095693226,0.00015706512,0.029566653,0.000015916106,0.0004939244,0.006439936,0.09370803,0.022063889],"study_design_scores_gemma":[0.001698151,0.0026367342,0.95178,0.0000022332974,0.000080326274,0.000015375756,0.01669837,0.0000035185171,0.00046529583,0.0027084646,0.023738362,0.00017313258],"about_ca_topic_score_codex":0.006302151,"about_ca_topic_score_gemma":0.0027466062,"teacher_disagreement_score":0.10831705,"about_ca_system_score_codex":0.000012994888,"about_ca_system_score_gemma":0.000042478547,"threshold_uncertainty_score":0.9527009},"labels":[],"label_agreement":null},{"id":"W2104441156","doi":"10.1093/annonc/mdv107","title":"Survival in stage I–III breast cancer patients by surgical treatment in a publicly funded health care system","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Hazard ratio; Mastectomy; Stage (stratigraphy); Radiation therapy; Cumulative incidence; Internal medicine; Proportional hazards model; Cancer; Cancer registry; Oncology; Breast-conserving surgery; Surgery; Cohort; Confidence interval","score_opus":0.055757127936273895,"score_gpt":0.3767742563148349,"score_spread":0.321017128378561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104441156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890457,0.004776354,0.0000012768893,0.0027804137,0.0002225881,0.00036363068,0.00085816253,0.000009140345,0.0019427419],"genre_scores_gemma":[0.998292,0.0007670787,0.000013806806,0.00019164971,0.000075355834,0.00017671083,0.00035394667,0.0000160713,0.00011332357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841446,0.00026515487,0.00038851987,0.00037711853,0.00014763341,0.0004071032],"domain_scores_gemma":[0.99920624,0.000023349081,0.00018841734,0.00020355133,0.00022809276,0.00015036551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020563426,0.00019311206,0.00052718894,0.00008027237,0.000026155854,0.000005534427,0.00011965909,0.00015815836,0.000007312018],"category_scores_gemma":[0.000011579341,0.00016619689,0.00007017638,0.00014582237,0.00007744919,0.000006335556,0.000088974775,0.00005852453,0.000002041499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019878517,0.0017476502,0.9587993,0.000083549756,0.00019315307,0.000035379704,0.0016373503,0.000047838406,0.000049660834,0.000088756395,0.0058234762,0.029506026],"study_design_scores_gemma":[0.04736703,0.014281383,0.59933543,0.00019329925,0.000044997665,0.00004528882,0.01632283,0.000017688346,0.0044208453,0.000010956742,0.3171133,0.000846942],"about_ca_topic_score_codex":0.032275047,"about_ca_topic_score_gemma":0.053530224,"teacher_disagreement_score":0.35946387,"about_ca_system_score_codex":0.0006061597,"about_ca_system_score_gemma":0.0005580504,"threshold_uncertainty_score":0.97416914},"labels":[],"label_agreement":null},{"id":"W2104967741","doi":"10.1093/annonc/mdq440","title":"Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Weight loss; Internal medicine; Lung cancer; Cachexia; Quality of life (healthcare); Oncology; Cancer; Performance status; Metastasis; Incidence (geometry); Chemotherapy; Obesity","score_opus":0.15659081298767874,"score_gpt":0.4927020205647803,"score_spread":0.33611120757710156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104967741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94157296,0.00271141,0.00006848181,0.04470153,0.0030589297,0.0011818149,0.00019859424,0.000025862662,0.0064804005],"genre_scores_gemma":[0.98278785,0.0012449069,0.008475786,0.0055077597,0.0005399141,0.0004902548,0.0008471428,0.00001839554,0.00008800082],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980086,0.0002529405,0.00063329923,0.00025735958,0.0005735512,0.00027424184],"domain_scores_gemma":[0.9978228,0.00046894932,0.00025151027,0.00014749478,0.0011465716,0.00016266534],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014291237,0.00012818463,0.00041100392,0.00036300608,0.000041910418,0.0000023172947,0.00007459772,0.00013346075,0.005519111],"category_scores_gemma":[0.00030636415,0.00013183903,0.000093824136,0.00015906495,0.00014810523,0.00011127247,0.00002093355,0.00043823823,0.000008457553],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007860889,0.0259266,0.3997289,0.0025606144,0.00043856748,0.00014442057,0.0005474427,0.00002975655,0.005263729,0.017078523,0.48360366,0.056816906],"study_design_scores_gemma":[0.04176411,0.0023687477,0.36616343,0.0004807279,0.0002693987,0.000024716623,0.0000722787,0.0065948353,0.00066066894,0.001898861,0.5794247,0.0002775309],"about_ca_topic_score_codex":0.000100007695,"about_ca_topic_score_gemma":0.00029872803,"teacher_disagreement_score":0.09582104,"about_ca_system_score_codex":0.00066960254,"about_ca_system_score_gemma":0.0017574234,"threshold_uncertainty_score":0.99539},"labels":[],"label_agreement":null},{"id":"W2105314246","doi":"10.1093/annonc/mdu371","title":"Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Ontario Clinical Oncology Group; University of Toronto","funders":"","keywords":"Exemestane; Everolimus; Medicine; Breast cancer; Oncology; Adverse effect; Internal medicine; Hazard ratio; Scopus; Cancer; Gynecology; Aromatase; MEDLINE; Confidence interval","score_opus":0.03922142997361332,"score_gpt":0.3289051840635258,"score_spread":0.2896837540899125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105314246","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.099143505,0.0005422569,0.0010984847,0.8923642,0.00017650568,0.002742109,0.0012102304,0.00014862485,0.0025740708],"genre_scores_gemma":[0.085492566,0.00019708015,0.0111933965,0.88875365,0.0036525324,0.0029311662,0.00049613544,0.00044883927,0.0068346458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676883,0.00007936613,0.0005427129,0.0008354374,0.0006095141,0.0011641256],"domain_scores_gemma":[0.9963824,0.0003434058,0.0009292308,0.00075984595,0.0013400635,0.0002450492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024415884,0.0007343066,0.002191717,0.00024845888,0.00008630379,0.000013895219,0.00036600948,0.00079031073,0.00050582015],"category_scores_gemma":[0.000014711411,0.00048249055,0.00011520167,0.00021055121,0.0007362413,0.00014602317,0.00005169607,0.0009849361,0.0000044090334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2458003,0.001079023,0.0066680303,0.0036831556,0.0065321554,0.0011909843,0.0022700927,0.00014712922,0.0005593224,0.00013933459,0.6310617,0.10086879],"study_design_scores_gemma":[0.014079243,0.05343049,0.00800995,0.00097077846,0.00048930664,0.0015925573,0.00017977775,0.000012182089,0.0006592017,0.0004591758,0.9193678,0.000749518],"about_ca_topic_score_codex":0.00021203369,"about_ca_topic_score_gemma":0.00065190636,"teacher_disagreement_score":0.28830615,"about_ca_system_score_codex":0.0004122861,"about_ca_system_score_gemma":0.0013641468,"threshold_uncertainty_score":0.99976265},"labels":[],"label_agreement":null},{"id":"W2105322112","doi":"10.1093/annonc/mds140","title":"Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; U.S. Public Health Service; National Institutes of Health; Public Health Institute","keywords":"Medicine; Pancreatic cancer; Pancreatitis; Odds ratio; Internal medicine; Gastroenterology; Cancer; Pancreatic disease; Pancreas; Population; Risk factor; Confidence interval; Pancreatic duct","score_opus":0.06485642925866293,"score_gpt":0.4138137283349691,"score_spread":0.3489572990763062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105322112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718849,0.009836594,0.00009318203,0.00879839,0.00016155536,0.0008084371,0.000250666,0.000018866984,0.008147397],"genre_scores_gemma":[0.9807607,0.0142674,0.0003472693,0.003104538,0.00036166006,0.000633956,0.000022712053,0.000020094052,0.0004817027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968957,0.00081529404,0.00076990435,0.00035254873,0.00043402583,0.00073255046],"domain_scores_gemma":[0.9962112,0.0023273465,0.00043872156,0.00041643396,0.0003415139,0.00026482207],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023924124,0.0002600327,0.0015827266,0.0005339939,0.00012349943,0.000017330827,0.00022927672,0.00027428317,0.0012869468],"category_scores_gemma":[0.0009696467,0.00018022353,0.00023351815,0.0007561186,0.00048416277,0.0001510182,0.0000681203,0.00049769,0.00001336658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073897064,0.00054796797,0.97233945,0.000075041076,0.0058208685,0.0005969632,0.002079754,0.00001899436,0.00022439232,0.00033327733,0.001836471,0.015387869],"study_design_scores_gemma":[0.003669593,0.0007918034,0.97797906,0.00008588698,0.009889713,0.0010490017,0.0011610248,0.0017283738,0.00009771809,0.00017904339,0.0031919258,0.00017686792],"about_ca_topic_score_codex":0.016190581,"about_ca_topic_score_gemma":0.005978707,"teacher_disagreement_score":0.015211001,"about_ca_system_score_codex":0.00016297103,"about_ca_system_score_gemma":0.00052293955,"threshold_uncertainty_score":0.99962604},"labels":[],"label_agreement":null},{"id":"W2105325986","doi":"10.1093/annonc/mdq745","title":"Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; Public Health Ontario; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Febrile neutropenia; Internal medicine; Confidence interval; Population; Neutropenia; Meta-analysis; Relative risk; Randomized controlled trial; Intensive care medicine; Chemotherapy","score_opus":0.20618102809475097,"score_gpt":0.4433997574533964,"score_spread":0.2372187293586454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105325986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016898193,0.9929838,0.0000030154454,0.00013431653,0.000038943803,0.00464797,0.00015556345,0.000013364159,0.002006126],"genre_scores_gemma":[0.00014547673,0.9964559,0.00007539542,0.00058025366,0.000008205413,0.0019898103,0.00005321259,0.000042237272,0.00064949505],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974764,0.0003178374,0.0013606495,0.0003951284,0.00023494274,0.0002150455],"domain_scores_gemma":[0.996784,0.00007482188,0.0018516288,0.0006338005,0.0005354965,0.00012029869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032533842,0.0003674685,0.010835484,0.00031353263,0.00002400996,0.0000034922582,0.00016758115,0.00015366814,0.00047541803],"category_scores_gemma":[0.0000121278945,0.00020395877,0.0016612138,0.0007532131,0.00011498353,0.00003982446,0.000107967666,0.00019715966,0.0000071091586],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021629608,0.0004127059,0.000043468932,0.7268058,0.2641677,0.000008082676,0.00002102802,2.0047463e-7,3.8731716e-9,0.00011602533,0.0005474119,0.007855966],"study_design_scores_gemma":[0.00025545235,0.0014909687,0.000070338516,0.03442399,0.76502913,0.0000066795374,0.000005104939,2.5050236e-8,4.28897e-7,0.0000018409089,0.19858749,0.00012854191],"about_ca_topic_score_codex":0.00020238713,"about_ca_topic_score_gemma":0.000094280265,"teacher_disagreement_score":0.6923818,"about_ca_system_score_codex":0.000057632922,"about_ca_system_score_gemma":0.00017926701,"threshold_uncertainty_score":0.8317197},"labels":[],"label_agreement":null},{"id":"W2105660133","doi":"10.1093/annonc/mdv208","title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Oncology; Lung cancer; Internal medicine; Cancer","score_opus":0.05669316549900459,"score_gpt":0.41655574449152644,"score_spread":0.35986257899252183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105660133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883034,0.0005223457,0.00001290939,0.0010268375,0.000033964086,0.00059767766,0.00001844974,0.000008765121,0.009475608],"genre_scores_gemma":[0.99261147,0.000040671282,0.0061983545,0.00049542496,0.000012988849,0.000091336085,0.000013866097,0.000011962844,0.0005239493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941105,0.000018577051,0.0001572684,0.00016686675,0.000096889875,0.0001493235],"domain_scores_gemma":[0.99932456,0.00011637475,0.00006744252,0.00010209699,0.00023869667,0.00015081593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006393471,0.00009101462,0.00024622577,0.00010777447,0.000016974935,0.0000026036553,0.000022470758,0.000042280168,0.00003568549],"category_scores_gemma":[0.00006812653,0.00006091162,0.000014503648,0.00017663515,0.000024109782,0.000044745473,0.000018430666,0.000025058278,0.000009845245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014318576,0.00091988733,0.5012333,0.000013557964,0.00008585349,0.000021930991,0.0005352626,0.0001177842,0.00022684083,0.0000015821638,0.0011334333,0.49427876],"study_design_scores_gemma":[0.017360108,0.01694502,0.9460138,0.00025267643,0.000212403,0.000005116744,0.00007963646,0.00032643502,0.00060803443,0.000027425343,0.018035816,0.00013354473],"about_ca_topic_score_codex":0.0003021957,"about_ca_topic_score_gemma":0.00008698539,"teacher_disagreement_score":0.4941452,"about_ca_system_score_codex":0.00018672502,"about_ca_system_score_gemma":0.0003501284,"threshold_uncertainty_score":0.24839038},"labels":[],"label_agreement":null},{"id":"W2105765694","doi":"10.1093/annonc/mdp373","title":"An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"GlaxoSmithKline","keywords":"Capecitabine; Medicine; Lapatinib; Metastatic breast cancer; Oncology; Expanded access; Internal medicine; Breast cancer; Cancer; Trastuzumab; Colorectal cancer","score_opus":0.12627047852334472,"score_gpt":0.49292940128938106,"score_spread":0.36665892276603634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105765694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971506,0.00015937215,0.0000034033349,0.00087087875,0.000043320684,0.0013480944,0.000051936648,0.00000773958,0.0003646356],"genre_scores_gemma":[0.9981062,0.00014819822,0.0004476584,0.0011119598,0.000020094987,0.00008425796,0.000021118658,0.000013215301,0.000047293444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988019,0.00014053611,0.00039557822,0.0002802155,0.00015872056,0.00022305842],"domain_scores_gemma":[0.9990472,0.00009226641,0.00029136654,0.0001807053,0.00027867334,0.00010978252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014230066,0.00015898846,0.0007521295,0.00012842238,0.000028928602,0.000010073112,0.00017398103,0.000050123803,0.00020872793],"category_scores_gemma":[0.000015286701,0.00010998409,0.000011179653,0.00024334496,0.0000838775,0.00031841206,0.000058871832,0.00010636948,2.105977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05779705,0.053531762,0.47069547,0.000103290324,0.0003856865,0.00010834745,0.0025187102,0.00010931312,0.0051002475,0.000008475885,0.00038430365,0.40925735],"study_design_scores_gemma":[0.061378747,0.07243306,0.86376435,0.00017541014,0.00019906677,0.000011468501,0.00046471757,0.000041570638,0.0012809028,0.000033277884,0.00009299448,0.00012444805],"about_ca_topic_score_codex":0.0010021692,"about_ca_topic_score_gemma":0.0027736346,"teacher_disagreement_score":0.4091329,"about_ca_system_score_codex":0.00004633718,"about_ca_system_score_gemma":0.0003021138,"threshold_uncertainty_score":0.4485021},"labels":[],"label_agreement":null},{"id":"W2106014642","doi":"10.1093/annonc/11.suppl_1.s69","title":"Non-Hodgkin's lymphoma and occupational exposure to chemicals in Canada","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Carcinogens and Genotoxicity Assessment","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Odds ratio; Benzidine; Confidence interval; Logistic regression; Incidence (geometry); Population; Hodgkin lymphoma; Pesticide; Non-Hodgkin's lymphoma; Environmental health; Toxicology; Lymphoma; Internal medicine; Biology","score_opus":0.020602349591989304,"score_gpt":0.31616931948348326,"score_spread":0.29556696989149395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106014642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965659,0.000195682,0.0000097089205,0.0010435471,0.000034755256,0.00011030981,0.000038779224,9.2972124e-7,0.0020003957],"genre_scores_gemma":[0.9964865,0.00019070493,0.00024964657,0.002806609,0.00006123059,0.000016920869,0.00003400165,0.0000056093427,0.00014876515],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99934185,0.00002255053,0.00018653132,0.00019262683,0.000082032486,0.00017442556],"domain_scores_gemma":[0.9996783,0.000014398342,0.0000351384,0.00013233107,0.000055347307,0.00008446286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010407147,0.0000783974,0.00016292605,0.000026907623,0.000016077569,0.0000026945352,0.00008255972,0.00008462865,0.00011389592],"category_scores_gemma":[0.00001541957,0.000080677884,0.000027224658,0.00006250533,0.000027616194,0.0000014846573,0.000044264863,0.00002615435,0.0000019623196],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006636476,0.0002279549,0.07394421,0.000022094931,0.000049220223,0.00003120963,0.000106304484,0.00042176055,0.58908755,0.000028612445,0.026215233,0.30920222],"study_design_scores_gemma":[0.00086449576,0.0012760431,0.54229563,0.000009101891,0.000004603701,0.00002228843,0.00007557757,0.000021821785,0.29777324,0.000034397675,0.15745977,0.0001630341],"about_ca_topic_score_codex":0.12702298,"about_ca_topic_score_gemma":0.49506927,"teacher_disagreement_score":0.46835142,"about_ca_system_score_codex":0.000034909623,"about_ca_system_score_gemma":0.000675631,"threshold_uncertainty_score":0.87879026},"labels":[],"label_agreement":null},{"id":"W2106198267","doi":"10.1093/annonc/mdn757","title":"Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut Claudius Regaud; Institut National Du Cancer","keywords":"Medicine; Sarcoma; Soft tissue sarcoma; Multivariate analysis; Soft tissue; Univariate analysis; Trunk; Overall survival; Radiation therapy; Internal medicine; Database; Surgery; Oncology; Pathology","score_opus":0.061899169158917064,"score_gpt":0.3603088248790247,"score_spread":0.29840965572010764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106198267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954946,0.0021798147,0.000003061485,0.005896595,0.00014779875,0.0011285422,0.00015290739,0.000010914082,0.0009309047],"genre_scores_gemma":[0.99719614,0.00017023677,0.00017692194,0.002215422,0.000069364985,0.000036940626,0.00008785301,0.000014062382,0.000033063916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997928,0.00033919653,0.0006941858,0.00030352524,0.00046175133,0.00027330944],"domain_scores_gemma":[0.99742204,0.0007669623,0.00049528055,0.0009614625,0.00026631265,0.00008794273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032695962,0.00020576,0.00074748835,0.00007077058,0.00006867313,0.0000036216225,0.00040548889,0.00011244889,0.00015965958],"category_scores_gemma":[0.00024994664,0.00011339806,0.00017332505,0.00024818556,0.0001775322,0.000053648168,0.00014353238,0.00018539923,0.000007817094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004040858,0.029639367,0.75751173,0.000022914046,0.00048421993,0.000058973703,0.0028751388,0.0000020802809,0.0015662996,0.00016059396,0.01781373,0.18946086],"study_design_scores_gemma":[0.0056352834,0.012494068,0.9612016,0.00010576653,0.0003534817,0.0000061421674,0.00048352644,0.0000090241165,0.0054779584,0.00035506315,0.01378976,0.00008831095],"about_ca_topic_score_codex":0.0035924998,"about_ca_topic_score_gemma":0.0013321353,"teacher_disagreement_score":0.20368987,"about_ca_system_score_codex":0.000034777207,"about_ca_system_score_gemma":0.00010497575,"threshold_uncertainty_score":0.5430809},"labels":[],"label_agreement":null},{"id":"W2106314180","doi":"10.1093/annonc/mdq309","title":"Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Thunder Bay Regional Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Cetuximab; Univariate analysis; Hazard ratio; Proportional hazards model; Multivariate analysis; Cancer; Gastroenterology; Colorectal cancer; Confidence interval","score_opus":0.05681807282855239,"score_gpt":0.39860252888909486,"score_spread":0.3417844560605425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106314180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868775,0.00033295507,2.3666978e-7,0.00030348593,0.00059082574,0.0013703067,0.0024467588,0.000016946253,0.0062507563],"genre_scores_gemma":[0.99820673,0.0005923579,0.00007411303,0.000071352784,0.000104145955,0.00013792403,0.000740716,0.000022858825,0.000049767197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981199,0.000092425376,0.0006261989,0.0004632935,0.00032316835,0.00037504546],"domain_scores_gemma":[0.9981732,0.00044834387,0.00047869486,0.00021518739,0.0005348732,0.00014970227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013119618,0.00029623395,0.001306788,0.00014159303,0.000060929335,0.0000059716813,0.00009802812,0.00020395081,0.000091741094],"category_scores_gemma":[0.00019117256,0.00023052824,0.0001063595,0.00018154911,0.00045160833,0.00009412582,0.00008564456,0.00030558804,0.0000011290426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86484873,0.007425051,0.0633009,0.000057369674,0.00088782265,0.0004011444,0.005395279,0.000003905204,0.0023902855,0.000010560114,0.00057298463,0.054705985],"study_design_scores_gemma":[0.6425953,0.081431724,0.26150566,0.00012497365,0.0004220684,0.0000022099507,0.0013578086,0.000010087994,0.009200179,0.000017522561,0.0030503902,0.0002820633],"about_ca_topic_score_codex":0.008568173,"about_ca_topic_score_gemma":0.039619915,"teacher_disagreement_score":0.22225341,"about_ca_system_score_codex":0.00014236291,"about_ca_system_score_gemma":0.00040568877,"threshold_uncertainty_score":0.9980339},"labels":[],"label_agreement":null},{"id":"W2106550415","doi":"10.1093/annonc/mdu162","title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","year":2014,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"European Society for Medical Oncology; Cancer Research UK","keywords":"Medicine; Chemotherapy; Oncology; Internal medicine; Cancer","score_opus":0.12137405163054374,"score_gpt":0.46515509798421983,"score_spread":0.3437810463536761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106550415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001930288,0.9904145,0.0000010520959,0.0025983413,0.00024002523,0.0034612038,0.00003994465,0.000024607183,0.003201024],"genre_scores_gemma":[0.000029937737,0.9897118,0.000047134636,0.0077520288,0.00019682795,0.001308346,0.000049765407,0.000057553436,0.0008465609],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968588,0.00035915882,0.0017337267,0.00046670713,0.00020888183,0.00037276893],"domain_scores_gemma":[0.9974186,0.00044992342,0.0011292056,0.0006677613,0.00022593571,0.00010860876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008706358,0.00045460512,0.009540755,0.0002803155,0.000019764304,0.000002669314,0.00025539496,0.00034097294,0.00028007338],"category_scores_gemma":[0.00030955978,0.0003181667,0.00089910935,0.00046951312,0.00010351032,0.000033580436,0.0000689411,0.00045183056,0.00003148558],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025122043,0.00010492328,0.00000994794,0.6435727,0.00044261143,0.00003391738,0.00004334593,3.4863195e-8,3.6142367e-7,0.000009112385,0.0062569003,0.349501],"study_design_scores_gemma":[0.0005187172,0.00085039594,0.00001403404,0.43982065,0.0012955455,0.00007149206,0.0000071153418,3.7154842e-7,0.0000017846345,0.000007965724,0.5572666,0.00014534677],"about_ca_topic_score_codex":0.000038779777,"about_ca_topic_score_gemma":0.00021926584,"teacher_disagreement_score":0.5510097,"about_ca_system_score_codex":0.0001698683,"about_ca_system_score_gemma":0.00083873473,"threshold_uncertainty_score":0.99992704},"labels":[],"label_agreement":null},{"id":"W2106674962","doi":"10.1093/annonc/mdt594","title":"The role of body mass index in survival outcome for lymphoma patients: US intergroup experience","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; International Prognostic Index; Body mass index; Diffuse large B-cell lymphoma; Lymphoma; Follicular lymphoma; Overweight; Clinical trial; CHOP; Prospective cohort study; Proportional hazards model; Aggressive lymphoma; Rituximab; Oncology","score_opus":0.04314897365277536,"score_gpt":0.38736573950540026,"score_spread":0.3442167658526249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106674962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996063,0.00010686696,0.000120637626,0.00050562975,0.0003535299,0.00022404118,0.000010312667,0.000004895188,0.0026110876],"genre_scores_gemma":[0.9993612,0.00006232946,0.000038386024,0.00036591722,0.000054885226,0.000042544052,0.0000053297404,0.000008563024,0.000060833954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909824,0.000052068095,0.00040735575,0.0001249157,0.00012034805,0.00019704187],"domain_scores_gemma":[0.99909365,0.00030885256,0.00019391527,0.00019225923,0.00016269046,0.000048602356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032170414,0.00007676495,0.00036416328,0.00006141358,0.000021621356,0.000002404087,0.0001294995,0.00008885772,0.00001532594],"category_scores_gemma":[0.0003249452,0.00005244456,0.000091387665,0.00007827566,0.00013804862,0.000034487344,0.00003685587,0.000051154548,0.0000011851805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006776833,0.0002663008,0.88220537,0.000016706248,0.000019711226,5.306575e-7,0.00047363524,0.0000018938389,0.0006055661,0.0006520734,0.00014731837,0.11493319],"study_design_scores_gemma":[0.002188844,0.002475806,0.8396638,0.000019639947,0.000008348479,7.3972967e-7,0.00068047683,0.00027016597,0.0028187088,0.00060675066,0.15121272,0.000053995253],"about_ca_topic_score_codex":0.0007111139,"about_ca_topic_score_gemma":0.00044693382,"teacher_disagreement_score":0.15106541,"about_ca_system_score_codex":0.00003979932,"about_ca_system_score_gemma":0.000057403973,"threshold_uncertainty_score":0.21386272},"labels":[],"label_agreement":null},{"id":"W2106926219","doi":"10.1093/annonc/mdi226","title":"Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Creatinine; Albumin; Refractory (planetary science); Alkaline phosphatase; Oncology; Surgery","score_opus":0.04433238645170595,"score_gpt":0.35053545970824257,"score_spread":0.3062030732565366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106926219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597144,0.0017675502,0.0000019112745,0.0009182225,0.00028870418,0.00027026053,0.000027392698,0.00001274867,0.00074174587],"genre_scores_gemma":[0.99861616,0.0008030476,0.000023736926,0.00017594898,0.000023308748,0.000021517524,0.00006250111,0.000007429001,0.00026632476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850416,0.00038710222,0.0006427082,0.00018368778,0.000032830874,0.00024953275],"domain_scores_gemma":[0.9990026,0.00017441915,0.00035527247,0.00019954598,0.00025522508,0.0000129719465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003816117,0.000115496725,0.00042390497,0.00025057077,0.000022933182,0.0000012344918,0.00016251905,0.00029386434,0.000417032],"category_scores_gemma":[0.0001824647,0.00010482524,0.00007945627,0.00022074957,0.00012542083,0.000120154415,0.000060080816,0.00017704736,0.00006380705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068189283,0.0033672971,0.71522266,0.000107368985,0.00017183616,0.0000034509158,0.002096241,0.00009381499,0.09460873,0.00034524,0.007789595,0.16937482],"study_design_scores_gemma":[0.0036835035,0.0018421602,0.7539766,0.000026909647,0.00002602081,0.000002296459,0.000040387844,0.0000033235399,0.22996907,0.00009782552,0.010219368,0.0001125657],"about_ca_topic_score_codex":0.0008359747,"about_ca_topic_score_gemma":0.00039125638,"teacher_disagreement_score":0.16926226,"about_ca_system_score_codex":0.00007374577,"about_ca_system_score_gemma":0.00018541266,"threshold_uncertainty_score":0.45662078},"labels":[],"label_agreement":null},{"id":"W2107074225","doi":"10.1093/annonc/mdl232","title":"Treatment of germ cell tumors – update 2006","year":2006,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Germ cell; Cancer research; Oncology; Internal medicine; Chemotherapy; Genetics","score_opus":0.1189563470541656,"score_gpt":0.44370714357083807,"score_spread":0.3247507965166725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107074225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038153704,0.9889917,0.0000012572223,0.00010990656,0.00008824734,0.0008135631,0.0004175377,0.000017616003,0.009178685],"genre_scores_gemma":[0.00090522895,0.99637383,0.00021211818,0.00005712688,0.00011280514,0.00008066818,0.0008014667,0.00004182479,0.0014149472],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835753,0.00011418678,0.00078703853,0.0003035574,0.00016133465,0.00027633063],"domain_scores_gemma":[0.9980795,0.00014471261,0.0010379408,0.00044768886,0.00013867901,0.00015147156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005399836,0.00035696442,0.0028892825,0.00019262971,0.000016852115,0.0000020661757,0.00008959485,0.00027574023,0.00011848877],"category_scores_gemma":[0.000026009748,0.00023978754,0.001075426,0.00016193997,0.00011161537,0.000014901758,0.000026935584,0.00007058904,0.00008814426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043531134,0.004421266,0.00032628526,0.008012431,0.0006202109,0.0008331383,0.000007022957,5.074721e-7,4.476062e-7,0.000051699455,0.00392923,0.98175424],"study_design_scores_gemma":[0.0012842324,0.005597055,0.00037353195,0.0016272779,0.004154103,0.00014689977,0.000002538834,5.8558425e-7,0.000035323512,0.000035954225,0.98660904,0.00013343085],"about_ca_topic_score_codex":0.00026022282,"about_ca_topic_score_gemma":0.000009097186,"teacher_disagreement_score":0.98267984,"about_ca_system_score_codex":0.00010354691,"about_ca_system_score_gemma":0.0010895393,"threshold_uncertainty_score":0.9778252},"labels":[],"label_agreement":null},{"id":"W2107233903","doi":"10.1093/annonc/mdp254","title":"Small molecules and targeted therapies in distant metastatic disease","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Targeted therapy; Sorafenib; Cancer research; Imatinib; Temsirolimus; Axitinib; Melanoma; Trametinib; Pazopanib; Pharmacology; Tyrosine kinase; Oncology; PI3K/AKT/mTOR pathway; Internal medicine; Cancer; Kinase; MAPK/ERK pathway; Signal transduction; Biology; Receptor; Discovery and development of mTOR inhibitors","score_opus":0.12445407943585476,"score_gpt":0.377092111462753,"score_spread":0.2526380320268983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107233903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016993227,0.9969258,0.00005344387,0.00014556659,0.000070320006,0.0003777002,0.000116849646,0.000004845038,0.0006061918],"genre_scores_gemma":[0.0010246746,0.99756986,0.00048419306,0.000263023,0.0000588098,0.000056523066,0.00041255166,0.00002460501,0.00010574585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984685,0.00032909663,0.00048308208,0.0003899097,0.00006515527,0.00026422867],"domain_scores_gemma":[0.99917126,0.000051130028,0.00028591562,0.0003112277,0.00005324451,0.00012721067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025538792,0.00028602476,0.0010706177,0.00012011021,0.000020325702,0.0000074528753,0.00019777322,0.00018771853,0.00000965694],"category_scores_gemma":[0.00011776816,0.00022769983,0.0002360994,0.000090351416,0.00012075729,0.0000017310538,0.00008734947,0.00012610151,0.0000027139693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007226168,0.00021503554,0.000011950567,0.0022482672,0.00017194859,0.00014138463,0.000031288386,8.0117724e-7,0.0003327153,0.0005562801,0.0006443577,0.9955737],"study_design_scores_gemma":[0.00024588354,0.0010708332,0.00007484752,0.000567554,0.00015095746,0.000018437288,0.000015876074,0.0000017598193,0.0001264664,0.00063164317,0.99686706,0.0002286661],"about_ca_topic_score_codex":0.000013212782,"about_ca_topic_score_gemma":0.000060490907,"teacher_disagreement_score":0.99622273,"about_ca_system_score_codex":0.000007551289,"about_ca_system_score_gemma":0.00036295145,"threshold_uncertainty_score":0.92853296},"labels":[],"label_agreement":null},{"id":"W2107367330","doi":"10.1093/annonc/mdr428","title":"Future research and methodological approaches","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Observational study; Medicine; Research design; Randomized controlled trial; Health care; Clinical study design; Clinical trial; Management science; Surgery; Pathology; Political science; Social science; Engineering","score_opus":0.9774666961868901,"score_gpt":0.6461620872950666,"score_spread":0.33130460889182345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107367330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58373165,0.0113804415,0.0013962195,0.15247422,0.0007371628,0.00078179967,0.000098020406,0.000044055505,0.24935643],"genre_scores_gemma":[0.94055784,0.0021892919,0.045689527,0.009793427,0.0008114396,0.00011661849,0.000010859716,0.000025896896,0.0008051086],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9959664,0.0012734004,0.0019095334,0.00040755305,0.000062017956,0.00038111006],"domain_scores_gemma":[0.99641275,0.002146152,0.00085699855,0.00031716164,0.00011701509,0.00014992594],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.048746478,0.00009661668,0.00089933025,0.00030758165,0.000106334184,0.000009595112,0.00023895294,0.0003004709,0.0005333791],"category_scores_gemma":[0.0035504238,0.00010440602,0.000063263724,0.0001687622,0.00035807915,0.00016331037,0.00010601713,0.00026600456,0.00032889683],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007236812,0.00030999645,0.020459319,0.00014372313,0.00006637519,0.0000026466062,0.0050504263,8.1846554e-7,0.0000035308497,0.9320592,0.033643384,0.008188203],"study_design_scores_gemma":[0.00050666294,0.0020419313,0.1015248,0.000015298943,0.000002746601,0.000016871214,0.004994546,0.00013267221,0.000092658294,0.47801766,0.4124549,0.00019923276],"about_ca_topic_score_codex":0.00033846326,"about_ca_topic_score_gemma":0.00005878443,"teacher_disagreement_score":0.45404154,"about_ca_system_score_codex":0.000051154842,"about_ca_system_score_gemma":0.00009528533,"threshold_uncertainty_score":0.9795157},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["insufficient_payload"],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2107405743","doi":"10.1093/annonc/mdq607","title":"Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?","year":2010,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Sanofi","keywords":"Medicine; Cardiotoxicity; Ejection fraction; Internal medicine; Breast cancer; Cardiology; Oncology; Trastuzumab; Clinical trial; Epirubicin; Heart failure; Cancer; Chemotherapy","score_opus":0.31839839261824016,"score_gpt":0.5148579846961103,"score_spread":0.19645959207787017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107405743","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1254112,0.87068933,0.0000055021364,0.00057637313,0.00039957574,0.0020835106,0.00044172117,0.000012520491,0.00038024358],"genre_scores_gemma":[0.089373045,0.9097986,0.000047672987,0.0002258393,0.00024521857,0.00016565439,0.00009511028,0.000038511072,0.000010300531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957099,0.00096606516,0.002118679,0.00049900037,0.00032609148,0.00038026876],"domain_scores_gemma":[0.99713403,0.0006525958,0.001481237,0.00035762982,0.00022755314,0.00014697103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031239714,0.00040258595,0.006167031,0.0007508755,0.000019947185,0.0000065938375,0.00017039629,0.0010798965,0.00008677428],"category_scores_gemma":[0.00051049015,0.00035176714,0.0008244157,0.00060644187,0.0001692971,0.000081880586,0.00006523541,0.0010800278,0.0000016462077],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016343512,0.00042258494,0.00069203036,0.010286013,0.00035669908,0.000034469616,0.00028447938,7.4189245e-7,0.006733079,0.000019407362,0.00025615105,0.9807509],"study_design_scores_gemma":[0.00793838,0.0010193724,0.0141527075,0.04348116,0.0016598965,0.00028632942,0.00007191428,0.00002587764,0.04864511,0.00032513347,0.8815953,0.00079882424],"about_ca_topic_score_codex":0.00037982498,"about_ca_topic_score_gemma":0.0001363843,"teacher_disagreement_score":0.9799521,"about_ca_system_score_codex":0.0002091755,"about_ca_system_score_gemma":0.001564712,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W2108034425","doi":"10.1093/annonc/mdh174","title":"Assessing websites on complementary and alternative medicine for cancer","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Park","funders":"","keywords":"Medicine; Alternative medicine; Quality (philosophy); MEDLINE; Complementary medicine; Family medicine; Cancer; Evidence-based medicine; Medical physics; Pathology; Internal medicine","score_opus":0.36364571899934994,"score_gpt":0.5529954139281086,"score_spread":0.18934969492875864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108034425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9251494,0.0012989754,0.00035745726,0.066427514,0.00031843522,0.00046360557,0.00004393195,0.000012996853,0.0059277075],"genre_scores_gemma":[0.98958385,0.0010801643,0.001086529,0.0073479777,0.00072249694,0.000049428312,0.000040337447,0.000009882729,0.00007935305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991079,0.000031175685,0.0002957069,0.00020991503,0.00015429378,0.00020104],"domain_scores_gemma":[0.999006,0.00046391253,0.0001604868,0.000089553294,0.00020194346,0.00007810213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026442847,0.00012971523,0.0005012376,0.00012789226,0.00008798438,0.00000235317,0.000056611538,0.000013081693,0.000272029],"category_scores_gemma":[0.00013722581,0.00009342311,0.00004786281,0.00007124669,0.0003345117,0.00006601158,0.00004868515,0.00009395877,0.000001378704],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031442042,0.001849413,0.12009496,0.0007986038,0.0029302323,0.00020915575,0.00802376,0.00011390842,0.03228319,0.03232667,0.030472916,0.767753],"study_design_scores_gemma":[0.034242347,0.06783006,0.26260775,0.002382676,0.0006326409,0.00008499889,0.012544615,0.00011555668,0.05613739,0.027894085,0.5351063,0.00042158863],"about_ca_topic_score_codex":0.00058985094,"about_ca_topic_score_gemma":0.0002001187,"teacher_disagreement_score":0.7673314,"about_ca_system_score_codex":0.000047676593,"about_ca_system_score_gemma":0.00007280211,"threshold_uncertainty_score":0.38096836},"labels":[],"label_agreement":null},{"id":"W2108080169","doi":"10.1093/annonc/mdu331.30","title":"A Phase I Study of Eribulin and Gemcitabine in Patients with Avanced Solid Tumours. a Study of the Princess Margaret Phase Ii Consortium","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Eribulin; Gemcitabine; Neutropenia; Internal medicine; Cohort; Chemotherapy; Oncology; Phases of clinical research; Gastroenterology; Cancer; Metastatic breast cancer; Breast cancer","score_opus":0.020321147543672476,"score_gpt":0.33916479521871556,"score_spread":0.3188436476750431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108080169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988265,0.00008496462,0.00001587583,0.00009196123,0.000060556886,0.0007461455,0.000054166958,0.0000012471236,0.00011855024],"genre_scores_gemma":[0.99971944,0.000044598106,0.000030256591,0.000117442,0.000023144039,0.000030925225,0.00001511263,0.000010196503,0.000008911459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897176,0.00012633322,0.00039910438,0.00023492286,0.00011292415,0.00015496182],"domain_scores_gemma":[0.99898356,0.00004792127,0.00038288682,0.00031898022,0.00022331988,0.00004333043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024731242,0.0001164321,0.00038311907,0.00004632548,0.000032368484,0.000002387183,0.00017690941,0.00006451381,0.0000041334138],"category_scores_gemma":[0.0001671488,0.00008658144,0.000027465456,0.00009196745,0.0001456711,0.0000029223415,0.00021392625,0.00006641169,6.5472605e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009709655,0.09195042,0.84186095,0.00007655857,0.00034538165,0.0000062245444,0.003146881,0.00051961857,0.03052852,0.000063495005,0.0005084466,0.021283856],"study_design_scores_gemma":[0.09071893,0.3222804,0.5081613,0.000050362156,0.00015374781,0.0000025353588,0.002038292,0.00010418146,0.07272988,0.00006782543,0.00337509,0.0003174502],"about_ca_topic_score_codex":0.00013651978,"about_ca_topic_score_gemma":0.0011996622,"teacher_disagreement_score":0.33369964,"about_ca_system_score_codex":0.0000060544903,"about_ca_system_score_gemma":0.00010492439,"threshold_uncertainty_score":0.3530689},"labels":[],"label_agreement":null},{"id":"W2108605309","doi":"10.1093/annonc/mdr580","title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canarie","funders":"Bayer HealthCare","keywords":"Medicine; Sorafenib; Foot (prosody); Internal medicine; Renal cell carcinoma; Oncology; Surgery; Nuclear medicine; Hepatocellular carcinoma","score_opus":0.09082843345727756,"score_gpt":0.38938158655833666,"score_spread":0.2985531531010591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108605309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799716,0.0004450774,0.000021973367,0.00030042802,0.00016765915,0.0003675876,0.0000119785645,0.00000374068,0.0006844094],"genre_scores_gemma":[0.99909264,0.00033223082,0.0002476174,0.000051496976,0.00004831396,0.0001542304,0.000027018137,0.0000048388274,0.00004163466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994591,0.00001848302,0.0002394077,0.00008522774,0.000076964505,0.00012083834],"domain_scores_gemma":[0.99957347,0.00005298168,0.00014948251,0.000034925346,0.00015877851,0.000030337365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019403466,0.000057971498,0.00022144301,0.00009613248,0.000030298523,0.0000010849134,0.0000110665615,0.00006370992,0.000005364713],"category_scores_gemma":[0.000064585896,0.00004911056,0.000021932397,0.00007274141,0.000033648615,0.00007317709,0.000014589673,0.00003449682,1.5676817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009720642,0.0006697394,0.6818431,0.00009608484,0.000100399884,1.5731725e-7,0.0042942544,0.0000015649227,0.001872721,0.000011990961,0.0002821548,0.3098558],"study_design_scores_gemma":[0.0020215511,0.0013284682,0.9351585,0.000078822435,0.000034935052,9.0753514e-7,0.0002151209,0.000011244233,0.047106944,0.000021282029,0.013987262,0.000034943394],"about_ca_topic_score_codex":0.00018909166,"about_ca_topic_score_gemma":0.00041443235,"teacher_disagreement_score":0.30982083,"about_ca_system_score_codex":0.00010839545,"about_ca_system_score_gemma":0.00008322357,"threshold_uncertainty_score":0.20026706},"labels":[],"label_agreement":null},{"id":"W2108624538","doi":"10.1093/annonc/mds220","title":"Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Koning Boudewijnstichting; European Organisation for Research and Treatment of Cancer; Pfizer","keywords":"Medicine; Cancer; Quality of life (healthcare); Gerontology; Surgery; Internal medicine; Nursing","score_opus":0.1070324413650985,"score_gpt":0.45100239746274584,"score_spread":0.34396995609764736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108624538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959523,0.0012357377,9.695617e-7,0.0018014017,0.00010038598,0.0003477536,0.00008677768,0.000002143536,0.00047251026],"genre_scores_gemma":[0.99917,0.00008883141,0.0000030282981,0.00064365065,0.000008374531,0.000021060387,0.0000483599,0.000004381059,0.000012294259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701697,0.0013683322,0.0010780947,0.000095138275,0.00025652233,0.00018492699],"domain_scores_gemma":[0.9976847,0.0011044792,0.0007684777,0.0002145924,0.00017957971,0.000048165788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031918255,0.000085104366,0.0015752862,0.00031549597,0.000007815085,3.3387988e-7,0.00009953216,0.00010216942,0.00016632456],"category_scores_gemma":[0.00044557697,0.000057156354,0.00022735483,0.0007835678,0.00011648025,0.00002923548,0.00002341913,0.00011574611,8.8976964e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067557517,0.00089822407,0.98623365,0.0002850347,0.00047025637,2.076197e-7,0.0044992357,0.00004641457,0.00014336292,0.00003656528,0.0001720407,0.006539403],"study_design_scores_gemma":[0.0017731857,0.001845004,0.9952499,0.00005154628,0.00016537282,8.6904166e-8,0.00021564784,0.000019556854,0.00045139616,0.000006669785,0.00018429017,0.00003732823],"about_ca_topic_score_codex":0.040081102,"about_ca_topic_score_gemma":0.010516914,"teacher_disagreement_score":0.02956419,"about_ca_system_score_codex":0.000048027665,"about_ca_system_score_gemma":0.00014295435,"threshold_uncertainty_score":0.9663111},"labels":[],"label_agreement":null},{"id":"W2108932832","doi":"10.1093/annonc/mdp253","title":"Immunotherapy of distant metastatic disease","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Hotel Dieu Hospital","funders":"","keywords":"Medicine; Immunotherapy; Melanoma; CD137; Immunology; Metastatic melanoma; Monoclonal antibody; Chimeric antigen receptor; Clinical trial; Antigen; Adoptive cell transfer; Oncology; T cell; Cancer research; Internal medicine; Antibody; Immune system","score_opus":0.11864381371579805,"score_gpt":0.42062929024356505,"score_spread":0.30198547652776697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108932832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000106516294,0.9969142,0.000028113918,0.00016113384,0.0006614146,0.00074015255,0.00028629505,0.00003157969,0.001070603],"genre_scores_gemma":[0.00028265722,0.996828,0.00006290485,0.00022868144,0.000020336516,0.00006564712,0.00035937794,0.000057380046,0.0020950206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99535376,0.0018255002,0.0017858229,0.00041569167,0.00007120982,0.00054800144],"domain_scores_gemma":[0.99595404,0.0011195565,0.0017543418,0.0009277661,0.0002069254,0.000037375987],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084352744,0.000569316,0.0040712184,0.0004786366,0.00008445474,0.0000055190785,0.00079595245,0.0004529606,0.00091513497],"category_scores_gemma":[0.0002118207,0.00043600236,0.0015012254,0.00035432194,0.00071219535,0.00007636741,0.00007820777,0.0005271851,0.00016404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013053667,0.0009805959,6.3343066e-7,0.0027698954,0.0021322768,0.000030487588,0.00013380407,2.6912588e-7,0.00081305776,0.001143915,0.0028866574,0.98780304],"study_design_scores_gemma":[0.00094632595,0.00258198,0.000018863757,0.0031812582,0.00064030517,0.000075028096,0.00003333825,4.923045e-8,0.0008177291,0.0004659462,0.9908846,0.0003545617],"about_ca_topic_score_codex":0.000037315407,"about_ca_topic_score_gemma":0.0000018536372,"teacher_disagreement_score":0.98799795,"about_ca_system_score_codex":0.000043193115,"about_ca_system_score_gemma":0.0012748075,"threshold_uncertainty_score":0.99999815},"labels":[],"label_agreement":null},{"id":"W2109126782","doi":"10.1093/annonc/mdq405","title":"Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Medicine; Diabetes mellitus; Hazard ratio; Cancer; Confidence interval; Internal medicine; Population; Demography; Cohort study; Cohort; Mortality rate; Standardized mortality ratio; Proportional hazards model; Pancreatic cancer; Environmental health; Endocrinology","score_opus":0.05765657460642906,"score_gpt":0.3432009284069877,"score_spread":0.28554435380055865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109126782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9608544,0.035009876,0.000005672074,0.00050379965,0.00018230388,0.00015141146,0.00007836292,0.0000027569963,0.003211428],"genre_scores_gemma":[0.9771133,0.022074737,0.000055964905,0.00038632136,0.00019811201,0.000052273415,0.00006419225,0.0000096668855,0.000045407658],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989982,0.00015286187,0.00027397287,0.00020850555,0.00013579539,0.00023061161],"domain_scores_gemma":[0.9990593,0.000056094206,0.00026827035,0.00036660428,0.00021446927,0.00003522647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005089727,0.00010478093,0.00028349098,0.000043676708,0.00003299234,0.0000056320323,0.00021012525,0.00019894692,0.000036343466],"category_scores_gemma":[0.000060263344,0.00007491558,0.00008067556,0.00014791655,0.00021490852,0.0000044939698,0.000026235302,0.0001590944,0.0000013765475],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012267329,0.00088350195,0.51702803,0.00005899921,0.00028288647,0.0000046486757,0.0010971426,0.00006940349,0.28331587,0.002673637,0.03254512,0.1619181],"study_design_scores_gemma":[0.0004899625,0.0005223985,0.23548107,0.000010415612,0.000033757922,8.5847705e-7,0.000175454,0.000004061151,0.1557358,0.00037061356,0.60704553,0.00013009853],"about_ca_topic_score_codex":0.0001290575,"about_ca_topic_score_gemma":0.0025285867,"teacher_disagreement_score":0.5745004,"about_ca_system_score_codex":0.000006328729,"about_ca_system_score_gemma":0.00014796747,"threshold_uncertainty_score":0.30549687},"labels":[],"label_agreement":null},{"id":"W2109283397","doi":"10.1093/annonc/mds340","title":"Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case–control studies","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; University of California, San Francisco; Blood Cancer UK; Associazione Italiana per la Ricerca sul Cancro; Ministry of Education, Culture, Sports, Science and Technology; Leukaemia and Lymphoma Research","keywords":"Medicine; Odds ratio; Internal medicine; Hormone therapy; Confidence interval; Menopause; Oncology; Lymphoma; Non-Hodgkin's lymphoma; Hormone replacement therapy (female-to-male); Breast cancer; Cancer","score_opus":0.07709461144010266,"score_gpt":0.3936857988991771,"score_spread":0.31659118745907444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109283397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94936943,0.04726334,0.000009549757,0.0020408004,0.000074970965,0.00032364213,0.00005058561,0.000010773553,0.00085692573],"genre_scores_gemma":[0.9912539,0.0069015943,0.00024187514,0.0014097955,0.000072778814,0.00006426042,0.000011669589,0.000012335075,0.000031804073],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987383,0.0001224453,0.00047570508,0.00019910462,0.00014897088,0.00031549373],"domain_scores_gemma":[0.99848396,0.00051700324,0.00028793258,0.00026466616,0.00028870875,0.00015775819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046253603,0.00018933896,0.0012751677,0.00037522125,0.00003858425,0.0000030853112,0.00004987389,0.00012412194,0.000033699114],"category_scores_gemma":[0.0000873508,0.00013301152,0.00020830869,0.00035915416,0.0002066683,0.000078722565,0.000042156837,0.000029882913,0.0000033310794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037484665,0.008995875,0.34015635,0.0000727608,0.06348195,0.0013940714,0.0065988703,0.000006717079,0.00756585,0.0004017568,0.0022858195,0.5652915],"study_design_scores_gemma":[0.013538508,0.014442884,0.95519626,0.000030320458,0.008882697,0.00073691184,0.0012949604,0.00019662299,0.0039445227,0.000043126838,0.0015450397,0.00014817079],"about_ca_topic_score_codex":0.00037072942,"about_ca_topic_score_gemma":0.0000511374,"teacher_disagreement_score":0.6150399,"about_ca_system_score_codex":0.000078156605,"about_ca_system_score_gemma":0.00009513667,"threshold_uncertainty_score":0.54240525},"labels":[],"label_agreement":null},{"id":"W2109333569","doi":"10.1093/annonc/mdi122","title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":360,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Radiation therapy; Placebo; Internal medicine; Oncology; Zoledronic acid; Clinical trial; Prostate; Cancer; Physical therapy; Pathology","score_opus":0.09199894573191564,"score_gpt":0.4262829673396755,"score_spread":0.3342840216077599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109333569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752951,0.004322878,0.0000110601695,0.017517056,0.00008570464,0.0024090356,0.00025718915,0.0000057214993,0.00009621214],"genre_scores_gemma":[0.9974937,0.0011231048,0.00025722882,0.0006685714,0.000005977918,0.0001755222,0.00003463097,0.000014490094,0.0002268111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765915,0.00028229403,0.0013222881,0.00015537188,0.00027895634,0.0003019174],"domain_scores_gemma":[0.9961262,0.0009352002,0.001842847,0.00028687628,0.0006868673,0.00012205733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010618311,0.0001234116,0.0008206388,0.000047805504,0.00007387627,5.8531e-7,0.00010596041,0.00006830295,0.00002667205],"category_scores_gemma":[0.0003140755,0.00006339182,0.00012101599,0.00022469259,0.00031456657,0.000036084213,0.00001728145,0.0001217617,0.0000010936477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028156707,0.007972681,0.48531023,0.0031427064,0.00529602,0.0000015691321,0.0047271354,0.0004781199,0.00020999221,0.0015971696,0.0040682806,0.4590394],"study_design_scores_gemma":[0.014597436,0.012507048,0.963012,0.0002078529,0.00028868974,0.000001059626,0.00023688939,0.00012630226,0.0012296898,0.00048268537,0.0072179125,0.000092471244],"about_ca_topic_score_codex":0.0023251374,"about_ca_topic_score_gemma":0.0008402699,"teacher_disagreement_score":0.47770172,"about_ca_system_score_codex":0.000047205463,"about_ca_system_score_gemma":0.0011517751,"threshold_uncertainty_score":0.3514928},"labels":[],"label_agreement":null},{"id":"W2109362035","doi":"10.1093/annonc/mdu010","title":"Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Alberta; Institute of Health Services and Policy Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Logistic regression; Internal medicine; Intensive care unit; Comorbidity; Prospective cohort study; Performance status; Univariate analysis; Cancer; Physical therapy; Multivariate analysis","score_opus":0.1495393917303485,"score_gpt":0.4498326209629911,"score_spread":0.30029322923264257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109362035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896708,0.000059276877,0.000019049794,0.008915065,0.00008883662,0.00039747477,0.000012013661,0.000022200564,0.0008152622],"genre_scores_gemma":[0.9965455,0.00042926008,0.000049804617,0.0024158547,0.00019560296,0.00007323624,0.000013345099,0.000022509219,0.00025487578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814475,0.0002939014,0.00058863894,0.000299254,0.00033944516,0.00033400016],"domain_scores_gemma":[0.99757606,0.0011478368,0.00020462954,0.00038172555,0.0005286093,0.0001611223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074922334,0.00015618537,0.0010547176,0.0002047462,0.000026281665,0.0000026103517,0.00014377582,0.00019800171,0.00019556122],"category_scores_gemma":[0.0026179762,0.00011357518,0.00018509975,0.00021654309,0.00027407391,0.000066341316,0.00013416345,0.00029778027,0.00001452993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078080203,0.0007935671,0.94540536,0.00028583544,0.00026930423,0.00001931454,0.0010304201,0.000006613848,0.01823533,0.00007403096,0.003796987,0.022275202],"study_design_scores_gemma":[0.0040142783,0.0035673243,0.96605486,0.00007122134,0.00002855201,0.0000075928197,0.0003018292,0.000097982665,0.024211742,0.00008300626,0.0014678697,0.000093755276],"about_ca_topic_score_codex":0.00016698282,"about_ca_topic_score_gemma":0.00013882076,"teacher_disagreement_score":0.022181446,"about_ca_system_score_codex":0.00020073808,"about_ca_system_score_gemma":0.00024797607,"threshold_uncertainty_score":0.46314615},"labels":[],"label_agreement":null},{"id":"W2109381544","doi":"10.1093/annonc/mdu009","title":"Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Cambridge Memorial Hospital; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Everolimus; Discontinuation; Adverse effect; Exemestane; Internal medicine; Pneumonitis; Placebo; Population; Breast cancer; Incidence (geometry); Hazard ratio; Clinical endpoint; Randomized controlled trial; Oncology; Cancer; Surgery; Confidence interval; Tamoxifen","score_opus":0.006743580355968832,"score_gpt":0.2761653726675962,"score_spread":0.2694217923116274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109381544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969414,0.0019254928,0.000018789746,0.00032681267,0.00007396327,0.00021236815,0.00021149789,0.0000067759593,0.0002829221],"genre_scores_gemma":[0.9980702,0.0010676981,0.0002190605,0.0003977847,0.00005551633,0.000044905944,0.00007664715,0.00002353665,0.0000446812],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986021,0.000202471,0.00037150676,0.00039339584,0.0001423617,0.00028818002],"domain_scores_gemma":[0.9989057,0.0000783426,0.00038087583,0.00025254756,0.000268883,0.000113652095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002084088,0.00019946978,0.0004584587,0.00006429349,0.000027456446,0.0000011765353,0.00019366057,0.00026027305,0.000039295406],"category_scores_gemma":[0.000037797494,0.00017947264,0.00002999544,0.00013862224,0.00025667154,0.00001709897,0.00010664987,0.00013500392,0.000004198215],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041809455,0.0002845393,0.009234478,0.0000124038215,0.00026328597,0.0000050018193,0.00062903133,0.0005044623,0.9721571,0.000015582997,0.00021389769,0.012499227],"study_design_scores_gemma":[0.008234376,0.021236883,0.6091951,0.00038250524,0.00008126222,0.000037496506,0.00041196836,0.00024309893,0.35582474,0.0007702328,0.0029005948,0.00068171567],"about_ca_topic_score_codex":0.0003033225,"about_ca_topic_score_gemma":0.00012818455,"teacher_disagreement_score":0.6163324,"about_ca_system_score_codex":0.000056847908,"about_ca_system_score_gemma":0.00027500684,"threshold_uncertainty_score":0.7318682},"labels":[],"label_agreement":null},{"id":"W2109624315","doi":"10.1093/annonc/mdm448","title":"Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Tumor marker; Oncology; Cancer research; Pathology; Internal medicine; Cancer","score_opus":0.08096756892943151,"score_gpt":0.3841325118452024,"score_spread":0.3031649429157709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109624315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980417,0.00035838957,0.0011772965,0.0011547748,0.00016794016,0.00034997496,0.0000031257352,0.000020583557,0.016350918],"genre_scores_gemma":[0.9956418,0.000008982407,0.0017208287,0.0018007696,0.00034358876,0.000012364777,0.000016198732,0.0000230125,0.0004324097],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888325,0.000021809132,0.0004367521,0.00019792137,0.00012835051,0.0003319232],"domain_scores_gemma":[0.99894893,0.00030732603,0.00018070987,0.00015777891,0.00027381748,0.00013144751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091643847,0.00011450712,0.0004375076,0.000120804674,0.000036931582,0.000003385586,0.00006850421,0.00011290088,0.00031413411],"category_scores_gemma":[0.00034133816,0.00010395174,0.0002190067,0.00011357647,0.000062064,0.000027895387,0.000033870823,0.00012714174,0.000013041866],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027113033,0.0007571924,0.46333006,0.0006380527,0.00030145893,0.0012329917,0.0011947068,0.0000034899713,0.40377498,0.0014427113,0.009547443,0.11506561],"study_design_scores_gemma":[0.0039341664,0.005634794,0.027946655,0.00022186556,0.0001444617,0.0011797183,0.00088699674,0.002496842,0.66073173,0.0012921224,0.29523012,0.00030050782],"about_ca_topic_score_codex":0.00008394728,"about_ca_topic_score_gemma":0.000007725457,"teacher_disagreement_score":0.43538338,"about_ca_system_score_codex":0.000047548376,"about_ca_system_score_gemma":0.0001687108,"threshold_uncertainty_score":0.4239029},"labels":[],"label_agreement":null},{"id":"W2109925286","doi":"10.1093/annonc/mdt237","title":"Quality indicators in ovarian cancer surgery: Report from the French Society of Gynecologic Oncology (Société Française d'Oncologie Gynécologique, SFOG)","year":2013,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Ovarian cancer; Gynecologic oncology; Mindset; General partnership; Multidisciplinary approach; Quality (philosophy); Cancer; Family medicine; Gynecology; General surgery; Oncology; Internal medicine; Finance","score_opus":0.12709067241690333,"score_gpt":0.4293995267101241,"score_spread":0.30230885429322074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109925286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6922979,0.051272284,0.0000336904,0.2304937,0.0070403605,0.002926583,0.0005570993,0.000046693604,0.015331689],"genre_scores_gemma":[0.9291263,0.049979407,0.0019538132,0.013780335,0.0013858554,0.0020909829,0.00017145074,0.000058213554,0.0014536455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99044895,0.002872679,0.0034131743,0.001167417,0.0006035572,0.0014942085],"domain_scores_gemma":[0.971315,0.022699721,0.0034431277,0.001286301,0.00082008494,0.00043575282],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059846956,0.0006804555,0.0036665648,0.0003279384,0.0001625309,0.000018770523,0.00069083273,0.0024867314,0.014184593],"category_scores_gemma":[0.0037847564,0.0005093098,0.0012134941,0.0015195864,0.0022737712,0.00023712136,0.00041441614,0.001400042,0.00009878724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013926649,0.0041735265,0.39635134,0.00015071378,0.0012107214,0.00037774304,0.0013901357,0.000023347604,0.0001350946,0.0003967245,0.2595062,0.33614522],"study_design_scores_gemma":[0.0027163415,0.0022994657,0.64186823,0.00024798722,0.0003693078,0.000029381414,0.0013515997,0.000021461803,0.0012416707,0.0020110074,0.34755424,0.00028928058],"about_ca_topic_score_codex":0.14828202,"about_ca_topic_score_gemma":0.017861312,"teacher_disagreement_score":0.33585593,"about_ca_system_score_codex":0.0021077697,"about_ca_system_score_gemma":0.009941199,"threshold_uncertainty_score":0.99973583},"labels":[],"label_agreement":null},{"id":"W2110487507","doi":"10.1093/annonc/mdu382","title":"Reply to the letter to the editor ‘Second-line chemotherapy in advanced biliary cancer: the present now will later be past’ by Vivaldi et al.","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"Cancer Research UK","keywords":"Medicine; Biliary tract cancer; Cancer; Internal medicine; Chemotherapy; Oncology; Gemcitabine","score_opus":0.04095800632157601,"score_gpt":0.35800586240350635,"score_spread":0.3170478560819303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110487507","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071397508,0.0040559433,0.00001150317,0.98166156,0.003943315,0.0018709607,0.00019499587,0.000025358084,0.0010965866],"genre_scores_gemma":[0.0035082363,0.0021066584,0.000034403176,0.9554958,0.032158427,0.0009705803,0.000084651365,0.00008226882,0.005558974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690396,0.00044706182,0.00067013653,0.0007192306,0.00054850307,0.0007111326],"domain_scores_gemma":[0.99707985,0.0008919408,0.00032033716,0.0013087227,0.00030601284,0.00009316634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010212085,0.0004704761,0.0010624388,0.00012963195,0.00011289489,0.000022676737,0.00079541386,0.00036328105,0.00030927183],"category_scores_gemma":[0.00010600402,0.00022530236,0.00030520232,0.00027586863,0.00024432794,0.00006196552,0.00027343413,0.001731039,0.000037767677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000562884,0.0000829233,0.0007306023,0.0000636939,0.0003636701,0.000047320744,0.0017430302,0.00003108187,0.0003077822,7.653338e-7,0.9875573,0.008508955],"study_design_scores_gemma":[0.0012088896,0.0019309601,0.003460212,0.00014062955,0.00007789036,0.000017859196,0.00006838173,0.000005346636,0.0007681464,0.000016169066,0.99205387,0.00025164377],"about_ca_topic_score_codex":0.000588066,"about_ca_topic_score_gemma":0.0014192451,"teacher_disagreement_score":0.02821511,"about_ca_system_score_codex":0.00011548687,"about_ca_system_score_gemma":0.00020847724,"threshold_uncertainty_score":0.9187563},"labels":[],"label_agreement":null},{"id":"W2110636137","doi":"10.1093/annonc/mdn195","title":"Radiotherapy in non-Hodgkin lymphomas","year":2008,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Radiation therapy; Hodgkin lymphoma; Lymphoma; Oncology; Internal medicine","score_opus":0.1490769391752207,"score_gpt":0.464937773801715,"score_spread":0.31586083462649434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110636137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021289407,0.98424375,9.426254e-7,0.0008678624,0.0001961027,0.00091870624,0.00002049448,0.000015111708,0.013524145],"genre_scores_gemma":[0.0001238215,0.9976407,0.00038722108,0.0008823313,0.00021872576,0.0002502919,0.000084192536,0.000046978123,0.00036568398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980715,0.0001643121,0.00084690365,0.00037998907,0.00017754501,0.00035977527],"domain_scores_gemma":[0.9985295,0.000384674,0.0004343195,0.00043765223,0.00007833892,0.0001355008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017339474,0.00036612965,0.0035560504,0.00042318544,0.000020481553,0.0000028237828,0.00015250836,0.00061745296,0.00017895106],"category_scores_gemma":[0.000048935402,0.00026615142,0.00076011557,0.0003376378,0.00012864808,0.000026220314,0.000035651632,0.00015680109,0.000077860495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055171673,0.0017124127,0.0003486699,0.0021591221,0.00050955475,0.0014341451,0.00008702837,1.681027e-7,2.62974e-7,0.00009540692,0.01859096,0.9750071],"study_design_scores_gemma":[0.0026811946,0.0027709426,0.0009843153,0.004701475,0.00021938892,0.0011677925,0.000004922104,0.000001217867,0.000010173327,0.000020881998,0.9872624,0.00017527076],"about_ca_topic_score_codex":0.00019325681,"about_ca_topic_score_gemma":0.000023460238,"teacher_disagreement_score":0.9748318,"about_ca_system_score_codex":0.00042001097,"about_ca_system_score_gemma":0.0014950079,"threshold_uncertainty_score":0.9999791},"labels":[],"label_agreement":null},{"id":"W2110697333","doi":"10.1093/annonc/mdt130","title":"A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Cancer; Targeted therapy; Nephrectomy; Clinical trial; Confidence interval; Surgery; Kidney","score_opus":0.15171743016833295,"score_gpt":0.4181931238162052,"score_spread":0.26647569364787227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110697333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885414,0.0015379501,0.0000058443816,0.0011915156,0.000045252862,0.0015744609,0.000009082912,0.000006829576,0.0070876344],"genre_scores_gemma":[0.99837273,0.00027526772,0.00044567487,0.00009186417,0.000026586276,0.00058230467,0.00002847438,0.000011810566,0.00016525613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99862885,0.00025408133,0.0004074729,0.00020373966,0.00032972384,0.00017614127],"domain_scores_gemma":[0.99864525,0.000096714066,0.00029641265,0.00017287189,0.0007264072,0.0000623476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041058395,0.000121050834,0.00046692824,0.00019400452,0.00001248358,0.0000021094183,0.00003777374,0.00006840855,0.00058819],"category_scores_gemma":[0.00006689228,0.00009215296,0.00009072153,0.0002034769,0.00006471598,0.00007457021,0.000012083885,0.00006204633,0.000019488114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039746524,0.011206005,0.2243059,0.0004601675,0.0015222388,0.00008886958,0.012870321,0.0030277318,0.3511792,0.00021953562,0.0024211255,0.38872424],"study_design_scores_gemma":[0.0070032915,0.012168796,0.5875474,0.00006429315,0.0004924467,0.0000074121967,0.0004362755,0.0026166386,0.38823575,0.0010882061,0.0002566009,0.000082885424],"about_ca_topic_score_codex":0.0030569064,"about_ca_topic_score_gemma":0.00040919994,"teacher_disagreement_score":0.38864136,"about_ca_system_score_codex":0.00049582747,"about_ca_system_score_gemma":0.000607834,"threshold_uncertainty_score":0.6440268},"labels":[],"label_agreement":null},{"id":"W2111207763","doi":"10.1093/annonc/mdt515","title":"Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Imperial Oil Limited","keywords":"Carboplatin; Medicine; Internal medicine; Randomized controlled trial; Ovarian cancer; Oncology; Placebo; Chemotherapy; Confidence interval; Gastroenterology; Surgery; Urology; Cisplatin; Cancer; Pathology","score_opus":0.05009334027789121,"score_gpt":0.37173640505091216,"score_spread":0.32164306477302096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111207763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863888,0.000076984135,0.00008803749,0.0070811645,0.0000861713,0.005658107,0.00003598006,0.0000407272,0.000544006],"genre_scores_gemma":[0.99579877,0.000027474733,0.0012132347,0.0020076376,0.00014288141,0.0003259785,0.00002377008,0.00006339157,0.00039687273],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99665827,0.0006996142,0.0012039073,0.00045656727,0.00050641934,0.0004752234],"domain_scores_gemma":[0.99697566,0.0008232686,0.00092552183,0.00053950003,0.0005945665,0.000141472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011930699,0.00038641953,0.0021440133,0.00024070314,0.000069060465,0.000017436378,0.0001917263,0.0003071222,0.00060078665],"category_scores_gemma":[0.00042609827,0.00022371064,0.00014685269,0.00053278945,0.00050704647,0.0001596576,0.00006395974,0.0004009885,0.000004411577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29339936,0.003087073,0.005510494,0.00011528064,0.0012002139,0.00011726046,0.021004329,0.000049814073,0.6696638,0.000020982681,0.0008989591,0.004932426],"study_design_scores_gemma":[0.63115513,0.008184504,0.019427108,0.0005313613,0.0005618646,0.000059897226,0.008493423,0.004759036,0.32617447,0.000089380264,0.00013525311,0.00042854098],"about_ca_topic_score_codex":0.0046599736,"about_ca_topic_score_gemma":0.0055379597,"teacher_disagreement_score":0.34348932,"about_ca_system_score_codex":0.00013133486,"about_ca_system_score_gemma":0.0005914783,"threshold_uncertainty_score":0.91226554},"labels":[],"label_agreement":null},{"id":"W2111378135","doi":"10.1093/annonc/mdr362","title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":658,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Lung; Bone metastasis; Internal medicine; Brain metastasis; Logistic regression; Oncology; Radiology; Cancer; Metastasis","score_opus":0.11916439843814368,"score_gpt":0.35111740990645196,"score_spread":0.23195301146830827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111378135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975846,0.0003285939,0.0002033388,0.00020740995,0.000014241322,0.00021133655,0.000040137587,0.000009397574,0.0014009343],"genre_scores_gemma":[0.9980221,0.000009298048,0.0013468867,0.00008091242,0.000008587885,0.000016571525,0.00047712686,0.000009117364,0.000029398303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988233,0.00014382014,0.00050935807,0.00018100732,0.00016498518,0.0001775495],"domain_scores_gemma":[0.99902743,0.00015025056,0.0003007315,0.0002427496,0.00020268025,0.00007616039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002924518,0.00010953324,0.00064323173,0.0003597495,0.000009641725,8.706048e-7,0.00005864241,0.000071559654,0.00013020958],"category_scores_gemma":[0.00007806699,0.000092195136,0.0002451697,0.00064658077,0.000060306687,0.00003092722,0.000015384734,0.00007544225,0.0000031796326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063029025,0.0014138281,0.991711,0.00011123462,0.00024733585,0.00012535456,0.00026588092,0.0001792057,0.0040480676,0.00009882306,0.00011668247,0.0010522688],"study_design_scores_gemma":[0.0012140938,0.0025227375,0.8941062,0.000010673152,0.000913935,0.0000037133734,0.000053207503,0.0004856572,0.100453116,0.00013719502,0.000043042055,0.000056404297],"about_ca_topic_score_codex":0.0028058544,"about_ca_topic_score_gemma":0.0004492739,"teacher_disagreement_score":0.097604804,"about_ca_system_score_codex":0.00008035327,"about_ca_system_score_gemma":0.00015592224,"threshold_uncertainty_score":0.42416313},"labels":[],"label_agreement":null},{"id":"W2111879252","doi":"10.1093/annonc/mdt397","title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"Canadian Institutes of Health Research; Swiss Cancer Research Foundation","keywords":"Medicine; Docetaxel; Prostate cancer; Prednisone; Oncology; Clinical trial; Internal medicine; Castration; Cancer; Hormone","score_opus":0.5467539969191952,"score_gpt":0.6379546010847985,"score_spread":0.09120060416560327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111879252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97565055,0.0013902273,0.000021341446,0.018234314,0.000054157146,0.003797765,0.00010138882,0.000008282383,0.0007419555],"genre_scores_gemma":[0.98745936,0.005335207,0.0062841563,0.00028722436,0.00007378146,0.0002247644,0.000018842482,0.000022071394,0.00029461866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988399,0.005516553,0.0048921034,0.00047592603,0.0004016604,0.00031471605],"domain_scores_gemma":[0.98276573,0.013509342,0.0022802956,0.00025936367,0.00086092466,0.00032432948],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029769542,0.00021789236,0.00406025,0.00018583525,0.000026702117,0.0000124395365,0.00007163746,0.00022375074,0.00004274716],"category_scores_gemma":[0.013769279,0.00011874311,0.00020165333,0.00022886514,0.00064838043,0.00019488936,0.000031912172,0.0003730693,8.9269764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07143323,0.0023811774,0.6722616,0.00035100582,0.0026734031,0.00009206056,0.0017203775,0.0000075571593,0.0015911323,0.000029594206,0.00052289607,0.24693596],"study_design_scores_gemma":[0.059038844,0.058689177,0.87245256,0.00072750566,0.0017785295,0.000020787604,0.0031850883,0.00020067088,0.00248317,0.00014052606,0.0010682108,0.00021495846],"about_ca_topic_score_codex":0.001158997,"about_ca_topic_score_gemma":0.0008815051,"teacher_disagreement_score":0.246721,"about_ca_system_score_codex":0.000022330987,"about_ca_system_score_gemma":0.0012070963,"threshold_uncertainty_score":0.99905646},"labels":[],"label_agreement":null},{"id":"W2112620415","doi":"10.1093/annonc/mdr593","title":"The sequential use of endocrine treatment for advanced breast cancer: where are we?","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Fulvestrant; Tamoxifen; Breast cancer; Oncology; Endocrine system; Aromatase; Internal medicine; Metastatic breast cancer; Cancer; Gynecology; Hormone","score_opus":0.3123031055212625,"score_gpt":0.498874483100001,"score_spread":0.18657137757873848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112620415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034607183,0.9892171,0.00004938906,0.006102568,0.0006064354,0.002084974,0.0018134156,0.000024870174,0.00006666167],"genre_scores_gemma":[0.000091519905,0.99546033,0.00080218265,0.00011138085,0.0007053146,0.0012368108,0.000083793384,0.000090382746,0.0014182604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778,0.00016555535,0.00091880985,0.00034973613,0.00019470019,0.0005911849],"domain_scores_gemma":[0.9962096,0.0008204091,0.0016425769,0.00062849344,0.00054252153,0.00015635598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001531598,0.00047481616,0.002979573,0.00011847318,0.00007823671,0.0000052452406,0.00021754848,0.00026042532,0.00012060488],"category_scores_gemma":[0.000029709416,0.00028274796,0.0008992505,0.00017271045,0.0003487479,0.000115809955,0.000066034634,0.0002021241,0.0000042220295],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012527753,0.00037905044,0.000039206916,0.007895939,0.0016253218,0.000012615432,0.00006021626,0.0000051879106,0.000023058952,0.00012007225,0.0007201126,0.98786646],"study_design_scores_gemma":[0.001921057,0.0016309666,0.000027543365,0.0062410356,0.0020207965,0.0004032482,0.00006843288,6.671987e-7,0.00013857402,0.000036857957,0.9873152,0.00019566457],"about_ca_topic_score_codex":0.00012356794,"about_ca_topic_score_gemma":0.00031767794,"teacher_disagreement_score":0.9876708,"about_ca_system_score_codex":0.00038243507,"about_ca_system_score_gemma":0.0010243217,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W2112648444","doi":"10.1093/annonc/mdu191","title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":790,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"NIHR Cambridge Biomedical Research Centre; Academy of Medical Sciences; Pathological Society of Great Britain and Ireland; Breast Cancer Campaign; Cancer Research UK; National Institute for Health and Care Research; Sanofi","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Estrogen receptor; Internal medicine; CD8; FOXP3; Cytotoxic T cell; Immunohistochemistry; Proportional hazards model; Pathology; Cancer; Immunology; Confidence interval; Immune system; Biology","score_opus":0.049513549492197446,"score_gpt":0.3511729877674861,"score_spread":0.3016594382752887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112648444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98931944,0.00009281089,0.000006885311,0.005417531,0.0001557707,0.00014061072,0.00003127596,0.0000063138905,0.004829382],"genre_scores_gemma":[0.9982054,0.0005063904,0.000021719698,0.0008812862,0.00013142948,0.000007733281,0.000033735254,0.00000595648,0.00020629846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928576,0.00010375866,0.0002434205,0.0001076845,0.00012450946,0.00013486354],"domain_scores_gemma":[0.99944085,0.00014325675,0.00019139037,0.00006655506,0.00012174071,0.00003620965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049740216,0.000062405525,0.0002465017,0.00007390149,0.000016658318,0.0000032737994,0.000028905959,0.00013794564,0.00006177571],"category_scores_gemma":[0.000049738217,0.000056891502,0.000034592013,0.000081963924,0.000031585536,0.000054794105,0.000010498544,0.00008116977,0.000001936261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004920103,0.00013336142,0.88074684,0.000027858527,0.000055223307,2.5688442e-7,0.00016377239,6.299319e-7,0.002442811,0.0000066294024,0.0014736097,0.11445697],"study_design_scores_gemma":[0.003082419,0.0009300129,0.9726734,0.00002954518,0.000030013014,5.659285e-7,0.000022504317,0.000011677703,0.0016846539,0.000043165248,0.021439282,0.000052762734],"about_ca_topic_score_codex":0.0009949892,"about_ca_topic_score_gemma":0.0010444482,"teacher_disagreement_score":0.11440421,"about_ca_system_score_codex":0.00008726107,"about_ca_system_score_gemma":0.00007931817,"threshold_uncertainty_score":0.2319968},"labels":[],"label_agreement":null},{"id":"W2113183935","doi":"10.1093/annonc/mdm576","title":"Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oncology; Nucleoside transporter; Internal medicine; Nucleoside; Transporter; Gene; Genetics","score_opus":0.08231909379634023,"score_gpt":0.353507848069409,"score_spread":0.27118875427306877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113183935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956283,0.00069963024,0.000046617235,0.0006726594,0.000028369841,0.00024252792,0.00003956949,0.0000098818755,0.0026324438],"genre_scores_gemma":[0.9982876,0.00015055125,0.00008164871,0.0006155744,0.00010085819,0.000048882575,0.00012367594,0.000024353722,0.00056684983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877506,0.00014567253,0.0003232092,0.00030514933,0.00014905795,0.00030182465],"domain_scores_gemma":[0.99943626,0.000016878172,0.00012321619,0.00017870127,0.00018099135,0.000063931904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018563216,0.00015901627,0.00033771127,0.00006901946,0.00005760643,0.000002828813,0.00016024508,0.00025388488,0.0001257447],"category_scores_gemma":[0.000027446327,0.00014060778,0.000073934636,0.00018002155,0.00017911877,0.000007988199,0.00003718192,0.00015588877,7.2854243e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006522309,0.00054977357,0.081837006,0.00001951929,0.00033684782,0.0002834267,0.0008432505,0.0001445928,0.9007565,0.00004960028,0.014159015,0.0003682692],"study_design_scores_gemma":[0.001943647,0.0044921637,0.10598896,0.00011438466,0.00003112709,0.000022897348,0.00016115785,0.00002655757,0.8803628,0.00012143517,0.0063257474,0.00040912395],"about_ca_topic_score_codex":0.00031003717,"about_ca_topic_score_gemma":0.0007340227,"teacher_disagreement_score":0.02415195,"about_ca_system_score_codex":0.000014966169,"about_ca_system_score_gemma":0.00024237768,"threshold_uncertainty_score":0.5733819},"labels":[],"label_agreement":null},{"id":"W2113201023","doi":"10.1093/annonc/mdm370","title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Incidence (geometry); Retrospective cohort study; Internal medicine; Comorbidity; Oncology; Surgery","score_opus":0.06168737708404148,"score_gpt":0.3853668677071316,"score_spread":0.3236794906230901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113201023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981969,0.00014213432,8.065536e-7,0.00022437134,0.00010742267,0.0007303413,0.000030206767,0.000004516369,0.00056331255],"genre_scores_gemma":[0.9997759,0.00008156703,0.000023850154,0.000076377466,0.0000036086817,0.000007689685,0.0000046261302,0.0000076075207,0.000018808892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986622,0.00023436554,0.00054974074,0.00013885825,0.00021600034,0.00019883599],"domain_scores_gemma":[0.998446,0.00050630677,0.0005809665,0.00019567934,0.00021986818,0.000051185863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007139921,0.00010502648,0.00047711175,0.000106352876,0.00008035167,0.000001977889,0.00007663152,0.00011079266,0.0000075180624],"category_scores_gemma":[0.0006381497,0.000056487916,0.0000619161,0.00028757064,0.00033799643,0.000058743957,0.000066902365,0.0002247591,2.6219632e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002102477,0.0013904,0.9876663,0.000023452953,0.00011213209,0.000005465477,0.0054458133,0.000001620115,0.00006709465,0.000015466869,0.000029823026,0.005032187],"study_design_scores_gemma":[0.002880068,0.0030263478,0.98880774,0.000069679,0.000072992276,0.0000019351264,0.0030133438,0.000018988427,0.0018225705,0.00021769029,0.000031233776,0.000037385198],"about_ca_topic_score_codex":0.010320432,"about_ca_topic_score_gemma":0.0045035244,"teacher_disagreement_score":0.005816907,"about_ca_system_score_codex":0.000062537874,"about_ca_system_score_gemma":0.00012894195,"threshold_uncertainty_score":0.99626994},"labels":[],"label_agreement":null},{"id":"W2113708580","doi":"10.1093/annonc/mdr519","title":"Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Dalhousie University","funders":"Merck","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Ejection fraction; Internal medicine; Breast cancer; Regimen; Doxorubicin; Cyclophosphamide; Anthracycline; Metastatic breast cancer; Heart failure; Cardiology; Cancer; Chemotherapy; Gastroenterology; Urology; Surgery","score_opus":0.08758399274204345,"score_gpt":0.3688849666775735,"score_spread":0.28130097393553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113708580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583055,0.0005750629,0.00028553177,0.0006260224,0.00036653384,0.0020432435,0.00005095638,0.000032557855,0.010189546],"genre_scores_gemma":[0.9983448,0.0006391462,0.00026851043,0.00028899027,0.00020245826,0.000065314525,0.0000629096,0.000021159876,0.00010670286],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980303,0.00037771152,0.00080030924,0.0002524079,0.00027260225,0.00026666612],"domain_scores_gemma":[0.9984231,0.00026509646,0.00050875515,0.00025779987,0.0003992797,0.00014596718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010174547,0.00019916093,0.001965581,0.00014348383,0.000047858226,0.0000015247357,0.000086471046,0.00024256864,0.0002080987],"category_scores_gemma":[0.00019030462,0.00014693524,0.0005183538,0.00019180386,0.0004508051,0.000062764906,0.000025731531,0.00022626415,0.0000027734654],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7711318,0.0028311422,0.000022256736,0.00006794054,0.0012918896,0.000026431815,0.0040283543,0.0000014700497,0.14242537,0.0005265334,0.0003904338,0.07725636],"study_design_scores_gemma":[0.53023773,0.02514756,0.00012411505,0.000106529944,0.00045692537,0.000026575797,0.00020772456,0.000024557614,0.44088566,0.00006678635,0.002610522,0.00010527659],"about_ca_topic_score_codex":0.00014285324,"about_ca_topic_score_gemma":0.0000113610995,"teacher_disagreement_score":0.29846027,"about_ca_system_score_codex":0.000044138073,"about_ca_system_score_gemma":0.00050283846,"threshold_uncertainty_score":0.5991845},"labels":[],"label_agreement":null},{"id":"W2113822020","doi":"10.1093/annonc/mdh132","title":"Hodgkin’s lymphoma in Chinese migrants to British Columbia:a 25-year survey","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Incidence (geometry); Population; Lymphoma; Demography; Cancer registry; Nodular sclerosis; Hodgkin lymphoma; Pediatrics; Internal medicine; Environmental health","score_opus":0.05037512773404305,"score_gpt":0.36194546206197237,"score_spread":0.3115703343279293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113822020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915306,0.00041989738,0.0000016375327,0.0030116912,0.00016172977,0.000441371,0.00009112982,0.000021126063,0.0043208147],"genre_scores_gemma":[0.99528724,0.00048428524,0.00041764666,0.0032923785,0.00005990229,0.00006695302,0.000053032647,0.000018571938,0.00031996885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866134,0.00010163599,0.00039131934,0.0003024515,0.00018942452,0.0003538258],"domain_scores_gemma":[0.99909145,0.00016442609,0.00009091569,0.00025235108,0.00018684624,0.00021402966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042773312,0.00011505283,0.00063700025,0.00009918854,0.000032249223,0.000021285769,0.000107039974,0.00016355983,0.00017999063],"category_scores_gemma":[0.0003937423,0.00014091741,0.00011348107,0.00038939295,0.00006899675,0.000047103873,0.000056781082,0.000048684717,0.000102427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021504126,0.0031983154,0.9062887,0.000021501848,0.000084398205,0.0009411107,0.00019342202,0.000008918445,0.000060211198,0.000014111869,0.0127177425,0.076256566],"study_design_scores_gemma":[0.008919685,0.0031545984,0.9781812,0.0001352241,0.00001792248,0.00017436565,0.000035773504,7.9769154e-7,0.0002249475,0.0002898014,0.008752207,0.00011352022],"about_ca_topic_score_codex":0.22188042,"about_ca_topic_score_gemma":0.45485052,"teacher_disagreement_score":0.2329701,"about_ca_system_score_codex":0.00019525661,"about_ca_system_score_gemma":0.00042180065,"threshold_uncertainty_score":0.7833011},"labels":[],"label_agreement":null},{"id":"W2113898985","doi":"10.1093/annonc/mdu326.1","title":"Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"Medicine; Oncology; Biomarker; Internal medicine; Adjuvant; Lung cancer; ERCC1","score_opus":0.027900055226187572,"score_gpt":0.38879716577754386,"score_spread":0.3608971105513563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113898985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820801,0.0017348748,0.00038441847,0.0063218144,0.00013181411,0.0017192011,0.00006969991,0.00001719531,0.007540891],"genre_scores_gemma":[0.9967453,0.0007449938,0.00073971757,0.00089367176,0.000083277155,0.00038200442,0.00004719338,0.00002064269,0.0003432107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991688,0.00005382241,0.00022538684,0.00023818233,0.000069505215,0.0002443147],"domain_scores_gemma":[0.9991529,0.00031084544,0.0001293161,0.00012721577,0.00018819617,0.00009155472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022835303,0.00011922375,0.00035783803,0.0001350494,0.000038507955,0.0000039853508,0.000048113812,0.00012171931,0.000024889867],"category_scores_gemma":[0.000112569425,0.000095934585,0.00005502701,0.00014143821,0.0000847619,0.000037086946,0.000016023598,0.00008726131,6.7165627e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006571253,0.0021426207,0.72714466,0.0011845573,0.0015342206,0.000031873835,0.007262459,0.000057202156,0.016709749,0.00008124816,0.02323842,0.21404177],"study_design_scores_gemma":[0.018435368,0.010071127,0.9170347,0.0005201407,0.00072938745,0.0000112489915,0.00037490876,0.005668697,0.019074459,0.00023923568,0.027615571,0.00022519544],"about_ca_topic_score_codex":0.00030428352,"about_ca_topic_score_gemma":0.00028414186,"teacher_disagreement_score":0.21381657,"about_ca_system_score_codex":0.00008497327,"about_ca_system_score_gemma":0.00040104263,"threshold_uncertainty_score":0.3912099},"labels":[],"label_agreement":null},{"id":"W2113964935","doi":"10.1093/annonc/mdt473","title":"Targeted therapies and clinical trials in ovarian cancer","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Impact; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Ovarian cancer; Druggability; Clinical trial; Targeted therapy; Oncology; Olaparib; Bioinformatics; Cancer; Cancer research; Computational biology; Internal medicine; Gene; Biology; Genetics","score_opus":0.5412878740202864,"score_gpt":0.6029907062384672,"score_spread":0.061702832218180736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113964935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013259989,0.98980093,8.477262e-7,0.006623746,0.0004758052,0.0017552377,0.00007674112,0.000008467178,0.0011256202],"genre_scores_gemma":[0.00013186442,0.9972432,0.00032105364,0.00088686956,0.00047493278,0.000642589,0.000045911893,0.000031977786,0.00022156103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953021,0.0017978199,0.0021114943,0.00041192924,0.00011614951,0.00026051188],"domain_scores_gemma":[0.9953024,0.0029885555,0.0011271377,0.0003009966,0.00012311958,0.00015779144],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003623512,0.0002934118,0.006486086,0.0002343644,0.000015500944,0.000008236441,0.00009162708,0.00070712034,0.000938494],"category_scores_gemma":[0.00085409643,0.00018427343,0.0007460872,0.00017932481,0.00016144654,0.0000320386,0.000049096605,0.0003815446,0.000024240806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063896376,0.0006648496,0.001205178,0.0024403255,0.0018228759,0.00006181894,0.000053449676,2.0973197e-8,2.2148735e-7,0.00018328664,0.01195761,0.98154646],"study_design_scores_gemma":[0.0022008396,0.0019209986,0.0034364783,0.0054251826,0.0015624526,0.000019861685,0.000014463591,4.9174565e-7,0.000002296095,0.00012228994,0.9851617,0.00013292086],"about_ca_topic_score_codex":0.00070365897,"about_ca_topic_score_gemma":0.00016687864,"teacher_disagreement_score":0.98141354,"about_ca_system_score_codex":0.0000829232,"about_ca_system_score_gemma":0.0012679017,"threshold_uncertainty_score":0.9999748},"labels":[],"label_agreement":null},{"id":"W2114363508","doi":"10.1093/annonc/mdu086","title":"Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"European Commission","keywords":"Medicine; Cancer; Consensus conference; Cachexia; Medical physics; Internal medicine","score_opus":0.6960035539468846,"score_gpt":0.5820377601904861,"score_spread":0.11396579375639848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114363508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871535,0.000022462375,0.00048670542,0.008367467,0.000131399,0.0013824882,0.00038798607,0.000006061275,0.00050007197],"genre_scores_gemma":[0.9963679,0.000032014803,0.0021900833,0.00073273684,0.00006501154,0.00008493272,0.00051687186,0.000006581724,0.000003884609],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99870235,0.00035216348,0.00036917874,0.00019557687,0.00031043947,0.00007026537],"domain_scores_gemma":[0.997997,0.00032391967,0.00043892572,0.0003279647,0.0008847258,0.000027461747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015693142,0.000059329737,0.00020640787,0.000101040925,0.000033958015,0.0000026864313,0.00010023199,0.00006845779,0.000020917174],"category_scores_gemma":[0.000661814,0.000047457637,0.000023735332,0.00006520064,0.000063978594,0.000055097837,0.000021269803,0.0000653782,1.914947e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016929198,0.020218296,0.5526517,0.0014979937,0.00064854097,7.6554716e-7,0.010097541,0.011525782,0.097144365,0.0051772385,0.0077984002,0.27631018],"study_design_scores_gemma":[0.0049694856,0.0010687953,0.14956914,0.0001346667,0.00020346312,4.0221016e-7,0.00054949033,0.83832985,0.0040024864,0.00078087277,0.00035341736,0.000037912563],"about_ca_topic_score_codex":0.0002775687,"about_ca_topic_score_gemma":0.0002270021,"teacher_disagreement_score":0.8268041,"about_ca_system_score_codex":0.000043279717,"about_ca_system_score_gemma":0.00040339478,"threshold_uncertainty_score":0.19352663},"labels":[],"label_agreement":null},{"id":"W2114486723","doi":"10.1093/annonc/mdt506","title":"Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Sleep and related disorders","field":"Psychology","cited_by":248,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; Ottawa Hospital; University of Alberta; Université Laval; Cape Breton University; Canadian Partnership Against Cancer; University of Calgary; Toronto Rehabilitation Institute; Canadian Sleep & Circadian Network; Kingston Health Sciences Centre; University of Toronto; Queen's University","funders":"Partenariat Canadien Contre Le Cancer","keywords":"Medicine; Sleep disorder; Randomized controlled trial; Systematic review; Guideline; Evidence-based practice; MEDLINE; Evidence-based medicine; Insomnia; Alternative medicine; Psychiatry; Pathology","score_opus":0.48717212048880376,"score_gpt":0.6293552385910487,"score_spread":0.14218311810224493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114486723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009911143,0.97874,0.00006648273,0.0024403338,0.00039310605,0.016073242,0.00003662617,0.0000055259284,0.0022348126],"genre_scores_gemma":[0.000013108034,0.9804996,0.002566382,0.0007580592,0.00003913634,0.015878381,0.000023192411,0.000035383167,0.00018674506],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99453044,0.001576671,0.0026582528,0.0006758815,0.00020106237,0.00035771172],"domain_scores_gemma":[0.9799607,0.012224646,0.0067808363,0.00053610763,0.00042999905,0.00006770407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045312024,0.00034027608,0.0039811106,0.00022862507,0.000021145639,0.000007969719,0.0004035383,0.0005105606,0.000027093374],"category_scores_gemma":[0.0029730059,0.00021252451,0.00030180137,0.00038077505,0.00017557757,0.00020325059,0.000073427436,0.0004274676,0.000005239904],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026788499,0.001030706,0.00005722744,0.5943159,0.0014193361,0.00001595482,0.00010034034,2.945504e-7,1.1538613e-9,0.0005104942,0.0020301985,0.4002517],"study_design_scores_gemma":[0.0014258,0.0026408806,0.000031642117,0.6024314,0.005175256,0.00002272988,0.00047460222,0.000006767096,7.28155e-9,0.000018432384,0.38759747,0.0001750039],"about_ca_topic_score_codex":0.00049469946,"about_ca_topic_score_gemma":0.0003054961,"teacher_disagreement_score":0.4000767,"about_ca_system_score_codex":0.0000846703,"about_ca_system_score_gemma":0.00030683682,"threshold_uncertainty_score":0.8666498},"labels":[],"label_agreement":null},{"id":"W2114744705","doi":"10.1093/annonc/mdp060","title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Chemotherapy; Lung cancer; Vinorelbine; Everolimus; Pneumonitis; Lung","score_opus":0.012607862207898007,"score_gpt":0.29576622364707483,"score_spread":0.28315836143917683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114744705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774086,0.0005795287,0.000042314015,0.0006243968,0.00001598901,0.0006832486,0.000010751632,0.00001161481,0.0002913133],"genre_scores_gemma":[0.9965037,0.0006578093,0.001342403,0.0012875694,0.000047437796,0.000023251223,0.000040644813,0.000037883252,0.000059266342],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985953,0.00007539581,0.00036257773,0.00043267148,0.00019031897,0.00034372558],"domain_scores_gemma":[0.998905,0.000043027358,0.00037315045,0.0003341456,0.00025467973,0.00009001275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015424918,0.0002682932,0.00055749004,0.0000908849,0.000024625355,0.0000049557725,0.0001617285,0.00020942347,0.000015726688],"category_scores_gemma":[0.000027928947,0.00017987618,0.000041551055,0.00025103282,0.00025132933,0.0000122176225,0.000016417336,0.00010999833,3.2447863e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15878206,0.004765365,0.24783441,0.00012456275,0.0008369884,0.000041390842,0.0010396078,0.000762836,0.18319142,0.000013618854,0.0013650033,0.40124273],"study_design_scores_gemma":[0.03735777,0.089033484,0.32569954,0.00034906616,0.000054425996,0.000022243928,0.000055342687,0.000008758914,0.53954625,0.000015404818,0.007326082,0.00053161575],"about_ca_topic_score_codex":0.00003718305,"about_ca_topic_score_gemma":0.00009556303,"teacher_disagreement_score":0.40071112,"about_ca_system_score_codex":0.000028465003,"about_ca_system_score_gemma":0.00022438554,"threshold_uncertainty_score":0.7335138},"labels":[],"label_agreement":null},{"id":"W2115275439","doi":"10.1093/annonc/mdu164.18","title":"An Indirect Treatment Comparison and Cost-Effectiveness Analysis Comparing Folfirinox with Nab-Paclitaxel Plus Gemcitabine for First-Line Treatment for Patients with Metastatic Pancreatic Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Sanofi (Canada)","funders":"","keywords":"FOLFIRINOX; Gemcitabine; Medicine; Internal medicine; Oncology; Pancreatic cancer; Hazard ratio; Antimetabolite; Chemotherapy; Cancer; Irinotecan; Confidence interval","score_opus":0.18167094723903096,"score_gpt":0.4696375586611725,"score_spread":0.2879666114221415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115275439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98376906,0.00048545428,0.009419998,0.0004999174,0.000029519531,0.005338355,0.00018565984,0.000028663784,0.00024338176],"genre_scores_gemma":[0.98868,0.0003624917,0.005896235,0.000098694894,0.00006026732,0.0042313384,0.0005177552,0.000039119463,0.00011408216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997795,0.00031327945,0.00052412326,0.00055687304,0.00023785,0.0005729026],"domain_scores_gemma":[0.995265,0.002966575,0.00038619776,0.00039808403,0.0006583727,0.0003257365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006082777,0.00037058137,0.0028529656,0.00037186322,0.00019310015,0.000014617403,0.000093791394,0.00012264955,0.000023021106],"category_scores_gemma":[0.00017592893,0.00022943382,0.00018285043,0.0003592193,0.0003005158,0.000087140346,0.00001947133,0.00007905697,8.663181e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019158863,0.0041358625,0.9225854,0.00036410303,0.009017753,0.000006176299,0.00090073916,0.0015798128,0.000021762897,0.0000883842,0.00003344286,0.042107686],"study_design_scores_gemma":[0.04378032,0.14478254,0.7350982,0.00020194377,0.013968416,0.000008003463,0.0002267657,0.057825133,0.0006997138,0.000087982226,0.0030375263,0.00028348976],"about_ca_topic_score_codex":0.0012923349,"about_ca_topic_score_gemma":0.007740567,"teacher_disagreement_score":0.18748724,"about_ca_system_score_codex":0.00051396445,"about_ca_system_score_gemma":0.00044921957,"threshold_uncertainty_score":0.935604},"labels":[],"label_agreement":null},{"id":"W2115330744","doi":"10.1093/annonc/mdq020","title":"Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Placebo; Lung cancer; Oncology; Cisplatin; Progression-free survival; Chemotherapy; Confidence interval; Surgery; Urology; Gastroenterology; Clinical trial; Pathology","score_opus":0.0480325960961244,"score_gpt":0.4125897085681237,"score_spread":0.3645571124719993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115330744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837746,0.0005276717,0.00026215566,0.0058971574,0.0005610621,0.005474567,0.00081192283,0.000031315438,0.0026595655],"genre_scores_gemma":[0.9903521,0.0017921394,0.0021885308,0.00089668564,0.00068736845,0.0011104688,0.00047851662,0.000047617912,0.0024465702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983355,0.00005714193,0.0006184321,0.0004583981,0.00018526736,0.00034528604],"domain_scores_gemma":[0.9971866,0.0014557982,0.00044180933,0.0003345599,0.00036198605,0.00021922038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003924069,0.0002756609,0.00095165195,0.000105086525,0.00014077892,0.000016474665,0.000102727114,0.0002283768,0.00027032956],"category_scores_gemma":[0.00022459947,0.00018023927,0.00013741733,0.00010894031,0.00013360719,0.00007596688,0.000024347159,0.00022066827,0.0000020526454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95913005,0.0024178214,0.00017051194,0.000062634106,0.00097444246,0.00007885626,0.002021065,0.000022083752,0.0037487862,0.000027113618,0.0036907892,0.027655832],"study_design_scores_gemma":[0.9376195,0.027388342,0.00030356093,0.00007558196,0.00082783523,0.00001952854,0.00011499417,0.00090201996,0.005866012,0.00007637573,0.026592184,0.00021405594],"about_ca_topic_score_codex":0.0027624066,"about_ca_topic_score_gemma":0.0046266946,"teacher_disagreement_score":0.027441775,"about_ca_system_score_codex":0.000050919152,"about_ca_system_score_gemma":0.0012678847,"threshold_uncertainty_score":0.73499435},"labels":[],"label_agreement":null},{"id":"W2115527952","doi":"10.1093/annonc/mdg447","title":"A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Letrozole; Medicine; Tamoxifen; Breast cancer; Cost effectiveness; Quality-adjusted life year; Oncology; Quality of life (healthcare); Pound (networking); Gynecology; Internal medicine; Cancer; Risk analysis (engineering)","score_opus":0.03156705343475747,"score_gpt":0.3794179773843029,"score_spread":0.3478509239495454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115527952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900241,0.004281764,0.0011527064,0.0003623871,0.00048624846,0.0016458178,0.0013363551,0.000016237407,0.0006943783],"genre_scores_gemma":[0.99714875,0.00035721407,0.0002845006,0.0003156393,0.000042806558,0.0006415596,0.0009845699,0.000047901427,0.0001770521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752873,0.0005434393,0.00056459627,0.0005827308,0.00021548473,0.0005650019],"domain_scores_gemma":[0.99807787,0.00036383158,0.0005351319,0.00044025187,0.00039850816,0.00018442622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069803174,0.00034391214,0.001014409,0.00019658703,0.000089391346,0.00000870567,0.0002765644,0.0005665601,0.000041619256],"category_scores_gemma":[0.00026837512,0.00032610845,0.00060876907,0.00058325427,0.00019674213,0.00001225893,0.00004478682,0.0001520255,0.0000017213857],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05816898,0.0011422167,0.0010545312,0.000051202627,0.0034688772,0.0000041269045,0.000018977176,0.0012479058,0.91988283,0.00005670773,0.0113223195,0.003581301],"study_design_scores_gemma":[0.056120142,0.01444373,0.00048015086,0.000023537126,0.0013182627,0.000002197943,0.000031373318,0.00017392603,0.8805751,0.000012317957,0.04642925,0.00039001167],"about_ca_topic_score_codex":0.00012548345,"about_ca_topic_score_gemma":0.00004450924,"teacher_disagreement_score":0.03930775,"about_ca_system_score_codex":0.00006437963,"about_ca_system_score_gemma":0.0004108907,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W2115684400","doi":"10.1093/annonc/mdg455","title":"Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital","funders":"","keywords":"Vinorelbine; Medicine; Lung cancer; Regimen; Internal medicine; Neutropenia; Cisplatin; Chemotherapy; Oncology; Gastroenterology; Surgery","score_opus":0.03387055618300612,"score_gpt":0.39976659891928085,"score_spread":0.36589604273627474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115684400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97076344,0.00032287173,0.00014621689,0.0021326412,0.00006377378,0.0007152672,0.000011465325,0.0000069383664,0.025837371],"genre_scores_gemma":[0.99609697,0.00018918219,0.0021797884,0.00059329864,0.000009182531,0.00020484051,0.000025547768,0.000013803225,0.0006873964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925256,0.000034670455,0.00022338648,0.00019199966,0.000092195674,0.00020518308],"domain_scores_gemma":[0.99944705,0.00006651824,0.00015185185,0.00011813597,0.00016363732,0.0000528254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110869936,0.0001076578,0.00033853587,0.00017502515,0.00001780421,0.0000019281565,0.000036885922,0.00008589897,0.00005165264],"category_scores_gemma":[0.00003079537,0.00008801202,0.000027528546,0.00031880147,0.000041200063,0.00008108992,0.000009016536,0.00012917547,0.0000013296834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065608867,0.015448495,0.791313,0.00058085,0.00079568045,0.00044926672,0.01751126,0.0041459925,0.027304828,0.0043162815,0.0020993047,0.12947415],"study_design_scores_gemma":[0.07666401,0.013523374,0.8322332,0.00085521006,0.00042398914,0.00005487892,0.0029037353,0.0014851453,0.055626273,0.00039884148,0.015373292,0.0004580497],"about_ca_topic_score_codex":0.0008393121,"about_ca_topic_score_gemma":0.002239831,"teacher_disagreement_score":0.12901609,"about_ca_system_score_codex":0.00024186382,"about_ca_system_score_gemma":0.0006564732,"threshold_uncertainty_score":0.3589026},"labels":[],"label_agreement":null},{"id":"W2115689952","doi":"10.1093/annonc/mds055","title":"Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Weyerhauser (Canada)","funders":"Pfizer","keywords":"Medicine; myalgia; Exemestane; Tamoxifen; Breast cancer; Internal medicine; Retrospective cohort study; Adverse effect; Cohort; Cancer; Oncology","score_opus":0.021486396747790678,"score_gpt":0.3854084780273463,"score_spread":0.3639220812795556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115689952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99869937,0.000591095,0.0000039528054,0.00018489746,0.00008074907,0.00029276827,0.00007191238,8.900199e-7,0.00007434442],"genre_scores_gemma":[0.99673635,0.0031074719,0.000021797849,0.000034477,0.000021055757,0.000013532835,0.000010285429,0.000005473215,0.000049570855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988982,0.00036397701,0.00039387916,0.00013714089,0.00007584049,0.00013095938],"domain_scores_gemma":[0.9992455,0.000057157362,0.00031698786,0.00019794532,0.00012762126,0.000054787928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046206915,0.000083209576,0.00038634313,0.00010869766,0.000011728324,2.0160394e-7,0.000073237774,0.00013588242,0.000008884401],"category_scores_gemma":[0.000060330614,0.000057959613,0.0001982921,0.00027378494,0.000106759326,0.0000039638185,0.000044607124,0.000057465648,2.0460587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031246447,0.0005493065,0.89231277,0.0000030637807,0.001353491,3.6716457e-7,0.0002962099,0.00010991937,0.09868348,0.000009167861,0.000039767147,0.003517808],"study_design_scores_gemma":[0.0009505549,0.003986867,0.9423035,0.000010441933,0.00024187623,0.0000026841012,0.000034692315,0.000042862517,0.05214788,0.000004216211,0.0002305023,0.000043949534],"about_ca_topic_score_codex":0.0005003435,"about_ca_topic_score_gemma":0.00010353613,"teacher_disagreement_score":0.049990695,"about_ca_system_score_codex":0.000025496121,"about_ca_system_score_gemma":0.00009497433,"threshold_uncertainty_score":0.23635244},"labels":[],"label_agreement":null},{"id":"W2115753233","doi":"10.1093/annonc/mdt155","title":"Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Temsirolimus; Everolimus; Medicine; Meta-analysis; Internal medicine; Oncology; Randomized controlled trial; Adverse effect; Relative risk; Clinical trial; PI3K/AKT/mTOR pathway; Sirolimus; Discovery and development of mTOR inhibitors; Cancer; Subgroup analysis; Incidence (geometry); Pharmacology; Confidence interval","score_opus":0.05054984411088854,"score_gpt":0.37231340605036745,"score_spread":0.3217635619394789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115753233","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5145419,0.48454332,4.928241e-7,0.000013810992,0.000045071232,0.0005109663,0.0002453941,0.0000016800155,0.00009735415],"genre_scores_gemma":[0.17101476,0.82849646,0.000031817875,0.00001606008,0.000033076256,0.00016442532,0.00014073314,0.000026714406,0.000075990494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791366,0.0005276358,0.0007920948,0.00039468575,0.00012990159,0.00024202646],"domain_scores_gemma":[0.99762875,0.00010489324,0.0015262137,0.00039915112,0.0002822864,0.000058713587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000336608,0.00032985813,0.0013600361,0.00010701888,0.000023066716,0.0000029411985,0.0002472448,0.00053267716,0.000035739875],"category_scores_gemma":[0.000074295516,0.00019835438,0.00020928787,0.00024403613,0.00046114967,0.0000055260143,0.000084767,0.00016905987,7.497973e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026953223,0.0008702198,0.39825088,0.0028532064,0.0031319966,0.000008190891,0.00029665843,0.00009157483,0.001255317,0.0000066962048,0.0015491938,0.59141654],"study_design_scores_gemma":[0.004715759,0.027854607,0.036380697,0.0057263775,0.0031770174,0.000017074675,0.000094086354,0.000012020062,0.05308057,0.000056535093,0.8677644,0.0011208577],"about_ca_topic_score_codex":0.0038560722,"about_ca_topic_score_gemma":0.0011112083,"teacher_disagreement_score":0.8662152,"about_ca_system_score_codex":0.00006670472,"about_ca_system_score_gemma":0.0006598742,"threshold_uncertainty_score":0.80886567},"labels":[],"label_agreement":null},{"id":"W2115885368","doi":"10.1093/annonc/mdp038","title":"Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"GiST; Medicine; Internal medicine; Growth factor; Stromal cell; Insulin-like growth factor-binding protein; Insulin-like growth factor; Endocrinology; Cyst; Gastroenterology; Insulin-like growth factor 2; Insulin; Lactate dehydrogenase; Pathology; Receptor; Biology; Enzyme","score_opus":0.0328682960352249,"score_gpt":0.31429042805281276,"score_spread":0.28142213201758787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115885368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979409,0.00009263731,0.00003247893,0.0006624331,0.000011208437,0.001133935,0.000057848847,0.0000129637965,0.00005562363],"genre_scores_gemma":[0.99616176,0.000044988803,0.0036062612,0.00008751565,0.000010278563,0.000022488344,0.000045850007,0.000014733657,0.000006136231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801147,0.00014415034,0.0005045228,0.00038917334,0.00040570786,0.00054499303],"domain_scores_gemma":[0.9984699,0.00021618992,0.00023976798,0.00014106205,0.00035821737,0.0005748528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022156058,0.00024326821,0.00055798364,0.0005541935,0.000034432906,0.000009585914,0.00007881471,0.000046585857,0.000006521127],"category_scores_gemma":[0.001315044,0.0001916071,0.000037794918,0.00040695912,0.00015640496,0.0001937501,0.00007502638,0.0003273646,0.0000011410216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006311927,0.0013219009,0.9883161,0.00010962065,0.000015069605,0.00035525716,0.00037956928,0.000006606365,0.0015622285,0.00008691306,0.0000078086105,0.001526993],"study_design_scores_gemma":[0.0049857106,0.028322155,0.9647758,0.00074756384,0.000020065236,0.000047414756,0.00013518271,0.000027544293,0.00058482285,0.00023554379,0.0000026029634,0.00011557196],"about_ca_topic_score_codex":0.0006498329,"about_ca_topic_score_gemma":0.00019970248,"teacher_disagreement_score":0.027000254,"about_ca_system_score_codex":0.00017338387,"about_ca_system_score_gemma":0.00039224658,"threshold_uncertainty_score":0.7813511},"labels":[],"label_agreement":null},{"id":"W2116036495","doi":"10.1093/annonc/mdi013","title":"Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Vinorelbine; Docetaxel; Medicine; Cisplatin; Internal medicine; Lung cancer; Chemotherapy; Oncology; Gastroenterology","score_opus":0.1282926510778313,"score_gpt":0.49958957761632844,"score_spread":0.3712969265384971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116036495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583126,0.0008592934,0.00047113936,0.001459113,0.0005983452,0.0071815113,0.0022756648,0.000043955388,0.0012796982],"genre_scores_gemma":[0.9896959,0.00010860841,0.0022361293,0.00030413238,0.00026016872,0.0011503836,0.00069478044,0.00006635071,0.005483512],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99626386,0.000114783696,0.0015819625,0.00080067513,0.0005295888,0.00070915284],"domain_scores_gemma":[0.9967968,0.00039262025,0.0010752403,0.0005407203,0.000781401,0.00041326013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061988406,0.0005073089,0.0013997703,0.00023540131,0.00028572395,0.000026941982,0.0002533413,0.00023321476,0.0003850309],"category_scores_gemma":[0.0002692656,0.00038506548,0.00036974618,0.0004464257,0.00017743428,0.00013908406,0.00016627558,0.00021527847,0.0000043151445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75145096,0.03749681,0.0024906262,0.0008076594,0.0032957285,0.0006224576,0.0058957515,0.011441957,0.1444044,0.000033947672,0.018699253,0.023360476],"study_design_scores_gemma":[0.7307933,0.13707829,0.0007761601,0.0003795909,0.0024143625,0.000017830998,0.00046822985,0.0009488141,0.11848548,0.000011394913,0.008134666,0.0004918648],"about_ca_topic_score_codex":0.0012048209,"about_ca_topic_score_gemma":0.001907651,"teacher_disagreement_score":0.09958148,"about_ca_system_score_codex":0.00060638273,"about_ca_system_score_gemma":0.0016870663,"threshold_uncertainty_score":0.9998601},"labels":[],"label_agreement":null},{"id":"W2116291560","doi":"10.1093/annonc/mdq692","title":"Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Internal medicine; Lung cancer; Cancer; Oncology; Cancer registry; Medical record; Stage (stratigraphy); Radiation therapy; Disease","score_opus":0.2596387767009012,"score_gpt":0.45136750798488595,"score_spread":0.19172873128398477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116291560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504524,0.0008367181,0.000015917562,0.0002997014,0.000047353526,0.00039628046,0.00009927358,0.000009148782,0.0032503705],"genre_scores_gemma":[0.9982984,0.0007170717,0.00063841196,0.00020022491,0.000035418976,0.000022540999,0.000043679385,0.000010015547,0.00003420069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891007,0.00009624045,0.00047079893,0.00019043911,0.00014363755,0.00018882196],"domain_scores_gemma":[0.99841917,0.00011157895,0.00060533726,0.00014412399,0.00062618003,0.00009364363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015936318,0.00012671076,0.00080538314,0.00010561438,0.000026559075,0.0000011707784,0.0000778021,0.00017195716,0.00013973204],"category_scores_gemma":[0.000021001835,0.00008739248,0.0000418184,0.00022222241,0.00019304191,0.000092807895,0.000032973236,0.000067556066,4.4014166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005594744,0.00046913527,0.85530907,0.00020810479,0.00029266527,0.0000046787377,0.0026606682,0.0000034390487,0.0000912251,0.000019381037,0.0003799573,0.13496692],"study_design_scores_gemma":[0.0037750655,0.03511288,0.94830835,0.00040207122,0.00048030412,0.000013611956,0.00069075613,0.00008495199,0.006296215,0.000026512904,0.0047160583,0.00009322257],"about_ca_topic_score_codex":0.005382094,"about_ca_topic_score_gemma":0.003500005,"teacher_disagreement_score":0.1348737,"about_ca_system_score_codex":0.00009721984,"about_ca_system_score_gemma":0.00045999547,"threshold_uncertainty_score":0.8136152},"labels":[],"label_agreement":null},{"id":"W2116682901","doi":"10.1093/annonc/mdq194","title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","year":2010,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":685,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Society for Medical Oncology; Eisai","keywords":"Nausea; Medicine; Vomiting; Antiemetic; Guideline; Chemotherapy; Radiation therapy; Chemotherapy-induced nausea and vomiting; Intensive care medicine; Cancer; Oncology; Internal medicine","score_opus":0.18029014686133404,"score_gpt":0.46301551962480114,"score_spread":0.2827253727634671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116682901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1412345,0.83720857,0.000028201004,0.01598886,0.00014877171,0.00420367,0.000118085445,0.000008743687,0.0010606167],"genre_scores_gemma":[0.03037148,0.96754265,0.0011840793,0.0005772766,0.00008472546,0.00004304739,0.000027982975,0.000022380224,0.0001464002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980444,0.0003151858,0.0010490599,0.00028016476,0.00013657694,0.00017461153],"domain_scores_gemma":[0.99752533,0.00072994526,0.0011142562,0.00035941286,0.00023318057,0.00003787032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023490307,0.00020715965,0.0013812778,0.00013503348,0.00003340737,0.0000069331954,0.00015907975,0.0003103442,0.0000057970433],"category_scores_gemma":[0.0004691241,0.00011902796,0.00015601798,0.00012566746,0.00033648958,0.000015385662,0.000061313185,0.00028287942,6.635945e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050891546,0.00021426323,0.00007382431,0.005906426,0.0002693579,0.0000033606125,0.00041742605,5.092959e-8,0.00037344772,0.00082424737,0.0025033131,0.9889054],"study_design_scores_gemma":[0.0050957957,0.0021536457,0.00083887123,0.0036272027,0.0005462853,0.000081408034,0.00015543427,0.000037101494,0.00041303874,0.00044212182,0.98647827,0.00013081421],"about_ca_topic_score_codex":0.00005311431,"about_ca_topic_score_gemma":0.000076116405,"teacher_disagreement_score":0.98877454,"about_ca_system_score_codex":0.000010539121,"about_ca_system_score_gemma":0.0002602213,"threshold_uncertainty_score":0.48538193},"labels":[],"label_agreement":null},{"id":"W2117085599","doi":"10.1093/annonc/mdt336","title":"Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case–Control Consortium (PanC4)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Public Health Ontario; University of Toronto; Toronto General Hospital","funders":"National Health and Medical Research Council; National Institutes of Health; National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Cancer Research Society","keywords":"Medicine; Gastrectomy; Pancreatic cancer; Internal medicine; Odds ratio; Gastroenterology; Cancer; Case-control study","score_opus":0.044433024107612004,"score_gpt":0.3362958268542831,"score_spread":0.2918628027466711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117085599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714146,0.004298078,0.000075133146,0.022742685,0.0003758045,0.00046128774,0.00042916837,0.000035284003,0.0001679091],"genre_scores_gemma":[0.982744,0.009973348,0.00013884912,0.006220744,0.00037909293,0.00036159632,0.00005295465,0.000022679651,0.00010678401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756676,0.0005115026,0.0007411563,0.00045874366,0.00023268933,0.00048916246],"domain_scores_gemma":[0.9961665,0.0019403592,0.0005934025,0.0004207897,0.0006580682,0.0002208727],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059121643,0.00027052104,0.00129874,0.00030589287,0.00013629679,0.000021980915,0.00016984141,0.0001990974,0.0011006797],"category_scores_gemma":[0.000657035,0.00018772237,0.00022994091,0.0004155033,0.00047198014,0.00016532376,0.000080546946,0.00038321764,0.000016644355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039954676,0.00019117442,0.95448786,0.000011605044,0.012005283,0.00019690391,0.00051316316,0.00006449008,0.00025790042,0.0000032408477,0.0070338286,0.02483501],"study_design_scores_gemma":[0.0015222352,0.0005524532,0.98827636,0.000052061143,0.0062916297,0.00020641409,0.0005463303,0.0011569068,0.00007025679,0.000057356974,0.0011470994,0.00012092281],"about_ca_topic_score_codex":0.041870635,"about_ca_topic_score_gemma":0.01273987,"teacher_disagreement_score":0.03378848,"about_ca_system_score_codex":0.00010115424,"about_ca_system_score_gemma":0.0002344408,"threshold_uncertainty_score":0.9998124},"labels":[],"label_agreement":null},{"id":"W2117120512","doi":"10.1093/annonc/mdg414","title":"Limited-stage mantle-cell lymphoma","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Mantle cell lymphoma; Stage (stratigraphy); Lymphoma; Cancer research; Oncology; Internal medicine; Paleontology; Geology","score_opus":0.08338842833118928,"score_gpt":0.36283467821477877,"score_spread":0.27944624988358946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117120512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69537526,0.0012185901,0.0000050148537,0.0021703152,0.00012451322,0.0001703398,0.00000948598,0.000020506666,0.30090597],"genre_scores_gemma":[0.9886152,0.0011058322,0.0006338516,0.0035806992,0.000039510105,0.000027647146,0.0000136906065,0.000014193427,0.0059693693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907184,0.0000713258,0.00026222612,0.00019767601,0.00013219361,0.00026472192],"domain_scores_gemma":[0.9991855,0.00015546977,0.00012173947,0.0002734917,0.00012201953,0.00014179117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017712786,0.00012353061,0.0003921887,0.00009268342,0.00003137905,0.0000034397078,0.00005486311,0.00013880288,0.00050391635],"category_scores_gemma":[0.00008702964,0.000098769815,0.0001454058,0.00012222913,0.00007531563,0.00003145868,0.00001925497,0.000034968085,0.00020822098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011001998,0.035340082,0.26693892,0.00041594417,0.0009277513,0.0038471743,0.0009937835,0.000012404547,0.00718427,0.050825894,0.21744357,0.41496998],"study_design_scores_gemma":[0.0060397573,0.0038086819,0.047121074,0.000024839792,0.000080583326,0.000115754774,0.00012525335,0.0000069659027,0.104073904,0.00018836255,0.8383177,0.00009714414],"about_ca_topic_score_codex":0.000051287057,"about_ca_topic_score_gemma":0.000009476719,"teacher_disagreement_score":0.6208741,"about_ca_system_score_codex":0.000060899667,"about_ca_system_score_gemma":0.000271343,"threshold_uncertainty_score":0.5517531},"labels":[],"label_agreement":null},{"id":"W2117460748","doi":"10.1093/annonc/mdv257","title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"National Cancer Institute; Swiss Cancer Foundation; Astellas Pharma; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Amgen; European School of Oncology; Swiss Cancer Research Foundation; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Sanofi; Prostate Cancer UK; Cancer Research UK","keywords":"Medicine; Prostate cancer; Expert opinion; Consensus conference; Cancer; Management of prostate cancer; Gynecology; Hormonal therapy; Intensive care medicine; Oncology; Disease; Family medicine; Internal medicine; Medical physics","score_opus":0.10097020056016866,"score_gpt":0.4302916006142122,"score_spread":0.32932140005404353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117460748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560233,0.003097723,0.0000029821276,0.03230858,0.00027827887,0.0026520567,0.0010120097,0.000017060025,0.0046080244],"genre_scores_gemma":[0.98379934,0.010652225,0.0008772731,0.0002052947,0.000015703174,0.000448331,0.00010721761,0.0000251947,0.0038694236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825156,0.00012941305,0.00051835075,0.00028858255,0.00044219333,0.00036992787],"domain_scores_gemma":[0.99675643,0.00007250122,0.0006056003,0.0003888183,0.0020124842,0.00016418216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027434665,0.00018667638,0.0005773662,0.00009960037,0.000051060302,0.0000035136943,0.0001886556,0.00007136271,0.00007815696],"category_scores_gemma":[0.000040710005,0.000115633964,0.000070555296,0.00033531012,0.0004990776,0.0000779427,0.0001330984,0.0001671461,0.0000018617235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031829484,0.0036408915,0.26225123,0.0017406072,0.0023746109,0.000057597597,0.0061742594,0.00094974635,0.0012618949,0.0007950775,0.048953526,0.6399711],"study_design_scores_gemma":[0.074698865,0.028480656,0.36831027,0.005199089,0.001028925,0.000009721993,0.010672552,0.00015079035,0.07197707,0.001570219,0.43705034,0.00085149874],"about_ca_topic_score_codex":0.0003148544,"about_ca_topic_score_gemma":0.00030380525,"teacher_disagreement_score":0.63911957,"about_ca_system_score_codex":0.00015982914,"about_ca_system_score_gemma":0.0012914104,"threshold_uncertainty_score":0.4715416},"labels":[],"label_agreement":null},{"id":"W2117775530","doi":"10.1093/annonc/mdt303","title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3715,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Trastuzumab; Oncology; Cancer; Disease; Radiation therapy; Internal medicine; Surrogate endpoint; Systemic therapy; Bioinformatics","score_opus":0.03251626647592759,"score_gpt":0.3067521116577411,"score_spread":0.2742358451818135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117775530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94713926,0.0033812628,5.1859325e-7,0.04784627,0.00013542578,0.00042897894,0.0004982374,0.000002891076,0.0005671293],"genre_scores_gemma":[0.98232126,0.016188879,0.000019019046,0.00075027114,0.00015913018,0.00039896893,0.0000067999654,0.00001764025,0.00013801281],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988262,0.0001549796,0.0002943867,0.00023336856,0.00023872445,0.00025234956],"domain_scores_gemma":[0.9984884,0.000121913945,0.00046698007,0.00037196654,0.0005109011,0.000039809005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010856746,0.0002033192,0.00037745695,0.000031099455,0.00007605586,0.0000054015777,0.0003518226,0.000091913025,0.0001696859],"category_scores_gemma":[0.000004231352,0.00008911203,0.00013499288,0.00008050023,0.0006789442,0.000006048098,0.000065077125,0.000055347842,9.209462e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023296075,0.007483691,0.3024153,0.000101465135,0.020414213,0.000008964051,0.042297035,0.0002504606,0.31455982,0.0011457201,0.049808223,0.23821901],"study_design_scores_gemma":[0.0022277138,0.0033150988,0.91819024,0.000090172696,0.00004246868,0.000027040365,0.001136058,0.0000028608058,0.05177297,0.000043532964,0.023009282,0.00014253653],"about_ca_topic_score_codex":0.013736764,"about_ca_topic_score_gemma":0.0006163261,"teacher_disagreement_score":0.6157749,"about_ca_system_score_codex":0.00012266269,"about_ca_system_score_gemma":0.00031461663,"threshold_uncertainty_score":0.9928309},"labels":[],"label_agreement":null},{"id":"W2117924296","doi":"10.1093/annonc/mdr533","title":"Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Alberta Health Services; London Health Sciences Centre; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Vascular endothelial growth factor; Refractory (planetary science); VEGF receptors; Oncology; Internal medicine; Vascular endothelial growth factor A; Risk factor; Cancer research","score_opus":0.14149633116960145,"score_gpt":0.3444685042515667,"score_spread":0.20297217308196527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117924296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377286,0.0027572801,0.000034878412,0.000116658,0.00036204647,0.0007338445,0.00027435142,0.000039479593,0.001908611],"genre_scores_gemma":[0.9873125,0.010722317,0.0009612306,0.0004917759,0.00022578325,0.000023789475,0.00012175316,0.00005948219,0.00008135204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659866,0.0007297008,0.0011128997,0.00062478206,0.0003979236,0.00053605175],"domain_scores_gemma":[0.9971786,0.000618411,0.0007998865,0.0005675351,0.00037899072,0.0004565661],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007252177,0.00044914513,0.0016124167,0.00021454509,0.00007862296,0.000009651588,0.00019476602,0.00028775923,0.0003187763],"category_scores_gemma":[0.000252421,0.00032220068,0.00054610503,0.00010553749,0.00050459016,0.00012158022,0.000096877535,0.000538033,0.0000257502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013290792,0.0033733577,0.96096134,0.00016624488,0.0007478051,0.0005871564,0.001274953,4.42806e-8,0.017812476,0.00003393293,0.0003414824,0.013372139],"study_design_scores_gemma":[0.0041196034,0.010871498,0.9007611,0.000020224494,0.00039546305,0.000048005055,0.00007405672,0.0000032905446,0.079238124,0.00007774219,0.004150982,0.00023988313],"about_ca_topic_score_codex":0.0007924158,"about_ca_topic_score_gemma":0.000009350459,"teacher_disagreement_score":0.061425645,"about_ca_system_score_codex":0.000096601696,"about_ca_system_score_gemma":0.0005000541,"threshold_uncertainty_score":0.999923},"labels":[],"label_agreement":null},{"id":"W2117985979","doi":"10.1093/annonc/mds503","title":"A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); University of Toronto; Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Hôpital Notre-Dame","funders":"Pfizer","keywords":"Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Mucositis; Phases of clinical research; Gastroenterology; Toxicity; Response Evaluation Criteria in Solid Tumors; Oncology; Diarrhea; Clinical trial; Surgery","score_opus":0.1637312590794041,"score_gpt":0.4497710802575013,"score_spread":0.2860398211780972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117985979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241763,0.0029991386,2.4535566e-7,0.0027739329,0.00024493205,0.0009207673,0.00005926956,0.0000048752454,0.0005791928],"genre_scores_gemma":[0.9984345,0.00080891605,0.00011941076,0.00024060266,0.00016270258,0.0000736607,0.000013954002,0.00001294473,0.00013333539],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985298,0.00023091784,0.0006255902,0.00019299968,0.00014510711,0.00027556514],"domain_scores_gemma":[0.99901634,0.00024698573,0.00028940444,0.00021750799,0.00009771467,0.0001320159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004591817,0.00017309708,0.0010041122,0.000098964556,0.00007127469,0.000001547324,0.00005966236,0.0000852514,0.00005920392],"category_scores_gemma":[0.00017489321,0.00010554553,0.00009625893,0.00014146826,0.0002649835,0.000063131716,0.00008010691,0.000113860566,6.378086e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19673741,0.2000128,0.07477076,0.0017164057,0.00049787544,0.00005986652,0.04847382,0.0000014053134,0.027472999,0.00036660294,0.007940632,0.44194943],"study_design_scores_gemma":[0.2596375,0.6005063,0.022130853,0.00029724772,0.00045220283,0.00003129925,0.0017284526,0.000025872283,0.066965714,0.000088164605,0.04790143,0.00023496193],"about_ca_topic_score_codex":0.00096742716,"about_ca_topic_score_gemma":0.0019093365,"teacher_disagreement_score":0.44171447,"about_ca_system_score_codex":0.000049315047,"about_ca_system_score_gemma":0.0002155078,"threshold_uncertainty_score":0.4304022},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2117992805","doi":"10.1093/annonc/mdu021","title":"Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer","year":2014,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Astellas Pharma; Eisai; Genentech; AstraZeneca; Les Laboratories Pierre Fabre; Celgene; GlaxoSmithKline; Pfizer","keywords":"Everolimus; Medicine; Breast cancer; Cancer; Internal medicine; Oncology; Adverse effect; Population; Hormonal therapy","score_opus":0.03595096550956829,"score_gpt":0.38843435273570964,"score_spread":0.35248338722614136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117992805","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009645302,0.9852094,0.000030587733,0.0002893033,0.0008991954,0.0016201618,0.0004960926,0.000017269846,0.0017926567],"genre_scores_gemma":[0.018213034,0.97963613,0.00015117745,0.000580834,0.00023891714,0.0007166267,0.00015184209,0.00009439176,0.00021702153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726313,0.00031095123,0.00075552706,0.000805004,0.00029828507,0.00056710263],"domain_scores_gemma":[0.9981104,0.00004803311,0.00087730563,0.00060624274,0.00023886088,0.00011915157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036536143,0.00051988516,0.0014769619,0.00020727371,0.000038128197,0.0000053099857,0.0004902404,0.0005071226,0.00010819727],"category_scores_gemma":[0.00002592416,0.00042687065,0.0003123411,0.00024334335,0.00011546841,0.000007143071,0.00019419868,0.00031309677,0.00001083498],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006490074,0.00034011554,0.0007823816,0.0018949009,0.0006270754,0.000009917276,0.000014437851,0.00056743657,0.000006286034,0.000013998368,0.0024423962,0.99265206],"study_design_scores_gemma":[0.0019488254,0.0024639096,0.0024937326,0.006972081,0.00030329637,0.0000036138904,0.000006838293,0.0000020893317,0.00007935141,0.000015621255,0.98517805,0.0005326129],"about_ca_topic_score_codex":0.00016650643,"about_ca_topic_score_gemma":0.00059642654,"teacher_disagreement_score":0.99211943,"about_ca_system_score_codex":0.00027362318,"about_ca_system_score_gemma":0.00051598187,"threshold_uncertainty_score":0.9998183},"labels":[],"label_agreement":null},{"id":"W2118075066","doi":"10.1093/annonc/mdr154","title":"Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Carcinoembryonic antigen; Internal medicine; Basal (medicine); Metastasis; CA 15-3; Oncology; Cancer; Incidence (geometry); Metastatic breast cancer; CA15-3; Pathology; Gastroenterology","score_opus":0.05411568647001463,"score_gpt":0.3327933372036676,"score_spread":0.27867765073365297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118075066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786675,0.00056976196,0.00007780465,0.00034751784,0.000036242287,0.000118270276,0.00004950021,0.000002022052,0.0009321529],"genre_scores_gemma":[0.9987357,0.0002251064,0.00080610195,0.00015265163,0.000011132595,0.000030964922,0.000016406826,0.0000069694784,0.000014962718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994495,0.000047385754,0.00020792866,0.0001409434,0.00004955062,0.000104720086],"domain_scores_gemma":[0.9995555,0.000018679075,0.00018877473,0.00009243454,0.00012390138,0.000020681557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001173523,0.000080196434,0.00019671852,0.000052308198,0.000011791721,6.9186416e-7,0.000041607862,0.00003964512,0.00002623339],"category_scores_gemma":[0.000021399757,0.00006500353,0.000021704323,0.00007427494,0.00012528813,0.000005798524,0.00002089709,0.00003199972,4.3572336e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006126277,0.0001564222,0.98831695,0.000036983503,0.00014652041,0.0000044606973,0.00025735426,0.000010368988,0.0028269677,0.00017489251,0.00007383837,0.0073826252],"study_design_scores_gemma":[0.0008570686,0.000669267,0.99308515,0.000020673006,0.000042588912,0.000022902264,0.0001917274,0.000007457619,0.0047669006,0.00019295346,0.0000773562,0.00006597502],"about_ca_topic_score_codex":0.0016459425,"about_ca_topic_score_gemma":0.0019478723,"teacher_disagreement_score":0.00731665,"about_ca_system_score_codex":0.000012555524,"about_ca_system_score_gemma":0.00008369616,"threshold_uncertainty_score":0.2650767},"labels":[],"label_agreement":null},{"id":"W2118097985","doi":"10.1093/annonc/mdq615","title":"Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Internal medicine; Clinical endpoint; Aggressive lymphoma; Randomized controlled trial; Confidence interval; Progression-free survival; Proportional hazards model; Oncology; Clinical trial; Log-rank test; Lymphoma; Overall survival; Rituximab","score_opus":0.1132801754187347,"score_gpt":0.41383054635094546,"score_spread":0.30055037093221076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118097985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660534,0.0004575274,0.00011062068,0.0009286867,0.00020873213,0.001349638,0.0001466629,0.000003905389,0.00018891142],"genre_scores_gemma":[0.9983732,0.0010123528,0.00036150543,0.00008940647,0.00002708442,0.000039575814,0.000044479475,0.0000122519095,0.000040126808],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927697,0.0036086622,0.0028050346,0.00032521435,0.00030438596,0.00018697802],"domain_scores_gemma":[0.99074745,0.004840187,0.0035980484,0.00025741156,0.0004220602,0.00013486312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01357927,0.0001762724,0.0025425178,0.00035954418,0.000018130722,0.0000029010578,0.00007992181,0.00022417362,0.00014022423],"category_scores_gemma":[0.0062302365,0.0001421813,0.0003245858,0.00012348895,0.00046411197,0.00006494172,0.00009494175,0.00006380681,0.0000060822254],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75103074,0.008834481,0.087379575,0.00030361433,0.0019281447,0.00018061916,0.004063789,0.000023551695,0.033108916,0.0004939659,0.0005078486,0.11214474],"study_design_scores_gemma":[0.16945806,0.0037961812,0.79561,0.0003786823,0.00044918648,0.000029004988,0.0000952661,0.0005277563,0.028958514,0.0005457931,0.0000532197,0.00009832597],"about_ca_topic_score_codex":0.00035938845,"about_ca_topic_score_gemma":0.00002553668,"teacher_disagreement_score":0.70823044,"about_ca_system_score_codex":0.00004260313,"about_ca_system_score_gemma":0.0002704865,"threshold_uncertainty_score":0.7458625},"labels":[],"label_agreement":null},{"id":"W2118192033","doi":"10.1093/annonc/mdm471","title":"Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Internal medicine; International Prognostic Index; Diffuse large B-cell lymphoma; Anthracycline; Oncology; Mastectomy; Lymphoma; Radiation therapy; Chemotherapy regimen; Chemotherapy; Surgery; Breast cancer; Cancer","score_opus":0.028926218165787256,"score_gpt":0.3264011218535761,"score_spread":0.29747490368778884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118192033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958563,0.0004590876,0.0000030388458,0.0010504305,0.00018150755,0.0014001473,0.00009372692,0.000009613455,0.00094616896],"genre_scores_gemma":[0.9992931,0.00005714271,0.000015034589,0.00044599012,0.000024414085,0.000041904314,0.000014329855,0.00001507622,0.00009304461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982616,0.00014891684,0.0006113207,0.00024518694,0.0004835003,0.00024953234],"domain_scores_gemma":[0.99806356,0.00090948725,0.0004053334,0.00035577634,0.00018657332,0.0000792651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070446555,0.00020114874,0.00064491254,0.00009114459,0.00006207996,0.0000058773794,0.000271266,0.000083410334,0.00002064292],"category_scores_gemma":[0.00010944725,0.000099245204,0.00017442733,0.00014447693,0.00019777544,0.000047799927,0.00019869853,0.000044535434,9.0270265e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047882035,0.093844585,0.8837232,0.0000291964,0.0007606477,0.000040374016,0.0027457182,4.5580315e-8,0.00063558505,0.000047980317,0.00046879795,0.017225077],"study_design_scores_gemma":[0.023730239,0.0049594063,0.9634459,0.000022410437,0.0003498742,0.000054659387,0.0041223606,0.0000020191899,0.0025221247,0.000016193206,0.00070195145,0.00007288578],"about_ca_topic_score_codex":0.000529953,"about_ca_topic_score_gemma":0.0003062268,"teacher_disagreement_score":0.08888518,"about_ca_system_score_codex":0.0000866109,"about_ca_system_score_gemma":0.00014839169,"threshold_uncertainty_score":0.40471017},"labels":[],"label_agreement":null},{"id":"W2118515024","doi":"10.1093/annonc/mdm287","title":"Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; University of Toronto; University of British Columbia; Queen's University","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Vinblastine; Internal medicine; Hazard ratio; Radiation therapy; Randomized controlled trial; Bleomycin; Confidence interval; Oncology; Progression-free survival; Cancer; Hodgkin's lymphoma; Lymphoma; Surgery; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.054794425521469195,"score_gpt":0.38218034545652624,"score_spread":0.32738591993505706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118515024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607867,0.00018152618,0.000032909116,0.0006871502,0.0000558609,0.0027586576,0.000055168035,0.000009294996,0.00014076968],"genre_scores_gemma":[0.9980302,0.00005606667,0.001308161,0.00025401532,0.000026753112,0.00023007933,0.000047762616,0.000010896887,0.000036091198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878263,0.00008371295,0.00054191926,0.0001965391,0.00017160854,0.0002235616],"domain_scores_gemma":[0.9972865,0.0018556594,0.0003876201,0.00013489931,0.00020966363,0.0001256862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006625582,0.0001350921,0.0010440581,0.00016455965,0.00002020347,0.00000365994,0.000035976096,0.000078006036,0.0000031159736],"category_scores_gemma":[0.0011619858,0.00008239948,0.00011378171,0.000089180314,0.000071636125,0.000051211922,0.000027877615,0.000024427245,1.909995e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39802712,0.003930982,0.5167851,0.00008834828,0.00010069066,0.00004013468,0.00008384411,3.474296e-7,0.0000075965645,0.000033767275,0.000012925494,0.080889165],"study_design_scores_gemma":[0.4904299,0.0065933038,0.5020691,0.00018486315,0.000111839334,8.0211424e-7,0.000020672622,0.000013981761,0.00040826874,0.000022471682,0.000099518504,0.0000452406],"about_ca_topic_score_codex":0.00011718822,"about_ca_topic_score_gemma":0.000054536882,"teacher_disagreement_score":0.0924028,"about_ca_system_score_codex":0.00003844385,"about_ca_system_score_gemma":0.00014312645,"threshold_uncertainty_score":0.3360153},"labels":[],"label_agreement":null},{"id":"W2118564089","doi":"10.1093/annonc/mdt138","title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Docetaxel; Urology; Internal medicine; Oncology; Chemotherapy; Cancer; Androgen deprivation therapy","score_opus":0.09984311915605092,"score_gpt":0.4478292512835438,"score_spread":0.34798613212749285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118564089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957325,0.0005396601,0.00000194929,0.0021857647,0.000045193527,0.0012644443,0.00003669785,0.000007109961,0.00018668937],"genre_scores_gemma":[0.9983258,0.00027020343,0.0007013715,0.00014422745,0.00001764701,0.00031505426,0.00001623436,0.000015923371,0.00019353227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847233,0.00020138365,0.00049559516,0.00023818605,0.00026708495,0.0003254054],"domain_scores_gemma":[0.99877304,0.00011098571,0.00029704047,0.0001801771,0.00052307534,0.00011566703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035750106,0.00013391598,0.0005954623,0.00012922044,0.000019309451,0.000007757739,0.000055946268,0.00007054543,0.00013039577],"category_scores_gemma":[0.000046740715,0.000086055166,0.00006201602,0.00019508261,0.0003695438,0.00018965431,0.000033438457,0.0001928748,0.0000056337935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01119285,0.002035387,0.8248733,0.00029382118,0.00027862084,0.00006160241,0.00047967152,0.000009319245,0.002877956,0.000002527776,0.0001520429,0.15774286],"study_design_scores_gemma":[0.0067254133,0.0068265246,0.97555166,0.00027745025,0.00006712302,0.0000012224641,0.000054114793,0.000030639865,0.010120017,0.000056330766,0.00020953221,0.000079940066],"about_ca_topic_score_codex":0.0006020105,"about_ca_topic_score_gemma":0.0004057357,"teacher_disagreement_score":0.15766291,"about_ca_system_score_codex":0.00006611695,"about_ca_system_score_gemma":0.0005670248,"threshold_uncertainty_score":0.3509228},"labels":[],"label_agreement":null},{"id":"W2118572322","doi":"10.1093/annonc/mdm077","title":"The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ontario Institute for Cancer Research; Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Anemia; Internal medicine; Multivariate analysis; Cancer; Lung cancer; Clinical trial; Hemoglobin; Oncology; Randomized controlled trial","score_opus":0.3185087878505417,"score_gpt":0.553432666531666,"score_spread":0.2349238786811243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118572322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318933,0.001670773,0.0000062516547,0.0036370412,0.00025682186,0.0006277708,0.00030373462,0.0000016799988,0.00030658412],"genre_scores_gemma":[0.9974968,0.0019494893,0.000121900564,0.00021727869,0.00006120303,0.000025999192,0.000025021342,0.0000063630946,0.000095978365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973126,0.00020389912,0.001851412,0.00013789936,0.00033104853,0.00016311409],"domain_scores_gemma":[0.9922594,0.0036991537,0.002485191,0.0002000387,0.0013050736,0.000051167033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033973132,0.00012312988,0.0016373538,0.00015112101,0.000036416393,5.2303596e-7,0.00013494719,0.0001240827,0.000019225368],"category_scores_gemma":[0.0025271748,0.00006640288,0.0006622368,0.0004892132,0.00039349115,0.000014994934,0.000029395547,0.000095311945,1.2813795e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00827876,0.0025119463,0.9371978,0.0010190401,0.014605897,0.0000023400153,0.00075525115,0.00349056,0.011454781,0.0005539668,0.011975564,0.0081541035],"study_design_scores_gemma":[0.010016718,0.006082776,0.9025098,0.00027912267,0.004204034,7.444845e-7,0.00057105103,0.0008971477,0.07475158,0.00007198878,0.00051574875,0.00009926428],"about_ca_topic_score_codex":0.07453847,"about_ca_topic_score_gemma":0.1495149,"teacher_disagreement_score":0.07497644,"about_ca_system_score_codex":0.0002598731,"about_ca_system_score_gemma":0.0017076381,"threshold_uncertainty_score":0.93162423},"labels":[],"label_agreement":null},{"id":"W2118608422","doi":"10.1093/annonc/mdt168","title":"Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut Gustave-Roussy; Associazione Iblea per la Ricerca Epidemiologica; Deutsche Krebshilfe; Mutuelle Générale de l'Education Nationale; Associazione Italiana per la Ricerca sul Cancro; European Commission; Cancer Research UK; Ministry of Health and Social Solidarity, Greece; British Heart Foundation; Wellcome Trust; Ligue Contre le Cancer; National Institute for Health and Care Research; Bundesministerium für Bildung und Forschung; Centre International de Recherche sur le Cancer; Deutsches Krebsforschungszentrum; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Hellenic Health Foundation; Stavros Niarchos Foundation; Kræftens Bekæmpelse; Compagnia di San Paolo","keywords":"European Prospective Investigation into Cancer and Nutrition; Medicine; EPIC; Hepatocellular carcinoma; Fish <Actinopterygii>; Prospective cohort study; Cancer; Environmental health; Oncology; Internal medicine; Fishery","score_opus":0.061329763242738956,"score_gpt":0.3191488954394556,"score_spread":0.25781913219671665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118608422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778754,0.005969978,0.000002268065,0.0053660367,0.000018090075,0.00045882814,0.000026504395,0.000003007967,0.00036774276],"genre_scores_gemma":[0.9819928,0.017491963,0.00013374568,0.00028397926,0.000037934624,0.00003781163,0.000007689261,0.000004262614,0.000009813885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994622,0.00010393167,0.00019068824,0.000108162,0.00007149734,0.00006351188],"domain_scores_gemma":[0.99931663,0.00011881551,0.00017592158,0.000056094806,0.0002966235,0.00003588503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023415907,0.000057808134,0.00022261922,0.000035118766,0.000048033464,0.0000021763801,0.00001691878,0.000040039868,0.000010413536],"category_scores_gemma":[0.00008077625,0.00004168037,0.00002008788,0.000043559823,0.00047817957,0.000044665085,0.000037847636,0.00006056639,3.4444744e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013893384,0.00012651387,0.9805613,0.00044152196,0.00009225262,0.0000017824646,0.0009072686,1.1923163e-7,0.007018297,0.000479469,0.0026829217,0.0075496105],"study_design_scores_gemma":[0.0014529971,0.0012560091,0.9807146,0.00011157416,0.000097072545,0.00000966753,0.00036253483,0.000053017156,0.009389874,0.005469521,0.0010464406,0.00003668551],"about_ca_topic_score_codex":0.0024487888,"about_ca_topic_score_gemma":0.00016358157,"teacher_disagreement_score":0.011521986,"about_ca_system_score_codex":0.000011921977,"about_ca_system_score_gemma":0.000017671655,"threshold_uncertainty_score":0.37018523},"labels":[],"label_agreement":null},{"id":"W2118632896","doi":"10.1093/annonc/mdt494","title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":399,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; China Scholarship Council; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Internal medicine; Anastrozole; Oncology; Breast cancer; Tamoxifen; Estrogen receptor; Clinical trial; Randomized controlled trial; Adjuvant therapy; Chemotherapy; Cancer; Gynecology","score_opus":0.030910715026720017,"score_gpt":0.3148753856041773,"score_spread":0.28396467057745733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118632896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964315,0.0006400168,0.0000040203977,0.00019653393,0.0001256457,0.0014478368,0.0011257228,0.0000035801752,0.000025099067],"genre_scores_gemma":[0.99704635,0.0024760498,0.00008915119,0.00005987491,0.00004410241,0.00017445073,0.000091597794,0.000016915214,0.0000015010176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749327,0.0008052783,0.00067267154,0.0004391321,0.00024501147,0.0003446647],"domain_scores_gemma":[0.9974532,0.00021692648,0.0012309358,0.000342936,0.00071163167,0.000044378692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029780678,0.0002681384,0.0005988326,0.000062067586,0.00007995001,0.0000046387513,0.0002753835,0.00013418782,0.0000120848],"category_scores_gemma":[0.00021651803,0.00013495928,0.000076395634,0.0003778687,0.0006409036,0.000017294109,0.00014746099,0.0002611442,2.2027838e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030435707,0.0019902845,0.9421741,0.000010169859,0.00017099657,0.000001440324,0.00035785852,0.000095651805,0.0011752472,0.0000011477614,0.000022630946,0.023564797],"study_design_scores_gemma":[0.019907914,0.010406525,0.9609705,0.00027358398,0.00007330234,0.0000031840907,0.000115300594,0.000020782994,0.008060395,0.000014036689,0.000013510902,0.00014093012],"about_ca_topic_score_codex":0.0041574473,"about_ca_topic_score_gemma":0.0013240065,"teacher_disagreement_score":0.023423867,"about_ca_system_score_codex":0.000057930625,"about_ca_system_score_gemma":0.00019673252,"threshold_uncertainty_score":0.6284844},"labels":[],"label_agreement":null},{"id":"W2118783447","doi":"10.1093/annonc/mdu526","title":"EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; BC Children's Hospital; University of British Columbia","funders":"National Cancer Institute; Medical Research Council","keywords":"Medicine; Osteosarcoma; Ifosfamide; Etoposide; Chemotherapy; Regimen; Neutropenia; Surgery; Internal medicine; Chemotherapy regimen; Pathology","score_opus":0.11625186505668095,"score_gpt":0.42338882379395054,"score_spread":0.3071369587372696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118783447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904276,0.00009581959,0.00008881143,0.004375707,0.0002845713,0.0024256855,0.00013264988,0.000029830278,0.0035241907],"genre_scores_gemma":[0.99655634,0.00012498866,0.0011337496,0.0005091931,0.0003449293,0.000581575,0.00060565135,0.000016029317,0.00012753771],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852747,0.0002498736,0.00054803636,0.00033571493,0.00016982299,0.0001690963],"domain_scores_gemma":[0.99732023,0.001705604,0.00027174954,0.00034289548,0.00024589148,0.000113607915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005849942,0.00015503683,0.00061593734,0.00009359663,0.000045329747,0.00000955704,0.00009766173,0.000100087665,0.00004198803],"category_scores_gemma":[0.0006351205,0.000113105256,0.00019554472,0.00004373253,0.000041186948,0.00007732667,0.000017762604,0.000043907254,0.0000072495986],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1853154,0.02618503,0.07699443,0.000010187714,0.0018593533,0.000045345303,0.0044457195,0.000043974513,0.0009792179,0.00023344456,0.0018057452,0.70208216],"study_design_scores_gemma":[0.53129166,0.042115316,0.3484971,0.000033890654,0.0007143301,0.000012843042,0.00056663115,0.001287742,0.010454091,0.0006977624,0.06415693,0.00017174295],"about_ca_topic_score_codex":0.00068384333,"about_ca_topic_score_gemma":0.00028088628,"teacher_disagreement_score":0.70191044,"about_ca_system_score_codex":0.00007954118,"about_ca_system_score_gemma":0.000083819774,"threshold_uncertainty_score":0.46122986},"labels":[],"label_agreement":null},{"id":"W2118835404","doi":"10.1093/annonc/mdf054","title":"Raltitrexed: current clinical status and future directions","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Raltitrexed; Medicine; Oxaliplatin; Irinotecan; Thymidylate synthase; Oncology; Mesothelioma; Internal medicine; Chemotherapy; Colorectal cancer; Radiation therapy; Cancer research; Cancer; Pharmacology; Fluorouracil; Pathology","score_opus":0.3015928507274742,"score_gpt":0.5428028709588282,"score_spread":0.24121002023135396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118835404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039774943,0.9830991,9.732663e-8,0.0009774085,0.0013403402,0.00051892194,0.00007759765,0.000020697746,0.013926045],"genre_scores_gemma":[0.00000703723,0.9977655,0.000046258625,0.00012620566,0.001229662,0.00008912334,0.000043711105,0.000018923327,0.00067357894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850917,0.00015725671,0.0006532151,0.0003161194,0.000104641425,0.00025957118],"domain_scores_gemma":[0.9989181,0.0002447589,0.00033866434,0.00019484463,0.00013235139,0.00017127693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015996525,0.00024216148,0.0024400218,0.00012931915,0.000057326848,0.0000035611813,0.00004399352,0.0002959057,0.00020194144],"category_scores_gemma":[0.000078234356,0.00016019717,0.00051453145,0.00016757261,0.00018732245,0.000017943912,0.00007336268,0.00041211018,0.000021995727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003838285,0.00056795607,0.00025689424,0.002564312,0.0006584844,0.00002217977,0.00006322963,1.070253e-9,1.8223365e-9,0.000051282423,0.017471666,0.97830564],"study_design_scores_gemma":[0.00055221946,0.0030920962,0.0010160636,0.0013097747,0.0014303998,0.00005157184,0.00002215335,1.6584471e-7,2.6886234e-8,0.000014519053,0.9924024,0.000108637876],"about_ca_topic_score_codex":0.000022570724,"about_ca_topic_score_gemma":0.000049716695,"teacher_disagreement_score":0.978197,"about_ca_system_score_codex":0.00006481687,"about_ca_system_score_gemma":0.00032688913,"threshold_uncertainty_score":0.6532651},"labels":[],"label_agreement":null},{"id":"W2119018891","doi":"10.1093/annonc/mdi240","title":"Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Oncosuisse; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Cyclophosphamide; Metastatic breast cancer; Breast cancer; Oncology; Chemotherapy; Methotrexate; Internal medicine; Cancer; Nitrogen mustard; Clinical trial; Palliative care; Nursing","score_opus":0.25147634853736733,"score_gpt":0.5328897417986063,"score_spread":0.28141339326123893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119018891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95972323,0.009361029,0.00010958795,0.026668135,0.0002565542,0.0024669468,0.00041116282,0.000010897616,0.0009924382],"genre_scores_gemma":[0.9852735,0.01033721,0.0011700029,0.0014792994,0.00028378362,0.0010583278,0.000048570393,0.000016241764,0.0003330668],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881524,0.00015704232,0.00046883835,0.0002301907,0.00009468175,0.00023398314],"domain_scores_gemma":[0.9979942,0.00091424485,0.00051703665,0.00015441488,0.00034924838,0.000070873095],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041970416,0.00018979648,0.00079705805,0.000094476316,0.00005177307,0.0000026286398,0.000084801504,0.000051384144,0.0014932791],"category_scores_gemma":[0.000008611605,0.0001286263,0.00025924854,0.00010892558,0.0001886186,0.000058255875,0.0000090483045,0.000052780215,0.000008676243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010894965,0.004273168,0.006186512,0.000058493206,0.006422814,0.0000015622352,0.005227744,0.0035455818,0.010304905,0.00012857538,0.009716036,0.9432396],"study_design_scores_gemma":[0.066221245,0.020124935,0.17766456,0.00006349286,0.0064189583,0.00003405685,0.0011473402,0.036758218,0.38850725,0.00047585112,0.30218765,0.0003964246],"about_ca_topic_score_codex":0.00043814105,"about_ca_topic_score_gemma":0.00023557144,"teacher_disagreement_score":0.9428432,"about_ca_system_score_codex":0.00047167874,"about_ca_system_score_gemma":0.0006130148,"threshold_uncertainty_score":0.9994195},"labels":[],"label_agreement":null},{"id":"W2119034557","doi":"10.1093/annonc/mdt581","title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Internal medicine; Univariate analysis; Cohort; Cancer; Androgen deprivation therapy; Urology; Multivariate analysis","score_opus":0.09108394557001714,"score_gpt":0.4321348236176081,"score_spread":0.34105087804759093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119034557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272424,0.000080697006,0.000014147148,0.005655272,0.000047877038,0.000994544,0.00007444991,0.000015722228,0.000393068],"genre_scores_gemma":[0.9971423,0.000082067614,0.00073883915,0.00084070396,0.000019161671,0.00015249605,0.00006920311,0.000024202092,0.0009310298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775857,0.0006650096,0.0004995178,0.00031958162,0.00033727603,0.0004200763],"domain_scores_gemma":[0.99818164,0.0005333541,0.00022640788,0.00021892537,0.0006297568,0.00020993437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016633442,0.00016291058,0.00065812515,0.00018858377,0.000042055945,0.000010268968,0.00008172709,0.000081601436,0.000054307187],"category_scores_gemma":[0.0004670056,0.00010131319,0.000038468323,0.00040571162,0.00019557509,0.00008056662,0.000029112318,0.00019951424,0.000007582505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1606238,0.0030602338,0.80824417,0.00010464597,0.00089507736,0.00017617433,0.0011324562,0.00028786308,0.0018111769,0.00004797579,0.001479255,0.022137182],"study_design_scores_gemma":[0.016137669,0.031956077,0.94664574,0.00033207983,0.00011555653,0.000001502978,0.00007591649,0.00003397336,0.0010542689,0.000052320804,0.0034644336,0.00013044736],"about_ca_topic_score_codex":0.00025903183,"about_ca_topic_score_gemma":0.0013133775,"teacher_disagreement_score":0.14448613,"about_ca_system_score_codex":0.00013324535,"about_ca_system_score_gemma":0.0010666451,"threshold_uncertainty_score":0.4131432},"labels":[],"label_agreement":null},{"id":"W2119038990","doi":"10.1093/annonc/mds461","title":"Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Hazard ratio; Gastroenterology; Lung cancer; Anemia; Carboplatin; Clinical endpoint; Adverse effect; Surgery; Chemotherapy; Randomized controlled trial; Confidence interval","score_opus":0.019705394086644214,"score_gpt":0.3615424749756235,"score_spread":0.34183708088897924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119038990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938371,0.0015745441,0.000021529051,0.0014687384,0.00004381278,0.0009731898,0.000017779648,0.000005102231,0.002058206],"genre_scores_gemma":[0.99780256,0.0013190899,0.0003989614,0.00022842313,0.000014359776,0.00007431521,0.000045760968,0.000015443235,0.000101092024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991868,0.000038611273,0.0002920776,0.00015067866,0.00012171264,0.00021013305],"domain_scores_gemma":[0.9992509,0.00014112523,0.00021744243,0.000121178884,0.00019860138,0.000070742295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012093326,0.00012196818,0.0003884188,0.00013704337,0.00002201496,0.0000015053059,0.000034748864,0.00007921984,0.000021391781],"category_scores_gemma":[0.000020880689,0.000086406966,0.000020888816,0.00021412582,0.000066889486,0.000099240926,0.000010493135,0.0000991789,3.767851e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040377434,0.0032464275,0.904748,0.000105673105,0.00013359614,0.0000057559664,0.004410376,0.00023372484,0.0001479269,0.000049964892,0.000030041254,0.08285073],"study_design_scores_gemma":[0.029705547,0.013390546,0.95409065,0.0002640786,0.00007588578,0.0000018153988,0.00024764842,0.00005333423,0.0012265065,0.000013925252,0.0008384616,0.000091567475],"about_ca_topic_score_codex":0.001406335,"about_ca_topic_score_gemma":0.0012601583,"teacher_disagreement_score":0.082759164,"about_ca_system_score_codex":0.000094688156,"about_ca_system_score_gemma":0.00025276668,"threshold_uncertainty_score":0.3523574},"labels":[],"label_agreement":null},{"id":"W2119065193","doi":"10.1093/annonc/mdp028","title":"Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":288,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Biopsy; Concordance; Breast cancer; Progesterone receptor; Primary tumor; Prospective cohort study; Internal medicine; Oncology; Hormone receptor; Cancer; Estrogen receptor; Pathology; Metastasis","score_opus":0.013874068098973506,"score_gpt":0.3064562687115082,"score_spread":0.2925822006125347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119065193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935744,0.0006719918,0.000021070333,0.0038607868,0.0001209109,0.00025037333,0.00049615913,0.0000045615247,0.0009997367],"genre_scores_gemma":[0.99836254,0.00037177638,0.00014898712,0.00094544375,0.00004152986,0.00003915764,0.0000434883,0.000007976519,0.000039075454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923277,0.00005008738,0.00020696364,0.00020208952,0.000120929886,0.00018718532],"domain_scores_gemma":[0.9992923,0.000010862251,0.00021814514,0.00025242302,0.0001918514,0.000034387325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008170084,0.0001353211,0.0002323583,0.000021781714,0.000043210144,0.000002770585,0.00014998927,0.000034335008,0.000032096952],"category_scores_gemma":[0.0000020244424,0.00006340053,0.00006773374,0.000063292646,0.00021604013,0.000003590482,0.000060800106,0.00003420254,0.0000010260105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021161625,0.013907851,0.48153946,0.0008894661,0.019444775,0.00022744498,0.0014848813,0.00022681392,0.05370127,0.0070888503,0.042564437,0.35776314],"study_design_scores_gemma":[0.0021848285,0.0014622493,0.9189791,0.000068940106,0.00024800622,0.000013275731,0.0002709752,7.683022e-7,0.05007151,0.00013979687,0.026378904,0.00018165453],"about_ca_topic_score_codex":0.00006491707,"about_ca_topic_score_gemma":0.000037628037,"teacher_disagreement_score":0.43743965,"about_ca_system_score_codex":0.000012132557,"about_ca_system_score_gemma":0.00004597347,"threshold_uncertainty_score":0.25853986},"labels":[],"label_agreement":null},{"id":"W2119152456","doi":"10.1093/annonc/mdu334.77","title":"Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients with Metastatic Pancreatic Cancer (Mpc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gemcitabine; Medicine; Nab-paclitaxel; Pancreatic cancer; Oncology; Internal medicine; Paclitaxel; Deoxycytidine; Pancreatic tumor; Chemotherapy; Cancer","score_opus":0.06827039939905974,"score_gpt":0.3881665036950904,"score_spread":0.31989610429603066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119152456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362177,0.0004856024,0.00005671174,0.0013175748,0.000030230589,0.003947179,0.00005848044,0.000007885863,0.0004745855],"genre_scores_gemma":[0.99708205,0.0006392594,0.00080150337,0.00054292113,0.00006297147,0.0007003595,0.000062642874,0.00002388431,0.00008439748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728733,0.0005861738,0.0009036362,0.0003434531,0.00046380344,0.0004156261],"domain_scores_gemma":[0.99446666,0.0036547447,0.00067410176,0.00048525722,0.0005946792,0.0001245286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013321398,0.00027058396,0.0019149443,0.00026843295,0.000055269367,0.0000047310227,0.0001706673,0.00012059766,0.000016245482],"category_scores_gemma":[0.0015567661,0.00016080943,0.00009891452,0.00034588441,0.000506951,0.00008245302,0.000029693378,0.0001632433,0.000001621459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3248796,0.012857606,0.61107796,0.002676954,0.0019108714,0.000031817744,0.0055119595,0.0012094477,0.0010048494,0.00055736,0.00045518196,0.03782638],"study_design_scores_gemma":[0.10292102,0.10039374,0.79350024,0.0005560665,0.0010351919,0.000010019178,0.00021797193,0.0003404128,0.00039194777,0.00019741927,0.00030274378,0.00013319823],"about_ca_topic_score_codex":0.00092122215,"about_ca_topic_score_gemma":0.00019008895,"teacher_disagreement_score":0.22195858,"about_ca_system_score_codex":0.00021187965,"about_ca_system_score_gemma":0.00092308654,"threshold_uncertainty_score":0.65576184},"labels":[],"label_agreement":null},{"id":"W2119234062","doi":"10.1093/annonc/mdm112","title":"Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency","keywords":"Medicine; Cohort; Ambulatory; Febrile neutropenia; Incidence (geometry); Internal medicine; Ambulatory care; Neutropenia; Retrospective cohort study; Chemotherapy; Intensive care medicine; Health care","score_opus":0.03210571869994898,"score_gpt":0.3772648139760547,"score_spread":0.3451590952761057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119234062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98254305,0.000078198565,0.00013550078,0.00027879525,0.00008065656,0.000520271,0.000070025955,0.0000057508337,0.016287731],"genre_scores_gemma":[0.9989035,0.0005004543,0.00018289643,0.00026342587,0.000027110085,0.000013255451,0.000005900793,0.000010132306,0.000093315466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988338,0.0001039204,0.00047037026,0.00015587965,0.000221444,0.00021461799],"domain_scores_gemma":[0.99804825,0.0003904875,0.0006474571,0.00027241398,0.00058238156,0.000059018003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005129473,0.000118141994,0.0004996463,0.00014069505,0.00003829995,7.7915337e-7,0.000121593665,0.000102777936,0.0000660433],"category_scores_gemma":[0.000048663736,0.00007890629,0.0002087812,0.0003357482,0.0002527882,0.00003006244,0.000057339177,0.00020952304,0.0000043042987],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044899873,0.009061186,0.2453531,0.0009194098,0.027679773,0.0006327549,0.02351018,0.004898402,0.27467984,0.030723203,0.01815365,0.31948864],"study_design_scores_gemma":[0.0011458476,0.02626235,0.65830344,0.00016171901,0.0005635623,0.000030058372,0.00047704976,0.0000066198572,0.31240913,0.00046376363,0.00010857189,0.00006784546],"about_ca_topic_score_codex":0.0023116076,"about_ca_topic_score_gemma":0.00012611743,"teacher_disagreement_score":0.41295037,"about_ca_system_score_codex":0.0002817676,"about_ca_system_score_gemma":0.00034281207,"threshold_uncertainty_score":0.34944746},"labels":[],"label_agreement":null},{"id":"W2119237890","doi":"10.1093/annonc/mdt368","title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Medicine; Cetuximab; Anal cancer; Chemoradiotherapy; Toxicity; Oncology; Phases of clinical research; Internal medicine; Colorectal cancer; Cancer","score_opus":0.02941426372315074,"score_gpt":0.33703093690702934,"score_spread":0.3076166731838786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119237890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954758,0.000103909915,0.0000060446596,0.002394424,0.00007200897,0.0010585466,0.00007553108,0.0000061655796,0.0008075587],"genre_scores_gemma":[0.999173,0.000049620638,0.000101460326,0.00040243648,0.000037432837,0.00006470254,0.000033727923,0.000010505512,0.00012710103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986635,0.00008839604,0.00054828764,0.00020290905,0.00030423328,0.00019269352],"domain_scores_gemma":[0.9982919,0.00009197719,0.00070220407,0.00022243368,0.0006237526,0.00006773099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000133912,0.00013496145,0.00072958256,0.00009280834,0.000027658418,0.0000013860978,0.00014914566,0.000086864864,0.00017986735],"category_scores_gemma":[0.00007229285,0.00007904947,0.00010095893,0.00044589827,0.00038792117,0.000066657194,0.000040875395,0.00015316658,2.0494372e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84817356,0.011846052,0.07756515,0.00009896539,0.00037129517,0.0000059745994,0.0003683469,0.00006756006,0.012742204,0.00015054208,0.0010261743,0.047584165],"study_design_scores_gemma":[0.44646206,0.14605795,0.35266998,0.0003482162,0.00007940879,0.0000026650582,0.00015054634,0.00012713423,0.05307297,0.00014491327,0.0007181992,0.0001659612],"about_ca_topic_score_codex":0.00071373594,"about_ca_topic_score_gemma":0.0012805904,"teacher_disagreement_score":0.40171152,"about_ca_system_score_codex":0.000087338936,"about_ca_system_score_gemma":0.00065187644,"threshold_uncertainty_score":0.32235435},"labels":[],"label_agreement":null},{"id":"W2119750849","doi":"10.1093/annonc/mdv033","title":"A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; Mount Sinai Hospital; University of Calgary; McGill University; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Alberta Cancer Foundation; University of Alberta","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Medicine; Chromosomal translocation; Cancer research; Population; Histone deacetylase 2; Internal medicine; Oncology; Fusion gene; PTEN; PI3K/AKT/mTOR pathway; Histone deacetylase; Histone; Apoptosis; Biology; Genetics; Gene","score_opus":0.07395527588728779,"score_gpt":0.40082570793998334,"score_spread":0.32687043205269556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119750849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756175,0.00058269233,0.00006126117,0.00018578318,0.000117547504,0.0010612913,0.00015532521,0.000008558263,0.00026577656],"genre_scores_gemma":[0.9990644,0.00003556323,0.00022988586,0.00007664783,0.000038506332,0.00009545863,0.00031888613,0.000037301925,0.00010334736],"study_design_codex":"nonrandomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720407,0.0004336681,0.0008447553,0.00049233687,0.0005606989,0.00046447662],"domain_scores_gemma":[0.997706,0.000061588406,0.00046689453,0.0004535789,0.0010983372,0.00021357684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010039142,0.00026300302,0.00064765866,0.00033394684,0.00006497513,0.0000055402197,0.00030293575,0.00021804638,0.000011043098],"category_scores_gemma":[0.0006546226,0.00025128268,0.00008544183,0.00058817083,0.0002729107,0.000017665612,0.000124706,0.00027370613,0.000003713917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035937376,0.39189276,0.031950388,0.00027214453,0.0017705833,0.00012359256,0.023169953,0.00050598476,0.35418642,0.000054141896,0.030527452,0.1296092],"study_design_scores_gemma":[0.16407698,0.38620606,0.015455648,0.00033215797,0.00020441829,0.000019068453,0.004244636,0.00018525202,0.41247186,0.000054314078,0.01545929,0.0012902905],"about_ca_topic_score_codex":0.000493278,"about_ca_topic_score_gemma":0.002775705,"teacher_disagreement_score":0.1283189,"about_ca_system_score_codex":0.00012148865,"about_ca_system_score_gemma":0.0010325403,"threshold_uncertainty_score":0.9999939},"labels":[],"label_agreement":null},{"id":"W2119777146","doi":"10.1093/annonc/mdn752","title":"Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"Sanofi","keywords":"Medicine; Docetaxel; Hazard ratio; Chemoradiotherapy; Surgery; Confidence interval; Fluorouracil; Internal medicine; Radiation therapy; Subgroup analysis; Hypopharyngeal cancer; Cancer","score_opus":0.1381080017445164,"score_gpt":0.4217159470941321,"score_spread":0.28360794534961575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119777146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9266455,0.017520435,0.000047954538,0.05476225,0.00016611238,0.00055619143,0.00002088976,0.000010680313,0.0002699599],"genre_scores_gemma":[0.9369557,0.058177307,0.0000877008,0.0044351183,0.00013464625,0.000073475334,0.000007863197,0.0000091206275,0.00011907329],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991782,0.00006282202,0.0002595621,0.0001845673,0.00009904955,0.00021580074],"domain_scores_gemma":[0.99901766,0.0005612979,0.00010014851,0.000113487295,0.00015767182,0.000049759034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005173759,0.000103849095,0.00047863545,0.00006247171,0.00006291542,0.0000049357072,0.000045893346,0.000084268824,0.000017390706],"category_scores_gemma":[0.00014177263,0.00007130503,0.00004292736,0.00012168623,0.00011690328,0.00009847813,0.000019433048,0.000091767935,2.0042971e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045400024,0.00034430303,0.06752991,0.00010859192,0.00015686822,0.000018390692,0.0009642258,0.000011625678,0.019699877,0.00030503655,0.0151507845,0.8911704],"study_design_scores_gemma":[0.005333805,0.0045345663,0.81200707,0.00013785243,0.000042493226,0.000011718065,0.00023201376,0.0001956554,0.009114092,0.001008964,0.16722357,0.00015819036],"about_ca_topic_score_codex":0.00044342363,"about_ca_topic_score_gemma":0.0014207888,"teacher_disagreement_score":0.8910122,"about_ca_system_score_codex":0.000020013576,"about_ca_system_score_gemma":0.00019983665,"threshold_uncertainty_score":0.29077348},"labels":[],"label_agreement":null},{"id":"W2119851749","doi":"10.1093/annonc/mdv004","title":"Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Prostate cancer; Internal medicine; Odds ratio; Oncology; Prostate-specific antigen; Confidence interval; Single-nucleotide polymorphism; Missense mutation; Population; Germline mutation; Family history; Cancer; Gynecology; Genotype; Mutation; Genetics; Gene","score_opus":0.06841544777944147,"score_gpt":0.4061647599432376,"score_spread":0.3377493121637961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119851749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958943,0.001903407,0.000009626557,0.0014335758,0.00004985878,0.00045452366,0.0001244981,0.000005089905,0.0001251342],"genre_scores_gemma":[0.97452945,0.024891412,0.00023619877,0.0001666952,0.000022908629,0.000044613425,0.000019721158,0.0000073922033,0.000081591796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999134,0.00009193027,0.00040024423,0.00016574163,0.000102217135,0.000105878404],"domain_scores_gemma":[0.99902827,0.00019565999,0.00036933823,0.00007141089,0.00024770587,0.00008762127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045363256,0.000072241084,0.00040349862,0.00004226854,0.000011452075,0.00000390795,0.000020091427,0.00006609905,0.0000069948055],"category_scores_gemma":[0.00022180511,0.00005983642,0.000021603648,0.00005388959,0.00015962866,0.00006636071,0.000020155067,0.00009939476,3.5655697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056600664,0.00033164094,0.89423853,0.0001218251,0.00007676105,0.00005343478,0.0006463236,0.000009487518,0.0000072371577,0.0000065436407,0.00014026991,0.10380191],"study_design_scores_gemma":[0.0036208446,0.004427336,0.9905703,0.00025619433,0.00015398975,0.00003311755,0.00016693921,0.00036608646,0.000120830555,0.00011260821,0.00011885656,0.000052915424],"about_ca_topic_score_codex":0.0013581895,"about_ca_topic_score_gemma":0.00063543423,"teacher_disagreement_score":0.103749,"about_ca_system_score_codex":0.000031711617,"about_ca_system_score_gemma":0.00019866189,"threshold_uncertainty_score":0.24400583},"labels":[],"label_agreement":null},{"id":"W2120241552","doi":"10.1093/annonc/mds636","title":"Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Toxicity; Clinical trial; Randomized controlled trial; Publication bias; Internal medicine; Clinical endpoint; Oncology; End point; Cancer; Meta-analysis","score_opus":0.9114153273375074,"score_gpt":0.6688162599341168,"score_spread":0.24259906740339066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120241552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407375,0.00037279876,0.00025351593,0.0024743301,0.000059061273,0.0018414714,0.000018187488,5.0955384e-7,0.00090634753],"genre_scores_gemma":[0.99775445,0.00018917583,0.0014511653,0.00019094505,0.000026232308,0.00019464438,5.605519e-7,0.0000040481596,0.00018876886],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9064528,0.040314674,0.05069953,0.0007547703,0.001431943,0.0003463155],"domain_scores_gemma":[0.7836833,0.13937014,0.07246421,0.0014816597,0.0028184368,0.00018225684],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5365885,0.00013115448,0.012517882,0.0003574961,0.000010587815,0.000021580512,0.0003595339,0.00012713834,0.0017659544],"category_scores_gemma":[0.3848041,0.000056808272,0.0007948781,0.0005228135,0.00026714426,0.00010612704,0.000062283856,0.000089921145,0.000004621883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021902341,0.000880044,0.31862333,0.00029014953,0.00085463695,0.000005552078,0.002353401,0.00009694991,0.0006996205,0.0003467597,0.004940406,0.6490068],"study_design_scores_gemma":[0.13772672,0.002330576,0.8257092,0.00059561455,0.00039622776,0.000036653535,0.002785004,0.0035846734,0.0012668147,0.021999838,0.0032527468,0.0003159023],"about_ca_topic_score_codex":0.00037231494,"about_ca_topic_score_gemma":0.00039650276,"teacher_disagreement_score":0.6486909,"about_ca_system_score_codex":0.000012366924,"about_ca_system_score_gemma":0.00023175549,"threshold_uncertainty_score":0.9991466},"labels":[],"label_agreement":null},{"id":"W2120396201","doi":"10.1093/annonc/mdi268","title":"High-dose mitoxantrone–vinblastine–cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Mitoxantrone; Breast cancer; Cyclophosphamide; Vinblastine; Surgery; Autologous stem-cell transplantation; Chemotherapy; Regimen; Internal medicine; Transplantation; ThioTEPA; Oncology; Cancer","score_opus":0.02194020293195497,"score_gpt":0.3165765137893186,"score_spread":0.29463631085736364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120396201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945608,0.0012960188,0.00006767848,0.001237963,0.00010010214,0.0009121595,0.0016980125,0.000009643919,0.0001176491],"genre_scores_gemma":[0.99714077,0.001466375,0.0006469485,0.000084155065,0.00013800198,0.00018332832,0.000067777306,0.000016334958,0.0002563393],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987418,0.000070507565,0.0004190069,0.0004034057,0.00010011896,0.0002651636],"domain_scores_gemma":[0.9990394,0.00009271596,0.00035910922,0.00016871198,0.0002836987,0.000056341552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014760638,0.00019511531,0.00042624233,0.000045315486,0.00006851239,0.0000034566121,0.000100225,0.00012334037,0.000005197438],"category_scores_gemma":[0.00001255641,0.00017592759,0.00007312264,0.0000635182,0.00014083173,0.00000832208,0.000046242803,0.000057822726,4.550876e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13223584,0.012264418,0.24397385,0.00084622967,0.003113526,0.00007482279,0.015389457,0.003614347,0.11744521,0.00013188436,0.0049774987,0.4659329],"study_design_scores_gemma":[0.023924647,0.005583946,0.7656963,0.00003927069,0.00029705712,0.000027862963,0.0016141421,0.000051009316,0.20003231,0.000010837392,0.0024731718,0.0002494819],"about_ca_topic_score_codex":0.0007948424,"about_ca_topic_score_gemma":0.0025771214,"teacher_disagreement_score":0.52172244,"about_ca_system_score_codex":0.000034530934,"about_ca_system_score_gemma":0.00015104946,"threshold_uncertainty_score":0.7174119},"labels":[],"label_agreement":null},{"id":"W2120431466","doi":"10.1093/annonc/mdu450","title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Tumor-infiltrating lymphocytes; H&E stain; Breast cancer; Oncology; Medical physics; Cancer; Pathology; Internal medicine; Immunotherapy; Staining","score_opus":0.08993888139496703,"score_gpt":0.42382210720944913,"score_spread":0.3338832258144821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120431466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680704,0.0011788808,0.000059457565,0.022843778,0.00057769485,0.00029498976,0.000036982914,0.000011815529,0.0069259834],"genre_scores_gemma":[0.99645966,0.0018737204,0.0001509087,0.0012342755,0.00013989866,0.000051663865,0.00005719033,0.000008259383,0.000024444164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987235,0.00028616257,0.00045127366,0.0001427518,0.0002464063,0.00014990904],"domain_scores_gemma":[0.99882907,0.0003141205,0.00035659826,0.00016636436,0.00030074717,0.00003312276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025697383,0.000077734716,0.00020938272,0.000089682166,0.000054948567,0.000009053675,0.00014688646,0.00006001882,0.00030232078],"category_scores_gemma":[0.00012120231,0.000060550872,0.000060281123,0.0001317501,0.00011438827,0.00010183997,0.000018722048,0.00008369033,0.0000013210597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010889545,0.00022574925,0.03689572,0.000010225605,0.00010773412,3.4698692e-7,0.0003293404,0.000031691965,0.026517479,0.00020666135,0.008277467,0.92630863],"study_design_scores_gemma":[0.01335192,0.0028456696,0.584641,0.0008675837,0.00017592614,0.00012006139,0.0018726409,0.028089544,0.029674748,0.0011702902,0.3368494,0.00034126508],"about_ca_topic_score_codex":0.0011396364,"about_ca_topic_score_gemma":0.001033477,"teacher_disagreement_score":0.9259674,"about_ca_system_score_codex":0.00016050962,"about_ca_system_score_gemma":0.00025482307,"threshold_uncertainty_score":0.33102006},"labels":[],"label_agreement":null},{"id":"W2120470536","doi":"10.1093/annonc/mdg101","title":"Cancer physicians’ attitudes toward colorectal cancer follow-up","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"Armstrong Foundation; Lance Armstrong Foundation","keywords":"Medicine; Colorectal cancer; Oncology; Cancer; Family medicine; Internal medicine","score_opus":0.11933546561227519,"score_gpt":0.4285964599732111,"score_spread":0.3092609943609359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120470536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95692825,0.003929993,0.0000053657614,0.004199106,0.0011116271,0.0004341961,0.00004809831,0.0000471111,0.033296235],"genre_scores_gemma":[0.992827,0.0027468158,0.00016231282,0.002332214,0.0001783798,0.00033181047,0.000009322125,0.000029305253,0.0013828158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984577,0.000114662194,0.00033836722,0.00035907887,0.00027737746,0.00045282612],"domain_scores_gemma":[0.9989705,0.00016184058,0.00018781431,0.0001801712,0.00033540497,0.0001642426],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016709945,0.00021561382,0.0007833703,0.000090090514,0.000048349768,0.000005099865,0.0001058528,0.00018760546,0.001633466],"category_scores_gemma":[0.00012844296,0.00018550713,0.00027152416,0.00033825776,0.0002049935,0.00007130983,0.000038290833,0.00019188641,0.000037051315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046226354,0.0025434506,0.64238036,0.00027880704,0.0022362373,0.00033576947,0.0019098127,0.000047618603,0.01696495,0.0015066725,0.020730017,0.30644366],"study_design_scores_gemma":[0.00744703,0.0068775066,0.4507019,0.00026536972,0.00037981296,0.000050142666,0.00016222196,0.000016180094,0.1303825,0.00046951763,0.4028669,0.0003809354],"about_ca_topic_score_codex":0.0008787977,"about_ca_topic_score_gemma":0.00091712613,"teacher_disagreement_score":0.38213688,"about_ca_system_score_codex":0.00024718785,"about_ca_system_score_gemma":0.0006700059,"threshold_uncertainty_score":0.9992792},"labels":[],"label_agreement":null},{"id":"W2120642008","doi":"10.1093/annonc/mdl056","title":"Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Hôpital Notre-Dame; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Temozolomide; Oncology; Clinical trial; Breast cancer; Internal medicine; Cancer; Gynecology; Chemotherapy","score_opus":0.26585996108081555,"score_gpt":0.5287769800145659,"score_spread":0.2629170189337503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120642008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747452,0.0008926691,0.000009431318,0.0197946,0.0010682639,0.0011064529,0.0015088769,0.0000033990898,0.0008710776],"genre_scores_gemma":[0.9969948,0.00032251424,0.0003039754,0.0015624017,0.0003991576,0.00014360168,0.000038006034,0.000010451453,0.00022509795],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99638504,0.0008193912,0.0018423124,0.00022844084,0.00048022548,0.00024461225],"domain_scores_gemma":[0.99723285,0.0009670046,0.00114295,0.0001909115,0.0003821131,0.00008416323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038829048,0.00015303033,0.0014527431,0.00010682034,0.000041078878,0.0000014453727,0.00013709233,0.00010145473,0.00027451935],"category_scores_gemma":[0.0010752218,0.000096918186,0.00034626716,0.0002929665,0.00030054478,0.000049209197,0.000053685548,0.0001757859,2.486878e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23231353,0.054502312,0.027706271,0.00066603435,0.0061942553,0.0003172365,0.0003276781,0.0020399834,0.006445235,0.010288913,0.2803739,0.37882465],"study_design_scores_gemma":[0.520524,0.024332305,0.1533262,0.0007336443,0.0025395933,0.0001395313,0.00018140416,0.00041633783,0.010065788,0.0030784737,0.2841912,0.0004715271],"about_ca_topic_score_codex":0.39804623,"about_ca_topic_score_gemma":0.5813831,"teacher_disagreement_score":0.37835312,"about_ca_system_score_codex":0.0002144639,"about_ca_system_score_gemma":0.0058280635,"threshold_uncertainty_score":0.99980795},"labels":[],"label_agreement":null},{"id":"W2120672148","doi":"10.1093/annonc/mdh064","title":"The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Exemestane; Oncology; Internal medicine; Cancer; Metastatic breast cancer; Breast cancer; Randomized controlled trial; Menopause; Postmenopausal women; Hormonal therapy; Hormone; Aromatase","score_opus":0.020545330563512355,"score_gpt":0.3526353880587899,"score_spread":0.33209005749527754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120672148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834549,0.00029394322,0.0000053480762,0.00073636154,0.00009752864,0.014771139,0.00062008726,0.000007688815,0.000013000947],"genre_scores_gemma":[0.99283594,0.00029237499,0.00008366093,0.0000795162,0.000055372064,0.0064524016,0.00011403378,0.000051961866,0.00003475765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99642915,0.0009636082,0.0009636622,0.00062465813,0.00033924897,0.00067968795],"domain_scores_gemma":[0.99830157,0.000444219,0.00051547814,0.00034853193,0.00022305,0.00016716353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013657935,0.00050995586,0.0016386195,0.00025786652,0.000109550594,0.00001353119,0.00024389451,0.000102073995,0.000012802808],"category_scores_gemma":[0.000082557926,0.00026941948,0.00008164602,0.0005084917,0.0001830656,0.000017777207,0.00008681072,0.00019327104,5.6972567e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9348029,0.03333055,0.0061128526,0.000073843956,0.0016322026,0.00016555104,0.0024826608,0.0026889,0.0026161948,0.0000048487373,0.000017662105,0.016071875],"study_design_scores_gemma":[0.5177536,0.46685186,0.010349363,0.00012883458,0.00034345986,0.000033374075,0.0007785772,0.00003776566,0.0034330133,0.0000056649737,0.00003344894,0.00025106673],"about_ca_topic_score_codex":0.001981554,"about_ca_topic_score_gemma":0.010801216,"teacher_disagreement_score":0.4335213,"about_ca_system_score_codex":0.00033809023,"about_ca_system_score_gemma":0.0007268856,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2120703089","doi":"10.1093/annonc/mdh069","title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Mantle cell lymphoma; Rituximab; Autologous stem-cell transplantation; Chemotherapy; Oncology; Lymphoma; Stage (stratigraphy); Transplantation; Internal medicine","score_opus":0.030222630829341558,"score_gpt":0.32999387399501345,"score_spread":0.2997712431656719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120703089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787091,0.0009137175,0.002024047,0.016348196,0.00007796217,0.0014637972,0.00026941887,0.00005994529,0.00013381697],"genre_scores_gemma":[0.97785836,0.0022187917,0.004965593,0.013946297,0.000032033826,0.0003629758,0.00016470149,0.000045055596,0.00040621287],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831665,0.0000464965,0.0005349255,0.000514921,0.0002067578,0.00038024053],"domain_scores_gemma":[0.9984663,0.00032990516,0.0002463407,0.00025239366,0.0004913773,0.00021366814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017610846,0.0002926128,0.001139754,0.0002889542,0.0000647579,0.000013906701,0.00009459211,0.00021818429,0.0001031035],"category_scores_gemma":[0.000017247386,0.00025921772,0.00040121193,0.00031985657,0.00012208939,0.00008177606,0.000014492175,0.000049737297,0.000010946335],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068244204,0.04498556,0.050755937,0.0034592275,0.01371929,0.002628817,0.057280283,0.0016319315,0.05992352,0.0018120464,0.011956514,0.6836027],"study_design_scores_gemma":[0.29009193,0.020982418,0.2032828,0.00022249651,0.0028097194,0.00017102937,0.0044773924,0.00053851545,0.45380306,0.00080325606,0.021997675,0.0008196955],"about_ca_topic_score_codex":0.00032001242,"about_ca_topic_score_gemma":0.000104237784,"teacher_disagreement_score":0.68278295,"about_ca_system_score_codex":0.00023706432,"about_ca_system_score_gemma":0.0004110085,"threshold_uncertainty_score":0.999986},"labels":[],"label_agreement":null},{"id":"W2120707401","doi":"10.1093/annonc/mdr420","title":"How may clinical research improve healthcare outcomes?","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Health care; Medicine; Psychological intervention; Healthcare system; Quality (philosophy); Work (physics); Nursing","score_opus":0.9622005923542554,"score_gpt":0.7246693377391987,"score_spread":0.23753125461505664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120707401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002370302,0.90029436,0.00003435327,0.08234549,0.0026595925,0.0020601472,0.0010066573,0.000034951103,0.0115407165],"genre_scores_gemma":[0.00007728,0.98294854,0.0008478027,0.008960251,0.0011451404,0.0004473189,0.00011102273,0.00010716382,0.0053554983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97874486,0.005947354,0.012485614,0.0014151408,0.00018523511,0.0012217799],"domain_scores_gemma":[0.97687876,0.009648828,0.010552183,0.0017431198,0.00060482137,0.0005722647],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09945094,0.00050218654,0.010239291,0.0012392101,0.00019128731,0.00006329745,0.0013124482,0.0020212114,0.00035203138],"category_scores_gemma":[0.020095672,0.00053061044,0.0014821965,0.00045732298,0.00054770475,0.00030623563,0.00037148606,0.0018564437,0.0040778657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013337381,0.0003953139,0.00146672,0.018860985,0.00049600215,0.000006582961,0.0002640529,3.1323395e-8,1.6450075e-9,0.19139346,0.12680165,0.66030186],"study_design_scores_gemma":[0.00035789012,0.0013992822,0.00028903785,0.0012390995,0.000030805044,0.0000085158545,0.00017123832,0.0000026049222,4.030293e-8,0.013196691,0.9829165,0.00038830002],"about_ca_topic_score_codex":0.0014064816,"about_ca_topic_score_gemma":0.0003164807,"teacher_disagreement_score":0.85611486,"about_ca_system_score_codex":0.0005804802,"about_ca_system_score_gemma":0.0026151082,"threshold_uncertainty_score":0.99971455},"labels":[],"label_agreement":null},{"id":"W2121293811","doi":"10.1093/annonc/mdr026","title":"Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Sunitinib; Medicine; Cisplatin; Internal medicine; Mucositis; Germ cell tumors; Oncology; Gastroenterology; Refractory (planetary science); Nausea; Cancer; Chemotherapy; Rash; Urology; Biology","score_opus":0.14290059689412618,"score_gpt":0.4321987028377244,"score_spread":0.28929810594359817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121293811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614275,0.00014051622,0.0000014659512,0.00008929266,0.0000929259,0.0030852766,0.00008428967,0.000016591548,0.00034687232],"genre_scores_gemma":[0.99897397,0.000053653657,0.0002929413,0.0003874218,0.000032162956,0.00018370767,0.000028559016,0.000029598896,0.000018008843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964978,0.0012555732,0.0009533055,0.00060537097,0.00025253193,0.00043539194],"domain_scores_gemma":[0.9965268,0.0013991786,0.0007130887,0.000395227,0.00044138465,0.0005243698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008079189,0.00030241522,0.0013518604,0.00022722501,0.00006499945,0.0000039467027,0.00014176402,0.00028277517,0.00012995988],"category_scores_gemma":[0.0011177434,0.00020597568,0.00010013349,0.00027684306,0.00044356083,0.00009975708,0.000094922616,0.00049590727,0.0000032018704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011371927,0.06621335,0.9021403,0.000043573255,0.00057998137,0.0015943629,0.0017844881,0.000001884386,0.000012540492,0.000003571007,0.000025704985,0.016228285],"study_design_scores_gemma":[0.02138434,0.14952739,0.8274227,0.00006041098,0.0006301274,0.0000073807337,0.00066555594,0.00003260514,0.000014355781,0.0000059555964,0.00009521576,0.00015398284],"about_ca_topic_score_codex":0.050858274,"about_ca_topic_score_gemma":0.16910924,"teacher_disagreement_score":0.118250966,"about_ca_system_score_codex":0.00013245794,"about_ca_system_score_gemma":0.0013863301,"threshold_uncertainty_score":0.95546216},"labels":[],"label_agreement":null},{"id":"W2121589028","doi":"10.1093/annonc/mdu220","title":"Early-stage lung cancer—what do the experts recommend?","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Guideline; Lung cancer; Stage (stratigraphy); Family medicine; Lung cancer screening; Treatment of lung cancer; Evidence-based practice; Alternative medicine; Oncology; Pathology","score_opus":0.08884588986495034,"score_gpt":0.42213926785915956,"score_spread":0.3332933779942092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121589028","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066346056,0.023126425,0.000002338831,0.9594491,0.001676805,0.0007513245,0.00004450259,0.000028678973,0.00828619],"genre_scores_gemma":[0.011934862,0.067455836,0.000035061003,0.91083133,0.0044141496,0.0006726617,0.00012446084,0.00006530733,0.004466308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799615,0.00024033133,0.00047077893,0.0004630448,0.00032367633,0.0005060126],"domain_scores_gemma":[0.9977763,0.00064181327,0.0004677622,0.00078974036,0.00023171,0.00009263624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003021255,0.0003403262,0.0010397361,0.000115402545,0.00007786162,0.000037110283,0.00027866627,0.0007854731,0.0013403078],"category_scores_gemma":[0.00003789279,0.00020852333,0.00036776823,0.00009990815,0.00017776086,0.000078636906,0.00008844052,0.00076654856,0.000027264858],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008663548,0.00015812983,0.0031168505,0.00030671596,0.00086418283,0.0004180053,0.0005463453,0.0000012322369,0.0000032310534,0.000027548982,0.9335251,0.060946066],"study_design_scores_gemma":[0.0011142484,0.0017542719,0.0009903167,0.00095691415,0.00040883978,0.00003477243,0.000085776934,0.000005462385,0.0003354495,0.000042612304,0.99408877,0.00018257234],"about_ca_topic_score_codex":0.0012961611,"about_ca_topic_score_gemma":0.000109061606,"teacher_disagreement_score":0.060763493,"about_ca_system_score_codex":0.00033112633,"about_ca_system_score_gemma":0.00038087947,"threshold_uncertainty_score":0.9995726},"labels":[],"label_agreement":null},{"id":"W2121607722","doi":"10.1093/annonc/mdj965","title":"Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":116,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Vinblastine; Gemcitabine; Internal medicine; Oncology; Hazard ratio; Bladder cancer; Cisplatin; Transitional cell carcinoma; Progression-free survival; Chemotherapy; Urology; Confidence interval; Cancer","score_opus":0.04530653708582257,"score_gpt":0.36108207929186137,"score_spread":0.3157755422060388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121607722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460244,0.0008388073,0.00012310538,0.00038970474,0.00011426713,0.0020239635,0.000076866614,0.000013074233,0.0018177715],"genre_scores_gemma":[0.9975007,0.0002549193,0.0017213009,0.00009730319,0.00005084461,0.00011980034,0.000068227004,0.000028151308,0.00015873868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974416,0.00038735985,0.0011089985,0.0004006366,0.0003271201,0.0003343074],"domain_scores_gemma":[0.99778074,0.0009387487,0.00063681364,0.00019969103,0.0003350928,0.00010889984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007844592,0.00028201684,0.0020733688,0.0002363533,0.000032019307,0.0000072430475,0.00006627789,0.00010313062,0.00003282128],"category_scores_gemma":[0.00028430205,0.00020229413,0.000099093835,0.00023950373,0.00037653584,0.00010165468,0.000051978033,0.00017380211,5.2667724e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8292875,0.0011304476,0.15127999,0.00017037852,0.0006025949,0.00003639455,0.00027833978,0.00014315899,0.00038839778,0.000049089136,0.000051211555,0.016582498],"study_design_scores_gemma":[0.68589574,0.005236481,0.30606246,0.00028412906,0.0005379933,0.0000050728654,0.000028681461,0.0001426236,0.0015580871,0.00007932754,0.00002470906,0.00014472511],"about_ca_topic_score_codex":0.001673668,"about_ca_topic_score_gemma":0.002134534,"teacher_disagreement_score":0.15478246,"about_ca_system_score_codex":0.00003673025,"about_ca_system_score_gemma":0.00023710572,"threshold_uncertainty_score":0.82493156},"labels":[],"label_agreement":null},{"id":"W2121866021","doi":"10.1093/annonc/mdl495","title":"Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Erlotinib; Pharmacodynamics; Head and neck cancer; Head and neck; Oncology; Internal medicine; Skin cancer; Cancer; Pharmacokinetics; Surgery; Epidermal growth factor receptor","score_opus":0.047141615813195384,"score_gpt":0.4408392469350251,"score_spread":0.3936976311218297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121866021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956977,0.0006886266,0.0000063422576,0.0005708118,0.000036833895,0.00021715226,0.000022738981,0.000002212454,0.002757621],"genre_scores_gemma":[0.99789095,0.0012147763,0.0004956872,0.0003505778,0.000014620361,0.0000063622842,0.0000033941517,0.000006087329,0.00001755893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992949,0.00002134842,0.000307202,0.00011316969,0.00011434362,0.00014903315],"domain_scores_gemma":[0.99945533,0.00009277938,0.00016572665,0.000058983467,0.00017267505,0.000054524837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025488736,0.00007246064,0.0005086299,0.000100027195,0.000009732464,4.041337e-7,0.000023437973,0.000042998166,0.000012438598],"category_scores_gemma":[0.000018806282,0.000055779572,0.000017075145,0.00011467322,0.00017328313,0.000024698174,0.0000290245,0.00008299766,3.1340686e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006825932,0.00048785744,0.9356931,0.00023081443,0.000068671456,0.000009246803,0.0005765298,0.0000043543637,0.00053161214,0.000074161086,0.00011061865,0.06153045],"study_design_scores_gemma":[0.0039784857,0.004661809,0.9880645,0.0002141737,0.000028770997,0.0000018818135,0.00016772508,0.000048472753,0.00173232,0.000013020093,0.0010435451,0.000045252087],"about_ca_topic_score_codex":0.00047133313,"about_ca_topic_score_gemma":0.0015261247,"teacher_disagreement_score":0.061485197,"about_ca_system_score_codex":0.000023980465,"about_ca_system_score_gemma":0.00016028427,"threshold_uncertainty_score":0.22746249},"labels":[],"label_agreement":null},{"id":"W2121944733","doi":"10.1093/annonc/mds594","title":"An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; London Health Sciences Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Lapatinib; Medicine; Breast cancer; Internal medicine; Oncology; Clinical endpoint; Estrogen receptor; Cancer; Biomarker; Adverse effect; Clinical trial; Trastuzumab","score_opus":0.19327971489460452,"score_gpt":0.5173170746045165,"score_spread":0.324037359709912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121944733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886172,0.00012231486,2.7879702e-7,0.0014684642,0.00010129396,0.0072535104,0.000060798895,0.000019709716,0.0023564256],"genre_scores_gemma":[0.99673843,0.000051374845,0.00004227591,0.000268829,0.00019319353,0.0024702952,0.0000019272402,0.000051203268,0.00018243784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99450433,0.0022288882,0.00088171667,0.0005213749,0.0009968817,0.00086678145],"domain_scores_gemma":[0.9967657,0.0007462821,0.0004336691,0.00093532,0.0007539918,0.00036507196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042914734,0.00028650882,0.0012878762,0.00021572475,0.0001023804,0.000024369887,0.0009261772,0.00013075484,0.0004202394],"category_scores_gemma":[0.0001699125,0.00018153494,0.000024927409,0.00094640325,0.00035487398,0.00030716186,0.00044710768,0.0007188587,0.000008399242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014275823,0.08978207,0.7302342,0.000039151204,0.00056753843,0.00014039325,0.12373707,0.000013121066,0.000075796845,0.0000099273575,0.00028882432,0.04083611],"study_design_scores_gemma":[0.022346336,0.12409738,0.7737611,0.000076321856,0.000074920325,0.000025006897,0.078757465,0.000011236626,0.000099848956,0.000011937438,0.00059281435,0.00014561952],"about_ca_topic_score_codex":0.02223237,"about_ca_topic_score_gemma":0.012272324,"teacher_disagreement_score":0.0449796,"about_ca_system_score_codex":0.00023561048,"about_ca_system_score_gemma":0.0009095804,"threshold_uncertainty_score":0.9842787},"labels":[],"label_agreement":null},{"id":"W2122128102","doi":"10.1093/annonc/mdt029","title":"Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Rituximab; Internal medicine; Oncology; Chemotherapy; Anthracycline; Surgery; Lymphoma; Transplantation; Chemotherapy regimen; Population; Cancer; Breast cancer","score_opus":0.04044351815891215,"score_gpt":0.3309081552942166,"score_spread":0.2904646371353044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122128102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932433,0.00008888801,0.0003785061,0.0011661655,0.000092319,0.0011939814,0.00007462275,0.000015126508,0.0037471007],"genre_scores_gemma":[0.9982444,0.00017864515,0.00029166907,0.000843226,0.000011682807,0.00012976154,0.000121886675,0.000017964492,0.00016077001],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988868,0.000034726057,0.00048376396,0.00016517534,0.00017212771,0.00025738747],"domain_scores_gemma":[0.99907434,0.00008509254,0.00028348784,0.000120305944,0.0003584149,0.00007837155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012831864,0.00012844062,0.00055598735,0.00010881353,0.000026648948,0.0000021867438,0.000071656876,0.00019421862,0.00004527402],"category_scores_gemma":[0.000010048277,0.00009814585,0.00012272933,0.000109784254,0.000079607074,0.00007688818,0.000003614819,0.000056555626,0.000004351232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012978564,0.003994895,0.39836758,0.0015331064,0.00051894545,0.000010662218,0.0050592325,0.00006718086,0.0025959334,0.00008665913,0.006418467,0.5683688],"study_design_scores_gemma":[0.029713798,0.019328592,0.93404746,0.000087675755,0.00027001402,0.0000028900336,0.00068141404,0.00008058365,0.0129801305,0.00014301138,0.0024794012,0.00018500666],"about_ca_topic_score_codex":0.00025846114,"about_ca_topic_score_gemma":0.00012565551,"teacher_disagreement_score":0.5681838,"about_ca_system_score_codex":0.000052170544,"about_ca_system_score_gemma":0.00019579714,"threshold_uncertainty_score":0.40022716},"labels":[],"label_agreement":null},{"id":"W2122178864","doi":"10.1093/annonc/mds579","title":"Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Survivorship curve; Consensus conference; Intensive care medicine; Cancer; Germ cell tumors; Oncology; Surgery; Internal medicine; Chemotherapy","score_opus":0.14557847372669022,"score_gpt":0.3828413065599136,"score_spread":0.23726283283322339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122178864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97649527,0.008278212,7.2453224e-7,0.009581733,0.00016270824,0.0004412261,0.00010740468,0.000019509558,0.004913211],"genre_scores_gemma":[0.9921667,0.006944109,0.00008533464,0.00027113833,0.0003232178,0.000054741566,0.000032074335,0.000023870289,0.00009881128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985475,0.00037681562,0.00032229413,0.00027497316,0.00016022872,0.00031821828],"domain_scores_gemma":[0.9978865,0.001123687,0.00035660522,0.0003249049,0.00010892839,0.00019941469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016324411,0.00024160983,0.000545058,0.000057979105,0.000096763724,0.000009440692,0.000059150996,0.00007248496,0.000071213646],"category_scores_gemma":[0.00007683978,0.00014026402,0.00013087476,0.000064983535,0.00017629663,0.000025279507,0.0000212548,0.000056600184,0.00001006244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002264478,0.00853534,0.6750366,0.00006842318,0.001823108,0.0005265801,0.007586663,0.00013149483,0.002196906,0.0022269136,0.0006234888,0.29898],"study_design_scores_gemma":[0.008742749,0.022937438,0.8658149,0.0010240283,0.0018429721,0.0000294067,0.0009312879,0.000067547044,0.0820337,0.00019966265,0.016030662,0.00034563956],"about_ca_topic_score_codex":0.015815033,"about_ca_topic_score_gemma":0.00041194484,"teacher_disagreement_score":0.29863435,"about_ca_system_score_codex":0.00014514921,"about_ca_system_score_gemma":0.00017534243,"threshold_uncertainty_score":0.99073875},"labels":[],"label_agreement":null},{"id":"W2122233345","doi":"10.1093/annonc/mds144","title":"Risk of treatment-related esophageal cancer among breast cancer survivors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Breast cancer; Esophageal cancer; Radiation therapy; Esophagus; Cancer; Internal medicine; Oncology; Population; Odds ratio","score_opus":0.05637601612324898,"score_gpt":0.4108937809404897,"score_spread":0.3545177648172407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122233345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96869093,0.024682771,0.0000013344663,0.0015114112,0.00025202293,0.00046298365,0.0005091034,0.00002358955,0.0038658618],"genre_scores_gemma":[0.9842259,0.013866565,0.000039535378,0.0001214131,0.00020210656,0.00016248872,0.00002816638,0.000025546078,0.0013282299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983579,0.00019416146,0.00041133474,0.00021085837,0.00024076982,0.0005849692],"domain_scores_gemma":[0.99853426,0.00016600732,0.0003296527,0.0002745602,0.00029458271,0.0004009429],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032386405,0.00019658459,0.0006990487,0.00016088231,0.0000500795,0.0000021213898,0.00008931226,0.00018238153,0.001892065],"category_scores_gemma":[0.000038554812,0.00014209328,0.00023204478,0.000273655,0.00031924783,0.00011994387,0.000037642152,0.00017526797,0.000021775226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008271919,0.0012406475,0.89382064,0.000063513646,0.00138408,0.000047987593,0.00079553085,0.000028033051,0.0001542162,0.00008901639,0.00068933424,0.10085978],"study_design_scores_gemma":[0.0032073725,0.0039733923,0.97862065,0.00006098744,0.00039398554,0.000033202294,0.000079304154,0.00002769401,0.011706866,0.000049147577,0.0017564995,0.0000908716],"about_ca_topic_score_codex":0.057958685,"about_ca_topic_score_gemma":0.0047958572,"teacher_disagreement_score":0.10076892,"about_ca_system_score_codex":0.00032903635,"about_ca_system_score_gemma":0.0006507242,"threshold_uncertainty_score":0.99902034},"labels":[],"label_agreement":null},{"id":"W2122247274","doi":"10.1093/annonc/mdi149","title":"Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre; University of Toronto; Jewish General Hospital; McGill University","funders":"Susan G. Komen; Susan G. Komen for the Cure","keywords":"Medicine; Breast cancer; Oncology; Germline mutation; Internal medicine; Cancer research; Cancer; Cyclin E; Cyclin D1; Cell cycle; Mutation; Biology; Genetics; Gene","score_opus":0.04548036043176453,"score_gpt":0.3873312615565698,"score_spread":0.34185090112480526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122247274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512045,0.001446184,0.000021889478,0.046306334,0.00005670416,0.0005848404,0.00006772817,0.000028662753,0.00028318018],"genre_scores_gemma":[0.9953326,0.0011761705,0.0017783074,0.0012323668,0.00013129368,0.00021020616,0.000014815178,0.000018641435,0.000105615436],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988438,0.0001552474,0.00038083756,0.0002633001,0.00012538675,0.0002314545],"domain_scores_gemma":[0.99926025,0.00017990668,0.00012527754,0.00015713209,0.00012115567,0.00015630851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036206833,0.00012127302,0.00035261273,0.0002534132,0.000032340085,0.0000035573485,0.00004142261,0.00015432,0.00006231385],"category_scores_gemma":[0.00015910438,0.00010800981,0.0000531354,0.00021280846,0.000055127948,0.00004814662,0.000036629375,0.00012444735,0.000006176557],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00800927,0.0012089129,0.051320713,0.000038427304,0.00008898933,0.00013656949,0.0030822984,0.00085298216,0.33786792,0.000005526763,0.0015657715,0.59582263],"study_design_scores_gemma":[0.010161079,0.00813615,0.56345505,0.0009713165,0.00015854856,0.00045829345,0.0005637496,0.0011874558,0.31895757,0.000025357765,0.09565119,0.00027423413],"about_ca_topic_score_codex":0.0002932796,"about_ca_topic_score_gemma":0.00044268955,"teacher_disagreement_score":0.5955484,"about_ca_system_score_codex":0.00026783324,"about_ca_system_score_gemma":0.00040518306,"threshold_uncertainty_score":0.4404512},"labels":[],"label_agreement":null},{"id":"W2122301998","doi":"10.1093/annonc/mdl011","title":"Shifting to outpatient management of acute myeloid leukemia: a prospective experience","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Chemotherapy; Induction chemotherapy; Myeloid leukemia; Leukemia; Outpatient clinic; Internal medicine; Chemotherapy regimen; Intensive care medicine; Surgery","score_opus":0.04314083264412813,"score_gpt":0.37888871388129775,"score_spread":0.3357478812371696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122301998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92009664,0.000061223756,0.00017083598,0.0012734251,0.00013652451,0.00046169912,0.0000071197924,0.000017600612,0.07777495],"genre_scores_gemma":[0.99694735,0.000072352675,0.0011847621,0.00063962635,0.00006244152,0.00014319464,0.0000032621817,0.000008357682,0.0009386832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991838,0.000019184412,0.00029462343,0.00018006783,0.00013900344,0.00018336023],"domain_scores_gemma":[0.99943656,0.00002061323,0.00012908285,0.0001733628,0.00018433497,0.00005607288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009097668,0.000080029116,0.0002876945,0.000087090026,0.000033792963,0.0000020368518,0.00006905365,0.000055100252,0.00006421824],"category_scores_gemma":[0.000006951201,0.000071541595,0.00007530581,0.00023914546,0.000075496515,0.000038322367,0.000066705215,0.00008406612,0.000013550763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064724167,0.006453407,0.41299894,0.0011119639,0.0027923903,0.0010417385,0.023003804,0.0009288474,0.16618322,0.08042432,0.052468624,0.24612032],"study_design_scores_gemma":[0.0027873598,0.0117779365,0.6042776,0.00026916087,0.00031290323,0.000069828,0.0018948445,0.000010677936,0.30231988,0.00093647937,0.07511635,0.00022696784],"about_ca_topic_score_codex":0.00025696406,"about_ca_topic_score_gemma":0.00003435287,"teacher_disagreement_score":0.24589334,"about_ca_system_score_codex":0.00012780042,"about_ca_system_score_gemma":0.00009544063,"threshold_uncertainty_score":0.29173815},"labels":[],"label_agreement":null},{"id":"W2122343496","doi":"10.1093/annonc/mdl042","title":"A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Paclitaxel; Pharmacokinetics; Neutropenia; Tolerability; Lung cancer; Epidermal growth factor receptor; Pharmacology; Rash; Internal medicine; Toxicity; Adverse effect; Gastroenterology; Chemotherapy; Oncology; Cancer","score_opus":0.016704306551795816,"score_gpt":0.36909628742680917,"score_spread":0.35239198087501333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122343496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549943,0.0001575897,0.000023680916,0.00058428117,0.00008430204,0.002616545,0.00015036328,0.000010464762,0.0008733362],"genre_scores_gemma":[0.99907416,0.000040376992,0.00023715805,0.00018135663,0.000022005705,0.00016413117,0.00015918208,0.000028281249,0.00009334673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839413,0.00015863568,0.00053506845,0.00032342252,0.00028863753,0.0003001226],"domain_scores_gemma":[0.9986037,0.000111170615,0.00048262722,0.00020795708,0.0005404045,0.000054126012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001093585,0.00022486226,0.00066218677,0.00022482534,0.00006515397,0.0000058449004,0.000111520916,0.000095501404,0.00003813549],"category_scores_gemma":[0.000019025605,0.00014659541,0.000057379024,0.00045448673,0.00011106273,0.00015351434,0.000031649703,0.00019668684,7.2453525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039874106,0.025464142,0.9605815,0.000104604136,0.0002746796,0.00003447618,0.0045739873,0.00016117466,0.0025672934,0.00003755612,0.00013614961,0.0020770398],"study_design_scores_gemma":[0.062372442,0.014662844,0.91553104,0.00033044297,0.00020199297,0.0000017323604,0.00085571717,0.00007892969,0.0057706865,0.00001224641,0.000033237524,0.00014867182],"about_ca_topic_score_codex":0.0039751595,"about_ca_topic_score_gemma":0.0018116502,"teacher_disagreement_score":0.058385033,"about_ca_system_score_codex":0.00030638586,"about_ca_system_score_gemma":0.00057574443,"threshold_uncertainty_score":0.6009278},"labels":[],"label_agreement":null},{"id":"W2122540950","doi":"10.1093/annonc/mdp403","title":"Global drug development in cancer: a cross-sectional study of clinical trial registries","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cross-sectional study; Clinical trial; Drug development; Cancer drugs; Family medicine; Drug; Cancer; Internal medicine; Pharmacology; Pathology","score_opus":0.14557669844721974,"score_gpt":0.49261634166622614,"score_spread":0.3470396432190064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122540950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973271,0.00052831374,0.000010845609,0.00025962587,0.00046140503,0.00028289726,0.000033829274,0.0000020445063,0.0010939204],"genre_scores_gemma":[0.9984931,0.0005848585,0.00015942892,0.00036136518,0.0002862392,0.0000212328,0.000021653692,0.000003478677,0.00006863818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985323,0.000085433574,0.0008527606,0.00025664206,0.00011337544,0.00015947579],"domain_scores_gemma":[0.99918854,0.000058388992,0.0003261429,0.00017838625,0.00019629588,0.000052224572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006874982,0.00008918371,0.0003296803,0.000030451627,0.000023876397,0.000005682755,0.0001699005,0.00015933058,0.000010171504],"category_scores_gemma":[0.00035427898,0.00009032335,0.00008386529,0.00009282537,0.00010032935,0.0000021005678,0.0000699462,0.00006499978,6.1517665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024743104,0.004076058,0.9129613,0.000008597415,0.000107685955,0.000010164401,0.00014715975,0.000476122,0.00038803267,0.0001963998,0.0055048317,0.051380523],"study_design_scores_gemma":[0.019795923,0.009133563,0.89932346,0.0000054992806,0.000007328053,0.000002376646,0.00007229339,0.0000030698816,0.0030314676,0.00021079638,0.06830728,0.00010693935],"about_ca_topic_score_codex":0.00043562162,"about_ca_topic_score_gemma":0.00396498,"teacher_disagreement_score":0.06280245,"about_ca_system_score_codex":0.000026834987,"about_ca_system_score_gemma":0.0009516329,"threshold_uncertainty_score":0.36832795},"labels":[],"label_agreement":null},{"id":"W2122825994","doi":"10.1093/annonc/mdt201.31","title":"Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"KRAS; Panitumumab; Neuroblastoma RAS viral oncogene homolog; Medicine; Colorectal cancer; Exon; Internal medicine; Oncology; Cancer research; Cancer; Gene; Biology; Genetics","score_opus":0.11501106641552987,"score_gpt":0.42742348457580925,"score_spread":0.31241241816027937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122825994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881394,0.0036379218,0.0000019577292,0.0036438843,0.000033367975,0.001452064,0.000023654171,0.0000058230235,0.0023874126],"genre_scores_gemma":[0.99695206,0.0015941861,0.00018193969,0.00011561673,0.000014018125,0.00099913,0.00002055335,0.000009974915,0.00011249768],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988717,0.00012727003,0.00035729527,0.00020227369,0.00025784527,0.00018363935],"domain_scores_gemma":[0.9989893,0.0002250708,0.00017518994,0.00008894199,0.00046912007,0.000052406664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003065606,0.0001401529,0.0005745254,0.00018550755,0.00002820845,0.000003096114,0.00002814674,0.000051502644,0.00026212193],"category_scores_gemma":[0.000127744,0.000098080614,0.000039546438,0.00024259197,0.0001512461,0.00007312827,0.000018767778,0.000059356054,0.0000029337523],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021412666,0.004690924,0.29152608,0.00013912507,0.0015382153,0.0000775142,0.008426152,0.00057216163,0.0016578119,0.00011390094,0.00019531195,0.6889216],"study_design_scores_gemma":[0.012954442,0.022890788,0.9496482,0.00016084287,0.00077258167,0.000036138114,0.0012688772,0.001197885,0.008996231,0.0011468675,0.00079697045,0.00013020087],"about_ca_topic_score_codex":0.01550778,"about_ca_topic_score_gemma":0.07638856,"teacher_disagreement_score":0.68879133,"about_ca_system_score_codex":0.00032027924,"about_ca_system_score_gemma":0.00073339255,"threshold_uncertainty_score":0.99104804},"labels":[],"label_agreement":null},{"id":"W2122940064","doi":"10.1093/annonc/mdq770","title":"Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Oncology; Carcinoma; Internal medicine; Cancer; Ovarian cancer; Breast cancer; Ovarian carcinoma; Pathology; Gynecology","score_opus":0.053025355201351515,"score_gpt":0.34716117111946126,"score_spread":0.2941358159181098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122940064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383897,0.0004025333,0.00006208784,0.0002638604,0.00024834712,0.0012216695,0.00009616983,0.00001123684,0.0038551162],"genre_scores_gemma":[0.9979739,0.00003578732,0.00042285328,0.00017298512,0.00019191351,0.0006166254,0.00004809366,0.00003703804,0.0005007911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800366,0.00045176173,0.0004467192,0.0005632287,0.00016708019,0.00036754648],"domain_scores_gemma":[0.99882543,0.000023888648,0.0002879755,0.00045055297,0.00029168656,0.00012048217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049193524,0.00022630859,0.00034023693,0.00014296552,0.00006201702,0.0000066139737,0.0003118542,0.0002992018,0.0005389052],"category_scores_gemma":[0.000091174785,0.00021118454,0.00007553463,0.00020829335,0.0002047062,0.000017671648,0.00014892913,0.00020413093,0.000013031966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070320736,0.006115921,0.6819039,0.00007147982,0.00030363916,0.00015756268,0.009805933,0.0000808641,0.24792671,0.00015169615,0.0027040283,0.043746173],"study_design_scores_gemma":[0.0030903672,0.0067286487,0.8358904,0.00007628689,0.000059614486,0.00010410749,0.0022872675,0.00003525912,0.14758776,0.00073423097,0.0029953397,0.00041068223],"about_ca_topic_score_codex":0.0022435486,"about_ca_topic_score_gemma":0.0020335931,"teacher_disagreement_score":0.1539865,"about_ca_system_score_codex":0.000104613326,"about_ca_system_score_gemma":0.0009554697,"threshold_uncertainty_score":0.86118555},"labels":[],"label_agreement":null},{"id":"W2123811123","doi":"10.1093/annonc/mdn370","title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute for Health and Care Research; Roche","keywords":"FOLFOX; Medicine; Oxaliplatin; Folinic acid; Internal medicine; Capecitabine; Irinotecan; Colorectal cancer; FOLFIRINOX; Neutropenia; Oncology; FOLFIRI; Population; Clinical endpoint; Fluorouracil; Surgery; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.1341549568313934,"score_gpt":0.4386820001262048,"score_spread":0.3045270432948114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123811123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810724,0.0065119527,0.0000106184725,0.0020829067,0.0007667238,0.0043405355,0.00013808765,0.00007178966,0.0050049373],"genre_scores_gemma":[0.98975116,0.006925115,0.00025606228,0.0006126897,0.00026846392,0.0014250637,0.00008451589,0.00005099786,0.00062593963],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954724,0.0007596433,0.001685662,0.0007386296,0.000576159,0.0007675094],"domain_scores_gemma":[0.99639726,0.0016203106,0.000771168,0.00039579318,0.00054730964,0.0002681809],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013376889,0.0006158305,0.004100292,0.00038175256,0.00024295197,0.000012426361,0.0002268079,0.00021635879,0.0017912221],"category_scores_gemma":[0.0006836801,0.00048283325,0.0005180115,0.0006552096,0.00059908436,0.00016879791,0.00014442207,0.0005436183,0.000025301448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89458,0.008218027,0.004272386,0.00007519769,0.005103199,0.0019352877,0.021741107,0.00009025665,0.0019648122,0.00007010716,0.0010341731,0.060915414],"study_design_scores_gemma":[0.90598774,0.06813596,0.009970656,0.000080388476,0.0007792264,0.00016411886,0.0036076643,0.00086878,0.0064657168,0.00010844635,0.003279195,0.00055210886],"about_ca_topic_score_codex":0.0054439316,"about_ca_topic_score_gemma":0.012996686,"teacher_disagreement_score":0.060363304,"about_ca_system_score_codex":0.00062593265,"about_ca_system_score_gemma":0.0022825398,"threshold_uncertainty_score":0.99976236},"labels":[],"label_agreement":null},{"id":"W2124012346","doi":"10.1093/annonc/mdp019","title":"Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer","year":2009,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Trastuzumab; ThioTEPA; Intrathecal; Breast cancer; Oncology; Internal medicine; Cancer; Chemotherapy; Surgery; Cyclophosphamide","score_opus":0.07736218046749738,"score_gpt":0.40604323436223794,"score_spread":0.32868105389474056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124012346","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03873803,0.0028732691,0.0000624639,0.95418894,0.00022214155,0.0009149501,0.0014697644,0.000016000971,0.001514427],"genre_scores_gemma":[0.20610479,0.004421849,0.004886267,0.77688926,0.0049555576,0.00025093716,0.00085473224,0.0001081156,0.0015285083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986265,0.000081839666,0.00045028978,0.00031398487,0.00018507663,0.00034236317],"domain_scores_gemma":[0.9987906,0.00030040095,0.00035993147,0.00022332043,0.00024706178,0.0000786387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024858603,0.00024917838,0.0011828361,0.00014698706,0.000024915047,0.0000034590898,0.00008430469,0.0006466568,0.00013580725],"category_scores_gemma":[0.000029010713,0.00019234032,0.00024929168,0.00006838193,0.00021157616,0.000024498044,0.000024524272,0.0004604836,0.0000011893844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006608026,0.00034613695,0.00019166947,0.00040759725,0.00072003785,0.00019465463,0.0001485454,7.0099424e-7,0.00015876062,0.00006545395,0.6693224,0.32778326],"study_design_scores_gemma":[0.0035817837,0.013299818,0.010581409,0.000346936,0.0010296521,0.00060991076,0.00003925892,0.000013952546,0.0013326281,0.0005897449,0.9683645,0.00021043258],"about_ca_topic_score_codex":0.0002085032,"about_ca_topic_score_gemma":0.000027600237,"teacher_disagreement_score":0.32757285,"about_ca_system_score_codex":0.00005462739,"about_ca_system_score_gemma":0.0004026257,"threshold_uncertainty_score":0.78434104},"labels":[],"label_agreement":null},{"id":"W2124311886","doi":"10.1093/annonc/mdt560","title":"Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Medicine; Internal medicine; Bone mineral; Chemotherapy; Femoral neck; Prospective cohort study; Lymphoma; Chemotherapy regimen; Gastroenterology; Bone remodeling; Surgery; Urology; Osteoporosis","score_opus":0.03279673341429484,"score_gpt":0.3471327880499942,"score_spread":0.31433605463569936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124311886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925027,0.00014410978,0.000004477372,0.0047538937,0.000028107494,0.0014386434,0.000002244697,0.000012214212,0.0011136209],"genre_scores_gemma":[0.9977057,0.00017184658,0.00044243276,0.0013711508,0.00005933288,0.000115108945,0.0000060379075,0.000018253142,0.00011014931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837905,0.00026832035,0.00040230862,0.00033946376,0.00022627505,0.00038455776],"domain_scores_gemma":[0.9989307,0.00034174795,0.00012200616,0.00020694631,0.00022238391,0.0001762385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001019208,0.00013721005,0.0005894545,0.0002763017,0.00004275026,0.000008679737,0.000044873148,0.000081439335,0.000026435286],"category_scores_gemma":[0.00049202977,0.00011416974,0.000021563745,0.0003514792,0.00013365595,0.00008637369,0.00003716221,0.0002146523,0.0000028089298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019853545,0.0041185776,0.9385147,0.00011128474,0.000033680564,0.00019260858,0.0039681355,0.0000026623325,0.0008914184,0.000027308404,0.0007247125,0.031561363],"study_design_scores_gemma":[0.022633962,0.028817188,0.9465763,0.00017075747,0.000009284868,0.00005369273,0.0010080965,0.00016482732,0.00020305319,0.000040465347,0.00022656274,0.000095813244],"about_ca_topic_score_codex":0.0033472548,"about_ca_topic_score_gemma":0.032132454,"teacher_disagreement_score":0.031465553,"about_ca_system_score_codex":0.00010534494,"about_ca_system_score_gemma":0.0003243776,"threshold_uncertainty_score":0.9855286},"labels":[],"label_agreement":null},{"id":"W2124573409","doi":"10.1093/annonc/mdt383","title":"Associations of bread and pasta with the risk of cancer of the breast and colorectum","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Food composition and properties","field":"Nursing","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Odds ratio; Breast cancer; Overweight; Cancer; Confidence interval; Colorectal cancer; Confounding; Internal medicine; Case-control study; Gynecology; Obesity","score_opus":0.039430659809452005,"score_gpt":0.31899755687650955,"score_spread":0.27956689706705756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124573409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749373,0.0005997616,6.834305e-7,0.022913575,0.00004892518,0.00014604734,0.000115878036,0.0000022975232,0.0012355151],"genre_scores_gemma":[0.99943304,0.000107664244,0.000031311254,0.00037084043,0.000011243398,0.000008631096,7.930985e-7,0.0000036361382,0.00003285345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947363,0.0001759664,0.00015279082,0.00005481169,0.00007294586,0.000069874535],"domain_scores_gemma":[0.99908304,0.00021678761,0.0003324018,0.000092911105,0.0002604475,0.000014422037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001482503,0.000044727516,0.00018454669,0.000021444235,0.000048361268,0.000002855363,0.000071747054,0.000044305405,0.00003078024],"category_scores_gemma":[0.000025536803,0.000022318667,0.000026268968,0.00007557248,0.00037147474,0.000033850123,0.00003148314,0.00006380835,2.1368426e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023824726,0.0005786373,0.6564828,0.00017832106,0.0008491807,2.6350378e-7,0.016028147,0.0001481659,0.0478647,0.0006865973,0.02917529,0.24562544],"study_design_scores_gemma":[0.0004304147,0.0023765077,0.963979,0.000050689145,0.00008262089,0.000007522222,0.00061060267,0.0000892018,0.030295702,0.0004623633,0.0015759321,0.00003946689],"about_ca_topic_score_codex":0.004606468,"about_ca_topic_score_gemma":0.0015151732,"teacher_disagreement_score":0.3074962,"about_ca_system_score_codex":0.0000056237773,"about_ca_system_score_gemma":0.000035020803,"threshold_uncertainty_score":0.6963633},"labels":[],"label_agreement":null},{"id":"W2124729407","doi":"10.1093/annonc/mdp410","title":"The role of VEGF in triple-negative breast cancer: where do we go from here?","year":2009,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Triple-negative breast cancer; VEGF receptors; Oncology; Internal medicine; Breast cancer; Cancer; Triple negative","score_opus":0.01916600296680198,"score_gpt":0.31580374017089957,"score_spread":0.2966377372040976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124729407","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025629878,0.13901074,0.0000010580512,0.82756525,0.00044343396,0.00043999305,0.0023625344,0.000008165765,0.0045389533],"genre_scores_gemma":[0.50132155,0.34816414,0.0002668401,0.13989256,0.0069848313,0.0005642643,0.0006588954,0.00016322969,0.0019836742],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981954,0.0002618237,0.00048604692,0.00047009785,0.00017756822,0.0004090326],"domain_scores_gemma":[0.99846405,0.00019149648,0.000571707,0.00047605185,0.00026306594,0.00003362353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012529483,0.00033224624,0.0007428108,0.00006152122,0.000055583685,0.000007325935,0.00044446785,0.00085773465,0.000047828362],"category_scores_gemma":[0.00003178091,0.00025147796,0.00022882866,0.00011538839,0.00036184883,0.00000355575,0.0001499599,0.00046635163,0.000005598625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008044244,0.00019238112,0.005521308,0.00003733243,0.0009509678,0.000037607217,0.00028614784,0.0000062634617,0.0018056064,0.000011470889,0.76949954,0.22084695],"study_design_scores_gemma":[0.0012418889,0.00061902904,0.014827534,0.00018256814,0.00008380252,0.000013025637,0.00029059814,8.273604e-7,0.010504342,0.0018444239,0.97015923,0.00023270524],"about_ca_topic_score_codex":0.0029284798,"about_ca_topic_score_gemma":0.0034189296,"teacher_disagreement_score":0.6876727,"about_ca_system_score_codex":0.00006314885,"about_ca_system_score_gemma":0.00038348726,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W2124905075","doi":"10.1093/annonc/mdj020","title":"Selecting predictors of cancer patients' overall perceptions of the quality of care received","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Government of Ontario","keywords":"Medicine; Cancer; Quality (philosophy); Family medicine; Oncology; Internal medicine","score_opus":0.17442239502925533,"score_gpt":0.5440545723204467,"score_spread":0.3696321772911914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124905075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356043,0.00020802704,0.0000037388056,0.001732257,0.000778198,0.0006958215,0.0005409463,0.00001264135,0.0024679422],"genre_scores_gemma":[0.998787,0.00027957145,0.00016252944,0.00046906987,0.00010560534,0.00006914399,0.000020460478,0.000011633797,0.00009499522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963744,0.0014683225,0.0014245816,0.00015880867,0.00030475,0.00026912452],"domain_scores_gemma":[0.99461675,0.00097496726,0.0019854142,0.00029957687,0.0020610113,0.000062276325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053837046,0.00009787625,0.00051942485,0.0000970193,0.00018400245,2.4060182e-7,0.00018310413,0.0002735409,0.0005016142],"category_scores_gemma":[0.0009302492,0.00007774929,0.00013786531,0.00022543847,0.00017394904,0.00007259307,0.00008969848,0.00038682594,0.0000027178962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013363751,0.00010911022,0.9692758,0.0007284271,0.00004425482,1.1663095e-8,0.020637892,0.00017994067,0.0010526968,0.00014279176,0.002037544,0.005657925],"study_design_scores_gemma":[0.0006839156,0.00065494294,0.9892758,0.00026484177,0.00002008808,3.8495056e-8,0.0044950764,0.000009472961,0.001707328,0.000055505792,0.0027795194,0.000053477645],"about_ca_topic_score_codex":0.008971815,"about_ca_topic_score_gemma":0.010883946,"teacher_disagreement_score":0.020000024,"about_ca_system_score_codex":0.0002077035,"about_ca_system_score_gemma":0.00085948966,"threshold_uncertainty_score":0.99762756},"labels":[],"label_agreement":null},{"id":"W2125354192","doi":"10.1093/annonc/mds177","title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Lymphoma; Adverse effect; Confidence interval; Population; Oncology; Progression-free survival; Gastroenterology; Surgery; Chemotherapy","score_opus":0.11021171750183127,"score_gpt":0.39544526286376036,"score_spread":0.2852335453619291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125354192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990346,0.0029432068,0.00018813112,0.003953994,0.00049022894,0.00071887486,0.000032919583,0.000040604806,0.0012860277],"genre_scores_gemma":[0.9961567,0.0008949519,0.0010946633,0.00065032736,0.0006067607,0.00023034833,0.00009867508,0.000040094386,0.00022745729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848604,0.000077012584,0.00041296714,0.00027592957,0.00026275354,0.00048530864],"domain_scores_gemma":[0.9985726,0.00023641596,0.00027924182,0.00037281972,0.00036611667,0.00017280766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003959887,0.0002466657,0.0009000104,0.00016405215,0.0001044777,0.0000091853735,0.00009896355,0.000169614,0.00011019712],"category_scores_gemma":[0.00008694514,0.0001756972,0.0003207266,0.00023535102,0.000117837946,0.00015208761,0.000026691143,0.00005338314,0.00003147881],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03824132,0.045456596,0.34730536,0.00096311845,0.015517987,0.00040081335,0.004478758,0.00018081516,0.01684876,0.005562801,0.02377852,0.50126517],"study_design_scores_gemma":[0.14207977,0.03056088,0.29759225,0.00042740436,0.0020910685,0.00047510993,0.0015337638,0.000105487896,0.15440692,0.0005872511,0.3692554,0.00088467315],"about_ca_topic_score_codex":0.0004240797,"about_ca_topic_score_gemma":0.00009402904,"teacher_disagreement_score":0.5003805,"about_ca_system_score_codex":0.00014875554,"about_ca_system_score_gemma":0.00024195788,"threshold_uncertainty_score":0.71647245},"labels":[],"label_agreement":null},{"id":"W2125602401","doi":"10.1093/annonc/mdr326","title":"Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Mastectomy; Breast cancer; Confidence interval; Cumulative incidence; Univariate analysis; Internal medicine; Logistic regression; Ductal carcinoma; Oncology; Proportional hazards model; Multivariate analysis; Gynecology; Cancer; Cohort","score_opus":0.061044089261904466,"score_gpt":0.3233263302948403,"score_spread":0.26228224103293585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125602401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980985,0.00038199808,0.0002602516,0.00052685576,0.000042670752,0.00034563476,0.00013326376,0.0000049099676,0.00020592155],"genre_scores_gemma":[0.9954557,0.00029871508,0.0028045035,0.0012873854,0.00003656026,0.00006105117,0.000032810516,0.000011400869,0.000011893135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993416,0.000041021936,0.00014838272,0.0002373334,0.000053020118,0.00017861737],"domain_scores_gemma":[0.99935275,0.00003340325,0.0001387849,0.00014339412,0.00028536306,0.000046314188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008605295,0.00011740987,0.00019005232,0.00002629998,0.000055579265,0.0000025645584,0.00006724187,0.00007141925,0.000010901872],"category_scores_gemma":[0.000029097144,0.00009135675,0.000047541882,0.00003511802,0.0001233233,0.0000052503947,0.000050001443,0.00002680975,7.8921346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008842723,0.0021084282,0.8466743,0.00006199219,0.0006759451,0.0000026806745,0.0013500969,0.0000015014665,0.0032777893,0.00007722509,0.0009643439,0.13596295],"study_design_scores_gemma":[0.0049362187,0.0030356816,0.95681363,0.000015713595,0.000037314876,0.000010269255,0.00011693292,0.000021241649,0.028935466,0.000115960254,0.005811754,0.00014979563],"about_ca_topic_score_codex":0.00022954076,"about_ca_topic_score_gemma":0.000061824896,"teacher_disagreement_score":0.13581316,"about_ca_system_score_codex":0.000008267934,"about_ca_system_score_gemma":0.000044968336,"threshold_uncertainty_score":0.37254202},"labels":[],"label_agreement":null},{"id":"W2125643269","doi":"10.1023/a:1008382516636","title":"Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"University of California, San Francisco","keywords":"Medicine; Temozolomide; Internal medicine; Clinical endpoint; Phases of clinical research; Chemotherapy; Lomustine; Population; Progression-free survival; Surgery; Oncology; Gliosarcoma; Progressive disease; Clinical trial; Glioblastoma; Vincristine; Cyclophosphamide","score_opus":0.03575505135581412,"score_gpt":0.34775119330931037,"score_spread":0.31199614195349623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125643269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959501,0.00006666756,5.417574e-7,0.0020514417,0.00011251508,0.0009551335,0.000026340618,0.000009423446,0.0008278402],"genre_scores_gemma":[0.99922943,0.00011866775,0.00015057449,0.00028262252,0.00003423993,0.0000628567,0.000032934127,0.0000147267,0.000073933596],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987753,0.000044314085,0.0005048442,0.00021120466,0.0001992452,0.00026508185],"domain_scores_gemma":[0.99899435,0.000160981,0.00029193345,0.00024790483,0.00019526579,0.000109574285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001471877,0.00014486849,0.0005863145,0.00021088039,0.00003957311,0.0000011993541,0.00006443865,0.00013007922,0.0001617644],"category_scores_gemma":[0.00014383327,0.00010316346,0.0001079635,0.00018539085,0.000112807866,0.00005813922,0.00006341076,0.000082532046,0.000014046184],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4229225,0.051483583,0.48717788,0.0000527011,0.000276523,0.00029741414,0.0005580203,0.000016915708,0.00040007455,0.000014212698,0.0031892946,0.033610895],"study_design_scores_gemma":[0.55377674,0.17972948,0.21842301,0.00021917497,0.00015195463,0.000014172439,0.00006262675,0.000065056534,0.015109937,0.0000086591945,0.032294028,0.00014514691],"about_ca_topic_score_codex":0.00010588133,"about_ca_topic_score_gemma":0.00080384855,"teacher_disagreement_score":0.26875487,"about_ca_system_score_codex":0.00008993212,"about_ca_system_score_gemma":0.000054799006,"threshold_uncertainty_score":0.4206884},"labels":[],"label_agreement":null},{"id":"W2125752253","doi":"10.1093/annonc/mdv076","title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Central China Normal University; Freiwillige Akademische Gesellschaft","keywords":"Medicine; Primary central nervous system lymphoma; Meta-analysis; Lymphoma; Oncology; Outcome (game theory); Central nervous system; Internal medicine; Pediatrics","score_opus":0.32929991219062216,"score_gpt":0.4163677463938709,"score_spread":0.08706783420324876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125752253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009561598,0.98938435,0.0000018714796,0.00023438281,0.000042452408,0.006032957,0.0032477868,0.000026227894,0.00007378419],"genre_scores_gemma":[0.0036037825,0.99171513,0.00025018584,0.00025069565,0.000019180636,0.00070670404,0.0033620314,0.00006621179,0.000026054131],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947935,0.00064720924,0.0026870102,0.00085264153,0.00060292805,0.00041674182],"domain_scores_gemma":[0.9938648,0.0005951596,0.0029396801,0.0017222681,0.0004859346,0.0003921586],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0007589638,0.0008004375,0.017415142,0.0004197892,0.000042909534,0.000016721544,0.00030863524,0.00031965217,0.000014652623],"category_scores_gemma":[0.00012765346,0.00041885622,0.0012716454,0.0005180426,0.00016298382,0.00008854418,0.00032765235,0.00008406757,0.0000027386723],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004339283,0.0020463376,0.0009817451,0.49757054,0.20746125,0.00008872798,0.000072751354,5.3570034e-7,7.0574124e-10,0.000009896813,0.00023627409,0.29148856],"study_design_scores_gemma":[0.0019320798,0.010255659,0.0023593984,0.037629392,0.8867684,0.00020321681,0.000030098687,0.0000021078927,1.361808e-7,7.795216e-7,0.060527373,0.00029136275],"about_ca_topic_score_codex":0.00032883612,"about_ca_topic_score_gemma":0.00012546185,"teacher_disagreement_score":0.67930716,"about_ca_system_score_codex":0.00037025538,"about_ca_system_score_gemma":0.0006172534,"threshold_uncertainty_score":0.9998263},"labels":[],"label_agreement":null},{"id":"W2125775222","doi":"10.1093/annonc/mdg301","title":"Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Amifostine; Carboplatin; Leukopenia; Mucositis; Internal medicine; Neutropenia; Chemotherapy; Regimen; Ovarian cancer; Gastroenterology; Surgery; Toxicity; Multicenter trial; Randomized controlled trial; Cancer; Cisplatin; Multicenter study","score_opus":0.03138999075295546,"score_gpt":0.3888787607560491,"score_spread":0.35748877000309365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125775222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898739,0.00022977576,0.000034903016,0.0047278246,0.00024420282,0.0033434231,0.000011933514,0.00000755425,0.0015264708],"genre_scores_gemma":[0.99713916,0.00068419584,0.00031064547,0.0014490677,0.00006734878,0.00023918446,0.00001679127,0.000017988472,0.00007564953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797237,0.00042523828,0.0009403846,0.0002123251,0.00020779633,0.00024187945],"domain_scores_gemma":[0.9983801,0.0006087509,0.0004943333,0.00019323616,0.00024776917,0.000075775286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013623128,0.00015040234,0.0012506805,0.00029873,0.0000116422325,0.0000015564774,0.00007691845,0.00020275972,0.0003469856],"category_scores_gemma":[0.0026658424,0.00012501431,0.00014727098,0.00027295327,0.00011990085,0.000052352287,0.0000113428005,0.00020194003,0.0000032691034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96479696,0.009691105,0.0039458927,0.00009027783,0.00013564435,0.000032081483,0.0009015125,0.000060398677,0.004243469,0.000115696836,0.00020298015,0.015783995],"study_design_scores_gemma":[0.9491682,0.010254054,0.0018481676,0.00013321481,0.00003754812,0.0000020971802,0.000017756562,0.00028720105,0.035212833,0.00012230444,0.0028257584,0.000090888934],"about_ca_topic_score_codex":0.00080500194,"about_ca_topic_score_gemma":0.00039595968,"teacher_disagreement_score":0.030969363,"about_ca_system_score_codex":0.00007378734,"about_ca_system_score_gemma":0.00025345734,"threshold_uncertainty_score":0.5097936},"labels":[],"label_agreement":null},{"id":"W2125933401","doi":"10.1093/annonc/mds054","title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Medicine; Mantle cell lymphoma; Transplantation; Rituximab; Internal medicine; Surgery; Autologous stem-cell transplantation; Regimen; Lymphoma; Oncology","score_opus":0.06548935314046735,"score_gpt":0.35033610711244606,"score_spread":0.28484675397197873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125933401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940237,0.00108458,0.000113196016,0.00045987038,0.00040936397,0.00051101914,0.000049298407,0.000025138212,0.0033238356],"genre_scores_gemma":[0.9965585,0.00067468383,0.0008048644,0.0012511798,0.000120106146,0.0001731392,0.000104834915,0.0000173487,0.00029534748],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989296,0.000052185085,0.00032787453,0.00021396764,0.00012501187,0.00035131595],"domain_scores_gemma":[0.9990227,0.0002171702,0.0002117975,0.00017959779,0.00020501312,0.00016368342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017315701,0.00014564215,0.00037752552,0.000075832635,0.00007607921,0.000004394997,0.00005916325,0.00015142623,0.000053262444],"category_scores_gemma":[0.000012548588,0.0001253988,0.00015872873,0.00005361698,0.00008095767,0.00013559927,0.000014512606,0.000040646624,0.000034703506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009810237,0.03984267,0.34154466,0.0017689328,0.00066953554,0.0004573961,0.04202846,0.000024626255,0.41399547,0.00052583666,0.029754795,0.11957739],"study_design_scores_gemma":[0.008978084,0.0024527162,0.20442405,0.00007109848,0.00024643575,0.000095901996,0.0013802841,0.000030034587,0.7589718,0.000011050312,0.023188729,0.00014980535],"about_ca_topic_score_codex":0.00005030157,"about_ca_topic_score_gemma":0.0000051390307,"teacher_disagreement_score":0.34497634,"about_ca_system_score_codex":0.00011023046,"about_ca_system_score_gemma":0.000108257576,"threshold_uncertainty_score":0.5113615},"labels":[],"label_agreement":null},{"id":"W2126131588","doi":"10.1093/annonc/mdt042.16","title":"Small Molecular Subsets in Phase I Studies","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Druggability; Medicine; Clinical trial; Personalized medicine; Precision medicine; Genomics; Drug development; Massive parallel sequencing; Bioinformatics; Computational biology; DNA sequencing; Internal medicine; Drug; Genome; Pathology; Genetics; Biology; Gene","score_opus":0.09370844523778235,"score_gpt":0.39541092320110427,"score_spread":0.30170247796332195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126131588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893216,0.0060457955,0.000066792396,0.0017574262,0.00012659113,0.00017142721,0.000012021295,0.0000026556452,0.0024956898],"genre_scores_gemma":[0.99314356,0.0039253044,0.0005033129,0.002196131,0.000068151974,0.000049550166,0.000027137723,0.00001093874,0.00007590042],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992733,0.000043577606,0.00024417057,0.00018974562,0.000040811112,0.0002084064],"domain_scores_gemma":[0.99942285,0.00004261072,0.00009146141,0.00020245835,0.00018686886,0.000053747597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001468657,0.000094425304,0.00022591367,0.000052766824,0.000012893441,0.0000043229156,0.00012895794,0.000118251366,0.000024785568],"category_scores_gemma":[0.00023732688,0.00009357686,0.00006373814,0.000062516665,0.00010044394,0.0000017637392,0.00010442598,0.000053086573,0.000017666214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014970172,0.00076284475,0.002170792,0.000040003193,0.00017224859,0.000045665358,0.00022463889,0.00018105483,0.85925215,0.0009054808,0.03041919,0.10567624],"study_design_scores_gemma":[0.002963358,0.0046155713,0.0027938182,0.000022050832,0.000019081806,0.000015073258,0.00039152344,0.00004926078,0.79852,0.0036914677,0.18662742,0.00029136203],"about_ca_topic_score_codex":0.000118189004,"about_ca_topic_score_gemma":0.00023876365,"teacher_disagreement_score":0.15620823,"about_ca_system_score_codex":0.000009984994,"about_ca_system_score_gemma":0.00010165683,"threshold_uncertainty_score":0.38159537},"labels":[],"label_agreement":null},{"id":"W2126297967","doi":"10.1093/annonc/mdr347","title":"A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Research UK; National Institute for Health and Care Research; Imperial Oil Limited","keywords":"Medicine; Metabolic syndrome; Internal medicine; Breast cancer; Oncology; Cancer; Body mass index; Endocrinology; Waist; Metabolite; Cohort; Metabolome; Gastroenterology; Obesity","score_opus":0.3374540296936246,"score_gpt":0.38750111777977786,"score_spread":0.05004708808615327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126297967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364455,0.00087359827,0.0038733103,0.0048370934,0.00005890577,0.0005048415,0.0000412781,0.000036952846,0.0061294497],"genre_scores_gemma":[0.99483395,0.00022639673,0.0034816607,0.0011647259,0.0000964492,0.000027686554,0.000005696908,0.000028031054,0.00013540278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987742,0.0001476369,0.00033765548,0.0002903277,0.00014553593,0.00030470142],"domain_scores_gemma":[0.9991016,0.0001594849,0.00011688316,0.0002171607,0.00007490376,0.0003300063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007290773,0.00015554429,0.00071071164,0.00041526154,0.000092743736,0.000007712943,0.00009593233,0.00013314288,0.000048015256],"category_scores_gemma":[0.00012490332,0.00013783065,0.00008408749,0.00042722485,0.00008592718,0.00007913488,0.000052114003,0.00020946014,0.000011652058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007689898,0.001319838,0.73384947,0.00022597598,0.0020633335,0.00007279724,0.056313135,0.000011098698,0.0064198053,0.082173124,0.003358472,0.10650306],"study_design_scores_gemma":[0.00090575404,0.00076876034,0.9824856,0.000046005138,0.00015964676,0.00024130971,0.0014611374,0.0000069394805,0.0011106874,0.001497195,0.011158437,0.00015853775],"about_ca_topic_score_codex":0.00040717877,"about_ca_topic_score_gemma":0.000028964017,"teacher_disagreement_score":0.24863613,"about_ca_system_score_codex":0.00004215056,"about_ca_system_score_gemma":0.0001475023,"threshold_uncertainty_score":0.562057},"labels":[],"label_agreement":null},{"id":"W2126565162","doi":"10.1093/annonc/mdm554","title":"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; University Health Network; Hamilton Health Sciences; Juravinski Cancer Centre; CancerCare Manitoba; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Prostate cancer; Internal medicine; Prostate-specific antigen; Discontinuation; Oncology; Clinical endpoint; Adverse effect; Urology; Cancer; Clinical trial; Hepatocellular carcinoma","score_opus":0.08156833559138355,"score_gpt":0.4511618509292627,"score_spread":0.36959351533787915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126565162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669355,0.0002564107,7.870996e-7,0.0006687187,0.000033626373,0.0012835212,0.0000353187,0.000005579991,0.0010225021],"genre_scores_gemma":[0.99934393,0.000084564155,0.000048809936,0.00008440673,0.000021251402,0.0000564605,0.000029650766,0.000010328944,0.00032060174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887586,0.000037280948,0.00035699166,0.00017980463,0.00027583307,0.00027423663],"domain_scores_gemma":[0.9990375,0.000050346345,0.00017957776,0.00014405284,0.00050175417,0.000086761844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031248605,0.0001009277,0.00038310172,0.00018674492,0.00003366198,0.0000015532917,0.000052972533,0.000058428694,0.000051863324],"category_scores_gemma":[0.000027689479,0.000069802205,0.000028534912,0.0002975793,0.00012186046,0.000052848867,0.000028599889,0.00012078694,7.9173685e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07694255,0.054984745,0.73482823,0.00019572188,0.00054376625,0.00039188375,0.015742743,0.000015870342,0.008296926,0.000025611218,0.000819547,0.10721238],"study_design_scores_gemma":[0.0750731,0.17478506,0.70737964,0.00016078251,0.00009592363,0.0000018571391,0.0032299778,0.0000059486542,0.037727863,0.000034395704,0.0013771089,0.00012832414],"about_ca_topic_score_codex":0.0007754576,"about_ca_topic_score_gemma":0.0016673614,"teacher_disagreement_score":0.119800314,"about_ca_system_score_codex":0.00009361681,"about_ca_system_score_gemma":0.0004671826,"threshold_uncertainty_score":0.28464514},"labels":[],"label_agreement":null},{"id":"W2126750639","doi":"10.1093/annonc/mdi324","title":"PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Gastroenterology; Phases of clinical research; Adenocarcinoma; Surgery; Cancer; Chemotherapy","score_opus":0.031166575106202136,"score_gpt":0.32435526597426384,"score_spread":0.2931886908680617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126750639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952963,0.0024460526,0.000020687747,0.00032600123,0.000033437555,0.0016045368,0.00008495973,0.0000055842943,0.0001824417],"genre_scores_gemma":[0.99806625,0.00061899226,0.00036069044,0.0002653806,0.00007326571,0.00038274805,0.00013611084,0.000017809238,0.00007878372],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99843997,0.00034046147,0.00039582304,0.00034913328,0.00011793511,0.00035665339],"domain_scores_gemma":[0.9993351,0.000052908577,0.00019684999,0.00020737911,0.00009361222,0.000114133574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002598455,0.00021998792,0.00070754107,0.000080647624,0.000055892164,0.000006137981,0.0000958666,0.00006808612,0.00004000149],"category_scores_gemma":[0.000049744052,0.00015812274,0.00007946925,0.00009671428,0.00014492449,0.0000083058785,0.00006536456,0.000067458095,9.812526e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14050372,0.020089086,0.7101179,0.000074525364,0.0016448911,0.000043198434,0.0034274925,0.00010935975,0.0021677508,0.000059847902,0.00023054969,0.121531725],"study_design_scores_gemma":[0.6101035,0.082285486,0.28941962,0.000040732393,0.00060016976,0.000010070946,0.00035028058,0.0001380441,0.010315839,0.000037054968,0.0061949384,0.0005042502],"about_ca_topic_score_codex":0.0003940983,"about_ca_topic_score_gemma":0.0028901275,"teacher_disagreement_score":0.46959978,"about_ca_system_score_codex":0.000033009306,"about_ca_system_score_gemma":0.00014653434,"threshold_uncertainty_score":0.6448058},"labels":[],"label_agreement":null},{"id":"W2127143084","doi":"10.1093/annonc/mds060","title":"First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University; University of British Columbia","funders":"","keywords":"Medicine; Epirubicin; Carboplatin; Hazard ratio; Paclitaxel; Internal medicine; Oncology; Ovarian cancer; Chemotherapy; Gynecologic oncology; TEC; Cancer; Gynecology; Urology; Confidence interval; Breast cancer; Cisplatin","score_opus":0.11730253074379335,"score_gpt":0.41085849000406627,"score_spread":0.2935559592602729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127143084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889249,0.0036567976,0.0000062739564,0.0042961626,0.0003106665,0.0019205876,0.00007043098,0.000014882574,0.0007992816],"genre_scores_gemma":[0.99516606,0.0029531752,0.000389689,0.00028930645,0.00011873417,0.00082503154,0.000005537341,0.00003417158,0.00021829113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982259,0.0001441443,0.00055524934,0.00037311472,0.00028172773,0.0004198397],"domain_scores_gemma":[0.99791574,0.00045847136,0.0006759883,0.0005120826,0.00027144866,0.0001662537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019830614,0.00033548335,0.001248327,0.000105393876,0.00006968595,0.0000033646163,0.00011389912,0.000132245,0.00031957473],"category_scores_gemma":[0.00005438208,0.00016294932,0.00009330276,0.0003305831,0.0003108141,0.000087943736,0.000058941318,0.00012064522,7.2139966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021419942,0.0097020455,0.8700432,0.00017292131,0.0026089386,0.00004428052,0.0054796585,0.0002665918,0.00020899842,0.00008419059,0.00016272355,0.08980648],"study_design_scores_gemma":[0.0446109,0.13730364,0.79379046,0.0005659155,0.0023171408,0.00003563156,0.0046441453,0.00004364061,0.009066302,0.000014548054,0.007323286,0.00028442204],"about_ca_topic_score_codex":0.0042535346,"about_ca_topic_score_gemma":0.035644434,"teacher_disagreement_score":0.1276016,"about_ca_system_score_codex":0.00030097333,"about_ca_system_score_gemma":0.00045240007,"threshold_uncertainty_score":0.98195255},"labels":[],"label_agreement":null},{"id":"W2127287298","doi":"10.1093/annonc/mdu385","title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":539,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Human Epidermal Growth Factor Receptor 2; Oncology; Cancer; Internal medicine; Quality of life (healthcare); Disease; Intensive care medicine","score_opus":0.08484824683304443,"score_gpt":0.43557942711331143,"score_spread":0.350731180280267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127287298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77096266,0.0038386497,0.0016504459,0.20656136,0.0025899988,0.0006283749,0.0015294544,0.00003959313,0.012199465],"genre_scores_gemma":[0.988223,0.0010929016,0.0038132982,0.0051547466,0.0008783943,0.00016498989,0.00012006149,0.000021331627,0.0005312879],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913394,0.000035682562,0.00027636404,0.00026929873,0.0000783184,0.0002063901],"domain_scores_gemma":[0.99850434,0.00006577416,0.00018293322,0.00017916816,0.0010205029,0.00004727887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016369976,0.00013423795,0.00024349238,0.000035518904,0.000046824574,0.000003455598,0.0001594575,0.00011761855,0.00004037264],"category_scores_gemma":[0.00025910354,0.00011999625,0.000110983434,0.00003396364,0.00014280116,0.000002299389,0.00008097095,0.00003270481,0.0000025962702],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002623201,0.00042134247,0.014489007,0.000048680264,0.0011149879,0.000002948693,0.000082354185,0.00068292354,0.066998824,0.0011542658,0.3460476,0.5663339],"study_design_scores_gemma":[0.0027218908,0.0007690556,0.017822819,0.000026723046,0.000045627363,0.000042235544,0.00008814318,0.00008700934,0.049449645,0.00053319684,0.9282239,0.0001897251],"about_ca_topic_score_codex":0.00014191977,"about_ca_topic_score_gemma":0.00035108675,"teacher_disagreement_score":0.5821763,"about_ca_system_score_codex":0.00001696345,"about_ca_system_score_gemma":0.00010969193,"threshold_uncertainty_score":0.48933053},"labels":[],"label_agreement":null},{"id":"W2127363643","doi":"10.1093/annonc/mdp300","title":"The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Mucositis; Lung cancer; Chemotherapy; Confidence interval; Univariate analysis; Randomized controlled trial; Performance status; Gastroenterology; Surgery; Multivariate analysis","score_opus":0.46529234876494757,"score_gpt":0.5755875765724024,"score_spread":0.11029522780745488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127363643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9487624,0.022391321,0.000008382343,0.02616164,0.000070904636,0.001904947,0.00011825031,0.0000075403777,0.00057457085],"genre_scores_gemma":[0.95117533,0.047174,0.000048766466,0.0010266779,0.00026320215,0.00013477092,0.00001188751,0.000013920971,0.00015144347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9866434,0.007873226,0.0025433036,0.00045552943,0.001927364,0.00055721897],"domain_scores_gemma":[0.942547,0.054207828,0.0009606545,0.0005689639,0.0014967138,0.00021884135],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.060274314,0.00020277705,0.0030688527,0.00025101178,0.000090952504,0.000015764623,0.0004733613,0.00034933782,0.00033325198],"category_scores_gemma":[0.05572494,0.000105556224,0.00048163236,0.0010618693,0.0010679939,0.000038215778,0.0001542208,0.0008001286,6.0866427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011832467,0.0021114922,0.74209493,0.00026794817,0.012130445,0.000067239605,0.007385746,0.0000042396473,0.0020065114,0.000120298086,0.009294094,0.21268456],"study_design_scores_gemma":[0.019554738,0.009169717,0.94451255,0.00080448174,0.004139651,0.0000032692997,0.0037136131,0.0020592683,0.0040005087,0.0005251703,0.011302412,0.00021464171],"about_ca_topic_score_codex":0.0036597487,"about_ca_topic_score_gemma":0.0060878242,"teacher_disagreement_score":0.21246992,"about_ca_system_score_codex":0.00021488746,"about_ca_system_score_gemma":0.003635632,"threshold_uncertainty_score":0.96764535},"labels":[],"label_agreement":null},{"id":"W2127590261","doi":"10.1093/annonc/mdt389","title":"An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Juravinski Hospital; Queen's University","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Internal medicine; Hazard ratio; Vinblastine; Radiation therapy; Bleomycin; Confidence interval; Chemotherapy regimen; Progression-free survival; Oncology; Gastroenterology; Surgery; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.1481142623853248,"score_gpt":0.3927858500323817,"score_spread":0.2446715876470569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127590261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961235,0.0003487109,0.0000127029,0.0014104951,0.00004509419,0.0013961197,0.0005270246,0.000014425739,0.000121960504],"genre_scores_gemma":[0.99614394,0.00015889658,0.001678301,0.00071778795,0.000017027627,0.00011746426,0.0011399816,0.000016495695,0.000010105932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986789,0.000095608775,0.000442569,0.00031654112,0.00023245162,0.00023392857],"domain_scores_gemma":[0.998248,0.00024103747,0.00038873934,0.0005510887,0.00042903336,0.0001421206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001605671,0.00016695022,0.0007248124,0.00008624383,0.00004383415,0.0000124323,0.00016027616,0.00013125391,0.000024856847],"category_scores_gemma":[0.000050948816,0.00011639622,0.000045848446,0.00008816438,0.00015330048,0.00022422556,0.00007429685,0.000033571312,0.0000015467082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017383741,0.012010564,0.67416096,0.000046601686,0.00040215347,0.0000025804002,0.0006536597,0.0000016604605,0.000098289536,0.00011699408,0.0026724536,0.3080957],"study_design_scores_gemma":[0.01655714,0.044414733,0.93016595,0.000036200945,0.00010081909,0.0000017577765,0.00026808924,0.00027857584,0.0055214274,0.00010996003,0.0024365177,0.000108860295],"about_ca_topic_score_codex":0.0005518261,"about_ca_topic_score_gemma":0.000050909537,"teacher_disagreement_score":0.30798683,"about_ca_system_score_codex":0.00002379698,"about_ca_system_score_gemma":0.00013014009,"threshold_uncertainty_score":0.47465},"labels":[],"label_agreement":null},{"id":"W2127843387","doi":"10.1093/annonc/mdu165.35","title":"Variations in Practice - a Need for Regular Institutional Reviews and Participation in Clinical Trials","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Gastrectomy; Cancer; Melena; Surgery; Cohort; Clinical trial; General surgery; Internal medicine","score_opus":0.4278063132029187,"score_gpt":0.5879224179993182,"score_spread":0.16011610479639954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127843387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6371639,0.0031813672,0.029628959,0.29811427,0.0012547135,0.0069458927,0.000014183854,0.00003095245,0.0236658],"genre_scores_gemma":[0.98260635,0.0022466246,0.007848558,0.0066976994,0.0002404459,0.00019810478,0.000024230196,0.0000040506675,0.00013394367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981107,0.00067142176,0.0009316417,0.00012030914,0.00006267978,0.00010323776],"domain_scores_gemma":[0.99715984,0.0022539068,0.00036298722,0.000095499476,0.000088246285,0.00003952154],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011119259,0.000047797177,0.0005742184,0.00013717038,0.0000138425985,0.0000029460311,0.000027045251,0.00007925606,0.000012948798],"category_scores_gemma":[0.026873942,0.000039919112,0.00007285376,0.0001482096,0.00004989056,0.00008765655,0.000016626944,0.00007647947,0.0000021207798],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019453882,0.0010846427,0.1041934,0.00018572784,0.000092869326,0.0000060772777,0.00034099485,0.000035962847,0.00006281433,0.07734269,0.012946506,0.80176294],"study_design_scores_gemma":[0.004601568,0.0013074011,0.3508912,0.000057319347,0.0001288039,0.000002542612,0.00003789779,0.0010155336,0.000010420879,0.0018184043,0.6400923,0.000036598398],"about_ca_topic_score_codex":0.00006023127,"about_ca_topic_score_gemma":0.00015202578,"teacher_disagreement_score":0.80172634,"about_ca_system_score_codex":0.000020430012,"about_ca_system_score_gemma":0.00010370851,"threshold_uncertainty_score":0.9813231},"labels":[],"label_agreement":null},{"id":"W2127917633","doi":"10.1093/annonc/mdr522","title":"A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Adenoid cystic carcinoma; Sunitinib; Oncology; Internal medicine; Salivary gland; Carcinoma; Cancer","score_opus":0.4727351786374878,"score_gpt":0.47816730885720277,"score_spread":0.005432130219714948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127917633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97053367,0.027541613,1.6964691e-7,0.00035334195,0.00006687203,0.0014207141,0.000020189293,0.0000031358054,0.000060301998],"genre_scores_gemma":[0.99687374,0.0027361154,0.00010518983,0.00002791172,0.000008416103,0.00022582113,0.0000104418,0.000011456155,9.0837466e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790305,0.00065364834,0.0007220293,0.0002711718,0.00022461043,0.00022547832],"domain_scores_gemma":[0.9989814,0.00026347683,0.00035252678,0.00022001125,0.000116377785,0.000066209155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083127327,0.00016814689,0.0007582439,0.00031351062,0.000019105213,0.0000017087547,0.000101517755,0.000049719507,0.000020691466],"category_scores_gemma":[0.0002902536,0.000108218024,0.000046908735,0.00026379953,0.00011196907,0.0000466647,0.00013885197,0.00016409165,1.2974618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003371168,0.038716644,0.81201327,0.00064334046,0.00015959424,0.00043957634,0.02587409,0.0000012602071,0.00005211998,0.00004511335,0.000007651923,0.118676186],"study_design_scores_gemma":[0.01964947,0.05127856,0.9228643,0.0007007279,0.00020193588,0.000037855116,0.0038959654,0.00017418659,0.00095694576,0.00014015914,0.000011830982,0.00008804261],"about_ca_topic_score_codex":0.00042964297,"about_ca_topic_score_gemma":0.0008931759,"teacher_disagreement_score":0.11858814,"about_ca_system_score_codex":0.000027293181,"about_ca_system_score_gemma":0.00015158657,"threshold_uncertainty_score":0.44130027},"labels":[],"label_agreement":null},{"id":"W2128105335","doi":"10.1093/annonc/mdv331","title":"Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital; BC Cancer Agency; Dr. H. Bliss Murphy Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Neoadjuvant therapy; Internal medicine; Cancer","score_opus":0.16613508671969773,"score_gpt":0.479967925555033,"score_spread":0.31383283883533525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128105335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992061,0.0003643079,0.000051852076,0.0020547223,0.0007443409,0.0007478069,0.000033886394,0.0000198666,0.003922185],"genre_scores_gemma":[0.99653757,0.00030047176,0.0020262196,0.0006537924,0.000090866975,0.00011917072,0.000037569243,0.000018200119,0.00021612759],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99847054,0.00008566769,0.0007190207,0.0002514021,0.00023619927,0.00023716452],"domain_scores_gemma":[0.99763477,0.0005590304,0.00046652535,0.00018299348,0.0009550727,0.00020163806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047169806,0.00013230018,0.0008785572,0.00007355531,0.000015629912,0.0000016677258,0.000084827865,0.00018575223,0.000031255586],"category_scores_gemma":[0.0015861823,0.00010748622,0.00024305076,0.00014182113,0.00010889676,0.000075304975,0.000037885322,0.000109408225,0.0000039113693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002966152,0.0007535252,0.44299486,0.00003167534,0.00016994438,0.0000039017814,0.000120327255,0.000018431278,0.000036902646,0.000020712654,0.00097328384,0.5519103],"study_design_scores_gemma":[0.0143454205,0.027209913,0.93120795,0.000105929335,0.00013463647,0.0000025796471,0.0000638873,0.00009925144,0.0023101885,0.00046065386,0.02393201,0.00012757312],"about_ca_topic_score_codex":0.00015063683,"about_ca_topic_score_gemma":0.00017110912,"teacher_disagreement_score":0.5517827,"about_ca_system_score_codex":0.00013207729,"about_ca_system_score_gemma":0.0005749228,"threshold_uncertainty_score":0.4383161},"labels":[],"label_agreement":null},{"id":"W2128439362","doi":"10.1023/a:1008356806417","title":"Second primary malignancies following the treatment of early stage ovarian cancer: Update of a study by the National Cancer Institute of Canada—Clinical Trials Group (NCIC—CTG)","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of British Columbia; Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Medicine; Melphalan; Radiation therapy; Ovarian cancer; Cancer; Surgery; Stage (stratigraphy); Malignancy; Internal medicine; Uterine cancer; Oncology; Chemotherapy","score_opus":0.1861734927056167,"score_gpt":0.45525544891664477,"score_spread":0.26908195621102804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128439362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98526263,0.0033779826,0.000002305727,0.004207308,0.0005086487,0.0011755439,0.0012669951,0.0000045758566,0.0041939854],"genre_scores_gemma":[0.9908573,0.003639961,0.000054433243,0.003095269,0.0001861155,0.0001525857,0.000044091903,0.000014602719,0.0019556158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967196,0.0006373301,0.0015803038,0.0002642125,0.0005337406,0.00026484366],"domain_scores_gemma":[0.99750787,0.0009209498,0.00087848253,0.0003103869,0.00029090268,0.00009140003],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025580362,0.00018999573,0.0014784818,0.00006188427,0.00007893429,0.0000036010026,0.00025749745,0.000117662974,0.0019406534],"category_scores_gemma":[0.00015817833,0.00011093427,0.0003705101,0.00019508245,0.0003522119,0.00010158636,0.000028725832,0.00015310664,4.5894046e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020233143,0.008344243,0.16461228,0.0005037258,0.014588283,0.00011892597,0.011138901,0.0006076927,0.019567067,0.0004060004,0.11939685,0.6404829],"study_design_scores_gemma":[0.011350898,0.008971283,0.280878,0.000093099225,0.0006064928,0.000004887914,0.0006571904,0.000030496045,0.006692234,0.00003642668,0.69051397,0.00016500293],"about_ca_topic_score_codex":0.17503382,"about_ca_topic_score_gemma":0.26187608,"teacher_disagreement_score":0.6403179,"about_ca_system_score_codex":0.0002889937,"about_ca_system_score_gemma":0.0060912585,"threshold_uncertainty_score":0.9995433},"labels":[],"label_agreement":null},{"id":"W2128639169","doi":"10.1093/annonc/12.suppl_1.s43","title":"Pharmacologic insights into the future of trastuzumab","year":2001,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Clinical trial; Regimen; Breast cancer; Pharmacokinetics; Metastatic breast cancer; Pharmacodynamics; Pharmacology; Internal medicine; Cancer","score_opus":0.31034816364364753,"score_gpt":0.5674658620510857,"score_spread":0.2571176984074382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128639169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017512133,0.97431266,0.0000022980978,0.0035346088,0.0006475697,0.0013893275,0.00001254691,0.000018534505,0.019907337],"genre_scores_gemma":[0.00030025776,0.9960494,0.000076708624,0.0010020855,0.0014226998,0.00019934803,0.000040264178,0.000045796263,0.0008634476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968385,0.0008073493,0.0010318744,0.00038441995,0.0005042538,0.00043358872],"domain_scores_gemma":[0.9972771,0.0007749642,0.00067808677,0.000612554,0.0004856832,0.00017160947],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009392479,0.00033748202,0.0029151824,0.00034374566,0.00005740291,0.000003871006,0.00068546477,0.00077895867,0.0010805547],"category_scores_gemma":[0.00015712056,0.00018525572,0.00069989456,0.00088723574,0.00056053087,0.000028907618,0.00018152282,0.0012160711,0.00007778567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008728527,0.00041264002,0.000005079907,0.01080034,0.00047579996,0.00018753708,0.0004582237,2.2166795e-7,0.0000095895675,0.00017851229,0.05541376,0.931971],"study_design_scores_gemma":[0.00050070387,0.0038453592,0.00001314503,0.0025536683,0.0006305848,0.00015587285,0.00014358308,0.0000011875538,0.000062091596,0.00021211054,0.99175006,0.00013166125],"about_ca_topic_score_codex":0.000084443695,"about_ca_topic_score_gemma":0.000056014665,"teacher_disagreement_score":0.9363363,"about_ca_system_score_codex":0.00021830802,"about_ca_system_score_gemma":0.002744631,"threshold_uncertainty_score":0.9998326},"labels":[],"label_agreement":null},{"id":"W2128643078","doi":"10.1093/annonc/mds148","title":"Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Oxaliplatin; Colorectal cancer; Hazard ratio; Oncology; Chemotherapy; Internal medicine; Fluorouracil; Cancer; Confidence interval","score_opus":0.1958065939447201,"score_gpt":0.4039998642779945,"score_spread":0.2081932703332744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128643078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010537207,0.9860876,0.000015481173,0.00012866956,0.00023368043,0.0015073637,0.00067688146,0.00003390574,0.0007792051],"genre_scores_gemma":[0.07710594,0.9215269,0.00004467268,0.00053916883,0.00007248318,0.00039916704,0.00005440685,0.00010630412,0.00015093367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995986,0.001383552,0.00085842947,0.0006802581,0.0004954649,0.0005963272],"domain_scores_gemma":[0.9951739,0.0024766445,0.001464505,0.00047390792,0.00016767449,0.0002433994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055809756,0.00058099977,0.0067648883,0.0006849718,0.000053714368,0.000013267704,0.00039734223,0.00030806524,0.00022730784],"category_scores_gemma":[0.00014482188,0.00039215197,0.0020886506,0.0012097802,0.00026168,0.000099962206,0.00004345718,0.00036670672,0.00001656686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027466938,0.0016702634,0.000377375,0.0059209955,0.10420677,0.000046773657,0.0006225531,0.00008852321,0.00003097495,0.0017484922,0.00016460383,0.884848],"study_design_scores_gemma":[0.0013951877,0.0039644255,0.00056457386,0.00031167082,0.29147294,0.00001085769,0.000009156844,0.00001871886,0.016313234,0.0000558494,0.6849894,0.00089399284],"about_ca_topic_score_codex":0.00008049731,"about_ca_topic_score_gemma":0.00007895419,"teacher_disagreement_score":0.883954,"about_ca_system_score_codex":0.00007195848,"about_ca_system_score_gemma":0.00054804306,"threshold_uncertainty_score":0.999853},"labels":[],"label_agreement":null},{"id":"W2128784131","doi":"10.1023/a:1008340723974","title":"Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health; McGill University; University of Toronto; Jewish General Hospital; Montreal General Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Germline mutation; Missense mutation; Estrogen receptor; Mutation; Cancer; Genetics; Biology; Gene","score_opus":0.04255494950713673,"score_gpt":0.3619128434265801,"score_spread":0.31935789391944336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128784131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981233,0.0006261357,0.000042610063,0.009597161,0.00017250817,0.0002122999,0.00024556235,0.000007990902,0.007862725],"genre_scores_gemma":[0.9937744,0.0004458442,0.00058983924,0.0041952445,0.00014271654,0.000090571004,0.00006588859,0.000019774638,0.00067569816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99888116,0.00011300923,0.00035301695,0.00029840186,0.00010519966,0.0002492229],"domain_scores_gemma":[0.9994092,0.000031463125,0.00013234772,0.00020192943,0.00016587654,0.000059170237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000201227,0.00012994054,0.00024597632,0.000079285666,0.000043850472,0.0000074492946,0.00016308871,0.0002125621,0.0005728173],"category_scores_gemma":[0.00004383419,0.000135472,0.00008117548,0.00017401081,0.00023371668,0.000008210577,0.000036152273,0.00010884787,0.000013085173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001843551,0.0005353695,0.043135546,0.00009984706,0.00041821026,0.000061440194,0.0022866554,0.016240707,0.11172506,0.00006585493,0.025785057,0.7978027],"study_design_scores_gemma":[0.0060186693,0.001793049,0.5963406,0.00006918917,0.00008684967,0.00021484352,0.0007943851,0.00038493006,0.19430587,0.0010492258,0.19810975,0.00083265256],"about_ca_topic_score_codex":0.0007042698,"about_ca_topic_score_gemma":0.001166727,"teacher_disagreement_score":0.79697007,"about_ca_system_score_codex":0.000119925746,"about_ca_system_score_gemma":0.00072021387,"threshold_uncertainty_score":0.62719476},"labels":[],"label_agreement":null},{"id":"W2128964123","doi":"10.1093/annonc/mdq027","title":"Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Refractory (planetary science); Follicular lymphoma; Gastroenterology; Neutropenia; Adverse effect; Lymphoma; Cohort; Pharmacokinetics; CD20; Toxicity; Phases of clinical research; Oncology; Surgery","score_opus":0.06645319039979994,"score_gpt":0.4201120801170726,"score_spread":0.35365888971727266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128964123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948375,0.000099259196,0.0000011123402,0.00048747333,0.00014265355,0.0014988818,0.00006728959,0.000015764253,0.0028500669],"genre_scores_gemma":[0.99926645,0.000057277182,0.00023671037,0.00014328898,0.00005152953,0.000052037718,0.000034469707,0.000038333706,0.00011992842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968682,0.0002926726,0.0011237152,0.00043802662,0.00083028263,0.0004470981],"domain_scores_gemma":[0.99688375,0.0002669411,0.00065475266,0.0008461792,0.0011735953,0.00017476398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011972993,0.00021332545,0.0011818812,0.0005344402,0.000043908127,0.0000029660453,0.0003258777,0.00027747612,0.00018742615],"category_scores_gemma":[0.00089141726,0.00017343652,0.00010957882,0.0005735131,0.00036793487,0.000084911495,0.0001652676,0.00043620716,0.000005374223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15482445,0.21334113,0.3203138,0.00096205267,0.0015359839,0.0012087816,0.015083832,0.000018282662,0.077676274,0.00020702882,0.014735062,0.20009331],"study_design_scores_gemma":[0.2016475,0.25674537,0.49723643,0.00036447504,0.00014877475,0.00001962706,0.000978971,0.00003756288,0.016774733,0.000060464976,0.025697298,0.000288785],"about_ca_topic_score_codex":0.0012064992,"about_ca_topic_score_gemma":0.0009290901,"teacher_disagreement_score":0.19980453,"about_ca_system_score_codex":0.00007131648,"about_ca_system_score_gemma":0.0009868981,"threshold_uncertainty_score":0.70725363},"labels":[],"label_agreement":null},{"id":"W2129073959","doi":"10.1093/annonc/mdt122","title":"Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital; Université de Montréal; Hôpital Notre-Dame","funders":"Canadian Institutes of Health Research","keywords":"Multinomial distribution; Medicine; Clinical trial; Research design; Accrual; Randomized controlled trial; Clinical study design; Oncology; Internal medicine; Statistics; Mathematics","score_opus":0.7589916766225049,"score_gpt":0.632251201882201,"score_spread":0.12674047474030392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129073959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98163366,0.000047542206,0.014441488,0.0005339775,0.00017175448,0.0029273853,0.00010003885,0.000009855684,0.0001343131],"genre_scores_gemma":[0.7112001,0.0000382344,0.2882367,0.00010395344,0.000028918206,0.00035499898,0.0000019439228,0.000019440056,0.000015716287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9838314,0.010644963,0.0044476977,0.0003236189,0.00034654423,0.0004057612],"domain_scores_gemma":[0.8705461,0.12588994,0.0026505548,0.00034320154,0.0004688195,0.0001013645],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027985463,0.00024382098,0.004663286,0.00038974534,0.000025192752,0.000003472149,0.00033103095,0.00034366327,0.0007276487],"category_scores_gemma":[0.12403309,0.00018052782,0.00026037882,0.00042696003,0.00076025,0.00007020223,0.000059762933,0.00029522213,0.0000028047104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88132936,0.008482938,0.0065356707,0.0006207868,0.00043905032,0.000015126238,0.002191486,0.0017358171,0.06172339,0.00027254707,0.0022372704,0.034416556],"study_design_scores_gemma":[0.52844894,0.022557573,0.00990038,0.001099801,0.0003668033,9.3761275e-7,0.00022779236,0.062479552,0.3596668,0.014756181,0.000057492838,0.00043774687],"about_ca_topic_score_codex":0.00048828864,"about_ca_topic_score_gemma":0.00008136105,"teacher_disagreement_score":0.35288045,"about_ca_system_score_codex":0.00006276333,"about_ca_system_score_gemma":0.0006101532,"threshold_uncertainty_score":0.9699259},"labels":[],"label_agreement":null},{"id":"W2129303611","doi":"10.1093/annonc/mds518","title":"Adolescents with acute lymphoblastic leukemia treated at pediatric versus adult hospitals","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; McMaster Children's Hospital; Hospital for Sick Children; Children's Hospital of Eastern Ontario; Institute for Clinical Evaluative Sciences; Children's Hospital of Western Ontario; University of Toronto; University Health Network; Pediatric Oncology Group","funders":"Canadian Institutes of Health Research; Krebsliga Schweiz; Pediatric Oncology Group of Ontario; McMaster University","keywords":"Medicine; Young adult; Pediatrics; Confidence interval; Lymphoblastic Leukemia; Population; Acute lymphocytic leukemia; Internal medicine; Leukemia","score_opus":0.042009547731081155,"score_gpt":0.3528795163877803,"score_spread":0.31086996865669914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129303611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919696,0.00084229576,0.000013111944,0.0020258552,0.0005851094,0.00038678505,0.000031782445,0.000078401004,0.0040670773],"genre_scores_gemma":[0.99527806,0.0007511926,0.00019220434,0.0025540383,0.0007962642,0.000025194598,0.000037666014,0.000044306456,0.0003210946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997927,0.00014228327,0.00051625154,0.00030779836,0.00044183506,0.0006648489],"domain_scores_gemma":[0.9981401,0.00020079037,0.00039673218,0.0004266921,0.00038296444,0.00045273764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031717427,0.00026544734,0.0007744731,0.00017561522,0.00006318239,0.000004207302,0.0001571425,0.00025111318,0.00011304188],"category_scores_gemma":[0.00026257368,0.00022049097,0.00015739445,0.00035159456,0.00016565374,0.00014068554,0.00009653159,0.00017989172,0.00021135627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015521702,0.0013028436,0.9505217,0.0004824693,0.0007978058,0.0001581767,0.0020967063,0.0000064154233,0.0004192505,0.000103249564,0.024821004,0.003768672],"study_design_scores_gemma":[0.01816472,0.014149858,0.9534801,0.0002901081,0.0013059544,0.00022721487,0.00030770877,0.000012754507,0.0068081515,0.000014828673,0.0047914227,0.0004471729],"about_ca_topic_score_codex":0.000358599,"about_ca_topic_score_gemma":0.00016438418,"teacher_disagreement_score":0.020029582,"about_ca_system_score_codex":0.0004073119,"about_ca_system_score_gemma":0.0005653417,"threshold_uncertainty_score":0.89913607},"labels":[],"label_agreement":null},{"id":"W2129684544","doi":"10.1093/annonc/mdr476","title":"Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Princess Margaret Cancer Centre; University Health Network","funders":"Centre Léon Bérard; Académie française","keywords":"Medicine; Oncology; Clinical trial; Internal medicine","score_opus":0.7244290692160772,"score_gpt":0.6638508701986854,"score_spread":0.06057819901739181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129684544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054349575,0.9032305,0.000009853128,0.00008879994,0.0013589957,0.034200925,0.0017140288,0.00004769142,0.004999665],"genre_scores_gemma":[0.008637621,0.98007905,0.00025908707,0.0002442644,0.00031252037,0.009947502,0.00014989925,0.00010076377,0.0002693124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98014605,0.011530329,0.006139427,0.0008675233,0.00033021407,0.0009864604],"domain_scores_gemma":[0.9869657,0.0034995982,0.0074999174,0.00073514576,0.0008351607,0.00046443913],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011296752,0.00089115824,0.009598785,0.0012686447,0.000076085234,0.0000062240065,0.0012652727,0.0030253148,0.0013148271],"category_scores_gemma":[0.0014777945,0.00070884416,0.0015351886,0.001135063,0.0013439085,0.00012908745,0.00044592473,0.0017477182,0.000029918514],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054628057,0.008122311,0.0003122098,0.011371177,0.0018379655,0.00010908941,0.001288151,0.000007251591,0.0009916521,0.0004377257,0.0013335828,0.9687261],"study_design_scores_gemma":[0.00840606,0.0053321095,0.00013027525,0.0018591111,0.0019729557,0.000036009114,0.000028835184,0.000018798619,0.01880727,0.00021306766,0.9626468,0.000548701],"about_ca_topic_score_codex":0.00023010325,"about_ca_topic_score_gemma":0.00014639454,"teacher_disagreement_score":0.9681774,"about_ca_system_score_codex":0.00013451191,"about_ca_system_score_gemma":0.0035873712,"threshold_uncertainty_score":0.9995981},"labels":[],"label_agreement":null},{"id":"W2129822063","doi":"10.1093/annonc/mds150","title":"Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Fonds De La Recherche Scientifique - FNRS","keywords":"BCL6; Immunophenotyping; Germinal center; Subtyping; Medicine; Pathology; Lymphoma; Stage (stratigraphy); Follicular lymphoma; International Prognostic Index; Biopsy; Diffuse large B-cell lymphoma; B cell; Internal medicine; Biology; Immunology; Antibody; Flow cytometry","score_opus":0.11285357637503934,"score_gpt":0.3977432483262386,"score_spread":0.28488967195119924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129822063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856018,0.0031573505,0.0000043436507,0.0008751469,0.00028649234,0.000622042,0.000038232287,0.000032361462,0.009382272],"genre_scores_gemma":[0.9981978,0.00031652133,0.00022172948,0.00067584036,0.00017470097,0.000082658764,0.000021501912,0.000021790354,0.00028747684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809986,0.00023605548,0.0006148258,0.0002789463,0.0002434044,0.0005269069],"domain_scores_gemma":[0.99821347,0.00050031074,0.0004144724,0.00048092796,0.00016611019,0.00022468026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008224324,0.00022367512,0.000934023,0.00013186783,0.000075728276,0.000005656677,0.00014196376,0.00020797011,0.00007638299],"category_scores_gemma":[0.00028375324,0.00016141096,0.00026264242,0.00015693199,0.00015092024,0.00007186774,0.00015558641,0.00009391096,0.00004673422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058591604,0.11712931,0.8482062,0.00009702625,0.00023800062,0.0003299157,0.0024819854,2.0164815e-7,0.0003275675,0.00020793034,0.0034444113,0.026951509],"study_design_scores_gemma":[0.023961533,0.010094554,0.9403894,0.000056528013,0.00037526773,0.00011166936,0.0010998595,0.0000032936466,0.005840665,0.000043553977,0.01788778,0.00013590486],"about_ca_topic_score_codex":0.00014016964,"about_ca_topic_score_gemma":0.00006878376,"teacher_disagreement_score":0.10703476,"about_ca_system_score_codex":0.00007800016,"about_ca_system_score_gemma":0.00018670499,"threshold_uncertainty_score":0.6582148},"labels":[],"label_agreement":null},{"id":"W2130159340","doi":"10.1093/annonc/mds433","title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Follicular lymphoma; Medicine; Rituximab; Internal medicine; Lymphoma; Oncology; Radiation therapy; Stage (stratigraphy); Population; Gastroenterology; Multivariate analysis","score_opus":0.04268085807683187,"score_gpt":0.3507610932435733,"score_spread":0.30808023516674143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130159340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299103,0.002162815,0.00005910319,0.0018304635,0.000034643814,0.00063901494,0.00001928283,0.000015898817,0.0022477594],"genre_scores_gemma":[0.99656945,0.0012296757,0.00074834336,0.001207789,0.000035328892,0.00010712502,0.000026297801,0.000016145865,0.000059825667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987627,0.0000930935,0.0004338106,0.00016052996,0.00021990274,0.0003299072],"domain_scores_gemma":[0.9989573,0.0001416654,0.00030848334,0.00023467827,0.0001788184,0.00017909902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002419275,0.00016817672,0.00062004075,0.00028273588,0.000020416814,0.000002748446,0.000077770004,0.00014557189,0.00005098387],"category_scores_gemma":[0.0000525982,0.00012152362,0.00010172865,0.00040901618,0.00008153667,0.00016351407,0.0000111239115,0.000023739136,0.000008381061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037147407,0.005761043,0.5748312,0.00013319796,0.0004533465,0.00032009397,0.006419982,0.0000839353,0.005089361,0.0007723219,0.0004771717,0.4019436],"study_design_scores_gemma":[0.010442519,0.007970419,0.8150132,0.00033937412,0.000090618036,0.0001753846,0.00035276066,0.0000681807,0.15163635,0.000008489792,0.013762693,0.00014007288],"about_ca_topic_score_codex":0.0006509572,"about_ca_topic_score_gemma":0.000107612526,"teacher_disagreement_score":0.40180352,"about_ca_system_score_codex":0.00022113588,"about_ca_system_score_gemma":0.00021767263,"threshold_uncertainty_score":0.49555895},"labels":[],"label_agreement":null},{"id":"W2130160257","doi":"10.1093/annonc/mds204","title":"Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Pfizer","keywords":"Medicine; Exemestane; Hazard ratio; Internal medicine; Oncology; Breast cancer; Adverse effect; Tamoxifen; Proportional hazards model; Fulvestrant; Cancer; Confidence interval","score_opus":0.03909486803800578,"score_gpt":0.33796856680163756,"score_spread":0.2988736987636318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130160257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969321,0.0023110209,0.0000014805398,0.00012098846,0.00008330677,0.00020138621,0.00003964429,0.0000022915744,0.00030780415],"genre_scores_gemma":[0.99861544,0.0011016447,0.000051798153,0.00004451937,0.00008414402,0.0000075952244,0.000056478955,0.000011612235,0.000026764052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920774,0.00012850549,0.00024188892,0.00013513371,0.000076809636,0.00020994316],"domain_scores_gemma":[0.9995033,0.000069810754,0.00015300303,0.00011859443,0.000077800025,0.00007747727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019723193,0.00009777084,0.00019499342,0.00006392847,0.000020537243,6.381032e-7,0.000072640214,0.00022449862,0.0000081848775],"category_scores_gemma":[0.0000275079,0.000085775166,0.000040704115,0.000088519366,0.000086074586,0.000008391596,0.000040223866,0.000100365476,0.0000024148362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005018424,0.00045037997,0.97028863,0.000008220677,0.000051065264,7.542963e-7,0.00018003481,0.000002195394,0.017571872,0.000039176375,0.00014536323,0.010760451],"study_design_scores_gemma":[0.0017624105,0.0021450287,0.97854775,0.000014473528,0.000010756848,0.0000029734565,0.000011640629,2.4771717e-7,0.016401995,0.000025162686,0.0009979602,0.00007958227],"about_ca_topic_score_codex":0.000050782204,"about_ca_topic_score_gemma":0.0000028209142,"teacher_disagreement_score":0.010680868,"about_ca_system_score_codex":0.000008923524,"about_ca_system_score_gemma":0.000042573392,"threshold_uncertainty_score":0.34978095},"labels":[],"label_agreement":null},{"id":"W2130689654","doi":"10.1093/annonc/mdv284","title":"Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Denosumab; Meta-analysis; Breast cancer; Internal medicine; Adverse effect; Oncology; Bone pain; Confidence interval; Systematic review; Bone remodeling; Randomized controlled trial; Relative risk; Bone metastasis; MEDLINE; Cancer; Osteoporosis","score_opus":0.25158692065612437,"score_gpt":0.48614845612797186,"score_spread":0.2345615354718475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130689654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021789304,0.977188,0.000016835058,0.00040933333,0.000017934955,0.004758719,0.017367486,0.000008282881,0.00001551333],"genre_scores_gemma":[0.0026328617,0.9923899,0.00124514,0.00036597575,0.000009725931,0.00076034997,0.002534171,0.00004428015,0.000017557504],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964122,0.00055650785,0.0019592247,0.00035409775,0.00045515763,0.00026279123],"domain_scores_gemma":[0.99375856,0.00042058024,0.00341619,0.0003879194,0.001792023,0.0002247328],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0009773206,0.00036469218,0.01470101,0.00029064616,0.000027302885,0.0000026771506,0.00007404657,0.000242464,0.000051821156],"category_scores_gemma":[0.00027087066,0.00021605944,0.001301113,0.00042218497,0.0000797877,0.000048822578,0.000037413505,0.0001271893,2.275822e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036798243,0.00033682646,0.00050301047,0.85849893,0.11469876,0.000007501281,0.00014577007,6.7013536e-7,2.5414323e-8,0.0000032764074,0.00069763506,0.024739597],"study_design_scores_gemma":[0.0012780466,0.0027692926,0.00010749324,0.036372583,0.9304434,0.000009040725,0.00005214088,0.0000016049794,0.0000013678546,0.0000065065224,0.028817328,0.0001411976],"about_ca_topic_score_codex":0.00086332904,"about_ca_topic_score_gemma":0.00033055345,"teacher_disagreement_score":0.8221264,"about_ca_system_score_codex":0.00015597309,"about_ca_system_score_gemma":0.001018622,"threshold_uncertainty_score":0.9999268},"labels":[],"label_agreement":null},{"id":"W2131094814","doi":"10.1093/annonc/mdm009","title":"New drug development in digestive neuroendocrine tumors","year":2007,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Insulin-like growth factor 1 receptor; Medicine; Neuroendocrine tumors; PI3K/AKT/mTOR pathway; Cancer research; Epidermal growth factor receptor; Receptor tyrosine kinase; Tyrosine kinase; Growth factor receptor inhibitor; Vascular endothelial growth factor; Growth factor receptor; Receptor; Epidermal growth factor; Growth factor; Drug development; Pharmacology; Drug; Signal transduction; Internal medicine; Biology; VEGF receptors; Cell biology","score_opus":0.17979108463509635,"score_gpt":0.4906032740284463,"score_spread":0.3108121893933499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131094814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032265985,0.9871641,0.0000044577255,0.0012127195,0.00020653241,0.0015670919,0.000008871449,0.00004542032,0.009468141],"genre_scores_gemma":[0.000066944216,0.991343,0.0017433984,0.00048244355,0.00022441047,0.0000856466,0.00006170873,0.00008569115,0.0059067574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958923,0.00031216303,0.0015309543,0.0006685963,0.0005574436,0.0010385514],"domain_scores_gemma":[0.99721307,0.000989312,0.0005980172,0.00047137332,0.0002081541,0.0005200583],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038569633,0.0005217725,0.003452128,0.0012732869,0.000029250328,0.000006566375,0.00043803515,0.000033626453,0.0001903372],"category_scores_gemma":[0.0009792787,0.00042968808,0.00037138938,0.0009239199,0.00017376311,0.00008207615,0.00032432604,0.0012313189,0.00015970595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015457493,0.00033706514,0.00009102161,0.0062697553,0.00008858544,0.031302612,0.000036036658,5.1831563e-7,6.940963e-7,0.00006373513,0.01003106,0.95162433],"study_design_scores_gemma":[0.00083960535,0.0013334799,0.00023259611,0.0063768886,0.000077911885,0.004461009,0.000018730587,1.9003716e-7,0.00022006837,0.000038015038,0.9861609,0.000240631],"about_ca_topic_score_codex":0.0001329355,"about_ca_topic_score_gemma":0.00017710325,"teacher_disagreement_score":0.97612983,"about_ca_system_score_codex":0.00021489315,"about_ca_system_score_gemma":0.0045607253,"threshold_uncertainty_score":0.99981546},"labels":[],"label_agreement":null},{"id":"W2131326718","doi":"10.1093/annonc/mdr007","title":"An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada","funders":"Abbott Diagnostics","keywords":"Medicine; Lung; Oncology; Internal medicine; Neuroendocrine tumors","score_opus":0.0713031647313103,"score_gpt":0.3418136493957295,"score_spread":0.2705104846644192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131326718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679524,0.000058509293,0.000003636143,0.0009228036,0.000034042925,0.0012587159,0.000019069394,0.000031875043,0.0008761079],"genre_scores_gemma":[0.9989728,0.000118252356,0.00025711374,0.0004272176,0.00002514834,0.00006780371,0.000075838456,0.00003544035,0.000020426352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973155,0.00055634504,0.00051235635,0.00044388152,0.0004781044,0.00069381634],"domain_scores_gemma":[0.99892694,0.00018160741,0.00021933013,0.00028548366,0.00019666339,0.00018996708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024080902,0.00024911534,0.0005989458,0.0004672355,0.00004028292,0.000012963668,0.0002794392,0.000018498095,0.00003480856],"category_scores_gemma":[0.00019934043,0.00016829836,0.000038796476,0.00048828166,0.00030432412,0.00025218885,0.00010269235,0.0005838737,0.0000022372303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004076571,0.0026375616,0.98611045,0.0001234934,0.00003829322,0.0027572736,0.00043082438,0.0000025988334,0.001603442,0.000016200527,0.00018239529,0.002020924],"study_design_scores_gemma":[0.00554143,0.008957266,0.98054487,0.00012950329,0.0000366114,0.00029405512,0.00026621425,0.00006954714,0.0039351285,0.000038882645,0.00006634991,0.00012013576],"about_ca_topic_score_codex":0.0002780785,"about_ca_topic_score_gemma":0.00028822027,"teacher_disagreement_score":0.006319704,"about_ca_system_score_codex":0.000041288804,"about_ca_system_score_gemma":0.00019848705,"threshold_uncertainty_score":0.68630075},"labels":[],"label_agreement":null},{"id":"W2131451291","doi":"10.1093/annonc/mdi966","title":"The Gynecologic Cancer Intergroup (GCIG): history and current status","year":2005,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Surrogate endpoint; Randomized controlled trial; Clinical endpoint; Gynecologic cancer; Cancer; Intensive care medicine; Oncology; Internal medicine; Ovarian cancer","score_opus":0.2685363916126825,"score_gpt":0.49650688316372366,"score_spread":0.22797049155104115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131451291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021194823,0.9907375,4.8943616e-7,0.0026742725,0.0015286694,0.0007698728,0.000052075226,0.000015085943,0.0042008287],"genre_scores_gemma":[0.00005517118,0.99740404,0.000034496657,0.0006290034,0.00046864455,0.00062394387,0.000033674925,0.000028305427,0.00072273763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982895,0.00018473189,0.00062211434,0.0003619415,0.00013977193,0.00040189558],"domain_scores_gemma":[0.99802434,0.00075019005,0.0005793759,0.00034280962,0.00012785273,0.00017540483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029568333,0.0003024505,0.0017439399,0.000110128014,0.000050385697,0.0000055097007,0.00012806166,0.00026845303,0.00046121064],"category_scores_gemma":[0.00010300454,0.00017105676,0.00036688976,0.000079010664,0.00029075527,0.000025215142,0.00010333887,0.0003945257,0.000024632069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028531149,0.0003839836,0.00007386351,0.0020420966,0.0004962528,0.000026011612,0.000060203325,5.5771064e-8,2.0413307e-8,0.0003417657,0.09202868,0.90451854],"study_design_scores_gemma":[0.00056891097,0.0016822106,0.00044969405,0.0028484743,0.0012351614,0.000031349187,0.000010391696,5.815229e-7,2.6321482e-7,0.000025274578,0.9930167,0.00013097697],"about_ca_topic_score_codex":0.000110473346,"about_ca_topic_score_gemma":0.0003181422,"teacher_disagreement_score":0.90438753,"about_ca_system_score_codex":0.0011851458,"about_ca_system_score_gemma":0.0019777024,"threshold_uncertainty_score":0.6975492},"labels":[],"label_agreement":null},{"id":"W2131526871","doi":"10.1093/annonc/mdm069","title":"Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review","year":2007,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Lymphoma; Surgery; Stem cell; Cryopreservation; Haematopoiesis; Oncology; Transplantation; Internal medicine","score_opus":0.19121687715138294,"score_gpt":0.4184249631288664,"score_spread":0.22720808597748346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131526871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003062922,0.99092436,0.00009027626,0.00007685366,0.00007213046,0.0070743826,0.00023426535,0.00002988586,0.001191544],"genre_scores_gemma":[0.0002201734,0.9981053,0.0007710972,0.0002116791,0.00002905513,0.0001517537,0.00008300638,0.00006000546,0.00036793682],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9948468,0.0009439952,0.002712691,0.0005594173,0.00052719674,0.000409881],"domain_scores_gemma":[0.9955745,0.0013653855,0.0015919451,0.00080726354,0.00041713202,0.00024379783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026590014,0.0005390235,0.007786467,0.00019758823,0.000032433552,0.0000044831777,0.0002630704,0.000602619,0.00016293529],"category_scores_gemma":[0.00008333043,0.00032534305,0.000491809,0.0004252514,0.00026635485,0.000055784774,0.00002931842,0.00040345264,0.000006151619],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007383937,0.0004183999,0.000050371807,0.97162616,0.0011881976,0.0004444438,0.00019125381,9.76742e-8,0.000007961012,0.000016333439,0.000058695834,0.025259694],"study_design_scores_gemma":[0.0023414432,0.0036413008,0.000022183433,0.9483768,0.01824361,0.0034336864,0.000054601445,0.0000020493005,0.0001738244,0.000002030292,0.023388417,0.00032007875],"about_ca_topic_score_codex":0.000027430622,"about_ca_topic_score_gemma":0.00006312008,"teacher_disagreement_score":0.024939615,"about_ca_system_score_codex":0.000071762755,"about_ca_system_score_gemma":0.0011818734,"threshold_uncertainty_score":0.9999199},"labels":[],"label_agreement":null},{"id":"W2131765662","doi":"10.1093/annonc/mdg171","title":"A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Jewish General Hospital; BC Cancer Agency","funders":"AstraZeneca Canada","keywords":"Medicine; Neutropenia; Internal medicine; Docetaxel; Metastatic breast cancer; Breast cancer; Carboplatin; Cancer; Clinical trial; Oncology; Phases of clinical research; Chemotherapy; Toxicity; Cisplatin; Surgery","score_opus":0.22710454263369964,"score_gpt":0.540438615129528,"score_spread":0.31333407249582834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131765662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924194,0.00028199021,0.000004150461,0.0016071108,0.0009615864,0.0036399022,0.00064521184,0.000006057413,0.00043458902],"genre_scores_gemma":[0.99682105,0.00051796675,0.00017334684,0.0014785768,0.00012977395,0.00061785406,0.000050375136,0.000017852006,0.00019321803],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964336,0.0007247446,0.0015819551,0.00036260736,0.00060752867,0.00028953524],"domain_scores_gemma":[0.9968696,0.00075071823,0.00086265843,0.00018724705,0.0010733389,0.00025639308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015520261,0.00022854094,0.0018563144,0.00022583257,0.000065663866,0.0000018366544,0.00012254446,0.00010539899,0.0008128109],"category_scores_gemma":[0.00085624267,0.00015966345,0.00013873381,0.0004670928,0.00014404077,0.000106385545,0.00005396536,0.00018292986,4.4838103e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6184315,0.07635276,0.0452064,0.00018221074,0.0054960568,0.00013540761,0.0014312386,0.00030562654,0.0013253397,0.000048558893,0.02609609,0.22498882],"study_design_scores_gemma":[0.48263183,0.3681481,0.049324416,0.00035611793,0.0029179675,0.000028735829,0.0006092645,0.0000149614125,0.0017139826,0.000054977147,0.09381939,0.00038028075],"about_ca_topic_score_codex":0.093414076,"about_ca_topic_score_gemma":0.39616337,"teacher_disagreement_score":0.3027493,"about_ca_system_score_codex":0.00029701844,"about_ca_system_score_gemma":0.008774528,"threshold_uncertainty_score":0.9968448},"labels":[],"label_agreement":null},{"id":"W2131832494","doi":"10.1093/annonc/mdr492","title":"Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"Cancer Care Ontario","keywords":"Medicine; Randomized controlled trial; Internal medicine; Oncology; Breast cancer; Sample size determination; Biomarker; Lung cancer; Colorectal cancer; Cancer","score_opus":0.21544256533080539,"score_gpt":0.4646806095354798,"score_spread":0.2492380442046744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131832494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033047958,0.9885799,0.00014855458,0.00058639667,0.0026050967,0.00350949,0.00010952895,0.0000040799173,0.004126439],"genre_scores_gemma":[0.0001292562,0.99476224,0.0018198603,0.00085840945,0.001482613,0.00072586554,0.0001280834,0.00003802526,0.000055647117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9658932,0.029453538,0.0034483485,0.0006069888,0.00016393821,0.00043400106],"domain_scores_gemma":[0.98780346,0.007659706,0.0035496757,0.0006442626,0.00024860963,0.00009428347],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.041976836,0.0005339258,0.015802031,0.0003153745,0.00003100621,0.000007567121,0.0006093359,0.0014586002,0.00006994121],"category_scores_gemma":[0.013924938,0.00031087513,0.0029355849,0.00020145411,0.0011184266,0.0000042763736,0.00020427725,0.00047098479,0.0000019443178],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05340298,0.0003273027,9.854549e-7,0.0013026602,0.0044463025,0.000003108999,0.00023286487,1.839518e-7,0.0011601673,0.0019198591,0.0095802825,0.92762333],"study_design_scores_gemma":[0.09474919,0.0009855725,0.00000228434,0.0004699692,0.0028224296,0.0000849333,0.0000742837,3.225442e-7,0.0003783704,0.0008700445,0.89932907,0.00023356362],"about_ca_topic_score_codex":0.00023346164,"about_ca_topic_score_gemma":0.000107220236,"teacher_disagreement_score":0.92738974,"about_ca_system_score_codex":0.000016254617,"about_ca_system_score_gemma":0.0012906748,"threshold_uncertainty_score":0.9999343},"labels":[],"label_agreement":null},{"id":"W2131859250","doi":"10.1093/annonc/mdt492","title":"Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of British Columbia; BC Cancer Agency; London Health Sciences Centre; University of Toronto; Western University; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; Pfizer","keywords":"Medicine; Renal cell carcinoma; Oncology; Clinical trial; Internal medicine; Carcinoma; Intensive care medicine","score_opus":0.3613297907484573,"score_gpt":0.5129254630778948,"score_spread":0.1515956723294375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131859250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346256,0.00023881668,0.000059430833,0.0020199872,0.00019205894,0.002598965,0.0001866077,0.000011176813,0.0012304217],"genre_scores_gemma":[0.99295604,0.000043320422,0.005591433,0.00091454753,0.000054836753,0.00018638099,0.00007795591,0.000025660765,0.00014983506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627393,0.0009412061,0.0016485092,0.00042598706,0.00036403968,0.0003463141],"domain_scores_gemma":[0.9936136,0.0035511446,0.0011074786,0.00059393374,0.0008969033,0.00023691161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031228915,0.00025235943,0.0024143732,0.00013054411,0.0000268903,0.0000073846195,0.00015264786,0.00016481313,0.0003382513],"category_scores_gemma":[0.0014832239,0.00015257805,0.0005868245,0.00008651894,0.00027295857,0.000092589486,0.00005981436,0.000114090886,0.000012060717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061094356,0.0036019858,0.9613601,0.00036892176,0.0006455758,0.000016422719,0.00022843463,9.544576e-7,0.0012899233,0.00004730068,0.014146877,0.012184063],"study_design_scores_gemma":[0.011082951,0.019807803,0.91852313,0.000025948568,0.00073475635,0.0000031777938,0.000094908784,0.000011641237,0.047876574,0.00039355532,0.0013191219,0.00012640597],"about_ca_topic_score_codex":0.00016311732,"about_ca_topic_score_gemma":0.000016324517,"teacher_disagreement_score":0.04658665,"about_ca_system_score_codex":0.000045474622,"about_ca_system_score_gemma":0.00029958258,"threshold_uncertainty_score":0.62219524},"labels":[],"label_agreement":null},{"id":"W2132049541","doi":"10.1093/annonc/mds341","title":"Prognosticating in patients with advanced cancer—observational study comparing the accuracy of clinicians’ and patients’ estimates of survival","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"Cancer Research UK","keywords":"Medicine; Observational study; Cancer; Family medicine; Internal medicine","score_opus":0.4056946009060626,"score_gpt":0.49768222343574403,"score_spread":0.09198762252968146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132049541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843824,0.00028583745,0.000007822852,0.00026576602,0.000057546542,0.00057289196,0.000009845302,0.0000031801987,0.00035889185],"genre_scores_gemma":[0.9989568,0.000036710848,0.00078631734,0.00015453144,0.00002024199,0.000026933707,0.00001205555,0.0000055297387,9.009806e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989232,0.00006760923,0.00047866374,0.00010585272,0.00024734126,0.00017735186],"domain_scores_gemma":[0.9980883,0.00075860485,0.00048125227,0.00011881836,0.00051049027,0.000042529064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049763103,0.00007899472,0.00043613106,0.00004420016,0.000025131769,0.0000013604596,0.00008192075,0.000035657304,0.0000060819543],"category_scores_gemma":[0.0010064311,0.000052720683,0.000022474032,0.00016771547,0.00013167273,0.00013285207,0.000056384535,0.00009885614,1.3631596e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090684876,0.0010415812,0.96427435,0.000054928874,0.000055931912,2.9267127e-7,0.0012758967,0.000071804774,0.000017126707,0.000071437375,0.000017424865,0.03221238],"study_design_scores_gemma":[0.0025025716,0.003668774,0.99205774,0.00021179194,0.00005290242,2.1807698e-7,0.0011087086,0.0000786993,0.00019433994,0.000022700886,0.000056310844,0.000045248806],"about_ca_topic_score_codex":0.00054436014,"about_ca_topic_score_gemma":0.00025723755,"teacher_disagreement_score":0.03216713,"about_ca_system_score_codex":0.000017453749,"about_ca_system_score_gemma":0.0001101453,"threshold_uncertainty_score":0.21498871},"labels":[],"label_agreement":null},{"id":"W2132178271","doi":"10.1093/annonc/mdh303","title":"The difference between study recommendations, stated policy, and actual practice in a clinical trial","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; McMaster University; Ontario Institute for Cancer Research","funders":"AstraZeneca","keywords":"Medicine; Clinical Practice; Clinical trial; Family medicine; Medical physics; Internal medicine","score_opus":0.8068769448274646,"score_gpt":0.7443205845923665,"score_spread":0.06255636023509814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132178271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76974046,0.000060183138,0.00001471553,0.22736154,0.0000975267,0.0007693926,0.000006190328,0.000007675669,0.0019423018],"genre_scores_gemma":[0.9896382,0.006424093,0.00052589894,0.0027906173,0.00034310625,0.000034027962,0.0000061869464,0.00000850319,0.00022935547],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963703,0.0014673934,0.0011758244,0.00027643747,0.0004166884,0.00029336984],"domain_scores_gemma":[0.8790552,0.11930884,0.00037019365,0.00041275893,0.00065065786,0.00020235819],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016800737,0.000081807426,0.00048411393,0.000116531446,0.00008184721,0.000014263066,0.00020121556,0.00032986625,0.000009000864],"category_scores_gemma":[0.22367114,0.00005492117,0.000057744925,0.00029353672,0.0005802334,0.000055009274,0.00021166698,0.001831753,0.0000084832645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055941146,0.0094838,0.072211966,0.000029657158,0.000421441,0.00010350891,0.0035314946,5.8475234e-7,0.000020565614,0.011460847,0.0006763751,0.8461186],"study_design_scores_gemma":[0.10965219,0.09154321,0.6722069,0.0001229896,0.00011348258,0.000015683341,0.005601036,0.00000309083,0.00009169259,0.07081731,0.049692407,0.00014003152],"about_ca_topic_score_codex":0.0010675032,"about_ca_topic_score_gemma":0.0022568502,"teacher_disagreement_score":0.84597856,"about_ca_system_score_codex":0.000058457226,"about_ca_system_score_gemma":0.0024201714,"threshold_uncertainty_score":0.7958157},"labels":[],"label_agreement":null},{"id":"W2132193955","doi":"10.1093/annonc/mdq357","title":"A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Ovarian cancer; Dosing; Oncology; Tyrosine-kinase inhibitor; Adverse effect; Gastroenterology; Progressive disease; Phases of clinical research; Cancer; Clinical trial; Chemotherapy","score_opus":0.18159103005263225,"score_gpt":0.485284439144716,"score_spread":0.30369340909208375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132193955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958665,0.00006671372,3.9614278e-7,0.0005157342,0.00038453625,0.0029083916,0.000082253326,0.000008409352,0.00016710581],"genre_scores_gemma":[0.99914867,0.000036220146,0.00018884342,0.00017963185,0.00021503436,0.00015414874,0.00005429544,0.000018654082,0.0000045087595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656683,0.0011518333,0.0013013931,0.0004475453,0.0002932859,0.00023910566],"domain_scores_gemma":[0.9979806,0.0005341372,0.00057270005,0.00041793683,0.00027659867,0.00021805895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033386743,0.00019723408,0.0015916707,0.00019113992,0.00005350416,0.000005485129,0.00010036733,0.00015340405,0.000061149934],"category_scores_gemma":[0.0003359447,0.00014049202,0.0000896349,0.00016098408,0.00017670913,0.00007954162,0.00008676394,0.00036782844,5.676227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012461096,0.1715663,0.638114,0.000025604148,0.0002726198,0.00009354858,0.002823839,7.8483524e-8,0.00006720842,0.000020842286,0.00005418167,0.17450069],"study_design_scores_gemma":[0.06912021,0.28038827,0.6487996,0.000022700708,0.00031214044,0.0000037759628,0.0009026822,0.0000024586786,0.000035364228,0.000009313281,0.0003276234,0.00007585104],"about_ca_topic_score_codex":0.0006731362,"about_ca_topic_score_gemma":0.0021841505,"teacher_disagreement_score":0.17442483,"about_ca_system_score_codex":0.000030577434,"about_ca_system_score_gemma":0.00033500078,"threshold_uncertainty_score":0.57290983},"labels":[],"label_agreement":null},{"id":"W2132229544","doi":"10.1093/annonc/mdr043","title":"First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Western University","funders":"","keywords":"Medicine; Bevacizumab; Tolerability; Proteinuria; Internal medicine; Metastatic breast cancer; Breast cancer; Chemotherapy; Population; Oncology; Cancer; Adverse effect; Surgery","score_opus":0.1655933199108834,"score_gpt":0.42565664014882443,"score_spread":0.260063320237941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132229544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944444,0.00025977372,3.418929e-7,0.0022769212,0.00012182379,0.0018326684,0.00013266497,0.000011096581,0.0009203443],"genre_scores_gemma":[0.99749243,0.00069938385,0.00001689151,0.0011918026,0.00007956453,0.00039259664,0.00003966358,0.000015008641,0.00007264684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987481,0.00018970417,0.00043548612,0.00023765156,0.00010612938,0.0002828912],"domain_scores_gemma":[0.99920434,0.00027053384,0.00018029337,0.00018681565,0.00011456079,0.00004347469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005593164,0.00013560064,0.0004642473,0.00017242512,0.0000317523,0.0000021051567,0.0001368437,0.000102551494,0.00010853934],"category_scores_gemma":[0.00003487956,0.00009503038,0.00008011483,0.0002345588,0.00006084406,0.000040662053,0.000019227955,0.0001505761,0.0000022808708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053337947,0.010919724,0.7585243,0.00001435125,0.00025506932,0.00009847015,0.028894603,0.000008303725,0.000038277758,0.0000120904815,0.0014188716,0.14647797],"study_design_scores_gemma":[0.037251838,0.027398521,0.93211734,0.000031858464,0.000062916406,0.000004320897,0.00064535165,0.0000128870815,0.00017836873,0.00009316381,0.0021272965,0.000076118],"about_ca_topic_score_codex":0.0048562502,"about_ca_topic_score_gemma":0.009962357,"teacher_disagreement_score":0.17359303,"about_ca_system_score_codex":0.000091626636,"about_ca_system_score_gemma":0.000111565445,"threshold_uncertainty_score":0.734123},"labels":[],"label_agreement":null},{"id":"W2132230893","doi":"10.1093/annonc/mdu478","title":"Prioritizing targets for precision cancer medicine","year":2014,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prioritization; Precision medicine; Clinical trial; Identification (biology); Cancer; Disease; Clinical Practice; Personalized medicine; Bioinformatics; Genomics; Computational biology; Intensive care medicine; Genome; Internal medicine; Pathology; Family medicine; Management science; Genetics; Gene; Biology","score_opus":0.12643354354330907,"score_gpt":0.47387273025669224,"score_spread":0.34743918671338314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132230893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018118533,0.9957997,0.0005376548,0.00039158316,0.0008803988,0.0006478863,0.00022870733,0.000003933522,0.0014919806],"genre_scores_gemma":[0.00003871928,0.9957238,0.0005506452,0.0006388451,0.0020174335,0.00024435538,0.00045118606,0.000048519138,0.0002865155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852026,0.000082203536,0.00062728935,0.0004062105,0.00008338882,0.00028065464],"domain_scores_gemma":[0.99835074,0.0003368609,0.0005818115,0.00035672972,0.0002817597,0.00009212418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050043553,0.0002559668,0.0014181605,0.00008572023,0.000041056603,0.000004178102,0.0002921033,0.000567038,0.000019052162],"category_scores_gemma":[0.0006899707,0.00021098668,0.00037299466,0.000063465806,0.00011872357,0.0000010415313,0.00013349798,0.000108350345,0.0000033387919],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035816225,0.00003500073,0.0000011680083,0.0029081493,0.00014039603,0.0000010841335,0.000010515639,0.0000017330699,0.00019921991,0.00017946034,0.075868234,0.92061925],"study_design_scores_gemma":[0.0003699236,0.0022905231,0.0000016008474,0.0017588878,0.00025447717,0.000009011493,0.0000035740177,0.0000025910203,0.00020406202,0.00019729049,0.99470615,0.0002019279],"about_ca_topic_score_codex":0.000045937017,"about_ca_topic_score_gemma":0.00008521105,"teacher_disagreement_score":0.9204173,"about_ca_system_score_codex":0.000026792308,"about_ca_system_score_gemma":0.00060929824,"threshold_uncertainty_score":0.86037874},"labels":[],"label_agreement":null},{"id":"W2132550116","doi":"10.1093/annonc/mdf195","title":"Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BP (Canada); McGill University","funders":"","keywords":"Medicine; Refractory (planetary science); Renal cell carcinoma; Adverse effect; Internal medicine; Toxicity; Clinical trial; Cancer; Gastroenterology; Oncology; Carcinoma; Urology; Surgery","score_opus":0.057815647077404886,"score_gpt":0.34551973448211354,"score_spread":0.28770408740470865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132550116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920631,0.0010322804,0.000026527849,0.00016085619,0.0013900448,0.00033298746,0.000068019945,0.0000035153296,0.00492269],"genre_scores_gemma":[0.9960956,0.00028764096,0.0002505361,0.0002836043,0.0020593146,0.0000300749,0.0000727148,0.00001851061,0.0009020354],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846715,0.00012349573,0.00060701574,0.00034845254,0.00016559135,0.0002883236],"domain_scores_gemma":[0.99871176,0.00002449818,0.0004968696,0.00039699447,0.00027962998,0.00009024893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031009602,0.00016304317,0.00046191787,0.00011045566,0.000030634306,0.0000025635372,0.00015462324,0.00017847805,0.000097126365],"category_scores_gemma":[0.00011050961,0.00014497696,0.00012768901,0.00012564208,0.00017312044,0.000008638166,0.00008319815,0.0001244315,0.0000014170755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060398757,0.016437046,0.0031158775,0.000106760024,0.00019867852,0.00005444359,0.001581992,0.00006602959,0.61429924,0.00004522098,0.15114678,0.15254915],"study_design_scores_gemma":[0.07954429,0.02920082,0.002081661,0.000015525442,0.000043372693,0.000033731496,0.00006300776,0.000007223806,0.09546809,0.000021950762,0.7932918,0.00022851476],"about_ca_topic_score_codex":0.00020660424,"about_ca_topic_score_gemma":0.00023388561,"teacher_disagreement_score":0.64214504,"about_ca_system_score_codex":0.000015206192,"about_ca_system_score_gemma":0.00024197112,"threshold_uncertainty_score":0.5911989},"labels":[],"label_agreement":null},{"id":"W2132940815","doi":"10.1093/annonc/mdl355","title":"Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Montmorency","funders":"Sanofi; Amgen","keywords":"Medicine; Epirubicin; Docetaxel; Regimen; Internal medicine; Cyclophosphamide; Gastroenterology; Febrile neutropenia; Anthracycline; Breast cancer; Neutropenia; Chemotherapy regimen; Taxane; Chemotherapy; Oncology; Surgery; Urology; Cancer","score_opus":0.025552655059859108,"score_gpt":0.3412828668037834,"score_spread":0.3157302117439243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132940815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648844,0.019402813,0.00002239598,0.010881467,0.0006475359,0.0023779785,0.0010778331,0.00004509956,0.0006604953],"genre_scores_gemma":[0.9746762,0.019839028,0.00017893473,0.0028007326,0.00029725546,0.00074036117,0.0001781394,0.000093628136,0.0011957524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949841,0.0008981924,0.001339345,0.0012960314,0.00045887358,0.0010234758],"domain_scores_gemma":[0.99688625,0.0007887058,0.0009134055,0.00080045353,0.0004210667,0.00019010309],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013120761,0.00087905617,0.0021146126,0.00015698216,0.00039126578,0.000033498494,0.00055884017,0.00044863357,0.00012640482],"category_scores_gemma":[0.0002566648,0.00060108176,0.00041849737,0.00051532086,0.0012007458,0.000053764616,0.00038485712,0.00040579302,0.000009449824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7057801,0.0121280225,0.016721841,0.00012869769,0.005001704,0.0007039181,0.0024268518,0.0002893442,0.10325457,0.000057477613,0.10152004,0.051987424],"study_design_scores_gemma":[0.7355835,0.015650347,0.06512957,0.00040307298,0.0016799371,0.0003507755,0.0026974347,0.00007746578,0.1288302,0.00029638005,0.0469979,0.0023034401],"about_ca_topic_score_codex":0.013672867,"about_ca_topic_score_gemma":0.004216051,"teacher_disagreement_score":0.054522134,"about_ca_system_score_codex":0.00023289805,"about_ca_system_score_gemma":0.0006198207,"threshold_uncertainty_score":0.99964404},"labels":[],"label_agreement":null},{"id":"W2133050123","doi":"10.1093/annonc/mdq466","title":"Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Seminoma; Medicine; Testicular cancer; Population; Cohort; Radiation therapy; Chemotherapy; Internal medicine; Surgery; Gynecology","score_opus":0.04108127153693527,"score_gpt":0.3689397026561321,"score_spread":0.3278584311191968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133050123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985124,0.00019233144,0.0001696587,0.00023024633,0.00002277015,0.0003752476,0.000013300194,0.0000072892562,0.00047678038],"genre_scores_gemma":[0.9979482,0.000012115205,0.0019179152,0.000030849893,0.0000039099114,0.000021954898,0.000041636315,0.0000067272795,0.000016682607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943703,0.000031830452,0.00020086324,0.00011330444,0.00012944381,0.0000875143],"domain_scores_gemma":[0.9992688,0.00009743181,0.00023274808,0.00012925119,0.00024200839,0.000029782841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006470759,0.00007687248,0.0002819711,0.00012704053,0.000010737973,5.807873e-7,0.00002948286,0.00006046307,0.000023113562],"category_scores_gemma":[0.00006742717,0.00005677286,0.00005147657,0.00019594493,0.00006333871,0.0000322518,0.00000781676,0.000050124803,5.4952767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005069286,0.0015133085,0.9842519,0.00015789717,0.00028441666,0.000019943242,0.00011391065,0.00014306439,0.00086333073,0.0011283455,0.0000061368905,0.011010824],"study_design_scores_gemma":[0.0021539328,0.0014998773,0.9906017,0.00010774902,0.00018803377,0.0000027975973,0.00012837455,0.00024172888,0.004590892,0.00043395962,0.000009974328,0.000040941126],"about_ca_topic_score_codex":0.00041185363,"about_ca_topic_score_gemma":0.000114000744,"teacher_disagreement_score":0.010969883,"about_ca_system_score_codex":0.000032559583,"about_ca_system_score_gemma":0.00010970825,"threshold_uncertainty_score":0.231513},"labels":[],"label_agreement":null},{"id":"W2133208325","doi":"10.1093/annonc/mdh031","title":"Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Trastuzumab; Medicine; Internal medicine; Oncology; Chemotherapy; Cisplatin; Lung cancer; Breast cancer; Cancer","score_opus":0.09359131375202594,"score_gpt":0.46961814393279155,"score_spread":0.3760268301807656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133208325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710367,0.0007521531,0.00021502258,0.0016556876,0.0001720039,0.0040304977,0.000036349105,0.000011625381,0.022089975],"genre_scores_gemma":[0.99463844,0.00090440403,0.001353439,0.00046350935,0.00012273838,0.00064914423,0.000011493201,0.00004373403,0.0018130692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99691546,0.00077521184,0.0009249526,0.00038799303,0.0004531819,0.0005431993],"domain_scores_gemma":[0.9976724,0.00082898594,0.0004298276,0.00032839744,0.0005461326,0.00019426302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023456626,0.0002467242,0.0020453637,0.0003267022,0.000043104923,0.0000044319104,0.00016410109,0.0002471567,0.00083827524],"category_scores_gemma":[0.0006677067,0.00017043704,0.00018155151,0.000532261,0.00045498094,0.000058102487,0.000042473992,0.00045606509,0.000002925137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9727659,0.0051843524,0.0015476611,0.00038010732,0.00039732864,0.00020531724,0.0031035587,0.0000452561,0.003930291,0.00006374787,0.0019388204,0.010437643],"study_design_scores_gemma":[0.9094246,0.035389293,0.00012818455,0.00050033454,0.00025997,0.000033627155,0.00040375543,0.0006179571,0.050610527,0.000026201373,0.0024244008,0.0001811193],"about_ca_topic_score_codex":0.0015932829,"about_ca_topic_score_gemma":0.0012297885,"teacher_disagreement_score":0.06334128,"about_ca_system_score_codex":0.00018878667,"about_ca_system_score_gemma":0.003389291,"threshold_uncertainty_score":0.9178526},"labels":[],"label_agreement":null},{"id":"W2133373817","doi":"10.1093/annonc/mdn377","title":"Phase I clinical trial of i.v. ascorbic acid in advanced malignancy","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":372,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Lotte and John Hecht Memorial Foundation","keywords":"Medicine; Ascorbic acid; Malignancy; Clinical trial; Internal medicine; Oncology; Food science","score_opus":0.30114774149834606,"score_gpt":0.5451729856346759,"score_spread":0.2440252441363298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133373817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244004,0.00050039607,0.000016632146,0.0017907147,0.00065687875,0.00032993258,0.000011838559,0.000010744137,0.004242804],"genre_scores_gemma":[0.9977245,0.0012226194,0.00042707857,0.00028379433,0.00015162765,0.000012338576,0.0000047628205,0.000011935391,0.00016138614],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99787956,0.00043449106,0.0008942976,0.0002344685,0.0002210182,0.00033616272],"domain_scores_gemma":[0.99880105,0.00043400604,0.0002780227,0.0002449682,0.00016169118,0.0000802757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009811342,0.00009644328,0.0006300425,0.00018327883,0.000033106935,0.0000015399874,0.00022659166,0.00020448038,0.00009672181],"category_scores_gemma":[0.0008852089,0.00008946276,0.00018396175,0.0002746701,0.00037130323,0.00010153897,0.00005087726,0.0002580438,0.000023522232],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08899414,0.011797779,0.0064332765,0.000076381344,0.0000417679,0.00024184512,0.00042135696,0.00000470179,0.048877645,0.00015651749,0.005162721,0.83779186],"study_design_scores_gemma":[0.39368808,0.14839813,0.044679467,0.00037925845,0.00003353985,0.00008990494,0.0003629658,0.00013221226,0.34176496,0.0017420291,0.068275094,0.00045436333],"about_ca_topic_score_codex":0.00003468721,"about_ca_topic_score_gemma":0.0000267759,"teacher_disagreement_score":0.8373375,"about_ca_system_score_codex":0.000014297821,"about_ca_system_score_gemma":0.00016464555,"threshold_uncertainty_score":0.36481854},"labels":[],"label_agreement":null},{"id":"W2133885975","doi":"10.1093/annonc/mdj099","title":"The advisory process for anticancer drug regulation: a global perspective","year":2005,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Regulatory science; Medicine; Transparency (behavior); Agency (philosophy); Advisory committee; Drug development; Regulatory affairs; Regulatory agency; Food and drug administration; Public relations; Drug; Pharmacology; Political science; Public administration; Pathology; Law","score_opus":0.21860981753266653,"score_gpt":0.5513406216296822,"score_spread":0.3327308040970157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133885975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017943445,0.94291663,0.00006735238,0.047828928,0.00027590521,0.001148262,0.000043803302,0.000015718253,0.007701597],"genre_scores_gemma":[0.00027078486,0.9966223,0.00013181598,0.0006465489,0.0010535923,0.00014342215,0.000053796542,0.000018038541,0.001059647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985149,0.000112878035,0.0005622296,0.00027986275,0.00028364419,0.00024651174],"domain_scores_gemma":[0.9976995,0.00047280558,0.0005295352,0.00024017287,0.00095527375,0.00010271556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007862752,0.00018571787,0.0011403372,0.000054926724,0.00011262963,0.0000061167643,0.0001576065,0.0005967039,0.000040012885],"category_scores_gemma":[0.00027346407,0.00010428816,0.00045017543,0.0002868437,0.0010132884,0.000027551134,0.000031783067,0.0003020209,0.000006463584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094794304,0.00011921975,6.787383e-7,0.0033151908,0.00023956326,0.0000016055574,0.0001233311,4.983619e-7,6.0235415e-8,0.028013578,0.006619694,0.9614718],"study_design_scores_gemma":[0.0004142133,0.0005559661,0.000042358224,0.0023859525,0.00051399134,0.000046589023,0.00015116954,0.00004548843,6.8530954e-7,0.013189544,0.98255527,0.00009877272],"about_ca_topic_score_codex":0.000012680015,"about_ca_topic_score_gemma":0.00004510498,"teacher_disagreement_score":0.9759356,"about_ca_system_score_codex":0.00021616908,"about_ca_system_score_gemma":0.0023952546,"threshold_uncertainty_score":0.46023268},"labels":[],"label_agreement":null},{"id":"W2133950343","doi":"10.1093/annonc/13.s1.92","title":"Current clinical trials for advanced Hodgkin's lymphoma in North America: history, design and rationale","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Hodgkin lymphoma; Lymphoma; Clinical trial; Current (fluid); Medical physics; Oncology; Intensive care medicine; Internal medicine","score_opus":0.6356551969923488,"score_gpt":0.551617626287587,"score_spread":0.08403757070476181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133950343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018544454,0.9945708,0.0001059293,0.00040133353,0.0006012122,0.0038466153,0.00008163276,0.000011742823,0.00019526975],"genre_scores_gemma":[0.000043517826,0.99467146,0.0025549144,0.00040693404,0.00028031148,0.0016423375,0.00026439776,0.000029790226,0.00010636085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567527,0.0013064184,0.0020799772,0.0005082929,0.00015298105,0.00027703497],"domain_scores_gemma":[0.99156964,0.00634189,0.0014513563,0.0002810339,0.0001808465,0.00017523965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017779814,0.00033069754,0.005023722,0.00024915955,0.000021212221,0.000003258102,0.0001028344,0.00033257937,0.00008097312],"category_scores_gemma":[0.0022499457,0.00024191217,0.0008512019,0.00013825211,0.00018674279,0.000038028516,0.000037719434,0.000118711694,0.00001850137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029130734,0.0024485362,0.00017025348,0.0023004704,0.0003482297,0.000044852964,0.00004028051,0.0000010470276,3.1008252e-8,0.0000442501,0.030595897,0.96371484],"study_design_scores_gemma":[0.006030824,0.006048079,0.00046361837,0.0018165426,0.0011508219,0.000034534198,0.0000050367285,0.000016807518,5.0806113e-7,0.00003271822,0.9842298,0.00017071121],"about_ca_topic_score_codex":0.000008930283,"about_ca_topic_score_gemma":0.000017256176,"teacher_disagreement_score":0.96354413,"about_ca_system_score_codex":0.00047263535,"about_ca_system_score_gemma":0.0015351279,"threshold_uncertainty_score":0.98648924},"labels":[],"label_agreement":null},{"id":"W2133972053","doi":"10.1093/annonc/mdv039","title":"Choosing a better end point for trials of bone-protective agents","year":2015,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; End point; Clinical trial; Clinical endpoint; Point (geometry); Oncology; Medical physics; Intensive care medicine; Internal medicine; Cancer","score_opus":0.3414075982576814,"score_gpt":0.4863874198059971,"score_spread":0.14497982154831568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133972053","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0124164205,0.0015201424,0.00008653066,0.9755991,0.00081373064,0.004050156,0.0007318546,0.000022856788,0.004759217],"genre_scores_gemma":[0.01885684,0.0001981188,0.0030478796,0.9721874,0.0023888254,0.0006266231,0.00088903634,0.000096799435,0.001708463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996762,0.00047643212,0.0014790811,0.00038374405,0.00037489415,0.00052387844],"domain_scores_gemma":[0.99594134,0.0009780638,0.0017388336,0.0003931249,0.0007817878,0.00016682495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023967153,0.00029780492,0.0029064715,0.00035798724,0.00003366662,0.0000030901028,0.000089962174,0.0012297159,0.00018842329],"category_scores_gemma":[0.0018734628,0.00023463393,0.00060795277,0.00010087213,0.00014487786,0.000041842508,0.000044273682,0.00069281267,0.000018559162],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017564133,0.00033451684,0.00014412023,0.00094630785,0.0008172248,0.00027482086,0.00023441834,1.0338822e-7,0.00010673471,0.0000042259385,0.9260605,0.06932059],"study_design_scores_gemma":[0.007678376,0.009233153,0.0008261792,0.00042688928,0.0006808785,0.00009136013,0.000024543206,0.0000035263934,0.0026918545,0.0028293093,0.97535944,0.00015450211],"about_ca_topic_score_codex":0.00043192037,"about_ca_topic_score_gemma":0.000020228219,"teacher_disagreement_score":0.06916609,"about_ca_system_score_codex":0.00014534878,"about_ca_system_score_gemma":0.0011397066,"threshold_uncertainty_score":0.9568094},"labels":[],"label_agreement":null},{"id":"W2133980627","doi":"10.1093/annonc/mdr155","title":"Dietary cholesterol intake and cancer","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Medicine; Internal medicine; Prostate; Cholesterol; Cancer; Gastroenterology; Odds ratio; Pancreas; Physiology; Rectum; Lung; Oncology; Endocrinology","score_opus":0.0849307893482475,"score_gpt":0.3503520531963933,"score_spread":0.2654212638481458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133980627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97782576,0.008255669,0.000017680268,0.0005432787,0.0027333912,0.000104129416,0.000029937883,0.0000060521293,0.0104840975],"genre_scores_gemma":[0.9752512,0.016970614,0.0002789562,0.0031020115,0.0036652545,0.00003418184,0.000016236721,0.000015051245,0.00066650653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939716,0.00003951902,0.00015706247,0.00019336845,0.00004246716,0.0001703982],"domain_scores_gemma":[0.99958944,0.0000056875724,0.00008350874,0.00016985019,0.000078703684,0.000072807765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117359,0.0000891386,0.00018701206,0.000030409386,0.000022427475,0.000002044104,0.00009879077,0.0001409311,0.000063672844],"category_scores_gemma":[0.000020380721,0.00008258358,0.000053775566,0.000030723033,0.00014877456,0.0000033378606,0.00007697354,0.000056687302,0.0000026731552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004369642,0.00021671609,0.013599997,0.000041892286,0.00017224406,3.923467e-7,0.00082381873,0.000001864799,0.2524589,0.00015621253,0.09114069,0.6409503],"study_design_scores_gemma":[0.0004573431,0.0008235037,0.04922606,0.0000063816856,0.000019864485,0.000009887357,0.00006643099,0.0000014854621,0.063102484,0.00012697477,0.8860644,0.00009516616],"about_ca_topic_score_codex":0.0003470329,"about_ca_topic_score_gemma":0.00046954656,"teacher_disagreement_score":0.7949237,"about_ca_system_score_codex":0.0000025355148,"about_ca_system_score_gemma":0.00008676334,"threshold_uncertainty_score":0.33676606},"labels":[],"label_agreement":null},{"id":"W2134546050","doi":"10.1093/annonc/mdq361","title":"Clinical validation of an autoantibody test for lung cancer","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":242,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"University of Nottingham","keywords":"Medicine; Autoantibody; Lung cancer; Oncology; Test (biology); Internal medicine; Immunology; Antibody","score_opus":0.06774013688497481,"score_gpt":0.45795860631455415,"score_spread":0.39021846942957933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134546050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945775,0.0017281632,0.00012908563,0.0009080064,0.0016889136,0.00029756062,0.0000917506,0.000021246617,0.00055777084],"genre_scores_gemma":[0.99745935,0.0006431546,0.0004960841,0.00035313817,0.00007405068,0.000038595437,0.00009387804,0.0000145758395,0.0008271884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986554,0.00027773035,0.0006210631,0.0001860206,0.000021330303,0.00023846],"domain_scores_gemma":[0.99751765,0.0014271372,0.0004215864,0.00029340875,0.00032503062,0.000015204735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001164729,0.000107214495,0.0004616137,0.000097038275,0.00007141189,0.0000031990862,0.0002511844,0.00048196758,0.00067654485],"category_scores_gemma":[0.0006894875,0.00009417984,0.00017472642,0.00007569264,0.00042372747,0.00012986356,0.000030520267,0.00026491913,0.000008007515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012716256,0.0008486093,0.009069342,0.000026244812,0.00020764083,4.895525e-7,0.00018954655,0.0000024537683,0.85060596,0.000520805,0.002837329,0.13441992],"study_design_scores_gemma":[0.001870727,0.0038788314,0.030211251,0.00001764585,0.000049055267,0.0000141707815,0.000055882625,0.00002687857,0.79171735,0.00012956688,0.171924,0.00010463548],"about_ca_topic_score_codex":0.00012083102,"about_ca_topic_score_gemma":0.000039909595,"teacher_disagreement_score":0.16908666,"about_ca_system_score_codex":0.0000048461984,"about_ca_system_score_gemma":0.00031547202,"threshold_uncertainty_score":0.74076915},"labels":[],"label_agreement":null},{"id":"W2134726500","doi":"10.1093/annonc/mdn549","title":"Reply to the letter “About sorafenib in castration-resistant prostate cancer” by G. Colloca, F. Checcaglini and A. Venturino","year":2008,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia","funders":"","keywords":"Medicine; Sorafenib; Prostate cancer; Discontinuation; Castration; Population; Oncology; Internal medicine; Antiandrogen; Androgen; Urology; Gynecology; Cancer; Hepatocellular carcinoma; Hormone","score_opus":0.07694193941573961,"score_gpt":0.39032747025996956,"score_spread":0.31338553084422993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134726500","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.083979666,0.011404817,3.057621e-7,0.9012224,0.00024802895,0.0015880329,0.00038592948,0.00001308331,0.0011577382],"genre_scores_gemma":[0.016759627,0.023476489,0.000046942852,0.9399723,0.0015503694,0.00076273404,0.00046810176,0.00005840323,0.016905043],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977074,0.00018527711,0.0005666321,0.0005152617,0.00041434736,0.0006110587],"domain_scores_gemma":[0.99875605,0.00019222981,0.0002446874,0.00041072402,0.00027631092,0.00011999912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034179696,0.0002900376,0.0007810439,0.00021943793,0.00009340417,0.000017367394,0.00018520524,0.000443096,0.00007713254],"category_scores_gemma":[0.00006775665,0.00019496141,0.00010940046,0.0002751328,0.00035060354,0.000046237958,0.00008557221,0.0011239199,0.000017863707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013960684,0.00013145762,0.0013034556,0.00024540923,0.00019370497,0.0017985348,0.00092438323,0.0000033967824,0.0009336822,0.0000015323611,0.9871357,0.005932693],"study_design_scores_gemma":[0.0020207185,0.00228256,0.0032878558,0.00026163517,0.00005574107,0.000058774272,0.000045355162,0.0000026432801,0.0031647112,0.000019053718,0.98863,0.00017096628],"about_ca_topic_score_codex":0.0017928976,"about_ca_topic_score_gemma":0.00048777994,"teacher_disagreement_score":0.06722004,"about_ca_system_score_codex":0.00019458613,"about_ca_system_score_gemma":0.0010614408,"threshold_uncertainty_score":0.7950296},"labels":[],"label_agreement":null},{"id":"W2135001286","doi":"10.1093/annonc/mdv181","title":"Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":574,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Care Ontario","keywords":"Medicine; PsycINFO; CINAHL; MEDLINE; Patient-reported outcome; Systematic review; Health care; Standardization; Quality of life (healthcare); Family medicine; Nursing; Psychological intervention","score_opus":0.4290304824364584,"score_gpt":0.6549350456140346,"score_spread":0.22590456317757618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135001286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049816263,0.9879812,5.614006e-7,0.002912713,0.0005114081,0.003184035,0.00026762963,0.000010762658,0.0001500444],"genre_scores_gemma":[0.0008702299,0.9938317,0.000041511914,0.0046829064,0.000043166037,0.00012414042,0.0003564802,0.000034585802,0.000015289583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943537,0.001106568,0.00333512,0.00041984863,0.00044539638,0.00033933748],"domain_scores_gemma":[0.9926086,0.0018538497,0.0042490317,0.00042727488,0.00060003897,0.00026117425],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002723343,0.00038344934,0.0061287717,0.00028745687,0.000017125232,0.000005249138,0.000081806655,0.00030807836,0.000092777314],"category_scores_gemma":[0.0024422735,0.00024748745,0.0006627111,0.0003512495,0.00007922154,0.00011726031,0.00009663367,0.00050084345,9.867747e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106232255,0.0003373924,0.108337514,0.073446795,0.00057102146,0.000021276124,0.00023168804,6.4493214e-8,6.7679835e-9,0.000006125248,0.0025421851,0.8143997],"study_design_scores_gemma":[0.0018398202,0.007878987,0.04453561,0.33745143,0.0013041729,0.000040627314,0.00031166038,1.094809e-7,4.0413457e-7,0.0000053763542,0.6063623,0.00026954687],"about_ca_topic_score_codex":0.012713921,"about_ca_topic_score_gemma":0.0051767975,"teacher_disagreement_score":0.8141301,"about_ca_system_score_codex":0.0003716014,"about_ca_system_score_gemma":0.0060152262,"threshold_uncertainty_score":0.99999774},"labels":[],"label_agreement":null},{"id":"W2135250589","doi":"10.1093/annonc/mdp473","title":"Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Stage (stratigraphy); Germ cell tumors; Oncology; Testicular cancer; Intensive care medicine; Germ cell; Testicular Germ Cell Tumor; Internal medicine; Chemotherapy","score_opus":0.03548657279117345,"score_gpt":0.3241343894607712,"score_spread":0.28864781666959777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135250589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962926,0.00043472272,0.000108346874,0.00033979217,0.00005502219,0.0014691945,0.0002532515,0.00008251753,0.00096454116],"genre_scores_gemma":[0.99708265,0.00007772919,0.0018984604,0.00022286942,0.000040724233,0.000053021282,0.00045997935,0.000038451224,0.00012610832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982147,0.00008934097,0.000500002,0.0004532486,0.00023207367,0.00051060773],"domain_scores_gemma":[0.997652,0.0006045873,0.00065540033,0.0004208917,0.0003721987,0.0002949017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019926,0.0003275843,0.0008199674,0.00011258403,0.00013105817,0.000015276932,0.000103705104,0.00015636803,0.000029877316],"category_scores_gemma":[0.00045167754,0.00024669897,0.00022680408,0.00020057759,0.00009320852,0.00007896221,0.000021930193,0.00012592316,0.00001310479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026309097,0.0119482195,0.94273406,0.00008241368,0.0005844795,0.00067589624,0.0004169081,0.00038474367,0.00020453804,0.000029993751,0.0003886787,0.039919145],"study_design_scores_gemma":[0.016559666,0.02825683,0.9514537,0.00015200592,0.00042156025,0.000025649919,0.00008504598,0.00089019974,0.0008828786,0.000051628504,0.00097138045,0.00024947512],"about_ca_topic_score_codex":0.00016580256,"about_ca_topic_score_gemma":0.000016663225,"teacher_disagreement_score":0.03966967,"about_ca_system_score_codex":0.00011861006,"about_ca_system_score_gemma":0.00038161522,"threshold_uncertainty_score":0.9999985},"labels":[],"label_agreement":null},{"id":"W2135395701","doi":"10.1093/annonc/11.suppl_1.s107","title":"Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Medical Research Council; Genentech; International Myeloma Foundation","keywords":"Medicine; CD20; Plasma cell; Rituximab; Antigen; Multiple myeloma; Immunology; Macroglobulinemia; Antibody; Plasma cell leukemia; Cancer research","score_opus":0.052945559003264336,"score_gpt":0.39305950612971663,"score_spread":0.34011394712645227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135395701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936079,0.0024611882,0.0000063458747,0.0007391118,0.000029871904,0.00061237684,0.00015423176,0.000015544449,0.0023734348],"genre_scores_gemma":[0.98565775,0.013337926,0.00033807644,0.0000511801,0.000030509174,0.000023953788,0.00020874513,0.000018657873,0.0003332071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99862576,0.00014878045,0.0004506228,0.00025016014,0.00022482823,0.00029987912],"domain_scores_gemma":[0.99884444,0.0002736357,0.00021906967,0.00022382909,0.0003062263,0.0001328198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012535311,0.00017598788,0.00074716855,0.00018870659,0.00004136234,0.0000019731203,0.00005725189,0.00018669285,0.00028453485],"category_scores_gemma":[0.00008410647,0.00013770725,0.000118105294,0.00026345064,0.00032135457,0.00006578055,0.00001084001,0.00007787779,0.0000081954895],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042271847,0.0026404737,0.114578635,0.000045043194,0.0009284613,0.000037193004,0.00090489816,9.058797e-7,0.4417002,0.000008517991,0.00033922875,0.4345893],"study_design_scores_gemma":[0.009507646,0.020780047,0.5293503,0.000036626032,0.00005469428,0.00007083982,0.00014173768,0.00011556538,0.4278379,0.00003209105,0.011979662,0.000092927876],"about_ca_topic_score_codex":0.00092249736,"about_ca_topic_score_gemma":0.000041839714,"teacher_disagreement_score":0.43449634,"about_ca_system_score_codex":0.000054868564,"about_ca_system_score_gemma":0.0001968919,"threshold_uncertainty_score":0.56155384},"labels":[],"label_agreement":null},{"id":"W2135696440","doi":"10.1093/annonc/mds080","title":"Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; Universitat Autònoma de Barcelona; Japan Society for the Promotion of Science; National Cancer Institute; Sociedad Española de Oncología Médica; V Foundation for Cancer Research; Breast Cancer Research Foundation","keywords":"Medicine; Concordance; Tamoxifen; Breast cancer; Oncology; Adjuvant; Internal medicine; Cancer; Gynecology","score_opus":0.022681636330890816,"score_gpt":0.31721726711062553,"score_spread":0.2945356307797347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135696440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431515,0.0018933982,0.0006405679,0.0008353433,0.00013255277,0.00045544625,0.0012346136,0.00001652928,0.00047638774],"genre_scores_gemma":[0.99715775,0.00018833656,0.00079803896,0.0005761825,0.00036412192,0.000534966,0.00025454562,0.000032919375,0.000093150215],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988524,0.00007520378,0.00022170744,0.0003100493,0.00010623857,0.00043441297],"domain_scores_gemma":[0.99895644,0.00007265274,0.00025299174,0.00023746141,0.00034296612,0.00013751221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001139074,0.00022668189,0.00037669853,0.00004014826,0.000085078376,0.0000034942154,0.00012921919,0.00016856028,0.00002551728],"category_scores_gemma":[0.00002355824,0.00017110983,0.00010448553,0.00007912273,0.00031871776,0.000010651767,0.000051253057,0.000053746975,0.0000011474789],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036992093,0.0006866467,0.864248,0.00004311838,0.0005736044,0.000005311502,0.00022379194,0.0001564197,0.116920896,0.000011433962,0.0052945158,0.008137067],"study_design_scores_gemma":[0.0019604135,0.0012237675,0.41553205,0.000049025413,0.00009955877,0.000015357418,0.000058542544,0.000009268176,0.57837474,0.0000043094365,0.0025059567,0.00016702688],"about_ca_topic_score_codex":0.00031351397,"about_ca_topic_score_gemma":0.00014147254,"teacher_disagreement_score":0.46145383,"about_ca_system_score_codex":0.000040880874,"about_ca_system_score_gemma":0.00019686097,"threshold_uncertainty_score":0.69776565},"labels":[],"label_agreement":null},{"id":"W2135802413","doi":"10.1093/annonc/mdr541","title":"Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":411,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Toronto; Public Health Ontario; Toronto General Hospital","funders":"National Cancer Institute; National Institutes of Health; Associazione Italiana per la Ricerca sul Cancro; Canadian Institutes of Health Research; Cancer Research Society; Lustgarten Foundation","keywords":"Medicine; Pancreatic cancer; Odds ratio; Confidence interval; Internal medicine; Cigarette smoking; Case-control study; Cancer; Demography","score_opus":0.12252244218573848,"score_gpt":0.40988091880539856,"score_spread":0.2873584766196601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135802413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817289,0.0044693747,0.0001438503,0.007123956,0.00019877708,0.00047514922,0.00031368423,0.000029368619,0.0055169333],"genre_scores_gemma":[0.98971117,0.004097941,0.00036928797,0.004916641,0.00033042472,0.0002363129,0.000036904705,0.00002142679,0.00027990385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977336,0.00039358105,0.00062238827,0.0004461913,0.00035508897,0.00044915546],"domain_scores_gemma":[0.99714524,0.0012646262,0.0003719963,0.00048851676,0.00046778884,0.0002618453],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010021933,0.00022296888,0.0012750567,0.00022699604,0.00015089453,0.000015606614,0.00027810637,0.00026018554,0.002805499],"category_scores_gemma":[0.00038811643,0.00015549395,0.00018624372,0.00033028363,0.00060444087,0.00012005775,0.00008552539,0.0003787098,0.000004013573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010283949,0.0002680563,0.96111655,0.000024030367,0.010363515,0.0007913579,0.0023353815,0.000007641982,0.00030809006,0.00025351037,0.0010696771,0.022433791],"study_design_scores_gemma":[0.0027386853,0.0012032096,0.97657335,0.00009106877,0.011238675,0.00027363424,0.001316559,0.0038207956,0.0004033806,0.0005498438,0.0016192985,0.00017148806],"about_ca_topic_score_codex":0.03658863,"about_ca_topic_score_gemma":0.009098692,"teacher_disagreement_score":0.027489938,"about_ca_system_score_codex":0.000116433956,"about_ca_system_score_gemma":0.0006054256,"threshold_uncertainty_score":0.99810606},"labels":[],"label_agreement":null},{"id":"W2135936056","doi":"10.1093/annonc/mdp245","title":"Breast carcinoma—rare types: review of the literature","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Breast Lesions and Carcinomas","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Disease; Pathological; Cancer; Histopathology; Presentation (obstetrics); Pathology; Oncology; Internal medicine; Surgery","score_opus":0.09255720997854443,"score_gpt":0.4061033569379084,"score_spread":0.31354614695936395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135936056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015622638,0.9811194,1.668835e-7,0.0037628873,0.00017711207,0.0008309509,0.00025858512,0.000009703374,0.013825548],"genre_scores_gemma":[0.0001793535,0.99525136,0.000042453907,0.0027662248,0.00027401955,0.00002429748,0.00013965061,0.000028830567,0.0012937948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979146,0.00036433848,0.0009114539,0.00029608473,0.0002564982,0.00025701316],"domain_scores_gemma":[0.9973989,0.00011568353,0.0008350403,0.00093664153,0.000596664,0.00011705305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043145937,0.00032462843,0.0030617875,0.00014192548,0.000031190593,0.000003109995,0.00038931612,0.0005813185,0.00023773575],"category_scores_gemma":[0.00010221416,0.00017470917,0.0013449341,0.0006910847,0.00014717855,0.00002671244,0.00010935665,0.0006323256,0.000021683725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015057018,0.00016907499,0.000013190173,0.13101445,0.00010558563,0.000053434895,0.000025860092,4.095285e-9,4.7698455e-7,0.00019221182,0.029779019,0.83863163],"study_design_scores_gemma":[0.00014641295,0.0004542296,0.0007930723,0.22562169,0.0011052833,0.0038813157,0.0000044735143,4.6694222e-8,0.0000017028296,0.000023494606,0.7678687,0.00009959509],"about_ca_topic_score_codex":0.000010704698,"about_ca_topic_score_gemma":0.0000017567171,"teacher_disagreement_score":0.83853203,"about_ca_system_score_codex":0.000042339434,"about_ca_system_score_gemma":0.0013596155,"threshold_uncertainty_score":0.7124433},"labels":[],"label_agreement":null},{"id":"W2136250503","doi":"10.1093/annonc/mdt203.214","title":"Use of Adjuvant Chemotherapy (AC) and Outcomes in Stage II Colon Cancer (CC) with Versus Without Poor Prognostic Features","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Perineural invasion; Internal medicine; Lymphovascular invasion; Stage (stratigraphy); Proportional hazards model; Oncology; Perforation; Colorectal cancer; Cancer; Gastroenterology; Surgery; Metastasis","score_opus":0.10044342678060995,"score_gpt":0.40219273099062774,"score_spread":0.3017493042100178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136250503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911799,0.00075811567,4.790042e-7,0.006214419,0.00008282505,0.0009892383,0.000026965145,0.000014377788,0.0007336945],"genre_scores_gemma":[0.996648,0.00072719005,0.0004419819,0.0008467146,0.00001689532,0.0001933045,0.0000061854316,0.000018405077,0.0011013115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990505,0.000054685188,0.00025585815,0.00022410578,0.000172065,0.00024281391],"domain_scores_gemma":[0.9990165,0.00035419824,0.00018348535,0.00014872891,0.00019139447,0.00010564293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007991268,0.00015957243,0.0007472964,0.00010709854,0.000019787361,0.000004325836,0.000053452008,0.0001242542,0.00016735785],"category_scores_gemma":[0.00013010325,0.00010556339,0.00005198711,0.00015422859,0.0002225209,0.000093481176,0.000043757966,0.0001313355,0.0000015142865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00895148,0.002009749,0.9451757,0.00009647916,0.0004324344,0.00007849428,0.00061689154,0.000006379395,0.0011028808,0.00003244989,0.0007738359,0.0407232],"study_design_scores_gemma":[0.014860363,0.015347518,0.9588808,0.00012604693,0.000076529876,0.000012015049,0.00009828062,0.000026863117,0.0052151782,0.000016899632,0.0052341,0.00010539464],"about_ca_topic_score_codex":0.0035980337,"about_ca_topic_score_gemma":0.002905629,"teacher_disagreement_score":0.040617805,"about_ca_system_score_codex":0.00007222269,"about_ca_system_score_gemma":0.00020124076,"threshold_uncertainty_score":0.5439175},"labels":[],"label_agreement":null},{"id":"W2136285593","doi":"10.1093/annonc/mdu186","title":"Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF","funders":"Sanofi","keywords":"Medicine; Taxane; Epirubicin; Breast cancer; Internal medicine; Hazard ratio; Oncology; Cyclophosphamide; Surrogate endpoint; Clinical endpoint; Chemotherapy; Proportional hazards model; Chemotherapy regimen; Cancer; Clinical trial; Confidence interval","score_opus":0.025569960681268628,"score_gpt":0.3565985109362326,"score_spread":0.331028550254964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136285593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979395,0.000394488,0.000045717265,0.0002435227,0.0002205917,0.00039195066,0.0004842295,0.000002702293,0.00027725677],"genre_scores_gemma":[0.99903005,0.0006524261,0.00003455729,0.00002760276,0.00012920305,0.00008178909,0.000023912913,0.000008911992,0.000011570916],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986701,0.0002871787,0.0003903211,0.00032631712,0.00013691984,0.00018916444],"domain_scores_gemma":[0.9987657,0.00017299569,0.0005374762,0.00027464668,0.00020463597,0.00004453665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026381528,0.00015918915,0.00060066796,0.00011770578,0.000043052278,0.0000024933756,0.00017567501,0.00015540633,0.000009885488],"category_scores_gemma":[0.00017912038,0.00011555765,0.00017770565,0.00025961656,0.000438318,0.0000068928375,0.00019683818,0.00010852996,1.3705106e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46898213,0.004510753,0.38221073,0.00007085728,0.0073793805,0.00000393019,0.00435015,0.0013076484,0.07218646,0.000119446035,0.0005844037,0.058294114],"study_design_scores_gemma":[0.07110676,0.0077689355,0.835304,0.000054737076,0.0008527119,0.0000013331462,0.00018854329,0.00013350138,0.08424791,0.00005913433,0.00016758328,0.000114815346],"about_ca_topic_score_codex":0.00087780925,"about_ca_topic_score_gemma":0.0005620459,"teacher_disagreement_score":0.4530933,"about_ca_system_score_codex":0.0000335623,"about_ca_system_score_gemma":0.000136446,"threshold_uncertainty_score":0.47123042},"labels":[],"label_agreement":null},{"id":"W2136646477","doi":"10.1093/annonc/mdr435","title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":813,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Cancer Research UK","keywords":"Medicine; Osteonecrosis of the jaw; Denosumab; Zoledronic acid; Incidence (geometry); Internal medicine; Surgery; Bisphosphonate; Osteoporosis","score_opus":0.19935763775179896,"score_gpt":0.4697739067605519,"score_spread":0.27041626900875293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136646477","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6009667,0.3924627,0.000003050616,0.000038472983,0.00006818068,0.0025477107,0.003886739,0.0000039356923,0.000022502403],"genre_scores_gemma":[0.37615117,0.62317157,0.00008605196,0.00003806898,0.0000029916448,0.00020195583,0.0003183271,0.00001788237,0.0000119438655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99459714,0.0016988118,0.0026871138,0.00041165485,0.00031302625,0.00029224486],"domain_scores_gemma":[0.9895526,0.003236563,0.006060476,0.0004956491,0.0004969267,0.00015778904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012691178,0.0004842967,0.013381349,0.00083444477,0.000039144816,0.0000029608352,0.00017020894,0.0004290009,0.00017657327],"category_scores_gemma":[0.0016724645,0.0002134848,0.001256331,0.0010794775,0.00029114186,0.000065337146,0.00007007414,0.00038855182,4.0944096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01080346,0.00289105,0.4845785,0.00069750036,0.020876488,0.000005331742,0.00023321754,2.326668e-7,8.6920915e-7,0.0000028190327,0.000024192257,0.47988632],"study_design_scores_gemma":[0.107514866,0.008658031,0.74528587,0.005038801,0.12117411,0.0000012721895,0.00011243698,0.000004534824,0.00022206297,0.000075726835,0.011551134,0.00036117324],"about_ca_topic_score_codex":0.0892243,"about_ca_topic_score_gemma":0.056546178,"teacher_disagreement_score":0.47952515,"about_ca_system_score_codex":0.00009050392,"about_ca_system_score_gemma":0.0012983367,"threshold_uncertainty_score":0.9606694},"labels":[],"label_agreement":null},{"id":"W2136969752","doi":"10.1093/annonc/mdv045.12","title":"Development of Resistance Models to Tyrosine Kinase Inhibitors (TKIS) in Patient-Derived Xenograft Models (PDXS) of Lung Adenocarcinoma with Epidermal Growth Factor Receptor (EGFR) Mutations","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Crizotinib; Erlotinib; Medicine; Gefitinib; Epidermal growth factor receptor; Cancer research; Adenocarcinoma; Erlotinib Hydrochloride; Lung cancer; Afatinib; Osimertinib; Resistance mutation; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Cancer; Internal medicine; Biology; Receptor; Gene","score_opus":0.08761446753943258,"score_gpt":0.36196760566391345,"score_spread":0.27435313812448087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136969752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276614,0.0009637677,0.0016430379,0.0019061465,0.0000756617,0.0008404502,0.000120763485,0.000015737243,0.0016683175],"genre_scores_gemma":[0.9675197,0.00003970029,0.031861283,0.00024104673,0.000019865805,0.00012933402,0.000091556336,0.000024553645,0.00007297255],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982312,0.00007544682,0.00080512266,0.00027809085,0.00032393984,0.00028621804],"domain_scores_gemma":[0.9981196,0.000082478866,0.0003898714,0.0002201685,0.0009452526,0.00024265703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001519269,0.00018681922,0.00063024246,0.00035261596,0.0000353167,0.000002973115,0.000092148795,0.00011045509,0.000019437644],"category_scores_gemma":[0.00007180568,0.00015546624,0.00006574924,0.00045242198,0.00012980055,0.0002109554,0.00004750837,0.0000966841,0.0000019111724],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023446793,0.017498178,0.09827997,0.0029094392,0.0038567558,0.0005018611,0.5619204,0.037406545,0.14158182,0.007858247,0.02456644,0.08017357],"study_design_scores_gemma":[0.026267363,0.016986063,0.0545187,0.0027419513,0.000773156,0.000044526663,0.026648443,0.0031642718,0.8590137,0.0028537842,0.005767048,0.0012210158],"about_ca_topic_score_codex":0.00029946124,"about_ca_topic_score_gemma":0.00046186108,"teacher_disagreement_score":0.71743184,"about_ca_system_score_codex":0.00023524837,"about_ca_system_score_gemma":0.0013467585,"threshold_uncertainty_score":0.633973},"labels":[],"label_agreement":null},{"id":"W2137413455","doi":"10.1093/annonc/mdu569","title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Neutrophil to lymphocyte ratio; Cancer; Lymphocyte","score_opus":0.14609917533377262,"score_gpt":0.44647578360498136,"score_spread":0.3003766082712087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137413455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9443036,0.0022752038,0.007365865,0.026475413,0.00032126572,0.016471457,0.001782914,0.000121599456,0.000882736],"genre_scores_gemma":[0.97731924,0.0008875628,0.013681983,0.0029191156,0.00042122326,0.0032193784,0.0012525673,0.000100939105,0.00019797588],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955175,0.0010721739,0.0016817915,0.0007917321,0.0004185827,0.0005182303],"domain_scores_gemma":[0.9918674,0.0048332815,0.0012527453,0.00092554145,0.0007751151,0.00034589018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0056730057,0.00041348967,0.0025132129,0.00025883171,0.00015038223,0.0000474439,0.000375207,0.0001180111,0.00032035456],"category_scores_gemma":[0.0054694475,0.0002990383,0.00028011264,0.0003277105,0.00033056107,0.00021307702,0.000098053046,0.00010622385,0.000010764005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8650475,0.0011231828,0.0006587128,0.0004202992,0.005534213,0.000078840916,0.00087253057,0.00011213674,0.025292851,0.00010534918,0.008303292,0.092451066],"study_design_scores_gemma":[0.8848145,0.006992446,0.0015516792,0.001083533,0.0059697316,0.00003082993,0.00019982489,0.037101187,0.027310185,0.0012818226,0.032999013,0.00066522235],"about_ca_topic_score_codex":0.0008552704,"about_ca_topic_score_gemma":0.0006102544,"teacher_disagreement_score":0.09178584,"about_ca_system_score_codex":0.00010913288,"about_ca_system_score_gemma":0.0014264983,"threshold_uncertainty_score":0.9999462},"labels":[],"label_agreement":null},{"id":"W2137573211","doi":"10.1093/annonc/mdn696","title":"The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; International Prognostic Index; Peripheral T-cell lymphoma; Leukemia; Oncology; Aggressive lymphoma; Internal medicine; Pathology; Immunology; Diffuse large B-cell lymphoma; T cell; Rituximab","score_opus":0.02414386910890062,"score_gpt":0.2955972990056488,"score_spread":0.2714534298967482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137573211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859885,0.0019662704,0.000008653125,0.0019712746,0.001242341,0.00037000293,0.0002988979,0.000017774737,0.008136313],"genre_scores_gemma":[0.9964866,0.0011341382,0.000022729888,0.0011626235,0.000067012064,0.0000423872,0.0002934826,0.000010041976,0.00078097056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979078,0.0002807279,0.00087947864,0.00036347986,0.00018284742,0.0003856323],"domain_scores_gemma":[0.99714535,0.00091443234,0.0010255531,0.00029980685,0.00059472286,0.000020100411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034494165,0.00024241737,0.00060716015,0.000261669,0.00016461247,0.000017369377,0.0010229284,0.0003105076,0.00006896385],"category_scores_gemma":[0.0006142095,0.00014440522,0.00031017495,0.0003823453,0.0004889467,0.00008337073,0.0002626257,0.00020594284,0.000016262558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001597821,0.0026216025,0.91404355,0.000008671667,0.0024530692,0.000020092984,0.0030941654,0.00011833746,0.0055777277,0.00018190876,0.010352975,0.05993009],"study_design_scores_gemma":[0.008127063,0.0015050472,0.9560914,0.00004591785,0.000372264,0.0000048330335,0.0015221965,0.00030759053,0.007435272,0.0002367846,0.024120003,0.00023164203],"about_ca_topic_score_codex":0.0017072634,"about_ca_topic_score_gemma":0.0014252996,"teacher_disagreement_score":0.059698448,"about_ca_system_score_codex":0.00019398893,"about_ca_system_score_gemma":0.00034564867,"threshold_uncertainty_score":0.58886737},"labels":[],"label_agreement":null},{"id":"W2137730077","doi":"10.1093/annonc/mdi252","title":"Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Folinic acid; Medicine; Nausea; Fluorouracil; Regimen; Gastroenterology; Internal medicine; Cisplatin; Paclitaxel; Chemotherapy; Cancer; Oncology; Surgery","score_opus":0.09314427952994607,"score_gpt":0.4145038926934106,"score_spread":0.3213596131634645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137730077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960445,0.0009269912,0.00006331856,0.0018088546,0.00006675972,0.0009761744,0.000059691585,0.000011037174,0.000042670792],"genre_scores_gemma":[0.9971537,0.0008001408,0.0014072909,0.0004076818,0.00008804304,0.00003439527,0.000027267284,0.000016170152,0.000065286986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985013,0.00017518859,0.00052029773,0.00025683874,0.0002969577,0.00024942358],"domain_scores_gemma":[0.9983214,0.0001742792,0.000745658,0.0001973903,0.00050216535,0.000059072718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032754385,0.00019136604,0.00079192454,0.00021864913,0.000112476555,0.0000053430176,0.00008101477,0.00005895297,0.000024218882],"category_scores_gemma":[0.00022177823,0.000110111214,0.0000363763,0.0006511103,0.0002479725,0.00017025069,0.00007054997,0.00018647009,3.2419427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007954903,0.000703069,0.73963165,0.00008367338,0.0004356078,0.0000044510575,0.0020504443,0.0013754994,0.00022327488,0.000018274492,0.00044553858,0.2470736],"study_design_scores_gemma":[0.04196204,0.040978916,0.9076529,0.00033013758,0.0005968399,0.0000073669235,0.0009443238,0.0047023417,0.0021194066,0.000016540236,0.0004972458,0.00019192466],"about_ca_topic_score_codex":0.00090370874,"about_ca_topic_score_gemma":0.0024408763,"teacher_disagreement_score":0.2468817,"about_ca_system_score_codex":0.00017815606,"about_ca_system_score_gemma":0.0002983343,"threshold_uncertainty_score":0.4490205},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2138075845","doi":"10.1093/annonc/mdp533","title":"Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Cancer Care Ontario; McMaster University; London Health Sciences Centre","funders":"","keywords":"Bevacizumab; Medicine; Internal medicine; Colorectal cancer; Chemotherapy; Oncology; Hazard ratio; Irinotecan; Chemotherapy regimen; Adverse effect; Regimen; Cetuximab; Surgery; Gastrointestinal perforation; Cancer; Confidence interval","score_opus":0.05019558973070794,"score_gpt":0.40765349414573115,"score_spread":0.35745790441502323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138075845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001782086,0.9836542,0.000001981958,0.00085845677,0.00007007837,0.014229961,0.000174966,0.000032829223,0.00079933583],"genre_scores_gemma":[0.00013796394,0.9923073,0.0002882308,0.0012231611,0.000041469706,0.005502677,0.00023964814,0.00006543208,0.00019412085],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99779636,0.000115466,0.00092907145,0.00046611635,0.00030118073,0.00039181812],"domain_scores_gemma":[0.99706924,0.00033284002,0.0013274365,0.0003346081,0.00081754674,0.00011833165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017905707,0.0005757582,0.007606749,0.00012468558,0.00007047411,0.000004883158,0.00016066314,0.00020562415,0.000029044235],"category_scores_gemma":[0.00010203824,0.00030350426,0.0005150555,0.0003483466,0.00012549647,0.000040691804,0.000022154787,0.00017952328,0.0000025543695],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025699867,0.00076942303,0.000017342913,0.5050597,0.002288222,0.000012169529,0.000040486095,5.3102678e-8,1.8953653e-8,0.000011099794,0.0010481331,0.48818332],"study_design_scores_gemma":[0.006053525,0.07225103,0.00007381521,0.52416754,0.009166577,0.000032719192,0.000010675941,2.7922292e-7,0.0000017077241,0.000006526563,0.38793418,0.00030143815],"about_ca_topic_score_codex":0.00001353286,"about_ca_topic_score_gemma":0.000082183215,"teacher_disagreement_score":0.4878819,"about_ca_system_score_codex":0.00031207607,"about_ca_system_score_gemma":0.0009980864,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W2138269659","doi":"10.1093/annonc/mdl115","title":"Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?","year":2006,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Fenretinide; Breast cancer; Randomized controlled trial; Randomization; Gynecology; Cancer; Internal medicine; Mastectomy; Oncology","score_opus":0.03664891471383607,"score_gpt":0.3504580418620738,"score_spread":0.3138091271482377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138269659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92841583,0.0016145639,0.000013140567,0.06425056,0.0002030886,0.0004633563,0.00019856163,0.000003811793,0.0048370715],"genre_scores_gemma":[0.93175673,0.0021532131,0.00005253791,0.061226226,0.0010841041,0.00031541646,0.00048216654,0.000043782064,0.002885806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797106,0.00041002355,0.000632933,0.00036519702,0.00021410063,0.00040670324],"domain_scores_gemma":[0.99891835,0.00007419273,0.0004886478,0.00034734668,0.00015355603,0.000017899178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006392,0.00023009615,0.0004971916,0.000121952115,0.000016816166,0.000006629914,0.0005066853,0.0009925223,0.00014403893],"category_scores_gemma":[0.00006011423,0.00016608012,0.000094288545,0.00018128514,0.00019619841,0.000004487107,0.00008975298,0.0005653346,0.0000016484989],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010505363,0.0007357669,0.005936862,0.0014273965,0.00020330245,0.00025477732,0.0006168234,0.00016555264,0.14038645,0.0000141665405,0.8269626,0.022245789],"study_design_scores_gemma":[0.0014841283,0.0038343181,0.0150500955,0.0002914522,0.00004083327,0.000083156476,0.0002283936,0.000003659173,0.06991933,0.0005865226,0.9080454,0.00043270589],"about_ca_topic_score_codex":0.0002960518,"about_ca_topic_score_gemma":0.00060593564,"teacher_disagreement_score":0.08108282,"about_ca_system_score_codex":0.000051714556,"about_ca_system_score_gemma":0.0007032926,"threshold_uncertainty_score":0.7655241},"labels":[],"label_agreement":null},{"id":"W2138416295","doi":"10.1093/annonc/mdl353","title":"Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Topotecan; Carboplatin; Medicine; Regimen; Internal medicine; Lung cancer; Chemotherapy; Phases of clinical research; Progressive disease; Surgery; Cisplatin; Toxicity; Oncology","score_opus":0.19003189340734147,"score_gpt":0.49725881214030293,"score_spread":0.3072269187329615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138416295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98895335,0.001907427,0.000023322746,0.0019264041,0.000107763895,0.003402808,0.000034256776,0.0000074780237,0.003637215],"genre_scores_gemma":[0.9981631,0.00042335945,0.00009251742,0.00006849192,0.0001268509,0.0007939122,0.000023857083,0.00000935567,0.0002985432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988002,0.00013877841,0.00043550416,0.00019580462,0.0001849877,0.0002447074],"domain_scores_gemma":[0.99856216,0.00070839963,0.00021573945,0.0002097992,0.00026978547,0.00003410995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045465925,0.00012526746,0.00063302694,0.0001000466,0.000072409006,0.0000035615246,0.00008775631,0.00005227514,0.000019342058],"category_scores_gemma":[0.00010694451,0.000087009874,0.000112457616,0.00013351861,0.000096700904,0.000023962255,0.000021707214,0.00007395667,1.8692425e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5824407,0.10393249,0.09237206,0.0017540866,0.0035061238,0.0007357441,0.05753868,0.0022679316,0.050432365,0.0005825519,0.015525892,0.08891142],"study_design_scores_gemma":[0.6273245,0.21990839,0.03891647,0.00014221272,0.0011119014,0.0000047261224,0.012411842,0.0040526767,0.07731864,0.00006165847,0.018446779,0.0003001771],"about_ca_topic_score_codex":0.0023145357,"about_ca_topic_score_gemma":0.007856784,"teacher_disagreement_score":0.115975894,"about_ca_system_score_codex":0.00016178958,"about_ca_system_score_gemma":0.00040042296,"threshold_uncertainty_score":0.438427},"labels":[],"label_agreement":null},{"id":"W2138427587","doi":"10.1093/annonc/mdr120","title":"Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4)","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Toronto; Public Health Ontario; Université de Montréal; Toronto General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Pancreatic cancer; Odds ratio; Confidence interval; Pancreatitis; Internal medicine; Demography; Case-control study; Environmental health; Cancer","score_opus":0.15420398437148525,"score_gpt":0.43797463308626866,"score_spread":0.2837706487147834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138427587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812243,0.0037109142,0.00006671566,0.0062798974,0.00009347418,0.0007659873,0.00009558977,0.000015150693,0.0077479505],"genre_scores_gemma":[0.9880951,0.0075998493,0.00029370992,0.0031166016,0.00009650861,0.00047800838,0.000014927175,0.000011942797,0.00029335657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978631,0.0004594189,0.00063857686,0.00033631278,0.00029711754,0.00040548982],"domain_scores_gemma":[0.9979531,0.00097286666,0.00030317262,0.00031619464,0.00031283146,0.00014179418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013694302,0.00018504226,0.0011530466,0.00047723996,0.000072925584,0.000009570379,0.00019465359,0.0002128332,0.0015790755],"category_scores_gemma":[0.00036516663,0.00013021109,0.00015789366,0.0004256428,0.0005048422,0.00007889969,0.000047725316,0.00031244283,0.000012089464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013213883,0.0004685178,0.97541136,0.00008936158,0.0048363097,0.0013127002,0.0022287378,0.000005794439,0.0005188829,0.00045990173,0.0007824312,0.012564604],"study_design_scores_gemma":[0.00438995,0.0011041177,0.9820464,0.00009469792,0.006919744,0.00085007335,0.0008251228,0.0022573625,0.00020425857,0.0003498759,0.0008227267,0.0001356425],"about_ca_topic_score_codex":0.00945206,"about_ca_topic_score_gemma":0.0066427956,"teacher_disagreement_score":0.012428962,"about_ca_system_score_codex":0.000107343614,"about_ca_system_score_gemma":0.0004867288,"threshold_uncertainty_score":0.9993336},"labels":[],"label_agreement":null},{"id":"W2138498648","doi":"10.1093/annonc/mdm440","title":"Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin’s lymphoma","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mammography; Ductal carcinoma; Breast cancer; Lymphoma; Magnetic resonance imaging; Radiation therapy; Hodgkin lymphoma; Radiology; Cancer; Gynecology; Internal medicine","score_opus":0.04571391059470557,"score_gpt":0.35542855668697315,"score_spread":0.30971464609226756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138498648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167967,0.00048266668,0.0030755962,0.0013280729,0.00006556521,0.0014999278,0.00006544922,0.00004095678,0.0017620936],"genre_scores_gemma":[0.9891203,0.00014595251,0.008691642,0.00093823246,0.00012201937,0.0006453612,0.0001701183,0.000028450766,0.00013791966],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99873936,0.000025749667,0.00037461158,0.00023972336,0.00014002132,0.00048051594],"domain_scores_gemma":[0.9985533,0.00060310477,0.00024079553,0.00018827549,0.00023252152,0.00018202624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005946358,0.00016662448,0.00053472153,0.00029669117,0.000076713186,0.000007713378,0.0000581998,0.00014322292,0.000021934882],"category_scores_gemma":[0.000083204184,0.00012747114,0.00017836104,0.00023550162,0.00007890215,0.00006838,0.000008340916,0.000023093095,0.0000016831239],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005804174,0.0015811502,0.21304217,0.00018345423,0.0010537595,0.000053879157,0.0008911408,0.000008330989,0.00035069275,0.00095535483,0.004409876,0.771666],"study_design_scores_gemma":[0.030772025,0.031351857,0.7835172,0.00015456509,0.00054851314,0.00019362418,0.0010041319,0.000321174,0.02724483,0.00046370996,0.1241286,0.0002998018],"about_ca_topic_score_codex":0.000111046575,"about_ca_topic_score_gemma":0.00007386813,"teacher_disagreement_score":0.77136624,"about_ca_system_score_codex":0.00014551739,"about_ca_system_score_gemma":0.00014422154,"threshold_uncertainty_score":0.5198122},"labels":[],"label_agreement":null},{"id":"W2138877053","doi":"10.1093/annonc/mdn652","title":"Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Breast cancer; Oncology; Prospective cohort study; Internal medicine; Cancer","score_opus":0.024795680762682227,"score_gpt":0.33303018275493906,"score_spread":0.3082345019922568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138877053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993018,0.00006690774,0.0000067635046,0.0046812934,0.000047948834,0.0010961986,0.0000050157514,0.000019456602,0.0010584408],"genre_scores_gemma":[0.99660116,0.00009188682,0.000040975963,0.0030674192,0.000089113535,0.000046054636,0.000009036326,0.000014599194,0.00003977136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894667,0.000086934735,0.00030030982,0.0002622054,0.00020051026,0.00020338465],"domain_scores_gemma":[0.9993913,0.000038062488,0.00014168012,0.0001536466,0.00022525556,0.000050047212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034144436,0.00012787398,0.00043500063,0.00019880066,0.000019508454,0.000003389816,0.000045597382,0.00012736596,0.000042453197],"category_scores_gemma":[0.00002511944,0.00010839217,0.00004585116,0.00041451614,0.00003884158,0.000109520966,0.000009841395,0.00022069836,0.0000013090653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008866098,0.004065862,0.73635906,0.000012842279,0.000066348555,0.000027622043,0.0011276692,0.000023784478,0.005242797,0.0000051795664,0.000050123806,0.24415264],"study_design_scores_gemma":[0.008865056,0.006710495,0.9803897,0.00013282221,0.000024075676,0.000014297332,0.00030878917,0.000018621418,0.0031093792,0.0002207728,0.000107316235,0.00009866704],"about_ca_topic_score_codex":0.0003175118,"about_ca_topic_score_gemma":0.0007378663,"teacher_disagreement_score":0.24405397,"about_ca_system_score_codex":0.0001775821,"about_ca_system_score_gemma":0.00015655161,"threshold_uncertainty_score":0.44201043},"labels":[],"label_agreement":null},{"id":"W2138926750","doi":"10.1093/annonc/mdf089","title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":524,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Neutropenia; Fluorouracil; Gastroenterology; Regimen; Adverse effect; Colorectal cancer; Nausea; Febrile neutropenia; Oncology; Surgery; Cancer; Chemotherapy","score_opus":0.09844456695473171,"score_gpt":0.3593883428312434,"score_spread":0.2609437758765117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138926750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97429794,0.004661583,0.000015081725,0.007175839,0.000104194165,0.0011447169,0.00009831374,0.000037284703,0.012465027],"genre_scores_gemma":[0.9904985,0.006773556,0.0008509413,0.00054458645,0.00006307262,0.00037675985,0.000027663797,0.000026196753,0.0008387368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983422,0.000101575184,0.00050253473,0.00033564263,0.00023937515,0.00047865132],"domain_scores_gemma":[0.99902546,0.00017976493,0.00021141334,0.00017829252,0.00028568017,0.00011940856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002136499,0.00026633748,0.0011418426,0.00015482232,0.00009891771,0.000006517759,0.000099963676,0.000077531855,0.0011050514],"category_scores_gemma":[0.000040670868,0.00018735345,0.00009742535,0.00039353166,0.00021901091,0.00006752184,0.000038675284,0.00020989332,0.000012813357],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033570465,0.010382792,0.10855074,0.00037220944,0.003050343,0.0013448094,0.0115387,0.001164958,0.0014926936,0.00024628732,0.007340559,0.82094544],"study_design_scores_gemma":[0.06949682,0.16577114,0.48516583,0.00079711335,0.0007188258,0.00061410776,0.003267601,0.00813991,0.021889701,0.00043436844,0.24232502,0.0013795486],"about_ca_topic_score_codex":0.0030870202,"about_ca_topic_score_gemma":0.017008318,"teacher_disagreement_score":0.8195659,"about_ca_system_score_codex":0.0002396011,"about_ca_system_score_gemma":0.00022852942,"threshold_uncertainty_score":0.9998081},"labels":[],"label_agreement":null},{"id":"W2139126667","doi":"10.1093/annonc/mdu448","title":"Cognitive function and fatigue after diagnosis of colorectal cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital; McMaster University; Ontario HIV Treatment Network; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; University of California, San Diego; Cancer Institute NSW","keywords":"Medicine; Internal medicine; Colorectal cancer; Odds ratio; Quality of life (healthcare); Anxiety; Depression (economics); Stage (stratigraphy); Confidence interval; Disease; Cognition; Cancer; Oncology; Psychiatry","score_opus":0.06388207323955751,"score_gpt":0.3864697454873018,"score_spread":0.32258767224774426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139126667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891878,0.0016873677,0.00007873029,0.003281311,0.00019147235,0.00032451056,0.00004347361,0.00001214214,0.005193231],"genre_scores_gemma":[0.9959192,0.0019604638,0.000027469134,0.0016269383,0.000093179835,0.00029092608,0.0000067894166,0.000009730742,0.00006529324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927384,0.00007165968,0.00022766324,0.00016208777,0.000110855675,0.00015390574],"domain_scores_gemma":[0.99881357,0.0004467411,0.00016125997,0.000047038196,0.0004720987,0.00005927112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016670553,0.00009778015,0.00040649835,0.00010065329,0.000023750272,0.0000011766016,0.000017967364,0.000105311585,0.00026316912],"category_scores_gemma":[0.00034185266,0.00008563575,0.00006183838,0.0001128205,0.0003259021,0.000041640105,0.00003937205,0.000100964746,0.0000038915896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051916437,0.000518107,0.7623326,0.00017545577,0.0007990951,0.000006345164,0.0007573616,0.0000017286106,0.0010062348,0.000077122364,0.00453254,0.22460175],"study_design_scores_gemma":[0.0028060593,0.009692443,0.96361935,0.0003273977,0.0004888811,0.0000071216496,0.00030091152,0.000023361647,0.017300352,0.00025917465,0.0050888034,0.000086140644],"about_ca_topic_score_codex":0.0001716472,"about_ca_topic_score_gemma":0.00020843539,"teacher_disagreement_score":0.22451562,"about_ca_system_score_codex":0.000020412353,"about_ca_system_score_gemma":0.00007377963,"threshold_uncertainty_score":0.34921244},"labels":[],"label_agreement":null},{"id":"W2139142789","doi":"10.1093/annonc/mdm592","title":"A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Alberta Cancer Foundation","funders":"U.S. Food and Drug Administration","keywords":"Pemetrexed; Medicine; Hazard ratio; Lung cancer; Internal medicine; Interim analysis; Confidence interval; Oncology; Chemotherapy; Toxicity; Randomized controlled trial; Surgery; Cisplatin","score_opus":0.05161190808332462,"score_gpt":0.4126153450498675,"score_spread":0.3610034369665429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139142789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293727,0.0009203717,0.00016202613,0.00045216398,0.00012361478,0.0044277967,0.000084183965,0.000015171447,0.0008773751],"genre_scores_gemma":[0.9948964,0.0011449909,0.0017405095,0.00036007655,0.00003615744,0.00075454544,0.00011998515,0.000023977414,0.0009233577],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984839,0.00013030971,0.0006013859,0.0003083361,0.00019139725,0.00028465284],"domain_scores_gemma":[0.998746,0.00030886155,0.00034243945,0.00017398453,0.0002658016,0.00016296074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019035419,0.00023948519,0.0016196179,0.00020488718,0.000068582616,0.000005163818,0.0000461784,0.00005984229,0.0002491487],"category_scores_gemma":[0.000056823148,0.00014709779,0.000097907854,0.00020695436,0.00016674907,0.000082573446,0.000020260908,0.00009503452,0.0000011715999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9650739,0.004691476,0.004678301,0.0000977956,0.0013026485,0.0002097532,0.002089356,0.00017892169,0.000045065917,0.000010372189,0.0001492771,0.021473132],"study_design_scores_gemma":[0.9622555,0.031823914,0.0019563758,0.00012858525,0.0011567828,0.000010913568,0.00015527653,0.00033794093,0.0012599728,0.000013597431,0.00075974036,0.0001414055],"about_ca_topic_score_codex":0.0011802546,"about_ca_topic_score_gemma":0.0018060064,"teacher_disagreement_score":0.027132437,"about_ca_system_score_codex":0.00024438355,"about_ca_system_score_gemma":0.0014029355,"threshold_uncertainty_score":0.5998474},"labels":[],"label_agreement":null},{"id":"W2139191591","doi":"10.1093/annonc/mds323","title":"Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Chemotherapy; Adjuvant chemotherapy; Disease; Precision medicine; Internal medicine; Bioinformatics; Cancer; Pathology; Biology","score_opus":0.1523871034459548,"score_gpt":0.4523130633149529,"score_spread":0.2999259598689981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139191591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945505,0.0020021254,0.001494511,0.0007728191,0.0001590639,0.00043496655,0.00021774456,0.0000026616863,0.00036558686],"genre_scores_gemma":[0.99468315,0.0009397253,0.0017692673,0.00202389,0.00032792767,0.000050805436,0.00014433112,0.0000136823655,0.000047206526],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924034,0.000058940634,0.0002992064,0.00014683628,0.00003778917,0.00021689056],"domain_scores_gemma":[0.9992629,0.00017007356,0.00015556833,0.00013261788,0.00016874431,0.00011007295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000495778,0.000089335656,0.0003336252,0.00005386839,0.000038395443,0.000005337577,0.00006772868,0.00010593502,0.000010141156],"category_scores_gemma":[0.00065995054,0.0000824851,0.000099030025,0.00005227542,0.000030127429,0.0000024737399,0.00004382605,0.000021910304,0.0000018139918],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013480033,0.0007131857,0.049851865,0.000032941403,0.00048056216,1.2081253e-7,0.00034660683,0.00021115766,0.666073,0.00039107905,0.10309037,0.17746107],"study_design_scores_gemma":[0.0019674448,0.0033188313,0.089438856,0.0000042866354,0.000079427016,0.0000013965742,0.000027754135,0.000018745492,0.2168939,0.00020701994,0.6878716,0.00017078417],"about_ca_topic_score_codex":0.000018587483,"about_ca_topic_score_gemma":0.000025951504,"teacher_disagreement_score":0.58478117,"about_ca_system_score_codex":0.000010566189,"about_ca_system_score_gemma":0.00008576711,"threshold_uncertainty_score":0.33636448},"labels":[],"label_agreement":null},{"id":"W2139318317","doi":"10.1093/annonc/mdi061","title":"Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital du Sacré-Cœur de Montréal; Université de Montréal; Jewish General Hospital; Hôpital Saint-Luc; Centre Hospitalier de l’Université de Montréal","funders":"Shire","keywords":"Medicine; Neutropenia; Gastroenterology; Internal medicine; Pancreatic cancer; Regimen; Febrile neutropenia; Rash; Chemotherapy; Cancer; Phases of clinical research; Surgery","score_opus":0.057224556323643996,"score_gpt":0.4390147306841395,"score_spread":0.3817901743604955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139318317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933051,0.00029449764,0.00000293451,0.002905742,0.000029468756,0.0011027554,0.000019848407,0.00000412995,0.0023355624],"genre_scores_gemma":[0.99859506,0.00027378125,0.00026251777,0.00044937537,0.000034935823,0.00007872135,0.0000037681095,0.000012301988,0.00028956507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986026,0.00014978972,0.0005204072,0.00017421354,0.00030577483,0.0002471638],"domain_scores_gemma":[0.99865466,0.00016669773,0.00034616725,0.00032045005,0.00044705565,0.00006498108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003533787,0.00011536095,0.00088446063,0.00012724333,0.000029097304,4.4802985e-7,0.00015602933,0.000098192424,0.00021074657],"category_scores_gemma":[0.00014370182,0.000069599664,0.000060840586,0.00032684155,0.0002756669,0.000045923418,0.000054527838,0.00017932044,7.4931364e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007476417,0.025306713,0.7948103,0.00006026102,0.0002986226,0.000004061249,0.003175549,0.000022905177,0.0020021687,0.000026635,0.00039776188,0.16641864],"study_design_scores_gemma":[0.048317228,0.06683732,0.8746967,0.00014630721,0.00014480602,0.000002471475,0.00080658693,0.00009529991,0.0056520198,0.000029645296,0.0031916883,0.00007995971],"about_ca_topic_score_codex":0.0004340708,"about_ca_topic_score_gemma":0.0008908646,"teacher_disagreement_score":0.16633868,"about_ca_system_score_codex":0.00005843117,"about_ca_system_score_gemma":0.0004362788,"threshold_uncertainty_score":0.2838192},"labels":[],"label_agreement":null},{"id":"W2139436147","doi":"10.1093/annonc/mdm121","title":"Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer","year":2007,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Connaught Fund; European Society for Medical Oncology; University of Toronto","keywords":"Medicine; Checklist; Clinical endpoint; Quality of life (healthcare); Randomized controlled trial; Palliative care; Clinical trial; Physical therapy; Internal medicine","score_opus":0.4355978487088951,"score_gpt":0.6067880203567404,"score_spread":0.17119017164784528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139436147","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026207624,0.9890608,0.00017506124,0.00031208346,0.0006070151,0.006450007,0.00052325556,0.000008120388,0.00024288667],"genre_scores_gemma":[0.0041374257,0.99316937,0.000111120375,0.0012537736,0.00024328205,0.000894116,0.00009553813,0.000031868476,0.00006352298],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907798,0.0039636716,0.00432318,0.00039082128,0.0002530325,0.0002894487],"domain_scores_gemma":[0.9640692,0.03137975,0.003342753,0.0002847583,0.0007317772,0.00019179001],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.019438183,0.0002978996,0.015374306,0.00023076689,0.000011857074,0.0000020498924,0.00011401903,0.0006614077,0.00006351014],"category_scores_gemma":[0.016411752,0.0001692118,0.0012767824,0.00020193952,0.0003521462,0.00002909141,0.000024931416,0.000318897,3.8885437e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2566613,0.0004496591,0.0016696958,0.010080622,0.0009327815,0.0000018529315,0.000055101067,1.4162265e-7,4.158813e-8,0.000048628106,0.00024632172,0.72985387],"study_design_scores_gemma":[0.28960565,0.0042740246,0.00052173185,0.005731439,0.0014148736,8.4142545e-7,0.000034774286,0.0000014217054,3.3954882e-7,0.000023989507,0.69821954,0.00017140018],"about_ca_topic_score_codex":0.00041995628,"about_ca_topic_score_gemma":0.0020133676,"teacher_disagreement_score":0.72968245,"about_ca_system_score_codex":0.000053956,"about_ca_system_score_gemma":0.0022043143,"threshold_uncertainty_score":0.9992435},"labels":[],"label_agreement":null},{"id":"W2139468685","doi":"10.1093/annonc/mdt201.8","title":"Regard Phase 3, Randomized Trial of Ramucirumab in Patients with Metastatic Gastric or Gej Adenocarcinoma Following Progression on First-Line Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Ramucirumab; Internal medicine; Hazard ratio; Clinical endpoint; Progression-free survival; Oncology; Cancer; Gastroenterology; Bevacizumab; Placebo; Phases of clinical research; Chemotherapy; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.05884592573580101,"score_gpt":0.38841678431870746,"score_spread":0.32957085858290647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139468685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916017,0.00012558783,0.00008567429,0.0032729635,0.00015786709,0.004075873,0.0000029694147,0.000015031589,0.0006623365],"genre_scores_gemma":[0.99737006,0.00011577808,0.0012524119,0.00068289234,0.0000525472,0.00021806825,0.000028207836,0.000020633232,0.0002593846],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99820954,0.00016705345,0.0007225813,0.00023699504,0.0003801636,0.00028367038],"domain_scores_gemma":[0.9985624,0.00044235177,0.00050298724,0.0002548427,0.00015601561,0.00008140192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061724003,0.00018411782,0.0014022364,0.00039363196,0.000023855304,0.0000054153757,0.00010923716,0.00007006744,0.00030967707],"category_scores_gemma":[0.00037640517,0.00010887841,0.00023619272,0.00039432367,0.00009802827,0.00008591121,0.000028758814,0.00013066066,0.00000541176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8509658,0.0036313885,0.01900779,0.0001140296,0.00042519558,0.00003766958,0.00019900729,0.000008092677,0.000007878855,0.000012809426,0.0015925012,0.12399783],"study_design_scores_gemma":[0.94057894,0.038351275,0.019258153,0.0002301879,0.00025529382,0.0000018059266,0.000055984172,0.00009979191,0.00026972019,0.00006010165,0.00074529485,0.00009344246],"about_ca_topic_score_codex":0.0000859875,"about_ca_topic_score_gemma":0.00002783838,"teacher_disagreement_score":0.123904385,"about_ca_system_score_codex":0.00004846486,"about_ca_system_score_gemma":0.00011559452,"threshold_uncertainty_score":0.44399327},"labels":[],"label_agreement":null},{"id":"W2139862760","doi":"10.1093/annonc/mdh128","title":"Treatment for Waldenstrom’s macroglobulinemia","year":2004,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Macroglobulinemia; Waldenstrom macroglobulinemia; Internal medicine; Multiple myeloma; Lymphoma","score_opus":0.3053993242944,"score_gpt":0.5401525840802325,"score_spread":0.2347532597858325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139862760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001683302,0.99026674,0.000019625633,0.0008087864,0.0002228076,0.0027275253,0.00018850682,0.000033686094,0.0057154745],"genre_scores_gemma":[0.000020147447,0.99297714,0.0014980732,0.00014361618,0.00050017866,0.0005740996,0.00040028518,0.00007734179,0.0038091217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975896,0.000093816176,0.0009103135,0.00049778307,0.00026158147,0.000646919],"domain_scores_gemma":[0.99763715,0.0006927914,0.00044039782,0.00064585585,0.00032101868,0.00026279956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002729512,0.0004179416,0.0035113136,0.00025735298,0.00003736037,0.0000058435317,0.00024026663,0.00081659434,0.00015763332],"category_scores_gemma":[0.0002816772,0.00029299714,0.0013305943,0.00021516638,0.00023049183,0.00001951577,0.000081176986,0.00023750428,0.00014630484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020464747,0.0005079371,1.6573803e-7,0.028568875,0.000831866,0.00043982986,0.000035323672,7.956386e-7,8.949417e-7,0.0003879156,0.006017141,0.9630046],"study_design_scores_gemma":[0.010915354,0.011660681,1.5143446e-7,0.006662058,0.001273195,0.0019956033,0.000008237642,0.000011945416,0.00004326436,0.00013230735,0.96712184,0.00017536868],"about_ca_topic_score_codex":0.000254238,"about_ca_topic_score_gemma":0.00001977119,"teacher_disagreement_score":0.96282923,"about_ca_system_score_codex":0.01643505,"about_ca_system_score_gemma":0.055700723,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W2140060467","doi":"10.1093/annonc/mdp452","title":"Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Vascular endothelial growth factor; Vascular endothelial growth factor A; Medicine; Angiogenesis; Genotype; Haplotype; Kinase insert domain receptor; Imatinib; Imatinib mesylate; Myeloid leukemia; Internal medicine; Cancer research; Immunology; Oncology; Biology; VEGF receptors; Genetics; Gene","score_opus":0.12275547772386922,"score_gpt":0.41081870463318776,"score_spread":0.2880632269093185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140060467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866888,0.0026548062,0.000008399209,0.008286779,0.0003034874,0.00077391096,0.000050003422,0.00002984617,0.0012039834],"genre_scores_gemma":[0.9818388,0.013502621,0.0011373104,0.002927693,0.0002571867,0.000031867647,0.000016651857,0.000027444403,0.00026039762],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977059,0.00029478015,0.00089821406,0.00040723712,0.00033142805,0.00036243544],"domain_scores_gemma":[0.99738026,0.0013787857,0.00041870144,0.0005590601,0.00011057988,0.00015264185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160765,0.00029166823,0.0011267316,0.0000955843,0.00006625688,0.000004802847,0.00016233478,0.0002485001,0.00013097234],"category_scores_gemma":[0.0005493183,0.00017811338,0.00058574294,0.0001227086,0.00019638953,0.000049307822,0.000021776004,0.00021980554,0.000021754731],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004107599,0.0076914188,0.11881523,0.000059521182,0.0032196182,0.0002188463,0.0022261962,0.0000026506402,0.07878656,0.0012988556,0.0015284382,0.78204507],"study_design_scores_gemma":[0.04587253,0.09311214,0.45956743,0.00032804447,0.0005612629,0.00007397835,0.00018486522,0.00006233861,0.31171408,0.0011938158,0.086738035,0.000591473],"about_ca_topic_score_codex":0.000089277746,"about_ca_topic_score_gemma":0.0000046589757,"teacher_disagreement_score":0.7814536,"about_ca_system_score_codex":0.00021744554,"about_ca_system_score_gemma":0.00033259534,"threshold_uncertainty_score":0.7263253},"labels":[],"label_agreement":null},{"id":"W2140104756","doi":"10.1093/annonc/mdg496","title":"Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gemcitabine; Neutropenia; Regimen; Internal medicine; Salvage therapy; Dexamethasone; Phases of clinical research; Chemotherapy; Surgery; Transplantation; Progressive disease; Gastroenterology; Chemotherapy regimen; Cisplatin; Refractory (planetary science); Oncology","score_opus":0.23709605487564997,"score_gpt":0.5114015104831595,"score_spread":0.2743054556075095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140104756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041325,0.0013956681,0.0000015805934,0.0062257424,0.00015830548,0.001161982,0.00023843066,0.000004269444,0.00040075913],"genre_scores_gemma":[0.99420244,0.0014922738,0.0001191539,0.003621707,0.000071534814,0.00021824152,0.000024405586,0.000012854651,0.000237412],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99733675,0.0009154553,0.00086061907,0.0003366064,0.00034580307,0.00020476966],"domain_scores_gemma":[0.9973944,0.0014116692,0.0005688228,0.00021329947,0.00021049494,0.0002013336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026035982,0.00016853328,0.0009478609,0.00007845311,0.000069944894,0.0000036562865,0.000083545936,0.000117568554,0.00023334865],"category_scores_gemma":[0.0017289027,0.00010333825,0.00008298116,0.00019532778,0.00019268591,0.000082558305,0.000021598122,0.0001407666,1.7375379e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056801222,0.077214904,0.18385763,0.00010325877,0.0037570037,0.00040075646,0.0052440944,0.000009851365,0.002827942,0.00034139855,0.14769164,0.5217503],"study_design_scores_gemma":[0.13244118,0.056892555,0.6371329,0.00020064984,0.0006920316,0.00003021356,0.0015812455,0.00011392982,0.007931527,0.00034183118,0.16225588,0.00038607893],"about_ca_topic_score_codex":0.024825506,"about_ca_topic_score_gemma":0.078016736,"teacher_disagreement_score":0.5213642,"about_ca_system_score_codex":0.00023924663,"about_ca_system_score_gemma":0.0029748604,"threshold_uncertainty_score":0.9816683},"labels":[],"label_agreement":null},{"id":"W2140216617","doi":"10.1093/annonc/mdl041","title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Zoledronic acid; Medicine; Placebo; Prostate cancer; Brief Pain Inventory; Internal medicine; Bone pain; Bone metastasis; Oncology; Cancer; Physical therapy; Chronic pain; Pathology","score_opus":0.018159111369386936,"score_gpt":0.34380762417906874,"score_spread":0.3256485128096818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140216617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717367,0.0004079032,6.764081e-7,0.0008626662,0.000019671057,0.00079656043,0.00005275012,0.000010571077,0.0006755348],"genre_scores_gemma":[0.9990892,0.000039823302,0.000034601642,0.00050816406,0.000005890801,0.000099367426,0.00009583347,0.000016344253,0.00011080616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867046,0.00034571474,0.00030069405,0.00016715105,0.00020980008,0.00030618664],"domain_scores_gemma":[0.9991151,0.0002235533,0.0003030048,0.00013110125,0.00015698493,0.00007023597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006496859,0.00013563684,0.00065694674,0.00013540723,0.000017174052,8.830617e-7,0.000027264061,0.00008849327,0.000022084538],"category_scores_gemma":[0.00007672696,0.0000829961,0.000040212857,0.0002455157,0.000077383535,0.000028752776,0.000007462314,0.0001241752,0.0000022050904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013030144,0.0020926404,0.8829083,0.00014989103,0.00022892003,0.000058973772,0.000058284186,0.00002528006,0.000028354943,0.0000057460584,0.0005131743,0.100900315],"study_design_scores_gemma":[0.017036038,0.08043113,0.89443743,0.0003896035,0.0001683136,0.0000013175658,0.0000049236787,0.000010430221,0.0069174287,0.000012276235,0.00051704707,0.00007405654],"about_ca_topic_score_codex":0.0015746467,"about_ca_topic_score_gemma":0.0022808795,"teacher_disagreement_score":0.100826256,"about_ca_system_score_codex":0.00011796042,"about_ca_system_score_gemma":0.00026689918,"threshold_uncertainty_score":0.33844826},"labels":[],"label_agreement":null},{"id":"W2140510616","doi":"10.1093/annonc/mdm399","title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital","funders":"Amgen","keywords":"Panitumumab; Medicine; Internal medicine; Colorectal cancer; Adverse effect; Refractory (planetary science); Oncology; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progressive disease; Chemotherapy; Progression-free survival; Surgery; Cancer; Clinical trial; Cetuximab","score_opus":0.08917227959175789,"score_gpt":0.44305208880225994,"score_spread":0.35387980921050205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140510616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965668,0.00028254482,0.000018631617,0.00037350235,0.00005534385,0.0014760197,0.00003261329,0.000008277983,0.0011862969],"genre_scores_gemma":[0.99854124,0.00010104323,0.0008888998,0.00038545235,0.000016371345,0.00002659272,0.000008214613,0.000019606245,0.000012580979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99867195,0.00009584122,0.0004461563,0.00028575162,0.00024590796,0.0002544089],"domain_scores_gemma":[0.9989079,0.00022556618,0.0002346221,0.00014575855,0.00037051676,0.000115632545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054753,0.00016325196,0.0008485031,0.00015709423,0.000054858083,0.0000109753555,0.00009485603,0.000045214587,0.000036760375],"category_scores_gemma":[0.00007137239,0.00011913506,0.000015917758,0.00028066812,0.00012389604,0.00013180391,0.00006481751,0.00010425761,1.9063788e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060856763,0.026031476,0.45135808,0.000039745748,0.00059737795,0.000051393312,0.0054406594,0.0000055876344,0.0016221459,0.0000073960637,0.000046855534,0.4539425],"study_design_scores_gemma":[0.023615222,0.13281278,0.8390162,0.00009500994,0.0001091513,0.0000016077548,0.0015292591,0.0000016120631,0.001675317,0.000006583448,0.0010352568,0.0001020046],"about_ca_topic_score_codex":0.00066686823,"about_ca_topic_score_gemma":0.0040005785,"teacher_disagreement_score":0.4538405,"about_ca_system_score_codex":0.00023164584,"about_ca_system_score_gemma":0.00026052367,"threshold_uncertainty_score":0.48581868},"labels":[],"label_agreement":null},{"id":"W2140563000","doi":"10.1093/annonc/mdv278","title":"BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":222,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Genetic testing; CLARITY; Genetic counseling; Clinical significance; Clinical Practice; Family medicine; Bioinformatics; Genetics; Internal medicine","score_opus":0.32074314372816004,"score_gpt":0.5085057765275492,"score_spread":0.1877626327993892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140563000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034946075,0.99617726,0.00068380224,0.00064696954,0.000291675,0.0007966132,0.0003199258,0.0000050414715,0.0007292802],"genre_scores_gemma":[0.00034024965,0.9730254,0.025653346,0.00024972373,0.0002474749,0.00015082385,0.00017080201,0.000037202957,0.00012498269],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789876,0.000322676,0.0009490761,0.0005315462,0.00007497854,0.00022297491],"domain_scores_gemma":[0.99769217,0.000521716,0.00084883504,0.00036715495,0.00046795717,0.00010214756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001153838,0.00022574572,0.0010931828,0.000098746845,0.000043656695,0.0000085601105,0.00023541479,0.0004719631,0.0000052129312],"category_scores_gemma":[0.0008351385,0.00022009079,0.00013203571,0.00014102076,0.0003360362,0.0000035764865,0.00017872843,0.00014012604,8.3358697e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002384468,0.00007871878,0.000057524445,0.0018590122,0.00028097478,0.0000014894357,0.000023779106,0.0000064944643,0.000056771576,0.00009382818,0.012584741,0.98493284],"study_design_scores_gemma":[0.00043461344,0.0018329207,0.000117005184,0.0005977852,0.0003203937,0.000041884563,0.000030724692,0.000027866692,0.00003587287,0.00094456907,0.99540794,0.00020841855],"about_ca_topic_score_codex":0.000025105324,"about_ca_topic_score_gemma":0.000025932148,"teacher_disagreement_score":0.9847244,"about_ca_system_score_codex":0.000028315755,"about_ca_system_score_gemma":0.0012936448,"threshold_uncertainty_score":0.8975042},"labels":[],"label_agreement":null},{"id":"W2140885542","doi":"10.1093/annonc/mdq320","title":"Temsirolimus in VEGF-refractory metastatic renal cell carcinoma","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Temsirolimus; Medicine; Renal cell carcinoma; Refractory (planetary science); VEGF receptors; Oncology; Internal medicine; Cancer research; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway","score_opus":0.07894114752279004,"score_gpt":0.3604743647877649,"score_spread":0.2815332172649749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140885542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509777,0.0006533638,0.0000028724162,0.0015268434,0.00022864885,0.00032622946,0.000007693547,0.000015653415,0.04626099],"genre_scores_gemma":[0.9972878,0.00006313039,0.0010015932,0.00076248223,0.00011920924,0.00003477346,0.000020736237,0.000024486062,0.00068578153],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985117,0.00011599415,0.00048138548,0.00028505037,0.00022685192,0.00037902157],"domain_scores_gemma":[0.9987767,0.00024268153,0.00020416058,0.0004165187,0.00015832011,0.00020165041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040711297,0.00018210645,0.0006264625,0.00029196346,0.00002115838,0.0000033584138,0.0001252373,0.00016564348,0.00032110285],"category_scores_gemma":[0.00010287424,0.00015091329,0.00015576484,0.00018656558,0.00016164292,0.00005705353,0.00004913405,0.00047767776,0.000087705535],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014721538,0.0046423655,0.10013524,0.000307386,0.00013854381,0.003890338,0.0012727365,0.000010761697,0.82665175,0.0003378983,0.0067331055,0.0544077],"study_design_scores_gemma":[0.0055740434,0.0109958695,0.5414557,0.000031632524,0.00017957356,0.00039185063,0.00020358864,0.00005371761,0.36930373,0.0004342349,0.071140446,0.00023561476],"about_ca_topic_score_codex":0.00039696437,"about_ca_topic_score_gemma":0.00030941312,"teacher_disagreement_score":0.45734805,"about_ca_system_score_codex":0.00005663882,"about_ca_system_score_gemma":0.0004375852,"threshold_uncertainty_score":0.6154066},"labels":[],"label_agreement":null},{"id":"W2140949677","doi":"10.1093/annonc/mdl400","title":"Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens","year":2006,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Chemotherapy; Paclitaxel; Cyclophosphamide; Oncology; Population; Cancer; Gynecology; Surgery; Cisplatin","score_opus":0.07145167684246971,"score_gpt":0.37961758614551344,"score_spread":0.3081659093030437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140949677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95832235,0.022908904,0.00007631792,0.010024484,0.00087708124,0.0017720461,0.0043778606,0.000018546381,0.0016223852],"genre_scores_gemma":[0.9896013,0.0043786773,0.0032354495,0.0011912414,0.00033383764,0.0004520929,0.0005195826,0.00005709314,0.00023073798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941963,0.001238106,0.0021541293,0.00084187044,0.000689063,0.00088053837],"domain_scores_gemma":[0.98967505,0.0060686385,0.002153524,0.0006018322,0.0012372072,0.00026376327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013311099,0.00060264935,0.0029887876,0.00046898742,0.00014476731,0.000022539736,0.00030979153,0.00035873978,0.0007554509],"category_scores_gemma":[0.0012293303,0.00041674834,0.00046261246,0.0023770698,0.0013902343,0.00020493988,0.00007192654,0.0004038092,0.0000033082704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00522377,0.0020546126,0.85783035,0.00009774501,0.010743539,0.00018633682,0.0045975135,0.026472492,0.00018954054,0.003695836,0.0013014467,0.08760683],"study_design_scores_gemma":[0.019962445,0.004868281,0.9565716,0.0011147062,0.0077188076,0.000002703375,0.0014877236,0.0006381371,0.0024752547,0.002723811,0.0020367184,0.0003998084],"about_ca_topic_score_codex":0.31196198,"about_ca_topic_score_gemma":0.25316134,"teacher_disagreement_score":0.09874126,"about_ca_system_score_codex":0.0014055669,"about_ca_system_score_gemma":0.00482266,"threshold_uncertainty_score":0.99982846},"labels":[],"label_agreement":null},{"id":"W2141117259","doi":"10.1093/annonc/mds606","title":"Patients’ and physicians’ roles in detecting recurrent Hodgkin lymphoma following complete remission","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"National Institutes of Health","keywords":"Medicine; Asymptomatic; Internal medicine; Complete remission; Lymphoma; Anxiety; Pediatrics; Gastroenterology; Chemotherapy; Psychiatry","score_opus":0.07420821571337413,"score_gpt":0.3646897573913303,"score_spread":0.29048154167795615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141117259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994328,0.002183343,0.0000022865067,0.00096162444,0.0001925261,0.00020848177,0.0000041627386,0.000011553621,0.002107982],"genre_scores_gemma":[0.9985943,0.00028075278,0.00036097306,0.0006349696,0.000074115254,0.000021216716,0.000014254048,0.000010002599,0.000009406936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990716,0.000083852276,0.00027382365,0.00015418301,0.0001264955,0.00029003693],"domain_scores_gemma":[0.9994193,0.00018343618,0.00013646977,0.00011040076,0.000049277336,0.000101125384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024784394,0.000112663234,0.00039567347,0.00009522023,0.000039907205,0.0000031405632,0.000033740893,0.000084512016,0.000007821394],"category_scores_gemma":[0.00012797475,0.000093191156,0.000092883936,0.00010352512,0.000033149223,0.000078493584,0.000049739323,0.000044596956,0.000005242801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112233574,0.0011485348,0.45209584,0.000019957788,0.00004104188,0.000011072867,0.00063359604,2.2508848e-7,0.00087802374,0.00003107011,0.00027053608,0.5447579],"study_design_scores_gemma":[0.004275111,0.0019760053,0.96358985,0.00027682103,0.000059185848,0.000009772314,0.00025674506,0.000031658634,0.010643306,0.000063940744,0.01872285,0.00009474415],"about_ca_topic_score_codex":0.0000779806,"about_ca_topic_score_gemma":0.000027256645,"teacher_disagreement_score":0.54466313,"about_ca_system_score_codex":0.000088790985,"about_ca_system_score_gemma":0.000038783975,"threshold_uncertainty_score":0.38002253},"labels":[],"label_agreement":null},{"id":"W2141226562","doi":"10.1093/annonc/mdq574","title":"Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Anthracycline; Internal medicine; Follicular lymphoma; International Prognostic Index; Grading (engineering); Chemotherapy; Lymphoma; Oncology; Population; Retrospective cohort study; Survival analysis; Cancer; Gastroenterology; Surgery; Rituximab; Breast cancer","score_opus":0.05823165632258045,"score_gpt":0.3776472863348455,"score_spread":0.3194156300122651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141226562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837996,0.0012138585,0.000018124301,0.013497504,0.000060639806,0.0005110135,0.000014895395,0.000023219036,0.0008611725],"genre_scores_gemma":[0.9927851,0.0012754468,0.0019420087,0.0037492402,0.00006722139,0.00007311681,0.000017069928,0.00002486575,0.00006590873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988272,0.000059052752,0.00031738775,0.00032966278,0.00017295242,0.000293729],"domain_scores_gemma":[0.99889576,0.000284273,0.00017666147,0.00030254456,0.0001407739,0.00019999118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033236833,0.00022648026,0.00068276573,0.00012199935,0.000084081425,0.000015579193,0.00006495368,0.00020048511,0.00005136376],"category_scores_gemma":[0.000069296,0.00014789263,0.00008760633,0.00009229314,0.00035091717,0.0000671809,0.000030541953,0.000098746335,0.000003821596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010675619,0.002289593,0.83910245,0.000077898156,0.0003381062,0.0004703262,0.00024787852,0.0000024485987,0.0053031137,0.00017183345,0.000937783,0.14999104],"study_design_scores_gemma":[0.023133641,0.01173265,0.81057495,0.000106642576,0.00020254623,0.00032939258,0.00016766875,0.00046549764,0.0658225,0.00019839332,0.08697257,0.00029355672],"about_ca_topic_score_codex":0.00042756647,"about_ca_topic_score_gemma":0.00027305583,"teacher_disagreement_score":0.14969747,"about_ca_system_score_codex":0.00001905582,"about_ca_system_score_gemma":0.00017100638,"threshold_uncertainty_score":0.6030886},"labels":[],"label_agreement":null},{"id":"W2141303400","doi":"10.1093/annonc/mdu517","title":"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Erlotinib Hydrochloride; Internal medicine; Lung cancer; Hazard ratio; Clinical endpoint; Oncology; Regimen; Randomized controlled trial; Adverse effect; Phases of clinical research; Gastroenterology; Clinical trial; Epidermal growth factor receptor; Cancer; Confidence interval","score_opus":0.033394814567876636,"score_gpt":0.38624635300747656,"score_spread":0.35285153843959993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141303400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987836,0.00018663655,0.000057957768,0.0009797136,0.00019142289,0.0028407203,0.000027731736,0.000009025134,0.0058284304],"genre_scores_gemma":[0.99882114,0.0000677794,0.00027231427,0.00017375914,0.00003993821,0.00034189265,0.00013657984,0.00002003916,0.0001265789],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99849045,0.00018718428,0.0005783366,0.00024408706,0.00025818672,0.00024175431],"domain_scores_gemma":[0.99851304,0.00042495303,0.0004577349,0.0001966811,0.00032945676,0.00007810874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039259947,0.00016525247,0.0010159818,0.00027087826,0.000020028381,0.000003416374,0.000074801595,0.00010797945,0.00006175006],"category_scores_gemma":[0.000095673175,0.00011766803,0.00007343576,0.0002779637,0.00016626283,0.00008991148,0.000016903266,0.00013740387,0.0000011547445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9526064,0.0071235704,0.029000064,0.00010176009,0.00031993404,0.000014614001,0.0014412173,0.00009124186,0.000018002467,0.00019049502,0.00018915249,0.008903541],"study_design_scores_gemma":[0.9604019,0.0211486,0.016412968,0.00017493084,0.00043797973,0.0000010808819,0.00009840282,0.00033993338,0.00049877877,0.000019797439,0.00035510625,0.00011050653],"about_ca_topic_score_codex":0.0015365044,"about_ca_topic_score_gemma":0.0012436346,"teacher_disagreement_score":0.01402503,"about_ca_system_score_codex":0.00012630117,"about_ca_system_score_gemma":0.0005864966,"threshold_uncertainty_score":0.47983631},"labels":[],"label_agreement":null},{"id":"W2141391177","doi":"10.1093/annonc/mdm277","title":"A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Juravinski Hospital; Sault Area Hospital; Saint John Regional Hospital; Mount Sinai Hospital; Essar Steel Algoma (Canada); Sunnybrook Health Science Centre; Hotel Dieu Shaver Health and Rehabilitation Centre; BC Cancer Agency; Hotel Dieu Hospital","funders":"National Cancer Institute; Amgen Canada; Women's College Hospital; Amgen","keywords":"Medicine; Epirubicin; Fluorouracil; Cyclophosphamide; Oncology; Adjuvant; Breast cancer; Internal medicine; Gynecology; Cancer; Chemotherapy","score_opus":0.04339102697354184,"score_gpt":0.3557379631357599,"score_spread":0.31234693616221804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141391177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980289,0.00018407003,0.00045876807,0.00050682353,0.000034257286,0.0006261384,0.00010407932,0.0000033772696,0.00005361688],"genre_scores_gemma":[0.99806815,0.00016821435,0.0013897973,0.00014880867,0.000055214638,0.00009686876,0.00003894893,0.000016550248,0.000017455957],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990499,0.00004192372,0.00029499814,0.0002432201,0.00011089604,0.0002590354],"domain_scores_gemma":[0.9990895,0.00008167275,0.00030695027,0.00009683455,0.00037870972,0.000046356858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036650966,0.00014588881,0.0003516599,0.00007567184,0.00004276872,0.000003757083,0.00004936766,0.00010605287,0.000004431193],"category_scores_gemma":[0.000038468792,0.00010761027,0.000019047719,0.00011300165,0.00016335005,0.000017466968,0.000040010516,0.000044353157,3.267282e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53524286,0.001830951,0.21359174,0.00024318327,0.00096347806,0.00005231302,0.0036069553,0.00050380884,0.14093626,0.00008100691,0.00006340263,0.10288407],"study_design_scores_gemma":[0.05330424,0.018868364,0.848872,0.00017476676,0.00012017961,0.000090279806,0.0013458106,0.00010158725,0.07669556,0.000075577715,0.000103771614,0.0002478288],"about_ca_topic_score_codex":0.0006716503,"about_ca_topic_score_gemma":0.0017948549,"teacher_disagreement_score":0.6352803,"about_ca_system_score_codex":0.00009241646,"about_ca_system_score_gemma":0.00030071742,"threshold_uncertainty_score":0.43882194},"labels":[],"label_agreement":null},{"id":"W2141428376","doi":"10.1093/annonc/mds067","title":"Targeting triple-negative breast cancer: optimising therapeutic outcomes","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; St. John’s Health Sciences Centre; University of Alberta; Memorial University of Newfoundland; University of British Columbia; BC Cancer Agency","funders":"Sanofi","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Targeted therapy; Oncology; Clinical trial; Internal medicine; Cancer; Cancer research; Bioinformatics; Biology","score_opus":0.13492989400903901,"score_gpt":0.43993605897164234,"score_spread":0.30500616496260335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141428376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037662645,0.99678457,0.00002311443,0.00064971263,0.00058307813,0.00046729925,0.0005020485,0.000014062606,0.00093843194],"genre_scores_gemma":[0.0013778566,0.99656636,0.00029995662,0.00043716969,0.0006094402,0.00023840477,0.00019054109,0.00007024405,0.00021004216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978689,0.00032388367,0.00064600125,0.00047641707,0.00013965333,0.00054514204],"domain_scores_gemma":[0.9983024,0.00017106868,0.00083973387,0.00035810866,0.00022838617,0.000100312274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002974404,0.00052418525,0.0019571744,0.00010191921,0.00010109936,0.000008172967,0.00032284504,0.0005361179,0.00008495825],"category_scores_gemma":[0.000055348086,0.00039573142,0.0006312828,0.000147391,0.00022679928,0.0000061554665,0.00023174974,0.00021462193,0.0000148732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058782338,0.00021053519,0.00042132701,0.001142289,0.0023893497,0.0000033205638,0.00007823297,0.000003458315,0.000014334574,0.000022164633,0.0015199613,0.9941363],"study_design_scores_gemma":[0.0005238594,0.0002464086,0.00051427784,0.0006765897,0.0011826463,0.000057385794,0.000056657525,3.6780594e-7,0.000086511995,0.000022837063,0.99624234,0.0003901257],"about_ca_topic_score_codex":0.00018493665,"about_ca_topic_score_gemma":0.000036498233,"teacher_disagreement_score":0.99472237,"about_ca_system_score_codex":0.00007937129,"about_ca_system_score_gemma":0.0005171465,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W2141593354","doi":"10.1093/annonc/mdg201","title":"Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Genentech; IC Design Education Center","keywords":"Medicine; Rituximab; Mantle cell lymphoma; Follicular lymphoma; Lymphoma; Oncology; Autologous stem-cell transplantation; Transplantation; Purge; In vivo; Internal medicine; Cancer research; Biology","score_opus":0.02221958073040302,"score_gpt":0.3093099517854315,"score_spread":0.2870903710550285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141593354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629825,0.0005017499,0.000004635711,0.00004896087,0.000024184146,0.0013257419,0.000023420265,0.000011360622,0.0017617091],"genre_scores_gemma":[0.99893004,0.000503416,0.0001417073,0.00016873897,0.000002699392,0.0001092222,0.00001588917,0.000021154043,0.00010712323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872524,0.0002077179,0.0003669134,0.00027542823,0.00020191906,0.00022279228],"domain_scores_gemma":[0.9992328,0.00017754835,0.00024008015,0.00015125192,0.00012957018,0.00006873364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011694738,0.00020428676,0.00070501416,0.00015139407,0.000036466667,0.000004238196,0.000044563454,0.000070718655,0.000060337687],"category_scores_gemma":[0.0000033651995,0.00012971435,0.000053262727,0.0002115867,0.00006821672,0.000058553185,0.0000054437614,0.00003841954,0.0000016735006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01531894,0.042011146,0.91248626,0.00020111415,0.0011273039,0.002437385,0.0059818276,0.000030028583,0.002797269,0.000012248256,0.000056547346,0.017539911],"study_design_scores_gemma":[0.14575647,0.05142935,0.46336967,0.00015322621,0.00087592565,0.00008252162,0.0024550874,0.000012622396,0.33481857,0.0000054883635,0.0008086018,0.00023247059],"about_ca_topic_score_codex":0.00030833454,"about_ca_topic_score_gemma":0.00008355789,"teacher_disagreement_score":0.44911662,"about_ca_system_score_codex":0.00005482386,"about_ca_system_score_gemma":0.00018267511,"threshold_uncertainty_score":0.52895975},"labels":[],"label_agreement":null},{"id":"W2141700931","doi":"10.1093/annonc/mdg320","title":"Mammographic screening: case–control studies","year":2003,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; McMaster University Medical Centre","funders":"","keywords":"Medicine; Mammography; Context (archaeology); Breast cancer; Breast cancer screening; Randomized controlled trial; Screening mammography; Population; Clinical trial; Medical physics; Cancer; Surgery; Environmental health; Internal medicine","score_opus":0.582553997724399,"score_gpt":0.5610916413157256,"score_spread":0.021462356408673333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141700931","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024293813,0.9904447,0.00004757659,0.0005136753,0.00030077217,0.0007704805,0.000056409517,0.000032121832,0.0078099575],"genre_scores_gemma":[0.00024528147,0.99582165,0.0008460457,0.0022427149,0.00026847163,0.00009888751,0.000016347785,0.000039415714,0.00042118478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99727947,0.000413806,0.0010448617,0.00045097587,0.000295115,0.00051576504],"domain_scores_gemma":[0.99736893,0.0006080744,0.00076839305,0.0004772083,0.00057102053,0.00020637352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011301641,0.00042468813,0.0042144726,0.00043121405,0.000078703495,0.000006067337,0.00017636022,0.0005873983,0.00010397478],"category_scores_gemma":[0.00049586204,0.00032230068,0.0011228293,0.000588721,0.00032018902,0.000056785833,0.00005852199,0.0005716633,0.000028343684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006121858,0.0000714208,0.000057585446,0.006281599,0.0024886574,0.0072745895,0.00003634164,5.3909713e-7,8.6157414e-8,0.00022260057,0.018140068,0.9653653],"study_design_scores_gemma":[0.0006686483,0.0024741432,0.000007086166,0.007997682,0.0037795613,0.016135663,0.00020224832,6.578862e-7,6.664293e-7,0.00008088742,0.9684284,0.00022440107],"about_ca_topic_score_codex":0.000060203456,"about_ca_topic_score_gemma":0.000050577168,"teacher_disagreement_score":0.9651409,"about_ca_system_score_codex":0.000061917664,"about_ca_system_score_gemma":0.00065125315,"threshold_uncertainty_score":0.99992293},"labels":[],"label_agreement":null},{"id":"W2141920998","doi":"10.1093/annonc/mdn031","title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":180,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"U.S. Food and Drug Administration","keywords":"Medicine; Gastroenterology; Diffuse large B-cell lymphoma; Internal medicine; Vorinostat; Nausea; Adverse effect; Anemia; Tolerability; Neutropenia; Vomiting; Toxicity; Phases of clinical research; Surgery; Lymphoma","score_opus":0.04978978159332966,"score_gpt":0.3682998098545144,"score_spread":0.31851002826118474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141920998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598056,0.0006115903,0.000021083788,0.00024011095,0.00021633218,0.0003974968,0.00006826241,0.000008439228,0.0024561156],"genre_scores_gemma":[0.9976669,0.00066512654,0.00021136129,0.00016958373,0.00011861103,0.000034702487,0.00010869664,0.000030260757,0.0009947708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781704,0.0003343641,0.0006655566,0.00040367083,0.00026402852,0.0005153149],"domain_scores_gemma":[0.9988534,0.000057372275,0.0002595669,0.00049888936,0.00019968068,0.00013112412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005994708,0.000195026,0.0005396588,0.00020857166,0.00007539973,0.0000019150468,0.0003280373,0.0004050662,0.000026198264],"category_scores_gemma":[0.00035912078,0.00020020566,0.00019846932,0.00023084987,0.000320261,0.0000059006056,0.0002347516,0.00015646133,0.0000142541985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027155979,0.030071398,0.00025340074,0.00003756561,0.000054584205,0.00016705185,0.00045029892,0.000008562796,0.9215275,0.000023447155,0.011776257,0.008473945],"study_design_scores_gemma":[0.15286666,0.022386448,0.00009004671,0.00000938812,0.0000079845095,0.000030181845,0.000039702307,0.000053759977,0.7757161,0.0000187021,0.04862565,0.0001553302],"about_ca_topic_score_codex":0.00014310476,"about_ca_topic_score_gemma":0.00025648778,"teacher_disagreement_score":0.14581136,"about_ca_system_score_codex":0.000035387176,"about_ca_system_score_gemma":0.00057107775,"threshold_uncertainty_score":0.81641495},"labels":[],"label_agreement":null},{"id":"W2142088037","doi":"10.1093/annonc/mdu087","title":"Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Propensity score matching; Prostate cancer; Internal medicine; Radiation therapy; Number needed to treat; Cancer; Population; Confidence interval; Randomized controlled trial; Oncology; Relative risk","score_opus":0.0271043041895069,"score_gpt":0.33055527135605817,"score_spread":0.3034509671665513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142088037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505323,0.00008661532,0.0000034453258,0.0028897075,0.00015711643,0.0016955552,0.00005363743,0.000021178863,0.000039527265],"genre_scores_gemma":[0.9979585,0.00018178824,0.000076321376,0.0013423425,0.000040795105,0.0001725217,0.00019078904,0.000021472293,0.000015505031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987512,0.00011954375,0.00036910558,0.0002994158,0.00022619858,0.00023449275],"domain_scores_gemma":[0.9988324,0.00012556532,0.0002521802,0.00023178359,0.00045150844,0.00010658469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030363773,0.00015745891,0.00056418846,0.00019224412,0.000037937443,0.0000059113813,0.000053294356,0.00006821413,0.00002530343],"category_scores_gemma":[0.00007794108,0.00011813209,0.000039365932,0.00029035736,0.000019479494,0.000047566562,0.000013731847,0.000104602885,0.0000036442111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003836935,0.0024815414,0.8276684,0.000009747105,0.00011440176,0.0000045694887,0.00045435491,0.0018432577,0.000009975567,0.0000120326295,0.0000614668,0.16350327],"study_design_scores_gemma":[0.011829708,0.027065316,0.959754,0.00006253274,0.000052356565,1.4949842e-7,0.000028809645,0.00007209934,0.00045595708,0.000062439016,0.00050758896,0.00010907941],"about_ca_topic_score_codex":0.009230848,"about_ca_topic_score_gemma":0.005182223,"teacher_disagreement_score":0.1633942,"about_ca_system_score_codex":0.00019640886,"about_ca_system_score_gemma":0.00018162413,"threshold_uncertainty_score":0.9973668},"labels":[],"label_agreement":null},{"id":"W2142190412","doi":"10.1093/annonc/mdr336","title":"A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Cancer; Urology; Surgery; Toxicity; Clinical trial","score_opus":0.12227081436402093,"score_gpt":0.4053715914620224,"score_spread":0.28310077709800147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142190412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923102,0.0003663056,4.249125e-7,0.00028843613,0.0000275788,0.00597288,0.00010272639,0.000015376965,0.0009160479],"genre_scores_gemma":[0.99855715,0.0001117393,0.0001485403,0.00013465468,0.000010082661,0.0008270513,0.000079406855,0.000030972446,0.00010038351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737066,0.0004816235,0.0006703577,0.00046412737,0.00037828757,0.0006349493],"domain_scores_gemma":[0.99814016,0.00009067752,0.00041671284,0.00034965875,0.0006732204,0.000329601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005191224,0.00027870425,0.0010792257,0.0005473529,0.00006583534,0.000005066384,0.00014842524,0.00009215943,0.00015391971],"category_scores_gemma":[0.00003992314,0.00017328499,0.00004340079,0.0007339644,0.00026210284,0.00011256033,0.000030588297,0.000271768,0.000002201889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044567708,0.054895718,0.8703356,0.00009665007,0.0012642221,0.0019196821,0.014047659,0.000009652992,0.00008904817,0.0000070295187,0.00008060772,0.012686458],"study_design_scores_gemma":[0.053380646,0.34769142,0.5931748,0.00006685828,0.0005063276,0.000008097506,0.0045361603,0.0000057280636,0.0002398592,0.000012155987,0.00023487912,0.00014306637],"about_ca_topic_score_codex":0.19010043,"about_ca_topic_score_gemma":0.5451847,"teacher_disagreement_score":0.35508427,"about_ca_system_score_codex":0.0003214687,"about_ca_system_score_gemma":0.0018675149,"threshold_uncertainty_score":0.8152928},"labels":[],"label_agreement":null},{"id":"W2142353844","doi":"10.1093/annonc/mdr583","title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Quality of life (healthcare); Carboplatin; Ovarian cancer; Internal medicine; Paclitaxel; Chemotherapy; Cancer; Physical therapy; Surgery; Cisplatin","score_opus":0.22290881291297554,"score_gpt":0.4564747042049889,"score_spread":0.23356589129201338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142353844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9242003,0.0038433275,0.0000047006674,0.06743236,0.0008663527,0.00083110307,0.00068940147,0.000008869587,0.0021236087],"genre_scores_gemma":[0.9967919,0.0007782362,0.00010083773,0.0016614802,0.00042474974,0.000059716247,0.00014848067,0.000009959722,0.00002462359],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972978,0.0006430526,0.0013043752,0.00021713538,0.00021377695,0.00032381306],"domain_scores_gemma":[0.99694824,0.0015355698,0.0009126777,0.0002925699,0.00015274866,0.0001581717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015380408,0.00013535176,0.0010082152,0.000057921352,0.000031935655,0.000001960802,0.000070325674,0.00016830605,0.00007898595],"category_scores_gemma":[0.0006725953,0.000092533264,0.00014799027,0.00019896677,0.00012899177,0.000039277787,0.00003659713,0.00021746363,0.000006024915],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2212353,0.013953855,0.2456944,0.0001525975,0.0022525347,0.000046073572,0.019560369,0.00010863578,0.00015933524,0.0061621536,0.07378285,0.4168919],"study_design_scores_gemma":[0.069168694,0.003528898,0.9187995,0.00022300314,0.00008313159,0.0000023522034,0.0003483064,0.000023896137,0.00056251924,0.00027238022,0.006890364,0.000096952295],"about_ca_topic_score_codex":0.0957111,"about_ca_topic_score_gemma":0.0083935,"teacher_disagreement_score":0.6731051,"about_ca_system_score_codex":0.00016995863,"about_ca_system_score_gemma":0.00083159277,"threshold_uncertainty_score":0.9103106},"labels":[],"label_agreement":null},{"id":"W2142391402","doi":"10.1093/annonc/mdv251","title":"Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; Kelowna General Hospital; University of British Columbia; BC Cancer Agency","funders":"Michael Smith Health Research BC","keywords":"Medicine; Tamoxifen; Ductal carcinoma; Internal medicine; Hazard ratio; Oncology; Population; Cohort; Breast cancer; Gynecology; Cancer; Confidence interval","score_opus":0.038863185177406084,"score_gpt":0.3528306983675647,"score_spread":0.3139675131901586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142391402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985017,0.00012396858,0.0000010916199,0.0005508004,0.00003182331,0.00053169933,0.00023174877,5.438165e-7,0.000026620699],"genre_scores_gemma":[0.9998485,0.000005625036,0.000011320362,0.00007033991,0.00001084226,0.000026393214,0.000019461631,0.000005323996,0.000002180495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991712,0.00021559802,0.000234422,0.00015503388,0.0001248865,0.000098890894],"domain_scores_gemma":[0.99891406,0.00005242572,0.00035893003,0.00037361344,0.0002836367,0.000017327873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015924571,0.00010016496,0.00031966658,0.00003786416,0.000025859905,9.2540887e-7,0.0001500056,0.000038101767,0.0000013575377],"category_scores_gemma":[0.00006669244,0.000044315988,0.00015340355,0.00022834007,0.00016835854,0.0000021245196,0.00006552102,0.000028724622,6.704043e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013218005,0.001388741,0.9924461,0.0000065653535,0.0006284141,6.731757e-8,0.00031270276,0.0010670478,0.0020087226,0.000003326776,0.000034124423,0.0007823776],"study_design_scores_gemma":[0.0025368426,0.0023759587,0.9766182,0.00000474188,0.00014253131,5.697529e-7,0.0001251331,0.00002051346,0.018105129,0.000022102526,0.000009571539,0.000038713573],"about_ca_topic_score_codex":0.0018183093,"about_ca_topic_score_gemma":0.0019482059,"teacher_disagreement_score":0.016096408,"about_ca_system_score_codex":0.000022039898,"about_ca_system_score_gemma":0.00012611515,"threshold_uncertainty_score":0.2748752},"labels":[],"label_agreement":null},{"id":"W2142413768","doi":"10.1093/annonc/mdt433","title":"Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Council of University Libraries; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; Toronto General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Medicine; CINAHL; MEDLINE; Observational study; Cochrane Library; Quality of life (healthcare); Breast cancer; Family medicine; Cancer; Systematic review; Gerontology; Meta-analysis; Psychological intervention; Internal medicine; Psychiatry; Nursing","score_opus":0.2653460981351488,"score_gpt":0.4898717046662034,"score_spread":0.22452560653105458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142413768","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000824019,0.98888063,0.000002013976,0.00064491236,0.000099382785,0.008830758,0.00003061704,0.000018168927,0.00066947134],"genre_scores_gemma":[0.00013144586,0.98287547,0.000045590055,0.0021594698,0.00004782489,0.012868228,0.000030572424,0.000030140276,0.0018112465],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972984,0.00024299661,0.0013215082,0.00047609603,0.0002968435,0.00036416497],"domain_scores_gemma":[0.99734664,0.0002354288,0.0011734153,0.0005960505,0.00037140376,0.00027707443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022630318,0.00044694598,0.005165607,0.00021813731,0.000019558447,0.000004909307,0.0002757786,0.00023815702,0.0014757022],"category_scores_gemma":[0.00018979606,0.00024507905,0.00025680606,0.00062355417,0.000060434006,0.00005220318,0.000034519115,0.00024682996,0.00026026144],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011103898,0.00014118591,0.00012647924,0.5776386,0.00020182169,0.000014086505,0.00033439373,1.7917014e-7,9.194996e-8,0.0000031848342,0.0023603698,0.4191685],"study_design_scores_gemma":[0.00039689735,0.0018714593,0.000098732555,0.7713488,0.0011744443,0.000014060066,0.00014084857,6.872158e-7,0.000002739901,7.606769e-7,0.2247689,0.00018171652],"about_ca_topic_score_codex":0.002922159,"about_ca_topic_score_gemma":0.00060937885,"teacher_disagreement_score":0.4189868,"about_ca_system_score_codex":0.000414011,"about_ca_system_score_gemma":0.002699547,"threshold_uncertainty_score":0.9994371},"labels":[],"label_agreement":null},{"id":"W2142453326","doi":"10.1093/annonc/mdt218","title":"Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph)","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Canadian Science Centre for Human and Animal Health; Lunenfeld-Tanenbaum Research Institute; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Odds ratio; Internal medicine; Confidence interval; Epidemiology; Etiology; Lymphoma; Confounding; Nodular sclerosis; Case-control study; Oncology; Hodgkin lymphoma","score_opus":0.11935347982163717,"score_gpt":0.3995361259983531,"score_spread":0.2801826461767159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142453326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1569152,0.8395714,0.000005728986,0.0015488414,0.00022963656,0.0006652103,0.00055768323,0.000014498693,0.00049179775],"genre_scores_gemma":[0.0728744,0.9252001,0.00011519131,0.0010149284,0.00017075373,0.00017579422,0.00033754244,0.000031636544,0.00007962494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596035,0.0010518418,0.0016442692,0.00071716495,0.00024640758,0.00037998604],"domain_scores_gemma":[0.98985344,0.0067177922,0.0022893946,0.00056168047,0.00038160718,0.00019609883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012752657,0.00050166267,0.0045285197,0.00043163725,0.00006790346,0.000014414448,0.00034785617,0.00069687114,0.00025634977],"category_scores_gemma":[0.0015630849,0.0003057721,0.0009624524,0.00034942434,0.00042518743,0.00006299494,0.00029156887,0.00013532276,0.000010466197],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111646055,0.00043739114,0.058454167,0.0005224957,0.03799386,0.00005743825,0.00016559445,4.3212492e-7,9.882888e-7,0.0003129352,0.0018874118,0.90005565],"study_design_scores_gemma":[0.004286275,0.0016784936,0.18549514,0.003298096,0.067070976,0.00030122325,0.00013663687,0.00016572236,0.00005612202,0.00036570826,0.7367576,0.00038802292],"about_ca_topic_score_codex":0.0027227893,"about_ca_topic_score_gemma":0.000248036,"teacher_disagreement_score":0.8996676,"about_ca_system_score_codex":0.00018492115,"about_ca_system_score_gemma":0.0005636489,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W2142580579","doi":"10.1093/annonc/mdu353.1","title":"Author Financial Conflicts of Interest (Fcois) in Clinical Practice Guidelines (Cpgs) for Systemic Anti-Cancer Drugs","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Practice; Cancer; Family medicine; Internal medicine","score_opus":0.8795847194007581,"score_gpt":0.7275724472455258,"score_spread":0.15201227215523228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142580579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89697784,0.001729394,0.00015633299,0.09505813,0.0023918161,0.0009112891,0.0001666855,0.000033433615,0.0025751041],"genre_scores_gemma":[0.9573161,0.0020276036,0.0006240108,0.038281716,0.0011107578,0.00013622356,0.000019448355,0.000023514755,0.00046062164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945055,0.0020126724,0.0022919667,0.0004268389,0.00013476892,0.00062824093],"domain_scores_gemma":[0.99148387,0.004880222,0.0010798809,0.00024993974,0.0019259163,0.00038017135],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0091467295,0.00023988925,0.0010955271,0.00016571279,0.000087039385,0.0000047041935,0.00044798345,0.0015903817,0.00023237393],"category_scores_gemma":[0.010847407,0.00023009516,0.00024389614,0.00024319396,0.00048736765,0.00016064031,0.00010975496,0.0015895017,0.000023433258],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010502044,0.004443503,0.0221443,0.0022821412,0.0006002606,0.00006882479,0.002271869,0.000733996,0.026983052,0.059445284,0.27834526,0.5921795],"study_design_scores_gemma":[0.003593841,0.0017724656,0.0016686992,0.00017844122,0.00015281435,0.000034046676,0.00031413473,0.0021634297,0.026568936,0.0006781978,0.96265405,0.00022093637],"about_ca_topic_score_codex":0.00011782517,"about_ca_topic_score_gemma":0.000086764485,"teacher_disagreement_score":0.68430877,"about_ca_system_score_codex":0.000047496153,"about_ca_system_score_gemma":0.0006651377,"threshold_uncertainty_score":0.9997058},"labels":[],"label_agreement":null},{"id":"W2142660045","doi":"10.1093/annonc/mdq609","title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","year":2010,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Sanofi","keywords":"Medicine; Cardiotoxicity; Anthracycline; Cancer; Oncology; Internal medicine; Chemotherapy; Breast cancer","score_opus":0.11116914729111185,"score_gpt":0.454645427319166,"score_spread":0.3434762800280542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142660045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008569748,0.9805674,0.000006132143,0.0042289677,0.00040397563,0.0016372564,0.000078329984,0.000020741361,0.0044874637],"genre_scores_gemma":[0.011595278,0.98132867,0.00007592454,0.005645741,0.0007105291,0.0004002789,0.00017093675,0.00003953627,0.000033095133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976289,0.00048499592,0.00082991604,0.00038427126,0.00034220307,0.00032971625],"domain_scores_gemma":[0.9982863,0.0003747638,0.00051718723,0.0005336216,0.00020145439,0.00008666338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006254322,0.00033570625,0.002109879,0.00021958193,0.00005762484,0.000009778187,0.00020646492,0.0010661046,0.0001380538],"category_scores_gemma":[0.00013812214,0.00022330772,0.0008398976,0.00036825627,0.00017664865,0.000090529065,0.000034381243,0.0010730346,0.000009741966],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068773086,0.00041149431,0.0000034411166,0.0013115844,0.00018529213,0.00007061858,0.0006954498,3.426731e-7,0.0026986694,0.000037926246,0.002499011,0.9920174],"study_design_scores_gemma":[0.00064290443,0.0019022237,0.000041686086,0.0038095405,0.00029465288,0.0002790733,0.000094510986,8.768553e-7,0.0033797892,0.000070072085,0.9892869,0.0001977514],"about_ca_topic_score_codex":0.0003837276,"about_ca_topic_score_gemma":0.00023520096,"teacher_disagreement_score":0.9918196,"about_ca_system_score_codex":0.00011830556,"about_ca_system_score_gemma":0.0006809279,"threshold_uncertainty_score":0.9106225},"labels":[],"label_agreement":null},{"id":"W2143017332","doi":"10.1093/annonc/mds337","title":"Light alcohol drinking and cancer: a meta-analysis","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Pharynx; Breast cancer; Esophagus; Larynx; Cancer; Relative risk; Internal medicine; Oncology; Gastroenterology; Confidence interval; Surgery","score_opus":0.6909387066955786,"score_gpt":0.5841122499766241,"score_spread":0.10682645671895441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143017332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015071313,0.9930471,0.0000057026236,0.0035120223,0.0001373144,0.0008214133,0.000013300007,0.000039705636,0.0024083257],"genre_scores_gemma":[0.0003490458,0.99573195,0.0001482355,0.0026488043,0.0002213384,0.00030452292,0.000033149052,0.00004271145,0.00052025745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772775,0.00043463206,0.00085084926,0.0003652813,0.00021197018,0.00040952713],"domain_scores_gemma":[0.9977912,0.00039589955,0.00087185134,0.00040629314,0.00019801296,0.00033680082],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011131726,0.00033031218,0.007014427,0.00067329936,0.000046175865,0.0000056659255,0.00010931803,0.00058258924,0.0009546709],"category_scores_gemma":[0.00007142066,0.0002239946,0.0022319115,0.00053197495,0.00007747801,0.00004160567,0.000084551466,0.00045708672,0.00004307985],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016841594,0.00010807095,0.000112776106,0.009925726,0.12726052,0.000024329373,0.00007876,5.5176596e-8,5.7788657e-7,0.0001835159,0.0013624831,0.86092633],"study_design_scores_gemma":[0.00014031275,0.00019899727,0.000053932963,0.00024176843,0.3755225,0.00004617078,0.0000020086366,6.177044e-7,0.0000012937088,0.000004820903,0.6236907,0.00009688206],"about_ca_topic_score_codex":0.000112611364,"about_ca_topic_score_gemma":0.000141248,"teacher_disagreement_score":0.8608295,"about_ca_system_score_codex":0.000058118694,"about_ca_system_score_gemma":0.0006116292,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W2143351292","doi":"10.1093/annonc/mdn477","title":"The changing face of hormonal therapy for prostate cancer","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Hormonal therapy; Oncology; Hormone; Prostate; Cancer; Internal medicine","score_opus":0.16613090493638386,"score_gpt":0.45866731350037276,"score_spread":0.2925364085639889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143351292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579772,0.020091077,0.000017315826,0.019794222,0.00008546401,0.0007698757,0.000039983064,0.0000074427376,0.001217448],"genre_scores_gemma":[0.93924767,0.055957593,0.000072771254,0.0004167347,0.00008512447,0.00020118407,0.000010669248,0.000009499757,0.003998744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993266,0.00002554563,0.00016012594,0.000094165836,0.00012769185,0.00026589798],"domain_scores_gemma":[0.99928576,0.00017812566,0.00009505025,0.00010666298,0.00028929385,0.000045112527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002521895,0.00006155944,0.0002203145,0.00006185888,0.00010415081,0.0000011254332,0.0000669021,0.000048732865,0.000019160476],"category_scores_gemma":[0.00003067054,0.000034192173,0.000086045315,0.00012184338,0.00025345324,0.00002167181,0.00001884369,0.00006270252,0.0000010845202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012484878,0.0006957009,0.021098075,0.00013295513,0.00077547785,0.00004186104,0.0095452545,0.000017017283,0.025251085,0.0004864533,0.035561424,0.8939098],"study_design_scores_gemma":[0.008631343,0.013977282,0.041762028,0.000077357494,0.000035160883,0.00003958836,0.0010612456,0.00016840562,0.32721013,0.0007183046,0.60619926,0.000119920674],"about_ca_topic_score_codex":0.00005102059,"about_ca_topic_score_gemma":0.0000107535525,"teacher_disagreement_score":0.8937899,"about_ca_system_score_codex":0.000023119386,"about_ca_system_score_gemma":0.00044251874,"threshold_uncertainty_score":0.13943163},"labels":[],"label_agreement":null},{"id":"W2143550524","doi":"10.1093/annonc/mdq221","title":"Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Placebo; Vascular endothelial growth factor; Chemotherapy; Carboplatin; Adverse effect; Bevacizumab; Pathology","score_opus":0.07189018913128711,"score_gpt":0.3951001062812657,"score_spread":0.3232099171499786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143550524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407625,0.00009636171,0.000021338677,0.0012147081,0.0004695757,0.004034712,0.000030803458,0.000026916734,0.000029360262],"genre_scores_gemma":[0.99649745,0.0013758185,0.00059026096,0.0008545608,0.00031674444,0.00023322608,0.000015392046,0.000058403486,0.000058142658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741966,0.00051589956,0.00086374395,0.0005224342,0.00034691574,0.00033132703],"domain_scores_gemma":[0.9978069,0.00080042775,0.00053370226,0.0003769972,0.00031869148,0.00016329055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011795562,0.0003444689,0.0016491533,0.00009711603,0.000087904926,0.000012418295,0.000109148896,0.0002679251,0.00006825863],"category_scores_gemma":[0.0003605026,0.00017033001,0.00020794185,0.00019551649,0.00015807453,0.00010899695,0.000024637133,0.00043730866,8.734624e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009133123,0.003461515,0.84251195,0.00005233897,0.00070845796,0.00000926735,0.0018365134,0.0000012327006,0.069618784,7.5733925e-7,0.000034339366,0.07263175],"study_design_scores_gemma":[0.058442514,0.024568228,0.8392886,0.00013498832,0.0004538498,0.0000070298665,0.0010307918,0.000036183254,0.0749101,0.0000020755758,0.0008337828,0.00029184905],"about_ca_topic_score_codex":0.00036919417,"about_ca_topic_score_gemma":0.0014831392,"teacher_disagreement_score":0.07233989,"about_ca_system_score_codex":0.00007824861,"about_ca_system_score_gemma":0.0002957452,"threshold_uncertainty_score":0.6945856},"labels":[],"label_agreement":null},{"id":"W2143695427","doi":"10.1093/annonc/mdm109","title":"Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"Wellcome Trust","keywords":"Methylenetetrahydrofolate reductase; Medicine; Odds ratio; Leukemia; Single-nucleotide polymorphism; Lung cancer; Cancer; Oncology; Myeloid leukemia; Internal medicine; Bladder cancer; Case-control study; Allele; Genotype; Immunology; Genetics; Cancer research; Gene; Biology","score_opus":0.03048870424028253,"score_gpt":0.3114338016942445,"score_spread":0.28094509745396196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143695427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541676,0.003637241,0.000051544153,0.00039130708,0.000056744564,0.00024804717,0.000012434521,0.0000010725016,0.0001848731],"genre_scores_gemma":[0.9981679,0.0010764933,0.00023308676,0.00047994626,0.000020594634,0.000008920092,0.0000017715103,0.000007630201,0.000003688646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902636,0.000074658834,0.00034398845,0.00023963592,0.00006232236,0.00025300923],"domain_scores_gemma":[0.9996204,0.000052548294,0.000060297938,0.00017810291,0.00003427099,0.000054415665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058339856,0.000103332975,0.00026267188,0.00010909689,0.000015199842,0.0000022893375,0.00011340719,0.00015170258,0.000004013681],"category_scores_gemma":[0.0000651071,0.000087122055,0.000041337647,0.00019467028,0.00014532005,0.0000037885302,0.00008271302,0.00010981617,1.0993861e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031171914,0.000051630515,0.60724676,0.00002262294,0.00001736277,0.000007573432,0.00048994157,0.00042681216,0.3765038,0.000043943397,0.000028740107,0.014849081],"study_design_scores_gemma":[0.00086091063,0.00034702296,0.91727567,0.000023517341,0.000008157488,0.000007524417,0.00040706617,0.00005555913,0.08038984,0.00011605919,0.0004137834,0.00009488882],"about_ca_topic_score_codex":0.0026481051,"about_ca_topic_score_gemma":0.049085192,"teacher_disagreement_score":0.31002888,"about_ca_system_score_codex":0.000024073623,"about_ca_system_score_gemma":0.00018978237,"threshold_uncertainty_score":0.96826655},"labels":[],"label_agreement":null},{"id":"W2143866789","doi":"10.1093/annonc/mdv027","title":"A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Amgen","keywords":"Medicine; Gemcitabine; Placebo; Internal medicine; Metastatic adenocarcinoma; Oncology; Double blind; Randomized controlled trial; Pancreatic ductal adenocarcinoma; Adenocarcinoma; Pancreatic cancer; Chemotherapy; Cancer; Pathology","score_opus":0.2032388795859554,"score_gpt":0.45263894581852937,"score_spread":0.24940006623257396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143866789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95717406,0.0007318601,0.0002536482,0.011082402,0.0002193355,0.028976437,0.000019788227,0.000009049568,0.0015334277],"genre_scores_gemma":[0.9931583,0.0005246424,0.000366299,0.00031393426,0.00018682053,0.0045242705,0.000025376055,0.000027093465,0.00087330124],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99550647,0.0016637328,0.0015252774,0.0002765296,0.00063663005,0.0003913614],"domain_scores_gemma":[0.9881718,0.008837872,0.001226672,0.00051049824,0.0011173767,0.00013574306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008692187,0.00025398014,0.0032034824,0.00028558073,0.00006828615,0.0000064174747,0.0003499082,0.00021227478,0.000111635345],"category_scores_gemma":[0.005548762,0.0001124809,0.00041532356,0.00044947775,0.00089998095,0.00007194167,0.00005320185,0.00030635615,0.000002347836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9831769,0.009416869,0.00023158231,0.00010776472,0.0016333923,0.00002128136,0.0016345375,0.000016698383,0.00006919864,0.0009828794,0.00061222096,0.0020966826],"study_design_scores_gemma":[0.89473003,0.09893993,0.00004544124,0.00009546324,0.0010991547,0.00004757634,0.0006718572,0.0014027194,0.0009438049,0.0014290136,0.0005003839,0.00009459764],"about_ca_topic_score_codex":0.00047250208,"about_ca_topic_score_gemma":0.00041970203,"teacher_disagreement_score":0.08952306,"about_ca_system_score_codex":0.000075994576,"about_ca_system_score_gemma":0.0030776071,"threshold_uncertainty_score":0.66427875},"labels":[],"label_agreement":null},{"id":"W2144125193","doi":"10.1023/a:1011141530545","title":"A National Cancer Institute of Canada Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Nausea; Vomiting; Leukopenia; Lethargy; Mucositis; Toxicity; Rash; Gastroenterology; Head and neck cancer; Internal medicine; Fluorouracil; Stomatitis; Anorexia; Cancer; Surgery; Chemotherapy","score_opus":0.16315542802933153,"score_gpt":0.4812285438689634,"score_spread":0.3180731158396319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144125193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949554,0.0020854906,9.124948e-7,0.001250513,0.00021749632,0.0007997333,0.00012272035,0.000003812516,0.00056392536],"genre_scores_gemma":[0.99744993,0.0016516945,0.00010923754,0.00055281806,0.000061219886,0.00008356056,0.000009510798,0.000009577709,0.000072432966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977504,0.00023236946,0.0011071806,0.0002829632,0.00038380866,0.00024327701],"domain_scores_gemma":[0.99816036,0.0004018541,0.00056894834,0.00011426484,0.00061972195,0.00013486695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010373555,0.00016144787,0.0015103014,0.000105284176,0.00005371883,0.0000013642359,0.00005727607,0.00009337884,0.00003425183],"category_scores_gemma":[0.0005866281,0.00012209166,0.00004304864,0.0002171959,0.00020944753,0.00010184848,0.000060831884,0.00017085134,4.2800593e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017388675,0.008322324,0.75185865,0.00017189619,0.00024033102,0.000043820033,0.0014952689,0.00006955622,0.00016370618,0.000011750023,0.0024259994,0.21780801],"study_design_scores_gemma":[0.0780667,0.06980387,0.8285853,0.00023747252,0.00018411709,0.000004508538,0.0006492435,0.000049010014,0.0003059876,0.000019049483,0.021900197,0.0001945422],"about_ca_topic_score_codex":0.13323584,"about_ca_topic_score_gemma":0.7173579,"teacher_disagreement_score":0.584122,"about_ca_system_score_codex":0.00010553954,"about_ca_system_score_gemma":0.0019260987,"threshold_uncertainty_score":0.872536},"labels":[],"label_agreement":null},{"id":"W2144249267","doi":"10.1093/annonc/mdu215","title":"In reply to the letter to the editor ‘in Reply to Gandaglia et al.’ by De Bari et al.","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Scopus; Prostate cancer; Population; Radiation therapy; Cancer; Oncology; MEDLINE; Internal medicine","score_opus":0.04513792577677822,"score_gpt":0.381398072069766,"score_spread":0.3362601462929878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144249267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030661267,0.0005160545,0.000035835525,0.9901347,0.0027087363,0.001660806,0.00016903951,0.000015698899,0.0016929726],"genre_scores_gemma":[0.001190182,0.0008020902,0.00021509943,0.98813766,0.0065311054,0.001199165,0.00013459587,0.00006139321,0.0017287295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968941,0.0006043099,0.0006563946,0.0007280653,0.00040610495,0.0007110037],"domain_scores_gemma":[0.9973948,0.0009319668,0.00021936158,0.0010956028,0.00018437952,0.00017386513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021748224,0.00035519956,0.0009302006,0.00022125561,0.000039932947,0.00002475718,0.00044454148,0.00031446634,0.00014574651],"category_scores_gemma":[0.00051505887,0.00021143332,0.0001720555,0.00026630014,0.00007163091,0.00004408587,0.00018586431,0.0013026574,0.00020933177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000320732,0.0002041889,0.00070437544,0.000028053048,0.00011263236,0.00050012366,0.0010443989,0.00002476074,0.000108265886,0.000010666575,0.9945429,0.0023989049],"study_design_scores_gemma":[0.0009958026,0.0037585697,0.0016112521,0.00029151223,0.00004728626,0.000029095605,0.000029546367,0.0000019844758,0.00087016716,0.00005348818,0.99210936,0.00020194372],"about_ca_topic_score_codex":0.002689228,"about_ca_topic_score_gemma":0.00094629044,"teacher_disagreement_score":0.003822369,"about_ca_system_score_codex":0.0003126367,"about_ca_system_score_gemma":0.00042137713,"threshold_uncertainty_score":0.8622},"labels":[],"label_agreement":null},{"id":"W2144330604","doi":"10.1093/annonc/mdv026","title":"Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Medical Research Council","keywords":"Medicine; Pharmacokinetics; Dosing; Nausea; Cohort; Internal medicine; Gastroenterology; Pharmacodynamics; Pharmacology; Peripheral neuropathy; Peripheral edema; Adverse effect; Endocrinology","score_opus":0.11643806936949803,"score_gpt":0.3845771656980994,"score_spread":0.2681390963286014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144330604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988571,0.0001265598,0.00005575205,0.00019913485,0.000056745845,0.00044029567,0.00007313761,0.0000051075385,0.00018620412],"genre_scores_gemma":[0.99971676,0.000025741378,0.000120008364,0.0000693899,0.00001845521,0.000012617576,0.0000147377905,0.00001193874,0.000010370355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898636,0.00006373617,0.00044878683,0.0001774947,0.00019246417,0.00013116245],"domain_scores_gemma":[0.9990879,0.00007143536,0.00022780277,0.000105093546,0.00041118817,0.00009657922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025610713,0.00011668058,0.0004974823,0.00023477344,0.000014328422,0.00000232454,0.00003143123,0.00008384809,0.000025088179],"category_scores_gemma":[0.000046840945,0.00009154139,0.000035393863,0.00014470768,0.00015662308,0.00014256411,0.000011070413,0.000114207374,1.2489676e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0117660435,0.021201111,0.024758382,0.00014641893,0.00021303727,0.000011010788,0.009497125,0.0000046426717,0.91727185,0.000012335533,0.0003144845,0.014803579],"study_design_scores_gemma":[0.07781458,0.17199045,0.30211714,0.00071036967,0.0003384555,0.00003097783,0.011267476,0.00012149474,0.43096542,0.000035477915,0.0043097874,0.00029837433],"about_ca_topic_score_codex":0.00025544767,"about_ca_topic_score_gemma":0.00009799865,"teacher_disagreement_score":0.48630643,"about_ca_system_score_codex":0.000021277177,"about_ca_system_score_gemma":0.00018654951,"threshold_uncertainty_score":0.37329495},"labels":[],"label_agreement":null},{"id":"W2144335178","doi":"10.1093/annonc/mds334","title":"EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":216,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Gynecology; Cancer; Clinical trial; Chemotherapy; Population","score_opus":0.10502075971506147,"score_gpt":0.4284765327166134,"score_spread":0.3234557730015519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144335178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857073,0.0023220975,0.000026800357,0.010384955,0.00030208615,0.00031928156,0.00031899792,0.000007929732,0.0006105524],"genre_scores_gemma":[0.9953119,0.0020434004,0.0002690468,0.0013829636,0.000679724,0.0001936982,0.00007586205,0.000015612883,0.00002776564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847484,0.00035612826,0.0005024908,0.00027057045,0.000101545666,0.0002944272],"domain_scores_gemma":[0.99871296,0.0003453387,0.0003020289,0.00025269244,0.00031867597,0.00006830068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036187138,0.00016342882,0.00033174173,0.000028001807,0.00005958983,0.0000057816474,0.00019096682,0.00019997373,0.00001819052],"category_scores_gemma":[0.00026212705,0.000116165786,0.00010786528,0.00008598221,0.0003786787,0.000011500918,0.00013088284,0.00013305245,0.000005279521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005541465,0.000416827,0.85553366,0.000004513956,0.0003295856,0.0000015409648,0.00036238966,0.0000029152932,0.018035624,0.000026580434,0.0019702222,0.122761995],"study_design_scores_gemma":[0.00089584896,0.00047004147,0.9799338,0.00003187163,0.000066858636,0.000006104321,0.0002822082,0.000015242508,0.015723396,0.00009565934,0.002371926,0.000107040316],"about_ca_topic_score_codex":0.0047170725,"about_ca_topic_score_gemma":0.0023448213,"teacher_disagreement_score":0.12440014,"about_ca_system_score_codex":0.000026247262,"about_ca_system_score_gemma":0.00013985479,"threshold_uncertainty_score":0.7130834},"labels":[],"label_agreement":null},{"id":"W2144906866","doi":"10.1093/annonc/mdu049","title":"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University College London; Cancer Research UK; Wellcome Trust; Harry J. Lloyd Charitable Trust","keywords":"Vemurafenib; Dabrafenib; Sanger sequencing; Cancer research; PTEN; Medicine; GNAQ; Melanoma; MEK inhibitor; Mutation; Biology; MAPK/ERK pathway; Genetics; PI3K/AKT/mTOR pathway; Kinase; Signal transduction; Gene","score_opus":0.06010748525716944,"score_gpt":0.3109945371453774,"score_spread":0.2508870518882079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144906866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97036296,0.000110871035,0.0137494225,0.0016816511,0.00011268796,0.00022368549,0.00007476131,0.000009528468,0.013674433],"genre_scores_gemma":[0.9929081,0.000030672407,0.0043837824,0.0018969243,0.0001320604,0.00001370549,0.00014272387,0.000013650345,0.00047833167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988876,0.00015171108,0.0003721194,0.00025971053,0.00010449513,0.00022437838],"domain_scores_gemma":[0.99909025,0.000031572323,0.0002309613,0.00031746484,0.00023795135,0.00009179074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004621555,0.00011350642,0.00031637526,0.000075966214,0.000034610377,0.0000032475298,0.00014693243,0.00016976435,0.000020536436],"category_scores_gemma":[0.00020028761,0.00011621542,0.00008121408,0.00010096418,0.00006846265,0.0000034852076,0.00010859526,0.000055559667,0.000013512092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119950535,0.00004569432,0.000032294818,0.000055574146,0.000021055836,0.0000040437926,0.00007056839,0.000018987053,0.9842906,0.009704838,0.0032101523,0.0024262378],"study_design_scores_gemma":[0.00039089515,0.0025580323,0.0017369628,0.00003101492,0.000009168163,0.000012797472,0.00005051889,0.0000032106393,0.84398454,0.0071857534,0.14390421,0.00013289966],"about_ca_topic_score_codex":0.000012067758,"about_ca_topic_score_gemma":0.00009503208,"teacher_disagreement_score":0.14069407,"about_ca_system_score_codex":0.000014244374,"about_ca_system_score_gemma":0.0000908764,"threshold_uncertainty_score":0.47391275},"labels":[],"label_agreement":null},{"id":"W2145300558","doi":"10.1093/annonc/mdm083","title":"Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Montmorency","funders":"Sanofi","keywords":"Docetaxel; Estramustine; Medicine; Prostate cancer; Internal medicine; Oncology; Chemotherapy; Clinical endpoint; Prostate-specific antigen; Urology; Phases of clinical research; Cancer; Randomized controlled trial","score_opus":0.09273829699834261,"score_gpt":0.42329552431899564,"score_spread":0.330557227320653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145300558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149287,0.0043292064,0.000008758917,0.0005314806,0.00005254739,0.0031084802,0.00003999326,0.000010790358,0.00042587434],"genre_scores_gemma":[0.99782735,0.0013839301,0.00018800561,0.00011445378,0.000021333828,0.00012934417,0.000037432652,0.00002103975,0.0002770872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997924,0.0001904419,0.0007375372,0.00030239165,0.0004205046,0.00042513575],"domain_scores_gemma":[0.9984073,0.0003136758,0.00041613026,0.00020225471,0.00047914233,0.00018151694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011569055,0.00021169914,0.0012839867,0.00036553372,0.000047282505,0.0000044353756,0.00007495464,0.00006835604,0.000035626705],"category_scores_gemma":[0.00016039413,0.0001356426,0.00006855668,0.00032833946,0.00040426,0.00009938467,0.00006568682,0.00021951001,5.8867283e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7970939,0.03659889,0.031899557,0.00031457611,0.0015509635,0.00039199513,0.009596857,0.000042425403,0.0020726784,0.000011865297,0.00027553437,0.12015071],"study_design_scores_gemma":[0.85802543,0.07869925,0.05790488,0.0001533169,0.00055770413,0.0000066212406,0.001480296,0.000048754537,0.0022215405,0.00003804371,0.00069225626,0.00017193069],"about_ca_topic_score_codex":0.0006810251,"about_ca_topic_score_gemma":0.00032552794,"teacher_disagreement_score":0.11997878,"about_ca_system_score_codex":0.00012399394,"about_ca_system_score_gemma":0.0003810296,"threshold_uncertainty_score":0.55313444},"labels":[],"label_agreement":null},{"id":"W2145330014","doi":"10.1093/annonc/mdu327.46","title":"Data-Driven Timing of Optimal Lvef Assessment in Breast Cancer Patients Exposed to Trastuzumab","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.2328503529427616,"score_gpt":0.5129398822640531,"score_spread":0.2800895293212915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145330014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852744,0.0000377527,0.00014345002,0.008952466,0.00014682839,0.0004979206,0.0003012854,0.000009301874,0.0046366155],"genre_scores_gemma":[0.99560076,0.000105610896,0.002978359,0.0010046706,0.00010938857,0.000055022374,0.00007283865,0.000020132902,0.00005324316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99816865,0.0001820404,0.00050983165,0.000328045,0.000434422,0.00037703497],"domain_scores_gemma":[0.9985751,0.00019151662,0.00015804003,0.0005074496,0.00038914484,0.00017873474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079057517,0.0001141737,0.0005775406,0.00023605478,0.000017425209,0.0000034686025,0.0003693226,0.00011410572,0.00047193677],"category_scores_gemma":[0.00016667429,0.00010468115,0.000046292844,0.00025448948,0.00010295064,0.00007582963,0.00026625497,0.00025371826,0.000010796158],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001853204,0.0038501804,0.36382186,0.00052727124,0.0002340271,0.000041637657,0.0017350384,0.00121593,0.018617308,0.000117541065,0.061045587,0.54694045],"study_design_scores_gemma":[0.005125073,0.009603108,0.91887283,0.0005388936,0.00005237661,0.000012834253,0.00031287348,0.007361751,0.0063718986,0.000021533655,0.051515743,0.00021109729],"about_ca_topic_score_codex":0.000701804,"about_ca_topic_score_gemma":0.0003710671,"teacher_disagreement_score":0.55505097,"about_ca_system_score_codex":0.00020635915,"about_ca_system_score_gemma":0.00087475276,"threshold_uncertainty_score":0.51673764},"labels":[],"label_agreement":null},{"id":"W2145378676","doi":"10.1093/annonc/mdn292","title":"Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies","year":2008,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Dalhousie University","funders":"","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Anthracycline; Doxorubicin; Breast cancer; Oncology; Internal medicine; Adjuvant; Pharmacology; Cancer; Chemotherapy","score_opus":0.2965734513227626,"score_gpt":0.5799490487503968,"score_spread":0.2833755974276342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145378676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026046176,0.9927558,0.000019624193,0.0024529824,0.0008531776,0.0016850575,0.0007344216,0.000038950104,0.0011995331],"genre_scores_gemma":[0.00020048016,0.9955008,0.0003457162,0.00016983706,0.0026924873,0.0007764129,0.00010496736,0.000087317756,0.000121959354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674165,0.00023311003,0.0010046419,0.00078631844,0.00046696025,0.0007673426],"domain_scores_gemma":[0.99736834,0.00043106233,0.00072443875,0.000579071,0.0005742107,0.00032285982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030965838,0.00053382065,0.0029554944,0.00028361782,0.00015938238,0.000032141066,0.00034949483,0.0006254889,0.00018217156],"category_scores_gemma":[0.00008410895,0.0004226257,0.00046572828,0.00032897716,0.0008528144,0.0001676116,0.00015699615,0.00088776933,0.0000047076733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015119949,0.00030578935,0.00002483258,0.018359981,0.00018414427,0.000067625435,0.0005721363,3.6410984e-7,0.00001012203,0.00014791555,0.029766995,0.9504089],"study_design_scores_gemma":[0.0007440863,0.0011406526,0.00013135748,0.012510355,0.00021294472,0.001200414,0.0004543597,0.000006295968,0.000019073328,0.000046477824,0.9832161,0.00031787972],"about_ca_topic_score_codex":0.00020215512,"about_ca_topic_score_gemma":0.000032405518,"teacher_disagreement_score":0.95344913,"about_ca_system_score_codex":0.00026559772,"about_ca_system_score_gemma":0.0052251867,"threshold_uncertainty_score":0.99982256},"labels":[],"label_agreement":null},{"id":"W2145620806","doi":"10.1093/annonc/mds235","title":"Glycemic index, glycemic load and cancer risk","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Agency of Canada","funders":"","keywords":"Medicine; Internal medicine; Odds ratio; Glycemic index; Glycemic load; Gastroenterology; Rectum; Population; Quartile; Cancer; Prostate cancer; Oncology; Confidence interval; Glycemic; Insulin","score_opus":0.06672695634870578,"score_gpt":0.392639598777528,"score_spread":0.32591264242882223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145620806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95337707,0.027431378,0.0000064911983,0.0060146973,0.00020110181,0.00011950698,0.00003473449,0.000012028948,0.012802979],"genre_scores_gemma":[0.97317916,0.023723336,0.000106853855,0.0024143555,0.0003894821,0.00002074558,0.0000042066536,0.000007061721,0.00015481346],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99934167,0.000021170874,0.00016649503,0.00010318984,0.00012084921,0.00024660723],"domain_scores_gemma":[0.99942446,0.00010726763,0.00010136418,0.00008506784,0.00015598575,0.00012585649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012950746,0.000077918165,0.00029350637,0.00003539814,0.000045840785,0.0000011810331,0.000030520354,0.00010368506,0.00017835062],"category_scores_gemma":[0.000092401315,0.00006425679,0.00005216994,0.00006915933,0.00014025778,0.00004270468,0.000050919436,0.00012760721,0.00001618225],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0128476005,0.0009510409,0.7329415,0.00016631816,0.00040477552,0.000017641,0.00052184344,0.0000016967473,0.0013796454,0.0010631037,0.13367495,0.11602986],"study_design_scores_gemma":[0.0045135664,0.002897671,0.2456696,0.00005634652,0.00010298243,0.000067117486,0.00020492412,0.000007946872,0.00058850326,0.001001569,0.7447861,0.00010367527],"about_ca_topic_score_codex":0.0008237247,"about_ca_topic_score_gemma":0.000071951334,"teacher_disagreement_score":0.61111116,"about_ca_system_score_codex":0.000041802854,"about_ca_system_score_gemma":0.00009663146,"threshold_uncertainty_score":0.26203158},"labels":[],"label_agreement":null},{"id":"W2145708032","doi":"10.1023/a:1012208711013","title":"Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Vindesine; Gemcitabine; Internal medicine; Lung cancer; Nausea; Leukopenia; Performance status; Phases of clinical research; Clinical endpoint; Neutropenia; Chemotherapy; Gastroenterology; Surgery; Clinical trial; Oncology; Vincristine; Cyclophosphamide","score_opus":0.0746373964756905,"score_gpt":0.4710071340295249,"score_spread":0.39636973755383437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145708032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911168,0.0009444288,0.000040807485,0.00081139756,0.00033955617,0.0039800913,0.0000272196,0.00001783942,0.0027218326],"genre_scores_gemma":[0.99738085,0.0007478721,0.00050893775,0.00019388348,0.00006815621,0.0003687329,0.000019125328,0.000024922352,0.00068750867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978303,0.0002059073,0.0010347305,0.00040181298,0.00019798666,0.00032929497],"domain_scores_gemma":[0.997449,0.0009705568,0.0005866011,0.0003351076,0.000502347,0.00015641315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006064213,0.00020801004,0.0010415972,0.00021798939,0.00004682712,0.0000034547716,0.000101314756,0.00013217956,0.00014548011],"category_scores_gemma":[0.0003702007,0.00017848481,0.00016078055,0.00040338453,0.00008375748,0.00006983764,0.000045779427,0.00017785301,0.0000023767045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7321852,0.04738107,0.13516048,0.00011835208,0.001388267,0.00057427015,0.01136618,0.0013297274,0.010911563,0.000005692069,0.0002698478,0.05930936],"study_design_scores_gemma":[0.7609506,0.05334926,0.1722619,0.00025977945,0.0013494103,0.0000075625876,0.0051186634,0.0010267969,0.004110827,0.000010297229,0.001330724,0.00022416325],"about_ca_topic_score_codex":0.00056495046,"about_ca_topic_score_gemma":0.001260751,"teacher_disagreement_score":0.059085198,"about_ca_system_score_codex":0.00029911034,"about_ca_system_score_gemma":0.00055981585,"threshold_uncertainty_score":0.72783995},"labels":[],"label_agreement":null},{"id":"W2145958517","doi":"10.1093/annonc/mdp307","title":"Malignant peritoneal mesothelioma: a multicenter study on 81 cases","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Thrombocytosis; Ascites; Vomiting; Abdominal pain; Laparotomy; Mesothelioma; Peritoneal mesothelioma; Abdominal mass; Abdominal distension; Malignancy; Surgery; Radiology; Internal medicine; Pathology","score_opus":0.08841458553500976,"score_gpt":0.4117028534851097,"score_spread":0.32328826795009996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145958517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899939,0.0001711094,6.3272466e-7,0.0044374163,0.000056713252,0.00029744772,0.000025217729,0.000015331501,0.005002256],"genre_scores_gemma":[0.9949574,0.000039183695,0.00006272595,0.0045310194,0.000075016826,0.00001087538,0.000015025499,0.0000061838105,0.00030257713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927294,0.00004840981,0.00019348765,0.00016018478,0.00017647282,0.00014848764],"domain_scores_gemma":[0.9995875,0.00007465083,0.000061615065,0.00014370124,0.000031563683,0.000100963174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007869876,0.00009223124,0.00023961891,0.00007157577,0.000030803938,0.0000021478936,0.000046864592,0.000043971966,0.0002088807],"category_scores_gemma":[0.000050164534,0.000069130816,0.000083290346,0.00005174646,0.00005737454,0.00002848951,0.00001605108,0.000054823064,0.00007827356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014129712,0.05577426,0.78753597,0.00006586753,0.0004024798,0.0042316755,0.0017303496,0.00003176267,0.019987429,0.00060623366,0.021330073,0.09417419],"study_design_scores_gemma":[0.0016851181,0.02204173,0.9660956,0.00002860352,0.000068185785,0.00004266709,0.0005186304,0.000012082678,0.003120378,0.00005995636,0.006259478,0.00006751381],"about_ca_topic_score_codex":0.000034508357,"about_ca_topic_score_gemma":0.0000056196354,"teacher_disagreement_score":0.17855969,"about_ca_system_score_codex":0.000023826138,"about_ca_system_score_gemma":0.000035134977,"threshold_uncertainty_score":0.2819073},"labels":[],"label_agreement":null},{"id":"W2146171264","doi":"10.1093/annonc/mdt386","title":"An update on a systematic review of the use of geriatric assessment for older adults in oncology","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Council of University Libraries; Université de Montréal; McGill University; Jewish General Hospital; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Geriatric oncology; Oncology; Gerontology; Clinical Oncology; Internal medicine; Cancer","score_opus":0.18382306977443985,"score_gpt":0.4823751972316865,"score_spread":0.29855212745724663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146171264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012258605,0.98073155,0.000014586457,0.0020088668,0.0004006514,0.016164852,0.00018836591,0.000010869525,0.0003576701],"genre_scores_gemma":[0.00008767046,0.99337673,0.0017312011,0.0023013223,0.00007722738,0.002026796,0.00015149008,0.000060897248,0.00018666523],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9933677,0.0018904255,0.0034430448,0.0004897052,0.00040830768,0.00040085177],"domain_scores_gemma":[0.9904572,0.0026413985,0.0043295417,0.0015085313,0.00093821133,0.0001251252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018146476,0.00045895288,0.00817446,0.0004638714,0.000017868404,0.000003646317,0.00063849695,0.00073606503,0.000118822354],"category_scores_gemma":[0.0022775568,0.0002717844,0.0010513061,0.00061541575,0.00018530533,0.000085880354,0.00012186768,0.00052365195,0.000013636823],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045305238,0.0012455537,0.0000039920387,0.6919259,0.00029644946,0.000008368172,0.00006173261,6.4718927e-7,7.0582746e-7,0.00011456873,0.009648881,0.2966479],"study_design_scores_gemma":[0.0011312146,0.00464673,0.000059403454,0.62356734,0.0022489356,0.00007319528,0.000020272317,0.000015574795,0.000005932004,0.000013956765,0.36806914,0.00014829791],"about_ca_topic_score_codex":0.000105689265,"about_ca_topic_score_gemma":0.000051123054,"teacher_disagreement_score":0.35842025,"about_ca_system_score_codex":0.00027479176,"about_ca_system_score_gemma":0.0019998855,"threshold_uncertainty_score":0.9999734},"labels":[],"label_agreement":null},{"id":"W2146186748","doi":"10.1093/annonc/mdt120","title":"Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostatectomy; Lymph node; Prostate cancer; Dissection (medical); Stage (stratigraphy); Logistic regression; Nomogram; Cancer; Urology; Internal medicine; Oncology; Surgery","score_opus":0.04226267820794874,"score_gpt":0.3525576686654594,"score_spread":0.31029499045751063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146186748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776914,0.0010652955,6.6975275e-7,0.016507672,0.00016678609,0.0006589762,0.000025390525,0.0000139569465,0.0038698632],"genre_scores_gemma":[0.99492973,0.0027668516,0.00009172387,0.0012056384,0.00005441427,0.0005870902,0.00003174634,0.000015297515,0.00031750428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989437,0.00005676398,0.000333743,0.00024328513,0.000103432554,0.00031909527],"domain_scores_gemma":[0.99946296,0.000050278424,0.00012460368,0.00015377789,0.0001227602,0.00008563747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011146038,0.00012009872,0.00039434808,0.00017848026,0.000013549856,0.0000059868416,0.0000455659,0.00007939018,0.00034943197],"category_scores_gemma":[0.0000348231,0.000101101876,0.00006112959,0.00020788272,0.0000591395,0.00009828254,0.000029088522,0.000096752614,0.000040671777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065625645,0.0038302834,0.8783384,0.00013327932,0.000076432414,0.00018138996,0.0010200519,0.000035779754,0.0044100606,0.00004027961,0.0061040865,0.1051737],"study_design_scores_gemma":[0.0070906044,0.0024733795,0.9686725,0.0004377854,0.000023520588,0.00003937518,0.00032902713,0.000093326475,0.008313412,0.0005418145,0.011857278,0.00012794629],"about_ca_topic_score_codex":0.002382489,"about_ca_topic_score_gemma":0.0014214327,"teacher_disagreement_score":0.10504576,"about_ca_system_score_codex":0.00034895825,"about_ca_system_score_gemma":0.00021132968,"threshold_uncertainty_score":0.41228148},"labels":[],"label_agreement":null},{"id":"W2146200359","doi":"10.1093/annonc/mdu550","title":"A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"National Cancer Institute; Moffitt Cancer Center","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Neutropenia; Clinical endpoint; Oncology; Chemotherapy; Gastroenterology; Randomized controlled trial; Confidence interval","score_opus":0.04112178112110001,"score_gpt":0.3901629102489096,"score_spread":0.3490411291278096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146200359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888943,0.001702716,0.00022966847,0.0027979815,0.00057831634,0.0048531033,0.00003383478,0.000025805866,0.00088429375],"genre_scores_gemma":[0.99252754,0.001831448,0.0005056193,0.0029679174,0.00020936837,0.00071357697,0.0000071675136,0.000042323223,0.0011950083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99745417,0.00039442256,0.00091888517,0.0004427953,0.000297365,0.0004923793],"domain_scores_gemma":[0.99668586,0.0010452309,0.00076540443,0.0006153187,0.0007261723,0.00016198808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013090678,0.00029956078,0.0016496807,0.00016336209,0.00015224879,0.0000051206403,0.00032284413,0.00015716786,0.000083428466],"category_scores_gemma":[0.00075445604,0.0001877365,0.00042669327,0.00033866748,0.00033751363,0.00007049388,0.00009037654,0.00023319063,0.00000191899],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4099067,0.01797535,0.0034213318,0.0006066784,0.0010646944,0.000029070554,0.01260353,0.00008819204,0.23448221,0.00018041201,0.010071817,0.30957],"study_design_scores_gemma":[0.6484593,0.02657133,0.00074144,0.00028027545,0.00038814807,0.000014370296,0.0016972582,0.0008764662,0.2954869,0.00020841381,0.024953883,0.00032220696],"about_ca_topic_score_codex":0.000436293,"about_ca_topic_score_gemma":0.00016419114,"teacher_disagreement_score":0.30924782,"about_ca_system_score_codex":0.000041549218,"about_ca_system_score_gemma":0.0005069289,"threshold_uncertainty_score":0.76556724},"labels":[],"label_agreement":null},{"id":"W2146778300","doi":"10.1093/annonc/mdm500","title":"Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cognition; Neuropsychology; Cancer; Breast cancer; Psychiatry; Internal medicine","score_opus":0.09333407593134974,"score_gpt":0.444702588378495,"score_spread":0.3513685124471453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146778300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9422398,0.013702857,0.00008399152,0.028038384,0.0009985709,0.00077333377,0.00028367245,0.00004765208,0.013831744],"genre_scores_gemma":[0.96696985,0.02405003,0.000021480066,0.007407787,0.0007535383,0.00012375454,0.00006410698,0.000026718672,0.0005827375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99844235,0.00012289494,0.00037760395,0.00044990142,0.00028623,0.0003210448],"domain_scores_gemma":[0.99581736,0.0016682828,0.00032163115,0.00011650119,0.0019453669,0.00013086623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004806941,0.00021703706,0.00044216885,0.00012487204,0.00016297225,0.000011103853,0.000099141376,0.00021762351,0.0007710538],"category_scores_gemma":[0.0006083182,0.0001686364,0.00010204579,0.00031847245,0.0007097038,0.00018958395,0.000070390335,0.0004929161,0.000010095522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021382954,0.0012335869,0.118260324,0.0000110570045,0.0069196457,0.00014386627,0.024862928,0.000005912447,0.0008479318,0.00040654317,0.00440328,0.821522],"study_design_scores_gemma":[0.012266692,0.004319855,0.8978358,0.00077208044,0.00071942504,0.00006453325,0.056500852,0.000050824343,0.0044662957,0.0009824993,0.021703828,0.00031733906],"about_ca_topic_score_codex":0.003001392,"about_ca_topic_score_gemma":0.0021378228,"teacher_disagreement_score":0.8212046,"about_ca_system_score_codex":0.00023935236,"about_ca_system_score_gemma":0.0003399458,"threshold_uncertainty_score":0.8442498},"labels":[],"label_agreement":null},{"id":"W2146792947","doi":"10.1093/annonc/mdt132","title":"Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; CancerCare Manitoba; Sunnybrook Health Science Centre; University of Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation","keywords":"Tamoxifen; Estrogen receptor; Breast cancer; Tissue microarray; Hazard ratio; Medicine; Internal medicine; Oncology; Estrogen receptor alpha; Immunohistochemistry; Estrogen; Placebo; Progesterone receptor; Endocrinology; Cancer; Confidence interval; Pathology","score_opus":0.013597968954814665,"score_gpt":0.2701196207935026,"score_spread":0.2565216518386879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146792947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923001,0.0017095582,0.000010859276,0.0003899823,0.00011298168,0.0029783265,0.0024355277,0.000017095497,0.000045563334],"genre_scores_gemma":[0.9968237,0.000620906,0.00084020454,0.00011153732,0.00017505011,0.00081791444,0.00044954225,0.0000797816,0.00008133188],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975748,0.00026642287,0.00058720587,0.00074606924,0.00028988966,0.00053559715],"domain_scores_gemma":[0.9977305,0.00010586935,0.00087901286,0.00037815206,0.0006561501,0.00025029603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001966305,0.0004528793,0.00077242625,0.0001238664,0.00009220589,0.00001945807,0.00032800448,0.0007130957,0.00013040964],"category_scores_gemma":[0.00005212316,0.00035898184,0.00015932269,0.00016514305,0.00026306103,0.000069869435,0.000117245756,0.00026578445,0.0000049013556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008654089,0.0007945558,0.09208473,0.000050322767,0.00061973167,6.2924545e-7,0.0005138521,0.000017463124,0.8840761,0.000012438967,0.001703043,0.011473003],"study_design_scores_gemma":[0.0054944693,0.008944366,0.09682266,0.00029225159,0.000032670046,9.436013e-7,0.00015108025,0.0000102682625,0.88683724,0.00005025985,0.0010180019,0.00034579504],"about_ca_topic_score_codex":0.00041496335,"about_ca_topic_score_gemma":0.000014247351,"teacher_disagreement_score":0.011127207,"about_ca_system_score_codex":0.000059541973,"about_ca_system_score_gemma":0.00023336743,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W2147002657","doi":"10.1093/annonc/mdu272","title":"Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis","year":2014,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; Ottawa Hospital; McMaster University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Meta-analysis; Colorectal cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.2106963248666733,"score_gpt":0.48585097930410576,"score_spread":0.2751546544374325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147002657","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043747463,0.9943597,0.0000021379387,0.0012143869,0.00006371878,0.003364152,0.00008111218,0.000020608766,0.0008504438],"genre_scores_gemma":[0.0006612381,0.9957574,0.000047551144,0.0007444243,0.000017295773,0.0025340314,0.000032973923,0.00003754364,0.00016755624],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969362,0.0005967394,0.0014982085,0.00046355237,0.00020637365,0.00029893892],"domain_scores_gemma":[0.9973488,0.0007905268,0.0012274848,0.0003137149,0.0002263076,0.00009318253],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0007355596,0.00051865587,0.020293009,0.00039241262,0.000022634824,0.000013633295,0.00014747708,0.00015824373,0.00015536997],"category_scores_gemma":[0.00016993734,0.00030239054,0.002420377,0.00062610494,0.00017756308,0.00003890673,0.00006718519,0.00023951444,0.0000030906795],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013485948,0.00021100751,0.0000026037353,0.5931341,0.35222763,0.00006290756,0.00013495407,2.0444413e-7,3.659081e-8,0.000048177106,0.00030466664,0.05373887],"study_design_scores_gemma":[0.000890409,0.00322008,0.000013365125,0.019600617,0.88194054,0.0000426606,0.00013621821,0.0000014773309,4.4933088e-7,0.000011778799,0.09393329,0.00020909251],"about_ca_topic_score_codex":0.00037045626,"about_ca_topic_score_gemma":0.0015348913,"teacher_disagreement_score":0.5735335,"about_ca_system_score_codex":0.00015432111,"about_ca_system_score_gemma":0.00048206607,"threshold_uncertainty_score":0.99994284},"labels":[],"label_agreement":null},{"id":"W2147306113","doi":"10.1093/annonc/mdt549","title":"The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Observational study; Parenteral nutrition; Cachexia; Cancer; Internal medicine; Prospective cohort study; Intensive care medicine","score_opus":0.16845293359747496,"score_gpt":0.4200986462848196,"score_spread":0.2516457126873446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147306113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489415,0.0000735175,0.0000030578292,0.002783103,0.00021403455,0.0017892827,0.000048950176,0.000009475116,0.00018443438],"genre_scores_gemma":[0.99870425,0.00008264948,0.00018015785,0.00057948864,0.000049686612,0.00028585643,0.000039557697,0.000012002453,0.00006632553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985563,0.00016914199,0.0005094074,0.00019456602,0.0003567189,0.0002138674],"domain_scores_gemma":[0.99755746,0.000229072,0.0004819929,0.00014558445,0.0015083145,0.00007758858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026173808,0.00011557815,0.00045085265,0.00009095683,0.00009311062,0.0000030753426,0.00008505447,0.00006157997,0.0000247856],"category_scores_gemma":[0.00017834821,0.00007814119,0.00006484149,0.00021097958,0.00012036383,0.000054963588,0.000025711075,0.00013894548,0.0000013665098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030572896,0.014155573,0.9769108,0.0003353108,0.00014221523,7.618432e-7,0.0011685684,0.0000027525,0.000016704076,0.00015501793,0.0013656365,0.0026893555],"study_design_scores_gemma":[0.018899571,0.01680818,0.96034896,0.00052388536,0.00006501965,4.4380806e-7,0.0004796727,0.00006507111,0.0007976289,0.0001068703,0.0018356998,0.00006898681],"about_ca_topic_score_codex":0.00021248525,"about_ca_topic_score_gemma":0.00043948073,"teacher_disagreement_score":0.016561843,"about_ca_system_score_codex":0.000080148384,"about_ca_system_score_gemma":0.00015993761,"threshold_uncertainty_score":0.3186505},"labels":[],"label_agreement":null},{"id":"W2147461138","doi":"10.1093/annonc/mdp326","title":"A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ontario Institute for Cancer Research; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital du Saint-Sacrement; Alberta Cancer Foundation","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Tamoxifen; Epirubicin; Breast cancer; Internal medicine; Oncology; Hazard ratio; Cyclophosphamide; Chemotherapy; Placebo; Fluorouracil; Randomization; Gynecology; Cancer; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.06129752899936249,"score_gpt":0.40586603943245997,"score_spread":0.3445685104330975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147461138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334574,0.00088371936,0.000007636002,0.0023101189,0.00024033042,0.0027478458,0.00021463457,0.000003293293,0.00024668672],"genre_scores_gemma":[0.9960249,0.0009300679,0.000050728602,0.00073240255,0.0002831389,0.0018760287,0.000010934835,0.000015316584,0.00007650355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99624795,0.0010729356,0.0015699621,0.00039992583,0.0003737256,0.0003355085],"domain_scores_gemma":[0.9977349,0.00033404835,0.0011641877,0.00022410926,0.00045291273,0.00008983141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032130885,0.00026337887,0.002602701,0.000098010976,0.00002572052,0.000003935707,0.00019334152,0.0001711777,0.00008256309],"category_scores_gemma":[0.00036262049,0.00018478237,0.00015880668,0.00012525532,0.00026059398,0.000012434149,0.00004330639,0.000110070505,9.1753755e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9737913,0.0029731924,0.00833132,0.000016591064,0.0028025983,0.000009482596,0.00065731775,0.0001471024,0.0013793516,0.000009847754,0.0007592665,0.00912263],"study_design_scores_gemma":[0.82375884,0.008325801,0.16594914,0.00005454358,0.00019121589,0.0000030080002,0.00015615308,0.000005828206,0.0007664211,0.00005396993,0.0005660669,0.00016904286],"about_ca_topic_score_codex":0.04362625,"about_ca_topic_score_gemma":0.24848256,"teacher_disagreement_score":0.2048563,"about_ca_system_score_codex":0.00012952092,"about_ca_system_score_gemma":0.002184529,"threshold_uncertainty_score":0.9627423},"labels":[],"label_agreement":null},{"id":"W2147621714","doi":"10.1093/annonc/mdl072","title":"Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Carcinoembryonic antigen; Antigen; Lymph node; Immune system; T cell; Immunology; Colorectal cancer; Lymph; Cytotoxic T cell; Dendritic cell; Pathology; Cancer; Internal medicine; Biology; In vitro","score_opus":0.02009555390906697,"score_gpt":0.28968728052316295,"score_spread":0.269591726614096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147621714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868111,0.011301936,0.000012274664,0.00015613956,0.00035083646,0.00038475703,0.000081775484,0.000017962217,0.0008832057],"genre_scores_gemma":[0.9972808,0.001860655,0.000075934935,0.00008057837,0.000011823552,0.000038033384,0.000072491064,0.000023330096,0.0005563951],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979111,0.0006672316,0.00065607385,0.000277349,0.000066565655,0.0004217026],"domain_scores_gemma":[0.99835026,0.0006498847,0.00045229454,0.00019997617,0.00033527898,0.000012326331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034517664,0.00021120292,0.0005775274,0.0004085459,0.000073264026,0.000004838801,0.00023870623,0.00034701196,0.0004530565],"category_scores_gemma":[0.00003281283,0.00018582154,0.00009398368,0.00034729793,0.0002572221,0.000119742115,0.000041748866,0.00023179191,0.000028841894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009772008,0.0022726685,0.051788133,0.00003293915,0.00008320203,0.000008745627,0.00051549583,0.00004320799,0.9212476,0.00010793436,0.0016812129,0.0124468515],"study_design_scores_gemma":[0.0029002333,0.0021795928,0.40208042,0.0000356446,0.000006654853,0.000004063063,0.000069399335,5.1053865e-7,0.5795324,0.00004432692,0.013027061,0.00011969296],"about_ca_topic_score_codex":0.0006257022,"about_ca_topic_score_gemma":0.0002561745,"teacher_disagreement_score":0.3502923,"about_ca_system_score_codex":0.000059823233,"about_ca_system_score_gemma":0.00025647943,"threshold_uncertainty_score":0.75775826},"labels":[],"label_agreement":null},{"id":"W2147663823","doi":"10.1093/annonc/mdq651","title":"Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Onyx Pharmaceuticals; Canadian Centre for Applied Research in Cancer Control; Bayer HealthCare; Bayer","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Internal medicine; Rash; Oncology; Expanded access; Population; Adverse effect; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Hepatocellular carcinoma; Surgery; Phases of clinical research; Chemotherapy","score_opus":0.3243979502389615,"score_gpt":0.4237045269783182,"score_spread":0.09930657673935667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147663823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95303243,0.00008229574,9.019961e-7,0.00036312308,0.000100538644,0.0025718051,0.00006924492,0.000014973962,0.043764673],"genre_scores_gemma":[0.9988343,0.00001559975,0.00017605626,0.00044995605,0.000027279955,0.00006249124,0.000021381726,0.000032474734,0.0003804458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944338,0.0033523715,0.000979247,0.00040673162,0.0003722445,0.00045561173],"domain_scores_gemma":[0.99721754,0.00027989136,0.00075659924,0.0012247603,0.00038039743,0.00014079426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034198456,0.0002823358,0.00090948323,0.000194415,0.00018019139,0.000011789118,0.0013059243,0.00008502821,0.000042147818],"category_scores_gemma":[0.00026694196,0.00020335676,0.00010552498,0.00043986275,0.00020600343,0.00019187001,0.0020872734,0.00064966886,0.00001039715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019847127,0.11155052,0.765044,0.0001883994,0.00030809417,0.0020870767,0.07452385,0.0000068730164,0.0075985733,0.00001708158,0.0033589029,0.015469529],"study_design_scores_gemma":[0.042506836,0.028066296,0.8915161,0.00008129745,0.00018169856,0.000022676419,0.020229742,0.000003461519,0.016755877,0.000039919898,0.00043952998,0.00015659178],"about_ca_topic_score_codex":0.005231015,"about_ca_topic_score_gemma":0.004246558,"teacher_disagreement_score":0.1264721,"about_ca_system_score_codex":0.000094981755,"about_ca_system_score_gemma":0.000292302,"threshold_uncertainty_score":0.8292648},"labels":[],"label_agreement":null},{"id":"W2147734913","doi":"10.1093/annonc/mds081","title":"Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; SABR volatility model; Radiation therapy; Lung cancer; Stage (stratigraphy); Population; Relative survival; Cancer; Cancer registry; Surgery; Internal medicine","score_opus":0.06298838990505283,"score_gpt":0.40353988643464966,"score_spread":0.3405514965295968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147734913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968172,0.0005008571,1.951524e-7,0.0016833195,0.00006600492,0.0008196944,0.000030865045,0.000001911741,0.000080002326],"genre_scores_gemma":[0.99904627,0.00037181968,0.0000032269293,0.00019284418,0.000031676067,0.00032305534,0.00001610303,0.000006622229,0.00000840405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917036,0.00018268438,0.00023560223,0.00011717647,0.00011672096,0.00017746985],"domain_scores_gemma":[0.99949783,0.00020207498,0.00011004759,0.0001251915,0.00003297636,0.000031860178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002455387,0.000092076916,0.00035602058,0.00013904636,0.000008678673,0.0000017897897,0.000034472578,0.00005433194,0.00003506162],"category_scores_gemma":[0.000013144576,0.000058010533,0.000022881639,0.0001245453,0.000012264102,0.000030144649,0.000009058273,0.000053482363,1.12950715e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002497443,0.006259668,0.9671932,0.000049765713,0.000055242494,0.0000110036035,0.008856487,0.00003236702,0.0000016626883,0.0000062434037,0.00001023765,0.017274363],"study_design_scores_gemma":[0.006799331,0.0080086775,0.9837678,0.00009870703,0.000046172474,1.4280664e-7,0.0010592531,0.000024351593,0.00005649161,0.0000021097628,0.000093854505,0.00004310756],"about_ca_topic_score_codex":0.054151263,"about_ca_topic_score_gemma":0.21044587,"teacher_disagreement_score":0.15629461,"about_ca_system_score_codex":0.00017205923,"about_ca_system_score_gemma":0.000045838762,"threshold_uncertainty_score":0.95214725},"labels":[],"label_agreement":null},{"id":"W2147927085","doi":"10.1093/annonc/mdq727","title":"Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Ottawa; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Delta-9-tetrahydrocannabinol; Placebo; Double blind; Perception; Cancer; Randomized controlled trial; Dronabinol; Internal medicine; Oncology; Alternative medicine; Cannabinoid; Pathology; Neuroscience","score_opus":0.16811002713513581,"score_gpt":0.4118915007383453,"score_spread":0.24378147360320948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147927085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750826,0.00031188977,0.000004943498,0.005547564,0.00045556613,0.0064397207,0.000066859764,0.000022839653,0.012068055],"genre_scores_gemma":[0.9933154,0.0012379513,0.00007844055,0.0005045156,0.00027058815,0.0015660786,0.0000722465,0.000038935104,0.0029158667],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99550015,0.0006582461,0.0020589326,0.0005104273,0.00062550924,0.00064675347],"domain_scores_gemma":[0.9971059,0.00015166575,0.00092461857,0.00043511135,0.0011357828,0.00024692251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002971811,0.00030976356,0.002610141,0.00065177534,0.00004124728,0.0000071018903,0.00024214014,0.00033799137,0.00052028126],"category_scores_gemma":[0.0010694491,0.00023956038,0.00059747725,0.00040766984,0.00052622124,0.000107821696,0.00008332209,0.00046895555,0.00001323811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96926755,0.004775484,0.00048297652,0.0001611835,0.0004355045,0.000022947348,0.0018837921,0.000011822507,0.0023998693,0.00006943917,0.012080227,0.0084091965],"study_design_scores_gemma":[0.97175413,0.014895569,0.0034647365,0.00014185888,0.00023339632,0.00000478415,0.00024192638,0.00014403119,0.0060383747,0.000119934484,0.0027604154,0.00020086566],"about_ca_topic_score_codex":0.0058277007,"about_ca_topic_score_gemma":0.0010795721,"teacher_disagreement_score":0.018232815,"about_ca_system_score_codex":0.00016969308,"about_ca_system_score_gemma":0.00085568865,"threshold_uncertainty_score":0.97689885},"labels":[],"label_agreement":null},{"id":"W2148407853","doi":"10.1093/annonc/mdq682","title":"An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Gefitinib; Docetaxel; Oncology; Lung cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.1087354976583922,"score_gpt":0.450226711195727,"score_spread":0.3414912135373348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148407853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873452,0.0007031327,0.0000068869826,0.0004806041,0.00062749966,0.0021955087,0.000088641704,0.0000057715697,0.008546707],"genre_scores_gemma":[0.9970821,0.0017933734,0.00016421401,0.00029099794,0.00008155774,0.00033139516,0.000028087568,0.000013804999,0.00021447813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99834687,0.00026214018,0.0008983681,0.00023322308,0.00008032676,0.00017905339],"domain_scores_gemma":[0.99808353,0.00043934234,0.0008454949,0.00039524774,0.00017088909,0.000065514454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060270715,0.00015081573,0.0015002841,0.00030408436,0.0000203719,0.0000022724003,0.00018259823,0.00013287627,0.0008898839],"category_scores_gemma":[0.00009090101,0.00009891334,0.00053249917,0.00027277117,0.00018124987,0.0000657129,0.000024854207,0.000118461336,0.0000012423625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9818797,0.002017505,0.0008218373,0.000032624463,0.004062944,0.000004020231,0.002937946,0.0001780534,0.001193394,0.00013575093,0.00008471421,0.0066514774],"study_design_scores_gemma":[0.9665066,0.010960674,0.0018018371,0.000041599204,0.002615633,5.3453846e-7,0.0003959542,0.00043728502,0.01670366,0.00007891126,0.00037347473,0.00008385917],"about_ca_topic_score_codex":0.002804496,"about_ca_topic_score_gemma":0.0045283935,"teacher_disagreement_score":0.015510267,"about_ca_system_score_codex":0.00008754669,"about_ca_system_score_gemma":0.0009370679,"threshold_uncertainty_score":0.97436047},"labels":[],"label_agreement":null},{"id":"W2149111231","doi":"10.1093/annonc/mdm231","title":"Emotional expression and coping style in female breast cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alexithymia; Coping (psychology); Medicine; Breast cancer; Dysfunctional family; Trait; Locus of control; Etiology; Clinical psychology; Breast carcinoma; Toronto Alexithymia Scale; Developmental psychology; Internal medicine; Psychology; Cancer","score_opus":0.06702244309746705,"score_gpt":0.4029974214923093,"score_spread":0.33597497839484225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149111231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888356,0.001135347,0.000070194146,0.0046940683,0.00017667665,0.00008350581,0.000014857939,0.0000072604353,0.00498253],"genre_scores_gemma":[0.9973554,0.00042143202,0.00007824815,0.0018211616,0.00014502837,0.0000053115837,0.000005268087,0.0000052968844,0.00016284257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945736,0.000022805689,0.00016149016,0.00011441828,0.00009370661,0.00015022019],"domain_scores_gemma":[0.99964666,0.00007165883,0.000054871405,0.00006789511,0.00009185653,0.00006705066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028404436,0.00005145698,0.00019087005,0.00008725697,0.000015685479,0.0000014202669,0.000025576634,0.00008677203,0.00024482905],"category_scores_gemma":[0.000015824346,0.000046101362,0.000026854108,0.00009131266,0.000058984573,0.00003444206,0.00002566865,0.0000919847,0.0000015886836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014204222,0.00036779823,0.69763213,0.00025624415,0.000032680044,0.000121097546,0.0034916804,0.000008415512,0.033376936,0.00036654552,0.0056235,0.25730252],"study_design_scores_gemma":[0.0012957716,0.00041321575,0.9612834,0.00029816595,0.00000866487,0.00010151366,0.000978473,0.000010585628,0.008701911,0.000076244716,0.026761226,0.00007082303],"about_ca_topic_score_codex":0.0007951155,"about_ca_topic_score_gemma":0.0025470285,"teacher_disagreement_score":0.26365125,"about_ca_system_score_codex":0.000032040443,"about_ca_system_score_gemma":0.00010509378,"threshold_uncertainty_score":0.26807064},"labels":[],"label_agreement":null},{"id":"W2149160061","doi":"10.1093/annonc/mdt011","title":"Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Natural Science Foundation of China","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Oncology; Internal medicine; Methylation; Hazard ratio; Chemotherapy; Cancer; Adjuvant; Univariate analysis; Confidence interval; Multivariate analysis; Biology","score_opus":0.03102484468926354,"score_gpt":0.35464010712313065,"score_spread":0.3236152624338671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149160061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906939,0.00018128773,0.00046819766,0.0069910972,0.00013303212,0.0005826079,0.00010801521,0.0000041022463,0.00083776127],"genre_scores_gemma":[0.9968501,0.0002160799,0.0012982681,0.0012314612,0.000107087755,0.00012604943,0.000019497864,0.000014663274,0.0001368334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897504,0.00017182548,0.00030808963,0.00025455683,0.00010149051,0.00018897209],"domain_scores_gemma":[0.99905735,0.000043670378,0.00018815455,0.0002121478,0.00044360134,0.000055050612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003413168,0.000110052286,0.00027141895,0.000096303076,0.0000140507755,0.0000030128613,0.00009052523,0.0001773762,0.00011936765],"category_scores_gemma":[0.00010533985,0.000105515945,0.000060106784,0.00018315302,0.00010263344,0.0000088986435,0.000053194373,0.00006981673,0.0000051544653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031416013,0.00024304852,0.0054015536,0.000027748278,0.00010908029,0.000001457564,0.0008837702,0.00070080016,0.7921166,0.000016690003,0.006356048,0.19382904],"study_design_scores_gemma":[0.0010098697,0.00076886115,0.25567293,0.0000257045,0.00000790601,0.000008239829,0.00009544507,0.00023910224,0.738982,0.0002641404,0.0028145516,0.000111246576],"about_ca_topic_score_codex":0.00095395715,"about_ca_topic_score_gemma":0.0008910735,"teacher_disagreement_score":0.25027138,"about_ca_system_score_codex":0.000049785853,"about_ca_system_score_gemma":0.00031944408,"threshold_uncertainty_score":0.43028152},"labels":[],"label_agreement":null},{"id":"W2149306989","doi":"10.1093/annonc/mdl426","title":"Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; American Society of Hematology","keywords":"Medicine; Lymphoblastic lymphoma; Hematopoietic stem cell transplantation; Lymphoma; Chemotherapy; Transplantation; Internal medicine; Surgery; Regimen; Chemotherapy regimen; Stem cell; Oncology; Immunology; T cell","score_opus":0.02289958350213624,"score_gpt":0.2851067968960264,"score_spread":0.2622072133938902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149306989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862257,0.0009780021,0.00007746142,0.0017122165,0.000036511923,0.0012279035,0.000077786346,0.000028118222,0.009636288],"genre_scores_gemma":[0.9959789,0.0010263094,0.0010194991,0.00086610747,0.000026592055,0.0002881715,0.00019938916,0.000030955063,0.00056410383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985026,0.000055426935,0.0005035287,0.00036121593,0.00022489535,0.0003523352],"domain_scores_gemma":[0.99873,0.00049799314,0.00027564578,0.00024243696,0.0001766848,0.00007722354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018236064,0.00023928788,0.00069564674,0.0001608437,0.000040288953,0.0000077029545,0.00007603627,0.00013579418,0.0000062401355],"category_scores_gemma":[0.000003649622,0.00015249872,0.000097325545,0.000182325,0.00008849744,0.00007475722,0.0000059873873,0.000034147866,0.0000064797678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18299155,0.056741014,0.57288265,0.00465898,0.000728876,0.0027588212,0.0073398966,0.0013543646,0.004284745,0.0006753965,0.009567865,0.15601581],"study_design_scores_gemma":[0.16038978,0.037718084,0.68398756,0.00074416597,0.00029177527,0.00028242744,0.00062008505,0.000077543526,0.11008229,0.00015293248,0.005218946,0.00043442077],"about_ca_topic_score_codex":0.00061177905,"about_ca_topic_score_gemma":0.00040851813,"teacher_disagreement_score":0.15558138,"about_ca_system_score_codex":0.00014608131,"about_ca_system_score_gemma":0.0005532175,"threshold_uncertainty_score":0.62187177},"labels":[],"label_agreement":null},{"id":"W2149564448","doi":"10.1093/annonc/mdt235","title":"Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Carboplatin; Paclitaxel; Oncology; Nab-paclitaxel; Internal medicine; Lung cancer; Chemotherapy; Cisplatin","score_opus":0.012136169378837273,"score_gpt":0.33752077610764764,"score_spread":0.32538460672881037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149564448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938241,0.0011676579,0.000053692227,0.0027830522,0.00002064875,0.0010104849,0.000026098183,0.000004828457,0.0011093876],"genre_scores_gemma":[0.997824,0.0010697033,0.00034007092,0.00032214326,0.0000041193243,0.00011894862,0.0001231071,0.000012457204,0.00018545164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906474,0.000052041978,0.00036222272,0.00022507751,0.00011494335,0.00018097545],"domain_scores_gemma":[0.9990598,0.00013535081,0.0002906437,0.00014980228,0.00030390648,0.000060472325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008162257,0.00013162733,0.00060574623,0.000275005,0.000022240913,0.000001859787,0.000045494453,0.0000961207,0.000071057046],"category_scores_gemma":[0.000018445675,0.00009469242,0.000035030833,0.00045981884,0.00010099473,0.00006963471,0.000011721884,0.000097131,5.0029166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024001459,0.002528705,0.9572202,0.00006335568,0.0006353729,0.0000058508535,0.0018378586,0.00079417287,0.00019446513,0.000017764838,0.00015284533,0.03414925],"study_design_scores_gemma":[0.023033367,0.010225027,0.964661,0.00007719854,0.00032073256,7.24329e-7,0.00015411062,0.00037812037,0.0005157976,0.000016758348,0.00052199134,0.00009514075],"about_ca_topic_score_codex":0.00576087,"about_ca_topic_score_gemma":0.0029819591,"teacher_disagreement_score":0.034054108,"about_ca_system_score_codex":0.00013616016,"about_ca_system_score_gemma":0.00021880884,"threshold_uncertainty_score":0.87087506},"labels":[],"label_agreement":null},{"id":"W2149584982","doi":"10.1093/annonc/mdu574","title":"A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Clinical endpoint; Tolerability; Phases of clinical research; Head and neck cancer; Cancer; Mucositis; Randomized controlled trial; Chemotherapy; Colorectal cancer; Adverse effect","score_opus":0.036974883950853965,"score_gpt":0.3559445261094128,"score_spread":0.31896964215855883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149584982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974771,0.00046627974,0.00014780664,0.00012953942,0.00017656208,0.0013669037,0.00006233217,0.00000841037,0.00016504522],"genre_scores_gemma":[0.9962864,0.00012922878,0.0026158495,0.00039469314,0.00009527935,0.00017366806,0.000071955095,0.000040715015,0.00019223988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977482,0.00050334,0.0006206229,0.0005007684,0.0002543458,0.00037273852],"domain_scores_gemma":[0.9983521,0.00016026093,0.00061652134,0.00037253083,0.00034753437,0.00015101576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069877337,0.0002980792,0.0011653149,0.00011999881,0.00006197037,0.000009543102,0.00020233219,0.0002000078,0.000048983035],"category_scores_gemma":[0.00021699701,0.00019530892,0.00008390668,0.00020988012,0.00040805212,0.00002506365,0.000080977814,0.00015464319,4.6108588e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.976041,0.004873699,0.004183586,0.00014598912,0.00017195845,0.000013312217,0.00038110296,0.0001758556,0.006484864,0.000007643132,0.00059837196,0.006922614],"study_design_scores_gemma":[0.7675705,0.10406006,0.00011321885,0.000097964185,0.00022063515,0.0000043714203,0.000065258064,0.0002338202,0.124115504,0.000018018643,0.0032054163,0.00029524267],"about_ca_topic_score_codex":0.0006039024,"about_ca_topic_score_gemma":0.0016979586,"teacher_disagreement_score":0.20847052,"about_ca_system_score_codex":0.000028122031,"about_ca_system_score_gemma":0.00074660755,"threshold_uncertainty_score":0.7964467},"labels":[],"label_agreement":null},{"id":"W2149924707","doi":"10.1093/annonc/mdi032","title":"Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Workgroup; Medicine; Quality assurance; Colorectal cancer screening; Colorectal cancer; Population; Quality (philosophy); Cancer; Family medicine; Environmental health; Internal medicine; External quality assessment; Colonoscopy; Pathology","score_opus":0.13344246400233975,"score_gpt":0.4362800486733689,"score_spread":0.30283758467102917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149924707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92251444,0.0038357475,0.063393824,0.0060520037,0.00084232964,0.0021124526,0.00047845425,0.0000787755,0.0006919803],"genre_scores_gemma":[0.9588822,0.0005273524,0.03743277,0.00062104006,0.00051896955,0.0016524111,0.00008979527,0.000041010357,0.00023444468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968569,0.00020322329,0.0009276179,0.0008180408,0.00059173413,0.00060245517],"domain_scores_gemma":[0.9943491,0.0033026892,0.0006605924,0.00019102117,0.001267636,0.0002289638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025785656,0.00036666033,0.0009099405,0.00027597896,0.00042697313,0.000047143483,0.00017835454,0.00033384212,0.00011836762],"category_scores_gemma":[0.0037520342,0.0003753316,0.00022066588,0.00033846498,0.00031181469,0.0002495892,0.0001115678,0.0004189246,0.0000015211536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02575201,0.00022774623,0.0055873045,0.00034340858,0.000625311,0.0000043467358,0.0037980264,0.012841153,0.013260723,0.00015816037,0.0018381799,0.9355636],"study_design_scores_gemma":[0.107645035,0.060389448,0.3640308,0.00876848,0.0017747424,0.00024934835,0.033041615,0.30510795,0.06187723,0.0044313166,0.04882004,0.0038639894],"about_ca_topic_score_codex":0.001634609,"about_ca_topic_score_gemma":0.003604689,"teacher_disagreement_score":0.93169963,"about_ca_system_score_codex":0.00032499607,"about_ca_system_score_gemma":0.0005129823,"threshold_uncertainty_score":0.9998699},"labels":[],"label_agreement":null},{"id":"W2149953725","doi":"10.1093/annonc/mdt069","title":"Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Capital District Health Authority","funders":"Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Chemotherapy; Cancer","score_opus":0.14112045725974376,"score_gpt":0.4968204685723518,"score_spread":0.35570001131260803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149953725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8421176,0.0041437284,0.00022968171,0.12961632,0.00046344605,0.01479422,0.0009889562,0.00006814959,0.007577895],"genre_scores_gemma":[0.9769383,0.0029311918,0.00019035,0.010912477,0.00045625103,0.0076276995,0.000026018093,0.000057455673,0.0008602453],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99795586,0.00020325198,0.00038252145,0.00044387675,0.00033586545,0.00067860144],"domain_scores_gemma":[0.9971198,0.0006928545,0.00017876863,0.00033418147,0.0013858421,0.00028858206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047992976,0.00022753388,0.00080750394,0.00016663277,0.00007753688,0.0000129971495,0.00021008629,0.00025894333,0.0015844805],"category_scores_gemma":[0.00010066899,0.00018398424,0.0003006939,0.00025475913,0.0003253087,0.000109223576,0.000052384283,0.00033726858,0.0001082989],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024083753,0.0008217493,0.0041023716,0.00011929772,0.00055213185,0.00002403781,0.0016612323,0.0000058132896,0.01095334,0.00005948241,0.09447311,0.8848191],"study_design_scores_gemma":[0.014589598,0.035513975,0.41852266,0.00053876813,0.0001493844,0.0003091059,0.0011284682,0.0008319172,0.13522723,0.0011762173,0.39148334,0.0005293224],"about_ca_topic_score_codex":0.002611666,"about_ca_topic_score_gemma":0.00014417965,"teacher_disagreement_score":0.88428974,"about_ca_system_score_codex":0.0003701688,"about_ca_system_score_gemma":0.001166813,"threshold_uncertainty_score":0.9993282},"labels":[],"label_agreement":null},{"id":"W2150153870","doi":"10.1093/annonc/mdu154","title":"Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dabrafenib; Medicine; Dacarbazine; Nausea; Vomiting; Quality of life (healthcare); Internal medicine; Oncology; Chemotherapy; Vemurafenib; Cancer; Metastatic melanoma","score_opus":0.10730208951411321,"score_gpt":0.37843127100091906,"score_spread":0.27112918148680587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150153870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986744,0.00013427128,0.00005229986,0.00010208157,0.00005903446,0.00032409403,0.000029667468,0.0000011320767,0.000623051],"genre_scores_gemma":[0.9996963,0.000017108176,0.00015252242,0.000071010574,0.0000202937,0.000011435579,0.000013099981,0.0000082045735,0.0000099992585],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99821776,0.00049207115,0.0007655774,0.00018477943,0.00020955077,0.0001302391],"domain_scores_gemma":[0.9982783,0.000092212314,0.0008843943,0.0004639522,0.00025053596,0.000030581068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057406764,0.000118900665,0.0006106033,0.00006500389,0.000020448146,0.000001159485,0.00025377533,0.00007682264,0.000007420762],"category_scores_gemma":[0.00020987999,0.00006962415,0.00014293083,0.00018810651,0.00022030661,0.0000042636975,0.00018702478,0.00007426243,1.4752526e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047511663,0.0012085871,0.28151715,0.00013967103,0.00021736816,2.906483e-7,0.0011085131,0.0006043026,0.71284807,0.00021786608,0.000056774516,0.001606287],"study_design_scores_gemma":[0.001757848,0.0055880714,0.5501263,0.000063873944,0.00009835919,0.0000027371414,0.0016957632,0.00007269649,0.44023398,0.00008536363,0.00018358194,0.000091396425],"about_ca_topic_score_codex":0.0010738454,"about_ca_topic_score_gemma":0.0019128309,"teacher_disagreement_score":0.2726141,"about_ca_system_score_codex":0.0000057960733,"about_ca_system_score_gemma":0.00013825402,"threshold_uncertainty_score":0.28391904},"labels":[],"label_agreement":null},{"id":"W2150368358","doi":"10.1093/annonc/mdf255","title":"Informing breast cancer patients about clinical trials:a randomized clinical trial of an educational booklet","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"Medical Research Council","keywords":"Medicine; Randomized controlled trial; Clinical trial; Breast cancer; Odds ratio; Confidence interval; Cancer; Stage (stratigraphy); Internal medicine; Family medicine; Physical therapy","score_opus":0.8100968177993866,"score_gpt":0.7299979456105016,"score_spread":0.080098872188885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150368358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93959683,0.00032547966,0.000010145784,0.04138217,0.0024118023,0.0020799823,0.000109296816,0.000015234578,0.0140690785],"genre_scores_gemma":[0.9747332,0.013666812,0.00094980036,0.005635621,0.0032807763,0.00016393077,0.00005406575,0.000028675267,0.0014871603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9835984,0.006927536,0.0073332055,0.0004934985,0.0012070554,0.00044030204],"domain_scores_gemma":[0.81907463,0.17295681,0.002940883,0.00076570467,0.0035756913,0.0006862551],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08964371,0.00018169527,0.003532459,0.00019848633,0.000052933225,0.000008454466,0.0004024428,0.0012394472,0.0036400089],"category_scores_gemma":[0.28670764,0.00013572327,0.0013097314,0.00019954891,0.0020328288,0.00013884473,0.0001541881,0.0019476587,0.000049144975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5836645,0.010034575,0.016965043,0.00010830279,0.0005710384,0.0000047385874,0.00014838007,9.763805e-7,0.0000056438353,0.002821358,0.009447024,0.37622845],"study_design_scores_gemma":[0.92646563,0.015880639,0.034113694,0.00032125742,0.000377427,0.000008948709,0.000043354856,0.00065973867,0.000051291205,0.008507075,0.013393334,0.00017763083],"about_ca_topic_score_codex":0.00013859059,"about_ca_topic_score_gemma":0.0000884596,"teacher_disagreement_score":0.37605083,"about_ca_system_score_codex":0.00004311121,"about_ca_system_score_gemma":0.0022828905,"threshold_uncertainty_score":0.9972708},"labels":[],"label_agreement":null},{"id":"W2150453648","doi":"10.1093/annonc/mdr465","title":"Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University","funders":"","keywords":"Medicine; Docetaxel; Perioperative; Regimen; Chemotherapy; Cisplatin; Fluorouracil; Clinical endpoint; Surgery; Internal medicine; Adenocarcinoma; Folinic acid; Chemotherapy regimen; Esophagus; Gastrectomy; Phases of clinical research; Gastroenterology; Cancer; Clinical trial","score_opus":0.12416171801942247,"score_gpt":0.4218895061696848,"score_spread":0.29772778815026235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150453648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221743,0.012850619,0.0001738034,0.0010776347,0.000079275436,0.0021796692,0.00008002943,0.000017271175,0.0013242674],"genre_scores_gemma":[0.9928415,0.00080640014,0.004964141,0.0005229397,0.000117522955,0.00030553245,0.0000250332,0.000017461234,0.00039946582],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99863416,0.00008470074,0.00036182968,0.00035756823,0.00016484405,0.00039691338],"domain_scores_gemma":[0.99886477,0.00017165153,0.0001417673,0.000166585,0.00033681793,0.00031843453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027849872,0.00019105918,0.0005839859,0.00012631396,0.00012951357,0.000007655878,0.000064176624,0.00011496609,0.00012445063],"category_scores_gemma":[0.00023218949,0.00014873523,0.000092463306,0.00009338722,0.00027061318,0.00013648762,0.000085375534,0.00016247109,0.0000030197525],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44246855,0.0065755234,0.007517658,0.0002992049,0.000650492,0.0008680695,0.0048601734,6.4217096e-7,0.0013284446,0.00060978584,0.001041947,0.5337795],"study_design_scores_gemma":[0.4880015,0.4621858,0.026103148,0.00011442851,0.00039108173,0.0003174593,0.0008380499,0.00038774632,0.01813007,0.00031913366,0.002928444,0.00028313993],"about_ca_topic_score_codex":0.00006065293,"about_ca_topic_score_gemma":0.000034171902,"teacher_disagreement_score":0.5334964,"about_ca_system_score_codex":0.0000424389,"about_ca_system_score_gemma":0.00029410058,"threshold_uncertainty_score":0.6065247},"labels":[],"label_agreement":null},{"id":"W2150475127","doi":"10.1093/annonc/mdh278","title":"A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; BC Cancer Agency","funders":"AstraZeneca Canada","keywords":"Docetaxel; Medicine; Taxane; Neutropenia; Regimen; Internal medicine; Carboplatin; Cancer; Clinical trial; Prostate cancer; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cisplatin; Breast cancer","score_opus":0.19890703960412862,"score_gpt":0.5251946068362316,"score_spread":0.32628756723210306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150475127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450946,0.0011525358,0.0000014024456,0.0014325934,0.00059032143,0.0018513444,0.00021773511,0.0000041566914,0.00024044352],"genre_scores_gemma":[0.99758834,0.0012807603,0.00007555133,0.0005952294,0.00015261042,0.00022204069,0.000029492867,0.0000117095005,0.000044282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974603,0.00035106982,0.0012639917,0.00030828244,0.0003928759,0.00022344521],"domain_scores_gemma":[0.99759275,0.0005493979,0.0010933771,0.00013414575,0.00049909565,0.00013126184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011104854,0.00017153104,0.0014906737,0.00018414659,0.000028470307,0.0000013881374,0.000091496644,0.00013812097,0.00008318037],"category_scores_gemma":[0.00046023726,0.00013638055,0.000077228804,0.00025258274,0.00024479374,0.00012837761,0.000036394016,0.00023348331,1.1173784e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.548533,0.08226018,0.21897204,0.00030794495,0.0031450465,0.00013847621,0.0024953976,0.00065534655,0.0015904389,0.00006641581,0.005010811,0.13682486],"study_design_scores_gemma":[0.6104865,0.11183002,0.25913897,0.00033463349,0.00056392455,0.0000026479622,0.0002977277,0.0000056836197,0.0009414429,0.0000935754,0.016099816,0.0002050819],"about_ca_topic_score_codex":0.12758403,"about_ca_topic_score_gemma":0.3719148,"teacher_disagreement_score":0.2443308,"about_ca_system_score_codex":0.00036320603,"about_ca_system_score_gemma":0.005407495,"threshold_uncertainty_score":0.95926636},"labels":[],"label_agreement":null},{"id":"W2150775371","doi":"10.1093/annonc/mdp281","title":"The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Expert opinion; Cirrhosis; Intensive care medicine; Gastrointestinal cancer; Cancer; Multidisciplinary approach; General surgery; Internal medicine; Colorectal cancer","score_opus":0.15831733246594853,"score_gpt":0.3751268870748225,"score_spread":0.21680955460887397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150775371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9144649,0.023343686,0.000039230992,0.059337314,0.00046445575,0.00086260115,0.000059417893,0.000016942377,0.0014114873],"genre_scores_gemma":[0.9813184,0.01674836,0.0006833851,0.00080764137,0.00012785183,0.00007994683,0.00009318117,0.000010133819,0.00013106829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877954,0.00016911408,0.00037757138,0.00023537528,0.00018577422,0.00025265187],"domain_scores_gemma":[0.9988429,0.00036792396,0.00022296296,0.00030825604,0.00015673906,0.000101199985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026052102,0.0001668426,0.00033293213,0.00006428812,0.00015571875,0.000009618864,0.00014880019,0.000036413716,0.00009556903],"category_scores_gemma":[0.000021164062,0.00010150502,0.000112595764,0.0001488126,0.00018677315,0.000031234693,0.000051821815,0.00016308535,0.0000037981408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079277344,0.00063864543,0.50345933,0.000035473768,0.00022637726,0.000057756246,0.00035688566,8.7559135e-7,0.00089349004,0.0009114381,0.029882602,0.46274439],"study_design_scores_gemma":[0.0040967283,0.0054378766,0.5816942,0.0013462586,0.00025244325,0.000040975057,0.00074256654,0.0016852536,0.02170485,0.00069655146,0.38205007,0.00025222605],"about_ca_topic_score_codex":0.00032826856,"about_ca_topic_score_gemma":0.000076295844,"teacher_disagreement_score":0.46249214,"about_ca_system_score_codex":0.000039998326,"about_ca_system_score_gemma":0.00009252952,"threshold_uncertainty_score":0.41392547},"labels":[],"label_agreement":null},{"id":"W2150912285","doi":"10.1093/annonc/mdp311","title":"A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Abbott Laboratories","keywords":"Docetaxel; Medicine; Prostate cancer; Adverse effect; Pharmacokinetics; Internal medicine; Urology; Toxicity; Population; Chemotherapy; Taxane; Cancer; Phases of clinical research; Oncology; Pharmacology; Gastroenterology; Breast cancer","score_opus":0.05257857176817571,"score_gpt":0.4300862478470566,"score_spread":0.3775076760788809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150912285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628174,0.00023023592,6.686789e-7,0.0013267057,0.000013673855,0.0017042723,0.000018664912,0.0000051859042,0.00041883715],"genre_scores_gemma":[0.99944407,0.0001468419,0.000076771445,0.000090747046,0.000005012983,0.00010776221,0.000038970975,0.000007366746,0.00008243716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989423,0.000067535686,0.00031782972,0.0001877857,0.00027133952,0.00021319347],"domain_scores_gemma":[0.9992009,0.000033085184,0.00018175664,0.0001298511,0.0004008339,0.00005357828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015942457,0.00010399791,0.00039033132,0.0002380723,0.000016844733,0.0000025405907,0.00004692399,0.000043108517,0.000013897788],"category_scores_gemma":[0.000018917242,0.00006932179,0.000015205451,0.00040629331,0.00007115463,0.00010719606,0.0000075192656,0.00012058411,3.3143223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07560972,0.05538479,0.7017864,0.00012860112,0.00015708357,0.00025064827,0.0071464265,0.00025077627,0.0030249204,0.00006576021,0.00008751638,0.15610734],"study_design_scores_gemma":[0.072264805,0.11623771,0.8072278,0.00019607248,0.000028182418,8.8815955e-7,0.00085117953,0.000020722768,0.0029566009,0.0000553776,0.00008977222,0.00007088522],"about_ca_topic_score_codex":0.00040708866,"about_ca_topic_score_gemma":0.0022370175,"teacher_disagreement_score":0.15603645,"about_ca_system_score_codex":0.00010593342,"about_ca_system_score_gemma":0.00039699394,"threshold_uncertainty_score":0.28268602},"labels":[],"label_agreement":null},{"id":"W2150981643","doi":"10.1093/annonc/mdp238","title":"Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Follicular lymphoma; Lymphoma; Follicular phase; Internal medicine; Radiation therapy; Stage (stratigraphy); Oncology; Marginal zone B-cell lymphoma; Marginal zone; Pathology; Gastroenterology; B cell; Immunology; Antibody","score_opus":0.05293562114077078,"score_gpt":0.37530783533212936,"score_spread":0.3223722141913586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150981643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715127,0.0016627432,0.0000015751276,0.008950427,0.00017884038,0.0016067836,0.000044856264,0.000012771845,0.0003907416],"genre_scores_gemma":[0.99788845,0.00025822964,0.000034584642,0.0015752842,0.000064425854,0.0000480833,0.000017381826,0.000011802683,0.00010173274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979593,0.00032674032,0.0006791284,0.00036848843,0.0004434626,0.00022286549],"domain_scores_gemma":[0.9983771,0.00066193135,0.00033086934,0.00036542307,0.0001472356,0.00011745452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075932936,0.00023244797,0.00075367955,0.00006404894,0.00009213179,0.00001747486,0.00023706978,0.00012877156,0.000012887904],"category_scores_gemma":[0.00016046592,0.00011634822,0.00018321603,0.00013360643,0.00027093757,0.00005714402,0.00014930556,0.00008743165,6.9455433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070230325,0.017832873,0.8426887,0.000013185554,0.0006990096,0.0001011225,0.00062899163,1.0475365e-7,0.00006602728,0.00006352729,0.0018303533,0.1353738],"study_design_scores_gemma":[0.011859211,0.010286291,0.973311,0.00003325194,0.0005167087,0.00041789512,0.0010819025,0.0000036645336,0.00007584987,0.000038495604,0.0022817717,0.00009394256],"about_ca_topic_score_codex":0.0003126774,"about_ca_topic_score_gemma":0.000106735424,"teacher_disagreement_score":0.13527986,"about_ca_system_score_codex":0.00007120106,"about_ca_system_score_gemma":0.00014481012,"threshold_uncertainty_score":0.47445428},"labels":[],"label_agreement":null},{"id":"W2151067943","doi":"10.1093/annonc/mdp478","title":"Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Clinical trial; Internal medicine; Progression-free survival; Overall survival","score_opus":0.7811995527025647,"score_gpt":0.7408788541978925,"score_spread":0.04032069850467224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151067943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915898,0.00040809409,0.0007038002,0.0050411266,0.0001581528,0.00147436,0.00011842101,0.000012512683,0.00049371854],"genre_scores_gemma":[0.7946617,0.005085911,0.19810037,0.0019985286,0.0000789186,0.00004350422,0.000002454343,0.000017220238,0.000011406694],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9241662,0.066548176,0.007636964,0.000555201,0.0007338243,0.00035962183],"domain_scores_gemma":[0.76126385,0.23410174,0.0030863795,0.000900472,0.0004603684,0.00018721801],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.19712624,0.00019986895,0.003709533,0.00014865061,0.000019738553,0.0000042055763,0.0005107609,0.00036939,0.00006316072],"category_scores_gemma":[0.48985198,0.00015084553,0.00023117308,0.00025154668,0.0004716717,0.00006947882,0.00015500713,0.00051504665,6.1908065e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043127302,0.020619629,0.0025891226,0.0016130009,0.00026325986,0.00015439556,0.00015573094,0.000021900916,0.00428858,0.056788456,0.0028974079,0.86748123],"study_design_scores_gemma":[0.024209615,0.050553083,0.16395473,0.004785189,0.00026723812,0.000006160739,0.000047082965,0.00012424692,0.0042439555,0.75086033,0.00066503,0.00028332285],"about_ca_topic_score_codex":0.000008250718,"about_ca_topic_score_gemma":0.000009053223,"teacher_disagreement_score":0.8671979,"about_ca_system_score_codex":0.000021187316,"about_ca_system_score_gemma":0.00039856005,"threshold_uncertainty_score":0.8267275},"labels":[],"label_agreement":null},{"id":"W2151082560","doi":"10.1093/annonc/mdu456","title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Exemestane; Human Epidermal Growth Factor Receptor 2; Everolimus; Oncology; Internal medicine; Hormone receptor; Breast cancer; Cancer research; Cancer; Aromatase","score_opus":0.0499435101726918,"score_gpt":0.36322891224759973,"score_spread":0.31328540207490796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151082560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635448,0.0010103785,0.0018412368,0.018064544,0.00110147,0.0016632943,0.009624958,0.00018496097,0.0029643856],"genre_scores_gemma":[0.98797923,0.0007705692,0.0058335247,0.0025021895,0.0012266365,0.00023928525,0.0007613286,0.00011531145,0.0005719418],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963523,0.00034000204,0.0010547343,0.0009007655,0.00046185628,0.00089029764],"domain_scores_gemma":[0.99520177,0.0015893435,0.00093934534,0.0005474329,0.001334639,0.0003874701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004370143,0.0005397518,0.001643782,0.00017600498,0.00019358737,0.000013467547,0.00034251978,0.0003844004,0.00032229803],"category_scores_gemma":[0.0005505847,0.0005082938,0.00034985936,0.00020993894,0.00048013846,0.00038048037,0.00011302243,0.00042092978,0.000023680182],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11369114,0.0013905811,0.0026928787,0.00023183295,0.0022187307,0.000031478543,0.0052713505,0.00037000424,0.3965859,0.002771002,0.014460493,0.4602846],"study_design_scores_gemma":[0.091790006,0.020049527,0.5504739,0.0008658407,0.00043815226,0.00007336158,0.001137575,0.0003817494,0.18713245,0.008502736,0.1371137,0.0020409902],"about_ca_topic_score_codex":0.0020701678,"about_ca_topic_score_gemma":0.00031558325,"teacher_disagreement_score":0.54778105,"about_ca_system_score_codex":0.00046703013,"about_ca_system_score_gemma":0.0004472021,"threshold_uncertainty_score":0.99973685},"labels":[],"label_agreement":null},{"id":"W2151352506","doi":"10.1093/annonc/mdu501","title":"Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Overweight; Internal medicine; Cancer; Malnutrition; Obesity; Demographics; Demography","score_opus":0.06222120371478008,"score_gpt":0.43052905429403265,"score_spread":0.3683078505792526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151352506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95568323,0.0001884088,0.000033697528,0.040125705,0.00008586654,0.0002948782,0.000034302186,0.000007795209,0.0035460973],"genre_scores_gemma":[0.9832258,0.0009021964,0.0042379303,0.0114006195,0.000063275154,0.000044596723,0.00003452811,0.000007927119,0.00008308909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991172,0.00010351529,0.00027105317,0.00015062145,0.00017382634,0.00018378574],"domain_scores_gemma":[0.9993204,0.00018436155,0.00011504292,0.00008458718,0.00018849519,0.000107121814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029631692,0.00007815658,0.00034664624,0.00013488444,0.000029650688,0.0000031448903,0.000021137037,0.000046258963,0.00016389975],"category_scores_gemma":[0.00003437086,0.00005374881,0.000021706961,0.00009033037,0.00008706573,0.000033837176,0.00001588589,0.00014927036,0.0000016372013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009221199,0.0026134972,0.9406401,0.0013139275,0.00009277151,0.000060482656,0.0003519818,0.0000036907284,0.00015549315,0.005070137,0.0064957403,0.042280048],"study_design_scores_gemma":[0.008258901,0.0027939074,0.85581034,0.0005624902,0.000039302784,0.00001971739,0.00013665411,0.00017172175,0.0002075971,0.0036463412,0.12825572,0.00009733098],"about_ca_topic_score_codex":0.00010739071,"about_ca_topic_score_gemma":0.00059899164,"teacher_disagreement_score":0.12175998,"about_ca_system_score_codex":0.000045664066,"about_ca_system_score_gemma":0.00016992119,"threshold_uncertainty_score":0.21918127},"labels":[],"label_agreement":null},{"id":"W2151494200","doi":"10.1093/annonc/mdv356","title":"High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Germline; Prostate cancer; Germline mutation; BRCA2 Protein; Oncology; Mutation; Cancer; Cancer research; Prostate; Internal medicine; Genetics; Biology; Gene","score_opus":0.10567736926503578,"score_gpt":0.4453790284623112,"score_spread":0.3397016591972754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151494200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855023,0.001160658,0.00001832832,0.012070079,0.00007539772,0.00039935365,0.00014220427,0.0000069586067,0.00062471256],"genre_scores_gemma":[0.9970272,0.0014246865,0.00048244823,0.00014797442,0.00009773417,0.000080687954,0.00030450337,0.000008206884,0.0004265134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922186,0.00006830376,0.0002766226,0.00015375765,0.00014418788,0.00013529054],"domain_scores_gemma":[0.99915653,0.0000776021,0.00013145166,0.00011295122,0.00041926847,0.0001021636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020618405,0.00006911787,0.00027292714,0.000088041525,0.000016495498,0.0000038690496,0.000033384884,0.00006868897,0.00007869485],"category_scores_gemma":[0.00006683797,0.000057899262,0.000021754675,0.00015095978,0.00014212003,0.00007603726,0.000016940254,0.000083169754,0.000004407911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009634302,0.0013329118,0.61626935,0.00039146622,0.00083867105,0.00024628,0.045610625,0.0016790999,0.055535115,0.0016532767,0.030280279,0.23652864],"study_design_scores_gemma":[0.044924583,0.00977599,0.5098395,0.00077427685,0.00047970682,0.0000739074,0.009273407,0.003677218,0.33778062,0.021784155,0.06097198,0.00064465514],"about_ca_topic_score_codex":0.008945334,"about_ca_topic_score_gemma":0.0003850169,"teacher_disagreement_score":0.28224552,"about_ca_system_score_codex":0.000081127706,"about_ca_system_score_gemma":0.0004983306,"threshold_uncertainty_score":0.9976542},"labels":[],"label_agreement":null},{"id":"W2151570682","doi":"10.1093/annonc/mdt393","title":"Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"Roche","keywords":"Medicine; CISH; Trastuzumab; Immunohistochemistry; Adenocarcinoma; Internal medicine; Biopsy; Pathology; Oncology; Cancer; Gastroenterology; In situ hybridization; Breast cancer; Gene expression","score_opus":0.07667223111877967,"score_gpt":0.4079110863048577,"score_spread":0.331238855186078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151570682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743307,0.00020883529,0.0000110780065,0.0006583828,0.000041732303,0.0011417116,0.000017519447,0.0000070148585,0.00048067555],"genre_scores_gemma":[0.99931306,0.00017479995,0.00025932133,0.0000638233,0.000018160497,0.00008525947,0.0000076221,0.000012346613,0.00006561323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980163,0.000253763,0.0007335382,0.00029686047,0.0003905803,0.0003089456],"domain_scores_gemma":[0.99826705,0.0003473948,0.00020337373,0.00028081448,0.00073266967,0.00016869493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005969996,0.00013257292,0.0010714593,0.0013208935,0.000018268065,0.000004459967,0.00012031184,0.00012535363,0.00023631899],"category_scores_gemma":[0.00029435745,0.000115659124,0.000118231634,0.0018299397,0.00016074195,0.000054363427,0.00011067516,0.00017310918,0.000005774332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016042247,0.004161895,0.9717328,0.00009584192,0.00074277766,0.000038470946,0.0015684743,0.0001880547,0.003991291,0.0000040671043,0.00043920375,0.01543292],"study_design_scores_gemma":[0.003902698,0.022038557,0.96655077,0.00002901623,0.00025561854,0.000004297603,0.0011522755,0.00045756894,0.005413012,0.0000135501605,0.000107531756,0.000075085925],"about_ca_topic_score_codex":0.00481116,"about_ca_topic_score_gemma":0.00068356626,"teacher_disagreement_score":0.01787666,"about_ca_system_score_codex":0.00009965928,"about_ca_system_score_gemma":0.000145729,"threshold_uncertainty_score":0.7273066},"labels":[],"label_agreement":null},{"id":"W2151580438","doi":"10.1093/annonc/mdu095","title":"Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cetuximab; Oncology; Internal medicine; Head and neck cancer; Cancer; Head and neck squamous-cell carcinoma; Targeted therapy; Chemotherapy; Population; Radiation therapy; Colorectal cancer","score_opus":0.09349020636548584,"score_gpt":0.3706288683009515,"score_spread":0.27713866193546566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151580438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79293805,0.02153545,7.168316e-7,0.18164791,0.00016731722,0.00059560535,0.000058955273,0.0000034316654,0.003052567],"genre_scores_gemma":[0.9281018,0.0010903185,0.0000795551,0.07041258,0.00016594554,0.000037113135,0.0000067410983,0.000019426598,0.00008651491],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827,0.0003304301,0.00059889734,0.00023843034,0.00021472022,0.00034756362],"domain_scores_gemma":[0.9980381,0.00096724473,0.00050255226,0.00029469436,0.0001505803,0.000046819525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004285906,0.00020241765,0.0012452767,0.000116868345,0.000042931177,0.0000022005445,0.00013284995,0.00015662778,0.000020996047],"category_scores_gemma":[0.00027563918,0.00010528428,0.000104880455,0.00013707862,0.00045649434,0.000015961086,0.00013761404,0.0006536741,5.3399066e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034008238,0.0013234151,0.16547781,0.014069468,0.000496998,0.00048122194,0.015838385,0.000005945131,0.002019517,0.00010969524,0.5897163,0.20706041],"study_design_scores_gemma":[0.0037507599,0.011655545,0.1283089,0.0006631791,0.00045432418,0.00013390108,0.001069099,0.00007063405,0.0049199495,0.0003606119,0.8483971,0.00021599968],"about_ca_topic_score_codex":0.0008462863,"about_ca_topic_score_gemma":0.0005307119,"teacher_disagreement_score":0.2586808,"about_ca_system_score_codex":0.00002950647,"about_ca_system_score_gemma":0.00037857305,"threshold_uncertainty_score":0.42933685},"labels":[],"label_agreement":null},{"id":"W2151625289","doi":"10.1093/annonc/mdq462","title":"Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Ovarian cancer; Metastasis; Kallikrein; Oncology; Cancer; Primary tumor; Internal medicine; Plasminogen activator; Cancer research; Biology","score_opus":0.046596859913082087,"score_gpt":0.37976088039535555,"score_spread":0.33316402048227345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151625289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594253,0.0031951827,0.0000028104723,0.0003110897,0.000034020446,0.00022985745,0.00009728551,0.0000044888,0.00018274848],"genre_scores_gemma":[0.99816436,0.0013407292,0.00038234008,0.00003037062,0.000018621358,0.00000762775,0.000015968957,0.000008498498,0.000031484018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895275,0.00006643166,0.0005252557,0.0001805819,0.00012155606,0.000153427],"domain_scores_gemma":[0.99886197,0.00033638667,0.00045163452,0.00012725922,0.00012800965,0.00009475477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026834608,0.00012620978,0.00081728585,0.00018167989,0.00001742818,0.0000017819691,0.000048004455,0.000106510524,0.00008653684],"category_scores_gemma":[0.000115947834,0.00009488423,0.00006574807,0.0001276853,0.00034936052,0.00009326837,0.00005683409,0.00010726333,4.674017e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043306182,0.00018033553,0.7812769,0.0002048532,0.00012218612,0.0000030352753,0.0006500476,0.0000012952428,0.16654623,0.000044164193,0.00004622968,0.05049171],"study_design_scores_gemma":[0.0021557347,0.001900373,0.93963206,0.0002765445,0.0000964916,0.000006396073,0.00011066272,0.000020020028,0.055240188,0.0004346152,0.000056840254,0.00007008611],"about_ca_topic_score_codex":0.0010872171,"about_ca_topic_score_gemma":0.00013089283,"teacher_disagreement_score":0.15835519,"about_ca_system_score_codex":0.000008210489,"about_ca_system_score_gemma":0.00015708315,"threshold_uncertainty_score":0.38692665},"labels":[],"label_agreement":null},{"id":"W2151629361","doi":"10.1093/annonc/mdu165.154","title":"Diagnosis, Staging and Treatment of Cholangiocarcinoma; a Retrospective Analysis of Our Last Decade of Experience","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Stage (stratigraphy); Retrospective cohort study; Biopsy; Cancer; Survival analysis; Bile duct cancer; Survival rate; Chemotherapy; Internal medicine; Surgery; Gastroenterology","score_opus":0.07539345219522121,"score_gpt":0.3900820299994379,"score_spread":0.3146885778042167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151629361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468094,0.0029828097,0.000022021992,0.00084583217,0.000041180785,0.00015450802,0.000042125084,0.000005220773,0.001225339],"genre_scores_gemma":[0.9976497,0.0019378526,0.00021141992,0.00009203889,0.000041810625,0.000028195913,0.000007005781,0.0000073260053,0.000024607865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895954,0.000062052415,0.00042459622,0.00022084848,0.00016887195,0.00016411173],"domain_scores_gemma":[0.9988335,0.00015648354,0.00037306856,0.00025325565,0.0003165196,0.00006722124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001577148,0.00012358486,0.0011310816,0.0003393337,0.000019748537,0.0000012003223,0.00006396764,0.00007165222,0.000013202022],"category_scores_gemma":[0.00013997353,0.000100164216,0.00023995458,0.00044462032,0.00019113504,0.000036108566,0.00004437875,0.000043754462,1.9722016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019717182,0.0004697427,0.9701647,0.00006279178,0.0016156097,0.000005425669,0.00813462,0.0000054212082,0.003871325,0.00013984017,0.00016917444,0.015164172],"study_design_scores_gemma":[0.0011962296,0.004534376,0.9443824,0.00004659869,0.00097630586,0.0000030785889,0.002320424,0.000038121656,0.045749895,0.000024347832,0.00066678156,0.00006139631],"about_ca_topic_score_codex":0.0005603167,"about_ca_topic_score_gemma":0.00026239723,"teacher_disagreement_score":0.04187857,"about_ca_system_score_codex":0.00004124101,"about_ca_system_score_gemma":0.00005881131,"threshold_uncertainty_score":0.40845782},"labels":[],"label_agreement":null},{"id":"W2151709942","doi":"10.1093/annonc/mdg248","title":"Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Pharmacokinetics; Fluorouracil; Rash; Toxicity; Pharmacology; Stomatitis; Sirolimus; Gastroenterology; Internal medicine; Chemotherapy; Urology","score_opus":0.01873212553169653,"score_gpt":0.3301273170118476,"score_spread":0.3113951914801511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151709942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989264,0.00025170294,0.000063918895,0.000031227202,0.000029496461,0.0005251539,0.000011698171,0.000002402364,0.00015801036],"genre_scores_gemma":[0.9993705,0.000068763846,0.0003843599,0.000084319465,0.000006640196,0.000044920056,0.000015710984,0.000016617658,0.000008123706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893624,0.00011405563,0.00033193317,0.00028980387,0.00013067968,0.00019728734],"domain_scores_gemma":[0.99937546,0.00003987302,0.00023967595,0.00013482223,0.0001584229,0.000051726252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022010473,0.00014537881,0.00031679854,0.00011055822,0.00001794307,0.0000037563166,0.00006569382,0.00006844166,0.000003915343],"category_scores_gemma":[0.00004795368,0.00013010393,0.000012027585,0.00015861896,0.000110760506,0.0000146051825,0.000034362223,0.000096086565,1.1743739e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007651905,0.02588132,0.3070573,0.00025711456,0.00014839966,0.0000370061,0.0025316912,0.002985988,0.6178197,0.000031609277,0.000056574743,0.035541385],"study_design_scores_gemma":[0.09418485,0.103521526,0.09284883,0.00017276217,0.000065258406,0.000013053309,0.0015201049,0.00018555357,0.70634604,0.00008373093,0.0005697853,0.0004884737],"about_ca_topic_score_codex":0.000055948723,"about_ca_topic_score_gemma":0.00016727098,"teacher_disagreement_score":0.21420847,"about_ca_system_score_codex":0.000018803074,"about_ca_system_score_gemma":0.00012945953,"threshold_uncertainty_score":0.53054845},"labels":[],"label_agreement":null},{"id":"W2151882006","doi":"10.1093/annonc/mdl334","title":"Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Oncology; Postmenopausal women; Estrogen; Internal medicine; Gynecology; Obstetrics; Cancer","score_opus":0.009342063345948167,"score_gpt":0.28263588646220544,"score_spread":0.2732938231162573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151882006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976299,0.001188816,0.000001908867,0.0001518727,0.00002355047,0.00013675344,0.00069250667,0.0000030882281,0.00017161386],"genre_scores_gemma":[0.9990415,0.0005947595,0.00011261667,0.000057018864,0.000048068545,0.000063861,0.000013155415,0.000014095528,0.00005495321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999115,0.000105009676,0.00024428192,0.00022931235,0.00009995036,0.00020647362],"domain_scores_gemma":[0.9991592,0.00003228475,0.00032440232,0.00021278043,0.00022457053,0.000046769714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015149747,0.00012402982,0.0003345291,0.000043341533,0.000017520837,0.0000018359599,0.00007238255,0.00012049457,0.000012943892],"category_scores_gemma":[0.000016159633,0.000108174034,0.0000379336,0.00007407271,0.00048288758,0.0000063392863,0.00008551892,0.000054325286,2.9827578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044315816,0.00021435562,0.97069776,0.000024127192,0.0007653785,0.000020896958,0.0003900149,0.00003811068,0.020098584,0.000014323855,0.00013364284,0.003171231],"study_design_scores_gemma":[0.00095832907,0.002077778,0.9781385,0.000020409696,0.00010870366,0.000010314734,0.00006195777,4.895915e-7,0.01811111,0.00014688126,0.00027267216,0.00009283042],"about_ca_topic_score_codex":0.0046026115,"about_ca_topic_score_gemma":0.0010820569,"teacher_disagreement_score":0.007440769,"about_ca_system_score_codex":0.00001736183,"about_ca_system_score_gemma":0.00012457145,"threshold_uncertainty_score":0.6957802},"labels":[],"label_agreement":null},{"id":"W2152033211","doi":"10.1093/annonc/mds343","title":"Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Gastroenterology; Liver function; Prospective cohort study; Adverse effect; Oncology","score_opus":0.06417526761877117,"score_gpt":0.31007532293989964,"score_spread":0.24590005532112846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152033211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948967,0.0011890131,0.000014074729,0.0006713376,0.000031361422,0.0012675199,0.000018304205,0.000028071396,0.0018835817],"genre_scores_gemma":[0.9990139,0.0000432605,0.00049821666,0.00020060004,0.000035404442,0.00008829898,0.00007153702,0.000023356904,0.000025415182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984689,0.00014740574,0.00036425533,0.00035855873,0.0002197842,0.00044111034],"domain_scores_gemma":[0.9989391,0.00007551231,0.00018565841,0.00031655654,0.0002552618,0.00022794148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003679607,0.00021470025,0.00087953394,0.00032402197,0.0000400247,0.0000042935367,0.000057273,0.00016517926,0.00003387687],"category_scores_gemma":[0.000069603826,0.00016521549,0.00016079567,0.00074099476,0.00017030483,0.00016227791,0.000048110058,0.0001900325,0.0000032906767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020118854,0.0025319282,0.99071026,0.00005839171,0.0005782759,0.00004025333,0.00086359243,6.9638196e-7,0.00003534459,0.00009477562,0.000017275483,0.003057345],"study_design_scores_gemma":[0.005979423,0.0038938273,0.9862913,0.00002361473,0.0007660053,0.0000067976257,0.00011264053,0.00015177605,0.0020131762,0.0000412765,0.0005698023,0.00015037492],"about_ca_topic_score_codex":0.0001288458,"about_ca_topic_score_gemma":0.00008315005,"teacher_disagreement_score":0.0044189505,"about_ca_system_score_codex":0.000107529064,"about_ca_system_score_gemma":0.000096529344,"threshold_uncertainty_score":0.6737292},"labels":[],"label_agreement":null},{"id":"W2152409486","doi":"10.1093/annonc/mdm442","title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","year":2007,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":460,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Calgary","funders":"","keywords":"Medicine; Zoledronic acid; Breast cancer; Dosing; Cancer; Adverse effect; Clinical trial; Disease; Internal medicine; Intensive care medicine; Oncology","score_opus":0.5799143699677424,"score_gpt":0.5581730129892306,"score_spread":0.02174135697851176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152409486","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026822286,0.9847792,0.0000032823507,0.007973025,0.000509608,0.0011068063,0.00024281109,0.00000967795,0.002693386],"genre_scores_gemma":[0.0012525624,0.9956868,0.00086217053,0.0016018539,0.00003542812,0.000073951625,0.00020502532,0.000018625155,0.00026357875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821985,0.00019571609,0.0010224404,0.0001951533,0.00017103473,0.00019578602],"domain_scores_gemma":[0.99744916,0.001034291,0.0008332558,0.00033931975,0.00026507507,0.000078913195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005000454,0.00016910175,0.0012413845,0.00028992738,0.000016018119,0.0000017456491,0.00018262344,0.0002419627,0.000100734534],"category_scores_gemma":[0.00046993163,0.000109032866,0.00019559143,0.00021608437,0.00012097745,0.000058208567,0.000036648165,0.0002421996,0.000008042788],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016798542,0.0014654911,0.00021036503,0.00068064843,0.00017181803,0.000026025407,0.00014418476,6.7745555e-7,0.0000011172943,0.0004034837,0.004829965,0.99189824],"study_design_scores_gemma":[0.00051414187,0.0017168281,0.0009647978,0.0054304227,0.00007101086,0.00003119551,0.000031206175,0.000006397835,0.0001484811,0.0000385525,0.99098504,0.000061931205],"about_ca_topic_score_codex":0.0008964503,"about_ca_topic_score_gemma":0.00019929264,"teacher_disagreement_score":0.9918363,"about_ca_system_score_codex":0.00007761171,"about_ca_system_score_gemma":0.00054886035,"threshold_uncertainty_score":0.4446231},"labels":[],"label_agreement":null},{"id":"W2152511454","doi":"10.1093/annonc/mdg500","title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Internal medicine; Neutropenia; Fluorouracil; Stomatitis; Nausea; Regimen; Gastroenterology; Colorectal cancer; Adjuvant therapy; Surgery; Cancer; Oncology; Chemotherapy","score_opus":0.09975016200087691,"score_gpt":0.454884961949826,"score_spread":0.35513479994894914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152511454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97837526,0.0019424405,0.0001730632,0.0078004804,0.00048329553,0.005361925,0.0004942551,0.000016483309,0.00535279],"genre_scores_gemma":[0.99356925,0.00202727,0.0008585869,0.0017888556,0.00015835123,0.0011262823,0.000067632194,0.00001791983,0.00038586158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797493,0.00034207857,0.00083852594,0.0003278825,0.00022220313,0.0002943545],"domain_scores_gemma":[0.9975143,0.00086950103,0.00047677435,0.00021408165,0.00077043613,0.00015489841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012417248,0.00020767181,0.0018926184,0.00013471588,0.000068803274,0.0000031450018,0.00008631933,0.000102257516,0.00013177482],"category_scores_gemma":[0.0009958595,0.0001458256,0.00033893067,0.0001706924,0.00019266455,0.000044538214,0.0000140921065,0.00008045639,0.0000011962342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8516691,0.0029505386,0.000018740076,0.00001776364,0.0008500207,0.00002024106,0.0015254818,0.000044888562,0.0008533488,0.00032869368,0.0019773801,0.1397438],"study_design_scores_gemma":[0.81686276,0.079705164,0.000054769484,0.00004698101,0.00023106168,0.0000037231403,0.00023013329,0.00010148337,0.032111954,0.00029685174,0.07024076,0.00011435708],"about_ca_topic_score_codex":0.0021798995,"about_ca_topic_score_gemma":0.0011050459,"teacher_disagreement_score":0.13962945,"about_ca_system_score_codex":0.00012432388,"about_ca_system_score_gemma":0.0007442543,"threshold_uncertainty_score":0.5946595},"labels":[],"label_agreement":null},{"id":"W2152630182","doi":"10.1023/a:1008324131519","title":"A phase I–II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute","keywords":"Medicine; Mucositis; Regimen; Concomitant; Radiation therapy; Chemoradiotherapy; Fluorouracil; Chemotherapy; Surgery; Paclitaxel; Head and neck cancer; Granulocyte colony-stimulating factor; Gastroenterology; Internal medicine","score_opus":0.06287406031283435,"score_gpt":0.3846188977215374,"score_spread":0.3217448374087031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152630182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950143,0.0004884301,0.0000043474893,0.0013118773,0.000014201818,0.0027006716,0.00016765921,0.000021589427,0.00027691823],"genre_scores_gemma":[0.99713516,0.0005941268,0.0010284963,0.00067373435,0.000038413094,0.0003689465,0.000015454842,0.00003701542,0.000108664404],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99845773,0.000051025454,0.00045510454,0.00038372373,0.0002969269,0.00035547922],"domain_scores_gemma":[0.99866635,0.0001787063,0.00031319176,0.00015827015,0.0005060282,0.00017743617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001631296,0.00027099092,0.0013440284,0.00008594119,0.00015724734,0.0000066522575,0.00005563522,0.00009377289,0.000081067374],"category_scores_gemma":[0.000028930463,0.00017242007,0.000037947426,0.00017457582,0.00027706308,0.0001099767,0.000023947394,0.00012994921,1.4650617e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0351627,0.009082696,0.78847027,0.00031234845,0.0010132614,0.000024456975,0.007930096,0.000008264699,0.00064770103,0.000002582511,0.00029127108,0.15705436],"study_design_scores_gemma":[0.08742077,0.47941467,0.42509025,0.0005296538,0.00045396725,0.000017272261,0.00081589934,0.00012639622,0.0016509171,0.00000518104,0.0041628275,0.00031216684],"about_ca_topic_score_codex":0.00054240687,"about_ca_topic_score_gemma":0.001201447,"teacher_disagreement_score":0.470332,"about_ca_system_score_codex":0.00004406534,"about_ca_system_score_gemma":0.00032722086,"threshold_uncertainty_score":0.7031086},"labels":[],"label_agreement":null},{"id":"W2152757219","doi":"10.1093/annonc/mdf314","title":"DNA methyltransferase inhibitors—state of the art","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"York University; AstraZeneca Canada","keywords":"DNA methylation; Methyltransferase; DNA methyltransferase; Epigenetics; Methylation; DNA; Cancer research; Chromatin; Biology; Molecular biology; Medicine; Genetics; Gene expression; Gene","score_opus":0.09690084542322627,"score_gpt":0.38979031360127875,"score_spread":0.2928894681780525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152757219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012908892,0.9929984,0.000062163694,0.00013853786,0.00033133276,0.00038647544,0.00010533114,0.000002805922,0.0046840464],"genre_scores_gemma":[0.0010711389,0.9974593,0.00009404225,0.00007976067,0.00016414323,0.000025044426,0.00009087606,0.00003275419,0.0009829643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981404,0.0004292127,0.00076345936,0.00030023124,0.0001493549,0.00021736884],"domain_scores_gemma":[0.99856246,0.000080019425,0.0005678573,0.0005415745,0.00018916857,0.000058938167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045965958,0.00024548112,0.00096544554,0.00008078269,0.000031349948,0.0000036996669,0.00035426702,0.00044407664,0.000030821888],"category_scores_gemma":[0.0001449008,0.00017191088,0.0007054888,0.00018189257,0.00019206223,0.0000015226476,0.00011403173,0.00018364041,0.000012097454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009839785,0.00012970723,0.0000050690787,0.0010920904,0.00020813663,0.0000014312742,0.000020373007,0.0000061921296,0.0054915026,0.000019330671,0.0031823313,0.989834],"study_design_scores_gemma":[0.00012898895,0.0006634659,0.0000063696584,0.00042249003,0.00017608718,0.000003705112,0.0000015286137,5.918959e-7,0.06957497,0.00011848162,0.9287589,0.00014438048],"about_ca_topic_score_codex":0.0000066345815,"about_ca_topic_score_gemma":0.000021995173,"teacher_disagreement_score":0.9896896,"about_ca_system_score_codex":0.0000084992935,"about_ca_system_score_gemma":0.00025632093,"threshold_uncertainty_score":0.7010322},"labels":[],"label_agreement":null},{"id":"W2152961124","doi":"10.1093/annonc/mdr001","title":"Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Gastroenterology; Neutropenia; myalgia; Leukopenia; Taxane; Ovarian cancer; Paclitaxel; Cancer; Surgery; Chemotherapy; Breast cancer; Cisplatin","score_opus":0.07139436111871882,"score_gpt":0.3530403629742522,"score_spread":0.28164600185553335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152961124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922085,0.003057246,3.2887633e-7,0.0014248888,0.00044271088,0.0012427982,0.00006846463,0.000022248218,0.001532826],"genre_scores_gemma":[0.9973017,0.0017284242,0.000083443505,0.00028870162,0.00005269272,0.00044532763,0.000018452736,0.000031681964,0.000049551556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976557,0.0002541164,0.00078160205,0.0006161869,0.00018501238,0.0005073721],"domain_scores_gemma":[0.99876046,0.00032111036,0.00031806823,0.00026289307,0.00016789013,0.00016957834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036145424,0.00032584634,0.000970385,0.0003582034,0.00004318501,0.000009746065,0.00008989474,0.00032121784,0.00015554714],"category_scores_gemma":[0.00013570067,0.00028155863,0.00006617587,0.00040682236,0.00016975118,0.00011513216,0.00011181503,0.00037417462,0.0000019333986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030965086,0.0030755203,0.910862,0.00007110772,0.00034165566,0.00044644094,0.0057039573,0.000020293777,0.00039932554,0.00007000231,0.00021478438,0.07569835],"study_design_scores_gemma":[0.01984483,0.014496303,0.96336216,0.00021988347,0.00022194402,0.0000039058964,0.00048315173,0.00013204789,0.00065066625,0.00011932382,0.00023213297,0.00023368036],"about_ca_topic_score_codex":0.053526975,"about_ca_topic_score_gemma":0.12073913,"teacher_disagreement_score":0.07546467,"about_ca_system_score_codex":0.0003131984,"about_ca_system_score_gemma":0.0002862639,"threshold_uncertainty_score":0.99996364},"labels":[],"label_agreement":null},{"id":"W2153022550","doi":"10.1093/annonc/mdu165.25","title":"Subgroup Analyses Based on Liver Metastases and the Number of Metastatic Sites from the Mpact Phase III Trial of Nab-Paclitaxel Plus Gemcitabine Vs Gemcitabine Alone for Metastatic Pancreatic Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Oncology; Paclitaxel; Performance status; Subgroup analysis; Metastasis; Nab-paclitaxel; Chemotherapy; Cancer; Urology; Confidence interval; Randomized controlled trial; Breast cancer","score_opus":0.08409434528319716,"score_gpt":0.4103033320384105,"score_spread":0.32620898675521337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153022550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682874,0.0049541923,0.0032612307,0.0016705436,0.00012192048,0.0009871753,0.002036848,0.0000032542016,0.00013610916],"genre_scores_gemma":[0.99308646,0.0025873166,0.001973792,0.0015541,0.00018376521,0.0001906698,0.0003630708,0.000026255639,0.00003457654],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99795085,0.00051777414,0.0007240943,0.0003323051,0.0001991989,0.00027578144],"domain_scores_gemma":[0.9942938,0.0039964695,0.0007461625,0.0005327693,0.00035009795,0.000080707825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012371384,0.00025577965,0.0011221854,0.000059832022,0.0000746957,0.000013400166,0.00027772324,0.00007916628,0.00008862023],"category_scores_gemma":[0.0019260873,0.00015422491,0.00036129446,0.0001433052,0.0006292562,0.000007870183,0.00008439462,0.000085107065,7.7553017e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61284214,0.007215534,0.0022480427,0.0009923497,0.013130664,0.000017892475,0.0017510607,0.009512152,0.2659472,0.0064049354,0.03306941,0.046868626],"study_design_scores_gemma":[0.4736215,0.034507312,0.0025486269,0.00022942491,0.010614515,0.00001569422,0.00093939644,0.029462041,0.40907905,0.006061954,0.031917203,0.0010033008],"about_ca_topic_score_codex":0.002973552,"about_ca_topic_score_gemma":0.000954659,"teacher_disagreement_score":0.14313185,"about_ca_system_score_codex":0.000015597412,"about_ca_system_score_gemma":0.00028072944,"threshold_uncertainty_score":0.62891096},"labels":[],"label_agreement":null},{"id":"W2153285528","doi":"10.1093/annonc/mds623","title":"Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Radiation therapy; Retrospective cohort study; Gastric lymphoma; Internal medicine; Term (time); Outcome (game theory); Oncology","score_opus":0.05928667877931365,"score_gpt":0.36606790598217875,"score_spread":0.3067812272028651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153285528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927202,0.00028185066,0.00035837488,0.0012255522,0.00019618946,0.004820569,0.00004919202,0.00006908766,0.00027900827],"genre_scores_gemma":[0.9956049,0.000103301456,0.0018106863,0.00042863554,0.00016661316,0.00094260916,0.000078424826,0.000056384943,0.0008084579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975102,0.00015700786,0.0007102137,0.00065272313,0.00045063128,0.0005192097],"domain_scores_gemma":[0.9981354,0.0001918749,0.00038154895,0.00042969466,0.0006263281,0.00023515582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002853995,0.00040368387,0.0010981135,0.00034831895,0.000094882475,0.000036193585,0.00023497002,0.00013552583,0.00036898724],"category_scores_gemma":[0.000049696377,0.00029103644,0.00023241593,0.00029437654,0.00013352718,0.00017208315,0.000051919258,0.00005689782,0.000025105352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034134914,0.061809026,0.841691,0.000025983716,0.0025014903,0.0006032307,0.00066550774,0.0000014606765,0.00015758035,0.000023130706,0.00043113486,0.08867693],"study_design_scores_gemma":[0.07389919,0.033446554,0.89036196,0.000037930742,0.00041164152,0.00022361624,0.00078033854,0.00012125335,0.00013534904,0.0000034584739,0.00036375073,0.00021493886],"about_ca_topic_score_codex":0.00096254726,"about_ca_topic_score_gemma":0.00049908354,"teacher_disagreement_score":0.08846199,"about_ca_system_score_codex":0.0006475098,"about_ca_system_score_gemma":0.00017664972,"threshold_uncertainty_score":0.99995416},"labels":[],"label_agreement":null},{"id":"W2153491150","doi":"10.1093/annonc/mdf651","title":"Novel endpoints and design of early clinical trials","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Clinical study design; Endpoint Determination; Surrogate endpoint; Medical physics; Intensive care medicine; Oncology; Internal medicine","score_opus":0.9128397694569303,"score_gpt":0.7023489934726278,"score_spread":0.21049077598430255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153491150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022544797,0.99281347,0.00023677446,0.0005779963,0.0003000193,0.0019881465,0.0000970834,0.000011241954,0.003952747],"genre_scores_gemma":[0.000025103518,0.9957432,0.0025305306,0.00023624444,0.0005053795,0.00008758937,0.000012015347,0.0000496344,0.00081030076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922151,0.0032715313,0.0031901568,0.00047823126,0.0004381874,0.00040680624],"domain_scores_gemma":[0.9869481,0.010155328,0.0015869373,0.0005710831,0.00042713428,0.00031146966],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016567973,0.00028648405,0.007371359,0.0003647541,0.000017342138,0.0000052351647,0.0002897027,0.001131027,0.00062886067],"category_scores_gemma":[0.011170239,0.0002107793,0.00084891956,0.00028514987,0.0005980891,0.000028483444,0.00015012336,0.00090811733,0.00006410969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026393755,0.00060107093,0.00002503027,0.009308824,0.0006385355,0.00006415826,0.00003769756,5.7454262e-8,0.00001006151,0.00005359144,0.020620648,0.9683764],"study_design_scores_gemma":[0.0014876295,0.009610493,0.000056624565,0.0072301156,0.0008201963,0.00016754282,0.000005183088,0.0000036786719,0.000019343952,0.000047369987,0.98042023,0.00013160084],"about_ca_topic_score_codex":0.00005491195,"about_ca_topic_score_gemma":0.000002478002,"teacher_disagreement_score":0.9682448,"about_ca_system_score_codex":0.000051259067,"about_ca_system_score_gemma":0.0020083238,"threshold_uncertainty_score":0.9971591},"labels":[],"label_agreement":null},{"id":"W2153734611","doi":"10.1093/annonc/mdt406","title":"Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data","year":2013,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Cancer Research UK","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Ovarian cancer; Meta-analysis; Randomized controlled trial; Carboplatin; Cancer; Paclitaxel; Cisplatin; Surgery","score_opus":0.5102139847643494,"score_gpt":0.49961723618323384,"score_spread":0.01059674858111559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153734611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009384852,0.9902837,0.000018105606,0.0015226223,0.0005980098,0.0030079414,0.0026951993,0.000025084219,0.00091081584],"genre_scores_gemma":[0.0029665024,0.9892405,0.00232131,0.00041046142,0.00019550486,0.000634708,0.0041155755,0.00008111559,0.000034278695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949833,0.0006689782,0.0019303947,0.0011846914,0.0006621453,0.0005704729],"domain_scores_gemma":[0.99465764,0.0011036249,0.0023352357,0.0012958472,0.0004063713,0.0002013005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008329591,0.00075366674,0.0070365565,0.001072502,0.000069655856,0.000034202523,0.00042232007,0.0007138486,0.001143297],"category_scores_gemma":[0.00018040359,0.00058155105,0.0016121177,0.0014182368,0.00013267428,0.00018793072,0.00030074254,0.00063812255,0.000019160787],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002527674,0.0013870326,0.000046910318,0.0009240712,0.16665551,0.00009128359,0.0006793836,0.000029499,3.016697e-7,0.000089167355,0.001886027,0.82795805],"study_design_scores_gemma":[0.0058241813,0.004135863,0.00033954118,0.0015378826,0.4133338,0.00003349333,0.00018628112,0.00046607933,0.000029343295,0.000046936602,0.57341015,0.00065643346],"about_ca_topic_score_codex":0.0020163818,"about_ca_topic_score_gemma":0.00081744633,"teacher_disagreement_score":0.8273016,"about_ca_system_score_codex":0.0006052158,"about_ca_system_score_gemma":0.00161149,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W2153871840","doi":"10.1093/annonc/mdu519","title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Amgen","keywords":"Medicine; Denosumab; Zoledronic acid; Spinal cord compression; Prostate cancer; Pathologic fracture; Bisphosphonate; Internal medicine; Urology; Placebo; Hazard ratio; Bone metastasis; Surgery; Oncology; Osteoporosis; Confidence interval; Cancer; Spinal cord; Pathology","score_opus":0.07897869920983895,"score_gpt":0.4387958787476891,"score_spread":0.35981717953785014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153871840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934203,0.0014687506,0.0001861248,0.0026789375,0.00007223083,0.0019480735,0.00007817968,0.000007685454,0.00013970972],"genre_scores_gemma":[0.99835587,0.0002694371,0.0007985668,0.00006844427,0.0000065979443,0.00029628552,0.00009795895,0.00001374653,0.00009312724],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981554,0.00020064808,0.0010147112,0.0001927577,0.00019545505,0.0002409986],"domain_scores_gemma":[0.99812937,0.0005104441,0.0007996614,0.00022175215,0.00025382047,0.00008492962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051667873,0.00013922901,0.0006988193,0.00013680018,0.00006728774,0.0000015929396,0.00008065998,0.00008237835,0.000015036927],"category_scores_gemma":[0.00015212051,0.00010560533,0.00012022604,0.00019711445,0.0001485179,0.000059648915,0.000022778626,0.00010797599,0.0000017098803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024220939,0.012741763,0.42674983,0.00696721,0.0030333835,0.0000052451487,0.004924784,0.00059786695,0.011887367,0.006822022,0.00073898805,0.52310944],"study_design_scores_gemma":[0.00865893,0.007260034,0.970704,0.00054148474,0.0006277521,0.000018906036,0.00028744043,0.0049913037,0.001776705,0.004174655,0.00084026856,0.000118507356],"about_ca_topic_score_codex":0.0005878587,"about_ca_topic_score_gemma":0.000978297,"teacher_disagreement_score":0.5439542,"about_ca_system_score_codex":0.000046337274,"about_ca_system_score_gemma":0.00030223848,"threshold_uncertainty_score":0.43064603},"labels":[],"label_agreement":null},{"id":"W2153964141","doi":"10.1093/annonc/mdi312","title":"Smoking and lung cancer in Harbin, northeast China","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Lung cancer; Odds ratio; Confidence interval; Internal medicine; Lung; Case-control study; Cancer; Incidence (geometry)","score_opus":0.03279184355381752,"score_gpt":0.43606015689424726,"score_spread":0.40326831334042973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153964141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508145,0.005226794,0.0000062104286,0.023441171,0.00006356772,0.0001585848,0.0000126149525,0.000008076593,0.020268502],"genre_scores_gemma":[0.99700093,0.0009781051,0.00015636806,0.0013006809,0.00009328246,0.000027622167,0.0000049390983,0.000006046408,0.00043203574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995743,0.000013649796,0.00013809057,0.00009970347,0.00005217198,0.00012208635],"domain_scores_gemma":[0.9997743,0.000018968614,0.000050386487,0.00006644467,0.00004136519,0.000048537986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067883666,0.00005267256,0.00018051281,0.00007192465,0.000019531688,0.0000017714625,0.000019625124,0.000048886795,0.00014193197],"category_scores_gemma":[0.000011807763,0.00004327396,0.000023201577,0.00007238407,0.000038686365,0.000045438366,0.000012338534,0.00006716988,0.0000011130528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011597368,0.0003438135,0.55291873,0.000057240915,0.00020389182,0.00003345865,0.0021292788,0.00008736605,0.00030352632,0.0004042413,0.0025388997,0.44086358],"study_design_scores_gemma":[0.0022498295,0.00049025624,0.9318586,0.00010540798,0.00013373973,0.000025145995,0.000081904465,0.00040988566,0.00063482986,0.00006153,0.063888416,0.000060445593],"about_ca_topic_score_codex":0.0005790781,"about_ca_topic_score_gemma":0.0011748427,"teacher_disagreement_score":0.44080314,"about_ca_system_score_codex":0.00006053536,"about_ca_system_score_gemma":0.00016593574,"threshold_uncertainty_score":0.17646609},"labels":[],"label_agreement":null},{"id":"W2154197604","doi":"10.1093/annonc/mds581","title":"Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; State Key Laboratory of Oncology in South China; Bayer Corporation","keywords":"Medicine; Nasopharyngeal carcinoma; Fluorouracil; Sorafenib; Cisplatin; Oncology; Internal medicine; Carcinoma; Chemotherapy; Radiation therapy; Hepatocellular carcinoma","score_opus":0.15620410697700615,"score_gpt":0.44097413291310733,"score_spread":0.2847700259361012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154197604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566823,0.0010278844,0.0000036621725,0.0015933246,0.000053893258,0.000711497,0.000010145296,0.0000054078528,0.0009259679],"genre_scores_gemma":[0.999246,0.000101000136,0.00023586614,0.00021140689,0.00002467628,0.000066703724,0.0000053429826,0.000008009098,0.00010096477],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99906355,0.00010786451,0.00032851732,0.00013888355,0.00015098888,0.00021020682],"domain_scores_gemma":[0.99934334,0.00015764147,0.00012232659,0.00011127756,0.00014993998,0.00011549184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003573342,0.00010909763,0.0006715392,0.00016332876,0.000034421468,0.0000010387067,0.000033769724,0.000031301774,0.000030339763],"category_scores_gemma":[0.00009872924,0.00007353293,0.000020258049,0.0002176681,0.000054056258,0.0000724456,0.000045533732,0.00008191204,0.0000010516037],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024189467,0.048800196,0.14080982,0.0004975487,0.00027451196,0.00017217506,0.05920309,0.0000022324114,0.002923315,0.00014966234,0.0032900837,0.7196879],"study_design_scores_gemma":[0.06418105,0.58531755,0.32404572,0.0002459088,0.0004119305,0.00009595991,0.0108947605,0.00005376344,0.011530043,0.00003764416,0.0029470224,0.00023867516],"about_ca_topic_score_codex":0.00021809243,"about_ca_topic_score_gemma":0.0005911784,"teacher_disagreement_score":0.7194492,"about_ca_system_score_codex":0.00003414736,"about_ca_system_score_gemma":0.00010668947,"threshold_uncertainty_score":0.2998586},"labels":[],"label_agreement":null},{"id":"W2154208670","doi":"10.1093/annonc/mdf642","title":"Hormonal replacement therapy in breast cancer","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Hormonal therapy; Oncology; Hormonal replacement therapy; Cancer; Gynecology; Internal medicine; Hormone","score_opus":0.07868784954464393,"score_gpt":0.4065091250700126,"score_spread":0.32782127552536866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154208670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011661611,0.9956555,6.194886e-7,0.0003680927,0.00017794002,0.00042351492,0.000080693084,0.0000048090074,0.002122663],"genre_scores_gemma":[0.00022445264,0.9983605,0.0000211062,0.00035875585,0.00023537021,0.00014771937,0.00013656724,0.00003685296,0.00047868458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983887,0.00026669598,0.0005142412,0.00039833155,0.00010649756,0.00032551252],"domain_scores_gemma":[0.9991347,0.000031988307,0.00035897573,0.0003227524,0.000075207405,0.000076341676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028148293,0.00029381775,0.0010154458,0.00012565491,0.00002115239,0.0000041617564,0.0002562249,0.0008979221,0.00011811575],"category_scores_gemma":[0.000011245755,0.00022707993,0.00039237685,0.00015520382,0.00009730615,0.0000017429712,0.00008916745,0.00030443558,0.000019283689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013504895,0.00028190686,0.00002447305,0.00047137617,0.00035603388,0.000020373345,0.0000114545755,0.0000019786778,0.00016398728,0.000013634817,0.020963935,0.9775558],"study_design_scores_gemma":[0.00054862315,0.0017982457,0.00002485097,0.00071260036,0.000057043402,0.000119098644,0.00000290383,0.0000012891362,0.00021619232,0.000005872867,0.99629647,0.00021684308],"about_ca_topic_score_codex":0.0000424434,"about_ca_topic_score_gemma":0.000007568219,"teacher_disagreement_score":0.97733897,"about_ca_system_score_codex":0.000030738945,"about_ca_system_score_gemma":0.000364577,"threshold_uncertainty_score":0.9260051},"labels":[],"label_agreement":null},{"id":"W2154320833","doi":"10.1093/annonc/mdq067","title":"The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Histology; Pooled analysis; Oncology; Randomized controlled trial; Internal medicine; Meta-analysis","score_opus":0.03235035266287021,"score_gpt":0.42815541762568093,"score_spread":0.3958050649628107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154320833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285454,0.0008701674,0.000010174827,0.004113432,0.00008713903,0.00074382895,0.000038114867,0.0000027390117,0.0012798967],"genre_scores_gemma":[0.9975222,0.0013325311,0.00019185647,0.000471507,0.000010817931,0.00013080891,0.0000068805152,0.000004976439,0.00032844575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985726,0.0002964574,0.00076118286,0.00014513881,0.000091082045,0.00013355081],"domain_scores_gemma":[0.9949993,0.0038451955,0.0006757513,0.00020816326,0.00022766746,0.000043936067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013678051,0.00009723364,0.0019680732,0.00029490623,0.00002490068,0.0000014402799,0.00007696216,0.000118259806,0.00003563803],"category_scores_gemma":[0.0011785704,0.00005592826,0.00026210165,0.0002452747,0.00029964303,0.00001755115,0.000021166983,0.000121311285,1.8523896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11824677,0.0040166173,0.6880525,0.00053399015,0.047365785,0.00007295004,0.022127118,0.019720074,0.040818397,0.0017927767,0.0010747934,0.056178242],"study_design_scores_gemma":[0.331168,0.0036733677,0.6060726,0.0001568028,0.03515987,0.000006928122,0.001221271,0.0056932573,0.014583888,0.00048055773,0.0015132722,0.00027017097],"about_ca_topic_score_codex":0.0030894817,"about_ca_topic_score_gemma":0.0022420725,"teacher_disagreement_score":0.21292123,"about_ca_system_score_codex":0.000027437722,"about_ca_system_score_gemma":0.0003214942,"threshold_uncertainty_score":0.4670393},"labels":[],"label_agreement":null},{"id":"W2154552323","doi":"10.1093/annonc/mdq613","title":"Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Public Health Ontario; University of Toronto; Toronto General Hospital","funders":"National Institutes of Health; National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Smokeless tobacco; Medicine; Odds ratio; Pancreatic cancer; Logistic regression; Confidence interval; Tobacco control; Case-control study; Pack-year; Risk factor; Environmental health; Internal medicine; Cancer; Cigarette smoking; Tobacco use; Public health; Pathology; Population","score_opus":0.13713651983693645,"score_gpt":0.4008857055573657,"score_spread":0.26374918572042927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154552323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902645,0.0038051677,0.00008423564,0.0033849294,0.00014718092,0.00053203566,0.00040199843,0.000025967942,0.0013540258],"genre_scores_gemma":[0.98655826,0.008858672,0.0004153432,0.003447023,0.00022371805,0.00020080034,0.00003658507,0.000022887907,0.00023670463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773455,0.00040717024,0.0006053318,0.0004984418,0.00030865578,0.0004458308],"domain_scores_gemma":[0.99672484,0.0016031986,0.0003604463,0.00048423748,0.0005189429,0.0003083555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083137164,0.00025041323,0.0013323262,0.0002316982,0.00015583055,0.00003243379,0.00022726537,0.00027517145,0.0014461068],"category_scores_gemma":[0.0005122494,0.00017635476,0.00013621578,0.00028322704,0.0007677299,0.00020722546,0.000109105924,0.00034420376,0.00000252423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011555025,0.00028360428,0.97152776,0.000024915857,0.005769836,0.000591104,0.0019756313,0.0000032793064,0.00031232007,0.00023739257,0.0006949037,0.017423782],"study_design_scores_gemma":[0.0027902331,0.001095183,0.98452413,0.000083971136,0.0064860405,0.00024264539,0.0011542254,0.0015839201,0.00030965352,0.0002932666,0.001264821,0.00017188228],"about_ca_topic_score_codex":0.067084394,"about_ca_topic_score_gemma":0.017805388,"teacher_disagreement_score":0.049279004,"about_ca_system_score_codex":0.000094461175,"about_ca_system_score_gemma":0.00049271225,"threshold_uncertainty_score":0.9994667},"labels":[],"label_agreement":null},{"id":"W2154753744","doi":"10.1093/annonc/mdu205","title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University of Alberta","funders":"","keywords":"Tremelimumab; Medicine; Tolerability; Gemcitabine; Internal medicine; Oncology; Pancreatic cancer; Chemotherapy; Gastroenterology; Cancer; Adverse effect; Immunotherapy; Ipilimumab","score_opus":0.041193015539834725,"score_gpt":0.3675221896947738,"score_spread":0.32632917415493906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154753744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965023,0.00015358206,0.000083141465,0.0015280511,0.000056449393,0.0012095975,0.000012503054,0.0000073616065,0.0004470349],"genre_scores_gemma":[0.99874055,0.00023829001,0.000288371,0.0004937302,0.000023679304,0.000108429194,0.000057384368,0.0000177161,0.000031849177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99863553,0.0001785659,0.0005460071,0.00019650071,0.00024957984,0.00019381885],"domain_scores_gemma":[0.9989377,0.00016907605,0.00043670277,0.00017400923,0.00024154676,0.00004091925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005020084,0.00014441521,0.00066775567,0.0002958443,0.000013064753,0.0000026539235,0.00006036698,0.00007807962,0.00008128395],"category_scores_gemma":[0.00006471608,0.00010357423,0.000056345638,0.0004436697,0.00014605084,0.00009194277,0.0000066396938,0.000104894694,5.248646e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5894599,0.012043388,0.0568247,0.00020611205,0.00038785997,0.0000073184406,0.0015409798,0.000045438846,0.00370829,0.00008787647,0.00011721414,0.33557093],"study_design_scores_gemma":[0.56146693,0.06506621,0.36635196,0.00045257478,0.0001404723,0.000002658847,0.00013535662,0.0005375356,0.004583063,0.00014220057,0.00096423354,0.00015681492],"about_ca_topic_score_codex":0.001159313,"about_ca_topic_score_gemma":0.0012979616,"teacher_disagreement_score":0.3354141,"about_ca_system_score_codex":0.00011117299,"about_ca_system_score_gemma":0.00028381785,"threshold_uncertainty_score":0.42236346},"labels":[],"label_agreement":null},{"id":"W2155151539","doi":"10.1093/annonc/mdq460","title":"Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health","funders":"National Cancer Institute","keywords":"Medicine; Population; Breast cancer; Confidence interval; Loss of heterozygosity; Cohort; Proband; Founder effect; Internal medicine; Odds ratio; Family history; Mutation; Genetics; Oncology; Gynecology; Cancer; Demography; Gene; Biology; Genotype; Haplotype; Allele","score_opus":0.04936176075918808,"score_gpt":0.3699374404745606,"score_spread":0.32057567971537254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155151539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925332,0.0007967956,0.000010168328,0.0049841697,0.00013551171,0.00017379707,0.000004763514,0.0000015174759,0.0013600562],"genre_scores_gemma":[0.99746037,0.00023770286,0.00019059039,0.0019015974,0.00012145888,0.000036907084,0.000029076786,0.000004777235,0.00001754573],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993441,0.00012752514,0.00017039248,0.00015887975,0.00007053988,0.00012854414],"domain_scores_gemma":[0.99957156,0.00004529948,0.00007176026,0.00025463378,0.000044629098,0.000012134114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067785324,0.000064667045,0.000098028875,0.000039033515,0.00003704247,0.000010578439,0.00022094199,0.00015065193,0.0000072824723],"category_scores_gemma":[0.000043066826,0.000044165816,0.000029174522,0.00009749977,0.000102358616,0.0000045468305,0.00004749168,0.0001368384,9.982792e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038099868,0.00059027213,0.3805146,0.000039601036,0.00005896381,0.000017347898,0.0036404168,0.0003002636,0.38409835,0.0025519186,0.009627704,0.21817955],"study_design_scores_gemma":[0.0012068689,0.0006278838,0.8148248,0.0000048917495,0.000010649715,0.000079586855,0.00041044812,0.00004190336,0.04399469,0.002557317,0.13610421,0.000136722],"about_ca_topic_score_codex":0.00031242956,"about_ca_topic_score_gemma":0.00749262,"teacher_disagreement_score":0.43431023,"about_ca_system_score_codex":0.0000067033925,"about_ca_system_score_gemma":0.000055468176,"threshold_uncertainty_score":0.41810578},"labels":[],"label_agreement":null},{"id":"W2155424734","doi":"10.1093/annonc/mdr318","title":"Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Merkel cell carcinoma; Adjuvant; Radiation therapy; Adjuvant radiotherapy; Stage (stratigraphy); Oncology; Randomized controlled trial; Carcinoma; Internal medicine","score_opus":0.15340780940337398,"score_gpt":0.37662752296589314,"score_spread":0.22321971356251916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155424734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946077,0.004235019,0.000012485706,0.00033745976,0.00020244785,0.0024571093,0.000005662447,0.000020876083,0.0032681585],"genre_scores_gemma":[0.9982864,0.0004384926,0.00039753196,0.00024963898,0.000053523272,0.00015247919,0.0000075272687,0.00001860628,0.00039578672],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983674,0.00037843786,0.0004953793,0.0002763269,0.00021539653,0.00026704537],"domain_scores_gemma":[0.99880666,0.00031914073,0.000322143,0.00021333252,0.00021615169,0.00012257569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004946895,0.00016047597,0.0008155685,0.00023893871,0.00003345019,0.0000026111234,0.00008651002,0.00014452613,0.00013610214],"category_scores_gemma":[0.00023397997,0.00011847168,0.00016857355,0.0002962821,0.00017408664,0.000085392676,0.000020442074,0.0002105398,0.00000777442],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74657506,0.018888572,0.21301793,0.0001577172,0.0005191152,0.0007667042,0.012800734,0.000016927057,0.0015539778,0.00028454885,0.00024642766,0.0051722727],"study_design_scores_gemma":[0.46510074,0.010902213,0.5185488,0.000024219662,0.0003785221,0.000007014122,0.0018094713,0.0006104114,0.002015506,0.000079989746,0.00035665586,0.00016643891],"about_ca_topic_score_codex":0.001281516,"about_ca_topic_score_gemma":0.000058748672,"teacher_disagreement_score":0.30553088,"about_ca_system_score_codex":0.00010801753,"about_ca_system_score_gemma":0.00042746565,"threshold_uncertainty_score":0.4831135},"labels":[],"label_agreement":null},{"id":"W2155655370","doi":"10.1093/annonc/mds330","title":"Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Letrozole; Hazard ratio; Tamoxifen; Breast cancer; Placebo; Postmenopausal women; Gynecology; Confidence interval; Internal medicine; Oncology; Adjuvant; Cancer","score_opus":0.04220965986834028,"score_gpt":0.37223904411605274,"score_spread":0.33002938424771244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155655370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953016,0.0016949489,6.147912e-7,0.0008554727,0.00018347382,0.0007260601,0.00056846044,0.0000029128323,0.00066645275],"genre_scores_gemma":[0.9962314,0.0022459442,0.000008247915,0.00016946062,0.0001617638,0.0010958976,0.000021855445,0.000016779954,0.00004867884],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982906,0.00030243976,0.00048913667,0.00021566048,0.00016535037,0.0005368239],"domain_scores_gemma":[0.99875486,0.00020655303,0.00048775936,0.0003164906,0.00014446254,0.000089898705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045438588,0.00020779888,0.00073522684,0.00008042065,0.000031744454,0.0000018166197,0.0001661041,0.00013784792,0.0002642842],"category_scores_gemma":[0.00013629721,0.00013469045,0.00020102707,0.00009285492,0.0001904252,0.000006617563,0.00014312944,0.00007632235,0.0000021377953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6524355,0.005622311,0.23318578,0.000050208386,0.002906528,0.0000036364381,0.001639608,0.00008854158,0.07263569,0.0000383881,0.007518317,0.023875523],"study_design_scores_gemma":[0.12634403,0.012599181,0.7883517,0.00006503149,0.00012680706,0.0000075957355,0.00030389137,0.0000041237713,0.07008145,0.000035602483,0.0018678274,0.00021275146],"about_ca_topic_score_codex":0.0008355327,"about_ca_topic_score_gemma":0.00029184003,"teacher_disagreement_score":0.55516595,"about_ca_system_score_codex":0.00020592533,"about_ca_system_score_gemma":0.00024532454,"threshold_uncertainty_score":0.54925174},"labels":[],"label_agreement":null},{"id":"W2156753629","doi":"10.1093/annonc/dkg022","title":"Dietary glycemic index, glycemic load and ovarian cancer risk:a case–control study in Italy","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Glycemic load; Hyperinsulinemia; Quartile; Odds ratio; Glycemic index; Ovarian cancer; Internal medicine; Glycemic; Insulin; Case-control study; Confidence interval; Cancer; Insulin resistance; Logistic regression; Endocrinology; Oncology","score_opus":0.06809387408262906,"score_gpt":0.36554379176686813,"score_spread":0.29744991768423906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156753629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97955596,0.009369073,0.0000023232578,0.0071459212,0.00017218576,0.0008786177,0.000091085654,0.000018138668,0.0027666953],"genre_scores_gemma":[0.99367946,0.0044721765,0.000043309326,0.0013573365,0.00013573207,0.00018699876,0.0000019521187,0.000019913701,0.000103146594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984822,0.00013852325,0.000452363,0.0003980458,0.00018340554,0.0003454427],"domain_scores_gemma":[0.998952,0.00025109065,0.00021031516,0.00030254078,0.00012540232,0.0001586706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002444448,0.00020127432,0.0007285234,0.00016579902,0.000050610688,0.0000067570763,0.000065695625,0.00016612573,0.00060687884],"category_scores_gemma":[0.00008066573,0.0001718619,0.0000869587,0.00021492153,0.00010884601,0.000074254705,0.00004057284,0.00027356498,0.000015625084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004203658,0.0031940436,0.6976704,0.000039274753,0.0007863246,0.0065820958,0.0019599453,0.000039456707,0.000036740003,0.000011726838,0.0018100885,0.28366625],"study_design_scores_gemma":[0.04211099,0.021946095,0.9264742,0.00011676893,0.00077416,0.0011319563,0.00084902486,0.0007595773,0.00007284488,0.00015525744,0.0053493367,0.0002597916],"about_ca_topic_score_codex":0.0098192515,"about_ca_topic_score_gemma":0.008708303,"teacher_disagreement_score":0.28340644,"about_ca_system_score_codex":0.00020242725,"about_ca_system_score_gemma":0.0001780713,"threshold_uncertainty_score":0.99677444},"labels":[],"label_agreement":null},{"id":"W2157717971","doi":"10.1093/annonc/mdp328","title":"N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Docetaxel; Irinotecan; Metastatic breast cancer; Internal medicine; Regimen; Taxane; Neutropenia; Breast cancer; Oncology; Febrile neutropenia; Cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Surgery; Phases of clinical research; Colorectal cancer","score_opus":0.09833561280837098,"score_gpt":0.44932290861313745,"score_spread":0.35098729580476645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157717971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830744,0.0028264066,0.0000018139922,0.0107907485,0.0006534662,0.0017245688,0.00038389358,0.000017607721,0.0005270808],"genre_scores_gemma":[0.98424745,0.013580033,0.000048416485,0.0008673449,0.00070644176,0.0002563528,0.0000638595,0.00001727763,0.00021284824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978893,0.00018110286,0.00080128846,0.00039381356,0.00020868143,0.00052582246],"domain_scores_gemma":[0.99874854,0.0001961491,0.00048095937,0.00021133912,0.00010658098,0.00025640524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020262902,0.0002948908,0.0013589681,0.0002837779,0.00003541383,0.000004121684,0.00009386706,0.00013784932,0.00032346082],"category_scores_gemma":[0.000025175032,0.00024056745,0.00022325706,0.00027699588,0.00019358259,0.00010097812,0.000019942177,0.00019528573,0.0000011801056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6105252,0.018961698,0.002351698,0.000060849565,0.0006724814,0.00021509988,0.0008487593,0.000020612628,0.0031432186,0.000034418495,0.0013789359,0.36178705],"study_design_scores_gemma":[0.7990536,0.1335287,0.03580589,0.0000884655,0.001248221,0.00006947876,0.00008470052,0.0000696138,0.00340501,0.00011457065,0.026286336,0.00024543243],"about_ca_topic_score_codex":0.006701345,"about_ca_topic_score_gemma":0.0075404528,"teacher_disagreement_score":0.3615416,"about_ca_system_score_codex":0.0003999831,"about_ca_system_score_gemma":0.00095436006,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W2157977749","doi":"10.1093/annonc/mds174","title":"Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Absolute risk reduction; Clinical trial; Colorectal cancer; Randomized controlled trial; Adjuvant therapy; Adjuvant; Internal medicine; Clinical endpoint; Oncology; Confidence interval; Cancer","score_opus":0.8201028135580092,"score_gpt":0.6917364243737233,"score_spread":0.1283663891842859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157977749","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511856,0.0050418014,0.03745108,0.00095357466,0.0005112214,0.0004216735,0.00022719482,0.000016155924,0.004191702],"genre_scores_gemma":[0.45408335,0.00035800863,0.54536927,0.00011009397,0.000044802775,0.000008487191,0.0000011415748,0.000011116871,0.000013715136],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9969759,0.0011123999,0.0012725561,0.00016428667,0.00018722753,0.00028762303],"domain_scores_gemma":[0.94697744,0.051448587,0.00094356434,0.00028425953,0.00024034196,0.000105828556],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047481665,0.00014284343,0.0015123182,0.00006461965,0.000018998568,0.0000022071783,0.00018378058,0.00023536156,0.00032357397],"category_scores_gemma":[0.022298738,0.000115299605,0.000115516836,0.00011794816,0.0005502195,0.000051901046,0.00010040416,0.00013691577,5.753007e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087593764,0.0028180568,0.024744308,0.0007181433,0.000736638,6.5772787e-7,0.002919451,0.0000022311622,0.05006893,0.09817205,0.017141728,0.80180186],"study_design_scores_gemma":[0.0019919323,0.0042949347,0.032983426,0.0001885427,0.00037906697,0.000005417029,0.00037755194,0.00024522442,0.4012055,0.5508833,0.007119007,0.00032607184],"about_ca_topic_score_codex":0.000015398653,"about_ca_topic_score_gemma":0.0000039402566,"teacher_disagreement_score":0.80147576,"about_ca_system_score_codex":0.0000070652077,"about_ca_system_score_gemma":0.00003488947,"threshold_uncertainty_score":0.9859369},"labels":[],"label_agreement":null},{"id":"W2158371220","doi":"10.1093/annonc/mdh133","title":"A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Hamilton Regional Laboratory Medicine Program","funders":"National Cancer Institute","keywords":"Medicine; Cisplatin; Intravenous Infusions; Oncology; Internal medicine; Chemotherapy","score_opus":0.02357478316002732,"score_gpt":0.3396303289529543,"score_spread":0.316055545792927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158371220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989952,0.00013256956,0.000016724,0.00015219786,0.00004024338,0.00031871547,0.00002982339,0.0000015340264,0.00031302863],"genre_scores_gemma":[0.9990178,0.0003615501,0.000060999813,0.00048644634,0.000017614839,0.000017839471,0.00001570791,0.000009769706,0.000012305946],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99934906,0.000035630663,0.0001875314,0.00020260004,0.00008057273,0.00014458205],"domain_scores_gemma":[0.99958533,0.0000132065015,0.00012528645,0.00013912881,0.00008265555,0.000054374188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009768694,0.000099406425,0.00022724074,0.000066075285,0.000027734115,0.000002742362,0.000060820574,0.00009538918,0.000005051211],"category_scores_gemma":[0.000014665455,0.00008745352,0.00001661357,0.000059235783,0.000078162564,0.0000028785155,0.000055896646,0.00006788856,1.9830276e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022926578,0.027910639,0.023972873,0.00014733397,0.0010784356,0.00007980308,0.014979312,0.0019768984,0.54727733,0.0010175038,0.0003252286,0.35830808],"study_design_scores_gemma":[0.0683929,0.4747071,0.10102479,0.00021547108,0.00016189474,0.000021395052,0.003269714,0.0000266887,0.3404535,0.001966196,0.009073318,0.0006870353],"about_ca_topic_score_codex":0.0004991827,"about_ca_topic_score_gemma":0.0010071842,"teacher_disagreement_score":0.44679645,"about_ca_system_score_codex":0.00001837959,"about_ca_system_score_gemma":0.00018260932,"threshold_uncertainty_score":0.35662508},"labels":[],"label_agreement":null},{"id":"W2158475201","doi":"10.1093/annonc/mdm492","title":"EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Cancer Center, University of Colorado; Università degli Studi di Napoli Federico II","keywords":"Cetuximab; Medicine; Colorectal cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Fluorescence in situ hybridization; Lung cancer; KRAS; Confidence interval; Cancer; Chemotherapy; Gene; Biology","score_opus":0.04960752627918864,"score_gpt":0.403707058447591,"score_spread":0.3540995321684024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158475201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831051,0.00022191301,0.000013085187,0.01143066,0.00026249685,0.0010454219,0.00009373659,0.00001860847,0.003808946],"genre_scores_gemma":[0.9930621,0.0002945121,0.00028800842,0.0053973743,0.00011839892,0.0002243844,0.000017660966,0.000020334963,0.0005772433],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987497,0.00006665437,0.00036970747,0.00025538928,0.00017422125,0.00038434681],"domain_scores_gemma":[0.9986531,0.0006189916,0.00013022331,0.00010715721,0.00036180942,0.0001286995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083994586,0.00014441354,0.0005267847,0.00020066072,0.000040155664,0.0000023487703,0.00007058055,0.00014905666,0.00007528132],"category_scores_gemma":[0.0004187256,0.000110607594,0.000099077595,0.00021748367,0.00007419479,0.000037428537,0.000033326865,0.000102536294,0.0000024107458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14015286,0.004341243,0.24418645,0.00007943573,0.00038843337,0.00006093105,0.0051142485,0.0000035935693,0.008119363,0.000010903052,0.040134013,0.5574085],"study_design_scores_gemma":[0.0065609626,0.019259373,0.71592987,0.000053387095,0.000025123754,0.0000017561465,0.0001527243,0.0000037437092,0.013755158,0.000021662268,0.24414842,0.00008784496],"about_ca_topic_score_codex":0.0002705935,"about_ca_topic_score_gemma":0.002266087,"teacher_disagreement_score":0.55732065,"about_ca_system_score_codex":0.00037182512,"about_ca_system_score_gemma":0.0002883918,"threshold_uncertainty_score":0.45104468},"labels":[],"label_agreement":null},{"id":"W2158610416","doi":"10.1093/annonc/mdu164.22","title":"Decline in CA19-9 During Chemotherapy Predicts Survival in Four Independent Cohorts of Patients with Inoperable Cholangiocarcinoma.","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; CA19-9; Oncology; Biomarker; Proportional hazards model; Cohort; Chemotherapy; Pancreatic cancer; Multivariate analysis; Cancer; Gastroenterology; Confidence interval","score_opus":0.032271817728230956,"score_gpt":0.3033167940202165,"score_spread":0.27104497629198554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158610416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941023,0.00035549124,0.0000062450945,0.0012423474,0.00010363773,0.00043138338,0.000009043179,0.000010612571,0.0037389242],"genre_scores_gemma":[0.99882627,0.000236957,0.00009970231,0.0006272099,0.00007051461,0.000028069313,0.00001562147,0.000021165406,0.00007448936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984628,0.00009998542,0.000507001,0.00027775968,0.00031902126,0.00033343828],"domain_scores_gemma":[0.9991187,0.00010133891,0.00019585117,0.0002612049,0.00024118516,0.00008174608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004736348,0.00016595238,0.000827167,0.00027281969,0.000019354713,0.0000027824658,0.00011588916,0.00013542653,0.000033552697],"category_scores_gemma":[0.00010065542,0.00013594767,0.00006888616,0.0002760313,0.00010274293,0.000073005016,0.00008043413,0.00021479405,0.0000015772603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019210533,0.00065233745,0.99192834,0.00014020054,0.00009898034,0.000039682647,0.0007672336,0.00003740716,0.00030556048,0.000019728794,0.00013986608,0.0039496394],"study_design_scores_gemma":[0.010511355,0.0024666765,0.98300165,0.00014112152,0.000023776749,0.000006965704,0.00008448076,0.00002310843,0.0026690394,0.000035405665,0.00092518405,0.000111245],"about_ca_topic_score_codex":0.0009658598,"about_ca_topic_score_gemma":0.0028898816,"teacher_disagreement_score":0.008926668,"about_ca_system_score_codex":0.000069870606,"about_ca_system_score_gemma":0.00013858768,"threshold_uncertainty_score":0.5543785},"labels":[],"label_agreement":null},{"id":"W2159054910","doi":"10.1093/annonc/mdl177","title":"Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Letrozole; Breast cancer; Tamoxifen; Aromatase inhibitor; Internal medicine; Quality of life (healthcare); Placebo; Oncology; Gynecology; Stage (stratigraphy); Cancer","score_opus":0.02136297973265248,"score_gpt":0.35498551202930445,"score_spread":0.33362253229665195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159054910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985041,0.00053080573,6.351923e-7,0.00009443915,0.000059466784,0.0002827768,0.00011689741,0.0000017104599,0.00040914075],"genre_scores_gemma":[0.9991664,0.00032015154,0.000057749847,0.00007617588,0.00004862553,0.00006251977,0.00000992284,0.0000111238005,0.00024728032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998383,0.00024164599,0.0006823576,0.00022074081,0.0001316503,0.00034061196],"domain_scores_gemma":[0.99916416,0.00007708599,0.00037896537,0.00022064547,0.000096451535,0.00006266166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074534357,0.00012320303,0.0006718771,0.00011436465,0.000003909607,0.0000010461658,0.00014897008,0.00036981175,0.000028852182],"category_scores_gemma":[0.000038009846,0.00010575163,0.00008299174,0.00017696343,0.0002779894,0.0000058427922,0.00007495311,0.00017511754,5.049873e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07107643,0.0025351967,0.8512503,0.00008203801,0.00032667414,0.000051044284,0.00047056747,0.00007504556,0.06588979,0.000018331728,0.00013054637,0.008094058],"study_design_scores_gemma":[0.014809872,0.012110349,0.96443003,0.000020602012,0.0000142310655,0.0000028789493,0.00008793494,0.0000013718675,0.008071249,0.00003588808,0.00031150872,0.000104077546],"about_ca_topic_score_codex":0.0016002029,"about_ca_topic_score_gemma":0.0005958277,"teacher_disagreement_score":0.11317976,"about_ca_system_score_codex":0.00003191678,"about_ca_system_score_gemma":0.000288948,"threshold_uncertainty_score":0.43124261},"labels":[],"label_agreement":null},{"id":"W2159141926","doi":"10.1093/annonc/mds575","title":"Prevalence of depression in adults with cancer: a systematic review","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Medicine; Depression (economics); Sample size determination; Cancer; Quality of life (healthcare); Psychiatry; Statistics; Internal medicine","score_opus":0.11202756757068891,"score_gpt":0.440134100371758,"score_spread":0.32810653280106905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159141926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034044413,0.9954768,9.5337174e-7,0.000102619466,0.00014643367,0.002795882,0.00006306636,0.0000077167115,0.001372491],"genre_scores_gemma":[0.0007180391,0.99777377,0.000014424957,0.00028031014,0.00006316926,0.0008962739,0.000019987217,0.000027050035,0.00020698097],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99766016,0.00043055226,0.0011342338,0.0002583375,0.00027162101,0.0002451125],"domain_scores_gemma":[0.99745893,0.0002613808,0.001360408,0.0005377074,0.00028095904,0.000100603436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072788884,0.0002537674,0.004688664,0.00016554042,0.000006916557,7.3575126e-7,0.00020664842,0.00028776916,0.0001535272],"category_scores_gemma":[0.00013837877,0.00015369515,0.00033213344,0.000360894,0.0000805667,0.0000383447,0.000053087737,0.0002850381,0.000006175504],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062468476,0.000111652545,0.00029542932,0.7385199,0.00011143071,0.0000138584855,0.00014232511,2.0848228e-8,4.3619092e-8,0.000004418664,0.00018643461,0.26055202],"study_design_scores_gemma":[0.0002561292,0.0006489103,0.000054539134,0.8566065,0.004041294,0.00009462208,0.000020381676,1.2822372e-7,0.000002398964,7.721411e-7,0.13816354,0.000110780864],"about_ca_topic_score_codex":0.00048473926,"about_ca_topic_score_gemma":0.00057808135,"teacher_disagreement_score":0.26044124,"about_ca_system_score_codex":0.00008136306,"about_ca_system_score_gemma":0.0008057831,"threshold_uncertainty_score":0.6267506},"labels":[],"label_agreement":null},{"id":"W2159179344","doi":"10.1093/annonc/mdu141","title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Panitumumab; KRAS; Internal medicine; Hazard ratio; Colorectal cancer; Clinical endpoint; Randomized controlled trial; Oxaliplatin; Confidence interval; Oncology; Adverse effect; Gastroenterology; Cancer","score_opus":0.1282057758737968,"score_gpt":0.4285832052192958,"score_spread":0.30037742934549905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159179344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304295,0.0012265798,0.00014122225,0.0011212854,0.000100551195,0.0032052142,0.00050684705,0.000011066819,0.0006443138],"genre_scores_gemma":[0.99717516,0.0008798633,0.00062504754,0.0000544591,0.00007490952,0.00093176804,0.000089357985,0.000016691774,0.00015274585],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982392,0.00016710354,0.0008556676,0.00030801364,0.00021013047,0.00021988335],"domain_scores_gemma":[0.99660605,0.0018413609,0.0007536445,0.00021363774,0.00051332195,0.00007196411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036339025,0.00022854538,0.0023335626,0.000104838815,0.00005567128,0.0000018315225,0.000065355554,0.00005485798,0.000043565364],"category_scores_gemma":[0.00028351485,0.00013763069,0.00023881948,0.00013063448,0.0002524133,0.000027875874,0.000023501436,0.000043085874,3.722904e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86149096,0.018797169,0.0010709818,0.00007075431,0.0066661625,0.000024069748,0.0082934145,0.00006825875,0.0006047694,0.000033247827,0.00028469294,0.10259549],"study_design_scores_gemma":[0.7819562,0.18517245,0.003532069,0.000098597,0.0034847367,0.0000047142657,0.0009435942,0.00046607055,0.021639856,0.00015421875,0.002423671,0.00012381336],"about_ca_topic_score_codex":0.0052047228,"about_ca_topic_score_gemma":0.0075087673,"teacher_disagreement_score":0.1663753,"about_ca_system_score_codex":0.00008348451,"about_ca_system_score_gemma":0.0002803397,"threshold_uncertainty_score":0.7868019},"labels":[],"label_agreement":null},{"id":"W2159274727","doi":"10.1093/annonc/mds476","title":"From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multidisciplinary approach; Family medicine; Statement (logic); Lung cancer; Randomized controlled trial; Lung cancer screening; Clinical trial; Internal medicine","score_opus":0.2056503484937791,"score_gpt":0.5273528145136473,"score_spread":0.32170246601986824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159274727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81445825,0.0048165447,0.000088883535,0.17508051,0.00055056467,0.0039771046,0.00048536912,0.000008925625,0.00053385325],"genre_scores_gemma":[0.9725793,0.0017790606,0.00255693,0.020158056,0.00079151563,0.0019633991,0.000047783273,0.000023191373,0.00010075756],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99243134,0.0038955875,0.002220572,0.00045324807,0.0005138612,0.00048538335],"domain_scores_gemma":[0.9723707,0.025483755,0.0010952537,0.00064603676,0.00017576049,0.00022848681],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014212795,0.00028520147,0.002101379,0.000096643846,0.00009659394,0.000016050271,0.00039769677,0.00022412358,0.0020469334],"category_scores_gemma":[0.0052805115,0.0001300691,0.00052338646,0.00018162995,0.0002689841,0.00009267904,0.0005998111,0.0003538382,0.000020442314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077947244,0.0050833654,0.15310791,0.00003341131,0.005094244,0.000030235899,0.08487867,0.00002851242,0.00007078804,0.000031628784,0.5441816,0.12951243],"study_design_scores_gemma":[0.24137554,0.0064371796,0.61707556,0.0012431319,0.0042287963,0.0000066122643,0.008944928,0.00026159495,0.0015942616,0.00024798806,0.11821156,0.00037287956],"about_ca_topic_score_codex":0.023586655,"about_ca_topic_score_gemma":0.0025871473,"teacher_disagreement_score":0.46396762,"about_ca_system_score_codex":0.00015634217,"about_ca_system_score_gemma":0.00030999546,"threshold_uncertainty_score":0.9988653},"labels":[],"label_agreement":null},{"id":"W2159433570","doi":"10.1093/annonc/mdu204","title":"Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Medicine; Bladder cancer; Carboplatin; Gemcitabine; Hazard ratio; Cystectomy; Internal medicine; Oncology; Cancer registry; Regimen; Population; Vinblastine; Cancer; Chemotherapy; Confidence interval; Surgery; Cisplatin","score_opus":0.11257244180116344,"score_gpt":0.4948351416433074,"score_spread":0.38226269984214395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159433570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9330953,0.001507621,0.00026999952,0.032068897,0.0003284115,0.00092170003,0.000056358764,0.000011721853,0.031739995],"genre_scores_gemma":[0.98443204,0.0022399565,0.002463776,0.010098055,0.00025428977,0.00007654352,0.000006544601,0.000015381975,0.0004134019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894416,0.00014000596,0.00046892161,0.00018304153,0.00009918811,0.00016467106],"domain_scores_gemma":[0.99853545,0.00057315285,0.00021336332,0.00014793698,0.00047001324,0.0000601049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006186955,0.000093942625,0.00056299235,0.00005474836,0.0000138940095,0.0000013672634,0.000057548415,0.0001425001,0.00022130222],"category_scores_gemma":[0.0003985303,0.000074911804,0.00012158949,0.00008432274,0.00012836106,0.000058215206,0.000013637022,0.00010851238,0.000002713992],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018386535,0.005417894,0.09672143,0.00017610002,0.0014416531,0.000018589299,0.0035814582,0.000036530007,0.004317144,0.0018715926,0.010404397,0.8576267],"study_design_scores_gemma":[0.031897217,0.034738474,0.20643929,0.00018288336,0.00042044974,0.000028627888,0.001029106,0.00058135675,0.037878565,0.00028836948,0.6862724,0.0002432969],"about_ca_topic_score_codex":0.000508945,"about_ca_topic_score_gemma":0.00016593716,"teacher_disagreement_score":0.8573834,"about_ca_system_score_codex":0.000028480561,"about_ca_system_score_gemma":0.0004346412,"threshold_uncertainty_score":0.30548146},"labels":[],"label_agreement":null},{"id":"W2159578337","doi":"10.1093/annonc/mdg216","title":"A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Ottawa Regional Cancer Foundation","funders":"National Cancer Institute","keywords":"Medicine; Pharmacokinetics; Chills; Nausea; Pharmacology; Vomiting; Pharmacodynamics; Gastroenterology; Peripheral blood mononuclear cell; DNA methyltransferase; Methyltransferase; Toxicity; DNMT1; Internal medicine; Chemistry","score_opus":0.05875775179680439,"score_gpt":0.40097828435152927,"score_spread":0.3422205325547249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159578337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563926,0.0017499346,0.00012236078,0.00030748997,0.00021960874,0.0004737192,0.000031403746,0.0000034669802,0.0014527257],"genre_scores_gemma":[0.9987234,0.0007243076,0.00010557256,0.00024161101,0.000055909582,0.000024629522,0.000009706733,0.000016936056,0.00009794813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849,0.00048353276,0.0004190167,0.00027950606,0.00013620338,0.00019177892],"domain_scores_gemma":[0.9992101,0.00005949193,0.00020308327,0.00027442395,0.00017071227,0.00008215379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046888384,0.00015169554,0.00026989632,0.000056787685,0.000053874533,0.000004646994,0.00016165912,0.00011626234,0.000024059756],"category_scores_gemma":[0.00011526475,0.00012282102,0.00009006376,0.00013825296,0.00014253195,0.000003893188,0.0000576522,0.00009864414,6.310374e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035443253,0.0022023742,0.0010508382,0.000026548105,0.00014340463,0.0000030171814,0.00032311265,0.00002307844,0.9760725,0.000028164446,0.00011809375,0.019654451],"study_design_scores_gemma":[0.0054648668,0.010248361,0.0011558674,0.0000075869148,0.00012344225,0.0000054969764,0.00025035543,0.0000462613,0.9571475,0.00009043701,0.025332132,0.00012768664],"about_ca_topic_score_codex":0.000022919412,"about_ca_topic_score_gemma":0.000044807166,"teacher_disagreement_score":0.025214039,"about_ca_system_score_codex":0.0000047800486,"about_ca_system_score_gemma":0.0001191356,"threshold_uncertainty_score":0.50084955},"labels":[],"label_agreement":null},{"id":"W2159946871","doi":"10.1093/annonc/mdu276","title":"Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Public Health Ontario; University of Toronto; University Health Network","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Institutes of Health; National Cancer Institute; National Health and Medical Research Council; Cancer Research Society; World Health Organization","keywords":"Medicine; Pancreatic cancer; Diabetes mellitus; Cancer; Internal medicine; Type 2 Diabetes Mellitus; Oncology; Type 2 diabetes; Endocrinology","score_opus":0.0438648560885324,"score_gpt":0.3921314917463535,"score_spread":0.34826663565782107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159946871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972856,0.0050763176,0.00034227347,0.019555753,0.00015820038,0.00049128523,0.00043116522,0.000027727543,0.0010612806],"genre_scores_gemma":[0.9853063,0.0089650545,0.00049830996,0.004178751,0.0004230878,0.0003241707,0.00008534669,0.000019792835,0.00019916982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719733,0.00087410596,0.00064643484,0.00044774477,0.0003911539,0.00044322066],"domain_scores_gemma":[0.994446,0.0037092874,0.00047368373,0.0005759129,0.00048272274,0.00031238756],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018169371,0.00021162271,0.0012542314,0.00023282834,0.0001942788,0.00001952259,0.0002831127,0.00023488252,0.0015409087],"category_scores_gemma":[0.0013217784,0.0001447655,0.00016213523,0.00037446097,0.000748944,0.00009166738,0.00007084788,0.00036923285,0.000011217404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019357761,0.00025297824,0.958882,0.000029584035,0.0059105353,0.000047886006,0.00046652945,0.000029303872,0.00043568996,0.00012209728,0.0016468925,0.03198293],"study_design_scores_gemma":[0.002456593,0.0008966347,0.94415057,0.000075144315,0.010139383,0.000036636673,0.0003445554,0.036547102,0.00023704949,0.00046307087,0.004510223,0.00014303553],"about_ca_topic_score_codex":0.014789159,"about_ca_topic_score_gemma":0.0052949414,"teacher_disagreement_score":0.0365178,"about_ca_system_score_codex":0.000087343265,"about_ca_system_score_gemma":0.00057187036,"threshold_uncertainty_score":0.9993718},"labels":[],"label_agreement":null},{"id":"W2160048203","doi":"10.1093/annonc/mdp404","title":"Aging and the management of cancer pain","year":2009,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University Health Network","funders":"","keywords":"Medicine; Scopus; Cancer; Cancer pain; Pain management; Ambulatory; MEDLINE; Physical therapy; Internal medicine","score_opus":0.05474776175539992,"score_gpt":0.37874343639832175,"score_spread":0.32399567464292184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160048203","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024407618,0.0057546147,0.000040284573,0.9661235,0.0001157536,0.0005368831,0.0000046724954,0.00001161129,0.02497188],"genre_scores_gemma":[0.0049253097,0.019554384,0.00039121645,0.9656103,0.0007556921,0.000040286464,0.000030767158,0.000016359347,0.008675687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887353,0.00021877247,0.00031771066,0.00018095062,0.000192846,0.00021617641],"domain_scores_gemma":[0.99906504,0.00026341414,0.00029057474,0.00028138197,0.000078059566,0.000021533595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012477827,0.00014006469,0.0006127185,0.00012928311,0.00002219902,0.0000032863582,0.00014694037,0.00022520925,0.00007494065],"category_scores_gemma":[0.000025562367,0.000091595066,0.00012428217,0.000096024174,0.0002453478,0.00001308185,0.00007727267,0.00039811217,0.0000020558623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012478212,0.00003380453,0.0008212325,0.001097509,0.0006632616,0.00023765292,0.00010960386,0.0000010451643,0.0000028513873,0.00045692627,0.8398106,0.15664074],"study_design_scores_gemma":[0.0016182066,0.0003724168,0.008537636,0.0004644415,0.00045131755,8.0393096e-7,0.000054498854,0.000038291197,0.000025234383,0.0010000293,0.9873605,0.00007662194],"about_ca_topic_score_codex":0.000095830044,"about_ca_topic_score_gemma":0.0000074011655,"teacher_disagreement_score":0.15656412,"about_ca_system_score_codex":0.000015312895,"about_ca_system_score_gemma":0.0000365361,"threshold_uncertainty_score":0.37351385},"labels":[],"label_agreement":null},{"id":"W2160139566","doi":"10.1093/annonc/mdr467","title":"Optimal assessment of response in ovarian cancer","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Oncology; Ovarian cancer; Clinical trial; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Progression-free survival; Internal medicine; Cancer; Randomized controlled trial; Tumor progression; Phases of clinical research; Overall survival","score_opus":0.16914206435670756,"score_gpt":0.45985911768495225,"score_spread":0.2907170533282447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160139566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97299004,0.0004091832,0.000026129957,0.006927093,0.00011924757,0.0002289027,0.000019110892,0.000004580005,0.019275717],"genre_scores_gemma":[0.9935513,0.00062847906,0.004978696,0.00062123366,0.000028047361,0.00007469673,0.000002508825,0.000008136613,0.000106911124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991611,0.00011411261,0.0003137089,0.00014709044,0.00010239203,0.00016159045],"domain_scores_gemma":[0.9993557,0.00011750184,0.00015034829,0.00019089768,0.0001203926,0.00006521545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004692846,0.00007653263,0.00040622836,0.00013821929,0.0000076219803,6.3557314e-7,0.000055520944,0.00009104749,0.0009254747],"category_scores_gemma":[0.00004025424,0.00006411904,0.000073299554,0.00013289129,0.00007681111,0.000027417647,0.000026556148,0.0000821184,0.0000027262072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01465564,0.0081811305,0.8845695,0.00014745277,0.00071560754,0.00070181466,0.0033307583,0.000104568266,0.0070138145,0.00565086,0.004648083,0.070280775],"study_design_scores_gemma":[0.0027385114,0.006734486,0.96476114,0.00009422097,0.00005658912,0.000009798414,0.00010321703,0.000028256783,0.018132294,0.00008206837,0.007210001,0.000049422993],"about_ca_topic_score_codex":0.0011744179,"about_ca_topic_score_gemma":0.00012011816,"teacher_disagreement_score":0.080191635,"about_ca_system_score_codex":0.00008305509,"about_ca_system_score_gemma":0.00072177756,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W2160216944","doi":"10.1093/annonc/mdv215","title":"Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Anastrozole; Tamoxifen; Confidence interval; Stage (stratigraphy); Adjuvant therapy; Multivariate analysis; Cancer","score_opus":0.04354790960364367,"score_gpt":0.3334416530865995,"score_spread":0.2898937434829558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160216944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541533,0.002929074,0.000055269942,0.00020416129,0.000015281275,0.00041406057,0.0009421387,0.000003646955,0.000021032774],"genre_scores_gemma":[0.9927342,0.006708254,0.0003642855,0.000043566008,0.000017855189,0.000041765026,0.0000678736,0.000017322833,0.000004858351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844766,0.00029392904,0.0004646701,0.00036625838,0.00017963738,0.00024786819],"domain_scores_gemma":[0.9975241,0.00021252796,0.00093160284,0.00025594782,0.0009891693,0.00008667043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036516305,0.00022069931,0.00077025435,0.000117277785,0.000054231597,0.0000062190306,0.000120198725,0.00009059915,0.0000032058688],"category_scores_gemma":[0.00007761814,0.00013976342,0.000050164796,0.00045631855,0.00090244506,0.000015939015,0.00012803882,0.000108351036,4.9643408e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024327565,0.0004981376,0.9267157,0.000035846428,0.0068638125,0.000009876897,0.002054523,0.000060043123,0.033238553,0.000012784842,0.000008777679,0.0061743874],"study_design_scores_gemma":[0.003343592,0.01500667,0.9524115,0.00011577698,0.0011521525,0.000021086398,0.0008723148,0.000029127254,0.026879739,0.000013427743,0.000006167395,0.00014849623],"about_ca_topic_score_codex":0.0025151083,"about_ca_topic_score_gemma":0.00043225585,"teacher_disagreement_score":0.025695754,"about_ca_system_score_codex":0.000034426164,"about_ca_system_score_gemma":0.00024043965,"threshold_uncertainty_score":0.56993866},"labels":[],"label_agreement":null},{"id":"W2160248310","doi":"10.1093/annonc/mdl329","title":"A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; International Prognostic Index; Cyclophosphamide; Internal medicine; Vincristine; Prednisone; CHOP; Chemotherapy; Nodular sclerosis; Lymphoma; Cancer; Population; Oncology; Surgery; Hodgkin lymphoma","score_opus":0.02963235841265658,"score_gpt":0.32330615225135845,"score_spread":0.29367379383870185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160248310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99653745,0.00036720716,3.624477e-7,0.00010468779,0.00005688155,0.002350866,0.00029039153,0.000016894199,0.00027528967],"genre_scores_gemma":[0.99911594,0.000035509198,0.000041068426,0.00020277804,0.000040981606,0.0003115941,0.00019443968,0.000016891752,0.000040770206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775916,0.00033253018,0.00084263686,0.00041020583,0.00045324292,0.00020220729],"domain_scores_gemma":[0.9976519,0.0003258717,0.0009050775,0.0003348683,0.0007259324,0.000056403107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020793585,0.00015518386,0.0011657408,0.00004090749,0.00012295516,0.000015591602,0.00010056054,0.00012413325,0.0000959489],"category_scores_gemma":[0.00009399845,0.00012518038,0.00010638283,0.00030123387,0.000121676516,0.00004282836,0.00004541954,0.00006426334,4.864011e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012121737,0.06876093,0.9179791,0.0000148181325,0.00034512518,0.00034399988,0.0003480149,0.000017021783,0.000010917548,7.162835e-7,0.0008891014,0.010078036],"study_design_scores_gemma":[0.02377003,0.030352388,0.944608,0.00011755159,0.00068976305,0.0000033847612,0.00027908353,0.0000036243853,0.000030533232,0.00003077493,0.000016205131,0.000098676755],"about_ca_topic_score_codex":0.42742592,"about_ca_topic_score_gemma":0.20052668,"teacher_disagreement_score":0.22689924,"about_ca_system_score_codex":0.00020228057,"about_ca_system_score_gemma":0.0002960189,"threshold_uncertainty_score":0.81406164},"labels":[],"label_agreement":null},{"id":"W2160328243","doi":"10.1093/annonc/mdl387","title":"Dietary intake of fruit and vegetable and lung cancer risk: a case–control study in Harbin, northeast China","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Lung cancer; Odds ratio; Confidence interval; Case-control study; Cancer; Internal medicine; Environmental health","score_opus":0.029998913477054252,"score_gpt":0.3494269955326429,"score_spread":0.31942808205558865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160328243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751428,0.020518914,0.0000013309564,0.0023383286,0.000038147897,0.00043610227,0.000116646486,0.000004078712,0.0014036659],"genre_scores_gemma":[0.99789894,0.001645896,0.000054206805,0.00022374986,0.00008562625,0.00004130626,0.0000029066002,0.0000062890126,0.00004110506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992385,0.000062953004,0.00029539835,0.00015815071,0.0000847861,0.00016020694],"domain_scores_gemma":[0.99953735,0.00011624734,0.00012735868,0.000078901125,0.000094958035,0.000045208486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025744046,0.00008994338,0.00050415413,0.00007471478,0.000045372857,0.000001727299,0.000022291772,0.000055502504,0.00003043677],"category_scores_gemma":[0.000036065463,0.00007458875,0.0000356292,0.00009525653,0.00011361403,0.00003253369,0.00003767873,0.000113438204,2.032005e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006582726,0.0011574449,0.98841935,0.00012650201,0.00020148825,0.00043477668,0.00028010498,0.0000135875225,0.0001493568,0.000037225887,0.0013610515,0.0071608075],"study_design_scores_gemma":[0.0046219733,0.0024551244,0.9907648,0.000056653374,0.00017886962,0.00012063148,0.00033047452,0.00012018884,0.000044095195,0.0002601408,0.0009878622,0.000059205933],"about_ca_topic_score_codex":0.017948136,"about_ca_topic_score_gemma":0.022318384,"teacher_disagreement_score":0.02275613,"about_ca_system_score_codex":0.000015422733,"about_ca_system_score_gemma":0.00004484109,"threshold_uncertainty_score":0.9955218},"labels":[],"label_agreement":null},{"id":"W2160900629","doi":"10.1093/annonc/mdi158","title":"The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Queen's University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Letrozole; Tamoxifen; Breast cancer; Internal medicine; Placebo; Cholesterol; Lipid profile; Lipoprotein; Endocrinology; Cancer; Gastroenterology; Oncology; Pathology","score_opus":0.013637308226810037,"score_gpt":0.2915273400655455,"score_spread":0.27789003183873545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160900629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959661,0.0010285642,0.000003906082,0.0015266906,0.00020959521,0.00022605082,0.00033357023,0.0000029355529,0.00070259813],"genre_scores_gemma":[0.9952885,0.0023050809,0.000045242552,0.0014218829,0.00070107967,0.000045871297,0.000024033025,0.0000133570975,0.00015496655],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99884266,0.000104293424,0.00038211257,0.00020882653,0.00015016293,0.00031194606],"domain_scores_gemma":[0.99906486,0.000050828647,0.00029615825,0.00028034335,0.00024043414,0.00006739839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023060759,0.000123648,0.00037226838,0.00005351069,0.000032396307,0.0000037010204,0.00021756825,0.000118564916,0.000020255651],"category_scores_gemma":[0.000028304388,0.000100518344,0.000040390638,0.00010728939,0.00036612034,0.000009169426,0.000061852246,0.000108552835,0.0000010610712],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004670457,0.0007294485,0.026510052,0.000077916084,0.00029402997,0.0000010743631,0.0014183436,0.007105344,0.84364146,0.00051563344,0.01006863,0.10496759],"study_design_scores_gemma":[0.0015992374,0.0022981195,0.7265207,0.000054800366,0.000018629982,0.000012191646,0.0002410756,0.000022441016,0.024442919,0.000018538007,0.24463339,0.00013791176],"about_ca_topic_score_codex":0.00027967815,"about_ca_topic_score_gemma":0.001411549,"teacher_disagreement_score":0.81919855,"about_ca_system_score_codex":0.000045941753,"about_ca_system_score_gemma":0.00052720006,"threshold_uncertainty_score":0.4099019},"labels":[],"label_agreement":null},{"id":"W2160949640","doi":"10.1093/annonc/mdi211","title":"Communicating prognosis in cancer care: a systematic review of the literature","year":2005,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":505,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Psychological intervention; Disease; Systematic review; MEDLINE; Family medicine; Intensive care medicine; Nursing; Internal medicine","score_opus":0.5439604219978684,"score_gpt":0.6053382896193756,"score_spread":0.06137786762150721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160949640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026326404,0.9797434,3.6155104e-8,0.0064710854,0.00032282027,0.010908799,0.00026524428,0.000018788229,0.0022671695],"genre_scores_gemma":[0.0001440109,0.98572695,0.00019351189,0.0035956607,0.0000698275,0.010017256,0.000101676225,0.000048029717,0.00010309048],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97934943,0.015209126,0.004372968,0.00028693018,0.000320886,0.00046065048],"domain_scores_gemma":[0.9846536,0.0043346626,0.006800006,0.0026365872,0.0014966098,0.0000785296],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015326272,0.00035047744,0.0046773334,0.0002330471,0.00024378454,0.0000025849126,0.0024544888,0.0009062407,0.000053935397],"category_scores_gemma":[0.0031149292,0.00022019632,0.0006178875,0.0012350825,0.00016212191,0.00006803908,0.001038512,0.0025642647,0.000015881917],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002498288,0.00007942643,0.00011737107,0.8567593,0.00007395725,5.3003544e-7,0.008296101,8.994838e-8,1.7957161e-8,0.00015190481,0.0012787592,0.13324003],"study_design_scores_gemma":[0.00008449705,0.000070259775,0.000006153486,0.5868176,0.00028613594,0.0000023644286,0.00067524647,4.3150757e-7,1.1040104e-7,0.000008052468,0.41196236,0.000086773245],"about_ca_topic_score_codex":0.000501994,"about_ca_topic_score_gemma":0.001047633,"teacher_disagreement_score":0.4106836,"about_ca_system_score_codex":0.00056118576,"about_ca_system_score_gemma":0.0038076956,"threshold_uncertainty_score":0.99973685},"labels":[],"label_agreement":null},{"id":"W2160967394","doi":"10.1093/annonc/mdt148","title":"Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Niilo Helanderin Säätiö; Bob Champion Cancer Trust; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Carboplatin; Seminoma; Radiation therapy; Oncology; Chemotherapy; Neoadjuvant therapy; Internal medicine; Cisplatin; Cancer; Breast cancer","score_opus":0.03831857947488127,"score_gpt":0.36577513690275887,"score_spread":0.3274565574278776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160967394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899896,0.005555975,0.0000044074413,0.0027683075,0.000032812863,0.00034671742,0.000010375581,0.000011548564,0.0012803065],"genre_scores_gemma":[0.99762315,0.0003101672,0.00064464496,0.00089401193,0.000034063287,0.000027597804,0.00001397272,0.000010502919,0.000441908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993902,0.00003084305,0.00018807573,0.00014484297,0.00007270859,0.00017334783],"domain_scores_gemma":[0.99955314,0.000049177008,0.00008162165,0.00014132056,0.000053437525,0.0001213121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060663326,0.000090034446,0.00031500467,0.00007536221,0.0000132244395,0.0000034749694,0.000031314932,0.00008225037,0.000245295],"category_scores_gemma":[0.0000431527,0.00006972468,0.000047634614,0.00006600846,0.00007033049,0.00004012321,0.000018238672,0.000062461855,0.000007917252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012849839,0.00064223993,0.6660173,0.00006814208,0.00014117843,0.0003138125,0.00059572054,0.0000038598437,0.0018118174,0.00019250231,0.0010246221,0.32906032],"study_design_scores_gemma":[0.0028782648,0.003009991,0.98836553,0.000047960522,0.000032131717,0.000042884512,0.00010846815,0.00035463632,0.00039200674,0.0002901959,0.004420238,0.000057696976],"about_ca_topic_score_codex":0.0008535674,"about_ca_topic_score_gemma":0.00010234354,"teacher_disagreement_score":0.32900262,"about_ca_system_score_codex":0.000025130503,"about_ca_system_score_gemma":0.00008993272,"threshold_uncertainty_score":0.284329},"labels":[],"label_agreement":null},{"id":"W2161317196","doi":"10.1093/annonc/mdq599","title":"A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Pharmacology; Toxicity; Phases of clinical research; Internal medicine; Oncology; Urology","score_opus":0.044384554209597936,"score_gpt":0.3921113069598411,"score_spread":0.3477267527502432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161317196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717563,0.00008962996,0.000006569177,0.0007555606,0.00007041521,0.0017690855,0.00004187503,0.0000064727637,0.000084748746],"genre_scores_gemma":[0.99839044,0.00008023479,0.00095077336,0.0004534022,0.000025321087,0.00004273693,0.000010836542,0.000021743552,0.0000244898],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986414,0.000115723466,0.00050977105,0.0002557916,0.00023406913,0.00024326507],"domain_scores_gemma":[0.99889195,0.00027384094,0.00023304996,0.0002050596,0.00022532613,0.00017075604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003280468,0.00019072284,0.00064439786,0.00016530155,0.000029114586,0.000004089462,0.00007271259,0.000030186235,0.000021837695],"category_scores_gemma":[0.00012469526,0.00011361726,0.000030007328,0.0002194313,0.00019915999,0.00005317328,0.000108588596,0.00021417168,6.3231096e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072251864,0.040592358,0.2188965,0.00048008515,0.0010348101,0.0017788678,0.0111077605,0.000114928975,0.12823269,0.000017415046,0.0002139664,0.52527875],"study_design_scores_gemma":[0.11694832,0.2199486,0.5791508,0.00020083632,0.0012497876,0.00037526287,0.0018836207,0.0012649719,0.07713392,0.000037855923,0.0013712558,0.00043476166],"about_ca_topic_score_codex":0.000043055938,"about_ca_topic_score_gemma":0.00026476034,"teacher_disagreement_score":0.524844,"about_ca_system_score_codex":0.000022796232,"about_ca_system_score_gemma":0.00013856622,"threshold_uncertainty_score":0.46331772},"labels":[],"label_agreement":null},{"id":"W2161613264","doi":"10.1093/annonc/mdu019","title":"Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies","year":2014,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Pancreatic cancer; Hazard ratio; Proportional hazards model; Internal medicine; Cancer; Body mass index; Prospective cohort study; Cohort study; Relative risk; Food group; Confidence interval; Physiology; Environmental health","score_opus":0.20437416109836898,"score_gpt":0.5186202750633736,"score_spread":0.3142461139650046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161613264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018495478,0.9771104,0.0000053377057,0.0006512071,0.00010626657,0.0014265245,0.00011865994,0.000014529657,0.0020716332],"genre_scores_gemma":[0.0013363529,0.99612117,0.00034879375,0.00014898623,0.00018478712,0.00038013887,0.000090861184,0.000031518477,0.0013574063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610406,0.0010565666,0.0014220834,0.0006025459,0.00037709076,0.00043765432],"domain_scores_gemma":[0.99395424,0.0023977594,0.001553625,0.0006936557,0.0012230934,0.00017759624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026676522,0.00038536367,0.011011903,0.0010166394,0.000060853545,0.0000029034766,0.00019642137,0.0005568393,0.00012973389],"category_scores_gemma":[0.0038028017,0.0002635276,0.00060685526,0.0012760867,0.0009486103,0.000027386941,0.00017727354,0.0005180442,0.000008517278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020449777,0.00042171666,0.0757813,0.037993804,0.117855884,0.000048449183,0.0003881365,8.012331e-7,0.000002486772,0.000070900714,0.006946027,0.760286],"study_design_scores_gemma":[0.0008423588,0.003012688,0.020584343,0.0061665224,0.23775467,0.000042921383,0.0000949917,0.000043063035,0.0000064510077,0.00005967994,0.7311526,0.00023971315],"about_ca_topic_score_codex":0.00049571553,"about_ca_topic_score_gemma":0.000198914,"teacher_disagreement_score":0.7600463,"about_ca_system_score_codex":0.00011298967,"about_ca_system_score_gemma":0.0018371966,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W2161692381","doi":"10.1093/annonc/mdr021","title":"Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Response Biomedical (Canada)","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Medicine; Lapatinib; Internal medicine; Cancer; Metastatic breast cancer; Oncology; Crizotinib; Angiogenesis; Phases of clinical research; Epidermal growth factor receptor; Gastroenterology; Breast cancer; Chemotherapy; Trastuzumab; Lung cancer","score_opus":0.14511006447840344,"score_gpt":0.4255288335353503,"score_spread":0.28041876905694685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161692381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941849,0.00014628297,0.00002343098,0.0006879005,0.00030192852,0.0033464697,0.000036113852,0.00002038901,0.0012525709],"genre_scores_gemma":[0.9968535,0.0006984677,0.000777014,0.00086784083,0.0000708659,0.00042214018,0.000031101896,0.000029549072,0.0002495321],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99774027,0.000193733,0.0009233018,0.00037512506,0.00035631558,0.00041125342],"domain_scores_gemma":[0.9981724,0.0002445011,0.0007742556,0.00036097498,0.00032534727,0.0001225131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005292191,0.00026343903,0.0013258074,0.00046349363,0.00004644335,0.0000022027739,0.0002039919,0.0000922938,0.0009604566],"category_scores_gemma":[0.00018659125,0.000175527,0.0001213974,0.00066590717,0.00016145267,0.000111263376,0.00008949045,0.00020041461,0.0000047315666],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38611808,0.044877753,0.17805034,0.00007708922,0.0007779539,0.00013828353,0.0050469297,0.000010946803,0.000019127703,0.000025278836,0.00048014685,0.38437808],"study_design_scores_gemma":[0.33660144,0.45306036,0.20120446,0.000065459775,0.0003161858,0.0000031548293,0.0012663413,0.0000053974723,0.00009926562,0.00004214525,0.0071805166,0.0001552537],"about_ca_topic_score_codex":0.0016558773,"about_ca_topic_score_gemma":0.003860091,"teacher_disagreement_score":0.40818262,"about_ca_system_score_codex":0.00009267731,"about_ca_system_score_gemma":0.00044825216,"threshold_uncertainty_score":0.9999528},"labels":[],"label_agreement":null},{"id":"W2161756110","doi":"10.1093/annonc/mdr608","title":"How valid are claims for synergy in published clinical studies?","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Animal testing and alternatives","field":"Veterinary","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Drug; Clinical study design; Phases of clinical research; Oncology; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.763186398303488,"score_gpt":0.6111141147865045,"score_spread":0.15207228351698354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161756110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565733,0.0013125691,0.000060655646,0.008841133,0.0007021922,0.00016026065,0.000016410571,0.00003663285,0.003212812],"genre_scores_gemma":[0.9961377,0.00022007231,0.0013161646,0.00091503694,0.00069980446,0.000050620925,0.00000498401,0.000015910271,0.0006397181],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855846,0.0003025297,0.00043441931,0.00022068329,0.0000879403,0.00039595945],"domain_scores_gemma":[0.99719036,0.0018948365,0.00039616783,0.00017410617,0.00025404725,0.00009048906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016226596,0.000118021715,0.00055871106,0.00008841422,0.000036897312,0.0000121407675,0.00019542381,0.00015093444,0.00001885746],"category_scores_gemma":[0.003439004,0.000098414705,0.00014691011,0.00010312426,0.00017473711,0.00028232328,0.000118480275,0.00017690595,0.000008549839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034118749,0.004336375,0.62277067,0.0003599659,0.00082593854,0.0001931688,0.0024866948,0.000005336982,0.001430793,0.016193664,0.18182094,0.1661646],"study_design_scores_gemma":[0.0033703914,0.026288277,0.4258705,0.00023025021,0.000058186535,0.000093142895,0.006232428,0.00015592242,0.00090458995,0.012153971,0.524116,0.0005263656],"about_ca_topic_score_codex":0.000017360824,"about_ca_topic_score_gemma":0.000021059644,"teacher_disagreement_score":0.34229502,"about_ca_system_score_codex":0.000021146063,"about_ca_system_score_gemma":0.000040039453,"threshold_uncertainty_score":0.41170576},"labels":[],"label_agreement":null},{"id":"W2162318396","doi":"10.1093/annonc/mdr441","title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Neutropenia; Hazard ratio; Gastroenterology; Paclitaxel; Ovarian cancer; Oncology; Chemotherapy; Clinical endpoint; Surgery; Confidence interval; Randomized controlled trial; Cancer; Cisplatin","score_opus":0.09745928418949434,"score_gpt":0.37125514234528034,"score_spread":0.273795858155786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162318396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494463,0.0003604762,0.0000015967395,0.00095026963,0.00026775597,0.0008402928,0.0015388898,0.000008279728,0.001087836],"genre_scores_gemma":[0.99910975,0.00022332897,0.00012090246,0.00015709003,0.00008143093,0.00005774527,0.00022186174,0.000014527379,0.000013392353],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99779993,0.00028114897,0.00094774686,0.0004526282,0.00023678453,0.000281744],"domain_scores_gemma":[0.9979439,0.0006915483,0.0006603815,0.00032389033,0.00025671898,0.00012358521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033597494,0.00022658566,0.0011013354,0.00019953953,0.000045270568,0.000005680151,0.0000698536,0.00024135655,0.000057003635],"category_scores_gemma":[0.0002985386,0.00016632199,0.0001635813,0.00059717445,0.00025863957,0.00005707331,0.00007337643,0.00018978762,3.1988426e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53812885,0.00869859,0.330412,0.00005113624,0.011334214,0.00032886752,0.026823478,0.00014108198,0.0024394488,0.0002920492,0.0007293969,0.0806209],"study_design_scores_gemma":[0.19657846,0.007383585,0.783942,0.0001117698,0.002902448,0.0000011702165,0.00034604143,0.00096050656,0.00744744,0.000043163764,0.00012943955,0.00015396583],"about_ca_topic_score_codex":0.067695536,"about_ca_topic_score_gemma":0.047401696,"teacher_disagreement_score":0.45353,"about_ca_system_score_codex":0.00008707545,"about_ca_system_score_gemma":0.0002620188,"threshold_uncertainty_score":0.9699807},"labels":[],"label_agreement":null},{"id":"W2162771614","doi":"10.1093/annonc/mdx096","title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":872,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Cilag; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; European Society for Medical Oncology; Bristol-Myers Squibb","keywords":"Medicine; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Asymptomatic; Stage (stratigraphy); Incidence (geometry); Scopus; Internal medicine; MEDLINE; Monoclonal; Immunology","score_opus":0.4685253170586109,"score_gpt":0.5882108824589835,"score_spread":0.11968556540037256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162771614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87437737,0.00258799,0.00005096207,0.116163835,0.0005580933,0.0017327666,0.00012411694,0.000029698633,0.004375142],"genre_scores_gemma":[0.9548633,0.015585336,0.023734838,0.0030210905,0.00055639533,0.00053587375,0.00006484766,0.000027547741,0.0016107673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998346,0.00011609579,0.00062449917,0.0003702764,0.00016746379,0.00037570455],"domain_scores_gemma":[0.9944699,0.0025598665,0.00043203443,0.0005965131,0.0016092276,0.00033247386],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00091716304,0.00017662418,0.0007184487,0.0000699017,0.00024852986,0.000023627455,0.00014056188,0.0002115843,0.000029535318],"category_scores_gemma":[0.033564,0.00012710913,0.0002484419,0.000025653046,0.00029821426,0.00016329503,0.00010131665,0.00009912005,0.000019383575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038786277,0.0016832788,0.29184344,0.000042143827,0.0007871089,0.00015323605,0.000069425354,1.9176423e-7,0.00005303856,0.00009750508,0.041213457,0.66017854],"study_design_scores_gemma":[0.01890836,0.014523738,0.2553948,0.000051583887,0.00027094528,0.000069301044,0.00012445376,0.00019863082,0.0026238495,0.00014776658,0.7075855,0.000101091675],"about_ca_topic_score_codex":0.0007733858,"about_ca_topic_score_gemma":0.00041579994,"teacher_disagreement_score":0.66637206,"about_ca_system_score_codex":0.000040512605,"about_ca_system_score_gemma":0.00035367341,"threshold_uncertainty_score":0.9745767},"labels":[],"label_agreement":null},{"id":"W2163188114","doi":"10.1093/annonc/mdl165","title":"Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Microbial Natural Products and Biosynthesis","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Northeast Cancer Centre; Université de Montréal; Hôpital Notre-Dame; Children's Hospital of Eastern Ontario; Ottawa Hospital; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Rash; Nausea; Adverse effect; Vomiting; myalgia; Mucositis; Internal medicine; Phases of clinical research; Progressive disease; Gastroenterology; Toxicity; Lung cancer; Surgery; Chemotherapy","score_opus":0.13199147238728373,"score_gpt":0.4477888923124596,"score_spread":0.31579741992517585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163188114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960355,0.00015987924,5.767517e-7,0.001099272,0.00022137728,0.00224761,0.0001549465,0.0000039509832,0.00007684152],"genre_scores_gemma":[0.99911475,0.0000719194,0.000054971744,0.00051924144,0.00015407478,0.00001595095,0.000025355675,0.000013503357,0.000030221705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625176,0.0006352582,0.0018510664,0.00036219208,0.00065811793,0.00024157605],"domain_scores_gemma":[0.99761325,0.00036038493,0.00087874505,0.00021295597,0.0008481797,0.00008646607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003765677,0.00017976211,0.0016031205,0.00038085377,0.000026100965,0.000002718155,0.00014390446,0.00013084603,0.00006534604],"category_scores_gemma":[0.0013457895,0.00012709208,0.00006414924,0.00052672456,0.000090163565,0.0000930334,0.00006463359,0.00029402436,1.8787928e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09327543,0.07427521,0.7019393,0.00012093368,0.0005573326,0.000099795325,0.0013082725,0.00014599059,0.020506823,0.000008624311,0.009491511,0.098270796],"study_design_scores_gemma":[0.037494637,0.057822984,0.8935692,0.0002931749,0.00006567982,8.513051e-7,0.00043322885,0.0000026068392,0.005416477,0.000016896,0.004716497,0.00016777504],"about_ca_topic_score_codex":0.16350862,"about_ca_topic_score_gemma":0.5680266,"teacher_disagreement_score":0.40451798,"about_ca_system_score_codex":0.00023828556,"about_ca_system_score_gemma":0.0023470237,"threshold_uncertainty_score":0.84206164},"labels":[],"label_agreement":null},{"id":"W2163274852","doi":"10.1093/annonc/mdt258","title":"Concern on quality-of-life analysis in the OPTIMAL study","year":2013,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Carboplatin; Erlotinib; Lung cancer; Quality of life (healthcare); Oncology; Gemcitabine; Internal medicine; Gefitinib; Scopus; Chemotherapy; Cancer; MEDLINE; Epidermal growth factor receptor","score_opus":0.22547308270688926,"score_gpt":0.5238021405454498,"score_spread":0.29832905783856056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163274852","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3913518,0.00034083438,0.0000063484586,0.59179497,0.000116831776,0.0010076999,0.00007483327,0.0000068401114,0.015299846],"genre_scores_gemma":[0.5834092,0.00008154243,0.00005403312,0.41463795,0.00037875987,0.00014504929,0.0002241617,0.000012861513,0.0010564832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809456,0.00048813768,0.00062835205,0.00024712627,0.00034276006,0.00019904945],"domain_scores_gemma":[0.9980799,0.00071147125,0.00047709706,0.00047185112,0.0002255804,0.000034131113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046799483,0.00016304354,0.0011179856,0.00036252785,0.000022529448,0.0000046349955,0.00018483416,0.0003114981,0.00034059276],"category_scores_gemma":[0.00014111977,0.00009893651,0.0002864794,0.00040119077,0.00012259596,0.000021643802,0.000024000778,0.0005405002,0.000023877534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023720514,0.0023962953,0.04887392,0.00011642071,0.008117323,0.00024513665,0.005374858,0.00011599588,0.000004307691,0.00008698231,0.9299566,0.004474933],"study_design_scores_gemma":[0.0043732617,0.013282786,0.22945336,0.00006236626,0.004938357,0.0000042407696,0.0036710114,0.00001861396,0.000015286296,0.00006779452,0.74390906,0.00020385341],"about_ca_topic_score_codex":0.0028849489,"about_ca_topic_score_gemma":0.00020761513,"teacher_disagreement_score":0.19205737,"about_ca_system_score_codex":0.00005456607,"about_ca_system_score_gemma":0.0004262793,"threshold_uncertainty_score":0.43611988},"labels":[],"label_agreement":null},{"id":"W2163510906","doi":"10.1093/annonc/mdh392","title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":365,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; CHOP; Anaplastic large-cell lymphoma; Peripheral T-cell lymphoma; Lymphoma; Internal medicine; International Prognostic Index; T-cell lymphoma; Oncology; Not Otherwise Specified; Chemotherapy; B symptoms; Gastroenterology; Pathology; Diffuse large B-cell lymphoma; T cell; Immunology","score_opus":0.051622763006591105,"score_gpt":0.3209718690295545,"score_spread":0.26934910602296336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163510906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114186,0.0000854655,0.00004934787,0.0056150625,0.000043757726,0.00025490983,0.000016414178,0.000007018111,0.0027861758],"genre_scores_gemma":[0.99849564,0.00044168526,0.000062779654,0.00077581126,0.000024707966,0.00003825401,0.000115605784,0.0000054172124,0.00004009025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993379,0.00004613835,0.00027417048,0.0001225187,0.000103394086,0.00011585704],"domain_scores_gemma":[0.9994372,0.000023451652,0.00026258704,0.00014249815,0.000099890465,0.00003437002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007985114,0.000073919975,0.00025999316,0.00006004321,0.000023138553,0.0000027438994,0.000048742415,0.000043628326,0.0000074705326],"category_scores_gemma":[0.000024818042,0.000052782878,0.00004949084,0.00025334652,0.000194506,0.00005551332,0.000011273604,0.000032934702,0.0000029415796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005243928,0.0076173805,0.46702665,0.0000559941,0.00006926324,0.000019561332,0.0018228149,0.00003593396,0.3180526,0.0012720107,0.00030612195,0.2031973],"study_design_scores_gemma":[0.0022793896,0.0024674537,0.8952154,0.000028497572,0.000025700278,0.000010802456,0.00011579256,0.000026452037,0.090839855,0.000018412276,0.008927866,0.00004440953],"about_ca_topic_score_codex":0.0006456764,"about_ca_topic_score_gemma":0.0004185402,"teacher_disagreement_score":0.42818874,"about_ca_system_score_codex":0.00020042113,"about_ca_system_score_gemma":0.0002335688,"threshold_uncertainty_score":0.21524233},"labels":[],"label_agreement":null},{"id":"W2163693301","doi":"10.1093/annonc/mdl302","title":"Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials","year":2006,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Confidence interval; Radiation therapy; Internal medicine; Breast cancer; Odds ratio; Chemoradiotherapy; Chemotherapy; Clinical trial; Lymphoma; Cancer; Oncology; Nuclear medicine","score_opus":0.34287321402057147,"score_gpt":0.45399459057918434,"score_spread":0.11112137655861287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163693301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035112647,0.98664314,0.0000014316367,0.00016515361,0.00007567578,0.0033007984,0.0027876643,0.000010042583,0.0035048064],"genre_scores_gemma":[0.009072587,0.9882509,0.00006639612,0.00006509537,0.00004281807,0.00083426986,0.0005137909,0.000041856925,0.0011122753],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99251646,0.0031588706,0.0030181871,0.0005044332,0.00046771008,0.00033432123],"domain_scores_gemma":[0.98425573,0.0059774695,0.008155243,0.000992205,0.0005193174,0.000100021185],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0020318641,0.00065312017,0.022692857,0.00056747516,0.000048085327,0.0000049423143,0.00022934037,0.0005928964,0.0007337603],"category_scores_gemma":[0.00070901454,0.00027718404,0.013776506,0.0012315086,0.0002689844,0.000023191345,0.000040077433,0.00006928162,0.0000028772529],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009817369,0.0066820495,0.00037742997,0.0010022398,0.66794467,0.00006537015,0.000068263194,0.000007957264,7.1475597e-7,0.000032048967,0.0013361594,0.32150137],"study_design_scores_gemma":[0.022665234,0.003897176,0.0016705497,0.00044071497,0.67051566,0.000012226722,0.000006769968,0.0000010104427,0.0002853011,0.000014854912,0.30034858,0.00014195808],"about_ca_topic_score_codex":0.0006564302,"about_ca_topic_score_gemma":0.00061591604,"teacher_disagreement_score":0.32135943,"about_ca_system_score_codex":0.00032700924,"about_ca_system_score_gemma":0.0015240264,"threshold_uncertainty_score":0.99996805},"labels":[],"label_agreement":null},{"id":"W2163749153","doi":"10.1093/annonc/mdu099","title":"Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Medicine; Gemcitabine; Ifosfamide; Regimen; Neutropenia; Internal medicine; Febrile neutropenia; Chemotherapy; Germ cell tumors; Phases of clinical research; Oncology; Salvage therapy; Chemotherapy regimen; Cisplatin; Gastroenterology; Surgery","score_opus":0.02404329417683855,"score_gpt":0.33937262120698153,"score_spread":0.315329327030143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163749153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680936,0.00011593299,0.000023898574,0.00038222913,0.00006140247,0.0016769314,0.000052414667,0.000018086403,0.00085973286],"genre_scores_gemma":[0.99827415,0.000012356162,0.0007720255,0.00065732613,0.000024321647,0.0001033514,0.00005927382,0.000026837992,0.00007036431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847686,0.00016352539,0.00042896988,0.00037526008,0.00024346469,0.00031193194],"domain_scores_gemma":[0.99859524,0.00030452744,0.00041211245,0.0002192502,0.00027642128,0.00019243262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019044726,0.0002253529,0.0007287748,0.00016297965,0.000063761174,0.000007305036,0.000056111294,0.00007343827,0.000041258154],"category_scores_gemma":[0.00045206456,0.00016895593,0.000088457324,0.00015650752,0.00014800805,0.00011810243,0.000060257255,0.0001773204,0.0000057547145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21693368,0.042693403,0.674286,0.00028669825,0.0011270187,0.00034474736,0.006180225,0.000013987125,0.00024408968,0.00018720022,0.00036695896,0.057335995],"study_design_scores_gemma":[0.33619282,0.060104694,0.60052943,0.00019008269,0.000545076,0.0000073159254,0.00020958007,0.00050791394,0.0010999853,0.00022997899,0.00019763086,0.0001855074],"about_ca_topic_score_codex":0.000111331065,"about_ca_topic_score_gemma":0.000024906174,"teacher_disagreement_score":0.119259134,"about_ca_system_score_codex":0.000057792167,"about_ca_system_score_gemma":0.00015258868,"threshold_uncertainty_score":0.68898225},"labels":[],"label_agreement":null},{"id":"W2163760444","doi":"10.1093/annonc/mdt375","title":"Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Bayer HealthCare","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Interquartile range; Internal medicine; Confidence interval; Oncology; Refractory (planetary science); Urology; Surgery; Gastroenterology; Hepatocellular carcinoma","score_opus":0.15243239292797406,"score_gpt":0.35343033272481045,"score_spread":0.2009979397968364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163760444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943233,0.00024962024,0.00006479509,0.0035855295,0.0002580864,0.0031558592,0.00012691907,0.0000125969045,0.0031142368],"genre_scores_gemma":[0.99638206,0.000016733635,0.0016566399,0.00029964474,0.000119011886,0.00026756976,0.00011296894,0.000036044585,0.0011093541],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970168,0.0004019425,0.0011634916,0.00044544134,0.00044690495,0.00052540854],"domain_scores_gemma":[0.9971054,0.00079370366,0.00078498456,0.00061696925,0.00054399966,0.00015491966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070684426,0.00032019016,0.0014272041,0.00021063742,0.000044741137,0.000010377939,0.00031115353,0.00014615181,0.00006888671],"category_scores_gemma":[0.00020459082,0.00020232624,0.0003435463,0.00025486862,0.00033535695,0.000097659,0.00010491366,0.0002840145,0.0000104587325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8520337,0.01138781,0.008608479,0.0013011547,0.0012479617,0.00059341063,0.0063550947,0.0021003105,0.0642787,0.00043652827,0.044622157,0.007034731],"study_design_scores_gemma":[0.5309058,0.06737654,0.09623475,0.00036812184,0.00087839784,0.00016799047,0.001118679,0.0015985626,0.29333025,0.0010763475,0.0063506677,0.0005939475],"about_ca_topic_score_codex":0.0024168836,"about_ca_topic_score_gemma":0.0010780698,"teacher_disagreement_score":0.32112792,"about_ca_system_score_codex":0.00019389977,"about_ca_system_score_gemma":0.00094266044,"threshold_uncertainty_score":0.8250624},"labels":[],"label_agreement":null},{"id":"W2163907105","doi":"10.1093/annonc/mdq233","title":"Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Cytopenia; Medicine; Myelodysplastic syndromes; Clinical significance; Internal medicine; Oncology; Bone marrow; Pediatrics","score_opus":0.07041987427966254,"score_gpt":0.375204870353179,"score_spread":0.3047849960735165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163907105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997154,0.00009277808,0.000050443115,0.00055734307,0.00021755807,0.00054697075,0.00018232816,0.000014007683,0.0011845925],"genre_scores_gemma":[0.99855083,0.000048846483,0.000983038,0.00015437133,0.0000796258,0.000027902217,0.00007066149,0.000027759192,0.00005693873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997077,0.000305298,0.001191436,0.00042561305,0.000545314,0.00045537445],"domain_scores_gemma":[0.9964683,0.001325738,0.0007415186,0.00054854684,0.0007425592,0.00017335286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013355654,0.00021711594,0.0012617384,0.00028406837,0.00003223683,0.0000056795116,0.00043378476,0.00036482813,0.00016089088],"category_scores_gemma":[0.0041741906,0.000198096,0.00015003835,0.00040830433,0.00063365826,0.00010485827,0.00021677812,0.00078715605,0.000008178628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028470438,0.0017055538,0.6961251,0.0008022266,0.00019147154,0.00028357597,0.001416584,0.000009969055,0.2811857,0.000641296,0.0002523006,0.014539178],"study_design_scores_gemma":[0.0036489444,0.0029445419,0.9403941,0.0003714559,0.0000616076,0.0000138010255,0.00009823702,0.0003099098,0.0506017,0.00091454224,0.0004743712,0.00016679152],"about_ca_topic_score_codex":0.0026650962,"about_ca_topic_score_gemma":0.0009313063,"teacher_disagreement_score":0.244269,"about_ca_system_score_codex":0.00011778248,"about_ca_system_score_gemma":0.0009688154,"threshold_uncertainty_score":0.80781204},"labels":[],"label_agreement":null},{"id":"W2163909367","doi":"10.1093/annonc/mds473","title":"Public health oncology: a framework for progress in low- and middle-income countries","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Cancer Institute; Breast Cancer Research Foundation","keywords":"Medicine; Public health; Psychological intervention; Population; Population health; Public relations; Economic growth; Environmental health; Political science; Nursing; Economics","score_opus":0.14967471209128472,"score_gpt":0.49615827807071006,"score_spread":0.3464835659794253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163909367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65957975,0.06623647,0.0040783114,0.26413572,0.001768746,0.0020674823,0.000044683275,0.000075854805,0.002012962],"genre_scores_gemma":[0.91260093,0.008276123,0.05673546,0.021242037,0.00075289374,0.00024412508,0.000014217731,0.000028330936,0.00010589206],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982089,0.00020255217,0.0005241794,0.00022047783,0.000108658984,0.00073523563],"domain_scores_gemma":[0.9976242,0.0013485021,0.00036549979,0.0002053137,0.00017074731,0.00028571815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017779449,0.00015553668,0.00088401936,0.00021288774,0.000085984335,0.0000037225404,0.00010676321,0.0005128705,0.000058504946],"category_scores_gemma":[0.00044318233,0.00012978351,0.00007390291,0.00019288775,0.00086627755,0.00016971042,0.000038821123,0.00034293195,0.0000044329727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023505709,0.0028430773,0.6381763,0.0017085846,0.00026604088,0.000039881408,0.008023099,9.2886467e-7,0.0000051286465,0.09196971,0.0016447875,0.2529719],"study_design_scores_gemma":[0.004942152,0.016389778,0.15829372,0.0007586191,0.000027273578,0.00031408624,0.0007345195,0.000034492215,0.00012009925,0.010760728,0.8074023,0.00022221864],"about_ca_topic_score_codex":0.0000056565996,"about_ca_topic_score_gemma":0.00003298429,"teacher_disagreement_score":0.8057575,"about_ca_system_score_codex":0.00020741754,"about_ca_system_score_gemma":0.0008888976,"threshold_uncertainty_score":0.5292418},"labels":[],"label_agreement":null},{"id":"W2164307561","doi":"10.1093/annonc/mdn461","title":"The treatment of advanced pancreatic cancer: current evidence and future challenges","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Current (fluid); Oncology; Intensive care medicine; Internal medicine; Cancer","score_opus":0.24850644117962445,"score_gpt":0.4833257529017067,"score_spread":0.23481931172208226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164307561","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6776202,0.30212107,9.976894e-7,0.018419275,0.000107544394,0.00032308904,0.000004022764,0.0000059276995,0.0013978739],"genre_scores_gemma":[0.41054693,0.58886075,0.00011432882,0.00004528623,0.00015752847,0.00007929307,8.6071316e-7,0.000004421168,0.00019063168],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989342,0.00014390395,0.0003129333,0.00017622688,0.00018110637,0.00025163768],"domain_scores_gemma":[0.99815196,0.0010339335,0.00017345362,0.00025779216,0.00026892268,0.00011392997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002545495,0.000112687165,0.00068438787,0.000056315148,0.00010234703,8.982784e-7,0.0000801586,0.000096317206,0.00003678095],"category_scores_gemma":[0.00013263164,0.00006501396,0.000079968966,0.000086770786,0.0005968426,0.000035926136,0.000021745473,0.000094719384,0.0000028648162],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010276879,0.00079673965,0.08022835,0.00017622746,0.0002487106,0.00003745359,0.0025198995,5.8544856e-7,0.00038874923,0.00065305637,0.0007757642,0.9131468],"study_design_scores_gemma":[0.0021668791,0.016786285,0.53935516,0.00024307467,0.00022404834,0.00012710862,0.00097357493,0.00004356147,0.0017989371,0.00028552057,0.43791193,0.00008395119],"about_ca_topic_score_codex":0.000084272455,"about_ca_topic_score_gemma":0.000096217234,"teacher_disagreement_score":0.9130628,"about_ca_system_score_codex":0.000055081277,"about_ca_system_score_gemma":0.00053580507,"threshold_uncertainty_score":0.26511925},"labels":[],"label_agreement":null},{"id":"W2164353421","doi":"10.1093/annonc/mdm486","title":"Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006","year":2007,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Distributed File System; Breast cancer; Internal medicine; Correlation; Confidence interval; Significant difference; Sample size determination; Oncology; Randomized controlled trial; Overall survival; Cancer; Statistics","score_opus":0.15234064296531255,"score_gpt":0.42901602723105037,"score_spread":0.2766753842657378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164353421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007345998,0.9755866,0.000023665243,0.0010373106,0.00052286906,0.00081708387,0.014238328,0.000006536761,0.0004215855],"genre_scores_gemma":[0.0073668147,0.99020267,0.00009140099,0.000080909194,0.00095917855,0.00010436338,0.0010778388,0.000045544486,0.00007130001],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973747,0.000593887,0.00089063944,0.00056591537,0.00022807895,0.00034677977],"domain_scores_gemma":[0.9978948,0.0005144174,0.00077503093,0.00045561104,0.00020010264,0.0001600069],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009744206,0.00039220124,0.0027395547,0.00019819278,0.00002666215,0.0000054884345,0.00028379206,0.00049050373,0.000045219997],"category_scores_gemma":[0.00034269667,0.00033593117,0.00029622987,0.0001635723,0.00014642769,0.000004682239,0.00033872784,0.00015008802,0.000003610563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012003846,0.00023766536,0.05027366,0.0012793798,0.0014070271,0.000012587192,0.00006738378,0.000007085409,0.000026699789,0.00007858139,0.0035713909,0.94183815],"study_design_scores_gemma":[0.0027937398,0.0007515845,0.18864974,0.002444031,0.0012730309,0.0000028340407,0.000060208255,2.5993415e-7,0.00007718982,0.00013781872,0.8033025,0.00050704],"about_ca_topic_score_codex":0.0020050278,"about_ca_topic_score_gemma":0.00331059,"teacher_disagreement_score":0.9413311,"about_ca_system_score_codex":0.00006301432,"about_ca_system_score_gemma":0.0004162947,"threshold_uncertainty_score":0.9999093},"labels":[],"label_agreement":null},{"id":"W2164526402","doi":"10.1093/annonc/mdu387","title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Internal medicine; Refractory (planetary science); Chemotherapy; Lymphoma; Transplantation; Oncology; Surgery; Cohort; Chemotherapy regimen; Gastroenterology","score_opus":0.026469964237844316,"score_gpt":0.30107362316226977,"score_spread":0.27460365892442545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164526402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899885,0.0007620228,0.000048017577,0.007845144,0.000041119558,0.00043752568,0.00004499001,0.000021061036,0.0008116353],"genre_scores_gemma":[0.9927468,0.0026240204,0.0014457953,0.0027659182,0.000038303366,0.0000770314,0.00004171123,0.00001961132,0.00024083476],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991818,0.00004888905,0.00021292616,0.00026176946,0.0001009107,0.00019367423],"domain_scores_gemma":[0.9991322,0.0003431381,0.00016841448,0.00015982064,0.00009173407,0.00010469049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017132814,0.00014951806,0.00047554044,0.000062221676,0.00004893632,0.0000057840502,0.000035729976,0.00014022665,0.0000070553456],"category_scores_gemma":[0.000009952091,0.00011256659,0.000039648556,0.000049991726,0.00014510196,0.000040614297,0.000005662211,0.00003264524,4.1562416e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016165875,0.003128456,0.04724083,0.0012784628,0.00052024244,0.00019295813,0.0028596455,0.0000035872451,0.01684688,0.0029358251,0.0043216,0.9045056],"study_design_scores_gemma":[0.03175462,0.017180081,0.8341218,0.00012471004,0.000287742,0.00019297352,0.00011993275,0.000044128636,0.08213143,0.00033683592,0.033491064,0.00021468764],"about_ca_topic_score_codex":0.00017244522,"about_ca_topic_score_gemma":0.00017817282,"teacher_disagreement_score":0.904291,"about_ca_system_score_codex":0.00005176265,"about_ca_system_score_gemma":0.00012558387,"threshold_uncertainty_score":0.45903322},"labels":[],"label_agreement":null},{"id":"W2164730570","doi":"10.1093/annonc/mdt009","title":"Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Lung cancer; Oncology; Chemotherapy; Cisplatin; Chemotherapy regimen; Small Cell Lung Carcinoma; Small-cell carcinoma; Gastroenterology","score_opus":0.05888404863705851,"score_gpt":0.45237937195816075,"score_spread":0.39349532332110226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164730570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023033,0.0009257738,0.00000986996,0.009488409,0.00014677671,0.008202838,0.000026468755,0.00002407135,0.0009454321],"genre_scores_gemma":[0.996608,0.0002229074,0.00012756565,0.0010437239,0.00011566998,0.0008172492,0.000007247062,0.00003691467,0.0010206748],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9977834,0.00021982258,0.0006270614,0.00038344815,0.00040040456,0.0005858324],"domain_scores_gemma":[0.99739283,0.00070700655,0.00034681184,0.00059144036,0.00083582156,0.00012606353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039647127,0.0002302388,0.00086491724,0.00012680906,0.0001907495,0.0000058639807,0.00029147815,0.000035107543,0.000127799],"category_scores_gemma":[0.0003840832,0.00015261654,0.00014570491,0.00023778282,0.00013602985,0.000094954295,0.00023403781,0.00024984186,0.0000043927416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021885535,0.21391393,0.36405352,0.0015534898,0.0036651818,0.00045457672,0.069240205,0.00009365495,0.063702084,0.000077184035,0.14461286,0.11674779],"study_design_scores_gemma":[0.27574596,0.3331288,0.20419285,0.00010131782,0.0010781372,0.000043001208,0.082794555,0.0024176436,0.062130827,0.00011448914,0.037695743,0.00055669853],"about_ca_topic_score_codex":0.0004638105,"about_ca_topic_score_gemma":0.0002973028,"teacher_disagreement_score":0.2538604,"about_ca_system_score_codex":0.000057671077,"about_ca_system_score_gemma":0.00017335055,"threshold_uncertainty_score":0.6223522},"labels":[],"label_agreement":null},{"id":"W2164811818","doi":"10.1093/annonc/mdu349.56","title":"Prophylactic Treatment for Rash Induced By Egfr Inhibitor Improves Rash Without Compromising on Efficacy the Pancanadian Rash Trial: a Randomized Phase III Trial in Nsclc","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Mount Sinai Hospital; Burnaby Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Randomized controlled trial; Dermatology; Oncology; Internal medicine","score_opus":0.0762739308251862,"score_gpt":0.44747249216685153,"score_spread":0.37119856134166535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164811818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973912,0.00017455935,0.00006581375,0.010260897,0.0007408107,0.013379494,0.00003510829,0.000028725217,0.0014025773],"genre_scores_gemma":[0.9954856,0.000045521574,0.00015574302,0.0013664695,0.0006416665,0.0016911458,0.000105197876,0.000038783397,0.0004698537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99761677,0.0005459972,0.00082571135,0.00039721586,0.00018991808,0.0004243857],"domain_scores_gemma":[0.99695885,0.0018056657,0.00051942,0.00036227098,0.00015820209,0.00019559462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010578316,0.00028678577,0.001537718,0.00019373912,0.0001394291,0.000024642646,0.00010980345,0.00020063957,0.000020750453],"category_scores_gemma":[0.0009795243,0.00017179493,0.00036376575,0.00017212951,0.0001828449,0.00006313993,0.0000147189485,0.00016936073,0.000004534102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86206305,0.0048933458,0.000011399373,0.00003224766,0.00054020947,0.000005713648,0.0012251554,0.0000027144324,0.0071134926,0.00014968065,0.0010317954,0.122931175],"study_design_scores_gemma":[0.95012134,0.027471555,0.00006487938,0.00007548007,0.0007834243,0.0000033771882,0.00013440901,0.0001839333,0.0065729525,0.00016809328,0.014270335,0.00015019388],"about_ca_topic_score_codex":0.0015255124,"about_ca_topic_score_gemma":0.0005843115,"teacher_disagreement_score":0.12278098,"about_ca_system_score_codex":0.0003399106,"about_ca_system_score_gemma":0.0010265535,"threshold_uncertainty_score":0.70055944},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2165071697","doi":"10.1093/annonc/mdm331","title":"Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-α2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Dacarbazine; Immunotherapy; Melanoma; Oncology; Histamine; Internal medicine; Randomized controlled trial; Cancer research; Cancer","score_opus":0.024214262704384943,"score_gpt":0.3278205079881186,"score_spread":0.3036062452837337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165071697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558467,0.000066901186,0.00010706914,0.0005953171,0.0000927941,0.002740353,0.000011063514,0.000007704288,0.00079410744],"genre_scores_gemma":[0.99940217,0.000075033844,0.00011590014,0.00016595755,0.000010228211,0.000016687596,0.000009807047,0.000015485426,0.00018875554],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99832857,0.0002120859,0.00078038767,0.00024179197,0.0002499001,0.0001872589],"domain_scores_gemma":[0.9981861,0.0008630629,0.0003335901,0.0002982484,0.00024986317,0.000069104724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016224354,0.00016753907,0.0009067552,0.00024899427,0.00002111139,0.0000034085863,0.00008914855,0.00004056337,0.000013705739],"category_scores_gemma":[0.0002493514,0.00009657556,0.00004487818,0.00018313831,0.00025844932,0.00002862109,0.0000855978,0.0001259612,4.2495e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96517503,0.0024896278,0.0120708775,0.000051407347,0.0007465109,0.000035691584,0.0058392473,0.000015495403,0.00060925714,0.000018182167,0.000024236952,0.012924407],"study_design_scores_gemma":[0.6265072,0.0787653,0.2888175,0.0001728586,0.00022647956,0.000005677462,0.002003649,0.00010574855,0.0020350458,0.000001706941,0.0012440141,0.00011481668],"about_ca_topic_score_codex":0.00034363614,"about_ca_topic_score_gemma":0.0012806713,"teacher_disagreement_score":0.33866784,"about_ca_system_score_codex":0.00005342958,"about_ca_system_score_gemma":0.000033921107,"threshold_uncertainty_score":0.39382368},"labels":[],"label_agreement":null},{"id":"W2165109429","doi":"10.1093/annonc/mdt536","title":"Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Erlotinib; Medicine; Everolimus; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Phases of clinical research; Erlotinib Hydrochloride; Progressive disease; Cancer; Chemotherapy; Gastroenterology; Randomized controlled trial; Epidermal growth factor receptor","score_opus":0.027617763052634362,"score_gpt":0.40064832894675095,"score_spread":0.3730305658941166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165109429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352324,0.00034422826,0.0000025379313,0.00031927347,0.000053749598,0.0032260267,0.000021941858,0.0000116346055,0.002497354],"genre_scores_gemma":[0.99829704,0.000142458,0.00015784251,0.00027699393,0.000016217151,0.00060550874,0.00003730962,0.000019389841,0.00044726135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989481,0.000047896378,0.0003973251,0.00022469334,0.00013837297,0.00024361283],"domain_scores_gemma":[0.9988958,0.000048142432,0.00028046768,0.00021666205,0.0004642889,0.00009460056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006044167,0.00014448239,0.0005301784,0.00014280461,0.000032730084,0.0000018678421,0.000070426824,0.000068278394,0.00016570778],"category_scores_gemma":[0.000015894377,0.00010380891,0.00004243268,0.00024088351,0.000042451316,0.0000879897,0.0000286107,0.00008673194,0.000002693346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016718906,0.044012304,0.8501588,0.00017199089,0.00055673334,0.000024627485,0.010680236,0.00016865892,0.0008788812,0.0000020148993,0.0013304069,0.09034345],"study_design_scores_gemma":[0.09770053,0.13344151,0.7609322,0.00031579286,0.0008076819,0.0000018102334,0.0017471893,0.00013794913,0.0036593652,0.000007942926,0.0010445126,0.00020352949],"about_ca_topic_score_codex":0.0027839805,"about_ca_topic_score_gemma":0.00085564423,"teacher_disagreement_score":0.09602864,"about_ca_system_score_codex":0.00008501884,"about_ca_system_score_gemma":0.00031428653,"threshold_uncertainty_score":0.42332044},"labels":[],"label_agreement":null},{"id":"W2165111191","doi":"10.1093/annonc/mdq446","title":"Quality of life during the course of cancer treatment in older newly diagnosed patients. Results of a prospective pilot study","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; McGill University; Jewish General Hospital; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Prospective cohort study; Gerontology; Physical therapy; Oncology; Internal medicine; Nursing","score_opus":0.0823977451129298,"score_gpt":0.4273337896469297,"score_spread":0.3449360445339999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165111191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948203,0.0001460271,2.1882983e-7,0.0020868317,0.00015691412,0.0019177487,0.00018869116,0.000006172288,0.0006770718],"genre_scores_gemma":[0.99941635,0.000115634306,0.000036206624,0.00009654201,0.00004549582,0.00015848124,0.000007087984,0.000011952651,0.00011222843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998094,0.0002281575,0.0009844374,0.0002288271,0.00026846564,0.00019611747],"domain_scores_gemma":[0.9972417,0.0007076656,0.00081038335,0.00047198456,0.00069805223,0.00007025956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005682695,0.00013989133,0.0008526109,0.00009686416,0.00001641841,8.1208844e-7,0.0001393125,0.00007880924,0.000042965094],"category_scores_gemma":[0.0012123365,0.000091509355,0.00008259425,0.00021245767,0.0003135014,0.00003685695,0.00005389902,0.00018470036,6.4049254e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060302475,0.023680229,0.9443049,0.00013097328,0.0003539432,0.0000071626077,0.01252124,0.000018864024,0.00618394,0.000017469218,0.00031233495,0.006438727],"study_design_scores_gemma":[0.02400822,0.021831648,0.93206733,0.00008016238,0.00005796515,5.1128904e-7,0.0016233369,0.0000034885243,0.020156773,0.00002690859,0.00008352822,0.000060144543],"about_ca_topic_score_codex":0.019648748,"about_ca_topic_score_gemma":0.0477091,"teacher_disagreement_score":0.02806035,"about_ca_system_score_codex":0.00006269245,"about_ca_system_score_gemma":0.00048339632,"threshold_uncertainty_score":0.98687947},"labels":[],"label_agreement":null},{"id":"W2165741055","doi":"10.1093/annonc/mdp233","title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":534,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Roche","keywords":"Medicine; Bevacizumab; Irinotecan; Oxaliplatin; Internal medicine; Capecitabine; FOLFOX; FOLFIRI; Colorectal cancer; Oncology; Fluorouracil; Surgery; Chemotherapy; Chemotherapy regimen; Cancer","score_opus":0.05728466980328281,"score_gpt":0.3809595963763208,"score_spread":0.323674926573038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165741055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97995955,0.007384201,0.0000023850362,0.0107705295,0.000032628534,0.0010108595,0.000020144216,0.000008570974,0.00081110594],"genre_scores_gemma":[0.99384654,0.0056783915,0.0000941021,0.00025322108,0.000026734566,0.00004773676,0.000003942802,0.0000083158475,0.000041004994],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99893713,0.00007966645,0.0003807896,0.00023943897,0.00015753806,0.0002054529],"domain_scores_gemma":[0.99906516,0.0004210878,0.00016821339,0.00013220422,0.00015486305,0.00005845737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002592434,0.00017297252,0.0008164067,0.00009498497,0.00008190419,0.0000037702703,0.000058815505,0.00004177831,0.000016388743],"category_scores_gemma":[0.00010093235,0.00009702013,0.000045410135,0.00022525596,0.00025147808,0.000040492338,0.000049945425,0.00010496874,1.6483877e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03338212,0.0054524774,0.44820336,0.00014836836,0.0016470505,0.0002363987,0.013450617,0.00007526408,0.0003539927,0.00014673822,0.0004266736,0.49647692],"study_design_scores_gemma":[0.010944355,0.043581415,0.9403004,0.000093197275,0.00047050763,0.00005281216,0.0016305752,0.00006040074,0.0009715042,0.00011400739,0.0016781406,0.00010266203],"about_ca_topic_score_codex":0.00086096395,"about_ca_topic_score_gemma":0.007874603,"teacher_disagreement_score":0.49637428,"about_ca_system_score_codex":0.00004553675,"about_ca_system_score_gemma":0.000115558534,"threshold_uncertainty_score":0.43942136},"labels":[],"label_agreement":null},{"id":"W2166926027","doi":"10.1093/annonc/mdp605","title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":424,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sarcopenia; Toxicity; Sorafenib; Internal medicine; Renal cell carcinoma; Body mass index; Urology; Cancer; Oncology; Gastroenterology; Surgery","score_opus":0.03590324930171333,"score_gpt":0.3283784264298889,"score_spread":0.29247517712817556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166926027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956647,0.000021756081,0.000007447371,0.0011509197,0.000038201946,0.00033732774,0.000014917101,0.000009321759,0.002755377],"genre_scores_gemma":[0.9983221,0.000009413157,0.0006839664,0.00087414274,0.00002776464,0.0000073831766,0.000022984868,0.000013401735,0.000038826176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989348,0.00007782425,0.00035565975,0.00017672202,0.00019134773,0.00026365096],"domain_scores_gemma":[0.99893683,0.00014049349,0.0003316667,0.0001275054,0.0003381103,0.00012538349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003922691,0.000103985156,0.000466526,0.00016277189,0.00003470945,0.000002958142,0.000055383254,0.00016232135,0.0000482187],"category_scores_gemma":[0.00009836191,0.00008230938,0.000021725691,0.00018036869,0.00016612835,0.00005605437,0.00002374715,0.00038920675,7.509663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017135458,0.0009000054,0.98247975,0.00018383493,0.000017876971,0.000029633433,0.00017148709,0.000001367009,0.012539901,0.000031229676,0.00017920419,0.0017521653],"study_design_scores_gemma":[0.009243546,0.0045157275,0.9573573,0.00020278458,0.000019204961,0.0000046285336,0.00006857433,0.0000623943,0.028178649,0.000054067103,0.00021173543,0.00008141022],"about_ca_topic_score_codex":0.000079279474,"about_ca_topic_score_gemma":0.00040040753,"teacher_disagreement_score":0.025122471,"about_ca_system_score_codex":0.000026694881,"about_ca_system_score_gemma":0.00023848053,"threshold_uncertainty_score":0.3356479},"labels":[],"label_agreement":null},{"id":"W2167571882","doi":"10.1093/annonc/mdt066","title":"Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Astellas Pharma; Genentech; Amgen","keywords":"Gemcitabine; Medicine; Clinical endpoint; Pancreatic cancer; Internal medicine; Adenocarcinoma; Phases of clinical research; Oncology; Gastroenterology; Deoxycytidine; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.049947938342987164,"score_gpt":0.4032117858356602,"score_spread":0.35326384749267303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167571882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884808,0.0014812059,0.000055197874,0.0017328089,0.0000822983,0.006003426,0.00006378365,0.0000160255,0.002084476],"genre_scores_gemma":[0.99445045,0.0026739459,0.0014486101,0.00040231616,0.00004580006,0.0005698312,0.00006405522,0.00002269989,0.00032231127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99677247,0.0006259453,0.0011835317,0.00039202254,0.000429659,0.0005963896],"domain_scores_gemma":[0.99707204,0.0008990763,0.00059201557,0.00036168538,0.00078901,0.00028614953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010568949,0.00030132095,0.0029665544,0.00027108373,0.000054284024,0.000007048691,0.00015008036,0.00017890865,0.0007297507],"category_scores_gemma":[0.0011218284,0.00020216014,0.00014937794,0.00041293725,0.0008903071,0.00015263828,0.00012006509,0.00020673066,0.00000774591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7922311,0.008837756,0.16017954,0.0005123758,0.0016727007,0.000055673023,0.00093314657,0.000012300333,0.00006137503,0.00010893663,0.0009450985,0.03445001],"study_design_scores_gemma":[0.9135455,0.032562323,0.05011648,0.00032999465,0.00134647,0.00001295158,0.00016669412,0.0012276514,0.00006182259,0.00019258718,0.00026254356,0.00017496712],"about_ca_topic_score_codex":0.005026743,"about_ca_topic_score_gemma":0.00049242424,"teacher_disagreement_score":0.12131443,"about_ca_system_score_codex":0.00016125194,"about_ca_system_score_gemma":0.0007556083,"threshold_uncertainty_score":0.8243851},"labels":[],"label_agreement":null},{"id":"W2167865797","doi":"10.1093/annonc/mds322","title":"Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Squamous cell cancer; Head and neck cancer; Head and neck; Drug; Oncology; Medical prescription; Cancer; Cancer drugs; Internal medicine; Intensive care medicine; Surgery; Pharmacology","score_opus":0.06132193737321315,"score_gpt":0.3731085620028792,"score_spread":0.311786624629666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167865797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98473656,0.009450045,0.000015653359,0.0018278054,0.0001947451,0.00034392407,0.00002845097,0.000023237695,0.003379565],"genre_scores_gemma":[0.99089766,0.0072713303,0.0006167543,0.00083520444,0.00011596286,0.000048448444,0.0000065937656,0.000014642067,0.00019338375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910384,0.000075086195,0.00020529835,0.00020451362,0.000102799924,0.00030848515],"domain_scores_gemma":[0.99918246,0.00028875686,0.00013444526,0.00013141515,0.00007354654,0.00018939533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000124794,0.00016985735,0.0005177667,0.00007420588,0.000086124266,0.0000033229783,0.000025287458,0.000083660285,0.00002284034],"category_scores_gemma":[0.00006647946,0.0001240414,0.000052795043,0.000059799193,0.00009295054,0.00007927779,0.000019952331,0.00010806488,0.000001384333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020760389,0.0018192229,0.78249943,0.0002616515,0.00011474512,0.000009288992,0.004732109,0.0004507178,0.0043382226,0.000013561064,0.0028074987,0.20087753],"study_design_scores_gemma":[0.013249855,0.024127696,0.7637512,0.00025563024,0.00033708065,0.000005840291,0.0008273985,0.0011049182,0.050473418,0.000010830315,0.14553814,0.00031797233],"about_ca_topic_score_codex":0.0019121782,"about_ca_topic_score_gemma":0.0005173947,"teacher_disagreement_score":0.20055956,"about_ca_system_score_codex":0.00009379025,"about_ca_system_score_gemma":0.00010573962,"threshold_uncertainty_score":0.5058261},"labels":[],"label_agreement":null},{"id":"W2167921436","doi":"10.1093/annonc/mdp392","title":"Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Gemcitabine; Internal medicine; Oncology; Lung cancer; Population; Cisplatin; Performance status; Predictive marker; Hazard ratio; Chemotherapy; Cancer; Confidence interval","score_opus":0.05359093777156162,"score_gpt":0.43231529474374103,"score_spread":0.37872435697217943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167921436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890953,0.0013737916,0.00010371682,0.00063457136,0.0002827275,0.0034224845,0.000028095763,0.00001702512,0.0050423457],"genre_scores_gemma":[0.9983941,0.0005311293,0.00035849548,0.0001335838,0.00006244005,0.00034523974,0.00009348269,0.000013277501,0.000068270056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99836797,0.00012695634,0.00070464134,0.00032039412,0.00014915956,0.00033086896],"domain_scores_gemma":[0.99835026,0.0009260555,0.0003287916,0.00013834074,0.00013234073,0.0001241931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035919982,0.00021439717,0.0013789898,0.0003558156,0.000037690035,0.0000065752765,0.00006137989,0.00013436782,0.000037388127],"category_scores_gemma":[0.00034270718,0.00017425188,0.000116504925,0.0003554654,0.00009383707,0.00010387872,0.000023979415,0.0002139666,4.298189e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9277024,0.0029948964,0.0440722,0.00009811151,0.00042054692,0.00009338477,0.004716252,0.00065544667,0.0009167041,0.000052445357,0.00012324647,0.018154325],"study_design_scores_gemma":[0.941119,0.0077829557,0.040874314,0.00027443774,0.0006521536,0.0000021285414,0.00061493553,0.0074638515,0.00094744907,0.000048383838,0.000076733195,0.00014362783],"about_ca_topic_score_codex":0.00052844663,"about_ca_topic_score_gemma":0.0005601645,"teacher_disagreement_score":0.018010698,"about_ca_system_score_codex":0.0001667341,"about_ca_system_score_gemma":0.00049059815,"threshold_uncertainty_score":0.71057856},"labels":[],"label_agreement":null},{"id":"W2167948661","doi":"10.1093/annonc/mdv236","title":"Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Cancer Care Ontario; University of Toronto","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research; Associazione Italiana per la Ricerca sul Cancro; National Cancer Institute; National Institutes of Health; California Department of Public Health","keywords":"Medicine; Pancreatic cancer; Cancer; Internal medicine; Oncology; Gastroenterology","score_opus":0.07739783412699956,"score_gpt":0.4059414758266095,"score_spread":0.3285436416996099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167948661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9386083,0.027658189,0.000042766198,0.031712245,0.00008833119,0.0005460875,0.00031161506,0.000022031221,0.0010104433],"genre_scores_gemma":[0.9899935,0.0058399797,0.00011818098,0.002931621,0.00023353397,0.00030538224,0.000011979032,0.00001627371,0.0005495326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979787,0.00046000464,0.00044384488,0.000337437,0.00033942173,0.0004406279],"domain_scores_gemma":[0.9966693,0.0017525167,0.0002400672,0.00041316097,0.0006336061,0.00029137346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008613386,0.0001999981,0.0012436049,0.00017265747,0.000104570594,0.000012476405,0.00013283895,0.00013372212,0.00022199165],"category_scores_gemma":[0.0014207095,0.00012379751,0.00017074808,0.0005396798,0.00060576625,0.000054158827,0.0001050041,0.0002434086,0.000007794806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009879669,0.0003592338,0.8785926,0.000121160054,0.025702469,0.002187188,0.003958711,0.000094931514,0.0017203502,0.000054123197,0.034903202,0.05131805],"study_design_scores_gemma":[0.0077131707,0.0026471124,0.9499288,0.00018450689,0.020517614,0.0002747492,0.0054308833,0.0022575646,0.0009811887,0.0003052051,0.009485611,0.00027356416],"about_ca_topic_score_codex":0.02347102,"about_ca_topic_score_gemma":0.011069791,"teacher_disagreement_score":0.07133621,"about_ca_system_score_codex":0.000117640666,"about_ca_system_score_gemma":0.00067952374,"threshold_uncertainty_score":0.98303175},"labels":[],"label_agreement":null},{"id":"W2167955103","doi":"10.1093/annonc/mdq786","title":"Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Breast Cancer Research Foundation","keywords":"Medicine; Coping (psychology); Breast cancer; Oncology; Internal medicine; Gynecology; Clinical psychology; Cancer","score_opus":0.2047006578842925,"score_gpt":0.45608003687345433,"score_spread":0.25137937898916185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167955103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74044687,0.011512312,0.00008429647,0.09812764,0.0004392382,0.0028869007,0.00051108847,0.00013972963,0.14585194],"genre_scores_gemma":[0.9856619,0.009745528,0.00043283773,0.002179726,0.00028979944,0.00031891657,0.000015936705,0.000052776653,0.0013025478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805653,0.00012976084,0.00035230228,0.00044554094,0.00038013252,0.000635743],"domain_scores_gemma":[0.9983025,0.00014799947,0.00018283752,0.0004373578,0.0006202835,0.0003090244],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030656977,0.0002525157,0.00075420615,0.0001817879,0.00007390751,0.000008562013,0.0001785606,0.00020266355,0.0014119588],"category_scores_gemma":[0.000022283502,0.00018076511,0.0001280233,0.00023417483,0.00048029702,0.000066495864,0.00006982792,0.00027026486,0.000038895054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016938752,0.00479081,0.14932717,0.0005059574,0.0027157564,0.002659722,0.019645374,0.00009773708,0.002113708,0.0020532156,0.04111424,0.75803757],"study_design_scores_gemma":[0.026302323,0.12858813,0.18333659,0.00505604,0.0011271735,0.0032436922,0.00804497,0.00043843608,0.09167555,0.0027098542,0.5478695,0.0016077581],"about_ca_topic_score_codex":0.009259902,"about_ca_topic_score_gemma":0.002788246,"teacher_disagreement_score":0.7564298,"about_ca_system_score_codex":0.0005116776,"about_ca_system_score_gemma":0.0016980978,"threshold_uncertainty_score":0.9995009},"labels":[],"label_agreement":null},{"id":"W2168023789","doi":"10.1093/annonc/mds011","title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Discovery and development of mTOR inhibitors; Pharmacology; Kinase; Phosphatidylinositol; PI3K/AKT/mTOR pathway; Signal transduction; Biochemistry","score_opus":0.018334838071565357,"score_gpt":0.3544517604242383,"score_spread":0.336116922352673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168023789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746823,0.0013843073,0.0000071540017,0.000120086384,0.00023642834,0.0006264296,0.00005585232,0.000003885505,0.00009763498],"genre_scores_gemma":[0.99923795,0.00021459337,0.00009788149,0.0002797733,0.00008107901,0.000032723972,0.000016243952,0.000021638089,0.000018124712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870163,0.0001772912,0.00039062797,0.00026447524,0.00015985586,0.00030613109],"domain_scores_gemma":[0.9991933,0.000038376766,0.00030386914,0.00020844181,0.00015310972,0.00010289534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027423038,0.00018423915,0.0003538533,0.000056486722,0.000044813976,0.0000034346715,0.0001624573,0.00009039967,0.000011495296],"category_scores_gemma":[0.00004474143,0.00013921333,0.000035130426,0.00012625741,0.0002239114,0.000016143322,0.00017856587,0.00012629556,2.840626e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068931966,0.008544546,0.40271944,0.00009394246,0.00025388072,0.0000058468363,0.0010111706,0.00021429037,0.48032713,0.000008502253,0.00048191796,0.09944615],"study_design_scores_gemma":[0.027955083,0.018349364,0.19160405,0.00007531784,0.000122001125,0.0000069138932,0.0003368003,0.00009551393,0.7555194,0.000009963773,0.0055798003,0.0003458241],"about_ca_topic_score_codex":0.000033065204,"about_ca_topic_score_gemma":0.00004143925,"teacher_disagreement_score":0.27519223,"about_ca_system_score_codex":0.000017363336,"about_ca_system_score_gemma":0.000081463455,"threshold_uncertainty_score":0.5676955},"labels":[],"label_agreement":null},{"id":"W2168063883","doi":"10.1093/annonc/mdt571","title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Pharmaceuticals; Amgen; Astellas Pharma; Association for Federal Information Resources Management","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Placebo; Internal medicine; Population; Docetaxel; Adverse effect; Progression-free survival; Urology; Confidence interval; Oncology; Androgen receptor; Chemotherapy; Cancer; Pathology","score_opus":0.058052921820775295,"score_gpt":0.3790785064417077,"score_spread":0.3210255846209324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168063883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805026,0.0002495416,0.0000023842103,0.015444619,0.00007815722,0.002909887,0.00066296436,0.000016098998,0.00013371586],"genre_scores_gemma":[0.9979202,0.0001425712,0.000094855684,0.0004538099,0.000099057346,0.0004555304,0.0003852526,0.000024000676,0.00042472148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805665,0.00034365,0.00051167386,0.00034389657,0.0003659364,0.00037816676],"domain_scores_gemma":[0.99797124,0.00079025124,0.00037151048,0.00035683773,0.0004015779,0.00010857004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718435,0.00022412754,0.00062277936,0.000060669256,0.00011311211,0.00002234833,0.00014097596,0.00007648967,0.00004204429],"category_scores_gemma":[0.00017938047,0.0000908219,0.00007068413,0.00029004875,0.00031598296,0.0000931803,0.000026372454,0.00025891347,0.0000025513107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8480211,0.003980683,0.028717762,0.00004139901,0.0015494408,0.00005474835,0.005229273,0.000021822983,0.0046904506,0.000015008503,0.0039389716,0.10373934],"study_design_scores_gemma":[0.79711103,0.105419666,0.041725196,0.00032011973,0.000700726,0.0000029017017,0.0018115062,0.00015417353,0.032088976,0.00004721239,0.02022964,0.00038882872],"about_ca_topic_score_codex":0.0035825688,"about_ca_topic_score_gemma":0.006076887,"teacher_disagreement_score":0.10335051,"about_ca_system_score_codex":0.000100054196,"about_ca_system_score_gemma":0.000592367,"threshold_uncertainty_score":0.54157966},"labels":[],"label_agreement":null},{"id":"W2168115952","doi":"10.1093/annonc/mdq665","title":"Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Breast cancer; Psychosocial; Fertility; Referral; Premature Menopause; Mammography; Menopause; Cancer; Fertility preservation; Mastectomy; Gynecology; Obstetrics; Young adult; Family medicine; Population; Internal medicine; Psychiatry","score_opus":0.026832447532053428,"score_gpt":0.33833367123860214,"score_spread":0.3115012237065487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168115952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821186,0.00024824563,0.00016960931,0.00009687734,0.000043599102,0.0000945675,0.00007776661,0.0000024510969,0.0010549952],"genre_scores_gemma":[0.9991501,0.00046344433,0.00023370543,0.000031812277,0.000028246825,0.00005376865,0.00000724905,0.000009199293,0.000022484464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943024,0.00005536998,0.00016476143,0.00015690071,0.000044613324,0.00014809174],"domain_scores_gemma":[0.9994978,0.000012212453,0.00013617649,0.00012864807,0.00018982742,0.000035388955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001527771,0.000073376585,0.00015266298,0.00006905681,0.00001642681,0.000001569987,0.00006186062,0.00009372618,0.000046662117],"category_scores_gemma":[0.000016383381,0.000064230255,0.000024127428,0.00013166598,0.00015584475,0.0000051110446,0.000025261323,0.000045420213,3.320291e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001514156,0.00026086633,0.74256647,0.000031841373,0.00028314994,0.0000031756665,0.002308062,0.00065425975,0.1905969,0.0000133299045,0.00019443108,0.06157339],"study_design_scores_gemma":[0.00053665694,0.0017943411,0.9521961,0.0000067887117,0.00000479079,0.00004777306,0.00019225827,0.000024151785,0.044897314,0.000081364684,0.00014265846,0.00007579772],"about_ca_topic_score_codex":0.0014569105,"about_ca_topic_score_gemma":0.006675284,"teacher_disagreement_score":0.20962965,"about_ca_system_score_codex":0.000054087905,"about_ca_system_score_gemma":0.00029371565,"threshold_uncertainty_score":0.37249652},"labels":[],"label_agreement":null},{"id":"W2168153626","doi":"10.1093/annonc/mdg497","title":"Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Oncology; Breast cancer; Adjuvant chemotherapy; Internal medicine; Chemotherapy; Adjuvant; Cancer","score_opus":0.034513500918348754,"score_gpt":0.35602344184962254,"score_spread":0.3215099409312738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168153626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776186,0.0006461887,0.00004890745,0.016937785,0.00024496883,0.0007228455,0.00013173498,0.000019314835,0.0036296928],"genre_scores_gemma":[0.98783326,0.0019243967,0.000080892045,0.0072495393,0.0001335661,0.00038543556,0.000007999954,0.000025189298,0.0023597344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872196,0.000042124047,0.00031233346,0.00024819488,0.00013745273,0.00053795986],"domain_scores_gemma":[0.99922884,0.000109160814,0.00013359252,0.00010594221,0.00031377032,0.00010872229],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023707395,0.00014529344,0.00046701584,0.0001699008,0.00004634374,0.0000021828475,0.000028402765,0.0001119664,0.003461683],"category_scores_gemma":[0.000058929483,0.00013392072,0.0000898485,0.00018962992,0.000112107824,0.000046561236,0.000015424415,0.00013627778,0.000011147393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03340598,0.0054391874,0.60252553,0.0010595145,0.0032006374,0.00011944534,0.012761451,0.00013957583,0.015750062,0.0006772699,0.15664916,0.1682722],"study_design_scores_gemma":[0.016207438,0.0015926403,0.9113224,0.00012468058,0.00004038358,0.00005412153,0.0015774183,0.000018519464,0.008121523,0.00044640974,0.06033661,0.00015784119],"about_ca_topic_score_codex":0.00009174694,"about_ca_topic_score_gemma":0.00007529077,"teacher_disagreement_score":0.30879688,"about_ca_system_score_codex":0.00042922836,"about_ca_system_score_gemma":0.00040904415,"threshold_uncertainty_score":0.9974493},"labels":[],"label_agreement":null},{"id":"W2168302323","doi":"10.1093/annonc/mdq254","title":"Severe novel influenza A (H1N1) infection in cancer patients","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Lung cancer; Autopsy; Cancer; Respiratory failure; Internal medicine; Mechanical ventilation; Diffuse alveolar damage; Intensive care unit; Respiratory distress; Lung; Surgery; Acute respiratory distress","score_opus":0.20484188841347256,"score_gpt":0.5002352257172921,"score_spread":0.2953933373038195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168302323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867102,0.00011157598,0.0000014386618,0.0012750366,0.0002584304,0.00034106462,0.000020981255,0.000016660439,0.011264597],"genre_scores_gemma":[0.9948598,0.0003855181,0.0001557166,0.0042509167,0.00011812058,0.00008564541,0.0000043471678,0.000012242015,0.00012765657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893916,0.000034410332,0.00031863185,0.00017200303,0.00022044068,0.00031537065],"domain_scores_gemma":[0.9989124,0.00012034877,0.000119057404,0.00016471367,0.00059813133,0.000085372754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032266573,0.00010281978,0.0003503543,0.00025153958,0.00003561425,0.0000028814982,0.00006432559,0.00019000591,0.00019216952],"category_scores_gemma":[0.0010080356,0.000088384746,0.00006245575,0.00026337188,0.00016690014,0.00009374791,0.00009123227,0.00047232962,0.00003189262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005586941,0.001171956,0.94253814,0.00008553654,0.000080775935,0.0000066770012,0.00051783584,0.000017039643,0.011993036,0.00015964241,0.0038405494,0.039030116],"study_design_scores_gemma":[0.0027052832,0.0014072387,0.7967619,0.00003925966,0.00001094761,0.0000039083106,0.000012703353,0.000017885974,0.003420045,0.00006777324,0.1954809,0.00007217335],"about_ca_topic_score_codex":0.0030923309,"about_ca_topic_score_gemma":0.004294337,"teacher_disagreement_score":0.19164035,"about_ca_system_score_codex":0.000061053586,"about_ca_system_score_gemma":0.0003204706,"threshold_uncertainty_score":0.46747},"labels":[],"label_agreement":null},{"id":"W2168681651","doi":"10.1093/annonc/mdj030","title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; CHOP; International Prognostic Index; Cohort; Internal medicine; Radiation therapy; Lymphoma; Diffuse large B-cell lymphoma; Oncology; Chemotherapy regimen; Stage (stratigraphy); Chemotherapy; Surgery","score_opus":0.07205577914638595,"score_gpt":0.3388548055384577,"score_spread":0.26679902639207176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168681651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671407,0.0016631221,0.0000058467754,0.0020819681,0.00010060142,0.0002827522,0.000020183805,0.000011015306,0.02869385],"genre_scores_gemma":[0.9958247,0.0003675337,0.00047488319,0.0025592817,0.000075794196,0.00006755875,0.00001246144,0.0000070539318,0.0006107247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987614,0.00006426183,0.0005035781,0.00018813876,0.00020858264,0.00027401862],"domain_scores_gemma":[0.9992158,0.00016204623,0.00019594627,0.00021562229,0.00013372109,0.00007687478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000299097,0.00008212659,0.00048031268,0.000036695463,0.000085271764,0.000021007841,0.00012170845,0.0001038518,0.00016732639],"category_scores_gemma":[0.00011765055,0.00008302618,0.00010164036,0.00019366542,0.00024362915,0.000091387104,0.00006691591,0.000053450494,0.000012139062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017020288,0.017307604,0.79183185,0.000106174535,0.000046961028,0.00039957682,0.0011764053,0.000008055082,0.00082193036,0.00009920777,0.010335851,0.17769615],"study_design_scores_gemma":[0.009817917,0.002129141,0.8294996,0.00013676188,0.00004127545,0.00028629598,0.00044396223,0.00002329572,0.0047468883,0.00003722018,0.15274061,0.00009702694],"about_ca_topic_score_codex":0.0070974636,"about_ca_topic_score_gemma":0.023267737,"teacher_disagreement_score":0.17759913,"about_ca_system_score_codex":0.00018652507,"about_ca_system_score_gemma":0.00037001792,"threshold_uncertainty_score":0.99951434},"labels":[],"label_agreement":null},{"id":"W2168932004","doi":"10.1093/annonc/mdu300.1","title":"Emerging Molecular Targets in Gynaecological Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gynaecological cancer; Cancer; Oncology; Internal medicine","score_opus":0.056015479729446586,"score_gpt":0.40925738928241695,"score_spread":0.35324190955297036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168932004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9137861,0.0022986874,0.00008989105,0.04634322,0.00026901398,0.00024342228,0.000004136656,0.000016271744,0.036949273],"genre_scores_gemma":[0.99342513,0.0008170632,0.0004921082,0.005046022,0.00006337076,0.00008287423,0.0000045501397,0.0000076853,0.00006119831],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99923027,0.00006952509,0.000217731,0.00017731996,0.000090213616,0.00021496402],"domain_scores_gemma":[0.9995472,0.00009903053,0.00007604743,0.00013144706,0.00007056402,0.00007573543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022172579,0.00008069992,0.00036951396,0.000080578175,0.000012140319,0.0000014499132,0.00004778256,0.0001037389,0.00078700203],"category_scores_gemma":[0.000103972,0.0000645169,0.00007411038,0.00010775356,0.000049287628,0.000017784443,0.000026391323,0.00009289466,0.0000145414815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018728436,0.0016434318,0.19150919,0.000059589456,0.0001771156,0.00040295027,0.00024067007,0.00019820224,0.0017609653,0.006329806,0.0066826926,0.7908081],"study_design_scores_gemma":[0.0034303304,0.0040913126,0.6710009,0.000054536296,0.000065243774,0.000012042111,0.000038803948,0.00022282901,0.019598532,0.0016177145,0.2997483,0.000119439566],"about_ca_topic_score_codex":0.0001964302,"about_ca_topic_score_gemma":0.00012063077,"teacher_disagreement_score":0.79068863,"about_ca_system_score_codex":0.00006422591,"about_ca_system_score_gemma":0.00011533236,"threshold_uncertainty_score":0.86171204},"labels":[],"label_agreement":null},{"id":"W2169159750","doi":"10.1093/annonc/mdm526","title":"Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Oxaliplatin; Chemotherapy; Internal medicine; Chemotherapy regimen; Oncology; Cisplatin; Germ cell tumors; Regimen; Gastroenterology; Paclitaxel; Combination chemotherapy; Surgery; Urology; Cancer; Colorectal cancer","score_opus":0.024404324933117217,"score_gpt":0.34382447946669764,"score_spread":0.3194201545335804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169159750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969368,0.0001704815,0.000005323035,0.000094934585,0.000027089314,0.0026635653,0.000012178667,0.0000122084775,0.00007740166],"genre_scores_gemma":[0.9994672,0.000011554079,0.00015495632,0.0002052952,0.000011972127,0.00007298874,0.000010944295,0.000027355321,0.000037765483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998509,0.00013392721,0.00045402598,0.00028696356,0.00038748255,0.00022862283],"domain_scores_gemma":[0.9984561,0.00028330684,0.00052617176,0.00031259868,0.00032245184,0.00009934656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029537172,0.00020190437,0.00052121683,0.00012973035,0.000049189934,0.000004316878,0.000078918776,0.00006717734,0.00001655043],"category_scores_gemma":[0.0001132579,0.000108693814,0.000036454334,0.00032104104,0.00012337587,0.00007001413,0.000033968307,0.00014660168,3.6107684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052781394,0.03400999,0.9510498,0.0000786401,0.00027576776,0.00012925739,0.0029413446,0.000008695829,0.00013689074,0.0000043203795,0.000016931692,0.006070195],"study_design_scores_gemma":[0.039085064,0.038910132,0.91996485,0.00015621631,0.00026033574,0.0000046095543,0.0013496054,0.00003147733,0.000100291436,0.000010565233,0.000019024841,0.00010783649],"about_ca_topic_score_codex":0.00089056446,"about_ca_topic_score_gemma":0.0013147121,"teacher_disagreement_score":0.033806924,"about_ca_system_score_codex":0.00006026361,"about_ca_system_score_gemma":0.00014830867,"threshold_uncertainty_score":0.44324052},"labels":[],"label_agreement":null},{"id":"W2169278779","doi":"10.1093/annonc/mdv188","title":"Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Institute of Cancer Research; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; MEK inhibitor; Medicine; Growth inhibition; Cell growth; Cancer research; Pharmacology; Cell biology; Biology; Signal transduction; Biochemistry","score_opus":0.13088846515186378,"score_gpt":0.3920301638741505,"score_spread":0.26114169872228676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169278779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453765,0.00092267856,0.0005755261,0.00026094588,0.00015804754,0.0000852075,0.000004153198,0.0000021344604,0.0034536598],"genre_scores_gemma":[0.9987284,0.00033302064,0.0006541242,0.000108497305,0.00007800263,0.0000032989892,0.00003677896,0.000004966685,0.000052928648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991855,0.00011912568,0.00041577255,0.00013026038,0.00007738201,0.0000719474],"domain_scores_gemma":[0.9991586,0.000051002826,0.00025266252,0.00011351642,0.00035685053,0.00006734325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040710653,0.00006041824,0.00022558116,0.00004936803,0.000014063373,0.0000013702663,0.00007111689,0.00018557011,0.0000017226887],"category_scores_gemma":[0.00025631502,0.000055736396,0.000057455647,0.000047967063,0.00017344412,0.0000043802834,0.000055176177,0.000047162088,8.825076e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037102707,0.0015418235,0.0120031,0.00010750347,0.00019020907,0.000005023762,0.0016249502,0.00005857922,0.9217725,0.009758394,0.010269145,0.042297736],"study_design_scores_gemma":[0.0015988573,0.0078080497,0.0026743507,0.00002079937,0.000028163131,0.000003809598,0.00030002894,0.00008759546,0.9351786,0.0044457344,0.04775152,0.00010250158],"about_ca_topic_score_codex":0.00003658511,"about_ca_topic_score_gemma":0.0000630397,"teacher_disagreement_score":0.042195234,"about_ca_system_score_codex":0.000002461899,"about_ca_system_score_gemma":0.00018147213,"threshold_uncertainty_score":0.22728643},"labels":[],"label_agreement":null},{"id":"W2169351454","doi":"10.1093/annonc/mdv182","title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Tolerability; Clinical trial; Internal medicine; Regimen; MEDLINE; Oncology","score_opus":0.33926319126792126,"score_gpt":0.5585464306597261,"score_spread":0.21928323939180483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169351454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038793348,0.99193555,8.215775e-7,0.00037408818,0.0007814871,0.005647202,0.00003354868,0.000012529042,0.0008268476],"genre_scores_gemma":[0.0003068514,0.99888176,0.000058091122,0.00013819354,0.00008027522,0.0002009501,0.00011288898,0.00004585079,0.00017514123],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9431364,0.005513553,0.050073028,0.0004287443,0.0005197278,0.0003285604],"domain_scores_gemma":[0.93317944,0.0020703159,0.062756464,0.001050698,0.0008246269,0.00011846349],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11638736,0.00044787323,0.02276523,0.00049805234,0.000011927089,0.0000013092324,0.00031953838,0.0010042222,0.00015896643],"category_scores_gemma":[0.051485706,0.0003038167,0.007784983,0.0008677396,0.00033974912,0.000042719254,0.00013315697,0.00072811573,0.0000082451925],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005036207,0.0006701205,0.000008265635,0.7606428,0.0025925334,0.000081771504,0.00009041876,8.686374e-8,0.00004381836,0.00000607287,0.00052809267,0.23483239],"study_design_scores_gemma":[0.0024823037,0.0027222633,0.000031586405,0.8673376,0.0050948444,0.00027757118,0.000100669124,9.0945184e-7,0.00010213708,0.000014769307,0.12163946,0.00019589161],"about_ca_topic_score_codex":0.00023373943,"about_ca_topic_score_gemma":0.000007109828,"teacher_disagreement_score":0.23463649,"about_ca_system_score_codex":0.00022792492,"about_ca_system_score_gemma":0.0036782487,"threshold_uncertainty_score":0.9999414},"labels":[],"label_agreement":null},{"id":"W2169767481","doi":"10.1023/a:1008336607135","title":"NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94)","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"National Cancer Institute","keywords":"Medicine; Gemcitabine; Anaplastic astrocytoma; Internal medicine; Regimen; Glioma; Toxicity; Phases of clinical research; Chemotherapy; Performance status; Chemotherapy regimen; Gastroenterology; Surgery; Adjuvant therapy; Oncology; Astrocytoma","score_opus":0.04273151727747712,"score_gpt":0.36115588087923667,"score_spread":0.3184243636017595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169767481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961086,0.00017861527,1.6711722e-7,0.00082390197,0.00003521952,0.0008717355,0.000020277756,0.000009381862,0.0019521135],"genre_scores_gemma":[0.9995102,0.000035537527,0.00004479456,0.00023091702,0.000020342019,0.00006325164,0.000028169663,0.000014533551,0.000052228344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868166,0.00007534785,0.00047751257,0.00024484558,0.00026195546,0.00025868576],"domain_scores_gemma":[0.9991532,0.00006150967,0.00017213472,0.0003016045,0.00021086194,0.000100685276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017055438,0.00015156553,0.0006600125,0.000244094,0.000029004554,0.0000016058092,0.00008127275,0.00008339499,0.00051646435],"category_scores_gemma":[0.000026918184,0.000106024614,0.00006036518,0.00034609315,0.000071305,0.000046663845,0.000031485746,0.0000764781,0.000010508622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069931573,0.13766967,0.67827034,0.00004708383,0.00049671525,0.00083539373,0.0018291317,0.000028388451,0.0007172361,0.000054801636,0.0016271957,0.17143089],"study_design_scores_gemma":[0.04751422,0.14817059,0.79232293,0.00010857477,0.00017009642,0.000012149506,0.00027889365,0.000007673291,0.008011718,0.000029774694,0.0032599536,0.00011340099],"about_ca_topic_score_codex":0.00032471932,"about_ca_topic_score_gemma":0.00021657509,"teacher_disagreement_score":0.17131749,"about_ca_system_score_codex":0.00003452635,"about_ca_system_score_gemma":0.00010026217,"threshold_uncertainty_score":0.5654923},"labels":[],"label_agreement":null},{"id":"W2169962529","doi":"10.1093/annonc/mds538","title":"A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Hôtel-Dieu de Québec","funders":"Medical Research Council","keywords":"Nomogram; Medicine; Confidence interval; Oncology; Ovarian cancer; Internal medicine; Chemotherapy; Multivariate analysis; Multivariate statistics; Metastasis; Cancer; Statistics","score_opus":0.051415355228568674,"score_gpt":0.3561148298264661,"score_spread":0.3046994745978974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169962529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905166,0.00019194158,0.000013216276,0.0043527014,0.00041490173,0.0011701116,0.000100230376,0.000015561802,0.0032247363],"genre_scores_gemma":[0.99773866,0.000076489836,0.00055181916,0.0010884806,0.00019350187,0.00024465736,0.000052918662,0.00001901806,0.00003447655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987079,0.000087502434,0.00029667802,0.00023464626,0.00023773448,0.00043551924],"domain_scores_gemma":[0.9990203,0.00015983204,0.00013801496,0.00017778973,0.00025179994,0.00025229043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021560933,0.00016245361,0.00049689505,0.00013304921,0.000020530342,0.000003857563,0.000046165795,0.00009856787,0.000105155996],"category_scores_gemma":[0.00009444507,0.00012225226,0.000056851375,0.00020262004,0.000050228755,0.00007138833,0.000038204456,0.00013520973,0.000013856309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019188863,0.0035365399,0.9100466,0.000034801607,0.00023308682,0.00002401299,0.00093947345,0.000015256329,0.0000047321514,0.00021283144,0.0016333256,0.08140045],"study_design_scores_gemma":[0.0050124354,0.009215334,0.97430146,0.0002868817,0.00011263487,0.0000030416259,0.000043154752,0.000008126818,0.0001839913,0.000013297388,0.010706155,0.00011348812],"about_ca_topic_score_codex":0.00055438303,"about_ca_topic_score_gemma":0.00048753776,"teacher_disagreement_score":0.08128696,"about_ca_system_score_codex":0.00017452813,"about_ca_system_score_gemma":0.00025196775,"threshold_uncertainty_score":0.49853024},"labels":[],"label_agreement":null},{"id":"W2170049466","doi":"10.1093/annonc/mdv191","title":"Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Jewish General Hospital","funders":"Fondation ARC pour la Recherche sur le Cancer; Novartis; Pfizer; Eli Lilly and Company","keywords":"Medicine; Clinical trial; Personalized medicine; Precision medicine; Cancer; Medical physics; Bioinformatics; Internal medicine; Pathology","score_opus":0.46433011053062706,"score_gpt":0.4587322569215321,"score_spread":0.005597853609094983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170049466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8975724,0.09578599,0.000017619448,0.0031138733,0.00046104184,0.00037624224,0.000058257552,0.000004640408,0.002609923],"genre_scores_gemma":[0.95102423,0.0458406,0.0005174915,0.0009197887,0.0015267828,0.00009608293,0.00003249222,0.000019615736,0.00002294065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827075,0.00051326904,0.0005094655,0.00036744392,0.000088330395,0.00025073226],"domain_scores_gemma":[0.99826574,0.0006616081,0.00045052066,0.00015397731,0.00039444052,0.00007368376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017399151,0.00015983134,0.0006191676,0.00005981275,0.00003336334,0.000012668123,0.000107781656,0.0001903955,0.000029764044],"category_scores_gemma":[0.0023122896,0.00014836407,0.00007141379,0.00013452816,0.00022551246,0.0000072907706,0.000085191205,0.00013731944,4.6125814e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13000548,0.0015150728,0.011679014,0.00004417019,0.0022746443,0.00005231282,0.050077453,0.00074700563,0.08799167,0.0073368438,0.017493157,0.6907832],"study_design_scores_gemma":[0.21925974,0.021068528,0.0063892948,0.00035340548,0.00014345092,0.000018805966,0.107689865,0.0001613366,0.07072795,0.014314459,0.55821174,0.0016614064],"about_ca_topic_score_codex":0.0006132595,"about_ca_topic_score_gemma":0.0012146214,"teacher_disagreement_score":0.6891218,"about_ca_system_score_codex":0.00003040177,"about_ca_system_score_gemma":0.00058723637,"threshold_uncertainty_score":0.6050111},"labels":[],"label_agreement":null},{"id":"W2170066063","doi":"10.1093/annonc/mdp250","title":"Utility of adjuvant systemic therapy in melanoma","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Melanoma; Population; Clinical trial; Disease; Stage (stratigraphy); Chemotherapy; Immunology; Surgery; Cancer research","score_opus":0.1734020847816883,"score_gpt":0.43372853647608267,"score_spread":0.2603264516943944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170066063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089190755,0.9753862,0.000004226235,0.00018131975,0.00022791848,0.0012296579,0.000014118947,0.000019047415,0.022045605],"genre_scores_gemma":[0.01124636,0.98774123,0.000033244727,0.00023173174,0.0000721032,0.000029623207,0.000024394285,0.000017698549,0.0006036172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979343,0.00029543825,0.0010997888,0.00027978508,0.00017176753,0.00021890968],"domain_scores_gemma":[0.9985242,0.00015361309,0.00068237004,0.00044004046,0.000129209,0.00007058015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055283745,0.00023197391,0.0029788448,0.00043661517,0.000009115559,0.0000015392304,0.00015216488,0.00039601463,0.00022419912],"category_scores_gemma":[0.00007729976,0.00017673256,0.00048139272,0.0002877253,0.00007307182,0.00001311264,0.000037532733,0.00027629038,0.000022124423],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015472625,0.0004654602,0.00002952592,0.008119636,0.00019188091,0.00021707153,0.000047386297,9.5884545e-8,0.00000489564,0.0000797642,0.0019158534,0.9887737],"study_design_scores_gemma":[0.0006307542,0.0038251206,0.00023436907,0.005734324,0.00018513447,0.00079703383,0.000035717687,0.0000030627025,0.000023426917,0.000034689936,0.9883885,0.0001078754],"about_ca_topic_score_codex":0.00007232599,"about_ca_topic_score_gemma":0.000039998766,"teacher_disagreement_score":0.9886658,"about_ca_system_score_codex":0.00004638884,"about_ca_system_score_gemma":0.00040813777,"threshold_uncertainty_score":0.7206945},"labels":[],"label_agreement":null},{"id":"W2170362988","doi":"10.1093/annonc/mdl316","title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Mantle cell lymphoma; Bortezomib; Discontinuation; Internal medicine; Adverse effect; Toxicity; Clinical trial; Surgery; Lymphoma; Multiple myeloma","score_opus":0.23859705678650286,"score_gpt":0.5021967957604048,"score_spread":0.2635997389739019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170362988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914647,0.0005512808,5.532982e-7,0.0024402034,0.0006344119,0.0013136591,0.00011472537,0.0000028753163,0.0034775927],"genre_scores_gemma":[0.9984683,0.00020805969,0.000025347583,0.0005884864,0.00036411468,0.00018467967,0.000025282496,0.0000072450994,0.00012849923],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969891,0.0004907407,0.0016926501,0.00021279512,0.00042305465,0.00019169533],"domain_scores_gemma":[0.9975718,0.0010364022,0.000878169,0.00017390471,0.0002780226,0.00006168616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026594102,0.00012758268,0.0011835747,0.000107399035,0.000041661056,0.0000016889338,0.00012292323,0.00012784565,0.00006618423],"category_scores_gemma":[0.00055680465,0.00008214933,0.00017952322,0.00020436762,0.00014379207,0.000037652444,0.000053539326,0.000069876216,4.4905525e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12617126,0.4039244,0.115131944,0.00015261701,0.0019393819,0.00050722284,0.0011562922,0.00017053795,0.00093431555,0.0018915974,0.1958363,0.15218411],"study_design_scores_gemma":[0.6430099,0.053904016,0.21484503,0.00008096424,0.0005166858,0.000010928028,0.00045511842,0.000056634733,0.005065845,0.00030449164,0.08159461,0.00015576444],"about_ca_topic_score_codex":0.35061225,"about_ca_topic_score_gemma":0.48184562,"teacher_disagreement_score":0.51683867,"about_ca_system_score_codex":0.00020015458,"about_ca_system_score_gemma":0.0035807996,"threshold_uncertainty_score":0.6537121},"labels":[],"label_agreement":null},{"id":"W2170649858","doi":"10.1093/annonc/mdm527","title":"Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Paclitaxel; Oncology; Hazard ratio; Metastatic breast cancer; Internal medicine; Taxane; Breast cancer; Population; Confidence interval; Chemotherapy; Proportional hazards model; Survival analysis; Cancer","score_opus":0.11243892965338927,"score_gpt":0.48361352427535886,"score_spread":0.3711745946219696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170649858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711794,0.00025167406,0.000041525233,0.00093510206,0.0000581197,0.0013431838,0.00005457761,0.000007155846,0.00019071368],"genre_scores_gemma":[0.99920064,0.000028949156,0.0001554222,0.00038314273,0.00001897587,0.00011376277,0.00007908449,0.000011407344,0.000008611952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896854,0.0001856824,0.00023718001,0.00020561086,0.00020666281,0.00019632367],"domain_scores_gemma":[0.9989561,0.00041077187,0.00015845244,0.00007969737,0.00030355278,0.000091433765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008814515,0.00012644763,0.00046085104,0.00017066501,0.000027769034,0.0000030969463,0.000020624837,0.000053646916,0.000053406697],"category_scores_gemma":[0.000028807714,0.00008903035,0.000019222505,0.00018118182,0.00009838164,0.00006417831,0.000008806765,0.00008806041,3.0986791e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008900711,0.00085848005,0.9347513,0.00011357712,0.00015542627,0.000014971333,0.0000824191,0.000086693624,0.0000355694,0.000027219885,0.000009556663,0.0549641],"study_design_scores_gemma":[0.02064289,0.0045187226,0.97393405,0.00007051061,0.00034521284,0.000010704265,0.000039478662,0.00016281706,0.000063563544,0.000032814,0.00009210482,0.00008710514],"about_ca_topic_score_codex":0.0016950442,"about_ca_topic_score_gemma":0.0038816675,"teacher_disagreement_score":0.054876994,"about_ca_system_score_codex":0.00013927302,"about_ca_system_score_gemma":0.00020373375,"threshold_uncertainty_score":0.36305523},"labels":[],"label_agreement":null},{"id":"W2170805911","doi":"10.1093/annonc/mdq469","title":"Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Cancer Research UK","keywords":"Sunitinib; Medicine; Hazard ratio; Internal medicine; Univariate analysis; Oncology; Haematopoiesis; Progenitor cell; Growth factor; CD34; Renal cell carcinoma; Gastroenterology; Confidence interval; Multivariate analysis; Stem cell; Receptor; Biology","score_opus":0.05701477999175684,"score_gpt":0.3329043085578549,"score_spread":0.27588952856609805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170805911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703693,0.000043030883,0.0000019514448,0.00074318366,0.00003621435,0.0013952007,0.000104973165,0.000037228463,0.00060128665],"genre_scores_gemma":[0.9981496,0.000005327687,0.00064836757,0.0005035352,0.000025571086,0.00023446657,0.00015453582,0.00005673253,0.00022191755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979438,0.00020699551,0.0005113747,0.00037779112,0.00047347232,0.0004865504],"domain_scores_gemma":[0.99777246,0.00023294767,0.0006073214,0.0003317717,0.000795177,0.0002603182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002650562,0.00033472976,0.0011035285,0.00026458618,0.000043118278,0.0000089405485,0.0001159273,0.0001518439,0.00017106296],"category_scores_gemma":[0.00010530949,0.00019742287,0.000074088886,0.0004765831,0.00027880343,0.000077939454,0.000023737719,0.00039535272,0.000008298287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005985249,0.0029346019,0.9854576,0.00010326866,0.0007629209,0.0010687329,0.00016509257,0.000016050783,0.002596786,0.0000052261403,0.0001746646,0.0007298263],"study_design_scores_gemma":[0.0158633,0.014428808,0.9212464,0.00032643773,0.0007334706,0.00004967968,0.0001178804,0.000019287972,0.046770234,0.000005116786,0.0001972787,0.00024211993],"about_ca_topic_score_codex":0.001107615,"about_ca_topic_score_gemma":0.0043280353,"teacher_disagreement_score":0.06421119,"about_ca_system_score_codex":0.00013994721,"about_ca_system_score_gemma":0.0005372501,"threshold_uncertainty_score":0.80506706},"labels":[],"label_agreement":null},{"id":"W2170903770","doi":"10.1093/annonc/mdp016","title":"A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Breast cancer; Axillary Lymph Node Dissection; Sentinel lymph node; Biopsy; Lymph node; Sentinel node; Axillary Dissection; Oncology; Radiology; Internal medicine; Cancer","score_opus":0.046732244733900696,"score_gpt":0.38908018533178523,"score_spread":0.34234794059788454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170903770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688566,0.00009921585,0.00002517005,0.0019784288,0.00017207791,0.0005047378,0.00017932022,0.000008845547,0.0001465414],"genre_scores_gemma":[0.9976115,0.00007842268,0.000101429396,0.0019354135,0.00009257801,0.0000971691,0.00005585186,0.000015108762,0.0000125045635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982726,0.00017122593,0.0006005678,0.00045541598,0.00018242942,0.0003177448],"domain_scores_gemma":[0.99889195,0.000034295368,0.0002574027,0.0002921747,0.00039701213,0.00012714173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002463748,0.00021510967,0.0006107205,0.000120796554,0.00004935429,0.0000057341445,0.00017546694,0.00007441968,0.000014384242],"category_scores_gemma":[0.00012907751,0.00018673591,0.000092157024,0.0002534693,0.00004363909,0.00000840578,0.00017357258,0.000041093757,0.0000032145558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037966515,0.003552059,0.9803605,0.00003219833,0.0002625087,0.000005427283,0.00042819453,0.00016923995,0.008497142,0.0000011311388,0.00023373509,0.0026612321],"study_design_scores_gemma":[0.0029293278,0.00028001683,0.99369687,0.000050887877,0.000036894424,0.0000046919904,0.0010403622,0.000008203728,0.0017236026,0.0000022318259,0.000047902224,0.00017898652],"about_ca_topic_score_codex":0.0032435528,"about_ca_topic_score_gemma":0.00050189754,"teacher_disagreement_score":0.013336412,"about_ca_system_score_codex":0.0000958576,"about_ca_system_score_gemma":0.00013845834,"threshold_uncertainty_score":0.76148695},"labels":[],"label_agreement":null},{"id":"W2171208631","doi":"10.1093/annonc/mdl410","title":"Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre","funders":"National Comprehensive Cancer Network","keywords":"Medicine; Aromatase inhibitor; Aromatase; Adjuvant; Breast cancer; Oncology; Postmenopausal women; Internal medicine; Gynecology; Cancer","score_opus":0.029721493389397186,"score_gpt":0.3534447439547189,"score_spread":0.32372325056532175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171208631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97134477,0.0008358199,0.022361886,0.0013654358,0.00016681361,0.0018190058,0.0018394477,0.000012180625,0.00025462962],"genre_scores_gemma":[0.9915551,0.000062864405,0.002333171,0.00049183884,0.00049722684,0.0046672993,0.0003001348,0.000032471195,0.000059900754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899805,0.00003524935,0.00023389813,0.00031542542,0.00007055594,0.00034685226],"domain_scores_gemma":[0.9991398,0.000042494703,0.00012485063,0.00018533414,0.00045723378,0.000050272447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020670539,0.00015352391,0.00025152788,0.00004953628,0.00007167534,0.000013701832,0.00011844978,0.00015634431,0.000009155273],"category_scores_gemma":[0.000015233383,0.00013477822,0.000048684757,0.00006061227,0.00010774488,0.000010778281,0.000033216296,0.000045552162,4.7464013e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009464523,0.00073786377,0.0002961286,0.0002495595,0.00051796495,0.0000049654714,0.00031006406,0.15733139,0.70348555,0.001366117,0.024940824,0.10129505],"study_design_scores_gemma":[0.013584035,0.03335502,0.003238726,0.00012086987,0.00024285715,0.00017045818,0.0027884343,0.016908027,0.6479085,0.01156176,0.2687682,0.001353115],"about_ca_topic_score_codex":0.00014036546,"about_ca_topic_score_gemma":0.00048091053,"teacher_disagreement_score":0.24382737,"about_ca_system_score_codex":0.00008686191,"about_ca_system_score_gemma":0.00072986283,"threshold_uncertainty_score":0.54960966},"labels":[],"label_agreement":null},{"id":"W2171584647","doi":"10.1093/annonc/mdv269","title":"Indicators of integration of oncology and palliative care programs: an international consensus","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Medicine; Palliative care; Oncology; Consensus conference; Radiation oncology; Medical physics; Internal medicine; Family medicine; Intensive care medicine; Nursing; Radiation therapy","score_opus":0.40111607245708075,"score_gpt":0.5444653474502715,"score_spread":0.14334927499319078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171584647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98174083,0.0013396943,0.00003880958,0.001358205,0.00016317549,0.00023651858,0.000047154135,0.000008161357,0.015067467],"genre_scores_gemma":[0.9937229,0.00079803966,0.0051081455,0.00016085838,0.000059861268,0.000010822918,0.00010725694,0.0000072314288,0.000024885547],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989076,0.00014445347,0.00048714466,0.00015004649,0.00019700995,0.0001137374],"domain_scores_gemma":[0.9975986,0.00023253317,0.0005828864,0.00013155815,0.0013409241,0.00011350343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031572173,0.00009653529,0.0005814448,0.00023893337,0.000007659211,0.0000010354164,0.00009534561,0.00019321612,0.000016089853],"category_scores_gemma":[0.0007455728,0.00008062104,0.00006306262,0.00015551636,0.000545125,0.000044282606,0.000041694988,0.00011357395,7.502414e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020339037,0.0011805509,0.4754894,0.00022683074,0.0004767469,0.000031422358,0.05235818,0.0000049905784,0.005160442,0.0038699915,0.0012838339,0.45788372],"study_design_scores_gemma":[0.011708787,0.07914244,0.19112645,0.0014971406,0.00044135965,0.00003531251,0.1426676,0.00018937317,0.276051,0.0026677933,0.29410377,0.0003689823],"about_ca_topic_score_codex":0.00028413182,"about_ca_topic_score_gemma":0.00020317826,"teacher_disagreement_score":0.45751473,"about_ca_system_score_codex":0.000058081016,"about_ca_system_score_gemma":0.0005197541,"threshold_uncertainty_score":0.32876304},"labels":[],"label_agreement":null},{"id":"W2171744360","doi":"10.1093/annonc/mdt289","title":"Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Doxorubicin; CHOP; Cardiotoxicity; Regimen; Ejection fraction; Diffuse large B-cell lymphoma; Gastroenterology; Oncology; Lymphoma; Heart failure; Chemotherapy","score_opus":0.0883804530999401,"score_gpt":0.39367191242018873,"score_spread":0.30529145932024865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171744360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908935,0.0019428314,0.00014421996,0.0036572218,0.000054482804,0.00201688,0.00010095393,0.000022307633,0.0011675903],"genre_scores_gemma":[0.9957502,0.00032107462,0.002236544,0.0008412419,0.000044254844,0.0005251905,0.00010546589,0.000035735833,0.00014028065],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982134,0.00009836865,0.00069290464,0.000322663,0.00025342047,0.00041924114],"domain_scores_gemma":[0.99743456,0.00064715935,0.00070348685,0.0005446004,0.0005063976,0.00016380368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014112768,0.00029447878,0.0014797181,0.00018453818,0.000045230816,0.0000045090833,0.000113894355,0.00018134962,0.000116567266],"category_scores_gemma":[0.000021601092,0.00018877361,0.00033002446,0.00015288885,0.0001942103,0.00004010229,0.00001025256,0.000022465887,0.000008941043],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017711602,0.28026512,0.48723093,0.00055832806,0.0017914851,0.00004381971,0.0014532926,0.00011048695,0.0435037,0.00043651796,0.013117172,0.15377754],"study_design_scores_gemma":[0.11687896,0.074238904,0.07267506,0.00011758656,0.00032578903,0.0000037859984,0.0002620728,0.0009582221,0.70520014,0.000034926958,0.029132377,0.00017220963],"about_ca_topic_score_codex":0.0006763072,"about_ca_topic_score_gemma":0.00006748369,"teacher_disagreement_score":0.66169643,"about_ca_system_score_codex":0.00015052898,"about_ca_system_score_gemma":0.0006278748,"threshold_uncertainty_score":0.7697965},"labels":[],"label_agreement":null},{"id":"W2172041560","doi":"10.1093/annonc/mdi274","title":"A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Mastectomy; Radiation therapy; Breast cancer; Oncology; Cancer; Internal medicine; Stage (stratigraphy); Male breast cancer; Surgery","score_opus":0.1743386062242497,"score_gpt":0.46359743352798155,"score_spread":0.28925882730373187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172041560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811384,0.0040780487,0.0000043678783,0.014326256,0.000007523218,0.00021982421,0.0000561845,0.000003848398,0.00016554374],"genre_scores_gemma":[0.99471533,0.0024563903,0.0011407338,0.0016191526,0.000015672846,0.000020862539,0.0000024171325,0.0000041178832,0.000025308458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916506,0.0000704346,0.00035886173,0.00015640062,0.000097298485,0.00015192816],"domain_scores_gemma":[0.9992273,0.00020508973,0.00021445972,0.000097001524,0.00018507605,0.00007108993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120670455,0.00009809786,0.0009378724,0.00029256855,0.000016911621,0.0000017516818,0.000021641856,0.00005128706,0.000041541225],"category_scores_gemma":[0.000014660246,0.00006921527,0.0000345201,0.00027968758,0.00028529039,0.000055244254,0.000019454357,0.000069851034,1.225098e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012678183,0.00027647807,0.97111315,0.00009177456,0.0008773765,0.000009784489,0.0036212767,0.00011086981,0.00012283609,0.00007278899,0.000111161215,0.022324694],"study_design_scores_gemma":[0.0011931292,0.0012227596,0.9939337,0.0000604618,0.00022438655,0.000042314834,0.0005769745,0.00035989762,0.0000961666,0.0000017011092,0.0022320454,0.000056493434],"about_ca_topic_score_codex":0.0009916738,"about_ca_topic_score_gemma":0.0059423787,"teacher_disagreement_score":0.022820529,"about_ca_system_score_codex":0.00003163403,"about_ca_system_score_gemma":0.00007852564,"threshold_uncertainty_score":0.33159867},"labels":[],"label_agreement":null},{"id":"W2173572264","doi":"10.1093/annonc/mdv324","title":"A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Celgene","keywords":"Dacarbazine; Medicine; Paclitaxel; Internal medicine; Clinical endpoint; Hazard ratio; Chemotherapy; Melanoma; Neutropenia; Oncology; Randomized controlled trial; Gastroenterology; Progression-free survival; Confidence interval; Urology; Cancer research","score_opus":0.07239729487824467,"score_gpt":0.38088961846906666,"score_spread":0.308492323590822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173572264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97702444,0.00020617146,0.00009536476,0.001571244,0.0004474059,0.0040601986,0.000008962403,0.00001645739,0.016569754],"genre_scores_gemma":[0.99820554,0.00009854136,0.00034202685,0.0005030337,0.00006428158,0.00019297103,0.000024660407,0.000016975397,0.0005519725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979663,0.00036610942,0.0008943067,0.00020265703,0.0003490255,0.00022160941],"domain_scores_gemma":[0.99802166,0.0005955042,0.0005994353,0.00023922243,0.0004045355,0.00013964613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014380757,0.00017249012,0.0022952852,0.00031833016,0.000011543116,0.0000033012702,0.00007946004,0.00008196147,0.00012255422],"category_scores_gemma":[0.00088874385,0.00011664074,0.0002480128,0.00021485372,0.00018213001,0.000040059585,0.000025314172,0.00011969562,0.0000056388803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9789918,0.0038248177,0.00004857248,0.000034548757,0.0012723245,0.00007351797,0.0005687532,0.000009593501,0.00005661397,0.00019779934,0.0012634153,0.01365824],"study_design_scores_gemma":[0.95703995,0.033883516,0.00003570638,0.0000336405,0.00047077012,0.000010058885,0.00034039398,0.00019336764,0.00034846633,0.00010303823,0.0074488604,0.00009223559],"about_ca_topic_score_codex":0.00014523651,"about_ca_topic_score_gemma":0.000085015534,"teacher_disagreement_score":0.030058697,"about_ca_system_score_codex":0.000060868148,"about_ca_system_score_gemma":0.00024244506,"threshold_uncertainty_score":0.47564712},"labels":[],"label_agreement":null},{"id":"W2178360273","doi":"10.1093/annonc/mdv283","title":"Planning and reporting of quality-of-life outcomes in cancer trials","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Hamilton Health Sciences Foundation; Sigrid Juséliuksen Säätiö; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Deutsche Forschungsgemeinschaft; Hamilton Health Sciences; Fondation Brocher","keywords":"Medicine; Quality of life (healthcare); Cancer; Clinical trial; Quality (philosophy); Intensive care medicine; Oncology; Internal medicine; Nursing","score_opus":0.6907242039751149,"score_gpt":0.5991990042228662,"score_spread":0.09152519975224871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178360273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879285,0.004112126,0.000009969069,0.004006448,0.00025907555,0.00013840877,0.00001251643,0.0000047482836,0.003528173],"genre_scores_gemma":[0.9987897,0.00013574405,0.00008768574,0.0008167221,0.00005762888,0.000011001103,0.000002962398,0.0000055848136,0.00009297261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974184,0.00025166242,0.001934419,0.00011307265,0.00016346032,0.00011895614],"domain_scores_gemma":[0.9966209,0.0006260024,0.002259819,0.00013069216,0.0002730959,0.00008952619],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056369016,0.000065905435,0.001527941,0.00011694934,0.000005073493,8.4147285e-7,0.000037692178,0.00010318831,0.000022411803],"category_scores_gemma":[0.009986499,0.0000520391,0.00009593097,0.00010911298,0.00008163776,0.000027800404,0.00003141951,0.00008771427,1.5569611e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008601367,0.00010777316,0.97722006,0.00023710725,0.00009535934,0.000014470686,0.0045147636,0.000016154232,0.0014706616,0.00017606375,0.0007859998,0.014501428],"study_design_scores_gemma":[0.0053472808,0.0023121554,0.9551948,0.00042993674,0.000089802765,0.000010315818,0.009322862,0.000012869172,0.014961965,0.00088289316,0.011294654,0.00014049705],"about_ca_topic_score_codex":0.00700226,"about_ca_topic_score_gemma":0.00200092,"teacher_disagreement_score":0.022025313,"about_ca_system_score_codex":0.000019358216,"about_ca_system_score_gemma":0.0005548258,"threshold_uncertainty_score":0.9996102},"labels":[],"label_agreement":null},{"id":"W2178732328","doi":"10.1093/annonc/mdv395","title":"Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Immune system; Immunology; Trastuzumab; Cancer research; Breast cancer; Cancer; Internal medicine","score_opus":0.2799415670746014,"score_gpt":0.4692287805792134,"score_spread":0.18928721350461203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178732328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882634,0.002196804,0.000016364473,0.016185438,0.0001647446,0.0008648077,0.000016812055,0.000020260444,0.001708419],"genre_scores_gemma":[0.99804896,0.00020241583,0.00048271444,0.0008612651,0.000101764796,0.00011762968,0.000011534957,0.000013800539,0.00015990718],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99674445,0.00182055,0.00056465855,0.00018585366,0.00040944823,0.00027505797],"domain_scores_gemma":[0.9981094,0.00074979116,0.00020105485,0.00043169924,0.00044368673,0.000064339365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040952372,0.00011424118,0.0005604958,0.00011922884,0.000017082175,0.0000047498906,0.00020818223,0.0001845074,0.000206494],"category_scores_gemma":[0.0012283192,0.000074854,0.00010575552,0.00035001035,0.0003048891,0.000041944455,0.000058840564,0.00028310157,0.00001520206],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7236115,0.0023980783,0.01178126,0.00012738793,0.00016039287,0.0010033435,0.019667517,0.00011052414,0.04179356,0.00017967664,0.010417912,0.18874885],"study_design_scores_gemma":[0.065142006,0.047164273,0.77591467,0.00024435375,0.000047975325,0.00016304675,0.004083752,0.00094694,0.0026670368,0.0035853717,0.09979353,0.00024705037],"about_ca_topic_score_codex":0.00046626988,"about_ca_topic_score_gemma":0.00013475904,"teacher_disagreement_score":0.7641334,"about_ca_system_score_codex":0.000064782784,"about_ca_system_score_gemma":0.0005177424,"threshold_uncertainty_score":0.30524573},"labels":[],"label_agreement":null},{"id":"W2179389093","doi":"10.1093/annonc/mdv382","title":"Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; European Research Council; National Institutes of Health; Genome British Columbia; Canadian Cancer Society; Ludwig Institute for Cancer Research; Canadian Institutes of Health Research; Genome Canada; Ovarian Cancer Research Fund; U.S. Department of Defense","keywords":"Immunotherapy; Medicine; Personalized medicine; Cancer immunotherapy; Precision medicine; Clinical trial; Cancer; Computational biology; Genomic sequencing; Bioinformatics; Internal medicine; Gene; Genome; Biology; Genetics; Pathology","score_opus":0.24542338659995216,"score_gpt":0.5002399680797417,"score_spread":0.25481658147978953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179389093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020823469,0.9467931,0.0000017836753,0.010334096,0.0004050157,0.0028106691,0.000031493586,0.0000208551,0.039394747],"genre_scores_gemma":[0.00003918216,0.9900567,0.00012012578,0.0027465948,0.00073096174,0.00046309162,0.00013120423,0.00010410408,0.005608051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924991,0.0040125917,0.0014344467,0.0005354759,0.00066017674,0.0008581975],"domain_scores_gemma":[0.9943478,0.0031683352,0.0009011864,0.0009885727,0.00046083378,0.00013327465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009742085,0.00050332193,0.0035988197,0.0004096992,0.000116107374,0.000020080588,0.0012707677,0.0008949257,0.0032426014],"category_scores_gemma":[0.00046659412,0.00026719825,0.00082439097,0.00081419444,0.0008119091,0.00004391147,0.00019434682,0.0021173595,0.00013870254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058685016,0.00048963405,0.0000056792805,0.0014777975,0.0006808134,0.0001661081,0.0024243975,0.0000016011018,0.00022299487,0.00028119466,0.050750274,0.94291264],"study_design_scores_gemma":[0.0019965807,0.0028300495,0.000009983539,0.00084601395,0.0002706421,0.00049648626,0.0007235553,0.000008293344,0.0000044287394,0.0001647236,0.99243116,0.00021806093],"about_ca_topic_score_codex":0.00031826165,"about_ca_topic_score_gemma":0.00006822311,"teacher_disagreement_score":0.9426946,"about_ca_system_score_codex":0.00067428563,"about_ca_system_score_gemma":0.006009441,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W2182085870","doi":"10.1023/a:1011197007606","title":"The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives","year":2001,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osteoporosis; Menopause; Breast cancer; Hormone replacement therapy (female-to-male); Estrogen; Vasomotor; Endometrial cancer; Tamoxifen; Internal medicine; Genitourinary system; Cancer; Disease; Raloxifene; Selective estrogen receptor modulator; Oncology; Vaginal atrophy; Gynecology; Testosterone (patch)","score_opus":0.02411885828206576,"score_gpt":0.3608373485184942,"score_spread":0.3367184902364284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182085870","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054772276,0.94391,2.138303e-7,0.00012099062,0.000014091009,0.0007800127,0.000070497066,9.87701e-7,0.00033093503],"genre_scores_gemma":[0.0032426468,0.99618065,0.00001887527,0.00005871486,0.000022592907,0.0004100347,0.000014618729,0.00001843188,0.00003345655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984832,0.00029344996,0.0006678048,0.00023580273,0.000116901545,0.00020283887],"domain_scores_gemma":[0.9982695,0.000108819906,0.0010893537,0.0003062119,0.00018120151,0.00004489181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056461414,0.00020740119,0.001303838,0.000066420354,0.000014905812,0.0000015817504,0.0002217236,0.00022866744,0.0000069855973],"category_scores_gemma":[0.000035711288,0.00011767478,0.00014687523,0.00020300847,0.00026571593,0.000002716661,0.00008470224,0.00012982854,1.1139547e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007679093,0.00031792204,0.00032752898,0.0065576485,0.00090568024,0.0000029714404,0.00007701671,5.975414e-7,0.00041573672,0.000012992357,0.00034333236,0.9902707],"study_design_scores_gemma":[0.0012286832,0.012309642,0.00036418156,0.027682964,0.0002395094,0.00008435981,0.00006116261,5.1046834e-7,0.0051558623,0.000032047396,0.9526335,0.00020757903],"about_ca_topic_score_codex":0.00012466352,"about_ca_topic_score_gemma":0.00001474816,"teacher_disagreement_score":0.9900631,"about_ca_system_score_codex":0.000018621688,"about_ca_system_score_gemma":0.00037650255,"threshold_uncertainty_score":0.47986382},"labels":[],"label_agreement":null},{"id":"W2182443159","doi":"10.1093/annonc/mdv484","title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"NIH Clinical Center; National Cancer Institute; Tays; University of Texas MD Anderson Cancer Center; Università degli Studi di Milano; Barts Health NHS Trust; European Society for Medical Oncology; Institut Bergonié; Servicio Gallego de Salud; Haukeland Universitetssjukehus; Università degli Studi di Torino; Rigshospitalet; Royal Marsden NHS Foundation Trust; Universitair Medisch Centrum Groningen; McGill University; Georg-August-Universität Göttingen; Universitat de Lleida; Gentofte Hospital; Leids Universitair Medisch Centrum; Universiteit Leiden; McGill University Health Centre; Tampereen Yliopisto; Rijksuniversiteit Groningen; Institut Gustave-Roussy; Univerzita Karlova v Praze","keywords":"Medicine; Consensus conference; Endometrial cancer; Gynecology; Oncology; Medical physics; Cancer; Internal medicine","score_opus":0.2885455903458931,"score_gpt":0.44439248846006557,"score_spread":0.15584689811417246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182443159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616238,0.004097062,0.000001426699,0.016059166,0.0009973827,0.0006056679,0.00016130389,0.000032212243,0.016421996],"genre_scores_gemma":[0.98889,0.008104695,0.00013300199,0.0013399598,0.00035957844,0.00032647199,0.000027104436,0.0000148033405,0.0008044108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863493,0.00013347463,0.00036001793,0.00032082293,0.0002303034,0.00032044548],"domain_scores_gemma":[0.9981075,0.00075517804,0.00018429014,0.00021417325,0.0003058154,0.00043302865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002244396,0.00021114675,0.00084932527,0.00022487914,0.00003695714,0.000007677441,0.00006706462,0.00017024887,0.00027406643],"category_scores_gemma":[0.00066896545,0.00015175612,0.0001388395,0.00030304093,0.00019791829,0.000023791326,0.00003614373,0.0001086596,0.000026113614],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02573401,0.0034058173,0.13244729,0.0000660839,0.001456262,0.000391584,0.0006625075,0.0000057495204,0.0004356767,0.0024895086,0.02857975,0.80432576],"study_design_scores_gemma":[0.15002418,0.15671867,0.040990554,0.00029472384,0.0013017267,0.00015580628,0.0006792375,0.000028241142,0.05923792,0.0034289157,0.58656055,0.00057948],"about_ca_topic_score_codex":0.0026033602,"about_ca_topic_score_gemma":0.00030945853,"teacher_disagreement_score":0.8037463,"about_ca_system_score_codex":0.00019795314,"about_ca_system_score_gemma":0.0006467713,"threshold_uncertainty_score":0.6188435},"labels":[],"label_agreement":null},{"id":"W2187680199","doi":"10.1093/annonc/mdu334.87","title":"Standard Clinical Practice of Folfirinox (Ffx) in Advanced/Metastatic Pancreatic Cancer (Pc) Patients: a Canadian Retrospective Registry","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Jewish General Hospital; McGill University; Windsor Regional Hospital; Sunnybrook Health Science Centre; Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRINOX; Cancer registry; Retrospective cohort study; Pancreatic cancer; Oncology; Cancer; Internal medicine; General surgery; Oxaliplatin; Colorectal cancer","score_opus":0.08682785937670183,"score_gpt":0.48806897300927127,"score_spread":0.4012411136325694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187680199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91905904,0.0006389404,0.000074961485,0.006779092,0.0001914093,0.0007463133,0.0000933676,0.000009877268,0.07240702],"genre_scores_gemma":[0.98954374,0.002425597,0.0049912473,0.0023746244,0.00009383326,0.00008841803,0.000022043474,0.000022931667,0.00043755324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966746,0.00073788606,0.0011686522,0.00038966403,0.000449214,0.0005800137],"domain_scores_gemma":[0.99484843,0.0020842475,0.00066992996,0.0004955627,0.0014799098,0.00042192516],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026399093,0.00017981879,0.0016515681,0.000319916,0.00004439304,0.00000347694,0.00019340236,0.00026465268,0.0002585931],"category_scores_gemma":[0.014245489,0.00015895566,0.00014789775,0.00040722868,0.0005607282,0.00012425854,0.000055188633,0.00055391033,0.00001424788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002755365,0.0009347932,0.93522614,0.00018769408,0.000343983,0.000095308,0.00036262692,0.0000056740855,0.000027066986,0.0011250703,0.006471299,0.05246495],"study_design_scores_gemma":[0.0069817463,0.016032707,0.8899587,0.00038281074,0.00035520358,0.000028051147,0.0004863348,0.00013919246,0.000137772,0.0014349397,0.08390634,0.00015623057],"about_ca_topic_score_codex":0.031413533,"about_ca_topic_score_gemma":0.039793473,"teacher_disagreement_score":0.07743504,"about_ca_system_score_codex":0.0004259643,"about_ca_system_score_gemma":0.0032109546,"threshold_uncertainty_score":0.99405795},"labels":[],"label_agreement":null},{"id":"W2196689106","doi":"10.1093/annonc/mdv594","title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Toronto; BC Cancer Agency","funders":"Janssen Pharmaceuticals; Genomic Health; Foundation Medicine; Chugai Pharmaceutical; Genentech; Bavarian Nordic; MannKind Corporation; Astellas Pharma; Teva Pharmaceutical Industries; Janssen Biotech; Les Laboratories Pierre Fabre; Endocyte; Exelixis; Sanofi; National Cancer Institute; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Abiraterone acetate; Medicine; Docetaxel; Prostate cancer; Proportional hazards model; Hazard ratio; Internal medicine; Prednisone; Oncology; Univariate analysis; Population; Androgen deprivation therapy; Cancer; Multivariate analysis; Confidence interval","score_opus":0.10167911792994017,"score_gpt":0.37997730679471775,"score_spread":0.2782981888647776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196689106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995542,0.0003216629,0.000102293496,0.0010509854,0.00002640002,0.0025240863,0.00023927115,0.000020903291,0.00017242394],"genre_scores_gemma":[0.99697137,0.00005694307,0.0008008845,0.00013580499,0.00002101437,0.0011876676,0.00015489614,0.000037440714,0.0006339672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983168,0.000085186606,0.00038352743,0.00033086073,0.00038887918,0.0004946928],"domain_scores_gemma":[0.9983855,0.00008485295,0.00020641317,0.00016574931,0.0009502723,0.00020722172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032544733,0.00021864501,0.0005767152,0.00017891177,0.000032330285,0.000014843041,0.000062976396,0.00006959118,0.000009517077],"category_scores_gemma":[0.000061029354,0.00013568126,0.00004070655,0.00022358657,0.00016001854,0.00018588184,0.000024084782,0.00015208795,0.0000010163412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067495175,0.0012180597,0.92259103,0.00028742166,0.00047118877,0.00011659468,0.0018063713,0.0035927144,0.000116178424,0.000009463754,0.000117701275,0.0021780943],"study_design_scores_gemma":[0.05478973,0.027481152,0.891131,0.0005716516,0.0004122636,0.0000073444344,0.00033954685,0.023761665,0.0008414071,0.00021809712,0.00014037717,0.00030579153],"about_ca_topic_score_codex":0.00049642654,"about_ca_topic_score_gemma":0.0018512221,"teacher_disagreement_score":0.03146006,"about_ca_system_score_codex":0.00017453845,"about_ca_system_score_gemma":0.001256477,"threshold_uncertainty_score":0.5532921},"labels":[],"label_agreement":null},{"id":"W2200375883","doi":"10.1093/annonc/mdv619","title":"Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Neutropenia; Febrile neutropenia; Intensive care medicine; Internal medicine; Chemotherapy","score_opus":0.3906521819645971,"score_gpt":0.5174020976375747,"score_spread":0.1267499156729776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200375883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015876125,0.9699047,0.00003087167,0.0013488139,0.000060313854,0.027341077,0.00018128566,0.0000102603635,0.0011068026],"genre_scores_gemma":[0.0006408194,0.985608,0.00017815623,0.0013824498,0.00006111319,0.011725732,0.00017034721,0.000029105558,0.00020426992],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98152024,0.012375105,0.0052922294,0.00037072203,0.0002606091,0.000181105],"domain_scores_gemma":[0.9679365,0.025059994,0.0056439,0.0005095103,0.0007864251,0.00006363319],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.024561081,0.0003947051,0.056857787,0.0006274984,0.000031310694,0.000025051031,0.0001768962,0.00021440114,0.00009584829],"category_scores_gemma":[0.008603249,0.00017344656,0.006826678,0.0006256284,0.00019254706,0.00005787784,0.000047169906,0.00028486477,0.0000014184734],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016730562,0.00027431996,0.0000021013577,0.6337506,0.34099722,0.0000118984835,0.00024246515,0.0000013553189,0.0000025779907,0.00054338836,0.0021302302,0.0053132595],"study_design_scores_gemma":[0.034294385,0.0007393133,4.898675e-7,0.0204512,0.9285899,0.000017154141,0.00002891271,0.0000040021832,0.0000022273234,0.00024231321,0.01549983,0.00013028157],"about_ca_topic_score_codex":0.0004162684,"about_ca_topic_score_gemma":0.0003610234,"teacher_disagreement_score":0.6132994,"about_ca_system_score_codex":0.00007307939,"about_ca_system_score_gemma":0.0009808115,"threshold_uncertainty_score":0.9997477},"labels":[],"label_agreement":null},{"id":"W2207022446","doi":"10.1023/a:1008348010437","title":"Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inimex Pharmaceuticals (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Vincristine; Internal medicine; Regimen; Gastroenterology; Lymphoma; Chemotherapy; Surgery; Cyclophosphamide","score_opus":0.07069277781017202,"score_gpt":0.4396739486290902,"score_spread":0.3689811708189182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2207022446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718763,0.00018949523,4.6427908e-7,0.0024349513,0.00027257073,0.00062456686,0.00007535381,0.000021918833,0.024504371],"genre_scores_gemma":[0.99670064,0.00025469402,0.00030662707,0.00063796696,0.00045650295,0.000036374895,0.00008942196,0.000019264417,0.0014985193],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99816996,0.00018336254,0.00082423276,0.00031339782,0.00016894123,0.0003401239],"domain_scores_gemma":[0.9989131,0.00024302243,0.00028120333,0.0002779435,0.00013082054,0.00015392559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052321976,0.00017046789,0.00081384886,0.00024046114,0.000042064534,0.000002202854,0.0001275373,0.00024093776,0.0008706135],"category_scores_gemma":[0.000106700856,0.0001581017,0.00014258003,0.0002887864,0.00016882707,0.000075925665,0.000031673975,0.00017354496,0.000014077532],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5535226,0.02065843,0.00054435607,0.000047770143,0.00023316294,0.00062089297,0.0028912409,0.000024010247,0.0225536,0.000030467638,0.0062418845,0.3926316],"study_design_scores_gemma":[0.5969347,0.28040972,0.011640181,0.00013529047,0.00027613936,0.00009678835,0.00008426677,0.0002926286,0.04637146,0.00015303017,0.06336974,0.00023607894],"about_ca_topic_score_codex":0.0017649058,"about_ca_topic_score_gemma":0.00037395564,"teacher_disagreement_score":0.3923955,"about_ca_system_score_codex":0.000075917706,"about_ca_system_score_gemma":0.00047479584,"threshold_uncertainty_score":0.9532607},"labels":[],"label_agreement":null},{"id":"W2223761815","doi":"10.1016/s0923-7534(20)31970-0","title":"Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Regorafenib; Medicine; GiST; Sunitinib; Imatinib; Oncology; Internal medicine; Sunitinib malate; Stromal tumor; Stromal cell; Colorectal cancer; Cancer","score_opus":0.09573382842189562,"score_gpt":0.3966884140924295,"score_spread":0.3009545856705339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223761815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931145,0.00014398238,0.000019788391,0.00022789788,0.00004054303,0.00613253,0.000104449,0.000016089305,0.00020024458],"genre_scores_gemma":[0.9874417,0.000019187026,0.011804644,0.000023633236,0.00008171662,0.0003557841,0.00015815844,0.000036350717,0.000078822726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99668276,0.00066977664,0.00091970013,0.00037854066,0.00055374927,0.00079546846],"domain_scores_gemma":[0.99696904,0.0009952856,0.00081956317,0.0002523566,0.0004757361,0.00048802435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096963585,0.0003852133,0.0017765296,0.00031849107,0.00009920462,0.000020073507,0.00007613289,0.000033505286,0.000071560615],"category_scores_gemma":[0.001031905,0.00021992439,0.00012078076,0.00024089309,0.0008489217,0.00021232139,0.00008060896,0.0001913816,0.0000016266747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84408355,0.015780278,0.13039511,0.00017612662,0.00027407432,0.00023469259,0.00025062813,0.0000010906588,0.000053681793,0.000014567548,0.000019392712,0.008716793],"study_design_scores_gemma":[0.7552633,0.22940037,0.013084991,0.00054095703,0.0003985889,0.00036541832,0.00014547851,0.000044828834,0.0005720587,0.000005144434,0.000055982244,0.00012282941],"about_ca_topic_score_codex":0.00017955808,"about_ca_topic_score_gemma":0.000104254075,"teacher_disagreement_score":0.2136201,"about_ca_system_score_codex":0.00016174611,"about_ca_system_score_gemma":0.00053775706,"threshold_uncertainty_score":0.8968257},"labels":[],"label_agreement":null},{"id":"W2227420607","doi":"10.1093/annonc/mdu333.33","title":"Angiogenic Switch As Predictor of Response to Chemotherapy+ Bevacizumab in Patients with Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bevacizumab; Colorectal cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.026825767277023526,"score_gpt":0.35363562063213183,"score_spread":0.3268098533551083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227420607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944778,0.00029067066,0.0000040813934,0.0032966803,0.000063527936,0.000650946,0.00004024623,0.000009176143,0.001166873],"genre_scores_gemma":[0.99845165,0.00008175698,0.0002368327,0.00092860823,0.000020990232,0.00012588306,0.0000068681056,0.000015913274,0.00013151662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989324,0.00011374739,0.00030429795,0.00020523954,0.00021726973,0.00022700008],"domain_scores_gemma":[0.9991097,0.00021224655,0.00014996475,0.00014046433,0.0002956828,0.000091948255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002642794,0.00013556393,0.0006371008,0.00017590522,0.000019482246,0.0000014163561,0.00006747031,0.00005280737,0.00012672305],"category_scores_gemma":[0.00017718878,0.000096537246,0.00007905496,0.000284533,0.0000934445,0.000028352808,0.000032068376,0.00006134542,0.0000041617513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14749667,0.0024557924,0.74690944,0.000097821656,0.0012320958,0.000021585889,0.004177144,0.0000295678,0.0033569424,0.00003989753,0.0015549774,0.09262806],"study_design_scores_gemma":[0.009016709,0.03888173,0.93732554,0.000085268475,0.000112764734,0.0000031380728,0.00010250615,0.000008404369,0.008047404,0.000049008402,0.0062805177,0.0000870212],"about_ca_topic_score_codex":0.00044967045,"about_ca_topic_score_gemma":0.0007088085,"teacher_disagreement_score":0.19041608,"about_ca_system_score_codex":0.00011253837,"about_ca_system_score_gemma":0.00030162037,"threshold_uncertainty_score":0.39366746},"labels":[],"label_agreement":null},{"id":"W2229303152","doi":"10.1093/annonc/mdu336.19","title":"Analysis of Overall Survival (Os) for Patients (Pts) with Different Prognostic Risk Factors Treated with Cabazitaxel and Prednisone (Cbz + P) After Docetaxel (D) in the Tropic Trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cabazitaxel; Docetaxel; Prednisone; Oncology; Internal medicine; Chemotherapy; Prostate cancer; Cancer; Androgen deprivation therapy","score_opus":0.05122056784148065,"score_gpt":0.35210127048466067,"score_spread":0.30088070264318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229303152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975058,0.00013075801,0.000035045232,0.00032438806,0.000020955333,0.0016939654,0.00014132794,0.0000053990307,0.00014240597],"genre_scores_gemma":[0.99918246,0.0002331621,0.00003286374,0.000039221228,0.000028918827,0.00023962524,0.0001546017,0.000012231692,0.00007691201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986405,0.0002628043,0.00030201976,0.0002467021,0.0002756886,0.00027230696],"domain_scores_gemma":[0.99856514,0.00069172826,0.00022281095,0.00020936351,0.00023454045,0.00007643127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024530574,0.00016595006,0.00078539725,0.0002577572,0.000032378804,0.0000068880536,0.0000761859,0.00009002229,0.00001895212],"category_scores_gemma":[0.0001564454,0.00007504729,0.000109526256,0.00028418863,0.0002005657,0.000039903876,0.00001979784,0.00011654552,1.5778578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07618425,0.0020281528,0.9157132,0.00007587422,0.0015120095,0.0000055453957,0.00079477596,0.000010053575,0.0000138859705,0.0000141645105,0.00003058151,0.0036175244],"study_design_scores_gemma":[0.056510873,0.03968239,0.90130883,0.000042821266,0.0016410131,5.114951e-7,0.00013135582,0.00022319995,0.00020221321,0.000029287914,0.000152031,0.00007545198],"about_ca_topic_score_codex":0.0004748749,"about_ca_topic_score_gemma":0.0009823459,"teacher_disagreement_score":0.037654232,"about_ca_system_score_codex":0.000034846304,"about_ca_system_score_gemma":0.00007633725,"threshold_uncertainty_score":0.30603397},"labels":[],"label_agreement":null},{"id":"W2233226443","doi":"10.1093/annonc/mdv389","title":"A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Pegfilgrastim; Breast cancer; Internal medicine; Filgrastim; Oncology; Granulocyte colony-stimulating factor; Clinical trial; Randomized controlled trial; Chemotherapy; Cancer; Surgery","score_opus":0.10707499824737168,"score_gpt":0.40935330442139106,"score_spread":0.3022783061740194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233226443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891984,0.00042417293,0.00107812,0.0015561231,0.00035087642,0.0064225295,0.00090391515,0.00001034891,0.00005553821],"genre_scores_gemma":[0.99828017,0.00008240776,0.0005276151,0.00042878286,0.00019950334,0.00041292902,0.00001787886,0.000024370907,0.000026317986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853677,0.00016707955,0.00065006455,0.0002386211,0.00016537604,0.00024210785],"domain_scores_gemma":[0.997332,0.0006682956,0.0005842504,0.00016288212,0.0011476664,0.00010495507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010807216,0.00017013824,0.0011848884,0.00007514168,0.000102592785,0.000007688819,0.00007373932,0.00013822914,0.000029694304],"category_scores_gemma":[0.00038208405,0.000116074174,0.00020532438,0.00014394715,0.0003790832,0.000072993105,0.000029720542,0.00015894989,3.7248796e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9128425,0.00036650896,0.00042038757,0.0001535979,0.00041903026,0.0000014318159,0.0016692004,0.00005102998,0.030940475,0.00004416299,0.00064582436,0.052445814],"study_design_scores_gemma":[0.9120993,0.049169835,0.00052431406,0.00014850087,0.00033030927,0.000034015487,0.001039037,0.0009196457,0.03281592,0.00017020044,0.0025918188,0.00015707804],"about_ca_topic_score_codex":0.00035060997,"about_ca_topic_score_gemma":0.00013182005,"teacher_disagreement_score":0.052288737,"about_ca_system_score_codex":0.000121453,"about_ca_system_score_gemma":0.001026017,"threshold_uncertainty_score":0.47333676},"labels":[],"label_agreement":null},{"id":"W2233652744","doi":"10.1093/annonc/mdv233.279","title":"P-282 Palliative chemotherapy for patients 70 and above with metastatic colorectal cancer: How Much Chemotherapy is Enough?","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Colorectal cancer; Chemotherapy; Oncology; Multivariate analysis; Progression-free survival; Chemotherapy regimen; Performance status; Cancer","score_opus":0.08721286544607312,"score_gpt":0.39699295960730724,"score_spread":0.3097800941612341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233652744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95865893,0.0022695456,0.000031703035,0.03598169,0.00010304508,0.0012540466,0.00016745737,0.000017609074,0.0015159769],"genre_scores_gemma":[0.9881351,0.0046861935,0.0017870594,0.004333506,0.00008384988,0.0003810595,0.000026201422,0.00003057821,0.0005364608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989887,0.000032232125,0.00019393461,0.0002943585,0.00019971527,0.0002910626],"domain_scores_gemma":[0.9986457,0.00014894841,0.00022618867,0.000105305124,0.0007276441,0.00014619951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012522769,0.00021411618,0.00073485647,0.00006484222,0.00005724588,0.00000832422,0.000054648495,0.00007569212,0.000039644445],"category_scores_gemma":[0.000052124113,0.00014648722,0.000080051526,0.00013617576,0.00021518076,0.00006279555,0.000019446268,0.00007430956,9.078208e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045009214,0.004732112,0.27187124,0.0003909625,0.0069994116,0.000046338093,0.041733988,0.000001706844,0.0006662973,0.0002995634,0.096578434,0.53167075],"study_design_scores_gemma":[0.07404657,0.16257203,0.27640465,0.00023442422,0.0008518051,0.000029965004,0.0060350774,0.00017874064,0.055630017,0.0018986025,0.42136732,0.0007507987],"about_ca_topic_score_codex":0.00019089301,"about_ca_topic_score_gemma":0.0002553485,"teacher_disagreement_score":0.5309199,"about_ca_system_score_codex":0.00012243993,"about_ca_system_score_gemma":0.00032817572,"threshold_uncertainty_score":0.5973576},"labels":[],"label_agreement":null},{"id":"W2240521537","doi":"10.1093/annonc/mdv233.35","title":"P-035 The plasminogen receptor P11 contributes to KRAS-driven invasiveness of pancreatic cancer cells and is upregulated in human pancreatic tumors","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pancreatic cancer; Cancer research; Cancer; Cancer cell; Medicine; KRAS; Plasmin; Receptor; Biology; Pathology; Internal medicine; Enzyme; Colorectal cancer","score_opus":0.04805011673722776,"score_gpt":0.3269198776661864,"score_spread":0.27886976092895865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240521537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609196,0.0018213594,0.00002984833,0.0011013175,0.00008650084,0.00047670116,0.000091183014,0.0000037380069,0.0002973855],"genre_scores_gemma":[0.9980682,0.00041561297,0.0001111971,0.001056996,0.00006197274,0.0000987774,0.000030368416,0.000014542626,0.00014232802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883735,0.00018835223,0.000370058,0.00025553897,0.00010205775,0.00024666952],"domain_scores_gemma":[0.99913204,0.00005584237,0.00020198962,0.00026207973,0.00024506703,0.000102990794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003659511,0.00014536067,0.00043443101,0.00006947037,0.000034334604,0.0000055733294,0.00021011259,0.00018742993,0.000024240535],"category_scores_gemma":[0.00013865218,0.000114750685,0.00005749951,0.00013768715,0.00014512437,0.0000056090475,0.00014721388,0.00007223363,0.000002924681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002619476,0.000098229415,0.0036650395,0.000037534068,0.00010866074,0.0000032146518,0.0003710828,0.00006943095,0.9875162,0.00011449693,0.00689032,0.0008638076],"study_design_scores_gemma":[0.0009150105,0.0016735953,0.0012234955,0.00011044703,0.000037074027,0.0000030559827,0.00022802243,0.000022774744,0.98725766,0.0005696958,0.007839521,0.00011965903],"about_ca_topic_score_codex":0.00060108176,"about_ca_topic_score_gemma":0.00020363631,"teacher_disagreement_score":0.002441544,"about_ca_system_score_codex":0.00002064001,"about_ca_system_score_gemma":0.00023995776,"threshold_uncertainty_score":0.4679397},"labels":[],"label_agreement":null},{"id":"W2249979977","doi":"10.1093/annonc/mdu438.51","title":"Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Cancer research; PD-L1; Internal medicine; Immunotherapy; Cancer","score_opus":0.016153954546913596,"score_gpt":0.3261462411814098,"score_spread":0.3099922866344962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249979977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963701,0.00014880554,0.0009797032,0.000099845754,0.000021346093,0.000860333,0.00002653934,0.000008060152,0.0014853127],"genre_scores_gemma":[0.997981,0.0000489005,0.0016967686,0.000046783076,0.000008125706,0.00006586635,0.000089924055,0.000015508338,0.00004710076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988765,0.000086843196,0.00034820286,0.0002852791,0.00019340958,0.00020974655],"domain_scores_gemma":[0.99859136,0.00013060597,0.0005549179,0.00023583167,0.00039232618,0.000094937706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013929134,0.00016383943,0.0007910483,0.000378622,0.00003202795,0.0000033291492,0.000052793508,0.00010174849,0.000006716599],"category_scores_gemma":[0.0000409047,0.00011499597,0.00007254162,0.0004894365,0.00010146577,0.00010575857,0.000026709617,0.00010042034,1.7931012e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062896316,0.0021050866,0.9549244,0.0003043817,0.00058273243,0.000011238975,0.0014252579,0.00056080846,0.010073649,0.000013016759,0.000013347566,0.02369642],"study_design_scores_gemma":[0.012532021,0.00857184,0.9357005,0.0002260984,0.0022770339,0.0000028399504,0.00014675775,0.0027372227,0.03762515,0.000006389171,0.00006773293,0.00010646959],"about_ca_topic_score_codex":0.00036078037,"about_ca_topic_score_gemma":0.00038680172,"teacher_disagreement_score":0.027551498,"about_ca_system_score_codex":0.000059540343,"about_ca_system_score_gemma":0.00027046778,"threshold_uncertainty_score":0.46893996},"labels":[],"label_agreement":null},{"id":"W2252597222","doi":"10.1093/annonc/mdv233.185","title":"P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Nab-paclitaxel; Pancreatic cancer; Clinical endpoint; Internal medicine; Oncology; Adjuvant; Chemotherapy; Paclitaxel; Cancer; Adjuvant therapy; Adjuvant chemotherapy; Randomized controlled trial; Breast cancer","score_opus":0.11810337230004588,"score_gpt":0.4540785049946711,"score_spread":0.33597513269462526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252597222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98062056,0.002117866,0.00025448672,0.0040124333,0.00029112783,0.008294908,0.00016222402,0.000040405692,0.0042060097],"genre_scores_gemma":[0.9901573,0.0037720173,0.0012830229,0.0008547844,0.00033412973,0.0015615283,0.00026709412,0.00005934015,0.0017107741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955989,0.0008473189,0.0014141535,0.00051008735,0.0008321048,0.0007974064],"domain_scores_gemma":[0.9924849,0.002814374,0.0010117772,0.0006259032,0.00253798,0.0005250454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003158547,0.00038734957,0.004487065,0.0003890147,0.000088538174,0.000008123283,0.00029002782,0.00042249894,0.00034407203],"category_scores_gemma":[0.004098836,0.00025719442,0.0003951761,0.0004263329,0.0010198199,0.00012342144,0.00007080842,0.00034639105,0.000009978742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9597952,0.0055292654,0.005836381,0.0001624974,0.0021999262,0.000043897464,0.0014245623,0.000007569644,0.0004798215,0.0001389635,0.0122372825,0.012144657],"study_design_scores_gemma":[0.8930759,0.09409069,0.0017650042,0.00020552182,0.0009133059,0.0000150714495,0.0002785349,0.0006990572,0.0010677286,0.0008062886,0.006856264,0.0002266513],"about_ca_topic_score_codex":0.0017337318,"about_ca_topic_score_gemma":0.00012730941,"teacher_disagreement_score":0.08856143,"about_ca_system_score_codex":0.00023502948,"about_ca_system_score_gemma":0.0036406664,"threshold_uncertainty_score":0.999988},"labels":[],"label_agreement":null},{"id":"W2253305012","doi":"10.1023/a:1013176129380","title":"Dietary glycemic index and glycemic load, and breast cancer risk: A case-control study","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Glycemic load; Glycemic index; Breast cancer; Glycemic; Hyperinsulinemia; Internal medicine; Odds ratio; Cancer; Oncology; Insulin resistance; Endocrinology; Insulin","score_opus":0.04607321402314904,"score_gpt":0.37363794467715644,"score_spread":0.3275647306540074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253305012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918381,0.004245096,0.000008291008,0.0025523019,0.0001302554,0.000517809,0.00017615466,0.000020925325,0.00051105005],"genre_scores_gemma":[0.9918648,0.0067423773,0.0000079380225,0.0010523329,0.00019493826,0.000035270063,0.0000015775222,0.000017422695,0.00008335588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988817,0.00007068274,0.0003057179,0.00030539237,0.00014870967,0.00028780347],"domain_scores_gemma":[0.99910474,0.00014891206,0.00018258789,0.00020012641,0.00016832569,0.00019533283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019250237,0.00016716459,0.00059206295,0.00010366279,0.00006959178,0.0000065652052,0.00004643393,0.00014593595,0.0002146878],"category_scores_gemma":[0.000040597475,0.00013727769,0.000060097664,0.00013283637,0.00019196402,0.000069440895,0.000047396075,0.00027265577,0.0000023959935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01974813,0.00042078595,0.6965864,0.000028675984,0.00034126447,0.0015956835,0.001155469,0.000008188458,0.00019328292,0.0000012414492,0.0009114484,0.27900946],"study_design_scores_gemma":[0.018224822,0.00932629,0.95394295,0.00004641282,0.00047494503,0.009403686,0.0014986697,0.0003660285,0.000014475452,0.000070430615,0.006444055,0.00018725106],"about_ca_topic_score_codex":0.020729482,"about_ca_topic_score_gemma":0.008708255,"teacher_disagreement_score":0.2788222,"about_ca_system_score_codex":0.00006620096,"about_ca_system_score_gemma":0.0002482795,"threshold_uncertainty_score":0.98579156},"labels":[],"label_agreement":null},{"id":"W2255756510","doi":"10.1023/a:1008391401404","title":"Breast cancer in women ≤35 years: Review of 1002 cases from a single institution","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Mastectomy; Cancer; Cohort; Surgery; Internal medicine","score_opus":0.040583937309721006,"score_gpt":0.34956174229950415,"score_spread":0.30897780498978317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255756510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96255195,0.034164,9.3382505e-7,0.0011959323,0.00004923959,0.0001027936,0.00034885624,0.0000030273227,0.0015832601],"genre_scores_gemma":[0.9140356,0.08451849,0.000046137655,0.0011902493,0.000079911995,0.000052289917,0.000030851534,0.000005913563,0.00004052894],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993206,0.00005861365,0.00023249099,0.00017228504,0.00006097962,0.00015500908],"domain_scores_gemma":[0.999621,0.00001953432,0.000103808525,0.00015563928,0.00006999339,0.000030059298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008115721,0.000085054846,0.00028873482,0.000027399105,0.000010455525,9.979175e-7,0.00008172497,0.00008234373,0.0005119049],"category_scores_gemma":[0.000023369932,0.00008114022,0.000052068826,0.000089892324,0.00012441332,0.0000041032736,0.000034613087,0.00003345871,0.0000050991853],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008381648,0.00084428745,0.0059116865,0.00031137513,0.0002525929,0.000036238514,0.00035313852,0.0000309895,0.018501299,0.000011133543,0.005205328,0.96770376],"study_design_scores_gemma":[0.0036759975,0.0028215132,0.5591931,0.0045292876,0.00011820495,0.00016750644,0.00027975134,0.0000029296261,0.04566832,0.00021494289,0.3828545,0.00047397142],"about_ca_topic_score_codex":0.0016091727,"about_ca_topic_score_gemma":0.0005849581,"teacher_disagreement_score":0.9672298,"about_ca_system_score_codex":0.000043556156,"about_ca_system_score_gemma":0.00013905842,"threshold_uncertainty_score":0.5604999},"labels":[],"label_agreement":null},{"id":"W2256487119","doi":"10.1093/annonc/mdq701","title":"Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Deutsche Forschungsgemeinschaft","keywords":"Ovarian cancer; Kallikrein; Medicine; Internal medicine; Biomarker; Cancer; Oncology; Ovarian tumor; Gastroenterology; Biology","score_opus":0.13506822105871472,"score_gpt":0.38067642967435866,"score_spread":0.24560820861564395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256487119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96342593,0.0009714152,0.000025535697,0.0011976687,0.0006551526,0.00038425293,0.000028003642,0.000070087226,0.033241972],"genre_scores_gemma":[0.9977308,0.00021631725,0.0002722165,0.00081162516,0.00013865672,0.000016238659,0.00008874562,0.000040112245,0.00068529247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810725,0.0001279597,0.0006867482,0.0003315022,0.0002597055,0.00048681122],"domain_scores_gemma":[0.9983755,0.00014325751,0.00042737921,0.00029665447,0.0004741509,0.0002830852],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042256762,0.00022826665,0.0006165641,0.00018710771,0.000090653804,0.0000068873396,0.0001233681,0.00029662333,0.0023163322],"category_scores_gemma":[0.00026734298,0.000207002,0.00017214043,0.00031854515,0.0001709744,0.00014015862,0.00006197597,0.00015680993,0.000053718217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086813857,0.0017484712,0.7356371,0.0001787361,0.00080445,0.00023544978,0.0056382422,0.000007719946,0.009949048,0.0018080624,0.0057800696,0.23734447],"study_design_scores_gemma":[0.0028062528,0.0016717912,0.97655976,0.00015441941,0.00014557547,0.000029711555,0.000113515154,0.00015119898,0.0071989056,0.0005422902,0.010394666,0.00023194394],"about_ca_topic_score_codex":0.002803983,"about_ca_topic_score_gemma":0.00025128745,"teacher_disagreement_score":0.24092259,"about_ca_system_score_codex":0.00005839431,"about_ca_system_score_gemma":0.0003220447,"threshold_uncertainty_score":0.9985957},"labels":[],"label_agreement":null},{"id":"W2259528854","doi":"10.1093/annonc/mdv600","title":"Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy","year":2015,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Chemotherapy; Cancer; Prostate; Internal medicine; Gynecology","score_opus":0.19323197578410067,"score_gpt":0.44471214094112205,"score_spread":0.2514801651570214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259528854","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016434724,0.0017172104,0.00000492658,0.9511189,0.00015785439,0.0020556885,0.000545991,0.000043314052,0.027921388],"genre_scores_gemma":[0.012429522,0.01851923,0.00081405626,0.8720941,0.002052142,0.0007476723,0.0014677433,0.00025447793,0.091621056],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971185,0.0002520683,0.00045676404,0.0006000635,0.0007828794,0.00078974676],"domain_scores_gemma":[0.997205,0.00021321826,0.00044154626,0.0004185972,0.0015109717,0.00021066281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004826102,0.00046698799,0.0014900307,0.00029224186,0.000049589173,0.000015464062,0.00016277915,0.00055962143,0.00029429508],"category_scores_gemma":[0.000037179165,0.00030636735,0.00016678417,0.00027697586,0.00056277186,0.000079606245,0.000046576628,0.0015090302,0.000042151714],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071063605,0.00024797692,0.00020339293,0.0004604963,0.00246499,0.006916653,0.0014652513,0.000005365769,0.00046353295,0.000005864057,0.9608148,0.019845335],"study_design_scores_gemma":[0.007409736,0.01179575,0.0005421396,0.00047799863,0.0005891749,0.00028777678,0.0004627024,0.000028726141,0.02435138,0.00015554333,0.9535179,0.00038117985],"about_ca_topic_score_codex":0.0010792171,"about_ca_topic_score_gemma":0.000119022174,"teacher_disagreement_score":0.0790248,"about_ca_system_score_codex":0.00036454652,"about_ca_system_score_gemma":0.0031713478,"threshold_uncertainty_score":0.99993885},"labels":[],"label_agreement":null},{"id":"W2260503332","doi":"10.1093/annonc/mdv584","title":"Reply to the letter to the editor ‘Integration between oncology and palliative care: does one size fit all?’ by Verna et al.","year":2015,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Palliative care; Scopus; Oncology; Family medicine; MEDLINE; Health care; Internal medicine; Library science; Nursing","score_opus":0.2591876808736437,"score_gpt":0.4857068373939897,"score_spread":0.226519156520346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260503332","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050191716,0.0022163675,0.00008171256,0.9858054,0.002377382,0.0011299087,0.0007547261,0.000023067982,0.0025922724],"genre_scores_gemma":[0.002659483,0.0019798093,0.000837995,0.9716467,0.020482779,0.0001751832,0.00045530562,0.000049191534,0.0017135162],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682105,0.00074890605,0.00072320824,0.00057865924,0.0006558485,0.00047233075],"domain_scores_gemma":[0.9934924,0.003808661,0.00060355145,0.0006668045,0.001254047,0.00017448395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011432155,0.00040006702,0.0014068272,0.000121250494,0.000062857274,0.000017068644,0.00046401162,0.0008005618,0.000064886575],"category_scores_gemma":[0.0026619185,0.00020688052,0.00019471372,0.00019064004,0.00029489267,0.000060576425,0.0002204261,0.0015472787,0.00005446179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031245835,0.00006352657,0.0008017191,0.00007024081,0.0005752192,0.000046704983,0.0098956935,0.0000012227224,0.0002711145,0.000005534304,0.9765689,0.011387661],"study_design_scores_gemma":[0.00077365345,0.0054347822,0.0011286901,0.00035897226,0.00033347678,0.0000024604512,0.0008709949,7.517541e-7,0.0019360943,0.000075721175,0.9888648,0.00021964702],"about_ca_topic_score_codex":0.0014455206,"about_ca_topic_score_gemma":0.00054309325,"teacher_disagreement_score":0.018105397,"about_ca_system_score_codex":0.00023834984,"about_ca_system_score_gemma":0.00049665914,"threshold_uncertainty_score":0.8436343},"labels":[],"label_agreement":null},{"id":"W2261765766","doi":"10.1093/annonc/mdw047","title":"Statistical controversies in clinical research: statistical significance—too much of a good thing …","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Breast cancer; Hazard ratio; Oncology; Trastuzumab; Internal medicine; Clinical trial; Statistical significance; Medical physics; Cancer; Confidence interval","score_opus":0.7268183586394775,"score_gpt":0.6943052263126884,"score_spread":0.032513132326789096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261765766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005376966,0.9693535,0.0004395415,0.003431123,0.00039169725,0.0023988711,0.0016282981,0.000017366321,0.02228584],"genre_scores_gemma":[0.0009775354,0.99532074,0.0020108852,0.0002968697,0.000454257,0.0001959592,0.00007828578,0.000073716306,0.0005917532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98784983,0.0053696726,0.00317354,0.00087810983,0.0014860131,0.0012428274],"domain_scores_gemma":[0.9455471,0.05118682,0.0007061842,0.00083682034,0.0011917613,0.0005313332],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014226026,0.00037499383,0.005568401,0.0008352818,0.000044220542,0.000011606646,0.0006371779,0.0011619532,0.0012740002],"category_scores_gemma":[0.032886516,0.00027065462,0.00047881636,0.0006222383,0.0030236193,0.000045622153,0.00039294024,0.002802022,0.00020488312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076618424,0.0009357567,0.00024988074,0.014522037,0.0003753881,0.00082449894,0.00008745696,3.444987e-8,0.0000040483415,0.022913394,0.075835966,0.8834854],"study_design_scores_gemma":[0.0020050085,0.008360625,0.0003024598,0.012687507,0.00019155885,0.000051738847,0.00012089001,0.000004966433,0.000007355612,0.0025730003,0.97349304,0.00020185724],"about_ca_topic_score_codex":0.000385938,"about_ca_topic_score_gemma":0.00009847388,"teacher_disagreement_score":0.8976571,"about_ca_system_score_codex":0.00043843695,"about_ca_system_score_gemma":0.0099185975,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W2263254645","doi":"10.1093/annonc/mdq541","title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Anastrozole; Bone mineral; Osteoporosis; Tamoxifen; Lumbar spine; Bone density; Surgery; Urology; Internal medicine; Breast cancer; Cancer","score_opus":0.06926204639395901,"score_gpt":0.41515466638466764,"score_spread":0.34589261999070864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263254645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982082,0.00010682395,0.000001284957,0.014876699,0.0005997176,0.00077042886,0.000055477823,0.00001088947,0.0014966407],"genre_scores_gemma":[0.9961223,0.00015379333,0.0001595776,0.0024293414,0.00073634175,0.000016507074,0.000087141656,0.000012436361,0.0002825602],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983664,0.00021297332,0.0004900515,0.00023234625,0.00034697336,0.00035126755],"domain_scores_gemma":[0.9971303,0.0016240947,0.00024148056,0.00052990695,0.0002599577,0.00021431176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008518592,0.000111495465,0.0005579946,0.00008620283,0.000049419377,0.000004062395,0.0001441805,0.0002453935,0.000059822178],"category_scores_gemma":[0.0020560548,0.0000739345,0.0001311572,0.00013296906,0.00025865715,0.000028855562,0.000071082795,0.00057735684,0.000035641264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42455512,0.0038205732,0.0693894,0.0004083329,0.00027823797,0.00058100827,0.00096571964,8.632025e-7,0.18110898,0.0003671176,0.13639021,0.18213443],"study_design_scores_gemma":[0.07159221,0.022628864,0.81319606,0.00013791934,0.00006852597,0.000022650114,0.00003660397,0.000009015308,0.0811439,0.000072382405,0.010996205,0.000095683594],"about_ca_topic_score_codex":0.0005533147,"about_ca_topic_score_gemma":0.0008048958,"teacher_disagreement_score":0.74380666,"about_ca_system_score_codex":0.000012728313,"about_ca_system_score_gemma":0.0003917404,"threshold_uncertainty_score":0.30149615},"labels":[],"label_agreement":null},{"id":"W2263836274","doi":"10.1093/annonc/mdu349.29","title":"Epidermal Growth Factor Receptor (Egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; Lung cancer; Docetaxel; Epidermal growth factor receptor; Pharmacology; Gastroenterology; Cancer","score_opus":0.04311287922148474,"score_gpt":0.40817573337076535,"score_spread":0.36506285414928064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263836274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088633,0.00094908936,0.00002412296,0.003700626,0.00026402902,0.0027623859,0.00005250586,0.000006779797,0.001354111],"genre_scores_gemma":[0.99627316,0.0014090958,0.00020485705,0.0011231191,0.00009994617,0.000635922,0.00004602753,0.0000143307225,0.00019351557],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984391,0.0003041271,0.00059092656,0.00027354405,0.00011985213,0.00027248228],"domain_scores_gemma":[0.9987098,0.00070878473,0.0002451377,0.00015063146,0.00008533706,0.000100298996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003731679,0.000194962,0.0009764127,0.0001519364,0.000045136276,0.0000073755896,0.000060306695,0.000114027665,0.000051704195],"category_scores_gemma":[0.00013978979,0.00011832054,0.00010273149,0.00010817684,0.00011517568,0.0000715955,0.000021125334,0.000106549516,9.913445e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53970474,0.006895635,0.25024116,0.0001415753,0.00049851293,0.000036334324,0.017530989,0.0000096240465,0.0010176866,0.00017142699,0.0005497629,0.18320253],"study_design_scores_gemma":[0.95418984,0.006380541,0.035601377,0.00006557894,0.00028818386,0.000002072312,0.00020849219,0.00013084704,0.0010029733,0.000037471673,0.0019582969,0.00013429842],"about_ca_topic_score_codex":0.0019356245,"about_ca_topic_score_gemma":0.0003851061,"teacher_disagreement_score":0.41448513,"about_ca_system_score_codex":0.00014251012,"about_ca_system_score_gemma":0.00019378688,"threshold_uncertainty_score":0.48249716},"labels":[],"label_agreement":null},{"id":"W2265279401","doi":"10.1093/annonc/mdu333.59","title":"Cpg Island Methylator Phenotype is Associated with the Efficacy of Chemotherapy in Patients with Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.028863245114678027,"score_gpt":0.34066030003084447,"score_spread":0.31179705491616644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265279401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993975,0.0003010984,0.000005924284,0.0031978302,0.000031318094,0.0004550794,0.000032695287,0.00000588945,0.0019951933],"genre_scores_gemma":[0.99853075,0.000084921914,0.000049321243,0.0011499932,0.000016936432,0.00006334024,0.000009185829,0.000013704328,0.0000818659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991728,0.00009216101,0.00020053612,0.00015376972,0.00019690677,0.00018381071],"domain_scores_gemma":[0.99894327,0.0003777328,0.00024086809,0.00010944474,0.0002937532,0.00003492691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019962675,0.00012714993,0.0006096958,0.00005747969,0.000030675423,0.0000018300929,0.000060393926,0.00004541123,0.00012392852],"category_scores_gemma":[0.00008419638,0.00006340815,0.00004933739,0.00024431106,0.00019238565,0.000022307806,0.000015548016,0.000091406015,7.7303764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021895675,0.0035512452,0.8546462,0.000063496445,0.0037262249,0.000008655822,0.0066269455,0.0000345234,0.00019291308,0.000084269275,0.0045829643,0.1045869],"study_design_scores_gemma":[0.01203387,0.015401623,0.96584743,0.00007199272,0.00022240759,5.0170286e-7,0.00010169106,0.000021395874,0.0021872835,0.000034651424,0.0039992183,0.00007792366],"about_ca_topic_score_codex":0.00036530168,"about_ca_topic_score_gemma":0.0024722514,"teacher_disagreement_score":0.11120125,"about_ca_system_score_codex":0.000058271908,"about_ca_system_score_gemma":0.0001566631,"threshold_uncertainty_score":0.25857094},"labels":[],"label_agreement":null},{"id":"W2266079976","doi":"10.1093/annonc/mdu338.35","title":"Etoposide Benefit in 2Nd Line and Beyond Relapsed Epithelial Ovarian Cancer (Eoc): a Population Based Analysis","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epithelial ovarian cancer; Ovarian cancer; Oncology; Etoposide; Internal medicine; Population; Gynecology; Cancer; Chemotherapy; Environmental health","score_opus":0.038298457132991334,"score_gpt":0.36425134458623293,"score_spread":0.3259528874532416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266079976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662444,0.0005056936,0.0001250527,0.031509873,0.00010467748,0.00026092088,0.000043366927,0.000018662673,0.0011873387],"genre_scores_gemma":[0.9946917,0.00041249505,0.001204711,0.0033301755,0.0001266793,0.000063124135,0.00008529074,0.000016055792,0.00006973473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890846,0.000083613624,0.000382695,0.00028660984,0.00013629602,0.00020233759],"domain_scores_gemma":[0.99916,0.0002101447,0.0001853808,0.00022436891,0.00011092106,0.00010919929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037658022,0.0001282928,0.00064247893,0.00036183075,0.000024817738,0.000005679245,0.00004111159,0.00016148154,0.00017317744],"category_scores_gemma":[0.00008038851,0.000110342706,0.00012546222,0.00041948567,0.00004082945,0.000042542208,0.000018405339,0.00010464521,0.0000016174466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073375815,0.0008406489,0.80663896,0.00005619499,0.0007230006,0.00003537317,0.00021737379,0.0015289418,0.00045502212,0.0017937255,0.00026455222,0.18671249],"study_design_scores_gemma":[0.0045995545,0.0020080982,0.9785046,0.000056431894,0.0008377605,0.0000030990227,0.000014274826,0.0035364535,0.0024343715,0.0009691163,0.0069341823,0.00010206114],"about_ca_topic_score_codex":0.0066679716,"about_ca_topic_score_gemma":0.010912804,"teacher_disagreement_score":0.18661042,"about_ca_system_score_codex":0.00008701044,"about_ca_system_score_gemma":0.00010994564,"threshold_uncertainty_score":0.9999467},"labels":[],"label_agreement":null},{"id":"W2267133977","doi":"10.1023/a:1008389706725","title":"Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance","year":2001,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Breast cancer; Internal medicine; Chemotherapy regimen; Disease; Cancer; Surgery; Oncology","score_opus":0.224575961975959,"score_gpt":0.5280030167004287,"score_spread":0.30342705472446974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267133977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060924806,0.98492444,0.00008865156,0.008606635,0.00014776598,0.0034810097,0.0005591131,0.000009402331,0.00157372],"genre_scores_gemma":[0.0003738533,0.9952201,0.0009959202,0.0007153267,0.00008751007,0.00042998418,0.00028572459,0.00003318823,0.0018583444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998325,0.0001811816,0.0009088892,0.00027713648,0.00011318351,0.00019461475],"domain_scores_gemma":[0.9964466,0.0011164022,0.0014410004,0.00044838744,0.00048243135,0.00006516906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004083698,0.00022539138,0.0022486805,0.0000889937,0.000030073394,8.8384184e-7,0.0001870442,0.0002461329,0.00008731417],"category_scores_gemma":[0.000040534993,0.00012529492,0.00058773643,0.00023839629,0.00026966192,0.0000131898905,0.000025015766,0.00014901877,0.0000012811845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018638467,0.0039200042,0.0006668656,0.0038690818,0.0025714547,0.0000017813975,0.00010057147,5.4684847e-8,0.0000016586106,0.0013951106,0.06129009,0.9243195],"study_design_scores_gemma":[0.003217445,0.0057644383,0.0014511651,0.00092948665,0.0026191918,0.0000029775588,0.000010105163,5.8241877e-8,0.000037949787,0.0006598762,0.9852223,0.00008500243],"about_ca_topic_score_codex":0.00001573442,"about_ca_topic_score_gemma":0.000075278134,"teacher_disagreement_score":0.92423445,"about_ca_system_score_codex":0.00007251428,"about_ca_system_score_gemma":0.00068396697,"threshold_uncertainty_score":0.5109378},"labels":[],"label_agreement":null},{"id":"W2269021429","doi":"10.1023/a:1011183905848","title":"Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bayer Canada","keywords":"Medicine; Pyridinoline; Deoxypyridinoline; Vascular endothelial growth factor; Internal medicine; Pharmacokinetics; Gastroenterology; Matrix metalloproteinase inhibitor; Matrix metalloproteinase; VEGF receptors; Alkaline phosphatase","score_opus":0.04761669532929767,"score_gpt":0.36610264619160415,"score_spread":0.31848595086230647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269021429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562216,0.00056356343,0.00007244991,0.00048764792,0.00023906455,0.00060647976,0.000015451973,0.000006204194,0.0023869723],"genre_scores_gemma":[0.9984197,0.00014104001,0.000111870526,0.00035094956,0.00021045396,0.000049454462,0.000010426126,0.000015451556,0.0006906584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873483,0.00021832273,0.00038440002,0.00025962683,0.0001740151,0.00022880916],"domain_scores_gemma":[0.99895716,0.000014148746,0.0002755995,0.0005163293,0.00016991967,0.00006682576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040343532,0.00014336625,0.00028866695,0.000049129943,0.000058952945,0.000003812458,0.00031383138,0.00018209043,0.000058957048],"category_scores_gemma":[0.00012431639,0.00010594935,0.0001661212,0.00012408626,0.00009755466,0.0000055257033,0.0002189622,0.00010435786,0.000005504667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053049263,0.0039016658,0.0003715424,0.000013566102,0.00012763607,0.000018394008,0.00011919359,0.000008576381,0.98527396,0.00014590546,0.0029442655,0.006544825],"study_design_scores_gemma":[0.0028297591,0.013358092,0.00009957236,0.000010546541,0.00003886344,0.000020370899,0.00026110365,0.000006667081,0.9071298,0.00027966866,0.07585712,0.000108387474],"about_ca_topic_score_codex":0.00006269603,"about_ca_topic_score_gemma":0.00010131546,"teacher_disagreement_score":0.07814408,"about_ca_system_score_codex":0.000006282562,"about_ca_system_score_gemma":0.00012976727,"threshold_uncertainty_score":0.43204892},"labels":[],"label_agreement":null},{"id":"W2272494096","doi":"10.1093/annonc/mdu337.10","title":"Prognostic Impact of Change in Neutrophil to Lymphocyte Ratio (Nlr) in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Neutrophil to lymphocyte ratio; Oncology; Internal medicine; Targeted therapy; Lymphocyte; Immunology; Cancer","score_opus":0.10425896873008773,"score_gpt":0.40157458924794515,"score_spread":0.2973156205178574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272494096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314666,0.000525746,0.000056600184,0.0030375975,0.000078385805,0.002963322,0.000063150765,0.000013363602,0.00011515843],"genre_scores_gemma":[0.9947918,0.0000292518,0.0021274632,0.0020015216,0.00006926477,0.00090405956,0.000023463157,0.000034477504,0.000018695791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976473,0.0006429072,0.000706068,0.0003337073,0.00019602233,0.00047401237],"domain_scores_gemma":[0.9979643,0.000835821,0.00024068028,0.0003538045,0.00034874238,0.000256656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017525249,0.00021602173,0.0007832053,0.0008304555,0.000019492525,0.0000042539405,0.00018395386,0.00012388952,0.0000524249],"category_scores_gemma":[0.0012058378,0.00018767848,0.00021238619,0.000577051,0.00007901407,0.00006557066,0.000053964217,0.00008559778,0.000008519445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14389369,0.0025502574,0.43330768,0.00049615925,0.00019223144,0.00021621658,0.005415263,0.0002175564,0.36660236,0.0000438585,0.0027215662,0.044343166],"study_design_scores_gemma":[0.0071923984,0.019426117,0.9071083,0.0001005861,0.000048448863,0.000008360178,0.00006235621,0.0006228887,0.06365273,0.00007656532,0.0015367988,0.00016446292],"about_ca_topic_score_codex":0.00027210874,"about_ca_topic_score_gemma":0.000098622964,"teacher_disagreement_score":0.4738006,"about_ca_system_score_codex":0.00020686422,"about_ca_system_score_gemma":0.0007866538,"threshold_uncertainty_score":0.7653306},"labels":[],"label_agreement":null},{"id":"W2272567705","doi":"10.1093/annonc/mdv563","title":"Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Prospective cohort study; Internal medicine","score_opus":0.10137213430937522,"score_gpt":0.38299706551908197,"score_spread":0.2816249312097068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272567705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922196,0.00005678036,0.0000040722543,0.00055725157,0.000031741693,0.005587314,0.0006788595,0.000007690863,0.0008566662],"genre_scores_gemma":[0.99911046,0.000011334843,0.00016989747,0.00004763878,0.000013061453,0.00034563305,0.0002442367,0.00001305776,0.000044672128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982189,0.00017438852,0.00058891246,0.00035903614,0.0004236728,0.00023508497],"domain_scores_gemma":[0.99791914,0.00019537582,0.00044310404,0.00023090826,0.0010104857,0.00020099709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025713083,0.00017845766,0.00067486486,0.00014941514,0.000021368567,0.0000062554163,0.000071430346,0.000107901564,0.000007142546],"category_scores_gemma":[0.00034082934,0.00014344623,0.000044835546,0.00022098426,0.00024013086,0.0001348219,0.00004456374,0.00012078827,0.0000012771196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046459753,0.023102313,0.9143981,0.00006691004,0.00039118945,0.00006268392,0.006349656,3.7432946e-7,0.00024316621,0.0000015155441,0.0014490983,0.0074752793],"study_design_scores_gemma":[0.04370117,0.12854707,0.80384946,0.00009377075,0.00004864463,0.000010309641,0.0015041301,0.00006626067,0.021849422,0.000014463129,0.0002183043,0.00009697198],"about_ca_topic_score_codex":0.00019419786,"about_ca_topic_score_gemma":0.00057385094,"teacher_disagreement_score":0.110548586,"about_ca_system_score_codex":0.00010696934,"about_ca_system_score_gemma":0.00035756818,"threshold_uncertainty_score":0.58495677},"labels":[],"label_agreement":null},{"id":"W2272568747","doi":"10.1093/annonc/mdv262.08","title":"LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Oncology; Internal medicine; Colorectal cancer; Cancer","score_opus":0.07104973586052514,"score_gpt":0.39449787310513673,"score_spread":0.3234481372446116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272568747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938504,0.00036373167,0.000006303419,0.00054903637,0.00009233864,0.004386871,0.0005694854,0.00000750985,0.0001743363],"genre_scores_gemma":[0.998705,0.00011020803,0.00034277406,0.000045749865,0.000015448491,0.0006716875,0.000042680706,0.000022682549,0.000043766067],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9979608,0.00018210207,0.00080990116,0.00034333582,0.00043374125,0.00027009932],"domain_scores_gemma":[0.99670136,0.00035253796,0.001017331,0.00022029421,0.0016314441,0.00007706206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022450468,0.00026215316,0.0014492751,0.00018620072,0.000041487692,0.000002003836,0.00009435801,0.000061687446,0.0000045063457],"category_scores_gemma":[0.00023535045,0.00013789398,0.00009301254,0.00062146556,0.00025794824,0.00009322196,0.00003892681,0.00006433605,1.160448e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52189195,0.21194048,0.10375998,0.0003504553,0.004614783,0.00007240581,0.05144049,0.00026969373,0.004040286,0.00002073559,0.00045042034,0.101148315],"study_design_scores_gemma":[0.29111788,0.4745119,0.13837409,0.00025409635,0.000994945,0.0000073832252,0.0065785022,0.000073501746,0.08757424,0.000047384845,0.0002903972,0.00017568677],"about_ca_topic_score_codex":0.0015651134,"about_ca_topic_score_gemma":0.014103556,"teacher_disagreement_score":0.2625714,"about_ca_system_score_codex":0.0003853905,"about_ca_system_score_gemma":0.0010303813,"threshold_uncertainty_score":0.7870115},"labels":[],"label_agreement":null},{"id":"W2274765772","doi":"10.1093/annonc/mdu347.5","title":"Egfr Del19/L858R Activating Mutation (M+) Subgroup in Radiant: Baseline Characteristics, Prognostic Role, and Disease-Free Survival (Dfs) By Stage","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Distributed File System; Stage (stratigraphy); Oncology; Internal medicine; Disease; Baseline (sea); Subgroup analysis; Mutation; Survival analysis; Overall survival; Meta-analysis; Genetics","score_opus":0.027277831118630698,"score_gpt":0.3616885405395957,"score_spread":0.334410709420965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274765772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657864,0.0005604738,0.0005053774,0.009614331,0.00015479745,0.00049891113,0.00025585576,0.000026106263,0.00180552],"genre_scores_gemma":[0.99742854,0.00022134352,0.00036916047,0.0009907259,0.00014403218,0.00005106941,0.00045380564,0.00002002098,0.00032128548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988949,0.00014288217,0.00034692805,0.00023781054,0.00014355358,0.00023394426],"domain_scores_gemma":[0.99874544,0.00047741484,0.00019652289,0.0001984638,0.00015585341,0.00022631812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039927708,0.00013071336,0.00036790431,0.000116641706,0.00004865475,0.00001003187,0.00006161701,0.0000781023,0.00004253643],"category_scores_gemma":[0.0018757763,0.00010747516,0.000039587067,0.00012165322,0.00008577111,0.00010885561,0.000031803655,0.00011373684,0.0000037100826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010609153,0.0016887832,0.5536021,0.00041136204,0.00024422523,0.00018966253,0.0014684988,0.000019834459,0.0027698358,0.0012801748,0.003213253,0.43405136],"study_design_scores_gemma":[0.0064408127,0.002423984,0.93317205,0.00020923073,0.00023621191,0.000017405297,0.00057279575,0.0039086468,0.00064531725,0.0009596898,0.051177844,0.00023602966],"about_ca_topic_score_codex":0.00032256873,"about_ca_topic_score_gemma":0.00014647728,"teacher_disagreement_score":0.43381533,"about_ca_system_score_codex":0.000060280756,"about_ca_system_score_gemma":0.00023278249,"threshold_uncertainty_score":0.43827102},"labels":[],"label_agreement":null},{"id":"W2275071246","doi":"10.1093/annonc/mdu349.85","title":"Effective Knowledge Dissemination Improves Histological Classification of Non Small Cell Lung Cancer: Reducing the Rates of Nsclc – not Otherwise Specified (Nos)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Lung cancer; Oncology; Internal medicine; Pathology","score_opus":0.048154059760466536,"score_gpt":0.4275572446699737,"score_spread":0.37940318490950714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275071246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969372,0.0014426596,0.00046794506,0.0021090144,0.00018368813,0.0007899212,0.000015186394,0.000009100843,0.025610525],"genre_scores_gemma":[0.99864113,0.00027576782,0.0002558007,0.0000777813,0.000096745986,0.0001381342,0.000016864835,0.000010542837,0.0004872482],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99913996,0.00013690897,0.0003355865,0.00018114073,0.00008064129,0.0001257661],"domain_scores_gemma":[0.9982631,0.00064910867,0.0004588796,0.0002030782,0.00038626316,0.00003952271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032740217,0.000100525205,0.0003803035,0.000081116246,0.000042275627,0.0000018730192,0.00008535811,0.00011272836,0.000028284201],"category_scores_gemma":[0.0001479294,0.00006483426,0.00009493366,0.00014245458,0.00017773536,0.000030974585,0.000019204579,0.000090071866,0.0000016372734],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009259775,0.0012266607,0.0071113487,0.00040200638,0.00023531896,0.0000011442287,0.005257714,0.000025591342,0.6216783,0.001184824,0.0024995701,0.35945153],"study_design_scores_gemma":[0.0015899575,0.0032394396,0.51955295,0.00021701073,0.00047064284,0.0000025861725,0.0005638406,0.0027093184,0.46877798,0.00008887194,0.0027031866,0.0000841827],"about_ca_topic_score_codex":0.00025460013,"about_ca_topic_score_gemma":0.00008483566,"teacher_disagreement_score":0.51244164,"about_ca_system_score_codex":0.000106857246,"about_ca_system_score_gemma":0.00021104219,"threshold_uncertainty_score":0.26438645},"labels":[],"label_agreement":null},{"id":"W2276172426","doi":"10.1093/annonc/mdu356.34","title":"Risk Factors for Hypocalcemia in Patients with Cancer Receiving Denosumab","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Oncology; Internal medicine; Cancer; Osteoporosis","score_opus":0.05583445735638335,"score_gpt":0.3864133384402377,"score_spread":0.3305788810838543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276172426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756885,0.00008551554,0.000032980413,0.0007575146,0.00010382398,0.00046584016,0.000026041147,0.000009321676,0.000950089],"genre_scores_gemma":[0.9984362,0.00010264743,0.00053680147,0.00071159337,0.000020988084,0.00005841586,0.00002736804,0.000012429668,0.00009354629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992427,0.000052395077,0.00021368606,0.00014892554,0.00008735479,0.00025491504],"domain_scores_gemma":[0.9991811,0.00028516699,0.0001652686,0.00011924654,0.00014155738,0.00010766232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015209141,0.00008613148,0.0003494682,0.00007732813,0.000031145533,0.0000010723732,0.000032787982,0.00010672272,0.000027248161],"category_scores_gemma":[0.00026737418,0.00005975276,0.00003745042,0.00008034485,0.000038833005,0.000030027699,0.000008958398,0.000094941955,0.0000029124558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011446017,0.00040515407,0.90154415,0.00004207584,0.0000494817,8.896403e-7,0.00015713285,0.000006242157,0.0000024689273,0.000015746857,0.00089229096,0.09573979],"study_design_scores_gemma":[0.005892205,0.006377773,0.977063,0.000056901943,0.000047731166,3.9373725e-7,0.000017517703,0.000027265787,0.00027460378,0.00012621252,0.010064826,0.000051588762],"about_ca_topic_score_codex":0.0015802457,"about_ca_topic_score_gemma":0.0010659276,"teacher_disagreement_score":0.095688194,"about_ca_system_score_codex":0.00006183909,"about_ca_system_score_gemma":0.00016531225,"threshold_uncertainty_score":0.2436647},"labels":[],"label_agreement":null},{"id":"W2277756860","doi":"10.1093/annonc/mdu358.46","title":"Practical Guidelines for Ethical and Policy Issues that Arise from the Clinical Application of Whole Genome Sequencing in Cancer Patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Genome; Engineering ethics; Intensive care medicine; Computational biology; Internal medicine; Genetics; Gene","score_opus":0.215574812069164,"score_gpt":0.5229185165926362,"score_spread":0.3073437045234722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277756860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659857,0.00070717046,0.00081683276,0.03203076,0.000045922683,0.00020979073,0.00015270186,0.0000013067888,0.00004977958],"genre_scores_gemma":[0.9893461,0.0015536492,0.0019063146,0.0066444078,0.0003617821,0.000036794972,0.00013346398,0.000007331818,0.000010194051],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991792,0.00013009818,0.0003362168,0.00018859455,0.00005459659,0.000111300746],"domain_scores_gemma":[0.99906147,0.00021504782,0.00019944095,0.00015894562,0.00032093786,0.000044164226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053831044,0.00006515634,0.00019480602,0.000018770485,0.000022766819,0.0000035150695,0.000098936835,0.00025241938,0.0000015627578],"category_scores_gemma":[0.0014978348,0.00004754552,0.000061043276,0.000028544431,0.00014518495,0.0000022153113,0.000079058584,0.00008574108,4.019491e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002242411,0.0013721158,0.35706434,0.0001623433,0.00044032148,0.0000022026352,0.00087105285,0.00049030746,0.3083396,0.0051099523,0.058488786,0.26541656],"study_design_scores_gemma":[0.0016785893,0.0021465027,0.18696886,0.000022979091,0.0000532017,0.0000016266914,0.00024188615,0.00093531836,0.011140979,0.004834277,0.7917982,0.00017761142],"about_ca_topic_score_codex":0.0009428364,"about_ca_topic_score_gemma":0.00042285566,"teacher_disagreement_score":0.7333094,"about_ca_system_score_codex":0.000008158614,"about_ca_system_score_gemma":0.00028242552,"threshold_uncertainty_score":0.19468896},"labels":[],"label_agreement":null},{"id":"W2281123640","doi":"10.1023/a:1008347630465","title":"A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Ontario Institute for Cancer Research; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program","funders":"Bayer Canada","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Pharmacology; Toxicity; Internal medicine; Gastroenterology; Oral administration; Anemia; Adverse effect","score_opus":0.02097979016798312,"score_gpt":0.3324782400271061,"score_spread":0.31149844985912295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281123640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982126,0.000073476775,0.000008015052,0.00013766339,0.00006368758,0.0011292541,0.000029266213,0.0000046114505,0.00034142987],"genre_scores_gemma":[0.99929345,0.000017894472,0.00020507377,0.00015770251,0.00004401247,0.00007595115,0.00003983711,0.00001719989,0.0001488525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986627,0.00020957617,0.00042935798,0.00028631676,0.00019262804,0.00021943165],"domain_scores_gemma":[0.9991193,0.000010086337,0.00028101733,0.0003704503,0.00015852113,0.00006062895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022433611,0.00015889142,0.0003144867,0.000056197958,0.0000383783,0.000004460616,0.00020373636,0.00013763037,0.00005024152],"category_scores_gemma":[0.000053574164,0.00011453928,0.00007982646,0.00013449726,0.000072704235,0.000013485449,0.00007196681,0.000098781195,0.0000023802295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019450773,0.026135407,0.013017675,0.00006480873,0.00023957505,0.000027944043,0.00084351865,0.00035802397,0.86713403,0.000032596658,0.00038077857,0.07231487],"study_design_scores_gemma":[0.017273031,0.06148298,0.014787195,0.0000586812,0.000051566793,0.000003029839,0.00021685539,0.000022017051,0.9037468,0.000085488326,0.0020417697,0.00023057443],"about_ca_topic_score_codex":0.000025151976,"about_ca_topic_score_gemma":0.00016154636,"teacher_disagreement_score":0.0720843,"about_ca_system_score_codex":0.000011573276,"about_ca_system_score_gemma":0.0001501251,"threshold_uncertainty_score":0.46707764},"labels":[],"label_agreement":null},{"id":"W2281646699","doi":"10.1093/annonc/mdu344.2","title":"Phase Ib/Ii Study of Lee011 (Cdk4/6 Inhibitor) and Lgx818 (Braf Inhibitor) in Braf-Mutant Melanoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Cancer research; Melanoma; Mutant; Genetics; Gene; Biology","score_opus":0.08539922642463935,"score_gpt":0.42152955639009143,"score_spread":0.3361303299654521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281646699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869779,0.00054656644,0.000002753178,0.004404637,0.00016883033,0.00055657665,0.000021949321,0.0000140887605,0.0073067276],"genre_scores_gemma":[0.99804157,0.00030561874,0.0000922518,0.0006118174,0.00028887682,0.000021432063,0.000013766945,0.000020269566,0.0006043931],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99770206,0.00029550673,0.00077089533,0.0003709633,0.00042188083,0.0004386683],"domain_scores_gemma":[0.9986742,0.00030851163,0.00022569207,0.00029212006,0.0002694946,0.00022993797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093736313,0.00021032561,0.00094849116,0.00037425425,0.00007219153,0.0000051679485,0.0001575795,0.00019707307,0.00014998514],"category_scores_gemma":[0.00029770777,0.00016934927,0.000099400204,0.00029752598,0.00034749016,0.00008180544,0.00028048598,0.0003621428,0.000012029182],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012514194,0.043759894,0.25527102,0.00095904816,0.0006678817,0.0010293719,0.010510993,0.000007594589,0.31628108,0.00241359,0.015116183,0.34146914],"study_design_scores_gemma":[0.05423913,0.3207921,0.1814555,0.0006466461,0.00019691908,0.00066890055,0.003929114,0.00072159077,0.21563019,0.0017484367,0.21914925,0.000822223],"about_ca_topic_score_codex":0.0008039312,"about_ca_topic_score_gemma":0.00048287015,"teacher_disagreement_score":0.34064692,"about_ca_system_score_codex":0.000024615592,"about_ca_system_score_gemma":0.00020262266,"threshold_uncertainty_score":0.69058627},"labels":[],"label_agreement":null},{"id":"W2283867889","doi":"10.1093/annonc/mdu438.33","title":"Cross-Comparison of Cancer Drug Approvals Among International Regulatory Bodies","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Drug; Cancer drugs; Drug approval; Cancer; Oncology; Pharmacology; Internal medicine","score_opus":0.15396424428328415,"score_gpt":0.44321385571232835,"score_spread":0.2892496114290442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283867889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86735123,0.001181819,0.000044011,0.0033936873,0.00064366835,0.0000673646,0.000116071664,0.000008165092,0.12719396],"genre_scores_gemma":[0.997036,0.0005298449,0.00013171375,0.001215307,0.00021501124,0.00001627816,0.0000065119434,0.000011483996,0.00083786884],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987133,0.000019649113,0.00082099834,0.000216817,0.000025608064,0.00020362153],"domain_scores_gemma":[0.9987634,0.00012438372,0.0007624244,0.00019285509,0.00008557006,0.00007136412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073796394,0.00009486606,0.00056153355,0.00016529053,0.000029290582,0.00001327969,0.00030805587,0.000104965926,0.0006265245],"category_scores_gemma":[0.00014647079,0.00010985877,0.00013888859,0.000047213205,0.0002960791,0.00013202487,0.000087860906,0.0001134445,0.00005421525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053255695,0.00027976747,0.71236295,0.0000450698,0.00016997664,2.1457072e-7,0.0006626688,0.00061632175,0.000094715695,0.25089854,0.011280933,0.023535598],"study_design_scores_gemma":[0.00069719256,0.00013195004,0.28073427,0.000011163858,0.0000053324143,3.2081567e-7,0.000023783505,0.0066448105,0.007002409,0.037664544,0.66693264,0.0001516074],"about_ca_topic_score_codex":0.0005676161,"about_ca_topic_score_gemma":0.00014498144,"teacher_disagreement_score":0.6556517,"about_ca_system_score_codex":0.00003482986,"about_ca_system_score_gemma":0.000032099364,"threshold_uncertainty_score":0.6860004},"labels":[],"label_agreement":null},{"id":"W2285463317","doi":"10.1093/annonc/mdv233.175","title":"P-175 Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Oncolytic virus; Gemcitabine; Pancreatic cancer; Oncology; Internal medicine; Pharmacodynamics; Adenocarcinoma; Combination therapy; Cancer; Pharmacokinetics","score_opus":0.055488054782214406,"score_gpt":0.4077841005694687,"score_spread":0.35229604578725426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285463317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966434,0.0023412576,0.00001016957,0.00021779508,0.000018511286,0.00067363563,0.000022110193,0.0000030984538,0.00007000185],"genre_scores_gemma":[0.99581337,0.003657818,0.00012892115,0.00017663401,0.000011701202,0.00007006637,0.000106470434,0.00002130208,0.00001373116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777675,0.00059189537,0.0006543037,0.0004163754,0.0002482606,0.00031240433],"domain_scores_gemma":[0.9988111,0.00015214938,0.00032509226,0.00030838762,0.0002983563,0.00010486737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009762748,0.0001853927,0.000831138,0.0005378196,0.000011936939,0.0000040019586,0.00019013324,0.00016192766,0.000010315738],"category_scores_gemma":[0.00011593678,0.00015276768,0.000056120898,0.0010441685,0.00026045938,0.000014011054,0.000050306317,0.00018876247,3.8194935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035743274,0.0018881086,0.90531784,0.000020941301,0.00052652374,0.000011611962,0.00020424151,0.0029867545,0.010465781,0.0000030881154,0.000011329667,0.042820506],"study_design_scores_gemma":[0.020813605,0.037814915,0.93066615,0.00005643295,0.00011514344,6.740656e-7,0.0000702666,0.0012213262,0.008998164,0.000018291674,0.000058804657,0.0001662187],"about_ca_topic_score_codex":0.0006835621,"about_ca_topic_score_gemma":0.010083631,"teacher_disagreement_score":0.042654287,"about_ca_system_score_codex":0.00007551371,"about_ca_system_score_gemma":0.0005202563,"threshold_uncertainty_score":0.6229685},"labels":[],"label_agreement":null},{"id":"W2286143684","doi":"10.1093/annonc/mdu336.36","title":"Efficacy of Enzalutamide (Enza) Following Abiraterone Acetate (Abi) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Prostate cancer; Abiraterone; Oncology; Chemotherapy; Internal medicine; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.07218588100082024,"score_gpt":0.409645634980664,"score_spread":0.33745975397984374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286143684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404186,0.00090990734,0.000007971071,0.0026836772,0.0001430178,0.0010087953,0.000042289652,0.000015159121,0.0011472931],"genre_scores_gemma":[0.99759525,0.0007846507,0.00039136838,0.00049190945,0.00003756293,0.000114366754,0.00006453478,0.00003194109,0.00048843864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99790484,0.00021835677,0.00069321354,0.0003246059,0.00037995298,0.00047902763],"domain_scores_gemma":[0.9986983,0.00025574575,0.00032266538,0.0002691114,0.0003153142,0.00013889151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063568243,0.0002091557,0.00081852044,0.00025618298,0.000040911043,0.000007609962,0.00012602803,0.000095579235,0.000089647656],"category_scores_gemma":[0.00018040842,0.00016426624,0.00016939043,0.0003411202,0.00017969694,0.00011481216,0.00003790535,0.00018758612,0.000008198696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023298778,0.007224811,0.23181963,0.0013860812,0.0021936412,0.00022468848,0.010194976,0.00047260337,0.20812583,0.00024364224,0.002213452,0.51260185],"study_design_scores_gemma":[0.053016145,0.013976462,0.64360803,0.0008203269,0.00033193085,0.0000055657247,0.0004393206,0.00032947198,0.27619213,0.0006525789,0.010205356,0.00042266434],"about_ca_topic_score_codex":0.0006767334,"about_ca_topic_score_gemma":0.00038318476,"teacher_disagreement_score":0.5121792,"about_ca_system_score_codex":0.00014370977,"about_ca_system_score_gemma":0.00045783026,"threshold_uncertainty_score":0.6698583},"labels":[],"label_agreement":null},{"id":"W2286422058","doi":"10.1093/annonc/mdw020","title":"Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Celgene","keywords":"Medicine; Gemcitabine; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Positron emission tomography; Pancreatic cancer; Internal medicine; Nuclear medicine; Standardized uptake value; Adenocarcinoma; Oncology; Cancer; Progressive disease; Chemotherapy; Confidence interval","score_opus":0.09115762483535532,"score_gpt":0.42011523929443906,"score_spread":0.3289576144590837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286422058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98625416,0.00086291204,0.0005328457,0.004863373,0.00023832291,0.0066348007,0.00032278502,0.000010918136,0.00027990443],"genre_scores_gemma":[0.99683774,0.00013997253,0.0019257074,0.00009267073,0.00008699785,0.000546898,0.00010242755,0.000026499134,0.00024110387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947247,0.002336405,0.0012481129,0.00037532125,0.0009128751,0.0004026002],"domain_scores_gemma":[0.98674077,0.009398076,0.001173578,0.0006204257,0.001884141,0.00018298507],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005192277,0.0002495493,0.002473527,0.0003329551,0.00007412136,0.0000027663716,0.0002454609,0.00020977012,0.0001914957],"category_scores_gemma":[0.008525153,0.00012659545,0.00049428083,0.00036649485,0.00091434724,0.00009793402,0.00008097352,0.00014582343,0.0000014930877],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96503305,0.003010502,0.006687928,0.000086311775,0.0020044558,0.000004155641,0.0005040588,8.705672e-7,0.013717538,0.000059671835,0.0009555946,0.007935846],"study_design_scores_gemma":[0.90696716,0.047573555,0.033279285,0.00032773812,0.0037041483,0.0000030156853,0.00015967405,0.00032973348,0.0066253524,0.00069466163,0.0002112025,0.00012447314],"about_ca_topic_score_codex":0.00033511894,"about_ca_topic_score_gemma":0.000026006588,"teacher_disagreement_score":0.058065906,"about_ca_system_score_codex":0.00013473484,"about_ca_system_score_gemma":0.0015778937,"threshold_uncertainty_score":0.99982643},"labels":[],"label_agreement":null},{"id":"W2288916040","doi":"10.1093/annonc/mdu290.4","title":"Targeting Cancer Aneuploidy: Light at the End of the Tunnel?","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Aneuploidy; Cancer; Cancer research; Genetics; Internal medicine; Gene; Chromosome","score_opus":0.019064715999730215,"score_gpt":0.3041010015199625,"score_spread":0.2850362855202323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288916040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875355,0.0017453448,0.000048910813,0.006346536,0.00025637145,0.0001234877,0.000023671075,0.0000024447063,0.003917747],"genre_scores_gemma":[0.99517083,0.0012138943,0.0000395879,0.0022381737,0.00020309932,0.0000145970325,0.000014588836,0.000011438691,0.0010937699],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992198,0.00013927779,0.00022191042,0.0001617645,0.00007457271,0.00018267434],"domain_scores_gemma":[0.9992617,0.00003988122,0.0002208887,0.00032947457,0.0001212916,0.000026815032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032560574,0.00008963942,0.00016635371,0.000012804991,0.0000739617,0.0000021057397,0.0003050831,0.00014625821,0.000063796346],"category_scores_gemma":[0.000110547335,0.000052018648,0.00011788374,0.00005506969,0.00020825682,0.0000014255106,0.00024136186,0.00007534217,0.0000032033417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041956206,0.000047857466,0.0031689983,0.000017527027,0.000051157516,1.9590826e-7,0.00008816217,0.00013968389,0.959848,0.00016470996,0.02947182,0.006959973],"study_design_scores_gemma":[0.00014110109,0.00023193248,0.0016751095,0.000006258645,0.000013040714,0.0000035736518,0.000023172968,0.000031092375,0.5510232,0.000057870147,0.44674572,0.000047914382],"about_ca_topic_score_codex":0.00009657115,"about_ca_topic_score_gemma":0.0005107884,"teacher_disagreement_score":0.4172739,"about_ca_system_score_codex":0.000007599722,"about_ca_system_score_gemma":0.00008745924,"threshold_uncertainty_score":0.21212588},"labels":[],"label_agreement":null},{"id":"W2289494355","doi":"10.1093/annonc/mdu333.95","title":"Effect of Resection of Metastasis (Rom) and All 3, 4 and 5 Active Agents in Metastatic Colorectal Cancer (Mcrc) Between 1995-2010","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Metastasis; Internal medicine; Resection; Cancer; Surgery","score_opus":0.1045778137302007,"score_gpt":0.4383607804563657,"score_spread":0.333782966726165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289494355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964467,0.0013974196,0.0000015994597,0.0006366913,0.00006885292,0.0004118697,0.000071782466,0.0000035246082,0.00096155214],"genre_scores_gemma":[0.9980642,0.0016865915,0.000068537054,0.00005599217,0.000022954333,0.000056933808,0.000009903496,0.000007985445,0.000026893576],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99896383,0.00026578084,0.00030317294,0.00018375585,0.00012712044,0.00015632392],"domain_scores_gemma":[0.9988061,0.00071788515,0.00023629125,0.00007549744,0.00010564986,0.000058542188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000524494,0.00012362478,0.0009031659,0.00016372997,0.000019098059,0.0000011995331,0.000031582113,0.00006686479,0.000026560425],"category_scores_gemma":[0.00022658409,0.00009134356,0.00006309176,0.00013666462,0.00022871608,0.00004181208,0.00005555838,0.00009584081,2.4113987e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009406398,0.00044611807,0.36286655,0.00087185204,0.0032230974,0.000015597296,0.0025121933,0.0000046415494,0.01211948,0.00003928928,0.00061623997,0.60787857],"study_design_scores_gemma":[0.0046247174,0.037752483,0.82474303,0.00011963454,0.0009894687,0.000008760905,0.00014579423,0.00002743024,0.12946332,0.0001411127,0.001902579,0.000081682665],"about_ca_topic_score_codex":0.002625915,"about_ca_topic_score_gemma":0.002570632,"teacher_disagreement_score":0.60779685,"about_ca_system_score_codex":0.000042114934,"about_ca_system_score_gemma":0.000050568247,"threshold_uncertainty_score":0.39696154},"labels":[],"label_agreement":null},{"id":"W2294307578","doi":"10.1093/annonc/mdw098","title":"Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Université Laval; Brampton Civic Hospital; Ontario Institute for Cancer Research","funders":"Pfizer; Halozyme; GlaxoSmithKline; Amgen","keywords":"Medicine; Docetaxel; Cyclophosphamide; Breast cancer; Regimen; Internal medicine; Febrile neutropenia; Oncology; Metastatic breast cancer; Chemotherapy; Neutropenia; Doxorubicin; Surgery; Cancer","score_opus":0.0269477683234731,"score_gpt":0.3422365740486171,"score_spread":0.315288805725144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294307578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390227,0.0019220662,0.000029609115,0.0027835674,0.00021667262,0.0007281426,0.00027507616,0.000004317651,0.00013825634],"genre_scores_gemma":[0.9940161,0.0053121876,0.000043576805,0.00009745146,0.000066896646,0.0003599703,0.00003676069,0.000014524238,0.00005250252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987813,0.00018047029,0.000374565,0.00031932947,0.00011435319,0.00022997762],"domain_scores_gemma":[0.9991572,0.000182209,0.00029191727,0.00017487131,0.00014322542,0.00005057606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001399636,0.00022197177,0.0008439965,0.0000723223,0.000023670129,0.0000033412086,0.00006533989,0.0001335857,0.00002314638],"category_scores_gemma":[0.000028530545,0.00013147063,0.00014043266,0.000056464385,0.00043501923,0.000010710287,0.000051546547,0.000026457315,7.374506e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8128692,0.0011069727,0.1415655,0.00002007462,0.0011539649,0.000028981167,0.00022176268,0.0000040150135,0.0042994674,0.00003324889,0.000020337951,0.038676467],"study_design_scores_gemma":[0.58068424,0.0031333675,0.3717386,0.000072155206,0.00019383928,0.000010313728,0.000021497946,6.641381e-7,0.043960404,0.00002359109,0.000030671268,0.00013064044],"about_ca_topic_score_codex":0.0007359752,"about_ca_topic_score_gemma":0.0014829068,"teacher_disagreement_score":0.23218496,"about_ca_system_score_codex":0.00008637879,"about_ca_system_score_gemma":0.00016111122,"threshold_uncertainty_score":0.53612167},"labels":[],"label_agreement":null},{"id":"W2294343390","doi":"10.1093/annonc/mdu337.58","title":"The Significance of Complete Response (Cr) in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma (Uc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Urothelial carcinoma; Salvage therapy; Oncology; Carcinoma; Internal medicine; Urology; Chemotherapy; Cancer; Bladder cancer","score_opus":0.06490892029599489,"score_gpt":0.363615231792738,"score_spread":0.29870631149674315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294343390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368286,0.00030624834,0.00008098306,0.002850838,0.00020266426,0.0012151583,0.000059016398,0.000009337251,0.0015928647],"genre_scores_gemma":[0.9978783,0.0001935348,0.00036571082,0.0011537235,0.00006597656,0.00015442428,0.00000985374,0.00002200258,0.00015648076],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859035,0.00031562572,0.00042391705,0.00020754202,0.00015867478,0.00030389996],"domain_scores_gemma":[0.99794215,0.0011893967,0.00024441638,0.00030115657,0.00026435827,0.000058529615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000793054,0.00012759551,0.00046564025,0.00007845286,0.00006233398,0.000002793279,0.00014596469,0.000087471606,0.000014475737],"category_scores_gemma":[0.00045975886,0.00008993876,0.00011715205,0.00012110138,0.00016727023,0.00003635681,0.000022667558,0.00009455072,0.0000024110493],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11109116,0.0015824107,0.20845959,0.00010915746,0.00018481525,0.0000052142345,0.0015871319,0.00002297286,0.061129607,0.00040868815,0.002130936,0.61328834],"study_design_scores_gemma":[0.014617665,0.021101117,0.84772813,0.0000564214,0.000022654947,0.0000013341922,0.00008506479,0.0000443643,0.031852134,0.00062230334,0.08376393,0.00010488986],"about_ca_topic_score_codex":0.00010469471,"about_ca_topic_score_gemma":0.00007293145,"teacher_disagreement_score":0.6392685,"about_ca_system_score_codex":0.000045298068,"about_ca_system_score_gemma":0.0002317647,"threshold_uncertainty_score":0.3667596},"labels":[],"label_agreement":null},{"id":"W2294633761","doi":"10.1093/annonc/mdw133","title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Myriad Genetics; AstraZeneca","keywords":"Olaparib; Medicine; Internal medicine; Ovarian cancer; Oncology; PARP inhibitor; Population; BRCA mutation; Chemotherapy; Cancer","score_opus":0.03294610948529814,"score_gpt":0.38652179802397246,"score_spread":0.3535756885386743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294633761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923383,0.00065335294,0.00017364221,0.0061872727,0.00002704519,0.00044810708,0.00011187938,0.000008639471,0.000051733507],"genre_scores_gemma":[0.99672,0.001383746,0.0009382768,0.0007789257,0.000011763855,0.000064614505,0.000013221933,0.000012988804,0.00007647037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987764,0.00020231507,0.00046176816,0.00025930896,0.00014715754,0.00015306944],"domain_scores_gemma":[0.99852145,0.0005436644,0.00033287128,0.00018943689,0.00034026627,0.00007230949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046849545,0.00012114533,0.00065858924,0.0003866107,0.000023672837,0.0000018715402,0.000038207305,0.000093987794,0.00010237677],"category_scores_gemma":[0.00012219691,0.000082362145,0.000042996002,0.00051522464,0.00024087782,0.00008585193,0.000013306364,0.000066723536,2.8386717e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12519008,0.000829696,0.6876582,0.000034277295,0.0014377458,0.000021618445,0.00247802,0.000070394795,0.014251975,0.00006006682,0.0000804912,0.16788742],"study_design_scores_gemma":[0.030742662,0.00487998,0.9578866,0.0001552572,0.00017476881,0.0000025726438,0.00007722479,0.0000709407,0.0045736306,0.000061630584,0.0012805874,0.000094173236],"about_ca_topic_score_codex":0.00015839051,"about_ca_topic_score_gemma":0.00039485135,"teacher_disagreement_score":0.27022836,"about_ca_system_score_codex":0.00006744774,"about_ca_system_score_gemma":0.00016896676,"threshold_uncertainty_score":0.33586308},"labels":[],"label_agreement":null},{"id":"W2294989188","doi":"10.1093/annonc/mdw100","title":"Ocular toxicities of MEK inhibitors and other targeted therapies","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Toxicity; Retinopathy; Targeted therapy; Pharmacology; Bioinformatics; Cancer; Internal medicine","score_opus":0.07494947418798979,"score_gpt":0.367025249348498,"score_spread":0.2920757751605082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294989188","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024209525,0.9935603,0.000017875635,0.000060872673,0.0001787288,0.00023286269,0.0002424711,0.000004689306,0.003281258],"genre_scores_gemma":[0.0010503993,0.99792606,0.000118010474,0.00017491373,0.00024515286,0.000030028596,0.000045961566,0.000033876575,0.00037561788],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987114,0.00022348088,0.0004990476,0.00027689,0.000083301944,0.00020586769],"domain_scores_gemma":[0.99899006,0.00006366696,0.0004902302,0.0002969082,0.000102889855,0.00005627406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027979235,0.00024575496,0.001091048,0.000098199,0.00002099462,0.000002989509,0.0001827753,0.0005569005,0.00005305225],"category_scores_gemma":[0.000072937684,0.00016666821,0.00030521097,0.000049270442,0.00029940275,0.0000020558662,0.00011581901,0.00007462732,0.0000039903694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032924898,0.00007338881,0.000019082101,0.0021997956,0.0005134415,0.000004983554,0.00007536992,3.0665863e-8,0.011203966,0.0006437425,0.0053742314,0.97985905],"study_design_scores_gemma":[0.00018113693,0.0013125701,0.0000029568282,0.00085841893,0.000056458382,0.00002028985,0.00003054297,3.0442248e-8,0.019575784,0.00015978854,0.97763187,0.00017017883],"about_ca_topic_score_codex":0.00001339516,"about_ca_topic_score_gemma":0.000007852608,"teacher_disagreement_score":0.9796889,"about_ca_system_score_codex":0.000004312875,"about_ca_system_score_gemma":0.00023349513,"threshold_uncertainty_score":0.6796532},"labels":[],"label_agreement":null},{"id":"W2296795896","doi":"10.1093/annonc/mdu358.1","title":"Demonstration of Temporal Heterogeneity Identified By Genome Sequencing and the Potential Effect on Treatment Decisions for Advanced Cancer Patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Computational biology; Genome; Cancer; Tumor heterogeneity; Oncology; Bioinformatics; Internal medicine; Genetics; Gene; Biology","score_opus":0.025118447213451568,"score_gpt":0.33662353373839354,"score_spread":0.31150508652494197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296795896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969845,0.0006021,0.0013419392,0.00022239331,0.00013415498,0.00041951402,0.00019843932,0.0000013216312,0.000095637784],"genre_scores_gemma":[0.9982138,0.001083615,0.0001374419,0.00023561055,0.000058638907,0.00008526265,0.00015953541,0.000007729618,0.000018332861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99935913,0.00008262896,0.00021551903,0.00017463243,0.000054097905,0.000113966504],"domain_scores_gemma":[0.9993136,0.00020052081,0.00018838006,0.00014227496,0.00011925234,0.000036005826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022332437,0.00009197902,0.00022024472,0.000019451676,0.000046139343,0.0000050512217,0.000068659334,0.00008470173,0.0000011221755],"category_scores_gemma":[0.00016349403,0.00006331675,0.00009559148,0.000020576084,0.00011292433,0.0000022360327,0.000029408082,0.000020944392,1.868924e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003481688,0.00025038052,0.0053543653,0.00002355743,0.00020415464,2.8824994e-7,0.00006649062,0.0014576135,0.8514629,0.00021734148,0.00073802465,0.13674319],"study_design_scores_gemma":[0.008179484,0.017621215,0.006014252,0.000017684699,0.00010113773,0.00000149034,0.000019250998,0.0003091763,0.9526089,0.00037148703,0.014611188,0.000144741],"about_ca_topic_score_codex":0.00011094701,"about_ca_topic_score_gemma":0.0002689465,"teacher_disagreement_score":0.13659844,"about_ca_system_score_codex":0.00002231933,"about_ca_system_score_gemma":0.000069372305,"threshold_uncertainty_score":0.25819823},"labels":[],"label_agreement":null},{"id":"W2296940157","doi":"10.1093/annonc/mdu331.40","title":"Phase Ii, Multicenter, Open-Label, Proof of Concept Study of Tasquinimod in Patients with Advanced Hepatocellular (Hcc), Ovarian (Oc), Renal Cell (Rcc) and Gastric (Gc) Carcinomas","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clear cell; Hepatocellular carcinoma; Open label; Proof of concept; Oncology; Gastroenterology; Renal cell carcinoma; Clinical trial","score_opus":0.03769151185533347,"score_gpt":0.3160010859164408,"score_spread":0.27830957406110735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296940157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954433,0.0017537575,0.000052544652,0.000057499146,0.00027150335,0.0016882635,0.000060830167,0.0000074905115,0.00066483434],"genre_scores_gemma":[0.99911827,0.00004092281,0.0003975751,0.00009555063,0.000008860774,0.00007080406,0.0000724192,0.000026489728,0.00016911185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740607,0.00065592496,0.00093353837,0.00047254594,0.00008807692,0.0004438615],"domain_scores_gemma":[0.99786144,0.00022702031,0.00094737683,0.00051931327,0.00040705514,0.00003780307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055649056,0.00027053463,0.0011136096,0.00023561399,0.00007382505,0.0000036152255,0.0005449216,0.00026246722,0.00010520909],"category_scores_gemma":[0.00009151567,0.00023785153,0.000037594342,0.0002616762,0.00056398293,0.0001488075,0.00046567834,0.00032188278,0.0000019110462],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03723202,0.13861401,0.25434023,0.00040646974,0.0010543144,0.00003383895,0.015581514,0.0002251206,0.36142206,0.00014740076,0.001963323,0.18897967],"study_design_scores_gemma":[0.17661607,0.21124682,0.026571354,0.00020087759,0.00019580696,0.0000075507205,0.0012180579,0.00007392392,0.5752331,0.00004400089,0.008128663,0.0004637857],"about_ca_topic_score_codex":0.00036040958,"about_ca_topic_score_gemma":0.00009361672,"teacher_disagreement_score":0.22776888,"about_ca_system_score_codex":0.000035871373,"about_ca_system_score_gemma":0.00017034376,"threshold_uncertainty_score":0.9699304},"labels":[],"label_agreement":null},{"id":"W2301375938","doi":"10.1093/annonc/mdu340.48","title":"Subgroup Analyses of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial of Lenvatinib (E7080) in Patients with 131I-Refractory Differentiated Thyroid Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenvatinib; Medicine; Refractory (planetary science); Placebo; Oncology; Internal medicine; Thyroid cancer; Double blind; Clinical trial; Phases of clinical research; Thyroid; Pathology; Alternative medicine","score_opus":0.10234511863117615,"score_gpt":0.4283035591414361,"score_spread":0.3259584405102599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301375938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554193,0.0008414179,0.000010879386,0.0004137495,0.00018254701,0.0024883389,0.00005486602,0.000010396545,0.00045587105],"genre_scores_gemma":[0.9983325,0.00073821575,0.000063754356,0.0001779669,0.00007203393,0.0004687558,0.00008929335,0.000022903449,0.000034564633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978044,0.0002252747,0.0010083566,0.00030595917,0.00036057993,0.0002954436],"domain_scores_gemma":[0.99754995,0.00043963685,0.0010763166,0.0003451944,0.00047304257,0.00011584308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003125849,0.00024277144,0.0017632954,0.00033800156,0.000020526302,0.0000028781174,0.0001224367,0.00016270886,0.00014210485],"category_scores_gemma":[0.000118290656,0.00016484167,0.00024181032,0.0002494875,0.0001605176,0.000071023744,0.000033481094,0.00015251267,0.0000014428671],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88692737,0.025521114,0.070995495,0.00010855858,0.0013757052,0.0000051076295,0.0003210183,0.000025545154,0.003547145,0.000022821576,0.00024118993,0.010908908],"study_design_scores_gemma":[0.8919462,0.037371445,0.04875532,0.00021196392,0.0007496346,2.7203092e-7,0.000043361662,0.00007767589,0.020303363,0.0000068768495,0.00041248428,0.00012137419],"about_ca_topic_score_codex":0.0015518323,"about_ca_topic_score_gemma":0.0007027971,"teacher_disagreement_score":0.022240173,"about_ca_system_score_codex":0.00007790301,"about_ca_system_score_gemma":0.00025183446,"threshold_uncertainty_score":0.6722048},"labels":[],"label_agreement":null},{"id":"W2301752124","doi":"10.1093/annonc/mdu344.44","title":"A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Cyclophosphamide; Oncology; Chemotherapy; Internal medicine","score_opus":0.06449802489123993,"score_gpt":0.40676060335234526,"score_spread":0.3422625784611053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301752124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972465,0.00036583527,0.00007038861,0.00016379262,0.00005986044,0.0018963168,0.000006457581,0.000013838376,0.00017702964],"genre_scores_gemma":[0.9982692,0.00007537452,0.0012528442,0.00025918003,0.000026642816,0.000054209326,0.000011191614,0.00003614983,0.000015231824],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970069,0.0008066287,0.0008516824,0.00041913954,0.00052585837,0.0003898038],"domain_scores_gemma":[0.99745494,0.0011467431,0.00058106444,0.0003282092,0.00038967773,0.00009935986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029565394,0.00027759932,0.0009879282,0.00031474166,0.00017326813,0.000016238775,0.00013384724,0.00007686449,0.000036878493],"category_scores_gemma":[0.0007189473,0.0001863769,0.0000859957,0.00044205075,0.0003133678,0.0001519397,0.0001589326,0.00021758261,3.332159e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015773714,0.003881945,0.26441103,0.0001226447,0.0004912256,0.000054642667,0.014687162,0.00016432603,0.16186836,0.0000089474925,0.000003861658,0.53853214],"study_design_scores_gemma":[0.1175284,0.28418782,0.47616175,0.0012285837,0.00039560883,0.00015591233,0.006849101,0.07514193,0.03742568,0.00030313228,0.00008494892,0.00053713314],"about_ca_topic_score_codex":0.0006467542,"about_ca_topic_score_gemma":0.000094583986,"teacher_disagreement_score":0.53799504,"about_ca_system_score_codex":0.00014021613,"about_ca_system_score_gemma":0.00038784553,"threshold_uncertainty_score":0.76002294},"labels":[],"label_agreement":null},{"id":"W2301784264","doi":"10.1093/annonc/mdv233.37","title":"P-037 Advanced Pancreatic Cancer Patients' Characteristics, Treatment and Outcome Based on Three Age Groups: ≤ 39, 39-74 and ≥ 75, a Report from Single Cancer Institution","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Demographics; Pancreatic cancer; Internal medicine; Cancer; Retrospective cohort study; Adenocarcinoma; Oncology; Demography","score_opus":0.16801160505115384,"score_gpt":0.4315253930103957,"score_spread":0.26351378795924185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301784264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991949,0.0010424086,0.00008826809,0.0028860134,0.00028110662,0.00079871353,0.0001642475,0.000027674427,0.002762572],"genre_scores_gemma":[0.99576867,0.0011833328,0.0007739426,0.0012783059,0.00018492182,0.00025950756,0.00018012502,0.000021065058,0.0003501355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819624,0.00012405957,0.0006169353,0.00043252358,0.00027136583,0.0003588908],"domain_scores_gemma":[0.99826354,0.00035019784,0.00036891797,0.00032139866,0.0003526758,0.00034326574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034483228,0.00023963742,0.001147148,0.00014523466,0.00007248065,0.00000998212,0.0000634119,0.00023284007,0.00008892506],"category_scores_gemma":[0.00068529847,0.00018377011,0.0000667068,0.00010105973,0.0004240915,0.00008225385,0.000048598355,0.00016987036,0.000006168067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002224301,0.0013534705,0.92753154,0.000070122485,0.00023513718,0.00044088686,0.0003925476,0.0000045265697,0.00063596177,0.00003678277,0.00040712013,0.06666761],"study_design_scores_gemma":[0.007863775,0.0107936,0.9661823,0.00023575232,0.00046887377,0.000022864771,0.00008935482,0.00073634327,0.00035894578,0.0002637201,0.012802061,0.00018241153],"about_ca_topic_score_codex":0.004247295,"about_ca_topic_score_gemma":0.0012607574,"teacher_disagreement_score":0.0664852,"about_ca_system_score_codex":0.0004236688,"about_ca_system_score_gemma":0.0006723499,"threshold_uncertainty_score":0.7493928},"labels":[],"label_agreement":null},{"id":"W2303194908","doi":"10.1093/annonc/mdu356.66","title":"Assessment of Older Patients with Cancer: Edmonton Frail Scale (Efs) As a Predictor of Adverse Outcomes in a Cohort of Older Patients Undergoing Systemic Therapy","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Geriatric oncology; Internal medicine; Mood; Cohort; Performance status; Marital status; Cancer; Physical therapy; Population; Psychiatry","score_opus":0.01934008883002615,"score_gpt":0.3432453177324868,"score_spread":0.32390522890246065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303194908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957517,0.00014372116,0.000046451787,0.00037298448,0.00022052662,0.001588188,0.000087487075,0.00001381386,0.0017751206],"genre_scores_gemma":[0.9985884,0.0003377636,0.00036254886,0.0003620775,0.000024887177,0.00010641153,0.00004772315,0.000033513283,0.00013671289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972829,0.00022473124,0.0011196788,0.0003360982,0.0007107163,0.00032585193],"domain_scores_gemma":[0.996828,0.00043536632,0.0011193174,0.0004789472,0.0010233367,0.00011499729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004234673,0.0002428184,0.0014140347,0.00028149865,0.000016497104,0.0000010693249,0.00019959238,0.00023145972,0.000116315074],"category_scores_gemma":[0.00020093069,0.00018613826,0.00014793708,0.00024017532,0.00023873535,0.00010871373,0.000063041974,0.00018466637,0.0000012340655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061170274,0.003222036,0.98653495,0.00080180465,0.00046607043,0.0000022576364,0.001510832,0.000094285766,0.00045720465,0.000024347799,0.0003950795,0.0058794343],"study_design_scores_gemma":[0.015759857,0.009087315,0.97039765,0.0018978069,0.00010885707,0.0000016232099,0.000238118,0.00007983572,0.0021334677,0.000019717108,0.00014221379,0.0001335489],"about_ca_topic_score_codex":0.0016283572,"about_ca_topic_score_gemma":0.0010400404,"teacher_disagreement_score":0.016137306,"about_ca_system_score_codex":0.00015066928,"about_ca_system_score_gemma":0.000612751,"threshold_uncertainty_score":0.75904983},"labels":[],"label_agreement":null},{"id":"W2303647913","doi":"10.1093/annonc/mdu337.32","title":"Phase Ii Study of Individualized Sunitinib As First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Regional Municipality of Durham; BC Cancer Agency; Ottawa Hospital; Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Oncology; Renal cell carcinoma; Internal medicine; Cancer","score_opus":0.17602858154999643,"score_gpt":0.4470818414900797,"score_spread":0.2710532599400832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303647913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890907,0.0010550043,0.000048529022,0.0016446004,0.000109424946,0.0019344123,0.00008053071,0.000017450388,0.006201005],"genre_scores_gemma":[0.9955281,0.0007425093,0.00093117624,0.0011121704,0.00012360698,0.0002904595,0.00007051861,0.000040040584,0.001161389],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796855,0.0002895208,0.0007235709,0.00033691133,0.00032536418,0.00035608638],"domain_scores_gemma":[0.99770397,0.0006446068,0.00058893056,0.00041436031,0.0004744231,0.0001736906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076348183,0.0002451087,0.0010746288,0.00021159646,0.00008841418,0.000003810356,0.00017299883,0.00010840655,0.00055794534],"category_scores_gemma":[0.00010816809,0.00019009721,0.00022799477,0.0001830461,0.00011807371,0.000042204883,0.00006055968,0.000147224,0.000011263812],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08101283,0.23679717,0.0044725337,0.0018336449,0.004503535,0.00037576133,0.03164387,0.00038834097,0.16951981,0.00027197116,0.03664425,0.4325363],"study_design_scores_gemma":[0.076099776,0.38154736,0.0013287608,0.000057476012,0.00078912935,0.000015674232,0.0010366071,0.0001330423,0.41886285,0.00032475055,0.11959335,0.00021124544],"about_ca_topic_score_codex":0.0005813858,"about_ca_topic_score_gemma":0.00015882701,"teacher_disagreement_score":0.43232504,"about_ca_system_score_codex":0.000040145,"about_ca_system_score_gemma":0.00028547092,"threshold_uncertainty_score":0.7751939},"labels":[],"label_agreement":null},{"id":"W2305876893","doi":"10.1093/annonc/mdw062","title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":444,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"","keywords":"Medicine; Oxaliplatin; Colorectal cancer; Bolus (digestion); Randomized controlled trial; Urology; Toxicity; Chemotherapy; Clinical endpoint; Radiation therapy; Surgery; Cumulative incidence; Nuclear medicine; Gastroenterology; Internal medicine; Cancer; Cohort","score_opus":0.09973923631022293,"score_gpt":0.4517231968530698,"score_spread":0.35198396054284686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305876893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895473,0.0002853526,0.00015111119,0.005227287,0.00020499452,0.003943133,0.00020444338,0.000021130327,0.00041525142],"genre_scores_gemma":[0.9978777,0.000434798,0.0003104549,0.0001995074,0.000096091644,0.00076454395,0.000053208452,0.000017351178,0.00024634376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983334,0.00027077863,0.0006825535,0.0003225128,0.00019114358,0.0001996418],"domain_scores_gemma":[0.99545723,0.003090402,0.00059368776,0.00018235072,0.00057398196,0.00010237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081785326,0.00017656086,0.0012226702,0.0001000756,0.000039212875,0.0000040123778,0.00005372248,0.00012716968,0.00016164784],"category_scores_gemma":[0.0012616101,0.000107913176,0.00014701141,0.00016212225,0.0002628954,0.00007417061,0.0000141103765,0.00005369674,8.1038985e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88140434,0.0027071002,0.0015240479,0.000043005395,0.000963133,0.000014430188,0.0011465838,0.0000062453882,0.0029601855,0.000013049067,0.00046745437,0.108750425],"study_design_scores_gemma":[0.8783868,0.034373578,0.0060723145,0.00011522167,0.000525156,0.0000039131205,0.00018048615,0.00054502627,0.07922777,0.000024211222,0.0004207736,0.00012474413],"about_ca_topic_score_codex":0.00022658851,"about_ca_topic_score_gemma":0.0004089123,"teacher_disagreement_score":0.10862569,"about_ca_system_score_codex":0.00011346206,"about_ca_system_score_gemma":0.00065153127,"threshold_uncertainty_score":0.44005716},"labels":[],"label_agreement":null},{"id":"W2307238247","doi":"10.1093/annonc/mdu337.60","title":"Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; BC Cancer Agency","funders":"","keywords":"Medicine; Cisplatin; Oncology; Perioperative; Urothelial carcinoma; Internal medicine; Carcinoma; Urology; Chemotherapy; Surgery; Bladder cancer; Cancer","score_opus":0.06617528993288303,"score_gpt":0.3766195366427865,"score_spread":0.3104442467099035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307238247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811096,0.0008424211,0.0040062023,0.008413674,0.00026861226,0.002841611,0.000083445826,0.00007408333,0.0023603027],"genre_scores_gemma":[0.98379874,0.00011508224,0.004585217,0.010098229,0.000186624,0.0007026703,0.00008072369,0.00008574969,0.000346951],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792796,0.00015227114,0.0005307574,0.0005166905,0.000327797,0.00054454565],"domain_scores_gemma":[0.99784225,0.00080570165,0.0002965672,0.0004839043,0.0003931167,0.00017844755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037072052,0.00042985118,0.0011885938,0.00015131576,0.0002052902,0.000014371415,0.00017456339,0.00020365503,0.00014278642],"category_scores_gemma":[0.00014056305,0.00028878057,0.00043933486,0.00017890919,0.00015904101,0.00007570777,0.000012555743,0.0001732849,0.0000063914326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053299326,0.004499959,0.42035165,0.0002865699,0.0019068464,0.0001133395,0.0024108354,0.0022418338,0.011576283,0.0002987076,0.000663696,0.502351],"study_design_scores_gemma":[0.20022245,0.19502787,0.21664833,0.0004905751,0.0006631924,0.000029853765,0.00025429248,0.006262207,0.24916644,0.00032573115,0.12956639,0.0013426848],"about_ca_topic_score_codex":0.00012418139,"about_ca_topic_score_gemma":0.00013105782,"teacher_disagreement_score":0.5010083,"about_ca_system_score_codex":0.00007042714,"about_ca_system_score_gemma":0.0007943735,"threshold_uncertainty_score":0.9999564},"labels":[],"label_agreement":null},{"id":"W2307275292","doi":"10.1093/annonc/mdu334.78","title":"Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients (Pts) with Metastatic Pancreatic Cancer (Pc): Subgroup Analyses of the Mpact Trial Based on the Presence of Liver Metastases (Lms) and Number of Metastatic Sites","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Population; Gastroenterology; Performance status; Nab-paclitaxel; Paclitaxel; Oncology; Chemotherapy; Urology; Cancer; Randomized controlled trial; Breast cancer","score_opus":0.15051140802297275,"score_gpt":0.44228411505572196,"score_spread":0.2917727070327492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307275292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933476,0.0006330238,0.0005234583,0.0018381131,0.000053092957,0.00266902,0.0004042402,0.000007190283,0.00052429724],"genre_scores_gemma":[0.99547446,0.0004262276,0.0029052615,0.00055781816,0.000043339238,0.00032290025,0.00004143638,0.00003064964,0.00019789435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593085,0.0013742992,0.00106328,0.00037906715,0.0007794268,0.00047307083],"domain_scores_gemma":[0.98650223,0.010312856,0.0012195577,0.0007086162,0.0011027303,0.00015398912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002298883,0.0003203911,0.0023293835,0.00021778264,0.00009846165,0.0000067387527,0.00034569023,0.00010536578,0.0003412345],"category_scores_gemma":[0.005080095,0.00016270328,0.00033062554,0.00050709216,0.0014236841,0.00009639997,0.00009978301,0.0002280565,0.000001929635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24783652,0.012564209,0.6836155,0.0068358607,0.012680743,0.000033240827,0.0031320103,0.00093453244,0.008591043,0.0027347978,0.010957777,0.0100837825],"study_design_scores_gemma":[0.20618126,0.12657906,0.5221441,0.00259946,0.026296517,0.00005615659,0.0019114612,0.05634773,0.051671103,0.0031171886,0.002161085,0.0009348897],"about_ca_topic_score_codex":0.0020354092,"about_ca_topic_score_gemma":0.0003617048,"teacher_disagreement_score":0.16147141,"about_ca_system_score_codex":0.000058918715,"about_ca_system_score_gemma":0.0007615546,"threshold_uncertainty_score":0.6634847},"labels":[],"label_agreement":null},{"id":"W2308057476","doi":"10.1093/annonc/mdw060","title":"Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency; Vancouver General Hospital; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; University of British Columbia; Canada Research Chairs; Canada Foundation for Innovation","keywords":"Medicine; Irbesartan; Colorectal cancer; Blockade; Bevacizumab; Oncology; Repurposing; Angiotensin II; Bioinformatics; Internal medicine; Pharmacology; Cancer; Chemotherapy; Receptor; Biology","score_opus":0.05204728125203615,"score_gpt":0.36422156373339054,"score_spread":0.31217428248135437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308057476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93674344,0.00036972476,0.000028007573,0.061510585,0.000060487753,0.0007538423,0.000027134167,0.000020673457,0.00048612177],"genre_scores_gemma":[0.99532557,0.000042932537,0.0024430063,0.0016813136,0.00003462611,0.000113522554,9.174462e-7,0.000029152205,0.00032897363],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99825096,0.0002952631,0.00040654623,0.00033175602,0.0003016858,0.00041380912],"domain_scores_gemma":[0.9983246,0.0005308795,0.0001995206,0.00024812482,0.00053163135,0.000165278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045619183,0.00019746531,0.00085820426,0.0003073661,0.000027834774,0.000002894977,0.00006766906,0.00007347982,0.000032326065],"category_scores_gemma":[0.00034820777,0.00010271419,0.00006506255,0.00043820587,0.00021604456,0.00004140101,0.00004987797,0.00008265232,0.000019485129],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1696214,0.0015291218,0.27739617,0.000057784706,0.002202501,0.008770538,0.013877188,0.00011116638,0.39244407,0.000059671678,0.040517766,0.09341263],"study_design_scores_gemma":[0.008870914,0.060041938,0.73891664,0.0017851881,0.0002694487,0.0016000431,0.0007618373,0.0000097849315,0.12717736,0.000025127132,0.060121004,0.00042074342],"about_ca_topic_score_codex":0.00036419448,"about_ca_topic_score_gemma":0.0024082507,"teacher_disagreement_score":0.46152043,"about_ca_system_score_codex":0.00014063367,"about_ca_system_score_gemma":0.0005043388,"threshold_uncertainty_score":0.41885632},"labels":[],"label_agreement":null},{"id":"W2308390995","doi":"10.1093/annonc/mdu438.55","title":"Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: a Meta-Analysis","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Meta-analysis; Oncology; Pharmacology; Internal medicine","score_opus":0.11364372364281203,"score_gpt":0.3314736982470561,"score_spread":0.21782997460424405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308390995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96767604,0.005524856,0.00056769553,0.00092353876,0.00008100192,0.00011491121,0.00054300035,0.000008494676,0.024560485],"genre_scores_gemma":[0.99676853,0.0020603947,0.00032331934,0.0005241312,0.000032428794,0.000004663009,0.000007076847,0.000012368184,0.0002670744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985557,0.000054793716,0.000930693,0.00022041348,0.000037642214,0.00020074197],"domain_scores_gemma":[0.9976674,0.00027658284,0.001657874,0.00021587289,0.00010474994,0.000077575794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013330154,0.00012291543,0.0018135112,0.0003036308,0.000021518545,0.0000063200814,0.00015246749,0.00014154104,0.0003585307],"category_scores_gemma":[0.0005014433,0.00012724042,0.0005242125,0.00024255832,0.0002158776,0.00013971486,0.00005782061,0.000083521,0.0000049569003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044236024,0.0008561927,0.44480947,0.00010073415,0.1659686,0.000001120053,0.004789362,0.00064985786,0.00022500913,0.33566192,0.012024031,0.034471367],"study_design_scores_gemma":[0.006023684,0.0073605324,0.6590062,0.00003241483,0.04356993,0.0000019548677,0.0011993054,0.0031478473,0.014514907,0.18632218,0.07756337,0.0012576827],"about_ca_topic_score_codex":0.0063328785,"about_ca_topic_score_gemma":0.00080184866,"teacher_disagreement_score":0.21419673,"about_ca_system_score_codex":0.000043388893,"about_ca_system_score_gemma":0.00006066136,"threshold_uncertainty_score":0.957346},"labels":[],"label_agreement":null},{"id":"W2309303154","doi":"10.1093/annonc/mdu342.5","title":"Nivolumab (N) (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Sunitinib (S) or Pazopanib (P) in Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Renal cell carcinoma; Pazopanib; Adverse effect; Internal medicine; Sunitinib; Peripheral edema; Nausea; Oncology; Toxicity; Urology; Gastroenterology; Immunotherapy; Cancer","score_opus":0.054480412696279776,"score_gpt":0.31141016778675606,"score_spread":0.2569297550904763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309303154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897658,0.00007965559,0.00004770005,0.0008674225,0.00005717965,0.0011179423,0.000014277374,0.000021934653,0.008028045],"genre_scores_gemma":[0.9974732,0.000029221086,0.0012113989,0.00058125553,0.000030267704,0.00009603696,0.00016268456,0.000052434727,0.00036350818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972521,0.00046514,0.00072628795,0.0005020272,0.000484168,0.00057029654],"domain_scores_gemma":[0.9980841,0.00037112104,0.0004514926,0.00045871825,0.00043862752,0.00019592294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006066475,0.00034684438,0.0010838391,0.0005884704,0.000042192052,0.000010559948,0.00017288676,0.000150041,0.0001204761],"category_scores_gemma":[0.000119101795,0.00024079146,0.00008036538,0.0005896133,0.000204921,0.00015530737,0.000055091085,0.0003378802,0.000027615877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016219394,0.010445093,0.9268892,0.0005425724,0.0001743419,0.0012917706,0.0017136348,0.00018113306,0.0008892795,0.00037458452,0.0009015971,0.04037739],"study_design_scores_gemma":[0.03152863,0.057256237,0.8912897,0.00027555707,0.00019829848,0.000083539744,0.0004005765,0.00026636294,0.016571043,0.00008714769,0.0017313258,0.00031155162],"about_ca_topic_score_codex":0.0009781518,"about_ca_topic_score_gemma":0.0023689594,"teacher_disagreement_score":0.046811145,"about_ca_system_score_codex":0.00025709072,"about_ca_system_score_gemma":0.0005278387,"threshold_uncertainty_score":0.98191905},"labels":[],"label_agreement":null},{"id":"W2310705163","doi":"10.1093/annonc/mdv233.313","title":"P-317 Outcome of elderly patients with non-metastatic rectal cancer: a retrospective study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Colorectal cancer; Adenocarcinoma; Concomitant; Retrospective cohort study; Chemoradiotherapy; Internal medicine; Multivariate analysis; Population; Proportional hazards model; Surgery; Neoadjuvant therapy; Radiation therapy; Cancer","score_opus":0.11054214515757213,"score_gpt":0.4041557074060555,"score_spread":0.29361356224848334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2310705163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339646,0.00009620874,0.0000039395572,0.0006662992,0.00011763505,0.0005774488,0.000028762912,0.000010131222,0.005103098],"genre_scores_gemma":[0.9993005,0.0000080332475,0.00011725064,0.00020687892,0.000044531957,0.00003242547,0.0000072254566,0.0000124963035,0.00027068172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988348,0.00007004934,0.00037364976,0.00020114475,0.00032452942,0.00019583589],"domain_scores_gemma":[0.99845403,0.000049656333,0.00027914834,0.00017039008,0.0009009087,0.00014588123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027782278,0.00012494261,0.00072477164,0.00012043764,0.000017603665,0.0000018177311,0.00008061326,0.00004720329,0.00004717468],"category_scores_gemma":[0.0001817905,0.00008742998,0.00008142493,0.00026452818,0.00012284101,0.000051137864,0.000045929653,0.00014766425,0.0000050418794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024134421,0.0022007471,0.9806744,0.00004281448,0.00023173112,0.0000671334,0.0017696504,0.0000027523345,0.00008292333,0.000014404595,0.0009166547,0.011583354],"study_design_scores_gemma":[0.0050683655,0.07385032,0.9183351,0.00003813508,0.00017226052,0.000008093174,0.0015950495,0.000010818055,0.00040803303,0.00009673059,0.0003317653,0.00008534457],"about_ca_topic_score_codex":0.0010930622,"about_ca_topic_score_gemma":0.0011044415,"teacher_disagreement_score":0.071649574,"about_ca_system_score_codex":0.000075891425,"about_ca_system_score_gemma":0.00029402875,"threshold_uncertainty_score":0.35652912},"labels":[],"label_agreement":null},{"id":"W2313479654","doi":"10.1093/annonc/mdw139","title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Internal medicine; Quality of life (healthcare); Breast cancer; Metastatic breast cancer; Oncology; Cancer; Confidence interval; Anastrozole; Gynecology; Estrogen receptor; Tamoxifen","score_opus":0.08696416881545778,"score_gpt":0.3862310724140349,"score_spread":0.29926690359857716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313479654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819459,0.0010101834,0.00009091135,0.014183859,0.00009787821,0.0016788972,0.0008087656,0.000030442008,0.00015317975],"genre_scores_gemma":[0.9971638,0.0007366595,0.0006337848,0.0010247955,0.00007119131,0.00025160363,0.000033438748,0.000034730543,0.00005000457],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966678,0.00077837217,0.001290485,0.00042075952,0.00043380295,0.00040877587],"domain_scores_gemma":[0.9953089,0.0020848333,0.0013986196,0.0004727977,0.00056800287,0.00016689581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054383307,0.0003088017,0.0016333046,0.00009506706,0.000039202023,0.0000037933455,0.00017253398,0.00012823178,0.00022630984],"category_scores_gemma":[0.0005261194,0.00015410711,0.00019497356,0.00034040958,0.0007033798,0.00014611703,0.00004213138,0.00019683554,0.0000029688554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41611362,0.0020526682,0.26299283,0.00007141413,0.0041976776,0.000087467924,0.0068239407,0.000026896792,0.015286267,0.00007891057,0.0003376536,0.29193068],"study_design_scores_gemma":[0.10531777,0.00754232,0.8771815,0.00041224103,0.0002500655,0.00002196959,0.0014644979,0.0000023655084,0.0068202917,0.00038911434,0.00035971083,0.00023820206],"about_ca_topic_score_codex":0.011347513,"about_ca_topic_score_gemma":0.0025615022,"teacher_disagreement_score":0.6141886,"about_ca_system_score_codex":0.00019517302,"about_ca_system_score_gemma":0.0009843336,"threshold_uncertainty_score":0.995236},"labels":[],"label_agreement":null},{"id":"W2313559881","doi":"10.1093/annonc/mdv532.29","title":"445P Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Pemetrexed; Subgroup analysis; Gemcitabine; Lung cancer; Oncology; Gastroenterology; Chemotherapy; Cancer; Gefitinib; Cisplatin; Epidermal growth factor receptor; Confidence interval","score_opus":0.05072019802966627,"score_gpt":0.4117482572379524,"score_spread":0.3610280592082861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313559881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911376,0.0009904265,0.000115755654,0.0027553774,0.00008175879,0.0007749099,0.00004363697,0.00002643212,0.004074073],"genre_scores_gemma":[0.99755824,0.00024904095,0.0008761778,0.0006442956,0.00004299914,0.0001044697,0.00019282098,0.000040203424,0.00029174678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982861,0.00013076,0.0004507892,0.00040511737,0.00033437365,0.00039284176],"domain_scores_gemma":[0.9988309,0.00016969458,0.00022239641,0.0002463137,0.00032015334,0.00021051978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028898148,0.0002546699,0.000701956,0.00028827,0.00005212799,0.000017373615,0.000089659385,0.0000944595,0.000048400863],"category_scores_gemma":[0.00007610567,0.00019735916,0.000046914472,0.0004425834,0.00016079767,0.0002720039,0.000027371281,0.00020744863,0.000002405414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027048264,0.001859976,0.98176914,0.00008555552,0.0005326633,0.00011938396,0.0031080174,0.00047783437,0.00027054493,0.00014893578,0.0026374734,0.006285639],"study_design_scores_gemma":[0.03960642,0.0073572267,0.94066554,0.00040842924,0.00045434872,0.000028979463,0.001500924,0.00082338264,0.0015382044,0.00008647658,0.0071006883,0.00042939617],"about_ca_topic_score_codex":0.0019196367,"about_ca_topic_score_gemma":0.0014270135,"teacher_disagreement_score":0.041103624,"about_ca_system_score_codex":0.00029017832,"about_ca_system_score_gemma":0.0005101245,"threshold_uncertainty_score":0.8048073},"labels":[],"label_agreement":null},{"id":"W2313812295","doi":"10.1093/annonc/mdv048.07","title":"Prognostic Classification of Lung Adenocarcinoma by Integrated Mirna-Mrna Expression Profiles","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"microRNA; Medicine; Adenocarcinoma; Oncology; Lung cancer; Internal medicine; Gene expression profiling; Gene expression; Cancer; Gene; Biology; Genetics","score_opus":0.10538770042695247,"score_gpt":0.4342140308115797,"score_spread":0.3288263303846273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313812295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804022,0.0027400132,0.00014775113,0.0041705025,0.00013309158,0.00063044234,0.0000559627,0.000026085581,0.011693958],"genre_scores_gemma":[0.9977967,0.00008208631,0.0008482492,0.00016138295,0.000034778583,0.000079093064,0.00023984721,0.000010694369,0.0007471725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992178,0.00006458965,0.00029591686,0.00014693911,0.00014669597,0.00012807261],"domain_scores_gemma":[0.9989051,0.0000674368,0.00023621376,0.00016067407,0.00051893183,0.00011159608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013458842,0.00008496579,0.00027600594,0.00008487471,0.000018253346,0.0000022401846,0.0000583219,0.000108417764,0.000057751786],"category_scores_gemma":[0.00019192217,0.00006220543,0.000048205682,0.00014300065,0.00009450429,0.000060575643,0.000016482201,0.00007469007,0.0000066499592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092093856,0.0022609867,0.51634675,0.00024105911,0.00033008304,0.000027453005,0.0026787054,0.0000044362005,0.121509105,0.00049280026,0.3120064,0.043181274],"study_design_scores_gemma":[0.007065594,0.011324039,0.57586735,0.0006605864,0.0007680237,0.00007209669,0.003321517,0.0007392054,0.30506077,0.0005684887,0.094298914,0.00025340795],"about_ca_topic_score_codex":0.000098381635,"about_ca_topic_score_gemma":0.0000048988263,"teacher_disagreement_score":0.21770751,"about_ca_system_score_codex":0.00006740626,"about_ca_system_score_gemma":0.000531462,"threshold_uncertainty_score":0.25366637},"labels":[],"label_agreement":null},{"id":"W2315450747","doi":"10.1093/annonc/mdu331.38","title":"A Phase I Open-Labelled, Single-Arm, Dose-Escalation, Study of Dichloroacetate (Dca) in Patients with Advanced Solid Tumours","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Solid tumor; Nuclear medicine; Internal medicine; Oncology; Cancer","score_opus":0.03412354744623893,"score_gpt":0.35257308109889746,"score_spread":0.31844953365265855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315450747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969588,0.00032118644,0.00007219449,0.00013061971,0.00026314933,0.00068278244,0.000018541583,0.0000041320914,0.0015486305],"genre_scores_gemma":[0.9989557,0.00014943242,0.00026890324,0.00028543215,0.00011755655,0.000044976514,0.00006584108,0.000021882739,0.00009024],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99858713,0.00018539792,0.0004548756,0.0003522831,0.00015324277,0.0002670856],"domain_scores_gemma":[0.9987885,0.000028494433,0.00038779955,0.00035922538,0.0003531889,0.0000827941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035519147,0.00016395794,0.00051424705,0.000093562594,0.000035361736,0.0000072572534,0.0003038324,0.00011324211,0.000012920198],"category_scores_gemma":[0.00012470961,0.0001456983,0.00004474785,0.00016485399,0.00011273054,0.000014066446,0.00015958409,0.00008299436,0.0000012896326],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023880733,0.10567758,0.06848146,0.000107864194,0.0006048821,0.000005141573,0.0027925584,0.0026235024,0.27632764,0.00015688557,0.0047780755,0.5145637],"study_design_scores_gemma":[0.14809644,0.23363823,0.2024591,0.00011367363,0.00024360242,0.00000677444,0.0012397273,0.00013506401,0.20745091,0.00031541637,0.2052702,0.001030867],"about_ca_topic_score_codex":0.000073132454,"about_ca_topic_score_gemma":0.00052177446,"teacher_disagreement_score":0.5135328,"about_ca_system_score_codex":0.000009404814,"about_ca_system_score_gemma":0.000116030125,"threshold_uncertainty_score":0.5941404},"labels":[],"label_agreement":null},{"id":"W2315722463","doi":"10.1093/annonc/mdw147","title":"Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Kyowa Hakko Kirin; National Comprehensive Cancer Network; Sanofi; PharmaMar; AstraZeneca; Chugai Pharmaceutical; Pfizer; Amgen","keywords":"Medicine; Paclitaxel; Placebo; Oncology; Ovarian cancer; Gynecology; Internal medicine; Cancer; Alternative medicine; Pathology","score_opus":0.13738594973953594,"score_gpt":0.4197746250834984,"score_spread":0.28238867534396245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315722463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91762847,0.0023702683,0.000014544288,0.07694956,0.00019956265,0.0007453695,0.000096624535,0.00002029068,0.0019753405],"genre_scores_gemma":[0.99234664,0.005209959,0.00024505364,0.0014800788,0.00005945176,0.00025565564,0.0000050193235,0.000021486758,0.0003766516],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997448,0.00033313566,0.0011157511,0.00036651795,0.00024595647,0.00049059064],"domain_scores_gemma":[0.9977288,0.00062630547,0.0007984151,0.00034851098,0.00021514016,0.00028277814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012035647,0.00018990293,0.001381458,0.00019711803,0.000028173561,0.0000024689134,0.000098173325,0.00015988463,0.00077909447],"category_scores_gemma":[0.00034714912,0.00010882267,0.00007238437,0.00038585023,0.00015377898,0.000065636676,0.00003742887,0.00014395487,0.000006334669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050450854,0.0025385115,0.1389904,0.0006565929,0.0011373957,0.00009701415,0.00533183,0.00002305698,0.00025659677,0.0012618614,0.0071808877,0.792075],"study_design_scores_gemma":[0.03309798,0.017579246,0.92936224,0.0021523307,0.000055865687,0.000019433171,0.0007185926,0.0000064059886,0.00054046884,0.00025497001,0.015976146,0.00023633504],"about_ca_topic_score_codex":0.008045148,"about_ca_topic_score_gemma":0.008088328,"teacher_disagreement_score":0.79183865,"about_ca_system_score_codex":0.0010674611,"about_ca_system_score_gemma":0.0033921283,"threshold_uncertainty_score":0.99856037},"labels":[],"label_agreement":null},{"id":"W2316464911","doi":"10.1093/annonc/mdv233.257","title":"P-260 Complication rate of palliative colonic stenting for metastatic colorectal cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Stent; Perforation; Surgery; Colorectal cancer; Complication; Bowel obstruction; Palliative care; Population; Chemotherapy; Cancer; Radiology; Internal medicine; Nursing","score_opus":0.30093092936274124,"score_gpt":0.4855493754398557,"score_spread":0.18461844607711447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316464911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917409,0.0008725749,0.00012553751,0.0032354356,0.00016408299,0.0010179366,0.00009392009,0.00001592716,0.0027337086],"genre_scores_gemma":[0.99744,0.00016698902,0.0013362805,0.0004187473,0.000042137686,0.0003814467,0.00004477463,0.000014074426,0.00015559213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989207,0.0001167954,0.00041157796,0.00019914868,0.0001299868,0.00022182334],"domain_scores_gemma":[0.9978342,0.00055538036,0.0004395307,0.00011510244,0.00092882605,0.00012697825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004718115,0.000112664384,0.00063582597,0.00007833469,0.000022697503,0.0000020160646,0.00007425134,0.000069712005,0.000049278697],"category_scores_gemma":[0.00040086106,0.000095449344,0.00013835172,0.00021693342,0.0001456197,0.000042874246,0.000038159757,0.0000710611,0.0000052815185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06143203,0.010169444,0.51091665,0.0020579733,0.007959555,0.00014854544,0.009886002,0.0009367092,0.07214146,0.009539275,0.027419915,0.28739247],"study_design_scores_gemma":[0.024076255,0.04429576,0.66283244,0.00034059238,0.0011823833,0.0000269157,0.0011000431,0.003522302,0.20366544,0.006234785,0.05233129,0.00039181142],"about_ca_topic_score_codex":0.0002859577,"about_ca_topic_score_gemma":0.00019376808,"teacher_disagreement_score":0.28700066,"about_ca_system_score_codex":0.00015924104,"about_ca_system_score_gemma":0.00058282417,"threshold_uncertainty_score":0.38923115},"labels":[],"label_agreement":null},{"id":"W2316907872","doi":"10.1093/annonc/mdt086.4","title":"BRCA1 Inactivation Induces Alternative NF-κB Pathway Activation in Human Breast Cancer Cells and Mammary Glands","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"RELB; Cancer research; Breast cancer; Mammary tumor; Medicine; Stem cell; Biology; Cancer; Molecular biology; Cell biology; NFKB1; Internal medicine; Transcription factor; Genetics; Gene","score_opus":0.038010706790033405,"score_gpt":0.32452613435984645,"score_spread":0.2865154275698131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316907872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967609,0.00008849937,0.00016680559,0.0012326101,0.000082768376,0.00020773539,0.000024785566,0.000006530626,0.001429332],"genre_scores_gemma":[0.99868476,0.00019181168,0.00012687704,0.0006148158,0.00015826647,0.000067324734,0.00006295841,0.000013514854,0.00007965593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990754,0.00011385053,0.00024737304,0.0002784333,0.00009049904,0.00019440599],"domain_scores_gemma":[0.9993254,0.000032494965,0.00022528032,0.00015816298,0.00020700072,0.000051661144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001963923,0.00012850086,0.00019975723,0.000107879154,0.000039187067,0.00001310604,0.0001367255,0.00022348975,0.000030543313],"category_scores_gemma":[0.000028000708,0.0001247678,0.000033053166,0.00009423347,0.0000802345,0.000027248383,0.00009571944,0.000117183845,0.0000019981112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047955305,0.00012471297,0.002630873,0.000017084463,0.000036852038,0.000001612975,0.00018464716,0.000029408517,0.9675828,0.00019454701,0.0007616859,0.028387781],"study_design_scores_gemma":[0.0005848389,0.0005744578,0.03347464,0.000029891598,0.0000029544192,0.0000052120795,0.00007505243,0.000024841802,0.9627453,0.0008418543,0.0015123883,0.00012856747],"about_ca_topic_score_codex":0.0013305058,"about_ca_topic_score_gemma":0.00014549105,"teacher_disagreement_score":0.030843765,"about_ca_system_score_codex":0.00002743133,"about_ca_system_score_gemma":0.000120379795,"threshold_uncertainty_score":0.50878835},"labels":[],"label_agreement":null},{"id":"W2319490355","doi":"10.1093/annonc/mdu193.2","title":"Prognosis Model for Overall Survival in Locally Advanced Pancreatic Cancer (LAPC): An Ancillary Study of the Lap 07 Trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Multivariate analysis; Prognostic model; Univariate analysis; Oncology; Overall survival","score_opus":0.17494968789033216,"score_gpt":0.463794688817662,"score_spread":0.28884500092732984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319490355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920406,0.00016538637,0.0002595533,0.0020392707,0.0001701018,0.003451319,0.000019009645,0.000011439742,0.0018433616],"genre_scores_gemma":[0.99698687,0.00023936179,0.00078351045,0.00062371284,0.00014340415,0.000785527,0.00000664712,0.000021321664,0.00040966232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976695,0.0005386334,0.000703062,0.00031058074,0.00036231262,0.00041586926],"domain_scores_gemma":[0.99783164,0.00082685973,0.00030617946,0.00042414325,0.0004890052,0.00012215863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018066677,0.00015937089,0.001232483,0.00011636775,0.000053103453,0.000002660516,0.00025800598,0.00021356222,0.00003839027],"category_scores_gemma":[0.0009418,0.000109350425,0.00013246578,0.00017848914,0.00021368486,0.00006739736,0.00008290868,0.00022641885,0.0000012290134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12872611,0.015202151,0.7840849,0.0005110286,0.00067182904,0.000014362255,0.004722665,0.0025910565,0.002774389,0.0011192702,0.0013969683,0.05818526],"study_design_scores_gemma":[0.23811676,0.11022267,0.44750506,0.00040077552,0.0008900003,0.00000923221,0.0019681847,0.19312043,0.0012010676,0.0036288707,0.002529845,0.00040711372],"about_ca_topic_score_codex":0.0006277655,"about_ca_topic_score_gemma":0.003230708,"teacher_disagreement_score":0.33657986,"about_ca_system_score_codex":0.00007705715,"about_ca_system_score_gemma":0.0011144188,"threshold_uncertainty_score":0.4459181},"labels":[],"label_agreement":null},{"id":"W2320076910","doi":"10.1093/annonc/mdu193.1","title":"Phase 2 Double-Blind, Placebo–Controlled Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer (LAPC)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Gemcitabine; Internal medicine; Clinical endpoint; Pancreatic cancer; Oncology; Cancer; Progression-free survival; Performance status; Placebo; Gastroenterology; Surgery; Randomized controlled trial; Chemotherapy; Pathology; Tyrosine kinase","score_opus":0.11965324960275193,"score_gpt":0.46480444485169664,"score_spread":0.3451511952489447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320076910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96912587,0.00017228961,0.0028802482,0.0058808336,0.00018734325,0.009605214,0.00003546411,0.000029346209,0.012083423],"genre_scores_gemma":[0.9863879,0.00021614364,0.005635181,0.0011933127,0.0004058871,0.0041591,0.000043991426,0.000042984222,0.0019154854],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972599,0.00026477923,0.0009783962,0.00042950053,0.00041970937,0.0006476861],"domain_scores_gemma":[0.99518996,0.0022722012,0.00055212056,0.0004964171,0.001109674,0.00037962737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017721249,0.00027452232,0.00262431,0.00032844354,0.000072139635,0.00000490281,0.00022146259,0.00028205392,0.00025401512],"category_scores_gemma":[0.0015159759,0.00019657059,0.00023249812,0.00034893648,0.00032379752,0.00006363476,0.000051775027,0.00022816434,0.000010306225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95660436,0.0035231106,0.0006952625,0.00028166978,0.001013356,0.000013714585,0.00051698467,0.000049734026,0.006270925,0.00073431735,0.0018184899,0.028478047],"study_design_scores_gemma":[0.87248266,0.10899435,0.00023872755,0.00022456588,0.00082980434,0.000013717298,0.00017409887,0.00088315824,0.0083528925,0.00017849338,0.0074480027,0.00017952043],"about_ca_topic_score_codex":0.00019368283,"about_ca_topic_score_gemma":0.00042429203,"teacher_disagreement_score":0.10547124,"about_ca_system_score_codex":0.00007542222,"about_ca_system_score_gemma":0.0015630528,"threshold_uncertainty_score":0.8015916},"labels":[],"label_agreement":null},{"id":"W2320121320","doi":"10.1093/annonc/mdw163","title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute","keywords":"Medicine; KRAS; Pemetrexed; Discontinuation; ROS1; Internal medicine; Lung cancer; Oncology; Crizotinib; Retrospective cohort study; Anaplastic lymphoma kinase; Lung; Gene rearrangement; Gastroenterology; Adenocarcinoma; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.07948592838997814,"score_gpt":0.47377688865988016,"score_spread":0.394290960269902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320121320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756621,0.00097551465,0.00008630321,0.01802866,0.00019333321,0.000419312,0.00002157538,0.000024653218,0.004588508],"genre_scores_gemma":[0.9967038,0.00052708766,0.0003758606,0.0016852103,0.00004796541,0.000068612295,0.0000059339577,0.000013615868,0.000571903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903244,0.00010829561,0.00035688627,0.00018672433,0.00012656898,0.00018907875],"domain_scores_gemma":[0.99897325,0.00042660802,0.0001646569,0.00021013476,0.00015054831,0.00007478057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029754872,0.000101518526,0.00051455136,0.0001203796,0.000019503848,0.0000018222324,0.00005708221,0.000099313154,0.00009881606],"category_scores_gemma":[0.00009933384,0.00005159087,0.000097540884,0.00012973598,0.0001508202,0.000047885256,0.000007187657,0.00007303341,0.0000070374244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007340125,0.00024799886,0.9484602,0.000052720065,0.0004519001,0.00006287077,0.00036948954,0.0000058172773,0.00026872012,0.0001099454,0.0015727635,0.04766355],"study_design_scores_gemma":[0.013123582,0.00477398,0.9621949,0.0006790804,0.00025821556,0.000016632503,0.0004795841,0.000016246053,0.00038167927,0.000047625228,0.017898044,0.00013042803],"about_ca_topic_score_codex":0.0005223591,"about_ca_topic_score_gemma":0.00078742893,"teacher_disagreement_score":0.047533125,"about_ca_system_score_codex":0.00018223227,"about_ca_system_score_gemma":0.00086907565,"threshold_uncertainty_score":0.21038146},"labels":[],"label_agreement":null},{"id":"W2321231905","doi":"10.1093/annonc/mdt084.1","title":"Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Metastasis; Retrospective cohort study; Cancer","score_opus":0.04042241227615178,"score_gpt":0.34329314301862135,"score_spread":0.30287073074246956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321231905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339867,0.00069574034,0.0000061629353,0.0008041875,0.00015128059,0.0036881226,0.0012310694,0.0000103321245,0.0000144426585],"genre_scores_gemma":[0.99699324,0.0006944408,0.00012923325,0.0003118911,0.00013705598,0.001687978,0.000007726704,0.000030760384,0.000007697711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978767,0.00046658533,0.00062118826,0.0003133772,0.00035476114,0.0003673905],"domain_scores_gemma":[0.9970804,0.00097310345,0.00094228116,0.0004613211,0.00047857338,0.00006435764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006079126,0.00020799176,0.00073922466,0.00009174504,0.000043343352,0.0000058309893,0.00026189766,0.000060672286,0.00008422525],"category_scores_gemma":[0.00016257445,0.00011363342,0.00007708075,0.00025019512,0.0002869114,0.00011052809,0.00005459683,0.0003196428,0.0000013396867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119896665,0.0014762318,0.5673466,0.0000115846415,0.00089855323,0.0000033206366,0.009328895,0.000040171348,0.00013696974,0.0000016527044,0.00002028725,0.3008391],"study_design_scores_gemma":[0.039793786,0.039222375,0.91770065,0.0001578957,0.00015642552,0.0000017244755,0.0020420232,0.000009383787,0.000302488,0.00030727035,0.00021389741,0.00009206155],"about_ca_topic_score_codex":0.007633042,"about_ca_topic_score_gemma":0.00065859075,"teacher_disagreement_score":0.3503541,"about_ca_system_score_codex":0.00006819741,"about_ca_system_score_gemma":0.00019899363,"threshold_uncertainty_score":0.9989752},"labels":[],"label_agreement":null},{"id":"W2322672763","doi":"10.1093/annonc/mdt459.52","title":"PH 1 Study of PI3KMTOR Inhibitors PF-04691502 or PF-05212384 + MEK Inhibitor PD-0325901 or Irinotecan in Advanced Cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Nausea; Gastroenterology; Internal medicine; Irinotecan; Vomiting; Mucositis; Diarrhea; Cancer; Colorectal cancer; Toxicity","score_opus":0.07367149013791352,"score_gpt":0.4553707728587884,"score_spread":0.3816992827208749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322672763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904046,0.00057368824,0.0000027550939,0.004079657,0.0005733599,0.0020475436,0.0000658445,0.000033736058,0.0022188006],"genre_scores_gemma":[0.99439186,0.0004760452,0.00028957755,0.00089065824,0.0002633785,0.00067444536,0.000026771871,0.000039535775,0.0029477044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99787176,0.00011491768,0.000855191,0.00040759513,0.0003101924,0.0004403517],"domain_scores_gemma":[0.99824905,0.00023980347,0.0004138239,0.00037813128,0.0005197626,0.00019942876],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017777743,0.0002593124,0.0009288761,0.00027026734,0.00005110381,0.00000685634,0.00014516425,0.00018239624,0.0013109385],"category_scores_gemma":[0.00021670133,0.00017639091,0.00010630916,0.0005441596,0.00014642005,0.00019715069,0.00007794451,0.00021556714,0.00002902004],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008302885,0.025941,0.12444909,0.0006987783,0.0018396152,0.00055251486,0.02240026,0.00039354104,0.016452143,0.000078013836,0.073183134,0.725709],"study_design_scores_gemma":[0.0632657,0.12548126,0.46344995,0.0016047661,0.0014055698,0.00009941709,0.037040778,0.00014612706,0.09558078,0.00028206673,0.21042046,0.0012230894],"about_ca_topic_score_codex":0.006078972,"about_ca_topic_score_gemma":0.006910591,"teacher_disagreement_score":0.72448593,"about_ca_system_score_codex":0.00023623959,"about_ca_system_score_gemma":0.001087177,"threshold_uncertainty_score":0.999602},"labels":[],"label_agreement":null},{"id":"W2323493518","doi":"10.1093/annonc/mdt046.10","title":"Potential Therapeutic Implications of Altered Atm and P53 Status in Solid Tumours","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cancer research; Clonogenic assay; Cell culture; DNA damage; Cytotoxic T cell; Medicine; Apoptosis; Molecular biology; Biology; DNA; In vitro; Genetics","score_opus":0.05168015891089815,"score_gpt":0.37558140119417766,"score_spread":0.3239012422832795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323493518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865244,0.0017819954,0.00015798722,0.008302053,0.00007869207,0.00039669216,0.000014518171,0.00000949833,0.0027341903],"genre_scores_gemma":[0.9977257,0.00090076367,0.0002694646,0.0009748725,0.000031433854,0.00003365214,0.000013479946,0.000011638803,0.000038991864],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992067,0.000055333086,0.0002986712,0.00014269746,0.00007448541,0.0002221036],"domain_scores_gemma":[0.9993369,0.000046323945,0.0001444703,0.00019719166,0.0001866212,0.00008852323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010396889,0.00007386244,0.00031213363,0.00012618655,0.000012449313,0.0000020620907,0.0000507632,0.000111531095,0.000116998686],"category_scores_gemma":[0.000043900072,0.00006933335,0.000053037715,0.00012464865,0.00014450398,0.000034230896,0.000031939016,0.00012383335,0.000008920907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002702416,0.0006737968,0.018911812,0.00007617301,0.00017444743,0.00001649051,0.0007422865,0.000070963935,0.78419095,0.00085090013,0.003367726,0.19065422],"study_design_scores_gemma":[0.0028592644,0.0030378315,0.9336871,0.00005657259,0.00008851368,0.00010800089,0.00020655824,0.00024563208,0.051148307,0.0034411314,0.005013652,0.0001074534],"about_ca_topic_score_codex":0.00048500238,"about_ca_topic_score_gemma":0.00009414429,"teacher_disagreement_score":0.91477525,"about_ca_system_score_codex":0.000028072423,"about_ca_system_score_gemma":0.00023048588,"threshold_uncertainty_score":0.2827332},"labels":[],"label_agreement":null},{"id":"W2323669177","doi":"10.1093/annonc/mdt083.5","title":"Unravelling the Effect of Estrogen on Breast Cancer Cell Proteome Using Quantitative Proteomics","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Stable isotope labeling by amino acids in cell culture; Estrogen; Estrogen receptor; Proteome; Estrogen receptor beta; Proteomics; Estrogen receptor alpha; Quantitative proteomics; GPER; Biology; Cell biology; Cancer research; Breast cancer; Biochemistry; Cancer; Endocrinology; Gene; Genetics","score_opus":0.05287605181403237,"score_gpt":0.3868050271640458,"score_spread":0.3339289753500134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323669177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911007,0.00014862584,0.0038950813,0.000892816,0.00001696504,0.0010093834,0.00008863178,0.00002477754,0.002822964],"genre_scores_gemma":[0.96933377,0.00019934772,0.029266346,0.00008941079,0.00006363311,0.0009483056,0.00000533462,0.000025859685,0.00006800507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991487,0.00004829755,0.00031060266,0.00018759951,0.00009786192,0.00020692346],"domain_scores_gemma":[0.99877983,0.0002391718,0.00045768224,0.0002938655,0.00018898085,0.000040448143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019026954,0.00013940493,0.00029838295,0.000023932804,0.00007307236,0.0000057637767,0.0002543687,0.0001365759,0.00020043136],"category_scores_gemma":[0.000024681307,0.00009719433,0.000097500386,0.00009272477,0.00016796275,0.000065727625,0.000057363046,0.00019360152,0.0000059922427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016536264,0.00010079841,0.00075528707,0.00015655786,0.000043767956,5.2278597e-7,0.00013163804,0.0013330042,0.9897005,0.0015667762,0.0000998693,0.0059459014],"study_design_scores_gemma":[0.0002405685,0.0005759194,0.000053574266,0.000070682465,0.000019961115,0.0000052739856,0.00007203054,0.0016556034,0.9947407,0.0019185516,0.0005529025,0.000094179835],"about_ca_topic_score_codex":0.0009338851,"about_ca_topic_score_gemma":0.0000067937294,"teacher_disagreement_score":0.025371265,"about_ca_system_score_codex":0.00005199283,"about_ca_system_score_gemma":0.000079317535,"threshold_uncertainty_score":0.396347},"labels":[],"label_agreement":null},{"id":"W2324727998","doi":"10.1093/annonc/mdu165.209","title":"Use of Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC): A Post-Hoc Analysis of the Glutox Study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Regional Municipality of Durham; Sanofi (Canada); Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Notre-Dame; Hôtel-Dieu de Québec; London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Cégep de Rimouski; Hôpital Maisonneuve-Rosemont; Hôpital Saint-Luc","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Bevacizumab; Colorectal cancer; Regimen; Oncology; Chemotherapy regimen; Chemotherapy; Post-hoc analysis; Adverse effect; Clinical endpoint; FOLFOX; Cancer; Clinical trial","score_opus":0.05428356770031273,"score_gpt":0.3637884548834499,"score_spread":0.3095048871831372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324727998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799305,0.00009150683,0.0000019070038,0.0008839145,0.00003715803,0.000764184,0.00008070019,0.0000040265472,0.00014353498],"genre_scores_gemma":[0.9991582,0.000026256397,0.00012856958,0.00057138025,0.0000058945293,0.000065302724,0.000011258225,0.000010185609,0.00002296699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878687,0.00017790921,0.0004197137,0.00018310657,0.0002726394,0.00015976068],"domain_scores_gemma":[0.99848706,0.00033607695,0.00041310332,0.00021349703,0.0005155892,0.00003466133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020850226,0.00013560716,0.0009705937,0.000234852,0.000024738407,0.0000017033074,0.000080076315,0.000039061997,0.00007582014],"category_scores_gemma":[0.00010681991,0.00007676078,0.00016161497,0.00080537406,0.00018259125,0.000028143284,0.000027313099,0.00007095101,1.5217644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010151587,0.0039305026,0.96229887,0.000036158348,0.003884922,0.0000021106325,0.0018198645,0.0004903783,0.00031694633,0.000008087653,0.000054270768,0.017006287],"study_design_scores_gemma":[0.006335586,0.026591098,0.96332365,0.00003952354,0.0014455632,1.4089787e-7,0.00026069925,0.0003107023,0.0013745022,0.0000036461606,0.00025271357,0.00006219543],"about_ca_topic_score_codex":0.0024974495,"about_ca_topic_score_gemma":0.01317953,"teacher_disagreement_score":0.022660596,"about_ca_system_score_codex":0.000061540115,"about_ca_system_score_gemma":0.0002082411,"threshold_uncertainty_score":0.7354487},"labels":[],"label_agreement":null},{"id":"W2325102243","doi":"10.1093/annonc/mdt084.9","title":"Identification of Brcaness in Sporadic Breast Cancers Using a Model that Integrates Multiple Assays","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immunohistochemistry; Cancer research; Breast cancer; Medicine; DNA methylation; TaqMan; Methylation; Cancer; Biology; Oncology; Pathology; Gene; Polymerase chain reaction; Internal medicine; Gene expression; Genetics","score_opus":0.06837776410317604,"score_gpt":0.358909513067906,"score_spread":0.29053174896473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325102243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960697,0.0004801824,0.0024447471,0.00039036662,0.00010555528,0.00019370257,0.00005371183,0.0000029884511,0.00025900765],"genre_scores_gemma":[0.99837357,0.00020397824,0.001077621,0.00015018621,0.00003304291,0.00004523791,0.000041619027,0.000013061552,0.00006167273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991259,0.00006113092,0.00036049052,0.00020935596,0.00008197942,0.00016112748],"domain_scores_gemma":[0.9991205,0.000023019753,0.00030468492,0.00023279598,0.0002860688,0.000032976084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002613762,0.000091743445,0.0001973236,0.00010235226,0.000018126811,0.0000049803366,0.00017113873,0.00016170809,0.000021436528],"category_scores_gemma":[0.000064089945,0.00009335736,0.000055483757,0.00013195243,0.00016108919,0.000010760264,0.000045752855,0.0000633211,0.0000019678432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069736205,0.00010392908,0.020007346,0.000039467595,0.00004777516,7.2509516e-7,0.00027901007,0.03592105,0.9296796,0.00004736645,0.0011689895,0.012635019],"study_design_scores_gemma":[0.00071747106,0.00022153446,0.018150216,0.00003734753,0.000017760029,0.000026812644,0.0009146905,0.09377271,0.8846029,0.0008810771,0.0004783436,0.00017912449],"about_ca_topic_score_codex":0.0017378101,"about_ca_topic_score_gemma":0.0008262817,"teacher_disagreement_score":0.05785166,"about_ca_system_score_codex":0.00009000909,"about_ca_system_score_gemma":0.00058898644,"threshold_uncertainty_score":0.38070026},"labels":[],"label_agreement":null},{"id":"W2325353319","doi":"10.1093/annonc/mdt084.3","title":"Prognostic and Predictive Value of IHC4 and ERB1 in the Intergroup Exemestane Study (IES) - On Behalf of the Pathies Investigators","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Exemestane; Internal medicine; Oncology; Breast cancer; Proportional hazards model; Gynecology; Biomarker; Immunohistochemistry; Cancer; Tamoxifen","score_opus":0.09515554137456515,"score_gpt":0.41380081089359,"score_spread":0.31864526951902483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325353319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900594,0.0004664502,9.109699e-7,0.0066427058,0.000052647214,0.0016256163,0.000011717958,0.000003534869,0.0011370202],"genre_scores_gemma":[0.99892956,0.00023828293,0.00003220171,0.0005849095,0.000027242522,0.00014847293,0.0000011318854,0.000009325866,0.000028852732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837977,0.00054751884,0.00037475722,0.00017632364,0.0003381392,0.00018351924],"domain_scores_gemma":[0.99828917,0.0009678195,0.00016738498,0.00029091001,0.00021968875,0.00006502636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010797024,0.00010047401,0.00039452928,0.00012632509,0.000025299178,0.0000043518326,0.00018346524,0.00008930361,0.00002051119],"category_scores_gemma":[0.0015216005,0.00005493612,0.000034037927,0.00024203154,0.0010549582,0.00004548422,0.00014761352,0.00030151164,8.161558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035429292,0.0015609429,0.95893824,0.00030501568,0.00012886261,0.000024297036,0.021141915,0.0000049988907,0.0019331055,0.00071832404,0.0023831422,0.012506837],"study_design_scores_gemma":[0.0010403452,0.017814225,0.9659927,0.00033718217,0.000054098917,0.000020008883,0.009832884,0.000087178014,0.0029961953,0.0014570362,0.0003227759,0.000045368168],"about_ca_topic_score_codex":0.00088732684,"about_ca_topic_score_gemma":0.00018081737,"teacher_disagreement_score":0.016253281,"about_ca_system_score_codex":0.000022260247,"about_ca_system_score_gemma":0.00021700765,"threshold_uncertainty_score":0.38870373},"labels":[],"label_agreement":null},{"id":"W2326948361","doi":"10.1093/annonc/mdw137","title":"The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Danish; Bone marrow; Lymphoma; Biopsy; Diffuse large B-cell lymphoma; Radiology; Nuclear medicine; Pathology","score_opus":0.015777188157726694,"score_gpt":0.27672746232095025,"score_spread":0.26095027416322353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326948361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445206,0.00013336491,9.97938e-7,0.0028069543,0.000043013653,0.0009437121,0.00009321998,0.000008486084,0.0015182201],"genre_scores_gemma":[0.9990518,0.00007595332,0.00008486651,0.00035999317,0.000015005803,0.0000803783,0.000014404086,0.000023575785,0.00029398678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983577,0.000167351,0.00040377097,0.00027452467,0.00029460332,0.00050204777],"domain_scores_gemma":[0.998551,0.00025922584,0.00027553816,0.0004588556,0.00024076425,0.00021458854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044005405,0.00019206757,0.0005698051,0.00015672843,0.00007820335,0.0000055843984,0.00012804427,0.000025844209,0.000033207314],"category_scores_gemma":[0.00007033259,0.00008748636,0.00005846879,0.00022108175,0.00015871448,0.00005337671,0.000047069196,0.00004558589,0.000009912861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019625975,0.026111528,0.962348,0.000019509731,0.00024033687,0.001341737,0.00031870895,2.8909648e-7,0.00003524346,0.00022594543,0.00045389886,0.0069422233],"study_design_scores_gemma":[0.063878484,0.015427173,0.9159142,0.0001090473,0.000119200835,0.000056359513,0.0005463333,0.0000021332098,0.0010810053,0.000014730767,0.0027425182,0.00010881131],"about_ca_topic_score_codex":0.011667707,"about_ca_topic_score_gemma":0.044064518,"teacher_disagreement_score":0.061915882,"about_ca_system_score_codex":0.0002027317,"about_ca_system_score_gemma":0.00057715084,"threshold_uncertainty_score":0.9949137},"labels":[],"label_agreement":null},{"id":"W2327662331","doi":"10.1093/annonc/mdt203.267","title":"Causes of Urban-Rural Disparities in Adjuvant Chemotherapy (AC) for Rectal Cancer (RC)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Quartile; Logistic regression; Demography; Rural area; Cancer; Internal medicine; Confidence interval; Pathology","score_opus":0.08531093783584762,"score_gpt":0.33291088772033167,"score_spread":0.24759994988448406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327662331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737219,0.008810902,0.000092384114,0.0066368775,0.0004721147,0.00041367946,0.00037396146,0.000008569356,0.009469569],"genre_scores_gemma":[0.99167067,0.0053194966,0.00022560255,0.0015200968,0.00015324612,0.00018000053,0.00000842967,0.000020819785,0.0009016659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986581,0.00001005833,0.0007772861,0.00019500456,0.000017263039,0.00034229222],"domain_scores_gemma":[0.9989927,0.000113194284,0.00056158076,0.00016717968,0.000107857624,0.00005750352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002818737,0.00012984205,0.00081904937,0.00018231438,0.00002213894,0.00000972217,0.00018853392,0.00016990703,0.00056069565],"category_scores_gemma":[0.00012938639,0.00014342662,0.00014705326,0.00009579628,0.00016743469,0.00028680952,0.000026634512,0.000088470755,0.000025241015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004153062,0.00053255336,0.6684988,0.00021606064,0.00021448494,0.0000013083447,0.001812656,0.00012517389,0.00040454048,0.118369035,0.12341156,0.08599849],"study_design_scores_gemma":[0.0027286997,0.0016823723,0.69306695,0.000081832506,0.000007848917,0.0000018396812,0.00026358422,0.00035908286,0.0058999136,0.07567773,0.21980515,0.00042501136],"about_ca_topic_score_codex":0.011211131,"about_ca_topic_score_gemma":0.00110964,"teacher_disagreement_score":0.09639359,"about_ca_system_score_codex":0.000073869676,"about_ca_system_score_gemma":0.00010076213,"threshold_uncertainty_score":0.9953733},"labels":[],"label_agreement":null},{"id":"W2328376199","doi":"10.1093/annonc/mdu329.5","title":"Overall Survival (Os) Endpoint: an Incomplete Evaluation of Metastatic Breast Cancer (Mbc) Treatment Outcome","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical endpoint; Outcome (game theory); Breast cancer; Overall survival; Gynecology; Cancer; Clinical trial","score_opus":0.2909496066262447,"score_gpt":0.5014498677820636,"score_spread":0.21050026115581888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328376199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934126,0.000524409,0.0005857758,0.0060749147,0.00030084516,0.0005739279,0.00020293865,0.00002918139,0.0023667333],"genre_scores_gemma":[0.99708635,0.00011411983,0.001482328,0.00087211555,0.0001853451,0.00009130288,0.000050303377,0.00002703647,0.00009111286],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99790287,0.00048911537,0.00057927344,0.00027523897,0.00047548529,0.00027802473],"domain_scores_gemma":[0.9980519,0.00020777734,0.00044757858,0.00040662833,0.00075128884,0.00013487431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011478758,0.00019580167,0.00089823065,0.00014458518,0.000030501007,0.0000025900922,0.00010821188,0.00007218367,0.00086514966],"category_scores_gemma":[0.00009520346,0.00015619125,0.00014894072,0.000113742586,0.0001746512,0.00012850559,0.000027788481,0.00008528531,0.000008643709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025727013,0.001662992,0.029227853,0.00014642267,0.000825818,0.0000074057957,0.0010768079,0.0013964486,0.014528745,0.0021366265,0.000062244224,0.94635594],"study_design_scores_gemma":[0.021014865,0.013761905,0.8902577,0.00013957053,0.0015503273,0.00015767323,0.00046670795,0.0052712266,0.01449641,0.009474933,0.042980164,0.00042846997],"about_ca_topic_score_codex":0.0010705305,"about_ca_topic_score_gemma":0.00066558266,"teacher_disagreement_score":0.94592744,"about_ca_system_score_codex":0.00027243985,"about_ca_system_score_gemma":0.00039317235,"threshold_uncertainty_score":0.9472782},"labels":[],"label_agreement":null},{"id":"W2328480975","doi":"10.1093/annonc/mdu338.4","title":"Beneficial Effect of Adjuvant Chemotherapy and Whole Abdominal or Pelvic Radiotherapy (Waprt) on Progression Free and Overall Survival Following Primary Surgery in Patients with Ovarian Clear Cell Carcinoma (Occc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Clear cell carcinoma; Radiation therapy; Overall survival; Chemotherapy; Internal medicine; Adjuvant; Carcinoma","score_opus":0.0171053854701012,"score_gpt":0.29827104399901005,"score_spread":0.28116565852890885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328480975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677366,0.0006385659,0.000003924905,0.001415641,0.00013564005,0.00064222544,0.000014797918,0.000007704796,0.00036784634],"genre_scores_gemma":[0.9986076,0.0002513543,0.00040134572,0.00055689627,0.00008853365,0.00002752139,0.000023272529,0.000030932937,0.000012551961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860597,0.00021863088,0.00034249653,0.00032197539,0.00025775944,0.00025314625],"domain_scores_gemma":[0.9986834,0.0006800206,0.00023133591,0.0002475186,0.000053511976,0.00010424864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005974654,0.00021025843,0.0010190116,0.00015794717,0.000033342298,0.000006452757,0.00005579613,0.00014239596,0.000019372988],"category_scores_gemma":[0.000044087585,0.00013638026,0.00009635531,0.00009599567,0.000086962755,0.000054963537,0.000026018373,0.000117097334,3.750081e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022882983,0.0012759103,0.78619707,0.00026803254,0.00011014305,0.000045631215,0.00023478243,0.000002434244,0.00037756597,0.000012878349,0.00033182238,0.18826073],"study_design_scores_gemma":[0.022509633,0.036396727,0.935628,0.00031919638,0.0000807075,0.0000033975784,0.000010049805,0.000030672796,0.0036738105,0.000014896759,0.0012104453,0.00012248592],"about_ca_topic_score_codex":0.000147717,"about_ca_topic_score_gemma":0.000046963163,"teacher_disagreement_score":0.18813825,"about_ca_system_score_codex":0.00006696957,"about_ca_system_score_gemma":0.00014355157,"threshold_uncertainty_score":0.55614257},"labels":[],"label_agreement":null},{"id":"W2328702979","doi":"10.1093/annonc/mdv532.27","title":"443P Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Gefitinib; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer; Epidermal growth factor receptor; Chemotherapy","score_opus":0.04387169014604697,"score_gpt":0.39460912769524864,"score_spread":0.35073743754920167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328702979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043155,0.00023523753,0.000022203973,0.0012468955,0.00021984936,0.0012056516,0.00006215056,0.000005285533,0.006571156],"genre_scores_gemma":[0.9993025,0.000008565055,0.00015980321,0.00019994056,0.000022123082,0.000049164566,0.000042344516,0.000014161815,0.00020141937],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987405,0.00014220538,0.0005050674,0.00017413913,0.00026548278,0.0001726],"domain_scores_gemma":[0.99871635,0.00015014764,0.00038907854,0.00026229816,0.00038567293,0.000096450334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023317085,0.00013830485,0.0006152413,0.000112100905,0.00002868377,0.0000026818002,0.00008413634,0.000092411334,0.000016531667],"category_scores_gemma":[0.00013574389,0.000085225925,0.000087749155,0.00019441958,0.00016650601,0.000055859975,0.000039845243,0.00009907992,3.514175e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028722404,0.008974785,0.9470567,0.0002027371,0.0003382136,0.000030537212,0.008497552,0.0001453128,0.00055657397,0.0005785527,0.002336807,0.0025598248],"study_design_scores_gemma":[0.5014703,0.033213787,0.44955763,0.000092819435,0.0012777792,0.0000056322597,0.001996025,0.00022869513,0.010441078,0.00010331118,0.0013665718,0.00024634323],"about_ca_topic_score_codex":0.0007153392,"about_ca_topic_score_gemma":0.0002005549,"teacher_disagreement_score":0.49749908,"about_ca_system_score_codex":0.00006002403,"about_ca_system_score_gemma":0.00061392726,"threshold_uncertainty_score":0.34754124},"labels":[],"label_agreement":null},{"id":"W2330051434","doi":"10.1093/annonc/mdv049.06","title":"Can Concurrent Chemo-Radiation Be Delayed by Induction Chemotherapy in the Curative Treatment of Stage Iii Non-Small Cell Lung Carcinoma? a Pooled Analysis","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Regimen; Carboplatin; Gemcitabine; Stage (stratigraphy); Chemotherapy; Induction chemotherapy; Chemotherapy regimen; Radiation therapy; Internal medicine; Surgery; Lung cancer; Gastroenterology; Cisplatin","score_opus":0.06678706004619615,"score_gpt":0.37854957311841586,"score_spread":0.3117625130722197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330051434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810819,0.0020767953,0.000034419627,0.0150434375,0.000078015386,0.00085029297,0.00008137218,0.0000076267584,0.0007461121],"genre_scores_gemma":[0.99718034,0.0013623844,0.000035680165,0.0008062264,0.000048419486,0.00019521793,0.00024351085,0.000012280309,0.00011592947],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988509,0.00013567247,0.0004021166,0.00023258512,0.00018798179,0.00019078716],"domain_scores_gemma":[0.99898446,0.000092826784,0.00037383416,0.00023761859,0.00021755429,0.00009373829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024372229,0.00016285422,0.0006493746,0.00017950998,0.00001787675,0.0000040919463,0.00006886079,0.0001143973,0.000026042002],"category_scores_gemma":[0.000011893039,0.00010851725,0.0001771494,0.00044342875,0.00006490258,0.000035783305,0.000008219467,0.00007076207,4.9092415e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035765234,0.023328407,0.6428128,0.00020096432,0.010398458,0.00011466864,0.12677355,0.000619981,0.0062185517,0.00020617415,0.050121013,0.13562891],"study_design_scores_gemma":[0.052549053,0.047175158,0.40492266,0.00006873166,0.00783512,0.000013846894,0.014656596,0.0036049036,0.4268393,0.00005835499,0.04178168,0.0004946128],"about_ca_topic_score_codex":0.0069436776,"about_ca_topic_score_gemma":0.0017367164,"teacher_disagreement_score":0.42062074,"about_ca_system_score_codex":0.0006274306,"about_ca_system_score_gemma":0.0004432887,"threshold_uncertainty_score":0.9996692},"labels":[],"label_agreement":null},{"id":"W2331931903","doi":"10.1093/annonc/mdu165.213","title":"Timing and Regimens of Adjuvant Therapy for Resected Stage II and III Colon Cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Stage (stratigraphy); Oxaliplatin; Colorectal cancer; Internal medicine; Chemotherapy; Cancer; Adjuvant therapy; Pathological staging; Population; Colonoscopy; Surgery; Oncology; Gastroenterology","score_opus":0.12870818198952677,"score_gpt":0.4358061880517246,"score_spread":0.30709800606219784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331931903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860653,0.006126077,0.000007283092,0.004866444,0.000052755186,0.00037846234,0.000027539041,0.0000063929983,0.0024697266],"genre_scores_gemma":[0.9906871,0.007491561,0.00019379599,0.0005721742,0.00004415357,0.000069484275,0.0000040931955,0.0000069389384,0.00093070447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994938,0.000026131072,0.00016086345,0.00013403124,0.000056637924,0.0001285479],"domain_scores_gemma":[0.99939966,0.00018208323,0.00012173517,0.00007711991,0.00017781493,0.000041600462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016561442,0.00007360975,0.00043939336,0.000046372465,0.00006322064,0.0000010649065,0.000020029569,0.00005835522,0.000023771478],"category_scores_gemma":[0.000060842718,0.000053339307,0.000032313357,0.00004432639,0.00014462792,0.000016796306,0.00003458293,0.000037639024,4.617187e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015487102,0.0007774278,0.027834034,0.00037202903,0.0011004835,0.00001085204,0.007987953,0.0000037782386,0.052923743,0.0012009667,0.014490335,0.8778113],"study_design_scores_gemma":[0.022952491,0.083807334,0.23972921,0.0002529716,0.0002589878,0.000016592167,0.0010222797,0.00036450624,0.076384686,0.0006663511,0.57431275,0.00023184554],"about_ca_topic_score_codex":0.00040431158,"about_ca_topic_score_gemma":0.0004695322,"teacher_disagreement_score":0.87757945,"about_ca_system_score_codex":0.00001551113,"about_ca_system_score_gemma":0.00006780847,"threshold_uncertainty_score":0.21751139},"labels":[],"label_agreement":null},{"id":"W2332945822","doi":"10.1093/annonc/mdt460.85","title":"Potential Predictive Markers of Efficacy of Dacomitinib in Patients with Recurrent/Metastatic Scchn from a Phase 2 Trial","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; PTEN; Oncology; Internal medicine; Immunohistochemistry; Clinical endpoint; Predictive marker; Clinical trial; Cancer research; Pathology; Cancer; PI3K/AKT/mTOR pathway; Apoptosis; Biology","score_opus":0.03272214602876293,"score_gpt":0.39986339364829837,"score_spread":0.3671412476195354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332945822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637145,0.00008923637,0.000041385865,0.00041765915,0.00014293032,0.001437325,0.00030873754,0.000004691855,0.0011865842],"genre_scores_gemma":[0.99870497,0.000027655351,0.0007870616,0.000083517945,0.00003130962,0.00006583327,0.0002692631,0.000009110799,0.000021275284],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989822,0.00008165813,0.00046180148,0.00015393834,0.00018179118,0.00013861773],"domain_scores_gemma":[0.9989168,0.00016622418,0.00037760785,0.00015257197,0.0003190199,0.00006778479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008987841,0.00009472204,0.000505212,0.00014134722,0.000010288182,0.0000014274207,0.000056068166,0.000053499974,0.00032334574],"category_scores_gemma":[0.000114994895,0.00006998088,0.000078303325,0.00014355443,0.0001451982,0.00006897403,0.000017886083,0.00007782616,0.0000027504614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5704465,0.0465351,0.06683323,0.00019785091,0.003539796,0.000037422706,0.0028845093,0.00008362542,0.0007832462,0.0000567128,0.00648086,0.30212116],"study_design_scores_gemma":[0.37176448,0.09206504,0.5325138,0.00029793766,0.0008401308,0.0000011457049,0.000459596,0.0001432676,0.0011178618,0.00020898704,0.00048755552,0.00010020185],"about_ca_topic_score_codex":0.000666921,"about_ca_topic_score_gemma":0.000019904328,"teacher_disagreement_score":0.46568057,"about_ca_system_score_codex":0.000033877594,"about_ca_system_score_gemma":0.0003028583,"threshold_uncertainty_score":0.3540409},"labels":[],"label_agreement":null},{"id":"W2334334427","doi":"10.1093/annonc/mdt203.229","title":"Time From Surgery to First Adjuvant Chemotherapy: Single Canadian Institution Experience","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Regimen; FOLFOX; Surgery; Referral; Chemotherapy regimen; Surgical oncology; Cancer; Internal medicine; Chemotherapy; General surgery; Oxaliplatin; Family medicine","score_opus":0.08598794346987985,"score_gpt":0.34257645790858493,"score_spread":0.25658851443870506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334334427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668541,0.0002202047,0.0000036129522,0.017305965,0.00022367822,0.00035133396,0.000019188537,0.000022887461,0.01499901],"genre_scores_gemma":[0.99274415,0.00006617955,0.00018967119,0.0063734394,0.00009224498,0.000095714924,0.000026264142,0.000010565089,0.00040176287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907005,0.000027628877,0.00023289362,0.00021355416,0.00012315756,0.00033273516],"domain_scores_gemma":[0.9989298,0.00018218231,0.00006419886,0.00019475,0.00015331972,0.0004757301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000082094164,0.00010649261,0.0004161364,0.00013228091,0.000041950763,0.0000056350395,0.00006806679,0.000114252616,0.003968857],"category_scores_gemma":[0.00018692369,0.00009304549,0.0000858179,0.00019745741,0.00011351751,0.00008215991,0.000021046544,0.000058287016,0.0006403457],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011229945,0.0015328571,0.13504066,0.00003290231,0.0003291662,0.00042960115,0.004728428,0.00002318455,0.016320191,0.000026587866,0.14790067,0.69251275],"study_design_scores_gemma":[0.00078179414,0.0019936594,0.44581005,0.00009412646,0.000018455159,0.00002136506,0.000100404766,0.00005069468,0.018514058,0.00008739392,0.5323707,0.00015730927],"about_ca_topic_score_codex":0.14503837,"about_ca_topic_score_gemma":0.0319289,"teacher_disagreement_score":0.69235545,"about_ca_system_score_codex":0.00032407523,"about_ca_system_score_gemma":0.00046719614,"threshold_uncertainty_score":0.9969416},"labels":[],"label_agreement":null},{"id":"W2334914145","doi":"10.1093/annonc/mdw068","title":"A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"Terry Fox Research Institute","keywords":"Medicine; Hsp27; Prostate cancer; Castration; Cancer research; Heat shock protein; Internal medicine; Shock (circulatory); Oncology; Cancer; Hsp70; Hormone; Gene","score_opus":0.03044738267149603,"score_gpt":0.3700541498515756,"score_spread":0.33960676718007954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334914145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751467,0.00015326044,0.000009907472,0.00017983146,0.000025855346,0.0019362947,0.00012077113,0.0000047955923,0.000054594195],"genre_scores_gemma":[0.99937487,0.00004621955,0.00019747514,0.000039066883,0.000042983313,0.0001991938,0.000020371075,0.000026516649,0.000053301337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983679,0.00026283844,0.00043284852,0.0003972345,0.00022821933,0.00031094978],"domain_scores_gemma":[0.999118,0.00002018204,0.0001717726,0.00023111377,0.00034965458,0.00010933138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003639498,0.00015882653,0.00030198015,0.00010565368,0.00004359806,0.0000052660657,0.00009388637,0.0001271863,0.000014051183],"category_scores_gemma":[0.00011346196,0.000114223876,0.000022650049,0.00014519361,0.00013951275,0.00002592161,0.00007632867,0.00008115854,4.2845025e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005381308,0.0015863975,0.08105631,0.000047573103,0.000058643207,0.0000065046133,0.0005993624,0.000091149515,0.8818125,0.0000025883965,0.000039966577,0.029317675],"study_design_scores_gemma":[0.020414751,0.04637528,0.04534952,0.00023050694,0.00001832368,0.0000011356325,0.0007874982,0.00006266412,0.8846169,0.000014447756,0.0017915003,0.00033743816],"about_ca_topic_score_codex":0.0012503046,"about_ca_topic_score_gemma":0.0038298406,"teacher_disagreement_score":0.044788882,"about_ca_system_score_codex":0.000055533892,"about_ca_system_score_gemma":0.00041592206,"threshold_uncertainty_score":0.46579143},"labels":[],"label_agreement":null},{"id":"W2336057475","doi":"10.1093/annonc/mdw179","title":"Diagnostic Gleason score and castration-resistant prostate cancer","year":2016,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Docetaxel; Internal medicine; Oncology; Prednisone; Cabazitaxel; Taxane; Cancer; Androgen deprivation therapy; Androgen receptor; Breast cancer","score_opus":0.11695407753687155,"score_gpt":0.42132227972682934,"score_spread":0.3043682021899578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336057475","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060996942,0.017475404,5.983393e-7,0.91659194,0.00025771442,0.0009878048,0.0004469878,0.000020478896,0.0032221237],"genre_scores_gemma":[0.08786491,0.1439084,0.00015945177,0.7060119,0.00839128,0.0012600246,0.0010322941,0.00017913379,0.05119264],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839973,0.00009695427,0.00032377732,0.00037713873,0.0003061733,0.00049623486],"domain_scores_gemma":[0.9983678,0.00064052205,0.0002230447,0.00024955577,0.00039901672,0.00012010372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016917477,0.00023502427,0.00066038023,0.00017049572,0.000053395426,0.000011143374,0.0000863283,0.0005356899,0.0003082369],"category_scores_gemma":[0.00019165798,0.00015058141,0.000098012526,0.000094113995,0.00039151846,0.000053099986,0.000053132815,0.00057516515,0.00002127962],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071260676,0.000064473476,0.004912177,0.0007989715,0.00032206374,0.0023106392,0.00015292928,1.0433442e-7,0.0014972411,0.00001648784,0.9151156,0.07409668],"study_design_scores_gemma":[0.00206095,0.0034613307,0.007592377,0.0011349982,0.00016527285,0.00005668825,0.000017195276,7.1869476e-7,0.0031802237,0.00032632344,0.98184454,0.00015936683],"about_ca_topic_score_codex":0.00033163,"about_ca_topic_score_gemma":0.0000864772,"teacher_disagreement_score":0.21058008,"about_ca_system_score_codex":0.00011577835,"about_ca_system_score_gemma":0.0011795183,"threshold_uncertainty_score":0.61405313},"labels":[],"label_agreement":null},{"id":"W2337992458","doi":"10.1093/annonc/mdu329.21","title":"Targeted Chemotherapy with Albumin-Bound Paclitaxel (Nab-Paclitaxel) for Metastatic Breast Cancer (Mbc): Which Benefit for Which Patients? a Real World Multicenter Italian Experience on 150 Women","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Paclitaxel; Metastatic breast cancer; Nab-paclitaxel; Oncology; Chemotherapy; Internal medicine; Breast cancer; Cancer","score_opus":0.04636067163229297,"score_gpt":0.3985789024234224,"score_spread":0.35221823079112946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337992458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814598,0.00012568539,0.00007195828,0.013328861,0.00036914586,0.0024698137,0.00069346896,0.00003990095,0.0014413731],"genre_scores_gemma":[0.9856168,0.00029806476,0.0013697238,0.006580866,0.00033703365,0.0033064068,0.00023109387,0.00007660869,0.0021833745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976205,0.00009297692,0.0005684817,0.000608792,0.00026030603,0.00084891927],"domain_scores_gemma":[0.997021,0.0006356575,0.00043653185,0.00035500998,0.0012306981,0.00032107587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036976574,0.00038696497,0.0010190717,0.0002425645,0.00013022592,0.000016754695,0.00018367641,0.00013835401,0.00057330064],"category_scores_gemma":[0.00009561849,0.0002999729,0.00015675518,0.0004121876,0.000184671,0.00013458829,0.000026735082,0.00015832591,0.0000067074707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18496378,0.03139651,0.2719516,0.0022310955,0.007858158,0.000025482897,0.050616555,0.00020641049,0.013132496,0.0017723299,0.081184275,0.35466135],"study_design_scores_gemma":[0.09449393,0.1121999,0.27523327,0.00056106655,0.0011732418,0.000025950854,0.0023410765,0.0013809656,0.021801194,0.0010103026,0.48845223,0.0013268625],"about_ca_topic_score_codex":0.000788933,"about_ca_topic_score_gemma":0.0057691894,"teacher_disagreement_score":0.40726796,"about_ca_system_score_codex":0.00037797686,"about_ca_system_score_gemma":0.00033270224,"threshold_uncertainty_score":0.9999452},"labels":[],"label_agreement":null},{"id":"W2338036249","doi":"10.1093/annonc/mdu337.28","title":"Updated Os Analysis, Multivariate and Qtwist Analysis of a Randomized Sequential Open-Label Study (Switch) to Evaluate Efficacy and Safety of Sorafenib (So) / Sunitinib (Su) Versus Su/So in the Treatment of Metastatic Renal Cell Cancer (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Weyerhauser (Canada)","funders":"","keywords":"Medicine; Sorafenib; Sunitinib; Multivariate analysis; Oncology; Randomized controlled trial; Internal medicine; Hepatocellular carcinoma; Renal cell carcinoma","score_opus":0.15832574604703198,"score_gpt":0.44939084254868117,"score_spread":0.2910650965016492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338036249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941703,0.0010239981,0.00006839898,0.0007059658,0.00003916201,0.0034743135,0.00014381828,0.000004413075,0.00036964193],"genre_scores_gemma":[0.9981709,0.00064437365,0.00062379934,0.00009283757,0.000015062054,0.00020015544,0.00017833375,0.000016866206,0.00005765319],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943049,0.0028091113,0.0015908995,0.00050528056,0.00047692034,0.00031287095],"domain_scores_gemma":[0.9947991,0.0027191988,0.001119389,0.00061559473,0.00058967597,0.00015708744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003375345,0.00033616283,0.00402537,0.0010032657,0.000060923485,0.000020469153,0.00024364352,0.0000940294,0.00015240948],"category_scores_gemma":[0.00037340858,0.00021250572,0.00036265643,0.0017223167,0.0004509883,0.000054005734,0.000117454016,0.00010599318,8.3470223e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7367189,0.03721689,0.019844195,0.0002355653,0.10601292,0.000178752,0.03351114,0.006102,0.035759863,0.00015518664,0.00008071294,0.02418389],"study_design_scores_gemma":[0.67526865,0.03857947,0.13504742,0.000076480814,0.11878897,0.0000049775485,0.002111766,0.007202983,0.022127382,0.000030909905,0.00046067033,0.00030034373],"about_ca_topic_score_codex":0.01965559,"about_ca_topic_score_gemma":0.006204968,"teacher_disagreement_score":0.115203224,"about_ca_system_score_codex":0.000108020526,"about_ca_system_score_gemma":0.00035200513,"threshold_uncertainty_score":0.9868726},"labels":[],"label_agreement":null},{"id":"W2339181300","doi":"10.1093/annonc/mdv233.286","title":"P-289 Preliminary data of a pilot study of combined stereotactic body radiotherapy (SBRT) and bevacizumab as a radiosensitizer for colorectal liver metastases","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Bevacizumab; Colorectal cancer; Radiosurgery; Radiology; Internal medicine; Oncology; Nuclear medicine; Radiation therapy; Cancer; Chemotherapy","score_opus":0.13150704721549616,"score_gpt":0.40941857474481175,"score_spread":0.2779115275293156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339181300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991601,0.0011640631,0.0049510067,0.00015680506,0.00006374196,0.0014824956,0.00032005933,0.00002262344,0.00023819144],"genre_scores_gemma":[0.98705995,0.00014436089,0.012455313,0.00007306788,0.00006236765,0.00007187677,0.00006405668,0.000032384756,0.00003664843],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985104,0.00026032084,0.00051242596,0.00033243786,0.00016275389,0.00022166432],"domain_scores_gemma":[0.99785894,0.0006005934,0.0005851298,0.000533281,0.00033083168,0.00009119642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052235374,0.00019741608,0.0008421764,0.00013381477,0.000032982836,0.0000055907494,0.0003243709,0.000044667686,0.000037387388],"category_scores_gemma":[0.00005663666,0.00018065108,0.000058875463,0.00012980115,0.00021856472,0.00021903851,0.0001334968,0.00009713696,2.2610939e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16630293,0.092176534,0.061490823,0.00084321405,0.01848998,0.0001801544,0.026125798,0.0002534177,0.18041109,0.016650463,0.056937277,0.3801383],"study_design_scores_gemma":[0.04466762,0.7667389,0.011192927,0.00014609065,0.0010644171,0.00011754293,0.005142093,0.006184159,0.1318065,0.0069446205,0.024872059,0.0011231046],"about_ca_topic_score_codex":0.0004181333,"about_ca_topic_score_gemma":0.000011838093,"teacher_disagreement_score":0.67456234,"about_ca_system_score_codex":0.000023604121,"about_ca_system_score_gemma":0.00019701238,"threshold_uncertainty_score":0.7366738},"labels":[],"label_agreement":null},{"id":"W2339365887","doi":"10.1093/annonc/mdu334.114","title":"Impact of Neutrophil-To-Lymphocyte Ratio (Nlr) and Platelet-To-Lymphocyte Ratio (Plr) on Outcomes in Hepatocellular Carcinoma (Hcc) Patients Treated with Sorafenib (Sor)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Lymphocyte; Neutrophil to lymphocyte ratio; Platelet; Internal medicine; Oncology; Gastroenterology; Immunology","score_opus":0.02847417592416899,"score_gpt":0.3159311771562647,"score_spread":0.28745700123209567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339365887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966157,0.00009721353,0.000022261032,0.0006364076,0.000077536875,0.0015769462,0.000069691494,0.000036435118,0.0008677981],"genre_scores_gemma":[0.9981607,0.000044024953,0.00028097286,0.0011610723,0.00004902897,0.00011884207,0.00006698329,0.000058929476,0.000059409238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726325,0.0003199443,0.0008804827,0.00056312076,0.00040986514,0.00056331913],"domain_scores_gemma":[0.9977352,0.00027993336,0.00042239638,0.0005874587,0.0005077508,0.0004672754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004316847,0.00043398846,0.0013427332,0.0007713519,0.000059548533,0.000012975817,0.00020338772,0.0002713132,0.000050636827],"category_scores_gemma":[0.000328469,0.00033594162,0.00020597407,0.0005095482,0.00021038335,0.00010942888,0.00010069985,0.00014672402,0.000027862035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012961267,0.0011235761,0.969733,0.0001469626,0.00029073976,0.00019701612,0.00045662015,0.00013387275,0.0045293686,0.00005199974,0.00043333817,0.0099422205],"study_design_scores_gemma":[0.011632557,0.017433988,0.92816144,0.0001340981,0.00011906781,0.000019114077,0.000030210433,0.00095962454,0.04050973,0.000017617573,0.0006816646,0.00030090235],"about_ca_topic_score_codex":0.00049581565,"about_ca_topic_score_gemma":0.0000580859,"teacher_disagreement_score":0.041571595,"about_ca_system_score_codex":0.00034510507,"about_ca_system_score_gemma":0.000600405,"threshold_uncertainty_score":0.9999093},"labels":[],"label_agreement":null},{"id":"W2341235120","doi":"10.1093/annonc/mdw170","title":"Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto; Cancer Research UK","keywords":"Medicine; Fibroblast growth factor receptor 3; Fibroblast growth factor receptor; Cancer research; Fibroblast growth factor; Fibroblast growth factor receptor 2; Bladder cancer; Oncology; Cancer; Perioperative; Internal medicine; Receptor; Surgery","score_opus":0.10870815571985691,"score_gpt":0.41077029809141236,"score_spread":0.30206214237155543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341235120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821504,0.00035790697,0.00009831283,0.012746483,0.00008184346,0.0013006148,0.0027300683,0.000014975124,0.00051940203],"genre_scores_gemma":[0.99652374,0.0010175882,0.0006252868,0.0005404391,0.000080416765,0.00088174583,0.00005908491,0.000022976374,0.00024871685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881774,0.000078611934,0.00044512574,0.00030622908,0.00008219015,0.0002701094],"domain_scores_gemma":[0.99859893,0.00031100147,0.0002300788,0.000218676,0.00052458845,0.0001167113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056465764,0.000186224,0.0006147164,0.0001489062,0.000053866785,0.0000029921255,0.00008536797,0.00010704134,0.00027707536],"category_scores_gemma":[0.00014578943,0.00012364089,0.00018026413,0.00016299418,0.00020534915,0.000093796836,0.000021557824,0.000044000324,0.00000894888],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014314912,0.0037508998,0.2801382,0.00021582833,0.0015407092,0.000010340351,0.0039692665,0.000013396239,0.6371583,0.0008491548,0.0031028038,0.067819655],"study_design_scores_gemma":[0.006049827,0.009076948,0.36322075,0.00016488467,0.0001247244,0.000011870482,0.00022071865,0.0000019273082,0.61702085,0.00020283619,0.0037647625,0.00013990319],"about_ca_topic_score_codex":0.00073667755,"about_ca_topic_score_gemma":0.0014685015,"teacher_disagreement_score":0.08308254,"about_ca_system_score_codex":0.00023600008,"about_ca_system_score_gemma":0.0010923925,"threshold_uncertainty_score":0.5041929},"labels":[],"label_agreement":null},{"id":"W2341303931","doi":"10.1093/annonc/mdw178","title":"Anti-PD-1-associated organizing pneumonia in a responding melanoma patient","year":2016,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Pneumonitis; Internal medicine; Melanoma; Nivolumab; Lung cancer; Cancer; Oncology; Immunotherapy; Lung; Cancer research","score_opus":0.058271392711950115,"score_gpt":0.34924950369503355,"score_spread":0.29097811098308346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341303931","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3952163,0.00096487656,8.279762e-7,0.59841436,0.00052673114,0.00034637374,0.00006466737,0.00003087943,0.0044349795],"genre_scores_gemma":[0.33036956,0.0015146477,0.000043237498,0.6646179,0.0009469441,0.000031357027,0.00015124587,0.00009092565,0.0022341646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759233,0.0003121965,0.0008018499,0.0003961669,0.0003056293,0.0005918403],"domain_scores_gemma":[0.99830097,0.0004127554,0.00066667714,0.00034928278,0.00022013966,0.000050157618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060974987,0.00027973598,0.0011355188,0.0008239052,0.00003730598,0.000007148422,0.00018219004,0.0012533369,0.000376963],"category_scores_gemma":[0.00027667655,0.00021994919,0.00024506354,0.0005216583,0.00014956662,0.00004897588,0.0000715792,0.00084976165,0.000031317108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017615157,0.00019063853,0.005398035,0.00014618393,0.0005945072,0.0027103154,0.00068330765,6.5665844e-8,0.05976496,0.0000057341977,0.8701937,0.058551013],"study_design_scores_gemma":[0.002500859,0.0036907273,0.013562041,0.0010536616,0.0000599554,0.00010233036,0.000054129876,8.163905e-7,0.0060164304,0.000054022825,0.97266436,0.00024064587],"about_ca_topic_score_codex":0.00018125137,"about_ca_topic_score_gemma":0.000050389022,"teacher_disagreement_score":0.10247066,"about_ca_system_score_codex":0.0003744816,"about_ca_system_score_gemma":0.0006108299,"threshold_uncertainty_score":0.96668816},"labels":[],"label_agreement":null},{"id":"W2341554232","doi":"10.1093/annonc/mdv233.303","title":"P-306 A phase II biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Quebec - Clinical Research Organization in Cancer; Cégep de Lévis; St Mary's Hospital Centre; Hôpital Notre-Dame; Moncton Hospital","funders":"","keywords":"Regorafenib; Medicine; Colorectal cancer; Bevacizumab; Oncology; Internal medicine; FOLFIRI; Phases of clinical research; Biopsy; FOLFOX; Progressive disease; Response Evaluation Criteria in Solid Tumors; Cancer; Irinotecan; Clinical trial; Oxaliplatin; Chemotherapy","score_opus":0.15355677159254288,"score_gpt":0.5075699747036002,"score_spread":0.35401320311105733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341554232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941719,0.00013655635,0.0000074433415,0.0024064148,0.0002514956,0.002403959,0.0003140181,0.000013863846,0.00029433123],"genre_scores_gemma":[0.9986741,0.0000148540175,0.00045303756,0.00037985848,0.000036440684,0.00029121974,0.000015837904,0.000019478744,0.000115200724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974359,0.0005089893,0.0009281735,0.00043380845,0.00038866315,0.00030443328],"domain_scores_gemma":[0.9977295,0.00037751297,0.00036224222,0.00023056893,0.00095705007,0.0003431591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012633896,0.00021024277,0.0012877351,0.00037885542,0.00003707774,0.000003066059,0.00012242033,0.0000688065,0.000071638715],"category_scores_gemma":[0.0009536524,0.00015366255,0.000106914405,0.00066786027,0.00018646115,0.00006575651,0.00018493042,0.00013926257,0.0000041673306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34671366,0.02218728,0.5958744,0.000031225918,0.0023378485,0.00021892539,0.011194178,0.00005728572,0.00043084988,0.0000013562604,0.0044976682,0.016455295],"study_design_scores_gemma":[0.025485232,0.23004866,0.73947513,0.00008430194,0.000272634,0.0000030545534,0.0026468898,0.000019448846,0.0005047712,0.0000069049847,0.0013433135,0.00010964113],"about_ca_topic_score_codex":0.0007105988,"about_ca_topic_score_gemma":0.0038684064,"teacher_disagreement_score":0.32122844,"about_ca_system_score_codex":0.0001804781,"about_ca_system_score_gemma":0.0008485724,"threshold_uncertainty_score":0.6266177},"labels":[],"label_agreement":null},{"id":"W2342992502","doi":"10.1093/annonc/mdu333.79","title":"Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer: a Multi-Institution Study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen's University; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Essar Steel Algoma (Canada); Group Health Centre; St. Michael's Hospital; Health Sciences Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Adjuvant chemotherapy; Colorectal cancer; Oncology; Cancer; Chemotherapy; Adjuvant; Internal medicine; Surgery","score_opus":0.10747352927970814,"score_gpt":0.4461781845925919,"score_spread":0.33870465531288374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342992502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924435,0.00008763613,0.0008453321,0.0030887628,0.000078824254,0.0029232579,0.00006023325,0.000011639203,0.0004607903],"genre_scores_gemma":[0.9960732,0.00004421245,0.0017828525,0.00082854915,0.0000505728,0.0010630062,0.0000226691,0.000011129026,0.0001238097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99918026,0.00006139333,0.00030991068,0.00018346908,0.000101230646,0.00016371561],"domain_scores_gemma":[0.9990756,0.00030487025,0.00015589756,0.0001165821,0.0002823742,0.000064665284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004602308,0.000087752735,0.0005062861,0.00012065667,0.000018619094,0.0000012882393,0.000058871152,0.000092104645,0.000040192717],"category_scores_gemma":[0.0003420629,0.0000776327,0.000081188555,0.0001574624,0.000035908368,0.000030999217,0.000015084246,0.000038885504,0.000003662819],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043151706,0.015495905,0.22505537,0.00034056985,0.0006229469,0.000016467828,0.0035588138,0.00041299663,0.01687523,0.00027566534,0.005949727,0.6882446],"study_design_scores_gemma":[0.0502419,0.09567571,0.6936814,0.00032477407,0.000269643,0.000009863126,0.00015661669,0.0045336876,0.035418138,0.00024493906,0.11917131,0.00027199576],"about_ca_topic_score_codex":0.0002623441,"about_ca_topic_score_gemma":0.0010301084,"teacher_disagreement_score":0.6879726,"about_ca_system_score_codex":0.00013684352,"about_ca_system_score_gemma":0.0001921846,"threshold_uncertainty_score":0.31657696},"labels":[],"label_agreement":null},{"id":"W2343851725","doi":"10.1093/annonc/mdv337.07","title":"Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): results of a phase III study (CheckMate 066)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Internal medicine; Dacarbazine; Oncology; Temozolomide; Visual analogue scale; Randomized controlled trial; Cancer; Chemotherapy; Surgery; Immunotherapy; Nursing","score_opus":0.07227636460268878,"score_gpt":0.4092405092119963,"score_spread":0.3369641446093075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343851725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921525,0.000052334475,0.00000411594,0.00017958203,0.000113489914,0.0018559115,0.00005779953,0.000016139951,0.0055681327],"genre_scores_gemma":[0.99942523,0.00003050027,0.000059460013,0.00007621851,0.00001707949,0.000049382,0.000028425275,0.000016569373,0.0002971463],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974255,0.000567687,0.0010791327,0.0003083748,0.00039874908,0.00022056662],"domain_scores_gemma":[0.9976348,0.0003340504,0.0009890738,0.00047872757,0.00041206746,0.00015125738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010506305,0.00020894433,0.0013966629,0.00031057137,0.000013516037,0.0000013326307,0.00010288983,0.000104692874,0.000018321385],"category_scores_gemma":[0.0006226531,0.00015322893,0.00011949886,0.00028312087,0.00012799089,0.00004401595,0.00004814336,0.00009669156,0.0000037355699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5596401,0.04899466,0.083395,0.0006584347,0.0015758943,0.00017961596,0.0066543072,0.00023007458,0.0035065005,0.000052942352,0.0009964379,0.29411605],"study_design_scores_gemma":[0.24790409,0.6474783,0.04605087,0.00022513034,0.00032835203,0.000008302715,0.0023452183,0.00006726948,0.053076454,0.00001581401,0.0022882943,0.00021191199],"about_ca_topic_score_codex":0.0014995225,"about_ca_topic_score_gemma":0.00079608115,"teacher_disagreement_score":0.5984836,"about_ca_system_score_codex":0.00013122485,"about_ca_system_score_gemma":0.00018797595,"threshold_uncertainty_score":0.62484944},"labels":[],"label_agreement":null},{"id":"W2345013950","doi":"10.1093/annonc/mdv532.30","title":"446P Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Pemetrexed; Gemcitabine; Afatinib; Lung cancer; Oncology; Gastroenterology; Chemotherapy; Stage (stratigraphy); Cisplatin; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.10346504082146057,"score_gpt":0.4721182781609065,"score_spread":0.36865323733944594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345013950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919328,0.0014816481,0.0002909488,0.0010665464,0.0002992497,0.00099339,0.00017646782,0.000021219392,0.0037377414],"genre_scores_gemma":[0.9966577,0.0002003059,0.0017691017,0.0005284624,0.000098913995,0.00009066541,0.00036934446,0.000027597564,0.00025787446],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99876285,0.0000794742,0.0004209084,0.00026892897,0.00022487347,0.00024298379],"domain_scores_gemma":[0.9982504,0.00037107515,0.00036355446,0.00019179608,0.0006602894,0.00016285351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021750933,0.00016638095,0.00054931565,0.00017322767,0.000048235135,0.000007857511,0.00007356036,0.00009753617,0.000053773143],"category_scores_gemma":[0.00024135991,0.00014897432,0.00013425323,0.0001990521,0.00015635519,0.00012876718,0.000023615232,0.00008249781,0.0000028487757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032188334,0.0119139645,0.27510628,0.0012500028,0.015063179,0.0003162141,0.04389422,0.0004348657,0.009666351,0.0026024505,0.12155813,0.48600602],"study_design_scores_gemma":[0.12039746,0.036566522,0.7640633,0.0005714733,0.0048059514,0.00004477359,0.0059022335,0.0016335245,0.040146388,0.0011141592,0.023922002,0.0008322023],"about_ca_topic_score_codex":0.00037676722,"about_ca_topic_score_gemma":0.00006949927,"teacher_disagreement_score":0.48895705,"about_ca_system_score_codex":0.00013706587,"about_ca_system_score_gemma":0.00036872944,"threshold_uncertainty_score":0.60749966},"labels":[],"label_agreement":null},{"id":"W2345440189","doi":"10.1093/annonc/mdu338.1","title":"Quality of Life in a Randomised Double-Blind Phase III Trial of Cediranib (Azd2171) in Relapsed Platinum Sensitive Ovarian Cancer (Icon6)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Ovarian cancer; Internal medicine; Oncology; Quality of life (healthcare); Double blind; Cancer; Clinical trial; Platinum; Alternative medicine; Pathology","score_opus":0.17128800009953832,"score_gpt":0.45360664158874164,"score_spread":0.2823186414892033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345440189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858524,0.00022813519,0.000027941287,0.005446293,0.00031283256,0.0019701133,0.000057974277,0.000006849902,0.00609744],"genre_scores_gemma":[0.9983874,0.00030283604,0.00012386714,0.0006868996,0.0002026983,0.00020827832,0.000026945714,0.000015706964,0.000045389308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99703074,0.00052054017,0.0015733677,0.0003265803,0.00026815644,0.00028063866],"domain_scores_gemma":[0.99715096,0.0011659114,0.00092768867,0.0003216679,0.00029648034,0.00013728287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021843526,0.00018645498,0.0019560626,0.00029941063,0.000013932566,0.0000020218808,0.000080215475,0.00027687373,0.00018211483],"category_scores_gemma":[0.00057012995,0.00016089491,0.00023486312,0.00032569742,0.0001794112,0.00004225067,0.000030738258,0.00021287017,0.0000015132453],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9578522,0.00665931,0.006955539,0.00017765282,0.00050280057,0.000037470738,0.0021556267,0.0000872956,0.002752406,0.0012456534,0.0004990301,0.021075044],"study_design_scores_gemma":[0.9573412,0.007391361,0.017432367,0.00025040933,0.00013272994,0.0000020692923,0.00022025462,0.00013683333,0.016077952,0.0001770712,0.00071387267,0.0001238886],"about_ca_topic_score_codex":0.006857255,"about_ca_topic_score_gemma":0.0030986753,"teacher_disagreement_score":0.020951156,"about_ca_system_score_codex":0.000100703306,"about_ca_system_score_gemma":0.00087164575,"threshold_uncertainty_score":0.99975616},"labels":[],"label_agreement":null},{"id":"W2345584475","doi":"10.1093/annonc/mdu339.4","title":"Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hypomethylating agent; Refractory (planetary science); Myeloid leukemia; Oncology; Internal medicine","score_opus":0.08143848979823845,"score_gpt":0.3963737014011789,"score_spread":0.31493521160294047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345584475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993982,0.0025602754,0.00013920412,0.00091162446,0.000052918065,0.0007637361,0.00006440344,0.000007478668,0.0015183623],"genre_scores_gemma":[0.9933933,0.0040948433,0.002201843,0.000079737874,0.000047804144,0.00001621043,0.000027259375,0.000026482749,0.00011253834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967421,0.0006461827,0.0013886188,0.00035787284,0.00047322887,0.00039197548],"domain_scores_gemma":[0.99362427,0.004228801,0.0010504818,0.0005516007,0.00041207246,0.00013275158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123136,0.0002668967,0.001756179,0.00041855057,0.000042783613,0.0000030499984,0.0002478373,0.0003225341,0.000038863647],"category_scores_gemma":[0.0011121314,0.0001880291,0.00015914896,0.00039474436,0.0009839548,0.000056177738,0.0001228094,0.00032548152,0.0000012933057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009680469,0.005919204,0.0348261,0.00089152163,0.0013499262,0.00008038106,0.017940013,0.00025952375,0.56718373,0.0010085097,0.0005916325,0.36026898],"study_design_scores_gemma":[0.03401303,0.10638815,0.3604443,0.0010347782,0.0010886734,0.00028720184,0.0046713,0.0049376814,0.4551128,0.00029635694,0.031179953,0.00054578943],"about_ca_topic_score_codex":0.00047786155,"about_ca_topic_score_gemma":0.000110008645,"teacher_disagreement_score":0.35972318,"about_ca_system_score_codex":0.000233446,"about_ca_system_score_gemma":0.0005805575,"threshold_uncertainty_score":0.7667604},"labels":[],"label_agreement":null},{"id":"W2345845042","doi":"10.1093/annonc/mdu356.52","title":"The Evaluation of Paclitaxel Hypersensitivity Reactions (Hsrs) Following the Discontinuation of Prophylactic Pre-Medications","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Discontinuation; Paclitaxel; Hypersensitivity reaction; Delayed hypersensitivity; Chemotherapy; Anesthesia; Oncology; Surgery; Internal medicine; Immunology","score_opus":0.11904380367118754,"score_gpt":0.4400192107061777,"score_spread":0.32097540703499017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345845042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9309193,0.000108702334,0.0004355328,0.017017528,0.0003855287,0.0008698319,0.00000889723,0.00001583359,0.050238863],"genre_scores_gemma":[0.99928397,0.00006249955,0.00013922172,0.00009142253,0.00009928603,0.000070077185,0.000016093938,0.000010393485,0.00022701742],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796516,0.0006544076,0.0005233937,0.00015062791,0.00054653507,0.00015987609],"domain_scores_gemma":[0.9958746,0.0017103977,0.0006751482,0.0005224186,0.0011649734,0.000052503805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004026488,0.00008920082,0.0003132185,0.00010102042,0.000165931,0.0000035582639,0.00009402218,0.00010176708,0.0000042702663],"category_scores_gemma":[0.005818444,0.000055100736,0.00016536738,0.00037114957,0.000317771,0.00012306978,0.000028580336,0.00020447577,0.0000054022416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006958586,0.00096882915,0.0011023897,0.000059889204,0.00051986147,7.902714e-7,0.0019172108,0.00020963585,0.11833531,0.0071207033,0.00023204315,0.86946374],"study_design_scores_gemma":[0.0041037053,0.002002129,0.8171378,0.000353185,0.00393929,0.00009592705,0.011635786,0.013434504,0.05555434,0.006311326,0.08516168,0.0002703339],"about_ca_topic_score_codex":0.00026411645,"about_ca_topic_score_gemma":0.00018979459,"teacher_disagreement_score":0.86919343,"about_ca_system_score_codex":0.000067016605,"about_ca_system_score_gemma":0.00066298596,"threshold_uncertainty_score":0.6965641},"labels":[],"label_agreement":null},{"id":"W2345967756","doi":"10.1023/a:1011617707999","title":"Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Adenocarcinoma; Medicine; Stage (stratigraphy); Immunohistochemistry; Lung; Proportional hazards model; Pathology; Lung cancer; Hazard ratio; Oncology; Clinical significance; Internal medicine; Cancer; Gastroenterology; Biology","score_opus":0.029217393690597993,"score_gpt":0.3015897732261667,"score_spread":0.2723723795355687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345967756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950724,0.0005522668,0.00003846866,0.0007220683,0.000043514916,0.0015619899,0.000027998716,0.000024681513,0.001956585],"genre_scores_gemma":[0.99865043,0.00005164297,0.0007841642,0.00021422058,0.000027608578,0.00008944027,0.000034267938,0.000032003012,0.00011622559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998481,0.00011268437,0.00045928694,0.00028196283,0.00035401195,0.00031106896],"domain_scores_gemma":[0.9989437,0.000030828374,0.00033056337,0.00024910082,0.0003231159,0.00012272318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002172944,0.00015258657,0.0005083656,0.00023913183,0.000019116109,0.000002083661,0.00011517251,0.00023444675,0.00010550504],"category_scores_gemma":[0.00013593398,0.00012688128,0.00007199161,0.0003298688,0.00012730173,0.00008242877,0.00006581124,0.00024710604,0.000004313576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005816752,0.002525969,0.9107436,0.0003617185,0.00010276263,0.00027848975,0.000634484,0.00003648156,0.069943756,0.00003149067,0.0013655323,0.0081589995],"study_design_scores_gemma":[0.008368682,0.013752188,0.68086165,0.0010223385,0.00006584309,0.000013545988,0.000104279075,0.000084222695,0.29174128,0.0000144412425,0.003822083,0.00014946557],"about_ca_topic_score_codex":0.00008648065,"about_ca_topic_score_gemma":0.000033849952,"teacher_disagreement_score":0.22988193,"about_ca_system_score_codex":0.00007193598,"about_ca_system_score_gemma":0.0002795683,"threshold_uncertainty_score":0.5174069},"labels":[],"label_agreement":null},{"id":"W2346388928","doi":"10.1093/annonc/mdu338.62","title":"A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Progressive disease; Phases of clinical research; Clinical trial; Chemotherapy; Immunology","score_opus":0.06180391013388024,"score_gpt":0.3804247568531686,"score_spread":0.31862084671928836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346388928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972659,0.00026306268,9.957851e-7,0.00071641715,0.00005761776,0.0014684304,0.000008813149,0.000005176054,0.00021363772],"genre_scores_gemma":[0.99960726,0.000056958368,0.000015901553,0.00019274118,0.0000070885067,0.00008428077,0.0000012807749,0.00001079102,0.000023707984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981002,0.0005342433,0.0006897436,0.00023272591,0.0002371162,0.00020593843],"domain_scores_gemma":[0.9987735,0.0002614279,0.00043074784,0.00032691637,0.00014537666,0.00006203583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008549383,0.00013837701,0.0007943277,0.00013102805,0.000025452322,0.0000021921535,0.00014293728,0.000058920214,0.00010064081],"category_scores_gemma":[0.000094694944,0.00007609224,0.000036313446,0.00040667588,0.00028505796,0.000027626564,0.00006995154,0.00018032562,1.7509795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2343898,0.105231404,0.33493468,0.00081211666,0.00333034,0.00014497143,0.09224857,0.000011099001,0.00465581,0.000037320213,0.00024652694,0.22395736],"study_design_scores_gemma":[0.067703076,0.14294724,0.76925737,0.00011090996,0.0002502505,0.000044306784,0.018337043,0.000066905035,0.000728924,0.00002798486,0.00042541313,0.000100564015],"about_ca_topic_score_codex":0.00055915705,"about_ca_topic_score_gemma":0.0015769381,"teacher_disagreement_score":0.43432269,"about_ca_system_score_codex":0.000039978142,"about_ca_system_score_gemma":0.00025390578,"threshold_uncertainty_score":0.31029516},"labels":[],"label_agreement":null},{"id":"W2358862840","doi":"10.1093/annonc/mdu349.74","title":"Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Ceritinib; Anaplastic lymphoma kinase; Medicine; Crizotinib; Lung cancer; ALK inhibitor; Alectinib; Anaplastic large-cell lymphoma; Cancer research; Lymphoma; Oncology; Internal medicine","score_opus":0.014815493515201703,"score_gpt":0.34389950172465844,"score_spread":0.3290840082094567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2358862840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402696,0.00043428154,0.000056845878,0.00035044222,0.00007730278,0.00068092626,0.000113124646,0.000008758017,0.0042513707],"genre_scores_gemma":[0.9980893,0.00051805144,0.00088702474,0.00027895384,0.000027620626,0.00004423221,0.0000967561,0.000023303004,0.000034744466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987859,0.00008824128,0.00045328707,0.00027172195,0.00015112394,0.0002496855],"domain_scores_gemma":[0.9988147,0.00014114857,0.00034849317,0.00024520807,0.00031051337,0.0001399416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014465247,0.00016618942,0.0006388399,0.00015934103,0.000030266767,0.0000021481635,0.00007810072,0.00010196637,0.000043153643],"category_scores_gemma":[0.00004830502,0.00013473998,0.000045771154,0.00018776773,0.000156803,0.000085686894,0.000027537108,0.00006999911,7.9533453e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021354314,0.0074979584,0.3912747,0.0011980446,0.0005325365,0.00003773792,0.0035143518,0.0006431457,0.006015308,0.0001669713,0.00035487735,0.56741005],"study_design_scores_gemma":[0.043849453,0.015724478,0.9238765,0.00066178676,0.0004221434,0.0000039775596,0.00021685782,0.00027844918,0.010374294,0.000014395496,0.0043908567,0.0001867887],"about_ca_topic_score_codex":0.0005401487,"about_ca_topic_score_gemma":0.00068968395,"teacher_disagreement_score":0.56722325,"about_ca_system_score_codex":0.000071688664,"about_ca_system_score_gemma":0.0003526366,"threshold_uncertainty_score":0.54945374},"labels":[],"label_agreement":null},{"id":"W2397992828","doi":"10.1093/annonc/mdv336.12","title":"First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO)adjuvant trastuzumab","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Lapatinib; Trastuzumab; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Adjuvant therapy; Adjuvant; Cohort; Cancer","score_opus":0.1588409169490382,"score_gpt":0.45825894837672276,"score_spread":0.29941803142768453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397992828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810307,0.0009964238,0.000042823438,0.0145588685,0.00026542987,0.0016525197,0.0005640121,0.000031944244,0.0008572774],"genre_scores_gemma":[0.9931871,0.0008847791,0.0004991584,0.004175875,0.00016711227,0.0006998161,0.00006627837,0.00006771135,0.00025213716],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966857,0.00043384644,0.0008381557,0.0005166269,0.0007764344,0.0007492549],"domain_scores_gemma":[0.9973054,0.00042372715,0.0002705228,0.00038076905,0.0011727811,0.00044683472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089904055,0.00032942928,0.0011022903,0.0003651423,0.000042409043,0.000012944476,0.00024771155,0.00020658699,0.0013345366],"category_scores_gemma":[0.00033384137,0.00024408649,0.00015978616,0.0005932039,0.0003316787,0.00011260972,0.000061104,0.00048649465,0.00004801163],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053246588,0.014914503,0.20700468,0.0005929824,0.0006143455,0.0012298912,0.00849509,0.00052322814,0.00024236075,0.000009980585,0.013863996,0.6992624],"study_design_scores_gemma":[0.032955017,0.059018534,0.8561931,0.0012606157,0.00014533324,0.00007302514,0.000685953,0.0014144675,0.0062716273,0.000121611156,0.04125327,0.0006074103],"about_ca_topic_score_codex":0.0023920874,"about_ca_topic_score_gemma":0.005356982,"teacher_disagreement_score":0.69865495,"about_ca_system_score_codex":0.000674,"about_ca_system_score_gemma":0.0033637877,"threshold_uncertainty_score":0.99957836},"labels":[],"label_agreement":null},{"id":"W2398639944","doi":"10.1093/annonc/mdu333.103","title":"Patient-Provider Communication in Colorectal Cancer: an International Study of Oncologists’ Challenges","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Colorectal cancer; Family medicine; Cancer; General surgery; Oncology; Medical physics; Intensive care medicine; Internal medicine","score_opus":0.44248125259220883,"score_gpt":0.5347565494214754,"score_spread":0.0922752968292666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398639944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97065645,0.0016236781,0.0000020958848,0.011513761,0.0006304248,0.0014074879,0.000024712672,0.000039966966,0.014101441],"genre_scores_gemma":[0.9943991,0.0031545667,0.00048973167,0.00091113686,0.000061329134,0.00090776884,0.00004169125,0.000020686808,0.000014015722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99265116,0.0049599605,0.001421371,0.00030767292,0.00030661357,0.0003532116],"domain_scores_gemma":[0.99441403,0.0020504387,0.0013942264,0.0009149103,0.0011196295,0.00010678054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010293699,0.0001536199,0.0005879646,0.00029285345,0.00018741806,0.0000021602184,0.0009247096,0.00032385706,0.00013792863],"category_scores_gemma":[0.0010801787,0.00015235867,0.00004916526,0.00021089078,0.00019572633,0.00026805693,0.00049935526,0.0006565488,0.000011606461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001069296,0.0050826333,0.5754619,0.00027471862,0.00009611884,0.0000017772575,0.1491447,0.0002611836,0.00035167925,0.0057094363,0.0007846202,0.2617619],"study_design_scores_gemma":[0.004727427,0.01425288,0.7822935,0.00036706397,0.000021181073,0.0000013268668,0.15887627,0.0012487952,0.00039271236,0.002325914,0.03522476,0.00026819],"about_ca_topic_score_codex":0.007823276,"about_ca_topic_score_gemma":0.03468778,"teacher_disagreement_score":0.2614937,"about_ca_system_score_codex":0.00024513385,"about_ca_system_score_gemma":0.00052845746,"threshold_uncertainty_score":0.9987837},"labels":[],"label_agreement":null},{"id":"W2402915536","doi":"10.1093/annonc/mdv527.02","title":"315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tolerability; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Adverse effect; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Cancer; Immunotherapy","score_opus":0.06563245932026754,"score_gpt":0.3743396067828195,"score_spread":0.308707147462552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402915536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670833,0.00025368904,0.000003942429,0.0006313191,0.00009503667,0.000741124,0.00038833526,0.00000699065,0.001171211],"genre_scores_gemma":[0.9995369,0.000040948824,0.000056943994,0.00022378647,0.000031359265,0.000010251682,0.00006809938,0.000011073115,0.000020665864],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987113,0.00019847522,0.0004262481,0.00028024305,0.00020242341,0.00018130537],"domain_scores_gemma":[0.9989431,0.00014231575,0.00031079593,0.00022536192,0.00027927232,0.00009918745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004044239,0.00014342036,0.0006419319,0.0001366196,0.000018579287,0.0000031011737,0.00007714345,0.000085741674,0.000012451885],"category_scores_gemma":[0.00008796984,0.000112332316,0.000048355258,0.0001615333,0.0002281965,0.00010647592,0.000061596555,0.00014739197,6.428922e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6918357,0.016147697,0.22501792,0.000034682114,0.00047536404,0.00017657854,0.0070118355,6.134753e-7,0.0036771914,0.000002603871,0.00065940217,0.05496039],"study_design_scores_gemma":[0.108933404,0.045119528,0.8374209,0.000090604,0.00006739952,0.0000070151964,0.00067209103,0.000012135561,0.0072865873,0.00000804348,0.0002909959,0.00009132486],"about_ca_topic_score_codex":0.0035510615,"about_ca_topic_score_gemma":0.00056167954,"teacher_disagreement_score":0.612403,"about_ca_system_score_codex":0.00008712728,"about_ca_system_score_gemma":0.00033405208,"threshold_uncertainty_score":0.5368166},"labels":[],"label_agreement":null},{"id":"W2411965298","doi":"10.1093/annonc/mdh933","title":"Cancer prevention: a worldwide overview","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Cancer prevention; Intensive care medicine; Cancer; Internal medicine","score_opus":0.07014591539764496,"score_gpt":0.4037789072627197,"score_spread":0.3336329918650747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411965298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492319,0.03780453,0.00030755182,0.0055682827,0.00028944315,0.00021496811,0.00005283999,0.0000107961205,0.0065196655],"genre_scores_gemma":[0.97687334,0.017877907,0.00068949576,0.0031885284,0.0003962527,0.00005179962,0.00006957166,0.000013156959,0.0008399383],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993061,0.000046601785,0.00019988716,0.00019873909,0.00007354888,0.00017513531],"domain_scores_gemma":[0.99943316,0.000005740329,0.000098745426,0.00021027625,0.0001597612,0.00009231411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010575221,0.00008836157,0.00015564477,0.000034001052,0.00003221757,0.0000038258454,0.00012030658,0.000111322406,0.0001182216],"category_scores_gemma":[0.00003943178,0.00009117068,0.00012884557,0.0000686239,0.00009005975,0.000002467363,0.00005134569,0.00003657413,0.000009556002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022694892,0.0063955314,0.016740834,0.00076901884,0.00094410096,0.000076151795,0.00041799585,0.0016478756,0.47562176,0.01059466,0.17332618,0.3111964],"study_design_scores_gemma":[0.0022524572,0.0020641354,0.009926237,0.00007290255,0.000047473364,0.000012482081,0.00004999725,0.000001009181,0.22363953,0.013321561,0.74840176,0.0002104282],"about_ca_topic_score_codex":0.00004685284,"about_ca_topic_score_gemma":0.00025666936,"teacher_disagreement_score":0.5750756,"about_ca_system_score_codex":0.000010167015,"about_ca_system_score_gemma":0.00034421173,"threshold_uncertainty_score":0.37178326},"labels":[],"label_agreement":null},{"id":"W2416433681","doi":"10.1093/annonc/mdv341.37","title":"De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clear cell; Papillary renal cell carcinomas; Pathology; Transplantation; Renal cell carcinoma; Clear cell renal cell carcinoma; Kidney; Kidney cancer; Carcinoma; Internal medicine","score_opus":0.08637666193163186,"score_gpt":0.36384777815583164,"score_spread":0.2774711162241998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416433681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9292847,0.00017032346,0.0010077811,0.06482505,0.00041233367,0.00026563165,0.000068433255,0.000010509644,0.0039552376],"genre_scores_gemma":[0.98454875,0.00071270735,0.0018284975,0.012411243,0.0001719996,0.000115275434,0.00003957081,0.000007039483,0.0001649196],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915737,0.0000571297,0.00028537202,0.00017597947,0.0001635193,0.00016062446],"domain_scores_gemma":[0.99915147,0.00012566306,0.00013757589,0.00014683332,0.00029091703,0.00014754849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037520524,0.000086524626,0.00023811175,0.000046122204,0.000018948522,0.0000038183057,0.00010941679,0.00012951856,0.000100773956],"category_scores_gemma":[0.000059336966,0.00005908876,0.00012499256,0.00008592428,0.0000839379,0.000038439637,0.00002772517,0.00010325436,0.00001425153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030067482,0.0013609515,0.20584255,0.00005977916,0.0002234741,0.00011087488,0.004081054,0.00018055839,0.01034101,0.00018968976,0.7579642,0.016639143],"study_design_scores_gemma":[0.0056370255,0.005903021,0.29494312,0.00007668554,0.00031951515,0.0002630907,0.0014374566,0.0003674705,0.025410524,0.00046935023,0.66500723,0.0001654882],"about_ca_topic_score_codex":0.000077736644,"about_ca_topic_score_gemma":0.00014450017,"teacher_disagreement_score":0.09295692,"about_ca_system_score_codex":0.000087580855,"about_ca_system_score_gemma":0.00042158496,"threshold_uncertainty_score":0.24095698},"labels":[],"label_agreement":null},{"id":"W2418487199","doi":"10.1093/annonc/mdv586.02","title":"LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Clinical endpoint; Lung cancer; Oncology; Randomized controlled trial; Adverse effect; Progression-free survival; Gastroenterology; Cancer; Epidermal growth factor receptor; Overall survival","score_opus":0.09753371172681696,"score_gpt":0.4686301177362061,"score_spread":0.37109640600938915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418487199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711879,0.00092348724,0.00031066325,0.004003521,0.0006368014,0.011437343,0.00086767774,0.000026779879,0.010605865],"genre_scores_gemma":[0.98897356,0.0005638134,0.005177861,0.0005094776,0.00021730679,0.0035362777,0.00032856103,0.000043776578,0.0006493605],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975372,0.00018633342,0.0010510131,0.0004803814,0.00032653275,0.0004185723],"domain_scores_gemma":[0.9958293,0.0009296235,0.0013770194,0.0004421562,0.0012054648,0.00021645532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054629357,0.00033544053,0.0012688919,0.000086813394,0.00020257152,0.000023939323,0.000255158,0.00014778566,0.000020172227],"category_scores_gemma":[0.0009951113,0.00021120324,0.0001916713,0.0003418159,0.00017564752,0.00022513841,0.000093996256,0.000115741495,0.0000013499788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9139771,0.012286393,0.0021377977,0.00024968624,0.0017922125,0.000014901526,0.0037420928,0.0012638747,0.00014075833,0.00016212753,0.0017552138,0.062477842],"study_design_scores_gemma":[0.95161724,0.028316597,0.00017740928,0.0006565516,0.0016805968,0.000004060647,0.00047751796,0.0012202454,0.0062812143,0.0001066037,0.009248257,0.00021369845],"about_ca_topic_score_codex":0.0014847592,"about_ca_topic_score_gemma":0.00038953315,"teacher_disagreement_score":0.062264144,"about_ca_system_score_codex":0.00066642504,"about_ca_system_score_gemma":0.0023851232,"threshold_uncertainty_score":0.8612618},"labels":[],"label_agreement":null},{"id":"W2428369555","doi":"10.1093/annonc/mdu330.5","title":"Temozolomide for 1P19Q Co-Deleted and Partially Deleted Gliomas","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Trillium Health Centre; St. Michael's Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Medicine; Glioma; Oncology; Cancer research","score_opus":0.079460316209176,"score_gpt":0.39611768324072566,"score_spread":0.3166573670315497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2428369555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98222464,0.00055475545,0.00015808595,0.013135454,0.000078352336,0.0005220625,0.000020999869,0.000032473552,0.0032731919],"genre_scores_gemma":[0.9959404,0.00017972897,0.0009314301,0.002609976,0.000116339004,0.00010919115,0.000047444446,0.000017076036,0.000048406815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990062,0.00006751958,0.00031810402,0.00022815201,0.00010044428,0.00027955117],"domain_scores_gemma":[0.9987917,0.00047620296,0.00014974571,0.00020018734,0.00022338636,0.00015880112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033334087,0.00012936504,0.0005198042,0.00012285967,0.000049266167,0.0000053575686,0.000051875366,0.00015374002,0.000045394412],"category_scores_gemma":[0.0003421294,0.00010424322,0.000109046654,0.00009236494,0.00012131093,0.000030491059,0.000021888054,0.000056154022,0.000012983649],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029736378,0.0036386822,0.07884279,0.0003360593,0.0013315778,0.00019599995,0.00044288655,0.000020242443,0.11166487,0.009116416,0.13951139,0.65192544],"study_design_scores_gemma":[0.012492269,0.019359726,0.08303354,0.00007928747,0.00036907085,0.00013385068,0.00006661574,0.0011252263,0.23541439,0.0019754088,0.64570946,0.00024113149],"about_ca_topic_score_codex":0.000037200694,"about_ca_topic_score_gemma":0.000062315274,"teacher_disagreement_score":0.6516843,"about_ca_system_score_codex":0.000016377497,"about_ca_system_score_gemma":0.00007876034,"threshold_uncertainty_score":0.42509153},"labels":[],"label_agreement":null},{"id":"W2462016111","doi":"10.1093/annonc/mdv522.01","title":"134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Everolimus; Internal medicine; Gastroenterology; Population; Placebo; Neuroendocrine tumors; Phases of clinical research; Surgery; Randomized controlled trial; Urology; Clinical trial; Pathology","score_opus":0.07191084224250151,"score_gpt":0.39176217221050275,"score_spread":0.31985132996800125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462016111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911685,0.00046962293,0.000008675633,0.0056350906,0.00009775433,0.0006173665,0.000025996655,0.000010830063,0.0019661768],"genre_scores_gemma":[0.9982636,0.00022736727,0.0007329377,0.00035234512,0.00006401511,0.000014871197,0.0000048518464,0.000019924857,0.00032008014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793565,0.00023567196,0.0006883357,0.00027738596,0.0004335691,0.00042935924],"domain_scores_gemma":[0.9978936,0.0008431755,0.00036388848,0.0003100272,0.00035364396,0.00023570986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027679856,0.00016984841,0.00067770225,0.00022198448,0.000022701675,0.000001947577,0.00020592009,0.000007977765,0.00008471908],"category_scores_gemma":[0.0027544312,0.00011661217,0.00009206055,0.00038784143,0.00051717117,0.00012036255,0.00014425094,0.0003834244,0.0000019344454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078998,0.005891332,0.8018252,0.0010868179,0.00014200446,0.012958904,0.00033491067,0.0032366137,0.036490213,0.0007342753,0.0119396895,0.046361987],"study_design_scores_gemma":[0.017857784,0.021089593,0.8993239,0.00064325205,0.000059366692,0.026122905,0.00034251664,0.00056186813,0.016018849,0.00029248706,0.01751137,0.0001761538],"about_ca_topic_score_codex":0.00009918556,"about_ca_topic_score_gemma":0.000099021076,"teacher_disagreement_score":0.0974986,"about_ca_system_score_codex":0.00004551665,"about_ca_system_score_gemma":0.00075788406,"threshold_uncertainty_score":0.47553062},"labels":[],"label_agreement":null},{"id":"W2463699773","doi":"10.1093/annonc/mdw199.262","title":"P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Capecitabine; Oncology; Hazard ratio; Progressive disease; Pancreatic cancer; Gastroenterology; Cancer; Surgery; Chemotherapy","score_opus":0.04985052564566315,"score_gpt":0.39039942951429757,"score_spread":0.3405489038686344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463699773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130994,0.00050281006,0.0008698486,0.0037762888,0.00055220583,0.0014847488,0.00090037467,0.00000317899,0.0006006203],"genre_scores_gemma":[0.9939019,0.0025014563,0.000890484,0.001512112,0.0002469635,0.0003725834,0.00012510021,0.000028548175,0.00042085213],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881196,0.000049824026,0.00042479436,0.0003101515,0.00014232905,0.00026095222],"domain_scores_gemma":[0.9981725,0.00026209673,0.00045140457,0.00036334412,0.00067860895,0.000072002666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025831306,0.00016622219,0.00036840292,0.000037974707,0.000046269488,0.000013883926,0.00054292864,0.00014993091,0.000042797383],"category_scores_gemma":[0.0005593007,0.000099315665,0.000078388504,0.000051640374,0.00019908785,0.000014023903,0.00021736775,0.000058033736,0.0000016082371],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42647815,0.0074541876,0.0039911405,0.000104568615,0.0015837455,0.000004717295,0.00021687562,0.0001606883,0.1624205,0.00065622095,0.04382284,0.35310638],"study_design_scores_gemma":[0.33344084,0.04930784,0.0013629703,0.00017937011,0.00018866037,0.0000017436737,0.000094256284,0.000113510345,0.077782325,0.000301369,0.53682595,0.0004011642],"about_ca_topic_score_codex":0.00010337688,"about_ca_topic_score_gemma":0.00032913915,"teacher_disagreement_score":0.4930031,"about_ca_system_score_codex":0.00004901197,"about_ca_system_score_gemma":0.00040975076,"threshold_uncertainty_score":0.40499753},"labels":[],"label_agreement":null},{"id":"W2468909592","doi":"10.1093/annonc/mdw199.279","title":"P-289 Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Oxaliplatin; Neutropenia; Regimen; Colorectal cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Internal medicine; Chemotherapy regimen; Surgery; Gastroenterology; Cancer; Oncology; Progressive disease","score_opus":0.10217309633717923,"score_gpt":0.36375324527456154,"score_spread":0.2615801489373823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468909592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959658,0.00041321115,0.000046517067,0.0011812969,0.0001550241,0.0018715358,0.00015363033,0.000014893362,0.00019808525],"genre_scores_gemma":[0.998082,0.00071594224,0.00046833453,0.00015787539,0.00010428008,0.0003166346,0.000013763192,0.000019457522,0.00012173675],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988695,0.00013037049,0.00035975367,0.00023742023,0.0001627182,0.00024027347],"domain_scores_gemma":[0.99885786,0.00024376101,0.00024477008,0.00015703584,0.00042056447,0.0000760195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032242644,0.00014590101,0.0006754543,0.00011452429,0.00003448739,0.0000026566931,0.00007084418,0.000097838376,0.0005112918],"category_scores_gemma":[0.00015053016,0.00009294976,0.00018832799,0.000114370596,0.00011302065,0.000065041415,0.000032402666,0.000043491702,0.0000044111753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090959035,0.0031586192,0.82776713,0.00007681612,0.0007578568,0.000037014084,0.0012324264,7.510525e-8,0.11433101,0.000021747584,0.0012322273,0.042289175],"study_design_scores_gemma":[0.023793528,0.042773105,0.40114403,0.00016638318,0.0005946913,0.000008223698,0.0002599641,0.00022680123,0.5251998,0.00009119743,0.0055690836,0.00017324164],"about_ca_topic_score_codex":0.00056204636,"about_ca_topic_score_gemma":0.00034382287,"teacher_disagreement_score":0.4266231,"about_ca_system_score_codex":0.000078240286,"about_ca_system_score_gemma":0.00017153364,"threshold_uncertainty_score":0.55982864},"labels":[],"label_agreement":null},{"id":"W2470583568","doi":"10.1093/annonc/mdw265","title":"Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Flatiron Health; Helsinn; Genentech; Celgene; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Phases of clinical research; Internal medicine; Oncology; Cancer; Nursing; Immunotherapy; Chemotherapy","score_opus":0.058747586539183036,"score_gpt":0.4089947964497547,"score_spread":0.3502472099105717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470583568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432933,0.0005246093,7.0549163e-7,0.0029782508,0.000084129795,0.0015190858,0.0002988017,0.000009084216,0.0002559766],"genre_scores_gemma":[0.99932534,0.0002508009,0.000010204833,0.00025543928,0.000012803541,0.000033708675,0.000046141653,0.000011624826,0.00005391194],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974143,0.0008281514,0.0010864929,0.00024842366,0.00022173522,0.00020093135],"domain_scores_gemma":[0.99699426,0.0013466519,0.0010377511,0.00043067234,0.00012887854,0.00006178869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012136756,0.00015936446,0.0010742444,0.0000777714,0.000025260104,8.165003e-7,0.0001014508,0.0000927318,0.000036397687],"category_scores_gemma":[0.00030422155,0.00007368573,0.00011066188,0.00018407215,0.00018942473,0.000036430734,0.000016842318,0.000072661234,0.0000017242653],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47918713,0.0075912285,0.11705659,0.000037841426,0.0009142449,0.0000056219465,0.0024905554,0.0000018173582,0.0022094685,0.0000033877093,0.00029281265,0.39020932],"study_design_scores_gemma":[0.22163238,0.18836893,0.5785328,0.00029069505,0.00005847872,3.3348525e-7,0.00027093675,0.000001158562,0.010352359,0.000008325129,0.00040813923,0.00007546952],"about_ca_topic_score_codex":0.0078876205,"about_ca_topic_score_gemma":0.001319498,"teacher_disagreement_score":0.4614762,"about_ca_system_score_codex":0.00012291384,"about_ca_system_score_gemma":0.00026138284,"threshold_uncertainty_score":0.9987189},"labels":[],"label_agreement":null},{"id":"W2473581189","doi":"10.1093/annonc/mdv532.60","title":"476TiP Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; T790M; Epidermal growth factor receptor; Tyrosine kinase; Tyrosine-kinase inhibitor; Lung cancer; Internal medicine; Oncology; Cancer research; Phases of clinical research; Cancer; Receptor; Chemotherapy; Gefitinib","score_opus":0.039078873484982665,"score_gpt":0.3792393443305347,"score_spread":0.340160470845552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473581189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953721,0.00044953992,0.000010144311,0.0006895092,0.00012382252,0.0022451254,0.00040156933,0.000015991,0.0006922056],"genre_scores_gemma":[0.99793077,0.00008877667,0.0005450881,0.00036974877,0.00011205437,0.00057301717,0.0001653993,0.000043931585,0.00017121373],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.998269,0.0001422339,0.0004858627,0.0004425416,0.00028803467,0.000372325],"domain_scores_gemma":[0.9981238,0.000057365858,0.00035243036,0.00029109238,0.0008428802,0.00033240253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009647575,0.00032357415,0.00079526094,0.00024699696,0.00005087487,0.000006210916,0.000074572396,0.00011938944,0.000060906495],"category_scores_gemma":[0.000014615652,0.00021285229,0.00006149699,0.0003047458,0.00011820736,0.00019294476,0.000039251812,0.000121577854,0.0000024617211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024801956,0.07611723,0.8406388,0.00010993332,0.0009748752,0.0002718947,0.032828454,0.000032239812,0.0008303823,0.000003202206,0.0007940095,0.022596998],"study_design_scores_gemma":[0.12920181,0.48722082,0.32942593,0.00055449636,0.0011847803,0.0000073814995,0.0039708167,0.000037081845,0.04706959,0.0000055928963,0.0008549437,0.00046674153],"about_ca_topic_score_codex":0.004604133,"about_ca_topic_score_gemma":0.0024305033,"teacher_disagreement_score":0.5112129,"about_ca_system_score_codex":0.0005185036,"about_ca_system_score_gemma":0.001019946,"threshold_uncertainty_score":0.86798644},"labels":[],"label_agreement":null},{"id":"W2474070100","doi":"10.1093/annonc/mdw242","title":"The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Targeted therapy; Medicine; CDKN2A; Vulvar intraepithelial neoplasia; PTEN; Cancer; Cancer research; Vulvar cancer; Oncology; Disease; Internal medicine; Vulva; Pathology; PI3K/AKT/mTOR pathway; Biology; Signal transduction","score_opus":0.13018787060917034,"score_gpt":0.4102552689897721,"score_spread":0.2800673983806018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474070100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00073701073,0.98143536,0.0000042406414,0.001752208,0.00026815865,0.0018450803,0.0001314533,0.000020970423,0.013805531],"genre_scores_gemma":[0.0036966952,0.99131185,0.00009409386,0.0015694988,0.00049661973,0.0008510065,0.000037100202,0.000055687582,0.0018874692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978366,0.0002617638,0.0006330698,0.00049107533,0.00025626543,0.0005212217],"domain_scores_gemma":[0.9977641,0.0008468618,0.00041604348,0.00046166815,0.00020037459,0.00031095903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003798302,0.00040662455,0.002220906,0.00020564109,0.00010649163,0.000010771513,0.00029176677,0.0004035372,0.00007380282],"category_scores_gemma":[0.00011803573,0.00019152917,0.00042366367,0.00044406895,0.00016087054,0.000026406871,0.00011541349,0.00026101328,0.000024810975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005162561,0.00037873717,0.00008908499,0.0021945962,0.00026604143,0.000024191679,0.000083248204,3.494168e-8,0.0000046025752,0.000058036057,0.007759737,0.9886254],"study_design_scores_gemma":[0.0028313159,0.0048662685,0.0003018412,0.00048561426,0.00038018415,0.000041174837,0.000022072936,2.4056706e-7,0.00005387654,0.000064322354,0.99076205,0.00019102867],"about_ca_topic_score_codex":0.00035501,"about_ca_topic_score_gemma":0.000023402014,"teacher_disagreement_score":0.98843443,"about_ca_system_score_codex":0.00014726978,"about_ca_system_score_gemma":0.0007023016,"threshold_uncertainty_score":0.7810333},"labels":[],"label_agreement":null},{"id":"W2491578150","doi":"10.1093/annonc/mdw252","title":"Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"Cancer Institute NSW","keywords":"Medicine; Colorectal cancer; Chemotherapy; Oncology; Prospective cohort study; Internal medicine; Cancer; Chemotherapy regimen","score_opus":0.04840475864278916,"score_gpt":0.3733302099511962,"score_spread":0.32492545130840705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491578150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076337,0.0005533019,0.000031129315,0.0056970897,0.000094888084,0.00093795185,0.000020204505,0.000016042311,0.0018860389],"genre_scores_gemma":[0.9979032,0.00099225,0.000027606378,0.00050309865,0.00008183259,0.0002692731,0.000001096381,0.00001980435,0.00020181952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883133,0.000102491635,0.00024200015,0.0003672548,0.00019974068,0.0002571653],"domain_scores_gemma":[0.9991448,0.00016761452,0.00013655379,0.00015434631,0.00029932955,0.00009733658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002894811,0.00015867544,0.00066732324,0.00011996166,0.000027214825,0.0000065885697,0.00006705343,0.000111127745,0.00023095198],"category_scores_gemma":[0.000052921932,0.000098612545,0.000044404183,0.00028421922,0.0002003932,0.000066724315,0.00003371845,0.00013235741,0.0000016249043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010356997,0.00059615774,0.9292213,0.00003902565,0.00022017419,0.00006370046,0.011700508,9.85976e-7,0.00069047697,0.00007614983,0.00040594186,0.04662862],"study_design_scores_gemma":[0.0099440245,0.01222929,0.96543,0.0002695964,0.00006198692,0.000033262935,0.0031276436,0.0000036149013,0.006624786,0.00010195002,0.0020187406,0.00015506925],"about_ca_topic_score_codex":0.0041097593,"about_ca_topic_score_gemma":0.07089742,"teacher_disagreement_score":0.06678766,"about_ca_system_score_codex":0.0001423472,"about_ca_system_score_gemma":0.00034662292,"threshold_uncertainty_score":0.9460563},"labels":[],"label_agreement":null},{"id":"W2493288410","doi":"10.1093/annonc/mdw237.01","title":"LBA-01 Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Atezolizumab; Colorectal cancer; Oncology; Internal medicine; Rash; Blockade; Cancer; Gastroenterology; Nivolumab; Immunotherapy; Receptor","score_opus":0.0880581425312575,"score_gpt":0.4344553581050803,"score_spread":0.3463972155738228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493288410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936822,0.003041132,0.0000024261822,0.0012310072,0.000057556208,0.00084592565,0.000100720186,0.0000065009044,0.0010325243],"genre_scores_gemma":[0.99589294,0.003831584,0.000055067787,0.00006417003,0.000015840038,0.000051304076,0.000002455984,0.000011315407,0.000075344564],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863654,0.00013798606,0.00059890084,0.0002614198,0.00014800888,0.00021716616],"domain_scores_gemma":[0.9987284,0.0005821643,0.00030784385,0.0001239906,0.00017828665,0.00007930687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030291817,0.00016145455,0.0011147578,0.0001631599,0.00002859249,0.0000013396079,0.000050157094,0.000058122965,0.00010100807],"category_scores_gemma":[0.00019593356,0.00010204977,0.00005763268,0.00018883598,0.00036456322,0.000041353094,0.0000874228,0.00006663263,5.0219546e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060588002,0.0256841,0.18076283,0.00039592627,0.0029459007,0.00024141055,0.014967584,0.0000034619834,0.020926872,0.0001832921,0.0004833344,0.6928173],"study_design_scores_gemma":[0.09168424,0.078879625,0.8068661,0.00033525197,0.0007018559,0.000047179143,0.002818018,0.000019117106,0.016024904,0.00011333538,0.0023140362,0.00019636097],"about_ca_topic_score_codex":0.0015707029,"about_ca_topic_score_gemma":0.0030445736,"teacher_disagreement_score":0.69262093,"about_ca_system_score_codex":0.00005531887,"about_ca_system_score_gemma":0.00018491845,"threshold_uncertainty_score":0.4161469},"labels":[],"label_agreement":null},{"id":"W2501562494","doi":"10.1093/annonc/mdv343.14","title":"Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Rash; Internal medicine; Tolerability; Adverse effect; Lung cancer; Pharmacokinetics; Gastroenterology; Oncology; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.02164130412154888,"score_gpt":0.3719260686575253,"score_spread":0.35028476453597646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501562494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282587,0.00056072266,0.000013963283,0.00064773485,0.000053047148,0.0010482743,0.000066046836,0.000006850358,0.0047775162],"genre_scores_gemma":[0.99812204,0.00034034092,0.0005504566,0.00071778515,0.0000185823,0.00007902979,0.00005739017,0.000013908881,0.000100446894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900806,0.000052102474,0.00034175828,0.00023240007,0.00017794778,0.00018775041],"domain_scores_gemma":[0.9987794,0.0001485613,0.00027886755,0.00014993218,0.0005103366,0.00013290491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010202388,0.00014111912,0.0004005959,0.00012393006,0.000022723641,0.0000018408513,0.000048647344,0.00007459467,0.000008906318],"category_scores_gemma":[0.000053826716,0.00010784048,0.000029882476,0.00017756234,0.000096172924,0.00007845391,0.000022711161,0.00009766444,0.0000018331116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027795974,0.013326389,0.5418858,0.00061468955,0.0009923775,0.00014492961,0.034808755,0.080305174,0.0010339771,0.00032658572,0.0007523523,0.29801297],"study_design_scores_gemma":[0.021441834,0.01247333,0.9599775,0.0004964004,0.00019792406,0.0000023819168,0.00038951,0.000094701696,0.0043803654,0.000012170397,0.00042250552,0.00011137521],"about_ca_topic_score_codex":0.00050896563,"about_ca_topic_score_gemma":0.00016186558,"teacher_disagreement_score":0.41809168,"about_ca_system_score_codex":0.00020464853,"about_ca_system_score_gemma":0.00061821885,"threshold_uncertainty_score":0.4397607},"labels":[],"label_agreement":null},{"id":"W2501767467","doi":"10.1093/annonc/mdv341.17","title":"Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Meta-analysis; Renal cell carcinoma; Cochrane Library; Internal medicine; Oncology; Population; Clear cell renal cell carcinoma; MEDLINE; Kidney cancer","score_opus":0.24433423157634268,"score_gpt":0.4282160250311953,"score_spread":0.18388179345485264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501767467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002148078,0.99332887,0.0000011994606,0.00012618287,0.000011545163,0.0046912227,0.00006115334,0.00001120384,0.0015538349],"genre_scores_gemma":[0.0049650655,0.993156,0.00030247722,0.00013435114,0.000015635353,0.000917839,0.00012588673,0.000050819755,0.00033188256],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947229,0.00149257,0.002428618,0.0005630977,0.00047004342,0.00032279268],"domain_scores_gemma":[0.99539316,0.000655938,0.0022876728,0.00092162035,0.0004985781,0.00024306297],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0018629334,0.00053800544,0.018071463,0.0008004134,0.000011124386,0.0000039954452,0.00023748103,0.0004236922,0.00008727504],"category_scores_gemma":[0.0004061431,0.000316983,0.0025433414,0.00090407784,0.00011631895,0.000039832936,0.00015569839,0.0003310206,0.000010864151],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030935676,0.00056207343,0.000049572664,0.96987283,0.02613778,0.00019858942,0.00009829059,5.050105e-7,0.000008575563,0.0000043991377,0.00045842413,0.0025780303],"study_design_scores_gemma":[0.0003606809,0.0021394119,0.00004285395,0.037780218,0.92902344,0.00016276073,0.00003320523,0.0000016974544,0.00010368658,0.000019809182,0.030119322,0.00021291466],"about_ca_topic_score_codex":0.00007671061,"about_ca_topic_score_gemma":0.0000183261,"teacher_disagreement_score":0.9320926,"about_ca_system_score_codex":0.00011945549,"about_ca_system_score_gemma":0.0007406023,"threshold_uncertainty_score":0.99992824},"labels":[],"label_agreement":null},{"id":"W2505623435","doi":"10.1093/annonc/mdw263","title":"Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; BC Cancer Agency","funders":"Institut Gustave-Roussy; National Cancer Institute; Ligue Contre le Cancer; Sanofi; Eli Lilly and Company","keywords":"Medicine; Radiation therapy; Hazard ratio; Lung cancer; Randomized controlled trial; Meta-analysis; Stage (stratigraphy); Log-rank test; Clinical trial; Survival analysis; Surgery; Internal medicine; Oncology; Confidence interval","score_opus":0.5676325483529087,"score_gpt":0.5740618394205091,"score_spread":0.006429291067600484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505623435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039952034,0.98970497,0.000015387726,0.00049674726,0.00007609683,0.0017225277,0.003749545,0.000009256634,0.00023029515],"genre_scores_gemma":[0.003452957,0.9956306,0.00012463552,0.00009206359,0.000064948836,0.0002443632,0.00012582232,0.0000618308,0.0002027803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99515337,0.0013854485,0.0016163745,0.000614095,0.0007123475,0.00051834184],"domain_scores_gemma":[0.9935114,0.0015097416,0.0023485324,0.0020333016,0.00048370488,0.000113354836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020193786,0.00045889305,0.007466447,0.0009858978,0.000032094835,0.000005841755,0.0013673094,0.00035695932,0.00042175714],"category_scores_gemma":[0.00043936635,0.00021999818,0.0029183498,0.0016969958,0.0004085152,0.00007945398,0.0008849289,0.000543527,6.2965756e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020313388,0.0006690929,0.0039439364,0.016491748,0.31184614,0.000027834261,0.00068612996,0.00004444741,0.000008475054,0.0000036910008,0.0033965877,0.6626788],"study_design_scores_gemma":[0.0010628651,0.0029098524,0.0020518163,0.005251379,0.40214968,0.000011384009,0.00009878568,0.000053688116,0.00022139544,0.000004109353,0.58572596,0.00045907425],"about_ca_topic_score_codex":0.0016821536,"about_ca_topic_score_gemma":0.0006409544,"teacher_disagreement_score":0.6622197,"about_ca_system_score_codex":0.00034650118,"about_ca_system_score_gemma":0.003201362,"threshold_uncertainty_score":0.89712656},"labels":[],"label_agreement":null},{"id":"W2507338796","doi":"10.1093/annonc/mdv341.06","title":"Outcome of patients with pancreatic metastases from renal cell carcinoma: when the site matters","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Outcome (game theory); Pancreatic carcinoma; General surgery; Pancreatic cancer; Cancer","score_opus":0.08674135965123447,"score_gpt":0.3385064470705405,"score_spread":0.25176508741930603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507338796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903193,0.00079613883,0.0000067304577,0.0073524565,0.000057487072,0.00027954392,0.00022580018,0.000004690545,0.0009578381],"genre_scores_gemma":[0.99627644,0.000027184455,0.00048429097,0.002955926,0.00003493508,0.000028832352,0.000100143174,0.000010071442,0.000082169565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917275,0.00007382037,0.0002791698,0.00013524038,0.00020159529,0.00013745544],"domain_scores_gemma":[0.99901116,0.00020729042,0.00021631234,0.0002617925,0.00020949922,0.00009392103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012755732,0.000101606296,0.0004711847,0.000043815046,0.000014140597,0.000002318561,0.000059299033,0.000037725596,0.00012976496],"category_scores_gemma":[0.000025661295,0.000054685886,0.0000800988,0.000055209017,0.00011035294,0.00002949401,0.000033225948,0.00005728563,0.000013599436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073685125,0.0009565984,0.96152294,0.000027635499,0.0002067198,0.000024943834,0.00082727947,0.000007337272,0.00004680283,0.00001011209,0.033811722,0.0018210757],"study_design_scores_gemma":[0.005212026,0.006049998,0.9580126,0.000033223267,0.000692426,0.0000021206276,0.00022158951,0.0000029974549,0.006300943,0.000093808565,0.02331154,0.000066759196],"about_ca_topic_score_codex":0.0034382744,"about_ca_topic_score_gemma":0.00029552213,"teacher_disagreement_score":0.010500182,"about_ca_system_score_codex":0.00004061611,"about_ca_system_score_gemma":0.00011320866,"threshold_uncertainty_score":0.5197665},"labels":[],"label_agreement":null},{"id":"W2511015053","doi":"10.1093/annonc/mdu347.6","title":"Common and Rare Egfr Mutations (Egfrm) in the Radiant Trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine","score_opus":0.058904018534504464,"score_gpt":0.3991315133615536,"score_spread":0.34022749482704917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511015053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428853,0.00029786257,0.00001551906,0.04580929,0.00011915264,0.00050062453,0.000004249265,0.000009835527,0.010358194],"genre_scores_gemma":[0.9941182,0.00007836121,0.00015769097,0.0053566266,0.00017693733,0.000030896867,0.0000187297,0.0000060564416,0.000056460485],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990847,0.00034951756,0.00023072293,0.00010209576,0.00010615156,0.0001268103],"domain_scores_gemma":[0.99851334,0.0010976132,0.000103420905,0.00017621288,0.000057383568,0.00005201889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008942264,0.00006268213,0.00027812805,0.00010700777,0.000031945943,0.0000045374386,0.00007393568,0.000104798,0.000027306553],"category_scores_gemma":[0.00069855095,0.00004427402,0.000043460837,0.00011922076,0.00011211225,0.00004137171,0.000011907504,0.00015115652,0.0000094251545],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020410564,0.00282568,0.06733198,0.0003208237,0.00023608838,0.00027530087,0.015029898,0.00015992016,0.0031758293,0.031242829,0.122526534,0.73646456],"study_design_scores_gemma":[0.08693597,0.028029889,0.44481644,0.00008927172,0.00013705643,0.00025450988,0.0011741237,0.0011474036,0.0015170255,0.0059378347,0.42973623,0.0002242416],"about_ca_topic_score_codex":0.00007499333,"about_ca_topic_score_gemma":0.0001863622,"teacher_disagreement_score":0.7362403,"about_ca_system_score_codex":0.000011323232,"about_ca_system_score_gemma":0.00007730538,"threshold_uncertainty_score":0.18054421},"labels":[],"label_agreement":null},{"id":"W2512922897","doi":"10.1093/annonc/mdw322","title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Lung cancer; Adenocarcinoma; Adverse effect; Pharmacokinetics; Oncology; Gastroenterology; Post-hoc analysis; Incidence (geometry); Chemotherapy; Urology; Pharmacology; Surgery; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.061415987782471974,"score_gpt":0.4621472999199842,"score_spread":0.40073131213751223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512922897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98339224,0.0051935776,0.000111540554,0.006746369,0.000088843386,0.0035229854,0.0003300499,0.0000032330404,0.0006111419],"genre_scores_gemma":[0.99863964,0.00079419353,0.00009374536,0.00020603745,0.000038570233,0.000118097625,0.000019212368,0.000008760902,0.00008174866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794227,0.00096259156,0.0006836076,0.0001549035,0.00014302747,0.000113591435],"domain_scores_gemma":[0.98183477,0.016793689,0.000807221,0.00018982409,0.00033433197,0.000040181454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017753374,0.00012702437,0.0012274684,0.00008579455,0.000049146453,0.0000015807624,0.00005924454,0.00007309479,0.000029264276],"category_scores_gemma":[0.0028955722,0.000049456703,0.00029776862,0.000094694486,0.00040595085,0.000030079975,0.000027911072,0.0000394204,1.3933182e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7281753,0.0015063022,0.0070345737,0.0011561196,0.011730692,0.000007768,0.0065717855,0.00005242995,0.052258633,0.0064088516,0.0013852008,0.1837124],"study_design_scores_gemma":[0.44087407,0.021447407,0.20076245,0.0010554333,0.0105033945,0.00001890079,0.00046434844,0.00015543142,0.3241898,0.00025453776,0.00014418761,0.0001300365],"about_ca_topic_score_codex":0.00010732123,"about_ca_topic_score_gemma":0.000008079627,"teacher_disagreement_score":0.28730118,"about_ca_system_score_codex":0.000038020284,"about_ca_system_score_gemma":0.00018762096,"threshold_uncertainty_score":0.34664795},"labels":[],"label_agreement":null},{"id":"W2520458330","doi":"10.1016/s0923-7534(20)34031-x","title":"Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Regorafenib; Medicine; GiST; Sunitinib; Imatinib; Internal medicine; Oncology; Stromal tumor; Stromal cell; Colorectal cancer; Cancer","score_opus":0.0502119255854298,"score_gpt":0.43970556705428315,"score_spread":0.38949364146885335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520458330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996752,0.00018765523,0.000007045382,0.0009788309,0.00005585594,0.0017657517,0.00013929445,0.000026757683,0.00008677262],"genre_scores_gemma":[0.9888138,0.000025540872,0.010317816,0.0002487897,0.00015695128,0.00017807586,0.00020944589,0.000037432703,0.000012110623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713886,0.00022690091,0.0006915595,0.00048976176,0.0005120508,0.00094085245],"domain_scores_gemma":[0.997767,0.0003230681,0.00045281902,0.00029520298,0.00048478498,0.00067714456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008234318,0.00034109215,0.00081954716,0.00014429764,0.00009282244,0.00002367779,0.00008631612,0.00006890721,0.000038050748],"category_scores_gemma":[0.00044414587,0.00021265837,0.00007044855,0.00016295881,0.0006653794,0.00023992083,0.00012938255,0.0005194607,0.0000052859314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33328393,0.0069051646,0.5879668,0.000077906705,0.000034266704,0.0006480396,0.00007620006,4.461955e-7,0.00006632488,0.00001583666,0.000027992352,0.070897095],"study_design_scores_gemma":[0.106025845,0.20425667,0.68704486,0.001226764,0.00004610215,0.0006524334,0.00015752972,0.000014705625,0.00025236633,0.000009350329,0.00017038484,0.00014296376],"about_ca_topic_score_codex":0.000021185944,"about_ca_topic_score_gemma":0.000047831054,"teacher_disagreement_score":0.22725807,"about_ca_system_score_codex":0.000046987436,"about_ca_system_score_gemma":0.00016137018,"threshold_uncertainty_score":0.86719567},"labels":[],"label_agreement":null},{"id":"W252362330","doi":"10.1093/annonc/mdj078","title":"Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Comprehensive Cancer Network; Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Antiemetic; Guideline; Radiation therapy; MEDLINE; Chemotherapy; Intensive care medicine; Pharmacy; Clinical trial; Confusion; Professional association; Oncology; Family medicine; Internal medicine","score_opus":0.09291749008605017,"score_gpt":0.3974724363939923,"score_spread":0.30455494630794216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W252362330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650293,0.00039325008,0.000039120587,0.02798924,0.000097961034,0.00026713932,0.000008666098,0.000005764599,0.006169553],"genre_scores_gemma":[0.9968201,0.00050816947,0.0010667697,0.00062516285,0.000063718566,0.0000030445203,0.0000027193462,0.0000060066964,0.00090431713],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914765,0.00008290198,0.0003982607,0.00012265479,0.0001532479,0.00009529017],"domain_scores_gemma":[0.99909234,0.00008929018,0.0003708638,0.00017619156,0.0002447929,0.000026514912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004544627,0.00006863805,0.00028042856,0.000082443745,0.000014130105,0.0000019287775,0.00009796812,0.00006797904,0.00006604464],"category_scores_gemma":[0.00013950092,0.000050769642,0.00007576483,0.00007909599,0.00014956121,0.000018394425,0.000027247443,0.000067270834,5.320734e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042414116,0.0018368753,0.011047935,0.0003073665,0.0011506766,0.0000066173257,0.0025591939,0.000028389839,0.3215947,0.0025522944,0.020518104,0.63415647],"study_design_scores_gemma":[0.021158325,0.006795751,0.30526575,0.00075337914,0.00024900964,0.000064412576,0.0009151961,0.0012281724,0.5648309,0.00093244156,0.09758611,0.00022053575],"about_ca_topic_score_codex":0.00004171989,"about_ca_topic_score_gemma":0.00001797208,"teacher_disagreement_score":0.6339359,"about_ca_system_score_codex":0.000016721184,"about_ca_system_score_gemma":0.000118064825,"threshold_uncertainty_score":0.20703259},"labels":[],"label_agreement":null},{"id":"W2524609866","doi":"10.1093/annonc/mdw438","title":"Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"University of Hong Kong","keywords":"Medicine; Palliative care; Quality of life (healthcare); Referral; Randomized controlled trial; Patient satisfaction; Intervention (counseling); Physical therapy; Cancer; Clinical trial; Family medicine; Internal medicine; Nursing","score_opus":0.03998687363790372,"score_gpt":0.38411680217191885,"score_spread":0.34412992853401514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524609866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959313,0.000225935,0.000009224552,0.00034483758,0.00024446813,0.00093545363,0.00032348867,0.0000061012724,0.0019791787],"genre_scores_gemma":[0.9994302,0.00024233804,0.000013436954,0.00010144436,0.000059129223,0.000050728675,0.000015163666,0.0000141156725,0.000073463925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989531,0.000102575614,0.00032386687,0.00017843395,0.00025551842,0.00018649688],"domain_scores_gemma":[0.99796784,0.00030157305,0.00045080896,0.00021868451,0.0009722049,0.00008890481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008516499,0.00013366812,0.00073491596,0.00010521522,0.000012105765,7.064468e-7,0.00008206703,0.000113965616,0.00014009884],"category_scores_gemma":[0.00009927764,0.00007430035,0.00025417807,0.00011883082,0.00016988697,0.00004564752,0.000017891738,0.00007110653,0.0000010491209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74090743,0.00034611148,0.15777615,0.00009661953,0.00047280162,0.0000034695965,0.007364899,0.000019637077,0.0003732347,0.00000999289,0.00056370674,0.092065945],"study_design_scores_gemma":[0.50311077,0.08040197,0.4060979,0.0005550935,0.0001889805,1.4997538e-7,0.00088157697,3.7966902e-7,0.007323102,0.000013282752,0.0012834725,0.00014334642],"about_ca_topic_score_codex":0.001430836,"about_ca_topic_score_gemma":0.0008801626,"teacher_disagreement_score":0.24832174,"about_ca_system_score_codex":0.00014025564,"about_ca_system_score_gemma":0.0005360523,"threshold_uncertainty_score":0.30298802},"labels":[],"label_agreement":null},{"id":"W2525265150","doi":"10.1093/annonc/mdw434","title":"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation; Yale University; U.S. Department of Health and Human Services","keywords":"Lapatinib; Trastuzumab; Medicine; RHOA; Gene; Mutation; Internal medicine; Oncology; Proportional hazards model; Cancer; Cancer research; Genetics; Breast cancer; Biology; Signal transduction","score_opus":0.2949287766874463,"score_gpt":0.4705472389473932,"score_spread":0.17561846225994687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525265150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88148105,0.00039779078,0.00013949123,0.115334205,0.00016255458,0.0012469579,0.000079421094,0.000015991995,0.0011425507],"genre_scores_gemma":[0.9955157,0.00013522147,0.00040884232,0.0021474864,0.00022836174,0.0004661008,0.0000091862985,0.000021998474,0.0010670875],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971162,0.0014138841,0.000503148,0.00025437967,0.00033331552,0.00037908228],"domain_scores_gemma":[0.99732935,0.0018523686,0.00009027296,0.00039249085,0.00023859205,0.000096934775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026041882,0.00012585813,0.00035432435,0.00039511517,0.00005263685,0.000012923201,0.00023598895,0.00014438246,0.0003090707],"category_scores_gemma":[0.0017681615,0.00007469055,0.00008107387,0.0005196254,0.0001904997,0.00007783691,0.000042728057,0.00017880293,0.000041808482],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11525254,0.0041948757,0.0148387635,0.000048764985,0.0001689497,0.000338871,0.034980677,0.0000739634,0.50792515,0.0006218661,0.018335894,0.3032197],"study_design_scores_gemma":[0.059033163,0.04195344,0.2679591,0.00048541193,0.00003258429,0.00007172674,0.0049973303,0.000054501415,0.08561249,0.0026316051,0.53676635,0.00040230874],"about_ca_topic_score_codex":0.0003235836,"about_ca_topic_score_gemma":0.0029969753,"teacher_disagreement_score":0.5184305,"about_ca_system_score_codex":0.00012894353,"about_ca_system_score_gemma":0.0011278292,"threshold_uncertainty_score":0.3384107},"labels":[],"label_agreement":null},{"id":"W2527377692","doi":"10.1093/annonc/mdw270","title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"School of Medicine, Indiana University; Health Science Center, University of Tennessee; Connecticut Children's Medical Center; Universitair Medisch Centrum Groningen; Cleveland Clinic; National University of Singapore; University of Toronto; Rijksuniversiteit Groningen; Multinational Association of Supportive Care in Cancer; University of Ottawa; European Society for Medical Oncology; University of Connecticut; Ottawa Hospital Research Institute; Hospital for Sick Children","keywords":"Medicine; Nausea; Vomiting; Antiemetic; Guideline; Radiation therapy; Chemotherapy; Chemotherapy-induced nausea and vomiting; Cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.04682507143648812,"score_gpt":0.39716421380231703,"score_spread":0.3503391423658289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527377692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889647,0.0035540662,0.00019869178,0.0063186777,0.000041948468,0.0008280147,0.00002398894,0.000005863742,0.00006407892],"genre_scores_gemma":[0.983064,0.014546543,0.0016017939,0.0005860985,0.00005280735,0.00003533287,0.0000033469425,0.00001895989,0.00009109755],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988117,0.000067968,0.0005529628,0.00026115135,0.00010049105,0.00020568879],"domain_scores_gemma":[0.9987391,0.00044626123,0.0004426844,0.00012440502,0.00018739994,0.00006011062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008310419,0.00013836393,0.00050263305,0.00012470393,0.00004488203,0.000005314766,0.000044438642,0.00009722673,0.000008920668],"category_scores_gemma":[0.00020374391,0.00008953282,0.000031187607,0.00006967619,0.00019855979,0.000102772334,0.00006406722,0.00006180411,2.9655036e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001744985,0.00020880502,0.19675176,0.0005268609,0.00027732714,0.0000015081605,0.00055472064,8.9415505e-7,0.05369169,0.00019243738,0.00059603335,0.745453],"study_design_scores_gemma":[0.04509642,0.008810617,0.84132797,0.002206987,0.00031325893,0.000016529375,0.0005885374,0.0008246171,0.08251888,0.0015623351,0.016351724,0.00038214028],"about_ca_topic_score_codex":0.000103989696,"about_ca_topic_score_gemma":0.00011093176,"teacher_disagreement_score":0.7450709,"about_ca_system_score_codex":0.000017601911,"about_ca_system_score_gemma":0.00004909927,"threshold_uncertainty_score":0.36510426},"labels":[],"label_agreement":null},{"id":"W2528229149","doi":"10.1093/annonc/mdw198.25","title":"O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Tolerability; Oncology; Internal medicine; Colorectal cancer; Clinical endpoint; Randomized controlled trial; Cancer; Adverse effect","score_opus":0.034334000722710756,"score_gpt":0.373598782940577,"score_spread":0.33926478221786627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528229149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955204,0.00028942153,0.0000069884723,0.0018426694,0.00006707615,0.00082129374,0.00017322783,0.000013422135,0.0012655093],"genre_scores_gemma":[0.99871624,0.0006482556,0.00019949916,0.00016218654,0.000014264068,0.00009472449,0.000018207187,0.000017210368,0.00012939173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873716,0.000054266442,0.00040938723,0.0003103027,0.0002389854,0.0002499264],"domain_scores_gemma":[0.99873984,0.00015640842,0.00036110918,0.00013723536,0.00052183744,0.0000835589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013277178,0.00018576602,0.0007532708,0.00014493287,0.00003491948,0.0000024755263,0.00005408951,0.000082448474,0.000037000438],"category_scores_gemma":[0.00009791767,0.00009285891,0.000030597435,0.00023473322,0.00033012946,0.00012969013,0.000038096976,0.000072952214,6.606457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15782037,0.005663093,0.49927115,0.00012040859,0.00047593634,0.00007807798,0.0022233936,0.000003433443,0.0044369036,0.000050905834,0.0003229008,0.32953343],"study_design_scores_gemma":[0.10941013,0.11527712,0.7461351,0.0007065467,0.00016395339,0.000014294593,0.00036682986,0.00001461166,0.026237225,0.00004807158,0.0014113898,0.00021472717],"about_ca_topic_score_codex":0.00023033786,"about_ca_topic_score_gemma":0.0024582713,"teacher_disagreement_score":0.3293187,"about_ca_system_score_codex":0.000113828566,"about_ca_system_score_gemma":0.00032894194,"threshold_uncertainty_score":0.37866765},"labels":[],"label_agreement":null},{"id":"W2528766886","doi":"10.1093/annonc/mdv336.24","title":"First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Proportional hazards model; Retrospective cohort study; Adjuvant therapy; Cohort; Cancer; Stage (stratigraphy)","score_opus":0.19802956454535903,"score_gpt":0.4781728379178396,"score_spread":0.2801432733724806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528766886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98203963,0.0006122966,0.000060813592,0.015534443,0.00009106209,0.0010185918,0.00022315352,0.000017267626,0.00040272324],"genre_scores_gemma":[0.9970663,0.0005517288,0.00036934376,0.0014354091,0.00010698535,0.00028896146,0.00004629216,0.00003453837,0.000100420795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799955,0.00029392992,0.00037687493,0.0003073223,0.000503729,0.00051857193],"domain_scores_gemma":[0.99805206,0.00026290666,0.00016866752,0.00022643287,0.00080798566,0.00048197538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005949195,0.0001754309,0.0004959593,0.00019777934,0.00003320691,0.000008814202,0.0001502974,0.000064697706,0.00023010162],"category_scores_gemma":[0.0003223517,0.00012150056,0.00006397333,0.00041263862,0.0002048011,0.00006939856,0.0000388402,0.00028170066,0.0000060933453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035438444,0.008624769,0.8296197,0.00049102516,0.00029728524,0.00095750595,0.002292566,0.0013763107,0.000042859025,0.00000993313,0.004885891,0.1159637],"study_design_scores_gemma":[0.020273661,0.025659634,0.93294066,0.0010807383,0.00012330805,0.000046204612,0.00029128164,0.0031332718,0.0017358572,0.000108708526,0.014280999,0.0003256709],"about_ca_topic_score_codex":0.0012797763,"about_ca_topic_score_gemma":0.0026262465,"teacher_disagreement_score":0.115638025,"about_ca_system_score_codex":0.0004193325,"about_ca_system_score_gemma":0.0035477604,"threshold_uncertainty_score":0.62935746},"labels":[],"label_agreement":null},{"id":"W2530600980","doi":"10.1093/annonc/mdw538","title":"Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"National Cancer Institute; European Society for Medical Oncology","keywords":"Medicine; Randomized controlled trial; Clinical trial; Sample size determination; Breast cancer; Pancreatic cancer; Oncology; Internal medicine; Cancer","score_opus":0.8301739516436359,"score_gpt":0.6886675466209815,"score_spread":0.14150640502265444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530600980","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2755125,0.007717869,0.0036075623,0.47352841,0.003286049,0.018701172,0.00028094885,0.00016780054,0.2171977],"genre_scores_gemma":[0.9749627,0.008445248,0.001995077,0.007561348,0.0011359504,0.0007382587,0.000012099645,0.00004577663,0.0051035066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9871725,0.0042530107,0.006299029,0.0006940824,0.0009749891,0.0006063952],"domain_scores_gemma":[0.3186255,0.6719773,0.002996149,0.0011570393,0.004585145,0.0006588789],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18201871,0.00026871092,0.010598853,0.00024132508,0.000067828034,0.000014252831,0.0004325996,0.0015128673,0.00053833413],"category_scores_gemma":[0.5684907,0.00013251403,0.0035665839,0.000124575,0.0017437278,0.00008566264,0.00017529073,0.0007495306,0.00003154151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75429416,0.0010500136,0.0026074112,0.00011776432,0.0030824493,0.000041177715,0.00007656474,3.1628826e-7,0.00056025584,0.17113328,0.03855458,0.028482005],"study_design_scores_gemma":[0.6608932,0.008072761,0.00020646639,0.00048915605,0.00047327645,0.000008801146,0.000053175503,0.000026788906,0.0013123082,0.2970793,0.031242909,0.00014184488],"about_ca_topic_score_codex":0.00002517826,"about_ca_topic_score_gemma":0.00004688679,"teacher_disagreement_score":0.69945025,"about_ca_system_score_codex":0.000036319972,"about_ca_system_score_gemma":0.0022580922,"threshold_uncertainty_score":0.9997834},"labels":[],"label_agreement":null},{"id":"W2531859512","doi":"10.1093/annonc/mdw412","title":"Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; McGill University; Regional Municipality of Durham; Hamilton Health Sciences; Kelowna General Hospital; Sunnybrook Health Science Centre; Trillium Health Centre; Juravinski Cancer Centre; Mount Sinai Hospital; Nova Scotia Cancer Centre; Ottawa Hospital; BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Ramucirumab; Medicine; Oncology; Internal medicine; Overall survival","score_opus":0.06133612399779004,"score_gpt":0.3986167426972846,"score_spread":0.33728061869949455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531859512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915295,0.00059709145,0.000008560647,0.0022810737,0.000050255665,0.0053699226,0.000071726434,0.000014615114,0.00007724473],"genre_scores_gemma":[0.9963499,0.00051252206,0.000031381107,0.0003698532,0.000013137872,0.002612339,0.000026148522,0.00002823461,0.00005649199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800885,0.0003269151,0.0006051771,0.0003800117,0.0004009956,0.00027803995],"domain_scores_gemma":[0.9983683,0.0004917016,0.00043136213,0.00021162431,0.00039888988,0.00009812149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034070289,0.00029359377,0.0013194814,0.00032389353,0.000055520413,0.0000034316868,0.0000778464,0.00006175416,0.00025157593],"category_scores_gemma":[0.00010564285,0.00013196496,0.00008973908,0.00032038716,0.00023282887,0.00007481338,0.000022815695,0.000109576016,5.1464696e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7467787,0.043821402,0.03921322,0.000038091785,0.0005528487,0.000113342205,0.0012790284,0.00006598668,0.00003509306,0.000005251624,0.000011061555,0.16808596],"study_design_scores_gemma":[0.6213698,0.24014373,0.13521454,0.00043406125,0.000108449574,5.369685e-7,0.000072039846,0.00010358032,0.0022934687,0.000036348574,0.00008593952,0.000137546],"about_ca_topic_score_codex":0.00034918962,"about_ca_topic_score_gemma":0.005030112,"teacher_disagreement_score":0.19632232,"about_ca_system_score_codex":0.000171711,"about_ca_system_score_gemma":0.00044489736,"threshold_uncertainty_score":0.5381375},"labels":[],"label_agreement":null},{"id":"W2547680646","doi":"10.1093/annonc/mdw435.39","title":"NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Ipilimumab; Response Evaluation Criteria in Solid Tumors; Oncology; Docetaxel; Progression-free survival; Phases of clinical research; Chemotherapy; Adverse effect; Randomization; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy","score_opus":0.12810382298844694,"score_gpt":0.4189531583647975,"score_spread":0.2908493353763506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547680646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97872937,0.0016211128,0.00079791853,0.012619531,0.00035728383,0.0048813415,0.000678806,0.000046296733,0.00026836735],"genre_scores_gemma":[0.99170643,0.0021492355,0.0016836588,0.0030402865,0.00025983946,0.000615519,0.00014655203,0.000082379076,0.00031608922],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967348,0.0002228089,0.0014485887,0.0005220052,0.00047426496,0.00059751485],"domain_scores_gemma":[0.9956117,0.0012862652,0.0015106621,0.00053850305,0.0007656205,0.00028722672],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013184301,0.00044499946,0.0016655253,0.00030731288,0.000074931646,0.000010966708,0.0002911854,0.00027606534,0.00023861969],"category_scores_gemma":[0.0005713183,0.0003095716,0.0006484712,0.00038636432,0.0006998622,0.00012643231,0.000027768278,0.00016672465,0.0000025940972],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53859466,0.006134148,0.00031016945,0.0004218225,0.0016673913,0.000012398512,0.00081910804,0.00000154202,0.18106773,0.000086563625,0.0018385411,0.26904592],"study_design_scores_gemma":[0.3154622,0.07723813,0.0007111248,0.0006523921,0.00020953282,0.0000076183674,0.0000652328,0.00008208126,0.5456101,0.00019402239,0.059500247,0.00026737156],"about_ca_topic_score_codex":0.0004844208,"about_ca_topic_score_gemma":0.00012490933,"teacher_disagreement_score":0.3645423,"about_ca_system_score_codex":0.00012563009,"about_ca_system_score_gemma":0.001666943,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W2547926635","doi":"10.1093/annonc/mdv530.02","title":"359O A whole genome approach to better understand the link between Kaposi's sarcoma-associated herpesvirus and human cancers","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill Genome Centre","funders":"","keywords":"Primary effusion lymphoma; Carcinogenesis; Kaposi's sarcoma-associated herpesvirus; Biology; Hypoxia (environmental); Cancer research; microRNA; Transfection; Immune system; Virology; Virus; Gene; Immunology; Viral disease; Herpesviridae; Genetics","score_opus":0.13277072506961954,"score_gpt":0.3712362374368395,"score_spread":0.23846551236721994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547926635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88832426,0.0014230462,0.00006847282,0.063896306,0.00007695343,0.0006175409,0.00009264324,0.00004113653,0.045459617],"genre_scores_gemma":[0.9884163,0.00007114753,0.00011310605,0.010361325,0.00031336962,0.000029718605,0.000101672435,0.000029078961,0.0005642661],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984067,0.00016234735,0.00035530367,0.00030199173,0.000282789,0.0004908565],"domain_scores_gemma":[0.99889743,0.0000842704,0.00021038929,0.00026052218,0.00021583075,0.00033153218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007812501,0.00018388235,0.00061919814,0.000111511916,0.00013212864,0.000018332765,0.00016879571,0.00027310103,0.000017358345],"category_scores_gemma":[0.00011336493,0.000139966,0.0001016796,0.00030167523,0.00024821947,0.000058517948,0.00008604895,0.0003032093,0.000010807875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029987379,0.0014617479,0.1859507,0.0003177772,0.0062263203,0.00012530934,0.04743536,0.0005672127,0.007395106,0.0029761638,0.4671115,0.27743408],"study_design_scores_gemma":[0.015081826,0.010732838,0.14542295,0.00008927766,0.00065149047,0.000015657197,0.009070222,0.00006148361,0.0003710486,0.007766338,0.8101231,0.0006138087],"about_ca_topic_score_codex":0.0018032952,"about_ca_topic_score_gemma":0.0006248164,"teacher_disagreement_score":0.34301156,"about_ca_system_score_codex":0.00043389414,"about_ca_system_score_gemma":0.0004943212,"threshold_uncertainty_score":0.5707648},"labels":[],"label_agreement":null},{"id":"W2549249508","doi":"10.1093/annonc/mdw561","title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University; McGill University Health Centre","funders":"","keywords":"Medicine; Sunitinib; Placebo; Internal medicine; Clinical endpoint; Neuroendocrine tumors; Progression-free survival; Confidence interval; Oncology; Randomized controlled trial; Surgery; Overall survival; Cancer; Pathology","score_opus":0.09109473406666649,"score_gpt":0.4336538198558955,"score_spread":0.342559085789229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549249508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98392034,0.00032046033,0.000008270458,0.0115479855,0.0001624906,0.0024571843,0.000106837375,0.00006320415,0.0014132345],"genre_scores_gemma":[0.99782884,0.00071997783,0.00020215352,0.00028927784,0.00015445196,0.0002352051,0.000047061505,0.000042070405,0.00048097046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949804,0.0018982792,0.0010780315,0.0006217701,0.00067396066,0.00074755686],"domain_scores_gemma":[0.99478906,0.003520856,0.00038377766,0.0006540152,0.0003074834,0.00034482457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009949211,0.0003325947,0.0022085432,0.0003861397,0.00005068541,0.000014608229,0.0003372115,0.00001919914,0.0005095697],"category_scores_gemma":[0.0048046755,0.00021304942,0.0001457565,0.00028796797,0.00062380626,0.00021431164,0.0004032362,0.00036350967,0.000010245387],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75858754,0.014631398,0.10433297,0.00013813132,0.00067610474,0.054991197,0.00033890273,0.000001319397,0.022225836,0.00068582204,0.0036274656,0.03976334],"study_design_scores_gemma":[0.9275699,0.019372273,0.035039585,0.00040312172,0.00019008333,0.00062587415,0.00060103956,0.000059233353,0.008018802,0.003071477,0.0047114994,0.00033707812],"about_ca_topic_score_codex":0.0008814748,"about_ca_topic_score_gemma":0.00056496955,"teacher_disagreement_score":0.16898242,"about_ca_system_score_codex":0.00003446767,"about_ca_system_score_gemma":0.00030869863,"threshold_uncertainty_score":0.8687903},"labels":[],"label_agreement":null},{"id":"W2550414527","doi":"10.1093/annonc/mdw606","title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"Italfarmaco; Ministero della Salute; Prothena; Celgene; Takeda Oncology; Gilead Sciences; Sanofi; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Melphalan; Bortezomib; Thalidomide; Oncology; Hematology; Transplantation; Incidence (geometry); Surgery; Intensive care medicine","score_opus":0.3007739062417689,"score_gpt":0.4743367711595702,"score_spread":0.17356286491780126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550414527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052180197,0.98821,2.489348e-7,0.00035343686,0.00008147531,0.0013261058,0.00036460606,0.000019770641,0.00442634],"genre_scores_gemma":[0.00073351903,0.9972176,0.0003257028,0.00031269516,0.00010138501,0.00015125897,0.00019562899,0.00004708008,0.0009151549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99727815,0.00052159483,0.0008505094,0.0005329596,0.0002381991,0.00057859306],"domain_scores_gemma":[0.9974215,0.0011473487,0.0003988049,0.0004949947,0.00018659986,0.0003507268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006167552,0.00039691574,0.0030258372,0.00043353697,0.000039207673,0.000007815582,0.0001575333,0.0005266281,0.0003541546],"category_scores_gemma":[0.00040712088,0.00026210267,0.00029013323,0.0001944505,0.00039058263,0.00005923154,0.00016169749,0.00032661256,0.00006670695],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022052282,0.00050961704,0.0008023389,0.018227065,0.000340122,0.0011199507,0.000041652824,4.299818e-9,0.000019126477,0.000100786885,0.0014057494,0.9772131],"study_design_scores_gemma":[0.002908184,0.0023876473,0.008536857,0.0101947915,0.00015708571,0.0004544932,0.000014184748,0.0000010659448,0.000022088241,0.00009020005,0.9750211,0.00021227682],"about_ca_topic_score_codex":0.00007160741,"about_ca_topic_score_gemma":0.00029852477,"teacher_disagreement_score":0.9770008,"about_ca_system_score_codex":0.00013842515,"about_ca_system_score_gemma":0.0013173419,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W2553905728","doi":"10.1093/annonc/mdw392.07","title":"Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"PTEN; Medicine; Tissue microarray; Internal medicine; Lung cancer; Oncology; Histology; Cohort; Adenocarcinoma; Carcinoma; Immunohistochemistry; Cancer; Pathology","score_opus":0.043999489136557365,"score_gpt":0.36669460340429433,"score_spread":0.32269511426773695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553905728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050796,0.0004314413,0.000051253413,0.00033930375,0.00026882978,0.00037746452,0.00014250555,0.0000029824125,0.007878272],"genre_scores_gemma":[0.99863297,0.00065079686,0.0001487865,0.00023315001,0.00009718067,0.000012731086,0.0000145320155,0.000019718405,0.0001901513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978563,0.0005327128,0.00082848687,0.00035669818,0.00015028722,0.00027550303],"domain_scores_gemma":[0.9979497,0.00030925256,0.0008572371,0.0004128388,0.00040063518,0.000070327675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001567862,0.00014924383,0.0004459612,0.00005966536,0.000031931606,0.0000021108578,0.00043771282,0.00032950542,0.000016199801],"category_scores_gemma":[0.00045544514,0.000106510175,0.00016108324,0.00010506965,0.00041976618,0.0000084741505,0.00032921124,0.00015429109,0.0000019822544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001644635,0.00045998459,0.93505955,0.000079295976,0.000085309664,0.0000028911368,0.00011188327,0.000005180157,0.046135176,0.00001182712,0.0012495652,0.01663485],"study_design_scores_gemma":[0.0012863575,0.0018851226,0.92119306,0.00007517317,0.00007264211,0.0000023585128,0.000012840787,0.000014136434,0.07358442,0.000045555287,0.0017118797,0.00011644677],"about_ca_topic_score_codex":0.0000700053,"about_ca_topic_score_gemma":0.00016891545,"teacher_disagreement_score":0.02744925,"about_ca_system_score_codex":0.000051893137,"about_ca_system_score_gemma":0.0003514148,"threshold_uncertainty_score":0.4343359},"labels":[],"label_agreement":null},{"id":"W2555099733","doi":"10.1093/annonc/mdw571","title":"Research needs in breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Cancer; Disease; Precision medicine; Translational research; Oncology; Triple-negative breast cancer; Metastatic breast cancer; Survivorship curve; Internal medicine; Pathology","score_opus":0.08248536685961652,"score_gpt":0.42862508202891586,"score_spread":0.3461397151692993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555099733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97422236,0.0010802259,0.00002431452,0.01722246,0.00014359823,0.000079201345,0.00009566782,0.0000017953106,0.0071303775],"genre_scores_gemma":[0.98943263,0.009004447,0.000033203225,0.0007868539,0.00024413137,0.000028843517,0.000004424795,0.000009517177,0.0004559746],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926615,0.00007429693,0.00016354586,0.00015027456,0.00007879496,0.00026691283],"domain_scores_gemma":[0.99938405,0.00008901188,0.000045342436,0.0001955352,0.0002285658,0.000057478377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004501932,0.00005818473,0.00012740518,0.00012700717,0.000017716742,0.0000027498204,0.00015654445,0.00014038004,0.00009141639],"category_scores_gemma":[0.00008676405,0.00004429393,0.00003963874,0.00014921895,0.00015801199,0.0000017295745,0.00012107004,0.00005840364,0.000011639899],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043954636,0.00022157519,0.038331,0.000011827108,0.000035916248,0.000009148014,0.00007607943,0.000022344508,0.6378907,0.0018292047,0.079383485,0.2417492],"study_design_scores_gemma":[0.0012397561,0.0012278026,0.06395558,0.0000435345,0.0000036778138,0.000016648186,0.00013526974,0.0000029511775,0.19872278,0.0011866264,0.7333199,0.00014550315],"about_ca_topic_score_codex":0.00035045305,"about_ca_topic_score_gemma":0.00061013654,"teacher_disagreement_score":0.6539364,"about_ca_system_score_codex":0.000023916984,"about_ca_system_score_gemma":0.00034269007,"threshold_uncertainty_score":0.18062541},"labels":[],"label_agreement":null},{"id":"W2555459688","doi":"10.1093/annonc/mdw570","title":"Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Stanford Cancer Institute; National Cancer Institute; Anticancer Fund; Leukemia and Lymphoma Society","keywords":"CD137; Medicine; Oncology; Breast cancer; Nomogram; Internal medicine; Head and neck cancer; Immunotherapy; Cancer; Monoclonal antibody; Immunology; Antibody","score_opus":0.0583383124896076,"score_gpt":0.3665372311762007,"score_spread":0.3081989186865931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555459688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927839,0.000109389126,0.000010417497,0.004454554,0.00028292078,0.00025031532,0.000009114597,0.0000127605035,0.0020866187],"genre_scores_gemma":[0.9956289,0.0017606836,0.00006915949,0.0022352703,0.00009008764,0.000007803958,0.00001778446,0.000012679278,0.00017765895],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990771,0.000081102306,0.00032753017,0.00017670452,0.00013943626,0.00019816346],"domain_scores_gemma":[0.9993953,0.00012688486,0.00018764242,0.00015926856,0.00009250244,0.00003840761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031668457,0.00009942498,0.00027417237,0.00014816115,0.000020390271,0.0000028082122,0.000061876875,0.00012278584,0.00016653222],"category_scores_gemma":[0.000029658579,0.00006731557,0.00008394422,0.00011335282,0.00006493888,0.00008154925,0.000012345219,0.00006659933,0.000013342748],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005099691,0.00038463366,0.07446759,0.000009560735,0.00004010779,0.000003112424,0.00017413987,2.7672942e-7,0.4711716,0.000011457495,0.00037801484,0.44825983],"study_design_scores_gemma":[0.0044542924,0.0036260558,0.8027354,0.0002266311,0.0000031745624,0.0000013075228,0.000010505382,0.0000041104386,0.16440244,0.000036696903,0.024427801,0.00007158245],"about_ca_topic_score_codex":0.000035031833,"about_ca_topic_score_gemma":0.0000071012646,"teacher_disagreement_score":0.7282678,"about_ca_system_score_codex":0.00006455778,"about_ca_system_score_gemma":0.000076140954,"threshold_uncertainty_score":0.2745049},"labels":[],"label_agreement":null},{"id":"W2558592416","doi":"10.1093/annonc/mdw392.28","title":"Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PALB2; Germline; Medicine; Olaparib; Germline mutation; Breast cancer; Cancer; Cancer research; Triple-negative breast cancer; Genetic testing; Ovarian cancer; Somatic cell; Oncology; Internal medicine; Gene; Mutation; Genetics; Biology","score_opus":0.02975269438257382,"score_gpt":0.3272143129081854,"score_spread":0.2974616185256116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558592416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959683,0.0008372556,0.00022916977,0.0021836886,0.00012295798,0.00034392308,0.00028385414,0.0000067031815,0.000024159443],"genre_scores_gemma":[0.99347633,0.0022451477,0.0033239785,0.0005687441,0.00007188952,0.00016371408,0.000020110805,0.000025640036,0.00010446846],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99884653,0.0000977208,0.000292104,0.00039101555,0.00009630393,0.0002763121],"domain_scores_gemma":[0.9992039,0.000043764205,0.00023554164,0.00019138193,0.00024433184,0.00008103753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012940397,0.00017642195,0.00030889927,0.00007669786,0.000048142374,0.000005839469,0.000099661345,0.00016022346,0.00002311858],"category_scores_gemma":[0.000054556727,0.00013051655,0.000025323729,0.00012384022,0.0002328322,0.00001752543,0.00008143568,0.000070804446,5.107504e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017631399,0.0004405737,0.21013029,0.00013090733,0.00039502623,0.000020021245,0.0013130285,0.00082773913,0.44714296,0.000039583778,0.0004788213,0.3373179],"study_design_scores_gemma":[0.014770435,0.002225334,0.720313,0.00022510822,0.000064585154,0.00003786638,0.00023941773,0.00012201789,0.2602515,0.00024599177,0.0010383113,0.0004664384],"about_ca_topic_score_codex":0.0012591678,"about_ca_topic_score_gemma":0.0044190153,"teacher_disagreement_score":0.5101827,"about_ca_system_score_codex":0.00017208506,"about_ca_system_score_gemma":0.0004889753,"threshold_uncertainty_score":0.53223103},"labels":[],"label_agreement":null},{"id":"W2559317205","doi":"10.1093/annonc/mdw435.26","title":"gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Neutropenia; Placebo; Chemotherapy; Progression-free survival; Ovarian cancer; Oncology; Surgery; Cancer; Gastroenterology; Pathology","score_opus":0.11926694906777008,"score_gpt":0.4135565817748023,"score_spread":0.29428963270703223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559317205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981641,0.00017274807,0.0002714893,0.005364407,0.00083364523,0.008579054,0.0001501572,0.00002820485,0.0029592854],"genre_scores_gemma":[0.9948618,0.0014899649,0.0003685221,0.0012275517,0.00029907742,0.0015576702,0.00003307382,0.000041125964,0.000121240046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962566,0.0006675965,0.0012831511,0.0006072068,0.0005889171,0.000596556],"domain_scores_gemma":[0.9956191,0.0013959352,0.001361986,0.00041952613,0.0010107369,0.00019269522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015568027,0.00039492425,0.0023006331,0.00033863998,0.000045075092,0.0000063126367,0.00017705571,0.0003450964,0.00078526797],"category_scores_gemma":[0.00027175888,0.0002140368,0.00023646094,0.0004970724,0.0010953236,0.00013808002,0.000029333674,0.00036045437,0.0000039360248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9354093,0.0036296418,0.0010463365,0.000024172172,0.00079349405,0.000046876048,0.0007192496,0.000028208231,0.00016935998,0.00029431417,0.0011963884,0.05664265],"study_design_scores_gemma":[0.9225729,0.0667882,0.0011493457,0.000491603,0.00010772539,0.0000071672744,0.00007044272,0.0000119220895,0.0055402634,0.00011353914,0.0028808988,0.00026599134],"about_ca_topic_score_codex":0.0006146976,"about_ca_topic_score_gemma":0.00081043516,"teacher_disagreement_score":0.06315855,"about_ca_system_score_codex":0.0005877931,"about_ca_system_score_gemma":0.0019186549,"threshold_uncertainty_score":0.87281674},"labels":[],"label_agreement":null},{"id":"W2560118741","doi":"10.1093/annonc/mdv347.14","title":"Cross-cultural adaptation, evaluation and validation of the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE): a study protocol","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Terminology; Protocol (science); Adaptation (eye); Adverse effect; Medical physics; Intensive care medicine; Alternative medicine; Internal medicine; Pathology; Linguistics","score_opus":0.43793950604981463,"score_gpt":0.6210455806597567,"score_spread":0.18310607460994205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560118741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458421,0.000008479227,0.0000072813777,0.0026026883,0.00042173403,0.050494134,0.000025052022,0.000008721066,0.0005898209],"genre_scores_gemma":[0.9611106,9.414578e-7,0.00013741519,0.00034202499,0.000017131119,0.038293466,0.000011843381,0.0000076380975,0.000078956895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951144,0.0031294147,0.0011784988,0.00014327753,0.00027157864,0.000162847],"domain_scores_gemma":[0.99307054,0.00067226804,0.0019326883,0.0005402047,0.0037497326,0.000034555087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00248991,0.0000942527,0.00033274092,0.000048462698,0.00028505144,0.0000015154756,0.00028776928,0.00016598482,0.000024630126],"category_scores_gemma":[0.0031068348,0.000054847027,0.00007585821,0.000117734395,0.00019209873,0.00009935391,0.00021445002,0.00019171338,7.1860916e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067066174,0.00041588466,0.9522657,0.00018079355,0.00006630274,6.33377e-8,0.038322687,0.00006465926,0.00012383892,0.0001951014,0.0005671019,0.0071272217],"study_design_scores_gemma":[0.0041990075,0.0027778544,0.9559543,0.00019894745,0.000081267746,0.0000023067414,0.028899293,0.001144366,0.0012007278,0.0031052607,0.002355089,0.000081590646],"about_ca_topic_score_codex":0.0006828162,"about_ca_topic_score_gemma":0.00031189053,"teacher_disagreement_score":0.015268493,"about_ca_system_score_codex":0.00006491962,"about_ca_system_score_gemma":0.00064368086,"threshold_uncertainty_score":0.37193957},"labels":[],"label_agreement":null},{"id":"W2560635244","doi":"10.1093/annonc/mdw544","title":"3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2062,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Cancer; Male breast cancer","score_opus":0.2306265813022292,"score_gpt":0.5370334859628867,"score_spread":0.30640690466065745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560635244","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38615918,0.001269282,0.00012667019,0.6005257,0.0021932835,0.00058954355,0.0007294832,0.000045066605,0.008361828],"genre_scores_gemma":[0.9652876,0.0034551779,0.002380011,0.016168797,0.0013902182,0.00028308528,0.00003949986,0.000027177543,0.010968384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99909484,0.000025608551,0.00035207078,0.00020458587,0.00009809203,0.00022478687],"domain_scores_gemma":[0.99810326,0.0003150466,0.00018424321,0.00011662088,0.0011880802,0.000092764625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015083504,0.000114959046,0.00035998356,0.000090726375,0.000026895661,0.0000014486982,0.00008897664,0.000107306536,0.0012860763],"category_scores_gemma":[0.00015676826,0.000075804215,0.00013213973,0.00005371514,0.00015579791,0.000032532847,0.00002962347,0.00004375785,0.000016024745],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004780488,0.0004627411,0.007269146,0.00002771368,0.0004922017,0.000026459658,0.0000454639,0.000008086417,0.043121543,0.00044770484,0.47714254,0.4661759],"study_design_scores_gemma":[0.010007045,0.0022722604,0.009419343,0.00009414365,0.00014060551,0.00014541647,0.000036952963,0.00003552597,0.024102574,0.0006882215,0.9529472,0.00011072889],"about_ca_topic_score_codex":0.00010674719,"about_ca_topic_score_gemma":0.00015748735,"teacher_disagreement_score":0.58435684,"about_ca_system_score_codex":0.00008388021,"about_ca_system_score_gemma":0.00035613976,"threshold_uncertainty_score":0.9996269},"labels":[],"label_agreement":null},{"id":"W2560862072","doi":"10.1093/annonc/mdw663","title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Eisai; Clovis Oncology; F. Hoffmann-La Roche; Eisai Canada; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Gynecologic cancer; Cancer; Ovarian cancer; Gynecology; Oncology; Disease; Internal medicine","score_opus":0.14624053974814977,"score_gpt":0.40663889857462115,"score_spread":0.2603983588264714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560862072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80298865,0.0039539803,0.00001142567,0.18875766,0.0010774313,0.00056550355,0.00037790692,0.000014624851,0.0022528027],"genre_scores_gemma":[0.9917838,0.005217985,0.000052588508,0.002058615,0.000106201296,0.00022066338,0.0000027189396,0.000010397401,0.00054702285],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988289,0.00012580222,0.0003737276,0.00025873986,0.00016280978,0.00025001625],"domain_scores_gemma":[0.99839866,0.00033073063,0.0003458937,0.00036502612,0.00039872917,0.00016097858],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015559333,0.00014351441,0.00047347095,0.000049970586,0.000033143773,0.0000025735603,0.00015177506,0.00009301405,0.0018240223],"category_scores_gemma":[0.0002474369,0.000071011134,0.00017598677,0.0001165801,0.00036773112,0.000021690073,0.00008757106,0.0000869536,0.0000075108405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017001935,0.0018374851,0.31942332,0.00018222751,0.0006954136,0.00007432808,0.00043060238,0.000006063112,0.0017985954,0.0063589825,0.034000415,0.6334924],"study_design_scores_gemma":[0.0037109072,0.0022384687,0.82522744,0.000909542,0.00035534764,0.000006792064,0.000046316036,0.00001608782,0.0073583354,0.0013514714,0.15864806,0.00013123485],"about_ca_topic_score_codex":0.0006191766,"about_ca_topic_score_gemma":0.00092596136,"teacher_disagreement_score":0.63336116,"about_ca_system_score_codex":0.00015139962,"about_ca_system_score_gemma":0.0012157355,"threshold_uncertainty_score":0.99908847},"labels":[],"label_agreement":null},{"id":"W2560928882","doi":"10.1093/annonc/mdw662","title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Eisai Canada; Cancer Research UK; F. Hoffmann-La Roche; Pfizer","keywords":"Medicine; Ovarian cancer; Clinical trial; Oncology; Germ cell tumors; Serous fluid; Randomized controlled trial; Internal medicine; Consensus conference; Gynecology; Cancer; Chemotherapy","score_opus":0.35440996851121664,"score_gpt":0.47570331080435985,"score_spread":0.1212933422931432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560928882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75431657,0.0017548178,0.0015392259,0.22889368,0.0052543627,0.005316892,0.00075768825,0.000044695527,0.002122074],"genre_scores_gemma":[0.9921562,0.0018274729,0.0013117582,0.0027084053,0.0005158817,0.00087875954,0.0000046716605,0.000024092125,0.0005727752],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974647,0.00048475334,0.0009928079,0.00044881945,0.00019806196,0.00041085505],"domain_scores_gemma":[0.9950665,0.0027790638,0.00081536075,0.00047809852,0.0006943233,0.00016664062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010761725,0.0002274641,0.0010818528,0.00007203108,0.000066067354,0.0000063904995,0.00027663112,0.0003335284,0.001008824],"category_scores_gemma":[0.0012389737,0.00012074111,0.00044085216,0.0001454611,0.0005664675,0.000035482695,0.00008879734,0.00016410097,0.0000046208424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13359052,0.0055748234,0.08949239,0.00023275333,0.002811516,0.00010366025,0.0007102401,0.000031992266,0.0016745506,0.013327729,0.122578956,0.6298709],"study_design_scores_gemma":[0.25671884,0.062758006,0.42587608,0.0017830362,0.0021867682,0.00005298686,0.0002826326,0.00014524,0.025244338,0.007386262,0.21691635,0.0006494488],"about_ca_topic_score_codex":0.00054599013,"about_ca_topic_score_gemma":0.00071843265,"teacher_disagreement_score":0.62922144,"about_ca_system_score_codex":0.00015926272,"about_ca_system_score_gemma":0.0025947832,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W2561439167","doi":"10.1093/annonc/mdw665","title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; University of Toronto; Sunnybrook Health Science Centre; Canadian Red Cross Society","funders":"Eisai; Genentech; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; F. Hoffmann-La Roche","keywords":"Medicine; Bevacizumab; Adjuvant; Adjuvant therapy; Triple-negative breast cancer; Breast cancer; Oncology; Randomized controlled trial; Internal medicine; Surgery; Cancer; Chemotherapy","score_opus":0.06968499473878104,"score_gpt":0.4052475702943823,"score_spread":0.33556257555560126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561439167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251217,0.0014891425,0.000017864339,0.0039770193,0.00016689762,0.0011302665,0.0003891816,0.000004192451,0.0003132835],"genre_scores_gemma":[0.99668854,0.002697848,0.000068926434,0.00016882044,0.00013626757,0.00012795745,0.00001771648,0.000012141707,0.00008180482],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997764,0.00076643686,0.00071594625,0.0003453674,0.00015471393,0.00025351794],"domain_scores_gemma":[0.99810565,0.0006576296,0.0006443305,0.00023869096,0.0003122044,0.00004152313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012141145,0.00018901774,0.00077951944,0.00006340493,0.00007241716,0.0000034052455,0.00016551404,0.00014808831,0.000017795579],"category_scores_gemma":[0.00069857156,0.000104935454,0.00015491273,0.0001669577,0.00042368696,0.000008843816,0.000114877344,0.00008255465,3.0476917e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78411096,0.0003681135,0.0003682331,0.0000032075693,0.00042872087,0.000001676096,0.00070321833,0.000006285827,0.018797902,0.000014829666,0.00016261343,0.1950342],"study_design_scores_gemma":[0.93900895,0.005587197,0.021411758,0.00008310435,0.0000985372,0.000008527339,0.00010881731,0.00001205794,0.033075135,0.0000843391,0.00038886466,0.00013269915],"about_ca_topic_score_codex":0.001173687,"about_ca_topic_score_gemma":0.0003118782,"teacher_disagreement_score":0.19490151,"about_ca_system_score_codex":0.0000387136,"about_ca_system_score_gemma":0.00035967794,"threshold_uncertainty_score":0.42791438},"labels":[],"label_agreement":null},{"id":"W2562028759","doi":"10.1093/annonc/mdv340.05","title":"Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; FOLFIRI; Ramucirumab; Internal medicine; Clinical endpoint; Irinotecan; Bevacizumab; Progression-free survival; Hazard ratio; KRAS; Oncology; Population; Fluorouracil; Adverse effect; Colorectal cancer; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval","score_opus":0.08266802494232954,"score_gpt":0.38261422849642773,"score_spread":0.2999462035540982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562028759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96617544,0.0258952,0.000007759012,0.00031524987,0.000027679485,0.0074031916,0.00011339497,0.000013814392,0.000048270154],"genre_scores_gemma":[0.9873662,0.011245506,0.00032065556,0.00009291443,0.0000089961295,0.0007042244,0.00020391923,0.00003023343,0.000027347687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965159,0.0004776015,0.0014424573,0.0006157806,0.000548013,0.00040022633],"domain_scores_gemma":[0.9966421,0.000746571,0.0013389176,0.00026976335,0.000783019,0.00021963878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011396338,0.00044072326,0.0032341236,0.00042631585,0.00009439462,0.000014316456,0.000084659,0.000101543395,0.000010516513],"category_scores_gemma":[0.0004322251,0.00025867965,0.00013399527,0.00077671703,0.0003719837,0.00021188195,0.00012724656,0.00019340761,8.005948e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92017573,0.007979421,0.037950512,0.0015691054,0.005879747,0.0002077389,0.008040991,0.000011627349,0.00004596723,7.6375267e-7,0.00004094819,0.018097451],"study_design_scores_gemma":[0.87271065,0.09429259,0.024086636,0.0014685469,0.0043087495,0.00003173718,0.0016935286,0.0002745428,0.00083787425,0.0000025020433,0.000036967736,0.0002556645],"about_ca_topic_score_codex":0.0013289921,"about_ca_topic_score_gemma":0.0037438131,"teacher_disagreement_score":0.086313166,"about_ca_system_score_codex":0.0002280259,"about_ca_system_score_gemma":0.0004221171,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W2562686592","doi":"10.1093/annonc/mdw671","title":"Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; Women's College Hospital; University Health Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Dexrazoxane; Cardiotoxicity; Ejection fraction; Heart failure; Internal medicine; Odds ratio; Cardiology; Anthracycline; Cancer; Breast cancer; Chemotherapy","score_opus":0.36389521577638845,"score_gpt":0.5132624710771325,"score_spread":0.14936725530074407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562686592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000119262195,0.96022666,0.034071174,0.0017442249,0.00023398554,0.0024838117,0.00022433014,0.00005401761,0.00094990124],"genre_scores_gemma":[0.00047223116,0.9917427,0.003590817,0.00075377396,0.0011098358,0.0010826264,0.0002497919,0.000089202505,0.00090903154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676,0.00047282627,0.0015448497,0.0005680701,0.00020969106,0.00044453546],"domain_scores_gemma":[0.9967533,0.0008490841,0.0010838748,0.0006616522,0.00044907173,0.00020304459],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020073587,0.00039453118,0.008385305,0.0006112485,0.00006683085,0.000011866677,0.00022176058,0.00055208843,0.00015384072],"category_scores_gemma":[0.00046812918,0.00027908979,0.017376192,0.000950535,0.00007129777,0.000056154324,0.00007741762,0.00022504575,0.000012689996],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041727115,0.0001654379,0.0000014315565,0.011462054,0.16661152,0.000019877722,0.00004260584,0.0000082309225,0.000007916496,0.00015054383,0.0037204216,0.8177682],"study_design_scores_gemma":[0.00032715205,0.0007352769,0.0000033585009,0.0031491725,0.2805326,0.000059152546,0.000011972309,0.0000017900048,0.00007885233,0.00023160543,0.7146867,0.0001823761],"about_ca_topic_score_codex":0.000014878838,"about_ca_topic_score_gemma":0.000048177433,"teacher_disagreement_score":0.8175859,"about_ca_system_score_codex":0.000079494814,"about_ca_system_score_gemma":0.0003841411,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W2562790498","doi":"10.1093/annonc/mdw607","title":"Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Dasatinib; Gemcitabine; Medicine; Internal medicine; Placebo; Oncology; Clinical endpoint; Pancreatic cancer; Phases of clinical research; Clinical trial; Cancer; Pathology; Tyrosine kinase","score_opus":0.11360953834422417,"score_gpt":0.4626879517170715,"score_spread":0.34907841337284734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562790498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805884,0.0001235812,0.0011522762,0.00584437,0.00016550091,0.008543984,0.00014242086,0.000017966233,0.0034215245],"genre_scores_gemma":[0.9907433,0.00026658893,0.0032734745,0.0006225532,0.00022513715,0.0028787146,0.00003556437,0.000035501726,0.0019192037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99761194,0.00014601942,0.0009054439,0.0003757483,0.00041155866,0.00054928975],"domain_scores_gemma":[0.9955536,0.0018177474,0.00051291985,0.00040688858,0.001393098,0.0003157189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086573005,0.00023108964,0.0019798041,0.00026860944,0.0000517202,0.0000028192471,0.00018398165,0.00022485679,0.00042230965],"category_scores_gemma":[0.0012033137,0.00013203853,0.00018490598,0.00023555603,0.00031424063,0.00008058104,0.000051165516,0.000115347575,0.000011978523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89862394,0.0049966937,0.006268441,0.00012929043,0.0008785509,0.000007598713,0.00020111154,0.0000032462422,0.002555847,0.00019787464,0.0022748837,0.083862536],"study_design_scores_gemma":[0.8836493,0.10357413,0.0013255423,0.00031767605,0.0005530654,0.0000024702047,0.00006108796,0.00003573258,0.00336354,0.00012538982,0.0068415347,0.00015051538],"about_ca_topic_score_codex":0.00007443361,"about_ca_topic_score_gemma":0.00009893265,"teacher_disagreement_score":0.09857743,"about_ca_system_score_codex":0.0000952332,"about_ca_system_score_gemma":0.0012607254,"threshold_uncertainty_score":0.5384375},"labels":[],"label_agreement":null},{"id":"W2563958965","doi":"10.1093/annonc/mdw673","title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":212,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; AstraZeneca; Pfizer; McGill University; Amgen","keywords":"Medicine; Tamoxifen; Placebo; Internal medicine; Breast cancer; Meta-analysis; Randomized controlled trial; Oncology; Relative risk; Adjuvant therapy; Aromatase inhibitor; Adjuvant; Gynecology; Cancer; Confidence interval; Pathology","score_opus":0.04694015671354284,"score_gpt":0.383392683506923,"score_spread":0.33645252679338017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563958965","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030626396,0.98944837,0.0000018063712,0.00012999306,0.000015930795,0.0060879085,0.0012079227,0.0000020397367,0.000043362277],"genre_scores_gemma":[0.005449154,0.9924609,0.000017083781,0.00008652637,0.000017274248,0.0018464803,0.000068193236,0.000021305934,0.000033054086],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98972017,0.006286505,0.0031631833,0.00040541493,0.00018497983,0.00023974454],"domain_scores_gemma":[0.99289423,0.0016677463,0.004656052,0.00041575514,0.0002556502,0.00011057216],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009758377,0.00044806747,0.042498756,0.00038830837,0.000013805747,0.000004246823,0.00016355849,0.0005247391,0.000021602544],"category_scores_gemma":[0.0013707092,0.0001997446,0.0025493756,0.00033247872,0.00037724496,0.000004728625,0.0000940702,0.00013210249,2.0384499e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017487705,0.00018227202,0.0000017641615,0.32158127,0.65685827,0.000014317123,0.000038732724,0.0000013168998,0.00042209172,0.000017115599,0.00008886109,0.0033062736],"study_design_scores_gemma":[0.034442976,0.0014802993,0.0000011031799,0.021525742,0.9410963,0.00008119581,0.000011293936,6.340839e-7,0.00023790268,0.000008353957,0.0008498011,0.00026436435],"about_ca_topic_score_codex":0.00006352175,"about_ca_topic_score_gemma":0.000010905135,"teacher_disagreement_score":0.30005553,"about_ca_system_score_codex":0.000020428386,"about_ca_system_score_gemma":0.00038214415,"threshold_uncertainty_score":0.97171634},"labels":[],"label_agreement":null},{"id":"W2564457125","doi":"10.1093/annonc/mdw682","title":"Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Clinical trial; Protocol (science); Confidence interval; Internal medicine; MEDLINE; Clinical Oncology; Oncology; Family medicine; Alternative medicine; Cancer; Pathology","score_opus":0.987881683864212,"score_gpt":0.7759222350249599,"score_spread":0.2119594488392521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564457125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78728133,0.0012130558,0.0026742993,0.15834266,0.0005691069,0.03648771,0.0003197484,0.000005650273,0.013106409],"genre_scores_gemma":[0.9923763,0.00057576905,0.0029238265,0.0005353159,0.000112609865,0.0025286132,0.000007284348,0.000009355203,0.00093088916],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.64784956,0.27007,0.0724658,0.002120723,0.0064596375,0.0010342927],"domain_scores_gemma":[0.27645627,0.69163644,0.022437898,0.004009446,0.005186103,0.00027381707],"candidate_categories":["metaresearch","sts"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.54441863,0.00018598972,0.010380407,0.0008096912,0.000058265392,0.000083988,0.0018490278,0.00040526022,0.00083122036],"category_scores_gemma":[0.72596073,0.000073400966,0.0009721945,0.001175457,0.0028193614,0.00020780125,0.00045368625,0.00043569654,0.00003252893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031788447,0.001958888,0.568364,0.00004382303,0.00022209795,0.0000015179685,0.0002352859,2.9559985e-7,0.000018103938,0.057572354,0.10485046,0.2635543],"study_design_scores_gemma":[0.012933599,0.005205193,0.31222883,0.0000480617,0.000052500356,0.0000012127842,0.0008355568,0.000028917462,0.000013946683,0.02659477,0.64198136,0.00007601831],"about_ca_topic_score_codex":0.00024905344,"about_ca_topic_score_gemma":0.0013306577,"teacher_disagreement_score":0.53713095,"about_ca_system_score_codex":0.000049690316,"about_ca_system_score_gemma":0.001687846,"threshold_uncertainty_score":0.9998944},"labels":[],"label_agreement":null},{"id":"W2564775203","doi":"10.1093/annonc/mdw653","title":"Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Credit Valley Hospital; Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; Queen's University; Princess Margaret Cancer Centre; Royal Victoria Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre; McGill University Health Centre","funders":"Canadian Cancer Society Research Institute; Eli Lilly Canada; Roche Canada","keywords":"Medicine; Internal medicine; Transplantation; Salvage therapy; Autologous stem-cell transplantation; Neutropenia; Gemcitabine; Febrile neutropenia; Surgery; Aggressive lymphoma; Chemotherapy regimen; Adverse effect; Chemotherapy; Oncology; Lymphoma; Rituximab","score_opus":0.029004844295455367,"score_gpt":0.3193116384750785,"score_spread":0.29030679417962313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564775203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194115,0.00025716505,0.00013442924,0.0042772787,0.00014405865,0.0023853644,0.0007901217,0.000024126835,0.000046276815],"genre_scores_gemma":[0.99618036,0.00094182405,0.00020168311,0.0016891528,0.00006086014,0.0005114325,0.00027846335,0.000029831182,0.00010641569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829835,0.00015526,0.0005053294,0.00047815236,0.00025041908,0.00031250616],"domain_scores_gemma":[0.99720716,0.0012857255,0.0007312142,0.0003493374,0.00026817524,0.0001583742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011863408,0.00031097396,0.0009934019,0.0001531086,0.00011094116,0.0000127070025,0.00008843362,0.0001790005,0.000043225682],"category_scores_gemma":[0.000043270433,0.00014781364,0.0002758278,0.00015181923,0.00008869236,0.00011914578,0.000013429383,0.000028839864,0.0000025998197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054146256,0.009316458,0.59632546,0.000019965988,0.002891301,0.000051284365,0.0030625404,0.0000012775524,0.000046843455,0.000003066411,0.00066677714,0.33346874],"study_design_scores_gemma":[0.23226924,0.01824243,0.74348146,0.00009795422,0.0021426333,0.0000013076069,0.00016741097,0.0000039379483,0.001527647,0.0000070870033,0.001913728,0.00014517253],"about_ca_topic_score_codex":0.00023736821,"about_ca_topic_score_gemma":0.00024812805,"teacher_disagreement_score":0.33332357,"about_ca_system_score_codex":0.00026441232,"about_ca_system_score_gemma":0.00012010704,"threshold_uncertainty_score":0.6027665},"labels":[],"label_agreement":null},{"id":"W2564893835","doi":"10.1093/annonc/mdw372.09","title":"Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Cohort; Adenocarcinoma; Cancer; Prostate; Clinical trial; Phases of clinical research; Immunotherapy","score_opus":0.04219005847890556,"score_gpt":0.33884572222919324,"score_spread":0.2966556637502877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564893835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838497,0.0006083554,0.000019266654,0.012377168,0.00014106827,0.0021839235,0.0003704499,0.000020781155,0.0004292587],"genre_scores_gemma":[0.9976158,0.00017842639,0.0002028684,0.0011898276,0.00008689344,0.00016642752,0.000054541582,0.000021996095,0.0004832289],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998729,0.00009446518,0.00041173407,0.0003099828,0.00019373276,0.00026110822],"domain_scores_gemma":[0.9981032,0.000769559,0.0002998633,0.00042705552,0.00034480417,0.00005553703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029075082,0.00014539559,0.0003568439,0.000041303574,0.00006942854,0.0000036940794,0.0001512861,0.00007900179,0.000025419366],"category_scores_gemma":[0.00020587147,0.00006725983,0.000093768045,0.000097993354,0.0001849974,0.000074107455,0.000039760842,0.00007069109,0.0000042247493],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.548891,0.002495423,0.11486348,0.00002130125,0.0005596954,0.000018784925,0.0026784895,9.1230044e-7,0.00097385864,0.000006707148,0.014722168,0.3147682],"study_design_scores_gemma":[0.049891837,0.09039187,0.82622063,0.00012637985,0.000114852286,0.000003758729,0.0005192918,0.000002102268,0.0015059047,0.00007794941,0.031035414,0.000109988956],"about_ca_topic_score_codex":0.00016115808,"about_ca_topic_score_gemma":0.00006669464,"teacher_disagreement_score":0.7113572,"about_ca_system_score_codex":0.000046142683,"about_ca_system_score_gemma":0.00022765133,"threshold_uncertainty_score":0.27427766},"labels":[],"label_agreement":null},{"id":"W2565605421","doi":"10.1093/annonc/mdv336.16","title":"Does body mass index impact on clinical outcomes in her-2 positive metastatic breast cancer?","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Underweight; Internal medicine; Overweight; Body mass index; Breast cancer; Metastatic breast cancer; Multivariate analysis; Proportional hazards model; Univariate analysis; Oncology; Trastuzumab; Cancer","score_opus":0.07145782680717686,"score_gpt":0.4521574238980306,"score_spread":0.38069959709085377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565605421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982716,0.0071493085,0.000019225683,0.0009163839,0.00060577114,0.00018235236,0.00031609347,0.0000052008813,0.0009785295],"genre_scores_gemma":[0.9868498,0.009798601,0.00006327511,0.0027714348,0.0002673107,0.000036803973,0.00003940999,0.000018430886,0.0001549486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983186,0.00038064105,0.00046788272,0.0003308954,0.00015384154,0.0003481364],"domain_scores_gemma":[0.9989689,0.00008986848,0.00023501136,0.00027814345,0.00023730799,0.0001907794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007555697,0.00018911746,0.00062063464,0.0000769172,0.000015406637,0.00000721707,0.0002078819,0.00021287976,0.0000662196],"category_scores_gemma":[0.00016241388,0.00011379827,0.00022690502,0.00009119733,0.00015692935,0.0000067578453,0.00005958462,0.00016581976,0.000009483074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019811983,0.0011728532,0.74855363,0.000018962943,0.00082047575,0.000031598887,0.00009984387,0.0002586419,0.0025097902,0.00009591026,0.010989285,0.23346782],"study_design_scores_gemma":[0.0043305648,0.0060996176,0.89518434,0.000037705813,0.00008622669,0.000008820644,0.00028776002,0.000051228395,0.017101707,0.0013642014,0.07503533,0.00041246967],"about_ca_topic_score_codex":0.00054201554,"about_ca_topic_score_gemma":0.00041012527,"teacher_disagreement_score":0.23305534,"about_ca_system_score_codex":0.000034056913,"about_ca_system_score_gemma":0.00055977347,"threshold_uncertainty_score":0.46405587},"labels":[],"label_agreement":null},{"id":"W2566055673","doi":"10.1093/annonc/mdv343.02","title":"Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Erlotinib; Clinical endpoint; Lung cancer; Oncology; Gefitinib; Progression-free survival; Chemotherapy; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.042023443954744014,"score_gpt":0.41986721954357664,"score_spread":0.37784377558883264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566055673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928443,0.0007035201,0.00014360831,0.002373215,0.00024824814,0.0016633762,0.00039434142,0.000014202902,0.0016151816],"genre_scores_gemma":[0.9970205,0.000030592997,0.00059854204,0.0018535247,0.00008834356,0.00006931904,0.00025707696,0.000018574212,0.0000635631],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982384,0.00018143906,0.00064823846,0.0002630759,0.0004473045,0.0002215332],"domain_scores_gemma":[0.99772215,0.00034519046,0.0008241996,0.00050266035,0.0005013631,0.000104417966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031971256,0.00021345803,0.0009252829,0.00007182637,0.00006663894,0.000005413336,0.00021409552,0.0001166069,0.00027964453],"category_scores_gemma":[0.00014136542,0.00010883769,0.00043257297,0.00067493715,0.00016822289,0.000075245574,0.000024649098,0.000113671515,6.953501e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33120328,0.011169014,0.5402516,0.00005890414,0.024758974,0.000019545143,0.008018093,0.001764131,0.00081076904,0.00015595576,0.003962306,0.0778274],"study_design_scores_gemma":[0.75802964,0.03276998,0.16963394,0.00025634858,0.0061943056,0.0000012821822,0.0013434486,0.0016260357,0.017086433,0.00028314878,0.012397861,0.0003775913],"about_ca_topic_score_codex":0.00043976752,"about_ca_topic_score_gemma":0.00020114293,"teacher_disagreement_score":0.42682636,"about_ca_system_score_codex":0.00010623166,"about_ca_system_score_gemma":0.0010244278,"threshold_uncertainty_score":0.4438272},"labels":[],"label_agreement":null},{"id":"W2566519625","doi":"10.1093/annonc/mdv341.09","title":"Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Taxane; Docetaxel; Gemcitabine; Oncology; Meta-analysis; Paclitaxel; Confidence interval; Carboplatin; Adverse effect; Chemotherapy; Clinical trial; Cancer; Breast cancer; Cisplatin","score_opus":0.23291121346663723,"score_gpt":0.43319080693029927,"score_spread":0.20027959346366203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566519625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86861384,0.016979609,0.0012267355,0.105804816,0.00017547325,0.0040751398,0.000639373,0.00014019641,0.002344812],"genre_scores_gemma":[0.9667445,0.004869288,0.0041668895,0.017241985,0.00036882327,0.0012074177,0.000068925525,0.000106624335,0.0052255434],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982852,0.000072190174,0.00047263422,0.00045941237,0.0003291961,0.0003814131],"domain_scores_gemma":[0.9982337,0.00022276561,0.00033695166,0.00036228128,0.0005577058,0.00028662232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040488996,0.00032544715,0.0019165884,0.00020951671,0.000053529646,0.000011726377,0.00011317214,0.00018218352,0.0008781452],"category_scores_gemma":[0.00008418449,0.00018891277,0.00045213616,0.00045651014,0.00019418997,0.000080339385,0.000022085422,0.000118250944,0.0000042495667],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19206773,0.0070433794,0.019645594,0.00033514982,0.56536174,0.00038754725,0.008015165,0.00037649335,0.0023370327,0.00025743194,0.030862099,0.17331064],"study_design_scores_gemma":[0.08751184,0.11533819,0.008047633,0.00004458726,0.1369585,0.0003067203,0.0005732667,0.0004357017,0.03724929,0.0014222646,0.611137,0.00097503024],"about_ca_topic_score_codex":0.0021471719,"about_ca_topic_score_gemma":0.0024343324,"teacher_disagreement_score":0.5802749,"about_ca_system_score_codex":0.000056115317,"about_ca_system_score_gemma":0.0007773278,"threshold_uncertainty_score":0.96150744},"labels":[],"label_agreement":null},{"id":"W2567343182","doi":"10.1093/annonc/mdv341.14","title":"Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Internal medicine; Sorafenib; Population; Renal cell carcinoma; Gastroenterology; Oncology; Surgery; Hepatocellular carcinoma","score_opus":0.167415488593777,"score_gpt":0.3621885307379039,"score_spread":0.1947730421441269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567343182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900874,0.0017063695,0.00005851266,0.0025405332,0.00010255133,0.0011865662,0.00006261694,0.000034136796,0.004221349],"genre_scores_gemma":[0.9913619,0.00006431105,0.006361549,0.00021158895,0.00017678183,0.00014428936,0.00015872833,0.000048670667,0.0014721891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815434,0.00011632242,0.00052144035,0.0004260239,0.0003160255,0.0004658638],"domain_scores_gemma":[0.99812686,0.00015340892,0.00033293312,0.00042590336,0.00046326843,0.0004976446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026162202,0.00031972417,0.00087338075,0.00021026768,0.00007286139,0.0000075270905,0.00008848652,0.00010495691,0.000033736174],"category_scores_gemma":[0.00006388593,0.00021583006,0.00020968053,0.00018373583,0.00014171605,0.000069408066,0.000044558798,0.00010299418,0.000016650794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038852293,0.009757806,0.035724565,0.0014438091,0.0011062037,0.0054166764,0.0038010199,0.00045671526,0.8471696,0.00019160508,0.018804075,0.03727563],"study_design_scores_gemma":[0.02067631,0.058550894,0.01287034,0.00014880803,0.0007091046,0.00047232347,0.0004297045,0.0001309899,0.8475376,0.00010019895,0.05808918,0.00028457987],"about_ca_topic_score_codex":0.00025740766,"about_ca_topic_score_gemma":0.000040018636,"teacher_disagreement_score":0.04879309,"about_ca_system_score_codex":0.00039601556,"about_ca_system_score_gemma":0.00056012615,"threshold_uncertainty_score":0.88012946},"labels":[],"label_agreement":null},{"id":"W2580802759","doi":"10.1093/annonc/mdx010","title":"Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai; Clovis Oncology; F. Hoffmann-La Roche; Eisai Canada; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Consensus conference; Ovarian cancer; Deliberation; Family medicine; Epithelial ovarian cancer; Clinical trial; Disease; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.22618192601324963,"score_gpt":0.4375265894691654,"score_spread":0.21134466345591577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580802759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544903,0.0019726984,7.1022487e-7,0.0360968,0.00024548586,0.00033956143,0.00009877534,0.000010555008,0.0067450893],"genre_scores_gemma":[0.99221224,0.005638728,0.00024182291,0.0017004512,0.000047316025,0.000051375755,0.000010182104,0.000010263071,0.000087613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991946,0.000050944025,0.00022278457,0.00021131514,0.00012667567,0.00019364044],"domain_scores_gemma":[0.9989376,0.00010963886,0.0003102256,0.00032788783,0.000181314,0.00013331126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009565289,0.00012996863,0.00046872723,0.000050808965,0.0001248723,0.000020569063,0.00007467065,0.00012645667,0.00051326014],"category_scores_gemma":[0.00007284454,0.00009291445,0.00006745204,0.000021760397,0.00026289772,0.000028981696,0.000045704972,0.00008831709,0.0000026282805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058170594,0.0007139079,0.37463465,0.000026187125,0.00069756736,0.000088520326,0.0033050582,4.3170536e-7,0.00027347042,0.0019865264,0.0076959473,0.609996],"study_design_scores_gemma":[0.0045603137,0.0031519816,0.7537132,0.000066254324,0.00006571168,0.000011277828,0.00020778355,0.000004309118,0.0057431804,0.0004219293,0.23196405,0.00009001532],"about_ca_topic_score_codex":0.0017080004,"about_ca_topic_score_gemma":0.0001632342,"teacher_disagreement_score":0.609906,"about_ca_system_score_codex":0.000025503137,"about_ca_system_score_gemma":0.00037593432,"threshold_uncertainty_score":0.5619839},"labels":[],"label_agreement":null},{"id":"W2582960575","doi":"10.1093/annonc/mdx003","title":"PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"Duke Clinical Research Institute; Fondation Gustave Roussy; Canadian Cancer Society Research Institute; Institut Gustave-Roussy; National Cancer Institute; Institut National Du Cancer; Ligue Contre le Cancer; Princess Margaret Cancer Foundation; AstraZeneca","keywords":"Medicine; Immunohistochemistry; Chemotherapy; Lung cancer; Oncology; Adjuvant; KRAS; Internal medicine; Pathology; Cancer; Colorectal cancer","score_opus":0.02672653027178159,"score_gpt":0.3590182722130548,"score_spread":0.33229174194127326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582960575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879507,0.0055570663,0.000033678,0.0020142368,0.00011522163,0.0012657477,0.00033082397,0.000014501592,0.0027180172],"genre_scores_gemma":[0.99623513,0.0012312742,0.00032698273,0.0005239038,0.00009177013,0.00031277147,0.000060379603,0.000038907532,0.0011788845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840695,0.00004997234,0.00058813224,0.00039580386,0.00023458405,0.000324589],"domain_scores_gemma":[0.99793094,0.00010960654,0.0008753703,0.0006761023,0.0003271524,0.00008080584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025358124,0.00023233722,0.00073241803,0.00008096356,0.00007323585,0.000010612579,0.00036603562,0.00038208056,0.0005703252],"category_scores_gemma":[0.00008457308,0.00020030103,0.00015993723,0.00010063288,0.00026156518,0.00008987247,0.00007047659,0.00028105848,0.000001125965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01307945,0.0009789735,0.04421193,0.00025891114,0.00023108591,0.000014423676,0.0011128277,0.0000014149759,0.9229481,2.5819824e-7,0.0064933975,0.010669234],"study_design_scores_gemma":[0.006738804,0.0013392995,0.23362431,0.0011314903,0.000050768525,0.000001294698,0.0001243326,0.00012735334,0.7547631,0.000022115239,0.0019343729,0.00014271431],"about_ca_topic_score_codex":0.0056490214,"about_ca_topic_score_gemma":0.00012615131,"teacher_disagreement_score":0.18941239,"about_ca_system_score_codex":0.00013923648,"about_ca_system_score_gemma":0.0005490821,"threshold_uncertainty_score":0.8539668},"labels":[],"label_agreement":null},{"id":"W2586122800","doi":"10.1093/annonc/mdw388.01","title":"Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Soft tissue sarcoma; Internal medicine; Trabectedin; Chemotherapy; Liposarcoma; Doxorubicin; Sarcoma; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Phases of clinical research; Gastroenterology; Surgery; Oncology; Urology; Randomized controlled trial; Soft tissue; Pathology","score_opus":0.07448211169238557,"score_gpt":0.4098059849627034,"score_spread":0.3353238732703178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586122800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98690075,0.0003285767,0.000034506236,0.0018870368,0.00008785362,0.010368487,0.000010049455,0.00002704037,0.00035570384],"genre_scores_gemma":[0.99762726,0.00012680418,0.00053099915,0.00042124614,0.000015091613,0.0011368647,0.000037596805,0.00004681131,0.000057347464],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622107,0.0009393933,0.001104624,0.0006840764,0.0005088346,0.0005420185],"domain_scores_gemma":[0.9971502,0.0010992925,0.0005856859,0.0005527646,0.00044363906,0.00016840594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012830332,0.0003999131,0.0023606538,0.00046277954,0.00006596923,0.000020665288,0.0003082094,0.00009695268,0.00003949965],"category_scores_gemma":[0.000316724,0.00023821596,0.00005003686,0.0004352749,0.00020336678,0.00032556307,0.00020494431,0.00021028159,0.00001650704],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2214185,0.14649451,0.55832976,0.000022543587,0.0003947633,0.00044634464,0.0015246889,0.000007244216,0.00013262978,0.000016908918,0.00005774712,0.07115433],"study_design_scores_gemma":[0.6110806,0.041770726,0.34410235,0.00040515908,0.00021035169,0.0000058794635,0.0008870117,0.00007743035,0.0011261902,0.000021794829,0.0001315339,0.00018095301],"about_ca_topic_score_codex":0.0019863772,"about_ca_topic_score_gemma":0.005527361,"teacher_disagreement_score":0.38966212,"about_ca_system_score_codex":0.00025481347,"about_ca_system_score_gemma":0.00016124712,"threshold_uncertainty_score":0.97141653},"labels":[],"label_agreement":null},{"id":"W2586144993","doi":"10.1093/annonc/mdx053","title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"European Society for Medical Oncology; American Society of Clinical Oncology","keywords":"Medicine; Cancer drugs; Clinical trial; Food and drug administration; Interquartile range; Drug; Clinical Oncology; Clinical research; Cancer; Internal medicine; Family medicine; Pharmacology","score_opus":0.125701668879619,"score_gpt":0.41326456733722067,"score_spread":0.28756289845760163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586144993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96997094,0.0035746282,0.0009782613,0.0041612936,0.0009826603,0.00047608957,0.0007015548,0.000011932518,0.019142637],"genre_scores_gemma":[0.98471963,0.0076967888,0.004098183,0.000666945,0.00062919786,0.000043419746,0.0000137641155,0.00003159814,0.0021004882],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978943,0.000010132302,0.0013057652,0.00040006908,0.000024039342,0.00036569155],"domain_scores_gemma":[0.9962084,0.00023741045,0.0027700444,0.00043680103,0.00017789386,0.00016944477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087659084,0.00017311986,0.0012555091,0.00009144747,0.0001337244,0.000030929554,0.00035951627,0.0002618807,0.00004704939],"category_scores_gemma":[0.001008419,0.00019786986,0.0001954149,0.00003463976,0.0002735671,0.00032642015,0.00010926676,0.000138474,0.000006749546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072375406,0.0002479653,0.077595025,0.00014099786,0.00019408193,9.913747e-7,0.000730314,0.000016070833,0.00008948611,0.02939818,0.0038228913,0.88704026],"study_design_scores_gemma":[0.0055423984,0.0029855806,0.4993409,0.00010439651,0.000046805904,0.000002890319,0.000114763985,0.0014516204,0.0009181327,0.03778011,0.4511877,0.0005246941],"about_ca_topic_score_codex":0.0007849432,"about_ca_topic_score_gemma":0.00010978773,"teacher_disagreement_score":0.88651556,"about_ca_system_score_codex":0.000051826293,"about_ca_system_score_gemma":0.00030940276,"threshold_uncertainty_score":0.80688983},"labels":[],"label_agreement":null},{"id":"W2586170806","doi":"10.1093/annonc/mdw373.08","title":"Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"Amgen","keywords":"Medicine; Internal medicine; Adverse effect; Interim analysis; Response Evaluation Criteria in Solid Tumors; Cancer; Gastroenterology; Phases of clinical research; Chemotherapy; Surgery; Urology; Clinical trial","score_opus":0.06243164239010057,"score_gpt":0.4239651933169824,"score_spread":0.36153355092688183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586170806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963785,0.000071067494,0.00005681508,0.001465156,0.00017697387,0.00089889,0.0003026375,0.0000055410237,0.00064444874],"genre_scores_gemma":[0.99918604,0.00018231107,0.000053921223,0.00029149716,0.000037654157,0.00007494665,0.000022876893,0.000015153836,0.00013562733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983058,0.0002641416,0.00068339915,0.00023208576,0.00031010163,0.00020449061],"domain_scores_gemma":[0.9984632,0.00019525192,0.00061693153,0.00031650026,0.00034151258,0.00006656667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030844854,0.00015917719,0.0009566963,0.0003069473,0.000018176583,0.000002014285,0.00013060548,0.000065475215,0.0003195567],"category_scores_gemma":[0.00013719224,0.000081998754,0.00023736795,0.0005848234,0.0002677109,0.00008039609,0.000038823076,0.00007958768,0.0000017679429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32397142,0.018695543,0.3688247,0.00024382274,0.010634283,0.000028711296,0.0038212999,0.000087774,0.041445352,0.00015024356,0.00067992206,0.23141693],"study_design_scores_gemma":[0.40108037,0.03486912,0.43769848,0.0008055104,0.008407213,0.0000031551594,0.00021339188,0.00023021699,0.11410589,0.00019604027,0.0020748717,0.0003157376],"about_ca_topic_score_codex":0.0015978732,"about_ca_topic_score_gemma":0.0008562185,"teacher_disagreement_score":0.23110119,"about_ca_system_score_codex":0.00007187618,"about_ca_system_score_gemma":0.00044089978,"threshold_uncertainty_score":0.34989217},"labels":[],"label_agreement":null},{"id":"W2586187189","doi":"10.1093/annonc/mdw370.03","title":"A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Alberta; University of Toronto; Vancouver General Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"NAPA; Medicine; Internal medicine; Gastroenterology; Placebo; Nausea; Clinical endpoint; Phases of clinical research; Cancer; Progression-free survival; Randomized controlled trial; Clinical trial; Overall survival; Pathology","score_opus":0.1505263278603289,"score_gpt":0.49311956011415614,"score_spread":0.3425932322538272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586187189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907485,0.00017818593,0.000010464352,0.0011960155,0.00084867317,0.004841681,0.00020806014,0.000028623252,0.0019397765],"genre_scores_gemma":[0.99781835,0.00047222103,0.000015361324,0.00049756636,0.000101268255,0.0007278434,0.000022701523,0.0000308613,0.00031380903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948409,0.0027313435,0.0010529716,0.0004879353,0.00030503655,0.00058179686],"domain_scores_gemma":[0.9958615,0.0022193,0.0010098577,0.00025894324,0.00049624895,0.00015416666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017565516,0.00037143912,0.0015401995,0.00022394642,0.00015980385,0.000007858357,0.00046025944,0.00032524072,0.00069837214],"category_scores_gemma":[0.00029524157,0.00020610944,0.0001995164,0.00040004513,0.0010723494,0.00016077183,0.00010733333,0.00046208047,0.000011247169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92557895,0.014502372,0.023074972,0.000024775876,0.0012010381,0.000039986146,0.0021954074,0.000031845913,0.0037080827,0.000056106925,0.0019434959,0.027642937],"study_design_scores_gemma":[0.93987,0.021756418,0.005577152,0.00007152375,0.0003344177,0.0000039948186,0.00052454916,0.00008757102,0.02397621,0.000050214934,0.0074696066,0.0002783384],"about_ca_topic_score_codex":0.00020557735,"about_ca_topic_score_gemma":0.00069225125,"teacher_disagreement_score":0.0273646,"about_ca_system_score_codex":0.00010879479,"about_ca_system_score_gemma":0.0003295023,"threshold_uncertainty_score":0.84048986},"labels":[],"label_agreement":null},{"id":"W2586189263","doi":"10.1093/annonc/mdw371.105","title":"Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Placebo; Hepatocellular carcinoma; Randomized controlled trial; Oncology; Milan criteria; Transplantation; Cancer; Surgery; Clinical trial; Liver transplantation; Phases of clinical research; Immunotherapy; Pathology","score_opus":0.11312320891519345,"score_gpt":0.3784021611375279,"score_spread":0.26527895222233444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586189263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853418,0.002828954,0.0003939409,0.002450186,0.0002664269,0.0063383593,0.00031961413,0.00005545445,0.0020052711],"genre_scores_gemma":[0.99538934,0.00023243565,0.00044037367,0.0004041584,0.0002404936,0.0012937604,0.0002102559,0.00006752321,0.0017216586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996988,0.0003865634,0.0010284916,0.0006487638,0.000298343,0.0006498246],"domain_scores_gemma":[0.99658597,0.0009738038,0.00049969234,0.000564308,0.0010451471,0.0003311131],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075119646,0.00042405236,0.0021827884,0.00027465515,0.00011657372,0.000007908381,0.00018998735,0.00027823995,0.00067967887],"category_scores_gemma":[0.000473283,0.00028208105,0.0007741084,0.0001822077,0.00030969954,0.00014489425,0.000077743694,0.00015018907,0.00006047814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5288787,0.010111996,0.2977415,0.0006266008,0.001558188,0.0016959291,0.005395634,3.957465e-7,0.011800066,0.0001892356,0.0014878388,0.1405139],"study_design_scores_gemma":[0.7245722,0.06900686,0.0011467969,0.00014154502,0.001872704,0.000090142654,0.002342944,0.0002336596,0.16725263,0.0002703164,0.032590237,0.00047997205],"about_ca_topic_score_codex":0.00008449318,"about_ca_topic_score_gemma":0.00007754718,"teacher_disagreement_score":0.2965947,"about_ca_system_score_codex":0.0001266078,"about_ca_system_score_gemma":0.0005546995,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W2586322118","doi":"10.1093/annonc/mdw435.42","title":"Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Vancouver General Hospital; BC Cancer Agency; Ottawa Hospital; University of British Columbia; McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Clinical endpoint; Discontinuation; Lung cancer; T790M; Gastroenterology; Oncology; Cancer; Clinical trial; Epidermal growth factor receptor","score_opus":0.06096577234198846,"score_gpt":0.4218890440377996,"score_spread":0.3609232716958111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586322118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98042995,0.00045938132,0.0002748873,0.007907005,0.0006170006,0.002243559,0.0027815863,0.00002234472,0.0052642715],"genre_scores_gemma":[0.99442977,0.00038983265,0.00033119836,0.0019698795,0.00047360617,0.00026502192,0.0015160689,0.000043131226,0.00058148976],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977687,0.00023580692,0.0006098478,0.00058315217,0.00036990762,0.00043256214],"domain_scores_gemma":[0.99721056,0.0010329188,0.0004827933,0.0006865909,0.00043392638,0.00015320457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035866088,0.00027629393,0.0006595509,0.000102787395,0.00010658357,0.000017683777,0.0003454221,0.00016574652,0.00048612358],"category_scores_gemma":[0.0001628143,0.00015702136,0.00009198386,0.0001974093,0.00016684516,0.00026447317,0.00012696681,0.00019574216,0.000017232129],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22985798,0.021000786,0.4694072,0.00024379043,0.0054595447,0.00056897773,0.012693519,0.00009880967,0.0017495023,0.00042855096,0.0889017,0.16958964],"study_design_scores_gemma":[0.5913413,0.018538553,0.36269745,0.0014002825,0.0025217913,0.000007662478,0.00074994523,0.00072203693,0.0031540836,0.00014257258,0.018039575,0.0006847094],"about_ca_topic_score_codex":0.0036486469,"about_ca_topic_score_gemma":0.0020841274,"teacher_disagreement_score":0.36148337,"about_ca_system_score_codex":0.00024481575,"about_ca_system_score_gemma":0.0012940179,"threshold_uncertainty_score":0.6403145},"labels":[],"label_agreement":null},{"id":"W2586406195","doi":"10.1016/s0923-7534(21)00604-9","title":"446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Afatinib; Erlotinib; Medicine; Lung cancer; Internal medicine; Oncology; Immunohistochemistry; Predictive marker; Adenocarcinoma; Carcinoma; KRAS; Epidermal growth factor receptor; Cancer","score_opus":0.020458390560395893,"score_gpt":0.3443730455752647,"score_spread":0.3239146550148688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586406195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996162,0.00025980017,0.00002522445,0.0011695937,0.000057403595,0.00075223565,0.00046932828,0.000003216608,0.0011012015],"genre_scores_gemma":[0.99920326,0.000012945609,0.00024282899,0.00020383539,0.000011015698,0.00004528949,0.00002916783,0.000011703155,0.00023992127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990619,0.00005447194,0.00040488126,0.0001839843,0.000119781515,0.00017500178],"domain_scores_gemma":[0.99872726,0.00028749456,0.00040497392,0.00021762608,0.0003076402,0.00005499421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516671,0.000107856205,0.0005309334,0.00023635842,0.00002320431,0.0000011631379,0.0000696601,0.00005903171,0.00008580999],"category_scores_gemma":[0.00006987737,0.000057397552,0.00012042123,0.0003678068,0.00015314721,0.000042874177,0.000028713383,0.00003534143,1.4042057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001179618,0.0007390302,0.9925627,0.00022196907,0.0007022514,0.0000032359949,0.0006516471,0.000010490993,0.00073420774,0.000031183015,0.0007246279,0.002439007],"study_design_scores_gemma":[0.0077852537,0.0036568756,0.977794,0.000059871556,0.0015538903,0.0000015051398,0.00018458409,0.00019767953,0.008331121,0.000014461784,0.00035654535,0.000064231455],"about_ca_topic_score_codex":0.00017527443,"about_ca_topic_score_gemma":0.0005751175,"teacher_disagreement_score":0.014768751,"about_ca_system_score_codex":0.000046068293,"about_ca_system_score_gemma":0.00023016908,"threshold_uncertainty_score":0.23406042},"labels":[],"label_agreement":null},{"id":"W2586425418","doi":"10.1093/annonc/mdw385.19","title":"Aspirin utilization, compliance and prevention of colorectal cancer – A single centre perspective","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Upper River Valley Hospital","funders":"","keywords":"Aspirin; Medicine; Colorectal cancer; Population; Prospective cohort study; Cancer; Internal medicine; Diabetes mellitus; Adverse effect; Surgery","score_opus":0.14752445133098815,"score_gpt":0.4220227079253508,"score_spread":0.27449825659436267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586425418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931666,0.00081486424,0.00009824243,0.0028798243,0.0001182303,0.000250422,0.000012829965,0.000009870091,0.0026491093],"genre_scores_gemma":[0.99907076,0.0002928799,0.00013884317,0.00012851848,0.00005831914,0.000009188965,0.0000021319568,0.0000068831,0.0002924429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99941796,0.000066087785,0.0001804908,0.00012659676,0.000086263404,0.00012258027],"domain_scores_gemma":[0.9991799,0.000103280836,0.00016919382,0.00006760384,0.00042088196,0.00005913348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015288533,0.00006500005,0.00027078306,0.000055347773,0.000016068567,7.638491e-7,0.000027249107,0.00008037254,0.00012386272],"category_scores_gemma":[0.00016796043,0.000045842127,0.000043728134,0.00007483983,0.00017110567,0.000042861968,0.000018415694,0.000032386517,0.0000033903145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023784803,0.0010464792,0.14902064,0.0005773672,0.00029467334,0.00003609866,0.0029099816,0.000002184618,0.49980327,0.0060453564,0.0057544,0.33213106],"study_design_scores_gemma":[0.004727648,0.0076835616,0.33005628,0.0011895382,0.000113905946,0.000030227384,0.00063204486,0.000052945168,0.6372961,0.0021745716,0.015881514,0.00016168256],"about_ca_topic_score_codex":0.000038289978,"about_ca_topic_score_gemma":0.00012779133,"teacher_disagreement_score":0.33196938,"about_ca_system_score_codex":0.0000481404,"about_ca_system_score_gemma":0.00015113056,"threshold_uncertainty_score":0.18693878},"labels":[],"label_agreement":null},{"id":"W2586488666","doi":"10.1016/s0923-7534(21)00577-9","title":"419P Optimal follow-up strategy for resected neuroendocrine tumours: A systematic review","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Merkel cell carcinoma; MEDLINE; Population; Systematic review; Prospective cohort study; Retrospective cohort study; Cochrane Library; Incidence (geometry); Oncology; Internal medicine; Meta-analysis; Carcinoma","score_opus":0.2208877204229933,"score_gpt":0.5033366553627243,"score_spread":0.282448934939731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586488666","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000067889605,0.9822155,0.000012967309,0.002821731,0.00035621258,0.012701225,0.00031242843,0.000100379584,0.0014727521],"genre_scores_gemma":[0.000016662685,0.9883184,0.00019691949,0.0008833396,0.0003529921,0.003269085,0.00017734095,0.00018270565,0.0066025993],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99294615,0.0013638089,0.0027029964,0.0009552375,0.0007160864,0.0013157364],"domain_scores_gemma":[0.9920152,0.0029633497,0.0019232437,0.0013740005,0.0012053618,0.00051884673],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008401731,0.00081143255,0.009801904,0.00063085835,0.00006934549,0.000017596463,0.00086349953,0.000064820386,0.00023449991],"category_scores_gemma":[0.009591066,0.0005126083,0.0019264931,0.0006638307,0.00029561436,0.00014973554,0.00026756956,0.00075637916,0.00017697529],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000242275,0.00024048265,2.38679e-7,0.83744746,0.0005452248,0.0037581956,0.0000020457621,8.155188e-8,0.0000049168493,0.00015672485,0.038646188,0.118956156],"study_design_scores_gemma":[0.0011080948,0.0068225586,1.6143119e-7,0.40806812,0.00206765,0.006287047,0.0000059755794,8.198621e-7,0.000030583677,0.00003769581,0.57534826,0.00022301979],"about_ca_topic_score_codex":0.000009505037,"about_ca_topic_score_gemma":0.000010065982,"teacher_disagreement_score":0.5367021,"about_ca_system_score_codex":0.00013185976,"about_ca_system_score_gemma":0.0021080743,"threshold_uncertainty_score":0.99973255},"labels":[],"label_agreement":null},{"id":"W2586528038","doi":"10.1016/s0923-7534(21)00568-8","title":"410P Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Adverse effect; Oncology; Metastatic melanoma; Retrospective cohort study; Confidence interval; Surgery; Immunotherapy; Cancer; Cancer research","score_opus":0.08230944959589033,"score_gpt":0.40613393726275415,"score_spread":0.32382448766686384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586528038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97654665,0.00045403023,0.000008374836,0.013259042,0.00003807121,0.0006193606,0.000012339248,0.000010710293,0.009051429],"genre_scores_gemma":[0.9949755,0.00062423944,0.00046800368,0.00042885437,0.0000366237,0.000035815578,0.0000054896996,0.000017252694,0.0034082027],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985326,0.00025708985,0.00041600238,0.00025063343,0.00018032448,0.00036333568],"domain_scores_gemma":[0.99860024,0.0007980261,0.00007907337,0.00031979752,0.00008841091,0.000114443574],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010200822,0.000110841,0.0005579055,0.0002971559,0.000012226732,0.0000023822595,0.00012138927,0.000104729326,0.00196995],"category_scores_gemma":[0.00044297279,0.00007644503,0.000047625505,0.0002476129,0.0002163412,0.000053839925,0.000095787975,0.00017774188,0.00003215124],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059002535,0.0009037752,0.022693869,0.00010089722,0.000088954985,0.0002938234,0.0017820997,7.4751733e-7,0.14216585,0.00012081193,0.0013063648,0.82464254],"study_design_scores_gemma":[0.048351698,0.018113568,0.71001136,0.00064345193,0.00005756128,0.00027385628,0.0027644937,0.00007159901,0.09431571,0.002457305,0.12253301,0.00040639596],"about_ca_topic_score_codex":0.00030909042,"about_ca_topic_score_gemma":0.0016396382,"teacher_disagreement_score":0.82423615,"about_ca_system_score_codex":0.00008648447,"about_ca_system_score_gemma":0.0004269467,"threshold_uncertainty_score":0.9989424},"labels":[],"label_agreement":null},{"id":"W2586606433","doi":"10.1093/annonc/mdw364.39","title":"Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Confidence interval; Oncology; Estrogen receptor; Prospective cohort study; Adjuvant; Cancer; Lymph node; Stage (stratigraphy); Gynecology","score_opus":0.0477637790261292,"score_gpt":0.354872802774319,"score_spread":0.30710902374818977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586606433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959602,0.00018765208,0.000006826752,0.0013220182,0.00007981264,0.0007427097,0.0012720738,5.7897455e-7,0.00042814304],"genre_scores_gemma":[0.9992803,0.00010408027,0.000016723663,0.00006760992,0.000019642981,0.00044111285,0.0000064163473,0.00000743187,0.00005671802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990366,0.00014953538,0.00020089708,0.00022457994,0.00019504505,0.00019332203],"domain_scores_gemma":[0.99864304,0.00013868354,0.00029175103,0.0002792432,0.0006175499,0.000029747991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024553057,0.00013600952,0.00027646107,0.000022123904,0.00004312949,9.485162e-7,0.00014041226,0.00005917943,0.000023136743],"category_scores_gemma":[0.00010140875,0.000056713376,0.0000850132,0.00009038411,0.00016567881,0.0000034400528,0.000050110506,0.000033972796,6.0163444e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061539467,0.00095819106,0.82138187,0.000005797504,0.0012407651,7.506816e-7,0.0011681567,0.0014535151,0.04250332,0.00002511085,0.0007785222,0.124330044],"study_design_scores_gemma":[0.0021079995,0.0021300393,0.8591397,0.00011776761,0.000053189375,0.0000045934153,0.00006915463,0.0000039115293,0.13612363,0.00012560592,0.00006571048,0.000058713442],"about_ca_topic_score_codex":0.5347118,"about_ca_topic_score_gemma":0.9474509,"teacher_disagreement_score":0.41273907,"about_ca_system_score_codex":0.0014331129,"about_ca_system_score_gemma":0.0047030863,"threshold_uncertainty_score":0.8343073},"labels":[],"label_agreement":null},{"id":"W2586817040","doi":"10.1016/s0923-7534(21)00602-5","title":"444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ceritinib; Medicine; ALK inhibitor; Anaplastic lymphoma kinase; Lung cancer; Pemetrexed; Internal medicine; Docetaxel; Oncology; non-small cell lung cancer (NSCLC); Crizotinib; Chemotherapy","score_opus":0.021495627258612666,"score_gpt":0.36108279209954686,"score_spread":0.3395871648409342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586817040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420047,0.00020047177,0.0000072388243,0.000597805,0.000035076173,0.004398156,0.000044150172,0.000025620902,0.0004910339],"genre_scores_gemma":[0.99870783,0.00023638588,0.00018477572,0.00021072976,0.0000071274094,0.00050684606,0.00003904723,0.000040066927,0.00006717655],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99770397,0.00026005929,0.0009209869,0.00046208248,0.00029407235,0.00035883355],"domain_scores_gemma":[0.99810976,0.00040368704,0.0006682551,0.0003342394,0.00034138578,0.00014267738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025388546,0.0003062629,0.001602634,0.00034342852,0.000033192748,0.0000048683646,0.00006780683,0.0000473886,0.000045782243],"category_scores_gemma":[0.00027664923,0.00017058372,0.000079449725,0.00036645666,0.00024244681,0.00014107418,0.00001988627,0.00007335957,7.593944e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27909186,0.014964544,0.50030303,0.00007191021,0.00087488483,0.0005820733,0.0019192154,0.0000050485783,0.00017466067,0.00000532325,0.000030409241,0.20197703],"study_design_scores_gemma":[0.6468585,0.052454673,0.29739434,0.0005650485,0.0004213802,0.00004655,0.00075714634,0.000007376036,0.0010705156,0.000009863412,0.00023688744,0.00017769012],"about_ca_topic_score_codex":0.00090356334,"about_ca_topic_score_gemma":0.0010806937,"teacher_disagreement_score":0.36776668,"about_ca_system_score_codex":0.00013423954,"about_ca_system_score_gemma":0.00030898512,"threshold_uncertainty_score":0.69562024},"labels":[],"label_agreement":null},{"id":"W2586863229","doi":"10.1093/annonc/mdw390.10","title":"Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Docetaxel; Chemotherapy; Chemotherapy-induced nausea and vomiting; Nausea; Vomiting; Concomitant; Pharmacology; Aprepitant; Internal medicine; Oncology; Anesthesia; Antiemetic","score_opus":0.05935063978607472,"score_gpt":0.3663237423438431,"score_spread":0.30697310255776833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586863229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941905,0.00007164169,0.000048020534,0.003794822,0.000042183467,0.0014120707,0.000044980636,0.000009034936,0.000386756],"genre_scores_gemma":[0.9986904,0.0003895628,0.00043410438,0.00018932942,0.000041651823,0.00006106553,0.0000055324826,0.00002420523,0.00016409993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99847734,0.00009483313,0.0007304014,0.00025226778,0.00018104559,0.00026411493],"domain_scores_gemma":[0.99863386,0.000114372764,0.00067719416,0.00018500327,0.00033059693,0.000058995032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080503325,0.00013908464,0.00057552836,0.00016435687,0.00002432486,0.0000022842817,0.00008291413,0.00012391068,0.000053035143],"category_scores_gemma":[0.00011232354,0.00010558924,0.000094709045,0.00014031478,0.00007256976,0.00007692961,0.000027986694,0.000064433356,2.493459e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01526024,0.0013416186,0.1989066,0.00097542256,0.00037197923,0.0000028701434,0.0005525188,9.756742e-7,0.38356116,0.00022349434,0.0002556797,0.39854744],"study_design_scores_gemma":[0.0120625505,0.0029953546,0.78119415,0.0014313544,0.00003643172,8.639063e-7,0.00007081116,0.000015623285,0.20142859,0.0003441981,0.0003229198,0.00009713487],"about_ca_topic_score_codex":0.00013980233,"about_ca_topic_score_gemma":0.00014671663,"teacher_disagreement_score":0.58228755,"about_ca_system_score_codex":0.00007888549,"about_ca_system_score_gemma":0.00011186401,"threshold_uncertainty_score":0.43058044},"labels":[],"label_agreement":null},{"id":"W2586921579","doi":"10.1093/annonc/mdw383.30","title":"Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Gefitinib; Lung cancer; Tolerability; Population; Oncology; Randomized controlled trial; Gastroenterology; Cancer; Adverse effect; Epidermal growth factor receptor","score_opus":0.01587110195835063,"score_gpt":0.36530185834130474,"score_spread":0.3494307563829541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586921579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97714007,0.00028446323,0.00060907955,0.009780707,0.00015814931,0.008288373,0.00037565205,0.000045030574,0.003318505],"genre_scores_gemma":[0.9892698,0.00037867756,0.002385894,0.0010301069,0.00019622434,0.0031574809,0.00038973405,0.00007747392,0.0031146049],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743223,0.00020239552,0.0008033872,0.00063971244,0.00035408343,0.00056817627],"domain_scores_gemma":[0.99701166,0.0009237264,0.0006219611,0.00035990702,0.0007779037,0.00030481108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025347163,0.00046355303,0.0015497181,0.000315316,0.000115139526,0.000012795934,0.00012147414,0.00018273667,0.000555911],"category_scores_gemma":[0.00014046313,0.0002629271,0.00019897452,0.0003816993,0.00021661277,0.00018895895,0.0000330209,0.00012925161,0.000038983217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9189696,0.008793841,0.004907424,0.00014886743,0.002272485,0.0002465192,0.0054912646,0.0008106018,0.00033641022,0.000020453974,0.002003135,0.055999413],"study_design_scores_gemma":[0.94753695,0.03903473,0.001835867,0.001223618,0.001658856,0.000010324149,0.00020740692,0.00025167386,0.004527563,0.000010478218,0.0033339097,0.0003686306],"about_ca_topic_score_codex":0.00043172378,"about_ca_topic_score_gemma":0.0014825326,"teacher_disagreement_score":0.05563078,"about_ca_system_score_codex":0.0006476472,"about_ca_system_score_gemma":0.0014083055,"threshold_uncertainty_score":0.9999823},"labels":[],"label_agreement":null},{"id":"W2586934550","doi":"10.1093/annonc/mdw435.40","title":"KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Carboplatin; Medicine; Pemetrexed; Pembrolizumab; Oncology; Internal medicine; Gemcitabine; Lung cancer; Cisplatin; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04888819655693708,"score_gpt":0.35420473796828106,"score_spread":0.30531654141134396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586934550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96093255,0.001253833,0.0037458844,0.029931094,0.00019776808,0.0025263121,0.000059218874,0.00011717929,0.0012361768],"genre_scores_gemma":[0.98261225,0.0017358811,0.0023935924,0.011342298,0.00027077075,0.0004651725,0.000058612837,0.00009634079,0.0010250888],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762994,0.00006684486,0.0007441007,0.0005805197,0.00038357868,0.00059499044],"domain_scores_gemma":[0.9976398,0.00034629143,0.00069926836,0.0005579933,0.00059354305,0.0001631053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050443417,0.0003963466,0.000925122,0.00021154602,0.00011857785,0.000010644306,0.00021586013,0.00026096098,0.00057090574],"category_scores_gemma":[0.00012968399,0.00024400988,0.00034992516,0.00027919,0.00042232778,0.00014879987,0.000015950458,0.0001572844,0.000014826101],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43960628,0.001343683,0.002668954,0.00021516696,0.0004566264,0.00004050339,0.00023882376,0.000014090002,0.14404544,0.00007325443,0.002701967,0.4085952],"study_design_scores_gemma":[0.10673046,0.061517075,0.03597818,0.0010227158,0.000091190814,0.0002186785,0.000086193,0.00012366558,0.50079304,0.0007852267,0.29205173,0.0006018173],"about_ca_topic_score_codex":0.00009201727,"about_ca_topic_score_gemma":0.00008885571,"teacher_disagreement_score":0.4079934,"about_ca_system_score_codex":0.00017367772,"about_ca_system_score_gemma":0.0010761739,"threshold_uncertainty_score":0.9950434},"labels":[],"label_agreement":null},{"id":"W2586963550","doi":"10.1093/annonc/mdw368.27","title":"Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; BMI1; Pharmacodynamics; Oncology; Cancer; Dosing; Internal medicine; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Pharmacology; Clinical trial","score_opus":0.2256337365421335,"score_gpt":0.4568286881907551,"score_spread":0.2311949516486216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586963550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793121,0.00047770134,0.00033321016,0.008515108,0.00009551677,0.0011429737,0.00051920826,0.000018417175,0.009585771],"genre_scores_gemma":[0.9949476,0.00023653089,0.000570516,0.000340124,0.00011555617,0.00019268795,0.000014643145,0.000029245502,0.0035530701],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748033,0.00021197244,0.0008933955,0.00045413786,0.0003285797,0.0006315656],"domain_scores_gemma":[0.99797654,0.00049048394,0.0005104371,0.0004132651,0.00038280222,0.00022647745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001178352,0.00021905452,0.0011390387,0.00026037198,0.000059777973,0.0000033500985,0.0002461067,0.00036124737,0.00032138661],"category_scores_gemma":[0.00026984568,0.00016034252,0.00013078812,0.00019846922,0.0005530461,0.00007651943,0.00011408286,0.000267818,0.000011622354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041706446,0.0029394215,0.0023010357,0.00028637698,0.00024580702,0.00016625343,0.0009444944,0.0000026668815,0.9612151,0.0001712792,0.010918757,0.016638173],"study_design_scores_gemma":[0.021818224,0.008296971,0.0017384902,0.00092606485,0.0000850987,0.000020644167,0.0001472194,0.00008317263,0.95310146,0.000118934455,0.013469192,0.00019450688],"about_ca_topic_score_codex":0.0019740483,"about_ca_topic_score_gemma":0.0005497679,"teacher_disagreement_score":0.01764758,"about_ca_system_score_codex":0.00015827394,"about_ca_system_score_gemma":0.0009479816,"threshold_uncertainty_score":0.6538578},"labels":[],"label_agreement":null},{"id":"W2587007369","doi":"10.1093/annonc/mdw390.33","title":"Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Zoledronic acid; Denosumab; Medicine; Urothelial cancer; Oncology; Bone Density Conservation Agents; Cancer; Internal medicine; Osteoporosis; Bone density","score_opus":0.02816356361327357,"score_gpt":0.3513253555109582,"score_spread":0.3231617918976847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587007369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594903,0.0014496935,0.0000030724223,0.0010664185,0.00008621721,0.0011506232,0.000089363966,0.000038463586,0.00016711005],"genre_scores_gemma":[0.99798167,0.0009738785,0.00022613985,0.00019815507,0.000009042444,0.00017195518,0.00007079787,0.000044458924,0.00032391024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978701,0.000145926,0.0005823606,0.00043419894,0.00034391097,0.0006235059],"domain_scores_gemma":[0.9985523,0.00020842893,0.00041016503,0.00030008412,0.0002241674,0.00030485913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014853998,0.00032813608,0.000937791,0.0002525193,0.000059759182,0.0000023347968,0.00007775943,0.00017185655,0.00016601433],"category_scores_gemma":[0.00010301506,0.00017494995,0.000061791136,0.00036905214,0.00016500118,0.00020665547,0.000040301537,0.00014676215,0.000021261963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029665774,0.0028973543,0.7273642,0.00024652862,0.001283929,0.00023652692,0.000110502704,0.0000047702597,0.000115818395,0.00002102019,0.000086281274,0.2379673],"study_design_scores_gemma":[0.080900416,0.031705268,0.88391906,0.0010244765,0.00051724224,0.00004726138,0.000030735006,0.000007173483,0.0010321027,0.000039220522,0.0005265577,0.00025045918],"about_ca_topic_score_codex":0.00031238727,"about_ca_topic_score_gemma":0.001448079,"teacher_disagreement_score":0.23771684,"about_ca_system_score_codex":0.00022567906,"about_ca_system_score_gemma":0.0005616776,"threshold_uncertainty_score":0.71342516},"labels":[],"label_agreement":null},{"id":"W2587089540","doi":"10.1016/s0923-7534(21)00598-6","title":"440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Eisai; Ariad Pharmaceuticals; Gilead Sciences; Chugai Pharmaceutical; Amgen; Pfizer; Genentech; AstraZeneca; Allergan; Eli Lilly and Company","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Gastroenterology; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.03230020250565641,"score_gpt":0.3771746745983067,"score_spread":0.3448744720926503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587089540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713058,0.00014693502,0.000174265,0.0073614186,0.00026564414,0.0007267898,0.000855754,0.00003038704,0.01913299],"genre_scores_gemma":[0.9959074,0.000119333745,0.00078167353,0.0015064919,0.0001328395,0.000078656994,0.0007917455,0.000031817493,0.0006500077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983003,0.00013443126,0.0004657727,0.0004187981,0.00031908683,0.00036160267],"domain_scores_gemma":[0.9982456,0.0005221719,0.000299866,0.00033672815,0.00044209947,0.0001535278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016701706,0.00021477429,0.0005710639,0.00015588591,0.000054419615,0.000008928476,0.00012625272,0.0001539708,0.00046389218],"category_scores_gemma":[0.00016517517,0.00014256506,0.00008076085,0.00016275438,0.00014688571,0.00023895144,0.000053105454,0.00012531727,0.00005242038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077156373,0.004606398,0.77943224,0.00008091196,0.0017768516,0.000430491,0.003969221,0.00002414092,0.0008665811,0.0023027323,0.014532841,0.18426193],"study_design_scores_gemma":[0.020620896,0.0060334615,0.9602947,0.0004865411,0.00031636373,0.000008404262,0.00023660682,0.000022903334,0.0017918953,0.00048835063,0.009457861,0.00024199011],"about_ca_topic_score_codex":0.0013213224,"about_ca_topic_score_gemma":0.00065251294,"teacher_disagreement_score":0.18401994,"about_ca_system_score_codex":0.00021903418,"about_ca_system_score_gemma":0.00048441466,"threshold_uncertainty_score":0.58136344},"labels":[],"label_agreement":null},{"id":"W2587099123","doi":"10.1093/annonc/mdw435.41","title":"Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ceritinib; Medicine; Crizotinib; Anaplastic lymphoma kinase; Internal medicine; ALK inhibitor; non-small cell lung cancer (NSCLC); Lung cancer; Gastroenterology; Oncology","score_opus":0.02151021713983857,"score_gpt":0.34944480111477094,"score_spread":0.32793458397493236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587099123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231315,0.0008450646,0.000011008931,0.0016745132,0.000071767834,0.0029008086,0.0005443681,0.00003491938,0.0016043957],"genre_scores_gemma":[0.9974869,0.00077642326,0.0001187209,0.00083256623,0.000054951208,0.0003761418,0.00010570785,0.00005366428,0.00019492663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805444,0.00017995296,0.0005331277,0.00055951666,0.00024499913,0.00042796796],"domain_scores_gemma":[0.99819213,0.00045567247,0.0004132329,0.0004347204,0.00031191003,0.00019231427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017795093,0.0003366818,0.0007359193,0.00011183609,0.00009878013,0.000012845958,0.00013555073,0.000051822222,0.00007564439],"category_scores_gemma":[0.00005630695,0.00017778747,0.000055722343,0.00022336945,0.00022722787,0.00012544825,0.000025967822,0.000109165325,0.0000030381882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06539376,0.0128545305,0.6278999,0.00012437599,0.0014077867,0.0008096793,0.0069750533,0.000018053519,0.0011497333,0.0000037223624,0.0022846733,0.28107876],"study_design_scores_gemma":[0.2529891,0.03891126,0.686983,0.001292716,0.00095087424,0.00002769997,0.0015999487,0.000041405357,0.0053256936,0.0000036928723,0.011469429,0.000405211],"about_ca_topic_score_codex":0.002950405,"about_ca_topic_score_gemma":0.0031364819,"teacher_disagreement_score":0.28067356,"about_ca_system_score_codex":0.00019442373,"about_ca_system_score_gemma":0.0006539436,"threshold_uncertainty_score":0.72499627},"labels":[],"label_agreement":null},{"id":"W2587145330","doi":"10.1093/annonc/mdw373.44","title":"Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Pazopanib; Internal medicine; Renal cell carcinoma; Sunitinib; Proportional hazards model; Quality of life (healthcare); Oncology; Urology","score_opus":0.11052725328309958,"score_gpt":0.3582128302810531,"score_spread":0.24768557699795352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587145330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923775,0.00051450625,0.00004138652,0.0023934788,0.00006446212,0.0007324252,0.000023021805,0.000010642753,0.0038425652],"genre_scores_gemma":[0.99748355,0.000059410453,0.0020073496,0.0001996276,0.00001701237,0.00006509196,0.000007336006,0.000016676957,0.00014394225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804103,0.0002920155,0.000720004,0.00033007015,0.00025242314,0.00036446273],"domain_scores_gemma":[0.9978389,0.0010084889,0.0003220515,0.000440242,0.00023503769,0.00015528084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058537064,0.00018144683,0.00082591793,0.00022669196,0.000011219476,0.0000013935652,0.00012372,0.000107602325,0.00011558952],"category_scores_gemma":[0.00047414776,0.000116303745,0.00020277528,0.00020910494,0.00032625228,0.00005469652,0.000053979966,0.00011309338,0.000024967263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024469001,0.0038071992,0.6915953,0.00070929225,0.00020773735,0.0008230051,0.00077349774,0.00002074215,0.23678656,0.00013208186,0.00124995,0.061447687],"study_design_scores_gemma":[0.0032761977,0.009921556,0.6112219,0.00010719662,0.00017021995,0.00005501301,0.00008939856,0.000013768124,0.3738275,0.0006664166,0.00054548,0.000105354535],"about_ca_topic_score_codex":0.00027339748,"about_ca_topic_score_gemma":0.00005463308,"teacher_disagreement_score":0.13704093,"about_ca_system_score_codex":0.00012088918,"about_ca_system_score_gemma":0.00040431033,"threshold_uncertainty_score":0.4742729},"labels":[],"label_agreement":null},{"id":"W2587146185","doi":"10.1093/annonc/mdw370.136","title":"Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; St. Boniface Hospital; Centre hospitalier universitaire de Québec; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Performance status; Oncology; Multivariate analysis; Neutrophil to lymphocyte ratio; Cetuximab; Colorectal cancer; Cancer; Lymphocyte","score_opus":0.053176750696643224,"score_gpt":0.3762611443213522,"score_spread":0.323084393624709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587146185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934948,0.0005238435,0.0000044646704,0.004347889,0.000055776214,0.0012723418,0.00017091297,0.000008077449,0.00012191279],"genre_scores_gemma":[0.9975099,0.00022368152,0.00008110785,0.0018258848,0.00001539781,0.0002831287,0.0000097216125,0.00001606412,0.00003509765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980671,0.0004372639,0.00050071726,0.00032056146,0.00039711624,0.0002772543],"domain_scores_gemma":[0.998082,0.0004925496,0.0003785838,0.00033591772,0.0005933629,0.00011761992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054818246,0.00019245007,0.00071524584,0.0002675191,0.0000753278,0.0000064497717,0.00019382522,0.000070939415,0.00009559048],"category_scores_gemma":[0.00032570786,0.00008921428,0.000119323755,0.0005816715,0.00062758056,0.000085348256,0.00010759898,0.00007390157,0.0000014224802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044721044,0.0004601848,0.9784258,0.00007095101,0.00443428,0.000016148499,0.0017686702,0.000021551306,0.0025282449,0.00001004236,0.0007745248,0.0070175095],"study_design_scores_gemma":[0.003193533,0.001745169,0.9828045,0.00014508615,0.0018408163,0.0000022732395,0.0004504945,0.00005947951,0.009290337,0.00002151387,0.00033538346,0.00011143266],"about_ca_topic_score_codex":0.000061235995,"about_ca_topic_score_gemma":0.0008532136,"teacher_disagreement_score":0.006906077,"about_ca_system_score_codex":0.00013922859,"about_ca_system_score_gemma":0.00040471548,"threshold_uncertainty_score":0.36380526},"labels":[],"label_agreement":null},{"id":"W2587256875","doi":"10.1093/annonc/mdw372.23","title":"Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Placebo; Incidence (geometry); Adverse effect; Internal medicine; Physical therapy; Cancer; Oncology; Alternative medicine","score_opus":0.4907561625931201,"score_gpt":0.5522924709673996,"score_spread":0.061536308374279536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587256875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97828245,0.0016368459,0.000056511806,0.014974301,0.000034906283,0.0025195086,0.0010618835,0.000021329524,0.0014122896],"genre_scores_gemma":[0.9918656,0.0050956705,0.00071922765,0.0002720454,0.000096741314,0.00035671316,0.00040473923,0.000028956458,0.0011603291],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99650633,0.0012127971,0.0010794913,0.00050526654,0.00033209182,0.00036404363],"domain_scores_gemma":[0.9954214,0.0029831452,0.00050674495,0.00057042047,0.00031971882,0.00019856838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033027183,0.0002004085,0.0014623725,0.000145547,0.000031783915,0.000010219391,0.00019041455,0.00010319146,0.0003772437],"category_scores_gemma":[0.00091835525,0.000088385445,0.00007714205,0.00024487043,0.0003872288,0.00017217438,0.00004893187,0.00016405428,0.000007546122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58278686,0.002431107,0.17396715,0.0001478159,0.0047896006,0.0018284634,0.000661773,0.000017261757,0.034393333,0.000044438893,0.014995122,0.18393707],"study_design_scores_gemma":[0.6707621,0.028203974,0.20421144,0.0026077358,0.0024679466,0.000041174444,0.0010835738,0.00039286568,0.07229341,0.0005456563,0.01671209,0.0006780233],"about_ca_topic_score_codex":0.002503676,"about_ca_topic_score_gemma":0.0039333785,"teacher_disagreement_score":0.18325904,"about_ca_system_score_codex":0.00008859352,"about_ca_system_score_gemma":0.001744607,"threshold_uncertainty_score":0.4130554},"labels":[],"label_agreement":null},{"id":"W2587280945","doi":"10.1093/annonc/mdw372.03","title":"First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Internal medicine; Oncology; Clinical endpoint; Prostate-specific antigen; Cancer; Progressive disease; Urology; Androgen receptor; Clinical trial; Chemotherapy; Immunotherapy","score_opus":0.209904179058089,"score_gpt":0.47190292722071725,"score_spread":0.26199874816262825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587280945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860475,0.0012433806,0.000021717327,0.011899145,0.00015917789,0.00042459974,0.00004589952,0.0000045347842,0.00015404628],"genre_scores_gemma":[0.9921148,0.00734322,0.00023192629,0.00014217974,0.000038278224,0.000029286071,8.513971e-7,0.000007850681,0.00009160275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982864,0.00022851872,0.0009008179,0.00020403256,0.0002028852,0.00017728974],"domain_scores_gemma":[0.9979035,0.0008735301,0.00068080565,0.00021187478,0.000275724,0.0000545584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015394619,0.00009806176,0.00061649526,0.000119090146,0.00001233872,0.0000011456914,0.000076862925,0.00010002163,0.00011008597],"category_scores_gemma":[0.00048472208,0.00006468317,0.00015140708,0.00021107876,0.00045121938,0.00010757685,0.000022331606,0.000093839364,9.301376e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031453136,0.00079386483,0.04137484,0.00036840283,0.00018912519,0.000026475487,0.00041174405,0.000003968517,0.73719674,0.000029259485,0.0012671195,0.18688533],"study_design_scores_gemma":[0.0039655273,0.009822022,0.4256671,0.0019493378,0.00007835514,0.000004712752,0.00013622882,0.000011878349,0.5534197,0.00009791777,0.0047468864,0.000100306126],"about_ca_topic_score_codex":0.0019851336,"about_ca_topic_score_gemma":0.0027250038,"teacher_disagreement_score":0.38429227,"about_ca_system_score_codex":0.00007144523,"about_ca_system_score_gemma":0.00081236265,"threshold_uncertainty_score":0.30009416},"labels":[],"label_agreement":null},{"id":"W2587327379","doi":"10.1093/annonc/mdx008","title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; Internal medicine; First line therapy; Phases of clinical research; Clinical trial; Cancer; Immunotherapy","score_opus":0.044464290305860014,"score_gpt":0.40573394879088776,"score_spread":0.36126965848502773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587327379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880193,0.0011998406,0.00009148757,0.0038954017,0.00052662374,0.0031563013,0.00018806753,0.000015879092,0.002907122],"genre_scores_gemma":[0.9921461,0.0039656158,0.0003187882,0.0019523086,0.00032380453,0.0005061991,0.000082598424,0.000036763628,0.0006678667],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99871576,0.0000349053,0.00038764748,0.00032924724,0.00017027337,0.00036218535],"domain_scores_gemma":[0.9980817,0.00016977642,0.00065823464,0.00045272463,0.0005253944,0.00011219306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020477282,0.00021925117,0.000650619,0.00008369912,0.00024079264,0.000015552152,0.00022657697,0.00017353873,0.00013462639],"category_scores_gemma":[0.00006399638,0.00016391695,0.00022867334,0.000059035312,0.00020766309,0.00010924367,0.000028923687,0.00012743594,0.0000019138183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76374084,0.0034996215,0.0028395301,0.00009883346,0.0005228788,0.000016282343,0.00060901936,0.0000039321712,0.002008303,0.0000059960134,0.0025811086,0.22407366],"study_design_scores_gemma":[0.697059,0.14627756,0.026788516,0.00031286362,0.00023005652,0.000006382758,0.00006947049,0.000106988984,0.041903414,0.000046660367,0.0868698,0.0003292826],"about_ca_topic_score_codex":0.00044733722,"about_ca_topic_score_gemma":0.00020523083,"teacher_disagreement_score":0.22374439,"about_ca_system_score_codex":0.00008923395,"about_ca_system_score_gemma":0.0006512694,"threshold_uncertainty_score":0.6684339},"labels":[],"label_agreement":null},{"id":"W2587330905","doi":"10.1016/s0923-7534(21)00219-2","title":"99O_PR Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Proportional hazards model; Oncology; Neoadjuvant therapy; Stage (stratigraphy); Cancer","score_opus":0.01240850321268477,"score_gpt":0.28164454467004013,"score_spread":0.26923604145735536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587330905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680364,0.0006708095,0.00003197492,0.0013286939,0.00008475516,0.00022818703,0.00057804503,0.0000042574006,0.00026960735],"genre_scores_gemma":[0.99804276,0.0013714618,0.00011457451,0.00014163625,0.000041039988,0.0001688951,0.00002814108,0.000013384051,0.0000780936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991755,0.000048693386,0.00024160916,0.00025040802,0.000089985224,0.00019380898],"domain_scores_gemma":[0.9993527,0.00001872597,0.0001609069,0.00020443193,0.00022229138,0.000040977797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046169185,0.00014061497,0.00027192867,0.000049131027,0.000012769821,7.813799e-7,0.000062372426,0.00011322313,0.000030793348],"category_scores_gemma":[0.000010801083,0.00008408832,0.00005420087,0.00006022648,0.00014761461,0.0000074328827,0.000042263277,0.000023887687,0.0000016217017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068316474,0.0009065365,0.74533546,0.00001155336,0.00024003469,0.0000041658723,0.00009275319,0.000027881335,0.0051722694,0.000006730208,0.000231511,0.24113949],"study_design_scores_gemma":[0.0062741195,0.0051572695,0.96241134,0.00010762031,0.000033795637,0.0000032075297,0.000021844873,4.347027e-7,0.021820119,0.000018159191,0.0040663346,0.000085742475],"about_ca_topic_score_codex":0.00014922529,"about_ca_topic_score_gemma":0.0005716784,"teacher_disagreement_score":0.24105373,"about_ca_system_score_codex":0.00007296323,"about_ca_system_score_gemma":0.00014748487,"threshold_uncertainty_score":0.3429022},"labels":[],"label_agreement":null},{"id":"W2587370908","doi":"10.1093/annonc/mdw387.02","title":"Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Clinical endpoint; Breast cancer; Sample size determination; Oncology; Surrogate endpoint; Clinical trial; Cancer","score_opus":0.7286972974741612,"score_gpt":0.5681810570550706,"score_spread":0.16051624041909063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587370908","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17526464,0.019012513,0.029356549,0.61014646,0.00542744,0.018161386,0.0030928494,0.00018156377,0.13935658],"genre_scores_gemma":[0.96438533,0.001837338,0.003387329,0.026075233,0.00097358564,0.0016861273,0.00002932416,0.000055752203,0.0015700074],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97550166,0.0031709392,0.01986103,0.0007537545,0.00013587075,0.0005767297],"domain_scores_gemma":[0.88515127,0.09585224,0.017350907,0.0007611898,0.0005891429,0.0002952461],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23803939,0.0003191969,0.013403583,0.00046609153,0.000120763325,0.00003833717,0.00049200375,0.00055013906,0.0007262965],"category_scores_gemma":[0.15777731,0.00023970412,0.0020745834,0.000105750085,0.00036183177,0.0003694345,0.00007150079,0.000112921305,0.00025911254],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09246793,0.00041921338,0.0044722417,0.0001558128,0.002055725,0.0000016933654,0.0006982982,0.000016756954,0.000017787894,0.73222935,0.16448492,0.0029802592],"study_design_scores_gemma":[0.4146724,0.0016802246,0.00029772543,0.00018790949,0.00008442816,0.0000035279331,0.000248475,0.0003377193,0.00004286623,0.41273347,0.16930276,0.00040848463],"about_ca_topic_score_codex":0.00015775018,"about_ca_topic_score_gemma":0.00005005623,"teacher_disagreement_score":0.7891207,"about_ca_system_score_codex":0.00013019098,"about_ca_system_score_gemma":0.0006146169,"threshold_uncertainty_score":0.97748506},"labels":[],"label_agreement":null},{"id":"W2587420003","doi":"10.1093/annonc/mdw611","title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Chugai Pharmaceutical; Genentech; Ono Pharmaceutical; Astellas Pharma; Chinese University of Hong Kong; GlaxoSmithKline; AstraZeneca Korea; Clovis Oncology; Vertex Pharmaceuticals; International Association for the Study of Lung Cancer; Amgen; ACEA Biosciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Afatinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Epidermal growth factor receptor; T790M; Proportional hazards model; Gastroenterology; Confidence interval; Cancer","score_opus":0.08223081129384406,"score_gpt":0.4570319687057121,"score_spread":0.37480115741186804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587420003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98536754,0.00037978555,0.00004137723,0.0030956154,0.0009961897,0.0018509192,0.0018154548,0.000011937738,0.006441195],"genre_scores_gemma":[0.9958762,0.0002306448,0.00048651788,0.0005101748,0.00030186147,0.000166329,0.0022301245,0.00002617568,0.00017199013],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985179,0.000103652674,0.0003949507,0.00042588197,0.0002565163,0.00030111134],"domain_scores_gemma":[0.99750996,0.0005897768,0.00058476196,0.00088638684,0.00032643744,0.00010266271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021109775,0.00019800794,0.00051348325,0.00005275829,0.00021849229,0.000028456192,0.00041001232,0.00010947762,0.00013105174],"category_scores_gemma":[0.00021395019,0.00013740858,0.0000628543,0.000069753056,0.00014539,0.00028416663,0.00013672494,0.0001991474,0.0000045296215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43746075,0.012344293,0.37311152,0.00015667733,0.004163429,0.00038283356,0.009790896,0.00039111063,0.00025323243,0.00020164969,0.0150372,0.1467064],"study_design_scores_gemma":[0.5263442,0.011044046,0.45454535,0.000318082,0.0013191412,9.300358e-7,0.0006896824,0.0009254987,0.0006052862,0.00003582943,0.0038857814,0.00028622494],"about_ca_topic_score_codex":0.0048604123,"about_ca_topic_score_gemma":0.0032561102,"teacher_disagreement_score":0.14642017,"about_ca_system_score_codex":0.00015195076,"about_ca_system_score_gemma":0.0009045755,"threshold_uncertainty_score":0.7347522},"labels":[],"label_agreement":null},{"id":"W2587454754","doi":"10.1093/annonc/mdw333.11","title":"Prognostic significance of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma: the ARQ197-215 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Internal medicine; Neutrophil to lymphocyte ratio; Hazard ratio; Gastroenterology; Univariate analysis; Hepatocellular carcinoma; Proportional hazards model; Confidence interval; Post-hoc analysis; Multivariate analysis; Absolute neutrophil count; Lymphocyte; Oncology; Neutropenia; Toxicity","score_opus":0.02696928258871427,"score_gpt":0.2912311864072045,"score_spread":0.26426190381849024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587454754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931087,0.00015247306,0.000014313086,0.0025502169,0.0001231606,0.0037521163,0.000020008532,0.000012090863,0.00026691594],"genre_scores_gemma":[0.9988903,0.000011664653,0.00009492161,0.00053463044,0.0000307438,0.00037418547,0.0000019834079,0.000022458593,0.00003912031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812335,0.00035745764,0.00051991723,0.00030481143,0.00038798814,0.00030647306],"domain_scores_gemma":[0.99809456,0.00032147666,0.00034996922,0.0006443359,0.00049454643,0.000095108975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043365985,0.0001771891,0.00045318095,0.00010704528,0.000052874624,0.0000028977204,0.00033338848,0.000075228665,0.000021928747],"category_scores_gemma":[0.00040825887,0.00008097379,0.00008900466,0.0004065694,0.0003445781,0.00006083198,0.00012338773,0.00009633846,0.0000067977257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003706933,0.0015140813,0.9813654,0.000055320957,0.00010990711,0.000033483695,0.00048520172,0.000010589178,0.003061014,0.0000343467,0.0001947554,0.009429002],"study_design_scores_gemma":[0.005547253,0.005352674,0.97357255,0.00015214572,0.00010844461,0.0000018518317,0.00019831154,0.00001461853,0.0143185295,0.000039021317,0.0005932225,0.00010138808],"about_ca_topic_score_codex":0.000030777515,"about_ca_topic_score_gemma":0.000035291516,"teacher_disagreement_score":0.011257515,"about_ca_system_score_codex":0.000093594266,"about_ca_system_score_gemma":0.0005593717,"threshold_uncertainty_score":0.33020154},"labels":[],"label_agreement":null},{"id":"W2587481440","doi":"10.1093/annonc/mdw435.05","title":"Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Letrozole; Internal medicine; Breast cancer; Hazard ratio; Oncology; Fulvestrant; Clinical endpoint; Population; Progression-free survival; Biomarker; Cancer; Metastatic breast cancer; Gynecology; Gastroenterology; Estrogen receptor; Tamoxifen; Clinical trial; Chemotherapy; Confidence interval; Biology","score_opus":0.08366119973742049,"score_gpt":0.4202396635614648,"score_spread":0.3365784638240443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587481440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987764,0.00077876495,0.00036059003,0.0088437665,0.00008195139,0.0011515433,0.00050498295,0.000034848395,0.00047955045],"genre_scores_gemma":[0.9969664,0.00017459488,0.00096181716,0.0011083595,0.00014840132,0.00040813402,0.00002659814,0.000060097005,0.00014560453],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975509,0.00024928025,0.00061295443,0.0004977193,0.00047609696,0.00061304995],"domain_scores_gemma":[0.9973814,0.00066634355,0.0007045812,0.0005958146,0.00046770467,0.00018417586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030753156,0.0003745634,0.0013164085,0.00017570471,0.000060960465,0.000006324073,0.00026471206,0.00012897597,0.0004504886],"category_scores_gemma":[0.00003776427,0.00017189197,0.000060137845,0.0005486053,0.0010833478,0.00022406579,0.00005079239,0.00019849326,0.000003280539],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76842713,0.0014800467,0.008628198,0.00003697808,0.0015915841,0.00014115642,0.0014944504,0.00017620572,0.060329996,0.000018162098,0.00017527469,0.15750079],"study_design_scores_gemma":[0.6938983,0.052608836,0.20947905,0.0015993504,0.0005640784,0.00026253963,0.0051577967,0.000052128675,0.024215208,0.00020595606,0.01122682,0.00072989444],"about_ca_topic_score_codex":0.0014956984,"about_ca_topic_score_gemma":0.0026723405,"teacher_disagreement_score":0.20085086,"about_ca_system_score_codex":0.00029616785,"about_ca_system_score_gemma":0.00096879713,"threshold_uncertainty_score":0.7009551},"labels":[],"label_agreement":null},{"id":"W2587551547","doi":"10.1016/s0923-7534(21)00459-2","title":"301O Exploring perceptions of cervical cancer in Dhaka, Bangladesh","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University; Women's College Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cervical cancer; Family medicine; Cancer; Cross-sectional study; Outpatient clinic; Gynecology; Cervical cancer screening; Risk perception; Internal medicine; Perception","score_opus":0.2577517991842225,"score_gpt":0.4776531144168909,"score_spread":0.21990131523266843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587551547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436261,0.00052911125,0.000028790248,0.021469444,0.00010350045,0.00016182882,0.000030951353,0.000010443782,0.034039848],"genre_scores_gemma":[0.9956997,0.0031417205,0.000059488204,0.0004766915,0.00017085994,0.00007653044,0.0000017195682,0.000009672438,0.00036361904],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99900967,0.00006130162,0.00030394353,0.0001571706,0.0002020862,0.00026580135],"domain_scores_gemma":[0.9991582,0.0002119401,0.000050617233,0.00017479049,0.00027919418,0.00012527138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026262508,0.00006754419,0.00037773015,0.00017075935,0.000013064095,9.904172e-7,0.00009669224,0.00010437659,0.018288666],"category_scores_gemma":[0.00013600264,0.0000458371,0.00009330941,0.00021351635,0.00018172017,0.00006290058,0.00006415134,0.00013951413,0.000030739302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007593012,0.00045651072,0.17756937,0.00017029044,0.0000451362,0.000024404904,0.00059537945,0.000002746611,0.020240882,0.0007488486,0.0030760963,0.796311],"study_design_scores_gemma":[0.001897255,0.0013336571,0.96778876,0.000091056856,0.000015354848,0.000005961304,0.0003258041,0.000010850767,0.00996098,0.0004291372,0.018079706,0.000061500046],"about_ca_topic_score_codex":0.00057743414,"about_ca_topic_score_gemma":0.0010305194,"teacher_disagreement_score":0.7962495,"about_ca_system_score_codex":0.000065547625,"about_ca_system_score_gemma":0.0002846154,"threshold_uncertainty_score":0.98260874},"labels":[],"label_agreement":null},{"id":"W2587638249","doi":"10.1093/annonc/mdw392.01","title":"Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Clinical trial; Genomics; Cancer; DNA sequencing; Bioinformatics; Oncology; Gene; Computational biology; Internal medicine; Genome; Genetics; Biology","score_opus":0.06061047968088594,"score_gpt":0.4021710272701791,"score_spread":0.34156054758929316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587638249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224937,0.00042914844,0.005076891,0.00014386879,0.0001880213,0.0002835367,0.0015512061,0.0000024498347,0.00007549333],"genre_scores_gemma":[0.9820747,0.00105485,0.016461752,0.0001715767,0.00007327054,0.000018486608,0.00012336095,0.000011325249,0.000010724055],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988205,0.000048552636,0.00046250768,0.0003995224,0.00008905667,0.00017988148],"domain_scores_gemma":[0.99783313,0.000734111,0.0003198706,0.00061404385,0.00043912826,0.00005968752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041676755,0.00010075209,0.00029077477,0.00002294169,0.00002601822,0.0000014892894,0.00033054576,0.00012666915,0.000015133612],"category_scores_gemma":[0.0021191665,0.00006740214,0.00006982346,0.000032390722,0.00019873402,0.000007179589,0.00025595335,0.0000308761,9.096675e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007862926,0.00067967095,0.14944118,0.00005538314,0.000121646175,0.0000011039598,0.000038108596,0.00013220827,0.26869234,0.000019908837,0.012550008,0.5604055],"study_design_scores_gemma":[0.009968607,0.026437381,0.17183687,0.00038943996,0.00008163524,0.0000020508026,0.000100704965,0.000054538064,0.547739,0.0017936266,0.24103132,0.00056478556],"about_ca_topic_score_codex":0.000011017353,"about_ca_topic_score_gemma":0.000091116424,"teacher_disagreement_score":0.5598407,"about_ca_system_score_codex":0.000016539023,"about_ca_system_score_gemma":0.00035256395,"threshold_uncertainty_score":0.27485797},"labels":[],"label_agreement":null},{"id":"W2587689992","doi":"10.1093/annonc/mdw590.003","title":"417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Radionuclide therapy; Medicine; Peptide receptor; Radionuclide; Nuclear medicine; Medical physics; Internal medicine; Receptor; Nuclear physics","score_opus":0.11139162808555302,"score_gpt":0.3816349765725513,"score_spread":0.27024334848699827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587689992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.899355,0.0002516924,0.00008158585,0.09981869,0.000023098479,0.00028070324,0.00002531405,0.0000064231353,0.00015752099],"genre_scores_gemma":[0.9959167,0.0010771083,0.00087728363,0.0017847568,0.000039279676,0.000015379817,0.000010180903,0.0000035581631,0.00027575094],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9992213,0.00011130571,0.00027523848,0.00015836368,0.0001234326,0.000110350775],"domain_scores_gemma":[0.9990791,0.00042382846,0.000111948204,0.00016554138,0.00012569997,0.000093868715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006603248,0.000070258524,0.0002272829,0.00003180736,0.000028106519,0.0000038626717,0.000045298933,0.00004813301,0.00014528944],"category_scores_gemma":[0.00021278122,0.000041795625,0.00001346802,0.0000943649,0.00030889505,0.00004806078,0.000020946702,0.0000907544,2.2538617e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003351408,0.00014530511,0.42851615,0.000033932825,0.00002017539,0.0000027976835,0.00034109218,5.0382262e-8,0.014332027,0.00030068465,0.46044308,0.09552958],"study_design_scores_gemma":[0.0013637556,0.00033235346,0.74821264,0.000056890396,0.000013236123,0.000033988777,0.00014293964,0.00004841072,0.0031613393,0.0018710372,0.2447052,0.000058218633],"about_ca_topic_score_codex":0.086964756,"about_ca_topic_score_gemma":0.044845063,"teacher_disagreement_score":0.3196965,"about_ca_system_score_codex":0.000019033267,"about_ca_system_score_gemma":0.000344675,"threshold_uncertainty_score":0.972584},"labels":[],"label_agreement":null},{"id":"W2587732794","doi":"10.1093/annonc/mdw390.06","title":"Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; Augmentium Pharma Consulting (Canada)","funders":"Eisai; Teva Pharmaceutical Industries; Pfizer; Helsinn; Amgen","keywords":"Medicine; Receiver operating characteristic; Vomiting; Nausea; Internal medicine; Chemotherapy-induced nausea and vomiting; Oncology; Antiemetic","score_opus":0.09373904875350547,"score_gpt":0.38099163107261863,"score_spread":0.28725258231911316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587732794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996275,0.000062289444,0.00036148302,0.0022517715,0.00016312457,0.000655591,0.00003086689,0.000013804855,0.00018607879],"genre_scores_gemma":[0.9979146,0.00025547092,0.0010260233,0.00038700466,0.00009825716,0.00009547556,0.000006249143,0.000011690584,0.00020519321],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990356,0.00004607217,0.00040981785,0.00017347265,0.0001482557,0.00018679323],"domain_scores_gemma":[0.9989575,0.00026272624,0.00038668016,0.00012741746,0.00022863391,0.000037001653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006144742,0.00008914911,0.00026364197,0.00006851651,0.000105191895,0.0000030216681,0.000060962786,0.000072730225,0.000029526833],"category_scores_gemma":[0.00019827252,0.00005231226,0.000051264265,0.000060023605,0.00005552099,0.000045421693,0.000067883244,0.00004656988,0.0000012667463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010214287,0.00025622567,0.32485035,0.00024860146,0.00045434458,6.274754e-7,0.0015317458,4.078559e-7,0.030135268,0.0001102605,0.002916457,0.6384743],"study_design_scores_gemma":[0.006519068,0.0014149651,0.7635453,0.0002883462,0.00012972836,0.0000010874955,0.00011189328,0.00002098803,0.21133105,0.0002616806,0.016290527,0.000085404245],"about_ca_topic_score_codex":0.00005070953,"about_ca_topic_score_gemma":0.000088835244,"teacher_disagreement_score":0.6383889,"about_ca_system_score_codex":0.00007849666,"about_ca_system_score_gemma":0.00008872918,"threshold_uncertainty_score":0.21332322},"labels":[],"label_agreement":null},{"id":"W2587744462","doi":"10.1016/s0923-7534(21)00552-4","title":"394TiP KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Response Evaluation Criteria in Solid Tumors; Regimen; Oncology; Internal medicine; Phases of clinical research; Progressive disease; Chemotherapy; Chemotherapy regimen; Surgery; Immunotherapy; Cancer","score_opus":0.13968135926207415,"score_gpt":0.45143079712999923,"score_spread":0.3117494378679251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587744462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931736,0.0026308412,0.0000042480506,0.0011186793,0.00025058378,0.00082717976,0.00015130048,0.000013548475,0.0018300487],"genre_scores_gemma":[0.9984424,0.0011225694,0.00014097708,0.00010239979,0.000052129766,0.000051548726,0.000007833721,0.000022539818,0.00005758207],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99809474,0.000182514,0.00076246413,0.0003031946,0.00033421224,0.00032289035],"domain_scores_gemma":[0.99820054,0.0005590311,0.0003529399,0.00032139328,0.0004631018,0.000102975544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027873836,0.00021338683,0.0015237476,0.00024766877,0.00002643757,0.000001273171,0.00013172484,0.000090592504,0.0002263301],"category_scores_gemma":[0.0002866669,0.00013376425,0.0001275364,0.00030106673,0.00018706702,0.000056427933,0.000053714066,0.00012774888,0.0000024717822],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3537874,0.009769507,0.022749437,0.0007102083,0.0010051725,0.00040485262,0.016309336,0.0000013249178,0.0030258223,0.00004266669,0.0029347353,0.5892595],"study_design_scores_gemma":[0.36238876,0.5121563,0.0436489,0.00091403956,0.0004916233,0.000030151048,0.012189258,0.000017887309,0.058708943,0.000052961957,0.009047726,0.0003534512],"about_ca_topic_score_codex":0.00016061062,"about_ca_topic_score_gemma":0.00071662694,"teacher_disagreement_score":0.5889061,"about_ca_system_score_codex":0.0001450104,"about_ca_system_score_gemma":0.0005805757,"threshold_uncertainty_score":0.54547477},"labels":[],"label_agreement":null},{"id":"W2587799561","doi":"10.1093/annonc/mdw373.10","title":"IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Urology; Oncology; Gastroenterology; Clinical trial; Cancer; Urothelial carcinoma; Nivolumab; Bladder cancer; Immunotherapy","score_opus":0.11868851925964756,"score_gpt":0.4243890684159451,"score_spread":0.3057005491562975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587799561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98564804,0.0011158303,0.000715963,0.004374688,0.00018515726,0.000689272,0.00025240748,0.00003664186,0.006981983],"genre_scores_gemma":[0.99646974,0.0011360972,0.00098963,0.0005298946,0.00008119716,0.000083625004,0.00003978206,0.000042599037,0.0006274574],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99754083,0.00014509214,0.0010355462,0.00043606773,0.0003281409,0.0005143027],"domain_scores_gemma":[0.9981377,0.00032655173,0.00042691722,0.00047098458,0.00045264725,0.00018516339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028244217,0.00030820226,0.001233938,0.00043462645,0.000034606448,0.0000035223943,0.00020734427,0.00017053074,0.0008051405],"category_scores_gemma":[0.00025236874,0.00020908169,0.000227752,0.0005358974,0.00026938348,0.00013723767,0.000077041346,0.00014570706,0.000051259496],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040697638,0.0078036427,0.19734189,0.0010027117,0.0022419535,0.0018599338,0.0011722198,0.000660747,0.26124895,0.0005473792,0.01158143,0.47384152],"study_design_scores_gemma":[0.04347269,0.026983485,0.08873529,0.0010160017,0.0008618623,0.00023996051,0.00022297648,0.00042834037,0.81732,0.0034339384,0.01660725,0.0006782279],"about_ca_topic_score_codex":0.0012818403,"about_ca_topic_score_gemma":0.00057154405,"teacher_disagreement_score":0.55607104,"about_ca_system_score_codex":0.000111665155,"about_ca_system_score_gemma":0.00066584663,"threshold_uncertainty_score":0.88157237},"labels":[],"label_agreement":null},{"id":"W2587799962","doi":"10.1093/annonc/mdw371.79","title":"Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); Simon Fraser University; BC Cancer Agency","funders":"","keywords":"Medicine; KRAS; Biomarker; Internal medicine; Oncology; Circulating tumor DNA; Multiplex; Liquid biopsy; Minimal residual disease; Pancreatic ductal adenocarcinoma; Mutation; Digital polymerase chain reaction; Pancreatic cancer; Gastroenterology; Cancer; Bioinformatics; Polymerase chain reaction; Gene; Genetics","score_opus":0.08102196964689239,"score_gpt":0.38217903078776533,"score_spread":0.30115706114087293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587799962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940461,0.0013501385,0.000087693305,0.0005893803,0.00017689457,0.00014813285,0.000055939323,0.00000291725,0.0035428351],"genre_scores_gemma":[0.9982279,0.00081283785,0.00039015652,0.0002823232,0.00018754503,0.000011264809,0.000012959199,0.000013446584,0.000061577084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984735,0.00016591517,0.00065815216,0.00032656337,0.00009111142,0.0002847578],"domain_scores_gemma":[0.9987671,0.0002991371,0.0002970593,0.00038131035,0.00017417726,0.00008124961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080468226,0.00011221794,0.00042184896,0.000055555698,0.00001861488,0.0000024508538,0.00019599656,0.00018668937,0.00006345959],"category_scores_gemma":[0.001369733,0.00009383808,0.00014519054,0.000087752116,0.00025587992,0.0000040101195,0.00016455301,0.00007930061,0.0000038182816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004795133,0.0003486312,0.7349519,0.000045780827,0.000071415234,0.00003308098,0.000040894818,0.0000049915866,0.24625152,0.00024407482,0.0027451103,0.014783078],"study_design_scores_gemma":[0.002129665,0.003303581,0.8212292,0.00007876531,0.000030337898,0.000040776045,0.00009101001,0.00005436708,0.15827543,0.0014330184,0.013122546,0.0002112685],"about_ca_topic_score_codex":0.00017441533,"about_ca_topic_score_gemma":0.00029920976,"teacher_disagreement_score":0.087976106,"about_ca_system_score_codex":0.000012548674,"about_ca_system_score_gemma":0.00038645463,"threshold_uncertainty_score":0.3826606},"labels":[],"label_agreement":null},{"id":"W2587825039","doi":"10.1093/annonc/mdw435.20","title":"genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Université de Montréal; Vancouver General Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Internal medicine; Prednisone; Hazard ratio; Urology; Population; Docetaxel; Gastroenterology; Cancer; Androgen deprivation therapy; Confidence interval","score_opus":0.10647691816400179,"score_gpt":0.39658378525867183,"score_spread":0.29010686709467004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587825039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885831,0.00074251444,0.0000065531635,0.0067545893,0.00008391223,0.0021606525,0.0011466469,0.000018354376,0.00050368207],"genre_scores_gemma":[0.99778885,0.000898937,0.00029131118,0.00013731305,0.00010682703,0.0002849017,0.00007055217,0.00002880655,0.00039253331],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975074,0.00063615566,0.00075212534,0.00041270474,0.00028454876,0.0004070951],"domain_scores_gemma":[0.99775535,0.0008638922,0.0005490342,0.00038096207,0.00028899798,0.00016173837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006910134,0.00025623434,0.0009113556,0.000116736664,0.00004739577,0.000007583084,0.00013793183,0.00009770386,0.00014995772],"category_scores_gemma":[0.00036736028,0.00014684295,0.00008354901,0.00016275508,0.0005541297,0.00011097371,0.00009198405,0.0001692815,0.00000229881],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7768801,0.006550669,0.078961454,0.00041132214,0.0009979364,0.0029026936,0.005494106,0.000058658617,0.086537465,0.00007968539,0.0051523307,0.03597357],"study_design_scores_gemma":[0.4249833,0.05650031,0.4932409,0.0012010654,0.00169104,0.00029473534,0.0014186893,0.00018576194,0.01689004,0.00082908483,0.0021211002,0.000643981],"about_ca_topic_score_codex":0.0032091935,"about_ca_topic_score_gemma":0.0034237443,"teacher_disagreement_score":0.41427946,"about_ca_system_score_codex":0.000082485014,"about_ca_system_score_gemma":0.0008774465,"threshold_uncertainty_score":0.5988082},"labels":[],"label_agreement":null},{"id":"W2587867179","doi":"10.1093/annonc/mdw379.07","title":"PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Oncology; Hazard ratio; Cancer; Immunotherapy; Confidence interval","score_opus":0.04392144402831851,"score_gpt":0.37215963198604646,"score_spread":0.32823818795772797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587867179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864091,0.0035029815,0.00039352276,0.007314241,0.00013233881,0.0007330474,0.000044949596,0.000043697713,0.0014261086],"genre_scores_gemma":[0.9944955,0.0018260063,0.00087022304,0.0012499524,0.000052384345,0.00013132092,0.00002297667,0.000033645636,0.0013179583],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981371,0.00013085811,0.000630256,0.00047617435,0.000194638,0.00043097002],"domain_scores_gemma":[0.9985173,0.00043509895,0.0003188339,0.000394587,0.00019929577,0.00013488076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005941058,0.00022448669,0.0009818688,0.0005809933,0.00004692953,0.000006470835,0.00013461278,0.00028517927,0.0002858024],"category_scores_gemma":[0.00020258027,0.00015732917,0.00033096946,0.00056176144,0.0002463379,0.00013470514,0.00006441423,0.00008491477,0.0000047774615],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07516679,0.0005548751,0.007189464,0.00011389281,0.0018395191,0.000073638,0.0005773492,0.0000018360369,0.54648894,0.00003998984,0.0037777366,0.36417598],"study_design_scores_gemma":[0.12972315,0.022864748,0.32587415,0.0013010605,0.002299957,0.00023179536,0.0013284337,0.0008937782,0.30506352,0.0015855738,0.20776272,0.001071103],"about_ca_topic_score_codex":0.00034912265,"about_ca_topic_score_gemma":0.00053075206,"teacher_disagreement_score":0.36310485,"about_ca_system_score_codex":0.00015131336,"about_ca_system_score_gemma":0.00031555974,"threshold_uncertainty_score":0.64156973},"labels":[],"label_agreement":null},{"id":"W2587925559","doi":"10.1093/annonc/mdw376.08","title":"Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiomics; Radiology; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical trial; Internal medicine; Phases of clinical research","score_opus":0.025677252376424303,"score_gpt":0.3219564177527042,"score_spread":0.2962791653762799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587925559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944279,0.00025610728,0.0003841344,0.003605739,0.00010522539,0.0011428364,0.00003241999,0.0000036797828,0.000041923395],"genre_scores_gemma":[0.992031,0.0000143471625,0.0075913914,0.00020516735,0.000014344774,0.000058171423,0.0000053282547,0.000017584463,0.000062676845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985104,0.0001489379,0.0006872784,0.00021085492,0.00022186596,0.00022066534],"domain_scores_gemma":[0.9984716,0.00055206363,0.0004141874,0.00019251977,0.000267054,0.00010253114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010142504,0.00013628235,0.00057015364,0.00018069414,0.000029356186,0.0000014640262,0.000111564914,0.000078998084,0.0000075721982],"category_scores_gemma":[0.001247696,0.00006852755,0.00007325799,0.00020004541,0.0002034435,0.000031273874,0.00008409358,0.0001745375,1.8485572e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16901128,0.005101507,0.180579,0.0015422031,0.00032309516,0.000033700046,0.018225746,0.00013911969,0.16346708,0.000037589918,0.0013279496,0.46021172],"study_design_scores_gemma":[0.018759942,0.019552024,0.8366828,0.0009173124,0.0001187796,0.000011437905,0.00044598762,0.00019345601,0.11783854,0.000050182414,0.005255603,0.00017391078],"about_ca_topic_score_codex":0.000023287244,"about_ca_topic_score_gemma":0.000028823068,"teacher_disagreement_score":0.6561038,"about_ca_system_score_codex":0.00008171926,"about_ca_system_score_gemma":0.000524447,"threshold_uncertainty_score":0.27944726},"labels":[],"label_agreement":null},{"id":"W2587948128","doi":"10.1093/annonc/mdw377.20","title":"Dalteparin vs. vitamin K antagonist (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency: A patient level pharmacoeconomic analysis in three European countries","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Population; Randomized controlled trial; Cost-effectiveness analysis; Subgroup analysis; Randomization; Pediatrics; Vitamin K antagonist; Internal medicine; Quality of life (healthcare); Cost effectiveness; Confidence interval; Environmental health; Warfarin","score_opus":0.06072425653322976,"score_gpt":0.35897358684359565,"score_spread":0.2982493303103659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587948128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394965,0.0004980119,0.00037937684,0.0028513586,0.00017777662,0.0014257454,0.00019281649,0.000008004569,0.00051724096],"genre_scores_gemma":[0.99661785,0.0024818322,0.00011102507,0.0004750486,0.00004122086,0.00020380004,0.0000311131,0.000020811902,0.000017318514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99815434,0.00014726605,0.00077468436,0.00034609466,0.00021942914,0.0003582029],"domain_scores_gemma":[0.99857813,0.00023053543,0.0006033214,0.0002830204,0.00024659742,0.000058369817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075856835,0.00018474949,0.0009807197,0.0003894199,0.00005809499,0.000006872695,0.0002008736,0.000059430495,0.0000736446],"category_scores_gemma":[0.000055996556,0.000111973975,0.00016104801,0.00036459867,0.00022776933,0.00009200434,0.000095474876,0.00009716377,0.0000029118976],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050859996,0.029807093,0.36387566,0.0004282149,0.003485495,0.000025957805,0.0046032583,0.0013316798,0.0010179246,0.0021024921,0.0045571215,0.5836791],"study_design_scores_gemma":[0.0047439747,0.009809945,0.97175664,0.00030739102,0.0006476689,6.691917e-7,0.00010534061,0.0001598944,0.0016893842,0.00011876027,0.010509501,0.00015082599],"about_ca_topic_score_codex":0.0008613935,"about_ca_topic_score_gemma":0.0072519807,"teacher_disagreement_score":0.607881,"about_ca_system_score_codex":0.0001780792,"about_ca_system_score_gemma":0.000277502,"threshold_uncertainty_score":0.4566166},"labels":[],"label_agreement":null},{"id":"W2587966486","doi":"10.1093/annonc/mdw372.54","title":"TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Placebo; Prostate cancer; Oncology; Internal medicine; Antiandrogen; Double blind; Urology; Cancer; Pathology","score_opus":0.13255004626248107,"score_gpt":0.44675993276647247,"score_spread":0.3142098865039914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587966486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97838515,0.00496331,0.00007359238,0.0068804985,0.00014612533,0.008401024,0.000092046044,0.000017788378,0.0010404676],"genre_scores_gemma":[0.97065204,0.02617783,0.00013845087,0.00024944168,0.000115418414,0.0017853681,0.000041357445,0.000029063282,0.0008110337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721956,0.0005618679,0.0009842645,0.00035677192,0.00041628344,0.000461242],"domain_scores_gemma":[0.9971756,0.0012428464,0.00058968714,0.00026426915,0.0005834888,0.00014414433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020324604,0.000247557,0.0020523316,0.00045627556,0.000032879372,0.0000067231304,0.00011048966,0.00014941789,0.000083298415],"category_scores_gemma":[0.00038213385,0.00014060928,0.00033553035,0.0003375137,0.0004807697,0.00015369857,0.000038694598,0.00016927221,0.0000101341175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9135679,0.001304007,0.00009424043,0.000045065488,0.0014828108,0.0001393207,0.0016457563,0.000012863646,0.013084826,0.00013904167,0.0003069141,0.06817723],"study_design_scores_gemma":[0.94025254,0.007685696,0.000048014514,0.00014223988,0.00024930757,0.000013378113,0.0001749974,0.00016057109,0.049420312,0.0005707023,0.0011496419,0.00013259356],"about_ca_topic_score_codex":0.00060257106,"about_ca_topic_score_gemma":0.00018633105,"teacher_disagreement_score":0.06804463,"about_ca_system_score_codex":0.0002206258,"about_ca_system_score_gemma":0.0013289887,"threshold_uncertainty_score":0.573388},"labels":[],"label_agreement":null},{"id":"W2588044436","doi":"10.1093/annonc/mdw379.26","title":"Radiographic myosteatosis is prognostic and predictive of ipilimumab outcomes in melanoma","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Hazard ratio; Proportional hazards model; Retrospective cohort study; Melanoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Nuclear medicine; Oncology; Cancer; Progressive disease; Immunotherapy; Confidence interval; Chemotherapy","score_opus":0.03614394298042268,"score_gpt":0.32399757354107894,"score_spread":0.28785363056065627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588044436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863788,0.00027421524,0.0000454631,0.008434338,0.00009113896,0.00042649006,0.000020258967,0.000014549286,0.004314784],"genre_scores_gemma":[0.9979331,0.0008597145,0.00008626698,0.00060445705,0.000016339805,0.00002643814,0.0000012218399,0.000008308434,0.00046413697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991632,0.00005882046,0.00032150338,0.00017681178,0.00012102154,0.00015861187],"domain_scores_gemma":[0.99926937,0.00026394532,0.00013787324,0.00016156479,0.00009784518,0.00006939854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019008442,0.000092858376,0.0004543564,0.0003772874,0.000011650596,0.0000011909223,0.000047786918,0.00009627603,0.00010469465],"category_scores_gemma":[0.00017099855,0.000061727485,0.0000857274,0.00017301014,0.00017310999,0.00003236711,0.000043814456,0.000055720742,0.000004081821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010959046,0.00066444464,0.85896266,0.0001305926,0.00038599275,0.00009104021,0.00069572043,3.656343e-7,0.004642297,0.0002843381,0.001576585,0.13147005],"study_design_scores_gemma":[0.0042173187,0.011470734,0.957758,0.00019403176,0.00015641253,0.00014808738,0.0003559662,0.000025865307,0.011059367,0.00061314687,0.013890591,0.00011049474],"about_ca_topic_score_codex":0.00004305547,"about_ca_topic_score_gemma":0.000042513788,"teacher_disagreement_score":0.13135956,"about_ca_system_score_codex":0.000018252447,"about_ca_system_score_gemma":0.000043125554,"threshold_uncertainty_score":0.2517174},"labels":[],"label_agreement":null},{"id":"W2588062955","doi":"10.1093/annonc/mdw383.52","title":"Addressing disease progression in EGFRmut+ NSCLC patients","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Progression-free survival; Lung cancer; Discontinuation; Log-rank test; Adenocarcinoma; Progressive disease; Chemotherapy; Survival analysis; Cancer","score_opus":0.1087581454542716,"score_gpt":0.49244884498441693,"score_spread":0.38369069953014534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588062955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97500855,0.00046063008,0.00001852799,0.010764488,0.00012616563,0.00033555427,0.000021732887,0.000014702943,0.01324963],"genre_scores_gemma":[0.99862343,0.00011628894,0.00018847304,0.0006334664,0.000039679555,0.000040419978,0.000018233537,0.0000074338404,0.00033258394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994172,0.00003391171,0.0001738582,0.00012458423,0.00010344845,0.00014699419],"domain_scores_gemma":[0.99951464,0.000052944437,0.00008570668,0.00011627754,0.000120043675,0.000110376764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006259587,0.00005922148,0.00016604147,0.000083604995,0.000019394409,0.0000015395885,0.00003129723,0.000046059948,0.00008622722],"category_scores_gemma":[0.00011940499,0.00003395994,0.00004164454,0.000073152696,0.000060635022,0.00006359586,0.000019709407,0.00003146353,0.000015507514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045335817,0.0010106306,0.34390298,0.000027923026,0.000029661942,0.000044105127,0.0001560035,2.817361e-7,0.00036571568,0.0001317506,0.0022685782,0.651609],"study_design_scores_gemma":[0.0054309745,0.0017726296,0.9464365,0.000783849,0.000064324515,0.0000016247066,0.00002732468,0.000003991803,0.0014369299,0.00046014434,0.04351625,0.000065427965],"about_ca_topic_score_codex":0.000014458378,"about_ca_topic_score_gemma":0.000008778719,"teacher_disagreement_score":0.65154356,"about_ca_system_score_codex":0.000064416934,"about_ca_system_score_gemma":0.000246407,"threshold_uncertainty_score":0.13848461},"labels":[],"label_agreement":null},{"id":"W2588067263","doi":"10.1093/annonc/mdw372.34","title":"Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Concomitant; Medicine; Denosumab; Prostate cancer; Urology; Internal medicine; Radium-223; Zoledronic acid; Bristol-Myers; Oncology; Cancer; Bone metastasis; Osteoporosis","score_opus":0.1547421441975983,"score_gpt":0.4803471151410488,"score_spread":0.3256049709434505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588067263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475676,0.00005667913,0.0000032377222,0.003341903,0.000032593332,0.0008502211,0.000090479014,0.000021448028,0.00084667065],"genre_scores_gemma":[0.9986043,0.00015731338,0.0003124767,0.0002536417,0.00003379407,0.00044309566,0.00008134411,0.000014443967,0.000099603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986698,0.00007462212,0.0005037494,0.0002804625,0.0001960447,0.0002753372],"domain_scores_gemma":[0.99912596,0.000098044155,0.00022146456,0.00013623036,0.00027182497,0.00014644902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019857021,0.00013429711,0.00033429533,0.00010196382,0.000024613417,0.000015330266,0.00014724702,0.00006530809,0.00011442759],"category_scores_gemma":[0.00008536873,0.00009063365,0.000035337893,0.00025062013,0.00014272323,0.00027497965,0.000024532865,0.00013270491,0.000002727612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002799774,0.0031685673,0.89851564,0.000072047216,0.000109393746,0.00015672966,0.0003337894,0.00002376844,0.036327407,0.000062582585,0.000187729,0.05824258],"study_design_scores_gemma":[0.010150835,0.002256543,0.929079,0.00025164898,0.00005988193,0.000008333781,0.000063534455,0.00025131984,0.05187917,0.000075456854,0.005744295,0.00017999012],"about_ca_topic_score_codex":0.00032169325,"about_ca_topic_score_gemma":0.00034420303,"teacher_disagreement_score":0.05806259,"about_ca_system_score_codex":0.00013088627,"about_ca_system_score_gemma":0.00017777534,"threshold_uncertainty_score":0.3695933},"labels":[],"label_agreement":null},{"id":"W2588072385","doi":"10.1093/annonc/mdw379.18","title":"Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis; Pfizer; GlaxoSmithKline Australia; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Discontinuation; Internal medicine; Nivolumab; Adverse effect; Regimen; Toxicity; Melanoma; Gastroenterology; Oncology; Immunotherapy; Cancer","score_opus":0.023034425118017395,"score_gpt":0.3101263806729594,"score_spread":0.287091955554942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588072385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943196,0.0004901387,0.000012806534,0.00210238,0.00006224671,0.0005122813,0.000021250878,0.000008846885,0.0024704027],"genre_scores_gemma":[0.9970313,0.0021692254,0.00017614473,0.000334706,0.000010464363,0.000019830244,0.000013425792,0.000011647849,0.00023330258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991073,0.00007246918,0.00034247254,0.0001715447,0.00014532924,0.00016087286],"domain_scores_gemma":[0.99922544,0.000105139145,0.00024030502,0.00016668491,0.00022615858,0.000036287853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002338197,0.00010088838,0.0003759006,0.00012270901,0.00001811347,0.0000011175057,0.000057775855,0.00010148537,0.00012809389],"category_scores_gemma":[0.000031132004,0.00006287524,0.00004270298,0.00014654781,0.0002075164,0.00008900241,0.000015579228,0.00005327861,0.00000140155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03940254,0.0010383296,0.106092654,0.000044878474,0.0001129732,0.0000033614185,0.00036646094,1.8436647e-7,0.01557248,0.00012485111,0.0003025608,0.83693874],"study_design_scores_gemma":[0.044739734,0.033820372,0.8707369,0.0002622987,0.000012799036,0.000006421729,0.000096931406,0.000004714779,0.038782053,0.00012838155,0.011299338,0.000110072666],"about_ca_topic_score_codex":0.000072360795,"about_ca_topic_score_gemma":0.00006966386,"teacher_disagreement_score":0.83682865,"about_ca_system_score_codex":0.00006141934,"about_ca_system_score_gemma":0.00014149249,"threshold_uncertainty_score":0.25639778},"labels":[],"label_agreement":null},{"id":"W2588076823","doi":"10.1093/annonc/mdw435.22","title":"genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Eisai; GlaxoSmithKline Australia; Exelixis; Roche; Bayer; Novartis; British Microcirculation Society; Pfizer","keywords":"Medicine; Clinical endpoint; Renal cell carcinoma; Adverse effect; Urology; Placebo; Internal medicine; Sunitinib; Nephrectomy; Surgery; Randomized controlled trial; Kidney; Pathology","score_opus":0.04961390079722365,"score_gpt":0.34960734874100846,"score_spread":0.2999934479437848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588076823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827136,0.0008724616,0.000045309247,0.0025098096,0.0003969217,0.004794587,0.00061004004,0.000036432146,0.0024630607],"genre_scores_gemma":[0.99214554,0.00072898815,0.0009716078,0.00021146219,0.00068161084,0.0012646111,0.00015778052,0.00008143535,0.0037569485],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966023,0.00034670028,0.0011919815,0.00066711765,0.00040504767,0.00078688195],"domain_scores_gemma":[0.99654263,0.0008657774,0.0009524365,0.0006992947,0.00052711775,0.0004127175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005840652,0.0005346212,0.0016681704,0.00037003978,0.000079874735,0.00000809456,0.00018282642,0.0003206324,0.00036512152],"category_scores_gemma":[0.00011062315,0.0003483254,0.0006065718,0.00016336737,0.00031067745,0.00011852613,0.0000797725,0.00017332275,0.000045352106],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80546,0.010619251,0.00417034,0.00022040932,0.00057456875,0.0020025962,0.001248614,0.000003246749,0.054426573,0.000028512612,0.0052565737,0.11598933],"study_design_scores_gemma":[0.29177642,0.18332848,0.008462366,0.000121798024,0.001021422,0.00014913469,0.00013163875,0.000006755294,0.49952966,0.00016378133,0.015035758,0.00027277687],"about_ca_topic_score_codex":0.0009620734,"about_ca_topic_score_gemma":0.00008167719,"teacher_disagreement_score":0.51368356,"about_ca_system_score_codex":0.00030370028,"about_ca_system_score_gemma":0.0010782355,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W2588078738","doi":"10.1093/annonc/mdw383.27","title":"Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Adverse effect; Cohort; Internal medicine; Lung cancer; Cancer; Health care; Population; Disease; Emergency medicine; Environmental health","score_opus":0.02375497880615168,"score_gpt":0.3987762668068963,"score_spread":0.37502128800074463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588078738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996883,0.00034117117,0.0000020885716,0.00078778417,0.00007884249,0.0008605497,0.00025563128,0.000007675362,0.00078325416],"genre_scores_gemma":[0.99827063,0.00082877075,0.000078641046,0.00032425503,0.000026026692,0.00007232342,0.000029917815,0.00002168195,0.0003477465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990495,0.00004403236,0.0002962716,0.00021444443,0.00013504206,0.00026070763],"domain_scores_gemma":[0.99905807,0.00006038181,0.00026686638,0.00020492951,0.00029896223,0.000110821486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005381065,0.00015042051,0.0004178304,0.00013642933,0.000022833945,4.1038518e-7,0.000060287064,0.00008874022,0.0001968222],"category_scores_gemma":[0.00000983372,0.0000872007,0.000091896145,0.0001311626,0.000033239146,0.000072914874,0.000012861683,0.00008388686,0.000002269775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056631626,0.0014136686,0.9549325,0.00013243192,0.0002801708,0.000012527269,0.0007305709,0.00015059105,0.0014432926,0.0000022514475,0.00009883628,0.035140004],"study_design_scores_gemma":[0.019553257,0.011368728,0.9632443,0.0006101613,0.000035312867,0.0000012978292,0.000039602084,0.0000022501724,0.004916918,0.00000554976,0.0001340721,0.00008855461],"about_ca_topic_score_codex":0.0006242721,"about_ca_topic_score_gemma":0.0006059171,"teacher_disagreement_score":0.03505145,"about_ca_system_score_codex":0.00045682353,"about_ca_system_score_gemma":0.00064115744,"threshold_uncertainty_score":0.35559413},"labels":[],"label_agreement":null},{"id":"W2588085167","doi":"10.1093/annonc/mdw334.19","title":"Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Logistic regression; Proportional hazards model; Internal medicine; Prostate cancer; Surgery; Cancer","score_opus":0.15251213454962662,"score_gpt":0.5233643924927793,"score_spread":0.3708522579431527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588085167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906112,0.000065761276,0.00001593689,0.0027952015,0.0001049298,0.00027275598,0.00010471591,0.0000105204645,0.0060189706],"genre_scores_gemma":[0.997616,0.0012140955,0.000112879825,0.00005714079,0.000031641226,0.00005078158,0.00012402365,0.000007101242,0.0007863148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989051,0.00012869369,0.00037764476,0.000180994,0.00022967772,0.00017789399],"domain_scores_gemma":[0.99892575,0.00016731575,0.00019539692,0.00018373533,0.00045043914,0.00007736751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031172187,0.00007858658,0.0004955716,0.00035672061,0.000011400435,0.0000035860774,0.00017044385,0.00010644281,0.00060062465],"category_scores_gemma":[0.000103621634,0.000052547948,0.00013003817,0.0004826812,0.00019409227,0.00017358012,0.00005212552,0.000074055366,0.0000017328786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018721449,0.0029467167,0.8890941,0.00002285523,0.0014233299,0.000009953576,0.00026723454,0.000005005173,0.015671737,0.000082368315,0.0010182359,0.08758633],"study_design_scores_gemma":[0.007087743,0.0032307934,0.9407502,0.00007325429,0.00027773782,0.000003887988,0.0001281594,0.00012719944,0.041266512,0.00030644744,0.006651742,0.000096355216],"about_ca_topic_score_codex":0.0007087092,"about_ca_topic_score_gemma":0.0005174056,"teacher_disagreement_score":0.08748998,"about_ca_system_score_codex":0.000074096,"about_ca_system_score_gemma":0.00020136086,"threshold_uncertainty_score":0.6576419},"labels":[],"label_agreement":null},{"id":"W2588091899","doi":"10.1093/annonc/mdw368.45","title":"Retrospective review of new phase I clinic referrals and enrolment in the molecular screening era","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Demographics; Clinical trial; Profiling (computer programming); Internal medicine; Retrospective cohort study; Molecular diagnostics; Bioinformatics","score_opus":0.08229589332991764,"score_gpt":0.4211231559248956,"score_spread":0.3388272625949779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588091899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90311074,0.07492103,0.0008797941,0.01620911,0.000079039935,0.00041519318,0.00006146484,0.0000019967642,0.004321658],"genre_scores_gemma":[0.83921134,0.15447384,0.000503147,0.0056338976,0.000069729824,0.000011973177,0.000011276361,0.0000073648985,0.0000774018],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991727,0.00009836318,0.00033097158,0.00018512794,0.000076760865,0.00013606573],"domain_scores_gemma":[0.99933726,0.00006819494,0.00020226643,0.00025164062,0.00009818123,0.000042485437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050059555,0.00008130458,0.00026313504,0.000028235625,0.0000110480805,0.0000019646022,0.00014076885,0.00008781334,0.0000369159],"category_scores_gemma":[0.00044618826,0.00005276164,0.00007468554,0.000060605744,0.000091194874,0.0000021865617,0.00007495388,0.000053353448,0.0000011729365],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006355696,0.00055330025,0.0034098139,0.0003450171,0.0001814924,0.000027938355,0.00021552402,0.0000020963191,0.52356756,0.0022389991,0.06586186,0.40296087],"study_design_scores_gemma":[0.0059310584,0.013119239,0.014754357,0.0016345982,0.00009012189,0.00003441368,0.00011315871,0.0000022885247,0.30052838,0.003379315,0.6600985,0.00031456404],"about_ca_topic_score_codex":0.00004454929,"about_ca_topic_score_gemma":0.000031463394,"teacher_disagreement_score":0.5942367,"about_ca_system_score_codex":0.0000074718405,"about_ca_system_score_gemma":0.000142319,"threshold_uncertainty_score":0.21515572},"labels":[],"label_agreement":null},{"id":"W2588106160","doi":"10.1093/annonc/mdw378.16","title":"Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Tolerability; Renal cell carcinoma; Adverse effect; Sunitinib; Oncology; Toxicity; Gastroenterology; Immunotherapy; Cancer","score_opus":0.06595504791265101,"score_gpt":0.36861642131899086,"score_spread":0.30266137340633986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588106160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953208,0.00019463754,0.0000057232533,0.0022401991,0.00006309078,0.0016147447,0.00008458039,0.000009814869,0.00046643504],"genre_scores_gemma":[0.9994719,0.00005539186,0.00003345493,0.00016768278,0.0000133379235,0.000063302396,0.00003112373,0.000016226513,0.00014758288],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976579,0.00058507686,0.0008910379,0.00032468297,0.00029667362,0.00024463833],"domain_scores_gemma":[0.99842477,0.0003722861,0.0005047965,0.0004521038,0.0002042098,0.00004182834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012311548,0.0001679277,0.0006538706,0.00027402703,0.000027827553,0.0000038818985,0.00018913865,0.00006633805,0.0000863048],"category_scores_gemma":[0.000073406096,0.00009160877,0.000057248933,0.0004931057,0.00016984304,0.00008485072,0.00004354554,0.00014911317,0.0000027644244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4224386,0.11209392,0.10986375,0.000087260705,0.0014715085,0.001031827,0.057487383,0.000022767312,0.15302111,0.000014806682,0.0035274578,0.13893962],"study_design_scores_gemma":[0.26574203,0.087675564,0.603561,0.00017447838,0.00022793122,0.000011767434,0.016487345,0.000082584935,0.024921002,0.000081605926,0.0008441545,0.00019050884],"about_ca_topic_score_codex":0.0066853175,"about_ca_topic_score_gemma":0.007286399,"teacher_disagreement_score":0.49369726,"about_ca_system_score_codex":0.00010537632,"about_ca_system_score_gemma":0.00030586516,"threshold_uncertainty_score":0.99992925},"labels":[],"label_agreement":null},{"id":"W2588109063","doi":"10.1093/annonc/mdw376.33","title":"Pharmacogenomic predictors of cisplatin oto- and nephrotoxicity in head and neck cancer patients treated with chemoradiation","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ear and Head Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Nephrotoxicity; Ototoxicity; Internal medicine; Hazard ratio; Oncology; Head and neck squamous-cell carcinoma; Cisplatin; Prospective cohort study; Renal function; Head and neck cancer; Urology; Confidence interval; Cancer; Chemotherapy; Toxicity","score_opus":0.03928305659469425,"score_gpt":0.35601177363253317,"score_spread":0.3167287170378389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588109063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824303,0.00013453444,7.0575453e-7,0.00074007123,0.000016369535,0.0003415876,0.000038902916,0.0000049995942,0.00047977472],"genre_scores_gemma":[0.9991346,0.00048231735,0.000037788537,0.0002458833,0.000027135848,0.00001757459,0.0000064672813,0.000007110772,0.000041151237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994664,0.000029674162,0.00020209224,0.000118698794,0.00006659097,0.00011654132],"domain_scores_gemma":[0.9996015,0.00006589567,0.0001244414,0.0000539773,0.00008618549,0.000068043395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008820867,0.0000687095,0.00029092224,0.00008850867,0.000009618042,6.95012e-7,0.000018721454,0.000060855007,0.000055020475],"category_scores_gemma":[0.00003573585,0.000044125718,0.000013912565,0.00007373382,0.00009368519,0.000045352746,0.000012151016,0.00004567109,7.39222e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011490992,0.00020790982,0.956376,0.000058739595,0.000036015586,0.000004985674,0.00027112357,5.448984e-7,0.029163295,0.0000048200814,0.00024382136,0.012483623],"study_design_scores_gemma":[0.005399058,0.003057131,0.92688084,0.00013466725,0.00003143436,0.000004538454,0.000010929874,0.00002218645,0.06397717,0.000009007996,0.00043019786,0.00004284931],"about_ca_topic_score_codex":0.00042386717,"about_ca_topic_score_gemma":0.0002012248,"teacher_disagreement_score":0.034813873,"about_ca_system_score_codex":0.000026399057,"about_ca_system_score_gemma":0.00008855754,"threshold_uncertainty_score":0.17993945},"labels":[],"label_agreement":null},{"id":"W2588136622","doi":"10.1093/annonc/mdw390.08","title":"Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Nausea; Chemotherapy-induced nausea and vomiting; Vomiting; Internal medicine; Aprepitant; Gastroenterology; Antiemetic; Anesthesia; Oncology","score_opus":0.04064810763060098,"score_gpt":0.34505966485782047,"score_spread":0.30441155722721946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588136622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984892,0.000028842274,0.000081224054,0.0006208224,0.00001250868,0.00059504487,0.000006680955,0.000003972494,0.00016168071],"genre_scores_gemma":[0.9984931,0.000025276551,0.0013707894,0.000054023,0.00001575089,0.000012162169,0.0000026027092,0.000008511249,0.000017823431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933374,0.000030733037,0.0002758652,0.00013574536,0.00008408663,0.00013983634],"domain_scores_gemma":[0.9992323,0.00022421918,0.00027743448,0.000065081134,0.00016165728,0.000039330775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002607322,0.000071716495,0.00032654143,0.000099004494,0.000010287046,9.0809056e-7,0.000027958333,0.00003400653,0.000005423814],"category_scores_gemma":[0.00018654478,0.000048893307,0.000028117196,0.000059284255,0.00009322131,0.000033530916,0.000019030314,0.000034549994,5.473401e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010988544,0.0005558671,0.8400343,0.00029411458,0.00010706433,0.0000025100428,0.0002321948,0.0000010230341,0.03792228,0.00017474456,0.00007173616,0.10961561],"study_design_scores_gemma":[0.015535295,0.018695198,0.93222284,0.0006989532,0.000042208103,0.000004495623,0.00006618442,0.000019979398,0.032535408,0.00008171459,0.00004874125,0.000049001672],"about_ca_topic_score_codex":0.000043880063,"about_ca_topic_score_gemma":0.00005588964,"teacher_disagreement_score":0.10956661,"about_ca_system_score_codex":0.000029870125,"about_ca_system_score_gemma":0.00007849911,"threshold_uncertainty_score":0.19938111},"labels":[],"label_agreement":null},{"id":"W2588151113","doi":"10.1093/annonc/mdw369.09","title":"Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; European union; Incidence (geometry); Neuroendocrine tumors; Population; MEDLINE; Disease; Epidemiology; Internal medicine; Demography; Environmental health","score_opus":0.04581870356947835,"score_gpt":0.37731139534747443,"score_spread":0.33149269177799606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588151113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745593,0.00043849245,0.000014204041,0.020320341,0.000027762826,0.0002983596,0.000008834088,0.000008109855,0.004324614],"genre_scores_gemma":[0.9964558,0.0027109806,0.000078444,0.0004023259,0.00003717456,0.000008511836,6.7153167e-7,0.000011669182,0.00029444243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979233,0.0010972857,0.00031016118,0.00018211309,0.00019764519,0.00028949036],"domain_scores_gemma":[0.9990324,0.00039888837,0.00014247111,0.00026159332,0.0000930568,0.00007159123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005302845,0.00009027,0.00027462112,0.0001403963,0.000013164208,0.0000019145837,0.00018029411,0.0000026908085,0.00002720396],"category_scores_gemma":[0.0006033795,0.000049299353,0.000040834268,0.00011854085,0.00032660074,0.00007991647,0.00009735511,0.00011691374,0.000003084242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005832027,0.00058512285,0.8850836,0.0008555552,0.000026402422,0.004645341,0.00012835782,0.0000017398623,0.050404858,0.00024648922,0.0036193882,0.053819906],"study_design_scores_gemma":[0.0021844872,0.006311827,0.96814746,0.00036727544,0.000033343422,0.002590925,0.000100041376,0.0000073414517,0.017739644,0.00016729216,0.002302015,0.000048342572],"about_ca_topic_score_codex":0.000023848746,"about_ca_topic_score_gemma":0.000014376912,"teacher_disagreement_score":0.08306383,"about_ca_system_score_codex":0.000009944907,"about_ca_system_score_gemma":0.000038731534,"threshold_uncertainty_score":0.20103693},"labels":[],"label_agreement":null},{"id":"W2588167612","doi":"10.1093/annonc/mdw372.05","title":"FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Internal medicine; Neutropenia; Clinical endpoint; Adverse effect; Urology; Post-hoc analysis; Progression-free survival; Oncology; Randomized controlled trial; Chemotherapy; Cancer; Androgen deprivation therapy","score_opus":0.2073846625539299,"score_gpt":0.49537599031462526,"score_spread":0.28799132776069536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588167612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97649986,0.001963102,0.00022421766,0.017338937,0.000050607454,0.0035070288,0.00034746548,0.000012974759,0.00005581824],"genre_scores_gemma":[0.9966302,0.00043651377,0.00078999647,0.0016614302,0.0000117408335,0.00026039127,0.000036180358,0.000027851658,0.00014573181],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967905,0.0004993673,0.0014617847,0.0004022598,0.00046840156,0.00037763515],"domain_scores_gemma":[0.9962133,0.0010548339,0.0014058066,0.00037665595,0.0007532208,0.00019613658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019574268,0.00024912765,0.0012356244,0.00023838272,0.000098467324,0.000015689111,0.00012727235,0.000045712528,0.00009240312],"category_scores_gemma":[0.00071321725,0.00013895602,0.00011027754,0.00035157395,0.00028564548,0.00020313043,0.00003803588,0.00010675604,4.654092e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16674212,0.041506827,0.14875185,0.0047453297,0.0127966795,0.000121094556,0.023637893,0.00018121385,0.007788717,0.0005570009,0.0048503936,0.58832085],"study_design_scores_gemma":[0.12363139,0.036214534,0.81953734,0.0006025134,0.0014936486,0.000002767637,0.016254965,0.00034186715,0.0003496146,0.00024479933,0.0009425211,0.000384021],"about_ca_topic_score_codex":0.003693128,"about_ca_topic_score_gemma":0.0039696847,"teacher_disagreement_score":0.6707855,"about_ca_system_score_codex":0.00009261262,"about_ca_system_score_gemma":0.00093358714,"threshold_uncertainty_score":0.5666462},"labels":[],"label_agreement":null},{"id":"W2588171532","doi":"10.1093/annonc/mdw373.54","title":"Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Pazopanib; Sunitinib; Sorafenib; Renal cell carcinoma; Axitinib; Hazard ratio; Internal medicine; Oncology; Targeted therapy; Proportional hazards model; Everolimus; Dosing; Progression-free survival; Temsirolimus; Cancer; Overall survival; Confidence interval; Hepatocellular carcinoma","score_opus":0.15936970711736387,"score_gpt":0.4342919707927113,"score_spread":0.27492226367534744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588171532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96323144,0.015071047,0.000004147948,0.020549614,0.00004163496,0.00073344156,0.000015211228,0.000003378711,0.00035010974],"genre_scores_gemma":[0.9679927,0.029030519,0.0001287307,0.0027302133,0.000026962349,0.00004209056,0.000005486121,0.000009718854,0.000033546916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790365,0.0006402647,0.0007980042,0.00024673002,0.00019896828,0.0002123899],"domain_scores_gemma":[0.99837756,0.0008344944,0.00031370143,0.0002922648,0.00012673435,0.00005527029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014770824,0.0001408347,0.001091725,0.00012673433,0.000010673094,0.0000014876316,0.000090597096,0.0000716817,0.000065473054],"category_scores_gemma":[0.0003547798,0.00006725938,0.00017072378,0.00015488087,0.00015908439,0.00004185089,0.000025778185,0.00013326143,0.0000017071691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036130246,0.0006981888,0.9612703,0.0001516622,0.000110317145,0.00023445078,0.0005012928,2.5331882e-8,0.00079519686,0.000074446616,0.0002926444,0.035510182],"study_design_scores_gemma":[0.004182826,0.0059373076,0.98611635,0.0006262126,0.00007053575,0.00005262311,0.00008819423,0.000001030469,0.0013908976,0.00016797817,0.001305719,0.00006031772],"about_ca_topic_score_codex":0.00025769006,"about_ca_topic_score_gemma":0.00015225554,"teacher_disagreement_score":0.035449866,"about_ca_system_score_codex":0.000050606366,"about_ca_system_score_gemma":0.000113751456,"threshold_uncertainty_score":0.2742758},"labels":[],"label_agreement":null},{"id":"W2588188936","doi":"10.1093/annonc/mdw372.31","title":"Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Bicalutamide; Androgen; Internal medicine; Oncology; Prostate-specific antigen; Androgen receptor; Cancer; Hormone","score_opus":0.12338188511774176,"score_gpt":0.44527526900509845,"score_spread":0.32189338388735667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588188936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94339067,0.0008114751,0.000025557614,0.0378676,0.00022772062,0.001176449,0.014111124,0.00004738259,0.0023419943],"genre_scores_gemma":[0.9781999,0.006915459,0.00016219068,0.00064099923,0.00019696455,0.00030161988,0.0008131664,0.00002171447,0.012747995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843264,0.000066122186,0.0004165551,0.00041142185,0.00017781273,0.0004954801],"domain_scores_gemma":[0.9987366,0.00020210168,0.00020384867,0.00032554058,0.00032377703,0.00020812324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001759957,0.00019250355,0.00053270464,0.000064589054,0.000052698797,0.000006401176,0.00010395018,0.00016180199,0.00026791354],"category_scores_gemma":[0.00007007298,0.00010786596,0.00015879367,0.000120377474,0.00013421875,0.000070039896,0.000042830892,0.00004293587,0.000023841865],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033462636,0.0015163266,0.12203424,0.0000728331,0.0014501777,0.00032449924,0.00070192444,0.000018472536,0.005534127,0.00012823577,0.031026114,0.8037304],"study_design_scores_gemma":[0.044800524,0.022235803,0.10759782,0.00031639487,0.00025223137,0.000004495033,0.00014629557,0.00009126859,0.08794663,0.00068835285,0.7356347,0.00028551716],"about_ca_topic_score_codex":0.0039947387,"about_ca_topic_score_gemma":0.0015585767,"teacher_disagreement_score":0.8034449,"about_ca_system_score_codex":0.00041017286,"about_ca_system_score_gemma":0.0006946847,"threshold_uncertainty_score":0.6038877},"labels":[],"label_agreement":null},{"id":"W2588189979","doi":"10.1093/annonc/mdw390.31","title":"Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Denosumab; Zoledronic acid; Breast cancer; Pathologic fracture; Spinal cord compression; Hazard ratio; Surgery; Internal medicine; Bone metastasis; Population; Oncology; Urology; Osteoporosis; Cancer; Confidence interval; Spinal cord","score_opus":0.03401052323014495,"score_gpt":0.37444077960409744,"score_spread":0.34043025637395247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588189979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408305,0.0004079136,0.00017583203,0.0027755604,0.00008403978,0.0022872265,0.000115910734,0.000013479222,0.00005701673],"genre_scores_gemma":[0.998834,0.0001385876,0.00032488108,0.00013417227,0.000009681704,0.0002932571,0.00004577749,0.000029121487,0.00019047996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980337,0.00015921576,0.00077352335,0.0002620659,0.00035558722,0.0004159076],"domain_scores_gemma":[0.9981147,0.00033885072,0.00077351613,0.00028705926,0.00035636165,0.00012953485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003235524,0.00020946494,0.00081702985,0.00016907587,0.000054212487,0.0000015012981,0.000106597014,0.000102530685,0.00006081355],"category_scores_gemma":[0.000049185845,0.000104496045,0.00011340504,0.0002711577,0.00013739448,0.00010956905,0.00002589476,0.000109338456,0.0000069994544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047217733,0.004346502,0.8388578,0.00045963752,0.0008567885,0.0000064960495,0.00021118618,0.000014719919,0.000028524883,0.000052559255,0.00021474264,0.15022922],"study_design_scores_gemma":[0.024585562,0.012013994,0.9607055,0.0013004882,0.0004785691,0.000031022966,0.00005533475,0.000095584255,0.00015000098,0.00026515368,0.00020419715,0.00011458022],"about_ca_topic_score_codex":0.0003697718,"about_ca_topic_score_gemma":0.0006780753,"teacher_disagreement_score":0.15011464,"about_ca_system_score_codex":0.00012541114,"about_ca_system_score_gemma":0.0004985047,"threshold_uncertainty_score":0.4261225},"labels":[],"label_agreement":null},{"id":"W2588199706","doi":"10.1093/annonc/mdw390.28","title":"A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Taxane; Discontinuation; Prostate cancer; Breast cancer; myalgia; Chemotherapy; Internal medicine; Brief Pain Inventory; Cancer; Oncology; Physical therapy; Chronic pain","score_opus":0.059749570670552574,"score_gpt":0.37985821728456703,"score_spread":0.32010864661401445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588199706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97297496,0.00030424967,0.000005853352,0.023375282,0.00042214955,0.0027256326,0.00016109066,0.000014582149,0.000016210184],"genre_scores_gemma":[0.9902158,0.00012305648,0.00029878365,0.005958105,0.000042539898,0.00036137825,0.000013999286,0.000027160211,0.0029591934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847513,0.00029785105,0.00043788322,0.00028962607,0.00014922608,0.00035028468],"domain_scores_gemma":[0.9985505,0.00046592765,0.00035504482,0.00020728767,0.00030552133,0.00011574212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061653403,0.00018705653,0.000611958,0.00015963208,0.000022570384,0.0000014099807,0.00014588611,0.00007478992,0.00022167755],"category_scores_gemma":[0.00016479025,0.000102436155,0.000096804244,0.00016341486,0.00017397534,0.000046974583,0.000030474443,0.00010715301,0.0000025379018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029381061,0.010588875,0.5332202,0.00021523495,0.0010983751,0.00012701,0.009196457,0.0000131259,0.021768823,0.0000017130182,0.042780478,0.3516087],"study_design_scores_gemma":[0.07394155,0.033651054,0.83813155,0.00065150164,0.00044715984,0.00002839984,0.0005673863,0.0001515376,0.0054333066,0.000010246009,0.04660772,0.0003786145],"about_ca_topic_score_codex":0.0006022973,"about_ca_topic_score_gemma":0.0021030088,"teacher_disagreement_score":0.35123006,"about_ca_system_score_codex":0.0005463707,"about_ca_system_score_gemma":0.00088514,"threshold_uncertainty_score":0.41772252},"labels":[],"label_agreement":null},{"id":"W2588216634","doi":"10.1093/annonc/mdw383.96","title":"A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Pemetrexed; Internal medicine; Oncology; Metastatic breast cancer; Taxane; Clinical endpoint; Phases of clinical research; Cancer; Chemotherapy; Breast cancer; Randomized controlled trial","score_opus":0.034498615738255564,"score_gpt":0.3920148553917564,"score_spread":0.3575162396535008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588216634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994241,0.00022038659,0.0001946623,0.00077468,0.00011413285,0.003807775,0.00020344499,0.00001827382,0.00042562105],"genre_scores_gemma":[0.9965958,0.00020398694,0.0015660402,0.00017302785,0.000015399144,0.00053936895,0.00008036223,0.000051079453,0.00077494705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974977,0.00021397788,0.000812597,0.0005452283,0.00045075372,0.0004797898],"domain_scores_gemma":[0.99731797,0.0005208822,0.0007148687,0.0003555099,0.00092974363,0.00016104849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002479674,0.000371834,0.0012311838,0.0005524049,0.000050224284,0.000007613713,0.00016067528,0.00009856573,0.00022173596],"category_scores_gemma":[0.00014916652,0.00019322043,0.00006301845,0.0011145597,0.00015897842,0.00026478886,0.000048073885,0.00016518057,0.0000025626757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.550191,0.107858084,0.15342087,0.00086829194,0.003487645,0.001523249,0.012122042,0.00032523283,0.0014080121,0.000020622409,0.00041477784,0.16836022],"study_design_scores_gemma":[0.5168155,0.23688926,0.23005249,0.0018663233,0.0018711874,0.000013846443,0.005304809,0.00021787632,0.0062896595,0.000010254757,0.00017862885,0.0004902044],"about_ca_topic_score_codex":0.0015933602,"about_ca_topic_score_gemma":0.01962021,"teacher_disagreement_score":0.16787001,"about_ca_system_score_codex":0.0004645898,"about_ca_system_score_gemma":0.0017998905,"threshold_uncertainty_score":0.99826914},"labels":[],"label_agreement":null},{"id":"W2588229474","doi":"10.1093/annonc/mdw435.09","title":"CNS tumours The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"North Carolina GlaxoSmithKline Foundation","keywords":"Medicine; Dabrafenib; Trametinib; Internal medicine; Rash; Adverse effect; Refractory (planetary science); Oncology; Gastroenterology; Cancer; Kinase; Vemurafenib; MAPK/ERK pathway","score_opus":0.05040336938385071,"score_gpt":0.354387140936592,"score_spread":0.3039837715527413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588229474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956088,0.00006320197,5.7428514e-7,0.0027687622,0.00006636716,0.0010554511,0.000022142161,0.000013663929,0.000401059],"genre_scores_gemma":[0.9993,0.00018504518,0.000011517375,0.00020081697,0.000047576064,0.00005552457,0.000003607657,0.000024171586,0.00017175284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981674,0.00021173149,0.00044654193,0.00029188942,0.00048523248,0.0003972145],"domain_scores_gemma":[0.99819154,0.0007122289,0.00029379717,0.00042996343,0.00022617204,0.00014632576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025934208,0.0001673831,0.0004982404,0.00033674153,0.000047793623,0.0000028106406,0.00020670982,0.0000857904,0.00009861009],"category_scores_gemma":[0.00037377662,0.00007314676,0.000061858664,0.0005378907,0.00017974258,0.000090344256,0.00008699667,0.00018931647,0.00001912528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009261089,0.018841393,0.9592278,0.000080121325,0.00016944259,0.0010708221,0.00074146653,0.0000015456365,0.0005189004,0.000009690582,0.0011326723,0.008945033],"study_design_scores_gemma":[0.018515792,0.048143793,0.9294794,0.00008326391,0.000082232764,0.00001726348,0.00018361061,9.930638e-7,0.0023741904,0.000021069369,0.0010178207,0.00008052197],"about_ca_topic_score_codex":0.00010864609,"about_ca_topic_score_gemma":0.0012205426,"teacher_disagreement_score":0.029748373,"about_ca_system_score_codex":0.00006354023,"about_ca_system_score_gemma":0.0003642912,"threshold_uncertainty_score":0.29828382},"labels":[],"label_agreement":null},{"id":"W2588242485","doi":"10.1093/annonc/mdx023","title":"Data resources for the identification and interpretation of actionable mutations by clinicians","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Identification (biology); Medicine; Computational biology; Genomic information; Genomics; Data science; Relevance (law); Profiling (computer programming); Population; Bioinformatics; Genome; Computer science; Genetics; Biology; Gene","score_opus":0.22929040078322338,"score_gpt":0.5013816274467378,"score_spread":0.2720912266635144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588242485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008916112,0.9940303,0.0015699676,0.00037001647,0.00020370321,0.000420139,0.003086942,0.0000010549303,0.00022872623],"genre_scores_gemma":[0.0013177705,0.9957148,0.00011488879,0.00006723476,0.00013270258,0.00007042536,0.0022843694,0.000012250678,0.00028556725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991569,0.000051260246,0.00045348093,0.00022372385,0.000038924914,0.00007570617],"domain_scores_gemma":[0.99777406,0.0004634282,0.0009772604,0.00061163295,0.00015561469,0.000017979166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005165973,0.00008647147,0.00038297262,0.000030679133,0.0000795264,0.000015356634,0.0004233814,0.00019576012,0.0000019409601],"category_scores_gemma":[0.00092760805,0.00006858164,0.00010116275,0.000020847128,0.00017418065,0.000004173224,0.00015196923,0.000052498614,5.8215113e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029813518,0.000036869922,0.0000016877569,0.00065031956,0.00016588565,5.4130837e-8,0.000025047882,0.0000035153953,0.000097201104,0.00004247395,0.031781048,0.96716607],"study_design_scores_gemma":[0.000097595315,0.00036344124,0.0000073810343,0.00016145014,0.00030143393,0.0000027795793,0.000038625363,0.000091737915,0.00010844154,0.00010471891,0.99866307,0.000059338094],"about_ca_topic_score_codex":0.000036122092,"about_ca_topic_score_gemma":0.0001224363,"teacher_disagreement_score":0.96710676,"about_ca_system_score_codex":0.0000048459283,"about_ca_system_score_gemma":0.00022931841,"threshold_uncertainty_score":0.27966782},"labels":[],"label_agreement":null},{"id":"W2588263979","doi":"10.1093/annonc/mdw391.06","title":"Wait times for diagnosis and treatment of lung cancer: a single centre experience","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Referral; Lung cancer; Retrospective cohort study; Internal medicine; Cancer; Biopsy; Surgery; Family medicine","score_opus":0.08030331435305532,"score_gpt":0.4092052998195316,"score_spread":0.32890198546647625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588263979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698184,0.00655396,0.0000061109367,0.022107,0.00009338466,0.0005894074,0.00010225743,0.000009271711,0.00072020624],"genre_scores_gemma":[0.98162633,0.016744964,0.00022160473,0.0002612002,0.000071044764,0.00055837334,0.0000037891318,0.000009642347,0.00050306006],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993364,0.000017851931,0.00020724752,0.00019034513,0.00006984326,0.00017826109],"domain_scores_gemma":[0.9991543,0.0003551566,0.00013031632,0.00013924025,0.00013509774,0.00008583291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003510499,0.00010080263,0.00041702308,0.00004445692,0.000020553773,0.0000015134434,0.000030123338,0.000062155865,0.00021570563],"category_scores_gemma":[0.000037935264,0.00005843387,0.00009629727,0.000042713487,0.00011807786,0.000034774697,0.000013447817,0.000008573482,8.172966e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048146243,0.0023065403,0.5261528,0.000109039014,0.00040269486,0.000012239223,0.001741934,3.068191e-7,0.0015103398,0.00040804344,0.011205606,0.455669],"study_design_scores_gemma":[0.01062528,0.023243908,0.07454594,0.0008304365,0.00060356624,0.000010844194,0.00030867147,0.000025421468,0.5489423,0.00018518612,0.34049535,0.00018304962],"about_ca_topic_score_codex":0.00023009359,"about_ca_topic_score_gemma":0.00017159284,"teacher_disagreement_score":0.547432,"about_ca_system_score_codex":0.00017092098,"about_ca_system_score_gemma":0.0001120509,"threshold_uncertainty_score":0.2382864},"labels":[],"label_agreement":null},{"id":"W2588270533","doi":"10.1093/annonc/mdw370.126","title":"Family history of colorectal cancer (CRC) in first degree relatives and survival in patients with newly diagnosed synchronous metastatic CRC","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Family history; Oncology; Proportional hazards model; Cancer; First-degree relatives; Stage (stratigraphy); Cohort","score_opus":0.06834155026335785,"score_gpt":0.3201601214771804,"score_spread":0.25181857121382256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588270533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398136,0.002265032,0.000012611353,0.00066890183,0.00029719152,0.0005383031,0.000033021384,0.0000072062876,0.0021963753],"genre_scores_gemma":[0.9982218,0.00078820984,0.0006132127,0.00014997702,0.0000144053265,0.00008306637,0.0000033749006,0.000021309444,0.00010463747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857795,0.00015889698,0.00045771577,0.00028527708,0.00023662086,0.00028355428],"domain_scores_gemma":[0.99839735,0.00086429855,0.00027389207,0.0001518992,0.00022232358,0.00009022884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026921422,0.00016901553,0.00072955695,0.00023436573,0.000009735958,8.4371834e-7,0.00009117479,0.00012395233,0.00013585693],"category_scores_gemma":[0.00033958047,0.00011675459,0.000043006807,0.00016164455,0.00052938703,0.00006836707,0.00005247746,0.00014162017,0.0000017025051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034088942,0.00065498095,0.9525979,0.00011804311,0.000110892426,0.000042646006,0.0016463319,0.000026293235,0.0019664892,0.000016052354,0.00084666815,0.038564797],"study_design_scores_gemma":[0.008451476,0.0080545815,0.98033875,0.000325525,0.000045749468,0.00000201439,0.00011841976,0.000013733493,0.00070073025,0.000051009367,0.0017714343,0.00012660133],"about_ca_topic_score_codex":0.0018904614,"about_ca_topic_score_gemma":0.010685899,"teacher_disagreement_score":0.038438194,"about_ca_system_score_codex":0.00062232255,"about_ca_system_score_gemma":0.00089836115,"threshold_uncertainty_score":0.5962983},"labels":[],"label_agreement":null},{"id":"W2588338928","doi":"10.1093/annonc/mdw376.24","title":"Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Ontario Clinical Oncology Group; Ottawa Regional Cancer Foundation; Ottawa Hospital; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Adenoid cystic carcinoma; Internal medicine; Salivary gland cancer; Cancer; Oncology; Clinical trial; Malignancy; Gastroenterology; Carcinoma","score_opus":0.1353759683207808,"score_gpt":0.42389027378506977,"score_spread":0.28851430546428897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588338928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828192,0.00041287037,0.0000035215492,0.0072465874,0.0009767975,0.00089843717,0.00003103585,0.000010646279,0.0076009203],"genre_scores_gemma":[0.9974858,0.00027657783,0.00021643558,0.00134293,0.0002879195,0.00010297543,0.000014922132,0.000017136292,0.00025530436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972647,0.00054252153,0.0012233318,0.00037139963,0.00023304256,0.00036501078],"domain_scores_gemma":[0.9961965,0.0024328337,0.0005928527,0.00048725342,0.00013998944,0.00015054655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009835932,0.00019550107,0.001238441,0.000120139826,0.000028000792,0.0000016794064,0.00021132572,0.0003257614,0.00030370572],"category_scores_gemma":[0.0006906234,0.00010144005,0.00038600425,0.00015706103,0.0003282927,0.000056140827,0.00011822672,0.0002705126,0.00001693148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047150847,0.005009695,0.8977883,0.000029156186,0.00017723229,0.00037262074,0.00032089232,7.262967e-7,0.00018177085,0.0006760505,0.0013385037,0.04695423],"study_design_scores_gemma":[0.088382505,0.034952596,0.8584079,0.00015325927,0.00015345801,0.00009382431,0.000073650706,0.0000014043209,0.0010457776,0.0006878413,0.015943382,0.000104367755],"about_ca_topic_score_codex":0.004405369,"about_ca_topic_score_gemma":0.019838924,"teacher_disagreement_score":0.04684986,"about_ca_system_score_codex":0.0002222786,"about_ca_system_score_gemma":0.0009439999,"threshold_uncertainty_score":0.99804646},"labels":[],"label_agreement":null},{"id":"W2588351420","doi":"10.1093/annonc/mdw376.14","title":"Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genzyme","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Lymph; Lenvatinib; Gastroenterology; Urology; Metastasis; Oncology; Thyroid cancer; Thyroid; Cancer; Pathology","score_opus":0.16931094090994553,"score_gpt":0.4268932684996274,"score_spread":0.25758232758968186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588351420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96567947,0.0029539142,0.0000067926558,0.029110381,0.00014119117,0.00080843066,0.0004001217,0.000016920689,0.0008828071],"genre_scores_gemma":[0.99500626,0.0033781847,0.0003024724,0.00053929986,0.00023328788,0.0001966567,0.00005019638,0.000015964106,0.00027769431],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843854,0.00031958046,0.0004582505,0.00033084108,0.00018616352,0.0002666299],"domain_scores_gemma":[0.9962704,0.0029962868,0.0002064327,0.00038763968,0.00006217502,0.00007701818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044466747,0.00017599086,0.00060885365,0.00008586906,0.000042258765,0.000006046292,0.000081338614,0.000069060836,0.00008299509],"category_scores_gemma":[0.00023886545,0.00007548859,0.00017498601,0.000174908,0.00010100526,0.0000534075,0.000016367732,0.000058335474,0.000014547631],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47701666,0.0063277395,0.0049720514,0.0000028152822,0.0011679658,0.0009109359,0.0010009783,0.0000013181593,0.005856095,0.00009142989,0.01708455,0.48556748],"study_design_scores_gemma":[0.3962094,0.08480715,0.012503679,0.0002583443,0.0003504609,0.000017457718,0.00027710097,7.4170254e-7,0.08848538,0.00012392602,0.4168159,0.00015045625],"about_ca_topic_score_codex":0.0007624939,"about_ca_topic_score_gemma":0.0008226926,"teacher_disagreement_score":0.485417,"about_ca_system_score_codex":0.00015719907,"about_ca_system_score_gemma":0.0004235319,"threshold_uncertainty_score":0.30783355},"labels":[],"label_agreement":null},{"id":"W2588381983","doi":"10.1093/annonc/mdw383.38","title":"Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Erlotinib; Gastroenterology; Population; Lung cancer; Oncology; Epidermal growth factor receptor; Cancer","score_opus":0.1378102222120783,"score_gpt":0.4826661338630271,"score_spread":0.34485591165094875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588381983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807869,0.0013252912,0.000022464017,0.002665115,0.00024332567,0.012874388,0.00051689165,0.000002206444,0.00156337],"genre_scores_gemma":[0.9975995,0.00011999927,0.00021027344,0.00004719576,0.000058563146,0.0016908058,0.000018159615,0.000013101913,0.00024239568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99785614,0.00054363767,0.0009128002,0.00018465423,0.00033118928,0.00017160323],"domain_scores_gemma":[0.99450654,0.0031627151,0.0011552853,0.0004579353,0.0006898252,0.000027680191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019587209,0.0001519099,0.00089422095,0.00006747969,0.00004234978,0.000002260373,0.0002483626,0.000086930595,0.00008850931],"category_scores_gemma":[0.00096137804,0.00006406916,0.00021081808,0.00016940435,0.00029039377,0.00006150368,0.00003114276,0.000048878654,2.0102898e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85989153,0.01613027,0.0009870194,0.0003792858,0.0009349297,0.0000028817299,0.005126714,0.00011802877,0.038713492,0.00021336717,0.00079168566,0.07671079],"study_design_scores_gemma":[0.82699203,0.02882641,0.0011603492,0.00008290046,0.002251141,0.000002548026,0.0005916222,0.000757863,0.13883641,0.00013909875,0.00030378046,0.000055825425],"about_ca_topic_score_codex":0.00020988863,"about_ca_topic_score_gemma":0.00021306452,"teacher_disagreement_score":0.10012291,"about_ca_system_score_codex":0.00013231546,"about_ca_system_score_gemma":0.0014428599,"threshold_uncertainty_score":0.26126644},"labels":[],"label_agreement":null},{"id":"W2588388450","doi":"10.1093/annonc/mdw382.08","title":"Reaching the pinnacle of stage III NSCLC treatment","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Lung cancer; Stage (stratigraphy); Internal medicine; Chemotherapy; Cohort; Cancer; Surgery; Oncology","score_opus":0.10413635329029632,"score_gpt":0.41629703733108003,"score_spread":0.31216068404078373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588388450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92436826,0.0011612723,0.00002760317,0.045696307,0.00011707378,0.00035549604,0.000029628272,0.00001329494,0.028231066],"genre_scores_gemma":[0.9946654,0.0023705848,0.00008493049,0.0008396167,0.00007513926,0.00004717143,0.0000028991712,0.0000085718375,0.0019056775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992835,0.00006520638,0.00024665138,0.00013605636,0.0001080391,0.00016056777],"domain_scores_gemma":[0.9990565,0.00031959522,0.00016769822,0.00030816547,0.00009256968,0.00005543447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020415183,0.0000881836,0.00035310158,0.00004067493,0.000029023306,0.0000011648059,0.00006260926,0.000062410414,0.00020525116],"category_scores_gemma":[0.00004224176,0.000037585178,0.0001314031,0.000054774373,0.00012051925,0.000027371329,0.000024451054,0.000034010354,0.00001330949],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009896162,0.0026294687,0.040115144,0.000055399447,0.00096483453,0.00006598217,0.0015757468,0.000002214765,0.009906461,0.006182257,0.013262041,0.92425084],"study_design_scores_gemma":[0.011901898,0.02390322,0.11149791,0.00042346123,0.00038735385,0.00003273162,0.000442103,0.000005831852,0.2290453,0.00056581345,0.6216558,0.00013852683],"about_ca_topic_score_codex":0.0005727722,"about_ca_topic_score_gemma":0.00013107198,"teacher_disagreement_score":0.9241123,"about_ca_system_score_codex":0.00015897347,"about_ca_system_score_gemma":0.0001900351,"threshold_uncertainty_score":0.22473562},"labels":[],"label_agreement":null},{"id":"W2588389646","doi":"10.1093/annonc/mdw387.16","title":"Clinicians identify high need to increase their genomic literacy to applied cancer genomics","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; BC Cancer Agency","funders":"","keywords":"Genomics; Medicine; Literacy; Personalized medicine; Cancer; Family medicine; Bioinformatics; Genome; Internal medicine; Genetics; Gene; Biology","score_opus":0.033388268040397615,"score_gpt":0.36836560927253814,"score_spread":0.3349773412321405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588389646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98784494,0.00050538266,0.0010528506,0.0077810762,0.00048559427,0.00039096238,0.0005386252,0.000009373614,0.001391201],"genre_scores_gemma":[0.9800036,0.0022035115,0.0010289463,0.0154037895,0.0007929345,0.00011583764,0.000041834286,0.000041432064,0.0003681108],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985473,0.000048582202,0.00046773048,0.0004593682,0.00007229435,0.00040470422],"domain_scores_gemma":[0.99864143,0.00012937645,0.00018426268,0.0005173351,0.00024205884,0.00028555133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003011247,0.00019990376,0.00037422092,0.00011054773,0.000048615006,0.000016275222,0.0003974224,0.00021512051,0.000078043806],"category_scores_gemma":[0.00018019538,0.00016354327,0.00012420329,0.000109402456,0.00007190363,0.0000037417049,0.00036794934,0.000060618466,0.000090120266],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007030601,0.00011729765,0.0009555872,0.000008334796,0.00009586773,0.0000037121004,0.0001937323,0.0001424464,0.7962743,0.0003382765,0.028061876,0.17310548],"study_design_scores_gemma":[0.00090714457,0.0012966789,0.014326158,0.000020267258,0.000023126377,0.0000037711186,0.000050691695,0.0000018076746,0.2691918,0.00058731594,0.7133249,0.00026635762],"about_ca_topic_score_codex":0.0005796678,"about_ca_topic_score_gemma":0.0006343922,"teacher_disagreement_score":0.68526304,"about_ca_system_score_codex":0.0000674012,"about_ca_system_score_gemma":0.00043024402,"threshold_uncertainty_score":0.6669101},"labels":[],"label_agreement":null},{"id":"W2588395233","doi":"10.1093/annonc/mdw365.94","title":"HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Anthracycline; Internal medicine; Metastatic breast cancer; Trastuzumab emtansine; Taxane; Oncology; Clinical endpoint; Capecitabine; Vinorelbine; Breast cancer; Epirubicin; Chemotherapy; Cancer; Clinical trial","score_opus":0.0772610085246743,"score_gpt":0.4431137932374388,"score_spread":0.3658527847127645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588395233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876701,0.000735531,0.00025371776,0.002951823,0.000054322118,0.0073003736,0.00023344035,0.000026084654,0.0007746013],"genre_scores_gemma":[0.99407005,0.0031057305,0.0006668198,0.00077087013,0.00009618045,0.0009382001,0.000049016446,0.00009619465,0.00020693534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99577886,0.00073913933,0.0011919364,0.00079858163,0.0007012802,0.00079020543],"domain_scores_gemma":[0.99605274,0.0012888693,0.0008846642,0.0004330386,0.0010220448,0.00031864966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091041176,0.00051373156,0.003306858,0.00031070338,0.00008113069,0.000023736839,0.00032730403,0.0001606046,0.00012063173],"category_scores_gemma":[0.00022027726,0.00031508112,0.00012331821,0.00061949994,0.0012933539,0.00039284222,0.000121970974,0.0003820428,0.000002431186],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.767844,0.007456395,0.002941711,0.00030519904,0.00093693286,0.00014975201,0.0014434686,0.000066394045,0.0016667212,0.000012581104,0.00020693627,0.21696986],"study_design_scores_gemma":[0.94305146,0.03894016,0.007023792,0.0037573213,0.0002939145,0.00009948843,0.00026875964,0.00093151693,0.004839536,0.000032305146,0.00036557447,0.00039616556],"about_ca_topic_score_codex":0.0037406061,"about_ca_topic_score_gemma":0.0017703051,"teacher_disagreement_score":0.2165737,"about_ca_system_score_codex":0.00082954945,"about_ca_system_score_gemma":0.0023358797,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W2588397197","doi":"10.1093/annonc/mdw370.55","title":"A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Renal function; Urology; Adverse effect; Creatinine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Dosing; Internal medicine; Gastroenterology; Chemotherapy; Randomized controlled trial","score_opus":0.05591337534715176,"score_gpt":0.4009282352519746,"score_spread":0.34501485990482283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588397197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960588,0.00015716728,0.000010041521,0.001271511,0.000019598567,0.0019336429,0.000020854186,0.000008045286,0.00052031653],"genre_scores_gemma":[0.9991117,0.000072537005,0.00049566274,0.00015884449,0.00002031438,0.000055683104,0.0000074365175,0.000017848588,0.00005995221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821675,0.00024535906,0.0005319007,0.00029246724,0.00043324553,0.00028027885],"domain_scores_gemma":[0.99848694,0.00024844467,0.00044380457,0.000307271,0.00040968484,0.000103882376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058031763,0.00019662081,0.0006104336,0.000109668494,0.000036079677,0.0000019831202,0.0000913304,0.00004323925,0.000035691224],"category_scores_gemma":[0.00006729166,0.00008926402,0.000040192463,0.0001894699,0.00021850283,0.00006113417,0.00006481346,0.00011735368,9.297554e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11857529,0.020580087,0.4980122,0.0001744838,0.00096599077,0.00035409743,0.0052826274,0.00036834783,0.014181401,0.000015083386,0.00022543609,0.34126493],"study_design_scores_gemma":[0.09622563,0.31307942,0.56636006,0.00059340266,0.00039772168,0.000080265345,0.0010297714,0.000068184294,0.021781238,0.000024624194,0.00017092747,0.00018879233],"about_ca_topic_score_codex":0.00002593852,"about_ca_topic_score_gemma":0.000032938013,"teacher_disagreement_score":0.34107617,"about_ca_system_score_codex":0.00009384517,"about_ca_system_score_gemma":0.00025913765,"threshold_uncertainty_score":0.3640081},"labels":[],"label_agreement":null},{"id":"W2588401744","doi":"10.1093/annonc/mdw363.71","title":"Signal transducer and activator of transcription–3 (STAT3) expression concordance in paired primary and metastatic colorectal cancers (mCRC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Concordance; Immunohistochemistry; STAT3; Primary tumor; Colorectal cancer; Tissue microarray; Oncology; Metastasis; Internal medicine; STAT protein; Correlation; Pathology; Cancer research; Cancer; Gene; Biology","score_opus":0.061826946388014836,"score_gpt":0.33830276032072687,"score_spread":0.27647581393271203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588401744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490196,0.0016060278,0.0001820289,0.0020570823,0.00011448991,0.00044711406,0.000055714765,0.000010415281,0.0006251542],"genre_scores_gemma":[0.99677557,0.00146263,0.0012124531,0.0003962359,0.000024028746,0.00005477193,0.000003232842,0.000016693386,0.000054388795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986969,0.00015401457,0.00043548417,0.00028104166,0.0001918737,0.00024069056],"domain_scores_gemma":[0.9990385,0.00042429325,0.00017733396,0.00011195875,0.00012345858,0.0001244655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030228912,0.00015217725,0.0006437917,0.00013256446,0.000018251973,0.0000017337532,0.000061379826,0.00011796213,0.00018563504],"category_scores_gemma":[0.00007777723,0.00010876152,0.000059968308,0.0001272664,0.00052211236,0.000091947746,0.000020274381,0.00011265384,4.4928564e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035256322,0.00014826449,0.01071412,0.00025425042,0.000065762615,0.000017906563,0.001141207,0.000002919878,0.89256734,0.000019158246,0.00040053364,0.09114292],"study_design_scores_gemma":[0.0054663415,0.0063979416,0.16309866,0.00045433617,0.00006914904,0.000046988454,0.000284318,0.000022568107,0.820842,0.00032105355,0.0028437003,0.00015289716],"about_ca_topic_score_codex":0.00013343182,"about_ca_topic_score_gemma":0.00017980082,"teacher_disagreement_score":0.15238455,"about_ca_system_score_codex":0.000118790624,"about_ca_system_score_gemma":0.0005394825,"threshold_uncertainty_score":0.44351658},"labels":[],"label_agreement":null},{"id":"W2588408422","doi":"10.1093/annonc/mdw386.01","title":"Unsung heroes of lung cancer: Perspectives from caregivers in the lung cancer Canada survey","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Feeling; Cancer; Depression (economics); Family medicine; Quality of life (healthcare); Internal medicine; Nursing; Psychology","score_opus":0.0625692391787453,"score_gpt":0.4010606547543955,"score_spread":0.3384914155756502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588408422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96891785,0.005622386,0.0000022476077,0.01754059,0.0007322381,0.00022103608,0.00053514255,0.0000066044113,0.0064218794],"genre_scores_gemma":[0.994861,0.004297949,0.0000071944737,0.0004055407,0.00012295411,0.00003861483,0.000003343559,0.000007873035,0.0002555084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779165,0.0009597484,0.00027230298,0.00022923076,0.00038739174,0.0003596812],"domain_scores_gemma":[0.9971593,0.0019361442,0.00025880718,0.00019509654,0.00038865992,0.000061992774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010998723,0.00010315282,0.00034639848,0.000058068286,0.0001122373,0.000005785532,0.00055035437,0.00012090521,0.0005155784],"category_scores_gemma":[0.0004999621,0.00006850198,0.000053038464,0.0003163228,0.00059221307,0.00012541286,0.00004572945,0.00010171348,3.4040403e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072079,0.000056338184,0.83226687,0.000012284299,0.00010679626,0.000016614778,0.06603833,0.000025660547,0.000118906435,0.001018399,0.09367107,0.006596635],"study_design_scores_gemma":[0.00053901604,0.00007198812,0.84864026,0.00010996919,0.000029855548,1.9518004e-7,0.102828145,0.000009157678,0.0004667388,0.00019088753,0.046934932,0.00017882108],"about_ca_topic_score_codex":0.99696124,"about_ca_topic_score_gemma":0.9985369,"teacher_disagreement_score":0.04673614,"about_ca_system_score_codex":0.0005651661,"about_ca_system_score_gemma":0.0045359666,"threshold_uncertainty_score":0.804661},"labels":[],"label_agreement":null},{"id":"W2588421393","doi":"10.1093/annonc/mdw372.24","title":"Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Discontinuation; Adverse effect; Abiraterone acetate; Prednisone; Gastroenterology; Peripheral edema; Androgen deprivation therapy; Placebo; Surgery; Cancer","score_opus":0.0736474234287881,"score_gpt":0.39458428387988065,"score_spread":0.32093686045109254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588421393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341756,0.0009051224,0.00007590823,0.0021021564,0.000059719652,0.0024038076,0.00081464363,0.000012907858,0.00020816766],"genre_scores_gemma":[0.9916366,0.004660211,0.0007831187,0.000086697044,0.000032577955,0.0003816769,0.00013051162,0.00004295292,0.002245668],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816763,0.00007873868,0.0006461153,0.00034239018,0.00033485456,0.0004302561],"domain_scores_gemma":[0.99807394,0.00017466872,0.00055184367,0.00031841136,0.0007358315,0.00014533714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022306506,0.00024523982,0.0009346194,0.00015028074,0.000036598114,0.000004216986,0.000109050896,0.000092040114,0.00016381135],"category_scores_gemma":[0.000027939184,0.00014192784,0.00015197737,0.00017016508,0.000401389,0.000104623134,0.000023942473,0.00005348758,0.000002946458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1047102,0.0054935226,0.10246751,0.0014954713,0.0049396786,0.00011734587,0.0047887284,0.000050992483,0.18773282,0.00008090431,0.0009085885,0.58721423],"study_design_scores_gemma":[0.06511655,0.04110838,0.3255759,0.0007519336,0.00055729423,0.000010361071,0.00015181483,0.000018920497,0.5642551,0.00009324662,0.002101664,0.0002588276],"about_ca_topic_score_codex":0.00023439925,"about_ca_topic_score_gemma":0.00041530066,"teacher_disagreement_score":0.5869554,"about_ca_system_score_codex":0.00038164257,"about_ca_system_score_gemma":0.001074554,"threshold_uncertainty_score":0.578765},"labels":[],"label_agreement":null},{"id":"W2588436059","doi":"10.1093/annonc/mdw372.52","title":"ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Oncology; Internal medicine; Androgen deprivation therapy; Urology; Placebo; Radiation therapy; Randomized controlled trial; Cancer; Androgen receptor; Pathology","score_opus":0.07262357971532579,"score_gpt":0.44034117849108056,"score_spread":0.3677175987757548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588436059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927181,0.0011810691,0.000025129715,0.0025913238,0.0001273709,0.0032129264,0.000055149147,0.000014540541,0.00007441225],"genre_scores_gemma":[0.9900686,0.008632513,0.00025559874,0.00025667058,0.000090229005,0.00036375184,0.000039011353,0.000026167281,0.0002674647],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978103,0.00048055223,0.00058321166,0.00029350855,0.00047224632,0.0003601527],"domain_scores_gemma":[0.99750817,0.0010703985,0.00057181006,0.00027149572,0.0004972965,0.00008082641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010283161,0.00016892776,0.000614508,0.00014838592,0.000059742448,0.0000044498365,0.00012563742,0.000102369384,0.00009645899],"category_scores_gemma":[0.000644268,0.00007279959,0.00007429245,0.00036013793,0.00027963196,0.00012146626,0.000033710392,0.00016968537,0.0000021287856],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3919849,0.0012667022,0.03480314,0.00003592223,0.00017214644,0.000005940453,0.0006482153,0.00004469612,0.0018676502,0.0000022282181,0.00007727721,0.56909114],"study_design_scores_gemma":[0.5820621,0.09548131,0.30788007,0.00076264894,0.00010582932,0.0000010884813,0.000071276,0.00007097349,0.011533262,0.00010049568,0.0017735185,0.00015740987],"about_ca_topic_score_codex":0.00038537828,"about_ca_topic_score_gemma":0.00012190782,"teacher_disagreement_score":0.5689337,"about_ca_system_score_codex":0.000231053,"about_ca_system_score_gemma":0.0013393736,"threshold_uncertainty_score":0.29686812},"labels":[],"label_agreement":null},{"id":"W2588439324","doi":"10.1093/annonc/mdw365.04","title":"Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Letrozole; Palbociclib; Medicine; Quality of life (healthcare); Metastatic breast cancer; Breast cancer; Internal medicine; Placebo; Oncology; Cancer; Tamoxifen; Alternative medicine","score_opus":0.08483000578050044,"score_gpt":0.411805459225645,"score_spread":0.32697545344514456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588439324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872426,0.00082339946,0.000029038756,0.0058517526,0.000051908126,0.0009852311,0.004865133,0.00002580132,0.00012517419],"genre_scores_gemma":[0.99816006,0.00026987222,0.00069261674,0.00043061216,0.00003159263,0.000060365695,0.00026404695,0.000050525512,0.000040330404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635386,0.000536705,0.0015030826,0.00052159105,0.0005291158,0.00055564655],"domain_scores_gemma":[0.99586505,0.0007154665,0.001932113,0.00060437893,0.0005772865,0.0003056791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039960054,0.00039797425,0.0022403332,0.00025416978,0.000034300512,0.0000022966206,0.00014940138,0.00011793055,0.00012130102],"category_scores_gemma":[0.00010518281,0.00022359463,0.00014056942,0.00040665737,0.00047180778,0.00013169622,0.000032883272,0.00017362871,0.0000040879318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33318773,0.011303241,0.5267341,0.00021900235,0.005157058,0.000072042836,0.0048354683,0.0017854291,0.007080564,0.000061202096,0.0003610119,0.10920312],"study_design_scores_gemma":[0.05816354,0.03908925,0.8992811,0.00084592187,0.000103542356,0.000011007192,0.00027444528,0.0000115368575,0.0018207225,0.000082737424,0.000108010056,0.00020822014],"about_ca_topic_score_codex":0.04493201,"about_ca_topic_score_gemma":0.0069079883,"teacher_disagreement_score":0.37254694,"about_ca_system_score_codex":0.0010636314,"about_ca_system_score_gemma":0.0018876127,"threshold_uncertainty_score":0.96142787},"labels":[],"label_agreement":null},{"id":"W2588459214","doi":"10.1093/annonc/mdw372.01","title":"Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Surrogate endpoint; Randomization; Prostate cancer; Internal medicine; Randomized controlled trial; Stage (stratigraphy); Oncology; Clinical endpoint; Disease; Radiation therapy; Survival analysis; Cancer; Surgery","score_opus":0.1488525946476359,"score_gpt":0.44678848335507515,"score_spread":0.29793588870743926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588459214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89723676,0.004758375,0.000099562036,0.09014441,0.00060233567,0.0019155858,0.0013468725,0.000044354354,0.0038517255],"genre_scores_gemma":[0.96635437,0.019233882,0.0006508128,0.0018998034,0.00026007043,0.0007682629,0.00005843642,0.00007374611,0.010700614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771976,0.00021640329,0.0005133597,0.00043940014,0.00037412878,0.0007369296],"domain_scores_gemma":[0.9980432,0.00060970517,0.00018434081,0.0004181064,0.0005313066,0.00021334086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010998846,0.00022767608,0.0009382167,0.00024060426,0.00004416922,0.000007565764,0.00021656319,0.00018119717,0.00066328264],"category_scores_gemma":[0.00032182623,0.0001425499,0.00023907125,0.00024391168,0.0002742845,0.00012250735,0.00011970288,0.00014023771,0.000019518859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04928708,0.0030461303,0.16854574,0.0010008371,0.0026657516,0.00048987824,0.0023595751,0.0000112666785,0.025514841,0.0026600838,0.093951486,0.65046734],"study_design_scores_gemma":[0.08818218,0.0118485335,0.041009415,0.0008229421,0.00036955913,0.000018919924,0.0004276348,0.00010880131,0.14080729,0.013746069,0.7019859,0.000672761],"about_ca_topic_score_codex":0.001506508,"about_ca_topic_score_gemma":0.0019446164,"teacher_disagreement_score":0.6497946,"about_ca_system_score_codex":0.00018792828,"about_ca_system_score_gemma":0.00083644135,"threshold_uncertainty_score":0.72624797},"labels":[],"label_agreement":null},{"id":"W2588506855","doi":"10.1093/annonc/mdw333.04","title":"Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Quality of life (healthcare); Gemcitabine; Internal medicine; Clinical endpoint; Performance status; Surgery; Physical therapy; Gastroenterology; Clinical trial; Cancer","score_opus":0.09235539799579844,"score_gpt":0.38641679563918335,"score_spread":0.2940613976433849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588506855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351376,0.00094143586,0.000024693005,0.0015503748,0.000019429848,0.0034899113,0.00018695074,0.000019076297,0.0002543795],"genre_scores_gemma":[0.9985493,0.0003733218,0.000250662,0.00044642834,0.000036442972,0.00020474328,0.000036908554,0.000038286304,0.00006392697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945197,0.0022550728,0.0012970443,0.0005874151,0.0007610305,0.00057970174],"domain_scores_gemma":[0.99045056,0.0069136727,0.0010032514,0.00077347836,0.0005754374,0.00028361217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001690307,0.0004027597,0.0022181584,0.0002828521,0.00006727381,0.0000060682005,0.0002781721,0.00017290065,0.00003294224],"category_scores_gemma":[0.0019805154,0.00019608383,0.000114011724,0.00044729613,0.00090517296,0.00009188219,0.000060413404,0.00029263578,0.0000032894866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09496722,0.013473838,0.8616296,0.0003040192,0.0015067101,0.00012487687,0.0026182148,0.0000035114026,0.0022101854,0.000027040809,0.00011998982,0.023014775],"study_design_scores_gemma":[0.084798664,0.10505753,0.79847556,0.00064672134,0.00047025186,0.0000049192668,0.0004652537,0.00003393548,0.009811396,0.000026231228,0.000034770106,0.0001747924],"about_ca_topic_score_codex":0.0066331266,"about_ca_topic_score_gemma":0.0009932055,"teacher_disagreement_score":0.09158369,"about_ca_system_score_codex":0.00012467748,"about_ca_system_score_gemma":0.0011616582,"threshold_uncertainty_score":0.99998176},"labels":[],"label_agreement":null},{"id":"W2588521106","doi":"10.1093/annonc/mdw332.04","title":"Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Internal medicine; ALK inhibitor; Adverse effect; Phases of clinical research; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Lung cancer; Randomized controlled trial; Oncology; Refractory (planetary science); Gastroenterology; Surgery; Clinical trial","score_opus":0.0444454593184638,"score_gpt":0.4245253480343797,"score_spread":0.3800798887159159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588521106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733848,0.0020160207,0.00009175384,0.007664622,0.00054909923,0.0026388175,0.00070118083,0.000026652044,0.012927033],"genre_scores_gemma":[0.9936623,0.0028529093,0.00044978448,0.0009586973,0.0004359626,0.00024291786,0.0001341711,0.000029371107,0.0012339015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99768007,0.00029731638,0.0009992676,0.000477633,0.00017980908,0.00036589956],"domain_scores_gemma":[0.9964878,0.002298317,0.00050691195,0.00029946823,0.00018795556,0.00021956056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006409144,0.00023918533,0.001231543,0.0001571587,0.000055076292,0.0000076562665,0.00009575033,0.0002244518,0.00026534527],"category_scores_gemma":[0.0006968916,0.00015626325,0.00018767844,0.00012733336,0.00026963954,0.00009482873,0.00004749633,0.00017996045,0.000009647405],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8619995,0.0029807633,0.00032299783,0.000042616113,0.0006072974,0.000113055794,0.002771485,0.000003380887,0.0067629674,0.000031197364,0.0041389675,0.12022578],"study_design_scores_gemma":[0.96755844,0.003935066,0.0027839192,0.00041891594,0.00068755785,0.0000049470596,0.000095100724,0.00006609304,0.0037355707,0.00007629563,0.02046055,0.00017754153],"about_ca_topic_score_codex":0.0030766511,"about_ca_topic_score_gemma":0.0005310491,"teacher_disagreement_score":0.12004824,"about_ca_system_score_codex":0.0001287839,"about_ca_system_score_gemma":0.001025672,"threshold_uncertainty_score":0.63722306},"labels":[],"label_agreement":null},{"id":"W2588541651","doi":"10.1093/annonc/mdw363.84","title":"Serum phosphorylated neurofilament heavy subunit as a predictive marker of chemotherapy-induced cognitive impairment: a preliminary result","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Breast cancer; Internal medicine; Oncology; Cognition; Verbal learning; Cancer; Psychiatry","score_opus":0.04314750593924666,"score_gpt":0.35525130477355077,"score_spread":0.3121037988343041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588541651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967004,0.00051250384,0.000025199879,0.017795714,0.00024066833,0.0019225487,0.00022804824,0.000073319265,0.012198019],"genre_scores_gemma":[0.9927119,0.002092992,0.000029145971,0.0033222118,0.00009612064,0.00017415118,0.000018951774,0.000054356515,0.0015001659],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997376,0.00022307878,0.000830293,0.0005306079,0.00045263782,0.00058732956],"domain_scores_gemma":[0.9965401,0.0008443888,0.0006560377,0.00031550557,0.0014266248,0.00021731932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005459715,0.0003546411,0.0009835204,0.00029660124,0.000072763476,0.0000031136353,0.00013568545,0.00029958953,0.00069840864],"category_scores_gemma":[0.0006709431,0.0002631351,0.00027290607,0.00043352303,0.000542037,0.00012349154,0.00015616846,0.0002776632,0.000056314107],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38639832,0.012497032,0.05557743,0.00061883143,0.009718193,0.00075120485,0.00990044,0.0000027097228,0.1083658,0.000116204574,0.037881363,0.3781725],"study_design_scores_gemma":[0.017927988,0.09799245,0.4612188,0.001690921,0.00051690027,0.00015514437,0.0015943216,0.000026973743,0.41520134,0.00027623805,0.0031026383,0.0002962841],"about_ca_topic_score_codex":0.00012961471,"about_ca_topic_score_gemma":0.000009842078,"teacher_disagreement_score":0.40564138,"about_ca_system_score_codex":0.00017557004,"about_ca_system_score_gemma":0.00060116436,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W2588544085","doi":"10.1093/annonc/mdw370.92","title":"Capecitabine (cape) dosing using skeletal muscle index (SMI) compared to body surface area (BSA)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Alberta","funders":"","keywords":"Medicine; Capecitabine; Body surface area; Dosing; Sarcopenia; Internal medicine; Pharmacology; Cancer; Colorectal cancer","score_opus":0.09052691156723067,"score_gpt":0.3777492635909964,"score_spread":0.2872223520237658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588544085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816859,0.0002273571,0.0022442401,0.011051572,0.00025638955,0.00044033595,0.00002440199,0.00007581168,0.003994004],"genre_scores_gemma":[0.99405843,0.00008473192,0.0026244796,0.0026000065,0.00017426506,0.00000361524,0.000006789915,0.00004833919,0.0003993395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979943,0.00012268614,0.00058198726,0.0004140774,0.00031961108,0.00056734664],"domain_scores_gemma":[0.99824166,0.00034698093,0.00026211076,0.0004749133,0.0003598793,0.00031447905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046303583,0.00024703128,0.0008111963,0.00017973523,0.00007041023,0.0000073936126,0.00018771873,0.00031417338,0.0008012431],"category_scores_gemma":[0.00028039177,0.00019125397,0.00017408878,0.0003530856,0.00021402987,0.00011244267,0.00010038321,0.0002302345,0.00006237897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005834147,0.0007113316,0.010857405,0.000039310984,0.00020955593,0.00010345577,0.0004607601,0.00020496752,0.94418526,0.000039845596,0.00688662,0.03571808],"study_design_scores_gemma":[0.018564215,0.0057575447,0.23150799,0.001327591,0.00027202725,0.00050421746,0.000456323,0.0044412576,0.5201445,0.0006723822,0.21520844,0.0011435156],"about_ca_topic_score_codex":0.00026199082,"about_ca_topic_score_gemma":0.00008807426,"teacher_disagreement_score":0.42404076,"about_ca_system_score_codex":0.00019958786,"about_ca_system_score_gemma":0.00027934814,"threshold_uncertainty_score":0.87730503},"labels":[],"label_agreement":null},{"id":"W2588586288","doi":"10.1093/annonc/mdw370.100","title":"Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; FOLFIRI; Aflibercept; Oxaliplatin; Bevacizumab; Internal medicine; Population; Adverse effect; Oncology; Surgery; Colorectal cancer; Cancer; Chemotherapy","score_opus":0.20030864271915036,"score_gpt":0.45737918609571154,"score_spread":0.2570705433765612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588586288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770196,0.0071804794,0.00021694122,0.010655477,0.00021232157,0.0022836584,0.001966127,0.000026504991,0.00043888052],"genre_scores_gemma":[0.98610145,0.011083322,0.0013464824,0.00040814746,0.00015252046,0.00046876154,0.00015113218,0.000020679792,0.0002675222],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99789166,0.00019306074,0.0009700037,0.00037123694,0.0002503137,0.0003237478],"domain_scores_gemma":[0.9971506,0.001330024,0.00065741513,0.00025546903,0.00047464244,0.00013185736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003172119,0.0002795184,0.0013854225,0.000037603255,0.00010115201,0.000004565163,0.00010713709,0.00013139257,0.0001511221],"category_scores_gemma":[0.00026169274,0.00015008266,0.00029394464,0.0001860517,0.00052723027,0.000077845434,0.00006648658,0.00004533662,0.0000010216033],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023538755,0.001822538,0.26901814,0.00016849356,0.002654506,0.0000056188146,0.0021541694,0.0000069434327,0.0009187668,0.00032482718,0.0003312183,0.699056],"study_design_scores_gemma":[0.0132470215,0.019518679,0.9460342,0.00016962427,0.0008440404,0.000004114069,0.0003447445,0.000028079277,0.0018153543,0.0002969948,0.017536359,0.0001608053],"about_ca_topic_score_codex":0.0028480121,"about_ca_topic_score_gemma":0.0141297355,"teacher_disagreement_score":0.6988952,"about_ca_system_score_codex":0.00040977038,"about_ca_system_score_gemma":0.0005596278,"threshold_uncertainty_score":0.7884724},"labels":[],"label_agreement":null},{"id":"W2588600208","doi":"10.1093/annonc/mdw371.75","title":"Impact of age, bilirubin, and disease burden in unresectable pancreatic cancer patients receiving first-line chemotherapy: A population-based analysis","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; FOLFIRINOX; Pancreatic cancer; Chemotherapy; Gastroenterology; Irinotecan; Population; Cancer; Performance status; Oncology; Colorectal cancer","score_opus":0.06010110459135667,"score_gpt":0.4241805259259643,"score_spread":0.36407942133460763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588600208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946534,0.00040811708,0.00005709745,0.004103406,0.000015860898,0.00043714515,0.00005485519,0.000012209873,0.00025791634],"genre_scores_gemma":[0.9978242,0.001465731,0.00016523573,0.00018349712,0.000038099806,0.000061292376,0.000033785698,0.000018257062,0.00020989015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998488,0.0001721644,0.00052376016,0.00026179297,0.00022957777,0.00032471967],"domain_scores_gemma":[0.99789417,0.0009786469,0.00025909345,0.00027240138,0.00032853254,0.00026715721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004697887,0.00014159278,0.0010441293,0.00056228676,0.000026036656,0.000002668054,0.00008535468,0.00013304273,0.00044660314],"category_scores_gemma":[0.001482737,0.00008980414,0.00018888428,0.0006709603,0.00017602529,0.000058138146,0.00003141299,0.000087844055,0.0000012003089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023011994,0.00072485174,0.9786184,0.00013495909,0.0008286241,0.000020156078,0.00016182606,0.00016234533,0.00041823767,0.0000065927666,0.00022402623,0.016398812],"study_design_scores_gemma":[0.0046578175,0.0024736305,0.98991853,0.00025832458,0.0004993652,4.4983125e-7,0.000009483829,0.0016484596,0.0000742743,0.0002863911,0.000088420056,0.000084878404],"about_ca_topic_score_codex":0.009709731,"about_ca_topic_score_gemma":0.0023017437,"teacher_disagreement_score":0.016313933,"about_ca_system_score_codex":0.00018570512,"about_ca_system_score_gemma":0.00071154366,"threshold_uncertainty_score":0.9968847},"labels":[],"label_agreement":null},{"id":"W2588609033","doi":"10.1093/annonc/mdw365.92","title":"SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Cancer; PI3K/AKT/mTOR pathway; Aromatase inhibitor; Oncology; Breast cancer; Placebo; Estrogen receptor; Cancer research; Aromatase; Biology; Pathology; Signal transduction; Genetics","score_opus":0.02271555053021598,"score_gpt":0.3300113679872997,"score_spread":0.30729581745708373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588609033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943692,0.00017683335,0.00041283653,0.00071437925,0.00018225222,0.0025578823,0.0015406193,0.000010048132,0.000035922083],"genre_scores_gemma":[0.99789226,0.00014730418,0.0006803822,0.00033804306,0.00009960075,0.0006459,0.000055410066,0.000065346605,0.000075762866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971138,0.0003937371,0.0007622737,0.000735533,0.00040430023,0.0005903491],"domain_scores_gemma":[0.99724644,0.00023221583,0.0008375615,0.00051439524,0.0010031842,0.00016618418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039894407,0.0004410526,0.00084704056,0.000106857304,0.00009760127,0.000010031658,0.00045140384,0.00016992442,0.00006593279],"category_scores_gemma":[0.00016783712,0.000240683,0.00013165899,0.00034948505,0.0005068213,0.000031045995,0.00011431373,0.00016241221,9.648932e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16937752,0.01415505,0.029663617,0.00023250488,0.0023690881,0.000077532626,0.0028132913,0.0015739056,0.718409,0.000027183287,0.0022412501,0.05906006],"study_design_scores_gemma":[0.089653604,0.083409354,0.016419983,0.00072648743,0.00045482148,0.000032188756,0.0021178017,0.00003225538,0.8050487,0.000042396412,0.001270569,0.00079184514],"about_ca_topic_score_codex":0.00059288356,"about_ca_topic_score_gemma":0.0033507887,"teacher_disagreement_score":0.0866397,"about_ca_system_score_codex":0.00017610691,"about_ca_system_score_gemma":0.0014038432,"threshold_uncertainty_score":0.9814768},"labels":[],"label_agreement":null},{"id":"W2588611749","doi":"10.1093/annonc/mdw371.108","title":"Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Hepatocellular carcinoma; Internal medicine; Adverse effect; Clinical endpoint; Progressive disease; Milan criteria; Oncology; Cancer; Surgery; Clinical trial; Liver transplantation; Transplantation; Disease; Immunotherapy","score_opus":0.07670647370780202,"score_gpt":0.3305121050339059,"score_spread":0.25380563132610384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588611749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951354,0.00039068607,0.000010394242,0.00069020846,0.00004721024,0.002531272,0.000024705201,0.000044629236,0.0011254873],"genre_scores_gemma":[0.99906856,0.0000667492,0.00010029237,0.0001412906,0.00003296793,0.0002034515,0.00005786301,0.000042924486,0.00028587432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978502,0.00024364925,0.0005766395,0.00048574744,0.00031901957,0.00052473915],"domain_scores_gemma":[0.9985512,0.00013944664,0.00024222369,0.00048253915,0.00036123607,0.00022334572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027193569,0.0003028859,0.0009111587,0.0003008053,0.000039712526,0.000004500469,0.0001321804,0.000165329,0.00016628623],"category_scores_gemma":[0.000085988395,0.00018413497,0.00013697967,0.00035104502,0.00012466765,0.00013437109,0.000048682617,0.00012769972,0.000035413253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009894523,0.010598282,0.90292525,0.00004127505,0.000190927,0.0007630654,0.00049957546,1.381316e-7,0.00053688546,0.00000886007,0.00012912127,0.07441208],"study_design_scores_gemma":[0.08082738,0.073090926,0.8319349,0.00014620647,0.00030924278,0.000013983082,0.0001045303,0.000047086858,0.010812483,0.00002296037,0.002420626,0.00026966567],"about_ca_topic_score_codex":0.00015746863,"about_ca_topic_score_gemma":0.000058275076,"teacher_disagreement_score":0.07414241,"about_ca_system_score_codex":0.00013183,"about_ca_system_score_gemma":0.0002483649,"threshold_uncertainty_score":0.75088066},"labels":[],"label_agreement":null},{"id":"W2588623515","doi":"10.1093/annonc/mdw367.33","title":"METIS: A phase III study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical endpoint; Radiosurgery; Neurocognitive; Lung cancer; Population; Oncology; Internal medicine; Clinical trial; Radiation therapy; Cognition","score_opus":0.05360992888925007,"score_gpt":0.4039098194191932,"score_spread":0.3502998905299431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588623515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70595527,0.0001438049,0.29036248,0.0013535593,0.000050509552,0.0007339019,0.00040783547,0.000033168457,0.00095950434],"genre_scores_gemma":[0.98431605,0.000016664108,0.014882515,0.00018469812,0.00011981015,0.00019264322,0.000016118067,0.000022006623,0.00024948266],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899024,0.00012142529,0.0003684944,0.00022429595,0.00009583039,0.00019971273],"domain_scores_gemma":[0.99792445,0.001192987,0.00038176982,0.00028546312,0.00016518173,0.00005015287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028111687,0.00014116267,0.00060852506,0.000071063376,0.000029240298,0.0000028068864,0.00015742442,0.00004998073,0.0007764251],"category_scores_gemma":[0.000027154483,0.000091116155,0.00011375152,0.0000909233,0.00010904976,0.00011723322,0.000023164968,0.000048738206,6.89591e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040641,0.005892399,0.006611427,0.000011784625,0.0018933688,0.000008532398,0.0009047076,0.0000063835378,0.040281724,0.0032729998,0.039285388,0.8977672],"study_design_scores_gemma":[0.040156703,0.04140598,0.0006027661,0.000170696,0.00035571103,0.000003796653,0.002039271,0.000037097787,0.5054567,0.015022746,0.39403605,0.0007125121],"about_ca_topic_score_codex":0.0002533523,"about_ca_topic_score_gemma":0.000017948394,"teacher_disagreement_score":0.8970547,"about_ca_system_score_codex":0.000008599666,"about_ca_system_score_gemma":0.00009153724,"threshold_uncertainty_score":0.8501311},"labels":[],"label_agreement":null},{"id":"W2588623890","doi":"10.1093/annonc/mdw390.39","title":"Mannitol dosing and cisplatin-induced acute nephrotoxicity","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nephrotoxicity; Renal function; Common Terminology Criteria for Adverse Events; Urology; Cisplatin; Diabetes mellitus; Odds ratio; Adverse effect; Internal medicine; Toxicity; Chemotherapy; Endocrinology","score_opus":0.0831567262737403,"score_gpt":0.3912411451315784,"score_spread":0.3080844188578381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588623890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971348,0.000045119217,0.00017242126,0.024723167,0.000082263505,0.0003515819,0.000008412983,0.000044820747,0.003224211],"genre_scores_gemma":[0.99551433,0.00016698794,0.0010818194,0.0027754346,0.00017365073,0.000009842214,0.0000032315431,0.000023098188,0.00025160512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989566,0.0000648053,0.0003211765,0.00024383538,0.00016089878,0.00025267378],"domain_scores_gemma":[0.99904925,0.00020737013,0.00019674879,0.0002365507,0.000166078,0.00014402291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002632853,0.00013653716,0.00040898443,0.00012859143,0.000046035733,0.0000050278354,0.00006669971,0.00023274032,0.00015062503],"category_scores_gemma":[0.00016663157,0.000099894736,0.00007014956,0.00013125257,0.00014708244,0.00011878552,0.000042780117,0.00012379081,0.000024746845],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023744072,0.000110122906,0.0023638492,0.000022227581,0.00010147137,0.00002857387,0.00021930074,2.133904e-8,0.8316678,0.0001392055,0.0011464751,0.1639635],"study_design_scores_gemma":[0.0024053056,0.0017988743,0.036100812,0.00011219923,0.000054282336,0.00018706666,0.000041134725,0.000010204689,0.95424545,0.0007850541,0.0041496796,0.00010991607],"about_ca_topic_score_codex":0.000021662241,"about_ca_topic_score_gemma":0.000011155438,"teacher_disagreement_score":0.16385359,"about_ca_system_score_codex":0.00005079468,"about_ca_system_score_gemma":0.00013461275,"threshold_uncertainty_score":0.4073589},"labels":[],"label_agreement":null},{"id":"W2588676979","doi":"10.1093/annonc/mdw372.43","title":"Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Prostate cancer; Proportional hazards model; Enzalutamide; Prostate-specific antigen; Bicalutamide; Confidence interval; Biochemical recurrence; Androgen deprivation therapy; Gynecology; Cancer; Androgen receptor; Prostatectomy","score_opus":0.1044892592278731,"score_gpt":0.4020163358150616,"score_spread":0.29752707658718847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588676979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990318,0.0003825522,0.0000062536124,0.0063782344,0.000013218749,0.0017191014,0.000109867055,0.000026756083,0.0010460083],"genre_scores_gemma":[0.9964603,0.0006878614,0.00021349208,0.00013671345,0.000018241186,0.00052007625,0.000038649716,0.000037018857,0.0018876005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978522,0.00022390982,0.0005195439,0.0003845019,0.00036981583,0.0006500448],"domain_scores_gemma":[0.99859166,0.0005284586,0.00020410685,0.00023579063,0.00024021456,0.00019978151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003616919,0.00027624317,0.00075967785,0.0004469393,0.00003529924,0.000010084511,0.00010827959,0.00009933123,0.00019576254],"category_scores_gemma":[0.00018320348,0.0001228796,0.0000467157,0.0006846217,0.00039949518,0.00016137301,0.000027349202,0.00019105703,0.0000047333433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034749784,0.0015286489,0.8946774,0.00028788872,0.0005235545,0.0026214065,0.0030662103,0.00004354013,0.03743199,0.00005459841,0.00036124478,0.024653714],"study_design_scores_gemma":[0.023249684,0.020290852,0.88636994,0.0018660339,0.00020916764,0.00007766519,0.0023787674,0.00005570731,0.06322077,0.00014844057,0.0017607068,0.0003722799],"about_ca_topic_score_codex":0.0031308813,"about_ca_topic_score_gemma":0.01903022,"teacher_disagreement_score":0.02578878,"about_ca_system_score_codex":0.0003514304,"about_ca_system_score_gemma":0.0016746888,"threshold_uncertainty_score":0.9988699},"labels":[],"label_agreement":null},{"id":"W2588677369","doi":"10.1093/annonc/mdw372.20","title":"Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Prostate cancer; Regimen; Enzalutamide; Prednisone; Chemotherapy regimen; Oncology; Chemotherapy; Cancer; Surgery; Urology; Clinical trial; Androgen receptor","score_opus":0.10849510741443154,"score_gpt":0.4210841554450015,"score_spread":0.31258904803056997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588677369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98301744,0.0030580522,0.000034015527,0.006907478,0.00009618929,0.0020590287,0.0001649989,0.000042869968,0.004619936],"genre_scores_gemma":[0.9919002,0.0020730547,0.0003885331,0.00016484738,0.000105896805,0.00049602817,0.000018817505,0.000038714195,0.004813876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973269,0.00029881488,0.000654111,0.00051071943,0.00042410506,0.0007853347],"domain_scores_gemma":[0.9983388,0.00034732433,0.00040355476,0.0003462281,0.00033035054,0.00023374769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010832371,0.0002810462,0.0009533438,0.00027773058,0.00012859766,0.000011815244,0.00014023605,0.000109508495,0.00015516052],"category_scores_gemma":[0.00014970834,0.00016038946,0.000114819304,0.00045345104,0.0003421961,0.00018868607,0.000068657806,0.00024097026,0.0000070204983],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58044827,0.0050681406,0.0008455591,0.0005496363,0.00085368974,0.0038090448,0.0034156812,0.000007438756,0.2346372,0.00022748145,0.0029125263,0.16722535],"study_design_scores_gemma":[0.5626662,0.07721966,0.0034665493,0.0020034832,0.0004167012,0.000102165526,0.0010431703,0.00008769869,0.32763666,0.0016678058,0.023070581,0.0006193686],"about_ca_topic_score_codex":0.00046971618,"about_ca_topic_score_gemma":0.0019298438,"teacher_disagreement_score":0.16660598,"about_ca_system_score_codex":0.0002968052,"about_ca_system_score_gemma":0.0014338526,"threshold_uncertainty_score":0.6540492},"labels":[],"label_agreement":null},{"id":"W2588714680","doi":"10.1093/annonc/mdw368.15","title":"A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Monoclonal antibody; Oncology; Cancer research; Lung cancer; Cancer; Internal medicine; Antibody; Chemotherapy; Immunology; Cisplatin","score_opus":0.03133282435025224,"score_gpt":0.3781762109981817,"score_spread":0.34684338664792946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588714680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678963,0.00049520493,0.000013618925,0.00079660583,0.00002491162,0.0015375224,0.0000601101,0.0000068931345,0.00027551482],"genre_scores_gemma":[0.9990573,0.00024852096,0.00021210038,0.00005512376,0.000026257198,0.0001080472,0.000049425496,0.000022637449,0.00022059372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983298,0.00012931986,0.00051349984,0.00033138055,0.00032272414,0.0003732549],"domain_scores_gemma":[0.99887496,0.00028702055,0.00022882594,0.00015153167,0.0003256828,0.00013198043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002566713,0.00022640388,0.00072741794,0.00032251913,0.000027519316,0.000003536431,0.000074393545,0.00009980876,0.00003707481],"category_scores_gemma":[0.00005175731,0.0001328276,0.00003888605,0.00028208102,0.00011890843,0.00006800633,0.0000439297,0.00014497792,7.627768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015275937,0.01689038,0.93991625,0.00022671901,0.00016812868,0.00022532661,0.0029245745,0.00007028026,0.007976463,0.000011835547,0.000033180673,0.016280899],"study_design_scores_gemma":[0.08312717,0.11870823,0.78721756,0.00041511655,0.00010184937,0.000009375086,0.0007947111,0.0017375661,0.007487371,0.000015863277,0.00014750478,0.00023768727],"about_ca_topic_score_codex":0.006646396,"about_ca_topic_score_gemma":0.0020436426,"teacher_disagreement_score":0.15269871,"about_ca_system_score_codex":0.00013616052,"about_ca_system_score_gemma":0.0003653566,"threshold_uncertainty_score":0.9999684},"labels":[],"label_agreement":null},{"id":"W2588717486","doi":"10.1093/annonc/mdw373.07","title":"Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Logistic regression; Venous thromboembolism; Risk factor; Receiver operating characteristic; Chemotherapy; Surgery; Oncology; Thrombosis","score_opus":0.016696706646266678,"score_gpt":0.31560178000530253,"score_spread":0.2989050733590359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588717486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944752,0.003284743,0.000006276787,0.00010866967,0.00007558135,0.0010570106,0.00064044975,0.000017707935,0.00033435313],"genre_scores_gemma":[0.99884105,0.00064887817,0.00014961601,0.00018159463,0.000032162345,0.00007400233,0.000026130423,0.000030054398,0.000016526003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978247,0.0003925848,0.0005180828,0.00043012737,0.0003781978,0.00045630767],"domain_scores_gemma":[0.9983609,0.00015063932,0.0006336203,0.00033926184,0.0002479953,0.00026758172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003117961,0.00027756474,0.0010777755,0.00011154061,0.00004932772,0.0000054630536,0.00011497826,0.00009178512,0.000054338358],"category_scores_gemma":[0.00011107435,0.00017409147,0.0000999552,0.00022685224,0.00017365026,0.00008917143,0.00008906213,0.00008589744,0.000005918507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020726456,0.02212467,0.9592544,0.00016374065,0.0003317533,0.00046377,0.0006948324,0.0000012946603,0.00024917134,0.000013485948,0.00008168047,0.014548596],"study_design_scores_gemma":[0.023183513,0.020108242,0.9539931,0.00015718989,0.0011960721,0.000014978888,0.00044957385,0.000007495661,0.0005546877,0.000071608956,0.000099573794,0.00016398603],"about_ca_topic_score_codex":0.0045060944,"about_ca_topic_score_gemma":0.0008742277,"teacher_disagreement_score":0.021110868,"about_ca_system_score_codex":0.00017337008,"about_ca_system_score_gemma":0.0004435392,"threshold_uncertainty_score":0.70992446},"labels":[],"label_agreement":null},{"id":"W2588722468","doi":"10.1093/annonc/mdw379.17","title":"Impact of ipilimumab on metastatic melanoma: Evaluation using patient registry in Canada","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Cohort; Metastatic melanoma; Disease registry; Melanoma; Clinical trial; Overall survival; Oncology; Cancer; Disease; Immunotherapy","score_opus":0.09076096803751592,"score_gpt":0.3757494754393978,"score_spread":0.28498850740188186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588722468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775934,0.00021200196,0.000039058796,0.000113933216,0.000102123835,0.00015664879,0.00006930259,8.202296e-7,0.0015467956],"genre_scores_gemma":[0.9996756,0.000052741845,0.000113517075,0.0000836918,0.000024128723,0.000008827417,0.000020815492,0.0000074260906,0.000013273292],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899125,0.00018633848,0.00031152053,0.0001757811,0.00015570782,0.00017938625],"domain_scores_gemma":[0.9992084,0.000051785555,0.0002631725,0.00024939654,0.0001781009,0.000049131748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027852834,0.000094565694,0.00022935428,0.0000536538,0.000010613497,8.155115e-7,0.00009428737,0.00006740131,0.000050630802],"category_scores_gemma":[0.00023407587,0.00006574865,0.00007431544,0.000056680736,0.000041813768,0.0000027260598,0.00003431298,0.000033001026,8.5597924e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006276603,0.00027678764,0.022407658,0.000022584392,0.0001369757,0.000019127052,0.000055861365,0.0007112312,0.8613644,0.00006041072,0.00237545,0.11194183],"study_design_scores_gemma":[0.003530432,0.01333229,0.09391975,0.00011042952,0.00005733051,0.000043617332,0.00017172299,0.00035504138,0.884211,0.0004111439,0.0035635044,0.00029371947],"about_ca_topic_score_codex":0.12949482,"about_ca_topic_score_gemma":0.16186218,"teacher_disagreement_score":0.111648105,"about_ca_system_score_codex":0.00014097572,"about_ca_system_score_gemma":0.002524064,"threshold_uncertainty_score":0.87630194},"labels":[],"label_agreement":null},{"id":"W2588777013","doi":"10.1093/annonc/mdw373.16","title":"Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Oncology; Interim analysis; Gastroenterology; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.0723208167170428,"score_gpt":0.4419982571152622,"score_spread":0.36967744039821937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588777013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702984,0.00007126934,0.00013576292,0.0004740725,0.00016857807,0.0009668383,0.00046335623,0.000012065182,0.0006782324],"genre_scores_gemma":[0.9989845,0.00022443483,0.0001696125,0.0002102412,0.00005904701,0.00010012222,0.00012430317,0.000025730267,0.00010201046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99767965,0.00028517566,0.0009849189,0.00035942387,0.00038667777,0.00030413645],"domain_scores_gemma":[0.99798346,0.00020261976,0.0007974329,0.00037992647,0.0004907468,0.00014581603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043672958,0.00023557869,0.0013905801,0.00058805244,0.000021188058,0.0000036758352,0.00014496259,0.00009911532,0.00048985274],"category_scores_gemma":[0.00013971906,0.00015308509,0.00023098062,0.0005926102,0.00027029717,0.00020264248,0.000033957036,0.000102237485,0.0000029764185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40828392,0.02605293,0.2099537,0.0003067363,0.009058163,0.00007321939,0.004343441,0.000114590366,0.031096052,0.00016000376,0.00030420962,0.31025305],"study_design_scores_gemma":[0.50818014,0.100060396,0.27925304,0.0008316793,0.009595508,0.000006714007,0.0004075196,0.00072472426,0.09842229,0.00020070883,0.00174671,0.00057057437],"about_ca_topic_score_codex":0.002491146,"about_ca_topic_score_gemma":0.0011951727,"teacher_disagreement_score":0.30968246,"about_ca_system_score_codex":0.0001007634,"about_ca_system_score_gemma":0.00068778027,"threshold_uncertainty_score":0.62426287},"labels":[],"label_agreement":null},{"id":"W2588782541","doi":"10.1093/annonc/mdw373.66","title":"Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; McMaster University","funders":"","keywords":"Medicine; Concomitant; Taxane; Regimen; Proportional hazards model; Radiation therapy; Internal medicine; Chemotherapy; Urology; Lymphadenectomy; Surgery; Oncology; Cancer; Breast cancer","score_opus":0.03870089627637327,"score_gpt":0.38755645087681934,"score_spread":0.34885555460044604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588782541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892556,0.0004793287,0.00033660408,0.0061540958,0.00007273117,0.0007031202,0.00078150094,0.000020365313,0.002196671],"genre_scores_gemma":[0.99431247,0.000026701706,0.0016285712,0.0027173895,0.000047060505,0.00005980516,0.000083127474,0.000024149538,0.0011007009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839187,0.000108869375,0.00066446536,0.000341856,0.00016598697,0.00032692848],"domain_scores_gemma":[0.9974078,0.001091138,0.00033245372,0.0003627026,0.00051117595,0.00029475897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023227233,0.00017379057,0.0008541221,0.0001631012,0.00002885197,0.000002406228,0.00011717216,0.0001015539,0.0001767429],"category_scores_gemma":[0.00051355996,0.00011400317,0.00037846068,0.00015567693,0.00015629214,0.00006240877,0.000027310256,0.000065915825,0.000012293351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.125889,0.01073814,0.6280832,0.00094544725,0.0009948784,0.00029953,0.0073823365,0.000087043045,0.05608224,0.00009054845,0.013808049,0.15559958],"study_design_scores_gemma":[0.056996524,0.010635676,0.7873941,0.00002515193,0.0010875037,0.000004086561,0.0010325572,0.00042234227,0.12222603,0.0001627821,0.01970663,0.00030663094],"about_ca_topic_score_codex":0.0003786771,"about_ca_topic_score_gemma":0.00018361099,"teacher_disagreement_score":0.15931088,"about_ca_system_score_codex":0.000040695028,"about_ca_system_score_gemma":0.00043104312,"threshold_uncertainty_score":0.4648914},"labels":[],"label_agreement":null},{"id":"W2588805927","doi":"10.1093/annonc/mdw374.46","title":"Defining the genomic landscape of vulvar squamous cell carcinoma (VSCC) using next generation sequencing: the role of HPV infection","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; KRAS; PTEN; Oncology; Internal medicine; Vulvar cancer; Cancer; Genetics; Biology; Colorectal cancer","score_opus":0.15248380346844562,"score_gpt":0.37605962720426744,"score_spread":0.22357582373582183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588805927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775079,0.002765925,0.00008930817,0.0009879827,0.00006944894,0.00019230455,0.000007144229,0.000004637719,0.018375356],"genre_scores_gemma":[0.99921787,0.00023891748,0.000058317717,0.00023215586,0.000191287,0.0000074421973,0.0000037937223,0.000010213952,0.00004002332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990411,0.00016148842,0.0003120736,0.00012267836,0.00017951474,0.00018318933],"domain_scores_gemma":[0.99882954,0.00034219533,0.0001988256,0.00023298712,0.00035330802,0.000043116466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006219665,0.00007248199,0.00025783363,0.00008184305,0.000061053026,0.000003456211,0.00009602055,0.00009818313,0.0006684029],"category_scores_gemma":[0.00015017194,0.00003636847,0.00009115265,0.00014307615,0.0001590212,0.000045345234,0.000059656075,0.000119011835,0.000005596996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040827363,0.00012417417,0.07056178,0.00009786414,0.00003357249,0.0000032680468,0.0010064784,0.00017151827,0.7242522,0.0009545521,0.0004232113,0.20196308],"study_design_scores_gemma":[0.0019468083,0.003804021,0.26469222,0.000011896707,0.0001240182,0.0000500546,0.00060629856,0.0049312515,0.71717215,0.000548187,0.006018079,0.000095060765],"about_ca_topic_score_codex":0.0016081473,"about_ca_topic_score_gemma":0.0002970246,"teacher_disagreement_score":0.20186801,"about_ca_system_score_codex":0.000067881716,"about_ca_system_score_gemma":0.00048561356,"threshold_uncertainty_score":0.73185426},"labels":[],"label_agreement":null},{"id":"W2588818478","doi":"10.1093/annonc/mdw365.39","title":"Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2- metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fulvestrant; Medicine; Palbociclib; Visual analogue scale; Metastatic breast cancer; Placebo; Breast cancer; Cancer; Anxiety; Internal medicine; Physical therapy; Oncology; Alternative medicine; Tamoxifen; Psychiatry","score_opus":0.09186327907846892,"score_gpt":0.42821981872231596,"score_spread":0.33635653964384704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588818478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901846,0.0009659481,0.00014193419,0.0072702602,0.00008737549,0.0007274769,0.00045919043,0.000027306785,0.00013590245],"genre_scores_gemma":[0.9967617,0.00086224213,0.0012764399,0.0008662745,0.000051099418,0.000070869835,0.00002924756,0.000042824966,0.000039302802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971548,0.00022208955,0.001062625,0.00041836908,0.0004039639,0.00073818344],"domain_scores_gemma":[0.9976486,0.00016805987,0.0010125341,0.0004503466,0.00037510955,0.00034532996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028985232,0.00030686462,0.0014517236,0.00025312311,0.000027623597,0.000002522042,0.00009797103,0.0000801543,0.00021347697],"category_scores_gemma":[0.000034421784,0.00018064489,0.00017116757,0.00033133177,0.00039098706,0.0001027345,0.000021712358,0.00019182316,0.000002080318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067249775,0.004906418,0.20420584,0.00047072125,0.0027833441,0.00082230254,0.0051035914,0.005661082,0.03986259,0.00014702532,0.00078587804,0.6680014],"study_design_scores_gemma":[0.01749166,0.022308448,0.9521517,0.001073195,0.00009071039,0.0005048109,0.00035619643,0.000058989488,0.0044824923,0.00018253682,0.0010337669,0.00026548086],"about_ca_topic_score_codex":0.0087877745,"about_ca_topic_score_gemma":0.0018465162,"teacher_disagreement_score":0.74794585,"about_ca_system_score_codex":0.000628144,"about_ca_system_score_gemma":0.0028256082,"threshold_uncertainty_score":0.9978128},"labels":[],"label_agreement":null},{"id":"W2588842038","doi":"10.1093/annonc/mdw382.14","title":"The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Population; Positron emission tomography; Hazard ratio; Regimen; Oncology; Internal medicine; Subgroup analysis; Progression-free survival; Nuclear medicine; Stage (stratigraphy); Lung cancer; Randomized controlled trial; Pemetrexed; Carboplatin; Etoposide; Cisplatin; Chemotherapy; Confidence interval","score_opus":0.038459242891521826,"score_gpt":0.46535531133918057,"score_spread":0.42689606844765876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588842038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894007,0.00049289415,0.000005794425,0.0066672144,0.0000689689,0.0010222067,0.000053903546,0.000009307714,0.00227903],"genre_scores_gemma":[0.9993124,0.00031080097,0.000014231021,0.00010095633,0.000038398593,0.00006547936,0.000010890852,0.000010714556,0.00013613656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986754,0.00027413078,0.0003205675,0.00019834531,0.00029398125,0.00023759306],"domain_scores_gemma":[0.9986292,0.00061554596,0.00021182119,0.00033779058,0.0001297761,0.000075841504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879606,0.00013744955,0.00034840163,0.00009484883,0.000101891,0.000009380374,0.00016310834,0.00004537709,0.000016942831],"category_scores_gemma":[0.00012692214,0.000053472108,0.00009629204,0.00015497365,0.00014086434,0.00006791618,0.00005135851,0.00010639785,3.7751255e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011482168,0.0150969755,0.6421963,0.000057937294,0.0012197779,0.0001280213,0.0066902065,0.0000028245267,0.02067642,0.00041502365,0.023131242,0.27890313],"study_design_scores_gemma":[0.070194274,0.08630769,0.81988215,0.0007176687,0.00048633618,0.000033580553,0.0056365575,0.00003969918,0.00662542,0.0018052089,0.007940109,0.00033132182],"about_ca_topic_score_codex":0.00044111555,"about_ca_topic_score_gemma":0.00006616356,"teacher_disagreement_score":0.2785718,"about_ca_system_score_codex":0.00005496213,"about_ca_system_score_gemma":0.00021683742,"threshold_uncertainty_score":0.21805292},"labels":[],"label_agreement":null},{"id":"W2588845480","doi":"10.1093/annonc/mdw379.46","title":"Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Saint Louis University","keywords":"Medicine; Regimen; Vismodegib; Placebo; Population; Internal medicine; Dosing; Urology; Clinical endpoint; Pharmacokinetics; Basal cell carcinoma; Randomized controlled trial; Gastroenterology; Surgery; Basal cell; Pathology","score_opus":0.08781250879323721,"score_gpt":0.38576564431779653,"score_spread":0.2979531355245593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588845480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976548,0.00023533453,0.000006096274,0.000283272,0.000074026866,0.0013213321,0.000058046237,0.0000014316166,0.00036564437],"genre_scores_gemma":[0.9995716,0.000037794878,0.000022256345,0.000089939895,0.000023458617,0.00019343004,0.000008477507,0.000012438341,0.000040600935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978704,0.0008417914,0.00043125817,0.00027828268,0.0003397309,0.0002385402],"domain_scores_gemma":[0.9986732,0.00010841291,0.0003404294,0.0003869115,0.0004704593,0.000020575113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011853548,0.0001578155,0.00031135316,0.00004876087,0.0000294395,0.0000019089132,0.00027233656,0.000067467365,0.0000058412156],"category_scores_gemma":[0.00014088911,0.00007756265,0.00007954357,0.00012634468,0.00020709804,0.000004436748,0.00013025494,0.000056141136,7.9003036e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082935987,0.004732458,0.7860677,0.0000249059,0.00017704067,0.000003413758,0.0057260585,0.00032646803,0.17248037,0.000001426351,0.00017331632,0.029457422],"study_design_scores_gemma":[0.010074667,0.007917706,0.55615,0.00004422527,0.00007925631,6.815502e-7,0.0011924509,0.000087891254,0.42408568,0.000010278837,0.00026464422,0.000092496346],"about_ca_topic_score_codex":0.00027640574,"about_ca_topic_score_gemma":0.0011395738,"teacher_disagreement_score":0.2516053,"about_ca_system_score_codex":0.000058025635,"about_ca_system_score_gemma":0.0001907156,"threshold_uncertainty_score":0.3162913},"labels":[],"label_agreement":null},{"id":"W2588907697","doi":"10.1093/annonc/mdw374.03","title":"Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Nausea; Adverse effect; BRCA mutation; Anemia; PARP inhibitor; Gastroenterology; Surgery; Oncology; Cancer; Ovarian cancer; Poly ADP ribose polymerase","score_opus":0.09173674282299754,"score_gpt":0.38385199959226735,"score_spread":0.2921152567692698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588907697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440163,0.0005539007,0.000030355073,0.0034682248,0.0000893592,0.0007172666,0.0006928438,0.0000072581674,0.00003913949],"genre_scores_gemma":[0.9991317,0.00018728996,0.00016746232,0.0003106016,0.00007618079,0.000021170288,0.000065061395,0.000016743206,0.000023830004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732614,0.0006421839,0.00083629764,0.0006406508,0.0003227033,0.00023203314],"domain_scores_gemma":[0.997154,0.0009585306,0.0007884613,0.00072320964,0.0002017125,0.00017411349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082728814,0.00022279852,0.0011851485,0.00030268653,0.000055760192,0.0000094779825,0.00013298618,0.00020573461,0.00005820175],"category_scores_gemma":[0.00026089192,0.00014431971,0.000056761037,0.0004082333,0.00087948743,0.00023238233,0.00022796018,0.00017710461,2.5431785e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005089515,0.0022052275,0.9634939,0.00003652704,0.0012989466,0.00002009814,0.0009198243,5.426981e-7,0.003066554,0.000028272714,0.000370062,0.02347057],"study_design_scores_gemma":[0.015538889,0.0052819443,0.9692561,0.00012817909,0.0012771556,0.0000076273413,0.0002574931,0.00009204553,0.0077153225,0.00011101974,0.00019337323,0.00014083012],"about_ca_topic_score_codex":0.0032878981,"about_ca_topic_score_gemma":0.0027472356,"teacher_disagreement_score":0.023329739,"about_ca_system_score_codex":0.0000311012,"about_ca_system_score_gemma":0.00022877766,"threshold_uncertainty_score":0.58851874},"labels":[],"label_agreement":null},{"id":"W2588938618","doi":"10.1093/annonc/mdw390.65","title":"Impact of cognitive functions on oral anticancer therapies adherence","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Montreal Cognitive Assessment; Depression (economics); Internal medicine; Anxiety; Cognition; Population; Verbal memory; Oncology; Physical therapy; Psychiatry; Cognitive impairment","score_opus":0.12752160018011832,"score_gpt":0.4576071437664722,"score_spread":0.3300855435863539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588938618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97848797,0.00038488055,0.0001175705,0.0039911387,0.00016849655,0.00033335472,0.00014971833,0.000021957949,0.016344903],"genre_scores_gemma":[0.997342,0.0009608862,0.000018774515,0.00061768346,0.000080758844,0.000037440033,0.0000045521165,0.00001192942,0.0009259642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906904,0.0000768333,0.0002757564,0.00018239647,0.00016081052,0.00023516659],"domain_scores_gemma":[0.998055,0.00080319034,0.00021056601,0.00012308932,0.00073989155,0.00006829914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016141486,0.00013111539,0.00048344076,0.00014127715,0.00003390932,0.0000011081248,0.000045035264,0.00009220491,0.0012060027],"category_scores_gemma":[0.0005779301,0.00007651858,0.00019859732,0.00018113577,0.0005453114,0.000055854285,0.0000292131,0.00009873942,0.00006972037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010171988,0.0022335812,0.28292194,0.00004223298,0.0033452425,0.00002591443,0.0011337812,0.0000015287346,0.01808932,0.00020885964,0.029819263,0.6520063],"study_design_scores_gemma":[0.004961888,0.048526254,0.931948,0.00079486804,0.00021880644,0.00001776065,0.0005369665,0.0000016243903,0.010037589,0.00036173852,0.002470973,0.00012351149],"about_ca_topic_score_codex":0.00013414888,"about_ca_topic_score_gemma":0.000038866565,"teacher_disagreement_score":0.6518828,"about_ca_system_score_codex":0.000070809685,"about_ca_system_score_gemma":0.00031523334,"threshold_uncertainty_score":0.99970704},"labels":[],"label_agreement":null},{"id":"W2588978198","doi":"10.1093/annonc/mdw364.02","title":"Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Neutrophil to lymphocyte ratio; Oncology; Cancer; Inflammatory breast cancer; Clinical endpoint; Gastroenterology; Proportional hazards model; Retrospective cohort study; Lymphocyte; Randomized controlled trial","score_opus":0.040664982946743616,"score_gpt":0.35514200562461185,"score_spread":0.31447702267786826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588978198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798524,0.0003872517,0.00009833488,0.017625459,0.0001643895,0.0012298116,0.00012597145,0.000031457203,0.0004849273],"genre_scores_gemma":[0.99610674,0.00015292222,0.0006116324,0.001971445,0.00018262603,0.00084005576,0.000004987086,0.000027585458,0.00010202262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987188,0.00007384454,0.00039270092,0.0002838304,0.00013660453,0.0003942174],"domain_scores_gemma":[0.99879,0.0002476927,0.00014398606,0.00022497601,0.00039398743,0.00019932422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002560139,0.00014402285,0.0004121854,0.00020858385,0.000029070487,0.000004464461,0.00013150102,0.00015138798,0.00010889832],"category_scores_gemma":[0.00024803056,0.000106777494,0.00011828109,0.00017427436,0.00012799694,0.00008205497,0.000054392345,0.000047166403,0.00003064757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075202347,0.0005222336,0.6066678,0.00015347355,0.00021923476,0.00007568591,0.00038001087,0.000004743963,0.15085635,0.00024194628,0.0029882537,0.23037003],"study_design_scores_gemma":[0.004266186,0.0015099719,0.9504432,0.0003030837,0.00008253002,0.000026925123,0.000037348636,0.00003993054,0.034547348,0.00031509952,0.008279915,0.00014846456],"about_ca_topic_score_codex":0.000087347515,"about_ca_topic_score_gemma":0.00008775303,"teacher_disagreement_score":0.3437754,"about_ca_system_score_codex":0.00013681778,"about_ca_system_score_gemma":0.00066533993,"threshold_uncertainty_score":0.43542597},"labels":[],"label_agreement":null},{"id":"W2588980997","doi":"10.1093/annonc/mdw373.41","title":"Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Cabozantinib; Internal medicine; Progression-free survival; Renal cell carcinoma; Target lesion; Gastroenterology; Oncology; Everolimus; Urology; Surgery; Overall survival; Myocardial infarction","score_opus":0.04003420815654439,"score_gpt":0.3361023108916654,"score_spread":0.296068102735121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588980997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958584,0.0005162928,0.0000044362428,0.0011262451,0.000040453524,0.0016311456,0.0000800818,0.000005650725,0.0007373006],"genre_scores_gemma":[0.99906087,0.0000733445,0.00024967003,0.0003207742,0.000035599875,0.00008398212,0.000041479743,0.000022698348,0.0001115709],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764293,0.000529415,0.000718755,0.00036815522,0.0003594438,0.0003813154],"domain_scores_gemma":[0.99788344,0.000998392,0.00045750823,0.0003651658,0.00017888044,0.000116591575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000665454,0.00024145126,0.0009432359,0.00023678722,0.000022910763,0.0000035251317,0.00014661056,0.00007172913,0.00005003846],"category_scores_gemma":[0.000259576,0.00012808772,0.00009730029,0.00027098283,0.00022473467,0.0000894867,0.000046131885,0.00017231089,0.0000060555603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66309845,0.017801462,0.102037184,0.0004039401,0.00036152167,0.0013651275,0.0051341397,0.000019844487,0.10230117,0.000028970328,0.0034749925,0.10397322],"study_design_scores_gemma":[0.5517499,0.100874946,0.24210908,0.00023932473,0.00042411484,0.000051554547,0.00032580268,0.000018139477,0.09960539,0.000034752484,0.0042801867,0.00028684214],"about_ca_topic_score_codex":0.00031715896,"about_ca_topic_score_gemma":0.000073959294,"teacher_disagreement_score":0.14007188,"about_ca_system_score_codex":0.000059646354,"about_ca_system_score_gemma":0.00022091377,"threshold_uncertainty_score":0.5223265},"labels":[],"label_agreement":null},{"id":"W2588989861","doi":"10.1093/annonc/mdw435.04","title":"FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Fulvestrant; Anastrozole; Medicine; Hazard ratio; Clinical endpoint; Internal medicine; Oncology; Breast cancer; Adverse effect; Estrogen receptor; Cancer; Clinical trial; Confidence interval; Tamoxifen","score_opus":0.018851179311353824,"score_gpt":0.3469741085115958,"score_spread":0.328122929200242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588989861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992831,0.0015987827,0.0007126871,0.0022340931,0.00028533846,0.0012490454,0.0006279702,0.000008635379,0.00045248304],"genre_scores_gemma":[0.994673,0.0038864214,0.0003562931,0.0002107829,0.00029793667,0.000240318,0.00009493664,0.000024372926,0.00021591836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985629,0.00014793532,0.0004996729,0.00032980315,0.000104664505,0.00035502276],"domain_scores_gemma":[0.9987738,0.00013002765,0.0004123783,0.0002360061,0.00031904902,0.00012874899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003510572,0.00019901118,0.0005930016,0.000060938688,0.000045523186,0.0000027782974,0.00017511526,0.00035027825,0.00003086917],"category_scores_gemma":[0.00008278115,0.00014053626,0.00033195887,0.00007683938,0.00025698476,0.0000092515,0.00004431348,0.00007605357,0.000002128997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30960962,0.0004509838,0.000006064448,0.000011408195,0.0002974268,0.0000020570253,0.000030096437,0.0000051005513,0.5973011,0.000035776535,0.003152903,0.08909744],"study_design_scores_gemma":[0.31101474,0.017136285,0.000066784734,0.00004488455,0.00007635529,0.000012251359,0.000027902732,0.000006880976,0.6595491,0.000029632409,0.011882901,0.00015227107],"about_ca_topic_score_codex":0.00002512563,"about_ca_topic_score_gemma":0.0000066298603,"teacher_disagreement_score":0.088945165,"about_ca_system_score_codex":0.000016335292,"about_ca_system_score_gemma":0.0002956049,"threshold_uncertainty_score":0.5730902},"labels":[],"label_agreement":null},{"id":"W2588993630","doi":"10.1093/annonc/mdw363.08","title":"Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Cancer","score_opus":0.07038801026314985,"score_gpt":0.3661946169553027,"score_spread":0.29580660669215286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588993630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973289,0.00036955113,0.000010138994,0.00096864015,0.00010900894,0.0005785957,0.00058609335,0.0000045165743,0.00004455706],"genre_scores_gemma":[0.9975103,0.0012263036,0.00021427001,0.0006040246,0.000038790495,0.0001557199,0.00019319066,0.000023274759,0.000034113622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839014,0.00024927876,0.0006322366,0.00033851602,0.00008821986,0.0003015874],"domain_scores_gemma":[0.9987187,0.0003015167,0.0005080774,0.00018663074,0.00021241246,0.00007269594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029330567,0.00018570665,0.00047197094,0.00008359152,0.00005027046,0.000011709322,0.0000986842,0.00009415682,0.000019998419],"category_scores_gemma":[0.00033810525,0.00013290471,0.00009262489,0.00010642539,0.00009572152,0.000010626928,0.000031008716,0.000063882755,0.0000013976717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006168019,0.00083231815,0.9254367,0.000005187866,0.0002825476,0.000016673732,0.00031176663,0.00019893456,0.062481463,0.000010146979,0.0001444088,0.009663089],"study_design_scores_gemma":[0.008258225,0.004607436,0.95666754,0.000096585085,0.000033417222,0.0000013667242,0.00022430734,0.000039005306,0.028094092,0.00006569249,0.00164479,0.00026754345],"about_ca_topic_score_codex":0.00059665396,"about_ca_topic_score_gemma":0.014123688,"teacher_disagreement_score":0.03438737,"about_ca_system_score_codex":0.00016822733,"about_ca_system_score_gemma":0.0005329001,"threshold_uncertainty_score":0.78813493},"labels":[],"label_agreement":null},{"id":"W2588999445","doi":"10.1093/annonc/mdw379.10","title":"Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Population; Confidence interval; Survival analysis; Ipilimumab; Internal medicine; Cancer; Immunotherapy","score_opus":0.03141026450130777,"score_gpt":0.33654428113419116,"score_spread":0.30513401663288336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588999445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967845,0.00024492064,0.00011090973,0.0013089874,0.00008294356,0.00055731134,0.0000218128,0.000010751077,0.0008778273],"genre_scores_gemma":[0.9989226,0.00015048565,0.00055418763,0.00016461917,0.00003236087,0.000033099095,0.000013774613,0.000019810637,0.00010905279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988374,0.0001136113,0.00036995247,0.0002123269,0.00020351501,0.00026316362],"domain_scores_gemma":[0.9989872,0.00025092906,0.0003106437,0.00029063242,0.00011427066,0.000046319157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020077582,0.00016755001,0.00049519073,0.000088072455,0.000038216986,0.0000028206769,0.00010924551,0.00007188685,0.000082944316],"category_scores_gemma":[0.00002819776,0.000074178235,0.00007929138,0.00011811889,0.00025654602,0.00007784676,0.00002396516,0.00006721625,0.0000013633601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023949118,0.0007133826,0.6976515,0.00005541658,0.00022904253,0.000025685942,0.0005155126,0.000012377631,0.004114062,0.000008015114,0.000009148914,0.2727167],"study_design_scores_gemma":[0.017517513,0.0151209,0.9628628,0.00043894807,0.000062999476,0.000015668147,0.00009518449,0.000008172741,0.0034666725,0.0000037636064,0.0003068906,0.00010048398],"about_ca_topic_score_codex":0.00020513634,"about_ca_topic_score_gemma":0.0006653242,"teacher_disagreement_score":0.27261624,"about_ca_system_score_codex":0.00013508795,"about_ca_system_score_gemma":0.0002117293,"threshold_uncertainty_score":0.30249006},"labels":[],"label_agreement":null},{"id":"W2589024279","doi":"10.1093/annonc/mdw373.46","title":"Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Juravinski Cancer Centre; Montreal General Hospital; Ottawa Regional Cancer Foundation; Health Sciences Centre; CancerCare Manitoba; Ottawa Hospital; BC Cancer Agency; University of Calgary; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; McGill University; University of Alberta","funders":"","keywords":"Sunitinib; Pazopanib; Medicine; Renal cell carcinoma; Hazard ratio; Mucositis; Internal medicine; Oncology; Proportional hazards model; Urology; Toxicity; Confidence interval","score_opus":0.1504262990127663,"score_gpt":0.36758658108210895,"score_spread":0.21716028206934265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589024279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308133,0.000057055222,0.000011310739,0.0026120595,0.000070824615,0.00055818475,0.000084914675,0.0000081732105,0.00351617],"genre_scores_gemma":[0.9976347,0.000030987536,0.0008286651,0.000511267,0.00003213428,0.000032073556,0.00001699022,0.00002680196,0.0008863565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998294,0.00014156703,0.0005171648,0.0002567384,0.000349667,0.0004408501],"domain_scores_gemma":[0.99786115,0.00054084073,0.00037660977,0.00045939098,0.0004836474,0.0002783927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023582767,0.00021637732,0.0006680999,0.00024966281,0.00010722018,0.0000046778596,0.00018672377,0.00006198054,0.00032765223],"category_scores_gemma":[0.00011935266,0.000095136704,0.00011097411,0.0002860067,0.00041032545,0.00007291398,0.000046415476,0.00010150386,0.0000060719294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017650423,0.00061400695,0.9884943,0.00007660344,0.00019446423,0.0003632555,0.0014757739,0.000013299967,0.00087333366,0.00008720473,0.0003837582,0.005658971],"study_design_scores_gemma":[0.003983066,0.0062294058,0.9550154,0.000088514644,0.00026687037,0.00002362527,0.00026733542,0.000013062794,0.03055851,0.000029966366,0.0033749226,0.00014930165],"about_ca_topic_score_codex":0.0768289,"about_ca_topic_score_gemma":0.31133184,"teacher_disagreement_score":0.23450294,"about_ca_system_score_codex":0.00023709013,"about_ca_system_score_gemma":0.0011437046,"threshold_uncertainty_score":0.9293186},"labels":[],"label_agreement":null},{"id":"W2589028903","doi":"10.1093/annonc/mdw370.43","title":"Cetuximab (Cmab) plus irinotecan (I) versus panitumumab (Pmab) in patients with refractory metastatic colorectal cancer (mCRC) in Ontario","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Irinotecan; Internal medicine; Cetuximab; Colorectal cancer; Discontinuation; Regorafenib; Panitumumab; KRAS; Cancer registry; Oncology; Cancer","score_opus":0.07878255496714472,"score_gpt":0.3551703761196338,"score_spread":0.2763878211524891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589028903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027735,0.00039039235,0.0000012556837,0.0013613505,0.00027486376,0.0006030518,0.000037256024,0.000014908708,0.007039567],"genre_scores_gemma":[0.99879575,0.00025501757,0.000088561916,0.00023053288,0.000025153131,0.00017929958,0.000012441399,0.000021047734,0.00039217641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841595,0.00008564763,0.00042708282,0.00035173466,0.00027150038,0.0004480891],"domain_scores_gemma":[0.99904054,0.00025775746,0.00020695748,0.00017565678,0.00021944313,0.00009963259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014809374,0.00023045497,0.00086145784,0.00023654802,0.000032826716,0.0000032578557,0.000092949565,0.00009926772,0.00037535082],"category_scores_gemma":[0.00008504197,0.0001424385,0.00007734147,0.000216556,0.00020715338,0.00010908524,0.00006786575,0.0002180057,0.000009785296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052950878,0.0034722101,0.7667612,0.00004890001,0.0006615524,0.00027681317,0.0029265324,0.000007953391,0.0001705258,0.000050327657,0.00062009995,0.172053],"study_design_scores_gemma":[0.03388641,0.025440324,0.92796874,0.00018849169,0.00011008365,0.000002990343,0.0001947343,0.0000023392943,0.0004587507,0.000036745045,0.01153791,0.00017246553],"about_ca_topic_score_codex":0.057053935,"about_ca_topic_score_gemma":0.7213725,"teacher_disagreement_score":0.66431856,"about_ca_system_score_codex":0.0019068619,"about_ca_system_score_gemma":0.0013823924,"threshold_uncertainty_score":0.94922525},"labels":[],"label_agreement":null},{"id":"W2589047004","doi":"10.1093/annonc/mdw370.111","title":"Cascade testing following universal immunohistochemistry for mismatch repair protiens","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; MLH1; Lynch syndrome; Internal medicine; Oncology; Cohort; DNA mismatch repair; Retrospective cohort study; Immunohistochemistry; Cancer; Colorectal cancer; Referral; Family medicine","score_opus":0.09909058748553651,"score_gpt":0.3930638542239459,"score_spread":0.2939732667384094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589047004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98071957,0.00031881215,0.00020074913,0.0037880219,0.00035002374,0.0004918953,0.000018173994,0.00007777456,0.014034998],"genre_scores_gemma":[0.9824165,0.000018299119,0.014029988,0.00044906253,0.00012780908,0.00006288096,0.0000037500843,0.000023522565,0.0028682065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990079,0.000028437325,0.00028413607,0.00024915388,0.0001313852,0.0002989891],"domain_scores_gemma":[0.9985493,0.0005760144,0.00014688414,0.00025839524,0.00037839648,0.00009104335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025313598,0.00011304182,0.00034793897,0.00004257873,0.000042989384,0.0000013007789,0.000088928515,0.00019073964,0.000055031738],"category_scores_gemma":[0.001658147,0.00008725599,0.00023150127,0.00010917101,0.00011358507,0.000029136017,0.000052198433,0.00008483251,0.0000065909508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049835193,0.00013757127,0.0057826927,0.00015357482,0.000172326,0.000079916106,0.00019102286,0.0000014832301,0.94841725,0.000030237714,0.013415346,0.031120239],"study_design_scores_gemma":[0.003312926,0.004658029,0.0042570117,0.0003101028,0.00014368142,0.0001850749,0.00019698527,0.000034971086,0.894235,0.00062376144,0.09184774,0.00019470479],"about_ca_topic_score_codex":0.000020520769,"about_ca_topic_score_gemma":0.0000032875007,"teacher_disagreement_score":0.078432396,"about_ca_system_score_codex":0.0001608967,"about_ca_system_score_gemma":0.00075605814,"threshold_uncertainty_score":0.35581958},"labels":[],"label_agreement":null},{"id":"W2589048165","doi":"10.1093/annonc/mdw371.98","title":"Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Hazard ratio; Neutrophil to lymphocyte ratio; Hepatocellular carcinoma; Portal vein thrombosis; Univariate analysis; Confidence interval; Post-hoc analysis; Cohort; Multivariate analysis; Proportional hazards model; Thrombosis; Oncology; Lymphocyte","score_opus":0.10600796715231706,"score_gpt":0.32607113567009793,"score_spread":0.22006316851778088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589048165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257326,0.001038858,0.000061559076,0.004019328,0.00011823081,0.0019934403,0.000051234794,0.00001828479,0.00012578283],"genre_scores_gemma":[0.9986622,0.00009315102,0.00011962844,0.000653224,0.00008951593,0.0002846353,0.000021533644,0.000026770858,0.000049379716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997073,0.0009965289,0.0007223147,0.0004741993,0.00037930388,0.00035467662],"domain_scores_gemma":[0.9975401,0.00064197794,0.0003312281,0.0010154812,0.00030704783,0.00016413753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007502864,0.00025255466,0.0009104173,0.00025695804,0.000073291194,0.0000065422328,0.00039910284,0.00014026412,0.0000669274],"category_scores_gemma":[0.00028757367,0.00012691933,0.00033862249,0.0011431739,0.00018622243,0.00011920907,0.00014447307,0.0001357476,0.000014795328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070498144,0.0016263037,0.9728488,0.000011476815,0.00066238595,0.00014248503,0.003140781,0.000026459285,0.012573726,0.00006692365,0.0000652094,0.008130474],"study_design_scores_gemma":[0.0037951416,0.005146161,0.955896,0.000061217965,0.0013945452,0.0000032513897,0.0012985216,0.00078483106,0.03064292,0.00013865656,0.0006893337,0.0001493852],"about_ca_topic_score_codex":0.0008169885,"about_ca_topic_score_gemma":0.000915571,"teacher_disagreement_score":0.018069195,"about_ca_system_score_codex":0.00010085373,"about_ca_system_score_gemma":0.0005206117,"threshold_uncertainty_score":0.51756203},"labels":[],"label_agreement":null},{"id":"W2589070781","doi":"10.1093/annonc/mdw375.43","title":"Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Mitoxantrone; Idarubicin; Oncology; Salvage therapy; Phases of clinical research; Febrile neutropenia; Etoposide; Chemotherapy regimen; Myeloid leukemia; Chemotherapy; Surgery; Neutropenia","score_opus":0.05300243935670836,"score_gpt":0.3718103538949401,"score_spread":0.31880791453823176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589070781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895196,0.00007934492,0.00014291877,0.002570504,0.000056856286,0.0073734536,0.00010378471,0.00004826016,0.00010530834],"genre_scores_gemma":[0.9954014,0.0005946707,0.00018597735,0.0010653264,0.000068143905,0.0010747447,0.000019145855,0.00012543132,0.0014651612],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9954692,0.00074914435,0.0013082797,0.0008496198,0.000878875,0.00074485544],"domain_scores_gemma":[0.996516,0.0007324523,0.00063072715,0.0012138502,0.00058881275,0.0003181636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000801317,0.000609679,0.0018216536,0.00044452632,0.000089538386,0.00001532393,0.00043749507,0.00022557242,0.0002811416],"category_scores_gemma":[0.00002351773,0.0002621354,0.00011510055,0.000743713,0.00035769382,0.00017645229,0.00005242839,0.00036097135,0.000023510998],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59887815,0.062229823,0.18089947,0.00016316818,0.0025872893,0.0016743932,0.074959114,0.00001839012,0.010455203,0.0000044923004,0.0006357523,0.06749477],"study_design_scores_gemma":[0.22986336,0.6801387,0.027048312,0.00055440504,0.00068558066,0.00010320024,0.011619713,0.00008361802,0.045564976,0.0000036720626,0.0037372978,0.0005971565],"about_ca_topic_score_codex":0.00036843945,"about_ca_topic_score_gemma":0.0014425155,"teacher_disagreement_score":0.6179089,"about_ca_system_score_codex":0.00081592175,"about_ca_system_score_gemma":0.0018734819,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W2589075590","doi":"10.1093/annonc/mdw389.05","title":"A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Refractory (planetary science); Monoclonal antibody; Oncology; Cancer; Clinical trial; Lung cancer; Monoclonal; Internal medicine; Cancer research; Antibody; Immunology","score_opus":0.03853249975163586,"score_gpt":0.3950706369412427,"score_spread":0.35653813718960686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589075590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941749,0.002764834,0.00020684174,0.00095030875,0.00009893838,0.00060388586,0.00006813999,0.00000438446,0.0011277535],"genre_scores_gemma":[0.99484044,0.0042232857,0.0002629808,0.0000963549,0.00013525214,0.000035307658,0.000043393935,0.000016583303,0.00034638852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844223,0.0002547862,0.00051987433,0.00033374722,0.00013788776,0.0003114962],"domain_scores_gemma":[0.9990603,0.00015638491,0.00027069758,0.00021480507,0.00019562304,0.00010223387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006860956,0.00014106452,0.0003400415,0.00013180895,0.00003569377,0.0000034020418,0.00016634628,0.00027057095,0.00008500103],"category_scores_gemma":[0.00037339912,0.00011102109,0.00009435394,0.00010864314,0.00017079677,0.000006348589,0.000153764,0.00013180613,0.0000015552909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0675269,0.0017521926,0.0016296073,0.00007308533,0.00004952163,0.000015859661,0.000114596005,0.000019853707,0.8695711,0.000023837794,0.00086447643,0.058358964],"study_design_scores_gemma":[0.13791014,0.02628252,0.0066206413,0.00015299955,0.000029983807,0.0000069344655,0.00007590244,0.00031745335,0.7479074,0.00004826011,0.080318466,0.00032927524],"about_ca_topic_score_codex":0.00012965791,"about_ca_topic_score_gemma":0.000055246765,"teacher_disagreement_score":0.12166368,"about_ca_system_score_codex":0.000019502819,"about_ca_system_score_gemma":0.00037760846,"threshold_uncertainty_score":0.45273083},"labels":[],"label_agreement":null},{"id":"W2589078008","doi":"10.1093/annonc/mdw376.01","title":"Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Cohort; Nausea; Oncology; Gastroenterology; Cancer; Immunotherapy; Nivolumab","score_opus":0.023916400266900773,"score_gpt":0.3244297351281284,"score_spread":0.3005133348612276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589078008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973442,0.0006433138,0.0000027943254,0.0010377151,0.000118684235,0.0004973062,0.00009815038,0.000005500838,0.00025235984],"genre_scores_gemma":[0.99884313,0.0006793961,0.000041973206,0.00032819287,0.000020765225,0.0000023514583,0.00004537222,0.000012735788,0.000026070753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862397,0.00017754696,0.00057278847,0.00025075112,0.00018782684,0.00018709958],"domain_scores_gemma":[0.9989184,0.00018395153,0.00033697637,0.00033496754,0.0001583794,0.000067331595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032536648,0.00013228886,0.0005957333,0.00010318054,0.00002687569,0.00000149502,0.00010802783,0.0001752738,0.000065523964],"category_scores_gemma":[0.000073069525,0.00007883988,0.00007210411,0.00016194266,0.0004191984,0.000068472174,0.000072348696,0.000084868276,4.2483828e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010496596,0.0009840591,0.8327457,0.00004596977,0.000042531363,0.000004953634,0.00047882902,3.1740208e-7,0.12326633,0.000003159148,0.00023686577,0.03169472],"study_design_scores_gemma":[0.015517889,0.005419384,0.92320114,0.00014703948,0.000048956957,0.0000040383115,0.00006850145,0.000010513058,0.054526288,0.000015236431,0.00096222846,0.00007877211],"about_ca_topic_score_codex":0.0021705579,"about_ca_topic_score_gemma":0.00020133269,"teacher_disagreement_score":0.09045549,"about_ca_system_score_codex":0.000027637843,"about_ca_system_score_gemma":0.00016162854,"threshold_uncertainty_score":0.32812488},"labels":[],"label_agreement":null},{"id":"W2589081360","doi":"10.1093/annonc/mdw373.38","title":"Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Pazopanib; Proportional hazards model; Sunitinib; Renal cell carcinoma; Internal medicine; Urology; Oncology; Survival analysis; Nuclear medicine","score_opus":0.09992246030689454,"score_gpt":0.3604701264236741,"score_spread":0.26054766611677954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589081360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941195,0.00007251698,0.000013345501,0.0006844057,0.000090839414,0.0015468186,0.000026295233,0.000013980722,0.0034323023],"genre_scores_gemma":[0.99942756,0.0000086357395,0.00017639225,0.00008127154,0.00003541971,0.00009477365,0.000009541825,0.000021476984,0.00014494671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997323,0.0006869537,0.000782653,0.0004242565,0.0004434204,0.00033971088],"domain_scores_gemma":[0.9976948,0.0010005159,0.0003886094,0.0004932468,0.00028791802,0.00013489263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011055669,0.00021856469,0.00086823426,0.00027043963,0.000017578855,0.0000033849199,0.00013481479,0.00006849447,0.00014117638],"category_scores_gemma":[0.000434581,0.0001459391,0.00016126249,0.00019473804,0.00013642211,0.000078452504,0.000063285064,0.00014149093,0.000030104424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031345529,0.008126875,0.91687614,0.00019335393,0.0001210511,0.0006930826,0.00091685343,0.000011372706,0.064754084,0.00009507758,0.00011058691,0.004966962],"study_design_scores_gemma":[0.0056647467,0.031947006,0.8646625,0.000074961674,0.00015307576,0.000013710517,0.00012690072,0.000005298782,0.0969298,0.00026096878,0.000057384772,0.00010363319],"about_ca_topic_score_codex":0.0006427651,"about_ca_topic_score_gemma":0.00010112552,"teacher_disagreement_score":0.05221364,"about_ca_system_score_codex":0.0001578062,"about_ca_system_score_gemma":0.0003456213,"threshold_uncertainty_score":0.5951224},"labels":[],"label_agreement":null},{"id":"W2589130880","doi":"10.1093/annonc/mdw383.16","title":"Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Pneumonitis; Discontinuation; Gastroenterology; Lung cancer; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Surgery; Toxicity; Lung; Pembrolizumab; Immunotherapy","score_opus":0.05181691926919445,"score_gpt":0.4093947081574053,"score_spread":0.35757778888821085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589130880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977262,0.00014147039,0.0000066386456,0.00079319184,0.000099941164,0.0006893006,0.000028746517,0.0000017382316,0.0005127632],"genre_scores_gemma":[0.99921435,0.0004926711,0.000012714414,0.00016536588,0.000017189739,0.000008235552,4.5495133e-7,0.0000068402082,0.00008215584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989922,0.00017831268,0.0004260234,0.00015260109,0.00013029664,0.00012056341],"domain_scores_gemma":[0.9989624,0.00023063508,0.00039101,0.00022599756,0.00015625292,0.00003368235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005058339,0.00007960411,0.00046769218,0.000047133755,0.0000140896955,4.98238e-7,0.000080917685,0.00008512433,0.00003750567],"category_scores_gemma":[0.000041149728,0.000039719267,0.00006538428,0.00011972352,0.00023740678,0.000029282413,0.00004302944,0.00008885344,9.1899395e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034547962,0.0077820774,0.76479715,0.000052835632,0.00020026401,0.0000016358094,0.00044320858,2.9479838e-7,0.0030827262,4.803847e-7,0.00012894027,0.18896241],"study_design_scores_gemma":[0.045507442,0.019222146,0.927807,0.00018346166,0.00009015689,4.27321e-7,0.000092819944,0.000005527897,0.006539551,0.0000011387039,0.00050428376,0.000046084773],"about_ca_topic_score_codex":0.00088789134,"about_ca_topic_score_gemma":0.001066561,"teacher_disagreement_score":0.18891633,"about_ca_system_score_codex":0.00003330305,"about_ca_system_score_gemma":0.00029451915,"threshold_uncertainty_score":0.16197048},"labels":[],"label_agreement":null},{"id":"W2589722562","doi":"10.1093/annonc/mdx075","title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Everolimus; Sunitinib; Medicine; Hazard ratio; Internal medicine; Oncology; Confidence interval; Renal cell carcinoma; Urology; Gastroenterology","score_opus":0.26146280799231525,"score_gpt":0.44297335488792794,"score_spread":0.1815105468956127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589722562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872237,0.0008733277,0.00014069384,0.0068698525,0.0005297929,0.0026558656,0.00071030966,0.000026484306,0.0009700085],"genre_scores_gemma":[0.9962912,0.000846535,0.00021892128,0.00029525792,0.00012337186,0.00041343833,0.0005199353,0.000063423904,0.0012279213],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957264,0.00044246306,0.0015890502,0.0007280838,0.0006967683,0.0008172023],"domain_scores_gemma":[0.9923366,0.0035664684,0.0015221435,0.001561522,0.00073316233,0.00028013941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018217983,0.0005640743,0.0024706998,0.00047404462,0.00050646113,0.00002809409,0.00076526124,0.00023588649,0.00031083822],"category_scores_gemma":[0.0016845379,0.00043612576,0.00085822167,0.00050591654,0.0003215213,0.00018542279,0.00027144182,0.0003886064,0.0000051524758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31142488,0.14387113,0.29076487,0.0011353138,0.060202405,0.0025754673,0.011114507,0.0028797395,0.0061841765,0.00013772085,0.1025213,0.0671885],"study_design_scores_gemma":[0.39680305,0.35662824,0.109977104,0.00027310316,0.029993776,0.000047829613,0.0042712935,0.0067484314,0.011883241,0.00035733072,0.081399344,0.0016172777],"about_ca_topic_score_codex":0.00656718,"about_ca_topic_score_gemma":0.022179011,"teacher_disagreement_score":0.2127571,"about_ca_system_score_codex":0.00017687218,"about_ca_system_score_gemma":0.00028099352,"threshold_uncertainty_score":0.999809},"labels":[],"label_agreement":null},{"id":"W2589731811","doi":"10.1093/annonc/mdx077","title":"Addressing the quality of the ESMO-MCBS","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Quality (philosophy); Medical physics; Intensive care medicine; Epistemology","score_opus":0.4848792684518027,"score_gpt":0.436601451174192,"score_spread":0.04827781727761066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589731811","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01388484,0.00413377,0.000030107534,0.74541706,0.0022322484,0.00029202687,0.0007056535,0.00000765,0.23329665],"genre_scores_gemma":[0.4199267,0.0016677075,0.00006907641,0.56444794,0.0035671827,0.00003907004,0.00002891942,0.00006457383,0.010188827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773276,0.000105663545,0.001331349,0.00035863213,0.000058029247,0.00041358205],"domain_scores_gemma":[0.99337125,0.00041239822,0.0046461876,0.0013850286,0.00015311709,0.000032018455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018196569,0.00023039024,0.0013024957,0.00010258718,0.00021601313,0.000038744263,0.0015759645,0.0009150131,0.00028764133],"category_scores_gemma":[0.00088520866,0.00016755008,0.00056396954,0.0000653043,0.0009098632,0.00015739328,0.00025593143,0.001085069,0.000081793565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025118088,0.00003742776,0.004625303,0.000113535556,0.00014969047,0.0000041993953,0.00023445404,0.000005436887,0.000002815708,0.017182067,0.96968865,0.007931294],"study_design_scores_gemma":[0.00025247794,0.00012608283,0.039112356,0.0000550697,0.000012020251,0.0000031408783,0.000012590198,0.0000050472663,0.00009300426,0.03887565,0.9212753,0.00017723537],"about_ca_topic_score_codex":0.0020636688,"about_ca_topic_score_gemma":0.00014623224,"teacher_disagreement_score":0.40604186,"about_ca_system_score_codex":0.00006698539,"about_ca_system_score_gemma":0.00028003522,"threshold_uncertainty_score":0.7057419},"labels":[],"label_agreement":null},{"id":"W2590203295","doi":"10.1093/annonc/mdx011","title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kitasato University; Eisai; Clovis Oncology; F. Hoffmann-La Roche; Eisai Canada; Jikei University School of Medicine; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Gynecologic cancer; Ovarian cancer; Cancer; Consensus conference; Oncology; Gynecology; Internal medicine","score_opus":0.29648010047028445,"score_gpt":0.46893896384838774,"score_spread":0.1724588633781033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590203295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7960707,0.0026540726,0.000025152816,0.19035347,0.0013525578,0.00063066406,0.0002666241,0.000014118888,0.008632654],"genre_scores_gemma":[0.9938883,0.003517253,0.00013142524,0.00114515,0.00011432296,0.00019731198,0.000005008303,0.000010786052,0.0009904506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988778,0.0000719995,0.00046296456,0.000233101,0.00012886582,0.00022522509],"domain_scores_gemma":[0.997851,0.00019618773,0.00075423747,0.000648145,0.00046735266,0.00008305332],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022404802,0.00014063029,0.0005767311,0.000052869076,0.00016268797,0.00001152222,0.0003132867,0.0001396177,0.0017702522],"category_scores_gemma":[0.00037048664,0.00009132747,0.0003304838,0.00006127479,0.0005205543,0.000035520752,0.0001852342,0.00015994944,0.000005758704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092382205,0.004340284,0.5958798,0.0008708961,0.0024801174,0.00012388651,0.0013621809,0.00011532543,0.0006995999,0.010642623,0.03573482,0.34682667],"study_design_scores_gemma":[0.0035435755,0.0027861828,0.9091693,0.0012337733,0.00046155357,0.000017473132,0.000082759005,0.00008628967,0.006108015,0.0011575271,0.07523516,0.00011839902],"about_ca_topic_score_codex":0.0050771465,"about_ca_topic_score_gemma":0.017258205,"teacher_disagreement_score":0.34670827,"about_ca_system_score_codex":0.00009816395,"about_ca_system_score_gemma":0.00054509327,"threshold_uncertainty_score":0.9991423},"labels":[],"label_agreement":null},{"id":"W2590946443","doi":"10.1093/annonc/mdx074","title":"Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Associazione Italiana per la Ricerca sul Cancro; National Institute for Health and Care Research; European Commission; Royal Marsden NHS Foundation Trust; National Cancer Institute; National Institutes of Health; Cancer Research UK; Wellcome Trust; Pancreatic Cancer UK","keywords":"Medicine; Primary tumor; Cancer; Thyroid cancer; Colorectal cancer; Metastasis; Pathology; Somatic evolution in cancer; Oncology; Internal medicine","score_opus":0.049827686302054114,"score_gpt":0.4108058589485773,"score_spread":0.3609781726465232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590946443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987732,0.0075986073,0.0000053125627,0.0016478808,0.00027213516,0.00016791932,0.000051840212,0.0000015557449,0.0025227778],"genre_scores_gemma":[0.9938499,0.005517486,0.00022208694,0.00018966192,0.000089256595,0.0000928439,0.000014472302,0.000011101,0.000013236011],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991601,0.00007105586,0.00028942153,0.00019708686,0.00006452882,0.0002177941],"domain_scores_gemma":[0.9989736,0.00008603578,0.0005150106,0.00027836818,0.00011749641,0.00002946791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003320358,0.0000956826,0.00027196747,0.000035448596,0.00007500108,0.0000070610395,0.0003281703,0.00010940357,0.00001520407],"category_scores_gemma":[0.00038247445,0.00007561862,0.000054807482,0.00003541485,0.00030758674,0.0000029616785,0.00023301582,0.00009622178,2.9902264e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005815136,0.00025185294,0.19750871,0.00009107636,0.00022165744,0.000013648581,0.0004419964,0.0010935442,0.4559459,0.0010336369,0.0013448406,0.3414716],"study_design_scores_gemma":[0.0015443868,0.0024597535,0.09760516,0.00012720432,0.000060386712,0.000009483408,0.00023003388,0.00064076623,0.8783402,0.00035852464,0.018420728,0.00020337036],"about_ca_topic_score_codex":0.0031251807,"about_ca_topic_score_gemma":0.0076845232,"teacher_disagreement_score":0.4223943,"about_ca_system_score_codex":0.000020313873,"about_ca_system_score_gemma":0.00048614954,"threshold_uncertainty_score":0.47243592},"labels":[],"label_agreement":null},{"id":"W2591748434","doi":"10.1093/annonc/mdx079","title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nilotinib; Dacarbazine; Melanoma; Internal medicine; Clinical endpoint; Imatinib; Oncology; Progressive disease; Tyrosine-kinase inhibitor; Phases of clinical research; Adverse effect; Gastroenterology; Randomized controlled trial; Surgery; Clinical trial; Chemotherapy; Cancer; Cancer research","score_opus":0.10930130301220728,"score_gpt":0.3778659373283518,"score_spread":0.2685646343161445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591748434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901938,0.00004608147,0.000008122248,0.0029522318,0.00018867335,0.0012184359,0.00016444341,0.000011924872,0.005216311],"genre_scores_gemma":[0.998846,0.000050820752,0.0002795058,0.00038624124,0.00004734184,0.000010839717,0.00006052724,0.000008829643,0.0003098871],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99860525,0.00015422763,0.0005790116,0.0002541371,0.00020418604,0.00020320703],"domain_scores_gemma":[0.9984636,0.00032846868,0.0005299997,0.00043063198,0.00016748639,0.000079832105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043962404,0.00013985099,0.0005688263,0.00005799822,0.0001493766,0.000013386493,0.00015765229,0.00006802214,0.00007924711],"category_scores_gemma":[0.0011019611,0.00008278096,0.000043851764,0.000106244086,0.00024502442,0.00006150752,0.00012064905,0.00012916343,0.000002734188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85207963,0.01417089,0.0026912652,0.000039956743,0.0005285344,0.00017566708,0.000870565,0.000029312227,0.00018147033,0.00006168309,0.0040000104,0.12517104],"study_design_scores_gemma":[0.6317164,0.19717209,0.084085286,0.00029114535,0.0005273412,0.00005226269,0.00046307666,0.00013880579,0.0013920009,0.00012629965,0.08379277,0.00024255745],"about_ca_topic_score_codex":0.0009695357,"about_ca_topic_score_gemma":0.0006745008,"teacher_disagreement_score":0.22036324,"about_ca_system_score_codex":0.00004696137,"about_ca_system_score_gemma":0.00016174669,"threshold_uncertainty_score":0.33757097},"labels":[],"label_agreement":null},{"id":"W2592928189","doi":"10.1093/annonc/mdx037","title":"Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"Institut Gustave-Roussy; Universidade de São Paulo; National Cancer Institute; Cancer Research UK; National University Cancer Institute, Singapore; Cancer Care Ontario; Deutsches Krebsforschungszentrum; Medical Research Council; Sociedade Beneficente Israelita Brasileira Albert Einstein; Jewish General Hospital; Howard Hughes Medical Institute","keywords":"Medicine; Harmonization; Interoperability; Data sharing; Exome sequencing; Raw data; DNA sequencing; Data science; World Wide Web; Computer science; Genetics; Alternative medicine; Mutation; Biology; Pathology; Gene","score_opus":0.08116997020149776,"score_gpt":0.4296559745266543,"score_spread":0.3484860043251566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592928189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483242,0.025328254,0.00015070899,0.0038009984,0.004682809,0.00015375887,0.0001993593,0.00000525435,0.01735466],"genre_scores_gemma":[0.9789871,0.017227404,0.00006538713,0.00047366912,0.0030681419,0.00005565891,0.000025183295,0.000011093353,0.00008638839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916905,0.000035493737,0.0002159615,0.00023653351,0.00006969697,0.00027325834],"domain_scores_gemma":[0.99897176,0.000026710433,0.00029863068,0.00033973003,0.00030269206,0.00006046932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027277396,0.00011851366,0.00017498845,0.0000117550935,0.00022406632,0.000041488813,0.0005623279,0.00009041893,0.000045617366],"category_scores_gemma":[0.00021895899,0.00009511762,0.00010710969,0.00002805295,0.00012812827,0.0000047520625,0.00042644405,0.00010747954,0.00000304477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019988048,0.00008613038,0.080191836,0.000025674488,0.00029258578,0.0000046861082,0.00023063361,0.002805492,0.0068610664,0.0008334017,0.062797464,0.8456712],"study_design_scores_gemma":[0.0007134915,0.00031709284,0.086559236,0.00006456627,0.000052938234,0.000011042157,0.00008180007,0.0008003095,0.0054810396,0.0008258346,0.90485793,0.00023472514],"about_ca_topic_score_codex":0.0007113801,"about_ca_topic_score_gemma":0.0065804613,"teacher_disagreement_score":0.84543645,"about_ca_system_score_codex":0.00008237146,"about_ca_system_score_gemma":0.000890126,"threshold_uncertainty_score":0.38787842},"labels":[],"label_agreement":null},{"id":"W2593126380","doi":"10.1093/annonc/mdx005","title":"ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; BC Children's Hospital","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; Genome British Columbia; Genome Canada","keywords":"Medicine; ABVD; Hodgkin lymphoma; Radiation therapy; Chemotherapy; Lymphoma; Chemotherapy regimen; Dacarbazine; Pediatrics; Oncology; Internal medicine; Vincristine; Cyclophosphamide","score_opus":0.029486455225050095,"score_gpt":0.3421117743743025,"score_spread":0.3126253191492524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593126380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957494,0.0012267695,7.447027e-7,0.00210199,0.00002403552,0.0005922482,0.000010883135,0.000007231107,0.00028666813],"genre_scores_gemma":[0.98956335,0.009657895,0.00015648964,0.00049129716,0.000033439464,0.00003500712,0.00002000496,0.000016204227,0.000026336826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917895,0.00004538072,0.00022319012,0.0002295207,0.0001396974,0.0001832711],"domain_scores_gemma":[0.99909747,0.000028628067,0.00038538812,0.00030123777,0.00012240025,0.0000648901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013490343,0.00014884128,0.00046262864,0.00009369629,0.000039162678,0.000012541648,0.000085033906,0.00009651449,0.000006712354],"category_scores_gemma":[0.000020453777,0.00009701008,0.000034308956,0.00004639544,0.00018097264,0.00011889826,0.000013814597,0.000035072157,5.8706866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004070208,0.001401851,0.78786916,0.00002822981,0.0002527601,0.000024906221,0.0006419413,6.125277e-7,0.00086946116,0.00001732556,0.0001133841,0.20471014],"study_design_scores_gemma":[0.023369767,0.0068636807,0.9014681,0.00032299102,0.000030485182,0.000059271424,0.000052607997,0.000005458799,0.067552306,0.000014110516,0.00017672685,0.00008447617],"about_ca_topic_score_codex":0.0011249355,"about_ca_topic_score_gemma":0.00020158029,"teacher_disagreement_score":0.20462567,"about_ca_system_score_codex":0.000038362927,"about_ca_system_score_gemma":0.00015340016,"threshold_uncertainty_score":0.39559564},"labels":[],"label_agreement":null},{"id":"W2604580699","doi":"10.1093/annonc/mdx097","title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":377,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Cancer Institute; Genentech; University of Iowa; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Lymphoma; Clinical trial; Response Evaluation Criteria in Solid Tumors; Oncology; Positron emission tomography; Internal medicine; Nuclear medicine; Phases of clinical research","score_opus":0.5210154106997881,"score_gpt":0.5584069266435905,"score_spread":0.03739151594380241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604580699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018929574,0.9595043,2.468091e-7,0.002225922,0.001284167,0.0010973365,0.00005388042,0.00001363934,0.03392756],"genre_scores_gemma":[0.009701129,0.9885786,0.00021573828,0.00025511376,0.0003050976,0.000383279,0.00028524603,0.00002888376,0.00024692368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691844,0.0009720781,0.00095555506,0.0004525326,0.0004131527,0.00028826957],"domain_scores_gemma":[0.9967244,0.0011977511,0.001035803,0.00059139734,0.00034425824,0.00010638006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002931275,0.00031501745,0.0020323095,0.00051956135,0.00005154949,0.000022990554,0.0002791469,0.0005326919,0.00029135984],"category_scores_gemma":[0.0017247207,0.00025684995,0.00046255402,0.00010423809,0.00015575862,0.000037616384,0.000121881385,0.00012383462,0.00008619003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010525548,0.0010393879,0.00021071706,0.000633159,0.000512164,0.00087160117,0.00007025585,1.1765085e-7,0.000002847195,0.000061751336,0.009411063,0.9861344],"study_design_scores_gemma":[0.003765405,0.0010902754,0.0054179346,0.009944938,0.0007553622,0.0007283637,0.00001478745,0.000015301493,0.0000049619384,0.000059485348,0.97803324,0.00016995078],"about_ca_topic_score_codex":0.00011810262,"about_ca_topic_score_gemma":0.000050944178,"teacher_disagreement_score":0.9859644,"about_ca_system_score_codex":0.0007948977,"about_ca_system_score_gemma":0.001858029,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W2604708549","doi":"10.1093/annonc/mdx100","title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institute for Health and Care Research","keywords":"Nausea; Medicine; Vomiting; Chemotherapy-induced nausea and vomiting; Chemotherapy; Anthracycline; Receiver operating characteristic; Internal medicine; Anesthesia; Oncology; Antiemetic; Cancer; Breast cancer","score_opus":0.0893305109677382,"score_gpt":0.42570584349670465,"score_spread":0.33637533252896645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604708549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558,0.00003372034,0.000060369122,0.0029075593,0.000239001,0.0007704433,0.0000257233,0.000008258016,0.0003749337],"genre_scores_gemma":[0.9980473,0.00015224778,0.0010099332,0.0003343979,0.000095467694,0.000114963535,0.0000064696605,0.000009529718,0.00022971455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99914753,0.000024946225,0.0003495479,0.00015943857,0.0001381224,0.00018041076],"domain_scores_gemma":[0.99886566,0.0001357539,0.00045838632,0.00021775448,0.000271066,0.00005139232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066100387,0.00007833822,0.00023981338,0.00004661206,0.0003598868,0.000011739778,0.00010720003,0.00006483421,0.000007964473],"category_scores_gemma":[0.00043990093,0.000057488003,0.00004222911,0.000025700992,0.00005109212,0.00004028866,0.000115464114,0.00005191745,0.0000012971899],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013324122,0.00020731312,0.31175837,0.00014884718,0.0003661143,6.570779e-7,0.0011156807,9.85706e-7,0.007428579,0.00007847129,0.0051242756,0.6724383],"study_design_scores_gemma":[0.0028257433,0.001161284,0.89461434,0.00008617153,0.00005987762,3.2314313e-7,0.000053246164,0.000022608157,0.06521591,0.000099156365,0.035808105,0.000053223805],"about_ca_topic_score_codex":0.000105569256,"about_ca_topic_score_gemma":0.00025396058,"teacher_disagreement_score":0.6723851,"about_ca_system_score_codex":0.000057697645,"about_ca_system_score_gemma":0.00008409033,"threshold_uncertainty_score":0.27679947},"labels":[],"label_agreement":null},{"id":"W2605027303","doi":"10.1093/annonc/mdx152","title":"Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre; BC Cancer Agency; Alberta Health Services; Saint John Regional Hospital; University of Calgary; Canadian Cancer Society; McGill University; McMaster University; Queen's University; University of Toronto","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; National Institutes of Health","keywords":"Medicine; Oncology; Breast cancer; Adjuvant; Internal medicine; Baseline (sea); Cancer; Weight change; Gynecology; Obesity; Weight loss","score_opus":0.28691312124228974,"score_gpt":0.537653625518548,"score_spread":0.25074050427625827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605027303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98593724,0.00262597,0.0000017572331,0.009957269,0.00018872214,0.0003108745,0.0003868351,0.0000039288416,0.00058740133],"genre_scores_gemma":[0.988875,0.0102936085,0.000021516928,0.00031790516,0.00039607112,0.00002542867,0.00000814448,0.000009696858,0.000052658797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900866,0.00009750689,0.0004463993,0.00015473846,0.00009894026,0.00019374627],"domain_scores_gemma":[0.9987795,0.0001582115,0.00051830854,0.0002795567,0.000153598,0.000110844216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010204484,0.00010633646,0.0010175782,0.0001290568,0.000026074375,0.000003635604,0.0000850918,0.00012946822,0.0006211956],"category_scores_gemma":[0.0002993226,0.00007262839,0.00015648523,0.000046767334,0.00016653675,0.00008206926,0.000049012117,0.00010807691,0.0000013056994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018299719,0.0003187062,0.5954971,0.000060821945,0.00012875284,0.000029698436,0.00035430706,7.7450215e-7,0.0026787885,0.00001797431,0.0034851013,0.39559802],"study_design_scores_gemma":[0.0037053982,0.0016155263,0.98713964,0.00016020628,0.00006795095,0.000027234631,0.000018801775,0.00006989606,0.0012326512,0.000044501874,0.005852385,0.00006580833],"about_ca_topic_score_codex":0.024162874,"about_ca_topic_score_gemma":0.0033393733,"teacher_disagreement_score":0.3955322,"about_ca_system_score_codex":0.000044503664,"about_ca_system_score_gemma":0.0002825088,"threshold_uncertainty_score":0.9823353},"labels":[],"label_agreement":null},{"id":"W2607072129","doi":"10.1093/annonc/mdx182","title":"Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"KWF Kankerbestrijding; Ministry of Education, India; Ministry of Earth Sciences; Rijksuniversiteit Groningen","keywords":"Medicine; Lung cancer; Copy-number variation; Metastasis; Oncology; Cancer; Cancer research; Internal medicine; Pathology; Genome; Biology; Genetics; Gene","score_opus":0.07500882505652583,"score_gpt":0.34333770595980956,"score_spread":0.2683288809032837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607072129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94358855,0.0035451439,0.00014253597,0.047620114,0.00041695518,0.00047183456,0.0030323577,0.0000020617008,0.0011804269],"genre_scores_gemma":[0.95181215,0.0053597908,0.00032287047,0.039870486,0.000642395,0.00014609867,0.0008348523,0.000053469896,0.0009578977],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984056,0.00013666169,0.00055317354,0.00043841847,0.00012640473,0.00033974956],"domain_scores_gemma":[0.9981986,0.00021233912,0.0008232158,0.00048365825,0.00022760661,0.000054535638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002155474,0.00027061507,0.0005463824,0.000060630893,0.00010155659,0.000028982355,0.00029205266,0.00048638225,0.00005670731],"category_scores_gemma":[0.00007677094,0.00023142983,0.00016367952,0.000038409078,0.0001546186,0.0000044419476,0.00034191046,0.0003340751,7.5276847e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000384041,0.00068645,0.067736804,0.0008020549,0.0004978103,0.00014910226,0.000646692,0.00014412368,0.1616835,0.000017327558,0.76186603,0.0053860415],"study_design_scores_gemma":[0.0019292393,0.0013427994,0.0034667035,0.00022185156,0.000340647,0.00003359803,0.00010886027,0.000051257644,0.29517007,0.000062244384,0.69669473,0.00057798467],"about_ca_topic_score_codex":0.001451118,"about_ca_topic_score_gemma":0.0033157312,"teacher_disagreement_score":0.13348657,"about_ca_system_score_codex":0.00007335297,"about_ca_system_score_gemma":0.00040022997,"threshold_uncertainty_score":0.94374347},"labels":[],"label_agreement":null},{"id":"W2607167117","doi":"10.1093/annonc/mdx169","title":"Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Medicine; Glioblastoma; CRISPR; Clinical trial; Oncology; Acquired resistance; Bioinformatics; Cancer research; Internal medicine; Cancer; Biology; Gene; Genetics","score_opus":0.24206641753994654,"score_gpt":0.46436327875179734,"score_spread":0.2222968612118508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607167117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046818078,0.94885796,8.9757904e-8,0.0008082211,0.00010351025,0.001259606,0.00008909085,0.00001504534,0.002048415],"genre_scores_gemma":[0.012273561,0.9866552,0.00009458695,0.00015667797,0.00010449237,0.00046362053,0.000052581774,0.000039762912,0.00015954454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805063,0.0001689859,0.0007272889,0.0005398225,0.00013925973,0.00037400043],"domain_scores_gemma":[0.99831533,0.00013631921,0.0005011109,0.00070074183,0.00008449662,0.00026197114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024983502,0.00041248955,0.0030152332,0.00042684234,0.000078069585,0.000017084874,0.00014759666,0.0003755943,0.000015486698],"category_scores_gemma":[0.00009380812,0.00030525148,0.00036535843,0.00013550579,0.00012988999,0.00003547571,0.00009664642,0.00017219149,0.000019427136],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001331393,0.0014201904,0.00026610313,0.0023861546,0.00037930068,0.0023795855,0.0001250361,7.974239e-8,0.000013776341,0.00042628043,0.0017245208,0.99074584],"study_design_scores_gemma":[0.0015284925,0.009070908,0.0006104553,0.007097982,0.0005352934,0.0001265753,0.000009953337,8.685839e-8,0.00027554546,0.00007926936,0.98047125,0.00019419748],"about_ca_topic_score_codex":0.00006516346,"about_ca_topic_score_gemma":0.001980764,"teacher_disagreement_score":0.99055165,"about_ca_system_score_codex":0.00024744926,"about_ca_system_score_gemma":0.00036756467,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W2609430257","doi":"10.1093/annonc/mdx173","title":"Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"University of California, San Francisco; University of Warwick; Cancer Research UK; Sanofi","keywords":"Medicine; Epirubicin; Docetaxel; Bevacizumab; Fluorouracil; Cyclophosphamide; Oncology; Internal medicine; Chemotherapy; Breast cancer; Disease; Surgery; Cancer","score_opus":0.025950712902101655,"score_gpt":0.3272912708754922,"score_spread":0.30134055797339054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609430257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98706526,0.0011657274,0.00002809166,0.0066685397,0.0001586933,0.0012135159,0.0035854522,0.0000072371267,0.000107491534],"genre_scores_gemma":[0.9959725,0.0011556174,0.00040249096,0.0004576615,0.00021864135,0.0010878723,0.0000549433,0.000033361157,0.0006169181],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99868995,0.000043449952,0.00023289383,0.00050415564,0.00011316957,0.00041635573],"domain_scores_gemma":[0.99872434,0.00011540081,0.0002884522,0.0004308192,0.00020174663,0.00023926025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017790822,0.00023755104,0.0005302229,0.000025999427,0.00023498423,0.000027555125,0.00021839561,0.00012454609,0.00000767613],"category_scores_gemma":[0.00015380267,0.00020622715,0.00007809035,0.000021818929,0.00024437535,0.000016056863,0.00021370285,0.00004173912,4.4478065e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6554926,0.0009786555,0.058158536,0.00024914,0.003419984,0.00003171746,0.0023128928,0.000019418427,0.023874586,0.00011212557,0.082958445,0.17239192],"study_design_scores_gemma":[0.13554175,0.018695569,0.75345516,0.00009725088,0.00033201114,0.000020617652,0.00033508267,0.00001030794,0.014273028,0.0009826692,0.075471126,0.0007853965],"about_ca_topic_score_codex":0.00084462244,"about_ca_topic_score_gemma":0.001535741,"teacher_disagreement_score":0.69529665,"about_ca_system_score_codex":0.000064863714,"about_ca_system_score_gemma":0.00017321836,"threshold_uncertainty_score":0.8409699},"labels":[],"label_agreement":null},{"id":"W2610230715","doi":"10.1093/annonc/mdx137.004","title":"Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Tolerability; Breast cancer; Letrozole; Progression-free survival; Oncology; Clinical endpoint; Inflammatory breast cancer; Cancer; Surgery; Clinical trial; Adverse effect; Chemotherapy","score_opus":0.01767865693688511,"score_gpt":0.3340196490867851,"score_spread":0.3163409921499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610230715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96645004,0.0016014252,0.000029234652,0.029085724,0.0001249207,0.00094235374,0.00054946734,0.00004714135,0.0011697189],"genre_scores_gemma":[0.9943715,0.0015829043,0.0009758345,0.0015804784,0.00031278713,0.00048386693,0.00003210337,0.000073994466,0.0005865796],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976069,0.00016617768,0.00044744142,0.00065611495,0.0003200116,0.0008034008],"domain_scores_gemma":[0.99759454,0.0002016818,0.00063012325,0.00061950454,0.00045352327,0.00050065067],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029274524,0.00041643664,0.0010741067,0.00019150971,0.00022823988,0.000028712893,0.0002899405,0.00017750586,0.0002444698],"category_scores_gemma":[0.00014085046,0.00035716122,0.0000538445,0.00017530593,0.0011271407,0.00054885296,0.00018475985,0.00043133198,0.000012980712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31715685,0.001993043,0.06857412,0.00035285484,0.0017221356,0.0008963699,0.009330658,0.00046006596,0.0406915,0.0007365417,0.0010823915,0.55700344],"study_design_scores_gemma":[0.02043516,0.010773469,0.95337516,0.00056684285,0.000111533016,0.00011614264,0.0018623432,0.000040986022,0.0028743143,0.00092426897,0.008396072,0.0005236797],"about_ca_topic_score_codex":0.0032706424,"about_ca_topic_score_gemma":0.00052912626,"teacher_disagreement_score":0.8848011,"about_ca_system_score_codex":0.00049862626,"about_ca_system_score_gemma":0.00061625696,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W2610248350","doi":"10.1093/annonc/mdx140.006","title":"Distinct immune microenvironments stratify triple-negative breast cancer and predict outcome","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto; McGill University","funders":"","keywords":"Triple-negative breast cancer; Tumor microenvironment; Immune system; Medicine; CD8; Cytotoxic T cell; Stroma; Cancer research; Tumor-infiltrating lymphocytes; Immunotherapy; Breast cancer; T cell; Immunology; Cancer; Biology; Internal medicine; Immunohistochemistry","score_opus":0.07393463096564874,"score_gpt":0.40217304690720296,"score_spread":0.32823841594155423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610248350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784264,0.0011385232,0.000003986767,0.015756242,0.00027293267,0.00032619733,0.0002462817,0.000009594268,0.0038198507],"genre_scores_gemma":[0.9956236,0.0019460737,0.00008379527,0.0007114381,0.0001007598,0.000025162914,0.000009403371,0.000011996936,0.0014877622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990717,0.000036191803,0.00036641135,0.0001994561,0.000117720716,0.00020851685],"domain_scores_gemma":[0.9990668,0.00005590966,0.00039759415,0.00034618398,0.00005235736,0.00008113078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025071634,0.00012964109,0.00044219577,0.000042358723,0.00014531211,0.00001311206,0.00013677576,0.00011854942,0.0003620182],"category_scores_gemma":[0.00006107439,0.0001029556,0.000105969855,0.000024364708,0.00060052023,0.00009169598,0.000067357716,0.0001318618,0.000004140651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073198196,0.00045151947,0.6314211,0.00010685317,0.00071294646,0.000053204672,0.00035348578,1.5772592e-7,0.036211185,0.000023066079,0.0030585965,0.3202881],"study_design_scores_gemma":[0.0046656933,0.0011920044,0.9776401,0.000071064336,0.00007428304,0.0000761184,0.00007651318,0.000007593369,0.005602845,0.000057893423,0.010446737,0.00008917423],"about_ca_topic_score_codex":0.0013865099,"about_ca_topic_score_gemma":0.00019385602,"teacher_disagreement_score":0.346219,"about_ca_system_score_codex":0.00004758756,"about_ca_system_score_gemma":0.000107934175,"threshold_uncertainty_score":0.41984075},"labels":[],"label_agreement":null},{"id":"W2610765810","doi":"10.1093/annonc/mdx138.005","title":"Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Adjuvant; Breast cancer; Triple-negative breast cancer; Oncology; Clinical significance; Internal medicine; Clinical trial; Cancer","score_opus":0.186880146060704,"score_gpt":0.4942207772683204,"score_spread":0.30734063120761645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610765810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379706,0.0015664861,0.00013292568,0.0022462371,0.0010042818,0.00041705027,0.00024671428,0.0000029708197,0.00058624864],"genre_scores_gemma":[0.9941027,0.0026843073,0.00015493181,0.00063221523,0.0021805225,0.00004686455,0.000037101006,0.000013243699,0.00014808598],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99742585,0.00062713074,0.0011440732,0.00042486764,0.00013995108,0.00023809915],"domain_scores_gemma":[0.9972587,0.0006081233,0.0011620851,0.0006634175,0.0002167434,0.0000909197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014667463,0.0001567685,0.0007067541,0.000025217736,0.00009326775,0.000008967207,0.0006254715,0.00041966958,0.00009680261],"category_scores_gemma":[0.0010983773,0.00010950808,0.00028919624,0.000045206172,0.0006394078,0.000008029586,0.00023839388,0.00028983402,0.0000020559462],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20760863,0.0056954795,0.06728292,0.000028648203,0.0006577348,0.00006722497,0.00041405152,0.0000729475,0.16904555,0.00005440209,0.13386917,0.4152032],"study_design_scores_gemma":[0.27093464,0.019086555,0.23376088,0.00041780254,0.00024975016,0.000010965158,0.0006312761,0.00019271894,0.38827246,0.0011851256,0.084470384,0.00078742096],"about_ca_topic_score_codex":0.0014351496,"about_ca_topic_score_gemma":0.00037980115,"teacher_disagreement_score":0.4144158,"about_ca_system_score_codex":0.0000062378085,"about_ca_system_score_gemma":0.00051469984,"threshold_uncertainty_score":0.446561},"labels":[],"label_agreement":null},{"id":"W2610845435","doi":"10.1093/annonc/mdx142.004","title":"A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Vitamin D and neurology; Placebo; Internal medicine; Prospective cohort study; Cancer; Vitamin; Randomized controlled trial; Cohort; Gastroenterology; Clinical trial; Surgery; Oncology; Pathology","score_opus":0.18255096814446853,"score_gpt":0.49794172138446935,"score_spread":0.3153907532400008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610845435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889905,0.00013558951,0.0000027376377,0.0023871795,0.00035173734,0.0073725157,0.00003083614,0.0000061931546,0.0007227003],"genre_scores_gemma":[0.9983444,0.00036410024,0.00013949985,0.00010847806,0.00017948876,0.0007080569,0.000010343609,0.000018502558,0.00012708794],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99548596,0.0015348489,0.001516363,0.00032718122,0.0007374779,0.00039816182],"domain_scores_gemma":[0.99063736,0.0049709603,0.0020542827,0.000615158,0.0015124461,0.00020979733],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077394997,0.00021952191,0.0037518619,0.00026274205,0.0000826166,0.000005945072,0.00029872495,0.00025839987,0.000060514274],"category_scores_gemma":[0.013791116,0.0001391982,0.00037025567,0.00011335435,0.0013798131,0.00011275868,0.00022929044,0.00042399342,0.0000012362788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8987008,0.0034468232,0.06757961,0.00039257048,0.0015782698,0.000035060966,0.00021138821,0.0000065059708,0.000097921875,0.000023413573,0.00020998919,0.027717678],"study_design_scores_gemma":[0.7214026,0.013778758,0.2632626,0.00047230005,0.0004406568,0.0000016364233,0.00003228421,0.000035857945,0.00045301218,0.000037569866,0.000004249952,0.00007849738],"about_ca_topic_score_codex":0.0014097105,"about_ca_topic_score_gemma":0.00036653658,"teacher_disagreement_score":0.19568299,"about_ca_system_score_codex":0.00005284795,"about_ca_system_score_gemma":0.0013977058,"threshold_uncertainty_score":0.99451613},"labels":[],"label_agreement":null},{"id":"W2611078875","doi":"10.1093/annonc/mdx138.009","title":"Pharmacogenomics of aromatase inhibitor associated arthralgia in patients with ER+ breast cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Letrozole; Aromatase inhibitor; Pharmacogenomics; Internal medicine; Anastrozole; Breast cancer; Pharmacogenetics; Adverse effect; Oncology; Cancer; Aromatase; Pharmacology; Genotype","score_opus":0.015755871707427517,"score_gpt":0.32022868463373155,"score_spread":0.304472812926304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611078875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840623,0.0003394468,7.3381915e-7,0.00029003966,0.000106478146,0.00016210461,0.0002709841,0.0000023804619,0.00042158633],"genre_scores_gemma":[0.9992288,0.00041108788,0.000031276635,0.000113309376,0.000042575535,0.000009527966,0.000118113654,0.000012957614,0.000032367334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928313,0.00006166481,0.00021402622,0.0001703121,0.0000771625,0.00019369303],"domain_scores_gemma":[0.9991387,0.000010155641,0.00039422145,0.00024139693,0.00015787504,0.000057648136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015057703,0.00010626477,0.00024487425,0.000039667157,0.000045016677,0.000004393068,0.00018049651,0.00021201442,0.000011921174],"category_scores_gemma":[0.000039894516,0.00008859015,0.000056416124,0.000033549884,0.00016439884,0.000006400805,0.00008370202,0.00009818328,0.0000018296303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031340385,0.0016287519,0.6855755,0.00004340556,0.0005199563,0.000020282872,0.00008180499,0.00009974276,0.27681687,0.000018005805,0.004850572,0.02721107],"study_design_scores_gemma":[0.004968856,0.0024860993,0.66470593,0.00006858703,0.00004321995,0.000003926279,0.000010691229,0.000015247986,0.32575,0.000017715101,0.0017556254,0.00017412083],"about_ca_topic_score_codex":0.000114136,"about_ca_topic_score_gemma":0.000068886504,"teacher_disagreement_score":0.048933122,"about_ca_system_score_codex":0.000012374339,"about_ca_system_score_gemma":0.00014226782,"threshold_uncertainty_score":0.36126018},"labels":[],"label_agreement":null},{"id":"W2612146719","doi":"10.1093/annonc/mdx195.001","title":"Use of G-CSF and prophylactic antibiotics with concurrent chemo-radiotherapy in limited-stage small cell lung cancer: Results from the Phase III CONVERT trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Antibiotics; Gastroenterology; Chemotherapy; Context (archaeology); Granulocyte colony-stimulating factor; Surgery; Leukocytopenia","score_opus":0.194582472380949,"score_gpt":0.46416702038981633,"score_spread":0.26958454800886733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612146719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840685,0.0031412365,0.000012273667,0.010297921,0.00020457098,0.0015125176,0.0002627329,0.000007393496,0.0004928398],"genre_scores_gemma":[0.9868546,0.011951629,0.0001467248,0.00047608503,0.00019533433,0.000012524703,0.000014839903,0.000016421622,0.0003318154],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998601,0.00013568994,0.00044228917,0.00029574317,0.00023701512,0.00028825755],"domain_scores_gemma":[0.99764574,0.00078847416,0.00060617476,0.00054193824,0.00032368762,0.000094018505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004774591,0.00015770474,0.0007402907,0.000067400426,0.00009108001,0.000022306172,0.00020574122,0.00010874328,0.000018386827],"category_scores_gemma":[0.0006406122,0.00009666687,0.00005673767,0.000076216274,0.00082721136,0.00009759002,0.0000998639,0.0002947846,2.5630584e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6578245,0.006377709,0.1323849,0.0015218498,0.002307457,0.0005886362,0.016818238,0.0000388393,0.04078872,0.00014650011,0.0173135,0.123889156],"study_design_scores_gemma":[0.65757,0.044170987,0.07434127,0.0012688759,0.0006075063,0.00001260851,0.0009933773,0.0040506353,0.14388275,0.000021799277,0.07257154,0.0005086575],"about_ca_topic_score_codex":0.006680098,"about_ca_topic_score_gemma":0.0017891513,"teacher_disagreement_score":0.1233805,"about_ca_system_score_codex":0.00008916518,"about_ca_system_score_gemma":0.00070328196,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W2612276480","doi":"10.1093/annonc/mdx093.010","title":"LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Pemetrexed; Oncology; Platelet-derived growth factor receptor; Progression-free survival; Phases of clinical research; Placebo; Vascular endothelial growth factor; Gastroenterology; Surgery; Clinical trial; Confidence interval; Chemotherapy; Growth factor; Pathology; Receptor; Cisplatin","score_opus":0.04067277901438484,"score_gpt":0.3659618327502897,"score_spread":0.3252890537359049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612276480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538916,0.00009583556,0.000009391141,0.0006223975,0.00010001244,0.0017643083,0.00017791707,0.000013334977,0.001827633],"genre_scores_gemma":[0.9974043,0.00005285877,0.0001505146,0.00034897053,0.000026660937,0.0001220743,0.000119705335,0.00002902731,0.0017459096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979037,0.00011741179,0.0007324662,0.0004024328,0.00047329746,0.00037070765],"domain_scores_gemma":[0.9981586,0.0002227973,0.000778745,0.0005014541,0.0001551824,0.00018325372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000383401,0.00027354588,0.0009933941,0.00016115588,0.00014156094,0.000008623705,0.00028583704,0.000114024486,0.00044318676],"category_scores_gemma":[0.0003958233,0.00018323377,0.00014070838,0.00012612977,0.0003159411,0.00016291298,0.00014682945,0.00014378644,0.000007727142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39872447,0.032506365,0.5274329,0.00012748533,0.0006508409,0.00034129902,0.0012050027,0.000018623403,0.0064608003,0.000018429542,0.017738702,0.014775041],"study_design_scores_gemma":[0.39030445,0.05864418,0.53632194,0.00037726897,0.00038804693,0.000019692567,0.0012019634,0.00023419863,0.009992776,0.00003440907,0.002094422,0.0003866445],"about_ca_topic_score_codex":0.0003882249,"about_ca_topic_score_gemma":0.00029023498,"teacher_disagreement_score":0.026137812,"about_ca_system_score_codex":0.00007943039,"about_ca_system_score_gemma":0.00014214219,"threshold_uncertainty_score":0.7472056},"labels":[],"label_agreement":null},{"id":"W2612481440","doi":"10.1093/annonc/mdx091.031","title":"Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York Central Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Afatinib; Rash; Nausea; Internal medicine; Diarrhea; Adverse effect; Stomatitis; Anorexia; Algorithm; Gastroenterology; Surgery; Erlotinib; Cancer","score_opus":0.07598121900764358,"score_gpt":0.47676101371144064,"score_spread":0.40077979470379704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612481440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8549226,0.0001464696,0.0011401471,0.010511538,0.0020380663,0.0046192817,0.001119042,0.000048436745,0.12545444],"genre_scores_gemma":[0.991591,0.000066428605,0.003724554,0.0014913937,0.00013787232,0.0003732436,0.00023756064,0.000022260961,0.0023557192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991582,0.000028983763,0.00021084378,0.00024307118,0.00013184105,0.00022706293],"domain_scores_gemma":[0.9985913,0.0001337756,0.00033335507,0.00024935434,0.0005902935,0.000101912156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008382585,0.00013477699,0.00037270976,0.0000619661,0.00022602729,0.000009128406,0.000098625256,0.000081243255,0.0000300651],"category_scores_gemma":[0.00018507647,0.00010961103,0.00014310435,0.000030320345,0.000109211505,0.00012452292,0.00002634443,0.00008271867,0.000015434189],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002566695,0.0015674992,0.0018888537,0.000021500764,0.0008048023,0.000016532278,0.00091901596,0.0000012545752,0.00038350315,0.00020277375,0.004136151,0.9874914],"study_design_scores_gemma":[0.16086015,0.08180841,0.31049055,0.000574525,0.002489139,0.000025780206,0.0010146698,0.0008128695,0.24012092,0.0020196869,0.1989398,0.0008435051],"about_ca_topic_score_codex":0.00004349812,"about_ca_topic_score_gemma":0.000011835099,"teacher_disagreement_score":0.9866479,"about_ca_system_score_codex":0.000108885775,"about_ca_system_score_gemma":0.00024272544,"threshold_uncertainty_score":0.4469808},"labels":[],"label_agreement":null},{"id":"W2612554234","doi":"10.1093/annonc/mdx091.058","title":"An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Discontinuation; Lung cancer; Adverse effect; Cohort; Cancer; Phases of clinical research; Chemotherapy; Immunotherapy","score_opus":0.061340445049482356,"score_gpt":0.41847537420991215,"score_spread":0.35713492916042977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612554234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905343,0.00046489315,0.000014303686,0.0007062158,0.00044884786,0.002195706,0.00010275602,0.000008908942,0.005524067],"genre_scores_gemma":[0.99745405,0.00091434503,0.00051781704,0.00052714074,0.0000913518,0.0000939078,0.000049413542,0.00003200292,0.00031994435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982392,0.000100539095,0.0006858265,0.00037841342,0.00022714821,0.00036882824],"domain_scores_gemma":[0.9977644,0.00006948956,0.0008747249,0.00082654465,0.00034168278,0.00012313173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005196861,0.00021359201,0.0009360966,0.00013314668,0.00011361984,0.000016082997,0.0005799257,0.00019972927,0.00012086365],"category_scores_gemma":[0.0000488917,0.00017713441,0.00007058615,0.00012268091,0.00027442112,0.0002913018,0.00011620713,0.0002023505,0.0000012712577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7196561,0.006865192,0.009557492,0.0001476646,0.00022505042,0.000026032125,0.0007516315,0.000011320327,0.0155823445,0.000005766052,0.00073215045,0.24643925],"study_design_scores_gemma":[0.8389813,0.06873744,0.06673099,0.0005044214,0.00015065735,0.0000019587962,0.00014061923,0.00026899742,0.017855152,0.000010233075,0.006330561,0.00028767218],"about_ca_topic_score_codex":0.0021268139,"about_ca_topic_score_gemma":0.0016390384,"teacher_disagreement_score":0.24615157,"about_ca_system_score_codex":0.00018867386,"about_ca_system_score_gemma":0.0013667651,"threshold_uncertainty_score":0.72233313},"labels":[],"label_agreement":null},{"id":"W2612571093","doi":"10.1093/annonc/mdx091.039","title":"A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pemetrexed; Ramucirumab; Internal medicine; Oncology; Cisplatin; non-small cell lung cancer (NSCLC); Chemotherapy; Phases of clinical research; Lung cancer","score_opus":0.08800601839666418,"score_gpt":0.4505259432474428,"score_spread":0.3625199248507786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612571093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020785,0.0003207373,0.00006638874,0.0015198549,0.0002242213,0.006011179,0.0004953623,0.0000124461285,0.001141957],"genre_scores_gemma":[0.996532,0.00025230047,0.0013613577,0.0004408489,0.000053677955,0.00075440505,0.00024591564,0.000037246,0.00032221887],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772936,0.0001494673,0.0009607294,0.00053291314,0.00028783345,0.0003397156],"domain_scores_gemma":[0.99665487,0.0005874239,0.0013954767,0.00071025983,0.0005119208,0.00014005597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039431808,0.00030256814,0.0016160726,0.00015010539,0.00014520019,0.000021173739,0.00037318136,0.00013636285,0.00009611449],"category_scores_gemma":[0.00034466045,0.00020623158,0.00008244567,0.00014024404,0.0001603965,0.0001318688,0.00008115349,0.00020170577,0.0000014870681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8204702,0.054118156,0.0068326867,0.00014334814,0.00067977956,0.000117336625,0.0070816856,0.0006963016,0.00008998959,0.0000012972727,0.0008916586,0.10887756],"study_design_scores_gemma":[0.94295025,0.04008703,0.009844365,0.00065936946,0.0006144149,7.379826e-7,0.00028164397,0.0033100822,0.0014207858,0.000010996663,0.0006116145,0.00020869612],"about_ca_topic_score_codex":0.006825402,"about_ca_topic_score_gemma":0.010246394,"teacher_disagreement_score":0.122480065,"about_ca_system_score_codex":0.0002521338,"about_ca_system_score_gemma":0.0014781691,"threshold_uncertainty_score":0.9997882},"labels":[],"label_agreement":null},{"id":"W2612619886","doi":"10.1093/annonc/mdx094.013","title":"TTFields and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Clinical endpoint; Internal medicine; Lung cancer; Neurocognitive; Oncology; Population; Clinical trial; Radiation therapy","score_opus":0.19717789985935408,"score_gpt":0.48616112597545086,"score_spread":0.2889832261160968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612619886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94611114,0.0013254286,0.00017462917,0.049599476,0.00019419656,0.0010117159,0.00033992736,0.000011577689,0.0012318918],"genre_scores_gemma":[0.9950306,0.00018473138,0.0012419992,0.0026647202,0.00018060903,0.000117284326,0.000050611834,0.000013652802,0.0005157799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893713,0.00019848901,0.00028923797,0.0002447212,0.00012367842,0.00020672844],"domain_scores_gemma":[0.9970863,0.0018080199,0.00027147034,0.00060962746,0.000121030505,0.0001035677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011177636,0.00013755039,0.00060743006,0.000040667648,0.00023544514,0.00002447706,0.0001390883,0.00007529174,0.00038468352],"category_scores_gemma":[0.0010621843,0.00008389499,0.00016680369,0.000028243936,0.00021803375,0.000063445805,0.00007487976,0.000087272296,0.000006669557],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027006292,0.004791172,0.011147264,0.000033470184,0.0025716892,0.0003085041,0.0007395234,3.7527525e-7,0.00046717783,0.0006302067,0.15635848,0.8202515],"study_design_scores_gemma":[0.03234352,0.030675849,0.08897103,0.00006461423,0.0023666061,0.00011813774,0.0021665923,0.00008612354,0.0072329286,0.0032919901,0.8323963,0.00028626455],"about_ca_topic_score_codex":0.0005595118,"about_ca_topic_score_gemma":0.00012751378,"teacher_disagreement_score":0.81996524,"about_ca_system_score_codex":0.000008259464,"about_ca_system_score_gemma":0.0001012497,"threshold_uncertainty_score":0.42120147},"labels":[],"label_agreement":null},{"id":"W2612623181","doi":"10.1093/annonc/mdx091.061","title":"ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Internal medicine; Oncology; Ceritinib; Lung cancer; Hazard ratio; Clinical trial; Cancer; Crizotinib; Gefitinib; Epidermal growth factor receptor; Confidence interval; Erlotinib","score_opus":0.06719118390064971,"score_gpt":0.4620846983699624,"score_spread":0.3948935144693127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612623181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689459,0.00047580898,0.0000040113655,0.0013765305,0.00016954866,0.0014710878,0.00007385319,0.000007775336,0.027475486],"genre_scores_gemma":[0.996981,0.0007684046,0.00020210273,0.00016508557,0.00007160281,0.0002632018,0.000018793415,0.000017280243,0.0015125282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884236,0.00007001909,0.00043277777,0.00027109584,0.00012072161,0.00026303745],"domain_scores_gemma":[0.99870026,0.00010406657,0.0004769177,0.00039980878,0.00021578767,0.00010313179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011060683,0.00016737962,0.0006167949,0.00018478316,0.00008025282,0.000006969833,0.00012572171,0.00007328164,0.000056811274],"category_scores_gemma":[0.000023371147,0.00013251921,0.000104161714,0.00008896882,0.00008236383,0.000065461696,0.000051695442,0.00009348813,0.0000032890152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001616901,0.015954666,0.9206266,0.0000790661,0.0010302209,0.00022911181,0.013376974,0.000043152126,0.001120344,0.000010576777,0.0006402439,0.04527218],"study_design_scores_gemma":[0.02164516,0.010512212,0.95038104,0.00028695594,0.0008528551,0.0000018537081,0.0019802367,0.00013806338,0.013175876,0.000005218862,0.00090971444,0.00011083513],"about_ca_topic_score_codex":0.03824922,"about_ca_topic_score_gemma":0.022793978,"teacher_disagreement_score":0.045161344,"about_ca_system_score_codex":0.00027065128,"about_ca_system_score_gemma":0.0005335789,"threshold_uncertainty_score":0.9950375},"labels":[],"label_agreement":null},{"id":"W2612729833","doi":"10.1093/annonc/mdx195.002","title":"Establishment of a diagnostic algorithm for ROS1 testing in Canada","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Institut universitaire de cardiologie et de pneumologie de Québec; Capital District Health Authority; University Health Network; CancerCare Manitoba; Health Sciences Centre; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; University of Alberta; William Osler Health System; Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Crizotinib; Medicine; Immunohistochemistry; Lung cancer; Fluorescence in situ hybridization; Adenocarcinoma; Oncology; Fish <Actinopterygii>; Pathology; Internal medicine; Cancer; Algorithm; Biology; Gene; Computer science; Genetics","score_opus":0.08863118656972734,"score_gpt":0.43400513045276834,"score_spread":0.345373943883041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612729833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696834,0.00074138405,0.00031754264,0.01025755,0.00041754733,0.0010363008,0.00021959288,0.0000058213673,0.017320849],"genre_scores_gemma":[0.99294007,0.000062085346,0.0064089587,0.00035020133,0.00003751933,0.00007367053,0.000013021171,0.00000524484,0.00010922631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995255,0.000008367051,0.00018882893,0.00008408018,0.000066018896,0.00012720161],"domain_scores_gemma":[0.99877757,0.0006450929,0.00018861334,0.00015670471,0.00018771423,0.00004432197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009403702,0.000045743396,0.00023451116,0.000034256787,0.000035945166,0.0000022549727,0.000058776273,0.000026329419,0.000010103881],"category_scores_gemma":[0.0013970515,0.000039053702,0.000024539519,0.000030196721,0.000037182115,0.000032808653,0.000018726882,0.000030947496,2.2868981e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029847683,0.0002685078,0.12662135,0.00006690107,0.0000854198,0.00006178168,0.0001628413,0.000024671554,0.00012068439,0.000066678775,0.0036042659,0.86888707],"study_design_scores_gemma":[0.005906361,0.004037764,0.93805486,0.0003388862,0.00021656633,0.000021540247,0.0004617058,0.0014820491,0.0068978188,0.0006383906,0.041832764,0.00011127944],"about_ca_topic_score_codex":0.7142676,"about_ca_topic_score_gemma":0.5420548,"teacher_disagreement_score":0.8687758,"about_ca_system_score_codex":0.00013805958,"about_ca_system_score_gemma":0.0022594775,"threshold_uncertainty_score":0.4663015},"labels":[],"label_agreement":null},{"id":"W2612777803","doi":"10.1093/annonc/mdx091.013","title":"Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Discontinuation; Clinical endpoint; Lung cancer; Gastroenterology; Oncology; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.08899710198320918,"score_gpt":0.4670936908508817,"score_spread":0.3780965888676725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612777803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976984,0.00012029637,0.000045729877,0.010762886,0.00033624406,0.001744619,0.0019039839,0.000017822995,0.008084365],"genre_scores_gemma":[0.99109066,0.00003894215,0.00038889644,0.0016977089,0.00024154992,0.000084171545,0.0062620817,0.00002182237,0.00017416556],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99850965,0.00013889636,0.00043198065,0.00038929092,0.00026606864,0.0002641058],"domain_scores_gemma":[0.9976142,0.00034687872,0.0005515182,0.0010338,0.00035465418,0.00009894938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026829593,0.00017444904,0.00048243807,0.000068465735,0.0002317624,0.0000340633,0.00041462702,0.00012343818,0.00029906374],"category_scores_gemma":[0.00038270134,0.00011197033,0.000054698565,0.00009516789,0.00023979678,0.00031540668,0.00012712445,0.00018948571,0.00002095598],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2947929,0.02019582,0.2696606,0.00006364217,0.0052248463,0.0007200779,0.009382182,0.00003482296,0.00018444446,0.000787515,0.13511607,0.2638371],"study_design_scores_gemma":[0.30150798,0.013386795,0.6599296,0.00026882679,0.0010874623,0.0000063363577,0.0004966021,0.00034811767,0.000555358,0.0002030589,0.021954903,0.00025496545],"about_ca_topic_score_codex":0.0016094137,"about_ca_topic_score_gemma":0.00069000374,"teacher_disagreement_score":0.39026898,"about_ca_system_score_codex":0.00007263614,"about_ca_system_score_gemma":0.0005975329,"threshold_uncertainty_score":0.45660174},"labels":[],"label_agreement":null},{"id":"W2613503690","doi":"10.1093/annonc/mdx088.001","title":"Early limited-stage small cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Radiation therapy; Etoposide; Stage (stratigraphy); Conventional PCI; Chemotherapy; Lung cancer; Randomized controlled trial; Internal medicine; Surgery","score_opus":0.14425836304562678,"score_gpt":0.45388087881650246,"score_spread":0.3096225157708757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613503690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759047,0.008401786,0.000029402714,0.0076353904,0.0016397986,0.0012673251,0.0001597741,0.000024045148,0.004937764],"genre_scores_gemma":[0.9835775,0.013874898,0.000047490357,0.000599788,0.00046222412,0.00014561934,0.000012182571,0.000031412746,0.0012488804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972852,0.00033737763,0.0006959656,0.0004730417,0.0006063548,0.0006020715],"domain_scores_gemma":[0.9961594,0.00072040525,0.0010762447,0.0012235963,0.0006189612,0.00020144435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086595817,0.00027795177,0.0014694248,0.00031389578,0.00026205517,0.000029118173,0.00085251086,0.00023235097,0.00021299205],"category_scores_gemma":[0.00053910766,0.00019821912,0.0007571557,0.0004657129,0.0009779005,0.0001137116,0.00028015915,0.0004624928,0.0000032581895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2453979,0.0040888535,0.4519805,0.0014655424,0.043531477,0.00019393048,0.010073328,0.00020998079,0.043206025,0.00082923885,0.06556385,0.13345939],"study_design_scores_gemma":[0.18851385,0.029221928,0.5401752,0.00034798912,0.0077185514,0.0000022352303,0.0006201246,0.002314822,0.029774673,0.000015723239,0.2006337,0.00066119304],"about_ca_topic_score_codex":0.0057054367,"about_ca_topic_score_gemma":0.0036831663,"teacher_disagreement_score":0.13506985,"about_ca_system_score_codex":0.0003332144,"about_ca_system_score_gemma":0.0009266775,"threshold_uncertainty_score":0.8624952},"labels":[],"label_agreement":null},{"id":"W2613561165","doi":"10.1093/annonc/mdx091.022","title":"LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Afatinib; Medicine; Oncology; Squamous-cell carcinoma of the lung; Lung; Internal medicine; Carcinoma; Basal cell; Cancer; Gefitinib","score_opus":0.03757846680497356,"score_gpt":0.4270860889978361,"score_spread":0.38950762219286256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613561165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961897,0.00016992679,0.000016711729,0.0008605589,0.000121728175,0.0013025256,0.00016498782,0.0000040263735,0.0011698059],"genre_scores_gemma":[0.9989921,0.000008218846,0.000118851545,0.00023385692,0.000018837338,0.00005810046,0.00005241039,0.000013672573,0.000503951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986608,0.00014053442,0.0005675924,0.0002257517,0.00020844614,0.00019689118],"domain_scores_gemma":[0.99776375,0.00023074335,0.0007980501,0.00071603246,0.00040116656,0.00009026472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031355408,0.00014071882,0.00082133507,0.0003175344,0.00006400663,0.0000037858563,0.00020217967,0.00008402156,0.00012287122],"category_scores_gemma":[0.00025579278,0.000088331006,0.00018334427,0.0003325551,0.00013541937,0.00007321258,0.00006395685,0.00009002088,4.945322e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18317398,0.0046466165,0.79742634,0.00013142922,0.000843843,0.00003934547,0.0025095248,0.00024416388,0.0018760512,0.000007197857,0.00031640375,0.008785111],"study_design_scores_gemma":[0.09738126,0.011349479,0.87918204,0.000054310716,0.0016082737,4.3802015e-7,0.000082171464,0.00005199521,0.010081152,0.0000018336294,0.00013257345,0.00007445414],"about_ca_topic_score_codex":0.00019571347,"about_ca_topic_score_gemma":0.0005785144,"teacher_disagreement_score":0.08579273,"about_ca_system_score_codex":0.00008529024,"about_ca_system_score_gemma":0.0004219597,"threshold_uncertainty_score":0.3602034},"labels":[],"label_agreement":null},{"id":"W2613815573","doi":"10.1093/annonc/mdx091.040","title":"Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Internal medicine; Oncology; Adverse effect; Adenocarcinoma; Neutropenia; Chemotherapy; Phases of clinical research; Surgery; Cancer; Gastroenterology","score_opus":0.06405871301770999,"score_gpt":0.4300355723682339,"score_spread":0.36597685935052393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613815573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033767,0.0008184051,0.00053723744,0.0005066807,0.00008075046,0.0056483825,0.0017967798,0.0000072499006,0.00026685826],"genre_scores_gemma":[0.9955435,0.00060278,0.0009765847,0.0001708151,0.00005322825,0.00080599333,0.0002618273,0.000035241203,0.0015500241],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979506,0.00009815438,0.0010370333,0.0004207516,0.00023942105,0.00025402417],"domain_scores_gemma":[0.99586695,0.0005519447,0.0018276541,0.00076492975,0.00083953637,0.00014900704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028043025,0.00028703647,0.0027060108,0.00035203565,0.00008448141,0.0000054730262,0.00018993033,0.00012280206,0.00042283267],"category_scores_gemma":[0.00009166707,0.00018484608,0.00037837602,0.00022335569,0.00014686173,0.00007114218,0.000030874508,0.000057914007,2.6648937e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75583804,0.04025606,0.12602079,0.00048531705,0.032384593,0.000036137975,0.022225816,0.00038843893,0.0019991738,0.0000033115787,0.0004700155,0.019892316],"study_design_scores_gemma":[0.82902044,0.06272741,0.064671814,0.00019837018,0.01781508,4.516132e-7,0.0010589006,0.0009023524,0.02224771,0.000005310112,0.0011372901,0.00021488777],"about_ca_topic_score_codex":0.008429721,"about_ca_topic_score_gemma":0.012255232,"teacher_disagreement_score":0.073182404,"about_ca_system_score_codex":0.00017427791,"about_ca_system_score_gemma":0.0005970282,"threshold_uncertainty_score":0.99817324},"labels":[],"label_agreement":null},{"id":"W2613860182","doi":"10.1093/annonc/mdx091.055","title":"Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital","funders":"","keywords":"KRAS; Coxsackievirus; Lung cancer; Epidermal growth factor receptor; Medicine; Cancer research; Virology; Oncolytic virus; Cancer; Cytopathic effect; Virus; Pathology; Enterovirus; Internal medicine; Colorectal cancer","score_opus":0.06710289965522913,"score_gpt":0.404642931531948,"score_spread":0.3375400318767189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613860182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023474,0.005457228,0.000023895029,0.0021018824,0.00042945243,0.00046017155,0.000114669776,0.000009733335,0.011168214],"genre_scores_gemma":[0.978513,0.015092359,0.000097034674,0.0041663423,0.00040293383,0.00006491284,0.000033290733,0.000054153556,0.001575976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980205,0.00014130806,0.00040302955,0.0005482739,0.00024080972,0.0006460263],"domain_scores_gemma":[0.99763685,0.000027573178,0.0004227886,0.0011625204,0.0005223346,0.00022791751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056039053,0.000271947,0.00046949243,0.00008783341,0.00025467554,0.000040692994,0.0009313123,0.00039970735,0.00017361215],"category_scores_gemma":[0.000108785476,0.00026013525,0.00020986663,0.00008327992,0.0003080125,0.000008624122,0.00038422726,0.00024985886,0.0000685892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024602208,0.0003665017,0.0014901011,0.00006910103,0.00023810705,0.000055053963,0.0001430695,0.00006705825,0.90618026,0.000003333041,0.014994719,0.073932454],"study_design_scores_gemma":[0.0014082647,0.0067958534,0.0014422399,0.00003571259,0.000038531238,0.0000053496997,0.000032690397,0.00031669,0.90704817,0.000022241882,0.08257344,0.00028078994],"about_ca_topic_score_codex":0.00054514944,"about_ca_topic_score_gemma":0.0014242823,"teacher_disagreement_score":0.073651664,"about_ca_system_score_codex":0.00006170165,"about_ca_system_score_gemma":0.001195288,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W2614025577","doi":"10.1093/annonc/mdx091.020","title":"Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Clinical endpoint; Post-hoc analysis; Log-rank test; Gastroenterology; Clinical trial; Oncology; Survival analysis; Cancer","score_opus":0.04144403855572252,"score_gpt":0.43218556591083973,"score_spread":0.3907415273551172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614025577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916772,0.00022736259,0.000024119176,0.0012498343,0.000030071678,0.0020660036,0.0015846451,0.00001119846,0.0031295156],"genre_scores_gemma":[0.99596053,0.00016786964,0.0020268527,0.00009809508,0.000047021826,0.00029802756,0.000556382,0.000026304486,0.0008189153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985294,0.000046554283,0.00053533266,0.00037086775,0.00019858291,0.00031930182],"domain_scores_gemma":[0.9975057,0.00022552212,0.00080942264,0.00061857863,0.0006036348,0.000237125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010079944,0.00029679947,0.0013912604,0.00035992925,0.00011394585,0.00001026617,0.00010515476,0.00012664127,0.00027026676],"category_scores_gemma":[0.000089040535,0.00018729048,0.0004379986,0.00019675252,0.00017238449,0.00010265123,0.000035221365,0.000029050741,0.000003950806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011346783,0.009991124,0.6589935,0.00017938844,0.04254138,0.000025122896,0.004565093,0.00046234997,0.0012634624,0.00013639603,0.0027215858,0.2677738],"study_design_scores_gemma":[0.017798454,0.06689463,0.8979975,0.00012588361,0.011273472,0.0000034441323,0.00019512833,0.000207249,0.0022048801,0.000017692111,0.0030990494,0.00018262852],"about_ca_topic_score_codex":0.0012545616,"about_ca_topic_score_gemma":0.00036459975,"teacher_disagreement_score":0.26759118,"about_ca_system_score_codex":0.00027973615,"about_ca_system_score_gemma":0.00047951122,"threshold_uncertainty_score":0.7637484},"labels":[],"label_agreement":null},{"id":"W2615017225","doi":"10.1093/annonc/mdx109","title":"Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Cancer","score_opus":0.14698867853623845,"score_gpt":0.4818995002038666,"score_spread":0.3349108216676282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615017225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744524,0.0037669274,0.0000011375728,0.005854292,0.00011246769,0.00038094952,0.000080778686,0.000008591908,0.0023495941],"genre_scores_gemma":[0.9642126,0.03511691,0.00009209251,0.00022025769,0.000051009956,0.00006508341,0.0000051438037,0.0000064650067,0.00023042569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988353,0.00009074101,0.00024713797,0.0002689405,0.00018242064,0.00037540926],"domain_scores_gemma":[0.9989668,0.0001723272,0.00017206155,0.00029170053,0.00023082274,0.00016628597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004981098,0.0001082857,0.0004904433,0.00006369597,0.00010812204,0.000010532273,0.00009965211,0.00012703774,0.000025557554],"category_scores_gemma":[0.0014338015,0.000090908834,0.000022832048,0.00006240396,0.00096094544,0.00010121593,0.00021246194,0.00023673086,9.49296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001773904,0.00016891483,0.93742573,0.00023763759,0.00008813597,0.00010576428,0.00056486274,3.8320476e-7,0.0012189787,0.000052722393,0.0032615475,0.05669794],"study_design_scores_gemma":[0.0016928656,0.0015191064,0.9893829,0.00021906293,0.000027891681,0.000008507748,0.00013467515,0.00007718792,0.0011077431,0.00020949556,0.005548901,0.000071669885],"about_ca_topic_score_codex":0.0026927395,"about_ca_topic_score_gemma":0.0049597654,"teacher_disagreement_score":0.056626268,"about_ca_system_score_codex":0.000047602603,"about_ca_system_score_gemma":0.00027107808,"threshold_uncertainty_score":0.40706345},"labels":[],"label_agreement":null},{"id":"W2615527679","doi":"10.1093/annonc/mdx264","title":"Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Progression-free survival; Breast cancer; Docetaxel; Retrospective cohort study; Placebo; Oncology; Cancer; Surgery; Chemotherapy; Pathology","score_opus":0.01824104660455638,"score_gpt":0.3472350176246785,"score_spread":0.3289939710201221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615527679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945404,0.00026468936,3.2490684e-7,0.0037306873,0.00009357327,0.0010735568,0.00011856289,0.0000064201013,0.00017180956],"genre_scores_gemma":[0.9994063,0.00027022726,0.00005104499,0.000084026666,0.000036015925,0.00007143403,0.000004248276,0.000014939602,0.00006179227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849457,0.00021669477,0.0003793608,0.0003230367,0.00033070685,0.00025561455],"domain_scores_gemma":[0.997553,0.00016301766,0.0008073755,0.00083479256,0.0005681717,0.00007366477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039664225,0.00017833164,0.0010248503,0.00019677974,0.00013508776,0.000010200762,0.00030775287,0.000087960245,0.000019305495],"category_scores_gemma":[0.00033916885,0.000112224974,0.00013354508,0.00040255566,0.00059482944,0.00011398034,0.0001642531,0.00020912423,1.1034058e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011910552,0.0015050343,0.9464992,0.00002558376,0.0012911323,0.000008700511,0.001554292,0.000006541278,0.00009601836,0.0000040985356,0.00007544622,0.037023358],"study_design_scores_gemma":[0.009057125,0.005864187,0.9821296,0.00014699368,0.0007448217,0.0000027585127,0.0011915341,0.000039691837,0.00056797947,0.000013803021,0.00013355685,0.00010798017],"about_ca_topic_score_codex":0.0036698729,"about_ca_topic_score_gemma":0.01108693,"teacher_disagreement_score":0.036915377,"about_ca_system_score_codex":0.00010007178,"about_ca_system_score_gemma":0.0003622531,"threshold_uncertainty_score":0.61867666},"labels":[],"label_agreement":null},{"id":"W2615533737","doi":"10.1093/annonc/mdx266","title":"Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"European Commission; Francis Crick Institute; Academy of Medical Sciences; Cancer Research UK; National Institute for Health and Care Research; Medical Research Council; Sanofi","keywords":"Medicine; Breast cancer; Epirubicin; Internal medicine; Univariate analysis; Lymphocyte; Neoadjuvant therapy; Docetaxel; Oncology; Cancer; Clinical endpoint; Pathology; Clinical trial; Multivariate analysis","score_opus":0.030982719544327197,"score_gpt":0.37205805626123867,"score_spread":0.3410753367169115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615533737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882519,0.00008647592,0.0000118531125,0.009988409,0.00016148092,0.0006626017,0.0006773854,0.000008403212,0.00015148618],"genre_scores_gemma":[0.9978782,0.00005746028,0.00020084667,0.0016962435,0.00003445966,0.000055714198,0.000030594976,0.000012553108,0.000033949003],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979462,0.00052062806,0.0007527027,0.00027948729,0.0002806434,0.00022031639],"domain_scores_gemma":[0.99753183,0.0003671013,0.0008929057,0.0006057484,0.0004829699,0.00011943767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001144827,0.00014893664,0.0009566582,0.00032375078,0.00006300492,0.0000046619684,0.00034969603,0.00021357938,0.00021815434],"category_scores_gemma":[0.0005552146,0.00012045877,0.0003088146,0.00032131237,0.0004928143,0.000047590023,0.0001256833,0.00010263445,0.0000012458405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4865319,0.001365965,0.36664945,0.00010867812,0.0027663384,0.00015979102,0.0011328544,0.00012573665,0.09974353,0.000010024665,0.0034147745,0.037990946],"study_design_scores_gemma":[0.030985344,0.0013037915,0.9250347,0.000084866784,0.0005554866,0.000036820613,0.00004351638,0.0007103297,0.040622633,0.0000893398,0.0004387808,0.0000943875],"about_ca_topic_score_codex":0.00028961824,"about_ca_topic_score_gemma":0.00009531576,"teacher_disagreement_score":0.55838525,"about_ca_system_score_codex":0.000116867035,"about_ca_system_score_gemma":0.0013661494,"threshold_uncertainty_score":0.4912166},"labels":[],"label_agreement":null},{"id":"W2619591234","doi":"10.1093/annonc/mdx274","title":"Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Les Laboratories Pierre Fabre","keywords":"Busulfan; Medicine; Fludarabine; Internal medicine; Univariate analysis; Cumulative incidence; Gastroenterology; Lymphoma; Surgery; Transplantation; Hematopoietic stem cell transplantation; Chemotherapy; Multivariate analysis; Cyclophosphamide","score_opus":0.04443666498109376,"score_gpt":0.3786825139286443,"score_spread":0.33424584894755055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619591234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898624,0.000034498968,0.00004954287,0.005180319,0.00045752907,0.0019288122,0.00023124464,0.000030616433,0.002225047],"genre_scores_gemma":[0.9970357,0.000031924097,0.0006032091,0.0016770979,0.00011244683,0.00038859752,0.000066094966,0.000038872993,0.000046049838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978118,0.00029132163,0.00052252715,0.0004994099,0.00034217158,0.00053277146],"domain_scores_gemma":[0.9960117,0.0006055746,0.0010289958,0.0008131619,0.0013606651,0.00017989932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007121932,0.00032195164,0.0009770651,0.00011776133,0.00048664768,0.000016577396,0.00030478375,0.00029580572,0.000020234856],"category_scores_gemma":[0.0017145211,0.00025170724,0.00043718345,0.00016081496,0.00046137624,0.00007975885,0.000100592784,0.00018498866,0.000003010715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033053864,0.035160948,0.8397474,0.00016881463,0.0039653257,0.00020783336,0.015420658,0.00022367584,0.03939454,0.00052389427,0.017620938,0.014512098],"study_design_scores_gemma":[0.02323496,0.014561839,0.75160867,0.0002225575,0.00033526824,0.0000055287915,0.0014304837,0.00025734442,0.20783453,0.00029479983,0.000059880833,0.00015413227],"about_ca_topic_score_codex":0.0015826261,"about_ca_topic_score_gemma":0.0003452224,"teacher_disagreement_score":0.16843998,"about_ca_system_score_codex":0.0010313953,"about_ca_system_score_gemma":0.0013742946,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W2625888083","doi":"10.1093/annonc/mdx312","title":"Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer","year":2017,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University of British Columbia; BC Cancer Agency","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; Enzalutamide; Clinical trial; Oncology; Cancer; Androgen deprivation therapy; Internal medicine; Abiraterone acetate; Gynecology; Androgen receptor","score_opus":0.09460516190054016,"score_gpt":0.4550171178689679,"score_spread":0.3604119559684278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625888083","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6307067,0.027744336,0.0000012455487,0.11522039,0.17485213,0.009705083,0.03466063,0.00010378983,0.0070056547],"genre_scores_gemma":[0.056262344,0.22915672,0.003057395,0.009891055,0.4135689,0.009693438,0.011528091,0.0007417593,0.2661003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628574,0.00019126877,0.00087829295,0.0010878776,0.0007357261,0.0008210819],"domain_scores_gemma":[0.9962549,0.00069001695,0.0006973903,0.0007285669,0.0012576365,0.00037148804],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049694494,0.00052850624,0.0017586924,0.0003824917,0.00018315708,0.000051532486,0.00039061287,0.00095132395,0.00094615633],"category_scores_gemma":[0.00070100557,0.00043749053,0.00013341928,0.00018679842,0.000709789,0.00020269102,0.00029225278,0.00093318115,0.00005933667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011823118,0.00028622185,0.0029830737,0.0002989797,0.00039940124,0.00025326727,0.0017176482,0.0000070433794,0.0025814916,0.0000013813958,0.8482076,0.1314408],"study_design_scores_gemma":[0.0069452645,0.0032618458,0.030817356,0.0016702393,0.00015624102,0.000002214051,0.000095849515,0.000024406236,0.0032558013,0.0007160509,0.9526533,0.00040141665],"about_ca_topic_score_codex":0.0054932293,"about_ca_topic_score_gemma":0.0054603247,"teacher_disagreement_score":0.5744444,"about_ca_system_score_codex":0.00044241414,"about_ca_system_score_gemma":0.0042855954,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2628252608","doi":"10.1093/annonc/11.suppl_1.s113","title":"Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":376,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Rituximab; Post-transplant lymphoproliferative disorder; Internal medicine; Bone marrow; Gastroenterology; Chemotherapy; Organ transplantation; Lymphoproliferative disorders; Transplantation; Lymphoma; Surgery","score_opus":0.018568810263630258,"score_gpt":0.3395043995064477,"score_spread":0.3209355892428174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2628252608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820802,0.00026922158,0.0000085840475,0.0026612082,0.000056848625,0.00047462463,0.0002495355,0.000028474633,0.014171292],"genre_scores_gemma":[0.9942189,0.0018316759,0.00003682482,0.0031139238,0.000037289537,0.00002860116,0.0005143379,0.00002249088,0.00019599944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979489,0.00017095986,0.00058027013,0.00047249868,0.00036338018,0.00046399634],"domain_scores_gemma":[0.9990168,0.00007842432,0.00021663352,0.00023672111,0.00032884,0.00012258452],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024748605,0.0002566162,0.0012478861,0.0004976681,0.000093127805,0.000008671718,0.00012652908,0.00026596768,0.0011017036],"category_scores_gemma":[0.000073534655,0.00022883387,0.00037913892,0.0009465541,0.00016367233,0.00009383142,0.00001269508,0.0002883343,0.000038954073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051261024,0.0074684494,0.9615887,0.000025142877,0.0015783357,0.000102187056,0.0022363947,0.00016985001,0.00035118262,0.00023364347,0.00062725355,0.020492764],"study_design_scores_gemma":[0.018895227,0.0077917334,0.96981496,0.00005618411,0.0004759781,0.0000031915188,0.00023931071,0.0003291573,0.00028452402,0.00022840223,0.0016480518,0.00023327317],"about_ca_topic_score_codex":0.0011788213,"about_ca_topic_score_gemma":0.0013828158,"teacher_disagreement_score":0.020259492,"about_ca_system_score_codex":0.00019177832,"about_ca_system_score_gemma":0.0002692561,"threshold_uncertainty_score":0.9998114},"labels":[],"label_agreement":null},{"id":"W2693468451","doi":"10.1016/s0923-7534(20)33072-6","title":"Lux-Lung 8: A Randomized, Open-Label, Phase III Trial of Afatinib vs. Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung as Second-Line Therapy Following First-Line Platinum-Based Chemotherapy","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Oncology; Internal medicine; Squamous-cell carcinoma of the lung; Lung; Basal cell; Platinum; Lung cancer; Gefitinib; Carcinoma; Open label; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.03861108824468808,"score_gpt":0.3984599953154056,"score_spread":0.35984890707071754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2693468451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893243,0.0011569905,0.00004324371,0.0010169554,0.0003256941,0.0060839336,0.00007051752,0.0000095200485,0.0023607176],"genre_scores_gemma":[0.99727607,0.000064087755,0.0007268748,0.0011743086,0.00007389935,0.00034453778,0.00010121708,0.0000417182,0.00019727577],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99781513,0.00024990065,0.0009973265,0.0002574976,0.00031855813,0.00036160508],"domain_scores_gemma":[0.997461,0.0007176275,0.0010021123,0.00042221262,0.0002853971,0.000111617665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071689667,0.0002627411,0.0015054432,0.00014853227,0.000065247805,0.000004883941,0.00023427718,0.00014913772,0.00022900605],"category_scores_gemma":[0.00015246426,0.00016334257,0.000226203,0.00033011,0.00016600505,0.00016327015,0.00004101501,0.00017099861,6.7755155e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9237254,0.01937143,0.03980543,0.00015847087,0.0005021881,0.0000069596804,0.003447507,0.00011124899,0.0006862529,0.000035227902,0.00039150857,0.011758339],"study_design_scores_gemma":[0.9487826,0.019002788,0.005758795,0.0001403717,0.00034042774,0.0000012041215,0.00010168803,0.0002477426,0.024586024,0.000017081402,0.0008728894,0.00014834174],"about_ca_topic_score_codex":0.00026450827,"about_ca_topic_score_gemma":0.00006149585,"teacher_disagreement_score":0.03404664,"about_ca_system_score_codex":0.000086682434,"about_ca_system_score_gemma":0.0006626036,"threshold_uncertainty_score":0.6660916},"labels":[],"label_agreement":null},{"id":"W2724318712","doi":"10.1093/annonc/mdx334","title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mantle cell lymphoma; Stage (stratigraphy); Lymphoma; Oncology; Internal medicine; Radiation oncology; Radiation therapy","score_opus":0.046306779075229725,"score_gpt":0.3621593806278016,"score_spread":0.3158526015525719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724318712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93862647,0.00048403774,0.000039227638,0.014552968,0.00054220913,0.00035628377,0.00018417055,0.000024371991,0.045190282],"genre_scores_gemma":[0.9946933,0.0013050658,0.0004121125,0.0020956397,0.0003921823,0.00009729835,0.00020636145,0.000017536928,0.0007804963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983056,0.00013231229,0.00045517975,0.00044415082,0.0003575706,0.00030518498],"domain_scores_gemma":[0.99748677,0.00045303692,0.0008069392,0.00083861,0.00027841097,0.00013621758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042983048,0.0002060806,0.000750634,0.0001686644,0.00026648806,0.000054585762,0.00049373467,0.0002645511,0.00048131283],"category_scores_gemma":[0.0002518171,0.00014765134,0.0004418802,0.00015523446,0.00027460238,0.00015677414,0.00019586553,0.00007093929,0.0000991887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071626535,0.0038743212,0.80729246,0.000006339197,0.0034848724,0.00035500497,0.0009329398,0.0000041559606,0.00041442204,0.0014273721,0.008856123,0.17263569],"study_design_scores_gemma":[0.0074702045,0.0019295835,0.86968565,0.000012108359,0.0009430011,0.000010585816,0.00016771935,0.00024180436,0.0037746811,0.00035470282,0.11530126,0.00010869086],"about_ca_topic_score_codex":0.0072833966,"about_ca_topic_score_gemma":0.0010470218,"teacher_disagreement_score":0.172527,"about_ca_system_score_codex":0.00063938275,"about_ca_system_score_gemma":0.00034076994,"threshold_uncertainty_score":0.9993272},"labels":[],"label_agreement":null},{"id":"W2726940470","doi":"10.1093/annonc/mdx333","title":"Observation as the initial management strategy in patients with mantle cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency","funders":"BC Cancer Agency; BC Cancer Foundation; Michael Smith Health Research BC; Leukemia and Lymphoma Society of Canada","keywords":"Medicine; Mantle cell lymphoma; Asymptomatic; Blastoid; Internal medicine; Lymphoma; Population; Gastroenterology; Surgery","score_opus":0.09104855501445426,"score_gpt":0.372146900938614,"score_spread":0.2810983459241598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726940470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90574116,0.000042777123,6.326285e-7,0.0034804349,0.00005290065,0.00037300546,0.0000044158483,0.0000043712294,0.0903003],"genre_scores_gemma":[0.9978785,0.00012811366,0.00007216295,0.0013981177,0.000028477047,0.000047203048,0.000024116676,0.0000068639806,0.00041643932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99936414,0.000031422594,0.00017037029,0.00013408232,0.00014868204,0.00015132102],"domain_scores_gemma":[0.99931026,0.00003863179,0.00018270416,0.00033921376,0.00009162748,0.000037578946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011191694,0.00008281655,0.0001953422,0.000041203737,0.000077600795,0.000012761851,0.00011552982,0.00005602754,0.00004435875],"category_scores_gemma":[0.000013642427,0.000049076927,0.00003541514,0.00003438566,0.000084080515,0.000071173505,0.000048449747,0.000027093542,0.000032231084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009963302,0.0040614246,0.7122325,0.000044499047,0.00012490513,0.00022468812,0.00014267438,0.000008795398,0.0000044340404,0.001694629,0.00234712,0.27811804],"study_design_scores_gemma":[0.008674346,0.0037595981,0.9732726,0.00004092293,0.000052040567,0.0000025763259,0.0000836872,0.000008004862,0.001248659,0.00024646084,0.01256336,0.00004774683],"about_ca_topic_score_codex":0.0004340937,"about_ca_topic_score_gemma":0.00009072058,"teacher_disagreement_score":0.2780703,"about_ca_system_score_codex":0.000050323237,"about_ca_system_score_gemma":0.00009038405,"threshold_uncertainty_score":0.2001299},"labels":[],"label_agreement":null},{"id":"W2727639121","doi":"10.1093/annonc/mdx302.009","title":"Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; FOLFOX; Oncology; CD8; Colorectal cancer; Stage (stratigraphy); Immune system; Gastroenterology; Cancer; Immunology; Oxaliplatin","score_opus":0.06638419118006342,"score_gpt":0.36024510469506704,"score_spread":0.29386091351500365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727639121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970089,0.00032426303,8.7309564e-7,0.00021774165,0.000054247,0.0014403875,0.0000535146,0.0000045395695,0.00089552195],"genre_scores_gemma":[0.9996279,0.00011383769,0.000021282436,0.000019661871,0.0000135320115,0.000045277004,0.000077146324,0.000009838983,0.000071536604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837935,0.00014480732,0.00080332265,0.00025283024,0.00018880048,0.00023091631],"domain_scores_gemma":[0.99835676,0.00015276266,0.0008196837,0.00030941897,0.0002961978,0.00006520256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055793166,0.00015656068,0.0010044615,0.00015021155,0.0000374527,0.0000040475416,0.0001255313,0.00014318743,0.000042471955],"category_scores_gemma":[0.00038856373,0.00012642064,0.000087128516,0.0001449827,0.00038598097,0.000109043496,0.000078602105,0.00015801714,2.4541814e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20315857,0.0027246245,0.77315897,0.00021740311,0.000064649925,0.00007847738,0.0006384825,8.140506e-7,0.0061273403,0.000008684969,0.000022479759,0.013799484],"study_design_scores_gemma":[0.102964796,0.028212562,0.845318,0.0002608329,0.0000817075,0.0000032849364,0.00021040914,0.0001840332,0.02261123,0.000019087598,0.00004671893,0.00008729147],"about_ca_topic_score_codex":0.0031971629,"about_ca_topic_score_gemma":0.00086278847,"teacher_disagreement_score":0.100193776,"about_ca_system_score_codex":0.0000372016,"about_ca_system_score_gemma":0.0002573678,"threshold_uncertainty_score":0.5155284},"labels":[],"label_agreement":null},{"id":"W2729141564","doi":"10.1093/annonc/mdx289","title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":272,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Bayer HealthCare; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Internal medicine; Neutropenia; Lymphoma; Gastroenterology; Aggressive lymphoma; Follicular lymphoma; Adverse effect; Rituximab; Phases of clinical research; Oncology; Chemotherapy","score_opus":0.09953814874158444,"score_gpt":0.43731434497751137,"score_spread":0.3377761962359269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2729141564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971429,0.00068545097,0.000004966678,0.0003133427,0.0004728061,0.00046355135,0.000052858122,0.000006472259,0.0008576554],"genre_scores_gemma":[0.99837506,0.00043386588,0.00009704137,0.0003096824,0.00025130506,0.00007659811,0.000017985887,0.000028829665,0.0004096465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809206,0.00022056515,0.0006590184,0.00046417263,0.0002220445,0.00034215167],"domain_scores_gemma":[0.99719477,0.0000838065,0.0013739159,0.000921583,0.0003282344,0.00009770126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051140005,0.00022142145,0.00059446134,0.00012222517,0.00013448433,0.00001099171,0.00064349506,0.00036554752,0.00006985218],"category_scores_gemma":[0.0012410922,0.00017766713,0.00009973533,0.000087494926,0.00030230396,0.000010043061,0.00043123445,0.0001336113,0.000002937211],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031846117,0.030395102,0.0065225465,0.00012854785,0.0005713442,0.00081694504,0.0033344633,0.00005436516,0.60566545,0.00001713491,0.020814408,0.2998336],"study_design_scores_gemma":[0.038811453,0.24967152,0.0059843403,0.00030018025,0.00007476591,0.000057275043,0.0012909569,0.000024529694,0.63209754,0.000054488435,0.07115529,0.00047766822],"about_ca_topic_score_codex":0.00032024347,"about_ca_topic_score_gemma":0.0013207002,"teacher_disagreement_score":0.29935592,"about_ca_system_score_codex":0.00004460731,"about_ca_system_score_gemma":0.00088040944,"threshold_uncertainty_score":0.7245055},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2731503788","doi":"10.1093/annonc/mdx261.362","title":"Prognostic markers of tumour recurrence and survival of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and radical surgery: A retrospective study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Total mesorectal excision; Colorectal cancer; Chemoradiotherapy; Abdominoperineal resection; Retrospective cohort study; Neoadjuvant therapy; Radical surgery; Surgery; Stage (stratigraphy); Radiation therapy; Proportional hazards model; Adenocarcinoma; Oncology; Cancer; Internal medicine; Breast cancer","score_opus":0.030588194345266204,"score_gpt":0.3248807093256164,"score_spread":0.2942925149803502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731503788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818283,0.0003856225,0.0000027026472,0.00042553683,0.000032363117,0.0006808868,0.00003641656,0.0000060449765,0.00024760354],"genre_scores_gemma":[0.9995008,0.0003147096,0.00007524784,0.000026402222,0.000018444985,0.000026952164,0.0000056542963,0.000012821402,0.00001895473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895954,0.00008246532,0.0002756604,0.0002806504,0.00022226768,0.00017938786],"domain_scores_gemma":[0.9985965,0.00016180953,0.0004705591,0.00017280022,0.00048794868,0.000110410685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026794666,0.00014913244,0.0009393753,0.00008019826,0.00005116027,0.0000041925355,0.0000665803,0.000060445094,0.0000141240125],"category_scores_gemma":[0.00025770947,0.00009837839,0.000040250125,0.00010876092,0.0007112469,0.00006879072,0.00003409167,0.000121786325,4.447135e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020936267,0.00092691474,0.938331,0.000098306264,0.00023140915,0.00006086993,0.00030703432,4.2685096e-7,0.00071723026,0.00000463498,0.000029244995,0.038356654],"study_design_scores_gemma":[0.004778071,0.031157907,0.96184945,0.00031890487,0.000119425684,0.000013477667,0.00020909171,0.00002298226,0.0014006287,0.000009680988,0.00002101545,0.000099353274],"about_ca_topic_score_codex":0.0004863451,"about_ca_topic_score_gemma":0.00064330536,"teacher_disagreement_score":0.0382573,"about_ca_system_score_codex":0.000027184473,"about_ca_system_score_gemma":0.00026502088,"threshold_uncertainty_score":0.40117544},"labels":[],"label_agreement":null},{"id":"W2732470776","doi":"10.1093/annonc/mdx302.002","title":"Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRI; Internal medicine; Cancer; Colorectal cancer; Gastroenterology; Oncology; Combination therapy; Irinotecan","score_opus":0.2443052311328311,"score_gpt":0.5327082909976887,"score_spread":0.2884030598648576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732470776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957766,0.0003271753,0.0000018885406,0.00090446486,0.0009300512,0.001243127,0.00019091036,0.000009662818,0.0006161402],"genre_scores_gemma":[0.99893814,0.00031748932,0.000019955005,0.0002559632,0.000046988618,0.00030479187,0.000019721785,0.000022766983,0.000074189484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975243,0.0006649341,0.00072310376,0.00039912201,0.00024974946,0.00043877983],"domain_scores_gemma":[0.9979872,0.00022796767,0.0009771141,0.00023370769,0.0004614246,0.00011258351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069421995,0.0002636835,0.0008253245,0.00030403442,0.00025949406,0.000013311029,0.0004403305,0.00021122393,0.00023039112],"category_scores_gemma":[0.00009517964,0.00023354204,0.00006987396,0.0002447206,0.00042691373,0.0002754224,0.00019175309,0.00048293665,0.0000024201552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008684257,0.07060647,0.796228,0.00015338424,0.0005725339,0.00014838493,0.0051884456,0.00015395554,0.0056257555,0.00010199882,0.00082255935,0.11171427],"study_design_scores_gemma":[0.11981753,0.036194704,0.77049464,0.00024434645,0.00036022486,0.0000054267894,0.0020103524,0.0010177796,0.061087206,0.00020777264,0.007981521,0.000578505],"about_ca_topic_score_codex":0.0028515174,"about_ca_topic_score_gemma":0.024815409,"teacher_disagreement_score":0.111135766,"about_ca_system_score_codex":0.00016745552,"about_ca_system_score_gemma":0.00033411666,"threshold_uncertainty_score":0.99297917},"labels":[],"label_agreement":null},{"id":"W2732921111","doi":"10.1093/annonc/mdx261.301","title":"Incidence of oxaliplatin-induced peripheral sensory neuropathy in patients with colorectal cancer treated by FOLFOX regimen at a regional community hospital in Québec","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université de Sherbrooke","funders":"","keywords":"Medicine; Oxaliplatin; FOLFOX; Bevacizumab; Regimen; Internal medicine; Discontinuation; Colorectal cancer; Peripheral neuropathy; Surgery; Fluorouracil; Chemotherapy; Gastroenterology; Cancer; Diabetes mellitus","score_opus":0.06442179793898725,"score_gpt":0.3751321489538139,"score_spread":0.3107103510148267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732921111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947391,0.00017497454,4.764444e-8,0.003231376,0.000087036184,0.0005234662,0.000051235234,0.000008406883,0.0011843609],"genre_scores_gemma":[0.9989734,0.00012842355,0.000014245993,0.000463745,0.000026275731,0.00006804859,0.000044236895,0.000017020948,0.00026456252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987078,0.00029672604,0.00035904002,0.00020437759,0.00016642186,0.00026567516],"domain_scores_gemma":[0.9987319,0.00019179484,0.00049110537,0.0002882771,0.00021069615,0.00008619433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019317395,0.00017010525,0.0006261747,0.00010382429,0.000103478706,0.0000030666904,0.00018480727,0.00014918871,0.00009932652],"category_scores_gemma":[0.0000860244,0.00014510915,0.000063030035,0.00009176399,0.00038048674,0.000100168574,0.000103783364,0.00032755424,0.0000014161537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008472471,0.0028746475,0.9671594,0.000031183095,0.00010623448,0.00007904481,0.0026267548,0.0000040079567,0.012647055,0.0000029782009,0.0024610045,0.0035352104],"study_design_scores_gemma":[0.009980269,0.016226564,0.9622043,0.00009155488,0.0000527393,0.0000079547735,0.00009963626,0.000021424063,0.010471796,0.0000070646042,0.0007180986,0.000118645454],"about_ca_topic_score_codex":0.11334995,"about_ca_topic_score_gemma":0.11995893,"teacher_disagreement_score":0.013351915,"about_ca_system_score_codex":0.00036372602,"about_ca_system_score_gemma":0.0005229258,"threshold_uncertainty_score":0.8960995},"labels":[],"label_agreement":null},{"id":"W2734369657","doi":"10.1093/annonc/mdx356","title":"Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Proton therapy; Hodgkin lymphoma; Lymphoma; Nuclear medicine; Radiology; Proton; Medical physics; Radiation therapy; Oncology; Internal medicine; Nuclear physics","score_opus":0.2756096697942528,"score_gpt":0.4805219273679085,"score_spread":0.20491225757365572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734369657","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49622497,0.0042620003,0.000067657464,0.494007,0.0019614864,0.0023054522,0.00009117396,0.00005662295,0.0010236318],"genre_scores_gemma":[0.23013681,0.01087525,0.00091013423,0.7410085,0.015577971,0.00048357242,0.00025439073,0.000092783615,0.00066057895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629647,0.0007025343,0.001272161,0.0007049773,0.0005755244,0.00044830807],"domain_scores_gemma":[0.99497616,0.0026841229,0.0010070448,0.00084165874,0.0003138208,0.00017721702],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020761727,0.00032190618,0.0013791118,0.0009540602,0.00006531137,0.000023203242,0.0004883916,0.0017725042,0.00028655387],"category_scores_gemma":[0.0031283027,0.00028368825,0.0003162934,0.0004217586,0.00020317527,0.00017007331,0.000074201394,0.0012050427,0.00007210967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002407543,0.0005174391,0.14797518,0.00010617841,0.0002395531,0.0006391435,0.0002174603,0.0000025015136,0.00021811585,0.0000011275689,0.5038591,0.34381667],"study_design_scores_gemma":[0.0033611169,0.010080927,0.3479637,0.00085372693,0.000063754334,0.00003700638,0.000011269284,0.00006465242,0.001634905,0.0001705446,0.6355378,0.00022059037],"about_ca_topic_score_codex":0.0005775678,"about_ca_topic_score_gemma":0.0000136184935,"teacher_disagreement_score":0.34359607,"about_ca_system_score_codex":0.0001476733,"about_ca_system_score_gemma":0.000974815,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W2735659479","doi":"10.1093/annonc/mdx243","title":"Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Hysterectomy; Cancer; Gynecology; General surgery; Surgery; Internal medicine","score_opus":0.25691196488422907,"score_gpt":0.4764717899016911,"score_spread":0.21955982501746202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735659479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.762606,0.0057539004,0.000033930617,0.15201345,0.009260613,0.0017286838,0.0009659528,0.00016436982,0.06747306],"genre_scores_gemma":[0.9610854,0.015416624,0.001243513,0.009178113,0.0035621931,0.00019472394,0.00053369114,0.000055242912,0.00873049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641085,0.00015431842,0.0012360747,0.00076161843,0.0006185923,0.00081854063],"domain_scores_gemma":[0.9952513,0.0004451964,0.0013251341,0.0012186503,0.0012331,0.00052660285],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001062069,0.00040865332,0.0018070987,0.0004444264,0.00035320796,0.000059248214,0.00086332543,0.00052580517,0.009059657],"category_scores_gemma":[0.0060495837,0.00030177206,0.00051441835,0.000463836,0.0005451544,0.00037611322,0.0004191688,0.00055153883,0.00034393792],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01304694,0.0039495835,0.10175829,0.00024038032,0.0024474775,0.0010121429,0.000086037566,0.000038631904,0.002039645,0.0008435043,0.33641234,0.53812504],"study_design_scores_gemma":[0.022672756,0.0063004266,0.18376878,0.00010184061,0.00046858186,0.000044679895,0.00005140855,0.000056485045,0.0039363774,0.00083305966,0.78140384,0.0003617468],"about_ca_topic_score_codex":0.003167886,"about_ca_topic_score_gemma":0.001440627,"teacher_disagreement_score":0.5377633,"about_ca_system_score_codex":0.00034670366,"about_ca_system_score_gemma":0.0011302627,"threshold_uncertainty_score":0.99994344},"labels":[],"label_agreement":null},{"id":"W2736712994","doi":"10.1016/s0923-7534(20)33023-4","title":"A Phase I Study of Daily Afatinib, an Irreversible Erbb Family Blocker, Combined With Weekly Paclitaxel and 2-Weekly Bevacizumab in Patients with Advanced Solid Tumours","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Bevacizumab; Afatinib; Paclitaxel; ErbB; Oncology; Internal medicine; Pharmacology; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.038400199057915245,"score_gpt":0.40077139395288713,"score_spread":0.3623711948949719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736712994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709713,0.00025084798,0.0000045304705,0.0004041854,0.0000563341,0.0012595996,0.00005114725,0.00001540565,0.0008608152],"genre_scores_gemma":[0.9985933,0.000032649838,0.00085544644,0.00023647184,0.000018809213,0.00005780316,0.00008795354,0.000023533252,0.00009405763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987073,0.00009678081,0.00037197434,0.00024779123,0.00024337668,0.00033276647],"domain_scores_gemma":[0.99884564,0.00007889874,0.00029852957,0.0002715144,0.0003042756,0.00020112171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016862967,0.00018738878,0.00066074997,0.00019451576,0.00004836227,0.0000036544875,0.00006983307,0.00006985115,0.000013954118],"category_scores_gemma":[0.000029676718,0.00013487539,0.00002842943,0.00026047774,0.0001185287,0.00026230936,0.00002925992,0.0001198711,0.0000011031386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01402897,0.04582809,0.90734357,0.0000807473,0.0004978125,0.00003058447,0.009534629,0.000015338766,0.00021877636,0.000035132914,0.0003355453,0.02205079],"study_design_scores_gemma":[0.06020462,0.14960214,0.7798662,0.000098555836,0.00037069406,0.000005812765,0.009239277,0.000009109339,0.00023912775,0.00001635114,0.00021691684,0.00013118681],"about_ca_topic_score_codex":0.0004066713,"about_ca_topic_score_gemma":0.00027339382,"teacher_disagreement_score":0.1274774,"about_ca_system_score_codex":0.000060867544,"about_ca_system_score_gemma":0.00021527491,"threshold_uncertainty_score":0.55000585},"labels":[],"label_agreement":null},{"id":"W2739036608","doi":"10.1093/annonc/mdx400","title":"Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Notre-Dame; BC Cancer Agency","funders":"","keywords":"Medicine; Placebo; Gemcitabine; Hazard ratio; Internal medicine; Chemotherapy; Adverse effect; Clinical endpoint; Gastroenterology; Surgery; Randomized controlled trial; Urology; Confidence interval; Pathology","score_opus":0.06507839117461117,"score_gpt":0.4452299838262008,"score_spread":0.38015159265158965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739036608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852158,0.00035096123,0.000070514245,0.00344005,0.00017286776,0.009218097,0.00024192804,0.000020464704,0.0012693463],"genre_scores_gemma":[0.9946157,0.00054541975,0.0005958205,0.0009780644,0.00022889902,0.0027288443,0.00002953858,0.000042651747,0.00023510215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99844575,0.000118119715,0.00048349917,0.00037176115,0.00027139345,0.0003094865],"domain_scores_gemma":[0.9978846,0.00038501463,0.0006430907,0.00040677976,0.000541051,0.00013950828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070683664,0.0002575811,0.0015438035,0.0000789977,0.00039638003,0.000017433424,0.00013209792,0.00010321919,0.000059133894],"category_scores_gemma":[0.0005618849,0.00016864519,0.00017398078,0.00003556978,0.00024465125,0.00011627865,0.000042743235,0.00009725997,4.854101e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7335304,0.004413721,0.011753493,0.000053430915,0.0013464441,0.0000063182365,0.0014115034,0.0000085950505,0.000044990185,0.000015368209,0.00041000024,0.24700575],"study_design_scores_gemma":[0.92001927,0.070502885,0.0044499715,0.00009817691,0.0009031206,0.0000024701658,0.00010800928,0.00040061274,0.00033055255,0.00015962466,0.0028628912,0.00016240227],"about_ca_topic_score_codex":0.0009276164,"about_ca_topic_score_gemma":0.0005181811,"teacher_disagreement_score":0.24684335,"about_ca_system_score_codex":0.000042709493,"about_ca_system_score_gemma":0.00034842035,"threshold_uncertainty_score":0.6877151},"labels":[],"label_agreement":null},{"id":"W2739919047","doi":"10.1093/annonc/11.suppl_1.s59","title":"Allografting for indolent lymphoid neoplasms","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"BC Cancer Agency","keywords":"Medicine; Stage (stratigraphy); Surgery; Refractory (planetary science); Internal medicine; Lymphoma; Transplantation; Chronic lymphocytic leukemia; Leukemia; Gastroenterology","score_opus":0.11575796180668947,"score_gpt":0.4414156314809154,"score_spread":0.32565766967422594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739919047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416432,0.00052193867,0.000078237055,0.004869211,0.00009811724,0.0006178568,0.000011936073,0.000039603572,0.052119933],"genre_scores_gemma":[0.98976535,0.00071268197,0.0022708417,0.0031467204,0.0002595795,0.0000854637,0.00002744353,0.000025994124,0.0037059002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863404,0.00005166726,0.00036902525,0.00023918081,0.00022725822,0.00047884232],"domain_scores_gemma":[0.99878544,0.00047153636,0.00008116883,0.00027839898,0.0002169502,0.0001664954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053898164,0.00011188326,0.00043344917,0.00010654043,0.00004490382,0.0000044242174,0.00013836348,0.00018573718,0.00085963565],"category_scores_gemma":[0.0002738284,0.000097582684,0.00017227061,0.00015712393,0.00016736111,0.000039976923,0.00003713402,0.000105196785,0.00008936762],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028996603,0.000679731,0.0006706932,0.00025199712,0.00019045621,0.00013697987,0.0007122898,0.00009645814,0.0048876596,0.00040048023,0.03312819,0.95594543],"study_design_scores_gemma":[0.029379377,0.009137369,0.0006501031,0.00012044088,0.000071087605,0.0009350848,0.00014857792,0.00588001,0.039584585,0.00063308264,0.913278,0.0001822838],"about_ca_topic_score_codex":0.0002463489,"about_ca_topic_score_gemma":0.000030813724,"teacher_disagreement_score":0.9557631,"about_ca_system_score_codex":0.0010713933,"about_ca_system_score_gemma":0.004469294,"threshold_uncertainty_score":0.9412407},"labels":[],"label_agreement":null},{"id":"W2740393355","doi":"10.1093/annonc/mdx339","title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":258,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Confidence interval; Hazard ratio; Internal medicine; Metastatic melanoma; Progression-free survival; Melanoma; Gastroenterology; Oncology; Chemotherapy; Cancer; Cancer research","score_opus":0.04370504422132651,"score_gpt":0.32638251676067626,"score_spread":0.2826774725393497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740393355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946056,0.000043745174,0.000020363355,0.000338125,0.00016607127,0.00082203886,0.00010472526,0.0000017021599,0.0038976346],"genre_scores_gemma":[0.99941975,0.000012459609,0.000113669135,0.00009608618,0.000031050302,0.000029667975,0.000068912836,0.000010151663,0.00021823467],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99832344,0.0005846559,0.00046517648,0.00025551356,0.00018707156,0.0001841595],"domain_scores_gemma":[0.9983073,0.00015712605,0.0006972569,0.0005126448,0.0002876611,0.000038022652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008253628,0.00013830833,0.0005504427,0.000043317603,0.000082820574,0.000009352439,0.00035131385,0.000080312406,0.0000051608345],"category_scores_gemma":[0.00065403624,0.0000898216,0.00011962717,0.0000376459,0.00028125313,0.000008944715,0.0001441733,0.00008718829,0.0000011527916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5510487,0.011583482,0.39156237,0.00013179635,0.002845347,0.00015487634,0.00488879,0.00039116232,0.016783243,0.0015484795,0.0023219415,0.016739836],"study_design_scores_gemma":[0.18556072,0.0075840624,0.7776275,0.000033187265,0.00010856729,0.0000039591578,0.00014905767,0.000015275278,0.028011115,0.00022411458,0.00051201036,0.00017037947],"about_ca_topic_score_codex":0.00048029947,"about_ca_topic_score_gemma":0.00090273377,"teacher_disagreement_score":0.38606519,"about_ca_system_score_codex":0.0000072606417,"about_ca_system_score_gemma":0.00018214984,"threshold_uncertainty_score":0.36628187},"labels":[],"label_agreement":null},{"id":"W2742282063","doi":"10.1093/annonc/mdx308","title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"National Cancer Institute; Cancer Research UK; American Society for Radiation Oncology","keywords":"Medicine; Breast cancer; Oncology; Radiation therapy; Cancer; Internal medicine; Hormonal therapy; Adjuvant therapy; Stage (stratigraphy); Neoadjuvant therapy; Sentinel node; Gynecology","score_opus":0.10528674523656073,"score_gpt":0.3997160847113345,"score_spread":0.2944293394747738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742282063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670009,0.0011415263,0.000012909815,0.028004378,0.00015340671,0.00036040504,0.0012472005,0.000004346516,0.0020749443],"genre_scores_gemma":[0.9912811,0.0071667,0.00010957701,0.00075943774,0.00022470584,0.00023903494,0.000015588328,0.000016360804,0.00018750988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905825,0.000084500345,0.00022904247,0.0002689742,0.00012020995,0.00023903495],"domain_scores_gemma":[0.9986444,0.00015947346,0.000493103,0.0003527573,0.00030860762,0.000041636846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021699874,0.00017576113,0.00027006917,0.000019928151,0.00032422063,0.000031689156,0.00034376082,0.00011183632,0.00003279189],"category_scores_gemma":[0.000041812527,0.00010731386,0.000098096076,0.000015037056,0.00050304737,0.000008486013,0.00014927422,0.000075420015,2.7078377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004863582,0.00057516363,0.52867186,0.00003123495,0.0032502953,0.0000069105636,0.0023104805,0.00003428642,0.05437003,0.0006500745,0.006011643,0.39922443],"study_design_scores_gemma":[0.0018565081,0.00063152047,0.9855482,0.00008326651,0.000035556728,0.000023227889,0.00024066788,0.00006265777,0.008654928,0.00012049314,0.0026160835,0.00012691414],"about_ca_topic_score_codex":0.0032702165,"about_ca_topic_score_gemma":0.00036229752,"teacher_disagreement_score":0.4568763,"about_ca_system_score_codex":0.000039657618,"about_ca_system_score_gemma":0.00022176135,"threshold_uncertainty_score":0.4943611},"labels":[],"label_agreement":null},{"id":"W2743419024","doi":"10.1093/annonc/mdx286","title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Rash; Nivolumab; Immunology; Pneumonitis; Cancer; Immunotherapy; Lung","score_opus":0.1276813283897447,"score_gpt":0.41766562727838813,"score_spread":0.2899842988886434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743419024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006649307,0.9944398,9.930897e-7,0.00035557136,0.0003925106,0.0034235106,0.000119266486,0.000011876947,0.0005915708],"genre_scores_gemma":[0.0024060255,0.99679726,0.0000189576,0.000072295596,0.000051573385,0.00014280513,0.00011669106,0.00005342549,0.00034093283],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9931529,0.0005903462,0.0052095773,0.00038648525,0.0003509851,0.00030969325],"domain_scores_gemma":[0.9897381,0.00028855342,0.008304123,0.0011736517,0.00040141746,0.00009415533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027948348,0.00048413905,0.008362968,0.0003360725,0.00004181751,0.0000023749035,0.00042778975,0.000601493,0.00016520968],"category_scores_gemma":[0.00041881524,0.0003508773,0.0022918435,0.00021523572,0.0003262661,0.000069770336,0.00016239667,0.00043938344,0.000011982788],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023155726,0.00036224144,0.00001660614,0.8680839,0.0022010305,0.000038943548,0.00010329901,1.1181729e-8,0.0003502142,0.000014006812,0.00029408233,0.12830412],"study_design_scores_gemma":[0.0015317224,0.0017456486,0.0002147749,0.7563117,0.0029772818,0.00032977058,0.00004907003,2.3128419e-7,0.00028761732,0.000007953844,0.23632382,0.00022038196],"about_ca_topic_score_codex":0.00016558442,"about_ca_topic_score_gemma":0.000006503562,"teacher_disagreement_score":0.23602973,"about_ca_system_score_codex":0.000109777306,"about_ca_system_score_gemma":0.00064245146,"threshold_uncertainty_score":0.9998943},"labels":[],"label_agreement":null},{"id":"W2744317320","doi":"10.1093/annonc/mdx285","title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; University of Calgary","funders":"National Cancer Institute; Cancer Research UK; National Institutes of Health; Canadian Cancer Society Research Institute; Ipsen; National Health and Medical Research Council; Pfizer; Amgen","keywords":"Medicine; Endocrine system; Oncology; Breast cancer; Chemotherapy; Gynecology; Cancer; Internal medicine; Obstetrics; Hormone","score_opus":0.03184080907807043,"score_gpt":0.33911350970303294,"score_spread":0.30727270062496254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744317320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893975,0.00029371094,0.00007520061,0.0003525024,0.00002530292,0.00013601265,0.0001333652,0.0000017170587,0.000042409643],"genre_scores_gemma":[0.9991989,0.00058602134,0.00003675887,0.00005328771,0.000028907674,0.000053959,0.0000302049,0.000007802139,0.0000041237754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929,0.00008855156,0.0001798699,0.00022483456,0.000085482854,0.00013128588],"domain_scores_gemma":[0.9991273,0.000017686958,0.0003811664,0.00019261029,0.000238248,0.00004296677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011887159,0.00011079514,0.00033756267,0.00010561995,0.000047428046,0.0000060888788,0.00006370138,0.000062628016,0.00001332776],"category_scores_gemma":[0.00001096518,0.000086612585,0.000015900398,0.00006837778,0.0003086644,0.000025678337,0.000050928644,0.000037925452,2.9590336e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017173868,0.0004983725,0.67416525,0.0000671609,0.0024854725,0.0000067656374,0.0030875239,0.00009896954,0.23247992,0.000042513504,0.000030483632,0.069863714],"study_design_scores_gemma":[0.0028642754,0.0046485034,0.94335586,0.000034704,0.00021233223,0.000006345898,0.00048575405,0.000017404192,0.04816325,0.000013017486,0.00011315681,0.000085408086],"about_ca_topic_score_codex":0.00045148373,"about_ca_topic_score_gemma":0.0014771491,"teacher_disagreement_score":0.2691906,"about_ca_system_score_codex":0.000017108481,"about_ca_system_score_gemma":0.000120568824,"threshold_uncertainty_score":0.35319588},"labels":[],"label_agreement":null},{"id":"W2751901379","doi":"10.1093/annonc/mdx495","title":"Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Adenocarcinoma; Chemotherapy; Internal medicine; Radiological weapon; FOLFIRINOX; Oncology; Primary tumor; Surgery; Gastroenterology; Radiology; Cancer; Metastasis","score_opus":0.1032604041988744,"score_gpt":0.43971957010932344,"score_spread":0.33645916591044905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751901379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98585093,0.00019145923,0.0013212443,0.0031443338,0.00016905784,0.0023036045,0.000034742967,0.000013881201,0.006970766],"genre_scores_gemma":[0.9847617,0.00019638208,0.0107563045,0.0015017509,0.0002597537,0.00089980254,0.000055019365,0.000035134566,0.0015341295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985254,0.000066061206,0.0004430749,0.00030239634,0.00018838764,0.00047468967],"domain_scores_gemma":[0.99740714,0.0008136908,0.00040596456,0.00044163645,0.0007977505,0.0001338229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009207991,0.0001538591,0.0008660332,0.00014668563,0.00027429164,0.00001530939,0.00017470538,0.00017903514,0.000050968225],"category_scores_gemma":[0.0014000835,0.00013179214,0.00019769145,0.00005660879,0.00022716814,0.00011092151,0.00004625094,0.00014983755,0.0000074464538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015095081,0.0011736121,0.89544433,0.0012310537,0.0006549178,0.00001060208,0.0006201905,3.4394358e-7,0.0017008283,0.000052525767,0.014959731,0.06905679],"study_design_scores_gemma":[0.011196012,0.019386139,0.95482093,0.00015191999,0.00032403177,0.000019410249,0.000078605335,0.0005959419,0.003657217,0.001167844,0.008463757,0.00013817637],"about_ca_topic_score_codex":0.00006801967,"about_ca_topic_score_gemma":0.00003685379,"teacher_disagreement_score":0.06891861,"about_ca_system_score_codex":0.000100225465,"about_ca_system_score_gemma":0.0005053618,"threshold_uncertainty_score":0.53743273},"labels":[],"label_agreement":null},{"id":"W2753841357","doi":"10.1093/annonc/mdx514","title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Ramucirumab; Medicine; Placebo; Oncology; Monoclonal antibody; Internal medicine; Randomized controlled trial; Bevacizumab; Monoclonal; VEGF receptors; Antibody; Chemotherapy; Immunology; Pathology; Alternative medicine","score_opus":0.5467726718018913,"score_gpt":0.5184122577197179,"score_spread":0.02836041408217338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753841357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072777993,0.98210937,0.000020711945,0.001357751,0.000179211,0.0056427363,0.008472958,0.000012102652,0.0014773785],"genre_scores_gemma":[0.00569463,0.98709977,0.0002113454,0.00015313762,0.00015903596,0.00059813214,0.005867615,0.000042718202,0.0001736129],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9904281,0.0039952537,0.0033962028,0.000871796,0.0008751206,0.00043350854],"domain_scores_gemma":[0.97432125,0.015307779,0.007814096,0.002011377,0.0004257614,0.000119755074],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.010000039,0.00077046984,0.041474685,0.0006696228,0.000239516,0.00004513245,0.0011173349,0.0004272689,0.000750295],"category_scores_gemma":[0.0026620284,0.00032166386,0.011197562,0.00046807036,0.0007087578,0.00010220517,0.0006711187,0.00038508378,0.000008208411],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112940036,0.00036021328,0.0000069772973,0.0003464193,0.65888584,0.000056414625,0.00025213693,0.0000031725694,4.8913546e-7,0.000013085813,0.0010760138,0.22605918],"study_design_scores_gemma":[0.074606456,0.0013093061,0.000022710481,0.00033010019,0.65079874,0.000011356957,0.000084242696,0.000012310915,0.0000027977608,0.000005944233,0.27263576,0.0001802769],"about_ca_topic_score_codex":0.00054607104,"about_ca_topic_score_gemma":0.00050346664,"teacher_disagreement_score":0.27155975,"about_ca_system_score_codex":0.000073179806,"about_ca_system_score_gemma":0.0012889589,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W2753944011","doi":"10.1093/annonc/mdx523","title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Vancouver General Hospital; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Afatinib; Medicine; Lung cancer; Fusion gene; Cancer research; Adenocarcinoma; Cancer; Transcriptome; Epigenetics; Bioinformatics; Oncology; Internal medicine; Gene; Epidermal growth factor receptor; Biology; Gefitinib; Genetics; Gene expression","score_opus":0.16885170927104307,"score_gpt":0.4920367757455327,"score_spread":0.32318506647448964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753944011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977953,0.001550021,0.000101930855,0.012216374,0.0002600298,0.0009824791,0.00045180623,0.000008041058,0.0064762766],"genre_scores_gemma":[0.99784386,0.00031468537,0.0006539881,0.00024061011,0.00006368223,0.00020617191,0.000022085698,0.000010435987,0.00064450747],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993349,0.000019138515,0.00024944343,0.00013168773,0.000086538,0.00017832642],"domain_scores_gemma":[0.99888194,0.0001142793,0.0005018099,0.00024685933,0.00020769266,0.000047417063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013021364,0.00009307057,0.00034971503,0.000035109944,0.0001664552,0.0000066117545,0.00012698937,0.000045755245,0.000056307777],"category_scores_gemma":[0.00011003422,0.000052655305,0.00013899214,0.000034083463,0.00016422984,0.000053467775,0.00002749499,0.000036352038,8.557445e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012036709,0.0070295287,0.15716736,0.00079065014,0.006830895,0.000028688108,0.0056111705,0.00057478494,0.06875176,0.00943268,0.0063400916,0.7362387],"study_design_scores_gemma":[0.01970807,0.014699614,0.25816512,0.00035432712,0.0028390537,0.000023179484,0.0024205407,0.00035276797,0.54488164,0.0026546111,0.15359437,0.00030667544],"about_ca_topic_score_codex":0.0016716314,"about_ca_topic_score_gemma":0.000378627,"teacher_disagreement_score":0.73593205,"about_ca_system_score_codex":0.00006111639,"about_ca_system_score_gemma":0.0007809701,"threshold_uncertainty_score":0.25270176},"labels":[],"label_agreement":null},{"id":"W2754017378","doi":"10.1093/annonc/mdx540","title":"Toxicity adjustment in the ESMO-MCBS: a gestalt approach?","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Scopus; Oncology; MEDLINE","score_opus":0.16828031651152106,"score_gpt":0.33566534278920007,"score_spread":0.167385026277679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754017378","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057989117,0.0053627496,0.00007670868,0.5322067,0.001039321,0.0005590433,0.00044876224,0.000012656249,0.4544951],"genre_scores_gemma":[0.107955694,0.0053157913,0.00032670426,0.8768183,0.004649941,0.00023686522,0.0001796105,0.00007287146,0.004444218],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754196,0.00007716429,0.0010828129,0.0005866875,0.00005682329,0.00065453484],"domain_scores_gemma":[0.9968717,0.0002039487,0.0017685276,0.0010428533,0.000063451,0.00004950914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001478513,0.00032771606,0.0013824132,0.00031969533,0.00009640355,0.000053251453,0.0013399771,0.0012186858,0.0001983106],"category_scores_gemma":[0.0002653797,0.0003027059,0.0003415376,0.00008454092,0.0003496283,0.00023258023,0.00013358201,0.0013833606,0.00023044668],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029107032,0.00021560308,0.00127021,0.000101496844,0.00008625941,0.00007472644,0.00061013084,0.000013355116,2.159094e-7,0.01553809,0.9738235,0.008237315],"study_design_scores_gemma":[0.0004775939,0.0005601249,0.013665796,0.00002766386,0.000010181402,0.00001900849,0.000037709196,0.00003433601,0.000005773992,0.024489753,0.9603671,0.00030496815],"about_ca_topic_score_codex":0.0014582662,"about_ca_topic_score_gemma":0.00013067847,"teacher_disagreement_score":0.4500509,"about_ca_system_score_codex":0.00015937792,"about_ca_system_score_gemma":0.00020493715,"threshold_uncertainty_score":0.9999425},"labels":[],"label_agreement":null},{"id":"W2757328282","doi":"10.1093/annonc/mdx557","title":"LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society","keywords":"Medicine; Breast cancer; Oncology; Tumor-infiltrating lymphocytes; Internal medicine; Cancer; Hazard ratio; Immune checkpoint; Proportional hazards model; PD-L1; Tissue microarray; Immunohistochemistry; Estrogen receptor; Immunotherapy; Confidence interval","score_opus":0.059523721403723875,"score_gpt":0.40956022298624556,"score_spread":0.3500365015825217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757328282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98295283,0.0008071016,0.0000010989964,0.013301031,0.00019281554,0.00018745138,0.000023949307,0.000012520369,0.0025211712],"genre_scores_gemma":[0.9951822,0.002194461,0.00008895413,0.0021378656,0.00015600515,0.000018215014,0.000005020438,0.00001176767,0.00020551337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885017,0.000091321206,0.0004759461,0.00020470402,0.0001442819,0.00023355758],"domain_scores_gemma":[0.9984972,0.0003328438,0.0007344425,0.00020191107,0.0001627346,0.00007089447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000982929,0.00011258255,0.0005160209,0.000067482586,0.00009827094,0.00001889034,0.000098506374,0.00015733225,0.00006573272],"category_scores_gemma":[0.00026171975,0.00008854419,0.00006907126,0.00006690071,0.00026480044,0.00012014493,0.000034663863,0.00019482688,0.0000022205738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050516957,0.00017263935,0.9252747,0.00003778559,0.0001561617,0.00006052713,0.00019440091,0.0000018370014,0.0008222709,0.000018435172,0.0015675834,0.06664196],"study_design_scores_gemma":[0.005272945,0.0018487294,0.9871578,0.00035041638,0.000045345907,0.0001620379,0.0001875467,0.00012980419,0.0009771973,0.00003577664,0.0037306726,0.000101719226],"about_ca_topic_score_codex":0.0021638146,"about_ca_topic_score_gemma":0.0012035429,"teacher_disagreement_score":0.066540234,"about_ca_system_score_codex":0.0001358455,"about_ca_system_score_gemma":0.00056222896,"threshold_uncertainty_score":0.36107272},"labels":[],"label_agreement":null},{"id":"W2760826273","doi":"10.1093/annonc/mdx387.017","title":"Primary cardiac sarcoma (PCS): A multi-national retrospective review of clinical experience","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Sarcoma; Angiosarcoma; Hazard ratio; Internal medicine; Cohort; Proportional hazards model; Retrospective cohort study; Surgery; Stage (stratigraphy); Oncology; Pathology; Confidence interval","score_opus":0.25548343515042915,"score_gpt":0.5420665962883691,"score_spread":0.2865831611379399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760826273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7630851,0.020879773,0.000024115623,0.009905125,0.0013109641,0.0008116716,0.0001235503,0.000021401063,0.20383829],"genre_scores_gemma":[0.9625389,0.031839956,0.0012489124,0.0035601147,0.0003637214,0.000028504297,0.000017753657,0.000011459013,0.0003906771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983756,0.00013810843,0.00071441976,0.00024773763,0.0003582328,0.00016589914],"domain_scores_gemma":[0.99750537,0.00018529287,0.00072695373,0.00052133267,0.000949459,0.00011162178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015823491,0.00009969607,0.0013297356,0.000041379426,0.000060446684,0.000003158484,0.00017550099,0.00012555717,0.00010686985],"category_scores_gemma":[0.0029768331,0.00008535406,0.00054839376,0.000052184187,0.0005859783,0.00008094314,0.0001381457,0.00019818198,0.00001298458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000601626,0.002061866,0.81200045,0.0024326108,0.000574039,0.00012842666,0.00047154873,1.18920624e-7,0.0019066909,0.0041763852,0.08287978,0.09276648],"study_design_scores_gemma":[0.0010763239,0.0012600167,0.91903764,0.0009870919,0.00006402748,0.000024356206,0.00002654693,0.0000033525444,0.00076278555,0.0001611806,0.07652662,0.00007005008],"about_ca_topic_score_codex":0.00007437621,"about_ca_topic_score_gemma":0.0000037974526,"teacher_disagreement_score":0.20344763,"about_ca_system_score_codex":0.000040745697,"about_ca_system_score_gemma":0.00055797515,"threshold_uncertainty_score":0.35637626},"labels":[],"label_agreement":null},{"id":"W2760864027","doi":"10.1093/annonc/mdx372.036","title":"Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Hazard ratio; Regimen; Oncology; Chemotherapy; Ovarian cancer; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Progressive disease; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.2223933784517272,"score_gpt":0.4614255025643219,"score_spread":0.2390321241125947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760864027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170655,0.00015065883,0.000003916698,0.004696866,0.0001415892,0.0018839038,0.00005592951,0.00000653999,0.0013540746],"genre_scores_gemma":[0.9987148,0.00015332826,0.00007853328,0.0006160632,0.000099673154,0.000251217,0.000013101478,0.000016266416,0.00005703848],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970226,0.0011951008,0.0005160012,0.00028949743,0.00074001757,0.00023672634],"domain_scores_gemma":[0.99723417,0.0006672095,0.00066599273,0.000414068,0.0009329498,0.00008561338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037356105,0.00015688462,0.00059624924,0.00018385943,0.00010108159,0.000012483694,0.0001395753,0.00013310392,0.000054327484],"category_scores_gemma":[0.0031722602,0.0001020345,0.000048357524,0.00014386154,0.0003698659,0.0001432825,0.00002876922,0.00025708854,0.0000012384717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7591725,0.0035420535,0.1876885,0.00009689592,0.0002691496,0.000090904294,0.008677457,0.00027135218,0.00418656,0.000101094854,0.0010170913,0.034886416],"study_design_scores_gemma":[0.15591082,0.006646963,0.82976216,0.00059807446,0.00022922861,0.000007528877,0.00034916334,0.0005626562,0.0051853694,0.00024372966,0.00036730038,0.00013699976],"about_ca_topic_score_codex":0.0012338234,"about_ca_topic_score_gemma":0.0023209574,"teacher_disagreement_score":0.64207363,"about_ca_system_score_codex":0.000158581,"about_ca_system_score_gemma":0.001764701,"threshold_uncertainty_score":0.41608465},"labels":[],"label_agreement":null},{"id":"W2760940301","doi":"10.1093/annonc/mdx363","title":"Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Clinical endpoint; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical trial; Population; Oncology; Surrogate endpoint; Phases of clinical research; Cancer; Gastroenterology; Immunotherapy","score_opus":0.15942913122050914,"score_gpt":0.4775674784646882,"score_spread":0.3181383472441791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760940301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526423,0.0001861698,0.000011984302,0.0028481232,0.00019354273,0.0009896109,0.000028427614,0.000005518505,0.00047239603],"genre_scores_gemma":[0.9974969,0.00022292363,0.0015994844,0.00027481717,0.00008878058,0.000045842622,0.000005219117,0.000011744239,0.0002542861],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99790174,0.0004241695,0.0010824538,0.00023050267,0.00017673314,0.00018439724],"domain_scores_gemma":[0.9975161,0.0009358179,0.00076668675,0.0005020593,0.00017644792,0.00010290375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00292597,0.000108311826,0.0007432969,0.00019845892,0.00004500885,0.0000030552314,0.0001499926,0.0002560586,0.000036114263],"category_scores_gemma":[0.0034244987,0.000091928894,0.00014423764,0.00008853549,0.00037793664,0.000059046786,0.00009378432,0.00018939085,0.0000020147004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5769384,0.00088101375,0.0866416,0.00007911134,0.000040885712,0.000028193715,0.0007280685,0.0000021857577,0.32405746,0.0000025528718,0.0010312044,0.009569366],"study_design_scores_gemma":[0.045046955,0.013010714,0.713211,0.00023784924,0.000032672542,0.000007855526,0.000094912626,0.000029057017,0.2265328,0.000036691225,0.0016799038,0.00007958775],"about_ca_topic_score_codex":0.00013209805,"about_ca_topic_score_gemma":0.000049029823,"teacher_disagreement_score":0.6265694,"about_ca_system_score_codex":0.000023343599,"about_ca_system_score_gemma":0.0004723402,"threshold_uncertainty_score":0.4099692},"labels":[],"label_agreement":null},{"id":"W2760959429","doi":"10.1093/annonc/mdx363.043","title":"EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Epidermal growth factor receptor; Liquid biopsy; Exon; Cancer research; Mutation; Deep sequencing; Osimertinib; Resistance mutation; Oncology; Gefitinib; Internal medicine; Cancer; Gene; Polymerase chain reaction; Biology; Erlotinib; Genetics; Genome","score_opus":0.04919668819991271,"score_gpt":0.4522982180161306,"score_spread":0.40310152981621794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760959429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401473,0.00005745096,0.000017989225,0.0045634992,0.00026057725,0.00031264103,0.00007890208,0.000014129469,0.05454756],"genre_scores_gemma":[0.997254,0.00008728393,0.0010713945,0.000623994,0.000047559322,0.00005469194,0.00014092613,0.000010080073,0.0007100762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999333,0.000027432558,0.00023129657,0.00015974932,0.00009321805,0.00015526556],"domain_scores_gemma":[0.99912554,0.000058025693,0.0001983736,0.00032175818,0.0002257287,0.000070565446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004223438,0.00008168648,0.00026131386,0.000045593704,0.00009677087,0.00000716302,0.00008649195,0.00009554624,0.00029252065],"category_scores_gemma":[0.00021533713,0.00006429866,0.00004660489,0.000050817518,0.00008419744,0.000119291326,0.000028193215,0.00008490493,0.00005535123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044604996,0.0013056864,0.80161303,0.0000120420455,0.00020733454,0.000034096032,0.0010766513,0.0000072833514,0.00078970444,0.0001799372,0.0055686473,0.18875952],"study_design_scores_gemma":[0.0052681346,0.0008097476,0.9518162,0.00005991011,0.00007530277,0.000001400279,0.000081646416,0.000015886817,0.0023067298,0.0006300615,0.038866486,0.00006850359],"about_ca_topic_score_codex":0.0008942058,"about_ca_topic_score_gemma":0.0010826926,"teacher_disagreement_score":0.188691,"about_ca_system_score_codex":0.000065761735,"about_ca_system_score_gemma":0.0002290371,"threshold_uncertainty_score":0.32028958},"labels":[],"label_agreement":null},{"id":"W2761006751","doi":"10.1093/annonc/mdx393.112","title":"Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Panitumumab; Cetuximab; Internal medicine; Colorectal cancer; Oncology; Population; Refractory (planetary science); Cohort; Epidermal growth factor receptor; Chemotherapy; Chemotherapy regimen; Cancer","score_opus":0.07152556101337543,"score_gpt":0.3899273340932189,"score_spread":0.31840177307984346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761006751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969292,0.0002501411,4.984283e-7,0.0009614634,0.00010568123,0.0010120891,0.00030959118,0.000007575605,0.00042374016],"genre_scores_gemma":[0.9995163,0.000100946396,0.000034502005,0.000096731805,0.000019800027,0.00011482933,0.00007546043,0.000016446053,0.000024966463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820817,0.00033321723,0.0005835336,0.0002588062,0.000371323,0.00024493207],"domain_scores_gemma":[0.99760365,0.000572166,0.00094114436,0.00026539818,0.00056949316,0.000048148784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028907883,0.00021564263,0.0010309123,0.00012305152,0.00013239517,0.000006536688,0.00018069288,0.00006696976,0.00004521962],"category_scores_gemma":[0.00042366193,0.0001291156,0.000091257796,0.00013650447,0.00021866501,0.00009408723,0.000044171164,0.0001298211,3.6190843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036416969,0.004674237,0.98182184,0.0001278529,0.00063057826,0.000017052356,0.0028881282,0.0000074873205,0.0005913603,0.0000047092167,0.00041520203,0.005179852],"study_design_scores_gemma":[0.0060797306,0.015629478,0.971976,0.0001060906,0.00023807336,6.5496636e-7,0.0021012106,0.000011270075,0.0036327208,0.000006218996,0.0001101302,0.00010844279],"about_ca_topic_score_codex":0.016400876,"about_ca_topic_score_gemma":0.009060535,"teacher_disagreement_score":0.010955241,"about_ca_system_score_codex":0.00009344099,"about_ca_system_score_gemma":0.00021387896,"threshold_uncertainty_score":0.990149},"labels":[],"label_agreement":null},{"id":"W2761052585","doi":"10.1093/annonc/mdx371.069","title":"The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Absolute neutrophil count; Neutrophil to lymphocyte ratio; Hazard ratio; Proportional hazards model; Germ cell tumors; Oncology; Receiver operating characteristic; Cohort; Chemotherapy; Cancer; Chemotherapy regimen; White blood cell; Gastroenterology; Lymphocyte; Confidence interval; Neutropenia","score_opus":0.024466757835031754,"score_gpt":0.31865273694404017,"score_spread":0.2941859791090084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761052585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938097,0.00028066055,0.0000026692874,0.0010830044,0.00007520237,0.0010719772,0.000018315648,0.000009312936,0.0036491756],"genre_scores_gemma":[0.99898463,0.000033821074,0.00045360837,0.0003176016,0.000024673986,0.00010680986,0.000008798225,0.000021314117,0.000048761387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985097,0.00015012425,0.00050789537,0.00021942833,0.0002921767,0.00032064447],"domain_scores_gemma":[0.99788034,0.00026623544,0.00063856365,0.0006387722,0.00043600923,0.00014010018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050410285,0.00015329082,0.00047681673,0.00013297763,0.00012675369,0.0000143467805,0.00033451244,0.000059747483,0.000018411847],"category_scores_gemma":[0.00062884926,0.000101708596,0.0000852426,0.00010716837,0.00038098963,0.00008440011,0.000119227334,0.0001015968,0.000014128226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004126279,0.0009616638,0.97207594,0.00016890543,0.00013538406,0.0000694986,0.00032273453,0.00001681078,0.00086397247,0.00014254377,0.00040495707,0.020711297],"study_design_scores_gemma":[0.003401366,0.0032498818,0.97878146,0.00011752431,0.00012251259,0.0000031799407,0.00012186041,0.00006432462,0.011939326,0.00017885314,0.0019182477,0.00010146532],"about_ca_topic_score_codex":0.000050467832,"about_ca_topic_score_gemma":0.000042484044,"teacher_disagreement_score":0.020609831,"about_ca_system_score_codex":0.000048728994,"about_ca_system_score_gemma":0.00053291774,"threshold_uncertainty_score":0.41475564},"labels":[],"label_agreement":null},{"id":"W2761091964","doi":"10.1093/annonc/mdx377","title":"Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Cohort; Post-hoc analysis; Oncology; Cancer; Immunotherapy","score_opus":0.05034381694852815,"score_gpt":0.33696388372828484,"score_spread":0.2866200667797567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761091964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996096,0.00010840167,0.000009254067,0.00271757,0.00008359636,0.0005857394,0.00006796981,0.0000051519596,0.00032629305],"genre_scores_gemma":[0.99854916,0.00082013995,0.00007513344,0.00025743787,0.000012616866,0.000014753422,0.000055272692,0.000012159051,0.00020329688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891025,0.00016038436,0.00044024963,0.00016690364,0.00017974293,0.0001424717],"domain_scores_gemma":[0.9982279,0.00017377894,0.00083506195,0.00036601088,0.00036864544,0.000028620636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038346904,0.00011182111,0.0005189207,0.00012533809,0.00007855722,0.0000055740525,0.00014660366,0.00009997759,0.00004630478],"category_scores_gemma":[0.00017618913,0.00007418381,0.000043731932,0.00010167449,0.0004592645,0.00014660804,0.00004097918,0.00008516256,4.0933642e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19622064,0.0014114071,0.36663285,0.00025146402,0.00032955257,0.000009450066,0.0021867657,0.0000013322939,0.26137823,0.000073771254,0.0001413511,0.1713632],"study_design_scores_gemma":[0.014746108,0.009456834,0.9508837,0.00028383255,0.000032000244,0.0000046559235,0.0001140712,0.000027967377,0.022193385,0.000025193387,0.0021568756,0.000075384036],"about_ca_topic_score_codex":0.00021870829,"about_ca_topic_score_gemma":0.0003111402,"teacher_disagreement_score":0.58425087,"about_ca_system_score_codex":0.000034093882,"about_ca_system_score_gemma":0.00015760117,"threshold_uncertainty_score":0.3025128},"labels":[],"label_agreement":null},{"id":"W2761093127","doi":"10.1093/annonc/mdx370.020","title":"Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic “hormone-sensitive” prostate cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Abiraterone acetate; Abiraterone; Oncology; Prostate cancer; Internal medicine; Population; Enzalutamide; Androgen deprivation therapy; Randomized controlled trial; Cancer","score_opus":0.2439804040378298,"score_gpt":0.5046447256598042,"score_spread":0.2606643216219744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761093127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858941,0.00849629,0.000008237797,0.003481624,0.000059050264,0.0010775474,0.00025912788,0.000005497611,0.0007185212],"genre_scores_gemma":[0.98720556,0.010977803,0.0006440082,0.00003504269,0.00002573436,0.00013297243,0.000031021144,0.000014457373,0.00093337847],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895203,0.000058005106,0.00039331344,0.00019944669,0.00013951081,0.00025768598],"domain_scores_gemma":[0.99852586,0.00015468305,0.0005528388,0.0002581464,0.0004120657,0.000096382166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022548657,0.00014054772,0.0011159681,0.00011552559,0.00008072447,0.000005621045,0.00006666251,0.0000621429,0.000010571609],"category_scores_gemma":[0.00006566725,0.00009680537,0.00010697981,0.000044539604,0.00052486977,0.00006842868,0.00003628284,0.000039891624,7.707993e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02420472,0.004195506,0.11475107,0.0013554782,0.004189741,0.00008791318,0.011537401,0.000020569649,0.1935628,0.0001488572,0.0021310237,0.6438149],"study_design_scores_gemma":[0.014076203,0.026646012,0.15892611,0.00013901886,0.0005748969,0.000011007913,0.000574103,0.00022748263,0.79224855,0.00026667936,0.006195165,0.00011476868],"about_ca_topic_score_codex":0.00052610924,"about_ca_topic_score_gemma":0.00015212627,"teacher_disagreement_score":0.6437001,"about_ca_system_score_codex":0.000047815964,"about_ca_system_score_gemma":0.00028970634,"threshold_uncertainty_score":0.39476085},"labels":[],"label_agreement":null},{"id":"W2761102138","doi":"10.1093/annonc/mdx361.056","title":"Integrated molecular signatures of TERT promoter deregulation predict disease outcomes in non-muscle invasive bladder cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Bladder cancer; Telomerase; DNA methylation; Medicine; Epigenetics; Promoter; Sanger sequencing; Cancer research; Cancer; Methylation; Bisulfite sequencing; Oncology; Internal medicine; Gene expression; Gene; Biology; Genetics; Mutation","score_opus":0.047165155117322596,"score_gpt":0.3831475053201856,"score_spread":0.335982350202863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761102138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911815,0.0004120098,0.000023451305,0.0057716314,0.00012820569,0.00060521974,0.000102476864,0.000008375579,0.0017671322],"genre_scores_gemma":[0.99848086,0.00013970751,0.00014326238,0.00083762646,0.00003580097,0.00008861971,0.000030033347,0.000016508691,0.00022760536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908966,0.000048446014,0.00029764092,0.00020889887,0.0001680956,0.00018723738],"domain_scores_gemma":[0.998984,0.000043964345,0.00025352123,0.00037376984,0.0002366461,0.000108113134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009550421,0.00014000513,0.0004667051,0.000116943556,0.000033807184,0.000005969429,0.0001399396,0.00013713092,0.00014430947],"category_scores_gemma":[0.00017312753,0.000104700695,0.00011527688,0.000054056665,0.00016802475,0.00009741616,0.00004802778,0.00011824797,0.0000021492808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017491693,0.001998403,0.8584025,0.00030588327,0.0009941919,0.0004073471,0.0010112552,0.000088281464,0.052306857,0.00006226602,0.0018236744,0.08085021],"study_design_scores_gemma":[0.0026031726,0.0011910293,0.9490027,0.00022097719,0.00016287684,0.0000014510247,0.00003773832,0.00008863932,0.04568709,0.00050621614,0.00041604345,0.00008209155],"about_ca_topic_score_codex":0.0013837924,"about_ca_topic_score_gemma":0.00056895346,"teacher_disagreement_score":0.09060021,"about_ca_system_score_codex":0.000043637123,"about_ca_system_score_gemma":0.0005545303,"threshold_uncertainty_score":0.42695707},"labels":[],"label_agreement":null},{"id":"W2761120197","doi":"10.1093/annonc/mdx369.115","title":"Prognosis of familial pancreatic cancer (FPC): A matched case analysis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pancreatic cancer; Gemcitabine; Internal medicine; Cohort; FOLFIRINOX; Stage (stratigraphy); Oncology; Cancer; Adjuvant therapy; Erlotinib; Pancreatectomy; Cancer registry; Germline mutation; Surgery; Pancreas; Irinotecan; Mutation; Colorectal cancer","score_opus":0.17931258922924465,"score_gpt":0.4931325103414037,"score_spread":0.31381992111215906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761120197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812943,0.00048161557,0.00005058727,0.005885643,0.00006921293,0.00044820574,0.000046133016,0.000019349976,0.011704961],"genre_scores_gemma":[0.9959909,0.0014114692,0.0012286288,0.0003055994,0.00010662411,0.00012624614,0.000008631109,0.000017011444,0.00080493884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998385,0.0001530696,0.0005709745,0.00026262936,0.00026204519,0.00036629618],"domain_scores_gemma":[0.9975719,0.0003569803,0.000584515,0.00068676507,0.00060662936,0.00019319831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077615195,0.0001420754,0.0016200276,0.00030534464,0.000116639116,0.000006629033,0.00022850622,0.00025483765,0.00044108203],"category_scores_gemma":[0.00077326724,0.000114092836,0.000332147,0.0002481641,0.00072856504,0.0000647605,0.000117471114,0.0001891743,0.000008526229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000930633,0.0007986128,0.96467763,0.00023490711,0.0043043094,0.0015765566,0.00061044295,0.000003372374,0.0021582108,0.00016569642,0.001831886,0.022707712],"study_design_scores_gemma":[0.0030891309,0.0041359873,0.9745801,0.00011169382,0.0064408192,0.00038504196,0.0005766778,0.001191678,0.0063232523,0.00030225798,0.002713105,0.00015021683],"about_ca_topic_score_codex":0.008117142,"about_ca_topic_score_gemma":0.0014333716,"teacher_disagreement_score":0.022557495,"about_ca_system_score_codex":0.00004752756,"about_ca_system_score_gemma":0.00073810294,"threshold_uncertainty_score":0.9984879},"labels":[],"label_agreement":null},{"id":"W2761156597","doi":"10.1093/annonc/mdx374.019","title":"Immune profile analysis of head and neck squamous cell carcinoma before and after neoadjuvant treatment with the IRX-2 regimen","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tumor microenvironment; Immune system; CD8; Head and neck squamous-cell carcinoma; Immunotherapy; Chemokine; Tumor-infiltrating lymphocytes; Cancer research; T cell; Oncology; Pathology; Internal medicine; Immunology; Cancer; Head and neck cancer","score_opus":0.030849452074828518,"score_gpt":0.3311706744289176,"score_spread":0.3003212223540891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761156597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852002,0.0047406172,0.0000012208566,0.0075146514,0.000021318436,0.00032772156,0.000032439144,0.0000035784328,0.0021582446],"genre_scores_gemma":[0.99800843,0.00048680464,0.000096186806,0.00030764524,0.000024382363,0.000039041115,0.000010867726,0.000008559165,0.0010180646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993262,0.000038581988,0.00021330295,0.00017362765,0.00009007701,0.00015817302],"domain_scores_gemma":[0.9990488,0.000048395108,0.00029762977,0.00046603422,0.00009059717,0.000048539674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016583959,0.00011819794,0.00053490436,0.00009128187,0.00008689649,0.0000084198455,0.00007580952,0.00007895282,0.000060535043],"category_scores_gemma":[0.000006909809,0.000062943356,0.00011364451,0.000082173836,0.00045475163,0.000039291786,0.0000378703,0.00005215971,4.1312353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022906804,0.0008948116,0.7174269,0.00015905302,0.0025174692,0.0001567931,0.006226177,0.0000011118988,0.012725173,0.000018906801,0.0007471016,0.23621969],"study_design_scores_gemma":[0.0043226983,0.016676242,0.9580842,0.000023473642,0.0010019362,0.00002675392,0.00034602487,0.00004908173,0.010961852,0.0000066863245,0.0084369965,0.000064022846],"about_ca_topic_score_codex":0.001986324,"about_ca_topic_score_gemma":0.0019875756,"teacher_disagreement_score":0.24065731,"about_ca_system_score_codex":0.00002389606,"about_ca_system_score_gemma":0.00010210345,"threshold_uncertainty_score":0.3002741},"labels":[],"label_agreement":null},{"id":"W2761180418","doi":"10.1093/annonc/mdx637","title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Public Health Agency","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cohort; Radiation therapy; Androgen deprivation therapy; Proportional hazards model; Concordance; Hazard ratio; Metastasis; Biopsy; Prostate; Prostate biopsy; Cancer; Urology","score_opus":0.08788200398846026,"score_gpt":0.42301228717324885,"score_spread":0.3351302831847886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761180418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972508,0.000155187,0.000032888995,0.0010900744,0.00002098201,0.0012728862,0.00007880298,0.000005343799,0.00009306476],"genre_scores_gemma":[0.998558,0.00055216206,0.00060907466,0.00003422609,0.000014578769,0.00009619198,0.00008002327,0.000012183039,0.00004357764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902856,0.00013095363,0.00024991593,0.00018938744,0.00022780111,0.00017338422],"domain_scores_gemma":[0.99876744,0.000057448204,0.0004453642,0.00023661391,0.00042526063,0.000067906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003538234,0.00010107093,0.0003286594,0.00017418402,0.00006727966,0.000012305107,0.00006585246,0.000050657043,0.000016071313],"category_scores_gemma":[0.00009019226,0.00006243368,0.00002434444,0.00015061391,0.00017749878,0.0001532948,0.000010262934,0.000086115484,5.9928965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105512645,0.0007097763,0.8368367,0.000050157145,0.00024546066,0.0000056678514,0.00078438397,0.00015714452,0.00977726,0.0000078209605,0.000023968892,0.14085038],"study_design_scores_gemma":[0.007630628,0.007975147,0.8112727,0.00009793131,0.000075830525,6.5431834e-7,0.00006674245,0.0002521989,0.17243887,0.000033334494,0.00008831069,0.00006765218],"about_ca_topic_score_codex":0.0016933887,"about_ca_topic_score_gemma":0.00011133123,"teacher_disagreement_score":0.16266161,"about_ca_system_score_codex":0.00009475252,"about_ca_system_score_gemma":0.00041927103,"threshold_uncertainty_score":0.25599083},"labels":[],"label_agreement":null},{"id":"W2761220959","doi":"10.1093/annonc/mdx368.013","title":"Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): Consensus guidelines from the Commonwealth NET collaboration (CommNETs) in conjunction with the North American NET Society (NANETS)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Population; MEDLINE; Multidisciplinary approach; Family medicine; Internal medicine","score_opus":0.1523359268620207,"score_gpt":0.43699148573927415,"score_spread":0.28465555887725347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761220959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6476891,0.00010261799,0.000051343664,0.3500261,0.00018134499,0.0014415208,0.00035626246,0.000028800861,0.00012287937],"genre_scores_gemma":[0.981777,0.001015962,0.0019463017,0.013882267,0.00025230373,0.0002875641,0.00056795235,0.00004758155,0.00022307351],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9970093,0.000675378,0.0007907171,0.0004642869,0.00037340017,0.00068692793],"domain_scores_gemma":[0.99453807,0.0019044019,0.0011301138,0.0010381485,0.001213936,0.00017533074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046718906,0.00028887994,0.00084200315,0.0000877323,0.00063797494,0.00007765952,0.00057534315,0.0000126308105,0.00002571613],"category_scores_gemma":[0.0016228983,0.00018094735,0.00014506018,0.00036904035,0.0011956301,0.00013993157,0.0001705568,0.00049837446,0.0000038447947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007228217,0.00034597606,0.29215923,0.00004533345,0.00022066847,0.00016651196,0.00023054365,0.0003286502,0.00060312613,0.00007218264,0.69168705,0.0069124973],"study_design_scores_gemma":[0.011177729,0.015961451,0.66451764,0.00015005951,0.00019569711,0.00043360662,0.003230434,0.003827957,0.000673736,0.00015710075,0.29943377,0.00024085683],"about_ca_topic_score_codex":0.006632761,"about_ca_topic_score_gemma":0.12116996,"teacher_disagreement_score":0.39225328,"about_ca_system_score_codex":0.0000869548,"about_ca_system_score_gemma":0.00049525226,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W2761301751","doi":"10.1093/annonc/mdx375.008","title":"Real world comparison of common patient reported symptoms with health utility scores in cancer outpatients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; Hôpital du Sacré-Cœur de Montréal; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Depression (economics); Anxiety; Quality of life (healthcare); Cancer; Physical therapy; Internal medicine; Psychiatry","score_opus":0.675164494756163,"score_gpt":0.5775445898670116,"score_spread":0.0976199048891514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761301751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696846,0.0008094144,0.000020272832,0.02019296,0.0004002398,0.00066632795,0.00020304215,0.00001077751,0.008012366],"genre_scores_gemma":[0.9971596,0.00021297164,0.00031940962,0.0020855186,0.000043160453,0.0000732114,0.000023888271,0.000015509977,0.00006673406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935123,0.0003657769,0.005202014,0.0004207083,0.000112250054,0.00038696654],"domain_scores_gemma":[0.9872382,0.00042037218,0.011177461,0.00085928914,0.00015959144,0.00014508657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068741567,0.00015220251,0.0019590855,0.00034323582,0.0001534891,0.000015411988,0.00033838235,0.00011827539,0.00009998847],"category_scores_gemma":[0.0009132523,0.00017027039,0.000082008075,0.00012117547,0.00027654142,0.00024028457,0.00008970036,0.0001859993,0.000016303798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014554705,0.00075793325,0.9768489,0.0002235142,0.00007331001,0.0000012606351,0.003239466,0.00010508658,3.695943e-7,0.0036851384,0.0057888143,0.009130682],"study_design_scores_gemma":[0.0010304858,0.0017226583,0.98495644,0.00023451363,0.0000038207704,6.630337e-7,0.00041288233,0.0009591489,0.0000439075,0.0014969961,0.008992212,0.00014626938],"about_ca_topic_score_codex":0.079342104,"about_ca_topic_score_gemma":0.07335739,"teacher_disagreement_score":0.027474996,"about_ca_system_score_codex":0.00032952003,"about_ca_system_score_gemma":0.0005458951,"threshold_uncertainty_score":0.9435514},"labels":[],"label_agreement":null},{"id":"W2761304093","doi":"10.1093/annonc/mdx388.056","title":"Cancer patient attitudes and preferences towards smoking status assessment","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Cancer; Logistic regression; Family medicine; Multivariate analysis; Head and neck cancer; Health care; Physical therapy; Internal medicine; Pathology","score_opus":0.18379671836573858,"score_gpt":0.48965540836306864,"score_spread":0.30585868999733007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761304093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857758,0.000232991,0.0000080836135,0.0020633088,0.00026032998,0.0001186199,0.000012051282,0.000009851145,0.01151896],"genre_scores_gemma":[0.9980994,0.0013345233,0.00012206619,0.00030444632,0.00005135317,0.000028489187,0.000007413477,0.0000050216518,0.000047307232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993656,0.00002700836,0.00015428352,0.00013408663,0.0001666196,0.00015237315],"domain_scores_gemma":[0.99935544,0.000025623085,0.00020870968,0.00018583152,0.00015652383,0.00006786575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015451413,0.00006600487,0.0002162198,0.00004141897,0.00010676692,0.00001790543,0.000056116965,0.00008454523,0.0001501952],"category_scores_gemma":[0.00005541798,0.000052514733,0.000029050108,0.000015817941,0.0001272568,0.00007858703,0.000056582063,0.0001003706,1.8822402e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029224368,0.00010004422,0.62057227,0.000027234188,0.00003446452,0.0000054406064,0.00024959788,4.892544e-7,0.000342936,0.00008545767,0.00027328296,0.37827957],"study_design_scores_gemma":[0.0004999842,0.0014190044,0.98565674,0.000084327046,0.000059376885,0.0000043036252,0.0001319261,0.000004042017,0.004634311,0.00014166512,0.007313215,0.000051108545],"about_ca_topic_score_codex":0.001436791,"about_ca_topic_score_gemma":0.00013814104,"teacher_disagreement_score":0.37822846,"about_ca_system_score_codex":0.000038579332,"about_ca_system_score_gemma":0.00026171497,"threshold_uncertainty_score":0.21720079},"labels":[],"label_agreement":null},{"id":"W2761355884","doi":"10.1093/annonc/mdx440.045","title":"Impact of licensing and reimbursement discrepancies on patient access to cancer treatments across Europe and Canada","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reimbursement; Population; Years of potential life lost; Demography; Family medicine; Environmental health; Life expectancy; Health care; Economic growth","score_opus":0.5895300875360997,"score_gpt":0.5825428661378887,"score_spread":0.006987221398210952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761355884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670136,0.00059824274,0.000004445615,0.029592,0.00023639419,0.00033457292,0.0006379212,0.0000027408507,0.0015800853],"genre_scores_gemma":[0.9950198,0.00068617205,0.00009472918,0.0040176604,0.00004990142,0.000024123452,0.0000039444653,0.000010609229,0.000093037655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804276,0.00008889864,0.0012597082,0.00029116194,0.000054390424,0.00026307127],"domain_scores_gemma":[0.9971748,0.00026408362,0.0019269187,0.00036632433,0.00011143141,0.0001564647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016169029,0.000115689574,0.00073164393,0.00007098184,0.00019361041,0.000046584122,0.00016716044,0.000052185693,0.00003343427],"category_scores_gemma":[0.001245631,0.000117530944,0.00003970794,0.000030881107,0.000096145784,0.00020870227,0.00014676397,0.000049119513,0.000004732981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013677907,0.0001807239,0.95212847,0.00011848897,0.0002935764,0.0000038636244,0.0029560842,0.0002944854,0.000020042788,0.0015588137,0.020601971,0.021706717],"study_design_scores_gemma":[0.00046354102,0.0012106175,0.97401565,0.000071962,0.0000051999023,0.0000014280516,0.0001717349,0.000083859646,0.000081369,0.00019019232,0.023592466,0.00011195779],"about_ca_topic_score_codex":0.8046767,"about_ca_topic_score_gemma":0.5097097,"teacher_disagreement_score":0.29496697,"about_ca_system_score_codex":0.00026375562,"about_ca_system_score_gemma":0.00037026618,"threshold_uncertainty_score":0.4992368},"labels":[],"label_agreement":null},{"id":"W2761389141","doi":"10.1093/annonc/mdx368.016","title":"Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carcinoid syndrome; Gastroenterology; Internal medicine; Octreotide; Carcinoid Heart Disease; Metanephrines; Somatostatin; Urinary system","score_opus":0.07375205398455316,"score_gpt":0.3775186508586257,"score_spread":0.30376659687407254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761389141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96753573,0.00041031404,0.0000027425615,0.023681054,0.00023423572,0.00039439622,0.00009930265,0.0000308611,0.007611351],"genre_scores_gemma":[0.99623567,0.0009432566,0.00071757764,0.0012887128,0.000051127427,0.0000071307163,0.000016020209,0.000038744285,0.0007017445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766296,0.0002557029,0.0005948977,0.00043781087,0.0004872001,0.0005614022],"domain_scores_gemma":[0.9974555,0.00029236265,0.0006463675,0.0009850739,0.00034567286,0.00027507055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014645391,0.00022804951,0.00085599435,0.00008108752,0.00012516686,0.000012868417,0.00056194083,0.000011199671,0.0002484829],"category_scores_gemma":[0.0009214907,0.00019054403,0.00034355218,0.00007018615,0.0005284348,0.00014163238,0.00056832354,0.00033663132,0.00004441852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013091908,0.0032002244,0.6987053,0.0005713653,0.00061156746,0.050708495,0.00086842396,0.00002897657,0.08315948,0.00012077244,0.06466429,0.096051894],"study_design_scores_gemma":[0.0041826474,0.006816254,0.8007103,0.00020410851,0.00010231063,0.0013982678,0.00055095897,0.00008474499,0.13002117,0.00025481847,0.055401657,0.00027272516],"about_ca_topic_score_codex":0.000637395,"about_ca_topic_score_gemma":0.000055483848,"teacher_disagreement_score":0.102005005,"about_ca_system_score_codex":0.000024483661,"about_ca_system_score_gemma":0.00016833743,"threshold_uncertainty_score":0.777016},"labels":[],"label_agreement":null},{"id":"W2761393054","doi":"10.1093/annonc/mdx375.009","title":"Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Jewish General Hospital; Sunnybrook Health Science Centre; University of Toronto; Hôpital Notre-Dame; Queen's University; McMaster University; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Internal medicine; Lung cancer; Oncology; Placebo; Cancer; Pathology","score_opus":0.05790885297384296,"score_gpt":0.37695647449262687,"score_spread":0.3190476215187839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761393054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614072,0.00011702409,0.0000035931018,0.00077327,0.00017587845,0.0006052453,0.000038531656,0.000020725607,0.036858566],"genre_scores_gemma":[0.9987525,0.00023903356,0.00029010934,0.00040497078,0.000026757227,0.000026353493,0.00008359802,0.000024316367,0.0001523818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987415,0.000089959525,0.00040904572,0.00026366912,0.00019086343,0.00030496268],"domain_scores_gemma":[0.9982164,0.00026949655,0.00050986855,0.00047999763,0.00041121422,0.00011303069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017386193,0.00015892248,0.0006629979,0.00014941537,0.000054146425,0.000004349228,0.00020375928,0.00016862895,0.00015806046],"category_scores_gemma":[0.00046346697,0.00013619525,0.00006479525,0.00011802213,0.00026471072,0.00014782646,0.000045940258,0.00021288298,0.0000065936542],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16927734,0.0026357379,0.3754861,0.00026638506,0.00067833473,0.00017518616,0.0011650327,0.000103756145,0.00884544,0.00014409685,0.0066961762,0.4345264],"study_design_scores_gemma":[0.09634224,0.030027183,0.8234025,0.0004700037,0.00011749337,0.000010213574,0.00018173763,0.00023711882,0.031241018,0.000018213355,0.017657593,0.00029465716],"about_ca_topic_score_codex":0.00041164208,"about_ca_topic_score_gemma":0.0011345119,"teacher_disagreement_score":0.44791642,"about_ca_system_score_codex":0.000126329,"about_ca_system_score_gemma":0.0005262309,"threshold_uncertainty_score":0.5553881},"labels":[],"label_agreement":null},{"id":"W2761441866","doi":"10.1093/annonc/mdx365.027","title":"Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Capecitabine; Progression-free survival; Gastroenterology; Neratinib; Oncology; Hazard ratio; Trastuzumab; Surgery; Cancer; Breast cancer; Chemotherapy; Confidence interval; Colorectal cancer","score_opus":0.10330412980613862,"score_gpt":0.48193589572345796,"score_spread":0.37863176591731934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761441866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901219,0.0019934266,0.0000134686625,0.005425852,0.000054810756,0.0011516738,0.001163832,0.0000087754015,0.00006624281],"genre_scores_gemma":[0.99451035,0.000822535,0.0041038147,0.00015945041,0.000018875027,0.00020764863,0.00011108451,0.000024382918,0.00004186319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744725,0.0003705668,0.00085806655,0.00044473572,0.00053905597,0.00034033007],"domain_scores_gemma":[0.99612904,0.00055716885,0.0015540617,0.0008003703,0.00079049,0.00016886431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012008372,0.0003076356,0.002222809,0.00045790095,0.00011811341,0.000010794493,0.00020521444,0.00007876221,0.00011342203],"category_scores_gemma":[0.00087271363,0.0001772536,0.00019052789,0.0004888788,0.0007254552,0.0001524843,0.00021754918,0.00013141862,4.09706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01041444,0.009818062,0.82122505,0.0008989954,0.011539677,0.00015002755,0.0022371234,0.00001641424,0.00016110006,0.00002656059,0.0004837079,0.14302886],"study_design_scores_gemma":[0.053505708,0.035341073,0.87951016,0.0032805472,0.019165961,0.00004928289,0.0032786375,0.0006581012,0.003519453,0.00008699686,0.0011432962,0.000460782],"about_ca_topic_score_codex":0.0010488657,"about_ca_topic_score_gemma":0.011628475,"teacher_disagreement_score":0.14256807,"about_ca_system_score_codex":0.000054234322,"about_ca_system_score_gemma":0.00031074422,"threshold_uncertainty_score":0.7228192},"labels":[],"label_agreement":null},{"id":"W2761447110","doi":"10.1093/annonc/mdx390.031","title":"Role of UBR5 mutations in DNA damage response in mantle cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mantle cell lymphoma; Biology; Proteome; Cancer research; Ubiquitin ligase; Immunoprecipitation; Proteomics; Molecular biology; Genetics; Gene; Ubiquitin; Lymphoma; Immunology","score_opus":0.038171062665676485,"score_gpt":0.3412954344685325,"score_spread":0.303124371802856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761447110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97866523,0.00028678734,0.000004087294,0.0005199326,0.00003466095,0.00012306485,0.00003530312,0.0000016711467,0.020329243],"genre_scores_gemma":[0.9991811,0.00011935311,0.00023176003,0.00013184006,0.000025468324,0.000018626644,0.000020796651,0.000008334203,0.00026275142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919015,0.00018060661,0.00024417826,0.00016141238,0.000052767096,0.00017086919],"domain_scores_gemma":[0.99927294,0.000048205853,0.00020721095,0.0003700604,0.00006645619,0.00003514382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005587839,0.00007398525,0.00018740543,0.000087805565,0.000033662796,0.000004559556,0.00026463284,0.00017294892,0.000025099098],"category_scores_gemma":[0.00029107323,0.00007859673,0.000053050724,0.0000392022,0.00014941531,0.0000049651503,0.000119676915,0.000045578963,0.0000067212627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009925577,0.0003823404,0.0056048627,0.000017855536,0.000007689895,0.000016143216,0.00027684332,0.000015750315,0.9837443,0.00010520622,0.00019293421,0.008643469],"study_design_scores_gemma":[0.0011126596,0.0011493964,0.12664156,0.0000136938725,0.0000024808098,0.000003393024,0.0001887344,0.000026546764,0.85413736,0.00060210406,0.016051123,0.000070971364],"about_ca_topic_score_codex":0.0001440292,"about_ca_topic_score_gemma":0.0003478274,"teacher_disagreement_score":0.129607,"about_ca_system_score_codex":0.0000075554367,"about_ca_system_score_gemma":0.00019634987,"threshold_uncertainty_score":0.32050815},"labels":[],"label_agreement":null},{"id":"W2761452338","doi":"10.1093/annonc/mdx440.005","title":"Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tumor-infiltrating lymphocytes; Cohort; Internal medicine; Oncology; Breast cancer; Triple-negative breast cancer; Lymph node; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.1800278887842173,"score_gpt":0.4355927975528641,"score_spread":0.2555649087686468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761452338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735937,0.0004964266,0.000018945384,0.022590654,0.00015185276,0.0006098506,0.0014426258,0.000018026136,0.0010779127],"genre_scores_gemma":[0.99656844,0.00008603065,0.0010492973,0.0016789321,0.00013478739,0.000058736245,0.00002437981,0.000024529178,0.00037489462],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99759036,0.000497306,0.00087155873,0.00043719652,0.00023562432,0.0003679236],"domain_scores_gemma":[0.99546874,0.0028747586,0.000707398,0.0005445735,0.0002203222,0.00018421818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016740017,0.0002250721,0.0007893217,0.00028925203,0.00020587776,0.000035346435,0.0002239877,0.00014192714,0.00006251775],"category_scores_gemma":[0.003912494,0.00020380455,0.00010906084,0.00021603839,0.00033606222,0.0002206808,0.00008877303,0.00025323092,0.0000076005986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40504187,0.00035586412,0.35497954,0.00011984784,0.00063377165,0.00029906706,0.012889508,0.000027874366,0.024373801,0.000058772486,0.0026232284,0.19859686],"study_design_scores_gemma":[0.021365471,0.0014990055,0.96596634,0.00038622864,0.000093972325,0.000053998858,0.0006418939,0.000036939095,0.0073295175,0.00042972193,0.0020025908,0.00019434182],"about_ca_topic_score_codex":0.014798441,"about_ca_topic_score_gemma":0.002490331,"teacher_disagreement_score":0.61098677,"about_ca_system_score_codex":0.0002823111,"about_ca_system_score_gemma":0.0011900873,"threshold_uncertainty_score":0.9917621},"labels":[],"label_agreement":null},{"id":"W2761480337","doi":"10.1093/annonc/mdx372.057","title":"A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Debulking; Internal medicine; Ovarian cancer; Tolerability; Oncology; Chemotherapy; Placebo; Maintenance therapy; Surgery; Cancer; Adverse effect; Pathology","score_opus":0.07278291588345867,"score_gpt":0.43210840106546566,"score_spread":0.359325485182007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761480337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98370224,0.0003079948,0.00020314228,0.005058497,0.00057468447,0.008051662,0.000043923115,0.000015553298,0.0020422956],"genre_scores_gemma":[0.9948408,0.000806964,0.00090551004,0.00078361935,0.00016319953,0.0020729725,0.00003162316,0.00003641971,0.00035888221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772316,0.00020051289,0.0010096598,0.0003738421,0.00030598303,0.00038681296],"domain_scores_gemma":[0.9972794,0.00029135722,0.0013485483,0.000608233,0.000354698,0.00011773865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081843,0.0002901018,0.0025032063,0.00019584133,0.00007305355,0.000010232769,0.00018570905,0.0001789883,0.00015138545],"category_scores_gemma":[0.00017576289,0.00019597179,0.00047903566,0.00007896942,0.00030365106,0.00016592395,0.000019774183,0.00015128996,0.0000019367799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9525692,0.005891161,0.0027921717,0.000025316676,0.0015568997,0.000024398916,0.00055612525,0.000044327666,0.00041445703,0.000033375232,0.00012301785,0.03596957],"study_design_scores_gemma":[0.9752372,0.014760352,0.00061467924,0.00033527694,0.0002753874,8.5074106e-7,0.000038655464,0.00016723687,0.0059123137,0.00004509554,0.0024517893,0.00016115836],"about_ca_topic_score_codex":0.0006501437,"about_ca_topic_score_gemma":0.00036450324,"teacher_disagreement_score":0.035808414,"about_ca_system_score_codex":0.00022379802,"about_ca_system_score_gemma":0.00044568107,"threshold_uncertainty_score":0.79914975},"labels":[],"label_agreement":null},{"id":"W2761499066","doi":"10.1093/annonc/mdx362.027","title":"Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Breast cancer; Quality of life (healthcare); Oncology; Stage (stratigraphy); Health related quality of life; Internal medicine; Gerontology; Cancer; Gynecology; Trastuzumab; Disease; Nursing","score_opus":0.22954304827326835,"score_gpt":0.5096455933815812,"score_spread":0.2801025451083129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761499066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888797,0.0019360721,0.0000034419563,0.0070189224,0.00030760327,0.00111535,0.0003469047,0.000009825248,0.00037390966],"genre_scores_gemma":[0.997656,0.0012651546,0.000045278186,0.00056855567,0.00020239297,0.00006639376,0.000054328106,0.000017841305,0.00012407616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968887,0.0007256961,0.0013233473,0.00036236426,0.00036292867,0.0003369478],"domain_scores_gemma":[0.99537313,0.0014826364,0.0019602065,0.00081670465,0.0001978979,0.00016942593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010170696,0.0002248181,0.0016935491,0.00010377832,0.000096982476,0.000007120806,0.00030157645,0.0002282122,0.00026067795],"category_scores_gemma":[0.0010109342,0.00015515694,0.00025184144,0.00013130659,0.00041430083,0.0000792069,0.000085132655,0.00032075215,0.000004411058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50082237,0.021034963,0.2647671,0.0010827737,0.006505191,0.00041374005,0.0052816775,0.00028542234,0.012127448,0.00048489944,0.013621506,0.17357288],"study_design_scores_gemma":[0.16579853,0.009005282,0.8150625,0.00041186687,0.00020428014,0.000003195112,0.000079284095,0.00007251173,0.008879022,0.00006762329,0.0003043269,0.00011155695],"about_ca_topic_score_codex":0.2749864,"about_ca_topic_score_gemma":0.014459964,"teacher_disagreement_score":0.5502954,"about_ca_system_score_codex":0.00023593547,"about_ca_system_score_gemma":0.0018565761,"threshold_uncertainty_score":0.8068999},"labels":[],"label_agreement":null},{"id":"W2761520588","doi":"10.1093/annonc/mdx369.013","title":"Sarcopenia, myosteatosis, and weight loss as determinants of survival and toxicity in patients with resectable esophageal and gastroesophageal junction (GEJ) cancer receiving preoperative chemoradiotherapy (CRT)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sarcopenia; Medicine; Chemoradiotherapy; Internal medicine; Gastroenterology; Esophageal cancer; Univariate analysis; Adenocarcinoma; Urology; Oncology; Cancer; Multivariate analysis","score_opus":0.04531772916964162,"score_gpt":0.391579484886242,"score_spread":0.3462617557166004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761520588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965178,0.0010262622,0.0000024345388,0.001323151,0.000088593326,0.00043286083,0.000015930482,0.000004848249,0.00058814144],"genre_scores_gemma":[0.99601144,0.0030171205,0.00040082762,0.0003523734,0.000060835708,0.000019861047,0.0000035556639,0.000012763368,0.00012123609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989554,0.00010900696,0.0003028724,0.00025204918,0.0001464673,0.0002341565],"domain_scores_gemma":[0.9991589,0.00008139884,0.00028178512,0.00016342376,0.00018356873,0.00013092883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040790238,0.00012350456,0.0006225097,0.00012646805,0.00014306986,0.000012947336,0.000054512988,0.00010724905,0.00004336983],"category_scores_gemma":[0.000084770705,0.00010189568,0.00001558818,0.000061241386,0.00034027026,0.00019393557,0.00004949746,0.00016312773,2.278017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002604349,0.00023974924,0.97587764,0.00031862626,0.000027814618,0.000024753372,0.0005934659,2.9730535e-7,0.00045522905,0.000015494477,0.00007494644,0.019767625],"study_design_scores_gemma":[0.007015313,0.0037248936,0.9737945,0.0004160187,0.00001969617,0.000019858953,0.000050016934,0.00003841951,0.014671398,0.00004072343,0.00014094105,0.0000681931],"about_ca_topic_score_codex":0.000810566,"about_ca_topic_score_gemma":0.0010141209,"teacher_disagreement_score":0.019699432,"about_ca_system_score_codex":0.000039935123,"about_ca_system_score_gemma":0.0001530096,"threshold_uncertainty_score":0.41551852},"labels":[],"label_agreement":null},{"id":"W2761532450","doi":"10.1093/annonc/mdx365.025","title":"PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Progression-free survival; Surrogate endpoint; Oncology; Clinical endpoint; Randomized controlled trial; Pearson product-moment correlation coefficient; Overall survival; Statistics","score_opus":0.10834300483768006,"score_gpt":0.47686343894957156,"score_spread":0.3685204341118915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761532450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94744956,0.0010694994,0.00042765902,0.03981147,0.0005289486,0.00067635387,0.000022530297,0.000029825376,0.0099841375],"genre_scores_gemma":[0.9945482,0.00017946586,0.001597896,0.0019730371,0.00028800505,0.000074321055,0.000007263872,0.000022630005,0.0013091743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903107,0.0000368679,0.00027293633,0.0002179521,0.00011608584,0.00032508044],"domain_scores_gemma":[0.9989167,0.00008860956,0.00027288488,0.00041280664,0.00022031993,0.00008867256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030917823,0.00011667745,0.00047949198,0.00009211257,0.000076957665,0.000006893733,0.00019586239,0.00014685665,0.00014027089],"category_scores_gemma":[0.00030426568,0.00010790372,0.00012131402,0.00003711762,0.00024331744,0.00012038632,0.00006120693,0.00013051265,0.000026880547],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009258564,0.00091726746,0.0079266345,0.00020073762,0.0002815812,0.00040012848,0.00086808746,0.000059122387,0.035460018,0.0016565513,0.002367715,0.9406036],"study_design_scores_gemma":[0.022936337,0.012787003,0.124536425,0.00036787678,0.00011492007,0.00047271396,0.0007858233,0.00021576935,0.07064698,0.027955463,0.73873264,0.00044803802],"about_ca_topic_score_codex":0.00027863367,"about_ca_topic_score_gemma":0.00026292496,"teacher_disagreement_score":0.94015557,"about_ca_system_score_codex":0.000044763914,"about_ca_system_score_gemma":0.0002584353,"threshold_uncertainty_score":0.4400186},"labels":[],"label_agreement":null},{"id":"W2761538011","doi":"10.1093/annonc/mdx369.155","title":"PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Docetaxel; Medicine; Regimen; Neutropenia; Oxaliplatin; Internal medicine; FOLFOX; Taxane; Folinic acid; Febrile neutropenia; Gastroenterology; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cancer; Fluorouracil; Colorectal cancer; Breast cancer","score_opus":0.18879329840720196,"score_gpt":0.4860872129868768,"score_spread":0.2972939145796748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761538011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96817,0.0007159146,0.0059079374,0.0092603,0.00052609015,0.013507908,0.00003532315,0.00008778846,0.0017887673],"genre_scores_gemma":[0.9660889,0.000383335,0.01942573,0.0030029109,0.00069199986,0.0013093922,0.000057338755,0.00008962594,0.008950759],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968183,0.00013449111,0.0010870972,0.0006569867,0.00057223235,0.00073089165],"domain_scores_gemma":[0.99604046,0.0006122892,0.0015608846,0.000859703,0.00066643633,0.00026021915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016975227,0.00045335575,0.0020531537,0.0002942141,0.00030628903,0.000058416743,0.00046897418,0.00012922249,0.00048813436],"category_scores_gemma":[0.0018573237,0.00028424035,0.00034359423,0.00024454077,0.00031649906,0.0002838198,0.00008908565,0.00023959603,0.000009676954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74990594,0.0014674682,0.00072352623,0.0002930975,0.0009397924,0.00016581034,0.0003358329,0.000020994654,0.0004920117,0.00003043349,0.0017500046,0.2438751],"study_design_scores_gemma":[0.8548915,0.1308779,0.0011277328,0.00022591,0.0014220237,0.00014133558,0.0003657052,0.0015403685,0.002358487,0.00014579047,0.006590112,0.00031314106],"about_ca_topic_score_codex":0.00008507975,"about_ca_topic_score_gemma":0.00014535974,"teacher_disagreement_score":0.24356195,"about_ca_system_score_codex":0.000086723725,"about_ca_system_score_gemma":0.0015616905,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W2761612944","doi":"10.1093/annonc/mdx371.037","title":"Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Metastasis; Proportional hazards model; Oncology; Nephrectomy; Disease; Performance status; Gastroenterology; Cancer; Kidney","score_opus":0.07206200555757965,"score_gpt":0.37027241758150353,"score_spread":0.2982104120239239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761612944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462813,0.0006745974,0.000010389035,0.00053803367,0.00002776335,0.0018748138,0.00034763603,0.000019104296,0.001879527],"genre_scores_gemma":[0.9978709,0.000067236855,0.0010555016,0.00025296223,0.000018097284,0.00011999132,0.00018353135,0.000069162175,0.00036257406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679357,0.00043683755,0.0009689784,0.0005914831,0.0005649314,0.0006441924],"domain_scores_gemma":[0.99646723,0.0002987202,0.00095554115,0.0012499721,0.00047861386,0.0005499484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047691807,0.0005351913,0.0020845071,0.00062122,0.00010001063,0.000018387578,0.00037024618,0.00006574635,0.0005838555],"category_scores_gemma":[0.00019808163,0.0003483285,0.0005360123,0.00027970105,0.00024582373,0.00014871823,0.000064091306,0.00020986663,0.00010539773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037502926,0.014243196,0.90610564,0.00038081128,0.003653495,0.0028435222,0.0006903534,0.0013800277,0.00709912,0.000010408362,0.0011163335,0.024974165],"study_design_scores_gemma":[0.009826913,0.05645424,0.8959944,0.00007699278,0.00096364116,0.000018994017,0.000018893108,0.00011485967,0.03605485,0.0000141176615,0.0001871172,0.00027496633],"about_ca_topic_score_codex":0.0021293943,"about_ca_topic_score_gemma":0.00007411157,"teacher_disagreement_score":0.042211045,"about_ca_system_score_codex":0.00038617093,"about_ca_system_score_gemma":0.0008011233,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W2761652264","doi":"10.1093/annonc/mdx372.059","title":"ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; BRCA mutation; PARP inhibitor; Internal medicine; Oncology; Olaparib; Chemotherapy; Regimen; Ovarian cancer; Chemotherapy regimen; Cancer; Poly ADP ribose polymerase; Genetics; Biology; Polymerase","score_opus":0.12541029186495134,"score_gpt":0.4641550448215745,"score_spread":0.33874475295662315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761652264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718516,0.00036615317,0.000078569974,0.023050789,0.0012586842,0.002875936,0.00017452406,0.000012424739,0.00033130735],"genre_scores_gemma":[0.99436873,0.0026901138,0.0001890044,0.0011223583,0.0005181348,0.0007529485,0.000018235916,0.000028884515,0.00031155843],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835914,0.00016550189,0.0006906434,0.00027777505,0.00029468388,0.00021225748],"domain_scores_gemma":[0.9968309,0.0004457384,0.0011782353,0.0009826595,0.00048744908,0.00007501887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049668364,0.00019380427,0.00076787616,0.00007952774,0.00019664712,0.000012516431,0.00047787436,0.00014187067,0.00018746709],"category_scores_gemma":[0.00012696772,0.00011234878,0.0002640493,0.00007824807,0.00046033485,0.000107003994,0.000025907668,0.000109782835,6.320328e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33773518,0.07243951,0.03334602,0.000180523,0.010396469,0.00003828507,0.03954868,0.00047433088,0.15535001,0.0017516674,0.018332042,0.3304073],"study_design_scores_gemma":[0.3966364,0.035989568,0.028875053,0.0001463421,0.00061013945,0.00001586768,0.0014005664,0.00031456698,0.42960688,0.0009930647,0.10520281,0.00020874299],"about_ca_topic_score_codex":0.0019347173,"about_ca_topic_score_gemma":0.00046843477,"teacher_disagreement_score":0.33019856,"about_ca_system_score_codex":0.00011950662,"about_ca_system_score_gemma":0.0004036174,"threshold_uncertainty_score":0.45814502},"labels":[],"label_agreement":null},{"id":"W2761654623","doi":"10.1093/annonc/mdx388.037","title":"Current perspectives of healthcare providers on weight loss and supportive nutritional care in cancer patients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Weight loss; Malnutrition; Discontinuation; Quality of life (healthcare); Wasting; Cachexia; Cancer; Weight management; Distress; Palliative care; Internal medicine; Obesity; Nursing","score_opus":0.1181305947736017,"score_gpt":0.493572153001959,"score_spread":0.3754415582283573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761654623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9390465,0.0053812233,3.2217955e-7,0.053938895,0.0001701119,0.0004205067,0.00012683526,0.0000039468637,0.0009116475],"genre_scores_gemma":[0.9914682,0.007538517,0.000058614616,0.0007693286,0.00008476656,0.000042056177,0.000023948158,0.0000057086813,0.000008857079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991952,0.000053401876,0.0002718605,0.00017251655,0.00014076004,0.0001662374],"domain_scores_gemma":[0.99889517,0.000051594703,0.00027955053,0.00012020262,0.00055445137,0.00009903127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010361078,0.00007165156,0.0003259058,0.00013975425,0.00006879211,0.0000023158093,0.00005154606,0.00007239948,0.000041590323],"category_scores_gemma":[0.00010253226,0.00006537242,0.000039930263,0.000032838845,0.00023536762,0.00005539553,0.000025422532,0.00017361267,8.165856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013780665,0.0014673574,0.9178986,0.001794842,0.000020885553,0.000014791307,0.0065792482,1.8149436e-7,0.000020493244,0.0026448579,0.001908201,0.066272505],"study_design_scores_gemma":[0.0043630474,0.0041757124,0.96678746,0.0010511576,0.000010302484,0.0000025459692,0.0024695199,0.0000029374128,0.0009522866,0.0007396395,0.01938282,0.000062602194],"about_ca_topic_score_codex":0.00042515303,"about_ca_topic_score_gemma":0.00043262655,"teacher_disagreement_score":0.0662099,"about_ca_system_score_codex":0.00010355852,"about_ca_system_score_gemma":0.00037119794,"threshold_uncertainty_score":0.266581},"labels":[],"label_agreement":null},{"id":"W2761687318","doi":"10.1093/annonc/mdx372.061","title":"A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Fallopian tube cancer; Internal medicine; Carboplatin; Ovarian cancer; Clinical endpoint; Fallopian tube; Oncology; Chemotherapy; Gastroenterology; Cancer; Urology; Surgery; Clinical trial; Cisplatin; Adverse effect","score_opus":0.058536181589457136,"score_gpt":0.39402566456565635,"score_spread":0.33548948297619924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761687318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333394,0.00011228496,9.317172e-7,0.0034294936,0.00015917125,0.001555424,0.00015249853,0.000009118441,0.0012471654],"genre_scores_gemma":[0.9983043,0.00022236838,0.0003350706,0.0006014566,0.000105467276,0.00015855058,0.000022569753,0.000027877053,0.00022233985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843514,0.000069297705,0.0005160319,0.00035608475,0.0003142577,0.0003091615],"domain_scores_gemma":[0.9984315,0.00007637282,0.0005422245,0.00054434134,0.00028280725,0.00012276894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016316125,0.0002172435,0.0009452818,0.000111089445,0.0001259531,0.000009385739,0.00018704208,0.00012444207,0.00024395724],"category_scores_gemma":[0.000048154154,0.00014802332,0.000063368294,0.000088903806,0.00015385574,0.00009682965,0.00007619413,0.00014268384,0.0000011441692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085989155,0.053393755,0.6494988,0.00022796956,0.0013837327,0.0004366537,0.009684415,0.00003664624,0.00051756966,0.000041592382,0.0007657684,0.19802395],"study_design_scores_gemma":[0.10019483,0.053834632,0.8393806,0.0002620475,0.00017984744,0.0000019803424,0.00039593404,0.000025096118,0.0009642132,0.0000054232555,0.004613978,0.0001414103],"about_ca_topic_score_codex":0.0038484414,"about_ca_topic_score_gemma":0.006479318,"teacher_disagreement_score":0.19788255,"about_ca_system_score_codex":0.00021172101,"about_ca_system_score_gemma":0.00082457456,"threshold_uncertainty_score":0.60362154},"labels":[],"label_agreement":null},{"id":"W2761725905","doi":"10.1093/annonc/mdx380.051","title":"Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Afatinib; Medicine; Osimertinib; Internal medicine; Oncology; Lung cancer; Erlotinib; Clinical trial; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.028470831148526596,"score_gpt":0.3871186485849103,"score_spread":0.3586478174363837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761725905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824626,0.00041660498,0.000012201186,0.0047697057,0.00007712347,0.0005938782,0.000045042467,0.000010059104,0.011612774],"genre_scores_gemma":[0.9983416,0.00018867086,0.00029925167,0.000732987,0.000030561954,0.000065565684,0.000090994945,0.000014566144,0.00023577953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999192,0.000049027873,0.00022585501,0.00020642798,0.00013553283,0.00019114478],"domain_scores_gemma":[0.99893874,0.00009202201,0.00027445072,0.00021849218,0.000392887,0.00008340729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108216074,0.00012460319,0.00031596786,0.00010570162,0.00013348677,0.000018751862,0.00006931329,0.00008399684,0.000037535865],"category_scores_gemma":[0.000083991625,0.000091159796,0.00003797304,0.000048183767,0.0002805135,0.00019693171,0.000027996257,0.00009395333,0.0000030616243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007753693,0.0008981378,0.90443015,0.00005445274,0.000491122,0.0001642635,0.0077434373,0.000007315369,0.00019106035,0.0005968819,0.0003215494,0.084326245],"study_design_scores_gemma":[0.005094002,0.003648838,0.9885793,0.00018027908,0.00012904975,0.000012285593,0.00074496295,0.00003011238,0.00087521406,0.000138255,0.00047584355,0.00009191207],"about_ca_topic_score_codex":0.0014204192,"about_ca_topic_score_gemma":0.0011857216,"teacher_disagreement_score":0.08423433,"about_ca_system_score_codex":0.00008145989,"about_ca_system_score_gemma":0.000221458,"threshold_uncertainty_score":0.37173885},"labels":[],"label_agreement":null},{"id":"W2761753158","doi":"10.1093/annonc/mdx369.036","title":"Iron deficiency anemia in gastric cancer: A Canadian single site retrospective cohort study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Interquartile range; Transferrin saturation; Anemia; Internal medicine; Cancer; Retrospective cohort study; Gastroenterology; Iron-deficiency anemia; Chemotherapy regimen; Population; Surgery; Cohort; Iron deficiency","score_opus":0.046260530353241514,"score_gpt":0.3661080629680213,"score_spread":0.3198475326147798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761753158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9382593,0.00074878044,0.0000010135517,0.0024391166,0.00021212814,0.0005614525,0.000022759421,0.000007817731,0.05774761],"genre_scores_gemma":[0.99848384,0.00036740108,0.000043151278,0.000678333,0.00006930911,0.00003266754,0.000006905252,0.000011243637,0.0003071424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883956,0.00005995912,0.00025338947,0.0002730672,0.00017486268,0.0003991586],"domain_scores_gemma":[0.9990027,0.000022772156,0.00019332608,0.00043414903,0.00016380302,0.00018328396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043616458,0.00011364557,0.00047342273,0.0002754965,0.00012769755,0.000010353738,0.00016720132,0.00011538977,0.0001835641],"category_scores_gemma":[0.0003682363,0.00010744255,0.00004712294,0.00014798576,0.00015841218,0.00007923631,0.000040279014,0.0001807013,0.000017804065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107574524,0.0006870662,0.98460037,0.000025908712,0.000004756807,0.00013036077,0.00079389237,0.0000065179634,0.00039835012,0.00006236226,0.0020966681,0.011086147],"study_design_scores_gemma":[0.0016606825,0.00219705,0.99344593,0.000013562004,0.00006255649,0.000010177646,0.0004925301,0.0000032874123,0.0000898394,0.00006062512,0.0018768351,0.00008691511],"about_ca_topic_score_codex":0.39084822,"about_ca_topic_score_gemma":0.5732742,"teacher_disagreement_score":0.18242599,"about_ca_system_score_codex":0.00019485675,"about_ca_system_score_gemma":0.0007753606,"threshold_uncertainty_score":0.6132082},"labels":[],"label_agreement":null},{"id":"W2761767010","doi":"10.1093/annonc/mdx372","title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Placebo; Internal medicine; Quality of life (healthcare); Cohort; Ovarian cancer; Oncology; Adverse effect; Population; PARP inhibitor; Cancer; Gynecology; Poly ADP ribose polymerase; Pathology","score_opus":0.23592794112937082,"score_gpt":0.45832444436392733,"score_spread":0.2223965032345565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761767010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331547,0.0001608979,0.0000053532467,0.010998813,0.0002719583,0.0009285752,0.00052109803,0.000012193503,0.0037856326],"genre_scores_gemma":[0.99802953,0.00020579892,0.0001394177,0.0011180266,0.0002649944,0.00007370089,0.000105834195,0.000017278942,0.00004543693],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979066,0.00034030492,0.00080887676,0.0003237027,0.00037518318,0.00024531598],"domain_scores_gemma":[0.9967325,0.000462439,0.0013369643,0.0008429901,0.00052091817,0.00010419387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000827812,0.00016948907,0.0008164362,0.00007038845,0.000075742064,0.000008497596,0.000253737,0.00016629293,0.00013926666],"category_scores_gemma":[0.00060035894,0.000100359626,0.000074176336,0.00013460957,0.00044897656,0.00008608492,0.000036884052,0.000265229,0.0000027881229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50602263,0.0016711378,0.45451263,0.00002192487,0.00045182338,0.000006350063,0.0012018414,0.00001068447,0.00019466411,0.00009596543,0.0064628385,0.029347531],"study_design_scores_gemma":[0.16117094,0.008021781,0.8226665,0.00026557883,0.000045722703,3.1583988e-7,0.000065382534,0.0000038532894,0.0011599788,0.00006852598,0.006423379,0.00010799077],"about_ca_topic_score_codex":0.0182683,"about_ca_topic_score_gemma":0.008168434,"teacher_disagreement_score":0.36815393,"about_ca_system_score_codex":0.00008536491,"about_ca_system_score_gemma":0.000731898,"threshold_uncertainty_score":0.98826915},"labels":[],"label_agreement":null},{"id":"W2761819177","doi":"10.1093/annonc/mdx365.080","title":"IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Atezolizumab; Paclitaxel; Triple-negative breast cancer; Oncology; Placebo; Internal medicine; Breast cancer; Chemotherapy; Cancer; Immunotherapy; Pathology; Pembrolizumab","score_opus":0.09233901511981349,"score_gpt":0.44344857244973124,"score_spread":0.3511095573299178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761819177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167335,0.0001617458,0.000021878663,0.0019030281,0.00012883541,0.004307784,0.00024732298,0.00003292636,0.0015231506],"genre_scores_gemma":[0.9961627,0.00029457986,0.00046885438,0.00040190128,0.00005903933,0.0013523663,0.000070404276,0.00005816795,0.0011319749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732,0.00027170577,0.0006225035,0.00068589265,0.00037270004,0.0007272063],"domain_scores_gemma":[0.9972884,0.00032141863,0.0008426503,0.0005978629,0.0006182989,0.00033134132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002171877,0.0005455527,0.0018624504,0.00025733712,0.00031425047,0.00003150993,0.00023745713,0.000101652804,0.0003919275],"category_scores_gemma":[0.000049131857,0.00030236455,0.00008430394,0.00028740198,0.0005030775,0.0004290474,0.000077247794,0.00029577236,0.0000065977874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40682063,0.02664079,0.5088013,0.00009645715,0.0031382297,0.0011253441,0.0058659352,0.0003311109,0.000106580475,0.000011945567,0.00072476,0.046336927],"study_design_scores_gemma":[0.3818388,0.19682162,0.41159344,0.00061986677,0.0015760721,0.00011760952,0.004001658,0.0002462037,0.0013248302,0.00001855376,0.0013222456,0.0005190792],"about_ca_topic_score_codex":0.009652377,"about_ca_topic_score_gemma":0.031873785,"teacher_disagreement_score":0.17018083,"about_ca_system_score_codex":0.00060616306,"about_ca_system_score_gemma":0.0015717563,"threshold_uncertainty_score":0.99994284},"labels":[],"label_agreement":null},{"id":"W2761835542","doi":"10.1093/annonc/mdx374.056","title":"Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Regimen; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Surgery; Radiation therapy; Head and neck cancer; Immunotherapy; Cancer; Pathology","score_opus":0.0787968731189083,"score_gpt":0.4089477882456363,"score_spread":0.330150915126728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761835542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98817307,0.004518115,0.00007603765,0.0037759144,0.0003031535,0.0014486382,0.000047307803,0.000007728259,0.0016500201],"genre_scores_gemma":[0.99681896,0.0019630548,0.00017183377,0.0002881803,0.00021389883,0.00012310705,0.00001944298,0.000015339874,0.00038620728],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99908316,0.00004542346,0.00036891,0.0001941284,0.00010793361,0.00020041413],"domain_scores_gemma":[0.99852264,0.0003871404,0.00046678525,0.0004139954,0.000146557,0.000062887884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022212003,0.00014159553,0.00052387867,0.00005216473,0.00013471491,0.000010357153,0.00011702355,0.00014463694,0.00002582849],"category_scores_gemma":[0.0000949989,0.00009665649,0.00020562744,0.000034363467,0.00030047251,0.000058189515,0.000014331195,0.000051331037,6.905156e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48847836,0.0018708154,0.00027746416,0.0001072827,0.000121622266,0.000014496953,0.0008780567,0.000008534046,0.012858656,0.000030328365,0.0008716575,0.49448273],"study_design_scores_gemma":[0.6445132,0.10699482,0.014044743,0.00003096791,0.00030520838,0.00003374349,0.00020063683,0.00078160065,0.0968486,0.000083501516,0.13600966,0.0001533086],"about_ca_topic_score_codex":0.0003998446,"about_ca_topic_score_gemma":0.00012240768,"teacher_disagreement_score":0.4943294,"about_ca_system_score_codex":0.0000931705,"about_ca_system_score_gemma":0.00044673018,"threshold_uncertainty_score":0.39415374},"labels":[],"label_agreement":null},{"id":"W2761888485","doi":"10.1093/annonc/mdx372.003","title":"The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Cohort; Oncology; Proportional hazards model; Logistic regression; Cmax; Pharmacokinetics","score_opus":0.12579169649568753,"score_gpt":0.403958231024017,"score_spread":0.2781665345283295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761888485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766409,0.00021657663,0.000006714434,0.019197134,0.00030696555,0.00079617306,0.00011416448,0.0000064050237,0.0027150123],"genre_scores_gemma":[0.9987617,0.00014041654,0.000117404285,0.0006149077,0.00016346583,0.000038238504,0.00002395561,0.000013867848,0.00012603648],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982196,0.00044092268,0.0006256526,0.00022986114,0.00027769728,0.00020624546],"domain_scores_gemma":[0.9942738,0.0037178511,0.00079361367,0.00085512426,0.00029644565,0.00006317128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019945565,0.00012759029,0.0004100631,0.00006850245,0.00022109674,0.000016659886,0.0002598072,0.00017247384,0.000020862315],"category_scores_gemma":[0.0026927125,0.00007276924,0.000061956955,0.00009422532,0.0007032462,0.0000955821,0.000058603713,0.00028920604,0.000004273875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60848385,0.0006043593,0.35888714,0.000008957707,0.00018231494,0.000010660283,0.0031556354,0.000007875172,0.0004911659,0.0002549767,0.008519971,0.019393127],"study_design_scores_gemma":[0.08430857,0.0067656175,0.89575714,0.00011528733,0.00003291321,0.0000016278037,0.00015919298,0.0000063080734,0.0017140692,0.0005740875,0.010492588,0.00007259056],"about_ca_topic_score_codex":0.00044730725,"about_ca_topic_score_gemma":0.0005243892,"teacher_disagreement_score":0.53687,"about_ca_system_score_codex":0.000037482405,"about_ca_system_score_gemma":0.00033929845,"threshold_uncertainty_score":0.3223623},"labels":[],"label_agreement":null},{"id":"W2761902517","doi":"10.1093/annonc/mdx370.051","title":"Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prednisone; Internal medicine; Prednisolone; Prostate cancer; Population; Oncology; Placebo; Clinical endpoint; Abiraterone acetate; Androgen deprivation therapy; Gastroenterology; Cancer; Randomized controlled trial; Pathology","score_opus":0.08097807817073079,"score_gpt":0.422389176494606,"score_spread":0.34141109832387523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761902517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98662,0.001954637,0.000008211267,0.0020470787,0.000060422724,0.008117406,0.00022971701,0.000028442006,0.00093406555],"genre_scores_gemma":[0.992177,0.004452435,0.00034540272,0.00008310657,0.000030313877,0.0014793238,0.00010961321,0.00004517925,0.0012776349],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964741,0.00061187556,0.0012946364,0.0004917945,0.00044707165,0.000680532],"domain_scores_gemma":[0.99691796,0.0006194049,0.0011957171,0.0006560066,0.00033417568,0.00027673386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516245,0.00040306154,0.0028751886,0.00031809183,0.00014521099,0.000044613098,0.0002566985,0.00015513149,0.0001174374],"category_scores_gemma":[0.000404542,0.000241981,0.00013502174,0.0001985365,0.0011863704,0.00024544456,0.00010300208,0.00021850673,0.0000027147591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9803103,0.0019101733,0.00042923118,0.0014974915,0.0019145618,0.0006744027,0.0032061497,0.000032176933,0.002230835,0.000020589918,0.000414508,0.007359585],"study_design_scores_gemma":[0.9557037,0.02497221,0.00091027713,0.001493799,0.0012127483,0.00006624598,0.00044370856,0.0025345627,0.012236087,0.000105234896,0.00008072995,0.00024071951],"about_ca_topic_score_codex":0.0036875315,"about_ca_topic_score_gemma":0.0017402641,"teacher_disagreement_score":0.024606617,"about_ca_system_score_codex":0.00017697224,"about_ca_system_score_gemma":0.0019746223,"threshold_uncertainty_score":0.9867699},"labels":[],"label_agreement":null},{"id":"W2761935628","doi":"10.1093/annonc/mdx375.002","title":"All.Can initiative: improving efficiency in cancer care","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Inefficiency; Psychological intervention; Health care; Accountability; Stakeholder; Stakeholder engagement; Obsolescence; Focus group; Nursing; Best practice; Public relations; Business; Marketing; Economic growth; Political science; Management; Economics","score_opus":0.16604742473187012,"score_gpt":0.3853138619212918,"score_spread":0.21926643718942168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761935628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76704854,0.005257544,0.00009205695,0.007617207,0.0007971508,0.00019245158,0.00026152103,0.00001108401,0.21872248],"genre_scores_gemma":[0.99597466,0.0016169816,0.000086775064,0.001967516,0.00014702819,0.000030797917,0.0000042588554,0.000015109828,0.00015687964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987358,0.000011618987,0.0005596142,0.00030121315,0.000019032592,0.00037272973],"domain_scores_gemma":[0.99851143,0.000043555385,0.0009037292,0.0003852964,0.00008227063,0.000073704796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037884462,0.00012316006,0.00055051356,0.00017953577,0.00011113122,0.000035087083,0.0004547355,0.0001684997,0.00020150555],"category_scores_gemma":[0.00035952477,0.00014753712,0.00009672527,0.000048002454,0.00019472252,0.00030424364,0.00011264754,0.00016387636,0.000047753354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014001779,0.0003209538,0.6081614,0.00013931443,0.00008477028,0.000030916068,0.007357487,0.00023994897,0.000073162104,0.10961516,0.002998923,0.27083796],"study_design_scores_gemma":[0.0019312956,0.00095592014,0.7361052,0.000052555195,0.0000069877324,0.000001858322,0.00051053154,0.00033240678,0.0010342627,0.019622147,0.238995,0.00045183965],"about_ca_topic_score_codex":0.006195812,"about_ca_topic_score_gemma":0.0029329725,"teacher_disagreement_score":0.27038613,"about_ca_system_score_codex":0.00014464211,"about_ca_system_score_gemma":0.0001851406,"threshold_uncertainty_score":0.9366256},"labels":[],"label_agreement":null},{"id":"W2761943820","doi":"10.1093/annonc/mdx365.018","title":"Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Lapatinib; Internal medicine; Adverse effect; Immunohistochemistry; HER2/neu; Oncology; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Cancer; Phases of clinical research; Chemotherapy","score_opus":0.14573779454573088,"score_gpt":0.45307702530923877,"score_spread":0.3073392307635079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761943820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348724,0.00015467458,0.0000068593226,0.0011392469,0.00012248878,0.00074211543,0.000025826866,0.000009121276,0.004312406],"genre_scores_gemma":[0.99916804,0.00013210966,0.00016755424,0.00010694611,0.0000779236,0.000017333556,0.000054612334,0.00001956636,0.00025590623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808437,0.0001648374,0.0005399145,0.00032220344,0.00051704893,0.00037163112],"domain_scores_gemma":[0.9983444,0.00010246754,0.0005047995,0.0004414532,0.00046265012,0.00014421895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003586551,0.00017631619,0.0006642154,0.00024002722,0.00013741048,0.000016088343,0.00022952192,0.00011676805,0.000118839496],"category_scores_gemma":[0.00013534357,0.00013466227,0.000076311204,0.00015683116,0.0003403734,0.00013350637,0.00011274913,0.00022835148,0.0000056133863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011605471,0.019626677,0.8275753,0.00018995324,0.0002511465,0.00017722513,0.0022738506,0.00006028822,0.032737073,0.00001550274,0.00081745983,0.10467002],"study_design_scores_gemma":[0.014982149,0.0405983,0.9268527,0.00032321404,0.00004523626,0.0000056184917,0.0006095588,0.00019735067,0.010387212,0.000019798626,0.0058230488,0.00015582945],"about_ca_topic_score_codex":0.0034868545,"about_ca_topic_score_gemma":0.001064965,"teacher_disagreement_score":0.10451419,"about_ca_system_score_codex":0.000101066136,"about_ca_system_score_gemma":0.00025424175,"threshold_uncertainty_score":0.5491368},"labels":[],"label_agreement":null},{"id":"W2761978682","doi":"10.1093/annonc/mdx382.011","title":"Increasing palliative interventions at the end of life: patterns in metastatic colorectal cancer (mCRC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto; Sinai Health System; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Psychological intervention; Palliative care; Internal medicine; Cancer; Nursing","score_opus":0.43979538802270285,"score_gpt":0.5572120932949155,"score_spread":0.11741670527221265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761978682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877207,0.0034146328,0.00002506806,0.005459025,0.00013054276,0.00022393008,0.00013894714,0.000003382605,0.0028837319],"genre_scores_gemma":[0.99602455,0.0032066766,0.00022485721,0.0003149899,0.000044285072,0.000034383276,0.000015220421,0.000008397971,0.00012663497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885875,0.00022252709,0.00047477023,0.00013235031,0.00014355715,0.00016806973],"domain_scores_gemma":[0.99804384,0.0007303045,0.0006773939,0.00023159532,0.00025873727,0.000058140795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056655565,0.00009718819,0.00059873494,0.000091285125,0.000056865094,0.0000031085788,0.0001780427,0.00006386493,0.00038527555],"category_scores_gemma":[0.0016907054,0.00006868203,0.00019810679,0.00006411019,0.00046124883,0.000057848087,0.00013162699,0.00012941392,0.000003317294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007997975,0.00037191514,0.97137433,0.00034785093,0.00047975124,0.000025924808,0.0036115104,0.000010752791,0.0045962785,0.00017771286,0.0007497644,0.01745442],"study_design_scores_gemma":[0.0017377536,0.0014671193,0.951879,0.0017409939,0.00017432263,0.000004583424,0.001524336,0.00004228526,0.036058478,0.00023315776,0.0050622122,0.0000757172],"about_ca_topic_score_codex":0.0069026654,"about_ca_topic_score_gemma":0.014313362,"teacher_disagreement_score":0.0314622,"about_ca_system_score_codex":0.0000586503,"about_ca_system_score_gemma":0.00022395619,"threshold_uncertainty_score":0.99971044},"labels":[],"label_agreement":null},{"id":"W2761992904","doi":"10.1093/annonc/mdx388.068","title":"A novel multimodal treatment strategy for cancer cachexia; rationale and motivation for the MENAC (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hospice Palliative Care Association","funders":"","keywords":"Medicine; Cachexia; Sarcopenia; Weight loss; Randomized controlled trial; Cancer; Multimodal therapy; Quality of life (healthcare); Physical therapy; Clinical endpoint; Clinical trial; Intensive care medicine; Internal medicine; Obesity","score_opus":0.2886056015704746,"score_gpt":0.4801348503426114,"score_spread":0.19152924877213678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761992904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.867983,0.0029170404,0.011097032,0.09855227,0.00068139,0.017787404,0.00085471495,0.000034822424,0.00009233915],"genre_scores_gemma":[0.97947645,0.0046263253,0.0068129324,0.00061709224,0.0009805791,0.0069666593,0.00029710843,0.000021733258,0.00020113197],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990147,0.000021564229,0.00038447446,0.0002458967,0.000108286535,0.00022507754],"domain_scores_gemma":[0.9981336,0.0007467253,0.00041683376,0.0001751742,0.00042723605,0.000100457866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006020662,0.00012564979,0.00039361053,0.00007833694,0.00051697256,0.000021077765,0.000060953727,0.00017257554,0.000007882383],"category_scores_gemma":[0.00033048945,0.000096589494,0.00008519854,0.000019397246,0.00019072057,0.00012958163,0.000013865995,0.000058673337,1.409435e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10607619,0.0056476747,0.008749548,0.0052630063,0.0007949585,0.0000025968927,0.0031954881,0.000104032755,0.051916037,0.010218133,0.012452799,0.79557955],"study_design_scores_gemma":[0.48570648,0.01575558,0.20337443,0.0009228414,0.0011550854,0.0000364096,0.0018974452,0.07319818,0.031116387,0.004989983,0.1813163,0.0005308619],"about_ca_topic_score_codex":0.00026404276,"about_ca_topic_score_gemma":0.00026642703,"teacher_disagreement_score":0.79504865,"about_ca_system_score_codex":0.000064404274,"about_ca_system_score_gemma":0.00035389268,"threshold_uncertainty_score":0.39761874},"labels":[],"label_agreement":null},{"id":"W2762015266","doi":"10.1093/annonc/mdx365.051","title":"Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Proportional hazards model; Cancer registry; Oncology; Cancer; Confidence interval; Population","score_opus":0.18102858587068804,"score_gpt":0.42767477475422716,"score_spread":0.24664618888353912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762015266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963271,0.010375461,0.0000140764805,0.020951573,0.0003605349,0.00025524807,0.0044742986,0.000004276336,0.00029351172],"genre_scores_gemma":[0.9923953,0.005811869,0.00011281777,0.0007343278,0.0005121811,0.00019487101,0.00014494428,0.000014548954,0.00007916443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881434,0.000068612506,0.00025176574,0.000464084,0.00016217507,0.00023904572],"domain_scores_gemma":[0.9979825,0.00004928026,0.00046749547,0.0012174437,0.00023400008,0.000049252012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015738438,0.00016130583,0.00031225273,0.000017527615,0.000108530054,0.000014273799,0.0009711731,0.00013301264,0.00011160881],"category_scores_gemma":[0.00004982449,0.00012103229,0.000093496434,0.000034824305,0.0007524064,0.000016492142,0.00073232065,0.0000925504,0.0000039291854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013439162,0.00029157745,0.81465846,0.000023012915,0.00079057313,0.00001099551,0.00016577213,0.0000053590493,0.0016814122,0.000013016622,0.08702618,0.09398971],"study_design_scores_gemma":[0.00062830426,0.00019855361,0.92370516,0.000109821936,0.00010789143,0.000009875011,0.00003701854,0.0000039765005,0.0021816238,0.000043187203,0.07285393,0.00012063338],"about_ca_topic_score_codex":0.0074425074,"about_ca_topic_score_gemma":0.0087172175,"teacher_disagreement_score":0.109046705,"about_ca_system_score_codex":0.000018722634,"about_ca_system_score_gemma":0.00030033546,"threshold_uncertainty_score":0.999167},"labels":[],"label_agreement":null},{"id":"W2762016591","doi":"10.1093/annonc/mdx393.016","title":"Role of body composition in early stage colorectal cancer (CRC) outcomes","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hospice Palliative Care Association; University of Alberta","funders":"","keywords":"Medicine; Sarcopenia; Stage (stratigraphy); Cohort; Colorectal cancer; Internal medicine; Retrospective cohort study; Cancer; Body mass index; Gastroenterology","score_opus":0.12018630178367477,"score_gpt":0.48364363062847476,"score_spread":0.3634573288448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762016591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771806,0.00020792811,0.0000016616237,0.012110745,0.00012081202,0.00021025872,0.000026332975,0.000007766968,0.010133888],"genre_scores_gemma":[0.9980565,0.00038826754,0.00018927798,0.0011370931,0.00004704434,0.000019748948,0.000006410439,0.000006139253,0.000149543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929625,0.000043207325,0.00029863682,0.000098717035,0.00010188243,0.00016133027],"domain_scores_gemma":[0.9992999,0.00006301727,0.00028055892,0.00014769983,0.00014253308,0.00006630873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002343118,0.000058190395,0.00040573993,0.00011000766,0.000051147585,0.0000032218022,0.00008207227,0.00009662857,0.00012251145],"category_scores_gemma":[0.000050415783,0.000053808963,0.00005418371,0.00003148605,0.0001259631,0.000060058206,0.000030319316,0.0001305165,0.000005217776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005706303,0.0004685687,0.9504728,0.00014064962,0.000029579714,0.000019410229,0.00043103157,0.0000013196549,0.039310753,0.0011524284,0.00046010027,0.0069427793],"study_design_scores_gemma":[0.0019073567,0.001133689,0.9546836,0.00011550727,0.000010511608,0.0000032944686,0.000083197534,0.000048603113,0.03482085,0.00032504485,0.006828069,0.000040286417],"about_ca_topic_score_codex":0.0019564815,"about_ca_topic_score_gemma":0.00053163845,"teacher_disagreement_score":0.020875867,"about_ca_system_score_codex":0.000035144665,"about_ca_system_score_gemma":0.00014284968,"threshold_uncertainty_score":0.29576278},"labels":[],"label_agreement":null},{"id":"W2762025473","doi":"10.1093/annonc/mdx369.050","title":"Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Centre Hospitalier Universitaire de Sherbrooke; Hôpital Notre-Dame; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Regorafenib; Oncology; Randomized controlled trial; Cancer; Proportional hazards model; Overall survival; Survival analysis; Quality of life (healthcare); Clinical trial; Colorectal cancer","score_opus":0.10224790698558808,"score_gpt":0.44411575129133024,"score_spread":0.34186784430574213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762025473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313176,0.00080931623,0.00004599251,0.0025118194,0.00012379253,0.002999659,0.000026614902,0.0000054119364,0.0003456263],"genre_scores_gemma":[0.9968108,0.0015260772,0.0012237218,0.0000559392,0.00004455233,0.00023406398,0.000007798983,0.000009632995,0.00008742105],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99872357,0.00006680044,0.000619471,0.00023527723,0.00011979171,0.00023512274],"domain_scores_gemma":[0.99717325,0.001585469,0.00081341335,0.00021738389,0.00015257137,0.000057885492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083433604,0.00013207957,0.0010860738,0.00022313895,0.000028126722,0.0000058223895,0.00012695107,0.000094859446,0.000019495403],"category_scores_gemma":[0.0038103042,0.00011376726,0.000071862734,0.00011877471,0.00033370286,0.0001037919,0.000067539135,0.00009241239,1.3144346e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43680212,0.002012928,0.1572229,0.0011269212,0.00018343833,0.000052756724,0.00044957217,0.0001177489,0.012268209,0.00006269344,0.00050020963,0.3892005],"study_design_scores_gemma":[0.77519655,0.018096002,0.19739415,0.00048126752,0.00028306633,0.0000055265864,0.00019019336,0.0020937852,0.0043007787,0.00042345608,0.0013488348,0.00018642639],"about_ca_topic_score_codex":0.00040903123,"about_ca_topic_score_gemma":0.00037549165,"teacher_disagreement_score":0.3890141,"about_ca_system_score_codex":0.00003417659,"about_ca_system_score_gemma":0.00030868815,"threshold_uncertainty_score":0.4639294},"labels":[],"label_agreement":null},{"id":"W2762055209","doi":"10.1093/annonc/mdx369.144","title":"Impact of advances in systemic chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC) in Alberta, Canada","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Context (archaeology); Chemotherapy; Oncology; Systemic therapy; Population; Pancreatic cancer; Cancer; Chemotherapy regimen; Oxaliplatin; Breast cancer","score_opus":0.06215649309270591,"score_gpt":0.43364902385932824,"score_spread":0.3714925307666223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762055209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859932,0.0031185958,0.000008060741,0.0022675102,0.000073125135,0.0008365518,0.000024862948,0.0000022380423,0.007675829],"genre_scores_gemma":[0.99678093,0.0020662327,0.00020527278,0.00011718207,0.00006120048,0.0001018213,0.000010970151,0.000015588259,0.00064077356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842346,0.000105048035,0.0005725143,0.00023104958,0.00018354772,0.00048441085],"domain_scores_gemma":[0.9979156,0.00090292067,0.00038717448,0.00044625375,0.00022979727,0.00011822919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006180456,0.00014417456,0.0012570714,0.00018606745,0.000048980164,0.0000035247479,0.00026651667,0.00017599332,0.00010342349],"category_scores_gemma":[0.0011158723,0.00011625841,0.00011962401,0.000105933235,0.0002371652,0.00011402912,0.000039848546,0.00017146963,0.0000013478009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025190036,0.00033931216,0.9902285,0.00040981703,0.00015958736,0.00008856272,0.0003127736,0.000013968699,0.0015345302,0.00014286219,0.001085684,0.0031654458],"study_design_scores_gemma":[0.0058512855,0.0047924756,0.98617494,0.00031671455,0.00004427086,0.000112823946,0.0002151593,0.00046507313,0.00092273357,0.00036921137,0.0006389776,0.00009633902],"about_ca_topic_score_codex":0.7065742,"about_ca_topic_score_gemma":0.7121165,"teacher_disagreement_score":0.010787733,"about_ca_system_score_codex":0.00031128005,"about_ca_system_score_gemma":0.0038288082,"threshold_uncertainty_score":0.6792141},"labels":[],"label_agreement":null},{"id":"W2762084864","doi":"10.1093/annonc/mdx365.052","title":"The CAN BEAR study: A systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC)","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Adverse effect; Odds ratio; Cochrane Library; Confidence interval; Randomized controlled trial; Targeted therapy; Metastatic breast cancer; Breast cancer; Pharmacology; Cancer","score_opus":0.19634231387762996,"score_gpt":0.4687768820763335,"score_spread":0.27243456819870354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762084864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025327923,0.9835898,0.000002977693,0.001578377,0.000031241405,0.01087524,0.0013631204,0.0000108303075,0.000015612743],"genre_scores_gemma":[0.010714697,0.983974,0.00036180177,0.0013995181,0.000015190599,0.0031663792,0.00015684075,0.00008439655,0.00012718416],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99400204,0.002104994,0.0020522883,0.0006688908,0.00067837496,0.00049341767],"domain_scores_gemma":[0.9933616,0.0005622978,0.0037878787,0.0010541624,0.00097033964,0.00026372523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013550124,0.000725695,0.011234751,0.0004907456,0.00011766311,0.000008711744,0.00052201975,0.00009984031,0.00006606352],"category_scores_gemma":[0.000473695,0.00039032765,0.0010401931,0.0009757303,0.00026502192,0.0001274281,0.0001592652,0.00040602373,0.000003432112],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010931683,0.002660308,0.0010310977,0.25477913,0.58778834,0.000070341805,0.0033122804,0.000020866875,0.000003351116,0.000011084824,0.00014797765,0.14908206],"study_design_scores_gemma":[0.006416238,0.009262152,0.0074032797,0.0758507,0.887188,0.000071840586,0.0009777328,0.0000026653656,0.000008652016,0.000018410687,0.011901028,0.0008992614],"about_ca_topic_score_codex":0.0012416624,"about_ca_topic_score_gemma":0.0011057912,"teacher_disagreement_score":0.2993997,"about_ca_system_score_codex":0.00025430636,"about_ca_system_score_gemma":0.0007979941,"threshold_uncertainty_score":0.99985486},"labels":[],"label_agreement":null},{"id":"W2762098071","doi":"10.1093/annonc/mdx365.086","title":"EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Oncology; Exemestane; Anastrozole; Placebo; Tamoxifen; Docetaxel; Gastroenterology; Cancer; Surgery; Pathology","score_opus":0.0632172734733662,"score_gpt":0.40724478441418716,"score_spread":0.34402751094082096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762098071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018806,0.0005555224,0.000055816792,0.0014652512,0.00014782693,0.0034020378,0.004075063,0.000027772938,0.00008264497],"genre_scores_gemma":[0.99603945,0.0016802108,0.0009221195,0.00013582151,0.00019761642,0.00069739536,0.000114628696,0.000085761276,0.00012697525],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972201,0.0003369376,0.0008703409,0.00059864647,0.0004332202,0.0005407606],"domain_scores_gemma":[0.99454314,0.00042773702,0.002263978,0.0006823313,0.0018716651,0.00021115795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019383804,0.00049100706,0.001822895,0.0001933682,0.00024562492,0.000011277765,0.00030057257,0.00013962509,0.00022140895],"category_scores_gemma":[0.00010912088,0.0003555594,0.00024455466,0.0001331931,0.00066927803,0.00035431472,0.00006460523,0.00020350002,0.0000023044902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08846752,0.03398091,0.2790337,0.00010079005,0.0056315553,0.000025982767,0.020702852,0.0000101240275,0.024924064,0.00009075206,0.0002917296,0.54674006],"study_design_scores_gemma":[0.062142886,0.13143376,0.72143334,0.00011181955,0.00025616243,0.0000054434604,0.00087041844,0.0000021481037,0.082682885,0.000115700415,0.00068926736,0.0002561517],"about_ca_topic_score_codex":0.016405163,"about_ca_topic_score_gemma":0.0009650771,"teacher_disagreement_score":0.5464839,"about_ca_system_score_codex":0.0002661141,"about_ca_system_score_gemma":0.00031794442,"threshold_uncertainty_score":0.9998896},"labels":[],"label_agreement":null},{"id":"W2762156928","doi":"10.1093/annonc/mdx526","title":"The use of antidepressants in oncology: a review and practical tips for oncologists","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Università degli Studi di Ferrara","keywords":"Medicine; Oncology; Medical physics; Internal medicine; Family medicine","score_opus":0.6699843654823663,"score_gpt":0.5962282959897072,"score_spread":0.07375606949265912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762156928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036737467,0.98710686,0.0000032905257,0.008651891,0.0002299198,0.0030479229,0.00007167474,0.000009004104,0.00084268843],"genre_scores_gemma":[0.000013617852,0.9970422,0.00045031722,0.0010197244,0.0001831678,0.0004271836,0.000035084173,0.000040061677,0.00078863814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628335,0.001044614,0.0015712617,0.00044080993,0.00018973902,0.0004701937],"domain_scores_gemma":[0.9873342,0.008812215,0.002372045,0.0009337576,0.00042116977,0.00012661378],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002677696,0.0003643555,0.0052494323,0.00019986139,0.000107056454,0.000015697044,0.00028558352,0.00080281985,0.000017386259],"category_scores_gemma":[0.011302151,0.0002313186,0.0006355932,0.00014245746,0.001164496,0.00011825019,0.00016899325,0.00062064204,0.0000044650883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010865375,0.00045906153,0.00003500127,0.032717627,0.0003287938,0.00017007689,0.00002902686,2.8181038e-8,6.7931626e-7,0.00008130967,0.067904614,0.89718723],"study_design_scores_gemma":[0.0010510975,0.0042936984,0.00028311726,0.025747217,0.0019856817,0.001730212,0.000013585028,0.0000018295658,0.0000031489215,0.000025430618,0.96469283,0.00017217513],"about_ca_topic_score_codex":0.00013500755,"about_ca_topic_score_gemma":0.0002071933,"teacher_disagreement_score":0.8970151,"about_ca_system_score_codex":0.00012361431,"about_ca_system_score_gemma":0.003965462,"threshold_uncertainty_score":0.9970261},"labels":[],"label_agreement":null},{"id":"W2762161610","doi":"10.1093/annonc/mdx377.003","title":"KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Pembrolizumab; Neutropenia; Discontinuation; Regimen; Melanoma; Internal medicine; Oncology; Metastatic melanoma; Vemurafenib; Gastroenterology; Cancer research; Cancer; Chemotherapy; Immunotherapy; MAPK/ERK pathway","score_opus":0.06839828692160825,"score_gpt":0.39015154680752706,"score_spread":0.3217532598859188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762161610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553525,0.00060109945,0.0005307285,0.00068503123,0.00024717476,0.000902975,0.00023184101,0.000008891912,0.001257028],"genre_scores_gemma":[0.9980697,0.00056528684,0.00063231133,0.00018603052,0.00015192018,0.0001028677,0.000116716794,0.00003043906,0.00014472198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835956,0.00009393177,0.00056064595,0.00050153024,0.00012763104,0.00035669957],"domain_scores_gemma":[0.9980262,0.00007381182,0.00066289614,0.00083159003,0.00027145696,0.0001340432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041634619,0.00023982314,0.00066191744,0.00007167052,0.00021277589,0.000016092923,0.00047497888,0.00026314607,0.000023386485],"category_scores_gemma":[0.00045425733,0.00022151228,0.00014155828,0.00003561384,0.00023736861,0.000013870507,0.0002537345,0.00009783836,0.0000014131657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018415283,0.0063797175,0.0024840252,0.0003670295,0.00071043073,0.00008450218,0.0010040348,0.00012526252,0.7450622,0.000705812,0.0035982882,0.22106345],"study_design_scores_gemma":[0.05662424,0.07669604,0.004702145,0.00004564601,0.00020756588,0.00010313072,0.0007721548,0.00041293737,0.6921769,0.00088211376,0.16675499,0.00062217226],"about_ca_topic_score_codex":0.00006249415,"about_ca_topic_score_gemma":0.00039739077,"teacher_disagreement_score":0.22044128,"about_ca_system_score_codex":0.000009264716,"about_ca_system_score_gemma":0.00016837049,"threshold_uncertainty_score":0.9033009},"labels":[],"label_agreement":null},{"id":"W2762165713","doi":"10.1093/annonc/mdx440.030","title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Asymptomatic; Progression-free survival; Hazard ratio; Internal medicine; Urology; Adverse effect; Log-rank test; Oncology; Surgery; Chemotherapy; Survival analysis; Confidence interval","score_opus":0.07552152128933143,"score_gpt":0.34000845849170674,"score_spread":0.2644869372023753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762165713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826003,0.0003157442,0.0000052205883,0.000602866,0.0003362735,0.00093398907,0.00004271501,0.00002196665,0.015140968],"genre_scores_gemma":[0.99812555,0.00005299189,0.0011733592,0.00011029222,0.00011377783,0.00007526125,0.00012909735,0.00005629689,0.00016335117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744934,0.00027432616,0.0006231186,0.00053845375,0.00043050424,0.0006842615],"domain_scores_gemma":[0.99715126,0.00040974346,0.00078125024,0.0008402569,0.00052426406,0.00029325302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045254946,0.0003714866,0.0010614882,0.0003206914,0.00015295371,0.000024885338,0.00030376547,0.00016379986,0.00012969892],"category_scores_gemma":[0.00033492158,0.00030462162,0.00017309493,0.00015797807,0.0004227592,0.00024180493,0.00013715086,0.00036603038,0.00004267233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03098193,0.004320628,0.9132351,0.00028153407,0.000910016,0.0020902655,0.0026394217,0.00008343969,0.0020520021,0.000036392812,0.0011796344,0.042189587],"study_design_scores_gemma":[0.019465594,0.01585963,0.94162524,0.00010855657,0.00039906253,0.000027148957,0.00031078482,0.000024783942,0.021111287,0.000039282513,0.000750942,0.0002776638],"about_ca_topic_score_codex":0.0012524145,"about_ca_topic_score_gemma":0.0004579521,"teacher_disagreement_score":0.041911922,"about_ca_system_score_codex":0.00033393878,"about_ca_system_score_gemma":0.0007456552,"threshold_uncertainty_score":0.9999406},"labels":[],"label_agreement":null},{"id":"W2762169730","doi":"10.1093/annonc/mdx365.054","title":"PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Palbociclib; Gastroenterology; Anemia; Breast cancer; Adverse effect; Progression-free survival; Metastatic breast cancer; Febrile neutropenia; Chemotherapy regimen; Cancer; Chemotherapy","score_opus":0.03672575176968415,"score_gpt":0.35281412984469135,"score_spread":0.3160883780750072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762169730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832835,0.00018205146,0.000070903254,0.012801374,0.00036014608,0.0012559793,0.0011915399,0.00006858458,0.00078588584],"genre_scores_gemma":[0.99552673,0.000591468,0.0011848757,0.0014448446,0.00046180596,0.00028125753,0.00016289063,0.00013393204,0.00021219031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963205,0.00028340274,0.0009277845,0.0009315094,0.00051608647,0.0010207469],"domain_scores_gemma":[0.9958321,0.00031201745,0.0014657272,0.0008624936,0.0011537378,0.00037391428],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028053898,0.0006285187,0.0015104924,0.0002589655,0.000447911,0.000039036146,0.0005945101,0.00032277833,0.0011113855],"category_scores_gemma":[0.00025894993,0.0005416599,0.00021302995,0.0002284132,0.0006785164,0.0008799238,0.00025050848,0.000701226,0.000035905738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008106437,0.0012067221,0.83036476,0.00016647181,0.0005197397,0.000058403926,0.0018065813,0.00006315256,0.004348075,0.00007672845,0.00031788048,0.15296504],"study_design_scores_gemma":[0.014347156,0.005598323,0.95444655,0.00094498653,0.000080929785,0.000031369265,0.00026082539,0.000007708372,0.020675905,0.00012934642,0.002919121,0.00055776606],"about_ca_topic_score_codex":0.0029489591,"about_ca_topic_score_gemma":0.0026149375,"teacher_disagreement_score":0.15240727,"about_ca_system_score_codex":0.00057698134,"about_ca_system_score_gemma":0.0003264208,"threshold_uncertainty_score":0.99980175},"labels":[],"label_agreement":null},{"id":"W2762200842","doi":"10.1093/annonc/mdx385.023","title":"Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Concordance; Medicine; Machine learning; MEDLINE; Algorithm; Artificial intelligence; Interim; Clinical trial; Systematic review; Logistic regression; Natural language processing; Medical physics; Information retrieval; Computer science; Pathology; Internal medicine","score_opus":0.8328462362553098,"score_gpt":0.5783315057393391,"score_spread":0.25451473051597073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762200842","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4640767,0.035862546,0.47417566,0.004643271,0.0006681404,0.010574158,0.000101134036,0.000019822517,0.009878562],"genre_scores_gemma":[0.69831604,0.00025652582,0.2970064,0.00067552197,0.000058278074,0.00033822047,0.000022481314,0.000019977118,0.0033065726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98271877,0.005978478,0.008851175,0.00060188334,0.001631497,0.00021820485],"domain_scores_gemma":[0.98265344,0.001301158,0.011482612,0.002718647,0.0017112608,0.00013285843],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09711108,0.00023181995,0.004681505,0.00040461856,0.00024961703,0.00019315085,0.0016697493,0.000118071424,0.00027201133],"category_scores_gemma":[0.033148304,0.00011921537,0.0008798975,0.0005463797,0.00006137167,0.00014811351,0.00016425329,0.00013682038,0.00044944507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011917816,0.000765179,0.015292043,0.055452015,0.0011539797,0.000020566846,0.01996277,0.00231605,0.040166084,0.0010896917,0.012263047,0.8513994],"study_design_scores_gemma":[0.0005887595,0.00038448515,0.0022052843,0.006837605,0.00031598672,0.0000148517665,0.0004076138,0.13570097,0.002134447,0.0004915026,0.8505312,0.0003872992],"about_ca_topic_score_codex":0.000016094686,"about_ca_topic_score_gemma":0.00007102517,"teacher_disagreement_score":0.8510121,"about_ca_system_score_codex":0.000029102655,"about_ca_system_score_gemma":0.00019133027,"threshold_uncertainty_score":0.9749959},"labels":[],"label_agreement":null},{"id":"W2762356068","doi":"10.1093/annonc/mdx371.070","title":"Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Seminoma; Medicine; Germ cell tumors; Testicular cancer; Pathology; Pathological; Lymph; Embryonal carcinoma; Chemotherapy; Stage (stratigraphy); Teratoma; Germ cell; Internal medicine; Biology","score_opus":0.0701221180738871,"score_gpt":0.39545663541666914,"score_spread":0.32533451734278207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762356068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965513,0.00028820898,0.000008908457,0.00010851453,0.000037819154,0.0003736241,0.00002436351,0.000004606591,0.002602677],"genre_scores_gemma":[0.99774486,0.00004800711,0.0019834216,0.0001409866,0.00001756586,0.000012286556,0.000016955366,0.000010265696,0.000025645504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999075,0.00003954188,0.0002858516,0.00023990708,0.00013247553,0.00022722008],"domain_scores_gemma":[0.9988657,0.000078026686,0.00047903485,0.00031898113,0.00013155812,0.00012668231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013621898,0.0001383335,0.0005282466,0.00007792204,0.000058288253,0.000007096732,0.00009312151,0.00009239478,0.000029455146],"category_scores_gemma":[0.000079173115,0.00009719789,0.000059094524,0.00004271178,0.00018518907,0.000061630555,0.00009500981,0.000082192404,0.0000012037664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034485935,0.0023236054,0.9897626,0.00011127859,0.000069203576,0.00021410076,0.000037969134,0.000003568816,0.0013849357,0.000020191419,0.000055933997,0.0056717535],"study_design_scores_gemma":[0.00476305,0.0066116326,0.9846049,0.00015581047,0.00009850447,0.000018308678,0.000038149992,0.00024862142,0.0031847986,0.000036888057,0.00015162706,0.00008768417],"about_ca_topic_score_codex":0.0003028862,"about_ca_topic_score_gemma":0.000016779963,"teacher_disagreement_score":0.0055840695,"about_ca_system_score_codex":0.00004342952,"about_ca_system_score_gemma":0.00023318222,"threshold_uncertainty_score":0.3963615},"labels":[],"label_agreement":null},{"id":"W2762393705","doi":"10.1093/annonc/mdx375.010","title":"Feasibility of routine collection of health state utilities using EQ-5D in a breast cancer outpatient clinic","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Public Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Population; Cancer; Outpatient clinic; Pediatrics; Physical therapy; Internal medicine","score_opus":0.8420384043493592,"score_gpt":0.5842933362113278,"score_spread":0.25774506813803133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762393705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704966,0.0013540371,0.00015888207,0.024973439,0.00052884483,0.0006179722,0.00094129157,0.0000051112283,0.0009238027],"genre_scores_gemma":[0.99721485,0.00092136196,0.00048334606,0.0011750797,0.000045901932,0.000024431012,0.00000660651,0.000011904854,0.00011653478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993222,0.00064328016,0.0053995326,0.00033866544,0.0000743816,0.00032213275],"domain_scores_gemma":[0.9895571,0.00054443564,0.00900732,0.00055622944,0.00025548975,0.0000794464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020796826,0.00011965959,0.0017142177,0.00031296746,0.00012854615,0.000008177467,0.00024642103,0.00013926117,0.00023599873],"category_scores_gemma":[0.0019999347,0.00015133909,0.00013212404,0.00011293176,0.00027584538,0.00025074024,0.0000786506,0.00013413122,0.000012169953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020357264,0.00049343344,0.9901281,0.0006864291,0.0000629922,1.8431095e-7,0.0036284456,0.00023724702,0.0000038273597,0.0010327453,0.0016130303,0.0019099705],"study_design_scores_gemma":[0.0014538591,0.00076806697,0.98668283,0.00020435332,0.000003820523,0.0000018873795,0.0011912001,0.0023106423,0.000031097992,0.0060954536,0.0011317066,0.00012507492],"about_ca_topic_score_codex":0.051361807,"about_ca_topic_score_gemma":0.0063503287,"teacher_disagreement_score":0.04501148,"about_ca_system_score_codex":0.0005595773,"about_ca_system_score_gemma":0.0010880299,"threshold_uncertainty_score":0.9549553},"labels":[],"label_agreement":null},{"id":"W2762401852","doi":"10.1093/annonc/mdx388.053","title":"Management of chemotherapy-related side effects- do patients know where to get help?","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; St. Michael's Hospital; Sinai Health System; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Attendance; Family medicine; Chemotherapy; Chemotherapy regimen; Descriptive statistics; Internal medicine","score_opus":0.024190563372269613,"score_gpt":0.35815851983373154,"score_spread":0.33396795646146193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762401852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91117215,0.0009117694,0.000011436917,0.0059437403,0.00055559044,0.00052720506,0.000011198882,0.0000146202065,0.08085227],"genre_scores_gemma":[0.99561983,0.0010809719,0.0001276396,0.001120212,0.000048714595,0.000026665644,0.000007595276,0.000017524035,0.001950833],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990935,0.00004458031,0.0002693007,0.00019473156,0.00019053156,0.00020738518],"domain_scores_gemma":[0.99881643,0.000049207858,0.00024432704,0.0005375039,0.00024370068,0.00010884579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020695914,0.00011276121,0.00044269086,0.00007183617,0.00004553256,0.0000056576014,0.00020243062,0.00013076639,0.0001238488],"category_scores_gemma":[0.00004228256,0.000100336685,0.00012093936,0.00006489643,0.00008745811,0.000039058756,0.00009816968,0.00008999668,0.000033257173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088238914,0.00064003706,0.04612453,0.000770045,0.00046750135,0.00007227462,0.0012171007,0.0000026278922,0.0006650052,0.00043775336,0.014626347,0.93409437],"study_design_scores_gemma":[0.005599259,0.007524581,0.5914649,0.0010549403,0.00015327388,0.0000039879096,0.0003529854,0.000004874806,0.018633759,0.0005288459,0.37448156,0.00019705544],"about_ca_topic_score_codex":0.00036779844,"about_ca_topic_score_gemma":0.00028117708,"teacher_disagreement_score":0.9338973,"about_ca_system_score_codex":0.000033664204,"about_ca_system_score_gemma":0.000044371056,"threshold_uncertainty_score":0.40916112},"labels":[],"label_agreement":null},{"id":"W2762414010","doi":"10.1093/annonc/mdx370.011","title":"EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Enzalutamide; Prostate cancer; Pharmacokinetics; Cmax; Adverse effect; Internal medicine; Abiraterone acetate; Gastroenterology; Phases of clinical research; Urology; Nausea; Pharmacology; Oncology; Cancer; Chemotherapy; Androgen deprivation therapy; Androgen receptor","score_opus":0.08809003921003584,"score_gpt":0.43830772066008306,"score_spread":0.3502176814500472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762414010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780237,0.00079397846,0.0000058092387,0.01690588,0.00007483359,0.001596478,0.00048217276,0.0000162466,0.002100894],"genre_scores_gemma":[0.9941243,0.003362074,0.0012012998,0.00039123456,0.000102418286,0.00013937932,0.0001469075,0.00003533911,0.0004970536],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978691,0.00015341396,0.0005742234,0.0004963635,0.00037351678,0.0005333887],"domain_scores_gemma":[0.998462,0.00016760672,0.00038813165,0.00041958317,0.00028711135,0.00027553554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069469964,0.00029171014,0.0007870927,0.00020546692,0.00019132854,0.0000479225,0.00018392767,0.00009513768,0.0001440778],"category_scores_gemma":[0.00008192667,0.00020881933,0.00007023308,0.0001444262,0.00061444566,0.00018271244,0.00010916495,0.0003146444,0.0000071913505],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18886447,0.01698053,0.039802298,0.0015642053,0.0024466165,0.004370263,0.009522654,0.00015784374,0.29729423,0.00041604883,0.008518082,0.43006274],"study_design_scores_gemma":[0.28466266,0.0756943,0.13154402,0.0027286785,0.001329746,0.00064191927,0.0020787285,0.0011120841,0.34281665,0.0011478672,0.15453042,0.0017129243],"about_ca_topic_score_codex":0.00040307845,"about_ca_topic_score_gemma":0.00043460872,"teacher_disagreement_score":0.42834982,"about_ca_system_score_codex":0.00016176274,"about_ca_system_score_gemma":0.0007300571,"threshold_uncertainty_score":0.85154057},"labels":[],"label_agreement":null},{"id":"W2762414606","doi":"10.1093/annonc/mdx440.051","title":"ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Durvalumab; Neutropenia; Internal medicine; Gastroenterology; Adverse effect; Lung cancer; Chemotherapy; Surgery; Urology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.03829033952117692,"score_gpt":0.3702188285745939,"score_spread":0.33192848905341693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762414606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819776,0.0020648865,0.0000068699596,0.0020161376,0.00028831908,0.0014911629,0.000055508044,0.000026935057,0.012072598],"genre_scores_gemma":[0.98923945,0.0035990295,0.00029468143,0.0016323453,0.000093311166,0.00021845514,0.000033495424,0.000051722676,0.004837512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979531,0.00009525967,0.00061163097,0.00047068283,0.00025682387,0.000612515],"domain_scores_gemma":[0.9978455,0.00010704147,0.00071502343,0.000761207,0.00041464632,0.0001566165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003241713,0.00031082396,0.0008798194,0.00018014575,0.00016190512,0.000025176189,0.0003452763,0.00027162614,0.00022095517],"category_scores_gemma":[0.00010452617,0.00022405761,0.00015773943,0.00018912852,0.00033239368,0.00019712669,0.00007011045,0.0002568981,0.0000079472575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040268086,0.0048019164,0.7649158,0.00058782136,0.00048883056,0.00017753837,0.0016242465,0.0000072216603,0.0020345734,0.0000056220015,0.0045366725,0.18055166],"study_design_scores_gemma":[0.052653693,0.01001497,0.88954425,0.0008680489,0.00015576524,0.000011272578,0.00017213981,0.00004529322,0.0050769923,0.000013074802,0.041098252,0.00034624466],"about_ca_topic_score_codex":0.003331792,"about_ca_topic_score_gemma":0.0062172427,"teacher_disagreement_score":0.18020542,"about_ca_system_score_codex":0.00025349748,"about_ca_system_score_gemma":0.0009961167,"threshold_uncertainty_score":0.91368043},"labels":[],"label_agreement":null},{"id":"W2762440037","doi":"10.1093/annonc/mdx393.049","title":"Mechanism of pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"FOLFIRI; Medicine; Irinotecan; KRAS; Bevacizumab; Oxaliplatin; Neutropenia; Internal medicine; Colorectal cancer; Fluorouracil; Cancer research; Toxicity; Gastroenterology; Oncology; Cancer; Chemotherapy","score_opus":0.03956383169501896,"score_gpt":0.37132070523630895,"score_spread":0.33175687354128996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762440037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981241,0.00012193197,0.000014963356,0.00010204945,0.00003288102,0.0012141234,0.00013227534,0.0000027321696,0.0002548962],"genre_scores_gemma":[0.99931586,0.00016344232,0.000085896754,0.000025732268,0.000007103059,0.0002502421,0.00011860399,0.000020074905,0.000013071547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983243,0.00020479059,0.00040874485,0.0003930266,0.00028818185,0.0003810027],"domain_scores_gemma":[0.99884796,0.000040649204,0.00041406197,0.00034340337,0.0002664386,0.0000874885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033640832,0.00020071832,0.00050301116,0.00022703009,0.00004480473,0.00001190824,0.00026828202,0.00010428007,0.000020382502],"category_scores_gemma":[0.00010598528,0.00016280472,0.000041030897,0.00016008424,0.00012371103,0.000022588323,0.00011985166,0.00015596977,0.0000011905931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015168837,0.020450143,0.9342688,0.000073850126,0.00032379967,0.00037875024,0.000928067,0.00009778959,0.01728195,0.00004323975,0.000014690606,0.010970097],"study_design_scores_gemma":[0.05539578,0.06488812,0.7135499,0.00008745809,0.000057140795,0.0000047951,0.0004060495,0.00011625601,0.16498792,0.00015517561,0.00007452315,0.00027683977],"about_ca_topic_score_codex":0.0073589324,"about_ca_topic_score_gemma":0.047264125,"teacher_disagreement_score":0.22071885,"about_ca_system_score_codex":0.00012643999,"about_ca_system_score_gemma":0.0005667865,"threshold_uncertainty_score":0.9992511},"labels":[],"label_agreement":null},{"id":"W2762452584","doi":"10.1093/annonc/mdx388.035","title":"Body mass index (BMI), lifestyle behaviors, and perceptions in cancer survivors","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Centre for Addiction and Mental Health; University of British Columbia; Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Body mass index; Logistic regression; Cancer; Obesity; Alcohol consumption; Smoking cessation; Internal medicine; Alcohol intake; Quality of life (healthcare); Physical activity; Physical therapy; Alcohol; Pathology","score_opus":0.06184007712160761,"score_gpt":0.4191738566090733,"score_spread":0.3573337794874657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762452584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837581,0.0004597149,0.000006560173,0.007231716,0.00042403126,0.00016838644,0.0000349031,0.00001261394,0.007903988],"genre_scores_gemma":[0.9960661,0.0020689168,0.000023703715,0.00064569054,0.00015686204,0.000050719773,0.0000094922625,0.000013959381,0.00096457254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991403,0.00005795693,0.00022808128,0.00020960403,0.00012810399,0.00023594064],"domain_scores_gemma":[0.99917775,0.00005235547,0.00014385348,0.00036082012,0.00013815396,0.00012708516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027880727,0.00010580304,0.00037831735,0.00011983789,0.000090609596,0.0000124362,0.00012609118,0.00019253882,0.0003553131],"category_scores_gemma":[0.00007856931,0.000100217345,0.000065537046,0.000058437545,0.00024991785,0.00009041314,0.000065737935,0.00021250619,0.00000609907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013526047,0.00016264012,0.969671,0.000043726694,0.000022527487,0.00004988243,0.0006324719,0.0000010786852,0.001856743,0.000098796954,0.00120666,0.026119225],"study_design_scores_gemma":[0.00080302294,0.00063015055,0.966496,0.000065824686,0.000038292725,0.000013867924,0.0007281012,0.000016551694,0.00035348735,0.00013147101,0.030627819,0.000095428],"about_ca_topic_score_codex":0.0378399,"about_ca_topic_score_gemma":0.13015248,"teacher_disagreement_score":0.09231258,"about_ca_system_score_codex":0.00004278749,"about_ca_system_score_gemma":0.00022124047,"threshold_uncertainty_score":0.9685672},"labels":[],"label_agreement":null},{"id":"W2762460629","doi":"10.1093/annonc/mdx374","title":"Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"MacroGenics; Genentech; AstraZeneca; Celgene; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Head and neck squamous-cell carcinoma; Internal medicine; Clinical endpoint; Oncology; Immunotherapy; Regimen; Chemotherapy; Phases of clinical research; Radiation therapy; Cancer; Head and neck cancer; Clinical trial; Pembrolizumab","score_opus":0.16130445258756126,"score_gpt":0.4264112029151277,"score_spread":0.2651067503275664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762460629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892314,0.0028708086,0.00001227009,0.0037968154,0.0004170644,0.0015214179,0.00043213705,0.00001792332,0.0017001813],"genre_scores_gemma":[0.99790365,0.00014623778,0.000745259,0.0005265881,0.00015782278,0.0000760687,0.000098668635,0.000025461799,0.00032025957],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9983207,0.00013179683,0.0006210639,0.00043805147,0.00017066383,0.0003177487],"domain_scores_gemma":[0.99786556,0.0005178641,0.00060157455,0.00067535794,0.00020756968,0.00013205817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059337047,0.00020290393,0.0006595311,0.000104115425,0.000203519,0.000025368947,0.00020154889,0.000109882014,0.000039964812],"category_scores_gemma":[0.00046975986,0.00017843308,0.00015978607,0.000050198858,0.00025427656,0.00010002795,0.00008070931,0.00013671933,0.0000032762498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3843017,0.029702818,0.004931696,0.00030556883,0.00038779608,0.000360468,0.006469677,6.629998e-7,0.013245406,0.000004221568,0.022441046,0.53784895],"study_design_scores_gemma":[0.19644336,0.5687387,0.14833057,0.00020443194,0.0008301198,0.0000852042,0.0026861297,0.00037989853,0.023702497,0.00030164153,0.05783622,0.000461249],"about_ca_topic_score_codex":0.0010963879,"about_ca_topic_score_gemma":0.0003120833,"teacher_disagreement_score":0.53903586,"about_ca_system_score_codex":0.000046170073,"about_ca_system_score_gemma":0.00022683588,"threshold_uncertainty_score":0.727629},"labels":[],"label_agreement":null},{"id":"W2762476265","doi":"10.1093/annonc/mdx440.031","title":"Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Paclitaxel; Urothelial cancer; Internal medicine; Pembrolizumab; Oncology; Phases of clinical research; Chemotherapy; Cancer","score_opus":0.21489378205266058,"score_gpt":0.49785635348724117,"score_spread":0.2829625714345806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762476265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88737214,0.004792958,0.00006783793,0.062852174,0.009241913,0.006173925,0.014367548,0.000113810165,0.015017682],"genre_scores_gemma":[0.9817182,0.004567153,0.0011388988,0.0029554714,0.0046662274,0.0009460703,0.00047004392,0.0000915625,0.0034464062],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751014,0.00015188947,0.00076454855,0.0006294859,0.00035375782,0.0005901599],"domain_scores_gemma":[0.9960148,0.0010969095,0.00090679486,0.0012770483,0.000470917,0.00023356419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041978154,0.00038207145,0.0010246368,0.000068113935,0.0004390136,0.000045945195,0.0005885609,0.00037123795,0.00044429058],"category_scores_gemma":[0.0022402443,0.00023733337,0.00038603376,0.00009517004,0.0003788805,0.00020287979,0.00011967036,0.0003837402,0.000020819733],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74650687,0.0011344462,0.000033286342,0.00003981355,0.0006774269,0.00004510228,0.0004810332,0.0000027510468,0.0010399064,0.00008697842,0.040029123,0.20992324],"study_design_scores_gemma":[0.4589138,0.039962042,0.0010666698,0.00018524409,0.0006456926,0.000008931523,0.000115643736,0.00003505867,0.005681448,0.00036998047,0.49278194,0.00023354506],"about_ca_topic_score_codex":0.0013102309,"about_ca_topic_score_gemma":0.0015120435,"teacher_disagreement_score":0.45275283,"about_ca_system_score_codex":0.00012379045,"about_ca_system_score_gemma":0.0012676133,"threshold_uncertainty_score":0.96781737},"labels":[],"label_agreement":null},{"id":"W2762485081","doi":"10.1093/annonc/mdx373.006","title":"Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Clinical endpoint; Follicular lymphoma; Subgroup analysis; Lymphoma; Rituximab; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Confidence interval","score_opus":0.16493439728604195,"score_gpt":0.44832213333161947,"score_spread":0.28338773604557754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762485081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943488,0.00036727544,0.0000013971096,0.00081071793,0.00010907062,0.001455069,0.000031997093,0.000013565728,0.002862092],"genre_scores_gemma":[0.99845725,0.0002727836,0.00006471993,0.0003218155,0.000118598444,0.00010384591,0.00004808029,0.000029088818,0.00058381323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977424,0.00032400806,0.0005024891,0.00044747605,0.0005389473,0.00044467082],"domain_scores_gemma":[0.99688995,0.00078282267,0.0004602171,0.0014463826,0.00026767832,0.00015293347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004374368,0.00024118331,0.000810373,0.00012484567,0.00016635392,0.000025794989,0.0004707955,0.00016225486,0.00015428486],"category_scores_gemma":[0.00038320755,0.00012365778,0.0001021648,0.00013664472,0.00039535054,0.00011979999,0.00018729034,0.00016269342,0.000038166825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.032563098,0.044079877,0.8135019,0.00006271995,0.0013209321,0.0015591558,0.0061876294,0.000021553398,0.00031957118,0.0000060011143,0.005056362,0.09532122],"study_design_scores_gemma":[0.12435939,0.04163384,0.82539684,0.00008577814,0.00020486063,0.000005248471,0.0010191282,0.00007605538,0.0020217258,0.000009099689,0.0050524804,0.00013556436],"about_ca_topic_score_codex":0.020703321,"about_ca_topic_score_gemma":0.0069840536,"teacher_disagreement_score":0.09518566,"about_ca_system_score_codex":0.0047493656,"about_ca_system_score_gemma":0.007051517,"threshold_uncertainty_score":0.99907124},"labels":[],"label_agreement":null},{"id":"W2762573395","doi":"10.1093/annonc/mdx364.008","title":"Clinical outcomes of single versus double hormone receptor positive breast cancer patients treated with neoadjuvant chemotherapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Chemotherapy; Progesterone receptor; Cancer; Oncology; Gastroenterology; Hormone receptor; Retrospective cohort study; Estrogen receptor; Gynecology","score_opus":0.06003380894871402,"score_gpt":0.390841762159138,"score_spread":0.330807953210424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762573395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944599,0.00030031256,0.000002599789,0.002571125,0.00019222665,0.000198345,0.00035247148,0.000005345487,0.0019176236],"genre_scores_gemma":[0.9979275,0.0013051013,0.00015494417,0.00025586688,0.000106363856,0.000029621153,0.00008396328,0.000020071206,0.00011656892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990027,0.00004742396,0.00030890325,0.0003096741,0.000110810346,0.0002204894],"domain_scores_gemma":[0.9984646,0.000043547054,0.0005548284,0.0003998599,0.000471645,0.00006552692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096610784,0.00017659103,0.00051190675,0.00002506792,0.00009145563,0.0000060684133,0.00021590177,0.00017383261,0.000022277885],"category_scores_gemma":[0.00003199896,0.00013045844,0.00014062018,0.000029815841,0.00046961382,0.000008460653,0.000098433295,0.000055736225,0.000002388629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021877661,0.0020249553,0.8995435,0.000006842822,0.0018749885,0.0000026288856,0.000087679866,0.000001772468,0.009055988,0.000011326395,0.003241197,0.062271442],"study_design_scores_gemma":[0.012642707,0.0069971127,0.9219479,0.000018838498,0.00008021546,0.0000015755538,0.000029900306,2.5103492e-7,0.055166427,0.0000029147388,0.0029796232,0.00013254456],"about_ca_topic_score_codex":0.0009719063,"about_ca_topic_score_gemma":0.0003504095,"teacher_disagreement_score":0.0621389,"about_ca_system_score_codex":0.000025745065,"about_ca_system_score_gemma":0.00010848915,"threshold_uncertainty_score":0.5319941},"labels":[],"label_agreement":null},{"id":"W2762636298","doi":"10.1093/annonc/mdx440.029","title":"CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Ipilimumab; Nivolumab; Gastroenterology; Sunitinib; Urology; Oncology; Cancer; Immunotherapy","score_opus":0.1354962718192336,"score_gpt":0.39838214762304164,"score_spread":0.26288587580380807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762636298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347895,0.0019557127,0.00009360816,0.00055813155,0.000092598806,0.0016275297,0.00020805691,0.00002035434,0.0019650725],"genre_scores_gemma":[0.9908981,0.0028059902,0.0054009594,0.000060656334,0.00007293997,0.0001182969,0.000070787144,0.000048389073,0.000523905],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776846,0.00021105901,0.0007663202,0.00055160624,0.00021848819,0.00048404047],"domain_scores_gemma":[0.99650204,0.0010355904,0.0011543325,0.0007198377,0.00030908716,0.00027908938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005263275,0.00038072505,0.0013913051,0.00019602737,0.00039482326,0.000018320326,0.0001717601,0.00017497186,0.000051649873],"category_scores_gemma":[0.00045573516,0.0002745271,0.00019659268,0.00006794135,0.0004370899,0.00018752442,0.00020149208,0.00013111957,0.00000216094],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10725496,0.0044974294,0.030092407,0.0020789427,0.00106914,0.0007068038,0.0053317794,0.000041219584,0.39245537,0.00016136111,0.00072527886,0.45558533],"study_design_scores_gemma":[0.04815006,0.03733446,0.19639856,0.00035580917,0.0013027106,0.00019813127,0.00086480106,0.00022507693,0.70952606,0.00027091926,0.005025657,0.00034772966],"about_ca_topic_score_codex":0.0002994931,"about_ca_topic_score_gemma":0.00011459527,"teacher_disagreement_score":0.4552376,"about_ca_system_score_codex":0.00012393469,"about_ca_system_score_gemma":0.0002810135,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W2762643147","doi":"10.1093/annonc/mdx364.015","title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Placebo; Oncology; Breast cancer; Chemotherapy; Internal medicine; Adjuvant; Cancer; Alternative medicine; Immunotherapy; Pathology","score_opus":0.05267274810334072,"score_gpt":0.41567765299517073,"score_spread":0.36300490489183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762643147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969497,0.0023836913,0.000039892904,0.016009778,0.0008431646,0.006488688,0.0005969164,0.000079973346,0.004060871],"genre_scores_gemma":[0.98089546,0.0066650477,0.00014975083,0.005944035,0.00041211944,0.0010070271,0.0000869095,0.00015281189,0.0046868525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952319,0.00028310344,0.0015954843,0.0010782501,0.00077196205,0.0010392858],"domain_scores_gemma":[0.9941819,0.0006589857,0.0022545329,0.0015226118,0.0010114844,0.0003705313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013242892,0.0008255578,0.0027878059,0.00030950367,0.00048304332,0.000054131433,0.0009794325,0.00061886146,0.001558343],"category_scores_gemma":[0.00032997693,0.00069596514,0.0008387632,0.0002813965,0.00083064544,0.00032040486,0.00012555788,0.00049719366,0.0000132009445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6138034,0.009684311,0.0011075884,0.00016715426,0.003264929,0.000073115705,0.005134975,0.0000032720382,0.119092666,0.00001967836,0.06712094,0.18052799],"study_design_scores_gemma":[0.508128,0.061808366,0.014627969,0.00044843182,0.0005283833,0.00024010336,0.0032284635,0.00020573333,0.3221379,0.00020276078,0.08742824,0.0010156895],"about_ca_topic_score_codex":0.0073326887,"about_ca_topic_score_gemma":0.00063428184,"teacher_disagreement_score":0.2030452,"about_ca_system_score_codex":0.00033145654,"about_ca_system_score_gemma":0.001693944,"threshold_uncertainty_score":0.99954915},"labels":[],"label_agreement":null},{"id":"W2762643573","doi":"10.1093/annonc/mdx385.001","title":"Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Randomized controlled trial; Logistic regression; Food and drug administration; Internal medicine; Adjuvant; Oncology; Pharmacology","score_opus":0.6039000558799366,"score_gpt":0.5920798127647546,"score_spread":0.011820243115181928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762643573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753189,0.0010875802,0.0004417815,0.016197756,0.00050856435,0.0030396718,0.00058117585,0.000004991197,0.0028195668],"genre_scores_gemma":[0.994867,0.0005109494,0.0034675894,0.0005577633,0.00023377979,0.00020115524,0.000023395756,0.000015455676,0.00012288368],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97853833,0.0014435609,0.019246854,0.00038128858,0.00010764814,0.00028229013],"domain_scores_gemma":[0.93533623,0.021363387,0.04209274,0.00048821335,0.0006000893,0.00011931317],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.16882183,0.00016325574,0.010914595,0.00024979917,0.00009019953,0.000017463342,0.00031030818,0.0002507085,0.00005792415],"category_scores_gemma":[0.1227264,0.00016342015,0.0011419643,0.000031572734,0.00050882215,0.0002089572,0.00005914106,0.00010561555,0.0000028426023],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2693289,0.0038240375,0.12717158,0.0065124505,0.007967408,0.0000017181734,0.008234412,0.00021726023,0.00020522944,0.54556066,0.009773523,0.021202799],"study_design_scores_gemma":[0.7610497,0.009997147,0.043805767,0.00049419905,0.0008405364,0.0000072729526,0.0031594748,0.008970585,0.0056676273,0.16203828,0.0032697876,0.0006996244],"about_ca_topic_score_codex":0.00030138734,"about_ca_topic_score_gemma":0.00017221447,"teacher_disagreement_score":0.4917208,"about_ca_system_score_codex":0.000020117857,"about_ca_system_score_gemma":0.00053396233,"threshold_uncertainty_score":0.8846632},"labels":[],"label_agreement":null},{"id":"W2762648551","doi":"10.1093/annonc/mdx372.004","title":"Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Adverse effect; Gastroenterology; Cohort; Nausea; Ovarian cancer; Placebo; Chemotherapy; Oncology; Surgery; Cancer; Pathology","score_opus":0.0827514955526723,"score_gpt":0.4175936866276472,"score_spread":0.33484219107497487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762648551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98387176,0.00048887107,0.000016140737,0.0064455066,0.00017796928,0.00036038604,0.00004199007,0.0000059456174,0.0085914135],"genre_scores_gemma":[0.9973379,0.0017637134,0.00020722937,0.00051463494,0.00005942111,0.000022587854,0.000010108837,0.000010627151,0.00007381804],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999066,0.000057555993,0.00035208755,0.0001920069,0.00015202657,0.00018035017],"domain_scores_gemma":[0.9988302,0.000092620154,0.00043178195,0.00032644678,0.0002401225,0.000078833065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002395052,0.000099966084,0.00046551644,0.0000950977,0.00004832745,0.0000037418083,0.0001022416,0.00010726878,0.00010999287],"category_scores_gemma":[0.00010242373,0.000081433616,0.000037344977,0.000059485992,0.00030362708,0.00006959353,0.000032492408,0.00014393436,0.0000015250989],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010220146,0.0013000137,0.3355132,0.00011863564,0.00016031257,0.000016641965,0.0010236748,0.00000835704,0.00075987313,0.00052908796,0.0020811737,0.6482689],"study_design_scores_gemma":[0.016316038,0.0074406466,0.92609185,0.00044234403,0.00003302846,0.0000054040006,0.000030803298,0.000010570716,0.0032923885,0.0001541465,0.046090093,0.00009266973],"about_ca_topic_score_codex":0.0006887349,"about_ca_topic_score_gemma":0.00065526675,"teacher_disagreement_score":0.6481762,"about_ca_system_score_codex":0.00005372212,"about_ca_system_score_gemma":0.00024706978,"threshold_uncertainty_score":0.33207664},"labels":[],"label_agreement":null},{"id":"W2762651948","doi":"10.1093/annonc/mdx367.030","title":"Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Internal medicine; Gastroenterology; Endocrine system; Surgery","score_opus":0.2148737949930711,"score_gpt":0.5153160146034517,"score_spread":0.30044221961038053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762651948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741636,0.0009734647,0.00025658845,0.02071747,0.0005105046,0.002049148,0.0001476783,0.000030920346,0.001150621],"genre_scores_gemma":[0.9953842,0.0020974854,0.0006897995,0.0007813258,0.00008519175,0.00035758232,0.00014543638,0.000032176173,0.00042679938],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99756384,0.00026920222,0.0014197308,0.00030648353,0.00010990897,0.0003308237],"domain_scores_gemma":[0.9969437,0.00047161558,0.0014559717,0.0007718586,0.00028005618,0.00007681462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003014059,0.00019531987,0.0009156885,0.00028034177,0.00020535555,0.0000096672275,0.00030955323,0.00030196994,0.00018250516],"category_scores_gemma":[0.00087134575,0.00017838042,0.00049522525,0.00013978414,0.00014210766,0.00024717266,0.00003293981,0.00018098984,0.0000068662675],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02934639,0.0030457636,0.0012647939,0.000035294473,0.00035900096,0.0000082074475,0.00076260214,3.8413876e-7,0.18381114,0.00009919221,0.00086606416,0.7804012],"study_design_scores_gemma":[0.31304216,0.033761177,0.42362645,0.000509572,0.00037182827,0.000101292506,0.0003346,0.00036935543,0.058118373,0.0062580486,0.1628339,0.000673245],"about_ca_topic_score_codex":0.0003375692,"about_ca_topic_score_gemma":0.00010800502,"teacher_disagreement_score":0.77972794,"about_ca_system_score_codex":0.0001268096,"about_ca_system_score_gemma":0.00029656396,"threshold_uncertainty_score":0.72741425},"labels":[],"label_agreement":null},{"id":"W2762701444","doi":"10.1093/annonc/mdx370.055","title":"ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen receptor; Randomization; Randomized controlled trial; Chemotherapy; Cancer; Pathology","score_opus":0.166572910446867,"score_gpt":0.4890637230435366,"score_spread":0.3224908125966696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762701444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892831,0.0012879331,0.0000037705072,0.005907649,0.00006160119,0.0011745712,0.00015188083,0.000006494414,0.0021229854],"genre_scores_gemma":[0.99475247,0.004055324,0.00026740407,0.00014642526,0.000056471134,0.00012897568,0.00002526589,0.000015721389,0.00055197283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99873954,0.000108340035,0.00035290502,0.00022607116,0.00024380573,0.00032933208],"domain_scores_gemma":[0.998676,0.00014675652,0.00040041222,0.00033922333,0.00033242413,0.00010516512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042755553,0.00013631493,0.00073908764,0.00017855277,0.00004871972,0.0000071864115,0.00010280651,0.000062720515,0.000021611597],"category_scores_gemma":[0.00020669444,0.00009272635,0.00007972987,0.000098299664,0.0006277442,0.000107416825,0.000046314213,0.00016658974,0.000003250374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8192639,0.0055687493,0.010866406,0.00037116365,0.0013916404,0.0037247802,0.0045543816,0.000026992633,0.026213905,0.00015556971,0.0014790772,0.12638344],"study_design_scores_gemma":[0.60604656,0.09804507,0.09470494,0.0008944669,0.0006246523,0.00011968735,0.0021438722,0.00028013322,0.18698789,0.0007837252,0.008971575,0.00039742293],"about_ca_topic_score_codex":0.0010436171,"about_ca_topic_score_gemma":0.00059204374,"teacher_disagreement_score":0.21321733,"about_ca_system_score_codex":0.000060954404,"about_ca_system_score_gemma":0.00087742414,"threshold_uncertainty_score":0.3781271},"labels":[],"label_agreement":null},{"id":"W2762702614","doi":"10.1093/annonc/mdx361.058","title":"Clinical dysregulation of DNA repair by the polynucleotide kinase/phosphatase-XRCC4-DNA ligase IV in neurological disease","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"DNA repair protein XRCC4; DNA repair; DNA ligase; Genome instability; Non-homologous end joining; Phosphorylation; Biology; Mutation; DNA mismatch repair; DNA; Molecular biology; Cell biology; Biochemistry; DNA damage; Gene","score_opus":0.05118015149388621,"score_gpt":0.3725756177688934,"score_spread":0.3213954662750072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762702614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934339,0.0008097004,0.000021064317,0.004459769,0.0002429234,0.00028504626,0.00011273306,0.000014801241,0.0006200413],"genre_scores_gemma":[0.9970722,0.00038359957,0.00022361113,0.001892712,0.00012698656,0.000020946416,0.00009862148,0.00001771044,0.0001635877],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980241,0.00040498262,0.0006564306,0.0004540444,0.00016073314,0.00029969442],"domain_scores_gemma":[0.99783105,0.0001299243,0.00058920955,0.0011702327,0.000121525656,0.00015805644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012423879,0.00016427295,0.00037984984,0.000034173943,0.00009434845,0.000010363582,0.00060523424,0.0002966872,0.00003148125],"category_scores_gemma":[0.0017176411,0.0001283999,0.00030337434,0.000045272216,0.0005737684,0.000011139275,0.00037090684,0.00015687097,0.00000633342],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00782227,0.004641384,0.32450774,0.000118314056,0.00036176742,0.00036610808,0.000080337864,0.0000951253,0.4063971,0.0055078487,0.1274466,0.12265541],"study_design_scores_gemma":[0.002235854,0.0065441653,0.52451754,0.000033148677,0.00008268426,0.00001398804,0.00003106479,0.0006820698,0.36283135,0.0021320248,0.100577034,0.00031908904],"about_ca_topic_score_codex":0.000061459505,"about_ca_topic_score_gemma":0.00007151574,"teacher_disagreement_score":0.2000098,"about_ca_system_score_codex":0.0000046212267,"about_ca_system_score_gemma":0.00015180532,"threshold_uncertainty_score":0.52359957},"labels":[],"label_agreement":null},{"id":"W2762733456","doi":"10.1093/annonc/mdx371.054","title":"Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; University of Alberta; Regional Municipality of Durham; London Health Sciences Centre; BC Cancer Agency; Hôpital Notre-Dame; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; Western University; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Toxicity; Pharmacokinetics; Sunitinib; Urology; Internal medicine; Nuclear medicine; Cancer","score_opus":0.3869043426930212,"score_gpt":0.5269391595123061,"score_spread":0.14003481681928487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762733456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882639,0.002226974,0.000018441566,0.0039282097,0.00017956017,0.0024170855,0.0006063742,0.000014062702,0.0023453934],"genre_scores_gemma":[0.9942651,0.0030498235,0.00070953876,0.0006026192,0.0001625961,0.00026943104,0.00032442636,0.00003561096,0.0005808849],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980152,0.00016874801,0.0007035638,0.00043626,0.00033386168,0.00034237048],"domain_scores_gemma":[0.9966259,0.00041138107,0.0009844903,0.0013725946,0.0004360797,0.00016953073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007579976,0.0002446307,0.0010697272,0.00016599744,0.00021368623,0.000009846085,0.0007031764,0.00007542414,0.0004547112],"category_scores_gemma":[0.00022522571,0.00019167113,0.00013719352,0.00008183156,0.00020424457,0.0001164642,0.00029934227,0.00014299626,0.0000040693403],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032496683,0.091691285,0.0036771188,0.0007129446,0.004996989,0.00069675676,0.005915127,0.00005806037,0.060905833,0.000042988406,0.026161477,0.77264476],"study_design_scores_gemma":[0.15646794,0.26973945,0.0056165517,0.00013527357,0.0025109404,0.000059214064,0.00068574125,0.00037327618,0.37363833,0.0002734368,0.190168,0.00033183332],"about_ca_topic_score_codex":0.0011982209,"about_ca_topic_score_gemma":0.00027715258,"teacher_disagreement_score":0.7723129,"about_ca_system_score_codex":0.000030025112,"about_ca_system_score_gemma":0.00044011846,"threshold_uncertainty_score":0.7816122},"labels":[],"label_agreement":null},{"id":"W2762745551","doi":"10.1093/annonc/mdx376.056","title":"Pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500 + cancer patients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Paclitaxel; Tolerability; Carboplatin; Internal medicine; Adverse effect; Oncolytic virus; Chemotherapy; Cancer; Oncology; Neutropenia; Breast cancer; Gastroenterology; Surgery","score_opus":0.04830839971635676,"score_gpt":0.38845872837213463,"score_spread":0.3401503286557779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762745551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981509,0.00020232245,0.000008895203,0.0011226949,0.000014668561,0.00022072201,0.000116707655,4.6059904e-7,0.00016265351],"genre_scores_gemma":[0.9988891,0.00088264566,0.000025008043,0.00010905957,0.000005570268,0.000006028937,0.00006774964,0.000005350756,0.000009504206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990495,0.00018223416,0.00029502835,0.00022873342,0.00012111197,0.00012341593],"domain_scores_gemma":[0.9985903,0.000029301935,0.00032875146,0.00082999223,0.00020109619,0.000020574975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006944241,0.00006967438,0.0003348916,0.00008510561,0.000029096043,0.0000029415198,0.0004778623,0.00009960479,0.00001593395],"category_scores_gemma":[0.00013186791,0.000051651772,0.00003554397,0.00015492967,0.00033112135,0.0000066676594,0.00018085541,0.00007252621,3.272855e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065962565,0.0010125852,0.8751181,0.000031841948,0.00046381573,5.5422726e-7,0.00031509245,0.00021756366,0.041553307,0.000019491856,0.000021683616,0.07464975],"study_design_scores_gemma":[0.0018750165,0.0034625712,0.89417946,0.000014126187,0.00003670131,1.4314696e-7,0.000025294297,0.0002912787,0.09979147,0.000063977604,0.00020945723,0.000050485716],"about_ca_topic_score_codex":0.0009996898,"about_ca_topic_score_gemma":0.019503083,"teacher_disagreement_score":0.074599266,"about_ca_system_score_codex":0.000015096222,"about_ca_system_score_gemma":0.00018065923,"threshold_uncertainty_score":0.9983884},"labels":[],"label_agreement":null},{"id":"W2762790960","doi":"10.1093/annonc/mdx375.004","title":"Palbociclib in advanced breast cancer: A cost-utility analysis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Cost effectiveness; Breast cancer; Statistics; Cancer; Internal medicine; Risk analysis (engineering); Mathematics; Metastatic breast cancer; Tamoxifen","score_opus":0.09860095043635311,"score_gpt":0.4710322987665924,"score_spread":0.3724313483302393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762790960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704193,0.0010531438,0.00013648439,0.023654772,0.00015358531,0.00040900498,0.000117510215,0.000045949,0.0040102648],"genre_scores_gemma":[0.99708664,0.00076772436,0.00046304322,0.0013057113,0.00008847376,0.0000991356,0.000009734553,0.00002076942,0.00015877718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863046,0.00006915903,0.00040384638,0.00034171698,0.00017727178,0.00037753306],"domain_scores_gemma":[0.9981808,0.000096147225,0.0004556584,0.0008158245,0.00031252555,0.0001390634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035805805,0.00015571273,0.0008995085,0.00022603695,0.00007210098,0.0000073180777,0.00026500548,0.00014253503,0.00034078344],"category_scores_gemma":[0.0001472912,0.00014177196,0.0002195332,0.00028273347,0.0003899467,0.00018897928,0.00008726039,0.00021728661,0.0000052911446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019609728,0.00028932895,0.4230461,0.000033102693,0.00046645588,0.000045815003,0.00020741756,0.00009415566,0.00096439733,0.000079353966,0.00008684473,0.572726],"study_design_scores_gemma":[0.0030873425,0.0003480125,0.96318763,0.000059816146,0.00021126145,0.000026557786,0.00013971748,0.00022586458,0.0017060562,0.0006148805,0.030274691,0.000118135904],"about_ca_topic_score_codex":0.0010246082,"about_ca_topic_score_gemma":0.0031274436,"teacher_disagreement_score":0.5726079,"about_ca_system_score_codex":0.000100197314,"about_ca_system_score_gemma":0.00030125462,"threshold_uncertainty_score":0.5781293},"labels":[],"label_agreement":null},{"id":"W2762812042","doi":"10.1093/annonc/mdx362.001","title":"Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Trastuzumab; Oncology; Adjuvant; Internal medicine; Breast cancer; Stage (stratigraphy); Adjuvant therapy; Cancer","score_opus":0.1519478025427769,"score_gpt":0.5029018058917327,"score_spread":0.3509540033489558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762812042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869511,0.00039553922,0.000008404767,0.009605079,0.0002549367,0.0010128923,0.00037875172,0.00000829231,0.0013849995],"genre_scores_gemma":[0.9968362,0.0010209436,0.00004709046,0.0010244009,0.00024336576,0.00027509857,0.000012585955,0.000026292777,0.00051401247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752384,0.00038628138,0.00070342905,0.00037184064,0.00055908307,0.000455502],"domain_scores_gemma":[0.9976219,0.00019405592,0.00050206814,0.0011433532,0.0003916657,0.00014693406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011644398,0.00019374731,0.0011350438,0.00035116656,0.00008887867,0.000021063,0.00052167184,0.00022581877,0.0024884155],"category_scores_gemma":[0.00017428881,0.00013165628,0.00043357877,0.00046322774,0.00058094185,0.0000808585,0.000085747575,0.0004016863,0.000004501216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30349448,0.0068066334,0.33987758,0.00014476327,0.002741754,0.00028469157,0.0023453254,0.00035850384,0.005297549,0.000067993074,0.0053804778,0.33320025],"study_design_scores_gemma":[0.11353684,0.008634131,0.8507398,0.00015355177,0.0003435422,0.0000030061249,0.00013328147,0.0010125638,0.009526142,0.000021220501,0.015708063,0.00018790377],"about_ca_topic_score_codex":0.015276616,"about_ca_topic_score_gemma":0.008811958,"teacher_disagreement_score":0.5108622,"about_ca_system_score_codex":0.0001315723,"about_ca_system_score_gemma":0.0015455306,"threshold_uncertainty_score":0.99842346},"labels":[],"label_agreement":null},{"id":"W2762812418","doi":"10.1093/annonc/mdx386.002","title":"Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Internal medicine; Refractory (planetary science); Oncology; Toxicity; Lung cancer; Pharmacology; Gastroenterology; Cancer; Adverse effect; Immunotherapy","score_opus":0.04583309178589952,"score_gpt":0.36345108324960834,"score_spread":0.31761799146370884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762812418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877412,0.00048708203,0.000019038753,0.0019633118,0.00007279714,0.0006118229,0.000042160565,0.0000051315205,0.00905751],"genre_scores_gemma":[0.99809057,0.0008967839,0.00018541582,0.00013371506,0.000044544046,0.00010926986,0.000061570296,0.00002886464,0.00044926652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818635,0.0002001907,0.0005308689,0.00043275784,0.0002396058,0.00041021375],"domain_scores_gemma":[0.9984418,0.00007189357,0.00050427695,0.00055053923,0.00034863403,0.00008286674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006712768,0.00018728529,0.00041097787,0.00028594548,0.00006634011,0.000014762735,0.000393979,0.00036433822,0.000030215298],"category_scores_gemma":[0.00026701475,0.00016703425,0.000050907176,0.00017579741,0.0002736576,0.000024302186,0.00014613004,0.0003273321,0.000002534882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077039376,0.011699109,0.6083633,0.0015087299,0.0003851739,0.0010407427,0.0034311132,0.004814076,0.20816892,0.0005955306,0.009161874,0.07379209],"study_design_scores_gemma":[0.053425014,0.018066585,0.53888255,0.0008239445,0.00003148696,0.000021178927,0.0004249176,0.0017752557,0.3416717,0.00017704915,0.043938708,0.00076160335],"about_ca_topic_score_codex":0.0042645354,"about_ca_topic_score_gemma":0.08531421,"teacher_disagreement_score":0.1335028,"about_ca_system_score_codex":0.00007659296,"about_ca_system_score_gemma":0.00064988737,"threshold_uncertainty_score":0.9313764},"labels":[],"label_agreement":null},{"id":"W2762830460","doi":"10.1093/annonc/mdx371.006","title":"Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Paclitaxel; Internal medicine; Oncology; Pembrolizumab; Chemotherapy; Cancer","score_opus":0.30800080682063685,"score_gpt":0.5058922580437564,"score_spread":0.19789145122311952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762830460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850211,0.0036028342,0.000008524114,0.004944418,0.0008176439,0.000705336,0.000711382,0.00003307178,0.004155683],"genre_scores_gemma":[0.9905234,0.0052130185,0.0010832425,0.0020955415,0.00048294166,0.00013869876,0.00008241732,0.000060042647,0.00032070457],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973144,0.00018552972,0.0008668068,0.0005958263,0.00048272105,0.0005547025],"domain_scores_gemma":[0.9969284,0.00046130642,0.000979184,0.00094535586,0.0003309313,0.0003548412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002675768,0.0004099388,0.0014317094,0.00029229405,0.00012148886,0.000023750845,0.0006057801,0.00036080924,0.00086621894],"category_scores_gemma":[0.001164397,0.00033555686,0.00026448595,0.0002568236,0.00062634016,0.00031233203,0.00013793635,0.00038089007,0.000011509806],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15423723,0.005679232,0.2872222,0.0007352742,0.0058155567,0.00032662824,0.0051696775,0.00007525261,0.07901859,0.0002358432,0.014278184,0.44720632],"study_design_scores_gemma":[0.087836385,0.018074635,0.678865,0.00093650434,0.0010341397,0.000010506808,0.00042695226,0.00005339025,0.14555867,0.0005853489,0.06592539,0.00069305766],"about_ca_topic_score_codex":0.016378924,"about_ca_topic_score_gemma":0.0071393303,"teacher_disagreement_score":0.44651327,"about_ca_system_score_codex":0.00015728537,"about_ca_system_score_gemma":0.0016566165,"threshold_uncertainty_score":0.99990964},"labels":[],"label_agreement":null},{"id":"W2762897192","doi":"10.1093/annonc/mdx440.063","title":"Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Orphan drug; Medicine; Clinical trial; Randomized controlled trial; Drug; Food and drug administration; Pharmacology; Internal medicine; Oncology; Bioinformatics","score_opus":0.6756940398681958,"score_gpt":0.6315672353693981,"score_spread":0.04412680449879769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762897192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631437,0.00026800332,0.00025971874,0.03094297,0.0008863224,0.0011823382,0.00031271923,0.000005394852,0.0029988042],"genre_scores_gemma":[0.99396265,0.0003423111,0.0032183093,0.0018491109,0.0004885188,0.000039920782,0.00002541044,0.00002409829,0.000049653503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.975869,0.0032081744,0.019585758,0.00066436717,0.00022935789,0.0004433271],"domain_scores_gemma":[0.96405005,0.011302404,0.023283798,0.0007627406,0.00036839204,0.000232639],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.18870464,0.00019291691,0.0043270197,0.00013030719,0.00015038897,0.000015703778,0.000822259,0.0005950345,0.000066462024],"category_scores_gemma":[0.03769191,0.00019044057,0.0009045233,0.00008400856,0.0011479106,0.00018979312,0.0002825841,0.00045100314,0.0000068936624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006052975,0.0021315976,0.93961203,0.00082233764,0.00033749928,7.5044335e-7,0.0033273292,0.000019154231,0.000014260366,0.005375858,0.009151414,0.038602456],"study_design_scores_gemma":[0.00895763,0.0067888866,0.95548755,0.0002648972,0.000090732305,0.000005327884,0.002656799,0.0051006647,0.0006686423,0.005036572,0.014659351,0.00028292576],"about_ca_topic_score_codex":0.00042380163,"about_ca_topic_score_gemma":0.0020045817,"teacher_disagreement_score":0.15101273,"about_ca_system_score_codex":0.00005873383,"about_ca_system_score_gemma":0.0012028352,"threshold_uncertainty_score":0.97041404},"labels":[],"label_agreement":null},{"id":"W2762908383","doi":"10.1093/annonc/mdx372.002","title":"Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Olaparib; Medicine; Hazard ratio; Internal medicine; Oncology; Placebo; Regimen; Chemotherapy; Ovarian cancer; Urology; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.06535725050932524,"score_gpt":0.4049167432473832,"score_spread":0.33955949273805797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762908383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99116254,0.00022033871,0.00007778634,0.0047322097,0.00032431865,0.0017989154,0.00018848789,0.000017670094,0.0014777188],"genre_scores_gemma":[0.99565274,0.0014553907,0.00043052706,0.0017895759,0.00022113712,0.00011584235,0.000047429607,0.000046061235,0.0002413113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975841,0.00017049511,0.0010364733,0.0004248749,0.00037957536,0.00040448233],"domain_scores_gemma":[0.9960767,0.00032700287,0.0019051457,0.00068507256,0.0008931523,0.000112912276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058265676,0.0002890329,0.0013951055,0.00017960076,0.000084507665,0.0000067911405,0.00027785485,0.00031664752,0.00015670249],"category_scores_gemma":[0.00028174077,0.00022976904,0.00017503717,0.00017640235,0.0007214983,0.00013744371,0.00003457781,0.00031810632,0.0000015896698],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.725066,0.009550442,0.010768858,0.00009733834,0.00089747546,0.000027555321,0.00393032,0.000027798911,0.054283082,0.00011544816,0.011183246,0.18405245],"study_design_scores_gemma":[0.59187263,0.031611856,0.037050333,0.00069562404,0.000060356953,0.000005571058,0.00011296674,0.000064248765,0.3281995,0.00009206324,0.009959785,0.00027506682],"about_ca_topic_score_codex":0.00087003125,"about_ca_topic_score_gemma":0.0001344219,"teacher_disagreement_score":0.27391642,"about_ca_system_score_codex":0.00011599718,"about_ca_system_score_gemma":0.00066360104,"threshold_uncertainty_score":0.93697095},"labels":[],"label_agreement":null},{"id":"W2762963596","doi":"10.1093/annonc/mdx362.009","title":"Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Lapatinib; Breast cancer; Trastuzumab; Confidence interval; Adjuvant; Gynecology; Cancer; Oncology; Gastroenterology","score_opus":0.1485413740334905,"score_gpt":0.43702328293874504,"score_spread":0.28848190890525455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762963596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870639,0.000493505,0.000003536257,0.00834579,0.00025488235,0.0017503541,0.00067797105,0.000016708029,0.00139338],"genre_scores_gemma":[0.9961055,0.0023432206,0.0000344468,0.00052387395,0.00046426617,0.00021939506,0.00010639806,0.000048219335,0.0001546885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966399,0.00070548244,0.0005802445,0.00070458645,0.0006849168,0.0006848704],"domain_scores_gemma":[0.9971688,0.0005248731,0.0005316346,0.0009468679,0.00056252663,0.00026530234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000772978,0.0003639915,0.0013998259,0.00022086703,0.00023957172,0.00007539372,0.00043618403,0.00026559486,0.00024387855],"category_scores_gemma":[0.000112694244,0.00022928762,0.00015788566,0.00036072763,0.0005099173,0.00015321116,0.00013730023,0.00041049096,0.0000122527335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036525883,0.002280574,0.7512379,0.000013554201,0.0031217798,0.00011652545,0.003024542,0.000006912852,0.0014368907,0.0000052348964,0.00030200597,0.20192814],"study_design_scores_gemma":[0.043881163,0.02042756,0.93110263,0.00012823411,0.00045180082,0.000004495826,0.00034394645,0.000035565863,0.0018789374,0.000027958504,0.0015022137,0.00021546376],"about_ca_topic_score_codex":0.12014898,"about_ca_topic_score_gemma":0.045797184,"teacher_disagreement_score":0.20171268,"about_ca_system_score_codex":0.00033294797,"about_ca_system_score_gemma":0.00096793345,"threshold_uncertainty_score":0.97161454},"labels":[],"label_agreement":null},{"id":"W2762989831","doi":"10.1093/annonc/mdx365.039","title":"Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; BC Cancer Agency","funders":"","keywords":"Medicine; Psychosocial; Interim; Family medicine; Breast cancer; General partnership; Population; Health care; Metastatic breast cancer; Cancer; Internal medicine; Psychiatry","score_opus":0.4008568898491728,"score_gpt":0.4611284510670105,"score_spread":0.06027156121783772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762989831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71173835,0.0038930944,0.000025487327,0.07579096,0.0016356842,0.0009211164,0.006222252,0.000011839667,0.19976123],"genre_scores_gemma":[0.9979302,0.00032749106,0.00029944506,0.0005092998,0.00014148539,0.00004657907,0.0000037709822,0.000015910906,0.0007257747],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99835634,0.000044910747,0.000749589,0.00026905484,0.000042527034,0.00053759164],"domain_scores_gemma":[0.99750584,0.00031669147,0.0011469703,0.0005546241,0.000345758,0.00013008631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035308127,0.00010972264,0.0005403599,0.00018438962,0.0005549875,0.00006615302,0.00063388736,0.00013294579,0.000041613777],"category_scores_gemma":[0.0023437527,0.000105172,0.00016279217,0.00007106149,0.00061759824,0.00026889186,0.0001336204,0.00023586469,0.000011354997],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060561736,0.000106402666,0.195445,0.00025995958,0.0002689221,0.0000038019332,0.0039525875,0.000053153133,0.000020155601,0.6776882,0.034004465,0.08759176],"study_design_scores_gemma":[0.0014797536,0.0005049175,0.5204864,0.00014974915,0.000014490836,0.0000055000355,0.0003241282,0.00018600737,0.00065320113,0.080556996,0.39541364,0.00022521442],"about_ca_topic_score_codex":0.21140784,"about_ca_topic_score_gemma":0.35348645,"teacher_disagreement_score":0.5971312,"about_ca_system_score_codex":0.00022011738,"about_ca_system_score_gemma":0.0012361791,"threshold_uncertainty_score":0.79384345},"labels":[],"label_agreement":null},{"id":"W2763129848","doi":"10.1093/annonc/mdx374.010","title":"Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nasopharyngeal carcinoma; Medicine; Radiation therapy; Stage (stratigraphy); Oncology; Hazard ratio; Internal medicine; Chemotherapy; Cohort; Cancer; AJCC staging system; Nuclear medicine; Staging system; Confidence interval; Biology","score_opus":0.12821484201373232,"score_gpt":0.3959780888557886,"score_spread":0.2677632468420563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763129848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891038,0.00068416464,0.0000170807,0.0042909933,0.00014842571,0.00026860298,0.00001118282,0.000039076524,0.005436653],"genre_scores_gemma":[0.9987092,0.00017606629,0.00017904871,0.0005237398,0.00015958543,0.000028323771,0.000019990022,0.000016622858,0.0001874051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992623,0.000028928798,0.0002141205,0.00018752766,0.0000890479,0.00021812826],"domain_scores_gemma":[0.99888325,0.00007519128,0.00026780344,0.0002674197,0.00044175025,0.00006456421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002589602,0.00010920585,0.00061913434,0.000075304124,0.0002223005,0.0000085381225,0.00007501577,0.00008617901,0.0000037293617],"category_scores_gemma":[0.000075792,0.00007961512,0.00006353387,0.000041722647,0.00009976165,0.00006796746,0.000020088039,0.00008017502,0.0000015340358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016381165,0.00027290804,0.5499538,0.00040365275,0.00083716575,0.00020453887,0.0018035418,0.000006063771,0.023009293,0.00017745825,0.0040992247,0.4028512],"study_design_scores_gemma":[0.009507655,0.014229585,0.8800016,0.00030095794,0.00009854531,0.000058247933,0.00038838363,0.00047567597,0.07682643,0.00000858344,0.017954562,0.00014977765],"about_ca_topic_score_codex":0.00043705248,"about_ca_topic_score_gemma":0.000038176975,"teacher_disagreement_score":0.4027014,"about_ca_system_score_codex":0.00006105727,"about_ca_system_score_gemma":0.00014742046,"threshold_uncertainty_score":0.32466105},"labels":[],"label_agreement":null},{"id":"W2763165688","doi":"10.1093/annonc/mdx364.004","title":"A clinically applicable model to predict risk of relapse in patients treated for locally advanced breast cancer: Potential utilization in future clinical trials","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Proportional hazards model; Oncology; Cancer","score_opus":0.10635720745475592,"score_gpt":0.46413413375296375,"score_spread":0.35777692629820784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763165688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942742,0.00022971684,0.0011549338,0.0015720698,0.0002291892,0.0011500228,0.001247126,0.000004665567,0.00013807841],"genre_scores_gemma":[0.9940037,0.003918205,0.0011224351,0.0002542184,0.00020568968,0.0003223108,0.00012663168,0.000018979707,0.00002781015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975423,0.00032406452,0.0013018808,0.00045770776,0.000109725355,0.00026432038],"domain_scores_gemma":[0.99775714,0.00012836617,0.0011186061,0.00045657885,0.00045389915,0.0000854401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016359126,0.00016988705,0.00090850476,0.000069818736,0.000058974303,0.0000048117786,0.00028554583,0.00039902003,0.00000398394],"category_scores_gemma":[0.0010438537,0.00014902643,0.000233279,0.000066637986,0.0001503113,0.000010398974,0.00015317759,0.000107725755,5.277694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023120135,0.0017013272,0.6828068,0.0000322337,0.00026182592,0.0000012709947,0.000049617753,0.004945647,0.0008299708,0.000020235246,0.0015559738,0.284675],"study_design_scores_gemma":[0.015773518,0.0045847995,0.97379154,0.000082229046,0.00012635694,7.5845026e-7,0.000048343063,0.0015601014,0.0020843362,0.00022184598,0.0015474558,0.00017874358],"about_ca_topic_score_codex":0.00027576467,"about_ca_topic_score_gemma":0.0011190985,"teacher_disagreement_score":0.29098475,"about_ca_system_score_codex":0.00002869563,"about_ca_system_score_gemma":0.00028911416,"threshold_uncertainty_score":0.60771215},"labels":[],"label_agreement":null},{"id":"W2763177383","doi":"10.1093/annonc/mdx370","title":"Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Discontinuation; Quality of life (healthcare); Abiraterone acetate; Prednisone; Internal medicine; Randomized controlled trial; Physical therapy; Urology; Oncology; Surgery; Cancer","score_opus":0.2045172065647001,"score_gpt":0.43758352072523554,"score_spread":0.23306631416053544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763177383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693085,0.000442664,0.0000036421654,0.009647637,0.00008863202,0.0011136583,0.000027297248,0.000013200784,0.0017324137],"genre_scores_gemma":[0.9973211,0.0010085049,0.00042756664,0.00064457237,0.000025832403,0.00010446009,0.00004315585,0.000016924152,0.00040783337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985696,0.00006798317,0.0005185087,0.00027102136,0.0002946342,0.00027821507],"domain_scores_gemma":[0.9985058,0.000076344084,0.00043207515,0.0005672428,0.00031005734,0.00010848035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003475706,0.00014426553,0.00061838306,0.00020324488,0.000060624414,0.000008834285,0.00015515691,0.0001307118,0.000065998094],"category_scores_gemma":[0.00024022562,0.00010384063,0.00007714271,0.0000781727,0.00010194254,0.00008752076,0.00008345699,0.00011583161,0.000009557995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011648985,0.0019468567,0.54337,0.00010316551,0.00072956126,0.00014903904,0.005622957,0.0003127682,0.011613015,0.0001667511,0.0018921518,0.42244473],"study_design_scores_gemma":[0.008757431,0.008468273,0.8416584,0.00015433178,0.000024351584,0.000006130651,0.000070357404,0.00003573457,0.13798822,0.00030803162,0.0024267721,0.00010192703],"about_ca_topic_score_codex":0.00045323605,"about_ca_topic_score_gemma":0.00032913144,"teacher_disagreement_score":0.4223428,"about_ca_system_score_codex":0.000099735,"about_ca_system_score_gemma":0.00025067464,"threshold_uncertainty_score":0.4234498},"labels":[],"label_agreement":null},{"id":"W2763178222","doi":"10.1093/annonc/mdx387.042","title":"Analysis of PD-L1 Expression in Patients with Gastrointestinal Stromal Tumors","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"CD117; Medicine; Stromal cell; Immunohistochemistry; GiST; Stromal tumor; PD-L1; Tissue microarray; Pathology; Immune system; Cancer research; Immunotherapy; CD34; Immunology; Biology","score_opus":0.06405545071523298,"score_gpt":0.3903132856632089,"score_spread":0.3262578349479759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763178222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965065,0.0000124721355,0.000030771884,0.0005207206,0.0000072907583,0.00022629026,0.000026411506,0.0000053262365,0.002664206],"genre_scores_gemma":[0.9958854,0.0000032797464,0.0039535826,0.000028814366,0.0000114832455,0.000010430791,0.000041036266,0.000008191036,0.00005779047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987506,0.00006273907,0.000332427,0.00021119647,0.00032413422,0.00031889495],"domain_scores_gemma":[0.99850416,0.000093175724,0.00040548202,0.00044021345,0.00038710638,0.0001698823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022146551,0.00011939827,0.00063836033,0.00038053968,0.00004652519,0.0000055144505,0.00016543151,0.000024740226,0.000101319805],"category_scores_gemma":[0.0005023286,0.000084162624,0.00012521647,0.0001686634,0.0002731349,0.000072726136,0.00008810106,0.00015050052,0.000003269664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038823881,0.0017690123,0.9897053,0.000034088156,0.0001791959,0.00036777224,0.000030349247,0.000027951868,0.0011244684,0.000018066596,0.00007511378,0.0027862664],"study_design_scores_gemma":[0.003112895,0.019391745,0.97381294,0.0003461262,0.00016579614,0.000035927707,0.000049362214,0.00007511144,0.0029260523,0.000017598819,0.00001999119,0.00004643584],"about_ca_topic_score_codex":0.00023910537,"about_ca_topic_score_gemma":0.00012734171,"teacher_disagreement_score":0.017622733,"about_ca_system_score_codex":0.000036225443,"about_ca_system_score_gemma":0.00018133866,"threshold_uncertainty_score":0.34320524},"labels":[],"label_agreement":null},{"id":"W2763224818","doi":"10.1093/annonc/mdx371.079","title":"A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Everolimus; Discovery and development of mTOR inhibitors; Investigational Drugs; Phases of clinical research; Oncology; Internal medicine; Pharmacology; PI3K/AKT/mTOR pathway; Clinical trial","score_opus":0.11530180118172613,"score_gpt":0.35859554422307705,"score_spread":0.24329374304135093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763224818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271506,0.000872722,0.0000056006616,0.0015159801,0.00013837552,0.004092,0.00010103869,0.000034273544,0.0005249389],"genre_scores_gemma":[0.99619097,0.000095080024,0.0019639947,0.0006034522,0.0001752124,0.00057844154,0.00016632746,0.00008593139,0.00014060803],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99581325,0.0005358984,0.0010384703,0.0009978651,0.00097345357,0.00064106996],"domain_scores_gemma":[0.9957618,0.00053196517,0.0015842317,0.0007520437,0.0008750981,0.00049487874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056156446,0.0006367119,0.001549364,0.0005031045,0.000287286,0.000048064594,0.00032933854,0.00025074324,0.000060192317],"category_scores_gemma":[0.00039257965,0.00047734912,0.00014177019,0.00037778827,0.0011590858,0.00038323808,0.00012209416,0.00053641706,0.000005680792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37247124,0.06945755,0.32025385,0.0020089431,0.00197958,0.0044555957,0.043355834,0.0010555104,0.15891337,0.00011441823,0.005229272,0.02070484],"study_design_scores_gemma":[0.10188795,0.18663402,0.27802134,0.0005816869,0.00028018877,0.00009669308,0.0018872377,0.00065749534,0.42886126,0.00021043922,0.00033263263,0.0005490621],"about_ca_topic_score_codex":0.00052204396,"about_ca_topic_score_gemma":0.00062880496,"teacher_disagreement_score":0.27058327,"about_ca_system_score_codex":0.00031299642,"about_ca_system_score_gemma":0.0021875268,"threshold_uncertainty_score":0.99976784},"labels":[],"label_agreement":null},{"id":"W2763262430","doi":"10.1093/annonc/mdx388.018","title":"A patient-centered approach to the re-development of supportive care services for oncology adolescent and young adult (AYA) patients (pt(s)) across McGill University hospitals (Rossy Cancer Network-RCN)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Likert scale; Delphi method; Family medicine; Population; Palliative care; Test (biology); Patient satisfaction; Nursing; Gerontology; Psychology","score_opus":0.06262407870698428,"score_gpt":0.3768648596592922,"score_spread":0.3142407809523079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763262430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871283,0.00033674578,0.000042935695,0.0073374594,0.00064953405,0.001975037,0.0013239792,0.000017825825,0.001188156],"genre_scores_gemma":[0.9940188,0.000306671,0.0017180988,0.0035312574,0.00014066028,0.000067848996,0.00011652028,0.000026019981,0.000074112584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768746,0.0001784331,0.00070076104,0.0005195821,0.00033814396,0.0005756203],"domain_scores_gemma":[0.99624497,0.00010984428,0.0012270735,0.00057924143,0.0015935313,0.00024532506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005313372,0.00025264654,0.00091299,0.000056639386,0.00058220385,0.000010400905,0.00043322772,0.00024514692,0.000008158922],"category_scores_gemma":[0.00016349198,0.00021219543,0.00016034974,0.00009260322,0.0002779164,0.00012812493,0.00053244404,0.00019336294,0.0000018581151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008351003,0.0027568021,0.5289317,0.0027939193,0.0010684633,0.000014518096,0.15569648,0.000053252028,0.00008454116,0.00013038967,0.020817578,0.27930135],"study_design_scores_gemma":[0.0069314595,0.005258537,0.783028,0.00070622994,0.00016730989,0.0000043246146,0.03363828,0.00002889459,0.0016869409,0.0000223669,0.168201,0.00032667053],"about_ca_topic_score_codex":0.0024626332,"about_ca_topic_score_gemma":0.016676426,"teacher_disagreement_score":0.27897468,"about_ca_system_score_codex":0.0003205026,"about_ca_system_score_gemma":0.0004412683,"threshold_uncertainty_score":0.9305837},"labels":[],"label_agreement":null},{"id":"W2763294721","doi":"10.1093/annonc/mdx367.008","title":"A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Nicotinamide phosphoribosyltransferase; Internal medicine; Adverse effect; Nausea; Anemia; Pharmacology; Gastroenterology; Pharmacokinetics; Oncology; NAD+ kinase; Enzyme; Biochemistry; Chemistry","score_opus":0.08063440243014508,"score_gpt":0.4291862201817902,"score_spread":0.3485518177516451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763294721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744487,0.000113023554,0.000001055255,0.0009594131,0.00006804489,0.001060486,0.00004588955,0.000005462866,0.00030177867],"genre_scores_gemma":[0.99939173,0.00013923226,0.00008826578,0.00016388264,0.000030779,0.00012863224,0.000008520927,0.000017957158,0.000030988576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982859,0.00009004595,0.0008080106,0.00029239102,0.00025044894,0.00027320656],"domain_scores_gemma":[0.9984166,0.00015929677,0.00070303853,0.0004059696,0.0002479421,0.00006714214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003919241,0.00017119228,0.000933502,0.0003511055,0.000055809167,0.0000043087425,0.00013042592,0.00013504938,0.00004345951],"category_scores_gemma":[0.00021257708,0.00014009002,0.00003451869,0.00017900071,0.0003947661,0.00015971382,0.0000805323,0.00018545431,4.254215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018587364,0.014970007,0.94605833,0.00040346256,0.00009513825,0.0001996716,0.010932267,0.00008746123,0.0040314975,0.000037213646,0.0004323181,0.0041652503],"study_design_scores_gemma":[0.07290135,0.047301054,0.8639042,0.001418384,0.000024879646,0.0000069541775,0.0018126015,0.000021917676,0.011046632,0.00009190763,0.0012936688,0.00017646844],"about_ca_topic_score_codex":0.00059309555,"about_ca_topic_score_gemma":0.017927349,"teacher_disagreement_score":0.08215417,"about_ca_system_score_codex":0.00008233774,"about_ca_system_score_gemma":0.00018284658,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W2763325663","doi":"10.1093/annonc/mdx380.049","title":"Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Internal medicine; Lung cancer; Progressive disease; Oncology; Anaplastic lymphoma kinase; Crizotinib; Progression-free survival; Disease; Chemotherapy","score_opus":0.05513182186318976,"score_gpt":0.46955359442437333,"score_spread":0.41442177256118357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763325663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7164014,0.0029926267,0.0000024009375,0.03776736,0.000405499,0.0010940703,0.000043472573,0.000029765386,0.24126343],"genre_scores_gemma":[0.99693024,0.0006767026,0.00042188732,0.00033476172,0.00012996102,0.00021856595,0.00005023365,0.000014764623,0.0012228717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991134,0.00003651396,0.00024912838,0.00023407716,0.00013317306,0.00023370495],"domain_scores_gemma":[0.9989936,0.00004314114,0.00021214431,0.00043641575,0.000107134205,0.00020756127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006884627,0.0001347361,0.0003728256,0.000091495946,0.00012287781,0.00000933188,0.000083227256,0.00008010243,0.000055154476],"category_scores_gemma":[0.0001063931,0.00009736217,0.00011070983,0.000049759747,0.00015403295,0.00011536913,0.000032478438,0.00006479408,0.000016158638],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012922728,0.0021615378,0.048728842,0.00003547552,0.00016317397,0.0005570002,0.0007411221,0.0000054186544,0.00073122117,0.00020088229,0.0015766425,0.9438064],"study_design_scores_gemma":[0.01643908,0.009651254,0.26535013,0.00038471306,0.00036599644,0.000024647263,0.00035313418,0.000029543722,0.0051927464,0.00082876015,0.7011714,0.00020860317],"about_ca_topic_score_codex":0.00014566208,"about_ca_topic_score_gemma":0.00014871528,"teacher_disagreement_score":0.9435978,"about_ca_system_score_codex":0.0001236068,"about_ca_system_score_gemma":0.0004882099,"threshold_uncertainty_score":0.39703143},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2763371635","doi":"10.1093/annonc/mdx388.046","title":"Cancer patient interest and perceptions of lifestyle behavior programs","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Smoking cessation; Logistic regression; Moderation; Cancer; Family medicine; Alcohol consumption; Environmental health; Alcohol; Internal medicine","score_opus":0.1252403225876603,"score_gpt":0.4382627022585609,"score_spread":0.31302237967090063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763371635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931217,0.00043678298,0.0000015246851,0.0033109388,0.00025034623,0.00019919674,0.000023419212,0.0000065544527,0.0026495422],"genre_scores_gemma":[0.9986947,0.0005972598,0.00004492858,0.00032533056,0.00007460056,0.000077162156,0.0000067815276,0.000006561597,0.00017268614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995321,0.000020419468,0.0001665424,0.000105829524,0.00006662471,0.00010845845],"domain_scores_gemma":[0.99929804,0.000017160028,0.00016757369,0.00024019292,0.00020071348,0.00007630176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072385286,0.000057044123,0.00024251273,0.000036043042,0.00004684862,0.0000047094895,0.000065830216,0.000078081284,0.00013925339],"category_scores_gemma":[0.00003886272,0.000048391106,0.00006053155,0.000019072151,0.00026672223,0.00003707991,0.000062415435,0.000077373355,0.0000018033712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103568906,0.0003645866,0.4457729,0.00005985775,0.00003186407,0.000012041528,0.0015607595,4.082318e-8,0.0017731135,0.00009298377,0.0010285211,0.54919976],"study_design_scores_gemma":[0.0006413989,0.00464063,0.9357987,0.00016066403,0.00012128085,0.00002508979,0.0015793783,0.0000023792727,0.0030127985,0.000038616996,0.053907096,0.000071967086],"about_ca_topic_score_codex":0.0027876107,"about_ca_topic_score_gemma":0.009164266,"teacher_disagreement_score":0.5491278,"about_ca_system_score_codex":0.000012933391,"about_ca_system_score_gemma":0.000099479505,"threshold_uncertainty_score":0.5113875},"labels":[],"label_agreement":null},{"id":"W2763382947","doi":"10.1093/annonc/mdx372.047","title":"Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Endometrial cancer; Internal medicine; Stage (stratigraphy); Adjuvant; Oncology; Adjuvant therapy; Radiation therapy; Cancer; Gynecology","score_opus":0.10844390269505888,"score_gpt":0.42766519918483725,"score_spread":0.31922129648977837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763382947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926719,0.00019346838,2.3308563e-7,0.00022199827,0.00042297837,0.0004500053,0.00028919036,0.0000025770814,0.005747659],"genre_scores_gemma":[0.9973246,0.0023043214,0.0000071886043,0.00004460982,0.00005017946,0.000014942865,0.0000065184972,0.0000072292723,0.00024042426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990256,0.000105941006,0.00027754126,0.00016586167,0.00023782442,0.00018724878],"domain_scores_gemma":[0.99886316,0.00025645018,0.00042110245,0.00030168652,0.00008158723,0.00007598411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021747922,0.000114667484,0.000506573,0.00016047049,0.000057573292,0.0000045163256,0.00014763282,0.000076209784,0.00016722616],"category_scores_gemma":[0.0005250208,0.00006204946,0.00016365285,0.00014234202,0.00012195779,0.000037600978,0.00011552285,0.00012281623,0.0000011906922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023783299,0.0008365231,0.93647516,0.000031752403,0.00038856026,0.0000066212738,0.000091124486,0.000009718079,0.000019668936,0.00003350625,0.00012667818,0.05960238],"study_design_scores_gemma":[0.010724975,0.005672363,0.98125297,0.000056251505,0.000092488,1.05058184e-7,0.000025011737,0.0000023417044,0.0010530292,0.000060987953,0.0010113302,0.000048157424],"about_ca_topic_score_codex":0.008101513,"about_ca_topic_score_gemma":0.0005347898,"teacher_disagreement_score":0.059554223,"about_ca_system_score_codex":0.00009566108,"about_ca_system_score_gemma":0.00006602732,"threshold_uncertainty_score":0.9985036},"labels":[],"label_agreement":null},{"id":"W2763417272","doi":"10.1093/annonc/mdx369.157","title":"KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Internal medicine; Adverse effect; Placebo; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical trial; Surgery; Phases of clinical research; Cancer; Immunotherapy; Pathology; Alternative medicine","score_opus":0.09005920300160238,"score_gpt":0.42564074388608303,"score_spread":0.33558154088448067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763417272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893324,0.0022630591,0.0000812055,0.0012866221,0.0004458049,0.004005067,0.00023105169,0.000019032454,0.0023357759],"genre_scores_gemma":[0.99734086,0.0003250296,0.00025002542,0.00048619395,0.00015935939,0.00035926758,0.00010670633,0.000042831205,0.00092971936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974879,0.0002198737,0.0011459212,0.00045247487,0.000264521,0.00042932967],"domain_scores_gemma":[0.9961089,0.00043764018,0.0013845167,0.0009131235,0.0010096302,0.00014620871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085208105,0.0003061903,0.002229439,0.00019223134,0.00019584913,0.000011667903,0.00035858483,0.00024065354,0.00033662145],"category_scores_gemma":[0.0005125523,0.00025602634,0.0006426794,0.00008377658,0.00056625635,0.00013338473,0.00008755484,0.0001863545,0.0000035773216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89080447,0.0048288684,0.005233305,0.0006489603,0.0012104133,0.0001563687,0.0054654246,0.0000029306068,0.03620316,0.000028958611,0.0012122067,0.05420493],"study_design_scores_gemma":[0.7644432,0.05707903,0.003283771,0.00014997943,0.00077160506,0.00004352762,0.005337071,0.00021341137,0.14954743,0.00009322307,0.01873618,0.00030153754],"about_ca_topic_score_codex":0.0005651652,"about_ca_topic_score_gemma":0.00038218615,"teacher_disagreement_score":0.12636124,"about_ca_system_score_codex":0.00007791067,"about_ca_system_score_gemma":0.0005932662,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W2763494323","doi":"10.1093/annonc/mdx389.003","title":"Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Placebo; Interim analysis; Gastroenterology; Progression-free survival; Pemetrexed; Confidence interval; Phases of clinical research; Urology; Surgery; Toxicity; Clinical trial; Chemotherapy; Cisplatin; Pathology","score_opus":0.06856131402586725,"score_gpt":0.33290196137719924,"score_spread":0.264340647351332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763494323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950545,0.000063342224,0.0000032410828,0.0011081869,0.00013605118,0.00094627356,0.00081264955,0.000011949538,0.0018638184],"genre_scores_gemma":[0.9989547,0.000056661207,0.00013111129,0.000303506,0.00007293088,0.00003301499,0.00019189833,0.000026902093,0.00022928491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766535,0.00022339147,0.0006883887,0.00049443525,0.0005848896,0.00034356132],"domain_scores_gemma":[0.9977383,0.0006233495,0.00070344034,0.00061914366,0.00015013185,0.00016564202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005101871,0.00028994412,0.00078451115,0.00010720636,0.00016989929,0.000020937645,0.00030969988,0.00014059647,0.000094647],"category_scores_gemma":[0.00055536313,0.00019224612,0.000109708955,0.0000853204,0.00048563565,0.00020263599,0.00023975193,0.00021925909,0.0000090280055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037194006,0.0036478292,0.9490571,0.0000505478,0.00037600394,0.000085770655,0.0029861096,0.000032839416,0.0014633938,0.00005404917,0.0012652221,0.0037871334],"study_design_scores_gemma":[0.019471847,0.010672292,0.965606,0.00014279931,0.00016925311,0.0000093237595,0.0012895945,0.00018991034,0.0018194111,0.00012342815,0.00031112175,0.00019507257],"about_ca_topic_score_codex":0.0057689785,"about_ca_topic_score_gemma":0.0029101167,"teacher_disagreement_score":0.017722161,"about_ca_system_score_codex":0.0000799637,"about_ca_system_score_gemma":0.000086944056,"threshold_uncertainty_score":0.87210083},"labels":[],"label_agreement":null},{"id":"W2763540369","doi":"10.1093/annonc/mdx363.031","title":"Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Radiomics; Pembrolizumab; Melanoma; Oncology; Internal medicine; Progressive disease; Radiology; Cancer; Disease; Immunotherapy; Cancer research","score_opus":0.07723398424837682,"score_gpt":0.43951287049092774,"score_spread":0.3622788862425509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763540369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95649296,0.0006133443,0.0013641173,0.037486658,0.0004384078,0.0011266181,0.000025036912,0.000011740335,0.0024411036],"genre_scores_gemma":[0.99654835,0.000057560243,0.0022846083,0.0005601788,0.00021081258,0.000092452494,0.000014500246,0.000019039026,0.00021248114],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838823,0.00024028831,0.00051723176,0.00021363693,0.00043537692,0.000205239],"domain_scores_gemma":[0.99724877,0.00038574918,0.000571781,0.00044032198,0.0012211922,0.0001322159],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00875549,0.00010699857,0.000512912,0.00017277896,0.00009478689,0.0000073838874,0.00018667412,0.00018393477,0.000032671393],"category_scores_gemma":[0.017544974,0.00009328384,0.00020078699,0.0000627524,0.00023386488,0.00006223083,0.00007707362,0.00025043555,0.0000017801317],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012738042,0.00048924354,0.0009116707,0.00012287364,0.00039274746,0.000012419307,0.0019910568,0.000982268,0.39329752,0.00009326777,0.005702504,0.5832664],"study_design_scores_gemma":[0.023667715,0.026859708,0.2599651,0.001030934,0.0017085511,0.00011447222,0.00084030814,0.07984221,0.47862893,0.005555675,0.12130253,0.00048387152],"about_ca_topic_score_codex":0.00006104035,"about_ca_topic_score_gemma":0.0000049803107,"teacher_disagreement_score":0.5827825,"about_ca_system_score_codex":0.000106883366,"about_ca_system_score_gemma":0.00081306696,"threshold_uncertainty_score":0.99073064},"labels":[],"label_agreement":null},{"id":"W2763650383","doi":"10.1093/annonc/mdx369.084","title":"Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Liver cancer; Akaike information criterion; Oncology; Stage (stratigraphy); Cohort; Survival analysis; Cancer; Log-rank test; Database; Statistics","score_opus":0.24957962706810063,"score_gpt":0.36509946218376704,"score_spread":0.11551983511566641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763650383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236125,0.00025369704,0.000043998396,0.0029900973,0.000046531604,0.0021819382,0.0015691979,0.000009229378,0.00054403476],"genre_scores_gemma":[0.9970616,0.000022943219,0.0007135644,0.00018257012,0.000033779495,0.00015658105,0.0017292793,0.000030215288,0.00006945693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982922,0.00012778716,0.00056993455,0.0003800148,0.00019584243,0.00043420828],"domain_scores_gemma":[0.99777174,0.0002586977,0.0005157989,0.00078622764,0.0004381277,0.00022942078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003215294,0.0002287549,0.00084868877,0.00017792509,0.00014893977,0.000014173747,0.00029244932,0.00018312159,0.000010252077],"category_scores_gemma":[0.00023773954,0.00015385504,0.00013358021,0.00008928377,0.00023454057,0.00012701319,0.000056724675,0.00016272315,0.0000040096343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003435371,0.0022763135,0.9888686,0.000058878948,0.00019424957,0.00010916512,0.0010908056,0.0000047168555,0.00009615817,0.000017290611,0.0011494594,0.0026990087],"study_design_scores_gemma":[0.028337361,0.00665532,0.8976607,0.00027320633,0.0004043957,0.0000027916471,0.00020256774,0.05328844,0.010011286,0.00002503626,0.0029116299,0.0002273003],"about_ca_topic_score_codex":0.10603995,"about_ca_topic_score_gemma":0.085341886,"teacher_disagreement_score":0.09120792,"about_ca_system_score_codex":0.0000750414,"about_ca_system_score_gemma":0.00046420336,"threshold_uncertainty_score":0.93134826},"labels":[],"label_agreement":null},{"id":"W2763663030","doi":"10.1093/annonc/mdx440.034","title":"ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; BRCA mutation; Oncology; Placebo; Response Evaluation Criteria in Solid Tumors; PARP inhibitor; Progression-free survival; Population; Cancer; Gastroenterology; Ovarian cancer; Phases of clinical research; Chemotherapy; Clinical trial; Pathology; Genetics; Poly ADP ribose polymerase","score_opus":0.2027541194714337,"score_gpt":0.4880903689704883,"score_spread":0.28533624949905456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763663030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763785,0.00010607425,0.00095694774,0.014771535,0.000616593,0.006017371,0.000061951796,0.000027145692,0.0010638695],"genre_scores_gemma":[0.99471015,0.000011272386,0.0015372635,0.0021191924,0.00022784568,0.0010752383,0.000022998649,0.00004725253,0.0002487646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99752396,0.00028904158,0.0009286573,0.00047205243,0.0003651385,0.00042112658],"domain_scores_gemma":[0.99630535,0.0011040579,0.00085723284,0.0010206148,0.0004551087,0.00025764704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026596657,0.00027319693,0.0012798645,0.00033778546,0.00022705014,0.000022641867,0.00035944034,0.00022450517,0.00010996012],"category_scores_gemma":[0.0007221034,0.00025733912,0.00039095496,0.0001419712,0.00015000091,0.000078521894,0.000043242395,0.00020559506,0.000004200549],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9330648,0.0047299587,0.0016429134,0.000076434946,0.00048095649,0.000052278883,0.003563222,0.000031412983,0.029070402,0.000037603884,0.003952872,0.023297125],"study_design_scores_gemma":[0.79015005,0.054665018,0.00365133,0.00020110338,0.00021737842,0.000010942873,0.00052864605,0.00020693411,0.123682305,0.000110245855,0.026322579,0.00025347597],"about_ca_topic_score_codex":0.00016495322,"about_ca_topic_score_gemma":0.000111369256,"teacher_disagreement_score":0.14291479,"about_ca_system_score_codex":0.00011523455,"about_ca_system_score_gemma":0.0010030284,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W2763685583","doi":"10.1093/annonc/mdx369.137","title":"Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; FOLFIRINOX; Hazard ratio; Proportional hazards model; Gastroenterology; Neutrophil to lymphocyte ratio; Adenocarcinoma; Pancreatic cancer; Gemcitabine; Univariate analysis; Oncology; Progression-free survival; Confidence interval; Multivariate analysis; Cancer; Lymphocyte; Chemotherapy","score_opus":0.12347992923850594,"score_gpt":0.40242822987219956,"score_spread":0.27894830063369364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763685583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083024,0.0020257572,0.000075289354,0.003968697,0.0001374106,0.0019908724,0.00007055761,0.000015051234,0.0008861443],"genre_scores_gemma":[0.9957792,0.00066313293,0.002554514,0.0002130367,0.000088099936,0.0005479098,0.000037898342,0.000027166252,0.000089040936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841785,0.00010400543,0.00069945044,0.00028693533,0.0001602477,0.00033151772],"domain_scores_gemma":[0.99776053,0.0005536124,0.0006330638,0.0006326405,0.00028797355,0.00013218042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040375412,0.0002056304,0.0009190841,0.00020608734,0.00010059826,0.0000089629475,0.00021022213,0.00011727216,0.000035103963],"category_scores_gemma":[0.0010573656,0.0001730662,0.00025168766,0.000075559146,0.0003274009,0.00008679626,0.00005906634,0.000054225227,0.000005992594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432213,0.0042326227,0.9174927,0.002309333,0.0016888728,0.0005797533,0.0009340611,0.00011862725,0.0026542363,0.0018086177,0.00067391363,0.05807507],"study_design_scores_gemma":[0.014011343,0.015036976,0.92707974,0.0005309832,0.0013522459,0.000060552047,0.000109759116,0.0031707669,0.034305006,0.0013428727,0.0027806424,0.00021911714],"about_ca_topic_score_codex":0.00016276927,"about_ca_topic_score_gemma":0.000113504124,"teacher_disagreement_score":0.057855956,"about_ca_system_score_codex":0.00014663386,"about_ca_system_score_gemma":0.0006509893,"threshold_uncertainty_score":0.7057435},"labels":[],"label_agreement":null},{"id":"W2763716595","doi":"10.1093/annonc/mdx371.029","title":"Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Internal medicine; Chemotherapy; Oncology; Population; Response Evaluation Criteria in Solid Tumors; Proportional hazards model; Statistical significance; Progression-free survival; Chemotherapy regimen; Progressive disease; Surgery; Radiology; Cancer; Urothelial carcinoma; Bladder cancer","score_opus":0.05301032029617119,"score_gpt":0.3564630192788795,"score_spread":0.3034526989827083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763716595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940635,0.00005109919,0.0000057031234,0.0022869627,0.00011899195,0.00081573153,0.0002712362,0.0000054200596,0.0023813434],"genre_scores_gemma":[0.99879295,0.00002352065,0.00058181473,0.00030995076,0.0000864161,0.00010277057,0.000057292567,0.000018897692,0.000026382864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987807,0.000063744636,0.00036432652,0.00023675378,0.00035665528,0.00019781006],"domain_scores_gemma":[0.99832946,0.00014107111,0.00074853847,0.00043540512,0.00024890463,0.00009664714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007836111,0.00018023931,0.0008271795,0.0001259213,0.00008640196,0.0000072205353,0.000068652866,0.00004345696,0.00012892959],"category_scores_gemma":[0.00010040209,0.0001098888,0.00011572673,0.00004899151,0.00015024899,0.00007548917,0.000041603616,0.00007225754,0.000003716142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006303309,0.0034729152,0.9125034,0.000049949063,0.0007354611,0.00015249071,0.00044824718,0.000018636712,0.00000900394,0.0006181798,0.00056772295,0.07512064],"study_design_scores_gemma":[0.0076034036,0.025146715,0.96156764,0.00008362519,0.00055942975,0.00000637848,0.000085707325,0.0000023302077,0.0034998083,0.00014663719,0.0011964634,0.00010184365],"about_ca_topic_score_codex":0.001097146,"about_ca_topic_score_gemma":0.0006805025,"teacher_disagreement_score":0.0750188,"about_ca_system_score_codex":0.000060736988,"about_ca_system_score_gemma":0.00015630444,"threshold_uncertainty_score":0.44811353},"labels":[],"label_agreement":null},{"id":"W2763734756","doi":"10.1093/annonc/mdx370.057","title":"Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"SABR volatility model; Medicine; Prostate cancer; Abiraterone; Clinical endpoint; Oncology; Internal medicine; Radiation therapy; Systemic therapy; Abiraterone acetate; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Breast cancer","score_opus":0.19445316079601055,"score_gpt":0.5169005609501007,"score_spread":0.3224474001540902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763734756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98627377,0.0042373356,0.000006932236,0.0047379807,0.00014533916,0.0041776025,0.00016097557,0.000021715521,0.00023835627],"genre_scores_gemma":[0.9937041,0.0031384241,0.00030043183,0.00016360616,0.0001266523,0.0009901581,0.000023910461,0.000041354648,0.0015113724],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982552,0.00014662798,0.00044449876,0.00039211175,0.00027497456,0.00048658362],"domain_scores_gemma":[0.99802333,0.00014465822,0.00058986864,0.0004869195,0.00059039204,0.00016485281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041640416,0.00024069476,0.000736627,0.00014887149,0.00040017304,0.00005947659,0.00018845522,0.00006696752,0.00012807222],"category_scores_gemma":[0.00008096817,0.00017168184,0.00013524185,0.00008325188,0.00032714888,0.00024844994,0.000034996774,0.00015982926,0.0000024139692],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1609414,0.023467358,0.059706114,0.0009251267,0.019956985,0.002419546,0.039748985,0.000039119102,0.30784208,0.000105036284,0.0013072705,0.38354096],"study_design_scores_gemma":[0.20055526,0.1433212,0.2659101,0.000529449,0.0009316832,0.000098295386,0.006339787,0.0003596041,0.3701787,0.0006061503,0.010359215,0.0008105677],"about_ca_topic_score_codex":0.00040616762,"about_ca_topic_score_gemma":0.00018420303,"teacher_disagreement_score":0.3827304,"about_ca_system_score_codex":0.00015661579,"about_ca_system_score_gemma":0.0006641107,"threshold_uncertainty_score":0.7000982},"labels":[],"label_agreement":null},{"id":"W2763742548","doi":"10.1093/annonc/mdx440.008","title":"MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Metastatic breast cancer; Oncology; Hazard ratio; Letrozole; Anastrozole; Aromatase inhibitor; Tolerability; Cancer; Adverse effect; Estrogen receptor; Tamoxifen; Confidence interval","score_opus":0.07265391653121518,"score_gpt":0.46237463407396856,"score_spread":0.3897207175427534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763742548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981782,0.0005692566,0.00008566192,0.0131718395,0.00028596944,0.0010842283,0.00023402247,0.000034532175,0.0027524817],"genre_scores_gemma":[0.99382925,0.0006746919,0.0015120076,0.002877653,0.0003238357,0.00036788834,0.000031325202,0.000053355187,0.00032997015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866825,0.00003461873,0.00028735635,0.00033715295,0.00025059943,0.0004220072],"domain_scores_gemma":[0.997819,0.00012325047,0.00045679073,0.0005493736,0.00090561464,0.00014597907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013418864,0.00021107946,0.0005933876,0.00007805915,0.00019091438,0.000010822815,0.0002651799,0.00013787556,0.00023298369],"category_scores_gemma":[0.00006859337,0.00015986168,0.000112224094,0.000054743225,0.00045639795,0.0002404933,0.000047940644,0.00015518957,0.000007987154],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027965829,0.0008945694,0.07376616,0.000059267702,0.0003084221,0.000015489259,0.0003483929,0.000015216659,0.0009073412,0.00018529112,0.00029070754,0.8952433],"study_design_scores_gemma":[0.024670811,0.015360501,0.7958494,0.00023200385,0.00006325604,0.000059991296,0.00012806132,0.000012912985,0.010444754,0.0019181758,0.15093897,0.00032117552],"about_ca_topic_score_codex":0.00018867648,"about_ca_topic_score_gemma":0.000060763134,"teacher_disagreement_score":0.89492214,"about_ca_system_score_codex":0.00006147865,"about_ca_system_score_gemma":0.00045545943,"threshold_uncertainty_score":0.651897},"labels":[],"label_agreement":null},{"id":"W2763755836","doi":"10.1093/annonc/mdx365.011","title":"Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Palbociclib; Adverse effect; Neutropenia; Progression-free survival; Letrozole; Adjuvant; Discontinuation; Oncology; Chemotherapy; Gastroenterology; Surgery; Gynecology; Clinical trial; Metastatic breast cancer; Breast cancer; Cancer; Tamoxifen","score_opus":0.03404481043125903,"score_gpt":0.37548382599165103,"score_spread":0.341439015560392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763755836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950495,0.00024743343,0.000032269225,0.0018349276,0.000057186277,0.0012498625,0.0013599568,0.00003297155,0.00013589977],"genre_scores_gemma":[0.99795794,0.0008036816,0.00062020094,0.00012303222,0.00009915631,0.00012391512,0.00015223272,0.00006912645,0.00005068729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973693,0.0002032666,0.0007776,0.0006891328,0.00035782752,0.00060287095],"domain_scores_gemma":[0.99673265,0.0004046143,0.0012876517,0.0006472747,0.0006318159,0.00029601593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016841156,0.00052318635,0.0018662338,0.0003901312,0.00021865794,0.0000139376025,0.00023529341,0.0002135127,0.00027175763],"category_scores_gemma":[0.00014878802,0.00038048296,0.0003494539,0.0003620693,0.0006761618,0.00030604383,0.00008275562,0.00025875674,0.0000027563592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040786482,0.0026509285,0.7422572,0.00007223418,0.0039880513,0.00002284177,0.0018048303,0.0005437943,0.0015554827,0.000033847362,0.000016946544,0.20626736],"study_design_scores_gemma":[0.028270554,0.021477548,0.94166094,0.00032005733,0.00044603393,0.000007235686,0.00008568119,0.000027729404,0.007224362,0.000022892022,0.0001553683,0.0003015737],"about_ca_topic_score_codex":0.0046992954,"about_ca_topic_score_gemma":0.0019867562,"teacher_disagreement_score":0.20596579,"about_ca_system_score_codex":0.0011261656,"about_ca_system_score_gemma":0.00038443223,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W2763758495","doi":"10.1093/annonc/mdx372.032","title":"ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survival","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Chemotherapy; Internal medicine; Oncology; Progression-free survival; Cancer; Ovarian cancer; Platinum; Carboplatin; Tumor progression; Surgery; Cisplatin","score_opus":0.11069261496525798,"score_gpt":0.41777760376043144,"score_spread":0.30708498879517343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763758495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89427805,0.001236597,0.000007510443,0.06456562,0.00047747692,0.00028231737,0.0000674489,0.00001471287,0.039070234],"genre_scores_gemma":[0.9888765,0.005061203,0.00034298308,0.0038541146,0.0003909492,0.00003605365,0.000010779661,0.000017825769,0.0014095514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991689,0.00002791275,0.00023369335,0.00024470422,0.000105622996,0.00021919422],"domain_scores_gemma":[0.99900556,0.00008778727,0.00026087114,0.00039951206,0.00011542748,0.0001308497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019940964,0.00013338885,0.0005290236,0.000043388343,0.00010446072,0.00001766518,0.00009637846,0.0001357194,0.0012659368],"category_scores_gemma":[0.000044975903,0.00011104952,0.000079388294,0.000019357954,0.0001584088,0.000073128154,0.00004571315,0.00010633738,0.0000064945552],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014259893,0.0012690913,0.2618827,0.00015799174,0.001140607,0.00019175406,0.0007141259,0.0000026456344,0.0018477901,0.0063112546,0.020603761,0.7044523],"study_design_scores_gemma":[0.0077490923,0.0025947,0.70654356,0.000075056654,0.00007308275,0.000023115506,0.000023539355,0.000030889634,0.007850537,0.00092483783,0.2739979,0.000113678885],"about_ca_topic_score_codex":0.00097476796,"about_ca_topic_score_gemma":0.0007986237,"teacher_disagreement_score":0.7043386,"about_ca_system_score_codex":0.00003715019,"about_ca_system_score_gemma":0.00023832313,"threshold_uncertainty_score":0.999647},"labels":[],"label_agreement":null},{"id":"W2763765527","doi":"10.1093/annonc/mdx380.047","title":"Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiosurgery; Crizotinib; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Lung cancer; Asymptomatic; Chemotherapy; Oncology; Cancer; Gastroenterology; Radiation therapy; Surgery; Metastasis","score_opus":0.023965181839550615,"score_gpt":0.36322897004167853,"score_spread":0.33926378820212794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763765527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948792,0.0005830894,0.00006572089,0.0006466769,0.00015513928,0.00078313745,0.0004939185,0.000008571747,0.0023845567],"genre_scores_gemma":[0.99828035,0.0003237061,0.00071561727,0.00031484352,0.00008664001,0.000054724365,0.000117535834,0.000026384247,0.00008020086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986425,0.00009434893,0.00045200496,0.00033324963,0.00018350992,0.00029436927],"domain_scores_gemma":[0.99811655,0.0003820263,0.0005748359,0.00032457086,0.00043398244,0.00016801056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001805401,0.00021800258,0.0006755522,0.0001607941,0.00010866722,0.000011602472,0.00011988713,0.00011421951,0.00007228477],"category_scores_gemma":[0.00023051404,0.0001709045,0.000074262825,0.00009191297,0.00030604104,0.00013689607,0.000058880465,0.0001155557,0.0000017553682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01153195,0.011413104,0.6024373,0.0006643933,0.0012829794,0.00042302982,0.0036151572,0.00013130363,0.002098347,0.00005431087,0.001281173,0.36506695],"study_design_scores_gemma":[0.025254615,0.009613956,0.95494205,0.0005861549,0.0009336649,0.000009500538,0.00018212723,0.00027145675,0.0070759137,0.000008334412,0.0009372364,0.00018496868],"about_ca_topic_score_codex":0.0027564089,"about_ca_topic_score_gemma":0.0016995687,"teacher_disagreement_score":0.364882,"about_ca_system_score_codex":0.00010129411,"about_ca_system_score_gemma":0.00077929185,"threshold_uncertainty_score":0.6969284},"labels":[],"label_agreement":null},{"id":"W2763770203","doi":"10.1093/annonc/mdx440.040","title":"Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Population; Cetuximab; Internal medicine; Oncology; Head and neck cancer; Radiation therapy; Cancer","score_opus":0.15442504290915085,"score_gpt":0.46381746255342543,"score_spread":0.30939241964427455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763770203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98366046,0.006502333,0.000033486038,0.003594348,0.0006422551,0.0016146994,0.00053064,0.0000149009265,0.0034068755],"genre_scores_gemma":[0.99684244,0.0010363718,0.0010916404,0.000326083,0.00026089573,0.00013149803,0.000028609627,0.00002799409,0.00025443852],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982027,0.0001004373,0.00066476944,0.00035948298,0.00025172575,0.00042092212],"domain_scores_gemma":[0.99762285,0.00044220945,0.00057772617,0.0004969945,0.00066365587,0.00019654242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037621157,0.0002386009,0.001691936,0.00011960415,0.0002186309,0.000011385391,0.00017929399,0.00013696548,0.00005748014],"category_scores_gemma":[0.00086863834,0.00018151836,0.00024305773,0.000055235258,0.000361274,0.00007660501,0.00010779246,0.00016480304,0.0000015456598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78775936,0.0017074685,0.00087371905,0.0031166896,0.00019612518,0.000119827855,0.004428918,8.3197324e-7,0.0007738924,0.000118747645,0.022760414,0.17814398],"study_design_scores_gemma":[0.4117429,0.38994467,0.003527322,0.00026640846,0.00078742474,0.00004290987,0.001471436,0.000057239045,0.026905295,0.00018531692,0.16475211,0.00031698222],"about_ca_topic_score_codex":0.00018326376,"about_ca_topic_score_gemma":0.0007253683,"teacher_disagreement_score":0.38823718,"about_ca_system_score_codex":0.00007439494,"about_ca_system_score_gemma":0.0009355859,"threshold_uncertainty_score":0.7402104},"labels":[],"label_agreement":null},{"id":"W2763770778","doi":"10.1093/annonc/mdx368","title":"Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Neuroendocrine tumors; Internal medicine; Carcinoid syndrome; Clinical endpoint; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Carcinoid tumors; Phases of clinical research; Toxicity; Cancer; Clinical trial; Immunotherapy","score_opus":0.07114646937290031,"score_gpt":0.40651533305627974,"score_spread":0.3353688636833794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763770778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819473,0.00008671829,0.0000059730214,0.011622349,0.00015425417,0.0040345998,0.00061072264,0.00003920371,0.0014988575],"genre_scores_gemma":[0.99660045,0.0001245805,0.00046170907,0.0011297227,0.00022230016,0.00033889158,0.00011750734,0.000060486465,0.0009443243],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969706,0.00030558548,0.00065849593,0.0007045476,0.00059794524,0.0007628208],"domain_scores_gemma":[0.99424756,0.0023183716,0.00075674837,0.0014871223,0.0009424161,0.00024776053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001994864,0.00033426296,0.0009891457,0.00010267218,0.00042426016,0.000040241626,0.0007124877,0.000013813783,0.00003245232],"category_scores_gemma":[0.0060952357,0.00019082942,0.00013661943,0.00012549605,0.0005179325,0.0002834511,0.00030364556,0.00038681913,0.000011626856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50190085,0.011250924,0.39605042,0.00024086949,0.0011563769,0.013919792,0.0016726011,0.00005840051,0.0011072868,0.000084572384,0.014153187,0.058404714],"study_design_scores_gemma":[0.038528237,0.078822464,0.8642873,0.00019995746,0.00023664536,0.00017504104,0.0007709307,0.000034134813,0.0058376007,0.00017836374,0.010700559,0.00022877345],"about_ca_topic_score_codex":0.00093274313,"about_ca_topic_score_gemma":0.0007400747,"teacher_disagreement_score":0.46823686,"about_ca_system_score_codex":0.00005395478,"about_ca_system_score_gemma":0.00040664652,"threshold_uncertainty_score":0.7781798},"labels":[],"label_agreement":null},{"id":"W2763825531","doi":"10.1093/annonc/mdx365.079","title":"BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Olaparib; BRCA mutation; Internal medicine; Oncology; CHEK2; Breast cancer; Population; PARP inhibitor; Metastatic breast cancer; Gynecology; Cancer; Germline mutation; Mutation; Genetics","score_opus":0.08106876672432517,"score_gpt":0.4149393833989728,"score_spread":0.3338706166746476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763825531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973377,0.00005169747,0.000037155347,0.00030464504,0.00015150831,0.00089648354,0.00046450872,0.000007980759,0.0007483368],"genre_scores_gemma":[0.9977702,0.00017393171,0.00069634424,0.00012871835,0.000070907874,0.00031639694,0.00006768508,0.000028674896,0.0007471305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817693,0.00015211791,0.0005555381,0.00054706214,0.00034054767,0.00022777391],"domain_scores_gemma":[0.99673826,0.000110896784,0.0010535544,0.000468468,0.001555013,0.00007379275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034657144,0.00023051642,0.00041322617,0.000104663886,0.00024699845,0.000039696875,0.00029505297,0.0001078625,0.00007861699],"category_scores_gemma":[0.0002228167,0.00020112249,0.00007242073,0.00012650547,0.000693624,0.000055565237,0.00015953237,0.00011840033,0.0000010363428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057777314,0.0012705709,0.9940023,0.00009237248,0.000576243,0.0000036971803,0.0005785685,0.00048200318,0.00048547177,0.000046051053,0.00018805177,0.0016968902],"study_design_scores_gemma":[0.0030067444,0.0024704228,0.99014455,0.00003638123,0.00009022615,0.000007669621,0.00014627365,0.00004085676,0.0035466196,0.00021721974,0.00009645623,0.00019656442],"about_ca_topic_score_codex":0.0039398153,"about_ca_topic_score_gemma":0.014527778,"teacher_disagreement_score":0.010587963,"about_ca_system_score_codex":0.000100330064,"about_ca_system_score_gemma":0.00043338316,"threshold_uncertainty_score":0.8201537},"labels":[],"label_agreement":null},{"id":"W2763851422","doi":"10.1093/annonc/mdx372.021","title":"Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Progression-free survival; Bevacizumab; Proportional hazards model; Population; Cancer; KRAS; Carboplatin; CDKN2A; Chemotherapy; Colorectal cancer; Confidence interval","score_opus":0.3737642270618406,"score_gpt":0.5146022868673332,"score_spread":0.14083805980549263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763851422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98072785,0.0037705617,0.00006650945,0.013730303,0.00018194753,0.0009831334,0.00033435083,0.0000059365952,0.00019940283],"genre_scores_gemma":[0.99584043,0.0011341698,0.001123156,0.0010430285,0.0003119852,0.00041823788,0.00008506961,0.00001686143,0.000027068361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871445,0.00010351277,0.00049049885,0.00029091956,0.00018828563,0.00021234693],"domain_scores_gemma":[0.99794984,0.0007153044,0.0005283393,0.00047144556,0.00028059777,0.000054455006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033632296,0.00015198167,0.0007020259,0.000076796554,0.00013656986,0.000014537982,0.00022000559,0.00009542654,0.00022204516],"category_scores_gemma":[0.00018487133,0.0001013204,0.00013992602,0.000050455255,0.000111519636,0.000067807756,0.000042235257,0.000094228315,0.0000011693729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006231861,0.0053107925,0.7077032,0.000022702294,0.0031096928,0.000068502435,0.007869242,0.00042751708,0.0025192325,0.00029146412,0.0017212577,0.26472455],"study_design_scores_gemma":[0.015038112,0.0067118728,0.96464723,0.000071588394,0.00027036734,0.0000023648931,0.0014881813,0.00013006761,0.0082412185,0.0007997369,0.002511083,0.00008817445],"about_ca_topic_score_codex":0.03091231,"about_ca_topic_score_gemma":0.021868136,"teacher_disagreement_score":0.26463637,"about_ca_system_score_codex":0.00007923336,"about_ca_system_score_gemma":0.0004432282,"threshold_uncertainty_score":0.9959802},"labels":[],"label_agreement":null},{"id":"W2763865735","doi":"10.1093/annonc/mdx368.031","title":"Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Population; Rectum; Cancer registry; Retrospective cohort study; Cumulative incidence; Stomach; Internal medicine; Incidence (geometry); Cohort; Cancer; Radiology; Gastroenterology","score_opus":0.09674874614913223,"score_gpt":0.4375627394265389,"score_spread":0.3408139932774067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763865735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913714,0.000101322235,0.000001669412,0.0070071113,0.00012699097,0.000855337,0.000008787343,0.000020667196,0.00050671626],"genre_scores_gemma":[0.99913526,0.00008520933,0.00015911981,0.00029800777,0.0000451676,0.00006842596,0.000009726275,0.000018277036,0.00018080721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981564,0.00029134474,0.00042126994,0.0003753245,0.00029671195,0.0004589394],"domain_scores_gemma":[0.9984449,0.00026694033,0.0002892398,0.0006180537,0.00019743775,0.00018338556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002322267,0.00015563771,0.0006060406,0.00030780912,0.0001011921,0.000022750595,0.0002510974,0.000007112328,0.000033681456],"category_scores_gemma":[0.0033740485,0.00014047201,0.00005527086,0.00012030685,0.00015330805,0.00016397654,0.0001482188,0.00029609,0.0000039415686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021031362,0.00087076315,0.9859481,0.00008235873,0.00001905676,0.0044507924,0.000037227685,0.0000050707476,0.0006441968,0.00001390214,0.00030540692,0.005519991],"study_design_scores_gemma":[0.0063921246,0.011859182,0.9792657,0.00013967355,0.000025158313,0.0002561485,0.00012268857,0.00013762276,0.0013089764,0.00012141243,0.00030058055,0.000070745395],"about_ca_topic_score_codex":0.0010735362,"about_ca_topic_score_gemma":0.002310213,"teacher_disagreement_score":0.010988419,"about_ca_system_score_codex":0.00003148816,"about_ca_system_score_gemma":0.00013839437,"threshold_uncertainty_score":0.57282823},"labels":[],"label_agreement":null},{"id":"W2763906335","doi":"10.1093/annonc/mdx387","title":"Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"GiST; Medicine; Stromal tumor; Stromal cell; Cancer research; Internal medicine; Oncology","score_opus":0.0777078252688287,"score_gpt":0.3777298021226437,"score_spread":0.300021976853815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763906335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652416,0.000018881632,0.000051985713,0.0014309431,0.000021672611,0.00039789316,0.000034564073,0.000008676794,0.001511256],"genre_scores_gemma":[0.99544615,0.000005872105,0.0043708105,0.00004602667,0.000043123706,0.000017159944,0.00000721376,0.000015337713,0.0000482887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985755,0.000054743607,0.00030539674,0.00029385713,0.00032730197,0.00044316333],"domain_scores_gemma":[0.9984834,0.00015632287,0.0004337493,0.0003469613,0.00036347893,0.00021604635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031829817,0.00017993712,0.00057485723,0.00015864757,0.000084095256,0.000013172804,0.00014006437,0.000029021887,0.000016288634],"category_scores_gemma":[0.0006351529,0.00013945095,0.00006116312,0.00006276532,0.000515825,0.00014575894,0.00014430891,0.00027371026,0.0000021362148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039658807,0.0033626894,0.96951675,0.00013549063,0.00005688999,0.00057089096,0.00006880448,0.0000021256703,0.010255817,0.00004520553,0.00009083723,0.011928642],"study_design_scores_gemma":[0.008498158,0.0282415,0.95162964,0.0006749598,0.000037272468,0.00064067886,0.00009742376,0.00011025841,0.009920654,0.000025284866,0.000040603907,0.00008356965],"about_ca_topic_score_codex":0.0007624585,"about_ca_topic_score_gemma":0.00023997875,"teacher_disagreement_score":0.024878811,"about_ca_system_score_codex":0.00006882225,"about_ca_system_score_gemma":0.00032905856,"threshold_uncertainty_score":0.56866443},"labels":[],"label_agreement":null},{"id":"W2763985514","doi":"10.1093/annonc/mdx365.042","title":"Real-world everolimus experience in postmenopausal HR+ HER2- advanced breast cancer women: Treat ER+ight Canadian prospective observational study 2nd subgroup analysis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); BC Cancer Agency; Cambridge Memorial Hospital; Ottawa Hospital; Grand River Hospital","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Exemestane; Anastrozole; Breast cancer; Adverse effect; Everolimus; Letrozole; Hazard ratio; Oncology; Cancer; Surgery; Tamoxifen; Confidence interval","score_opus":0.0827013783738517,"score_gpt":0.418636474548602,"score_spread":0.33593509617475026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763985514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461734,0.00026757663,0.000003191051,0.0012243887,0.00022171684,0.0004637162,0.0002478638,0.0000109660305,0.0029432592],"genre_scores_gemma":[0.9973675,0.00031804456,0.00008973866,0.00065784354,0.00020465195,0.00054562546,0.00005524618,0.00003334608,0.00072799955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978514,0.00014308684,0.00045382645,0.0006905408,0.00023215935,0.0006290163],"domain_scores_gemma":[0.998103,0.000038555256,0.00040963327,0.00076229055,0.00043449897,0.00025199368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037587903,0.00026306647,0.0005712154,0.0002840047,0.00019452853,0.000032087493,0.0006052509,0.00019374641,0.00021291201],"category_scores_gemma":[0.00009399403,0.0002650229,0.00010431388,0.00037202498,0.00027304166,0.00003216062,0.00013204759,0.00015811193,0.0000022530267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092537195,0.0005155991,0.9630983,0.000009533325,0.0006084248,0.000065092485,0.00149776,0.0006368937,0.027944569,0.000074475836,0.00037470358,0.004249276],"study_design_scores_gemma":[0.0013219932,0.0020359207,0.98187476,0.000013160855,0.000071121314,0.0000049114606,0.00055649655,0.000030825075,0.008173329,0.000083549385,0.0055518285,0.00028211295],"about_ca_topic_score_codex":0.1431999,"about_ca_topic_score_gemma":0.6937402,"teacher_disagreement_score":0.55054027,"about_ca_system_score_codex":0.0004799467,"about_ca_system_score_gemma":0.0010525851,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W2764012433","doi":"10.1093/annonc/mdx440.065","title":"Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Randomized controlled trial; Clinical endpoint; Surrogate endpoint; Food and drug administration; Clinical research; Internal medicine; Oncology; Pharmacology","score_opus":0.627560153000654,"score_gpt":0.5608649571324651,"score_spread":0.06669519586818895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764012433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9499956,0.00082272466,0.00047943118,0.04223822,0.0008693799,0.0025385679,0.00040326972,0.000013835262,0.0026389945],"genre_scores_gemma":[0.99278736,0.0005982786,0.00224607,0.003606863,0.00038791326,0.00014033078,0.000057064746,0.000017216149,0.00015891402],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98368627,0.0021105052,0.013192116,0.0005695403,0.00011704813,0.0003245047],"domain_scores_gemma":[0.9593773,0.018584244,0.02074863,0.0006324872,0.00039499803,0.00026235633],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11104773,0.00020354058,0.008594914,0.00025071768,0.00019057322,0.000072136514,0.00036013476,0.0003341679,0.0003443195],"category_scores_gemma":[0.101501375,0.0002053978,0.0006974317,0.00004799294,0.00026815344,0.0003212928,0.0001096332,0.00016428201,0.00007152248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50061435,0.003393255,0.21625294,0.0016038268,0.011231627,0.000016891738,0.008825944,0.00021693444,0.0005598565,0.15770724,0.06949802,0.030079134],"study_design_scores_gemma":[0.79872376,0.00928071,0.08150739,0.0004830773,0.0005892919,0.000009456981,0.0022483836,0.010978974,0.0021897699,0.06563531,0.02713492,0.0012189709],"about_ca_topic_score_codex":0.0009139184,"about_ca_topic_score_gemma":0.0004990459,"teacher_disagreement_score":0.2981094,"about_ca_system_score_codex":0.000051581508,"about_ca_system_score_gemma":0.00043294491,"threshold_uncertainty_score":0.91536343},"labels":[],"label_agreement":null},{"id":"W2764048552","doi":"10.1093/annonc/mdx374.022","title":"Hyperfractionated twice daily re-irradiation (bid re-RT) and chemotherapy (CT) for locoregionally recurrent head and neck squamous cell carcinoma (LR HNSCC): A systematic review (SR)","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Hyperfractionation; Regimen; Radiation therapy; Clinical trial; Oncology; Nuclear medicine; Debulking; Internal medicine; Dose fractionation; Urology; Head and neck cancer; Cancer","score_opus":0.21824217974386856,"score_gpt":0.45665439840570915,"score_spread":0.2384122186618406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764048552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003938105,0.98738277,0.0000028687127,0.0044630594,0.00026697858,0.0054898965,0.0000687166,0.000027010497,0.0019049142],"genre_scores_gemma":[0.0016501441,0.99412245,0.00011698873,0.0019343239,0.00024656346,0.0009829984,0.00019300474,0.000063985775,0.00068952015],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704945,0.00034493237,0.0013533192,0.0006184458,0.00026201367,0.00037186086],"domain_scores_gemma":[0.9958464,0.0010011008,0.0018606683,0.00055023655,0.0005404656,0.00020111984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010712045,0.00050351967,0.005414475,0.00020336197,0.00019086257,0.000016571777,0.00017957872,0.0003128964,0.000023042126],"category_scores_gemma":[0.0008851011,0.00038375397,0.00045948144,0.00014282417,0.00017785314,0.00008578564,0.00006157857,0.00040615667,0.00000883217],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018895918,0.00022674119,0.000025814074,0.70867056,0.0002353366,0.000028086053,0.000109870816,2.0926146e-8,0.000001176275,0.00002337004,0.02419146,0.2662986],"study_design_scores_gemma":[0.001973201,0.0050810995,0.00015453255,0.16552506,0.0023540042,0.000242852,0.000027562963,0.000007810981,0.0000023325015,0.00001906531,0.8243464,0.00026606754],"about_ca_topic_score_codex":0.00006451502,"about_ca_topic_score_gemma":0.000073627976,"teacher_disagreement_score":0.8001549,"about_ca_system_score_codex":0.00016512694,"about_ca_system_score_gemma":0.0008432063,"threshold_uncertainty_score":0.9998614},"labels":[],"label_agreement":null},{"id":"W2764094032","doi":"10.1093/annonc/mdx372.062","title":"FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Ovarian cancer; Internal medicine; Oncology; Clinical endpoint; Chemotherapy regimen; Cancer; Phases of clinical research; Topotecan; Chemotherapy; Clinical trial; Adverse effect","score_opus":0.051037166988478856,"score_gpt":0.3993897319209964,"score_spread":0.34835256493251754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764094032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642552,0.0023648934,0.000007691343,0.02762798,0.00044608198,0.0035510357,0.0010561561,0.000017217388,0.00067370647],"genre_scores_gemma":[0.98638266,0.010276532,0.0005736758,0.001548172,0.00032209614,0.0006226657,0.000046942863,0.00006561632,0.00016164662],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971534,0.0002335671,0.0008136733,0.00072721264,0.0005129637,0.00055918365],"domain_scores_gemma":[0.9975414,0.0003945187,0.0005770013,0.00073935813,0.00048934313,0.00025832964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066925824,0.00044175106,0.0015219145,0.00015540306,0.0002647966,0.00002946657,0.00033737908,0.00015654622,0.00025566336],"category_scores_gemma":[0.00010148926,0.00028015111,0.00012457151,0.00024759106,0.0003887633,0.00014118965,0.00013624926,0.00028826453,0.0000013295755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44355953,0.008841163,0.024094116,0.0003179013,0.0028149544,0.00023099835,0.009838225,0.00005064547,0.0039963704,0.000043308406,0.0008591139,0.5053537],"study_design_scores_gemma":[0.15824436,0.058242362,0.76543635,0.0016451877,0.0008045652,0.000012119143,0.00059385854,0.00006831102,0.005463599,0.0000073264077,0.009075747,0.00040622105],"about_ca_topic_score_codex":0.021227816,"about_ca_topic_score_gemma":0.027640752,"teacher_disagreement_score":0.74134225,"about_ca_system_score_codex":0.00061120075,"about_ca_system_score_gemma":0.0021487486,"threshold_uncertainty_score":0.9999651},"labels":[],"label_agreement":null},{"id":"W2764125469","doi":"10.1093/annonc/mdx363.013","title":"Large-scale DNA organization is a prognostic marker of breast cancer survival","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine; Pathology","score_opus":0.031287884804708746,"score_gpt":0.33874207349556273,"score_spread":0.307454188690854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764125469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992502,0.00036333626,0.00018898972,0.0030120264,0.00032684804,0.00012742389,0.0005619003,0.0000027889944,0.0029147188],"genre_scores_gemma":[0.9962631,0.0025018442,0.00011180748,0.00060473103,0.00021943475,0.000008988995,0.000057830952,0.000017972547,0.00021429399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999294,0.000029255329,0.00021517639,0.00019875301,0.00007752465,0.00018532205],"domain_scores_gemma":[0.99871075,0.000026035019,0.00031681848,0.00039339074,0.00049628393,0.000056706762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017595798,0.00009311688,0.00021839052,0.000025208536,0.0000793333,0.000010663392,0.0002442504,0.0001612969,0.0001636424],"category_scores_gemma":[0.00023680893,0.00009343893,0.00006213469,0.00004063408,0.00012931859,0.0000041260637,0.00018910039,0.000041930034,0.0000037970117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004086983,0.0007293985,0.6926345,0.000110760346,0.0002764176,0.000006371206,0.00040446754,0.000032750348,0.2475477,0.0003869813,0.035424445,0.022037469],"study_design_scores_gemma":[0.0011455857,0.0007612015,0.6960178,0.00003287705,0.000059369508,0.000012969962,0.000113792536,0.000043718133,0.20527293,0.0001865452,0.096155696,0.00019750888],"about_ca_topic_score_codex":0.00015124086,"about_ca_topic_score_gemma":0.0004973502,"teacher_disagreement_score":0.06073125,"about_ca_system_score_codex":0.000008151091,"about_ca_system_score_gemma":0.00027366768,"threshold_uncertainty_score":0.3810329},"labels":[],"label_agreement":null},{"id":"W2764130147","doi":"10.1093/annonc/mdx365.024","title":"Is PFS a more relevant endpoint than OS in 1L HR+, HER2– MBC? A systematic literature review","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Progression-free survival; Oncology; Randomized controlled trial; Clinical endpoint; Cancer; Breast cancer; Chemotherapy","score_opus":0.08035043177986463,"score_gpt":0.44206763810045724,"score_spread":0.3617172063205926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764130147","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082303025,0.6794276,0.000086991364,0.2247926,0.0005795966,0.0041342033,0.000090644935,0.00008772042,0.008497595],"genre_scores_gemma":[0.8370624,0.12723525,0.0019262003,0.030499589,0.00034032273,0.00045157745,0.000027154494,0.000071242066,0.0023862615],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99819875,0.00017075235,0.0007010252,0.00032536229,0.00025330568,0.00035081763],"domain_scores_gemma":[0.9975734,0.00013617071,0.00073153013,0.0011082052,0.00032634838,0.00012438856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074079674,0.00022345538,0.0014353647,0.00012854162,0.000062051375,0.000014455662,0.00032300246,0.00019385682,0.000087610424],"category_scores_gemma":[0.00082266424,0.00016583902,0.00021726587,0.0001380732,0.00019636861,0.00016633628,0.00009815619,0.00035481068,0.00002938777],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038263372,0.0023561097,0.010339021,0.76184887,0.001573501,0.0056645973,0.022057539,0.000005193399,0.0064623016,0.0023802763,0.019936403,0.16354984],"study_design_scores_gemma":[0.0077338694,0.0057948236,0.04802591,0.72186893,0.0006060136,0.0028749546,0.0013702204,0.00008063966,0.0062951758,0.00393103,0.20061834,0.00080006185],"about_ca_topic_score_codex":0.00004129226,"about_ca_topic_score_gemma":0.000061987645,"teacher_disagreement_score":0.7547594,"about_ca_system_score_codex":0.000093519026,"about_ca_system_score_gemma":0.00020495645,"threshold_uncertainty_score":0.6762719},"labels":[],"label_agreement":null},{"id":"W2764133116","doi":"10.1093/annonc/mdx387.003","title":"Tumour necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma (STS)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Hazard ratio; Odds ratio; Chemotherapy; Necrosis; Neoadjuvant therapy; Soft tissue sarcoma; Oncology; Meta-analysis; Sarcoma; Surgery; Soft tissue; Cancer; Confidence interval; Pathology; Breast cancer","score_opus":0.15354822020433256,"score_gpt":0.47876622468921154,"score_spread":0.325218004484879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764133116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672791,0.0028663184,0.0000023190803,0.027603965,0.00023925253,0.00031149582,0.0000036957074,0.000012899352,0.0016810023],"genre_scores_gemma":[0.9935005,0.0032671117,0.00053125893,0.0025079618,0.000053874304,0.000019349194,0.000004219047,0.0000151467275,0.00010062958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988173,0.000084951804,0.0004354068,0.00027180044,0.0001286093,0.00026190616],"domain_scores_gemma":[0.99866104,0.00051154086,0.00022711471,0.00041302753,0.00005435888,0.00013291714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005764566,0.00014193497,0.0008544476,0.00006686465,0.000103133236,0.000018295283,0.00014168481,0.00016966998,0.00008088439],"category_scores_gemma":[0.00041652046,0.00010752743,0.00022814565,0.000026128513,0.00017405757,0.00007273613,0.00008871249,0.00015090393,0.000024847606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000859223,0.00094349467,0.61610705,0.000004461503,0.00014833467,0.00039144454,0.00011820572,8.62187e-8,0.0001525982,0.0000290201,0.000750058,0.3812693],"study_design_scores_gemma":[0.0055846036,0.0030676343,0.9752634,0.00006393424,0.000059168728,0.00001996675,0.000057747744,0.000009440458,0.0010832113,0.00060205633,0.0141008515,0.00008795079],"about_ca_topic_score_codex":0.001180167,"about_ca_topic_score_gemma":0.000586071,"teacher_disagreement_score":0.38118136,"about_ca_system_score_codex":0.000016478714,"about_ca_system_score_gemma":0.000092322305,"threshold_uncertainty_score":0.43848413},"labels":[],"label_agreement":null},{"id":"W2764212714","doi":"10.1093/annonc/mdx370.023","title":"Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Prostate cancer; Docetaxel; Hazard ratio; Oncology; Internal medicine; Androgen deprivation therapy; Confidence interval; Cohort; Cancer; Androgen receptor","score_opus":0.16848164959237202,"score_gpt":0.46569964776925504,"score_spread":0.297217998176883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764212714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97012454,0.0034163224,0.0006161636,0.013061402,0.00024501045,0.008606907,0.0038707687,0.000033279783,0.000025577328],"genre_scores_gemma":[0.97073555,0.005182897,0.0131371515,0.00064869376,0.000053316664,0.0066924603,0.00020695089,0.000086315136,0.0032566402],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965967,0.00018685145,0.0011541747,0.00073180307,0.0004336811,0.0008967922],"domain_scores_gemma":[0.99593925,0.00051761075,0.0013029578,0.0006702181,0.0013358118,0.00023416862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009700029,0.00051889697,0.0018237415,0.00029116613,0.00019209209,0.000049551625,0.00025105148,0.00017599254,0.000049845294],"category_scores_gemma":[0.00067380455,0.00034955234,0.0003110852,0.00023553472,0.0008491067,0.00040162937,0.0000556876,0.00025914228,0.00000212485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.527227,0.012194563,0.047131773,0.01200644,0.010009754,0.0023872487,0.018864874,0.0014868785,0.24625166,0.000105729865,0.0035411604,0.11879291],"study_design_scores_gemma":[0.12255654,0.030216426,0.27331415,0.0023042215,0.0020888268,0.000038461825,0.0020816687,0.00448116,0.55494094,0.00044910092,0.0063018855,0.0012265953],"about_ca_topic_score_codex":0.002516711,"about_ca_topic_score_gemma":0.010417126,"teacher_disagreement_score":0.40467048,"about_ca_system_score_codex":0.00039837655,"about_ca_system_score_gemma":0.003323244,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W2764212839","doi":"10.1093/annonc/mdx380.002","title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Discontinuation; Randomized controlled trial; Internal medicine; Adverse effect; Lung cancer; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.02308003937331568,"score_gpt":0.3364791698968296,"score_spread":0.31339913052351387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764212839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858757,0.00064218027,0.000025787514,0.0018131024,0.0002478896,0.0012627629,0.000041554045,0.000008014526,0.010082956],"genre_scores_gemma":[0.99715406,0.0012368371,0.0003155103,0.0004586781,0.00004465921,0.000087095344,0.000031617114,0.00001634957,0.00065518613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846417,0.00012048286,0.0007549873,0.00024462215,0.00017622515,0.00023948977],"domain_scores_gemma":[0.9977122,0.00018409261,0.0012004385,0.00042126508,0.00042969856,0.000052320895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007046175,0.00015139632,0.0010071418,0.00011951306,0.00005691473,0.000007058878,0.00016729545,0.0001575463,0.000037055903],"category_scores_gemma":[0.00024442925,0.00011572044,0.00014383248,0.00007883192,0.0002910737,0.00010697827,0.000032400287,0.00013217627,0.0000010756538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8618175,0.0008608957,0.049777012,0.000196726,0.00025942823,0.000016134725,0.001614772,0.000016775537,0.0064167106,0.0000042710676,0.0022686422,0.076751135],"study_design_scores_gemma":[0.7228142,0.007274636,0.21802832,0.00076412916,0.00015119604,0.0000024287472,0.00014102973,0.00016700917,0.045898765,0.000010872617,0.0045567653,0.00019065558],"about_ca_topic_score_codex":0.002362406,"about_ca_topic_score_gemma":0.0013133334,"teacher_disagreement_score":0.1682513,"about_ca_system_score_codex":0.000088078916,"about_ca_system_score_gemma":0.0005175459,"threshold_uncertainty_score":0.47189426},"labels":[],"label_agreement":null},{"id":"W2764236574","doi":"10.1093/annonc/mdx377.025","title":"Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nomogram; Proportional hazards model; Concordance; Internal medicine; AJCC staging system; Survival analysis; Cancer; Oncology; Nuclear medicine; Staging system","score_opus":0.22688224412256797,"score_gpt":0.46138411653191325,"score_spread":0.23450187240934528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764236574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96022105,0.00010038937,0.00005768368,0.0031067247,0.0002519591,0.00035006125,0.000037666694,0.000012635015,0.03586183],"genre_scores_gemma":[0.99670964,0.00010331041,0.00210663,0.00077430374,0.0000675909,0.000062926105,0.00008373443,0.000012279079,0.0000796057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893075,0.00015277241,0.00031289636,0.00023374181,0.00014404397,0.0002258141],"domain_scores_gemma":[0.998901,0.00016757022,0.00035069854,0.0002807764,0.00020662251,0.00009334118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034083132,0.000119931836,0.00044969315,0.00013862642,0.00008288204,0.000010670914,0.0002063458,0.00011222861,0.000101113925],"category_scores_gemma":[0.00047928724,0.000106796746,0.00006662401,0.000042024516,0.00019327928,0.00040295374,0.000071377726,0.0001702761,0.000011177913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013884574,0.0019550847,0.87345684,0.000079020836,0.0012858938,0.0028920409,0.0036217659,0.0004557447,0.00026629918,0.0037788698,0.00031627112,0.1105037],"study_design_scores_gemma":[0.015597265,0.016818114,0.92384756,0.000426103,0.00053933344,0.00036427603,0.0019063641,0.010761837,0.0056314943,0.020185696,0.003519253,0.0004027384],"about_ca_topic_score_codex":0.00040494843,"about_ca_topic_score_gemma":0.0006684425,"teacher_disagreement_score":0.11010096,"about_ca_system_score_codex":0.00013855129,"about_ca_system_score_gemma":0.0005640513,"threshold_uncertainty_score":0.4355045},"labels":[],"label_agreement":null},{"id":"W2764242811","doi":"10.1093/annonc/mdx440.044","title":"Real-world productivity, healthcare resource utilization (HRU), and quality of life (QOL) in patients with advanced gastric cancer (GC) in Canada and Europe","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Productivity; Quality of life (healthcare); Cancer; Health care; Quality (philosophy); Intensive care medicine; Internal medicine; Nursing; Economic growth","score_opus":0.12177650669810271,"score_gpt":0.40008595745114056,"score_spread":0.27830945075303787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764242811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065363,0.00029908077,7.9273053e-7,0.00749499,0.00004644759,0.00040933897,0.00001405349,0.0000028282489,0.0010788561],"genre_scores_gemma":[0.99834657,0.00097545935,0.0000518319,0.00043072796,0.00001983886,0.00001111611,0.000009440743,0.000007791191,0.00014723021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899673,0.0001024114,0.00033306016,0.00021678979,0.00017566477,0.00017531047],"domain_scores_gemma":[0.99903005,0.000059531547,0.00042189515,0.00023835196,0.00017357728,0.0000765777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030386317,0.00008729965,0.00046522333,0.0001503799,0.00003095536,0.0000032920254,0.00006597802,0.000025979769,0.0000065936406],"category_scores_gemma":[0.0002957504,0.00007474359,0.000009404281,0.00021461675,0.00009527154,0.000081363796,0.00008130569,0.00009872019,4.0491148e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011100307,0.00008708478,0.9214824,0.00029786845,0.000016732994,0.0000039676584,0.00010244884,0.000016264778,0.000006965988,0.000052483294,0.00031833505,0.07650541],"study_design_scores_gemma":[0.0028257314,0.00071835204,0.99311453,0.00010886028,0.000011362727,2.1522725e-7,0.00007983832,0.000007324336,0.00003361557,0.000009793844,0.0030358848,0.00005448519],"about_ca_topic_score_codex":0.80824804,"about_ca_topic_score_gemma":0.97744906,"teacher_disagreement_score":0.16920099,"about_ca_system_score_codex":0.00011280754,"about_ca_system_score_gemma":0.0007410026,"threshold_uncertainty_score":0.3047955},"labels":[],"label_agreement":null},{"id":"W2764336049","doi":"10.1093/annonc/mdx371.073","title":"Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital","funders":"","keywords":"Medicine; Urothelial cancer; Pembrolizumab; Chemotherapy; Oncology; Internal medicine; Cancer; Bladder cancer; Immunotherapy","score_opus":0.1276922113237782,"score_gpt":0.48509128756598274,"score_spread":0.35739907624220457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764336049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96289945,0.00074256764,0.000011128948,0.015059781,0.001398111,0.0012702998,0.000067758294,0.000035353572,0.018515553],"genre_scores_gemma":[0.9900708,0.005254593,0.00018588614,0.0025472965,0.00083226245,0.00022378021,0.000013783694,0.000052204603,0.00081936095],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982842,0.00006746983,0.0004882931,0.0004191282,0.00026424276,0.00047665252],"domain_scores_gemma":[0.9984403,0.00009638669,0.0004158519,0.00071805133,0.00016010703,0.00016929845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000227657,0.00027071388,0.0009171599,0.00014066219,0.0001232906,0.000017606319,0.00032391315,0.00026411706,0.00080097007],"category_scores_gemma":[0.00012949639,0.00024069357,0.00023969129,0.00008978736,0.00026606742,0.00015249505,0.00003641984,0.00024328702,0.00002070614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4855563,0.0020438405,0.0010864905,0.000031474105,0.00028817277,0.00007752377,0.00055833993,0.0000032980481,0.004165958,0.00007104731,0.001519485,0.5045981],"study_design_scores_gemma":[0.74465567,0.033649452,0.008754181,0.00010011738,0.000096612275,0.00001303653,0.00007607758,0.000038327016,0.05032915,0.00033327896,0.16168158,0.00027252725],"about_ca_topic_score_codex":0.0010594015,"about_ca_topic_score_gemma":0.00034917932,"teacher_disagreement_score":0.50432557,"about_ca_system_score_codex":0.00015679783,"about_ca_system_score_gemma":0.0009047786,"threshold_uncertainty_score":0.9815199},"labels":[],"label_agreement":null},{"id":"W2765224458","doi":"10.1093/annonc/mdx721","title":"Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital; University of Toronto","funders":"","keywords":"Medicine; Oncology; Medical physics; Cancer; Internal medicine","score_opus":0.2218380937966657,"score_gpt":0.4163079281284451,"score_spread":0.1944698343317794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765224458","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009316891,0.035625506,0.0010078438,0.9275908,0.002691408,0.0006188235,0.0010807922,0.000019056133,0.02204892],"genre_scores_gemma":[0.10727287,0.043535635,0.00070252153,0.8331921,0.0094225565,0.0003310067,0.000062187995,0.00012524343,0.005355879],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749714,0.000034031447,0.0012302604,0.0006397028,0.000035818095,0.00056301645],"domain_scores_gemma":[0.99565524,0.0010136378,0.0023260596,0.00076952117,0.00016713911,0.00006841158],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015342591,0.00031908136,0.0015818661,0.00013272425,0.0002685206,0.00010454666,0.0007627365,0.0026133384,0.00014612259],"category_scores_gemma":[0.00054457225,0.0002847694,0.0004426716,0.000032501088,0.00062506815,0.00021213437,0.00014348849,0.001754669,0.000021239453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008332147,0.00003464273,0.006709395,0.000079121724,0.00048590614,0.000007043683,0.000527735,0.00001660817,1.5494696e-7,0.009655505,0.8533365,0.12906405],"study_design_scores_gemma":[0.00045263843,0.00045850177,0.0048098215,0.00006852763,0.00002963035,0.0000016746271,0.00002170565,0.00019561673,0.000003990439,0.18704222,0.8066462,0.00026943543],"about_ca_topic_score_codex":0.00090074085,"about_ca_topic_score_gemma":0.00040449938,"teacher_disagreement_score":0.17738672,"about_ca_system_score_codex":0.000054338852,"about_ca_system_score_gemma":0.00017079334,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2766828098","doi":"10.1093/annonc/mdx651","title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":399,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Center for Research Resources; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung","keywords":"Medicine; Cancer; Male breast cancer; Oncology; Breast cancer; Internal medicine; Gynecology","score_opus":0.08452901527199244,"score_gpt":0.4313827596922344,"score_spread":0.34685374442024197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766828098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87673455,0.00017051646,0.000002798564,0.10868597,0.0010653853,0.0007641827,0.0017935367,0.000015949608,0.0107670985],"genre_scores_gemma":[0.99325037,0.0021431758,0.000078534635,0.0007350836,0.00067815604,0.00015956751,0.00004486188,0.000018713738,0.002891511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981509,0.00008526477,0.00078462786,0.00028103328,0.00038542817,0.00031276527],"domain_scores_gemma":[0.9961855,0.000058744015,0.0016782817,0.00060044107,0.0013778708,0.000099170495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044401275,0.00016776874,0.0006453102,0.000104873936,0.00013406118,0.0000070954725,0.00045565754,0.00016648367,0.00046934077],"category_scores_gemma":[0.00016394287,0.00012434906,0.00014787039,0.00011354248,0.00051334634,0.00011006732,0.0002627121,0.00018369762,0.00000424496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003687502,0.0011543633,0.51541936,0.00064654247,0.00031664412,0.000016184373,0.00059455243,0.00000482522,0.02255435,0.00019207216,0.004579159,0.45083442],"study_design_scores_gemma":[0.0021591713,0.00045851932,0.96075124,0.00049519615,0.000083791914,0.00030828625,0.00006487303,0.00006219359,0.0038839073,0.000016964937,0.03162826,0.000087602566],"about_ca_topic_score_codex":0.004509696,"about_ca_topic_score_gemma":0.0014099267,"teacher_disagreement_score":0.4507468,"about_ca_system_score_codex":0.000086070955,"about_ca_system_score_gemma":0.0007928024,"threshold_uncertainty_score":0.68173414},"labels":[],"label_agreement":null},{"id":"W2767050613","doi":"10.1093/annonc/mdx565","title":"Learning points from a study on access to service at a tertiary cancer centre","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Medicine; Referral; Cancer; Family medicine; Checklist; Palliative care; Residence; Distress; Logistic regression; Demography; Nursing; Internal medicine","score_opus":0.42439171746353027,"score_gpt":0.569464483191902,"score_spread":0.14507276572837174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767050613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96234196,0.0002650331,0.0000016842162,0.030626262,0.0001721656,0.00028565052,0.000024376752,0.000010777349,0.0062720943],"genre_scores_gemma":[0.990661,0.0002801511,0.00007652669,0.008138325,0.00016110798,0.000017521255,0.00000894858,0.000012226132,0.0006441794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991138,0.000095476964,0.00021848627,0.00022035104,0.00016492276,0.0001869783],"domain_scores_gemma":[0.9987849,0.00020496825,0.0002535353,0.00034623954,0.00029470221,0.00011567573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001499251,0.00010597978,0.0004531802,0.000066122775,0.00008053178,0.000008227851,0.0002657617,0.00008064839,0.00036462772],"category_scores_gemma":[0.0004321202,0.00008814039,0.000057523608,0.00005236758,0.000037045196,0.000072777744,0.00025891987,0.00013155384,0.000076240765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009477121,0.0004973123,0.95555764,0.000037148915,0.00024256804,0.00009318678,0.009441735,0.000014156298,0.0022324459,0.000002284038,0.008706806,0.022226993],"study_design_scores_gemma":[0.0016363782,0.0019930347,0.88793886,0.0005618136,0.00007760272,7.476076e-7,0.0016323639,0.000015004072,0.017302496,0.000025557634,0.088733666,0.00008245015],"about_ca_topic_score_codex":0.005063371,"about_ca_topic_score_gemma":0.004038874,"teacher_disagreement_score":0.080026865,"about_ca_system_score_codex":0.000041725612,"about_ca_system_score_gemma":0.000090280206,"threshold_uncertainty_score":0.76543355},"labels":[],"label_agreement":null},{"id":"W2767140416","doi":"10.1093/annonc/mdx716","title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cancerfonden","keywords":"Medicine; Low molecular weight heparin; Randomized controlled trial; Heparin; Lung cancer; Oncology; Surgery; Internal medicine","score_opus":0.05836007538503154,"score_gpt":0.41265134889684724,"score_spread":0.3542912735118157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767140416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492355,0.00041986315,0.000047907834,0.008256895,0.00054024067,0.00732669,0.000049795108,0.0000071423733,0.008427914],"genre_scores_gemma":[0.9939698,0.0030135638,0.00008495199,0.00062465516,0.00023495071,0.0018429026,0.00003031827,0.000016852619,0.00018199305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978189,0.0004419467,0.0009081,0.0002948302,0.00021086962,0.00032538103],"domain_scores_gemma":[0.9982546,0.00035000316,0.00061977,0.0005543273,0.000121675665,0.00009965065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016498165,0.00019348798,0.0019624713,0.00022795817,0.000061814506,0.00001418643,0.00024241843,0.00013842114,0.00020425236],"category_scores_gemma":[0.00035686436,0.00013218542,0.0002970556,0.0001034306,0.00015872405,0.000046303914,0.0001074944,0.00012307797,0.0000023988052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93805903,0.006683131,0.00006547188,0.000075717384,0.00037171328,0.00009937018,0.0011657713,0.0000687528,0.0006476017,0.0004920435,0.003513467,0.048757903],"study_design_scores_gemma":[0.9634119,0.012254113,0.00031019477,0.00018599878,0.0004048987,7.955313e-7,0.0001058596,0.00011568056,0.014208262,0.00016064066,0.008731761,0.00010985209],"about_ca_topic_score_codex":0.0050642733,"about_ca_topic_score_gemma":0.0043248157,"teacher_disagreement_score":0.048648052,"about_ca_system_score_codex":0.00019500498,"about_ca_system_score_gemma":0.00047345628,"threshold_uncertainty_score":0.76557},"labels":[],"label_agreement":null},{"id":"W2767332835","doi":"10.1093/annonc/mdx426.009","title":"Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"PDGFRA; Medicine; Cancer research; Transcriptome; Oncology; Biology; Genetics; Gene; Stromal cell","score_opus":0.038125030446366254,"score_gpt":0.39023209872016196,"score_spread":0.3521070682737957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767332835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949917,0.0006743828,0.00007591745,0.00062439236,0.000099575496,0.00065727584,0.00017795146,0.000016074608,0.002682736],"genre_scores_gemma":[0.9963513,0.00008700709,0.0021341585,0.00009993023,0.000027380187,0.00004278232,0.00032372394,0.000017851997,0.0009158662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845475,0.00006950611,0.0006147977,0.00037855408,0.0001725043,0.00030989214],"domain_scores_gemma":[0.9982358,0.000107046835,0.00056576234,0.0005172765,0.00039480315,0.00017930083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004027332,0.00018885244,0.0007587295,0.00046026893,0.00011174837,0.000017756012,0.00015599844,0.00019976654,0.000057758607],"category_scores_gemma":[0.00042450792,0.000145404,0.0001471727,0.00032212352,0.00021606895,0.00020152015,0.00006218443,0.00013378919,0.0000026519156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055989656,0.005260795,0.9497264,0.0004134939,0.0018370281,0.0009729797,0.005060596,0.00018294966,0.010671143,0.000034646273,0.001810206,0.018430801],"study_design_scores_gemma":[0.011457152,0.0038742821,0.96780455,0.000057376154,0.0016101366,0.000029215413,0.0007865251,0.008074145,0.0050258357,0.00008319307,0.0010238781,0.00017373847],"about_ca_topic_score_codex":0.0087992335,"about_ca_topic_score_gemma":0.0011304383,"teacher_disagreement_score":0.018257063,"about_ca_system_score_codex":0.000083077925,"about_ca_system_score_gemma":0.00046562543,"threshold_uncertainty_score":0.99780124},"labels":[],"label_agreement":null},{"id":"W2767918609","doi":"10.1093/annonc/mdx429.004","title":"ARIEL4: An international, randomised phase 3 study of rucaparib vs chemotherapy as treatment for BRCA1- or BRCA2-mutated, relapsed ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Olaparib; Chemotherapy; Regimen; Progressive disease; Cancer; PARP inhibitor; Chemotherapy regimen; Poly ADP ribose polymerase; Genetics; Biology","score_opus":0.20836374787434364,"score_gpt":0.5285145537961317,"score_spread":0.320150805921788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767918609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806722,0.0001133733,0.000118381264,0.012009417,0.0007022835,0.00264691,0.00013451089,0.000029982402,0.0035729753],"genre_scores_gemma":[0.99197304,0.0015831938,0.00066265714,0.0023556636,0.0004085326,0.00090716383,0.00006218524,0.000041834683,0.0020057382],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983274,0.00011543012,0.000680248,0.00038024777,0.00023928598,0.00025740222],"domain_scores_gemma":[0.9973351,0.00025338397,0.0009163075,0.00074266974,0.000595975,0.00015655904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047910088,0.00021846892,0.00094949553,0.00015801867,0.00014255651,0.000018366929,0.00032480477,0.00017797745,0.0011864087],"category_scores_gemma":[0.00022908843,0.0001692036,0.00019126925,0.00006311629,0.00022148553,0.00018064551,0.000021327713,0.00009972069,0.000003915234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59896934,0.029902365,0.0053289295,0.00008566659,0.004825009,0.00015562351,0.01220829,0.00006442421,0.039230946,0.0003988472,0.008443734,0.3003868],"study_design_scores_gemma":[0.6027455,0.088291,0.005631625,0.00014107753,0.00037264102,0.00005492368,0.0010856148,0.0003031204,0.14689183,0.0007917494,0.15341328,0.00027765112],"about_ca_topic_score_codex":0.0017011786,"about_ca_topic_score_gemma":0.000543177,"teacher_disagreement_score":0.30010915,"about_ca_system_score_codex":0.00017749508,"about_ca_system_score_gemma":0.0008327357,"threshold_uncertainty_score":0.99972665},"labels":[],"label_agreement":null},{"id":"W2767995711","doi":"10.1093/annonc/mdx436.015","title":"Clinical trials and risk-based approach: reality or Utopia?","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quarter (Canadian coin); Clinical trial; Data collection; Medical emergency; Statistics; Pathology","score_opus":0.9618667575287084,"score_gpt":0.7822164604037476,"score_spread":0.17965029712496083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767995711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75681716,0.0003581602,0.0011670422,0.10874786,0.0005999889,0.0013275268,0.00009619279,0.0000485702,0.1308375],"genre_scores_gemma":[0.97197294,0.012053023,0.008016076,0.0035018572,0.0007342337,0.000029445458,0.000010884574,0.000019196435,0.0036623396],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9945877,0.0026505499,0.0015318677,0.0004513507,0.00046835287,0.00031018525],"domain_scores_gemma":[0.930925,0.06474621,0.0014968608,0.0015267538,0.00085551,0.000449651],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.079468854,0.00011337969,0.0015084073,0.00006508658,0.00018631571,0.000021815371,0.00038733584,0.0009909776,0.00017138319],"category_scores_gemma":[0.41939008,0.000074421034,0.00029479188,0.000044110096,0.0020003659,0.000045584016,0.00024826935,0.001817201,0.000015513937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0118331015,0.0027389291,0.33264574,0.00062440295,0.0005065759,0.00014410137,0.00009531765,0.0000019436068,0.00007729836,0.016595248,0.013098427,0.6216389],"study_design_scores_gemma":[0.01322484,0.019995807,0.713173,0.00025430645,0.00039504035,0.000025096231,0.000092672824,0.0009134387,0.0009686904,0.047293846,0.20343554,0.00022772807],"about_ca_topic_score_codex":0.0004374839,"about_ca_topic_score_gemma":0.0003804986,"teacher_disagreement_score":0.6214112,"about_ca_system_score_codex":0.000014953727,"about_ca_system_score_gemma":0.0015543968,"threshold_uncertainty_score":0.9478805},"labels":[],"label_agreement":null},{"id":"W2768323313","doi":"10.1093/annonc/mdx666.003","title":"Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Adverse effect; Placebo; Clinical endpoint; Hepatocellular carcinoma; Oncology; Surgery; Randomized controlled trial; Clinical trial; Phases of clinical research; Cancer; Pathology; Immunotherapy","score_opus":0.20992758690112645,"score_gpt":0.4216010728658582,"score_spread":0.21167348596473173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768323313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864197,0.0019572654,0.0000561006,0.000741807,0.00050550717,0.005622358,0.0002468179,0.000030132807,0.0044203405],"genre_scores_gemma":[0.99733025,0.00016470213,0.00051554636,0.00010020784,0.00018875652,0.00073553197,0.00030442097,0.00006266145,0.00059790123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694854,0.0003271353,0.0011805085,0.00061453116,0.00035254186,0.0005767364],"domain_scores_gemma":[0.99519783,0.0008296119,0.0013032546,0.0010988583,0.0012836583,0.00028676674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072819943,0.00043775904,0.002715228,0.0002580659,0.00026242642,0.000017042792,0.0003848,0.0003216688,0.00027101234],"category_scores_gemma":[0.00090044603,0.00037552905,0.00081789977,0.000103733735,0.00046338773,0.0001807402,0.00014123687,0.0002293408,0.000013874826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79099,0.015337989,0.11332787,0.0010299389,0.002441037,0.0010490675,0.0076944516,0.0000024897006,0.007047388,0.00014226607,0.0006204853,0.060317032],"study_design_scores_gemma":[0.76819307,0.08793613,0.0015093021,0.00009815818,0.0023514256,0.00002379861,0.0041559925,0.000988726,0.12873664,0.00008702517,0.0055619604,0.00035775927],"about_ca_topic_score_codex":0.00034672834,"about_ca_topic_score_gemma":0.00024384631,"teacher_disagreement_score":0.12168925,"about_ca_system_score_codex":0.000089437584,"about_ca_system_score_gemma":0.00056933693,"threshold_uncertainty_score":0.99986964},"labels":[],"label_agreement":null},{"id":"W2768408204","doi":"10.1093/annonc/mdx663.002","title":"Effect of sentinel node mapping strategy in robotic surgical treatment of endometrial cancers","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Lymphadenectomy; Stage (stratigraphy); Sentinel lymph node; Hysterectomy; Endometrial cancer; Adjuvant therapy; Radiology; Logistic regression; Sentinel node; Biopsy; Surgery; Oncology; Lymph node; Internal medicine; Cancer; Breast cancer","score_opus":0.13346745897094847,"score_gpt":0.4371989065385324,"score_spread":0.3037314475675839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768408204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826216,0.0011979328,0.0000025079753,0.0006973433,0.00020917498,0.00041867205,0.000015001294,0.0000049623272,0.014832804],"genre_scores_gemma":[0.9981258,0.0014645259,0.000035459027,0.000024774303,0.00015678698,0.000029400224,0.0000114278355,0.000009178965,0.00014263397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986148,0.00017168188,0.0005551154,0.00020115913,0.00020162668,0.00025560346],"domain_scores_gemma":[0.9981405,0.00083544524,0.0004954246,0.00032154872,0.00010628087,0.00010078688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004105675,0.00015077055,0.0013168197,0.0003144793,0.000027868138,0.0000030237607,0.000118438744,0.0001447598,0.00014019434],"category_scores_gemma":[0.00039448362,0.00010600274,0.00027627216,0.00023909213,0.00020122097,0.000041406696,0.000034746095,0.000071139395,0.0000030376677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025500273,0.0030102076,0.51826173,0.00080387,0.0013223791,0.00081795064,0.00023434528,0.0005829085,0.008101765,0.00017719046,0.00013403836,0.44105333],"study_design_scores_gemma":[0.14703213,0.09077203,0.504393,0.0005898612,0.0007884412,0.000085310465,0.000113425005,0.00028965817,0.24995941,0.00018270672,0.005474193,0.0003198236],"about_ca_topic_score_codex":0.0036474094,"about_ca_topic_score_gemma":0.00009278861,"teacher_disagreement_score":0.4407335,"about_ca_system_score_codex":0.0001543964,"about_ca_system_score_gemma":0.00026554635,"threshold_uncertainty_score":0.55138165},"labels":[],"label_agreement":null},{"id":"W2768791003","doi":"10.1093/annonc/mdx665.036","title":"KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Placebo; Head and neck cancer; Oncology; Regimen; Phases of clinical research; Larynx; Response Evaluation Criteria in Solid Tumors; Urology; Cancer; Surgery; Clinical trial; Immunotherapy; Pathology","score_opus":0.06201928635590589,"score_gpt":0.39645764806864353,"score_spread":0.33443836171273766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768791003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895275,0.0014600427,0.0001294214,0.00383267,0.00037101452,0.001192993,0.000061769184,0.000013717322,0.003410862],"genre_scores_gemma":[0.99746686,0.0005246312,0.00051344244,0.0007338392,0.00024149001,0.00006995697,0.000041462077,0.000024787261,0.0003835038],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99864924,0.000061788895,0.000556414,0.00028303158,0.00016606107,0.00028347288],"domain_scores_gemma":[0.99821424,0.000258721,0.0006820848,0.00045923228,0.0002755905,0.000110102126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044508657,0.00017679276,0.0008196538,0.00010785158,0.000112882844,0.000012197428,0.00016531072,0.0002526594,0.000037275633],"category_scores_gemma":[0.00029750133,0.00016370484,0.00021005815,0.000054352884,0.00035205833,0.00011683337,0.000039186703,0.0001187642,0.0000013458675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75850356,0.0015463989,0.0004571938,0.0004069777,0.000091139984,0.000032456486,0.00044625648,0.000006790649,0.055624165,0.000039571376,0.0036420817,0.17920339],"study_design_scores_gemma":[0.7076209,0.06306266,0.017174086,0.00008316437,0.00019609577,0.000059444792,0.00009949908,0.0005521686,0.14937253,0.00015768636,0.061373807,0.00024793757],"about_ca_topic_score_codex":0.00030586234,"about_ca_topic_score_gemma":0.00009263789,"teacher_disagreement_score":0.17895545,"about_ca_system_score_codex":0.00007391545,"about_ca_system_score_gemma":0.00065627875,"threshold_uncertainty_score":0.667569},"labels":[],"label_agreement":null},{"id":"W2769245406","doi":"10.1093/annonc/mdx746","title":"Novel treatment options for refractory Germ Cell Tumours: back to the bench!","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Germ cell tumors; Internal medicine; Chemotherapy; Refractory (planetary science); Pazopanib; Targeted therapy; Testicular cancer; Cancer; Cancer research; Sunitinib; Biology","score_opus":0.15907670877149185,"score_gpt":0.4193209944744669,"score_spread":0.2602442857029751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769245406","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00454604,0.0036940724,0.00008619431,0.9793916,0.00060637697,0.0023198104,0.0015219011,0.000022021215,0.007812013],"genre_scores_gemma":[0.040327344,0.0016950016,0.0059190323,0.88590056,0.0077648005,0.0014847129,0.003317655,0.00017641066,0.053414512],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868333,0.000048607675,0.00031269828,0.00038467397,0.00017832834,0.0003923756],"domain_scores_gemma":[0.99778676,0.00037434234,0.0004855305,0.00091991486,0.00027933906,0.00015413493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108711254,0.0002972693,0.0007161003,0.00010408003,0.00013625824,0.000016346234,0.00023924751,0.00045115128,0.00015924907],"category_scores_gemma":[0.00015804922,0.00018351189,0.0005207238,0.00003628112,0.00010961241,0.00002908293,0.00005266759,0.00025793407,0.00020329929],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015816458,0.0015959131,0.00021485415,0.00014577532,0.00039946905,0.00030708572,0.00008601821,0.0000041386515,0.0000927099,0.000013288015,0.98205024,0.014932351],"study_design_scores_gemma":[0.0023288336,0.008416372,0.005953064,0.00010456157,0.0010810773,0.000070704074,0.000014342872,0.0000048934476,0.0001929191,0.00005189018,0.98163664,0.00014469058],"about_ca_topic_score_codex":0.0002523897,"about_ca_topic_score_gemma":0.000042111435,"teacher_disagreement_score":0.09349104,"about_ca_system_score_codex":0.00014687056,"about_ca_system_score_gemma":0.0007083287,"threshold_uncertainty_score":0.7483398},"labels":[],"label_agreement":null},{"id":"W2769367424","doi":"10.1093/annonc/mdx707","title":"The European Society for Medical Oncology (ESMO) Precision Medicine Glossary","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"European Society for Medical Oncology; Cancer Research UK; Wellcome Trust","keywords":"Glossary; Medicine; Context (archaeology); Precision medicine; CLARITY; MEDLINE; Oncology; Internal medicine; Medical education; Pathology","score_opus":0.059888754691879535,"score_gpt":0.4068108173641823,"score_spread":0.34692206267230274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769367424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4092723,0.01471645,0.006855607,0.2568573,0.005314053,0.0013752868,0.00019768687,0.000027874772,0.30538338],"genre_scores_gemma":[0.9580061,0.028698726,0.0012490636,0.00789955,0.0030168514,0.000046079418,0.000102830476,0.000039341554,0.0009415035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880475,0.000119997516,0.0003705759,0.00026904617,0.00015072235,0.00028490674],"domain_scores_gemma":[0.9980731,0.0004915403,0.00037806542,0.0006450817,0.00028092047,0.0001313081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002367456,0.00011990156,0.00026259097,0.000012464271,0.00044407934,0.000015021037,0.00078398833,0.0002686799,0.000022572118],"category_scores_gemma":[0.00290794,0.00008359188,0.00022563184,0.00001734445,0.00084441144,0.0000029493142,0.0004128626,0.00012008205,0.0000053415256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030381212,0.00011610225,0.00029595924,0.00001275339,0.00014148715,0.000008370509,0.000091028494,0.0000044143935,0.010824163,0.0010489448,0.43143195,0.55572104],"study_design_scores_gemma":[0.0014153048,0.003799499,0.0035192443,0.000017639912,0.000027098436,0.000019414852,0.00007705051,0.00007381619,0.0055848695,0.0015214472,0.98385036,0.00009427833],"about_ca_topic_score_codex":0.000081908474,"about_ca_topic_score_gemma":0.00039392398,"teacher_disagreement_score":0.55562675,"about_ca_system_score_codex":0.000016320204,"about_ca_system_score_gemma":0.00043240626,"threshold_uncertainty_score":0.3481286},"labels":[],"label_agreement":null},{"id":"W2769450157","doi":"10.1093/annonc/mdx673.003","title":"Can we use Chinese revised version of Edmonton Symptom Assessment System to assess symptom burden of Chinese caregivers of advanced cancer patients? PACSSIVE-6","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Caregiver burden; Cronbach's alpha; Palliative care; Family caregivers; Distress; Depression (economics); Anxiety; Physical therapy; Clinical psychology; Family medicine; Psychiatry; Psychometrics; Disease; Nursing; Internal medicine; Dementia","score_opus":0.0380596591693098,"score_gpt":0.39244667477788775,"score_spread":0.35438701560857794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769450157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925112,0.00043246176,0.000008676561,0.0021822585,0.0009233559,0.0008134099,0.0005186252,0.000015756385,0.0025942537],"genre_scores_gemma":[0.99846315,0.0009088628,0.00010273552,0.000088794644,0.00011944289,0.000049865404,0.000056242032,0.00002879199,0.00018210777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783844,0.0001647751,0.0007573441,0.0003636577,0.00057369575,0.00030208688],"domain_scores_gemma":[0.99524945,0.00025425496,0.0015204808,0.0009112452,0.0018393155,0.00022525867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030181336,0.000273037,0.0014604069,0.00023764337,0.00007440022,0.000008082806,0.00040841906,0.00020707923,0.000059856626],"category_scores_gemma":[0.000368881,0.00021893317,0.00029304705,0.00022847114,0.00020088025,0.00019159913,0.00020420265,0.00016298641,8.8544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002723389,0.0005635349,0.938482,0.0033927031,0.0005479995,0.000027889322,0.007585665,0.00038154365,0.022233697,0.00012449341,0.0010795433,0.02285754],"study_design_scores_gemma":[0.0059776185,0.00574737,0.97065,0.003110694,0.00028069003,0.0000035397743,0.0034797,0.00009780584,0.006376324,0.00001769816,0.003978196,0.00028032975],"about_ca_topic_score_codex":0.018452253,"about_ca_topic_score_gemma":0.0037746402,"teacher_disagreement_score":0.03216803,"about_ca_system_score_codex":0.00029896144,"about_ca_system_score_gemma":0.0006613628,"threshold_uncertainty_score":0.98808396},"labels":[],"label_agreement":null},{"id":"W2769596292","doi":"10.1093/annonc/mdx740","title":"Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiosurgery; Brain metastasis; Hazard ratio; Internal medicine; Salvage therapy; Oncology; Proportional hazards model; Radiation therapy; Multivariate analysis; Metastasis; Surgery; Cancer; Chemotherapy; Confidence interval","score_opus":0.1120970295276918,"score_gpt":0.42594431925040765,"score_spread":0.31384728972271586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769596292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91089565,0.0016965946,0.022094617,0.06255141,0.00012921805,0.0007433748,0.0018299924,0.000017760705,0.000041363528],"genre_scores_gemma":[0.97257745,0.00013163917,0.02323282,0.0033582815,0.000106667576,0.00010579667,0.00031114384,0.000028463915,0.00014771165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978899,0.0002959526,0.00069250615,0.0004782323,0.00025182817,0.0003916001],"domain_scores_gemma":[0.9970375,0.0011626518,0.000733424,0.00064310664,0.00022126107,0.0002020962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018189892,0.0002979863,0.0015993236,0.00035837907,0.00021893509,0.000030788404,0.0001624686,0.00016415499,0.00013082995],"category_scores_gemma":[0.0008002851,0.00022877009,0.0006527326,0.00013107582,0.0005023393,0.00013065872,0.00007060077,0.0001461614,8.7057623e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038456793,0.0028173532,0.7868491,0.00061956747,0.024425438,0.0005167475,0.0020919885,0.00024886456,0.018956771,0.0007697583,0.0120327,0.14682606],"study_design_scores_gemma":[0.009976881,0.0029127602,0.844732,0.00022392727,0.002991958,0.000078487275,0.00053957687,0.0044239084,0.0024815674,0.00006072404,0.13120306,0.0003751807],"about_ca_topic_score_codex":0.0005469484,"about_ca_topic_score_gemma":0.0013902038,"teacher_disagreement_score":0.14645088,"about_ca_system_score_codex":0.000067671346,"about_ca_system_score_gemma":0.00018494978,"threshold_uncertainty_score":0.9328973},"labels":[],"label_agreement":null},{"id":"W2769765347","doi":"10.1093/annonc/mdx729.007","title":"CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Gefitinib; Erlotinib; Lung cancer; non-small cell lung cancer (NSCLC); Cancer; Epidermal growth factor receptor","score_opus":0.04141203295170755,"score_gpt":0.42077395280170077,"score_spread":0.37936191984999323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769765347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878963,0.0007910493,0.000056632623,0.006343778,0.00020379,0.002680203,0.0014067781,0.000012428906,0.00060903816],"genre_scores_gemma":[0.9973908,0.0003705581,0.00049430394,0.0010426191,0.00008225468,0.00011554464,0.00039559588,0.000038954753,0.000069352325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809974,0.00024704638,0.0004983937,0.0005048352,0.00034698244,0.00030302446],"domain_scores_gemma":[0.9967496,0.0005232402,0.0006118117,0.0010541215,0.0009475255,0.00011371825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037052468,0.0002416977,0.0006884172,0.000117818185,0.00026341257,0.00002498747,0.00035169718,0.0001042162,0.000035677036],"category_scores_gemma":[0.00024998354,0.00017055449,0.000060702503,0.00016270851,0.0001372951,0.00020237363,0.00014979651,0.0001872581,0.0000033363965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111844555,0.0031489348,0.6205359,0.00010988107,0.0014529341,0.00038883163,0.090890676,0.0011415557,0.0018747842,0.000004770157,0.0014755245,0.16713166],"study_design_scores_gemma":[0.02309813,0.033123847,0.9208191,0.00085310393,0.00055010634,0.0000030449737,0.008063364,0.00009076811,0.0110968305,0.000016812517,0.002054401,0.0002305178],"about_ca_topic_score_codex":0.006290781,"about_ca_topic_score_gemma":0.010996811,"teacher_disagreement_score":0.30028316,"about_ca_system_score_codex":0.00029610164,"about_ca_system_score_gemma":0.0009769024,"threshold_uncertainty_score":0.95098203},"labels":[],"label_agreement":null},{"id":"W2769890142","doi":"10.1093/annonc/mdx730","title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Clinical significance; Triple-negative breast cancer; Multiplex; Phases of clinical research; Internal medicine; Cancer; Bioinformatics","score_opus":0.17916940091764766,"score_gpt":0.5192750189657375,"score_spread":0.3401056180480898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769890142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973273,0.00051749276,0.00015104364,0.00056307303,0.00028337113,0.0003402279,0.00026111552,0.0000020859156,0.00055426406],"genre_scores_gemma":[0.9970427,0.0018990949,0.0002750424,0.00017765372,0.0004146023,0.000028716282,0.000040844727,0.000009793839,0.000111522386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715066,0.0004494777,0.0016307712,0.00040729233,0.00013603905,0.0002257892],"domain_scores_gemma":[0.9967066,0.0003944227,0.0018052759,0.0006023811,0.00039554952,0.000095744545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017603616,0.00014628611,0.001250398,0.00014036629,0.000041725005,0.0000040519076,0.00048107925,0.00040408768,0.00008380445],"category_scores_gemma":[0.0012533095,0.00013368297,0.00062644476,0.0001871594,0.00070087693,0.000007915536,0.00015003496,0.00018511013,4.8938637e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28143483,0.013337679,0.37980348,0.000101343256,0.009284429,0.000060534738,0.00043425927,0.00094509573,0.07907225,0.00017871647,0.016085971,0.21926141],"study_design_scores_gemma":[0.34290338,0.032778244,0.4618112,0.00015789557,0.0025565038,0.000008484959,0.0004971629,0.0034872128,0.14054807,0.0002749269,0.01409246,0.00088447786],"about_ca_topic_score_codex":0.0015682937,"about_ca_topic_score_gemma":0.00063016487,"teacher_disagreement_score":0.21837692,"about_ca_system_score_codex":0.000006612687,"about_ca_system_score_gemma":0.0004577079,"threshold_uncertainty_score":0.5451433},"labels":[],"label_agreement":null},{"id":"W2770195530","doi":"10.1093/annonc/mdx543","title":"Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Radiation therapy; Cancer; Oncology; Clinical endpoint; Family medicine; Clinical trial; Medical physics; Internal medicine","score_opus":0.07921095680611104,"score_gpt":0.3942723907797337,"score_spread":0.31506143397362263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770195530","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15466978,0.0030376115,0.0000034929817,0.8378687,0.00056345516,0.0005338445,0.0017155012,0.0000021064702,0.0016055007],"genre_scores_gemma":[0.4381793,0.037320957,0.00011094281,0.52236503,0.0007108115,0.00039265398,0.00069468777,0.000045981455,0.00017963791],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788415,0.0004983101,0.0007017509,0.00037362982,0.00035200472,0.00019017326],"domain_scores_gemma":[0.99681586,0.00034758684,0.0014570758,0.000755026,0.00060071377,0.000023766786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006910748,0.00024504462,0.00063256384,0.00009511306,0.00003986222,0.000005099456,0.00096779055,0.00030390653,0.00005556235],"category_scores_gemma":[0.00012629587,0.00014426632,0.00019732022,0.00004791416,0.00059495226,0.000009562334,0.00020902467,0.00025660088,4.8728197e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018841504,0.0005515135,0.0011494799,0.000019403382,0.0011110533,0.000008723075,0.0012462137,0.00002048369,0.015442494,0.000024008445,0.93573534,0.04280713],"study_design_scores_gemma":[0.0012263743,0.0016718647,0.03292962,0.00013530566,0.000021286058,0.000032165353,0.00018469013,0.0000028873399,0.01705339,0.000026520476,0.9465871,0.00012880367],"about_ca_topic_score_codex":0.0033956403,"about_ca_topic_score_gemma":0.00033920215,"teacher_disagreement_score":0.3155037,"about_ca_system_score_codex":0.000083951534,"about_ca_system_score_gemma":0.00046516952,"threshold_uncertainty_score":0.588301},"labels":[],"label_agreement":null},{"id":"W2770612488","doi":"10.1093/annonc/mdx663.008","title":"Quality of life evaluation in patients with ovarian cancer on chemotherapy and its impact on patients’ perception of maintenance therapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health and Wellbeing Research","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Ovarian cancer; Quality of life (healthcare); Maintenance therapy; Chemotherapy; Oncology; Cancer; Internal medicine; Nursing","score_opus":0.26118060802919846,"score_gpt":0.595377101014894,"score_spread":0.3341964929856956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770612488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935804,0.000040164232,0.0000017884647,0.0033287616,0.000089720044,0.0012856484,0.000051007326,0.000002678924,0.001619809],"genre_scores_gemma":[0.99759066,0.00082206726,0.000013673149,0.0014118538,0.0000373489,0.000072756186,0.000014884052,0.000010735508,0.000026027068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974802,0.0010424851,0.00055425905,0.00018659458,0.00041697506,0.0003194784],"domain_scores_gemma":[0.9971679,0.00043189173,0.00087614905,0.00029466904,0.0011128307,0.00011655275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028037515,0.000099110955,0.00043829385,0.00012218882,0.0001555188,0.0000017144476,0.0001387131,0.00018643077,0.00029027346],"category_scores_gemma":[0.0009639065,0.000065969325,0.000034890225,0.000066103086,0.000098977645,0.00008057032,0.000021423695,0.00027316084,0.0000040786194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00791109,0.00064819405,0.83524925,0.00013311105,0.000021025555,5.1800594e-8,0.0018206465,0.000018114375,0.00008054083,0.000067922,0.00038151722,0.15366857],"study_design_scores_gemma":[0.008337383,0.0061841216,0.984573,0.000232859,0.0000016060027,4.747023e-9,0.00011158699,0.00012142659,0.00006080568,0.00013813004,0.00018486909,0.000054217016],"about_ca_topic_score_codex":0.003335824,"about_ca_topic_score_gemma":0.0004260276,"teacher_disagreement_score":0.15361434,"about_ca_system_score_codex":0.00013589527,"about_ca_system_score_gemma":0.00089265266,"threshold_uncertainty_score":0.504279},"labels":[],"label_agreement":null},{"id":"W2770677135","doi":"10.1093/annonc/mdx754","title":"OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Ottawa Hospital; Queen's University","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Debulking; Chemotherapy; Epithelial ovarian cancer; Ovarian cancer; Gynecologic cancer; Gynecologic oncology; Cancer; Oncology; Intraperitoneal chemotherapy; Surgery; Internal medicine","score_opus":0.07607567898418639,"score_gpt":0.4194733978391326,"score_spread":0.34339771885494624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770677135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863145,0.002316204,0.000013725977,0.008465969,0.0011268072,0.0014546447,0.000024983523,0.00001832343,0.00026487024],"genre_scores_gemma":[0.9889079,0.009099349,0.00035696267,0.0007016487,0.00027617897,0.00058971933,0.000006375066,0.000039535447,0.00002236533],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976007,0.00022689332,0.0009255134,0.00051403913,0.0002461964,0.0004866706],"domain_scores_gemma":[0.9975947,0.0008605295,0.0008038621,0.00044869728,0.00014381761,0.0001483586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011164312,0.000334784,0.0024301314,0.0002652581,0.00019268275,0.000024330066,0.00020412714,0.0002307129,0.00029716545],"category_scores_gemma":[0.00029816,0.0002714348,0.000416215,0.00012395895,0.00032810046,0.00013296293,0.00009754844,0.00025589307,4.5396723e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18430343,0.011350661,0.032493137,0.000083956795,0.003771078,0.0004987619,0.00798824,0.00003092939,0.002586669,0.00004157694,0.00014502894,0.75670654],"study_design_scores_gemma":[0.8377859,0.033979397,0.108040355,0.0006911178,0.0010458872,0.000027996382,0.0014854934,0.0005080758,0.013904299,0.00009176467,0.001929061,0.0005106608],"about_ca_topic_score_codex":0.007969723,"about_ca_topic_score_gemma":0.0026565,"teacher_disagreement_score":0.75619584,"about_ca_system_score_codex":0.00022322663,"about_ca_system_score_gemma":0.0005746596,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W2771658548","doi":"10.1093/annonc/mdx764","title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre","funders":"","keywords":"Everolimus; Medicine; Internal medicine; Hazard ratio; Rituximab; Placebo; Common Terminology Criteria for Adverse Events; Clinical endpoint; Oncology; Adverse effect; Randomized controlled trial; Surgery; Gastroenterology; Lymphoma; Confidence interval; Pathology","score_opus":0.0702101635286362,"score_gpt":0.37389617729927827,"score_spread":0.3036860137706421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771658548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98165035,0.0015519606,0.0000055460423,0.010608922,0.000662581,0.0016130693,0.0005882159,0.000018614903,0.0033007474],"genre_scores_gemma":[0.9913876,0.005943571,0.000105366846,0.0014289758,0.0004883559,0.00019064925,0.00017107419,0.000018928813,0.00026547062],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99723417,0.0006028746,0.0009834588,0.00042943415,0.00029831732,0.00045174852],"domain_scores_gemma":[0.99476343,0.0027737636,0.0010966216,0.0010632592,0.00014749756,0.00015539785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018088765,0.00025864545,0.0016989189,0.0000802093,0.00024285993,0.00002763045,0.0003449832,0.00025858168,0.0000618732],"category_scores_gemma":[0.0024451155,0.00015251772,0.00042253878,0.0000601085,0.0003193692,0.000084083535,0.00016045386,0.00014210255,0.00004683344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89953643,0.031711858,0.0018335093,0.000007652648,0.00042394662,0.000657695,0.0008577402,9.783604e-7,0.0000448759,0.00017953628,0.01197442,0.05277138],"study_design_scores_gemma":[0.94685435,0.004673218,0.025551649,0.00007265196,0.00055016985,0.000009735828,0.000085684216,0.00011814915,0.0018140106,0.0005665164,0.019571228,0.00013262146],"about_ca_topic_score_codex":0.009776102,"about_ca_topic_score_gemma":0.001115792,"teacher_disagreement_score":0.052638758,"about_ca_system_score_codex":0.00009851445,"about_ca_system_score_gemma":0.00042956902,"threshold_uncertainty_score":0.9968179},"labels":[],"label_agreement":null},{"id":"W2771706601","doi":"10.1093/annonc/mdx711.077","title":"Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Placebo; Oncology; Head and neck cancer; Regimen; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Chemoradiotherapy; Urology; Cancer; Surgery; Clinical trial; Immunotherapy; Pathology","score_opus":0.06854208842948625,"score_gpt":0.4002969800796791,"score_spread":0.3317548916501929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771706601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428696,0.002394703,0.00015937665,0.0067932718,0.00046178742,0.0014338166,0.00005032703,0.000028105786,0.0043916553],"genre_scores_gemma":[0.99582195,0.00065610604,0.000556867,0.0016585923,0.0003162419,0.00012256566,0.000055611832,0.000035560784,0.0007765159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99851245,0.000070158574,0.00052377704,0.0003587953,0.00016577303,0.0003690303],"domain_scores_gemma":[0.998225,0.00027279364,0.0005709195,0.0005253799,0.00025227698,0.00015364075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048731238,0.000215129,0.0008054497,0.00011256815,0.00019068719,0.000027307686,0.00018578726,0.00028814623,0.000046965404],"category_scores_gemma":[0.00030941612,0.00019960447,0.00021476469,0.00005888913,0.0003180021,0.00015579295,0.00004487203,0.00015061484,0.0000038113612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7036425,0.0019487806,0.0004765625,0.00036233003,0.00010084645,0.00007046194,0.0005362472,0.00000602069,0.033621356,0.000049759597,0.008560833,0.2506243],"study_design_scores_gemma":[0.6864308,0.062032897,0.015306617,0.000075989454,0.00019853853,0.00009907666,0.00010566921,0.0006696919,0.07078579,0.00019526434,0.16376981,0.00032983266],"about_ca_topic_score_codex":0.00033793523,"about_ca_topic_score_gemma":0.0001251309,"teacher_disagreement_score":0.25029448,"about_ca_system_score_codex":0.00010874995,"about_ca_system_score_gemma":0.0006711248,"threshold_uncertainty_score":0.8139634},"labels":[],"label_agreement":null},{"id":"W2772341954","doi":"10.1093/annonc/mdx711.078","title":"KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cetuximab; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Oncology; Clinical endpoint; Regimen; Phases of clinical research; Head and neck squamous-cell carcinoma; Clinical trial; Head and neck cancer; Cancer; Adverse effect; Immunotherapy; Colorectal cancer","score_opus":0.09981705411407019,"score_gpt":0.4088673511182487,"score_spread":0.3090502970041785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772341954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888622,0.00034076668,0.0000050707076,0.0008854982,0.00043264852,0.0011750798,0.00007003841,0.00000757656,0.008221094],"genre_scores_gemma":[0.99887866,0.00013586695,0.00035986846,0.0001732125,0.00010530772,0.000067533714,0.000016171394,0.000027873639,0.00023551976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99806297,0.00013665658,0.0006963279,0.00034449244,0.0003654523,0.00039408522],"domain_scores_gemma":[0.9976315,0.000321666,0.0008962561,0.0006769654,0.0003511218,0.00012249274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023930705,0.00023404369,0.0011976531,0.00019593647,0.000078607554,0.000006362925,0.00027076734,0.00010387258,0.00011136694],"category_scores_gemma":[0.0005473799,0.00016865245,0.00012242484,0.00010161905,0.00039040842,0.00007303783,0.00012601534,0.00022117133,0.0000086202335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7505192,0.016528646,0.068878606,0.00083822216,0.00026442553,0.0018771301,0.0018441258,0.0000072075836,0.00018435602,0.00003232287,0.0055506513,0.15347509],"study_design_scores_gemma":[0.56150067,0.2836941,0.129058,0.0002156031,0.0006127406,0.00018045852,0.0003426592,0.000054482633,0.010827469,0.000109313034,0.0129746,0.00042993884],"about_ca_topic_score_codex":0.00034151642,"about_ca_topic_score_gemma":0.00045954887,"teacher_disagreement_score":0.26716542,"about_ca_system_score_codex":0.00011641804,"about_ca_system_score_gemma":0.00058828783,"threshold_uncertainty_score":0.6877447},"labels":[],"label_agreement":null},{"id":"W2773085872","doi":"10.1093/annonc/mdx785","title":"Prostate cancers that ‘Wnt’ respond to abiraterone","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"UCLH Biomedical Research Centre; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute for Health and Care Research; University College London","keywords":"Wnt signaling pathway; Prostate cancer; Medicine; Cancer research; Androgen receptor; Cancer; Prostate; Oncology; Internal medicine; Biology; Signal transduction; Genetics","score_opus":0.2095874997858294,"score_gpt":0.4678823498535755,"score_spread":0.2582948500677461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773085872","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044141833,0.0016801727,9.386122e-7,0.91982174,0.00066945964,0.001349438,0.00024037572,0.000033039618,0.032062978],"genre_scores_gemma":[0.030768609,0.004293232,0.00017008877,0.7752129,0.00312263,0.00043902846,0.00067093037,0.0001285695,0.18519406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997593,0.00014885311,0.00035507014,0.00056066125,0.00051853334,0.0008238739],"domain_scores_gemma":[0.99797565,0.00014437163,0.00036295116,0.0008351994,0.00045447977,0.00022737154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044104795,0.00033408776,0.0011135184,0.00042399266,0.0001269617,0.000027461092,0.0003914305,0.0008456595,0.0003424146],"category_scores_gemma":[0.00012793789,0.0002540767,0.00020445134,0.000110030465,0.0004324301,0.000076365686,0.00013247538,0.0011696571,0.00020627471],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027133008,0.00006876198,0.0005272857,0.00041536478,0.00043012245,0.0049402122,0.00061659265,8.0228074e-7,0.0006648455,0.000003484729,0.9673593,0.022259945],"study_design_scores_gemma":[0.0019454848,0.006829246,0.0013850174,0.0003915513,0.000101514226,0.00007195624,0.00003891981,5.290454e-7,0.012754935,0.00011548395,0.9761531,0.00021227988],"about_ca_topic_score_codex":0.0007641008,"about_ca_topic_score_gemma":0.00009545966,"teacher_disagreement_score":0.15313108,"about_ca_system_score_codex":0.00038870753,"about_ca_system_score_gemma":0.0024943796,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W2774246425","doi":"10.1093/annonc/mdx798","title":"Funding sources of practice-changing trials","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine","score_opus":0.8694914738966034,"score_gpt":0.6938986717286593,"score_spread":0.17559280216794415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774246425","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060755475,0.0054811826,0.000016168276,0.9090073,0.0045384597,0.0008977797,0.0007004481,0.000061009792,0.073222116],"genre_scores_gemma":[0.0713256,0.005485596,0.0002198613,0.9035689,0.01191725,0.000104555504,0.00021728339,0.000095156065,0.007065783],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98872024,0.006741567,0.0020803616,0.0006106659,0.00042520429,0.001421967],"domain_scores_gemma":[0.9799449,0.013333362,0.0048172735,0.00065366336,0.000877914,0.0003728755],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.014712894,0.00053232815,0.0027549337,0.00062706764,0.0004781138,0.000023071463,0.0011656815,0.006851317,0.0025943045],"category_scores_gemma":[0.0096268095,0.00049965054,0.00070334726,0.0002140013,0.001048889,0.00027204843,0.00036311307,0.009413941,0.00010409605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009015507,0.000362432,0.0003130632,0.0010155299,0.0015440494,0.0014720653,0.0011346979,0.000022229415,0.0008367965,0.0006908426,0.9195651,0.072141655],"study_design_scores_gemma":[0.0013086839,0.0011318089,0.00002339594,0.00020529295,0.000961987,0.0001868279,0.00031541107,0.00003871963,0.019569498,0.0010003451,0.9748741,0.00038396387],"about_ca_topic_score_codex":0.00009063886,"about_ca_topic_score_gemma":0.000004841007,"teacher_disagreement_score":0.0717577,"about_ca_system_score_codex":0.00008205049,"about_ca_system_score_gemma":0.0009713551,"threshold_uncertainty_score":0.9997455},"labels":[],"label_agreement":null},{"id":"W2775269156","doi":"10.1093/annonc/mdx443","title":"Real-world evidence in the treatment of ovarian cancer","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.5808560222584642,"score_gpt":0.5780192370724677,"score_spread":0.0028367851859965043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775269156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006823302,0.9796151,1.196494e-7,0.005927247,0.0002591394,0.0014418839,0.00007684784,0.0000046111036,0.012606813],"genre_scores_gemma":[0.000669781,0.9969254,0.00006614757,0.00018801009,0.0003066865,0.00096216996,0.000025885927,0.000022611908,0.0008332812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809355,0.0002956451,0.00079903536,0.00034407526,0.00020352258,0.00026419025],"domain_scores_gemma":[0.9968854,0.0009051126,0.0010454415,0.0009698182,0.00012554394,0.0000686536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046565707,0.00029875126,0.002928417,0.00025361148,0.000036380192,0.000006819111,0.00029919817,0.00023801012,0.00020417865],"category_scores_gemma":[0.00007312096,0.0001610847,0.00063111103,0.00021633349,0.00017359652,0.00003774609,0.000025502162,0.00014620674,0.000012789476],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007335648,0.0016779377,0.001057549,0.0035168538,0.00068519975,0.00024223422,0.00030886414,2.3065337e-7,9.738025e-8,0.00044713175,0.003021315,0.9889692],"study_design_scores_gemma":[0.00085306755,0.004618047,0.0051916693,0.018190466,0.0018982651,0.000022075039,0.0000117632,2.4819653e-7,0.000008542254,0.000042125976,0.96906507,0.000098653036],"about_ca_topic_score_codex":0.009412463,"about_ca_topic_score_gemma":0.0052511888,"teacher_disagreement_score":0.98887056,"about_ca_system_score_codex":0.0003897016,"about_ca_system_score_gemma":0.0021013552,"threshold_uncertainty_score":0.9971839},"labels":[],"label_agreement":null},{"id":"W2776194348","doi":"10.1093/annonc/mdx820","title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; T790M; Oncology; Ceritinib; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Clinical trial; Lung cancer; Cancer; Epidermal growth factor receptor; Erlotinib; Crizotinib; Gefitinib","score_opus":0.12983846215596354,"score_gpt":0.5199645404744228,"score_spread":0.39012607831845925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776194348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827991,0.00013198593,0.000042100528,0.011973504,0.00015089533,0.0011517524,0.0016255341,0.000011977964,0.0021131444],"genre_scores_gemma":[0.9957092,0.000025099014,0.0014343653,0.0016383034,0.000078799734,0.000055148612,0.00076662516,0.000017408594,0.0002750438],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99847686,0.00026763554,0.0004661482,0.00037650336,0.00017661318,0.00023622006],"domain_scores_gemma":[0.99756306,0.00053854554,0.00045723002,0.0010113308,0.0002698036,0.00016000697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006900486,0.00014401201,0.00075016863,0.00012697361,0.00014449225,0.000011320795,0.00028343222,0.000072610856,0.00012259427],"category_scores_gemma":[0.0021539086,0.00010583727,0.000052183346,0.00007849943,0.00009452758,0.00021815105,0.00018024455,0.00009716569,0.000019903899],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26340935,0.011292102,0.057158098,0.000015738922,0.002045411,0.00026664056,0.004187874,0.000027184637,0.008670388,0.000046205703,0.008079071,0.644802],"study_design_scores_gemma":[0.118371,0.03809195,0.7965129,0.0004189682,0.0008957221,0.0000021224537,0.00022832662,0.000027551905,0.008930996,0.00014625282,0.03613888,0.0002353523],"about_ca_topic_score_codex":0.00066370686,"about_ca_topic_score_gemma":0.00034801554,"teacher_disagreement_score":0.7393548,"about_ca_system_score_codex":0.000070752634,"about_ca_system_score_gemma":0.0005191211,"threshold_uncertainty_score":0.43159187},"labels":[],"label_agreement":null},{"id":"W2781013411","doi":"10.1093/annonc/mdx822","title":"Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Tamoxifen; Breast cancer; Hazard ratio; Internal medicine; Colorectal cancer; Oncology; Aromatase inhibitor; Cumulative incidence; Proportional hazards model; Gynecology; Cancer; Aromatase; Confidence interval; Cohort","score_opus":0.008102417457498451,"score_gpt":0.2990324591611161,"score_spread":0.29093004170361764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781013411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955972,0.002302291,3.1495804e-7,0.001235633,0.000066256485,0.00018026496,0.00019070793,0.0000014900158,0.00042587306],"genre_scores_gemma":[0.9943344,0.0054035466,0.000015526992,0.0000941707,0.000052265805,0.000063566404,0.0000054660077,0.000008506378,0.00002252332],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993369,0.000114463066,0.00015329542,0.00015460044,0.00005888384,0.00018183542],"domain_scores_gemma":[0.99936324,0.00003245074,0.00029817224,0.00018725997,0.000069472255,0.000049396338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031241038,0.000094265546,0.00023982038,0.000025736039,0.00007150064,0.000005746831,0.00014399784,0.00015016989,0.0000094025945],"category_scores_gemma":[0.000041291994,0.000055424163,0.000024953526,0.000029406416,0.00065510045,0.0000048671945,0.000096479795,0.000111881986,3.300336e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024661524,0.00051729736,0.33481967,0.000080400474,0.0012325264,0.000050263665,0.0013229526,0.00026251574,0.5505786,0.00018039899,0.0019047294,0.08438915],"study_design_scores_gemma":[0.007845211,0.00612177,0.6692838,0.000084941865,0.00009747246,0.00009321459,0.0003040408,0.000055175216,0.3136948,0.00017414153,0.0020171043,0.00022831318],"about_ca_topic_score_codex":0.0015328715,"about_ca_topic_score_gemma":0.00058302423,"teacher_disagreement_score":0.33446413,"about_ca_system_score_codex":0.000009952329,"about_ca_system_score_gemma":0.00016314577,"threshold_uncertainty_score":0.2413745},"labels":[],"label_agreement":null},{"id":"W2782355925","doi":"10.1093/annonc/mdx361.028","title":"Treatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council","keywords":"Enzalutamide; LNCaP; Prostate cancer; Cancer research; Medicine; Hypoxia (environmental); Angiogenesis; In vivo; Androgen receptor; Cancer; Internal medicine; Biology; Chemistry","score_opus":0.2287695680566501,"score_gpt":0.4957445275805871,"score_spread":0.266974959523937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782355925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97799426,0.0043169186,3.5707325e-7,0.0153571945,0.000059149672,0.0008506489,0.00006124993,0.000009161677,0.0013510842],"genre_scores_gemma":[0.98566514,0.010405391,0.0002629229,0.000082289385,0.000041293584,0.00013656396,0.0000064709193,0.000016682323,0.0033832677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998381,0.00026699196,0.00052095193,0.000333294,0.0001658941,0.0003318613],"domain_scores_gemma":[0.9982811,0.00048709102,0.00037657,0.00046254921,0.0002560574,0.00013660388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008309536,0.00015258742,0.0007335798,0.00013209943,0.0000742155,0.000009767651,0.00013383363,0.00017345326,0.000015171679],"category_scores_gemma":[0.00051959325,0.00010999562,0.00008924656,0.00006951341,0.00051413145,0.00014325342,0.00007801679,0.00015146146,0.0000014507343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11331911,0.0030383898,0.63134754,0.00048017612,0.00077880634,0.0006484858,0.0070145447,0.0000070547408,0.066273764,0.00026875542,0.0008852008,0.17593819],"study_design_scores_gemma":[0.010980452,0.011412725,0.8900229,0.0004293519,0.00009115478,0.0000104584005,0.000114207614,0.00017914925,0.08121136,0.0030056627,0.0024004076,0.0001421872],"about_ca_topic_score_codex":0.0009276866,"about_ca_topic_score_gemma":0.0014182978,"teacher_disagreement_score":0.25867537,"about_ca_system_score_codex":0.000083812534,"about_ca_system_score_gemma":0.0008674422,"threshold_uncertainty_score":0.44854912},"labels":[],"label_agreement":null},{"id":"W2783025226","doi":"10.1093/annonc/mdx370.045","title":"Durable prostate cancer control in a randomized trial of optimal timing of dose escalated (76 Gy) radiation and 6 months ADT in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Urology; Goserelin; Radiation therapy; Context (archaeology); Proctitis; Internal medicine; Randomized controlled trial; Cancer; Oncology; Disease","score_opus":0.06274418392944638,"score_gpt":0.4282275056798431,"score_spread":0.3654833217503967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783025226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846533,0.0047724186,0.000001030339,0.006247899,0.00012241524,0.0034971524,0.000081378035,0.0000051178527,0.00061928155],"genre_scores_gemma":[0.97970545,0.01903675,0.000051093506,0.00007315917,0.0000416144,0.0006739305,0.000014516603,0.0000143539555,0.00038912758],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99820507,0.00025516408,0.0007588783,0.00023766312,0.00020431017,0.00033894432],"domain_scores_gemma":[0.9983799,0.00031896128,0.0007056945,0.0002138888,0.00029496846,0.000086617125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013572364,0.00014483056,0.0014204395,0.00028633184,0.000041631847,0.000008185507,0.00009516234,0.0001375686,0.000056847228],"category_scores_gemma":[0.0005172498,0.00010871714,0.00010706651,0.0001315063,0.00046159138,0.0001560911,0.00004162209,0.0001888749,3.6224773e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8774269,0.0006422096,0.037975892,0.0002901642,0.0003365097,0.000071788716,0.0025260723,0.0002622276,0.008584051,0.00001448538,0.00021008578,0.07165961],"study_design_scores_gemma":[0.9340782,0.0028213249,0.040495086,0.0005189474,0.00013763382,0.0000025493223,0.00013236912,0.0061650444,0.01517625,0.000110554894,0.00025542622,0.00010657406],"about_ca_topic_score_codex":0.008547603,"about_ca_topic_score_gemma":0.00093531446,"teacher_disagreement_score":0.07155303,"about_ca_system_score_codex":0.000102104445,"about_ca_system_score_gemma":0.00087745395,"threshold_uncertainty_score":0.99805456},"labels":[],"label_agreement":null},{"id":"W2783341375","doi":"10.1093/annonc/mdx797","title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Letrozole; Fulvestrant; Internal medicine; Hazard ratio; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Placebo; Gynecology; Gastroenterology; Confidence interval; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04509901211439402,"score_gpt":0.41487364688864137,"score_spread":0.3697746347742473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783341375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961059,0.0005201312,0.000010741634,0.0020171923,0.00004422741,0.00045741434,0.00010496189,0.0000024416368,0.0007369582],"genre_scores_gemma":[0.99760926,0.00018288408,0.0014878295,0.0006441201,0.000025915031,0.000027600609,0.0000025467816,0.000007816274,0.000012059503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989488,0.00015095704,0.0004656621,0.0001334499,0.00018088814,0.00012020573],"domain_scores_gemma":[0.9987439,0.00015369692,0.0004379182,0.0002442329,0.00039454713,0.000025724581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002811744,0.00008547995,0.00043774044,0.00004241518,0.000023982111,9.1334135e-7,0.00008674542,0.000041258132,0.000053028394],"category_scores_gemma":[0.000027396947,0.000045520082,0.00005416133,0.00013843286,0.0009645617,0.00005048328,0.000049529128,0.00008606859,1.5239742e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029814614,0.0010695856,0.85853416,0.00011866621,0.00053100043,0.0000013029043,0.0012482626,0.000032588883,0.00074336416,0.0020690297,0.000059696256,0.13261087],"study_design_scores_gemma":[0.004143289,0.0022583788,0.98442596,0.00026531162,0.0001620981,0.000010527746,0.0011604421,0.000008719469,0.004352129,0.0015742062,0.0015904316,0.000048496557],"about_ca_topic_score_codex":0.00008948827,"about_ca_topic_score_gemma":0.00031075868,"teacher_disagreement_score":0.13256237,"about_ca_system_score_codex":0.000009790336,"about_ca_system_score_gemma":0.00011240554,"threshold_uncertainty_score":0.35539678},"labels":[],"label_agreement":null},{"id":"W2788160989","doi":"10.1093/annonc/mdy072","title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; Cancer Research UK; Sanofi; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Pfizer; Royal Marsden NHS Foundation Trust; Astellas Pharma; Ipsen; Clovis Oncology; Institute of Cancer Research; Medical Research Council; National Institute on Handicapped Research; Public Health Agency; Eli Lilly and Company","keywords":"Medicine; Docetaxel; Prostate cancer; Abiraterone acetate; Androgen deprivation therapy; Oncology; Abiraterone; Prednisolone; Internal medicine; Protocol (science); Randomized controlled trial; Cancer; Androgen receptor; Pathology","score_opus":0.39583597424977157,"score_gpt":0.5256163290702124,"score_spread":0.1297803548204408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788160989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7982756,0.0017719218,0.000748313,0.008470363,0.0002505183,0.18611033,0.0040416787,0.00010022396,0.00023105447],"genre_scores_gemma":[0.52048945,0.009612642,0.01458457,0.008333503,0.0023597009,0.4227449,0.0024713927,0.00029314242,0.019110704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997567,0.00012508211,0.0006136826,0.0006533757,0.0003092536,0.0007315969],"domain_scores_gemma":[0.9972627,0.0006396992,0.00032235577,0.00091885147,0.0005887807,0.00026760218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009881554,0.00031596894,0.00082490407,0.00011185615,0.00026677758,0.000042913824,0.0006249565,0.00017096922,0.00048561467],"category_scores_gemma":[0.00030570955,0.00016706839,0.00012035793,0.00024700898,0.00038499065,0.00022368318,0.00026994094,0.00022293338,0.00002632311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45958364,0.003919965,0.019922856,0.00029763978,0.001986941,0.00014170357,0.0051928316,0.000004152374,0.10259876,0.000005878895,0.038199738,0.36814588],"study_design_scores_gemma":[0.33617458,0.034314897,0.07616043,0.0005702282,0.00022535937,0.000012373996,0.0005431611,0.0015487294,0.22237988,0.000024781008,0.32742885,0.000616717],"about_ca_topic_score_codex":0.0010615072,"about_ca_topic_score_gemma":0.0026264812,"teacher_disagreement_score":0.36752918,"about_ca_system_score_codex":0.00012434622,"about_ca_system_score_gemma":0.0009761278,"threshold_uncertainty_score":0.6812851},"labels":[],"label_agreement":null},{"id":"W2789444788","doi":"10.1093/annonc/mdy047.014","title":"Epigenetic regulation of tumor metabolism","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Toronto General Hospital; University of Toronto","funders":"","keywords":"Epigenetics; Biology; Reprogramming; Warburg effect; Cancer cell; Population; Cancer research; Chromatin; Cancer stem cell; Cell biology; Carcinogenesis; Transcription factor; Cancer; Stem cell; Genetics; Cell; Gene; Medicine","score_opus":0.04556624255740941,"score_gpt":0.35765683931229986,"score_spread":0.3120905967548904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789444788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98568064,0.0020587547,0.002097808,0.0002454179,0.00019757221,0.000101305566,0.0000104646315,0.0000032657294,0.009604787],"genre_scores_gemma":[0.99688923,0.00040053783,0.0020116817,0.00016828883,0.0002995902,0.000004771355,0.00002791003,0.000010808082,0.00018716023],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918234,0.000095805706,0.00031228707,0.0001736308,0.00009286915,0.00014305607],"domain_scores_gemma":[0.9989955,0.000020113785,0.00025293548,0.00026024616,0.00042758865,0.000043661224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003354146,0.00007980205,0.00019577029,0.00006138719,0.000026090906,0.0000018814197,0.00011806581,0.00012196535,0.000062634535],"category_scores_gemma":[0.00014483301,0.00007778778,0.00007868785,0.00009241793,0.00021062692,0.000002097689,0.00005564046,0.000029860726,0.000007184192],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009695566,0.0000804828,0.00087201654,0.000010415727,0.000034844335,2.5485278e-7,0.00005628686,0.000030918185,0.9702298,0.0005892047,0.00054562057,0.027453192],"study_design_scores_gemma":[0.0002455628,0.0014527049,0.03770734,0.0000041743365,0.000013229468,0.0000011147557,0.000012800705,0.000033288678,0.84402686,0.0019188848,0.11452009,0.00006395073],"about_ca_topic_score_codex":0.000023130684,"about_ca_topic_score_gemma":0.00003142797,"teacher_disagreement_score":0.12620294,"about_ca_system_score_codex":0.0000024086294,"about_ca_system_score_gemma":0.00009325153,"threshold_uncertainty_score":0.31720936},"labels":[],"label_agreement":null},{"id":"W2789493667","doi":"10.1093/annonc/mdy046.021","title":"A novel drug conjugate platform: Redefining the therapeutic window for ADCs","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cytotoxicity; Medicine; Tolerability; Pharmacology; Pharmacokinetics; In vivo; Monoclonal antibody; Therapeutic index; Antibody-drug conjugate; Conjugate; Trastuzumab; Drug; In vitro; Antibody; Cancer research; Cancer; Immunology; Internal medicine; Chemistry; Adverse effect; Biochemistry; Biology","score_opus":0.19687484142115136,"score_gpt":0.426774330430288,"score_spread":0.22989948900913665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789493667","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07095613,0.00022858515,0.8953684,0.023140794,0.0009082612,0.00039980756,0.000015165588,0.000059403803,0.008923428],"genre_scores_gemma":[0.88139933,0.000018617082,0.10907336,0.009017769,0.00024907064,0.000046199384,0.0000030465294,0.000011938676,0.00018066056],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987982,0.00012309042,0.00032042523,0.00027208604,0.00018443582,0.0003017584],"domain_scores_gemma":[0.9967547,0.0021922814,0.00024603377,0.00038864737,0.00037084086,0.00004747275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016744089,0.0001157849,0.00024280923,0.000078484925,0.00017150649,0.00004170631,0.0009101832,0.00006182206,0.000009332653],"category_scores_gemma":[0.00021429626,0.00008399259,0.00011566656,0.00025933777,0.0002726071,0.0002611208,0.00024109043,0.00010477925,0.000017044258],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014411392,0.00017254846,0.00004972416,0.000014811548,0.0001126598,0.0000017015553,0.0034393005,0.0012968065,0.0032248013,0.5648318,0.0043238765,0.42238787],"study_design_scores_gemma":[0.002223257,0.0034445317,0.006821631,0.000050366092,0.000033963184,0.000101334175,0.0002686446,0.23291048,0.027331594,0.35710892,0.3692921,0.00041317544],"about_ca_topic_score_codex":0.000032100652,"about_ca_topic_score_gemma":0.000030242658,"teacher_disagreement_score":0.8104432,"about_ca_system_score_codex":0.00001851885,"about_ca_system_score_gemma":0.00035122337,"threshold_uncertainty_score":0.34251186},"labels":[],"label_agreement":null},{"id":"W2789571329","doi":"10.1093/annonc/mdy047.056","title":"Multiphysics modelling of alpha-immuno-conjugate delivery and background dose","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"Multiphysics; Monte Carlo method; Computational fluid dynamics; Physics; Radiation therapy; Alpha (finance); Alpha particle; Medicine; Mechanics; Nuclear physics; Statistics; Surgery; Mathematics; Finite element method","score_opus":0.09386297294476428,"score_gpt":0.37303624936136526,"score_spread":0.27917327641660095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789571329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.835747,0.0003484657,0.15956242,0.00009283171,0.000056277946,0.00012470358,0.000020359565,0.000017990349,0.004029955],"genre_scores_gemma":[0.9640307,0.0002652547,0.0353317,0.00012890398,0.00015862953,0.000007571271,0.000005437657,0.000015985299,0.00005582214],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99929273,0.00004287009,0.00026516907,0.00015893858,0.00006226671,0.00017800966],"domain_scores_gemma":[0.9992053,0.00010499503,0.00023396104,0.00019531582,0.00022450145,0.000035907568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013550722,0.000111121844,0.00031185537,0.000048191258,0.000044676002,0.000004199811,0.00012018451,0.00005622646,0.00007292703],"category_scores_gemma":[0.00000148896,0.00010800816,0.00006646512,0.00007093018,0.00034896098,0.00015124695,0.00004947994,0.00008614545,0.0000019473805],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006927302,0.0010004895,0.0069219037,0.00006641074,0.00068406726,0.0000035319408,0.0024543672,0.0012765443,0.16352102,0.045176055,0.001342661,0.77686024],"study_design_scores_gemma":[0.0031605605,0.0062722047,0.0011772427,0.00013971426,0.000082800914,0.000005096469,0.0007378328,0.038708936,0.7849419,0.08059414,0.083475865,0.00070368074],"about_ca_topic_score_codex":0.00026001842,"about_ca_topic_score_gemma":0.0000024499554,"teacher_disagreement_score":0.77615654,"about_ca_system_score_codex":0.0000074365694,"about_ca_system_score_gemma":0.0000483773,"threshold_uncertainty_score":0.4404445},"labels":[],"label_agreement":null},{"id":"W2790006193","doi":"10.1093/annonc/mdy023","title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Population; Ovarian cancer; Confidence interval; Cancer; Pharmacology","score_opus":0.0897298999838671,"score_gpt":0.46234936169323504,"score_spread":0.37261946170936794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790006193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876961,0.00029138717,0.000007887288,0.0026414387,0.00015485246,0.0067092264,0.0001248883,0.000035384834,0.0023388271],"genre_scores_gemma":[0.99802184,0.00009520501,0.000389399,0.0006280631,0.000117264826,0.00036108404,0.00008536106,0.00008002084,0.0002217509],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99446493,0.0012834856,0.0014154409,0.00087987445,0.00093910826,0.001017156],"domain_scores_gemma":[0.99658513,0.00049043796,0.0006530323,0.0006938198,0.0012527779,0.00032481886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002738113,0.00046815144,0.0030072134,0.00069039856,0.00016252579,0.000044566474,0.00062389125,0.00018604872,0.00063578767],"category_scores_gemma":[0.0003700684,0.00034009854,0.00005594026,0.0013436617,0.0010112431,0.00023986572,0.00039633908,0.0007394483,0.00001851929],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.697211,0.02818426,0.2492703,0.00017209999,0.0010326394,0.0009852989,0.007606222,0.000067624605,0.005801899,0.000038400703,0.0013017906,0.008328408],"study_design_scores_gemma":[0.7701317,0.08103573,0.14022335,0.0015304367,0.0002126421,0.000016696038,0.0008980176,0.0012347249,0.0029280288,0.0000205975,0.0012928644,0.00047517745],"about_ca_topic_score_codex":0.012693472,"about_ca_topic_score_gemma":0.02263868,"teacher_disagreement_score":0.10904696,"about_ca_system_score_codex":0.0003307452,"about_ca_system_score_gemma":0.0023768793,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W2790030462","doi":"10.1093/annonc/mdy046.015","title":"AKT inhibitors and other new kids on the block","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; AKT1; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer; Cancer research; AKT2; PTEN; Oncology; Internal medicine; Signal transduction; Biology; Genetics","score_opus":0.0645016500563089,"score_gpt":0.3649257291624963,"score_spread":0.3004240791061874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790030462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720811,0.00069939444,0.000028738592,0.006385088,0.0003441364,0.00010927224,0.00001038924,0.0000070502015,0.020334806],"genre_scores_gemma":[0.98698694,0.000076978555,0.00011448751,0.010450616,0.0012094703,0.0000067508126,0.00000217976,0.000016635862,0.0011359348],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99927735,0.000075328695,0.00015912023,0.00021743379,0.00008071887,0.00019005462],"domain_scores_gemma":[0.9994167,0.000051268165,0.000101067286,0.00027192116,0.000091576294,0.0000674594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025383764,0.00010406054,0.00013671865,0.000026443122,0.000050026796,0.0000062627787,0.00016680504,0.00018583136,0.00010815128],"category_scores_gemma":[0.00012568106,0.00007498989,0.000053428867,0.000055733843,0.00032370127,0.0000013911448,0.0000807486,0.00007663434,0.000023489754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030625306,0.00009949398,0.0019170999,0.0000078760995,0.00012689669,0.0000023668608,0.00023117822,0.000007692812,0.5225608,0.0009567969,0.44770133,0.026082253],"study_design_scores_gemma":[0.00019612965,0.0023725666,0.00018957788,0.000009236258,0.0000057861603,0.0000061925534,0.000020273174,0.000002510489,0.4555005,0.00030336945,0.5413318,0.000062014435],"about_ca_topic_score_codex":0.000067694295,"about_ca_topic_score_gemma":0.000064133805,"teacher_disagreement_score":0.09363047,"about_ca_system_score_codex":0.0000059733234,"about_ca_system_score_gemma":0.00015073952,"threshold_uncertainty_score":0.3057999},"labels":[],"label_agreement":null},{"id":"W2790483577","doi":"10.1093/annonc/mdy068","title":"Should de-escalation of bone-targeting agents be standard of care?","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University","funders":"","keywords":"Medicine; Denosumab; Scopus; Breast cancer; Oncology; Bisphosphonate; Internal medicine; MEDLINE; Cancer; Osteoporosis","score_opus":0.15132229391885496,"score_gpt":0.44919950853312035,"score_spread":0.2978772146142654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790483577","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3526977,0.0027958201,0.000031191736,0.62620234,0.0006918861,0.0010352043,0.0005932818,0.000028119104,0.01592443],"genre_scores_gemma":[0.60504466,0.0010586705,0.0026599797,0.3878952,0.0010822589,0.000032495962,0.001290525,0.00007123637,0.0008649709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980071,0.00015510047,0.0008285405,0.00023581655,0.00039220834,0.00038121085],"domain_scores_gemma":[0.9976871,0.00018039657,0.000928873,0.00028666205,0.00081767666,0.00009926365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039202493,0.00018883326,0.0012365968,0.00022657649,0.000028638839,0.0000011284706,0.00007652003,0.0010203086,0.00020587],"category_scores_gemma":[0.00024454345,0.00016742278,0.00022198464,0.000109512155,0.00019424118,0.000027630183,0.000040711784,0.00049150747,0.0000053003946],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010547214,0.00016637852,0.014700996,0.002191579,0.00027980676,0.00019046557,0.0008429745,6.6121896e-7,0.00012408981,0.000007338422,0.9684271,0.012013858],"study_design_scores_gemma":[0.0020180882,0.0104634315,0.008904851,0.00042913362,0.00033655856,0.000025484245,0.000077830526,0.000005211671,0.006476993,0.00011574538,0.9710382,0.00010846741],"about_ca_topic_score_codex":0.0003797167,"about_ca_topic_score_gemma":0.000047492238,"teacher_disagreement_score":0.25234696,"about_ca_system_score_codex":0.0001199243,"about_ca_system_score_gemma":0.0008647719,"threshold_uncertainty_score":0.7869554},"labels":[],"label_agreement":null},{"id":"W2791557665","doi":"10.1093/annonc/mdy085","title":"CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Norges Forskningsråd; Kreftforeningen; Stiftelsen Kristian Gerhard Jebsen","keywords":"KRAS; Medicine; Colorectal cancer; Microsatellite instability; Oncology; Hazard ratio; Gene mutation; Cancer research; Internal medicine; Mutation; Biomarker; Cancer; Gene; Biology; Genetics; Allele; Microsatellite; Confidence interval","score_opus":0.0582355178895747,"score_gpt":0.4222692228116025,"score_spread":0.3640337049220278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791557665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863259,0.0017996064,0.0000012703017,0.0011228386,0.00007505606,0.0003930814,0.00004475115,0.000007578298,0.010229891],"genre_scores_gemma":[0.9986994,0.0008124822,0.0000770478,0.00017634971,0.00006042967,0.00007159666,0.000008913706,0.0000075946323,0.00008616604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992764,0.000037310623,0.00025399151,0.00015181256,0.00010270323,0.00017777747],"domain_scores_gemma":[0.99934137,0.00016760967,0.00012389846,0.00006694741,0.00024140204,0.000058791717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011581594,0.00010267166,0.00046516213,0.00011992877,0.000028741832,0.0000017577198,0.000033133983,0.000069653564,0.00012335058],"category_scores_gemma":[0.000109414155,0.000071545604,0.00007118992,0.00015421481,0.00033156265,0.000037127866,0.000045481924,0.00006892752,0.000001982661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016710806,0.00083117216,0.9076245,0.000079748446,0.0004763518,0.000046921057,0.0023829616,0.0000051595157,0.00631221,0.00003727016,0.00092262094,0.07961003],"study_design_scores_gemma":[0.0016650511,0.012751937,0.98104835,0.00006540269,0.000093073766,0.00003032264,0.0001344032,0.000019846162,0.0036834206,0.00014416636,0.0003079444,0.00005608645],"about_ca_topic_score_codex":0.0016324234,"about_ca_topic_score_gemma":0.0024657373,"teacher_disagreement_score":0.07955395,"about_ca_system_score_codex":0.0001274018,"about_ca_system_score_gemma":0.00049265474,"threshold_uncertainty_score":0.2917545},"labels":[],"label_agreement":null},{"id":"W2791840917","doi":"10.1093/annonc/mdy012","title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Letrozole; Medicine; Palbociclib; Quality of life (healthcare); Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Placebo; Gynecology; Cancer; Tamoxifen","score_opus":0.20865205586815688,"score_gpt":0.47838773484195324,"score_spread":0.26973567897379636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791840917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98895216,0.0007303304,0.000017215383,0.007543191,0.0003710347,0.00071976206,0.00037336678,0.00002406064,0.0012688758],"genre_scores_gemma":[0.99783486,0.00008854597,0.00017357415,0.0014735014,0.00027327528,0.000012331269,0.00008898679,0.000019860687,0.0000350877],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99650645,0.00057509076,0.0019380964,0.00029052875,0.00037641358,0.00031342244],"domain_scores_gemma":[0.9945548,0.0012502773,0.0026855615,0.00072024914,0.0006350526,0.00015401498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011197617,0.00017602537,0.0012184251,0.00008383189,0.00004937645,0.0000015220354,0.00016251377,0.0001986275,0.00016181973],"category_scores_gemma":[0.0023051593,0.000114097755,0.00031558413,0.00028437574,0.0006398166,0.00004664585,0.00004947964,0.00023956738,0.0000069414855],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7630915,0.0022885134,0.010296394,0.00005512231,0.0023482782,0.000014641993,0.009777103,0.000089233785,0.010344913,0.00017175624,0.00960608,0.19191645],"study_design_scores_gemma":[0.1866594,0.09808912,0.69042104,0.00034472888,0.00011831466,0.000015685035,0.0010478346,0.000040663697,0.012251964,0.0019897446,0.008766989,0.00025452],"about_ca_topic_score_codex":0.0093646515,"about_ca_topic_score_gemma":0.00026880298,"teacher_disagreement_score":0.68012464,"about_ca_system_score_codex":0.00012188323,"about_ca_system_score_gemma":0.0013824047,"threshold_uncertainty_score":0.9972321},"labels":[],"label_agreement":null},{"id":"W2793060055","doi":"10.1093/annonc/mdy046.005","title":"MDICT consensus report: Recommendations regarding response criteria, endpoints and study designs for the development of immunotherapy combinations","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer","funders":"","keywords":"Task force; Medicine; Cancer; Mandate; Targeted therapy; Internal medicine; Political science","score_opus":0.33939859833657604,"score_gpt":0.5344369770478551,"score_spread":0.19503837871127905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793060055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701019,0.00023871966,0.0015087214,0.02538085,0.0002657222,0.001162431,0.0000079559695,0.000010734292,0.0013229625],"genre_scores_gemma":[0.9925785,0.00012248421,0.0058365148,0.000570024,0.00005648477,0.00008722982,0.0000063263055,0.000008259182,0.0007341707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985951,0.00025993123,0.00054914167,0.00018187545,0.00021151334,0.0002023966],"domain_scores_gemma":[0.99622613,0.0022296149,0.00023844853,0.00028890025,0.00093579513,0.000081123544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061609717,0.00007684015,0.00031552435,0.00021243069,0.0002529213,0.000004921612,0.000107541695,0.000050881186,0.000087864166],"category_scores_gemma":[0.0028066623,0.000051748306,0.000041079667,0.00022104132,0.00062521454,0.000027038004,0.0000432552,0.000081831946,0.0000012768028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017740417,0.004631961,0.013040457,0.000104498606,0.0010436269,0.0001121988,0.06956398,3.6347555e-7,0.23297921,0.0005665354,0.05627873,0.60393804],"study_design_scores_gemma":[0.019405292,0.040961903,0.36921912,0.000381342,0.00020976816,0.00073473447,0.04611965,0.00028976332,0.12706356,0.0010626278,0.3942924,0.00025983158],"about_ca_topic_score_codex":0.000030479687,"about_ca_topic_score_gemma":0.00007801683,"teacher_disagreement_score":0.60367817,"about_ca_system_score_codex":0.000030100293,"about_ca_system_score_gemma":0.0007775408,"threshold_uncertainty_score":0.336004},"labels":[],"label_agreement":null},{"id":"W2793281906","doi":"10.1093/annonc/mdy058","title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":756,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Classifier (UML); Carcinoma; Series (stratigraphy); Population; Oncology; Gynecology; Internal medicine; Artificial intelligence; Environmental health","score_opus":0.12548214201262034,"score_gpt":0.4036135900757979,"score_spread":0.2781314480631776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793281906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608,0.0000817302,0.000074090174,0.0022107344,0.00019581041,0.00076784816,0.00006945343,0.000004253681,0.00051611103],"genre_scores_gemma":[0.9988868,0.0000030015194,0.0004030684,0.00040354318,0.0001307464,0.0000782614,0.000034436725,0.0000074808136,0.000052617674],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914193,0.00010698221,0.0003311006,0.00013174824,0.00013063509,0.00015759894],"domain_scores_gemma":[0.99910116,0.0002463677,0.00018616999,0.00015950721,0.00026512606,0.000041660536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032654675,0.00007539974,0.00032708765,0.00017597628,0.00003324709,0.0000018696918,0.000052577343,0.0001013776,0.000095650386],"category_scores_gemma":[0.000912384,0.000051443734,0.000137357,0.0004571788,0.0000713668,0.000033979835,0.00001932966,0.00005459282,9.706293e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035072323,0.003636503,0.90274584,0.0005596708,0.0003032451,0.0005006474,0.000612479,0.000046683912,0.017478501,0.003125117,0.00068363134,0.03523536],"study_design_scores_gemma":[0.045534458,0.020960603,0.2805595,0.00010837143,0.00031072702,0.00023473501,0.00014182595,0.00029104177,0.643992,0.0023449024,0.0053508137,0.00017100004],"about_ca_topic_score_codex":0.00033304503,"about_ca_topic_score_gemma":0.00024626972,"teacher_disagreement_score":0.6265135,"about_ca_system_score_codex":0.000049499802,"about_ca_system_score_gemma":0.00023144363,"threshold_uncertainty_score":0.20978145},"labels":[],"label_agreement":null},{"id":"W2793647445","doi":"10.1093/annonc/mdy047.050","title":"Functional characterization of mammagliobin-1 isoform in breast cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. Georges-L.-Dumont University Hospital Centre; Université de Moncton","funders":"","keywords":"Breast cancer; Medicine; Cancer; Cancer research; Malignancy; Lymph node; CA15-3; Oncology; Pathology; Internal medicine","score_opus":0.07069740131165757,"score_gpt":0.3712863983116975,"score_spread":0.30058899700003994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793647445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675805,0.00008242576,0.00004805732,0.0076072114,0.00032046254,0.00011197801,0.00008681404,0.0000048383886,0.004980187],"genre_scores_gemma":[0.99674946,0.00076820684,0.0000685437,0.0014875872,0.00032588842,0.000012966472,0.000030197574,0.0000068365403,0.0005503098],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99940073,0.000017529515,0.0002513764,0.00010353096,0.00009884138,0.00012797637],"domain_scores_gemma":[0.9993932,0.000016072498,0.00014631948,0.00009613773,0.0003055283,0.00004270846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001607661,0.000055563913,0.00026467573,0.00013460765,0.000009987647,8.102938e-7,0.000030761137,0.000068525536,0.0020317014],"category_scores_gemma":[0.000010835274,0.00004866968,0.00005183626,0.0001904184,0.00012386814,0.00004709708,0.000017916596,0.00005477568,0.000011931209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020560196,0.0005503939,0.044626333,0.00012289025,0.00008373925,0.000008004409,0.00031532734,0.0000013655043,0.58582866,0.00033546457,0.006025592,0.3600462],"study_design_scores_gemma":[0.0012983483,0.001058355,0.7812999,0.00006595504,0.000032784345,0.000039036793,0.000039511746,0.000015364963,0.12606625,0.000049259696,0.08998418,0.00005106558],"about_ca_topic_score_codex":0.00033482086,"about_ca_topic_score_gemma":0.0001926945,"teacher_disagreement_score":0.73667353,"about_ca_system_score_codex":0.00003351478,"about_ca_system_score_gemma":0.00027876755,"threshold_uncertainty_score":0.99888057},"labels":[],"label_agreement":null},{"id":"W2793677489","doi":"10.1093/annonc/mdx753","title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Universiteit Leiden; Cancer Research UK; KWF Kankerbestrijding; National Cancer Research Institute; Cancer Research Institute","keywords":"Medicine; Surgical pathology; Radiation therapy; Endometrial cancer; Internal medicine; Clinical trial; Carboplatin; Cancer; Surgery; Pathology; Chemotherapy; Cisplatin","score_opus":0.25649401005086087,"score_gpt":0.5179855272343417,"score_spread":0.2614915171834808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793677489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341489,0.027445208,0.000021570804,0.02771844,0.002198888,0.005453055,0.00022882826,0.000008043989,0.0027770295],"genre_scores_gemma":[0.8862802,0.10912365,0.00025276505,0.0028819416,0.000722254,0.00065113633,0.000019311525,0.000008450143,0.000060309474],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970849,0.0007787678,0.0013605413,0.00028204065,0.00023285851,0.00026089328],"domain_scores_gemma":[0.9934222,0.004082916,0.0015889964,0.00052562146,0.00029966055,0.0000805773],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005224055,0.00014286589,0.0018390348,0.00012443021,0.00007387253,0.000004457088,0.00036662383,0.00022521052,0.00022833757],"category_scores_gemma":[0.014571679,0.00008139714,0.0005089799,0.00015549624,0.00070051075,0.000042431526,0.000045161825,0.00022830076,0.0000024698995],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48042595,0.0020116547,0.016875498,0.0005094392,0.0006366803,0.0001355994,0.000092293376,4.4852246e-7,0.00017816963,0.000534495,0.006730952,0.49186882],"study_design_scores_gemma":[0.87655735,0.032961823,0.046638243,0.00060868805,0.0013708983,0.000025419191,0.000047178848,0.0000012404986,0.0018432535,0.003951965,0.035851497,0.00014245497],"about_ca_topic_score_codex":0.0015668102,"about_ca_topic_score_gemma":0.0003348904,"teacher_disagreement_score":0.49172637,"about_ca_system_score_codex":0.00002683104,"about_ca_system_score_gemma":0.0005881827,"threshold_uncertainty_score":0.993729},"labels":[],"label_agreement":null},{"id":"W2793877664","doi":"10.1093/annonc/mdy042","title":"Developing androgen receptor targeting for salivary gland cancers","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Geoffrey Beene Cancer Research Center","keywords":"Medicine; Androgen receptor; Salivary gland; Androgen; Internal medicine; Bicalutamide; Oncology; Prospective cohort study; Cancer research; Cancer; Prostate cancer; Hormone","score_opus":0.1339564664802975,"score_gpt":0.4029339680108096,"score_spread":0.26897750153051214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793877664","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018793985,0.0055196877,0.00004563031,0.9703565,0.0010188223,0.0010180641,0.00023950265,0.00003753054,0.0029702818],"genre_scores_gemma":[0.0027986432,0.0029897413,0.01829662,0.9640087,0.00860293,0.00046363118,0.0020734502,0.00009551716,0.0006707854],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984746,0.00007062855,0.00045876997,0.00037441836,0.00017260291,0.0004489585],"domain_scores_gemma":[0.9984006,0.00053043745,0.00036905447,0.0002246292,0.00040946243,0.000065813474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027673336,0.0002486925,0.00090615987,0.00014452626,0.000064832915,0.000006006757,0.00012054238,0.00072347344,0.00023593464],"category_scores_gemma":[0.00018777479,0.00020500357,0.0002513882,0.00008752834,0.00012161485,0.000025566149,0.000047745358,0.00029326984,0.000034443357],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017964123,0.00007144867,0.0034640182,0.000341479,0.0006813552,0.00018626322,0.0001047065,1.5977373e-7,0.00003538668,0.00002004707,0.9754276,0.019487856],"study_design_scores_gemma":[0.0014173663,0.002098979,0.00037198575,0.0003211908,0.00021423481,0.000041680178,0.000026541094,0.000002762635,0.004518834,0.00019796882,0.9906031,0.0001853826],"about_ca_topic_score_codex":0.00019219492,"about_ca_topic_score_gemma":0.00002379,"teacher_disagreement_score":0.019302472,"about_ca_system_score_codex":0.0002748858,"about_ca_system_score_gemma":0.0010236222,"threshold_uncertainty_score":0.8359803},"labels":[],"label_agreement":null},{"id":"W2794250053","doi":"10.1093/annonc/mdy047.007","title":"Pharmacokinetics of ZR2002, a combi-molecule with EGFR and DNA-damaging properties and its efficacy in an orthotopic glioblastoma mouse model","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"In vivo; Medicine; Pharmacokinetics; Bioluminescence imaging; Pharmacology; Luciferase; In vitro; Brain tumor; Striatum; Cancer research; Glioma; Pathology; Cell culture; Biology; Internal medicine; Transfection","score_opus":0.07058379892321666,"score_gpt":0.34379990672413513,"score_spread":0.2732161078009185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794250053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984221,0.0007818715,0.000104091865,0.0002340647,0.000020163721,0.00018340193,0.000010603687,0.000003940139,0.00023975428],"genre_scores_gemma":[0.99843645,0.0005734677,0.00026937033,0.00054733397,0.000034715133,0.000010538412,0.0000034369284,0.00001582496,0.00010884337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993191,0.00004669524,0.00018007266,0.00021495367,0.00006395034,0.00017522911],"domain_scores_gemma":[0.99952054,0.0000060422035,0.000097270866,0.00014083018,0.00017217656,0.00006314638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011953467,0.00011008073,0.00020741968,0.000062790896,0.000024995114,0.000005382035,0.00009050287,0.000089846704,0.000003475236],"category_scores_gemma":[0.000009084402,0.00009506063,0.00001853359,0.000057089943,0.00018466053,0.0000049345995,0.00007752244,0.00005517938,1.670575e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007041249,0.00027672152,0.0001785398,0.00003855251,0.00003717203,0.0000026115833,0.0004007256,0.000094812196,0.9928403,0.00020272353,0.000019356687,0.005204357],"study_design_scores_gemma":[0.001599895,0.00733788,0.00019029938,0.000023895054,0.000019185167,0.000013249388,0.000075640804,0.00528906,0.9840527,0.000051360414,0.001231237,0.00011559842],"about_ca_topic_score_codex":0.000015762651,"about_ca_topic_score_gemma":0.00020238804,"teacher_disagreement_score":0.008787603,"about_ca_system_score_codex":0.000003895824,"about_ca_system_score_gemma":0.00008759428,"threshold_uncertainty_score":0.38764602},"labels":[],"label_agreement":null},{"id":"W2794284428","doi":"10.1093/annonc/mdy047.044","title":"Delivery of paclitaxel and everolimus in dual-targeted polymeric nanoparticles to breast cancer cells","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Paclitaxel; Everolimus; Breast cancer; Oncology; Dual (grammatical number); Cancer; Internal medicine","score_opus":0.031283971898003485,"score_gpt":0.31786592275532666,"score_spread":0.2865819508573232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794284428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625057,0.0006620272,0.0000036931733,0.0022809696,0.00029519197,0.00019052227,0.00015494798,0.000020223264,0.0001418374],"genre_scores_gemma":[0.9980765,0.00012710778,0.00043038692,0.0012253287,0.00007620204,0.000022495891,7.2483135e-7,0.000014153286,0.000027122658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829555,0.00021609908,0.00052035315,0.00031795248,0.00019435676,0.0004557],"domain_scores_gemma":[0.9988544,0.0002132791,0.00021412932,0.0002542288,0.00030035205,0.00016359169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055818155,0.00014129131,0.00043527217,0.00018815856,0.000038979426,0.000008787596,0.00014595453,0.000096517644,0.00042770442],"category_scores_gemma":[0.000055735738,0.00013388635,0.000041157717,0.00040808244,0.0004557006,0.00017391786,0.00015466003,0.00005525301,0.00008344308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006531986,0.00031102574,0.0036475467,0.000026517586,0.000011588948,0.000020024838,0.00078756595,0.00005483559,0.98422605,0.00004974237,0.0014754512,0.008736467],"study_design_scores_gemma":[0.0006682825,0.0013714827,0.030900415,0.0000441393,0.000014475547,0.000014380727,0.00018193801,0.00007923641,0.96605724,0.000104861174,0.000430597,0.00013293604],"about_ca_topic_score_codex":0.002401144,"about_ca_topic_score_gemma":0.00069396524,"teacher_disagreement_score":0.027252868,"about_ca_system_score_codex":0.000035494893,"about_ca_system_score_gemma":0.00022830174,"threshold_uncertainty_score":0.5459727},"labels":[],"label_agreement":null},{"id":"W2794306149","doi":"10.1093/annonc/mdy084","title":"Taking it in the chin: vitamin K1 for the prevention of acneiform rash","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Cetuximab; Rash; Dermatology; Cancer; Internal medicine; Epidermal growth factor receptor; Oncology; Pharmacology; Colorectal cancer","score_opus":0.16343580443342706,"score_gpt":0.4472243546240764,"score_spread":0.2837885501906493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794306149","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02408169,0.0017273991,0.000024244082,0.9522803,0.00043588388,0.0016248798,0.000059429087,0.0000055418227,0.019760625],"genre_scores_gemma":[0.46608084,0.0024560534,0.00016718413,0.5232405,0.0033003099,0.00075383106,0.00015171082,0.00003520934,0.0038143715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989393,0.000085937216,0.00038667762,0.00017368635,0.00018794165,0.00022645298],"domain_scores_gemma":[0.9982065,0.00082152704,0.00051213417,0.00025868003,0.00019181581,0.000009325838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005970701,0.00015234332,0.0006023928,0.000089626265,0.00006220138,0.000003567468,0.00019363561,0.00029773053,0.000103856575],"category_scores_gemma":[0.00019240327,0.00007543043,0.00025516967,0.00011076162,0.00021163192,0.000021951751,0.000053786993,0.00033472583,0.0000024131882],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040296343,0.00020623535,0.00049164647,0.00025459225,0.0005055824,0.000025117857,0.002002605,2.3419179e-7,0.00002350449,0.00003618581,0.9214608,0.074590534],"study_design_scores_gemma":[0.0013335234,0.005928523,0.018620878,0.0002111615,0.00030659663,0.000019750087,0.00042815055,0.0000061007304,0.00019156288,0.00047554472,0.9724111,0.00006710287],"about_ca_topic_score_codex":0.0001690535,"about_ca_topic_score_gemma":0.0007460086,"teacher_disagreement_score":0.44199917,"about_ca_system_score_codex":0.000049956812,"about_ca_system_score_gemma":0.00016257264,"threshold_uncertainty_score":0.30759636},"labels":[],"label_agreement":null},{"id":"W2794311213","doi":"10.1093/annonc/mdx810","title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":356,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sarcopenia; Medicine; Sarcopenic obesity; Cancer; Lean body mass; Geriatric oncology; Wasting; Internal medicine; Adipose tissue; Pathological; Oncology; Body weight","score_opus":0.2802819989295027,"score_gpt":0.533546997789248,"score_spread":0.2532649988597453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794311213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98049253,0.0034787657,0.00002818392,0.014186467,0.000060387483,0.0003502785,0.000036464935,0.000007744742,0.0013591757],"genre_scores_gemma":[0.9947526,0.0030486793,0.00073896564,0.0012038237,0.00017568593,0.00002196219,0.0000054258294,0.0000067158953,0.00004612845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994953,0.000032407967,0.00019037808,0.00010279372,0.000047426984,0.00013166509],"domain_scores_gemma":[0.9991995,0.00019769529,0.00011994102,0.00007271523,0.00032970431,0.000080410864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002829013,0.000049416114,0.00026173747,0.000060421833,0.000061452556,0.0000018860701,0.00003050108,0.000050925886,0.00006664185],"category_scores_gemma":[0.000060030303,0.000041420037,0.000029025176,0.00006276954,0.00010774887,0.00002805444,0.000017817256,0.000047446076,7.9938513e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001067267,0.000860063,0.22711764,0.0011647462,0.0002424096,0.000002117157,0.002473288,4.198286e-7,0.11292965,0.0033596477,0.011690197,0.63909256],"study_design_scores_gemma":[0.0035261605,0.0037209291,0.9421889,0.00022078118,0.000030017896,0.000014216782,0.0002497093,0.00037124188,0.011177811,0.0013120336,0.03711444,0.00007372742],"about_ca_topic_score_codex":0.00016422791,"about_ca_topic_score_gemma":0.00007751828,"teacher_disagreement_score":0.7150713,"about_ca_system_score_codex":0.000012313579,"about_ca_system_score_gemma":0.0001347138,"threshold_uncertainty_score":0.168906},"labels":[],"label_agreement":null},{"id":"W2794327154","doi":"10.1093/annonc/mdy048.003","title":"CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Nausea; Internal medicine; Toxicity; Gastroenterology; Cohort; Vomiting; Progressive disease; Tolerability; Oncology; Adverse effect; Chemotherapy","score_opus":0.05164381180588392,"score_gpt":0.41791089092633543,"score_spread":0.36626707912045153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794327154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970422,0.00004503044,0.000090046655,0.00010639855,0.00022538108,0.0005817452,0.000016506883,0.000010023779,0.0018827083],"genre_scores_gemma":[0.9971221,0.000011040362,0.0020094004,0.000426686,0.00020099527,0.00006085492,0.00006931001,0.000023359038,0.00007626158],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985006,0.00018231175,0.0004108382,0.00036911236,0.00019003998,0.00034711536],"domain_scores_gemma":[0.9988921,0.000027468159,0.00030577782,0.00032805634,0.00036848368,0.000078073244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054926396,0.00015728064,0.00034279338,0.00008739224,0.00003943838,0.000004884358,0.00020350005,0.00019031495,0.000049715934],"category_scores_gemma":[0.00039358984,0.00014078066,0.00006748148,0.00013348692,0.00015689229,0.00000763554,0.00011422768,0.00009767828,0.000010298209],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17016536,0.0049598217,0.0026590752,0.00003710821,0.00020889993,0.000022290342,0.00053010206,0.000052158957,0.5871435,0.00018494058,0.0016151804,0.23242159],"study_design_scores_gemma":[0.09889372,0.15697476,0.0018504526,0.000053243995,0.000025650848,0.000004744314,0.0001126374,0.000102477614,0.7349969,0.00048296788,0.006178162,0.0003242485],"about_ca_topic_score_codex":0.000011099025,"about_ca_topic_score_gemma":0.000044800003,"teacher_disagreement_score":0.23209736,"about_ca_system_score_codex":0.00001748026,"about_ca_system_score_gemma":0.00029060768,"threshold_uncertainty_score":0.57408684},"labels":[],"label_agreement":null},{"id":"W2795186863","doi":"10.1093/annonc/mdy103","title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":871,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; Agence Nationale de la Recherche; Institut Gustave-Roussy; Fondation Philanthropia","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Gastroenterology; Renal cell carcinoma; Cancer; Oncology; Confidence interval","score_opus":0.01902601079876553,"score_gpt":0.3506638988168615,"score_spread":0.33163788801809596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795186863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988318,0.000085037645,0.000013009662,0.00015704565,0.0000974372,0.00024236793,0.00004347344,9.684577e-7,0.00052884535],"genre_scores_gemma":[0.9988742,0.0005355978,0.00037267464,0.0001019044,0.000049330305,7.7807965e-7,0.000015691418,0.000008390566,0.000041441694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990083,0.0001239052,0.0004304273,0.00019967211,0.000068532914,0.00016915819],"domain_scores_gemma":[0.9986485,0.0000581791,0.00077296305,0.00013217963,0.00034942053,0.000038712704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040915213,0.00009425649,0.0003443351,0.000046878427,0.000018065182,0.0000010833676,0.00006417151,0.00024397859,0.0000037472826],"category_scores_gemma":[0.00007623859,0.00008271575,0.00005481943,0.00007674132,0.00014349782,0.000004060933,0.000057447654,0.00012136707,2.7183276e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001258144,0.0008472053,0.37453476,0.00008401569,0.000040547013,2.3684113e-7,0.00015791606,0.000010686871,0.61981535,9.399067e-7,0.00021600748,0.003034197],"study_design_scores_gemma":[0.001655173,0.0063952794,0.42333606,0.000042546275,0.000010629137,4.1792866e-8,0.000016609218,0.000005851558,0.5683614,0.000002000898,0.00012787365,0.00004654405],"about_ca_topic_score_codex":0.0001521359,"about_ca_topic_score_gemma":0.00037461187,"teacher_disagreement_score":0.051453974,"about_ca_system_score_codex":0.00002595257,"about_ca_system_score_gemma":0.00024437395,"threshold_uncertainty_score":0.33730504},"labels":[],"label_agreement":null},{"id":"W2795439944","doi":"10.1093/annonc/mdy115","title":"Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Tamoxifen; Clinical trial; Cancer; Adjuvant therapy; Hormonal therapy; Chemotherapy; Stage (stratigraphy); Randomized controlled trial; Adjuvant; Gynecology","score_opus":0.1989915160118517,"score_gpt":0.42249642279291466,"score_spread":0.22350490678106297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795439944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8341138,0.00048135006,0.00008918753,0.15384457,0.0010394594,0.0013362478,0.007196238,0.00006106846,0.0018381269],"genre_scores_gemma":[0.55133486,0.0017490151,0.0021396475,0.4395151,0.0028388125,0.00041146646,0.0010674335,0.00018950088,0.00075413566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966926,0.00040606703,0.00070166995,0.0011338141,0.00034971413,0.00071611034],"domain_scores_gemma":[0.9968096,0.0013645982,0.0007379593,0.00067076186,0.00032265985,0.000094402865],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00033155605,0.0006758759,0.0010988425,0.00026950135,0.00015269076,0.000016476122,0.00045089604,0.001505535,0.0002443905],"category_scores_gemma":[0.00059577543,0.00045026845,0.00025641228,0.00024688378,0.00033878375,0.000007731106,0.00019315587,0.00078948954,0.0000061341993],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023549262,0.0025245417,0.0628229,0.00015051452,0.00070234085,0.0021612442,0.0006580881,0.00046506178,0.04115861,0.0000016480789,0.8044726,0.06133318],"study_design_scores_gemma":[0.009942914,0.032091446,0.29985276,0.0034902105,0.0002492128,0.00010207208,0.00025707137,0.00007206405,0.27127627,0.000026094827,0.38050434,0.0021355576],"about_ca_topic_score_codex":0.00036880633,"about_ca_topic_score_gemma":0.0003013227,"teacher_disagreement_score":0.4239683,"about_ca_system_score_codex":0.000159828,"about_ca_system_score_gemma":0.00074230775,"threshold_uncertainty_score":0.9997949},"labels":[],"label_agreement":null},{"id":"W2801625460","doi":"10.1093/annonc/mdy126","title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Fondation de l'Hôpital général juif","keywords":"Medicine; Cytology; Immunohistochemistry; Lung cancer; Pathology; Immunostaining; Biopsy; Fixative; Cancer; Staining; Internal medicine","score_opus":0.08965536908357587,"score_gpt":0.42444060635135045,"score_spread":0.3347852372677746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801625460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834247,0.005277686,0.00018840551,0.0053897817,0.000456742,0.0010164187,0.00006353212,0.00002158231,0.004161146],"genre_scores_gemma":[0.9917088,0.00015191533,0.0029923634,0.0030772937,0.0003999481,0.00041242153,0.000018935945,0.000024491083,0.0012138382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998823,0.000026863823,0.00041842114,0.00024517046,0.00006464756,0.00042192443],"domain_scores_gemma":[0.9985139,0.0005563531,0.00025228824,0.00017823314,0.0004488603,0.00005040591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045356926,0.00012200581,0.0005063631,0.000112611706,0.0000570352,0.0000026329476,0.000116092364,0.00026750824,0.00012691603],"category_scores_gemma":[0.00032322382,0.000113383554,0.00013186941,0.00017494697,0.00024370209,0.000030409024,0.00002822591,0.00011661491,0.0000010229529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017906291,0.000658645,0.036109693,0.00059581443,0.0002127892,0.000011303669,0.0006408589,0.000003028273,0.79674745,0.000035584973,0.10480852,0.042270035],"study_design_scores_gemma":[0.016967827,0.013649516,0.023106134,0.00045689667,0.00019444653,0.000066462475,0.00042875373,0.0011984428,0.52852196,0.00042544547,0.41460833,0.00037576718],"about_ca_topic_score_codex":0.00057653786,"about_ca_topic_score_gemma":0.00033851617,"teacher_disagreement_score":0.30979982,"about_ca_system_score_codex":0.00013694109,"about_ca_system_score_gemma":0.00044237182,"threshold_uncertainty_score":0.4623647},"labels":[],"label_agreement":null},{"id":"W2802374582","doi":"10.1093/annonc/mdy114","title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Nutritional Supplementation; Polyunsaturated fatty acid; Internal medicine; Weight loss; Medical nutrition therapy; Malnutrition; Subgroup analysis; Quality of life (healthcare); Psychological intervention; Obesity; Fatty acid","score_opus":0.8477895094622832,"score_gpt":0.6642220610960837,"score_spread":0.18356744836619943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802374582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010277635,0.9836222,0.00027149922,0.006936756,0.00014669278,0.00849811,0.00041651525,0.0000048917973,5.526094e-7],"genre_scores_gemma":[0.00015452178,0.99455905,0.0027997338,0.0007969173,0.00017143734,0.0014423531,0.000034271718,0.0000163043,0.000025418787],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9928411,0.0023318366,0.0038789078,0.00045968778,0.0003049558,0.0001835008],"domain_scores_gemma":[0.9818541,0.012806324,0.0039166207,0.00036417018,0.0009521303,0.000106689906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012577094,0.00030233912,0.010519338,0.00031210046,0.00007793739,0.000008333545,0.00018018697,0.00027241005,0.000037298938],"category_scores_gemma":[0.008071502,0.00017336063,0.0033792318,0.0003065042,0.00032312347,0.0000809602,0.000051112173,0.0002208533,1.9072066e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005535108,0.0006044959,0.00012756977,0.95956755,0.029977094,4.574606e-7,0.000012667061,6.064217e-8,7.1872483e-7,0.00031485056,0.001526449,0.0073145977],"study_design_scores_gemma":[0.0028273945,0.003445249,0.0009982816,0.48667878,0.48342913,0.00005033944,0.000012315179,0.000020432939,0.000012454436,0.00046139536,0.021852694,0.00021151964],"about_ca_topic_score_codex":0.0000022061001,"about_ca_topic_score_gemma":0.0000033906458,"teacher_disagreement_score":0.47288874,"about_ca_system_score_codex":0.000045815992,"about_ca_system_score_gemma":0.0002490666,"threshold_uncertainty_score":0.9662924},"labels":[],"label_agreement":null},{"id":"W2804717005","doi":"10.1093/annonc/mdy181","title":"Safety and dose modification for patients receiving niraparib","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Adverse effect; Population; Gastroenterology; Surgery","score_opus":0.13754265967460957,"score_gpt":0.4458181394990429,"score_spread":0.3082754798244334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804717005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96748614,0.00020210326,0.0016725231,0.0096258335,0.0003409883,0.0006587352,0.000038226728,0.000027636976,0.019947786],"genre_scores_gemma":[0.9948344,0.00050071115,0.0017760134,0.0023992816,0.00021468518,0.000032626554,0.00003264428,0.000009271998,0.00020032395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939346,0.00003290362,0.0002351879,0.00014083067,0.00007129808,0.00012632167],"domain_scores_gemma":[0.9990834,0.00013515302,0.00014381706,0.00013334751,0.000449157,0.00005514794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026219315,0.000056484947,0.00019998383,0.000060455575,0.000048351398,0.0000019652082,0.00003338145,0.00009007713,0.00005391928],"category_scores_gemma":[0.00016139487,0.000052611576,0.00003387572,0.000066740475,0.00016509007,0.000046391964,0.00001171674,0.00004279804,0.000006989476],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070655025,0.0008480507,0.023686267,0.000116730764,0.0001319577,8.3816104e-7,0.001628735,0.0000016261858,0.01413335,0.002836217,0.0374557,0.912095],"study_design_scores_gemma":[0.00881297,0.012454886,0.25268492,0.00010021415,0.00004095557,0.000008541599,0.00006949549,0.0002649801,0.028320178,0.003285427,0.69382745,0.00013001292],"about_ca_topic_score_codex":0.00001012359,"about_ca_topic_score_gemma":0.0000075880416,"teacher_disagreement_score":0.911965,"about_ca_system_score_codex":0.000030368154,"about_ca_system_score_gemma":0.00007183004,"threshold_uncertainty_score":0.21454379},"labels":[],"label_agreement":null},{"id":"W2805278470","doi":"10.1093/annonc/mdy124","title":"Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Durham University","keywords":"Medicine; Stage (stratigraphy); Asymptomatic; Melanoma; Radiology; Nuclear medicine; Surgery","score_opus":0.03453312850709432,"score_gpt":0.3468765521627405,"score_spread":0.31234342365564616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805278470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94345,0.00009665538,0.000032533,0.007341962,0.0001652745,0.00036005775,0.000010480534,0.0000126598,0.048530385],"genre_scores_gemma":[0.99514943,0.00004846057,0.00015409676,0.003032826,0.00006179035,0.000013437253,0.000006630642,0.000009730671,0.0015235988],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990511,0.00016147374,0.00026375704,0.00016807084,0.00016722105,0.00018837352],"domain_scores_gemma":[0.99909395,0.00014390974,0.00015400135,0.0002551061,0.00031713405,0.00003587892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005349231,0.00009945937,0.0003385582,0.00013046376,0.00003466487,0.000004608572,0.00011304198,0.000010782329,0.00024058417],"category_scores_gemma":[0.000109899986,0.00006278502,0.000054513002,0.00020825445,0.00023651651,0.00003628937,0.000036057325,0.00010922425,0.0000161412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024583764,0.004234711,0.51210433,0.00074483705,0.0016938495,0.02234696,0.024205435,0.000054388896,0.06807314,0.01110113,0.048524983,0.28233248],"study_design_scores_gemma":[0.0130673535,0.041925482,0.34773904,0.0002407483,0.00013060165,0.007123481,0.019892685,0.000588,0.04757682,0.00019004961,0.5210094,0.00051632966],"about_ca_topic_score_codex":0.0005072182,"about_ca_topic_score_gemma":0.0025959236,"teacher_disagreement_score":0.47248444,"about_ca_system_score_codex":0.000023017383,"about_ca_system_score_gemma":0.00011260165,"threshold_uncertainty_score":0.2634228},"labels":[],"label_agreement":null},{"id":"W2806455772","doi":"10.1093/annonc/mdy147","title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Bruyère; University of Ottawa","funders":"","keywords":"Delirium; Medicine; Cancer; Population; Guideline; Intensive care medicine; Incidence (geometry); Malignancy; Disease; Internal medicine; Psychiatry; Oncology; Pathology","score_opus":0.16704400829917487,"score_gpt":0.5382160627434784,"score_spread":0.37117205444430357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806455772","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7243836,0.00032696285,0.000059825426,0.21572836,0.0012865339,0.000430099,0.000023799545,0.000020636293,0.057740215],"genre_scores_gemma":[0.4299682,0.0014257024,0.0016559223,0.5662421,0.00047028207,0.000023317116,0.0000255558,0.000017402293,0.0001715152],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981931,0.00020525052,0.0008706916,0.0002589123,0.00019733811,0.00027469365],"domain_scores_gemma":[0.8656845,0.0006046268,0.00031530266,0.00017654237,0.13312675,0.000092238304],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0006341044,0.00012069253,0.0004663315,0.00015711518,0.000021469117,0.0000020942718,0.00009211125,0.00023514645,0.00019952678],"category_scores_gemma":[0.1613574,0.0001062291,0.00011615659,0.00022312548,0.0004300404,0.00009844715,0.00005831117,0.0002712615,0.000086120155],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022005697,0.0015249858,0.076370455,0.000023034545,0.00015865546,0.000059184156,0.00035971892,4.6346443e-7,0.000070450005,0.00024358906,0.74784166,0.17114727],"study_design_scores_gemma":[0.0067455545,0.013442584,0.1300362,0.00030489036,0.00016196804,0.000026652573,0.0048951935,0.0000918057,0.0018132253,0.00017369083,0.8421054,0.00020283714],"about_ca_topic_score_codex":0.0010487137,"about_ca_topic_score_gemma":0.0010115238,"teacher_disagreement_score":0.35051376,"about_ca_system_score_codex":0.000039148752,"about_ca_system_score_gemma":0.00049223204,"threshold_uncertainty_score":0.8457068},"labels":[],"label_agreement":null},{"id":"W2808742107","doi":"10.1093/annonc/mdy151.133","title":"Antibodies matter: A meta-analysis of the prognostic value of human equilibrative nucleoside transporter 1 (hENT1) antibodies in pancreatobiliary cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Immunohistochemistry; Internal medicine; Population; Antibody; Cancer; Pathology; Immunology","score_opus":0.18058168080064008,"score_gpt":0.46326239546957887,"score_spread":0.2826807146689388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808742107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842713,0.0016783967,0.000011892931,0.00443291,0.000037452588,0.00065909605,0.00013252046,0.0000068962504,0.008769556],"genre_scores_gemma":[0.99784607,0.00046063174,0.0003396746,0.0008178481,0.000034322507,0.000070689435,0.000015530777,0.000015130576,0.00040011527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747217,0.0004925074,0.0010060503,0.00031226655,0.00034847495,0.0003685231],"domain_scores_gemma":[0.99771255,0.00063378236,0.0005372852,0.00049296493,0.0005502719,0.00007313145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008926703,0.00019893177,0.0028341748,0.00048760395,0.00005501768,0.0000022571332,0.00027123667,0.00019478836,0.0019944494],"category_scores_gemma":[0.00016732542,0.00012100717,0.00085700286,0.00082437677,0.0019260048,0.00007505846,0.000093931776,0.0002084676,0.0000052063388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037532204,0.00078236964,0.9319781,0.00021782197,0.045668192,0.000017770131,0.0033660082,0.000006936507,0.015936792,0.0006591581,0.0008412693,0.00015024975],"study_design_scores_gemma":[0.00074167305,0.0019922291,0.9205141,0.00007644243,0.058048237,0.000004854035,0.00047211102,0.00015701454,0.017150702,0.0006255959,0.00012797726,0.00008907264],"about_ca_topic_score_codex":0.0022674827,"about_ca_topic_score_gemma":0.0023031675,"teacher_disagreement_score":0.013574778,"about_ca_system_score_codex":0.000029445937,"about_ca_system_score_gemma":0.0004329779,"threshold_uncertainty_score":0.9989179},"labels":[],"label_agreement":null},{"id":"W2808910921","doi":"10.1093/annonc/mdy150.005","title":"Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Mount Sinai Hospital; Cégep de Lévis; Jewish General Hospital; Sunnybrook Health Science Centre; Dr. Georges-L.-Dumont University Hospital Centre; Hôpital Maisonneuve-Rosemont; St Mary's Hospital Centre; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal; McGill University; Centre de Santé et de Services Sociaux de Chicoutimi","funders":"","keywords":"Medicine; Colorectal cancer; Concordance; Metastasis; Copy-number variation; Copy number analysis; Tumour heterogeneity; Single-nucleotide polymorphism; SNP; Transcriptome; Biopsy; Gene expression profiling; Cancer research; SNP array; Liquid biopsy; Oncology; Cancer; Pathology; Internal medicine; Gene; Genotype; Gene expression; Biology; Genome; Genetics","score_opus":0.026848215464341865,"score_gpt":0.3205735582745008,"score_spread":0.29372534281015894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808910921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783856,0.0001232589,0.00014483648,0.00017319327,0.00016147032,0.00014785724,0.001205952,0.0000017492215,0.00020314749],"genre_scores_gemma":[0.99768555,0.00065368944,0.00059764745,0.00041289796,0.00012193967,0.000026930795,0.00048800046,0.000009252697,0.000004087079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929625,0.000060149778,0.00027463466,0.00018926023,0.000054197106,0.00012551121],"domain_scores_gemma":[0.99931276,0.00004476482,0.00021186049,0.00010787649,0.00027424388,0.000048469617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083555904,0.00008592754,0.0002090104,0.00003703274,0.000028784334,0.0000048638926,0.00007858133,0.00009215945,0.00011502285],"category_scores_gemma":[0.00010819377,0.0000912911,0.000039549854,0.000077719225,0.00015872525,0.000005815483,0.000087830864,0.00003624026,0.0000023802208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042558313,0.00064162805,0.8890908,0.000016409711,0.0001711681,0.0000020923096,0.00035753092,0.000010613219,0.099095896,0.00021203597,0.0014952836,0.008480997],"study_design_scores_gemma":[0.0008134224,0.0011359546,0.5478067,0.000010967219,0.00003521382,0.0000011026244,0.000014197673,0.00009892003,0.43706095,0.00010028026,0.012807412,0.000114877985],"about_ca_topic_score_codex":0.0014972884,"about_ca_topic_score_gemma":0.006995185,"teacher_disagreement_score":0.34128407,"about_ca_system_score_codex":0.000013598686,"about_ca_system_score_gemma":0.00016592702,"threshold_uncertainty_score":0.39034772},"labels":[],"label_agreement":null},{"id":"W2809550395","doi":"10.1093/annonc/mdy149.020","title":"Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Irinotecan; Colorectal cancer; Oncology; Microsatellite instability; Cohort; Progression-free survival; Cancer; Response Evaluation Criteria in Solid Tumors; Oxaliplatin; Surgery; Phases of clinical research; Chemotherapy; Immunotherapy","score_opus":0.02001962532734314,"score_gpt":0.3241695053630242,"score_spread":0.30414988003568105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809550395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969979,0.0003017032,0.000008255626,0.0005038011,0.00022879391,0.0007326613,0.000106204665,0.000013188045,0.0011074936],"genre_scores_gemma":[0.9986081,0.0004287565,0.00061656407,0.0002298089,0.000041894353,0.000021308088,0.0000127286385,0.000021870424,0.00001898025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984628,0.00011552721,0.00043670888,0.00039157286,0.00024098314,0.0003524242],"domain_scores_gemma":[0.9985668,0.00015431353,0.0003252875,0.00025443084,0.0005846329,0.00011452498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002379135,0.00019935062,0.00081852364,0.00015315377,0.000036864767,0.0000026735893,0.000108727996,0.00018295478,0.00012999418],"category_scores_gemma":[0.00015505379,0.00016695586,0.000051851515,0.00032337118,0.0009701573,0.00008576677,0.00009833142,0.00020803235,0.0000015579559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05301393,0.0012082908,0.7542081,0.0002446907,0.0001175966,0.000008693598,0.000763212,0.000020318279,0.04946832,0.0000333032,0.000052733125,0.14086083],"study_design_scores_gemma":[0.005899351,0.015836641,0.79149747,0.00014739465,0.000031388587,0.0000053732765,0.000024895058,0.000012967096,0.18467334,0.00004899397,0.0016986197,0.00012354874],"about_ca_topic_score_codex":0.0005884292,"about_ca_topic_score_gemma":0.0015036033,"teacher_disagreement_score":0.14073727,"about_ca_system_score_codex":0.00015998124,"about_ca_system_score_gemma":0.0005292389,"threshold_uncertainty_score":0.6808262},"labels":[],"label_agreement":null},{"id":"W2810960090","doi":"10.1093/annonc/mdy225","title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Drug development; Dosing; Clinical trial; Drug; Face (sociological concept); Intensive care medicine; Immunotherapy; Competition (biology); Toxicity; Maximum tolerated dose; Pharmacology; Oncology; Medical physics; Risk analysis (engineering); Immune system; Internal medicine; Immunology","score_opus":0.3627134592304156,"score_gpt":0.5024936264408392,"score_spread":0.13978016721042358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810960090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015454429,0.9456171,0.0000011015605,0.033155564,0.00025200535,0.0028704645,0.000021907683,0.0000125459865,0.016523909],"genre_scores_gemma":[0.00035983676,0.9955168,0.00014174517,0.0011092273,0.0003073696,0.000528421,0.000024022112,0.000056827612,0.0019557702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950028,0.0018536962,0.0013472834,0.000504016,0.0006410725,0.0006511201],"domain_scores_gemma":[0.99509317,0.0021470082,0.0008689823,0.0012280832,0.000536955,0.00012580882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054841605,0.0004137149,0.0029501736,0.00034436426,0.0000722688,0.000008241315,0.0012873724,0.0006428993,0.00046714325],"category_scores_gemma":[0.00041094024,0.00022276671,0.00041025132,0.00059372606,0.00048305807,0.00003062006,0.00038958524,0.0013841105,0.00017548793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029189832,0.00057916535,0.000007726943,0.003560559,0.00051213574,0.00009225288,0.01058355,1.5793086e-7,0.000017472148,0.000130054,0.019783894,0.9644411],"study_design_scores_gemma":[0.0005963583,0.002959679,0.00032394638,0.005899585,0.00014907907,0.00013644158,0.0016178663,1.7191753e-7,0.00008430783,0.000046870806,0.9880095,0.00017619498],"about_ca_topic_score_codex":0.00013950524,"about_ca_topic_score_gemma":0.00058870745,"teacher_disagreement_score":0.9682256,"about_ca_system_score_codex":0.00031192237,"about_ca_system_score_gemma":0.0026749007,"threshold_uncertainty_score":0.9084163},"labels":[],"label_agreement":null},{"id":"W2838357484","doi":"10.1093/annonc/mdy232","title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Prostate cancer; Oncology; Clinical endpoint; Cohort; Adverse effect; Progressive disease; Cancer; Urology; Surgery; Clinical trial; Disease; Immunotherapy","score_opus":0.06985392706225708,"score_gpt":0.4013476399603873,"score_spread":0.33149371289813023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2838357484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912642,0.0005741762,0.000011503965,0.004775171,0.00032416076,0.0013573768,0.000022481045,0.000010319983,0.0016605963],"genre_scores_gemma":[0.9973448,0.00007282074,0.00015953302,0.0013080555,0.000097772456,0.000050854855,0.0000029121052,0.000014472417,0.0009487868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990171,0.00005732897,0.0003797496,0.00018090925,0.000144859,0.00022000888],"domain_scores_gemma":[0.9989369,0.00011779972,0.00022668082,0.00031274604,0.00037024057,0.000035654983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925452,0.00010232072,0.0003816715,0.00006760663,0.000059862683,0.0000020706245,0.0001621611,0.00008253736,0.00007164196],"category_scores_gemma":[0.00012747322,0.00006747011,0.00017409083,0.00019001964,0.00035735438,0.000037079786,0.00004821135,0.000077788165,0.0000029077062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16278616,0.005687639,0.3096102,0.0006071655,0.001801713,0.000021854616,0.017266987,0.000003071825,0.21251617,0.00040713258,0.051340222,0.23795168],"study_design_scores_gemma":[0.018781297,0.049619153,0.660506,0.00010722693,0.00016231163,0.00003550561,0.0013092041,0.0000145525,0.18725564,0.00032714568,0.08174423,0.00013771877],"about_ca_topic_score_codex":0.00007839741,"about_ca_topic_score_gemma":0.000064855165,"teacher_disagreement_score":0.35089582,"about_ca_system_score_codex":0.000032773885,"about_ca_system_score_gemma":0.000268593,"threshold_uncertainty_score":0.27513513},"labels":[],"label_agreement":null},{"id":"W2885324169","doi":"10.1093/annonc/mdy305","title":"Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Medicine; Clinical trial; Hazard ratio; Publication bias; Odds ratio; Logistic regression; Internal medicine; Family medicine; Odds; Confidence interval","score_opus":0.44616523967655064,"score_gpt":0.5966019706784258,"score_spread":0.15043673100187516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885324169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93388575,0.00034184518,8.7913213e-7,0.057230957,0.00016170807,0.0008040673,0.00007649556,0.00001273991,0.0074855844],"genre_scores_gemma":[0.9932083,0.00022731374,0.00004556502,0.00589503,0.00024739178,0.000052964795,0.000017954162,0.000012632245,0.00029284737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996404,0.0016599924,0.0008355447,0.00032758818,0.00019176985,0.00058113656],"domain_scores_gemma":[0.99641913,0.0015023793,0.00064163015,0.00012021776,0.0007663081,0.00055030937],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045903097,0.00018543078,0.0007502742,0.00055343454,0.00010794633,0.000016870874,0.000197357,0.002033014,0.002683406],"category_scores_gemma":[0.002093552,0.0001645408,0.000038930957,0.00075012783,0.0002435877,0.0003711566,0.00015148548,0.0020372847,0.000023512544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10875277,0.006679203,0.4622472,0.00019228074,0.000989349,0.00008526531,0.0096007055,0.00025318153,0.12476914,0.0048889895,0.057268944,0.22427298],"study_design_scores_gemma":[0.1129966,0.04783444,0.4584868,0.00029583473,0.00034585196,0.0001399747,0.002208856,0.0025449267,0.07936743,0.0075603165,0.28716815,0.0010508345],"about_ca_topic_score_codex":0.00017897724,"about_ca_topic_score_gemma":0.00032592795,"teacher_disagreement_score":0.2298992,"about_ca_system_score_codex":0.00031449698,"about_ca_system_score_gemma":0.0008695031,"threshold_uncertainty_score":0.9992626},"labels":[],"label_agreement":null},{"id":"W2886615577","doi":"10.1093/annonc/mdy217","title":"ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":328,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Consensus conference; Panel discussion; Family medicine; Testicular cancer; Multidisciplinary approach; Working group; Disease; Survivorship curve; MEDLINE; Cancer; Medical education; Gynecology; Pathology; Internal medicine","score_opus":0.1267539250852099,"score_gpt":0.41203524678921843,"score_spread":0.28528132170400855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886615577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859682,0.0038410896,0.0000016527067,0.0048548565,0.00017915506,0.00037503339,0.00008978208,0.000025899863,0.0046643685],"genre_scores_gemma":[0.99476236,0.0031517688,0.00020274983,0.0011563682,0.00010044905,0.00015907716,0.000017705604,0.000013759843,0.00043574593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913514,0.000056429843,0.00019909232,0.00027054577,0.00010199786,0.00023682317],"domain_scores_gemma":[0.9988955,0.0002491737,0.00014989478,0.00023103761,0.00024771324,0.00022667316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053313135,0.00016852705,0.00042382113,0.00005865548,0.000056945744,0.0000055331507,0.000038221402,0.00010077437,0.00023401494],"category_scores_gemma":[0.00013763671,0.0001239079,0.000094755495,0.000065574975,0.0002914891,0.000011494122,0.00002262205,0.000046687415,0.000039022005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017675009,0.005927814,0.67410296,0.00015984318,0.0009890703,0.0011252343,0.0005229016,0.0000024653482,0.0013766027,0.0012130871,0.016400032,0.29641247],"study_design_scores_gemma":[0.022318948,0.07606081,0.6985061,0.0004999157,0.0021909387,0.00018758471,0.00020787708,0.00023084616,0.081428,0.0013260212,0.116575375,0.0004675917],"about_ca_topic_score_codex":0.00085807644,"about_ca_topic_score_gemma":0.0001465276,"teacher_disagreement_score":0.29594487,"about_ca_system_score_codex":0.00005590952,"about_ca_system_score_gemma":0.0003828209,"threshold_uncertainty_score":0.50528175},"labels":[],"label_agreement":null},{"id":"W2888034354","doi":"10.1093/annonc/mdy263","title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":787,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; Stand Up To Cancer; National Cancer Institute; Servier; European Society for Medical Oncology; CRUK Lung Cancer Centre of Excellence; Rosetrees Trust; National Institute for Health and Care Research; University College London; Wellcome Trust; Cancer Research UK; AstraZeneca; Invitae; Syndax Pharmaceuticals; Biomedical Research Council; Francis Crick Institute; Genentech; Seattle Genetics; National Institute on Handicapped Research; PTC Therapeutics; Novartis; Celgene; Sanofi; Wellcome; Roche; Merck; GlaxoSmithKline; University College London Hospitals NHS Foundation Trust; Prostate Cancer Foundation; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Breast Cancer Research Foundation; Boehringer Ingelheim","keywords":"Medicine; Precision medicine; Scale (ratio); Cancer; Computational biology; Rank (graph theory); Oncology; Bioinformatics; Medical physics; Internal medicine; Pathology; Cartography; Biology","score_opus":0.07024010369804076,"score_gpt":0.46415126368722553,"score_spread":0.3939111599891848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888034354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91173095,0.002380796,0.064863935,0.017799838,0.001155106,0.0013840494,0.00030401157,0.0000041034123,0.00037720907],"genre_scores_gemma":[0.97966295,0.0018898252,0.0104916645,0.006085275,0.0013086967,0.00039322188,0.00007624769,0.00002127653,0.00007082894],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987154,0.0000854832,0.0005418693,0.00034837725,0.00008571212,0.00022315438],"domain_scores_gemma":[0.99773496,0.00064352725,0.00024847343,0.00042142998,0.00085224834,0.00009937406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000855514,0.000120420205,0.00033902968,0.000036477777,0.0001009172,0.0000045353554,0.00026684688,0.00025776488,0.000051078332],"category_scores_gemma":[0.0024053787,0.000094793235,0.00020309913,0.00007101695,0.0003697467,0.0000028402044,0.00010438911,0.00007453786,0.0000024942892],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057377485,0.0008817494,0.0037913343,0.00011167656,0.00049693894,7.341418e-7,0.0009507728,0.0008720403,0.6226921,0.0035054428,0.23781125,0.12314821],"study_design_scores_gemma":[0.0009440359,0.007890545,0.0052578314,0.000027250035,0.00007355175,0.0000020219964,0.00006351212,0.00010792387,0.301403,0.012547085,0.67155075,0.0001325189],"about_ca_topic_score_codex":0.00012714198,"about_ca_topic_score_gemma":0.00039904457,"teacher_disagreement_score":0.43373948,"about_ca_system_score_codex":0.000021255315,"about_ca_system_score_gemma":0.00043454673,"threshold_uncertainty_score":0.3865556},"labels":[],"label_agreement":null},{"id":"W2888480300","doi":"10.1093/annonc/mdy245","title":"Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Medical Research Council; Imperial Experimental Cancer Medicine Centre; Public Health Agency; King’s College London; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust; Institute of Cancer Research; National Institute on Handicapped Research; Christie NHS Foundation Trust; AstraZeneca","keywords":"Medicine; Paclitaxel; Serous fluid; Ovarian cancer; Serous ovarian cancer; Oncology; Lung cancer; Internal medicine; Cancer","score_opus":0.014610357007388993,"score_gpt":0.2913217063593029,"score_spread":0.2767113493519139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888480300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983884,0.0003401742,0.00007685204,0.00032228313,0.00015858392,0.00040158172,0.000026654425,0.0000062166737,0.00027925507],"genre_scores_gemma":[0.9987343,0.00006012281,0.00035335697,0.0005146658,0.00014078718,0.00006539428,0.000054085194,0.000030871182,0.00004639753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869263,0.00010920746,0.00030099667,0.0004150151,0.00014198606,0.0003401519],"domain_scores_gemma":[0.9991854,0.000033174983,0.00021542913,0.00023077437,0.0002596902,0.00007555661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002305939,0.00019331012,0.00030218522,0.00011189891,0.000037552796,0.000010325114,0.00012591883,0.00025356028,0.000010324216],"category_scores_gemma":[0.000029149936,0.00016915446,0.000021597862,0.00018706835,0.00022211562,0.0000116926685,0.000076976205,0.00014353017,8.568649e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024723087,0.0013819307,0.9370424,0.00010655122,0.0000822385,0.00002209987,0.0007652547,0.00020251653,0.05257988,0.000037299196,0.0012184705,0.0040890593],"study_design_scores_gemma":[0.013296888,0.019897826,0.7581131,0.00013394703,0.000043575492,0.0000055759187,0.00010658943,0.00015274872,0.2059159,0.00006375394,0.0018137842,0.00045633328],"about_ca_topic_score_codex":0.001194417,"about_ca_topic_score_gemma":0.00486207,"teacher_disagreement_score":0.1789293,"about_ca_system_score_codex":0.00006593904,"about_ca_system_score_gemma":0.00030433756,"threshold_uncertainty_score":0.68979186},"labels":[],"label_agreement":null},{"id":"W2889810537","doi":"10.1093/annonc/mdy398","title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"European Society for Medical Oncology; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Clinical trial; Task force; Immunotherapy; Medical physics; Drug development; Inefficiency; Intensive care medicine; Risk analysis (engineering); Cancer; Internal medicine; Pharmacology; Drug","score_opus":0.83767867545436,"score_gpt":0.6555024798137091,"score_spread":0.1821761956406509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889810537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023180877,0.986723,0.0026133447,0.0043940293,0.00035595256,0.003381697,0.00015700852,0.0000040255104,0.000052830354],"genre_scores_gemma":[0.00020396615,0.9791299,0.01906727,0.00043514016,0.0000799599,0.000736266,0.000042900097,0.000029422885,0.00027518882],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947923,0.0027288373,0.0017948649,0.00027532977,0.00021567766,0.00019298136],"domain_scores_gemma":[0.95578104,0.03977637,0.0018112151,0.00044420856,0.0021622714,0.000024917199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00761838,0.00023140904,0.002519956,0.00018435845,0.000098450546,0.0000026536977,0.000356987,0.00027827884,0.00016631273],"category_scores_gemma":[0.0015006438,0.0001196487,0.00028750516,0.00039335297,0.0016112424,0.0000230913,0.00010510087,0.0003429079,6.030009e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011425643,0.00042568936,0.000034929075,0.0008571375,0.009379283,2.1533349e-7,0.0076880264,3.5751938e-7,0.00040647548,0.0005319779,0.0038960879,0.97563726],"study_design_scores_gemma":[0.0023954818,0.009130055,0.00043964456,0.003428681,0.00047969297,0.0000022975007,0.0018326576,0.000002360215,0.0020919316,0.0020503236,0.9780237,0.00012317579],"about_ca_topic_score_codex":0.00009653183,"about_ca_topic_score_gemma":0.000052422438,"teacher_disagreement_score":0.97551405,"about_ca_system_score_codex":0.00006439383,"about_ca_system_score_gemma":0.0016318192,"threshold_uncertainty_score":0.593669},"labels":[],"label_agreement":null},{"id":"W2890261294","doi":"10.1093/annonc/mdz135","title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":840,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Oncology; Internal medicine; Cancer; Phases of clinical research; Gynecology; Chemotherapy; Immunotherapy","score_opus":0.03553001180780957,"score_gpt":0.3693015059763449,"score_spread":0.33377149416853535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890261294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951013,0.00046734826,0.0000014806049,0.0023594298,0.00017547594,0.0011796445,0.00029022666,0.0000055911255,0.00041953352],"genre_scores_gemma":[0.99887806,0.00069375674,0.000031224026,0.00028806657,0.000024249359,0.0000168302,0.000027673448,0.000008972296,0.000031166044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886173,0.00014127849,0.00038078567,0.0002594382,0.0001877252,0.00016901831],"domain_scores_gemma":[0.99894744,0.0001988833,0.00035431175,0.00031886186,0.00014136653,0.000039136397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003516461,0.00012159128,0.000505354,0.00006181496,0.000037567785,0.0000020611285,0.00009457162,0.00006336725,0.000059419257],"category_scores_gemma":[0.00005291757,0.000076712575,0.000045311484,0.0001885993,0.00012781279,0.000070038084,0.000052159947,0.00015530946,4.9530905e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36108613,0.005710503,0.1525756,0.000029461302,0.0003124589,0.0000070081587,0.0023990797,0.00000692178,0.003527343,0.0000052099326,0.0002345242,0.47410578],"study_design_scores_gemma":[0.07304067,0.03593862,0.8835418,0.00018804135,0.000048045942,9.0663184e-7,0.00027665106,0.000014555674,0.0019945567,0.000007711286,0.0048671314,0.00008127078],"about_ca_topic_score_codex":0.0026529806,"about_ca_topic_score_gemma":0.0013165121,"teacher_disagreement_score":0.73096627,"about_ca_system_score_codex":0.00005616922,"about_ca_system_score_gemma":0.00025195166,"threshold_uncertainty_score":0.40105307},"labels":[],"label_agreement":null},{"id":"W2891804494","doi":"10.1093/annonc/mdy403","title":"Neoadjuvant rectal score: run with the hare and hunt with the hounds","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pelican Cancer Foundation; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust; Institute of Cancer Research; Cancer Research UK; National Institute on Handicapped Research","keywords":"Medicine; Colorectal cancer; Nomogram; Neoadjuvant therapy; Oncology; Internal medicine; Surrogate endpoint; Clinical endpoint; Adjuvant therapy; Clinical trial; Randomized controlled trial; Chemoradiotherapy; Cancer; Breast cancer","score_opus":0.07662403154553372,"score_gpt":0.3455194820225221,"score_spread":0.2688954504769884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891804494","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19859691,0.0013252273,0.0000028115244,0.7821515,0.00014893408,0.00081694557,0.00005410145,0.000027773842,0.01687576],"genre_scores_gemma":[0.24179766,0.0005981624,0.0001205204,0.74787,0.0031127578,0.0003096625,0.00015060094,0.000100826845,0.0059398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818325,0.00020327479,0.000236594,0.00045727985,0.00046462275,0.00045499008],"domain_scores_gemma":[0.99802417,0.0005985274,0.00034391522,0.0005724559,0.00037570507,0.000085254724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027679393,0.00036114772,0.00086350506,0.00007656116,0.00013711238,0.000022133152,0.00025009393,0.00048468733,0.00025046777],"category_scores_gemma":[0.00004229368,0.00014308059,0.000118128984,0.00022771442,0.0013351397,0.00004115742,0.00012381218,0.001110704,0.000019812984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025436627,0.00009738645,0.0021317983,0.00009228521,0.0008023374,0.0016164003,0.00042571753,2.7167638e-7,0.0000102646945,0.000007933742,0.97005993,0.022211984],"study_design_scores_gemma":[0.001754264,0.02142766,0.018017348,0.00026052093,0.00043404222,0.0010362878,0.000109510365,0.0000018447224,0.0001780026,0.000031262432,0.9565705,0.00017877723],"about_ca_topic_score_codex":0.00021440581,"about_ca_topic_score_gemma":0.00058882183,"teacher_disagreement_score":0.043200742,"about_ca_system_score_codex":0.00009055176,"about_ca_system_score_gemma":0.0004951823,"threshold_uncertainty_score":0.5834657},"labels":[],"label_agreement":null},{"id":"W2895789306","doi":"10.1093/annonc/mdy304.002","title":"Single-cell RNA sequencing of triple negative breast cancer patient-derived xenograft reveals distinct cellular populations spatially mapped to histological sections","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre; Jewish General Hospital; McGill University Health Centre; McGill University","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Cancer research; Multiplex; Cell; Single-cell analysis; Population; Cancer; Oncology; Pathology; Biology; Internal medicine; Bioinformatics; Genetics","score_opus":0.08308218603239081,"score_gpt":0.31714359277965276,"score_spread":0.23406140674726195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895789306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911387,0.00017163591,0.003755273,0.00075539475,0.0006209334,0.0003639499,0.00030472755,0.000016247712,0.0028731516],"genre_scores_gemma":[0.99610347,0.000038774862,0.0027028166,0.0005699171,0.00027094985,0.000033767,0.000090890455,0.000024763653,0.00016464361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832696,0.00019733777,0.00059983897,0.00038849577,0.00014294911,0.0003444309],"domain_scores_gemma":[0.9984583,0.00003681639,0.00038999724,0.0002962506,0.00066677586,0.00015185682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016696236,0.00020580266,0.0004271354,0.00010913993,0.0001404963,0.0000076005854,0.00021232919,0.00027855264,0.00011211644],"category_scores_gemma":[0.00015051551,0.00019759551,0.00018136272,0.00023427822,0.00032737624,0.000008327197,0.00007369547,0.00011446051,0.0000051289876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047203343,0.00044634656,0.0028191912,0.000026015638,0.00006692522,0.0000037914936,0.0005971299,0.00010385789,0.9857851,0.00003023084,0.0016482094,0.008001129],"study_design_scores_gemma":[0.0007421742,0.0047393204,0.005395811,0.000032445452,0.00005633911,0.000011968073,0.00018599679,0.00005504867,0.983282,0.00021017804,0.0050521903,0.00023652446],"about_ca_topic_score_codex":0.0012923279,"about_ca_topic_score_gemma":0.0022650654,"teacher_disagreement_score":0.007764605,"about_ca_system_score_codex":0.00007041882,"about_ca_system_score_gemma":0.00024441574,"threshold_uncertainty_score":0.8057711},"labels":[],"label_agreement":null},{"id":"W2895829368","doi":"10.1093/annonc/mdy299.014","title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Tolerability; Epithelioid sarcoma; Internal medicine; Clinical endpoint; Oncology; Interim analysis; Response Evaluation Criteria in Solid Tumors; Sarcoma; Phases of clinical research; Cohort; Adverse effect; Clinical trial; Surgery; Pathology; Immunohistochemistry","score_opus":0.029151433921987394,"score_gpt":0.36191841412841536,"score_spread":0.332766980206428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895829368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970931,0.00050692464,0.00003335879,0.00032079045,0.00025123704,0.0006034097,0.000028844961,0.000002781486,0.0011596007],"genre_scores_gemma":[0.9990486,0.00024180657,0.00014654355,0.00024279929,0.00017750758,0.000027708567,0.000016859056,0.000014307515,0.00008386778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986009,0.0002501841,0.00049690076,0.00028360114,0.00015074298,0.00021768008],"domain_scores_gemma":[0.99885684,0.00003512468,0.0002896912,0.00042582778,0.0003455776,0.0000469314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005093836,0.00012903594,0.00026815137,0.00008153184,0.000057466223,0.0000029738776,0.00024594326,0.00015876691,0.000027203878],"category_scores_gemma":[0.00022965178,0.0000988361,0.00008748248,0.00017046626,0.00020923435,0.00000407056,0.0002389881,0.000089350586,0.0000024186654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021289745,0.010306842,0.18895377,0.000034417648,0.00016175884,0.000004556638,0.0024628511,0.000021276575,0.7380037,0.00001793915,0.0010371533,0.05686676],"study_design_scores_gemma":[0.0073723765,0.034997243,0.052845176,0.000043382224,0.000028936365,8.420027e-7,0.0006843609,0.00009137304,0.8755042,0.00008182092,0.028199028,0.0001512664],"about_ca_topic_score_codex":0.00016846284,"about_ca_topic_score_gemma":0.0009896164,"teacher_disagreement_score":0.1375005,"about_ca_system_score_codex":0.000009433417,"about_ca_system_score_gemma":0.0000880001,"threshold_uncertainty_score":0.4030419},"labels":[],"label_agreement":null},{"id":"W2895872316","doi":"10.1093/annonc/mdy281.157","title":"Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; European Regional Development Fund; Engineering and Physical Sciences Research Council; Agència de Gestió d'Ajuts Universitaris i de Recerca; Canadian Institutes of Health Research; Knut och Alice Wallenbergs Stiftelse; Koning Boudewijnstichting; Cancer Research Foundation in Northern Sweden; Generalitat de Catalunya; Umeå Universitet; Vetenskapsrådet; Fondation contre le Cancer; Cancerfonden; McGill University","keywords":"Medicine; Chimeric antigen receptor; NKG2D; FOLFOX; Colorectal cancer; Oncology; Internal medicine; Clinical trial; Context (archaeology); Tumor microenvironment; Bevacizumab; Immunotherapy; Cancer; Chemotherapy; Oxaliplatin; Cytotoxic T cell","score_opus":0.335728840455008,"score_gpt":0.5838037167005191,"score_spread":0.2480748762455111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895872316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935714,0.0022770294,0.000022762244,0.0030393768,0.00011246256,0.000613624,0.00003712291,0.0000060759703,0.00032015145],"genre_scores_gemma":[0.99437225,0.0048953365,0.0002274798,0.0003389711,0.00008630239,0.00002815774,0.0000023242544,0.0000141585,0.00003501972],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977375,0.0008876074,0.00062805373,0.00022959009,0.00026404756,0.00025319326],"domain_scores_gemma":[0.99412376,0.0046284464,0.00039427803,0.0002318884,0.00055519573,0.000066452056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025557827,0.00013112887,0.0010296467,0.00013993523,0.000048058322,0.000003307859,0.000118534306,0.00010132955,0.00018650484],"category_scores_gemma":[0.0012563538,0.00008457244,0.00014814397,0.00029654853,0.0019604168,0.00005978351,0.00007065877,0.0002648133,3.9619817e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015455915,0.0039903237,0.109805,0.00016284118,0.0010036579,0.000022385106,0.0018042129,0.0000068613153,0.41973713,0.000008792039,0.00021059132,0.4477923],"study_design_scores_gemma":[0.027678214,0.029441101,0.27376315,0.00027350785,0.00018738717,0.000014064703,0.0023368855,0.0023283262,0.65744853,0.000090013025,0.0062821163,0.00015672712],"about_ca_topic_score_codex":0.0012396506,"about_ca_topic_score_gemma":0.0026279066,"teacher_disagreement_score":0.44763556,"about_ca_system_score_codex":0.000052894065,"about_ca_system_score_gemma":0.0007919082,"threshold_uncertainty_score":0.7223237},"labels":[],"label_agreement":null},{"id":"W2895876062","doi":"10.1093/annonc/mdy289.011","title":"Impact of intralesional interleukin 2 (IL2) for in-transit melanoma in two Canadian centres","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of British Columbia, Okanagan Campus; University of British Columbia; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Surgery; Refractory (planetary science); Head and neck; Demographics; Stage (stratigraphy); Internal medicine; Demography","score_opus":0.05269668447394214,"score_gpt":0.4047585645953829,"score_spread":0.35206188012144074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895876062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879397,0.000053406013,0.000027015074,0.0030141834,0.00016388544,0.0003753737,0.000026070858,0.000005047924,0.008395304],"genre_scores_gemma":[0.99879175,0.00003649936,0.00020887474,0.000605493,0.0000935017,0.000010922988,0.000012648638,0.000008223398,0.00023210456],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991562,0.000039964347,0.0003269031,0.00013817627,0.000069322705,0.0002694272],"domain_scores_gemma":[0.9994656,0.00007946514,0.00007814855,0.00011893822,0.00013129816,0.00012657605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002146177,0.00008231595,0.00033258728,0.00049291184,0.000011893448,0.0000017444286,0.000071210525,0.00006861751,0.00050067424],"category_scores_gemma":[0.00008363676,0.00007286251,0.000108201646,0.00013247249,0.00010152871,0.000023593977,0.000013784268,0.000078585945,0.000008494049],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015617082,0.0026464968,0.4331909,0.00039501165,0.0007335224,0.0010647221,0.0062327087,0.00015390481,0.028958846,0.0036031988,0.058134973,0.4492686],"study_design_scores_gemma":[0.007932142,0.022983802,0.8229878,0.00026078464,0.000059097598,0.00029172213,0.00053141796,0.00072097545,0.019592058,0.0011215059,0.12327784,0.0002408274],"about_ca_topic_score_codex":0.073259175,"about_ca_topic_score_gemma":0.61748517,"teacher_disagreement_score":0.544226,"about_ca_system_score_codex":0.00017064792,"about_ca_system_score_gemma":0.00042544986,"threshold_uncertainty_score":0.93291205},"labels":[],"label_agreement":null},{"id":"W2895953025","doi":"10.1093/annonc/mdy287.008","title":"Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Head and neck cancer; Hazard ratio; Proportional hazards model; Oncology; Cancer; Relative risk; Confidence interval","score_opus":0.12142193033817274,"score_gpt":0.43603747809655263,"score_spread":0.3146155477583799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895953025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459434,0.00066825305,0.0000020035714,0.0009437314,0.000150901,0.000253693,0.000025072497,0.0000035307696,0.003358501],"genre_scores_gemma":[0.99765843,0.0020378435,0.000027799286,0.00013399248,0.00006198232,0.000029388317,0.0000040465384,0.000005129773,0.000041363346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937755,0.000098107084,0.00022198552,0.00012962629,0.00006852058,0.000104233804],"domain_scores_gemma":[0.999252,0.00023207921,0.000106368316,0.0001082462,0.0002684911,0.000032797416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022628083,0.0000716,0.0005636301,0.000078886595,0.000009258812,3.2752453e-7,0.000022693153,0.00006554199,0.000013193748],"category_scores_gemma":[0.000086503445,0.000053723244,0.000035968897,0.0000734425,0.00019800517,0.000016311371,0.0000143106745,0.000037107246,6.6605895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015773036,0.0022390888,0.7757311,0.0010159814,0.00051581697,0.00001053359,0.0041414625,0.000007407363,0.09042491,0.0013981127,0.0007303971,0.10801219],"study_design_scores_gemma":[0.0031683913,0.027453097,0.90784675,0.0005646834,0.000030293022,0.0000014580395,0.00006771703,0.000021386404,0.057583097,0.00010834217,0.0031194326,0.000035355297],"about_ca_topic_score_codex":0.0020841586,"about_ca_topic_score_gemma":0.0011065857,"teacher_disagreement_score":0.13211568,"about_ca_system_score_codex":0.00007834799,"about_ca_system_score_gemma":0.00016932064,"threshold_uncertainty_score":0.31506383},"labels":[],"label_agreement":null},{"id":"W2895961390","doi":"10.1093/annonc/mdy279.399","title":"Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Bromodomain; Pharmacokinetics; Pharmacodynamics; Cancer; Internal medicine; Pharmacology; Mucositis; Gastroenterology; Toxicity; Oncology","score_opus":0.06594714153376163,"score_gpt":0.4142067863036477,"score_spread":0.3482596447698861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895961390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807256,0.000097814336,0.000019736868,0.00024700878,0.00019662734,0.00089888275,0.0002364124,0.0000033234855,0.00022761452],"genre_scores_gemma":[0.9981949,0.000030428944,0.0009044939,0.00023372313,0.0004032285,0.000082229795,0.0001154562,0.0000128543525,0.000022730717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845856,0.00033827126,0.00048292943,0.00033540837,0.00019315773,0.00019168033],"domain_scores_gemma":[0.9988849,0.000032436874,0.00044839468,0.00028436593,0.00028793517,0.000061948434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044679656,0.00013588025,0.00025995242,0.000048846854,0.00005508518,0.0000063922503,0.00016478858,0.00017436703,0.00001685566],"category_scores_gemma":[0.0004132174,0.00009984243,0.000043375385,0.00010436531,0.00033900348,0.00001802393,0.00009011577,0.00009841502,3.6789996e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15745538,0.0017409514,0.0018054441,0.00002188685,0.00006310093,0.0000036067236,0.00073661294,0.0000072303164,0.5728343,0.00001674787,0.0005322018,0.26478252],"study_design_scores_gemma":[0.07877342,0.046635356,0.005083319,0.00013305142,0.000022107015,0.0000019286874,0.00010128548,0.000082840015,0.8651012,0.00010267181,0.0037788402,0.00018396824],"about_ca_topic_score_codex":0.0002595747,"about_ca_topic_score_gemma":0.00082200527,"teacher_disagreement_score":0.2922669,"about_ca_system_score_codex":0.0000151030645,"about_ca_system_score_gemma":0.00033910124,"threshold_uncertainty_score":0.40714562},"labels":[],"label_agreement":null},{"id":"W2895976669","doi":"10.1093/annonc/mdy299.053","title":"Return to work and quality of life in disease-free adult sarcoma patients","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcoma; Quality of life (healthcare); Multivariate analysis; Univariate analysis; Disease; Soft tissue sarcoma; Young adult; Gerontology; Physical therapy; Internal medicine; Pathology","score_opus":0.10382857375351459,"score_gpt":0.3970944565385164,"score_spread":0.29326588278500176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895976669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482376,0.0004885663,8.7272855e-7,0.01331362,0.00006516402,0.00028993504,0.000029357016,0.0000054472307,0.0009832723],"genre_scores_gemma":[0.9953144,0.00011146218,0.0003018185,0.0041638166,0.00005139832,0.000024420644,0.000009011675,0.000006796028,0.000016869099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903846,0.00009922646,0.00038782303,0.00016943639,0.00014559345,0.00015945874],"domain_scores_gemma":[0.9988021,0.00022078143,0.0001334293,0.0003045681,0.00031684779,0.00022223374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001976623,0.00008141373,0.00043172247,0.000095018,0.000012929769,0.0000013675126,0.00007242764,0.000065308566,0.00004735998],"category_scores_gemma":[0.0013519658,0.00006538087,0.000054667376,0.00016070149,0.00012844433,0.00002145864,0.00008674672,0.000047187383,0.000006411971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017667706,0.0019273463,0.96264035,0.000048149162,0.00004825948,0.000010124657,0.00038326107,6.949956e-8,0.000021159723,0.00035677216,0.0055136895,0.02728404],"study_design_scores_gemma":[0.0030705943,0.0027832494,0.9894273,0.00009989369,0.000022798673,2.8096864e-7,0.00004188385,8.4721506e-7,0.00042240764,0.00035150273,0.0037278973,0.000051300365],"about_ca_topic_score_codex":0.00027967754,"about_ca_topic_score_gemma":0.00038675888,"teacher_disagreement_score":0.02723274,"about_ca_system_score_codex":0.000020688996,"about_ca_system_score_gemma":0.0000815723,"threshold_uncertainty_score":0.26661542},"labels":[],"label_agreement":null},{"id":"W2896013468","doi":"10.1093/annonc/mdy270.241","title":"Toxicity and clinical outcomes of partial breast irradiation (PBI) compared to whole breast irradiation (WBI) for early stage breast cancer: A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Odds ratio; Brachytherapy; Subgroup analysis; Oncology; Internal medicine; Radiation therapy; Confidence interval; Cancer; Surgery","score_opus":0.18407881094642062,"score_gpt":0.47451337793333925,"score_spread":0.2904345669869186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896013468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010795888,0.98065317,0.0000684709,0.0022200986,0.00008235223,0.0028939706,0.012978715,0.00001195385,0.0000116668025],"genre_scores_gemma":[0.010899065,0.9862468,0.000177699,0.00075186515,0.00014601953,0.0011388677,0.0004973247,0.00004980964,0.000092525595],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960423,0.0007466483,0.0018956899,0.00078216475,0.00020101547,0.00033215285],"domain_scores_gemma":[0.9961031,0.00033172072,0.0021080945,0.0006166547,0.0006470229,0.00019339868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001172952,0.00052435,0.007816555,0.00018792547,0.00007068747,0.000018013763,0.00026325285,0.00041416317,0.000020847701],"category_scores_gemma":[0.00017683757,0.00038182392,0.0018706991,0.00032155885,0.00025880671,0.000014169682,0.00018606297,0.000105559826,0.0000022609884],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050335337,0.0014383489,0.009084465,0.42097324,0.5255945,0.0000035607475,0.00017775071,0.0000069296752,0.0000057717048,0.000052603125,0.004020103,0.038139414],"study_design_scores_gemma":[0.0013679066,0.0014870678,0.05755106,0.004689638,0.8894016,0.00012811634,0.00003761962,0.000010348436,0.000006123275,0.000010490163,0.0445317,0.0007783455],"about_ca_topic_score_codex":0.00048550035,"about_ca_topic_score_gemma":0.0007779455,"teacher_disagreement_score":0.4162836,"about_ca_system_score_codex":0.000051605326,"about_ca_system_score_gemma":0.00029059034,"threshold_uncertainty_score":0.9998634},"labels":[],"label_agreement":null},{"id":"W2896068855","doi":"10.1093/annonc/mdy288.114","title":"Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Microsatellite instability; Blockade; Internal medicine; Colorectal cancer; Oncology; Cancer research; Cancer; Phases of clinical research; Receptor; Clinical trial; Adverse effect; Biology; Microsatellite","score_opus":0.024037371716843267,"score_gpt":0.3505419665554048,"score_spread":0.32650459483856153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896068855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919605,0.003821044,0.000013456613,0.00014836002,0.00025826987,0.0031424668,0.00041011782,0.000028987857,0.0002167518],"genre_scores_gemma":[0.99628156,0.002263613,0.00020825388,0.00057120254,0.00004068079,0.00032751026,0.00006018344,0.00010799912,0.0001390104],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624074,0.00027429173,0.0011933843,0.0008962209,0.00045516837,0.00094020413],"domain_scores_gemma":[0.99766684,0.00013253198,0.0009949673,0.0004316471,0.00056546205,0.00020857276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005091555,0.00060753606,0.0020264809,0.0005893156,0.00010594258,0.00001933849,0.00025426495,0.00021195126,0.00015733982],"category_scores_gemma":[0.000024223096,0.00047009613,0.00010503188,0.0012219781,0.00061886356,0.0002316812,0.0000829419,0.00033548503,0.0000011907164],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05789696,0.0077640754,0.54806066,0.00059606216,0.0011574139,0.00016798475,0.012603216,0.00037853673,0.3588261,2.9333256e-7,0.0010418633,0.011506816],"study_design_scores_gemma":[0.14053494,0.06630923,0.16968274,0.0029734715,0.0007361735,0.000022163691,0.0053837704,0.001153984,0.6109263,0.0000016861666,0.001240004,0.0010355813],"about_ca_topic_score_codex":0.02957386,"about_ca_topic_score_gemma":0.03313514,"teacher_disagreement_score":0.37837794,"about_ca_system_score_codex":0.00057127385,"about_ca_system_score_gemma":0.0016518573,"threshold_uncertainty_score":0.99977505},"labels":[],"label_agreement":null},{"id":"W2896232608","doi":"10.1093/annonc/mdy359","title":"Three cases of venous thromboembolism in advanced cancer patients","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; FOLFIRI; Pulmonary embolism; Thrombus; Bevacizumab; Chemotherapy; Asymptomatic; Colorectal cancer; Surgery; Cancer; Radiology; Internal medicine; Irinotecan","score_opus":0.0717866359074801,"score_gpt":0.3990621738072908,"score_spread":0.3272755378998107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896232608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862691,0.00059367035,0.0000074278023,0.0013461158,0.00038283668,0.00048004108,0.000021013962,0.0000124623175,0.01088729],"genre_scores_gemma":[0.9967194,0.001183174,0.00026325238,0.0016094835,0.00012507642,0.00004997565,0.00000938901,0.000016528074,0.000023691184],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988348,0.000030553158,0.0004411331,0.00021399934,0.00018513849,0.00029441604],"domain_scores_gemma":[0.99893254,0.00009095165,0.0002529863,0.00025070237,0.0004024467,0.00007038074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018166924,0.00012121139,0.00089371984,0.00017890794,0.000025228046,0.0000014402958,0.00011645554,0.0001077357,0.0003118471],"category_scores_gemma":[0.00014299282,0.000107959146,0.00008444994,0.00021703055,0.00023460254,0.00005770798,0.000083199404,0.00008736777,0.000015187268],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010527542,0.019172689,0.21242465,0.000574357,0.00059894845,0.00013834868,0.0033740257,0.000034596083,0.003936476,0.0041244063,0.03570908,0.7188597],"study_design_scores_gemma":[0.0021012072,0.013773744,0.9449569,0.00022656957,0.00009243038,0.000003840329,0.00012346821,0.000014447075,0.010700968,0.00082851766,0.027067795,0.00011010552],"about_ca_topic_score_codex":0.0017124551,"about_ca_topic_score_gemma":0.0029523156,"teacher_disagreement_score":0.73253226,"about_ca_system_score_codex":0.000044705044,"about_ca_system_score_gemma":0.00016298982,"threshold_uncertainty_score":0.44024462},"labels":[],"label_agreement":null},{"id":"W2896260190","doi":"10.1093/annonc/mdy281.131","title":"Clinical benefit of whole genome and transcriptome analysis (WGTA) in metastatic colorectal cancer (MCRC): Results from the personalized oncogenomics program (POG)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Concordance; Regorafenib; Oncology; PDGFRA; Internal medicine; Bevacizumab; Transcriptome; Trametinib; Cancer; Bioinformatics; Chemotherapy; Gene; Genetics; Gene expression; Stromal cell","score_opus":0.06606040137371953,"score_gpt":0.3995727697867605,"score_spread":0.33351236841304094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896260190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917693,0.0037354226,0.000050849234,0.0014759508,0.00013185332,0.0003675599,0.0021109537,0.000003472078,0.000354625],"genre_scores_gemma":[0.9913281,0.005860522,0.0013173489,0.000763993,0.00024736472,0.000051888765,0.0003682609,0.000015207082,0.000047303634],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832,0.0001501217,0.0007557017,0.0004126655,0.00010504888,0.00025645853],"domain_scores_gemma":[0.9986695,0.00030685178,0.00037019688,0.0002883101,0.00027547873,0.000089660665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007434717,0.0001536781,0.00060153444,0.000077948614,0.000044776614,0.000010585347,0.0002598106,0.00018669234,0.000027724289],"category_scores_gemma":[0.00023979954,0.00012715394,0.00024911694,0.00027306026,0.00078005774,0.0000038753014,0.00010094743,0.00011495083,0.0000012954492],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0138883265,0.0028661161,0.118682474,0.00006857681,0.008092269,0.000028425351,0.0053589963,0.000876032,0.6024182,0.00046556402,0.0029049038,0.24435017],"study_design_scores_gemma":[0.009593701,0.0149193555,0.4488711,0.000044239754,0.001763157,0.000007430524,0.0009905318,0.0011537321,0.034465846,0.0009373982,0.48666674,0.0005867503],"about_ca_topic_score_codex":0.0016127547,"about_ca_topic_score_gemma":0.014971651,"teacher_disagreement_score":0.56795233,"about_ca_system_score_codex":0.000019059285,"about_ca_system_score_gemma":0.00030200745,"threshold_uncertainty_score":0.8354533},"labels":[],"label_agreement":null},{"id":"W2896329990","doi":"10.1093/annonc/mdy419","title":"Developing prognostic models for advanced prostate cancer when the goal line keeps changing","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Docetaxel; Internal medicine; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.18683034033751908,"score_gpt":0.44791591836440925,"score_spread":0.26108557802689014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896329990","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005990101,0.007236144,0.0008990861,0.9798727,0.000640895,0.004052148,0.00027887794,0.0000489387,0.0009811192],"genre_scores_gemma":[0.008276531,0.0141494125,0.008460437,0.9112416,0.0111899115,0.0068951654,0.0018447059,0.00025860302,0.03768367],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975874,0.000100408695,0.00047688873,0.00048225568,0.00035839755,0.0009946399],"domain_scores_gemma":[0.9975177,0.0005173371,0.00036720914,0.000357051,0.0011649573,0.00007576264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053587224,0.00032864514,0.0008422885,0.00028953658,0.00017750471,0.00001582817,0.00028350294,0.000556584,0.000058845555],"category_scores_gemma":[0.00016550429,0.00020431464,0.00021528486,0.00022170595,0.00036563879,0.00009118421,0.00014912186,0.0007581042,0.000009919914],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018410258,0.0001081613,0.00014463584,0.0018454159,0.0009544424,0.00022581333,0.0026318692,0.000046279467,0.00016137588,0.000114691014,0.8926061,0.09932023],"study_design_scores_gemma":[0.0026804106,0.0037282973,0.000032571883,0.001085687,0.000249799,0.000029699242,0.00012139899,0.00065971195,0.0028129572,0.0059416327,0.98240936,0.00024848751],"about_ca_topic_score_codex":0.000053002517,"about_ca_topic_score_gemma":0.00003356898,"teacher_disagreement_score":0.09907175,"about_ca_system_score_codex":0.00023578633,"about_ca_system_score_gemma":0.0019246878,"threshold_uncertainty_score":0.8331709},"labels":[],"label_agreement":null},{"id":"W2896410911","doi":"10.1093/annonc/mdy288.113","title":"Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer research; T-cell receptor; Cytotoxic T cell; Immunology; Epitope; Viral vector; Antigen; Cancer immunotherapy; Genetic enhancement; T cell; Immunotherapy; Immune system; Biology; Gene; In vitro","score_opus":0.0837797317816706,"score_gpt":0.3920301412292962,"score_spread":0.3082504094476256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896410911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932715,0.00013742346,0.0000043103273,0.0003927158,0.00012215212,0.0012065792,0.0000120686755,0.000022460037,0.004830743],"genre_scores_gemma":[0.9988892,0.0000956295,0.00017552705,0.00027493315,0.00012629437,0.000033582564,0.00001644619,0.000038509163,0.0003498815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755883,0.00027927826,0.0007073803,0.00040531784,0.0005242588,0.0005249085],"domain_scores_gemma":[0.99818355,0.00018128351,0.00024885868,0.0005442812,0.0006899263,0.00015213],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063683884,0.00020296907,0.0010119566,0.00042712546,0.000037759197,0.000003790026,0.00025241196,0.00016721468,0.0010459754],"category_scores_gemma":[0.00007422367,0.00016459273,0.00008410921,0.0005484042,0.00045726198,0.000053439326,0.000057755722,0.00022708494,0.000027366952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0357207,0.02508784,0.62511873,0.00015550946,0.00081849546,0.0007674985,0.016054396,0.000035490695,0.08464807,0.000033780187,0.002762161,0.2087973],"study_design_scores_gemma":[0.019957637,0.08545036,0.78665894,0.00007751701,0.000044513148,0.00004152019,0.0010981237,0.000024743056,0.10292849,0.00003552289,0.0034927095,0.00018990085],"about_ca_topic_score_codex":0.00026003455,"about_ca_topic_score_gemma":0.00034031586,"teacher_disagreement_score":0.2086074,"about_ca_system_score_codex":0.00014327058,"about_ca_system_score_gemma":0.00050494383,"threshold_uncertainty_score":0.9998672},"labels":[],"label_agreement":null},{"id":"W2896515906","doi":"10.1093/annonc/mdy283.073","title":"Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Bladder cancer; Cystectomy; Internal medicine; Population; Urology; Carcinoma in situ; Oncology; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy","score_opus":0.08749010236186354,"score_gpt":0.4272855037666303,"score_spread":0.3397954014047668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896515906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97845733,0.00035297056,0.0004905753,0.01123631,0.0016612335,0.0033493128,0.0011510047,0.000051402683,0.0032498592],"genre_scores_gemma":[0.9829476,0.00046264852,0.0009764859,0.009698306,0.0025438073,0.0009966645,0.00007357881,0.00007451245,0.0022264202],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972311,0.00020593368,0.000720816,0.0007018384,0.0003612232,0.0007790802],"domain_scores_gemma":[0.9967601,0.0006100464,0.00039860338,0.00059067894,0.0011706206,0.0004699796],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042853242,0.00039782198,0.0011700289,0.00032361867,0.00027686474,0.00001227163,0.00026151966,0.00037778734,0.0012430743],"category_scores_gemma":[0.000954486,0.0003410834,0.00033078392,0.00038523547,0.00034587106,0.00011140432,0.00015407302,0.00025337783,0.00011692777],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30508944,0.0041975225,0.00022306849,0.00009468186,0.0017958479,0.0001455388,0.0037975141,0.000016867692,0.013185293,0.00020190475,0.14250216,0.5287502],"study_design_scores_gemma":[0.2507233,0.3397396,0.004255801,0.00014500815,0.0012702874,0.00003528695,0.00038920552,0.000031433763,0.13266794,0.0010730927,0.26910695,0.00056209817],"about_ca_topic_score_codex":0.0036665108,"about_ca_topic_score_gemma":0.0021754978,"teacher_disagreement_score":0.52818805,"about_ca_system_score_codex":0.00023361138,"about_ca_system_score_gemma":0.002129263,"threshold_uncertainty_score":0.9999041},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2896725950","doi":"10.1093/annonc/mdy288.094","title":"Potential drug cost impact of dual agent immunotherapy (DAIO) with nivolumab (N) plus ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care South East; Queen's University","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Colorectal cancer; Oncology; Internal medicine; Context (archaeology); Immunotherapy; Cancer","score_opus":0.15390602535463963,"score_gpt":0.41190672512980725,"score_spread":0.2580006997751676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896725950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945961,0.0007277914,0.000039882867,0.00197969,0.0003416926,0.0012283344,0.0006760611,0.000010273115,0.00040013262],"genre_scores_gemma":[0.99788654,0.00011422907,0.00039543174,0.0012907285,0.000048321057,0.00013688598,0.00004307865,0.00003517355,0.000049625498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516034,0.00043966458,0.0030709736,0.0005114768,0.00019979203,0.000617733],"domain_scores_gemma":[0.9962821,0.00038056946,0.0025091032,0.00037770477,0.00030876268,0.00014176084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039980053,0.0002570363,0.0016113314,0.00043203315,0.00006783608,0.00001101525,0.00024237005,0.00009204177,0.00038393075],"category_scores_gemma":[0.00022082946,0.0002528626,0.00012490345,0.00040586444,0.0002285045,0.00021290164,0.000044061126,0.00018460093,0.000021714102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034884254,0.0011147124,0.96736264,0.00021632812,0.0005822668,0.000018712828,0.0056677903,0.009959727,0.000013609005,0.00035031946,0.01004865,0.0011768201],"study_design_scores_gemma":[0.009866446,0.0039689303,0.97749573,0.0001500466,0.00001520696,0.0000062984436,0.0014756195,0.0044924947,0.0000869076,0.00016692356,0.0018962888,0.00037908147],"about_ca_topic_score_codex":0.8259438,"about_ca_topic_score_gemma":0.89951485,"teacher_disagreement_score":0.07357102,"about_ca_system_score_codex":0.0034969933,"about_ca_system_score_gemma":0.005155983,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W2896753349","doi":"10.1093/annonc/mdy299.011","title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Adverse effect; SMARCA4; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Clinical trial","score_opus":0.026935297379988562,"score_gpt":0.3615123025811358,"score_spread":0.33457700520114725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896753349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975716,0.00024523062,0.000011062514,0.00026320768,0.0002807785,0.000477533,0.000026275009,0.000004164279,0.001120138],"genre_scores_gemma":[0.99886507,0.00006109196,0.000097133125,0.0006004005,0.00021043366,0.00003125213,0.000009517857,0.000013695041,0.00011143281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987531,0.00014944699,0.0004496578,0.00028533308,0.0001413408,0.00022117877],"domain_scores_gemma":[0.9989754,0.00002070262,0.00026453374,0.00040303552,0.00029217798,0.000044158296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032403084,0.00012804221,0.00028013787,0.000048321443,0.00005269555,0.000002485245,0.0002508591,0.00010561526,0.000035737878],"category_scores_gemma":[0.00016481343,0.00009614862,0.00009305647,0.00012780596,0.000201324,0.0000034007332,0.0002185488,0.00009340498,0.000002442565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007151076,0.023376936,0.07136084,0.00015728427,0.00042554838,0.000019663874,0.0066683018,0.00014590155,0.7930218,0.000016265933,0.024302673,0.073353685],"study_design_scores_gemma":[0.01975826,0.055512328,0.013666355,0.00020706803,0.00006629097,0.000010125912,0.0024886827,0.0010121898,0.8662306,0.00004671867,0.04065615,0.00034519495],"about_ca_topic_score_codex":0.00026595552,"about_ca_topic_score_gemma":0.0010823639,"teacher_disagreement_score":0.07320882,"about_ca_system_score_codex":0.000013876033,"about_ca_system_score_gemma":0.0001497913,"threshold_uncertainty_score":0.39208272},"labels":[],"label_agreement":null},{"id":"W2896783336","doi":"10.1093/annonc/mdy283.088","title":"Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Cabozantinib; Renal cell carcinoma; Internal medicine; Immune checkpoint; Oncology; Surgery; Cancer; Urology; Gastroenterology; Immunotherapy","score_opus":0.06585146620734529,"score_gpt":0.33995755899635066,"score_spread":0.2741060927890054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896783336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766954,0.0015404775,0.000016563165,0.001263202,0.0001844754,0.0007439514,0.000040857933,0.000020658917,0.019494385],"genre_scores_gemma":[0.99680245,0.00017771035,0.0014112712,0.0002878323,0.00016053233,0.0000651002,0.000018190149,0.000056248376,0.0010206468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99678713,0.00040121112,0.0010918104,0.00057363557,0.00043661092,0.0007095863],"domain_scores_gemma":[0.99753314,0.00027379263,0.00069173373,0.0008056224,0.00044951675,0.00024616538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008416252,0.00039321894,0.0014574948,0.00043901283,0.00004084423,0.000006189882,0.00023882545,0.00026330366,0.0007363819],"category_scores_gemma":[0.00010190299,0.00033947465,0.00042863714,0.00042980874,0.00056227064,0.000104359424,0.00020096134,0.00043386375,0.00011015762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012462599,0.004943819,0.029090328,0.0007254142,0.00021986957,0.0012698765,0.0021035173,0.000010222646,0.94071394,0.000012935768,0.00058528356,0.0078621805],"study_design_scores_gemma":[0.003667945,0.010328347,0.3113095,0.00006948774,0.00020637976,0.000070094495,0.0001508356,0.00007043489,0.6711085,0.000045838024,0.002800353,0.0001722991],"about_ca_topic_score_codex":0.0019399842,"about_ca_topic_score_gemma":0.0002616632,"teacher_disagreement_score":0.28221917,"about_ca_system_score_codex":0.0001289474,"about_ca_system_score_gemma":0.00057483686,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W2896903565","doi":"10.1093/annonc/mdy283.083","title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Randomization; Adverse effect; Intention-to-treat analysis; Randomized controlled trial; Surgery; Ipilimumab; Interim analysis; Gastroenterology; Cancer; Immunotherapy","score_opus":0.0451959082111775,"score_gpt":0.34429111020888037,"score_spread":0.2990952019977029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896903565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968029,0.00017620271,0.00007080464,0.00065610034,0.000114402705,0.0005192047,0.000057121753,0.000020184538,0.0015830236],"genre_scores_gemma":[0.9985434,0.00011808434,0.0005040512,0.00013851038,0.000061826424,0.00003871274,0.00015209959,0.00002848439,0.0004148711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982629,0.00011187238,0.0007289187,0.0003230107,0.00024700022,0.0003262889],"domain_scores_gemma":[0.99850017,0.00013278174,0.00050370704,0.0004892227,0.00029957198,0.000074547104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026218322,0.0002210942,0.00095127255,0.00043746273,0.000043550815,0.0000052868045,0.00018162736,0.00013327067,0.00015990302],"category_scores_gemma":[0.00009024207,0.00015744132,0.0003285045,0.0007748575,0.00022868709,0.00012159694,0.000055913857,0.000090317124,0.0000018074417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19925779,0.00621741,0.48222926,0.00021212816,0.0037908335,0.00015503909,0.006753622,0.00009530957,0.0072760927,0.000009756213,0.00053063856,0.29347214],"study_design_scores_gemma":[0.10246202,0.12907197,0.66140485,0.0003742794,0.0018633369,0.000010567595,0.0013243555,0.0011247296,0.09570702,0.000024575422,0.0061969804,0.00043530305],"about_ca_topic_score_codex":0.0013494783,"about_ca_topic_score_gemma":0.012517913,"teacher_disagreement_score":0.29303682,"about_ca_system_score_codex":0.0002637106,"about_ca_system_score_gemma":0.00031276463,"threshold_uncertainty_score":0.69852895},"labels":[],"label_agreement":null},{"id":"W2897008012","doi":"10.1093/annonc/mdy283.098","title":"Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Axitinib; Pazopanib; Sunitinib; Temsirolimus; Sorafenib; Everolimus; Cabozantinib; Discontinuation; Internal medicine; Hazard ratio; Oncology; Renal cell carcinoma; Tyrosine-kinase inhibitor; Lenvatinib; Urology; Cancer; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; Confidence interval; Discovery and development of mTOR inhibitors","score_opus":0.03005668430230609,"score_gpt":0.3013022353966353,"score_spread":0.27124555109432924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897008012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957409,0.0007173082,0.000012665472,0.0004347445,0.00044948628,0.001741401,0.0003912172,0.00003437385,0.00047789942],"genre_scores_gemma":[0.994845,0.00013238618,0.003922252,0.00021603476,0.00033132892,0.00011219161,0.00018373365,0.00011780921,0.00013931045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941146,0.00083194184,0.0024454002,0.0009433178,0.0008661694,0.00079856964],"domain_scores_gemma":[0.9945126,0.00063955033,0.0017942002,0.00077564426,0.0017320284,0.0005459489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008864837,0.00079361047,0.002932377,0.0006242049,0.000080900085,0.0000106755315,0.0002338314,0.00051458925,0.00030653892],"category_scores_gemma":[0.00034254327,0.0005308045,0.0006119322,0.00056152296,0.0019424295,0.00020787364,0.00018921867,0.00046070354,0.000012231693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01576863,0.0049041696,0.94998294,0.00045096866,0.0012591919,0.0002276057,0.001205636,0.0000013114264,0.022566475,0.0000089573605,0.000630004,0.0029941385],"study_design_scores_gemma":[0.013830646,0.050920814,0.50884277,0.00015729427,0.00074003654,0.000018009396,0.00021904329,0.0000022386935,0.4229226,0.000014151959,0.0020031915,0.00032917171],"about_ca_topic_score_codex":0.0007663178,"about_ca_topic_score_gemma":0.0001323548,"teacher_disagreement_score":0.44114012,"about_ca_system_score_codex":0.00025728028,"about_ca_system_score_gemma":0.0007912469,"threshold_uncertainty_score":0.9997144},"labels":[],"label_agreement":null},{"id":"W2897022880","doi":"10.1093/annonc/mdy286.002","title":"Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Janssen Research and Development; Bayer","keywords":"Medicine; Internal medicine; Adverse effect; Nausea; Phases of clinical research; Gastroenterology; Lymphoma; Common Terminology Criteria for Adverse Events; Pneumonitis; Clinical endpoint; Tolerability; Follicular lymphoma; Refractory (planetary science); Rituximab; Bendamustine; Surgery; Chemotherapy; Clinical trial; Lung","score_opus":0.1147246556444247,"score_gpt":0.4352797038092064,"score_spread":0.3205550481647817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897022880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920984,0.003900106,0.0000026821108,0.0029403286,0.00010251427,0.0003172626,0.00005763927,0.000018066237,0.000563028],"genre_scores_gemma":[0.99062353,0.007366291,0.00021156545,0.0014620749,0.00007530544,0.00005510212,0.0000274539,0.000012325368,0.00016634857],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99869424,0.00016357905,0.00037869776,0.0003561923,0.00016998607,0.00023729289],"domain_scores_gemma":[0.99857104,0.0005236473,0.0002686993,0.0003155815,0.00020490745,0.00011615448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028627596,0.0001882429,0.0010558587,0.00029945484,0.00007297649,0.0000046613663,0.00007111829,0.00016492589,0.00012655322],"category_scores_gemma":[0.0001041686,0.00013408138,0.0001333496,0.00040221383,0.00029558162,0.00005507071,0.00007868259,0.000060853246,0.000006585891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04615039,0.089246586,0.20056993,0.00010061383,0.011098029,0.00093733496,0.012843819,0.000002930593,0.017547667,0.00007169953,0.011882457,0.60954857],"study_design_scores_gemma":[0.12510598,0.08061133,0.6126807,0.00013807465,0.001985704,0.000010187982,0.001330201,0.00030437307,0.15123902,0.0002925018,0.02595738,0.000344544],"about_ca_topic_score_codex":0.00091789896,"about_ca_topic_score_gemma":0.0009701321,"teacher_disagreement_score":0.609204,"about_ca_system_score_codex":0.00016572728,"about_ca_system_score_gemma":0.00023274633,"threshold_uncertainty_score":0.546768},"labels":[],"label_agreement":null},{"id":"W2897125715","doi":"10.1093/annonc/mdy472","title":"Avoiding the hazards of misinterpreting treatment effects","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Society for Medical Oncology; American Statistical Association","keywords":"Medicine; Intensive care medicine","score_opus":0.08626627155553357,"score_gpt":0.3300085813060742,"score_spread":0.24374230975054062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897125715","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07168031,0.016907796,0.00044530065,0.6064552,0.0039730202,0.0008682269,0.0007058848,0.000033144588,0.29893115],"genre_scores_gemma":[0.6112927,0.0051489333,0.00028282907,0.37189052,0.0062760226,0.00008652814,0.0000616022,0.00011492797,0.004845946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795824,0.00010329316,0.0010518443,0.00039772558,0.00003487878,0.0004540286],"domain_scores_gemma":[0.9965804,0.0009190013,0.0018400014,0.0005006903,0.000118535354,0.00004133625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010291025,0.00028532543,0.0013721319,0.00022583097,0.000105382416,0.000018730465,0.00047994877,0.0007429335,0.00026539268],"category_scores_gemma":[0.0006330769,0.00024237637,0.00046013767,0.00009804888,0.0003819536,0.000094042414,0.000085365,0.00062822696,0.00018297274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006150727,0.00008923933,0.0005281444,0.00021035467,0.00046260844,0.000032156357,0.0011422455,0.000007659387,0.000014007343,0.004501857,0.9561724,0.03677779],"study_design_scores_gemma":[0.00038397685,0.0021319608,0.0003768918,0.00012586746,0.000028749255,0.000009448312,0.000023189723,0.00006002295,0.0013250881,0.009811446,0.985509,0.00021436813],"about_ca_topic_score_codex":0.0007332857,"about_ca_topic_score_gemma":0.000025800391,"teacher_disagreement_score":0.53961235,"about_ca_system_score_codex":0.00017332278,"about_ca_system_score_gemma":0.00017304948,"threshold_uncertainty_score":0.9883821},"labels":[],"label_agreement":null},{"id":"W2897300072","doi":"10.1093/annonc/mdy283.080","title":"KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Clear cell renal cell carcinoma; Clinical endpoint; Oncology; Renal cell carcinoma; Progressive disease; Response Evaluation Criteria in Solid Tumors; Surgery; Urology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","score_opus":0.05574008702059895,"score_gpt":0.3487237175352484,"score_spread":0.29298363051464943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897300072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9406052,0.0026671907,0.000022226344,0.0027293824,0.00021297995,0.0011154842,0.000010915687,0.000045632463,0.05259099],"genre_scores_gemma":[0.98977774,0.0040729847,0.00074466463,0.002731988,0.00036101718,0.00009597907,0.000036978694,0.000080676466,0.0020979517],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99724275,0.00019836289,0.00079168973,0.00067106466,0.00039731918,0.00069881097],"domain_scores_gemma":[0.99792427,0.00022463445,0.00037608622,0.00076040387,0.00044074646,0.00027385546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041980957,0.00040552288,0.0010605656,0.0003462159,0.00008391607,0.000008397914,0.00026874398,0.00036819765,0.00082178705],"category_scores_gemma":[0.00004431678,0.00034495088,0.00028394331,0.000364553,0.000341667,0.000099385004,0.00006740895,0.00035746727,0.00024947393],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11449586,0.014039533,0.34781092,0.0004282317,0.00062976027,0.0033672526,0.006519396,0.00032672947,0.3028634,0.00019884403,0.017721903,0.19159816],"study_design_scores_gemma":[0.018557223,0.06740283,0.27987728,0.000054376167,0.00006527004,0.00011892223,0.000115016526,0.00013572689,0.5605758,0.0003516891,0.07240287,0.00034304644],"about_ca_topic_score_codex":0.0007122857,"about_ca_topic_score_gemma":0.00020614485,"teacher_disagreement_score":0.25771236,"about_ca_system_score_codex":0.0002225172,"about_ca_system_score_gemma":0.00048397257,"threshold_uncertainty_score":0.9999002},"labels":[],"label_agreement":null},{"id":"W2897430180","doi":"10.1093/annonc/mdy300.005","title":"Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Cancer; Smoking cessation; Lung cancer; Cancer survivorship; Disease; Survivorship curve; Logistic regression; Internal medicine; Pathology","score_opus":0.09328897115499343,"score_gpt":0.4353967970117773,"score_spread":0.3421078258567839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897430180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923278,0.0027424372,0.0000025358115,0.0030232973,0.00066560914,0.00026035722,0.00006028192,0.000005474949,0.00091218477],"genre_scores_gemma":[0.9940253,0.0052368497,0.000011599166,0.00043284413,0.00009186162,0.00003709032,0.0000013222482,0.000013873319,0.00014925757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989497,0.000052968746,0.00045657554,0.00019275055,0.00014527242,0.0002027522],"domain_scores_gemma":[0.9988722,0.00009276168,0.00042173744,0.0002126832,0.0003522138,0.000048370748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003187509,0.000107052,0.00060801534,0.00010027531,0.000024825104,0.0000014214593,0.000120458084,0.00016627004,0.00026212254],"category_scores_gemma":[0.000052846808,0.0000742101,0.00007827622,0.00032434848,0.00042923956,0.000039096652,0.00006834206,0.00015793787,2.3511235e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036077638,0.00014134301,0.95880437,0.00014861238,0.00017880627,0.0000022895647,0.0029348002,0.000019454525,0.009713916,0.000035470533,0.0008868832,0.026773287],"study_design_scores_gemma":[0.0018880398,0.00057266565,0.91350204,0.0005255553,0.00009728691,0.0000018607537,0.0002094193,0.00012872633,0.072909735,0.000083882376,0.010002246,0.0000785563],"about_ca_topic_score_codex":0.094862916,"about_ca_topic_score_gemma":0.04670004,"teacher_disagreement_score":0.06319582,"about_ca_system_score_codex":0.0000619028,"about_ca_system_score_gemma":0.0005595944,"threshold_uncertainty_score":0.9706952},"labels":[],"label_agreement":null},{"id":"W2897581755","doi":"10.1093/annonc/mdy283.110","title":"Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Urothelial cancer; Chemotherapy; Oncology; Internal medicine; Randomization; Pembrolizumab; Gemcitabine; Post-hoc analysis; Overall survival; Clinical trial; Cancer; Bladder cancer; Immunotherapy","score_opus":0.034400133800335804,"score_gpt":0.3667194996359786,"score_spread":0.3323193658356428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897581755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997396,0.000108708686,0.0000050905683,0.00017338405,0.000051352727,0.0010589974,0.0010523885,0.000011162899,0.0001429117],"genre_scores_gemma":[0.99898255,0.0004018207,0.00008398007,0.00024735817,0.00005243052,0.000060907772,0.000115531715,0.0000346697,0.000020725785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850154,0.000116936986,0.00046740434,0.00035426335,0.00024197847,0.00031787175],"domain_scores_gemma":[0.99806154,0.00035394536,0.0005244934,0.00025172168,0.0006220564,0.00018623348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001229779,0.00027676602,0.0011935078,0.00041302486,0.00003276783,0.0000032163803,0.00009198989,0.0001620646,0.00008595007],"category_scores_gemma":[0.0002791385,0.00018727002,0.00022914601,0.00048549174,0.0003261728,0.00007800287,0.000015968348,0.00010908269,3.5070371e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04260031,0.0013983208,0.9441203,0.00006538549,0.003181459,0.0000015138963,0.0007830323,0.00004422079,0.0011033951,0.000007648654,0.000056018136,0.006638387],"study_design_scores_gemma":[0.019669022,0.06992586,0.90214574,0.00009944312,0.0011676935,3.544666e-7,0.000023762961,0.0000647747,0.0066721397,0.00002036816,0.00007741019,0.00013342808],"about_ca_topic_score_codex":0.008671404,"about_ca_topic_score_gemma":0.0029333564,"teacher_disagreement_score":0.06852754,"about_ca_system_score_codex":0.00013042912,"about_ca_system_score_gemma":0.00050943316,"threshold_uncertainty_score":0.99792993},"labels":[],"label_agreement":null},{"id":"W2897631076","doi":"10.1093/annonc/mdy374.041","title":"A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Pharmacokinetics; Internal medicine; Oncology; Cancer; Pharmacology","score_opus":0.05004048888174779,"score_gpt":0.39877375961944994,"score_spread":0.34873327073770216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897631076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965336,0.00011508629,0.000005490561,0.00087345653,0.00028129976,0.0013104001,0.000020323932,0.000016056492,0.00084429997],"genre_scores_gemma":[0.9982143,0.00007747864,0.0007826288,0.000562621,0.00016647506,0.000083209474,0.000034225584,0.00001782359,0.00006125352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99858606,0.00008520967,0.00058930804,0.00022095202,0.00022338219,0.00029509285],"domain_scores_gemma":[0.99884367,0.00006403607,0.00039635456,0.0002256727,0.00038816058,0.00008210414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036528782,0.00013925263,0.0006227238,0.0001963286,0.000020827858,0.0000022868442,0.000088882625,0.00012833354,0.000112500944],"category_scores_gemma":[0.00013308626,0.00010431017,0.000102097656,0.0003518642,0.0003462627,0.00006452337,0.000022236074,0.00011013493,0.0000036815525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6150658,0.008409459,0.007723352,0.000057292695,0.00016236327,0.000008412375,0.00064180564,1.464706e-7,0.010375703,0.000008173251,0.0014002927,0.3561472],"study_design_scores_gemma":[0.4771073,0.3306416,0.018314956,0.0004783078,0.000057451773,0.000005092678,0.00020448813,0.000005607356,0.107146785,0.000033657067,0.0657917,0.00021305942],"about_ca_topic_score_codex":0.00009280251,"about_ca_topic_score_gemma":0.00009556918,"teacher_disagreement_score":0.35593414,"about_ca_system_score_codex":0.000058129903,"about_ca_system_score_gemma":0.00047883805,"threshold_uncertainty_score":0.42536452},"labels":[],"label_agreement":null},{"id":"W2897797073","doi":"10.1093/annonc/mdy289.004","title":"Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Metastatic melanoma; Internal medicine; Oncology; Incidence (geometry); Surgery; Immunotherapy; Cancer","score_opus":0.02282625944279762,"score_gpt":0.3306976374599298,"score_spread":0.30787137801713216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897797073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607015,0.00021516466,0.00019531755,0.0012274483,0.000025954403,0.0007517212,0.00020381363,0.000025168845,0.0012852761],"genre_scores_gemma":[0.9945918,0.00004461749,0.0041394997,0.00070294156,0.000032192722,0.000041566826,0.0002334182,0.000036981153,0.00017700951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768823,0.00035809446,0.00059110415,0.00050845585,0.00042321702,0.00043090168],"domain_scores_gemma":[0.99745315,0.00045205932,0.0005445616,0.0005518008,0.0008334213,0.00016497936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006162312,0.00027912544,0.001435386,0.0005179558,0.0000451534,0.0000037626166,0.00011478133,0.00010171941,0.0003708457],"category_scores_gemma":[0.00035714285,0.00018747307,0.00020351444,0.0013145168,0.000364774,0.00009122864,0.00006736852,0.00013386547,0.00000704753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07783343,0.010841535,0.86169773,0.00015020923,0.011803956,0.00031009977,0.00087919174,0.00043577375,0.0008889632,0.00039938872,0.0029298826,0.03182983],"study_design_scores_gemma":[0.038656577,0.059304625,0.8772537,0.00013407903,0.0030701205,0.000023471512,0.0001919392,0.00013737596,0.01688623,0.00003647732,0.004059677,0.00024573746],"about_ca_topic_score_codex":0.0004001847,"about_ca_topic_score_gemma":0.0020300585,"teacher_disagreement_score":0.048463088,"about_ca_system_score_codex":0.00019559952,"about_ca_system_score_gemma":0.00027710144,"threshold_uncertainty_score":0.764493},"labels":[],"label_agreement":null},{"id":"W2897963283","doi":"10.1093/annonc/mdy292.082","title":"Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; AstraZeneca (Canada); University of Alberta","funders":"","keywords":"Medicine; Osimertinib; T790M; Lung cancer; Biopsy; Internal medicine; Cancer; Oncology; Erlotinib; ROS1; Adenocarcinoma; Epidermal growth factor receptor","score_opus":0.024889791945023658,"score_gpt":0.41918213251374986,"score_spread":0.3942923405687262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897963283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97791237,0.00024563895,0.00001448454,0.0016467809,0.00030260117,0.0008928475,0.000064299355,0.000010488721,0.01891048],"genre_scores_gemma":[0.99699295,0.0000914676,0.00059312064,0.0016059416,0.00007304085,0.00027649247,0.00008809861,0.000016163678,0.0002627039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896294,0.00004135198,0.0002578983,0.00027746495,0.0001340196,0.0003263394],"domain_scores_gemma":[0.99904424,0.000041288225,0.00015844847,0.00015117002,0.00041234313,0.00019249662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062745494,0.00013405204,0.0002537815,0.00023954948,0.000079059784,0.0000048195448,0.00006853653,0.00011783452,0.00009833689],"category_scores_gemma":[0.000035132776,0.00011320124,0.000045295863,0.00025503073,0.00010860115,0.00008631505,0.000013978839,0.000095663185,0.000012957557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019641176,0.0031248578,0.4826283,0.00017155563,0.0001842935,0.0003404306,0.049611695,0.000086475535,0.0060660196,0.00012194297,0.0028945387,0.4528058],"study_design_scores_gemma":[0.008342677,0.012884992,0.9049848,0.000953908,0.00013186931,0.000010951452,0.0015871512,0.0003690355,0.06255961,0.000047158377,0.007848019,0.0002798537],"about_ca_topic_score_codex":0.031220725,"about_ca_topic_score_gemma":0.03706949,"teacher_disagreement_score":0.4525259,"about_ca_system_score_codex":0.0004694166,"about_ca_system_score_gemma":0.0009407145,"threshold_uncertainty_score":0.9805015},"labels":[],"label_agreement":null},{"id":"W2898012179","doi":"10.1093/annonc/mdy283.105","title":"Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Radiomics; Radiology; Nephrectomy; Biopsy; Imaging biomarker; Clear cell renal cell carcinoma; Oncology; Internal medicine; Magnetic resonance imaging; Immunotherapy; Kidney; Cancer","score_opus":0.018601118334254183,"score_gpt":0.3371707721320479,"score_spread":0.3185696537977937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898012179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131167,0.0001121222,0.0009037425,0.0052171075,0.00014278799,0.00094671454,0.00003997099,0.000015293885,0.0013106023],"genre_scores_gemma":[0.99037665,0.00002096306,0.0068154526,0.0019112757,0.00015114514,0.0000739987,0.000047585396,0.000028337001,0.0005745787],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987523,0.0001236273,0.00029070047,0.00032726736,0.0001623224,0.00034377063],"domain_scores_gemma":[0.99879265,0.00029421,0.00014730045,0.00022826937,0.00033600462,0.00020154989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040109432,0.00015924225,0.0004995192,0.0002222075,0.000047286612,0.0000036599602,0.00009458048,0.00014200785,0.00002283411],"category_scores_gemma":[0.0004064127,0.0001214344,0.00007360953,0.00019286445,0.00017512054,0.00004309334,0.00002772467,0.00015474498,0.0000044121516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24844758,0.0047830953,0.10518144,0.00014070618,0.00025517328,0.00018917565,0.0074652173,0.0009461514,0.032339923,0.000044363722,0.026420277,0.5737869],"study_design_scores_gemma":[0.049435444,0.32599014,0.34976733,0.0002559912,0.00018885407,0.00003301012,0.00041019116,0.0034631228,0.048781592,0.00012415509,0.22114938,0.00040076996],"about_ca_topic_score_codex":0.00005819395,"about_ca_topic_score_gemma":0.000035880996,"teacher_disagreement_score":0.57338613,"about_ca_system_score_codex":0.00022038033,"about_ca_system_score_gemma":0.00039187897,"threshold_uncertainty_score":0.49519512},"labels":[],"label_agreement":null},{"id":"W2898110679","doi":"10.1093/annonc/mdy424.067","title":"Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Lung cancer; Biomarker; Population; Gastroenterology; Cancer; Nivolumab; Immunotherapy","score_opus":0.047011484572663235,"score_gpt":0.3925385242952531,"score_spread":0.34552703972258986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898110679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907366,0.0008123786,0.0005699661,0.00071786746,0.0004364653,0.0022429342,0.0019400583,0.000009701695,0.0025340405],"genre_scores_gemma":[0.9938709,0.00014376493,0.0020006988,0.00065418053,0.0014181006,0.000626601,0.0011055521,0.00004085067,0.00013931145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781346,0.00013538718,0.0007105518,0.0007246397,0.00018601073,0.00042996884],"domain_scores_gemma":[0.9977575,0.0005091371,0.00054575066,0.00029029016,0.0007787104,0.00011864377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006350208,0.00026254647,0.00046501186,0.00012375914,0.00013247997,0.000017348852,0.00025791905,0.00032245688,0.000029978502],"category_scores_gemma":[0.0009767521,0.00027299023,0.0001940846,0.00015428827,0.00021554816,0.000007797867,0.00015762486,0.0001288522,0.0000022684887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3806567,0.004972112,0.00045606747,0.00008214303,0.0006712818,0.0000371267,0.002102581,0.0018865938,0.5802417,0.000027958318,0.0067680227,0.022097753],"study_design_scores_gemma":[0.3147674,0.09110426,0.0063445037,0.00020157834,0.00046818357,0.000006316769,0.00018644157,0.016475067,0.5627308,0.0005830669,0.0064704334,0.0006619934],"about_ca_topic_score_codex":0.0012180451,"about_ca_topic_score_gemma":0.0005183736,"teacher_disagreement_score":0.08613215,"about_ca_system_score_codex":0.000111352674,"about_ca_system_score_gemma":0.0028275705,"threshold_uncertainty_score":0.9999722},"labels":[],"label_agreement":null},{"id":"W2898114527","doi":"10.1093/annonc/mdy293.020","title":"Improved quality of life in patients with GEP-NETs treated with 177Lu-dotatate","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Oncology; Nursing","score_opus":0.044557760257179585,"score_gpt":0.3500205822611221,"score_spread":0.3054628220039425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898114527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479294,0.000076669974,0.0000025846161,0.00041299683,0.000030028395,0.0003602463,0.000035801146,0.000019553374,0.004269155],"genre_scores_gemma":[0.99876684,0.000025115958,0.00009164761,0.00090128736,0.00003101638,0.000010414485,0.000051860905,0.000015916037,0.00010589653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874234,0.00011978298,0.0005190763,0.00019906736,0.00017189908,0.000247822],"domain_scores_gemma":[0.9985103,0.00007206897,0.00038081862,0.00024679242,0.00063862617,0.00015139177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002217416,0.00013542162,0.00060668204,0.00012871197,0.000020848278,0.0000015927936,0.00007494619,0.000093001734,0.000116432355],"category_scores_gemma":[0.0001685909,0.00009076929,0.000048014004,0.00021265469,0.00038672198,0.00008434442,0.000021829803,0.00010878569,0.000010097976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01530556,0.0015179567,0.9759777,0.00012928751,0.00024091851,0.000022544415,0.00030038657,0.000002694534,0.0011222088,0.00009649063,0.00127713,0.0040071076],"study_design_scores_gemma":[0.008629222,0.01517991,0.96957517,0.00013192336,0.000060586794,0.0000018452312,0.000089337,0.000020917909,0.0048911674,0.00002014224,0.0012874441,0.00011235505],"about_ca_topic_score_codex":0.00033531163,"about_ca_topic_score_gemma":0.0002495548,"teacher_disagreement_score":0.013661953,"about_ca_system_score_codex":0.000020439838,"about_ca_system_score_gemma":0.0003712818,"threshold_uncertainty_score":0.37014642},"labels":[],"label_agreement":null},{"id":"W2898119006","doi":"10.1093/annonc/mdy287.078","title":"KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; MorphoSys; Swedish Orphan Biovitrum; Astellas Pharma; Genentech; Symphogen; AstraZeneca; Amgen; Pfizer; Eisai; Merck; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Oncology; Head and neck; Internal medicine; Chemoradiotherapy; Basal cell; Phases of clinical research; Head and neck cancer; Radiation therapy; Chemotherapy; Cancer; Overall survival; Surgery; Immunotherapy","score_opus":0.04605862990792877,"score_gpt":0.3704412387882663,"score_spread":0.32438260888033754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898119006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481666,0.0010237982,0.00015991754,0.001313667,0.00020964677,0.0015190456,0.00002841095,0.000020301775,0.00090857723],"genre_scores_gemma":[0.99789107,0.00013130004,0.0003870862,0.0010010003,0.00022755029,0.000078201636,0.000054973247,0.000025691823,0.00020315332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853134,0.00005629426,0.0006235491,0.00031958983,0.0001900166,0.0002791894],"domain_scores_gemma":[0.9984691,0.00014131962,0.00049529644,0.00029078094,0.0005015287,0.00010195888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034160973,0.00018174724,0.00074780005,0.00016840758,0.00007293163,0.0000051811526,0.00009579246,0.00017459717,0.000048139857],"category_scores_gemma":[0.00008888873,0.00017422835,0.000107768996,0.00022007248,0.00020081736,0.0001021339,0.000026663323,0.00009031718,0.0000018401855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39362806,0.009732233,0.00504058,0.0007963724,0.00030663106,0.00003299104,0.010908304,0.00004538232,0.22852625,0.000024530149,0.008533072,0.34242558],"study_design_scores_gemma":[0.38278255,0.18447295,0.06384786,0.00007198817,0.00037002424,0.00006015887,0.0018493994,0.003408206,0.34203294,0.00007966609,0.020615602,0.0004086655],"about_ca_topic_score_codex":0.00047662717,"about_ca_topic_score_gemma":0.00026398222,"teacher_disagreement_score":0.3420169,"about_ca_system_score_codex":0.00011191215,"about_ca_system_score_gemma":0.000412042,"threshold_uncertainty_score":0.71048254},"labels":[],"label_agreement":null},{"id":"W2898122595","doi":"10.1093/annonc/mdy284.036","title":"Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; Cancer","score_opus":0.22798249949642282,"score_gpt":0.485327753437376,"score_spread":0.2573452539409532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898122595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939486,0.0002046629,0.000003466939,0.0005886893,0.000056186025,0.003986527,0.0007053791,0.000030941737,0.0004755711],"genre_scores_gemma":[0.9967922,0.000515612,0.0007469171,0.0001670678,0.00008584497,0.00029312825,0.00037844433,0.000063113046,0.0009576516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957307,0.0005642313,0.0013045318,0.0009808284,0.00077045837,0.0006492426],"domain_scores_gemma":[0.9963132,0.0003049313,0.0008821759,0.0010500604,0.0011768821,0.00027273194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088353065,0.00041156658,0.0017461817,0.0002734057,0.00008756521,0.000018832021,0.0003545957,0.00011069269,0.00018725458],"category_scores_gemma":[0.00014389183,0.00022405747,0.00005162319,0.0009442887,0.0008599057,0.0002754789,0.0001347783,0.00040640938,0.0000066999273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09046406,0.010008294,0.88924813,0.0001262416,0.0018923149,0.0005562849,0.002354074,0.0000078085195,0.000121450255,0.0000043763043,0.00058483594,0.0046321284],"study_design_scores_gemma":[0.043419328,0.09950576,0.8534672,0.00048259366,0.00073414587,0.0000056942145,0.0010413838,0.00003948489,0.00080201356,0.000014752652,0.0002578487,0.00022976499],"about_ca_topic_score_codex":0.026217477,"about_ca_topic_score_gemma":0.22341421,"teacher_disagreement_score":0.19719674,"about_ca_system_score_codex":0.00039721615,"about_ca_system_score_gemma":0.0015115342,"threshold_uncertainty_score":0.98026705},"labels":[],"label_agreement":null},{"id":"W2898127005","doi":"10.1093/annonc/mdy285.155","title":"Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Chemotherapy; Placebo; Population; Adverse effect; BRCA mutation; Chemotherapy regimen; Clinical endpoint; Subgroup analysis; Randomized controlled trial; Cancer; Ovarian cancer; Confidence interval; Pathology","score_opus":0.0491810136000829,"score_gpt":0.39925487450453656,"score_spread":0.35007386090445364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898127005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933354,0.00024683203,0.000053801086,0.0017339247,0.00013539138,0.0005006347,0.00003646459,0.0000078105895,0.0039497204],"genre_scores_gemma":[0.998689,0.00017295057,0.00040078626,0.0005522372,0.000082678045,0.00002791727,0.000030059464,0.00001540349,0.000028968083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979575,0.0003765792,0.0008524655,0.00030494598,0.00022854767,0.00027990635],"domain_scores_gemma":[0.9980118,0.00059774244,0.0005918326,0.00037916432,0.00035023657,0.00006918586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011848287,0.0001724326,0.001419051,0.00092580396,0.000013965555,0.0000013035562,0.00010224561,0.00024079082,0.00021087764],"category_scores_gemma":[0.00018646421,0.00015707345,0.00023004173,0.001363834,0.00047317162,0.000043947763,0.000026069796,0.00021537134,0.0000026536243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026711235,0.002293794,0.75737983,0.0003754869,0.0024254804,0.0001249512,0.015202812,0.000053131032,0.13319132,0.0010969838,0.0022284084,0.058916576],"study_design_scores_gemma":[0.007951311,0.011306292,0.5927875,0.00020463832,0.00025400223,0.000010353881,0.00014181265,0.00038557278,0.38579357,0.00013190815,0.000913197,0.00011986638],"about_ca_topic_score_codex":0.0009932492,"about_ca_topic_score_gemma":0.0010850809,"teacher_disagreement_score":0.25260225,"about_ca_system_score_codex":0.00013668198,"about_ca_system_score_gemma":0.0002506555,"threshold_uncertainty_score":0.64052695},"labels":[],"label_agreement":null},{"id":"W2898129267","doi":"10.1093/annonc/mdy297.022","title":"How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Cancer Care Ontario; Canadian Partnership Against Cancer; Statistics Canada; McMaster University","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Cancer registry; Clinical trial; Cancer; Population; Cohort; Internal medicine; Surgery; Oncology","score_opus":0.05598679549635099,"score_gpt":0.3689331218343658,"score_spread":0.3129463263380148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898129267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967719,0.0004068661,5.8678063e-7,0.029660532,0.00035153882,0.00047274813,0.000048271166,0.000006973128,0.0013334361],"genre_scores_gemma":[0.9927498,0.00020312604,0.000016552389,0.0035171465,0.000100186655,0.00019799346,0.00004836699,0.000009708092,0.0031571176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911934,0.000052465843,0.00018106635,0.00019930274,0.00022942039,0.00021839472],"domain_scores_gemma":[0.99895614,0.00009218194,0.00024537227,0.00028014323,0.00036148174,0.000064648586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061298204,0.00011613169,0.00024998124,0.000017473527,0.00017137146,0.000006540953,0.00010047926,0.000056545716,0.00024843804],"category_scores_gemma":[0.000051388823,0.000059317008,0.00005065073,0.00009984596,0.00011959219,0.0000498692,0.000042950494,0.00007201756,0.0000010181901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003012989,0.00014332612,0.92965776,0.000011659728,0.00012526796,0.000009254371,0.0013588377,0.000006688209,0.000031648717,0.0000141528135,0.048201818,0.02013831],"study_design_scores_gemma":[0.0009791797,0.00089088705,0.88988674,0.00006540238,0.0000770594,0.00000271665,0.00015942758,0.000009153968,0.0034679451,0.0000064970436,0.1043979,0.00005707794],"about_ca_topic_score_codex":0.920734,"about_ca_topic_score_gemma":0.9969809,"teacher_disagreement_score":0.0762469,"about_ca_system_score_codex":0.0013977224,"about_ca_system_score_gemma":0.0005184952,"threshold_uncertainty_score":0.36549956},"labels":[],"label_agreement":null},{"id":"W2898155733","doi":"10.1093/annonc/mdy284.013","title":"Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Placebo; Quality of life (healthcare); Cancer; Randomized controlled trial; Oncology; Urology; Surgery; Gastroenterology; Pathology","score_opus":0.13434613337518478,"score_gpt":0.4763691454765236,"score_spread":0.3420230121013388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898155733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868461,0.002738259,0.0000014895234,0.006161363,0.000092165144,0.0034435755,0.0002642004,0.000008339041,0.00044453164],"genre_scores_gemma":[0.9982086,0.0005004131,0.0001245205,0.00012223057,0.000053475553,0.0007394588,0.00007155827,0.000020052245,0.00015973572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967989,0.00054758287,0.0013262355,0.00035854918,0.00047935732,0.000489391],"domain_scores_gemma":[0.997733,0.00033203137,0.0008590279,0.00029711935,0.0004600489,0.00031876334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011551265,0.00020589086,0.0012161032,0.00031335256,0.000030255307,0.0000043051177,0.00009822229,0.000100572586,0.00017036892],"category_scores_gemma":[0.00032687417,0.00015254699,0.00009235902,0.0005334575,0.0007814632,0.000105715,0.000039259437,0.00021375115,0.000002098757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96790284,0.0040083453,0.014384652,0.0007390923,0.00045991867,0.00030791556,0.004593596,0.000027953165,0.00086675095,0.000059251703,0.0003071875,0.0063425195],"study_design_scores_gemma":[0.7719162,0.07995762,0.13677084,0.0016389404,0.00025450924,0.0000049664095,0.0020003128,0.00039244807,0.0060684485,0.00024694038,0.00039463417,0.00035411742],"about_ca_topic_score_codex":0.0046996786,"about_ca_topic_score_gemma":0.008586998,"teacher_disagreement_score":0.1959866,"about_ca_system_score_codex":0.00022366378,"about_ca_system_score_gemma":0.00419608,"threshold_uncertainty_score":0.7443666},"labels":[],"label_agreement":null},{"id":"W2898156792","doi":"10.1093/annonc/mdy424.048","title":"Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Fludarabine; Gastroenterology; Leukopenia; Context (archaeology); Cyclophosphamide; Oncology; Surgery; Chemotherapy","score_opus":0.21175907972974456,"score_gpt":0.5512415840560463,"score_spread":0.3394825043263017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898156792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862202,0.0007527589,0.000028564937,0.0022140539,0.00040823768,0.0009134592,0.00001116062,0.0000108230615,0.009440761],"genre_scores_gemma":[0.9931902,0.003445909,0.0003348878,0.0014655895,0.0005003656,0.000010032607,0.0000041424173,0.000021168282,0.0010276837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960141,0.0017832745,0.0012999167,0.0003073036,0.0002453023,0.00035006856],"domain_scores_gemma":[0.99338025,0.0053614792,0.0003952292,0.00036812056,0.00031144006,0.00018347282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009606749,0.00013344771,0.0017533072,0.00023926533,0.000019830257,0.0000033225956,0.00013707225,0.00016896162,0.00088955887],"category_scores_gemma":[0.003810319,0.000108373984,0.0002091992,0.0002491667,0.00085368735,0.000038002807,0.00011501255,0.00033137383,0.00003257162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008511046,0.0013221544,0.028445393,0.00034520717,0.00024404335,0.00028838284,0.00030054167,5.6568933e-7,0.5970695,0.00016202015,0.0063977423,0.3569134],"study_design_scores_gemma":[0.025759613,0.02252982,0.1421336,0.00033595948,0.0001380695,0.00008440654,0.00009085563,0.000126011,0.6165146,0.0004788042,0.19161038,0.00019789225],"about_ca_topic_score_codex":0.00017850578,"about_ca_topic_score_gemma":0.00010051427,"teacher_disagreement_score":0.35671547,"about_ca_system_score_codex":0.000023409102,"about_ca_system_score_gemma":0.00034030998,"threshold_uncertainty_score":0.97400457},"labels":[],"label_agreement":null},{"id":"W2898160956","doi":"10.1093/annonc/mdy287.044","title":"Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Cohort; Progression-free survival; Gastroenterology; Head and neck cancer; Cancer; Immunotherapy; Overall survival","score_opus":0.03747969952877649,"score_gpt":0.33219550749977383,"score_spread":0.29471580797099733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898160956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711555,0.0015564779,3.894084e-7,0.00016019159,0.000008900988,0.00048668258,0.000032290696,0.0000028472007,0.0006366784],"genre_scores_gemma":[0.9997122,0.0001284432,0.00003400119,0.00006888007,0.000008362227,0.000017396196,0.000014575351,0.000008008904,0.000008086025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897295,0.0001413261,0.00038606572,0.00018881509,0.00014956089,0.00016128989],"domain_scores_gemma":[0.9990988,0.00014408871,0.0002613664,0.00019771363,0.00026000378,0.000038027498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021303298,0.00012821074,0.00092926325,0.00027654596,0.0000343322,0.0000019436443,0.0000634759,0.00003384797,0.000010089325],"category_scores_gemma":[0.000025247293,0.000071151626,0.000039904833,0.000512137,0.00024605158,0.000028227436,0.000034509594,0.00007765789,1.7823757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004931241,0.0018638212,0.97872436,0.00012859658,0.00046261644,0.000014599529,0.008822348,0.0000023498026,0.0001289218,0.0000019788588,0.000026572581,0.004892565],"study_design_scores_gemma":[0.009381915,0.052150436,0.9347324,0.000035987858,0.0011028845,0.0000031320067,0.0021160776,0.00004654796,0.0002955974,0.0000016330259,0.00007122506,0.00006218332],"about_ca_topic_score_codex":0.0010529241,"about_ca_topic_score_gemma":0.0044975313,"teacher_disagreement_score":0.050286613,"about_ca_system_score_codex":0.000012852633,"about_ca_system_score_gemma":0.0000862457,"threshold_uncertainty_score":0.2901479},"labels":[],"label_agreement":null},{"id":"W2898180551","doi":"10.1093/annonc/mdy297.021","title":"Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; McMaster University; Public Health Ontario; William Osler Health System; Health Sciences Centre; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; Children's Hospital of Eastern Ontario; Hospital for Sick Children; North York General Hospital; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Influenza vaccine; Cancer registry; Vaccination; Cancer; Malignancy; Logistic regression; Breast cancer; Population; Immunology; Environmental health","score_opus":0.3677108334076681,"score_gpt":0.5228801672800311,"score_spread":0.15516933387236298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898180551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761146,0.0004266492,0.000003297424,0.0002136745,0.00011129253,0.0010012515,0.0005587768,0.00001175381,0.00006182815],"genre_scores_gemma":[0.99733406,0.000004482212,0.00033660044,0.0020890955,0.00010999983,0.000034677552,0.00007332426,0.000015202587,0.00000254493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980651,0.0004298799,0.00044968785,0.0003994012,0.00033025886,0.000325652],"domain_scores_gemma":[0.99679977,0.00093258277,0.00035479202,0.00038071442,0.0013586606,0.0001734767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067715195,0.00016541101,0.0006387872,0.00009501763,0.00021340477,0.0000082140905,0.00013925301,0.000061987404,0.000060849525],"category_scores_gemma":[0.001647238,0.00014567278,0.000013175059,0.00028088116,0.00010465841,0.00013840983,0.00018788778,0.00021501748,4.506655e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009012322,0.0005051992,0.99476016,0.000080160244,0.00026719715,0.000016524045,0.0006963771,0.00001876493,0.00009302943,6.2212416e-7,0.00058162777,0.0020791052],"study_design_scores_gemma":[0.003100207,0.0057065883,0.98876387,0.00023830686,0.000059566544,2.1131297e-7,0.00036340486,0.00027144662,0.00026020777,0.000005465113,0.00112501,0.00010574653],"about_ca_topic_score_codex":0.99078786,"about_ca_topic_score_gemma":0.9948426,"teacher_disagreement_score":0.00775547,"about_ca_system_score_codex":0.0007567108,"about_ca_system_score_gemma":0.00851218,"threshold_uncertainty_score":0.99710864},"labels":[],"label_agreement":null},{"id":"W2898183703","doi":"10.1093/annonc/mdy285.160","title":"Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"OncoMed Pharmaceutical","keywords":"Olaparib; Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; PARP inhibitor; Placebo; Vomiting; Oncology; Gastroenterology; Surgery; Pathology","score_opus":0.12348903694260692,"score_gpt":0.46366195840004004,"score_spread":0.3401729214574331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898183703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796968,0.00036916393,0.0014420864,0.008988474,0.0013489317,0.002723541,0.00028547324,0.00004401323,0.005101503],"genre_scores_gemma":[0.9891869,0.00071257545,0.0007427823,0.0069790375,0.0012574309,0.00040850358,0.000063500804,0.000039552728,0.00060973334],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735314,0.00023186654,0.0010639536,0.0005244364,0.00029051743,0.00053606374],"domain_scores_gemma":[0.99620706,0.00063151645,0.00090430136,0.00054967724,0.0015349133,0.00017254465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011557633,0.00026897693,0.0012704764,0.00014203317,0.00010506642,0.0000060658103,0.00017619091,0.0003832682,0.0010637598],"category_scores_gemma":[0.00039279327,0.00023476126,0.0003102056,0.00025104164,0.0009300909,0.00011789969,0.00003435839,0.00025551286,0.000010860854],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6682809,0.004522265,0.0015278585,0.00015352045,0.0010180284,0.000055352903,0.0032541852,0.0000068572017,0.16136041,0.0013888658,0.035494998,0.122936726],"study_design_scores_gemma":[0.36946815,0.0592101,0.0059222477,0.00041074047,0.00013133383,0.00007145185,0.00016630406,0.000116664385,0.5204673,0.0024205204,0.041260052,0.0003551463],"about_ca_topic_score_codex":0.0003382413,"about_ca_topic_score_gemma":0.00018183833,"teacher_disagreement_score":0.35910687,"about_ca_system_score_codex":0.00017398893,"about_ca_system_score_gemma":0.0011170416,"threshold_uncertainty_score":0.9998494},"labels":[],"label_agreement":null},{"id":"W2898186613","doi":"10.1093/annonc/mdy272.320","title":"Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Aromatase inhibitor; Tamoxifen; Oncology; Internal medicine; Breast cancer; Subgroup analysis; Antiestrogen; Gynecology; Hormone receptor; Aromatase; Cancer; Meta-analysis","score_opus":0.019010494655576235,"score_gpt":0.32799831450718436,"score_spread":0.3089878198516081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898186613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388146,0.00029927853,0.00032256465,0.0021738121,0.00011109702,0.001541891,0.001187138,0.00008658924,0.000396137],"genre_scores_gemma":[0.9919068,0.00024028188,0.0049739517,0.0013942597,0.00033616825,0.00049354776,0.00027599226,0.00013039893,0.00024855102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961649,0.0002623866,0.00088261446,0.0010105452,0.0007421037,0.00093742245],"domain_scores_gemma":[0.99622285,0.00027650394,0.0009242454,0.00062040926,0.0015674012,0.00038857435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032743195,0.0006386821,0.0016948134,0.0005667283,0.00011784814,0.000017981798,0.00030021355,0.00028719727,0.0003394118],"category_scores_gemma":[0.000068054316,0.00045888682,0.00014297769,0.0019717817,0.001213209,0.0005722594,0.00012974264,0.00047660776,0.000021396096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33780545,0.009970537,0.40107328,0.0003514983,0.011420472,0.0006372312,0.015209179,0.0006743672,0.03361571,0.000035841404,0.0026008338,0.1866056],"study_design_scores_gemma":[0.025955072,0.04727373,0.8880179,0.0008583073,0.0010768991,0.000104692284,0.0015243334,0.00012930292,0.03086936,0.00007852515,0.0032401048,0.0008717966],"about_ca_topic_score_codex":0.0019094812,"about_ca_topic_score_gemma":0.010052384,"teacher_disagreement_score":0.4869446,"about_ca_system_score_codex":0.00062728784,"about_ca_system_score_gemma":0.00071185135,"threshold_uncertainty_score":0.99978626},"labels":[],"label_agreement":null},{"id":"W2898199426","doi":"10.1093/annonc/mdy299.002","title":"Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"GiST; Medicine; Tolerability; PDGFRA; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Stromal tumor; Gastroenterology; Surgery; Adverse effect; Stromal cell; Clinical trial","score_opus":0.044055305491913055,"score_gpt":0.3964032216199674,"score_spread":0.35234791612805433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898199426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972036,0.000021200465,0.0000058704545,0.00036623888,0.000018656718,0.00090073765,0.00017409283,0.0000075428875,0.0013020645],"genre_scores_gemma":[0.9984378,0.00000398244,0.0013600237,0.000028719936,0.000045297737,0.000019191366,0.000034126475,0.000019129324,0.000051715862],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975957,0.00019814257,0.00090600667,0.00035839403,0.0005069681,0.00043473204],"domain_scores_gemma":[0.997825,0.00022146932,0.00068929995,0.00031687578,0.00072785,0.00021948134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041955453,0.00021304257,0.00087115634,0.00021147949,0.00002639838,0.0000029341368,0.00011719594,0.000037038408,0.000047455207],"category_scores_gemma":[0.00050146313,0.00016797084,0.000060734284,0.00027414766,0.00076543697,0.00006848504,0.00010916757,0.00022251927,0.0000027142726],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08265599,0.043498445,0.8571586,0.00024665127,0.0002749312,0.0008491502,0.0013794426,8.323417e-7,0.008235689,0.00003607727,0.0021172469,0.0035469655],"study_design_scores_gemma":[0.08504538,0.5279758,0.33140284,0.0010376811,0.00016086605,0.0008663555,0.0016660084,0.000029866233,0.051484507,0.000057735146,0.00011562534,0.00015735265],"about_ca_topic_score_codex":0.0012453003,"about_ca_topic_score_gemma":0.0003474382,"teacher_disagreement_score":0.52575576,"about_ca_system_score_codex":0.00005373145,"about_ca_system_score_gemma":0.00039400114,"threshold_uncertainty_score":0.6849652},"labels":[],"label_agreement":null},{"id":"W2898200753","doi":"10.1093/annonc/mdy300.086","title":"What information and features do young and older adults with cancer want in their hospital-based social media cancer resource?","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Psychosocial; Social media; Young adult; Cancer; Demographics; Gerontology; Family medicine; Internal medicine; Demography; Psychiatry; World Wide Web","score_opus":0.043436470832476246,"score_gpt":0.44724904775121616,"score_spread":0.4038125769187399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898200753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973424,0.0008734335,0.000011873795,0.016382918,0.00049700774,0.0006336497,0.00008380568,0.000017446744,0.0017656035],"genre_scores_gemma":[0.98565346,0.0014525175,0.00010856989,0.012279268,0.00023114705,0.00021142635,0.000037348193,0.0000060804236,0.000020190482],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99834996,0.00028281007,0.00075704633,0.00013574584,0.00013837735,0.00033603012],"domain_scores_gemma":[0.99825525,0.00037070012,0.0006004862,0.00011388162,0.0005573135,0.00010237219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010002034,0.00011736496,0.0003031947,0.00014244887,0.00030439402,0.000022827013,0.00008335349,0.0002708991,0.00020914523],"category_scores_gemma":[0.00016492032,0.00007956739,0.000016481572,0.00017727369,0.00025706185,0.0016389232,0.000052237134,0.00035345732,0.0000035878022],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001188489,0.0000650447,0.13841374,0.0007162803,0.000013303046,5.161817e-7,0.3109754,0.0000013133847,0.0000017856211,0.00015050964,0.0114003485,0.53707325],"study_design_scores_gemma":[0.0025586046,0.00041911786,0.84697247,0.0009240976,0.000005632243,5.93861e-7,0.033096027,0.00019996964,0.000068610854,0.00013203865,0.11549855,0.00012431799],"about_ca_topic_score_codex":0.0010238332,"about_ca_topic_score_gemma":0.00783916,"teacher_disagreement_score":0.7085587,"about_ca_system_score_codex":0.00007246646,"about_ca_system_score_gemma":0.0006345632,"threshold_uncertainty_score":0.4374435},"labels":[],"label_agreement":null},{"id":"W2898201251","doi":"10.1093/annonc/mdy341.028","title":"The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; MEDLINE; PsycINFO; CINAHL; Observational study; Clinical trial; Systematic review; Protocol (science); Cancer; Cochrane Library; Quality of life (healthcare); Family medicine; Alternative medicine; Psychological intervention; Internal medicine; Meta-analysis; Pathology; Psychiatry","score_opus":0.3139636080246317,"score_gpt":0.4635268026791106,"score_spread":0.14956319465447893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898201251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010152197,0.9862743,6.808751e-7,0.0010179882,0.0006373468,0.010931918,0.00006766324,0.000010748816,0.000044154775],"genre_scores_gemma":[0.000087653745,0.9955309,0.00007059823,0.0011360497,0.000071833056,0.0027762768,0.000052978347,0.000049671795,0.00022404188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99338263,0.00050205825,0.0050720675,0.0003625832,0.0003171315,0.00036354252],"domain_scores_gemma":[0.9925662,0.00061981456,0.0052604587,0.00094408594,0.00054928585,0.0000601329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022687232,0.00040257914,0.0054925424,0.00025432027,0.000049673734,0.000007727711,0.0002746663,0.00037231427,0.000030349775],"category_scores_gemma":[0.0009535158,0.00021897203,0.0014725481,0.0005591376,0.00032428064,0.00005122489,0.00006567696,0.00025273452,0.0000019214506],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084096665,0.00030806355,0.000024798806,0.49341458,0.001582149,0.000007237628,0.000096702184,1.4267449e-8,0.000011444692,0.000004747885,0.0011995671,0.5025097],"study_design_scores_gemma":[0.001068325,0.0027956688,0.000014968404,0.35340968,0.0008667415,0.00005010439,0.000019308327,6.624621e-7,0.00008906284,0.0000045792826,0.6415546,0.00012630028],"about_ca_topic_score_codex":0.00037042866,"about_ca_topic_score_gemma":0.0000843541,"teacher_disagreement_score":0.64035505,"about_ca_system_score_codex":0.00029324996,"about_ca_system_score_gemma":0.0011474586,"threshold_uncertainty_score":0.892942},"labels":[],"label_agreement":null},{"id":"W2898209645","doi":"10.1093/annonc/mdy300.056","title":"Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Weight loss; Weight change; Obesity; Body mass index; Cohort; Weight gain; Prospective cohort study; Breast cancer; Population; Internal medicine; Cancer; Physical therapy; Pediatrics; Body weight","score_opus":0.057253910789985804,"score_gpt":0.39171668076801386,"score_spread":0.33446276997802804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898209645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574363,0.000048548405,0.0000025358702,0.0020251642,0.00021516503,0.00034583316,0.00004628878,0.000027055814,0.0015457527],"genre_scores_gemma":[0.99841547,0.00017771006,0.000046490994,0.0009941016,0.00020505626,0.000038851173,0.000010014667,0.000018251012,0.000094050134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986648,0.000043639735,0.00034330838,0.0003775767,0.0002637896,0.0003068671],"domain_scores_gemma":[0.9987163,0.000047860045,0.0003006837,0.00027618103,0.00045090518,0.00020810173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007517343,0.00018357234,0.0005938633,0.00007154438,0.000052864303,0.0000066016314,0.0000650002,0.00014747516,0.00017171071],"category_scores_gemma":[0.000035187022,0.0001123431,0.00008835171,0.00015175866,0.0007310893,0.00008490199,0.000052683237,0.00018973222,0.000007685675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014137815,0.0016333748,0.91917074,0.00001791245,0.00016343438,0.00006465046,0.0007323138,1.6635317e-7,0.00005421462,0.000022839831,0.0029362543,0.07379032],"study_design_scores_gemma":[0.0026113107,0.011985518,0.97968084,0.00006855951,0.000089002955,0.00003974659,0.000033048913,0.0000072256244,0.00032319326,0.00009796773,0.0049309693,0.00013262282],"about_ca_topic_score_codex":0.002063049,"about_ca_topic_score_gemma":0.00043914607,"teacher_disagreement_score":0.0736577,"about_ca_system_score_codex":0.000041773343,"about_ca_system_score_gemma":0.000075312884,"threshold_uncertainty_score":0.45812187},"labels":[],"label_agreement":null},{"id":"W2898216850","doi":"10.1093/annonc/mdy288.033","title":"Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Solid tumor; Phase (matter); Nuclear medicine; Oncology; Medical physics; Internal medicine; Cancer","score_opus":0.1158729565935464,"score_gpt":0.4892065840187681,"score_spread":0.3733336274252217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898216850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96068007,0.00031417052,0.036037624,0.00057821046,0.000107782005,0.0008135416,0.0001147624,0.00000924246,0.0013446214],"genre_scores_gemma":[0.9951551,0.00004250529,0.004337334,0.000039341907,0.00023749896,0.00013145346,0.000011942666,0.000008286814,0.00003656458],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993577,0.000058147714,0.0002823968,0.0000948179,0.00009169762,0.00011525803],"domain_scores_gemma":[0.9988327,0.00014008318,0.00034392887,0.0001827948,0.00048314894,0.000017323187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032727403,0.000076186705,0.00027445753,0.00003977608,0.00004307648,8.3498696e-7,0.00010049962,0.00002823589,0.0001581653],"category_scores_gemma":[0.000012867348,0.00005196554,0.00010233701,0.000065874316,0.00024749278,0.000040443454,0.000009645382,0.000022557146,2.2275904e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039256393,0.0027855502,0.00026398178,0.0000059402873,0.00021371026,7.728369e-8,0.0013310983,0.000044867156,0.031102862,0.005444021,0.0016247925,0.9567905],"study_design_scores_gemma":[0.003188907,0.039281208,0.00019271534,0.000013160369,0.000090314716,4.4774924e-7,0.00017610157,0.003068904,0.9022489,0.01682011,0.034852885,0.0000663197],"about_ca_topic_score_codex":0.000055153654,"about_ca_topic_score_gemma":0.0000065972818,"teacher_disagreement_score":0.9567242,"about_ca_system_score_codex":0.000022428489,"about_ca_system_score_gemma":0.0001487294,"threshold_uncertainty_score":0.21190932},"labels":[],"label_agreement":null},{"id":"W2898217141","doi":"10.1093/annonc/mdy424.041","title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Clinical endpoint; BRCA mutation; Ovarian cancer; Placebo; Chemotherapy; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Cancer; Pathology","score_opus":0.04305060990265014,"score_gpt":0.3968295337381739,"score_spread":0.3537789238355238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898217141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916055,0.0001729473,0.0007742129,0.0043505556,0.00041677523,0.0015328241,0.000034887635,0.000038810165,0.001073447],"genre_scores_gemma":[0.9902874,0.00017405143,0.0018429491,0.006897588,0.00026029363,0.00037714106,0.00005419895,0.00003947336,0.00006690777],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981112,0.00012909912,0.00061206915,0.0004400945,0.0002832232,0.00042432215],"domain_scores_gemma":[0.9985023,0.00027495684,0.00046648417,0.00025630477,0.00036073916,0.00013921285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039948957,0.00023582164,0.00073827576,0.00021838576,0.000073570096,0.000009684626,0.00009369526,0.00019954832,0.00018732689],"category_scores_gemma":[0.00016202491,0.00020507228,0.00008837688,0.0003675781,0.0002928259,0.00017331344,0.00001360122,0.000204612,0.0000032478772],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3122214,0.0038629519,0.014894521,0.00008304753,0.00036084454,0.0002018734,0.0039252727,0.00009495015,0.009361549,0.00011813426,0.0033209743,0.65155447],"study_design_scores_gemma":[0.90735966,0.034193106,0.018964352,0.0006646558,0.000076257726,0.000010516459,0.00023627398,0.00079097773,0.024511669,0.0002942486,0.012551247,0.00034701842],"about_ca_topic_score_codex":0.00044702302,"about_ca_topic_score_gemma":0.00077641616,"teacher_disagreement_score":0.65120745,"about_ca_system_score_codex":0.000193399,"about_ca_system_score_gemma":0.0006272193,"threshold_uncertainty_score":0.8362605},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2898217468","doi":"10.1093/annonc/mdy281.111","title":"Dose finding and safety study of reovirus (Reo) with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final results","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"FOLFIRI; Medicine; Irinotecan; Neutropenia; KRAS; Bevacizumab; Internal medicine; Oxaliplatin; Colorectal cancer; Gastroenterology; Febrile neutropenia; Oncology; Cancer; Chemotherapy","score_opus":0.058129477398106165,"score_gpt":0.3745575300499034,"score_spread":0.31642805265179724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898217468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982551,0.00023315694,0.000005523905,0.00012083535,0.00003575907,0.00072916725,0.00023995704,0.000003663939,0.0003768707],"genre_scores_gemma":[0.99932724,0.00023940549,0.00016097982,0.000045399964,0.000035461584,0.00007305212,0.00006058615,0.00001779434,0.000040092535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983348,0.00017216784,0.00040330665,0.000439156,0.000270591,0.00037994835],"domain_scores_gemma":[0.9989469,0.000056652105,0.00028262186,0.00025176816,0.0003523026,0.000109772765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028300303,0.00019706733,0.00042297057,0.00012468782,0.000074117575,0.0000073585766,0.00015107771,0.00008470197,0.000017866147],"category_scores_gemma":[0.000085844935,0.00014611176,0.00003372402,0.0002188053,0.0003082506,0.000013309344,0.00012924505,0.00011751233,0.0000012194554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18816489,0.009274972,0.6283403,0.00012987645,0.0022618214,0.0002765352,0.0036652058,0.00019842836,0.022465393,0.00001935624,0.00051358197,0.14468965],"study_design_scores_gemma":[0.031869143,0.120408006,0.74303985,0.00009754224,0.00011407745,0.000020931722,0.0005056842,0.000013805209,0.10102574,0.000020481713,0.0025801319,0.00030460084],"about_ca_topic_score_codex":0.0035328614,"about_ca_topic_score_gemma":0.033423625,"teacher_disagreement_score":0.15629575,"about_ca_system_score_codex":0.0000643975,"about_ca_system_score_gemma":0.00043618405,"threshold_uncertainty_score":0.9842139},"labels":[],"label_agreement":null},{"id":"W2898220308","doi":"10.1093/annonc/mdy292.064","title":"Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Oncology; Internal medicine; Squamous-cell carcinoma of the lung; Lung; Phases of clinical research; Basal cell; Clinical trial; Epidermal growth factor receptor; Cancer","score_opus":0.053951533739119546,"score_gpt":0.4301635303496723,"score_spread":0.37621199661055277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898220308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841271,0.00037874185,0.000015905067,0.0003607157,0.00037997877,0.0013403236,0.00058165623,0.000010498329,0.012805051],"genre_scores_gemma":[0.99867606,0.000030072179,0.00024232501,0.00014184417,0.000110379675,0.00007642507,0.00024443533,0.000014408992,0.00046401966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983049,0.00010819469,0.00066884176,0.00032060788,0.00030962046,0.00028783214],"domain_scores_gemma":[0.9977697,0.00018774788,0.0007845023,0.00046188955,0.00067058374,0.00012553368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009623334,0.00022833953,0.00095401803,0.00015289489,0.0000790588,0.0000030892993,0.00013106476,0.0001208689,0.00056578196],"category_scores_gemma":[0.000065828295,0.00014337193,0.00036228623,0.0007002001,0.00030625897,0.000060045666,0.00003359319,0.00005967412,0.0000024383382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67551064,0.04289925,0.17086506,0.000292085,0.012412947,0.00009041202,0.007316844,0.0004856058,0.0009008278,0.00048100203,0.0019178032,0.0868275],"study_design_scores_gemma":[0.602694,0.24460223,0.09049005,0.00004952312,0.019451324,0.0000054421057,0.0008619063,0.0006671835,0.030312475,0.000024284247,0.01055045,0.0002911327],"about_ca_topic_score_codex":0.00051337865,"about_ca_topic_score_gemma":0.0008540663,"teacher_disagreement_score":0.20170298,"about_ca_system_score_codex":0.00029139017,"about_ca_system_score_gemma":0.00083370256,"threshold_uncertainty_score":0.6194916},"labels":[],"label_agreement":null},{"id":"W2898221500","doi":"10.1093/annonc/mdy284.052","title":"The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Abiraterone acetate; Proportional hazards model; Internal medicine; Prednisone; Hazard ratio; Prostate cancer; Progression-free survival; Enzalutamide; Placebo; Survival analysis; Oncology; Neutrophil to lymphocyte ratio; Lymphocyte; Gastroenterology; Cancer; Chemotherapy; Androgen deprivation therapy; Confidence interval; Pathology","score_opus":0.05054912373938179,"score_gpt":0.418073508341856,"score_spread":0.3675243846024742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898221500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623145,0.00022539182,0.000014177015,0.00996048,0.00011738093,0.001636491,0.00008226489,0.000008078589,0.0017242722],"genre_scores_gemma":[0.99667645,0.0001441058,0.00002725534,0.00055515725,0.000057835063,0.00012402932,0.000003228253,0.000014027254,0.0023979126],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978006,0.0006184473,0.00047765815,0.0003007746,0.0004897832,0.00031276426],"domain_scores_gemma":[0.99694717,0.00046399722,0.0002744763,0.0006572709,0.0015218975,0.00013516347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016273226,0.00014352832,0.00070706196,0.0003331583,0.00012844874,0.000006592781,0.00028460147,0.000083178435,0.000094513],"category_scores_gemma":[0.00073574734,0.000075792406,0.0001954172,0.0017135036,0.0006149446,0.00003740943,0.00020980915,0.0001298438,0.000013752046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40728885,0.004468995,0.34158877,0.000054651784,0.01893684,0.00011758967,0.038485184,0.00020780966,0.16909577,0.00024629058,0.011333863,0.008175402],"study_design_scores_gemma":[0.0030912473,0.04187852,0.9014887,0.000031895244,0.0009122483,0.0000040092013,0.0021343331,0.000103044316,0.047724158,0.000074772026,0.0024947564,0.000062266525],"about_ca_topic_score_codex":0.00032424091,"about_ca_topic_score_gemma":0.00042040195,"teacher_disagreement_score":0.5599,"about_ca_system_score_codex":0.00022688044,"about_ca_system_score_gemma":0.0009668071,"threshold_uncertainty_score":0.30907246},"labels":[],"label_agreement":null},{"id":"W2898226771","doi":"10.1093/annonc/mdy287.027","title":"Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Internal medicine; Phases of clinical research; Clinical endpoint; Toxicity; Neutropenia; Gastroenterology; Pharmacokinetics; Surgery; Oncology; Urology; Clinical trial","score_opus":0.06985598141590381,"score_gpt":0.45456290614222555,"score_spread":0.38470692472632173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898226771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408746,0.00031526358,0.0000054530847,0.000725627,0.000081272665,0.0015056003,0.00013060335,0.000014010107,0.0031347277],"genre_scores_gemma":[0.9982079,0.00015304945,0.00033885683,0.00042993273,0.00004213783,0.00018478998,0.000086545624,0.000018192355,0.00053854473],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99849874,0.00009239234,0.00058799784,0.00030728226,0.0002328735,0.00028068724],"domain_scores_gemma":[0.9985055,0.00007643904,0.00037457707,0.00025360548,0.00068214204,0.0001077336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015018303,0.00016891897,0.00061484735,0.0001831538,0.000055200784,0.0000020545947,0.000086588654,0.000054188455,0.00004673611],"category_scores_gemma":[0.00007817194,0.00012224432,0.0000454995,0.0003654381,0.00017862697,0.00009395311,0.00003340553,0.000099212164,0.000003844576],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048148554,0.23407395,0.05888352,0.00022709281,0.0016357898,0.0003625316,0.01872879,0.00008306371,0.00030926333,0.000030167355,0.004920082,0.6325972],"study_design_scores_gemma":[0.3642744,0.53639036,0.0846273,0.00066299,0.0010365763,0.000016364122,0.0014917208,0.000110868496,0.0029428713,0.000054959368,0.008138268,0.00025329096],"about_ca_topic_score_codex":0.0013640296,"about_ca_topic_score_gemma":0.0030729661,"teacher_disagreement_score":0.6323439,"about_ca_system_score_codex":0.00013468676,"about_ca_system_score_gemma":0.00056825636,"threshold_uncertainty_score":0.4984979},"labels":[],"label_agreement":null},{"id":"W2898234054","doi":"10.1093/annonc/mdy273.374","title":"Clinical characteristics of glioblastoma multiforme (GBM) patients who reached 400 days post diagnostic from a retrospective real-world data","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Malignancy; Glioblastoma; Retrospective cohort study; Population; Chemotherapy; Internal medicine; Surgery; Pediatrics","score_opus":0.104954262661431,"score_gpt":0.4251544531857864,"score_spread":0.3202001905243554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898234054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234146,0.00005173574,0.0000037237414,0.0018145853,0.00042646096,0.0005465898,0.0023723836,0.000024618108,0.0024184298],"genre_scores_gemma":[0.99603736,0.0007711613,0.0005735054,0.00089236465,0.0004931453,0.000022536968,0.0011490788,0.000031309635,0.000029539051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974225,0.00018886708,0.00113046,0.0005828472,0.00032322173,0.0003521144],"domain_scores_gemma":[0.9945055,0.0018861477,0.00093944283,0.0011921745,0.0012378182,0.00023889843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005176642,0.00023254799,0.0013407216,0.00019701675,0.00005018507,0.0000065071454,0.0003334887,0.00020296684,0.00018401926],"category_scores_gemma":[0.0043407897,0.00019199525,0.00017124285,0.00029151601,0.0006738202,0.00010748481,0.000350404,0.0002210752,0.000073804295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016388136,0.0053172214,0.91751075,0.000024648602,0.000540689,0.00008412321,0.00029426423,2.0547434e-8,0.00026961748,0.0001568072,0.009810136,0.06435294],"study_design_scores_gemma":[0.0042252247,0.018116316,0.9682506,0.0002312499,0.00036270524,0.0000027041574,0.0000496288,0.00006463022,0.00256579,0.00014255651,0.0058516716,0.0001369263],"about_ca_topic_score_codex":0.0018233093,"about_ca_topic_score_gemma":0.0028480135,"teacher_disagreement_score":0.06421601,"about_ca_system_score_codex":0.00007989827,"about_ca_system_score_gemma":0.00021105094,"threshold_uncertainty_score":0.78293395},"labels":[],"label_agreement":null},{"id":"W2898234770","doi":"10.1093/annonc/mdy289.062","title":"ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Melanoma; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Oncology; Progressive disease; Clinical trial; Gastroenterology; Immunotherapy; Chemotherapy; Cancer; Cancer research","score_opus":0.06381902280130473,"score_gpt":0.3998208149114062,"score_spread":0.33600179211010145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898234770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878015,0.0017932054,0.00003795465,0.0012248751,0.00025553076,0.0008673608,0.000014274794,0.000023505474,0.00798178],"genre_scores_gemma":[0.9982442,0.0006299409,0.00036362864,0.0003988126,0.00009376249,0.000040673487,0.000029301791,0.00002802102,0.00017163147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99789727,0.00028557848,0.00079823827,0.00033020836,0.00029904777,0.00038964435],"domain_scores_gemma":[0.9978085,0.00057080697,0.00070946885,0.00039615948,0.00041364817,0.00010138693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000991708,0.00024537314,0.0019102421,0.000315719,0.000044722903,0.000004244076,0.00015382576,0.00021284465,0.00027944302],"category_scores_gemma":[0.00011122693,0.00016964441,0.00016203545,0.00043977832,0.0015448615,0.000097420205,0.000031129766,0.00023090612,0.000005513179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9404801,0.0024696009,0.0016585711,0.00010135655,0.0010562821,0.00010943184,0.003092357,0.0000016082895,0.02589018,0.000025809382,0.001888341,0.02322636],"study_design_scores_gemma":[0.817569,0.057287,0.007102404,0.00043922936,0.00035369614,0.00006391225,0.0014865567,0.00013802129,0.10224462,0.000013812453,0.013035634,0.0002661033],"about_ca_topic_score_codex":0.0010607386,"about_ca_topic_score_gemma":0.0015894285,"teacher_disagreement_score":0.122911096,"about_ca_system_score_codex":0.00008130049,"about_ca_system_score_gemma":0.0005626725,"threshold_uncertainty_score":0.6917898},"labels":[],"label_agreement":null},{"id":"W2898236034","doi":"10.1093/annonc/mdy292.130","title":"Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Osimertinib; Medicine; Gefitinib; T790M; Oncology; Internal medicine; Erlotinib; Randomized controlled trial; Progression-free survival; Lung cancer; Epidermal growth factor receptor; Chemotherapy; Cancer","score_opus":0.07165732510328492,"score_gpt":0.4499715277299406,"score_spread":0.37831420262665566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898236034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663276,0.00008094877,0.0060686814,0.0011122865,0.00012651738,0.0049549104,0.00010346711,0.000016814696,0.0009036383],"genre_scores_gemma":[0.99521554,0.0000817432,0.0031248594,0.0006515061,0.00008041914,0.00046264674,0.00018315975,0.000024207195,0.00017593076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986537,0.00013466028,0.0005562063,0.00021891911,0.0002233594,0.00021314132],"domain_scores_gemma":[0.9976816,0.0004009175,0.00057958876,0.00020428427,0.0010395708,0.00009401353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003457864,0.0001692196,0.001084498,0.000114735296,0.000082683735,0.0000035668388,0.000056639896,0.00006053839,0.0001461704],"category_scores_gemma":[0.00015184742,0.000087568405,0.00011428983,0.00015731102,0.00063453865,0.00008062546,0.000009884898,0.000051836538,0.0000015476242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92077017,0.0060179397,0.00030235449,0.00003874577,0.001963616,0.0000045533975,0.001468148,0.0000034531904,0.00011155621,0.000108755055,0.00033916425,0.06887153],"study_design_scores_gemma":[0.83173203,0.1520905,0.000065137545,0.00008600367,0.0011599505,0.0000064634887,0.00020285613,0.00018482044,0.006998474,0.00007771889,0.0073016407,0.000094391435],"about_ca_topic_score_codex":0.00010244497,"about_ca_topic_score_gemma":0.000091228445,"teacher_disagreement_score":0.14607257,"about_ca_system_score_codex":0.00003593613,"about_ca_system_score_gemma":0.00097633916,"threshold_uncertainty_score":0.35709357},"labels":[],"label_agreement":null},{"id":"W2898247418","doi":"10.1093/annonc/mdy273.372","title":"Clinical characteristics of 3,030 glioblastoma multiforme (GBM) patients in high, upper middle and lower middle economic regions based on real-world data (RWD)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glioblastoma; Incidence (geometry); Temozolomide; Population; Demography; Internal medicine; Oncology; Cancer research; Environmental health","score_opus":0.15432792841771426,"score_gpt":0.4045237888639636,"score_spread":0.25019586044624936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898247418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948914,0.000017154598,0.0000014719128,0.0025438182,0.00034519125,0.00034845193,0.00035566822,0.000009343866,0.0014874816],"genre_scores_gemma":[0.9976139,0.00034623226,0.0004332728,0.0011491883,0.00015541387,0.000015902639,0.0002220326,0.000019078443,0.00004497269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983529,0.00010477912,0.00077328115,0.00039761607,0.000113554,0.00025789285],"domain_scores_gemma":[0.9979817,0.0005405883,0.00042735232,0.00073032005,0.000167926,0.00015209845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039926032,0.00015880594,0.00076985464,0.0002823042,0.000028736555,0.0000040946293,0.00015775085,0.00013964885,0.00010076312],"category_scores_gemma":[0.00025006707,0.00013359949,0.000085644635,0.000115091585,0.0004293543,0.00006273768,0.0001267116,0.00012571897,0.000040854953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024042334,0.005982227,0.9565173,0.000050766317,0.00011332794,0.000047142443,0.00006940033,9.922805e-7,0.00002874995,0.00039754435,0.006721582,0.027666742],"study_design_scores_gemma":[0.005405342,0.013821751,0.9666913,0.00025109857,0.00008248191,0.000001936108,0.000021005793,0.0007502115,0.00074050855,0.00006006213,0.012068924,0.0001053407],"about_ca_topic_score_codex":0.00065944775,"about_ca_topic_score_gemma":0.0036511729,"teacher_disagreement_score":0.0275614,"about_ca_system_score_codex":0.000056241985,"about_ca_system_score_gemma":0.00016137365,"threshold_uncertainty_score":0.5448029},"labels":[],"label_agreement":null},{"id":"W2898251516","doi":"10.1093/annonc/mdy284.068","title":"TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Clinical endpoint; Internal medicine; PARP inhibitor; Urology; Oncology; Enzalutamide; Regimen; Surgery; Clinical trial; Cancer; Breast cancer; Poly ADP ribose polymerase","score_opus":0.12984503093746097,"score_gpt":0.44068231539701885,"score_spread":0.3108372844595579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898251516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909418,0.000642418,0.000006952894,0.002461916,0.000029904744,0.005544412,0.00012422513,0.000043710712,0.0002046226],"genre_scores_gemma":[0.99593806,0.00044347788,0.0009737319,0.0013666142,0.00004003781,0.000975439,0.000036754096,0.00006416845,0.00016171536],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99661946,0.0010042621,0.0008169879,0.00073930435,0.00037870623,0.00044128255],"domain_scores_gemma":[0.99739206,0.00042157265,0.0008074002,0.000546984,0.0006071379,0.00022484566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00255514,0.0003886258,0.001091849,0.00031928465,0.00016175836,0.00003293603,0.00019461277,0.000081908474,0.00006814513],"category_scores_gemma":[0.0001404155,0.0003083604,0.00003234823,0.0004951744,0.0007640431,0.00028891023,0.000048223013,0.00024390923,3.7371092e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27392125,0.019458588,0.003852965,0.0001404858,0.00054757175,0.0002477718,0.0064978325,0.000030886993,0.6817655,0.000024704066,0.0006291846,0.012883292],"study_design_scores_gemma":[0.1671317,0.47180656,0.08634186,0.0008700863,0.00017336816,0.000072241535,0.0015825826,0.0013911498,0.26707405,0.000071395654,0.002950634,0.0005343693],"about_ca_topic_score_codex":0.00058250834,"about_ca_topic_score_gemma":0.001372089,"teacher_disagreement_score":0.45234796,"about_ca_system_score_codex":0.00011678727,"about_ca_system_score_gemma":0.001223728,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W2898264974","doi":"10.1093/annonc/mdy285.190","title":"Risk of cancer associated death in younger vs older patients with FIGO stage I endometrial cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Endometrial cancer; Lymphovascular invasion; Internal medicine; Stage (stratigraphy); Odds ratio; Cancer; Oncology; Gynecology; Radiation therapy; Adjuvant therapy; Risk factor; Logistic regression; Surgery; Metastasis","score_opus":0.06139659467841884,"score_gpt":0.3961642760262716,"score_spread":0.33476768134785273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898264974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938249,0.000866925,0.0000024159062,0.0004652303,0.00038159208,0.00056809647,0.00054263364,0.000011959836,0.0033362757],"genre_scores_gemma":[0.99701256,0.001241521,0.00006985917,0.000799305,0.00022313348,0.000091492286,0.00004172647,0.00002033899,0.00050005846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983522,0.00015605053,0.00048617623,0.00026769322,0.00038292614,0.0003549466],"domain_scores_gemma":[0.9980579,0.00034508278,0.00052334554,0.0001896874,0.00076110684,0.00012287247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031157202,0.00016801295,0.00084486004,0.0003445539,0.000029338556,0.000002513473,0.000102164224,0.00019346416,0.0018833786],"category_scores_gemma":[0.00060508837,0.00011654884,0.00011333845,0.0009183064,0.00016169278,0.000076289296,0.000041623498,0.0001782627,0.0000066557664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00909406,0.001789567,0.96475124,0.00004132663,0.0007934993,0.000012069443,0.00021831908,0.000005466456,0.000075635005,0.000025650463,0.0005726731,0.022620514],"study_design_scores_gemma":[0.02480398,0.01045566,0.9535044,0.00015810604,0.00027987713,2.3160817e-7,0.000019496143,0.000004919955,0.0055974545,0.000045087574,0.005023762,0.000107050175],"about_ca_topic_score_codex":0.012872213,"about_ca_topic_score_gemma":0.0039764834,"teacher_disagreement_score":0.022513464,"about_ca_system_score_codex":0.00021922983,"about_ca_system_score_gemma":0.00040153705,"threshold_uncertainty_score":0.99902904},"labels":[],"label_agreement":null},{"id":"W2898265596","doi":"10.1093/annonc/mdy424.001","title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Cost-effectiveness analysis; Adjuvant; Internal medicine; Cost effectiveness; Oncology; Surgery; Cancer","score_opus":0.06745822084552353,"score_gpt":0.43022346759668556,"score_spread":0.36276524675116206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898265596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235934,0.0001306985,0.0000140017055,0.00089109124,0.0001696876,0.0010280331,0.00077153475,0.000011956327,0.0046236473],"genre_scores_gemma":[0.9992844,0.00015153701,0.000068589965,0.00012574451,0.00010319708,0.000115259754,0.00006558291,0.00002914732,0.000056559908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972661,0.00050050137,0.0005505749,0.0005102239,0.00063424086,0.00053834106],"domain_scores_gemma":[0.9968923,0.00055655336,0.00031876302,0.00043789213,0.0015830166,0.00021152088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088665745,0.00021832343,0.0011001811,0.00057277665,0.000044513163,0.000005542132,0.000199527,0.0002155731,0.00019241958],"category_scores_gemma":[0.00022425361,0.00017809276,0.00016891217,0.0012782217,0.00068855315,0.0000996573,0.000076495686,0.0003219741,0.000013455492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1565852,0.0031177101,0.7006858,0.00019239508,0.0033197668,0.0001336219,0.004857458,0.00019475997,0.0010662393,0.000016954913,0.0010763918,0.12875372],"study_design_scores_gemma":[0.016089668,0.025224905,0.95020616,0.0003569516,0.00042800241,0.000004615502,0.00036865278,0.000101980535,0.0064831567,0.000003295545,0.0005806126,0.00015199448],"about_ca_topic_score_codex":0.020286985,"about_ca_topic_score_gemma":0.011422443,"teacher_disagreement_score":0.24952038,"about_ca_system_score_codex":0.0005824976,"about_ca_system_score_gemma":0.0009287196,"threshold_uncertainty_score":0.986237},"labels":[],"label_agreement":null},{"id":"W2898267981","doi":"10.1093/annonc/mdy293.015","title":"The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Internal medicine; Family medicine; Oncology","score_opus":0.04015572396966918,"score_gpt":0.3815127445192545,"score_spread":0.3413570205495853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898267981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91571367,0.0020875754,0.000030331144,0.07661578,0.00044001834,0.003675023,0.0004452395,0.00016533694,0.0008270386],"genre_scores_gemma":[0.9661484,0.015116731,0.0028931182,0.014243187,0.00063013955,0.00022654403,0.00012560855,0.00025439024,0.0003618997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910137,0.0017034415,0.0023811932,0.0016055461,0.0010605075,0.002235607],"domain_scores_gemma":[0.9895741,0.003519042,0.0024657112,0.0013471065,0.0021059096,0.000988149],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0007629336,0.0010185074,0.0020664604,0.00025518343,0.0009215144,0.00013448685,0.00078905723,0.000006808373,0.000021331516],"category_scores_gemma":[0.0032026991,0.0008636544,0.00048275082,0.0013932781,0.0042100493,0.0004215681,0.0011588528,0.0011489757,0.000010161688],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040374205,0.011300333,0.0662978,0.0061742794,0.0032706314,0.06477569,0.0011472802,0.00054064725,0.04081729,0.0032796084,0.68111235,0.0809099],"study_design_scores_gemma":[0.013386059,0.04977576,0.016869612,0.00020399682,0.0008817934,0.058857493,0.0031027233,0.008620018,0.042006973,0.000106889005,0.80513203,0.0010566647],"about_ca_topic_score_codex":0.0006247447,"about_ca_topic_score_gemma":0.00095266994,"teacher_disagreement_score":0.12401969,"about_ca_system_score_codex":0.00011486647,"about_ca_system_score_gemma":0.0009563469,"threshold_uncertainty_score":0.9993814},"labels":[],"label_agreement":null},{"id":"W2898272327","doi":"10.1093/annonc/mdy285.144","title":"Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Endometrial cancer; Cohort; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Progressive disease; Oncology; Biomarker; Pharmacokinetics; Peripheral blood mononuclear cell; Clinical trial; Phases of clinical research; Cancer; Disease","score_opus":0.05334834220999658,"score_gpt":0.4158929776229871,"score_spread":0.36254463541299053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898272327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677855,0.00034023452,0.00006566943,0.0003161726,0.0009828305,0.0007830369,0.00066552724,0.0000022600345,0.000065718334],"genre_scores_gemma":[0.9945886,0.0038058818,0.00018327277,0.00027687062,0.00066235376,0.000023080356,0.00042740835,0.000015799631,0.000016726402],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9984613,0.00018679346,0.0006538757,0.00036068494,0.00013541838,0.00020190449],"domain_scores_gemma":[0.9985838,0.0002534867,0.00055660296,0.00028122327,0.00025462479,0.00007024024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003060538,0.00015104366,0.00045198534,0.00006183836,0.0000398793,0.000006151126,0.0001907385,0.00021166124,0.00003189444],"category_scores_gemma":[0.00064187485,0.000107323176,0.00008009246,0.00015792728,0.00034210738,0.000007363257,0.00019514766,0.00011160301,4.889764e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56936646,0.004647524,0.06143879,0.000025728172,0.00023722053,0.0000036000604,0.00015875667,0.000022187867,0.05213333,0.000017270895,0.0006880481,0.3112611],"study_design_scores_gemma":[0.15729296,0.07283528,0.6960122,0.00012689403,0.0001026728,0.000001285507,0.00001681463,0.00007037524,0.028561933,0.0000262299,0.044692926,0.0002603942],"about_ca_topic_score_codex":0.000079451085,"about_ca_topic_score_gemma":0.00022064187,"teacher_disagreement_score":0.63457346,"about_ca_system_score_codex":0.000015236221,"about_ca_system_score_gemma":0.0004308233,"threshold_uncertainty_score":0.43765122},"labels":[],"label_agreement":null},{"id":"W2898281580","doi":"10.1093/annonc/mdy424.035","title":"ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Clinical endpoint; Internal medicine; Asymptomatic; Denosumab; Prednisone; Gastroenterology; Phases of clinical research; Placebo; Urology; Randomized controlled trial; Clinical trial; Surgery; Cancer; Prostate cancer; Osteoporosis; Androgen deprivation therapy; Pathology","score_opus":0.05907478505180859,"score_gpt":0.39678210894735894,"score_spread":0.33770732389555036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898281580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894995,0.0010852683,0.0000751233,0.0020780687,0.000070919414,0.0074661695,0.00022816582,0.0000118413545,0.00003449415],"genre_scores_gemma":[0.9942664,0.0025769866,0.0011066598,0.00006961279,0.000035300487,0.0014512825,0.00008447045,0.00003860771,0.00037071377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99777627,0.00017342641,0.00089058763,0.00035327632,0.00038582392,0.0004205998],"domain_scores_gemma":[0.9976534,0.00045233098,0.00080298533,0.00032147384,0.0006591997,0.00011061275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043244788,0.00030490366,0.00116888,0.00022861703,0.00009683925,0.000013446926,0.0001029857,0.000088004555,0.000036820114],"category_scores_gemma":[0.00004163025,0.00015609806,0.00008741187,0.00033580742,0.00076515164,0.00012920437,0.000016954122,0.000077213444,6.008247e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77350664,0.030344138,0.0030989924,0.001377107,0.0030235099,0.000051335417,0.02106981,0.000023748617,0.012078336,0.00004234313,0.00024221862,0.15514185],"study_design_scores_gemma":[0.65149474,0.25540352,0.00899593,0.0007610521,0.001012258,0.000023803566,0.0010589123,0.002670179,0.07786695,0.00013079918,0.00035257026,0.00022929035],"about_ca_topic_score_codex":0.0007471034,"about_ca_topic_score_gemma":0.0013775156,"teacher_disagreement_score":0.22505939,"about_ca_system_score_codex":0.0002106055,"about_ca_system_score_gemma":0.00084320287,"threshold_uncertainty_score":0.6365494},"labels":[],"label_agreement":null},{"id":"W2898287315","doi":"10.1093/annonc/mdy295.025","title":"Factors associated with length of stay in an acute palliative care unit: A retrospective analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Delirium; Palliative care; Performance status; Retrospective cohort study; Cancer; Distress; Emergency medicine; Internal medicine; Intensive care medicine","score_opus":0.4077101063175467,"score_gpt":0.5301314291240772,"score_spread":0.12242132280653045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898287315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965771,0.00026454893,0.000036954032,0.00016950117,0.0000307623,0.00017541347,0.00019472332,0.000017684484,0.0025333036],"genre_scores_gemma":[0.9991972,0.00023109178,0.00021975025,0.00012012242,0.000029335735,0.0000053700805,0.00014367806,0.000015947404,0.000037519258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986837,0.00019671695,0.0003992845,0.00023715352,0.00025115977,0.0002320215],"domain_scores_gemma":[0.9969104,0.0002783729,0.0005054782,0.00023655039,0.0019816954,0.00008751947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021671834,0.00015639994,0.0011312127,0.0004436123,0.00001798794,0.0000015078759,0.0001136082,0.00018733619,0.000060631766],"category_scores_gemma":[0.00044000775,0.00011536728,0.00014530373,0.0012576882,0.00041332986,0.00007576293,0.000029168754,0.00016281162,5.125383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046795732,0.00036603032,0.96473634,0.00002104676,0.0033883285,0.000018036326,0.029507646,0.0000064127958,0.00073729135,0.000102704136,0.00005355227,0.00059465686],"study_design_scores_gemma":[0.0014198559,0.014230293,0.9364567,0.00018723267,0.00096357346,9.620582e-8,0.013637185,0.00003745977,0.03253939,0.000076001335,0.0003514986,0.00010071193],"about_ca_topic_score_codex":0.00045291288,"about_ca_topic_score_gemma":0.007392114,"teacher_disagreement_score":0.0318021,"about_ca_system_score_codex":0.00011619322,"about_ca_system_score_gemma":0.00024558033,"threshold_uncertainty_score":0.4704541},"labels":[],"label_agreement":null},{"id":"W2898290601","doi":"10.1093/annonc/mdy288.011","title":"First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Pembrolizumab; Nausea; Discontinuation; Agonist; Tolerability; Internal medicine; Toxicity; Immunotherapy; Oncology; Pharmacology; Receptor; Cancer","score_opus":0.07215735187253781,"score_gpt":0.39650708424536824,"score_spread":0.32434973237283043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898290601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885508,0.00008016183,6.037384e-7,0.0016104137,0.00007028838,0.0014624732,0.00017971414,0.000021982649,0.008023591],"genre_scores_gemma":[0.9976943,0.000044093358,0.00045379135,0.00043859603,0.00020258162,0.00008224802,0.00028927615,0.000043603955,0.0007515138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968589,0.00023054646,0.00087364326,0.00075048266,0.0006009282,0.0006854972],"domain_scores_gemma":[0.99797845,0.0003492698,0.00036875324,0.00054425834,0.0005023977,0.00025688065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005383477,0.00034209725,0.0010007,0.00040787613,0.00014924802,0.000013440512,0.0003210082,0.00023165425,0.00018476737],"category_scores_gemma":[0.0001391526,0.0002462712,0.000059732563,0.00052287895,0.00053982006,0.00016188722,0.00016337169,0.0006647099,0.00006719948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10415243,0.015406482,0.85960126,0.00015220707,0.00016914507,0.0005945368,0.006463739,0.00011643676,0.0022548148,0.000011879012,0.005666982,0.0054100677],"study_design_scores_gemma":[0.019621992,0.16658537,0.7842251,0.00063358503,0.00003205181,0.000008113592,0.0015191883,0.000049271846,0.016729305,0.000034529086,0.01022572,0.00033577965],"about_ca_topic_score_codex":0.0026333814,"about_ca_topic_score_gemma":0.0038045794,"teacher_disagreement_score":0.15117888,"about_ca_system_score_codex":0.00012936983,"about_ca_system_score_gemma":0.00044978826,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W2898304683","doi":"10.1093/annonc/mdy270.187","title":"Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Internal medicine; Oncology; Docetaxel; Population; Pertuzumab; Trastuzumab; Chemotherapy; Breast cancer; Cancer","score_opus":0.1758411817290713,"score_gpt":0.5024193249183248,"score_spread":0.3265781431892535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898304683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97392845,0.0021261019,0.0000069327566,0.017812598,0.00012091223,0.0006193861,0.0001170298,0.0000208071,0.0052478076],"genre_scores_gemma":[0.99649864,0.0015154091,0.0003445892,0.00077372923,0.00034393772,0.00011073618,0.000011430089,0.000034094857,0.00036745783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996232,0.0012787589,0.00056317216,0.00038158914,0.0008888633,0.0006556208],"domain_scores_gemma":[0.9967857,0.0008249249,0.00016053508,0.0007287628,0.0011743297,0.00032574873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003927975,0.00014163268,0.0005622717,0.00064850296,0.000050738872,0.000006050939,0.00027846056,0.00023136745,0.0010007819],"category_scores_gemma":[0.0022396126,0.00011797501,0.0001088555,0.0006867095,0.0025997504,0.000068198424,0.000137451,0.0006632841,0.000068677895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018225785,0.0024936912,0.86721015,0.0006612915,0.00022444951,0.0008140144,0.0024190615,0.000016674227,0.003320332,0.000247236,0.07198377,0.032383554],"study_design_scores_gemma":[0.0028956744,0.0101229735,0.9044827,0.0005175186,0.000036699344,0.0000037205464,0.0003143217,0.00011775745,0.014616434,0.0016864712,0.0650938,0.0001119225],"about_ca_topic_score_codex":0.00088168675,"about_ca_topic_score_gemma":0.0006081949,"teacher_disagreement_score":0.03727256,"about_ca_system_score_codex":0.00009318455,"about_ca_system_score_gemma":0.0020145052,"threshold_uncertainty_score":0.99991244},"labels":[],"label_agreement":null},{"id":"W2898307089","doi":"10.1093/annonc/mdy300.048","title":"Nutritional cancer care: Slowly evolving clinical practice reveals regional and professional HCP variability","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Ono Pharmaceutical; Helsinn; Danone; Celgene","keywords":"Medicine; Malnutrition; Discontinuation; Specialty; Weight loss; Quality of life (healthcare); Family medicine; Medical nutrition therapy; Cancer; Best practice; Intensive care medicine; Nursing; Internal medicine; Obesity","score_opus":0.2382280511207818,"score_gpt":0.5683527201608417,"score_spread":0.3301246690400599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898307089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63055634,0.0055031893,0.00014403157,0.33228657,0.0020452612,0.0009917668,0.00007943882,0.00006382627,0.028329583],"genre_scores_gemma":[0.90655047,0.0025924747,0.02999496,0.057539813,0.0027842736,0.00007741293,0.00004095396,0.000016146438,0.00040350473],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978078,0.00052675675,0.00073703524,0.00034517143,0.00030523288,0.0002779825],"domain_scores_gemma":[0.9952462,0.0018153482,0.00034033463,0.00019258553,0.0021407336,0.0002648338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023592887,0.00010933653,0.00048062953,0.00008746109,0.0001575809,0.000005023485,0.00006974281,0.00027956016,0.0006021552],"category_scores_gemma":[0.002372083,0.0000982993,0.00009170629,0.000139202,0.00059133454,0.00013897021,0.00006511763,0.00041670952,0.000015185041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050761374,0.0034068825,0.30903697,0.001500624,0.00021223899,0.00007036009,0.0012176968,1.4773248e-7,0.0011766487,0.01832788,0.58836323,0.07161117],"study_design_scores_gemma":[0.0028127688,0.0023208396,0.32102278,0.00050244725,0.000067308974,0.00018315908,0.00031317072,0.000041974927,0.0001233907,0.004695798,0.6678116,0.0001047969],"about_ca_topic_score_codex":0.000060377115,"about_ca_topic_score_gemma":0.000017268223,"teacher_disagreement_score":0.27599412,"about_ca_system_score_codex":0.00007769822,"about_ca_system_score_gemma":0.0011186214,"threshold_uncertainty_score":0.6593178},"labels":[],"label_agreement":null},{"id":"W2898319351","doi":"10.1093/annonc/mdy297.008","title":"Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Food and drug administration; Drug; Clinical research; Randomized controlled trial; Sample size determination; Intensive care medicine; Internal medicine; Pharmacology; Oncology","score_opus":0.6028446155138186,"score_gpt":0.5748976126229896,"score_spread":0.027947002890829076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898319351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832837,0.0007993831,0.00023454866,0.00910022,0.00036582985,0.000640128,0.00046381739,0.0000068164627,0.0051055863],"genre_scores_gemma":[0.99245447,0.00056941935,0.0052525173,0.0012547618,0.0003432724,0.000020613486,0.00002163035,0.00001826164,0.0000650453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98808414,0.0005889259,0.0104327705,0.00048161944,0.00011538391,0.0002971445],"domain_scores_gemma":[0.9830554,0.004054636,0.011913127,0.00039163753,0.00045153595,0.00013362886],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04024326,0.00017491728,0.0031024723,0.00022270925,0.000058009588,0.000009334689,0.00019885717,0.000316234,0.00012758406],"category_scores_gemma":[0.00869112,0.00020416621,0.00022683597,0.00014481814,0.0007264279,0.00028369392,0.000097854994,0.00013782679,0.000010792223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002344394,0.0033016542,0.7004131,0.0060419934,0.001838937,0.0000029036282,0.025079308,0.00003052368,0.00035726104,0.1693952,0.019694678,0.07150001],"study_design_scores_gemma":[0.015854368,0.03425368,0.76788086,0.00072223536,0.00028371342,0.000051684765,0.009520899,0.0023993838,0.015563896,0.111346915,0.040908244,0.0012141202],"about_ca_topic_score_codex":0.001081347,"about_ca_topic_score_gemma":0.00051939057,"teacher_disagreement_score":0.070285894,"about_ca_system_score_codex":0.000025717141,"about_ca_system_score_gemma":0.00041425254,"threshold_uncertainty_score":0.9996591},"labels":[],"label_agreement":null},{"id":"W2898328822","doi":"10.1093/annonc/mdy295.018","title":"Integration of oncology and palliative care","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palliative care; Multidisciplinary approach; Competence (human resources); Oncology; Health care; Commission; Focus group; Nursing; Family medicine; Internal medicine; Psychology","score_opus":0.38161138635363745,"score_gpt":0.5527711580623488,"score_spread":0.17115977170871133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898328822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440521,0.003048727,0.00019133496,0.0022038294,0.00015290407,0.00016951695,0.000024034913,0.0000083155455,0.050149236],"genre_scores_gemma":[0.9928002,0.002606557,0.0036149693,0.0006907029,0.00014381522,0.0000063074626,0.000022107133,0.0000067612914,0.00010860627],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992047,0.00009126796,0.00033721945,0.00013786923,0.00010089436,0.00012806324],"domain_scores_gemma":[0.99812794,0.00031491063,0.0002860971,0.00012906957,0.0010827254,0.000059260205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017384435,0.00008697754,0.0005485495,0.000113885675,0.000016665732,6.7546097e-7,0.000055565,0.00018198483,0.000078816156],"category_scores_gemma":[0.000495248,0.00007017976,0.00006483695,0.00012127372,0.00052884524,0.00003503971,0.00003617741,0.00009430448,0.0000052368237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021866725,0.00062698725,0.10263817,0.00048171356,0.00045244768,0.000034657383,0.072753586,9.2954076e-7,0.09954226,0.005262616,0.012027817,0.7039921],"study_design_scores_gemma":[0.0024993913,0.03236192,0.07957143,0.0006098976,0.00015477862,0.0000079167385,0.015762564,0.000039107596,0.4665232,0.0011339458,0.40120992,0.0001259218],"about_ca_topic_score_codex":0.00018897887,"about_ca_topic_score_gemma":0.0002889827,"teacher_disagreement_score":0.70386624,"about_ca_system_score_codex":0.000034377637,"about_ca_system_score_gemma":0.00022637928,"threshold_uncertainty_score":0.28618476},"labels":[],"label_agreement":null},{"id":"W2898330783","doi":"10.1093/annonc/mdy282.085","title":"Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Gastroenterology; Placebo; Cabozantinib; Progression-free survival; Overall survival; Cancer; Pathology","score_opus":0.17382696279746004,"score_gpt":0.39320746717857047,"score_spread":0.21938050438111042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898330783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037737,0.00086939754,0.000029857156,0.0029868495,0.00023808176,0.0039415765,0.00009370458,0.000021162767,0.0014419873],"genre_scores_gemma":[0.9983183,0.00014180335,0.00024972626,0.00038537124,0.0001570978,0.0003423873,0.00017777864,0.000034557423,0.0001929552],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99648106,0.0007865865,0.0012482149,0.00048087214,0.0003975105,0.0006057567],"domain_scores_gemma":[0.9976905,0.00083945337,0.0004873204,0.0005601975,0.0002777345,0.00014479096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018081174,0.0003680748,0.0014615497,0.00027698738,0.000051524225,0.0000064642745,0.00028823293,0.00034355483,0.00024788707],"category_scores_gemma":[0.0005501003,0.0002691399,0.00029235004,0.0005212697,0.0003578035,0.000101548685,0.000056805806,0.00029931133,0.000015931158],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30132064,0.008589961,0.5909444,0.0001429045,0.00031978966,0.0011505451,0.0027449336,8.59498e-7,0.023927653,0.00008110321,0.0019158979,0.06886132],"study_design_scores_gemma":[0.61925614,0.061456,0.018277707,0.00017058318,0.0004262444,0.0000342129,0.00052766333,0.0016852173,0.2744852,0.000047506193,0.02317409,0.00045943848],"about_ca_topic_score_codex":0.002033494,"about_ca_topic_score_gemma":0.0006473282,"teacher_disagreement_score":0.5726667,"about_ca_system_score_codex":0.00007163238,"about_ca_system_score_gemma":0.00042331012,"threshold_uncertainty_score":0.9999761},"labels":[],"label_agreement":null},{"id":"W2898340726","doi":"10.1093/annonc/mdy284.022","title":"Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Randomization; Chemotherapy; Proportional hazards model; Oncology; Progression-free survival; Cancer; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.21612272159089332,"score_gpt":0.5034199224800712,"score_spread":0.2872972008891779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898340726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920862,0.0036916556,0.0000016179353,0.0010302889,0.00011015965,0.0008891413,0.00033688082,0.0000062779986,0.0018478004],"genre_scores_gemma":[0.9922558,0.0060690097,0.00025121414,0.000014268311,0.000039226186,0.00008967827,0.00020720213,0.000013575648,0.0010600052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986876,0.00013463112,0.00052727916,0.00018743199,0.0002499528,0.00021308311],"domain_scores_gemma":[0.99824756,0.00013323114,0.00049199566,0.00020035249,0.000843843,0.00008300112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014765291,0.00014515182,0.000658882,0.00012355018,0.000034468285,0.000001367111,0.000044896988,0.000077139775,0.00022686599],"category_scores_gemma":[0.000035935627,0.00009375032,0.00010258042,0.00022399805,0.0003799644,0.000046217152,0.000018237544,0.000028065417,0.0000031845532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025091084,0.0067105233,0.0633577,0.0006474846,0.00191182,0.000049856088,0.0054376526,0.000010597749,0.7398851,0.00015834041,0.001658688,0.15508115],"study_design_scores_gemma":[0.0060373866,0.08076641,0.013612428,0.0001413145,0.0003079631,0.000005793687,0.00028293536,0.000039323248,0.8908698,0.00006556829,0.007798894,0.00007218952],"about_ca_topic_score_codex":0.0008780974,"about_ca_topic_score_gemma":0.0004125184,"teacher_disagreement_score":0.15500897,"about_ca_system_score_codex":0.00032401856,"about_ca_system_score_gemma":0.0009472891,"threshold_uncertainty_score":0.3823027},"labels":[],"label_agreement":null},{"id":"W2898345768","doi":"10.1093/annonc/mdy295.002","title":"A prospective study examining cachexia predictors in patients with incurable cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cachexia; Internal medicine; Cancer; Prospective cohort study; Weight loss; Breast cancer; Palliative care; Body mass index; Oncology; Obesity","score_opus":0.12696832871559907,"score_gpt":0.44500456388844933,"score_spread":0.3180362351728503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898345768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917878,0.00005969345,0.0000020472737,0.0009844768,0.00011507009,0.00081918854,0.000005182303,0.000017574883,0.006208984],"genre_scores_gemma":[0.99827594,0.000020032167,0.00017696571,0.0012105876,0.00010890717,0.00008982503,0.0000035165813,0.000010291809,0.000103956074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991303,0.00006650079,0.00025233315,0.0001775225,0.00015416174,0.00021916223],"domain_scores_gemma":[0.9992435,0.000045745575,0.00012306395,0.00011427831,0.00039085472,0.00008257519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002891968,0.00007481382,0.00031717602,0.00015156812,0.000039409722,0.0000018625342,0.000042827483,0.000059921094,0.00014196557],"category_scores_gemma":[0.000063283886,0.000058970818,0.0000113796095,0.00023918923,0.00011410639,0.000051844952,0.000022574248,0.00015210171,0.0000050821727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011612226,0.0017651839,0.98887163,0.00004482543,0.00004553697,0.000010087207,0.0032038295,4.8363376e-7,0.0000152566645,0.000023910194,0.0009652516,0.003892778],"study_design_scores_gemma":[0.0061163045,0.019498993,0.97101325,0.00015498967,0.000019888927,0.0000012465026,0.00071795325,0.000008443391,0.00022410428,0.000039829374,0.002153508,0.000051481173],"about_ca_topic_score_codex":0.00044664432,"about_ca_topic_score_gemma":0.0008572686,"teacher_disagreement_score":0.017858377,"about_ca_system_score_codex":0.00009173854,"about_ca_system_score_gemma":0.0002627735,"threshold_uncertainty_score":0.24047603},"labels":[],"label_agreement":null},{"id":"W2898348027","doi":"10.1093/annonc/mdy424.054","title":"Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Oncology; Melanoma; Internal medicine; Immunotherapy; Cancer; Cancer research","score_opus":0.07025226007946675,"score_gpt":0.3951179964264698,"score_spread":0.324865736347003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898348027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957672,0.000505225,0.000004511611,0.00055514777,0.00058703497,0.000737969,0.000017325006,0.000007791751,0.0018178271],"genre_scores_gemma":[0.99767864,0.0015568286,0.000053725955,0.0002183855,0.00005246952,0.000024908733,0.000023936664,0.000014499161,0.000376617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841213,0.00017796649,0.0007705085,0.0001969557,0.00021985362,0.00022259446],"domain_scores_gemma":[0.9989111,0.0001660667,0.00045683063,0.00024221414,0.00018768867,0.00003612023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000813,0.00011692649,0.0008033543,0.00026892291,0.000012912025,0.0000013058798,0.00011887132,0.0001796811,0.00019613966],"category_scores_gemma":[0.00009300249,0.00011536115,0.00016081294,0.0002798308,0.00026032346,0.00007006352,0.00003308629,0.000096631025,0.0000020647954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6544734,0.0021927957,0.0012209167,0.00004285046,0.00016382434,0.000022189397,0.002051787,0.000002051945,0.1248783,0.00010062467,0.00029448484,0.21455674],"study_design_scores_gemma":[0.80915457,0.059684154,0.039662506,0.0001879234,0.000026016,0.000010059212,0.00025615375,0.00013919504,0.07923193,0.00033745376,0.011143521,0.00016652471],"about_ca_topic_score_codex":0.0011239602,"about_ca_topic_score_gemma":0.0016180857,"teacher_disagreement_score":0.21439022,"about_ca_system_score_codex":0.00016054504,"about_ca_system_score_gemma":0.0003370509,"threshold_uncertainty_score":0.47042912},"labels":[],"label_agreement":null},{"id":"W2898349859","doi":"10.1093/annonc/mdy282.107","title":"Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Genentech; CYTED Ciencia y Tecnología para el Desarrollo; Novocure; Celgene; Pfizer","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Gastroenterology; Pancreatic cancer; Chemotherapy; Chemotherapy regimen; Cancer; Surgery; Irinotecan","score_opus":0.08451817346487583,"score_gpt":0.45015078741217307,"score_spread":0.36563261394729724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898349859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96445614,0.0003100006,0.000046723067,0.0005570078,0.00012626477,0.0016947284,0.000046492798,0.000022360937,0.032740258],"genre_scores_gemma":[0.996936,0.0005549241,0.0010638221,0.00024590993,0.000097041186,0.0003220762,0.00004232574,0.00003106709,0.00070681266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968052,0.000738065,0.0007986755,0.00049673626,0.00047885964,0.0006824739],"domain_scores_gemma":[0.99577075,0.0015295907,0.0004894948,0.00049193576,0.0014853218,0.00023288661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011206293,0.00030788785,0.0023874035,0.0004980235,0.00006882226,0.000003541377,0.00023178484,0.00022628914,0.00026820184],"category_scores_gemma":[0.00034430748,0.00023724046,0.00011589432,0.000819554,0.0012398077,0.00013402653,0.00011354943,0.00035983662,0.000025690284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03332304,0.0019781047,0.952591,0.00073851726,0.0006738823,0.000049459457,0.0015683228,0.000030706542,0.0015771778,0.00085862307,0.00085342757,0.005757749],"study_design_scores_gemma":[0.0155521715,0.030294273,0.9436462,0.0010709466,0.00024511968,0.000006672216,0.00025670746,0.00020215177,0.0068082106,0.00041450546,0.0012991944,0.00020385612],"about_ca_topic_score_codex":0.0032700112,"about_ca_topic_score_gemma":0.0040897285,"teacher_disagreement_score":0.032479856,"about_ca_system_score_codex":0.00044342253,"about_ca_system_score_gemma":0.0014265585,"threshold_uncertainty_score":0.9674385},"labels":[],"label_agreement":null},{"id":"W2898353693","doi":"10.1093/annonc/mdy287.074","title":"IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Oncology; Head and neck; Adjuvant; Internal medicine; Basal cell; Head and neck cancer; Adjuvant therapy; Cancer; Immunotherapy; Surgery; Nivolumab","score_opus":0.04919813182413135,"score_gpt":0.37082337033940665,"score_spread":0.3216252385152753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898353693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98681164,0.0074043074,0.00000638814,0.0006359291,0.00017799503,0.0019109112,0.000038457492,0.000006791762,0.0030075614],"genre_scores_gemma":[0.9960144,0.002627532,0.00005264078,0.0009991686,0.00005934057,0.0000816675,0.0000033709593,0.000025754336,0.00013612914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997657,0.00050217827,0.0010381188,0.00028148707,0.0002747148,0.0002465008],"domain_scores_gemma":[0.99754375,0.0004687694,0.00088126026,0.00049551856,0.0005477176,0.00006300341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007950555,0.00023199238,0.0015955828,0.00016386442,0.000042211166,0.0000025604797,0.00018573673,0.00018399447,0.00048653086],"category_scores_gemma":[0.000069310336,0.00014431057,0.00036620058,0.00025536225,0.0012456357,0.000047340058,0.00005174018,0.00013969878,0.0000016303172],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8442559,0.006593639,0.006224579,0.00009282672,0.0006807725,0.000019680143,0.016653234,4.4265218e-7,0.053644877,0.00002910089,0.00036211664,0.07144281],"study_design_scores_gemma":[0.5607765,0.048656892,0.047213364,0.000088948414,0.00019526754,0.000024929892,0.0020825928,0.000019152341,0.33895305,0.00017482328,0.0016610428,0.00015345836],"about_ca_topic_score_codex":0.0027295894,"about_ca_topic_score_gemma":0.00022009587,"teacher_disagreement_score":0.28530815,"about_ca_system_score_codex":0.000024102652,"about_ca_system_score_gemma":0.00032832834,"threshold_uncertainty_score":0.5884814},"labels":[],"label_agreement":null},{"id":"W2898360472","doi":"10.1093/annonc/mdy281.100","title":"KRAS-dependent and independent mechanisms of progressive disease (PD) in colorectal cancer (CRC) patients (pts) with liver metastases (LM) while monitoring on circulating cell free DNA (cfDNA)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; KRAS; Internal medicine; Colorectal cancer; Oncology; Gastroenterology; Liquid biopsy; Concordance; Cancer","score_opus":0.028047025183405707,"score_gpt":0.29932992625565336,"score_spread":0.2712829010722477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898360472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758303,0.0011651124,0.000056863915,0.00007921543,0.00017405766,0.00035881638,0.00028371444,0.0000032718822,0.00029591323],"genre_scores_gemma":[0.9985534,0.00066847535,0.00036905325,0.0001278063,0.00014199375,0.00007287029,0.000036316138,0.000021724101,0.000008348107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988497,0.0000713849,0.00027347825,0.00035813352,0.00019037112,0.00025692582],"domain_scores_gemma":[0.99899244,0.000057035162,0.00031131212,0.00021500613,0.00030130727,0.0001229102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014787969,0.00016710575,0.00027636896,0.00007903442,0.000045448214,0.000009313846,0.00016745034,0.00012317553,0.000022186707],"category_scores_gemma":[0.000090306865,0.00015292635,0.000049495546,0.00007147426,0.0001562834,0.0000071391896,0.00017824292,0.000084867184,8.0295206e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066872556,0.0037578915,0.37229124,0.0003407572,0.00048162628,0.00020718173,0.0011933632,0.0010134033,0.5639426,0.0006943966,0.0007104954,0.048679758],"study_design_scores_gemma":[0.002411731,0.0072202375,0.093348406,0.00010790569,0.00006590853,0.0000031473107,0.00012409696,0.000059163107,0.895801,0.00031561905,0.00032167617,0.00022107214],"about_ca_topic_score_codex":0.00031161826,"about_ca_topic_score_gemma":0.0007464509,"teacher_disagreement_score":0.3318584,"about_ca_system_score_codex":0.000034816254,"about_ca_system_score_gemma":0.00025485296,"threshold_uncertainty_score":0.6236156},"labels":[],"label_agreement":null},{"id":"W2898361810","doi":"10.1093/annonc/mdy288.029","title":"Initial safety assessment of MAGE-A4 SPEAR T-cells","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Context (archaeology); Internal medicine; Radioimmunotherapy; Oncology; Gastroenterology; Adverse effect; Immunology; Antibody","score_opus":0.1546058658359326,"score_gpt":0.5108487402034521,"score_spread":0.35624287436751945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898361810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5746314,0.00007838182,0.00015295148,0.0041877455,0.00030619622,0.00036947615,0.00002462939,0.00001561084,0.4202336],"genre_scores_gemma":[0.9906221,0.0004331273,0.0016609946,0.0013148896,0.00056402193,0.000005899961,0.000013107788,0.00002071301,0.0053651403],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985265,0.00018406968,0.0004335118,0.00019475508,0.0003536112,0.0003075151],"domain_scores_gemma":[0.9985135,0.00023535846,0.00016073129,0.00037024598,0.0005908216,0.0001293208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009686276,0.00010100647,0.00052008213,0.00016209293,0.000028169548,0.0000025840477,0.00015381059,0.00015761233,0.01286668],"category_scores_gemma":[0.000088568915,0.000089661735,0.00013587218,0.00018557395,0.00056804484,0.000035257304,0.000102554026,0.0002221749,0.000084391744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022615164,0.0011700522,0.0030255634,0.00012712202,0.0002818735,0.000116743104,0.00045490693,0.0000018907306,0.76124245,0.0008143793,0.025564877,0.20493864],"study_design_scores_gemma":[0.0030214437,0.016797362,0.027468342,0.000055780332,0.000044448363,0.00004760544,0.00016172434,0.00011300887,0.46750686,0.00034502023,0.48433504,0.00010335007],"about_ca_topic_score_codex":0.00012107299,"about_ca_topic_score_gemma":0.000038949005,"teacher_disagreement_score":0.45877016,"about_ca_system_score_codex":0.000053780856,"about_ca_system_score_gemma":0.0006177337,"threshold_uncertainty_score":0.9880357},"labels":[],"label_agreement":null},{"id":"W2898372506","doi":"10.1093/annonc/mdy284.014","title":"A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Internal medicine; Doubling time; Placebo; Oncology; Randomized controlled trial; Gynecology; Urology; Cancer; Androgen receptor; Pathology","score_opus":0.08967654066231087,"score_gpt":0.42629916082557195,"score_spread":0.33662262016326105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898372506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98601854,0.0013042245,0.000005918438,0.001360222,0.000026465248,0.008891431,0.00007388983,0.000007965153,0.0023113496],"genre_scores_gemma":[0.9958244,0.0011549752,0.00010555812,0.00006365733,0.000034406174,0.0010904133,0.000043021086,0.00002021454,0.0016633375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973654,0.0003679878,0.0011273309,0.0003834262,0.00040902052,0.00034682383],"domain_scores_gemma":[0.9978524,0.00044456313,0.0007541832,0.00027959602,0.00054335315,0.00012592769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015006377,0.00022334655,0.001843726,0.0003070083,0.00004617439,0.000008328432,0.000091740374,0.00010036863,0.00002200703],"category_scores_gemma":[0.00013412193,0.00013984332,0.00008331789,0.00034223867,0.00079456746,0.0001063357,0.000038454593,0.00016966433,4.7135455e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9625827,0.005319954,0.0010246543,0.00018607242,0.0011236632,0.00029820236,0.010292819,0.000010065462,0.015143627,0.00001971589,0.0012759396,0.0027225646],"study_design_scores_gemma":[0.93984824,0.032084707,0.00034969527,0.00027034094,0.00044897827,0.00001341492,0.0019758132,0.00015896365,0.024469538,0.00004924255,0.00021406764,0.000116984964],"about_ca_topic_score_codex":0.0033076452,"about_ca_topic_score_gemma":0.0035605226,"teacher_disagreement_score":0.026764754,"about_ca_system_score_codex":0.00007179415,"about_ca_system_score_gemma":0.00058612425,"threshold_uncertainty_score":0.5702645},"labels":[],"label_agreement":null},{"id":"W2898372971","doi":"10.1093/annonc/mdy281.119","title":"Influence of not having children on mortality in patients with metastatic (mCRC) colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Proportional hazards model; Chemotherapy; Hazard ratio; Multivariate analysis; Metastasectomy; Anemia; Leukocytosis; Cancer; Oncology; Gastroenterology; Confidence interval","score_opus":0.06268382674564384,"score_gpt":0.40011653806696956,"score_spread":0.33743271132132574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898372971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520046,0.000008345772,6.218645e-7,0.00030836975,0.00010472969,0.00031291842,0.00005410129,0.000009316971,0.0040011154],"genre_scores_gemma":[0.9992227,0.000017409,0.00007125613,0.0006054415,0.000033584252,0.000022339673,0.0000044622243,0.0000070992864,0.000015695448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856484,0.000253166,0.0003204755,0.00019653709,0.00037644512,0.00028853398],"domain_scores_gemma":[0.99888253,0.0002062903,0.0003135331,0.00013614501,0.00039964652,0.000061837665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070772064,0.00009034611,0.0003324207,0.00010048398,0.000078180754,0.0000041944186,0.00025445197,0.00008098459,0.000109316665],"category_scores_gemma":[0.0003384507,0.00007833261,0.0000328249,0.0003343951,0.0009967017,0.00015449717,0.000043034684,0.00010095669,0.000006095683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022396751,0.0003540105,0.9888768,0.000007428779,0.00004974481,0.000002084851,0.0041629467,0.00016160255,0.00005956263,0.0004732522,0.00017761691,0.005450985],"study_design_scores_gemma":[0.0005118108,0.0012947407,0.9947397,0.000041343337,0.000015510022,9.82355e-8,0.00023992998,0.0000030464807,0.0026115808,0.00016829745,0.00028618553,0.00008772011],"about_ca_topic_score_codex":0.024552954,"about_ca_topic_score_gemma":0.029113853,"teacher_disagreement_score":0.0058629387,"about_ca_system_score_codex":0.0000669889,"about_ca_system_score_gemma":0.00047932728,"threshold_uncertainty_score":0.9886023},"labels":[],"label_agreement":null},{"id":"W2898376257","doi":"10.1093/annonc/mdy424.043","title":"Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Eisai; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Internal medicine; Oncology; BRCA mutation; Population; Cancer; Immunotherapy","score_opus":0.06020003525901501,"score_gpt":0.4252376011103097,"score_spread":0.3650375658512947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898376257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516267,0.00018913292,0.000017486775,0.00294157,0.0001698772,0.0013236246,0.00014540294,0.000009332615,0.00004091332],"genre_scores_gemma":[0.997979,0.00018820808,0.0011486328,0.00042889165,0.000105332554,0.00006147988,0.000035679932,0.00001407584,0.000038739723],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9977219,0.00064342044,0.00071701297,0.00036913806,0.00034070748,0.0002078223],"domain_scores_gemma":[0.99782413,0.0006255076,0.00068078894,0.00033734934,0.00045223557,0.0000799989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016235486,0.0001406578,0.00049694837,0.00009148933,0.00008710003,0.000004199235,0.0001081523,0.00013593369,0.000021118263],"category_scores_gemma":[0.0005870447,0.000081889244,0.00004056414,0.00023798143,0.00012479401,0.000071823415,0.00007597047,0.00018488454,3.9850121e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69010806,0.0034405873,0.17243868,0.000008552949,0.00014459356,0.0000051420316,0.0040992294,0.0000043143677,0.056884933,1.7893532e-7,0.0008641994,0.07200152],"study_design_scores_gemma":[0.06823421,0.092307314,0.7610981,0.0006539602,0.00007075764,6.305052e-7,0.0005537658,0.000011497218,0.07419929,0.0000049634696,0.0027539954,0.000111504],"about_ca_topic_score_codex":0.00030407764,"about_ca_topic_score_gemma":0.00041356607,"teacher_disagreement_score":0.62187386,"about_ca_system_score_codex":0.000107110354,"about_ca_system_score_gemma":0.00032218124,"threshold_uncertainty_score":0.33393463},"labels":[],"label_agreement":null},{"id":"W2898384408","doi":"10.1093/annonc/mdy284.005","title":"Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Cancer; Loss of heterozygosity; Internal medicine; Prostate; Cell-free fetal DNA; Pathology; Gene; Allele; Biology; Genetics","score_opus":0.0390880378952891,"score_gpt":0.35354155037282914,"score_spread":0.31445351247754005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898384408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983951,0.00025306983,0.0002560131,0.00016304106,0.00010621288,0.00013052965,0.000057092035,0.0000017543086,0.0006371994],"genre_scores_gemma":[0.99876297,0.00027186342,0.00038216315,0.00042113173,0.00011049816,0.00001584634,0.000008612331,0.0000103266375,0.00001660309],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928284,0.00006530668,0.00025021873,0.00016127793,0.000044766883,0.00019557023],"domain_scores_gemma":[0.99937,0.00004035819,0.00019663323,0.00010997785,0.00024478295,0.000038266633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025338156,0.0000775402,0.00019437124,0.0000538125,0.000019233954,0.0000026872317,0.000051713192,0.000055884226,0.0000066730972],"category_scores_gemma":[0.00015577987,0.00008253188,0.000045815774,0.00009231328,0.00014072341,0.0000024699023,0.000040345756,0.000049298298,0.0000010450276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023935584,0.00007083416,0.0022598943,0.000028074537,0.000049299957,0.000023330307,0.0003684761,0.000342245,0.9779511,0.000033008044,0.000046757614,0.018587643],"study_design_scores_gemma":[0.0005560392,0.001681421,0.010100913,0.000023007751,0.000018030883,0.00004685475,0.00022344064,0.0002673151,0.9849031,0.0002114405,0.0018833389,0.00008512574],"about_ca_topic_score_codex":0.0006844696,"about_ca_topic_score_gemma":0.003985696,"teacher_disagreement_score":0.018502517,"about_ca_system_score_codex":0.000024428398,"about_ca_system_score_gemma":0.00035426096,"threshold_uncertainty_score":0.33655524},"labels":[],"label_agreement":null},{"id":"W2898387476","doi":"10.1093/annonc/mdy297.007","title":"Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Food and drug administration; Marketing authorization; Authorization; Family medicine; Internal medicine; Pharmacology; Bioinformatics","score_opus":0.4063064808284143,"score_gpt":0.4844896776090462,"score_spread":0.0781831967806319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898387476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921734,0.00029235048,0.00011726061,0.005309225,0.00030247643,0.00059800857,0.00026419485,0.0000097518505,0.003889395],"genre_scores_gemma":[0.99691623,0.00064357097,0.0009343894,0.0009158743,0.00045023937,0.0000140112,0.00008095144,0.000017675406,0.00002704754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454516,0.0007529448,0.0037989612,0.000513277,0.00006332353,0.00032633328],"domain_scores_gemma":[0.99469846,0.0019274756,0.0028447784,0.00013125908,0.000169487,0.00022850848],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033445496,0.00018009912,0.0014805872,0.00032149098,0.00008192144,0.000037023005,0.00011385397,0.00017174406,0.00023455925],"category_scores_gemma":[0.009414854,0.0001913689,0.00011999032,0.00015028006,0.00028257445,0.00019466801,0.00012307952,0.00018715649,0.0000066119055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010549448,0.0014791922,0.48549157,0.0013384549,0.000998762,0.000056158035,0.0069308495,0.000040511717,0.009836469,0.06504492,0.0064400355,0.41179362],"study_design_scores_gemma":[0.013223967,0.01002145,0.8987828,0.00019475726,0.00017553485,0.00006935987,0.0010012137,0.009883845,0.011945761,0.034091804,0.019719468,0.00089007843],"about_ca_topic_score_codex":0.0000693744,"about_ca_topic_score_gemma":0.00009244397,"teacher_disagreement_score":0.4132912,"about_ca_system_score_codex":0.000024806171,"about_ca_system_score_gemma":0.00011861162,"threshold_uncertainty_score":0.99892926},"labels":[],"label_agreement":null},{"id":"W2898389053","doi":"10.1093/annonc/mdy282.089","title":"Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Sorafenib; Hazard ratio; Proportional hazards model; Hepatitis B virus; Ethnic group; Hepatitis C virus; Hepatitis C; Liver cancer; Hepatitis B; Cohort; Cancer; Gastroenterology; Immunology; Virus; Confidence interval","score_opus":0.14225143200843965,"score_gpt":0.3159163087114056,"score_spread":0.17366487670296593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898389053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957998,0.0001957592,0.0000122559395,0.0013424684,0.000030378364,0.0010230606,0.001022406,0.000024800556,0.0005490636],"genre_scores_gemma":[0.9953917,0.000017239217,0.0013655297,0.0001991985,0.00006693734,0.000018800496,0.002793072,0.000036422305,0.00011106173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978936,0.00030020525,0.0004820055,0.0005666119,0.0002492742,0.00050834223],"domain_scores_gemma":[0.9980172,0.00041752344,0.00023719978,0.00045315808,0.0003954769,0.00047944093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032184168,0.00029101613,0.00074949156,0.00028547132,0.00010254808,0.000009318678,0.00010161253,0.00025507592,0.000040329094],"category_scores_gemma":[0.00022362712,0.00022789711,0.00005288212,0.0003316739,0.0002720793,0.00016161946,0.000040595347,0.0002752032,0.000014312125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004664958,0.00048434164,0.991125,0.000027307096,0.00012470662,0.00032430372,0.0009264316,4.3218617e-7,0.000032762582,0.000014927809,0.00014402176,0.0021308118],"study_design_scores_gemma":[0.020149458,0.004298499,0.9719962,0.00013610185,0.00021724944,0.0000020735965,0.000080700025,0.00029314982,0.0014361251,0.000013757654,0.0011468527,0.00022984459],"about_ca_topic_score_codex":0.12312402,"about_ca_topic_score_gemma":0.16535963,"teacher_disagreement_score":0.04223561,"about_ca_system_score_codex":0.00014459135,"about_ca_system_score_gemma":0.0005229211,"threshold_uncertainty_score":0.92933744},"labels":[],"label_agreement":null},{"id":"W2898391667","doi":"10.1093/annonc/mdy300.007","title":"Acceptability in cancer outpatients of completing routine assessments of patient reported outcomes of common terminology criteria for adverse events (PRO-CTCAE) versus other patient reported symptom outcome tools","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre; Public Health Ontario; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Cancer; Patient-reported outcome; Adverse effect; Internal medicine; Prostate cancer; Genitourinary system; Physical therapy; Quality of life (healthcare)","score_opus":0.6823911024910112,"score_gpt":0.583005353882235,"score_spread":0.09938574860877625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898391667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928297,0.00008582976,0.00011967979,0.0016647789,0.0014694396,0.001706626,0.0009668854,0.000012214475,0.001144836],"genre_scores_gemma":[0.9962622,0.00001636428,0.0022512018,0.0011099798,0.00004148521,0.00020095697,0.00006368878,0.000029638059,0.000024472993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9871789,0.00059928413,0.010987028,0.0005882673,0.00017573246,0.0004707553],"domain_scores_gemma":[0.98223215,0.0017235908,0.014421596,0.00081900036,0.00070469565,0.00009894876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071509173,0.00025809172,0.0027734807,0.0004564026,0.000053580687,0.0000031443099,0.00032492614,0.00029469354,0.00041374422],"category_scores_gemma":[0.0061796685,0.0002948422,0.00029867963,0.0002251819,0.00029630048,0.00025790397,0.00017534992,0.00013470849,0.000006234525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007398362,0.0014620259,0.9899371,0.0004669364,0.0003848472,8.9690184e-7,0.0023241437,0.000054669883,0.00003974681,0.00072565395,0.00033797653,0.003526129],"study_design_scores_gemma":[0.004322964,0.0043402687,0.98418355,0.000114790746,0.00003821827,0.0000012165734,0.0011415954,0.0005978287,0.0006404097,0.0011125649,0.0032650845,0.00024150069],"about_ca_topic_score_codex":0.0063019483,"about_ca_topic_score_gemma":0.001153339,"teacher_disagreement_score":0.0057535795,"about_ca_system_score_codex":0.0003888403,"about_ca_system_score_gemma":0.00028634456,"threshold_uncertainty_score":0.99995035},"labels":[],"label_agreement":null},{"id":"W2898393310","doi":"10.1093/annonc/mdy282.043","title":"Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Avelumab; Internal medicine; Oncology; Merkel cell carcinoma; Progressive disease; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Taxane; Merkel cell polyomavirus; Phases of clinical research; Chemotherapy; Cancer; Urology; Carcinoma; Immunotherapy; Nivolumab; Breast cancer","score_opus":0.045376441438664476,"score_gpt":0.3856050344160249,"score_spread":0.3402285929773604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898393310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519944,0.0003272022,0.000008866634,0.0015911375,0.0007600297,0.0010406587,0.00058635045,0.00003823989,0.00044810039],"genre_scores_gemma":[0.9965887,0.00035355642,0.000120377415,0.0013111003,0.00070953445,0.00005259301,0.000563986,0.0000317994,0.00026834742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99761564,0.00023615501,0.00080549193,0.00045734306,0.000357488,0.00052786316],"domain_scores_gemma":[0.99814844,0.0002197214,0.00054354494,0.000367123,0.00049724383,0.00022392311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030109618,0.0002651287,0.00069362234,0.0001792979,0.000110011446,0.00000999552,0.00018373386,0.0002323834,0.00040684507],"category_scores_gemma":[0.00043580195,0.0001501899,0.00010998228,0.0005418826,0.0003348065,0.00013488537,0.000055551838,0.00034545633,0.00004102941],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88453513,0.0072707916,0.0056365705,0.000019064762,0.00049293,0.00037470646,0.0018352338,0.00012650018,0.003064871,0.0000030314006,0.027426885,0.06921431],"study_design_scores_gemma":[0.60698485,0.06914775,0.30012277,0.0006475443,0.0008725154,0.00004452574,0.0011672832,0.0008597097,0.008007175,0.000043940167,0.011608297,0.0004936117],"about_ca_topic_score_codex":0.0017007078,"about_ca_topic_score_gemma":0.00083464646,"teacher_disagreement_score":0.29448622,"about_ca_system_score_codex":0.000097540185,"about_ca_system_score_gemma":0.00083232106,"threshold_uncertainty_score":0.6124566},"labels":[],"label_agreement":null},{"id":"W2898394782","doi":"10.1093/annonc/mdy424.045","title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Head and neck squamous-cell carcinoma; Internal medicine; Pembrolizumab; Interim analysis; Cisplatin; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Head and neck cancer; Radiation therapy; Nuclear medicine; Randomized controlled trial; Urology; Cancer; Immunotherapy","score_opus":0.10538821966103608,"score_gpt":0.416188050832784,"score_spread":0.3107998311717479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898394782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934772,0.0023600115,0.0000662443,0.0012750971,0.00030007382,0.0013831045,0.000068316695,0.000014537994,0.0010553624],"genre_scores_gemma":[0.9984374,0.00023671937,0.0002818513,0.0005323643,0.00017363015,0.00006432144,0.00002483606,0.000023576134,0.00022532295],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984479,0.00008383996,0.000681516,0.00030600274,0.00016924007,0.00031147944],"domain_scores_gemma":[0.99848,0.00028070385,0.0003851193,0.00032313817,0.000419747,0.00011126139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040828573,0.00018796122,0.0007676615,0.00018011637,0.000079859514,0.00000415995,0.000115971336,0.000100021876,0.00013816245],"category_scores_gemma":[0.00009892465,0.00016015267,0.0001442064,0.00019856641,0.0002988804,0.000049304945,0.000044214274,0.000103622806,0.0000021149174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42143852,0.040501427,0.018016974,0.0021178485,0.00086637744,0.0001261262,0.01633296,0.0000028890513,0.022501511,0.00005538638,0.03297477,0.4450652],"study_design_scores_gemma":[0.25971416,0.5510615,0.025354026,0.0001488331,0.000774984,0.00013567304,0.0027297179,0.00069382566,0.04384604,0.000215447,0.11490177,0.00042399793],"about_ca_topic_score_codex":0.0005555235,"about_ca_topic_score_gemma":0.0010551778,"teacher_disagreement_score":0.5105601,"about_ca_system_score_codex":0.000035504352,"about_ca_system_score_gemma":0.00019021622,"threshold_uncertainty_score":0.6530837},"labels":[],"label_agreement":null},{"id":"W2898400750","doi":"10.1093/annonc/mdy272.355","title":"LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Olaparib; Metastatic breast cancer; Oncology; Internal medicine; BRCA mutation; Breast cancer; Taxane; Cohort; Progression-free survival; Eribulin; Cancer; Chemotherapy","score_opus":0.05783370770299373,"score_gpt":0.43824251956716864,"score_spread":0.3804088118641749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898400750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996945,0.00004920366,0.00004301112,0.00088410324,0.000075073025,0.0010586673,0.00010363258,0.000015726748,0.0008255696],"genre_scores_gemma":[0.9984654,0.0000245015,0.00071499817,0.0004519059,0.000063256666,0.00015059934,0.000015692942,0.000026235779,0.00008737231],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99846494,0.00017692476,0.0005152583,0.0002841407,0.0002915542,0.0002671922],"domain_scores_gemma":[0.9980405,0.00014162183,0.0005272108,0.00022949214,0.000976282,0.00008492131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022063885,0.00017418407,0.0007314996,0.00032119377,0.000030403633,0.0000022057752,0.0000922137,0.00004286405,0.00021791358],"category_scores_gemma":[0.00005677336,0.00013732933,0.00004070181,0.0006516313,0.0003514614,0.00014893856,0.000030193818,0.00013945474,0.0000032554967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050979722,0.03568119,0.41861612,0.00028156044,0.0019248221,0.00016502706,0.053182274,0.0001529737,0.0011688733,0.0001491901,0.00031988817,0.43737838],"study_design_scores_gemma":[0.041693706,0.03626308,0.9118482,0.0003420896,0.00026880944,0.000022706468,0.00451758,0.00008016795,0.00366358,0.0004817116,0.0006189849,0.00019940338],"about_ca_topic_score_codex":0.005669982,"about_ca_topic_score_gemma":0.021539215,"teacher_disagreement_score":0.49323207,"about_ca_system_score_codex":0.00014215041,"about_ca_system_score_gemma":0.00037390663,"threshold_uncertainty_score":0.9963151},"labels":[],"label_agreement":null},{"id":"W2898401839","doi":"10.1093/annonc/mdy300.065","title":"Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Toronto General Hospital; Public Health Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; The Internet; Young adult; Cancer; Logistic regression; Confidence interval; Family medicine; Internal medicine; Gerontology; World Wide Web","score_opus":0.03996553468309583,"score_gpt":0.3479358625865385,"score_spread":0.3079703279034427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898401839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384165,0.0029423607,0.000002148502,0.0018849355,0.0003711142,0.00045425296,0.00023121864,0.000027400782,0.00024494596],"genre_scores_gemma":[0.9973999,0.0013148615,0.00003658153,0.0006476781,0.00046784265,0.000029055354,0.000044622273,0.000026709997,0.00003274293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815506,0.0001543394,0.00047843246,0.00049310195,0.0003523145,0.00036677456],"domain_scores_gemma":[0.9985911,0.0001429333,0.0003670833,0.00013795144,0.0005104395,0.00025046326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018050813,0.00025898777,0.0008015554,0.00011679191,0.000093357776,0.000015401287,0.00010636604,0.00027122462,0.000064775624],"category_scores_gemma":[0.00010644921,0.00020982011,0.00003996445,0.00013194357,0.0008843538,0.00011894872,0.00011827327,0.00026385856,0.000001461815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015194971,0.000111891946,0.7924644,0.00034228616,0.00021206134,0.000004119049,0.043166976,8.997159e-9,0.0000056841372,0.000005375388,0.0006614466,0.16150628],"study_design_scores_gemma":[0.007333053,0.004334153,0.9834854,0.0015859813,0.00018992725,0.0000037365314,0.001987566,0.000005584467,0.00015129375,0.000034550823,0.00066923024,0.00021949853],"about_ca_topic_score_codex":0.008744798,"about_ca_topic_score_gemma":0.032558776,"teacher_disagreement_score":0.19102105,"about_ca_system_score_codex":0.000049614944,"about_ca_system_score_gemma":0.00019247497,"threshold_uncertainty_score":0.9978561},"labels":[],"label_agreement":null},{"id":"W2898410765","doi":"10.1093/annonc/mdy287.064","title":"Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for Oil Sands Innovation, University of Alberta","keywords":"Medicine; Internal medicine; Concomitant; Odds ratio; Univariate analysis; Cumulative dose; Cisplatin; Logistic regression; Oncology; Surgery; Multivariate analysis; Chemotherapy","score_opus":0.06533599826466881,"score_gpt":0.3947368519462247,"score_spread":0.3294008536815559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898410765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960052,0.000044423432,0.00001649497,0.0014755783,0.0000612378,0.00080561027,0.00033045022,0.000007936466,0.0012530849],"genre_scores_gemma":[0.9991555,0.000009073002,0.00007181264,0.00053163926,0.000040856383,0.00007002392,0.00008356229,0.000009626743,0.000027902905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892586,0.00021480628,0.00029511258,0.00017522386,0.00023873846,0.00015027315],"domain_scores_gemma":[0.99877435,0.00018063824,0.00029577283,0.00037303419,0.0003035356,0.00007264451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015547546,0.00010963417,0.00048583982,0.00010084648,0.00006886391,0.0000044927465,0.00013420187,0.00004274227,0.000038653856],"category_scores_gemma":[0.000042850326,0.00005077443,0.00007345869,0.0004797818,0.0006495712,0.00005027225,0.000029919413,0.00008649103,4.949118e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043506164,0.0024331836,0.94131017,0.0000333295,0.0027928578,0.000016654096,0.0055932864,0.0003783248,0.000025272919,0.00029230653,0.00064267166,0.0029757603],"study_design_scores_gemma":[0.029190037,0.011292596,0.95523876,0.00009880134,0.001893046,0.0000012078406,0.0010741688,0.0002807738,0.00018141352,0.00002547445,0.0006543725,0.0000693515],"about_ca_topic_score_codex":0.00027149045,"about_ca_topic_score_gemma":0.002488467,"teacher_disagreement_score":0.014316129,"about_ca_system_score_codex":0.000078857374,"about_ca_system_score_gemma":0.0006662475,"threshold_uncertainty_score":0.2393372},"labels":[],"label_agreement":null},{"id":"W2898429292","doi":"10.1093/annonc/mdy284.006","title":"LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Abiraterone; Internal medicine; Prednisone; Progression-free survival; Overall survival; Urology; Cancer; Androgen deprivation therapy","score_opus":0.06094733675121776,"score_gpt":0.38036372163113374,"score_spread":0.31941638487991597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898429292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573535,0.000380606,0.000016906211,0.0014064484,0.00006386763,0.0021971958,0.00013764654,0.000019879184,0.00004207661],"genre_scores_gemma":[0.99740636,0.0011995296,0.0007999209,0.00008718642,0.00004073003,0.00013050757,0.00005800645,0.000028496725,0.00024925117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762785,0.0007293081,0.0003828913,0.00047813094,0.00036963617,0.00041220052],"domain_scores_gemma":[0.99825186,0.000614341,0.0002799585,0.00020653011,0.00045990213,0.00018740802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011295889,0.00026106206,0.00081113627,0.00016683275,0.000104399376,0.000025913141,0.000061274026,0.000104469065,0.000016217133],"category_scores_gemma":[0.00037110873,0.00015213613,0.00001502734,0.00019385098,0.0007305609,0.00017618426,0.0001399226,0.00025654206,9.825227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2564682,0.00088928157,0.72124016,0.00009144576,0.00040748657,0.00028587505,0.006438784,0.000003958808,0.00045002432,0.000004087244,0.00008492054,0.013635805],"study_design_scores_gemma":[0.026420144,0.040435128,0.93131757,0.00026701947,0.00015798424,0.000025805777,0.00070791115,0.00021658742,0.00012586766,0.000019059447,0.00013124291,0.00017569723],"about_ca_topic_score_codex":0.00015064396,"about_ca_topic_score_gemma":0.00073637714,"teacher_disagreement_score":0.23004805,"about_ca_system_score_codex":0.00008430794,"about_ca_system_score_gemma":0.0003174144,"threshold_uncertainty_score":0.6203931},"labels":[],"label_agreement":null},{"id":"W2898430617","doi":"10.1093/annonc/mdy284.058","title":"Quality of docetaxel toxicity reporting for castration resistant prostate cancer (CRPC): A systematic review","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Clinical trial; Consolidated Standards of Reporting Trials; Internal medicine; Oncology; Checklist; Cancer","score_opus":0.9294521394121379,"score_gpt":0.7524040361756805,"score_spread":0.17704810323645737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898430617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000088188335,0.98564106,0.0022054582,0.00023524399,0.00045774016,0.009546307,0.001262606,0.000028875082,0.00061386306],"genre_scores_gemma":[0.0000026030102,0.840685,0.15697743,0.00017222842,0.00020040017,0.0017274176,0.000014085475,0.00005205151,0.00016878026],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9747441,0.0064072646,0.01720291,0.0006664955,0.0005375202,0.00044170587],"domain_scores_gemma":[0.87238914,0.08252063,0.041739464,0.0011783583,0.002036394,0.0001360114],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.047701005,0.00046054687,0.01394998,0.00011289225,0.000055718938,0.000010137457,0.00048434682,0.0006656877,0.0000767812],"category_scores_gemma":[0.5473251,0.0003258432,0.0016580813,0.0003624921,0.0003312112,0.00004777331,0.00012659673,0.00034929856,0.0000040331192],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008520078,0.0002524134,2.9407232e-7,0.90982693,0.0006294278,0.000005484686,0.00003886837,1.738955e-8,0.000005208652,0.007512796,0.0038956825,0.07774765],"study_design_scores_gemma":[0.00037498694,0.0015627691,9.0978057e-7,0.77208555,0.0053217863,0.000016874445,0.00001840699,0.0000016292163,0.00005836924,0.17397995,0.04621646,0.0003622978],"about_ca_topic_score_codex":0.000038436316,"about_ca_topic_score_gemma":0.00007778632,"teacher_disagreement_score":0.49962407,"about_ca_system_score_codex":0.00012383296,"about_ca_system_score_gemma":0.0013257167,"threshold_uncertainty_score":0.99991935},"labels":[],"label_agreement":null},{"id":"W2898431693","doi":"10.1093/annonc/mdy297.002","title":"Worldwide comparison of colorectal cancer survival by topography and stage at diagnosis (CONCORD-2)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colorectal cancer; Rectum; Stage (stratigraphy); Cancer; Population; Internal medicine; Oncology; Relative survival; Cancer registry; Survival rate; Disease; Environmental health","score_opus":0.10754604284789382,"score_gpt":0.4239444173423288,"score_spread":0.316398374494435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898431693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886642,0.0025715206,0.000028712446,0.001567819,0.0003809927,0.0002040682,0.00006579153,0.000027139506,0.00648974],"genre_scores_gemma":[0.9981785,0.0008066917,0.00015464755,0.00032840815,0.0001249235,0.000053776883,0.000009611604,0.000012386476,0.00033104746],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895436,0.00008295658,0.00034706586,0.00022868998,0.00017309397,0.00021382153],"domain_scores_gemma":[0.99892116,0.00028447038,0.00027093213,0.00012253193,0.00028157386,0.00011932005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024437738,0.00011809814,0.000585566,0.00013902185,0.00006175419,0.0000029689656,0.00006015,0.00013826684,0.0003319711],"category_scores_gemma":[0.000099870056,0.00010904809,0.00009879707,0.00028823028,0.00047827762,0.000038949944,0.0000706896,0.00012390329,0.0000025971815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007913599,0.00030917412,0.8469378,0.000077002645,0.00017831083,0.0000036677948,0.0006717034,0.0000019306724,0.015740685,0.00003009669,0.02485743,0.10327863],"study_design_scores_gemma":[0.0019384122,0.032347098,0.32933348,0.00008421727,0.00011161218,0.000008684902,0.00034506113,0.0001746468,0.46026295,0.000036692487,0.17519724,0.00015988744],"about_ca_topic_score_codex":0.0026365481,"about_ca_topic_score_gemma":0.0074238176,"teacher_disagreement_score":0.5176043,"about_ca_system_score_codex":0.000046315177,"about_ca_system_score_gemma":0.0000955017,"threshold_uncertainty_score":0.4446852},"labels":[],"label_agreement":null},{"id":"W2898432988","doi":"10.1093/annonc/mdy287.034","title":"Genomic profiling and matched therapy for recurrent or metastatic malignant salivary gland tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; HRAS; Fluorescence in situ hybridization; Adenoid cystic carcinoma; Pathology; KRAS; Cancer; Carcinoma","score_opus":0.15508740834386506,"score_gpt":0.4170115692130755,"score_spread":0.26192416086921044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898432988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923423,0.0023871188,0.000029290792,0.0034752989,0.00015745472,0.0010324775,0.000050133112,0.000019885061,0.00050604483],"genre_scores_gemma":[0.99110603,0.0021246697,0.004794682,0.0014217646,0.0001968463,0.00018498529,0.000050373448,0.000022389568,0.000098227676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896175,0.00006381385,0.00035833084,0.00025919982,0.00009070893,0.00026621434],"domain_scores_gemma":[0.9990608,0.0003106574,0.00017133974,0.00017514003,0.000162751,0.00011928557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003452619,0.00015554925,0.00058292603,0.00009291577,0.000057498284,0.000006463846,0.000054576532,0.00005300734,0.000115481314],"category_scores_gemma":[0.000066043984,0.000095584786,0.00009108103,0.000076690776,0.00014135221,0.00003095973,0.000027480912,0.000052021343,0.000010075346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05597419,0.009683536,0.55291957,0.0011928946,0.003419113,0.0009960678,0.00390701,0.0000018911117,0.011389596,0.004692139,0.019756222,0.33606777],"study_design_scores_gemma":[0.03061388,0.16578111,0.53846383,0.00062165025,0.0007631605,0.0014101181,0.000983701,0.00037614137,0.20347022,0.0062611783,0.050609786,0.0006452053],"about_ca_topic_score_codex":0.00004142786,"about_ca_topic_score_gemma":0.000025291292,"teacher_disagreement_score":0.33542258,"about_ca_system_score_codex":0.000021951246,"about_ca_system_score_gemma":0.00020506278,"threshold_uncertainty_score":0.38978347},"labels":[],"label_agreement":null},{"id":"W2898439726","doi":"10.1093/annonc/mdy282.093","title":"Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Sorafenib; Internal medicine; Liver function; Population; Gastroenterology; Portal vein thrombosis; Clinical endpoint; Thrombosis; Clinical trial","score_opus":0.07361650887830953,"score_gpt":0.2965782951831292,"score_spread":0.2229617863048197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898439726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985501,0.0003636686,0.00018063273,0.00045919357,0.00003586476,0.00025632014,0.000023322973,0.0000019465915,0.00012893573],"genre_scores_gemma":[0.99916667,0.0003356029,0.00019921744,0.00018103814,0.000029388912,0.000013432094,0.000057328474,0.000007644095,0.000009682265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998983,0.00016780711,0.00041234522,0.00018674253,0.00012711035,0.00012294012],"domain_scores_gemma":[0.99922264,0.000079490754,0.00019850106,0.00011037249,0.00033943064,0.000049571245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027181522,0.00010058044,0.00048053698,0.00030085005,0.000010840493,0.0000030766635,0.000024854515,0.00010161931,0.00008747605],"category_scores_gemma":[0.00006873044,0.00009685213,0.000036951955,0.00041664974,0.00008313733,0.000108549706,0.000014936153,0.000055847064,1.8159697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022297997,0.00022332185,0.9807475,0.00012431333,0.00018005226,0.00012763547,0.0010856335,0.0000021413264,0.0078469915,0.0000050674175,0.000014722503,0.0074127777],"study_design_scores_gemma":[0.0014681085,0.0026453312,0.96847403,0.000041358668,0.00079010025,0.000012271689,0.0001150182,0.008571703,0.017437275,0.0000021679775,0.000372387,0.000070229085],"about_ca_topic_score_codex":0.13728364,"about_ca_topic_score_gemma":0.21445276,"teacher_disagreement_score":0.07716911,"about_ca_system_score_codex":0.000030499587,"about_ca_system_score_gemma":0.00022446872,"threshold_uncertainty_score":0.86846125},"labels":[],"label_agreement":null},{"id":"W2898443024","doi":"10.1093/annonc/mdy272.298","title":"Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: A systematic review (SR) of international breast cancer (BC) guidelines","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Guideline; Genetic testing; BRCA mutation; Breast cancer; Oncology; Cancer; Genetic counseling; MEDLINE; Family medicine; Internal medicine; Intensive care medicine; Pathology","score_opus":0.12204742700680392,"score_gpt":0.44667348897821274,"score_spread":0.3246260619714088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898443024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037272868,0.99675494,0.00029518554,0.0002018793,0.00026801863,0.0011658613,0.0008675274,0.000003872937,0.00006997741],"genre_scores_gemma":[0.00012540836,0.9971283,0.001378455,0.00016344838,0.00032422622,0.00035995973,0.000310918,0.000038555077,0.00017074442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723375,0.00027181284,0.0016658107,0.00042763128,0.00022449385,0.00017649982],"domain_scores_gemma":[0.99559194,0.00007464672,0.0021741255,0.0004703109,0.0016250862,0.00006386343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035773966,0.00032843967,0.0019652494,0.00015085735,0.000024874067,0.0000053085782,0.0003195109,0.00033148762,0.000054531618],"category_scores_gemma":[0.00013300875,0.00026684126,0.00041410883,0.0001661288,0.0002989507,0.0000049545806,0.000039788152,0.00005402821,0.0000017643257],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006326973,0.00025948058,0.00006192703,0.37248704,0.0035228736,0.000007637036,0.0002068895,0.00003670943,0.000047777776,0.000012142601,0.011701409,0.6115928],"study_design_scores_gemma":[0.00049697305,0.0014648852,0.00002030899,0.10259068,0.0027789974,0.00022988635,0.000026511265,0.000024389785,0.0003162869,0.0000142154995,0.89176816,0.00026873397],"about_ca_topic_score_codex":0.00015183305,"about_ca_topic_score_gemma":0.00023910555,"teacher_disagreement_score":0.88006675,"about_ca_system_score_codex":0.00007039936,"about_ca_system_score_gemma":0.0008410879,"threshold_uncertainty_score":0.99997836},"labels":[],"label_agreement":null},{"id":"W2898447893","doi":"10.1093/annonc/mdy269.181","title":"Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Palbociclib; Medicine; Breast cancer; Oncology; Tamoxifen; Internal medicine; Letrozole; Estrogen receptor; Biomarker; Gene signature; Neoadjuvant therapy; Cancer; Metastatic breast cancer; Gene expression; Gene","score_opus":0.14732162359298423,"score_gpt":0.49262454327951327,"score_spread":0.34530291968652904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898447893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97856724,0.00044781427,0.0000060671987,0.01692814,0.00017514796,0.0031468826,0.00011049623,0.000019306723,0.0005989206],"genre_scores_gemma":[0.99790144,0.00041984432,0.00016478401,0.00055391056,0.0003374919,0.00041812478,0.000011728089,0.000040906118,0.00015179736],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9968562,0.0009549456,0.000639961,0.00042212888,0.0005527751,0.00057395635],"domain_scores_gemma":[0.996732,0.0007302902,0.00039116282,0.0005123969,0.0015066117,0.00012755397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011202649,0.00024458347,0.00090418034,0.00028469847,0.00016846432,0.000005730304,0.00030901746,0.00009888117,0.0005477652],"category_scores_gemma":[0.000117256095,0.00014956364,0.00009029394,0.00094397535,0.0014668511,0.00011447276,0.00012178276,0.00040774167,0.000004012354],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5536288,0.011589584,0.0052224565,0.0000144180185,0.0008733091,0.00005861751,0.00979142,0.000003767566,0.01545666,0.00009628931,0.0007026233,0.40256205],"study_design_scores_gemma":[0.41425538,0.43471336,0.059963714,0.000324189,0.000094582836,0.00013038152,0.012040459,0.000050489925,0.06762852,0.00045611474,0.010046977,0.0002958435],"about_ca_topic_score_codex":0.004448839,"about_ca_topic_score_gemma":0.0013350572,"teacher_disagreement_score":0.42312378,"about_ca_system_score_codex":0.00013440211,"about_ca_system_score_gemma":0.0007436508,"threshold_uncertainty_score":0.67253435},"labels":[],"label_agreement":null},{"id":"W2898469774","doi":"10.1093/annonc/mdy297.006","title":"Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Food and drug administration; Randomized controlled trial; Sample size determination; Drug; Oncology; Medical physics; Internal medicine; Pharmacology; Statistics","score_opus":0.6532047734639038,"score_gpt":0.5622433032792514,"score_spread":0.0909614701846524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898469774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9373049,0.0012402884,0.00010931195,0.054163083,0.0005248008,0.00068768556,0.0008106221,0.000007684789,0.005151603],"genre_scores_gemma":[0.9884748,0.00026102862,0.0006191189,0.010032637,0.0003534215,0.00006084588,0.000026569955,0.00001597303,0.00015564388],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923857,0.0009203536,0.005963891,0.00038817705,0.00010781854,0.00023405068],"domain_scores_gemma":[0.9865387,0.00614007,0.006489677,0.0004245499,0.00030143198,0.00010557461],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03250428,0.00014545942,0.0018320883,0.00015384582,0.00007020766,0.000012120349,0.00024950883,0.00023412495,0.00024286353],"category_scores_gemma":[0.0076908227,0.00013860615,0.00020597361,0.000121266,0.00044822606,0.000103778155,0.00003566744,0.00014011345,0.000023954477],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007072483,0.014675559,0.28560272,0.002826953,0.002246147,0.0000013608352,0.01125579,0.00052424456,0.0005653099,0.1347712,0.33694243,0.20351578],"study_design_scores_gemma":[0.0190401,0.06757184,0.18187417,0.00063922076,0.00025444952,0.00000433052,0.00330028,0.015155742,0.021227444,0.043656576,0.64595854,0.0013172886],"about_ca_topic_score_codex":0.00077798316,"about_ca_topic_score_gemma":0.0012083579,"teacher_disagreement_score":0.3090161,"about_ca_system_score_codex":0.000059140202,"about_ca_system_score_gemma":0.0004087925,"threshold_uncertainty_score":0.99624044},"labels":[],"label_agreement":null},{"id":"W2898472087","doi":"10.1093/annonc/mdy424.036","title":"JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Medicine; Internal medicine; Clinical endpoint; Axitinib; Progression-free survival; Sunitinib; Renal cell carcinoma; Oncology; Randomized controlled trial; Gastroenterology; Urology; Overall survival","score_opus":0.0815391772182499,"score_gpt":0.3859280008197945,"score_spread":0.3043888236015446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898472087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788849,0.0010327653,0.000036637768,0.0009097903,0.00017758661,0.0035010374,0.00010256605,0.000028842012,0.0153259095],"genre_scores_gemma":[0.9962881,0.00053059467,0.0008810242,0.00019177662,0.00033393293,0.0003006008,0.00014969897,0.000056995188,0.0012672332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99543256,0.00062911655,0.0020553106,0.00065498997,0.0006193788,0.00060864416],"domain_scores_gemma":[0.99483484,0.0011110766,0.0014405857,0.0009183314,0.0013500095,0.00034517355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087417115,0.0005295962,0.0033100485,0.0004925927,0.000098169345,0.000004557383,0.00024602303,0.0002621888,0.00086555595],"category_scores_gemma":[0.00031012052,0.00040464278,0.00066966476,0.00039156026,0.0008667126,0.00007576272,0.00010541276,0.0001811386,0.000038804446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81907237,0.05672358,0.0016089848,0.00031502996,0.0019490609,0.0014323856,0.01433742,0.00006342796,0.03642847,0.00011565489,0.0011040872,0.06684955],"study_design_scores_gemma":[0.4371138,0.1818352,0.0016543625,0.00010468093,0.001079264,0.00013334448,0.001265953,0.00008540728,0.3724278,0.00010121311,0.003990682,0.00020832711],"about_ca_topic_score_codex":0.0017700179,"about_ca_topic_score_gemma":0.0004933169,"teacher_disagreement_score":0.38195854,"about_ca_system_score_codex":0.00017720151,"about_ca_system_score_gemma":0.00074944925,"threshold_uncertainty_score":0.99984056},"labels":[],"label_agreement":null},{"id":"W2898479222","doi":"10.1093/annonc/mdy272.283","title":"Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Clinical endpoint; Anastrozole; Hazard ratio; Aromatase inhibitor; Tamoxifen; Breast cancer; Quality of life (healthcare); Oncology; Goserelin; Progression-free survival; Placebo; Cancer; Randomized controlled trial; Gynecology; Chemotherapy; Confidence interval","score_opus":0.024362455649523745,"score_gpt":0.3395648336872037,"score_spread":0.3152023780376799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898479222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918844,0.00026382133,0.000053687556,0.003012594,0.00038034646,0.0024563107,0.0012710118,0.00009003177,0.0005877775],"genre_scores_gemma":[0.99255604,0.00017781726,0.0031666425,0.0024219304,0.000277392,0.00071083015,0.00023560536,0.00012864129,0.00032510044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556786,0.00024715165,0.0013414343,0.0010188449,0.0008058116,0.0010189257],"domain_scores_gemma":[0.99554706,0.00031160156,0.0013461694,0.0006581913,0.0017316388,0.00040533932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029464313,0.00070384436,0.0016254388,0.00034918697,0.00014587316,0.000017172279,0.0002789888,0.00035080357,0.00043150614],"category_scores_gemma":[0.00021758271,0.0005276681,0.0001427444,0.0007741531,0.0010415128,0.0006079802,0.00019615507,0.00052312814,0.00003930624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15424679,0.01010034,0.40141222,0.000297032,0.002867276,0.00068029715,0.014536061,0.00008767319,0.042048488,0.000021863714,0.005273845,0.3684281],"study_design_scores_gemma":[0.030324863,0.039865423,0.8668067,0.001048132,0.00023164884,0.0001759937,0.0017329484,0.00003455131,0.053132784,0.00017169799,0.0055837315,0.00089153094],"about_ca_topic_score_codex":0.0012243431,"about_ca_topic_score_gemma":0.0019779133,"teacher_disagreement_score":0.4653945,"about_ca_system_score_codex":0.00057961687,"about_ca_system_score_gemma":0.0008468601,"threshold_uncertainty_score":0.9997175},"labels":[],"label_agreement":null},{"id":"W2898480817","doi":"10.1093/annonc/mdy284.016","title":"Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Urology; Cancer; Androgen receptor","score_opus":0.0498774345410173,"score_gpt":0.37898335343399964,"score_spread":0.32910591889298235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898480817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859787,0.0006761363,0.0000012397486,0.007933091,0.0000148070585,0.003939882,0.0002311129,0.000014749863,0.0012102578],"genre_scores_gemma":[0.9978455,0.00027003782,0.0000826383,0.00032785934,0.000072018775,0.00066925446,0.000047470367,0.000023872277,0.0006614031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822146,0.00023252459,0.00040458978,0.0004338445,0.00031692313,0.00039066034],"domain_scores_gemma":[0.9985837,0.00031357753,0.0002139886,0.00031379718,0.00045803568,0.00011695165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005422184,0.00021569026,0.0005388502,0.000100043886,0.00011072405,0.000019524678,0.0000972681,0.000062539475,0.000029478633],"category_scores_gemma":[0.000052558462,0.00010614148,0.00002476326,0.0002869879,0.0005856536,0.0001021579,0.000030993837,0.00021478104,0.000003262663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12635207,0.0028524583,0.8426299,0.00006199812,0.0013164089,0.0012629797,0.014011519,0.000014952111,0.0051898607,0.000005147309,0.0012042766,0.0050984244],"study_design_scores_gemma":[0.036685146,0.042443324,0.91458124,0.0002553897,0.00029685142,0.000033812175,0.0024559072,0.00025076506,0.0025161107,0.000028159466,0.00031614033,0.0001371472],"about_ca_topic_score_codex":0.004495728,"about_ca_topic_score_gemma":0.0060275593,"teacher_disagreement_score":0.08966692,"about_ca_system_score_codex":0.00008763966,"about_ca_system_score_gemma":0.00075322454,"threshold_uncertainty_score":0.67962253},"labels":[],"label_agreement":null},{"id":"W2898484591","doi":"10.1093/annonc/mdy424.009","title":"Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palbociclib; Fulvestrant; Internal medicine; Hazard ratio; Clinical endpoint; Breast cancer; Metastatic breast cancer; Progression-free survival; Oncology; Cancer; Gastroenterology; Chemotherapy; Estrogen receptor; Confidence interval; Randomized controlled trial","score_opus":0.055907089637438304,"score_gpt":0.38229451582051993,"score_spread":0.32638742618308164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898484591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910492,0.0006602368,0.0002452614,0.004549977,0.00016002859,0.0008333277,0.0012138076,0.00008466542,0.0012035542],"genre_scores_gemma":[0.9926968,0.0006450943,0.0036746454,0.0017260934,0.00059951737,0.0002666404,0.00011083756,0.000107763444,0.00017259625],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996276,0.0003923325,0.00078757043,0.0009204299,0.00057608954,0.0010475353],"domain_scores_gemma":[0.99675816,0.00048407874,0.0007599064,0.00047754898,0.0011084831,0.00041181117],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025670897,0.00062065804,0.0017882208,0.00028808656,0.00015428595,0.000016988331,0.00029742657,0.00029147472,0.0016604072],"category_scores_gemma":[0.0000698349,0.00046845913,0.00012054901,0.00061897177,0.0014161312,0.0005141898,0.00008107857,0.0005578412,0.000023195083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22067377,0.0026226074,0.06603646,0.00020575573,0.0063370233,0.00045636084,0.03463684,0.00026482932,0.4933505,0.00033023139,0.0011129319,0.17397268],"study_design_scores_gemma":[0.020478053,0.016849397,0.89058965,0.0006006193,0.00015080199,0.000059217386,0.00405334,0.00001367031,0.0637643,0.00067541236,0.0019789313,0.0007866238],"about_ca_topic_score_codex":0.0056188935,"about_ca_topic_score_gemma":0.0036018535,"teacher_disagreement_score":0.8245532,"about_ca_system_score_codex":0.0008023793,"about_ca_system_score_gemma":0.00084008375,"threshold_uncertainty_score":0.9997767},"labels":[],"label_agreement":null},{"id":"W2898486244","doi":"10.1093/annonc/mdy296.001","title":"Health-related quality of life in randomized controlled trials: A systematic review of prognostic significance","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Quality of life (healthcare); Randomized controlled trial; Systematic review; Internal medicine; Meta-analysis; Lung cancer; Clinical trial; Multivariate analysis; Head and neck cancer; Cancer; MEDLINE; Oncology","score_opus":0.29580840431379957,"score_gpt":0.5128463597243131,"score_spread":0.21703795541051357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898486244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021022228,0.9693576,0.000012676274,0.0012310115,0.00044529623,0.027834026,0.00010679602,0.0000139291615,0.0009776296],"genre_scores_gemma":[0.00067873474,0.995049,0.000028072704,0.00086070504,0.00008229586,0.003061273,0.00008492674,0.000034190034,0.00012081517],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9424217,0.036637757,0.019555487,0.00043263976,0.0005972185,0.00035519854],"domain_scores_gemma":[0.9355019,0.03701715,0.025092933,0.0008202068,0.0013627039,0.00020512473],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.080158874,0.00046415144,0.094315566,0.0004809839,0.000012630469,0.0000021555854,0.00030517124,0.00057895645,0.00015998702],"category_scores_gemma":[0.14868872,0.00027340354,0.0056940923,0.00076521706,0.0004537576,0.000023533641,0.000047013167,0.00040809985,0.00000814208],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029030006,0.0004158754,0.0000030391848,0.9486457,0.0034269416,0.0000053487374,0.00021262362,3.6762195e-8,1.7296783e-7,0.0001733712,0.0008694531,0.017217392],"study_design_scores_gemma":[0.100972764,0.0014458135,0.0000014809829,0.8784233,0.00869569,0.000012395872,0.00005545521,0.0000012813937,6.056216e-7,0.00006563942,0.010167792,0.0001578059],"about_ca_topic_score_codex":0.001669321,"about_ca_topic_score_gemma":0.000424941,"teacher_disagreement_score":0.088621475,"about_ca_system_score_codex":0.000119770615,"about_ca_system_score_gemma":0.005986908,"threshold_uncertainty_score":0.9999718},"labels":[],"label_agreement":null},{"id":"W2898488397","doi":"10.1093/annonc/mdy282.095","title":"Molecular profiling of PDAC and response to chemotherapy: An update from the COMPASS trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Ontario Institute for Cancer Research; Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biopsy; Chemotherapy; Internal medicine; Oncology; Chemotherapy regimen; IDH2; Pathology; Gene; IDH1; Biology; Mutation; Genetics","score_opus":0.03814651750870469,"score_gpt":0.36302412057593386,"score_spread":0.3248776030672292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898488397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401236,0.0004009768,0.00043336072,0.004435659,0.00015599646,0.00025358898,0.00009404831,0.0000022144645,0.00021182271],"genre_scores_gemma":[0.9924824,0.0002453602,0.0018096506,0.0050912765,0.00030677355,0.00001185448,0.000033801505,0.000011959949,0.0000069208245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99924904,0.00014305359,0.00021153271,0.00020119696,0.000060558123,0.000134619],"domain_scores_gemma":[0.9992168,0.000107226035,0.00011732847,0.00031861558,0.00017501564,0.00006500069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044076634,0.0000825457,0.00018983778,0.000022091303,0.000031784624,0.000006485244,0.00018237403,0.000108102104,0.00001315296],"category_scores_gemma":[0.0002490687,0.00006771649,0.00004604138,0.000050243718,0.00019310617,0.0000017534353,0.000099101446,0.000039828756,0.0000018116922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041883763,0.00012901885,0.00031835094,0.0000025030104,0.000071132934,0.0000017320469,0.00022927212,0.000016146567,0.94075584,0.00022868812,0.0030498272,0.013313694],"study_design_scores_gemma":[0.005201141,0.007967294,0.0015757328,0.0000057210414,0.000014723454,0.0000016133203,0.00009478149,0.00002927273,0.871624,0.00047975982,0.112918325,0.00008765506],"about_ca_topic_score_codex":0.000096491654,"about_ca_topic_score_gemma":0.00010012758,"teacher_disagreement_score":0.1098685,"about_ca_system_score_codex":0.0000045180996,"about_ca_system_score_gemma":0.00016406628,"threshold_uncertainty_score":0.27613983},"labels":[],"label_agreement":null},{"id":"W2898490299","doi":"10.1093/annonc/mdy424.065","title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"KU Leuven; Genentech; AstraZeneca; Celgene; Novartis Pharma; Astellas Pharma; Clovis Oncology; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Atezolizumab; Pemetrexed; Oncology; Population; Carboplatin; Docetaxel; Progression-free survival; Adverse effect; Paclitaxel; Clinical endpoint; Chemotherapy; Randomized controlled trial; Cancer; Cisplatin; Nivolumab; Immunotherapy","score_opus":0.036991900916455926,"score_gpt":0.43898577525450966,"score_spread":0.4019938743380537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898490299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937338,0.00063701073,0.00010580116,0.0008506495,0.00008728645,0.0028162168,0.0001293478,0.000024033901,0.0016158193],"genre_scores_gemma":[0.9979145,0.00052315375,0.00077179866,0.00016941271,0.00007757251,0.00026297642,0.00010277302,0.00003191198,0.00014592435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99775547,0.00018850596,0.000845835,0.0005036711,0.00037642385,0.00033009233],"domain_scores_gemma":[0.99759805,0.00053824694,0.00057069445,0.0006042663,0.0005146927,0.00017402197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042770934,0.00029591686,0.0016458939,0.00034015262,0.00010385436,0.000007988491,0.00015651096,0.00015172892,0.00022469182],"category_scores_gemma":[0.00021182826,0.0001846727,0.00012668553,0.0007606557,0.0002972809,0.00010365252,0.000064342836,0.00015238844,0.0000013480856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59769326,0.01785969,0.18251976,0.00007428123,0.008523898,0.0003867766,0.03265039,0.00013451374,0.002106766,0.000011724082,0.00012471786,0.15791424],"study_design_scores_gemma":[0.74234086,0.13447154,0.10496654,0.00030287026,0.003195018,0.000023604462,0.0078766495,0.0012142645,0.0038608036,0.00013126456,0.0012007128,0.0004158544],"about_ca_topic_score_codex":0.006179543,"about_ca_topic_score_gemma":0.020678109,"teacher_disagreement_score":0.15749837,"about_ca_system_score_codex":0.0000824409,"about_ca_system_score_gemma":0.00055096834,"threshold_uncertainty_score":0.99719197},"labels":[],"label_agreement":null},{"id":"W2898508179","doi":"10.1093/annonc/mdy300.075","title":"A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; McMaster University","funders":"","keywords":"Medicine; Referral; Smoking cessation; Family medicine; Cancer; Environmental health; Internal medicine","score_opus":0.20719893891533223,"score_gpt":0.4036719865627136,"score_spread":0.19647304764738135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898508179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827089,0.00036386293,0.000018473856,0.004730454,0.00011970335,0.00034954108,0.0000019343736,0.0000036503288,0.011703526],"genre_scores_gemma":[0.99449927,0.000019381258,0.00023117759,0.004998096,0.00006559107,0.000057570287,0.0000052246423,0.000004179068,0.000119541335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895453,0.00006629227,0.00035604354,0.0001584845,0.00023799206,0.00022667469],"domain_scores_gemma":[0.9994719,0.000058693528,0.00011674943,0.000111894726,0.00016784164,0.000072914845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036840377,0.00007074789,0.00036455505,0.0001250953,0.000016180795,0.0000026983605,0.00008197241,0.00006890879,0.000068934394],"category_scores_gemma":[0.00011655376,0.000063006126,0.00002377436,0.00022212484,0.00003404879,0.000045750545,0.000022861333,0.0001197606,9.449787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006700056,0.00020557079,0.9549783,0.0015567192,0.00008396855,0.000093766204,0.0058739227,0.00055828603,0.00016795287,0.0011766419,0.03172886,0.0029060186],"study_design_scores_gemma":[0.0011561238,0.0007583403,0.97761846,0.004574815,0.000031833384,0.000039519666,0.0020681405,0.00031761685,0.00038870535,0.00013503962,0.012784538,0.00012688285],"about_ca_topic_score_codex":0.99258167,"about_ca_topic_score_gemma":0.9991195,"teacher_disagreement_score":0.02264016,"about_ca_system_score_codex":0.0010664695,"about_ca_system_score_gemma":0.0022193934,"threshold_uncertainty_score":0.39371085},"labels":[],"label_agreement":null},{"id":"W2898517298","doi":"10.1093/annonc/mdy424.074","title":"Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Carboplatin; Paclitaxel; Placebo; Clinical endpoint; Pembrolizumab; Internal medicine; Tolerability; Quality of life (healthcare); Oncology; Clinical trial; Chemotherapy; Cancer; Adverse effect; Nursing; Cisplatin","score_opus":0.20006962575984466,"score_gpt":0.4352044458391081,"score_spread":0.23513482007926345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898517298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909964,0.0017205939,0.00011411812,0.0035159728,0.00015935789,0.0017143979,0.001564962,0.00001949762,0.00019470659],"genre_scores_gemma":[0.9947823,0.00018330925,0.0019996122,0.002247723,0.00005552204,0.000046764315,0.0005050082,0.00003416637,0.00014556778],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99685794,0.00043173987,0.0014410255,0.00051704934,0.00031462937,0.00043758945],"domain_scores_gemma":[0.9960139,0.001680301,0.0010034475,0.00073733466,0.00036832248,0.00019671829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015665857,0.00025016256,0.0014995928,0.00019232703,0.00006880231,0.0000067418555,0.00024700214,0.00019551128,0.00021767053],"category_scores_gemma":[0.001658481,0.0001688788,0.00007777364,0.00033272355,0.0006117446,0.00013780345,0.000108703665,0.00018196374,0.0000022076554],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88170236,0.0023820007,0.03206139,0.0011628583,0.0015567488,0.000020611345,0.0053207222,0.000004509622,0.0006177865,0.00005220136,0.013596318,0.06152251],"study_design_scores_gemma":[0.1791887,0.07793422,0.7281553,0.0007994285,0.0003476214,0.00002297411,0.0033470665,0.00097169,0.00064640085,0.0003368754,0.00763896,0.00061072776],"about_ca_topic_score_codex":0.0150007885,"about_ca_topic_score_gemma":0.013781814,"teacher_disagreement_score":0.70251364,"about_ca_system_score_codex":0.000121984835,"about_ca_system_score_gemma":0.0019005176,"threshold_uncertainty_score":0.99155843},"labels":[],"label_agreement":null},{"id":"W2898547742","doi":"10.1093/annonc/mdy289","title":"KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma","year":2018,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Dabrafenib; Medicine; Tolerability; Discontinuation; Pembrolizumab; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Nuclear medicine; Clinical trial; Adverse effect; Metastatic melanoma; Immunotherapy; Cancer; Pathology; Vemurafenib","score_opus":0.0654847845609551,"score_gpt":0.3826286166165271,"score_spread":0.31714383205557195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898547742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817339,0.0069789723,0.000916814,0.0014262466,0.0015729051,0.0039332574,0.00056923245,0.000017530554,0.0028511258],"genre_scores_gemma":[0.9905027,0.0025453067,0.0015147598,0.00056597294,0.000819858,0.00044614298,0.00016023518,0.00007150314,0.0033734858],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99524015,0.0010731721,0.0016068309,0.00097082264,0.00025401806,0.00085500244],"domain_scores_gemma":[0.99623585,0.00074990717,0.0011609603,0.00077190023,0.0007632609,0.0003181311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018821002,0.0005728352,0.002303292,0.00017014991,0.00025606772,0.00001665011,0.000466018,0.0007602309,0.00034115236],"category_scores_gemma":[0.0015720741,0.0004940633,0.0004420355,0.00019753283,0.0013695621,0.000024395476,0.00037854945,0.00022002163,0.000005930903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6198724,0.00822306,0.000025108673,0.0004917526,0.0015923829,0.000075051605,0.003672162,0.000023855457,0.21232876,0.0011127124,0.0071151997,0.14546753],"study_design_scores_gemma":[0.39805177,0.11456429,0.000017625649,0.00009320642,0.0005174318,0.00014866542,0.0013260513,0.0004172758,0.23190337,0.00029470888,0.2521972,0.0004683986],"about_ca_topic_score_codex":0.000114025584,"about_ca_topic_score_gemma":0.0005539124,"teacher_disagreement_score":0.24508199,"about_ca_system_score_codex":0.00003275315,"about_ca_system_score_gemma":0.00094983616,"threshold_uncertainty_score":0.9997511},"labels":[],"label_agreement":null},{"id":"W2898560392","doi":"10.1093/annonc/mdy284.054","title":"Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; Weill Cornell Medical College; Cilag; Astellas Pharma; National Cancer Institute; Genomic Health; Memorial Sloan-Kettering Cancer Center; Prostate Cancer Foundation; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Abbott Laboratories; National Institutes of Health; London Health Sciences Centre; Amgen","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Denosumab; Urology; Randomized controlled trial; Placebo; Internal medicine; Surgery; Osteoporosis; Cancer; Pathology","score_opus":0.12411603002488919,"score_gpt":0.43485191892098507,"score_spread":0.3107358888960959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898560392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959693,0.00019836116,0.00039694272,0.00066470524,0.000091534246,0.0025202495,0.000074112875,0.000006514477,0.00007826355],"genre_scores_gemma":[0.99752873,0.00009609816,0.0009364104,0.00041573576,0.000111853835,0.0006549937,0.00018714032,0.00002526981,0.000043782253],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984344,0.00016165528,0.00047376644,0.00047109235,0.00011828633,0.00034080248],"domain_scores_gemma":[0.9984849,0.0000619768,0.00030241962,0.00033648862,0.00075123017,0.00006297439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070304837,0.0001773945,0.00036935136,0.00014444653,0.00011651193,0.000013034407,0.00016006123,0.00012168771,0.000025437488],"category_scores_gemma":[0.00010569155,0.00015207789,0.000049650833,0.00022714835,0.000121409124,0.000013062032,0.00006499907,0.00007248198,0.0000022791337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11474881,0.011415874,0.21092896,0.00005746545,0.0009020054,0.000010406766,0.009759423,0.00031701894,0.2345535,0.00009452109,0.00077198,0.41644],"study_design_scores_gemma":[0.29269493,0.23727739,0.17567883,0.00014585751,0.00024364231,0.000024658764,0.0031781776,0.00034523624,0.25603482,0.00024206564,0.03268959,0.0014448044],"about_ca_topic_score_codex":0.00015194164,"about_ca_topic_score_gemma":0.0019624948,"teacher_disagreement_score":0.41499522,"about_ca_system_score_codex":0.000030237306,"about_ca_system_score_gemma":0.0002642961,"threshold_uncertainty_score":0.62015563},"labels":[],"label_agreement":null},{"id":"W2898570310","doi":"10.1093/annonc/mdy295.026","title":"Medical-aid-in-dying use in the US Pacific Northwest","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine; Medical emergency","score_opus":0.3334732908519124,"score_gpt":0.5032873227337297,"score_spread":0.16981403188181726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898570310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976137,0.00072193035,0.000011779062,0.0072580446,0.0001370442,0.00013136715,0.0000059436506,0.000006616994,0.015590263],"genre_scores_gemma":[0.9941272,0.001780565,0.00025869036,0.0035645012,0.00017056259,0.000008946734,0.000010541783,0.0000066612765,0.000072330324],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886644,0.00015873698,0.00036748924,0.00014058572,0.00024374046,0.00022300977],"domain_scores_gemma":[0.9986582,0.0007571199,0.00011509982,0.00022336737,0.00018259071,0.000063633364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077662803,0.00008261601,0.00039104192,0.00014500962,0.00001628331,0.0000022923284,0.00014845053,0.00015624992,0.0001596086],"category_scores_gemma":[0.0011601433,0.00005562666,0.0000586156,0.0002812809,0.00032878126,0.000053938296,0.000032737185,0.00018972093,0.000023032238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025348735,0.00039135275,0.9666489,0.000046847945,0.000036422378,0.00031508823,0.006497598,0.0000011157531,0.0003391002,0.00024717153,0.0052841376,0.019938795],"study_design_scores_gemma":[0.0019733787,0.0027757837,0.4668107,0.0006373389,0.000024934743,0.00003838935,0.0025214262,0.0000651709,0.0032223836,0.00024429843,0.52158684,0.00009934836],"about_ca_topic_score_codex":0.0015839207,"about_ca_topic_score_gemma":0.006407752,"teacher_disagreement_score":0.5163027,"about_ca_system_score_codex":0.000018940738,"about_ca_system_score_gemma":0.00020670462,"threshold_uncertainty_score":0.3575676},"labels":[],"label_agreement":null},{"id":"W2898575906","doi":"10.1093/annonc/mdy284.033","title":"Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Denosumab; Concomitant; Docetaxel; Oncology; Cancer; Surgery; Osteoporosis","score_opus":0.07874569283824925,"score_gpt":0.46327529258668165,"score_spread":0.38452959974843237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898575906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978027,0.00006842047,0.000010189236,0.0008029101,0.000034704106,0.00094193756,0.00009455257,0.000013849775,0.00023074725],"genre_scores_gemma":[0.9983747,0.00010690567,0.00044013717,0.00025658624,0.000039505438,0.00059599534,0.00013321581,0.000015538084,0.000037432797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983122,0.00010504603,0.00067120016,0.00031931445,0.00031979472,0.00027244826],"domain_scores_gemma":[0.9988014,0.00006151903,0.00032256832,0.0002501804,0.0004374603,0.00012687563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024810724,0.00017153025,0.0005636968,0.00029411717,0.000022586739,0.000015397054,0.00022331059,0.000079127145,0.00025975198],"category_scores_gemma":[0.000027793078,0.00013610497,0.00008361767,0.00089834945,0.00025082592,0.00028850054,0.00002763067,0.0001493301,0.0000025508643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004759469,0.009176833,0.93310475,0.00014856302,0.0014145807,0.00002770115,0.0011644695,0.00011973533,0.008455931,0.00002690588,0.000024459336,0.041576605],"study_design_scores_gemma":[0.0053259297,0.0034347316,0.97704256,0.00009579165,0.00028797705,0.0000017354857,0.00004551616,0.00090844935,0.012331136,0.000051301893,0.0003449851,0.00012987466],"about_ca_topic_score_codex":0.00033541993,"about_ca_topic_score_gemma":0.0007682353,"teacher_disagreement_score":0.043937825,"about_ca_system_score_codex":0.000093640476,"about_ca_system_score_gemma":0.00018322153,"threshold_uncertainty_score":0.55502},"labels":[],"label_agreement":null},{"id":"W2898576001","doi":"10.1093/annonc/mdy287.066","title":"Patient reports of mouth symptoms after radiotherapy treatment for head and neck cancer: An international survey","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Head and neck cancer; Quality of life (healthcare); Family medicine; Radiation therapy; Demographics; Cancer; Health literacy; Health care; Surgery; Nursing; Demography; Internal medicine","score_opus":0.10223135631481178,"score_gpt":0.4478607993427169,"score_spread":0.3456294430279051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898576001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531627,0.0017366783,0.000007657276,0.001642754,0.00036523677,0.0002958579,0.000107526605,0.000006059767,0.000521969],"genre_scores_gemma":[0.9960245,0.0022625525,0.0003918776,0.0008736846,0.00019019697,0.00010157927,0.000020178983,0.000009035578,0.00012638286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929035,0.00003672864,0.0002904059,0.00017271256,0.00008238051,0.00012741162],"domain_scores_gemma":[0.99920136,0.0000648062,0.0001599875,0.00013558709,0.00037331434,0.000064928885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016151257,0.00008215296,0.0004200894,0.00005426795,0.000019483898,0.0000015756438,0.000021694472,0.000057025667,0.0000666041],"category_scores_gemma":[0.000040610423,0.00006119372,0.000049928683,0.00003759584,0.00014646877,0.00003441352,0.00001201368,0.000020682646,1.7580095e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038723534,0.0006636498,0.5143275,0.000028692399,0.0004503516,0.000017907132,0.0034989135,6.933232e-7,0.000699157,0.000010816096,0.0016210149,0.47480893],"study_design_scores_gemma":[0.002145574,0.029101323,0.86663496,0.00007263726,0.00003249577,0.00002498248,0.00005308339,0.000032954467,0.0060820426,0.000029522447,0.09572634,0.0000640645],"about_ca_topic_score_codex":0.0013134644,"about_ca_topic_score_gemma":0.0019318577,"teacher_disagreement_score":0.4747449,"about_ca_system_score_codex":0.000057921792,"about_ca_system_score_gemma":0.000159279,"threshold_uncertainty_score":0.24954076},"labels":[],"label_agreement":null},{"id":"W2898578088","doi":"10.1093/annonc/mdy304","title":"Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"SMARCB1; Epithelioid sarcoma; Medicine; Cancer research; EZH2; Cancer; DNA methylation; Loss function; Gene; Genetics; Internal medicine; Gene expression; Immunohistochemistry; Phenotype; Chromatin remodeling; Biology","score_opus":0.02554028624790891,"score_gpt":0.3357049370008055,"score_spread":0.31016465075289656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898578088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99902445,0.00009419345,0.00020630534,0.00004855031,0.00008101921,0.00033911713,0.000100292724,0.0000034962757,0.00010255789],"genre_scores_gemma":[0.999299,0.000078699886,0.00015324767,0.00016713451,0.000046600126,0.000018519477,0.0002130677,0.000016152095,0.000007578227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986484,0.00017938146,0.00060114125,0.00026109238,0.00014331056,0.00016665328],"domain_scores_gemma":[0.9987654,0.00001750392,0.00047519797,0.0002961306,0.00040421495,0.000041545856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018799902,0.00013086712,0.0004329261,0.00010356952,0.000025010413,0.000001685641,0.00017946772,0.00013076329,0.00003397712],"category_scores_gemma":[0.00011181791,0.00012784323,0.0000781533,0.0001433022,0.000116868054,0.000004920309,0.00012344772,0.000052412466,9.3404833e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00118273,0.003435155,0.0067103114,0.000016459917,0.000100147896,0.000002691787,0.0010906582,0.000021846057,0.9683016,0.0000027028964,0.000025660973,0.019110018],"study_design_scores_gemma":[0.0065551605,0.021389024,0.021110876,0.000035443518,0.000024148429,5.7751527e-7,0.00023640729,0.00022944971,0.9499654,0.00003618917,0.00030297873,0.000114334645],"about_ca_topic_score_codex":0.00019527435,"about_ca_topic_score_gemma":0.00009901769,"teacher_disagreement_score":0.018995684,"about_ca_system_score_codex":0.000008928724,"about_ca_system_score_gemma":0.00011510195,"threshold_uncertainty_score":0.5213295},"labels":[],"label_agreement":null},{"id":"W2898590125","doi":"10.1093/annonc/mdy287.080","title":"A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; London Health Sciences Centre; Jewish General Hospital; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Durvalumab; Oncology; Tremelimumab; Internal medicine; Radiation therapy; Cancer; Immunotherapy; Nivolumab; Ipilimumab","score_opus":0.06117280264449251,"score_gpt":0.4078237154637091,"score_spread":0.34665091281921656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898590125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90309215,0.078836486,0.00020914663,0.0022688757,0.0033917069,0.009111231,0.0020862538,0.00012990076,0.00087425695],"genre_scores_gemma":[0.9062156,0.08745939,0.00073449017,0.001242263,0.0008207886,0.0022580412,0.00027556837,0.0003440868,0.0006497649],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98389727,0.0055638393,0.0043497356,0.0022825506,0.0016461365,0.0022604396],"domain_scores_gemma":[0.98767155,0.0054963403,0.0032666512,0.0012717309,0.0010722223,0.0012215266],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0060070828,0.0018268393,0.0110067045,0.0013226456,0.0007128978,0.00006576162,0.00093836104,0.0010439327,0.0010551992],"category_scores_gemma":[0.0014625348,0.0016206461,0.0012839779,0.0013183595,0.002272957,0.00049153995,0.00018575808,0.0013168196,0.000005198807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7675367,0.0050722104,0.0005601046,0.00027607076,0.005207399,0.0004126314,0.020095581,0.00022496059,0.021654183,0.000016691605,0.02249305,0.1564504],"study_design_scores_gemma":[0.87144935,0.0913353,0.0014494542,0.00051446934,0.0019841401,0.00003669858,0.0023331335,0.0059149805,0.0028289815,0.000013780532,0.020635638,0.001504043],"about_ca_topic_score_codex":0.0791863,"about_ca_topic_score_gemma":0.1369188,"teacher_disagreement_score":0.15494636,"about_ca_system_score_codex":0.0042751394,"about_ca_system_score_gemma":0.005977507,"threshold_uncertainty_score":0.99985796},"labels":[],"label_agreement":null},{"id":"W2898590494","doi":"10.1093/annonc/mdy287.079","title":"Pembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; MorphoSys; Swedish Orphan Biovitrum; Astellas Pharma; Regeneron Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Phases of clinical research; Head and neck squamous-cell carcinoma; Cancer; Surgery; Clinical trial; Head and neck cancer; Immunotherapy","score_opus":0.06840397306266671,"score_gpt":0.38538115455605754,"score_spread":0.3169771814933908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898590494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250287,0.00041644328,0.000004632437,0.0012715204,0.0002928368,0.0016474943,0.000032003034,0.000014830993,0.0038173562],"genre_scores_gemma":[0.9985419,0.000025927438,0.00014352374,0.0007158811,0.00013305743,0.000107261854,0.000009554364,0.000031142004,0.00029175487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798054,0.00024731894,0.00053768634,0.00038652957,0.00038996775,0.0004579731],"domain_scores_gemma":[0.998273,0.0003635028,0.00031185494,0.0005116246,0.00043717545,0.000102832746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028164015,0.0002520533,0.00078217353,0.00016851649,0.0001469844,0.0000051147103,0.00022442592,0.000061299295,0.00020909354],"category_scores_gemma":[0.00018541621,0.00014225845,0.00006885541,0.00035554392,0.0004133837,0.00004609746,0.00017755832,0.00025556478,0.000023826644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09411696,0.05324534,0.63770336,0.0003192251,0.0005859333,0.0023082988,0.028590536,0.0000070539068,0.00007768571,0.000025245572,0.020158336,0.16286202],"study_design_scores_gemma":[0.046918847,0.43801522,0.4936465,0.000059107268,0.0005182708,0.00016370752,0.002793705,0.000040377166,0.001338717,0.00004687316,0.016139243,0.00031943244],"about_ca_topic_score_codex":0.00023918084,"about_ca_topic_score_gemma":0.0012692348,"teacher_disagreement_score":0.3847699,"about_ca_system_score_codex":0.00012758479,"about_ca_system_score_gemma":0.00040343252,"threshold_uncertainty_score":0.5801131},"labels":[],"label_agreement":null},{"id":"W2898594052","doi":"10.1093/annonc/mdy297.010","title":"Cascade BRCA germline mutation (BGM) testing of women with breast (BC) or epithelial ovarian cancer (EOC) and their families with subsequent risk reducing surgery (RRS): A Canadian economics model","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; BRCA mutation; Oncology; Ovarian cancer; Internal medicine; Breast cancer; Gynecology; Germline mutation; Cancer; Mutation; Genetics","score_opus":0.044032149272590554,"score_gpt":0.29709326942994796,"score_spread":0.2530611201573574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898594052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761045,0.00018948072,0.00039503348,0.00066972297,0.00007166666,0.0001846991,0.0005671858,0.0000058146097,0.00030593967],"genre_scores_gemma":[0.99522865,0.00068665924,0.0033354743,0.00033461076,0.00022507714,0.00007237871,0.000040371444,0.000031876414,0.000044910754],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878937,0.000079050995,0.0003378013,0.00034923558,0.000053235075,0.00039132682],"domain_scores_gemma":[0.9986298,0.00009831859,0.00039215363,0.00024734417,0.0004760468,0.00015631116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045812325,0.00017856645,0.00035319748,0.00014813023,0.000107501226,0.000010052114,0.00010937281,0.00016870598,0.000018708062],"category_scores_gemma":[0.000106831074,0.00013506584,0.000030828996,0.0001565836,0.0004598756,0.0000136362905,0.000038463517,0.000088878835,3.6514942e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008761739,0.00033997113,0.05614252,0.00027464575,0.0020557202,0.00004667158,0.014533945,0.11262924,0.14343737,0.00009923202,0.0015651464,0.6601138],"study_design_scores_gemma":[0.004920114,0.012048118,0.10081408,0.00040937387,0.00028040304,0.001615889,0.007039905,0.039548483,0.8176456,0.00080757553,0.01326214,0.0016082879],"about_ca_topic_score_codex":0.07363522,"about_ca_topic_score_gemma":0.22754748,"teacher_disagreement_score":0.6742082,"about_ca_system_score_codex":0.00021769294,"about_ca_system_score_gemma":0.0043327766,"threshold_uncertainty_score":0.9325335},"labels":[],"label_agreement":null},{"id":"W2898595037","doi":"10.1093/annonc/mdy272.322","title":"Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Letrozole; Breast cancer; Palbociclib; Estrogen receptor; Cancer; Phases of clinical research; Metastatic breast cancer; Progression-free survival; Gastroenterology; Oncology; Clinical trial; Gynecology; Overall survival; Tamoxifen","score_opus":0.04555222766477911,"score_gpt":0.4145697970891816,"score_spread":0.3690175694244025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898595037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273103,0.000051518524,0.00006924578,0.0028476627,0.00027434144,0.002856746,0.0008111211,0.00007992479,0.00027841888],"genre_scores_gemma":[0.99093646,0.00010823942,0.0050498787,0.0019425221,0.00023220044,0.0006406248,0.000035188583,0.00016517723,0.0008897211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99218655,0.002933056,0.001555799,0.0014121041,0.0007077113,0.0012048051],"domain_scores_gemma":[0.99091,0.004339755,0.0013342209,0.00068712013,0.002272421,0.00045647944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015354481,0.00087002956,0.0026991474,0.0007343795,0.0001880497,0.000016335387,0.00040450448,0.00054774416,0.0008593179],"category_scores_gemma":[0.0021785453,0.00054423336,0.00021400723,0.0013160418,0.0023787557,0.00068794034,0.00017016286,0.0010666965,0.000033750905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47718844,0.0017617218,0.49108842,0.000032173146,0.00069617515,0.0001354989,0.007520295,0.000007659732,0.00088376005,0.0000062113604,0.00006927109,0.020610388],"study_design_scores_gemma":[0.031099366,0.0697063,0.88351744,0.0009995493,0.00010136903,0.000095333104,0.004119912,0.000005055027,0.009161479,0.000054438326,0.00048922264,0.00065054547],"about_ca_topic_score_codex":0.0015425896,"about_ca_topic_score_gemma":0.00967302,"teacher_disagreement_score":0.44608906,"about_ca_system_score_codex":0.0014937691,"about_ca_system_score_gemma":0.003906384,"threshold_uncertainty_score":0.9997009},"labels":[],"label_agreement":null},{"id":"W2898602366","doi":"10.1093/annonc/mdy285.157","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Ovarian cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Adverse effect; Cohort; Interquartile range; Cancer; Phases of clinical research; Immunotherapy; Chemotherapy","score_opus":0.04508941207630825,"score_gpt":0.41096888463374603,"score_spread":0.3658794725574378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898602366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925293,0.00056009594,0.00002295302,0.0026149002,0.00030222986,0.0019764537,0.0010224921,0.000042359086,0.0009292243],"genre_scores_gemma":[0.9962146,0.00030954208,0.0017709055,0.00048149045,0.00041131477,0.00019337978,0.0005067788,0.000061194136,0.000050790688],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962908,0.00035035802,0.0013740477,0.0008800244,0.00051938306,0.00058536266],"domain_scores_gemma":[0.99717927,0.00024341946,0.00089646596,0.00060229347,0.00080878736,0.00026973922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093196804,0.0004189231,0.0015593853,0.00030452246,0.00014322494,0.000015544778,0.00020087289,0.00022170633,0.00030331005],"category_scores_gemma":[0.0001716068,0.0003339402,0.000120240846,0.0004693475,0.00030457677,0.00023823266,0.00010173526,0.000288867,0.0000056871195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42844942,0.07040174,0.12863699,0.00037468597,0.006246426,0.0032142093,0.046514183,0.00007840452,0.13655049,0.00013583049,0.011912601,0.16748501],"study_design_scores_gemma":[0.28145343,0.25851968,0.25983027,0.0028582108,0.0021684663,0.000055740973,0.004963768,0.001777789,0.17194861,0.00033720426,0.014784346,0.0013024877],"about_ca_topic_score_codex":0.018795686,"about_ca_topic_score_gemma":0.011299425,"teacher_disagreement_score":0.18811794,"about_ca_system_score_codex":0.00018815033,"about_ca_system_score_gemma":0.0010623295,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W2898607831","doi":"10.1093/annonc/mdy269.093","title":"Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Loss of heterozygosity; Human leukocyte antigen; Medicine; Immunology; Univariate analysis; Internal medicine; Allele; Oncology; Biology; Genetics; Antigen; Multivariate analysis","score_opus":0.06514329559478552,"score_gpt":0.400270124425917,"score_spread":0.33512682883113143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898607831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839605,0.0005393767,0.00014866634,0.0124132885,0.00011330246,0.00022341494,0.000022573671,0.000041806987,0.0025370428],"genre_scores_gemma":[0.99096733,0.0003008329,0.00081914366,0.007300046,0.00023721371,0.00000990846,0.0000065659524,0.000016681735,0.00034230054],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875087,0.0001667937,0.00040557396,0.00027764673,0.00013368895,0.00026544888],"domain_scores_gemma":[0.99897814,0.00023072278,0.0001658131,0.00029490326,0.00022263553,0.00010779468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085537025,0.00012174783,0.00052162114,0.00023353005,0.00006213668,0.0000064709134,0.00009036673,0.00015205295,0.00014725141],"category_scores_gemma":[0.00021867723,0.00010604648,0.0001659319,0.00053734274,0.0002897697,0.000050385755,0.000068751535,0.000101612124,0.0000075921903],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14608254,0.00073884707,0.04812872,0.00006727226,0.0038360008,0.00006994812,0.006729489,0.000010764168,0.7154361,0.00007581917,0.009898227,0.0689263],"study_design_scores_gemma":[0.0058817393,0.018506141,0.6526079,0.000053978205,0.0007204624,0.00011797155,0.0004710783,0.00040841536,0.0498821,0.00010928307,0.27101985,0.0002210509],"about_ca_topic_score_codex":0.0003511506,"about_ca_topic_score_gemma":0.00040333162,"teacher_disagreement_score":0.665554,"about_ca_system_score_codex":0.00007697408,"about_ca_system_score_gemma":0.00020458669,"threshold_uncertainty_score":0.43244496},"labels":[],"label_agreement":null},{"id":"W2898608732","doi":"10.1093/annonc/mdy273.395","title":"Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600–mutant high-grade glioma (HGG) or low-grade glioma (LGG)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Trametinib; Dabrafenib; Medicine; MEK inhibitor; Oncology; Internal medicine; Cohort; Glioma; Melanoma; Phases of clinical research; Clinical trial; Cancer research; Cancer; MAPK/ERK pathway; Metastatic melanoma; Kinase; Vemurafenib; Biology","score_opus":0.0996918227720206,"score_gpt":0.436226634191225,"score_spread":0.3365348114192044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898608732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928362,0.00012238708,0.0000037569805,0.0025777782,0.00016563555,0.0039863493,0.00006224791,0.000034880093,0.00021081614],"genre_scores_gemma":[0.99808145,0.000022157335,0.0009095579,0.00036349957,0.00009795639,0.00037605062,0.00009823619,0.000042696578,0.000008404986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623823,0.0005019232,0.0010089152,0.00077742944,0.0007971845,0.00067630317],"domain_scores_gemma":[0.99761367,0.00033624153,0.0006601824,0.0005045983,0.0006459542,0.00023937624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009775964,0.00042425777,0.001181581,0.0006538713,0.00014515863,0.00003736499,0.0003691373,0.00021305945,0.00009192802],"category_scores_gemma":[0.0003723319,0.00029027197,0.000045930396,0.002530771,0.00021744499,0.00029324292,0.00021419235,0.00022981603,0.000012266141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017661126,0.32984176,0.5967448,0.00011558826,0.00044568235,0.0026924112,0.0021669415,0.000019258243,0.0011831466,0.00020633035,0.00058503094,0.048337977],"study_design_scores_gemma":[0.20442471,0.26640224,0.52300656,0.00022625543,0.00043149648,0.00007083502,0.000519434,0.00019268412,0.0041476595,0.00016401762,0.00008080358,0.00033332786],"about_ca_topic_score_codex":0.000752489,"about_ca_topic_score_gemma":0.004229235,"teacher_disagreement_score":0.18676358,"about_ca_system_score_codex":0.00029200886,"about_ca_system_score_gemma":0.0006574332,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W2899537750","doi":"10.1093/annonc/mdy470","title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":308,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"Overseas Expertise Introduction Project for Discipline Innovation; National Natural Science Foundation of China","keywords":"Immune system; Head and neck squamous-cell carcinoma; Immunotherapy; Tumor microenvironment; Medicine; Cancer research; Stromal cell; Immunology; Cancer; Biology; Head and neck cancer; Internal medicine","score_opus":0.048417727648873074,"score_gpt":0.34405050609707116,"score_spread":0.2956327784481981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899537750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064237,0.002035016,0.0037774357,0.0028894113,0.000027030148,0.00049253175,0.000057561458,0.0000035335563,0.00007509564],"genre_scores_gemma":[0.9974723,0.0002170527,0.001912743,0.0002418985,0.000016726442,0.00006701244,0.000044973058,0.000012520904,0.000014807574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925536,0.00002474859,0.00039303614,0.00016291371,0.00005950595,0.00010443087],"domain_scores_gemma":[0.99911994,0.00006420759,0.00034284178,0.00022251077,0.00021900018,0.000031521584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020632712,0.00007611111,0.00028551056,0.00008098117,0.00003127195,0.000002428298,0.00005188222,0.000081947255,0.000011238209],"category_scores_gemma":[0.00002164565,0.000074905714,0.00006449877,0.000075711905,0.0002482511,0.000032323765,0.000015077547,0.00003101056,2.4022884e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040675985,0.0007512157,0.024486443,0.00018200028,0.00002394041,6.6605146e-8,0.00018417227,0.0000030734268,0.9666137,0.0001797047,0.000091676455,0.0070772613],"study_design_scores_gemma":[0.0024945808,0.0029974086,0.28208953,0.00001373632,0.000056977115,0.0000022774568,0.000040661693,0.00007214283,0.7115674,0.000052705353,0.0005726059,0.000039956307],"about_ca_topic_score_codex":0.00009423703,"about_ca_topic_score_gemma":0.000004580209,"teacher_disagreement_score":0.25760308,"about_ca_system_score_codex":0.000015442582,"about_ca_system_score_gemma":0.00005988161,"threshold_uncertainty_score":0.30545664},"labels":[],"label_agreement":null},{"id":"W2900483456","doi":"10.1093/annonc/mdy425.002","title":"Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Paclitaxel; Internal medicine; Clinical endpoint; Placebo; Oncology; Randomization; Taxane; Progression-free survival; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin; Pathology; Immunotherapy; Breast cancer","score_opus":0.09552856974600375,"score_gpt":0.37292295093702754,"score_spread":0.2773943811910238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900483456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677161,0.0013517672,0.00009119416,0.021536047,0.0002893768,0.0010281145,0.00028586594,0.00005002842,0.007651489],"genre_scores_gemma":[0.9938346,0.00034263838,0.0009957766,0.0033889145,0.00043497098,0.00006467672,0.00009923694,0.000053043437,0.00078612106],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969923,0.00032284067,0.0010443947,0.0005728547,0.0004481227,0.0006195015],"domain_scores_gemma":[0.99688566,0.0011814248,0.0005776256,0.0008026764,0.00039262473,0.00016001388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011491774,0.00036762588,0.001044501,0.00018178302,0.00014433265,0.00001973664,0.0003381166,0.00022106398,0.0003470475],"category_scores_gemma":[0.00075041223,0.00021273526,0.00018488026,0.0006375078,0.0010097271,0.000120041725,0.00007430418,0.00039675328,0.000033740565],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6936949,0.004737791,0.06156373,0.0003407256,0.003013095,0.0012908773,0.030729655,0.00004709365,0.012173805,0.00031428822,0.03640905,0.15568502],"study_design_scores_gemma":[0.14518893,0.10497848,0.4891525,0.0019820274,0.0012435265,0.0011331827,0.010413582,0.0018916546,0.01300724,0.0011131964,0.22834954,0.0015461579],"about_ca_topic_score_codex":0.00889128,"about_ca_topic_score_gemma":0.032586303,"teacher_disagreement_score":0.54850596,"about_ca_system_score_codex":0.0001354139,"about_ca_system_score_gemma":0.0007500843,"threshold_uncertainty_score":0.9977086},"labels":[],"label_agreement":null},{"id":"W2900568572","doi":"10.1093/annonc/mdy438.035","title":"Survival predictors of major salivary gland cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Head and neck cancer; Population; Oncology; Epidemiology; Internal medicine; Incidence (geometry); Retrospective cohort study; Survival analysis; Cancer; Environmental health","score_opus":0.0907895018719062,"score_gpt":0.40990361422716354,"score_spread":0.31911411235525733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900568572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961323,0.0009849963,0.00000268808,0.003410893,0.00056489167,0.00017936168,0.00006458717,0.000015639705,0.033453923],"genre_scores_gemma":[0.99727863,0.0010537441,0.000110598194,0.0006434576,0.00052927324,0.000025630781,0.000022330776,0.000012332532,0.00032398506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999118,0.00005782349,0.00030751224,0.00016192388,0.00016118144,0.00019361245],"domain_scores_gemma":[0.99910706,0.00015806046,0.00016458052,0.00020406178,0.00026084934,0.000105402985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018417239,0.00010448783,0.00048834074,0.00008610564,0.000022994567,0.0000012320471,0.00006667588,0.000097411925,0.0007113217],"category_scores_gemma":[0.00005673723,0.00007588978,0.00010532701,0.00012262155,0.00022652774,0.00002753635,0.00003466015,0.000058305133,0.000017332042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000829444,0.0010834782,0.9689394,0.000061012077,0.00047783088,0.000059517915,0.00025766733,3.99069e-7,0.00032069237,0.00046130054,0.021647999,0.0058612567],"study_design_scores_gemma":[0.0030100555,0.009675101,0.9180989,0.000106079846,0.00020880827,0.000029526911,0.00005560754,0.0000057993607,0.036918562,0.00022024877,0.031595256,0.00007600067],"about_ca_topic_score_codex":0.0008387058,"about_ca_topic_score_gemma":0.00021810809,"teacher_disagreement_score":0.05084045,"about_ca_system_score_codex":0.00001930786,"about_ca_system_score_gemma":0.00020666607,"threshold_uncertainty_score":0.7788474},"labels":[],"label_agreement":null},{"id":"W2900778417","doi":"10.1093/annonc/mdy425","title":"Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Gefitinib; Erlotinib; Oncology; Discontinuation; Hazard ratio; Lung cancer; Progression-free survival; Erlotinib Hydrochloride; Ceritinib; T790M; Chemotherapy; Cancer; Epidermal growth factor receptor; Confidence interval; Crizotinib","score_opus":0.02403826421624572,"score_gpt":0.4144345232529033,"score_spread":0.3903962590366576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900778417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959947,0.0007560948,0.0000037707384,0.004961954,0.00013348534,0.00089227577,0.0001184664,0.000025635114,0.0035088353],"genre_scores_gemma":[0.99739313,0.00045714708,0.000485258,0.0011999954,0.00003626872,0.000053506883,0.00022061882,0.000026466962,0.00012763079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870133,0.000054776887,0.00043799332,0.0002600113,0.00027611226,0.00026974326],"domain_scores_gemma":[0.9977774,0.00009462308,0.00033065956,0.0002826797,0.001415712,0.000098904275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007946302,0.00019250248,0.0006889252,0.0001678008,0.00006126104,0.00000326774,0.00008885639,0.00013557459,0.00018621588],"category_scores_gemma":[0.00009869106,0.00012373402,0.00008754985,0.00025456963,0.00021209831,0.00008543917,0.000027177666,0.00009867238,0.000009257844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02666808,0.0015407983,0.55748224,0.000087104214,0.0004431831,0.000033225835,0.0050419597,0.000011270194,0.00023239237,0.00004861365,0.00045833437,0.40795282],"study_design_scores_gemma":[0.03896366,0.1842601,0.71707046,0.0007172898,0.0002240905,0.0000060303564,0.0013241498,0.0000061614155,0.03121362,0.0000931146,0.025884612,0.00023668987],"about_ca_topic_score_codex":0.00029785384,"about_ca_topic_score_gemma":0.00057838904,"teacher_disagreement_score":0.40771613,"about_ca_system_score_codex":0.00013565968,"about_ca_system_score_gemma":0.00041126073,"threshold_uncertainty_score":0.5045727},"labels":[],"label_agreement":null},{"id":"W2900949430","doi":"10.1093/annonc/mdy443.004","title":"FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Medicine; Pathology; Molecular pathology; Sarcoma; Genetics; Gene","score_opus":0.08988588564300508,"score_gpt":0.4356594355922345,"score_spread":0.34577354994922943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900949430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583375,0.0022155656,0.00007058382,0.00088990363,0.00006484067,0.000396769,0.00005802348,0.000008188386,0.00046235725],"genre_scores_gemma":[0.99518704,0.00043618208,0.0034957775,0.00077731995,0.000032593296,0.00003173782,0.000014554823,0.000018138257,0.000006663229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984488,0.00013095599,0.0006486136,0.00032718328,0.00019970445,0.0002447428],"domain_scores_gemma":[0.99810326,0.00029686216,0.0005867958,0.000352399,0.0005270583,0.0001336205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000356013,0.000168941,0.0009809643,0.0001610465,0.000022986747,0.0000021290823,0.000079003774,0.00018918971,0.000051763385],"category_scores_gemma":[0.00033269986,0.00013228279,0.00018063466,0.00014550293,0.0013238952,0.000031495783,0.00010366583,0.0001308989,0.0000027088684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011628763,0.006888205,0.90908575,0.00008224215,0.0004625843,0.01024517,0.00021775301,3.8273046e-7,0.048676684,0.001873833,0.00036276443,0.020941779],"study_design_scores_gemma":[0.008898686,0.030112289,0.6586067,0.00027133097,0.0010094247,0.0038578995,0.00010082019,0.000006661504,0.2958779,0.0002477938,0.0008406449,0.00016983248],"about_ca_topic_score_codex":0.00024274303,"about_ca_topic_score_gemma":0.00009522933,"teacher_disagreement_score":0.250479,"about_ca_system_score_codex":0.000011889662,"about_ca_system_score_gemma":0.00018068175,"threshold_uncertainty_score":0.53943354},"labels":[],"label_agreement":null},{"id":"W2901017225","doi":"10.1093/annonc/mdy444.011","title":"A randomized study comparing two different training programs","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cognition; Pittsburgh Sleep Quality Index; Anxiety; Beck Anxiety Inventory; Episodic memory; Beck Depression Inventory; Cognitive training; Hospital Anxiety and Depression Scale; Quality of life (healthcare); Visual memory; Montreal Cognitive Assessment; Psychiatry; Clinical psychology; Cognitive impairment","score_opus":0.2727505351219595,"score_gpt":0.46928736887528993,"score_spread":0.19653683375333042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901017225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96875143,0.00017255772,0.00008450412,0.0022107204,0.00032316134,0.0020169034,9.807853e-7,0.000066485394,0.026373284],"genre_scores_gemma":[0.9983099,0.00005758532,0.000099746634,0.0006789502,0.0003560629,0.00023989263,0.00000521511,0.000016245056,0.00023641824],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99842006,0.00027838067,0.00050048315,0.00024483423,0.00021337286,0.00034289522],"domain_scores_gemma":[0.9987466,0.0003341162,0.00023394052,0.0001629132,0.00042288256,0.00009957709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007989735,0.00016649801,0.0013916058,0.00013320634,0.00008118532,0.0000055762243,0.00007409101,0.00005674699,0.000094862415],"category_scores_gemma":[0.00035301273,0.00012245102,0.00018671218,0.00015735139,0.00062683277,0.0000315397,0.0000926868,0.00017984751,0.000021149826],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3010941,0.01010569,0.14659175,0.000106598265,0.0059244195,0.00012791756,0.056231175,0.0000021364337,0.0006262434,0.00039352814,0.0029270116,0.47586942],"study_design_scores_gemma":[0.85510135,0.04105067,0.076804854,0.00044667552,0.0013455118,0.00007963017,0.015931683,0.000522932,0.0013811409,0.0007238669,0.0062780143,0.00033368517],"about_ca_topic_score_codex":0.00011776198,"about_ca_topic_score_gemma":0.00029581855,"teacher_disagreement_score":0.55400723,"about_ca_system_score_codex":0.000044628556,"about_ca_system_score_gemma":0.000093647956,"threshold_uncertainty_score":0.49934074},"labels":[],"label_agreement":null},{"id":"W2901151612","doi":"10.1093/annonc/mdy433","title":"Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; BC Cancer Agency; London Health Sciences Centre; Positive Living North","funders":"","keywords":"Medicine; SABR volatility model; Clinical endpoint; Randomized controlled trial; Internal medicine; Radiation therapy; Radiosurgery; Randomization; Prostate cancer; Performance status; Surgery; Oncology; Cancer","score_opus":0.12518010295923543,"score_gpt":0.4371153267759516,"score_spread":0.3119352238167162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901151612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97146946,0.002306628,0.00013899751,0.021262525,0.00040295772,0.003169276,0.0002792539,0.000012216597,0.00095869467],"genre_scores_gemma":[0.9904463,0.0031900026,0.0013105551,0.0039296024,0.0006627483,0.00031499594,0.00003531052,0.0000146709845,0.00009577749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99860877,0.00029828007,0.000492554,0.00026743184,0.00012819993,0.00020477343],"domain_scores_gemma":[0.9906199,0.008478452,0.0003601956,0.00026069785,0.00019605125,0.00008472775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094193075,0.00014265504,0.0010266156,0.000058301608,0.000073305324,0.000011277715,0.000070782204,0.00007643663,0.00010612915],"category_scores_gemma":[0.0012093349,0.0000829138,0.00018054542,0.00011212786,0.0004777698,0.00004078904,0.000017864255,0.00007571485,0.0000023399962],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93166566,0.00064217055,0.00009283253,0.000011897531,0.0026866961,0.0000056696895,0.0035794154,0.0000016805964,0.00022737245,0.00012891422,0.011298874,0.049658794],"study_design_scores_gemma":[0.93615645,0.018176755,0.0030089791,0.00008378413,0.0006970354,0.000005817482,0.00013538999,0.00014881026,0.0048714876,0.0007160268,0.035902776,0.000096692274],"about_ca_topic_score_codex":0.0017339998,"about_ca_topic_score_gemma":0.00042470178,"teacher_disagreement_score":0.049562104,"about_ca_system_score_codex":0.00010551998,"about_ca_system_score_gemma":0.00027336788,"threshold_uncertainty_score":0.33811268},"labels":[],"label_agreement":null},{"id":"W2901178661","doi":"10.1093/annonc/mdy430.011","title":"Phase I investigator’s perceptions to ‘supersized seamless trials in oncology'","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Clinical trial; Likert scale; Popularity; Oncology; Internal medicine; Psychology; Social psychology","score_opus":0.8991731111111113,"score_gpt":0.7310220453656908,"score_spread":0.1681510657454205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901178661","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91749716,0.0000289328,0.021126356,0.035771646,0.001736595,0.0017647566,0.00022230888,0.0000967762,0.021755466],"genre_scores_gemma":[0.22047329,0.00007846088,0.7681552,0.009869044,0.0009945919,0.00017805584,0.0000032241664,0.000041477026,0.00020662282],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9878585,0.0080579575,0.0027498011,0.0004950521,0.00029506668,0.0005436762],"domain_scores_gemma":[0.83997583,0.15651922,0.0010013895,0.00083192985,0.00081344834,0.0008581763],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.027525147,0.00023112014,0.0026696182,0.0003418145,0.00007018451,0.000011620189,0.00047937094,0.00057514914,0.002160515],"category_scores_gemma":[0.50224286,0.00020120668,0.00032078865,0.00057195575,0.00090736564,0.000068548805,0.0001954333,0.00038043625,0.00025759646],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004787917,0.010170706,0.00043066547,0.00015371651,0.00036271694,0.00010252499,0.006969703,0.0000021539909,0.039861683,0.15992634,0.3515755,0.42565638],"study_design_scores_gemma":[0.009947704,0.016531736,0.00029507335,0.000119646116,0.00013960642,0.000011123272,0.0009112434,0.00005961882,0.011898946,0.8792889,0.08049397,0.00030244308],"about_ca_topic_score_codex":0.000047349913,"about_ca_topic_score_gemma":0.00015650822,"teacher_disagreement_score":0.7470289,"about_ca_system_score_codex":0.00012228078,"about_ca_system_score_gemma":0.00080345024,"threshold_uncertainty_score":0.99875164},"labels":[],"label_agreement":null},{"id":"W2901182872","doi":"10.1093/annonc/mdy436.027","title":"GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cycle for Survival","keywords":"Medicine; Chemotherapy; Bevacizumab; Vinorelbine; Internal medicine; Gemcitabine; Irinotecan; Oncology; Surgery; Cancer; Cisplatin; Colorectal cancer","score_opus":0.38488253281798285,"score_gpt":0.5344764449217434,"score_spread":0.14959391210376055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901182872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893821,0.00079884834,0.000028318878,0.0044208397,0.0010014307,0.0029443256,0.00025226083,0.000025642295,0.0011462705],"genre_scores_gemma":[0.9888147,0.0016104031,0.0026514318,0.004865507,0.00097289466,0.0005787583,0.00023031121,0.000050581835,0.00022538203],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962488,0.00079049595,0.0013861987,0.00059787446,0.00052303047,0.0004536051],"domain_scores_gemma":[0.9959983,0.0014605414,0.00073270564,0.0004046868,0.0008640799,0.0005396346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001922992,0.0003415148,0.0023093005,0.00036368298,0.00006554279,0.000017417846,0.0004504455,0.00023273547,0.0029080762],"category_scores_gemma":[0.0022069986,0.00024732776,0.00014395357,0.00084221544,0.0006650629,0.00032693232,0.000110994835,0.00029013198,0.000010437989],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91543525,0.020812439,0.000082936895,0.00011935979,0.00090238824,0.000024432782,0.00060929894,0.000003277805,0.0036120752,0.0001625389,0.0011825196,0.05705349],"study_design_scores_gemma":[0.9225902,0.05242135,0.00035474516,0.00011013277,0.0003451051,0.000005542261,0.000098628014,0.0007557298,0.012438165,0.0002592943,0.010395135,0.00022599945],"about_ca_topic_score_codex":0.0019604294,"about_ca_topic_score_gemma":0.0045229923,"teacher_disagreement_score":0.056827493,"about_ca_system_score_codex":0.00020603786,"about_ca_system_score_gemma":0.0019244964,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W2901186138","doi":"10.1093/annonc/mdy446.007","title":"ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Internal medicine; Lung cancer; Oncology; Cancer; Gastroenterology; Adenocarcinoma","score_opus":0.07305210233867651,"score_gpt":0.4704252483093927,"score_spread":0.39737314597071616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901186138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882876,0.00010839284,0.000018831759,0.0002676346,0.00010819098,0.000814354,0.000041386775,0.0000090834255,0.010344484],"genre_scores_gemma":[0.99915195,0.000042641663,0.00023488476,0.00016987244,0.0000726241,0.0000578072,0.000048954185,0.000011145201,0.00021009866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988568,0.00006829436,0.00043122732,0.00023494271,0.00019644466,0.00021231662],"domain_scores_gemma":[0.99884534,0.00003735003,0.00034995133,0.00020363452,0.00048739932,0.00007635028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009867067,0.00013112144,0.00045890285,0.00017745973,0.00003457075,0.0000029707649,0.00006990083,0.00006448129,0.00008538868],"category_scores_gemma":[0.000015228926,0.00010008072,0.00004934705,0.000569319,0.00007542021,0.000060801747,0.000026718855,0.000067145775,0.0000024012493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012514495,0.0036178813,0.9785023,0.00004296692,0.00034697176,0.000009202375,0.001595468,0.000117721545,0.000072143455,0.0000052752257,0.0010777179,0.013360921],"study_design_scores_gemma":[0.0077387434,0.010694109,0.9787685,0.00010399777,0.0005612097,4.1888688e-7,0.00046268298,0.00010226199,0.001196469,0.000007981469,0.00028409346,0.000079503705],"about_ca_topic_score_codex":0.021407949,"about_ca_topic_score_gemma":0.03547636,"teacher_disagreement_score":0.0140684135,"about_ca_system_score_codex":0.0002063083,"about_ca_system_score_gemma":0.00040118344,"threshold_uncertainty_score":0.98510855},"labels":[],"label_agreement":null},{"id":"W2901630115","doi":"10.1093/annonc/mdy483.006","title":"Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Afatinib; Osimertinib; Medicine; T790M; Discontinuation; Internal medicine; Oncology; Erlotinib; Epidermal growth factor receptor; Cancer; Gefitinib","score_opus":0.023552021184561282,"score_gpt":0.4114248194822116,"score_spread":0.3878727982976503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901630115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96902126,0.000055279386,0.000016676313,0.0014655832,0.00011253572,0.0014588156,0.000049418388,0.000022982535,0.02779743],"genre_scores_gemma":[0.99716556,0.0000142464205,0.000541802,0.00097283314,0.000042511358,0.0001517335,0.00015275978,0.000022481858,0.0009360451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873865,0.0000950393,0.00038774524,0.00029768114,0.00022067687,0.00026023414],"domain_scores_gemma":[0.99878025,0.00013687107,0.0002447838,0.00021461776,0.00052314537,0.00010030671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012615719,0.00015508701,0.00044199667,0.00018132747,0.000062200554,0.000004665893,0.00006648645,0.000058145564,0.0001011164],"category_scores_gemma":[0.00006564245,0.00012055864,0.000048250018,0.00042179695,0.0001319348,0.000105821484,0.000021649614,0.00009555186,0.000017868957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063625304,0.009668534,0.8936452,0.000021232867,0.0008267,0.000084699306,0.008958322,0.000008656936,0.00027721273,0.000095147036,0.007514671,0.072537094],"study_design_scores_gemma":[0.018744223,0.033124764,0.9405908,0.00011070626,0.00025876547,0.0000016819349,0.0010265874,0.000009137437,0.0017929917,0.000042898486,0.004151142,0.00014630688],"about_ca_topic_score_codex":0.0007372292,"about_ca_topic_score_gemma":0.001640773,"teacher_disagreement_score":0.07239079,"about_ca_system_score_codex":0.00012236554,"about_ca_system_score_gemma":0.00028922653,"threshold_uncertainty_score":0.49162385},"labels":[],"label_agreement":null},{"id":"W2901903079","doi":"10.1093/annonc/mdy507","title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Immune system; Immune checkpoint; Biomarker; Immunotherapy; Oncology; Immunology; Head and neck cancer; Cancer research; Internal medicine; Cancer; Biology","score_opus":0.07791163796091786,"score_gpt":0.3930575096801219,"score_spread":0.315145871719204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901903079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22678882,0.7696241,4.3039734e-7,0.0007485327,0.00034006734,0.0011779658,0.00005032027,0.0000109056455,0.0012588628],"genre_scores_gemma":[0.07197626,0.9269053,0.00023065302,0.00023505779,0.00010763183,0.00008105455,0.000038201488,0.000068006586,0.00035787374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957967,0.0006740228,0.00226447,0.0005329279,0.00024100709,0.0004908641],"domain_scores_gemma":[0.9971307,0.0006686335,0.0010799642,0.0007187845,0.00023083619,0.00017107844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025087944,0.0004719655,0.0032502862,0.0010528761,0.000033496064,0.0000059502313,0.00027274297,0.0007513616,0.00010025572],"category_scores_gemma":[0.00038108186,0.00039641373,0.0008435752,0.0008243409,0.000511902,0.000042955948,0.00019393372,0.00035053425,0.000016058239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034479998,0.000999912,0.00033372117,0.016576147,0.00040517762,0.0002002392,0.000980435,7.454721e-8,0.011365383,0.0000022635015,0.003406814,0.93124986],"study_design_scores_gemma":[0.004255885,0.014640798,0.0061858385,0.0072584604,0.00030498175,0.000180537,0.00015933976,5.0153363e-7,0.005854532,0.0000064065302,0.96080947,0.00034327185],"about_ca_topic_score_codex":0.0015677395,"about_ca_topic_score_gemma":0.00011215956,"teacher_disagreement_score":0.95740265,"about_ca_system_score_codex":0.00021808805,"about_ca_system_score_gemma":0.0014421438,"threshold_uncertainty_score":0.9998488},"labels":[],"label_agreement":null},{"id":"W2901970540","doi":"10.1093/annonc/mdy506","title":"Evolutionary dynamics of residual disease in human glioblastoma","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Brain Tumour Charity; National Institute for Health and Care Research; University of Cambridge; Cancer Research UK; Wellcome Trust; National Institute on Handicapped Research","keywords":"Medicine; Glioblastoma; Residual; Minimal residual disease; Dynamics (music); Oncology; Cancer research; Internal medicine","score_opus":0.04496481680490641,"score_gpt":0.3829355003263072,"score_spread":0.3379706835214008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901970540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960626,0.00032787316,0.000001502958,0.0062282826,0.000053813816,0.00015215059,0.000035469217,0.0000076008087,0.003587063],"genre_scores_gemma":[0.9993936,0.00004468302,0.000113434864,0.0002629053,0.00008258403,0.000014847409,0.000030154446,0.000007116622,0.000050716877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992814,0.000046712565,0.00027150236,0.00013116038,0.00011938328,0.00014982345],"domain_scores_gemma":[0.9993469,0.00006752544,0.00011012653,0.00018667035,0.00019562252,0.00009312251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011248907,0.00006992907,0.00027882817,0.00018907314,0.00002080211,6.719666e-7,0.00005295858,0.000069608745,0.00014411002],"category_scores_gemma":[0.00008491164,0.00006143721,0.00006402199,0.00014908102,0.00025251455,0.000025924688,0.00003945897,0.0000490067,0.000009563281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023494908,0.0076698107,0.9256431,0.0001371532,0.00021117907,0.0006141911,0.00034779505,0.000019971169,0.0044158325,0.01903811,0.023418128,0.016135275],"study_design_scores_gemma":[0.0022429903,0.008972519,0.9737535,0.000111383655,0.00006370726,0.0000104238125,0.000069361,0.00022748411,0.008827529,0.0029611785,0.0026973677,0.00006252105],"about_ca_topic_score_codex":0.00014081702,"about_ca_topic_score_gemma":0.00056085945,"teacher_disagreement_score":0.04811047,"about_ca_system_score_codex":0.00005623763,"about_ca_system_score_gemma":0.00015030423,"threshold_uncertainty_score":0.25053367},"labels":[],"label_agreement":null},{"id":"W2902530914","doi":"10.1093/annonc/mdy517","title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":795,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Triple-negative breast cancer; Pembrolizumab; Metastatic breast cancer; Cohort; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","score_opus":0.07573474290946053,"score_gpt":0.43182966956319807,"score_spread":0.35609492665373754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902530914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012625,0.0007494268,0.00004141766,0.004168656,0.00022978874,0.003858562,0.00029616465,0.000019525305,0.00051020144],"genre_scores_gemma":[0.99639934,0.000685634,0.000121556346,0.0013886152,0.00013261402,0.0004351469,0.000008966687,0.000027984615,0.00080013653],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99830025,0.00023098559,0.0006488647,0.00028918177,0.00022089716,0.00030981627],"domain_scores_gemma":[0.9980381,0.0002100099,0.00057108403,0.0004184167,0.0006921516,0.00007025407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063741376,0.00020323796,0.0008608242,0.00011955355,0.00013431726,0.0000037743555,0.0002128679,0.0000890158,0.00035912642],"category_scores_gemma":[0.0000875361,0.00012968984,0.000317444,0.00040028268,0.0005312828,0.00005420063,0.000034408928,0.000100849036,0.0000010526248],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27421674,0.018434143,0.041375373,0.00025742888,0.0108714085,0.00001711434,0.016858784,0.0000037208392,0.04823326,0.000056293586,0.022758685,0.56691706],"study_design_scores_gemma":[0.20160553,0.24083613,0.3127547,0.0005024321,0.00301289,0.0002268952,0.002842128,0.0004452532,0.19463257,0.00048764996,0.042061683,0.0005921448],"about_ca_topic_score_codex":0.0023829709,"about_ca_topic_score_gemma":0.00086339924,"teacher_disagreement_score":0.5663249,"about_ca_system_score_codex":0.00009807641,"about_ca_system_score_gemma":0.00065460725,"threshold_uncertainty_score":0.5288598},"labels":[],"label_agreement":null},{"id":"W2902655481","doi":"10.1093/annonc/mdy518","title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":631,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Metastatic breast cancer; Breast cancer; Triple-negative breast cancer; Cohort; Oncology; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Immunotherapy","score_opus":0.05724842178695039,"score_gpt":0.41755175223619245,"score_spread":0.36030333044924207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902655481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821634,0.00096157275,0.00006912842,0.0049494435,0.00031644516,0.004069353,0.0005436026,0.000020477439,0.0008536317],"genre_scores_gemma":[0.99566734,0.000981009,0.0001616038,0.001748883,0.00016494398,0.0003647724,0.000015733058,0.000034331595,0.00086139725],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99800843,0.00028973017,0.00070807576,0.0003539212,0.00026610092,0.00037374865],"domain_scores_gemma":[0.99768597,0.00029210345,0.0006406608,0.0004495286,0.00084552285,0.00008620039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006636749,0.00024964326,0.0009461298,0.00013604871,0.00018164371,0.0000055215187,0.0002491269,0.00010859878,0.00038219447],"category_scores_gemma":[0.00008506741,0.00016502867,0.00034800865,0.00042286707,0.00068581785,0.00007533061,0.000048831065,0.0001316045,0.0000017458001],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35780403,0.019980514,0.033899352,0.00029915274,0.014214281,0.000032685755,0.020130733,0.0000084161675,0.04094805,0.00012406787,0.02335094,0.48920777],"study_design_scores_gemma":[0.17314035,0.21367937,0.3596962,0.00068350555,0.0032873554,0.00032304166,0.0034557753,0.00039520237,0.21913758,0.00055054016,0.02496914,0.0006819392],"about_ca_topic_score_codex":0.0026749908,"about_ca_topic_score_gemma":0.0008731129,"teacher_disagreement_score":0.48852584,"about_ca_system_score_codex":0.00013043999,"about_ca_system_score_gemma":0.0007559795,"threshold_uncertainty_score":0.6729674},"labels":[],"label_agreement":null},{"id":"W2903904475","doi":"10.1093/annonc/mdy415","title":"Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck; AstraZeneca","keywords":"Alectinib; Medicine; Crizotinib; Oncology; First line therapy; Internal medicine; Lung cancer","score_opus":0.1069926659110964,"score_gpt":0.4628576205310257,"score_spread":0.3558649546199293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903904475","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001909573,0.0015256944,0.000060652783,0.90323836,0.0010140126,0.0018660914,0.0002517115,0.000058339145,0.09007559],"genre_scores_gemma":[0.003065764,0.0020219462,0.0011588787,0.94162387,0.010502372,0.0007404416,0.0017128439,0.00011203336,0.039061856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983536,0.00006579085,0.00045448728,0.00044375152,0.0002231077,0.00045923947],"domain_scores_gemma":[0.9975839,0.00051856035,0.000377544,0.0004497086,0.0009777918,0.00009249542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020500986,0.00031627505,0.000932725,0.00020793645,0.00010370798,0.000008872029,0.00016073148,0.0008692334,0.0009048264],"category_scores_gemma":[0.0002700249,0.00024398866,0.00040429938,0.00013598251,0.00019541776,0.00003946235,0.000023621782,0.00044506404,0.00017849212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010783372,0.0004094927,0.000046219186,0.0001815542,0.0014152649,0.0001401816,0.00044175907,2.935771e-7,0.00010865293,0.000015732172,0.9505599,0.045602594],"study_design_scores_gemma":[0.005939327,0.01895491,0.00013066827,0.00016191025,0.00037502908,0.00007696539,0.000015104619,0.0000060825923,0.0005507408,0.00054625276,0.97305167,0.0001913667],"about_ca_topic_score_codex":0.00023839765,"about_ca_topic_score_gemma":0.000058397232,"teacher_disagreement_score":0.051013734,"about_ca_system_score_codex":0.0000887157,"about_ca_system_score_gemma":0.00090824685,"threshold_uncertainty_score":0.99495685},"labels":[],"label_agreement":null},{"id":"W2904245464","doi":"10.1093/annonc/mdy487.018","title":"New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ELISPOT; Immune system; Immunogenicity; Survivin; Oncology; T cell; Peripheral blood mononuclear cell; Clinical endpoint; Ovarian cancer; Clinical trial; Internal medicine; Immunology; Cancer; Biology","score_opus":0.11266069318481092,"score_gpt":0.41615835385231764,"score_spread":0.3034976606675067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904245464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727543,0.014702968,0.000028640428,0.0075269695,0.0028071485,0.0008650866,0.0007780746,0.00003063365,0.0005062031],"genre_scores_gemma":[0.96801805,0.026771307,0.0003642187,0.0033120196,0.0004413759,0.000043014516,0.0003728133,0.000044723314,0.0006324654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956289,0.0018208014,0.0011143509,0.0007725951,0.00008768579,0.00057564507],"domain_scores_gemma":[0.99358827,0.004354311,0.00062755536,0.0012461721,0.00012765978,0.000056044893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021823943,0.00032685316,0.0008923548,0.00010869494,0.00018289103,0.000017482418,0.0009044295,0.00052798196,0.00026690337],"category_scores_gemma":[0.001411961,0.00021306475,0.00009458826,0.00026610403,0.0009777772,0.00018102869,0.00031023053,0.00072645134,0.000085034364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46242246,0.00056760677,0.0011296286,0.0000046258056,0.00041351048,0.000019882671,0.00093691505,0.00000229975,0.006724809,0.000088274806,0.01645714,0.51123285],"study_design_scores_gemma":[0.109645665,0.024329145,0.16520362,0.000439584,0.00008516505,0.000024056852,0.00030054065,0.000005966125,0.029936356,0.0005157089,0.66907334,0.00044082935],"about_ca_topic_score_codex":0.0052243667,"about_ca_topic_score_gemma":0.00693824,"teacher_disagreement_score":0.6526162,"about_ca_system_score_codex":0.000035947116,"about_ca_system_score_gemma":0.00089085737,"threshold_uncertainty_score":0.8688528},"labels":[],"label_agreement":null},{"id":"W2907962807","doi":"10.1093/annonc/mdy543","title":"Disclosure—in the blink of an eye","year":2018,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Optometry; Ophthalmology","score_opus":0.63710166935585,"score_gpt":0.6725751914119803,"score_spread":0.0354735220561303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907962807","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08598196,0.0024144303,0.0000023552248,0.017887566,0.85440606,0.0011762435,0.001968883,0.00004741241,0.03611507],"genre_scores_gemma":[0.19577318,0.0042022453,0.00007706804,0.0073584476,0.7905266,0.00014471245,0.00073863566,0.00007438184,0.0011047004],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924972,0.004286274,0.0012979554,0.0005411799,0.00052973,0.00084766356],"domain_scores_gemma":[0.99293816,0.004411649,0.0008777345,0.0006023721,0.00081704144,0.0003530542],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0065504247,0.00041072085,0.0011806758,0.00025305586,0.00014652625,0.000008882667,0.0015232512,0.005807736,0.0014440459],"category_scores_gemma":[0.0014608252,0.00031226606,0.00026042084,0.00042889678,0.001349437,0.00013147571,0.00016811478,0.00614194,0.000072862684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014949318,0.001851828,0.00045566884,0.00039813117,0.00020337109,0.000117973555,0.0013407242,0.000013750863,0.00040243534,0.0006888195,0.9722958,0.02073654],"study_design_scores_gemma":[0.001497928,0.0039044723,0.0003619334,0.000069815294,0.00019136723,0.0000054776647,0.00027573205,0.000071782044,0.0035410512,0.0018755712,0.98793685,0.0002680203],"about_ca_topic_score_codex":0.00016271908,"about_ca_topic_score_gemma":0.0003398795,"teacher_disagreement_score":0.10979123,"about_ca_system_score_codex":0.000056974266,"about_ca_system_score_gemma":0.0015133431,"threshold_uncertainty_score":0.99993294},"labels":[],"label_agreement":null},{"id":"W2909427482","doi":"10.1093/annonc/mdy553","title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","year":2019,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Francis Crick Institute","keywords":"Durvalumab; Medicine; Lung cancer; Stage (stratigraphy); Chemoradiotherapy; Oncology; Cancer; Internal medicine; Position paper; Intensive care medicine; Immunotherapy; Pathology; Nivolumab","score_opus":0.09409710497506642,"score_gpt":0.4474031423284522,"score_spread":0.3533060373533858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909427482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7130521,0.005645072,0.0036479735,0.012187659,0.2122434,0.027315892,0.025458662,0.000020200161,0.00042903353],"genre_scores_gemma":[0.7941886,0.0061163455,0.0053544557,0.0022031863,0.14734273,0.018162008,0.011930737,0.00038547136,0.014316463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997722,0.000091967835,0.0009455319,0.0004214259,0.0005372136,0.0002818021],"domain_scores_gemma":[0.99186623,0.004178536,0.0013481934,0.0004490184,0.0021156562,0.00004237795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007075996,0.0002791103,0.0010038564,0.00021591145,0.00007736919,0.000009671523,0.00032324952,0.0004153417,0.000028434972],"category_scores_gemma":[0.00075136585,0.00017393322,0.0002715097,0.00012412731,0.00019097315,0.00010107193,0.000058798,0.00022725743,5.8367874e-8],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008352252,0.0013935802,0.0008929062,0.0016499648,0.0011947463,0.000001550118,0.002582029,0.00015289219,0.006344638,0.00015759213,0.9714643,0.0058135595],"study_design_scores_gemma":[0.042092834,0.015349585,0.0017695837,0.0060715824,0.0035722526,0.0000031246332,0.0015199672,0.0035167283,0.039770868,0.0001366001,0.8856708,0.00052612403],"about_ca_topic_score_codex":0.0059981155,"about_ca_topic_score_gemma":0.0011938575,"teacher_disagreement_score":0.08579354,"about_ca_system_score_codex":0.0003876973,"about_ca_system_score_gemma":0.0018111215,"threshold_uncertainty_score":0.9067396},"labels":[],"label_agreement":null},{"id":"W2909887958","doi":"10.1093/annonc/mdz003","title":"Novel patterns of response under immunotherapy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":511,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Radiation therapy; Clinical trial; Internal medicine; Melanoma; Cancer; Surgery; Cancer research","score_opus":0.04909859212237823,"score_gpt":0.340247598137447,"score_spread":0.29114900601506877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909887958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970115,0.0057909363,0.00036753953,0.0014731295,0.0007694063,0.00026499902,0.000062984494,0.000025710673,0.0015441161],"genre_scores_gemma":[0.9905665,0.0010226077,0.00007984649,0.0012210873,0.000009667224,0.000010636377,0.000022862207,0.000026224885,0.007040605],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980916,0.00063740567,0.0006159614,0.00023142723,0.000049187674,0.00037441906],"domain_scores_gemma":[0.9977399,0.001055901,0.00043101504,0.0005530827,0.00020769871,0.000012418892],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010371706,0.0001895567,0.00065811176,0.0002438332,0.000045790788,0.0000028990505,0.00039438493,0.00041034605,0.0028006868],"category_scores_gemma":[0.00008203189,0.00016745208,0.00024701466,0.00014286897,0.00024628633,0.00009175502,0.00007026104,0.0002417818,0.00030079248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018258281,0.000667449,0.002268126,0.000021905835,0.00051328575,0.0000011901842,0.0006828324,0.00001457019,0.9538865,0.001525471,0.0005181473,0.021642255],"study_design_scores_gemma":[0.0039407443,0.0049471045,0.08699396,0.000051793126,0.000011487745,0.00006939398,0.00052392296,6.524858e-7,0.69081867,0.00012199858,0.21235162,0.0001686566],"about_ca_topic_score_codex":0.00020392997,"about_ca_topic_score_gemma":0.0000060378406,"teacher_disagreement_score":0.2630678,"about_ca_system_score_codex":0.000021173048,"about_ca_system_score_gemma":0.00025922322,"threshold_uncertainty_score":0.9981109},"labels":[],"label_agreement":null},{"id":"W2912108694","doi":"10.1093/annonc/mdz016","title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neratinib; Breast cancer; Oncology; Quality of life (healthcare); Stage (stratigraphy); Internal medicine; Randomized controlled trial; Gynecology; Cancer; Trastuzumab; Nursing","score_opus":0.15561644541174927,"score_gpt":0.5094365783830779,"score_spread":0.35382013297132864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912108694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671025,0.00137133,0.000012527566,0.0077102394,0.00013477875,0.003336617,0.00031561,0.000008711171,0.00039993247],"genre_scores_gemma":[0.9974902,0.0009022734,0.000039382772,0.0010462527,0.00010669039,0.00027298724,0.000026915708,0.000020496109,0.000094794326],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99406505,0.003127318,0.0013911031,0.00037123097,0.0006092765,0.00043605035],"domain_scores_gemma":[0.9921635,0.005687783,0.0011097053,0.000419516,0.00041476227,0.00020477403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039684675,0.00020249572,0.0028305526,0.00017794075,0.00003080361,0.0000051504576,0.00020979664,0.00017648329,0.00050489046],"category_scores_gemma":[0.00081679155,0.00012394745,0.00018267252,0.00046164735,0.0005434713,0.000051101062,0.000054571006,0.0004699001,0.000003902716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96987313,0.002410228,0.0076934025,0.00031479276,0.0013030403,0.000030864125,0.003371842,0.0001495859,0.004389795,0.00006781553,0.00056914164,0.009826381],"study_design_scores_gemma":[0.8168931,0.026162624,0.14676584,0.0008199825,0.00009607559,0.000002636485,0.0004862929,0.00009576349,0.008404844,0.000059600505,0.000084784435,0.00012847564],"about_ca_topic_score_codex":0.09074892,"about_ca_topic_score_gemma":0.0019186296,"teacher_disagreement_score":0.15298003,"about_ca_system_score_codex":0.00018457288,"about_ca_system_score_gemma":0.0019883993,"threshold_uncertainty_score":0.91530585},"labels":[],"label_agreement":null},{"id":"W2912342925","doi":"10.1093/annonc/mdz036","title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Context (archaeology); PTEN; Breast cancer; Cancer; Germline; Oncology; Genetics; Bioinformatics; Internal medicine; Gene; Biology; PI3K/AKT/mTOR pathway","score_opus":0.28502468939011233,"score_gpt":0.4942545931218036,"score_spread":0.20922990373169126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912342925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901713,0.0003286196,0.0043621804,0.0028897175,0.000330624,0.0009050194,0.0009764352,0.000001487442,0.0000346182],"genre_scores_gemma":[0.99493784,0.0007175952,0.0035359352,0.000436218,0.000111450594,0.00017968354,0.000044914792,0.000011520385,0.000024825797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871063,0.0000666924,0.00062525406,0.00034969053,0.000065284294,0.00018244422],"domain_scores_gemma":[0.9982056,0.0004863243,0.00028572703,0.00032349708,0.0006360762,0.00006278673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007937347,0.00009830056,0.00039092364,0.000057466114,0.00002140582,0.0000028460315,0.0001806388,0.0001759783,0.000013585376],"category_scores_gemma":[0.00068754103,0.00009933046,0.00022039204,0.00007654475,0.00009971961,0.000008069415,0.00009568499,0.000056344627,5.7539455e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002341674,0.00050093496,0.27275398,0.00019849472,0.00007415087,9.984256e-8,0.000053950745,0.0035642094,0.6976361,0.00014002493,0.0013409365,0.021395404],"study_design_scores_gemma":[0.0013922721,0.0025117612,0.4839769,0.000058902668,0.000040038427,0.0000027343262,0.00013209989,0.0002607659,0.49982804,0.00095728046,0.010657274,0.00018194976],"about_ca_topic_score_codex":0.00044362666,"about_ca_topic_score_gemma":0.00063113315,"teacher_disagreement_score":0.2112229,"about_ca_system_score_codex":0.000057250425,"about_ca_system_score_gemma":0.00071591,"threshold_uncertainty_score":0.40505785},"labels":[],"label_agreement":null},{"id":"W2915579267","doi":"10.1093/annonc/mdz057","title":"Value assessment frameworks in oncology: championing concordance through shared standards","year":2019,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concordance; Cancer; Scopus; Family medicine; MEDLINE; Internal medicine","score_opus":0.06302613241636237,"score_gpt":0.39931366092847953,"score_spread":0.3362875285121172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915579267","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002069645,0.010310948,0.002834742,0.0039441553,0.68762195,0.00081407034,0.0057528294,0.000043071388,0.28660855],"genre_scores_gemma":[0.10731455,0.07566324,0.0115002,0.009725817,0.7866571,0.000580319,0.001584731,0.0005206729,0.006453383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951827,0.00012247286,0.002418196,0.0011060514,0.00020012648,0.00097043347],"domain_scores_gemma":[0.99354696,0.001731154,0.0031717308,0.00080178,0.0006068682,0.00014150965],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003469158,0.0005540603,0.0033446304,0.0004460998,0.00008183392,0.00006791882,0.0009171063,0.004745576,0.0008091322],"category_scores_gemma":[0.0031645976,0.00069014065,0.00042443824,0.00031511058,0.00031910697,0.00060444715,0.00029078338,0.0033313676,0.0001953297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026709586,0.00031305145,0.0012810958,0.00017505715,0.00019283782,0.00003206295,0.0008169639,0.0005386729,0.000001467994,0.07594622,0.912758,0.0076774615],"study_design_scores_gemma":[0.0019982725,0.0024155194,0.0010062548,0.00031453546,0.000013730426,0.0000015814859,0.0000980595,0.0002104999,0.000009579722,0.05913061,0.93419784,0.00060351845],"about_ca_topic_score_codex":0.0018799317,"about_ca_topic_score_gemma":0.0004473975,"teacher_disagreement_score":0.28015518,"about_ca_system_score_codex":0.002306242,"about_ca_system_score_gemma":0.0043202867,"threshold_uncertainty_score":0.999555},"labels":[],"label_agreement":null},{"id":"W2921347530","doi":"10.1093/annonc/mdz088","title":"Molecular screening to select therapy for advanced cancer?","year":2019,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Oncology; Medical physics; Internal medicine","score_opus":0.04743171679340498,"score_gpt":0.37408347551799437,"score_spread":0.3266517587245894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921347530","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12121426,0.016968321,0.008256594,0.84485614,0.0017493926,0.0028152317,0.00165414,0.000020656918,0.0024652344],"genre_scores_gemma":[0.012395953,0.007020497,0.003086806,0.97233236,0.0026877006,0.00046014637,0.0010305605,0.00011917028,0.00086680084],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843156,0.000055747245,0.000333276,0.00056314113,0.00012225915,0.00049401144],"domain_scores_gemma":[0.9986012,0.0001375211,0.0002830409,0.0004816053,0.00043787507,0.000058742302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016547438,0.00028752486,0.00055663503,0.000100652345,0.00003446542,0.00001151737,0.000401076,0.0008470299,0.000018558356],"category_scores_gemma":[0.00015744928,0.00030256683,0.00029420655,0.000086791864,0.000048836475,0.0000016600239,0.00011545267,0.00027657446,0.0000052559717],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041663685,0.000031911826,0.0000358373,0.000055198667,0.00023324958,0.000010834457,0.000016982836,0.0011821185,0.10875377,0.000011971143,0.80509937,0.084152095],"study_design_scores_gemma":[0.00081900845,0.0042596995,0.000021918977,0.000030171048,0.000022060642,0.000003299047,0.0000044665303,0.000011089975,0.18668875,0.000055847086,0.8078079,0.00027578048],"about_ca_topic_score_codex":0.00007526091,"about_ca_topic_score_gemma":0.0000415667,"teacher_disagreement_score":0.1274762,"about_ca_system_score_codex":0.000023588158,"about_ca_system_score_gemma":0.00059136574,"threshold_uncertainty_score":0.99994266},"labels":[],"label_agreement":null},{"id":"W2922063178","doi":"10.1093/annonc/mdx440.048","title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Hazard ratio; Clinical endpoint; Population; Melanoma; Stage (stratigraphy); Randomized controlled trial; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy","score_opus":0.24749111930518156,"score_gpt":0.4682165581798732,"score_spread":0.22072543887469162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922063178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97615623,0.00095967745,0.00005952505,0.0020767138,0.0006641991,0.00407658,0.00006476367,0.00003442243,0.015907856],"genre_scores_gemma":[0.9922304,0.0021062766,0.00015132122,0.00015165895,0.0005201404,0.00046144487,0.00005106957,0.000061654115,0.004266014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965833,0.000549999,0.0009558971,0.00052507926,0.0007635982,0.0006221411],"domain_scores_gemma":[0.9958874,0.0006776999,0.000998863,0.0013199946,0.00087959034,0.00023647452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026360503,0.00033470412,0.002155326,0.0003864138,0.0001894645,0.000038719358,0.00044348277,0.0003347402,0.0030186994],"category_scores_gemma":[0.00024102733,0.00024816883,0.0005132493,0.00017487512,0.0013090369,0.00021149246,0.00013490775,0.00051389384,0.000022843695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94137436,0.002209171,0.00007684908,0.00009893459,0.0014757211,0.00021296972,0.0007434034,0.000004148963,0.024194818,0.00010242531,0.0005192081,0.028988011],"study_design_scores_gemma":[0.8966685,0.052732915,0.0001232652,0.00009121375,0.00018123651,0.000030674077,0.0001795616,0.00016936573,0.02719334,0.00005528351,0.022372527,0.00020211353],"about_ca_topic_score_codex":0.001532107,"about_ca_topic_score_gemma":0.00087685476,"teacher_disagreement_score":0.050523743,"about_ca_system_score_codex":0.00011477593,"about_ca_system_score_gemma":0.0007102843,"threshold_uncertainty_score":0.9999971},"labels":[],"label_agreement":null},{"id":"W2924379719","doi":"10.1093/annonc/mdz046","title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi-Sankyo; Prospect Creek Foundation; Agios Pharmaceuticals; Bayer Fund; Bristol-Myers Squibb; FUJIFILM Pharmaceuticals U.S.A.; Genentech; Ovarian Cancer Research Fund; Valeant Pharmaceuticals International; Comprehensive Cancer Center, City of Hope; Takeda Pharmaceuticals U.S.A.; Comprehensive Cancer Center, University of Chicago Medical Center; Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; Illumina; National Cancer Institute; AbbVie; Novartis; AstraZeneca; National Institutes of Health; Breast Cancer Research Foundation; U.S. Department of Defense; Boehringer Ingelheim; Pfizer","keywords":"KRAS; Concordance; Genotyping; Medicine; Lung cancer; Digital polymerase chain reaction; Liquid biopsy; COLD-PCR; Genotype; ROS1; Cell-free fetal DNA; Cancer research; Oncology; Cancer; Internal medicine; Mutation; Gene; Point mutation; Biology; Adenocarcinoma; Genetics; Polymerase chain reaction; Colorectal cancer","score_opus":0.028711667661248923,"score_gpt":0.26545957509960255,"score_spread":0.23674790743835364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924379719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618906,0.0004651465,0.000034382552,0.00027248144,0.00019557515,0.00031354927,0.000344768,0.0000020174268,0.0021830427],"genre_scores_gemma":[0.99782354,0.0007246302,0.00036718196,0.00043287125,0.00010188961,0.000014959202,0.00047015984,0.000012808983,0.00005195243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990717,0.000050921062,0.0003316416,0.0002622275,0.00010222258,0.0001812959],"domain_scores_gemma":[0.99892277,0.00011890327,0.0003184411,0.0003936398,0.00021185393,0.000034382872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014817757,0.000106003434,0.00020836905,0.000030601925,0.000026952348,0.000006565706,0.00019973794,0.00012437302,0.00001828295],"category_scores_gemma":[0.0001378235,0.00008732889,0.000041753017,0.00007551763,0.00006989916,0.00000985588,0.00005041336,0.00007720573,0.0000016830257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016304908,0.00012055009,0.011760146,0.000017933275,0.000068980764,0.0000011957296,0.0003638947,0.029362598,0.95289475,0.0000283474,0.0013604666,0.0023906485],"study_design_scores_gemma":[0.0071448223,0.0032367918,0.026480112,0.00003140394,0.000032362284,9.157299e-7,0.00055045733,0.0006927499,0.94080323,0.000059027534,0.0207222,0.00024591258],"about_ca_topic_score_codex":0.00082569255,"about_ca_topic_score_gemma":0.0019633386,"teacher_disagreement_score":0.028669849,"about_ca_system_score_codex":0.00008545075,"about_ca_system_score_gemma":0.000465483,"threshold_uncertainty_score":0.35611686},"labels":[],"label_agreement":null},{"id":"W2929513598","doi":"10.1093/annonc/mdz113","title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Roche (Canada); University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Genentech","keywords":"Atezolizumab; Medicine; Tolerability; Internal medicine; Adverse effect; Oncology; Lung cancer; Rash; Discontinuation; Nivolumab; Gastroenterology; Cancer; Immunotherapy","score_opus":0.03361865556179713,"score_gpt":0.3662232353398603,"score_spread":0.3326045797780632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929513598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966023,0.00004616102,6.8009655e-7,0.0002955002,0.000052332474,0.0011404697,0.000009399098,0.000008255438,0.0018448895],"genre_scores_gemma":[0.9994028,0.000014675263,0.00003653285,0.00036711694,0.000008077109,0.000018006509,0.000018293846,0.000014904699,0.00011956132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892366,0.00007912742,0.00040586645,0.00018235049,0.00021464987,0.00019436043],"domain_scores_gemma":[0.999101,0.000063531115,0.00030328607,0.00025638688,0.00023007659,0.000045745855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022046185,0.00012003286,0.00065607333,0.0001588224,0.000010979641,0.0000014952791,0.00008618588,0.00006119758,0.0001583473],"category_scores_gemma":[0.000013399097,0.0000806245,0.000039907598,0.00027111053,0.00011650234,0.00004147417,0.000019360776,0.00010494751,0.0000044119706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21693261,0.02833322,0.7278097,0.00010814544,0.00058243854,0.00005079699,0.0022042468,0.000010232426,0.0017542815,0.0000116197,0.0004932151,0.02170946],"study_design_scores_gemma":[0.106158555,0.27933487,0.6075041,0.00016608102,0.00005236998,0.0000059221443,0.0010437066,0.000008151945,0.0046543027,0.000004593373,0.00096055615,0.00010679785],"about_ca_topic_score_codex":0.00029525225,"about_ca_topic_score_gemma":0.00018951732,"teacher_disagreement_score":0.25100163,"about_ca_system_score_codex":0.000031200037,"about_ca_system_score_gemma":0.00021511051,"threshold_uncertainty_score":0.32877716},"labels":[],"label_agreement":null},{"id":"W2935356429","doi":"10.1093/annonc/mdz112","title":"T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Direction Générale de l’offre de Soins; Ligue Contre le Cancer; Agence Nationale de la Recherche; National Institute for Health and Care Research; Fondation ISREC; Institut National Du Cancer; Cancer Research UK; Swiss Bridge Foundation; Wellcome Trust; Roche","keywords":"Medicine; Cancer research; Major histocompatibility complex; Immune system; Immunology; Breast cancer; MHC class I; Antibody; T cell; Cancer; Internal medicine","score_opus":0.03926484848163735,"score_gpt":0.3287131254605979,"score_spread":0.28944827697896053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935356429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97352153,0.018017795,0.00009087862,0.0036205659,0.0014245881,0.00069207535,0.0007014353,0.00002284262,0.0019082951],"genre_scores_gemma":[0.992267,0.0035124286,0.000043209933,0.0013322933,0.00003564411,0.00006368786,0.00006889862,0.000032096337,0.002644753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829763,0.00024863682,0.0004891742,0.00035513952,0.00003713566,0.000572268],"domain_scores_gemma":[0.998514,0.00060736143,0.00031520383,0.00032628237,0.00022202259,0.000015121698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004779865,0.00024000219,0.000695611,0.00023934478,0.00009294285,0.0000084290505,0.00034138432,0.00046027364,0.0004429527],"category_scores_gemma":[0.000018690755,0.00021950067,0.0001883249,0.00018303518,0.00033515424,0.0001219574,0.0000616675,0.0002985542,0.00016926372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007382171,0.00121357,0.011504023,0.000069424466,0.00043920378,0.0000058916903,0.0012879337,0.00003561973,0.94935226,0.0012180753,0.0019146611,0.025577143],"study_design_scores_gemma":[0.011717451,0.0033284717,0.33032012,0.00023095793,0.000065548724,0.00019736994,0.0007292964,0.000027634385,0.40314683,0.00041246344,0.24925981,0.0005640578],"about_ca_topic_score_codex":0.0003074569,"about_ca_topic_score_gemma":0.000043277214,"teacher_disagreement_score":0.54620546,"about_ca_system_score_codex":0.00005755508,"about_ca_system_score_gemma":0.0003102227,"threshold_uncertainty_score":0.89509773},"labels":[],"label_agreement":null},{"id":"W2938546950","doi":"10.1093/annonc/mdz094.003","title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Phases of clinical research; Oncology; Pemetrexed; Chemotherapy; Nuclear medicine; Clinical trial; Surgery; Cisplatin","score_opus":0.03306078952820038,"score_gpt":0.36945708844085207,"score_spread":0.33639629891265166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938546950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992572,0.00013420322,0.0000020293032,0.00072324346,0.00009005409,0.006192212,0.000026793923,0.000015313512,0.00024412065],"genre_scores_gemma":[0.9985808,0.00006810435,0.00001015051,0.0010109313,0.000016096967,0.00014969066,0.00003913495,0.00004825663,0.00007683926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966529,0.0010131028,0.00092729356,0.00042321772,0.00059747725,0.00038601234],"domain_scores_gemma":[0.9974492,0.001115851,0.00050673046,0.0006850848,0.00019714364,0.000045950295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020608925,0.0003913543,0.001602219,0.00037273526,0.000036813977,0.0000085007805,0.00028257893,0.00006453509,0.0002245006],"category_scores_gemma":[0.00006408752,0.00021039492,0.00014867773,0.0005818858,0.00014108844,0.000080014244,0.000017979835,0.0002945915,0.000005252889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30853158,0.021536931,0.65130854,0.000100025696,0.0010675569,0.00010419788,0.0027985866,0.00004966993,0.00034170126,0.0000019786432,0.000022908325,0.014136312],"study_design_scores_gemma":[0.16802487,0.24974781,0.58060473,0.00013331481,0.00012707707,0.000006848575,0.00063362194,0.00001765751,0.00043288796,0.0000014565488,0.00012058046,0.00014916412],"about_ca_topic_score_codex":0.0028487197,"about_ca_topic_score_gemma":0.0015589644,"teacher_disagreement_score":0.22821088,"about_ca_system_score_codex":0.00012430403,"about_ca_system_score_gemma":0.00016750292,"threshold_uncertainty_score":0.8579656},"labels":[],"label_agreement":null},{"id":"W2941467697","doi":"10.1093/annonc/mdz122","title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Cancer Society Research Institute; Cancer Research UK","keywords":"Medicine; Radiation therapy; Oncology; Lung cancer; Stage (stratigraphy); Randomized controlled trial; Internal medicine","score_opus":0.06480225364933935,"score_gpt":0.4011862293424574,"score_spread":0.33638397569311806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941467697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831913,0.0058981376,0.00002336791,0.0012647898,0.0008406485,0.0068728933,0.000055217795,0.0000132768455,0.0018403525],"genre_scores_gemma":[0.99630284,0.0025168646,0.000050011615,0.00025522677,0.00011539194,0.00037485478,0.000008677103,0.000026703132,0.00034940202],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961686,0.00092851144,0.0013595532,0.0004159623,0.00061157753,0.0005158003],"domain_scores_gemma":[0.99333185,0.004146953,0.0012928434,0.00047603488,0.00063836674,0.000113972186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016839247,0.0002722076,0.0028319391,0.00051836146,0.000039940413,0.0000061850865,0.00036512848,0.0001849711,0.0002278592],"category_scores_gemma":[0.0010998799,0.00018954575,0.00089937355,0.0011493723,0.00032489863,0.000051355713,0.00010716936,0.00039449683,0.0000013001402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7213031,0.0018770202,0.12347515,0.0013153668,0.013398767,0.000032913427,0.004104749,0.008337076,0.122136936,0.00009269993,0.0007133724,0.0032128652],"study_design_scores_gemma":[0.9137161,0.0068243206,0.019896952,0.00036571926,0.0035601244,7.204574e-7,0.0006200887,0.035676844,0.018474886,0.0000033759607,0.0006465744,0.00021429674],"about_ca_topic_score_codex":0.0015786121,"about_ca_topic_score_gemma":0.00043505867,"teacher_disagreement_score":0.19241302,"about_ca_system_score_codex":0.00031511203,"about_ca_system_score_gemma":0.0014921839,"threshold_uncertainty_score":0.77294517},"labels":[],"label_agreement":null},{"id":"W2943108118","doi":"10.1093/annonc/mdz127","title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":488,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Cilag; National Center for Advancing Translational Sciences; National Cancer Institute; Foundation Medicine; Ipsen; EMD Serono; Sanofi; Fidia Farmaceutici; Eisai; Astellas Pharma; Merck Sharp and Dohme; Genentech; GlaxoSmithKline; UroGen Pharma; Pfizer; Incyte; Exelixis; Kidney Cancer Association; Merck; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Amgen","keywords":"Medicine; Docetaxel; Urothelial cancer; Paclitaxel; Pembrolizumab; Oncology; Internal medicine; Cancer; Chemotherapy; Randomized controlled trial; Bladder cancer; Immunotherapy","score_opus":0.08149898714952458,"score_gpt":0.4267595225361745,"score_spread":0.3452605353866499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943108118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877571,0.0015402256,0.0000055794007,0.0007250923,0.0016277232,0.0028434985,0.0005644446,0.000012467916,0.004923911],"genre_scores_gemma":[0.9942096,0.0044133444,0.00017905023,0.00010135299,0.00013916497,0.00015167781,0.00005211673,0.000029492137,0.00072421884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99668056,0.00037321544,0.0017492129,0.00037768623,0.00045870076,0.0003606536],"domain_scores_gemma":[0.99661946,0.0010494968,0.0012420902,0.00051616784,0.0004492701,0.00012350132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091265154,0.00025338796,0.0027105373,0.00033294962,0.000011750669,0.000001638136,0.00020989745,0.0002445354,0.00039242842],"category_scores_gemma":[0.0011178483,0.00020355963,0.00047938552,0.00038664584,0.0003313766,0.00008801796,0.000063248684,0.00020405352,0.000004959696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91033447,0.0025984836,0.000044409822,0.00021846368,0.0007177831,0.000024063791,0.00096632534,0.00002785824,0.008117405,0.00011073136,0.0006399567,0.07620005],"study_design_scores_gemma":[0.9180848,0.04180964,0.00018688907,0.0003874239,0.00043629875,0.0000034823345,0.00012780521,0.000034501132,0.030614903,0.000094497846,0.008080275,0.00013948734],"about_ca_topic_score_codex":0.0013094884,"about_ca_topic_score_gemma":0.00035915567,"teacher_disagreement_score":0.07606056,"about_ca_system_score_codex":0.00009749288,"about_ca_system_score_gemma":0.0013270789,"threshold_uncertainty_score":0.8300921},"labels":[],"label_agreement":null},{"id":"W2943421228","doi":"10.1093/annonc/mdz136","title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":238,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; National Institutes of Health; Cancer Research UK; European Society for Medical Oncology; University of Arizona Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Precision medicine; Germline; Oncology; Medical physics; Internal medicine; Genetics; Pathology","score_opus":0.06291957842298881,"score_gpt":0.3538099618176872,"score_spread":0.2908903833946984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943421228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876518,0.001385305,0.00087007927,0.0063543445,0.00031304717,0.00016001523,0.0000977151,0.0000033092776,0.0031643333],"genre_scores_gemma":[0.99429405,0.0024236906,0.00072874787,0.0017208344,0.00021977378,0.000005921016,0.000514449,0.000010641156,0.00008191067],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989398,0.000107190586,0.0004394225,0.00025226158,0.00010630528,0.00015498983],"domain_scores_gemma":[0.9984414,0.0005321855,0.00037610688,0.00042374776,0.00018060421,0.00004594494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004919963,0.000106696316,0.0003821168,0.00009573764,0.00003580877,0.0000043729037,0.00027495474,0.00014511973,0.00021597609],"category_scores_gemma":[0.0003053323,0.00007917893,0.00016561539,0.000303493,0.000105537816,0.000002590921,0.00012424351,0.0000877327,0.0000038037263],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004346043,0.00021814188,0.05965404,0.000011874134,0.0018883025,0.0000031150048,0.0006537943,0.0015949338,0.8224885,0.0014340957,0.030184794,0.081433825],"study_design_scores_gemma":[0.0026715812,0.005114354,0.17862695,0.00015736042,0.0015011235,0.0000070555484,0.0012671223,0.0020930981,0.10715288,0.0022742639,0.69867814,0.00045610292],"about_ca_topic_score_codex":0.0008920446,"about_ca_topic_score_gemma":0.0016149218,"teacher_disagreement_score":0.7153356,"about_ca_system_score_codex":0.000018688525,"about_ca_system_score_gemma":0.00016666207,"threshold_uncertainty_score":0.3228823},"labels":[],"label_agreement":null},{"id":"W2944167983","doi":"10.1093/annonc/mdz128","title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; Novartis; Genentech; Merck","keywords":"Erlotinib; Gefitinib; Medicine; Tolerability; T790M; Internal medicine; Lung cancer; Hazard ratio; Erlotinib Hydrochloride; Oncology; Epidermal growth factor receptor; Cancer; Adverse effect; Confidence interval","score_opus":0.0629895344694283,"score_gpt":0.4538235096787264,"score_spread":0.39083397520929813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944167983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817042,0.0002719866,0.00000768448,0.00024051443,0.00029147358,0.0079023745,0.000103853155,0.00001065509,0.00946726],"genre_scores_gemma":[0.99566257,0.00018588192,0.0004878115,0.00034168403,0.00002206145,0.00073204713,0.000067490335,0.00003116954,0.002469265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982458,0.00013339157,0.0006914742,0.00037144223,0.00024073083,0.00031719077],"domain_scores_gemma":[0.9980837,0.0003973185,0.00060097425,0.0003601167,0.00044531503,0.000112542715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003378784,0.00021787488,0.00143097,0.00017390527,0.000033615655,0.000006904772,0.0001955102,0.00009538084,0.00042104025],"category_scores_gemma":[0.000068177644,0.00014583312,0.000057548055,0.00029600118,0.00008288613,0.00014667396,0.00009474603,0.00015507409,0.000004382828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8626268,0.05398091,0.051092472,0.00026350343,0.0017186725,0.00007498244,0.0065750135,0.00019206601,0.00022298764,0.000030352481,0.0005302393,0.022691999],"study_design_scores_gemma":[0.9430498,0.04687564,0.005133218,0.00021312357,0.00069765653,5.927845e-7,0.0022093921,0.0001505456,0.00048152983,0.000002174099,0.0010295865,0.0001567515],"about_ca_topic_score_codex":0.0017165138,"about_ca_topic_score_gemma":0.0013939957,"teacher_disagreement_score":0.08042299,"about_ca_system_score_codex":0.00011949681,"about_ca_system_score_gemma":0.0009564895,"threshold_uncertainty_score":0.59469026},"labels":[],"label_agreement":null},{"id":"W2944820163","doi":"10.1093/annonc/mdz100.006","title":"Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Letrozole; Metastatic breast cancer; Clinical endpoint; Breast cancer; Progression-free survival; Fulvestrant; Goserelin; Cancer; Oncology; Surgery; Tamoxifen; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.05001327186555722,"score_gpt":0.41572173290215414,"score_spread":0.36570846103659693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944820163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800469,0.004140698,0.000086535074,0.013388561,0.00017893671,0.00073978194,0.00015589407,0.000042171047,0.001220491],"genre_scores_gemma":[0.9905939,0.005658937,0.00047076048,0.0025122436,0.00008356545,0.000080859856,0.00006730615,0.000047424983,0.00048497],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976187,0.00014785765,0.00086756184,0.0004950537,0.0003412348,0.0005295999],"domain_scores_gemma":[0.99762404,0.00047352235,0.0006009902,0.0006402058,0.0005215622,0.00013968072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035652608,0.00030940777,0.0018457294,0.00067932816,0.000024268096,0.0000033203696,0.00025873,0.00016158762,0.0016117356],"category_scores_gemma":[0.00007552454,0.0002663311,0.00039992543,0.0014560041,0.0002205726,0.00016847586,0.00007491683,0.00031263122,0.000012639671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026421351,0.0031905111,0.24227212,0.00026386208,0.0069364607,0.00010802309,0.002465045,0.040833928,0.04458454,0.00051858445,0.00015489488,0.63225067],"study_design_scores_gemma":[0.027083384,0.0038657167,0.9068779,0.00033113576,0.0007076567,0.00006378142,0.00037800588,0.0014454836,0.020067712,0.00027824217,0.03848544,0.0004155854],"about_ca_topic_score_codex":0.0011336916,"about_ca_topic_score_gemma":0.0016426767,"teacher_disagreement_score":0.66460574,"about_ca_system_score_codex":0.00021435732,"about_ca_system_score_gemma":0.00041416244,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2945031363","doi":"10.1093/annonc/mdz118.002","title":"A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University; Ottawa Regional Cancer Foundation; University of Alberta; Ottawa Hospital","funders":"","keywords":"Medicine; Denosumab; Oncology; Bone metastasis; Bisphosphonate; Internal medicine; Surgery; Osteoporosis; Cancer; Breast cancer","score_opus":0.05765025397026355,"score_gpt":0.36105448181013006,"score_spread":0.30340422783986654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945031363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301755,0.00019760766,0.0000062381355,0.0010500598,0.00021237615,0.004334947,0.00006669684,0.000023277651,0.0010912247],"genre_scores_gemma":[0.9974761,0.000095582975,0.0009810037,0.00041382865,0.00002079684,0.00010282292,0.0004065651,0.00003051643,0.0004727983],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969686,0.00035149753,0.0013387025,0.00036453057,0.00047873385,0.0004979116],"domain_scores_gemma":[0.9977121,0.00038347358,0.0010074215,0.0003400352,0.00031861276,0.00023838754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005845531,0.00028167258,0.0016797157,0.00029752092,0.000037565114,0.0000064313035,0.000088074456,0.00019310311,0.00027926543],"category_scores_gemma":[0.00027473358,0.00020474552,0.00014841124,0.00022502603,0.0001016423,0.00016722998,0.00004204288,0.00022398049,0.0000336603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7889509,0.008890528,0.19237116,0.00064436643,0.00051466323,0.00020033692,0.00046936003,0.00003175616,0.00008390254,0.000020931413,0.00068552996,0.007136575],"study_design_scores_gemma":[0.61330944,0.030756118,0.35094368,0.00038855383,0.0003869859,0.000023435337,0.00016954802,0.00048786326,0.0009701704,0.000019344643,0.0023359677,0.00020884379],"about_ca_topic_score_codex":0.00038879254,"about_ca_topic_score_gemma":0.0005649854,"teacher_disagreement_score":0.17564142,"about_ca_system_score_codex":0.000098293596,"about_ca_system_score_gemma":0.00071340206,"threshold_uncertainty_score":0.83492804},"labels":[],"label_agreement":null},{"id":"W2945215070","doi":"10.1093/annonc/mdz101.012","title":"A cost-utility analysis of administration schedules of G-CSF for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer: Economic evaluation alongside the REaCT-G trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Filgrastim; Medicine; Febrile neutropenia; Neutropenia; Cost effectiveness; Granulocyte colony-stimulating factor; Breast cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Quality-adjusted life year; Surgery; Cancer","score_opus":0.1111780471864427,"score_gpt":0.43011604644313106,"score_spread":0.31893799925668836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945215070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946333,0.000068046545,0.000009549099,0.0011799842,0.00016674331,0.0029528171,0.00029819988,0.000004047327,0.00068732107],"genre_scores_gemma":[0.99928665,0.00010282939,0.000058926435,0.00010742972,0.0000591214,0.00027733084,0.00005723403,0.000010589492,0.00003990425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984372,0.0002064032,0.0007885737,0.00023248323,0.0001870645,0.00014826212],"domain_scores_gemma":[0.9978894,0.00024680496,0.00088628806,0.0003749846,0.00056489336,0.000037633214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001225393,0.00011058982,0.0008783276,0.0002494708,0.00001840514,0.0000036197127,0.00011910511,0.00013477156,0.00033386593],"category_scores_gemma":[0.000058437345,0.00008769066,0.00027720988,0.00034907254,0.00011880141,0.00011212213,0.000019196788,0.0001155991,0.0000010047673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17816308,0.003110509,0.41898084,0.00074526767,0.0036037292,0.0000018695275,0.0016729592,0.0010492167,0.21510747,0.00067697564,0.00020941632,0.17667866],"study_design_scores_gemma":[0.017738817,0.008254657,0.8850826,0.00004454778,0.0007507523,0.0000027941703,0.00018565709,0.00067022006,0.086740814,0.00005852052,0.00039294982,0.000077683355],"about_ca_topic_score_codex":0.0034971181,"about_ca_topic_score_gemma":0.003633914,"teacher_disagreement_score":0.46610174,"about_ca_system_score_codex":0.000144427,"about_ca_system_score_gemma":0.0017508673,"threshold_uncertainty_score":0.52866197},"labels":[],"label_agreement":null},{"id":"W2945268366","doi":"10.1093/annonc/mdz100.045","title":"Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Pertuzumab; Metastatic breast cancer; Oncology; Clinical endpoint; Breast cancer; Taxane; Population; Antibody-drug conjugate; Phases of clinical research; Cancer; Clinical trial; Immunology; Antibody","score_opus":0.12893878878310253,"score_gpt":0.5177291619702629,"score_spread":0.38879037318716037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945268366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402137,0.00045726498,0.000043685388,0.0070999144,0.00032164837,0.0029884174,0.00040413145,0.00002242495,0.004641168],"genre_scores_gemma":[0.99678504,0.00027026143,0.00012423572,0.0010045604,0.0002521852,0.000342916,0.000025692669,0.000047555768,0.0011475579],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99762547,0.00020448574,0.0006422795,0.0004530919,0.0004941487,0.0005805206],"domain_scores_gemma":[0.9974361,0.00042909634,0.0003143797,0.0004862311,0.0011037257,0.00023044233],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008077376,0.0002123503,0.0011100052,0.00024428236,0.000048281476,0.000005485991,0.00027813844,0.00020912889,0.001032005],"category_scores_gemma":[0.00009512549,0.00018872292,0.00018018851,0.0003094857,0.0002219901,0.00007616262,0.000093963245,0.00031051238,0.000023918847],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05281807,0.043530267,0.051519834,0.0014894656,0.0029066498,0.00019430328,0.013352922,0.00007374646,0.056127723,0.0003386713,0.07142926,0.7062191],"study_design_scores_gemma":[0.15739883,0.3623817,0.1920404,0.0012647226,0.0010050099,0.0003583621,0.016287366,0.00061829796,0.1257364,0.00047908208,0.14139606,0.001033769],"about_ca_topic_score_codex":0.00264091,"about_ca_topic_score_gemma":0.0010392946,"teacher_disagreement_score":0.7051853,"about_ca_system_score_codex":0.00022076587,"about_ca_system_score_gemma":0.0013579971,"threshold_uncertainty_score":0.9998812},"labels":[],"label_agreement":null},{"id":"W2945464982","doi":"10.1093/annonc/mdz095.073","title":"Hep par 1 immunohistochemistry in glycogen-rich clear cell carcinoma of the breast","year":2019,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Sinai Health System","funders":"","keywords":"Medicine; Immunohistochemistry; Pathology; Clear cell; GATA3; Breast carcinoma; Breast cancer; Carcinoma; Clear cell carcinoma; Glycogen; Cancer; Internal medicine; Biology","score_opus":0.031770114564646006,"score_gpt":0.3595129752717706,"score_spread":0.3277428607071246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945464982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321487,0.018785149,1.9029524e-7,0.012268719,0.0008795423,0.0005908533,0.00007533092,0.0000058913793,0.03524561],"genre_scores_gemma":[0.9866419,0.00118915,0.000055371802,0.0005161968,0.00019184078,0.000015814847,0.0000058765595,0.000034536075,0.011349351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972732,0.00038783927,0.0007163665,0.00037470664,0.00042481205,0.0008230496],"domain_scores_gemma":[0.99778533,0.0004454731,0.0004198237,0.0008403108,0.0003483437,0.00016069348],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040478885,0.00022498469,0.000791584,0.00012715996,0.000030370105,0.000003362277,0.0006010881,0.000074899835,0.0012745069],"category_scores_gemma":[0.00028452426,0.00018919444,0.00021835812,0.00048360674,0.00075139134,0.00009017883,0.00036658967,0.00074317586,0.0001976688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026131445,0.0024662516,0.34017494,0.0025472862,0.00007691228,0.0017004267,0.00040122497,0.00006658314,0.6230781,0.00025176117,0.013534766,0.013088609],"study_design_scores_gemma":[0.00429281,0.006353392,0.15897022,0.000440253,0.00005982358,0.0023551125,0.0010013173,0.000058860456,0.7677158,0.00026158345,0.058259506,0.00023132969],"about_ca_topic_score_codex":0.0007533207,"about_ca_topic_score_gemma":0.00003128568,"teacher_disagreement_score":0.1812047,"about_ca_system_score_codex":0.00013780166,"about_ca_system_score_gemma":0.0009157971,"threshold_uncertainty_score":0.99963844},"labels":[],"label_agreement":null},{"id":"W2945583063","doi":"10.1093/annonc/mdz101.006","title":"A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; Ottawa Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Randomization; Randomized controlled trial; Chemotherapy; Breast cancer; Internal medicine; Surgery; Stage (stratigraphy); Cancer; Chemotherapy regimen","score_opus":0.04578041278689667,"score_gpt":0.3910102600381371,"score_spread":0.34522984725124045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945583063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836952,0.00011206009,0.0018770666,0.0005446127,0.0004699051,0.011891736,0.00006791735,0.000048934406,0.0012925527],"genre_scores_gemma":[0.99667346,0.0002574166,0.0011313212,0.0005871324,0.00021869676,0.0008648318,0.00003316905,0.00006754383,0.00016640262],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978513,0.00012361995,0.0007723022,0.00047503714,0.0002573037,0.0005203968],"domain_scores_gemma":[0.99697804,0.0010845553,0.00068653765,0.00028607764,0.0008509162,0.000113868366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096776144,0.00028802382,0.0018557356,0.00014998297,0.00007782892,0.000047283524,0.00022760186,0.00028353647,0.00014226852],"category_scores_gemma":[0.00023226473,0.00024857986,0.00053486583,0.00015667101,0.00014106746,0.000313129,0.000041082305,0.00023877468,0.000002095125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90974873,0.001473343,0.07167033,0.00034323017,0.0017422083,0.0000013282117,0.0028802485,0.00016398224,0.0012427681,0.00010852797,0.00021928117,0.010406024],"study_design_scores_gemma":[0.9237691,0.0046884683,0.062291153,0.00029436182,0.0002178126,0.0000016540605,0.0003950454,0.003598511,0.0034538663,0.0002773523,0.00075466203,0.00025798735],"about_ca_topic_score_codex":0.00059379655,"about_ca_topic_score_gemma":0.00013173079,"teacher_disagreement_score":0.014020396,"about_ca_system_score_codex":0.00020442452,"about_ca_system_score_gemma":0.00055868604,"threshold_uncertainty_score":0.99999666},"labels":[],"label_agreement":null},{"id":"W2945664876","doi":"10.1093/annonc/mdz152","title":"Journey’s end: the quest for BRCA-like hereditary breast cancer genes is nearly over","year":2019,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer; Breast cancer; Gene; Oncology; Genetics; Internal medicine; Biology","score_opus":0.0499130223931575,"score_gpt":0.3677638843109602,"score_spread":0.3178508619178027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945664876","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010741316,0.017312365,0.000120247794,0.9597172,0.00477775,0.0008826867,0.0047322363,0.000013252998,0.0017029231],"genre_scores_gemma":[0.0082639465,0.0057855337,0.00033466355,0.9581874,0.01666257,0.0004347865,0.0010424745,0.0001385815,0.009150049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784917,0.00018511695,0.00048065826,0.0006445071,0.00024923473,0.00059128855],"domain_scores_gemma":[0.9978142,0.00015989767,0.00052562024,0.00083828403,0.00061699055,0.00004500072],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00039185304,0.0003643266,0.0005282264,0.00008621907,0.0001146369,0.000027400563,0.00074548536,0.0014431622,0.0005286941],"category_scores_gemma":[0.00003418645,0.0002904062,0.000357682,0.00009160736,0.0003304237,0.000007736093,0.00021494001,0.0005951074,0.000023476488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001351759,0.00004202792,0.00021602602,0.00011825331,0.0006329136,0.000014138969,0.00010111497,0.000048193517,0.0038575311,0.0000065940317,0.9751653,0.019662749],"study_design_scores_gemma":[0.00059928244,0.0007998097,0.0007021504,0.000035760193,0.00013245756,0.00013212032,0.000033704255,0.000016790184,0.0070505636,0.00012734176,0.9900443,0.000325724],"about_ca_topic_score_codex":0.0006128233,"about_ca_topic_score_gemma":0.00039202056,"teacher_disagreement_score":0.019337026,"about_ca_system_score_codex":0.00009282428,"about_ca_system_score_gemma":0.0018187269,"threshold_uncertainty_score":0.9999548},"labels":[],"label_agreement":null},{"id":"W2946162420","doi":"10.1093/annonc/mdz095.067","title":"Functional CRISPR knockout screens for modifiers of sensitivity to trastuzumab emtansine","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Trastuzumab emtansine; Trastuzumab; Medicine; Breast cancer; CRISPR; Cancer; Computational biology; Cancer research; Gene; Biology; Genetics; Internal medicine","score_opus":0.05010312441584526,"score_gpt":0.3672961790015932,"score_spread":0.317193054585748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946162420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96596783,0.000068812704,0.030698424,0.0014651511,0.00009386248,0.00030419987,0.00015602823,0.000013115246,0.0012325584],"genre_scores_gemma":[0.9903551,0.000060141618,0.007965256,0.0008742317,0.00009835671,0.000006462673,0.00012036132,0.000012468786,0.000507627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990753,0.0000634652,0.00027335217,0.0002865346,0.000098375785,0.00020298571],"domain_scores_gemma":[0.9989703,0.000070211834,0.00016458564,0.000261299,0.00047117597,0.000062377956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003501368,0.00012076861,0.0003418233,0.00008686148,0.00002633231,0.0000020935997,0.00006882751,0.00019049311,0.000004782173],"category_scores_gemma":[0.0001818279,0.00011060488,0.0001980298,0.00010740286,0.0000948218,0.0000032131677,0.00005288874,0.000050152477,0.000002542367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007539345,0.00015709466,0.00030440182,0.000025797746,0.00011999575,0.0000013575842,0.000016174432,0.00019120988,0.9684137,0.00016032986,0.011142261,0.018713709],"study_design_scores_gemma":[0.00040710243,0.0030407317,0.002483191,0.000014319168,0.000030472156,0.000010722683,0.000081304286,0.000098523495,0.9604895,0.00014886304,0.033063017,0.0001322183],"about_ca_topic_score_codex":0.00002636132,"about_ca_topic_score_gemma":0.00008712925,"teacher_disagreement_score":0.024387246,"about_ca_system_score_codex":0.000010286529,"about_ca_system_score_gemma":0.00011531432,"threshold_uncertainty_score":0.45103362},"labels":[],"label_agreement":null},{"id":"W2946192895","doi":"10.1093/annonc/mdz120","title":"Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cancer; Osteoporosis; Peak bone mass; Avascular necrosis; Pediatrics; Bone cancer; Bone mineral; Bone health; Adverse effect; Bone Density Conservation Agents; Quality of life (healthcare); Surgery; Internal medicine","score_opus":0.13222969796621475,"score_gpt":0.48379170857417136,"score_spread":0.3515620106079566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946192895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005939587,0.7591463,0.0000021861324,0.23162478,0.0005600686,0.0069552646,0.0015310337,0.0000074834834,0.000113496724],"genre_scores_gemma":[0.00006953487,0.9748164,0.00027194017,0.02336521,0.00017449741,0.0007910142,0.00031641065,0.00006442282,0.00013059446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936233,0.0013565377,0.0033775605,0.00065350655,0.00038371191,0.0006053914],"domain_scores_gemma":[0.99365705,0.000914835,0.003907946,0.0010988087,0.00027026082,0.0001510967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005352709,0.00050520484,0.005840303,0.0003961092,0.000082071725,0.0000066762814,0.0004657586,0.000324781,0.000059190876],"category_scores_gemma":[0.00019528545,0.0003263227,0.00072259945,0.0014298812,0.0001925845,0.00006696052,0.00027009993,0.0009553482,7.6035144e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000369045,0.0006795291,0.00008589092,0.22589947,0.0005414526,0.0000010160211,0.0022737621,0.0000012835333,2.1229274e-8,0.0003015912,0.017698748,0.7524803],"study_design_scores_gemma":[0.0012182139,0.0007118268,0.0037683088,0.31026697,0.0003974027,0.000022154372,0.0001837018,5.2338777e-7,4.685393e-7,0.00009262069,0.6831799,0.00015789382],"about_ca_topic_score_codex":0.00820447,"about_ca_topic_score_gemma":0.015234122,"teacher_disagreement_score":0.75232244,"about_ca_system_score_codex":0.00036149024,"about_ca_system_score_gemma":0.0038112123,"threshold_uncertainty_score":0.9999189},"labels":[],"label_agreement":null},{"id":"W2946690961","doi":"10.1093/annonc/mdz101.008","title":"After breast cancer: A nurse practitioner led model of care for women on adjuvant endocrine treatment","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; B.C. Women's Hospital & Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Anxiety; Tamoxifen; Depression (economics); Sexual function; Cancer; Psychosocial; Family medicine; Quality of life (healthcare); Physical therapy; Internal medicine; Nursing; Psychiatry","score_opus":0.03479461717377967,"score_gpt":0.3761420496167263,"score_spread":0.34134743244294663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946690961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831909,0.000690818,0.000009260641,0.0060838894,0.00027084138,0.0007584173,0.00087998965,0.000012166896,0.0081037255],"genre_scores_gemma":[0.99440104,0.00049238105,0.000049002836,0.0013538989,0.00011051734,0.00072008895,0.000042048727,0.000018418004,0.0028126235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991805,0.000029578101,0.00022580379,0.00019902052,0.00012555899,0.00023956972],"domain_scores_gemma":[0.99904966,0.0000791129,0.00014868985,0.00024347671,0.00038849504,0.00009055047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059403978,0.00012405455,0.0005627361,0.00008891716,0.000012139857,0.0000014326178,0.000044715405,0.00008435919,0.00048241045],"category_scores_gemma":[0.000010192995,0.00009624902,0.00015547703,0.000059628317,0.000036772228,0.000040410807,0.000010197088,0.000062962674,0.00000899448],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10939674,0.0061875647,0.080866255,0.003506126,0.0018782404,0.00010131344,0.05315254,0.0027418062,0.017712025,0.0019971153,0.006126873,0.7163334],"study_design_scores_gemma":[0.050578345,0.128875,0.116453856,0.0015993634,0.0011500153,0.00021874349,0.037644796,0.0026785443,0.09731196,0.0012832775,0.5610203,0.0011858045],"about_ca_topic_score_codex":0.0006872178,"about_ca_topic_score_gemma":0.001471231,"teacher_disagreement_score":0.7151476,"about_ca_system_score_codex":0.00028801427,"about_ca_system_score_gemma":0.0005141455,"threshold_uncertainty_score":0.52820563},"labels":[],"label_agreement":null},{"id":"W2946724159","doi":"10.1093/annonc/mdz095.069","title":"Long non-coding RNA PART1 contributes to cell proliferation and stem cell maintenance in triple-negative breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Cancer research; Triple-negative breast cancer; Cancer stem cell; Breast cancer; Medicine; Prostate cancer; Cancer; Stem cell; Cell growth; Biology; Internal medicine; Cell biology","score_opus":0.019398080062754588,"score_gpt":0.32291606008630086,"score_spread":0.3035179800235463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946724159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880674,0.000844526,0.0053781928,0.002252403,0.00019691086,0.0010943456,0.000078514895,0.0000047917893,0.0020828974],"genre_scores_gemma":[0.9963651,0.001070219,0.000097256416,0.0008989094,0.00005466268,0.00011649265,0.000016481972,0.00001942382,0.0013614874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869794,0.00012444967,0.00028229324,0.0003908959,0.000121111036,0.00038328965],"domain_scores_gemma":[0.99921685,0.000038332884,0.0001329272,0.00020713969,0.0003088218,0.000095952775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004020642,0.00014192029,0.00030059452,0.00012913316,0.000030578507,0.000014323206,0.00014764017,0.00023865272,0.000027965212],"category_scores_gemma":[0.000030895815,0.00014072964,0.00005270658,0.00019685614,0.000054446835,0.000008239275,0.00014145349,0.0001654828,0.000010511595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095895707,0.00012908969,0.0017971065,0.0000904501,0.00004149435,0.0000117130685,0.00019900035,0.000527219,0.98016226,0.000053673084,0.0024796599,0.013549386],"study_design_scores_gemma":[0.0022315243,0.0011440573,0.004675947,0.00006874871,0.0000083696505,0.000007656987,0.00017468577,0.00044198785,0.98839164,0.00005029294,0.0026527557,0.00015236222],"about_ca_topic_score_codex":0.00019322912,"about_ca_topic_score_gemma":0.00054893416,"teacher_disagreement_score":0.013397023,"about_ca_system_score_codex":0.000057674908,"about_ca_system_score_gemma":0.00031473834,"threshold_uncertainty_score":0.57387877},"labels":[],"label_agreement":null},{"id":"W2946776584","doi":"10.1093/annonc/mdz095.074","title":"An in vivo genome-wide RNAi screen identifies novel mediators of paclitaxel response in breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Paclitaxel; Gene knockdown; Medicine; Cancer research; Breast cancer; clone (Java method); RNA interference; In vivo; Small hairpin RNA; Cancer; Gene; Biology; Internal medicine; Genetics; RNA","score_opus":0.026987850646154953,"score_gpt":0.3455250965959548,"score_spread":0.3185372459497999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946776584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967669,0.00077427604,0.000028733137,0.001520196,0.0000916232,0.00015669061,0.00023904536,0.0000020770615,0.0004204227],"genre_scores_gemma":[0.99804497,0.0011257114,0.00008086428,0.0004536413,0.000044843968,0.00003185338,0.000023585324,0.000012147097,0.00018235933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99895793,0.00013402244,0.00036309246,0.00025228385,0.00009279198,0.00019987086],"domain_scores_gemma":[0.99921066,0.000046207304,0.00018571957,0.00035131106,0.00015523966,0.000050856735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006133895,0.000095639174,0.00025493946,0.00015203835,0.000010502265,0.0000036099989,0.00023428845,0.00018165985,0.00013331545],"category_scores_gemma":[0.000054904052,0.00009477466,0.000057884663,0.00016098861,0.00011132881,0.000010207748,0.00005091517,0.00007261244,0.0000028961356],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013784639,0.00026227496,0.12921122,0.000016260678,0.000025198768,0.0000014401489,0.0001681365,0.0003914536,0.8669882,0.000043536777,0.00044755527,0.0010662666],"study_design_scores_gemma":[0.0011172768,0.0007911738,0.81577075,0.000024350818,0.000005801716,0.0000037241584,0.00039611166,0.000031276497,0.17019236,0.00004661705,0.0114865955,0.00013395342],"about_ca_topic_score_codex":0.00087287434,"about_ca_topic_score_gemma":0.0013601491,"teacher_disagreement_score":0.6967958,"about_ca_system_score_codex":0.000024017296,"about_ca_system_score_gemma":0.00032194355,"threshold_uncertainty_score":0.38647985},"labels":[],"label_agreement":null},{"id":"W2947312373","doi":"10.1093/annonc/mdz247.158","title":"Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Gemcitabine; Open label; Cisplatin; Oncology; Internal medicine; Randomized controlled trial; Chromosomal translocation; Surgery; Chemotherapy; Gene; Genetics","score_opus":0.060119722695632434,"score_gpt":0.3937258460936424,"score_spread":0.33360612339801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947312373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98920375,0.00018144,0.00006222616,0.0003171986,0.00012957097,0.009583415,0.000040478382,0.0000053504314,0.00047658672],"genre_scores_gemma":[0.998188,0.000036463145,0.0005038622,0.000112643334,0.000041069557,0.0007486039,0.00023731138,0.000030351332,0.00010169327],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99761844,0.000632975,0.0005633869,0.0004785336,0.0003284386,0.00037821976],"domain_scores_gemma":[0.9982598,0.00028205218,0.00031698236,0.00061679515,0.00043881818,0.000085591055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008810854,0.00023704262,0.0006660848,0.00011395247,0.00007966618,0.000026941114,0.000596476,0.00013430897,0.000043635126],"category_scores_gemma":[0.00028232182,0.00014592803,0.000055146415,0.00028549842,0.00022493607,0.000028453389,0.00023746236,0.00023222232,0.0000061539395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9738689,0.0051894253,0.0056746826,0.000019130865,0.0003297184,0.0000051867323,0.00059997704,0.00018588851,0.009569426,0.000013606793,0.00010477969,0.0044392725],"study_design_scores_gemma":[0.9309543,0.054648567,0.0038498484,0.000033204877,0.000049822087,0.000001093916,0.0003954829,0.00014818062,0.009199522,0.0000028768122,0.00052685733,0.00019027191],"about_ca_topic_score_codex":0.00013797413,"about_ca_topic_score_gemma":0.00068517675,"teacher_disagreement_score":0.04945914,"about_ca_system_score_codex":0.000029249151,"about_ca_system_score_gemma":0.00043323403,"threshold_uncertainty_score":0.5950773},"labels":[],"label_agreement":null},{"id":"W2947474057","doi":"10.1093/annonc/mdz174","title":"Hodgkin lymphoma, treatment and thrombosis: a dangerous mix","year":2019,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Hodgkin lymphoma; Thrombosis; Lymphoma; Surgery; Internal medicine","score_opus":0.11110960581111327,"score_gpt":0.3804232436085686,"score_spread":0.2693136377974553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947474057","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05048283,0.0049039074,0.000007499969,0.9055731,0.0007860704,0.0015620496,0.000086320055,0.000059657537,0.03653855],"genre_scores_gemma":[0.014070001,0.022931652,0.00045308116,0.9549211,0.002075857,0.00021981796,0.00031748024,0.000096616175,0.004914348],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980353,0.00014031303,0.00048802068,0.0005687212,0.0002388908,0.0005287538],"domain_scores_gemma":[0.9984719,0.00027097182,0.00038312472,0.00064332306,0.0001486078,0.0000820289],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020474326,0.00041392358,0.0020513502,0.0002831135,0.00004231509,0.00001388951,0.0001487897,0.00092681416,0.00022310633],"category_scores_gemma":[0.000041361116,0.00033054186,0.000298626,0.00010091177,0.00018343236,0.00004050238,0.00012539473,0.00027114718,0.0001427149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046715428,0.0010150784,0.00023648943,0.0005369081,0.0013793,0.0004475314,0.00041884306,4.8378007e-7,0.000059715676,0.000058970218,0.89376885,0.102031104],"study_design_scores_gemma":[0.0021534038,0.011314407,0.005725726,0.00024526584,0.00097422407,0.000096952754,0.00006225771,0.0000031664179,0.00026888272,0.000097581076,0.97880673,0.00025137237],"about_ca_topic_score_codex":0.00061604305,"about_ca_topic_score_gemma":0.00003569792,"teacher_disagreement_score":0.10177973,"about_ca_system_score_codex":0.00015530345,"about_ca_system_score_gemma":0.00032522448,"threshold_uncertainty_score":0.99991465},"labels":[],"label_agreement":null},{"id":"W2947820344","doi":"10.1093/annonc/mdz176","title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Progression-free survival; Lactate dehydrogenase; Melanoma; Confidence interval; Multivariate analysis; Oncology; Metastasis; Gastroenterology; Cancer; Surgery; Overall survival; Cancer research","score_opus":0.33542574369565,"score_gpt":0.49217056980847534,"score_spread":0.15674482611282536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947820344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05434615,0.9372979,0.000007791365,0.00066204387,0.00038796134,0.004585683,0.0006231125,0.000017702818,0.0020716467],"genre_scores_gemma":[0.07554671,0.91664064,0.0023342618,0.0009058812,0.000155938,0.0013411432,0.002695169,0.00009423776,0.0002860426],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9951048,0.0017567598,0.0012824619,0.0009243752,0.00052208,0.0004095105],"domain_scores_gemma":[0.9969896,0.00068238407,0.0009382587,0.0008074391,0.00032048093,0.0002618512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012969286,0.0005953306,0.0069568977,0.001240131,0.00004605203,0.000016418257,0.0004552327,0.00040960487,0.0006569172],"category_scores_gemma":[0.00028417358,0.00042379726,0.001227339,0.0006131152,0.00012387744,0.0001973985,0.00032393332,0.00045320022,0.000012878475],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010253917,0.004875354,0.034180097,0.0021835708,0.49640548,0.0050158305,0.0016676465,0.000019209607,6.850599e-7,0.00006699102,0.00024395749,0.45431578],"study_design_scores_gemma":[0.008148795,0.037533008,0.020717822,0.0008459309,0.6953579,0.00022565346,0.0006373046,0.00006147155,0.000007842696,0.00014898962,0.23546296,0.000852289],"about_ca_topic_score_codex":0.00044777192,"about_ca_topic_score_gemma":0.00282324,"teacher_disagreement_score":0.4534635,"about_ca_system_score_codex":0.00032255703,"about_ca_system_score_gemma":0.0010073984,"threshold_uncertainty_score":0.99982136},"labels":[],"label_agreement":null},{"id":"W2951058429","doi":"10.1093/annonc/mdz192","title":"A decade of clinical development of PARP inhibitors in perspective","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":730,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundación Fero; Institute of Cancer Research; Prostate Cancer Foundation; Cancer Research UK; National Institute on Handicapped Research; Department of Health and Aged Care, Australian Government; Instituto de Salud Carlos III; National Institute for Health and Care Research","keywords":"Medicine; Perspective (graphical); Intensive care medicine; Medical physics; Artificial intelligence","score_opus":0.5086532471183037,"score_gpt":0.6122749549852945,"score_spread":0.10362170786699076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951058429","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018688104,0.98581624,0.000008455545,0.00035382994,0.00045972917,0.0010191533,0.000033240536,0.0000070972724,0.0104334215],"genre_scores_gemma":[0.0012388318,0.99668473,0.0014237734,0.00021037536,0.0001884124,0.00007351047,0.000024913843,0.000031940726,0.00012352443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955678,0.000450219,0.0030533196,0.00038785255,0.00029717997,0.00024360286],"domain_scores_gemma":[0.99578756,0.0009679334,0.0021891622,0.0003773144,0.0005822388,0.0000957911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017615033,0.00025394716,0.004792005,0.0004991971,0.000007580404,6.6463434e-7,0.00019353704,0.0008054019,0.00013696858],"category_scores_gemma":[0.000559534,0.00021086553,0.0007149464,0.0004145347,0.00032146845,0.000026878522,0.00007814182,0.0005912249,0.000025959462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003151231,0.0009869501,0.0003926357,0.009357343,0.0005856875,0.000017121729,0.0008920785,3.8032817e-7,0.000008866622,0.00036413714,0.0025283054,0.98455137],"study_design_scores_gemma":[0.0017962322,0.002001109,0.00040066673,0.016363904,0.00022866963,0.000024067305,0.00023528261,3.218567e-7,0.00049987726,0.00011594562,0.97818655,0.0001473472],"about_ca_topic_score_codex":0.000036995563,"about_ca_topic_score_gemma":0.000027948963,"teacher_disagreement_score":0.984404,"about_ca_system_score_codex":0.00022724818,"about_ca_system_score_gemma":0.006034455,"threshold_uncertainty_score":0.9996004},"labels":[],"label_agreement":null},{"id":"W2953106294","doi":"10.1093/annonc/mdx138.008","title":"Gene isoforms as expression-based biomarkers predictive of drug response in vitro","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pharmacogenomics; Medicine; Computational biology; Biomarker discovery; Biomarker; In silico; Precision medicine; Genomics; Drug response; Gene expression profiling; Drug; Bioinformatics; Gene expression; Biology; Proteomics; Genome; Gene; Pharmacology; Pathology; Genetics","score_opus":0.024294186741497914,"score_gpt":0.36505659496643245,"score_spread":0.34076240822493453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953106294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941152,0.00020610691,0.0010947245,0.0020945917,0.000035856636,0.00026076625,0.000083546365,0.0000066993243,0.0021025059],"genre_scores_gemma":[0.99587244,0.00015550265,0.0032232413,0.0004615132,0.000023306331,0.000088990084,0.000079665326,0.000011523873,0.0000838348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902046,0.00015370443,0.00029609862,0.00026880516,0.00006923703,0.000191683],"domain_scores_gemma":[0.9986793,0.0000506543,0.00037976785,0.00069854973,0.0001358534,0.00005587884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000606868,0.00011193633,0.0002359425,0.0000830459,0.000074786105,0.0000037200416,0.00042283584,0.00026024578,0.00001247671],"category_scores_gemma":[0.00036651042,0.00009975898,0.00011500109,0.000041681695,0.00040269305,0.0000035251217,0.0001609074,0.000075864584,0.0000017357137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004995194,0.00021648666,0.0010908901,0.000008338614,0.00003526499,0.0000058282762,0.000025756608,0.000013196284,0.9877698,0.000028557939,0.0014764615,0.0043342696],"study_design_scores_gemma":[0.00061805634,0.0013964861,0.008515221,0.000015697915,0.000006600637,0.00000432439,0.000030660656,0.00004078049,0.9771777,0.0003366973,0.011765797,0.00009202564],"about_ca_topic_score_codex":0.00008999088,"about_ca_topic_score_gemma":0.000011819589,"teacher_disagreement_score":0.010592102,"about_ca_system_score_codex":0.000008336892,"about_ca_system_score_gemma":0.00023742221,"threshold_uncertainty_score":0.4068053},"labels":[],"label_agreement":null},{"id":"W2953546931","doi":"10.1093/annonc/mdz155.224","title":"Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Progression-free survival; Chemotherapy; Clinical trial","score_opus":0.11148199376468634,"score_gpt":0.405950691722312,"score_spread":0.29446869795762565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953546931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833341,0.0012294318,0.000010188384,0.001929362,0.00013184107,0.01283779,0.000050698218,0.000005516305,0.00047103077],"genre_scores_gemma":[0.99805105,0.00024613185,0.00021700296,0.00020022265,0.000040815383,0.0011183961,0.00007613913,0.000017879092,0.000032370033],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979557,0.0003300906,0.00081251486,0.00030048404,0.0003721395,0.00022906877],"domain_scores_gemma":[0.99721444,0.0010554728,0.0006086552,0.00058433705,0.0004946996,0.00004239597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052597356,0.00024391196,0.0013838998,0.00013510819,0.00007214414,0.0000071244913,0.00028983093,0.000063941385,0.000026596028],"category_scores_gemma":[0.00014071843,0.00011184969,0.00009586159,0.00040591462,0.00023371384,0.00009431438,0.00005647262,0.00012447234,9.726467e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9133105,0.029521864,0.023576662,0.000065386084,0.0010209031,0.000013025991,0.018662294,0.000107746506,0.00008437618,0.000015193135,0.00006267758,0.0135593545],"study_design_scores_gemma":[0.82511675,0.13758616,0.0322326,0.00008379351,0.00059208996,0.0000019812464,0.003171679,0.000114282506,0.0005851065,0.0000032644632,0.0004150061,0.0000972734],"about_ca_topic_score_codex":0.000569449,"about_ca_topic_score_gemma":0.0021448804,"teacher_disagreement_score":0.1080643,"about_ca_system_score_codex":0.000055800327,"about_ca_system_score_gemma":0.00026474264,"threshold_uncertainty_score":0.45610976},"labels":[],"label_agreement":null},{"id":"W2954169816","doi":"10.1093/annonc/mdz155.290","title":"NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Afatinib; Oncology; Internal medicine; Irinotecan; FOLFOX; Colorectal cancer; KRAS; Adenocarcinoma; Gastroenterology; Cancer; Epidermal growth factor receptor; Oxaliplatin; Gefitinib","score_opus":0.05309594805223644,"score_gpt":0.37944268286191174,"score_spread":0.3263467348096753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954169816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96443325,0.00022819806,0.000077984354,0.004701925,0.00016177367,0.0005491873,0.000030936077,0.000021963768,0.029794764],"genre_scores_gemma":[0.996145,0.00020819127,0.0013728569,0.00049765763,0.00013047965,0.00003510159,0.000047012967,0.000011799636,0.001551913],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990831,0.00003185673,0.00023382,0.00024514968,0.00016271578,0.00024336926],"domain_scores_gemma":[0.99928993,0.000073324685,0.00015550021,0.00013284071,0.0002616544,0.00008676279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008359708,0.00015737834,0.00045899613,0.000087254084,0.000048310605,0.000004380799,0.000039403254,0.000055846664,0.0002869238],"category_scores_gemma":[0.00004116252,0.000116985735,0.00016082505,0.00008549947,0.00007732602,0.00004514661,0.000043911987,0.00007379221,0.000094084695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038898278,0.019734234,0.14173985,0.00021483896,0.0019516437,0.0015703383,0.004954021,0.00017087856,0.37687603,0.004656057,0.0038137566,0.4054201],"study_design_scores_gemma":[0.014944962,0.18399449,0.7606728,0.00049884175,0.00049594196,0.0026050103,0.0013641575,0.00035081233,0.02671324,0.00041619255,0.007645083,0.0002984347],"about_ca_topic_score_codex":0.00044969877,"about_ca_topic_score_gemma":0.000048013804,"teacher_disagreement_score":0.61893296,"about_ca_system_score_codex":0.00015826055,"about_ca_system_score_gemma":0.00022784741,"threshold_uncertainty_score":0.47705397},"labels":[],"label_agreement":null},{"id":"W2955224282","doi":"10.1093/annonc/mdz206","title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; Université de Montréal; McGill University Health Centre","funders":"Institut Du Cancer de Montréal; Agence Nationale de la Recherche","keywords":"Medicine; Dysbiosis; Microbiome; Cancer; Immunotherapy; Antibiotics; Oncology; Immunology; Internal medicine; Gut flora; Bioinformatics; Intensive care medicine; Microbiology","score_opus":0.13012124007633907,"score_gpt":0.4555019810436903,"score_spread":0.3253807409673512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955224282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17449448,0.8217584,3.1643154e-7,0.00017555867,0.00017152677,0.0028041557,0.00022790238,0.000009395117,0.00035829953],"genre_scores_gemma":[0.049724855,0.9495614,0.0000074675363,0.00012173276,0.000026483698,0.000011060827,0.00004117355,0.000048321934,0.0004574591],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99795187,0.00023398273,0.00088041206,0.00028519644,0.00030726628,0.00034129395],"domain_scores_gemma":[0.9971741,0.0008907165,0.001230254,0.00040089744,0.00023832667,0.000065742264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019243897,0.00041279916,0.0025128936,0.0002724246,0.00002539058,0.0000074601753,0.00023469618,0.000384307,0.000082573315],"category_scores_gemma":[0.00010001822,0.00019244482,0.0006779806,0.00041007678,0.0001848582,0.000032295524,0.000027165937,0.000390976,0.0000044018952],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037632636,0.0011015461,0.14819005,0.0012397171,0.0036127504,0.000008830417,0.0002584943,0.0000013114085,0.0000058807127,0.000003017216,0.00032779315,0.84148735],"study_design_scores_gemma":[0.011399098,0.05331157,0.6582689,0.019777156,0.0009311487,0.0000137983925,0.000049289116,0.0000014165945,0.00017146037,0.000009341298,0.2555805,0.0004862778],"about_ca_topic_score_codex":0.0032200806,"about_ca_topic_score_gemma":0.00047262266,"teacher_disagreement_score":0.8410011,"about_ca_system_score_codex":0.00040365476,"about_ca_system_score_gemma":0.0026931432,"threshold_uncertainty_score":0.78476715},"labels":[],"label_agreement":null},{"id":"W2955574442","doi":"10.1093/annonc/mdz155.186","title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Bevacizumab; Adjuvant therapy; Hepatocellular carcinoma; Oncology; Internal medicine; Adjuvant; Placebo; Clinical endpoint; Surgery; Cancer; Randomized controlled trial; Immunotherapy; Nivolumab; Chemotherapy; Pathology","score_opus":0.06692529537401778,"score_gpt":0.3296907541364201,"score_spread":0.2627654587624023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955574442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522483,0.00045471557,0.000003014066,0.000116563046,0.000054159555,0.0039566658,0.00007135939,0.000011245241,0.000107440974],"genre_scores_gemma":[0.99909675,0.00024841208,0.00008990124,0.000050961487,0.00001545669,0.00027785084,0.000052844942,0.000038325998,0.00012948744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972597,0.00061476073,0.0007193698,0.00050414517,0.00057268044,0.00032937565],"domain_scores_gemma":[0.99730283,0.00018943647,0.0009846345,0.0005583914,0.0008452733,0.00011941588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037604134,0.00032898175,0.0015487442,0.00033631688,0.000038466456,0.0000037338536,0.00012535215,0.0001661766,0.00021918878],"category_scores_gemma":[0.00007335671,0.0002050189,0.0001049147,0.0005292761,0.0001790799,0.00014229889,0.0000548867,0.00024169155,0.000009299594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10280945,0.01092354,0.8739486,0.00018521669,0.00053033466,0.00020552998,0.005374693,0.0000019593008,0.000103298764,0.0000018136082,0.000020013753,0.0058956016],"study_design_scores_gemma":[0.04455697,0.24560647,0.6951432,0.0005037885,0.00027933597,0.000011188808,0.000989777,0.00039391906,0.012265156,0.000010986732,0.000057633057,0.00018155546],"about_ca_topic_score_codex":0.0018027531,"about_ca_topic_score_gemma":0.0014945042,"teacher_disagreement_score":0.23468292,"about_ca_system_score_codex":0.00012766878,"about_ca_system_score_gemma":0.00033738447,"threshold_uncertainty_score":0.8360428},"labels":[],"label_agreement":null},{"id":"W2955875969","doi":"10.1093/annonc/mdz156.001","title":"CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pancreatic cancer; Hazard ratio; Proportional hazards model; Gemcitabine; Capecitabine; Univariate analysis; Biomarker; Gastroenterology; Cancer; Multivariate analysis; Confidence interval","score_opus":0.07562098436638041,"score_gpt":0.4260556752389468,"score_spread":0.35043469087256635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955875969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979939,0.000765086,0.000036624086,0.013108606,0.00008913433,0.00313131,0.00011136808,0.000022617842,0.0027962446],"genre_scores_gemma":[0.99423206,0.0007750863,0.00022629123,0.0026964573,0.000070563925,0.000642575,0.00012548696,0.000023748045,0.0012077494],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693465,0.0006999853,0.00082357007,0.00047433676,0.0004988094,0.0005686174],"domain_scores_gemma":[0.9957619,0.0026825657,0.0004855737,0.0003847633,0.00050875446,0.00017645679],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016188012,0.00024699356,0.0021585894,0.00030582838,0.00008902046,0.000008870657,0.00025381497,0.00034313704,0.0018682685],"category_scores_gemma":[0.0010835188,0.00014876474,0.00033093797,0.0014150693,0.00036721656,0.000076934615,0.00007880646,0.00035527203,0.000021641947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48511124,0.0053763147,0.45132086,0.000037762602,0.011720469,0.00014276362,0.001331838,0.000018230756,0.0035851682,0.00001112626,0.004131321,0.037212912],"study_design_scores_gemma":[0.71218795,0.02669661,0.24310806,0.00042832,0.0059796846,0.0000061404353,0.0005516824,0.00579866,0.0022307553,0.00011230818,0.002594598,0.00030524877],"about_ca_topic_score_codex":0.0015889464,"about_ca_topic_score_gemma":0.0022262386,"teacher_disagreement_score":0.2270767,"about_ca_system_score_codex":0.00015444757,"about_ca_system_score_gemma":0.0012930998,"threshold_uncertainty_score":0.9990442},"labels":[],"label_agreement":null},{"id":"W2955982848","doi":"10.1093/annonc/mdz155.216","title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Durvalumab; Bevacizumab; Adjuvant; Adjuvant therapy; Refractory (planetary science); Resection; Oncology; Hepatocellular cancer; Internal medicine; Ablation; Surgery; Cancer; Chemotherapy; Nivolumab; Immunotherapy","score_opus":0.07664049788847313,"score_gpt":0.34100887509155525,"score_spread":0.26436837720308215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955982848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953266,0.00024687353,0.0000057134025,0.00016165247,0.000055972818,0.0040551857,0.000048248134,0.00001142131,0.000088370965],"genre_scores_gemma":[0.99896526,0.00018746556,0.00018924806,0.00006937487,0.000018503875,0.00028293417,0.00007418977,0.00003405913,0.00017896587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973651,0.0005633385,0.00076309324,0.0004621363,0.00055260194,0.0002937302],"domain_scores_gemma":[0.9975627,0.00020517438,0.0008127377,0.000496981,0.0008165004,0.00010592451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037787601,0.00030306508,0.0012047302,0.00030897584,0.00004155289,0.0000037583798,0.00010821155,0.0001494018,0.0005278702],"category_scores_gemma":[0.00007041788,0.00017673172,0.000087456196,0.0005921709,0.00014965003,0.00016899063,0.000043864315,0.00020354825,0.000009360416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14420748,0.008998534,0.8333912,0.00013435163,0.0004872855,0.00016113452,0.0053014783,0.0000031139755,0.00010800082,0.0000020109053,0.000019912297,0.0071854987],"study_design_scores_gemma":[0.04785754,0.2965045,0.6435696,0.00026712025,0.00028945878,0.000015253341,0.0005448012,0.0006939068,0.009970604,0.000011604133,0.00009341605,0.00018219912],"about_ca_topic_score_codex":0.0024116351,"about_ca_topic_score_gemma":0.0014755306,"teacher_disagreement_score":0.28750598,"about_ca_system_score_codex":0.000115333125,"about_ca_system_score_gemma":0.0004435524,"threshold_uncertainty_score":0.720691},"labels":[],"label_agreement":null},{"id":"W2957262648","doi":"10.1093/annonc/mdz154.019","title":"Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Mount Sinai Hospital; Jewish General Hospital; Sunnybrook Health Science Centre; Dr. Georges-L.-Dumont University Hospital Centre; Hôpital Maisonneuve-Rosemont; St Mary's Hospital Centre; McGill University Health Centre; McGill University; Hôpital du Sacré-Cœur de Montréal; Cégep de Lévis; Quebec - Clinical Research Organization in Cancer; Centre de Santé et de Services Sociaux de Chicoutimi","funders":"","keywords":"Medicine; KRAS; Context (archaeology); Colorectal cancer; Oncology; Metastasis; Cancer; Internal medicine; Copy-number variation; Chemotherapy regimen; Biopsy; Gene; Genetics","score_opus":0.024419975045697602,"score_gpt":0.34382352053566845,"score_spread":0.31940354548997085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957262648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966217,0.0014401231,0.000038188144,0.00058566604,0.00016513503,0.00025910363,0.00032077977,0.0000017822719,0.0005675095],"genre_scores_gemma":[0.99574226,0.0034298857,0.00034168665,0.00025620367,0.000031093256,0.000034043722,0.000036623227,0.000011522175,0.00011666333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999074,0.00006137327,0.00032844656,0.0002504808,0.00009468302,0.00019105569],"domain_scores_gemma":[0.9993889,0.000082994346,0.00016600767,0.00014194121,0.00018465132,0.00003552984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031073092,0.00010955693,0.00032388573,0.00010019207,0.0000108634495,0.000007115204,0.00012319384,0.00011761097,0.00015143707],"category_scores_gemma":[0.00010524527,0.000111999456,0.00005567831,0.00019061405,0.00007832885,0.0000068696495,0.00006270779,0.00004384491,0.000004659136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003728414,0.00017795645,0.45179012,0.00007274403,0.000109232766,0.000008097965,0.00041412984,0.0002569133,0.53455424,0.00016183699,0.00672657,0.001999757],"study_design_scores_gemma":[0.0010909522,0.00058979,0.34815198,0.000049681483,0.000010132211,0.0000016858974,0.00007779427,0.000012316978,0.6346149,0.00012761299,0.015143172,0.00012997523],"about_ca_topic_score_codex":0.0015190246,"about_ca_topic_score_gemma":0.019565739,"teacher_disagreement_score":0.103638135,"about_ca_system_score_codex":0.000043198786,"about_ca_system_score_gemma":0.00024682295,"threshold_uncertainty_score":0.99832463},"labels":[],"label_agreement":null},{"id":"W2959132529","doi":"10.1093/annonc/mdz154.026","title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Interim analysis; Interim; Mallinckrodt; Internal medicine; Clinical trial; Family medicine; Hepatocellular carcinoma","score_opus":0.09543393774102775,"score_gpt":0.3370100366263533,"score_spread":0.24157609888532555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959132529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726611,0.006375645,0.0000043727628,0.0018562508,0.00025379378,0.0017858634,0.000037542577,0.00004346848,0.016981963],"genre_scores_gemma":[0.9956876,0.0014376215,0.00029602207,0.0009862413,0.00009936608,0.00015183477,0.00022604379,0.000063795254,0.0010514809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733156,0.00024126993,0.00073275826,0.0006284585,0.00035516356,0.00071078225],"domain_scores_gemma":[0.9981605,0.00019498984,0.00030831542,0.00063538057,0.00045440422,0.00024644125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028866334,0.00039581195,0.0012964667,0.00038383604,0.000047293317,0.0000090790045,0.00022501338,0.00042749857,0.0007854502],"category_scores_gemma":[0.000058341633,0.00035227914,0.00039827084,0.00040817927,0.00014475767,0.00015359376,0.00007863183,0.00036936306,0.0003175455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047613587,0.0009446975,0.93490714,0.00022074973,0.0001279965,0.0009759939,0.002451303,0.000002957878,0.0071711307,0.00009804611,0.00034896084,0.047989666],"study_design_scores_gemma":[0.037359927,0.051660195,0.5241305,0.00040869106,0.00025579313,0.00024121233,0.003897451,0.0010393395,0.2616655,0.0002999306,0.11803325,0.0010081689],"about_ca_topic_score_codex":0.00048750825,"about_ca_topic_score_gemma":0.000077927834,"teacher_disagreement_score":0.41077662,"about_ca_system_score_codex":0.00017514326,"about_ca_system_score_gemma":0.00065589783,"threshold_uncertainty_score":0.9998929},"labels":[],"label_agreement":null},{"id":"W2961068656","doi":"10.1093/annonc/mdv480","title":"Correction to: Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium","year":2015,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Cancer Care Ontario; University of Toronto","funders":"National Cancer Institute","keywords":"Pancreatic cancer; Medicine; Internal medicine; Vitamin D and neurology; Cancer; Listing (finance); Oncology; Etiology; Gastroenterology","score_opus":0.0631379505613585,"score_gpt":0.4091483729785703,"score_spread":0.3460104224172118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961068656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73332953,0.10549929,0.00043116772,0.06315308,0.018922916,0.0059990375,0.0044738604,0.00015496131,0.068036154],"genre_scores_gemma":[0.74602515,0.043935716,0.0003358604,0.013298188,0.0047118366,0.0022492546,0.0007220702,0.00014432741,0.1885776],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995536,0.0011061197,0.0010881402,0.0008300689,0.00063861883,0.00080103974],"domain_scores_gemma":[0.99273735,0.0036336018,0.00080102606,0.0008691571,0.001324597,0.00063429435],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001623417,0.0005405727,0.00396175,0.00057892775,0.00019841404,0.000028900795,0.00030088268,0.0009800496,0.0012661683],"category_scores_gemma":[0.0024985122,0.0003778151,0.000423536,0.0010775356,0.00065383327,0.00005896216,0.00014950604,0.0013892093,0.00003369572],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015410986,0.00024960554,0.11149151,0.00014502235,0.017818084,0.0010753723,0.0010403455,0.000021865902,0.00007755404,0.0000071974405,0.8396959,0.026836466],"study_design_scores_gemma":[0.008291273,0.0085623795,0.39100206,0.0017970143,0.12943545,0.0012173366,0.0025334074,0.0134586925,0.00007562789,0.000244042,0.4424208,0.0009619097],"about_ca_topic_score_codex":0.0748517,"about_ca_topic_score_gemma":0.042757213,"teacher_disagreement_score":0.3972751,"about_ca_system_score_codex":0.00049555785,"about_ca_system_score_gemma":0.00507921,"threshold_uncertainty_score":0.9998674},"labels":[],"label_agreement":null},{"id":"W2961284463","doi":"10.1093/annonc/mdz154.022","title":"Significant differences in outcome between Immunoscore categories in stage I colon cancer patients","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Oncology; Colorectal cancer; Cancer; Cohort","score_opus":0.1209398430349357,"score_gpt":0.3876873384661781,"score_spread":0.2667474954312424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961284463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502236,0.00020514517,1.4143727e-7,0.0013576793,0.00015592277,0.000355553,0.000036966332,0.000007099032,0.002859108],"genre_scores_gemma":[0.9986419,0.00010914575,0.0000053212566,0.00031071497,0.000032721837,0.00002678865,0.000025522424,0.0000074968157,0.00084035913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989095,0.000068724396,0.0004347047,0.00018811048,0.00014518577,0.00025379725],"domain_scores_gemma":[0.99942493,0.00016100571,0.00014602726,0.000110840345,0.00010210344,0.00005505997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018275705,0.00011113881,0.00065473834,0.00017774617,0.000010518914,0.0000027622973,0.00009864595,0.00012286428,0.00018336388],"category_scores_gemma":[0.00006572064,0.00008647233,0.00006259324,0.00021714799,0.00008879965,0.00004741885,0.000057514404,0.00020837811,0.000015341484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041092417,0.0003054538,0.99193394,0.00009629054,0.000021307149,0.000024623823,0.0006724975,0.0000012337712,0.0013847715,0.00011736155,0.00005221106,0.004979405],"study_design_scores_gemma":[0.0014592657,0.0039820997,0.9905965,0.00005425115,0.000011953076,2.953271e-7,0.0003378711,0.000008395167,0.0018882147,0.00009874705,0.0014765195,0.00008588576],"about_ca_topic_score_codex":0.0032757798,"about_ca_topic_score_gemma":0.0016338443,"teacher_disagreement_score":0.0048935194,"about_ca_system_score_codex":0.000075128395,"about_ca_system_score_gemma":0.00017557172,"threshold_uncertainty_score":0.4952021},"labels":[],"label_agreement":null},{"id":"W2961406401","doi":"10.1093/annonc/mdz154","title":"An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Pancreatic cancer; Internal medicine; Randomization; Adenocarcinoma; Randomized controlled trial; Intention-to-treat analysis; Surgery; Oncology; Cancer","score_opus":0.16908054436671655,"score_gpt":0.4890651294177842,"score_spread":0.31998458505106764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961406401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860582,0.00094193843,0.0005941329,0.0038036252,0.0001611716,0.005188579,0.0003384215,0.000018539922,0.0028954118],"genre_scores_gemma":[0.99152756,0.0016443848,0.004087606,0.00067201076,0.000090788504,0.00031443356,0.00054747966,0.000028842413,0.0010868871],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940616,0.0014206476,0.0026715046,0.0006175149,0.0007272282,0.0005015268],"domain_scores_gemma":[0.9881512,0.007175517,0.0016333489,0.00087920815,0.0017587958,0.00040191493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007851231,0.00032655586,0.0075245597,0.0007906575,0.000056976016,0.000015670017,0.0006108178,0.00039547522,0.00057399087],"category_scores_gemma":[0.006230978,0.00024511374,0.0005005323,0.0006024484,0.000882162,0.00027495547,0.00028050606,0.00028251816,0.000002852681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7928019,0.0060554077,0.1817886,0.000500795,0.008474589,0.000014952588,0.00045157786,0.00000433267,0.007221836,0.00090364786,0.0003092873,0.0014730399],"study_design_scores_gemma":[0.80441684,0.022874322,0.16595462,0.00007878894,0.0028748994,0.000008085842,0.0002359645,0.002446847,0.00042181028,0.00027791286,0.00020980072,0.00020013432],"about_ca_topic_score_codex":0.0019251453,"about_ca_topic_score_gemma":0.0001808641,"teacher_disagreement_score":0.016818913,"about_ca_system_score_codex":0.000108663444,"about_ca_system_score_gemma":0.0014544013,"threshold_uncertainty_score":0.9995448},"labels":[],"label_agreement":null},{"id":"W2966632204","doi":"10.1093/annonc/mdz227","title":"How liquid biopsies can change clinical practice in oncology","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":353,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; Innovative Medicines Initiative; Cancer Research UK; Sanofi; Horizon 2020 Framework Programme; Asana Biosciences; AstraZeneca","keywords":"Liquid biopsy; Medicine; Circulating tumor DNA; Clinical Practice; Minimal residual disease; Precision oncology; Cell-free fetal DNA; Biopsy; Clinical Oncology; Precision medicine; Oncology; Medical physics; Cancer; Pathology; Internal medicine","score_opus":0.30377695949962585,"score_gpt":0.5146516784316199,"score_spread":0.210874718931994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966632204","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002684657,0.9874253,0.0000039789024,0.004975785,0.0014537192,0.00086627866,0.00026285485,0.0000053272815,0.0047382587],"genre_scores_gemma":[0.00019435793,0.99314386,0.00038498346,0.003702905,0.0015375409,0.00018517482,0.0004542329,0.000060369406,0.0003365564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969436,0.0007058586,0.0010388327,0.0006990095,0.00012293737,0.000489789],"domain_scores_gemma":[0.99641985,0.0011649017,0.0012576762,0.00069375837,0.00031895345,0.00014489182],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012060278,0.00038892054,0.0023109282,0.00019836564,0.000023343215,0.000017295222,0.00052709767,0.0017803282,0.000010636241],"category_scores_gemma":[0.0029617976,0.00036321126,0.0006097807,0.00019216418,0.00025991246,0.0000065781246,0.0004581742,0.0005246043,0.000021979884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022161358,0.0004837155,0.000011070421,0.001328959,0.0002748015,0.00008082425,0.00005672837,5.733098e-7,0.00001703658,0.00016043337,0.0117977215,0.9855665],"study_design_scores_gemma":[0.00050542754,0.010197721,0.000008452117,0.0005154977,0.0003006328,0.0001089195,0.00007848328,4.4630764e-7,0.000052833497,0.000012790639,0.9878812,0.00033762332],"about_ca_topic_score_codex":0.00017171616,"about_ca_topic_score_gemma":0.00079441717,"teacher_disagreement_score":0.9852289,"about_ca_system_score_codex":0.000076695775,"about_ca_system_score_gemma":0.002469122,"threshold_uncertainty_score":0.999882},"labels":[],"label_agreement":null},{"id":"W2970655683","doi":"10.1093/annonc/mdz292","title":"St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients’ overtreatment and breaking the bank?","year":2019,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Gynecology; Consensus conference; General surgery; Cancer; Oncology; Family medicine; Internal medicine","score_opus":0.04446748015710917,"score_gpt":0.3615835749389213,"score_spread":0.31711609478181213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970655683","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28888732,0.0020677738,0.0000013742256,0.70588577,0.0006799782,0.0005769877,0.0011216189,0.0000050211625,0.0007741482],"genre_scores_gemma":[0.39227146,0.006429622,0.00020751287,0.59502894,0.0030267157,0.0006308609,0.00074373855,0.00008917699,0.0015720048],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984361,0.000100476296,0.00043517764,0.0005061045,0.00020935122,0.00031281178],"domain_scores_gemma":[0.9988123,0.00009443429,0.000285209,0.00032813562,0.0004470873,0.00003282576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117737094,0.0003014794,0.0004409866,0.000088964916,0.000039959905,0.000011750584,0.0002621028,0.00037303532,0.000030832984],"category_scores_gemma":[0.000057631467,0.00021903684,0.00011106138,0.000049495426,0.00011731311,0.0000029041134,0.0003450443,0.00016389014,0.0000033186577],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002952219,0.00019575363,0.039130326,0.0000262602,0.0006849023,0.000027651811,0.0002341016,0.000027367969,0.000099921046,0.0000032849227,0.93392515,0.025350045],"study_design_scores_gemma":[0.0011480796,0.0007251112,0.07595209,0.00014765287,0.000055537646,0.00003737163,0.00004729367,0.0000023221626,0.0004197247,0.000022963453,0.9212042,0.00023765517],"about_ca_topic_score_codex":0.0024291892,"about_ca_topic_score_gemma":0.00097153155,"teacher_disagreement_score":0.110856846,"about_ca_system_score_codex":0.00009995709,"about_ca_system_score_gemma":0.00019037968,"threshold_uncertainty_score":0.8932063},"labels":[],"label_agreement":null},{"id":"W2971055962","doi":"10.1093/annonc/mdz289","title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"Cancer Research UK; Ontario Institute for Cancer Research; Massachusetts General Hospital; Breast Cancer Research Foundation; Pfizer; BioTheranostics","keywords":"Medicine; Tamoxifen; Breast cancer; Hazard ratio; Oncology; Internal medicine; Proportional hazards model; Adjuvant therapy; Clinical endpoint; Cancer; Confidence interval; Gynecology; Randomized controlled trial","score_opus":0.022742754932668006,"score_gpt":0.3227753770542787,"score_spread":0.3000326221216107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971055962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925642,0.0011908736,6.0636046e-7,0.0031828457,0.00017957891,0.00073960784,0.002065781,0.0000035957598,0.00007290583],"genre_scores_gemma":[0.9952604,0.0034403452,0.000005854987,0.00070476957,0.00013142754,0.00029841752,0.00012280539,0.000015910417,0.000020066389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987362,0.00010750344,0.0003794379,0.00036526896,0.00015766197,0.0002539462],"domain_scores_gemma":[0.99928635,0.000046150613,0.00019219823,0.00024190893,0.00018967783,0.00004369356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010894486,0.00019326674,0.00044935851,0.000101760226,0.00001928125,0.000003797924,0.00015795123,0.00013709269,0.00007102255],"category_scores_gemma":[0.000008464013,0.00013801066,0.000065516695,0.00017308228,0.000100498066,0.00000953692,0.000081855396,0.000088345456,8.177102e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030755011,0.0010550108,0.8919609,0.000010706608,0.00019296748,0.000002617614,0.0005628768,0.00005659125,0.009056645,0.0000043225373,0.00044442803,0.065897904],"study_design_scores_gemma":[0.025407922,0.0014661303,0.9660111,0.000047782058,0.00002271988,0.0000063057305,0.00011278895,0.000012633994,0.0062453537,0.00003532276,0.0005278867,0.00010404488],"about_ca_topic_score_codex":0.013675991,"about_ca_topic_score_gemma":0.003848961,"teacher_disagreement_score":0.07405019,"about_ca_system_score_codex":0.00004640057,"about_ca_system_score_gemma":0.00008870136,"threshold_uncertainty_score":0.992892},"labels":[],"label_agreement":null},{"id":"W2976281902","doi":"10.1093/annonc/mdz397","title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.0779698794022533,"score_gpt":0.4204154286154851,"score_spread":0.3424455492132318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976281902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876883,0.0013357683,7.060028e-7,0.005076903,0.000104551014,0.00063858187,0.000033537424,0.000005758415,0.0051158676],"genre_scores_gemma":[0.9945003,0.002502604,0.00010777585,0.0003347493,0.000026211106,0.00005059811,0.000020734107,0.00001069912,0.0024463776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990637,0.000060333783,0.00024581674,0.00019447358,0.00016629812,0.00026941625],"domain_scores_gemma":[0.9994596,0.00011810785,0.000080113066,0.00012448382,0.00012957571,0.00008806607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030193335,0.00009616456,0.00038333912,0.00012919428,0.000016071474,0.0000057157145,0.000039879727,0.00005243901,0.0001578791],"category_scores_gemma":[0.000029804767,0.000073895964,0.00003666466,0.00012356909,0.00009660532,0.000067846464,0.00002868605,0.00013080306,0.000013789318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010478238,0.0012984884,0.74203795,0.0013830074,0.00052252196,0.0007903586,0.0039105844,0.00013989117,0.14341861,0.0009557933,0.0025842574,0.0924803],"study_design_scores_gemma":[0.01117942,0.006250497,0.9603745,0.00028381508,0.000054029522,0.000022414362,0.000660101,0.00035827953,0.010251452,0.0009389399,0.009451497,0.0001750738],"about_ca_topic_score_codex":0.0010797135,"about_ca_topic_score_gemma":0.0007354115,"teacher_disagreement_score":0.21833654,"about_ca_system_score_codex":0.000062527295,"about_ca_system_score_gemma":0.0004503366,"threshold_uncertainty_score":0.301339},"labels":[],"label_agreement":null},{"id":"W2977285302","doi":"10.1093/annonc/mdz265.005","title":"Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Adverse effect; Homeopathy; Clinical trial; Colorectal cancer; Cancer; Quality of life (healthcare); Logistic regression; Incidence (geometry); Propensity score matching; Breast cancer; Oncology; Family medicine; Alternative medicine; Pathology","score_opus":0.9419416788129851,"score_gpt":0.7454897348363904,"score_spread":0.1964519439765947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977285302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.824148,0.0016221135,0.002731537,0.13259618,0.012843597,0.013084602,0.0067305346,0.00010693942,0.0061365077],"genre_scores_gemma":[0.8300911,0.0039359764,0.10797618,0.05131874,0.004127699,0.00071509293,0.00028820548,0.00020012265,0.0013468848],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.95531285,0.033709824,0.008916499,0.0006833937,0.00057581684,0.00080160255],"domain_scores_gemma":[0.6355664,0.35996,0.0028466734,0.00078414736,0.00038393537,0.000458831],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.13041009,0.00035056495,0.0059784707,0.00023599181,0.00009609174,0.000024254787,0.0007517586,0.00064731785,0.010125872],"category_scores_gemma":[0.40329087,0.00021785201,0.00050759927,0.00043158565,0.0009876117,0.000111201356,0.00013227508,0.0009147903,0.00003541491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049649463,0.0016547685,0.0033494532,0.00009653765,0.001148069,0.000052179537,0.00036198038,0.000001535465,0.0019201204,0.06151243,0.7563832,0.16855481],"study_design_scores_gemma":[0.06378316,0.00861218,0.001512782,0.00036888302,0.0008875496,0.000009018732,0.0005633029,0.00022256393,0.000965703,0.56862307,0.35391265,0.0005391129],"about_ca_topic_score_codex":0.1356924,"about_ca_topic_score_gemma":0.26377937,"teacher_disagreement_score":0.50711066,"about_ca_system_score_codex":0.00017694596,"about_ca_system_score_gemma":0.001006797,"threshold_uncertainty_score":0.990779},"labels":[],"label_agreement":null},{"id":"W2977310905","doi":"10.1093/annonc/mdz263.011","title":"Comparison between phase III randomized clinical trials and their preceeding phase II studies","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Phases of clinical research; Adverse effect; Clinical trial; Cancer; Randomized controlled trial; Oncology; Surgery; Confidence interval","score_opus":0.49348873228839624,"score_gpt":0.6171006475427235,"score_spread":0.1236119152543273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977310905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700798,0.016876902,0.000021275928,0.005889227,0.0004455303,0.0016331862,0.000038311995,0.00002545201,0.0049903444],"genre_scores_gemma":[0.9895485,0.008993177,0.00010135004,0.00047990057,0.0003696485,0.000078736455,0.00001966055,0.000010861751,0.00039816712],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969258,0.0008434151,0.0015706074,0.00030248004,0.000120107296,0.00023763429],"domain_scores_gemma":[0.9909396,0.0077637504,0.00073049107,0.0001539879,0.00029101927,0.00012112618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073776636,0.00020339618,0.005404894,0.00009927709,0.00009705977,0.0000046531627,0.00005872308,0.00014682428,0.000087860055],"category_scores_gemma":[0.0030762781,0.00011795588,0.00043750196,0.00009182346,0.00044385533,0.000050868577,0.00014435573,0.0001870537,0.0000046323844],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23287977,0.0032358896,0.013010313,0.0001033785,0.007802842,0.0000105800455,0.0057954844,3.0180652e-7,0.0006351734,0.00012459887,0.009435958,0.7269657],"study_design_scores_gemma":[0.8593947,0.056891937,0.0012029125,0.000192644,0.0016232146,0.000011703364,0.004307302,0.0001492355,0.0036258078,0.0006274048,0.071781315,0.000191779],"about_ca_topic_score_codex":0.000023786919,"about_ca_topic_score_gemma":0.000009937996,"teacher_disagreement_score":0.7267739,"about_ca_system_score_codex":0.000028799155,"about_ca_system_score_gemma":0.00010473801,"threshold_uncertainty_score":0.4810101},"labels":[],"label_agreement":null},{"id":"W2977364032","doi":"10.1093/annonc/mdz250.052","title":"Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Oncology; Internal medicine; Gynecology; Cancer; Immunotherapy","score_opus":0.04717057556773591,"score_gpt":0.37284516248565625,"score_spread":0.32567458691792034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977364032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920567,0.0006189061,7.3193695e-7,0.0014086377,0.0004603468,0.001588216,0.00006237434,0.000011717101,0.0037923364],"genre_scores_gemma":[0.998036,0.0001544941,0.000042800475,0.0012285729,0.00016297415,0.0000794496,0.000027345697,0.00001682981,0.0002515236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985186,0.0001518161,0.00036384808,0.00030264907,0.00038336604,0.0002797346],"domain_scores_gemma":[0.998472,0.0007051011,0.00019919784,0.0003314495,0.00020777174,0.00008453207],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018502134,0.00015784893,0.000697065,0.0001498503,0.000021929145,0.000004328196,0.00015760951,0.00009093146,0.00096543354],"category_scores_gemma":[0.00021388922,0.000087817396,0.000085968866,0.00066199346,0.000058270798,0.00006621135,0.000060500508,0.00020170776,0.00004263842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028416997,0.0026687386,0.8841519,0.000010199308,0.00032327735,0.000015343676,0.0003706538,0.000021504125,0.00004230277,0.000010664197,0.00023293064,0.08373551],"study_design_scores_gemma":[0.06327845,0.02090467,0.90855855,0.00005034316,0.000110598536,4.2124205e-7,0.0002219355,0.0000018577879,0.0002956827,0.00006135223,0.006428116,0.00008802148],"about_ca_topic_score_codex":0.002665476,"about_ca_topic_score_gemma":0.00088193873,"teacher_disagreement_score":0.08364749,"about_ca_system_score_codex":0.00010841573,"about_ca_system_score_gemma":0.00021250201,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W2977365200","doi":"10.1093/annonc/mdz255","title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Adjuvant; Oncology; Internal medicine; Stage (stratigraphy); Melanoma; Biomarker; Immunotherapy; Cancer; Cancer research","score_opus":0.09707293265296456,"score_gpt":0.3960347247990392,"score_spread":0.2989617921460746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977365200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98434556,0.0017028424,0.0000012819712,0.004769493,0.001020346,0.0014901258,0.00024974463,0.0000354829,0.0063851457],"genre_scores_gemma":[0.9963733,0.0013876264,0.00004912553,0.00059036264,0.00021399707,0.000025824236,0.00016947808,0.00002849063,0.001161779],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974881,0.00033744925,0.0009114405,0.00051186624,0.00030267655,0.00044847935],"domain_scores_gemma":[0.99736434,0.001278361,0.00042702048,0.00067035074,0.00014995762,0.00010998263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012950256,0.0002460732,0.0008564906,0.0001734484,0.000065365675,0.000016723418,0.0002416838,0.0003221512,0.0006216926],"category_scores_gemma":[0.00038721273,0.00017760838,0.0001684669,0.00038191117,0.00032672592,0.00009438957,0.00010775791,0.00032965702,0.000025965648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90283835,0.0011047649,0.00020416998,0.000022285285,0.00053284917,0.00008404526,0.0015278826,9.907583e-7,0.033343535,0.000024453353,0.009952332,0.050364364],"study_design_scores_gemma":[0.8454774,0.019772708,0.02852303,0.00017598987,0.0001204053,0.000009139755,0.0012485498,0.00017343619,0.0059001967,0.000023825854,0.09832055,0.00025476151],"about_ca_topic_score_codex":0.0033347593,"about_ca_topic_score_gemma":0.00093767414,"teacher_disagreement_score":0.08836822,"about_ca_system_score_codex":0.00010387665,"about_ca_system_score_gemma":0.00043132823,"threshold_uncertainty_score":0.724266},"labels":[],"label_agreement":null},{"id":"W2977386089","doi":"10.1093/annonc/mdz249.028","title":"Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Tissue microarray; Biomarker; Confidence interval; PD-L1; Ramucirumab; Gastroenterology; Immunohistochemistry; Cancer; Immunotherapy; Biology","score_opus":0.11531999902706094,"score_gpt":0.4482914297616633,"score_spread":0.33297143073460234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977386089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99090904,0.00090230827,0.000009316809,0.00021710695,0.00025039888,0.003423445,0.0003008555,0.000014204783,0.0039733336],"genre_scores_gemma":[0.9989914,0.000120206874,0.00006039246,0.00035797543,0.000055223492,0.00019711042,0.00007661371,0.000022619271,0.00011850369],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99784064,0.00026671053,0.0007827518,0.00039748938,0.00042608613,0.00028632506],"domain_scores_gemma":[0.9983842,0.00021233427,0.0005263664,0.00040147663,0.00036567918,0.000109984954],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003347431,0.00025434987,0.0017704336,0.00019999332,0.000022142496,0.0000046969208,0.00013782129,0.00016473648,0.0009861424],"category_scores_gemma":[0.000039609135,0.0001741647,0.00019605356,0.00037371388,0.00019313517,0.000101922626,0.000045664525,0.00014019458,0.000012150275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6526555,0.007984822,0.32455215,0.000027645614,0.0018932635,0.00002311675,0.00051255507,0.0000090502035,0.0002569864,0.0000036042338,0.00026364977,0.011817706],"study_design_scores_gemma":[0.85117793,0.009834469,0.1361257,0.00012198794,0.00084039505,9.673322e-7,0.00025417755,0.000015391504,0.0011219284,0.000034450444,0.00032844988,0.00014417926],"about_ca_topic_score_codex":0.015513066,"about_ca_topic_score_gemma":0.0014525261,"teacher_disagreement_score":0.19852245,"about_ca_system_score_codex":0.000113948845,"about_ca_system_score_gemma":0.0005364619,"threshold_uncertainty_score":0.9999271},"labels":[],"label_agreement":null},{"id":"W2977393636","doi":"10.1093/annonc/mdz240.050","title":"Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Breast cancer; Tamoxifen; Lumpectomy; Odds ratio; Cancer; Mastectomy; Oncology; Gynecology; Confidence interval","score_opus":0.04252472510759674,"score_gpt":0.339853959899806,"score_spread":0.29732923479220924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977393636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938584,0.0002561789,0.000002724019,0.0024419709,0.00034074,0.00068531587,0.00008426049,0.0000064325523,0.0023240033],"genre_scores_gemma":[0.99447143,0.0003011005,0.000049131337,0.0014697922,0.00004479617,0.00019924303,0.000014786692,0.0000100687275,0.0034396565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987761,0.000039071652,0.0004410235,0.00021362549,0.00020944941,0.0003207736],"domain_scores_gemma":[0.9988263,0.00014447744,0.00029901793,0.00022633265,0.00037757767,0.00012626371],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023900988,0.00011191218,0.0005277468,0.000074407806,0.000012446026,0.0000013639444,0.00015541879,0.000066059176,0.0055785547],"category_scores_gemma":[0.00005556099,0.00009537617,0.00002633401,0.0001248284,0.000078882586,0.00005962312,0.000023456574,0.00016420973,0.0000049652754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001143071,0.00024208135,0.9317746,0.00010727889,0.00011148908,0.000009920233,0.0007527944,0.00001612761,0.014194043,0.000027719658,0.004973207,0.04664764],"study_design_scores_gemma":[0.002137496,0.0041703037,0.97760755,0.00023242114,0.000008941878,0.000012970864,0.0004058799,0.000028442384,0.00234142,0.000034531382,0.012937945,0.00008211501],"about_ca_topic_score_codex":0.8249638,"about_ca_topic_score_gemma":0.8850347,"teacher_disagreement_score":0.06007088,"about_ca_system_score_codex":0.0002666054,"about_ca_system_score_gemma":0.004037753,"threshold_uncertainty_score":0.99533045},"labels":[],"label_agreement":null},{"id":"W2977398957","doi":"10.1093/annonc/mdz246.092","title":"Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Panitumumab; Medicine; Trametinib; Colorectal cancer; Oncology; Internal medicine; Cancer research; Cancer; KRAS; MAPK/ERK pathway; Kinase; Genetics","score_opus":0.09370440168895344,"score_gpt":0.43366384781995837,"score_spread":0.3399594461310049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977398957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98862815,0.0028321363,3.210835e-7,0.0019507012,0.00035741614,0.0009863361,0.00004234599,0.000009064923,0.005193507],"genre_scores_gemma":[0.9972275,0.001828337,0.0001199612,0.00030505582,0.00005596966,0.00007783801,0.0000110931505,0.000012838478,0.0003614048],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99883366,0.00008529619,0.00044700847,0.00023798842,0.00015779665,0.00023825347],"domain_scores_gemma":[0.9991694,0.00023960069,0.00022103517,0.00012226342,0.00017864442,0.00006903415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002827311,0.0001530169,0.00096549233,0.00014367512,0.000028683895,0.0000021805297,0.00005647661,0.0000872871,0.00033032164],"category_scores_gemma":[0.00016247111,0.00011906109,0.000094464594,0.00023660925,0.00016945395,0.000045450655,0.000060351773,0.00013248334,0.000003887512],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32276314,0.015410676,0.010808064,0.00041989508,0.0015753532,0.00013388567,0.004993471,0.0000090418125,0.01618817,0.00029672828,0.0030460712,0.6243555],"study_design_scores_gemma":[0.44376352,0.43055224,0.03243301,0.00027734388,0.0009215203,0.000056791814,0.001754991,0.0001660747,0.022278197,0.00051970157,0.06686618,0.000410428],"about_ca_topic_score_codex":0.00069535366,"about_ca_topic_score_gemma":0.0008759223,"teacher_disagreement_score":0.62394506,"about_ca_system_score_codex":0.00006335847,"about_ca_system_score_gemma":0.0003657862,"threshold_uncertainty_score":0.48551702},"labels":[],"label_agreement":null},{"id":"W2977420585","doi":"10.1093/annonc/mdz263.004","title":"Determinants of the cancer drug funding process in Canada","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Cancer drugs; Drug; Family medicine; Oncology; Pharmacology","score_opus":0.07177751147441978,"score_gpt":0.32760566126492197,"score_spread":0.25582814979050217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977420585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97401243,0.0012913835,8.382625e-7,0.0011106824,0.0007466756,0.00015524898,0.00009535833,0.0000014107165,0.02258594],"genre_scores_gemma":[0.9983473,0.0003878997,0.00000786834,0.0008022827,0.000031848354,0.000012283328,3.98656e-7,0.00000912777,0.00040101807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989201,0.000011063092,0.0006058738,0.00018277028,0.000023804854,0.00025641668],"domain_scores_gemma":[0.9989795,0.00005989064,0.00066672853,0.00021163464,0.00004655472,0.000035668712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034008236,0.0000802054,0.0005087122,0.00007784338,0.000016050206,0.000002941452,0.00033558827,0.00005850759,0.00029533994],"category_scores_gemma":[0.00007783079,0.00007497906,0.00006023965,0.00015283689,0.00004878223,0.00012197306,0.000051602558,0.0001026082,0.000013068281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025461868,0.000026472224,0.9891288,0.000057295132,0.000009964241,8.4810245e-7,0.00033679916,0.0003809237,0.000010031482,0.003256884,0.00088100246,0.0058855084],"study_design_scores_gemma":[0.0005380562,0.00008832627,0.9602769,0.00006884554,0.000002085105,0.0000011406617,0.0002409596,0.00037373675,0.0027660711,0.0065694046,0.028934073,0.00014041334],"about_ca_topic_score_codex":0.6918893,"about_ca_topic_score_gemma":0.8484867,"teacher_disagreement_score":0.15659744,"about_ca_system_score_codex":0.00022127437,"about_ca_system_score_gemma":0.0010404323,"threshold_uncertainty_score":0.32337654},"labels":[],"label_agreement":null},{"id":"W2977427874","doi":"10.1093/annonc/mdz283.003","title":"ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Sarcoma; Dermatology; Internal medicine; Oncology; Pathology","score_opus":0.053423593404045094,"score_gpt":0.38545028891373545,"score_spread":0.33202669550969033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977427874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520495,0.00007152779,0.0000016888599,0.0020159706,0.0001080836,0.0006046864,0.0000065069207,0.000012745346,0.045129307],"genre_scores_gemma":[0.9942478,0.00004518244,0.00013425147,0.0011891451,0.000067525696,0.000012387613,0.000023147928,0.00002219629,0.004258386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986947,0.00010927564,0.00026240502,0.00023047555,0.0003433275,0.00035979704],"domain_scores_gemma":[0.9990451,0.00016060164,0.00008854334,0.00033997092,0.0002601747,0.00010566253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036937025,0.00010856989,0.00046696397,0.00022447079,0.000011611164,0.0000033655804,0.0001303756,0.00014381172,0.0038020855],"category_scores_gemma":[0.000075408556,0.000085606065,0.000062794126,0.00024900073,0.00012265494,0.00005670421,0.000062734776,0.0002782755,0.00018868902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007384265,0.0017414178,0.84508103,0.00008712616,0.00011144048,0.00008357999,0.00032890032,0.000004757801,0.0078067547,0.00011997673,0.0043213353,0.13292943],"study_design_scores_gemma":[0.010609629,0.021942342,0.8422034,0.00008389219,0.000014460893,0.000012640978,0.00007963783,0.000023670755,0.004751467,0.00009816149,0.12005071,0.00012999873],"about_ca_topic_score_codex":0.00014402944,"about_ca_topic_score_gemma":0.00008575513,"teacher_disagreement_score":0.13279943,"about_ca_system_score_codex":0.00006219477,"about_ca_system_score_gemma":0.0002722204,"threshold_uncertainty_score":0.9971086},"labels":[],"label_agreement":null},{"id":"W2977439036","doi":"10.1093/annonc/mdz248.054","title":"A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prednisone; Abiraterone; Prostate cancer; Urology; Placebo; Internal medicine; Oncology; Cancer; Pathology; Androgen deprivation therapy","score_opus":0.06863615528930514,"score_gpt":0.39325762996660624,"score_spread":0.32462147467730107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977439036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823602,0.0021088156,0.00002323726,0.00085476495,0.00027469156,0.013879178,0.000102193815,0.000030374933,0.00036657456],"genre_scores_gemma":[0.9956118,0.0014323613,0.0002829737,0.00025180317,0.000034259,0.0018200121,0.000049518887,0.000065210734,0.00045206677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583954,0.0006467834,0.0015930699,0.0007457007,0.0005627439,0.0006121853],"domain_scores_gemma":[0.9968356,0.0005551903,0.0013042764,0.0004827155,0.0005846417,0.0002375735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015574739,0.0005112473,0.0037162423,0.00049023586,0.000060782302,0.000024776575,0.00014587128,0.00016373069,0.00014155784],"category_scores_gemma":[0.00006008943,0.0003821674,0.00011461875,0.00039069596,0.00062676455,0.00033513576,0.000103874576,0.00035082528,0.0000049807118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9686092,0.0055040945,0.006231735,0.00037320677,0.0027741664,0.000035802557,0.009773592,0.0004690885,0.0013097504,0.000023752957,0.000095878306,0.004799708],"study_design_scores_gemma":[0.95582354,0.036199518,0.0020128964,0.0003140571,0.0009473424,0.00001054616,0.0012389199,0.0004778966,0.0024670123,0.000051730054,0.00013742213,0.00031910386],"about_ca_topic_score_codex":0.00072200206,"about_ca_topic_score_gemma":0.00057291234,"teacher_disagreement_score":0.030695423,"about_ca_system_score_codex":0.00014218737,"about_ca_system_score_gemma":0.0004769096,"threshold_uncertainty_score":0.999863},"labels":[],"label_agreement":null},{"id":"W2977457247","doi":"10.1093/annonc/mdz249.018","title":"Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Docetaxel; Pembrolizumab; Urothelial cancer; Oncology; Paclitaxel; Internal medicine; Chemotherapy; Cancer; Bladder cancer; Immunotherapy","score_opus":0.13291646505372293,"score_gpt":0.4271093793534019,"score_spread":0.294192914299679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977457247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97644657,0.0029178495,0.000011602605,0.007928011,0.0039337254,0.0028680274,0.00046034405,0.00006901899,0.005364873],"genre_scores_gemma":[0.9891101,0.0022466893,0.00032476409,0.0050235903,0.0012479037,0.0005480549,0.0001231145,0.000097962504,0.0012777828],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968643,0.00026761356,0.0009237704,0.0007257484,0.0005078159,0.0007107466],"domain_scores_gemma":[0.99681884,0.0011270384,0.0005064317,0.00088268815,0.00028574266,0.00037928094],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000411566,0.00046299133,0.0013458058,0.00017356934,0.000088804125,0.00002055205,0.00046880305,0.00036324328,0.0021604362],"category_scores_gemma":[0.0010149807,0.00031680835,0.00032336608,0.00052335585,0.00029215895,0.00023340088,0.00013182551,0.0005866334,0.00013192867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8451033,0.0024577095,0.010339106,0.00011582789,0.001209925,0.00009271864,0.0015525789,0.00002094164,0.0046540946,0.00034385524,0.028492786,0.10561712],"study_design_scores_gemma":[0.67006177,0.03132587,0.007885432,0.0004217448,0.0005708885,0.0000072051957,0.00033620308,0.00008733231,0.0042513534,0.0005942557,0.28398222,0.00047573654],"about_ca_topic_score_codex":0.009331503,"about_ca_topic_score_gemma":0.011364071,"teacher_disagreement_score":0.25548944,"about_ca_system_score_codex":0.0002652573,"about_ca_system_score_gemma":0.0024436158,"threshold_uncertainty_score":0.9999284},"labels":[],"label_agreement":null},{"id":"W2977464555","doi":"10.1093/annonc/mdz248.040","title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen receptor; Oncology; Internal medicine; Antiandrogen; Castration; Enzalutamide; Androgen; Urology; Cancer; Hormone","score_opus":0.05544022874472218,"score_gpt":0.3598241595572264,"score_spread":0.30438393081250426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977464555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947565,0.00029628584,0.000003153745,0.0014076466,0.0000289172,0.0022361877,0.00008591224,0.0000148446015,0.0011705032],"genre_scores_gemma":[0.9972878,0.00097532215,0.00027065675,0.00026658273,0.000015655885,0.00025896172,0.00037690788,0.000027016096,0.00052105763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985181,0.00015505028,0.0003563159,0.0003318645,0.00029150798,0.0003471807],"domain_scores_gemma":[0.99894166,0.0000921158,0.00019588952,0.00019314031,0.00048384542,0.000093369155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021333354,0.00018845809,0.0005249001,0.00030790677,0.000037146307,0.000010335281,0.000056699926,0.00008782102,0.00010725238],"category_scores_gemma":[0.000021690876,0.00012875818,0.00003595048,0.00059629633,0.00013047566,0.00019874732,0.000013553912,0.00017849679,0.000015297539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013228053,0.0010999694,0.9510194,0.00007316049,0.00046787132,0.00010903506,0.0034917665,0.00047588994,0.0025046219,0.00004904038,0.0002390852,0.027242117],"study_design_scores_gemma":[0.048199125,0.022686517,0.86807615,0.00054484425,0.00011634704,0.000031349602,0.0016876308,0.0006646524,0.055556595,0.000078550875,0.001955556,0.0004026849],"about_ca_topic_score_codex":0.0011616186,"about_ca_topic_score_gemma":0.0033164928,"teacher_disagreement_score":0.08294324,"about_ca_system_score_codex":0.00034811962,"about_ca_system_score_gemma":0.0008857195,"threshold_uncertainty_score":0.5250606},"labels":[],"label_agreement":null},{"id":"W2977494420","doi":"10.1093/annonc/mdz260.104","title":"Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Ottawa Hospital; BC Cancer Agency; Saskatchewan Cancer Agency; Mount Sinai Hospital; University of Alberta; William Osler Health System; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Oncology","score_opus":0.054708360670253926,"score_gpt":0.4109913126050792,"score_spread":0.3562829519348253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977494420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98501515,0.000421311,0.00004505895,0.011106976,0.000023583343,0.00027309812,0.000012838381,0.0000013755496,0.00310061],"genre_scores_gemma":[0.99894273,0.000040373245,0.00026848156,0.000513401,0.000013274393,0.00000644231,0.0000033563879,0.000004582028,0.00020735052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996479,0.000024424087,0.00009740124,0.00006008648,0.000074850854,0.00009533127],"domain_scores_gemma":[0.99958503,0.00014235887,0.00007854352,0.00010939856,0.00005615677,0.000028490822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010017343,0.000050605468,0.0001817368,0.000016940834,0.00001678928,0.0000017693528,0.00004116524,0.000017092023,0.000021037038],"category_scores_gemma":[0.000011853376,0.000021139056,0.000019829331,0.00006385813,0.000045987414,0.000022922713,0.0000093068165,0.00005393929,2.1228831e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067476236,0.00014363714,0.81450945,0.000050917595,0.0008859988,0.00001283638,0.011810117,0.05519514,0.00062639185,0.00036943378,0.006055571,0.10966574],"study_design_scores_gemma":[0.0032234467,0.0023009637,0.9620497,0.00008145829,0.00012649166,0.000023033359,0.002878607,0.02763116,0.00013240574,0.00030671724,0.0011757803,0.00007021877],"about_ca_topic_score_codex":0.6472733,"about_ca_topic_score_gemma":0.53688896,"teacher_disagreement_score":0.14754026,"about_ca_system_score_codex":0.00006832528,"about_ca_system_score_gemma":0.0024318993,"threshold_uncertainty_score":0.4715616},"labels":[],"label_agreement":null},{"id":"W2977496966","doi":"10.1093/annonc/mdz247.062","title":"Second-line chemotherapy (SLC) in patients with advanced biliary tract and gallbladder cancers (ABGC) prolongs survival: A retrospective population-based cohort study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Internal medicine; Population; Cohort; Gallbladder; Retrospective cohort study; Chemotherapy; Surgery; Gallbladder cancer; Gastroenterology; Oncology","score_opus":0.01893219652121399,"score_gpt":0.3144620194345833,"score_spread":0.2955298229133693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977496966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471253,0.00024993034,0.0000011534135,0.0011193437,0.00012511062,0.0024353885,0.00002395128,0.000023201834,0.0013093646],"genre_scores_gemma":[0.99846864,0.00005253818,0.0000769584,0.0010763855,0.000037393078,0.000110187495,0.000043704036,0.000030069572,0.00010411048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985378,0.00008109308,0.0003595914,0.00045632696,0.00028912522,0.00027609133],"domain_scores_gemma":[0.99898857,0.000112737536,0.00022353615,0.00027655702,0.00032135815,0.000077255376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031029168,0.00020881183,0.0008464427,0.00016915002,0.000030526367,0.0000046252035,0.00006544056,0.00010123935,0.00010568535],"category_scores_gemma":[0.000045836285,0.00016531759,0.00005893202,0.00026250284,0.000079760386,0.0000982937,0.000021273747,0.00021644683,0.000003081321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036011839,0.0012504146,0.9903738,0.000064838714,0.00027363308,0.000013622511,0.00082816463,0.000036267113,0.0000393817,0.000003759134,0.00013056124,0.0033844009],"study_design_scores_gemma":[0.012188471,0.014127898,0.9726691,0.000055197557,0.00006129374,0.0000014776734,0.0003764294,0.00002911136,0.00008888367,0.000017038508,0.00022406688,0.00016099458],"about_ca_topic_score_codex":0.0012652702,"about_ca_topic_score_gemma":0.003434013,"teacher_disagreement_score":0.017704634,"about_ca_system_score_codex":0.00020785583,"about_ca_system_score_gemma":0.00025451928,"threshold_uncertainty_score":0.6741456},"labels":[],"label_agreement":null},{"id":"W2977502194","doi":"10.1093/annonc/mdz249.002","title":"Redefining the IGCCCG classification in advanced non-seminoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Seminoma; Internal medicine; Chemotherapy","score_opus":0.07885448451687664,"score_gpt":0.3989476224176795,"score_spread":0.32009313790080285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977502194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755364,0.0008395621,0.000004529552,0.0038878697,0.00007302292,0.00026149693,0.0000024215776,0.000007542224,0.01938713],"genre_scores_gemma":[0.9985856,0.00011356034,0.00024214304,0.000738624,0.00001764044,0.000022826247,0.000015851585,0.000006137397,0.00025760874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994996,0.00002645381,0.00016101399,0.000120463636,0.00007355311,0.00011891456],"domain_scores_gemma":[0.9994712,0.00011447018,0.000108820546,0.00021337198,0.000055357228,0.00003678922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010556816,0.000054607375,0.00018067328,0.000043461703,0.000012581222,0.0000015793803,0.00004904262,0.000054106,0.00005415156],"category_scores_gemma":[0.0000908904,0.00003651492,0.000053046875,0.000096637894,0.00003246994,0.00002541736,0.000017072296,0.00006463301,0.00007372503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039442835,0.0006973398,0.71795446,0.000052861444,0.000072577895,0.000054707165,0.00032442072,0.00002490601,0.00795472,0.00133184,0.00081954914,0.2703182],"study_design_scores_gemma":[0.0015303573,0.0012703699,0.98876333,0.00006592058,0.00002892276,0.000014192018,0.00028098706,0.0002543573,0.0008313865,0.00021579317,0.0067087505,0.000035606237],"about_ca_topic_score_codex":0.000036353973,"about_ca_topic_score_gemma":0.0000085900665,"teacher_disagreement_score":0.2708089,"about_ca_system_score_codex":0.000022757933,"about_ca_system_score_gemma":0.000115572795,"threshold_uncertainty_score":0.14890352},"labels":[],"label_agreement":null},{"id":"W2977538403","doi":"10.1093/annonc/mdz247.096","title":"Impact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcopenia; Internal medicine; Proportional hazards model; Hazard ratio; Cancer; Body mass index; Oncology; Lung cancer; Confidence interval","score_opus":0.13922259280801183,"score_gpt":0.4958282313986867,"score_spread":0.35660563859067484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977538403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946802,0.0017756056,0.0000025044467,0.0015479405,0.00007516767,0.0002466935,0.00003165065,0.0000026231062,0.0016375609],"genre_scores_gemma":[0.99849415,0.0006980197,0.00035168702,0.00034714382,0.000015960859,0.0000037559155,0.000004324097,0.000005174381,0.00007978487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992155,0.00009923643,0.0003480039,0.00009662414,0.00009560254,0.00014507405],"domain_scores_gemma":[0.99934024,0.00016123857,0.00018397949,0.0001013752,0.00013901886,0.000074128766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045311332,0.000058570986,0.0005897315,0.00013814519,0.0000061196783,5.6722183e-7,0.00003909901,0.000050692386,0.00040305892],"category_scores_gemma":[0.000045488978,0.000048839614,0.000058885533,0.0001225859,0.00007942441,0.00003270881,0.000022530832,0.000105821,0.0000025660108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011335778,0.00052804337,0.97054315,0.0009276455,0.00012557974,0.000018644909,0.0004507437,0.0000100174975,0.0115517825,0.000360997,0.0006451782,0.013704657],"study_design_scores_gemma":[0.0030106597,0.0031577274,0.98858523,0.00017556787,0.00003554595,0.000012402052,0.000051022886,0.00007290559,0.004180435,0.00025203198,0.00042985758,0.00003659568],"about_ca_topic_score_codex":0.0019492888,"about_ca_topic_score_gemma":0.00027263115,"teacher_disagreement_score":0.018042114,"about_ca_system_score_codex":0.000029722982,"about_ca_system_score_gemma":0.00031996507,"threshold_uncertainty_score":0.44132125},"labels":[],"label_agreement":null},{"id":"W2977560536","doi":"10.1093/annonc/mdz265.037","title":"Patients and physicians’ satisfaction with telemedicine (TM) in cancer care and factors that correlate with a positive patient’s experience","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Telemedicine; Patient satisfaction; Family medicine; Cancer; Internal medicine; Health care; Nursing","score_opus":0.03858488257976501,"score_gpt":0.3710385784277456,"score_spread":0.3324536958479806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977560536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997449,0.0003309692,0.000006493669,0.0009047122,0.000082434744,0.0008454102,0.000023569686,0.000008981439,0.00034844203],"genre_scores_gemma":[0.9976261,0.00042650587,0.00010148533,0.001709979,0.000015221447,0.00004066689,0.000056761317,0.000012248258,0.000010984154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990832,0.0000396886,0.00022308354,0.00023033337,0.00020712934,0.00021654251],"domain_scores_gemma":[0.9993207,0.000086508364,0.00023154273,0.00008541202,0.00019104415,0.00008480412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004198508,0.00013053356,0.00037603342,0.00012999088,0.00003001661,0.0000023190776,0.000018119094,0.000060989107,0.000038741546],"category_scores_gemma":[0.000013010784,0.00008821529,0.000010965923,0.00014596034,0.00012594569,0.00012989904,0.000015909416,0.00013589226,4.7664395e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007351564,0.00006613186,0.8123252,0.00010192471,0.000029702414,0.000010768128,0.022623882,0.0000015398282,0.00012284743,0.0000060810567,0.000067756155,0.163909],"study_design_scores_gemma":[0.0045194896,0.019987004,0.9484358,0.0003067744,0.000041856714,0.000012718699,0.024568183,0.000010465494,0.0013346695,0.0000036934066,0.0006939322,0.00008542987],"about_ca_topic_score_codex":0.004407758,"about_ca_topic_score_gemma":0.0028486568,"teacher_disagreement_score":0.16382357,"about_ca_system_score_codex":0.000055806548,"about_ca_system_score_gemma":0.00009793063,"threshold_uncertainty_score":0.66632414},"labels":[],"label_agreement":null},{"id":"W2977571468","doi":"10.1016/j.annonc.2019.12.006","title":"Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"Cilag; Genentech; Servier; Eisai; Ipsen; BeiGene; Baxalta; Array BioPharma; Halozyme; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Novartis Farmacéutica; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche; Chugai Pharmaceutical; Roche","keywords":"Bevacizumab; Medicine; Oxaliplatin; Internal medicine; Interquartile range; Colorectal cancer; Hazard ratio; Fluorouracil; Chemotherapy; Gastroenterology; Surgery; Oncology; Confidence interval; Cancer","score_opus":0.1335172886597523,"score_gpt":0.4333137783944712,"score_spread":0.29979648973471895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977571468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566345,0.0033521848,0.000001812653,0.034761224,0.00020900139,0.0020103252,0.0011390541,0.000031722742,0.0018601442],"genre_scores_gemma":[0.9943913,0.0019470362,0.0000173217,0.002700552,0.00015951054,0.0002533615,0.0002848794,0.00002125128,0.00022478103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779767,0.00036723542,0.00073085626,0.00044452562,0.0003594769,0.00030022906],"domain_scores_gemma":[0.99785584,0.00083048566,0.00046028532,0.00046709052,0.00019836647,0.00018792317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023231671,0.00024887765,0.0010002634,0.00002666824,0.000088095156,0.0000058300316,0.00024548869,0.000117364296,0.0004877623],"category_scores_gemma":[0.00014775617,0.0001266545,0.00020521371,0.00025880805,0.00023605126,0.000037842296,0.00009041639,0.00015357899,0.000025149193],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17687465,0.025323475,0.0077544507,0.000020225629,0.004970417,0.0009712537,0.027476855,0.000019724957,0.0142906895,0.000035606627,0.08930886,0.6529538],"study_design_scores_gemma":[0.1306998,0.23084088,0.026336944,0.000076655306,0.0020143045,0.000035251614,0.0051839906,0.00033296805,0.044638734,0.00009727484,0.5594246,0.00031864978],"about_ca_topic_score_codex":0.010237897,"about_ca_topic_score_gemma":0.0013935644,"teacher_disagreement_score":0.65263516,"about_ca_system_score_codex":0.0001938801,"about_ca_system_score_gemma":0.00033424544,"threshold_uncertainty_score":0.99635303},"labels":[],"label_agreement":null},{"id":"W2977581260","doi":"10.1093/annonc/mdz272.014","title":"Unmet needs in oncology research related to radiological response evaluation: A multi-center survey in three European countries","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Family medicine; Radiological weapon; Inclusion (mineral); Clinical trial; Oncology; Quarter (Canadian coin); Internal medicine; Radiology","score_opus":0.32607192902733756,"score_gpt":0.5695153433076221,"score_spread":0.24344341428028454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977581260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97150457,0.0011429065,0.00004160128,0.016044326,0.0005674864,0.0014753073,0.000017253748,0.000020722273,0.009185811],"genre_scores_gemma":[0.9922883,0.00088004576,0.0012553453,0.0044866046,0.00007196782,0.00006419701,0.000038456234,0.000027219789,0.00088789774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98697114,0.010679608,0.0008635795,0.00045443678,0.00039101977,0.00064023957],"domain_scores_gemma":[0.9929423,0.0055832914,0.00017427266,0.00046026966,0.0006897776,0.0001501069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027486898,0.0001795822,0.0009448423,0.0010930012,0.000047020494,0.000003925293,0.0003208235,0.0005442565,0.00067174033],"category_scores_gemma":[0.004870847,0.0001486099,0.00007581258,0.0012488948,0.00064003567,0.00008376429,0.00013415904,0.0009888903,0.00032817308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045533765,0.00296443,0.9044141,0.000026213978,0.00011177504,0.0006095768,0.0035618332,0.00045047203,0.0023394919,0.00051673315,0.0053732493,0.034098353],"study_design_scores_gemma":[0.013319554,0.015726965,0.81600934,0.000083382714,0.0000076872075,0.00015640093,0.00037719944,0.00029181532,0.00008039943,0.000407296,0.15340228,0.00013766212],"about_ca_topic_score_codex":0.00008659334,"about_ca_topic_score_gemma":0.0013121169,"teacher_disagreement_score":0.14802903,"about_ca_system_score_codex":0.0006352942,"about_ca_system_score_gemma":0.0011243016,"threshold_uncertainty_score":0.9526465},"labels":[],"label_agreement":null},{"id":"W2977585670","doi":"10.1093/annonc/mdz247.028","title":"Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FOLFIRINOX; Gemcitabine; Medicine; Paclitaxel; Oncology; Pancreatic cancer; Internal medicine; Cancer; Nab-paclitaxel; First line; Irinotecan","score_opus":0.07665398460389596,"score_gpt":0.4019257701704444,"score_spread":0.32527178556654845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977585670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994799,0.0006651794,0.000007957235,0.0018924774,0.000105940955,0.00078106136,0.00007056494,0.0000073660785,0.0016704077],"genre_scores_gemma":[0.99710995,0.0006774728,0.0014916955,0.00030424536,0.00001554408,0.000086630185,0.00003984107,0.0000118536245,0.0002627832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985119,0.000058521982,0.0004381276,0.0002917146,0.00026716007,0.00043257594],"domain_scores_gemma":[0.99842536,0.0004847833,0.00017343933,0.0002570621,0.00040384347,0.00025553265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021760241,0.00017290899,0.0009943972,0.00028268143,0.000051772935,0.0000023996354,0.000118309494,0.00015746856,0.00023431102],"category_scores_gemma":[0.0005046947,0.00013046007,0.000051936047,0.00023467204,0.00045953784,0.000116286144,0.00004997236,0.0001737473,0.000007855105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002724999,0.0005254286,0.98981583,0.00013789836,0.00019181364,0.000025213083,0.0006502239,0.000039843602,0.000088543144,0.00016308854,0.000042319123,0.0055947774],"study_design_scores_gemma":[0.014590105,0.005969693,0.9771353,0.00013991402,0.000066593995,0.0000035845214,0.0002667219,0.00031814323,0.00013509266,0.000017934779,0.0012409103,0.00011602267],"about_ca_topic_score_codex":0.025700971,"about_ca_topic_score_gemma":0.11379049,"teacher_disagreement_score":0.08808952,"about_ca_system_score_codex":0.00018382899,"about_ca_system_score_gemma":0.0010012479,"threshold_uncertainty_score":0.980787},"labels":[],"label_agreement":null},{"id":"W2977616112","doi":"10.1093/annonc/mdz265.020","title":"Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health; BC Cancer Agency","funders":"","keywords":"Medicine; Rivaroxaban; Anticoagulant; Internal medicine; Vitamin K antagonist; Venous thromboembolism; Thrombosis; Low molecular weight heparin; Patient satisfaction; Warfarin; Surgery","score_opus":0.037713926547842135,"score_gpt":0.3478385798149994,"score_spread":0.31012465326715727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977616112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933758,0.000076725795,0.000012909147,0.002341924,0.00016181469,0.0033694522,0.000042446925,0.000012760329,0.0006061659],"genre_scores_gemma":[0.9981495,0.00012615843,0.000088158944,0.0011607886,0.000016750346,0.00035540777,0.000027951082,0.00002852905,0.00004676413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986621,0.000047787053,0.00041335015,0.00027192023,0.0002700277,0.00033481765],"domain_scores_gemma":[0.9983886,0.00034218567,0.00048781483,0.0003238523,0.00038569164,0.00007188711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013625286,0.00019528056,0.001182986,0.00014695662,0.00004100843,0.000003839804,0.0000855518,0.000085150736,0.000039372582],"category_scores_gemma":[0.00006744589,0.000107040905,0.00010493601,0.000220011,0.000045544042,0.00005217785,0.000027023645,0.00006983052,0.0000017455491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002507863,0.01595417,0.79418033,0.00006610566,0.0040115453,0.000013196857,0.01227603,0.00060841965,0.0001336135,0.00013122207,0.00049270334,0.16962482],"study_design_scores_gemma":[0.0063672126,0.03418263,0.9539662,0.00017978223,0.000451631,4.4774748e-7,0.000592144,0.000015851308,0.0013011446,0.000041255655,0.002783048,0.00011867506],"about_ca_topic_score_codex":0.0016954215,"about_ca_topic_score_gemma":0.0013325516,"teacher_disagreement_score":0.16950615,"about_ca_system_score_codex":0.0001915178,"about_ca_system_score_gemma":0.00019930056,"threshold_uncertainty_score":0.43650013},"labels":[],"label_agreement":null},{"id":"W2977617488","doi":"10.1093/annonc/mdz246.008","title":"Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Oncology; Internal medicine; Colorectal cancer; Cohort; Cancer; Epidermal growth factor receptor; Gene signature; Clinical trial; Gene expression; Gene","score_opus":0.04000810584203818,"score_gpt":0.3426037506149242,"score_spread":0.30259564477288603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977617488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625,0.00053488114,4.2529527e-7,0.0019287176,0.000056394612,0.0005814665,0.00019885704,0.000010302638,0.00043897485],"genre_scores_gemma":[0.99821854,0.0013577093,0.000029351959,0.00022889758,0.000020755226,0.00002356282,0.000045498724,0.000012960503,0.00006270527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990788,0.000069323745,0.00028046395,0.00019245049,0.0001756595,0.00020327714],"domain_scores_gemma":[0.9991041,0.00026214294,0.00025394058,0.000052587027,0.0002826928,0.00004454519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091768095,0.00014812831,0.0008401057,0.000106527106,0.000023812749,0.0000024718324,0.00003667249,0.000171065,0.00008636685],"category_scores_gemma":[0.000040847954,0.00009880704,0.000066066605,0.00015661729,0.00004929643,0.00006499886,0.000013128917,0.00013002742,7.5978625e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012841615,0.00034005856,0.9744032,0.000048673515,0.0009452992,0.0000021930323,0.001152829,0.0000012208287,0.002279321,0.000002562122,0.00013645367,0.019404037],"study_design_scores_gemma":[0.0052155224,0.006661634,0.9732543,0.00005075842,0.000077756944,2.688282e-7,0.00008573552,0.0000015477175,0.014133704,0.0000053302365,0.00042655715,0.000086891065],"about_ca_topic_score_codex":0.00073116616,"about_ca_topic_score_gemma":0.00028738577,"teacher_disagreement_score":0.019317146,"about_ca_system_score_codex":0.00012622948,"about_ca_system_score_gemma":0.00008160894,"threshold_uncertainty_score":0.4029234},"labels":[],"label_agreement":null},{"id":"W2977635965","doi":"10.1093/annonc/mdz262","title":"5-year adherence to adjuvant endocrine therapy among women with breast cancer: A nationwide study using group-based trajectory modeling","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Quebec Population Health Research Network","funders":"","keywords":"Medicine; Breast cancer; Cancer; Ambulatory; Hormonal therapy; Logistic regression; Adjuvant therapy; Internal medicine; Demography","score_opus":0.1250717736840475,"score_gpt":0.4038605393597918,"score_spread":0.2787887656757443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977635965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962868,0.000115816394,0.000653518,0.0009800557,0.00009258971,0.0010834422,0.000010144019,0.000031561958,0.0007460504],"genre_scores_gemma":[0.9963655,0.00007043875,0.00067628233,0.0023262692,0.000072204624,0.00023872074,0.0000040040413,0.000018791543,0.0002277795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998612,0.00008713409,0.0003358799,0.00031840955,0.00033637846,0.00031018854],"domain_scores_gemma":[0.99882734,0.000057647965,0.00018270678,0.00031769465,0.00042148048,0.00019311292],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030499406,0.00014537865,0.00047896116,0.0001531464,0.00003696772,0.0000058019828,0.0001587703,0.00005034314,0.0013980563],"category_scores_gemma":[0.00002136686,0.00011363105,0.000037173366,0.00031809954,0.000057079083,0.00008786383,0.000020295904,0.00015839591,0.00005404513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057188636,0.002554136,0.8897998,0.00012362062,0.00029375043,0.000052271025,0.0027022234,0.009920681,0.015678182,0.00003554268,0.00036785338,0.07275312],"study_design_scores_gemma":[0.01705286,0.037394736,0.8833651,0.0008256494,0.000079477715,0.00006600099,0.009303247,0.04749726,0.0020663794,0.0000691656,0.0017282143,0.0005519252],"about_ca_topic_score_codex":0.0008905306,"about_ca_topic_score_gemma":0.00012138442,"teacher_disagreement_score":0.072201185,"about_ca_system_score_codex":0.000084668405,"about_ca_system_score_gemma":0.00059535756,"threshold_uncertainty_score":0.9995148},"labels":[],"label_agreement":null},{"id":"W2977678215","doi":"10.1093/annonc/mdz260.116","title":"Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Clinical endpoint; Lung cancer; Adverse effect; Oncology; Internal medicine; Radiology; Randomized controlled trial; Radiation therapy","score_opus":0.07650763567573134,"score_gpt":0.4033783991091861,"score_spread":0.3268707634334548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977678215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96888375,0.0011823205,0.00004278859,0.025746165,0.00026538718,0.0014257593,0.00017486158,0.00001171916,0.002267243],"genre_scores_gemma":[0.9943364,0.00008798738,0.00021368996,0.0043656533,0.00016870785,0.00031181058,0.00026965814,0.000013609701,0.00023246791],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985112,0.00025379178,0.00051375,0.00027496624,0.00016594343,0.00028037364],"domain_scores_gemma":[0.99481696,0.004523016,0.0002326986,0.0002905178,0.00007034603,0.00006648681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088270905,0.00016059725,0.00081479416,0.00011946729,0.000036220088,0.000010296274,0.00011880832,0.00017317693,0.000613042],"category_scores_gemma":[0.00066676165,0.00010657509,0.0003332148,0.00014956809,0.00003535714,0.000054011474,0.000020954723,0.00011696606,0.000011344953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043979336,0.008430597,0.0026777121,0.000044113003,0.00097402366,0.00026503406,0.0012413572,0.0000063283933,0.022373468,0.00034064252,0.7739198,0.14574756],"study_design_scores_gemma":[0.49909917,0.043915093,0.0014974225,0.00021179189,0.0010133088,0.00003582776,0.0019367308,0.0002682731,0.122295186,0.0008570065,0.3284415,0.0004286954],"about_ca_topic_score_codex":0.0007346176,"about_ca_topic_score_gemma":0.00014125615,"teacher_disagreement_score":0.45511982,"about_ca_system_score_codex":0.000024344923,"about_ca_system_score_gemma":0.00012919992,"threshold_uncertainty_score":0.67123795},"labels":[],"label_agreement":null},{"id":"W2977680118","doi":"10.1093/annonc/mdz253.023","title":"A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lag; Phase (matter); Internal medicine; Oncology","score_opus":0.0580734026653386,"score_gpt":0.4154281216832031,"score_spread":0.3573547190178645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977680118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620724,0.00044932886,0.000009290908,0.0011060267,0.00016023777,0.0014633067,0.000020175441,0.000025530386,0.00055885507],"genre_scores_gemma":[0.99823874,0.0009826932,0.00008317052,0.00039578276,0.000031189767,0.000022076118,0.00006331365,0.00003182242,0.00015122921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979794,0.00023152921,0.0007019137,0.00042965225,0.00031934076,0.00033818537],"domain_scores_gemma":[0.99857855,0.00016028257,0.00044331868,0.00044806258,0.000268538,0.000101244084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008350589,0.00023505824,0.0011499369,0.00044707645,0.000040012386,0.000010001834,0.00015639774,0.00018789362,0.00018229414],"category_scores_gemma":[0.000044719316,0.00017714134,0.000068006215,0.0005739112,0.00023542545,0.00021750588,0.000053001157,0.00020342672,0.0000043934356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039451838,0.04062281,0.4839122,0.0006558012,0.0010416233,0.0004749756,0.00415679,0.000031096984,0.39079797,0.00007742459,0.0005243182,0.038253147],"study_design_scores_gemma":[0.080247365,0.1352549,0.747572,0.0005006012,0.00023152797,0.00026168433,0.0056749424,0.00049626245,0.027227178,0.000021571572,0.0021291394,0.00038281557],"about_ca_topic_score_codex":0.00081424974,"about_ca_topic_score_gemma":0.00037774778,"teacher_disagreement_score":0.36357078,"about_ca_system_score_codex":0.000038457707,"about_ca_system_score_gemma":0.0002977931,"threshold_uncertainty_score":0.72236145},"labels":[],"label_agreement":null},{"id":"W2977733630","doi":"10.1093/annonc/mdz269.016","title":"The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Aptamer; Glioblastoma; Medicine; Stem cell; Cancer research; Computational biology; RNA; Molecular biology; Cell biology; Genetics; Biology; Gene","score_opus":0.014275415459555003,"score_gpt":0.27221556944117686,"score_spread":0.25794015398162184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977733630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964308,0.0024428226,0.00004992853,0.00026469678,0.00010036087,0.00020544777,0.00004680478,0.0000028447882,0.00045626983],"genre_scores_gemma":[0.9986288,0.0007241192,0.000039226627,0.000116380485,0.000034037883,0.000005435818,0.00001197706,0.000013705266,0.0004263466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991245,0.00012601551,0.00022932426,0.00022593029,0.00009760821,0.0001966041],"domain_scores_gemma":[0.99927574,0.000079413665,0.00030834362,0.00017461856,0.0001208022,0.000041060513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047063,0.00010891197,0.00019519904,0.000030881198,0.00004206533,0.000010140656,0.00012302103,0.00014481672,0.0000060422717],"category_scores_gemma":[0.000023901193,0.000086466796,0.00007544266,0.00006786031,0.00018236805,0.000010308551,0.00010641348,0.00005887325,0.0000028316008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029815157,0.00005527284,0.0017341048,0.00003055396,0.00009126686,5.3938413e-7,0.000047812377,0.000019579897,0.9823113,0.000034766315,0.00913893,0.0062377295],"study_design_scores_gemma":[0.00037874712,0.0010409986,0.0011946498,0.000012330677,0.000013361188,0.0000028444852,0.00021005118,0.000024690262,0.9692034,0.000035648878,0.02779447,0.0000887984],"about_ca_topic_score_codex":0.000013691964,"about_ca_topic_score_gemma":0.000010493002,"teacher_disagreement_score":0.01865554,"about_ca_system_score_codex":0.000009753646,"about_ca_system_score_gemma":0.00009885171,"threshold_uncertainty_score":0.35260135},"labels":[],"label_agreement":null},{"id":"W2977736422","doi":"10.1093/annonc/mdz265.075","title":"Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Pediatrics; Pregnancy; Cohort; Neuropsychology; Bayley Scales of Infant Development; Cognition; Internal medicine; Psychiatry; Psychomotor learning","score_opus":0.04446969433055233,"score_gpt":0.3531104026530721,"score_spread":0.3086407083225198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977736422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279106,0.004525723,9.325704e-8,0.0011082612,0.00013906127,0.00025683455,0.000017743088,0.000008445112,0.0011527741],"genre_scores_gemma":[0.98765653,0.010229347,0.000052486885,0.0002215459,0.000049620812,0.00023954116,0.0000031160623,0.000010830647,0.0015369633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943,0.000009886387,0.00015724348,0.00015837331,0.00007790288,0.00016657898],"domain_scores_gemma":[0.999717,0.000014456481,0.000065632834,0.000100087775,0.000026034575,0.00007677541],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000019390547,0.00008647821,0.0002629409,0.000051855728,0.000018396937,0.0000024705587,0.000023761859,0.000063360174,0.0011920028],"category_scores_gemma":[0.0000022718532,0.00006845752,0.000044005006,0.00002985805,0.00003093361,0.000025230336,0.000042625725,0.000039771217,0.000029593577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034662354,0.00011680827,0.8678576,0.00006700616,0.00011881447,0.00007156218,0.00080585864,0.0000010098211,0.00014562542,0.0000021879744,0.000113685805,0.13035323],"study_design_scores_gemma":[0.0013160704,0.00072265154,0.89193726,0.0003529794,0.000025735131,0.00002973616,0.000014603027,5.549059e-7,0.020277381,0.000001708868,0.085260466,0.000060868395],"about_ca_topic_score_codex":0.0004753284,"about_ca_topic_score_gemma":0.000487527,"teacher_disagreement_score":0.13029237,"about_ca_system_score_codex":0.0001446483,"about_ca_system_score_gemma":0.000073038245,"threshold_uncertainty_score":0.99972105},"labels":[],"label_agreement":null},{"id":"W2977739337","doi":"10.1093/annonc/mdz244.036","title":"Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Carboplatin; Tolerability; Internal medicine; Chemotherapy; Gemcitabine; Pemetrexed; Vinorelbine; Oncology; Cisplatin; Adverse effect; Cancer; Immunotherapy; Pembrolizumab; Ipilimumab","score_opus":0.16481319092961788,"score_gpt":0.4216233194782329,"score_spread":0.256810128548615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977739337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998165,0.0009214795,0.0000011236959,0.0064157974,0.0002089181,0.0015375661,0.00021640904,0.0000063060347,0.0007107774],"genre_scores_gemma":[0.9971474,0.0008910516,0.000025695226,0.0015070532,0.00005569068,0.000027484912,0.0002674639,0.00001821122,0.000059971513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981681,0.00047828682,0.00059893855,0.00029690505,0.00024950132,0.00020827889],"domain_scores_gemma":[0.9985229,0.00040143923,0.0004097388,0.00045769484,0.00014314865,0.000065071115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019268846,0.0001456594,0.000785327,0.00014369005,0.000036661826,0.000009646836,0.00026020617,0.00011164651,0.00071154296],"category_scores_gemma":[0.000048477177,0.00009555621,0.00003365187,0.00033625466,0.00012707895,0.00008800408,0.00003918147,0.00017318458,0.0000014701426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06737325,0.0036426962,0.5954252,0.00008575644,0.003236641,0.00004403206,0.008083035,0.000027231396,0.03429279,0.00005168247,0.011653429,0.27608427],"study_design_scores_gemma":[0.07754154,0.010635067,0.87879455,0.00014788822,0.00024145255,0.0000071894824,0.0025114089,0.00039647103,0.0026259047,0.000043885157,0.026859686,0.00019497311],"about_ca_topic_score_codex":0.4160529,"about_ca_topic_score_gemma":0.6984433,"teacher_disagreement_score":0.28336936,"about_ca_system_score_codex":0.00008846225,"about_ca_system_score_gemma":0.000626698,"threshold_uncertainty_score":0.7790896},"labels":[],"label_agreement":null},{"id":"W2977768268","doi":"10.1093/annonc/mdz276.026","title":"A modified Edmonton symptom assessment scale for assessing symptoms in one day chemotherapy clinic","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nausea; Regimen; Chemotherapy; Chemotherapy regimen; Internal medicine; Physical therapy; Cancer; Adverse effect; Breast cancer","score_opus":0.0896065430303352,"score_gpt":0.4374355523658554,"score_spread":0.3478290093355202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977768268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508801,0.00029730858,0.00050704967,0.0057319994,0.000541744,0.00083736796,0.000011275279,0.000027088443,0.041166082],"genre_scores_gemma":[0.9937218,0.00026532213,0.00056942535,0.0036539913,0.00018011814,0.000097332995,0.00003725803,0.000029414157,0.0014453481],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984953,0.000114881645,0.0004992059,0.00033137033,0.0002103281,0.0003489105],"domain_scores_gemma":[0.9986811,0.00043612003,0.00022758536,0.0003424391,0.00021621383,0.000096528536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010358944,0.00014594111,0.0007695246,0.00016086982,0.000021391772,0.000010973728,0.00012280335,0.00025847813,0.00028531894],"category_scores_gemma":[0.000039531173,0.00014025859,0.00019149765,0.0001858897,0.000064055675,0.000098496035,0.000030441599,0.00021255421,0.000013301144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028070034,0.004073549,0.4074048,0.0009664601,0.0004922164,0.00002059321,0.0039683767,0.00006407261,0.03411888,0.001121823,0.004980486,0.5399817],"study_design_scores_gemma":[0.01715289,0.010019842,0.8832394,0.00079154235,0.00014769842,0.000014574079,0.0014844199,0.0019854354,0.009282721,0.0015856018,0.07380752,0.00048834225],"about_ca_topic_score_codex":0.00033181376,"about_ca_topic_score_gemma":0.0005361283,"teacher_disagreement_score":0.5394934,"about_ca_system_score_codex":0.0001318429,"about_ca_system_score_gemma":0.0005151369,"threshold_uncertainty_score":0.5719579},"labels":[],"label_agreement":null},{"id":"W2977799542","doi":"10.1093/annonc/mdz250.036","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Bevacizumab; Carboplatin; Ovarian cancer; Folate receptor; Antibody-drug conjugate; Conjugate; Oncology; Internal medicine; Phases of clinical research; Antibody; Cancer research; Cancer; Chemotherapy; Monoclonal antibody; Immunology; Cisplatin; Cancer cell","score_opus":0.03156606835158248,"score_gpt":0.37021421649439595,"score_spread":0.33864814814281347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977799542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937049,0.00031333207,0.000002470693,0.0029343707,0.00015272856,0.0020437054,0.0003389098,0.000016399503,0.000493192],"genre_scores_gemma":[0.9983202,0.00019955063,0.00041778374,0.00037681003,0.000045136912,0.000101436526,0.00047973986,0.00003399948,0.000025342624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978403,0.00024325964,0.00068152585,0.0005877037,0.0002997751,0.00034747005],"domain_scores_gemma":[0.99864215,0.00024164203,0.00044314665,0.00025799443,0.0002996368,0.00011541249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045392735,0.0002666835,0.00088911824,0.0002618356,0.00003551198,0.000016175674,0.00007278381,0.00012557198,0.00007783244],"category_scores_gemma":[0.00006998409,0.00020796653,0.000034463625,0.0003543926,0.00008142124,0.00017454886,0.000041683605,0.0002608098,0.0000049517876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032739516,0.012861669,0.90650904,0.000060978506,0.00046424122,0.0002761048,0.0074770018,0.000035062967,0.00038163338,0.000029957058,0.0002862809,0.038878493],"study_design_scores_gemma":[0.18200247,0.033560436,0.7798715,0.0007180741,0.00017510379,0.0000032924793,0.0008804342,0.00033951542,0.0013822728,0.000043443182,0.0007486275,0.0002747786],"about_ca_topic_score_codex":0.014800492,"about_ca_topic_score_gemma":0.0076294355,"teacher_disagreement_score":0.14926295,"about_ca_system_score_codex":0.00018135051,"about_ca_system_score_gemma":0.00040167777,"threshold_uncertainty_score":0.99176},"labels":[],"label_agreement":null},{"id":"W2977827677","doi":"10.1093/annonc/mdz244.065","title":"EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Prostate; Androgen; Cancer research; Cancer; Urology; Hormone","score_opus":0.0977279940487419,"score_gpt":0.4305434687220062,"score_spread":0.33281547467326433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977827677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97007674,0.005487258,0.000006788206,0.021143049,0.0002460909,0.0021394067,0.00043884295,0.000007700954,0.00045409496],"genre_scores_gemma":[0.9696661,0.016555807,0.0009712105,0.0010414367,0.00039702878,0.001013014,0.00007909947,0.000039071874,0.010237182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989497,0.000029173594,0.00030458,0.00022186602,0.00017618215,0.00031847693],"domain_scores_gemma":[0.99893695,0.00024422488,0.00017695341,0.00024953764,0.00030564534,0.00008667743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020814988,0.00013624715,0.0004892572,0.00005886607,0.00004264491,0.000003562807,0.000084389576,0.00010487578,0.0003496473],"category_scores_gemma":[0.000014656943,0.00007577695,0.00019696653,0.00012333134,0.0001870751,0.000036509904,0.000021770558,0.000063732245,0.000015895355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029185966,0.0071794474,0.09330225,0.0009226884,0.002967586,0.000044445493,0.016858451,0.000009854824,0.12265595,0.00032077503,0.046310533,0.68024206],"study_design_scores_gemma":[0.011099842,0.023723844,0.0030431096,0.00011528922,0.00013881229,0.00001692007,0.0005717671,0.000039669558,0.2638674,0.00012949161,0.69715667,0.00009720878],"about_ca_topic_score_codex":0.00020740415,"about_ca_topic_score_gemma":0.000035846708,"teacher_disagreement_score":0.68014485,"about_ca_system_score_codex":0.0001221077,"about_ca_system_score_gemma":0.00053488463,"threshold_uncertainty_score":0.38283926},"labels":[],"label_agreement":null},{"id":"W2977927250","doi":"10.1093/annonc/mdz283.051","title":"A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Drug; Oncology; Prospective cohort study; Clinical trial; Drug holiday; Surgery; Pharmacology; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.054878589234309744,"score_gpt":0.3729655393967458,"score_spread":0.31808695016243604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977927250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052775,0.00088577427,0.000007777031,0.0008047033,0.0001986612,0.0071494295,0.0001036756,0.000011504945,0.00031075414],"genre_scores_gemma":[0.99735934,0.0002507237,0.0010602252,0.00037502684,0.000019246763,0.0006839318,0.0001143165,0.000029885092,0.00010731695],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998194,0.00020403368,0.0005893004,0.00036739555,0.00033446343,0.0003108307],"domain_scores_gemma":[0.99768555,0.00087250344,0.0005574989,0.00024622638,0.00054446294,0.0000937504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023813553,0.00024343708,0.0011136283,0.00020462711,0.000027442089,0.0000038678804,0.00008764265,0.00008235664,0.00026593122],"category_scores_gemma":[0.0002234976,0.00015549334,0.00016644926,0.00024353873,0.00017295619,0.0000820883,0.0000288052,0.0001334761,0.000013499228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47340718,0.021530233,0.25251272,0.00013560001,0.001533914,0.000044740187,0.012182838,0.0000065448594,0.00021920505,0.0002674416,0.00096648996,0.23719308],"study_design_scores_gemma":[0.45900103,0.29102916,0.21052873,0.0005343089,0.00043308482,0.0000123209975,0.0025763253,0.000034327484,0.01945736,0.0007542418,0.015237955,0.0004011524],"about_ca_topic_score_codex":0.00017432976,"about_ca_topic_score_gemma":0.0000967526,"teacher_disagreement_score":0.26949894,"about_ca_system_score_codex":0.00010324802,"about_ca_system_score_gemma":0.00039277854,"threshold_uncertainty_score":0.63408345},"labels":[],"label_agreement":null},{"id":"W2977936382","doi":"10.1093/annonc/mdz394.007","title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Hormone receptor; Cancer; Breast cancer; Gynecology","score_opus":0.02761816145389646,"score_gpt":0.3378950834321779,"score_spread":0.31027692197828144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977936382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903712,0.00015466464,0.000013097653,0.0014226389,0.00017328534,0.0026282095,0.003786593,0.000031757463,0.0014185115],"genre_scores_gemma":[0.99846214,0.00016514034,0.00029247187,0.00028094134,0.00012225968,0.00009709583,0.00021822889,0.000073196534,0.00028854268],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964244,0.00041996787,0.0011316751,0.0006444446,0.00078155764,0.0005979488],"domain_scores_gemma":[0.9950817,0.000482186,0.0018614336,0.00056864414,0.0018029959,0.00020303129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002700688,0.0005145223,0.0017202827,0.00016197196,0.00009242746,0.0000048668867,0.00031427667,0.00023722708,0.0001778364],"category_scores_gemma":[0.00008384008,0.00032502593,0.00020037613,0.00043453055,0.0009177456,0.00033576158,0.000081326485,0.00042325392,0.00000279693],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83544904,0.006105245,0.014832257,0.00013524047,0.0022544647,0.000025972495,0.002566282,0.00012797727,0.11458172,0.00024092292,0.00012277965,0.02355808],"study_design_scores_gemma":[0.37806457,0.082518764,0.40718648,0.00054310623,0.00037397706,0.000037106176,0.00050075096,0.000009256731,0.12983832,0.000119671255,0.0003473076,0.00046067964],"about_ca_topic_score_codex":0.002292084,"about_ca_topic_score_gemma":0.00038134868,"teacher_disagreement_score":0.4573845,"about_ca_system_score_codex":0.00023940063,"about_ca_system_score_gemma":0.00062887487,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W2977939617","doi":"10.1093/annonc/mdz265.002","title":"Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Clinical trial; Common Terminology Criteria for Adverse Events; Internal medicine; Tolerability; Physical therapy","score_opus":0.9240178606030828,"score_gpt":0.7853572982876386,"score_spread":0.1386605623154442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977939617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264944,0.00002497699,0.004088794,0.00044306,0.0007861365,0.0011722636,0.00006728279,0.000009264954,0.0007587695],"genre_scores_gemma":[0.8896763,0.000088131375,0.109923564,0.00011770517,0.000083932064,0.000024976325,0.0000037851207,0.000016041797,0.00006558344],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98050755,0.005375193,0.013146839,0.0003341799,0.0003799536,0.00025630606],"domain_scores_gemma":[0.904759,0.07980958,0.0143969,0.00045968825,0.0005025024,0.00007236146],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06678187,0.00012837868,0.0027007365,0.00015787843,0.000009594802,9.579468e-7,0.00020408061,0.00027878315,0.0007745995],"category_scores_gemma":[0.2716271,0.00010933193,0.00044902027,0.00021279082,0.00017884633,0.00007757605,0.00011452434,0.00021402998,0.000008008489],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006142809,0.0115060825,0.32194176,0.002834512,0.0016574659,0.00005366541,0.0017161928,0.000036148605,0.037967872,0.107963815,0.004193136,0.50398654],"study_design_scores_gemma":[0.009428199,0.0039844303,0.03780693,0.00024222933,0.0001865883,0.0000029292673,0.001809025,0.000038093796,0.05416928,0.89201826,0.00017456072,0.00013950156],"about_ca_topic_score_codex":0.00006278848,"about_ca_topic_score_gemma":0.00005526912,"teacher_disagreement_score":0.7840544,"about_ca_system_score_codex":0.0000210489,"about_ca_system_score_gemma":0.00031008807,"threshold_uncertainty_score":0.9609445},"labels":[],"label_agreement":null},{"id":"W2977941468","doi":"10.1093/annonc/mdz253.009","title":"Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Persistence (discontinuity); Cancer research; Genetic enhancement; Immunology; Gene; Genetics; Biology","score_opus":0.058004277633815986,"score_gpt":0.3346907633724914,"score_spread":0.2766864857386754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977941468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926837,0.00067387294,0.0000024830877,0.0006338535,0.000037563328,0.00096453284,0.000028660254,0.000015043314,0.0049602673],"genre_scores_gemma":[0.997194,0.000539685,0.00068648235,0.00026043822,0.000027568582,0.000019746987,0.000025909663,0.00004317298,0.0012030065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977843,0.0003176377,0.00042973962,0.00050145993,0.0004132492,0.00055357756],"domain_scores_gemma":[0.99847794,0.00042265916,0.00022946611,0.00036557965,0.00035585772,0.00014848223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074000034,0.0002452875,0.0007201149,0.00048279678,0.000031726504,0.0000143850175,0.00016693103,0.00017023149,0.000082944076],"category_scores_gemma":[0.00006624435,0.00018642227,0.000050724404,0.00042342956,0.00023048613,0.0001400431,0.00005692351,0.00044769648,0.000005784162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06633021,0.0023501127,0.6287989,0.00013508432,0.00007112506,0.0004346372,0.006225582,0.000623736,0.29090157,0.0000016072044,0.00028579717,0.003841636],"study_design_scores_gemma":[0.021617692,0.018604059,0.68997693,0.00028821966,0.000014907772,0.000030702813,0.001717322,0.00014394736,0.26667994,0.000003885653,0.00066173304,0.00026062317],"about_ca_topic_score_codex":0.0001195421,"about_ca_topic_score_gemma":0.000034121495,"teacher_disagreement_score":0.061178062,"about_ca_system_score_codex":0.00008768683,"about_ca_system_score_gemma":0.00044062245,"threshold_uncertainty_score":0.76020795},"labels":[],"label_agreement":null},{"id":"W2977997625","doi":"10.1093/annonc/mdz240.029","title":"Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tamoxifen; Adverse effect; Breast cancer; Internal medicine; Oncology; Adjuvant therapy; Cancer; Endometrial cancer; Odds ratio; Gynecology; Surgery","score_opus":0.009490327486222212,"score_gpt":0.29232580073378156,"score_spread":0.28283547324755937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977997625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982445,0.00090261566,0.0000015127861,0.00012291063,0.000037083963,0.0003007052,0.00006203951,0.0000010860355,0.00032749845],"genre_scores_gemma":[0.9975437,0.0022578915,0.000018939236,0.00006851268,0.000015792762,0.000026429729,0.000010154605,0.000007748041,0.000050809267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912846,0.00022143063,0.00021968553,0.00014220824,0.00009458528,0.00019364845],"domain_scores_gemma":[0.999458,0.00002785212,0.00022619162,0.00018772035,0.00007742725,0.000022766368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030674116,0.00009024993,0.00023655695,0.000065058164,0.0000073909837,2.7554591e-7,0.00013841112,0.00011271975,0.000021336162],"category_scores_gemma":[0.000009753371,0.000057188165,0.000035354227,0.00012729553,0.00007495099,0.0000045741217,0.000030365956,0.00011742981,0.0000013098146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036223775,0.0005380449,0.64329594,0.000025251578,0.00014129457,0.0000088941815,0.00047675625,0.0007990239,0.3478061,0.00004317968,0.000019365461,0.003223769],"study_design_scores_gemma":[0.0025127493,0.009369991,0.9348208,0.000031252028,0.000008910359,0.000013675955,0.0003291753,0.00001585294,0.0524718,0.00003699624,0.00031646626,0.0000723466],"about_ca_topic_score_codex":0.0011787438,"about_ca_topic_score_gemma":0.00013568795,"teacher_disagreement_score":0.2953343,"about_ca_system_score_codex":0.000018052626,"about_ca_system_score_gemma":0.00014048179,"threshold_uncertainty_score":0.23320657},"labels":[],"label_agreement":null},{"id":"W2978060560","doi":"10.1093/annonc/mdz242.077","title":"CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Internal medicine; Tolerability; Taxane; Oncology; Cohort; Triple-negative breast cancer; Metastatic breast cancer; Breast cancer; Nivolumab; Cancer; Adverse effect; Immunotherapy","score_opus":0.03578482217766499,"score_gpt":0.37684929556269836,"score_spread":0.3410644733850334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978060560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919695,0.00041735725,0.0000030000942,0.0009931679,0.00014820795,0.005098204,0.0013333475,0.000011062568,0.00002609859],"genre_scores_gemma":[0.9982481,0.0001920882,0.00010089978,0.00039545592,0.000020915168,0.00079301797,0.00011001687,0.000045596385,0.00009393268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972233,0.00036839326,0.000883293,0.0005672018,0.00049045996,0.000467352],"domain_scores_gemma":[0.99759895,0.00042877003,0.00080513186,0.00022685522,0.00076719985,0.00017308458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021627531,0.0004402877,0.0015655315,0.00053436036,0.000050798702,0.000008090895,0.0001302167,0.00008269722,0.0003453647],"category_scores_gemma":[0.000031306605,0.0003018149,0.00007967979,0.00051542313,0.00022505473,0.0002305538,0.000060548973,0.000294973,0.0000010521736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05542956,0.051102743,0.83768034,0.00020312055,0.001449863,0.000026590678,0.0053025093,0.000118365126,0.00018442694,0.00000225482,0.00011608686,0.048384137],"study_design_scores_gemma":[0.19187985,0.049265526,0.7559884,0.00031070077,0.0004305681,0.0000036659412,0.0011596183,0.0004028936,0.0002766841,0.0000074078334,0.000047912756,0.00022674815],"about_ca_topic_score_codex":0.010185554,"about_ca_topic_score_gemma":0.013769176,"teacher_disagreement_score":0.13645029,"about_ca_system_score_codex":0.00037546753,"about_ca_system_score_gemma":0.000375256,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2978063795","doi":"10.1093/annonc/mdz246.030","title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Regional Municipality of Durham; University of Ottawa; Lakeridge Health","funders":"","keywords":"Medicine; Bevacizumab; Oxaliplatin; Hazard ratio; Internal medicine; Surgery; Colorectal cancer; Chemotherapy; Perforation; Clinical endpoint; Gastroenterology; Stage (stratigraphy); Randomized controlled trial; Oncology; Cancer; Confidence interval","score_opus":0.05770164256582759,"score_gpt":0.4154097621979003,"score_spread":0.3577081196320727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978063795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726323,0.004647358,0.00003057675,0.013362395,0.00029618028,0.006013201,0.0027332357,0.000017250482,0.00026752372],"genre_scores_gemma":[0.99115473,0.0017542308,0.00003519789,0.0025670938,0.0001120942,0.0016470246,0.0009927598,0.000022118324,0.0017147359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99802756,0.00028745408,0.00073255977,0.00037752138,0.00027914956,0.00029572798],"domain_scores_gemma":[0.99667567,0.0018207774,0.00068456685,0.0004593421,0.00024919506,0.00011043725],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049794425,0.00028605518,0.0022578076,0.00009482898,0.00016459428,0.000007258387,0.00015668098,0.00010292799,0.0011888926],"category_scores_gemma":[0.00011581508,0.00013641013,0.0009394737,0.0002498139,0.00029795832,0.000029009549,0.000034288703,0.0000822094,0.0000020160269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9503152,0.00511646,0.00025517753,0.000016436688,0.013538153,0.000008625039,0.0017805791,0.00010346782,0.0011695202,0.00004498278,0.004817909,0.022833519],"study_design_scores_gemma":[0.9251491,0.018113673,0.0007255982,0.000029866906,0.008451626,2.40502e-7,0.00033933012,0.004960056,0.0024446181,0.000043779306,0.039606955,0.0001351585],"about_ca_topic_score_codex":0.00657025,"about_ca_topic_score_gemma":0.0020921323,"teacher_disagreement_score":0.034789048,"about_ca_system_score_codex":0.00026160496,"about_ca_system_score_gemma":0.0006605163,"threshold_uncertainty_score":0.99972415},"labels":[],"label_agreement":null},{"id":"W2978145474","doi":"10.1093/annonc/mdz267.001","title":"Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Discontinuation; Lenvatinib; Medical prescription; Thyroid cancer; Refractory (planetary science); Internal medicine; Demographics; Retrospective cohort study; Pediatrics; Cancer; Surgery; Demography; Pharmacology","score_opus":0.02287540788313664,"score_gpt":0.3089810292607351,"score_spread":0.2861056213775985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978145474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968106,0.00018942553,2.4295792e-7,0.0003967054,0.000067782974,0.0016149686,0.00056649366,0.0000048579627,0.00034891634],"genre_scores_gemma":[0.9991,0.00035787653,0.00001852879,0.00010696855,0.0000074631516,0.00023173321,0.00012225934,0.000012184474,0.000042969084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875325,0.0000901576,0.00039706068,0.00027947073,0.0002472989,0.00023277377],"domain_scores_gemma":[0.99872357,0.000043973574,0.0004930587,0.00028369098,0.0003495013,0.000106231986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006213414,0.00017221941,0.0008012638,0.00033266845,0.000024193458,0.0000031900706,0.00005702701,0.00010725687,0.00012993635],"category_scores_gemma":[0.000014065352,0.000104909326,0.00014444986,0.00038036253,0.000100669735,0.000050648407,0.000021766598,0.00009562323,3.1959544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090146915,0.003040549,0.9699101,0.00003214239,0.0026351416,0.0000036234808,0.001819828,0.000031241107,0.00014407495,0.000022909175,0.000040635823,0.021418288],"study_design_scores_gemma":[0.004819727,0.021379637,0.9687778,0.00009528039,0.0010712751,4.3524796e-7,0.00016127179,0.000027644404,0.0032442452,0.0000036729668,0.00033808098,0.00008095392],"about_ca_topic_score_codex":0.13876687,"about_ca_topic_score_gemma":0.3518669,"teacher_disagreement_score":0.21310002,"about_ca_system_score_codex":0.0006839183,"about_ca_system_score_gemma":0.0004809661,"threshold_uncertainty_score":0.86696815},"labels":[],"label_agreement":null},{"id":"W2978152795","doi":"10.1093/annonc/mdz239.006","title":"Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Enzalutamide; Oncology; Androgen receptor; Androgen deprivation therapy; Cancer","score_opus":0.08036228356401187,"score_gpt":0.3968418177278611,"score_spread":0.3164795341638492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978152795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952836,0.0001856862,6.911298e-7,0.00056542805,0.00003789877,0.0033547077,0.00012030452,0.000004777426,0.0004469039],"genre_scores_gemma":[0.9994513,0.00008597551,0.000030435876,0.000044855362,0.0000099145,0.00009571602,0.000128999,0.000014649849,0.000138204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979027,0.0005227498,0.0003620521,0.0002266475,0.00077954715,0.00020629159],"domain_scores_gemma":[0.9973894,0.000298196,0.00043125698,0.00021064046,0.0016294539,0.00004105334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010747026,0.00012823736,0.0005268312,0.000084133615,0.00002215251,0.000003526983,0.00007009379,0.00006723888,0.000066074404],"category_scores_gemma":[0.00012993197,0.000073334224,0.00003099004,0.0002853824,0.00017873223,0.000077048426,0.000027965842,0.00013971796,0.0000019211898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018932378,0.0026735605,0.94944227,0.000033927812,0.0016732835,0.000011332304,0.0102813095,0.0023905342,0.0010182499,0.0000016514429,0.000087488355,0.013454012],"study_design_scores_gemma":[0.032440264,0.014746296,0.9460975,0.0003173483,0.0003999059,3.3367905e-7,0.0015925146,0.0004513906,0.0038716702,0.0000094112875,0.000007699685,0.00006566626],"about_ca_topic_score_codex":0.0025550758,"about_ca_topic_score_gemma":0.0050179157,"teacher_disagreement_score":0.013507884,"about_ca_system_score_codex":0.0002477302,"about_ca_system_score_gemma":0.0011302761,"threshold_uncertainty_score":0.38625273},"labels":[],"label_agreement":null},{"id":"W2978186977","doi":"10.1093/annonc/mdz240.110","title":"Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Oncology; Immunotherapy; Neoadjuvant therapy; Internal medicine; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.09962862780967344,"score_gpt":0.4323160443553067,"score_spread":0.3326874165456333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978186977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98174274,0.00180721,0.00005135664,0.0037280188,0.00029208267,0.0071856934,0.000025917396,0.000071826034,0.005095162],"genre_scores_gemma":[0.98221576,0.0036334714,0.0018950423,0.007047116,0.0001992037,0.00045790133,0.00009722696,0.0001091693,0.0043451074],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697036,0.000611189,0.00085362344,0.00058569724,0.00043291852,0.0005462217],"domain_scores_gemma":[0.9974883,0.00029320034,0.00073254615,0.0008682106,0.00043475462,0.0001829675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016319558,0.00043792307,0.0024885882,0.00020213034,0.00013733284,0.00004290787,0.0005495238,0.00028011453,0.0026522686],"category_scores_gemma":[0.000034982364,0.00023576152,0.00017466178,0.00040294518,0.00055684365,0.0003197865,0.00006146709,0.0003061319,0.000011486669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83114624,0.007539463,0.00012598306,0.000025973313,0.0019185323,0.000058674104,0.0015275541,0.0000023970301,0.029672194,0.00004832949,0.00071706675,0.12721758],"study_design_scores_gemma":[0.7059697,0.23289002,0.00010321339,0.00013093658,0.00009546967,0.00013002126,0.00026450003,0.000110633504,0.008322885,0.000030982566,0.051668502,0.0002831742],"about_ca_topic_score_codex":0.0012748912,"about_ca_topic_score_gemma":0.00030886577,"teacher_disagreement_score":0.22535056,"about_ca_system_score_codex":0.0000675742,"about_ca_system_score_gemma":0.001608408,"threshold_uncertainty_score":0.9982594},"labels":[],"label_agreement":null},{"id":"W2978209786","doi":"10.1093/annonc/mdz260.108","title":"Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Ceritinib; Alectinib; Anaplastic lymphoma kinase; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; ALK inhibitor; Surrogate endpoint; Lung cancer; Tolerability; Clinical trial; Adverse effect; Chemotherapy","score_opus":0.025899461003756574,"score_gpt":0.3862981845905549,"score_spread":0.36039872358679836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978209786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815525,0.00022822645,0.000007722279,0.00030246744,0.0002766365,0.0045281705,0.00013586547,0.000024275665,0.006341407],"genre_scores_gemma":[0.9981478,0.00007394788,0.00019620145,0.0005724033,0.000038393056,0.0004629839,0.00012276963,0.000051620063,0.00033386637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977592,0.00014172289,0.0006240809,0.00058831036,0.00039530415,0.000491353],"domain_scores_gemma":[0.99785656,0.00029698524,0.00069328205,0.00040589555,0.0005669945,0.00018030267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014888767,0.0003446934,0.0010346164,0.00031010475,0.0000625292,0.00000784545,0.00015189414,0.00014212182,0.00011491441],"category_scores_gemma":[0.000044092278,0.00027211805,0.00010342163,0.00044760297,0.00011265203,0.00013553383,0.000047635713,0.00017696182,0.000007777892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06169685,0.093074046,0.63236386,0.00070313487,0.0018089622,0.00034934844,0.018438237,0.0008078594,0.0018469207,0.00002885922,0.0008404281,0.18804151],"study_design_scores_gemma":[0.22512068,0.23634753,0.49119994,0.001622842,0.0012124274,0.000008387963,0.004055684,0.0003458881,0.038500957,0.000008426325,0.0010723418,0.0005049126],"about_ca_topic_score_codex":0.00095739606,"about_ca_topic_score_gemma":0.0009669933,"teacher_disagreement_score":0.1875366,"about_ca_system_score_codex":0.00025319742,"about_ca_system_score_gemma":0.00088854734,"threshold_uncertainty_score":0.9999731},"labels":[],"label_agreement":null},{"id":"W2978231671","doi":"10.1093/annonc/mdz247.102","title":"Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Esophagogastric junction; Interim analysis; Interim; Adenocarcinoma; Chemotherapy; Internal medicine; Gastroenterology; Oncology; General surgery; Clinical trial; Cancer","score_opus":0.06667852007434914,"score_gpt":0.4030556491079632,"score_spread":0.33637712903361405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978231671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957397,0.00060404954,0.00004616898,0.001091342,0.00008848949,0.0006309039,0.0000117864965,0.0000045232186,0.0017830469],"genre_scores_gemma":[0.99841475,0.00044933922,0.00023820694,0.00031141288,0.00003343516,0.000013303766,0.000014777418,0.000008161987,0.0005166003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875504,0.0000711913,0.00059669977,0.00022089345,0.00017168456,0.00018448343],"domain_scores_gemma":[0.9991188,0.00010395755,0.00036072874,0.00021944851,0.00014335208,0.00005373158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032545725,0.00012848075,0.0012180926,0.001116439,0.0000106762145,0.0000021494254,0.00009870454,0.00008697642,0.00048200102],"category_scores_gemma":[0.00006636956,0.00011132671,0.00020573054,0.0012085944,0.00012228466,0.000054601052,0.000076991186,0.00010509403,0.0000010269416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2182453,0.008691131,0.48568425,0.0005881497,0.0071115703,0.00010426305,0.014045458,0.00020880732,0.011761683,0.00073659536,0.0010893495,0.25173342],"study_design_scores_gemma":[0.30902946,0.09795678,0.57938594,0.000093482806,0.0016594155,0.00001536156,0.002767623,0.003084941,0.0038801816,0.000025133635,0.0019060038,0.00019565246],"about_ca_topic_score_codex":0.00019934913,"about_ca_topic_score_gemma":0.00004336901,"teacher_disagreement_score":0.25153777,"about_ca_system_score_codex":0.00005249349,"about_ca_system_score_gemma":0.00018412073,"threshold_uncertainty_score":0.52775735},"labels":[],"label_agreement":null},{"id":"W2978318234","doi":"10.1093/annonc/mdz249.001","title":"An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Urothelial cancer; Biomarker; Bladder cancer; Oncology; Targeted therapy; Cancer; Cancer research; Internal medicine; Immunotherapy; Nivolumab; Genetics","score_opus":0.07869265397895547,"score_gpt":0.38046623947386193,"score_spread":0.30177358549490646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978318234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951955,0.0002904431,0.000009297851,0.00054906984,0.000061343475,0.0018078533,0.000026890808,0.000029008834,0.0020305803],"genre_scores_gemma":[0.99883634,0.00007662025,0.0003242323,0.00029648095,0.000011581025,0.00024018178,0.000024225954,0.00002923944,0.00016107447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987177,0.00017191096,0.0003001075,0.00029590892,0.0002551919,0.00025914484],"domain_scores_gemma":[0.999297,0.00007715144,0.00015208095,0.0002173389,0.00019244273,0.00006393576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002583089,0.0001853766,0.0006070516,0.00030909106,0.000019016501,0.0000054785464,0.00008250407,0.00006550231,0.00024023544],"category_scores_gemma":[0.000009398827,0.00012267222,0.000029731125,0.00046100662,0.000084209576,0.00017456933,0.000011580547,0.00013894818,0.0000052597047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03766817,0.009040883,0.90965986,0.00005449917,0.0009696529,0.00022552708,0.0063377907,0.0000873524,0.0022861382,0.000077785335,0.000059626087,0.03353273],"study_design_scores_gemma":[0.024714446,0.042452894,0.92756593,0.0001123426,0.00011424561,0.00001474705,0.0023535874,0.0004082804,0.001698582,0.00011239731,0.00029704152,0.00015552132],"about_ca_topic_score_codex":0.005073542,"about_ca_topic_score_gemma":0.0139412,"teacher_disagreement_score":0.03341201,"about_ca_system_score_codex":0.00010903962,"about_ca_system_score_gemma":0.0005193981,"threshold_uncertainty_score":0.7779517},"labels":[],"label_agreement":null},{"id":"W2978344564","doi":"10.1093/annonc/mdz253.038","title":"Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Capecitabine; Immunogenicity; Fluorouracil; Chemotherapy; Oncology; Cisplatin; Internal medicine; Peptide vaccine; Pharmacology; Immunology; Cancer; Immune system; Antibody","score_opus":0.05704754310577133,"score_gpt":0.41517005545163704,"score_spread":0.35812251234586573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978344564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956279,0.00047716874,0.000003852664,0.0015576442,0.000023014103,0.0019045331,0.00019611862,0.000009802669,0.00020001383],"genre_scores_gemma":[0.9966833,0.0008617716,0.001224297,0.0004620539,0.000029440203,0.00003018419,0.000037512604,0.000037445865,0.0006339705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969279,0.00053745415,0.000956829,0.0006138465,0.000509007,0.00045496912],"domain_scores_gemma":[0.99668276,0.0013606508,0.00062716595,0.00040336823,0.0006957397,0.00023030612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066745555,0.00034211876,0.0014024151,0.00020949796,0.0000604102,0.000010629473,0.00014028737,0.0001357686,0.000085475906],"category_scores_gemma":[0.000118794494,0.00020696167,0.00006120557,0.0003894669,0.00029314778,0.00013450762,0.00012461931,0.00044604507,9.996191e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.569111,0.0051190257,0.3980502,0.00018453936,0.00034001624,0.00016144765,0.0008255266,0.000017615039,0.0041973116,3.9660247e-7,0.0000701747,0.021922765],"study_design_scores_gemma":[0.09418383,0.15162244,0.74949217,0.00053946127,0.00008699436,0.000065074986,0.00085939263,0.00010884189,0.0013014683,0.0000012431628,0.0015350896,0.00020396204],"about_ca_topic_score_codex":0.0007570416,"about_ca_topic_score_gemma":0.0008928736,"teacher_disagreement_score":0.4749272,"about_ca_system_score_codex":0.00005331595,"about_ca_system_score_gemma":0.000627927,"threshold_uncertainty_score":0.84396523},"labels":[],"label_agreement":null},{"id":"W2978345396","doi":"10.1093/annonc/mdz101.020","title":"Feasibility of a self-screening for insomnia and acceptability of an online targeted video-based cognitive behavioral program in cancer outpatients: SLEEP-4-ALL-1 study design","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sleep and related disorders","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Insomnia; Randomized controlled trial; Cognitive behavioral therapy for insomnia; Population; Psychological intervention; Physical therapy; Cognitive behavioral therapy; Breast cancer; Cancer; Intervention (counseling); Psychiatry; Clinical psychology; Internal medicine","score_opus":0.2307594233129677,"score_gpt":0.493051086460907,"score_spread":0.2622916631479393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978345396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933124,0.00034009956,0.00016618954,0.000092070215,0.0001882187,0.0055378694,0.00024535903,0.000033797845,0.000083964864],"genre_scores_gemma":[0.99516386,0.000011313384,0.0041680494,0.00013149962,0.000009832199,0.00041044754,0.00007927918,0.000021868487,0.000003834737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733937,0.0008188846,0.0008233012,0.0005129886,0.00015656113,0.0003488917],"domain_scores_gemma":[0.99795943,0.00052131066,0.0005545656,0.00031377148,0.0005631903,0.00008771924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091263326,0.00019812032,0.000757793,0.00022385495,0.000021629363,0.0000029343432,0.00018578849,0.0003456369,0.00027448245],"category_scores_gemma":[0.00014237718,0.00018293905,0.0001134478,0.00030341555,0.00023662912,0.000106502004,0.00004787736,0.00022496072,6.725644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006587956,0.047439694,0.7683913,0.00006815581,0.00042513362,0.0000029523294,0.0067856424,0.00014380309,0.000112921836,0.0000047341205,0.000017675555,0.17002003],"study_design_scores_gemma":[0.018357841,0.042218417,0.92632836,0.00002990657,0.00035691116,5.2666246e-7,0.010716166,0.0010443215,0.000612484,0.0000775621,0.00006396159,0.0001935643],"about_ca_topic_score_codex":0.0023618003,"about_ca_topic_score_gemma":0.0016967896,"teacher_disagreement_score":0.16982648,"about_ca_system_score_codex":0.000034286957,"about_ca_system_score_gemma":0.00015579075,"threshold_uncertainty_score":0.7460038},"labels":[],"label_agreement":null},{"id":"W2978392529","doi":"10.1093/annonc/mdz252.041","title":"Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Basal cell; Oral cavity; Adjuvant; Oncology; Carcinoma; Pathology; Dentistry","score_opus":0.1207078024011228,"score_gpt":0.4045102476115195,"score_spread":0.28380244521039666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978392529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833108,0.0017260716,0.000009325694,0.012935038,0.00005153984,0.0006671708,0.00007837062,0.000009402724,0.0012122646],"genre_scores_gemma":[0.9977531,0.0007266333,0.0002444897,0.0006459119,0.000025195439,0.00013980629,0.000026217302,0.000006207558,0.00043246165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994196,0.000038356684,0.00015186447,0.00017776729,0.00003287601,0.00017950013],"domain_scores_gemma":[0.9995303,0.00014531467,0.00007863741,0.00012144102,0.00008233767,0.000041967392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016508167,0.00008336149,0.00040057415,0.000078050325,0.000029156552,0.000001779088,0.000023115575,0.000072246694,0.000010456069],"category_scores_gemma":[0.000028925053,0.00006456093,0.0000342882,0.0000600274,0.000040590603,0.000023596294,0.000018755123,0.000045232682,0.0000015866005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003378196,0.00064796204,0.87865,0.00021310296,0.000012609576,0.000016359154,0.0034291365,0.000004952184,0.031580485,0.00013934584,0.00056793605,0.084400274],"study_design_scores_gemma":[0.0036199398,0.014152926,0.94663817,0.000012960117,0.000039792394,0.000007972393,0.0012099403,0.00008298422,0.014434776,0.0001027891,0.019611137,0.00008659557],"about_ca_topic_score_codex":0.0006496239,"about_ca_topic_score_gemma":0.004149988,"teacher_disagreement_score":0.084313676,"about_ca_system_score_codex":0.00006966482,"about_ca_system_score_gemma":0.0001027392,"threshold_uncertainty_score":0.26327184},"labels":[],"label_agreement":null},{"id":"W2978429862","doi":"10.1093/annonc/mdz268.056","title":"Genomic characterisation of locally advanced pancreatic adenocarcinoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; McGill University Health Centre; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; FOLFIRINOX; KRAS; Internal medicine; Adenocarcinoma; Oncology; Pancreatic cancer; Univariate analysis; Gastroenterology; Multivariate analysis; Cancer; Colorectal cancer; Irinotecan","score_opus":0.06932381197297606,"score_gpt":0.3910588097768536,"score_spread":0.32173499780387754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978429862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97370756,0.0006745118,0.000054157324,0.0017842802,0.0000945314,0.00061963295,0.000008511992,0.000012985789,0.02304385],"genre_scores_gemma":[0.99588877,0.0007298915,0.0011803742,0.0006380266,0.000056017067,0.000023566025,0.000026717227,0.00001492422,0.0014417316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866575,0.00012300332,0.0005234793,0.0002060131,0.00020256896,0.0002791739],"domain_scores_gemma":[0.9985734,0.00031886247,0.00030782216,0.0003441278,0.00034674632,0.0001089903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004992856,0.00011095426,0.00092732965,0.0001704473,0.00001684302,0.0000013349927,0.00012143396,0.00019311046,0.0008188742],"category_scores_gemma":[0.00018744229,0.0000961444,0.000114666276,0.00014084137,0.00018719147,0.000056522964,0.000052845266,0.00016374067,0.00017901395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019326882,0.00040902215,0.8228089,0.00031571483,0.00022614769,0.000024026183,0.00043891757,0.0000040034147,0.14166863,0.0005812762,0.00037698942,0.031213662],"study_design_scores_gemma":[0.0026694424,0.008557458,0.9754485,0.000108906024,0.00011098078,0.000059381382,0.00022533842,0.0002810837,0.008492186,0.00027079828,0.0036966715,0.00007926549],"about_ca_topic_score_codex":0.00005798912,"about_ca_topic_score_gemma":0.000005373946,"teacher_disagreement_score":0.15263957,"about_ca_system_score_codex":0.00005331469,"about_ca_system_score_gemma":0.0006473971,"threshold_uncertainty_score":0.89660984},"labels":[],"label_agreement":null},{"id":"W2978458313","doi":"10.1093/annonc/mdz253.018","title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Solid tumor; Immunotherapy; Cancer","score_opus":0.012197201427352979,"score_gpt":0.30922483837680625,"score_spread":0.2970276369494533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978458313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996717,0.000047265818,0.0000023081088,0.0015229192,0.000022175398,0.0006095377,0.000019099774,0.000009475254,0.0010502356],"genre_scores_gemma":[0.9989686,0.000023198434,0.00018342001,0.00026217077,0.00000958639,0.000019533536,0.00006708718,0.000018101,0.00044829276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876374,0.0000834253,0.00037408728,0.00020027938,0.0003298426,0.0002486063],"domain_scores_gemma":[0.99884486,0.00015136099,0.00046184735,0.00011827589,0.0003884502,0.00003517607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021364736,0.0001448642,0.0006319697,0.0002497509,0.000009997678,0.0000024419226,0.00006432802,0.000104857456,0.00006587398],"category_scores_gemma":[0.00004321418,0.00009741767,0.000044356337,0.00039153913,0.000059722486,0.00009830784,0.000007910633,0.00013969372,0.0000027060285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03944294,0.0006160138,0.95408845,0.00004456125,0.00028155523,0.000015974712,0.00041894193,0.00046044088,0.0016573142,0.0000053526296,0.000058020232,0.0029104252],"study_design_scores_gemma":[0.027676279,0.014860314,0.95261735,0.00019238285,0.000044659642,0.0000067362953,0.000155826,0.000036000147,0.0041651134,0.000010448635,0.000121401754,0.00011348425],"about_ca_topic_score_codex":0.00043751352,"about_ca_topic_score_gemma":0.0010483023,"teacher_disagreement_score":0.0142443,"about_ca_system_score_codex":0.0002185463,"about_ca_system_score_gemma":0.00041236053,"threshold_uncertainty_score":0.39725775},"labels":[],"label_agreement":null},{"id":"W2978480841","doi":"10.1093/annonc/mdz246.006","title":"Impact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen's University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Population; Microsatellite instability; Cancer; Gastroenterology; Cancer research; Gene; Microsatellite; Genetics; Biology; Allele","score_opus":0.02590654407178802,"score_gpt":0.36206571138714694,"score_spread":0.33615916731535894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978480841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974,0.0016234118,0.0000025481934,0.00016844731,0.000047253474,0.0003647942,0.00021208037,0.0000035290388,0.0001779266],"genre_scores_gemma":[0.9965892,0.002984225,0.000165032,0.000093303,0.000021853975,0.000023655393,0.00008370701,0.000015888192,0.000023141663],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99902844,0.00009074293,0.00036353632,0.00025771913,0.00006548986,0.00019406788],"domain_scores_gemma":[0.9993051,0.00022788673,0.00020310485,0.00012396606,0.00009529013,0.000044599023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031838947,0.00012732983,0.00033818808,0.00010775427,0.000017411341,0.000006904365,0.00006487292,0.000107601794,0.00002290226],"category_scores_gemma":[0.00009708554,0.00012459695,0.000075892516,0.00010404085,0.00012316593,0.0000068101017,0.000032119682,0.00008393359,0.0000013277859],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022420099,0.00055459375,0.08316183,0.00007166371,0.00020718844,0.000013695476,0.0009538403,0.0065494245,0.89653474,0.00011741403,0.0001806569,0.009412949],"study_design_scores_gemma":[0.005123136,0.0060997666,0.67592895,0.00005761376,0.000024424384,0.000021223213,0.00022139592,0.0008078351,0.30929476,0.00035438797,0.0018344534,0.00023206291],"about_ca_topic_score_codex":0.0021330535,"about_ca_topic_score_gemma":0.0013179962,"teacher_disagreement_score":0.5927671,"about_ca_system_score_codex":0.000045203546,"about_ca_system_score_gemma":0.00030376893,"threshold_uncertainty_score":0.5080916},"labels":[],"label_agreement":null},{"id":"W2978507674","doi":"10.1093/annonc/mdz253.094","title":"Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Nivolumab; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","score_opus":0.08317332167414404,"score_gpt":0.3884031649587813,"score_spread":0.30522984328463726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978507674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894155,0.0015244822,0.000026006124,0.0028572464,0.0006725939,0.0031453695,0.00045357243,0.000027311538,0.0018779155],"genre_scores_gemma":[0.9967441,0.0014985079,0.00042650805,0.0005745794,0.00022312561,0.000030723677,0.00012449094,0.000056162753,0.00032180632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941077,0.0016353801,0.0019414136,0.00085493946,0.0007465196,0.0007140174],"domain_scores_gemma":[0.99481815,0.0020904425,0.0016831623,0.00089517084,0.0003308913,0.00018219196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0056745596,0.000479117,0.0024838408,0.00036355972,0.00018462453,0.000022251314,0.00039227476,0.000337811,0.00031833723],"category_scores_gemma":[0.00067322125,0.00036859323,0.00052200496,0.00056436454,0.00060616643,0.00022281337,0.00020155721,0.00066466694,0.000012146166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.564537,0.0025043264,0.00078478066,0.00018723114,0.00029768504,0.00007134371,0.0017066183,0.000029685725,0.41793588,0.0000024638957,0.0008938423,0.011049145],"study_design_scores_gemma":[0.70247173,0.04294544,0.049364448,0.00032009528,0.00067479984,0.000042423304,0.0007276437,0.0031007975,0.19712794,0.000039984847,0.002728773,0.00045589783],"about_ca_topic_score_codex":0.004085728,"about_ca_topic_score_gemma":0.00025075593,"teacher_disagreement_score":0.22080792,"about_ca_system_score_codex":0.00011098013,"about_ca_system_score_gemma":0.0011835203,"threshold_uncertainty_score":0.9998766},"labels":[],"label_agreement":null},{"id":"W2978530456","doi":"10.1093/annonc/mdz242.028","title":"Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Letrozole; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Breast cancer; Oncology; Internal medicine; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.0271541311051166,"score_gpt":0.3359975925979312,"score_spread":0.3088434614928146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978530456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959535,0.00094010466,0.00017453125,0.0018413309,0.0002517162,0.0024367087,0.00455002,0.00005155772,0.00015869612],"genre_scores_gemma":[0.99675125,0.00022736013,0.0005985099,0.0008763103,0.00025475043,0.00022269752,0.00096430973,0.00006277237,0.000042041516],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959519,0.000794418,0.0010187979,0.0008418243,0.00055126817,0.0008418082],"domain_scores_gemma":[0.9968139,0.00064174004,0.0010696388,0.0005135547,0.0006698811,0.0002912706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003255793,0.0005408545,0.0019388184,0.00029172594,0.00017464322,0.000025356252,0.00030321453,0.00019586094,0.0006820558],"category_scores_gemma":[0.00006453883,0.00038812094,0.00028851404,0.00086908095,0.00053026737,0.0004429408,0.00012524563,0.0004879214,0.0000119217075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39141044,0.0066167656,0.37120587,0.0002611362,0.016222218,0.00006695637,0.010440572,0.00044215267,0.020745318,0.00058031373,0.0011408121,0.18086745],"study_design_scores_gemma":[0.17168333,0.015361827,0.7997469,0.00032425605,0.0014009594,0.000010605649,0.004606343,0.000105833715,0.0041090604,0.000044732868,0.0019747638,0.00063140644],"about_ca_topic_score_codex":0.0059924037,"about_ca_topic_score_gemma":0.0012647557,"teacher_disagreement_score":0.428541,"about_ca_system_score_codex":0.00066783396,"about_ca_system_score_gemma":0.00024598723,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W2978537230","doi":"10.1093/annonc/mdz252.011","title":"Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Agonist; Oncology; Head and neck; Internal medicine; Cancer research; Receptor; Cancer; Immunotherapy; Head and neck cancer; Surgery","score_opus":0.034317671288232106,"score_gpt":0.29838349818667054,"score_spread":0.26406582689843844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978537230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073094,0.00345546,8.097406e-7,0.0013987725,0.00019270745,0.0011839644,0.000057397603,0.000019580291,0.0029603604],"genre_scores_gemma":[0.9975987,0.0008769317,0.00021063304,0.00072666333,0.00004024306,0.000033530294,0.00019610848,0.00003579201,0.00028139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776363,0.00022666108,0.00073231506,0.00063986436,0.0002588502,0.0003786896],"domain_scores_gemma":[0.9985044,0.00042451822,0.00037350302,0.00041536716,0.00014246788,0.00013972828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005809153,0.00027499342,0.0008094449,0.00037739842,0.000044259352,0.000013011876,0.00010198754,0.00044036048,0.000050629435],"category_scores_gemma":[0.000050392973,0.00025167954,0.00005313808,0.000316874,0.00019940526,0.00017609907,0.00007720835,0.00041628367,0.0000066871303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25632682,0.0047338596,0.46138296,0.00057963474,0.000068671514,0.000327655,0.0065377024,0.000083188,0.23532638,0.000007197107,0.0048244665,0.029801458],"study_design_scores_gemma":[0.057812918,0.023812719,0.8423783,0.00033796325,0.000043838227,0.00004610548,0.000641796,0.0002964357,0.07155918,0.000036986094,0.0027324543,0.00030127825],"about_ca_topic_score_codex":0.0048890267,"about_ca_topic_score_gemma":0.0007682202,"teacher_disagreement_score":0.38099536,"about_ca_system_score_codex":0.00015547046,"about_ca_system_score_gemma":0.0005024084,"threshold_uncertainty_score":0.99999356},"labels":[],"label_agreement":null},{"id":"W2978615859","doi":"10.1093/annonc/mdz260.112","title":"Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Receptor; Cancer research; Immunology; Pharmacology; Immunotherapy; Internal medicine; Adverse effect; Immune system","score_opus":0.03664897699676808,"score_gpt":0.3661601596427191,"score_spread":0.32951118264595103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978615859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878862,0.00019593172,0.00013960165,0.00052716467,0.00012484606,0.008789776,0.000018656354,0.000021725287,0.002296137],"genre_scores_gemma":[0.9972708,0.0007165754,0.00044649473,0.0001165288,0.000021139484,0.00036134766,0.000010387938,0.00005145443,0.0010052484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99649364,0.00072158175,0.00088012207,0.00080968434,0.00047898162,0.0006160084],"domain_scores_gemma":[0.9971778,0.0010258555,0.000494378,0.00062853436,0.00044508086,0.00022837761],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016636736,0.0003648084,0.0019281671,0.00053292135,0.00003813681,0.000009518702,0.00023509414,0.0001577931,0.00059717364],"category_scores_gemma":[0.00007080157,0.0002847754,0.00006472147,0.0008933382,0.00022261971,0.0001340692,0.00010592174,0.0005355456,0.0000043704017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36905953,0.014733122,0.030303884,0.00045075963,0.000083620886,0.00008256326,0.0031980164,0.00055502536,0.55417454,9.1867133e-7,0.000068258225,0.027289724],"study_design_scores_gemma":[0.27469322,0.14241956,0.05785982,0.00031269834,0.00006958451,0.0000115693365,0.0012099815,0.0005011459,0.5221818,0.0000069169214,0.00036500965,0.00036867152],"about_ca_topic_score_codex":0.0015553412,"about_ca_topic_score_gemma":0.006238485,"teacher_disagreement_score":0.12768644,"about_ca_system_score_codex":0.00039514498,"about_ca_system_score_gemma":0.00094020105,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2978627448","doi":"10.1093/annonc/mdz268.096","title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Afatinib; Medicine; Oncology; Cancer research; Computational biology; Internal medicine; Cancer; Gefitinib","score_opus":0.1542739538545159,"score_gpt":0.4589318350192664,"score_spread":0.30465788116475045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978627448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983596,0.00025672303,0.0000585143,0.0054796175,0.0002416955,0.00073440926,0.000017169985,0.000019990024,0.009595879],"genre_scores_gemma":[0.9961392,0.00046038983,0.001448253,0.00047866776,0.00016845956,0.00005817402,0.000039987623,0.000020055193,0.0011867653],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868053,0.00009313623,0.00035579802,0.00026023987,0.00024839622,0.00036187502],"domain_scores_gemma":[0.99916065,0.00019950155,0.000113730806,0.00020543802,0.00020344665,0.00011720899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046707847,0.00011456345,0.0004086918,0.00020244787,0.000030668176,0.0000045993106,0.000094457464,0.00016222619,0.0007665622],"category_scores_gemma":[0.00042756696,0.000097850825,0.000093213,0.00020366868,0.00006513542,0.000046045065,0.0000648709,0.00020184452,0.0003741369],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024566392,0.0042095976,0.054612204,0.00021340253,0.00018271251,0.0003023652,0.0021302977,0.0023040338,0.8705391,0.0005808347,0.003871453,0.058597337],"study_design_scores_gemma":[0.045641012,0.06649336,0.25208545,0.001198374,0.00020617411,0.00046313606,0.0053720875,0.041399367,0.18906684,0.0009267807,0.3961545,0.0009929327],"about_ca_topic_score_codex":0.0014665731,"about_ca_topic_score_gemma":0.0001669543,"teacher_disagreement_score":0.6814723,"about_ca_system_score_codex":0.00018781617,"about_ca_system_score_gemma":0.000657243,"threshold_uncertainty_score":0.8393318},"labels":[],"label_agreement":null},{"id":"W2978638108","doi":"10.1093/annonc/mdz249.007","title":"Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Foundation Medicine; EMD Serono; Genentech; EUSA Pharma; Ipsen; Incyte; Eisai; National Comprehensive Cancer Network; Alexion Pharmaceuticals; Sanofi; Exelixis; Genomic Health; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Cilag; Astellas Pharma; Celldex Therapeutics; Pfizer","keywords":"Medicine; Axitinib; Subgroup analysis; Nephrectomy; Javelin; Urology; Renal cell carcinoma; Surgery; Internal medicine; Oncology; Kidney; Sunitinib; Meta-analysis","score_opus":0.042156929675297175,"score_gpt":0.3215684474265392,"score_spread":0.279411517751242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978638108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898109,0.00034790084,0.0002417426,0.0015947446,0.0003508828,0.00430199,0.0011698174,0.000028615057,0.0021534],"genre_scores_gemma":[0.99347305,0.00015513886,0.001423521,0.000678631,0.00048138262,0.00034226567,0.0029257054,0.00008231206,0.00043797158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99416995,0.0006710072,0.0021883838,0.0011234386,0.000917402,0.0009298409],"domain_scores_gemma":[0.9938328,0.0020935654,0.0016806313,0.0010887602,0.0009791462,0.00032507553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012077519,0.0006794952,0.002879115,0.00069754774,0.00012806531,0.000018189523,0.00056520035,0.00043505745,0.00040324123],"category_scores_gemma":[0.00036145287,0.0005323367,0.0011171574,0.0008960728,0.0003725567,0.00022555595,0.00024416563,0.0006307999,0.000016165677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8348088,0.018825457,0.06354534,0.0004081348,0.0039179767,0.00030474126,0.0046705827,0.0010499766,0.041533783,0.00011340684,0.0036091346,0.027212668],"study_design_scores_gemma":[0.43101275,0.07023016,0.27494615,0.0003212295,0.003341274,0.00001376519,0.00077416236,0.0009475284,0.21074292,0.0002764012,0.006576539,0.00081710424],"about_ca_topic_score_codex":0.0014257766,"about_ca_topic_score_gemma":0.0010938018,"teacher_disagreement_score":0.40379605,"about_ca_system_score_codex":0.00057150633,"about_ca_system_score_gemma":0.0008905803,"threshold_uncertainty_score":0.9997128},"labels":[],"label_agreement":null},{"id":"W2978650206","doi":"10.1093/annonc/mdz250.009","title":"Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Ovarian cancer; Platinum; Ovarian carcinoma; Phases of clinical research; Cancer","score_opus":0.03346109098614352,"score_gpt":0.3772049853250598,"score_spread":0.3437438943389163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978650206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943546,0.00002182211,0.000015967069,0.0012382849,0.000073677875,0.0035194603,0.000055584333,0.0000062664835,0.0007143362],"genre_scores_gemma":[0.9988043,0.0000071239406,0.00010073603,0.0008199172,0.000018908291,0.00018145055,0.000022578677,0.000020504514,0.000024529067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972592,0.0010885557,0.00069981115,0.00032637623,0.00033925494,0.00028678938],"domain_scores_gemma":[0.99742746,0.0013184785,0.00045657888,0.00048016405,0.00025157942,0.00006573563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015400562,0.00023116413,0.0010080892,0.00033213763,0.000016065465,0.000002359212,0.00012953335,0.00011232901,0.00005585831],"category_scores_gemma":[0.00013508175,0.00014809445,0.000092646565,0.00048908027,0.00013550885,0.000035885947,0.000015088209,0.00018349806,0.0000036933538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42729223,0.01313993,0.49983653,0.0001033168,0.00018574798,0.00009086919,0.014772788,0.00027230155,0.008061151,0.000031407206,0.00038241746,0.035831306],"study_design_scores_gemma":[0.15162462,0.27053472,0.48322868,0.0004691312,0.000047882146,0.0000075425005,0.0011446526,0.00013063892,0.091682024,0.00000985331,0.0009635272,0.00015669825],"about_ca_topic_score_codex":0.0003373918,"about_ca_topic_score_gemma":0.0002975503,"teacher_disagreement_score":0.2756676,"about_ca_system_score_codex":0.00024376805,"about_ca_system_score_gemma":0.00038201618,"threshold_uncertainty_score":0.60391164},"labels":[],"label_agreement":null},{"id":"W2978687871","doi":"10.1093/annonc/mdz260.097","title":"Preliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Carboplatin; Lung cancer; Nausea; Chemotherapy; Discontinuation; Oncology; Gastroenterology; Cisplatin","score_opus":0.07776748119648753,"score_gpt":0.4609315789499341,"score_spread":0.38316409775344656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978687871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567903,0.002849748,0.000035286044,0.0028082374,0.00029048524,0.00398848,0.0003793528,0.000020167454,0.0039492208],"genre_scores_gemma":[0.99517703,0.0015856788,0.0005173354,0.0005227088,0.00018011758,0.00040071495,0.000057785786,0.000038215385,0.0015203953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99811625,0.0000754106,0.0006158346,0.00046824894,0.00030138172,0.00042289463],"domain_scores_gemma":[0.997701,0.00062197604,0.00042881732,0.0005416745,0.0005895276,0.00011704167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037025943,0.00020340756,0.0010131849,0.00012910408,0.00003897357,0.0000029309076,0.00022339437,0.00012729084,0.00011494571],"category_scores_gemma":[0.00015132022,0.00017245903,0.00014649234,0.00016395481,0.0001039373,0.00006387142,0.00010600324,0.00017694401,0.0000049880387],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4432263,0.02464546,0.029465355,0.0033096948,0.0050040446,0.00018020731,0.068995975,0.0011314492,0.13584772,0.000019002284,0.12405603,0.16411875],"study_design_scores_gemma":[0.34076777,0.24390727,0.043770712,0.0011975749,0.0008319829,0.000006044339,0.011528361,0.0036738252,0.2928795,0.00010119797,0.060654394,0.0006813725],"about_ca_topic_score_codex":0.0014336769,"about_ca_topic_score_gemma":0.00032896572,"teacher_disagreement_score":0.21926181,"about_ca_system_score_codex":0.00015339447,"about_ca_system_score_gemma":0.00079353416,"threshold_uncertainty_score":0.7032675},"labels":[],"label_agreement":null},{"id":"W2978738441","doi":"10.1093/annonc/mdz248","title":"Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.06691129783374594,"score_gpt":0.39689649757741396,"score_spread":0.329985199743668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978738441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931035,0.0002617179,3.926422e-7,0.0028957382,0.000096394986,0.0023381587,0.00054801116,0.000010130007,0.0007459713],"genre_scores_gemma":[0.9981638,0.0003053874,0.000035210367,0.00029027337,0.000031916537,0.000082546234,0.00040426894,0.000018503148,0.0006680829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981117,0.00025673647,0.00048593676,0.0003935067,0.0003983626,0.00035370712],"domain_scores_gemma":[0.99876565,0.00029425044,0.00023588553,0.00031941143,0.00026996725,0.00011484831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298783,0.00018297753,0.00055714074,0.00009284632,0.000055495308,0.000016926375,0.00010034925,0.0000615135,0.00011076246],"category_scores_gemma":[0.00005378243,0.00010703062,0.000033109936,0.00021649525,0.00016086677,0.000110155204,0.00005158181,0.00022196007,0.0000083299565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10762124,0.006639713,0.85175383,0.000062349885,0.0010453939,0.00029489645,0.009205556,0.00009153334,0.002670062,0.000035005585,0.00246747,0.018112943],"study_design_scores_gemma":[0.09724481,0.02148039,0.87430346,0.00015089463,0.00016688967,0.0000018159277,0.0021762827,0.00014262836,0.0011308372,0.00006144089,0.002967607,0.00017294561],"about_ca_topic_score_codex":0.0053279414,"about_ca_topic_score_gemma":0.006883213,"teacher_disagreement_score":0.02254962,"about_ca_system_score_codex":0.00008657775,"about_ca_system_score_gemma":0.00045444528,"threshold_uncertainty_score":0.8054289},"labels":[],"label_agreement":null},{"id":"W2978821325","doi":"10.1093/annonc/mdz253.081","title":"Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cancer; Population","score_opus":0.039236838387144014,"score_gpt":0.363956153621469,"score_spread":0.32471931523432496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978821325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888741,0.00020770603,0.000013685825,0.0029532455,0.00022695676,0.00051268155,0.000028840666,0.000009488195,0.00717333],"genre_scores_gemma":[0.998507,0.00038505674,0.00017452928,0.0006511557,0.000031852596,0.000019072508,0.000006060381,0.00001238004,0.0002128522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882627,0.0001311128,0.00043373264,0.00019471445,0.00018563245,0.0002285664],"domain_scores_gemma":[0.99901307,0.00017445268,0.00032608508,0.0002125725,0.00021628891,0.000057511435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058324373,0.00011824014,0.00063046,0.00019360089,0.000008162344,0.0000013391889,0.00007912804,0.00010301886,0.0002282761],"category_scores_gemma":[0.00013268832,0.00010146919,0.00017966743,0.00023265232,0.00018307669,0.00007583626,0.000031725518,0.00017077585,0.000008690022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10300482,0.0030757175,0.06480315,0.000921215,0.0011784157,0.0000809187,0.0018883094,0.000042402273,0.7296225,0.00009294763,0.004801515,0.09048808],"study_design_scores_gemma":[0.008988816,0.021347474,0.42188615,0.00047171974,0.00009912907,0.00004103555,0.0012584022,0.0003774664,0.543108,0.00013947532,0.0021162906,0.00016603812],"about_ca_topic_score_codex":0.00043841865,"about_ca_topic_score_gemma":0.00011815234,"teacher_disagreement_score":0.357083,"about_ca_system_score_codex":0.00007772912,"about_ca_system_score_gemma":0.00037584576,"threshold_uncertainty_score":0.41377935},"labels":[],"label_agreement":null},{"id":"W2978821371","doi":"10.1093/annonc/mdz260.065","title":"Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Crizotinib; Refractory (planetary science); Gastroenterology; Stock options; Randomized controlled trial; Surgery; Lung cancer","score_opus":0.038170941786937855,"score_gpt":0.41940971598255955,"score_spread":0.3812387741956217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978821371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90697455,0.000051704792,0.00000253072,0.008382759,0.00029175548,0.0018296079,0.00003241755,0.000009833079,0.082424834],"genre_scores_gemma":[0.99590534,0.000032672386,0.00012459458,0.0030000948,0.00012488135,0.00013405007,0.000148567,0.000021270216,0.00050855684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984555,0.00014880615,0.00048909144,0.00029703256,0.00026900155,0.00034053597],"domain_scores_gemma":[0.999011,0.0001320923,0.00026079692,0.00036044963,0.00014240784,0.00009325371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031904058,0.00017592977,0.00054700446,0.00019286302,0.00004929328,0.0000071136415,0.00016073219,0.00015076243,0.00020488448],"category_scores_gemma":[0.000088266956,0.00011313265,0.000086228174,0.0002959082,0.00010307378,0.00012077315,0.000031946365,0.00027611424,0.000032232725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10639944,0.047346905,0.11889959,0.00021197193,0.0007181551,0.00042214274,0.041168198,0.00001881774,0.00050608115,0.0007564528,0.017305737,0.66624653],"study_design_scores_gemma":[0.3956721,0.14012238,0.23477077,0.0004240126,0.00027375174,0.000027024216,0.0037212705,0.00003475667,0.00043761847,0.000215684,0.22396535,0.00033528137],"about_ca_topic_score_codex":0.00047444893,"about_ca_topic_score_gemma":0.00083158875,"teacher_disagreement_score":0.6659112,"about_ca_system_score_codex":0.00009675503,"about_ca_system_score_gemma":0.00063333794,"threshold_uncertainty_score":0.46134156},"labels":[],"label_agreement":null},{"id":"W2978823948","doi":"10.1093/annonc/mdz250.060","title":"Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Carboplatin; Randomized controlled trial; Internal medicine; Oncology; Cervix; Adjuvant; Cancer; Gynecology; Chemotherapy; Cisplatin","score_opus":0.09360955114738825,"score_gpt":0.4517429246874126,"score_spread":0.3581333735400244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978823948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94641227,0.0032403623,0.00009478738,0.041330125,0.0012676913,0.0037258656,0.00012886887,0.000022068985,0.0037779596],"genre_scores_gemma":[0.97459525,0.006739314,0.00016979365,0.015744595,0.00077239284,0.00084890134,0.000067502915,0.000028234736,0.0010340036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979944,0.00011201484,0.00081449543,0.0003261078,0.0003580121,0.00039493994],"domain_scores_gemma":[0.9979136,0.0010964599,0.00041252738,0.00023329983,0.00025094755,0.00009314292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009485783,0.0002054209,0.0009262288,0.00014428487,0.000040779967,0.000010128944,0.00032860192,0.00020662222,0.00086897943],"category_scores_gemma":[0.00039418094,0.00013597329,0.00027905134,0.00021360221,0.00009519578,0.00012418636,0.000044528406,0.0003125269,0.000012032491],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6494185,0.0015090653,0.0023172107,0.00012889226,0.00045959518,0.000014411576,0.00085519045,0.00007383791,0.0037633048,0.00031413455,0.0059928116,0.33515304],"study_design_scores_gemma":[0.86738676,0.008895915,0.0011196916,0.00021283075,0.00013091388,0.0000046007694,0.00055861834,0.00028188003,0.008524112,0.0014048718,0.11128473,0.00019504827],"about_ca_topic_score_codex":0.00043693904,"about_ca_topic_score_gemma":0.00017703952,"teacher_disagreement_score":0.334958,"about_ca_system_score_codex":0.00013112614,"about_ca_system_score_gemma":0.00032667865,"threshold_uncertainty_score":0.9514715},"labels":[],"label_agreement":null},{"id":"W2978854127","doi":"10.1093/annonc/mdz394.008","title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Carboplatin; Paclitaxel; Oncology; Metastatic breast cancer; PARP inhibitor; Internal medicine; Breast cancer; Cancer; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.09477682576886066,"score_gpt":0.47934025473107505,"score_spread":0.3845634289622144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978854127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944241,0.00041395324,0.0000014058985,0.001575879,0.00005544423,0.0014914618,0.000119063,0.000009917645,0.0019087789],"genre_scores_gemma":[0.9988461,0.00029961581,0.00012375957,0.00025769774,0.000017827206,0.0001281084,0.000007605061,0.000025113708,0.0002941851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980407,0.0003059394,0.00052522257,0.00033550864,0.00040998112,0.0003826778],"domain_scores_gemma":[0.9983302,0.0004004532,0.0003351264,0.00026846392,0.0005280813,0.00013767116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073433475,0.00016634392,0.0009896578,0.00022950066,0.000019664456,0.0000033272363,0.000105515406,0.00009142511,0.00027933484],"category_scores_gemma":[0.00020751139,0.00013369347,0.00003695916,0.00052341516,0.00021550948,0.000078412566,0.000066047505,0.00033937622,0.0000036904257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02262781,0.02387866,0.7036175,0.00084285246,0.0016670725,0.0004542642,0.024198852,0.0003623374,0.011843156,0.00006810403,0.0016050765,0.20883428],"study_design_scores_gemma":[0.10232467,0.07828344,0.7912093,0.0011618853,0.00023353919,0.00006678799,0.020274475,0.0005826876,0.0045154006,0.00022515628,0.00076193584,0.00036072297],"about_ca_topic_score_codex":0.0073462543,"about_ca_topic_score_gemma":0.007283806,"teacher_disagreement_score":0.20847355,"about_ca_system_score_codex":0.00015210574,"about_ca_system_score_gemma":0.0007666585,"threshold_uncertainty_score":0.9992639},"labels":[],"label_agreement":null},{"id":"W2978865612","doi":"10.1093/annonc/mdz265.055","title":"Psychosocial distress of adolescent and young adults with cancer at diagnosis: A case-matched retrospective cohort of 2045 patients in British Columbia","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Young adult; Worry; Distress; Cohort; Retrospective cohort study; Cancer; Pediatrics; Anxiety; Psychiatry; Gerontology; Clinical psychology; Internal medicine","score_opus":0.01930787230774814,"score_gpt":0.3300865341609933,"score_spread":0.31077866185324515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978865612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964241,0.00074726925,3.572415e-7,0.0005651069,0.00023187645,0.0010957245,0.0005713139,0.0000077860805,0.00035650225],"genre_scores_gemma":[0.9976032,0.0017228839,0.000034172583,0.00037325794,0.000053351945,0.00009373413,0.00003632183,0.000019715853,0.000063358675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983093,0.00012652269,0.00061562634,0.00034777162,0.00036290614,0.0002378534],"domain_scores_gemma":[0.9984611,0.00009792868,0.00058622,0.00022050287,0.0005317945,0.00010240317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002932912,0.00011234205,0.0010345186,0.000050484014,0.000022672823,0.000005036966,0.00007555818,0.00016385598,0.00016252112],"category_scores_gemma":[0.0001274406,0.00014856925,0.00007659133,0.0001901622,0.00027155603,0.000056943627,0.00006626782,0.00016932398,7.478117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012891789,0.001544055,0.98226315,0.0007417198,0.00020700782,0.00009193449,0.0033821284,8.466074e-7,0.000018494475,0.0000015495573,0.0054357136,0.0050242147],"study_design_scores_gemma":[0.006680471,0.0034536675,0.9858722,0.0021741998,0.000082029415,0.00006832636,0.0010708927,0.000003004684,0.00024392651,0.000016019178,0.00020877177,0.00012650565],"about_ca_topic_score_codex":0.263129,"about_ca_topic_score_gemma":0.7447591,"teacher_disagreement_score":0.48163012,"about_ca_system_score_codex":0.0001752169,"about_ca_system_score_gemma":0.00016918397,"threshold_uncertainty_score":0.7417779},"labels":[],"label_agreement":null},{"id":"W2978880457","doi":"10.1093/annonc/mdz394.065","title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.08452269851717625,"score_gpt":0.42905341939770825,"score_spread":0.344530720880532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978880457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836113,0.0001459106,0.0000027964097,0.0021609087,0.0005625016,0.0017969401,0.000017473949,0.00001093043,0.011691239],"genre_scores_gemma":[0.9956116,0.0006236002,0.000035115776,0.00015814876,0.000043301483,0.000030710322,0.0000139563745,0.000024852076,0.0034587272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774325,0.00040376288,0.0007649998,0.00024064298,0.000537502,0.00030986464],"domain_scores_gemma":[0.99797916,0.0004938819,0.0004757368,0.00058826944,0.0004047792,0.00005819216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013096689,0.0001580782,0.0011682139,0.00023863632,0.000019598074,0.000002590132,0.00031007963,0.00020494236,0.0010875409],"category_scores_gemma":[0.00021166391,0.00011464126,0.0002800408,0.00037026362,0.00023743644,0.00007461554,0.00008556482,0.00027475585,0.000009194555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4136187,0.007728448,0.044946317,0.0002146191,0.0006308196,0.000015861482,0.0023641381,0.00005529436,0.35529083,0.0022453289,0.0002995237,0.17259009],"study_design_scores_gemma":[0.7016314,0.039338503,0.082583465,0.00010869608,0.000041419575,0.000007233672,0.00088605465,0.00032818664,0.1662637,0.0007125775,0.007895023,0.00020371367],"about_ca_topic_score_codex":0.00030676264,"about_ca_topic_score_gemma":0.00010693139,"teacher_disagreement_score":0.2880127,"about_ca_system_score_codex":0.000106407126,"about_ca_system_score_gemma":0.0005562297,"threshold_uncertainty_score":0.9998256},"labels":[],"label_agreement":null},{"id":"W2978886033","doi":"10.1093/annonc/mdz407","title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Fondation ARC pour la Recherche sur le Cancer; CNIB","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; ROS1; Oncology; Internal medicine; Lung cancer; Clinical trial; Cancer; Adenocarcinoma","score_opus":0.08230904271557742,"score_gpt":0.4842450247288527,"score_spread":0.4019359820132753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978886033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95596236,0.000099950645,0.0000014647188,0.007948956,0.0004126566,0.0009973538,0.00013993327,0.000005660567,0.034431655],"genre_scores_gemma":[0.99465084,0.000053426134,0.00011136876,0.0009599491,0.00008393044,0.000027577624,0.00003068358,0.000007661952,0.0040745568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99909514,0.00009082762,0.00038521504,0.00015329954,0.00012492004,0.00015061119],"domain_scores_gemma":[0.9990828,0.00023715853,0.00023630222,0.00023816443,0.00016451647,0.000041079194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024021712,0.00007912649,0.0003843752,0.00007826866,0.000026249654,0.0000013842705,0.00008304712,0.00009544168,0.00012896828],"category_scores_gemma":[0.00028876937,0.00004537218,0.000102096325,0.00020175724,0.00008277542,0.000041938503,0.00004451527,0.00010126863,0.000009067102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5459845,0.022512054,0.0030332261,0.00015195792,0.0012560886,0.00014072593,0.016500896,0.000043415363,0.025465097,0.0021258383,0.034853335,0.34793285],"study_design_scores_gemma":[0.6096282,0.1547295,0.022254609,0.00048714346,0.0005298649,0.000039137307,0.0016848742,0.000036527592,0.07123021,0.00038149866,0.138799,0.00019945229],"about_ca_topic_score_codex":0.00023499828,"about_ca_topic_score_gemma":0.00011766948,"teacher_disagreement_score":0.34773338,"about_ca_system_score_codex":0.000044442106,"about_ca_system_score_gemma":0.0006244196,"threshold_uncertainty_score":0.18502238},"labels":[],"label_agreement":null},{"id":"W2979129329","doi":"10.1093/annonc/mdz398","title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Centre Hospitalier Universitaire Vaudois; Université de Lausanne; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Medicine; Meta-analysis; Melanoma; Internal medicine; Oncology; Confidence interval; Interleukin 2; Immunotherapy; Clinical endpoint; Aldesleukin; Surgery; Gastroenterology; Clinical trial; Cancer; Cytokine; Cancer research","score_opus":0.1985229517320195,"score_gpt":0.4500510520698057,"score_spread":0.2515281003377862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979129329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001139459,0.9924699,0.0000014220284,0.00021106216,0.000015271473,0.005690113,0.000023419347,0.000012453365,0.0004368835],"genre_scores_gemma":[0.0009234563,0.99752563,0.00030652093,0.0003521996,0.0000070636906,0.0003840719,0.000026619802,0.00006494639,0.0004094756],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956409,0.0012242642,0.0018400036,0.00060425384,0.00033721974,0.00035338517],"domain_scores_gemma":[0.99409497,0.0028156412,0.0018413516,0.00074090203,0.00038766308,0.00011949504],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0015641474,0.00051147357,0.016100328,0.0007156201,0.000016616721,0.000009416383,0.00023472289,0.00022147174,0.0002036088],"category_scores_gemma":[0.0004828772,0.00029340564,0.0012429458,0.0010095785,0.0002509539,0.000049640446,0.00008927034,0.00040881545,0.0000024192223],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006418717,0.00041947066,0.000015361811,0.74236274,0.113978915,0.00031583366,0.00032844036,0.0000011697108,0.000014762376,0.000017996812,0.0000152125795,0.1418882],"study_design_scores_gemma":[0.0044429135,0.01973804,0.000014714651,0.17145237,0.74687815,0.004415398,0.00029557527,0.000011021589,0.00009214677,0.000014742979,0.05198786,0.0006570449],"about_ca_topic_score_codex":0.00009437078,"about_ca_topic_score_gemma":0.000064357875,"teacher_disagreement_score":0.6328992,"about_ca_system_score_codex":0.00012794061,"about_ca_system_score_gemma":0.0007060097,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W2979257942","doi":"10.1093/annonc/mdz394.080","title":"Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Chemotherapy; First line therapy; Internal medicine; Cancer; Immunotherapy","score_opus":0.07576311777996377,"score_gpt":0.3943962022662226,"score_spread":0.3186330844862588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979257942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98497397,0.008471017,0.000014491615,0.0052679274,0.000051480347,0.00074678677,0.000007749679,0.000007370477,0.00045922512],"genre_scores_gemma":[0.9925791,0.0045592557,0.000278173,0.0023042574,0.000026934948,0.000059343132,0.000011455698,0.000017986018,0.00016346906],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998295,0.00021040314,0.0006745967,0.00029103033,0.0002366403,0.00029230816],"domain_scores_gemma":[0.99882066,0.00031931186,0.00032308014,0.00037221814,0.000118199634,0.000046530728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087083894,0.0001916998,0.000883332,0.00046791357,0.000016361695,0.000007156482,0.00014283665,0.00015169708,0.00059323723],"category_scores_gemma":[0.00004292318,0.00012277008,0.00023928942,0.00093510415,0.00026747806,0.00008137497,0.000031581498,0.00022482697,0.0000026454286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090791844,0.0018262704,0.24204695,0.00020594348,0.0009978784,0.000055198274,0.0026943951,0.000027167485,0.051309686,0.00001719488,0.00015342682,0.609874],"study_design_scores_gemma":[0.02334658,0.007869503,0.93071765,0.00021556021,0.00018477216,0.000048279126,0.00040820587,0.00084649445,0.030884545,0.00016518157,0.005099395,0.00021381813],"about_ca_topic_score_codex":0.0006095562,"about_ca_topic_score_gemma":0.0005340853,"teacher_disagreement_score":0.6886707,"about_ca_system_score_codex":0.000047244914,"about_ca_system_score_gemma":0.00021363261,"threshold_uncertainty_score":0.6495532},"labels":[],"label_agreement":null},{"id":"W2979282408","doi":"10.1093/annonc/mdz251.039","title":"DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Refractory (planetary science); Phases of clinical research; Oncology; Open label study; Internal medicine; Safety profile; Clinical trial; Adverse effect; Immunotherapy; Cancer","score_opus":0.17193234766611384,"score_gpt":0.44411592859264654,"score_spread":0.2721835809265327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979282408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940851,0.000021115999,0.0000052315395,0.00055901415,0.0000463876,0.0044464683,0.00006392926,0.000010978903,0.00076178357],"genre_scores_gemma":[0.9991053,0.00003235558,0.00043072118,0.00011965546,0.000009944514,0.00007724523,0.00009011119,0.000032987737,0.000101732345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971699,0.000559187,0.0007858961,0.0005861224,0.00046578838,0.00043307678],"domain_scores_gemma":[0.9977809,0.00066159625,0.00043083576,0.00047361062,0.0003656229,0.00028740303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008042998,0.0002569438,0.001221688,0.00039241466,0.000052032065,0.000009955918,0.0002140699,0.00015887931,0.00003810132],"category_scores_gemma":[0.00043698866,0.00019537249,0.00003833056,0.00038413546,0.00016125888,0.0002491054,0.00031954277,0.0003759508,0.0000058356954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14485134,0.13466154,0.6203265,0.00006333755,0.0002136996,0.00013990613,0.0011951859,0.0000010479016,0.0002208464,0.0000040280784,0.000020711153,0.098301865],"study_design_scores_gemma":[0.163028,0.22675534,0.6086333,0.00019873322,0.00003824746,0.0000062738286,0.00050547876,0.00007733298,0.00048984867,0.000003466078,0.00015081596,0.00011317447],"about_ca_topic_score_codex":0.00060527906,"about_ca_topic_score_gemma":0.0026149477,"teacher_disagreement_score":0.09818869,"about_ca_system_score_codex":0.00016486108,"about_ca_system_score_gemma":0.00038491245,"threshold_uncertainty_score":0.79670584},"labels":[],"label_agreement":null},{"id":"W2979594948","doi":"10.1093/annonc/mdz374.003","title":"Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Refractory (planetary science); Oncology; Internal medicine; Cancer research","score_opus":0.07441932910703952,"score_gpt":0.4003566984012877,"score_spread":0.32593736929424816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979594948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953054,0.00035068186,0.0000050500767,0.010355322,0.00074061943,0.0017096668,0.00006837366,0.00008516733,0.033631094],"genre_scores_gemma":[0.98996645,0.001316133,0.00029421423,0.0021084652,0.00037728713,0.000072627154,0.00020787804,0.0000702987,0.0055866414],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99546206,0.0005822329,0.0015209059,0.00075574865,0.0006596898,0.0010193537],"domain_scores_gemma":[0.9964025,0.0011992899,0.0005615524,0.0009556031,0.00053453393,0.00034650683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026154062,0.00034134267,0.0014331443,0.0007159333,0.000047608286,0.000012102664,0.00044979053,0.00086276897,0.00043495506],"category_scores_gemma":[0.0017809685,0.0003024905,0.0002841863,0.0008663255,0.00032314248,0.00022675928,0.0002361058,0.0015183304,0.0010084078],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63498104,0.0028686025,0.0047803004,0.0002985096,0.0012045915,0.0032088808,0.0028336612,0.00011664537,0.11660678,0.0011280027,0.18397167,0.04800132],"study_design_scores_gemma":[0.4251396,0.06869788,0.021567088,0.00043540995,0.00028659255,0.00049179513,0.0010638994,0.0022729223,0.042238895,0.00091904425,0.4359926,0.0008942831],"about_ca_topic_score_codex":0.00059116114,"about_ca_topic_score_gemma":0.00010509019,"teacher_disagreement_score":0.25202093,"about_ca_system_score_codex":0.00084713026,"about_ca_system_score_gemma":0.0038529418,"threshold_uncertainty_score":0.9999427},"labels":[],"label_agreement":null},{"id":"W2980213277","doi":"10.1093/annonc/mdz420","title":"Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Jewish General Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Trastuzumab; Internal medicine; Oncology; Breast cancer; Cancer; Adverse effect; Biomarker; Immunohistochemistry; Adenocarcinoma; Metastatic breast cancer; Gastroenterology; Phases of clinical research; Chemotherapy","score_opus":0.07070417056604587,"score_gpt":0.4109842123864601,"score_spread":0.3402800418204142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980213277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96371114,0.00076041726,0.0000020787443,0.01972627,0.00020345816,0.0004748623,0.000077940604,0.00001014212,0.015033707],"genre_scores_gemma":[0.99673176,0.0016188779,0.00009121342,0.00030580434,0.000065979475,0.0000033995825,0.00002324513,0.00002058831,0.001139117],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99774486,0.00036988218,0.00060772826,0.00037547713,0.0004255914,0.00047645357],"domain_scores_gemma":[0.99850124,0.00042097777,0.00033786503,0.0003731061,0.00024054824,0.00012626991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010081513,0.00019870036,0.0008222799,0.00026794497,0.000058510745,0.000009164072,0.00024751996,0.00020700232,0.00011105235],"category_scores_gemma":[0.00022951428,0.00013530169,0.0001657305,0.00043261983,0.0004983194,0.00009397865,0.00032895166,0.0004001943,0.000016662492],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004661165,0.00072821876,0.214164,0.0002593839,0.000102072714,0.000076035205,0.00042779327,0.000014856311,0.7619459,0.00008990215,0.0019212706,0.015609394],"study_design_scores_gemma":[0.0023854019,0.0011349915,0.851182,0.00036137583,0.000017192311,0.00007323188,0.00017248713,0.00029424264,0.13153034,0.00010983671,0.012617121,0.000121823665],"about_ca_topic_score_codex":0.0011007205,"about_ca_topic_score_gemma":0.00014245401,"teacher_disagreement_score":0.63701797,"about_ca_system_score_codex":0.000028870734,"about_ca_system_score_gemma":0.00029305628,"threshold_uncertainty_score":0.5517443},"labels":[],"label_agreement":null},{"id":"W2981839573","doi":"10.1093/annonc/mdz295","title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration","year":2019,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; Internal medicine; Pemetrexed; Cancer; Immunotherapy; Cisplatin","score_opus":0.06686532430890642,"score_gpt":0.3997437970675532,"score_spread":0.3328784727586468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981839573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97710186,0.0014069083,0.00057238503,0.0004818078,0.016164556,0.0025072766,0.0017112095,0.0000021198318,0.00005190082],"genre_scores_gemma":[0.99045396,0.0024446119,0.0006869569,0.0000906424,0.0051578665,0.0006581059,0.00036141765,0.00003388174,0.00011256168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981426,0.00009674543,0.00078695576,0.00033232805,0.00047250142,0.00016887952],"domain_scores_gemma":[0.9959086,0.0014855777,0.0014092266,0.0003097557,0.00085552083,0.000031309264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006069833,0.00022067555,0.00073380367,0.00015733152,0.000033999248,0.000003912249,0.00024544858,0.0003762035,0.000018027544],"category_scores_gemma":[0.00013957174,0.00013231955,0.00015627175,0.00010065298,0.0001710629,0.00010040452,0.000035386325,0.00016741379,9.106534e-9],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25998527,0.0014419737,0.0008532205,0.002629357,0.0005456905,0.0000011937829,0.0035217316,0.00016007843,0.5422091,0.000020228332,0.14573967,0.042892504],"study_design_scores_gemma":[0.023386069,0.022237072,0.0031038169,0.0059337434,0.00030933553,0.0000045924594,0.001349913,0.0013460433,0.9308282,0.000037071048,0.011200341,0.00026377564],"about_ca_topic_score_codex":0.00076890225,"about_ca_topic_score_gemma":0.0011021633,"teacher_disagreement_score":0.38861915,"about_ca_system_score_codex":0.00011790126,"about_ca_system_score_gemma":0.0012207922,"threshold_uncertainty_score":0.53958344},"labels":[],"label_agreement":null},{"id":"W2982637342","doi":"10.1093/annonc/mdz410","title":"Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":679,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; Baycrest Hospital; University of Toronto","funders":"National Cancer Institute; Ligue Contre le Cancer","keywords":"Medicine; Cancer; Cognitive impairment; Cognition; Cancer detection; Gerontology; Oncology; Internal medicine; Psychiatry","score_opus":0.08832052940753544,"score_gpt":0.43209332513512405,"score_spread":0.3437727957275886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982637342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02691798,0.96108055,0.0000023063697,0.00075933256,0.00082649983,0.0048304065,0.00046531163,0.000036825277,0.005080799],"genre_scores_gemma":[0.01849384,0.9797919,0.0000044437397,0.00037542754,0.00004266083,0.0006031927,0.000035850833,0.000053174936,0.00059951417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99708664,0.0005224785,0.0010555498,0.00056835514,0.00032276966,0.00044421278],"domain_scores_gemma":[0.99777657,0.0002910035,0.0011420761,0.0003136443,0.00038687498,0.00008984968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005411809,0.00047991236,0.0022517096,0.0005135525,0.00006151065,0.000009011144,0.00016823858,0.00029052192,0.000098764765],"category_scores_gemma":[0.00003533595,0.00033683458,0.0002984956,0.00070256536,0.000394388,0.00010811009,0.00017057252,0.0006168645,0.000015118076],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056775316,0.0007870504,0.0003538462,0.01385225,0.0031263211,0.000033741442,0.00065931515,0.00003325876,0.000001477243,0.000056263532,0.00041235724,0.98011637],"study_design_scores_gemma":[0.0057850936,0.010888718,0.023972118,0.055431034,0.006574212,0.000051930467,0.0013639857,0.000028809322,0.00013394262,0.00038579694,0.89463437,0.0007499695],"about_ca_topic_score_codex":0.0012101558,"about_ca_topic_score_gemma":0.008412914,"teacher_disagreement_score":0.9793664,"about_ca_system_score_codex":0.00031752037,"about_ca_system_score_gemma":0.00079380063,"threshold_uncertainty_score":0.9999084},"labels":[],"label_agreement":null},{"id":"W2988378549","doi":"10.1093/annonc/mdz394.042","title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostatectomy; Randomized controlled trial; Radiation therapy; Urology; Oncology; Prostate cancer; Internal medicine; Cancer","score_opus":0.059280476973893166,"score_gpt":0.38696669541707635,"score_spread":0.3276862184431832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988378549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552066,0.005765854,0.000017494318,0.025224753,0.0004433763,0.008554277,0.0001294236,0.000028260865,0.004629978],"genre_scores_gemma":[0.9912298,0.003906969,0.00031256603,0.001538185,0.00055577164,0.0006236003,0.000097395554,0.000037037968,0.0016987268],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968019,0.0005621681,0.0011267173,0.00043905774,0.0005593441,0.00051082857],"domain_scores_gemma":[0.9943702,0.0040777354,0.0004890004,0.0005942966,0.00026640616,0.00020235838],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001882387,0.00025480398,0.0017401656,0.00013619082,0.000066336084,0.0000122921965,0.00026739665,0.00031225028,0.0013514935],"category_scores_gemma":[0.00087093347,0.00014040459,0.0005355659,0.00019927548,0.0005996857,0.00007071645,0.000057791098,0.00038320743,0.00003319035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9701263,0.0010168742,0.0009671397,0.00005827881,0.0013211871,0.000094636074,0.0013093383,0.000006190955,0.0028784066,0.000021697448,0.013381585,0.008818396],"study_design_scores_gemma":[0.9115896,0.008542196,0.0024459339,0.00020066956,0.00019833475,0.000010541486,0.00010258784,0.00027248115,0.007542349,0.00013933892,0.06881635,0.00013961605],"about_ca_topic_score_codex":0.00021675078,"about_ca_topic_score_gemma":0.0000185836,"teacher_disagreement_score":0.05853667,"about_ca_system_score_codex":0.00009813666,"about_ca_system_score_gemma":0.00080516236,"threshold_uncertainty_score":0.9995614},"labels":[],"label_agreement":null},{"id":"W2989612821","doi":"10.1093/annonc/mdz426.039","title":"ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Pembrolizumab; Oncology; Chemotherapy; Ovarian cancer; Epithelial ovarian cancer; Internal medicine; Gynecology; Cancer; Immunotherapy; Poly ADP ribose polymerase","score_opus":0.05193308591041664,"score_gpt":0.39148638361326155,"score_spread":0.3395532977028449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989612821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98403114,0.0009679335,0.00016433849,0.008291036,0.00041667168,0.004458982,0.00067363714,0.000023581912,0.0009726661],"genre_scores_gemma":[0.99048835,0.00561025,0.0011387855,0.00054943236,0.00024877663,0.0009078705,0.00015873228,0.000053598105,0.00084421516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99786174,0.00005772226,0.00086322037,0.0004936003,0.0002540431,0.00046965617],"domain_scores_gemma":[0.9975064,0.00033295172,0.0008843308,0.00052401074,0.0005939692,0.00015837178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020039201,0.00034729714,0.0018642485,0.0001571199,0.000038863625,0.0000036124306,0.000129798,0.00020970935,0.000526329],"category_scores_gemma":[0.00003715896,0.00024565784,0.0003261579,0.00023006818,0.00019261088,0.000070308015,0.000016632042,0.00008467046,0.000004394723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5535305,0.01752226,0.0006707468,0.00037925772,0.0027408598,0.00005576623,0.0014735385,0.0005798019,0.0053329975,0.000702762,0.0011557877,0.41585574],"study_design_scores_gemma":[0.72937995,0.11206684,0.0010327719,0.0003332129,0.0005706768,0.000022292745,0.00009932526,0.00041149114,0.07053442,0.00012050816,0.085206866,0.00022161925],"about_ca_topic_score_codex":0.0010756155,"about_ca_topic_score_gemma":0.00046949048,"teacher_disagreement_score":0.4156341,"about_ca_system_score_codex":0.00034796607,"about_ca_system_score_gemma":0.001147995,"threshold_uncertainty_score":0.9999996},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2989838587","doi":"10.1093/annonc/mdz417","title":"Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Capecitabine; Triple-negative breast cancer; Adjuvant; Oncology; Breast cancer; Internal medicine; Immune system; Cancer; Immunology; Colorectal cancer","score_opus":0.02178207769440861,"score_gpt":0.3528573360992954,"score_spread":0.33107525840488683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989838587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97931474,0.0011412986,0.0000027791696,0.016604653,0.00049317355,0.0017720857,0.00005163113,0.0000090442945,0.0006105759],"genre_scores_gemma":[0.99593395,0.00034113223,0.00007324584,0.0025290102,0.00007941664,0.000103966384,0.000003934337,0.000017855731,0.0009174852],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99843925,0.0003398503,0.0005281364,0.00023842657,0.00019235745,0.0002619657],"domain_scores_gemma":[0.9983916,0.00087271375,0.000248111,0.00027664847,0.0001373645,0.00007352999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007574225,0.00015492439,0.00083188235,0.0003542958,0.000012129836,0.0000016006354,0.000121326,0.00015574347,0.00030296776],"category_scores_gemma":[0.00025536754,0.0001198794,0.00019165529,0.00043541662,0.00009517549,0.000023049022,0.000032154476,0.00020414469,0.00001288208],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59389174,0.0006335221,0.0002824582,0.00013198961,0.00012722537,0.000025882942,0.0011310058,0.000024561707,0.3096957,0.000008888141,0.0006239646,0.09342304],"study_design_scores_gemma":[0.15379167,0.050616268,0.45441732,0.00092198455,0.000059713577,0.000032970867,0.00023264406,0.000008146412,0.32606313,0.00009807559,0.013547258,0.00021082078],"about_ca_topic_score_codex":0.0012765372,"about_ca_topic_score_gemma":0.0002600385,"teacher_disagreement_score":0.45413485,"about_ca_system_score_codex":0.00011626277,"about_ca_system_score_gemma":0.00043930946,"threshold_uncertainty_score":0.488854},"labels":[],"label_agreement":null},{"id":"W2990458768","doi":"10.1093/annonc/mdz421","title":"Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Colorectal cancer; Internal medicine; Cancer","score_opus":0.05691471387842958,"score_gpt":0.34299004971402447,"score_spread":0.2860753358355949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990458768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393827,0.00014425472,1.3127028e-7,0.0014363779,0.00012791062,0.0005655803,0.000042981344,0.0000072052076,0.0037372936],"genre_scores_gemma":[0.9974618,0.00009510939,0.000011871415,0.00065787154,0.00002195334,0.000046963723,0.000015308888,0.0000062336553,0.0016828733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989381,0.00007231295,0.0003208878,0.00022558411,0.00018688798,0.0002562534],"domain_scores_gemma":[0.99945563,0.00011671886,0.00010178137,0.00011917973,0.000119310316,0.000087363806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020039167,0.00010263294,0.00047016525,0.00018943602,0.0000080729715,0.0000028783677,0.0001340868,0.00009924016,0.0006262854],"category_scores_gemma":[0.000116241274,0.00008412448,0.000043322252,0.0002997909,0.000051354342,0.00004089346,0.00006097276,0.00017041349,0.0001101747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012873093,0.00069919537,0.9735429,0.000069851536,0.000012342995,0.000029124822,0.0005876827,0.0000032814357,0.010758325,0.00001941954,0.0008049828,0.012185539],"study_design_scores_gemma":[0.0012682666,0.00845411,0.98354506,0.00026437364,0.0000059756794,6.117824e-7,0.000057791727,0.000064800435,0.0024776678,0.00003080568,0.0037452728,0.00008524625],"about_ca_topic_score_codex":0.0007874843,"about_ca_topic_score_gemma":0.00039750934,"teacher_disagreement_score":0.012100292,"about_ca_system_score_codex":0.00007382911,"about_ca_system_score_gemma":0.00021618296,"threshold_uncertainty_score":0.68573856},"labels":[],"label_agreement":null},{"id":"W2990777042","doi":"10.1093/annonc/mdz416.023","title":"KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Pembrolizumab; Breast cancer; Internal medicine; Chemotherapy; Adjuvant chemotherapy; Adjuvant; Stage (stratigraphy); Placebo; Cancer; Immunotherapy; Pathology","score_opus":0.036806059865985376,"score_gpt":0.36875877525549794,"score_spread":0.33195271538951254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990777042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920544,0.0018869346,0.00010626743,0.0011460527,0.00014153904,0.004199587,0.0003295242,0.000013939422,0.00012172875],"genre_scores_gemma":[0.98876154,0.0086240405,0.00019476528,0.00036178765,0.00016385,0.0012573558,0.00005315169,0.00005834164,0.00052517117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792165,0.00020420844,0.00058615004,0.00064924796,0.00020212894,0.00043659107],"domain_scores_gemma":[0.99803185,0.0002124056,0.00070931,0.00049129955,0.000455237,0.00009990716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039401988,0.00040672987,0.001475764,0.000106235115,0.000085563894,0.000010884589,0.00022412962,0.00015912838,0.00011490566],"category_scores_gemma":[0.000020402158,0.0002648987,0.00016439553,0.0001294476,0.00031733885,0.000014077994,0.00009400132,0.00012403344,0.000001043953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9281258,0.0031166452,0.010843032,0.000052320484,0.0031434065,0.000010802828,0.0009761574,0.00009230139,0.002940175,0.000034273784,0.00038464603,0.050280463],"study_design_scores_gemma":[0.9236881,0.022647092,0.009737728,0.000042574982,0.00028208806,0.00004386289,0.0006987204,0.000022727412,0.03920742,0.000024767187,0.0032693164,0.00033558148],"about_ca_topic_score_codex":0.005407271,"about_ca_topic_score_gemma":0.0020316765,"teacher_disagreement_score":0.04994488,"about_ca_system_score_codex":0.000025465557,"about_ca_system_score_gemma":0.00029702095,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W2990936758","doi":"10.1093/annonc/mdz437.001","title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Osimertinib; Internal medicine; T790M; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Phases of clinical research; Platinum; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Gefitinib; Erlotinib","score_opus":0.022808302268853824,"score_gpt":0.38039218338195413,"score_spread":0.3575838811131003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990936758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914966,0.0008271871,0.0000047707667,0.001892338,0.00034888426,0.0040317327,0.00016120396,0.000026265734,0.0012109985],"genre_scores_gemma":[0.99758095,0.0001764204,0.00029617077,0.0009851254,0.00011672199,0.00034526302,0.00016518812,0.00004724149,0.00028689997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786663,0.00016061957,0.0005647588,0.00059348886,0.000394301,0.00042019362],"domain_scores_gemma":[0.9982864,0.00035408704,0.000469456,0.0004366446,0.00028805685,0.0001653421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002367972,0.00033475907,0.00080294796,0.00014185716,0.00010361818,0.00001835281,0.00013912871,0.00014347672,0.00013805086],"category_scores_gemma":[0.000055304998,0.0002085533,0.00007492086,0.00026859593,0.00009017262,0.00013760047,0.00008737078,0.00029620377,0.0000070373585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021904089,0.011276175,0.84633577,0.00012037614,0.00043778642,0.00008104628,0.0057651745,0.00008663477,0.0027051275,0.00001076985,0.0015019106,0.10977512],"study_design_scores_gemma":[0.15068175,0.041581348,0.78839743,0.0014751088,0.0006496151,0.0000020062382,0.0014646474,0.0003751116,0.009787291,0.00001544575,0.005133687,0.0004365271],"about_ca_topic_score_codex":0.001409158,"about_ca_topic_score_gemma":0.000962139,"teacher_disagreement_score":0.12877767,"about_ca_system_score_codex":0.00021989197,"about_ca_system_score_gemma":0.0004863032,"threshold_uncertainty_score":0.8504557},"labels":[],"label_agreement":null},{"id":"W2991048535","doi":"10.1093/annonc/mdz433.012","title":"Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Soft tissue; Myoepithelial cell; Internal medicine; Carcinoma; Pathology; Immunohistochemistry","score_opus":0.04130381181714662,"score_gpt":0.3675160009074681,"score_spread":0.3262121890903215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991048535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900566,0.00062985707,0.0000010325124,0.0058636875,0.00010849092,0.0004683196,0.00002203089,0.000011496748,0.0028385124],"genre_scores_gemma":[0.9974,0.00085344154,0.00020218015,0.00094722194,0.000051947107,0.000018981895,0.000017062517,0.000013879784,0.0004953036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992108,0.00003476523,0.0002840509,0.00019503968,0.00010596942,0.00016941964],"domain_scores_gemma":[0.99914193,0.00028099792,0.00014535186,0.00023174525,0.00011378299,0.00008620191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006921741,0.00014475726,0.0007138722,0.0000757462,0.000013720835,0.0000017513772,0.00004050179,0.000091060916,0.000202482],"category_scores_gemma":[0.000031327512,0.00009469865,0.0001169553,0.000053354936,0.00007526117,0.00002150745,0.000015905625,0.000039110906,0.000025814694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074204896,0.0025393022,0.9291412,0.000049498078,0.00032466374,0.000047027144,0.0005056324,8.844262e-7,0.0005855145,0.00040271875,0.00038058156,0.06528089],"study_design_scores_gemma":[0.011399666,0.017737655,0.9193838,0.00003058134,0.000117159725,0.00003960513,0.000060323942,0.000006070277,0.04516325,0.00007938037,0.0059089568,0.00007354415],"about_ca_topic_score_codex":0.00043287364,"about_ca_topic_score_gemma":0.0000172685,"teacher_disagreement_score":0.06520735,"about_ca_system_score_codex":0.000025567602,"about_ca_system_score_gemma":0.000094847004,"threshold_uncertainty_score":0.38616988},"labels":[],"label_agreement":null},{"id":"W2991090638","doi":"10.1093/annonc/mdz420.002","title":"NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Afatinib; Series (stratigraphy); Oncology; Cancer research; Internal medicine; Cancer","score_opus":0.10946429398928428,"score_gpt":0.4602900680415992,"score_spread":0.35082577405231496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991090638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97487617,0.0005962487,0.000017543494,0.016062021,0.00018646843,0.00062373996,0.000018046865,0.000015889724,0.0076038516],"genre_scores_gemma":[0.99742454,0.00037016615,0.00032160923,0.0012408164,0.00016304172,0.00003339374,0.00000608971,0.000022129385,0.00041821026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834853,0.0002697114,0.00044584178,0.00020924612,0.00037696288,0.0003496946],"domain_scores_gemma":[0.99841034,0.00033654907,0.00031620002,0.0004599664,0.0003832,0.00009376121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008779777,0.000116149065,0.00048367295,0.00012836381,0.00006575804,0.0000059895588,0.00024012686,0.00014996738,0.000922659],"category_scores_gemma":[0.00022907028,0.00007896947,0.00013007494,0.00023898733,0.0004034497,0.00005756369,0.00015715972,0.0003608214,0.00005998374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039534434,0.002203183,0.11203202,0.0015283731,0.0012644383,0.0045073675,0.017142573,0.00030312894,0.44785056,0.0029187682,0.015338834,0.3909573],"study_design_scores_gemma":[0.017145632,0.08112713,0.15507224,0.0022060776,0.0009752761,0.04926144,0.04054616,0.0052467245,0.44666678,0.005537419,0.19485597,0.0013591541],"about_ca_topic_score_codex":0.00024835265,"about_ca_topic_score_gemma":0.00006688745,"teacher_disagreement_score":0.38959816,"about_ca_system_score_codex":0.000033551307,"about_ca_system_score_gemma":0.000711582,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W2991616458","doi":"10.1093/annonc/mdz296","title":"EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cilag; Pharmacyclics; Chugai Pharmaceutical; MSD Australia; EMD Serono; Genentech; Active Biotech; Medac; Ipsen; Bavarian Nordic; Shionogi; Astellas Pharma; Eisai; European Society for Medical Oncology; European Association of Urology; Sirtex Medical; Cancer Research UK; GlaxoSmithKline; UroGen Pharma; Pfizer; Incyte; Manchester Biomedical Research Centre; Accuray; National Institute for Health and Care Research; Clovis Oncology; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Celldex Therapeutics; Siemens Healthineers; Amgen; Elekta; Sanofi Pasteur; Royal Marsden NHS Foundation Trust; Alere; Bayer HealthCare; Exelixis; Sanofi; Endocyte; Novartis; Bayer; Allergan; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company","keywords":"Medicine; Delphi method; Stakeholder; Delphi; Bladder cancer; Voting; Consensus conference; Family medicine; Cancer; Public relations; Internal medicine; Political science","score_opus":0.16532931734192985,"score_gpt":0.4504202926011262,"score_spread":0.28509097525919636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991616458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699375,0.00067634345,0.000009222681,0.025112005,0.00031899917,0.001041957,0.00017349154,0.000004864809,0.002725589],"genre_scores_gemma":[0.9933047,0.0019907635,0.00044654947,0.0033560942,0.000028342254,0.00006210677,0.00000759479,0.000012186625,0.00079164904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998857,0.00011942614,0.0004125267,0.00020629093,0.00025751095,0.00014725303],"domain_scores_gemma":[0.9986037,0.00018790278,0.00037616503,0.00031727893,0.00047632316,0.000038619677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003199475,0.00014702062,0.00033043657,0.000041402815,0.00006622423,0.0000067783835,0.00018115906,0.000059399757,0.000112606125],"category_scores_gemma":[0.00001971105,0.000070662434,0.000043875385,0.00011431167,0.00037258083,0.000053821528,0.00010316261,0.000096824515,0.0000010065804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018359007,0.008941478,0.5704621,0.0016802486,0.038624518,0.00012565029,0.029292675,0.0075397,0.013797655,0.08296071,0.030709706,0.19750652],"study_design_scores_gemma":[0.011229119,0.004352849,0.91464186,0.0006011018,0.0006565717,0.000014237025,0.016840216,0.0006033287,0.013998384,0.0011707515,0.03568428,0.0002073104],"about_ca_topic_score_codex":0.00077914796,"about_ca_topic_score_gemma":0.0006531183,"teacher_disagreement_score":0.34417972,"about_ca_system_score_codex":0.000028005712,"about_ca_system_score_gemma":0.0001442311,"threshold_uncertainty_score":0.28815302},"labels":[],"label_agreement":null},{"id":"W2991620783","doi":"10.1093/annonc/mdz437.015","title":"Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Afatinib; Osimertinib; Internal medicine; Medical record; Observational study; Oncology; Pediatrics; Cancer; Erlotinib","score_opus":0.03242906789578016,"score_gpt":0.3811680364881982,"score_spread":0.34873896859241804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991620783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961875,0.000032636282,0.0000017430581,0.00056567276,0.00008857843,0.00063247746,0.000024022362,0.0000047042063,0.002462669],"genre_scores_gemma":[0.999511,0.000009964822,0.000042370022,0.00020102524,0.000008393984,0.000009342278,0.000042425912,0.000007799914,0.0001676972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909586,0.00012721063,0.0002923268,0.00017396397,0.00018119556,0.00012945198],"domain_scores_gemma":[0.9992558,0.00007668045,0.00022218804,0.00022006778,0.00018989945,0.000035405614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018386103,0.000085458225,0.0004659715,0.00015947822,0.000020172189,0.0000028612285,0.000057754594,0.000050015387,0.00012355334],"category_scores_gemma":[0.00003374042,0.00005241826,0.00006298461,0.00043792324,0.000057255147,0.000045282388,0.000040254967,0.00007680564,0.0000011010767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006162331,0.001275905,0.99147457,0.0000114865725,0.0020167627,0.000002454884,0.0014846893,0.00010283531,0.00012386029,0.000026375203,0.000069158006,0.0027956418],"study_design_scores_gemma":[0.005222181,0.003080804,0.98961663,0.000029844496,0.001199962,2.9848852e-7,0.00033427277,0.000057239264,0.00013465137,0.000007655556,0.00026820428,0.00004823978],"about_ca_topic_score_codex":0.0007356547,"about_ca_topic_score_gemma":0.00061438564,"teacher_disagreement_score":0.004605948,"about_ca_system_score_codex":0.000032620654,"about_ca_system_score_gemma":0.00014598777,"threshold_uncertainty_score":0.21375547},"labels":[],"label_agreement":null},{"id":"W2995798653","doi":"10.1093/annonc/mdz452","title":"Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; CD8; Cytotoxic T cell; Cancer research; Immunology; Antigen; Immune system; Biology; In vitro; Biochemistry","score_opus":0.02463949322853559,"score_gpt":0.31302863989151836,"score_spread":0.28838914666298276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995798653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744414,0.0014408522,0.000018590696,0.014258529,0.0003246626,0.0007279155,0.00016520837,0.000050122337,0.008572703],"genre_scores_gemma":[0.9678737,0.00084307865,0.0003427528,0.014505607,0.00007219833,0.0000385288,0.0000595624,0.000046456687,0.01621811],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980248,0.00013208127,0.0005269115,0.00043092069,0.000369497,0.00051577034],"domain_scores_gemma":[0.998479,0.00018725834,0.00038386698,0.0004605945,0.0003460902,0.00014317688],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043486393,0.00026218576,0.00083325314,0.00013328585,0.000058534886,0.00001272603,0.00025566615,0.0002641442,0.0013763115],"category_scores_gemma":[0.000032991455,0.00021499857,0.000178123,0.0004136199,0.00015399596,0.00007967667,0.000033518383,0.00023072428,0.00011043527],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012882877,0.00073926704,0.0070042643,0.000050814553,0.00094013574,0.000051828723,0.0009349593,0.000005819499,0.7073834,0.000043551612,0.2633223,0.0066407784],"study_design_scores_gemma":[0.009690048,0.012077952,0.05652756,0.00040877974,0.00007615267,0.000017100401,0.00021147315,0.0000069740827,0.33964622,0.000074743635,0.5808268,0.00043619098],"about_ca_topic_score_codex":0.00032121816,"about_ca_topic_score_gemma":0.00021353028,"teacher_disagreement_score":0.3677372,"about_ca_system_score_codex":0.00015611803,"about_ca_system_score_gemma":0.00036819789,"threshold_uncertainty_score":0.9995366},"labels":[],"label_agreement":null},{"id":"W2996463763","doi":"10.1093/annonc/mdz453.002","title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; KRAS; Chemotherapy; Placebo; Cancer; Immunotherapy; Pathology; Alternative medicine; Colorectal cancer","score_opus":0.042502437932729425,"score_gpt":0.40823391892670496,"score_spread":0.36573148099397557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996463763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816711,0.0016052005,0.00024294025,0.009147835,0.00018965665,0.003077556,0.00008646309,0.000033846474,0.003945378],"genre_scores_gemma":[0.9902116,0.0017959198,0.0017664485,0.004015585,0.00010558404,0.00033398264,0.00028259656,0.000061156694,0.0014271248],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980583,0.00005709702,0.0005856074,0.00048804138,0.0002704793,0.0005404795],"domain_scores_gemma":[0.99792063,0.0009686046,0.00030012886,0.0003036382,0.0003078516,0.00019916994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028616117,0.00031287092,0.0009609829,0.00025780062,0.000073803276,0.000015702806,0.000113052745,0.00018160968,0.00038386413],"category_scores_gemma":[0.0001447429,0.0002664691,0.00017438582,0.0002428188,0.00014913963,0.00012224716,0.00002354977,0.00018820672,0.000033574],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24830797,0.017195644,0.019032687,0.002755683,0.0065627536,0.0004710802,0.049102306,0.008945302,0.010256687,0.0051571294,0.012750816,0.61946195],"study_design_scores_gemma":[0.5428581,0.050246403,0.20042664,0.0005297078,0.0009195018,0.000463179,0.0018619888,0.011584029,0.028291702,0.005810839,0.15559581,0.0014121109],"about_ca_topic_score_codex":0.0005050968,"about_ca_topic_score_gemma":0.00015107098,"teacher_disagreement_score":0.61804986,"about_ca_system_score_codex":0.00032647865,"about_ca_system_score_gemma":0.0017242591,"threshold_uncertainty_score":0.9999788},"labels":[],"label_agreement":null},{"id":"W2998744744","doi":"10.1016/s0923-7534(20)33763-7","title":"Long-Term Efficacy and Safety of L-BLP25 Vaccine in a Multi-Centre Open-Label Study of Patients with Unresectable Stage III NSCLC","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Ottawa Hospital; CancerCare Manitoba; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Oncology; Open label; Internal medicine; Open label study; Stage (stratigraphy); Term (time); Adverse effect","score_opus":0.07572942215344558,"score_gpt":0.39960014364476615,"score_spread":0.32387072149132057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998744744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980208,0.00032889264,0.00003657285,0.000071895825,0.000021468208,0.0010981497,0.000032679243,0.00000141597,0.00038808497],"genre_scores_gemma":[0.9992318,0.00012954966,0.00016728263,0.000039765237,0.000010798622,0.0000151660715,0.00006106602,0.000011271676,0.00033325813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988071,0.00018767308,0.00037040492,0.00020551415,0.0001575409,0.00027182166],"domain_scores_gemma":[0.9990716,0.00004148441,0.00022097993,0.0002702298,0.0003044715,0.00009121875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044849367,0.000111155576,0.0003495063,0.000097659875,0.000025846432,0.000004297912,0.00023610762,0.00011545784,0.00005261796],"category_scores_gemma":[0.000119621924,0.00009095547,0.000015937658,0.0001600541,0.000061868195,0.00001442267,0.00035132925,0.00008903018,7.091727e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008486253,0.017039122,0.93876517,0.00007659826,0.00013506493,0.0000033359368,0.00057860586,0.000016842552,0.02160472,0.000017770355,0.00011189664,0.013164634],"study_design_scores_gemma":[0.038200904,0.0075940457,0.92331934,0.000034730565,0.000012279086,7.716787e-7,0.00031793592,0.000013455186,0.029308265,7.1737173e-7,0.0010890437,0.00010854197],"about_ca_topic_score_codex":0.00026877833,"about_ca_topic_score_gemma":0.0012197759,"teacher_disagreement_score":0.029714648,"about_ca_system_score_codex":0.000008125732,"about_ca_system_score_gemma":0.000090411915,"threshold_uncertainty_score":0.37090567},"labels":[],"label_agreement":null},{"id":"W2998769983","doi":"10.1016/s0923-7534(20)31363-6","title":"P3.10 Microrna Profiling in Gastric Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; microRNA; Profiling (computer programming); Cancer; Gene expression profiling; Oncology; Cancer research; Computational biology; Internal medicine; Gene expression; Genetics; Gene","score_opus":0.05148537801931091,"score_gpt":0.3691236896915721,"score_spread":0.3176383116722612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998769983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991905,0.0051879473,0.00006028094,0.00038115494,0.000127549,0.00013179825,0.00001658051,0.000003817308,0.0021859237],"genre_scores_gemma":[0.99802345,0.00037416795,0.0007293135,0.0003075029,0.00025284136,0.00002797921,0.000053040992,0.000011511839,0.00022017735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992463,0.00007337568,0.00020867574,0.00014157702,0.00005289659,0.00027715377],"domain_scores_gemma":[0.9995521,0.000011666707,0.00012241928,0.00015492253,0.0000897617,0.00006913246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024360504,0.00008252999,0.00014077878,0.00006746597,0.00001411187,0.000001924878,0.00009887183,0.00015323171,0.000110865556],"category_scores_gemma":[0.00006444441,0.0000839425,0.000056575725,0.00010289955,0.00005333694,0.000004761609,0.000060087674,0.000051243307,0.000013279394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015355075,0.00018905738,0.035504244,0.000023672308,0.000028840383,0.0000011501712,0.000033638495,0.00005537312,0.9440364,0.000041345604,0.0054384405,0.014494287],"study_design_scores_gemma":[0.00050585903,0.00035561214,0.0461787,0.000013997629,0.000011529825,0.000010278456,0.000030551975,0.00002003246,0.8313196,0.00003774844,0.121396996,0.000119127675],"about_ca_topic_score_codex":0.00003109952,"about_ca_topic_score_gemma":0.000029628456,"teacher_disagreement_score":0.11595856,"about_ca_system_score_codex":0.000018858358,"about_ca_system_score_gemma":0.00014188355,"threshold_uncertainty_score":0.34230757},"labels":[],"label_agreement":null},{"id":"W2998801500","doi":"10.1016/s0923-7534(20)33022-2","title":"Development of Cancer Stem Cells Therapeutics","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Animal Genetics and Reproduction","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trojan Technologies (Canada)","funders":"","keywords":"Medicine; Cancer stem cell; Stem cell; Cancer; Cancer research; Computational biology; Internal medicine; Cell biology","score_opus":0.11179506905306706,"score_gpt":0.3864258238091605,"score_spread":0.27463075475609344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998801500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928917,0.00517907,0.00020689952,0.00019875077,0.00027965265,0.000066582754,0.0000044348526,0.0000018579207,0.0011710362],"genre_scores_gemma":[0.99570763,0.001694748,0.0016721316,0.000205705,0.00019005564,0.000007083736,0.0000041777994,0.000008256561,0.0005102231],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994417,0.00002635162,0.00020533867,0.00011003762,0.000060486014,0.00015609754],"domain_scores_gemma":[0.999556,0.0000035629123,0.00014328571,0.00013323489,0.00012731484,0.000036617148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020098498,0.0000638318,0.00012292198,0.00002046447,0.000020670617,7.8714515e-7,0.000076004835,0.00011474542,0.000015055875],"category_scores_gemma":[0.0000018209544,0.000054481417,0.000043538606,0.00003741158,0.000077320474,0.0000013109498,0.000050649338,0.00003080362,0.0000030237804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051741834,0.00015395781,0.002061419,0.000015432572,0.000085450825,5.867655e-8,0.00025662064,0.0000138373925,0.87284344,0.000060240323,0.0004747226,0.12398308],"study_design_scores_gemma":[0.00006960469,0.00022705109,0.0028306965,0.0000023333114,0.000007723709,7.3776164e-7,0.00007196024,0.0000010583342,0.6156683,0.000004028399,0.38107747,0.000039060345],"about_ca_topic_score_codex":0.000006024113,"about_ca_topic_score_gemma":0.000012452661,"teacher_disagreement_score":0.38060275,"about_ca_system_score_codex":0.0000044715002,"about_ca_system_score_gemma":0.00012083971,"threshold_uncertainty_score":0.22216877},"labels":[],"label_agreement":null},{"id":"W2998853701","doi":"10.1016/s0923-7534(20)32913-6","title":"Safety of Everolimus For Women Over 65 Years of Age With Advanced Breast Cancer: 18-Mo Follow-Up of BOLERO-2","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Everolimus; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.016936108547038278,"score_gpt":0.31747302363373275,"score_spread":0.3005369150866945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998853701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647623,0.0020607538,0.000031991887,0.000060291284,0.00011488857,0.00025104452,0.0001977643,0.0000026739133,0.000804346],"genre_scores_gemma":[0.9978624,0.0014024777,0.0003006668,0.00008816874,0.000059731025,0.000032629716,0.000029455516,0.000018552695,0.00020592476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908763,0.0000556784,0.00031350748,0.00014769787,0.00009617383,0.00029930295],"domain_scores_gemma":[0.99912715,0.000047044225,0.0003739035,0.00019419081,0.00017417806,0.00008350546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002463361,0.00011327334,0.0004331509,0.000046796325,0.000013131083,5.9106094e-7,0.00013461256,0.0002402228,0.000021877506],"category_scores_gemma":[0.000030777624,0.00009843701,0.00013169901,0.00008491563,0.00018686279,0.0000067645155,0.000054350767,0.00006361772,4.0460412e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006998693,0.00046434265,0.007825322,0.00018992706,0.00065691577,0.0000018806677,0.00043550725,0.00013070939,0.93370163,0.00012811893,0.0014034873,0.04806345],"study_design_scores_gemma":[0.006348058,0.008261135,0.07496539,0.00009243154,0.000092329654,0.000020488176,0.00020052388,0.000007584348,0.88180137,0.00006407924,0.02793171,0.00021491881],"about_ca_topic_score_codex":0.00004796516,"about_ca_topic_score_gemma":0.000013337837,"teacher_disagreement_score":0.06714007,"about_ca_system_score_codex":0.000013794554,"about_ca_system_score_gemma":0.00013726289,"threshold_uncertainty_score":0.4014145},"labels":[],"label_agreement":null},{"id":"W2998884390","doi":"10.1016/s0923-7534(20)34338-6","title":"Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Crizotinib; Medicine; Pemetrexed; Docetaxel; Oncology; Lung cancer; Chemotherapy; Internal medicine; non-small cell lung cancer (NSCLC); Cisplatin","score_opus":0.039196196959662574,"score_gpt":0.42555613764309647,"score_spread":0.3863599406834339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998884390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005145,0.00049114175,0.000015347283,0.0002469971,0.0002356924,0.0020002984,0.000085026004,0.00001078915,0.0068632513],"genre_scores_gemma":[0.9981342,0.00014791869,0.0006093729,0.00032372386,0.00005971049,0.00024331501,0.00006443251,0.000028042316,0.00038929092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877036,0.000057311387,0.0003929001,0.0002332292,0.00019656867,0.00034962222],"domain_scores_gemma":[0.99877936,0.00013458844,0.00034716135,0.00022161925,0.00038858736,0.00012868464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011947381,0.00018672047,0.00062423456,0.00016940174,0.000036719393,0.0000021436697,0.000080445374,0.00008282149,0.00029933563],"category_scores_gemma":[0.000022269242,0.00013170409,0.000057340483,0.00031580604,0.000062264764,0.000121925674,0.000023638766,0.00011741637,0.0000022401055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1124784,0.09464073,0.57957166,0.00028395082,0.002459187,0.000046423404,0.035221744,0.000050986815,0.0019072657,0.000014186656,0.0024617084,0.17086378],"study_design_scores_gemma":[0.3448729,0.09766409,0.5228305,0.00027553792,0.0011333497,0.0000016077599,0.006042017,0.00004338523,0.024781402,0.0000014934948,0.002034394,0.00031934664],"about_ca_topic_score_codex":0.0006962904,"about_ca_topic_score_gemma":0.00035563894,"teacher_disagreement_score":0.2323945,"about_ca_system_score_codex":0.00014310323,"about_ca_system_score_gemma":0.0004282408,"threshold_uncertainty_score":0.5370737},"labels":[],"label_agreement":null},{"id":"W2998909083","doi":"10.1016/s0923-7534(20)33028-3","title":"Phase I Study to Compare Safety and Pharmacokinetics of Afatinib, An Oral Irreversible Erbb Family Blocker, in Non-Cancer Subjects with Hepatic Impairment to Matched Healthy Subjects","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Pharmacokinetics; Oncology; Internal medicine; Cancer; ErbB; Pharmacology; Erlotinib; Epidermal growth factor receptor","score_opus":0.09833943599749505,"score_gpt":0.46359237055575014,"score_spread":0.3652529345582551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998909083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949728,0.00046263053,0.000023169961,0.0013933558,0.0001135672,0.0027702928,0.00003498064,0.000015088982,0.0002140707],"genre_scores_gemma":[0.996343,0.0002714205,0.001065954,0.0020574615,0.00008781871,0.00007887877,0.000015915291,0.000032704193,0.00004684437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974093,0.00028850403,0.0006662315,0.00036067507,0.0004999097,0.000775389],"domain_scores_gemma":[0.99810004,0.00025738342,0.00018905221,0.00039016412,0.00032003896,0.0007432952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012840799,0.00023492516,0.0010895842,0.00037899855,0.000039534087,0.000004932188,0.00018043154,0.000064190186,0.000073866635],"category_scores_gemma":[0.00007655493,0.0001974008,0.000043287662,0.0007123619,0.00011147195,0.00010024625,0.00017396656,0.00021491155,0.000007991014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09945271,0.05932251,0.7077995,0.0023810815,0.00080760394,0.00046023325,0.061272226,0.00061209954,0.019504288,0.00001560624,0.006782657,0.041589506],"study_design_scores_gemma":[0.1621308,0.14641017,0.6503159,0.0005934664,0.00031398822,0.00010914348,0.0133204525,0.0030780388,0.02144553,0.000008342499,0.0017367126,0.000537487],"about_ca_topic_score_codex":0.009641959,"about_ca_topic_score_gemma":0.0033904628,"teacher_disagreement_score":0.08708765,"about_ca_system_score_codex":0.0018236733,"about_ca_system_score_gemma":0.0027226482,"threshold_uncertainty_score":0.9969529},"labels":[],"label_agreement":null},{"id":"W2998916467","doi":"10.1016/s0923-7534(20)30034-x","title":"P-0115 Pancreatic Ductal Adenocarcinoma Resection, a Decade Experience in a Low-Volume Reference Center","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Center (category theory); Adenocarcinoma; Resection; Oncology; Volume (thermodynamics); Internal medicine; General surgery; Pancreatic cancer; Surgery; Cancer","score_opus":0.18148915126778034,"score_gpt":0.4516408319151197,"score_spread":0.2701516806473394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998916467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670488,0.0015960867,0.000027960406,0.0023702886,0.00014102874,0.000405066,0.0000071089094,0.000020324245,0.028383303],"genre_scores_gemma":[0.99558526,0.00081496255,0.0007704196,0.0008119512,0.00017319503,0.00013846005,0.000016345917,0.000016577504,0.0016728371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977833,0.00029240022,0.00056543696,0.00028274138,0.00030159537,0.0007745117],"domain_scores_gemma":[0.99863386,0.00026469948,0.00015817175,0.00036639118,0.00025620218,0.00032068236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008137739,0.00016127617,0.00076861423,0.00029903132,0.000054387678,0.0000042065467,0.00017617761,0.00030753322,0.0008614374],"category_scores_gemma":[0.00074171124,0.00013975277,0.000082475184,0.00037081906,0.00041817193,0.00018154267,0.00010741408,0.00042370835,0.0001666034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011628589,0.0011767709,0.9880628,0.00010851719,0.00007140935,0.00012684855,0.0033723363,4.3727348e-7,0.0013897562,0.00035881525,0.0032419413,0.0009274822],"study_design_scores_gemma":[0.002023599,0.0027904997,0.9814884,0.00015658869,0.000043447388,0.00055013807,0.0011633832,0.00011014987,0.0010183037,0.00012257746,0.010411672,0.00012124101],"about_ca_topic_score_codex":0.00043736296,"about_ca_topic_score_gemma":0.00011662552,"teacher_disagreement_score":0.028536417,"about_ca_system_score_codex":0.00013525468,"about_ca_system_score_gemma":0.00042262778,"threshold_uncertainty_score":0.9432136},"labels":[],"label_agreement":null},{"id":"W2998933016","doi":"10.1016/s0923-7534(20)32761-7","title":"Prognostic and Predictive Values of KRAS in EGFR-Based Subgroups and Combined With p53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): A Lace-Bio Study","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Oncology; Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Cancer; Colorectal cancer","score_opus":0.04513412016362859,"score_gpt":0.3880614483762426,"score_spread":0.342927328212614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998933016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489707,0.0016851154,0.000016199645,0.00063873065,0.000035513433,0.0018392643,0.00004142234,0.0000068342747,0.00083987345],"genre_scores_gemma":[0.9992022,0.000104816056,0.00021669253,0.0001492752,0.000019949575,0.00023773454,0.000021596437,0.000013916731,0.00003380349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990119,0.00015083795,0.00028793718,0.00018900236,0.000115881325,0.00024449578],"domain_scores_gemma":[0.999106,0.0003370035,0.00015919334,0.000118734104,0.00018155364,0.00009750608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028070924,0.00012890121,0.0004957016,0.00020827157,0.00002629653,0.0000028306952,0.000038888465,0.00007365778,0.000011447542],"category_scores_gemma":[0.000053558335,0.0000979032,0.000018919136,0.0002467761,0.00015428655,0.000049136434,0.000026529102,0.00013689249,1.7996477e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002806889,0.0035689818,0.9819309,0.0002448157,0.00019182595,0.000033829507,0.009703724,0.000037799626,0.00069264544,0.000010558844,0.00010945299,0.0006685584],"study_design_scores_gemma":[0.012387818,0.0150858825,0.9680028,0.0002963622,0.00037531488,0.000004259007,0.0020476733,0.0005540445,0.001108372,0.000014050715,0.000042822037,0.00008062879],"about_ca_topic_score_codex":0.0017310374,"about_ca_topic_score_gemma":0.002709803,"teacher_disagreement_score":0.013928147,"about_ca_system_score_codex":0.00007764347,"about_ca_system_score_gemma":0.00036829532,"threshold_uncertainty_score":0.39923766},"labels":[],"label_agreement":null},{"id":"W2998980582","doi":"10.1016/j.annonc.2019.10.024","title":"Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Salivary gland; Carcinoma; Oncology; Internal medicine","score_opus":0.2798831470447674,"score_gpt":0.42863355766479666,"score_spread":0.14875041062002925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998980582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563617,0.00046157898,0.0002944059,0.0027196484,0.00004185357,0.000448328,0.00014213154,0.000007127004,0.000248748],"genre_scores_gemma":[0.9934645,0.00022844631,0.005445827,0.0005428089,0.000048423866,0.00007480144,0.00017802695,0.000008055014,0.000009099125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998881,0.000048966802,0.0006578719,0.00019917918,0.0000976644,0.000115342766],"domain_scores_gemma":[0.9992588,0.00027036935,0.000183312,0.0000827228,0.00009453499,0.0001102433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033008205,0.00008866289,0.00054304866,0.00005506601,0.00001606027,0.0000016963653,0.0000313914,0.000070615344,0.000010151995],"category_scores_gemma":[0.00016482282,0.00006805577,0.000076692384,0.00006969134,0.000053836648,0.000033801312,0.000027156468,0.000054827546,4.787872e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002446688,0.0012037777,0.9844518,0.00023982368,0.00019797515,0.00004682658,0.0010462095,0.00005700739,0.00007416814,0.0005152317,0.0014484376,0.00827206],"study_design_scores_gemma":[0.011903659,0.008056263,0.93968505,0.0001292794,0.00031370795,0.000023702021,0.00025659832,0.009860965,0.025526969,0.00043750528,0.0036869335,0.00011939185],"about_ca_topic_score_codex":0.000031513468,"about_ca_topic_score_gemma":0.000028690618,"teacher_disagreement_score":0.04476677,"about_ca_system_score_codex":0.000011838941,"about_ca_system_score_gemma":0.00025406873,"threshold_uncertainty_score":0.27752337},"labels":[],"label_agreement":null},{"id":"W2999043970","doi":"10.1016/s0923-7534(20)33538-9","title":"Platinum Combination Chemotherapy Versus Platinum Monotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomised Trials Using Individual Patient Data (IPD)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Ovarian cancer; Platinum; Chemotherapy; Meta-analysis; Oncology; Internal medicine; Cancer","score_opus":0.48230475903464526,"score_gpt":0.48457361767615015,"score_spread":0.0022688586415048895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999043970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824509,0.0071038925,0.00014922634,0.004528403,0.0007544619,0.0025240614,0.001765905,0.0000180949,0.0007050447],"genre_scores_gemma":[0.99487364,0.0013909106,0.0020034364,0.00069428154,0.00014866455,0.00017482143,0.0006775674,0.000029273513,0.0000074232385],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959822,0.0009586543,0.0016803374,0.00045976607,0.00050251983,0.00041651388],"domain_scores_gemma":[0.99478316,0.0022405453,0.0018426519,0.0006722156,0.00031176192,0.0001496572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003141665,0.00031804806,0.0035623289,0.0006440678,0.00004519018,0.000010058393,0.0001825989,0.00024912436,0.00068547396],"category_scores_gemma":[0.0004108313,0.00025034026,0.00081766624,0.0008274548,0.00011235544,0.00020108662,0.00007746839,0.00019455396,0.000001377956],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087007545,0.01102951,0.019258197,0.000106523796,0.5135937,0.0000395695,0.019353801,0.0009860388,0.0019285941,0.0005819479,0.0026711207,0.34344348],"study_design_scores_gemma":[0.3556055,0.015299664,0.104683384,0.0002232815,0.4422986,0.000017186321,0.0025544628,0.009676134,0.057114147,0.0002517453,0.011149662,0.0011262432],"about_ca_topic_score_codex":0.0013379364,"about_ca_topic_score_gemma":0.00039802043,"teacher_disagreement_score":0.34231722,"about_ca_system_score_codex":0.00019182067,"about_ca_system_score_gemma":0.0004106026,"threshold_uncertainty_score":0.9999949},"labels":[],"label_agreement":null},{"id":"W2999064056","doi":"10.1016/s0923-7534(20)33119-7","title":"Should Palliative Resection of Primary Tumor be Performed in Patients with Advanced Colorectal Cancer? A Systematic Review &amp; Meta-Analysis","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Meta-analysis; Colorectal cancer; Oncology; Primary tumor; Internal medicine; Cancer; Metastasis","score_opus":0.3354737071055839,"score_gpt":0.47300139082740184,"score_spread":0.13752768372181795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999064056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014027498,0.9917614,6.998015e-7,0.00022154099,0.00006423005,0.005564705,0.0002610965,0.000014135705,0.000709459],"genre_scores_gemma":[0.0027754079,0.9925124,0.00011119957,0.0003957534,0.000021640566,0.0037181303,0.0003120424,0.000044835724,0.00010860742],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99625367,0.00060194347,0.0017567939,0.0004462154,0.00056494755,0.0003764516],"domain_scores_gemma":[0.9955891,0.0005710125,0.0025092761,0.0004073025,0.0008150125,0.000108337284],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00078900444,0.0005225399,0.015059377,0.0005283846,0.000033695975,0.0000023819641,0.00015352582,0.0002065674,0.0001650367],"category_scores_gemma":[0.0002808254,0.0002880215,0.002037512,0.0014344177,0.0001546996,0.000078530655,0.000083598796,0.00034888915,0.0000020777766],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009587802,0.0011600552,0.0014986289,0.7726914,0.1886354,0.0000073039437,0.00025707376,0.0000013466129,1.1088483e-7,0.0000035960097,0.00012287116,0.034663413],"study_design_scores_gemma":[0.0013268237,0.008246243,0.0041160122,0.09547909,0.8297328,0.0000063195184,0.000035654157,2.8535672e-7,0.0000027959109,0.0000016356281,0.06073076,0.000321618],"about_ca_topic_score_codex":0.00023864397,"about_ca_topic_score_gemma":0.0025326693,"teacher_disagreement_score":0.67721236,"about_ca_system_score_codex":0.0006522393,"about_ca_system_score_gemma":0.0007622471,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W2999077673","doi":"10.1016/s0923-7534(19)66474-4","title":"O-0009 Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Hepatocellular carcinoma; Internal medicine; Oncology","score_opus":0.1417281524955682,"score_gpt":0.3679942408696421,"score_spread":0.22626608837407391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999077673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751305,0.00783148,0.00003307892,0.002454278,0.00026647424,0.007177915,0.000019668487,0.000038576596,0.007048017],"genre_scores_gemma":[0.9952283,0.00074583985,0.00032775282,0.0010873501,0.0005569347,0.0009356308,0.000109683824,0.000048112644,0.00096039503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633133,0.0010508237,0.0012040461,0.00035742592,0.0003351392,0.0007212166],"domain_scores_gemma":[0.9971572,0.0012696808,0.0005721191,0.00040050855,0.0002704368,0.0003300325],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029120257,0.000408297,0.0038576305,0.0004096381,0.000050483904,0.000010384209,0.00013363466,0.0003482579,0.0013410051],"category_scores_gemma":[0.0003342839,0.00026000835,0.0007348605,0.00032307798,0.00028712396,0.0001420071,0.000029372655,0.00032377543,0.00003481109],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8519459,0.0057641044,0.12740913,0.000048125916,0.00093086687,0.00042316088,0.00094707543,1.15455634e-7,0.0021441218,0.00012857984,0.00061922066,0.009639597],"study_design_scores_gemma":[0.9326956,0.01949303,0.0008325705,0.000050363866,0.00044917106,0.00007114994,0.00008866865,0.00068358856,0.028205497,0.000049894694,0.017139297,0.00024114268],"about_ca_topic_score_codex":0.000103928,"about_ca_topic_score_gemma":0.000021441192,"teacher_disagreement_score":0.12657657,"about_ca_system_score_codex":0.000044546265,"about_ca_system_score_gemma":0.00046391424,"threshold_uncertainty_score":0.9999852},"labels":[],"label_agreement":null},{"id":"W2999136960","doi":"10.1016/j.annonc.2019.10.022","title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"PharmaMar; Direction Générale de l’offre de Soins; Institut National Du Cancer; Chugai Pharmaceutical; Roche; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Novartis; Amgen; Pfizer; CNIB; AbbVie; Merck","keywords":"Vemurafenib; Medicine; Internal medicine; Oncology; Cohort; Lung cancer; Trametinib; Dabrafenib; Cancer; Metastatic melanoma","score_opus":0.02275642131417564,"score_gpt":0.29257216364256583,"score_spread":0.2698157423283902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999136960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963554,0.00036379087,0.00007915616,0.0010965536,0.000047336634,0.00022356222,0.00004771837,0.000003663249,0.0017827764],"genre_scores_gemma":[0.99757993,0.00018829468,0.00030191327,0.0016573671,0.00006949099,0.00003193138,0.00009365885,0.0000126830955,0.0000647427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993225,0.000041242663,0.00017398168,0.00023323129,0.000055175205,0.0001738798],"domain_scores_gemma":[0.9995946,0.000017753102,0.0000993842,0.00009700872,0.00009866053,0.00009258796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053647545,0.00010099965,0.00018515589,0.00003272113,0.000023990868,0.0000041976923,0.00009192018,0.00012044567,0.000021990245],"category_scores_gemma":[0.000022512784,0.00009003501,0.000025823314,0.000084090185,0.00006339547,0.000003908327,0.00006288952,0.00007181498,0.0000018130283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097290915,0.0008282957,0.7130746,0.00031069308,0.00017073497,0.00003893602,0.0020761578,0.00037648727,0.2487766,0.00013078726,0.007997088,0.025246697],"study_design_scores_gemma":[0.007793393,0.010249777,0.6170927,0.000058402296,0.00007721585,0.0000050074377,0.0002600707,0.00034882405,0.32570824,0.000059892845,0.037789624,0.00055683154],"about_ca_topic_score_codex":0.000107539956,"about_ca_topic_score_gemma":0.00026584882,"teacher_disagreement_score":0.0959819,"about_ca_system_score_codex":0.000004499764,"about_ca_system_score_gemma":0.00013545842,"threshold_uncertainty_score":0.36715212},"labels":[],"label_agreement":null},{"id":"W2999137240","doi":"10.1016/s0923-7534(20)34167-3","title":"Edmonton Symptom Assessment Scale (ESAS) For Routine Symptom Assessment of Non-Advanced Patients with Solid or Haematological Malignancies on Oncological Therapies","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Intensive care medicine; Oncology","score_opus":0.05918539703169052,"score_gpt":0.426713731025711,"score_spread":0.36752833399402046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999137240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875452,0.00019995049,0.00089975074,0.0021372123,0.000454383,0.0013682297,0.00008943173,0.00004122098,0.007264614],"genre_scores_gemma":[0.99226487,0.000218211,0.0048507727,0.0017380376,0.00015876781,0.00039256495,0.00009138424,0.00003099643,0.00025442665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756515,0.0001693276,0.0007038697,0.00037939343,0.00052562985,0.0006566035],"domain_scores_gemma":[0.9973806,0.00072091114,0.000557198,0.00038889874,0.0007190951,0.00023328539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065430254,0.00032384245,0.0014054179,0.00013050654,0.00008452458,0.0000074420195,0.00019351864,0.00032683508,0.00020937376],"category_scores_gemma":[0.00009213705,0.00019474265,0.0002398214,0.00020389608,0.00031075696,0.00012733147,0.00008489579,0.00024522038,0.0000024575083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008128326,0.0088054165,0.9324284,0.0005066237,0.0005582466,0.000021250351,0.0016563556,0.00004236757,0.0018624825,0.0023145354,0.0023506493,0.041325346],"study_design_scores_gemma":[0.0063152486,0.0400977,0.9336127,0.00034477672,0.00018738963,0.000018477069,0.0012420671,0.00006799768,0.005045285,0.00008282315,0.012710122,0.0002754046],"about_ca_topic_score_codex":0.000047385558,"about_ca_topic_score_gemma":0.00019332231,"teacher_disagreement_score":0.041049942,"about_ca_system_score_codex":0.00018410658,"about_ca_system_score_gemma":0.00046123762,"threshold_uncertainty_score":0.7941375},"labels":[],"label_agreement":null},{"id":"W2999168978","doi":"10.1016/s0923-7534(20)33514-6","title":"Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Androgen receptor; Oncology; Association (psychology); Androgen; Internal medicine; Baseline (sea); Endocrinology; Prostate cancer; Psychotherapist; Psychology; Biology; Cancer; Hormone","score_opus":0.08948615067222013,"score_gpt":0.43194192441410273,"score_spread":0.34245577374188263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999168978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998283,0.00024742426,0.000009539212,0.0005801986,0.000051597268,0.00068790617,0.00010211526,0.0000041208755,0.000034077973],"genre_scores_gemma":[0.9995349,0.00005204534,0.0001694003,0.00006306343,0.000027968446,0.000025238578,0.000037269012,0.00001002196,0.00008011282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806035,0.000481273,0.0006628255,0.00014979245,0.00040026414,0.00024552102],"domain_scores_gemma":[0.9979663,0.00044464503,0.00075542036,0.00025405962,0.0004966905,0.00008292322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014079678,0.0001134183,0.000911212,0.00036092527,0.000020120364,0.0000014616841,0.00009720205,0.0000985955,0.00006601726],"category_scores_gemma":[0.00036957592,0.00006763513,0.00013248764,0.0007827827,0.00008170878,0.00009525226,0.000044859265,0.0001244022,3.64604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030628673,0.011369488,0.88058203,0.00005197297,0.0028389487,0.0000034216378,0.005540957,0.00013382317,0.09299248,0.0000023046111,0.00003362806,0.0033880596],"study_design_scores_gemma":[0.019966818,0.016665392,0.5819336,0.00011808693,0.0026555634,0.0000011188547,0.0043540527,0.0005473291,0.37350085,0.0000056191343,0.00013822195,0.00011333399],"about_ca_topic_score_codex":0.00061074016,"about_ca_topic_score_gemma":0.00062891096,"teacher_disagreement_score":0.29864845,"about_ca_system_score_codex":0.00010375852,"about_ca_system_score_gemma":0.00018116817,"threshold_uncertainty_score":0.27580804},"labels":[],"label_agreement":null},{"id":"W2999193669","doi":"10.1016/s0923-7534(20)33813-8","title":"Metastatic Nsclc Outcomes at a Single Canadian Institution Over a Decade","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; Expanded access","score_opus":0.1073378157124141,"score_gpt":0.44809259043218,"score_spread":0.3407547747197659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999193669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9281721,0.0009102886,0.000023748853,0.008977739,0.00032680016,0.00024894066,0.000036686764,0.000013118414,0.06129057],"genre_scores_gemma":[0.99344665,0.000036700563,0.0005329673,0.004504648,0.000048144444,0.000024362505,0.00003590874,0.0000071450595,0.0013634728],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993953,0.000025630807,0.00015666157,0.000079530095,0.000082370796,0.0002605124],"domain_scores_gemma":[0.9994437,0.00004880624,0.000066972854,0.00011352745,0.00006996228,0.0002570103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009458873,0.00007211088,0.0002321249,0.00012691563,0.000062841296,0.000001919897,0.00002765458,0.000053398624,0.00030846687],"category_scores_gemma":[0.00008386553,0.000055475557,0.000069135,0.000090653906,0.00006119992,0.00008909607,0.000012113818,0.00004388874,0.000060575723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024922518,0.0024064167,0.82026845,0.000103958104,0.0016964347,0.00014313565,0.0057342444,0.000014387371,0.00384506,0.009993105,0.04412611,0.111419454],"study_design_scores_gemma":[0.0018349866,0.0009900654,0.43268514,0.000026448664,0.00040378512,0.00007523541,0.00013950691,0.0000056702875,0.0021561128,0.00011865308,0.5614808,0.000083550505],"about_ca_topic_score_codex":0.023713242,"about_ca_topic_score_gemma":0.038198646,"teacher_disagreement_score":0.5173547,"about_ca_system_score_codex":0.00035618592,"about_ca_system_score_gemma":0.0005008366,"threshold_uncertainty_score":0.9827879},"labels":[],"label_agreement":null},{"id":"W2999296276","doi":"10.1016/s0923-7534(20)33669-3","title":"Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; Université de Montréal","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Oncology; Progression-free survival; Overall survival; Leukemia; Internal medicine; Immunology; Cancer research","score_opus":0.15423032111716808,"score_gpt":0.4364968980467409,"score_spread":0.2822665769295728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999296276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806506,0.0031651268,0.000016332326,0.0012421078,0.00022271779,0.0005062612,0.000012932135,0.000039515253,0.014144385],"genre_scores_gemma":[0.9980267,0.00029018865,0.00030915494,0.00013087054,0.0006498891,0.000037940576,0.000036479083,0.0000352829,0.00048345633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722874,0.00037132783,0.0006183568,0.00031820952,0.0005938319,0.00086955744],"domain_scores_gemma":[0.99631536,0.0023492575,0.00019014701,0.00059365167,0.00015430126,0.0003972708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022590018,0.00020921319,0.0007650908,0.0003020417,0.00006079852,0.000008802624,0.0002437896,0.00041007577,0.00008982243],"category_scores_gemma":[0.0019855134,0.00018452205,0.000097040356,0.00034363283,0.00039904413,0.00021019364,0.0003338861,0.00041944883,0.000046738674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009261872,0.00017318466,0.96236175,0.0007262209,0.00013254768,0.0001403568,0.0007774008,0.000053819673,0.0004764406,0.00808239,0.0039495965,0.022200085],"study_design_scores_gemma":[0.029507875,0.002597296,0.95108765,0.00025819967,0.000082071805,0.00015209937,0.00014170828,0.0011075918,0.001338659,0.0021565515,0.011300668,0.00026961078],"about_ca_topic_score_codex":0.0012616211,"about_ca_topic_score_gemma":0.00022011955,"teacher_disagreement_score":0.028581688,"about_ca_system_score_codex":0.029478148,"about_ca_system_score_gemma":0.025860986,"threshold_uncertainty_score":0.97966146},"labels":[],"label_agreement":null},{"id":"W2999298181","doi":"10.1016/s0923-7534(20)33848-5","title":"Population Based Evaluation of Chemotherapy Use After First Line Gefitinib in Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gefitinib; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Chemotherapy; Mutation; Epidermal growth factor; Population; Internal medicine; non-small cell lung cancer (NSCLC); Cancer research; Cancer; Receptor; Gene; Genetics; Biology","score_opus":0.05289967424600631,"score_gpt":0.4266385546678521,"score_spread":0.3737388804218458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999298181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945495,0.0008420296,0.0003196966,0.0022991807,0.00020347192,0.001204057,0.00016803751,0.000010341331,0.0004036434],"genre_scores_gemma":[0.99606246,0.00023907289,0.0017640588,0.0010172531,0.000115813134,0.00031209568,0.0004130215,0.000023725615,0.00005249497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987356,0.00013493856,0.0004553025,0.00018908277,0.00023910479,0.00024593718],"domain_scores_gemma":[0.99846476,0.0002210313,0.00036894061,0.00013131993,0.0007261813,0.00008774999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003194986,0.00014798593,0.00038631493,0.00019505093,0.000027737316,0.0000033959886,0.00003508881,0.00014466427,0.00036085857],"category_scores_gemma":[0.00012372473,0.0001337057,0.00009249861,0.00019456937,0.000030338508,0.0002817269,0.00000834725,0.00009031106,0.0000026862667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017870938,0.0015709954,0.9300008,0.00023355197,0.00014419592,0.0000037825055,0.0041039367,0.0012255979,0.0048368634,0.000014686901,0.00016967858,0.05590886],"study_design_scores_gemma":[0.0065288926,0.000872359,0.94925296,0.00023921266,0.000266677,0.0000015221498,0.00008269569,0.0020034944,0.040423013,0.0000168656,0.00019988722,0.00011244251],"about_ca_topic_score_codex":0.0013041954,"about_ca_topic_score_gemma":0.00053302787,"teacher_disagreement_score":0.055796415,"about_ca_system_score_codex":0.00036501148,"about_ca_system_score_gemma":0.0003940236,"threshold_uncertainty_score":0.54523605},"labels":[],"label_agreement":null},{"id":"W2999407055","doi":"10.1016/s0923-7534(20)33391-3","title":"A Phase I Dose Escalation Study Investigating Dovitinib and Everolmus in Combination in Metastatic Clear Cell Renal Cancer Patients who have Previously Failed VEGF Targeted Therapy","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Oncology; Targeted therapy; Cancer; Internal medicine","score_opus":0.10603385744006608,"score_gpt":0.39948546792198775,"score_spread":0.2934516104819217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999407055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962804,0.0012258869,0.0000020584237,0.00033602054,0.00004437091,0.0017932315,0.000006585023,0.000008883344,0.00030259517],"genre_scores_gemma":[0.998955,0.00022518322,0.00018524281,0.00032097098,0.000026252374,0.00018682105,0.000052532472,0.000019463507,0.000028511166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981121,0.0005165072,0.0005775099,0.0002351832,0.00023962601,0.0003190735],"domain_scores_gemma":[0.9990336,0.00018448684,0.00033942657,0.00013752491,0.00016053233,0.00014443792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007245396,0.00016883608,0.00054777873,0.00026194463,0.000027767368,0.0000061711266,0.000046573314,0.00008303082,0.00003528761],"category_scores_gemma":[0.00013928303,0.00014398838,0.000042999854,0.00022028777,0.000070561415,0.00018606837,0.000030367633,0.00018430926,0.0000021548994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014127776,0.01248682,0.9317,0.000070057446,0.00007327667,0.000025232988,0.012777555,0.000020685238,0.0041079386,0.0000041460908,0.00008771145,0.03723378],"study_design_scores_gemma":[0.030283365,0.018503169,0.9387101,0.000095263465,0.00006433155,0.0000021188162,0.0007375527,0.00091663806,0.010431333,0.000060459995,0.00008533002,0.00011035497],"about_ca_topic_score_codex":0.0008039457,"about_ca_topic_score_gemma":0.0004274787,"teacher_disagreement_score":0.037123423,"about_ca_system_score_codex":0.00015260556,"about_ca_system_score_gemma":0.00012553422,"threshold_uncertainty_score":0.58716756},"labels":[],"label_agreement":null},{"id":"W2999423028","doi":"10.1016/s0923-7534(20)33475-x","title":"Metformin in Chemotherapy-Naïve Castration Resistant Prostate Cancer (CRPC): A Multicenter Phase II Trial (SAKK 08/09)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Metformin; Internal medicine; Chemotherapy; Cancer; Phases of clinical research; Urology; Insulin","score_opus":0.06904797505494932,"score_gpt":0.4242970018154786,"score_spread":0.3552490267605293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999423028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381226,0.0028571964,0.000036993883,0.0010278383,0.00059983385,0.0006554776,0.000083963525,0.000008464812,0.00091797166],"genre_scores_gemma":[0.99604225,0.0010535541,0.0005397258,0.00092213636,0.00066480425,0.0002090727,0.00007015798,0.00002921107,0.0004691145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998397,0.00014585597,0.0005121707,0.00030246287,0.0001510634,0.0004914276],"domain_scores_gemma":[0.999095,0.00003362277,0.00031459812,0.00027650272,0.0001696921,0.00011055942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006987228,0.00019189045,0.00034190956,0.00008812528,0.000051435876,0.00000718661,0.00017445274,0.00028067917,0.00012744934],"category_scores_gemma":[0.00010993252,0.00018090162,0.000120270684,0.00012388153,0.00012135385,0.000018736031,0.00006814584,0.00014136311,0.0000049560454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05154821,0.0018671904,0.0005743937,0.000035219924,0.00013818045,0.0000074963737,0.0008753783,0.000028429427,0.85655445,0.0000329927,0.0052866857,0.0830514],"study_design_scores_gemma":[0.03523557,0.011144025,0.00042418943,0.000034844525,0.00002882174,0.0000058695828,0.00012099144,0.000032591037,0.69728035,0.000037819227,0.25541905,0.00023587428],"about_ca_topic_score_codex":0.00019959366,"about_ca_topic_score_gemma":0.00041496268,"teacher_disagreement_score":0.25013235,"about_ca_system_score_codex":0.000063161184,"about_ca_system_score_gemma":0.0003158408,"threshold_uncertainty_score":0.7376954},"labels":[],"label_agreement":null},{"id":"W2999435318","doi":"10.1016/s0923-7534(20)34326-x","title":"Randomized Phase IIIB Trial of Temsirolimus and Bevacizumab Versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from Intoract","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temsirolimus; Bevacizumab; Renal cell carcinoma; Oncology; Internal medicine; Randomized controlled trial; Discovery and development of mTOR inhibitors; Chemotherapy; PI3K/AKT/mTOR pathway","score_opus":0.1350490563877559,"score_gpt":0.3991791572432816,"score_spread":0.2641301008555257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999435318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902982,0.0037077968,0.000008127861,0.00070435496,0.0003051294,0.0015302025,0.00011069113,0.000010323563,0.0033251343],"genre_scores_gemma":[0.9983674,0.00041789128,0.0006891662,0.00006533497,0.00017432336,0.00006780253,0.00011801828,0.00002390659,0.00007612072],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99696285,0.0007543791,0.001229675,0.0003711191,0.0002736412,0.0004083134],"domain_scores_gemma":[0.9960345,0.002508707,0.00066988077,0.00036824355,0.00014494291,0.00027370232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001569076,0.000288679,0.0018974252,0.00033755536,0.000025159532,0.000006155365,0.000090727626,0.00018468188,0.00003983666],"category_scores_gemma":[0.000860237,0.00022462159,0.00019715009,0.00014446797,0.00037444328,0.00014441482,0.00010866961,0.00025959013,0.000003970259],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97151256,0.0026679942,0.00023085742,0.0000996055,0.00031655945,0.00013570533,0.0028593196,0.0000011797092,0.006608189,0.000032070257,0.00025371092,0.015282239],"study_design_scores_gemma":[0.9227335,0.024072492,0.002068362,0.00007672775,0.0007592462,0.00003837177,0.0003968502,0.000093147304,0.0488696,0.00011649043,0.00062004424,0.00015517962],"about_ca_topic_score_codex":0.0016305639,"about_ca_topic_score_gemma":0.00009771071,"teacher_disagreement_score":0.04877908,"about_ca_system_score_codex":0.00011178563,"about_ca_system_score_gemma":0.00021551106,"threshold_uncertainty_score":0.9159803},"labels":[],"label_agreement":null},{"id":"W2999480386","doi":"10.1016/s0923-7534(20)33857-6","title":"Impact of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer research; Tyrosine kinase; Lung cancer; Oncology; Growth factor receptor inhibitor; Growth factor receptor; Internal medicine; Receptor; Cancer","score_opus":0.08292570209141926,"score_gpt":0.44010391423321615,"score_spread":0.3571782121417969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999480386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98443854,0.012230256,0.000033444714,0.0011794226,0.0001043903,0.0007474387,0.00038630568,0.000015894799,0.00086431147],"genre_scores_gemma":[0.9964929,0.0014350837,0.0010266618,0.00018114537,0.00009209799,0.00027843183,0.00009851454,0.000027108834,0.00036802236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984576,0.00011239896,0.0005982507,0.00025277855,0.00014659786,0.0004323897],"domain_scores_gemma":[0.99859977,0.00017448948,0.0004193423,0.0002825594,0.00028699823,0.0002368533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014913178,0.00025411838,0.0016705685,0.00040777627,0.000023252302,0.0000026115588,0.000066849076,0.000134309,0.000628362],"category_scores_gemma":[0.000040298775,0.00016962922,0.0012312918,0.00058282755,0.0000624129,0.00013331015,0.000024458051,0.00008968898,0.0000036337424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008347469,0.006591348,0.8681519,0.00016640684,0.088776745,0.000027961263,0.0040737465,0.00049299205,0.019804886,0.000023169434,0.0011577698,0.009898303],"study_design_scores_gemma":[0.008617006,0.009714669,0.6947242,0.00003727937,0.1367761,0.0000061277115,0.0002849299,0.00010400015,0.1466439,0.0000114540535,0.0027383224,0.00034197007],"about_ca_topic_score_codex":0.0061512757,"about_ca_topic_score_gemma":0.0004942195,"teacher_disagreement_score":0.1734277,"about_ca_system_score_codex":0.00048369064,"about_ca_system_score_gemma":0.0006322178,"threshold_uncertainty_score":0.92989296},"labels":[],"label_agreement":null},{"id":"W2999501412","doi":"10.1016/s0923-7534(20)33215-4","title":"Adjuvant Chemotherapy (AC) Initiation and Early Discontinuation in Elderly Patients (EPS) with Stage III Colon Cancer (CC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Adjuvant; Chemotherapy; Cancer; Adjuvant chemotherapy; Stage (stratigraphy); Internal medicine; Colorectal cancer; Oncology; Gastroenterology; Surgery; Breast cancer","score_opus":0.05454104924932323,"score_gpt":0.37411392307457053,"score_spread":0.3195728738252473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999501412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382967,0.001553691,0.000004949738,0.0015874761,0.000075382886,0.00044148535,0.000013164796,0.000007381826,0.002486795],"genre_scores_gemma":[0.9977677,0.0013371602,0.000053888765,0.0004703988,0.0000503737,0.000098607925,0.000012671223,0.000008978956,0.0002002547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935764,0.000034112454,0.00019181617,0.000117930314,0.00011028887,0.0001882334],"domain_scores_gemma":[0.9995534,0.000047058456,0.00014915263,0.00006311448,0.00013464324,0.000052673695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011842643,0.000093900824,0.00033566152,0.00007479217,0.000028732493,0.0000031165557,0.000019137135,0.0000620163,0.00002981542],"category_scores_gemma":[0.000018226134,0.00006739516,0.000022020857,0.00009637838,0.00006779131,0.0001351258,0.000013306967,0.00006478257,9.0015754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018258793,0.001485798,0.8128376,0.000021879114,0.00009563372,0.0000031994937,0.0051967986,5.0477695e-7,0.000114433315,0.00003946172,0.0002314364,0.17814739],"study_design_scores_gemma":[0.0093053905,0.008694289,0.9743724,0.000061147475,0.000038991126,9.708441e-7,0.00031180418,0.000004470575,0.0010620834,0.000013765719,0.006067136,0.00006756118],"about_ca_topic_score_codex":0.0010188982,"about_ca_topic_score_gemma":0.0019476344,"teacher_disagreement_score":0.17807983,"about_ca_system_score_codex":0.0000721119,"about_ca_system_score_gemma":0.00006702269,"threshold_uncertainty_score":0.27482948},"labels":[],"label_agreement":null},{"id":"W2999534522","doi":"10.1016/s0923-7534(20)33860-6","title":"Lux-Lung 3: Symptom and Health-Related Quality of Life Results from a Randomized Phase III Study in 1st-Line Advanced NSCLC Patients Harbouring EGFR Mutations","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Quality of life (healthcare); Lung cancer; Internal medicine; Lung; Nursing","score_opus":0.09859896412834444,"score_gpt":0.4854044553841062,"score_spread":0.38680549125576175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999534522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914308,0.0023136325,0.00003582485,0.0028855118,0.00017907341,0.002073696,0.00020719228,0.000018140887,0.0008561007],"genre_scores_gemma":[0.998389,0.0002163117,0.00040675112,0.00041509548,0.000036163474,0.00012054978,0.0003527141,0.000013109181,0.000050312083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973361,0.00046824513,0.0015197662,0.0002269082,0.00018476736,0.00026420195],"domain_scores_gemma":[0.9976186,0.00083652267,0.0008723746,0.00021286264,0.00024755448,0.00021205601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013428952,0.00014078354,0.0013068685,0.0001833162,0.000054005086,0.0000026333603,0.00004680462,0.00008777696,0.00002913937],"category_scores_gemma":[0.0009942556,0.000116712334,0.000093991075,0.00020407891,0.000118732976,0.00013765266,0.000033723918,0.000130948,0.0000014204215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38824677,0.049984146,0.36088935,0.00029564067,0.004670386,0.000027764303,0.0998266,0.00028065208,0.0005523052,0.0005276006,0.0006898647,0.09400892],"study_design_scores_gemma":[0.65203685,0.0026504095,0.3423933,0.00015334495,0.00031902743,9.431906e-7,0.0017821667,0.00017380678,0.00016329918,0.000119425364,0.00010395971,0.00010343021],"about_ca_topic_score_codex":0.0052946815,"about_ca_topic_score_gemma":0.00038013057,"teacher_disagreement_score":0.2637901,"about_ca_system_score_codex":0.00010055561,"about_ca_system_score_gemma":0.0003549984,"threshold_uncertainty_score":0.80040103},"labels":[],"label_agreement":null},{"id":"W2999546558","doi":"10.1016/s0923-7534(20)32889-1","title":"Progression-Free Survival as a Surrogate for Overall Survival in Metastatic Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National d'Excellence en Santé et en Services Sociaux; Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Surrogate endpoint; Internal medicine; Breast cancer; Overall survival; Progression-free survival; Cancer","score_opus":0.14704478219920217,"score_gpt":0.4943423350120266,"score_spread":0.3472975528128245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999546558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96281,0.0033205992,0.000009019313,0.025013078,0.0013995701,0.0009883688,0.0002422311,0.000026138528,0.006191008],"genre_scores_gemma":[0.9950528,0.0010865357,0.00046280905,0.0016894409,0.0004746929,0.0003962376,0.00004367331,0.000027270342,0.0007665411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849176,0.0001756824,0.00036635966,0.00020255288,0.00019954184,0.0005640962],"domain_scores_gemma":[0.9986772,0.0005266455,0.00018708933,0.0002037789,0.00019961486,0.00020569646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879237,0.0001716034,0.0007038164,0.00014243691,0.000030715382,0.0000029030812,0.000121680045,0.0001131765,0.00085277885],"category_scores_gemma":[0.00010877389,0.0001388211,0.00015557068,0.00015355098,0.000116240204,0.00010900271,0.00006548143,0.00014147756,0.000014757544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021986412,0.013560729,0.66548973,0.00073937234,0.0018570267,0.00019018813,0.0025849943,0.000020417672,0.009625992,0.005275222,0.04938842,0.22928151],"study_design_scores_gemma":[0.044312548,0.0122186355,0.67326987,0.00032908996,0.0010407538,0.0002987463,0.00044401654,0.00010253245,0.011642093,0.0038884971,0.25188285,0.00057037827],"about_ca_topic_score_codex":0.0010478443,"about_ca_topic_score_gemma":0.0009537462,"teacher_disagreement_score":0.22871113,"about_ca_system_score_codex":0.0001036019,"about_ca_system_score_gemma":0.00048781655,"threshold_uncertainty_score":0.93373305},"labels":[],"label_agreement":null},{"id":"W2999581422","doi":"10.1016/s0923-7534(20)34201-0","title":"Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Docetaxel; Trastuzumab; Metastatic breast cancer; Bevacizumab; Oncology; Internal medicine; HER2 negative; Breast cancer; Phases of clinical research; Chemotherapy; Cancer","score_opus":0.22965652475487,"score_gpt":0.5029663557028642,"score_spread":0.2733098309479942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999581422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919526,0.0054538837,0.0011934863,0.043719657,0.0022321795,0.006197615,0.01793243,0.000050017767,0.003694779],"genre_scores_gemma":[0.9937402,0.0016856903,0.00068358425,0.0012627166,0.0012338127,0.00043592256,0.00051728036,0.00006404549,0.0003767728],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99557525,0.00065759604,0.0014898387,0.0005370986,0.0007842727,0.00095595693],"domain_scores_gemma":[0.9939871,0.0028225258,0.0008122382,0.0007197816,0.0012579542,0.0004004191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026882754,0.00035977637,0.001345627,0.0001976639,0.0001152163,0.000012744128,0.00045497753,0.00028016517,0.00059768884],"category_scores_gemma":[0.0012622309,0.0002558636,0.0004349741,0.0004709885,0.0007017571,0.00016115751,0.0001414235,0.00050319824,0.000023989118],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42474425,0.0077867853,0.00012237502,0.00019933099,0.0015329059,0.000030200303,0.0025663914,0.000007709357,0.004663404,0.00012372492,0.06882152,0.4894014],"study_design_scores_gemma":[0.67927915,0.060678773,0.009606458,0.001790165,0.002185562,0.00024011442,0.0022924098,0.0017079101,0.05811625,0.00083309214,0.1823339,0.0009362314],"about_ca_topic_score_codex":0.003520055,"about_ca_topic_score_gemma":0.0005947901,"teacher_disagreement_score":0.4884652,"about_ca_system_score_codex":0.00032076865,"about_ca_system_score_gemma":0.001831279,"threshold_uncertainty_score":0.99998933},"labels":[],"label_agreement":null},{"id":"W2999586427","doi":"10.1016/s0923-7534(20)33484-0","title":"Clinical Activity of Abiraterone Acetate (AA) after Progression on Mdv3100 in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Abiraterone; Oncology; Internal medicine; Pharmacology; Castration; Cancer; Androgen receptor; Androgen deprivation therapy; Hormone","score_opus":0.12857814849242416,"score_gpt":0.48469412081688457,"score_spread":0.3561159723244604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999586427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965655,0.00050162553,0.0000012172741,0.001416727,0.00009005448,0.0009887181,0.000053065698,0.0000069377847,0.00037615144],"genre_scores_gemma":[0.9986866,0.0004420913,0.00029060853,0.00012532363,0.000036334706,0.00017268205,0.000030178044,0.000016287866,0.00019985816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838877,0.00027693532,0.00041971946,0.00020714462,0.0003366347,0.00037078653],"domain_scores_gemma":[0.9989897,0.00010614839,0.00029181474,0.00019164642,0.0002783599,0.00014234819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006603079,0.000136258,0.0005339492,0.00014132693,0.000019468258,0.0000029458388,0.000046272355,0.00008874049,0.00006840791],"category_scores_gemma":[0.000048941503,0.00008416424,0.000059492704,0.00018722937,0.000231951,0.00015732985,0.000029227358,0.00021870439,0.000005386634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052776787,0.004583835,0.79147464,0.00025458055,0.00018860196,0.000038174156,0.00060632825,0.000004644887,0.001863636,0.0000084475105,0.00024010775,0.1479602],"study_design_scores_gemma":[0.0070012202,0.014165632,0.9546701,0.00034990656,0.00006934349,9.994953e-7,0.000035401048,0.0000059801487,0.022960147,0.000016228232,0.0006486856,0.00007639938],"about_ca_topic_score_codex":0.00009804167,"about_ca_topic_score_gemma":0.00014193142,"teacher_disagreement_score":0.1631954,"about_ca_system_score_codex":0.00009065663,"about_ca_system_score_gemma":0.000333443,"threshold_uncertainty_score":0.3432118},"labels":[],"label_agreement":null},{"id":"W2999591965","doi":"10.1016/s0923-7534(20)33389-5","title":"Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (MRCC) – Final Results","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University Hospital Foundation","funders":"","keywords":"Medicine; Sunitinib; Dysgeusia; Nausea; Neutropenia; Internal medicine; Adverse effect; Renal cell carcinoma; Stomatitis; Vomiting; Mucositis; Diarrhea; Tolerability; Surgery; Gastroenterology; Chemotherapy","score_opus":0.3021703911164218,"score_gpt":0.44953780598919746,"score_spread":0.14736741487277566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999591965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9352811,0.001062507,0.000010167849,0.001606109,0.00037049848,0.0008104755,0.00007835453,0.000018673853,0.060762126],"genre_scores_gemma":[0.9975305,0.000077598634,0.00072390476,0.0006386336,0.000369814,0.00007705554,0.00010947402,0.00001792755,0.00045506324],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99733275,0.00039223762,0.00088528264,0.00032179992,0.00036389046,0.000704044],"domain_scores_gemma":[0.9983372,0.00033918454,0.00038254404,0.00040857613,0.00019343689,0.00033906192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000970496,0.0002541246,0.00087079534,0.00020193533,0.000035085835,0.000009999895,0.00021132104,0.00016931351,0.00016391832],"category_scores_gemma":[0.00027631086,0.00021265616,0.00022262239,0.00037707153,0.00015420765,0.00019639694,0.000121674006,0.0002326459,0.000048290334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5786141,0.021724766,0.24005063,0.00069130823,0.0005642734,0.0052990364,0.0031002758,0.000063218715,0.006299408,0.0010586055,0.051174257,0.091360115],"study_design_scores_gemma":[0.22351617,0.033207536,0.62134665,0.000113381146,0.00053363096,0.0007827162,0.0005554926,0.00002852901,0.088963665,0.00053214584,0.029908031,0.0005120572],"about_ca_topic_score_codex":0.000851672,"about_ca_topic_score_gemma":0.00017676016,"teacher_disagreement_score":0.38129604,"about_ca_system_score_codex":0.00020335946,"about_ca_system_score_gemma":0.0005756034,"threshold_uncertainty_score":0.86718667},"labels":[],"label_agreement":null},{"id":"W2999648542","doi":"10.1016/s0923-7534(19)66504-x","title":"PD-0010 Quality of Colonoscopy Performance Among Gastroenterologists and Surgeons in Single Tertiary Center in Quebec","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colonoscopy; Center (category theory); Tertiary care; General surgery; Family medicine; Medical physics; Internal medicine; Colorectal cancer; Cancer","score_opus":0.08303108311505522,"score_gpt":0.37477639636215154,"score_spread":0.2917453132470963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999648542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99796647,0.00021401314,0.000010787698,0.00065921486,0.0001267115,0.00015321908,0.000004625839,0.000009025081,0.0008559334],"genre_scores_gemma":[0.9994227,0.00009060784,0.00009131553,0.0002949141,0.000026563705,0.000015004099,0.0000058914807,0.0000053502176,0.000047619127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998959,0.00015536099,0.00040604966,0.00012472023,0.00008525949,0.00026957874],"domain_scores_gemma":[0.9994589,0.00012162846,0.00017691994,0.00011178121,0.000058023117,0.000072745024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069558976,0.00008027489,0.00039351603,0.00017525408,0.000010678644,0.0000015579704,0.00003728087,0.000117587646,0.000018289025],"category_scores_gemma":[0.00012372958,0.00007511111,0.0000424985,0.00012438418,0.00019409864,0.00012287316,0.000042363103,0.00016060095,7.414591e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057716235,0.0006538037,0.97900045,0.00009308662,0.0000127466865,0.0000035333514,0.0005217365,0.0000037547054,0.003082056,0.0000032728028,0.00013279068,0.010721146],"study_design_scores_gemma":[0.0013558252,0.005006113,0.9821107,0.000091608345,0.000005776336,0.000012882165,0.000119612996,0.000058115675,0.010736969,0.000004265218,0.00045473746,0.00004343834],"about_ca_topic_score_codex":0.019111684,"about_ca_topic_score_gemma":0.061180625,"teacher_disagreement_score":0.042068943,"about_ca_system_score_codex":0.00006530177,"about_ca_system_score_gemma":0.00004924067,"threshold_uncertainty_score":0.98742014},"labels":[],"label_agreement":null},{"id":"W2999685386","doi":"10.1016/s0923-7534(20)33845-x","title":"Activity of Afatinib in Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations in Lux-Lung 3, A Phase III Trial of Afatinib or Cisplatin/Pemetrexed in EGFR Mutation-Positive Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; T790M; Pemetrexed; Lung cancer; Internal medicine; Epidermal growth factor receptor; Population; Oncology; Cisplatin; Phases of clinical research; Gastroenterology; Erlotinib; Cancer; Chemotherapy; Gefitinib","score_opus":0.08199493858895551,"score_gpt":0.47671318873482305,"score_spread":0.39471825014586753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999685386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934102,0.00048223019,0.000082166254,0.0016056612,0.0003377148,0.0018906251,0.00046889886,0.00001089883,0.0017115853],"genre_scores_gemma":[0.99799144,0.00020833325,0.00079009635,0.00014774699,0.00011067415,0.00043894222,0.0001961972,0.000024791836,0.00009177085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974542,0.00040873376,0.0011484727,0.00027816728,0.00028097487,0.0004294226],"domain_scores_gemma":[0.9970679,0.0013975018,0.0008483773,0.00019722327,0.00035167506,0.00013731002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054571085,0.0002315875,0.0011047788,0.0007163105,0.000032650027,0.000003078586,0.00009826508,0.00022672993,0.00045136124],"category_scores_gemma":[0.0006988492,0.00020080013,0.000142473,0.00097596075,0.00016134598,0.00036506096,0.000037286518,0.00027621185,0.0000013429734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16885321,0.03699758,0.5044758,0.0013183278,0.0018534194,0.00018980076,0.06485227,0.00062797894,0.034713835,0.0010013208,0.001698743,0.18341775],"study_design_scores_gemma":[0.275602,0.009588451,0.60228914,0.0011595408,0.0006580328,0.000017245311,0.0035593237,0.0018179618,0.1045297,0.00012081156,0.0001912719,0.00046650498],"about_ca_topic_score_codex":0.007010652,"about_ca_topic_score_gemma":0.0047213254,"teacher_disagreement_score":0.18295124,"about_ca_system_score_codex":0.0004688001,"about_ca_system_score_gemma":0.0011365719,"threshold_uncertainty_score":0.9996017},"labels":[],"label_agreement":null},{"id":"W2999692341","doi":"10.1016/s0923-7534(20)33839-4","title":"A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Ramucirumab; Chemotherapy; Oncology; Internal medicine; Lung cancer; Cancer","score_opus":0.04621980569752529,"score_gpt":0.4137215862708068,"score_spread":0.36750178057328153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999692341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98955894,0.00031931477,0.00012995662,0.0005050524,0.00017318015,0.008184463,0.00016538416,0.00001330617,0.0009504096],"genre_scores_gemma":[0.99582446,0.000114526796,0.0018879387,0.0004476047,0.000030701205,0.0011852096,0.00035509685,0.000047168935,0.000107284766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974328,0.00029071316,0.0010231525,0.00046577698,0.00034700462,0.00044049753],"domain_scores_gemma":[0.9973254,0.000641383,0.0009825929,0.0004007273,0.0004943427,0.0001555355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006271392,0.0003310718,0.001528197,0.00031439192,0.00004761021,0.00001053009,0.00020011816,0.00014633182,0.000057353078],"category_scores_gemma":[0.00012669162,0.0002216881,0.000053207077,0.0005209909,0.00011036465,0.0002244038,0.000041743107,0.0002326882,0.000001401966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71667093,0.1237006,0.06893208,0.00015999808,0.0005599988,0.000040605395,0.017655365,0.00044048543,0.00026341667,0.0000029761288,0.0003936428,0.07117988],"study_design_scores_gemma":[0.9188989,0.037659474,0.03650961,0.0006954883,0.00045159564,6.675829e-7,0.0011651483,0.0016948853,0.002508108,0.0000064054384,0.00016618322,0.00024354024],"about_ca_topic_score_codex":0.0043285177,"about_ca_topic_score_gemma":0.005354306,"teacher_disagreement_score":0.20222794,"about_ca_system_score_codex":0.0003548483,"about_ca_system_score_gemma":0.0010631259,"threshold_uncertainty_score":0.9040178},"labels":[],"label_agreement":null},{"id":"W2999697937","doi":"10.1016/s0923-7534(20)30087-9","title":"P-0164 Online System For Decentralized Review of Digital Medical Images And its Use in Multicenter Clinical Trials","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Clinical trial; Medical physics; Multicenter study; Internal medicine; Randomized controlled trial","score_opus":0.2944690035533987,"score_gpt":0.5582311128523553,"score_spread":0.26376210929895655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999697937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92117727,0.04867699,0.00041482138,0.02745331,0.00057070766,0.0013509123,0.000114025446,0.000021832358,0.00022015237],"genre_scores_gemma":[0.94073105,0.05316888,0.001717956,0.003931672,0.00031535418,0.000017688884,0.000059808564,0.00001723967,0.000040328086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704444,0.0006035755,0.0016538063,0.00016790252,0.00023543889,0.00029480908],"domain_scores_gemma":[0.99455935,0.0041568,0.00055380404,0.00012272174,0.00024302052,0.00036431634],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008801619,0.00011075472,0.0015603935,0.00008293999,0.000010642211,0.0000044445205,0.00009006689,0.0001831901,0.000041112606],"category_scores_gemma":[0.05709548,0.00007809284,0.0002400211,0.00007630129,0.00016000218,0.00013222148,0.000058216945,0.00028738167,0.000002068412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032620828,0.005254304,0.34552145,0.024350978,0.0006388739,0.000098776814,0.00019831567,8.2518494e-7,0.00090757327,0.0013838258,0.029350601,0.5890324],"study_design_scores_gemma":[0.05608589,0.0065266816,0.2056599,0.056927186,0.0015742822,0.00071852497,0.00037674326,0.011452402,0.0019247142,0.00007899088,0.65804064,0.00063408195],"about_ca_topic_score_codex":0.000016368112,"about_ca_topic_score_gemma":0.0000016021132,"teacher_disagreement_score":0.62869,"about_ca_system_score_codex":0.000016433965,"about_ca_system_score_gemma":0.00014249096,"threshold_uncertainty_score":0.950847},"labels":[],"label_agreement":null},{"id":"W2999762293","doi":"10.1016/j.annonc.2019.11.017","title":"Flawed trials for cancer","year":2020,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Canada; Bayer Canada; Bristol-Myers Squibb Canada; Sanofi; Meso Scale Diagnostics; Astellas Pharma Canada; Roche","keywords":"Medicine; Cancer; Oncology; Intensive care medicine; Medical physics; Internal medicine","score_opus":0.3131264470494802,"score_gpt":0.4954558305697605,"score_spread":0.18232938352028027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999762293","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001022795,0.008631689,0.000022694208,0.019178959,0.9584988,0.0025338295,0.001452916,0.000048496295,0.008609831],"genre_scores_gemma":[0.0011721532,0.0040347236,0.00094612583,0.0011705396,0.98684716,0.00077242433,0.0012562159,0.00008312747,0.0037175284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974266,0.000269385,0.0010393596,0.00046529906,0.000455439,0.00034391662],"domain_scores_gemma":[0.99320996,0.0041930294,0.0009619956,0.00032776076,0.0010766991,0.00023053138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011497019,0.00031615768,0.003044786,0.00013235449,0.000027728176,0.000005705455,0.00017189655,0.0012186576,0.00028785202],"category_scores_gemma":[0.0070024896,0.00024450934,0.0008504897,0.000104994644,0.000098814235,0.000020553482,0.000054564152,0.00042688398,0.000028905144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046082963,0.00022154687,0.000014880061,0.0006928089,0.0012129195,0.00010638575,0.00009009284,9.229999e-7,0.0009279595,0.000025077341,0.9407361,0.051362995],"study_design_scores_gemma":[0.004516302,0.011532862,0.00004430927,0.00016266244,0.0013192911,0.0000031651002,0.000014187436,0.000004369776,0.010156486,0.00016439297,0.9719249,0.00015708167],"about_ca_topic_score_codex":0.00027349053,"about_ca_topic_score_gemma":0.00006187414,"teacher_disagreement_score":0.051205914,"about_ca_system_score_codex":0.00017847883,"about_ca_system_score_gemma":0.0031169124,"threshold_uncertainty_score":0.9970802},"labels":[],"label_agreement":null},{"id":"W2999808793","doi":"10.1016/s0923-7534(20)32799-x","title":"Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Expression (computer science); Solid tumor; Internal medicine; Cancer research; Pathology; Cancer; Programming language","score_opus":0.5046343515644572,"score_gpt":0.5479802251370528,"score_spread":0.04334587357259556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999808793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870487,0.006114467,0.0000063311463,0.003526081,0.000022983759,0.00028598218,0.000013128419,0.000005767036,0.0029765521],"genre_scores_gemma":[0.99831235,0.00041391738,0.00058755634,0.00038138192,0.000032076758,0.000074454765,0.0000056490617,0.000009091614,0.00018354687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985864,0.00022731342,0.00045065465,0.0001574795,0.00027269148,0.00030546868],"domain_scores_gemma":[0.9990138,0.00027172858,0.00017128423,0.00020992347,0.00018410145,0.00014919757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013919825,0.00008618683,0.0012703108,0.00048327702,0.000010982506,0.0000015666405,0.000082481114,0.00011703277,0.0007141609],"category_scores_gemma":[0.0002372451,0.000063283725,0.00028926414,0.000576282,0.00015773445,0.00006211718,0.00008196589,0.00015520494,0.000003840159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006981227,0.0027530722,0.8336287,0.0005152101,0.04859105,0.000069647125,0.00473025,0.000036191996,0.06999062,0.00013213484,0.0068186093,0.03203639],"study_design_scores_gemma":[0.001410093,0.004214283,0.5050117,0.000073135576,0.046634704,0.000029372715,0.00072215986,0.00015640334,0.42500266,0.00014750296,0.016391654,0.00020638309],"about_ca_topic_score_codex":0.00022010118,"about_ca_topic_score_gemma":0.00006179392,"teacher_disagreement_score":0.35501203,"about_ca_system_score_codex":0.000022875232,"about_ca_system_score_gemma":0.00012374784,"threshold_uncertainty_score":0.78195614},"labels":[],"label_agreement":null},{"id":"W2999830727","doi":"10.1016/s0923-7534(20)33529-8","title":"Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Castration; Internal medicine; Hormone","score_opus":0.10801698828208837,"score_gpt":0.4628636981609387,"score_spread":0.3548467098788503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999830727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97707206,0.015254191,0.0000014662081,0.00598722,0.00020901636,0.0008726696,0.00010967298,0.000010344437,0.0004833482],"genre_scores_gemma":[0.98772854,0.010795686,0.00022220158,0.00009234044,0.00006947011,0.00027241412,0.00008374482,0.000017558437,0.0007180324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829,0.0002662458,0.00045725674,0.00019908266,0.00033223088,0.00045519602],"domain_scores_gemma":[0.99898857,0.00014643332,0.0003998343,0.000099540644,0.0002460984,0.00011952208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001204998,0.00013620006,0.0004911374,0.00014496956,0.00004182773,0.000009182841,0.00004231953,0.00010479479,0.00006305679],"category_scores_gemma":[0.00009193905,0.00010571513,0.00004212978,0.00026658294,0.000104402,0.00018205041,0.00003712697,0.00016915544,6.493983e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00425702,0.0008285486,0.7507514,0.0005400551,0.00026364278,0.000018604598,0.0035926974,0.0000020068296,0.12299257,0.000046547906,0.0032487141,0.1134582],"study_design_scores_gemma":[0.01238583,0.0057493937,0.82997173,0.0017298782,0.00037464098,0.000009409485,0.001613174,0.00013323121,0.10918872,0.00033011037,0.03814805,0.00036585235],"about_ca_topic_score_codex":0.0010424693,"about_ca_topic_score_gemma":0.0010195278,"teacher_disagreement_score":0.11309235,"about_ca_system_score_codex":0.00025495893,"about_ca_system_score_gemma":0.00027838952,"threshold_uncertainty_score":0.43109378},"labels":[],"label_agreement":null},{"id":"W2999930180","doi":"10.1016/s0923-7534(20)34327-1","title":"Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temsirolimus; Sunitinib; Sorafenib; Renal cell carcinoma; Internal medicine; Clinical endpoint; Progression-free survival; Oncology; Gastroenterology; Urology; Surgery; Randomized controlled trial; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.1424243456853607,"score_gpt":0.3746924568130888,"score_spread":0.23226811112772813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999930180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778946,0.004411947,0.0000020113714,0.0046218857,0.00047901593,0.001164114,0.00009075129,0.00001644087,0.011319216],"genre_scores_gemma":[0.9953068,0.0003030991,0.00023552257,0.0022408178,0.0009243822,0.0000800417,0.00014210439,0.000031889173,0.0007353466],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972678,0.00064516504,0.0008837524,0.0003390782,0.00031914058,0.0005451025],"domain_scores_gemma":[0.99712145,0.0014872975,0.00042721807,0.00059678906,0.00014870372,0.00021853468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013668083,0.0002726023,0.00087968656,0.00015699146,0.000046583533,0.000007756575,0.00020697038,0.00018809712,0.00046857924],"category_scores_gemma":[0.00031552545,0.00016983405,0.0002548726,0.00024133973,0.00016735209,0.00009598726,0.00006547264,0.00039910138,0.000092139846],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.741737,0.01507629,0.030228848,0.000119583485,0.0012218287,0.0015109037,0.025026616,0.00003431519,0.06593921,0.00019831248,0.050446305,0.068460785],"study_design_scores_gemma":[0.22999446,0.06287193,0.2215819,0.00006143476,0.00039430373,0.00015063497,0.0010751324,0.0000377444,0.36374626,0.00080847944,0.118836634,0.000441084],"about_ca_topic_score_codex":0.0020263758,"about_ca_topic_score_gemma":0.00036404052,"teacher_disagreement_score":0.51174253,"about_ca_system_score_codex":0.00011109551,"about_ca_system_score_gemma":0.0004497059,"threshold_uncertainty_score":0.6925631},"labels":[],"label_agreement":null},{"id":"W2999937484","doi":"10.1016/s0923-7534(20)32016-0","title":"A Phase II Trial of the Multi-Targeted Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Lenvatinib; Medicine; Medullary thyroid cancer; Thyroid cancer; Oncology; Internal medicine; Cabozantinib; Cancer research; Cancer","score_opus":0.09112517178705909,"score_gpt":0.42589799940576795,"score_spread":0.33477282761870886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999937484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97193265,0.017991353,0.0000014105476,0.0074323067,0.00088109984,0.0011695181,0.00008810362,0.000013063655,0.00049052265],"genre_scores_gemma":[0.99434,0.00300189,0.00036451337,0.0013495937,0.0003457911,0.00042866572,0.000016170146,0.000021446162,0.0001319108],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983667,0.00016013409,0.00061562256,0.00021607798,0.00023645605,0.000405021],"domain_scores_gemma":[0.99874365,0.00017852169,0.0004073586,0.00036682395,0.00015834927,0.00014529584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038726063,0.00018473312,0.00070174655,0.00009723754,0.000048797054,0.0000013345407,0.00012778632,0.00016939171,0.00013374309],"category_scores_gemma":[0.00027028067,0.00012502796,0.00021571702,0.0002997792,0.00016247199,0.00009418882,0.00009546147,0.00020242108,0.0000032421544],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096219376,0.097332805,0.051881272,0.00028625334,0.0008002407,0.00007216853,0.0063237464,0.00006490764,0.1810794,0.0003936683,0.023006743,0.5425394],"study_design_scores_gemma":[0.3185621,0.03562228,0.035733465,0.00037126592,0.00025705536,0.000011965095,0.00043037592,0.000030187457,0.502774,0.00004852906,0.10591051,0.00024830972],"about_ca_topic_score_codex":0.00039238986,"about_ca_topic_score_gemma":0.00037643773,"teacher_disagreement_score":0.5422911,"about_ca_system_score_codex":0.00012344317,"about_ca_system_score_gemma":0.00044757975,"threshold_uncertainty_score":0.50984925},"labels":[],"label_agreement":null},{"id":"W2999970393","doi":"10.1016/s0923-7534(20)33403-7","title":"Neoadjuvant (NACT) and Adjuvant Chemotherapy (ACT) for Muscle-Invasive Bladder Cancer: A Population-Based Outcomes Study","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Bladder cancer; Oncology; Chemotherapy; Internal medicine; Adjuvant chemotherapy; Adjuvant; Neoadjuvant therapy; Cancer; Breast cancer","score_opus":0.08392121770293089,"score_gpt":0.42220445834939085,"score_spread":0.33828324064646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999970393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887099,0.0016451894,0.0000344149,0.007145532,0.00029827733,0.001624726,0.00006784315,0.000031116022,0.0004429774],"genre_scores_gemma":[0.99224144,0.00030793794,0.00041969906,0.0062100156,0.00021851645,0.00033255064,0.00003391833,0.00003503648,0.0002009053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987898,0.00006257431,0.00035329018,0.00024240828,0.00017269666,0.0003792447],"domain_scores_gemma":[0.9988364,0.0003487171,0.00019903392,0.00023312659,0.00018528318,0.00019741888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023068264,0.00020694172,0.00072569255,0.000112106456,0.000067293266,0.0000050295575,0.00006359499,0.000122031845,0.00018820491],"category_scores_gemma":[0.00008753805,0.00015684008,0.0001459806,0.00008648563,0.000055721575,0.0000857887,0.000017143842,0.00008870129,0.0000034010145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006518362,0.0022646834,0.8829882,0.0000567537,0.0005724652,0.0000061380947,0.0014157798,0.0000042984443,0.00032924447,0.000027921275,0.001438292,0.110244386],"study_design_scores_gemma":[0.009434794,0.006115066,0.97096586,0.000038939008,0.00034408047,0.000005087469,0.00051483704,0.000020055673,0.0026278512,0.00008157426,0.009702394,0.00014948357],"about_ca_topic_score_codex":0.0016850786,"about_ca_topic_score_gemma":0.0006552552,"teacher_disagreement_score":0.1100949,"about_ca_system_score_codex":0.00008001527,"about_ca_system_score_gemma":0.00036245334,"threshold_uncertainty_score":0.63957524},"labels":[],"label_agreement":null},{"id":"W2999984032","doi":"10.1016/s0923-7534(20)31311-9","title":"P1.20 CDX2 VDR Polymorphism Impinges on the Response of Cultured Breast Cancer Cell Lines to Vitamin D","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Calcitriol receptor; CDX2; Breast cancer; Vitamin D and neurology; Internal medicine; Cancer; Oncology; Gene; Genetics; Transcription factor; Biology","score_opus":0.10072910391878802,"score_gpt":0.4271882330588886,"score_spread":0.32645912914010056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999984032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8701674,0.0030191757,0.0000022493302,0.12290381,0.00020386376,0.00040663712,0.00011922545,0.000015343812,0.003162346],"genre_scores_gemma":[0.9905278,0.001269664,0.00012274922,0.004132091,0.00042956308,0.00009055003,0.0000033380752,0.000019551515,0.0034046774],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998275,0.0003619231,0.00032874214,0.00018414715,0.00034476497,0.00050543196],"domain_scores_gemma":[0.99783564,0.00096094684,0.00017082944,0.00036999787,0.00045715165,0.00020544125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012634097,0.00016554767,0.00053150335,0.00012799022,0.00007344027,0.0000028029185,0.00020944029,0.00014346083,0.00026113112],"category_scores_gemma":[0.00085761223,0.000096065334,0.00012896763,0.00024364612,0.0003003991,0.00005621329,0.00017132678,0.00019741547,0.00003512855],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006590559,0.0016137923,0.011091129,0.00018400556,0.00037786498,0.00002915104,0.0070497785,0.000007097253,0.67594045,0.00018629021,0.2841313,0.012798595],"study_design_scores_gemma":[0.0012645244,0.004459358,0.5122728,0.00022349194,0.00008221129,0.000048569105,0.0024817397,0.000004339181,0.40137187,0.00001989698,0.07761965,0.00015159626],"about_ca_topic_score_codex":0.00034840382,"about_ca_topic_score_gemma":0.00013668423,"teacher_disagreement_score":0.50118166,"about_ca_system_score_codex":0.00007801977,"about_ca_system_score_gemma":0.00022105481,"threshold_uncertainty_score":0.39174306},"labels":[],"label_agreement":null},{"id":"W3000047582","doi":"10.1016/s0923-7534(20)34342-8","title":"Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Internal medicine; Placebo; Discontinuation; Lung cancer; Randomized controlled trial; Progression-free survival; Oncology; Surgery; Chemotherapy; Gastroenterology; Pathology; Hepatocellular carcinoma","score_opus":0.04848366754662953,"score_gpt":0.42563248272010473,"score_spread":0.3771488151734752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000047582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885413,0.0008214564,0.00013654509,0.0007777129,0.0002390359,0.0060940315,0.000016781369,0.0000075912535,0.003365557],"genre_scores_gemma":[0.99804604,0.00029099517,0.00027864598,0.00019459456,0.00013369512,0.0005813648,0.00008775096,0.000015923515,0.00037096982],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986618,0.000117890406,0.0006600976,0.00015577814,0.00016983048,0.00023459342],"domain_scores_gemma":[0.9986896,0.00020240224,0.0005942098,0.0001522152,0.00023878065,0.0001227935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047261044,0.00015285746,0.0011367977,0.00017007496,0.000028504111,0.0000032716341,0.000051758514,0.00013983231,0.00013070156],"category_scores_gemma":[0.00002438168,0.00010115441,0.0001541365,0.00012871639,0.000069325,0.0000969674,0.000007265076,0.000095455354,8.926221e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9803579,0.0065790727,0.0051823375,0.000056941248,0.00051293056,0.0000036025676,0.0015054401,0.00003658856,0.00023139201,0.000022769244,0.00030834545,0.005202705],"study_design_scores_gemma":[0.9837394,0.0074236207,0.00040760162,0.00008423389,0.00070679426,7.979518e-7,0.00008370602,0.00012299912,0.006782235,0.0000067225365,0.0005549344,0.00008695221],"about_ca_topic_score_codex":0.00031011656,"about_ca_topic_score_gemma":0.000065189684,"teacher_disagreement_score":0.009504771,"about_ca_system_score_codex":0.000078536534,"about_ca_system_score_gemma":0.00076204,"threshold_uncertainty_score":0.4124957},"labels":[],"label_agreement":null},{"id":"W3000084601","doi":"10.1016/s0923-7534(20)33847-3","title":"Pooled Analysis of Clinical Outcomes for Patients with EGFR Mutations in Non-Small-Cell Lung Cancer: An Update","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Oncology; Gefitinib; Internal medicine; Lung cancer; Clinical trial; Chemotherapy regimen; Chemotherapy; Hazard ratio; Progression-free survival; Confidence interval; Cancer; Epidermal growth factor receptor","score_opus":0.06164023516607116,"score_gpt":0.4809542764778358,"score_spread":0.41931404131176464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000084601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680644,0.00015765232,0.00018231,0.0011140598,0.000114981056,0.00062297,0.00018981818,0.000005771881,0.0008059963],"genre_scores_gemma":[0.99601895,0.00009912481,0.0024036327,0.0007936971,0.00003405759,0.00014042876,0.0003927367,0.000011061202,0.0001063373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989509,0.000054258897,0.00054013333,0.00014889623,0.000097187454,0.00020863836],"domain_scores_gemma":[0.99876213,0.00023566252,0.00033802868,0.00018218604,0.00035816885,0.00012384247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025325423,0.0000924425,0.00071052235,0.00026023816,0.000023138262,0.0000015675936,0.00005625456,0.00009111544,0.00006301989],"category_scores_gemma":[0.000060142316,0.0000664927,0.00017621568,0.0003466349,0.00006134735,0.00009024722,0.000012051712,0.00006300047,8.655272e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032137605,0.003340843,0.9791554,0.000044935874,0.002983766,0.000001191811,0.00080566964,0.00018471344,0.000007802046,0.00006214777,0.00023774794,0.012854356],"study_design_scores_gemma":[0.0051107123,0.0018178726,0.98471546,0.00001778847,0.0065561715,1.3615335e-7,0.00017916522,0.0003992979,0.000090177324,0.0000117988275,0.0010386802,0.00006273362],"about_ca_topic_score_codex":0.0005990545,"about_ca_topic_score_gemma":0.0011833739,"teacher_disagreement_score":0.012791622,"about_ca_system_score_codex":0.00004449162,"about_ca_system_score_gemma":0.00029756373,"threshold_uncertainty_score":0.27114937},"labels":[],"label_agreement":null},{"id":"W3000306132","doi":"10.1016/s0923-7534(20)33008-8","title":"A Phase IB Combination Study of RO4929097 (RO), A Gamma-Secretase Inhibitor, and Temsirolimus (TEM) in Patients (PTS) with Advanced Solid Tumors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Temsirolimus; Medicine; Gamma secretase; Cancer research; Internal medicine; Oncology; Pharmacology; Discovery and development of mTOR inhibitors; Genetics; PI3K/AKT/mTOR pathway","score_opus":0.029912400606064395,"score_gpt":0.35702157694663134,"score_spread":0.32710917634056697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000306132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982447,0.00077608024,0.000020356927,0.000052951247,0.00012005822,0.0005217354,0.000028650464,0.000005156676,0.00023032055],"genre_scores_gemma":[0.9994546,0.00007015623,0.00009939842,0.00015138187,0.00006264657,0.000064790685,0.00006100113,0.000021010852,0.000015020899],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863774,0.0001691137,0.00044158692,0.000269755,0.00017433365,0.00030747248],"domain_scores_gemma":[0.9989771,0.00003691623,0.00038033357,0.00025016663,0.00025209418,0.00010338626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037865803,0.00016737207,0.00039604263,0.00011658299,0.000027698004,0.0000034259274,0.00012269562,0.00014425545,0.0000074272652],"category_scores_gemma":[0.00011082441,0.00015411375,0.00003726961,0.00013657678,0.00013515519,0.00001651435,0.00008709538,0.00010462658,8.0936144e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076285633,0.03482781,0.48475477,0.00019010062,0.0003536227,0.000022419077,0.003119044,0.00022754037,0.39680764,0.000060598726,0.0010854277,0.07092246],"study_design_scores_gemma":[0.05406228,0.14223893,0.1303124,0.00017405562,0.00011055067,0.000020183597,0.0015235225,0.00006848659,0.66388893,0.00009454803,0.006820833,0.0006852938],"about_ca_topic_score_codex":0.000051899595,"about_ca_topic_score_gemma":0.00009278417,"teacher_disagreement_score":0.3544424,"about_ca_system_score_codex":0.000024044162,"about_ca_system_score_gemma":0.000100873774,"threshold_uncertainty_score":0.6284576},"labels":[],"label_agreement":null},{"id":"W3000364350","doi":"10.1016/s0923-7534(20)33106-9","title":"Use of Palliative Chemotherapy and Targeted Agents in Elderly Patients with Metastatic Colorectal Cancer (MCRC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Colorectal cancer; Palliative chemotherapy; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.11895264461772376,"score_gpt":0.3978509603051074,"score_spread":0.27889831568738366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000364350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970693,0.0014005614,0.0000015912259,0.0006524936,0.00005371199,0.00045285342,0.000051529885,0.000004297115,0.00031365873],"genre_scores_gemma":[0.9976179,0.0013813288,0.00039654734,0.00045576127,0.000013403073,0.00006349812,0.000013096027,0.000010230283,0.000048253834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992672,0.000048077804,0.00022163746,0.00011992091,0.00012812576,0.00021500811],"domain_scores_gemma":[0.999385,0.0001228415,0.00017354876,0.00006004763,0.00018944411,0.00006914004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007523107,0.00011513536,0.0005046219,0.000083947736,0.000017407656,0.0000014644766,0.00002346011,0.00004362983,0.000084549276],"category_scores_gemma":[0.000044100187,0.00007850695,0.000035609,0.00014785932,0.00014092954,0.00008527195,0.000018936953,0.00006231924,4.7750353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029573177,0.0012780327,0.9411539,0.000050954175,0.00059489004,0.000005087253,0.0028747683,0.000002158481,0.00021885519,0.000015000808,0.0004549873,0.05039409],"study_design_scores_gemma":[0.003819217,0.0075775315,0.9818063,0.000059041977,0.000093297975,7.3415447e-7,0.00015454905,0.000007833648,0.003487588,0.000014837409,0.002912116,0.00006695825],"about_ca_topic_score_codex":0.0007341915,"about_ca_topic_score_gemma":0.0007299338,"teacher_disagreement_score":0.050327133,"about_ca_system_score_codex":0.000056353045,"about_ca_system_score_gemma":0.000085126936,"threshold_uncertainty_score":0.32014206},"labels":[],"label_agreement":null},{"id":"W3000398809","doi":"10.1016/j.annonc.2019.10.008","title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Randomized controlled trial; Discontinuation; Odds ratio; Meta-analysis; Placebo; Immunotherapy; Oncology; Cancer; Pathology","score_opus":0.3723914785504721,"score_gpt":0.5493400107631066,"score_spread":0.17694853221263446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000398809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019193163,0.97584945,0.0000858404,0.0016038246,0.000037135203,0.022050818,0.00029371868,0.00001193622,0.000048110167],"genre_scores_gemma":[0.00008369466,0.9922581,0.00043754373,0.0035479364,0.000031704327,0.0031928238,0.0002305794,0.000058651458,0.00015901962],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9832294,0.007274656,0.008330776,0.00056205684,0.00032315528,0.00027994253],"domain_scores_gemma":[0.9829569,0.0076175244,0.0082275085,0.0006485937,0.00042262222,0.00012686668],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.024345305,0.0005680522,0.05818938,0.0005359816,0.000020506703,0.000005512618,0.00028676336,0.00037613112,0.0004460619],"category_scores_gemma":[0.00334476,0.00030452694,0.01104184,0.0011231559,0.0003623572,0.000034628203,0.000029255505,0.00028282675,0.0000016984997],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036234744,0.0005995692,0.0000012291664,0.4449916,0.49608448,0.000014546891,0.00017313527,2.1461352e-7,0.000001910762,0.000005999357,0.0008080217,0.021084568],"study_design_scores_gemma":[0.07318768,0.0024383427,0.0000035488956,0.051335376,0.7842579,0.000029882154,0.00005598195,0.00002600607,0.000009194336,0.000005614325,0.088445745,0.0002047438],"about_ca_topic_score_codex":0.00004349945,"about_ca_topic_score_gemma":0.000019130952,"teacher_disagreement_score":0.3936562,"about_ca_system_score_codex":0.00006822986,"about_ca_system_score_gemma":0.0010575717,"threshold_uncertainty_score":0.9999407},"labels":[],"label_agreement":null},{"id":"W3000548081","doi":"10.1016/s0923-7534(20)33728-5","title":"KI-67 Index Variability in Neuroendocrine Tumors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Index (typography); Oncology; Internal medicine; World Wide Web","score_opus":0.0850074520154759,"score_gpt":0.43102393539416883,"score_spread":0.34601648337869295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000548081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651045,0.00022080241,0.000012947547,0.011008655,0.00019496908,0.00044103788,0.000006359698,0.000037187478,0.0229735],"genre_scores_gemma":[0.99709606,0.00017807807,0.00023072542,0.0018411841,0.00018614931,0.000042609892,0.0000055156715,0.000021449767,0.0003982305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763626,0.000455475,0.0004968496,0.00026440533,0.00030786375,0.0008391698],"domain_scores_gemma":[0.99831367,0.0006335032,0.00013430993,0.00041988931,0.00015918493,0.00033942418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071439,0.000153072,0.00057103985,0.00028158454,0.000020609861,0.0000027477677,0.000172764,0.000013106773,0.00037094144],"category_scores_gemma":[0.0027087901,0.000135846,0.0000969369,0.00039557158,0.00025099618,0.00020617642,0.00016488096,0.00046954525,0.000050699793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011633544,0.0024780664,0.94955784,0.00020376561,0.00002929924,0.003074762,0.00008204361,0.000012367047,0.004307068,0.0011873059,0.0047190078,0.033185143],"study_design_scores_gemma":[0.0026870018,0.0036677422,0.78300565,0.00005009911,0.000016105218,0.0027776798,0.00010402687,0.000071728384,0.034811497,0.0016765997,0.17095873,0.00017314691],"about_ca_topic_score_codex":0.00014904616,"about_ca_topic_score_gemma":0.000043940752,"teacher_disagreement_score":0.16655217,"about_ca_system_score_codex":0.00005211724,"about_ca_system_score_gemma":0.00021941427,"threshold_uncertainty_score":0.5539639},"labels":[],"label_agreement":null},{"id":"W3000563621","doi":"10.1016/s0923-7534(20)33006-4","title":"A Phase I Study of the Combination of RO4929097 (RO) And Cediranib (CD) in Patients with Advanced Solid Tumors (PJC-004/NCI 8503)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Solid tumor; Oncology; Pharmacology; Cancer","score_opus":0.020077391418851915,"score_gpt":0.33192998723512596,"score_spread":0.31185259581627406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000563621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988444,0.00031861148,0.0000068491427,0.00007582756,0.00008832034,0.00037230068,0.00003519612,9.0906553e-7,0.00025758217],"genre_scores_gemma":[0.99965274,0.00010995777,0.000047885736,0.00011795142,0.000021200487,0.000013861289,0.000018461158,0.000008661086,0.000009251387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992923,0.000060923387,0.00028100732,0.0001235763,0.00009247719,0.00014967672],"domain_scores_gemma":[0.99925756,0.000035820078,0.00028751593,0.00019482792,0.00018557506,0.000038677634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017359764,0.00008465443,0.00024116923,0.000041698044,0.000017817823,0.0000012943137,0.000104708495,0.000068961635,0.0000032433118],"category_scores_gemma":[0.00011173657,0.00006516527,0.000029356976,0.000083468716,0.000103778395,0.0000051792895,0.0000905536,0.000049745126,1.3069766e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031002928,0.021376086,0.84854,0.000093221155,0.00017436438,0.0000015261385,0.0025597888,0.00023923878,0.08257267,0.00036209953,0.000563866,0.040416863],"study_design_scores_gemma":[0.017997226,0.03319862,0.7911163,0.000042129534,0.00005315158,0.0000019641825,0.00092240993,0.000016172784,0.1543064,0.00011597061,0.0020499965,0.0001796368],"about_ca_topic_score_codex":0.00007366979,"about_ca_topic_score_gemma":0.00022875557,"teacher_disagreement_score":0.07173373,"about_ca_system_score_codex":0.000008656924,"about_ca_system_score_gemma":0.00007478093,"threshold_uncertainty_score":0.26573628},"labels":[],"label_agreement":null},{"id":"W3000596532","doi":"10.1016/s0923-7534(20)33372-x","title":"Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Urothelial carcinoma; Chemotherapy; Oncology; Internal medicine; Systemic therapy; Risk stratification; Stratification (seeds); Carcinoma; Cancer; Bladder cancer","score_opus":0.0880873230321215,"score_gpt":0.37543947145164697,"score_spread":0.2873521484195255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000596532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917074,0.0035006881,0.000053496304,0.00068510603,0.00024103685,0.0018860635,0.00014076945,0.00005257732,0.0017328608],"genre_scores_gemma":[0.9972942,0.00045477823,0.00071459555,0.0005230974,0.00038958614,0.00016560032,0.00008275227,0.000054420492,0.00032100856],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980611,0.00017488401,0.0006944156,0.00032861164,0.00028319084,0.0004577517],"domain_scores_gemma":[0.99809194,0.00046581303,0.0005557532,0.00036207476,0.00034126404,0.00018317986],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029056435,0.00027148137,0.0008164931,0.00014039024,0.00006539486,0.000007174512,0.000155638,0.00023244943,0.0010471481],"category_scores_gemma":[0.00024828655,0.00022671078,0.00015822597,0.00019575171,0.00011024974,0.00018270836,0.00003055404,0.00017952806,0.00005290699],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002664476,0.0017452405,0.22730774,0.00026952723,0.0005362248,0.000010823821,0.0049758595,0.000002836545,0.59024173,0.00004115851,0.00013840574,0.17206597],"study_design_scores_gemma":[0.007996601,0.00963691,0.5678538,0.00059408444,0.00019832871,0.00008713518,0.00038722943,0.000057318375,0.4105167,0.00024681905,0.0021171567,0.00030792394],"about_ca_topic_score_codex":0.00016786702,"about_ca_topic_score_gemma":0.000013430851,"teacher_disagreement_score":0.34054604,"about_ca_system_score_codex":0.00009848196,"about_ca_system_score_gemma":0.0005681646,"threshold_uncertainty_score":0.999866},"labels":[],"label_agreement":null},{"id":"W3000644704","doi":"10.1016/s0923-7534(20)30070-3","title":"P-0149 Small Bowel Adenocarcinoma: A Single Center Experience","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Center (category theory); Adenocarcinoma; Gynecology; Internal medicine; Cancer","score_opus":0.23136903588041172,"score_gpt":0.41929194576989187,"score_spread":0.18792290988948016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000644704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741333,0.0010512985,0.000034615576,0.00337793,0.00008517278,0.0002121117,0.0000059807676,0.000020224825,0.021079326],"genre_scores_gemma":[0.9962431,0.000040172574,0.002171145,0.0008056006,0.00016794418,0.000031700612,0.0000110137125,0.000011534007,0.00051776133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988858,0.00005929616,0.0002079961,0.00014557822,0.0001563393,0.0005449696],"domain_scores_gemma":[0.9991216,0.0000830839,0.000077478086,0.00021058714,0.0001506194,0.00035659847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017084565,0.00010571675,0.00026863065,0.00008286071,0.000029100163,0.0000032956414,0.000082034174,0.00004414408,0.0002312502],"category_scores_gemma":[0.00021055304,0.00008278376,0.000098907825,0.00008526917,0.00016051755,0.00006059925,0.000068976435,0.0001222235,0.000112779555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066496606,0.0045479503,0.96619356,0.00005593885,0.0000668608,0.00043858547,0.001059796,1.7635055e-7,0.008601881,0.00030122232,0.0048256037,0.013243452],"study_design_scores_gemma":[0.0039280383,0.021612618,0.8424391,0.00013960208,0.00005337259,0.0038473334,0.0010578816,0.000012008464,0.060898565,0.00012264421,0.06571709,0.00017173025],"about_ca_topic_score_codex":0.00006735955,"about_ca_topic_score_gemma":0.000010520123,"teacher_disagreement_score":0.12375445,"about_ca_system_score_codex":0.000049439044,"about_ca_system_score_gemma":0.00008338065,"threshold_uncertainty_score":0.33758235},"labels":[],"label_agreement":null},{"id":"W3000646347","doi":"10.1016/s0923-7534(20)33160-4","title":"Adjuvant Chemotherapy (AC) Use and Outcomes in Stage II Colon Cancer (CC) with vs. without Poor Prognostic Features","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Adjuvant; Adjuvant chemotherapy; Oncology; Colorectal cancer; Internal medicine; Chemotherapy; Stage (stratigraphy); Cancer; Breast cancer","score_opus":0.06834663947148599,"score_gpt":0.396832531917243,"score_spread":0.328485892445757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000646347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832687,0.0048503117,6.3970094e-7,0.01031306,0.00008889611,0.00062245445,0.000031072348,0.00001670122,0.00080820476],"genre_scores_gemma":[0.99211967,0.002485723,0.00023730901,0.00308783,0.00005133552,0.00015317294,0.000005230694,0.000017395505,0.0018423367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991466,0.000038230817,0.00018532235,0.0001766057,0.00012752209,0.00032572073],"domain_scores_gemma":[0.99942064,0.00013950485,0.00011829219,0.00010733481,0.00011255646,0.00010167883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012373445,0.00016687425,0.0006767505,0.00008672196,0.000053354204,0.0000048795273,0.00003592371,0.00009020082,0.00004160415],"category_scores_gemma":[0.00007594355,0.00010298584,0.00004144999,0.00010193537,0.00017030412,0.00010502415,0.000042270083,0.00012083707,7.054651e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029852588,0.0017892015,0.9730942,0.000058269463,0.00035667766,0.000037834136,0.0024092474,6.755076e-7,0.0001817405,0.00004831727,0.0014871197,0.01755144],"study_design_scores_gemma":[0.006598006,0.0073430734,0.9587846,0.000084135194,0.00009814726,0.000024089211,0.00026277773,0.0000027726892,0.0012214236,0.0000070756264,0.025468705,0.00010519665],"about_ca_topic_score_codex":0.0014245431,"about_ca_topic_score_gemma":0.004772431,"teacher_disagreement_score":0.023981586,"about_ca_system_score_codex":0.0000686567,"about_ca_system_score_gemma":0.00012882485,"threshold_uncertainty_score":0.41996405},"labels":[],"label_agreement":null},{"id":"W3000713139","doi":"10.1016/j.annonc.2019.10.025","title":"A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Health and Medical Research Council; Bayer","keywords":"Medicine; Regimen; Prostate cancer; Hazard ratio; Clinical endpoint; Confidence interval; Surgery; Internal medicine; Urology; Cancer; Randomized controlled trial","score_opus":0.11824262257958643,"score_gpt":0.4133955550670814,"score_spread":0.29515293248749497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000713139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99169785,0.0007989914,0.000008709071,0.004766173,0.000038224352,0.00229467,0.00011344933,0.000005267709,0.00027669204],"genre_scores_gemma":[0.99902576,0.00027983807,0.00029800044,0.00013604556,0.000029226081,0.00010951228,0.00005501549,0.000013179461,0.000053395936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99854386,0.00011277916,0.0006064817,0.00019064372,0.00031676263,0.0002294814],"domain_scores_gemma":[0.99883145,0.00013657798,0.0004210352,0.00013363978,0.00036266682,0.0001146373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032330788,0.00012090176,0.00083120156,0.00012989462,0.000026575071,0.0000020187954,0.00005590126,0.00004875763,0.000058703357],"category_scores_gemma":[0.000119897246,0.0000828949,0.00008699066,0.0003192457,0.00021271645,0.0000626146,0.00002542852,0.00011798107,3.7695293e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94642216,0.0056324215,0.0036310935,0.00040007746,0.0005596913,0.000089677524,0.0026843369,0.000029173303,0.01887369,0.00002318661,0.000482114,0.021172391],"study_design_scores_gemma":[0.8793929,0.07390271,0.0036785405,0.00026092486,0.00027738567,0.0000012106901,0.00018044816,0.00011383885,0.04146714,0.00006592895,0.0005620062,0.00009694211],"about_ca_topic_score_codex":0.0003072243,"about_ca_topic_score_gemma":0.00018471804,"teacher_disagreement_score":0.06827029,"about_ca_system_score_codex":0.000049700324,"about_ca_system_score_gemma":0.0008611468,"threshold_uncertainty_score":0.33803558},"labels":[],"label_agreement":null},{"id":"W3000728759","doi":"10.1016/s0923-7534(20)30103-4","title":"P-0018 Gastric Cancer Resection Outcome, a Single Center Experience","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Resection; Cancer; Single Center; Outcome (game theory); Center (category theory); Internal medicine; Oncology; General surgery; Surgery","score_opus":0.19471823846176706,"score_gpt":0.44663707309109435,"score_spread":0.2519188346293273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000728759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592318,0.0007654441,0.00011647375,0.0054106005,0.0010641543,0.00022784492,0.0000047671197,0.000032417185,0.033146515],"genre_scores_gemma":[0.99292064,0.00031872297,0.00029228194,0.0030265416,0.00042637225,0.000041542185,0.0000057887723,0.0000105944155,0.0029574954],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898267,0.00003433993,0.00029926482,0.00013553252,0.00017405904,0.00037415005],"domain_scores_gemma":[0.9993981,0.000044067623,0.00015231232,0.0001766025,0.00010735718,0.0001215359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020103855,0.00009695166,0.00030448593,0.00017321766,0.000031612635,0.0000037707748,0.00007356601,0.0000725398,0.0006672686],"category_scores_gemma":[0.000091535636,0.00008174948,0.000098560995,0.00027809088,0.00007573091,0.0001343904,0.00006036908,0.00010048404,0.000026945801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030547852,0.00057942263,0.9097832,0.00006007909,0.00005791405,0.000007405374,0.0006139297,0.000001418124,0.001203961,0.00009953063,0.029381063,0.05790663],"study_design_scores_gemma":[0.0015818216,0.0017769677,0.4808179,0.00003405681,0.000055733024,0.00005008282,0.0004600671,0.000007684469,0.002858523,0.000015393398,0.512248,0.000093814],"about_ca_topic_score_codex":0.00018740408,"about_ca_topic_score_gemma":0.000060025588,"teacher_disagreement_score":0.48286688,"about_ca_system_score_codex":0.000086987966,"about_ca_system_score_gemma":0.000037560396,"threshold_uncertainty_score":0.7306123},"labels":[],"label_agreement":null},{"id":"W3000729903","doi":"10.1016/s0923-7534(20)31932-3","title":"Lux-Lung 3: Afatinib Versus Cisplatin and Pemetrexed in Japanese Patients with Adenocarcinoma of the Lung Harboring an EGFR Mutation","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Cisplatin; Oncology; Adenocarcinoma; Internal medicine; Lung cancer; Lung; Chemotherapy; Cancer research; Erlotinib; Epidermal growth factor receptor; Cancer","score_opus":0.04714006362605189,"score_gpt":0.3980594596395092,"score_spread":0.35091939601345734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000729903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962152,0.0008683453,0.0000023837893,0.0003610786,0.00014964375,0.0004095839,0.000012577311,0.00000561195,0.0019755682],"genre_scores_gemma":[0.9994337,0.000022724415,0.0003069682,0.000093572635,0.000038551632,0.000026114703,0.000030671697,0.000010660902,0.00003705097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992767,0.00006647247,0.00022296494,0.00011526082,0.00014441514,0.00017421332],"domain_scores_gemma":[0.99932843,0.00011715102,0.00018443118,0.00015364427,0.00014425375,0.000072068804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013842424,0.00008642688,0.00023101328,0.0000961746,0.00003172758,0.0000021070719,0.00004348419,0.000061320425,0.00002711823],"category_scores_gemma":[0.00008127135,0.000057172656,0.000027420396,0.00018434419,0.00007855606,0.00015689526,0.000022274951,0.00007633813,4.8976807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007658537,0.00054936635,0.9835843,0.00007015956,0.000117532734,0.0000035166647,0.0065834564,0.000015997563,0.0001317779,0.0001106193,0.000081376325,0.00798605],"study_design_scores_gemma":[0.005580985,0.0017112335,0.99053156,0.00006901863,0.00020539411,0.0000038304393,0.00094651175,0.0001203125,0.0006909513,0.0000060213006,0.00008148744,0.000052689637],"about_ca_topic_score_codex":0.0003120431,"about_ca_topic_score_gemma":0.00010259073,"teacher_disagreement_score":0.0079333605,"about_ca_system_score_codex":0.000064933694,"about_ca_system_score_gemma":0.000102541046,"threshold_uncertainty_score":0.23314333},"labels":[],"label_agreement":null},{"id":"W3001536410","doi":"10.1016/s0923-7534(20)33874-6","title":"Cumulative Exposure (EXP) to Bevacizumab (BV) Maintenance after Induction Therapy and Survival in Advanced Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis from the Sail (MO19390) Study","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Oncology; Lung cancer; Internal medicine; Maintenance therapy; Chemotherapy","score_opus":0.039496959540608716,"score_gpt":0.39129361905550136,"score_spread":0.35179665951489264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001536410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917978,0.0034796773,0.00008366441,0.0022839042,0.00020942936,0.0012588054,0.00007553752,0.000010672403,0.0008004868],"genre_scores_gemma":[0.99700826,0.0005481889,0.00024137252,0.000962062,0.00014386486,0.0004960132,0.000022931297,0.000018275789,0.00055904774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866384,0.00019450622,0.000338615,0.0003054544,0.0001866827,0.00031090374],"domain_scores_gemma":[0.9990448,0.00018212295,0.00016706275,0.0002802662,0.00020223073,0.00012351261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000332479,0.00017960154,0.00053864444,0.0001572184,0.00005442187,0.000008532284,0.00008018504,0.000095125,0.00019158162],"category_scores_gemma":[0.000026723128,0.00011889068,0.00009381831,0.00042196817,0.0000439025,0.00012128998,0.000047656526,0.00016081975,0.0000067445403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020226294,0.0015516747,0.90381646,0.0000091847105,0.0017350094,0.000021312386,0.032011256,0.0003739365,0.0010000695,0.0000029568585,0.00023757268,0.057217922],"study_design_scores_gemma":[0.004846238,0.0016869216,0.9862117,0.0000407437,0.0007901671,0.0000014600699,0.004242089,0.00007560339,0.00068625814,0.000015253139,0.0012771279,0.000126433],"about_ca_topic_score_codex":0.003905541,"about_ca_topic_score_gemma":0.0040826946,"teacher_disagreement_score":0.082395226,"about_ca_system_score_codex":0.00018274905,"about_ca_system_score_gemma":0.00017203967,"threshold_uncertainty_score":0.59040356},"labels":[],"label_agreement":null},{"id":"W3003551038","doi":"10.1016/s0923-7534(20)33518-3","title":"Health-Related Quality of Life (QOL) in Patients with Metastatic Castration-Resistant Prostate Cancer (MCRPC): Cabazitaxel Early Access Program (EAP) Interim Results from Canada","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada); Hôpital Notre-Dame","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Interim; Oncology; Quality of life (healthcare); Docetaxel; Cancer; Internal medicine; Androgen deprivation therapy; Nursing","score_opus":0.5114594209546308,"score_gpt":0.5110058123418079,"score_spread":0.0004536086128229533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003551038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699916,0.0017212719,0.000009261823,0.020623354,0.0005451669,0.0015314951,0.0051368647,0.000014699203,0.0004262365],"genre_scores_gemma":[0.9955075,0.00008861168,0.00082493713,0.0029578682,0.000049648766,0.00020579879,0.00028835473,0.000025684738,0.000051633302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99077743,0.00093130756,0.0070323003,0.00044695838,0.0001896604,0.0006223505],"domain_scores_gemma":[0.99059457,0.0011257551,0.007206788,0.00042849485,0.00030971484,0.00033469094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009347377,0.00022004917,0.0019191855,0.00024794176,0.00007015554,0.00002333402,0.0003142431,0.00012128926,0.00010417925],"category_scores_gemma":[0.0025667248,0.00023838173,0.00007313902,0.00033676592,0.00013324273,0.0006400907,0.00006305971,0.00022142843,0.000014501679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015165705,0.0012978264,0.9777448,0.000462502,0.00034740774,9.849708e-7,0.0060712025,0.0003021503,0.0000020350114,0.0014077123,0.0073878174,0.003458965],"study_design_scores_gemma":[0.0034748304,0.0010161594,0.99078214,0.00012626783,0.0000070266015,1.6862637e-7,0.00055134995,0.000067227724,0.000010211972,0.00047409988,0.0032666223,0.00022388832],"about_ca_topic_score_codex":0.9347198,"about_ca_topic_score_gemma":0.80724424,"teacher_disagreement_score":0.12747559,"about_ca_system_score_codex":0.0006957344,"about_ca_system_score_gemma":0.0025934868,"threshold_uncertainty_score":0.9720925},"labels":[],"label_agreement":null},{"id":"W3004123626","doi":"10.1016/s0923-7534(20)33720-0","title":"Neuroendocrine Tumors: A Review of the Sunnybrook Odette Cancer Centre Database","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer; Neuroendocrine tumors; General surgery; Internal medicine","score_opus":0.20907113439108557,"score_gpt":0.49459927609190774,"score_spread":0.2855281417008222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004123626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017146498,0.9821898,1.8699278e-7,0.011668835,0.00038836294,0.0025590316,0.00052314374,0.000023066377,0.0026304699],"genre_scores_gemma":[0.000010289546,0.9920976,0.000080156395,0.004642033,0.00042714213,0.00020119202,0.00011333434,0.00008900835,0.0023392283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511904,0.0010428481,0.0016768138,0.000522496,0.00072647195,0.00091233675],"domain_scores_gemma":[0.9952649,0.0006287924,0.0017107858,0.0015296993,0.0005180091,0.00034780265],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044941498,0.000515327,0.004134261,0.00023503092,0.00004193038,0.0000031796355,0.00085257826,0.000027669123,0.001164157],"category_scores_gemma":[0.0015970366,0.00030864662,0.0010702927,0.0007787143,0.00048360793,0.00011718982,0.0007195127,0.0010872777,0.000054418295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045399964,0.00037975266,0.000052264695,0.28984126,0.000200456,0.0010698364,0.00000423625,4.244228e-8,0.000007990947,0.00006565834,0.07214007,0.63619304],"study_design_scores_gemma":[0.00032838626,0.0004662699,0.000009069112,0.1386519,0.0012593571,0.002462507,0.0000035946994,2.3640348e-7,0.00017964662,0.0000072567027,0.85647744,0.00015432514],"about_ca_topic_score_codex":0.00012862805,"about_ca_topic_score_gemma":0.00007667634,"teacher_disagreement_score":0.7843374,"about_ca_system_score_codex":0.00008715452,"about_ca_system_score_gemma":0.0018950182,"threshold_uncertainty_score":0.9999366},"labels":[],"label_agreement":null},{"id":"W3005467664","doi":"10.1016/s0923-7534(20)33522-5","title":"Cabazitaxel Early Access Program (EAP) - Canadian Interim Results: Safety, QOL, and Utility Values in Metastatic Castration Resistant Prostate Cancer (MCRPC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; CancerCare Manitoba; La Cité Médicale; Moncton Hospital; Sanofi (Canada); Hôpital Notre-Dame; Grand River Hospital","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Interim; Oncology; Docetaxel; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.2168137851922464,"score_gpt":0.4984612779337534,"score_spread":0.281647492741507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005467664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764828,0.004387353,8.1006704e-7,0.010652648,0.00013806396,0.001473246,0.00040564872,0.000020111054,0.006439302],"genre_scores_gemma":[0.9956148,0.00279124,0.00027103216,0.00026867818,0.00006312096,0.00022751388,0.00011710983,0.000015999036,0.0006304508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981053,0.0002191493,0.00051439437,0.0002810689,0.00020948927,0.0006706375],"domain_scores_gemma":[0.9988035,0.000113187874,0.00015586604,0.00021679343,0.0002823413,0.00042832026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010582992,0.00016245707,0.0004636504,0.00029361964,0.000074386044,0.000027079113,0.000105310144,0.00010677292,0.000066942666],"category_scores_gemma":[0.00019741333,0.00012778601,0.00005040994,0.00031395955,0.00030074394,0.00036366226,0.00006407626,0.00023813461,0.000003615485],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019369442,0.0020625566,0.32175368,0.00074204296,0.0005476637,0.0004188554,0.012085985,0.000004039019,0.0020493015,0.00019376448,0.00700613,0.63376653],"study_design_scores_gemma":[0.0044948165,0.0046254327,0.94341666,0.00025230367,0.00009365106,0.000025934354,0.00081523316,0.00005649975,0.00403016,0.0003446269,0.04167493,0.0001697784],"about_ca_topic_score_codex":0.1832626,"about_ca_topic_score_gemma":0.21740127,"teacher_disagreement_score":0.6335968,"about_ca_system_score_codex":0.00028156483,"about_ca_system_score_gemma":0.001329024,"threshold_uncertainty_score":0.8221761},"labels":[],"label_agreement":null},{"id":"W3005507634","doi":"10.1016/s0923-7534(20)34063-1","title":"Mutational Analysis Before and After Neoadjuvant Imatinib Mesylate for Locally Advanced Gastrointestinal Stromal Tumours","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; GiST; Oncology; Stromal cell; Neoadjuvant therapy; Cancer research; Internal medicine; Cancer; Breast cancer","score_opus":0.04466510800555347,"score_gpt":0.39459107134296334,"score_spread":0.3499259633374099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005507634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302024,0.00025350554,0.0029417572,0.0027146866,0.000023039796,0.00048297172,0.00010114607,0.0000183032,0.0004443251],"genre_scores_gemma":[0.94343793,0.000007832206,0.055824477,0.0002545257,0.000085121996,0.0001269003,0.00011554542,0.000014777907,0.00013290954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854237,0.000057463905,0.00035869685,0.00021800584,0.00023695671,0.00058652455],"domain_scores_gemma":[0.9985964,0.00024536904,0.0001682178,0.00014479911,0.00042810704,0.00041711482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003852512,0.00016702576,0.00052741705,0.0002346435,0.000045043977,0.0000065574445,0.000055815257,0.000035608566,0.00012471397],"category_scores_gemma":[0.00040665417,0.00013262694,0.00021700538,0.00019543259,0.00019854197,0.00010677813,0.000046827532,0.00014283511,0.0000084885305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005035391,0.0011864175,0.9414409,0.00012726674,0.00058457686,0.0003796348,0.0002429852,0.00005444092,0.0011853491,0.0005074753,0.00018977134,0.04906579],"study_design_scores_gemma":[0.0026932366,0.017019928,0.97507024,0.00010022559,0.0005081227,0.0018107314,0.00020666284,0.0009321228,0.000868562,0.00040762557,0.0002940414,0.000088524415],"about_ca_topic_score_codex":0.000025844922,"about_ca_topic_score_gemma":0.00007394968,"teacher_disagreement_score":0.05288272,"about_ca_system_score_codex":0.000040857005,"about_ca_system_score_gemma":0.00019307672,"threshold_uncertainty_score":0.540837},"labels":[],"label_agreement":null},{"id":"W3006357472","doi":"10.1016/s0923-7534(19)65687-5","title":"15P A Novel RNA Test to Guide Primary Systemic Breast Cancer Chemotherapy","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Mount Sinai Hospital; Health Sciences Centre; Laurentian University; University of Toronto; Sudbury Regional Hospital; University of Waterloo; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Oncology; Chemotherapy; Test (biology); Internal medicine; Cancer","score_opus":0.04441526785657005,"score_gpt":0.36822659557141163,"score_spread":0.32381132771484156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006357472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521145,0.0025070389,0.0019852696,0.016163118,0.0005329388,0.00041063203,0.00015303057,0.000019883446,0.026113577],"genre_scores_gemma":[0.9859794,0.0008473506,0.0005344251,0.009388954,0.0005085726,0.00010622761,0.000025133708,0.000020344722,0.0025896197],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991285,0.000035807785,0.00025402763,0.00021151852,0.00009935217,0.00027075154],"domain_scores_gemma":[0.99917996,0.000021616226,0.00015786866,0.000295727,0.00019669613,0.00014815193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002593949,0.00011567417,0.00019567329,0.000053819975,0.000029348506,0.0000041790177,0.00018497802,0.0001692837,0.00013556617],"category_scores_gemma":[0.000047565212,0.00010390762,0.00007077417,0.000107918466,0.00004098193,0.000004961463,0.000063249056,0.000051285715,0.000018563405],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087442015,0.00023810561,0.003794122,0.00002083844,0.000028428982,1.4389451e-7,0.00007500309,0.0000059306994,0.8416398,0.000060393293,0.12870307,0.025346728],"study_design_scores_gemma":[0.00038827877,0.0002793926,0.026257189,0.000032763364,0.000006610504,0.000030959392,0.00007231596,0.0000025178592,0.43941075,0.000004392602,0.5333951,0.00011972028],"about_ca_topic_score_codex":0.000034393302,"about_ca_topic_score_gemma":0.000008339207,"teacher_disagreement_score":0.40469202,"about_ca_system_score_codex":0.000036673755,"about_ca_system_score_gemma":0.0002240421,"threshold_uncertainty_score":0.42372298},"labels":[],"label_agreement":null},{"id":"W3006810687","doi":"10.1016/s0923-7534(19)65716-9","title":"63P Assessment of Sunitinib Therapy Using an Integrated Micro-Ultrasound and Photoacoustic System in Mouse Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Photoacoustic and Ultrasonic Imaging","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; FujiFilm VisualSonics (Canada)","funders":"","keywords":"Medicine; Sunitinib; Microbubbles; Ultrasound; Breast cancer; Photoacoustic imaging in biomedicine; Perfusion; Nuclear medicine; Blood flow; Biomedical engineering; Cancer; Urology; Radiology; Internal medicine","score_opus":0.06132546395998677,"score_gpt":0.3580703415033139,"score_spread":0.2967448775433271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006810687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958502,0.0009809578,0.0019994199,0.000012102064,0.0002062504,0.00017916458,0.00021116821,0.00004405124,0.0005166738],"genre_scores_gemma":[0.9977699,0.0007136323,0.0013343736,0.00006684031,0.00005362378,0.00001618823,0.000010466019,0.000028721688,0.0000062850463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989599,0.00009711975,0.00036283256,0.00011957071,0.0000929211,0.00036766817],"domain_scores_gemma":[0.9993427,0.0001986233,0.00010788596,0.00014155534,0.00011379863,0.00009546202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046447528,0.00015740014,0.00042010134,0.00015673958,0.000024386862,0.00000758782,0.000101712285,0.00011469771,0.00004246705],"category_scores_gemma":[0.000014372011,0.00014691187,0.000033866003,0.00016566776,0.00010382481,0.0001853011,0.000013354975,0.00018476725,2.4808983e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046255045,0.0003190905,0.034883194,0.00025585294,0.00011117057,0.0000059460185,0.0012890887,0.010954,0.9435565,0.00005588017,0.000060360824,0.008462646],"study_design_scores_gemma":[0.0056395684,0.0008821744,0.279841,0.0010215677,0.00018806677,0.001184092,0.019911515,0.3129076,0.37539306,0.000031833457,0.0017633784,0.0012361533],"about_ca_topic_score_codex":0.001257658,"about_ca_topic_score_gemma":0.00006141932,"teacher_disagreement_score":0.56816345,"about_ca_system_score_codex":0.00013081086,"about_ca_system_score_gemma":0.00014065491,"threshold_uncertainty_score":0.5990892},"labels":[],"label_agreement":null},{"id":"W3008940037","doi":"10.1093/annonc/mdy446","title":"ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; T790M; Internal medicine; Oncology; Asymptomatic; Interim analysis; Cancer; Clinical trial; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.04379992899427044,"score_gpt":0.43117338852474313,"score_spread":0.3873734595304727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008940037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906441,0.000028553824,0.0000062596446,0.0006812142,0.000049813552,0.00079412555,0.000088298475,0.000014980853,0.007692682],"genre_scores_gemma":[0.9975688,0.000029050503,0.00024971156,0.00020052449,0.000048042635,0.000050321174,0.000117910975,0.000017562692,0.0017181155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985365,0.0000849976,0.0005451891,0.0003079128,0.00026351144,0.00026186483],"domain_scores_gemma":[0.9984494,0.00032648476,0.0003554722,0.00032250583,0.00042912384,0.000117001764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014660884,0.0001629357,0.0007485438,0.00045733806,0.00004317616,0.0000040488994,0.00010885053,0.00008028572,0.00036888156],"category_scores_gemma":[0.00014450417,0.00011200976,0.00006145492,0.0013394956,0.00015619697,0.00005844939,0.00003574645,0.00010370965,0.000015096927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029443547,0.015658459,0.90353775,0.000020477912,0.0019931514,0.00003423605,0.0029827533,0.000021194957,0.00010424679,0.000004427663,0.007822489,0.06487648],"study_design_scores_gemma":[0.015140864,0.05720281,0.91234714,0.00006664873,0.0019972313,0.0000015274318,0.00072779186,0.000030952062,0.0027758968,0.0000025134743,0.009581511,0.00012510415],"about_ca_topic_score_codex":0.0028539365,"about_ca_topic_score_gemma":0.00960872,"teacher_disagreement_score":0.06475138,"about_ca_system_score_codex":0.00009265958,"about_ca_system_score_gemma":0.00027527843,"threshold_uncertainty_score":0.53618914},"labels":[],"label_agreement":null},{"id":"W3009012041","doi":"10.1016/s0923-7534(20)33525-0","title":"A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Prednisone; Prostate cancer; Internal medicine; Castration; Oncology; Urology; Prostate; Cancer; Gynecology; Hormone","score_opus":0.061466984418502665,"score_gpt":0.40710124064530434,"score_spread":0.34563425622680166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009012041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960083,0.000636059,0.0000357005,0.0002767903,0.000038923677,0.0027210147,0.0000656946,0.0000036543947,0.00021389166],"genre_scores_gemma":[0.9985357,0.00022173271,0.00030540122,0.0000639637,0.00003320189,0.00058421015,0.000075929376,0.000021412468,0.00015847747],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975022,0.00081069133,0.00064038375,0.0002776249,0.00031711176,0.00045198487],"domain_scores_gemma":[0.99875706,0.0000617232,0.00031261894,0.0003082542,0.0004361364,0.00012420001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013972697,0.00016967514,0.00075088895,0.00014462015,0.000050009152,0.000004468404,0.00015323258,0.00010569594,0.00003109491],"category_scores_gemma":[0.0003288191,0.000132781,0.000065190434,0.0002087035,0.00019235421,0.000016413705,0.00012340573,0.00012807632,0.0000011140866],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7091968,0.021890618,0.007903029,0.00025356995,0.0010036413,0.000023196171,0.0074959756,0.00038456699,0.22873567,0.000024919742,0.00063326047,0.022454748],"study_design_scores_gemma":[0.6073182,0.07788703,0.0051778452,0.000084502,0.00016059919,0.0000050005888,0.0009793874,0.00012089501,0.30528057,0.000023602302,0.0026212304,0.00034113866],"about_ca_topic_score_codex":0.0013802507,"about_ca_topic_score_gemma":0.0016352445,"teacher_disagreement_score":0.10187858,"about_ca_system_score_codex":0.000048420283,"about_ca_system_score_gemma":0.00047053088,"threshold_uncertainty_score":0.5414652},"labels":[],"label_agreement":null},{"id":"W3011568629","doi":"10.1016/j.annonc.2020.01.028","title":"19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Canadian Partnership Against Cancer; Princess Margaret Cancer Centre","funders":"Ontario Institute for Cancer Research; Canadian Cancer Society; Stand Up To Cancer Canada; Government of Ontario","keywords":"Medicine; Neutropenia; Internal medicine; Taxane; Breast cancer; Adverse effect; Nausea; Tolerability; Febrile neutropenia; Paclitaxel; Oncology; Cancer; Metastatic breast cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Phases of clinical research","score_opus":0.05386763053986506,"score_gpt":0.4132210440111539,"score_spread":0.35935341347128885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011568629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98058087,0.00009324035,0.0000045547417,0.016437324,0.000099474186,0.0014513222,0.00014068297,0.0000109494,0.0011816142],"genre_scores_gemma":[0.9978122,0.00019228885,0.00015349896,0.001448819,0.00006232772,0.0001906026,0.00006547289,0.00001903889,0.00005572145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986255,0.00017079554,0.00044616868,0.0002825285,0.00022039522,0.0002545688],"domain_scores_gemma":[0.998897,0.00017277413,0.00037192748,0.000111865775,0.0003259553,0.00012045952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001444276,0.00017540526,0.0007626913,0.00016061115,0.000015554575,0.0000016937803,0.0000765072,0.00011888896,0.00025265102],"category_scores_gemma":[0.00005252599,0.00013542638,0.000053931934,0.00048487316,0.0001995891,0.00011015865,0.00002313783,0.00021687444,0.0000021473181],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6545935,0.020305427,0.2074508,0.00018232656,0.00041159766,0.00010542279,0.004329179,0.000106860934,0.00067952374,0.000080199716,0.0016713333,0.11008378],"study_design_scores_gemma":[0.5192848,0.1349177,0.33799052,0.00024862212,0.00018057678,0.0000049131418,0.0004867294,0.00007633398,0.0035333205,0.00009429138,0.002978519,0.00020366593],"about_ca_topic_score_codex":0.0013175572,"about_ca_topic_score_gemma":0.0015888492,"teacher_disagreement_score":0.13530873,"about_ca_system_score_codex":0.00013897778,"about_ca_system_score_gemma":0.00047890312,"threshold_uncertainty_score":0.55225277},"labels":[],"label_agreement":null},{"id":"W3011992252","doi":"10.1016/j.annonc.2020.02.016","title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":551,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"European Society for Medical Oncology","keywords":"Medicine; Guideline; Multidisciplinary approach; Clinical Practice; MEDLINE; Medical physics; Intensive care medicine; Family medicine; Pathology","score_opus":0.5266570679024027,"score_gpt":0.5807834227627786,"score_spread":0.05412635486037587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011992252","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30681968,0.009181592,0.00005553978,0.6790609,0.00061434385,0.0007403553,0.000071564355,0.0000506597,0.0034054122],"genre_scores_gemma":[0.800371,0.07512107,0.0050786887,0.11724173,0.0012186996,0.0005792812,0.000047795173,0.00003538375,0.00030636953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988868,0.00008673454,0.00054545247,0.00023754247,0.00009243667,0.00015103722],"domain_scores_gemma":[0.99746436,0.0010003482,0.0002172836,0.00011453911,0.001015764,0.00018768091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033502508,0.000103845225,0.0005071827,0.00002512633,0.00002708269,0.0000033732967,0.000044110275,0.00018667552,0.00008145783],"category_scores_gemma":[0.0029013567,0.00008226163,0.00014575677,0.000099402496,0.00007164691,0.00004715582,0.00002316855,0.0000922621,0.0000030242488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001378199,0.0005553239,0.029280772,0.0000892861,0.0006627891,0.000040131195,0.0018983658,0.0000053546655,0.000023165485,0.00023108462,0.16611743,0.7997181],"study_design_scores_gemma":[0.002532116,0.011337799,0.004273232,0.00003921722,0.00042895894,0.000011207324,0.0007816396,0.00016574493,0.0008271559,0.000053609936,0.97947294,0.000076358025],"about_ca_topic_score_codex":0.0010290929,"about_ca_topic_score_gemma":0.0006080435,"teacher_disagreement_score":0.8133555,"about_ca_system_score_codex":0.0000307293,"about_ca_system_score_gemma":0.00036477254,"threshold_uncertainty_score":0.34734046},"labels":[],"label_agreement":null},{"id":"W3012157230","doi":"10.1016/j.annonc.2020.01.066","title":"Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Medical Research Council; World Health Organization; European Commission; Wellcome Trust; NIHR Bristol Biomedical Research Centre; National Institutes of Health; Cancer Research UK; Government of Canada; Ministère de l'Économie, de la Science et de l'Innovation - Québec; Canadian Institutes of Health Research; National Institute for Health and Care Research; Genome Canada","keywords":"Mendelian randomization; Medicine; Breast cancer; Hazard ratio; Internal medicine; Proportional hazards model; Oncology; Risk factor; Odds ratio; Insulin-like growth factor; Confidence interval; Confounding; Cancer; Growth factor; Genetics; Biology; Genotype","score_opus":0.0999716659115966,"score_gpt":0.3438202178596085,"score_spread":0.24384855194801186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012157230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881996,0.0011994125,0.0002382172,0.007771817,0.0001356058,0.0012286298,0.00075643894,0.00011079869,0.00035950667],"genre_scores_gemma":[0.9901924,0.0052906084,0.0006987246,0.00303436,0.00028362256,0.00016615113,0.00016205074,0.00008150314,0.00009054118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962566,0.00036024555,0.0010706199,0.0008828475,0.00066665094,0.0007630392],"domain_scores_gemma":[0.9966023,0.00036438584,0.0008699792,0.00026786685,0.0010680923,0.00082735234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043144103,0.00060521625,0.0015467172,0.00045157,0.00026597964,0.00005688373,0.00022095957,0.00044075458,0.00024666212],"category_scores_gemma":[0.00049667177,0.00048028934,0.00014975658,0.0009924835,0.0004276303,0.0006423034,0.00016037008,0.00064312306,0.000008435313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024585348,0.0010694802,0.8613456,0.0011846084,0.0029730527,0.00014260538,0.011834547,0.00003818642,0.0711897,0.00051855244,0.0025076917,0.022610622],"study_design_scores_gemma":[0.030594004,0.00784324,0.93306154,0.0003067174,0.00056206045,0.00013805661,0.001583402,0.00081353576,0.018643534,0.0004544196,0.0048797713,0.0011197188],"about_ca_topic_score_codex":0.00084246363,"about_ca_topic_score_gemma":0.000056332887,"teacher_disagreement_score":0.07171593,"about_ca_system_score_codex":0.0001647548,"about_ca_system_score_gemma":0.00061660423,"threshold_uncertainty_score":0.99976486},"labels":[],"label_agreement":null},{"id":"W3012235119","doi":"10.1016/j.annonc.2020.01.031","title":"30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Principia Biopharma; Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; Genentech; Foundation Medicine; King Abdullah International Medical Research Center; Sierra Oncology; European Society for Medical Oncology; PharmaMar; Novartis Farmacéutica; Servier; Menarini Group; Seagen; MacroGenics; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Halozyme; Array BioPharma; Ipsen; BeiGene; Spectrum Pharmaceuticals; Symphogen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; GlaxoSmithKline","keywords":"PI3K/AKT/mTOR pathway; Cancer research; Biology; Gene silencing; RNA interference; Small hairpin RNA; RPTOR; Cell growth; Polysomy; Cell culture; Signal transduction; Fluorescence in situ hybridization; Gene; Cell biology; Genetics; Gene knockdown; RNA; Chromosome","score_opus":0.049083825245765905,"score_gpt":0.38360323569670063,"score_spread":0.3345194104509347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012235119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953971,0.0020003926,0.00077039364,0.0008934726,0.000085355896,0.00031305375,0.00018025584,0.0000025925306,0.00035740153],"genre_scores_gemma":[0.9991774,0.00022240842,0.00020856038,0.00019048895,0.00009700782,0.0000484898,0.0000092887285,0.000013330508,0.000033018103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984864,0.00034970423,0.00057843555,0.00026258224,0.0001657182,0.00015714954],"domain_scores_gemma":[0.9987933,0.00012258695,0.0004518458,0.00025064556,0.00030246022,0.00007916558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031392043,0.00010968586,0.00032616692,0.000052111052,0.000022660077,0.0000030029742,0.00024637018,0.00022045257,0.000025809755],"category_scores_gemma":[0.00026959187,0.00008579301,0.00012826361,0.00013960662,0.00012819406,0.0000114321065,0.0001401411,0.00011227237,2.8372034e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026804984,0.00029685098,0.0014504126,0.000044207154,0.000025336154,0.000001030891,0.0009655729,0.0058297236,0.9845871,0.000008109169,0.00048038494,0.0036308265],"study_design_scores_gemma":[0.0006400376,0.0025682969,0.008019806,0.000041552008,0.000018125913,4.6564662e-7,0.00065204885,0.0014453301,0.9848527,0.000051420007,0.00162958,0.00008068793],"about_ca_topic_score_codex":0.0001143802,"about_ca_topic_score_gemma":0.000012263114,"teacher_disagreement_score":0.0065693934,"about_ca_system_score_codex":0.00001545572,"about_ca_system_score_gemma":0.0005721821,"threshold_uncertainty_score":0.34985375},"labels":[],"label_agreement":null},{"id":"W3013924915","doi":"10.1016/j.annonc.2020.02.011","title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1509,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Rosetrees Trust; National Cancer Institute; Cancer Research UK; Francis Crick Institute; Wellcome Trust; University Health Network; Medical Research Council; Wellcome; CRUK Lung Cancer Centre of Excellence; Breast Cancer Research Foundation","keywords":"Medicine; DNA methylation; Cell-free fetal DNA; DNA; Computational biology; Cancer research; Genetics; Gene; Gene expression; Biology","score_opus":0.05436995012175291,"score_gpt":0.32830147845300395,"score_spread":0.27393152833125106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013924915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787159,0.0036557429,0.016944958,0.00039068074,0.00005133293,0.0001170458,0.000022861772,0.000002452995,0.00009901002],"genre_scores_gemma":[0.99318033,0.0051062196,0.00078077504,0.0008022731,0.000106292464,0.000002934162,0.000009691758,0.000007631726,0.000003865592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99953926,0.000045002045,0.00012661384,0.00017567258,0.000031536987,0.0000819414],"domain_scores_gemma":[0.99969715,0.000028657823,0.00008192051,0.000060296727,0.000092603375,0.000039368293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007928322,0.00006406379,0.000115017414,0.000032364627,0.0000227612,0.0000054688617,0.000028409308,0.00013032841,0.0000024664134],"category_scores_gemma":[0.00009343998,0.00007001884,0.000014888407,0.00007215765,0.000055766246,0.0000035155422,0.00006158714,0.000047581692,1.1567976e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017132939,0.00003238733,0.0009856576,0.000020614203,0.000011652975,0.000002533313,0.00024996337,0.0053341384,0.9779044,0.00001821277,0.00028441593,0.014984738],"study_design_scores_gemma":[0.0009758271,0.000618719,0.0063265413,0.000007733606,0.000011375337,0.000001685919,0.00014601924,0.015672378,0.9648883,0.00007994623,0.011172617,0.000098885386],"about_ca_topic_score_codex":0.0000747618,"about_ca_topic_score_gemma":0.00026635174,"teacher_disagreement_score":0.016164184,"about_ca_system_score_codex":0.000008684752,"about_ca_system_score_gemma":0.00004072955,"threshold_uncertainty_score":0.28552854},"labels":[],"label_agreement":null},{"id":"W3014549147","doi":"10.1093/annonc/mdv559","title":"Correction to: Planning and reporting of quality-of-life outcomes in cancer trials","year":2015,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; McMaster University; Université de Sherbrooke; McMaster Children's Hospital; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Quality of life (healthcare); Cancer; Clinical trial; Outcome (game theory); Alternative medicine; Medical physics; Family medicine; Intensive care medicine; Internal medicine; Pathology; Nursing","score_opus":0.8844205484006507,"score_gpt":0.64884989862652,"score_spread":0.23557064977413067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014549147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56483686,0.07196054,0.0006382169,0.11784695,0.11045876,0.00441368,0.0029849492,0.000063175365,0.12679684],"genre_scores_gemma":[0.7907985,0.0127234245,0.0064310487,0.06245917,0.008501553,0.0014447344,0.0009028725,0.00044550493,0.11629323],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97282106,0.0014936992,0.024629723,0.0005513434,0.00015162952,0.00035252402],"domain_scores_gemma":[0.9420814,0.0056961905,0.051172357,0.00043709096,0.00041472775,0.00019823418],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.111975275,0.00024809758,0.007842705,0.0010209307,0.00003441753,0.000009960196,0.00023245368,0.0006417653,0.00010441343],"category_scores_gemma":[0.19633795,0.00029325832,0.0002721407,0.00025132197,0.00010637278,0.0001523317,0.00010140715,0.00045384336,0.000015194096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010489069,0.00013058518,0.19470882,0.001109051,0.00020660878,0.0000010064668,0.002736069,0.0003269415,0.0000030833369,0.0012351004,0.7981734,0.0012644008],"study_design_scores_gemma":[0.0024623184,0.0016307846,0.3214988,0.0020756386,0.000042041273,0.000004534808,0.0038921875,0.0007598667,0.000036421017,0.009008863,0.65781915,0.0007693521],"about_ca_topic_score_codex":0.016437922,"about_ca_topic_score_gemma":0.0027325626,"teacher_disagreement_score":0.2259616,"about_ca_system_score_codex":0.00030113058,"about_ca_system_score_gemma":0.0018260174,"threshold_uncertainty_score":0.99995196},"labels":[],"label_agreement":null},{"id":"W3015511562","doi":"10.1016/j.annonc.2020.03.309","title":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"U.S. Army Medical Command; National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Prostate cancer; Internal medicine; Regimen; Confidence interval; Oncology; Docetaxel; Prednisone; Cancer; Gynecology","score_opus":0.452501022673367,"score_gpt":0.5787407502072579,"score_spread":0.1262397275338909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015511562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018932062,0.9924848,6.967555e-7,0.0016382819,0.000084390966,0.0018973032,0.00032196555,0.00000984243,0.0016694875],"genre_scores_gemma":[0.00094875507,0.997005,0.00026551337,0.00012939225,0.000048280002,0.00026617135,0.0001458453,0.000034734014,0.0011563145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970522,0.0004923871,0.0013183746,0.00041347,0.00036847198,0.00035510346],"domain_scores_gemma":[0.99771374,0.0007094687,0.0007914362,0.00029164486,0.0003003368,0.00019336584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007259169,0.00031234554,0.0038090881,0.0002556249,0.000019136618,0.000004122304,0.00017571084,0.00022948712,0.00015513998],"category_scores_gemma":[0.0001369477,0.00018486867,0.00046477118,0.0005376155,0.0004168941,0.000058183563,0.000085188476,0.0005677083,0.000011802509],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017071132,0.0008577407,0.0040801642,0.012703957,0.002641687,0.0009594505,0.0003696983,9.350337e-7,0.0000026256464,0.000047865753,0.0012034258,0.97542536],"study_design_scores_gemma":[0.0065237577,0.013137987,0.0071238065,0.008239879,0.0028632362,0.00003233277,0.0005524718,0.0000038010571,0.000013693943,0.000048587448,0.961174,0.00028643734],"about_ca_topic_score_codex":0.0005878337,"about_ca_topic_score_gemma":0.00083135086,"teacher_disagreement_score":0.9751389,"about_ca_system_score_codex":0.00016998967,"about_ca_system_score_gemma":0.004257421,"threshold_uncertainty_score":0.7552482},"labels":[],"label_agreement":null},{"id":"W3015552022","doi":"10.1016/j.annonc.2020.03.299","title":"JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Shionogi; Sanofi K.K.; Pharmacyclics; Sierra Oncology; Eli Lilly Japan; Abbott Japan; Novartis Pharma; AstraZeneca; Genentech; Celgene; Yakult Honsha; Otsuka Pharmaceutical; Daiichi Sankyo Europe; European Society for Medical Oncology; Pfizer Japan; Meiji Seika Pharma; Daiichi-Sankyo; Seagen; Revolution Medicines; Japan Society of Clinical Oncology; Jiangsu Hengrui Medicine; BeiGene; Astellas Pharma; Eisai; FibroGen; Japan Blood Products Organization; Eli Lilly and Company; EA Pharma Co., Ltd.; Les Laboratories Pierre Fabre; Ipsen; Array BioPharma; MSD K.K.; F. Hoffmann-La Roche; Boehringer Ingelheim Japan; Halozyme; Servier; Gilead Sciences; GlaxoSmithKline; Foundation Medicine; Kowa Company; Sanofi; Medtronic Japan; Amgen; Chugai Pharmaceutical; Symphogen; Pfizer; Biogen","keywords":"Medicine; Pembrolizumab; Microsatellite instability; Oncology; Clinical trial; Companion diagnostic; Internal medicine; Clinical Oncology; Cancer; Trk receptor; Immunotherapy; Receptor; Neurotrophin; Gene; Microsatellite","score_opus":0.10427669191163111,"score_gpt":0.3936264719376828,"score_spread":0.2893497800260517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015552022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648625,0.00010331004,0.000048432696,0.032052577,0.00028047356,0.0015618397,0.0003439752,0.000027299324,0.00071959203],"genre_scores_gemma":[0.9881386,0.00024658046,0.007130632,0.003746036,0.000071989554,0.00024393343,0.00031457836,0.000033643133,0.00007397915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830735,0.00011158871,0.00054783834,0.0004454033,0.00023775815,0.0003500595],"domain_scores_gemma":[0.99801195,0.00070139475,0.00027789822,0.00021781493,0.00057973096,0.00021121553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001512668,0.00023544267,0.0006053745,0.00012666677,0.00006229006,0.000008656052,0.00016421663,0.00012930208,0.00036490706],"category_scores_gemma":[0.000702015,0.00016765966,0.00008095304,0.0002652753,0.0002674943,0.000051047387,0.00007123392,0.00018643323,0.0000058125984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04162991,0.0050597675,0.89945465,0.00013646002,0.00077652704,0.00007056162,0.005163276,0.00012920504,0.0040594046,0.000037052538,0.018049078,0.025434118],"study_design_scores_gemma":[0.024199922,0.04941545,0.8273874,0.0004787638,0.0002812082,0.000030266357,0.0014052431,0.00019132141,0.027360065,0.00011477047,0.06860451,0.00053109863],"about_ca_topic_score_codex":0.00011762582,"about_ca_topic_score_gemma":0.00039858764,"teacher_disagreement_score":0.07206725,"about_ca_system_score_codex":0.00020358541,"about_ca_system_score_gemma":0.0007623199,"threshold_uncertainty_score":0.68369627},"labels":[],"label_agreement":null},{"id":"W3016228656","doi":"10.1016/j.annonc.2020.03.308","title":"French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Institut National Du Cancer; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale","keywords":"Medicine; Sarcoma; Clinical Practice; Soft tissue sarcoma; Coronavirus disease 2019 (COVID-19); Scopus; Bone Sarcoma; MEDLINE; Internal medicine; Disease; Pathology; Family medicine","score_opus":0.08562884972844738,"score_gpt":0.3659036781769953,"score_spread":0.28027482844854795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016228656","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050154753,0.0016981921,0.000027338072,0.9410968,0.00038071492,0.0041236314,0.00058825157,0.000046266854,0.0018840485],"genre_scores_gemma":[0.17762063,0.0012323149,0.0014498926,0.8155108,0.00094605045,0.0012850148,0.0012021738,0.0001032361,0.0006498901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722326,0.00021358635,0.00092683185,0.0005754705,0.00053010986,0.0005307727],"domain_scores_gemma":[0.99737203,0.00072089647,0.0007712989,0.000677112,0.0002852006,0.0001734459],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002502087,0.00041033898,0.0013278171,0.00019490682,0.00011191885,0.000009155779,0.00041901818,0.0004673261,0.00013008023],"category_scores_gemma":[0.00015379589,0.00027694576,0.00058869435,0.00019520061,0.00027005174,0.00003357424,0.00026547976,0.00049008057,0.000018437137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040882215,0.0019147645,0.044219762,0.0042773513,0.002028417,0.001306594,0.00026223404,6.874158e-7,0.0000183403,0.00014780424,0.9270538,0.018361399],"study_design_scores_gemma":[0.0057997224,0.005105896,0.057500504,0.00023708596,0.0008112219,0.000044199984,0.00005032281,0.0000032300609,0.0003694899,0.0007813106,0.929078,0.00021903079],"about_ca_topic_score_codex":0.00026094652,"about_ca_topic_score_gemma":0.000027867272,"teacher_disagreement_score":0.12746587,"about_ca_system_score_codex":0.00019012373,"about_ca_system_score_gemma":0.00020747464,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W3016716571","doi":"10.1016/j.annonc.2020.04.005","title":"A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; Western University; McMaster University; London Health Sciences Centre; Grand River Hospital; Thunder Bay Regional Research Institute; University of Ottawa; Ottawa Hospital","funders":"Canadian Institutes of Health Research; Cancer Care Ontario","keywords":"Filgrastim; Medicine; Febrile neutropenia; Neutropenia; Breast cancer; Randomized controlled trial; Internal medicine; Chemotherapy; Granulocyte colony-stimulating factor; Pegfilgrastim; Surgery; Cancer","score_opus":0.10437817698121295,"score_gpt":0.39006281322494657,"score_spread":0.28568463624373364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016716571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941432,0.00008544318,0.000072901734,0.002472429,0.00015587815,0.00238147,0.00008969973,0.000012599905,0.00058641034],"genre_scores_gemma":[0.9985214,0.00011137619,0.00043545544,0.00046212663,0.0001776068,0.00022156624,0.000019012205,0.00001906651,0.000032373136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986388,0.00009425791,0.0006922116,0.00022612273,0.00015097973,0.00019763989],"domain_scores_gemma":[0.9987553,0.00016169512,0.00048953097,0.00014142197,0.0003491838,0.00010289869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021222948,0.00013427314,0.00093181065,0.00010258091,0.000022833457,0.000004641323,0.000096919684,0.00012413353,0.0001030605],"category_scores_gemma":[0.00008924712,0.00012200306,0.00018703575,0.00023622676,0.00009212373,0.00008551474,0.00002280813,0.0001547373,0.0000011153876],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61594445,0.0016672389,0.03465263,0.00090298377,0.00030864406,0.000008448064,0.0009905265,0.00010016719,0.32585377,0.00014558401,0.00024571133,0.019179842],"study_design_scores_gemma":[0.4351493,0.022878204,0.2083159,0.00023979366,0.00019994244,0.00000779763,0.00024913703,0.0004638826,0.33057,0.000023458984,0.0016865581,0.0002159947],"about_ca_topic_score_codex":0.00045121484,"about_ca_topic_score_gemma":0.00029541407,"teacher_disagreement_score":0.18079513,"about_ca_system_score_codex":0.000047193134,"about_ca_system_score_gemma":0.0007893575,"threshold_uncertainty_score":0.49751404},"labels":[],"label_agreement":null},{"id":"W3018979351","doi":"10.1016/j.annonc.2020.04.010","title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":461,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Foundation Medicine; Pharmacyclics; EMD Serono; Ipsen; Eisai; Merck KGaA; Exelixis; GlaxoSmithKline; Memorial Sloan-Kettering Cancer Center; Astellas Pharma; Alexion Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Axitinib; Sunitinib; Avelumab; Javelin; Renal cell carcinoma; Internal medicine; Oncology; Urology; Nivolumab; Immunotherapy; Cancer","score_opus":0.10304858030414081,"score_gpt":0.3299452875303705,"score_spread":0.22689670722622968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018979351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97943854,0.00021823909,0.0000073767624,0.012788309,0.00020819942,0.0018841372,0.00041991237,0.000044829812,0.0049904506],"genre_scores_gemma":[0.99496686,0.00007177862,0.00058217085,0.0015833619,0.00034572347,0.00005378999,0.0022576982,0.0000538238,0.00008478018],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966778,0.00037375977,0.0011374461,0.000698356,0.0005520942,0.00056050543],"domain_scores_gemma":[0.99643314,0.0014705209,0.00065541355,0.0006430439,0.00046710458,0.00033078677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036074696,0.000391749,0.0010559176,0.00011663274,0.000084678795,0.00001175106,0.00033204776,0.00025487685,0.00018788838],"category_scores_gemma":[0.00079139,0.00026578683,0.00019583876,0.00050510647,0.00022573504,0.00008150632,0.0001397065,0.0005529226,0.000059046943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9620368,0.0025536628,0.0036095425,0.00003574623,0.00028943588,0.0007049223,0.0027278925,0.00095030724,0.0003896054,0.000013660919,0.008761759,0.017926682],"study_design_scores_gemma":[0.6196542,0.08321969,0.24452147,0.00015292258,0.0003922448,0.0000048040974,0.0003758815,0.00024508077,0.017622426,0.000015970265,0.03337848,0.00041683757],"about_ca_topic_score_codex":0.0007618727,"about_ca_topic_score_gemma":0.0004509864,"teacher_disagreement_score":0.34238258,"about_ca_system_score_codex":0.00018188248,"about_ca_system_score_gemma":0.0006547281,"threshold_uncertainty_score":0.99997944},"labels":[],"label_agreement":null},{"id":"W3021245509","doi":"10.1016/s0923-7534(20)34093-x","title":"Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Lung cancer; Internal medicine; Chemotherapy regimen","score_opus":0.11391382267285063,"score_gpt":0.4960946420736674,"score_spread":0.3821808194008167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021245509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708619,0.00322636,0.000045209435,0.014105052,0.00017637412,0.00021555093,0.000014538402,0.00002472027,0.011330295],"genre_scores_gemma":[0.9892017,0.0069462718,0.00048519977,0.0023430742,0.00038217337,0.000051607825,0.000019529343,0.000014764384,0.0005556692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897426,0.00007547726,0.0002699996,0.00016523834,0.00017908438,0.00033594572],"domain_scores_gemma":[0.9992127,0.00009198962,0.00011513719,0.00020190072,0.00024630752,0.00013200312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005997621,0.00009441218,0.00045571977,0.0003700407,0.000014762744,0.0000030719393,0.00015514353,0.0000873244,0.0003015066],"category_scores_gemma":[0.00007254409,0.00007934637,0.00011447821,0.00042526127,0.000086193926,0.00010930649,0.00005619343,0.0001740657,0.0000031416778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056979264,0.00106043,0.9677783,0.000065599124,0.0011600086,0.000013512371,0.0018845896,0.00008088041,0.0021887098,0.00010454157,0.0037152003,0.021378413],"study_design_scores_gemma":[0.003149821,0.0014110436,0.89974153,0.000039012626,0.00033227736,0.0000044374515,0.0003328624,0.0015477724,0.01708407,0.000052394113,0.07615939,0.00014539446],"about_ca_topic_score_codex":0.0012981776,"about_ca_topic_score_gemma":0.0013192677,"teacher_disagreement_score":0.072444186,"about_ca_system_score_codex":0.0001547059,"about_ca_system_score_gemma":0.00019811404,"threshold_uncertainty_score":0.33012858},"labels":[],"label_agreement":null},{"id":"W3022214147","doi":"10.1016/j.annonc.2020.04.472","title":"Germline-somatic fluidity in guiding patient care","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Germline; Medicine; Somatic cell; Germline mutation; Exome sequencing; Genetics; Biology; Phenotype; Mutation","score_opus":0.06784304049267459,"score_gpt":0.3292228821095863,"score_spread":0.2613798416169117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022214147","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33088925,0.016737433,0.000066758425,0.6382696,0.0017690355,0.0008762876,0.0008155764,0.000019365198,0.010556706],"genre_scores_gemma":[0.23731649,0.0044053565,0.00047874963,0.7527534,0.0030056008,0.00006378452,0.0018431313,0.00006687484,0.00006665776],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848354,0.000107910404,0.0005298595,0.0004197029,0.0001300389,0.00032895172],"domain_scores_gemma":[0.9989821,0.00008284946,0.00030363843,0.000374498,0.00019821359,0.000058728816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007172415,0.00023447146,0.0005139375,0.000085610016,0.000025464651,0.000008632055,0.0002833021,0.00075855054,0.00002325905],"category_scores_gemma":[0.00032181552,0.00025316875,0.0001930525,0.00008090826,0.000080533886,0.0000013951155,0.00025481466,0.0003236124,0.000012296177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004696964,0.00004387924,0.00025149842,0.00023244672,0.000060222235,0.00028267945,0.00026076738,0.000038405542,0.009087844,0.0000057421944,0.9768975,0.012792068],"study_design_scores_gemma":[0.0003229052,0.0023178249,0.000064457025,0.000049647337,0.000023443476,0.0000096966405,0.000082015446,0.000008365037,0.029476933,0.00011942931,0.9672862,0.00023902867],"about_ca_topic_score_codex":0.00011559991,"about_ca_topic_score_gemma":0.000121996956,"teacher_disagreement_score":0.11448375,"about_ca_system_score_codex":0.00004441637,"about_ca_system_score_gemma":0.00045359888,"threshold_uncertainty_score":0.9999921},"labels":[],"label_agreement":null},{"id":"W3022950837","doi":"10.1093/annonc/mdy284.035","title":"Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Prostate cancer; Adverse effect; Internal medicine; Interim; Denosumab; Interim analysis; Oncology; Clinical trial; Cancer","score_opus":0.16098974051522139,"score_gpt":0.44976009837426906,"score_spread":0.2887703578590477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022950837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938922,0.0016885723,0.000007757662,0.0029334477,0.00001218084,0.001063866,0.00024948036,0.000009410692,0.00014310423],"genre_scores_gemma":[0.9942014,0.002776746,0.0008674326,0.0016717868,0.0000219973,0.00018023547,0.00014331828,0.00002076727,0.00011630966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982371,0.0001652333,0.00080676994,0.00028611635,0.00023898836,0.00026581035],"domain_scores_gemma":[0.9982048,0.000047917074,0.0005963009,0.00033188242,0.00061781734,0.00020122595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031217694,0.00018115838,0.00085398724,0.00007418819,0.000024246883,0.0000034467073,0.000074315525,0.000060188177,0.00017863141],"category_scores_gemma":[0.000048613765,0.00012766666,0.000047875168,0.000374508,0.00038154126,0.00012666291,0.0000161817,0.00014051222,0.0000016796131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112381235,0.052222606,0.41119853,0.07098321,0.0034885805,0.00047920007,0.006590483,0.00007802273,0.15069768,0.00017850522,0.019024216,0.17267774],"study_design_scores_gemma":[0.02368905,0.058961518,0.6546251,0.022630796,0.0012271989,0.000093028066,0.00024055867,0.00016383915,0.20252758,0.000035678524,0.035119977,0.000685671],"about_ca_topic_score_codex":0.00075036957,"about_ca_topic_score_gemma":0.00047300995,"teacher_disagreement_score":0.24342658,"about_ca_system_score_codex":0.000080644495,"about_ca_system_score_gemma":0.00039407643,"threshold_uncertainty_score":0.52060956},"labels":[],"label_agreement":null},{"id":"W3023300354","doi":"10.1016/j.annonc.2020.04.475","title":"Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Direction Générale de l’offre de Soins; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; CNIB; Taiho Pharmaceutical","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Cancer; Antibody; Virology; Internal medicine; Immunology; Outbreak; Infectious disease (medical specialty); Disease","score_opus":0.1884261728929208,"score_gpt":0.5017237660650377,"score_spread":0.31329759317211686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023300354","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28817195,0.002448896,0.000005221452,0.7066388,0.0013157554,0.0010322535,0.0002329815,0.000032326934,0.0001217913],"genre_scores_gemma":[0.4890998,0.0013058297,0.000023880415,0.5088792,0.00043087904,0.00006251799,0.00014539238,0.000033448712,0.000019067373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970841,0.00036204516,0.0010169727,0.00047132326,0.00043515276,0.00063043047],"domain_scores_gemma":[0.99749446,0.0005735746,0.0008601942,0.00032765823,0.00046492965,0.00027917183],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022013763,0.00035480227,0.0016166827,0.000575326,0.000049864397,0.000005847844,0.00014897974,0.00079232315,0.000104054154],"category_scores_gemma":[0.0010236921,0.0003285829,0.0002459806,0.00042052162,0.00022180477,0.00006481283,0.000076091426,0.0011035763,0.000010892906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008868033,0.00033513425,0.13641548,0.019845517,0.00040107672,0.000593651,0.0076698065,0.000010544147,0.00004077132,5.3853694e-7,0.7936864,0.03213306],"study_design_scores_gemma":[0.0071649123,0.020721134,0.13905902,0.0021352945,0.00020389371,0.0000067965684,0.000458594,0.000010681974,0.0006253389,0.000034631983,0.8291568,0.0004228597],"about_ca_topic_score_codex":0.011189355,"about_ca_topic_score_gemma":0.00467725,"teacher_disagreement_score":0.20092785,"about_ca_system_score_codex":0.0013491235,"about_ca_system_score_gemma":0.0060685067,"threshold_uncertainty_score":0.9999166},"labels":[],"label_agreement":null},{"id":"W3023558472","doi":"10.1093/annonc/mdw364.65","title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Population; Cohort; Adverse effect; Breast cancer; Internal medicine; Confidence interval; Surgery; Cancer","score_opus":0.056440000735117485,"score_gpt":0.40708711098821365,"score_spread":0.35064711025309614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023558472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924942,0.0012616327,0.00003151047,0.0018524863,0.00005797395,0.003348785,0.0005937747,0.000005840388,0.00035377828],"genre_scores_gemma":[0.9958184,0.0036636232,0.000032925385,0.000094101735,0.000059386286,0.00016998885,0.000005127881,0.000025452462,0.0001309878],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973943,0.0004691808,0.00089856354,0.00040270263,0.00047612915,0.00035910134],"domain_scores_gemma":[0.9966567,0.0014751252,0.0005408846,0.00041427978,0.0007779525,0.00013504495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012046171,0.00021411237,0.0016410858,0.0002334283,0.000055282355,0.0000036361112,0.00021376989,0.00013790949,0.000180041],"category_scores_gemma":[0.00018834759,0.00012480117,0.00026957833,0.00042880632,0.00081811537,0.000040490802,0.00006761321,0.00015826373,2.7978376e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18897976,0.0046286364,0.17460178,0.00019235282,0.011420479,0.000047206293,0.006744603,0.000042567557,0.022750013,0.000052443265,0.0002214242,0.59031874],"study_design_scores_gemma":[0.04996477,0.03164463,0.8967075,0.00029803975,0.0020728565,0.00013038819,0.0004571327,0.000033239598,0.017983424,0.00005871274,0.0005006799,0.00014864586],"about_ca_topic_score_codex":0.0022608733,"about_ca_topic_score_gemma":0.0006446513,"teacher_disagreement_score":0.7221057,"about_ca_system_score_codex":0.00010132963,"about_ca_system_score_gemma":0.0007835255,"threshold_uncertainty_score":0.5089244},"labels":[],"label_agreement":null},{"id":"W3025323637","doi":"10.1016/j.annonc.2020.05.009","title":"Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Public Health England; Institute of Cancer Research; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust; National Institute on Handicapped Research; Francis Crick Institute; Breast Cancer Now; Movember Foundation","keywords":"Medicine; Pandemic; Cancer; Observational study; Disease; Hazard ratio; Stage (stratigraphy); Surgery; Coronavirus disease 2019 (COVID-19); Internal medicine; Confidence interval; Infectious disease (medical specialty)","score_opus":0.48096171514266794,"score_gpt":0.5487580976107833,"score_spread":0.06779638246811537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025323637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6876438,0.0003065456,0.00000199198,0.31114498,0.00017225977,0.0002624193,0.00016117179,0.000015038882,0.00029174384],"genre_scores_gemma":[0.82232577,0.00048095433,0.0000031623729,0.17693703,0.00017301478,0.000009623104,0.000008435699,0.0000108810455,0.000051156792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855566,0.0003168705,0.00042935283,0.00017995172,0.00023995206,0.00027820945],"domain_scores_gemma":[0.9955098,0.0033407926,0.00033082734,0.00034702316,0.00013517104,0.00033638233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005169512,0.00014334793,0.00073180615,0.00005495953,0.00006721905,0.000003924253,0.00019029508,0.00015615654,0.000576627],"category_scores_gemma":[0.0021006905,0.000066895474,0.00032307705,0.00025425642,0.00019864053,0.000029182154,0.000070275106,0.00029606366,0.000008002345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013135836,0.00009653721,0.8903889,0.00009611587,0.00018207074,0.000021168707,0.0018736697,0.00012846061,0.00085450977,0.00001662603,0.09660406,0.008424287],"study_design_scores_gemma":[0.0009167657,0.0009162534,0.9389151,0.000044660752,0.000059493723,0.000006532622,0.00013478461,0.00004765607,0.000698502,0.00020557648,0.057989333,0.00006537364],"about_ca_topic_score_codex":0.016905146,"about_ca_topic_score_gemma":0.00093321136,"teacher_disagreement_score":0.13468191,"about_ca_system_score_codex":0.00015728986,"about_ca_system_score_gemma":0.0036962298,"threshold_uncertainty_score":0.98964137},"labels":[],"label_agreement":null},{"id":"W3026039042","doi":"10.1016/j.annonc.2020.03.039","title":"99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; Servier; Oncolytics Biotech; Eisai; Daiichi Sankyo Europe; Bayer HealthCare; Puma Biotechnology; Clovis Oncology; Merck KGaA; Baxalta; Genomic Health; Incyte; F. Hoffmann-La Roche; Ariad Pharmaceuticals; Amgen; Pfizer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Queen Mary University of London","keywords":"Breast cancer; Microbiome; Medicine; Internal medicine; Triple-negative breast cancer; Oncology; Chemotherapy; Firmicutes; Neoadjuvant therapy; Cancer; Gastroenterology; Biology; Bioinformatics; Genetics; 16S ribosomal RNA","score_opus":0.035238658773961366,"score_gpt":0.31127733979175704,"score_spread":0.27603868101779566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026039042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863635,0.00018108402,0.00003236085,0.012842507,0.000019828696,0.00018261228,0.0003521455,0.000002777589,0.00002318569],"genre_scores_gemma":[0.99539,0.00047593965,0.00026210837,0.0037830393,0.000028375724,0.000006075276,0.00003267015,0.000005422941,0.000016359885],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99915045,0.00024647516,0.00019075863,0.00020240407,0.00005221191,0.00015766693],"domain_scores_gemma":[0.9994911,0.00003722591,0.00020783118,0.00006762988,0.0001426207,0.00005358831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025420962,0.000089336296,0.00027571068,0.00003621803,0.000047349324,0.0000021293708,0.00006765262,0.00016995858,0.000024006868],"category_scores_gemma":[0.000018892686,0.0000776276,0.000038618775,0.00008934505,0.000113042224,0.000004641277,0.00012586538,0.00008317139,6.539834e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012512593,0.00015304048,0.0783221,0.000028749668,0.00004256574,0.000009516266,0.0011234267,0.000005635558,0.9060607,0.0000029136243,0.00078852044,0.00095022365],"study_design_scores_gemma":[0.0028133192,0.002759945,0.945323,0.000023318533,0.0000129278915,0.000016448172,0.000094366704,0.0000115601815,0.046956297,0.000012163387,0.001877598,0.00009906226],"about_ca_topic_score_codex":0.0001494109,"about_ca_topic_score_gemma":0.000150123,"teacher_disagreement_score":0.8670009,"about_ca_system_score_codex":0.00003086431,"about_ca_system_score_gemma":0.00008506999,"threshold_uncertainty_score":0.3165562},"labels":[],"label_agreement":null},{"id":"W3026076968","doi":"10.1016/j.annonc.2020.03.205","title":"71P Role of radiomics in predicting molecular phenotypes of female breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiomics; Breast cancer; Kappa; Biomarker; Population; Imaging biomarker; Artificial intelligence; False positive paradox; Categorization; Breast MRI; Feature selection; Oncology; Cancer; Radiology; Mammography; Internal medicine; Magnetic resonance imaging; Computer science","score_opus":0.029265435920107632,"score_gpt":0.3594159296272463,"score_spread":0.33015049370713867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026076968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98022336,0.001595323,0.00016372441,0.014788858,0.000052136893,0.000121939076,0.000017140166,0.000009203933,0.003028343],"genre_scores_gemma":[0.99650246,0.00041740897,0.0011712854,0.0017863223,0.000091339236,0.0000041546878,0.000005061737,0.000014208287,0.0000077586665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990389,0.00006647952,0.0004269572,0.00014791108,0.00015105965,0.00016869055],"domain_scores_gemma":[0.9992943,0.00009908621,0.00025787382,0.000110015455,0.00013187606,0.00010686219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030607075,0.00007985696,0.00053728203,0.00008696283,0.000008184368,9.955535e-7,0.00010894154,0.000089276175,0.00007262046],"category_scores_gemma":[0.00037538973,0.00007399706,0.000084828214,0.00020305239,0.00015344008,0.000027347529,0.000048578564,0.00024421973,7.478718e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073689426,0.00039451753,0.4552543,0.0005080141,0.00020671256,0.00006698072,0.003423005,0.0023995435,0.3226412,0.0008427857,0.0004167754,0.21310928],"study_design_scores_gemma":[0.011488314,0.006205724,0.49310103,0.0014765341,0.00046577808,0.00022218958,0.003519075,0.1552557,0.30499446,0.0014645217,0.021297727,0.0005089362],"about_ca_topic_score_codex":0.00048719102,"about_ca_topic_score_gemma":0.0000079746615,"teacher_disagreement_score":0.21260035,"about_ca_system_score_codex":0.000015777146,"about_ca_system_score_gemma":0.00022285385,"threshold_uncertainty_score":0.30175126},"labels":[],"label_agreement":null},{"id":"W3026173705","doi":"10.1016/j.annonc.2020.03.256","title":"156P Matching-adjusted indirect comparison (MAIC) of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2 ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Internal medicine; Oncology; Hazard ratio; Population; Breast cancer; Metastatic breast cancer; Cancer; Gynecology; Confidence interval; Estrogen receptor","score_opus":0.08939372414674518,"score_gpt":0.3920312772754311,"score_spread":0.3026375531286859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026173705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829188,0.0025234614,0.000055832017,0.011358102,0.00022030792,0.000915502,0.00078764604,0.000093787596,0.0011265879],"genre_scores_gemma":[0.9939931,0.0013801543,0.0026814963,0.001378731,0.00023999621,0.00010006951,0.00009068881,0.00008669924,0.00004903872],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99648404,0.0004202385,0.0012284035,0.00074324466,0.0004300791,0.00069399405],"domain_scores_gemma":[0.9969084,0.0008172171,0.0010320425,0.00025148765,0.00058377336,0.00040704198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028349835,0.0005043608,0.0021026677,0.0002653902,0.00010621846,0.000009601825,0.00026918814,0.00037433053,0.00057680847],"category_scores_gemma":[0.0002963944,0.00049268187,0.00020404764,0.0007289189,0.0007434941,0.00039929477,0.00016658039,0.0007364436,0.000013557319],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060076047,0.0018230898,0.08619591,0.00088912895,0.0018678174,0.000099862824,0.028599339,0.00018063393,0.5433637,0.0005308284,0.0023203045,0.27405336],"study_design_scores_gemma":[0.032885775,0.012279285,0.6938216,0.0007072031,0.00025554126,0.00006358338,0.0068250727,0.000105143015,0.24708124,0.00049836835,0.0044912794,0.0009859112],"about_ca_topic_score_codex":0.001016565,"about_ca_topic_score_gemma":0.00038197663,"teacher_disagreement_score":0.6076257,"about_ca_system_score_codex":0.00026326493,"about_ca_system_score_gemma":0.00032865716,"threshold_uncertainty_score":0.99975246},"labels":[],"label_agreement":null},{"id":"W3026301222","doi":"10.1016/j.annonc.2020.03.126","title":"187P Patient-reported outcomes near end-of-life in patients with breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Interquartile range; Depression (economics); Anxiety; Cancer; Cohort; Quality of life (healthcare); Internal medicine; Physical therapy; Psychiatry","score_opus":0.057027911913428604,"score_gpt":0.3492601027708088,"score_spread":0.2922321908573802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026301222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98512787,0.00018076862,0.0000022470608,0.0128089795,0.00015937653,0.00025362364,0.00008974094,0.000013876508,0.0013635189],"genre_scores_gemma":[0.9924755,0.000043357424,0.00003680904,0.0073372684,0.0000322135,0.000018954113,0.000025084912,0.00001454591,0.000016265998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988822,0.0000476793,0.00043463992,0.00018898988,0.00025282087,0.00019372391],"domain_scores_gemma":[0.99900365,0.00005296816,0.00028555057,0.00016244408,0.00033157022,0.00016380352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006743098,0.00011251497,0.0006000272,0.000057918292,0.000012469163,0.0000019556185,0.00006639907,0.000093815426,0.0003787636],"category_scores_gemma":[0.00008370448,0.00008530687,0.00007812927,0.00024036547,0.00012689085,0.00004623135,0.000037109727,0.00013419327,0.0000033209035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002098534,0.0003512959,0.94528383,0.00008475904,0.00014937409,0.000023846287,0.0018693088,0.000014595529,0.000021295371,0.000013960886,0.0013535676,0.04873566],"study_design_scores_gemma":[0.0032294889,0.0026111712,0.97983724,0.000060796425,0.000047782232,0.0000021553421,0.00031603916,0.000010332017,0.00022630628,0.00000550926,0.013567181,0.0000860126],"about_ca_topic_score_codex":0.0036010009,"about_ca_topic_score_gemma":0.0020857414,"teacher_disagreement_score":0.048649646,"about_ca_system_score_codex":0.00002998916,"about_ca_system_score_gemma":0.0005983681,"threshold_uncertainty_score":0.544366},"labels":[],"label_agreement":null},{"id":"W3026740871","doi":"10.1016/j.annonc.2020.03.139","title":"3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Fulvestrant; PTEN; Medicine; Internal medicine; Cancer research; Cancer; Oncology; PI3K/AKT/mTOR pathway; Estrogen receptor; Breast cancer; Biology; Genetics; Signal transduction","score_opus":0.04333580127687771,"score_gpt":0.3517512217719729,"score_spread":0.3084154204950952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026740871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598,0.0001614999,0.00026929678,0.00023635961,0.00001970139,0.0009050759,0.0024192522,0.0000029758053,0.00000580759],"genre_scores_gemma":[0.99867415,0.00020369046,0.00037589387,0.000079417354,0.000048281265,0.000076378,0.0005243793,0.000017056096,7.559383e-7],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980118,0.00034805495,0.0008205125,0.00047205458,0.00015733084,0.00019020303],"domain_scores_gemma":[0.9985385,0.00029697118,0.00064442464,0.00014323517,0.00029167937,0.00008520113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029127792,0.00020225353,0.00078188156,0.00018127606,0.000034788973,0.000007733729,0.00011372757,0.00008706513,0.000054618664],"category_scores_gemma":[0.00030599907,0.00017647506,0.00006561186,0.0004658906,0.00009504716,0.000019493516,0.00006455493,0.0000980694,6.4943215e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010470684,0.0034448619,0.2533469,0.000030330079,0.0010442645,0.000025046105,0.008046451,0.0038296755,0.70673484,0.0000045740735,0.000013621297,0.013008762],"study_design_scores_gemma":[0.030095099,0.018995767,0.6494674,0.0001011054,0.0007080357,0.0000030000956,0.020883296,0.001799183,0.2775029,0.000012337837,0.000013700643,0.00041820214],"about_ca_topic_score_codex":0.0056948247,"about_ca_topic_score_gemma":0.023675818,"teacher_disagreement_score":0.42923197,"about_ca_system_score_codex":0.00003180105,"about_ca_system_score_gemma":0.00020829312,"threshold_uncertainty_score":0.99413955},"labels":[],"label_agreement":null},{"id":"W3026759727","doi":"10.1016/j.annonc.2020.03.175","title":"41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Window of opportunity; Breast cancer; Oncology; Internal medicine; Cancer; Gynecology; Immunotherapy; Pembrolizumab","score_opus":0.07105510699963798,"score_gpt":0.3791602937760939,"score_spread":0.30810518677645593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026759727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246156,0.0007303455,0.000011311592,0.0052849883,0.000022898543,0.00071666884,0.000111559195,0.000005613431,0.0006550777],"genre_scores_gemma":[0.9971924,0.0011023482,0.000014495445,0.0014347075,0.00008999265,0.00008990317,0.000011106441,0.000022440781,0.00004263853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980119,0.0006420496,0.00040710057,0.00037536517,0.00023684785,0.00032676532],"domain_scores_gemma":[0.9988523,0.00007499787,0.00023368304,0.00036283137,0.00029403015,0.00018212288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008318462,0.00017903204,0.000492338,0.000062466854,0.000052978772,0.00000892561,0.00035052013,0.00014822478,0.00007630621],"category_scores_gemma":[0.00008995784,0.00012580611,0.00007522651,0.000240721,0.0005957858,0.000006264635,0.00022126024,0.0002429678,0.0000022094118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30380017,0.0035568993,0.3261255,0.00023561227,0.001955216,0.00030861492,0.010962917,0.0003352474,0.19322893,0.00013918271,0.0025801181,0.15677159],"study_design_scores_gemma":[0.045195766,0.19373369,0.47167724,0.00012353217,0.00024321917,0.00017287045,0.0057393834,0.00025494373,0.27338222,0.0005114127,0.007829041,0.0011367048],"about_ca_topic_score_codex":0.0019148467,"about_ca_topic_score_gemma":0.003727623,"teacher_disagreement_score":0.2586044,"about_ca_system_score_codex":0.000018238314,"about_ca_system_score_gemma":0.0007941605,"threshold_uncertainty_score":0.5130224},"labels":[],"label_agreement":null},{"id":"W3026866758","doi":"10.1016/j.annonc.2020.03.241","title":"140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; PharmaMar; Eisai; Daiichi-Sankyo; Invitae; Puma Biotechnology; Incyte; BeiGene; AbbVie; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Cilag; Celldex Therapeutics; Amgen; Vifor Pharma; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Carboplatin; Veliparib; Breast cancer; Hazard ratio; Metastatic breast cancer; Oncology; Population; Triple-negative breast cancer; Progression-free survival; Cancer; Chemotherapy; Confidence interval; Cisplatin","score_opus":0.03757875422880337,"score_gpt":0.34769198966008097,"score_spread":0.3101132354312776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026866758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618072,0.0015083454,0.00002819421,0.022861298,0.00019500409,0.0029514756,0.010475832,0.0000386819,0.00013394798],"genre_scores_gemma":[0.9943448,0.001180411,0.0003590753,0.0029848018,0.00024432762,0.00046649843,0.00031581608,0.000069036454,0.00003526559],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959103,0.000707483,0.0012078991,0.00087934174,0.00057574484,0.0007192596],"domain_scores_gemma":[0.9958312,0.0015904983,0.0012042101,0.0002980686,0.00076134637,0.00031469302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044320567,0.0005385271,0.0017887742,0.00016551456,0.00011024207,0.000016320626,0.0002495755,0.00024039099,0.00008562395],"category_scores_gemma":[0.00062517653,0.00040360968,0.000117706215,0.0011239477,0.0006872446,0.00038799612,0.000113295544,0.00088575814,0.0000026476912],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7957472,0.002103281,0.016457317,0.00004313749,0.0012974541,0.00007172878,0.026842395,0.0004677302,0.000752366,0.000023759862,0.00076272193,0.15543087],"study_design_scores_gemma":[0.4081727,0.010543737,0.5737582,0.0007537416,0.0002495481,0.000009203432,0.0043998477,0.00027556394,0.0008364144,0.00027799263,0.0002597113,0.00046332594],"about_ca_topic_score_codex":0.020050913,"about_ca_topic_score_gemma":0.009541632,"teacher_disagreement_score":0.55730087,"about_ca_system_score_codex":0.0008422974,"about_ca_system_score_gemma":0.00103865,"threshold_uncertainty_score":0.9998416},"labels":[],"label_agreement":null},{"id":"W3026927639","doi":"10.1016/j.annonc.2020.03.176","title":"42P Expression of WNT, Hedgehog and NOTCH signaling pathways in HER-2 overexpressed and triple negative subtypes of breast cancer with high and low content of cancer stem cells","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Grifols; Eisai; Breast Cancer Research Foundation; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company","keywords":"Wnt signaling pathway; Notch signaling pathway; Hedgehog; Cancer research; Cancer stem cell; PTEN; Hedgehog signaling pathway; Breast cancer; Triple-negative breast cancer; Stem cell; Cancer; PI3K/AKT/mTOR pathway; Medicine; Biology; Signal transduction; Internal medicine; Cell biology","score_opus":0.06444258779823711,"score_gpt":0.2979839002628509,"score_spread":0.23354131246461377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026927639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930561,0.0058895745,0.000025753667,0.00039025812,0.000027209613,0.00023112902,0.0003550782,0.0000022408967,0.000022656439],"genre_scores_gemma":[0.99668133,0.0029392983,0.00015003492,0.00014630947,0.000033787484,0.000021442815,0.0000041961575,0.0000134065085,0.000010188937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989511,0.00010940912,0.00038679058,0.00029161424,0.00010161928,0.0001595015],"domain_scores_gemma":[0.9990323,0.00009329488,0.00040754597,0.00009851999,0.00029862463,0.000069685484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014583164,0.00015190795,0.0005841629,0.00004299692,0.000020184058,0.000002300463,0.00007778467,0.00013889337,0.000006648271],"category_scores_gemma":[0.000030202662,0.00012294068,0.000033982913,0.00008611283,0.00040440902,0.000007495769,0.0001236079,0.00007230122,2.8110819e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015642375,0.00010570964,0.019723574,0.00046346174,0.00011709725,0.0000033099786,0.0017445184,0.00020400749,0.9737115,0.000012457266,0.00007110398,0.0022790078],"study_design_scores_gemma":[0.0018822129,0.0016470143,0.018641869,0.00035055028,0.000029999335,0.0000016161022,0.001030293,0.000035786292,0.9761948,0.000017593786,0.00005491022,0.000113347494],"about_ca_topic_score_codex":0.00083303056,"about_ca_topic_score_gemma":0.00024014623,"teacher_disagreement_score":0.0036252358,"about_ca_system_score_codex":0.0000061504666,"about_ca_system_score_gemma":0.00014292226,"threshold_uncertainty_score":0.5013375},"labels":[],"label_agreement":null},{"id":"W3027148827","doi":"10.1016/j.annonc.2020.03.266","title":"166P Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CMC Microsystems; Moroccan Foundation for Advanced Science, Innovation and Research; AstraZeneca; Pfizer","keywords":"Medicine; Reimbursement; Breast cancer; Genetic testing; Internal medicine; Guideline; Cancer; Oncology; BRCA mutation; Family medicine; Health care; Pathology","score_opus":0.07055336048542588,"score_gpt":0.30756770257246935,"score_spread":0.23701434208704347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027148827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471503,0.0006011798,0.00005081602,0.0020484328,0.00007177224,0.00025835438,0.00033570544,0.000007994734,0.001910732],"genre_scores_gemma":[0.9986023,0.00028060604,0.0002927731,0.0007215593,0.000041764204,0.0000226003,0.00001216884,0.000016329319,0.000009925769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836355,0.000025356272,0.0009456079,0.0003683398,0.00003127849,0.00026587435],"domain_scores_gemma":[0.9987148,0.0001147294,0.0007748903,0.00013955895,0.0001714684,0.0000845475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039193148,0.00014533683,0.0007487113,0.00015916624,0.000022990493,0.0000065682666,0.00012625252,0.00012125747,0.000091737864],"category_scores_gemma":[0.00029510527,0.00015955791,0.000033122033,0.00033257794,0.00014625216,0.00033147822,0.00005467375,0.00014641273,0.0000061823293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005007728,0.0002480478,0.95533806,0.000107568754,0.00001703437,0.0000035761468,0.00066092,0.0009875466,0.000039788512,0.00069072255,0.000032841028,0.041373145],"study_design_scores_gemma":[0.0028470466,0.00095052365,0.99295187,0.000055942473,0.0000036223023,0.0000013338484,0.000048331156,0.0012754009,0.0001526273,0.0008188504,0.00072942296,0.00016505326],"about_ca_topic_score_codex":0.0022220134,"about_ca_topic_score_gemma":0.0011411357,"teacher_disagreement_score":0.041208092,"about_ca_system_score_codex":0.00010044368,"about_ca_system_score_gemma":0.00014361858,"threshold_uncertainty_score":0.6506583},"labels":[],"label_agreement":null},{"id":"W3027216036","doi":"10.1016/j.annonc.2020.03.238","title":"137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Pertuzumab; Clinical endpoint; Metastatic breast cancer; Oncology; Progression-free survival; Trastuzumab; Gastroenterology; Placebo; Breast cancer; Regimen; Neutropenia; Tolerability; Surgery; Cancer; Chemotherapy; Randomized controlled trial; Adverse effect; Pathology; Colorectal cancer","score_opus":0.06609574792044615,"score_gpt":0.37656004254244624,"score_spread":0.3104642946220001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027216036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238121,0.0018602579,0.000036521727,0.07206755,0.000017925406,0.0014530353,0.00035979017,0.000029607085,0.00036320536],"genre_scores_gemma":[0.9854306,0.0005734064,0.0038061861,0.009647259,0.00005128964,0.0002561646,0.00006519278,0.00004207758,0.00012782359],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980015,0.0003333531,0.00049129507,0.00053190923,0.00021009652,0.0004318514],"domain_scores_gemma":[0.9985934,0.0003411807,0.00019513232,0.00020681045,0.00015164129,0.00051181763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004306208,0.00032488952,0.0012252075,0.00016481221,0.000041193238,0.0000140340635,0.0000744935,0.00007214342,0.0002904242],"category_scores_gemma":[0.00017717647,0.00023231369,0.00006631302,0.00042207315,0.00018986611,0.00008567383,0.000055951972,0.00018099711,0.000005296759],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064651966,0.006826042,0.39615408,0.0020076626,0.005963153,0.0019021559,0.016269708,0.0002212418,0.0044889445,0.000465262,0.029462496,0.4715873],"study_design_scores_gemma":[0.07902675,0.09746548,0.74883056,0.0014419918,0.0041237995,0.0032043923,0.0056187077,0.0007385539,0.007608254,0.00015491014,0.050373342,0.0014132438],"about_ca_topic_score_codex":0.0013534469,"about_ca_topic_score_gemma":0.0022745577,"teacher_disagreement_score":0.47017404,"about_ca_system_score_codex":0.00005613302,"about_ca_system_score_gemma":0.00032383137,"threshold_uncertainty_score":0.9473477},"labels":[],"label_agreement":null},{"id":"W3027570141","doi":"10.1016/j.annonc.2020.03.187","title":"53P Role of immune biomarkers in evaluating predictive and prognostic value in advanced stage HER2 positive breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; FOXP3; Immune system; CD8; Breast cancer; Internal medicine; Oncology; Tumor microenvironment; Stage (stratigraphy); Tumor-infiltrating lymphocytes; Gastroenterology; Immunology; Cancer; Biology","score_opus":0.041466627787901895,"score_gpt":0.38205366931636053,"score_spread":0.34058704152845864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027570141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831212,0.008944147,0.0000043818227,0.0060748984,0.000043596792,0.0007404799,0.00014517804,0.000008972087,0.00091713795],"genre_scores_gemma":[0.9968205,0.0021244362,0.0001940939,0.00074053573,0.000025145015,0.000058262714,0.000012726782,0.000014037304,0.000010247137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986288,0.00018716133,0.00054494163,0.00024932518,0.0001628072,0.00022694046],"domain_scores_gemma":[0.9991501,0.00023568425,0.00028422617,0.000097156066,0.00016473504,0.000068112095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051541,0.00012733413,0.00052944594,0.00013449637,0.000014733334,0.0000020138518,0.000069001246,0.000115027135,0.00007210688],"category_scores_gemma":[0.00018921989,0.00011798196,0.000072890805,0.00040072584,0.00021329167,0.0000821345,0.000046635305,0.00015608294,3.8854373e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039241202,0.0006101111,0.2480185,0.0003259955,0.00065324083,0.000056223642,0.0076310365,0.00024260799,0.36655173,0.000037601112,0.000054909884,0.33657685],"study_design_scores_gemma":[0.0067059086,0.0069919466,0.9523087,0.0006805435,0.000057190267,0.000019200863,0.0034837537,0.0027947228,0.02655996,0.000057629804,0.00022413676,0.00011629056],"about_ca_topic_score_codex":0.0026825638,"about_ca_topic_score_gemma":0.00021406224,"teacher_disagreement_score":0.7042902,"about_ca_system_score_codex":0.00008548479,"about_ca_system_score_gemma":0.00041854018,"threshold_uncertainty_score":0.48111644},"labels":[],"label_agreement":null},{"id":"W3027663151","doi":"10.1016/j.annonc.2020.05.012","title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Sunnybrook Hospital","funders":"National Cancer Institute; National Institutes of Health; Puma Biotechnology; American Society of Clinical Oncology","keywords":"Medicine; Neratinib; Tolerability; Oncology; Breast cancer; Internal medicine; Stage (stratigraphy); Metastatic breast cancer; Cancer; Trastuzumab; Adverse effect","score_opus":0.07013071804840221,"score_gpt":0.40395035431116005,"score_spread":0.33381963626275785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027663151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615331,0.00006806348,0.000012234798,0.035180498,0.000076415796,0.0019243605,0.00034957274,0.000007699162,0.0008479995],"genre_scores_gemma":[0.9967229,0.000033887078,0.0000353872,0.002864599,0.00016712298,0.00012642294,0.00000900104,0.000014635955,0.000026062065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822503,0.0003997225,0.00049063796,0.00025825735,0.00033210142,0.00029426618],"domain_scores_gemma":[0.9983855,0.00035236048,0.00023490677,0.0002521075,0.0006333676,0.00014179236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005853677,0.00012032465,0.0006733725,0.000042763684,0.000025648158,0.0000046519613,0.00017002001,0.00011975833,0.0003388728],"category_scores_gemma":[0.0002849328,0.00007605879,0.00008226469,0.00025630288,0.00035336846,0.000048102487,0.000048006044,0.00038418928,0.000001994674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28002214,0.0019564424,0.65993404,0.00019077724,0.0002893461,0.000021950305,0.0027920709,0.000052686995,0.0014020615,0.000061816245,0.0013775313,0.051899146],"study_design_scores_gemma":[0.0907827,0.034140013,0.8695524,0.000082650025,0.000046486926,0.0000012565248,0.00018578376,0.00033605006,0.002982181,0.000013075557,0.0017745066,0.00010289456],"about_ca_topic_score_codex":0.0038080295,"about_ca_topic_score_gemma":0.00071789854,"teacher_disagreement_score":0.20961837,"about_ca_system_score_codex":0.00008012859,"about_ca_system_score_gemma":0.000932429,"threshold_uncertainty_score":0.5756627},"labels":[],"label_agreement":null},{"id":"W3027689262","doi":"10.1016/j.annonc.2020.03.189","title":"55P Role of radiomics for predicting immunophenotypes in male breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Male Breast Health Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Population; Radiomics; Cancer; Oncology; Progesterone receptor; Immunophenotyping; Categorization; Internal medicine; Artificial intelligence; Radiology; Flow cytometry; Immunology; Computer science","score_opus":0.07384617652972031,"score_gpt":0.39617671801702126,"score_spread":0.32233054148730095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027689262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486949,0.0049813157,0.000018306244,0.04230324,0.00009920612,0.0005328802,0.00015706668,0.00001393371,0.0031991557],"genre_scores_gemma":[0.9958629,0.00094115955,0.00091378816,0.0019212514,0.00023367612,0.00006132565,0.000006525259,0.000013375504,0.000045983787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905235,0.00003458615,0.000439497,0.00015170759,0.00008724658,0.00023461672],"domain_scores_gemma":[0.99915993,0.00019096784,0.00022952775,0.0000981791,0.00024226234,0.00007911278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024146624,0.00008396159,0.0005627462,0.000065139124,0.00002078886,6.719662e-7,0.00007607276,0.000094014234,0.00009090423],"category_scores_gemma":[0.0002029109,0.000078560064,0.00006804337,0.00014373992,0.00009034198,0.000029391593,0.000049134393,0.00011195103,0.0000016489327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008439216,0.0006497872,0.71291965,0.002683392,0.00032058757,0.00001936535,0.0071853977,0.00025890587,0.02789026,0.00082349515,0.006269453,0.2325405],"study_design_scores_gemma":[0.0064772754,0.0050292676,0.9231811,0.00040005558,0.00014454577,0.00014421494,0.0028180778,0.004276314,0.007519576,0.00030822432,0.049509447,0.00019189269],"about_ca_topic_score_codex":0.0005976949,"about_ca_topic_score_gemma":0.00011343696,"teacher_disagreement_score":0.2323486,"about_ca_system_score_codex":0.000033113214,"about_ca_system_score_gemma":0.00035623476,"threshold_uncertainty_score":0.32035863},"labels":[],"label_agreement":null},{"id":"W3027723947","doi":"10.1016/j.annonc.2020.03.281","title":"181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Oncology; Genentech; Oncolytics Biotech; Astellas Pharma; Eisai; Bayer HealthCare; Seagen; MacroGenics; Pfizer; HCA Healthcare; Incyte; Moderna; Puma Biotechnology; Agios Pharmaceuticals; Queen Mary University of London; Clovis Oncology; Mylan; TG Therapeutics; Baxalta; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Amgen; Jounce Therapeutics; Ariad Pharmaceuticals; Array BioPharma; Daiichi Sankyo Europe; Servier; Gilead Sciences; GlaxoSmithKline; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Oncology; Metastatic breast cancer; Everolimus; Clinical endpoint; Breast cancer; Exemestane; Progression-free survival; Cancer; Chemotherapy; Clinical trial; Tamoxifen","score_opus":0.043014496191061784,"score_gpt":0.33808752632962485,"score_spread":0.29507303013856306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027723947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872798,0.00015775813,0.000034449404,0.011092146,0.000012161303,0.00095838384,0.00019863258,0.000012587458,0.0002541057],"genre_scores_gemma":[0.9970265,0.00041802722,0.0005978867,0.0015719304,0.000038538048,0.00014079863,0.00015831488,0.000023132197,0.000024842342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984592,0.0001202395,0.00043803002,0.00042589114,0.00024661736,0.00031000364],"domain_scores_gemma":[0.99892884,0.00014680653,0.00023756157,0.00010627241,0.0003033371,0.00027715712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013354876,0.00024243537,0.00061258173,0.00008913442,0.000057512312,0.000010831066,0.000074815965,0.000096833326,0.00011039917],"category_scores_gemma":[0.00004097952,0.00019604355,0.000028751172,0.00032965874,0.00033241694,0.00016727009,0.000039511342,0.00032874726,0.0000019005466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028029952,0.008994269,0.7973341,0.0012986502,0.0012656403,0.00013192502,0.013284303,0.0000811367,0.10351324,0.0006940987,0.0028952223,0.042477485],"study_design_scores_gemma":[0.016350403,0.007269095,0.9420475,0.0002011758,0.00011825762,0.000010586351,0.0004233637,0.00021856073,0.032732558,0.00008997942,0.00025031113,0.0002882583],"about_ca_topic_score_codex":0.0004444086,"about_ca_topic_score_gemma":0.00007469034,"teacher_disagreement_score":0.14471337,"about_ca_system_score_codex":0.00016649692,"about_ca_system_score_gemma":0.00016107368,"threshold_uncertainty_score":0.7994424},"labels":[],"label_agreement":null},{"id":"W3028057610","doi":"10.1016/j.annonc.2020.03.183","title":"49P BRCA mutation testing rates among breast cancer patients meeting testing criteria: A single-centre experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; BRCA mutation; Genetic testing; Cancer; Oncology; Breast cancer; Gynecology; Internal medicine; Obstetrics; Family medicine","score_opus":0.08759474358972326,"score_gpt":0.36118835055216897,"score_spread":0.2735936069624457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028057610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522024,0.00023901452,0.000097060045,0.0019406693,0.00023250462,0.00021221349,0.00006768966,0.000024038301,0.0019665891],"genre_scores_gemma":[0.99407154,0.00001571473,0.0037667532,0.0016135229,0.00037846417,0.000052051317,0.000052865664,0.000028673487,0.000020384121],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857754,0.00013220552,0.0004132006,0.0004243644,0.00014181527,0.00031089634],"domain_scores_gemma":[0.9983086,0.00013130961,0.00038493294,0.00014421779,0.00091997016,0.0001109815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001471549,0.0001682363,0.00022574986,0.000037560203,0.00010382888,0.000023040715,0.00020165264,0.00017151999,0.000053911],"category_scores_gemma":[0.0017372345,0.00018072657,0.000053556956,0.0003204954,0.00018770374,0.000018380853,0.00015025768,0.00010081585,0.0000042453003],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013990415,0.0002618981,0.26195246,0.00007812692,0.000077502715,0.000011763551,0.002849362,0.0012861438,0.6368836,0.0000025203394,0.0044789077,0.09197781],"study_design_scores_gemma":[0.002142244,0.003195628,0.18482462,0.00026778562,0.0000768562,0.000025937034,0.00269512,0.004932712,0.7915721,0.00006219272,0.009437475,0.000767322],"about_ca_topic_score_codex":0.00013932274,"about_ca_topic_score_gemma":0.00006457164,"teacher_disagreement_score":0.1546885,"about_ca_system_score_codex":0.00004837911,"about_ca_system_score_gemma":0.00025575125,"threshold_uncertainty_score":0.7369815},"labels":[],"label_agreement":null},{"id":"W3028288609","doi":"10.1016/j.annonc.2020.03.030","title":"90P Patient-reported outcomes among patients with HR+/HER2- early breast cancer: A systematic literature review","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Anxiety; Oncology; Neoadjuvant therapy; Cancer; MEDLINE; Adjuvant therapy; Physical therapy; Psychiatry","score_opus":0.019655589589394094,"score_gpt":0.30185642256246065,"score_spread":0.28220083297306653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028288609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95356256,0.036869925,0.0000071832774,0.0075632385,0.00012413862,0.0011010941,0.00031993908,0.000022985918,0.00042894995],"genre_scores_gemma":[0.9818494,0.011434458,0.00006489384,0.006149183,0.000061297585,0.00025083005,0.00012989053,0.00002792216,0.000032169766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984817,0.00014586878,0.00050888996,0.00038936254,0.0002108098,0.00026339607],"domain_scores_gemma":[0.99832493,0.000027634771,0.0005830036,0.0003205802,0.00061336946,0.00013050434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077937606,0.00026090155,0.0008133764,0.000029856568,0.000048355432,0.000009693414,0.00016644475,0.0001409861,0.000020815976],"category_scores_gemma":[0.00011018646,0.00017782621,0.00015913443,0.00021069616,0.00011898883,0.000010600151,0.000107384374,0.00009798443,0.000004041085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048011367,0.00042846386,0.9701734,0.013486593,0.0018011425,0.000048195412,0.0005971547,0.000004557967,0.000112218666,0.00000732532,0.008762883,0.004097912],"study_design_scores_gemma":[0.0020016753,0.002800515,0.9792681,0.011608674,0.000503133,0.000029385934,0.000060998504,0.0000010820061,0.0006537218,0.000004601823,0.0027270315,0.0003411363],"about_ca_topic_score_codex":0.00010477305,"about_ca_topic_score_gemma":0.000071783885,"teacher_disagreement_score":0.02828681,"about_ca_system_score_codex":0.000019182102,"about_ca_system_score_gemma":0.00010273814,"threshold_uncertainty_score":0.7251542},"labels":[],"label_agreement":null},{"id":"W3028347993","doi":"10.1016/j.annonc.2020.03.206","title":"72P Non-mass like enhancement patterns on MR mammography and their pathological correlation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Malignancy; Breast cancer; Radiology; Mammography; Biopsy; Pathology; Washout; Cancer; Internal medicine","score_opus":0.0883508120831691,"score_gpt":0.36242719278635216,"score_spread":0.2740763807031831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028347993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93853956,0.00028097015,0.001688516,0.0548254,0.00021403766,0.0003635295,0.000026559355,0.000024974712,0.004036446],"genre_scores_gemma":[0.97302365,0.0031511397,0.00036196326,0.023195509,0.00015938867,0.000054731787,0.000020273714,0.000010921662,0.000022421907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999058,0.00007164636,0.0002701018,0.00028002448,0.00012886329,0.00019136137],"domain_scores_gemma":[0.99919266,0.0002648014,0.0001427883,0.00015438699,0.00009324688,0.00015211232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018086907,0.0001293456,0.00039319732,0.000070009795,0.000026110012,0.0000035437017,0.00006822419,0.00016275064,0.00031205788],"category_scores_gemma":[0.000042443302,0.00009807383,0.000093121926,0.00012688436,0.00009520254,0.000021983498,0.000040239975,0.00019574445,0.000019220433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017178903,0.0012266249,0.67362875,0.0003028589,0.0002670739,0.00019729893,0.0037368333,0.000056794455,0.023045585,0.00015759292,0.0908504,0.2048123],"study_design_scores_gemma":[0.0049320483,0.05861996,0.58501995,0.00041640492,0.00016686635,0.00004120375,0.0010103075,0.0016695963,0.06964391,0.00071040326,0.27730384,0.0004654968],"about_ca_topic_score_codex":0.000019186122,"about_ca_topic_score_gemma":0.000008726485,"teacher_disagreement_score":0.2043468,"about_ca_system_score_codex":0.00001830373,"about_ca_system_score_gemma":0.00004448937,"threshold_uncertainty_score":0.3999335},"labels":[],"label_agreement":null},{"id":"W3028527898","doi":"10.1016/j.annonc.2020.03.245","title":"144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Servier; Eisai; Daiichi-Sankyo; Daiichi Sankyo Europe; Université de Liège; Curtin University of Technology; Incyte; Gilead Sciences; FibroGen; Merck KGaA; Genomic Health; Ariad Pharmaceuticals; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; PharmaMar; Celgene; BC Cancer Agency; Centro de Investigación Biomédica en Red de Cáncer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Progression-free survival; Fulvestrant; Placebo; Breast cancer; Oncology; Cancer; Urology; Gastroenterology; Overall survival; Estrogen receptor; Pathology","score_opus":0.05540093340937784,"score_gpt":0.357927209976405,"score_spread":0.30252627656702713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028527898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96358484,0.003182079,0.000017356457,0.03152166,0.00006234762,0.0011122054,0.00017102849,0.00007122815,0.00027723052],"genre_scores_gemma":[0.98847985,0.0028262571,0.0004384653,0.0076829283,0.000071938164,0.00023774616,0.0000603802,0.00007047127,0.00013195173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727726,0.00010443436,0.000996328,0.0007033699,0.00032273837,0.0005958432],"domain_scores_gemma":[0.9982556,0.00020876619,0.00054474745,0.0003424924,0.00034609067,0.00030229375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017716427,0.0004535285,0.0014261508,0.00023860115,0.000046994144,0.0000077277045,0.00014633605,0.00023871024,0.00047285933],"category_scores_gemma":[0.000085705586,0.00034826656,0.00011128241,0.00064764736,0.00033842787,0.00024779118,0.00005368159,0.0004630585,0.000004030203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02567098,0.0013330231,0.627448,0.00018529498,0.00057710026,0.00106059,0.0027749666,0.0009827901,0.010564638,0.000037077483,0.000055417728,0.3293101],"study_design_scores_gemma":[0.030210564,0.014707459,0.9196525,0.00041988792,0.0000852758,0.0005438704,0.000853077,0.00025314974,0.01711579,0.0003913011,0.015195236,0.0005718771],"about_ca_topic_score_codex":0.0010995711,"about_ca_topic_score_gemma":0.0038644746,"teacher_disagreement_score":0.3287382,"about_ca_system_score_codex":0.00013419945,"about_ca_system_score_gemma":0.000430024,"threshold_uncertainty_score":0.99989694},"labels":[],"label_agreement":null},{"id":"W3029272205","doi":"10.1016/j.annonc.2020.05.019","title":"Prognostic gene expression signature for high-grade serous ovarian cancer","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Vancouver General Hospital; Alberta Health Services; University of British Columbia; Royal Alexandra Hospital; Foothills Medical Centre; BC Cancer Agency","funders":"Medical Research and Materiel Command; National Cancer Institute; Cancer Council Tasmania; Cancer Council NSW; Cancer Council Victoria; Cancer Council South Australia; National Center for Advancing Translational Sciences; Medical Research Council; Oak Foundation; BC Cancer Foundation; U.S. Department of Defense; Eli Lilly and Company; Ignyta; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; National Institutes of Health; Canada Research Chairs; Canadian Institutes of Health Research; Cancer Institute NSW; Cancer Research UK; University College London; Cancer Australia; Ovarian Cancer Action; Clovis Oncology; National Institute for Health and Care Research; Horizon 2020 Framework Programme; National Health and Medical Research Council; Invitae; AstraZeneca; Carrick Therapeutics; Pfizer; University College London Hospitals NHS Foundation Trust; European Commission","keywords":"Medicine; Serous ovarian cancer; Ovarian cancer; Serous fluid; Gene signature; Oncology; Signature (topology); Internal medicine; Gene; Cancer; Cancer research; Gene expression; Genetics","score_opus":0.1541800533549264,"score_gpt":0.4447541924358067,"score_spread":0.2905741390808803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029272205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015641372,0.9847586,0.000047906608,0.010178891,0.0006666451,0.0032021427,0.00084445474,0.000039170405,0.00024652804],"genre_scores_gemma":[0.0002465762,0.9908541,0.002582614,0.0013616891,0.0011696587,0.0026789892,0.0007410901,0.00009045297,0.0002748488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791354,0.00014037458,0.0007035395,0.0006410614,0.0002080734,0.00039343262],"domain_scores_gemma":[0.9979344,0.0005329111,0.00067983806,0.0003770896,0.00022663266,0.0002491432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015482526,0.00044587385,0.0030633302,0.00013604164,0.00005078113,0.000008644326,0.0001762151,0.00080699945,0.00026841846],"category_scores_gemma":[0.00015108584,0.00031574673,0.00064032734,0.00024634297,0.00006900474,0.000031155105,0.00007650529,0.00039379022,0.000020067755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012462509,0.0007331881,0.000026897113,0.011922665,0.0011087037,0.00026765704,0.00004784521,0.0000010522702,0.000020186622,0.0001659438,0.049351133,0.9362301],"study_design_scores_gemma":[0.0017377982,0.003764599,0.000060576618,0.009718082,0.003448081,0.000061538754,0.000005026069,8.602965e-7,0.00065746735,0.000118724725,0.9801958,0.00023142752],"about_ca_topic_score_codex":0.000090716494,"about_ca_topic_score_gemma":0.000025046966,"teacher_disagreement_score":0.9359987,"about_ca_system_score_codex":0.00019298389,"about_ca_system_score_gemma":0.0019377979,"threshold_uncertainty_score":0.9999295},"labels":[],"label_agreement":null},{"id":"W3036749792","doi":"10.1016/j.annonc.2020.06.006","title":"HSD3B1 (1245A&gt;C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; Surrey Memorial Hospital; University of British Columbia, Okanagan Campus; Kelowna General Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Genentech; BC Cancer Foundation; Cilag; Astellas Pharma; Ministerio de Ciencia e Innovación; Instituto de Salud Carlos III; Prostate Cancer Canada; Ipsen; Clovis Oncology; Celgene; BC Cancer Agency; Prostate Cancer Foundation; Movember Foundation; Bristol-Myers Squibb; AstraZeneca; Pfizer; Sanofi; Jane ja Aatos Erkon Säätiö","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Proportional hazards model; Genotype; Androgen deprivation therapy; Confidence interval; Cancer; Androgen receptor; Biology; Genetics","score_opus":0.17040081192395942,"score_gpt":0.46908234109873437,"score_spread":0.298681529174775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036749792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846609,0.002405082,8.7478685e-7,0.010999646,0.00003562409,0.0012192355,0.0005753998,0.000016473427,0.00008675564],"genre_scores_gemma":[0.99320346,0.0054368535,0.0003703871,0.0005745346,0.00004544322,0.000093107126,0.00010626374,0.000018127368,0.00015179528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980603,0.00020512374,0.00072394917,0.00049991655,0.00022719588,0.000283528],"domain_scores_gemma":[0.99841946,0.00052929466,0.00026981317,0.00012842589,0.0004576123,0.00019540149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034054444,0.00021007331,0.0009711063,0.00008643642,0.0000488109,0.000011890853,0.00004565788,0.000064649415,0.0000099962035],"category_scores_gemma":[0.0004240538,0.00012966468,0.00004165037,0.00020602491,0.0004334632,0.00010440847,0.00006458228,0.00021312654,0.0000014478081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024601936,0.0008526991,0.9583079,0.000104337574,0.0017239166,0.0006375651,0.003998067,0.000009276148,0.00068575947,0.00001893973,0.00021272052,0.008846875],"study_design_scores_gemma":[0.028889641,0.01691219,0.95115083,0.00016526491,0.00031302148,0.000004313641,0.0005709364,0.00009405743,0.0014043405,0.00014757832,0.0002069373,0.00014087686],"about_ca_topic_score_codex":0.0012301658,"about_ca_topic_score_gemma":0.0023929805,"teacher_disagreement_score":0.016059492,"about_ca_system_score_codex":0.00007834811,"about_ca_system_score_gemma":0.0003217774,"threshold_uncertainty_score":0.5287572},"labels":[],"label_agreement":null},{"id":"W3040826944","doi":"10.1016/j.annonc.2020.04.070","title":"O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); TNM staging system; Internal medicine; Oncology; Cancer; Hazard ratio; Cancer staging; Colorectal cancer; Clinical endpoint; Staging system; Clinical trial; Confidence interval","score_opus":0.14403000498712717,"score_gpt":0.4274877786211341,"score_spread":0.2834577736340069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040826944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832844,0.00032723128,0.000076863,0.013621417,0.00052124535,0.0012792008,0.000044831002,0.000024422989,0.0008203947],"genre_scores_gemma":[0.9986245,0.000114373484,0.000076986595,0.0006855976,0.00015463059,0.00024849002,0.000022881568,0.000014395382,0.000058152007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861944,0.0001262341,0.00063053647,0.00025221496,0.00016909138,0.00020249985],"domain_scores_gemma":[0.99920416,0.00019237582,0.00027704652,0.00011038672,0.00017086981,0.00004513397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007527135,0.000104990526,0.00041409186,0.00015347477,0.000023512232,0.000007288479,0.0001286339,0.0000919376,0.00004899672],"category_scores_gemma":[0.00014735745,0.0001007647,0.000081536935,0.00021482806,0.000041574924,0.00007262798,0.00003825692,0.00015331114,0.0000010190697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023575863,0.0014681345,0.8323108,0.00036071055,0.00044197473,0.000053086,0.014145361,0.00012080586,0.08027254,0.000029237039,0.0004644902,0.04675699],"study_design_scores_gemma":[0.021883598,0.0040480313,0.91539073,0.0005295647,0.00006469324,0.0000041640387,0.0231134,0.021758078,0.0036948917,0.0000027887688,0.009349808,0.00016024044],"about_ca_topic_score_codex":0.0011145916,"about_ca_topic_score_gemma":0.0015158416,"teacher_disagreement_score":0.08307994,"about_ca_system_score_codex":0.00026589615,"about_ca_system_score_gemma":0.0002018342,"threshold_uncertainty_score":0.41090652},"labels":[],"label_agreement":null},{"id":"W3040832841","doi":"10.1016/j.annonc.2020.04.467","title":"PD-11 Impact of baseline symptom burden as assessed by patient-reported outcomes on overall survival of patients with metastatic gastrointestinal cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; Cancer; Patient-reported outcome; Nausea; Psychosocial; Depression (economics); Anxiety; Colorectal cancer; Confounding; Pancreatic cancer; Gastrointestinal cancer; Proportional hazards model; Quality of life (healthcare)","score_opus":0.0518601967394296,"score_gpt":0.4208504308919753,"score_spread":0.3689902341525457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040832841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994975,0.00005938304,0.00007654089,0.0031173283,0.000045447494,0.0004877099,0.00058795494,0.000012929104,0.0006377563],"genre_scores_gemma":[0.99822253,0.000020672722,0.00055723975,0.000757511,0.000019842171,0.000024973695,0.0003138214,0.000020871466,0.00006253985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985415,0.000095724085,0.00057417504,0.00021956794,0.00035980667,0.00020924721],"domain_scores_gemma":[0.99790853,0.0002767875,0.00071165984,0.0001818733,0.00074444915,0.00017672108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000939028,0.0001840935,0.00079401553,0.000078909776,0.00001752934,0.0000022575673,0.00006550199,0.00003498566,0.00037531092],"category_scores_gemma":[0.00035586394,0.0001203832,0.00016736155,0.0001634846,0.00009166291,0.00005774957,0.000020894458,0.000087336426,0.0000019638428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029276253,0.0022825282,0.98136175,0.00012724957,0.0018914224,0.00005500222,0.0006130009,0.00062136864,0.0016742852,0.0000324339,0.0042081075,0.0042052455],"study_design_scores_gemma":[0.012247807,0.045700837,0.9360279,0.00026022503,0.0011745781,0.000010935931,0.0002355306,0.00017954939,0.0027791474,0.000027090764,0.0011912725,0.00016514398],"about_ca_topic_score_codex":0.0033343495,"about_ca_topic_score_gemma":0.000054481126,"teacher_disagreement_score":0.045333847,"about_ca_system_score_codex":0.00008245689,"about_ca_system_score_gemma":0.000879635,"threshold_uncertainty_score":0.5040561},"labels":[],"label_agreement":null},{"id":"W3040892649","doi":"10.1016/j.annonc.2020.04.140","title":"P-58 Survival and prognostic factors in metastatic gastric cancer: Results from a Bangladeshi cohort","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Gastrectomy; Univariate analysis; Pleural effusion; Performance status; Hazard ratio; Ascites; Cohort; Oncology; Lung cancer; Metastasis; Survival analysis; Cancer; Multivariate analysis; Gastroenterology; Confidence interval","score_opus":0.13004275132537352,"score_gpt":0.37454412073582866,"score_spread":0.24450136941045514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040892649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975996,0.00066307484,0.000027443695,0.020271607,0.000134182,0.00048469752,0.000112387956,0.00002264509,0.0022879697],"genre_scores_gemma":[0.99707097,0.0010231303,0.00026090976,0.0013530352,0.00008956436,0.000021787313,0.000072238516,0.000011429427,0.00009695626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987805,0.000082730614,0.00041819966,0.0002890012,0.00018641709,0.0002431753],"domain_scores_gemma":[0.9990173,0.00047895836,0.00017204194,0.00011613277,0.00006512039,0.00015043592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022193743,0.00013242083,0.0006248312,0.0001296212,0.000014755907,0.000006056448,0.00008024646,0.000054395325,0.00012673836],"category_scores_gemma":[0.0006536703,0.000111764886,0.0000614847,0.00037995217,0.00007691693,0.000051931285,0.00006816502,0.00015633047,0.0000041571693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008436985,0.00011739457,0.97641486,0.000073104035,0.00023303332,0.00013441636,0.0007746894,0.00001453092,0.0001211133,0.0000547333,0.0047514425,0.016466985],"study_design_scores_gemma":[0.0036508925,0.001566837,0.9823917,0.00004360398,0.00022132052,0.0000020084544,0.0005644188,0.0001507183,0.00017931846,0.00007899018,0.01106432,0.00008585839],"about_ca_topic_score_codex":0.0023466367,"about_ca_topic_score_gemma":0.0005522109,"teacher_disagreement_score":0.021074956,"about_ca_system_score_codex":0.00003230851,"about_ca_system_score_gemma":0.00015330428,"threshold_uncertainty_score":0.45576397},"labels":[],"label_agreement":null},{"id":"W3041197920","doi":"10.1016/j.annonc.2020.04.078","title":"LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Sorafenib; Nivolumab; Tolerability; Internal medicine; Hazard ratio; Hepatocellular carcinoma; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Adverse effect; Phases of clinical research; Confidence interval; Immunotherapy; Cancer","score_opus":0.11017677015851374,"score_gpt":0.317012982306879,"score_spread":0.20683621214836528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041197920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173105,0.0004917638,0.000014732753,0.0040938337,0.00022751006,0.0021044551,0.00007475517,0.00007572721,0.0011861513],"genre_scores_gemma":[0.9980449,0.00022019152,0.00022203033,0.00040754423,0.00007371238,0.00023272097,0.0004299848,0.00008826184,0.00028061838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971818,0.00015443272,0.00068864896,0.00073841296,0.0005170034,0.0007197245],"domain_scores_gemma":[0.9980798,0.0002262057,0.00037272432,0.00051232165,0.000341688,0.0004672907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014355664,0.00059388706,0.0016597039,0.00019863836,0.00008849518,0.000014411111,0.00019584471,0.00026378632,0.00016015886],"category_scores_gemma":[0.0000895229,0.00042535344,0.0003021556,0.0004305383,0.00018015716,0.00016732291,0.000076586555,0.00022132258,0.00006204824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031771243,0.0023538142,0.9486496,0.00015056218,0.00073342293,0.001955452,0.0011117879,0.000010650555,0.000060493152,0.000016506376,0.000045534325,0.013140924],"study_design_scores_gemma":[0.07287882,0.07616522,0.8407753,0.00011185854,0.00070031,0.000010316055,0.00016869337,0.00037853234,0.006820101,0.00000713123,0.0015005403,0.00048318005],"about_ca_topic_score_codex":0.0005822251,"about_ca_topic_score_gemma":0.0011350218,"teacher_disagreement_score":0.10787432,"about_ca_system_score_codex":0.00023473047,"about_ca_system_score_gemma":0.00049393607,"threshold_uncertainty_score":0.9998198},"labels":[],"label_agreement":null},{"id":"W3041223647","doi":"10.1016/j.annonc.2020.04.058","title":"O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Tolerability; Internal medicine; Hepatocellular carcinoma; Sorafenib; Adverse effect; Expanded access; Gastroenterology; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.0628437597462007,"score_gpt":0.28944693646987274,"score_spread":0.22660317672367203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041223647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959326,0.00044547138,0.0000032483492,0.0016380734,0.000017783674,0.0013841906,0.00002195588,0.0000073803444,0.0005493196],"genre_scores_gemma":[0.99961716,0.00006356087,0.00011347755,0.0001198953,0.000011509864,0.000023228484,0.00002126044,0.000018473645,0.000011406692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983258,0.00023438419,0.00063549133,0.00029988599,0.00028736418,0.00021705651],"domain_scores_gemma":[0.9988,0.00009751147,0.00039504576,0.00033442676,0.00025826317,0.00011479557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023704162,0.00018211153,0.0009534222,0.00012148722,0.00003175258,0.0000018251403,0.00014053415,0.000099204924,0.000029855517],"category_scores_gemma":[0.0001094379,0.00012246415,0.00014140253,0.00057230185,0.00018526636,0.000049854552,0.00009295821,0.00014817933,0.0000010379464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043151104,0.0022849888,0.97759783,0.00015142508,0.0003541959,0.00004690523,0.0030946336,0.000004226824,0.0007694961,0.000010123149,0.00001868663,0.011352348],"study_design_scores_gemma":[0.015034514,0.011353668,0.9593398,0.00006171752,0.0005001839,0.0000019040947,0.00071766466,0.0003605629,0.012349625,0.0000064977526,0.00017525467,0.000098585886],"about_ca_topic_score_codex":0.00019523237,"about_ca_topic_score_gemma":0.000088506626,"teacher_disagreement_score":0.018258039,"about_ca_system_score_codex":0.00003173497,"about_ca_system_score_gemma":0.00016042322,"threshold_uncertainty_score":0.49939427},"labels":[],"label_agreement":null},{"id":"W3041246444","doi":"10.1016/j.annonc.2020.04.039","title":"SO-24 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; KRAS; Gastrointestinal tract; Internal medicine; Small molecule; Cancer research; Oncology; Cancer; Colorectal cancer; Genetics","score_opus":0.10533153586376608,"score_gpt":0.37338826770931044,"score_spread":0.26805673184554435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041246444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98650146,0.00027674827,0.0001883722,0.009012372,0.0001582825,0.0015779097,0.0017047976,0.000016322658,0.0005637438],"genre_scores_gemma":[0.99481165,0.000056487253,0.002449223,0.001971831,0.00029864383,0.00016626136,0.0001934946,0.000019276475,0.000033120246],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987359,0.000036095065,0.0004768693,0.00031395195,0.00018701109,0.00025015805],"domain_scores_gemma":[0.9982393,0.00052763737,0.0004141356,0.00017467332,0.00053040264,0.00011388693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096865144,0.00018365431,0.0006611086,0.000027783804,0.00006621802,0.0000041260346,0.00010614942,0.00004864721,0.00001754489],"category_scores_gemma":[0.000708771,0.0001122425,0.0001404913,0.00013578968,0.00022874793,0.00003208536,0.000054606626,0.00011312608,9.874454e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92771465,0.003962226,0.0017911312,0.00007113436,0.0007028074,0.000025809273,0.0029252374,0.000033623535,0.0066351807,0.000020730873,0.012449329,0.043668117],"study_design_scores_gemma":[0.5701678,0.34793103,0.009892334,0.0005649805,0.0007670381,0.000009903336,0.0013807984,0.00035428623,0.018641666,0.000041074363,0.04993216,0.00031693734],"about_ca_topic_score_codex":0.00090546435,"about_ca_topic_score_gemma":0.0009189961,"teacher_disagreement_score":0.35754687,"about_ca_system_score_codex":0.000071540875,"about_ca_system_score_gemma":0.00058475614,"threshold_uncertainty_score":0.45771164},"labels":[],"label_agreement":null},{"id":"W3041457641","doi":"10.1016/j.annonc.2020.04.220","title":"P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill Genome Centre","funders":"","keywords":"Medicine; Metastasectomy; Colorectal cancer; Rectum; Lung; Transcriptome; Metastasis; Lung cancer; Oncology; Primary tumor; KRAS; Pathology; Cancer; Internal medicine; Gene; Gene expression; Biology","score_opus":0.07437366104296167,"score_gpt":0.38922771873500095,"score_spread":0.3148540576920393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041457641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744341,0.013959604,0.000005652571,0.009896968,0.00012288,0.00048074534,0.00068250316,0.0000068134573,0.00041074114],"genre_scores_gemma":[0.9976559,0.00083672744,0.00024976462,0.0010960398,0.000047653917,0.000051124774,0.000037112753,0.000010685573,0.000014960414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991091,0.00008126959,0.00038904682,0.00017223714,0.0001297106,0.00011862429],"domain_scores_gemma":[0.9991383,0.00031897303,0.00029119253,0.00010032675,0.00008302761,0.000068197354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008818295,0.00010698326,0.0008092221,0.000039959017,0.00002124728,0.0000019115541,0.000073665564,0.00007137948,0.00029166488],"category_scores_gemma":[0.000043233373,0.00007531244,0.00010222188,0.0001186859,0.00019184336,0.00003162391,0.00004318288,0.00011032542,4.9371664e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046706884,0.001159075,0.3806664,0.0008945347,0.0013575617,0.000023149687,0.009838387,0.000019220208,0.47689384,0.00011303788,0.028062684,0.09630141],"study_design_scores_gemma":[0.0021367017,0.0021842949,0.3011264,0.00016730612,0.00046803924,0.0000039454885,0.000583226,0.000075940276,0.6857303,0.000020608893,0.007445859,0.000057433695],"about_ca_topic_score_codex":0.0010734556,"about_ca_topic_score_gemma":0.0002832159,"teacher_disagreement_score":0.2088364,"about_ca_system_score_codex":0.000037813264,"about_ca_system_score_gemma":0.00036397538,"threshold_uncertainty_score":0.3193526},"labels":[],"label_agreement":null},{"id":"W3041499641","doi":"10.1016/j.annonc.2020.04.321","title":"P-239 Patient-reported outcomes in patients with metastatic gastric and esophageal cancers near end-of-life","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Internal medicine; Psychosocial; Cancer; Nausea; Anxiety; Cohort; Depression (economics); Quality of life (healthcare); Esophagus; Esophageal cancer; Logistic regression; Performance status; Psychiatry","score_opus":0.05833608962038318,"score_gpt":0.3352464363454044,"score_spread":0.27691034672502124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041499641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449724,0.0002234173,0.000022106957,0.0040766927,0.00005621246,0.00047246704,0.00001594795,0.000012265118,0.00062367343],"genre_scores_gemma":[0.9953168,0.000062624626,0.0010053489,0.003531488,0.00001161507,0.000012564093,0.000020177618,0.000012366164,0.000027019505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872893,0.000048324793,0.00051906105,0.00021227116,0.000263757,0.00022767474],"domain_scores_gemma":[0.99910647,0.000104152365,0.00037163318,0.00013315577,0.00012224737,0.00016236304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010455818,0.00013766883,0.0007370202,0.0001459864,0.000016484155,0.0000037276889,0.000060957314,0.000039178296,0.00010533858],"category_scores_gemma":[0.00021668655,0.000105478066,0.00006187248,0.00034855536,0.00015231296,0.000065600165,0.000057116096,0.0001127874,0.0000016276718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001145838,0.00021296376,0.9542568,0.00012608907,0.00031684712,0.00006709478,0.0005582181,0.000058859994,0.00000520415,0.00002519556,0.0008578296,0.04236909],"study_design_scores_gemma":[0.0069355983,0.006933463,0.98322135,0.000025492463,0.00016306996,0.0000020400403,0.0002335993,0.000086698754,0.00005493185,0.000012040637,0.0022529291,0.000078793855],"about_ca_topic_score_codex":0.0004340314,"about_ca_topic_score_gemma":0.00007612122,"teacher_disagreement_score":0.042290296,"about_ca_system_score_codex":0.000038238468,"about_ca_system_score_gemma":0.0003078089,"threshold_uncertainty_score":0.43012705},"labels":[],"label_agreement":null},{"id":"W3041755538","doi":"10.1016/j.annonc.2020.04.061","title":"O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Clinical trial; Quality of life (healthcare); Cancer; Chemotherapy; Nivolumab; Immunotherapy","score_opus":0.07461654353671106,"score_gpt":0.34322698502193155,"score_spread":0.2686104414852205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041755538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968931,0.002983447,0.00001604013,0.020659095,0.00014980279,0.001418672,0.00038148122,0.0000340316,0.0054264134],"genre_scores_gemma":[0.99644285,0.00046947633,0.0003375703,0.0017922873,0.00023465294,0.00020871664,0.00022464825,0.000029435336,0.0002603534],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99800473,0.00008098997,0.00069006806,0.00055669877,0.00020278351,0.0004647034],"domain_scores_gemma":[0.9985918,0.0004314551,0.00023302337,0.00025449658,0.00029949998,0.00018973257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018018924,0.0002480642,0.0011140541,0.00010990792,0.00006570894,0.000006361696,0.00013780453,0.00020630019,0.00010900194],"category_scores_gemma":[0.00048377953,0.0002093772,0.00023477955,0.00026290066,0.000095661526,0.000059004375,0.000104121245,0.00017931587,0.00001601265],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55581653,0.00565076,0.17918396,0.001119841,0.0023060606,0.00252709,0.046089906,0.000057713234,0.005027715,0.00035682486,0.070030876,0.13183272],"study_design_scores_gemma":[0.24658906,0.06893718,0.44438705,0.0006881393,0.0007431666,0.000045804903,0.0054198075,0.009979912,0.07906689,0.0011402759,0.14184265,0.0011600676],"about_ca_topic_score_codex":0.0022768003,"about_ca_topic_score_gemma":0.0006761339,"teacher_disagreement_score":0.30922747,"about_ca_system_score_codex":0.00011612815,"about_ca_system_score_gemma":0.0003685381,"threshold_uncertainty_score":0.85381544},"labels":[],"label_agreement":null},{"id":"W3041917668","doi":"10.1016/j.annonc.2020.04.452","title":"P-370 Comprehensive targeted genomic profiling and comparative genomic analysis to identify molecular mechanisms driving cancer progression in young-onset sporadic colorectal cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor","funders":"National Cancer Institute; National Institutes of Health; Windsor Cancer Centre Foundation; U.S. Department of Defense","keywords":"Medicine; Colorectal cancer; Cancer; Oncology; Breast cancer; Germline mutation; Population; Wnt signaling pathway; Disease; Internal medicine; Bioinformatics; Genetics; Mutation; Gene; Biology","score_opus":0.09158194381641757,"score_gpt":0.42414221481902376,"score_spread":0.3325602710026062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041917668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99118835,0.003444215,0.0002926394,0.0031473483,0.00023364417,0.0014418588,0.00009486165,0.000033156233,0.00012393658],"genre_scores_gemma":[0.9933103,0.00047633686,0.0040231277,0.001735883,0.00006353639,0.00030173536,0.000051119976,0.000030040559,0.000007920491],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99767923,0.00022270464,0.00063947274,0.0006767674,0.0003033625,0.00047847175],"domain_scores_gemma":[0.99863577,0.00011436805,0.0003518238,0.00017840117,0.00036726578,0.00035234317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021289391,0.00030154156,0.0012717275,0.0004218713,0.000058684953,0.000014677762,0.00018641126,0.00022194254,0.0002032097],"category_scores_gemma":[0.00007674712,0.00029402127,0.00016421259,0.0010466083,0.00018083274,0.00005025763,0.0002203435,0.00034525958,0.0000072739517],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011733603,0.00012482225,0.19368654,0.000086083426,0.0009345805,0.000095455965,0.003360719,0.0035268413,0.79500085,0.000023017368,0.00022690932,0.0017608374],"study_design_scores_gemma":[0.0013185901,0.0024749236,0.64401275,0.00009391055,0.0005444894,0.000016338323,0.0008417751,0.004055523,0.34603637,0.000073579366,0.00025619936,0.0002755458],"about_ca_topic_score_codex":0.00070008583,"about_ca_topic_score_gemma":0.001685759,"teacher_disagreement_score":0.4503262,"about_ca_system_score_codex":0.00030814737,"about_ca_system_score_gemma":0.0006032405,"threshold_uncertainty_score":0.9999512},"labels":[],"label_agreement":null},{"id":"W3042213560","doi":"10.1016/j.annonc.2020.04.215","title":"P-133 Extramural venous invasion detected with an elastin stain is a powerful predictor of cancer-specific mortality in STAGE I-IIIB resected colorectal cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Stage (stratigraphy); Colorectal cancer; Nomogram; Proportional hazards model; Cancer; Oncology; Cohort; Pathology; T-stage; Internal medicine; Log-rank test","score_opus":0.12545267687681672,"score_gpt":0.3990424714466187,"score_spread":0.273589794569802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042213560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432003,0.0015118662,0.000007248292,0.0016433744,0.00011672439,0.001134709,0.00055253727,0.00006379176,0.00064969546],"genre_scores_gemma":[0.99800915,0.0009355124,0.00016621129,0.00047012808,0.0001136389,0.00016011165,0.000057176992,0.00004106102,0.000047008616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733156,0.0002951236,0.00072580844,0.0006033606,0.0005236012,0.00052052736],"domain_scores_gemma":[0.99814546,0.0002054514,0.00044045728,0.00028122033,0.0005388407,0.00038857514],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023997138,0.00029423498,0.0011138543,0.00017428909,0.000033419194,0.0000062733593,0.00019934072,0.00027035328,0.0012682861],"category_scores_gemma":[0.00015942175,0.00024240358,0.00012026144,0.0009784357,0.00034588235,0.00012485703,0.0000881558,0.0004097654,0.000003449356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05189338,0.0030542247,0.8383798,0.00039615383,0.0006579641,0.0011596935,0.005438834,0.00016637996,0.07552577,0.000022244498,0.0005623778,0.022743165],"study_design_scores_gemma":[0.0066824476,0.039048426,0.8463805,0.00021846835,0.00010442017,0.000012879543,0.00038216324,0.0004677004,0.103422076,0.00002195868,0.003047712,0.00021125968],"about_ca_topic_score_codex":0.0055871243,"about_ca_topic_score_gemma":0.0145863015,"teacher_disagreement_score":0.045210935,"about_ca_system_score_codex":0.00035797816,"about_ca_system_score_gemma":0.0012640766,"threshold_uncertainty_score":0.9996447},"labels":[],"label_agreement":null},{"id":"W3046400044","doi":"10.1093/annonc/mdx814","title":"Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma","year":2018,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"National Cancer Institute; Wyeth Pharmaceuticals; National Institutes of Health","keywords":"Mantle cell lymphoma; Medicine; Temsirolimus; Cladribine; Rituximab; Internal medicine; Oncology; Clinical trial; Family medicine; Randomized controlled trial; Regimen; Lymphoma","score_opus":0.11861295183526281,"score_gpt":0.43666112918011896,"score_spread":0.31804817734485613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046400044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8970785,0.017033596,0.000010649233,0.0022443812,0.010735448,0.0043384763,0.0017995039,0.000027739901,0.0667317],"genre_scores_gemma":[0.9228055,0.055129696,0.00087001355,0.0017993596,0.0061394954,0.0005695811,0.0016623274,0.00014621008,0.010877821],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978856,0.0001088951,0.0009851467,0.00040222026,0.00027987448,0.0003382899],"domain_scores_gemma":[0.9972268,0.000455544,0.0010975805,0.00044293032,0.0006374842,0.00013967129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037039016,0.00034278745,0.0020888261,0.00027921482,0.000036258054,0.000004078114,0.00015316688,0.0008665819,0.0001132987],"category_scores_gemma":[0.0001264796,0.00026912012,0.00045709283,0.000106312145,0.00047420885,0.00003628026,0.00005862278,0.00010458754,0.000004419405],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09525854,0.036964342,0.00004355873,0.0006441702,0.0008331142,0.00006879945,0.00025347088,2.6864925e-8,0.0005157473,0.00009020478,0.71068525,0.15464276],"study_design_scores_gemma":[0.32046685,0.09049806,0.00020493922,0.00019261017,0.00032292752,0.000028769498,0.00004208509,0.000010054489,0.029653795,0.0002100153,0.5582266,0.00014330636],"about_ca_topic_score_codex":0.00020390589,"about_ca_topic_score_gemma":0.000028436301,"teacher_disagreement_score":0.22520831,"about_ca_system_score_codex":0.000056742923,"about_ca_system_score_gemma":0.0013010484,"threshold_uncertainty_score":0.9999761},"labels":[],"label_agreement":null},{"id":"W3046901662","doi":"10.1016/j.annonc.2020.05.028","title":"A multi-cancer detection test: focus on the positive predictive value","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Abbott Diagnostics","keywords":"DNA methylation; Cancer; Medicine; Scopus; Cell-free fetal DNA; Computational biology; Oncology; Artificial intelligence; Molecular biology; Internal medicine; Computer science; Genetics; Biology; MEDLINE; Gene; Gene expression","score_opus":0.04389354440966801,"score_gpt":0.3303595714992729,"score_spread":0.2864660270896049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046901662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93733734,0.0018004645,0.0056280857,0.047304012,0.00028134036,0.0006564538,0.00055492885,0.00001844507,0.006418918],"genre_scores_gemma":[0.9893636,0.0011625416,0.00012421691,0.0088901855,0.0003486195,0.000051310843,0.000009864082,0.000012567304,0.000037088663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993734,0.00005829563,0.00014309006,0.0002163961,0.000062542866,0.00014631827],"domain_scores_gemma":[0.9993673,0.0001782964,0.00011382767,0.0001342808,0.00014139418,0.0000648974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009725109,0.00009484685,0.0001339305,0.00001504576,0.00005079909,0.000005224114,0.00012953323,0.00012453787,0.000015848136],"category_scores_gemma":[0.0005439021,0.000074267125,0.00008320548,0.00006819855,0.00009610318,0.0000015004057,0.00007638487,0.00009843016,0.000008439084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010804486,0.00042275322,0.00094193267,0.000011507651,0.00023003135,0.000008195902,0.00055930513,0.0013166189,0.9272742,0.00050190964,0.015710993,0.0519421],"study_design_scores_gemma":[0.0006607006,0.0087044025,0.0062432727,0.0000107016995,0.0000293404,0.0000031878737,0.00010972751,0.001361702,0.9388021,0.0002502778,0.043711286,0.00011330103],"about_ca_topic_score_codex":0.00007726112,"about_ca_topic_score_gemma":0.00008575009,"teacher_disagreement_score":0.052026253,"about_ca_system_score_codex":0.0000139924105,"about_ca_system_score_gemma":0.00012658843,"threshold_uncertainty_score":0.30285257},"labels":[],"label_agreement":null},{"id":"W3047400464","doi":"10.1016/j.annonc.2020.07.001","title":"The FDA approval of pembrolizumab for patients with TMB &gt;10 mut/Mb: was it a wise decision? No","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Arnold Ventures; Roche; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Ipilimumab; Oncology; Family medicine; Internal medicine; Lung cancer; Cancer; Immunotherapy","score_opus":0.07303249655138225,"score_gpt":0.4114210955109136,"score_spread":0.33838859895953133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047400464","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007659433,0.0012150495,0.000042232718,0.97757274,0.00052723876,0.0032710242,0.0004804257,0.00002903545,0.009202817],"genre_scores_gemma":[0.024843171,0.0046160133,0.0048276205,0.9345333,0.0076046158,0.0020581416,0.0011379377,0.00035460296,0.02002459],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968442,0.00016214339,0.00072621315,0.0005306717,0.0010525006,0.00068432733],"domain_scores_gemma":[0.9933837,0.002688852,0.0006189229,0.0006603695,0.0025167381,0.0001313967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386605,0.00035316104,0.0014328107,0.00016326852,0.00013477265,0.000010714925,0.0005407305,0.00045256366,0.00012991435],"category_scores_gemma":[0.002678256,0.00020450214,0.00034173834,0.00023135563,0.0008168601,0.000046598503,0.00029691568,0.00097942,0.00004660973],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011523173,0.00026967633,0.00045559029,0.0009298414,0.0011279739,0.00017524001,0.00024651602,7.6033496e-7,0.000009645928,0.000012593233,0.9648827,0.020366326],"study_design_scores_gemma":[0.006013174,0.021342026,0.0009016781,0.00036728615,0.0002648929,0.000009785106,0.00004885038,0.0000147772525,0.000066694556,0.00028085842,0.9705162,0.00017375973],"about_ca_topic_score_codex":0.000046645513,"about_ca_topic_score_gemma":0.000044834178,"teacher_disagreement_score":0.043039437,"about_ca_system_score_codex":0.00013577145,"about_ca_system_score_gemma":0.0012555799,"threshold_uncertainty_score":0.83393556},"labels":[],"label_agreement":null},{"id":"W3048934302","doi":"10.1016/j.annonc.2020.07.019","title":"Bone health in cancer: ESMO Clinical Practice Guidelines","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":518,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ipsen; Servier; European Society for Medical Oncology; Astellas Pharma; Sirtex Medical; Genomic Health; Purdue University; Eisai; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Bone health; Cancer; Clinical Practice; Medical physics; Oncology; Intensive care medicine; Family medicine; Internal medicine; Osteoporosis; Bone mineral","score_opus":0.5028078413498005,"score_gpt":0.6320067639356234,"score_spread":0.12919892258582288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048934302","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07804847,0.008589397,0.000011242398,0.9086409,0.00022097281,0.00035817124,0.00001333593,0.000020378255,0.004097097],"genre_scores_gemma":[0.30962327,0.041263364,0.0104250135,0.6381023,0.00035492756,0.00003166823,0.000022268037,0.00001621403,0.00016100473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981545,0.00019328442,0.0010392626,0.00021676188,0.00011889494,0.00027728546],"domain_scores_gemma":[0.99834454,0.0003064486,0.0003796836,0.00013219153,0.0004374951,0.00039962493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009184059,0.000083815765,0.0006980139,0.000046610625,0.000020246018,0.0000010748705,0.000043275373,0.00013581135,0.000059811548],"category_scores_gemma":[0.0031641815,0.000070875794,0.000074887146,0.0001866104,0.000057732123,0.000050202212,0.000028363347,0.00025250117,0.000040948467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017563949,0.0014260585,0.029992297,0.00009983089,0.00007551361,0.00023439503,0.00024612196,0.00000309074,0.0000039022084,0.0001406308,0.27998352,0.68603826],"study_design_scores_gemma":[0.00392612,0.008122523,0.040528044,0.00006221171,0.000028865015,0.000044816185,0.000102560356,0.00009001077,0.000027681115,0.00005985865,0.94696295,0.00004432974],"about_ca_topic_score_codex":0.0038912648,"about_ca_topic_score_gemma":0.0006253107,"teacher_disagreement_score":0.6859939,"about_ca_system_score_codex":0.000042273325,"about_ca_system_score_gemma":0.0018716333,"threshold_uncertainty_score":0.58824545},"labels":[],"label_agreement":null},{"id":"W3080334748","doi":"10.1016/j.annonc.2020.08.2104","title":"Cannabinoids as antiemetics: everything that’s old is new again","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metoclopramide; Antiemetic; Nausea; Vomiting; Prochlorperazine; Chemotherapy-induced nausea and vomiting; Chemotherapy; Anesthesia; Dexamethasone; Placebo; Internal medicine","score_opus":0.14794524204289594,"score_gpt":0.38579821114030743,"score_spread":0.2378529690974115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080334748","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019056536,0.00082230987,0.00004503107,0.94796413,0.0008609213,0.000524264,0.000028761991,0.00008507712,0.047763836],"genre_scores_gemma":[0.0022067998,0.0011866676,0.00065427774,0.92008084,0.0045998227,0.000012308399,0.00016068763,0.000078607656,0.07102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744606,0.00016118212,0.00059907837,0.0005967224,0.0005770079,0.0006199668],"domain_scores_gemma":[0.9982608,0.0001914781,0.0005258983,0.00059172255,0.00020825326,0.00022186828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003323613,0.00038383377,0.001279439,0.00033795484,0.000052646657,0.00002073748,0.0003633961,0.0009053558,0.00075315597],"category_scores_gemma":[0.0003683955,0.00036540168,0.00040239468,0.00022767721,0.00013401892,0.000054458174,0.00023885896,0.0017181177,0.00030650862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105571424,0.00006802301,0.0002472673,0.000666066,0.0005689557,0.0035686048,0.0006045877,3.7157142e-7,0.000085020234,0.0000899779,0.96332675,0.030668827],"study_design_scores_gemma":[0.0011584099,0.0026848512,0.00016443475,0.00030511722,0.00040758724,0.000064162574,0.000085810985,0.000009459092,0.0025608593,0.0015159387,0.990755,0.00028834504],"about_ca_topic_score_codex":0.0011934018,"about_ca_topic_score_gemma":0.0000097090915,"teacher_disagreement_score":0.030380482,"about_ca_system_score_codex":0.00008466427,"about_ca_system_score_gemma":0.0008933006,"threshold_uncertainty_score":0.9998798},"labels":[],"label_agreement":null},{"id":"W3082062836","doi":"10.1016/j.annonc.2020.08.2100","title":"Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Pemetrexed; T790M; Tyrosine-kinase inhibitor; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Tyrosine kinase; Cancer research; Chemotherapy; Epidermal growth factor receptor; Erlotinib; Cisplatin; Gefitinib; Lung cancer; Cancer; Receptor","score_opus":0.049211310333982565,"score_gpt":0.40766079895236074,"score_spread":0.35844948861837816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082062836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028575,0.00032084816,0.00007218865,0.006922503,0.000143615,0.0012061622,0.00013864932,0.000053587784,0.00085666386],"genre_scores_gemma":[0.9955388,0.00007055714,0.0028948435,0.0008449403,0.00009363999,0.000116934316,0.0003658444,0.00003108887,0.000043363398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987289,0.000047074438,0.00033198728,0.0003833298,0.0002534022,0.00025534918],"domain_scores_gemma":[0.99871165,0.00027508783,0.00028411715,0.00017546605,0.00033743336,0.00021623439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008202674,0.00019298929,0.0006132529,0.00014392896,0.00007322018,0.000008596059,0.000052627955,0.000101779064,0.000028832492],"category_scores_gemma":[0.00024384524,0.00013826112,0.00012944956,0.00036869713,0.00008257346,0.00008899846,0.000031994507,0.000096770535,0.0000019040548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105359524,0.0052084145,0.22276692,0.0003754691,0.0061111017,0.00006380734,0.0027665594,0.0002368325,0.0021149088,0.00038939208,0.0041917847,0.6504153],"study_design_scores_gemma":[0.14201818,0.17470963,0.56019795,0.0005761547,0.008761317,0.0000025461145,0.0007434119,0.0011814631,0.015248313,0.00007254427,0.09567597,0.0008125419],"about_ca_topic_score_codex":0.000026868594,"about_ca_topic_score_gemma":0.00003629485,"teacher_disagreement_score":0.6496027,"about_ca_system_score_codex":0.00007263691,"about_ca_system_score_gemma":0.00018024625,"threshold_uncertainty_score":0.5638125},"labels":[],"label_agreement":null},{"id":"W3084000608","doi":"10.1016/j.annonc.2020.08.2335","title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); William Osler Health System; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; Boehringer Ingelheim","keywords":"Afatinib; Neuregulin 1; Cancer research; ErbB; Medicine; Fusion gene; Adenocarcinoma; Neuregulin; Lung cancer; Targeted therapy; Cancer; Epidermal growth factor receptor; Gene; Gefitinib; Oncology; Biology; Internal medicine; Receptor; Genetics","score_opus":0.09157322375780692,"score_gpt":0.45679954810592427,"score_spread":0.36522632434811736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084000608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000609321,0.99486184,0.000010272699,0.0009681898,0.00007239414,0.000875973,0.0000616016,0.000010919753,0.0025294998],"genre_scores_gemma":[0.018006017,0.98081523,0.00011754048,0.0007762,0.00011815393,0.00007066077,0.000023895562,0.000024207697,0.00004808773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988269,0.0002539311,0.00048398232,0.00022812409,0.000067243775,0.00013981014],"domain_scores_gemma":[0.9987964,0.00036601638,0.0005288034,0.00014371162,0.000100740246,0.00006432424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022622875,0.00018258224,0.00130488,0.000082782855,0.000061816325,0.0000038048606,0.00007318592,0.0001870181,0.000059252387],"category_scores_gemma":[0.0001092768,0.00010153265,0.00017068625,0.0001330863,0.00036180287,0.000016544434,0.0000652176,0.00017063638,0.0000031903044],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008030993,0.00007706424,0.00020418866,0.0013315902,0.0009067049,0.000003950211,0.00090822496,1.1576837e-7,0.000035877234,0.00033465412,0.00011887144,0.99599844],"study_design_scores_gemma":[0.0012526874,0.0010426496,0.0001320492,0.0010651811,0.0014348321,0.000054374243,0.00027987917,0.000017490482,0.00002600195,0.00049820443,0.9941196,0.00007708698],"about_ca_topic_score_codex":0.00014715864,"about_ca_topic_score_gemma":0.000015161916,"teacher_disagreement_score":0.9959214,"about_ca_system_score_codex":0.00002200977,"about_ca_system_score_gemma":0.00026352698,"threshold_uncertainty_score":0.41403812},"labels":[],"label_agreement":null},{"id":"W3087766565","doi":"10.1016/j.annonc.2020.08.1849","title":"1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; GiST; Nausea; Adverse effect; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Stromal cell","score_opus":0.10420429524946852,"score_gpt":0.4530743945529795,"score_spread":0.348870099303511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087766565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879791,0.000113985516,0.0000494855,0.007881027,0.00006553278,0.0033951355,0.000027629563,0.00007117579,0.00041693903],"genre_scores_gemma":[0.9908717,0.0000057572233,0.008274087,0.0002824699,0.00012472857,0.0003252494,0.00006901413,0.000040422805,0.0000065311965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99494934,0.0008460756,0.001551945,0.00078958215,0.0010364066,0.0008266784],"domain_scores_gemma":[0.9970672,0.00065205584,0.00055497256,0.0004506028,0.00031320791,0.00096197095],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014275382,0.00037128574,0.0010151044,0.0002812357,0.00007010398,0.000027845294,0.0003179688,0.00005694935,0.000057756635],"category_scores_gemma":[0.009638149,0.00029960473,0.00025276627,0.0005319053,0.00021126628,0.00018640883,0.00035260705,0.0007204244,0.000012819104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02815902,0.019616697,0.8850692,0.00019937492,0.00006193426,0.017922394,0.000911231,0.00003581026,0.001522924,0.000021875407,0.00017963773,0.046299934],"study_design_scores_gemma":[0.038245108,0.21510604,0.7339398,0.0035859628,0.0001541859,0.00024788128,0.0025167111,0.0047337357,0.00066578883,0.00028943282,0.00014610436,0.00036918983],"about_ca_topic_score_codex":0.000080402664,"about_ca_topic_score_gemma":0.00010305031,"teacher_disagreement_score":0.19548935,"about_ca_system_score_codex":0.0001572931,"about_ca_system_score_gemma":0.0010196089,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W3087774204","doi":"10.1016/j.annonc.2020.08.1791","title":"1727P COVID-19 pandemic: Impact on doctors in training","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vifor Pharma; Astellas Pharma; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pandemic; Personal protective equipment; Coronavirus disease 2019 (COVID-19); Health care; Scale (ratio); Family medicine; Perceived Stress Scale; Public health; Nursing; Stress (linguistics)","score_opus":0.6423806929164265,"score_gpt":0.5957034674116577,"score_spread":0.04667722550476883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087774204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84647554,0.00020349018,0.00002389338,0.14930464,0.000079584126,0.00028534487,0.000025723226,0.000051313782,0.0035504615],"genre_scores_gemma":[0.85432386,0.0003126215,0.000042847932,0.14504129,0.00021387642,0.000006553034,0.000015750094,0.00001375676,0.000029459638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985011,0.00015366216,0.00044871832,0.0002609406,0.0001899597,0.0004455875],"domain_scores_gemma":[0.9977587,0.0009015307,0.00015693017,0.00017082624,0.00007411533,0.00093792717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006673591,0.00015184814,0.0006932995,0.00021107298,0.000031666612,0.0000034166496,0.000101656966,0.00023195088,0.00036871908],"category_scores_gemma":[0.0034358897,0.00012025384,0.00015310652,0.00034134087,0.00008716862,0.00004645313,0.00002969458,0.00041154318,0.000033436132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006272321,0.0005162748,0.7097887,0.00060110743,0.00013662201,0.00088945177,0.029071812,0.0004227619,0.0031388476,0.00048420456,0.035000898,0.21367703],"study_design_scores_gemma":[0.006036424,0.026514735,0.49086875,0.00014465724,0.000040127,0.00013982985,0.0016549097,0.00032245036,0.00046487205,0.00071913906,0.4728369,0.00025718712],"about_ca_topic_score_codex":0.0014227043,"about_ca_topic_score_gemma":0.00036411043,"teacher_disagreement_score":0.43783602,"about_ca_system_score_codex":0.00028080627,"about_ca_system_score_gemma":0.0036660521,"threshold_uncertainty_score":0.6503419},"labels":[],"label_agreement":null},{"id":"W3087777340","doi":"10.1016/j.annonc.2020.08.089","title":"1195P The value of detecting resistance through liquid biopsy","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Niagara; Juravinski Cancer Centre; McGill University; University of Calgary; Jewish General Hospital; University Health Network; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Liquid biopsy; Biopsy; T790M; Targeted therapy; Oncology; Lung cancer; Internal medicine; Cohort; Cancer; Clinical trial; Adenocarcinoma; Pathology; Bioinformatics; ROS1","score_opus":0.09487938942729415,"score_gpt":0.43981916246007013,"score_spread":0.344939773032776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087777340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.820565,0.0025985925,0.00039392247,0.10284862,0.00012640649,0.0003278446,0.000021660662,0.000024578036,0.07309339],"genre_scores_gemma":[0.99330264,0.0002018012,0.0015666935,0.0045835795,0.00009848946,0.000012467754,0.0000035220255,0.000007739786,0.00022305814],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942684,0.000042898682,0.00021754268,0.00010975198,0.00009136811,0.000111625144],"domain_scores_gemma":[0.9993828,0.00014403052,0.00015643935,0.00013790966,0.00013978417,0.000039039423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009399957,0.000057927533,0.00023009979,0.000014198141,0.00004061988,0.0000012145396,0.000067922476,0.00004911651,0.000044498658],"category_scores_gemma":[0.00019509735,0.00003722892,0.000074906435,0.00015941657,0.00010679916,0.000031371175,0.000023443314,0.000074494215,0.000005787097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022335026,0.0040481267,0.015256208,0.0030105915,0.007525787,0.0009072064,0.1625418,0.0006223517,0.38807476,0.13039787,0.109057434,0.15622284],"study_design_scores_gemma":[0.0038305249,0.013362593,0.010799027,0.00023153104,0.0006886261,0.00006658911,0.004172696,0.00006967184,0.3302859,0.0021432866,0.63416916,0.00018038765],"about_ca_topic_score_codex":0.00008260453,"about_ca_topic_score_gemma":0.000016960492,"teacher_disagreement_score":0.52511173,"about_ca_system_score_codex":0.000016361788,"about_ca_system_score_gemma":0.00019625376,"threshold_uncertainty_score":0.15181515},"labels":[],"label_agreement":null},{"id":"W3087796427","doi":"10.1016/j.annonc.2020.08.920","title":"661P Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Enzalutamide; Docetaxel; Medicine; Abiraterone; Prostate cancer; Internal medicine; Oncology; Cabazitaxel; Abiraterone acetate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.1667584045785049,"score_gpt":0.44440872277820376,"score_spread":0.2776503181996989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087796427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97648525,0.00047527396,8.409137e-7,0.019249428,0.000048707894,0.0011151747,0.0002843841,0.0000073922442,0.0023335307],"genre_scores_gemma":[0.9945889,0.0033650051,0.000049364968,0.0012275368,0.000043391097,0.00021490913,0.00012349845,0.000013514002,0.00037385433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985091,0.00019549302,0.00046968606,0.0002254222,0.00030484534,0.00029547364],"domain_scores_gemma":[0.999084,0.00016549903,0.00021626228,0.00018999795,0.00023481388,0.0001094532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019260719,0.00014946252,0.0004971964,0.000120940254,0.00003206273,0.0000054961056,0.0001090638,0.000040146748,0.00016286508],"category_scores_gemma":[0.000042864962,0.00008806163,0.000105157735,0.00030846102,0.00010217474,0.000053225824,0.000025488269,0.00011633377,0.000005769944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006423253,0.0037324326,0.88641834,0.00058568997,0.00075678807,0.00045935935,0.013597485,0.00009300861,0.0030572463,0.00023813723,0.003407517,0.08123076],"study_design_scores_gemma":[0.011052174,0.021031523,0.9215667,0.00018119407,0.0002704166,0.0000031439074,0.0011688321,0.00008101603,0.021661535,0.00012417808,0.022706691,0.0001525608],"about_ca_topic_score_codex":0.0056899404,"about_ca_topic_score_gemma":0.0067285667,"teacher_disagreement_score":0.0810782,"about_ca_system_score_codex":0.00014112155,"about_ca_system_score_gemma":0.0005418564,"threshold_uncertainty_score":0.86015254},"labels":[],"label_agreement":null},{"id":"W3087802908","doi":"10.1016/j.annonc.2020.08.1779","title":"1715P Plinabulin (Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company","keywords":"Medicine; Pegfilgrastim; Neutropenia; Febrile neutropenia; Docetaxel; Chemotherapy; Granulocyte colony-stimulating factor; Internal medicine; PEG ratio; Surgery","score_opus":0.20083915176203782,"score_gpt":0.4435143904053312,"score_spread":0.24267523864329338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087802908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8973598,0.00031601542,0.0023038017,0.09815754,0.00011993241,0.0014382062,0.000029515311,0.00003689922,0.00023830161],"genre_scores_gemma":[0.9869255,0.00103936,0.00014402726,0.010901895,0.00030041955,0.00023503388,0.000014076916,0.000025953133,0.00041377902],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877703,0.000095979165,0.0004449787,0.0002681972,0.00016969362,0.0002441413],"domain_scores_gemma":[0.99865556,0.00028370295,0.0003859711,0.00030230472,0.00023816357,0.00013430922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040705214,0.00015313906,0.00045203508,0.000058675265,0.00019986596,0.0000090155745,0.00021499419,0.00015508647,0.00018885669],"category_scores_gemma":[0.00015080348,0.00009654186,0.00026228948,0.0003009331,0.00015126234,0.000076737546,0.000052183637,0.00027144214,0.0000074779655],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02022598,0.0015967449,0.055154867,0.001869899,0.0017943787,0.000019761666,0.016411334,0.0021067243,0.806472,0.0019352286,0.026451716,0.06596135],"study_design_scores_gemma":[0.032632496,0.031020302,0.21656565,0.0002972765,0.0015621231,0.00048822304,0.0068383487,0.003804684,0.31587476,0.004161269,0.38596013,0.000794739],"about_ca_topic_score_codex":0.00019127125,"about_ca_topic_score_gemma":0.000104718776,"teacher_disagreement_score":0.49059725,"about_ca_system_score_codex":0.00007445272,"about_ca_system_score_gemma":0.00052941835,"threshold_uncertainty_score":0.39368626},"labels":[],"label_agreement":null},{"id":"W3087807683","doi":"10.1016/j.annonc.2020.08.816","title":"744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Foundation Medicine; Genentech; EUSA Pharma; EMD Serono; Bavarian Nordic; Merck Sharp and Dohme; Eisai; Incyte; Ipsen; Clovis Oncology; Mirati Therapeutics; Exelixis; Sanofi; Merck; GlaxoSmithKline; Heron Therapeutics; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Celldex Therapeutics; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Stromal cell; Hazard ratio; Progression-free survival; Proportional hazards model; Overall survival; Confidence interval","score_opus":0.04089900162685077,"score_gpt":0.34601037550287433,"score_spread":0.30511137387602355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087807683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378395,0.00071719865,0.0000129112395,0.003648431,0.00006882513,0.0006417643,0.00010739854,0.00002535519,0.0009941569],"genre_scores_gemma":[0.9966494,0.0005135313,0.00035796544,0.0020653864,0.00020980673,0.000052565403,0.0000571102,0.000026640393,0.00006761799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986899,0.00010792216,0.00030531987,0.00032673156,0.00029018405,0.0002799569],"domain_scores_gemma":[0.99913055,0.00014940694,0.00024527774,0.00011764134,0.0001873168,0.00016978491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089764355,0.00017839883,0.0005712951,0.000078893456,0.000038115122,0.000005434195,0.000074709584,0.0002134991,0.000076808035],"category_scores_gemma":[0.00013805268,0.00013843513,0.00005468131,0.00017007123,0.000046115798,0.00009337937,0.000042277436,0.00022935885,0.000004362982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010195283,0.0010059157,0.8472405,0.00012566663,0.0003569994,0.000029871871,0.0017412667,0.000098605946,0.015885742,0.000007657142,0.0018480007,0.12146446],"study_design_scores_gemma":[0.025418628,0.010146234,0.89089423,0.00015622901,0.00017680744,9.295453e-7,0.000039029354,0.0000112866655,0.066160105,0.000025620422,0.0067939404,0.00017696292],"about_ca_topic_score_codex":0.0001395102,"about_ca_topic_score_gemma":0.000040424657,"teacher_disagreement_score":0.1212875,"about_ca_system_score_codex":0.00012838763,"about_ca_system_score_gemma":0.00024772773,"threshold_uncertainty_score":0.5645221},"labels":[],"label_agreement":null},{"id":"W3087809661","doi":"10.1016/j.annonc.2020.08.1092","title":"977TiP Role of microbiome as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma 2 (ROMA LA-OPSCC2)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Microbiome; Biomarker; Oncology; Basal cell; Cancer research; Internal medicine; Bioinformatics; Genetics; Biology","score_opus":0.05417874753903319,"score_gpt":0.34802212921237213,"score_spread":0.29384338167333895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087809661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94838154,0.0045412146,0.0000017831369,0.011964047,0.00006312823,0.0003063545,0.000033838867,0.000017574572,0.034690514],"genre_scores_gemma":[0.995484,0.00030481294,0.00029335977,0.0036335227,0.000052903462,0.00002474541,0.000016028387,0.00002175558,0.00016890476],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99861294,0.000111083275,0.0004986004,0.0003023577,0.00015504946,0.00031999237],"domain_scores_gemma":[0.99904394,0.00022939689,0.00019644682,0.00017322613,0.00019415165,0.0001628147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017604906,0.00017253697,0.0009077212,0.00015213538,0.000021119682,0.0000015748063,0.00013639826,0.00016722963,0.00017372512],"category_scores_gemma":[0.00012822052,0.00015642389,0.0001482646,0.00035878312,0.0002529169,0.000044090397,0.00010255318,0.00017331539,0.000029582508],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00487856,0.0013257334,0.022493761,0.00059555116,0.00008057593,0.0006906353,0.0037112308,0.000003432648,0.9023074,0.00019959883,0.018359879,0.04535362],"study_design_scores_gemma":[0.015562408,0.024809314,0.36240086,0.00016362367,0.00012591995,0.0001886086,0.0018539574,0.00015911381,0.2721796,0.0005046127,0.32160968,0.00044228885],"about_ca_topic_score_codex":0.0002504694,"about_ca_topic_score_gemma":0.00007310239,"teacher_disagreement_score":0.6301278,"about_ca_system_score_codex":0.0000385966,"about_ca_system_score_gemma":0.00043141595,"threshold_uncertainty_score":0.6378781},"labels":[],"label_agreement":null},{"id":"W3087812632","doi":"10.1016/j.annonc.2020.08.274","title":"153P The Systemic Inflammation Response Index (SIRI) is a prognostic factor that correlates with tumor burden in advanced pancreatic cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"BeiGene; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Internal medicine; Hazard ratio; Pancreatic cancer; Confidence interval; Chemotherapy; Gastroenterology; Oncology; Cancer","score_opus":0.05226536428995832,"score_gpt":0.337951379284398,"score_spread":0.2856860149944397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087812632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753035,0.0013071189,0.000020982827,0.021279167,0.00007856149,0.001714882,0.00003239235,0.000055766464,0.00020766212],"genre_scores_gemma":[0.99693817,0.00020400797,0.00008471645,0.002303044,0.00009952783,0.00028699983,0.000007835968,0.000032684482,0.000043010532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980447,0.00043229677,0.00051544176,0.0003253203,0.00033903192,0.00034315095],"domain_scores_gemma":[0.9980064,0.0008024584,0.0004494851,0.0002880395,0.0002901483,0.00016345714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043694186,0.0002241991,0.0005963583,0.00014334623,0.000051580533,0.000011625066,0.0002033329,0.00014632111,0.00014765],"category_scores_gemma":[0.0009658793,0.00014932625,0.000092941904,0.0003979926,0.00022466945,0.0001276438,0.000067286586,0.00027335703,0.000023453722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030097108,0.00008027851,0.939163,0.00073170837,0.0003305651,0.00036128802,0.0064915055,0.00015704984,0.011207711,0.000014383844,0.0007083274,0.010657019],"study_design_scores_gemma":[0.005574844,0.0042659226,0.9507512,0.0022319085,0.00036256027,0.00015544772,0.0038434742,0.0034346317,0.025001472,0.000057124318,0.003971203,0.00035021768],"about_ca_topic_score_codex":0.000053362186,"about_ca_topic_score_gemma":0.000036733636,"teacher_disagreement_score":0.024522264,"about_ca_system_score_codex":0.00011760284,"about_ca_system_score_gemma":0.00078708085,"threshold_uncertainty_score":0.60893476},"labels":[],"label_agreement":null},{"id":"W3087814557","doi":"10.1016/j.annonc.2020.08.1666","title":"1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Lung cancer; T790M; Concordance; Oncology; Genotyping; Internal medicine; Cancer; ROS1; Genotype; Adenocarcinoma; Genetics; Gene","score_opus":0.0924449147374692,"score_gpt":0.3298265194009786,"score_spread":0.23738160466350944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087814557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941395,0.0018504376,0.0018477843,0.0005680073,0.00023791546,0.00026125682,0.000018606466,0.000006259216,0.0010702257],"genre_scores_gemma":[0.99517083,0.0010709974,0.0010765425,0.0021432731,0.0003886545,0.0000666482,0.00005595477,0.000016874319,0.000010237779],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998843,0.0000427882,0.0003756201,0.00038372198,0.00007929159,0.00027555673],"domain_scores_gemma":[0.99935,0.000024010369,0.00023071188,0.0001537423,0.0001426171,0.000098877696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011370952,0.00014878553,0.0002416987,0.000044929584,0.000059553833,0.000017821827,0.00015425801,0.00011023093,0.00001733591],"category_scores_gemma":[0.0001896174,0.0001716227,0.00007082232,0.00013237626,0.000061968945,0.000012817081,0.00010514804,0.000103031205,0.0000016330806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052258692,0.000052927895,0.004087942,0.00004352883,0.000010678298,0.000025947571,0.0009756647,0.019414498,0.9682175,0.000033213113,0.00029296448,0.0067928946],"study_design_scores_gemma":[0.0008389708,0.0006429586,0.0010927457,0.00003982582,0.000013084859,0.0000090389,0.00047624364,0.011302897,0.98136145,0.000015445885,0.0039831856,0.00022417044],"about_ca_topic_score_codex":0.00036387602,"about_ca_topic_score_gemma":0.0009470437,"teacher_disagreement_score":0.013143952,"about_ca_system_score_codex":0.0001031365,"about_ca_system_score_gemma":0.0005813985,"threshold_uncertainty_score":0.69985706},"labels":[],"label_agreement":null},{"id":"W3087827200","doi":"10.1016/j.annonc.2020.08.431","title":"329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Hazard ratio; Goserelin; Placebo; Progression-free survival; Cancer; Surgery; Gastroenterology; Oncology; Tamoxifen; Chemotherapy; Confidence interval; Pathology","score_opus":0.07957722803001016,"score_gpt":0.40408118477772087,"score_spread":0.3245039567477107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087827200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9128686,0.004192913,0.000017697665,0.08110811,0.000033197557,0.001270405,0.0001004743,0.000015595808,0.0003930097],"genre_scores_gemma":[0.97684914,0.0032026507,0.0012097078,0.018331828,0.00008196643,0.00023676346,0.00000920836,0.000030056191,0.00004869521],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980434,0.0003657903,0.00056692486,0.00042650432,0.00024330482,0.000354083],"domain_scores_gemma":[0.9986581,0.00048827802,0.0002847112,0.00022264976,0.00019484777,0.00015140398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060142967,0.0002323368,0.0009572156,0.00011359735,0.00003608177,0.000009024226,0.00014675548,0.00007368742,0.00004511238],"category_scores_gemma":[0.0002301916,0.00015148582,0.0000466701,0.0004096763,0.00019661627,0.00015518018,0.00004985796,0.00026094483,0.0000010409839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05709458,0.00089022296,0.27406648,0.00017993037,0.00020535724,0.000096844065,0.008449176,0.00007913356,0.003442782,0.0007045834,0.00048619215,0.65430474],"study_design_scores_gemma":[0.018901218,0.004266716,0.9018667,0.0002828139,0.000027865719,0.000028106577,0.0007383241,0.000005209932,0.0012822397,0.0005498043,0.07184275,0.00020826614],"about_ca_topic_score_codex":0.00018282187,"about_ca_topic_score_gemma":0.0014542734,"teacher_disagreement_score":0.6540965,"about_ca_system_score_codex":0.000069413414,"about_ca_system_score_gemma":0.00021056767,"threshold_uncertainty_score":0.6177412},"labels":[],"label_agreement":null},{"id":"W3087842901","doi":"10.1016/j.annonc.2020.08.438","title":"336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"EMD Serono; Genentech; PharmaMar; Springworks Therapeutics; MacroGenics; Silverback Therapeutics; Cilag; Puma Biotechnology; Relay Therapeutics; Eisai; Celltrion; Syndax Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Unum Therapeutics; Amgen; Radius Health; Clovis Oncology; Les Laboratories Pierre Fabre; Genomic Health; Ipsen; Array BioPharma; Mersana Therapeutics; Karyopharm Therapeutics; NuCana; Pfizer; Incyte; Taiho Pharmaceutical; F. Hoffmann-La Roche; GlaxoSmithKline; Jounce Therapeutics; PTC Therapeutics; Celgene; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Sanofi","keywords":"Medicine; Palbociclib; Breast cancer; Internal medicine; Fulvestrant; Oncology; Cancer; Estrogen receptor; Metastatic breast cancer","score_opus":0.09332269885895235,"score_gpt":0.45202263202816667,"score_spread":0.35869993316921434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087842901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772983,0.0009935991,0.00001763991,0.020128896,0.00008922098,0.0010801798,0.00020803287,0.000020329147,0.0001637889],"genre_scores_gemma":[0.99663275,0.0009194398,0.0004030719,0.0017719377,0.00011370259,0.000092613554,0.0000080267855,0.00003572552,0.000022732936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964531,0.0012065663,0.0011234146,0.0005666968,0.0002632582,0.0003869679],"domain_scores_gemma":[0.99740934,0.001242065,0.0005147361,0.0002559614,0.0003198248,0.00025805202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322533,0.0002630646,0.0013000605,0.00026501936,0.000027844313,0.0000035966546,0.00015656419,0.00023830548,0.00014370497],"category_scores_gemma":[0.0006705572,0.00024315233,0.00010726026,0.00070746784,0.00063117105,0.00013992302,0.00011755599,0.0004559295,0.000004306693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36893982,0.012082076,0.15454006,0.00011139712,0.0011382772,0.0006280114,0.023010647,0.000025617604,0.04769891,0.000018207917,0.00077882165,0.39102814],"study_design_scores_gemma":[0.037785083,0.04352536,0.900819,0.0002776927,0.00008290809,0.00004345651,0.0101261595,0.00008172549,0.004797082,0.000076469325,0.0021220443,0.0002630072],"about_ca_topic_score_codex":0.0026114066,"about_ca_topic_score_gemma":0.0012794463,"teacher_disagreement_score":0.74627894,"about_ca_system_score_codex":0.00014892309,"about_ca_system_score_gemma":0.0006205011,"threshold_uncertainty_score":0.99154645},"labels":[],"label_agreement":null},{"id":"W3087846510","doi":"10.1016/j.annonc.2020.08.1697","title":"1383P Lung cancer in adolescents and young adults (AYA) in Asia: Tumour characteristics and molecular profiles","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; KRAS; Internal medicine; Cohort; Cancer; Anaplastic lymphoma kinase; Oncogene; Lung cancer; Adenocarcinoma; Oncology; Stage (stratigraphy); Gastroenterology; Colorectal cancer; Cell cycle","score_opus":0.02435319907027539,"score_gpt":0.3794287028919217,"score_spread":0.3550755038216463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087846510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858832,0.0025007408,0.0000055959335,0.010582425,0.000051948216,0.00039256143,0.000040035786,0.0000064434375,0.00053709635],"genre_scores_gemma":[0.99710345,0.0013223955,0.000080948266,0.0013711337,0.000037755202,0.000047045825,0.000013790774,0.0000094390025,0.000014057286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999375,0.000031275682,0.0002070697,0.00017494269,0.000067194516,0.00014452932],"domain_scores_gemma":[0.9997106,0.000010008986,0.0000776838,0.000049142105,0.00006159643,0.00009094004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004866862,0.00008347983,0.00029366932,0.000066133,0.000011432926,0.0000033980386,0.000025483392,0.00007039309,0.000010793174],"category_scores_gemma":[0.000053057203,0.00007539547,0.00001742365,0.00010317038,0.00004921019,0.000039232906,0.000028637029,0.00010597592,5.8006793e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044180773,0.00023410354,0.9649383,0.0004772973,0.000057440666,0.0003675957,0.0023418986,0.0000016924338,0.0037530921,0.00006801426,0.00024583237,0.027072923],"study_design_scores_gemma":[0.0028989408,0.0007048056,0.99279654,0.0005192972,0.00006728673,0.000016554726,0.0003230695,0.00047380084,0.0016716032,0.00001575413,0.0004438726,0.000068489135],"about_ca_topic_score_codex":0.00034751097,"about_ca_topic_score_gemma":0.00020861426,"teacher_disagreement_score":0.027858226,"about_ca_system_score_codex":0.00003687096,"about_ca_system_score_gemma":0.00015160744,"threshold_uncertainty_score":0.3074538},"labels":[],"label_agreement":null},{"id":"W3087846511","doi":"10.1016/j.annonc.2020.08.1807","title":"1743P How I treat COVID-19 webinars: A rapid communication platform between patients and physicians","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Ottawa; Cegep regional de Lanaudiere","funders":"Eisai; GlaxoSmithKline; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medical physics; Virology; Internal medicine; Infectious disease (medical specialty)","score_opus":0.23127531559221925,"score_gpt":0.44738754480289544,"score_spread":0.2161122292106762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087846511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7853022,0.00027176365,0.00010920828,0.21221977,0.000022181888,0.0004828866,0.00005315476,0.000034095447,0.0015047328],"genre_scores_gemma":[0.9572293,0.0009453014,0.00042422744,0.040732455,0.0001555713,0.000020235895,0.00045660284,0.000011642175,0.000024671575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990755,0.000084712025,0.00031361016,0.00016555918,0.00015910581,0.00020153176],"domain_scores_gemma":[0.99884313,0.0002850645,0.00027953053,0.00016253622,0.00013815529,0.0002916086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020675048,0.00010399797,0.00042671364,0.00007755274,0.00007643826,0.000004356618,0.00007936326,0.00009180317,0.00005936017],"category_scores_gemma":[0.00037357816,0.00009423633,0.000044645843,0.00016227212,0.00012567823,0.000108933236,0.00005140151,0.00013965783,0.0000050418103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048802196,0.00025610512,0.16832434,0.0003580699,0.000096955635,0.0000069254943,0.006851148,3.0161618e-7,0.00028341002,0.00022044955,0.12864602,0.69446826],"study_design_scores_gemma":[0.01065937,0.020303395,0.23487805,0.00004803488,0.00021672329,0.0000064613387,0.0028565058,0.00004413473,0.0019180597,0.00046164333,0.72845244,0.00015518574],"about_ca_topic_score_codex":0.00012862966,"about_ca_topic_score_gemma":0.000032789012,"teacher_disagreement_score":0.69431305,"about_ca_system_score_codex":0.00004274825,"about_ca_system_score_gemma":0.00019620644,"threshold_uncertainty_score":0.38428462},"labels":[],"label_agreement":null},{"id":"W3087853974","doi":"10.1016/j.annonc.2020.08.454","title":"352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Pertuzumab; Hazard ratio; Trastuzumab; Internal medicine; Taxane; Breast cancer; Oncology; Clinical endpoint; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Placebo; Cancer; Clinical trial; Confidence interval; Pathology; Signal transduction","score_opus":0.06491574675293652,"score_gpt":0.4117682651337963,"score_spread":0.34685251838085973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087853974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897517,0.00033027245,0.000017411088,0.0056401193,0.000044648128,0.0030144837,0.00030441987,0.000038983573,0.0008579824],"genre_scores_gemma":[0.9966899,0.000779393,0.00012588201,0.0018197049,0.00007926351,0.00029800978,0.000060828246,0.00009049521,0.00005652224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960477,0.00050717714,0.0009248751,0.0008886298,0.00082502246,0.0008066061],"domain_scores_gemma":[0.9968749,0.00027796894,0.0005652142,0.00036917042,0.0014364284,0.0004762924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034533662,0.0004767132,0.0015998901,0.00027821996,0.00010486148,0.000013887419,0.00030873553,0.00020100926,0.0005623577],"category_scores_gemma":[0.00015434621,0.000349584,0.00008731308,0.00081762223,0.00063893676,0.00027441312,0.00010161637,0.0006930217,0.0000042473657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17301553,0.030047275,0.43352813,0.00058644614,0.0020960958,0.0010170772,0.055551354,0.00010996708,0.013188547,0.000069553505,0.0025164965,0.2882735],"study_design_scores_gemma":[0.1466756,0.23358645,0.5932944,0.0008815548,0.00013443296,0.00010440827,0.007734641,0.00014789929,0.015678642,0.000024729214,0.0010323237,0.0007049504],"about_ca_topic_score_codex":0.004231403,"about_ca_topic_score_gemma":0.0010390646,"teacher_disagreement_score":0.28756857,"about_ca_system_score_codex":0.00040929238,"about_ca_system_score_gemma":0.001063213,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W3087865502","doi":"10.1016/j.annonc.2020.08.896","title":"637P The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; EMD Serono; Servier; Astellas Pharma; Constellation Pharmaceuticals; Clovis Oncology; Advanced Accelerator Applications; Endocyte; Invitae; Gilead Sciences; Genentech; Valeant Pharmaceuticals International; Bayer HealthCare; Sanofi; Active Biotech; Celgene; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Radium-223; Post-hoc analysis; Neutrophil to lymphocyte ratio; Internal medicine; Post hoc; Urology; Cancer; Overall survival","score_opus":0.060852168536440016,"score_gpt":0.38004750527603737,"score_spread":0.3191953367395973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087865502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688127,0.00091173395,0.000014984798,0.025606345,0.000111269546,0.004055142,0.00039763708,0.0000075797866,0.00008259555],"genre_scores_gemma":[0.99756444,0.00033347798,0.00010489736,0.0014499223,0.000065725806,0.00027996633,0.00007857104,0.000023538669,0.000099448545],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967526,0.00086558016,0.0009422836,0.00035966255,0.000696872,0.00038299404],"domain_scores_gemma":[0.9972292,0.0006260406,0.0007013536,0.00046055272,0.0008442487,0.00013858196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089245744,0.00023166966,0.0009575459,0.00020704845,0.000116826275,0.000012116999,0.00034548383,0.00006821347,0.000072618284],"category_scores_gemma":[0.0006519193,0.00010627764,0.0002810713,0.002251677,0.0003637148,0.0000787663,0.000107671636,0.00023801342,9.779452e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74218386,0.011351167,0.103731364,0.00095415383,0.01189405,0.00009763579,0.025960341,0.014242684,0.027505826,0.00028629645,0.0022362797,0.059556324],"study_design_scores_gemma":[0.347361,0.071381226,0.51792413,0.000952862,0.010369297,0.0000059991107,0.002248861,0.010048198,0.03542474,0.00007775295,0.0036423292,0.00056361203],"about_ca_topic_score_codex":0.0012355208,"about_ca_topic_score_gemma":0.0013834769,"teacher_disagreement_score":0.41419277,"about_ca_system_score_codex":0.00016619322,"about_ca_system_score_gemma":0.0020462524,"threshold_uncertainty_score":0.43338767},"labels":[],"label_agreement":null},{"id":"W3087872591","doi":"10.1016/j.annonc.2020.08.882","title":"623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; Genentech; EMD Serono; MorphoSys; PharmaMar; Astellas Pharma; Eisai; Pfizer; Incyte; BeiGene; Menarini Silicon Biosystems; Beth Israel Deaconess Medical Center; Astex Pharmaceuticals; Valeant Pharmaceuticals International; Advanced Accelerator Applications; Endocyte; Sierra Oncology; Genomic Health; Ipsen; Array BioPharma; Daiichi-Sankyo; Teva Pharmaceutical Industries; Exelixis; Sanofi; Merck; GlaxoSmithKline; Amgen; Jounce Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Internal medicine; Docetaxel; Oncology; Abiraterone; Chemotherapy; Cancer; Immunotherapy; Androgen receptor","score_opus":0.14206301833293994,"score_gpt":0.4476406662763026,"score_spread":0.3055776479433627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087872591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805003,0.00473325,0.000028200198,0.009894133,0.00009219585,0.0036693253,0.00081551046,0.00003239677,0.00023472417],"genre_scores_gemma":[0.99561644,0.0019022673,0.00037297703,0.0009853685,0.00008876865,0.00055091456,0.00012343616,0.000045598314,0.00031422198],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972284,0.00019568157,0.0009533201,0.0005783643,0.00048399591,0.00056024024],"domain_scores_gemma":[0.9978622,0.00029019834,0.0004923931,0.0003053204,0.00066412817,0.0003857323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005144245,0.00031439716,0.001290052,0.00019468366,0.00017946647,0.000016457048,0.00015300003,0.00010501982,0.000100111065],"category_scores_gemma":[0.00024482195,0.00025172418,0.00015364376,0.00034546762,0.00032088932,0.00011752424,0.0001254537,0.0002218571,0.0000017833188],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31685796,0.018400805,0.005388756,0.0061413962,0.008227462,0.0023312443,0.040340584,0.0006407969,0.39870378,0.0011111825,0.014724193,0.18713182],"study_design_scores_gemma":[0.24137302,0.4101464,0.016913865,0.00084428414,0.005106387,0.00011107256,0.016739491,0.0040841606,0.21223241,0.0017787635,0.08921676,0.0014533944],"about_ca_topic_score_codex":0.00071624253,"about_ca_topic_score_gemma":0.0007870888,"teacher_disagreement_score":0.3917456,"about_ca_system_score_codex":0.00013968424,"about_ca_system_score_gemma":0.0014140431,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W3087874008","doi":"10.1016/j.annonc.2020.08.1667","title":"1353P Clinical utility of circulating tumour (ct) DNA next generation sequencing (NGS) for target identification in diagnostic and acquired resistance settings in metastatic NSCLC (mNSCLC): Single centre experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"EMD Serono; European Society for Medical Oncology; Genomic Health; AstraZeneca; Celgene; Clovis Oncology; Ariad Pharmaceuticals; Chugai Pharmaceutical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Genotyping; Oncology; Internal medicine; Circulating tumor DNA; Cancer; Genotype; Gene; Genetics; Biology","score_opus":0.162938646370291,"score_gpt":0.3753820068373604,"score_spread":0.21244336046706938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087874008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946574,0.0013597613,0.0019390744,0.0014596055,0.000089312234,0.00038576688,0.00006277419,0.0000029326682,0.00004338869],"genre_scores_gemma":[0.9954746,0.00038993542,0.0032342758,0.0006446432,0.000096447264,0.00003194914,0.00011213353,0.000011821165,0.0000041901385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982891,0.00015772488,0.0008747382,0.0003982887,0.00007846105,0.00020170375],"domain_scores_gemma":[0.9986369,0.0005158284,0.00045273892,0.00015471647,0.00017022257,0.00006957311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007030811,0.00011020515,0.00033701328,0.000039435203,0.000030565123,0.000012798762,0.000116386276,0.000080224345,0.000004943122],"category_scores_gemma":[0.0063700294,0.00012804143,0.00006855364,0.00011091659,0.00013027062,0.000015320042,0.000068989146,0.000054844462,2.6965455e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000191407,0.00016067896,0.017174635,0.00014465679,0.0000193468,0.000011022322,0.0011806443,0.00028967287,0.97358537,0.0000763394,0.0005694877,0.006596744],"study_design_scores_gemma":[0.0025187237,0.0010096034,0.034336194,0.00014150412,0.00004314433,0.000006096964,0.002607087,0.015600351,0.93776125,0.00080878125,0.004809949,0.0003573432],"about_ca_topic_score_codex":0.00005071607,"about_ca_topic_score_gemma":0.00043946764,"teacher_disagreement_score":0.035824142,"about_ca_system_score_codex":0.00002403447,"about_ca_system_score_gemma":0.00021384619,"threshold_uncertainty_score":0.76259804},"labels":[],"label_agreement":null},{"id":"W3087874197","doi":"10.1016/j.annonc.2020.08.776","title":"704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck KGaA; Pfizer","keywords":"Medicine; Internal medicine; Avelumab; Randomization; Hazard ratio; Gastroenterology; Metastatic Urothelial Carcinoma; Clinical endpoint; Carboplatin; Urology; Bladder cancer; Chemotherapy; Randomized controlled trial; Oncology; Urothelial carcinoma; Cisplatin; Cancer; Nivolumab; Immunotherapy; Confidence interval","score_opus":0.10648387693519867,"score_gpt":0.39048951855980796,"score_spread":0.2840056416246093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087874197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.947446,0.0035228254,0.0048337975,0.034757834,0.0003357119,0.0030569714,0.0029816416,0.000120168545,0.0029450604],"genre_scores_gemma":[0.9797559,0.0011286744,0.0053653945,0.01136461,0.0007930568,0.00031093214,0.00064604566,0.000122021775,0.0005133959],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709475,0.000073380754,0.000762382,0.0008913345,0.00039352424,0.00078464765],"domain_scores_gemma":[0.9974133,0.00026646926,0.0004787487,0.00050225307,0.0009213526,0.0004178936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011352303,0.0005334639,0.0015665333,0.00012869823,0.00013968683,0.000014748303,0.00028395883,0.00030878957,0.0007309597],"category_scores_gemma":[0.00014582984,0.00042168723,0.0003839881,0.00034916485,0.00032444857,0.00014351198,0.00006416415,0.00029506176,0.00004826577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29191464,0.010523718,0.086965784,0.0022344242,0.014416044,0.0029266553,0.049708914,0.000775455,0.09908421,0.00027881176,0.06925187,0.37191948],"study_design_scores_gemma":[0.10825133,0.13701895,0.049138907,0.0006781237,0.0034081643,0.00014478998,0.008498989,0.0007566187,0.46253535,0.00072440435,0.2269829,0.0018614717],"about_ca_topic_score_codex":0.0017203237,"about_ca_topic_score_gemma":0.0013454948,"teacher_disagreement_score":0.370058,"about_ca_system_score_codex":0.00015726706,"about_ca_system_score_gemma":0.00087756343,"threshold_uncertainty_score":0.9998235},"labels":[],"label_agreement":null},{"id":"W3087883993","doi":"10.1016/j.annonc.2020.08.2252","title":"LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Internal medicine; Randomization; Cisplatin; Pembrolizumab; Population; Interim analysis; Oncology; Clinical endpoint; Urology; Metastatic Urothelial Carcinoma; Chemotherapy; Gastroenterology; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy","score_opus":0.06526797045284466,"score_gpt":0.3556039308716964,"score_spread":0.29033596041885174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087883993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90136284,0.0010617931,0.0004695773,0.090224944,0.00018649151,0.0025361173,0.00013300992,0.00010677427,0.0039184494],"genre_scores_gemma":[0.9656119,0.001665094,0.0010994447,0.030149454,0.00046369425,0.00030824268,0.00008517692,0.000096997705,0.0005200293],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809355,0.000057908437,0.00046966196,0.0005290382,0.0002974849,0.0005523359],"domain_scores_gemma":[0.99846035,0.00018428758,0.00025969266,0.00037029767,0.00039929856,0.00032608846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012511878,0.00036816386,0.0011069004,0.00008829407,0.000110263725,0.000009253895,0.00020557758,0.00022679588,0.00040851018],"category_scores_gemma":[0.000072460294,0.00028113014,0.00025518355,0.00024488752,0.00019688388,0.00008883028,0.000030163994,0.00020086035,0.00003386439],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.670207,0.0057604546,0.01769126,0.00059705274,0.0024425099,0.00040958633,0.0049928087,0.000119869015,0.023794891,0.0007317108,0.017562188,0.25569066],"study_design_scores_gemma":[0.15520898,0.28960297,0.015409674,0.000118219294,0.0002983683,0.0001776516,0.00018716317,0.00028665288,0.20334403,0.0010877019,0.33365178,0.0006267926],"about_ca_topic_score_codex":0.00021111015,"about_ca_topic_score_gemma":0.000072430965,"teacher_disagreement_score":0.514998,"about_ca_system_score_codex":0.000062110776,"about_ca_system_score_gemma":0.0006962919,"threshold_uncertainty_score":0.99996406},"labels":[],"label_agreement":null},{"id":"W3087905898","doi":"10.1016/j.annonc.2020.08.2239","title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Puma Biotechnology; Syndax Pharmaceuticals; F. Hoffmann-La Roche; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Cyclophosphamide; Breast cancer; Oncology; Triple-negative breast cancer; Chemotherapy; Phases of clinical research; Placebo; Neoadjuvant therapy; Doxorubicin; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Pembrolizumab","score_opus":0.16364009510904998,"score_gpt":0.48364156771962136,"score_spread":0.3200014726105714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087905898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585097,0.00037434712,0.000006980215,0.036881763,0.00014632913,0.0016725232,0.0009241092,0.000029761399,0.0014544906],"genre_scores_gemma":[0.99619985,0.0009107703,0.0001117271,0.0020850734,0.00031811188,0.00015598032,0.000030945324,0.000045030214,0.00014249916],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99643147,0.0004263084,0.0012576528,0.0006484994,0.0006798034,0.00055624667],"domain_scores_gemma":[0.99744695,0.00051064783,0.0005370513,0.00049451843,0.0006112172,0.0003996137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006359616,0.00027330068,0.0014351789,0.0002592247,0.000038558115,0.0000076141578,0.0003695549,0.000259071,0.0008524531],"category_scores_gemma":[0.00049272936,0.00022999266,0.00015510852,0.0008416207,0.00025741977,0.00010351144,0.00013858124,0.0006432803,0.00001843346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21990429,0.018366767,0.027301416,0.00019497314,0.0013037205,0.001802246,0.102199554,0.000057865935,0.03773342,0.000022540777,0.052419234,0.53869396],"study_design_scores_gemma":[0.29773235,0.091194116,0.5245763,0.00091012515,0.00019092893,0.0000439274,0.011763063,0.0013033866,0.05085581,0.0003289518,0.020456191,0.00064481725],"about_ca_topic_score_codex":0.036883574,"about_ca_topic_score_gemma":0.0021111856,"teacher_disagreement_score":0.53804916,"about_ca_system_score_codex":0.00021335753,"about_ca_system_score_gemma":0.0013870342,"threshold_uncertainty_score":0.9695299},"labels":[],"label_agreement":null},{"id":"W3087931875","doi":"10.1016/j.annonc.2020.08.1708","title":"1394P Deep learning model to predict clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Receiver operating characteristic; Hazard ratio; Internal medicine; Oncology; Machine learning; Progression-free survival; Cancer; Artificial intelligence; Overall survival; Confidence interval","score_opus":0.027858380045234825,"score_gpt":0.3607937644516039,"score_spread":0.33293538440636905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087931875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988398,0.00012893524,0.0016481661,0.007979333,0.00006304853,0.00068060856,0.0000038771195,0.000042174754,0.0010558157],"genre_scores_gemma":[0.99033624,0.0001340289,0.0056778654,0.0035149094,0.000075466494,0.0000497552,0.000025473657,0.00004753964,0.0001387259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805784,0.00011077398,0.00075514946,0.00041673743,0.00026129308,0.00039820667],"domain_scores_gemma":[0.99871624,0.00015853881,0.0003346724,0.00017639191,0.00023039333,0.00038378467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040376958,0.00022372352,0.0009795676,0.00012506757,0.00003892966,0.0000058616124,0.00014028112,0.00012632339,0.000024958068],"category_scores_gemma":[0.00042535708,0.00015619154,0.00011814396,0.00028754378,0.00011829549,0.00006145057,0.00008174125,0.0008588389,0.0000031548864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022972934,0.000551292,0.91671735,0.00010242884,0.0001313828,0.000046863956,0.0009771293,0.044779055,0.0003908118,0.0000013106591,0.00013944886,0.03386565],"study_design_scores_gemma":[0.01235536,0.010621423,0.8155739,0.00033361913,0.0001521311,0.0000018861102,0.00015566939,0.15863682,0.0009179518,0.0000023682162,0.0010091069,0.00023979263],"about_ca_topic_score_codex":0.00018748411,"about_ca_topic_score_gemma":0.000044258595,"teacher_disagreement_score":0.11385776,"about_ca_system_score_codex":0.000058840975,"about_ca_system_score_gemma":0.00027028765,"threshold_uncertainty_score":0.6369306},"labels":[],"label_agreement":null},{"id":"W3087935245","doi":"10.1016/j.annonc.2020.08.1034","title":"919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Surrogate endpoint; Cohort; Notch signaling pathway; Oncology; Cancer; Clinical trial; Gastroenterology; Receptor","score_opus":0.10302272381272812,"score_gpt":0.39178986244287056,"score_spread":0.2887671386301425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087935245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942537,0.0004454508,0.0000389256,0.0030541408,0.00010777397,0.0015103869,0.00008032983,0.000027351996,0.0004819687],"genre_scores_gemma":[0.9980951,0.000078574085,0.0008049044,0.0004030868,0.00018790567,0.0002711233,0.00012221161,0.000031684693,0.000005439836],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774534,0.0002836187,0.0008164614,0.00044016057,0.00031885746,0.00039558834],"domain_scores_gemma":[0.99742717,0.0011515943,0.0006264624,0.00021713137,0.00033347486,0.00024417852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003202519,0.00027704076,0.0010411097,0.0002703887,0.00007696458,0.00000782725,0.000104280305,0.0000902893,0.000052501615],"category_scores_gemma":[0.0016434402,0.00022664163,0.0001557573,0.00079450716,0.00011868695,0.00016641895,0.000063241445,0.0003331408,0.000003785377],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5034664,0.07359585,0.1548275,0.002981553,0.003806937,0.009434607,0.06278012,0.000474022,0.04566848,0.0007163461,0.002666688,0.13958144],"study_design_scores_gemma":[0.3667895,0.2569996,0.061215308,0.0013417482,0.0013341187,0.00026424028,0.003372273,0.0017794094,0.30519843,0.00028285175,0.0007182948,0.00070421776],"about_ca_topic_score_codex":0.00032882823,"about_ca_topic_score_gemma":0.00009976588,"teacher_disagreement_score":0.25952995,"about_ca_system_score_codex":0.00010431,"about_ca_system_score_gemma":0.0010369333,"threshold_uncertainty_score":0.92421776},"labels":[],"label_agreement":null},{"id":"W3087940728","doi":"10.1016/j.annonc.2020.08.1790","title":"1726P Expanding the role of medical oncologist in the management of COVID-19","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vifor Pharma; Astellas Pharma; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Betacoronavirus; Family medicine; Internal medicine; Virology; Outbreak","score_opus":0.31582084413965533,"score_gpt":0.5439608071145222,"score_spread":0.22813996297486688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087940728","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36801675,0.0014950205,0.00009955872,0.6189728,0.000066274566,0.0005749093,0.000009678329,0.000011166232,0.010753886],"genre_scores_gemma":[0.9342649,0.0018603788,0.00007241761,0.06367,0.00009246827,0.00001826337,0.0000042087386,0.000005634993,0.000011729724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821883,0.00029143278,0.0005547567,0.0001517396,0.00054601755,0.0002372378],"domain_scores_gemma":[0.99807984,0.0010876432,0.0002677736,0.00025197948,0.000078335965,0.0002344189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002207417,0.000087495326,0.00048079382,0.00007728628,0.000034863624,0.0000019038291,0.00038930544,0.00016616064,0.00023454888],"category_scores_gemma":[0.0012674133,0.00004948331,0.0001021023,0.00035018567,0.00033238844,0.000020920015,0.00013465219,0.00028320902,0.000004077033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062897936,0.0035126947,0.11341801,0.007956548,0.00087392767,0.001845229,0.0798744,0.0001352747,0.002723291,0.074227765,0.066418454,0.64272463],"study_design_scores_gemma":[0.004809122,0.010647976,0.102210686,0.00033839743,0.00016887957,0.00007301866,0.034012266,0.0002966908,0.0029471295,0.0038916282,0.8404692,0.0001350472],"about_ca_topic_score_codex":0.0014705876,"about_ca_topic_score_gemma":0.00037313634,"teacher_disagreement_score":0.7740507,"about_ca_system_score_codex":0.00006486873,"about_ca_system_score_gemma":0.0011587559,"threshold_uncertainty_score":0.25681457},"labels":[],"label_agreement":null},{"id":"W3087941421","doi":"10.1016/j.annonc.2020.08.1893","title":"1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Merck Sharp and Dohme; Eisai","keywords":"Medicine; Ifosfamide; Etoposide; Internal medicine; Lenvatinib; Surgery; Chemotherapy regimen; Gastroenterology; Chemotherapy; Oncology; Cancer","score_opus":0.0634064902655568,"score_gpt":0.37318824401076517,"score_spread":0.3097817537452084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087941421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865494,0.0014103397,0.00000298889,0.0055800024,0.000027191993,0.0063167745,0.00003227866,0.000011777495,0.00006928501],"genre_scores_gemma":[0.9970365,0.0012750969,0.00038544758,0.0010484536,0.000013885083,0.0001748671,0.000034253866,0.000026178526,0.000005298727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754316,0.0006171226,0.0007567624,0.0005442497,0.00025547645,0.00028324444],"domain_scores_gemma":[0.9978274,0.0011588312,0.0003757512,0.000249683,0.00016408613,0.00022422554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069250906,0.00030619814,0.0014268465,0.00017864726,0.000100783276,0.000022343767,0.00013301097,0.00007415705,0.000004532186],"category_scores_gemma":[0.0005945993,0.00018716928,0.000023828494,0.00029405046,0.00034614064,0.00014204989,0.00028084713,0.00027926933,3.5104142e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46528116,0.011463458,0.49875936,0.00010231958,0.00034232624,0.00015567204,0.00844168,0.000002766895,0.0001168369,0.000022907778,0.000062064006,0.015249431],"study_design_scores_gemma":[0.46972463,0.027800083,0.49878216,0.00076260127,0.00025077813,0.000048132995,0.0020901475,0.00014213359,0.00024590796,0.0000042976826,0.000027108868,0.00012202049],"about_ca_topic_score_codex":0.0013557174,"about_ca_topic_score_gemma":0.004282636,"teacher_disagreement_score":0.016336625,"about_ca_system_score_codex":0.00004723259,"about_ca_system_score_gemma":0.00011837212,"threshold_uncertainty_score":0.76325417},"labels":[],"label_agreement":null},{"id":"W3087953324","doi":"10.1016/j.annonc.2020.08.710","title":"596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; EMD Serono; Genentech; PharmaMar; Astellas Pharma; Eisai; MacroGenics; Juno Therapeutics; Incyte; Five Prime Therapeutics; bluebird bio; Daiichi Sankyo Europe; Halozyme; Aptitude Health; SymBio Pharmaceuticals Limited; AbbVie; Takeda Oncology; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Oncology; Phase (matter); Internal medicine; Radiology","score_opus":0.05534409063387729,"score_gpt":0.4102253372847152,"score_spread":0.3548812466508379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087953324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978102,0.000082106904,0.000037139616,0.0007242471,0.000009688445,0.0012578035,0.000013608047,0.000003969027,0.00006128074],"genre_scores_gemma":[0.99894947,0.00011090173,0.00014278195,0.000570143,0.00000865738,0.00011592399,0.000050870818,0.00003056435,0.000020669926],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9982971,0.00028842187,0.00048060494,0.00037424537,0.00025039885,0.00030920454],"domain_scores_gemma":[0.99914473,0.000053735777,0.00024520737,0.0002399689,0.00023746997,0.00007889759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032440093,0.00018208133,0.00051118963,0.00017974892,0.000023133149,0.000004874829,0.0002542555,0.00007888279,0.000041292376],"category_scores_gemma":[0.000084265936,0.00013421437,0.000029211018,0.00043423392,0.00012149565,0.000012933831,0.000046048604,0.00014781143,0.0000011238753],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5905371,0.05007935,0.16664223,0.00026026063,0.00064177037,0.00045599876,0.006998967,0.01569115,0.11257368,0.000022379289,0.00018965766,0.05590748],"study_design_scores_gemma":[0.09635732,0.6533447,0.039612513,0.0000993669,0.000024578027,0.0000033738465,0.0019957635,0.00025585695,0.20752946,0.000056788358,0.00035140236,0.0003688629],"about_ca_topic_score_codex":0.0001375984,"about_ca_topic_score_gemma":0.011086875,"teacher_disagreement_score":0.60326535,"about_ca_system_score_codex":0.000031123935,"about_ca_system_score_gemma":0.00036231833,"threshold_uncertainty_score":0.6186736},"labels":[],"label_agreement":null},{"id":"W3087957163","doi":"10.1016/j.annonc.2020.08.1419","title":"1217P Breathomics eNose technology as a non-invasive, inexpensive, point-of-care predictive test to detect early stage lung cancer in never or former light smokers","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Chemical Sensor Technologies","field":"Engineering","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Internal medicine; Wilcoxon signed-rank test; Cancer; Oncology; Mann–Whitney U test","score_opus":0.02097054915904558,"score_gpt":0.31575528831839494,"score_spread":0.2947847391593494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087957163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123335,0.0008311548,0.0005397876,0.0046735876,0.00009990808,0.00069688784,0.00018868092,0.00034728175,0.001389364],"genre_scores_gemma":[0.9948456,0.0012189514,0.0028923939,0.0007621161,0.000035816367,0.00014928263,0.0000039334045,0.000059720187,0.000032156615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838597,0.000014788381,0.00053363724,0.00038645384,0.00013988632,0.00053924625],"domain_scores_gemma":[0.998742,0.00036207255,0.00015673364,0.00031276885,0.00029700747,0.00012942721],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00003097217,0.00029593412,0.0007584355,0.00036278937,0.000022339014,0.00000450839,0.00045981613,0.00056605815,0.000058072],"category_scores_gemma":[0.0014368581,0.0002780973,0.00009082104,0.0009758639,0.00018947368,0.00021450175,0.00023903954,0.0004924438,0.000010406831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010310282,0.00008225747,0.013168131,0.0005237549,0.0002216068,0.00032680796,0.0040912214,0.015866945,0.9317419,0.00008377056,0.002704186,0.030158378],"study_design_scores_gemma":[0.00092520256,0.0031924574,0.0016062744,0.0001589274,0.000028317014,0.0000074058566,0.0025195635,0.0005288421,0.98358154,0.00022880461,0.0069179363,0.00030474566],"about_ca_topic_score_codex":0.00008717587,"about_ca_topic_score_gemma":0.00028502115,"teacher_disagreement_score":0.05183961,"about_ca_system_score_codex":0.00021303128,"about_ca_system_score_gemma":0.00009278589,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W3087963873","doi":"10.1016/j.annonc.2020.08.2299","title":"LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Adverse effect; Placebo; Neoadjuvant therapy; Esophageal cancer; Adjuvant therapy; Clinical endpoint; Interim analysis; Randomized controlled trial; Oncology; Gastroenterology; Surgery; Cancer; Breast cancer; Immunotherapy; Pathology","score_opus":0.12922410463672968,"score_gpt":0.411330702803153,"score_spread":0.2821065981664233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087963873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812131,0.0040110257,0.0000034276452,0.011946254,0.0002811271,0.0019568491,0.00006204313,0.00003712962,0.00048907165],"genre_scores_gemma":[0.99719256,0.0010950986,0.00007457956,0.00085711246,0.00024318548,0.00021105398,0.000033841774,0.0000346339,0.00025793858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698865,0.00038090945,0.0009083209,0.00051097653,0.0006765365,0.0005345756],"domain_scores_gemma":[0.99835086,0.00021839366,0.00046464414,0.00043438238,0.00029258343,0.00023913512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007052935,0.00026601326,0.00093908096,0.00017510523,0.00010667108,0.000010541749,0.00027732598,0.00015869079,0.00017157517],"category_scores_gemma":[0.0005096044,0.00017395744,0.00025781116,0.00091381,0.00012935938,0.00013789746,0.0001181778,0.0004388986,0.0000073625447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12676056,0.010326166,0.59783256,0.0005014401,0.0023051032,0.004162678,0.021384493,0.0015304846,0.00543345,0.000029554969,0.011246549,0.21848698],"study_design_scores_gemma":[0.04505064,0.040106915,0.8667859,0.00022741708,0.00015784323,0.000022290084,0.001070136,0.00089968933,0.044133373,0.000045108678,0.001315685,0.00018501653],"about_ca_topic_score_codex":0.0037209361,"about_ca_topic_score_gemma":0.0037857506,"teacher_disagreement_score":0.26895332,"about_ca_system_score_codex":0.0002915854,"about_ca_system_score_gemma":0.0010719817,"threshold_uncertainty_score":0.7093778},"labels":[],"label_agreement":null},{"id":"W3087964189","doi":"10.1016/j.annonc.2020.08.1544","title":"1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Placebo; Discontinuation; Quality of life (healthcare); Nausea; Clinical trial; Clinical endpoint; Pembrolizumab; Internal medicine; Cancer; Alternative medicine","score_opus":0.28409615093826407,"score_gpt":0.5052354451313433,"score_spread":0.22113929419307926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087964189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8065711,0.0033203538,0.0000522034,0.1863721,0.00007370506,0.0024818603,0.000112465365,0.000036413167,0.0009798023],"genre_scores_gemma":[0.9799604,0.0038948208,0.00073167996,0.01469564,0.00013093775,0.00024793146,0.0000299,0.00003555301,0.00027314326],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99691135,0.00037869057,0.0012782866,0.00047659784,0.00037825518,0.00057685183],"domain_scores_gemma":[0.9962684,0.0020470035,0.00047091465,0.0002889056,0.00042613765,0.00049865677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014319834,0.00024205763,0.0016544948,0.00020370477,0.00007620099,0.0000054974926,0.00018775633,0.00021659925,0.0001814634],"category_scores_gemma":[0.005644383,0.00019101899,0.00014155646,0.00047770323,0.00023848761,0.00006477005,0.00015653874,0.0003376032,0.0000083325485],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59563744,0.0030775666,0.035342097,0.0070490204,0.002609754,0.00016387829,0.041599154,0.00047944195,0.012947958,0.0018816121,0.16350377,0.13570829],"study_design_scores_gemma":[0.18272328,0.23496681,0.31409344,0.0015394351,0.00015399186,0.000087158674,0.004387699,0.0017621594,0.03522507,0.0030833124,0.22062822,0.0013494216],"about_ca_topic_score_codex":0.0020934,"about_ca_topic_score_gemma":0.0019354266,"teacher_disagreement_score":0.4129142,"about_ca_system_score_codex":0.000121535486,"about_ca_system_score_gemma":0.0015027047,"threshold_uncertainty_score":0.77895284},"labels":[],"label_agreement":null},{"id":"W3087971842","doi":"10.1016/j.annonc.2020.08.1006","title":"867P Patterns of recurrence after minimally invasive and open abdominal radical hysterectomy for cervical cancer: A propensity-matched analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Ipsen; Clovis Oncology; Regeneron Pharmaceuticals; GlaxoSmithKline; Louisiana State University; Spectrum Pharmaceuticals; Takeda Oncology; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; King Abdullah International Medical Research Center; U.S. Department of Defense","keywords":"Medicine; Propensity score matching; Cervical cancer; Radical Hysterectomy; Surgery; Hysterectomy; Population; Abdominal surgery; Retrospective cohort study; Cancer; Internal medicine","score_opus":0.14895588569543045,"score_gpt":0.4087221803885114,"score_spread":0.25976629469308093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087971842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97760665,0.000783843,0.000095712065,0.019781776,0.000047171918,0.0010652001,0.00023535856,0.000009957226,0.00037434828],"genre_scores_gemma":[0.9930755,0.00056934817,0.0011842804,0.0047200057,0.00010671082,0.000268979,0.000033361477,0.00001416966,0.000027676311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985749,0.000120283126,0.0005075492,0.00037623555,0.0001872874,0.0002337589],"domain_scores_gemma":[0.9985154,0.00044239155,0.0002727691,0.00015439578,0.0003264344,0.00028859006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022294234,0.00015435803,0.0014022266,0.00012255482,0.00001910894,0.0000099181125,0.00020594688,0.0001343092,0.00029486747],"category_scores_gemma":[0.00034544666,0.000116624804,0.00022661945,0.0004805606,0.00013753172,0.00007469261,0.0002183208,0.00012025205,0.0000017772869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05024221,0.0015779318,0.7723651,0.0019264529,0.0050654807,0.0002101157,0.0020258874,0.0000025477189,0.005232631,0.00007245333,0.0009777829,0.16030139],"study_design_scores_gemma":[0.024533713,0.032364473,0.87444496,0.0004848156,0.005659236,0.000029813422,0.00039702808,0.00023368897,0.047456156,0.00034928197,0.013627443,0.00041936772],"about_ca_topic_score_codex":0.00071040686,"about_ca_topic_score_gemma":0.00072642404,"teacher_disagreement_score":0.15988202,"about_ca_system_score_codex":0.000032687778,"about_ca_system_score_gemma":0.0003758585,"threshold_uncertainty_score":0.47558215},"labels":[],"label_agreement":null},{"id":"W3087982127","doi":"10.1016/j.annonc.2020.08.395","title":"293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Capecitabine; Progression-free survival; Breast cancer; Oncology; Placebo; Gastroenterology; Surgery; Chemotherapy; Cancer; Pathology; Colorectal cancer","score_opus":0.0832211955087731,"score_gpt":0.4223984253781959,"score_spread":0.3391772298694228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087982127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988066,0.00018654752,0.0000051922398,0.009200345,0.000023484152,0.0007438991,0.0015888643,0.000007962874,0.00017769924],"genre_scores_gemma":[0.9979668,0.000082244915,0.0009219177,0.0008350356,0.000021287442,0.000048187638,0.00008880893,0.000020219493,0.000015452968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986011,0.0002509253,0.00033379463,0.00027187855,0.00028402597,0.0002582741],"domain_scores_gemma":[0.99862134,0.0004568213,0.00030915972,0.00020219247,0.00021626556,0.00019423802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027566933,0.00019407384,0.0008242353,0.00010510364,0.000021368198,0.0000037387872,0.00007471558,0.00004788153,0.0003244684],"category_scores_gemma":[0.0002577396,0.00010860124,0.000085053354,0.00028797422,0.00013689706,0.00008267653,0.000054172455,0.00013331283,0.0000011445969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057707235,0.0093965065,0.58476,0.000508334,0.0028145092,0.00022029936,0.0020187239,0.00011697742,0.00024286495,0.0001303021,0.0059699016,0.33611435],"study_design_scores_gemma":[0.011590971,0.03869872,0.94676113,0.00024783105,0.00025391162,0.000011389906,0.00029317074,0.000023440962,0.0014949936,0.000049450715,0.00045786044,0.00011711984],"about_ca_topic_score_codex":0.0012371592,"about_ca_topic_score_gemma":0.00040892512,"teacher_disagreement_score":0.36200112,"about_ca_system_score_codex":0.00006039528,"about_ca_system_score_gemma":0.00050004496,"threshold_uncertainty_score":0.442863},"labels":[],"label_agreement":null},{"id":"W3087985540","doi":"10.1016/j.annonc.2020.08.819","title":"747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme","keywords":"Medicine; Docetaxel; Internal medicine; Oncology; Pembrolizumab; Clinical trial; Cancer; Immunotherapy","score_opus":0.03333975512778601,"score_gpt":0.3257186515375333,"score_spread":0.2923788964097473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087985540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921217,0.00029176412,0.00001448622,0.0042809686,0.00006300885,0.0007020131,0.0006310733,0.000014563697,0.0018804318],"genre_scores_gemma":[0.99759007,0.00045393858,0.000541356,0.001123198,0.000083826795,0.000026889527,0.000084763065,0.00002936698,0.00006660331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821544,0.00011988043,0.0006098679,0.00038417752,0.0004017081,0.00026892],"domain_scores_gemma":[0.9982138,0.0003060662,0.00070170464,0.00021169914,0.00042645258,0.00014026422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001316532,0.00020912978,0.0009040382,0.00010008478,0.000021641034,0.0000027569379,0.00009839412,0.0001849309,0.00004993058],"category_scores_gemma":[0.00028816404,0.0001595783,0.0000661527,0.00028040493,0.00013200159,0.00009291829,0.000038818398,0.00019168979,0.0000020051575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24277686,0.003408185,0.63013846,0.00031827315,0.0013287321,0.000049321814,0.007889643,0.00044706374,0.006302424,0.00003175031,0.0015975448,0.10571177],"study_design_scores_gemma":[0.091257945,0.027120702,0.84407705,0.00042439275,0.00036020784,0.000001592759,0.00020041708,0.00005398373,0.033077348,0.000038381975,0.003178598,0.00020936041],"about_ca_topic_score_codex":0.00258462,"about_ca_topic_score_gemma":0.0006660546,"teacher_disagreement_score":0.21393864,"about_ca_system_score_codex":0.00011842524,"about_ca_system_score_gemma":0.00050997804,"threshold_uncertainty_score":0.6507414},"labels":[],"label_agreement":null},{"id":"W3087988414","doi":"10.1016/j.annonc.2020.08.952","title":"813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Chemotherapy; Internal medicine; Placebo; Progression-free survival; Oncology; Ovarian cancer; Gastroenterology; Surgery; Cancer; Pathology","score_opus":0.09531459648497898,"score_gpt":0.3987324027835507,"score_spread":0.30341780629857174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087988414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96513283,0.00011826761,0.00018106493,0.028875625,0.00053292426,0.004275845,0.0003586142,0.00004721901,0.00047758396],"genre_scores_gemma":[0.99120975,0.00014818386,0.00068948645,0.006538175,0.0007943457,0.00040644477,0.00013354329,0.000057767564,0.000022306187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975985,0.00029496508,0.0007617443,0.00046092935,0.00045246494,0.00043138544],"domain_scores_gemma":[0.9970013,0.0008377727,0.0009199813,0.00029335366,0.00078116095,0.00016647024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000483133,0.0002996047,0.0009302592,0.00009315905,0.00011153046,0.000011103828,0.00016784284,0.00021951944,0.00011880471],"category_scores_gemma":[0.00031506224,0.00020268555,0.0002231596,0.00029401298,0.0004464385,0.00005787749,0.000026438349,0.00035812837,0.0000039011456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8171312,0.0030811713,0.0011298441,0.00016140098,0.0011457105,0.000019325955,0.007057875,0.00018259787,0.0067566116,0.00023588978,0.006724704,0.15637363],"study_design_scores_gemma":[0.48539773,0.110036924,0.015066721,0.0012153481,0.00041893215,0.000015067556,0.00037409013,0.00092672504,0.33412692,0.00017580533,0.051642057,0.00060368155],"about_ca_topic_score_codex":0.0000657331,"about_ca_topic_score_gemma":0.000022826829,"teacher_disagreement_score":0.3317335,"about_ca_system_score_codex":0.0001541096,"about_ca_system_score_gemma":0.000778643,"threshold_uncertainty_score":0.8265277},"labels":[],"label_agreement":null},{"id":"W3088012427","doi":"10.1016/j.annonc.2020.08.1206","title":"1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Regimen; Oncology; Cancer; Immunotherapy","score_opus":0.08697317739299981,"score_gpt":0.3589568587274751,"score_spread":0.2719836813344753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088012427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265176,0.000042861866,0.000024192494,0.0046711494,0.00005260025,0.0010064405,0.000110601046,0.000026072677,0.0014143392],"genre_scores_gemma":[0.9965532,0.00032914052,0.00036009905,0.0011124727,0.00006684042,0.00003052829,0.00019420944,0.000044074754,0.0013094797],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99786353,0.00035841836,0.00059481116,0.000367069,0.0004438512,0.00037229861],"domain_scores_gemma":[0.9982285,0.00029286914,0.00034937492,0.00033744963,0.0006177713,0.00017401877],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030747193,0.00018716611,0.0009767519,0.0002635883,0.00003089221,0.000004820774,0.00019546687,0.00016837382,0.0012705316],"category_scores_gemma":[0.00041569403,0.00015573045,0.00007875808,0.00059365656,0.00023925558,0.00012665564,0.00008448691,0.00026974073,0.000018232473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32738793,0.0013024717,0.09232768,0.00040988266,0.0003190831,0.00015292129,0.0031880843,0.000027072576,0.495423,0.00003349687,0.00062963745,0.07879876],"study_design_scores_gemma":[0.03897931,0.048407204,0.8226659,0.0003391322,0.000053006148,0.000012510274,0.00032547358,0.00030904618,0.05185803,0.000015841948,0.036750652,0.0002838334],"about_ca_topic_score_codex":0.00006732077,"about_ca_topic_score_gemma":0.00009352853,"teacher_disagreement_score":0.7303383,"about_ca_system_score_codex":0.000118281154,"about_ca_system_score_gemma":0.0005994695,"threshold_uncertainty_score":0.99964243},"labels":[],"label_agreement":null},{"id":"W3088030098","doi":"10.1016/j.annonc.2020.08.006","title":"888MO Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Meta-analysis; Oncology; Confidence interval; Publication bias; Funnel plot; Adverse effect; Antibody-drug conjugate; Observational study; Lymphoma; Hodgkin lymphoma; Immunology; Monoclonal antibody","score_opus":0.16447647763766812,"score_gpt":0.43175853601136466,"score_spread":0.26728205837369656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088030098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006063829,0.9946242,0.0000014285459,0.0005538782,0.00003770183,0.0041898275,0.00012051813,0.000020363743,0.00039146113],"genre_scores_gemma":[0.0036554716,0.99408793,0.000051296836,0.00048522427,0.000014575712,0.0015068818,0.00010766204,0.000055231227,0.00003570565],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9931363,0.0031777837,0.0023312666,0.00069858064,0.00034866936,0.00030742312],"domain_scores_gemma":[0.9935321,0.0030949307,0.002181048,0.00075856113,0.00024349541,0.00018985293],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020139392,0.00062147324,0.024918022,0.00064799143,0.000016271892,0.000005718269,0.00022495205,0.0004863947,0.00006274558],"category_scores_gemma":[0.00082181056,0.00039154897,0.0040199393,0.0013512075,0.00016002975,0.000036985908,0.00013503796,0.00020077372,0.000017617484],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050561997,0.0018887302,0.0000277782,0.7904589,0.16655849,0.0003229671,0.000028912034,1.4349277e-7,2.1605022e-7,0.000094851275,0.00017832601,0.04039011],"study_design_scores_gemma":[0.0017413183,0.0021946453,0.00024577335,0.08714793,0.8234946,0.00013788372,0.000008266641,0.000001099038,0.0000053179538,0.000015668034,0.08478397,0.00022349117],"about_ca_topic_score_codex":0.00011876738,"about_ca_topic_score_gemma":0.000028250435,"teacher_disagreement_score":0.70331097,"about_ca_system_score_codex":0.00031170293,"about_ca_system_score_gemma":0.0009588848,"threshold_uncertainty_score":0.9998536},"labels":[],"label_agreement":null},{"id":"W3088071834","doi":"10.1016/j.annonc.2020.08.1528","title":"1881P Deterioration of sexual health of cancer survivors 5 years after diagnosis – French national cohort VICAN","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Cancer; Prostate cancer; Cohort; Multivariate analysis; Demography; Prospective cohort study; Gerontology; Internal medicine","score_opus":0.3097154405000849,"score_gpt":0.5680222499593975,"score_spread":0.2583068094593126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088071834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540132,0.00086971174,0.000017663018,0.042295028,0.0004381544,0.0005865134,0.00032296876,0.000011005314,0.0014457488],"genre_scores_gemma":[0.9920835,0.0008466482,0.0001975881,0.006240947,0.00026112606,0.0002634086,0.000021513302,0.0000120916775,0.00007321428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966662,0.0015215056,0.0010304111,0.00019730406,0.0003248677,0.00025970882],"domain_scores_gemma":[0.9966452,0.0010830885,0.0012319875,0.00011867175,0.00075896666,0.00016208834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018467172,0.000087159926,0.0005625226,0.00008595107,0.000065527674,0.0000012376222,0.000110754896,0.00020564342,0.000843629],"category_scores_gemma":[0.00061228103,0.000083434825,0.000040908486,0.00024381743,0.00007743496,0.00011314014,0.000051334348,0.0002579594,0.000014975972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016211878,0.00012952602,0.932206,0.0012198761,0.00008787115,0.0000023821638,0.010002654,0.000011208852,0.00026263943,0.00020242271,0.019818865,0.035894457],"study_design_scores_gemma":[0.00028641737,0.0019790397,0.771834,0.00010216832,0.000010854304,3.1701575e-7,0.0010557465,0.000023867377,0.000080105856,0.000052112002,0.2245075,0.00006784201],"about_ca_topic_score_codex":0.048682146,"about_ca_topic_score_gemma":0.045039438,"teacher_disagreement_score":0.20468864,"about_ca_system_score_codex":0.00007124593,"about_ca_system_score_gemma":0.0025212425,"threshold_uncertainty_score":0.9723861},"labels":[],"label_agreement":null},{"id":"W3088074831","doi":"10.1016/j.annonc.2020.08.062","title":"253P Preliminary report on survival outcomes of BRCA mutation carriers with triple-negative breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Triple-negative breast cancer; Confidence interval; BRCA mutation; Internal medicine; Breast cancer; Oncology; Genetic testing; Exact test; Germline mutation; Cancer; Germline; Mutation; Genetics; Gene","score_opus":0.0471911145993293,"score_gpt":0.36513959087069775,"score_spread":0.31794847627136846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088074831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98324794,0.00018535156,0.00026238954,0.012108393,0.00024954925,0.0002860879,0.00027613234,0.000009060492,0.0033751125],"genre_scores_gemma":[0.99746084,0.00011332421,0.00054684235,0.0013804077,0.00012256356,0.00005510283,0.00008001032,0.00002067154,0.00022024868],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888074,0.00010569166,0.0003485239,0.00032513018,0.0001757806,0.00016413636],"domain_scores_gemma":[0.99876803,0.0000639518,0.000413777,0.00023328405,0.00044054922,0.00008040272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016830933,0.00013920832,0.00033989106,0.000043449774,0.00003145732,0.0000026405285,0.00014353395,0.00015141028,0.00005063402],"category_scores_gemma":[0.0002242996,0.00011991846,0.000090502166,0.00015256119,0.00022147503,0.0000056600516,0.000048892187,0.0000894259,0.0000017820577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03465585,0.0019782826,0.38080883,0.0006012561,0.006585234,0.0008619514,0.010312035,0.036952145,0.23112452,0.00086897245,0.1056305,0.18962042],"study_design_scores_gemma":[0.003849876,0.014744904,0.33504477,0.000046151654,0.00017748395,0.00019052195,0.001612242,0.00012199777,0.62455064,0.00015175353,0.019058287,0.0004513777],"about_ca_topic_score_codex":0.00015160907,"about_ca_topic_score_gemma":0.00014610267,"teacher_disagreement_score":0.39342612,"about_ca_system_score_codex":0.00003337535,"about_ca_system_score_gemma":0.0007584344,"threshold_uncertainty_score":0.4890133},"labels":[],"label_agreement":null},{"id":"W3088108259","doi":"10.1016/j.annonc.2020.08.1062","title":"947P Association between genetic variants and cisplatin nephrotoxicity: A genome-wide approach","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Single-nucleotide polymorphism; Minor allele frequency; Medicine; Nephrotoxicity; Genotyping; Common Terminology Criteria for Adverse Events; Genome-wide association study; Genotype; SNP; Oncology; Internal medicine; Bioinformatics; Genetics; Cancer; Biology; Gene; Kidney","score_opus":0.08163299428443861,"score_gpt":0.3310502437180774,"score_spread":0.2494172494336388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088108259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700662,0.00012959426,0.0016430801,0.024715157,0.000020363324,0.0005590461,0.000019763942,0.000042145584,0.0028046542],"genre_scores_gemma":[0.98287815,0.00014096701,0.00672799,0.009731917,0.0003572072,0.000013394302,0.00004469251,0.000027051576,0.00007862819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998681,0.00012661226,0.0004076643,0.00029241285,0.0002400186,0.0002522838],"domain_scores_gemma":[0.99888945,0.00026437704,0.00033525543,0.00014589293,0.00015673095,0.00020826892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003425164,0.00013862806,0.0005393688,0.00008271237,0.00004163871,0.000009298996,0.000080578226,0.0003054289,0.00007956832],"category_scores_gemma":[0.00066005206,0.00014420375,0.00006871802,0.00025079522,0.000058378282,0.00006397905,0.00004823648,0.00023862273,0.000019307781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034247048,0.00042221422,0.47014636,0.0003515591,0.00084255915,0.00003265254,0.0050088377,0.000019281737,0.46575147,0.00007415039,0.0046715676,0.052336864],"study_design_scores_gemma":[0.0026475454,0.002685909,0.9049788,0.00002125333,0.00017546657,0.000018919061,0.00014392383,0.00048541598,0.08177699,0.00050522404,0.006378734,0.00018180779],"about_ca_topic_score_codex":0.000021816028,"about_ca_topic_score_gemma":0.0000030222277,"teacher_disagreement_score":0.43483245,"about_ca_system_score_codex":0.0000884606,"about_ca_system_score_gemma":0.00016864312,"threshold_uncertainty_score":0.58804584},"labels":[],"label_agreement":null},{"id":"W3088110133","doi":"10.1016/j.annonc.2020.08.1601","title":"1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Oncology; Internal medicine; Cancer research; Cancer; Adenocarcinoma","score_opus":0.03654913715870304,"score_gpt":0.40692508686977535,"score_spread":0.3703759497110723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088110133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909941,0.00041192706,0.0007493572,0.005386045,0.000030832693,0.0005008923,0.00011683547,0.000026454269,0.0017835383],"genre_scores_gemma":[0.9961836,0.0003152077,0.0017145909,0.0012881206,0.000011610819,0.000010153163,0.00042750564,0.000012286356,0.00003695697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99890906,0.00013352116,0.00044256123,0.00024822503,0.00010873235,0.0001579273],"domain_scores_gemma":[0.9990732,0.00015127822,0.00020227647,0.00012797362,0.00028979394,0.0001554876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012526663,0.0001201035,0.0006560195,0.00020996736,0.000020380552,0.0000027687895,0.000052714196,0.00006328085,0.0001557972],"category_scores_gemma":[0.0001337519,0.00009656534,0.000079023754,0.00091493904,0.00011016873,0.00007340646,0.000026641514,0.00011643109,0.0000018910731],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018685428,0.005534834,0.05058206,0.00015180389,0.00782588,0.00043990812,0.018879313,0.0037176842,0.02493575,0.00056510215,0.0012306501,0.8674516],"study_design_scores_gemma":[0.040618863,0.041699536,0.8403704,0.00042738643,0.008343043,0.00005012227,0.009480115,0.009131174,0.03216332,0.0002976185,0.01685549,0.0005629093],"about_ca_topic_score_codex":0.000280174,"about_ca_topic_score_gemma":0.00026924605,"teacher_disagreement_score":0.8668887,"about_ca_system_score_codex":0.000040751842,"about_ca_system_score_gemma":0.00029735453,"threshold_uncertainty_score":0.39378202},"labels":[],"label_agreement":null},{"id":"W3088134494","doi":"10.1016/j.annonc.2020.08.1004","title":"865P A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Ipsen; Clovis Oncology; Regeneron Pharmaceuticals; GlaxoSmithKline; Louisiana State University; Spectrum Pharmaceuticals; Takeda Oncology; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; King Abdullah International Medical Research Center; U.S. Department of Defense","keywords":"Medicine; Internal medicine; Progressive disease; Clinical endpoint; Oncology; Chemotherapy; Cancer; Response Evaluation Criteria in Solid Tumors; Cervical cancer; Adenosquamous carcinoma; Gastroenterology; Progression-free survival; Adenocarcinoma; Clinical trial","score_opus":0.1653421335762386,"score_gpt":0.44790414556087155,"score_spread":0.28256201198463293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088134494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921961,0.00072202634,0.000023633045,0.0047304253,0.00015608511,0.001759354,0.00021779972,0.000016627435,0.00017798187],"genre_scores_gemma":[0.9969605,0.0002001148,0.0002540042,0.0021891282,0.000075580385,0.00016042992,0.000047405472,0.000024397643,0.000088446126],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985269,0.00009196593,0.00056198635,0.00031300847,0.0002491003,0.0002570389],"domain_scores_gemma":[0.9986583,0.00014849791,0.00039524605,0.00019287462,0.00046273338,0.00014234158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001856395,0.00019391431,0.0008586035,0.000087870125,0.000060035192,0.000003273869,0.00013863074,0.00006260837,0.0002634168],"category_scores_gemma":[0.00015819378,0.0001223589,0.00022396226,0.0003761931,0.00014076187,0.00005835883,0.00005166553,0.00011750325,9.475361e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48933607,0.078513205,0.018941717,0.0015248065,0.0055645723,0.000062684114,0.02415953,0.000021631076,0.0021683022,0.0000061969613,0.012583145,0.36711812],"study_design_scores_gemma":[0.2712831,0.6525399,0.014520511,0.00026017585,0.0015538192,0.000022869892,0.006473841,0.0011575212,0.0010861275,0.000008303638,0.050721824,0.0003720238],"about_ca_topic_score_codex":0.00024105421,"about_ca_topic_score_gemma":0.00057207164,"teacher_disagreement_score":0.5740267,"about_ca_system_score_codex":0.000058263297,"about_ca_system_score_gemma":0.000458964,"threshold_uncertainty_score":0.4989651},"labels":[],"label_agreement":null},{"id":"W3088144056","doi":"10.1016/j.annonc.2020.08.2282","title":"LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Internal medicine; Interim analysis; Lung cancer; Clinical endpoint; ALK inhibitor; Oncology; Discontinuation; Adverse effect; Progression-free survival; Randomized controlled trial; Overall survival","score_opus":0.04310889108180626,"score_gpt":0.4027122095319315,"score_spread":0.3596033184501252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088144056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839956,0.00035867223,0.000012553661,0.0078809755,0.000077574085,0.0029986897,0.00044511785,0.0000058924006,0.004224892],"genre_scores_gemma":[0.9979452,0.00024783378,0.000097903634,0.0012166337,0.000050267576,0.00024793323,0.00006586887,0.000016723054,0.00011166057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985429,0.000115222465,0.0006119665,0.00028439524,0.00023460774,0.00021089955],"domain_scores_gemma":[0.9984138,0.00024527314,0.000567997,0.0003151992,0.00038985343,0.00006786618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011190685,0.00019204886,0.00063326705,0.000058371497,0.000059583057,0.0000026548994,0.00014969904,0.00006155605,0.0000237078],"category_scores_gemma":[0.000046304907,0.00009861294,0.00011437142,0.0003511859,0.00012936944,0.00004541908,0.00003433012,0.00009885698,6.6452094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09568713,0.08272744,0.3929923,0.000515542,0.0030453817,0.0002159048,0.27973825,0.0031102882,0.0012240056,0.00003079878,0.0042917593,0.1364212],"study_design_scores_gemma":[0.22198623,0.19512267,0.51767606,0.00055194384,0.0026694182,0.0000039998326,0.008773792,0.00044319982,0.039181586,0.000010993408,0.013273163,0.00030691206],"about_ca_topic_score_codex":0.0012349129,"about_ca_topic_score_gemma":0.0015305608,"teacher_disagreement_score":0.27096447,"about_ca_system_score_codex":0.00009907591,"about_ca_system_score_gemma":0.00046384655,"threshold_uncertainty_score":0.4021319},"labels":[],"label_agreement":null},{"id":"W3088146375","doi":"10.1016/j.annonc.2020.08.982","title":"843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"; Rockefeller University; Yale University; University College London; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Oncology; Gynecology; Cancer; Internal medicine; Immunotherapy","score_opus":0.029549381658524606,"score_gpt":0.3316080822242081,"score_spread":0.3020587005656835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088146375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933256,0.0006772429,0.000011396001,0.009096358,0.000047620804,0.00061101286,0.000028037413,0.000007303042,0.00018847334],"genre_scores_gemma":[0.99708945,0.0003198896,0.0004023062,0.002031218,0.000030026627,0.000052051248,0.000012169059,0.000014266612,0.000048625316],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986051,0.00027323206,0.00038749783,0.00025551402,0.00026736184,0.00021133928],"domain_scores_gemma":[0.99908864,0.00018746388,0.00030891574,0.00011817066,0.00020307445,0.00009371416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044562735,0.00013389341,0.000522256,0.0002005114,0.00001721902,0.0000033507388,0.00007000413,0.00017179153,0.000052344632],"category_scores_gemma":[0.00020273782,0.00009825317,0.000036997044,0.00040066068,0.0000462616,0.00005101806,0.00002619081,0.00018333372,4.3222894e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59154105,0.000775475,0.21705432,0.00012146835,0.00016282822,0.000028899512,0.0053127543,0.00012177773,0.15393037,0.0000028696268,0.0021468797,0.028801298],"study_design_scores_gemma":[0.033356197,0.020345934,0.89492065,0.00051456067,0.000035368797,0.0000018642766,0.00019721106,0.00003716865,0.044994257,0.000005651197,0.0054406957,0.00015046551],"about_ca_topic_score_codex":0.00033818706,"about_ca_topic_score_gemma":0.0006318634,"teacher_disagreement_score":0.67786634,"about_ca_system_score_codex":0.00019161784,"about_ca_system_score_gemma":0.00037674786,"threshold_uncertainty_score":0.4006648},"labels":[],"label_agreement":null},{"id":"W3088150228","doi":"10.1016/j.annonc.2020.08.828","title":"756P Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Cohort; Urology; Internal medicine; Oncology; Pembrolizumab; Carcinoma; Gastroenterology; Cancer; Immunotherapy","score_opus":0.10513952919844959,"score_gpt":0.39421539383965803,"score_spread":0.28907586464120844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088150228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98152226,0.008802951,0.00011628999,0.007898487,0.00020307045,0.0009681167,0.00020634843,0.000023987352,0.00025848334],"genre_scores_gemma":[0.9957499,0.0009257897,0.00058248214,0.0022463026,0.00022454943,0.000050281364,0.00014994593,0.00004299192,0.000027766602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976974,0.00017816028,0.0010601525,0.00047577886,0.00022483796,0.00036363452],"domain_scores_gemma":[0.99857897,0.0002204362,0.00047423327,0.00023148251,0.0002565675,0.00023831795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004778637,0.00026436368,0.001090936,0.00011294827,0.000070635666,0.000014115929,0.00009002611,0.00032910614,0.000065016415],"category_scores_gemma":[0.0003199052,0.00023634778,0.00028062382,0.00012850536,0.00034064168,0.00007897408,0.00011930931,0.0002497205,0.0000036733409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005011317,0.0008184028,0.008277394,0.00039936232,0.0008220534,0.00020664984,0.0009192582,0.0000060434945,0.97756577,0.00023992104,0.00040284643,0.0053310026],"study_design_scores_gemma":[0.008983887,0.011384973,0.072427474,0.0001081858,0.0005662504,0.000084649975,0.00021641982,0.00007106071,0.9039347,0.00094433763,0.0010723306,0.00020569704],"about_ca_topic_score_codex":0.0006637478,"about_ca_topic_score_gemma":0.000036405887,"teacher_disagreement_score":0.07363102,"about_ca_system_score_codex":0.00002893544,"about_ca_system_score_gemma":0.0003076058,"threshold_uncertainty_score":0.9637983},"labels":[],"label_agreement":null},{"id":"W3088153386","doi":"10.1016/j.annonc.2020.08.879","title":"620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Cohort; Prednisone; Abiraterone acetate; Internal medicine; Urology; Cancer; Oncology; Surgery; Androgen deprivation therapy; Androgen receptor","score_opus":0.06855141656529057,"score_gpt":0.3665041529986613,"score_spread":0.2979527364333707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088153386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869869,0.0019461034,0.000009848366,0.007571738,0.00005284798,0.0024953766,0.000419868,0.000050365477,0.0004669528],"genre_scores_gemma":[0.9935681,0.0033303068,0.00051560835,0.001199225,0.000038431113,0.00033831783,0.00030811326,0.00005994039,0.00064194214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969426,0.00025033666,0.0007789748,0.0006914994,0.00054480735,0.00079177646],"domain_scores_gemma":[0.99821544,0.00012843596,0.00036893462,0.00029682578,0.0005582121,0.00043217166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032290016,0.0004077569,0.0012066221,0.0001976748,0.00009916366,0.000034043172,0.00015027633,0.00014085403,0.0002263787],"category_scores_gemma":[0.00012277467,0.00027332915,0.000072938245,0.00062938343,0.00041946798,0.00027584104,0.000107086984,0.00036229484,0.000014958726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33820876,0.0031177595,0.5797699,0.002723406,0.0040807733,0.002613849,0.007913529,0.000991129,0.0119088935,0.00010873937,0.0034418555,0.04512138],"study_design_scores_gemma":[0.09484777,0.031642877,0.8421506,0.00065497163,0.0009684166,0.0000519067,0.00059173,0.0013011467,0.022557393,0.00010310856,0.004377712,0.00075234484],"about_ca_topic_score_codex":0.000832494,"about_ca_topic_score_gemma":0.0009391224,"teacher_disagreement_score":0.26238072,"about_ca_system_score_codex":0.00025626904,"about_ca_system_score_gemma":0.0014387047,"threshold_uncertainty_score":0.99997187},"labels":[],"label_agreement":null},{"id":"W3088154109","doi":"10.1016/j.annonc.2020.08.519","title":"408P A prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Foundation Medicine; Chugai Pharmaceutical; Pfizer Japan; Novartis Pharma; Genentech; Eli Lilly and Company; Ono Pharmaceutical; Yakult Honsha; Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; FibroGen; Astellas Pharma; Les Laboratories Pierre Fabre; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; BeiGene; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; Bristol-Myers Squibb; INCLIVA Instituto de Investigación Sanitaria; GlaxoSmithKline","keywords":"Medicine; Hazard ratio; Internal medicine; Randomization; Tegafur; Clinical endpoint; Propensity score matching; Gastroenterology; Surgery; Colorectal cancer; Confidence interval; Randomized controlled trial; Regimen; Chemotherapy; Cancer","score_opus":0.2526387887178259,"score_gpt":0.4609450428407273,"score_spread":0.20830625412290138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088154109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988895,0.0004233837,0.0005969317,0.0013666805,0.00012349196,0.008202681,0.00029355806,0.0000069558396,0.00009132153],"genre_scores_gemma":[0.9961615,0.00011611391,0.0029807347,0.00012100101,0.000058805224,0.00050921354,0.000003136422,0.000011665402,0.000037834743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99881554,0.00018446933,0.00040312854,0.00026980534,0.00014288381,0.00018420622],"domain_scores_gemma":[0.99707603,0.0012834191,0.0007668674,0.00013170984,0.00067871506,0.00006324395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004734361,0.00016515015,0.0012665763,0.00003873166,0.00013492037,0.0000026171695,0.00007185446,0.000079292884,0.000006823774],"category_scores_gemma":[0.0017640592,0.00008845955,0.00020087295,0.00017032516,0.00034573174,0.000030869727,0.000054305405,0.00010368064,1.1677798e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8665519,0.0014648132,0.10269491,0.00046673956,0.0016418719,0.0000017977621,0.0039638686,0.00017724464,0.004777549,0.000100210826,0.00011404266,0.018045057],"study_design_scores_gemma":[0.57750785,0.15097886,0.114663005,0.00039072335,0.0028240774,0.000001825375,0.0009077939,0.0023899856,0.14685969,0.00011047115,0.0030835285,0.00028217965],"about_ca_topic_score_codex":0.0007437126,"about_ca_topic_score_gemma":0.00046645635,"teacher_disagreement_score":0.28904402,"about_ca_system_score_codex":0.00007729571,"about_ca_system_score_gemma":0.00085544644,"threshold_uncertainty_score":0.36072758},"labels":[],"label_agreement":null},{"id":"W3088162954","doi":"10.1016/j.annonc.2020.08.675","title":"561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Oncology; Regimen; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Trametinib; Adverse effect; Gastroenterology; Urology; Chemotherapy; Kinase; MAPK/ERK pathway","score_opus":0.09530483402239531,"score_gpt":0.4358727483727366,"score_spread":0.3405679143503413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088162954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548733,0.0001704823,0.00013382306,0.002620934,0.00004798458,0.0010550254,0.000036341207,0.000024517838,0.00042355558],"genre_scores_gemma":[0.99568284,0.000028196866,0.0024413075,0.0016899954,0.00003250965,0.00005793407,0.000018463257,0.000033832403,0.000014926802],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9981929,0.00016324656,0.00066197105,0.00033490598,0.00032600178,0.00032098364],"domain_scores_gemma":[0.9985592,0.00017567167,0.00047640677,0.0002483975,0.0003700705,0.00017028594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020674261,0.0002010713,0.0010650923,0.00014024334,0.000018509356,0.0000018457512,0.00015058422,0.000052812527,0.000087023625],"category_scores_gemma":[0.00022465445,0.0001644873,0.00007190748,0.00044012975,0.00019067347,0.00012038856,0.000041926265,0.0002276693,0.000004449949],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0737381,0.047153212,0.14385784,0.00044622654,0.0013640033,0.00041412713,0.033991367,0.0019889388,0.011195999,0.000112992166,0.00035899977,0.6853782],"study_design_scores_gemma":[0.25204152,0.3814205,0.25295347,0.00038996604,0.000724193,0.000039273316,0.029151423,0.00028561422,0.06813748,0.000492679,0.013560936,0.00080296857],"about_ca_topic_score_codex":0.000038933707,"about_ca_topic_score_gemma":0.000057650075,"teacher_disagreement_score":0.68457526,"about_ca_system_score_codex":0.000043722455,"about_ca_system_score_gemma":0.00020506937,"threshold_uncertainty_score":0.67075974},"labels":[],"label_agreement":null},{"id":"W3088168102","doi":"10.1016/j.annonc.2020.08.1466","title":"1819P Determinants of new onset cardiovascular disease (CVD) in cancer patients","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Colorectal cancer; Internal medicine; Heart failure; Disease; Charlson comorbidity index; Breast cancer; Comorbidity; Logistic regression; Population; Stage (stratigraphy); Cancer registry; Oncology","score_opus":0.11950435145418677,"score_gpt":0.3834188800127629,"score_spread":0.26391452855857617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088168102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957544,0.0010442963,0.000010798055,0.0024423185,0.000073151794,0.00029557676,0.000036901096,0.00000762057,0.0003348873],"genre_scores_gemma":[0.99634343,0.0008537769,0.000053482097,0.002583384,0.000097144984,0.000011194806,0.000016308186,0.000011009197,0.000030264608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911517,0.00006287203,0.0002961527,0.00017622058,0.00020111621,0.00014847728],"domain_scores_gemma":[0.99935704,0.000032667067,0.00010914265,0.00017154016,0.0001248164,0.00020479965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012508829,0.00008590041,0.00054397865,0.00005912424,0.000008919943,0.0000010505914,0.00006460467,0.00009890341,0.0000489334],"category_scores_gemma":[0.00018739546,0.000083340834,0.00026065324,0.00016771117,0.000056273937,0.000042917774,0.000023529905,0.00009682002,0.0000038721946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019709845,0.0007647456,0.53431857,0.00047880205,0.0006107324,0.00010013648,0.002315429,0.0001819619,0.013102612,0.000011387877,0.0065743015,0.43957037],"study_design_scores_gemma":[0.0050738435,0.0020105194,0.6703405,0.00020747303,0.00021974221,0.000003734041,0.00008028224,0.000120457116,0.29553154,0.00011715127,0.0261564,0.00013834363],"about_ca_topic_score_codex":0.00046056235,"about_ca_topic_score_gemma":0.000050832234,"teacher_disagreement_score":0.43943202,"about_ca_system_score_codex":0.00003110812,"about_ca_system_score_gemma":0.0004373275,"threshold_uncertainty_score":0.33985406},"labels":[],"label_agreement":null},{"id":"W3088168604","doi":"10.1016/j.annonc.2020.09.011","title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Merck","keywords":"Pembrolizumab; Medicine; Cystectomy; Interquartile range; Internal medicine; Oncology; Confidence interval; Neoadjuvant therapy; Proportional hazards model; Population; Bladder cancer; Immunotherapy; Cancer","score_opus":0.08086946597310188,"score_gpt":0.3867370266547948,"score_spread":0.30586756068169296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088168604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7924572,0.00010331918,0.0000129992795,0.20383002,0.00013524157,0.0012783785,0.00011337116,0.000016242506,0.0020531907],"genre_scores_gemma":[0.99405867,0.000030494894,0.00003371867,0.005263357,0.00015965753,0.00006370878,0.000024640605,0.000013896337,0.00035184305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986851,0.00026040306,0.00037965568,0.00024395426,0.00025834137,0.00017251977],"domain_scores_gemma":[0.99855477,0.00049881,0.00016262179,0.0003080016,0.00037260965,0.00010316411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020533134,0.00015696882,0.0005525355,0.000023992336,0.00010197479,0.000008832745,0.00020613635,0.00008429878,0.00021645112],"category_scores_gemma":[0.00057135226,0.00006301493,0.00011324274,0.00016004672,0.00009379516,0.000046402514,0.00007817879,0.00014647107,0.000008431731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068146504,0.006171567,0.7398605,0.00030253694,0.004421723,0.00030457147,0.123609595,0.000045924036,0.01128398,0.00057679444,0.021925442,0.023350857],"study_design_scores_gemma":[0.007199793,0.0322713,0.8967107,0.000042306972,0.0006484768,0.0000064036185,0.028842976,0.000015920225,0.021689411,0.00010623523,0.012313443,0.0001530127],"about_ca_topic_score_codex":0.0008568444,"about_ca_topic_score_gemma":0.0017773405,"teacher_disagreement_score":0.20160145,"about_ca_system_score_codex":0.000032362317,"about_ca_system_score_gemma":0.00045347426,"threshold_uncertainty_score":0.25696743},"labels":[],"label_agreement":null},{"id":"W3088182134","doi":"10.1016/j.annonc.2020.08.1947","title":"1441P Outcomes of neoadjuvant chemoradiation (nCRT) +/- surgery and definitive CRT (dCRT) in a single institution using the CROSS trial regimen in esophageal (EC) and gastroesophageal junction cancer (GEJC) in Canada","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Esophageal cancer; Gastroesophageal Junction; Regimen; Neoadjuvant therapy; Internal medicine; Oncology; Surgery; Cancer; Adenocarcinoma; Breast cancer","score_opus":0.12862746728191538,"score_gpt":0.3614783085194829,"score_spread":0.23285084123756755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088182134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349374,0.00062034704,0.0000119529695,0.0049776905,0.00023259883,0.00047988808,0.0000108303375,0.0000039459755,0.00016900005],"genre_scores_gemma":[0.99805605,0.00032192387,0.000050182567,0.0014395941,0.00008262728,0.000022367307,0.000009897328,0.000007319058,0.000010009372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986973,0.00011200122,0.00057292945,0.0002139244,0.00017647119,0.00022738965],"domain_scores_gemma":[0.9992264,0.00028371325,0.00029166442,0.00008016927,0.000057711593,0.000060377846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044986166,0.00012436342,0.0006475527,0.0002389797,0.00002447995,0.000006602006,0.000043379598,0.000072913936,0.000011976377],"category_scores_gemma":[0.00030366183,0.0001028397,0.000044198725,0.00043712865,0.0001319855,0.00011863433,0.000048722326,0.00016651305,9.399343e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006340247,0.00010625016,0.96901435,0.00008616777,0.000040245817,0.00011682689,0.00066781987,0.0005988193,0.000111294336,0.000050988947,0.00015058057,0.022716409],"study_design_scores_gemma":[0.014297172,0.00060604233,0.98280185,0.000064352775,0.000040646704,0.0000062725376,0.0005011679,0.00088323385,0.0004918386,0.00003138636,0.00020964809,0.00006635534],"about_ca_topic_score_codex":0.35540766,"about_ca_topic_score_gemma":0.40422693,"teacher_disagreement_score":0.048819266,"about_ca_system_score_codex":0.00035718613,"about_ca_system_score_gemma":0.0011286361,"threshold_uncertainty_score":0.6488847},"labels":[],"label_agreement":null},{"id":"W3088189217","doi":"10.1016/j.annonc.2020.08.1812","title":"1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"EMD Serono; Incyte; Eli Lilly and Company; Accuray; Pfizer; AstraZeneca","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Betacoronavirus; Coronavirus; Respiratory system; Intensive care medicine; Internal medicine; Virology; Disease","score_opus":0.19034220114404504,"score_gpt":0.4666293872182733,"score_spread":0.27628718607422825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088189217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861592,0.0003205921,0.0000051386414,0.010114743,0.00014615792,0.00063934637,0.00008733194,0.00003517873,0.0024923282],"genre_scores_gemma":[0.9795034,0.0005324928,0.00010266795,0.019409698,0.000035292924,0.0002835291,0.000025571493,0.00001686723,0.00009049287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985483,0.00008597823,0.0004015792,0.00039935505,0.0002733128,0.00029146762],"domain_scores_gemma":[0.9989818,0.000101588936,0.0002420787,0.00022083485,0.00013953644,0.0003142038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009760704,0.00019617232,0.0006512864,0.00013077068,0.000055400553,0.0000064651676,0.000113671354,0.00010722729,0.00021855508],"category_scores_gemma":[0.0000890742,0.000147173,0.000076372045,0.0003749959,0.0001882052,0.00012889552,0.000058689413,0.00014931208,0.000014049695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016465185,0.0012526981,0.9817033,0.00012418425,0.00023088344,0.000770154,0.0017336226,0.000090896996,0.00009381685,0.00007500966,0.0014948911,0.010784037],"study_design_scores_gemma":[0.005251101,0.013980183,0.93011165,0.00022650133,0.00018846386,0.000024233863,0.0001771153,0.0000071162344,0.0024386626,0.000025940506,0.047336508,0.0002325391],"about_ca_topic_score_codex":0.0023022501,"about_ca_topic_score_gemma":0.0067461696,"teacher_disagreement_score":0.05159165,"about_ca_system_score_codex":0.0008383543,"about_ca_system_score_gemma":0.0008641315,"threshold_uncertainty_score":0.6001541},"labels":[],"label_agreement":null},{"id":"W3088227025","doi":"10.1016/j.annonc.2020.08.2274","title":"LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Clinical endpoint; Oncology; Tolerability; Surgery; Urology; Clinical trial; Adverse effect; Immunotherapy; Cancer","score_opus":0.1887182812101126,"score_gpt":0.4233166752367792,"score_spread":0.23459839402666657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088227025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94918203,0.0012962341,0.000055573822,0.034799352,0.0006146137,0.0023552277,0.000510501,0.00009984802,0.011086592],"genre_scores_gemma":[0.9899713,0.00049894996,0.0009946546,0.0072506443,0.00047990883,0.00017187606,0.00014731027,0.000051186653,0.00043421454],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997535,0.00014460203,0.0009689723,0.0005062438,0.00037238098,0.0004727899],"domain_scores_gemma":[0.9977045,0.00061116315,0.0007711892,0.0003786423,0.00035205542,0.00018243275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004609011,0.00030178827,0.0010980905,0.00015847276,0.00006563615,0.0000078036865,0.00024308242,0.00034438254,0.00016640796],"category_scores_gemma":[0.0006360603,0.00023757707,0.00036288588,0.00031963608,0.000346246,0.000118157484,0.000064809945,0.0002527558,0.00000978127],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6760263,0.0011216915,0.00012064688,0.00085343426,0.00064573286,0.00013163022,0.003328836,0.00001645863,0.058645464,0.00015220157,0.04095632,0.21800128],"study_design_scores_gemma":[0.07146292,0.076801315,0.0018128084,0.00055495306,0.000148671,0.00006302162,0.0009834457,0.00011889337,0.43364716,0.000079611214,0.41397372,0.0003534626],"about_ca_topic_score_codex":0.000058756432,"about_ca_topic_score_gemma":0.00008385848,"teacher_disagreement_score":0.60456336,"about_ca_system_score_codex":0.00009710912,"about_ca_system_score_gemma":0.001124236,"threshold_uncertainty_score":0.96881115},"labels":[],"label_agreement":null},{"id":"W3088233867","doi":"10.1016/j.annonc.2020.08.910","title":"651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Subgroup analysis; Internal medicine; Prednisone; Gastroenterology; Proportional hazards model; Enzalutamide; Placebo; Urology; Cancer; Confidence interval; Pathology","score_opus":0.11606796369809859,"score_gpt":0.4462474897081508,"score_spread":0.33017952601005224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088233867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969649,0.00039086933,0.0000020092991,0.00097036705,0.000014256321,0.0013418524,0.00024596,0.000003778457,0.00006606167],"genre_scores_gemma":[0.9995186,0.00021394328,0.000060953185,0.00008282927,0.000012555433,0.000034330427,0.000031024367,0.000011421648,0.000034390683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873763,0.00021018139,0.00036904222,0.00020794821,0.00026954158,0.00020563236],"domain_scores_gemma":[0.9989954,0.000067941735,0.0002872159,0.00014214484,0.00041675058,0.00009050774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017287934,0.00013952194,0.0006589991,0.00009124462,0.000025822674,0.0000043217196,0.000063575055,0.000042387685,0.00002657543],"category_scores_gemma":[0.000045151217,0.00007549644,0.000069919355,0.0003542191,0.000268835,0.00008880879,0.00006104657,0.00012888081,3.1533617e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01242568,0.0012844471,0.96448076,0.00014860119,0.0014878251,0.000038186234,0.009563728,0.0012494429,0.0067054536,0.0000027956046,0.00009199496,0.0025210606],"study_design_scores_gemma":[0.010514995,0.017696755,0.95407575,0.00008210886,0.00024008288,0.0000013641379,0.0007471027,0.00014895668,0.016416945,0.000005932842,0.0000070866654,0.00006289681],"about_ca_topic_score_codex":0.0029668636,"about_ca_topic_score_gemma":0.0010838292,"teacher_disagreement_score":0.016412307,"about_ca_system_score_codex":0.00007424133,"about_ca_system_score_gemma":0.0005500706,"threshold_uncertainty_score":0.448503},"labels":[],"label_agreement":null},{"id":"W3088254878","doi":"10.1016/j.annonc.2020.08.1896","title":"1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Concordance; Logistic regression; Internal medicine; Oncology; Family medicine","score_opus":0.5624217197742672,"score_gpt":0.5390716427271782,"score_spread":0.023350077047089024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088254878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8681032,0.0021385562,0.00003741728,0.12558752,0.00024497905,0.00033684526,0.000122003155,0.000008595124,0.0034208698],"genre_scores_gemma":[0.98012245,0.001305165,0.00020450524,0.017858502,0.00034215365,0.000052368472,0.000004415614,0.000015659587,0.000094762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484026,0.00028238705,0.00417657,0.0003522857,0.00006032341,0.000288156],"domain_scores_gemma":[0.9956212,0.0014319731,0.0024691413,0.0002710551,0.00008287629,0.00012374118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008642784,0.000111978465,0.0011877242,0.000118543445,0.000045841924,0.0000074259356,0.0003475761,0.00020421026,0.0002036462],"category_scores_gemma":[0.0024005645,0.000113596725,0.00015631694,0.0002066272,0.0001486529,0.00011962769,0.00008799264,0.00025049454,0.00011183254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018700924,0.00028160182,0.95199585,0.0005302475,0.00017768372,0.0000017288623,0.0074530267,0.0008405157,0.000035252728,0.022080269,0.012245654,0.004171145],"study_design_scores_gemma":[0.0022390399,0.0005554724,0.8571741,0.000071270464,0.000008254977,0.0000011725471,0.0017132523,0.0020053503,0.00014606879,0.004971852,0.13089755,0.00021661329],"about_ca_topic_score_codex":0.0015278964,"about_ca_topic_score_gemma":0.0017390036,"teacher_disagreement_score":0.1186519,"about_ca_system_score_codex":0.00008587667,"about_ca_system_score_gemma":0.00020669453,"threshold_uncertainty_score":0.463234},"labels":[],"label_agreement":null},{"id":"W3088257866","doi":"10.1016/j.annonc.2020.08.142","title":"1516P Real world implementation of Serious Illness Care Program (SICP) in cancer care","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Conversation; Advance care planning; Documentation; Medical record; Depression (economics); Randomized controlled trial; Family medicine; Emergency medicine; Palliative care; Internal medicine; Nursing","score_opus":0.09826604777646411,"score_gpt":0.4016150294340533,"score_spread":0.30334898165758917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088257866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95527387,0.005116534,0.000011580761,0.003232272,0.00030425726,0.0005054078,0.0005107728,0.000019087496,0.035026208],"genre_scores_gemma":[0.9961923,0.0023292773,0.00019391616,0.00094228226,0.00014378894,0.00010556953,0.000038487124,0.000018846325,0.0000355417],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985883,0.000016612275,0.0007952259,0.0002835854,0.000025536434,0.0002907237],"domain_scores_gemma":[0.9989779,0.000025969559,0.0006299604,0.00014361025,0.00013644458,0.000086119544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012449661,0.0001268063,0.0006559622,0.00018161784,0.000027423426,0.000008817671,0.00019301561,0.00011147411,0.00033401663],"category_scores_gemma":[0.000028010367,0.0001566826,0.00011048672,0.0002984289,0.00008571397,0.00018063988,0.0000552155,0.00011838568,0.000017156204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013897636,0.00008614579,0.3576142,0.00024828166,0.000051740506,0.0000056276745,0.017556578,0.000192506,0.000024733516,0.014991619,0.0016053854,0.6074842],"study_design_scores_gemma":[0.0023816528,0.0026942482,0.5024582,0.00003963911,0.000014383204,5.0233854e-7,0.011566098,0.00006495878,0.0032996393,0.0017464649,0.47531992,0.00041424768],"about_ca_topic_score_codex":0.011837594,"about_ca_topic_score_gemma":0.02176035,"teacher_disagreement_score":0.60706997,"about_ca_system_score_codex":0.00015474398,"about_ca_system_score_gemma":0.00021776903,"threshold_uncertainty_score":0.99609},"labels":[],"label_agreement":null},{"id":"W3088267903","doi":"10.1016/j.annonc.2020.08.883","title":"624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; AstraZeneca France; Meso Scale Diagnostics","keywords":"Medicine; Tolerability; Adverse effect; Enzalutamide; Internal medicine; Nausea; Prostate cancer; Population; Olaparib; Surgery; Oncology; Cancer","score_opus":0.09026358163181142,"score_gpt":0.38053623638333,"score_spread":0.2902726547515186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088267903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989185,0.00041050217,0.000042134394,0.008686266,0.00006612232,0.0011949348,0.00010071148,0.000024208744,0.0002901525],"genre_scores_gemma":[0.9955967,0.00031337384,0.0022468877,0.0014660717,0.000027311935,0.00022628024,0.000078664656,0.000014460023,0.000030223895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983394,0.00022477792,0.00069421093,0.00032462503,0.00022820705,0.00018876785],"domain_scores_gemma":[0.99850863,0.00013187756,0.0004227708,0.0001805538,0.0006560436,0.00010011049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039511305,0.00013933604,0.0005439185,0.00011188487,0.000040218427,0.000005830012,0.00004901681,0.000095610856,0.00007539812],"category_scores_gemma":[0.00018103178,0.00012180579,0.000049784903,0.00030488631,0.00022203045,0.0001594869,0.000018500506,0.0001998205,0.0000010887596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027107093,0.007049228,0.80832255,0.0025080666,0.0010700711,0.00014135489,0.017336749,0.0012316994,0.06228208,0.0013534212,0.0044818264,0.06711588],"study_design_scores_gemma":[0.026413186,0.04024688,0.8399936,0.00050568866,0.00027224357,0.00003680078,0.00075014285,0.0011728368,0.084527254,0.0021782287,0.003447967,0.0004551792],"about_ca_topic_score_codex":0.0002528289,"about_ca_topic_score_gemma":0.00048500602,"teacher_disagreement_score":0.0666607,"about_ca_system_score_codex":0.00012525263,"about_ca_system_score_gemma":0.0005357076,"threshold_uncertainty_score":0.4967096},"labels":[],"label_agreement":null},{"id":"W3088293910","doi":"10.1016/j.annonc.2020.08.1672","title":"1358P Efficacy and toxicity of combined inhibition of EGFR and VEGFR in advanced non-small cell lung cancer patients harboring activating EGFR mutations: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Lung cancer; Meta-analysis; Bevacizumab; Epidermal growth factor receptor; Adverse effect; Gefitinib; Odds ratio; Cancer; Confidence interval; Chemotherapy","score_opus":0.08631305186697011,"score_gpt":0.4419172480569191,"score_spread":0.355604196189949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088293910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018180296,0.977445,0.000013822939,0.00036064806,0.000015107277,0.003731063,0.00015511662,0.000007280827,0.000091645044],"genre_scores_gemma":[0.05135095,0.94726604,0.0004009149,0.00019525421,0.0000056315175,0.0006299103,0.000107602515,0.000026102074,0.000017567883],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99763775,0.0002694086,0.0014269522,0.0003583144,0.00015572642,0.00015182445],"domain_scores_gemma":[0.99693465,0.000584458,0.0018639298,0.00019696621,0.00033058235,0.00008942315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030347428,0.0002872679,0.006054101,0.00034217237,0.000028519213,0.000004709188,0.000051151732,0.00014777569,0.000011526544],"category_scores_gemma":[0.00029106988,0.00021283819,0.00040267993,0.00072440587,0.00008116363,0.000079628095,0.00006287318,0.00016802872,1.2041085e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036877453,0.0006117847,0.00033986868,0.944188,0.03701193,0.000010222305,0.0007616046,0.0000067687865,0.000041775944,0.000015359352,0.000011983294,0.016963853],"study_design_scores_gemma":[0.0033481598,0.0020191176,0.0007170305,0.09019778,0.90173596,0.0000055850624,0.00012850246,0.000046421406,0.0003677766,0.000011409603,0.0011293348,0.00029290767],"about_ca_topic_score_codex":0.00011607199,"about_ca_topic_score_gemma":0.000039013223,"teacher_disagreement_score":0.86472404,"about_ca_system_score_codex":0.000102737606,"about_ca_system_score_gemma":0.00031397492,"threshold_uncertainty_score":0.8679289},"labels":[],"label_agreement":null},{"id":"W3088299032","doi":"10.1016/j.annonc.2020.08.1730","title":"1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"KRAS; Docetaxel; Medicine; Clinical endpoint; Oncology; Internal medicine; Phases of clinical research; Progression-free survival; Expanded access; Cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Progressive disease; Clinical trial","score_opus":0.03654458867401471,"score_gpt":0.38859521344056674,"score_spread":0.352050624766552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088299032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417853,0.0005816656,0.000033364788,0.00046475162,0.00020455456,0.0037355497,0.00008478612,0.000034796354,0.0006819936],"genre_scores_gemma":[0.9983299,0.00014480263,0.00032273165,0.0004062842,0.0000738562,0.0004845475,0.00012389732,0.00004736283,0.000066635934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792063,0.0001097678,0.00074836815,0.0004987791,0.00031014683,0.0004123084],"domain_scores_gemma":[0.9982125,0.00012434548,0.0005811247,0.00025572008,0.0005973021,0.00022901989],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010772323,0.0003217587,0.0009083492,0.00020073939,0.000056530836,0.000008510657,0.00011798399,0.00012810137,0.0000665235],"category_scores_gemma":[0.000064364074,0.00026273003,0.000100931924,0.0004592519,0.00007183244,0.0001925571,0.000046636345,0.00020828922,0.0000036471818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05306464,0.023563283,0.8588649,0.0007169213,0.0017590475,0.00026465353,0.037268903,0.0012613265,0.0030745664,0.0000027374147,0.0007242649,0.019434724],"study_design_scores_gemma":[0.41942608,0.07478611,0.47241354,0.001146426,0.003410951,0.0000023252137,0.006981441,0.0025381371,0.017222552,0.0000016456465,0.0014006337,0.0006701365],"about_ca_topic_score_codex":0.0020921351,"about_ca_topic_score_gemma":0.0009642085,"teacher_disagreement_score":0.3864514,"about_ca_system_score_codex":0.00026704711,"about_ca_system_score_gemma":0.00056655,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W3088305507","doi":"10.1016/j.annonc.2020.08.343","title":"221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Pfizer Japan; Meso Scale Diagnostics; Novartis; AstraZeneca","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Lapatinib; Clinical endpoint; Anthracycline; Oncology; Median follow-up; Cancer; Gastroenterology; Surgery; Chemotherapy; Randomized controlled trial","score_opus":0.1255883365181992,"score_gpt":0.45173019833508016,"score_spread":0.326141861816881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088305507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670653,0.00011390489,0.000009642279,0.029112777,0.00007423956,0.00072378287,0.00014688875,0.000013685328,0.0027398232],"genre_scores_gemma":[0.9957701,0.00019595918,0.00019837891,0.0034421508,0.00007100792,0.000082839055,0.000019694684,0.00003044373,0.00018941975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805254,0.00016473276,0.00054027484,0.0003231567,0.00051009975,0.00040917512],"domain_scores_gemma":[0.99835837,0.0002722057,0.00025376063,0.0002637764,0.000612186,0.00023968765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024698186,0.0001808246,0.0009850767,0.00016844689,0.000018891875,0.0000033107558,0.00021988689,0.00013875785,0.0013659067],"category_scores_gemma":[0.00020898142,0.0001362702,0.000099325305,0.0004587406,0.0002882658,0.000073718,0.00010890528,0.00033193198,0.000020552752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031276892,0.00084321044,0.973557,0.00030284206,0.00025882307,0.00006804418,0.00086427777,0.000025506497,0.00014121956,0.0000135002065,0.0022853778,0.018512528],"study_design_scores_gemma":[0.006717626,0.0029141803,0.98707706,0.00016671386,0.0000357391,0.0000025602699,0.000082979015,0.000024559082,0.0020890415,0.000019383546,0.00075611717,0.00011403242],"about_ca_topic_score_codex":0.002034059,"about_ca_topic_score_gemma":0.0010364926,"teacher_disagreement_score":0.02870485,"about_ca_system_score_codex":0.000107343556,"about_ca_system_score_gemma":0.00086687435,"threshold_uncertainty_score":0.999547},"labels":[],"label_agreement":null},{"id":"W3088311877","doi":"10.1016/j.annonc.2020.08.377","title":"275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Capecitabine; Internal medicine; Visual analogue scale; Metastatic breast cancer; Placebo; Oncology; Depression (economics); Clinical trial; Breast cancer; Trastuzumab; Anxiety; Cancer; Surgery; Psychiatry; Alternative medicine; Pathology; Nursing","score_opus":0.13965578588046457,"score_gpt":0.4710488251463778,"score_spread":0.33139303926591324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088311877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97831523,0.00072647876,0.0000025986951,0.019393643,0.000024147932,0.0007472465,0.00060676667,0.000009201549,0.00017465393],"genre_scores_gemma":[0.99593896,0.00018829684,0.000168311,0.0035406612,0.000017246091,0.000033999124,0.00007608988,0.000020618829,0.000015803977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980165,0.00046435054,0.0007508415,0.00027472802,0.00022700534,0.00026659606],"domain_scores_gemma":[0.9981044,0.00035371925,0.0008488659,0.00015290183,0.0002625793,0.000277515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039541256,0.00020811099,0.0014602044,0.00014323034,0.000017922,0.0000015278196,0.00006573683,0.00006283323,0.00030398782],"category_scores_gemma":[0.000103921804,0.00013559939,0.00008939618,0.00037619116,0.0002786992,0.000057638044,0.000023298595,0.00017971233,9.464196e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035964977,0.0037414797,0.9397943,0.000535602,0.0019300457,0.000008076899,0.0023489632,0.00015181143,0.0003516937,0.000040078197,0.0031619743,0.011970974],"study_design_scores_gemma":[0.016219899,0.041992888,0.94049025,0.0001699909,0.00021247646,0.00000766353,0.00014396892,0.000016975333,0.00047496986,0.000022109783,0.00013897034,0.00010981602],"about_ca_topic_score_codex":0.012067959,"about_ca_topic_score_gemma":0.0019372704,"teacher_disagreement_score":0.038251407,"about_ca_system_score_codex":0.00008480107,"about_ca_system_score_gemma":0.0013001114,"threshold_uncertainty_score":0.99451077},"labels":[],"label_agreement":null},{"id":"W3088316576","doi":"10.1016/j.annonc.2020.08.663","title":"549P Identification of RET rearrangement in 12888 Chinese lung cancer patients by next-generation sequencing (NGS)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Ipsen; Astex Pharmaceuticals; G1 Therapeutics; Pfizer; Astellas Pharma; Clovis Oncology; Merck KGaA; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Fusion gene; Cancer research; Cancer; Exon; Intron; Internal medicine; Oncology; Crizotinib; Genetics; Gene; Biology","score_opus":0.10871192538947436,"score_gpt":0.43354725046363013,"score_spread":0.3248353250741558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088316576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922,0.0009845534,0.00006321269,0.008262619,0.00013027091,0.0004436366,0.000083897015,0.000008560758,0.00080325507],"genre_scores_gemma":[0.9973306,0.00063713157,0.00009792896,0.0013625784,0.00007815871,0.000070686765,0.00032397915,0.000009239362,0.00008968144],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991053,0.000045943932,0.00042489963,0.00016892901,0.0001455719,0.00010935943],"domain_scores_gemma":[0.9993268,0.000020549905,0.00025541597,0.00009938004,0.00023881382,0.0000589927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116730494,0.000077348144,0.00025273868,0.00006429816,0.000020762864,0.0000036540591,0.00004501612,0.00006368211,0.00007958657],"category_scores_gemma":[0.000099556,0.00006627399,0.00004343771,0.00020788386,0.000029966395,0.00010730919,0.000014795437,0.000059214566,0.0000020128289],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003088457,0.0007764396,0.3595986,0.00034366082,0.00029303605,0.000008331172,0.008375201,0.00035134878,0.556466,0.00007214747,0.03544727,0.037959106],"study_design_scores_gemma":[0.015110291,0.007604406,0.67286354,0.00043760004,0.00087199337,0.0000040642963,0.0011323001,0.019635772,0.2591016,0.00018484154,0.022545056,0.0005085108],"about_ca_topic_score_codex":0.00075624057,"about_ca_topic_score_gemma":0.00018939776,"teacher_disagreement_score":0.31326494,"about_ca_system_score_codex":0.00016231742,"about_ca_system_score_gemma":0.00022515655,"threshold_uncertainty_score":0.27025747},"labels":[],"label_agreement":null},{"id":"W3088330245","doi":"10.1016/j.annonc.2020.08.884","title":"625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck Sharp and Dohme","keywords":"Medicine; Enzalutamide; Prostate cancer; Cohort; Abiraterone acetate; Internal medicine; Abiraterone; Cancer; Urology; Oncology; Surgery; Androgen deprivation therapy; Androgen receptor","score_opus":0.06414097661310898,"score_gpt":0.3659130848340182,"score_spread":0.3017721082209092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088330245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98539764,0.0012160435,0.0000121123685,0.009454344,0.000080825674,0.0022836307,0.0003637517,0.000059183036,0.001132477],"genre_scores_gemma":[0.9951887,0.0013928504,0.00037094677,0.0016772947,0.000047417456,0.00033315664,0.00049058837,0.00006585486,0.0004331666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669915,0.00027853655,0.00081691996,0.00067441515,0.0006502833,0.0008806712],"domain_scores_gemma":[0.9980199,0.00010667819,0.0003867316,0.00035305953,0.00070949935,0.00042418035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033938762,0.00040678785,0.0011871307,0.00026043563,0.00009245014,0.000026620572,0.00019980062,0.00014416297,0.00027124776],"category_scores_gemma":[0.000105677675,0.00029935443,0.00011396459,0.00074358046,0.00035237637,0.0002545331,0.00009679795,0.0004242519,0.00004164707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18835275,0.0032730284,0.72570425,0.0018644342,0.0040676035,0.0026323968,0.00664586,0.0027356802,0.016454266,0.00017896981,0.005479009,0.042611726],"study_design_scores_gemma":[0.07040715,0.023699671,0.8590006,0.0005314182,0.0007915117,0.000023224235,0.00045652466,0.0010637006,0.03649352,0.00013708668,0.0066447,0.00075088383],"about_ca_topic_score_codex":0.0009773572,"about_ca_topic_score_gemma":0.00071250775,"teacher_disagreement_score":0.13329634,"about_ca_system_score_codex":0.00038612995,"about_ca_system_score_gemma":0.0015128463,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3088332096","doi":"10.1016/j.annonc.2020.08.659","title":"545P Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Loxo Oncology; Chugai Pharmaceutical; Shionogi; Pfizer Japan; Genentech; Eli Lilly Japan; Eisai; Astellas Pharma; Dainippon Sumitomo Pharma; Yakult Honsha; Sanofi; Kyowa Hakko Kirin; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Pfizer; Incyte; Taiho Pharmaceutical; GlaxoSmithKline; Teijin Pharma; Daiichi-Sankyo; Amgen; Bayer Yakuhin; Rakuten Medical; AstraZeneca; Bristol-Myers Squibb","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Medicine; In vivo; Tolerability; Cancer research; Pharmacology; Reporter gene; Cancer; Internal medicine; Gene expression; Biology; Gene; Adverse effect; Biochemistry","score_opus":0.19861082355544013,"score_gpt":0.46233925188934605,"score_spread":0.2637284283339059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088332096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694075,0.004525498,0.000011901922,0.02296935,0.00014614596,0.0021663469,0.0005761679,0.000007701761,0.00018937154],"genre_scores_gemma":[0.9899061,0.0058648954,0.0009835798,0.00046247983,0.00063605234,0.0009400287,0.000179869,0.000021117463,0.001005917],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878323,0.00009866878,0.00051199883,0.00022383373,0.00016390008,0.00021835256],"domain_scores_gemma":[0.99879605,0.00028596926,0.00028743414,0.00015715878,0.00036046418,0.00011294906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025069082,0.0001204008,0.00054633693,0.000033775505,0.000040983934,0.0000026361179,0.00007369717,0.00011548043,0.00039360498],"category_scores_gemma":[0.00007787478,0.000070899136,0.00019169367,0.0001256191,0.00024246279,0.000038304086,0.000021628104,0.000075116324,0.000003107647],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02876653,0.0042312103,0.021056233,0.0011960986,0.0018763512,0.00004223431,0.013297812,0.000019971125,0.2836289,0.00013499377,0.054012556,0.5917371],"study_design_scores_gemma":[0.0072933044,0.038148336,0.0013482774,0.00006327656,0.00016210673,0.000005819863,0.00032055928,0.00021563438,0.7534506,0.000055400935,0.19885935,0.00007739053],"about_ca_topic_score_codex":0.000043776025,"about_ca_topic_score_gemma":0.000073464675,"teacher_disagreement_score":0.5916597,"about_ca_system_score_codex":0.00006038291,"about_ca_system_score_gemma":0.0006585201,"threshold_uncertainty_score":0.43096983},"labels":[],"label_agreement":null},{"id":"W3088354354","doi":"10.1016/j.annonc.2020.08.1976","title":"1470P Urban-rural differences in outcomes of patients with advanced gastroesophageal cancers","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Referral; Cohort; Cancer registry; Cancer; Population; Internal medicine; Family medicine; Environmental health","score_opus":0.05789841571892312,"score_gpt":0.368867980666418,"score_spread":0.3109695649474949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088354354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421144,0.0010050182,0.0000042443176,0.0036725982,0.000028509852,0.00038549743,0.000052826017,0.000008865103,0.00063100277],"genre_scores_gemma":[0.998589,0.00014830408,0.00025629814,0.0008812915,0.000022372104,0.000033907574,0.000024023211,0.000009082545,0.000035713176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989381,0.00005322624,0.00027879258,0.00016232814,0.0002837438,0.00028385146],"domain_scores_gemma":[0.9992917,0.0000900693,0.00014406486,0.000115901974,0.00016826381,0.00018998732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056476416,0.00011946818,0.0006243467,0.00007803253,0.000012596879,0.0000014307997,0.00009327364,0.000047823803,0.00011190201],"category_scores_gemma":[0.00008554602,0.00007948105,0.00006677515,0.00018061597,0.00015905814,0.000057604535,0.000033106837,0.0001349981,0.0000031322054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031545514,0.00039539335,0.9800977,0.000077683784,0.00014381515,0.00008438881,0.0004717787,0.000010843015,0.000025221801,0.00003535611,0.00033308583,0.015170185],"study_design_scores_gemma":[0.005517585,0.018879043,0.97372687,0.000038535356,0.000023287097,6.250454e-7,0.00015683017,0.000010525364,0.0014718549,0.000019491037,0.000110544366,0.0000447874],"about_ca_topic_score_codex":0.00023260756,"about_ca_topic_score_gemma":0.000136432,"teacher_disagreement_score":0.018483648,"about_ca_system_score_codex":0.00007571853,"about_ca_system_score_gemma":0.000359663,"threshold_uncertainty_score":0.3241143},"labels":[],"label_agreement":null},{"id":"W3088368080","doi":"10.1016/j.annonc.2020.08.891","title":"632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Placebo; Internal medicine; Repeated measures design; Urology; Analysis of variance; Quality of life (healthcare); Oncology; Cancer; Nursing","score_opus":0.17824461829542312,"score_gpt":0.4239858116542255,"score_spread":0.24574119335880237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088368080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423915,0.0005683075,0.000002268487,0.0029904821,0.00002334834,0.0019838903,0.00013940682,0.000005234408,0.000047880992],"genre_scores_gemma":[0.998994,0.00048651575,0.00005956789,0.0002442421,0.0000071545846,0.00008465295,0.0000738329,0.000014388112,0.000035652873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690187,0.00064246013,0.0012971208,0.00030581336,0.0005903323,0.00026240174],"domain_scores_gemma":[0.9973711,0.00028383365,0.0013347934,0.00029492762,0.0005878002,0.0001275491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091095775,0.00016657509,0.0012218141,0.00025179304,0.000058794445,0.0000028479183,0.00014130307,0.00006606285,0.000060372597],"category_scores_gemma":[0.00022958148,0.00010832951,0.00012870914,0.0014875465,0.00020047129,0.00006707372,0.000055316792,0.00017183,3.6699768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029777352,0.00218351,0.943563,0.0003274859,0.0024175595,0.0000054767634,0.012742402,0.0017946528,0.003869998,0.0000057812513,0.0000769467,0.0032358503],"study_design_scores_gemma":[0.013802575,0.012731285,0.96582377,0.00013938305,0.00028934726,3.036374e-7,0.0015521809,0.0004967564,0.00505126,0.000010592847,0.000020126134,0.00008244306],"about_ca_topic_score_codex":0.0069543202,"about_ca_topic_score_gemma":0.015047961,"teacher_disagreement_score":0.02226076,"about_ca_system_score_codex":0.00016786046,"about_ca_system_score_gemma":0.0010821646,"threshold_uncertainty_score":0.99965847},"labels":[],"label_agreement":null},{"id":"W3088376321","doi":"10.1016/j.annonc.2020.08.838","title":"766P Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Internal medicine; Quartile; Lung cancer; Gastroenterology; Oncology; Cancer; Surgery; Confidence interval; Immunotherapy; Pembrolizumab","score_opus":0.0252027183277698,"score_gpt":0.3299045009590764,"score_spread":0.3047017826313066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088376321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931456,0.00032329117,0.0000024844417,0.0003660701,0.000027577487,0.005367356,0.00003145956,0.000032478394,0.0007036687],"genre_scores_gemma":[0.9992573,0.000027089929,0.000049727314,0.000075554286,0.000020733387,0.000470386,0.00006732308,0.000029148781,0.0000027070876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643236,0.0011995449,0.0010054908,0.0004143468,0.00055236503,0.00039586774],"domain_scores_gemma":[0.99797463,0.0005288861,0.0006896389,0.00039984376,0.00029220778,0.00011479689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007480714,0.00034017724,0.0011218353,0.00027284087,0.000035942674,0.00000743443,0.00026670416,0.00009762611,0.00001132212],"category_scores_gemma":[0.00028674267,0.0002131469,0.000101632555,0.001254857,0.00019252366,0.00013695293,0.000056633296,0.00025274363,0.0000036690747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026759373,0.0025309487,0.95480436,0.0013227528,0.00027719114,0.0017284574,0.0017051328,0.00012844401,0.00007498557,0.0000070405445,0.000018789193,0.010642544],"study_design_scores_gemma":[0.015162428,0.042819507,0.938508,0.0008824494,0.00041607043,0.000061322724,0.0012282592,0.00017577515,0.00056074903,0.000008290986,0.000005664942,0.00017149704],"about_ca_topic_score_codex":0.0002395074,"about_ca_topic_score_gemma":0.00014955664,"teacher_disagreement_score":0.040288556,"about_ca_system_score_codex":0.00020598352,"about_ca_system_score_gemma":0.00035315927,"threshold_uncertainty_score":0.8691878},"labels":[],"label_agreement":null},{"id":"W3088381067","doi":"10.1016/j.annonc.2020.08.1823","title":"1759P Cancer care during COVID-19: Data from 157 patient organisations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Medicine; Telemedicine; Pandemic; Health care; Cancer; Family medicine; Breast cancer; Nursing; Coronavirus disease 2019 (COVID-19); Public relations; Economic growth; Disease; Political science; Pathology","score_opus":0.4426989041928462,"score_gpt":0.5348234397307845,"score_spread":0.09212453553793831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088381067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7038465,0.0018991232,0.00005016204,0.292053,0.00015529037,0.00030712388,0.0010148522,0.000053778385,0.00062014355],"genre_scores_gemma":[0.89754546,0.00079568627,0.00018615815,0.10062512,0.0003888695,0.000010781679,0.0004125163,0.00001634658,0.000019047391],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998792,0.00007688836,0.00034183965,0.0003376491,0.0001959453,0.00025569941],"domain_scores_gemma":[0.9981475,0.00025379064,0.00016577175,0.0004828738,0.00022342733,0.00072662375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000075677104,0.00011017451,0.0003958732,0.000061422994,0.00009994076,0.000004961599,0.00019983722,0.00013806164,0.0015404813],"category_scores_gemma":[0.0018057037,0.00010244291,0.000046311412,0.00018473197,0.00006822938,0.00007771112,0.00021980473,0.00019758413,0.000046078778],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003196432,0.00086112035,0.32669702,0.0033763936,0.00070687634,0.00091577176,0.13642347,0.00027211607,0.025255099,0.00021676552,0.39250004,0.109578885],"study_design_scores_gemma":[0.0023222766,0.0028448396,0.122462094,0.00008127787,0.00014009794,0.000011477262,0.005382724,0.00010301853,0.0067773755,0.00009815483,0.8596002,0.00017646998],"about_ca_topic_score_codex":0.010278426,"about_ca_topic_score_gemma":0.003099206,"teacher_disagreement_score":0.46710014,"about_ca_system_score_codex":0.00022093701,"about_ca_system_score_gemma":0.003935293,"threshold_uncertainty_score":0.99937224},"labels":[],"label_agreement":null},{"id":"W3088392406","doi":"10.1016/j.annonc.2020.08.451","title":"349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Ipsen; Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; Chugai Pharmaceutical; Vifor Pharma; Oncolytics Biotech; Novo Nordisk; Astellas Pharma; Eisai; Seagen; Daiichi-Sankyo; MacroGenics; Japan Surgical Society; Puma Biotechnology; Pfizer; Incyte; Menarini Silicon Biosystems; Mylan; Clovis Oncology; Teva Pharmaceutical Industries; Sanofi; Foundation Medicine; Genomic Health; GlaxoSmithKline; Amgen; Novartis Pharmaceuticals Corporation; G1 Therapeutics; Jounce Therapeutics; Celgene; AstraZeneca; ImmunoMedics; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Triple-negative breast cancer; PTEN; Internal medicine; Oncology; Breast cancer; Population; Fulvestrant; Cancer; Cancer research; PI3K/AKT/mTOR pathway; Tamoxifen","score_opus":0.07964210492149927,"score_gpt":0.4290398262502009,"score_spread":0.3493977213287016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088392406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803568,0.0018779597,0.00007058825,0.007196229,0.0001861787,0.009517072,0.00029965086,0.00004540359,0.00045011088],"genre_scores_gemma":[0.9943844,0.00074878277,0.00027002857,0.0022648203,0.00017278647,0.0016128368,0.00014945862,0.00006134213,0.00033555957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963195,0.0005591224,0.0013418768,0.000809107,0.0004084682,0.0005619643],"domain_scores_gemma":[0.9963972,0.0009144646,0.0011952744,0.00028174894,0.00086305727,0.0003482312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007429467,0.0005418457,0.0025701162,0.00039480053,0.00009837835,0.000014583082,0.00015403153,0.0002769377,0.00053887453],"category_scores_gemma":[0.0002755321,0.0003919593,0.00017145603,0.00077616476,0.00048229814,0.00035099284,0.000058052738,0.0004223756,0.000005088834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93183917,0.00749862,0.005603263,0.00018754555,0.002049604,0.0019646254,0.013442686,0.00052650284,0.0016930228,0.00001576064,0.00075317477,0.03442602],"study_design_scores_gemma":[0.93970716,0.03734409,0.005828892,0.00019391769,0.0019269959,0.0004339671,0.0058016297,0.0016401646,0.0063176043,0.00004997116,0.0003499053,0.00040569558],"about_ca_topic_score_codex":0.002934463,"about_ca_topic_score_gemma":0.0045481757,"teacher_disagreement_score":0.034020323,"about_ca_system_score_codex":0.00017356538,"about_ca_system_score_gemma":0.0010077351,"threshold_uncertainty_score":0.99985325},"labels":[],"label_agreement":null},{"id":"W3088397291","doi":"10.1016/j.annonc.2020.08.004","title":"886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"Merck Sharp and Dohme","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Health related quality of life; Population; Brentuximab vedotin; Pembrolizumab; Phases of clinical research; Stock options; Oncology; Surgery; Clinical trial; Cancer; Lymphoma; Hodgkin lymphoma; Disease","score_opus":0.23029157352544738,"score_gpt":0.4550039072882897,"score_spread":0.22471233376284233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088397291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97301954,0.0024923722,0.000008832495,0.019234816,0.00020985988,0.004006447,0.00019520248,0.00004216075,0.0007907841],"genre_scores_gemma":[0.9930501,0.0009417702,0.00035975146,0.00495962,0.00008451141,0.00032118842,0.0001547836,0.00005118407,0.00007709578],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905951,0.0029512076,0.004260357,0.00089420384,0.0007030053,0.00059610436],"domain_scores_gemma":[0.99197084,0.0034846782,0.0027236908,0.0007717929,0.0004170987,0.0006319092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022777582,0.00049126864,0.0062670438,0.00027658851,0.00006859311,0.000012537198,0.00054145907,0.00047295835,0.00037865463],"category_scores_gemma":[0.0032641527,0.00037622653,0.00036420464,0.0006917852,0.00045422371,0.00013060367,0.00037915655,0.00033542584,0.000017714092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8036582,0.122976825,0.0046177306,0.00028471035,0.0021652267,0.0003948223,0.0075017693,0.000009741962,0.0010400981,0.00020440576,0.008052396,0.049094085],"study_design_scores_gemma":[0.9165548,0.048825998,0.027790306,0.0003221733,0.000424946,0.000014618126,0.0020155343,0.0005834938,0.0015591123,0.00013262483,0.0014852871,0.00029109788],"about_ca_topic_score_codex":0.02178721,"about_ca_topic_score_gemma":0.0014584407,"teacher_disagreement_score":0.11289662,"about_ca_system_score_codex":0.00033520817,"about_ca_system_score_gemma":0.002896524,"threshold_uncertainty_score":0.999869},"labels":[],"label_agreement":null},{"id":"W3088399963","doi":"10.1016/j.annonc.2020.08.1458","title":"1811MO Association of pre-existing cardiovascular disease (CVD) in older patients with breast cancer with treatment and survival outcomes","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Odds ratio; Confidence interval; Cancer; Logistic regression; Cancer registry; Radiation therapy; Population; Surgery","score_opus":0.045067662478939556,"score_gpt":0.3286426440223504,"score_spread":0.2835749815434108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088399963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510264,0.00019014833,0.000021972395,0.0038832424,0.000020084746,0.0004073213,0.00006503578,0.000008140786,0.00030138454],"genre_scores_gemma":[0.99919736,0.00019674274,0.000056893645,0.00041395397,0.000042942815,0.000025777477,0.000026026593,0.000011127621,0.000029191378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992303,0.000077788514,0.00017965565,0.00017203398,0.00021546053,0.00012470876],"domain_scores_gemma":[0.9993707,0.00006881649,0.00015273356,0.00010278194,0.0002065029,0.00009845472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013194543,0.000099243036,0.0005390198,0.00003834453,0.000015166143,0.0000022111349,0.000021641043,0.00006519836,0.000009446861],"category_scores_gemma":[0.00005013559,0.000070155795,0.00009180067,0.00011286306,0.000040860636,0.000050798983,0.000008952945,0.00006009585,1.939189e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012857136,0.0003341014,0.97087127,0.00010417606,0.0010699888,0.000009194866,0.00095623615,0.00016827176,0.00036164097,0.000007937334,0.000020329497,0.024811132],"study_design_scores_gemma":[0.006185824,0.0012518485,0.9885333,0.000086896085,0.000291964,0.0000012897776,0.000089323396,0.000026862901,0.0031099971,0.000004334604,0.00035039114,0.00006794415],"about_ca_topic_score_codex":0.0004875014,"about_ca_topic_score_gemma":0.00014154801,"teacher_disagreement_score":0.024743188,"about_ca_system_score_codex":0.000107385844,"about_ca_system_score_gemma":0.0001680845,"threshold_uncertainty_score":0.28608704},"labels":[],"label_agreement":null},{"id":"W3088404547","doi":"10.1016/j.annonc.2020.08.604","title":"493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Medicine; Cohort; Internal medicine; Oxaliplatin; FOLFIRI; Colorectal cancer; Tolerability; Oncology; Surgery; Cancer; Adverse effect","score_opus":0.07263663429772074,"score_gpt":0.35652005593744107,"score_spread":0.28388342163972036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088404547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98721534,0.0009542243,0.0000032725372,0.008272854,0.00011360465,0.0009402506,0.0005549115,0.00003375319,0.0019118156],"genre_scores_gemma":[0.9953687,0.00097595237,0.00027451618,0.0028245605,0.0000643403,0.00011879239,0.0002381326,0.000028865765,0.00010611325],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980379,0.000119605036,0.0006027282,0.00055524684,0.00029507006,0.00038949933],"domain_scores_gemma":[0.9987319,0.0002862333,0.00030654488,0.00015896614,0.00028595695,0.00023035893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012119706,0.0002914128,0.0011811749,0.00010634138,0.00006404953,0.00000968177,0.00009170604,0.00011803838,0.00017991342],"category_scores_gemma":[0.00024419118,0.00019728391,0.00007018025,0.00035963947,0.0002269506,0.000091687645,0.000110885485,0.00020799304,0.000006032325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40806934,0.0030856968,0.39908934,0.00026031086,0.004644233,0.0020076314,0.019350808,0.00017661213,0.0006381845,0.00003699363,0.042237226,0.12040363],"study_design_scores_gemma":[0.056843467,0.030694121,0.8918643,0.00019266416,0.0006556812,0.000016335214,0.000842324,0.00038615547,0.002000526,0.000053800206,0.01609172,0.00035892247],"about_ca_topic_score_codex":0.00484567,"about_ca_topic_score_gemma":0.008231951,"teacher_disagreement_score":0.49277493,"about_ca_system_score_codex":0.00018821578,"about_ca_system_score_gemma":0.0005935017,"threshold_uncertainty_score":0.8045004},"labels":[],"label_agreement":null},{"id":"W3088414576","doi":"10.1016/j.annonc.2020.08.1897","title":"1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Quality of life (healthcare); Logistic regression; Internal medicine; Food and drug administration; Surrogate endpoint; Sample size determination; Oncology; Pharmacology","score_opus":0.24776258854680933,"score_gpt":0.40751529856605323,"score_spread":0.1597527100192439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088414576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435146,0.0005095277,0.0000023843872,0.014812443,0.000012393884,0.00017211317,0.00005066409,0.0000052140144,0.00008380364],"genre_scores_gemma":[0.9992092,0.00025914997,0.000021200689,0.00042024636,0.00004482766,0.0000019311026,0.000029428033,0.0000067067963,0.000007298558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989531,0.0002777202,0.00034204128,0.00012865446,0.00018957222,0.0001089199],"domain_scores_gemma":[0.9987193,0.00060049444,0.00035025776,0.000047143058,0.0001914744,0.000091338916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011200327,0.0000755419,0.00062591437,0.000054428572,0.000011948001,0.0000013616029,0.00003143619,0.00022399977,0.000024562818],"category_scores_gemma":[0.0005278402,0.0000527476,0.000031099044,0.00011876125,0.0006214355,0.000032687287,0.000035032983,0.00015332719,3.395873e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041269293,0.00010016893,0.97583854,0.00027981988,0.0002124031,5.3640497e-7,0.0038274738,4.419986e-7,0.012607982,0.000052014493,0.000009218184,0.0066586914],"study_design_scores_gemma":[0.0014422601,0.0010987537,0.99574476,0.00013201096,0.000027512724,4.918967e-8,0.0003399496,0.000111602254,0.0009959369,0.000024456805,0.000031377236,0.000051300074],"about_ca_topic_score_codex":0.0008466466,"about_ca_topic_score_gemma":0.00014826952,"teacher_disagreement_score":0.019906234,"about_ca_system_score_codex":0.0000065726517,"about_ca_system_score_gemma":0.00009505759,"threshold_uncertainty_score":0.22897051},"labels":[],"label_agreement":null},{"id":"W3088422316","doi":"10.1016/j.annonc.2020.08.1536","title":"1889P Information access and use: A Grounded theory of how patients and their friends and family use information to navigate the cancer journey","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Manitoba","funders":"","keywords":"Grounded theory; Theoretical sampling; Credibility; Information needs; Qualitative research; Data collection; Medicine; Receipt; Coping (psychology); Expectancy theory; Coding (social sciences); Psychological intervention; Psychology; Social psychology; Nursing; Computer science; Clinical psychology; Sociology; World Wide Web","score_opus":0.11278073260126102,"score_gpt":0.3595835477246228,"score_spread":0.24680281512336177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088422316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883016,0.00019439077,0.00021306833,0.010465374,0.00009510369,0.00029711527,0.00011125517,0.000007988354,0.000314148],"genre_scores_gemma":[0.98485404,0.0011359695,0.000018794122,0.013907869,0.000024793091,0.000019148576,0.000029035644,0.0000040440436,0.000006317608],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99938214,0.00007307054,0.00024229515,0.00007339814,0.00011641735,0.00011267176],"domain_scores_gemma":[0.99903345,0.00017149247,0.00021580636,0.00009321377,0.00037079063,0.00011523547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023530942,0.00009119233,0.000246121,0.000068492016,0.000044740722,0.00006817294,0.00007012221,0.00007801725,0.000006084969],"category_scores_gemma":[0.00021009962,0.000058835496,0.000025281537,0.00015577894,0.000115101146,0.0015140808,0.00011846511,0.00010990828,3.5015546e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002772964,0.00005104671,0.17785086,0.0004666526,0.00021430757,8.8843154e-7,0.092881545,0.000007524807,0.00037161738,0.0014371271,0.0056594457,0.71828604],"study_design_scores_gemma":[0.0019047058,0.0020938904,0.8817693,0.00011531581,0.000071899565,0.0000066178745,0.008160204,0.00013388533,0.0014352024,0.00034496063,0.10384328,0.000120749195],"about_ca_topic_score_codex":0.0006500246,"about_ca_topic_score_gemma":0.00022390105,"teacher_disagreement_score":0.7181653,"about_ca_system_score_codex":0.0000136497965,"about_ca_system_score_gemma":0.00008335868,"threshold_uncertainty_score":0.23992419},"labels":[],"label_agreement":null},{"id":"W3088445873","doi":"10.1016/j.annonc.2020.08.651","title":"537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Neutropenia; Cmax; Adverse effect; Anemia; Internal medicine; Pharmacodynamics; Gastroenterology; Pharmacokinetics; Dosing; Nausea; Protein arginine methyltransferase 5; Dysgeusia; Oncology; Toxicity; Pharmacology; Methyltransferase","score_opus":0.019788273615009327,"score_gpt":0.3034656153079963,"score_spread":0.283677341692987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088445873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977049,0.00022612947,0.000023465896,0.000673063,0.000040403283,0.0011385876,0.000020044245,0.0000052244786,0.00016815658],"genre_scores_gemma":[0.9994692,0.00004270193,0.00011658312,0.00012983587,0.000050075032,0.000100263554,0.00005717489,0.000021384958,0.000012735713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986417,0.00012203068,0.00047558124,0.0003686703,0.00016477855,0.00022721906],"domain_scores_gemma":[0.9993215,0.000013359903,0.00020762763,0.00021049693,0.00017517415,0.00007184155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014870019,0.00015948711,0.00039800207,0.00010321374,0.000020277552,0.0000015436253,0.00013949387,0.00016721502,0.00001542039],"category_scores_gemma":[0.000053041287,0.00015580669,0.000048226357,0.0003134233,0.00008006305,0.0000085636375,0.000044787113,0.00013669419,4.9354543e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012838816,0.004441752,0.25233144,0.00028660503,0.00039262252,0.000024713105,0.0041963104,0.050613884,0.64682984,0.00003601324,0.0005232195,0.027484825],"study_design_scores_gemma":[0.023661464,0.067792,0.23748015,0.0001705672,0.000048898866,8.424431e-7,0.00076197746,0.00011476783,0.66299844,0.00003446043,0.006438002,0.0004984388],"about_ca_topic_score_codex":0.00043676214,"about_ca_topic_score_gemma":0.005556995,"teacher_disagreement_score":0.063350245,"about_ca_system_score_codex":0.000049909802,"about_ca_system_score_gemma":0.00022003881,"threshold_uncertainty_score":0.63536125},"labels":[],"label_agreement":null},{"id":"W3088460265","doi":"10.1016/j.annonc.2020.08.1881","title":"1655P Immune signature and molecular profiling of epithelioid hemangioendothelioma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pathology; Epithelioid hemangioendothelioma; CD20; CD8; Tumor-infiltrating lymphocytes; Sarcoma; Immune system; Cancer research; Immunohistochemistry; Immunology","score_opus":0.0433851267670574,"score_gpt":0.3295440174820107,"score_spread":0.28615889071495326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088460265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670578,0.011160931,0.00021730023,0.01930156,0.000029968027,0.000252304,0.0000120858185,0.000019632162,0.0019484127],"genre_scores_gemma":[0.99421555,0.00038131294,0.0025584071,0.0027256093,0.00006188835,0.0000048271368,0.000010748232,0.000017733557,0.000023952465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991394,0.000055375785,0.0003112415,0.00017782203,0.00014142632,0.00017472837],"domain_scores_gemma":[0.99936664,0.000048451468,0.00015401823,0.0001584635,0.00015335351,0.00011909773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017251795,0.00010792602,0.00053729035,0.0000830179,0.000016077096,0.000001675673,0.000078657424,0.0001096941,0.000041185143],"category_scores_gemma":[0.00016141403,0.00008987893,0.00020988754,0.00018905243,0.000120107456,0.000027146682,0.00006541955,0.00014443591,0.000004024378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026344578,0.0001795474,0.0022823133,0.0003250656,0.00020537307,0.00034152076,0.00038313103,0.0000057110233,0.98440397,0.0016621272,0.0003899815,0.009557815],"study_design_scores_gemma":[0.0014835764,0.003054914,0.0036727788,0.00008456092,0.000095514806,0.0001330385,0.00020992575,0.00013297077,0.9832236,0.00034443903,0.007470438,0.0000942237],"about_ca_topic_score_codex":0.000010732949,"about_ca_topic_score_gemma":3.627932e-7,"teacher_disagreement_score":0.027157715,"about_ca_system_score_codex":0.0000036515412,"about_ca_system_score_gemma":0.000078885336,"threshold_uncertainty_score":0.36651564},"labels":[],"label_agreement":null},{"id":"W3088465353","doi":"10.1016/j.annonc.2020.08.924","title":"665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Biotech; Genentech; Active Biotech; Astellas Pharma; Incyte; Gilead Sciences; Alere; Sanofi; Genomic Health; GlaxoSmithKline; Myriad Genetics; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; Ipsen; Constellation Pharmaceuticals; Clovis Oncology; Astellas Pharma US","keywords":"Medicine; Enzalutamide; Prostate cancer; Asymptomatic; Cancer; Placebo; Internal medicine; Disease; Oncology; Androgen receptor; Pathology; Alternative medicine","score_opus":0.18446280646921684,"score_gpt":0.46331229145432057,"score_spread":0.27884948498510376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088465353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854409,0.001792832,0.0000010321111,0.009278538,0.00006899593,0.0016970672,0.00058501266,0.000021657683,0.0011139767],"genre_scores_gemma":[0.9925995,0.005695489,0.00006437327,0.000838795,0.00006580814,0.0002591767,0.00009645064,0.000034840275,0.00034557725],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976085,0.00016222626,0.00081048853,0.0004352426,0.00042651032,0.00055704865],"domain_scores_gemma":[0.998018,0.00017835575,0.0005327269,0.00022131432,0.0007488553,0.00030071416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022176513,0.0002684123,0.00086778967,0.00021947459,0.00004424236,0.000008058744,0.00008582664,0.00014731046,0.00014897129],"category_scores_gemma":[0.0002828573,0.00018088214,0.00017318713,0.00062625686,0.00025484856,0.00011864909,0.00005050871,0.0003250363,0.000004566022],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18821189,0.0028574655,0.11213641,0.000784445,0.0028519216,0.0054531065,0.039532397,0.003930123,0.46114105,0.0000544184,0.01571999,0.16732676],"study_design_scores_gemma":[0.018809577,0.07027841,0.51847553,0.0010605465,0.00029199597,0.000042392767,0.0029661641,0.0006443662,0.382306,0.00010669339,0.004453803,0.00056451425],"about_ca_topic_score_codex":0.006962079,"about_ca_topic_score_gemma":0.0015357218,"teacher_disagreement_score":0.4063391,"about_ca_system_score_codex":0.00037109773,"about_ca_system_score_gemma":0.002994961,"threshold_uncertainty_score":0.99965066},"labels":[],"label_agreement":null},{"id":"W3088465742","doi":"10.1016/j.annonc.2020.08.427","title":"325P Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Hazard ratio; Metastatic breast cancer; Population; Clinical endpoint; Gastroenterology; Veliparib; Cancer; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.047831265155041415,"score_gpt":0.3822295165894681,"score_spread":0.33439825143442664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088465742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870751,0.000109872475,0.000046678026,0.010650349,0.000045036835,0.0014163238,0.0005714308,0.00001969015,0.00006553851],"genre_scores_gemma":[0.9959475,0.00008431148,0.00015562354,0.003513224,0.000034201275,0.00014329312,0.000034717737,0.00003527912,0.000051869156],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99746287,0.0007143056,0.00070307375,0.00032951203,0.0004250012,0.0003652548],"domain_scores_gemma":[0.997421,0.00067830464,0.0008128719,0.00027578222,0.0006896809,0.00012233127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005308831,0.0002499608,0.0010943239,0.000107977095,0.000053410964,0.000004671381,0.00023234289,0.00007548261,0.00010244288],"category_scores_gemma":[0.0005380123,0.00017225079,0.00007461671,0.0006759384,0.0002774684,0.00015650546,0.00004877125,0.00036202712,0.000002256476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.454445,0.021151002,0.32092413,0.000284689,0.0019151936,0.00031074413,0.057541434,0.00025512377,0.005353295,0.000021928303,0.0004952287,0.13730222],"study_design_scores_gemma":[0.032124333,0.02290479,0.93600804,0.00022484736,0.00019416814,0.0000088341685,0.006285975,0.00004399588,0.00095918414,0.000046404002,0.0010203064,0.00017913345],"about_ca_topic_score_codex":0.00018938837,"about_ca_topic_score_gemma":0.00015302033,"teacher_disagreement_score":0.6150839,"about_ca_system_score_codex":0.00011496044,"about_ca_system_score_gemma":0.00043791888,"threshold_uncertainty_score":0.7024183},"labels":[],"label_agreement":null},{"id":"W3088466047","doi":"10.1016/j.annonc.2020.08.2070","title":"799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Oncology; Placebo; Tolerability; Cisplatin; Adjuvant therapy; Urology; Chemotherapy; Randomized controlled trial; Adverse effect; Pathology; Confidence interval","score_opus":0.06522590316561952,"score_gpt":0.3628403563382298,"score_spread":0.29761445317261026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088466047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919001,0.00017523584,0.00007689411,0.0008528686,0.00007634214,0.005898,0.00005609091,0.000006430698,0.000958067],"genre_scores_gemma":[0.9982904,0.00012152916,0.00010725723,0.0003201514,0.0001980704,0.0007307174,0.00015505301,0.00003191937,0.00004488292],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99741405,0.0005504016,0.00087308686,0.0004363874,0.00033847417,0.00038761302],"domain_scores_gemma":[0.99824643,0.0002554778,0.0004969211,0.0002969444,0.0005428504,0.00016139697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006347882,0.0002579737,0.0011494874,0.00017686568,0.000049374787,0.000017151855,0.00030255437,0.00023644864,0.0000819633],"category_scores_gemma":[0.00062630273,0.00020022888,0.00024545906,0.00023889486,0.00028687302,0.000020703163,0.00010687152,0.0002328231,0.000003987228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8789885,0.0012444805,0.0012810618,0.00003692577,0.0002944993,0.000007276763,0.0006189526,0.00012131955,0.11600349,0.00006670225,0.0002031962,0.001133618],"study_design_scores_gemma":[0.68438464,0.031182103,0.000048258567,0.00002011713,0.000022335327,8.1696726e-7,0.0000532344,0.000046681616,0.28371593,0.000014636925,0.00037879663,0.00013246284],"about_ca_topic_score_codex":0.00019326084,"about_ca_topic_score_gemma":0.00022663326,"teacher_disagreement_score":0.19460386,"about_ca_system_score_codex":0.000016475346,"about_ca_system_score_gemma":0.001051712,"threshold_uncertainty_score":0.81650966},"labels":[],"label_agreement":null},{"id":"W3088473397","doi":"10.1016/j.annonc.2020.08.260","title":"139P Rearranged during transfection (RET) partners identified by next-generation sequencing in Chinese patients with solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; Ipsen; Cilag; Astellas Pharma; Eisai; Menarini Silicon Biosystems; Astex Pharmaceuticals; Sierra Oncology; Incyte; Taiho Pharmaceutical; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Johns Hopkins University; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cancer; Lung cancer; Colorectal cancer; Cancer research; Gene rearrangement; Internal medicine; Oncology; Fusion gene; Papillary thyroid cancer; Cabozantinib; Breast cancer; Vandetanib; Thyroid cancer; Hepatocellular carcinoma; Gene; Genetics; Biology; Sorafenib","score_opus":0.0595735486724997,"score_gpt":0.3239930595269423,"score_spread":0.2644195108544426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088473397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982545,0.00023793482,0.00016797926,0.0007013206,0.000091551745,0.00019044241,0.00003300864,0.000005731425,0.00031757273],"genre_scores_gemma":[0.9982723,0.00044302637,0.00006383044,0.0007260219,0.00016293392,0.000018965606,0.00028254424,0.000016520758,0.0000138862515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991818,0.000057714275,0.00023962653,0.0002569993,0.00008353666,0.00018031383],"domain_scores_gemma":[0.9995957,0.000013452327,0.00010203717,0.00010635218,0.00010535751,0.00007712336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010115141,0.000113089154,0.0001944626,0.000035963825,0.00003768342,0.000011840164,0.00007853106,0.00011728382,0.000008404924],"category_scores_gemma":[0.00010127555,0.000108439,0.000047935777,0.00011113192,0.000044389035,0.0000096936365,0.000022690776,0.00007979007,0.000001501462],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048971863,0.000075970966,0.032159086,0.000025389052,0.0000335926,0.0000049275586,0.00036966614,0.0016371782,0.9621739,0.000004107143,0.0016095198,0.0014169607],"study_design_scores_gemma":[0.004632943,0.0043499866,0.0781784,0.000026452553,0.000035043155,0.0000051370685,0.00020259895,0.0009582534,0.9074753,0.000031257605,0.0037017053,0.00040292353],"about_ca_topic_score_codex":0.0001220504,"about_ca_topic_score_gemma":0.00072983553,"teacher_disagreement_score":0.054698583,"about_ca_system_score_codex":0.00003635547,"about_ca_system_score_gemma":0.000138498,"threshold_uncertainty_score":0.4422014},"labels":[],"label_agreement":null},{"id":"W3088474072","doi":"10.1016/j.annonc.2020.08.1200","title":"1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Clinical endpoint; Stage (stratigraphy); Oncology; Adjuvant; Melanoma; Gastroenterology; Cancer; Immunotherapy; Randomized controlled trial; Cancer research","score_opus":0.0914736239595253,"score_gpt":0.34813811171124676,"score_spread":0.25666448775172146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088474072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626277,0.0030114772,0.000006651795,0.023889758,0.00037649673,0.0005066109,0.0006506989,0.000056012836,0.008874613],"genre_scores_gemma":[0.991674,0.0043095048,0.00025846256,0.0026511753,0.000251445,0.000018012817,0.00017523504,0.00003121712,0.0006309705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99727166,0.0002983283,0.0009647241,0.0006315679,0.000345309,0.00048839743],"domain_scores_gemma":[0.99818236,0.00042628637,0.00040715947,0.00055616925,0.00020081043,0.00022723268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007588538,0.0002747123,0.0010431936,0.00015941738,0.000053207168,0.000015206932,0.00032029903,0.00033211045,0.00046070185],"category_scores_gemma":[0.00069782,0.0002523269,0.00015027566,0.0003713897,0.00029851118,0.0001325285,0.0002030983,0.00043815724,0.000013631788],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52412647,0.0020245903,0.018390778,0.00056024396,0.0014628236,0.0016286089,0.01636484,0.000018500077,0.118150055,0.00042077593,0.16406979,0.15278253],"study_design_scores_gemma":[0.14613271,0.024817945,0.49152124,0.00080122723,0.00019009916,0.00004421593,0.0019897418,0.0013400518,0.028443718,0.0010350156,0.30267403,0.0010099977],"about_ca_topic_score_codex":0.005414145,"about_ca_topic_score_gemma":0.0029220874,"teacher_disagreement_score":0.47313046,"about_ca_system_score_codex":0.0000990807,"about_ca_system_score_gemma":0.00045910774,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W3088510493","doi":"10.1016/j.annonc.2020.08.638","title":"524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Tolerability; Internal medicine; Neutropenia; Phases of clinical research; Pharmacokinetics; Pharmacology; Pharmacodynamics; Pembrolizumab; Oncology; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy","score_opus":0.08599711741859951,"score_gpt":0.4161967174254941,"score_spread":0.3301996000068946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088510493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935069,0.00033173012,0.00000992389,0.0022096804,0.00014156164,0.002071053,0.0001824599,0.000018154446,0.0015285108],"genre_scores_gemma":[0.99850357,0.0007460978,0.00010802098,0.0003532532,0.000059685673,0.000038651953,0.00009504118,0.00004714064,0.00004851363],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961647,0.00038630908,0.0014953889,0.0005912537,0.0007672923,0.0005950512],"domain_scores_gemma":[0.9977654,0.00030616287,0.0005266995,0.00052589714,0.0006704228,0.00020539855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071229466,0.0003002896,0.001661068,0.0005119642,0.000030825908,0.000004332776,0.00037499532,0.00019549306,0.00018838674],"category_scores_gemma":[0.00023492162,0.00027115623,0.00015421855,0.0011501629,0.0003679899,0.00013329742,0.00008423851,0.00056256395,0.00000535284],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28832024,0.059528038,0.09968521,0.0007350449,0.00072803,0.0015385377,0.041239977,0.00062984106,0.4230559,0.000015845662,0.0017688103,0.082754515],"study_design_scores_gemma":[0.2654405,0.30556706,0.28131446,0.00087271805,0.00015483747,0.000028891036,0.0105537195,0.00035349937,0.106360555,0.000023741646,0.028699957,0.0006300669],"about_ca_topic_score_codex":0.00031781354,"about_ca_topic_score_gemma":0.00044969254,"teacher_disagreement_score":0.31669533,"about_ca_system_score_codex":0.00008953438,"about_ca_system_score_gemma":0.00042844814,"threshold_uncertainty_score":0.9999741},"labels":[],"label_agreement":null},{"id":"W3088534216","doi":"10.1016/j.annonc.2020.08.1166","title":"1046P Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Oncology; Nivolumab; Population; Clinical trial; Melanoma; Cancer; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.1754265286605803,"score_gpt":0.4738061029199914,"score_spread":0.2983795742594111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088534216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303347,0.0003781977,0.00038260393,0.0033417006,0.00018835899,0.0009956107,0.001432705,0.000008825721,0.00023851247],"genre_scores_gemma":[0.99298704,0.001901936,0.0010960799,0.0032875703,0.00021632132,0.000080810634,0.0003624137,0.00003686469,0.000030958177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997045,0.00039268823,0.0014510219,0.00057685433,0.00015957224,0.00037485495],"domain_scores_gemma":[0.99633497,0.0010179173,0.0011128881,0.00041954278,0.0009282319,0.00018644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013693748,0.00029322554,0.0016890547,0.000049075843,0.000060169183,0.000012491197,0.0003289617,0.00038587025,0.000040309173],"category_scores_gemma":[0.0034856966,0.0002167341,0.00034448793,0.000104326085,0.0003612602,0.00000786865,0.00017531023,0.00008862655,0.0000014349791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07941989,0.0064523146,0.70347005,0.00065523025,0.004114159,0.000041610536,0.000924944,0.00051718793,0.06791373,0.00028468517,0.113968424,0.022237785],"study_design_scores_gemma":[0.027437499,0.10564591,0.35510376,0.00010916621,0.0008118976,0.000006528025,0.00024231848,0.00012636078,0.29821298,0.000254482,0.2111624,0.0008866993],"about_ca_topic_score_codex":0.000059692098,"about_ca_topic_score_gemma":0.0003167494,"teacher_disagreement_score":0.3483663,"about_ca_system_score_codex":0.000024972738,"about_ca_system_score_gemma":0.0005534755,"threshold_uncertainty_score":0.883816},"labels":[],"label_agreement":null},{"id":"W3088563759","doi":"10.1016/j.annonc.2020.08.2084","title":"690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Nivolumab; Prostate cancer; Oncology; Internal medicine; Enzalutamide; Chemotherapy; Placebo; Cancer; Immunotherapy; Androgen receptor; Pathology","score_opus":0.23337521537375636,"score_gpt":0.47446785959615373,"score_spread":0.24109264422239737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088563759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960012,0.001166113,0.00016433746,0.022523267,0.0001487137,0.0144216595,0.000388161,0.000035125908,0.0011406229],"genre_scores_gemma":[0.99100345,0.0013991018,0.0011021462,0.0005826747,0.00015753329,0.0030612433,0.00021935995,0.0000431355,0.002431355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997581,0.00019312461,0.0009688909,0.00038225102,0.00041253958,0.0004621653],"domain_scores_gemma":[0.9973905,0.00063282694,0.00067088386,0.00022373236,0.00080294017,0.00027913245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009262885,0.00026755402,0.0019357844,0.00015753252,0.00007802377,0.000015688112,0.00013856075,0.000105696985,0.00029071668],"category_scores_gemma":[0.0002487605,0.00016162953,0.00027079045,0.00037947888,0.00049195706,0.000117672585,0.00003520079,0.00018653739,0.000002765442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.979449,0.0020216447,0.000009058307,0.0008409267,0.002175641,0.00015100082,0.0018117893,0.00004149961,0.005664743,0.00018558836,0.003109721,0.0045394218],"study_design_scores_gemma":[0.9002389,0.047296043,0.0000033614397,0.00015009599,0.00097010296,0.0000119258575,0.000441619,0.00064087956,0.046511747,0.00010625122,0.003480611,0.00014849482],"about_ca_topic_score_codex":0.00035265533,"about_ca_topic_score_gemma":0.00029612618,"teacher_disagreement_score":0.079210095,"about_ca_system_score_codex":0.00007010798,"about_ca_system_score_gemma":0.002552761,"threshold_uncertainty_score":0.65910614},"labels":[],"label_agreement":null},{"id":"W3088564351","doi":"10.1016/j.annonc.2020.08.533","title":"422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; Daiichi Sankyo Company; Sierra Oncology; Foundation Medicine; Chugai Pharmaceutical; Novartis Pharma; Genentech; Eli Lilly and Company; Ono Pharmaceutical; Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; Novo Nordisk; Danmarks Frie Forskningsfond; Daiichi-Sankyo; GlaxoSmithKline Japan; Sanofi; Les Laboratories Pierre Fabre; Strategiske Forskningsråd; FibroGen; BeiGene; Natera; Sanofi K.K.; INCLIVA Instituto de Investigación Sanitaria; GlaxoSmithKline; AstraZeneca","keywords":"Medicine; Oxaliplatin; Clinical endpoint; Colorectal cancer; Odds ratio; Internal medicine; Surgery; Confounding; Randomized controlled trial; Gastroenterology; Cancer","score_opus":0.5041576845492349,"score_gpt":0.4553447199322874,"score_spread":0.04881296461694751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088564351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905449,0.0021491603,0.000079220896,0.0042783823,0.000029045503,0.0018245125,0.0009745875,0.000018007966,0.00010219062],"genre_scores_gemma":[0.9949721,0.0002564558,0.0021623771,0.0018615384,0.000027183047,0.0004211652,0.00026969006,0.00001994699,0.00000955156],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957523,0.0014271302,0.0013263349,0.00068749813,0.000503209,0.00030352332],"domain_scores_gemma":[0.9959742,0.0022245059,0.00088162295,0.00047634388,0.00021425361,0.00022909263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022438366,0.000297433,0.004173716,0.00022043375,0.000024359248,0.000009558748,0.00019996967,0.00019434936,0.00067026756],"category_scores_gemma":[0.00231672,0.00017616134,0.00039250063,0.0008574211,0.00029439677,0.00011747501,0.00022656942,0.00023220648,0.0000011960201],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83400995,0.00094813306,0.054432947,0.000094083865,0.04266789,0.002181585,0.002461726,0.0006688815,0.0028215912,0.000005356002,0.00011152577,0.059596334],"study_design_scores_gemma":[0.102890715,0.035986684,0.738014,0.00010042531,0.110873066,0.00005800201,0.00036221728,0.0049568284,0.0028464585,0.000063166604,0.003277504,0.00057097076],"about_ca_topic_score_codex":0.00021526591,"about_ca_topic_score_gemma":0.00268173,"teacher_disagreement_score":0.7311192,"about_ca_system_score_codex":0.00006156051,"about_ca_system_score_gemma":0.00039181267,"threshold_uncertainty_score":0.733896},"labels":[],"label_agreement":null},{"id":"W3088566771","doi":"10.1016/j.annonc.2020.08.1260","title":"1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Rash; Internal medicine; Gastroenterology; Adverse effect; Diarrhea; Incidence (geometry); Population; Asymptomatic; Placebo; Pathology","score_opus":0.03152753028955441,"score_gpt":0.331205111221538,"score_spread":0.2996775809319836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088566771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981812,0.00022102201,0.000016654605,0.00072668196,0.0000084325,0.00048675106,0.000013660976,0.0000020803354,0.00034349694],"genre_scores_gemma":[0.999471,0.00008822659,0.00005983023,0.00030719265,0.000012284033,0.000022414562,0.000023511697,0.0000070731458,0.000008472231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991226,0.00019011655,0.0002311234,0.00022388696,0.000100521655,0.00013175499],"domain_scores_gemma":[0.9995166,0.00004494669,0.0001706499,0.0001398845,0.00008155378,0.000046355493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003225907,0.000108552704,0.0002700818,0.00003839224,0.000019603453,0.0000013834003,0.00012387615,0.00007625513,0.000004102193],"category_scores_gemma":[0.00004111369,0.00007402182,0.000015148677,0.00012722294,0.00013804552,0.0000071128293,0.0000638045,0.00007989068,6.3701503e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026248472,0.010389786,0.5330948,0.00025967852,0.0004486896,0.0005185359,0.020525577,0.00012933352,0.36074704,0.00052793615,0.0009049911,0.046205163],"study_design_scores_gemma":[0.07452522,0.18639335,0.55839485,0.0002398248,0.00021217245,0.00023716823,0.018255368,0.0009967547,0.15612157,0.00032986823,0.0034591104,0.00083476264],"about_ca_topic_score_codex":0.00006138532,"about_ca_topic_score_gemma":0.00018462804,"teacher_disagreement_score":0.20462546,"about_ca_system_score_codex":0.0000032738337,"about_ca_system_score_gemma":0.00010655482,"threshold_uncertainty_score":0.30185223},"labels":[],"label_agreement":null},{"id":"W3088567749","doi":"10.1016/j.annonc.2020.08.1970","title":"1464P Asian-ethnicity related differences among patients with metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Proportional hazards model; Confidence interval; Cancer; Ethnic group; Adenocarcinoma; Oncology; Gastroenterology","score_opus":0.05474946922956632,"score_gpt":0.3009760053618363,"score_spread":0.24622653613226997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088567749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210507,0.00023690442,0.00017045886,0.0053018597,0.00008224635,0.000414968,0.000006492078,0.000036590936,0.0016454305],"genre_scores_gemma":[0.99804455,0.000083964325,0.00049237406,0.0011163024,0.000042495634,0.000008023988,0.000029497993,0.000013213988,0.00016957233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878025,0.000089522844,0.00034013498,0.00028002512,0.00024933263,0.0002607099],"domain_scores_gemma":[0.99922353,0.000065987384,0.0002542201,0.000121479025,0.00013959779,0.00019520942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001231107,0.00016199061,0.00053732644,0.00013525362,0.00004228584,0.000007960844,0.00007491059,0.000061771156,0.00018103575],"category_scores_gemma":[0.00010310754,0.00011985949,0.00006723708,0.00030028366,0.00019048847,0.000111548026,0.00006119018,0.00019948868,0.000006914048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006663505,0.0001639612,0.97765714,0.00010336357,0.00023206127,0.000060059738,0.0004478135,0.0000035325934,0.000011698186,0.0000308172,0.0018703635,0.018752817],"study_design_scores_gemma":[0.0034094737,0.008344371,0.9871095,0.00002725039,0.0003157557,0.000011563198,0.00026337383,0.00010552879,0.000033889704,0.000045897807,0.00025918218,0.00007421095],"about_ca_topic_score_codex":0.000059291488,"about_ca_topic_score_gemma":0.000020280266,"teacher_disagreement_score":0.018678606,"about_ca_system_score_codex":0.000022852422,"about_ca_system_score_gemma":0.00006177144,"threshold_uncertainty_score":0.4887728},"labels":[],"label_agreement":null},{"id":"W3088574070","doi":"10.1016/j.annonc.2020.08.1751","title":"1687P Oncologists knowledge, attitude and practice in COVID-19 pandemic and its negative impact on them: An international study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Nordic Pharma Group; Celgene; Sanofi; Eli Lilly and Company; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Sirtex Medical; Servier; Amgen","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Family medicine; Virology; Medical education; Internal medicine; Infectious disease (medical specialty)","score_opus":0.5158347700505271,"score_gpt":0.6174949197403499,"score_spread":0.10166014968982273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088574070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92398024,0.000537813,0.0000052047612,0.07055172,0.000080366146,0.00075555523,0.000020905509,0.00003159832,0.004036576],"genre_scores_gemma":[0.9628544,0.002354037,0.000071110066,0.03447994,0.00017674657,0.000020724487,0.000008516506,0.00001230221,0.000022258137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981708,0.0006183152,0.00038675446,0.00037825856,0.00018746288,0.00025842342],"domain_scores_gemma":[0.994805,0.0038361887,0.0002422205,0.00013828863,0.00029473595,0.00068358023],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012807356,0.00017146539,0.0005581798,0.00015968201,0.000047798876,0.000013420675,0.00011856006,0.00017522393,0.000097036565],"category_scores_gemma":[0.014933859,0.00013472079,0.000040505936,0.00020955042,0.00012115184,0.0002794951,0.00010948279,0.00039959323,0.000013795064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018711213,0.0056384094,0.8084872,0.00028275896,0.00041205052,0.0008111975,0.06145907,0.000053935077,0.00077803235,0.00038092455,0.0023609765,0.10062423],"study_design_scores_gemma":[0.007716784,0.039113447,0.9209149,0.00007507798,0.00007626329,0.00028549394,0.005501838,0.00029241247,0.00007261883,0.00024765087,0.025534468,0.00016908335],"about_ca_topic_score_codex":0.0008179764,"about_ca_topic_score_gemma":0.001206868,"teacher_disagreement_score":0.11242767,"about_ca_system_score_codex":0.00028550226,"about_ca_system_score_gemma":0.0016852446,"threshold_uncertainty_score":0.9933638},"labels":[],"label_agreement":null},{"id":"W3088578246","doi":"10.1016/j.annonc.2020.08.517","title":"406MO Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; Sierra Oncology; Sirtex Medical; Ligue Contre le Cancer; FibroGen; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; Celgene; Eisai; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Servier; Amgen","keywords":"Somatic cell; Gene; Germline; DNA sequencing; Medicine; COLD-PCR; Cancer; Minimal residual disease; Germline mutation; Mutation; Genetics; Point mutation; Cancer research; Oncology; Biology; Internal medicine; Leukemia","score_opus":0.050041679305331974,"score_gpt":0.3090028326787866,"score_spread":0.2589611533734546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088578246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963302,0.00043593135,0.00011221988,0.0018065753,0.00009784922,0.0006194042,0.0005333758,0.000014242773,0.00005017684],"genre_scores_gemma":[0.99387795,0.00011429985,0.0012051184,0.004199063,0.0004093698,0.000101110716,0.000047249883,0.0000394598,0.0000063526168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814147,0.0001821833,0.00049159204,0.0006085079,0.000113435344,0.00046283074],"domain_scores_gemma":[0.9986077,0.00037514072,0.00028312943,0.00018488443,0.00018280446,0.00036636853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046346325,0.00024125846,0.00051594456,0.00007028526,0.0000925655,0.000024247962,0.00011320024,0.00012884224,0.0000062455183],"category_scores_gemma":[0.0016310404,0.0002761506,0.00011455745,0.00014307072,0.00011013033,0.000009268521,0.0001867287,0.00011704167,8.089042e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025228232,0.00028018295,0.0067735026,0.00022608573,0.000087273605,0.00026856014,0.00041882644,0.0021768846,0.9820901,0.000007927281,0.0009967991,0.0041510346],"study_design_scores_gemma":[0.005413222,0.0030186435,0.004623728,0.00012501107,0.0001548559,0.0000417538,0.0005686168,0.0052737887,0.97653604,0.000043506865,0.0037209522,0.00047988357],"about_ca_topic_score_codex":0.0005252427,"about_ca_topic_score_gemma":0.0031405345,"teacher_disagreement_score":0.005554062,"about_ca_system_score_codex":0.00004835504,"about_ca_system_score_gemma":0.00076535204,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W3088584326","doi":"10.1016/j.annonc.2020.08.1026","title":"911O Performance of dual p16 and HPV testing for determining prognosis in cancer of the oropharynx, the EPIC-OPC Study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Ipsen; Astellas Pharma; Ono Pharmaceutical; Eisai; EMD Serono; Rakuten Medical; Incyte; MacroGenics; Merck KGaA; Regeneron Pharmaceuticals; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Internal medicine; EPIC; Cohort; Biomarker; Proportional hazards model; Cancer; HPV infection; Cervical cancer","score_opus":0.27342604201621645,"score_gpt":0.44112738916033406,"score_spread":0.1677013471441176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088584326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902125,0.00088974944,3.6119584e-7,0.007618014,0.00005677106,0.00067169004,0.00000945892,0.0000037630214,0.00053771446],"genre_scores_gemma":[0.9985275,0.00021807822,0.00014476388,0.0009041162,0.00006524117,0.00011963972,2.124043e-7,0.000006877824,0.000013525404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992341,0.000057341127,0.00033658146,0.00012533396,0.000100810175,0.00014584094],"domain_scores_gemma":[0.9990678,0.000448166,0.00019936422,0.000083722516,0.00017266333,0.000028283768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033299148,0.00007357239,0.00046289316,0.000025231255,0.00004723421,9.721479e-7,0.00007740869,0.000035516754,0.00000805814],"category_scores_gemma":[0.0004898147,0.00004103352,0.000038620903,0.00019419013,0.0001628457,0.000026729029,0.000092770824,0.000098723875,9.535659e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002805502,0.00019749001,0.8408117,0.000304493,0.00007228816,0.0000026571154,0.0070935446,0.000009196329,0.002634482,0.0000035572566,0.00028989668,0.14830011],"study_design_scores_gemma":[0.0018372682,0.014201405,0.96330994,0.00019916108,0.00008807862,0.0000038424523,0.0019786851,0.0006049237,0.016861048,0.000006446463,0.00086074986,0.000048447597],"about_ca_topic_score_codex":0.000113255956,"about_ca_topic_score_gemma":0.0001706961,"teacher_disagreement_score":0.14825167,"about_ca_system_score_codex":0.000009888668,"about_ca_system_score_gemma":0.00018786741,"threshold_uncertainty_score":0.16732985},"labels":[],"label_agreement":null},{"id":"W3088586143","doi":"10.1016/j.annonc.2020.08.2294","title":"LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations &amp; other solid tumours with NRG1/ERBB gene fusions","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Oncology; Lung cancer; Progressive disease; Response Evaluation Criteria in Solid Tumors; KRAS; Clinical endpoint; ErbB; Chemotherapy; Cancer; Gastroenterology; Clinical trial; Colorectal cancer","score_opus":0.02996521785262123,"score_gpt":0.313001346641364,"score_spread":0.28303612878874274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088586143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977204,0.0004422748,0.0003480725,0.00035513012,0.00008327156,0.00057151006,0.0001500831,0.0000047634653,0.00032448338],"genre_scores_gemma":[0.9982546,0.00025192834,0.0006598914,0.00042061534,0.00013173708,0.00006345514,0.00014604474,0.000029471563,0.000042238393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847746,0.0001263209,0.00054852664,0.00039362945,0.00019266679,0.00026138764],"domain_scores_gemma":[0.9983885,0.000044218716,0.00063455995,0.0002880783,0.0005404107,0.0001041998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016701037,0.0001997949,0.00065617036,0.00019546696,0.000060493636,0.0000044952008,0.00019294808,0.00013152247,0.000054120082],"category_scores_gemma":[0.000061027964,0.00017295034,0.00011405974,0.0007521819,0.000115924624,0.000011065364,0.00007965624,0.00012013481,3.339886e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019770924,0.0029545024,0.78752905,0.00011804927,0.0015869411,0.000002025337,0.009334261,0.036496993,0.15773551,0.0000023761963,0.0009216723,0.0013415404],"study_design_scores_gemma":[0.008062736,0.006640915,0.86608315,0.00008574825,0.0011670412,7.701495e-7,0.0025603843,0.00035487022,0.103095256,0.0000020984266,0.01148742,0.00045959695],"about_ca_topic_score_codex":0.0023288082,"about_ca_topic_score_gemma":0.024005616,"teacher_disagreement_score":0.07855412,"about_ca_system_score_codex":0.000018893088,"about_ca_system_score_gemma":0.00035792077,"threshold_uncertainty_score":0.99380374},"labels":[],"label_agreement":null},{"id":"W3088595788","doi":"10.1016/j.annonc.2020.08.2246","title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Internal medicine; Hazard ratio; Fulvestrant; Population; Aromatase inhibitor; Progression-free survival; Oncology; Breast cancer; Cancer; Chemotherapy; Aromatase; Confidence interval; Estrogen receptor","score_opus":0.07991196063309068,"score_gpt":0.3941266836991093,"score_spread":0.3142147230660186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088595788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667387,0.0006272403,0.0005816248,0.015122763,0.00040726672,0.0029960393,0.0130619425,0.000099925295,0.0003645149],"genre_scores_gemma":[0.99323744,0.00050444243,0.0023517373,0.00196105,0.00086468965,0.00031161896,0.0005598092,0.00011579493,0.00009344345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99521947,0.00046341182,0.0017263286,0.0011503765,0.0006241991,0.00081620266],"domain_scores_gemma":[0.9945413,0.001205764,0.0015307969,0.00051498745,0.0016799679,0.000527199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040236735,0.0006492005,0.0023465354,0.00017299523,0.0001817939,0.000012748854,0.0004265599,0.0003403772,0.00047001278],"category_scores_gemma":[0.0005410875,0.00060410664,0.00039581023,0.0003969899,0.0004972441,0.00048656116,0.000148782,0.0005737379,0.000009442498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24159445,0.008808338,0.0013303419,0.00020923077,0.004297984,0.00008973445,0.038624596,0.00012474469,0.5369629,0.00017438325,0.0052002165,0.16258307],"study_design_scores_gemma":[0.30276656,0.115603775,0.17382343,0.0007077349,0.0012645876,0.000041788153,0.024293598,0.00019526106,0.3626474,0.001175359,0.01537804,0.0021024542],"about_ca_topic_score_codex":0.0038546566,"about_ca_topic_score_gemma":0.0007044554,"teacher_disagreement_score":0.17431551,"about_ca_system_score_codex":0.00025135197,"about_ca_system_score_gemma":0.00054511917,"threshold_uncertainty_score":0.999641},"labels":[],"label_agreement":null},{"id":"W3088602042","doi":"10.1016/j.annonc.2020.08.2250","title":"LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; PTEN; Prostate cancer; Internal medicine; Placebo; Androgen deprivation therapy; Prednisone; Gastroenterology; Asymptomatic; Clinical endpoint; Cancer; Urology; Oncology; Clinical trial; PI3K/AKT/mTOR pathway; Pathology","score_opus":0.19236414445010053,"score_gpt":0.45830870870332024,"score_spread":0.2659445642532197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088602042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874363,0.0017153946,0.000011882271,0.0068030073,0.00013711123,0.003126337,0.00040362097,0.000029168665,0.00033717335],"genre_scores_gemma":[0.9970152,0.0009691151,0.00009825354,0.0005923918,0.0000798962,0.00055969245,0.00022218766,0.00003979567,0.00042349144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99673176,0.0003629943,0.0011575328,0.0005512275,0.00056622503,0.000630287],"domain_scores_gemma":[0.9982315,0.00015805071,0.00045957128,0.00034567175,0.00046125508,0.0003439844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005843771,0.00031590255,0.0013595442,0.00027804376,0.00007187156,0.000014711127,0.00021692675,0.000115939445,0.0004677617],"category_scores_gemma":[0.0001223944,0.00025412798,0.00012605722,0.00061054796,0.00026208445,0.00017524035,0.000115859395,0.0003519785,0.000015517648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49820113,0.028606847,0.020146614,0.0042398195,0.0053221444,0.009768855,0.10382039,0.005154873,0.23441567,0.0001445933,0.018892707,0.07128635],"study_design_scores_gemma":[0.48443395,0.20551172,0.03446238,0.0010693027,0.002334624,0.00007127662,0.034810737,0.007893014,0.21423748,0.00024452692,0.013507048,0.0014239525],"about_ca_topic_score_codex":0.0049336585,"about_ca_topic_score_gemma":0.0037211813,"teacher_disagreement_score":0.17690487,"about_ca_system_score_codex":0.0002819138,"about_ca_system_score_gemma":0.001974506,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W3088603564","doi":"10.1016/j.annonc.2020.08.429","title":"327P Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Pfizer Pharmaceuticals; Novartis Pharmaceuticals Canada; Celldex Therapeutics; Astellas Pharma; Eisai; Chugai Pharmaceutical; Celltrion; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Daiichi-Sankyo; Pfizer; Genomic Health","keywords":"Medicine; Fulvestrant; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Clinical trial; First line treatment; Chemotherapy; Tamoxifen","score_opus":0.07734766725541938,"score_gpt":0.4071170968901116,"score_spread":0.32976942963469225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088603564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877275,0.0011953005,0.000048964008,0.008377798,0.00006048172,0.0015853612,0.000072958996,0.000042497206,0.0008891423],"genre_scores_gemma":[0.9947152,0.0014924455,0.0010637408,0.0020293542,0.00008860339,0.00032532602,0.000004138666,0.000041542513,0.00023961104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978508,0.00022405652,0.0006600978,0.0005778144,0.00023264925,0.00045461766],"domain_scores_gemma":[0.9989184,0.00017970995,0.0002916756,0.00024229064,0.00017461828,0.0001932847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031401348,0.00030454973,0.0012990456,0.00028867106,0.000031446812,0.0000058128867,0.000109707355,0.00006949596,0.00013036357],"category_scores_gemma":[0.000066293585,0.00024638977,0.000071013426,0.000887784,0.00019483497,0.00017515723,0.000057785343,0.00027306555,0.000003620639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014996217,0.0019506791,0.61522603,0.00031454308,0.00095230294,0.0034147108,0.02248003,0.0022301872,0.0076641375,0.00016131064,0.000035043817,0.33057484],"study_design_scores_gemma":[0.016754417,0.015782997,0.95693374,0.00039658856,0.00015264473,0.0001220224,0.0056774747,0.00070034375,0.00069342484,0.00030984127,0.002147424,0.00032907198],"about_ca_topic_score_codex":0.0052858917,"about_ca_topic_score_gemma":0.02512548,"teacher_disagreement_score":0.34170774,"about_ca_system_score_codex":0.0013116733,"about_ca_system_score_gemma":0.00108985,"threshold_uncertainty_score":0.9999988},"labels":[],"label_agreement":null},{"id":"W3088611248","doi":"10.1016/j.annonc.2020.08.2296","title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Interim analysis; Cancer; Oncology; FOLFOX; Randomized controlled trial; Population; Ipilimumab; Gastroesophageal Junction; Chemotherapy; Gastroenterology; Adenocarcinoma; Oxaliplatin; Immunotherapy; Colorectal cancer","score_opus":0.10348514728313105,"score_gpt":0.3842591844838083,"score_spread":0.2807740372006773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088611248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551005,0.002560543,0.00008509854,0.036158413,0.0012442588,0.003804507,0.0002040893,0.00008432836,0.00075826264],"genre_scores_gemma":[0.9917319,0.002836987,0.0002994366,0.0017936813,0.0008231258,0.0006200874,0.000061692925,0.00006961281,0.0017634867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968984,0.00007998818,0.001038306,0.00077454123,0.0005195164,0.0006892573],"domain_scores_gemma":[0.9975133,0.0002608051,0.00094452803,0.00061146944,0.00042450614,0.00024542524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028903937,0.00050295156,0.001381367,0.00017219158,0.00019641456,0.000013419978,0.00041765056,0.0001944736,0.00022878998],"category_scores_gemma":[0.00021023022,0.00038920945,0.00050649885,0.00082585483,0.00019598588,0.00013019994,0.00015401388,0.0002534984,0.0000076107135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2632803,0.0072856783,0.18872695,0.0017768438,0.007360672,0.00030623237,0.014287446,0.010304291,0.0021209237,0.00008358709,0.059062146,0.44540492],"study_design_scores_gemma":[0.27398384,0.111882254,0.46996534,0.00035708022,0.0034893616,0.000036150235,0.0033497077,0.0036579156,0.043708768,0.000058641275,0.08864015,0.00087079353],"about_ca_topic_score_codex":0.0028227516,"about_ca_topic_score_gemma":0.002478211,"teacher_disagreement_score":0.44453412,"about_ca_system_score_codex":0.0008415638,"about_ca_system_score_gemma":0.0007387254,"threshold_uncertainty_score":0.999856},"labels":[],"label_agreement":null},{"id":"W3088612260","doi":"10.1016/j.annonc.2020.08.2300","title":"LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; La Cité Médicale; Moncton Hospital; Jewish General Hospital; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Vancouver General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Hazard ratio; Durvalumab; Randomized controlled trial; Oncology; Nab-paclitaxel; Surrogate endpoint; Urology; Cancer; Gastroenterology; Confidence interval; Immunotherapy; Nivolumab","score_opus":0.17652113345783718,"score_gpt":0.4227879499531035,"score_spread":0.2462668164952663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088612260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93803465,0.026853936,0.000002436893,0.028090106,0.00018454787,0.0063984524,0.0002579995,0.000013257194,0.00016459083],"genre_scores_gemma":[0.979581,0.017589089,0.000066040746,0.001969979,0.00018573704,0.00045092014,0.000042822947,0.000040049563,0.00007439218],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935051,0.0021818762,0.0027957228,0.00056779897,0.00046775013,0.00048171607],"domain_scores_gemma":[0.9945624,0.0028050148,0.0015286226,0.00045745447,0.0003504746,0.000296035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007009735,0.0004074293,0.0040489766,0.0004072172,0.00016092391,0.000017174441,0.00024122655,0.00020096284,0.00016485488],"category_scores_gemma":[0.0039426642,0.00026622426,0.00041735152,0.00065571093,0.00076480675,0.0001048688,0.00007421844,0.00030992876,5.404511e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9450999,0.0028278409,0.0010221138,0.00023047197,0.0033638475,0.0001381775,0.016930941,0.000005720238,0.0030812377,0.000032040887,0.0010217127,0.026246019],"study_design_scores_gemma":[0.893371,0.087738715,0.009187746,0.00020921831,0.0013129384,0.00004803042,0.0037818989,0.00020230582,0.000901897,0.00017332961,0.0028295207,0.00024342899],"about_ca_topic_score_codex":0.19288522,"about_ca_topic_score_gemma":0.15470344,"teacher_disagreement_score":0.08491088,"about_ca_system_score_codex":0.000115183124,"about_ca_system_score_gemma":0.0011849151,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W3088636663","doi":"10.1016/j.annonc.2020.08.2150","title":"CN41 The use of the Edmonton Symptom Assessment scale in advanced lung cancer patients","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Anxiety; Internal medicine; Depression (economics); Statistical significance; Cancer; Hospital Anxiety and Depression Scale; Physical therapy; Psychiatry","score_opus":0.11641174638200676,"score_gpt":0.43524418944046467,"score_spread":0.3188324430584579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088636663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94909537,0.0007359751,0.0000029108064,0.047375254,0.00017777582,0.00039974734,0.00001935705,0.0000051185048,0.0021885065],"genre_scores_gemma":[0.9901302,0.0012345917,0.00008570407,0.008363976,0.00005045794,0.000051682004,0.0000018601526,0.000007041666,0.000074491916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915135,0.00009342719,0.0002869342,0.00013111735,0.00017376938,0.0001634051],"domain_scores_gemma":[0.9993241,0.00014856865,0.00015512784,0.00015291982,0.00017405754,0.000045229543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010483166,0.00007766502,0.0003927134,0.000020362297,0.00003340564,0.0000014695187,0.00010315811,0.00005253352,0.000036681253],"category_scores_gemma":[0.00012289773,0.000042243744,0.00007575151,0.00018668259,0.0001171948,0.00004387955,0.00009379945,0.00015084885,5.5125025e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032610758,0.0003650532,0.9272888,0.000112100526,0.00009381664,0.0000019578856,0.0024733439,0.000111598165,0.0019316424,0.00004729927,0.020443723,0.046804562],"study_design_scores_gemma":[0.0014391929,0.0014012009,0.92325,0.00015278395,0.000040393563,3.0314223e-7,0.00014046607,0.00027104127,0.002645908,0.000008169715,0.0706063,0.000044251705],"about_ca_topic_score_codex":0.00031863916,"about_ca_topic_score_gemma":0.000684014,"teacher_disagreement_score":0.050162576,"about_ca_system_score_codex":0.0000555487,"about_ca_system_score_gemma":0.00024656235,"threshold_uncertainty_score":0.172265},"labels":[],"label_agreement":null},{"id":"W3088662697","doi":"10.1016/j.annonc.2020.08.1622","title":"1308P Effect of current treatment evolution in advanced NSCLC on overall survival in the real world","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Oncology; Systemic therapy; Population; Log-rank test; Targeted therapy; Stage (stratigraphy); Immunotherapy; Cancer; Survival analysis","score_opus":0.10274801665465899,"score_gpt":0.432450848131473,"score_spread":0.329702831476814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088662697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97502625,0.0014009979,8.461999e-7,0.005699846,0.00012209397,0.0005720776,0.000010978749,0.000005972314,0.017160963],"genre_scores_gemma":[0.9981645,0.0014194923,0.000006644743,0.00022478522,0.000058630998,0.00008385949,0.000009160859,0.000005082534,0.000027856298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907106,0.0002075283,0.00025722463,0.00016536431,0.00013863256,0.00016018323],"domain_scores_gemma":[0.9993345,0.0003893134,0.00010015358,0.00010597703,0.000036010235,0.000034048528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019303782,0.0001173192,0.00055063295,0.000090540765,0.00001377148,8.8791063e-7,0.000049994687,0.000034269324,0.000014510111],"category_scores_gemma":[0.00008021805,0.000067884364,0.000098736775,0.00022116299,0.000053723783,0.000019320347,0.000019024888,0.00009837544,0.0000028249194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02280189,0.0023861672,0.53192294,0.00016091566,0.00019093107,0.0001093352,0.0037966603,0.00012913851,0.00070571393,0.0015340891,0.00073109986,0.4355311],"study_design_scores_gemma":[0.007854186,0.04708691,0.9337456,0.00012367516,0.00005979481,9.745089e-7,0.00015614994,0.0000352486,0.0013425433,0.000100448466,0.0094308015,0.00006366786],"about_ca_topic_score_codex":0.0005581093,"about_ca_topic_score_gemma":0.002664127,"teacher_disagreement_score":0.43546745,"about_ca_system_score_codex":0.00020152733,"about_ca_system_score_gemma":0.000091604365,"threshold_uncertainty_score":0.2768244},"labels":[],"label_agreement":null},{"id":"W3088668888","doi":"10.1016/j.annonc.2020.08.2085","title":"691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma Global Development; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Placebo; Internal medicine; Oncology; Urology; Discontinuation; Hazard ratio; Androgen deprivation therapy; Gynecology; Cancer; Androgen receptor; Pathology","score_opus":0.07288615058085053,"score_gpt":0.41586888639660835,"score_spread":0.34298273581575783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088668888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89028704,0.0018095142,0.00007896286,0.00092493946,0.000017779857,0.10664448,0.00011170382,0.00003298106,0.00009256477],"genre_scores_gemma":[0.91547793,0.0010123358,0.0003396333,0.00038027324,0.00006141816,0.08254368,0.00001857406,0.0000717106,0.00009447329],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99492,0.0014689956,0.0011904627,0.0008296946,0.000736844,0.00085397245],"domain_scores_gemma":[0.9974489,0.00053175836,0.00081679417,0.0003337057,0.00048402665,0.00038478657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012553002,0.0005422072,0.002696906,0.00035530946,0.00010384117,0.000033052333,0.0001441269,0.00014345383,0.000044602093],"category_scores_gemma":[0.00011507618,0.00035797223,0.00013585141,0.00058487,0.00089938805,0.00020199266,0.00011794049,0.00061216037,0.0000022999711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8089375,0.0058315103,0.019250788,0.00021939172,0.0022718457,0.0016503552,0.083611146,0.0004312674,0.0009078768,0.0000010695558,0.000108688044,0.07677857],"study_design_scores_gemma":[0.8706271,0.07812036,0.019729678,0.00029261602,0.0005709199,0.000024010811,0.019910388,0.0046982323,0.005268227,0.000045709483,0.0003125953,0.00040014228],"about_ca_topic_score_codex":0.0045425645,"about_ca_topic_score_gemma":0.00096245395,"teacher_disagreement_score":0.07637843,"about_ca_system_score_codex":0.00029441452,"about_ca_system_score_gemma":0.001962878,"threshold_uncertainty_score":0.9998872},"labels":[],"label_agreement":null},{"id":"W3088677947","doi":"10.1016/j.annonc.2020.08.1373","title":"1160O An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Concomitant; Gastroenterology; Somatostatin; Regimen; Interim analysis; Radionuclide therapy; Chemotherapy; Surgery; Urology; Clinical trial","score_opus":0.1274661445614277,"score_gpt":0.47172061388466446,"score_spread":0.3442544693232368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088677947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981846,0.000030664403,0.00000864902,0.015744625,0.00006897213,0.0010990513,0.00012928694,0.000033052416,0.0010397399],"genre_scores_gemma":[0.99667895,0.00018390403,0.00078095234,0.0021102617,0.0000532676,0.000022996666,0.0001025643,0.000039314902,0.00002777337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693614,0.0007400151,0.000839611,0.00066376,0.0004401118,0.00038037726],"domain_scores_gemma":[0.9980308,0.0005185807,0.00035570236,0.0003678381,0.00030925949,0.00041780915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000322692,0.00023760437,0.0010895394,0.0005653832,0.000030836287,0.000022874792,0.00056925096,0.000012214125,0.000084227504],"category_scores_gemma":[0.0012004932,0.00021925734,0.00007252531,0.000802665,0.00024694845,0.00039795824,0.00037690697,0.00041139347,0.0000040374166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055989683,0.03868685,0.80057895,0.0001127786,0.0018760657,0.010627984,0.0042460244,0.00027937372,0.03859886,0.000795854,0.0009342393,0.047273345],"study_design_scores_gemma":[0.019634785,0.099641584,0.84594226,0.000077560966,0.00023426826,0.00019268972,0.0038881348,0.0009835516,0.026746815,0.000045661985,0.0023505825,0.00026208305],"about_ca_topic_score_codex":0.00034994658,"about_ca_topic_score_gemma":0.00034789412,"teacher_disagreement_score":0.06095473,"about_ca_system_score_codex":0.000049488404,"about_ca_system_score_gemma":0.00016365024,"threshold_uncertainty_score":0.8941055},"labels":[],"label_agreement":null},{"id":"W3088702626","doi":"10.1016/j.annonc.2020.08.1381","title":"1168P Survey of challenges in access to diagnostics and treatment for neuroendocrine tumour (NET) patients (SCAN): Healthcare quality evaluation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Health care; Neuroendocrine tumors; Incidence (geometry); Health professionals; Family medicine; Internal medicine","score_opus":0.5717542048126968,"score_gpt":0.5606024080202858,"score_spread":0.011151796792410962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088702626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294331,0.0015775819,0.0000016608366,0.06656624,0.000051008046,0.0020797043,0.00017814896,0.000008272083,0.00010425345],"genre_scores_gemma":[0.9885593,0.009528039,0.00009223705,0.0014714787,0.000039512026,0.00020825457,0.0000801601,0.000016273627,0.0000047207836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779534,0.00067762734,0.0005390574,0.00034457195,0.00032938994,0.00031401744],"domain_scores_gemma":[0.9969203,0.0014788524,0.00021664987,0.0001713113,0.0009426881,0.0002702272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044034448,0.00013226674,0.0006532876,0.00014048819,0.000017327451,0.000003845449,0.00011926467,0.000010568906,0.000010257714],"category_scores_gemma":[0.008281539,0.000116229225,0.00004390221,0.00021477976,0.00006283945,0.00007900706,0.00010899798,0.00008954783,9.765737e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046497793,0.0013498233,0.70719606,0.00070098235,0.000040919807,0.000118463555,0.0003690015,0.000047931375,0.00030428314,0.000070348615,0.0014521497,0.28370026],"study_design_scores_gemma":[0.004124422,0.026142098,0.95918745,0.00004389274,0.000018581894,0.000008379248,0.000093976974,0.00009326141,0.007205535,0.00010159877,0.0029115402,0.00006923984],"about_ca_topic_score_codex":0.0015159056,"about_ca_topic_score_gemma":0.0076275095,"teacher_disagreement_score":0.283631,"about_ca_system_score_codex":0.0000638354,"about_ca_system_score_gemma":0.0003275221,"threshold_uncertainty_score":0.99143744},"labels":[],"label_agreement":null},{"id":"W3088708979","doi":"10.1016/j.annonc.2020.08.058","title":"80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"FUJIFILM Toyama Chemical; Chugai Pharmaceutical; Genentech; Sirtex Medical; Ipsen; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Eisai; Astellas Pharma; Pfizer; Incyte; NuCana; Agios Pharmaceuticals; Menarini Silicon Biosystems; Les Laboratories Pierre Fabre; Merck KGaA; Taiho Pharmaceutical; Amgen; Falk Foundation; Ariad Pharmaceuticals; Halozyme; Exelixis; G1 Therapeutics; Celgene; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca","keywords":"Gemcitabine; Medicine; Tolerability; Cisplatin; Internal medicine; Oncology; Gallbladder cancer; Cancer; Phases of clinical research; Chemotherapy; Gastroenterology; Adverse effect","score_opus":0.09547658375415796,"score_gpt":0.4017426350863002,"score_spread":0.30626605133214224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088708979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932326,0.0021327755,0.00007003679,0.0042034183,0.00015261763,0.0028162382,0.0009220207,0.00002481439,0.00035482662],"genre_scores_gemma":[0.9978529,0.0005217267,0.00038275318,0.0005495788,0.00016121732,0.00032607527,0.00013296932,0.000030326863,0.000042405332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997784,0.000055196037,0.000932412,0.00048779568,0.00035866612,0.00038190078],"domain_scores_gemma":[0.9978442,0.000266453,0.00069929846,0.00032215947,0.00067330804,0.00019456926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010819537,0.00034652062,0.0017595954,0.000087317996,0.00006849567,0.0000026975895,0.00013992589,0.00012128925,0.00008383072],"category_scores_gemma":[0.00011078981,0.00025863003,0.0002252093,0.00037293782,0.00017121845,0.0000881091,0.00006165646,0.000095064745,9.861454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15797828,0.028438184,0.60931,0.0012774799,0.0039982586,0.00016476045,0.022933738,0.0017741014,0.00068691553,0.00004189255,0.0059698448,0.16742657],"study_design_scores_gemma":[0.17850327,0.231024,0.5751128,0.00021706024,0.001629291,0.0000071973745,0.002410965,0.00070433883,0.002722261,0.000029372342,0.0072532776,0.00038617634],"about_ca_topic_score_codex":0.00077099487,"about_ca_topic_score_gemma":0.001599021,"teacher_disagreement_score":0.2025858,"about_ca_system_score_codex":0.0002699652,"about_ca_system_score_gemma":0.0004956861,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W3088741073","doi":"10.1016/j.annonc.2020.08.2266","title":"LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University Health Centre","funders":"North Carolina GlaxoSmithKline Foundation","keywords":"Medicine; Internal medicine; Discontinuation; Regimen; Oncology; Cancer; Pembrolizumab; Gastroenterology; Immunotherapy","score_opus":0.0811735064319226,"score_gpt":0.36147024817632906,"score_spread":0.28029674174440644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088741073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933057,0.00051491417,0.000013651878,0.0026223273,0.00048015648,0.0016926816,0.0008980019,0.000033139375,0.00043945832],"genre_scores_gemma":[0.99670196,0.0011114556,0.0014046169,0.0005093183,0.00008194514,0.000065340195,0.00006095857,0.000028232758,0.000036181584],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99708164,0.0002279227,0.0009412649,0.00073716976,0.0005714259,0.00044057806],"domain_scores_gemma":[0.99755985,0.0006798067,0.00071296876,0.00035668717,0.0004501646,0.00024053517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044323242,0.0002881825,0.0011863058,0.00019661526,0.000036215795,0.000004745185,0.00015907921,0.00018761812,0.00016650317],"category_scores_gemma":[0.0020067631,0.00019673698,0.00010425214,0.0007956159,0.0002794326,0.000066139786,0.00016835763,0.00032384778,0.0000021066817],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7052755,0.004513462,0.091056585,0.0006723641,0.00037916665,0.0001538092,0.0051788012,0.0005133255,0.012250907,0.000007728544,0.0034220873,0.1765763],"study_design_scores_gemma":[0.072622575,0.12224227,0.60990393,0.0010915328,0.0003155477,0.000014023752,0.00072335737,0.0009186591,0.15540113,0.000012499518,0.036094014,0.0006604744],"about_ca_topic_score_codex":0.0006103239,"about_ca_topic_score_gemma":0.0010466303,"teacher_disagreement_score":0.6326529,"about_ca_system_score_codex":0.0002255768,"about_ca_system_score_gemma":0.0010443794,"threshold_uncertainty_score":0.8022701},"labels":[],"label_agreement":null},{"id":"W3088741547","doi":"10.1016/j.annonc.2020.08.2240","title":"LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Samsung; Genentech; Servier; Astellas Pharma; Oncolytics Biotech; Eisai; Genomic Health; Teva Pharmaceutical Industries; Daiichi-Sankyo; PharmaMar; Celgene; G1 Therapeutics; Breast Cancer Research Foundation; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Hazard ratio; Breast cancer; Palbociclib; Internal medicine; Oncology; Adjuvant; Cancer; Interim analysis; Randomized controlled trial; Confidence interval; Metastatic breast cancer","score_opus":0.11069745047158958,"score_gpt":0.42758771260660927,"score_spread":0.3168902621350197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088741547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940514,0.008926664,0.0009111699,0.04231039,0.0005200837,0.0058103655,0.00042310738,0.00010318224,0.00048103655],"genre_scores_gemma":[0.9781279,0.013758806,0.0014632781,0.003846942,0.001146983,0.0013606097,0.00006351192,0.00010335656,0.00012863432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694186,0.00028451532,0.0010882196,0.00056657114,0.00045815753,0.00066067016],"domain_scores_gemma":[0.99634063,0.0011147015,0.0009403337,0.00043473244,0.0008567125,0.00031288245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042293876,0.0004649723,0.0030278203,0.00014751815,0.00006010896,0.000007888743,0.00027902646,0.00013212537,0.0006368259],"category_scores_gemma":[0.00016021538,0.00032518207,0.0005641842,0.00036568014,0.0006677156,0.00015184692,0.000042334425,0.0002820532,0.0000029494004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74252677,0.001576935,0.000089647045,0.00007058984,0.0022144162,0.000056392488,0.0013032174,0.000021794103,0.014402935,0.00012589469,0.00039259184,0.23721884],"study_design_scores_gemma":[0.8674712,0.041179955,0.00020133833,0.00009674789,0.00025247378,0.000059573293,0.00023733081,0.00006507799,0.037485905,0.00014790751,0.052532334,0.0002701243],"about_ca_topic_score_codex":0.00061666017,"about_ca_topic_score_gemma":0.00008096313,"teacher_disagreement_score":0.23694871,"about_ca_system_score_codex":0.00006221413,"about_ca_system_score_gemma":0.000721764,"threshold_uncertainty_score":0.99992},"labels":[],"label_agreement":null},{"id":"W3088751416","doi":"10.1016/j.annonc.2020.08.411","title":"309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Oncology; Cohort; Clinical endpoint; Fulvestrant; Progression-free survival; Metastatic breast cancer; Clinical trial; Cancer; Chemotherapy; Breast cancer; Estrogen receptor","score_opus":0.0303983865183438,"score_gpt":0.33920947785819866,"score_spread":0.30881109133985485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088751416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908143,0.00023378192,0.0002532295,0.0018711659,0.000101542486,0.002613426,0.0032327154,0.00011481841,0.00076501054],"genre_scores_gemma":[0.996872,0.00034453452,0.0012722395,0.00037709335,0.00012345947,0.00035260923,0.00048784225,0.000130586,0.000039622686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607575,0.00063196593,0.0009123599,0.0009245471,0.0006789501,0.0007764519],"domain_scores_gemma":[0.9952048,0.00057578605,0.0011604213,0.00038260964,0.0021285054,0.0005478775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001777766,0.0007688717,0.0023798195,0.00024030622,0.00016247013,0.000012677643,0.00024703474,0.00019516496,0.00027283563],"category_scores_gemma":[0.000052164934,0.00056436355,0.00023606278,0.0008188329,0.001156416,0.00048056175,0.000063939544,0.00039049573,0.0000051120983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33047765,0.005813529,0.4314488,0.0010989376,0.008419983,0.0002661627,0.018662,0.002059139,0.09130357,0.00024137142,0.00043393893,0.10977493],"study_design_scores_gemma":[0.02985131,0.04018491,0.75838304,0.0008821545,0.00037571642,0.000017439792,0.0010807234,0.000021607411,0.16823693,0.000032869753,0.00037376964,0.0005595456],"about_ca_topic_score_codex":0.004458347,"about_ca_topic_score_gemma":0.0017302965,"teacher_disagreement_score":0.32693425,"about_ca_system_score_codex":0.0011430572,"about_ca_system_score_gemma":0.0007821899,"threshold_uncertainty_score":0.99968076},"labels":[],"label_agreement":null},{"id":"W3088760968","doi":"10.1016/j.annonc.2020.08.2312","title":"LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Foundation Medicine; Merck Sharp and Dohme; EMD Serono; Genentech; NeraCare; Bavarian Nordic; Eisai; Puma Biotechnology; Mirati Therapeutics; Clovis Oncology; Eli Lilly and Company; National Comprehensive Cancer Network; Les Laboratories Pierre Fabre; Heron Therapeutics; TG Therapeutics; Celldex Therapeutics; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; PharmaMar; Alexion Pharmaceuticals; Bristol-Myers Squibb; Invitae; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Servier; Gilead Sciences; PTC Therapeutics; Exelixis; Sanofi; Ipsen; Array BioPharma; Spectrum Pharmaceuticals; Amgen","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Cancer; Asymptomatic; Cancer registry; Cohort; Chemotherapy; Incidence (geometry); Surgery; Immunotherapy","score_opus":0.14493013282315936,"score_gpt":0.4632121752870974,"score_spread":0.31828204246393804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088760968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97086394,0.00022842312,0.000009743674,0.027917555,0.00007039899,0.00044697814,0.000028100187,0.000053371743,0.0003814638],"genre_scores_gemma":[0.9916691,0.00036117318,0.00001581945,0.007765825,0.000038074602,0.00003350678,0.000033997003,0.000017259275,0.00006524804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987328,0.000104183244,0.00046416387,0.00026457876,0.00017142679,0.00026286402],"domain_scores_gemma":[0.998998,0.000105615305,0.00029728882,0.00022593528,0.00023067776,0.00014252444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010320865,0.00015831197,0.00097414764,0.00027821618,0.00002255661,0.000003782872,0.000050017396,0.0001983839,0.000035091474],"category_scores_gemma":[0.00017051757,0.000113552735,0.00016358992,0.0009300387,0.000057844358,0.000056065335,0.000017049622,0.00016124299,0.000008393589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009969963,0.00053083064,0.9875122,0.00018595356,0.0013513111,0.00006217354,0.0009981835,0.000080666345,0.00012232384,0.000010131383,0.0006396564,0.007509576],"study_design_scores_gemma":[0.00534347,0.0071715317,0.9808139,0.00010503578,0.00066176034,0.000005068975,0.000041287218,0.00007811149,0.0005235189,0.0000060394814,0.005149264,0.000101014884],"about_ca_topic_score_codex":0.009994105,"about_ca_topic_score_gemma":0.003925376,"teacher_disagreement_score":0.020805132,"about_ca_system_score_codex":0.00031255904,"about_ca_system_score_gemma":0.00081580295,"threshold_uncertainty_score":0.9965984},"labels":[],"label_agreement":null},{"id":"W3088769124","doi":"10.1016/j.annonc.2020.08.2271","title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Phases of clinical research; Lenvatinib; Clinical trial; Cancer; Gastroenterology; Sorafenib; Immunotherapy; Hepatocellular carcinoma","score_opus":0.0351059942400495,"score_gpt":0.34136055880324945,"score_spread":0.30625456456319994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088769124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972588,0.0003726186,0.000022147105,0.00036728452,0.000057109923,0.0007769638,0.00009065427,0.0000075535395,0.0010469097],"genre_scores_gemma":[0.9983749,0.00042597883,0.00012014196,0.00072519,0.00006714787,0.000054947155,0.00015435809,0.000031437536,0.000045916426],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9983963,0.000102739854,0.0005703477,0.0004396904,0.00015348247,0.0003374336],"domain_scores_gemma":[0.9988349,0.000045249548,0.00040020468,0.0003082158,0.00027435762,0.00013708607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012276825,0.00022252978,0.00060353254,0.000071321876,0.00004256952,0.0000045490897,0.0002575758,0.0001498628,0.000022886215],"category_scores_gemma":[0.0002064055,0.00020989153,0.00007860437,0.00019525072,0.00010684158,0.00000771431,0.00018271139,0.00012368821,0.0000019579154],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13040857,0.06124668,0.21273033,0.0006228246,0.0018132705,0.00025486454,0.018050304,0.02490219,0.24586976,0.00020883301,0.021192737,0.28269964],"study_design_scores_gemma":[0.13953984,0.5159617,0.035108924,0.00013378316,0.0002809694,0.000011767282,0.0023418942,0.00045925804,0.2636385,0.00005014824,0.041341793,0.0011314217],"about_ca_topic_score_codex":0.00014357883,"about_ca_topic_score_gemma":0.0005974889,"teacher_disagreement_score":0.454715,"about_ca_system_score_codex":0.000030553314,"about_ca_system_score_gemma":0.00035178105,"threshold_uncertainty_score":0.8559128},"labels":[],"label_agreement":null},{"id":"W3088788090","doi":"10.1016/j.annonc.2020.08.1873","title":"1647P Evaluation of baseline neutrophil to lymphocyte (NLR), platelet to lymphocyte (PLR) and lymphocyte to monocyte ratios (LMR) as prognostic factors in osteosarcoma – The Toronto Sarcoma Program Experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Osteosarcoma; Univariate analysis; Internal medicine; Sarcoma; Lymphocyte; Surgery; Survival analysis; Oncology; Gastroenterology; Multivariate analysis; Pathology","score_opus":0.10056526368073011,"score_gpt":0.4023068069707898,"score_spread":0.3017415432900597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088788090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98007673,0.002720973,0.00004176513,0.009297408,0.00021457582,0.0067674364,0.000055534485,0.00009710475,0.00072849094],"genre_scores_gemma":[0.98793256,0.00029884157,0.002055097,0.007747133,0.00016952962,0.0016669849,0.000044875465,0.0000663104,0.000018677778],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949587,0.00082956883,0.0013863178,0.0009299465,0.0011066833,0.0007887694],"domain_scores_gemma":[0.9962182,0.00057122926,0.00042081517,0.0007278906,0.0010841357,0.0009777106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001737503,0.0005167682,0.0011078869,0.0002820957,0.00011920163,0.000036089372,0.0005623249,0.0002762397,0.00017995389],"category_scores_gemma":[0.003296158,0.00042689618,0.00019928721,0.00091713876,0.00027082267,0.0002582585,0.00046398502,0.00013397865,0.000041985346],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021572111,0.0016057421,0.06578815,0.00053431845,0.00042964527,0.00031571387,0.030572368,0.0008457931,0.038418513,0.00013154068,0.0017954719,0.83799064],"study_design_scores_gemma":[0.022813885,0.03281263,0.38137951,0.00092849886,0.00086675055,0.0002275,0.010728285,0.014576652,0.4516651,0.00013968705,0.08229152,0.001569989],"about_ca_topic_score_codex":0.00087576505,"about_ca_topic_score_gemma":0.00058491476,"teacher_disagreement_score":0.83642066,"about_ca_system_score_codex":0.0009259478,"about_ca_system_score_gemma":0.0019553376,"threshold_uncertainty_score":0.99981827},"labels":[],"label_agreement":null},{"id":"W3088796366","doi":"10.1016/j.annonc.2020.08.950","title":"811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Progression-free survival; Ovarian cancer; Randomization; Oncology; Chemotherapy; Urology; Cancer; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.05051790121081382,"score_gpt":0.35246625525895836,"score_spread":0.3019483540481445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088796366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731692,0.0005829496,0.003701333,0.01928595,0.00038275655,0.0013310638,0.00047869488,0.000056272682,0.0010117777],"genre_scores_gemma":[0.9773923,0.0008115545,0.0064388304,0.014319111,0.00023503866,0.0004462167,0.0001757046,0.000044301938,0.00013692534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985062,0.00006579512,0.00041080487,0.0004570967,0.00021524135,0.00034488318],"domain_scores_gemma":[0.99826014,0.0003845195,0.0003657759,0.00019475505,0.0005647205,0.0002300707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011431043,0.00020461118,0.0006117167,0.000066220455,0.00006598471,0.000009371018,0.000100179335,0.00016843282,0.0001882644],"category_scores_gemma":[0.00034806604,0.00017727548,0.00009144868,0.00019122774,0.00017479947,0.00016381178,0.000029515737,0.00016759035,0.000008468977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081477195,0.001866061,0.07609982,0.0006416412,0.0017535902,0.0002258838,0.012540501,0.0004302249,0.018493915,0.0041993763,0.14895593,0.65331584],"study_design_scores_gemma":[0.29914373,0.05643654,0.16704744,0.0014461343,0.00074199523,0.000033309192,0.0021021285,0.0018120813,0.027859014,0.011066871,0.43097103,0.0013397152],"about_ca_topic_score_codex":0.00041273757,"about_ca_topic_score_gemma":0.0003972273,"teacher_disagreement_score":0.65197617,"about_ca_system_score_codex":0.000092202055,"about_ca_system_score_gemma":0.00035193644,"threshold_uncertainty_score":0.72290844},"labels":[],"label_agreement":null},{"id":"W3088815348","doi":"10.1016/j.annonc.2020.08.1030","title":"915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Population; Medicine","score_opus":0.14925297685095465,"score_gpt":0.3705115693477895,"score_spread":0.22125859249683485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088815348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948009,0.00732694,0.00031549612,0.041418374,0.00022782083,0.002063079,0.00020276377,0.000081300386,0.00035522075],"genre_scores_gemma":[0.9653929,0.0054761088,0.0019809937,0.025764542,0.00029320453,0.0001684791,0.00020378148,0.00012023895,0.000599789],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99687696,0.00016181014,0.0010036918,0.00084537285,0.0004185902,0.00069356343],"domain_scores_gemma":[0.9971785,0.0009219682,0.0006259794,0.0005511233,0.00032834316,0.00039406342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000314793,0.00061260286,0.0017724282,0.00017419126,0.00014580668,0.000033424276,0.0003150009,0.00028347233,0.00090847193],"category_scores_gemma":[0.00013841742,0.0004004373,0.00038611577,0.00035727088,0.00037058123,0.00014744679,0.00005532257,0.0003251213,0.000013689215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60674214,0.0039894134,0.103624724,0.0012549149,0.0015223861,0.0004821364,0.004982833,0.0000072681746,0.01391871,0.000014015294,0.011915101,0.25154635],"study_design_scores_gemma":[0.20917094,0.17219186,0.47021794,0.00039262537,0.0006655841,0.00030710752,0.00055343943,0.00040673802,0.056097,0.0001846943,0.08846333,0.0013487374],"about_ca_topic_score_codex":0.0010128558,"about_ca_topic_score_gemma":0.0009310402,"teacher_disagreement_score":0.3975712,"about_ca_system_score_codex":0.000089891204,"about_ca_system_score_gemma":0.00063422194,"threshold_uncertainty_score":0.99984473},"labels":[],"label_agreement":null},{"id":"W3088817799","doi":"10.1016/j.annonc.2020.08.419","title":"317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Ottawa Hospital; BC Cancer Agency; Sunnybrook Health Science Centre; McGill University; Jewish General Hospital; University of Alberta; Grand River Hospital","funders":"Medac; Eisai; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Neutropenia; Internal medicine; Breast cancer; Letrozole; Population; Febrile neutropenia; Interim analysis; Chemotherapy regimen; Progression-free survival; Cancer; Surgery; Chemotherapy; Clinical trial; Tamoxifen","score_opus":0.10344704891642564,"score_gpt":0.4071122338212833,"score_spread":0.30366518490485767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088817799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8515085,0.00044254342,0.000017044458,0.14347875,0.00043266226,0.00093234313,0.0026437263,0.000023684053,0.00052074157],"genre_scores_gemma":[0.9879077,0.00009117167,0.000114994364,0.010827577,0.00055173185,0.000041026684,0.00040648598,0.000025422543,0.000033870234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813783,0.00022349403,0.00067502557,0.00030672783,0.00031198494,0.00034494782],"domain_scores_gemma":[0.99820846,0.00019523253,0.0005977893,0.00042555103,0.0003596087,0.00021337955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024820855,0.0001821431,0.0005712238,0.000047280744,0.00014614622,0.0000069486455,0.00030487287,0.00013452751,0.00029669522],"category_scores_gemma":[0.00019651404,0.000120150515,0.00015835486,0.0003792869,0.00028064454,0.00009676727,0.000060204802,0.00028059483,0.000005785925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3097376,0.0011701873,0.013223731,0.00006457117,0.0012979247,0.000039326686,0.0050010527,0.0016225177,0.04874802,0.0005084392,0.026134767,0.5924519],"study_design_scores_gemma":[0.24192359,0.005468337,0.2315746,0.0002834929,0.00042701222,0.000026939797,0.0010890223,0.0007858807,0.031248014,0.00078842195,0.48592708,0.00045763957],"about_ca_topic_score_codex":0.13843568,"about_ca_topic_score_gemma":0.1747598,"teacher_disagreement_score":0.5919942,"about_ca_system_score_codex":0.00019624367,"about_ca_system_score_gemma":0.0008138465,"threshold_uncertainty_score":0.8673015},"labels":[],"label_agreement":null},{"id":"W3088825732","doi":"10.1016/j.annonc.2020.08.1076","title":"961P Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Quebec - Clinical Research Organization in Cancer; Jewish General Hospital","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Transcriptome; Cancer research; Copy number analysis; Oncology; Internal medicine; Bioinformatics; Head and neck cancer; Cancer; Copy-number variation; Gene; Gene expression; Biology; Genetics; Genome","score_opus":0.08692050790214205,"score_gpt":0.3944807226706895,"score_spread":0.30756021476854745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088825732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091643,0.00271571,0.000044482724,0.005602346,0.00008901995,0.00048195315,0.00002258868,0.0000021830756,0.00012526919],"genre_scores_gemma":[0.9941928,0.0031706938,0.0003178708,0.002049093,0.00015246273,0.00008700343,0.000007653678,0.000008956568,0.000013466894],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993516,0.000046950805,0.00019560335,0.0002308645,0.000032779164,0.00014220642],"domain_scores_gemma":[0.99970424,0.000033201126,0.000049274422,0.00010981419,0.000025181153,0.00007829018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009559412,0.00008963646,0.00017168921,0.000022964994,0.00003298084,0.000012492686,0.00008641371,0.00006945918,0.0000053422723],"category_scores_gemma":[0.000067979185,0.00007249829,0.000038351278,0.00004551406,0.000087803855,0.0000026368052,0.000051623283,0.000039714487,0.0000013755031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009272566,0.00022889269,0.0077429363,0.0000174837,0.000059019698,0.0000104443625,0.004598375,0.00028330006,0.95651156,0.00033010068,0.0006109085,0.020334402],"study_design_scores_gemma":[0.051565684,0.039683387,0.11480478,0.000055108878,0.00011087445,0.000051156425,0.0052834814,0.00042755136,0.5702131,0.0006883159,0.2163317,0.00078486756],"about_ca_topic_score_codex":0.000101216094,"about_ca_topic_score_gemma":0.00025336712,"teacher_disagreement_score":0.38629848,"about_ca_system_score_codex":0.000012872266,"about_ca_system_score_gemma":0.0000970513,"threshold_uncertainty_score":0.29563943},"labels":[],"label_agreement":null},{"id":"W3088837832","doi":"10.1016/j.annonc.2020.08.1088","title":"973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Tolerability; Head and neck squamous-cell carcinoma; Oncology; Adverse effect; Placebo; Phases of clinical research; Head and neck cancer; Clinical trial; Immunotherapy; Cancer; Pathology","score_opus":0.09192149957931987,"score_gpt":0.3708962029273843,"score_spread":0.2789747033480644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088837832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616617,0.00052338577,0.0000109957045,0.001140218,0.000045325232,0.0016360723,0.00003700337,0.000015398564,0.00042542926],"genre_scores_gemma":[0.9985788,0.00012558706,0.00021676702,0.0008607522,0.00003489866,0.000054545417,0.00003314464,0.00003405802,0.000061444516],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99807185,0.00014088105,0.0007304841,0.00041239633,0.00032374533,0.0003206698],"domain_scores_gemma":[0.99865484,0.00014901445,0.0004947718,0.0002691747,0.00026988616,0.00016228623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002077311,0.0002700625,0.0010716011,0.00017182494,0.000043920085,0.000005465436,0.00012466963,0.00008172286,0.00010305453],"category_scores_gemma":[0.00006222517,0.00018070152,0.00005535264,0.00049099023,0.00022397659,0.00008499829,0.00004629289,0.00023472829,0.0000012042692],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33233568,0.014357886,0.6058324,0.0007162409,0.00022348003,0.00017635862,0.009323735,0.000016529275,0.0003737378,0.0000013517018,0.0007201711,0.035922408],"study_design_scores_gemma":[0.30175987,0.4511941,0.23625578,0.00026250203,0.0003507652,0.0000477057,0.0037878123,0.00038002417,0.0024390141,0.000003284648,0.0031670493,0.00035208947],"about_ca_topic_score_codex":0.0009847801,"about_ca_topic_score_gemma":0.0035932355,"teacher_disagreement_score":0.4368362,"about_ca_system_score_codex":0.00004374397,"about_ca_system_score_gemma":0.00032376632,"threshold_uncertainty_score":0.7368794},"labels":[],"label_agreement":null},{"id":"W3088849252","doi":"10.1016/j.annonc.2020.08.922","title":"663P Sarcopenia assessment in men with metastatic castration-resistant prostate cancer (mCRPC) undergoing radium 223 (Ra223) therapy","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sarcopenia; Prostate cancer; Hounsfield scale; Osteopenia; Cancer; Internal medicine; Osteoporosis; Surgery; Computed tomography","score_opus":0.19855193088972262,"score_gpt":0.47112790876252625,"score_spread":0.27257597787280363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088849252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6520726,0.0026268223,0.00013665647,0.32880965,0.000091242044,0.001693256,0.000035016277,0.000049054088,0.0144856945],"genre_scores_gemma":[0.9753101,0.0036958442,0.004917728,0.015660565,0.000080430946,0.000118927914,0.000022172877,0.000021669082,0.00017255769],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99858916,0.00016266151,0.0004768332,0.000241852,0.00022580219,0.00030368255],"domain_scores_gemma":[0.9991298,0.00016673068,0.00022294316,0.00011834163,0.00017073854,0.00019147899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003962857,0.00013163696,0.0005150715,0.000108113636,0.000051487008,0.000009909976,0.000068963986,0.000048823495,0.00026424482],"category_scores_gemma":[0.000031527183,0.00010451861,0.000040986863,0.0002781912,0.00007958842,0.00008463086,0.00001588919,0.00026408688,0.0000057169077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051621698,0.009678769,0.23830293,0.009743968,0.002466076,0.0047222828,0.037715834,0.0015800028,0.23386723,0.0151357,0.13815254,0.25701296],"study_design_scores_gemma":[0.08582211,0.04799685,0.43138906,0.0026762432,0.0002957304,0.00018852246,0.011684186,0.0045213522,0.03752859,0.0025849713,0.37421024,0.0011021424],"about_ca_topic_score_codex":0.00041242185,"about_ca_topic_score_gemma":0.0009137507,"teacher_disagreement_score":0.3232375,"about_ca_system_score_codex":0.000112582915,"about_ca_system_score_gemma":0.0017207555,"threshold_uncertainty_score":0.42621452},"labels":[],"label_agreement":null},{"id":"W3088871285","doi":"10.1016/j.annonc.2020.08.1147","title":"1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; Université Laval; University of Alberta; Alberta Health Services; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Pembrolizumab; Pharmacodynamics; Discontinuation; Internal medicine; Pharmacology; Pharmacokinetics; Cancer; Chemotherapy; Phases of clinical research; Immunotherapy","score_opus":0.034447588844563753,"score_gpt":0.32729667239864746,"score_spread":0.2928490835540837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088871285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895456,0.00034440163,0.000014490598,0.008413854,0.000035061636,0.00040291142,0.0000067038072,0.00001390387,0.0012231009],"genre_scores_gemma":[0.9954376,0.00043223597,0.00013141199,0.0038625393,0.000022494201,0.000022827806,0.000020649511,0.000020093732,0.000050155042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989349,0.000087454064,0.00033294447,0.0002480617,0.00017495266,0.00022166764],"domain_scores_gemma":[0.9994188,0.000053853862,0.00019771207,0.00012720874,0.00011620557,0.00008623773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015875406,0.00014242603,0.0004405294,0.00013498156,0.000018815652,0.000005345939,0.00006613565,0.0001238735,0.00004869108],"category_scores_gemma":[0.000025718022,0.000111728776,0.000030464227,0.00026648847,0.00017240846,0.00009652343,0.000014146229,0.00019895997,0.0000015699671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15474448,0.0025303261,0.7148405,0.00020168319,0.00022285791,0.0001769526,0.004695958,0.000029516861,0.006628117,0.000043371518,0.0021811516,0.11370511],"study_design_scores_gemma":[0.040251676,0.02647236,0.91887176,0.00019185556,0.000022517914,0.00002232425,0.0004093699,0.000114090224,0.004802467,0.000027128603,0.008630543,0.00018390268],"about_ca_topic_score_codex":0.00015862727,"about_ca_topic_score_gemma":0.00034503365,"teacher_disagreement_score":0.20403129,"about_ca_system_score_codex":0.00007444253,"about_ca_system_score_gemma":0.00021164116,"threshold_uncertainty_score":0.4556167},"labels":[],"label_agreement":null},{"id":"W3088872436","doi":"10.1016/j.annonc.2020.08.1225","title":"1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Hazard ratio; Internal medicine; Vemurafenib; Lactate dehydrogenase; Gastroenterology; Oncology; Melanoma; Cancer; Confidence interval; Metastatic melanoma; Cancer research","score_opus":0.16536285663747388,"score_gpt":0.4136882348580487,"score_spread":0.2483253782205748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088872436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947356,0.0024410402,0.000087090644,0.0015782645,0.00007193046,0.00062614866,0.00028848764,0.000014068465,0.00015737793],"genre_scores_gemma":[0.9950161,0.0008420902,0.00031032684,0.0030996448,0.00016059277,0.00009858101,0.00042416283,0.000025427578,0.000023087294],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771553,0.00049119646,0.0006932193,0.00057675183,0.00014950651,0.0003738154],"domain_scores_gemma":[0.9985977,0.00039778915,0.0003089449,0.00028389596,0.00016329544,0.0002483653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004623785,0.00024015104,0.000539951,0.00003838059,0.00007558897,0.000022915441,0.00024213093,0.00023673924,0.000016245442],"category_scores_gemma":[0.0005501013,0.00017249808,0.00012871517,0.00017476162,0.00019613268,0.000013401892,0.00018190334,0.00019009589,0.0000057383527],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010159012,0.00590241,0.5735891,0.000058642865,0.0023509618,0.00082488084,0.009850987,0.000076140146,0.3041378,0.000119792065,0.012043594,0.08088666],"study_design_scores_gemma":[0.013604342,0.05955533,0.24216363,0.00006293285,0.00054306485,0.00003325868,0.011593924,0.00044488136,0.6296859,0.00050296495,0.040711746,0.0010980446],"about_ca_topic_score_codex":0.000405491,"about_ca_topic_score_gemma":0.0016877642,"teacher_disagreement_score":0.3314255,"about_ca_system_score_codex":0.000009508219,"about_ca_system_score_gemma":0.00027948673,"threshold_uncertainty_score":0.7034268},"labels":[],"label_agreement":null},{"id":"W3088906226","doi":"10.1016/j.annonc.2020.08.305","title":"183P Prognostic value of high mesenchymal-epithelial transition factor gene (MET) expression in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor negative (HER2-) early breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Proportional hazards model; Univariate analysis; Immunohistochemistry; Estrogen receptor; Multivariate analysis; Cancer; Carcinogenesis; Progesterone receptor; Pathology","score_opus":0.0317981546306393,"score_gpt":0.3071607012174891,"score_spread":0.27536254658684983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088906226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99136287,0.000113414084,0.00009682087,0.0032211782,0.00013234638,0.0012015518,0.0037760015,0.000022721535,0.0000730843],"genre_scores_gemma":[0.99689496,0.00014963558,0.0016351084,0.00069074205,0.00024458903,0.0000827301,0.00024115438,0.00004658249,0.000014524234],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99761665,0.00034384424,0.0006721426,0.0004986392,0.00045026102,0.00041847088],"domain_scores_gemma":[0.99813455,0.00016994467,0.00051864074,0.00016636432,0.0007060964,0.00030438846],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011563882,0.0003119697,0.0010244325,0.00016440694,0.00005451762,0.0000066703774,0.00013597262,0.00021904851,0.0010388072],"category_scores_gemma":[0.00009823106,0.00024981276,0.00018065464,0.0003602971,0.00024700613,0.00020040771,0.00004535069,0.00030847054,0.0000086578575],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02339991,0.0032240725,0.31773126,0.00063460943,0.0010559201,0.00004968056,0.02156056,0.00008288915,0.5861627,0.00014328094,0.0011018688,0.04485325],"study_design_scores_gemma":[0.0050163115,0.008941192,0.5343108,0.00026179897,0.0001234511,0.0000026258538,0.00017154207,0.0000034963098,0.45083782,0.000021105428,0.000119597484,0.00019022806],"about_ca_topic_score_codex":0.002342976,"about_ca_topic_score_gemma":0.00004738874,"teacher_disagreement_score":0.21657959,"about_ca_system_score_codex":0.00012924812,"about_ca_system_score_gemma":0.00039371324,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W3088940866","doi":"10.1016/j.annonc.2020.08.1966","title":"1460P Impact of sites of metastatic dissemination on survival in advanced gastroesophageal adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Hazard ratio; Cohort; Adenocarcinoma; Oncology; Performance status; Lymph node; Multivariate analysis; Cancer; Confidence interval","score_opus":0.10018151240520748,"score_gpt":0.4293590289715072,"score_spread":0.3291775165662997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088940866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950941,0.00026895315,0.00003400016,0.0025309464,0.00003506902,0.00024498117,0.00002216155,0.0000060271727,0.0017637531],"genre_scores_gemma":[0.9992151,0.00008155611,0.00037585926,0.00020910644,0.000027212001,0.0000051076827,0.000026781854,0.000006908302,0.00005232199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990368,0.00006566722,0.0004078996,0.00013594894,0.00019585324,0.00015782361],"domain_scores_gemma":[0.99917096,0.00024608863,0.00027786352,0.00011557914,0.0001231919,0.000066327506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022418013,0.000095978634,0.00060995086,0.00017774393,0.0000050624967,9.191018e-7,0.000078915225,0.000035892142,0.00014505017],"category_scores_gemma":[0.0003306428,0.00007919306,0.00015809953,0.00030096597,0.000060255734,0.000049110447,0.000031444804,0.000092217924,0.0000023858224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029814574,0.0006087277,0.93335533,0.00042882535,0.00026321554,0.00008925187,0.0010982931,0.00041528142,0.016241247,0.00033831407,0.0022209303,0.041959155],"study_design_scores_gemma":[0.0018937113,0.011739974,0.97605544,0.00005453803,0.0000706528,0.0000019139688,0.00032316247,0.00017448804,0.009523944,0.000057762554,0.00006384327,0.000040556555],"about_ca_topic_score_codex":0.000053909454,"about_ca_topic_score_gemma":0.00001761772,"teacher_disagreement_score":0.042700153,"about_ca_system_score_codex":0.000031634816,"about_ca_system_score_gemma":0.00008469716,"threshold_uncertainty_score":0.32293993},"labels":[],"label_agreement":null},{"id":"W3088950291","doi":"10.1016/j.annonc.2020.08.1480","title":"1833P Role of grip strength &amp; the short physical performance battery in prediction of chemotherapy related outcomes in older adults with cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Confidence interval; Logistic regression; Odds ratio; Grip strength; Cancer; Internal medicine; Chemotherapy; Physical therapy; Surgery","score_opus":0.054988143067593254,"score_gpt":0.377361468059258,"score_spread":0.32237332499166477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088950291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97675985,0.00018628697,0.0000016574967,0.022090489,0.00003869829,0.00030279878,0.0000138053465,0.000007625231,0.0005988021],"genre_scores_gemma":[0.9964162,0.0009183092,0.000063837455,0.0024830736,0.00005460326,0.00002723584,0.000010826298,0.00000777041,0.000018155491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992086,0.000048933198,0.00036573273,0.00011658082,0.00012916564,0.00013098579],"domain_scores_gemma":[0.99955046,0.00007881351,0.00012831952,0.000099760015,0.00010027454,0.00004238404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015035504,0.000069541435,0.00040972262,0.00007236864,0.000009590335,5.308824e-7,0.000054323813,0.00007018386,0.00006077037],"category_scores_gemma":[0.000022609061,0.000046129033,0.00003633153,0.00021452991,0.00009834342,0.00004193145,0.000010377335,0.00022184756,7.586964e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014381903,0.00079271896,0.96075445,0.00037699533,0.000041471656,0.0000019948932,0.0077680307,0.000058568614,0.001612582,0.000023315253,0.0006359563,0.026495721],"study_design_scores_gemma":[0.0033895494,0.0014133101,0.9840086,0.00047232118,0.000013161899,0.00000291805,0.0005497939,0.0016284902,0.0066562667,0.000018083372,0.001810212,0.00003726373],"about_ca_topic_score_codex":0.00014227537,"about_ca_topic_score_gemma":0.00013398597,"teacher_disagreement_score":0.026458457,"about_ca_system_score_codex":0.00002188531,"about_ca_system_score_gemma":0.00012218053,"threshold_uncertainty_score":0.18810874},"labels":[],"label_agreement":null},{"id":"W3088957028","doi":"10.1016/j.annonc.2020.08.771","title":"699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer UK; Merck KGaA; Pfizer","keywords":"Medicine; Avelumab; Oncology; Internal medicine; Hazard ratio; Bladder cancer; Immunotherapy; Immunology; Cancer; Nivolumab","score_opus":0.1225271632506196,"score_gpt":0.4084373490325594,"score_spread":0.28591018578193983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088957028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598705,0.0008805653,0.00029874043,0.034905184,0.00042629385,0.0015565412,0.0011657268,0.00005088905,0.00084552134],"genre_scores_gemma":[0.99191135,0.0007829171,0.00085869996,0.005329866,0.00048872747,0.00015707816,0.00020107947,0.000044900324,0.00022539105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780303,0.0001353269,0.00081717555,0.00051488477,0.0002495999,0.00047997522],"domain_scores_gemma":[0.9975839,0.00073500257,0.000525915,0.00021236954,0.000606565,0.0003362189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003826092,0.00026530432,0.0012411027,0.00007409937,0.000099375284,0.000007539421,0.00011995138,0.00033553902,0.000046371275],"category_scores_gemma":[0.0010440145,0.00023137908,0.00031127458,0.00013851501,0.00016921197,0.000120893834,0.00007786804,0.00021744375,0.000019529012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049923747,0.0003799386,0.92408514,0.00026603273,0.0012185236,0.00006195763,0.0020451497,0.0000014816047,0.0001377864,0.000017871642,0.0078074927,0.058986276],"study_design_scores_gemma":[0.03537076,0.038603548,0.830154,0.00014706813,0.0014441481,0.000008948137,0.002598452,0.00003341166,0.0060382173,0.00025863506,0.08486552,0.0004773165],"about_ca_topic_score_codex":0.00012648004,"about_ca_topic_score_gemma":0.00017314621,"teacher_disagreement_score":0.09393114,"about_ca_system_score_codex":0.0001739755,"about_ca_system_score_gemma":0.00053976837,"threshold_uncertainty_score":0.9435365},"labels":[],"label_agreement":null},{"id":"W3088957710","doi":"10.1016/j.annonc.2020.08.376","title":"274O Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Veliparib; Internal medicine; Breast cancer; Carboplatin; Brief Pain Inventory; Quality of life (healthcare); Oncology; Cancer; Metastatic breast cancer; Placebo; Hazard ratio; PARP inhibitor; Adverse effect; Paclitaxel; Physical therapy; Chemotherapy; Poly ADP ribose polymerase; Confidence interval; Chronic pain; Pathology","score_opus":0.17107674004817533,"score_gpt":0.47661155909900943,"score_spread":0.3055348190508341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088957710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96051687,0.00072022027,0.0000049813098,0.036506046,0.000043059736,0.0019714972,0.000115071,0.000010691621,0.000111558096],"genre_scores_gemma":[0.9889717,0.00031164414,0.000043725726,0.01032547,0.000028752082,0.000247889,0.0000302884,0.000016419135,0.000024081155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978378,0.000584071,0.0006757152,0.0002967629,0.00028565075,0.00032003963],"domain_scores_gemma":[0.99861866,0.00026869233,0.000583062,0.00016248866,0.00020845907,0.00015861713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005044985,0.00019096058,0.0011641379,0.00012189794,0.000026578662,0.000001923283,0.00013756014,0.000060965776,0.0002128618],"category_scores_gemma":[0.000050457093,0.00010768806,0.00003675129,0.00067479105,0.00016224403,0.000055598946,0.00002911672,0.0002707668,0.0000013769597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27865323,0.036640923,0.48268443,0.00079185487,0.0018191393,0.00027075782,0.042474974,0.00062143954,0.0003930036,0.00003497636,0.0025979672,0.15301731],"study_design_scores_gemma":[0.15122367,0.14060909,0.6984009,0.00023834367,0.00032134913,0.0000147433675,0.0069763376,0.00007669918,0.00025528015,0.00000823823,0.0016547699,0.00022056313],"about_ca_topic_score_codex":0.0039305678,"about_ca_topic_score_gemma":0.029572498,"teacher_disagreement_score":0.21571648,"about_ca_system_score_codex":0.00009342127,"about_ca_system_score_gemma":0.0010540037,"threshold_uncertainty_score":0.9881353},"labels":[],"label_agreement":null},{"id":"W3088970478","doi":"10.1016/j.annonc.2020.08.1005","title":"866P Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with stage IIA-IIIA cervical carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Ipsen; Clovis Oncology; Regeneron Pharmaceuticals; GlaxoSmithKline; Louisiana State University; Spectrum Pharmaceuticals; Takeda Oncology; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; King Abdullah International Medical Research Center; U.S. Department of Defense","keywords":"Medicine; Cervical cancer; Radical surgery; Stage (stratigraphy); Hazard ratio; Chemotherapy; Internal medicine; Surgery; Chemoradiotherapy; Oncology; Cancer; Confidence interval","score_opus":0.0757456598193814,"score_gpt":0.34853340235969643,"score_spread":0.272787742540315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088970478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822332,0.0011529124,0.000017677108,0.014838333,0.00028482778,0.00057175633,0.000079653044,0.000031399675,0.0007902273],"genre_scores_gemma":[0.99157655,0.00043593306,0.000092272036,0.0074443133,0.0001656115,0.00003466026,0.00016832499,0.00003665522,0.00004565667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980046,0.00012271052,0.00055047224,0.00042588406,0.00044142487,0.00045489505],"domain_scores_gemma":[0.99858844,0.00042271105,0.00021568463,0.00020193418,0.00014009325,0.00043114234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017044743,0.00026310305,0.0012581465,0.000119148724,0.000026869293,0.000006116179,0.00013366246,0.00021064498,0.00076153467],"category_scores_gemma":[0.00013137543,0.00019763368,0.00021164694,0.0005559725,0.00018895081,0.0000611302,0.000030009936,0.00026818344,0.000015493924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061134648,0.004213839,0.75750726,0.0001882864,0.0005457792,0.00020731524,0.00055967574,0.000002164248,0.0007495821,0.000037159985,0.017446112,0.1574082],"study_design_scores_gemma":[0.11667449,0.03416023,0.6709062,0.000087144435,0.00013109618,0.0000038175954,0.00009542643,0.00005037441,0.010592768,0.000010217471,0.16683064,0.0004576074],"about_ca_topic_score_codex":0.00017354498,"about_ca_topic_score_gemma":0.000019545916,"teacher_disagreement_score":0.1569506,"about_ca_system_score_codex":0.00014493735,"about_ca_system_score_gemma":0.0003429209,"threshold_uncertainty_score":0.8338271},"labels":[],"label_agreement":null},{"id":"W3088975884","doi":"10.1016/j.annonc.2020.08.1935","title":"1429P Phase II trial of perioperative mdcf + avelumab in locally advanced gastroesophageal adenocarcinoma: Safety/efficacy","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Perioperative; Regimen; Internal medicine; Chemotherapy regimen; Gastroenterology; Neutropenia; Chemotherapy; Surgery","score_opus":0.07674057340563627,"score_gpt":0.3923099879113279,"score_spread":0.3155694145056916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088975884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681269,0.0006066933,0.00028790627,0.022013579,0.00021453181,0.0012629331,0.000025000096,0.000024674917,0.0074378015],"genre_scores_gemma":[0.9955111,0.00025681502,0.00082850346,0.002694493,0.00024194026,0.000025249714,0.000031505548,0.00001679224,0.00039358746],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982265,0.00010712756,0.000775384,0.00031337014,0.00024983467,0.00032774376],"domain_scores_gemma":[0.999053,0.00012577791,0.0002805619,0.00020346668,0.00017535004,0.0001618546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002689325,0.00018161102,0.0009834768,0.00016481765,0.00003677148,0.000002932253,0.00016965349,0.00010460926,0.0003578375],"category_scores_gemma":[0.00037246905,0.0001650681,0.00019420902,0.000383334,0.00017442156,0.000088849905,0.0001366491,0.00025029804,0.00000892742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48102927,0.008365683,0.0071464325,0.00036220148,0.0005160287,0.00093485316,0.009612022,0.00043764414,0.0046132407,0.0015405297,0.005766894,0.4796752],"study_design_scores_gemma":[0.6744547,0.19683018,0.058102127,0.00015139699,0.00027997507,0.000022978813,0.0021374673,0.0006199026,0.0062903664,0.000035122615,0.060762353,0.00031342925],"about_ca_topic_score_codex":0.000033109754,"about_ca_topic_score_gemma":0.000026439999,"teacher_disagreement_score":0.47936177,"about_ca_system_score_codex":0.000057070716,"about_ca_system_score_gemma":0.000378339,"threshold_uncertainty_score":0.6731282},"labels":[],"label_agreement":null},{"id":"W3088992161","doi":"10.1016/j.annonc.2020.08.1696","title":"1382P Automating access to real-world evidence","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biomedical Text Mining and Ontologies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"EMD Serono; Servier; Merck KGaA; PharmaMar; Bristol-Myers Squibb","keywords":"Concordance; Medicine; Data extraction; Lung cancer; Data collection; Stage (stratigraphy); Artificial intelligence; Medical physics; MEDLINE; Oncology; Internal medicine; Computer science; Statistics","score_opus":0.29968038010396375,"score_gpt":0.48459280946797706,"score_spread":0.1849124293640133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088992161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8583595,0.0009364054,0.0013500723,0.116692685,0.00021952426,0.00020357352,0.000012968221,0.000066842265,0.022158401],"genre_scores_gemma":[0.9782099,0.00053579,0.005313457,0.015359825,0.00029093845,0.000016477823,0.000008507297,0.0000105792515,0.00025452208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990214,0.00009068273,0.00026579216,0.00028270675,0.00010463957,0.00023474477],"domain_scores_gemma":[0.99930376,0.00010015536,0.00012169627,0.00018677421,0.00011062333,0.0001769759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026624778,0.00009859876,0.00023895923,0.000041482337,0.000035083915,0.000011716155,0.00043634797,0.00014297308,0.000045217927],"category_scores_gemma":[0.0013618938,0.0000881437,0.000070152586,0.0002144587,0.00011671266,0.0000044095455,0.0003478308,0.00009418971,0.000023860503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031344968,0.00008858634,0.01015225,0.000089304376,0.00007937509,0.0000227899,0.00039674502,0.000052008872,0.17860457,0.00017373388,0.26503932,0.54498786],"study_design_scores_gemma":[0.00026731007,0.004032484,0.02072329,0.0000720138,0.00001331309,0.0000050555063,0.0001056665,0.00012980576,0.15607646,0.00013783464,0.8182374,0.0001993466],"about_ca_topic_score_codex":0.00010563532,"about_ca_topic_score_gemma":0.00013369595,"teacher_disagreement_score":0.5531981,"about_ca_system_score_codex":0.000005358948,"about_ca_system_score_gemma":0.00015966312,"threshold_uncertainty_score":0.35943955},"labels":[],"label_agreement":null},{"id":"W3089012621","doi":"10.1016/j.annonc.2020.08.851","title":"779P Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ipsen; Daiichi Sankyo Europe; Sanofi; Exelixis; Astellas Pharma; Cleveland Clinic; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Internal medicine; Hazard ratio; Progression-free survival; Oncology; Performance status; Proportional hazards model; Clinical trial; Overall survival; Confidence interval","score_opus":0.2700922670394051,"score_gpt":0.4825466236951804,"score_spread":0.21245435665577533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089012621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635214,0.0001579796,0.000024951012,0.0015364179,0.000061718136,0.0015122328,0.00004789345,0.0000072926937,0.0002993493],"genre_scores_gemma":[0.99873,0.000038093734,0.0003489825,0.0006882864,0.000051447343,0.00006520565,0.000053047606,0.000015629652,0.000009296647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972566,0.0008102414,0.0012414525,0.00025613178,0.00023828018,0.00019732522],"domain_scores_gemma":[0.998211,0.00080709584,0.00048503018,0.0001445202,0.00022236198,0.00012998565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010636802,0.00013842403,0.0012776908,0.00016320527,0.000008446358,0.0000028868342,0.00007482713,0.000097164804,0.00010255419],"category_scores_gemma":[0.0018730937,0.000099710385,0.00012880244,0.00030401032,0.00011398909,0.00007236266,0.00002250161,0.00016147598,0.0000062070008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016521504,0.004295587,0.95864856,0.00009314281,0.00030850948,0.00006761145,0.0010370053,0.000009520027,0.00011234029,0.0000124822145,0.00022435345,0.018669406],"study_design_scores_gemma":[0.052516565,0.03956741,0.9022852,0.000088497116,0.00034117853,0.0000011947956,0.000077786906,0.00003591869,0.0048340047,0.00008101026,0.00008844028,0.000082786384],"about_ca_topic_score_codex":0.00021145411,"about_ca_topic_score_gemma":0.00003895184,"teacher_disagreement_score":0.05636333,"about_ca_system_score_codex":0.000022308031,"about_ca_system_score_gemma":0.00047085635,"threshold_uncertainty_score":0.40660715},"labels":[],"label_agreement":null},{"id":"W3089021817","doi":"10.1016/j.annonc.2020.08.428","title":"326P Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McGill University Health Centre; Ottawa Regional Cancer Foundation; BC Cancer Agency; Ottawa Hospital; University of Saskatchewan; London Health Sciences Centre; Grand River Hospital; Windsor Regional Hospital; McGill University; Jewish General Hospital","funders":"Pfizer Pharmaceuticals; Novartis Pharmaceuticals Canada; Genentech; Eisai; Invitae; Puma Biotechnology; Incyte; BeiGene; Astellas Pharma; Celldex Therapeutics; Mylan; Aptitude Health; Sirtex Medical; Genomic Health; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Daiichi Sankyo Europe; U.S. Department of Defense","keywords":"Medicine; Observational study; Breast cancer; Real world evidence; Adverse effect; Oncology; Cancer; Exploratory research; Health care; Endocrine system; Internal medicine; Intensive care medicine","score_opus":0.19009863461993937,"score_gpt":0.4356159237488292,"score_spread":0.24551728912888982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089021817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98061556,0.00033732978,0.0000075653825,0.016548268,0.000054955042,0.00071750226,0.00033386605,0.00002095482,0.0013640109],"genre_scores_gemma":[0.9967513,0.00013383597,0.00021585291,0.002389946,0.00008836927,0.00023884217,0.000038467988,0.000023008932,0.00012038648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835736,0.00010974609,0.0005749539,0.00038893212,0.00024505574,0.00032396248],"domain_scores_gemma":[0.9985169,0.00007889921,0.00030729553,0.00024314522,0.000582377,0.00027136042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017924384,0.0001867375,0.001055342,0.00072152144,0.000030182126,0.0000023229293,0.00013947971,0.00007680193,0.00043222748],"category_scores_gemma":[0.000050692848,0.00017395751,0.00014252115,0.0023510975,0.00014374773,0.00016506824,0.000031789914,0.00017725342,0.0000028453985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025089863,0.00057969417,0.9646018,0.00003760582,0.0017331162,0.000094266,0.007482557,0.0013962009,0.0011640628,0.00022765766,0.00014360911,0.02003042],"study_design_scores_gemma":[0.0027195439,0.0015065512,0.98934186,0.000043208172,0.00042206378,0.0000024344943,0.0022755489,0.0001497008,0.000889163,0.00008838116,0.002429421,0.00013213773],"about_ca_topic_score_codex":0.06470717,"about_ca_topic_score_gemma":0.63466024,"teacher_disagreement_score":0.5699531,"about_ca_system_score_codex":0.0004289946,"about_ca_system_score_gemma":0.0014466838,"threshold_uncertainty_score":0.94152105},"labels":[],"label_agreement":null},{"id":"W3089025929","doi":"10.1016/j.annonc.2020.08.1716","title":"1402P Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; KRAS; Interquartile range; Cancer","score_opus":0.07062036124007424,"score_gpt":0.4127835892409054,"score_spread":0.34216322800083115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089025929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726066,0.0004671461,0.000056864636,0.01257689,0.00013267838,0.00076112815,0.000049460836,0.000034434866,0.013314783],"genre_scores_gemma":[0.9913758,0.00026576722,0.00518299,0.0026126055,0.00014325982,0.00016552291,0.000054483902,0.000027841328,0.00017174914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985553,0.000088130975,0.00055370195,0.000330999,0.00012081598,0.0003510732],"domain_scores_gemma":[0.99887925,0.00037052965,0.00028840656,0.00010156525,0.0002195751,0.00014066216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014954653,0.00016439523,0.0004886996,0.00021025895,0.000035473106,0.0000052511728,0.00007478777,0.00009886343,0.00009484906],"category_scores_gemma":[0.00033084446,0.0001573914,0.000065532324,0.0006302325,0.000035584526,0.00012811358,0.000032118864,0.00023626263,0.0000066911775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004643087,0.0005228798,0.8733978,0.0007402145,0.000104325445,0.00025148186,0.011756953,0.0013798587,0.027989348,0.000047744805,0.001405837,0.081939206],"study_design_scores_gemma":[0.009725286,0.0026307495,0.9372577,0.00086714345,0.00018058169,0.000008410856,0.0014774054,0.0056595798,0.03867953,0.00010090281,0.0030463855,0.00036634214],"about_ca_topic_score_codex":0.003495956,"about_ca_topic_score_gemma":0.0021154997,"teacher_disagreement_score":0.08157287,"about_ca_system_score_codex":0.00025241933,"about_ca_system_score_gemma":0.0007462678,"threshold_uncertainty_score":0.64182353},"labels":[],"label_agreement":null},{"id":"W3089035981","doi":"10.1016/j.annonc.2020.08.2325","title":"1678P_PR The impact of COVID-19 pandemic on cancer care: A global collaborative study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pandemic; Psychological intervention; Health care; Personal protective equipment; Family medicine; Harm; Coronavirus disease 2019 (COVID-19); Medical emergency; Emergency medicine; Nursing; Internal medicine; Disease","score_opus":0.35625799426436694,"score_gpt":0.59784402147619,"score_spread":0.24158602721182304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089035981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9008862,0.0016742545,0.000008518871,0.09413153,0.000087302455,0.0012066573,0.00032171907,0.00002822675,0.0016556205],"genre_scores_gemma":[0.9612402,0.00068254553,0.000007967669,0.03781537,0.00018419695,0.000039477087,0.000007901085,0.000009676804,0.000012692672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983889,0.0003730821,0.0004106488,0.00024963287,0.00027963845,0.00029809095],"domain_scores_gemma":[0.9977297,0.00057607144,0.0003136453,0.00026480036,0.0006088461,0.0005068929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038025196,0.0001628349,0.00070809387,0.000051315707,0.00006641634,0.0000037608797,0.00016793735,0.00014259882,0.000177198],"category_scores_gemma":[0.0018961113,0.00009952476,0.0001573726,0.00066536636,0.00017559442,0.000031378564,0.00006121736,0.00024282157,0.000008197468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084137395,0.000928711,0.86635685,0.00033177843,0.0006516726,0.00012497602,0.03834615,0.00055159896,0.0005316618,0.00015183602,0.050983097,0.032627936],"study_design_scores_gemma":[0.007142768,0.08185388,0.8282967,0.00007055002,0.00021963315,0.000024048511,0.019505026,0.00004775129,0.0002529756,0.00020850384,0.062199306,0.0001788352],"about_ca_topic_score_codex":0.01219848,"about_ca_topic_score_gemma":0.0037791936,"teacher_disagreement_score":0.08092517,"about_ca_system_score_codex":0.0006498966,"about_ca_system_score_gemma":0.010102125,"threshold_uncertainty_score":0.9955097},"labels":[],"label_agreement":null},{"id":"W3089046444","doi":"10.1016/j.annonc.2020.08.2279","title":"LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Oncology; Adjuvant; Internal medicine; Central nervous system; Adjuvant therapy; Disease; Chemotherapy; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.0504171646394417,"score_gpt":0.3656277545487134,"score_spread":0.3152105899092717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089046444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98840415,0.00095299666,0.000020662905,0.007540197,0.00015898702,0.00113821,0.00012064852,0.00006852919,0.0015955959],"genre_scores_gemma":[0.9971096,0.00025347286,0.00010015123,0.002033105,0.000071457944,0.00008681045,0.00027068277,0.000026903728,0.000047797097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983189,0.00015706032,0.00045398495,0.0003713454,0.0002764947,0.00042222437],"domain_scores_gemma":[0.99866146,0.000073580006,0.00023953832,0.00023278162,0.00036848764,0.00042413262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075814365,0.00020067826,0.0005391005,0.00010023826,0.000050557897,0.000007717492,0.0001213756,0.00009090013,0.000067229485],"category_scores_gemma":[0.000111616675,0.00014520573,0.00008228255,0.0004553777,0.00011170361,0.00009319273,0.000026970436,0.0001803322,0.000015480455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032250512,0.004925882,0.5879958,0.00055879576,0.0010066632,0.0013671699,0.00702376,0.00033620777,0.0006614224,0.00021619542,0.009362174,0.35429537],"study_design_scores_gemma":[0.016179366,0.016153654,0.9544764,0.0005337052,0.0002174036,0.000009255262,0.0005602316,0.0006234786,0.0010126686,0.0000141411,0.009982773,0.00023690528],"about_ca_topic_score_codex":0.0003592197,"about_ca_topic_score_gemma":0.000053763095,"teacher_disagreement_score":0.3664806,"about_ca_system_score_codex":0.00016031104,"about_ca_system_score_gemma":0.00074948935,"threshold_uncertainty_score":0.5921318},"labels":[],"label_agreement":null},{"id":"W3089048329","doi":"10.1016/j.annonc.2020.08.972","title":"833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; McGill University Health Centre","funders":"","keywords":"Medicine; Bevacizumab; Carboplatin; Neutropenia; Internal medicine; Ovarian cancer; Nausea; Gastroenterology; Adverse effect; Tolerability; Pharmacology; Surgery; Cancer; Chemotherapy; Cisplatin","score_opus":0.04605320350170147,"score_gpt":0.3358623265776068,"score_spread":0.28980912307590534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089048329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843574,0.00037228042,0.000007356553,0.012398997,0.00011282688,0.0019735172,0.0005055532,0.000025044603,0.00024700738],"genre_scores_gemma":[0.99745387,0.00030029865,0.00075693557,0.0006800121,0.00007572904,0.000097507334,0.0005849437,0.000040862942,0.000009863676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971381,0.00037486656,0.0008534978,0.00081120926,0.00039857335,0.00042378702],"domain_scores_gemma":[0.9982487,0.00032350738,0.00059277704,0.00021732268,0.0004139708,0.0002037304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041690862,0.00036981227,0.0011195566,0.00020017056,0.000057975696,0.00001939565,0.00007729538,0.00014177713,0.000026228396],"category_scores_gemma":[0.00017269044,0.0002974678,0.00004979118,0.00050908426,0.00011959526,0.00015009346,0.00007016914,0.00041487193,0.0000027225017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07075775,0.009511843,0.82096505,0.00013770805,0.0010185821,0.0010368855,0.032754157,0.00016362674,0.0006668266,0.000038010032,0.0009999282,0.061949614],"study_design_scores_gemma":[0.09655483,0.032512832,0.8638451,0.001029522,0.0002839204,0.000005353715,0.0018247091,0.0015342534,0.0015164897,0.000033190245,0.00047921552,0.0003806002],"about_ca_topic_score_codex":0.0099356705,"about_ca_topic_score_gemma":0.00873548,"teacher_disagreement_score":0.061569013,"about_ca_system_score_codex":0.00025561094,"about_ca_system_score_gemma":0.0004425616,"threshold_uncertainty_score":0.9999477},"labels":[],"label_agreement":null},{"id":"W3089050578","doi":"10.1016/j.annonc.2020.08.927","title":"668P Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech; European Society for Medical Oncology; Daiichi Sankyo Company; Emerson Collective; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; GlaxoSmithKline; Society for Immunotherapy of Cancer; Astellas Pharma Global Development; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Parker Institute for Cancer Immunotherapy; Gateway for Cancer Research; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Proportional hazards model; Internal medicine; Radium-223; Cohort; Oncology; Cancer; Retrospective cohort study; Urology; Surgery; Bone metastasis","score_opus":0.3090772894855692,"score_gpt":0.4777500778161739,"score_spread":0.16867278833060473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089050578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771656,0.00042716155,0.000014144785,0.019183282,0.000033819997,0.002445012,0.00026075623,0.00002964026,0.00044061773],"genre_scores_gemma":[0.9976196,0.00045839956,0.0003135461,0.00040694073,0.00003632814,0.00041293248,0.00014453675,0.00003516136,0.000572555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981615,0.00018456322,0.00048228016,0.00040185763,0.00031902472,0.00045075375],"domain_scores_gemma":[0.9981913,0.0007476709,0.00030051818,0.00015638256,0.00033314686,0.0002709948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003316614,0.0002385565,0.0010857924,0.000104764884,0.00004947956,0.000012781169,0.000097702556,0.00009154051,0.000044733486],"category_scores_gemma":[0.00021822858,0.00013292591,0.00011050619,0.00029143592,0.00027399338,0.00009480684,0.00002184136,0.00021608193,0.00000199795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014690712,0.00093747966,0.97834116,0.00029623325,0.00093875494,0.00037242915,0.00088162604,0.000023572524,0.0002074358,0.000021091462,0.0006798861,0.002609625],"study_design_scores_gemma":[0.018658256,0.021538937,0.95016676,0.00019126505,0.00040155632,0.00000606428,0.0024917102,0.00014140132,0.0041060722,0.000026931435,0.0020706742,0.00020036366],"about_ca_topic_score_codex":0.0006487923,"about_ca_topic_score_gemma":0.0022816283,"teacher_disagreement_score":0.028174387,"about_ca_system_score_codex":0.00008437835,"about_ca_system_score_gemma":0.0009567796,"threshold_uncertainty_score":0.5420561},"labels":[],"label_agreement":null},{"id":"W3089072541","doi":"10.1016/j.annonc.2020.08.1602","title":"1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Oncology; ROS1; Adenocarcinoma; Asymptomatic; Clinical trial; Cancer","score_opus":0.041363131630691455,"score_gpt":0.3780338126850281,"score_spread":0.3366706810543367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089072541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990559,0.00014284874,0.00006368885,0.006231447,0.00003155811,0.00066834944,0.00023467366,0.000013115671,0.0020553116],"genre_scores_gemma":[0.9962774,0.000056113255,0.0013880013,0.0018035733,0.000041485444,0.000022201171,0.00025985375,0.00001558877,0.00013579987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905854,0.000084102045,0.00028434867,0.00021599214,0.00018304044,0.00017396455],"domain_scores_gemma":[0.99891114,0.00031937784,0.00020817673,0.00012874906,0.00030543614,0.00012714526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007776508,0.00012726999,0.0004873803,0.00007926256,0.000028980294,0.0000016218739,0.000047130725,0.000050828592,0.00036950273],"category_scores_gemma":[0.00017430267,0.00007458473,0.00004842367,0.00029387116,0.000100228724,0.000043953572,0.000033069122,0.00007898489,0.000007129442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11107788,0.011701744,0.6662171,0.00031853444,0.0030874668,0.00064501015,0.012152635,0.0005332492,0.0015113174,0.000115517985,0.012783131,0.17985643],"study_design_scores_gemma":[0.042092323,0.059992336,0.8450542,0.00048601918,0.0012618095,0.000021564594,0.00085294235,0.000057696212,0.02613538,0.0000075629814,0.023782972,0.00025521332],"about_ca_topic_score_codex":0.00018378721,"about_ca_topic_score_gemma":0.00025262998,"teacher_disagreement_score":0.17960122,"about_ca_system_score_codex":0.00005552778,"about_ca_system_score_gemma":0.0003740688,"threshold_uncertainty_score":0.40457958},"labels":[],"label_agreement":null},{"id":"W3089087793","doi":"10.1016/j.annonc.2020.08.1747","title":"1683P SARS-CoV-2 infection and lung cancer management in Europe","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psychological intervention; Lung cancer; Family medicine; Pandemic; Health care; Coronavirus disease 2019 (COVID-19); Environmental health; Nursing; Disease; Economic growth; Internal medicine","score_opus":0.26611362152531365,"score_gpt":0.5277444175856033,"score_spread":0.26163079606028966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089087793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86888057,0.00094964163,0.000028182765,0.121989556,0.00008813095,0.00027992702,0.0000025769255,0.000018052751,0.007763371],"genre_scores_gemma":[0.9381171,0.0064892215,0.000053759704,0.055174753,0.00009922549,0.000011107124,0.0000024211329,0.00000768164,0.000044759174],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99938047,0.000050853563,0.0001914627,0.00014296582,0.00007342533,0.00016079769],"domain_scores_gemma":[0.9996503,0.000041689476,0.00006373778,0.000070097536,0.00009445822,0.00007972283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015484265,0.00006295735,0.00023891102,0.000095610616,0.000014436234,0.0000023622244,0.000024067991,0.00006247951,0.000024943403],"category_scores_gemma":[0.00013338629,0.000058107446,0.00001989768,0.00026623803,0.000032748318,0.00003817092,0.000043574495,0.00012167039,0.0000056158287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013445311,0.00035804373,0.32908106,0.0026184286,0.00020957699,0.00053122145,0.0028382647,0.000020701264,0.016463563,0.0010919719,0.09067804,0.5547646],"study_design_scores_gemma":[0.001617706,0.0019954303,0.56351584,0.000111257614,0.000052093044,0.000010417301,0.000029235713,0.00033538148,0.0056416555,0.000051966406,0.42656597,0.00007300472],"about_ca_topic_score_codex":0.0015527318,"about_ca_topic_score_gemma":0.00081037113,"teacher_disagreement_score":0.5546916,"about_ca_system_score_codex":0.000042142197,"about_ca_system_score_gemma":0.00018010783,"threshold_uncertainty_score":0.23695529},"labels":[],"label_agreement":null},{"id":"W3089106838","doi":"10.1016/j.annonc.2020.08.132","title":"1506P The predictive value of 2-D myocardial strain for epirubicin-induced cardiotoxicity","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Epirubicin; Medicine; Cardiotoxicity; Ejection fraction; Internal medicine; Breast cancer; Chemotherapy; Cardiology; Cancer; Heart failure","score_opus":0.11290769835752114,"score_gpt":0.37615472728798516,"score_spread":0.26324702893046403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089106838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96060485,0.00015751281,0.0024522096,0.027182769,0.00020423092,0.0014731876,0.0002456797,0.000034335328,0.007645248],"genre_scores_gemma":[0.9909611,0.00010028208,0.00035265306,0.0077144396,0.00074497337,0.000054021544,0.000031561834,0.00002175927,0.000019206893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985744,0.00018859243,0.00045155658,0.00026082376,0.00027082578,0.0002538362],"domain_scores_gemma":[0.99849343,0.00044094506,0.00027279087,0.00025862985,0.0003925465,0.00014165547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068484107,0.00015386313,0.0008029163,0.00005161987,0.000055742337,0.0000031382958,0.00014728626,0.00026800894,0.000017792849],"category_scores_gemma":[0.0006082089,0.00011925252,0.00053503795,0.00020795142,0.00020420231,0.000053220436,0.00003594221,0.00024473076,0.0000022983868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017535663,0.00017176862,0.00031183416,0.00015578826,0.0008937341,0.0000066738453,0.0030128912,0.00013989372,0.94753724,0.0016698174,0.004033843,0.04031296],"study_design_scores_gemma":[0.0028319822,0.007759121,0.009448071,0.000043797274,0.0002488201,0.000020965335,0.0009393935,0.000504486,0.9645695,0.0008722532,0.012650883,0.0001107043],"about_ca_topic_score_codex":0.00004254492,"about_ca_topic_score_gemma":0.000003898268,"teacher_disagreement_score":0.040202256,"about_ca_system_score_codex":0.000039203187,"about_ca_system_score_gemma":0.00042429805,"threshold_uncertainty_score":0.4862977},"labels":[],"label_agreement":null},{"id":"W3089112078","doi":"10.1016/j.annonc.2020.08.870","title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Meso Scale Diagnostics; AstraZeneca","keywords":"Olaparib; Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Population; Oncology; Cohort; Progression-free survival; Randomized controlled trial; Urology; Cancer; Chemotherapy; Androgen receptor","score_opus":0.12535697421102335,"score_gpt":0.3941244951630284,"score_spread":0.26876752095200507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089112078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575263,0.00017755937,0.00007207201,0.0026893376,0.000057192217,0.0007864054,0.00031520842,0.000017551978,0.00013204764],"genre_scores_gemma":[0.99685967,0.00027836286,0.0012093602,0.0011835828,0.00003340189,0.00014242684,0.00020500793,0.000018443408,0.00006973061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979401,0.00028082513,0.0008700176,0.0003561654,0.00032753838,0.000225352],"domain_scores_gemma":[0.9979379,0.0002395619,0.0007826794,0.00020555012,0.0007426421,0.00009164158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003193869,0.00018355623,0.0009818573,0.0003076216,0.000039650786,0.000006520779,0.00007212707,0.000075223565,0.000088452965],"category_scores_gemma":[0.00013578741,0.00015323082,0.00010420429,0.00079767243,0.0002034693,0.00018225044,0.000023182094,0.0001509521,6.269955e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06553342,0.009264202,0.6602392,0.0023564338,0.010758467,0.00016279587,0.015172034,0.015626619,0.1957659,0.0010571608,0.0020953314,0.02196841],"study_design_scores_gemma":[0.016391862,0.021552598,0.9077635,0.0002539088,0.001566508,0.0000041337034,0.00027925367,0.0026212467,0.048518945,0.00017363668,0.0005846949,0.00028974167],"about_ca_topic_score_codex":0.0010708031,"about_ca_topic_score_gemma":0.0032271228,"teacher_disagreement_score":0.24752425,"about_ca_system_score_codex":0.00012478235,"about_ca_system_score_gemma":0.00054422073,"threshold_uncertainty_score":0.6248571},"labels":[],"label_agreement":null},{"id":"W3089114680","doi":"10.1016/j.annonc.2020.08.1267","title":"1144P Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Melanoma; Proportional hazards model; Oncology; Cancer; Progression-free survival; Exact test; Cohort; Stage (stratigraphy); Surgery; Chemotherapy; Cancer research","score_opus":0.08082474101455296,"score_gpt":0.3677441352650549,"score_spread":0.28691939425050195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089114680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453485,0.0006749537,0.000008749846,0.0031067808,0.00022421144,0.0005928126,0.000061717736,0.000019207355,0.0007767086],"genre_scores_gemma":[0.9979639,0.00019985942,0.0005008424,0.0010549251,0.000084461404,0.000017308263,0.00013252301,0.00002622161,0.00001996328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975859,0.0002651745,0.0012070147,0.00037447974,0.00026665974,0.00030076056],"domain_scores_gemma":[0.99839306,0.00033420225,0.0005980119,0.00027940673,0.00020940452,0.00018592319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038463422,0.00022353097,0.0013628058,0.00011625673,0.00002403171,0.0000020148998,0.00014444579,0.00026298966,0.000129945],"category_scores_gemma":[0.00017161088,0.0001666459,0.00024655033,0.00026525298,0.00034094387,0.00007208559,0.00007422422,0.00034080003,0.0000232436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030798484,0.0038068236,0.9732964,0.000056102315,0.0016388764,0.00016805457,0.00073403824,0.000011516217,0.00037925152,0.000039799685,0.00009038481,0.016698908],"study_design_scores_gemma":[0.012942621,0.03014932,0.94665235,0.00010111334,0.0005552276,0.0000051077527,0.00018096209,0.000036757552,0.007942256,0.00014204546,0.0011730717,0.00011917464],"about_ca_topic_score_codex":0.00025774373,"about_ca_topic_score_gemma":0.000088957255,"teacher_disagreement_score":0.026644053,"about_ca_system_score_codex":0.00004212151,"about_ca_system_score_gemma":0.00028398365,"threshold_uncertainty_score":0.6795623},"labels":[],"label_agreement":null},{"id":"W3089120395","doi":"10.1016/j.annonc.2020.08.458","title":"356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Metastatic breast cancer; Induction chemotherapy; Breast cancer; Cancer; Immunotherapy; Polymerase","score_opus":0.09994990229484879,"score_gpt":0.4189594626512683,"score_spread":0.31900956035641953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089120395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9398067,0.0013189173,0.0004467277,0.04577614,0.0005234658,0.0099788,0.0003443026,0.000086378364,0.0017185683],"genre_scores_gemma":[0.9709304,0.009225475,0.0015977317,0.013809278,0.0005161831,0.0031783811,0.000084748506,0.00014574174,0.00051206694],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933013,0.0012032483,0.0025486967,0.0011399991,0.0008962304,0.00091057224],"domain_scores_gemma":[0.9952154,0.0006197213,0.0018118313,0.000691329,0.0011660189,0.0004956834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015695116,0.00082478294,0.004677182,0.0005597522,0.00013285385,0.0000467082,0.0006388604,0.00042714525,0.0035556355],"category_scores_gemma":[0.00033843872,0.00062107254,0.00036663917,0.001596596,0.0010197776,0.00061290525,0.00013819795,0.00093646767,0.000008167367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88817286,0.010271781,0.00002981507,0.00028482216,0.00158655,0.00011610085,0.005916544,0.000051541894,0.0031384977,0.00010063172,0.0055148364,0.084815994],"study_design_scores_gemma":[0.9098848,0.06001913,0.00011241415,0.0007680199,0.0004066189,0.00027267577,0.00038782365,0.0010767658,0.017860869,0.00028909274,0.008345691,0.0005761165],"about_ca_topic_score_codex":0.0011839462,"about_ca_topic_score_gemma":0.00035358523,"teacher_disagreement_score":0.08423988,"about_ca_system_score_codex":0.00053182605,"about_ca_system_score_gemma":0.004018574,"threshold_uncertainty_score":0.9996241},"labels":[],"label_agreement":null},{"id":"W3089125873","doi":"10.1016/j.annonc.2020.08.960","title":"821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Internal medicine; Placebo; PARP inhibitor; Population; Phases of clinical research; Ovarian cancer; Surgery; Cancer; Clinical trial; Poly ADP ribose polymerase","score_opus":0.1877396312442508,"score_gpt":0.46425494564890574,"score_spread":0.27651531440465493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089125873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840328,0.00025704925,0.00022841721,0.012959377,0.00010113556,0.0018089593,0.00007643537,0.000009602324,0.00052621285],"genre_scores_gemma":[0.9974412,0.00031358792,0.00023948599,0.0012508043,0.00011782466,0.00056726433,0.00000922348,0.000013309698,0.00004732906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988694,0.00009987126,0.00041412943,0.00022939582,0.00016400764,0.00022314776],"domain_scores_gemma":[0.9991788,0.00011613105,0.00029377895,0.00019078238,0.00015164203,0.00006884539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024803213,0.00013119985,0.00050189917,0.00006381666,0.000036837446,7.3869006e-7,0.00010268169,0.000051066156,0.000094246905],"category_scores_gemma":[0.000035068348,0.000084942854,0.00008435661,0.00019603806,0.00007406339,0.00004132129,0.000014610593,0.00010377836,8.8404516e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2902157,0.04759702,0.112804234,0.0013317979,0.004402627,0.0008851574,0.2060042,0.0020281707,0.03703786,0.0009238033,0.00696438,0.28980505],"study_design_scores_gemma":[0.3905341,0.3018177,0.090732366,0.0020382246,0.0012262823,0.00013121612,0.03777058,0.0024122964,0.09410321,0.0004932538,0.077887654,0.0008531451],"about_ca_topic_score_codex":0.00020393396,"about_ca_topic_score_gemma":0.00032594585,"teacher_disagreement_score":0.2889519,"about_ca_system_score_codex":0.00012742341,"about_ca_system_score_gemma":0.00031323195,"threshold_uncertainty_score":0.3463869},"labels":[],"label_agreement":null},{"id":"W3089134390","doi":"10.1016/j.annonc.2020.08.798","title":"726P Collecting duct and renal medullary carcinoma: A population based analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Surveillance, Epidemiology, and End Results; Epidemiology; Internal medicine; Lymph node; Proportional hazards model; Retrospective cohort study; Hazard ratio; Oncology; Population; Kidney disease; Cancer registry","score_opus":0.127607485889329,"score_gpt":0.3670435447146164,"score_spread":0.23943605882528743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089134390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832625,0.0007752132,0.00010828816,0.013674656,0.00002498844,0.00023809279,0.000006907143,0.00003623271,0.0018731463],"genre_scores_gemma":[0.9953035,0.00003145066,0.0020818524,0.0023438665,0.00009765632,0.000011323521,0.0000717743,0.000016641721,0.00004192054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885404,0.00013339259,0.00034759386,0.00028398752,0.00018964156,0.00019135648],"domain_scores_gemma":[0.99910086,0.00018395655,0.0001888398,0.00015649815,0.00015865338,0.00021117568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021471348,0.00012758559,0.00062189705,0.00023455461,0.000043220418,0.0000050335634,0.00004388253,0.00011129985,0.00007445443],"category_scores_gemma":[0.00021728166,0.000111267684,0.00018455472,0.00072440394,0.00004737519,0.000035154088,0.000033172833,0.00011725518,0.0000025381817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013294447,0.00027317824,0.97018456,0.00015966158,0.0010613018,0.00048907084,0.0006434753,0.00029187225,0.011690667,0.00004546819,0.0020808496,0.011750435],"study_design_scores_gemma":[0.0019601723,0.0047062533,0.9657119,0.00001614335,0.0015377947,0.000046330228,0.00012543514,0.004466199,0.018898444,0.000040131188,0.0023730344,0.00011816848],"about_ca_topic_score_codex":0.00044292602,"about_ca_topic_score_gemma":0.00007174981,"teacher_disagreement_score":0.012041039,"about_ca_system_score_codex":0.00005571891,"about_ca_system_score_gemma":0.00018855413,"threshold_uncertainty_score":0.45373645},"labels":[],"label_agreement":null},{"id":"W3089135437","doi":"10.1016/j.annonc.2020.08.2062","title":"1579P Burnout among oncology professionals in the Middle East and North Africa (MENA)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Burnout; Middle East; Family medicine; Oncology; Archaeology; Clinical psychology","score_opus":0.18842254215877502,"score_gpt":0.42083349626058425,"score_spread":0.23241095410180923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089135437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8694091,0.0034683554,0.000056704994,0.099634506,0.00022984587,0.0006116287,0.000011451259,0.0000224848,0.02655593],"genre_scores_gemma":[0.96926755,0.001255088,0.0010610038,0.02765006,0.00041040813,0.0000685886,0.000012076973,0.000014915476,0.00026033085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983446,0.00042148834,0.0004322381,0.00029020634,0.00016862793,0.00034286402],"domain_scores_gemma":[0.9985547,0.00074068655,0.00025061742,0.00019267773,0.00010539539,0.00015588834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056274567,0.00015578228,0.0006711871,0.000071231,0.00008115128,0.000002596142,0.00021084466,0.00031699223,0.00014093878],"category_scores_gemma":[0.00034115405,0.00009969592,0.000079427475,0.0002976691,0.0006709705,0.000080757585,0.00006651974,0.000547951,0.000012297728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008073225,0.0067260596,0.28910527,0.0005775885,0.00066588563,0.0028978384,0.24507412,0.00008325283,0.0019170231,0.004641089,0.14223209,0.29800656],"study_design_scores_gemma":[0.0047200113,0.015371957,0.10212279,0.00011204964,0.00007464856,0.0002595369,0.014871959,0.00022523142,0.00013550802,0.00078766054,0.8610937,0.00022491842],"about_ca_topic_score_codex":0.000010004072,"about_ca_topic_score_gemma":0.00011848628,"teacher_disagreement_score":0.71886164,"about_ca_system_score_codex":0.000040751343,"about_ca_system_score_gemma":0.0003578422,"threshold_uncertainty_score":0.40654817},"labels":[],"label_agreement":null},{"id":"W3089155296","doi":"10.1016/j.annonc.2020.08.834","title":"762P Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer (MIBC) reveals unique features that may inspire new sequential therapies in pathologically-nonresponders","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Bladder cancer; Pembrolizumab; Cystectomy; Medicine; Cancer research; Pathology; Immunotherapy; Cancer; Internal medicine","score_opus":0.10907715530434148,"score_gpt":0.38775969897862245,"score_spread":0.27868254367428097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089155296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95648634,0.00512511,0.000059719587,0.034498602,0.00011032848,0.00092259806,0.00010020271,0.00003907614,0.002657995],"genre_scores_gemma":[0.97910196,0.0020387566,0.0010399242,0.01739165,0.000123535,0.000071046656,0.000042186475,0.000037681573,0.00015327746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980112,0.00036601693,0.0004939461,0.000437046,0.00029565368,0.0003961423],"domain_scores_gemma":[0.9987396,0.00016630339,0.0003127467,0.00025901926,0.00030195538,0.00022039341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021510806,0.00027979008,0.0008862774,0.0001640132,0.000029321629,0.000006930587,0.00020608834,0.00036938232,0.0003187395],"category_scores_gemma":[0.00026544096,0.00022367344,0.000240839,0.00029789476,0.00021978162,0.00008947052,0.00008433144,0.00034175333,0.0000039682145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011394275,0.0009354944,0.037133366,0.00053319184,0.0012420513,0.0021469006,0.0105714025,0.00016912642,0.8781264,0.0011413269,0.0034642126,0.05314229],"study_design_scores_gemma":[0.010178093,0.013980829,0.1640017,0.00040904476,0.00035938495,0.000091948044,0.0023408355,0.0000065540758,0.80280894,0.0017749835,0.0036097895,0.00043786332],"about_ca_topic_score_codex":0.0011478321,"about_ca_topic_score_gemma":0.0002838099,"teacher_disagreement_score":0.12686834,"about_ca_system_score_codex":0.00007386164,"about_ca_system_score_gemma":0.0014553184,"threshold_uncertainty_score":0.91211385},"labels":[],"label_agreement":null},{"id":"W3089163327","doi":"10.1016/j.annonc.2020.08.2079","title":"685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma Global Development; EMD Serono; Genentech; Sanofi; BeiGene; Gilead Sciences; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Placebo; Urology; Gynecology; Hazard ratio; Oncology; Prostate-specific antigen; Cancer; Confidence interval; Androgen receptor; Alternative medicine; Pathology","score_opus":0.1158635947186557,"score_gpt":0.4313768723674121,"score_spread":0.3155132776487564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089163327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673176,0.002863457,0.000015652913,0.013799044,0.00004690742,0.01509911,0.0002309768,0.000031928455,0.00059531746],"genre_scores_gemma":[0.99333733,0.00195562,0.00015446485,0.00046881207,0.000031447173,0.0028497458,0.00009534187,0.000053723175,0.001053505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949626,0.0011801842,0.0016741643,0.00067018747,0.0008237878,0.0006890739],"domain_scores_gemma":[0.9964248,0.0013685627,0.00086950115,0.0003927595,0.0005929177,0.00035144037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025328305,0.00045091158,0.0032259908,0.0004379806,0.000091183996,0.000027639131,0.00022467913,0.00013841274,0.000180678],"category_scores_gemma":[0.00026944987,0.00029338888,0.00024092106,0.0007372216,0.00048700455,0.00019149171,0.00008886767,0.00039686385,0.0000058112787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9330738,0.005296366,0.0050365776,0.00016305286,0.0022475747,0.00076023623,0.01573908,0.00021263742,0.033104982,0.000012534782,0.0023294783,0.0020236743],"study_design_scores_gemma":[0.94542193,0.02669211,0.0010991107,0.00014499115,0.00041750283,0.000008009806,0.0068813837,0.00029169637,0.017430155,0.000024248693,0.0013226839,0.00026617284],"about_ca_topic_score_codex":0.0011649588,"about_ca_topic_score_gemma":0.00064955006,"teacher_disagreement_score":0.026019733,"about_ca_system_score_codex":0.00017471894,"about_ca_system_score_gemma":0.0015602757,"threshold_uncertainty_score":0.99995184},"labels":[],"label_agreement":null},{"id":"W3089166529","doi":"10.1016/j.annonc.2020.08.1616","title":"1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CMC Microsystems; Pfizer","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.04800706773866008,"score_gpt":0.4254812712738958,"score_spread":0.3774742035352357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089166529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716036,0.00014561169,0.0000060047455,0.012506539,0.00003679708,0.0006284248,0.00005615712,0.000022516406,0.014994356],"genre_scores_gemma":[0.99666995,0.000016604876,0.00022228104,0.0026619406,0.000055268327,0.000045724002,0.00027171857,0.00001259219,0.00004392248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928325,0.00003896155,0.0002045741,0.00017468752,0.0001437917,0.00015472995],"domain_scores_gemma":[0.99941164,0.000032122265,0.00010321177,0.00009730006,0.00014896374,0.00020677218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000303049,0.000094796065,0.00026077268,0.000061405284,0.000022519263,0.000002693283,0.00003606631,0.00005349826,0.00011183586],"category_scores_gemma":[0.000056629447,0.000065459346,0.000038459748,0.00018369517,0.000069643786,0.00006221944,0.000018239838,0.000076557146,0.000010955088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007112103,0.0020956467,0.83972824,0.00006911941,0.00016448686,0.00021837717,0.0010778367,0.0000128256515,0.000033419266,0.00009479641,0.002564403,0.14682877],"study_design_scores_gemma":[0.013036365,0.01245305,0.9612901,0.000147467,0.00021942657,0.0000012039872,0.000069837886,0.000050829924,0.0004963325,0.000086038795,0.012042584,0.000106717576],"about_ca_topic_score_codex":0.000026510104,"about_ca_topic_score_gemma":0.000011749816,"teacher_disagreement_score":0.14672205,"about_ca_system_score_codex":0.000030891137,"about_ca_system_score_gemma":0.0002949809,"threshold_uncertainty_score":0.26693547},"labels":[],"label_agreement":null},{"id":"W3089189913","doi":"10.1016/j.annonc.2020.08.1615","title":"1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Alectinib; Cohort; Internal medicine; Oncology; Hazard ratio; Biomarker; Gastroenterology; Confidence interval; Crizotinib; Lung cancer; Genetics; Biology","score_opus":0.07109172378761051,"score_gpt":0.3481032729130858,"score_spread":0.27701154912547526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089189913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478465,0.00031377363,0.00034487722,0.0015504683,0.00011040268,0.00040616145,0.000096838514,0.000007592019,0.0023852375],"genre_scores_gemma":[0.99652743,0.00032035809,0.00048356495,0.0019206612,0.00016768294,0.000027369382,0.00050435576,0.000024221841,0.000024333964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986121,0.000108415144,0.0004214519,0.00041292934,0.00014674081,0.00029834814],"domain_scores_gemma":[0.99908066,0.000071612034,0.00024590763,0.00024317576,0.00021815776,0.00014051858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025421547,0.0001832346,0.00040779824,0.00007540192,0.000048916118,0.000013502952,0.00021651926,0.00022281529,0.000057487807],"category_scores_gemma":[0.0003305456,0.00016807082,0.000108458014,0.00023378593,0.00012387837,0.000005486775,0.00014675371,0.00010576885,0.0000052199352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10111495,0.004064618,0.6809277,0.00008124073,0.0030641574,0.00014193391,0.0002899033,0.0021729711,0.076425806,0.000079516016,0.07202553,0.059611686],"study_design_scores_gemma":[0.13992333,0.047711223,0.32362807,0.000093791896,0.0007015546,0.000012788742,0.0002064361,0.00071442337,0.17934793,0.00004504695,0.3062578,0.0013575725],"about_ca_topic_score_codex":0.00018015735,"about_ca_topic_score_gemma":0.00038038223,"teacher_disagreement_score":0.35729963,"about_ca_system_score_codex":0.0000104604105,"about_ca_system_score_gemma":0.00018146996,"threshold_uncertainty_score":0.68537295},"labels":[],"label_agreement":null},{"id":"W3089194444","doi":"10.1016/j.annonc.2020.08.624","title":"514P Updated analysis of outcomes of elderly patients with resectable liver metastases from colorectal cancer (CRLM): Single center experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Single Center; Internal medicine; Overall survival; Colorectal cancer; Progression-free survival; Retrospective cohort study; Cancer; Gastroenterology; Oncology; Surgery","score_opus":0.081045092073618,"score_gpt":0.36573277520483594,"score_spread":0.28468768313121795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089194444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960226,0.00084797444,0.000007225767,0.0009039601,0.000047451696,0.00027051565,0.0009531504,0.000010590794,0.00093653164],"genre_scores_gemma":[0.9987485,0.000219858,0.0002505672,0.0005140029,0.000014002599,0.00003480898,0.00017919399,0.000010110817,0.000028981876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987729,0.00006639056,0.00041766345,0.00026797195,0.00027487843,0.00020016868],"domain_scores_gemma":[0.9986967,0.00014690768,0.00036196737,0.00014277783,0.0005569566,0.00009471693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004268699,0.00015623868,0.0011783774,0.00013594414,0.000028959123,0.0000024529666,0.0000970955,0.000062341525,0.0007685086],"category_scores_gemma":[0.00008704988,0.000105702726,0.00019058853,0.000615703,0.00023623569,0.0000720186,0.000073248004,0.00006558122,9.4594515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049914983,0.0017221733,0.96942544,0.000030147392,0.007988622,0.000021307405,0.004114138,0.000028700782,0.0023848827,0.0000057938055,0.0012046136,0.008082666],"study_design_scores_gemma":[0.0033365027,0.015077878,0.93644994,0.000033581797,0.00217009,3.5708752e-7,0.00082896755,0.0000561491,0.039155744,0.0000032507849,0.0027767206,0.00011079579],"about_ca_topic_score_codex":0.003930016,"about_ca_topic_score_gemma":0.0025842474,"teacher_disagreement_score":0.03677086,"about_ca_system_score_codex":0.000043013795,"about_ca_system_score_gemma":0.00010789696,"threshold_uncertainty_score":0.84146297},"labels":[],"label_agreement":null},{"id":"W3089203913","doi":"10.1016/j.annonc.2020.08.1977","title":"1471P 3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Instituto de Salud Carlos III; Sierra Oncology; Servier; European Society for Medical Oncology; BeiGene; Conselleria d'Educació, Investigació, Cultura i Esport; Genentech; Les Laboratories Pierre Fabre; FibroGen; Eli Lilly and Company","keywords":"Medicine; Cancer; Concordance; Cancer research; Precision medicine; Organoid; Pathology; Oncology; Internal medicine; Biology","score_opus":0.09552783941340205,"score_gpt":0.3778422346238096,"score_spread":0.2823143952104076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089203913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569826,0.0033444557,0.004878546,0.028759807,0.0015742818,0.002938204,0.0008159854,0.000045341043,0.0006607433],"genre_scores_gemma":[0.96524197,0.003821869,0.003315244,0.02346415,0.0018055056,0.0014561708,0.0004158951,0.000078316814,0.0004008624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804914,0.00004729878,0.0006480958,0.00045139014,0.00036826293,0.00043582948],"domain_scores_gemma":[0.99757963,0.00033939665,0.00041711022,0.00016762833,0.0012170096,0.00027919852],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018431338,0.00023029122,0.00077992445,0.00016527525,0.000082392195,0.000004434365,0.0001060281,0.00016032474,0.0016871325],"category_scores_gemma":[0.00082569825,0.00018469087,0.00021057445,0.00044199513,0.000111934416,0.00007583933,0.000058636462,0.00014211354,0.000008184121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008959021,0.0006052266,0.0067827757,0.00038528114,0.0003758176,0.0000045583165,0.0006825187,0.00009256278,0.044581912,0.000028572833,0.22998059,0.70752114],"study_design_scores_gemma":[0.017409064,0.041544467,0.016995873,0.0002445226,0.00084723585,0.000013442074,0.00022652055,0.0002681211,0.035789117,0.00013290024,0.8862173,0.00031143564],"about_ca_topic_score_codex":0.00027394138,"about_ca_topic_score_gemma":0.00005378314,"teacher_disagreement_score":0.7072097,"about_ca_system_score_codex":0.00014439339,"about_ca_system_score_gemma":0.00085877854,"threshold_uncertainty_score":0.99922544},"labels":[],"label_agreement":null},{"id":"W3089211409","doi":"10.1016/j.annonc.2020.08.500","title":"391P Cognitive impairment in primary brain tumour patients receiving systemic therapy: A cross-sectional study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cognition; Quality of life (healthcare); Cross-sectional study; Cognitive decline; Montreal Cognitive Assessment; Temporal lobe; Internal medicine; Dementia; Pediatrics; Disease; Cognitive impairment; Psychiatry; Pathology; Epilepsy","score_opus":0.08304291923991103,"score_gpt":0.39360078915064983,"score_spread":0.3105578699107388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089211409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896681,0.0004212152,0.000009379715,0.0038849378,0.00024100923,0.002449882,0.000047660244,0.000049419392,0.003228405],"genre_scores_gemma":[0.99115294,0.00021448784,0.000011569605,0.008072732,0.00018256338,0.0002202522,0.000041642663,0.000027685399,0.000076118304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764353,0.00033665937,0.00077434623,0.00045830593,0.00041593326,0.00037120818],"domain_scores_gemma":[0.9981112,0.0005747077,0.0003463387,0.0000975368,0.000728302,0.00014191173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006688218,0.0002234043,0.0007296004,0.00019439576,0.000072356845,0.00000983728,0.0000944682,0.00013584165,0.00010400255],"category_scores_gemma":[0.0007559897,0.00020520807,0.00013980448,0.00040167393,0.00015723474,0.000103109924,0.00013073365,0.00037122626,0.000036555437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005954607,0.0035615852,0.97278225,0.00012818938,0.0004926138,0.00009663056,0.004721476,0.000008716655,0.0006576117,0.0000014062648,0.0019799692,0.00961493],"study_design_scores_gemma":[0.015151694,0.024946652,0.95714474,0.00023904328,0.000039001647,0.000025382904,0.0017037038,0.000014072614,0.00032231055,0.000013436852,0.00024723736,0.00015272906],"about_ca_topic_score_codex":0.00009410985,"about_ca_topic_score_gemma":0.000034111334,"teacher_disagreement_score":0.021385068,"about_ca_system_score_codex":0.00028881815,"about_ca_system_score_gemma":0.00037774802,"threshold_uncertainty_score":0.83681417},"labels":[],"label_agreement":null},{"id":"W3089214942","doi":"10.1016/j.annonc.2020.08.1778","title":"1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Cancer; Coronavirus disease 2019 (COVID-19); Neutrophil to lymphocyte ratio; Inflammation; Clinical endpoint; Disease; Gastroenterology; Immunology; Lymphocyte; Clinical trial","score_opus":0.18948183838689442,"score_gpt":0.40803541676671734,"score_spread":0.21855357837982292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089214942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794313,0.0011048059,0.000011363562,0.015652915,0.00007532206,0.00302816,0.00040075456,0.000064837346,0.00023056958],"genre_scores_gemma":[0.9859119,0.00050078187,0.000069875125,0.011661352,0.00021487994,0.0014762351,0.00012995621,0.000032019896,0.000003014976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975233,0.00044717826,0.0007867628,0.0004431568,0.00041636033,0.00038325094],"domain_scores_gemma":[0.9973681,0.0008196508,0.00064666686,0.0002592751,0.00028141987,0.0006248952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007446674,0.00024203268,0.000649281,0.00020402674,0.000108044005,0.000009519265,0.00021313944,0.00030275568,0.00015380218],"category_scores_gemma":[0.0029162765,0.00020464811,0.00013178446,0.0003454921,0.0004535874,0.00018981259,0.00017379115,0.00027001541,0.0000018560518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010582772,0.00023293663,0.97582,0.0024398512,0.0002974639,0.000081061575,0.0058773137,0.0000131886945,0.0000761209,0.000030371957,0.0033221873,0.01075124],"study_design_scores_gemma":[0.003088407,0.0023324818,0.98833686,0.0003485826,0.00025893046,0.0000027075564,0.00030576758,0.00014629668,0.0005867748,0.00012964895,0.0042927833,0.00017075418],"about_ca_topic_score_codex":0.0006073829,"about_ca_topic_score_gemma":0.00013847102,"teacher_disagreement_score":0.012516879,"about_ca_system_score_codex":0.00024263875,"about_ca_system_score_gemma":0.0010159308,"threshold_uncertainty_score":0.8345308},"labels":[],"label_agreement":null},{"id":"W3089217367","doi":"10.1016/j.annonc.2020.08.314","title":"192P The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; CancerCare Manitoba; London Health Sciences Centre","funders":"Erasmus Universitair Medisch Centrum Rotterdam; Astellas Pharma; Servier; National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Aromatase inhibitor; Tamoxifen; Breast cancer; Osteoporosis; Hazard ratio; Internal medicine; Bisphosphonate; Proportional hazards model; Cancer; Oncology; Gynecology; Surgery; Confidence interval","score_opus":0.05414344467574305,"score_gpt":0.33399397870455766,"score_spread":0.2798505340288146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089217367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95474017,0.00010400484,2.6666478e-7,0.04382259,0.000036621663,0.0008603083,0.00035436152,0.00000787583,0.00007382747],"genre_scores_gemma":[0.9882358,0.00014442064,0.000009369732,0.010750034,0.0000506851,0.00012550132,0.00007906742,0.00001363587,0.0005915419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989769,0.00007628395,0.00027236925,0.0001759703,0.00013884137,0.000359661],"domain_scores_gemma":[0.99895316,0.00034908188,0.00021407049,0.000090886715,0.00018330898,0.00020946791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013070673,0.00012413676,0.0004384222,0.000033935008,0.00005024589,0.000007004985,0.000044481832,0.00010470515,0.00016388705],"category_scores_gemma":[0.00007480691,0.000084608,0.000020056632,0.00009119751,0.000026299609,0.00007479327,0.000013681961,0.00021762613,5.054052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011311999,0.00008093134,0.990151,0.00002539475,0.00028910302,0.000043600994,0.0016665113,0.00000397378,0.00007690365,0.0000017340382,0.0011151767,0.00541448],"study_design_scores_gemma":[0.0037592181,0.0033982021,0.9680421,0.000013967803,0.000053252646,0.000003442445,0.00010948338,0.000005551142,0.00023250817,0.000007235213,0.024315493,0.000059573704],"about_ca_topic_score_codex":0.9796536,"about_ca_topic_score_gemma":0.983501,"teacher_disagreement_score":0.0334956,"about_ca_system_score_codex":0.0006384555,"about_ca_system_score_gemma":0.00134945,"threshold_uncertainty_score":0.3450214},"labels":[],"label_agreement":null},{"id":"W3089242719","doi":"10.1016/j.annonc.2020.08.783","title":"711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Renal cell carcinoma; Nivolumab; Intention-to-treat analysis; Sunitinib; Nephrectomy; Post-hoc analysis; Subgroup analysis; Ipilimumab; Urology; Gastroenterology; Surgery; Adverse effect; Confidence interval; Kidney; Cancer; Immunotherapy","score_opus":0.06660639058166329,"score_gpt":0.3292410095913792,"score_spread":0.2626346190097159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089242719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959362,0.0006767696,0.00003170798,0.00080836617,0.00005825882,0.0013873925,0.00033307038,0.000015222716,0.0007530062],"genre_scores_gemma":[0.99720013,0.0005323855,0.001291016,0.0001804852,0.000044174485,0.00012520619,0.0004749268,0.000039699535,0.00011194895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975476,0.00013606566,0.001053818,0.000537349,0.0003003604,0.00042480108],"domain_scores_gemma":[0.99781215,0.00034380116,0.0006882883,0.00039714412,0.0005153573,0.00024324091],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019861679,0.00034452212,0.002019109,0.0005043068,0.000036368478,0.000003582594,0.00013157022,0.00019893597,0.00007387314],"category_scores_gemma":[0.00012643714,0.00029716635,0.00049495074,0.0007245074,0.00018787202,0.00007845516,0.000065986926,0.000100972204,0.0000021379133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045300573,0.005251898,0.8910171,0.0010628919,0.0022689695,0.00008811716,0.0058036866,0.00037924983,0.01155823,0.00004597524,0.00027105628,0.036952283],"study_design_scores_gemma":[0.058348548,0.07594237,0.6797788,0.000089871035,0.0036337913,0.0000041214316,0.0007606949,0.0016209518,0.17583321,0.000049211336,0.0035988467,0.000339568],"about_ca_topic_score_codex":0.0003655933,"about_ca_topic_score_gemma":0.00074005645,"teacher_disagreement_score":0.21123825,"about_ca_system_score_codex":0.00016180151,"about_ca_system_score_gemma":0.00022149358,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W3089255874","doi":"10.1016/j.annonc.2020.08.790","title":"718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"NIH Clinical Center; Universitätsklinikum Essen; Queen Mary University of London; Novartis Pharmaceuticals Corporation; Massachusetts General Hospital","keywords":"Medicine; Pazopanib; Clinical endpoint; Internal medicine; Renal cell carcinoma; Oncology; Progression-free survival; Phases of clinical research; Tyrosine-kinase inhibitor; Toxicity; Chemotherapy; Urology; Surgery; Sunitinib; Clinical trial; Cancer","score_opus":0.07611631056768055,"score_gpt":0.34847571067251193,"score_spread":0.2723594001048314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089255874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950506,0.0007096507,0.000009539688,0.0006397286,0.000053113676,0.002976165,0.00006728079,0.000025910727,0.00046799175],"genre_scores_gemma":[0.9975487,0.00007629489,0.0012995332,0.0003833902,0.00006584867,0.00036678952,0.000051573727,0.000050274026,0.00015759298],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974525,0.0002546476,0.00089573034,0.0005582801,0.00043869537,0.0004001754],"domain_scores_gemma":[0.99803895,0.00016099855,0.00059287413,0.0004400528,0.00042053056,0.00034660732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001523805,0.00038985402,0.0013304118,0.00014204148,0.0000520113,0.0000045368242,0.000114296585,0.00008314284,0.00023256526],"category_scores_gemma":[0.00010023443,0.00024474057,0.00019074211,0.00031757852,0.00010345192,0.000094460265,0.00010498927,0.00016063688,0.0000086426735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23139656,0.17256013,0.215674,0.0019906524,0.0033791177,0.0069795414,0.060809135,0.00013659538,0.033113822,0.0000028558138,0.0010881994,0.27286938],"study_design_scores_gemma":[0.05648452,0.67002535,0.11808844,0.00017067126,0.0016468622,0.00002671034,0.0019254849,0.00003697268,0.14949314,0.0000041476937,0.0017889031,0.00030878352],"about_ca_topic_score_codex":0.00008156146,"about_ca_topic_score_gemma":0.00008173933,"teacher_disagreement_score":0.49746522,"about_ca_system_score_codex":0.00018673617,"about_ca_system_score_gemma":0.00043029193,"threshold_uncertainty_score":0.99802303},"labels":[],"label_agreement":null},{"id":"W3089265467","doi":"10.1016/j.annonc.2020.08.958","title":"819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"North Carolina GlaxoSmithKline Foundation","keywords":"Medicine; Internal medicine; Adverse effect; Ovarian cancer; Clinical endpoint; Hazard ratio; Progression-free survival; Urology; Randomized controlled trial; Gastroenterology; Oncology; Chemotherapy; Gynecology; Cancer; Confidence interval","score_opus":0.0793094299621809,"score_gpt":0.3875644351331859,"score_spread":0.308255005171005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089265467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96074563,0.000674408,0.000043968223,0.034294315,0.00020653357,0.0014312653,0.00039938907,0.0000168605,0.0021876348],"genre_scores_gemma":[0.990862,0.0012838752,0.0004754716,0.0068668094,0.0002958014,0.000076352146,0.00009013739,0.000021603935,0.000027950167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809694,0.00022149281,0.00075800554,0.0003790661,0.00028631586,0.00025814975],"domain_scores_gemma":[0.9980712,0.00072283857,0.0005102396,0.00030754053,0.00025519045,0.00013299678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000344559,0.0001763369,0.0007094365,0.00005745854,0.000038234575,0.000003687994,0.00014382278,0.00016528119,0.00016109916],"category_scores_gemma":[0.00037299108,0.00012239552,0.00006385498,0.000300346,0.00027590475,0.00008063422,0.00005024725,0.00029463167,0.0000033768856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65099126,0.0019477482,0.019073999,0.00008364951,0.00046940125,0.00002608858,0.011560247,0.0001745854,0.0036473903,0.00019870987,0.014612785,0.29721412],"study_design_scores_gemma":[0.46921495,0.015640387,0.3939724,0.0005595239,0.0001329666,0.0000029162927,0.00035374484,0.00005911929,0.00977471,0.00013232246,0.10989315,0.00026383455],"about_ca_topic_score_codex":0.00053273706,"about_ca_topic_score_gemma":0.00023244691,"teacher_disagreement_score":0.37489837,"about_ca_system_score_codex":0.00006636949,"about_ca_system_score_gemma":0.000368461,"threshold_uncertainty_score":0.49911445},"labels":[],"label_agreement":null},{"id":"W3089267233","doi":"10.1016/j.annonc.2020.08.2329","title":"LBA87 A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Grand River Hospital; Markham Stouffville Hospital; Sault Area Hospital; St. Michael's Hospital; Sunnybrook Health Science Centre; Royal Victoria Regional Health Centre; Trillium Health Centre; Regional Municipality of Durham; Institute for Clinical Evaluative Sciences; Windsor Regional Hospital; Ottawa Regional Cancer Foundation; Ottawa Hospital; University Health Network; Health Sciences Centre; Ontario Clinical Oncology Group; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"Eisai; Exelixis","keywords":"Medicine; Breast cancer; Randomized controlled trial; Docetaxel; Ambulatory; Quality of life (healthcare); Internal medicine; Physical therapy; Cancer; Emergency medicine; Nursing","score_opus":0.05129152428465104,"score_gpt":0.37713771247068123,"score_spread":0.3258461881860302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089267233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864709,0.00008692791,0.00039605703,0.00705817,0.0003037959,0.0046522063,0.0001044932,0.000022123431,0.0009053571],"genre_scores_gemma":[0.9935491,0.0006567645,0.0004686872,0.0042198813,0.00014603432,0.0006685084,0.0000144716605,0.000029368373,0.00024717327],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99806786,0.00025935573,0.0008655871,0.00028392507,0.00023184884,0.00029141345],"domain_scores_gemma":[0.9985857,0.00031537068,0.00052362017,0.00020573562,0.00023558666,0.00013400173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071284384,0.00017616767,0.0013351369,0.00013981172,0.00003133339,0.0000053358235,0.00012111051,0.00011624948,0.00024848047],"category_scores_gemma":[0.00012453414,0.00013549284,0.0002524778,0.0002554772,0.00012422173,0.000083571635,0.00005229588,0.00015034935,0.000002789945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91145056,0.0017368395,0.0074070166,0.000775111,0.0006205338,0.000013891454,0.0013939749,0.00006760545,0.0003791563,0.00010022805,0.0024023717,0.07365272],"study_design_scores_gemma":[0.9205791,0.008816734,0.060034193,0.0002995365,0.00028510933,0.0000031951663,0.00017857691,0.0002631326,0.0016237504,0.00007884104,0.0076562893,0.00018158935],"about_ca_topic_score_codex":0.000249922,"about_ca_topic_score_gemma":0.00020126326,"teacher_disagreement_score":0.07347114,"about_ca_system_score_codex":0.00010434147,"about_ca_system_score_gemma":0.00027861865,"threshold_uncertainty_score":0.55252373},"labels":[],"label_agreement":null},{"id":"W3089274141","doi":"10.1016/j.annonc.2020.08.1780","title":"1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut Gustave-Roussy; Astellas Pharma; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company","keywords":"Furin; Transfection; Virology; Medicine; Molecular biology; Biology; Cell culture; Genetics; Biochemistry","score_opus":0.11852303879054235,"score_gpt":0.42568920284189293,"score_spread":0.30716616405135055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089274141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837179,0.0012969027,0.00003552724,0.010469553,0.0001633415,0.00025234517,0.0007399841,0.0000129607815,0.0033114667],"genre_scores_gemma":[0.98860085,0.0008876365,0.0003787965,0.009400393,0.0004083907,0.00007565048,0.00013573088,0.000022052413,0.00009050808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986157,0.00008431789,0.00026272796,0.000455983,0.00017783238,0.00040345528],"domain_scores_gemma":[0.99923414,0.000033727625,0.00010567499,0.00024172613,0.00015936125,0.00022537245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071710885,0.0001789058,0.00034220016,0.00004485008,0.000046667996,0.000013349705,0.0002310264,0.00018063792,0.0001317857],"category_scores_gemma":[0.00012235933,0.00016919377,0.00013087402,0.00013381137,0.00013232975,0.00000518726,0.00024418588,0.00011596661,0.00008829349],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001512746,0.0001829126,0.006899542,0.000018534296,0.0004558534,0.00009628151,0.00016789083,0.00001486854,0.8556702,0.000055770775,0.10155453,0.03337084],"study_design_scores_gemma":[0.0010471751,0.0022498954,0.00082424644,0.000009239918,0.000016256135,0.0000061808446,0.000029313098,0.000009000423,0.62758255,0.00008720479,0.36802042,0.000118549026],"about_ca_topic_score_codex":0.0021793523,"about_ca_topic_score_gemma":0.0018571438,"teacher_disagreement_score":0.26646587,"about_ca_system_score_codex":0.000025878264,"about_ca_system_score_gemma":0.00048373404,"threshold_uncertainty_score":0.6899522},"labels":[],"label_agreement":null},{"id":"W3089280807","doi":"10.1016/j.annonc.2020.08.1546","title":"1785P Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Regimen; Gastroenterology; Febrile neutropenia; Olaparib; Phases of clinical research; Lung cancer; Oncology; Toxicity","score_opus":0.1250206933812882,"score_gpt":0.44095299222944834,"score_spread":0.3159322988481601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089280807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385023,0.00085966825,0.000008427562,0.0025411537,0.00007711236,0.0020223355,0.000046177556,0.000019443207,0.0005754649],"genre_scores_gemma":[0.997503,0.0004159678,0.00010560829,0.0014264365,0.000049581213,0.00012776679,0.000015323758,0.000029245417,0.00032710258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979899,0.00018566096,0.0005540351,0.00040485302,0.00046473063,0.00040083568],"domain_scores_gemma":[0.99813306,0.00020608344,0.00031546043,0.00029458012,0.00085040636,0.00020042597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022510032,0.00019887953,0.00097549555,0.00015844239,0.00003971624,0.0000028052784,0.0001655752,0.00010016195,0.00014264465],"category_scores_gemma":[0.00039872545,0.00013767632,0.00005581637,0.000464202,0.00014188314,0.00007434647,0.0001712176,0.00032887544,0.0000022642157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.122629985,0.018333646,0.76607484,0.0023366443,0.0010450335,0.0011689364,0.043284103,0.000669399,0.00799901,0.00000721483,0.01708333,0.019367894],"study_design_scores_gemma":[0.1740636,0.22423898,0.5504735,0.0008712089,0.00057707366,0.0000025960633,0.016304798,0.0012385524,0.022103425,0.000004369293,0.009548144,0.0005737078],"about_ca_topic_score_codex":0.0013266717,"about_ca_topic_score_gemma":0.0017497789,"teacher_disagreement_score":0.21560127,"about_ca_system_score_codex":0.00016580983,"about_ca_system_score_gemma":0.0009622043,"threshold_uncertainty_score":0.5614278},"labels":[],"label_agreement":null},{"id":"W3089291062","doi":"10.1016/j.annonc.2020.08.1942","title":"1436P Comparison of perioperative chemotherapy versus postoperative chemoradiation therapy for operable stomach cancer: A western Canadian province experience","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Internal medicine; Perioperative; Chemotherapy; Cohort; Cancer; Multivariate analysis; Population; Gastroenterology; Surgery; Stomach cancer","score_opus":0.16804032752093645,"score_gpt":0.4486320720841202,"score_spread":0.28059174456318375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089291062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93227273,0.0010166818,0.00010935344,0.06166661,0.0001877192,0.0014416726,0.000051850962,0.000017728144,0.0032356551],"genre_scores_gemma":[0.9880594,0.0009011354,0.000478864,0.009864005,0.0001148713,0.00016436518,0.000029391827,0.000017463382,0.00037051903],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893975,0.00003816295,0.0003466335,0.00026000742,0.0001493693,0.0002660962],"domain_scores_gemma":[0.99905384,0.000075721284,0.00019260695,0.00013667879,0.0003613539,0.00017981643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009864328,0.00015204055,0.00063761603,0.00008685744,0.00006818885,0.000009787029,0.0001498202,0.00008835158,0.00017663985],"category_scores_gemma":[0.00006618735,0.00013348073,0.00009548491,0.00020645805,0.00012089426,0.00011553216,0.000017337727,0.00010047643,0.000002097476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024027325,0.00093243027,0.2574702,0.00037557734,0.0010839554,0.000023067236,0.1190691,0.0008431454,0.024090452,0.00084861094,0.025277495,0.54595864],"study_design_scores_gemma":[0.023476189,0.029144669,0.060622253,0.00007391497,0.00009230708,0.000002638668,0.010935524,0.004421983,0.1654245,0.000004252599,0.70541674,0.00038504825],"about_ca_topic_score_codex":0.017879996,"about_ca_topic_score_gemma":0.01732658,"teacher_disagreement_score":0.68013924,"about_ca_system_score_codex":0.00014173353,"about_ca_system_score_gemma":0.0011734868,"threshold_uncertainty_score":0.98866004},"labels":[],"label_agreement":null},{"id":"W3089292170","doi":"10.1016/j.annonc.2020.08.2088","title":"694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"Genentech; EUSA Pharma; Ipsen; Astellas Pharma; Eisai; Sanofi; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Docetaxel; Tolerability; Oncology; Antiandrogen; Hazard ratio; Randomized controlled trial; Urology; Cancer; Adverse effect; Confidence interval; Pathology","score_opus":0.11803724377700105,"score_gpt":0.4164679729252467,"score_spread":0.29843072914824564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089292170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975127,0.0015755156,0.0003056668,0.005466277,0.00014452274,0.016641876,0.00063223543,0.000018014121,0.0000889229],"genre_scores_gemma":[0.984105,0.011859646,0.00021084526,0.0011101621,0.00016295869,0.0023493045,0.000117635354,0.000036131074,0.000048322272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974548,0.0003940044,0.0009275224,0.00039539373,0.00046504047,0.00036320437],"domain_scores_gemma":[0.99701726,0.0010379994,0.0008995832,0.00024658628,0.0006101557,0.00018843217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011968234,0.00025521638,0.0013799669,0.00018489784,0.00012780582,0.00001377482,0.00016524554,0.00017989964,0.000066773006],"category_scores_gemma":[0.00045215467,0.00015482675,0.0002583022,0.0003879357,0.00023635376,0.000119994125,0.00004892603,0.00018832642,4.1194232e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88091713,0.00067436654,0.0010613246,0.000082539,0.0015887029,0.000006094006,0.002602249,0.00009296255,0.016546937,0.000040023366,0.00056272035,0.095824935],"study_design_scores_gemma":[0.81898946,0.021788664,0.00044375728,0.000092947266,0.0002587546,0.0000011029246,0.00016448174,0.00031845065,0.15581304,0.00012988188,0.0018814808,0.00011800242],"about_ca_topic_score_codex":0.0002270239,"about_ca_topic_score_gemma":0.00004666249,"teacher_disagreement_score":0.1392661,"about_ca_system_score_codex":0.00011507495,"about_ca_system_score_gemma":0.0013008842,"threshold_uncertainty_score":0.6313652},"labels":[],"label_agreement":null},{"id":"W3089313044","doi":"10.1016/j.annonc.2020.08.1463","title":"1816MO ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"Nausea; Carboplatin; Medicine; Antiemetic; Vomiting; Chemotherapy-induced nausea and vomiting; Chemotherapy; Regimen; Incidence (geometry); Internal medicine; Population; Anesthesia; Cisplatin","score_opus":0.298419766633905,"score_gpt":0.43660439083081665,"score_spread":0.13818462419691163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089313044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895474,0.00009317851,0.00028236263,0.0070326263,0.00013211781,0.002265984,0.00010886458,0.000009448405,0.0005280458],"genre_scores_gemma":[0.99868304,0.000018675326,0.00013531871,0.00094765204,0.00006407467,0.00007872723,0.000030534244,0.000020785084,0.000021194524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971181,0.0010149226,0.0005510465,0.00027315083,0.00087162096,0.00017115886],"domain_scores_gemma":[0.99577403,0.0019757922,0.0006950202,0.00036646728,0.0011435859,0.00004509369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055124746,0.00015627185,0.00053173356,0.00009562543,0.000054139204,0.000005913017,0.00031877967,0.00006867301,0.00006213088],"category_scores_gemma":[0.0014891186,0.000091175374,0.00014916196,0.00041188928,0.00013961535,0.000024037752,0.000047479538,0.00011752606,4.743071e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011607387,0.002905615,0.9331074,0.00019123734,0.002710829,0.0000028101817,0.0017451175,0.0016637049,0.0039949496,0.00011166995,0.0020832717,0.039876025],"study_design_scores_gemma":[0.007439912,0.00805265,0.95754015,0.000048014415,0.00044963666,4.7714997e-7,0.00039831642,0.0077802422,0.017979834,0.000037920665,0.0001870045,0.000085862535],"about_ca_topic_score_codex":0.0020976136,"about_ca_topic_score_gemma":0.0030485736,"teacher_disagreement_score":0.03979016,"about_ca_system_score_codex":0.000037781847,"about_ca_system_score_gemma":0.00029324048,"threshold_uncertainty_score":0.3718024},"labels":[],"label_agreement":null},{"id":"W3089332307","doi":"10.1016/j.annonc.2020.08.890","title":"631P Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Genentech; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Merck Sharp and Dohme; Cilag; Puma Biotechnology; Sierra Oncology; Pfizer; Incyte; Ipsen; Clovis Oncology; Astex Pharmaceuticals; Sanofi; Exelixis; Karyopharm Therapeutics; Teva Pharmaceutical Industries; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Number needed to harm; Enzalutamide; Adverse effect; Rate ratio; Prostate cancer; Internal medicine; Relative risk; Confidence interval; Number needed to treat; Cancer; Androgen receptor","score_opus":0.043929810108878836,"score_gpt":0.36777058779935035,"score_spread":0.3238407776904715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089332307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688626,0.00025943876,0.0000095381865,0.0102887275,0.00004829395,0.0018040756,0.00031798225,0.000010643325,0.00037501834],"genre_scores_gemma":[0.99720305,0.0006408934,0.0003802074,0.0013731146,0.000034098262,0.00015417383,0.000042701813,0.000029492017,0.00014225529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979694,0.0002003447,0.00057004724,0.00036683268,0.00045753655,0.00043582215],"domain_scores_gemma":[0.9985172,0.00020839428,0.0003337734,0.00024544582,0.00041553346,0.00027963083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031247447,0.00023073674,0.00065835635,0.00010695432,0.00006943601,0.0000038674902,0.0001431884,0.00007272776,0.0000783636],"category_scores_gemma":[0.00020708889,0.00014370977,0.00007982593,0.00053299865,0.0002449967,0.000121715966,0.00009203189,0.00027829406,0.000014435335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020316789,0.0008470333,0.95413303,0.0003867746,0.00067841465,0.000117584415,0.008946417,0.00062135473,0.0024839551,0.000016581442,0.0014511138,0.010000973],"study_design_scores_gemma":[0.013005294,0.0073686894,0.9665296,0.00032747124,0.00031203215,0.00000618152,0.00311498,0.00026853333,0.007239844,0.00009910519,0.0015158621,0.0002124043],"about_ca_topic_score_codex":0.00213191,"about_ca_topic_score_gemma":0.00075686665,"teacher_disagreement_score":0.012396594,"about_ca_system_score_codex":0.000098759854,"about_ca_system_score_gemma":0.0006092237,"threshold_uncertainty_score":0.58603144},"labels":[],"label_agreement":null},{"id":"W3092818483","doi":"10.1016/j.annonc.2020.08.2172","title":"13P Evaluating targeted next-generation sequencing (NGS) assays and reference materials for NTRK fusion detection","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; University of Toronto; Queen Elizabeth II Health Sciences Centre","funders":"Genentech","keywords":"Fusion gene; Medicine; Cancer research; Anaplastic lymphoma kinase; Fusion; Computational biology; Biomarker; Gene; Biology; Oncology; Genetics","score_opus":0.242798310422761,"score_gpt":0.3815919342175242,"score_spread":0.13879362379476318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092818483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941145,0.0005714661,0.003651166,0.0009559043,0.00017862303,0.00025211865,0.000068621026,0.0000060585166,0.00020150925],"genre_scores_gemma":[0.9949099,0.0008594953,0.0019721836,0.0015273918,0.00050065486,0.000035111334,0.00017406682,0.000012288567,0.000008908058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922246,0.00007104375,0.0002475876,0.00024548784,0.00007019862,0.00014320404],"domain_scores_gemma":[0.9993164,0.000048819278,0.00017749243,0.000094422525,0.0003021009,0.00006079525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043303726,0.00008933236,0.00017195275,0.000021083557,0.000071842616,0.00001847581,0.00006069655,0.00016558636,0.000015863981],"category_scores_gemma":[0.0008845923,0.00009287888,0.000030933308,0.000039247836,0.00003358039,0.000005648727,0.00006688104,0.000038250262,0.0000012237438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019709909,0.000011158602,0.000022179393,0.000028849065,0.000017759821,4.8556996e-7,0.00008370392,0.00014931841,0.95544344,0.00007105807,0.0010529896,0.04292194],"study_design_scores_gemma":[0.000477539,0.0033422187,0.00014500841,0.000006196727,0.000020118083,0.000003953916,0.000071677016,0.0026559308,0.97829485,0.00016504864,0.014716874,0.00010057323],"about_ca_topic_score_codex":0.000060516704,"about_ca_topic_score_gemma":0.00010864391,"teacher_disagreement_score":0.04282137,"about_ca_system_score_codex":0.000019464343,"about_ca_system_score_gemma":0.00018127865,"threshold_uncertainty_score":0.37874907},"labels":[],"label_agreement":null},{"id":"W3100553135","doi":"10.1016/j.annonc.2020.10.596","title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Fulvestrant; Medicine; Placebo; Hazard ratio; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Aromatase inhibitor; Metastatic breast cancer; Cancer; Estrogen receptor; Randomized controlled trial; Gynecology; Confidence interval; Aromatase; Pathology","score_opus":0.039813145040281356,"score_gpt":0.3696024707202757,"score_spread":0.3297893256799943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100553135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374,0.0005600379,0.00012747683,0.0021877596,0.00015540593,0.0025813999,0.00036621062,0.000009333408,0.00027234916],"genre_scores_gemma":[0.9973501,0.00077145826,0.00024851636,0.0008048117,0.00025688688,0.0004683821,0.00003965745,0.00003225672,0.000027913235],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972193,0.0008836709,0.0007898174,0.000509178,0.00025620157,0.0003418165],"domain_scores_gemma":[0.99822587,0.0004015032,0.0006159387,0.00031553215,0.00031961367,0.00012153835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075094996,0.0002856844,0.0011003164,0.000053519936,0.000056849505,0.000008502713,0.00039468196,0.0001854846,0.00015591577],"category_scores_gemma":[0.0002888914,0.00017973274,0.00016470604,0.00030011556,0.0004677163,0.000011835606,0.000090342415,0.00022822003,0.0000011863465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85939354,0.0018407337,0.00016894894,0.000023674147,0.00063653383,0.000025368627,0.001485104,0.00095837214,0.12733541,0.000010737553,0.00078603893,0.0073355157],"study_design_scores_gemma":[0.727251,0.027416753,0.00005793139,0.00006725679,0.00015414578,0.000017556316,0.001614644,0.00008592029,0.24072626,0.0000113182205,0.0023432067,0.00025399923],"about_ca_topic_score_codex":0.00049429754,"about_ca_topic_score_gemma":0.00052304164,"teacher_disagreement_score":0.13214256,"about_ca_system_score_codex":0.000027779257,"about_ca_system_score_gemma":0.0007224271,"threshold_uncertainty_score":0.7329288},"labels":[],"label_agreement":null},{"id":"W3101707478","doi":"10.1016/j.annonc.2020.11.001","title":"PARP inhibition in homologous-recombination-deficient early-stage breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Radius Health; Merck; AstraZeneca; Pfizer","keywords":"Olaparib; Medicine; Breast cancer; BRCA mutation; PARP inhibitor; Oncology; Internal medicine; Chemotherapy; Cancer; Poly ADP ribose polymerase; Polymerase; Genetics; Biology","score_opus":0.11407792136650188,"score_gpt":0.40758879029384,"score_spread":0.29351086892733813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101707478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90681404,0.00033349407,0.000075540775,0.08580516,0.00017641943,0.0003179182,0.00011036057,0.000039265633,0.006327797],"genre_scores_gemma":[0.9857108,0.00070864474,0.00009192364,0.013055853,0.00014195254,0.00009293824,0.000027974613,0.000017466018,0.00015246808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874,0.00010451452,0.00043317783,0.0002673442,0.00019782485,0.00025709686],"domain_scores_gemma":[0.9991918,0.00007505851,0.00020822411,0.00014125356,0.00024815582,0.00013546443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024788623,0.000121186495,0.00040737452,0.000153253,0.00002723056,0.000004310935,0.000054207158,0.00015599205,0.0011637383],"category_scores_gemma":[0.00004989906,0.000120743636,0.000089933834,0.0003936651,0.00014152795,0.00008470286,0.00003130274,0.00023278991,0.000053383603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009861892,0.007949411,0.42670125,0.0011451642,0.00056025386,0.0019671265,0.019228784,0.0026473708,0.15980266,0.016672477,0.12384937,0.22961424],"study_design_scores_gemma":[0.015585909,0.007847202,0.75073445,0.00043404495,0.00006467053,0.00019057622,0.0007549699,0.0007117874,0.123945065,0.0019671759,0.09727851,0.00048563804],"about_ca_topic_score_codex":0.00036895068,"about_ca_topic_score_gemma":0.00007329368,"teacher_disagreement_score":0.3240332,"about_ca_system_score_codex":0.00012580446,"about_ca_system_score_gemma":0.0003107709,"threshold_uncertainty_score":0.99974936},"labels":[],"label_agreement":null},{"id":"W3106902214","doi":"10.1016/j.annonc.2020.10.117","title":"97P A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Obesity and Health Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Residence; Odds ratio; Socioeconomic status; Population; Confidence interval; Demography; Colorectal cancer; Internal medicine; Cancer registry; Myocardial infarction; Gerontology; Cancer; Surgery; Environmental health","score_opus":0.1250004542314374,"score_gpt":0.46497776573446165,"score_spread":0.33997731150302424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106902214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873607,0.0001804423,0.000008180297,0.010238549,0.00005937681,0.0018978998,0.00018162822,0.00001023748,0.00006297524],"genre_scores_gemma":[0.99684525,0.00006132558,0.000056291414,0.0027459206,0.000045718924,0.00020342172,0.000024259918,0.000012251373,0.0000055876517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974321,0.0013328677,0.00045518612,0.00019341486,0.0002543462,0.0003320573],"domain_scores_gemma":[0.9973535,0.0013969077,0.00051084755,0.00017332922,0.00036146375,0.00020394872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084280776,0.000108272594,0.00049525505,0.00006774039,0.00030318275,0.0000051638026,0.00011807543,0.00007676228,0.000072220224],"category_scores_gemma":[0.00043157107,0.00007709728,0.00004275869,0.00018780335,0.000058401973,0.00017313016,0.000059778788,0.00034114797,0.000007745897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016291759,0.00045809324,0.9866756,0.00017801208,0.00017493307,0.0000024493984,0.007427905,0.002603568,9.724329e-7,0.000037560512,0.0002183092,0.0005934078],"study_design_scores_gemma":[0.0021250239,0.0022417137,0.98921496,0.00011401815,0.00011602097,1.542323e-8,0.005801642,0.0000924222,0.0000024061296,0.000021389857,0.0001865893,0.00008377617],"about_ca_topic_score_codex":0.013524053,"about_ca_topic_score_gemma":0.030172199,"teacher_disagreement_score":0.016648145,"about_ca_system_score_codex":0.0001509211,"about_ca_system_score_gemma":0.0015711633,"threshold_uncertainty_score":0.993045},"labels":[],"label_agreement":null},{"id":"W3107025032","doi":"10.1016/j.annonc.2020.10.394","title":"400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Afatinib; Osimertinib; Medicine; Oncology; Internal medicine; Erlotinib; Cancer; Epidermal growth factor receptor","score_opus":0.09305412879444001,"score_gpt":0.4502128618058295,"score_spread":0.35715873301138945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107025032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622435,0.000048649126,0.000008788075,0.006808915,0.000026557533,0.00071942975,0.000053210704,0.000004454216,0.0061056633],"genre_scores_gemma":[0.9985342,0.000041059713,0.00008295981,0.0010993656,0.000023004075,0.00004008418,0.00014885346,0.000006198066,0.000024248819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877465,0.00024276394,0.00045669702,0.00020467328,0.00018318115,0.00013800767],"domain_scores_gemma":[0.9992952,0.00015598966,0.00023101353,0.000110745495,0.00015483203,0.000052247793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021967864,0.000096859345,0.00046374174,0.0003364688,0.000024936098,0.0000043004084,0.00006211126,0.000048830465,0.000039332128],"category_scores_gemma":[0.00009637462,0.00007199694,0.00007691214,0.0010113925,0.00007496937,0.000057736586,0.000023306317,0.00010839079,0.000001076699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011069168,0.0027555216,0.9171501,0.000029414032,0.0013027091,0.00012153343,0.042564373,0.00012544236,0.000118416625,0.0001711573,0.00024118435,0.034313228],"study_design_scores_gemma":[0.0039378665,0.005067627,0.9853041,0.000025967593,0.0011686629,0.0000010364113,0.0038317402,0.00023546493,0.00020521197,0.000036998656,0.00013239023,0.000052919724],"about_ca_topic_score_codex":0.003133098,"about_ca_topic_score_gemma":0.0064555644,"teacher_disagreement_score":0.06815401,"about_ca_system_score_codex":0.00004904197,"about_ca_system_score_gemma":0.00015382355,"threshold_uncertainty_score":0.47363278},"labels":[],"label_agreement":null},{"id":"W3107071433","doi":"10.1016/j.annonc.2020.10.417","title":"425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; Solid tumor; First line; Obesity; Cancer","score_opus":0.08303739610919957,"score_gpt":0.3855960395124469,"score_spread":0.30255864340324734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107071433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994165,0.00008219199,0.0000027386945,0.0041706963,0.000032861688,0.00079155323,0.000116429466,0.000015522794,0.0006230129],"genre_scores_gemma":[0.99863696,0.0003507351,0.00002423437,0.0007865689,0.000030707935,0.000030998846,0.000051566687,0.000021846012,0.00006638142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865377,0.000100132595,0.00044854227,0.00025910028,0.00021061358,0.00032781257],"domain_scores_gemma":[0.99876076,0.00022901989,0.0003941375,0.000266623,0.00021901788,0.0001304349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103761275,0.00026959382,0.0011422175,0.000107561515,0.000044178327,0.000003259838,0.00012769643,0.00012825821,0.0001197024],"category_scores_gemma":[0.00007603705,0.00012416477,0.00018930534,0.00025737108,0.00020927988,0.000044236032,0.00003577893,0.00014103766,0.0000058791106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0098653175,0.0038595274,0.97685885,0.000032516833,0.00069571123,0.00008483373,0.0021757241,0.0005233716,0.0002262321,0.000006071027,0.00078252424,0.0048893085],"study_design_scores_gemma":[0.0084581785,0.09291076,0.89411706,0.00007401904,0.0001308909,0.000005150517,0.00018597167,0.000032243308,0.0030439484,0.0000066893926,0.00092960143,0.00010550122],"about_ca_topic_score_codex":0.004139412,"about_ca_topic_score_gemma":0.0016161874,"teacher_disagreement_score":0.08905123,"about_ca_system_score_codex":0.00032161077,"about_ca_system_score_gemma":0.00047071537,"threshold_uncertainty_score":0.62575805},"labels":[],"label_agreement":null},{"id":"W3107337141","doi":"10.1016/j.annonc.2020.10.441","title":"221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Chugai Pharmaceutical; Deutsche Krebshilfe; Astellas Pharma; Ipsen; Clovis Oncology; Eisai; Exelixis; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline","keywords":"Medicine; Sexual function; Prostate cancer; Androgen deprivation therapy; Urology; Internal medicine; Placebo; Cancer; Metastasis; Oncology; Pathology","score_opus":0.0956510077947232,"score_gpt":0.3548784918408807,"score_spread":0.25922748404615753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107337141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927073,0.0014084821,0.0000061200485,0.0044687325,0.0000136774315,0.0011993314,0.000022545608,0.000015401647,0.00015837688],"genre_scores_gemma":[0.99785143,0.0011941347,0.00014452335,0.00045311506,0.000022181897,0.00017013859,0.00009348225,0.000018264464,0.000052745956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866015,0.00012983459,0.00040383724,0.0003444517,0.00019641485,0.0002652901],"domain_scores_gemma":[0.9993494,0.00009796902,0.00019355006,0.00010169375,0.00012441752,0.00013294963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020497931,0.00016279527,0.0004115484,0.0001862959,0.00004308123,0.0000123087875,0.000027350408,0.000076105636,0.000033086704],"category_scores_gemma":[0.000036722402,0.00012465735,0.000016469294,0.0002864174,0.00013361091,0.00015292717,0.000022874052,0.00016258218,6.219611e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03276603,0.00046650972,0.8682558,0.00018452738,0.00029092247,0.0007250167,0.005611863,0.00008157909,0.020181742,0.000011078791,0.00010242461,0.07132253],"study_design_scores_gemma":[0.02284613,0.03164901,0.9257367,0.00023464215,0.00013451935,0.00011745382,0.0027342038,0.0014515216,0.013468599,0.00014350175,0.0012162847,0.00026741545],"about_ca_topic_score_codex":0.0010846157,"about_ca_topic_score_gemma":0.001055838,"teacher_disagreement_score":0.071055114,"about_ca_system_score_codex":0.00006344585,"about_ca_system_score_gemma":0.00036551687,"threshold_uncertainty_score":0.5083379},"labels":[],"label_agreement":null},{"id":"W3107357355","doi":"10.1016/j.annonc.2020.10.444","title":"224P Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Astellas Pharma; Sanofi; Amgen; Pfizer; Genentech; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Prostate cancer; Interquartile range; Cancer registry; Cancer; Internal medicine; Prostatectomy; Population; Odds ratio; Proportional hazards model; Oncology; Confidence interval; Localized disease; Comorbidity; Androgen deprivation therapy","score_opus":0.10014939714745508,"score_gpt":0.408071733717063,"score_spread":0.30792233656960794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107357355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958291,0.00018224429,0.0000060769016,0.0016888046,0.000015716614,0.0018791533,0.00031449343,0.000014529144,0.000069873524],"genre_scores_gemma":[0.9991814,0.0001359146,0.000060455404,0.00008305726,0.00001548249,0.00021265472,0.00023851983,0.000018859926,0.000053640055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985702,0.00020105153,0.00032210344,0.00028260774,0.000403323,0.00022069001],"domain_scores_gemma":[0.9990391,0.00014193772,0.00018897737,0.00018730565,0.00026786877,0.00017477208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016593064,0.00015582706,0.0008150498,0.00012334973,0.00004204341,0.000005101469,0.00004162798,0.000031961583,0.000010550687],"category_scores_gemma":[0.000059375492,0.0000985437,0.00008678049,0.00027189718,0.000052382027,0.000045595734,0.00002121981,0.000075237585,1.9234454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060185743,0.0020807013,0.9821732,0.00013553139,0.0015933785,0.000062227955,0.0011168732,0.0009835166,8.549348e-7,0.000003827877,0.0000038065916,0.0058274744],"study_design_scores_gemma":[0.01729405,0.008889194,0.9727219,0.000089208326,0.00048325298,4.9026927e-8,0.00018875865,0.00014388435,0.000037850987,0.0000036488493,0.000060637332,0.0000876187],"about_ca_topic_score_codex":0.017722324,"about_ca_topic_score_gemma":0.0069384053,"teacher_disagreement_score":0.011275474,"about_ca_system_score_codex":0.00019093213,"about_ca_system_score_gemma":0.00045750762,"threshold_uncertainty_score":0.98881876},"labels":[],"label_agreement":null},{"id":"W3107716360","doi":"10.1016/j.annonc.2020.11.019","title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Celgene; Gilead Sciences; Roche; AbbVie; Merck; European Commission; British Microcirculation Society; Amgen","keywords":"Medicine; Lymphoma; Diffuse large B-cell lymphoma; Risk stratification; Nuclear medicine; Positron emission tomography; Lesion; Radiology; Oncology; Internal medicine; Pathology","score_opus":0.05648362318366265,"score_gpt":0.3604426578138295,"score_spread":0.3039590346301668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107716360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412775,0.0019900491,0.000059805592,0.0032032165,0.00003238834,0.00031111366,0.00011561488,0.000017403308,0.00014263886],"genre_scores_gemma":[0.99710566,0.0013621709,0.00067903684,0.0004985001,0.000075942095,0.000015667818,0.00023852172,0.000013108283,0.00001136938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886197,0.00017299913,0.00038143442,0.00028276624,0.00013399392,0.00016686115],"domain_scores_gemma":[0.9991414,0.00023541057,0.00024229767,0.00014314888,0.00010582041,0.0001319453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023092069,0.00013056872,0.00043095349,0.00008670233,0.000039628547,0.0000079563815,0.00004295227,0.000029464594,0.000038848375],"category_scores_gemma":[0.00024240947,0.00011049421,0.000059658483,0.00018097031,0.00003616019,0.000070195165,0.000032780335,0.000054710243,0.000007601702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00245989,0.03621815,0.3857281,0.0002862941,0.00055436284,0.0044883215,0.0052865697,0.00011917068,0.22074424,0.00072300824,0.002133029,0.34125888],"study_design_scores_gemma":[0.031316914,0.0015894403,0.6911735,0.00016824776,0.0006548257,0.00011943853,0.0010229019,0.07686803,0.18890816,0.00016339218,0.007739971,0.00027520777],"about_ca_topic_score_codex":0.0013675737,"about_ca_topic_score_gemma":0.00009612718,"teacher_disagreement_score":0.34098366,"about_ca_system_score_codex":0.000046124063,"about_ca_system_score_gemma":0.00011150654,"threshold_uncertainty_score":0.45058233},"labels":[],"label_agreement":null},{"id":"W3108435873","doi":"10.1016/j.annonc.2020.10.088","title":"68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Pembrolizumab; Carboplatin; Induction chemotherapy; Phases of clinical research; Chemotherapy; Cancer; Immunotherapy; Cisplatin","score_opus":0.1168465376839712,"score_gpt":0.4061263004334042,"score_spread":0.289279762749433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108435873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983046,0.00040138722,0.0003833641,0.0076434715,0.0001753577,0.007442681,0.000059912047,0.00005625796,0.0007916021],"genre_scores_gemma":[0.98900604,0.00090204546,0.0017167941,0.0061247647,0.00013390061,0.0016201227,0.000110349814,0.00010841022,0.00027755572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948177,0.0007066359,0.0018967671,0.0010028983,0.00088428904,0.000691757],"domain_scores_gemma":[0.9959629,0.00047090452,0.0012681485,0.0006929674,0.0012100221,0.0003950391],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011554589,0.0006682533,0.003408522,0.00042803984,0.00012898169,0.000033437434,0.0004905707,0.0002422769,0.0010887065],"category_scores_gemma":[0.0003552221,0.00046674124,0.0001396482,0.0012933817,0.00050906395,0.00047879323,0.00018051974,0.000725319,0.000008646073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92609406,0.038503606,0.0013036453,0.00045214145,0.0015190323,0.00017121246,0.009252797,0.00020705245,0.0009128285,0.000014677421,0.0033858598,0.018183108],"study_design_scores_gemma":[0.8198687,0.16314042,0.0008607573,0.00078496785,0.0005227715,0.000052761716,0.0009776102,0.00064784376,0.0063993637,0.00004190132,0.006193753,0.00050919695],"about_ca_topic_score_codex":0.00043183652,"about_ca_topic_score_gemma":0.0008755355,"teacher_disagreement_score":0.12463681,"about_ca_system_score_codex":0.000284163,"about_ca_system_score_gemma":0.0013255411,"threshold_uncertainty_score":0.9998244},"labels":[],"label_agreement":null},{"id":"W3108850818","doi":"10.1016/j.annonc.2020.10.418","title":"426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Eisai","keywords":"Medicine; Clinical endpoint; Internal medicine; Adverse effect; Placebo; Refractory (planetary science); Confidence interval; Odds ratio; Phases of clinical research; Gastroenterology; Randomized controlled trial; Urology; Toxicity; Surgery","score_opus":0.11273664054026619,"score_gpt":0.405383435074202,"score_spread":0.29264679453393583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108850818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913355,0.0013894385,0.0000054646835,0.0026649402,0.00008777954,0.0043293512,0.00010592107,0.00000978778,0.00007181715],"genre_scores_gemma":[0.99820966,0.00078276114,0.000059726335,0.0005702033,0.00003267538,0.00027268572,0.00003401212,0.000026079817,0.000012229699],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99695367,0.0005118344,0.001340195,0.00040491423,0.00048001073,0.00030937398],"domain_scores_gemma":[0.99749964,0.0005631563,0.00089113106,0.0003387616,0.0005317206,0.000175578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007739131,0.00028551283,0.0019734702,0.00016856904,0.000052174262,0.0000041731164,0.000165622,0.00008857774,0.000084903215],"category_scores_gemma":[0.0003170901,0.00017383134,0.00015732135,0.00038054716,0.00024087657,0.00007365582,0.00014617464,0.00021054296,6.4942054e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8631082,0.022444908,0.07599899,0.00019513388,0.00141921,0.000013526112,0.016150951,0.00022292211,0.0023676758,0.000009771359,0.0003609094,0.017707793],"study_design_scores_gemma":[0.8630222,0.054865606,0.07419018,0.00034564687,0.0010815228,5.800713e-7,0.0010061759,0.00031284787,0.0048132683,0.0000023019297,0.00021977718,0.00013987302],"about_ca_topic_score_codex":0.0018966345,"about_ca_topic_score_gemma":0.0008617804,"teacher_disagreement_score":0.0324207,"about_ca_system_score_codex":0.00007466737,"about_ca_system_score_gemma":0.00025855543,"threshold_uncertainty_score":0.7088636},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3109003874","doi":"10.1016/j.annonc.2020.10.063","title":"43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Gemcitabine; Internal medicine; Carboplatin; Oncology; Taxane; Triple-negative breast cancer; Progression-free survival; Breast cancer; Population; Pembrolizumab; Metastatic breast cancer; Chemotherapy; Cancer; Cisplatin; Immunotherapy","score_opus":0.07946991080433974,"score_gpt":0.405684776383466,"score_spread":0.32621486557912627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109003874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795774,0.00046671566,0.000109766464,0.006994779,0.00020939765,0.011308147,0.0010757763,0.000033954737,0.00022402471],"genre_scores_gemma":[0.993815,0.0011097047,0.0005245595,0.0024282476,0.00009192495,0.0014254221,0.00018990548,0.000060956256,0.0003542517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963324,0.00032280543,0.0017364209,0.0006740621,0.0003482062,0.0005861079],"domain_scores_gemma":[0.9966112,0.00081364013,0.0010163898,0.00034061001,0.0010146897,0.00020349225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008075179,0.00042186424,0.0019011933,0.00025207465,0.000075269,0.000010703918,0.00027368523,0.00019900654,0.00019328392],"category_scores_gemma":[0.0006689777,0.00032380864,0.00031291068,0.0007197545,0.00017010077,0.00012513809,0.000042534288,0.00022530575,0.0000013370645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8216475,0.012544218,0.00059382454,0.00058514054,0.0017898503,0.000020325155,0.011010524,0.00004149378,0.0023082397,0.000003376139,0.0122858565,0.13716961],"study_design_scores_gemma":[0.79071105,0.16263074,0.00743735,0.0006387115,0.00069366005,0.00001780429,0.0032325527,0.0028113935,0.018661268,0.000033798264,0.012584058,0.0005475914],"about_ca_topic_score_codex":0.0011959531,"about_ca_topic_score_gemma":0.0013550658,"teacher_disagreement_score":0.15008652,"about_ca_system_score_codex":0.00028176466,"about_ca_system_score_gemma":0.0012281527,"threshold_uncertainty_score":0.9999214},"labels":[],"label_agreement":null},{"id":"W3109729264","doi":"10.1016/j.annonc.2020.10.099","title":"79O Clinical performance of Immunoscore® in early colon cancer in the Asian population","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Oncology; Stage (stratigraphy); Population; Cancer; Single Center; Cohort","score_opus":0.16578210253730258,"score_gpt":0.4427528249986851,"score_spread":0.27697072246138255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109729264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97889084,0.0002804624,2.1834413e-7,0.01824854,0.00006072284,0.00017489339,0.0000036002962,0.0000030031856,0.002337716],"genre_scores_gemma":[0.99751234,0.00032493207,0.000014928182,0.0020240764,0.000088222325,0.000010442269,0.000005060393,0.0000036835722,0.000016307788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991394,0.00011806859,0.0004233915,0.00010387389,0.000101517915,0.00011372715],"domain_scores_gemma":[0.9996035,0.000096837306,0.00013357998,0.000077085526,0.000056810175,0.00003215408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000395352,0.00005248801,0.00033563998,0.000051537576,0.000008564483,9.841707e-7,0.00008538566,0.0000921292,0.000037011472],"category_scores_gemma":[0.00012572536,0.000036956335,0.000067545196,0.00024744446,0.00007314874,0.000035432764,0.000024884412,0.00021756245,0.0000029567311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015617836,0.00018660343,0.93677086,0.000054524426,0.000010802479,0.000022895852,0.0015141291,0.000010594105,0.0009099142,0.000075153854,0.00018733494,0.058695406],"study_design_scores_gemma":[0.00084309024,0.006719061,0.9900158,0.00005364712,0.000011930913,0.0000035451942,0.00017366424,0.0004069296,0.00042243616,0.000036374462,0.0012815355,0.00003198155],"about_ca_topic_score_codex":0.00096497574,"about_ca_topic_score_gemma":0.0008887108,"teacher_disagreement_score":0.058663424,"about_ca_system_score_codex":0.0000151573795,"about_ca_system_score_gemma":0.0001032475,"threshold_uncertainty_score":0.15070355},"labels":[],"label_agreement":null},{"id":"W3109826360","doi":"10.1016/j.annonc.2020.10.426","title":"434P Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Protocol (science); Dosing; Usability; Family medicine; Point of care; MEDLINE; Alternative medicine; Nursing; Internal medicine; Pathology","score_opus":0.43217686092690294,"score_gpt":0.5259137053317239,"score_spread":0.09373684440482094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109826360","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31673202,0.0010500943,0.000009622583,0.65682584,0.0005922528,0.02358787,0.00044149728,0.000022168686,0.00073862064],"genre_scores_gemma":[0.9299087,0.0016850212,0.00033162354,0.02666465,0.0005305574,0.040779304,0.00004780842,0.000013858904,0.000038478567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806696,0.0005128262,0.0004914398,0.00015744353,0.00039873677,0.00037260915],"domain_scores_gemma":[0.9935234,0.0046514347,0.0005041265,0.0001499198,0.00076906895,0.00040200795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006742191,0.00011079082,0.0003464396,0.00005131264,0.00031510502,0.00001601545,0.0002809351,0.00032950702,0.000588103],"category_scores_gemma":[0.0068673594,0.00008344723,0.00012103024,0.00024738372,0.0006915117,0.00016403213,0.000021712069,0.000105420906,0.00001397863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086411077,0.00018171722,0.07327592,0.00038631784,0.000095306874,0.0000029025043,0.20688994,0.000035875855,0.00003788353,0.00071441557,0.25792465,0.45959097],"study_design_scores_gemma":[0.00069264096,0.0030535797,0.0039244955,0.00014013832,0.00003151452,2.676931e-7,0.01784478,0.000117500414,0.0009123117,0.000042052718,0.973149,0.000091728776],"about_ca_topic_score_codex":0.4151687,"about_ca_topic_score_gemma":0.46568534,"teacher_disagreement_score":0.7152243,"about_ca_system_score_codex":0.0011821939,"about_ca_system_score_gemma":0.012472707,"threshold_uncertainty_score":0.9931257},"labels":[],"label_agreement":null},{"id":"W3110160263","doi":"10.1016/j.annonc.2020.10.028","title":"8P Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Fertility preservation; Fertility; Family medicine; Oocyte cryopreservation; Pregnancy; Breast cancer; Interquartile range; Gynecology; Family planning; Obstetrics; Cancer; Population; Environmental health; Internal medicine","score_opus":0.04607486135100592,"score_gpt":0.3845291289680342,"score_spread":0.3384542676170283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110160263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845239,0.0032005478,1.16087676e-7,0.008043369,0.00011726771,0.0002953895,0.00006102615,0.0000095212345,0.0037488595],"genre_scores_gemma":[0.99583596,0.0036180555,0.000018226423,0.00045068795,0.00001435038,0.000016071323,0.0000020936805,0.000007153713,0.000037392572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864304,0.00034935688,0.00035966767,0.000260024,0.00016229559,0.00022559454],"domain_scores_gemma":[0.99887425,0.0004979479,0.00023982607,0.00007498397,0.00025379102,0.00005920317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041619147,0.00010901241,0.00040174508,0.0000702544,0.00006459035,0.000012417861,0.000105642466,0.00015402398,0.00001644153],"category_scores_gemma":[0.00047498656,0.0001093738,0.000017807424,0.0002651667,0.000704812,0.000325055,0.00008214889,0.00014464498,0.0000012400975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031294438,0.0005724503,0.9466243,0.00038560716,0.000031225463,0.000006626062,0.044387657,0.0000041536236,0.0000139492995,0.00043244872,0.00006670319,0.0071619544],"study_design_scores_gemma":[0.00071768044,0.00041165884,0.99408555,0.00123743,0.000013194899,3.3588682e-7,0.002184419,0.000021659615,0.000118902455,0.00016813245,0.00093793723,0.00010308166],"about_ca_topic_score_codex":0.008592237,"about_ca_topic_score_gemma":0.023176517,"teacher_disagreement_score":0.047461286,"about_ca_system_score_codex":0.000046308378,"about_ca_system_score_gemma":0.00017402596,"threshold_uncertainty_score":0.9980096},"labels":[],"label_agreement":null},{"id":"W3110384593","doi":"10.1016/j.annonc.2020.10.454","title":"190P Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Ipsen; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Internal medicine; Neutropenia; Gastroenterology; Clinical endpoint; Pancreatic cancer; Population; Adverse effect; Surgery; Cancer; Randomized controlled trial; Chemotherapy","score_opus":0.12974723132149507,"score_gpt":0.41626855138379837,"score_spread":0.2865213200623033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110384593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9450992,0.00053946336,0.00019062114,0.04819734,0.00020157304,0.0040055164,0.00044766208,0.00002069155,0.0012979816],"genre_scores_gemma":[0.99564767,0.00054233515,0.00040771702,0.0021794613,0.00028901515,0.0003700765,0.00012933642,0.0000430883,0.00039128936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964534,0.00055333925,0.001238029,0.00045770823,0.0007217507,0.0005757869],"domain_scores_gemma":[0.99446803,0.0022452155,0.001120743,0.0007692647,0.001139663,0.00025708642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007410984,0.00032990318,0.0025073793,0.00011264215,0.00013123613,0.000005469022,0.00052455004,0.0003065229,0.00020977514],"category_scores_gemma":[0.003390346,0.00017082643,0.00038932668,0.0005315282,0.0009310301,0.00008542355,0.00016125421,0.00043048232,0.000002464748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5734883,0.0062836297,0.33910006,0.0006732215,0.0043744454,0.00006431232,0.007936756,0.000017661343,0.00287083,0.0002947047,0.03907153,0.025824577],"study_design_scores_gemma":[0.5077555,0.10324929,0.3647524,0.00084958615,0.003534699,0.000018280412,0.0020827255,0.0015294928,0.0035695948,0.0007080906,0.011507103,0.00044322165],"about_ca_topic_score_codex":0.0024930597,"about_ca_topic_score_gemma":0.0006270282,"teacher_disagreement_score":0.096965656,"about_ca_system_score_codex":0.00013438168,"about_ca_system_score_gemma":0.0015326799,"threshold_uncertainty_score":0.69661},"labels":[],"label_agreement":null},{"id":"W3110464061","doi":"10.1016/j.annonc.2020.10.437","title":"217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Cohort; Enzalutamide; Abiraterone acetate; Docetaxel; Abiraterone; Prostate cancer; Internal medicine; Cancer; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.0810000559258849,"score_gpt":0.407301675363801,"score_spread":0.32630161943791613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110464061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871213,0.00058162183,0.0000016255959,0.0077068526,0.000053425767,0.0024974972,0.00009376354,0.000010106579,0.00034298867],"genre_scores_gemma":[0.99901646,0.00017809225,0.000032634012,0.00036933116,0.000014646912,0.0001831396,0.000045416386,0.00001786451,0.00014238844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983221,0.00024546296,0.00045814877,0.0002479435,0.00047362442,0.0002526738],"domain_scores_gemma":[0.99876404,0.0000886091,0.00030796396,0.000205092,0.0005444681,0.00008983528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024726696,0.00015829058,0.00055257,0.00010701469,0.000078597855,0.0000062522336,0.000120774894,0.00004546475,0.00006784385],"category_scores_gemma":[0.000072678326,0.00009270196,0.00006385995,0.0004443773,0.00021602132,0.000098354634,0.000055824297,0.00017958389,9.767194e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059667323,0.022349907,0.82287157,0.00058445835,0.0017295333,0.00014787544,0.035941314,0.00015764017,0.006028734,0.00018422396,0.0010995246,0.049237896],"study_design_scores_gemma":[0.05563519,0.05000671,0.8816344,0.00016212816,0.00025695685,0.0000018828767,0.0022371795,0.000105938925,0.008772057,0.00013976877,0.00090082694,0.00014695643],"about_ca_topic_score_codex":0.00044567688,"about_ca_topic_score_gemma":0.0004552171,"teacher_disagreement_score":0.05876283,"about_ca_system_score_codex":0.00008990617,"about_ca_system_score_gemma":0.00068260357,"threshold_uncertainty_score":0.37802762},"labels":[],"label_agreement":null},{"id":"W3111291785","doi":"10.1016/j.annonc.2020.10.486","title":"1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Cystectomy; Adjuvant; Adjuvant therapy; Clinical endpoint; Population; Bladder cancer; Interim analysis; Urology; Cancer; Clinical trial; Immunotherapy; Pembrolizumab","score_opus":0.08812706295566823,"score_gpt":0.4045047751558558,"score_spread":0.31637771220018757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111291785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164994,0.00044050725,0.0000033420865,0.01336007,0.0002917183,0.001201722,0.0004880586,0.000023985436,0.0025406876],"genre_scores_gemma":[0.9662564,0.00068965065,0.00009915793,0.032392517,0.0002336453,0.00012550355,0.00008485234,0.000038912116,0.000079376965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976183,0.00037951203,0.0007905968,0.00052011415,0.00027938784,0.0004120874],"domain_scores_gemma":[0.99836135,0.00036204685,0.00021360852,0.00024319834,0.0005245802,0.0002952039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015034087,0.00030653842,0.0011543729,0.00010798928,0.000037048976,0.00000746453,0.00015100306,0.00027452153,0.00038211394],"category_scores_gemma":[0.0003240972,0.00023023925,0.00035923242,0.00016592117,0.00023072255,0.0001147147,0.00008303779,0.00034648887,0.00009490301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011174804,0.0026522188,0.8942387,0.000025782916,0.0005079368,0.00055527646,0.005965955,9.217211e-7,0.00039023696,0.000020344844,0.0008870736,0.08358072],"study_design_scores_gemma":[0.014648681,0.028452756,0.9486641,0.000043090306,0.000081788814,0.000004466962,0.00032014947,0.0000053905273,0.0048215818,0.000040296032,0.0027278953,0.00018978852],"about_ca_topic_score_codex":0.0005614995,"about_ca_topic_score_gemma":0.0002517258,"teacher_disagreement_score":0.08339093,"about_ca_system_score_codex":0.00007963863,"about_ca_system_score_gemma":0.00084458437,"threshold_uncertainty_score":0.93888843},"labels":[],"label_agreement":null},{"id":"W3112014372","doi":"10.1016/j.annonc.2020.10.556","title":"68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Dosing; Nivolumab; Internal medicine; Regimen; Population; Pharmacokinetics; Hazard ratio; Cancer; Confidence interval; Immunotherapy","score_opus":0.1805615866130504,"score_gpt":0.4066973016192427,"score_spread":0.2261357150061923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112014372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915076,0.0011548571,0.00006218921,0.007132698,0.000106445186,0.00081971777,0.00014632045,0.0000183378,0.0014086937],"genre_scores_gemma":[0.997694,0.00023744568,0.00046241097,0.0010781371,0.00012651176,0.000075413576,0.00018635916,0.00002454077,0.000115147144],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982551,0.00010812548,0.00058919995,0.00030025005,0.00044890968,0.00029843434],"domain_scores_gemma":[0.9990168,0.00019514492,0.00026574385,0.0001798697,0.00020100424,0.00014141735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056992646,0.00016321348,0.0005436465,0.00013508684,0.000048377067,0.000004144678,0.00011716007,0.00012896278,0.00049967854],"category_scores_gemma":[0.00038737792,0.00014701708,0.00016721037,0.00022783522,0.00012593094,0.00011990939,0.000072938936,0.0000894934,0.000019439998],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05051144,0.005786896,0.2153519,0.0038414216,0.0010765083,0.00015291886,0.0033635627,0.018454295,0.5623119,0.0010470618,0.028195726,0.109906375],"study_design_scores_gemma":[0.034036122,0.019015387,0.5300936,0.00081518706,0.0010450422,0.000058602654,0.0007581478,0.12299645,0.27295107,0.003921408,0.013679299,0.00062970934],"about_ca_topic_score_codex":0.0001414056,"about_ca_topic_score_gemma":0.00009854951,"teacher_disagreement_score":0.3147417,"about_ca_system_score_codex":0.00012247698,"about_ca_system_score_gemma":0.00023505616,"threshold_uncertainty_score":0.5995183},"labels":[],"label_agreement":null},{"id":"W3113031448","doi":"10.1016/j.annonc.2020.10.555","title":"67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BeiGene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Clinical endpoint; Randomized controlled trial; Cancer; Immunotherapy","score_opus":0.15544898252665074,"score_gpt":0.42046484643018,"score_spread":0.26501586390352927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113031448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93848217,0.00096574845,0.00006828221,0.056269586,0.00027479383,0.0011721416,0.000093561655,0.000025516996,0.0026482048],"genre_scores_gemma":[0.9921424,0.0018175582,0.0004893851,0.004444303,0.00013633053,0.00013146726,0.000046490197,0.000029071754,0.000762995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984662,0.00007684137,0.00063284463,0.00032379958,0.00016478168,0.00033553905],"domain_scores_gemma":[0.9989172,0.00027988703,0.00022160976,0.0002521936,0.00017780284,0.0001512608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036374232,0.00018270615,0.00080602925,0.00014040218,0.000029082461,0.000002468819,0.00012403422,0.00015039832,0.00023034924],"category_scores_gemma":[0.0002577733,0.00016174241,0.00024452232,0.00034089584,0.000107896645,0.000046895195,0.000031526022,0.00007502161,0.000011276913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36593553,0.002696749,0.002139376,0.0005225132,0.0010133552,0.00010896543,0.0070023714,0.0003147266,0.10492632,0.0002453721,0.015420272,0.49967444],"study_design_scores_gemma":[0.036708947,0.067867644,0.0062358673,0.00026721237,0.00010694892,0.000013352408,0.001370279,0.00014001169,0.1326521,0.00016809965,0.75419134,0.00027816833],"about_ca_topic_score_codex":0.00029345832,"about_ca_topic_score_gemma":0.00084169535,"teacher_disagreement_score":0.7387711,"about_ca_system_score_codex":0.00014868226,"about_ca_system_score_gemma":0.00043270786,"threshold_uncertainty_score":0.6595664},"labels":[],"label_agreement":null},{"id":"W3113132520","doi":"10.1016/j.annonc.2020.12.004","title":"Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Oncology; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.06816358705992281,"score_gpt":0.3451095596220558,"score_spread":0.276945972562133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113132520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850333,0.0014208166,0.000051396048,0.0046054386,0.00024902882,0.001115144,0.00013974398,0.000015342732,0.007369834],"genre_scores_gemma":[0.9939355,0.0004728301,0.00012551459,0.0043831016,0.00039733143,0.000050572304,0.00048997364,0.000022552642,0.00012260748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719244,0.0009054325,0.0008582078,0.0005423919,0.00017551373,0.00032601983],"domain_scores_gemma":[0.99841774,0.00042792925,0.00039057646,0.00048323796,0.00015268668,0.00012782103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010881553,0.00023443424,0.00094646483,0.000038878716,0.00005975464,0.0000115108805,0.00047737535,0.0002511246,0.000041152372],"category_scores_gemma":[0.0010090258,0.00016966049,0.0001906933,0.00019206369,0.0002166057,0.0000061187657,0.00027514863,0.00021048305,0.00002228383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66780555,0.0027958378,0.0010699756,0.000029620549,0.0010392648,0.0003254377,0.0070078024,0.00010630277,0.23524792,0.00016965647,0.059768103,0.024634542],"study_design_scores_gemma":[0.7094726,0.018654961,0.0027386767,0.000029672465,0.0002239812,0.000018119968,0.0014350913,0.0002189094,0.07215981,0.00021642665,0.19426516,0.0005665947],"about_ca_topic_score_codex":0.0006123176,"about_ca_topic_score_gemma":0.00024465375,"teacher_disagreement_score":0.16308811,"about_ca_system_score_codex":0.000015169515,"about_ca_system_score_gemma":0.00043840878,"threshold_uncertainty_score":0.69185543},"labels":[],"label_agreement":null},{"id":"W3113288931","doi":"10.1016/j.annonc.2020.10.562","title":"74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Dosing; Outpatient clinic; Surgery; Gastroenterology","score_opus":0.16554887601399332,"score_gpt":0.4172979653210983,"score_spread":0.251749089307105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113288931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022853,0.00037900437,0.00006164415,0.004958952,0.00026952624,0.0030253867,0.00093383586,0.00002429477,0.00011883097],"genre_scores_gemma":[0.9967372,0.0016734924,0.0003158445,0.0003943606,0.0001945587,0.00016150027,0.00038008223,0.000039449616,0.0001035335],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99759275,0.00034911145,0.0008286247,0.00046035906,0.00043468765,0.00033445974],"domain_scores_gemma":[0.9966478,0.0012011167,0.0008060114,0.0008430922,0.0003349994,0.00016699417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000272708,0.00025955006,0.0008962816,0.00012295852,0.00008788159,0.000006964052,0.00033676016,0.00015628691,0.00012924535],"category_scores_gemma":[0.00055158226,0.00017122355,0.0002837745,0.00018938756,0.00022442284,0.00008271733,0.00005452058,0.0001806308,0.000011794399],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7926519,0.023011792,0.00026701944,0.00014432703,0.0026004242,0.00012552523,0.0014562004,0.000019965652,0.053504493,0.00016915113,0.008882184,0.11716704],"study_design_scores_gemma":[0.16598429,0.6501028,0.009446663,0.000051233706,0.0004531759,0.000012276256,0.00016293583,0.00055920816,0.13586453,0.000078903904,0.037112474,0.00017152296],"about_ca_topic_score_codex":0.00020140603,"about_ca_topic_score_gemma":0.000077019,"teacher_disagreement_score":0.627091,"about_ca_system_score_codex":0.000057699468,"about_ca_system_score_gemma":0.00054476806,"threshold_uncertainty_score":0.6982294},"labels":[],"label_agreement":null},{"id":"W3113331633","doi":"10.1016/j.annonc.2020.10.552","title":"64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Toray Industries; Astellas Pharma; Castle Biosciences; Moderna; Sanofi; Exelixis; Incyte; Taiho Pharmaceutical; Sun Pharma; Regeneron Pharmaceuticals; Plexxikon; Ipsen; BeiGene; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Regimen; Internal medicine; Refractory (planetary science); Melanoma; Phases of clinical research; Gastroenterology; Metastatic melanoma; Immunotherapy; Nuclear medicine; Oncology; Urology; Surgery; Cancer; Chemotherapy; Cancer research","score_opus":0.06684182245453124,"score_gpt":0.3730594717083754,"score_spread":0.30621764925384415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113331633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963552,0.000107508655,0.000006923489,0.0016865329,0.000053809,0.0013995206,0.00004703159,0.000006035225,0.00033747437],"genre_scores_gemma":[0.9989683,0.000034887064,0.00024287365,0.00065930176,0.000011326653,0.000014855614,0.000020428584,0.000014068211,0.000033946322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984293,0.00029990877,0.0005884699,0.00026453048,0.00021305968,0.00020475117],"domain_scores_gemma":[0.9989292,0.0001561054,0.000400667,0.0002412166,0.00016659852,0.00010621469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002074206,0.00016879315,0.0008762719,0.00009027824,0.00004118683,0.000001047139,0.00012053982,0.00008844565,0.0000423294],"category_scores_gemma":[0.00016256137,0.00010539981,0.00008506369,0.00024401864,0.00023210715,0.000046877594,0.0001350633,0.00017905822,0.0000019009699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01299586,0.06071228,0.89653647,0.00010610479,0.0011718841,0.00012798098,0.006847755,0.000011503075,0.00023561774,0.000018481864,0.0001396162,0.021096459],"study_design_scores_gemma":[0.15567029,0.087346666,0.7516703,0.0001001678,0.00060756144,0.00001665719,0.0011368368,0.000084240935,0.0015877518,0.000007123934,0.0016652955,0.000107099026],"about_ca_topic_score_codex":0.00012212488,"about_ca_topic_score_gemma":0.00025684552,"teacher_disagreement_score":0.14486614,"about_ca_system_score_codex":0.00003176906,"about_ca_system_score_gemma":0.00013848329,"threshold_uncertainty_score":0.42980796},"labels":[],"label_agreement":null},{"id":"W3119217389","doi":"10.1016/j.annonc.2020.12.017","title":"Have investigators forgotten how to write?","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Principal (computer security); Randomized controlled trial; Medical education; Family medicine; Pathology; Computer science","score_opus":0.17868539220082263,"score_gpt":0.450052422089461,"score_spread":0.27136702988863837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119217389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73975044,0.0011362699,0.000013054483,0.23983985,0.00010152248,0.0002105012,0.000014613367,0.00001577675,0.018917996],"genre_scores_gemma":[0.9630758,0.0006888054,0.0013948263,0.014421136,0.00018404431,0.000039959275,0.000049865128,0.000016696784,0.020128833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920374,0.000056135763,0.00012901731,0.00018301581,0.00016183495,0.0002662631],"domain_scores_gemma":[0.99901164,0.0000818141,0.000037903792,0.00020385938,0.00038351273,0.00028130275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016433376,0.000076316326,0.00030070328,0.00009908929,0.00002824895,0.0000060229236,0.000059086233,0.00009704242,0.00015351358],"category_scores_gemma":[0.00032312545,0.000060772272,0.00007977853,0.00019659672,0.00010690962,0.000048275415,0.00007319028,0.0001145317,0.000035716006],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009848409,0.0010324226,0.10977275,0.00027716698,0.0006265099,0.00267017,0.0017469939,0.0000035100632,0.09242756,0.0022992396,0.6292719,0.1588869],"study_design_scores_gemma":[0.0015091094,0.002898015,0.016296223,0.000060015955,0.000033952576,0.00006969329,0.0005956826,0.0000069019793,0.35527033,0.00080974936,0.6223734,0.00007695438],"about_ca_topic_score_codex":0.0000256567,"about_ca_topic_score_gemma":0.000033228007,"teacher_disagreement_score":0.26284277,"about_ca_system_score_codex":0.000042005624,"about_ca_system_score_gemma":0.0006621418,"threshold_uncertainty_score":0.24782214},"labels":[],"label_agreement":null},{"id":"W3119675888","doi":"10.1016/j.annonc.2020.12.011","title":"Corrigendum to ‘Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases’","year":2021,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Osteosarcoma; Lung; Chemotherapy; Oncology; Internal medicine; Lung cancer; Surgery; Radiology; Pathology","score_opus":0.05225931044744424,"score_gpt":0.36350905266723166,"score_spread":0.3112497422197874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119675888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9249799,0.058653556,0.000021631862,0.006051819,0.0030963141,0.001696147,0.000453901,0.00003107718,0.005015647],"genre_scores_gemma":[0.9839795,0.007689917,0.0006146134,0.0021457034,0.00025241394,0.00014790818,0.00087747304,0.00006278095,0.004229641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977372,0.00024747362,0.00053198,0.000717646,0.0003501812,0.00041552013],"domain_scores_gemma":[0.998551,0.000060754122,0.00028963026,0.00043135288,0.00033385906,0.00033339518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003110836,0.00038910285,0.0021615878,0.0007565179,0.000034727156,0.000017073029,0.00009130187,0.00037667574,0.000055722172],"category_scores_gemma":[0.00011668288,0.00030295295,0.00017880181,0.0007874959,0.00013451495,0.000039196206,0.00015022038,0.00043415237,0.000002157426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012931086,0.0016306844,0.903784,0.0005593737,0.0034498828,0.0013767291,0.00033373528,0.0000010001409,0.0000044414587,0.000018155397,0.060259014,0.027289912],"study_design_scores_gemma":[0.0048210584,0.00411642,0.9110681,0.0023057554,0.004691785,0.00014753194,0.00070450385,0.00006720007,0.000078279714,0.000005338309,0.071652986,0.00034103743],"about_ca_topic_score_codex":0.0012854413,"about_ca_topic_score_gemma":0.0108597865,"teacher_disagreement_score":0.058999643,"about_ca_system_score_codex":0.00007585155,"about_ca_system_score_gemma":0.00041598806,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W3124979526","doi":"10.1016/j.annonc.2020.12.014","title":"Diabetes, metformin and breast cancer: a tangled web","year":2021,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; London Health Sciences Centre; Mount Sinai Hospital; Western University","funders":"Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Metformin; Internal medicine; Type 2 diabetes; Cancer; Oncology; Hyperinsulinemia; Diabetes mellitus; Endocrinology; Insulin resistance; Obesity; Insulin","score_opus":0.03183174564681244,"score_gpt":0.3145185191330181,"score_spread":0.28268677348620563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124979526","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11263449,0.7685449,0.000002354276,0.11366579,0.0010380134,0.00027018087,0.0014848973,0.000013258474,0.0023461294],"genre_scores_gemma":[0.003925898,0.43809316,0.00012937449,0.5497942,0.005318783,0.00016896139,0.0009953022,0.000075439246,0.0014989234],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799114,0.00021857704,0.0004183593,0.0006073425,0.00018736054,0.0005772197],"domain_scores_gemma":[0.99863493,0.00004806374,0.00036291103,0.00048357685,0.00037002802,0.00010049244],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002855541,0.00034504378,0.00088857795,0.00009887821,0.00004510287,0.000017696566,0.00029306614,0.0013306767,0.000356168],"category_scores_gemma":[0.00006129552,0.00032854886,0.0002408267,0.000118192715,0.00024587475,0.0000047031376,0.00021582235,0.0005099649,0.000004358383],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026284326,0.00004141426,0.00023260685,0.00017196374,0.0003624937,0.000038020302,0.000014463846,5.0582173e-7,0.0075713927,0.0000065492745,0.75295186,0.23858248],"study_design_scores_gemma":[0.0005886183,0.0003887065,0.00013461585,0.00006238838,0.00013495579,0.000032240878,0.000014106046,0.000003853511,0.022446582,0.00006953577,0.97579247,0.0003319171],"about_ca_topic_score_codex":0.000058616308,"about_ca_topic_score_gemma":0.00011636318,"teacher_disagreement_score":0.43612838,"about_ca_system_score_codex":0.000017585055,"about_ca_system_score_gemma":0.00079759647,"threshold_uncertainty_score":0.9999658},"labels":[],"label_agreement":null},{"id":"W3127599355","doi":"10.1016/j.annonc.2021.01.075","title":"Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis","year":2021,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre; McGill Genome Centre; McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research; Pfizer Canada; Amgen Canada; Bristol-Myers Squibb Canada; National Institutes of Health; Merck Canada; Canada Foundation for Innovation; Advanced Accelerator Applications; Clovis Oncology; Fondation de l'Hôpital Général de Montréal; McMaster University; GlaxoSmithKline; Cancer Research Society; American Surgical Association Foundation; Leon Lowenstein Foundation; March of Dimes Foundation; F. Hoffmann-La Roche; Roche; Samsung; Genentech; Merck; California Institute for Regenerative Medicine; Fonds de Recherche du Québec - Santé; L'Oreal USA; AstraZeneca; Prostate Cancer Foundation; Amgen","keywords":"Medicine; Adenocarcinoma; Carcinoma; Small-cell carcinoma; Large cell; Lung; Pathology; Small Cell Lung Carcinoma; Metastasis; Oncology; Internal medicine; Cancer","score_opus":0.1112573168191713,"score_gpt":0.406147336166251,"score_spread":0.2948900193470797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127599355","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31259662,0.0048421193,0.000030054956,0.6797144,0.00018569759,0.0008877716,0.0003539776,0.00004882178,0.0013405341],"genre_scores_gemma":[0.15233879,0.0017476354,0.0021623226,0.83280456,0.0013681606,0.00034628672,0.0022555143,0.00015650467,0.0068202345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955204,0.0008913379,0.00087937235,0.0009557141,0.0007510201,0.0010021633],"domain_scores_gemma":[0.9964098,0.00042040134,0.00040697257,0.0011185487,0.0012474792,0.00039685305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059488736,0.00050327607,0.0027611295,0.0008839049,0.000076030454,0.000028905555,0.0005219381,0.0007092757,0.00040479543],"category_scores_gemma":[0.00033085313,0.00045806033,0.0006901462,0.0014298287,0.00023734636,0.00004375845,0.00036653265,0.00153613,0.000009208273],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032623767,0.00036056203,0.008243309,0.00084887835,0.005964399,0.0031092502,0.0005123909,0.0000049482983,0.0020844697,0.000002269182,0.977237,0.0013062743],"study_design_scores_gemma":[0.0035040053,0.01411612,0.026391694,0.00013222604,0.013914344,0.00007217577,0.00048557637,0.00010431346,0.009366347,0.000037993235,0.9310207,0.00085454696],"about_ca_topic_score_codex":0.0013008092,"about_ca_topic_score_gemma":0.0005158519,"teacher_disagreement_score":0.16025785,"about_ca_system_score_codex":0.000300282,"about_ca_system_score_gemma":0.0011033453,"threshold_uncertainty_score":0.9997871},"labels":[],"label_agreement":null},{"id":"W3128792891","doi":"10.1016/j.annonc.2021.01.065","title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Exelixis; Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Internal medicine; Tolerability; Oncology; Taxane; Cohort; Breast cancer; Cancer; Adverse effect; Immunotherapy; Pembrolizumab","score_opus":0.035305087332164566,"score_gpt":0.3644163185437791,"score_spread":0.3291112312116145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128792891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913441,0.00023264944,0.0032450168,0.00057696993,0.00007679681,0.0034341724,0.0008627647,0.000010955436,0.00021657496],"genre_scores_gemma":[0.98832756,0.0013876647,0.0058926316,0.000621265,0.00008992747,0.0014508974,0.00074812793,0.00005238006,0.0014295488],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980174,0.00027103518,0.000671901,0.00051469146,0.00020576868,0.00031922082],"domain_scores_gemma":[0.99746543,0.00029121852,0.0007943686,0.00037036525,0.0009535929,0.00012501907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027241057,0.00032784024,0.0019026734,0.00010977528,0.000071697534,0.000006518456,0.00014064142,0.00014027598,0.00014415805],"category_scores_gemma":[0.00019669192,0.00018697219,0.0003801842,0.00037472084,0.00027292938,0.000009934307,0.000046551217,0.000053150092,3.09101e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9484727,0.006659109,0.00009135653,0.00008903557,0.007262538,0.000022359975,0.00029539785,0.00028264394,0.0028474284,0.000009860552,0.00012393003,0.03384368],"study_design_scores_gemma":[0.81621903,0.10414594,0.00005738833,0.000051398038,0.0019538947,0.00001522354,0.00008666005,0.00017870452,0.07279265,0.000018305778,0.0042416337,0.00023917247],"about_ca_topic_score_codex":0.00020822625,"about_ca_topic_score_gemma":0.0020796903,"teacher_disagreement_score":0.13225362,"about_ca_system_score_codex":0.000057822355,"about_ca_system_score_gemma":0.0020225008,"threshold_uncertainty_score":0.76245046},"labels":[],"label_agreement":null},{"id":"W3134332329","doi":"10.1016/j.annonc.2021.01.053","title":"38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University Health Network; Queen's University; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Ontario Institute for Cancer Research; Canadian Cancer Society; Stand Up To Cancer Canada; Government of Ontario","keywords":"Medicine; Taxane; Internal medicine; Neutropenia; Febrile neutropenia; Chemotherapy; Breast cancer; Nausea; Adverse effect; Gastroenterology; Cancer; Oncology","score_opus":0.04667935103306406,"score_gpt":0.40746208288190044,"score_spread":0.36078273184883636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134332329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840229,0.00055604044,9.2820994e-7,0.010430952,0.00082912075,0.0020519888,0.00095302094,0.000011482743,0.0011435328],"genre_scores_gemma":[0.9958016,0.0012255255,0.000099946374,0.0015350623,0.00026709656,0.0004963582,0.00016807095,0.00003467865,0.00037164186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976897,0.0003148186,0.0006888745,0.00048310883,0.00027290644,0.0005505733],"domain_scores_gemma":[0.99803853,0.0002875804,0.00046191338,0.00023799148,0.000591722,0.00038229008],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025938422,0.00030000336,0.0012618862,0.00028682893,0.000059152688,0.0000063219704,0.00010383503,0.00027397592,0.0010733638],"category_scores_gemma":[0.00010226692,0.0002604417,0.0001257955,0.000509816,0.0003443754,0.00012296729,0.000045844292,0.00032299035,0.0000017434129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8103019,0.009675923,0.058099214,0.00013203925,0.0010311775,0.00021970969,0.0015400148,0.000010637936,0.00035702542,0.00008334195,0.0041552535,0.11439377],"study_design_scores_gemma":[0.7777364,0.054458164,0.15505639,0.0002495844,0.00044730378,0.000010913815,0.0003722748,0.000015687645,0.0016161696,0.00015199327,0.009594719,0.0002903639],"about_ca_topic_score_codex":0.21222508,"about_ca_topic_score_gemma":0.49523804,"teacher_disagreement_score":0.28301296,"about_ca_system_score_codex":0.00041425775,"about_ca_system_score_gemma":0.0029609022,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W3134581027","doi":"10.1016/j.annonc.2021.01.051","title":"36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Rash; Lung cancer; Internal medicine; Adverse effect; Oncology; Gastroenterology","score_opus":0.03507426874572082,"score_gpt":0.3850678834791013,"score_spread":0.3499936147333805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134581027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763226,0.0031479634,0.000023052828,0.0033708434,0.000060207305,0.0005589279,0.00006589633,0.00000826292,0.016442278],"genre_scores_gemma":[0.99752474,0.00095828605,0.000475133,0.0004309988,0.00004222253,0.00004070545,0.000047737165,0.000015517451,0.0004646408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879044,0.000089801615,0.00044208998,0.00032054298,0.00012266947,0.00023444963],"domain_scores_gemma":[0.9988918,0.00023079438,0.00020843388,0.00024998118,0.00031196585,0.00010702638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017681828,0.00014557844,0.0005833157,0.00007076467,0.00002903814,0.000003884878,0.000056970966,0.00012442563,0.0001472343],"category_scores_gemma":[0.00003569427,0.000116788,0.000056706485,0.00022093259,0.00013000137,0.000054057233,0.000045776815,0.00015542423,7.852892e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017996417,0.015589306,0.71562093,0.0037369237,0.0015718376,0.0020020187,0.015184547,0.004270976,0.05483886,0.00027894133,0.002546753,0.1663625],"study_design_scores_gemma":[0.011095085,0.010790554,0.9324401,0.00054289465,0.0005905822,0.0000879819,0.0017157351,0.0003537336,0.03872967,0.00004864577,0.0034130898,0.00019194954],"about_ca_topic_score_codex":0.0014899812,"about_ca_topic_score_gemma":0.0016800866,"teacher_disagreement_score":0.21681914,"about_ca_system_score_codex":0.00009981029,"about_ca_system_score_gemma":0.001432993,"threshold_uncertainty_score":0.47624764},"labels":[],"label_agreement":null},{"id":"W3135098376","doi":"10.1016/j.annonc.2021.02.017","title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Topotecan; Internal medicine; Clinical endpoint; Ovarian cancer; Tolerability; Oncology; Population; Hazard ratio; Chemotherapy; Chemotherapy regimen; Progression-free survival; Cancer; Randomized controlled trial; Surgery; Adverse effect; Confidence interval","score_opus":0.038649593173610164,"score_gpt":0.37204405156171444,"score_spread":0.3333944583881043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135098376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929359,0.00076587754,0.000036842048,0.003058135,0.00014782742,0.0011127249,0.00022305283,0.000005447867,0.0017141985],"genre_scores_gemma":[0.997061,0.0011470523,0.0009282472,0.00037261902,0.000040053514,0.000102069134,0.00029115175,0.000016119358,0.000041652278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99798495,0.00019395187,0.0009729627,0.00029256238,0.00034246605,0.00021310334],"domain_scores_gemma":[0.9977128,0.0005329628,0.0007425348,0.00034800908,0.0005817176,0.00008200246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047698768,0.00017654794,0.0027164519,0.00034164282,0.000014101871,0.0000025048457,0.000069502035,0.00013530525,0.0004041914],"category_scores_gemma":[0.00012232903,0.00013343585,0.00037953324,0.0009080002,0.00017718524,0.00004094459,0.000020967627,0.00009344493,2.1308199e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9324721,0.014174622,0.004011392,0.00007444015,0.010133531,0.00004464722,0.00038730132,0.000044215016,0.00033881885,0.0001236233,0.00024657944,0.03794874],"study_design_scores_gemma":[0.9512763,0.01614858,0.021343756,0.00011859832,0.0036953501,3.2020154e-7,0.000042772204,0.000054899523,0.0064558485,0.000025400368,0.00073881855,0.0000993323],"about_ca_topic_score_codex":0.0008114397,"about_ca_topic_score_gemma":0.0006573072,"teacher_disagreement_score":0.037849404,"about_ca_system_score_codex":0.00013469365,"about_ca_system_score_gemma":0.00091040594,"threshold_uncertainty_score":0.54413563},"labels":[],"label_agreement":null},{"id":"W3135437596","doi":"10.1016/j.annonc.2021.01.020","title":"7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Eisai; Incyte; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Servier; Amgen","keywords":"Medicine; Tolerability; Discontinuation; Internal medicine; Adverse effect; Clinical endpoint; Pharmacodynamics; Refractory (planetary science); Lymphoma; Pharmacokinetics; Neutropenia; Gastroenterology; Oncology; Toxicity; Clinical trial","score_opus":0.05688993279910743,"score_gpt":0.39542583558460176,"score_spread":0.33853590278549434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135437596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995987,0.00017982052,0.000001548743,0.0017798004,0.000163331,0.00091200304,0.00019028757,0.00003267636,0.0007535283],"genre_scores_gemma":[0.9982285,0.00048856164,0.00021907946,0.00048775753,0.00006190174,0.000033550063,0.0002534651,0.00005847466,0.0001687444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996091,0.00054219825,0.0011474383,0.0008355116,0.0006774224,0.0007064424],"domain_scores_gemma":[0.99689394,0.0007417674,0.0006269778,0.0006777044,0.0007294072,0.00033020586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002557028,0.00034732366,0.0012851595,0.0004884079,0.00006945338,0.000011308796,0.00024015292,0.000030570445,0.000042002812],"category_scores_gemma":[0.0013872497,0.00030789463,0.00007403074,0.00071883353,0.00029033067,0.00025549147,0.00041135921,0.00046017958,0.000005979588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105652265,0.2037212,0.4554436,0.00035460122,0.0009821148,0.10286735,0.0038772626,0.0001407281,0.028125057,0.00001605526,0.012046097,0.086773686],"study_design_scores_gemma":[0.3477656,0.12431875,0.36866528,0.0004930695,0.00026052672,0.0009208792,0.004544873,0.000272827,0.14141291,0.000106740066,0.010646165,0.0005923902],"about_ca_topic_score_codex":0.0010319073,"about_ca_topic_score_gemma":0.0013655642,"teacher_disagreement_score":0.24211332,"about_ca_system_score_codex":0.00008565195,"about_ca_system_score_gemma":0.0005142619,"threshold_uncertainty_score":0.9999373},"labels":[],"label_agreement":null},{"id":"W3136076419","doi":"10.1016/j.annonc.2021.02.024","title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":326,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; Merck Sharp and Dohme; EMD Serono; Bavarian Nordic; Sociedad Española de Oncología Médica; Swedish Orphan Biovitrum; Astellas Pharma; Janssen Pharmaceuticals; Korean Foundation for Cancer Research; Eisai; Natera; BeiGene; Daiichi-Sankyo; Aimmune Therapeutics; Daiichi Sankyo Europe; Agios Pharmaceuticals; Bayer Fund; Mirati Therapeutics; Incyte; Prostate Cancer Foundation; Hope Foundation; Halozyme; Clovis Oncology; American Society of Clinical Oncology; Heron Therapeutics; Sanofi; TG Therapeutics; Alexion Pharmaceuticals; Exelixis; Astellas Pharma US; Castle Biosciences; Dana-Farber Cancer Institute; PTC Therapeutics; Takeda Pharmaceuticals U.S.A.; Celgene; Ipsen Biopharmaceuticals; Genomic Health; F. Hoffmann-La Roche; National Comprehensive Cancer Network; American Cancer Society; American College of Radiology Imaging Network; Vanderbilt Institute for Clinical and Translational Research; Vanderbilt University; Harvard Medical School; Ipsen; Pancreatic Cancer Action Network; Bristol-Myers Squibb; Teva Pharmaceutical Industries; Foundation Medicine; GlaxoSmithKline; Dana-Farber/Harvard Cancer Center; Eli Lilly and Company; Genentech; AstraZeneca; National Cancer Institute; Genzyme; Kommission für Technologie und Innovation; Pfizer; Amgen; ECOG-ACRIN Cancer Research Group; Merck KGaA; National Institutes of Health; Conquer Cancer Foundation; Fonds de Recherche du Québec - Santé; Merck Canada; Array BioPharma","keywords":"Medicine; Internal medicine; Cancer; Absolute neutrophil count; Lung cancer; Chemotherapy; Neutropenia","score_opus":0.23302443522791771,"score_gpt":0.516212991868426,"score_spread":0.28318855664050824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136076419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8814744,0.0021334412,0.000021686705,0.115296975,0.00016827678,0.00052713224,0.00030265178,0.000014184398,0.000061279345],"genre_scores_gemma":[0.9193432,0.0350952,0.000056818055,0.045219515,0.00010438648,0.000029859617,0.00006938796,0.000014143454,0.00006751672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781066,0.0004164153,0.0006879903,0.0004048439,0.00040729507,0.00027279707],"domain_scores_gemma":[0.99462205,0.0025412692,0.0010722838,0.0002941213,0.0009108621,0.0005594402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009903816,0.0001663526,0.0008900215,0.000041029867,0.00010143161,0.000008644472,0.000058524347,0.00024468056,0.00027897133],"category_scores_gemma":[0.0044988818,0.00009790781,0.000058074376,0.00022066938,0.00045346527,0.0000697194,0.000044091692,0.000304686,1.1154857e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026640862,0.00035048003,0.96884847,0.00013788775,0.00057687826,0.000086635846,0.0016016554,0.000005193869,0.000019179968,0.000004635261,0.010186868,0.015518054],"study_design_scores_gemma":[0.0042455224,0.0014418632,0.8179343,0.0000625181,0.00015253336,0.0000088233,0.0002567237,0.000004618479,0.00018440365,0.000041895037,0.17557658,0.00009026065],"about_ca_topic_score_codex":0.04618483,"about_ca_topic_score_gemma":0.047266554,"teacher_disagreement_score":0.16538972,"about_ca_system_score_codex":0.00032044807,"about_ca_system_score_gemma":0.00923225,"threshold_uncertainty_score":0.9963845},"labels":[],"label_agreement":null},{"id":"W3137264295","doi":"10.1016/j.annonc.2020.08.1801","title":"1737P National approaches to managing cancer care: Responses of countries in the MENA region to COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; EMD Serono; Genentech; National Institutes of Health; Sierra Oncology; Astellas Pharma; Ribon Therapeutics; U.S. Department of Defense; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Pfizer; LUNGevity Foundation","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus Infections; Cancer; Virology; Family medicine; Internal medicine; Outbreak; Infectious disease (medical specialty); Disease","score_opus":0.5317793483467697,"score_gpt":0.3972307535048798,"score_spread":0.13454859484188986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137264295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66768265,0.006202083,0.0015425583,0.28951946,0.00022239726,0.0006542433,0.00043484726,0.000017261797,0.033724517],"genre_scores_gemma":[0.95263183,0.0011141046,0.00014005908,0.045824703,0.00012573694,0.00007212555,0.000004319842,0.000009396388,0.00007770663],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988752,0.000044813678,0.00055517873,0.0002621368,0.00004634533,0.00021634725],"domain_scores_gemma":[0.99907684,0.0002775915,0.0003240784,0.00013439028,0.00006742522,0.00011965237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008034949,0.00010044776,0.00044271137,0.00022154646,0.000043383516,0.000012264977,0.00032071842,0.000092688235,0.000056802724],"category_scores_gemma":[0.000756036,0.00009947939,0.000067300025,0.00024919747,0.0000927334,0.00011799911,0.000061941995,0.000099846155,0.000033518896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024548848,0.00013153843,0.3494259,0.00031508558,0.000118783544,0.000014437869,0.06319006,0.0110804355,0.000031495158,0.48303804,0.070156366,0.020042967],"study_design_scores_gemma":[0.00062368246,0.00080325274,0.04149872,0.00001754588,0.0000049277246,0.0000036227946,0.001795088,0.00011038598,0.00010682894,0.017272333,0.9375779,0.00018573723],"about_ca_topic_score_codex":0.001084211,"about_ca_topic_score_gemma":0.00077072665,"teacher_disagreement_score":0.8674215,"about_ca_system_score_codex":0.00021268478,"about_ca_system_score_gemma":0.00037570935,"threshold_uncertainty_score":0.40566516},"labels":[],"label_agreement":null},{"id":"W3143844999","doi":"10.1016/j.annonc.2021.03.205","title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; McGill University; University of Ottawa; Regional Municipality of Durham; Juravinski Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Jewish General Hospital; Kelowna General Hospital; CancerCare Manitoba; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Lakeridge Health; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Terry Fox Research Institute; Movember Foundation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Enzalutamide; Medicine; Abiraterone; Prostate cancer; Open label; Oncology; Docetaxel; Internal medicine; Phases of clinical research; Clinical trial; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.28529324821179536,"score_gpt":0.5082174511914536,"score_spread":0.2229242029796582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143844999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773959,0.0045669293,0.0000017129379,0.011628749,0.00039636134,0.004904432,0.00027147256,0.000018618408,0.00081580394],"genre_scores_gemma":[0.98281115,0.007619512,0.0016922405,0.00063677394,0.00013161216,0.0024341682,0.00026071855,0.000041230258,0.0043725856],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99726677,0.00041903774,0.0008497766,0.0004930622,0.00035802563,0.0006133322],"domain_scores_gemma":[0.9980627,0.00053060637,0.00030415624,0.0002456755,0.0006053086,0.00025156254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007034444,0.00024924203,0.0010697969,0.0001587236,0.00012472148,0.000040004456,0.00018409887,0.00011428366,0.0005727942],"category_scores_gemma":[0.00071755715,0.00018237838,0.00009487592,0.0005592681,0.00018843492,0.00021415253,0.00016623043,0.00025400738,0.000010154372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87001836,0.014265978,0.0001260236,0.00025420028,0.0009213664,0.0028459039,0.0012812695,0.0000082291535,0.042684525,0.000036238303,0.0027339275,0.06482398],"study_design_scores_gemma":[0.8736433,0.040332343,0.0001388266,0.00024956174,0.00040559,0.000023449244,0.0010164032,0.00016637269,0.07434037,0.000042826545,0.009449295,0.0001916626],"about_ca_topic_score_codex":0.0010344008,"about_ca_topic_score_gemma":0.004830962,"teacher_disagreement_score":0.06463232,"about_ca_system_score_codex":0.00025149374,"about_ca_system_score_gemma":0.003943232,"threshold_uncertainty_score":0.7437175},"labels":[],"label_agreement":null},{"id":"W3145141190","doi":"10.1093/annonc/mdr305","title":"Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?","year":2011,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Public Health Ontario; University of Toronto; Toronto General Hospital","funders":"","keywords":"Medicine; Smokeless tobacco; Snus; Pancreatic cancer; Cohort; Cancer; Snuff; Cohort study; Retrospective cohort study; Internal medicine; Oncology; Environmental health; Population; Tobacco use; Pathology","score_opus":0.46718689701928856,"score_gpt":0.4818342683318722,"score_spread":0.014647371312583646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145141190","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29985446,0.0010626097,0.0000067852798,0.6925384,0.00065797754,0.0025411774,0.0015467365,0.00007363988,0.0017182122],"genre_scores_gemma":[0.013867189,0.005179543,0.00013991186,0.9734218,0.0008472072,0.00021121766,0.001533317,0.00008093028,0.004718892],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969048,0.00035692702,0.0007245531,0.0009764272,0.00040165626,0.0006356246],"domain_scores_gemma":[0.99551266,0.0012378312,0.00068010006,0.0016872818,0.0005264545,0.00035563877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064805645,0.0004259402,0.0017091762,0.00028574342,0.0000821988,0.000034573062,0.00036335073,0.0010369064,0.0005764361],"category_scores_gemma":[0.0010364689,0.00037718023,0.000089505425,0.0001351726,0.00025552907,0.00017733454,0.0002420424,0.0013291822,0.00009411778],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005313862,0.00011771418,0.15131891,0.0004958092,0.00043250757,0.00037414924,0.0000714857,8.34639e-8,0.00004721756,0.000016139998,0.84318876,0.0034058557],"study_design_scores_gemma":[0.0011286861,0.0014320151,0.21053293,0.0007444174,0.00037976983,0.000054587566,0.0000101811665,0.0000027058609,0.00009025566,0.000008278762,0.7853656,0.0002505986],"about_ca_topic_score_codex":0.0059715225,"about_ca_topic_score_gemma":0.00031230142,"teacher_disagreement_score":0.2859873,"about_ca_system_score_codex":0.0001400227,"about_ca_system_score_gemma":0.00065179943,"threshold_uncertainty_score":0.99986804},"labels":[],"label_agreement":null},{"id":"W3146717266","doi":"10.1093/annonc/mdx370.053","title":"The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Olaparib; PARP inhibitor; PALB2; Prostate cancer; Oncology; Taxane; Internal medicine; CHEK2; Docetaxel; Cancer research; Germline mutation; Cancer; Androgen receptor; Breast cancer; Mutation; Genetics; Poly ADP ribose polymerase; Biology; Gene","score_opus":0.2420030461297958,"score_gpt":0.4813160704545564,"score_spread":0.23931302432476056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146717266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892886,0.00022020814,0.0000027292235,0.00558673,0.00055215124,0.003590113,0.000039907194,0.000009902241,0.0007096422],"genre_scores_gemma":[0.99871135,0.00018557448,0.00007899677,0.00014083814,0.00005939327,0.0007013344,0.000034634708,0.000017331868,0.00007055862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963364,0.0011371116,0.0010227314,0.00029785951,0.00088247994,0.00032344228],"domain_scores_gemma":[0.99474484,0.00054215896,0.0021602914,0.00051675754,0.0019719386,0.00006399726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005200168,0.00016230645,0.0005533283,0.000079119425,0.00028007233,0.000028786166,0.00023535614,0.00014274477,0.000022274342],"category_scores_gemma":[0.002510607,0.00008798456,0.000106011146,0.00025661383,0.000799251,0.00014300378,0.000030739677,0.00030990486,7.3242853e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15969934,0.011946532,0.28003356,0.000113649854,0.0007693377,0.000014664049,0.0020566797,0.00027412333,0.0005423081,0.0004662189,0.0018447803,0.54223883],"study_design_scores_gemma":[0.16330782,0.0340445,0.7951551,0.0005456388,0.00054347684,0.000004804205,0.0003338656,0.0003220707,0.003574063,0.0012403917,0.00073968986,0.00018859017],"about_ca_topic_score_codex":0.00040333584,"about_ca_topic_score_gemma":0.004282526,"teacher_disagreement_score":0.54205024,"about_ca_system_score_codex":0.00030320702,"about_ca_system_score_gemma":0.0022419426,"threshold_uncertainty_score":0.39771098},"labels":[],"label_agreement":null},{"id":"W3149716143","doi":"10.1093/annonc/mdt103","title":"Re: light drinking has positive public health consequences","year":2013,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Medicine; Cancer; Epidemiology; Disease; Relative risk; Incidence (geometry); Demography; Case fatality rate; Public health; Environmental health; Internal medicine; Confidence interval; Pathology","score_opus":0.43273044910634134,"score_gpt":0.4776365079272507,"score_spread":0.04490605882090937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149716143","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015987224,0.0030019414,0.000021568172,0.9727382,0.0007413337,0.0011246569,0.00002204365,0.00007473018,0.020676816],"genre_scores_gemma":[0.028643075,0.0020370823,0.00035280598,0.96442735,0.0018399496,0.000093519455,0.00032305592,0.000043416636,0.0022397607],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966148,0.000772202,0.00082714856,0.0004804972,0.00041339154,0.000891948],"domain_scores_gemma":[0.9967219,0.0007610085,0.0010097664,0.0004321785,0.0007281965,0.00034690418],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001104682,0.0003125546,0.0014498322,0.00047623107,0.00019000041,0.000031700176,0.00021208005,0.0012582045,0.0011915134],"category_scores_gemma":[0.00039369237,0.00026858493,0.00022455792,0.00019671682,0.00068044756,0.000095318086,0.00007403689,0.0019724108,0.00047003606],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039158782,0.00010460984,0.00043779096,0.00074024306,0.00019634778,0.0005163115,0.00067594455,2.3724825e-8,0.00004988855,0.00024789703,0.97423935,0.022752458],"study_design_scores_gemma":[0.0007393016,0.004026799,0.0019987812,0.0005561233,0.000039384515,0.00022473285,0.0000739173,0.0000025917825,0.0001394665,0.00025801625,0.9917551,0.00018573785],"about_ca_topic_score_codex":0.0005180258,"about_ca_topic_score_gemma":0.00012372078,"teacher_disagreement_score":0.027044352,"about_ca_system_score_codex":0.00022219804,"about_ca_system_score_gemma":0.0047337804,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W3152878368","doi":"10.1016/j.annonc.2021.04.008","title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Foundation Medicine; Samsung; Genentech; EMD Serono; Otsuka Pharmaceutical; Chugai Pharmaceutical; Seagen; Incyte; Mirati Therapeutics; Novocure; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Carboplatin; Internal medicine; Oncology; Lung cancer; Hazard ratio; Placebo; Chemotherapy; Progression-free survival; Cisplatin; Confidence interval; Cancer; Pathology; Immunotherapy","score_opus":0.07969916344976641,"score_gpt":0.37129884328562884,"score_spread":0.29159967983586244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152878368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822804,0.000117154195,0.00017208385,0.00067308353,0.000028653621,0.015057757,0.00008727033,0.00003597393,0.0015476506],"genre_scores_gemma":[0.9895866,0.000030659266,0.0029867117,0.0008755791,0.000035276254,0.0052514975,0.00037233657,0.00004298456,0.00081834296],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99736035,0.00031027012,0.00078390026,0.00057411456,0.0004946546,0.00047670954],"domain_scores_gemma":[0.9978784,0.00026354525,0.0005316703,0.000554777,0.0006252994,0.00014631901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002691567,0.0003374005,0.0015232036,0.00045473943,0.00005466673,0.000019604402,0.00015153569,0.00015527903,0.0014266204],"category_scores_gemma":[0.00010493673,0.00021712655,0.00019877708,0.002016737,0.00022664311,0.0001034932,0.000042774645,0.00026535318,0.0000067043766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53380305,0.004076429,0.39390486,0.00025140154,0.0081753675,0.0011426613,0.002183574,0.00019493685,0.000514758,0.000008456129,0.0010112827,0.05473321],"study_design_scores_gemma":[0.122778215,0.031411465,0.82594746,0.0006090401,0.0028379688,0.000068889334,0.00096294406,0.0005635494,0.005757387,0.000022381522,0.008437739,0.00060295814],"about_ca_topic_score_codex":0.0022736506,"about_ca_topic_score_gemma":0.010998184,"teacher_disagreement_score":0.4320426,"about_ca_system_score_codex":0.00022687993,"about_ca_system_score_gemma":0.0016824653,"threshold_uncertainty_score":0.9994862},"labels":[],"label_agreement":null},{"id":"W3154709616","doi":"10.1016/j.annonc.2021.03.208","title":"How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy","year":2021,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Immunotherapy; Biomarker; Cancer; Oncology; Cancer immunotherapy; Internal medicine; Cancer research","score_opus":0.0840677914914246,"score_gpt":0.437595009934382,"score_spread":0.3535272184429574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154709616","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082460694,0.12699892,0.000007854778,0.021166747,0.76327777,0.0021667627,0.001582815,0.000067443456,0.0022709798],"genre_scores_gemma":[0.053782173,0.37282023,0.00046838002,0.003640108,0.5476417,0.0010125679,0.0022483286,0.00052542053,0.017861107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951276,0.000979423,0.0018799944,0.00064720254,0.00083055877,0.00053522614],"domain_scores_gemma":[0.9942777,0.0017374998,0.0021599468,0.0007576392,0.0009445186,0.00012266493],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003002751,0.0004988384,0.0035418249,0.0005914568,0.000030943625,0.000022002856,0.00036887493,0.0020780137,0.00093472016],"category_scores_gemma":[0.0023064648,0.00040615172,0.001014181,0.00056211726,0.00038082124,0.00007301196,0.00008761265,0.00073083583,0.0000014974041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023516428,0.0006083128,0.000103927814,0.00048313086,0.0010734057,0.00011041273,0.0004273626,3.4592895e-7,0.21188186,0.000001636981,0.65297455,0.10881863],"study_design_scores_gemma":[0.010795941,0.0026915935,0.00080863386,0.0027559965,0.00014987301,0.000007526691,0.00025829114,0.000001416829,0.098607086,0.000043608918,0.8835769,0.0003030833],"about_ca_topic_score_codex":0.006190907,"about_ca_topic_score_gemma":0.0017924105,"teacher_disagreement_score":0.24582131,"about_ca_system_score_codex":0.00031972863,"about_ca_system_score_gemma":0.0052854195,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W3161001395","doi":"10.1016/j.annonc.2021.03.025","title":"11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Breast cancer; Cohort; Oncology; Cancer; Hazard ratio; Confidence interval","score_opus":0.06027420431974981,"score_gpt":0.381579929688216,"score_spread":0.32130572536846624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161001395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7145765,0.032809034,0.076203905,0.11046933,0.0035230229,0.0057539986,0.05513172,0.0001204556,0.0014120429],"genre_scores_gemma":[0.98738116,0.0051099923,0.002491727,0.0012608977,0.00036678466,0.0024453455,0.00032880195,0.00004845797,0.0005668479],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99834067,0.0000555602,0.00036839888,0.0006030225,0.0001207967,0.000511529],"domain_scores_gemma":[0.9981848,0.00010091182,0.00026630843,0.00030689864,0.0010297592,0.00011129284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015547458,0.0002714507,0.0005503729,0.00003796223,0.000119671655,0.000012284436,0.00019740767,0.00022622246,0.000038309983],"category_scores_gemma":[0.00008849122,0.00024862145,0.00025130538,0.00011879589,0.00018390194,0.000009703476,0.00015200421,0.00007882674,7.908182e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051139142,0.0065797223,0.098789066,0.0021156748,0.009603602,0.000070563656,0.0019752798,0.0678953,0.08256482,0.0017998446,0.11309399,0.564373],"study_design_scores_gemma":[0.08468028,0.007821476,0.32123533,0.0023362162,0.004475989,0.0008635634,0.0015695445,0.18707351,0.16539922,0.012922457,0.20518163,0.0064407815],"about_ca_topic_score_codex":0.00019395303,"about_ca_topic_score_gemma":0.0010346513,"teacher_disagreement_score":0.5579322,"about_ca_system_score_codex":0.00006897527,"about_ca_system_score_gemma":0.001067395,"threshold_uncertainty_score":0.9999966},"labels":[],"label_agreement":null},{"id":"W3162733280","doi":"10.1016/j.annonc.2021.04.009","title":"VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Daiichi-Sankyo; Bayer Fund; Regeneron Pharmaceuticals; Eisai; Sanofi; Clovis Oncology; Genentech; AstraZeneca","keywords":"Medicine; Internal medicine; Vinorelbine; Gemcitabine; Oncology; Cancer; Chemotherapy; Cisplatin","score_opus":0.12497667917821274,"score_gpt":0.435912532191295,"score_spread":0.31093585301308224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162733280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884905,0.0015879356,0.000032824348,0.006158915,0.00038067118,0.0006602957,0.0001632698,0.000014637941,0.002510912],"genre_scores_gemma":[0.995617,0.0008966694,0.0005368287,0.0022321788,0.0002215305,0.000073922565,0.00028889786,0.000033596236,0.00009939814],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995706,0.00055495417,0.0019171525,0.0006678439,0.00062871404,0.00052530103],"domain_scores_gemma":[0.99609476,0.0011583891,0.000794991,0.00069448916,0.0007762918,0.00048107828],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075174076,0.0003753572,0.0030762309,0.00091550965,0.000028458624,0.000007486263,0.00030926047,0.00033258845,0.0028123537],"category_scores_gemma":[0.0017563511,0.0003309644,0.00082253764,0.004151212,0.00038120514,0.00009101317,0.00016579959,0.0004416526,0.0000075400576],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42198193,0.07038889,0.084178284,0.0021238923,0.018083327,0.0009844155,0.0048756683,0.000026841975,0.071730524,0.00062616536,0.0039017005,0.32109836],"study_design_scores_gemma":[0.5807608,0.052573394,0.1057803,0.00050716416,0.0072077895,0.000044515396,0.0010889791,0.0007108861,0.22719418,0.00072905235,0.022606086,0.0007968934],"about_ca_topic_score_codex":0.0011049988,"about_ca_topic_score_gemma":0.0005199345,"teacher_disagreement_score":0.32030147,"about_ca_system_score_codex":0.00019203825,"about_ca_system_score_gemma":0.0012678684,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W3163030950","doi":"10.1016/j.annonc.2021.03.073","title":"59P Outcomes of women HER2 positive T1a/bN0M0 breast cancer treated with adjuvant trastuzumab: A retrospective population-based cohort study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Lumpectomy; Multivariate analysis; Adjuvant; Cohort; Cancer; Population; Oncology; Gynecology; Mastectomy","score_opus":0.014700824753409239,"score_gpt":0.3241713303712068,"score_spread":0.3094705056177976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163030950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969805,0.00029671815,0.000014467999,0.0011168848,0.000053474225,0.00045323957,0.0006563916,0.000010820473,0.0004175093],"genre_scores_gemma":[0.99884593,0.00008471099,0.000072293486,0.00037417322,0.000047736394,0.00025574246,0.00018899328,0.000026556367,0.0001038535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984502,0.0001848906,0.00033924598,0.00047667674,0.00020813568,0.00034083042],"domain_scores_gemma":[0.99844193,0.000054386714,0.00030497293,0.000321205,0.00079372677,0.00008380138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015673674,0.0002426925,0.0008077538,0.000061262035,0.00006403183,0.000004511341,0.00010672,0.0001231551,0.000051550924],"category_scores_gemma":[0.00004632157,0.00019423553,0.000115623916,0.0002154168,0.00014105153,0.0000058308638,0.00006219392,0.00007456314,0.000001508904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012091869,0.0019839292,0.98925275,0.000013892453,0.0025783065,0.00004057933,0.00042968828,0.0000976767,0.002153003,0.000013791915,0.0001261996,0.0021010176],"study_design_scores_gemma":[0.0025993262,0.003418382,0.977402,0.00002454207,0.00019087624,0.000015787973,0.00097491883,0.0000032856315,0.015122967,0.00001603051,0.00005470059,0.00017720832],"about_ca_topic_score_codex":0.0065811556,"about_ca_topic_score_gemma":0.0040710033,"teacher_disagreement_score":0.012969964,"about_ca_system_score_codex":0.00027292562,"about_ca_system_score_gemma":0.00045240184,"threshold_uncertainty_score":0.9948783},"labels":[],"label_agreement":null},{"id":"W3163240042","doi":"10.1016/j.annonc.2021.03.061","title":"47P The impact of endocrine therapy and chemotherapy on quality of life 5 years after a breast cancer diagnosis: VICAN5 survey","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; The Quebec Population Health Research Network","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Cancer; Chemotherapy; Adjuvant chemotherapy; Pediatrics; Database; Internal medicine","score_opus":0.14495511747565393,"score_gpt":0.451559960320621,"score_spread":0.3066048428449671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163240042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98736256,0.00418314,5.797888e-7,0.0072065582,0.000053864147,0.00019176523,0.0005375887,0.000003933503,0.00046002763],"genre_scores_gemma":[0.9730374,0.020048287,0.000017511726,0.00669512,0.00006564357,0.000059394384,0.000017248285,0.000012790167,0.000046584217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874705,0.000339361,0.00040363433,0.00018027281,0.00015636648,0.0001733165],"domain_scores_gemma":[0.99833417,0.00070620904,0.00025052106,0.00029883088,0.00031851625,0.00009178312],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005013714,0.00011543088,0.0006680544,0.000051883955,0.0000120165905,0.0000022877425,0.000077959885,0.00007358164,0.002053699],"category_scores_gemma":[0.00015668313,0.000075615455,0.00018060324,0.00015918732,0.00023178168,0.000032559306,0.000025301557,0.00013137785,6.516572e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007883926,0.0006519781,0.8468906,0.0000647998,0.0006832422,0.000013828193,0.0007457342,0.00000874112,0.0030850668,0.00001182815,0.0064687566,0.1334915],"study_design_scores_gemma":[0.0031108793,0.0015595262,0.9865617,0.000043177213,0.000012998442,0.000011096268,0.00007435549,0.000005443165,0.0049527115,0.00001920895,0.0035849584,0.000063919],"about_ca_topic_score_codex":0.008109457,"about_ca_topic_score_gemma":0.00093737565,"teacher_disagreement_score":0.13967112,"about_ca_system_score_codex":0.00003727493,"about_ca_system_score_gemma":0.00093771727,"threshold_uncertainty_score":0.9988586},"labels":[],"label_agreement":null},{"id":"W3167855488","doi":"10.1016/j.annonc.2021.05.353","title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals","keywords":"Medicine; Fulvestrant; Internal medicine; Hazard ratio; Population; Breast cancer; Placebo; Metastatic breast cancer; Progression-free survival; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Confidence interval; Chemotherapy; Estrogen receptor; Pathology","score_opus":0.04265747474552653,"score_gpt":0.3792816454752698,"score_spread":0.33662417072974327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167855488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741296,0.001107716,0.00034059896,0.017462157,0.00028477266,0.0041897413,0.0019420444,0.000054008935,0.00048931624],"genre_scores_gemma":[0.9915453,0.001140194,0.0014628555,0.0026229366,0.00039253492,0.0019744083,0.00048224715,0.00008174973,0.00029773495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958178,0.0010875149,0.0011001948,0.00066806516,0.00047427905,0.00085214816],"domain_scores_gemma":[0.99573857,0.0017047094,0.0007825748,0.00037487227,0.0011708959,0.00022836895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010634119,0.00048572817,0.0024569882,0.0001656542,0.00015134446,0.000018797724,0.00026064657,0.00023515282,0.00076749735],"category_scores_gemma":[0.0002773476,0.0003348687,0.00023085298,0.00044733097,0.0006769531,0.00032616456,0.0000541309,0.0004811682,0.0000029057103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88463044,0.0018436967,0.000031040818,0.00005985728,0.0013590154,0.00009446558,0.004889777,0.000049624126,0.080750346,0.00071101484,0.0003530891,0.025227638],"study_design_scores_gemma":[0.951797,0.01434466,0.0045188684,0.0001513401,0.00021414047,0.00011496144,0.0025732752,0.000029207553,0.021381263,0.0011556804,0.0032570306,0.000462569],"about_ca_topic_score_codex":0.00034992173,"about_ca_topic_score_gemma":0.00019722579,"teacher_disagreement_score":0.06716657,"about_ca_system_score_codex":0.00047093973,"about_ca_system_score_gemma":0.0011820422,"threshold_uncertainty_score":0.99991035},"labels":[],"label_agreement":null},{"id":"W3181941784","doi":"10.1016/j.annonc.2021.06.020","title":"Important news on nutritional support in cancer patients – but some EFFORT is still ahead","year":2021,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; Oncology; Gerontology; Internal medicine","score_opus":0.14683077521079296,"score_gpt":0.4386201201645097,"score_spread":0.2917893449537167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181941784","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.091045335,0.001118504,2.790121e-7,0.90181684,0.0012098645,0.0007828078,0.00088728,0.000020890495,0.0031181942],"genre_scores_gemma":[0.004544628,0.007855839,0.00013193194,0.9791712,0.0030682082,0.00020663034,0.0027614704,0.00004914837,0.002210929],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698883,0.000095060255,0.0011912631,0.0005273738,0.000568632,0.00062880985],"domain_scores_gemma":[0.9983047,0.00016800241,0.00053895806,0.0003097703,0.000506405,0.000172134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026746912,0.00029454223,0.0012438793,0.0005185781,0.000033651908,0.00000597198,0.00013070322,0.0010543808,0.00287405],"category_scores_gemma":[0.00007454048,0.0002886768,0.00025315845,0.00018866798,0.00011323058,0.000054151493,0.00004898263,0.0016781348,0.000046693574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030280606,0.0012515387,0.046319284,0.0013123573,0.00007841844,0.0017026094,0.00010065338,1.6984286e-7,0.00002120741,0.00004713367,0.9460874,0.0027764253],"study_design_scores_gemma":[0.0036859803,0.0030014652,0.02130972,0.0010578685,0.000048207825,0.000042153864,0.000023658475,0.0000027886924,0.00049039006,0.0006258407,0.9694991,0.00021283129],"about_ca_topic_score_codex":0.00050500775,"about_ca_topic_score_gemma":0.00012448347,"teacher_disagreement_score":0.086500704,"about_ca_system_score_codex":0.00028060583,"about_ca_system_score_gemma":0.0015522275,"threshold_uncertainty_score":0.99995655},"labels":[],"label_agreement":null},{"id":"W3184066167","doi":"10.1016/j.annonc.2021.07.008","title":"Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Merck Sharp and Dohme; Eisai; Les Laboratories Pierre Fabre; Merck KGaA; Mount Sylvia Diatomite; Roche; Novartis; Takeda Pharmaceutical Company; AbbVie; Sanofi; Merck; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Tolerability; Interquartile range; Internal medicine; Cohort; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Oncology; Adverse effect; Gastroenterology; Clinical trial; Cancer; Immunotherapy","score_opus":0.12107584230751171,"score_gpt":0.44821867097103685,"score_spread":0.3271428286635251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184066167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865842,0.0036341755,0.00015926456,0.001114935,0.00094442244,0.0060537145,0.000151226,0.000022927525,0.0013351351],"genre_scores_gemma":[0.9921953,0.0004054539,0.0051667294,0.0007931049,0.0002076041,0.0006691603,0.00007927179,0.000055033535,0.00042834895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698824,0.00046376276,0.0009535066,0.0007647154,0.00028084096,0.00054894167],"domain_scores_gemma":[0.99672765,0.0012360844,0.00047395864,0.00055317744,0.000732535,0.00027662187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057511125,0.00035356928,0.0018266452,0.00013020149,0.00021830547,0.000027394273,0.00028427638,0.000119127246,0.00008550266],"category_scores_gemma":[0.0009824333,0.00032439828,0.00011579129,0.00018580876,0.00019867803,0.00015856841,0.00042496214,0.00024308352,0.000003559997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7128288,0.04369286,0.00022886369,0.00032113458,0.00030369122,0.0014657761,0.002130037,0.0000033547942,0.0035075042,0.000016156271,0.0014899011,0.23401189],"study_design_scores_gemma":[0.71176183,0.27163365,0.00022398014,0.00005103646,0.000676732,0.00028745038,0.0014808715,0.00030698915,0.005075461,0.00006900276,0.008166987,0.00026598462],"about_ca_topic_score_codex":0.00010367573,"about_ca_topic_score_gemma":0.0003975177,"teacher_disagreement_score":0.2337459,"about_ca_system_score_codex":0.00009722337,"about_ca_system_score_gemma":0.0007185772,"threshold_uncertainty_score":0.9999208},"labels":[],"label_agreement":null},{"id":"W3184328705","doi":"10.1016/j.annonc.2021.07.009","title":"Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"Institut Servier; National Cancer Institute; Servier; Fondation ARC pour la Recherche sur le Cancer","keywords":"Medicine; Post-hoc analysis; Oncology; Colorectal cancer; Internal medicine; Stage (stratigraphy); Lymph node; Post hoc; Cancer","score_opus":0.05176823467468771,"score_gpt":0.41188057803871586,"score_spread":0.36011234336402814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184328705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910184,0.00097182894,0.000006077017,0.0052898885,0.00008973829,0.0018514756,0.0002655605,0.000008917659,0.000498099],"genre_scores_gemma":[0.99746644,0.00013160463,0.0000649529,0.0016095866,0.000020077403,0.0005206528,0.000019047053,0.000019506588,0.00014811571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974386,0.0005920322,0.0007051192,0.00040105064,0.00049799023,0.00036518183],"domain_scores_gemma":[0.9959835,0.0018073694,0.00067018915,0.0006422571,0.0007905821,0.00010612382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058104575,0.00023881542,0.0013032288,0.0000961719,0.0000942719,0.00001047052,0.0003442306,0.000061940635,0.00016606139],"category_scores_gemma":[0.00059439795,0.000117782736,0.00026776464,0.002243046,0.00028552336,0.00006034369,0.00025578463,0.00021530029,0.0000012531989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024271324,0.012005131,0.90658104,0.0001675257,0.010298697,0.0010079062,0.008773642,0.0011588897,0.010435231,0.00010206539,0.00018300477,0.025015552],"study_design_scores_gemma":[0.025937019,0.013290555,0.9026872,0.00034953083,0.0077263783,0.000061896455,0.00978607,0.00040871245,0.03853356,0.000010675455,0.0009419775,0.00026645613],"about_ca_topic_score_codex":0.004993545,"about_ca_topic_score_gemma":0.016703513,"teacher_disagreement_score":0.028098328,"about_ca_system_score_codex":0.00015833821,"about_ca_system_score_gemma":0.0010486402,"threshold_uncertainty_score":0.93209517},"labels":[],"label_agreement":null},{"id":"W3185053527","doi":"10.1016/j.annonc.2021.05.600","title":"MO14-2 KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"KRAS; Cancer research; Phosphorylation; Pancreatic cancer; GTPase; Cancer; MAPK/ERK pathway; Mutation; Signal transduction; Biology; Medicine; Cell biology; Genetics; Gene; Colorectal cancer","score_opus":0.03448340616863838,"score_gpt":0.3354783914600975,"score_spread":0.3009949852914591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185053527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777153,0.016587872,0.00032971005,0.004545588,0.0001571057,0.00028278062,0.00011854579,0.000005045283,0.00025802865],"genre_scores_gemma":[0.9972108,0.0010174246,0.000834232,0.00055653416,0.00008764645,0.00003348602,0.00010476168,0.000010897028,0.00014423062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912333,0.00011226086,0.0002789227,0.00023179493,0.000120612014,0.00013307529],"domain_scores_gemma":[0.99911463,0.000049689723,0.00021376615,0.00023002157,0.00034881462,0.00004307057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026243366,0.00009166674,0.00016293362,0.000031859083,0.00004858089,0.000007416422,0.00007960508,0.00012482729,0.000026597065],"category_scores_gemma":[0.00022784463,0.00007963861,0.000046007506,0.0001353319,0.000115721,0.000007189617,0.00008311216,0.000045740155,0.0000010670237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033764468,0.0000493143,0.0001864262,0.000033247532,0.00004297628,0.0000017174478,0.00015558282,0.0004207629,0.9730869,0.0006667852,0.0073183905,0.017700229],"study_design_scores_gemma":[0.0002998032,0.00065118796,0.010785598,0.000027629365,0.000022470427,0.0000033659492,0.00014771431,0.000031366624,0.9682368,0.00048958533,0.019224823,0.00007964692],"about_ca_topic_score_codex":0.0001630577,"about_ca_topic_score_gemma":0.0003366046,"teacher_disagreement_score":0.019495463,"about_ca_system_score_codex":0.000014774891,"about_ca_system_score_gemma":0.0001982636,"threshold_uncertainty_score":0.3247568},"labels":[],"label_agreement":null},{"id":"W3185775252","doi":"10.1016/j.annonc.2021.05.225","title":"P-170 Assessment of long-term outcomes and predictive factors of malignancy in branch-duct intraductal papillary mucinous neoplasms: A retrospective study in a Canadian referral center","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Malignancy; Single Center; Retrospective cohort study; Dysplasia; Incidence (geometry); Referral; Watchful waiting; Radiology; Internal medicine; General surgery; Cancer","score_opus":0.08907216606946709,"score_gpt":0.41606696535198595,"score_spread":0.32699479928251884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185775252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435675,0.00069285254,0.0000029586486,0.0026333206,0.00018111593,0.00040658726,0.00008137169,0.0000048056777,0.001640245],"genre_scores_gemma":[0.9988679,0.00056659506,0.00007320686,0.00038059428,0.000020401863,0.000016532442,0.000029268434,0.000009851747,0.00003559073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826336,0.0002935108,0.0005910967,0.000315756,0.00019262145,0.00034368457],"domain_scores_gemma":[0.9990375,0.00017448289,0.00019366773,0.00020062231,0.00023881406,0.00015489037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004442426,0.00015938382,0.0011044584,0.00031327287,0.000020267396,0.0000015328089,0.00006576521,0.00013975702,0.00003667149],"category_scores_gemma":[0.0005622058,0.00013183497,0.000070816095,0.00024479438,0.00036061308,0.000044818396,0.00007138975,0.00033162851,1.8997545e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010948393,0.0015093614,0.9871877,0.00013129722,0.0002526061,0.0015697392,0.0070163324,9.2599123e-7,0.00031888485,0.000024331512,0.000109113236,0.001770251],"study_design_scores_gemma":[0.002822808,0.0043217246,0.9897759,0.00023030235,0.00006268199,0.00010252922,0.002058537,0.0000064078745,0.00045963062,0.00006569065,0.000013345583,0.00008045311],"about_ca_topic_score_codex":0.019687552,"about_ca_topic_score_gemma":0.15085867,"teacher_disagreement_score":0.13117112,"about_ca_system_score_codex":0.0001224133,"about_ca_system_score_gemma":0.0008105624,"threshold_uncertainty_score":0.9868404},"labels":[],"label_agreement":null},{"id":"W3185843799","doi":"10.1016/j.annonc.2021.05.108","title":"P-53 Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Hazard ratio; Confidence interval; Oncology; Cochrane Library; Neuroendocrine tumors; Surgery","score_opus":0.2352545773798222,"score_gpt":0.4795689165910447,"score_spread":0.24431433921122253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185843799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015464904,0.98744315,0.000005102233,0.0016505106,0.000033696215,0.010394198,0.00022813243,0.000045778714,0.00004479744],"genre_scores_gemma":[0.00014774794,0.9941311,0.0002884101,0.00065713184,0.00001923866,0.0035834615,0.00033947514,0.00011745622,0.000715963],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9925569,0.002369221,0.0027320578,0.0009854111,0.00048726975,0.0008690837],"domain_scores_gemma":[0.99141306,0.0050136363,0.0015425946,0.0010634214,0.0006165977,0.000350679],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0007011018,0.0007357424,0.021936985,0.0013327057,0.000033007047,0.000020629377,0.00036537385,0.00004444081,0.00010798395],"category_scores_gemma":[0.015555168,0.00048662155,0.0035027005,0.0019888165,0.00019438377,0.000099229386,0.0002489534,0.0007321726,0.0000036662104],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004455493,0.00040014536,0.000048244463,0.92328227,0.070743576,0.003899269,0.000010379552,5.114356e-7,3.5493855e-7,0.000020451582,0.0008816853,0.00066856825],"study_design_scores_gemma":[0.00061357504,0.004095683,0.000009759546,0.06763351,0.85150176,0.0034323074,0.000040400882,0.000003583001,0.000005488418,0.000011897964,0.072404064,0.00024795893],"about_ca_topic_score_codex":0.00004418174,"about_ca_topic_score_gemma":0.00017798935,"teacher_disagreement_score":0.85564876,"about_ca_system_score_codex":0.00008549454,"about_ca_system_score_gemma":0.0005775422,"threshold_uncertainty_score":0.99975854},"labels":[],"label_agreement":null},{"id":"W3187019998","doi":"10.1016/j.annonc.2021.05.051","title":"SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cancer Research UK","keywords":"Medicine; Ipilimumab; Nivolumab; KRAS; Internal medicine; Microsatellite instability; Clinical endpoint; Colorectal cancer; Cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Immunotherapy","score_opus":0.03221800357437433,"score_gpt":0.31440067507297825,"score_spread":0.28218267149860393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187019998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930725,0.0027947908,0.0000050411095,0.0006258035,0.00080424966,0.0016383475,0.00043029446,0.00009764805,0.0005312976],"genre_scores_gemma":[0.99564046,0.0009331506,0.0016207489,0.0006558569,0.000051328072,0.0002077985,0.0005311299,0.000081027545,0.0002785188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959048,0.00047154166,0.0011330433,0.0010174874,0.00061835715,0.0008547411],"domain_scores_gemma":[0.99707454,0.0003393083,0.00047913202,0.0007123888,0.0011050563,0.00028957377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045767718,0.00047770905,0.0016344326,0.0002182878,0.00008351826,0.000024494791,0.00023716055,0.00031492102,0.000627313],"category_scores_gemma":[0.00037419546,0.00042082704,0.00029989166,0.00086499366,0.00046994508,0.00010468527,0.00019420465,0.00047356842,0.000037089732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03872641,0.007619551,0.8580167,0.0012581414,0.0020716034,0.00088028633,0.012260756,0.0006787409,0.04176338,0.00003701957,0.0034454416,0.033241928],"study_design_scores_gemma":[0.053965252,0.01703703,0.65891165,0.0015292915,0.0009922722,0.00004914183,0.0015425768,0.00037835244,0.25379875,0.0002713776,0.010449048,0.0010752607],"about_ca_topic_score_codex":0.0050583873,"about_ca_topic_score_gemma":0.011341759,"teacher_disagreement_score":0.21203537,"about_ca_system_score_codex":0.0009104421,"about_ca_system_score_gemma":0.0027177858,"threshold_uncertainty_score":0.99982435},"labels":[],"label_agreement":null},{"id":"W3190813322","doi":"10.1016/j.annonc.2021.05.033","title":"SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"Merck Sharp and Dohme; National Cancer Institute; Incyte; Sanofi; Merck; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Endometrial cancer; Internal medicine; Oncology; Cohort; Discontinuation; Immunohistochemistry; Cancer; Clinical endpoint; Colorectal cancer; Progressive disease; Clinical trial; Disease","score_opus":0.04539895578421938,"score_gpt":0.36586508245692106,"score_spread":0.3204661266727017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190813322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906635,0.0018079554,0.0000030372817,0.0024161632,0.0013691619,0.0009989496,0.00013711627,0.00000994453,0.002594156],"genre_scores_gemma":[0.99867713,0.0002684353,0.000046853347,0.0005626739,0.000060780105,0.000039701485,0.00001791012,0.000016393578,0.0003101267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678326,0.00072232774,0.001113206,0.0003728186,0.00072308624,0.0002853117],"domain_scores_gemma":[0.99582547,0.0011829262,0.0008823623,0.0013472878,0.0007067848,0.00005517342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001354363,0.00018510451,0.001207429,0.00014047386,0.00010051425,0.0000049847904,0.00053759594,0.00019170881,0.0007839426],"category_scores_gemma":[0.0016447549,0.000098086944,0.0009502258,0.0023733752,0.00059758214,0.000014520927,0.00039024095,0.00037272097,0.0000023729335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015268215,0.0018306025,0.89914364,0.00004029883,0.01751654,0.000025428211,0.009279977,0.0046022953,0.054630395,0.000020075788,0.008581755,0.0028021731],"study_design_scores_gemma":[0.002388312,0.0016559446,0.8781542,0.0000634589,0.004324453,0.000006061438,0.0029730278,0.0004974729,0.107818335,0.00005320309,0.0019707782,0.00009473802],"about_ca_topic_score_codex":0.0044358904,"about_ca_topic_score_gemma":0.002954613,"teacher_disagreement_score":0.053187944,"about_ca_system_score_codex":0.00017040777,"about_ca_system_score_gemma":0.0015258307,"threshold_uncertainty_score":0.8583622},"labels":[],"label_agreement":null},{"id":"W3191123002","doi":"10.1016/j.annonc.2021.05.032","title":"SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Discontinuation; Quality of life (healthcare); Cohort; Internal medicine; Clinical endpoint; Population; Microsatellite instability; Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Cohort study; Phases of clinical research; Clinical trial","score_opus":0.0746482828026317,"score_gpt":0.37942889100283156,"score_spread":0.30478060820019987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191123002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928785,0.0010252723,0.000005338881,0.0026886754,0.0001721627,0.0024972074,0.0005428572,0.00003862177,0.0001513523],"genre_scores_gemma":[0.99747777,0.00008985696,0.0008014923,0.0010426978,0.000023236926,0.000090217574,0.00040038908,0.00003222061,0.000042090032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523634,0.0009613372,0.0021945427,0.00069908274,0.0004309697,0.0004777511],"domain_scores_gemma":[0.9952035,0.0013886092,0.001093343,0.0008839833,0.0012680908,0.00016246072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014883069,0.00026473872,0.0015460533,0.000091018446,0.00007761657,0.0000062027775,0.00019199828,0.00019516193,0.000030007706],"category_scores_gemma":[0.0025658756,0.00019026094,0.00019018605,0.00056403485,0.00032199887,0.000040769195,0.000112425645,0.00030770284,0.0000021343928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08760808,0.011857063,0.8679144,0.0003720325,0.0006069484,0.000026793688,0.015189118,0.00077614764,0.0030447212,0.000025157035,0.00074271864,0.011836869],"study_design_scores_gemma":[0.024988446,0.021597046,0.9393751,0.00029027226,0.00006161291,0.0000026942287,0.0024034672,0.000040498988,0.010321837,0.00012817753,0.00061636156,0.0001744663],"about_ca_topic_score_codex":0.0059684734,"about_ca_topic_score_gemma":0.0056136106,"teacher_disagreement_score":0.07146076,"about_ca_system_score_codex":0.00023973393,"about_ca_system_score_gemma":0.0018922149,"threshold_uncertainty_score":0.90225863},"labels":[],"label_agreement":null},{"id":"W3192763781","doi":"10.1016/j.annonc.2021.05.045","title":"SO-21 Impact of timing of perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases: A propensity score matching of the national cancer database","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Propensity score matching; Colorectal cancer; Internal medicine; Perioperative; Chemotherapy; Oncology; Cancer; Malignancy; Stage (stratigraphy); Neoadjuvant therapy; Metastasis; Surgery; Breast cancer","score_opus":0.1225639093181261,"score_gpt":0.3997957706010987,"score_spread":0.2772318612829726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192763781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734265,0.0001757115,0.0000021444368,0.00031926917,0.00005619672,0.0004232094,0.00059308304,0.000002540575,0.0010852125],"genre_scores_gemma":[0.999415,0.00013786444,0.000122441,0.00019013317,0.000014738711,0.000022604407,0.00003460265,0.000009763354,0.00005285961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989193,0.00012321463,0.0002937636,0.00017318774,0.00036194024,0.00012860715],"domain_scores_gemma":[0.99811715,0.00018812939,0.00036507056,0.00011980702,0.0011754561,0.000034393364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017534407,0.0001387086,0.0007461512,0.000051850264,0.000058237652,0.000002425652,0.000066020126,0.000040578943,0.00019399117],"category_scores_gemma":[0.00014004073,0.000073025534,0.00017984555,0.0001729415,0.00034089913,0.00006345095,0.00007484933,0.00009629278,1.5299273e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032070426,0.0015134923,0.98462504,0.00009945696,0.0019035545,0.00000985284,0.0031732996,0.00009730232,0.0024708011,0.000044847286,0.00013404986,0.0027212475],"study_design_scores_gemma":[0.0026927972,0.003741811,0.96469504,0.00020408844,0.0001352369,0.0000020967354,0.0003242037,0.000017188855,0.02808967,0.000005116681,0.000032810658,0.00005994069],"about_ca_topic_score_codex":0.0025756944,"about_ca_topic_score_gemma":0.0021102233,"teacher_disagreement_score":0.02561887,"about_ca_system_score_codex":0.00010636486,"about_ca_system_score_gemma":0.0008635597,"threshold_uncertainty_score":0.38936964},"labels":[],"label_agreement":null},{"id":"W3194633883","doi":"10.1016/j.annonc.2021.06.012","title":"LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; TIGIT; Oncology; Esophageal cancer; Immunotherapy; Internal medicine; Cancer; Lung cancer; Pembrolizumab","score_opus":0.04275491701376318,"score_gpt":0.39406399826764876,"score_spread":0.3513090812538856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194633883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760884,0.0004452782,0.000002632546,0.00085445546,0.000074128046,0.00075113797,0.000019905874,0.0000041285402,0.00023948192],"genre_scores_gemma":[0.99936336,0.00012925865,0.00003075266,0.00034026767,0.000006636006,0.000029023562,0.00002741836,0.0000123319605,0.000060963375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987404,0.00019952902,0.00040701625,0.0001970285,0.0002754184,0.00018062687],"domain_scores_gemma":[0.9991036,0.00005995681,0.00027264212,0.00023837319,0.00029846185,0.00002698899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021396129,0.0001148769,0.00051214104,0.00013751605,0.000021943044,0.000003618932,0.00008916306,0.000046572088,0.00007437579],"category_scores_gemma":[0.000027573378,0.00007290869,0.00004321725,0.00065779523,0.00013192273,0.000058565856,0.000027927395,0.00013469992,3.662563e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012521063,0.015539533,0.91977423,0.00011115815,0.00044522007,0.00016339101,0.002372699,0.000051671428,0.0014138215,0.000019118832,0.000119616474,0.04746845],"study_design_scores_gemma":[0.05133692,0.014154115,0.92803407,0.00022936979,0.000087795146,0.000008417771,0.00076587044,0.000029542216,0.0050431723,0.00001425937,0.00022015322,0.000076290395],"about_ca_topic_score_codex":0.0011213184,"about_ca_topic_score_gemma":0.0025952503,"teacher_disagreement_score":0.04739216,"about_ca_system_score_codex":0.00007847723,"about_ca_system_score_gemma":0.0005305675,"threshold_uncertainty_score":0.29731303},"labels":[],"label_agreement":null},{"id":"W3195858209","doi":"10.1016/j.annonc.2021.05.110","title":"P-55 Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Sanofi; Genentech; F. Hoffmann-La Roche; Roche; Pfizer","keywords":"Medicine; Regorafenib; Colorectal cancer; Clinical trial; Internal medicine; Oncology; Randomized controlled trial; Propensity score matching; Cancer","score_opus":0.30321315312845115,"score_gpt":0.4655497599152947,"score_spread":0.16233660678684353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195858209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629365,0.013413759,0.00071053207,0.01430586,0.004235376,0.0028818054,0.00064880884,0.000024178169,0.0008431723],"genre_scores_gemma":[0.9948537,0.00081177324,0.0013918761,0.0009803105,0.0013121286,0.00035691672,0.000054457447,0.000022359864,0.00021649447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99833214,0.00016423222,0.00056832365,0.000380917,0.00021946755,0.0003349412],"domain_scores_gemma":[0.99686897,0.0018998865,0.00034993218,0.0003366441,0.00046272652,0.000081865735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005743649,0.0001734927,0.0010123915,0.000044714176,0.00017717047,0.000011413551,0.00016658801,0.00006144381,0.00015973482],"category_scores_gemma":[0.0014887124,0.000117291616,0.00023764369,0.00013761564,0.00019300556,0.000060840935,0.00013319319,0.00015667218,0.0000011581651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7644726,0.001524858,0.0005467523,0.000097750504,0.0049678194,0.00035210353,0.000321467,0.000042251508,0.0029106573,0.0002349195,0.032498665,0.19203015],"study_design_scores_gemma":[0.72990423,0.017893862,0.0002548055,0.00007285581,0.004925255,0.00047431284,0.0011353202,0.0044276007,0.0053070057,0.0003585922,0.2349225,0.00032363593],"about_ca_topic_score_codex":0.0007063954,"about_ca_topic_score_gemma":0.0004442087,"teacher_disagreement_score":0.20242383,"about_ca_system_score_codex":0.00034367834,"about_ca_system_score_gemma":0.0015491946,"threshold_uncertainty_score":0.47830135},"labels":[],"label_agreement":null},{"id":"W3196898938","doi":"10.1016/j.annonc.2021.08.2151","title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute, Cairo University; Fiona and Stanley Druckenmiller Center for Lung Cancer Research; Parker Institute for Cancer Immunotherapy; National Cancer Institute; Damon Runyon Cancer Research Foundation","keywords":"Medicine; Blockade; Immunotherapy; Clinical trial; Lung cancer; Oncology; Cancer; Disease; Internal medicine; Receptor","score_opus":0.07092507640607015,"score_gpt":0.3939201297053346,"score_spread":0.3229950532992644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196898938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918396,0.0028120088,0.00007969408,0.0021127209,0.00014129697,0.00041238952,0.000034108696,0.000004894204,0.0025632752],"genre_scores_gemma":[0.9880902,0.0023958343,0.005163957,0.003990315,0.000025281759,0.000049399285,0.00003028578,0.000018096936,0.00023659617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986112,0.0001494693,0.00065998983,0.00022026032,0.0001631252,0.00019592754],"domain_scores_gemma":[0.99879736,0.00017865913,0.00028713368,0.00025482802,0.000426075,0.000055928802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004358231,0.000107926615,0.0005942288,0.00010460175,0.000015011076,0.0000022938118,0.00007759835,0.0000886095,0.00018547528],"category_scores_gemma":[0.000047997055,0.00009044359,0.00011980954,0.00037537378,0.00010190727,0.00003458717,0.00001863317,0.00006701776,0.0000014659964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06399897,0.0051958347,0.8172999,0.00068024226,0.0010954762,0.000094685114,0.0015507673,0.00001232883,0.029267346,0.000080794845,0.006629997,0.074093655],"study_design_scores_gemma":[0.016121913,0.0046305275,0.9454108,0.0005924973,0.00009807263,0.0000018288297,0.00017144125,0.000004653836,0.023938034,0.000066347566,0.008820596,0.00014327891],"about_ca_topic_score_codex":0.00014115557,"about_ca_topic_score_gemma":0.0007950891,"teacher_disagreement_score":0.12811092,"about_ca_system_score_codex":0.000057676647,"about_ca_system_score_gemma":0.00065698544,"threshold_uncertainty_score":0.36881825},"labels":[],"label_agreement":null},{"id":"W3197269503","doi":"10.1016/j.annonc.2021.09.001","title":"The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews","year":2021,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Public Health Ontario; University of Toronto; University of Calgary","funders":"National Health and Medical Research Council","keywords":"Telemedicine; CINAHL; Psychosocial; Medicine; Survivorship curve; Health care; Psychological intervention; MEDLINE; Systematic review; Telehealth; Nursing; Family medicine; Cancer; Psychiatry","score_opus":0.43616359191399634,"score_gpt":0.5057656351647662,"score_spread":0.06960204325076991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197269503","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011504686,0.99391234,9.2895526e-8,0.0005292942,0.00039519562,0.0034768314,0.00015316653,0.0000059895515,0.00037661436],"genre_scores_gemma":[0.00095211074,0.9979885,0.000007665121,0.000090569025,0.00009637927,0.00065694086,0.000104860235,0.000033343793,0.00006963862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942525,0.0023921665,0.0022588845,0.00044337026,0.0003323267,0.00032076833],"domain_scores_gemma":[0.9946,0.0021975874,0.0014710857,0.0009423543,0.0006299985,0.00015897657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021138377,0.00044987074,0.0076502813,0.0002275249,0.00002438575,0.0000027740018,0.00024862814,0.00040364376,0.00003787072],"category_scores_gemma":[0.0008853206,0.0002513935,0.00070271903,0.00037637723,0.00027495844,0.00002936094,0.0000794751,0.00027209494,0.0000012613282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039182414,0.00016555321,0.00003788556,0.35975504,0.00036068106,0.000019709445,0.0030425664,4.501701e-8,5.1160345e-7,0.00018949935,0.000030050169,0.6363593],"study_design_scores_gemma":[0.0006301483,0.0040014577,0.00023153605,0.19054306,0.0018261306,0.000041736395,0.0035055203,1.2867697e-7,0.0000060364946,0.000005677391,0.7990506,0.00015792147],"about_ca_topic_score_codex":0.006502862,"about_ca_topic_score_gemma":0.073196,"teacher_disagreement_score":0.7990206,"about_ca_system_score_codex":0.00020510559,"about_ca_system_score_gemma":0.001313523,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W3197440330","doi":"10.1016/j.annonc.2021.05.164","title":"P-109 CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge™) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Cambridge University Hospitals; University of Oxford; University of Cambridge; Cancer Research UK; Bausch Health; Deciphera Pharmaceuticals; IFM Therapeutics; Jazz Pharmaceuticals; Abbott Laboratories","keywords":"Medicine; Dysphagia; Adverse effect; Chemoradiotherapy; Cancer; Atypia; Surgery; Internal medicine; Pathology","score_opus":0.12542297778021036,"score_gpt":0.4733588699697158,"score_spread":0.3479358921895055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197440330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990566,0.0058864783,0.000016034764,0.0008187761,0.000058120182,0.003086393,0.000116258954,0.000007701726,0.0001045897],"genre_scores_gemma":[0.99838585,0.00016912913,0.0004861638,0.00031320186,0.000034017718,0.0004845068,0.000092161914,0.00001558915,0.000019411802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771386,0.00047457323,0.0004655268,0.0004283537,0.00057123986,0.0003464716],"domain_scores_gemma":[0.9968491,0.00029572358,0.00022293748,0.00037633826,0.002154132,0.00010172188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012615889,0.00016831578,0.0008282031,0.00010758839,0.00003404431,0.0000044239923,0.00010734298,0.00011262757,0.00019341192],"category_scores_gemma":[0.00036892676,0.00012708927,0.0001013287,0.000357888,0.00011917238,0.000059960686,0.000037468715,0.00015711137,8.302704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010464104,0.007011667,0.9538712,0.00014900809,0.00041527415,0.000071384144,0.0004945633,0.00004412926,0.00057592796,0.0000036682304,0.000037284037,0.026861802],"study_design_scores_gemma":[0.02531584,0.027455604,0.9420415,0.000051189818,0.00008629638,0.0000032846172,0.00018301529,0.00012069211,0.0046163467,0.000035595367,0.000018813813,0.00007180941],"about_ca_topic_score_codex":0.0006839634,"about_ca_topic_score_gemma":0.0030148958,"teacher_disagreement_score":0.026789991,"about_ca_system_score_codex":0.0004353492,"about_ca_system_score_gemma":0.0016588457,"threshold_uncertainty_score":0.518255},"labels":[],"label_agreement":null},{"id":"W3198389785","doi":"10.1016/j.annonc.2021.08.2155","title":"Precision guidelines for soft tissue and visceral sarcomas: the evidence, expert experience and ensuring optimal care for rare cancers, a 2021 update from ESMO–EURACAN–GENTURIS","year":2021,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Soft tissue sarcoma; Multidisciplinary approach; Intensive care medicine; Sarcoma; Family medicine; Oncology; Pathology","score_opus":0.1267830966803016,"score_gpt":0.4641384496568448,"score_spread":0.3373553529765432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198389785","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.095511176,0.67786795,0.00026888517,0.019480469,0.20040482,0.0038416805,0.0025562276,0.00003105385,0.000037711958],"genre_scores_gemma":[0.03840208,0.30870843,0.030918876,0.0032488473,0.6090675,0.0057408134,0.0032978668,0.00019560356,0.0004199962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974618,0.00012382724,0.0007304348,0.00084755424,0.0004214282,0.00041493756],"domain_scores_gemma":[0.9925789,0.0043720608,0.00041491474,0.00047860894,0.001984444,0.00017103693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031584754,0.00041387117,0.0012459408,0.00009201372,0.00021910608,0.000055639557,0.00021883115,0.00064130424,0.000085890046],"category_scores_gemma":[0.0035506426,0.00028954726,0.00022749201,0.00008465154,0.00020566072,0.00011446093,0.00023868955,0.00024878193,6.9675446e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010971437,0.0000960634,0.00040289026,0.0001856976,0.0002968512,0.00007675154,0.0029831084,0.0000069053294,0.00016643305,0.00000282709,0.74897087,0.24571446],"study_design_scores_gemma":[0.0024795316,0.0023118893,0.0003628516,0.0017365185,0.0003571271,0.00001616908,0.0029699772,0.000082521045,0.0055971015,0.00003623894,0.98379606,0.00025399833],"about_ca_topic_score_codex":0.0020150575,"about_ca_topic_score_gemma":0.0005847811,"teacher_disagreement_score":0.40866268,"about_ca_system_score_codex":0.00015224278,"about_ca_system_score_gemma":0.0009250909,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W3200214671","doi":"10.1016/j.annonc.2021.09.021","title":"Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; University of Texas MD Anderson Cancer Center; EMD Serono; Genentech; Astellas Pharma; Ribon Therapeutics; National Institutes of Health; Innovent Biologics; Sanofi; Exelixis; GlaxoSmithKline; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tumor-infiltrating lymphocytes; Medicine; Flow cytometry; CD8; Cancer research; CD3; Pathology; Lung cancer; T cell; Immune system; Immunology","score_opus":0.05903546487884821,"score_gpt":0.39262687515047506,"score_spread":0.33359141027162686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200214671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140763,0.002376054,0.00001850687,0.0027807502,0.00020026979,0.00024248028,0.0000323977,0.000021846143,0.0029200534],"genre_scores_gemma":[0.9941288,0.001023985,0.00017638867,0.003949107,0.00007589459,0.000039905186,0.00003452944,0.000021236763,0.0005501383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830043,0.00021616243,0.0007027841,0.0002933297,0.00016637254,0.00032091208],"domain_scores_gemma":[0.9983252,0.0006343699,0.00047503863,0.00020675165,0.00026969367,0.000088893605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065755314,0.00016730455,0.0009543993,0.00007086381,0.000037088943,0.000008126803,0.0000905619,0.00017735195,0.00022195389],"category_scores_gemma":[0.00035044955,0.00012620151,0.00020987245,0.00030863206,0.000108254935,0.00003423076,0.00003619397,0.00021828568,0.000001716754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025807132,0.0008202334,0.9825077,0.00010072655,0.00051680946,0.0005851178,0.00019177863,0.000011202898,0.0008848589,0.0000016983956,0.0012627053,0.01053647],"study_design_scores_gemma":[0.014728447,0.0011755863,0.9729438,0.0005701095,0.0001440719,0.000029940305,0.0004463978,0.00044934364,0.004540428,0.0000053374765,0.004791262,0.0001752758],"about_ca_topic_score_codex":0.0006202799,"about_ca_topic_score_gemma":0.008509509,"teacher_disagreement_score":0.012147735,"about_ca_system_score_codex":0.00013251408,"about_ca_system_score_gemma":0.0013302454,"threshold_uncertainty_score":0.51463485},"labels":[],"label_agreement":null},{"id":"W3201683535","doi":"10.1016/j.annonc.2021.08.1386","title":"1002P Impact of pharmacodynamic biomarkers in phase I immune-oncology trials","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacodynamics; Oncology; Internal medicine; Clinical trial; Immune system; Pharmacokinetics; Immunology","score_opus":0.08272059419594574,"score_gpt":0.4736922243069023,"score_spread":0.39097163011095654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201683535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869446,0.00751257,0.00011616823,0.0006573198,0.00033920052,0.00020544672,0.00026110932,0.0000028736642,0.0039607147],"genre_scores_gemma":[0.989631,0.009199403,0.00036775126,0.00035068856,0.00012803054,0.00001991879,0.00023598777,0.00001799738,0.00004922061],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792916,0.00043669055,0.00095262146,0.000297122,0.00007851901,0.00030590937],"domain_scores_gemma":[0.99845684,0.00028301487,0.0005499031,0.00032321835,0.00029532664,0.00009172453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012597833,0.00016071017,0.0008578364,0.00013101098,0.000017656597,0.000004127545,0.00019833838,0.0002980136,0.00020024038],"category_scores_gemma":[0.0011775173,0.00015665729,0.00046087103,0.00020689477,0.00016712629,0.0000036256617,0.0001498217,0.00010358605,0.000003284748],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015086563,0.0011410803,0.00088940165,0.000023627652,0.0005887408,0.00006216776,0.00006874051,0.0002696512,0.8834835,0.000054413795,0.0043308525,0.10757916],"study_design_scores_gemma":[0.008860549,0.007983853,0.003350936,0.000024075782,0.00009029123,0.00006455983,0.00015930364,0.00019890252,0.90860766,0.00031828636,0.07010643,0.00023515841],"about_ca_topic_score_codex":0.00037527943,"about_ca_topic_score_gemma":0.00024097615,"teacher_disagreement_score":0.107343994,"about_ca_system_score_codex":0.000062049316,"about_ca_system_score_gemma":0.0016742382,"threshold_uncertainty_score":0.6388299},"labels":[],"label_agreement":null},{"id":"W3201697427","doi":"10.1016/j.annonc.2021.08.1225","title":"783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Daiichi-Sankyo; Novartis; Regeneron Pharmaceuticals; Eisai; Sanofi; Bayer","keywords":"Medicine; Quality of life (healthcare); Cervical carcinoma; Oncology; Internal medicine; Cervical cancer; Nursing; Cancer","score_opus":0.07336111082192427,"score_gpt":0.38140641411518517,"score_spread":0.3080453032932609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201697427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962381,0.00085268717,0.000007089707,0.0011074506,0.00013475413,0.00027685126,0.00035242914,0.000008331539,0.0010223052],"genre_scores_gemma":[0.998907,0.00018323884,0.00014405789,0.0004453527,0.000042704047,0.000009010161,0.00022309416,0.000017073156,0.00002844923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739677,0.00042844005,0.0011205464,0.00040500032,0.00036930823,0.0002799668],"domain_scores_gemma":[0.9976134,0.00078550697,0.00061100855,0.00039174652,0.00044518037,0.00015317799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063513295,0.00020637043,0.0010457877,0.00016660092,0.000027882228,0.000004803001,0.00008999553,0.00017558872,0.00019325629],"category_scores_gemma":[0.00053774676,0.00014753081,0.00020336983,0.00040053873,0.00024679714,0.00006195,0.00006035383,0.00027646092,0.0000017408246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12429953,0.0044587813,0.80569583,0.0003074933,0.0010242178,0.00003052279,0.0020694647,0.000021687933,0.003216925,0.00002620909,0.000917142,0.057932205],"study_design_scores_gemma":[0.021944875,0.017754244,0.95749754,0.00029101412,0.00008581556,0.000005293182,0.0004102008,0.0000394307,0.0013754168,0.000041255455,0.00041793543,0.00013697278],"about_ca_topic_score_codex":0.0032764296,"about_ca_topic_score_gemma":0.00055784825,"teacher_disagreement_score":0.15180174,"about_ca_system_score_codex":0.00011941682,"about_ca_system_score_gemma":0.0007213706,"threshold_uncertainty_score":0.6016132},"labels":[],"label_agreement":null},{"id":"W3201711148","doi":"10.1016/j.annonc.2021.08.1515","title":"1406P Survival outcomes in older adults with metastatic gastric and esophageal carcinoma receiving palliative chemotherapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Palliative chemotherapy; Chemotherapy; Oncology; Internal medicine; Carcinoma; Gastric carcinoma; Palliative care; Chemotherapy regimen; Cancer; Nursing","score_opus":0.051994736549696996,"score_gpt":0.35630927910549975,"score_spread":0.30431454255580276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201711148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912206,0.0013729171,0.000039396386,0.0047038235,0.00006632922,0.00025765746,0.000014905775,0.000008738283,0.002315642],"genre_scores_gemma":[0.99352664,0.0008937209,0.001951246,0.0031832021,0.000028926703,0.000017493105,0.000025222362,0.000016183783,0.00035739498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988829,0.00013593322,0.0003024615,0.0002757747,0.00015062676,0.00025230082],"domain_scores_gemma":[0.9990906,0.00034223477,0.00013066328,0.00016406541,0.00017312125,0.000099321944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022478779,0.00014271656,0.0007184747,0.00012274554,0.000021704604,0.0000044496646,0.000048099722,0.0000657522,0.00031589728],"category_scores_gemma":[0.00009926837,0.00011328705,0.000059651855,0.0002267879,0.000100763005,0.000069504276,0.000026164327,0.00018315438,0.0000015985684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013843244,0.0004362875,0.91996,0.00022289631,0.00022531183,0.0007889901,0.0034976392,0.000005419917,0.000375124,0.000037527218,0.0002736176,0.072792865],"study_design_scores_gemma":[0.008731295,0.0016676948,0.984983,0.00009046744,0.000040011495,0.00005981286,0.0014266144,0.0000806095,0.0022199836,0.000025690457,0.0005769175,0.000097883516],"about_ca_topic_score_codex":0.00016070258,"about_ca_topic_score_gemma":0.0005203481,"teacher_disagreement_score":0.07269498,"about_ca_system_score_codex":0.000052459985,"about_ca_system_score_gemma":0.00052975473,"threshold_uncertainty_score":0.4619712},"labels":[],"label_agreement":null},{"id":"W3201711247","doi":"10.1016/j.annonc.2021.08.263","title":"1809P Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Medicine; Lung cancer; Immunotherapy; Oncology; Mutation; Cancer research; Cancer; Internal medicine; Colorectal cancer; Biology; Genetics; Gene","score_opus":0.06389037474187814,"score_gpt":0.3823474344286752,"score_spread":0.31845705968679705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201711247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498826,0.0015813467,0.000035506633,0.00063952233,0.00022641616,0.00052100344,0.00001470784,0.0000045489696,0.0019886922],"genre_scores_gemma":[0.9983283,0.0006536102,0.00029453353,0.0005008434,0.000021788957,0.000041681298,0.00006145442,0.000017543172,0.000080228725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985507,0.000298496,0.0004128249,0.00019364717,0.00037772112,0.0001666215],"domain_scores_gemma":[0.99836165,0.00017226108,0.00034597752,0.00019145192,0.0009010322,0.00002760464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010075977,0.00011251974,0.00041263454,0.00014803302,0.000019304513,0.0000031798784,0.000053126583,0.00007350187,0.00034394144],"category_scores_gemma":[0.00007434084,0.000094956755,0.00007236636,0.00034761484,0.000055974175,0.00004786153,0.000008801659,0.00010818049,0.0000011099957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021971593,0.0033573427,0.55250686,0.00046906134,0.0010234384,0.000031644056,0.003825929,0.001154336,0.041712992,0.000020122114,0.00052552245,0.37340114],"study_design_scores_gemma":[0.013881578,0.0036882642,0.9258518,0.0003347858,0.00017153105,0.0000019069394,0.0003047019,0.00044929096,0.054790396,0.000031214753,0.00038224796,0.0001122591],"about_ca_topic_score_codex":0.0006247957,"about_ca_topic_score_gemma":0.00092779484,"teacher_disagreement_score":0.37334496,"about_ca_system_score_codex":0.00015286979,"about_ca_system_score_gemma":0.0009955358,"threshold_uncertainty_score":0.3872224},"labels":[],"label_agreement":null},{"id":"W3201746679","doi":"10.1016/j.annonc.2021.08.112","title":"716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Adjuvant; Placebo; Oncology; Internal medicine; Bladder cancer; Urology; Immunotherapy; Cancer; Pathology; Pembrolizumab","score_opus":0.04872930099097921,"score_gpt":0.36501031612659074,"score_spread":0.3162810151356115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201746679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99147856,0.0013067783,0.0000037368782,0.0007331073,0.00028058505,0.004742793,0.0003799813,0.00004530968,0.0010291409],"genre_scores_gemma":[0.9967375,0.0012385997,0.000033795404,0.0009992741,0.00013867671,0.0005605093,0.00014285107,0.00007777918,0.000071011185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956315,0.00062770315,0.0013145785,0.0009179565,0.00076058187,0.00074763893],"domain_scores_gemma":[0.9958048,0.00029257187,0.0013161376,0.0006592809,0.0016301932,0.00029702668],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040059755,0.0006037061,0.0024913622,0.0002723449,0.00014691825,0.000023627706,0.00026178072,0.0002262684,0.00042337913],"category_scores_gemma":[0.00016904596,0.00047761918,0.0002865498,0.00078829686,0.00019166268,0.00019846416,0.000097954195,0.00042095105,0.000010418547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5783696,0.026017364,0.33429527,0.00031975468,0.0052312124,0.0033863683,0.0075923232,0.0004120468,0.0034855555,0.000015072911,0.00044250023,0.0404329],"study_design_scores_gemma":[0.6998795,0.03084523,0.24249516,0.0007646339,0.00081022154,0.000091048176,0.004472216,0.000018716106,0.019976227,0.00003269172,0.0001832481,0.00043110634],"about_ca_topic_score_codex":0.019348266,"about_ca_topic_score_gemma":0.00696075,"teacher_disagreement_score":0.12150989,"about_ca_system_score_codex":0.00033203547,"about_ca_system_score_gemma":0.0020132214,"threshold_uncertainty_score":0.99976754},"labels":[],"label_agreement":null},{"id":"W3201793261","doi":"10.1016/j.annonc.2021.08.1599","title":"1606P Impact of COVID-19 (SARS-CoV-2, C19) on medical oncologists (MOs) and cancer care: A Canadian Association of Medical Oncologists (CAMO) survey study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Dalhousie University; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Family medicine; Cancer; Virology; Internal medicine; Infectious disease (medical specialty); Disease; Outbreak","score_opus":0.2977935076330029,"score_gpt":0.5768882835966771,"score_spread":0.2790947759636742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201793261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90772116,0.0014384667,0.0000063125426,0.08823881,0.00040734548,0.00076282275,0.00047031263,0.000022840095,0.0009319296],"genre_scores_gemma":[0.9745742,0.0031982607,0.00001964784,0.02175952,0.00019080401,0.00004018649,0.000117173855,0.000026314021,0.000073862735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99361026,0.0019960501,0.0012609767,0.0005652856,0.0017730708,0.0007943721],"domain_scores_gemma":[0.99064595,0.004547229,0.0008828529,0.0004841842,0.0017433099,0.0016964944],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00655793,0.0003059232,0.0018711657,0.00045256922,0.00009803989,0.00000856466,0.00032881188,0.0013143665,0.0007349584],"category_scores_gemma":[0.045258924,0.0002595665,0.0002589312,0.0007367826,0.00038571068,0.000058379508,0.00016249296,0.0008204552,0.0000048800457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015876828,0.002317916,0.8957863,0.0006132233,0.00075088005,0.0016096492,0.0042328937,0.000012754519,0.0003141584,0.00006308338,0.050354004,0.042357493],"study_design_scores_gemma":[0.006820054,0.019193832,0.9434232,0.0002310952,0.00016744142,0.000086023814,0.00104253,0.00004973306,0.0009954802,0.000054860033,0.027723227,0.00021254021],"about_ca_topic_score_codex":0.796807,"about_ca_topic_score_gemma":0.9525761,"teacher_disagreement_score":0.15576912,"about_ca_system_score_codex":0.0047033946,"about_ca_system_score_gemma":0.07818001,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W3201826926","doi":"10.1016/j.annonc.2021.08.953","title":"432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; Microsatellite instability; Medicine; Colorectal cancer; DNA mismatch repair; Oncology; Internal medicine; Cancer research; Cancer; Microsatellite; Immunotherapy; Genetics; Biology","score_opus":0.09913629479024987,"score_gpt":0.3980677324012728,"score_spread":0.2989314376110229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201826926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98759377,0.007461938,0.0001797792,0.0013939244,0.00042746216,0.001316521,0.0006850562,0.0000648582,0.00087666913],"genre_scores_gemma":[0.99144655,0.0014799564,0.004833069,0.00073602854,0.000073410665,0.0003709246,0.00033917508,0.00005571277,0.0006651598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957623,0.00040428792,0.0015344248,0.0009433286,0.0005478937,0.0008077741],"domain_scores_gemma":[0.99523944,0.00092112744,0.0007659215,0.0007837534,0.0020148072,0.00027493818],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009052026,0.00044208692,0.0024140854,0.0005381846,0.00009243875,0.000012789241,0.0002642607,0.00034651044,0.0010571721],"category_scores_gemma":[0.00085534435,0.00040728692,0.0012670971,0.0018959325,0.0005144823,0.00006453114,0.00015701685,0.00029655307,0.0000052277564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048155375,0.013427711,0.21680239,0.0068221525,0.03608653,0.00065787486,0.010245667,0.011363335,0.5326658,0.0010650442,0.010998052,0.11171011],"study_design_scores_gemma":[0.011915414,0.017755024,0.16357198,0.00046622488,0.015263904,0.00020736287,0.00086886506,0.0034795792,0.74759907,0.0006510221,0.037351046,0.0008705434],"about_ca_topic_score_codex":0.0012367014,"about_ca_topic_score_gemma":0.00295746,"teacher_disagreement_score":0.21493328,"about_ca_system_score_codex":0.00040752755,"about_ca_system_score_gemma":0.0020072325,"threshold_uncertainty_score":0.999856},"labels":[],"label_agreement":null},{"id":"W3201833011","doi":"10.1016/j.annonc.2021.08.1686","title":"1714P Edmonton symptom assessment system (ESAS)-total care (TC): Development and psychometric validation in Italian language of ESAS-TC in patients undergoing cancer treatment and follow-up","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Distress; Isolation (microbiology); Psychological distress; Intensive care medicine; Clinical Practice; Physical therapy; Psychiatry; Clinical psychology; Anxiety","score_opus":0.03952874856458448,"score_gpt":0.36965376063009636,"score_spread":0.33012501206551187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201833011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207515,0.005645118,0.000004121828,0.00024227794,0.00030607302,0.00033480418,0.000028570528,0.0000076936485,0.0013561958],"genre_scores_gemma":[0.99877673,0.00068981457,0.00013453091,0.00006555219,0.000025123903,0.00007010142,0.000100815356,0.000012451081,0.00012487613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988029,0.00011889093,0.00042078507,0.00027214826,0.00018999925,0.00019527189],"domain_scores_gemma":[0.999314,0.00010167339,0.00016638161,0.00013924458,0.00019983847,0.00007887599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001666109,0.00013894794,0.0005144345,0.00033749852,0.000021880056,0.0000069623416,0.00003130385,0.00012694027,0.000016767472],"category_scores_gemma":[0.00003357416,0.00012935775,0.000046144894,0.00043047935,0.000028147728,0.000055887736,0.000038786264,0.000078077035,3.4023364e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024218555,0.00037842029,0.80935895,0.00085084897,0.00012753616,0.000041710813,0.017498326,0.000010338674,0.0004003244,0.00004109812,0.000033922937,0.1710163],"study_design_scores_gemma":[0.006857323,0.002056744,0.9533366,0.0007612922,0.00006998438,0.000008632647,0.026012264,0.000014455766,0.010198484,0.0000031587667,0.00054260873,0.00013843057],"about_ca_topic_score_codex":0.0029063358,"about_ca_topic_score_gemma":0.02537426,"teacher_disagreement_score":0.17087789,"about_ca_system_score_codex":0.0006250998,"about_ca_system_score_gemma":0.0006240922,"threshold_uncertainty_score":0.9924101},"labels":[],"label_agreement":null},{"id":"W3201838411","doi":"10.1016/j.annonc.2021.08.1314","title":"904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Adenoid cystic carcinoma; Gamma secretase; Internal medicine; Phases of clinical research; Cancer research; Oncology; Carcinoma; Clinical trial; Genetics","score_opus":0.07139578323044105,"score_gpt":0.38712962376190735,"score_spread":0.3157338405314663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201838411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579,0.0005907796,0.000015804839,0.0009667545,0.00015991945,0.0013289128,0.00023929079,0.000015264926,0.00089324947],"genre_scores_gemma":[0.9980667,0.00015827613,0.0009640073,0.00008430968,0.00010396773,0.00023331262,0.00033859813,0.00002786631,0.000022928018],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709684,0.00042149637,0.0012060303,0.00048867706,0.00040151324,0.00038545168],"domain_scores_gemma":[0.99586904,0.0018316773,0.00096566766,0.00037172067,0.0008047462,0.00015715403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006770448,0.00026995494,0.0012706569,0.00035902672,0.00006565497,0.0000059620684,0.00009197391,0.000111643894,0.00003081901],"category_scores_gemma":[0.0027967892,0.00022790795,0.0001791841,0.00091871375,0.00015475173,0.0001361471,0.00007144069,0.00029904427,0.0000011793854],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46646,0.09462036,0.2571936,0.0023418292,0.005122164,0.010415563,0.02422812,0.00036784908,0.07063956,0.00046997232,0.0016769186,0.06646409],"study_design_scores_gemma":[0.22763865,0.07244873,0.13443391,0.0014522275,0.0010625166,0.0002854793,0.0016430018,0.00034095516,0.5599539,0.00018095074,0.00021560154,0.00034403667],"about_ca_topic_score_codex":0.0007482141,"about_ca_topic_score_gemma":0.0003969318,"teacher_disagreement_score":0.4893144,"about_ca_system_score_codex":0.00012930272,"about_ca_system_score_gemma":0.0018377792,"threshold_uncertainty_score":0.92938167},"labels":[],"label_agreement":null},{"id":"W3201850473","doi":"10.1016/j.annonc.2021.08.1098","title":"585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Abiraterone acetate; Internal medicine; Cancer; Gynecology; Androgen deprivation therapy; Androgen receptor","score_opus":0.08722032634478372,"score_gpt":0.41968051344682533,"score_spread":0.3324601871020416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201850473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954522,0.0007058244,0.000011013038,0.0014092396,0.00009476131,0.001155264,0.0010126989,0.0000038209773,0.00015515552],"genre_scores_gemma":[0.9981415,0.00062430685,0.000097260265,0.00009836368,0.000015128428,0.000076546945,0.00064547715,0.000012885387,0.00028848005],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978444,0.00028256173,0.0008022164,0.00027935562,0.00048824376,0.00030324483],"domain_scores_gemma":[0.9980734,0.000107209504,0.0005098225,0.00038897397,0.00083016953,0.00009042298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041936262,0.00015441158,0.0010445118,0.00022631469,0.00004681538,0.000004696879,0.000116422154,0.00007021416,0.00043462074],"category_scores_gemma":[0.00007825189,0.0000960757,0.00020200279,0.0011171354,0.00029857954,0.000075333024,0.000060348095,0.00014942505,6.997403e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79391813,0.015864486,0.09082303,0.00079118955,0.013323449,0.00032220795,0.006534736,0.0030479736,0.023852034,0.0000745834,0.0008114506,0.050636727],"study_design_scores_gemma":[0.48541072,0.023151262,0.38553056,0.0004816554,0.0062231,0.0000027459098,0.0012749359,0.0006496192,0.09535185,0.00008518133,0.0015388156,0.00029953942],"about_ca_topic_score_codex":0.0020839248,"about_ca_topic_score_gemma":0.0059417584,"teacher_disagreement_score":0.3085074,"about_ca_system_score_codex":0.00012697515,"about_ca_system_score_gemma":0.0016925797,"threshold_uncertainty_score":0.47587922},"labels":[],"label_agreement":null},{"id":"W3201866783","doi":"10.1016/j.annonc.2021.08.089","title":"693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Renal cell carcinoma; Exosome; Biomarker; microRNA; Cancer research; Oncology; Clear cell renal cell carcinoma; Microvesicles; Internal medicine; Immune checkpoint; Immunotherapy; Cancer; Gene","score_opus":0.016378119999405565,"score_gpt":0.2692565105405896,"score_spread":0.252878390541184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201866783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743855,0.0016612444,0.000085040774,0.00015100288,0.000046547644,0.0004636601,0.00008357152,0.0000054324514,0.00006492559],"genre_scores_gemma":[0.9982103,0.000060504848,0.0012516053,0.000075905176,0.00002281426,0.0000402934,0.00017703096,0.00003931703,0.00012221404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976964,0.0006723803,0.00062619016,0.00046110665,0.00022256612,0.0003213497],"domain_scores_gemma":[0.99843365,0.000046392623,0.00039931363,0.0005339448,0.000453863,0.00013284084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040460398,0.00024139174,0.0004693286,0.0001611521,0.000030082178,0.0000076428105,0.000212665,0.00017026339,0.000023832006],"category_scores_gemma":[0.000080318794,0.00019137282,0.0001258591,0.00026573692,0.00014861759,0.000009986742,0.00013280705,0.00009929979,0.0000027304045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029420674,0.0013373467,0.02009768,0.00007822213,0.00010277841,0.00020422213,0.0001481061,0.00013635166,0.94725835,4.0280975e-7,0.00017087269,0.0010449769],"study_design_scores_gemma":[0.006015494,0.0053784335,0.08208558,0.00014658978,0.00003213729,0.000033465545,0.00017102306,0.000007615432,0.9055473,0.0000028220052,0.00038144208,0.00019805491],"about_ca_topic_score_codex":0.000030339308,"about_ca_topic_score_gemma":0.000014959198,"teacher_disagreement_score":0.061987896,"about_ca_system_score_codex":0.000030302786,"about_ca_system_score_gemma":0.00039509175,"threshold_uncertainty_score":0.7803957},"labels":[],"label_agreement":null},{"id":"W3201893135","doi":"10.1016/j.annonc.2021.08.1095","title":"582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Taxane; Population; Cancer; Quality of life (healthcare); Breast cancer","score_opus":0.1432927834102591,"score_gpt":0.4299050447486323,"score_spread":0.28661226133837314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201893135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541295,0.0023755105,2.1649093e-7,0.000977261,0.000023661722,0.0009546196,0.00016315919,0.00000407172,0.00008853244],"genre_scores_gemma":[0.9992473,0.00035333168,0.00004344837,0.00009269078,0.000002515057,0.00004484755,0.00005924329,0.00000822941,0.00014837839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972995,0.00073103874,0.0010147559,0.00026839986,0.00045689603,0.00022941596],"domain_scores_gemma":[0.99770665,0.0002666649,0.0008374761,0.00032541587,0.00076536875,0.000098413024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008023047,0.00012628021,0.0011698015,0.00023023503,0.00004408507,0.0000017147509,0.00006303176,0.00005408389,0.000054746764],"category_scores_gemma":[0.0002384745,0.00007960452,0.0001391554,0.0012072372,0.00026623922,0.000040795963,0.00007188913,0.00013086761,1.0928558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007381424,0.003536442,0.9784033,0.00057531486,0.0033427987,0.000018263569,0.0042431112,0.00021485834,0.0013181933,0.000024375271,0.000109707624,0.00083224976],"study_design_scores_gemma":[0.008002797,0.007196977,0.97942674,0.00013155717,0.0006833965,6.7646255e-7,0.001470256,0.00003893064,0.0029494136,0.000020394968,0.000021169444,0.000057662648],"about_ca_topic_score_codex":0.0060758404,"about_ca_topic_score_gemma":0.030351428,"teacher_disagreement_score":0.024275588,"about_ca_system_score_codex":0.00011048474,"about_ca_system_score_gemma":0.0013866273,"threshold_uncertainty_score":0.9873421},"labels":[],"label_agreement":null},{"id":"W3201907175","doi":"10.1016/j.annonc.2021.08.2086","title":"LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Anastrozole; Medicine; Palbociclib; Gynecology; Breast cancer; Interim analysis; Oncology; Internal medicine; Letrozole; HER2 negative; Cancer; Tamoxifen; Metastatic breast cancer; Clinical trial","score_opus":0.039736183941007086,"score_gpt":0.37963328158910387,"score_spread":0.3398970976480968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201907175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986185,0.00041939903,0.00003496065,0.005686365,0.00012376733,0.0023452507,0.0011798306,0.000033641096,0.00031493668],"genre_scores_gemma":[0.99655277,0.00026847157,0.0004536032,0.0014602052,0.00006823347,0.00057822146,0.00013528578,0.0000815228,0.00040166877],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99519056,0.0010727246,0.0013179901,0.0009293685,0.00058383157,0.00090553495],"domain_scores_gemma":[0.99575704,0.00037541625,0.00092907785,0.0008859661,0.0017183262,0.00033419553],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007000038,0.00060708076,0.0027077287,0.00041026162,0.00018986956,0.000038706497,0.0006837357,0.00021805325,0.0013321463],"category_scores_gemma":[0.00013413887,0.00042980778,0.00014682423,0.0026456022,0.00073792296,0.0003399477,0.00041930124,0.00055357575,0.0000036769654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38978308,0.03527281,0.12977698,0.00014383493,0.030210208,0.0010860093,0.027886704,0.0013383604,0.25073195,0.000050254297,0.0002507862,0.13346902],"study_design_scores_gemma":[0.2526017,0.08130139,0.57801634,0.0008922659,0.0038874357,0.00023411433,0.014302449,0.00023981066,0.0660727,0.00004013128,0.0014828147,0.0009288044],"about_ca_topic_score_codex":0.008085876,"about_ca_topic_score_gemma":0.008298001,"teacher_disagreement_score":0.4482394,"about_ca_system_score_codex":0.00044940272,"about_ca_system_score_gemma":0.0016424113,"threshold_uncertainty_score":0.99981534},"labels":[],"label_agreement":null},{"id":"W3201918452","doi":"10.1016/j.annonc.2021.08.1117","title":"604P Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Androgen receptor; Metastasis; Cancer","score_opus":0.047387716425435746,"score_gpt":0.3588832135497775,"score_spread":0.3114954971243417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201918452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066186,0.0026992385,0.0000030304097,0.0033947087,0.00007764323,0.0010286358,0.00026905103,0.000019051144,0.0018467623],"genre_scores_gemma":[0.9950701,0.0028815165,0.00035310345,0.00016473945,0.0000582107,0.00027764167,0.0003173349,0.000031050742,0.0008462802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982623,0.00019313025,0.00044151116,0.00040787068,0.0002611765,0.00043402606],"domain_scores_gemma":[0.99882776,0.00009985662,0.0001947636,0.0002136682,0.0004918917,0.0001720819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003233916,0.00019664459,0.00054458744,0.00024482992,0.000053342574,0.000011065557,0.00005883505,0.0001146874,0.0001494877],"category_scores_gemma":[0.000053240623,0.00014666529,0.00007793407,0.0006114519,0.00023324684,0.00010535217,0.000035578985,0.00019125616,0.000008384153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03746131,0.002391813,0.16641757,0.00066768925,0.0028935769,0.0053326013,0.004568613,0.00014022723,0.6937176,0.000022153023,0.004963425,0.081423394],"study_design_scores_gemma":[0.01672887,0.016924528,0.13253209,0.0009439152,0.00026950554,0.00014453073,0.0036361688,0.00020998792,0.81848526,0.000089248264,0.009675031,0.00036089533],"about_ca_topic_score_codex":0.0007699624,"about_ca_topic_score_gemma":0.0012551013,"teacher_disagreement_score":0.12476761,"about_ca_system_score_codex":0.00035846475,"about_ca_system_score_gemma":0.0021602802,"threshold_uncertainty_score":0.59808373},"labels":[],"label_agreement":null},{"id":"W3201926698","doi":"10.1016/j.annonc.2021.08.1428","title":"1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; McGill University; Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Melanoma; Oncology; Immune checkpoint; Cancer research; Wild type; Mutation; Internal medicine; Immunotherapy; Genetics; Cancer; Mutant; Gene","score_opus":0.018644000686201933,"score_gpt":0.28473757577301784,"score_spread":0.2660935750868159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201926698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960282,0.00041722434,0.000018589577,0.00082265236,0.00009602936,0.00011830327,0.00002722753,0.0000038600097,0.002467948],"genre_scores_gemma":[0.99857175,0.00007127306,0.00050315616,0.00035082936,0.000034356293,0.000012831288,0.0001808461,0.000011277978,0.00026367814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991944,0.00007175285,0.0002590411,0.0002251695,0.00007427636,0.0001753893],"domain_scores_gemma":[0.99943626,0.000025828584,0.000109710556,0.00019757374,0.00017643807,0.000054189946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011199616,0.000106598025,0.00025505477,0.000046882724,0.000028154904,0.0000055048267,0.00006554042,0.00014225664,0.00002257128],"category_scores_gemma":[0.00011641419,0.00009131886,0.000048022484,0.00007681319,0.00008735296,0.0000050971225,0.00009009964,0.00006877673,0.0000035848886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043310985,0.0011381581,0.7953548,0.00005277595,0.0001932457,0.00006178993,0.00028401415,0.0000131945735,0.18678205,0.0005026011,0.0005514458,0.014632819],"study_design_scores_gemma":[0.0020891598,0.0028975937,0.70777035,0.000016798484,0.000014090707,0.000012025711,0.00009913057,0.0000023956559,0.27684453,0.00016995518,0.009938931,0.00014502677],"about_ca_topic_score_codex":0.000030515836,"about_ca_topic_score_gemma":0.00021026745,"teacher_disagreement_score":0.09006248,"about_ca_system_score_codex":0.000005765765,"about_ca_system_score_gemma":0.00015870579,"threshold_uncertainty_score":0.3723875},"labels":[],"label_agreement":null},{"id":"W3202121966","doi":"10.1016/j.annonc.2021.08.728","title":"1840P Impact of age, comorbidities and polypharmacy on survival in advanced cancers","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Polypharmacy; Comorbidity; Oncology; Gerontology; Internal medicine; Overall survival; Intensive care medicine","score_opus":0.13906244305785645,"score_gpt":0.49876909455505103,"score_spread":0.3597066514971946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202121966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798913,0.0020607838,3.557118e-7,0.0020308879,0.00023841452,0.00014200427,0.000046712576,0.0000063463863,0.015583202],"genre_scores_gemma":[0.99393475,0.0045616454,0.00004633074,0.0008188101,0.00006533722,0.000012767075,0.00002828971,0.000008884004,0.00052317727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992333,0.00009905778,0.00023802574,0.00015242933,0.00008524512,0.00019196594],"domain_scores_gemma":[0.99935234,0.00024885606,0.00010929954,0.00010353339,0.000106119274,0.00007988517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011403348,0.000103107996,0.0005397972,0.00011613171,0.000012376136,9.4287157e-7,0.000035364712,0.000065652304,0.0004743966],"category_scores_gemma":[0.000042552518,0.00009009342,0.00009957163,0.00015330798,0.00015142135,0.000032946184,0.000025975522,0.00012471576,0.0000017665027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01792835,0.0044372673,0.4968643,0.00045861347,0.0017826442,0.0035707224,0.0036395667,0.00056281994,0.23173441,0.0010744283,0.022758117,0.21518876],"study_design_scores_gemma":[0.015877357,0.016894443,0.8005639,0.00015619438,0.00016682732,0.00010947373,0.00056677475,0.00004479501,0.13885765,0.00036020053,0.026207246,0.00019518673],"about_ca_topic_score_codex":0.0016471636,"about_ca_topic_score_gemma":0.0008937636,"teacher_disagreement_score":0.30369955,"about_ca_system_score_codex":0.00012086171,"about_ca_system_score_gemma":0.0006917257,"threshold_uncertainty_score":0.519431},"labels":[],"label_agreement":null},{"id":"W3202183889","doi":"10.1016/j.annonc.2021.08.1872","title":"1270P Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; Pathology","score_opus":0.05559042050641958,"score_gpt":0.4291765549029728,"score_spread":0.3735861343965532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202183889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97850364,0.0038113613,0.000029884513,0.00457144,0.00009659763,0.00031352957,0.00023737203,0.000006087806,0.0124300765],"genre_scores_gemma":[0.98843765,0.003454078,0.001515523,0.00095746474,0.0000306323,0.000066763365,0.00007672918,0.000012576266,0.0054485765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916357,0.000053380838,0.00037246876,0.00017948927,0.00007051149,0.00016058613],"domain_scores_gemma":[0.9992834,0.00014323714,0.00016461361,0.0001710326,0.000168331,0.00006939547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011523614,0.00009862792,0.00051013916,0.00016848704,0.000027727905,0.000004016467,0.000028765746,0.00004581222,0.00021918981],"category_scores_gemma":[0.00002614268,0.00008479231,0.000072593335,0.00016934087,0.00005936175,0.00004393266,0.00003570229,0.0000713095,0.0000011832542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001829639,0.0016106762,0.9429642,0.00057188503,0.0008011609,0.0003466528,0.003148804,0.0002569659,0.03418231,0.0012032303,0.0040392065,0.010691932],"study_design_scores_gemma":[0.0052950648,0.0007621173,0.93677485,0.00015324248,0.00070470653,0.000010838186,0.0007632621,0.00015072785,0.035374448,0.00008349851,0.019781303,0.00014594628],"about_ca_topic_score_codex":0.0036687213,"about_ca_topic_score_gemma":0.012233725,"teacher_disagreement_score":0.015742095,"about_ca_system_score_codex":0.00007144452,"about_ca_system_score_gemma":0.00082083023,"threshold_uncertainty_score":0.6826706},"labels":[],"label_agreement":null},{"id":"W3202209089","doi":"10.1016/j.annonc.2021.08.1100","title":"587P Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Cabazitaxel; Docetaxel; Prostate cancer; Medicine; Oncology; Androgen receptor; Internal medicine; Chemotherapy; Cancer; Androgen deprivation therapy","score_opus":0.12874800077029838,"score_gpt":0.44628128748955603,"score_spread":0.3175332867192576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202209089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187213,0.0027295381,0.0000038091491,0.0011705987,0.00006653159,0.0029641334,0.0010989384,0.000007734807,0.0000865794],"genre_scores_gemma":[0.9922841,0.005114933,0.00044171562,0.00013571199,0.000036583697,0.0005295571,0.00028627025,0.000030577343,0.0011405281],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800885,0.00033909763,0.00058587367,0.00041542455,0.00026371374,0.0003870337],"domain_scores_gemma":[0.99721265,0.000769938,0.00045148455,0.00022376525,0.0011168168,0.00022532411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048514185,0.00025103692,0.0009694473,0.000070148526,0.00009061821,0.000021447573,0.00006862093,0.00007922664,0.00016531571],"category_scores_gemma":[0.00024531226,0.00012131373,0.000112289126,0.00022072946,0.0008598988,0.000115286624,0.000042348896,0.00016494059,7.340698e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6148012,0.003788061,0.31717837,0.0011407132,0.014213663,0.0004250694,0.00565686,0.00006284854,0.00410025,0.00007596034,0.00482718,0.03372983],"study_design_scores_gemma":[0.37362257,0.23308384,0.30984983,0.001326473,0.0040927925,0.00015419889,0.0027523183,0.00071158,0.06276969,0.00016042143,0.010629378,0.0008469094],"about_ca_topic_score_codex":0.0005840662,"about_ca_topic_score_gemma":0.0027470002,"teacher_disagreement_score":0.24117865,"about_ca_system_score_codex":0.00010425717,"about_ca_system_score_gemma":0.0014120893,"threshold_uncertainty_score":0.49470305},"labels":[],"label_agreement":null},{"id":"W3202237143","doi":"10.1016/j.annonc.2021.08.878","title":"1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antagonist; Sarcoma; Oncology; Internal medicine; Phases of clinical research; Pharmacology; Chemotherapy; Pathology; Receptor","score_opus":0.07771101551057516,"score_gpt":0.43856233399941363,"score_spread":0.36085131848883845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202237143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490356,0.00020752849,0.000008608105,0.0019195152,0.00010761396,0.0012246375,0.000022743121,0.000009709408,0.0015960676],"genre_scores_gemma":[0.9983941,0.00013845519,0.00021730326,0.00046897723,0.000027703281,0.000046047004,0.000033563447,0.000026693155,0.00064719556],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975787,0.0005186908,0.0006056945,0.00033680655,0.00062430155,0.000335799],"domain_scores_gemma":[0.9980264,0.0002984032,0.0002773955,0.0006018949,0.0006922904,0.00010364101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005041815,0.00016493414,0.00067377684,0.00020588093,0.000060036804,0.0000065017134,0.00017981157,0.00007706031,0.00049292535],"category_scores_gemma":[0.00027160504,0.00011358199,0.000102649254,0.0008612058,0.00022427639,0.000081869264,0.00012886687,0.00031761313,0.0000059787435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012780625,0.043515608,0.36916083,0.00027652676,0.00046854373,0.00041639953,0.0052593597,0.00016294571,0.07539924,0.0000442112,0.0010840998,0.4914316],"study_design_scores_gemma":[0.063324615,0.06485461,0.80275875,0.00038143588,0.00017709578,0.00006572784,0.0055873124,0.00024306352,0.051529348,0.00023139134,0.010573389,0.00027323107],"about_ca_topic_score_codex":0.00017814526,"about_ca_topic_score_gemma":0.00070124073,"teacher_disagreement_score":0.49115837,"about_ca_system_score_codex":0.00008413925,"about_ca_system_score_gemma":0.00056694495,"threshold_uncertainty_score":0.5397187},"labels":[],"label_agreement":null},{"id":"W3202260438","doi":"10.1016/j.annonc.2021.08.1951","title":"1350P Characteristics, treatment patterns and outcome of non-small cell lung cancer (NSCLC) patients presenting with brain-only metastatic disease","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Cohort; Brain metastasis; Oncology; Internal medicine; Disease; Lung cancer; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Metastasis; Cancer","score_opus":0.0440666885086134,"score_gpt":0.40140406024319986,"score_spread":0.35733737173458646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202260438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950487,0.0005283349,0.00007079705,0.0025571978,0.000092042246,0.00050501886,0.00045652624,0.000006796715,0.000734573],"genre_scores_gemma":[0.99686044,0.00044692022,0.0004074696,0.00075065636,0.000038757407,0.00007363033,0.0002143304,0.000019138737,0.0011886243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990443,0.00005087369,0.0003488821,0.00023127385,0.00012439993,0.0002002501],"domain_scores_gemma":[0.9988514,0.00013118444,0.00028362506,0.00019298306,0.0003711367,0.0001696787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045877667,0.00014588158,0.0005016265,0.00006274955,0.000037311445,0.000005974767,0.00003409319,0.000028288703,0.00008374082],"category_scores_gemma":[0.000048621227,0.00010593627,0.000080411286,0.000074956035,0.000056980924,0.000043050797,0.00003304002,0.000050015442,8.680033e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020527374,0.001555376,0.9801314,0.000601712,0.0006409161,0.0002223872,0.00094423216,0.0000045488696,0.00010448744,0.000010935413,0.00017708424,0.015401632],"study_design_scores_gemma":[0.004286482,0.0015924078,0.9888604,0.00013357284,0.0013876972,0.000007609479,0.00017477607,0.00007718821,0.00168613,0.0000060370753,0.0016944443,0.00009322678],"about_ca_topic_score_codex":0.00056466507,"about_ca_topic_score_gemma":0.0002619996,"teacher_disagreement_score":0.015308405,"about_ca_system_score_codex":0.000067601766,"about_ca_system_score_gemma":0.00066312833,"threshold_uncertainty_score":0.43199557},"labels":[],"label_agreement":null},{"id":"W3202278757","doi":"10.1016/j.annonc.2021.08.550","title":"267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Cancer research; Immunotherapy; Nivolumab","score_opus":0.19866682891896897,"score_gpt":0.4921568923871596,"score_spread":0.2934900634681906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202278757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97840065,0.0009007666,0.000037115697,0.012587805,0.00013914441,0.0010283502,0.00037549314,0.00002314081,0.0065075313],"genre_scores_gemma":[0.9903782,0.0011688984,0.0003498361,0.0029288956,0.00013873886,0.00021351755,0.0004912231,0.00002991483,0.0043007554],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99561644,0.001149897,0.0015615819,0.0005396923,0.000680818,0.00045157195],"domain_scores_gemma":[0.99565005,0.0004160448,0.0008829227,0.0004741824,0.0023752965,0.00020150628],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003298355,0.00028610937,0.0020716311,0.0004143542,0.00008913295,0.000020697793,0.00023303206,0.00024137847,0.02095235],"category_scores_gemma":[0.0011045878,0.00023339246,0.0003049336,0.000883316,0.00031167208,0.00024691975,0.00025373997,0.00030431367,0.00003517389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3068058,0.03592882,0.0014094197,0.001013667,0.004419047,0.0028758284,0.0044593373,0.00041067755,0.30612215,0.00090968877,0.051400635,0.28424495],"study_design_scores_gemma":[0.7777129,0.002778343,0.0028140827,0.0017615709,0.0019947405,0.0007219831,0.0010780375,0.010017728,0.19205756,0.0009206771,0.007615043,0.0005273438],"about_ca_topic_score_codex":0.0010314842,"about_ca_topic_score_gemma":0.003051712,"teacher_disagreement_score":0.4709071,"about_ca_system_score_codex":0.00014564836,"about_ca_system_score_gemma":0.002176812,"threshold_uncertainty_score":0.9799426},"labels":[],"label_agreement":null},{"id":"W3202319124","doi":"10.1016/j.annonc.2021.08.595","title":"312P Survival of breast cancer patients with brain metastases treated with radiotherapy in Ontario, Canada: A population-based study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Ottawa; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Breast cancer; Oncology; Cancer; Population; Internal medicine; Environmental health","score_opus":0.03618203964756094,"score_gpt":0.3276271457082416,"score_spread":0.29144510606068064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202319124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609166,0.00015812035,0.0000060891275,0.002778159,0.000032053707,0.0005541711,0.00030277853,0.0000048032807,0.00007214411],"genre_scores_gemma":[0.99830645,0.0000059429276,0.00036581815,0.00083423854,0.000010462729,0.000045416884,0.00032023346,0.000017337632,0.000094070645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861413,0.00027108367,0.00034331056,0.0002469197,0.00031704025,0.00020753249],"domain_scores_gemma":[0.99885315,0.00021347929,0.00021532227,0.00022285877,0.00040443015,0.00009078861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018036921,0.00016298589,0.0007625518,0.00009875215,0.000021713078,0.0000024132994,0.00004376405,0.000040980623,0.0005624708],"category_scores_gemma":[0.000021768168,0.00010983545,0.00004799216,0.00030194552,0.00003786991,0.000029604491,0.000008258391,0.00009772733,8.511563e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031799916,0.005232994,0.98492366,0.000027863276,0.000955829,0.00039871378,0.0001607507,0.0004415217,0.000023214565,0.000012002588,0.0003222333,0.0043212147],"study_design_scores_gemma":[0.012319019,0.006748162,0.97934246,0.00007952635,0.00021227598,0.000009644717,0.00021748633,0.0000097301,0.0002782738,0.0000014776355,0.000687119,0.000094849376],"about_ca_topic_score_codex":0.9742278,"about_ca_topic_score_gemma":0.9979838,"teacher_disagreement_score":0.023756031,"about_ca_system_score_codex":0.0003781512,"about_ca_system_score_gemma":0.0037558333,"threshold_uncertainty_score":0.6662687},"labels":[],"label_agreement":null},{"id":"W3202325290","doi":"10.1016/j.annonc.2021.08.403","title":"122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Endocrine system; Oncology; Gynecology; Cancer; Breast cancer; Internal medicine; Metastatic breast cancer; Hormone","score_opus":0.0899429528670888,"score_gpt":0.4043247517342565,"score_spread":0.3143817988671677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202325290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933721,0.0005195817,0.000015049177,0.004251066,0.00007280906,0.0010259366,0.00049189414,0.000037712412,0.00021385535],"genre_scores_gemma":[0.99610054,0.00067803444,0.00024464622,0.0022780704,0.00016333938,0.00017538764,0.000047341786,0.000061018083,0.0002516332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722844,0.0006899339,0.00062102394,0.0005161121,0.00057667604,0.00036778155],"domain_scores_gemma":[0.9964967,0.00061779405,0.00078712206,0.0007126063,0.0012278515,0.00015795733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002514182,0.00033380179,0.0012433107,0.000059001777,0.000084942825,0.00000896967,0.00021898907,0.000090388836,0.00050985924],"category_scores_gemma":[0.00010100637,0.00016787037,0.000089633824,0.00043206927,0.00035587716,0.0000994413,0.000052844476,0.00032193988,0.000004284769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05402997,0.0043181186,0.88536304,0.00001903155,0.0018443778,0.00004910146,0.0024527123,0.00002751275,0.0005427711,0.000011429153,0.000103515995,0.051238444],"study_design_scores_gemma":[0.021728922,0.019956078,0.94932777,0.00015722803,0.00017993669,0.000012303359,0.0019762227,0.0000012525555,0.005162983,0.00002973092,0.0012728869,0.00019466023],"about_ca_topic_score_codex":0.02013402,"about_ca_topic_score_gemma":0.007103359,"teacher_disagreement_score":0.06396478,"about_ca_system_score_codex":0.000072073,"about_ca_system_score_gemma":0.00080664334,"threshold_uncertainty_score":0.986391},"labels":[],"label_agreement":null},{"id":"W3202383065","doi":"10.1016/j.annonc.2021.08.065","title":"669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"Merck Sharp and Dohme; Genentech; Servier; Society for Immunotherapy of Cancer; Shionogi; Astellas Pharma; Eisai; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Exelixis; MEI Pharma; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; PTC Therapeutics; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; EUSA Pharma; AstraZeneca; American Society of Clinical Oncology; Arrowhead Pharmaceuticals; Merck; Amgen","keywords":"Medicine; Axitinib; Sunitinib; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Urology; Cancer; Immunotherapy","score_opus":0.20492641594701666,"score_gpt":0.4405689404238316,"score_spread":0.23564252447681494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202383065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561674,0.0029090364,0.000019456469,0.0030607712,0.00021289826,0.0035453688,0.000054045482,0.000026654408,0.004555007],"genre_scores_gemma":[0.9952234,0.00053975935,0.000445078,0.0012845757,0.00017588606,0.0010476226,0.00023510105,0.00005271484,0.0009958862],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967685,0.0006028287,0.000893829,0.000631818,0.00041450167,0.0006885345],"domain_scores_gemma":[0.99738437,0.0010089519,0.00031545505,0.00077398506,0.00033708007,0.00018014204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066457875,0.00042262202,0.0012333402,0.00020145462,0.00013464052,0.000018326093,0.00022961885,0.00017205326,0.0001660364],"category_scores_gemma":[0.00012221419,0.00026390236,0.0005776628,0.00040415017,0.00009007198,0.00008100434,0.000047941656,0.00021562804,0.0000069515904],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14380307,0.11162754,0.026512606,0.00031640113,0.0025591215,0.046789527,0.042899475,0.00012708287,0.13449277,0.00029865064,0.002982069,0.48759168],"study_design_scores_gemma":[0.23858233,0.18673727,0.03362224,0.00011031078,0.00080991635,0.00060873746,0.020102719,0.000060767652,0.47150305,0.00016488216,0.04713616,0.00056163134],"about_ca_topic_score_codex":0.000294957,"about_ca_topic_score_gemma":0.00054061395,"teacher_disagreement_score":0.48703006,"about_ca_system_score_codex":0.00032406402,"about_ca_system_score_gemma":0.0012663834,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W3202394648","doi":"10.1016/j.annonc.2021.08.1956","title":"1356P Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cumulative incidence; Incidence (geometry); Internal medicine; Brain metastasis; Histology; Pathology; Cancer; Metastasis","score_opus":0.025456983868278677,"score_gpt":0.41268124943199436,"score_spread":0.3872242655637157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202394648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98118824,0.008824155,0.00051578216,0.007579239,0.000046470224,0.0003172385,0.00024603488,0.0000043100986,0.0012785244],"genre_scores_gemma":[0.9942333,0.0016702065,0.0015271937,0.0022449554,0.000022678234,0.00003567709,0.00005808722,0.000010550984,0.00019736134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912375,0.00010734049,0.0002833491,0.00023903527,0.000082337974,0.00016416007],"domain_scores_gemma":[0.99887943,0.0004470634,0.00016878835,0.00010592909,0.00032397802,0.0000747921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018437464,0.00011173696,0.0004165864,0.000101843485,0.000024328305,0.0000033059368,0.00002771807,0.000040033083,0.0000497329],"category_scores_gemma":[0.00012357425,0.00010017936,0.00003892803,0.00012998862,0.00007574639,0.00009402959,0.000055431705,0.000087345536,1.9332852e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056189165,0.0008973051,0.7549698,0.0006027479,0.00044851482,0.00082736503,0.0096117435,0.00026067358,0.046264306,0.00015573628,0.00052811205,0.18487182],"study_design_scores_gemma":[0.010822749,0.001722212,0.7858733,0.0016269268,0.00076219183,0.000108740634,0.005198491,0.0024775858,0.18828663,0.00020732563,0.0026285823,0.0002852873],"about_ca_topic_score_codex":0.0018247855,"about_ca_topic_score_gemma":0.0013663128,"teacher_disagreement_score":0.18458654,"about_ca_system_score_codex":0.00005366418,"about_ca_system_score_gemma":0.0004441119,"threshold_uncertainty_score":0.40851957},"labels":[],"label_agreement":null},{"id":"W3202433444","doi":"10.1016/j.annonc.2021.08.1121","title":"608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"EMD Serono; Genentech; Astellas Pharma; Eisai; Flatiron Health; Endocyte; Sanofi; Exelixis; Genomic Health; Janssen Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; American Association for Cancer Research; AstraZeneca; Ipsen; Constellation Pharmaceuticals","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Overall survival; Cancer","score_opus":0.0543074712341284,"score_gpt":0.3914125880459866,"score_spread":0.33710511681185823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202433444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869823,0.000831301,0.0000038819376,0.008347195,0.000042221807,0.00064902176,0.00008638197,0.00000751806,0.0030501958],"genre_scores_gemma":[0.99686664,0.0014949382,0.00035781082,0.00048471135,0.0000213922,0.00004420227,0.00013536379,0.000013851498,0.0005810634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988677,0.00013482383,0.00025507904,0.0002564758,0.00020261572,0.00028330582],"domain_scores_gemma":[0.999049,0.00013725151,0.000098147444,0.00012687624,0.00046833168,0.00012041494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016494375,0.000119437274,0.00042406967,0.000108157736,0.00004039742,0.0000067606707,0.00002642481,0.000053404976,0.000058005568],"category_scores_gemma":[0.00008948611,0.00008814398,0.000029073042,0.0002710611,0.00019345863,0.000074500094,0.000030796666,0.00016343906,0.000003122735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017072763,0.0032085232,0.49581018,0.0004927032,0.0011722477,0.002748424,0.008366526,0.00009415394,0.0025795826,0.00035365208,0.0009054902,0.46719575],"study_design_scores_gemma":[0.013237826,0.0035342213,0.9684428,0.00025895098,0.00010595141,0.00003663606,0.00083750143,0.000024743547,0.009893538,0.000088109125,0.0034231106,0.000116641946],"about_ca_topic_score_codex":0.00019449387,"about_ca_topic_score_gemma":0.0010485842,"teacher_disagreement_score":0.4726326,"about_ca_system_score_codex":0.00008674435,"about_ca_system_score_gemma":0.0007952654,"threshold_uncertainty_score":0.3594407},"labels":[],"label_agreement":null},{"id":"W3202438775","doi":"10.1016/j.annonc.2021.08.507","title":"225P Prognostic factors of luminal A and luminal B intrinsic breast cancer subtypes of Croatian patients: A 5-year experience from Osijek","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Royal Columbian Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer; Population; Croatian","score_opus":0.024566239280060277,"score_gpt":0.3157500118399616,"score_spread":0.2911837725599013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202438775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969342,0.0018421194,0.000005028615,0.00035262507,0.00012958395,0.000098690565,0.0004991582,0.0000024766548,0.00013615377],"genre_scores_gemma":[0.99874055,0.00078135275,0.00016681793,0.00008403169,0.00008048022,0.000027433438,0.00009315502,0.000009819962,0.000016332275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990953,0.0000671,0.0002804564,0.00027636235,0.00011049618,0.00017028359],"domain_scores_gemma":[0.99899876,0.00005929883,0.00024371612,0.00017368663,0.00047044782,0.000054091175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036660804,0.00013436364,0.00035154275,0.000034943554,0.000027719174,0.0000026059304,0.00009314891,0.00010533988,0.000052276144],"category_scores_gemma":[0.000111223686,0.000121042016,0.000069867136,0.00009478051,0.00040327475,0.000006419098,0.00014261449,0.00004519199,3.8286123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043208292,0.000537202,0.9587835,0.000052871663,0.00026819055,0.0000052378555,0.0015526091,0.0000013975424,0.027726518,0.000015936504,0.00033100075,0.0102934465],"study_design_scores_gemma":[0.0007572849,0.00070743967,0.8026251,0.00004880963,0.000059211598,0.000005503111,0.0011423015,4.2811976e-7,0.19367623,0.000026178417,0.00086407404,0.00008741843],"about_ca_topic_score_codex":0.0010240905,"about_ca_topic_score_gemma":0.00057548535,"teacher_disagreement_score":0.16594972,"about_ca_system_score_codex":0.000011874428,"about_ca_system_score_gemma":0.00020500486,"threshold_uncertainty_score":0.49359503},"labels":[],"label_agreement":null},{"id":"W3202447968","doi":"10.1016/j.annonc.2021.08.1089","title":"576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"Advanced Accelerator Applications; Astellas Pharma; Peter MacCallum Cancer Centre; Clovis Oncology; Endocyte; Sanofi; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Taxane; Quality of life (healthcare); Glutamate carboxypeptidase II; Progression-free survival; Brief Pain Inventory; Randomized controlled trial; Cancer; Chemotherapy; Physical therapy; Breast cancer; Chronic pain","score_opus":0.12174853267378476,"score_gpt":0.4792702461281007,"score_spread":0.35752171345431594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202447968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901512,0.0015464262,0.0000014789591,0.0064830943,0.000022315575,0.001620029,0.00010926243,0.0000028156815,0.000063372434],"genre_scores_gemma":[0.99896276,0.0004460823,0.000047435387,0.00034621402,0.0000030269387,0.00006968248,0.000065581626,0.000008042343,0.000051174688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664444,0.0014435743,0.0010563538,0.00022572369,0.00039680072,0.00023312861],"domain_scores_gemma":[0.9982434,0.00058580935,0.00048479054,0.00022174153,0.0003829761,0.000081290644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024969762,0.00012333861,0.0009386168,0.00014556758,0.000037997805,0.0000035367032,0.00006390608,0.0000469739,0.00003067525],"category_scores_gemma":[0.00030298438,0.00007209442,0.00004114302,0.00042814063,0.00016046228,0.00006179442,0.000033449716,0.00016102847,1.1895027e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02197513,0.014168695,0.920084,0.00052102504,0.0004457573,0.00007849407,0.017751452,0.000047919926,0.0003398195,0.000051959076,0.00014243885,0.024393322],"study_design_scores_gemma":[0.038635917,0.01991644,0.9326113,0.00017695883,0.000041544503,7.544892e-7,0.008209946,0.000023883877,0.00020423066,0.00006167091,0.00005627923,0.00006111539],"about_ca_topic_score_codex":0.005629499,"about_ca_topic_score_gemma":0.012979174,"teacher_disagreement_score":0.024332207,"about_ca_system_score_codex":0.000073526106,"about_ca_system_score_gemma":0.0010704796,"threshold_uncertainty_score":0.85101557},"labels":[],"label_agreement":null},{"id":"W3202506818","doi":"10.1016/j.annonc.2021.08.1092","title":"579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec","funders":"Pharmacyclics; Genentech; Astellas Pharma; Eisai; Endocyte; Advanced Accelerator Applications; Incyte; Clovis Oncology; Exelixis; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Internal medicine; Cohort; Prostate cancer; Oncology; Nivolumab; Anemia; Docetaxel; Cancer; Immunotherapy; Androgen receptor","score_opus":0.13380879695539613,"score_gpt":0.45069543520493915,"score_spread":0.316886638249543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202506818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96822846,0.008528741,0.00014501427,0.0185055,0.00017800886,0.001571579,0.0005089541,0.000040102554,0.0022936207],"genre_scores_gemma":[0.97805065,0.006742264,0.0020577158,0.0012682996,0.00013770214,0.00079922564,0.0006651894,0.00003938136,0.010239576],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976316,0.00013674702,0.0006549753,0.00053864514,0.00040455282,0.0006334954],"domain_scores_gemma":[0.9977022,0.00019130866,0.00031823656,0.00040704984,0.001156113,0.00022511974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000578293,0.00026135854,0.0011158433,0.00027136717,0.0001311834,0.000027314629,0.00013047544,0.00009071357,0.00087472476],"category_scores_gemma":[0.000111781526,0.0002174388,0.0004403796,0.0008358379,0.0002351874,0.000108350265,0.00003788887,0.000196286,0.000009975894],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04116241,0.010791678,0.18492664,0.0042045396,0.07833803,0.005242495,0.0061610695,0.0013593473,0.2154152,0.004409008,0.08468469,0.36330488],"study_design_scores_gemma":[0.039202176,0.012997756,0.20129602,0.00048716448,0.011158158,0.00028620384,0.0029333653,0.0030279504,0.46723193,0.0036311825,0.25659016,0.0011579597],"about_ca_topic_score_codex":0.0007448268,"about_ca_topic_score_gemma":0.001110685,"teacher_disagreement_score":0.3621469,"about_ca_system_score_codex":0.00021732989,"about_ca_system_score_gemma":0.0023070893,"threshold_uncertainty_score":0.95776224},"labels":[],"label_agreement":null},{"id":"W3202516202","doi":"10.1016/j.annonc.2021.08.1169","title":"726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Endometrial cancer; Cervical cancer; Lenvatinib; Oncology; Gynecology; Cancer; Immunotherapy","score_opus":0.05284778229844425,"score_gpt":0.3777825332580952,"score_spread":0.32493475095965096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202516202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247307,0.0039333133,0.0000023797581,0.0015533377,0.00014016352,0.0013542218,0.00008411473,0.000012359847,0.00044702072],"genre_scores_gemma":[0.9965929,0.0016659007,0.00017660382,0.0009743177,0.000048523976,0.0002606386,0.000052015785,0.000027617141,0.0002015265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981753,0.00017592753,0.00051672733,0.0004601084,0.00032819714,0.00034374036],"domain_scores_gemma":[0.9982304,0.00060346787,0.00040129275,0.00028733152,0.00035941554,0.000118097305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074986056,0.00028971437,0.0016282996,0.00022676881,0.00003776387,0.0000034777363,0.00007615809,0.00011810401,0.00008936308],"category_scores_gemma":[0.000120823424,0.00018222563,0.00009726877,0.00064635824,0.00017071431,0.00007416213,0.000028916897,0.000111463676,9.187398e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043754812,0.009474541,0.68101245,0.00003501719,0.00096144807,0.000057895522,0.00061355974,0.000009722716,0.00022918636,0.000005856111,0.00005620889,0.26378933],"study_design_scores_gemma":[0.14401135,0.07758291,0.7660142,0.00004713722,0.00020484833,0.0000032875676,0.00016049131,0.0000010186468,0.004775806,0.000011416801,0.007036217,0.0001512945],"about_ca_topic_score_codex":0.0018770032,"about_ca_topic_score_gemma":0.001447576,"teacher_disagreement_score":0.26363802,"about_ca_system_score_codex":0.00030069068,"about_ca_system_score_gemma":0.0005183027,"threshold_uncertainty_score":0.74309456},"labels":[],"label_agreement":null},{"id":"W3202566111","doi":"10.1016/j.annonc.2021.08.1239","title":"797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Microsatellite instability; Internal medicine; Oncology; Quality of life (healthcare); Cancer; Gynecology; Microsatellite; Immunotherapy","score_opus":0.06522609440435553,"score_gpt":0.36221251850097236,"score_spread":0.2969864240966168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202566111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900318,0.004469052,0.000011146746,0.0022681854,0.00029310634,0.0016914977,0.00082589366,0.000041915,0.0003674508],"genre_scores_gemma":[0.99389464,0.0027301875,0.0015781785,0.0010013955,0.00005320994,0.00007616775,0.0005382376,0.000056211557,0.000071779636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99444944,0.0010987634,0.002242475,0.0009420437,0.0006145106,0.0006527472],"domain_scores_gemma":[0.9948136,0.0010413992,0.0016466393,0.0008679763,0.0012992002,0.00033117828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008924105,0.0004162473,0.0023747005,0.00027504298,0.00004646032,0.0000075732196,0.0002230956,0.00040160332,0.00022067035],"category_scores_gemma":[0.0012964648,0.00033488031,0.00016987747,0.0013234923,0.0004385015,0.00009717403,0.00007248994,0.00048447447,0.0000025607503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40157226,0.0046747243,0.47017035,0.0004225507,0.0010149922,0.000042783166,0.003984323,0.00084652315,0.010219122,0.000018794255,0.00028160732,0.10675196],"study_design_scores_gemma":[0.10646083,0.025153982,0.79484403,0.0006999294,0.000089618195,0.000005353956,0.00024948176,0.000016403825,0.07031595,0.0001389738,0.0016355731,0.00038986193],"about_ca_topic_score_codex":0.03518146,"about_ca_topic_score_gemma":0.0147196995,"teacher_disagreement_score":0.32467368,"about_ca_system_score_codex":0.00060941564,"about_ca_system_score_gemma":0.0033206653,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W3202609465","doi":"10.1016/j.annonc.2021.08.1230","title":"788P Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cervical cancer; Biomarker; Oncology; Human papillomavirus; Cancer; Internal medicine; Cancer research; Genetics","score_opus":0.05592361801114772,"score_gpt":0.40117377618679567,"score_spread":0.34525015817564797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202609465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295664,0.0030644585,0.000013772835,0.0010385348,0.00011930055,0.000091290116,0.000051519903,0.0000025268832,0.0026619763],"genre_scores_gemma":[0.99733406,0.00113286,0.00022552017,0.0010642359,0.0000568036,0.00002367815,0.000039225077,0.000015762775,0.00010785583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988509,0.00016671114,0.00039514253,0.0002776019,0.00008474681,0.00022489096],"domain_scores_gemma":[0.99911636,0.00012145443,0.00018663406,0.0002803742,0.00023183081,0.00006332572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032340974,0.00010757523,0.00030299526,0.00006077444,0.000026162563,0.0000035917874,0.00012369145,0.00019747028,0.00011738616],"category_scores_gemma":[0.00049814204,0.0001199528,0.00010811951,0.00015055075,0.00010408567,0.000002587616,0.00014890182,0.00007143867,0.0000018636017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011756112,0.00021542031,0.0066170897,0.000029354193,0.000056174566,0.00006673162,0.000100571495,0.0001546124,0.9706918,0.00020032116,0.00054114993,0.020151185],"study_design_scores_gemma":[0.0015638077,0.0015322487,0.10764339,0.000054239856,0.000016255879,0.000023498267,0.00018048036,0.000029228831,0.8379796,0.0006199604,0.050177384,0.00017991432],"about_ca_topic_score_codex":0.00029851412,"about_ca_topic_score_gemma":0.0009728356,"teacher_disagreement_score":0.13271219,"about_ca_system_score_codex":0.000024872184,"about_ca_system_score_gemma":0.00056032237,"threshold_uncertainty_score":0.4891533},"labels":[],"label_agreement":null},{"id":"W3202620686","doi":"10.1016/j.annonc.2021.08.1883","title":"1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab","score_opus":0.02076123226059324,"score_gpt":0.3031545853536468,"score_spread":0.2823933530930536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202620686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994431,0.00023890701,0.0010019799,0.0015438886,0.00016671709,0.00087475276,0.0013078176,0.000006126949,0.00042880798],"genre_scores_gemma":[0.9948634,0.00015604448,0.0022835648,0.00061951834,0.0001453238,0.000107568485,0.0017279147,0.000036638758,0.00006002064],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752986,0.00021235507,0.00092478824,0.00058286096,0.00035021178,0.00039992234],"domain_scores_gemma":[0.99706423,0.0007226744,0.0008163615,0.00043827103,0.00084703934,0.00011141797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047491217,0.00030068643,0.0006354347,0.00010082341,0.00011697818,0.000015256344,0.00028431544,0.00019459597,0.000027029559],"category_scores_gemma":[0.0014122174,0.00026243072,0.00021111534,0.0003269834,0.00024847873,0.000010341326,0.00012832865,0.00020170448,9.1951176e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37489977,0.02517215,0.023226717,0.00056180835,0.0027815716,0.00074965635,0.00086366606,0.445775,0.09772318,0.00020835026,0.0031849046,0.024853233],"study_design_scores_gemma":[0.26564476,0.01786323,0.008609017,0.0004092612,0.00043207023,0.000024269784,0.00009991423,0.00232532,0.70110464,0.000069392394,0.0029270404,0.0004910668],"about_ca_topic_score_codex":0.0002985354,"about_ca_topic_score_gemma":0.002291713,"teacher_disagreement_score":0.60338145,"about_ca_system_score_codex":0.000038948405,"about_ca_system_score_gemma":0.0013356546,"threshold_uncertainty_score":0.9999828},"labels":[],"label_agreement":null},{"id":"W3202673637","doi":"10.1016/j.annonc.2021.08.1247","title":"805P Clinically actionable alterations in adolescents and young adults (AYA) with gynaecological cancers","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Young adult; Oncology; Internal medicine; Pediatrics","score_opus":0.07534022524149364,"score_gpt":0.4087605693988979,"score_spread":0.33342034415740424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202673637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773753,0.00043428357,0.00004433245,0.0154967755,0.00027649105,0.00025270422,0.000012464909,0.000015188932,0.0060924166],"genre_scores_gemma":[0.9915471,0.0006954929,0.0010537553,0.0062695863,0.00013268113,0.00002896264,0.000021985103,0.0000106447205,0.00023976897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998456,0.00020079131,0.0005365714,0.00033759832,0.00021366814,0.00025536603],"domain_scores_gemma":[0.99892306,0.0001970492,0.00018294956,0.00020725059,0.00033177494,0.00015789227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045729108,0.00011451768,0.00051922334,0.00007360431,0.000045375164,0.0000072715384,0.000059939273,0.00017436233,0.00021873557],"category_scores_gemma":[0.0006121162,0.00010235124,0.00005874373,0.00021184549,0.00018059881,0.0000832606,0.000053995172,0.0002988383,0.000006759026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036031993,0.0017814566,0.95285624,0.00029477128,0.00016682615,0.00047402098,0.0021189773,0.00007376944,0.00022151771,0.0003446957,0.0026928415,0.03537167],"study_design_scores_gemma":[0.0046732933,0.004078897,0.98210096,0.00038802804,0.000039206076,0.00015639291,0.0013906973,0.00008459604,0.0005496353,0.00016029473,0.0062421616,0.00013582878],"about_ca_topic_score_codex":0.00096307165,"about_ca_topic_score_gemma":0.012659591,"teacher_disagreement_score":0.03523584,"about_ca_system_score_codex":0.000105425854,"about_ca_system_score_gemma":0.0011162258,"threshold_uncertainty_score":0.7064349},"labels":[],"label_agreement":null},{"id":"W3202712169","doi":"10.1016/j.annonc.2021.08.912","title":"390MO Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Imperial Experimental Cancer Medicine Centre; Cancerfonden; Rosetrees Trust; Royal College of Surgeons of England; Cancer Research UK","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); Colorectal cancer; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Colorectal cancer screening; Virology; Oncology; Family medicine; Cancer; Internal medicine; Colonoscopy; Disease; Infectious disease (medical specialty); Outbreak","score_opus":0.18002170085802158,"score_gpt":0.4642082422248463,"score_spread":0.28418654136682475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202712169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8204304,0.00437326,0.0000033741455,0.17468503,0.00010423659,0.00019298596,0.000024939929,0.000010761655,0.00017499496],"genre_scores_gemma":[0.9487197,0.006162216,0.000019918214,0.04449696,0.00011934335,0.000062628715,0.0000069544985,0.000010325498,0.00040195623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988013,0.00014238035,0.00030754003,0.00022198673,0.00017236295,0.0003544405],"domain_scores_gemma":[0.9980732,0.0011993473,0.00011608702,0.00015005181,0.00014058057,0.0003207017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032818358,0.000107667074,0.00041382617,0.00007805298,0.000094955256,0.0000064113433,0.00006686517,0.00012928355,0.00020575672],"category_scores_gemma":[0.0013923264,0.0000852454,0.000043062373,0.0002497621,0.000111773945,0.00004214918,0.000077402605,0.00028429774,4.3439277e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034974614,0.000060012982,0.96127635,0.0003103572,0.00005934268,0.0006552298,0.0011470765,0.00005609427,0.0007566712,0.000029843179,0.008286907,0.027012387],"study_design_scores_gemma":[0.0013941589,0.00020768415,0.81160927,0.000094003655,0.000025174453,0.00012809387,0.0007067278,0.000019567777,0.0013092193,0.00003796402,0.18438806,0.00008006723],"about_ca_topic_score_codex":0.96897244,"about_ca_topic_score_gemma":0.998702,"teacher_disagreement_score":0.17610115,"about_ca_system_score_codex":0.0005727226,"about_ca_system_score_gemma":0.008323346,"threshold_uncertainty_score":0.99729854},"labels":[],"label_agreement":null},{"id":"W3202729556","doi":"10.1016/j.annonc.2021.08.1436","title":"1051P Impacts of skeletal muscle on survival in resected stage III malignant melanoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sarcopenia; Skeletal muscle; Melanoma; Stage (stratigraphy); Internal medicine; Oncology; Cancer research","score_opus":0.06182565413493634,"score_gpt":0.36020870291669466,"score_spread":0.2983830487817583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202729556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94991094,0.00014244478,0.000008302368,0.0025947082,0.00025685175,0.00021262148,0.000015507787,0.000017848837,0.046840757],"genre_scores_gemma":[0.99571943,0.00026228133,0.000066850924,0.00067950855,0.00005845603,0.00000674063,0.000020958601,0.000013260233,0.0031725243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868023,0.00017144761,0.00043382964,0.00022244817,0.00023062884,0.00026140502],"domain_scores_gemma":[0.9990603,0.00015709718,0.00017231662,0.00029922603,0.00020767582,0.00010342259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003999906,0.00010947419,0.00051551894,0.0002340116,0.000015085335,0.000002614771,0.00006754832,0.00012604133,0.0007476357],"category_scores_gemma":[0.00028462562,0.000099948906,0.000117283336,0.00031802856,0.000068066714,0.000023384628,0.00007058743,0.0001614846,0.000017582513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047572167,0.006555734,0.007423793,0.0008426844,0.00070634775,0.013793703,0.002003132,0.000119561686,0.75535816,0.008537249,0.009785192,0.1901172],"study_design_scores_gemma":[0.008419135,0.018194923,0.297405,0.00031517269,0.00008601074,0.00029768737,0.002668214,0.00013077288,0.3933611,0.0002161738,0.2786046,0.00030120835],"about_ca_topic_score_codex":0.00037008265,"about_ca_topic_score_gemma":0.001485135,"teacher_disagreement_score":0.3619971,"about_ca_system_score_codex":0.000052688392,"about_ca_system_score_gemma":0.0002333413,"threshold_uncertainty_score":0.8186087},"labels":[],"label_agreement":null},{"id":"W3202730600","doi":"10.1016/j.annonc.2021.08.1316","title":"906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Foundation Medicine; Genentech; Merck Sharp and Dohme; Julius Clinical; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; European Society for Medical Oncology; Vifor Pharma; Basilea Pharmaceutica; Astellas Pharma; Eisai; Springworks Therapeutics; Celldex Therapeutics; MacroGenics; Pfizer; Incyte; Moderna; Shionogi; Actuate Therapeutics; BeiGene; Mirati Therapeutics; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Karyopharm Therapeutics; F. Hoffmann-La Roche; Bayer HealthCare; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Head and neck cancer; Internal medicine; Radiation therapy; Cancer; Surgery; Colorectal cancer","score_opus":0.045848847685371175,"score_gpt":0.3325130936566644,"score_spread":0.28666424597129325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202730600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623233,0.00024877017,0.000003994325,0.0017598126,0.000012353251,0.00016100607,0.000020904354,0.000002446816,0.0015583563],"genre_scores_gemma":[0.999066,0.00003339312,0.00011801775,0.0005235625,0.0000047722333,0.0000052354653,0.00002917208,0.0000056341282,0.00021421557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992134,0.00013668703,0.00024295875,0.00014430739,0.00014136807,0.00012129489],"domain_scores_gemma":[0.9992604,0.00013322836,0.00015240938,0.00013122885,0.00027154363,0.00005116546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013691177,0.000074753036,0.00034708084,0.00009755009,0.000027549899,0.0000034778254,0.000029126739,0.000042700263,0.00006577513],"category_scores_gemma":[0.00015964422,0.000047389516,0.0000361281,0.00031647313,0.00011513807,0.00004586579,0.00004083062,0.000100862795,4.8379883e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016918621,0.005418961,0.9773151,0.00067477365,0.00006551639,0.00007586004,0.000844943,0.000008807702,0.0019434572,0.00020127809,0.0012306342,0.010528775],"study_design_scores_gemma":[0.013770405,0.0067299474,0.9577083,0.00024855806,0.00012750208,0.000015268723,0.0004571823,0.00025583932,0.019692257,0.00015650348,0.0007488659,0.0000893633],"about_ca_topic_score_codex":0.000087947956,"about_ca_topic_score_gemma":0.00047594323,"teacher_disagreement_score":0.019606825,"about_ca_system_score_codex":0.000015445235,"about_ca_system_score_gemma":0.0001673007,"threshold_uncertainty_score":0.19324884},"labels":[],"label_agreement":null},{"id":"W3202782750","doi":"10.1016/j.annonc.2021.08.2137","title":"LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic ductal adenocarcinoma; Oncology; Gastroenterology; Pancreatic cancer; Chemotherapy; Cancer","score_opus":0.09165052601406397,"score_gpt":0.4167157518229661,"score_spread":0.3250652258089021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202782750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866525,0.00039087658,0.00001754803,0.002273425,0.0006879102,0.004385185,0.0001939991,0.000018922612,0.005379667],"genre_scores_gemma":[0.9960983,0.0008767016,0.0008885025,0.0001113795,0.00015383384,0.0003036213,0.0007110349,0.000032750566,0.0008239034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942077,0.001329345,0.002395706,0.0006064088,0.0009010708,0.00055979966],"domain_scores_gemma":[0.9934408,0.0021006851,0.0012990864,0.00068041385,0.0022650121,0.00021400166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002143358,0.0003165592,0.0032219773,0.0005317185,0.000036157282,0.0000066526186,0.00033341174,0.00031789372,0.00044907263],"category_scores_gemma":[0.006440525,0.00023998134,0.00031883986,0.0006999553,0.0008896855,0.00012981088,0.00020596855,0.00048006707,0.0000048409856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9639655,0.011755104,0.015402942,0.00012126894,0.0022076354,0.0003142451,0.0010516583,0.00000586679,0.0013563836,0.000055155786,0.0014751888,0.002289058],"study_design_scores_gemma":[0.9461454,0.032767903,0.01352941,0.00033404742,0.00074420555,0.000012665571,0.00027319396,0.0005553934,0.0045564366,0.000039350798,0.00086441095,0.00017756113],"about_ca_topic_score_codex":0.00066508783,"about_ca_topic_score_gemma":0.0004948415,"teacher_disagreement_score":0.021012798,"about_ca_system_score_codex":0.00020459358,"about_ca_system_score_gemma":0.002092269,"threshold_uncertainty_score":0.97861546},"labels":[],"label_agreement":null},{"id":"W3202877676","doi":"10.1016/j.annonc.2021.08.1134","title":"621P Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"Plexxikon; Ipsen; Astellas Pharma; Upsher-Smith; Prothena; Flatiron Health; Sunesis; Sanofi; Exelixis; Genomic Health; Medpace; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Subgroup analysis; Oncology; Internal medicine; HERO; Gynecology; Cancer; Phases of clinical research; Clinical trial; Meta-analysis","score_opus":0.0915332718256188,"score_gpt":0.4870020442695029,"score_spread":0.3954687724438841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202877676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412895,0.0049261507,0.0000061584306,0.0089764185,0.000034929333,0.0011565203,0.00008605412,0.00000888494,0.0006759598],"genre_scores_gemma":[0.98712736,0.011509598,0.00013401116,0.00041493666,0.00005809209,0.00011152481,0.00008427498,0.000015566955,0.00054464117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766374,0.0005066402,0.0007597748,0.00045218796,0.0003008037,0.00031687348],"domain_scores_gemma":[0.99783874,0.0008883637,0.0002918678,0.00043878486,0.0004015438,0.0001406948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094469887,0.00016374,0.0011717674,0.000121529636,0.00005213925,0.0000063009024,0.00011995254,0.00010788109,0.000119958655],"category_scores_gemma":[0.00019037089,0.000096600095,0.00012346405,0.0008327022,0.00037696792,0.00006415969,0.00010823087,0.00033293222,9.418759e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07172185,0.0058365394,0.81473917,0.000044421715,0.0043571442,0.0006176973,0.0042292182,0.00014132178,0.00079985126,0.000012302707,0.0006501954,0.0968503],"study_design_scores_gemma":[0.07634407,0.01463165,0.894089,0.00016629462,0.0014907249,0.000006457014,0.0038847355,0.00017590325,0.004520112,0.00006106422,0.004484306,0.00014571667],"about_ca_topic_score_codex":0.0018467705,"about_ca_topic_score_gemma":0.004412314,"teacher_disagreement_score":0.09670458,"about_ca_system_score_codex":0.000062361316,"about_ca_system_score_gemma":0.00075901917,"threshold_uncertainty_score":0.39392376},"labels":[],"label_agreement":null},{"id":"W3202885034","doi":"10.1016/j.annonc.2021.08.1257","title":"815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Sun Pharma; Puma Biotechnology; Pfizer; Clovis Oncology; Merck KGaA; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Olaparib; ARID1A; Oncology; Cancer research; Internal medicine; Mutation; Genetics; Gene; Poly ADP ribose polymerase; Biology","score_opus":0.032325568816516104,"score_gpt":0.32423934828861517,"score_spread":0.29191377947209907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202885034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955167,0.00037428507,0.00013636613,0.0012929777,0.0001584186,0.00019169819,0.000021726297,0.000008289716,0.0022994922],"genre_scores_gemma":[0.99685574,0.00059142296,0.000793913,0.0010511122,0.00011071046,0.000057325426,0.00012615103,0.00001858426,0.0003950614],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985082,0.0001594841,0.00037876726,0.00044801208,0.0001574698,0.00034806333],"domain_scores_gemma":[0.9990659,0.00006661644,0.000169853,0.00027349655,0.000349569,0.000074606935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030474435,0.00018097243,0.00040706134,0.000067178444,0.00003374565,0.000010553572,0.00015734526,0.00031976614,0.000108290435],"category_scores_gemma":[0.0001724705,0.00013885096,0.000052416453,0.00025947174,0.000216188,0.000009453415,0.000085564236,0.00022384302,0.000004378462],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030445406,0.008968081,0.5440106,0.001130485,0.0010626753,0.005615009,0.0026902594,0.039584637,0.18740296,0.0012180461,0.025586931,0.1522849],"study_design_scores_gemma":[0.040472217,0.055079397,0.21022205,0.0006663365,0.00014084425,0.00080797763,0.0022117647,0.0035305247,0.50670934,0.0007959471,0.17703049,0.002333124],"about_ca_topic_score_codex":0.00055780116,"about_ca_topic_score_gemma":0.014351047,"teacher_disagreement_score":0.33378854,"about_ca_system_score_codex":0.00012207532,"about_ca_system_score_gemma":0.0014450743,"threshold_uncertainty_score":0.80082214},"labels":[],"label_agreement":null},{"id":"W3202895789","doi":"10.1016/j.annonc.2021.08.054","title":"658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Carboplatin; Cisplatin; Oncology; Urothelial cancer; Chemotherapy; Internal medicine; Cancer; Cancer research; Bladder cancer; Immunotherapy; Nivolumab","score_opus":0.04713711442678768,"score_gpt":0.3681801738621347,"score_spread":0.321043059435347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202895789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743886,0.0020192568,0.000071908056,0.006207198,0.0001255761,0.00072163425,0.000060858507,0.000038079208,0.0033166418],"genre_scores_gemma":[0.99582916,0.00070210366,0.0010125863,0.0018311874,0.000054454977,0.00012352415,0.00008144062,0.00005892323,0.00030664034],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980281,0.00019437434,0.0006119309,0.00047828615,0.00028691886,0.0004003625],"domain_scores_gemma":[0.99870896,0.0002540659,0.00028128634,0.00033529956,0.00028718653,0.00013317098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023018992,0.0003074254,0.000936768,0.00020067455,0.000052573334,0.000013417235,0.000080824524,0.00019568055,0.0005748374],"category_scores_gemma":[0.000081185164,0.00025915404,0.000113642476,0.0004898571,0.0001830304,0.00007080667,0.000026202875,0.0002731979,0.0000064671967],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06018826,0.006290028,0.090098105,0.00090498745,0.0041715875,0.0022965663,0.005396602,0.0037706003,0.10022947,0.0004818939,0.0015759952,0.7245959],"study_design_scores_gemma":[0.09024854,0.015013732,0.54874814,0.0012910254,0.0011193011,0.00038445488,0.00033403095,0.0065149674,0.32963705,0.001095851,0.0046338835,0.000979022],"about_ca_topic_score_codex":0.0012809561,"about_ca_topic_score_gemma":0.00038809495,"teacher_disagreement_score":0.7236169,"about_ca_system_score_codex":0.00015224713,"about_ca_system_score_gemma":0.0012790397,"threshold_uncertainty_score":0.99998605},"labels":[],"label_agreement":null},{"id":"W3202897019","doi":"10.1016/j.annonc.2021.08.1804","title":"1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CMC Microsystems; Pfizer","keywords":"Medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; A549 cell","score_opus":0.08885980664759292,"score_gpt":0.46728384066499595,"score_spread":0.37842403401740304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202897019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992544,0.0006235523,0.00013986831,0.0019505924,0.00008882863,0.0021953085,0.000032630585,0.000001864246,0.0024233775],"genre_scores_gemma":[0.9979888,0.00053778273,0.00019671115,0.00026072396,0.000019536896,0.00062635844,0.00002689784,0.000007022554,0.00033617608],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99911684,0.000073517134,0.0004081188,0.0001504567,0.00012295734,0.00012812603],"domain_scores_gemma":[0.99914145,0.00016170506,0.00023733405,0.0002687941,0.00017139896,0.000019333398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032341748,0.00007699039,0.00027233837,0.00007431216,0.000027067079,6.9942644e-7,0.000105721185,0.000040246956,0.000031525055],"category_scores_gemma":[0.000011462272,0.0000489156,0.00006666301,0.00025043785,0.000032673142,0.000028021806,0.00002839472,0.000064832755,3.401646e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013417513,0.12333864,0.24405752,0.004044213,0.0064317975,0.0003778762,0.22761919,0.018873218,0.010838088,0.0017751012,0.0054385494,0.3437883],"study_design_scores_gemma":[0.077478014,0.0062817726,0.8249103,0.00053359783,0.0023206375,0.0000043130344,0.073095866,0.003489423,0.007217033,0.00018239678,0.0043144496,0.00017220687],"about_ca_topic_score_codex":0.0009997505,"about_ca_topic_score_gemma":0.0012672174,"teacher_disagreement_score":0.58085275,"about_ca_system_score_codex":0.00005697785,"about_ca_system_score_gemma":0.00021726052,"threshold_uncertainty_score":0.19947203},"labels":[],"label_agreement":null},{"id":"W3202928000","doi":"10.1016/j.annonc.2021.08.1097","title":"584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Enzalutamide; Androgen deprivation therapy; Oncology; Clinical endpoint; Internal medicine; Abiraterone; Acis; Antiandrogen; Quality of life (healthcare); Cancer; Clinical trial; Androgen receptor","score_opus":0.1693330360404185,"score_gpt":0.4695793393923535,"score_spread":0.30024630335193503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202928000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98086596,0.007892791,0.0000045808392,0.009080091,0.00005882309,0.00172817,0.00022563449,0.0000082507695,0.00013571377],"genre_scores_gemma":[0.9934481,0.0053469865,0.0003313821,0.00022142779,0.000016209951,0.00020550791,0.00009729595,0.000019542536,0.0003135508],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996433,0.0007291899,0.0016207052,0.0003839643,0.00038759725,0.00044553843],"domain_scores_gemma":[0.9979838,0.00028631458,0.00079598033,0.00026716068,0.00046096087,0.00020579789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015894644,0.00020357064,0.0016649493,0.00028219065,0.00003091754,0.0000062408944,0.00007371255,0.00011047924,0.000075642885],"category_scores_gemma":[0.00027300688,0.00015680355,0.00007569268,0.000650423,0.00041901835,0.000119602446,0.00004826269,0.00026680378,5.427977e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8178714,0.010024021,0.01684841,0.0037875918,0.0015813537,0.0007494462,0.017565874,0.0002931228,0.09241182,0.00022801632,0.00030563516,0.038333338],"study_design_scores_gemma":[0.7407815,0.057468906,0.102311485,0.0019700008,0.0003125406,0.000053069467,0.005590728,0.0004077805,0.08934339,0.0007684837,0.000543873,0.00044827547],"about_ca_topic_score_codex":0.0073016095,"about_ca_topic_score_gemma":0.014347901,"teacher_disagreement_score":0.08546307,"about_ca_system_score_codex":0.00014209011,"about_ca_system_score_gemma":0.0036516457,"threshold_uncertainty_score":0.9993089},"labels":[],"label_agreement":null},{"id":"W3203041075","doi":"10.1016/j.annonc.2021.08.058","title":"662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.03387022440427974,"score_gpt":0.3120583596990088,"score_spread":0.2781881352947291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203041075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784103,0.0072874706,0.000015781372,0.0016389012,0.00024475393,0.0011520691,0.00023382569,0.000018349325,0.010998538],"genre_scores_gemma":[0.9905566,0.0047046263,0.0013791797,0.0008403515,0.00011814959,0.00013728398,0.0001980968,0.00008616489,0.001979534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958818,0.00033126448,0.0016944677,0.00088657567,0.00059186877,0.00061400357],"domain_scores_gemma":[0.9962716,0.0006536066,0.0008838202,0.001176852,0.0007592699,0.00025482735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041366412,0.00049776695,0.0019602808,0.00034801834,0.000033146407,0.0000059274157,0.00029148284,0.0004884037,0.00042054916],"category_scores_gemma":[0.00013209828,0.00044860615,0.00059624965,0.00047918098,0.0002381968,0.000101120415,0.00011519995,0.00037818038,0.00002279046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23101103,0.008676528,0.13689905,0.0004865519,0.0008306476,0.0037272668,0.0072009824,0.00036576376,0.58814967,0.000008227061,0.0030420856,0.0196022],"study_design_scores_gemma":[0.035979483,0.018836867,0.24267577,0.00018276011,0.00014965721,0.00002352865,0.0004225925,0.00016011659,0.6978242,0.00012456893,0.003351655,0.0002688566],"about_ca_topic_score_codex":0.0033508793,"about_ca_topic_score_gemma":0.00080616033,"teacher_disagreement_score":0.19503155,"about_ca_system_score_codex":0.00018534377,"about_ca_system_score_gemma":0.0009144222,"threshold_uncertainty_score":0.99979657},"labels":[],"label_agreement":null},{"id":"W3203079930","doi":"10.1016/j.annonc.2021.08.178","title":"1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lanreotide; Depot; Internal medicine; Neuroendocrine tumors; Neuroendocrine carcinoma; Oncology; Carcinoma","score_opus":0.04491729742528582,"score_gpt":0.38448285023290246,"score_spread":0.33956555280761663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203079930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98285097,0.00039917967,0.0000015848788,0.0130889015,0.00016346811,0.0015527944,0.00022423893,0.000057389603,0.0016614762],"genre_scores_gemma":[0.9954993,0.00021334222,0.00028094967,0.0028212408,0.00012682349,0.00008959615,0.0004057789,0.00005278838,0.00051018316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604696,0.00061597273,0.0009834422,0.0008149549,0.00074964185,0.000789044],"domain_scores_gemma":[0.99703485,0.00084271235,0.00039024025,0.0009873343,0.00047927815,0.00026556425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002288263,0.00033839146,0.0009961545,0.00017887475,0.00007992434,0.000014639249,0.00038528544,0.00001432323,0.0001265271],"category_scores_gemma":[0.0013847732,0.00023653862,0.00010664063,0.00068968616,0.00024790238,0.00020008566,0.00032114002,0.00071936985,0.000020872218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092263125,0.03620234,0.5734716,0.00011707761,0.0005401587,0.16092885,0.00094743783,0.0011379427,0.003319648,0.000040633546,0.024832781,0.10619843],"study_design_scores_gemma":[0.085854046,0.044820264,0.7866642,0.00025568882,0.00010381848,0.00069239805,0.0015547932,0.0001245689,0.0074775144,0.00012915357,0.07193752,0.0003860842],"about_ca_topic_score_codex":0.0010156061,"about_ca_topic_score_gemma":0.0013962955,"teacher_disagreement_score":0.21319258,"about_ca_system_score_codex":0.00006093344,"about_ca_system_score_gemma":0.0004905379,"threshold_uncertainty_score":0.9645765},"labels":[],"label_agreement":null},{"id":"W3203163864","doi":"10.1016/j.annonc.2021.08.1062","title":"540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T-cell receptor; Spear; CD8; Receptor; Oncology; Pharmacology; Immunology; Internal medicine; T cell; Antigen; Immune system","score_opus":0.09642382633896207,"score_gpt":0.39833374095669943,"score_spread":0.30190991461773736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203163864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98638093,0.0016972551,0.00006262672,0.0064453315,0.00011340052,0.0011445559,0.00008534321,0.000036613998,0.0040339343],"genre_scores_gemma":[0.97692037,0.0063378187,0.0117254285,0.0023882815,0.0011986569,0.000048220016,0.00041722035,0.000091890804,0.0008721273],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967276,0.0013149097,0.0005721418,0.00054535485,0.00041130802,0.00042872492],"domain_scores_gemma":[0.99615103,0.002324479,0.00035018474,0.00047049538,0.00043804027,0.0002657902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021961338,0.00026120897,0.0009503215,0.000075597265,0.00020330763,0.00005565251,0.00017708873,0.00023470842,0.0016644789],"category_scores_gemma":[0.0005649242,0.00017774233,0.00011184843,0.00027924124,0.0005288154,0.000114677416,0.0001273603,0.0006108596,0.0000092476475],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3887689,0.0035099252,0.010893378,0.00008271369,0.0010367262,0.0004609965,0.0063182754,0.000059535134,0.40833563,0.00006241792,0.0063243294,0.17414719],"study_design_scores_gemma":[0.49230954,0.054579925,0.023561796,0.00035334914,0.00038275798,0.00021440545,0.0096581,0.0013558731,0.18902655,0.0003296486,0.22702402,0.0012040309],"about_ca_topic_score_codex":0.00050839386,"about_ca_topic_score_gemma":0.00016956122,"teacher_disagreement_score":0.2206997,"about_ca_system_score_codex":0.000038279868,"about_ca_system_score_gemma":0.00075103977,"threshold_uncertainty_score":0.99924815},"labels":[],"label_agreement":null},{"id":"W3203193843","doi":"10.1016/j.annonc.2021.08.1273","title":"863MO Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Nomogram; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Internal medicine; Basal cell; Chemoradiotherapy; Head and neck cancer; Overall survival; Radiation therapy; Surgery","score_opus":0.040716057913516346,"score_gpt":0.3391320606721518,"score_spread":0.29841600275863545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203193843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955878,0.0015501478,0.000053489086,0.00060076144,0.00007392759,0.00050411094,0.0001784544,0.0000030894964,0.0014481776],"genre_scores_gemma":[0.9987303,0.00022594786,0.00069320935,0.00019801705,0.000022784983,0.00004910675,0.00004307651,0.000009505957,0.00002805122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896663,0.000074510615,0.00045463257,0.00021646665,0.00010120452,0.00018657473],"domain_scores_gemma":[0.9980303,0.00093291776,0.00031105604,0.00011782463,0.000563442,0.000044429675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031937988,0.0000994046,0.00077997224,0.0001295428,0.00004404389,0.0000018125103,0.000038052753,0.00009373189,0.0000051612733],"category_scores_gemma":[0.00083638425,0.00008299982,0.00012750408,0.00034354223,0.000109428984,0.00004390379,0.000054639313,0.00008547218,2.846646e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012112549,0.0007031126,0.8850373,0.00072189956,0.0002459835,0.0000022562367,0.0033852945,0.00003277655,0.0014412323,0.000017789884,0.00009871375,0.10710238],"study_design_scores_gemma":[0.008068792,0.0048998697,0.9699236,0.00013156139,0.00042046283,0.0000015333886,0.0013294322,0.0008427476,0.013731637,0.00006611762,0.0005068643,0.00007737664],"about_ca_topic_score_codex":0.00014535924,"about_ca_topic_score_gemma":0.0021402866,"teacher_disagreement_score":0.107025005,"about_ca_system_score_codex":0.000030047422,"about_ca_system_score_gemma":0.00028830854,"threshold_uncertainty_score":0.33846346},"labels":[],"label_agreement":null},{"id":"W3203206766","doi":"10.1016/j.annonc.2021.08.736","title":"1848P Feasible 3D printed models of renal cell cancer with venous thrombus extension for surgical planning and simulation: Phase I NCT03738488","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ignyta; European Society for Medical Oncology; Eisai; MacroGenics; Grifols; Actuate Therapeutics; Servier; Tarveda Therapeutics; Sierra Oncology; Incyte; F. Hoffmann-La Roche; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Array BioPharma; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Centro de Investigación Biomédica en Red de Cáncer; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Surgical planning; Renal cell carcinoma; Radiology; Thrombus; Radiological weapon; Clinical trial; Radiation treatment planning; Cancer; Surgery; Medical physics; Oncology; Internal medicine; Radiation therapy","score_opus":0.19395884662410695,"score_gpt":0.4386280661718895,"score_spread":0.24466921954778253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203206766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99023306,0.0049380222,0.0013805846,0.0006094168,0.000042803407,0.0004164261,0.00002586049,0.000011707277,0.002342133],"genre_scores_gemma":[0.99659735,0.00026765955,0.0026170164,0.00014123258,0.00006444626,0.000023764744,0.000049369202,0.000017811597,0.00022133329],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899095,0.00005651336,0.00030931336,0.00027070692,0.00016846042,0.00020407187],"domain_scores_gemma":[0.99858034,0.00028683257,0.00020019889,0.00019398084,0.0006298597,0.0001088046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014777061,0.00012857419,0.0005910832,0.00007032481,0.00003792413,0.0000030387773,0.000032434073,0.00011316811,0.00005114883],"category_scores_gemma":[0.000028716722,0.00009856901,0.000075944365,0.00011780187,0.000103782724,0.000050502837,0.000034129218,0.00009097989,4.3217e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058830895,0.018248837,0.013060589,0.0027136034,0.0018611518,0.0103464965,0.0059019485,0.55911654,0.18430413,0.00047592985,0.0019006603,0.1432392],"study_design_scores_gemma":[0.04667447,0.055499393,0.010820206,0.0011387063,0.0011245168,0.0011639182,0.00052763976,0.14777362,0.71902186,0.00070092146,0.015107557,0.00044717392],"about_ca_topic_score_codex":0.00004729858,"about_ca_topic_score_gemma":0.00001210425,"teacher_disagreement_score":0.53471774,"about_ca_system_score_codex":0.000042437365,"about_ca_system_score_gemma":0.0004368816,"threshold_uncertainty_score":0.40195277},"labels":[],"label_agreement":null},{"id":"W3203211236","doi":"10.1016/j.annonc.2021.08.1768","title":"1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of Toronto; University Health Network; William Osler Health System","funders":"Roche; AstraZeneca","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Hazard ratio; Reimbursement; Overall survival; Placebo; Stage (stratigraphy); Cancer; Confidence interval; Adenocarcinoma; Pathology","score_opus":0.08022928519881459,"score_gpt":0.40717503482220657,"score_spread":0.32694574962339196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203211236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288386,0.0002537115,0.00022208154,0.004076322,0.0003554675,0.00060316175,0.00015339757,0.00001592012,0.0014360672],"genre_scores_gemma":[0.99716854,0.00009459162,0.00033298988,0.0012215971,0.00007747613,0.000024191384,0.00045812078,0.000019112014,0.0006033829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874157,0.00013996082,0.00037545254,0.0002530256,0.00024917247,0.00024081915],"domain_scores_gemma":[0.99873745,0.00033812693,0.0001747156,0.0002897513,0.00038578786,0.00007418765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013690455,0.00014556163,0.00053998054,0.000053028023,0.00005304927,0.000010668027,0.000086839114,0.00010002785,0.0001755292],"category_scores_gemma":[0.00008439505,0.00008890719,0.000092911934,0.0001840482,0.000075415235,0.00007549945,0.000038291957,0.00016302736,0.0000094679435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013576718,0.0022337139,0.9691063,0.000019085603,0.00092944846,0.00024150308,0.001423366,0.00072940387,0.000021008114,0.000067132314,0.00021694787,0.011435354],"study_design_scores_gemma":[0.078743264,0.0033720224,0.91499853,0.0001006282,0.00034168243,0.000001591626,0.00044247077,0.00013217115,0.00025106946,0.00010366592,0.0013690821,0.00014382278],"about_ca_topic_score_codex":0.00080696255,"about_ca_topic_score_gemma":0.0009484828,"teacher_disagreement_score":0.06516655,"about_ca_system_score_codex":0.000081944694,"about_ca_system_score_gemma":0.0005661778,"threshold_uncertainty_score":0.362553},"labels":[],"label_agreement":null},{"id":"W3203232737","doi":"10.1016/j.annonc.2021.08.1900","title":"1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"BeiGene","keywords":"Medicine; Immunotherapy; Myeloid; Immunosuppression; Debulking; Chemotherapy; Oncology; Cancer research; Internal medicine; Immunology; Immune system; Cancer; Ovarian cancer","score_opus":0.029457590352189863,"score_gpt":0.31698012425351346,"score_spread":0.2875225339013236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203232737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700012,0.0014301245,0.00015239442,0.020456739,0.00029617446,0.0010973306,0.00004625017,0.00004894288,0.006470794],"genre_scores_gemma":[0.9810577,0.0015948195,0.003453755,0.010508393,0.000095300056,0.00014451423,0.00015170767,0.00009057863,0.0029032568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976297,0.00022013673,0.00069619896,0.00051192107,0.0004424186,0.00049963896],"domain_scores_gemma":[0.99826795,0.00025947284,0.00032831362,0.00051410514,0.00048418881,0.00014597252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000625316,0.00032387787,0.0010597449,0.00023393812,0.000045228666,0.000017687114,0.00017630986,0.00015687809,0.00025850954],"category_scores_gemma":[0.000049148694,0.00024464144,0.00013662865,0.0009077218,0.00024439252,0.00010187909,0.000032455657,0.00027970332,0.000006701685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24751525,0.0031690365,0.010787153,0.0004646242,0.002038124,0.0004917838,0.0021137532,0.000011324722,0.6534271,0.00012195382,0.004869091,0.074990764],"study_design_scores_gemma":[0.0640083,0.034500726,0.26806155,0.0010762729,0.00018058732,0.00006594135,0.0013251362,0.0000062347913,0.4282476,0.00013720841,0.20142058,0.0009698566],"about_ca_topic_score_codex":0.0001799083,"about_ca_topic_score_gemma":0.0025515785,"teacher_disagreement_score":0.2572744,"about_ca_system_score_codex":0.00016945384,"about_ca_system_score_gemma":0.0016649984,"threshold_uncertainty_score":0.99761885},"labels":[],"label_agreement":null},{"id":"W3203244635","doi":"10.1016/j.annonc.2021.08.1375","title":"991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Oncology; Internal medicine; Adverse effect; Lung cancer; Endometrial cancer; Safety profile; Cancer","score_opus":0.10296879902182755,"score_gpt":0.4084979131402553,"score_spread":0.30552911411842776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203244635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928511,0.00096473715,2.8207378e-7,0.0013402158,0.00025220643,0.00075165386,0.000007694411,0.000017076694,0.0038150565],"genre_scores_gemma":[0.99806446,0.00077299844,0.00004954716,0.00077250623,0.000046401106,0.00007730276,0.000010763082,0.000016702155,0.00018933887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983945,0.00035002315,0.00041658172,0.0002931102,0.00023459602,0.00031117335],"domain_scores_gemma":[0.99910957,0.00019461363,0.00013068903,0.00037508496,0.00013131532,0.000058728423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033755373,0.0001648278,0.0004472017,0.00010519271,0.000043956876,0.000002228547,0.00013416923,0.0001263255,0.00039326944],"category_scores_gemma":[0.00010767585,0.00011548836,0.00013213383,0.00033397521,0.000059316717,0.00003411305,0.000045151002,0.00020644354,0.000017416423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023117084,0.009315427,0.89459103,0.000046775967,0.00080990006,0.0018646393,0.020656507,0.00024099374,0.017263869,0.000019255804,0.0003255722,0.052554343],"study_design_scores_gemma":[0.011848571,0.01325939,0.94174427,0.000055234785,0.0000803161,0.0001670743,0.006361778,0.000018320148,0.019373337,0.00010989278,0.0068358476,0.00014595737],"about_ca_topic_score_codex":0.0001780265,"about_ca_topic_score_gemma":0.0004158106,"teacher_disagreement_score":0.052408386,"about_ca_system_score_codex":0.0001341659,"about_ca_system_score_gemma":0.00033991877,"threshold_uncertainty_score":0.47094786},"labels":[],"label_agreement":null},{"id":"W3203284733","doi":"10.1016/j.annonc.2021.08.1445","title":"1060P Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Metabolome; Medicine; Melanoma; Metabolomics; Immune system; Cancer research; Oncology; Internal medicine; Immunology; Metabolite; Bioinformatics; Biology","score_opus":0.019772711923816345,"score_gpt":0.26961147073958225,"score_spread":0.2498387588157659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203284733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96410066,0.03471106,0.0000014624303,0.00059197267,0.00013269282,0.00023481672,0.000053613283,0.000010765182,0.00016293912],"genre_scores_gemma":[0.9962683,0.002782558,0.00019683452,0.0002838149,0.000008565205,0.00001771706,0.000049820035,0.000014198132,0.00037824857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801433,0.0007248476,0.00048455587,0.0003365952,0.0000349322,0.0004047623],"domain_scores_gemma":[0.99905205,0.00045018498,0.00019142333,0.00017935217,0.00010552977,0.00002145204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030340982,0.00021046597,0.00082619645,0.00025029716,0.00005857402,0.000009822038,0.00011693251,0.000278893,0.00009122949],"category_scores_gemma":[0.0001534924,0.00016774186,0.00004093726,0.00022044792,0.00029567245,0.000115299044,0.00009280591,0.00027094674,0.0000036245065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003771145,0.0005904302,0.7590598,0.00004553142,0.00026756086,0.00004622654,0.0007900916,2.99604e-7,0.20376126,0.00093177415,0.000023366312,0.03071253],"study_design_scores_gemma":[0.0038805197,0.0019455262,0.84007233,0.0000544957,0.000029545778,0.00011694854,0.00042730308,0.0000010946363,0.15161885,0.0002735436,0.0013975654,0.0001822424],"about_ca_topic_score_codex":0.00012674916,"about_ca_topic_score_gemma":0.00017053436,"teacher_disagreement_score":0.081012584,"about_ca_system_score_codex":0.000012340401,"about_ca_system_score_gemma":0.00014634864,"threshold_uncertainty_score":0.6840315},"labels":[],"label_agreement":null},{"id":"W3203295350","doi":"10.1016/j.annonc.2021.08.1131","title":"618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN &amp; SPARTAN","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Androgen deprivation therapy; Internal medicine; Prostate-specific antigen; Metastasis; Overall survival; Titan (rocket family); Urology; Cancer","score_opus":0.07562218545953421,"score_gpt":0.44387280410939806,"score_spread":0.36825061864986386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203295350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921996,0.0013876692,0.000010156263,0.0039805216,0.000109625944,0.000773601,0.00029490332,0.000008279418,0.0012356406],"genre_scores_gemma":[0.9938917,0.0020390765,0.0003760618,0.00038461885,0.000018370261,0.00020509411,0.0005176112,0.000016438755,0.0025510176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985978,0.00007887934,0.00046419943,0.00028446032,0.00022348367,0.00035116452],"domain_scores_gemma":[0.9983481,0.00018238231,0.00020409838,0.0002600437,0.0009000896,0.00010528777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022454401,0.00012460795,0.0008118761,0.00035211068,0.000025337335,0.000002943336,0.00007419183,0.00009124404,0.00027480297],"category_scores_gemma":[0.0001835924,0.00010507838,0.00020551193,0.0009297417,0.00012368227,0.00005457664,0.000044321478,0.000107121086,0.0000023611294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065914523,0.0037543683,0.88510585,0.0005023588,0.0029871305,0.00006322787,0.0016709528,0.0003797144,0.0119462,0.00018684605,0.0037282624,0.083083615],"study_design_scores_gemma":[0.021622444,0.004937143,0.8798279,0.00028263355,0.001136389,0.0000015253723,0.00043635268,0.00032228665,0.0646711,0.00048714565,0.026043298,0.00023177198],"about_ca_topic_score_codex":0.00015663859,"about_ca_topic_score_gemma":0.0024623838,"teacher_disagreement_score":0.08285184,"about_ca_system_score_codex":0.00012523397,"about_ca_system_score_gemma":0.00051697216,"threshold_uncertainty_score":0.42849723},"labels":[],"label_agreement":null},{"id":"W3203349714","doi":"10.1016/j.annonc.2021.08.430","title":"149P Can high Ki67 predict distant recurrence in early stage breast cancer with low oncotype Dx score?","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Oncology; Stage (stratigraphy); Internal medicine; Breast cancer; Gynecology; Cancer","score_opus":0.02381439275930179,"score_gpt":0.31481740951006765,"score_spread":0.29100301675076584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203349714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202794,0.0014390337,0.000021401216,0.0045150192,0.00021866898,0.00014591505,0.00081647,0.000008153316,0.0008074137],"genre_scores_gemma":[0.9958723,0.0028044814,0.00013954916,0.00055910746,0.00014070832,0.00008207737,0.00012986503,0.000020641548,0.0002512577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986731,0.0001037254,0.00025786657,0.00045720168,0.00014714793,0.0003609856],"domain_scores_gemma":[0.9990454,0.000029345307,0.00016477742,0.0003388179,0.0003330804,0.00008862805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103251725,0.00019673163,0.00037236867,0.00004442092,0.00004343739,0.000007915737,0.00015789777,0.00014873849,0.00006162898],"category_scores_gemma":[0.000033697743,0.00016725418,0.00005952739,0.00021107851,0.00023724239,0.0000062646923,0.00013261147,0.00012401301,0.000002271392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030587735,0.0014852915,0.9218842,0.00017634162,0.00080342573,0.0005165503,0.00087735214,0.00026443822,0.021478485,0.00045160967,0.0045009768,0.044502564],"study_design_scores_gemma":[0.0021175672,0.0016485297,0.9158072,0.0001920643,0.0000481169,0.00006145889,0.00021524244,0.0000035950954,0.06685082,0.00008462597,0.012688304,0.00028246598],"about_ca_topic_score_codex":0.003463271,"about_ca_topic_score_gemma":0.02166562,"teacher_disagreement_score":0.045372333,"about_ca_system_score_codex":0.00006594364,"about_ca_system_score_gemma":0.00080662133,"threshold_uncertainty_score":0.99618644},"labels":[],"label_agreement":null},{"id":"W3203355818","doi":"10.1016/j.annonc.2021.08.094","title":"698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Internal medicine; Subgroup analysis; Cancer; Bladder cancer; Meta-analysis","score_opus":0.06765254941092885,"score_gpt":0.3978981944408646,"score_spread":0.33024564502993575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203355818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993193,0.00088276266,0.00029154285,0.0012336702,0.00018434576,0.0019479133,0.0012129913,0.00002519499,0.0010286035],"genre_scores_gemma":[0.9948366,0.00060982356,0.0016096124,0.0010512845,0.00022242374,0.00026286853,0.00063236954,0.000047429716,0.0007275484],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974306,0.00015485527,0.0011163033,0.00055372436,0.00032508097,0.00041939053],"domain_scores_gemma":[0.99738926,0.00036682718,0.0005968544,0.00065842335,0.00075753755,0.0002311104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002652814,0.0003186691,0.002353364,0.00038667122,0.000040646777,0.000005128359,0.00017889288,0.00025365106,0.00068145484],"category_scores_gemma":[0.00021365231,0.00028045283,0.0009212298,0.0008281994,0.00013344445,0.00006481683,0.000024663876,0.00010944176,0.0000031754944],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5658718,0.009824913,0.013475049,0.00024339334,0.009295116,0.00012722146,0.0035319305,0.000051835068,0.2405055,0.00006465111,0.0018072684,0.15520133],"study_design_scores_gemma":[0.26878446,0.034631334,0.013290973,0.000094676994,0.0061610756,0.0000072393223,0.00024869785,0.00013076703,0.6701565,0.000103499246,0.0061571333,0.0002336792],"about_ca_topic_score_codex":0.0019987302,"about_ca_topic_score_gemma":0.00045110393,"teacher_disagreement_score":0.42965096,"about_ca_system_score_codex":0.000100044985,"about_ca_system_score_gemma":0.0010235843,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W3203371059","doi":"10.1016/j.annonc.2021.08.2108","title":"LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Internal medicine; Placebo; Oncology; Phases of clinical research; Cervical cancer; Cancer; Immunotherapy; Pathology","score_opus":0.21116087590729918,"score_gpt":0.4722033107881647,"score_spread":0.26104243488086554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203371059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9489897,0.010464418,0.0004249131,0.021009533,0.0023435045,0.011586644,0.0002449067,0.00011552253,0.0048208986],"genre_scores_gemma":[0.97902393,0.008485642,0.0008190534,0.004116074,0.0008416674,0.0030474144,0.00026291967,0.00010831404,0.0032949783],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961786,0.00043833852,0.0011954837,0.0008308339,0.00059914717,0.0007575556],"domain_scores_gemma":[0.9955354,0.002038368,0.00057993096,0.00056081766,0.00084666384,0.00043883116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000927593,0.00052144506,0.003197871,0.0002813702,0.00015081128,0.000029697407,0.00028271248,0.00025359934,0.0028997592],"category_scores_gemma":[0.00041132251,0.00038050703,0.001190135,0.00082579313,0.0002682018,0.00010712262,0.00007833326,0.00034126107,0.000016123651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8903356,0.007032112,0.000033370725,0.00026205514,0.006801198,0.00019380642,0.0017781105,0.00003161597,0.000112962465,0.000093805735,0.0020301912,0.09129514],"study_design_scores_gemma":[0.9410023,0.026249496,0.000028888931,0.000090500595,0.0025047567,0.000062932995,0.0017721913,0.00048500072,0.0034832475,0.0000846926,0.023902822,0.00033313374],"about_ca_topic_score_codex":0.00067067775,"about_ca_topic_score_gemma":0.0007594266,"teacher_disagreement_score":0.09096201,"about_ca_system_score_codex":0.00058022863,"about_ca_system_score_gemma":0.0022660727,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W3203410111","doi":"10.1016/j.annonc.2021.08.1237","title":"795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Microsatellite instability; Internal medicine; Oncology; Cohort; Clinical endpoint; Cancer; Population; Endometrial cancer; Clinical trial; Immunotherapy","score_opus":0.039490201485657496,"score_gpt":0.3396616355766867,"score_spread":0.3001714340910292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203410111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910679,0.0012581463,0.0000070031174,0.002140592,0.0011528052,0.0008191528,0.0009133653,0.000039063198,0.002601986],"genre_scores_gemma":[0.993816,0.00093339605,0.0020841993,0.001622066,0.00019020804,0.00005757687,0.000995801,0.00005282709,0.00024793737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963549,0.00037570976,0.0011494011,0.0009261312,0.00053981756,0.00065406685],"domain_scores_gemma":[0.99663,0.0006995476,0.0005089519,0.0007623737,0.0011614802,0.0002376368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037826525,0.00036345507,0.0012738663,0.00031618803,0.000044143286,0.000013209885,0.00023974106,0.0004300051,0.0007807956],"category_scores_gemma":[0.0014251046,0.0003222356,0.00015371351,0.0011643915,0.000317676,0.00011387167,0.00017365626,0.0005373209,0.000022238937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29844326,0.007335406,0.28382584,0.00026597411,0.0011635497,0.0006163394,0.003593792,0.0010402839,0.0732954,0.00004920374,0.007863341,0.3225076],"study_design_scores_gemma":[0.08243473,0.012190812,0.5284879,0.0004733917,0.00017364415,0.000015466348,0.00027573743,0.000026059739,0.3008876,0.00032094118,0.0741619,0.0005517997],"about_ca_topic_score_codex":0.0032444145,"about_ca_topic_score_gemma":0.0039420547,"teacher_disagreement_score":0.3219558,"about_ca_system_score_codex":0.0004321982,"about_ca_system_score_gemma":0.001629022,"threshold_uncertainty_score":0.999923},"labels":[],"label_agreement":null},{"id":"W3203448690","doi":"10.1016/j.annonc.2021.08.1193","title":"751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Meta-analysis; Oncology; Ovarian cancer; Internal medicine; Cancer","score_opus":0.19887061607185905,"score_gpt":0.40217141036449183,"score_spread":0.20330079429263279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203448690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94554234,0.02153003,0.000041619005,0.03060499,0.00019025912,0.00067816215,0.0010295624,0.000009251003,0.00037381402],"genre_scores_gemma":[0.9924697,0.005323807,0.000469546,0.001176069,0.0000695576,0.00016354052,0.00022849691,0.000018470771,0.000080795515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974624,0.0006734598,0.0006361485,0.0005876362,0.00034404497,0.00029633442],"domain_scores_gemma":[0.9955393,0.0023999782,0.00038885264,0.001278328,0.00029808635,0.0000954239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007122535,0.00022361566,0.0015953063,0.00008167495,0.00006460689,0.000015897142,0.00037810585,0.00012920026,0.0003916357],"category_scores_gemma":[0.0005683264,0.00012794785,0.00044425856,0.0008198563,0.0002109459,0.00011368059,0.0003228867,0.00020430856,0.0000019276333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095267047,0.0032038018,0.83062804,0.00009563952,0.13143253,0.00041474667,0.0022462895,0.0019543692,0.00052000204,0.0013526737,0.0030400213,0.024159202],"study_design_scores_gemma":[0.004814868,0.00069104607,0.92006624,0.000056471374,0.06840198,0.000003885995,0.00034694673,0.0010872958,0.00081286917,0.0017536685,0.0018146618,0.00015007789],"about_ca_topic_score_codex":0.019617505,"about_ca_topic_score_gemma":0.044101816,"teacher_disagreement_score":0.08943818,"about_ca_system_score_codex":0.000047548834,"about_ca_system_score_gemma":0.00050109206,"threshold_uncertainty_score":0.98691094},"labels":[],"label_agreement":null},{"id":"W3203496479","doi":"10.1016/j.annonc.2021.08.1348","title":"963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Stand Up To Cancer; Kom op tegen Kanker; Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Internal medicine; Population; Multicenter trial; Progressive disease; Phases of clinical research; Interim analysis; Salvage therapy; Clinical trial; Minimal residual disease; Surgery; Bone marrow; Chemotherapy; Randomized controlled trial; Multicenter study","score_opus":0.1351606975645585,"score_gpt":0.4364078917801264,"score_spread":0.3012471942155679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203496479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754094,0.0007269977,0.00003358521,0.019461637,0.0005127193,0.0014423487,0.0023005034,0.000013454904,0.000099392026],"genre_scores_gemma":[0.9899496,0.0068007093,0.00032805276,0.0007269193,0.00030492636,0.00006217012,0.0014119754,0.000023519116,0.00039213992],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828064,0.00027950708,0.00048508236,0.0004237675,0.0002785956,0.00025237765],"domain_scores_gemma":[0.9952144,0.003096395,0.000324508,0.0008996922,0.00034861063,0.00011640275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000269922,0.00017658553,0.00048610696,0.000054726548,0.00015916399,0.000014570432,0.0003495442,0.00009382305,0.00029476668],"category_scores_gemma":[0.00089188246,0.000097626755,0.00012714072,0.00010943289,0.00023643707,0.00008672196,0.00024373786,0.00015102937,0.0000095989],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50715595,0.038271103,0.0005568291,0.000020925483,0.0056283046,0.00038480764,0.00072619715,0.000008446966,0.022726731,0.000067027584,0.06875816,0.35569552],"study_design_scores_gemma":[0.34797174,0.07909199,0.010313941,0.000046104804,0.0009093965,0.000028660825,0.0001785698,0.0010084808,0.031316005,0.000066690955,0.5289551,0.00011333124],"about_ca_topic_score_codex":0.00038161053,"about_ca_topic_score_gemma":0.00029667045,"teacher_disagreement_score":0.4601969,"about_ca_system_score_codex":0.000040877156,"about_ca_system_score_gemma":0.00030500515,"threshold_uncertainty_score":0.39811033},"labels":[],"label_agreement":null},{"id":"W3203507075","doi":"10.1016/j.annonc.2021.08.892","title":"1746P Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eisai Incorporated; Merck Sharp and Dohme","keywords":"Medicine; Thyroid cancer; Refractory (planetary science); Quality of life (healthcare); Health related quality of life; Internal medicine; Oncology; Phases of clinical research; Thyroid; Nuclear medicine; Clinical trial","score_opus":0.20217155440781712,"score_gpt":0.4694646154738367,"score_spread":0.2672930610660196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203507075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99146974,0.005553754,0.0000025980235,0.00075766817,0.00006106163,0.0017045507,0.00034024028,0.00002988752,0.000080491394],"genre_scores_gemma":[0.99837637,0.0005948464,0.00007181586,0.00032203988,0.000026321064,0.00021798129,0.00031369613,0.00004303685,0.000033863715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951146,0.0011338097,0.0019925716,0.0006628705,0.0006523952,0.00044372908],"domain_scores_gemma":[0.9957393,0.000624109,0.0019224004,0.0006016322,0.0008739525,0.00023862052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047330628,0.00039900732,0.0025836257,0.00033277538,0.00006547089,0.0000074128875,0.00013921481,0.00012701644,0.0002722693],"category_scores_gemma":[0.00024196229,0.00028172054,0.00015001865,0.00095477543,0.00016441479,0.00011012218,0.00006514471,0.00028784803,0.0000011787762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014364861,0.06866134,0.89622325,0.0001294023,0.004519436,0.00013237372,0.0061641857,0.00010952894,0.0016396834,0.0000033045376,0.00025834088,0.0077942763],"study_design_scores_gemma":[0.07464352,0.05956456,0.8486612,0.00041000842,0.0007338065,7.893925e-7,0.007231045,0.000013949511,0.008485542,0.0000055665814,0.000039925293,0.00021011192],"about_ca_topic_score_codex":0.035925325,"about_ca_topic_score_gemma":0.021979587,"teacher_disagreement_score":0.060278665,"about_ca_system_score_codex":0.00023596798,"about_ca_system_score_gemma":0.0012538827,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W3203560672","doi":"10.1016/j.annonc.2021.08.1818","title":"1213P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Universitair Medisch Centrum Groningen; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Liquid biopsy; Lung cancer; Oncology; Clinical trial; Circulating tumor DNA; Mutation; Internal medicine; Biopsy; Cancer; Intensive care medicine; Gene","score_opus":0.06330274364038874,"score_gpt":0.42419314750913556,"score_spread":0.3608904038687468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203560672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904024,0.005896409,0.00014361167,0.002398122,0.00026861968,0.0002805877,0.0003629078,0.0000019363586,0.0002454317],"genre_scores_gemma":[0.97413373,0.024516884,0.0004882828,0.00058188,0.00013451472,0.00009562278,0.000021651675,0.0000139830545,0.000013438184],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985482,0.00012838925,0.0007304992,0.00028698498,0.000079967285,0.00022597348],"domain_scores_gemma":[0.9980094,0.0007954326,0.00041667387,0.00035341052,0.0003619682,0.00006310337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007351212,0.00010528042,0.0004253139,0.000028838105,0.000026567526,0.0000028430711,0.00019135715,0.00021949215,0.000029858038],"category_scores_gemma":[0.0016815576,0.000092753486,0.00021979793,0.00012014263,0.00020977577,0.000003047753,0.00015486909,0.000099569894,1.5876515e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009887355,0.0020939617,0.45383748,0.00052720687,0.00095293083,0.00002824577,0.0007843016,0.0012558751,0.35613623,0.000769937,0.006643826,0.16708264],"study_design_scores_gemma":[0.0031143285,0.0057101543,0.24703754,0.00015012233,0.00014713392,0.0000054441152,0.0005382674,0.00096586667,0.698287,0.00014760003,0.043627284,0.00026922586],"about_ca_topic_score_codex":0.000480221,"about_ca_topic_score_gemma":0.0011370968,"teacher_disagreement_score":0.34215078,"about_ca_system_score_codex":0.000011288368,"about_ca_system_score_gemma":0.00078142365,"threshold_uncertainty_score":0.37823772},"labels":[],"label_agreement":null},{"id":"W3203575639","doi":"10.1016/j.annonc.2021.08.1053","title":"531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Jewish General Hospital","funders":"Servier; Pfizer; American Association for Cancer Research","keywords":"Medicine; Clinical trial; Oncology; Internal medicine; Cancer research","score_opus":0.0708436817400616,"score_gpt":0.3694569890258601,"score_spread":0.2986133072857985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203575639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964401,0.00052573957,0.00005868951,0.0012504963,0.00013238852,0.0007665366,0.00041720722,0.0000026050466,0.00040622626],"genre_scores_gemma":[0.9980045,0.0003678008,0.00070658186,0.00024801353,0.00008453162,0.00012964956,0.0001964201,0.000012126408,0.00025037397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989761,0.00013181301,0.00042136628,0.00023341009,0.0000813851,0.00015589737],"domain_scores_gemma":[0.99862534,0.00025339157,0.00040984937,0.0003329358,0.00031119463,0.000067310255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018823518,0.00012816617,0.00032886554,0.000029136712,0.000093686096,0.0000025272063,0.00012131854,0.00011937075,0.0000039724277],"category_scores_gemma":[0.0004530644,0.00007615801,0.00012049794,0.00011466552,0.0003653051,0.0000045098764,0.000062691906,0.00004071099,1.4422976e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07802293,0.0037024384,0.0001499423,0.00007483899,0.0005602684,0.00001651354,0.0019948028,0.00022522973,0.88712615,0.00013468534,0.0029833894,0.025008839],"study_design_scores_gemma":[0.033649035,0.06854084,0.0005439163,0.000029253255,0.000118057775,0.00001964959,0.00038350516,0.000057106452,0.87449807,0.000099738696,0.021977974,0.00008284976],"about_ca_topic_score_codex":0.000020492109,"about_ca_topic_score_gemma":0.00004263314,"teacher_disagreement_score":0.0648384,"about_ca_system_score_codex":0.0000049986875,"about_ca_system_score_gemma":0.00070253375,"threshold_uncertainty_score":0.31056333},"labels":[],"label_agreement":null},{"id":"W3203649038","doi":"10.1016/j.annonc.2021.08.1597","title":"1604P Global survey of 104 cancer patient organisations reveals devastating impact of COVID-19","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Medicine; Pandemic; Cancer; Coronavirus disease 2019 (COVID-19); Family medicine; Internal medicine","score_opus":0.19215208655327284,"score_gpt":0.41719749999313066,"score_spread":0.22504541343985782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203649038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783217,0.0038269772,0.000652328,0.001164701,0.00026084337,0.00013354661,0.0051313,0.0000066241805,0.010501989],"genre_scores_gemma":[0.99712294,0.0013529565,0.0004644824,0.0008798038,0.000035019064,0.000009437552,0.00005098652,0.000012888252,0.00007149303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980791,0.00008333236,0.0012415228,0.00027008192,0.000037493544,0.00028847693],"domain_scores_gemma":[0.99715555,0.0003224894,0.0015856893,0.00028138145,0.0004908902,0.00016400113],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084326946,0.00013408423,0.000905715,0.00010310574,0.000044014338,0.000007635524,0.000172448,0.00015654264,0.0014313648],"category_scores_gemma":[0.0027090835,0.0001545305,0.0002057852,0.00041523212,0.00015655042,0.00014609865,0.000081861755,0.000083282706,0.000016112963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012894263,0.0003335948,0.9495227,0.00009753813,0.00030656895,0.000005329837,0.0011315763,0.0019138032,0.00023600423,0.021184374,0.010819172,0.014320446],"study_design_scores_gemma":[0.0007774201,0.0010294529,0.96730286,0.000025745865,0.000012700113,0.000006478086,0.00016390675,0.00008109066,0.0011032082,0.0198367,0.009457721,0.0002026967],"about_ca_topic_score_codex":0.031150421,"about_ca_topic_score_gemma":0.004199153,"teacher_disagreement_score":0.026951268,"about_ca_system_score_codex":0.00037927824,"about_ca_system_score_gemma":0.0018747187,"threshold_uncertainty_score":0.99948144},"labels":[],"label_agreement":null},{"id":"W3203660887","doi":"10.1016/j.annonc.2021.08.1226","title":"784P Survival outcomes in cervical cancer: What factors affect recurrence?","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of the Fraser Valley; University of British Columbia","funders":"","keywords":"Medicine; Affect (linguistics); Cervical cancer; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.15582643939372098,"score_gpt":0.4471352458268479,"score_spread":0.2913088064331269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203660887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97335064,0.0051597417,0.0000019924773,0.015516349,0.0012517924,0.00019000197,0.000027761951,0.000016583761,0.004485129],"genre_scores_gemma":[0.9900616,0.00771746,0.000053356038,0.0015602219,0.0001107826,0.000032197524,0.00004126741,0.00001160179,0.00041154202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856937,0.00019656806,0.00036606105,0.00028630052,0.00025593414,0.000325785],"domain_scores_gemma":[0.9986303,0.00069835223,0.0001054447,0.00020770742,0.00018904323,0.00016914569],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021613875,0.0001558179,0.00093537284,0.00013836415,0.00002100947,0.000009663168,0.00009046741,0.00018199108,0.0012033122],"category_scores_gemma":[0.00042873964,0.00011556312,0.0002126063,0.00054365123,0.00007630623,0.000115855764,0.00006853249,0.00021349022,0.000016889371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004536712,0.0012054653,0.83312666,0.00009233598,0.0002203818,0.00026791097,0.00026114794,0.0000024940177,0.0003009642,0.0001850002,0.0003555676,0.16352841],"study_design_scores_gemma":[0.0044775563,0.0021943357,0.9631938,0.00016492934,0.000082014005,0.000010024093,0.0006322955,0.0000031847171,0.0132533265,0.00046469376,0.015390705,0.00013313716],"about_ca_topic_score_codex":0.0008753981,"about_ca_topic_score_gemma":0.0020143944,"teacher_disagreement_score":0.16339527,"about_ca_system_score_codex":0.00010764666,"about_ca_system_score_gemma":0.00043136472,"threshold_uncertainty_score":0.9997097},"labels":[],"label_agreement":null},{"id":"W3203727420","doi":"10.1016/j.annonc.2021.08.2125","title":"LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Exon; Oncology; Multinational corporation; Internal medicine; Phases of clinical research; Phase (matter); Cancer research; Genetics; Gene; Chemotherapy","score_opus":0.07694720565537184,"score_gpt":0.47024311486773435,"score_spread":0.3932959092123625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203727420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914129,0.00093328225,0.000021761896,0.0031138458,0.00007658164,0.0007741582,0.00008559249,0.000012217332,0.003569662],"genre_scores_gemma":[0.9976999,0.0002690839,0.001035611,0.00015154426,0.00004644692,0.00008331304,0.00014673568,0.000012200684,0.0005551206],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988788,0.00010425068,0.00046260425,0.0002480599,0.00014250388,0.00016380558],"domain_scores_gemma":[0.9989461,0.0003141758,0.00017858812,0.00015804895,0.0003243599,0.00007874565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014816399,0.00012609575,0.00045750453,0.0001695734,0.000072680035,0.0000037952657,0.00003321032,0.0000694137,0.00012737724],"category_scores_gemma":[0.00021087455,0.0001108712,0.00006326175,0.00025834018,0.00007814251,0.000073276475,0.000034708148,0.00007351683,0.0000019760696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050414144,0.091627896,0.117846794,0.00017716276,0.0028450757,0.001242074,0.03693462,0.00024310606,0.015301741,0.0012209204,0.0003357552,0.72718346],"study_design_scores_gemma":[0.15702198,0.06958083,0.7117517,0.00048706305,0.001546489,0.00018755722,0.016132047,0.0006055448,0.019306216,0.00028356345,0.022703608,0.00039340826],"about_ca_topic_score_codex":0.00024946508,"about_ca_topic_score_gemma":0.00036854908,"teacher_disagreement_score":0.72679,"about_ca_system_score_codex":0.00011204806,"about_ca_system_score_gemma":0.0006074944,"threshold_uncertainty_score":0.45211965},"labels":[],"label_agreement":null},{"id":"W3203777222","doi":"10.1016/j.annonc.2021.08.1467","title":"1082P Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; PDGFRA; Melanoma; Broad spectrum; Cancer research; GiST","score_opus":0.06638569691715356,"score_gpt":0.396279916628074,"score_spread":0.3298942197109204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203777222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967352,0.00013359255,0.0000043214627,0.0012473606,0.000028713926,0.0009268237,0.00003327512,0.000013987232,0.0008766998],"genre_scores_gemma":[0.9991464,0.000033737528,0.0003693217,0.00013642602,0.000022816866,0.00004314105,0.00005914048,0.000019652416,0.00016938595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981189,0.00022902065,0.0005035776,0.00037137663,0.00035984672,0.00041731942],"domain_scores_gemma":[0.9985586,0.00025969406,0.00020494542,0.0002890295,0.00044225148,0.0002455154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002460008,0.00019026484,0.00074751565,0.00022027979,0.000031810105,0.000007050657,0.00007480686,0.00006184987,0.0002078241],"category_scores_gemma":[0.00048580233,0.00013486849,0.000048464455,0.00041410382,0.00016728621,0.000054906697,0.00009929746,0.0002330443,0.0000052292135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028953763,0.037495144,0.9084355,0.00019982885,0.00048612294,0.006087277,0.0014798708,0.0000048687084,0.0014878003,0.00004562371,0.0006705121,0.01465366],"study_design_scores_gemma":[0.056453202,0.19394061,0.73257893,0.00034781118,0.00013513758,0.00029480006,0.002064292,0.000026818154,0.013303314,0.00011304634,0.0005802511,0.00016179113],"about_ca_topic_score_codex":0.00045593144,"about_ca_topic_score_gemma":0.0005850394,"teacher_disagreement_score":0.1758566,"about_ca_system_score_codex":0.00005880639,"about_ca_system_score_gemma":0.0005592205,"threshold_uncertainty_score":0.5499777},"labels":[],"label_agreement":null},{"id":"W3203793933","doi":"10.1016/j.annonc.2021.08.1040","title":"518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Sierra Oncology; PharmaMar; Eisai; G1 Therapeutics; MacroGenics; Silverback Therapeutics; Astex Pharmaceuticals; Ribon Therapeutics; Syndax Pharmaceuticals; Pfizer; Innovent Biologics; Incyte; NuCana; Daiichi Sankyo Europe; Calithera Biosciences; Mersana Therapeutics; Amgen; Radius Health; Deciphera Pharmaceuticals; Jounce Therapeutics; Ipsen; Five Prime Therapeutics; Merck KGaA; Puma Biotechnology; Regeneron Pharmaceuticals; Plexxikon; Seagen; Relay Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Tolerability; Solid tumor; Pharmacology; Oncology; Internal medicine; Adverse effect; Cancer","score_opus":0.035548162021933026,"score_gpt":0.3668076639738672,"score_spread":0.3312595019519342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203793933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974753,0.00044109728,0.00002340482,0.0011058586,0.00008803022,0.00052173826,0.000022736958,0.000010739107,0.00031108165],"genre_scores_gemma":[0.9987759,0.0001876045,0.0006641836,0.00029553176,0.000020439318,0.000018175528,0.000012705741,0.000015356742,0.000010088046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983054,0.00030928486,0.0005308166,0.0004263576,0.00019185815,0.00023629633],"domain_scores_gemma":[0.99857247,0.00022510298,0.00029387992,0.0002380553,0.0005310346,0.00013947517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040415063,0.00014910132,0.0009106507,0.000088963505,0.00002142573,0.0000021293981,0.00003810979,0.00021591275,0.0000056883046],"category_scores_gemma":[0.0005336361,0.0001330691,0.00007041646,0.0002358636,0.0003656022,0.00007810225,0.000113757305,0.00037708328,3.4693073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029640708,0.007909067,0.64458495,0.0004062644,0.00036454565,0.00036641303,0.00096585345,0.00010038558,0.014925105,0.00003749688,0.00034467672,0.30035454],"study_design_scores_gemma":[0.006829621,0.026147652,0.91298836,0.0002372634,0.00007673188,0.000040067025,0.00007813943,0.00007697611,0.053124934,0.00009753898,0.00018790129,0.000114817405],"about_ca_topic_score_codex":0.00008112608,"about_ca_topic_score_gemma":0.00015742469,"teacher_disagreement_score":0.30023974,"about_ca_system_score_codex":0.00007239389,"about_ca_system_score_gemma":0.00069057697,"threshold_uncertainty_score":0.54264003},"labels":[],"label_agreement":null},{"id":"W3203807700","doi":"10.1016/j.annonc.2021.08.1043","title":"521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi; Meso Scale Diagnostics; Novartis; AstraZeneca; Amgen","keywords":"Medicine; Dosing; Carcinoembryonic antigen; Conjugate; Pharmacology; Toxicity; Limiting; Monoclonal antibody; Maximum tolerated dose; Pharmacokinetics; Antibody; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.06641753308482397,"score_gpt":0.41423351638436795,"score_spread":0.347815983299544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203807700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983463,0.00014783982,0.000032730255,0.00020176715,0.00005326505,0.0008000464,0.000026129406,0.0000058555615,0.00038604584],"genre_scores_gemma":[0.99893165,0.00008666843,0.0007725132,0.00003765909,0.00001920116,0.00002846915,0.000078796635,0.000016908507,0.000028166249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980517,0.00026706886,0.00062213023,0.00029473065,0.00047362628,0.00029071665],"domain_scores_gemma":[0.9981526,0.00022152366,0.00039562766,0.0002812188,0.00083500764,0.000113989874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016818078,0.00017273481,0.00087093574,0.00026378586,0.000024337161,0.0000029244281,0.0000826555,0.000057717993,0.00004811399],"category_scores_gemma":[0.00029303695,0.00013002797,0.00006830848,0.00030463559,0.00012899585,0.000090870366,0.00008338605,0.0001649418,0.0000016768752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060467827,0.016670585,0.89348364,0.00013163846,0.00049582525,0.00020793181,0.0012906431,0.0002815296,0.00806227,0.00006994353,0.000005918064,0.07325332],"study_design_scores_gemma":[0.02897086,0.01915619,0.85575706,0.00033379137,0.00006295467,0.0000046032924,0.0009342156,0.00036095298,0.09421666,0.00011213168,0.000006818113,0.0000837822],"about_ca_topic_score_codex":0.0002808763,"about_ca_topic_score_gemma":0.0006951456,"teacher_disagreement_score":0.086154394,"about_ca_system_score_codex":0.00009585539,"about_ca_system_score_gemma":0.0002087379,"threshold_uncertainty_score":0.5302387},"labels":[],"label_agreement":null},{"id":"W3203913124","doi":"10.1016/j.annonc.2021.08.855","title":"1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Novartis; Pfizer","keywords":"Medicine; Epithelioid sarcoma; Sarcoma; Internal medicine; Oncology; Dermatology; Pathology","score_opus":0.08651678022911768,"score_gpt":0.40228611834114575,"score_spread":0.31576933811202806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203913124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961137,0.0010550694,0.0000013517852,0.0011269726,0.00005770471,0.00054232636,0.000017985845,0.00000963726,0.0010752177],"genre_scores_gemma":[0.998626,0.0002591552,0.00047256282,0.00047781132,0.000015999372,0.000069631526,0.000023459668,0.000015890495,0.000039502727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986521,0.00011899117,0.0004717954,0.00026592173,0.00024591756,0.00024529186],"domain_scores_gemma":[0.9988065,0.00016949297,0.00024057938,0.00029847128,0.00041183984,0.00007315928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001709427,0.00014754418,0.0007485258,0.00017696896,0.000040670508,0.0000019698437,0.00007149835,0.000068037036,0.00007211821],"category_scores_gemma":[0.000131748,0.00011442303,0.00006891443,0.00034978607,0.000068940644,0.000057852238,0.00011590184,0.00009594494,0.0000030051822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019244541,0.06086698,0.72844976,0.00006810592,0.0002873261,0.000754438,0.0024331922,0.00001663295,0.0021839754,0.00007735525,0.00024760494,0.20269014],"study_design_scores_gemma":[0.041823044,0.087739885,0.8052604,0.00034476197,0.00016554592,0.000029665174,0.0034322687,0.0000067637507,0.05786957,0.000088632565,0.003085862,0.00015358171],"about_ca_topic_score_codex":0.00008828823,"about_ca_topic_score_gemma":0.00026384127,"teacher_disagreement_score":0.20253657,"about_ca_system_score_codex":0.000055771896,"about_ca_system_score_gemma":0.0001711955,"threshold_uncertainty_score":0.46660355},"labels":[],"label_agreement":null},{"id":"W3203946083","doi":"10.1016/j.annonc.2021.08.1135","title":"622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Subgroup analysis; HERO; Prostate cancer; Adverse effect; Internal medicine; Oncology; Testosterone (patch); Cancer; Gynecology; Confidence interval","score_opus":0.038564813141961446,"score_gpt":0.4342465178334426,"score_spread":0.3956817046914811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203946083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856505,0.0049528615,0.000034060507,0.0064814608,0.000019255085,0.002158891,0.0000952244,0.0000064785995,0.00060127623],"genre_scores_gemma":[0.9856837,0.013309466,0.00029773894,0.00015308577,0.000021173377,0.00031246681,0.00008503464,0.000013686612,0.00012367718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732447,0.0007492446,0.00079998473,0.00039771988,0.00042775387,0.00030081547],"domain_scores_gemma":[0.99735695,0.0012121781,0.0004060297,0.00039786493,0.0005138011,0.00011319641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013191905,0.00018337807,0.0018879627,0.000239234,0.00004458202,0.0000055614537,0.00011526699,0.00009305012,0.00010029598],"category_scores_gemma":[0.00014566674,0.00010389503,0.00020002847,0.0011163221,0.0005869169,0.000057650614,0.000100643134,0.000282567,1.0567265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5340138,0.0070396913,0.41632777,0.00011090493,0.010063405,0.00030178847,0.004369949,0.00048678496,0.0024655627,0.00006608516,0.000097392076,0.024656862],"study_design_scores_gemma":[0.5995741,0.008491533,0.37833285,0.00025248984,0.0029987635,0.0000058708933,0.0032655527,0.0007922456,0.005659174,0.00014446644,0.00033735074,0.00014559904],"about_ca_topic_score_codex":0.003582162,"about_ca_topic_score_gemma":0.0029568858,"teacher_disagreement_score":0.0655603,"about_ca_system_score_codex":0.0000585474,"about_ca_system_score_gemma":0.0007557104,"threshold_uncertainty_score":0.54151815},"labels":[],"label_agreement":null},{"id":"W3203949279","doi":"10.1016/j.annonc.2021.08.1541","title":"1432P Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; Foundation Medicine; Sierra Oncology; Medac; Servier; Vifor Pharma; Genentech; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; FibroGen; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; Celgene; BeiGene; Sanofi; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Immunotherapy; Transcriptome; Cancer; Tumor microenvironment; Gene signature; Immune system; Cancer immunotherapy; Cancer treatment; Cancer research; Oncology; Computational biology; Bioinformatics; Gene; Internal medicine; Immunology; Gene expression; Biology; Genetics","score_opus":0.0387863790187558,"score_gpt":0.3254107205136562,"score_spread":0.2866243414949004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203949279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982295,0.001352364,0.000012156341,0.014642811,0.0001956526,0.0009000297,0.00008123305,0.000008075603,0.0005127197],"genre_scores_gemma":[0.99347395,0.0012495506,0.00025500637,0.0038815257,0.000035931964,0.00012495104,0.00013939061,0.000009577162,0.0008301472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987347,0.00014377641,0.00031798164,0.00027089496,0.0002161269,0.00031652374],"domain_scores_gemma":[0.999481,0.000056978377,0.00012313371,0.00016245747,0.00011794317,0.00005844495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017419276,0.00015343283,0.0005506524,0.00017268863,0.000053729822,0.0000060881566,0.0001398788,0.00008896056,0.00024736108],"category_scores_gemma":[0.00003980478,0.00011733922,0.00015099332,0.000489132,0.00002759487,0.0000662519,0.000078254874,0.00015311633,0.000004491002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01079232,0.0056625335,0.4196437,0.00021471719,0.0005968916,0.00068879797,0.014285613,0.000059227154,0.22319421,0.00003111761,0.008998919,0.31583196],"study_design_scores_gemma":[0.020030646,0.0026478886,0.9207904,0.00010552966,0.00018864067,0.000007982608,0.0012089668,0.000020868165,0.018979851,0.000010874563,0.035825577,0.00018277805],"about_ca_topic_score_codex":0.000744581,"about_ca_topic_score_gemma":0.0005169768,"teacher_disagreement_score":0.5011467,"about_ca_system_score_codex":0.00024829438,"about_ca_system_score_gemma":0.00018828776,"threshold_uncertainty_score":0.47849548},"labels":[],"label_agreement":null},{"id":"W3203962015","doi":"10.1016/j.annonc.2021.08.1160","title":"647TiP PSMAddition: A phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Daiichi Sankyo Europe; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Eisai; AstraZeneca; Invitae; Myriad Genetics; Menarini Silicon Biosystems; Ipsen; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; Sierra Oncology; Endocyte; Taiho Pharmaceutical; Advanced Accelerator Applications; Sanofi; GlaxoSmithKline; Cardinal Health; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Prostate cancer; Oncology; Standard of care; Internal medicine; Cancer","score_opus":0.09691843788467025,"score_gpt":0.4308888205358018,"score_spread":0.33397038265113155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203962015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904813,0.0017860901,0.000009676652,0.002391628,0.00011327571,0.0025836478,0.0019590035,0.000013393392,0.00066197064],"genre_scores_gemma":[0.9965633,0.0009485397,0.00045855893,0.00015643195,0.00006055873,0.00044364177,0.0011375239,0.00002798954,0.00020344352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99801034,0.00017972877,0.00044277002,0.00040440753,0.0005218397,0.0004409039],"domain_scores_gemma":[0.9975692,0.00017000826,0.00024137723,0.00026987717,0.0015227563,0.00022678458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120151,0.0002555949,0.0013250959,0.0001943865,0.00006153541,0.000008058482,0.00005874414,0.00005607807,0.00010952528],"category_scores_gemma":[0.000035673173,0.0001724061,0.000102646205,0.0004769612,0.00024023921,0.00007971883,0.00004191893,0.00014638629,0.0000028438735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9419696,0.0031439895,0.0021513659,0.00016245426,0.0016700266,0.0011567924,0.011260798,0.000100639045,0.00016742248,0.000014807466,0.0016256109,0.036576543],"study_design_scores_gemma":[0.72077984,0.22470883,0.0060611386,0.00045991963,0.00072790124,0.000010245057,0.00919529,0.000012426931,0.03188311,0.000010581933,0.0058841477,0.0002665593],"about_ca_topic_score_codex":0.0006515029,"about_ca_topic_score_gemma":0.003961551,"teacher_disagreement_score":0.22156483,"about_ca_system_score_codex":0.00081030215,"about_ca_system_score_gemma":0.0028825232,"threshold_uncertainty_score":0.7030517},"labels":[],"label_agreement":null},{"id":"W3203963820","doi":"10.1016/j.annonc.2021.08.1755","title":"1152P Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Brampton Civic Hospital; Princess Margaret Cancer Centre; University of Toronto; Canada Health Infoway; William Osler Health System; AstraZeneca (Canada); Western University","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Stage (stratigraphy); Overall survival; Tyrosine kinase; Erlotinib; Epidermal growth factor receptor; Receptor","score_opus":0.06894350956014282,"score_gpt":0.4350006015565685,"score_spread":0.36605709199642567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203963820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782165,0.00027818725,0.0000021600783,0.016461631,0.00010160446,0.00044763766,0.00015716538,0.000008343589,0.004326712],"genre_scores_gemma":[0.996375,0.00015205942,0.000054696262,0.0016579482,0.000019569563,0.000056365836,0.00022987412,0.000010131028,0.0014443592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983605,0.00033053273,0.00051383907,0.00028287125,0.00025087464,0.000261355],"domain_scores_gemma":[0.9986553,0.00048917625,0.00014877021,0.00039020384,0.00023632719,0.00008023195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023039934,0.00012547069,0.0007152418,0.00025059367,0.000037742175,0.0000055902015,0.000102995065,0.00004673382,0.0003249934],"category_scores_gemma":[0.00018231147,0.00008599742,0.000098122975,0.0015080567,0.00003886564,0.000031368218,0.000057078127,0.00018965779,0.0000023264663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019385444,0.0012124003,0.98640805,0.000005164562,0.002390731,0.0018028207,0.0020517863,0.00037266055,0.00010729878,0.000027301938,0.00081633625,0.0046115764],"study_design_scores_gemma":[0.003221876,0.00042131863,0.98711765,0.000019698675,0.0007023274,0.0000011299198,0.006472523,0.00009486544,0.00022668726,0.000040020226,0.0016138443,0.000068080335],"about_ca_topic_score_codex":0.97709507,"about_ca_topic_score_gemma":0.9989381,"teacher_disagreement_score":0.021843024,"about_ca_system_score_codex":0.0006980046,"about_ca_system_score_gemma":0.0034903302,"threshold_uncertainty_score":0.6191696},"labels":[],"label_agreement":null},{"id":"W3203989804","doi":"10.1016/j.annonc.2021.08.056","title":"660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"EMD Serono; Genentech; Aptitude Health; Ipsen; PharmaMar; European Society for Medical Oncology; Cilag; Astellas Pharma; Eisai; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer; Invitae; Chugai Pharmaceutical; EUSA Pharma; Society for Immunotherapy of Cancer","keywords":"Medicine; Internal medicine; Toxicity; Renal cell carcinoma; Oncology; Carcinoma","score_opus":0.06371294213044976,"score_gpt":0.37594488959952876,"score_spread":0.312231947469079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203989804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036694,0.0012058257,0.0000043572704,0.003692937,0.00014462449,0.0006151997,0.000018366629,0.000011484505,0.0039402745],"genre_scores_gemma":[0.99767977,0.0003892194,0.00053129863,0.00090965844,0.000054750035,0.000041145708,0.0000553203,0.00001922258,0.0003196069],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998012,0.00025981286,0.0006923278,0.00042746513,0.00020698314,0.00040138752],"domain_scores_gemma":[0.99894375,0.00024329966,0.00019008598,0.00032799892,0.00012191406,0.0001729625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004326789,0.0002069515,0.0010390292,0.00023712996,0.000023220564,0.0000056837634,0.00008156217,0.00019493018,0.00013932913],"category_scores_gemma":[0.00014892769,0.00018387001,0.00014396153,0.00026577563,0.00011648687,0.00008567256,0.00010340508,0.00028437667,0.000009386802],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33772275,0.023234075,0.27074867,0.0005299959,0.0002760636,0.021284513,0.0029436606,0.000053744105,0.24235383,0.00049324625,0.0023609044,0.09799856],"study_design_scores_gemma":[0.30868462,0.023428345,0.23814979,0.000071165945,0.000106888954,0.00014901195,0.0005232024,0.000071185954,0.4233886,0.00037143665,0.004757249,0.0002985185],"about_ca_topic_score_codex":0.00018946925,"about_ca_topic_score_gemma":0.00043930238,"teacher_disagreement_score":0.18103476,"about_ca_system_score_codex":0.0001232991,"about_ca_system_score_gemma":0.00035021565,"threshold_uncertainty_score":0.74980015},"labels":[],"label_agreement":null},{"id":"W3204077794","doi":"10.1016/j.annonc.2021.08.326","title":"47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Baker Hughes (Canada)","funders":"Astellas Pharma; Eisai; Merck; Exelixis; Genentech; AstraZeneca; Pfizer","keywords":"Medicine; Fides; Intrahepatic Cholangiocarcinoma; Gastroenterology; Internal medicine; Cancer research; Oncology; Theology","score_opus":0.05819853437000666,"score_gpt":0.36047097577529,"score_spread":0.30227244140528337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204077794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650913,0.00029056647,0.000080493555,0.0010858281,0.00011185573,0.00092240504,0.00047525493,0.000008360216,0.0005161306],"genre_scores_gemma":[0.9970984,0.0000746182,0.00067210634,0.00058520323,0.00016542329,0.00010123401,0.001162876,0.000029442099,0.0001106904],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981954,0.00026330768,0.00041251906,0.00049189193,0.00025719716,0.00037968377],"domain_scores_gemma":[0.99830496,0.0002853891,0.00019887621,0.0005962568,0.0005243213,0.00009019834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004302113,0.00017827621,0.00030508998,0.000043165768,0.00019661462,0.000020410931,0.000329641,0.0001260426,0.00003437152],"category_scores_gemma":[0.0007529443,0.00013034184,0.000100729696,0.00015182132,0.000106532876,0.000010792463,0.00038696048,0.00015021807,0.0000033687763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02228986,0.01988768,0.3500002,0.00013402593,0.0022783526,0.00010351958,0.0027191236,0.00002860263,0.45560542,0.00003239171,0.047566675,0.09935415],"study_design_scores_gemma":[0.03585346,0.05426967,0.6517942,0.00012003827,0.0001731281,0.0000049677456,0.0008631865,0.000041840245,0.1503097,0.00007010398,0.10598274,0.0005169659],"about_ca_topic_score_codex":0.000111337074,"about_ca_topic_score_gemma":0.00020770422,"teacher_disagreement_score":0.3052957,"about_ca_system_score_codex":0.000016207652,"about_ca_system_score_gemma":0.0002933746,"threshold_uncertainty_score":0.5315186},"labels":[],"label_agreement":null},{"id":"W3204101060","doi":"10.1016/j.annonc.2021.08.995","title":"474P Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institutes of Health; Holden Comprehensive Cancer Center, University of Iowa; Boston Scientific Corporation; Emory University","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Metastasis; Cancer","score_opus":0.08535457776531782,"score_gpt":0.4135771303559599,"score_spread":0.32822255259064204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204101060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974308,0.0006051851,0.00000607954,0.000808102,0.00007378474,0.00058924523,0.0002550022,0.0000069815533,0.0002248199],"genre_scores_gemma":[0.9968147,0.001870567,0.0006273529,0.00033364305,0.000024119794,0.00010421199,0.00013450126,0.000015699652,0.00007516009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986914,0.0001520345,0.000487497,0.00028962086,0.00017392558,0.00020555664],"domain_scores_gemma":[0.99897194,0.0001865941,0.00029596643,0.00010823224,0.0003787153,0.00005855381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016596675,0.00016673564,0.0010075229,0.00010363427,0.00003179531,0.000004485754,0.000037674057,0.000055926837,0.000046769946],"category_scores_gemma":[0.00008749686,0.00010766797,0.000077601064,0.00021776462,0.00025672687,0.000064335436,0.000054572636,0.00010518695,4.3057778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005069176,0.0017473223,0.9503877,0.000105626226,0.0014477914,0.00012439094,0.0007763632,0.0000020192354,0.00083642325,0.000011765057,0.000042168343,0.03944921],"study_design_scores_gemma":[0.0054182685,0.01114527,0.97861546,0.000057447167,0.0005025241,0.000020838801,0.0004044362,0.000013989751,0.0018233056,0.0000036299373,0.0018932725,0.0001015243],"about_ca_topic_score_codex":0.00057615753,"about_ca_topic_score_gemma":0.0049498705,"teacher_disagreement_score":0.03934769,"about_ca_system_score_codex":0.00006766557,"about_ca_system_score_gemma":0.00068644306,"threshold_uncertainty_score":0.43905723},"labels":[],"label_agreement":null},{"id":"W3204109254","doi":"10.1016/j.annonc.2021.08.1797","title":"1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Combination therapy; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Cancer; Erlotinib; Phases of clinical research","score_opus":0.03634859327166554,"score_gpt":0.399588596682932,"score_spread":0.36324000341126644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204109254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981704,0.0009174144,0.000016169706,0.01611883,0.000027931768,0.0004849214,0.000032505668,0.000008670422,0.000689561],"genre_scores_gemma":[0.99688554,0.00041093642,0.000118710195,0.002333186,0.000016821023,0.000060716404,0.00009974224,0.000010918408,0.00006341663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998958,0.00018637326,0.0003205045,0.0002443152,0.00014154219,0.00014928769],"domain_scores_gemma":[0.99913216,0.0002738173,0.00012615252,0.00022492808,0.00020124044,0.000041715044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020441462,0.00010496405,0.0004477765,0.00016103448,0.000030902167,0.0000087901035,0.000052576408,0.000060465827,0.00007233828],"category_scores_gemma":[0.0000650369,0.000067746674,0.0000515964,0.00069382304,0.00006400307,0.000055918932,0.000021363645,0.00011135713,0.0000010588368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001526489,0.004180926,0.93416107,0.0000069778257,0.0022862405,0.00033891163,0.013490292,0.00006591742,0.0025049015,0.000083602645,0.00007871126,0.041275937],"study_design_scores_gemma":[0.008753716,0.0028745034,0.977975,0.000033925186,0.000729043,0.000007809755,0.0059459694,0.0001521238,0.002133538,0.00009483225,0.0012265696,0.00007295648],"about_ca_topic_score_codex":0.0042707636,"about_ca_topic_score_gemma":0.017595552,"teacher_disagreement_score":0.04381392,"about_ca_system_score_codex":0.00005720682,"about_ca_system_score_gemma":0.00028918163,"threshold_uncertainty_score":0.98187304},"labels":[],"label_agreement":null},{"id":"W3204129758","doi":"10.1016/j.annonc.2021.08.1064","title":"542P Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"Boehringer Ingelheim","keywords":"Medicine; Solid tumor; Internal medicine; Oncology; Cancer","score_opus":0.0395966453673123,"score_gpt":0.3746372658461154,"score_spread":0.3350406204788031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204129758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97902584,0.0015812649,0.0000033110784,0.0050783986,0.0001015849,0.00025728196,0.000013497631,0.000013300253,0.013925547],"genre_scores_gemma":[0.99530596,0.0015837896,0.00043652655,0.0021876842,0.000031928103,0.000050288676,0.000024781992,0.000015610924,0.00036343816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906266,0.000044917295,0.0002449111,0.00023905106,0.00015122497,0.00025722422],"domain_scores_gemma":[0.9992753,0.000064084925,0.00011112653,0.00016652765,0.00031980622,0.00006314537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006498917,0.00013319272,0.0005559784,0.00007674158,0.000031063897,0.0000026771718,0.000044884677,0.000090194815,0.00010233397],"category_scores_gemma":[0.000045726538,0.00010056057,0.000067956025,0.00020676274,0.000085691194,0.000047085603,0.000031730426,0.00013655337,0.0000057120255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009420408,0.0049330196,0.4906417,0.000067053,0.0005340737,0.00047514823,0.0019794137,0.00004465263,0.0008881486,0.00013335967,0.0027503483,0.4881327],"study_design_scores_gemma":[0.015823962,0.02244874,0.91707206,0.00012738825,0.00006645321,0.000017244833,0.0006894246,0.000011045881,0.012095331,0.00018800174,0.03129313,0.0001672152],"about_ca_topic_score_codex":0.00006268318,"about_ca_topic_score_gemma":0.0005620525,"teacher_disagreement_score":0.48796546,"about_ca_system_score_codex":0.00009112052,"about_ca_system_score_gemma":0.00025798974,"threshold_uncertainty_score":0.4100741},"labels":[],"label_agreement":null},{"id":"W3204152960","doi":"10.1016/j.annonc.2021.08.1055","title":"533P Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Trk receptor; Medicine; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Fusion gene; Cancer research; Solid tumor; Cancer; Receptor; Gene; Neurotrophin; Biology; Genetics","score_opus":0.017311276759919565,"score_gpt":0.3733421316483758,"score_spread":0.35603085488845626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204152960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301827,0.000650822,0.000084469575,0.0018003624,0.000075301454,0.00052580005,0.00007065791,0.000006964274,0.003767326],"genre_scores_gemma":[0.9969255,0.00038363374,0.0017487698,0.0006322207,0.000013787522,0.000015744152,0.000109340384,0.000012264591,0.00015877592],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901307,0.000083110026,0.00034098676,0.00021617228,0.00015230566,0.00019436475],"domain_scores_gemma":[0.99885505,0.00026352267,0.00019413546,0.00014008222,0.000453717,0.00009349626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088410394,0.0001156345,0.00049391855,0.00009309027,0.000031678333,0.0000023795499,0.00003286219,0.000047349586,0.00007877016],"category_scores_gemma":[0.00014648959,0.00009011534,0.00004057815,0.00021893349,0.00012324358,0.000056293993,0.000033884655,0.00009672551,0.0000022836452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011241765,0.009745721,0.38371834,0.00030855555,0.0013275743,0.0005957903,0.0063944594,0.00057420426,0.0011312071,0.00049515674,0.0008708375,0.58359635],"study_design_scores_gemma":[0.017893258,0.008862793,0.9643158,0.0005090322,0.00032654047,0.000030506131,0.00077612494,0.00001952115,0.0053361715,0.00012224633,0.0016919138,0.00011612669],"about_ca_topic_score_codex":0.000048045684,"about_ca_topic_score_gemma":0.00010359336,"teacher_disagreement_score":0.58348024,"about_ca_system_score_codex":0.000054605698,"about_ca_system_score_gemma":0.00051901786,"threshold_uncertainty_score":0.3674797},"labels":[],"label_agreement":null},{"id":"W3204209229","doi":"10.1016/j.annonc.2021.08.2131","title":"LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Ipilimumab; Cancer; Internal medicine; Esophageal cancer; Oncology; Chemotherapy; Adenocarcinoma; Immunotherapy","score_opus":0.1153346183679117,"score_gpt":0.44526075226561396,"score_spread":0.32992613389770226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204209229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774504,0.0059594996,0.00027983994,0.010481214,0.0006871202,0.0037614359,0.00016664424,0.00011684854,0.0010970545],"genre_scores_gemma":[0.9645838,0.012037573,0.0021208595,0.0019134019,0.0011127723,0.0025091125,0.0001984287,0.00012665156,0.015397398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951475,0.0002925407,0.0012721842,0.0012140765,0.0006820119,0.0013916658],"domain_scores_gemma":[0.9959098,0.00066667155,0.00065575895,0.00088097586,0.0013319189,0.0005548682],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006834589,0.00069454877,0.0027532708,0.00035555713,0.00035757083,0.000025145166,0.00035191968,0.0005234027,0.0022922298],"category_scores_gemma":[0.00039171663,0.0005785289,0.0004797571,0.0008447536,0.00036605124,0.00017851181,0.00014453776,0.00049256725,0.000044294102],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13737576,0.02250718,0.38536525,0.0014431605,0.0077959383,0.004453228,0.006614459,0.0007006828,0.00880437,0.00009488352,0.016116308,0.40872878],"study_design_scores_gemma":[0.21313076,0.20494793,0.4392399,0.0007065179,0.004432721,0.0017491219,0.005475239,0.0066948757,0.08650897,0.0003913488,0.03529933,0.0014232991],"about_ca_topic_score_codex":0.0022878316,"about_ca_topic_score_gemma":0.0034377251,"teacher_disagreement_score":0.40730548,"about_ca_system_score_codex":0.0020115478,"about_ca_system_score_gemma":0.0061146435,"threshold_uncertainty_score":0.99966663},"labels":[],"label_agreement":null},{"id":"W3204212303","doi":"10.1016/j.annonc.2021.08.622","title":"339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Oncolytics Biotech; Eisai; Daiichi-Sankyo; Astellas Pharma US; Roche; Seagen; Puma Biotechnology; Novartis; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; Daiichi Sankyo Europe; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Enzalutamide; Medicine; Androgen receptor; Internal medicine; Tamoxifen; Oncology; Breast cancer; Estrogen receptor; Cancer research; Prostate cancer; Population; Exemestane; Cancer; Endocrinology","score_opus":0.03930127710637511,"score_gpt":0.3517432248888993,"score_spread":0.3124419477825242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204212303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581548,0.009678432,0.00066000014,0.027848253,0.00028095554,0.0008198929,0.00019140485,0.00008247799,0.0022838055],"genre_scores_gemma":[0.985467,0.0022895187,0.008336254,0.002983287,0.0002640854,0.00015827894,0.000076535835,0.00008102977,0.00034400175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997098,0.0004631667,0.00070472463,0.00063311186,0.0003773139,0.00072363537],"domain_scores_gemma":[0.997163,0.00055880623,0.0005281518,0.0003587883,0.0011679492,0.00022327999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053273677,0.00038362655,0.0012412635,0.00023096713,0.00007649878,0.000013234476,0.00015917994,0.00018429845,0.00057871355],"category_scores_gemma":[0.0003615214,0.00033306878,0.00013664653,0.0009802923,0.00043414521,0.00025935238,0.000102917016,0.00059315213,0.00002739798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030749517,0.004711082,0.048377987,0.00061023055,0.004240095,0.0035356397,0.012897115,0.0010413761,0.32099137,0.0015123494,0.0038638103,0.5674694],"study_design_scores_gemma":[0.027086938,0.0077566584,0.71689975,0.0015280364,0.0006996823,0.0017388957,0.01243544,0.00014348637,0.1985917,0.003497619,0.028080905,0.0015409001],"about_ca_topic_score_codex":0.0014365937,"about_ca_topic_score_gemma":0.0012794464,"teacher_disagreement_score":0.66852176,"about_ca_system_score_codex":0.00035952363,"about_ca_system_score_gemma":0.0014617047,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W3204227453","doi":"10.1016/j.annonc.2021.08.449","title":"168P Change in distant DFS events in adjuvant breast cancer trials over time","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cardiac Imaging and Diagnostics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adjuvant; Oncology; Breast cancer; Distributed File System; Internal medicine; Cancer","score_opus":0.13108554771630587,"score_gpt":0.45886237722764545,"score_spread":0.3277768295113396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204227453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96349055,0.005974491,0.0000025699671,0.026005408,0.0005551949,0.000347556,0.00022752026,0.000012541276,0.0033841722],"genre_scores_gemma":[0.99312806,0.001953879,0.00003269853,0.004157323,0.00031565127,0.000062626794,0.000046739005,0.000014145469,0.0002888785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985942,0.0002838679,0.00049053616,0.00020599079,0.00015848124,0.0002669089],"domain_scores_gemma":[0.9988513,0.00057699793,0.00014303353,0.00019279476,0.00014898187,0.000086879634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009478848,0.00010465263,0.0009445252,0.00014152858,0.000008238755,0.0000020117309,0.00004423813,0.00011735661,0.0006515522],"category_scores_gemma":[0.001053722,0.00009298747,0.00015207639,0.00025582773,0.000043414697,0.000044442702,0.000053876305,0.00015542588,0.000027873371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008683797,0.0012267259,0.8840154,0.000098553806,0.000105507315,0.0010961139,0.00075894396,0.000007635794,0.0031190983,0.00009464856,0.01550323,0.093105786],"study_design_scores_gemma":[0.0039068926,0.00022799116,0.97604406,0.00041333254,0.000065467895,0.00008180059,0.0000640037,0.000050246545,0.002014334,0.00019096908,0.016841894,0.000099014374],"about_ca_topic_score_codex":0.0011023985,"about_ca_topic_score_gemma":0.0006801477,"teacher_disagreement_score":0.093006775,"about_ca_system_score_codex":0.000095203664,"about_ca_system_score_gemma":0.00041241283,"threshold_uncertainty_score":0.713404},"labels":[],"label_agreement":null},{"id":"W3204229826","doi":"10.1016/j.annonc.2021.08.1490","title":"1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Sirtex Medical; Servier; Astellas Pharma; Ipsen; BeiGene; Incyte; Taiho Pharmaceutical; Gilead Sciences; Merck KGaA; Daiichi Sankyo Europe; Halozyme; Sanofi; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Stryker; Amgen","keywords":"Medicine; Nivolumab; Internal medicine; Placebo; Adverse effect; Neoadjuvant therapy; Clinical endpoint; Gastroenterology; Esophageal cancer; Esophagectomy; Randomized controlled trial; Oncology; Surgery; Cancer; Pathology; Breast cancer; Immunotherapy","score_opus":0.07539090086295525,"score_gpt":0.41074128996198594,"score_spread":0.3353503890990307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204229826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967386,0.026165264,0.000038416954,0.0029179237,0.0008140515,0.00085205206,0.00008483499,0.000054203163,0.0016872258],"genre_scores_gemma":[0.989909,0.003942886,0.000874772,0.0007095954,0.0002815141,0.00020444745,0.000117310556,0.00006779143,0.0038927132],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99621844,0.00035092598,0.0010239843,0.0006862125,0.0007653946,0.0009550659],"domain_scores_gemma":[0.9977376,0.00022752641,0.0003970669,0.00060011237,0.0006568409,0.00038085127],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006941618,0.0003811904,0.0017569271,0.00039529632,0.00008240015,0.000014276564,0.00019284814,0.00031931238,0.0013710897],"category_scores_gemma":[0.00035278895,0.000317695,0.00048783154,0.000985818,0.00019849109,0.00018826027,0.00010777223,0.00052738056,0.000011904742],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07337222,0.010143141,0.27342826,0.001809737,0.005205452,0.058957774,0.00546966,0.00037583103,0.067488916,0.00023561681,0.025450075,0.47806332],"study_design_scores_gemma":[0.0795343,0.036074746,0.34830877,0.0013666039,0.0005575754,0.0006488085,0.0010171178,0.0007733965,0.5258022,0.0004051975,0.0048745293,0.0006367584],"about_ca_topic_score_codex":0.0024008243,"about_ca_topic_score_gemma":0.004779624,"teacher_disagreement_score":0.47742656,"about_ca_system_score_codex":0.0005735441,"about_ca_system_score_gemma":0.0028165248,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W3204239919","doi":"10.1016/j.annonc.2021.08.1957","title":"1357P A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Radiomics; Lung cancer; Oncology; PD-L1; Internal medicine; Cancer; Immune checkpoint; Immune system; Immunotherapy; Immunology; Radiology","score_opus":0.031731320779081355,"score_gpt":0.3765750969259539,"score_spread":0.34484377614687256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204239919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658674,0.00036249516,0.0006632056,0.00063473225,0.000095135816,0.0013064209,0.0000034572683,0.000016905915,0.00033089845],"genre_scores_gemma":[0.986324,0.00022002934,0.0126017565,0.0005860103,0.000048705588,0.00009414917,0.000025863757,0.000036927875,0.00006252043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784106,0.00026724942,0.00074375677,0.00052022515,0.0002630777,0.00036462652],"domain_scores_gemma":[0.9984473,0.0003039483,0.0003326205,0.00030383313,0.00034318,0.0002691008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005892624,0.00023188368,0.0010680637,0.00018980354,0.000045510023,0.000013485163,0.00010797608,0.00013944646,0.0000077864925],"category_scores_gemma":[0.000428293,0.000157398,0.00008132831,0.0003883866,0.000098201184,0.00006787003,0.00012355579,0.0005519509,4.6683678e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021298388,0.0070144343,0.9717836,0.00013590121,0.00020086957,0.00013861059,0.0012932935,0.00054887275,0.0009428363,5.2885173e-7,0.000034818997,0.015776426],"study_design_scores_gemma":[0.021490352,0.004666735,0.96488136,0.00031419512,0.00021849097,0.0000093285835,0.0011512686,0.0052361293,0.0017073012,6.674451e-7,0.00012919768,0.00019494531],"about_ca_topic_score_codex":0.0002469696,"about_ca_topic_score_gemma":0.000059510887,"teacher_disagreement_score":0.019360514,"about_ca_system_score_codex":0.00008419527,"about_ca_system_score_gemma":0.00029315532,"threshold_uncertainty_score":0.64185035},"labels":[],"label_agreement":null},{"id":"W3204242468","doi":"10.1016/j.annonc.2021.08.275","title":"1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.034635591958286145,"score_gpt":0.3402314134676476,"score_spread":0.3055958215093615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204242468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678105,0.0013699326,0.000005364779,0.0022163051,0.000100348036,0.00027714882,0.00003594253,0.000008647383,0.028175771],"genre_scores_gemma":[0.9974826,0.00076527253,0.0005017277,0.0005417873,0.00006491923,0.000006913858,0.000043649274,0.000012868534,0.00058027374],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99871993,0.00010682785,0.0005385004,0.00023248073,0.00014381528,0.0002584633],"domain_scores_gemma":[0.99906445,0.00026548794,0.00019142199,0.00020640616,0.00015645538,0.00011579674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020917921,0.00013297384,0.0006489144,0.00008953166,0.00002422405,0.0000020212615,0.000054908855,0.00011210991,0.00031644077],"category_scores_gemma":[0.00015998173,0.00011318516,0.00012442417,0.00017054979,0.00015430985,0.000041961855,0.00010777992,0.00013428449,0.000007214919],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029582553,0.026405856,0.1680565,0.0043726857,0.0010314431,0.009300607,0.004513966,0.000059610946,0.06662122,0.0046646246,0.004188474,0.6812025],"study_design_scores_gemma":[0.011922073,0.012727816,0.8841913,0.00027068984,0.00015287475,0.0003431177,0.0005416685,0.000051802865,0.054078575,0.00020962837,0.03531397,0.00019648344],"about_ca_topic_score_codex":0.0003295023,"about_ca_topic_score_gemma":0.000054210697,"teacher_disagreement_score":0.7161348,"about_ca_system_score_codex":0.000025747851,"about_ca_system_score_gemma":0.00029640392,"threshold_uncertainty_score":0.4615557},"labels":[],"label_agreement":null},{"id":"W3204256814","doi":"10.1016/j.annonc.2021.08.1132","title":"619P Immune profiling of advanced prostate cancer harbouring homologous recombination deficiency","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Immune system; Homologous recombination; Prostate; Homologous chromosome; Cancer research; Oncology; Tumor microenvironment; Cancer; Immunology; Internal medicine; Gene; Biology; Genetics","score_opus":0.046136250413522234,"score_gpt":0.37789281509396716,"score_spread":0.3317565646804449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204256814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97517467,0.015133723,0.00001694716,0.0042942846,0.00036360513,0.0002703706,0.000012616826,0.000017054386,0.0047167344],"genre_scores_gemma":[0.99165803,0.0059539685,0.0012205533,0.00048025316,0.000027201331,0.000040907235,0.00001985831,0.000012459588,0.00058674853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894506,0.00006564728,0.00046472752,0.0001862807,0.00012920996,0.00020908222],"domain_scores_gemma":[0.99890095,0.00006785873,0.00031742192,0.00019005494,0.00049087696,0.00003282721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035735342,0.000089442416,0.00039018164,0.00009450993,0.00003562694,0.0000023533107,0.00006494778,0.00009820856,0.00014398071],"category_scores_gemma":[0.00012775122,0.00008339711,0.00012560637,0.00028737017,0.00012042743,0.000060281276,0.000033017193,0.00011524468,0.0000013655825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017624104,0.00049238844,0.0038401547,0.0002674872,0.0001093542,0.000045618646,0.0004926076,0.000029507204,0.6815779,0.00021331177,0.00014066357,0.31102857],"study_design_scores_gemma":[0.002717328,0.0019871374,0.039307155,0.00022199364,0.00004090032,0.000057725716,0.00041041098,0.0000272558,0.94987696,0.00030200722,0.004960295,0.00009084954],"about_ca_topic_score_codex":0.0001347507,"about_ca_topic_score_gemma":0.00003508468,"teacher_disagreement_score":0.31093773,"about_ca_system_score_codex":0.000060622668,"about_ca_system_score_gemma":0.0005982985,"threshold_uncertainty_score":0.34008354},"labels":[],"label_agreement":null},{"id":"W3204281541","doi":"10.1016/j.annonc.2021.08.1339","title":"929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Eisai; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Exelixis; Bristol-Myers Squibb","keywords":"Medicine; Head and neck cancer; Odds ratio; Cancer registry; Pneumonia; Lung cancer; Cancer; Population; Internal medicine; Logistic regression; Cohort; Medical record; Pediatrics","score_opus":0.1228468384345663,"score_gpt":0.46814514883248926,"score_spread":0.34529831039792297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204281541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7795254,0.002308422,0.000036523368,0.2079116,0.00060497713,0.0002422092,0.00025583626,0.000034780172,0.009080228],"genre_scores_gemma":[0.90384007,0.012593389,0.0009370936,0.07992334,0.0006991767,0.00011654397,0.00017239369,0.00002713016,0.0016908518],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983754,0.00010707529,0.00036274767,0.0005339686,0.0003625875,0.0002582207],"domain_scores_gemma":[0.99811465,0.00022428788,0.0002258854,0.00026484436,0.0006295501,0.0005407638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000250975,0.00020502915,0.00056739064,0.00012804709,0.00014754805,0.000033671047,0.00013012571,0.0001572064,0.00042044432],"category_scores_gemma":[0.0007441914,0.00018172985,0.000040797502,0.00024615237,0.00038169225,0.00018228499,0.000083351915,0.00021682672,0.0000022382449],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017017394,0.0014681272,0.68331105,0.0008734107,0.0021332258,0.0020482563,0.0124311475,0.0012706536,0.0020773632,0.005800224,0.22345239,0.04811679],"study_design_scores_gemma":[0.007568872,0.004835441,0.071294226,0.00024638747,0.000063677704,0.0003139596,0.0023202857,0.00014735707,0.0006209186,0.00018139865,0.9121795,0.00022793932],"about_ca_topic_score_codex":0.0025146028,"about_ca_topic_score_gemma":0.023548739,"teacher_disagreement_score":0.68872714,"about_ca_system_score_codex":0.0006382188,"about_ca_system_score_gemma":0.0049282135,"threshold_uncertainty_score":0.99426895},"labels":[],"label_agreement":null},{"id":"W3204288268","doi":"10.1016/j.annonc.2021.08.1296","title":"886P Circulating tumor DNA kinetics in recurrent/metastatic head &amp; neck squamous cell cancer (R/M HNSCC) patients","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Division of Mathematical Sciences; European Society for Medical Oncology; Korea Health Industry Development Institute; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Ono Pharmaceutical; Eisai; Handok; Daiichi Sankyo Europe; Sanofi; Roche; Amgen","keywords":"Squamous cell cancer; Medicine; Liquid biopsy; Oncology; Head and neck cancer; Head and neck; Internal medicine; Biopsy; Circulating tumor DNA; Cancer research; DNA; Cancer; Surgery","score_opus":0.05381183057978956,"score_gpt":0.35526617366796903,"score_spread":0.3014543430881795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204288268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241173,0.0034535811,0.00004395715,0.00045487736,0.00048655382,0.00017291057,0.00016661483,0.0000038193702,0.0028059743],"genre_scores_gemma":[0.9954803,0.0012131323,0.0009858425,0.001650233,0.00014798534,0.000032916843,0.00032482736,0.000027299391,0.00013744406],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998514,0.00010750845,0.0004918597,0.0003858367,0.00012644673,0.00037435573],"domain_scores_gemma":[0.9988551,0.00009694177,0.00025798235,0.00032249893,0.00036274022,0.00010474133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013532737,0.00017455127,0.00034472978,0.00006460269,0.000030683077,0.000011817509,0.00015830257,0.00011871888,0.000081376485],"category_scores_gemma":[0.00048003436,0.00019805502,0.00011587294,0.00017414651,0.00006889701,0.0000035306764,0.00016611688,0.0001290715,0.00000940373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065293076,0.006068789,0.10903711,0.000558744,0.00014602009,0.0002083698,0.0008042825,0.004474155,0.73835385,0.00019741875,0.035494912,0.10400343],"study_design_scores_gemma":[0.006322268,0.0043834546,0.065602176,0.000120550525,0.00009286434,0.00003230107,0.00019455182,0.00017780144,0.3654422,0.0006114162,0.55622214,0.00079827843],"about_ca_topic_score_codex":0.00020819916,"about_ca_topic_score_gemma":0.0033990105,"teacher_disagreement_score":0.5207272,"about_ca_system_score_codex":0.00004527569,"about_ca_system_score_gemma":0.0004527525,"threshold_uncertainty_score":0.8076449},"labels":[],"label_agreement":null},{"id":"W3204288709","doi":"10.1016/j.annonc.2021.08.1435","title":"1050P Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Francis Xavier University; BC Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Melanoma; Oncology; Immune checkpoint; Internal medicine; Immune system; Immunotherapy; Immunology; Cancer research","score_opus":0.02104005985972968,"score_gpt":0.3314567446937864,"score_spread":0.3104166848340567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204288709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811995,0.00046627858,4.7374976e-7,0.0003497154,0.000032211738,0.00032828015,0.000015761469,0.00000871863,0.0006786309],"genre_scores_gemma":[0.99939615,0.00018170556,0.0001313233,0.00008115072,0.00000466446,0.000008046545,0.000058081816,0.000016296663,0.00012256946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876004,0.00007564076,0.0006201839,0.00019705783,0.00014833892,0.00019871851],"domain_scores_gemma":[0.9990508,0.000047452108,0.0003730785,0.00020610601,0.00025896684,0.00006361657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019388528,0.00014873756,0.0006214238,0.00014449582,0.000014529073,5.5079227e-7,0.000039423725,0.00012568914,0.00009509843],"category_scores_gemma":[0.00005063372,0.00009847926,0.00012939573,0.00039356397,0.00013859877,0.000073418945,0.00002367845,0.00012748524,8.111271e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020239947,0.00086237834,0.95817274,0.000055540033,0.0005365076,0.000060954735,0.00025990294,0.000014769659,0.009128725,0.0000022791771,0.000014494252,0.01065176],"study_design_scores_gemma":[0.018143382,0.014387309,0.95180756,0.00027003416,0.000060496124,0.000029397273,0.00018189689,0.0000037166774,0.014913578,0.0000057303037,0.00009681611,0.000100079895],"about_ca_topic_score_codex":0.00034132937,"about_ca_topic_score_gemma":0.00009973381,"teacher_disagreement_score":0.013524931,"about_ca_system_score_codex":0.00009146181,"about_ca_system_score_gemma":0.00025369835,"threshold_uncertainty_score":0.40158677},"labels":[],"label_agreement":null},{"id":"W3204308533","doi":"10.1016/j.annonc.2021.08.1063","title":"541P Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"EMD Serono; Genentech; Astellas Pharma; Eisai; Flatiron Health; MacroGenics; Tarveda Therapeutics; Pfizer; Incyte; BeiGene; Clovis Oncology; Astex Pharmaceuticals; Karyopharm Therapeutics; Exelixis; Revolution Medicines; Regeneron Pharmaceuticals; GlaxoSmithKline; G1 Therapeutics; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Array BioPharma; Mersana Therapeutics; Merck KGaA; Servier; Gilead Sciences","keywords":"Medicine; VEGF receptors; Blocking (statistics); Antibody; Blocking antibody; Pharmacology; Cancer research; Oncology; Immunology","score_opus":0.04145827966138752,"score_gpt":0.3893845382024157,"score_spread":0.34792625854102815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204308533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309915,0.00051192817,0.000008159435,0.0032325182,0.00005865203,0.0007752263,0.000024213276,0.000032953703,0.0022571874],"genre_scores_gemma":[0.99686575,0.00084177894,0.0005953167,0.0006457456,0.000042292926,0.00004375231,0.00056381396,0.00004696191,0.00035461478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700475,0.00035700286,0.0006446944,0.00060449715,0.000603517,0.0007855444],"domain_scores_gemma":[0.9980577,0.0001783985,0.00028776322,0.00036576737,0.0008785684,0.00023180478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043586752,0.00032002403,0.0010648194,0.0005245668,0.000076696684,0.000017472603,0.00019961686,0.00020897969,0.00007470247],"category_scores_gemma":[0.00014850276,0.00024783533,0.00008971586,0.0010471742,0.00027469333,0.0002673888,0.000110134584,0.0004621266,0.000010768793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007026649,0.0063722245,0.94070995,0.0003079999,0.00015209687,0.0016338679,0.0010931682,0.00013561216,0.012028676,0.00017077684,0.00013597138,0.030233026],"study_design_scores_gemma":[0.014560481,0.023174318,0.9306297,0.0010665539,0.00006136631,0.00015375367,0.0005266827,0.00047983683,0.027085984,0.00009887407,0.0018073473,0.00035512456],"about_ca_topic_score_codex":0.00072175136,"about_ca_topic_score_gemma":0.0018156958,"teacher_disagreement_score":0.029877901,"about_ca_system_score_codex":0.00012433996,"about_ca_system_score_gemma":0.0006772531,"threshold_uncertainty_score":0.9999974},"labels":[],"label_agreement":null},{"id":"W3204336527","doi":"10.1016/j.annonc.2021.08.1268","title":"858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Nasopharyngeal carcinoma; Oncology; Internal medicine; Phases of clinical research; Radiation therapy; Cancer; Immunotherapy","score_opus":0.14945585227408686,"score_gpt":0.44491465800962227,"score_spread":0.2954588057355354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204336527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903023,0.0032268523,0.00004812059,0.0028892658,0.00021728563,0.0016986592,0.0003186105,0.000024565361,0.0012743002],"genre_scores_gemma":[0.99483913,0.0020606297,0.0012192002,0.0008710421,0.00011987434,0.00018583583,0.00007418935,0.000048393365,0.0005817104],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969313,0.00023589928,0.0014482421,0.00055268285,0.0003761778,0.00045567428],"domain_scores_gemma":[0.9966328,0.00083419966,0.0007907545,0.0005780452,0.0010082291,0.00015593236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057335984,0.00033868023,0.0023723636,0.0002194812,0.000067123736,0.0000038395933,0.000182351,0.00015320949,0.00013673122],"category_scores_gemma":[0.0004361628,0.00026874262,0.00032694114,0.00048486504,0.00019212217,0.00006326958,0.0000611674,0.00020071246,0.0000012982696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4951961,0.04899332,0.0028513002,0.0018061604,0.004880629,0.0004999315,0.031204935,0.000012917156,0.046440754,0.00006112561,0.030338643,0.3377142],"study_design_scores_gemma":[0.42799523,0.17303087,0.011928894,0.0005197306,0.0009350798,0.00013703732,0.0067261057,0.0006018487,0.3568899,0.00014805255,0.020608786,0.00047848193],"about_ca_topic_score_codex":0.00034261515,"about_ca_topic_score_gemma":0.0004164051,"teacher_disagreement_score":0.3372357,"about_ca_system_score_codex":0.00008104991,"about_ca_system_score_gemma":0.00087842497,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W3204365794","doi":"10.1016/j.annonc.2021.08.1373","title":"989P Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Iterion Therapeutics; Sanofi; Symphogen; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Autoantibody; Adverse effect; Immune system; Immune checkpoint; Immunology; Microarray; Internal medicine; Antibody; Immunotherapy; Gene; Genetics; Gene expression","score_opus":0.021662015225602044,"score_gpt":0.2982200241457827,"score_spread":0.2765580089201807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204365794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932996,0.0016457973,8.602687e-7,0.0009692476,0.00036045298,0.00065593264,0.000032168966,0.00003827102,0.0029976733],"genre_scores_gemma":[0.99727774,0.0010966655,0.000051643776,0.00022104185,0.000025085732,0.00003247742,0.00022472345,0.000043121654,0.0010275305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996659,0.0002521898,0.0018294642,0.00039440772,0.0004135963,0.00045134776],"domain_scores_gemma":[0.9977606,0.00011005117,0.00090530224,0.0005529256,0.0005688176,0.00010231405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006129018,0.00030744684,0.0011602711,0.00033237616,0.000042275926,0.0000020150794,0.00017216147,0.00039320168,0.0005470217],"category_scores_gemma":[0.00020319354,0.00025646904,0.00044128922,0.00093206187,0.00032023975,0.00013100312,0.00009333473,0.00033568364,0.000016412985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029027257,0.007689637,0.65835977,0.00036634997,0.003043468,0.00039611143,0.0030050878,0.00006650794,0.2571053,0.00002474821,0.00034140502,0.040574368],"study_design_scores_gemma":[0.016167121,0.0077448767,0.77649957,0.00075221865,0.00013642012,0.00004645622,0.0004806915,0.000013637825,0.19548732,0.000022592232,0.0024505293,0.00019858209],"about_ca_topic_score_codex":0.0014593949,"about_ca_topic_score_gemma":0.00005129746,"teacher_disagreement_score":0.11813978,"about_ca_system_score_codex":0.0001882621,"about_ca_system_score_gemma":0.0007480299,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W3204399641","doi":"10.1016/j.annonc.2021.08.338","title":"59TiP Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Biliary tract cancer; Cisplatin; Oncology; Internal medicine; Biliary tract; Phases of clinical research; Chemotherapy","score_opus":0.07922289748400511,"score_gpt":0.4031511512382979,"score_spread":0.3239282537542928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204399641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262965,0.0029049367,0.000031408992,0.0017093441,0.00016783741,0.0017239234,0.00043117526,0.000013871417,0.00038785057],"genre_scores_gemma":[0.99738723,0.001047559,0.0004666808,0.0002411593,0.00010335882,0.00033986097,0.00016103347,0.000032088275,0.00022104492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807066,0.00006220143,0.00083465094,0.000418455,0.0002916143,0.00032239192],"domain_scores_gemma":[0.99738926,0.00043266022,0.0005862327,0.00040338194,0.0010798264,0.00010863391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013375422,0.00027550882,0.0014596863,0.0001436109,0.00006705044,0.0000021902451,0.0000855112,0.000111560825,0.00014007154],"category_scores_gemma":[0.000112346526,0.00020665873,0.00020772615,0.0003117739,0.00014839164,0.000074176736,0.000035553592,0.000092360075,5.5262075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040131424,0.05819947,0.67123795,0.00080629357,0.003093219,0.00016881974,0.012634059,0.0002204038,0.0035159562,0.000028066104,0.0024678735,0.20749645],"study_design_scores_gemma":[0.10419952,0.1295387,0.7272576,0.00025927226,0.0013086402,0.00001014279,0.002168259,0.00006708547,0.026811184,0.000042437627,0.008056495,0.00028066552],"about_ca_topic_score_codex":0.00034957367,"about_ca_topic_score_gemma":0.0018824313,"teacher_disagreement_score":0.20721577,"about_ca_system_score_codex":0.00010547053,"about_ca_system_score_gemma":0.00036547708,"threshold_uncertainty_score":0.8427298},"labels":[],"label_agreement":null},{"id":"W3204415649","doi":"10.1016/j.annonc.2021.08.1094","title":"581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis; AstraZeneca","keywords":"Medicine; Prostate cancer; Castration; Oncology; Internal medicine; Cancer; Hormone","score_opus":0.0881848129497501,"score_gpt":0.39892494546719337,"score_spread":0.31074013251744326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204415649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97756225,0.0032215759,0.000008654569,0.010452061,0.00006338647,0.0010206823,0.000052937747,0.000024976776,0.0075934953],"genre_scores_gemma":[0.9942561,0.0015694562,0.0007796035,0.00046992698,0.000031925865,0.00038650422,0.00018827672,0.000029816885,0.0022883972],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976442,0.00034470623,0.00066938903,0.00043199558,0.00040968595,0.0005000525],"domain_scores_gemma":[0.99830043,0.00020552773,0.0003304916,0.00031708632,0.00067043107,0.00017600178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008601812,0.0002002329,0.0006403988,0.00017677003,0.000062788975,0.000016196893,0.00006105093,0.000086755135,0.00026046584],"category_scores_gemma":[0.0003507644,0.00014774431,0.00008158347,0.00059600436,0.00017951596,0.00011332755,0.000051278254,0.00026034765,0.0000036331642],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015515064,0.0063660755,0.17022611,0.0017168914,0.0031221765,0.036185313,0.0117565375,0.00061524817,0.15759026,0.00026754042,0.021300992,0.5753378],"study_design_scores_gemma":[0.032972604,0.050047252,0.30167866,0.0037776679,0.0009463655,0.0012784926,0.017142683,0.0017120794,0.49142095,0.0015242252,0.09609814,0.0014008812],"about_ca_topic_score_codex":0.0010609032,"about_ca_topic_score_gemma":0.0025716492,"teacher_disagreement_score":0.57393694,"about_ca_system_score_codex":0.0002474412,"about_ca_system_score_gemma":0.0023025074,"threshold_uncertainty_score":0.6024838},"labels":[],"label_agreement":null},{"id":"W3204455199","doi":"10.1016/j.annonc.2021.08.1045","title":"523P AFP-maytansine conjugate: A novel targeted cancer immunotherapy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alpha Cancer Technologies","funders":"","keywords":"Medicine; Conjugate; Immunotherapy; Cancer immunotherapy; Cancer research; Oncology; Cancer; Internal medicine","score_opus":0.05512735016395275,"score_gpt":0.35445035275540804,"score_spread":0.2993230025914553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204455199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80593544,0.17064026,0.00035738965,0.01554348,0.00290518,0.00033123893,0.0002207675,0.00018309533,0.0038831548],"genre_scores_gemma":[0.9602881,0.017683713,0.0003409179,0.008023196,0.000075591444,0.00007355448,0.000177769,0.000079609104,0.01325752],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779403,0.00048720877,0.00066967064,0.00038430138,0.00005670446,0.0006080587],"domain_scores_gemma":[0.9980952,0.00042011886,0.0003423777,0.0005285078,0.00058781577,0.000025970143],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045538886,0.000282093,0.0008078296,0.00015358193,0.00014220206,0.000011202571,0.00032911182,0.0005389584,0.0042224876],"category_scores_gemma":[0.0001779915,0.000262353,0.00028237436,0.000360083,0.00051044946,0.00012090576,0.000087966204,0.00039051982,0.00013060051],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023239313,0.0011168965,0.00020481535,0.000017485556,0.0010252172,0.000026352358,0.00064627937,0.000009797404,0.9043971,0.0010639433,0.01444875,0.07471946],"study_design_scores_gemma":[0.0023328047,0.0007615019,0.0036882781,0.000029599547,0.000019459121,0.00012201161,0.00014716499,0.0000012295086,0.48521495,0.00009220293,0.5074299,0.00016086776],"about_ca_topic_score_codex":0.00044211952,"about_ca_topic_score_gemma":0.00009144399,"teacher_disagreement_score":0.49298117,"about_ca_system_score_codex":0.000042222528,"about_ca_system_score_gemma":0.0008566119,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W3204458306","doi":"10.1016/j.annonc.2021.08.248","title":"1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"Roche; Merck KGaA; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Carboplatin; Nivolumab; Etoposide; Monoclonal antibody; Chemotherapy; Antibody; Oncology; Internal medicine; Cytotoxicity; Cancer research; Pharmacology; Immunotherapy; Immunology; Cancer; In vitro; Cisplatin; Biology","score_opus":0.0357197452818391,"score_gpt":0.3796379834659818,"score_spread":0.34391823818414274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204458306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950988,0.0023938692,0.00005608394,0.0002891785,0.00006416658,0.0016938928,0.000088286055,0.0000068443087,0.00030884804],"genre_scores_gemma":[0.9960671,0.0026459577,0.00022171393,0.0003040026,0.000049672468,0.00010737673,0.0002564706,0.000033651057,0.0003140607],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99745446,0.0005654316,0.00064235425,0.00060586893,0.0003118678,0.00042002948],"domain_scores_gemma":[0.9977956,0.00009861914,0.0003852474,0.0004435379,0.0011155894,0.00016144758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005923463,0.00027753407,0.0009432001,0.00017434316,0.000110032226,0.000015825926,0.00020461345,0.00025009335,0.00012051222],"category_scores_gemma":[0.0001934607,0.00023701397,0.00011127347,0.0002640947,0.00022068065,0.000017748911,0.00020399163,0.00022195262,4.9909295e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27655858,0.027205905,0.20083234,0.00039563622,0.0014474584,0.0005306795,0.0054365927,0.0041983365,0.45730948,0.00007095047,0.0003628003,0.025651254],"study_design_scores_gemma":[0.5359926,0.04548006,0.047767565,0.00011388673,0.00011456009,0.000015263115,0.0010320831,0.003658797,0.3619201,0.00003393685,0.0031818363,0.00068927376],"about_ca_topic_score_codex":0.0018930112,"about_ca_topic_score_gemma":0.0039596376,"teacher_disagreement_score":0.25943407,"about_ca_system_score_codex":0.00002605943,"about_ca_system_score_gemma":0.00068441895,"threshold_uncertainty_score":0.96651495},"labels":[],"label_agreement":null},{"id":"W3204497870","doi":"10.1016/j.annonc.2021.08.1158","title":"645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"LEO Pharma; Unicancer; EUSA Pharma; Ipsen; Cilag; Astellas Pharma; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; Eisai; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Double blind; Oncology; Cancer; Pathology; Androgen receptor; Alternative medicine","score_opus":0.09777747175227228,"score_gpt":0.4186201061047073,"score_spread":0.320842634352435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204497870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99008083,0.0006038845,0.0001314693,0.0008559606,0.00024239007,0.0071356827,0.00027438585,0.000038169048,0.0006372416],"genre_scores_gemma":[0.9958509,0.00039801208,0.0005033054,0.00086639327,0.000067800895,0.0015289348,0.00044344316,0.00006311891,0.0002780575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951913,0.0009765681,0.0017125207,0.0007328067,0.00078639475,0.0006004194],"domain_scores_gemma":[0.9952752,0.00064835546,0.001313071,0.0004918403,0.0020328895,0.00023863639],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092266675,0.00046255253,0.0027746158,0.00047759942,0.00008156007,0.00001841158,0.00013312286,0.00018017236,0.00023510467],"category_scores_gemma":[0.00021819035,0.000397039,0.00021332529,0.000996456,0.00052363507,0.00022673502,0.00006837744,0.0004578634,0.000005474115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9498651,0.008090793,0.0016425725,0.00019216366,0.002403109,0.0012630573,0.018076643,0.004852013,0.010107253,0.00004182348,0.00036443508,0.0031010627],"study_design_scores_gemma":[0.8342311,0.010417625,0.001045325,0.0003507092,0.00067009317,0.00010511519,0.0032099052,0.0006500659,0.14878358,0.000047282978,0.00016427516,0.00032495536],"about_ca_topic_score_codex":0.001961177,"about_ca_topic_score_gemma":0.002857727,"teacher_disagreement_score":0.13867633,"about_ca_system_score_codex":0.00049291796,"about_ca_system_score_gemma":0.002935621,"threshold_uncertainty_score":0.9998481},"labels":[],"label_agreement":null},{"id":"W3204521299","doi":"10.1016/j.annonc.2021.08.1643","title":"1671MO Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Norgine; LEO Pharma; Ipsen; Servier; Eisai; Helsinn; Astellas Pharma; Mylan; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Teva Pharmaceutical Industries; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Conquer Cancer Foundation","keywords":"Medicine; Population; Oncology; Internal medicine; Retrospective cohort study; Cohort; Environmental health","score_opus":0.11254932358163024,"score_gpt":0.449594518224464,"score_spread":0.3370451946428338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204521299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931695,0.00024277504,0.000010017797,0.0028702985,0.00015128657,0.0012703775,0.000046821013,0.000019595433,0.0022193205],"genre_scores_gemma":[0.9982435,0.00006575213,0.0004537177,0.00025011954,0.00013679735,0.00003083204,0.00008310128,0.000026018412,0.0007101409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973709,0.0005003748,0.00086450315,0.00039570715,0.00042934905,0.0004391661],"domain_scores_gemma":[0.99758595,0.00066849304,0.000289867,0.0006055594,0.00058795104,0.00026217604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007560881,0.00024820567,0.0015890559,0.00027724146,0.00006114925,0.0000056439994,0.00011292593,0.00021889998,0.0005005114],"category_scores_gemma":[0.00074650056,0.00018690908,0.0004104995,0.00033100406,0.000087887376,0.000032631648,0.00006215731,0.00019107241,0.000034035376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005180411,0.01356087,0.9321633,0.000110665365,0.0011309847,0.00045447532,0.0011331231,0.00014985066,0.037498437,0.00004636727,0.0002910876,0.008280414],"study_design_scores_gemma":[0.0077314577,0.07024301,0.89839697,0.00014978855,0.00022956975,0.000016091473,0.00047867966,0.00008123464,0.022368925,0.000027086431,0.0001528856,0.00012429923],"about_ca_topic_score_codex":0.002014461,"about_ca_topic_score_gemma":0.00037366868,"teacher_disagreement_score":0.05668214,"about_ca_system_score_codex":0.0003916166,"about_ca_system_score_gemma":0.0018052877,"threshold_uncertainty_score":0.7621931},"labels":[],"label_agreement":null},{"id":"W3204548506","doi":"10.1016/j.annonc.2021.08.2089","title":"LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pembrolizumab; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Taxane; Clinical trial; Cancer; Cisplatin; Breast cancer","score_opus":0.14542339366557264,"score_gpt":0.42940929772729547,"score_spread":0.28398590406172286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204548506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97502965,0.0021337473,0.0008346476,0.016121766,0.0003312646,0.004354078,0.00032256934,0.00003549237,0.00083677797],"genre_scores_gemma":[0.9890017,0.003764186,0.0015437959,0.0032826539,0.0002972232,0.00043760682,0.0003638375,0.00006568639,0.0012432995],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962912,0.00032529872,0.0018391643,0.0006525238,0.00042894608,0.00046285227],"domain_scores_gemma":[0.9951587,0.0020863758,0.0010759147,0.0007293687,0.0008021481,0.00014753852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017844379,0.00039445146,0.0026967723,0.00023847693,0.0000951301,0.0000152576395,0.0002512036,0.00023961272,0.00068573473],"category_scores_gemma":[0.0003494117,0.00032579107,0.00074853585,0.00043685222,0.000347151,0.000089302506,0.000041438296,0.0002390224,0.0000030232766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9246075,0.010875621,0.000031939668,0.0001307417,0.004497397,0.000108739136,0.0046946565,0.000024138937,0.0060463557,0.000021094067,0.005479183,0.04348263],"study_design_scores_gemma":[0.88706344,0.017096488,0.00012803283,0.00015297066,0.0006692102,0.000048641203,0.0010563567,0.00046957523,0.061182126,0.000277295,0.03160187,0.00025396026],"about_ca_topic_score_codex":0.0011077237,"about_ca_topic_score_gemma":0.00073655875,"teacher_disagreement_score":0.05513577,"about_ca_system_score_codex":0.000079150916,"about_ca_system_score_gemma":0.0007467996,"threshold_uncertainty_score":0.9999194},"labels":[],"label_agreement":null},{"id":"W3204588330","doi":"10.1016/j.annonc.2021.08.1489","title":"1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"Astellas Pharma; Natera; Pharmacyclics; MacroGenics; BeiGene; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb; Incyte; Amgen","keywords":"Medicine; Internal medicine; Hypokalemia; Oxaliplatin; Gastroenterology; Vomiting; Nausea; Capecitabine; Adverse effect; Cancer; Colorectal cancer","score_opus":0.16177578153297198,"score_gpt":0.4767629339354125,"score_spread":0.3149871524024406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204588330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861605,0.0023279611,0.000050958737,0.006570379,0.00013991713,0.00071985996,0.00004160955,0.000023881437,0.001509395],"genre_scores_gemma":[0.9965077,0.00054552837,0.0010236852,0.0010764085,0.00025985864,0.00006107274,0.000047873826,0.000051338116,0.00042651745],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969248,0.0003146063,0.0009286894,0.000569953,0.00062589813,0.0006360546],"domain_scores_gemma":[0.99781716,0.00027674157,0.00029594658,0.0008115501,0.0005764193,0.0002222025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092832564,0.00024519578,0.0011418406,0.00029792992,0.00007490803,0.000009519046,0.00032750863,0.00022791972,0.0011365825],"category_scores_gemma":[0.0004379507,0.00024312481,0.00014301392,0.0006430386,0.00022625855,0.00010769803,0.00028553835,0.0005541551,0.000009457138],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012041784,0.069839805,0.31037015,0.001482713,0.0010083565,0.009467173,0.01872245,0.00017732172,0.21473493,0.000055726883,0.027574155,0.33452544],"study_design_scores_gemma":[0.07482397,0.08647568,0.20267747,0.00096171204,0.00019159532,0.0006084811,0.0072548594,0.00080413907,0.59262305,0.0002269961,0.032813385,0.00053864846],"about_ca_topic_score_codex":0.00045244073,"about_ca_topic_score_gemma":0.0004989855,"teacher_disagreement_score":0.37788814,"about_ca_system_score_codex":0.00015644432,"about_ca_system_score_gemma":0.0009591588,"threshold_uncertainty_score":0.99977654},"labels":[],"label_agreement":null},{"id":"W3204589683","doi":"10.1016/j.annonc.2021.08.394","title":"114P Changes in serum choline (Ch) levels to predict treatment outcomes in advanced cancer patients (pts) treated with immunotherapy (IO)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bundesministerium für Bildung und Forschung; European Commission","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Acetylcholine; Oncology; Immunotherapy; Choline; Cancer","score_opus":0.054717464186567664,"score_gpt":0.37767677073934774,"score_spread":0.3229593065527801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204589683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608905,0.0023000983,9.148071e-7,0.010260093,0.00010994794,0.0007164943,0.0001191632,0.000021213134,0.00038303528],"genre_scores_gemma":[0.98706615,0.007103581,0.00010006326,0.0025451095,0.000071073664,0.00030403773,0.000050232495,0.000037401216,0.002722325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843794,0.00016231298,0.00042803268,0.00035673316,0.00018923795,0.0004257369],"domain_scores_gemma":[0.9990136,0.00014235768,0.00015940832,0.00033583707,0.00024610222,0.00010270329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013239714,0.00025222733,0.0010112657,0.00030279902,0.00002496372,0.0000050970893,0.00009173996,0.00014574445,0.0002674025],"category_scores_gemma":[0.000074848256,0.00019023068,0.000092425726,0.00044604667,0.000071934424,0.000062743275,0.000023908571,0.000121921665,0.000005257133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070134304,0.0028521859,0.69375616,0.000039664763,0.00020525527,0.00019771395,0.001623089,0.00009316506,0.0031714002,0.0000021920791,0.00015362093,0.2908921],"study_design_scores_gemma":[0.013009575,0.01123674,0.8934002,0.00029062884,0.000034085526,0.000018790704,0.00029900434,0.000009810473,0.031865917,0.0000036125493,0.049669985,0.0001616295],"about_ca_topic_score_codex":0.002028057,"about_ca_topic_score_gemma":0.01474932,"teacher_disagreement_score":0.29073048,"about_ca_system_score_codex":0.0003532957,"about_ca_system_score_gemma":0.0005236209,"threshold_uncertainty_score":0.8230467},"labels":[],"label_agreement":null},{"id":"W3204618631","doi":"10.1016/j.annonc.2021.08.731","title":"1843P Impact of age, comorbidities and polypharmacy on receipt of systemic therapy in advanced cancers","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Polypharmacy; Receipt; Systemic therapy; Comorbidity; Oncology; Internal medicine; Cancer; Intensive care medicine; Gerontology; Breast cancer; World Wide Web","score_opus":0.11369274217570824,"score_gpt":0.3766727385048364,"score_spread":0.26297999632912816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204618631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96632755,0.015200046,0.0000074163127,0.0003436201,0.0002316392,0.00013369833,0.00024955167,0.0000037254663,0.017502772],"genre_scores_gemma":[0.9642297,0.035169777,0.00006114113,0.00032190996,0.000036114736,0.000010045303,0.000006400735,0.000013102539,0.00015182169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873334,0.000032872245,0.0007732633,0.0002168229,0.000022412783,0.00022127133],"domain_scores_gemma":[0.998777,0.00014641034,0.00072586426,0.00020175763,0.00009406016,0.00005493757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034370864,0.00012364896,0.00089785754,0.00022355733,0.000014664468,0.0000036768515,0.00012269783,0.000109528264,0.00016918735],"category_scores_gemma":[0.00012563306,0.00013447652,0.00014392716,0.0001675202,0.00016209665,0.00014128284,0.000028776449,0.00011272463,0.0000043206783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003419722,0.0010381775,0.5983578,0.00050829985,0.0008379804,0.000089149326,0.0066710925,0.0051059383,0.012096999,0.093958616,0.005348624,0.2725676],"study_design_scores_gemma":[0.00861896,0.008826535,0.892468,0.0005249312,0.000012856447,0.000037836882,0.001013816,0.00021971628,0.039095987,0.023930065,0.024601202,0.00065011386],"about_ca_topic_score_codex":0.002612882,"about_ca_topic_score_gemma":0.00022250132,"teacher_disagreement_score":0.29411018,"about_ca_system_score_codex":0.00013968784,"about_ca_system_score_gemma":0.00030481565,"threshold_uncertainty_score":0.54837936},"labels":[],"label_agreement":null},{"id":"W3204620091","doi":"10.1016/j.annonc.2021.08.195","title":"1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Family medicine","score_opus":0.12895133755951393,"score_gpt":0.45532227768284694,"score_spread":0.326370940123333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204620091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9448959,0.0034894259,0.00010864562,0.040334664,0.00075678574,0.0020308876,0.0034547793,0.00012943284,0.004799484],"genre_scores_gemma":[0.9795404,0.0024425208,0.0019749827,0.009171986,0.00033385557,0.00014798687,0.0058770166,0.000061853,0.0004493932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966096,0.0003813705,0.00069234316,0.00080211536,0.00077747705,0.0007370451],"domain_scores_gemma":[0.995426,0.0008708401,0.00033918465,0.0009570119,0.001872729,0.00053421577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000946209,0.0002738098,0.001131928,0.000110887966,0.000102005266,0.000013307241,0.00075326476,0.000014334035,0.00016568608],"category_scores_gemma":[0.004900954,0.00024048853,0.000119512006,0.0005155531,0.000664258,0.00017503124,0.000823307,0.00050487975,0.00003530264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076000476,0.008291665,0.06534959,0.0012068973,0.00051159953,0.037337307,0.00042619393,0.00005345478,0.0009916415,0.00010703129,0.8049764,0.0731482],"study_design_scores_gemma":[0.0052166553,0.015373208,0.007821108,0.0000644149,0.000068873946,0.0006015293,0.0006374736,0.00008815662,0.00903248,0.000021226424,0.9608897,0.00018516323],"about_ca_topic_score_codex":0.0001165192,"about_ca_topic_score_gemma":0.00030914272,"teacher_disagreement_score":0.15591334,"about_ca_system_score_codex":0.00008352826,"about_ca_system_score_gemma":0.0018599645,"threshold_uncertainty_score":0.9806838},"labels":[],"label_agreement":null},{"id":"W3204658474","doi":"10.1016/j.annonc.2021.08.1962","title":"1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Refractory (planetary science); Oncology; Lung cancer; Cancer; non-small cell lung cancer (NSCLC); Antibody-drug conjugate; Antibody; Breast cancer; Monoclonal antibody; Immunology","score_opus":0.09043951009908645,"score_gpt":0.4486056378400373,"score_spread":0.35816612774095086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204658474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905705,0.001298306,0.00007023551,0.002012192,0.00022045184,0.0024841721,0.00009442071,0.00004542212,0.0032043254],"genre_scores_gemma":[0.9961181,0.0003078505,0.0009942396,0.0009941049,0.00008778381,0.0005390925,0.00008268428,0.00010552515,0.0007706002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954667,0.00071288744,0.0010213965,0.0008748834,0.0008592013,0.0010649427],"domain_scores_gemma":[0.9966468,0.0004428861,0.00037398352,0.00070222147,0.0013735321,0.0004605313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010232405,0.00043339017,0.0014195326,0.00044649563,0.00012033881,0.000021842228,0.00034832384,0.0001878765,0.0009364082],"category_scores_gemma":[0.0003956231,0.0003802472,0.00014373795,0.0014124234,0.000243365,0.00011073465,0.00022620196,0.0008372557,0.000018779838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011274072,0.07273239,0.6533732,0.002059733,0.0020123357,0.00822277,0.020039517,0.00048040872,0.008016906,0.00000934558,0.013035263,0.20874408],"study_design_scores_gemma":[0.19000539,0.2276051,0.44358456,0.0032053979,0.0024684016,0.00025693487,0.014025887,0.0030285474,0.08924492,0.000118954544,0.02429521,0.0021607024],"about_ca_topic_score_codex":0.0032949308,"about_ca_topic_score_gemma":0.007749074,"teacher_disagreement_score":0.20978862,"about_ca_system_score_codex":0.0005711029,"about_ca_system_score_gemma":0.004510092,"threshold_uncertainty_score":0.9999769},"labels":[],"label_agreement":null},{"id":"W3204746685","doi":"10.1016/j.annonc.2021.08.412","title":"131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Internal medicine; Body mass index; Adjuvant","score_opus":0.033468116874818876,"score_gpt":0.36269041442558797,"score_spread":0.3292222975507691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204746685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629796,0.001246306,8.0933825e-7,0.0011956486,0.00005311267,0.00032287557,0.0004872957,0.0000033902993,0.00039258422],"genre_scores_gemma":[0.99764633,0.0017905566,0.000023238095,0.0002644148,0.00006886321,0.00007792595,0.0000292102,0.000013913981,0.00008552533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992036,0.000051431023,0.00020846786,0.00020294508,0.00011886482,0.0002146986],"domain_scores_gemma":[0.9993525,0.000032550215,0.00012493895,0.00013582931,0.00024400561,0.00011015775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042670745,0.0001381749,0.0005429345,0.00009001524,0.000009778697,0.0000025764411,0.000023894432,0.00009324445,0.00028630169],"category_scores_gemma":[0.0000041158055,0.00009131561,0.00008520512,0.00013404385,0.000093304894,0.00006322296,0.000019957759,0.000075324315,0.0000012059835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034114516,0.001034503,0.92901444,0.00003089012,0.00028536457,0.00016205771,0.0013027982,8.509242e-7,0.0003102441,0.0000026153673,0.00011374819,0.06433104],"study_design_scores_gemma":[0.0043218257,0.011375468,0.9812182,0.00018765166,0.00009792056,0.000018040162,0.00006886876,0.0000054076395,0.0020015447,0.000007663863,0.000613717,0.00008366426],"about_ca_topic_score_codex":0.013840835,"about_ca_topic_score_gemma":0.0026182088,"teacher_disagreement_score":0.06424738,"about_ca_system_score_codex":0.00019254004,"about_ca_system_score_gemma":0.0003042144,"threshold_uncertainty_score":0.9927261},"labels":[],"label_agreement":null},{"id":"W3204767207","doi":"10.1016/j.annonc.2021.08.057","title":"661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb","keywords":"Medicine; Progression-free survival; Ipilimumab; Intention-to-treat analysis; Sunitinib; Internal medicine; Clinical endpoint; Randomized controlled trial; Surgery; Oncology; Overall survival; Renal cell carcinoma; Cancer; Immunotherapy","score_opus":0.08853890813144567,"score_gpt":0.3488294023579169,"score_spread":0.2602904942264712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204767207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767714,0.0012497491,0.0000053302556,0.0025911275,0.00035730013,0.00036667773,0.00008870403,0.000017092534,0.018552609],"genre_scores_gemma":[0.9973577,0.0006009381,0.00045222483,0.00022080351,0.00010465041,0.00005348115,0.00047642578,0.00003282745,0.00070091087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977234,0.00024074924,0.00066652126,0.0005209005,0.0003307279,0.0005177163],"domain_scores_gemma":[0.99832284,0.0005884708,0.00020026404,0.00034408335,0.00033914464,0.00020516501],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040601753,0.00026823385,0.0008889627,0.00029243372,0.00004802149,0.000007980703,0.00010456963,0.00024013552,0.00044288152],"category_scores_gemma":[0.00024983363,0.00027671646,0.00015295988,0.0003748063,0.00020098126,0.00010575837,0.00012871924,0.000356829,0.00002670666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13805333,0.016130496,0.59094375,0.0029537436,0.0011843808,0.040470023,0.0066453223,0.0015010848,0.10711003,0.007587085,0.0075132726,0.079907484],"study_design_scores_gemma":[0.08417232,0.012197005,0.7700787,0.0002039132,0.00016263663,0.00023649403,0.0019830635,0.00019409928,0.1197411,0.0009017683,0.009648781,0.00048011923],"about_ca_topic_score_codex":0.0003017641,"about_ca_topic_score_gemma":0.0032740843,"teacher_disagreement_score":0.17913494,"about_ca_system_score_codex":0.0002141197,"about_ca_system_score_gemma":0.000664422,"threshold_uncertainty_score":0.9999685},"labels":[],"label_agreement":null},{"id":"W3204818878","doi":"10.1016/j.annonc.2021.08.537","title":"254P Impact of palbociclib-dose reduction on survival: A retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis","keywords":"Medicine; Palbociclib; Retrospective cohort study; Cohort; Oncology; Reduction (mathematics); Gynecology; Internal medicine; Cancer; Breast cancer","score_opus":0.08496692943628022,"score_gpt":0.4594045357469845,"score_spread":0.3744376063107043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204818878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917792,0.00032035768,0.000015736796,0.0013522578,0.00029423117,0.00048618208,0.000022202881,0.000027489696,0.0057023424],"genre_scores_gemma":[0.99890983,0.00017949405,0.00015650879,0.00012605738,0.00017514771,0.00002952949,0.000014113017,0.000023608025,0.00038571216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986072,0.0002006411,0.00037059165,0.00030947514,0.00029404368,0.00021805905],"domain_scores_gemma":[0.9982622,0.000104200975,0.00029540993,0.0004215649,0.0008339678,0.00008263422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043985632,0.00014183274,0.000809317,0.00011452172,0.000026311789,0.0000019280646,0.00006638308,0.00010497727,0.00031005376],"category_scores_gemma":[0.0002983266,0.00012125979,0.00020460531,0.00036142473,0.00015503581,0.0000600471,0.000036956237,0.00020887106,0.000007503469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049378285,0.004821592,0.89872104,0.00003923403,0.0018503299,0.0001627321,0.0019736923,0.000099368364,0.03942411,0.00029449305,0.00083532964,0.046840236],"study_design_scores_gemma":[0.002772657,0.014235653,0.9622591,0.000047381676,0.000097700184,0.00009455621,0.0014331844,0.0000038155354,0.017451307,0.0007700306,0.0007482507,0.00008637976],"about_ca_topic_score_codex":0.00026758856,"about_ca_topic_score_gemma":0.00004727143,"teacher_disagreement_score":0.06353803,"about_ca_system_score_codex":0.00022506808,"about_ca_system_score_gemma":0.0004612761,"threshold_uncertainty_score":0.49448308},"labels":[],"label_agreement":null},{"id":"W3204829131","doi":"10.1016/j.annonc.2021.08.516","title":"233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cohort; Surgery","score_opus":0.08109988633338527,"score_gpt":0.40707448615225167,"score_spread":0.3259745998188664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204829131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903388,0.0012006781,0.000018521767,0.0069640735,0.000031671105,0.0008481861,0.00024371524,0.0000120173845,0.00034231643],"genre_scores_gemma":[0.99614435,0.0018102768,0.00037698494,0.0013117912,0.000041044805,0.000117542186,0.00006940389,0.0000338804,0.00009469171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962156,0.001411719,0.000999841,0.00038883253,0.00062242325,0.0003615866],"domain_scores_gemma":[0.99581146,0.0012899954,0.0014232759,0.00034397465,0.0010476481,0.00008365403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016089904,0.00027658322,0.0017769114,0.0001406495,0.000025805835,0.0000055648325,0.0001257571,0.00012772334,0.000077972916],"category_scores_gemma":[0.0003734002,0.00016626302,0.00008611049,0.00054264796,0.00022867617,0.00019770443,0.00002882104,0.000281161,2.016288e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044869974,0.002024865,0.91463614,0.00013453703,0.0007170165,0.000024377498,0.0015329199,0.00031706016,0.0026261401,0.00020390723,0.000029184208,0.032883856],"study_design_scores_gemma":[0.035934728,0.0045265914,0.95315033,0.00030583615,0.0000744188,0.000014810405,0.00078648835,0.000006640798,0.0041113426,0.00014000964,0.00077633065,0.00017244468],"about_ca_topic_score_codex":0.0026251706,"about_ca_topic_score_gemma":0.007876955,"teacher_disagreement_score":0.038514197,"about_ca_system_score_codex":0.00018946939,"about_ca_system_score_gemma":0.00077225536,"threshold_uncertainty_score":0.6780009},"labels":[],"label_agreement":null},{"id":"W3204840943","doi":"10.1016/j.annonc.2021.08.1848","title":"1243P Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Histology; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Incidence (geometry); Cumulative incidence; Lung cancer; Cohort","score_opus":0.03865106962071749,"score_gpt":0.3980041069635633,"score_spread":0.35935303734284585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204840943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914531,0.00472629,0.0004773702,0.0016939469,0.00007575129,0.00042187472,0.00040514593,0.000007807899,0.0007386841],"genre_scores_gemma":[0.989268,0.006263156,0.001182232,0.0014032522,0.000018907518,0.000092551825,0.000099092715,0.000017488854,0.0016553334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988591,0.00012857714,0.00036143902,0.00026935496,0.00009648918,0.00028504513],"domain_scores_gemma":[0.99883014,0.00026734176,0.0003122416,0.0001556364,0.00028170698,0.00015294013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014003064,0.00014293064,0.0006328313,0.00008113988,0.000039289338,0.000004058799,0.000040245628,0.00009395561,0.00017158793],"category_scores_gemma":[0.000056667537,0.00012906818,0.000047966685,0.00009266571,0.000132494,0.000067730834,0.00005307127,0.00012551919,5.662365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016826426,0.0012372773,0.79307306,0.0021095432,0.0013173815,0.0006491335,0.01137607,0.000015719466,0.158572,0.00011131479,0.00091389235,0.028941976],"study_design_scores_gemma":[0.02332541,0.007281799,0.80502677,0.00065859576,0.0025360822,0.00022602994,0.0023835506,0.0006560514,0.11797209,0.000105388186,0.03935727,0.00047094768],"about_ca_topic_score_codex":0.0013413223,"about_ca_topic_score_gemma":0.00036031957,"teacher_disagreement_score":0.04059991,"about_ca_system_score_codex":0.00012371156,"about_ca_system_score_gemma":0.0009543594,"threshold_uncertainty_score":0.52632475},"labels":[],"label_agreement":null},{"id":"W3204843825","doi":"10.1016/j.annonc.2021.08.517","title":"234P Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Palbociclib; Internal medicine; Human Epidermal Growth Factor Receptor 2; Chemotherapy; Oncology; Endocrine system; Chemotherapy regimen; Endocrinology; Hormone receptor; Receptor; Hormone; Cancer; Metastatic breast cancer; Breast cancer","score_opus":0.026053341794756074,"score_gpt":0.3776716080813189,"score_spread":0.3516182662865628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204843825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746353,0.0023143524,0.000041863852,0.0043069874,0.0001058251,0.0012654045,0.0042846315,0.000049549897,0.00016782478],"genre_scores_gemma":[0.9913093,0.0034013686,0.0017341347,0.0024441823,0.00016025908,0.00016171725,0.0005088225,0.00013088303,0.00014937269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959976,0.00070557836,0.0009799949,0.0009406408,0.0006399704,0.0007362263],"domain_scores_gemma":[0.99488384,0.0012897941,0.0010427623,0.0005942093,0.0018411108,0.00034828484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027724504,0.00070688257,0.0023222493,0.00021374747,0.00012533806,0.000014745141,0.00026290986,0.00024488714,0.001257185],"category_scores_gemma":[0.00018081626,0.0005469237,0.00030680056,0.00064413535,0.000718668,0.00028909248,0.00011460757,0.000398707,0.000013011805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06365337,0.0016582991,0.04119324,0.00014281034,0.0020328052,0.0000390895,0.0035542913,0.00001733651,0.58213127,0.000012577724,0.00031056083,0.30525437],"study_design_scores_gemma":[0.016333286,0.025676616,0.46016195,0.00038437196,0.000079178906,0.000016434587,0.00028502606,0.0000023895866,0.49557477,0.000048451795,0.0010790995,0.00035841778],"about_ca_topic_score_codex":0.0010164325,"about_ca_topic_score_gemma":0.00026201006,"teacher_disagreement_score":0.4189687,"about_ca_system_score_codex":0.00020526587,"about_ca_system_score_gemma":0.00026195895,"threshold_uncertainty_score":0.9996982},"labels":[],"label_agreement":null},{"id":"W3204869428","doi":"10.1016/j.annonc.2021.08.1151","title":"638P Evaluating the contribution of virtual peer-led support to comprehensive prostate cancer (PCa) care: The AnCan experience","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Astellas Pharma; Eisai; AstraZeneca; Invitae; Bayer Fund; Pharmacyclics; Genentech; GlaxoSmithKline; UroGen Pharma; Advanced Accelerator Applications; Menarini Silicon Biosystems; Ipsen; Clovis Oncology; Sanofi Genzyme; Foundation Medicine; Sierra Oncology; Taiho Pharmaceutical; Vertex Pharmaceuticals; Boston Scientific Corporation; U.S. Department of Defense; Sanofi; Amgen; Pfizer; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Prostate cancer; Peer support; Disease; Family medicine; Cancer; Internal medicine; Nursing","score_opus":0.2849659946352303,"score_gpt":0.5697113648586218,"score_spread":0.2847453702233915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204869428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8889522,0.0006177554,0.000005613225,0.10551481,0.0028945936,0.0010720537,0.000019946461,0.000009705525,0.00091334776],"genre_scores_gemma":[0.9950892,0.00039042425,0.000069372596,0.0029801962,0.00047947478,0.0008720912,0.000012499626,0.0000058189944,0.000100944606],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973354,0.0011476228,0.00038375912,0.00018804117,0.00059839623,0.0003468142],"domain_scores_gemma":[0.99228257,0.0028638637,0.00036408717,0.00019668965,0.0041934946,0.000099295255],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014609707,0.000075993,0.0002625386,0.000027831187,0.00046049064,0.000013678684,0.0002662179,0.000104908315,0.00018053495],"category_scores_gemma":[0.0093369,0.00005640408,0.00005885442,0.0005128064,0.0005966012,0.00007494509,0.000064645894,0.00014596462,0.000005628426],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013733687,0.000092324975,0.02156607,0.000018750563,0.00003130728,0.0000022596048,0.76753366,0.0000812271,0.0038715482,0.0068436805,0.0042789285,0.1955429],"study_design_scores_gemma":[0.00049441314,0.001738211,0.102245554,0.00004937737,0.000035835536,0.0000015166902,0.42907503,0.000018584531,0.014850888,0.0005098563,0.45084915,0.00013158408],"about_ca_topic_score_codex":0.008674788,"about_ca_topic_score_gemma":0.011283043,"teacher_disagreement_score":0.44657022,"about_ca_system_score_codex":0.00019605564,"about_ca_system_score_gemma":0.004146429,"threshold_uncertainty_score":0.9990079},"labels":[],"label_agreement":null},{"id":"W3204898243","doi":"10.1016/j.annonc.2021.08.1863","title":"1260P Clinical outcomes of patients with BRAFv⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); University of British Columbia","funders":"EMD Serono; Merck KGaA","keywords":"Dabrafenib; Trametinib; Medicine; Oncology; Internal medicine; Standard of care; First line; Metastatic melanoma; Vemurafenib; Cancer","score_opus":0.08867224204008321,"score_gpt":0.45384738437075944,"score_spread":0.3651751423306762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204898243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98398393,0.0009905435,0.000008436489,0.005260605,0.00015901476,0.0005941251,0.00023707896,0.000014727629,0.008751541],"genre_scores_gemma":[0.9945996,0.0015241064,0.0027443396,0.0007944938,0.00002304895,0.000029859804,0.00006589931,0.00002932162,0.00018937846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973819,0.00038531199,0.0011818637,0.0003610567,0.00040624617,0.00028356732],"domain_scores_gemma":[0.99476993,0.0023206766,0.0008311479,0.0003365238,0.0016477901,0.000093920804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060846016,0.00021924947,0.0018033474,0.00018165466,0.00003474035,0.000003641831,0.00009185226,0.00009816928,0.0001712068],"category_scores_gemma":[0.002246937,0.00015831232,0.0002131613,0.00053091405,0.00027502878,0.00009421691,0.00008691714,0.0002340484,0.0000014174608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02136405,0.0034273884,0.9286381,0.00038043412,0.0019139978,0.00016850694,0.002628235,0.000035439843,0.000013189889,0.00008134162,0.0004088367,0.04094047],"study_design_scores_gemma":[0.011800683,0.021715492,0.9405784,0.00042691987,0.0007782425,0.0000051477145,0.0021401935,0.0000045513116,0.0014019229,0.000055476627,0.02093633,0.00015664393],"about_ca_topic_score_codex":0.0011054891,"about_ca_topic_score_gemma":0.024150077,"teacher_disagreement_score":0.04078383,"about_ca_system_score_codex":0.00010936548,"about_ca_system_score_gemma":0.0006616118,"threshold_uncertainty_score":0.99365664},"labels":[],"label_agreement":null},{"id":"W3204946916","doi":"10.1016/j.annonc.2021.08.1047","title":"525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; MacroGenics; Moderna; Innovent Biologics; Sierra Oncology; Incyte; Ipsen; BeiGene; Tizona Therapeutics; Puma Biotechnology; Revolution Medicines; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; Symphogen; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Cancer research; Pharmacodynamics; Transcription factor; Pharmacology; Pharmacokinetics; Biology","score_opus":0.04660825120478091,"score_gpt":0.3696147963894496,"score_spread":0.3230065451846687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204946916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939751,0.0044162152,0.00039518825,0.00024460704,0.00005683602,0.00050872477,0.00036163485,0.0000051056413,0.000036578145],"genre_scores_gemma":[0.99548274,0.002759705,0.00046297273,0.0001743139,0.000025353305,0.0000148053105,0.0010494937,0.000022977036,0.000007643824],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851936,0.00026317817,0.00044486628,0.00040863952,0.00013909058,0.00022488585],"domain_scores_gemma":[0.9991207,0.00013632257,0.0002825248,0.00026116532,0.00012938422,0.00006989172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023947327,0.00019176758,0.00036539073,0.00005412734,0.0000507528,0.00000800996,0.00017423586,0.00010243889,0.000016195694],"category_scores_gemma":[0.0000538315,0.0001431307,0.00005101165,0.00014685398,0.00017696274,0.000023512763,0.000111010035,0.00018361224,4.1510043e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002325442,0.0013124547,0.00092811347,0.000044760814,0.00032116022,0.000008531219,0.0002776935,0.00037700866,0.90690416,0.0000034578686,0.000018632116,0.08747858],"study_design_scores_gemma":[0.045208953,0.008358061,0.053217653,0.00019089438,0.0005979422,0.00004228933,0.0004199153,0.01650391,0.8720927,0.000047712903,0.0027828172,0.0005371029],"about_ca_topic_score_codex":0.000028086173,"about_ca_topic_score_gemma":0.000032535885,"teacher_disagreement_score":0.08694147,"about_ca_system_score_codex":0.000010991639,"about_ca_system_score_gemma":0.00012747162,"threshold_uncertainty_score":0.5836701},"labels":[],"label_agreement":null},{"id":"W3205205171","doi":"10.1016/j.annonc.2021.08.2053","title":"57P Patients’ and caregivers’ perspective on biomarker testing across Canada","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine; Descriptive statistics; Test (biology)","score_opus":0.3524477092504533,"score_gpt":0.5664074746744889,"score_spread":0.2139597654240356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205205171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8829828,0.00041264782,0.0000011036852,0.02966245,0.0008581839,0.000243183,0.000120722616,0.000011202171,0.0857077],"genre_scores_gemma":[0.99336016,0.000076998374,0.0000773531,0.005646374,0.00010730011,0.00001726991,0.000008132378,0.000010237542,0.0006961913],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755037,0.0012789993,0.00035465785,0.0002482075,0.00016279252,0.0004049948],"domain_scores_gemma":[0.99409735,0.003611549,0.00036239278,0.00015979295,0.0016173762,0.0001515301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076658704,0.00009321929,0.00030868655,0.000019473453,0.00043226258,0.0000034893517,0.000062162406,0.00017920033,0.00012420808],"category_scores_gemma":[0.0039241095,0.00008358851,0.000023062574,0.0001739883,0.000053220567,0.0000703851,0.00009043462,0.00034835844,0.00001063167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003726734,0.00031209915,0.53986275,0.0006707629,0.00021050496,0.00031728437,0.051602077,0.0000026469475,0.00019135266,0.004369448,0.1627613,0.23932712],"study_design_scores_gemma":[0.00068211334,0.00062604726,0.29844669,0.00013046182,0.000006333052,0.000004714754,0.067655236,0.0000066649604,0.000052140535,0.00010208216,0.6321918,0.000095734606],"about_ca_topic_score_codex":0.70496523,"about_ca_topic_score_gemma":0.76886016,"teacher_disagreement_score":0.4694305,"about_ca_system_score_codex":0.0002504383,"about_ca_system_score_gemma":0.0027681778,"threshold_uncertainty_score":0.49106285},"labels":[],"label_agreement":null},{"id":"W3206587650","doi":"10.1016/j.annonc.2021.10.005","title":"PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later","year":2021,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olympiad; Oncology; PARP inhibitor; Metastatic breast cancer; Internal medicine; Breast cancer; Cancer; Poly ADP ribose polymerase","score_opus":0.054898949890507795,"score_gpt":0.4199216757541365,"score_spread":0.3650227258636287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206587650","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18469372,0.004313077,0.000008645082,0.015078347,0.7889508,0.001063496,0.0033064832,0.0001264997,0.0024588932],"genre_scores_gemma":[0.21620773,0.0121054,0.0003702804,0.0037844237,0.7612941,0.00034666434,0.0035264674,0.0002751401,0.0020897666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561536,0.00093838543,0.001196452,0.000827623,0.00077569927,0.00064649584],"domain_scores_gemma":[0.99611217,0.0009515594,0.0007496197,0.00064910285,0.0012497525,0.000287784],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014777278,0.00049419113,0.0021659331,0.00044920205,0.000045833895,0.000016935153,0.00014694339,0.0014315279,0.0010989372],"category_scores_gemma":[0.00030319896,0.00048073806,0.00032497276,0.00052526203,0.00034741103,0.00017423781,0.0000886575,0.0014540226,0.000034070938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016641313,0.0014661963,0.0009824056,0.00042102422,0.00073379127,0.002138054,0.00059852714,0.00004854693,0.0051243077,0.000016288684,0.96598107,0.020825647],"study_design_scores_gemma":[0.009758873,0.0024388547,0.0037691502,0.0018267514,0.00039850042,0.00035226074,0.00014548244,0.00006605012,0.010304258,0.00029582097,0.9699981,0.00064584735],"about_ca_topic_score_codex":0.0015869656,"about_ca_topic_score_gemma":0.0025185444,"teacher_disagreement_score":0.031513996,"about_ca_system_score_codex":0.0005095727,"about_ca_system_score_gemma":0.0040063737,"threshold_uncertainty_score":0.9998648},"labels":[],"label_agreement":null},{"id":"W3207692553","doi":"10.1016/j.annonc.2021.08.2041","title":"45P Environmental scan of molecular profiling in Canada","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profiling (computer programming); Medicine; Family medicine; Health care; Descriptive statistics; Health professionals; Statistics","score_opus":0.04629923292828474,"score_gpt":0.2671780546161309,"score_spread":0.22087882168784617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207692553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95071715,0.004253697,0.000042490883,0.0009293107,0.00017845425,0.000060371174,0.00016301307,0.0000012671519,0.04365425],"genre_scores_gemma":[0.9979168,0.0008119032,0.00032117587,0.0008056533,0.000019950006,0.0000049267414,0.000011029819,0.000008640344,0.00009991169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990112,0.0000128369265,0.0005706719,0.00018093146,0.000019283258,0.00020505753],"domain_scores_gemma":[0.9994095,0.00003538125,0.00032910358,0.00016020772,0.000016954034,0.00004886256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019548537,0.00007158642,0.0004483379,0.00007308593,0.000009670838,0.0000022194738,0.00010823339,0.00006757969,0.00029877006],"category_scores_gemma":[0.00007819599,0.0000965447,0.000061174425,0.00008035477,0.000051606934,0.0000719961,0.00004493256,0.00008228173,0.000010438538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009458928,0.00039409657,0.811678,0.0000820246,0.00012718621,0.00017229626,0.0003218466,0.0013252228,0.006623186,0.1227722,0.0015390338,0.0548703],"study_design_scores_gemma":[0.0023414283,0.00071169576,0.51588213,0.000050191364,0.00000934313,0.000021136791,0.00085245946,0.0005229155,0.28048915,0.04127302,0.15726776,0.00057873735],"about_ca_topic_score_codex":0.24811329,"about_ca_topic_score_gemma":0.25629726,"teacher_disagreement_score":0.29579586,"about_ca_system_score_codex":0.00025015994,"about_ca_system_score_gemma":0.00074607,"threshold_uncertainty_score":0.7572734},"labels":[],"label_agreement":null},{"id":"W3215061648","doi":"10.1016/j.annonc.2021.11.007","title":"The enduring decision-making role of the surgeon in the multidisciplinary management of GIST","year":2021,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; GiST; General surgery; Resection margin; Imatinib mesylate; Imatinib; Surgery; Stromal cell; Internal medicine; Resection","score_opus":0.041132591860057306,"score_gpt":0.4182284813871198,"score_spread":0.3770958895270625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215061648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67752373,0.021616368,0.000021063237,0.013208634,0.23475097,0.0047126273,0.00031112492,0.000023389279,0.047832105],"genre_scores_gemma":[0.96940607,0.002834336,0.000616062,0.000023006587,0.02665293,0.00009708636,0.00003693888,0.000027178708,0.000306418],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974331,0.00037677577,0.0006463342,0.00024032094,0.0009525409,0.0003508876],"domain_scores_gemma":[0.99272346,0.005614257,0.00049772044,0.0007021853,0.00041956882,0.00004278426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017275319,0.00017150928,0.00061318197,0.00010013101,0.00009660779,0.0000072923635,0.0005412325,0.00013956144,0.000020469824],"category_scores_gemma":[0.0016838973,0.00008085796,0.000310879,0.00028191446,0.0003175763,0.000016578924,0.00053878396,0.0006076036,0.0000016376603],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006622674,0.005384958,0.021571347,0.0021356228,0.0017676591,0.004811616,0.0016589285,0.00011580321,0.0005465458,0.001288181,0.6274227,0.32667395],"study_design_scores_gemma":[0.004823038,0.008809307,0.16310017,0.015182763,0.0005700602,0.0002251151,0.012793615,0.00008657963,0.0026252256,0.0047479253,0.7867528,0.00028339602],"about_ca_topic_score_codex":0.00019070727,"about_ca_topic_score_gemma":0.0003980355,"teacher_disagreement_score":0.32639056,"about_ca_system_score_codex":0.00007765538,"about_ca_system_score_gemma":0.0005320026,"threshold_uncertainty_score":0.32972917},"labels":[],"label_agreement":null},{"id":"W3217079453","doi":"10.1016/j.annonc.2021.11.018","title":"Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; Vifor Pharma; AbbVie; Roche; Pfizer","keywords":"Carboplatin; Veliparib; Medicine; Internal medicine; Placebo; Hazard ratio; PARP inhibitor; Paclitaxel; Oncology; Breast cancer; Interim analysis; Clinical endpoint; Chemotherapy; Randomized controlled trial; Urology; Cancer; Confidence interval; Pathology; Cisplatin","score_opus":0.12010783699426184,"score_gpt":0.4370745556466084,"score_spread":0.3169667186523466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217079453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032116,0.0023378672,0.000060175873,0.0047500473,0.0004452679,0.0010675528,0.00080983463,0.0000315627,0.00017651942],"genre_scores_gemma":[0.9944679,0.0021506283,0.00013433101,0.0020590315,0.00015572955,0.00019359154,0.0007527402,0.00004234276,0.000043673568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99672693,0.0005883232,0.0012417441,0.00047504102,0.00060778443,0.00036017864],"domain_scores_gemma":[0.99647003,0.00075805566,0.0011312688,0.0004961213,0.001042063,0.00010246934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065637415,0.00028663,0.00125776,0.00017231437,0.00008062393,0.000010049883,0.00018569085,0.00026891104,0.00008074191],"category_scores_gemma":[0.00023350438,0.0002192172,0.00025331098,0.00083795656,0.00018311295,0.00020344641,0.000029324423,0.00035714594,9.471265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7267358,0.013599709,0.02426258,0.00003530011,0.0041484977,0.00008805224,0.01032904,0.0018266513,0.06724604,0.000074406686,0.0035145965,0.14813936],"study_design_scores_gemma":[0.80330336,0.012016857,0.12679735,0.000628808,0.0002289834,0.0000021944263,0.0009990374,0.0002609846,0.052911393,0.000316932,0.0021638947,0.00037021172],"about_ca_topic_score_codex":0.001365722,"about_ca_topic_score_gemma":0.00082879455,"teacher_disagreement_score":0.14776915,"about_ca_system_score_codex":0.00032855695,"about_ca_system_score_gemma":0.0013209562,"threshold_uncertainty_score":0.8939418},"labels":[],"label_agreement":null},{"id":"W4200007309","doi":"10.1016/j.annonc.2021.10.182","title":"163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Gemcitabine; Pembrolizumab; Internal medicine; Quality of life (healthcare); Clinical endpoint; Oncology; Chemotherapy; Cancer; Surgery; Clinical trial; Nursing","score_opus":0.19043215038222072,"score_gpt":0.483438736410642,"score_spread":0.2930065860284213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200007309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977407,0.010073088,0.000008161035,0.0098333815,0.00019083585,0.0013374082,0.00011240355,0.000040807656,0.0009969461],"genre_scores_gemma":[0.99159986,0.004590044,0.00032721242,0.0027587358,0.000056437257,0.00018268447,0.000059859412,0.000043611242,0.00038158352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955353,0.0008303122,0.0018995601,0.0006172568,0.0005140475,0.0006034948],"domain_scores_gemma":[0.99697304,0.00057202694,0.0009678039,0.0004820563,0.000702513,0.0003025375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011519801,0.00037435905,0.003200501,0.00023327861,0.00007918013,0.000004942449,0.0001527811,0.0001512335,0.00071373873],"category_scores_gemma":[0.00047945016,0.0002802326,0.00017130964,0.0010368419,0.00026267712,0.00008198509,0.000074842705,0.00046766642,0.0000031816949],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37713462,0.077739336,0.10846205,0.0038927111,0.008564105,0.0015702061,0.044273887,0.000067647234,0.0060347696,0.0001205441,0.01572375,0.35641637],"study_design_scores_gemma":[0.4635508,0.13308,0.35780615,0.0025551033,0.000725716,0.00017732319,0.013772268,0.00058587774,0.020239364,0.00013388948,0.0062416624,0.0011318417],"about_ca_topic_score_codex":0.005794613,"about_ca_topic_score_gemma":0.0109256115,"teacher_disagreement_score":0.3552845,"about_ca_system_score_codex":0.00030036364,"about_ca_system_score_gemma":0.0037545592,"threshold_uncertainty_score":0.999965},"labels":[],"label_agreement":null},{"id":"W4200112797","doi":"10.1016/j.annonc.2021.12.006","title":"COVID-19 vaccination and breakthrough infections in patients with cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Vaccination; Cancer; Immunology; Malignancy; Intensive care medicine; Internal medicine","score_opus":0.1249304241176766,"score_gpt":0.49403133655218107,"score_spread":0.3691009124345045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200112797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92507803,0.00040918245,0.000042280994,0.07281682,0.00007464762,0.00020428984,0.000015976222,0.000011499332,0.00134727],"genre_scores_gemma":[0.97530246,0.00086183165,0.000062062616,0.023604432,0.000036394867,0.000015953214,0.000024230518,0.0000058711935,0.00008678741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993926,0.00006284871,0.0001679501,0.0001383431,0.00009302625,0.00014521823],"domain_scores_gemma":[0.9991336,0.00018082235,0.000076962846,0.000098266566,0.00031326682,0.00019708567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012971634,0.000058307796,0.00023150859,0.000111855436,0.000033788605,0.0000024847504,0.000015215677,0.00009124735,0.00028794428],"category_scores_gemma":[0.0007513106,0.0000500573,0.000017843802,0.00025412408,0.00002885386,0.00006200641,0.000019493622,0.000108398104,0.000001341315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030585387,0.0005600407,0.92823476,0.00024067295,0.000029742017,0.000031054853,0.0007379121,0.000019267116,0.000025718362,0.00021642208,0.0032439874,0.06635458],"study_design_scores_gemma":[0.003121237,0.0021066638,0.91747206,0.000039580085,0.0000194308,0.00001676664,0.00006493932,0.000006566085,0.00013715273,0.00021510712,0.076756045,0.000044462824],"about_ca_topic_score_codex":0.0032991904,"about_ca_topic_score_gemma":0.011592692,"teacher_disagreement_score":0.073512055,"about_ca_system_score_codex":0.00017218773,"about_ca_system_score_gemma":0.0025324733,"threshold_uncertainty_score":0.6468994},"labels":[],"label_agreement":null},{"id":"W4200122615","doi":"10.1016/j.annonc.2021.10.132","title":"114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Oncology; Lung cancer; Internal medicine; Phases of clinical research; Stage (stratigraphy); Cancer; Immunotherapy","score_opus":0.1475345320760051,"score_gpt":0.46159411766718694,"score_spread":0.31405958559118186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200122615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769284,0.0031402274,0.000057644258,0.016265959,0.00012850948,0.0026896487,0.0001334845,0.0000267786,0.0006293249],"genre_scores_gemma":[0.9860033,0.004654491,0.0004487699,0.0052627344,0.00017720333,0.000612038,0.00008343542,0.000056160672,0.002701878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99776953,0.00014379638,0.0005769078,0.0005042236,0.00053259067,0.00047293174],"domain_scores_gemma":[0.9963109,0.00042025145,0.00042277222,0.00044424087,0.00219252,0.00020930934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035748884,0.0002877415,0.0010872255,0.00016376405,0.00017909003,0.0000074925806,0.00020246103,0.00012841531,0.0004050804],"category_scores_gemma":[0.0002517999,0.00022859727,0.00015704113,0.00037119337,0.000322691,0.00006563263,0.000116197145,0.00023919577,0.0000012824255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35462567,0.1063509,0.09793883,0.0073425733,0.022069052,0.0023958683,0.07739294,0.006593454,0.10958186,0.0010721823,0.1488443,0.06579235],"study_design_scores_gemma":[0.31740004,0.2808219,0.048043683,0.0006593653,0.00065128447,0.000048992708,0.004396981,0.0034922822,0.2502949,0.00040443923,0.093004175,0.0007819855],"about_ca_topic_score_codex":0.00048445663,"about_ca_topic_score_gemma":0.0007046879,"teacher_disagreement_score":0.17447099,"about_ca_system_score_codex":0.00019191489,"about_ca_system_score_gemma":0.0025275892,"threshold_uncertainty_score":0.9321927},"labels":[],"label_agreement":null},{"id":"W4200142029","doi":"10.1016/j.annonc.2021.10.139","title":"120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Eisai","keywords":"Medicine; Pembrolizumab; Internal medicine; First line treatment; Oncology; First line; Population; Placebo; Tolerability; Stock options; Phases of clinical research; Metastatic melanoma; Clinical trial; Adverse effect; Cancer; Chemotherapy; Immunotherapy; Pathology","score_opus":0.1440297160081384,"score_gpt":0.4343394679977686,"score_spread":0.2903097519896302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200142029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830241,0.0020970355,0.00040939476,0.005715019,0.00015063006,0.0042678793,0.000023557135,0.000051263007,0.004261128],"genre_scores_gemma":[0.99185985,0.0015176102,0.0013308221,0.0021120135,0.00012075061,0.0007159429,0.000076551034,0.00007168711,0.0021947792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99606407,0.0005637027,0.0013775117,0.00073428237,0.0006140471,0.000646367],"domain_scores_gemma":[0.9968702,0.00089127605,0.0007102322,0.000686066,0.0006326563,0.00020957258],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018965711,0.0004961467,0.0029003038,0.00042270677,0.000106866995,0.00002789676,0.00023062926,0.00017894525,0.0010541065],"category_scores_gemma":[0.0002012386,0.00030998362,0.00027082334,0.0011345808,0.00060481776,0.00018613179,0.000073934556,0.00047887483,0.000008611017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96250343,0.0093197,0.0017041992,0.00021821789,0.0029528465,0.0020403436,0.0033409933,0.000045170433,0.0007806416,0.00003713302,0.00064610504,0.016411187],"study_design_scores_gemma":[0.95060974,0.02930927,0.00075054745,0.0005601228,0.0010909113,0.0009793767,0.0033845936,0.00020911825,0.0054284604,0.000033367487,0.007234869,0.00040962204],"about_ca_topic_score_codex":0.0013452955,"about_ca_topic_score_gemma":0.011188768,"teacher_disagreement_score":0.01998957,"about_ca_system_score_codex":0.00011272928,"about_ca_system_score_gemma":0.0019823972,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W4200147408","doi":"10.1016/j.annonc.2021.10.018","title":"2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Oncology; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Distributed File System; Cancer; Immunotherapy; Breast cancer","score_opus":0.04314062178960634,"score_gpt":0.3874494096085126,"score_spread":0.3443087878189063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200147408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909294,0.004694805,0.0000026477207,0.0015468346,0.00028179685,0.0011056376,0.0004238223,0.0000111687605,0.0010038639],"genre_scores_gemma":[0.99755174,0.0015334561,0.00004082521,0.00045367482,0.000044635537,0.00009130852,0.0000907034,0.000039846876,0.00015380414],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968006,0.0003742842,0.0013796539,0.0005150295,0.00044710241,0.00048332068],"domain_scores_gemma":[0.99780524,0.00018894552,0.00055481534,0.0007801404,0.00050277304,0.00016809198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006440547,0.00030719946,0.0014575323,0.00045767106,0.000020730673,0.000004707718,0.00026554873,0.00020909372,0.0007113037],"category_scores_gemma":[0.00014177615,0.00028523616,0.00030918705,0.0007792923,0.0003695352,0.000097982964,0.00013706187,0.00022507747,0.0000015923192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4155019,0.03038416,0.3494054,0.0011906453,0.0022731156,0.00416395,0.034748837,0.0000062552194,0.055049784,0.000024781804,0.0011932752,0.106057905],"study_design_scores_gemma":[0.1426182,0.033937696,0.710883,0.0008530169,0.0002669464,0.000022965281,0.062304333,0.000022836964,0.043444674,0.0000695162,0.005056535,0.0005202727],"about_ca_topic_score_codex":0.0034385377,"about_ca_topic_score_gemma":0.008176238,"teacher_disagreement_score":0.3614776,"about_ca_system_score_codex":0.00017888464,"about_ca_system_score_gemma":0.0012843623,"threshold_uncertainty_score":0.99996},"labels":[],"label_agreement":null},{"id":"W4200185392","doi":"10.1016/j.annonc.2021.10.065","title":"48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Peripheral blood mononuclear cell; Antigen; Immune system; CD8; T cell; Regimen; Leukapheresis; Immunology; Oncology; Internal medicine; CD34","score_opus":0.03151643158945245,"score_gpt":0.33112453387452323,"score_spread":0.2996081022850708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200185392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960024,0.0021806725,0.000028748493,0.00022862085,0.00016040355,0.0010406703,0.000076636454,0.000012468159,0.00026937507],"genre_scores_gemma":[0.99884665,0.00021395514,0.0001922084,0.000083360836,0.0000041492826,0.00008226731,0.00023613227,0.000027005945,0.00031428802],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961495,0.0012654344,0.0015995973,0.00044472588,0.00010571489,0.00043506236],"domain_scores_gemma":[0.9968365,0.0009891136,0.0010798527,0.0005165618,0.00055580563,0.000022189563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007057756,0.0002923447,0.0012053342,0.0004895776,0.00006831317,0.0000031737197,0.00028941635,0.00021059667,0.00019347364],"category_scores_gemma":[0.00036275745,0.00023788295,0.00011478978,0.00065698085,0.00017886635,0.00013661027,0.00009685368,0.00035130794,0.0000048529614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5844473,0.08011429,0.075107075,0.00096004904,0.0012532105,0.00046218664,0.01338981,0.0068105357,0.17254287,0.0000296335,0.0013327649,0.06355025],"study_design_scores_gemma":[0.07140651,0.123099096,0.5354091,0.00072858523,0.00014581074,0.000028146053,0.0035825504,0.000054754233,0.26320192,0.000054250017,0.001853112,0.00043617672],"about_ca_topic_score_codex":0.0002774355,"about_ca_topic_score_gemma":0.0018266854,"teacher_disagreement_score":0.51304084,"about_ca_system_score_codex":0.000053059768,"about_ca_system_score_gemma":0.00048159898,"threshold_uncertainty_score":0.97005856},"labels":[],"label_agreement":null},{"id":"W4200187855","doi":"10.1016/j.annonc.2021.10.180","title":"161P Assessment of corticosteroid premedication for patients treated with the humanized GD2-binding monoclonal antibody naxitamab","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Premedication; Interim analysis; Population; Surgery; Internal medicine; Urology; Anesthesia; Clinical trial","score_opus":0.07680228325291658,"score_gpt":0.44381416104366544,"score_spread":0.36701187779074884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200187855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951935,0.000044363427,0.00013002889,0.0024423448,0.000032073396,0.0007488783,0.000042247735,0.00000914235,0.0013574457],"genre_scores_gemma":[0.99814767,0.00009450974,0.0008060611,0.00021870111,0.000022779259,0.00007866738,0.00035447392,0.0000139670965,0.0002631449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886537,0.00011414159,0.00028431712,0.00019521863,0.0003146186,0.00022631834],"domain_scores_gemma":[0.99835676,0.0002943434,0.00025197928,0.00022376073,0.0007853113,0.00008786448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016638039,0.00009923548,0.00035100177,0.000076564174,0.000061428604,0.000004781097,0.000076880344,0.00005790549,0.00005852026],"category_scores_gemma":[0.00014708271,0.000061999366,0.00008094995,0.00016304418,0.00012713987,0.00004579901,0.000039403527,0.00009709294,0.0000023698512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061409133,0.012289775,0.6040747,0.00047360326,0.0023754286,0.00023299933,0.00042024022,0.0000049035434,0.3129515,0.00055286055,0.004793546,0.05568951],"study_design_scores_gemma":[0.013702611,0.026272433,0.81883943,0.00013770175,0.0002648499,0.000043822467,0.00013808577,0.00021436204,0.1371216,0.000045385874,0.0031280916,0.000091630005],"about_ca_topic_score_codex":0.000013694587,"about_ca_topic_score_gemma":0.000018908217,"teacher_disagreement_score":0.2147647,"about_ca_system_score_codex":0.00004571609,"about_ca_system_score_gemma":0.00043132,"threshold_uncertainty_score":0.2528261},"labels":[],"label_agreement":null},{"id":"W4200216655","doi":"10.1016/j.annonc.2021.10.168","title":"149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Basal cell; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Internal medicine; Dermatology; Cancer research; Cancer; Chemotherapy; Phases of clinical research","score_opus":0.040726694827437536,"score_gpt":0.34813504704351783,"score_spread":0.3074083522160803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200216655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703707,0.020276666,0.000021712489,0.0015896399,0.00033344934,0.0005866895,0.000035199522,0.000020805512,0.0067651533],"genre_scores_gemma":[0.9932229,0.0038682134,0.0008462963,0.00046209202,0.000023480528,0.00002645858,0.000050837752,0.000041248015,0.0014584677],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99699795,0.0004580751,0.001311101,0.00049537135,0.00029701163,0.00044051625],"domain_scores_gemma":[0.9972018,0.0012497853,0.00051531906,0.00048998976,0.00040194587,0.00014117327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054735434,0.00030012414,0.0012219212,0.00025660568,0.00004537539,0.000008939696,0.0001693562,0.00025910055,0.0005549428],"category_scores_gemma":[0.00053670054,0.00025599985,0.00028996204,0.00050966215,0.0004293241,0.00006275951,0.00009441041,0.00041107327,0.0000074416953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.100610204,0.004660707,0.0015096251,0.0011593637,0.0003908679,0.0036075222,0.002714547,0.00006954448,0.18760863,0.00007740465,0.001333681,0.6962579],"study_design_scores_gemma":[0.17211993,0.0669753,0.18544978,0.0019592273,0.0013726255,0.014851137,0.0046415003,0.0010407186,0.37143874,0.00056858506,0.17767517,0.0019072979],"about_ca_topic_score_codex":0.00023968042,"about_ca_topic_score_gemma":0.00026457992,"teacher_disagreement_score":0.6943506,"about_ca_system_score_codex":0.00013790707,"about_ca_system_score_gemma":0.0012221131,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W4200221970","doi":"10.1016/j.annonc.2021.10.154","title":"135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Nausea; Adverse effect; Combination therapy; Tolerability; Anemia; Gastroenterology; Neutropenia; Toxicity","score_opus":0.028994902647386148,"score_gpt":0.36826343285521423,"score_spread":0.3392685302078281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200221970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99883354,0.00020014208,0.000025453644,0.00032835905,0.000049487142,0.0003182283,0.0000109304765,0.0000014313099,0.00023244982],"genre_scores_gemma":[0.999397,0.0002058559,0.00009545531,0.0001247454,0.000033709075,0.000028831395,0.000047800113,0.000012111749,0.000054530698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886745,0.00012793815,0.00047953107,0.00022938428,0.0001225521,0.00017314324],"domain_scores_gemma":[0.999194,0.000046239184,0.00032958077,0.00017239827,0.00022563862,0.000032108368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001961095,0.00011529011,0.00043519182,0.00013215381,0.0000127560825,0.000001800113,0.00010329426,0.00013732846,0.000022665045],"category_scores_gemma":[0.00012565675,0.00010313976,0.00005854619,0.00021648429,0.00007276416,0.0000088690485,0.000051963663,0.00008688121,1.985777e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17151731,0.034045093,0.03222659,0.00023890604,0.00021153702,0.00021510087,0.001288223,0.0033252584,0.71841735,0.00017928728,0.0011216037,0.037213773],"study_design_scores_gemma":[0.08885588,0.02631939,0.005532585,0.00011863848,0.0000075234343,0.0000037099044,0.00012699244,0.000026812515,0.8776682,0.00016562759,0.001032458,0.00014216664],"about_ca_topic_score_codex":0.00013430057,"about_ca_topic_score_gemma":0.00038073128,"teacher_disagreement_score":0.1592509,"about_ca_system_score_codex":0.00001850012,"about_ca_system_score_gemma":0.0002643081,"threshold_uncertainty_score":0.42059174},"labels":[],"label_agreement":null},{"id":"W4200256437","doi":"10.1016/j.annonc.2021.12.002","title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cilag; Pharmacyclics; Takeda Oncology; Chugai Pharmaceutical; Genentech; MorphoSys; Ono Pharmaceutical; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Celltrion; Eisai; Seagen; Pfizer; Incyte; Astex Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Bayer HealthCare; Celgene; Bristol-Myers Squibb; EUSA Pharma; AstraZeneca; TG Therapeutics; Amgen; Kite Pharma; Meiji Seika Pharma","keywords":"Brentuximab vedotin; Medicine; Oncology; Chemotherapy; Internal medicine; Peripheral T-cell lymphoma; Lymphoma; Peripheral; CD30; Immunology; T cell","score_opus":0.041469251079505644,"score_gpt":0.37409008026651946,"score_spread":0.3326208291870138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200256437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887781,0.00091511686,0.000021210255,0.0036796085,0.000113450355,0.003405718,0.00008059254,0.000008760762,0.0029974277],"genre_scores_gemma":[0.9973146,0.0009766256,0.00045428667,0.00031556629,0.000077769364,0.0004010939,0.00004655671,0.000022016664,0.00039148875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99791056,0.00037403838,0.00091307785,0.00029699504,0.00026403874,0.00024127979],"domain_scores_gemma":[0.99614364,0.0018153288,0.0007527872,0.00039265078,0.0008204563,0.00007511736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010047937,0.00018653405,0.0015956769,0.00005810111,0.000062178085,0.000006319749,0.0001059172,0.00010588423,0.00001848673],"category_scores_gemma":[0.0002996594,0.00010942081,0.0003713914,0.00017388967,0.0002584819,0.00002795321,0.00003124678,0.00004450276,6.547086e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9081843,0.042206384,0.000239208,0.000047341433,0.0019936848,0.00006996556,0.0034732225,0.000003291816,0.0010548026,0.00011685427,0.001686844,0.040924136],"study_design_scores_gemma":[0.8464577,0.043225087,0.0007860788,0.00007336475,0.0005754919,0.000018916546,0.0027882806,0.000031791908,0.10335856,0.000044162527,0.0025605408,0.000079983445],"about_ca_topic_score_codex":0.0003018032,"about_ca_topic_score_gemma":0.00011650395,"teacher_disagreement_score":0.10230376,"about_ca_system_score_codex":0.000064779975,"about_ca_system_score_gemma":0.0007376601,"threshold_uncertainty_score":0.4462051},"labels":[],"label_agreement":null},{"id":"W4200428978","doi":"10.1016/j.annonc.2021.10.181","title":"162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tremelimumab; Pharmacokinetics; Population; Internal medicine; Oncology; Durvalumab; Pharmacology; Immunology; Cancer; Immunotherapy; Nivolumab","score_opus":0.04898740511987927,"score_gpt":0.3773817252703681,"score_spread":0.32839432015048886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200428978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972898,0.0005524621,0.000040506886,0.0006680751,0.00007053047,0.0001760769,0.0000056806302,0.000006467146,0.0011904301],"genre_scores_gemma":[0.99853265,0.0003830831,0.0003819774,0.00058095355,0.000018943017,0.000007642146,0.000047741036,0.000010703911,0.000036277987],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99910444,0.00005017974,0.00040706026,0.00014500735,0.00014600849,0.00014731564],"domain_scores_gemma":[0.99938416,0.000026861793,0.00017072451,0.00012498889,0.00026100056,0.00003224542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012431694,0.00007990461,0.00037163973,0.000107626336,0.000010898016,0.0000010099379,0.000039110233,0.00005573909,0.00008294363],"category_scores_gemma":[0.000034239707,0.00006875079,0.000060814033,0.00023174979,0.00003628479,0.00004884564,0.000013664607,0.00007713156,6.3708353e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03101181,0.002903611,0.13451982,0.0003548372,0.0003281563,0.00008217512,0.0009963395,0.015236297,0.0676314,0.00003092218,0.0002305978,0.74667406],"study_design_scores_gemma":[0.05452567,0.020182129,0.7512148,0.0013687906,0.00019519606,0.00005049628,0.0007935556,0.023347326,0.14483212,0.0002826708,0.0027640732,0.0004431977],"about_ca_topic_score_codex":0.0001420288,"about_ca_topic_score_gemma":0.00009695885,"teacher_disagreement_score":0.74623084,"about_ca_system_score_codex":0.000045167337,"about_ca_system_score_gemma":0.0001479711,"threshold_uncertainty_score":0.2803576},"labels":[],"label_agreement":null},{"id":"W4200446741","doi":"10.1016/j.annonc.2021.10.100","title":"82P Exploring treatment patterns and outcomes of patients with advanced lung cancer (aLC) using artificial intelligence (AI)-extracted data","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Proportional hazards model; Retrospective cohort study; Cohort; Medical record; Lung cancer; Chart; Artificial intelligence; Emergency medicine; Internal medicine; Statistics","score_opus":0.18561029526929018,"score_gpt":0.46054737946719637,"score_spread":0.2749370841979062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200446741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931811,0.00038795001,0.0029867964,0.0029912533,0.00017002538,0.00015962348,0.000060006325,0.000009223206,0.000054039672],"genre_scores_gemma":[0.99461883,0.0011798107,0.003501377,0.000516848,0.00005027192,0.000009763701,0.00009648551,0.000015375555,0.000011253878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989683,0.00005695851,0.00035048567,0.0002676185,0.0001650163,0.00019161869],"domain_scores_gemma":[0.9990143,0.00015255502,0.00019501941,0.0003064931,0.00023497708,0.00009663846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001437079,0.000117298594,0.00049776916,0.0000708955,0.00003464104,0.0000054920424,0.000083252904,0.000049025755,0.000063503874],"category_scores_gemma":[0.0002401485,0.00008753269,0.00003519616,0.000108729124,0.00010108695,0.00013749363,0.00009187621,0.00014720882,1.8334879e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018291142,0.0004562673,0.5875245,0.00007933971,0.00021574677,0.0000488076,0.00031306414,0.0002100923,0.0008827034,0.00007872856,0.000010423797,0.40999746],"study_design_scores_gemma":[0.0017427539,0.002035865,0.95278996,0.0005101077,0.00047120664,0.000021870466,0.0006099201,0.022311583,0.016485037,0.00010052787,0.0027019538,0.00021919214],"about_ca_topic_score_codex":0.00050925725,"about_ca_topic_score_gemma":0.00013931349,"teacher_disagreement_score":0.40977827,"about_ca_system_score_codex":0.000040871528,"about_ca_system_score_gemma":0.00023205226,"threshold_uncertainty_score":0.35694793},"labels":[],"label_agreement":null},{"id":"W4200464492","doi":"10.1016/j.annonc.2021.10.201","title":"181P Poor response to PD-1 inhibitors in metastatic non-small cell lung cancer (mNSCLC) patients with liver metastases may be mediated by myeloid populations","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid; Internal medicine; Concomitant; Immunosuppression; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Oncology; Odds ratio; Lung cancer; Refractory (planetary science); Progressive disease; Chemotherapy","score_opus":0.036823627446685596,"score_gpt":0.3218090655773002,"score_spread":0.2849854381306146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200464492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98228544,0.01063547,0.000035712164,0.0041503333,0.00087707647,0.0006591909,0.0009263576,0.000023586972,0.00040684774],"genre_scores_gemma":[0.99175596,0.00076304167,0.0009184635,0.0033018654,0.000017452088,0.00020878196,0.00083365565,0.00004939607,0.0021513635],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99687606,0.0011689127,0.0007130873,0.0005121194,0.000097804135,0.0006320393],"domain_scores_gemma":[0.99784774,0.000808241,0.00036124213,0.00038222465,0.0005330517,0.00006747919],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000634257,0.00030714038,0.0007550535,0.0003371538,0.00010522234,0.000009478229,0.00028345833,0.00027073605,0.0011567883],"category_scores_gemma":[0.00036558363,0.00028061177,0.00011455107,0.00065701315,0.00023310792,0.00011859167,0.00019395589,0.00037882928,0.00008199731],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010312492,0.0041424255,0.07840209,0.00023334754,0.001233893,0.00024008613,0.004873826,0.00094970566,0.58865047,0.000052176325,0.30053246,0.010377052],"study_design_scores_gemma":[0.007012439,0.0020200196,0.07067335,0.00016924992,0.00032003137,0.000015058572,0.0007152801,0.000011449847,0.5707861,0.0000119971055,0.34767056,0.0005944547],"about_ca_topic_score_codex":0.0014404706,"about_ca_topic_score_gemma":0.0021507621,"teacher_disagreement_score":0.04713808,"about_ca_system_score_codex":0.00016617082,"about_ca_system_score_gemma":0.000896394,"threshold_uncertainty_score":0.9999646},"labels":[],"label_agreement":null},{"id":"W4205228191","doi":"10.1016/j.annonc.2021.12.012","title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Pharmacokinetics; Carcinoembryonic antigen; Internal medicine; Population; Oncology; Antibody-drug conjugate; Antibody; Cancer; Pharmacology; Gastroenterology; Monoclonal antibody; Immunology","score_opus":0.028699934998963415,"score_gpt":0.38138051632752673,"score_spread":0.35268058132856334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205228191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518913,0.00007096995,0.000004201249,0.0029575033,0.000040042596,0.0012023611,0.00006510983,0.000010670736,0.00046003735],"genre_scores_gemma":[0.9995142,0.000076645,0.000029594337,0.00022838934,0.00002412041,0.000041814634,0.000037155987,0.00001553305,0.00003254144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984644,0.00017362785,0.0005154319,0.00031239982,0.00029072378,0.00024342768],"domain_scores_gemma":[0.9990457,0.00013808263,0.0003325183,0.0002685984,0.00013882914,0.00007625797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041774305,0.00015867197,0.00058201933,0.0000998833,0.00012509647,0.000003273053,0.00015845189,0.000037251375,0.00006290239],"category_scores_gemma":[0.000053939297,0.0001271894,0.00004884281,0.00044224542,0.00025084752,0.0000774264,0.00014538695,0.0004111037,3.547872e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030073237,0.009263735,0.85273975,0.00019325725,0.0000935795,0.000037572845,0.00057363533,0.0014835406,0.1290061,0.000053872973,0.00009732394,0.0034502984],"study_design_scores_gemma":[0.010804779,0.0020261912,0.9283864,0.0000690894,0.00007209811,0.000009928342,0.00019592518,0.0005104264,0.056975264,0.00003468758,0.0007956603,0.00011954827],"about_ca_topic_score_codex":0.000049856306,"about_ca_topic_score_gemma":0.000027147446,"teacher_disagreement_score":0.07564664,"about_ca_system_score_codex":0.00006099173,"about_ca_system_score_gemma":0.00009648552,"threshold_uncertainty_score":0.5186633},"labels":[],"label_agreement":null},{"id":"W4206103426","doi":"10.1016/j.annonc.2020.10.469","title":"Cautionary tails","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; NOSM University; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Medicine","score_opus":0.909316191993618,"score_gpt":0.6858299607201127,"score_spread":0.2234862312735053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206103426","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0887906,0.0004361732,0.24746612,0.3562402,0.0020421848,0.0014330737,0.00041123095,0.00041901146,0.30276138],"genre_scores_gemma":[0.17630029,0.000087965054,0.8111245,0.011841327,0.00048307102,0.000015942223,0.0000012588739,0.000018708402,0.00012692614],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9982773,0.0005898267,0.00062359875,0.00017954582,0.00015344111,0.00017626416],"domain_scores_gemma":[0.9721281,0.02716391,0.00023941167,0.00016392398,0.00015482235,0.00014985962],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013166904,0.00007962018,0.00053783046,0.000021269809,0.000020257025,0.0000024164635,0.00019006556,0.00016190611,0.0010134456],"category_scores_gemma":[0.089273,0.000069487214,0.000115608345,0.00012942783,0.00018120087,0.000025691317,0.00008889064,0.0001654952,0.00009820067],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029213837,0.0003592418,0.00018591178,0.00012817829,0.0001065989,0.000055488395,0.00027185873,0.0000022097786,0.0010800957,0.6529319,0.2219321,0.12265426],"study_design_scores_gemma":[0.00041761607,0.0014216685,0.00029094407,0.0000088951665,0.0000272625,0.000003047897,0.00003696812,0.000070131726,0.0030324971,0.9278173,0.066801056,0.00007264442],"about_ca_topic_score_codex":0.0000027292876,"about_ca_topic_score_gemma":6.1557773e-7,"teacher_disagreement_score":0.5636584,"about_ca_system_score_codex":0.000006986072,"about_ca_system_score_gemma":0.00009554235,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W4206567797","doi":"10.1016/j.annonc.2022.01.003","title":"Improving access to immunotherapy in low- and middle-income countries","year":2022,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Low and middle income countries; Low income; Middle income; Immunotherapy; Socioeconomics; Environmental health; Immunology; Developing country; Economic growth; Demographic economics; Immune system","score_opus":0.05351350378388213,"score_gpt":0.3325440539371878,"score_spread":0.27903055015330563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206567797","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08735089,0.02742911,0.00009813273,0.005630698,0.8431646,0.0011173765,0.0037022028,0.000042628904,0.031464342],"genre_scores_gemma":[0.18184288,0.10896359,0.00077094755,0.013586076,0.68614537,0.0011172938,0.00039091913,0.0005378554,0.006645071],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975147,0.00003326018,0.0012617199,0.0006105267,0.00006479503,0.00051496754],"domain_scores_gemma":[0.9976989,0.00051207637,0.0011756731,0.0003914368,0.00011214117,0.00010977607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013613655,0.00028853994,0.0014573383,0.00070678623,0.00008103524,0.00009530056,0.0007315646,0.00066228874,0.00079858577],"category_scores_gemma":[0.00075848016,0.00037497532,0.00013409187,0.0002187014,0.00013408544,0.00041974112,0.00040220818,0.0006139757,0.00005169432],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013871626,0.0002871085,0.015149717,0.0012953718,0.00025862275,0.000050070583,0.0016794425,0.00013943856,0.0000030578667,0.01604087,0.94558305,0.018126063],"study_design_scores_gemma":[0.00093826855,0.0009888962,0.005330682,0.0001375602,0.0000034971686,9.609587e-7,0.000027068283,0.000016095595,0.00001602453,0.004855639,0.9873099,0.00037542635],"about_ca_topic_score_codex":0.0038941468,"about_ca_topic_score_gemma":0.00080546207,"teacher_disagreement_score":0.15701926,"about_ca_system_score_codex":0.00033515017,"about_ca_system_score_gemma":0.00047177085,"threshold_uncertainty_score":0.99987024},"labels":[],"label_agreement":null},{"id":"W4206666777","doi":"10.1016/j.annonc.2020.09.010","title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1356,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology; Novo Nordisk Fonden; European School of Oncology","keywords":"Medicine; Guideline; Multidisciplinary approach; Breast cancer; Expert opinion; Clinical Practice; Medical physics; Intensive care medicine; Cancer; Family medicine; Internal medicine; Pathology","score_opus":0.24432670650973862,"score_gpt":0.5038172245427751,"score_spread":0.25949051803303647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206666777","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.089132726,0.0022070054,0.0023268422,0.89978594,0.0009911924,0.0007565736,0.00075224164,0.00011212671,0.003935363],"genre_scores_gemma":[0.8713511,0.0011448618,0.032872617,0.09117873,0.0022326873,0.00023732454,0.000080003534,0.000068837464,0.00083380786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878824,0.000024080562,0.00046885174,0.00028370472,0.00017636472,0.00025874667],"domain_scores_gemma":[0.997509,0.00015524433,0.00026959166,0.00014809758,0.0017565775,0.0001614998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012728851,0.00015351312,0.0004940691,0.00006230113,0.000033562334,0.0000030690658,0.0001540189,0.00010404027,0.00051113334],"category_scores_gemma":[0.00042906057,0.00013676929,0.00014340719,0.00011843767,0.00018397633,0.000055863995,0.000048565027,0.00011556831,0.000012733088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010631848,0.0002442334,0.003230452,0.0001539783,0.00064310123,0.00004201241,0.00045000648,0.00093266775,0.031373143,0.0010729383,0.081463285,0.86976236],"study_design_scores_gemma":[0.0062320465,0.0015915838,0.0052161003,0.00011429311,0.00007166845,0.00017346091,0.00045107325,0.00086563744,0.012782208,0.0008456929,0.97147477,0.00018149505],"about_ca_topic_score_codex":0.000054598833,"about_ca_topic_score_gemma":0.00002896617,"teacher_disagreement_score":0.8900114,"about_ca_system_score_codex":0.00005726865,"about_ca_system_score_gemma":0.00039055568,"threshold_uncertainty_score":0.55965513},"labels":[],"label_agreement":null},{"id":"W4206953274","doi":"10.1016/j.annonc.2021.08.062","title":"666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Foundation Medicine; Genentech; Ipsen; Congressionally Directed Medical Research Programs; Celldex Therapeutics; Gateway for Cancer Research; Calithera Biosciences; Astellas Pharma; Eisai; U.S. Department of Defense; Exelixis; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Pfizer","keywords":"Medicine; Pembrolizumab; Cohort; Clear cell renal cell carcinoma; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.03871733226255215,"score_gpt":0.31502741374163873,"score_spread":0.2763100814790866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206953274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782099,0.009788419,0.00001228653,0.00177595,0.00021320867,0.0011027313,0.00023631814,0.00001999153,0.008641168],"genre_scores_gemma":[0.99057573,0.0052550104,0.0013564406,0.00086841604,0.00010851131,0.00013426456,0.00016495844,0.00008099023,0.0014556812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995933,0.0003877561,0.0016611621,0.00085077446,0.00057672214,0.00059058843],"domain_scores_gemma":[0.9963602,0.0006773358,0.0008626076,0.0011171309,0.00073777663,0.00024495966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004189327,0.0004728756,0.0018974406,0.00033752454,0.0000311861,0.000005663545,0.00027202675,0.0004694444,0.00041168902],"category_scores_gemma":[0.00015185513,0.00042477914,0.0005907805,0.00047245264,0.00023784791,0.00009563436,0.00010924996,0.0003649154,0.000019663663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31139472,0.009767581,0.0943054,0.00051765767,0.0009186017,0.0041145966,0.00879615,0.00042057416,0.5397123,0.000013481929,0.0028308239,0.027208123],"study_design_scores_gemma":[0.0379703,0.020895433,0.25207773,0.000189043,0.00015684954,0.000031524087,0.00042225444,0.00011801357,0.68268657,0.00019058901,0.0049893335,0.000272375],"about_ca_topic_score_codex":0.0030629993,"about_ca_topic_score_gemma":0.00089136994,"teacher_disagreement_score":0.27342442,"about_ca_system_score_codex":0.0001614693,"about_ca_system_score_gemma":0.00087185396,"threshold_uncertainty_score":0.9998204},"labels":[],"label_agreement":null},{"id":"W4210750855","doi":"10.1016/j.annonc.2022.01.076","title":"Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Vemurafenib; Internal medicine; Hazard ratio; Oncology; Confidence interval; Cancer; Pembrolizumab; Immunotherapy; Metastatic melanoma","score_opus":0.03356083637505654,"score_gpt":0.30657651588933427,"score_spread":0.27301567951427774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210750855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892612,0.0007600511,0.000043041815,0.0003830972,0.000096864154,0.00037282513,0.00023245906,0.000005751712,0.00884472],"genre_scores_gemma":[0.99832386,0.00014970308,0.00031593317,0.00020705647,0.000035667177,0.00011975741,0.000406395,0.00001933088,0.0004222887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987359,0.00017162829,0.0003677133,0.00032684044,0.0001305328,0.00026739817],"domain_scores_gemma":[0.9992034,0.00006151409,0.0002885934,0.0002582224,0.00012196148,0.000066350774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020140517,0.00017114157,0.00040818148,0.00014145015,0.00006290662,0.000002832984,0.00018111976,0.00011602033,0.00008973111],"category_scores_gemma":[0.000021889431,0.00015455749,0.00010692673,0.00018933101,0.00013820153,0.0000035312735,0.00011599857,0.000069318514,0.0000024081842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03783767,0.0034021405,0.017199855,0.00021587005,0.0036454264,0.0013452718,0.007791847,0.021618754,0.6869654,0.0066035255,0.0057474826,0.20762676],"study_design_scores_gemma":[0.014255329,0.07471192,0.027312618,0.000043280197,0.00012848561,0.00046904283,0.0023429685,0.00036763243,0.8221746,0.0004319502,0.0571553,0.0006068733],"about_ca_topic_score_codex":0.0005148377,"about_ca_topic_score_gemma":0.0004495404,"teacher_disagreement_score":0.2070199,"about_ca_system_score_codex":0.000104843915,"about_ca_system_score_gemma":0.0006288007,"threshold_uncertainty_score":0.63026714},"labels":[],"label_agreement":null},{"id":"W4213133535","doi":"10.1016/j.annonc.2022.02.003","title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; European Society for Medical Oncology; Incyte; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Guideline; Voting; Consensus conference; Clinical trial; Multidisciplinary approach; Lung cancer; Family medicine; Panel discussion; MEDLINE; Oncology; Medical physics; Intensive care medicine; Pathology; Internal medicine","score_opus":0.07375977406662172,"score_gpt":0.45261268578839703,"score_spread":0.3788529117217753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213133535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9221946,0.0011833264,0.000013945801,0.01966065,0.00034652365,0.0009552035,0.0001163398,0.000010065354,0.055519365],"genre_scores_gemma":[0.99124867,0.001139658,0.00021508358,0.004395324,0.00002584554,0.00045498853,0.000021034424,0.00001367982,0.0024857225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990947,0.00006705122,0.00028207197,0.00016332928,0.00020613393,0.00018668437],"domain_scores_gemma":[0.9993297,0.00008574999,0.00020254382,0.00023548507,0.00009881401,0.000047733007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018764855,0.000096008174,0.00024991413,0.00006502029,0.0000992444,0.0000017005638,0.00010081949,0.000025860041,0.00088884786],"category_scores_gemma":[0.0000034929776,0.000066545486,0.00007753936,0.00013023551,0.00006575608,0.000009757917,0.000083945655,0.00009582439,0.000003561506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007195833,0.021367256,0.027225815,0.002243495,0.020977682,0.0029182062,0.039430972,0.005106927,0.02526648,0.017619856,0.5554301,0.27521738],"study_design_scores_gemma":[0.017975703,0.01543396,0.024389438,0.000485073,0.002038315,0.000045642893,0.027199823,0.0009293566,0.07788647,0.000531059,0.8326451,0.0004400163],"about_ca_topic_score_codex":0.0006668187,"about_ca_topic_score_gemma":0.000023478677,"teacher_disagreement_score":0.27721506,"about_ca_system_score_codex":0.00016395397,"about_ca_system_score_gemma":0.00025885573,"threshold_uncertainty_score":0.9732261},"labels":[],"label_agreement":null},{"id":"W4213423873","doi":"10.1016/j.annonc.2022.02.222","title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Olaparib; Discontinuation; PARP inhibitor; Adverse effect; Proportional hazards model; Oncology; Ovarian cancer; Hazard ratio; Cancer; Gastroenterology; Surgery; Poly ADP ribose polymerase","score_opus":0.23275347347698438,"score_gpt":0.49864760601548924,"score_spread":0.26589413253850486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213423873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276967,0.0005671283,0.0000027751962,0.014067579,0.0003198922,0.0008003817,0.00011710508,0.00000818147,0.0013472751],"genre_scores_gemma":[0.996385,0.002554421,0.000018279068,0.00030066897,0.00013034297,0.0004537522,0.000032538457,0.000010225199,0.000114822986],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99849415,0.00049096666,0.0004319236,0.0002077346,0.0001759046,0.00019930796],"domain_scores_gemma":[0.9989541,0.00033544542,0.00033336572,0.0002486599,0.00008605627,0.000042359417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052470015,0.00015755063,0.00041161964,0.00012690353,0.00013227582,0.000004818278,0.000060713253,0.00006075039,0.000095471565],"category_scores_gemma":[0.000031914176,0.00008316395,0.0001637891,0.0001725767,0.00016411052,0.000030993764,0.000021826221,0.00017732581,0.0000012844681],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019551583,0.003994631,0.011972099,0.000016938788,0.0009905917,0.000056571687,0.031248232,0.0013358186,0.011813945,0.00105081,0.0031515518,0.9148172],"study_design_scores_gemma":[0.03406105,0.2144218,0.639521,0.00025597238,0.00042236826,0.0007996085,0.018123696,0.0011354262,0.033316936,0.001874281,0.055588953,0.0004789267],"about_ca_topic_score_codex":0.0024534527,"about_ca_topic_score_gemma":0.0003304326,"teacher_disagreement_score":0.9143383,"about_ca_system_score_codex":0.0012420454,"about_ca_system_score_gemma":0.00027962605,"threshold_uncertainty_score":0.3708903},"labels":[],"label_agreement":null},{"id":"W4214565177","doi":"10.1093/annonc/mdy131","title":"Purchasing silence","year":2018,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.0863886655008989,"score_gpt":0.3481756114666551,"score_spread":0.2617869459657562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214565177","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00147232,0.0063136206,0.00022167292,0.0009022962,0.7403864,0.00016269826,0.0011071265,0.000028285442,0.24940553],"genre_scores_gemma":[0.012935161,0.009289241,0.0005426815,0.0008672491,0.9703089,0.0000320079,0.00013271609,0.000094119234,0.005797901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975086,0.000023421653,0.0012423899,0.00061437616,0.000060843147,0.0005504029],"domain_scores_gemma":[0.9967376,0.00042490987,0.0018196922,0.0005418386,0.0003417611,0.00013417096],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001189576,0.0002919424,0.0014283299,0.0003270169,0.000074002295,0.000033099856,0.0006428253,0.0014271705,0.0009328909],"category_scores_gemma":[0.0021444135,0.00036478377,0.0002901178,0.00013999402,0.00040851187,0.000246008,0.0001535982,0.00054216624,0.001299041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006750165,0.00008443445,0.00011190312,0.000065761815,0.00008705018,0.0000057427337,0.00022274701,0.0000023252082,0.000001939747,0.010175134,0.9756387,0.013536763],"study_design_scores_gemma":[0.00036910744,0.0012075695,0.00012809351,0.000061179366,0.000008125638,0.0000010823252,0.000018423216,0.000014235019,0.00006388645,0.036801513,0.9609956,0.00033114577],"about_ca_topic_score_codex":0.0005871801,"about_ca_topic_score_gemma":0.00005953498,"teacher_disagreement_score":0.24360763,"about_ca_system_score_codex":0.00014165124,"about_ca_system_score_gemma":0.00047762983,"threshold_uncertainty_score":0.9999804},"labels":[],"label_agreement":null},{"id":"W4220704364","doi":"10.1016/j.annonc.2022.03.003","title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","year":2022,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; University of Calgary","funders":"Dana-Farber Cancer Institute","keywords":"Medicine; Tamoxifen; Breast cancer; Oncology; Internal medicine; Adjuvant therapy; Adjuvant; Population; Endocrine system; Letrozole; Gynecology; Aromatase inhibitor; Cancer; Hormone","score_opus":0.04882049634006941,"score_gpt":0.36429950356094076,"score_spread":0.31547900722087135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220704364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61663395,0.0030350958,0.000043051787,0.37375587,0.000151165,0.0026629951,0.0036368736,0.00006110168,0.000019886003],"genre_scores_gemma":[0.7847372,0.0037524127,0.0004092969,0.2049031,0.0014629085,0.0017596975,0.0023621889,0.00017493202,0.00043821603],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99637234,0.0006959398,0.00072597095,0.00093650125,0.0006159277,0.0006533091],"domain_scores_gemma":[0.99565417,0.0016150986,0.0010250421,0.0010309702,0.00055646675,0.00011826058],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041602977,0.00060038676,0.0022843608,0.00035076396,0.00023437294,0.000021591088,0.00052398565,0.00028154821,0.0010128025],"category_scores_gemma":[0.000037612437,0.0003758139,0.00029459118,0.0008218028,0.0004969032,0.00007744826,0.00016991838,0.0016563055,0.0000014733876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10701708,0.0037085004,0.26330984,0.00010880198,0.066944875,0.0012038277,0.004762048,0.00028485284,0.00021979425,0.000021015534,0.17839515,0.3740242],"study_design_scores_gemma":[0.023465222,0.027408967,0.5523562,0.000051514013,0.0059395824,0.00006083017,0.0005454907,0.000026550682,0.00013193104,0.0002842258,0.38928148,0.0004480426],"about_ca_topic_score_codex":0.012565068,"about_ca_topic_score_gemma":0.00101278,"teacher_disagreement_score":0.3735762,"about_ca_system_score_codex":0.00013326127,"about_ca_system_score_gemma":0.00043863847,"threshold_uncertainty_score":0.9999004},"labels":[],"label_agreement":null},{"id":"W4220744079","doi":"10.1016/j.annonc.2022.03.008","title":"VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; European Society for Medical Oncology; Cancer Council Victoria; Eisai; Department of Health, State Government of Victoria; National Breast Cancer Foundation; National Health and Medical Research Council; Cancer Research UK; Invitae; Gilead Sciences; Merck KGaA; Eli Lilly and Company; American Association for Cancer Research; AstraZeneca; Myriad Genetics; National Cancer Research Institute; Teva Pharmaceutical Industries; Pfizer; Daiichi Sankyo Europe; Breast Cancer Research Foundation; U.S. Department of Health and Human Services","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Placebo; Breast cancer; Cancer; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.07982892465250224,"score_gpt":0.4337723077020927,"score_spread":0.35394338304959044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220744079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112755,0.00043625906,0.00003494387,0.005551579,0.0003618543,0.0009820426,0.00095924566,0.000010657995,0.0005358639],"genre_scores_gemma":[0.9975221,0.0005934404,0.000013875024,0.00086937874,0.0001108701,0.00030949488,0.00046326235,0.000017663644,0.00009990169],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995909,0.001260045,0.0014423582,0.00033119452,0.0007470443,0.00031038251],"domain_scores_gemma":[0.99736774,0.0006258944,0.0012411698,0.00036793566,0.0003371338,0.00006009812],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002472454,0.00017875449,0.0013929652,0.00076181703,0.000043741646,0.0000029950886,0.00026181858,0.00014956213,0.0017256998],"category_scores_gemma":[0.00014961658,0.00015745145,0.00036822874,0.0017557386,0.0001481507,0.000067910325,0.000068966714,0.0003854995,4.971745e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6178739,0.046336383,0.044594876,0.00021711347,0.010006211,0.00045709344,0.0354862,0.071562275,0.08517339,0.0018812569,0.00969017,0.07672115],"study_design_scores_gemma":[0.36289543,0.011451127,0.5990668,0.00018485049,0.0015425634,0.000028940456,0.0021732608,0.010924657,0.006655209,0.0005074572,0.0041816165,0.00038811617],"about_ca_topic_score_codex":0.0030774928,"about_ca_topic_score_gemma":0.00372412,"teacher_disagreement_score":0.5544719,"about_ca_system_score_codex":0.0005017814,"about_ca_system_score_gemma":0.00071088696,"threshold_uncertainty_score":0.9991869},"labels":[],"label_agreement":null},{"id":"W4220752685","doi":"10.1016/j.annonc.2022.02.223","title":"VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Endometrial cancer; Clinical endpoint; Chemotherapy; Progression-free survival; Taxane; Oncology; Phases of clinical research; Gastroenterology; Proportional hazards model; Urology; Clinical trial; Cancer; Breast cancer; Cisplatin","score_opus":0.11711158870240214,"score_gpt":0.4570379121618395,"score_spread":0.33992632345943735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220752685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679498,0.0067497,0.000108443965,0.0046895747,0.001526403,0.018024778,0.00038578175,0.000054438144,0.00051108486],"genre_scores_gemma":[0.9693046,0.007717743,0.00031590532,0.0015996842,0.000503494,0.019138569,0.00008884143,0.000070006325,0.0012611222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958756,0.0004636341,0.0014759854,0.0007853079,0.0007488373,0.0006506659],"domain_scores_gemma":[0.9954948,0.0018465305,0.001040533,0.0004711085,0.00091360975,0.00023344578],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001622396,0.00047472585,0.002958498,0.0005874633,0.00017502844,0.000009617219,0.0003178239,0.00015434234,0.003565979],"category_scores_gemma":[0.0007545189,0.00032476083,0.0006994304,0.0015240831,0.0002256825,0.00011203941,0.00013050661,0.00043532814,0.0000028945294],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81399775,0.015446738,0.00031716656,0.00007419477,0.0020753872,0.00006634168,0.0032127192,0.00007670567,0.000375747,0.000053510354,0.00054015254,0.16376361],"study_design_scores_gemma":[0.85685414,0.077812135,0.00007091532,0.000053844833,0.00046645722,0.000018180572,0.0012050124,0.000061519546,0.007570448,0.00030550823,0.055312466,0.00026936716],"about_ca_topic_score_codex":0.000754815,"about_ca_topic_score_gemma":0.0005548002,"teacher_disagreement_score":0.16349424,"about_ca_system_score_codex":0.00039196722,"about_ca_system_score_gemma":0.00074700854,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4220938185","doi":"10.1016/j.annonc.2022.03.272","title":"Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future","year":2022,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Clinical trial; Oncology; Transparency (behavior); Prostate; Cancer; Intensive care medicine; Internal medicine","score_opus":0.1582618029126342,"score_gpt":0.5245485520031038,"score_spread":0.3662867490904696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220938185","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029565059,0.066823035,0.00015094552,0.10623077,0.74237406,0.025146356,0.05611922,0.000040598003,0.00015848418],"genre_scores_gemma":[0.012822839,0.06451168,0.000248444,0.0060069486,0.8595905,0.043712586,0.0027608096,0.00022057042,0.010125667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99509716,0.0014306513,0.0015971526,0.00054107356,0.0007107395,0.0006232296],"domain_scores_gemma":[0.9753668,0.020777771,0.001239888,0.0005265147,0.0019389539,0.0001500973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008159351,0.00035411984,0.001991597,0.000117508105,0.0003977339,0.00003933983,0.00037114986,0.00046477266,0.0003475719],"category_scores_gemma":[0.0043950016,0.00017233331,0.0010972464,0.00016998498,0.00043998676,0.000049877115,0.00008638598,0.0010544675,0.0000017155943],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041997,0.00052477815,0.0002687893,0.00047916645,0.0030937733,0.000019912042,0.0004379361,0.000005828338,0.000004708351,0.00003761757,0.8974094,0.05572109],"study_design_scores_gemma":[0.014027498,0.011285083,0.00048194354,0.00017381286,0.0029835354,0.0000011364962,0.00042714196,0.000049641883,0.000025609119,0.0004336935,0.9699548,0.00015611306],"about_ca_topic_score_codex":0.00023110858,"about_ca_topic_score_gemma":0.00041422583,"teacher_disagreement_score":0.11721637,"about_ca_system_score_codex":0.0002216259,"about_ca_system_score_gemma":0.004255275,"threshold_uncertainty_score":0.7548675},"labels":[],"label_agreement":null},{"id":"W4224250553","doi":"10.1016/j.annonc.2022.04.007","title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":480,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Medicine; Guideline; Clinical Practice; Continuum of care; Cancer; Outcome (game theory); Intensive care medicine; Family medicine; Medical physics; Internal medicine; Health care; Pathology","score_opus":0.17837845706375496,"score_gpt":0.5235778538299115,"score_spread":0.3451993967661565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224250553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389706,0.014326263,0.0000034325476,0.033128288,0.0016681771,0.00058730243,0.000049662038,0.000008701878,0.011257528],"genre_scores_gemma":[0.9889199,0.0014434918,0.00006967616,0.00922016,0.00018510266,0.00008292008,0.0000140560405,0.000011647076,0.000053015057],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99460685,0.0017069197,0.0026368776,0.00022765073,0.00060377567,0.0002179373],"domain_scores_gemma":[0.9934894,0.0030934915,0.0015480389,0.0005450253,0.001265129,0.000058912756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006863555,0.000105604544,0.00078337546,0.00005564682,0.00006112805,0.0000023572495,0.00030223123,0.00013794463,0.000083103405],"category_scores_gemma":[0.0051553794,0.000065218665,0.00035237352,0.00027502078,0.00035991505,0.000030872216,0.00015413396,0.0006304074,5.91131e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033447768,0.000983694,0.63213676,0.000024645027,0.00032961767,0.000056250134,0.0033043416,0.000014596599,0.00005931838,0.00024945367,0.021352278,0.33814427],"study_design_scores_gemma":[0.0014823709,0.004108289,0.0770156,0.000015445044,0.00022733925,0.000023738545,0.024729716,0.000008549731,0.00031692596,0.0001573117,0.89185655,0.000058135534],"about_ca_topic_score_codex":0.007194123,"about_ca_topic_score_gemma":0.013992046,"teacher_disagreement_score":0.8705043,"about_ca_system_score_codex":0.000039307735,"about_ca_system_score_gemma":0.0008592654,"threshold_uncertainty_score":0.99941707},"labels":[],"label_agreement":null},{"id":"W4225892150","doi":"10.1016/j.annonc.2022.02.054","title":"45P Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Multivariate analysis; Cancer; Immunotherapy","score_opus":0.06702358270823291,"score_gpt":0.37947969330167036,"score_spread":0.3124561105934375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225892150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98129153,0.0005498599,1.9047391e-7,0.0007937106,0.0010836247,0.00032743922,0.00014923503,0.0000122278925,0.015792187],"genre_scores_gemma":[0.9981128,0.0005575791,0.000018639377,0.00069843023,0.000029886845,0.00005982445,0.0001643265,0.000015989148,0.00034250293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858147,0.00012008618,0.00040711233,0.00021466825,0.00029135856,0.00038533425],"domain_scores_gemma":[0.9992183,0.00013071642,0.00019851232,0.00020264881,0.0001767946,0.00007306339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019845608,0.00013279567,0.00048011626,0.00018170703,0.00007682135,0.0000025802103,0.000117515716,0.00007289813,0.00071737554],"category_scores_gemma":[0.00005952529,0.00012451623,0.00013456303,0.00021945928,0.00010586363,0.00006481787,0.00009810003,0.00023351655,0.000009951879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036131073,0.0011997323,0.7736512,0.000082201404,0.00022698283,0.00004980456,0.0031491548,0.000019430441,0.0001258838,0.00001593091,0.0012722308,0.18407638],"study_design_scores_gemma":[0.021511097,0.022254605,0.8471578,0.00002049466,0.000041357416,0.0000048311394,0.0051043364,0.000010403161,0.0006648437,0.000004303606,0.10307022,0.00015575388],"about_ca_topic_score_codex":0.0006367146,"about_ca_topic_score_gemma":0.00043255667,"teacher_disagreement_score":0.18392062,"about_ca_system_score_codex":0.00032277172,"about_ca_system_score_gemma":0.0005338465,"threshold_uncertainty_score":0.7854759},"labels":[],"label_agreement":null},{"id":"W4226017594","doi":"10.1016/j.annonc.2022.02.060","title":"51P Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer","score_opus":0.036912437573272026,"score_gpt":0.3848027496706976,"score_spread":0.3478903120974256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226017594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927566,0.00013154242,0.0000028642257,0.0016494078,0.00009652418,0.0005898999,0.0004099468,0.000004632393,0.0043585957],"genre_scores_gemma":[0.99826425,0.00006729413,0.00021325024,0.000982078,0.000011160283,0.00015445132,0.00008120761,0.000015103603,0.00021117902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897176,0.00008755969,0.00034189233,0.00018570879,0.00012167617,0.0002914188],"domain_scores_gemma":[0.99911016,0.00027417383,0.00023086938,0.00010295791,0.0001381311,0.00014370086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013480311,0.000118799166,0.00044478453,0.0002969185,0.00007552773,0.0000028403476,0.000053768945,0.000022779086,0.00006585424],"category_scores_gemma":[0.000046320536,0.00010237528,0.000046877605,0.00018855683,0.000030458521,0.000027613445,0.00005711546,0.00013258205,1.8618366e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003736693,0.00042082698,0.983049,0.0001419533,0.00020246426,0.000053025826,0.0035721306,0.00005538235,0.000086345484,0.000017167053,0.00016258888,0.012201784],"study_design_scores_gemma":[0.002155772,0.0010948586,0.99460554,0.00011437223,0.00027437514,0.0000020836812,0.0007422152,0.0003018054,0.000493642,0.000019507526,0.00011699207,0.0000788104],"about_ca_topic_score_codex":0.52417,"about_ca_topic_score_gemma":0.4870063,"teacher_disagreement_score":0.03716368,"about_ca_system_score_codex":0.00042132442,"about_ca_system_score_gemma":0.000753184,"threshold_uncertainty_score":0.5223545},"labels":[],"label_agreement":null},{"id":"W4226065666","doi":"10.1016/j.annonc.2022.02.137","title":"110P Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Trk receptor; Internal medicine; Oncology; Receptor tyrosine kinase; Cohort; Fusion gene; Neurotrophin; Receptor; Gene","score_opus":0.018757779530853686,"score_gpt":0.3576391259504282,"score_spread":0.3388813464195745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226065666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879387,0.0001954867,0.0000057304323,0.0023948892,0.00008271067,0.0006116507,0.00012609769,0.000008827826,0.008635927],"genre_scores_gemma":[0.9986056,0.00009272111,0.00014001824,0.00067722186,0.000013844823,0.000030840623,0.00023674875,0.0000100633,0.0001929263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912107,0.00010476878,0.00027426987,0.00018127477,0.0001602035,0.00015840383],"domain_scores_gemma":[0.9993222,0.000137916,0.00018150211,0.00012256338,0.00017169278,0.00006412886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012199958,0.000091325455,0.00035138332,0.00013161452,0.00006565401,0.0000013107349,0.00004400136,0.000042699852,0.00032882445],"category_scores_gemma":[0.000039501894,0.000072924675,0.00003144574,0.00024391564,0.00008633929,0.000033722703,0.00006345857,0.000119697695,0.0000016908028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02216787,0.0118745435,0.5575875,0.00008726447,0.0013681189,0.00020127256,0.013034152,0.00031975738,0.00067769655,0.0008005872,0.00867034,0.3832109],"study_design_scores_gemma":[0.020663321,0.017947454,0.93405634,0.00008637174,0.00024513196,0.000023941522,0.000981792,0.000022577582,0.0011226573,0.000057451056,0.02468078,0.00011215492],"about_ca_topic_score_codex":0.00036491943,"about_ca_topic_score_gemma":0.00006346384,"teacher_disagreement_score":0.38309872,"about_ca_system_score_codex":0.000092387825,"about_ca_system_score_gemma":0.00025697393,"threshold_uncertainty_score":0.3600397},"labels":[],"label_agreement":null},{"id":"W4226113086","doi":"10.1016/j.annonc.2022.02.015","title":"6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; St Mary's Hospital Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Cancer; Immunotherapy","score_opus":0.07065250765017408,"score_gpt":0.349824965715346,"score_spread":0.2791724580651719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226113086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909546,0.0012439993,0.000024430487,0.0024630076,0.0002447238,0.0019740423,0.00004445834,0.00006403571,0.0029867245],"genre_scores_gemma":[0.9940906,0.0003516914,0.0002906781,0.0017873393,0.000050880033,0.0004130665,0.00011796437,0.00005083609,0.0028469274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742264,0.00035627472,0.00074796774,0.00045104258,0.0004895658,0.0005325127],"domain_scores_gemma":[0.99862915,0.0001591524,0.0004906808,0.00039832864,0.00020116905,0.00012150338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008483172,0.00027147465,0.0009068223,0.00037021993,0.000119101125,0.000009913052,0.00019995493,0.00008270686,0.0017282559],"category_scores_gemma":[0.0001364244,0.00020173588,0.00017743018,0.00074570597,0.00023113139,0.00010466209,0.00008380353,0.00038144516,0.0000124042035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88851696,0.0022738718,0.008827645,0.0006809016,0.0014124007,0.0026466113,0.0041514775,0.00030224098,0.006054861,0.00013078505,0.009615347,0.075386904],"study_design_scores_gemma":[0.36109546,0.20283419,0.11256559,0.0018024168,0.0019796179,0.0073328167,0.013660582,0.0013399945,0.017942851,0.0004571402,0.27696827,0.0020210724],"about_ca_topic_score_codex":0.0010857327,"about_ca_topic_score_gemma":0.0013925711,"teacher_disagreement_score":0.5274215,"about_ca_system_score_codex":0.00048425276,"about_ca_system_score_gemma":0.0022070238,"threshold_uncertainty_score":0.9991843},"labels":[],"label_agreement":null},{"id":"W4226117846","doi":"10.1016/j.annonc.2022.02.029","title":"20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Janssen Biotech; Sanofi Genzyme; EMD Serono; Nordic Pharma Group; Ono Pharmaceutical; Eisai; Merck KGaA; Yuhan; Puma Biotechnology; Teva Pharmaceutical Industries; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Chemotherapy; non-small cell lung cancer (NSCLC); Population; Cancer","score_opus":0.028155893834601615,"score_gpt":0.3790767388232577,"score_spread":0.3509208449886561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226117846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305946,0.0009294778,0.000031866046,0.0022578558,0.00026378373,0.0011487696,0.00019189615,0.000016277945,0.0021006297],"genre_scores_gemma":[0.99437714,0.003916945,0.00066492544,0.00036722762,0.0000410023,0.00030520212,0.000108631466,0.000020490159,0.0001984326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863833,0.00016270461,0.00044567138,0.00029067378,0.0002168031,0.00024580923],"domain_scores_gemma":[0.9992163,0.00007805865,0.0003706575,0.00013995304,0.00011114903,0.00008384595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021059274,0.00015332682,0.0004089947,0.00022130711,0.00008669489,0.000003395915,0.000074036616,0.0000833974,0.00024164707],"category_scores_gemma":[0.000015474585,0.00013276766,0.00006547509,0.00024642274,0.000060079135,0.00005910879,0.0000830323,0.00022561954,0.0000019092895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010652184,0.007885979,0.44515324,0.0019716946,0.0011019598,0.00053978444,0.0074672163,0.00058597425,0.030202035,0.00016711852,0.008148106,0.48612472],"study_design_scores_gemma":[0.018527182,0.013565471,0.91947657,0.00078969967,0.0007134358,0.000022787783,0.0016044358,0.0013284131,0.03359044,0.0000997547,0.009931693,0.00035009312],"about_ca_topic_score_codex":0.0009420373,"about_ca_topic_score_gemma":0.00013415638,"teacher_disagreement_score":0.4857746,"about_ca_system_score_codex":0.00024431606,"about_ca_system_score_gemma":0.00021497587,"threshold_uncertainty_score":0.5414108},"labels":[],"label_agreement":null},{"id":"W4226204497","doi":"10.1016/j.annonc.2022.02.086","title":"77TiP TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Solid tumor; Lung cancer; Cancer; Phase (matter); ROS1; Oncology; Internal medicine; Adenocarcinoma; Cancer research","score_opus":0.04924792611935426,"score_gpt":0.48957806313134566,"score_spread":0.4403301370119914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226204497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888114,0.0010712675,0.0000075706575,0.004689052,0.0001861001,0.0015119824,0.00066870026,0.000013369702,0.0030405743],"genre_scores_gemma":[0.9958414,0.000036448815,0.00008379512,0.0023036562,0.00007130022,0.0009173844,0.000028486647,0.000012607815,0.0007049091],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99911743,0.000059862294,0.00025656616,0.00023675516,0.00011718571,0.00021216855],"domain_scores_gemma":[0.99953467,0.000067241985,0.00013255971,0.000102257334,0.00009149646,0.00007178141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018738997,0.000106595486,0.00038125794,0.000087031105,0.00023494271,0.0000027824556,0.000048784666,0.000036197336,0.00026008647],"category_scores_gemma":[0.0000398696,0.00009435523,0.000058154867,0.00020369212,0.00005354461,0.000032623095,0.00010378894,0.00008743535,2.4337555e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014132698,0.0457447,0.3949521,0.00017724553,0.002834345,0.00064005743,0.059599876,0.0003514046,0.0019477915,0.0009508615,0.03513089,0.44353804],"study_design_scores_gemma":[0.13142549,0.2987804,0.2309319,0.00029829488,0.0026037244,0.0003976107,0.04039191,0.0026181058,0.0030598359,0.0010609282,0.2875783,0.00085348747],"about_ca_topic_score_codex":0.0016080172,"about_ca_topic_score_gemma":0.00086949905,"teacher_disagreement_score":0.44268456,"about_ca_system_score_codex":0.0002431907,"about_ca_system_score_gemma":0.00043072205,"threshold_uncertainty_score":0.38476944},"labels":[],"label_agreement":null},{"id":"W4226488138","doi":"10.1016/j.annonc.2022.02.121","title":"196P An international consensus on actions to improve lung cancer survival: A clinical review by the international cancer benchmarking partnership (ICBP)","year":2022,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Referral; Benchmarking; Delphi method; Excellence; Health care; Family medicine; Oncology; Business; Political science; Marketing","score_opus":0.48562452283871843,"score_gpt":0.6074551444987676,"score_spread":0.12183062166004915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226488138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000742123,0.92481005,7.146908e-7,0.057190448,0.00574612,0.0018696404,0.0009775688,0.000023584736,0.00930764],"genre_scores_gemma":[0.00009194483,0.97684354,0.000038540024,0.016058993,0.0017294569,0.0037537287,0.0005956415,0.00005033957,0.0008378465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99647975,0.00062419666,0.0012299251,0.0007283522,0.00060886855,0.00032889415],"domain_scores_gemma":[0.9960926,0.001780514,0.0009815787,0.00058870803,0.00031045085,0.00024612233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015098635,0.00037194908,0.0019104879,0.00014909993,0.00010578639,0.000019773903,0.0005949362,0.00023421357,0.004304356],"category_scores_gemma":[0.0004485419,0.00024936858,0.0007875102,0.000251169,0.00012467927,0.00003860145,0.00020783306,0.0008396512,0.0000136108665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109711225,0.00065584644,0.0005178878,0.0020591673,0.0020553442,0.000026763413,0.000029193792,0.0000021944563,1.41028e-7,0.00025598187,0.30635044,0.6879373],"study_design_scores_gemma":[0.0006481164,0.0015156217,0.00014578755,0.012497328,0.0020819113,0.000029581162,0.00001940119,0.000012175639,0.000001855407,0.000005382497,0.9828436,0.00019927142],"about_ca_topic_score_codex":0.0014833158,"about_ca_topic_score_gemma":0.0009527427,"teacher_disagreement_score":0.68773806,"about_ca_system_score_codex":0.0016589938,"about_ca_system_score_gemma":0.0022561504,"threshold_uncertainty_score":0.9999958},"labels":[],"label_agreement":null},{"id":"W4229030197","doi":"10.1016/j.annonc.2022.03.197","title":"178P Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Samsung; Genentech; Plexxikon; Eisai; Seagen; MacroGenics; Astellas Pharma; Mylan; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Genomic Health; GlaxoSmithKline","keywords":"Medicine; Quality of life (healthcare); Brief Pain Inventory; Anxiety; Breast cancer; Physical therapy; Family medicine; Internal medicine; Cancer; Chronic pain; Psychiatry; Nursing","score_opus":0.15594079365191868,"score_gpt":0.541123386923376,"score_spread":0.3851825932714573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229030197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954443,0.00034431816,0.000027084712,0.0010536616,0.0005856617,0.0013052763,0.0005646305,0.000010050629,0.0006650298],"genre_scores_gemma":[0.99728495,0.00084119826,0.000485065,0.00080548803,0.000056378383,0.00032675744,0.00013352545,0.000028458464,0.00003819165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99514806,0.0019628536,0.0016569667,0.0004140511,0.00042381953,0.00039422745],"domain_scores_gemma":[0.98885125,0.008577444,0.001534283,0.00034723562,0.0005458323,0.00014396208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004287982,0.00020741658,0.0014364992,0.0002573314,0.000046863992,0.0000028885213,0.0001281394,0.00013107102,0.000033797503],"category_scores_gemma":[0.0030388641,0.00019813937,0.00022956867,0.00053621014,0.00009493275,0.00012474666,0.00011092849,0.00034734418,1.6074719e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011234088,0.0062426897,0.92553383,0.00063824054,0.00030031864,0.000012378515,0.001005878,0.00061247393,0.00017960479,0.000057879122,0.00009290265,0.054089714],"study_design_scores_gemma":[0.01674131,0.00768699,0.97232914,0.00021960816,0.00008684941,0.000001698031,0.0018833502,0.00017180493,0.0001851963,0.000013573865,0.0005364887,0.00014397955],"about_ca_topic_score_codex":0.08734578,"about_ca_topic_score_gemma":0.30693036,"teacher_disagreement_score":0.2195846,"about_ca_system_score_codex":0.0009917126,"about_ca_system_score_gemma":0.0025633478,"threshold_uncertainty_score":0.9187317},"labels":[],"label_agreement":null},{"id":"W4229052424","doi":"10.1016/j.annonc.2022.03.089","title":"73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"Puma Biotechnology","keywords":"Loperamide; Medicine; Neratinib; Diarrhea; Internal medicine; Gastroenterology; Tolerability; Breast cancer; Adverse effect; Cancer; Trastuzumab","score_opus":0.029236687784158902,"score_gpt":0.3214730919460244,"score_spread":0.2922364041618655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229052424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941377,0.000026977224,0.0000013588634,0.003461039,0.0001684306,0.001798937,0.00034384118,0.000008959227,0.00005274133],"genre_scores_gemma":[0.9991001,0.000014415584,0.000004996106,0.00050106266,0.000058534795,0.00018864503,0.00005143508,0.000009747958,0.00007105622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982991,0.00053290516,0.00040032182,0.00023349287,0.00033240204,0.00020172665],"domain_scores_gemma":[0.99841493,0.0009977038,0.00029068987,0.00016311869,0.00008563456,0.000047928752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008193154,0.00013469957,0.0006506974,0.000081354636,0.0000785137,0.0000064167684,0.00008760834,0.000060651306,0.0002575172],"category_scores_gemma":[0.0002568142,0.00008005067,0.00006886478,0.00026537225,0.00010540189,0.000048119964,0.000052098083,0.0002734678,2.8423386e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15441443,0.0005939104,0.8263785,0.000031296724,0.00012493244,0.000007945849,0.00033073503,0.000089294175,0.000007153619,0.0000060005345,0.00033441235,0.017681384],"study_design_scores_gemma":[0.07827188,0.035496656,0.8857173,0.000031799813,0.00007945015,3.5575425e-7,0.000030127941,0.00009596056,0.000036505902,0.0000069401494,0.00017262627,0.000060399798],"about_ca_topic_score_codex":0.0036036924,"about_ca_topic_score_gemma":0.0008756805,"teacher_disagreement_score":0.07614255,"about_ca_system_score_codex":0.000136078,"about_ca_system_score_gemma":0.000154841,"threshold_uncertainty_score":0.54477286},"labels":[],"label_agreement":null},{"id":"W4229062082","doi":"10.1016/j.annonc.2022.03.185","title":"166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Tolerability; Adverse effect","score_opus":0.11293539615260782,"score_gpt":0.4609971678987615,"score_spread":0.34806177174615366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229062082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95276046,0.002110238,0.00074777403,0.016575413,0.000811781,0.0060186493,0.020261647,0.00013760637,0.0005764105],"genre_scores_gemma":[0.98857373,0.0004507674,0.0024640474,0.0016936099,0.00044919437,0.00407493,0.0009400461,0.00012747035,0.0012261982],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99522436,0.0004985984,0.0014026391,0.0011890905,0.0007207679,0.00096451846],"domain_scores_gemma":[0.9954918,0.0013631141,0.0010106764,0.00093177176,0.00081929186,0.00038334905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061176275,0.0006327445,0.0018323193,0.00036801255,0.000702266,0.000016137428,0.00045256747,0.00012396552,0.0014407753],"category_scores_gemma":[0.00054557977,0.00058605627,0.00034207114,0.0007022669,0.00036705876,0.00029910068,0.00033835997,0.0004610126,0.000011661571],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21665528,0.02613317,0.00037850105,0.00010720784,0.0039223777,0.0010049597,0.011357457,0.004961371,0.0017766709,0.00009273843,0.0017033375,0.7319069],"study_design_scores_gemma":[0.42824355,0.28429434,0.003568283,0.00045427223,0.0026402306,0.0012127458,0.024815636,0.0025036936,0.024825899,0.010627927,0.2151216,0.0016918222],"about_ca_topic_score_codex":0.007939098,"about_ca_topic_score_gemma":0.006312107,"teacher_disagreement_score":0.7302151,"about_ca_system_score_codex":0.001127165,"about_ca_system_score_gemma":0.0024543046,"threshold_uncertainty_score":0.99965906},"labels":[],"label_agreement":null},{"id":"W4229068667","doi":"10.1016/j.annonc.2022.03.183","title":"164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Gemcitabine; Pembrolizumab; Internal medicine; Breast cancer; Oncology; Cancer; Nursing","score_opus":0.07916337031695886,"score_gpt":0.40314876597677396,"score_spread":0.3239853956598151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229068667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93291545,0.0027616753,0.000024042512,0.05574961,0.00033287186,0.0027629887,0.003973415,0.00006502611,0.001414943],"genre_scores_gemma":[0.98428535,0.0029322247,0.0008078991,0.008663471,0.00013829255,0.0007958833,0.0005275,0.00007782297,0.0017715506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959284,0.0004785636,0.0017135581,0.00075240864,0.00051033316,0.00061672373],"domain_scores_gemma":[0.9955816,0.0010390147,0.0020056493,0.00064414885,0.00046509647,0.00026448045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010669157,0.00043983903,0.0019874808,0.00019212697,0.0002178687,0.0000060953034,0.000261658,0.00023643076,0.0011234286],"category_scores_gemma":[0.0002100325,0.00036305576,0.00046303408,0.0005306022,0.00038435165,0.000093914,0.000054129905,0.00030984456,0.0000026831465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8262804,0.0027393952,0.00065641495,0.00018459959,0.0029734494,0.000017077877,0.0067904973,0.0001486733,0.015054746,0.000048268048,0.009613148,0.13549334],"study_design_scores_gemma":[0.54671264,0.093883514,0.093920216,0.0006204913,0.00048643613,0.00021171758,0.009922973,0.0003683797,0.14314574,0.00084416795,0.108526476,0.0013572221],"about_ca_topic_score_codex":0.039546944,"about_ca_topic_score_gemma":0.002033651,"teacher_disagreement_score":0.27956775,"about_ca_system_score_codex":0.0010639505,"about_ca_system_score_gemma":0.0034053195,"threshold_uncertainty_score":0.99988216},"labels":[],"label_agreement":null},{"id":"W4229070154","doi":"10.1016/j.annonc.2022.03.280","title":"LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Population; Breast cancer; Hazard ratio; Cancer; Randomized controlled trial; Adjuvant; Oncology; Confidence interval","score_opus":0.039587239532819306,"score_gpt":0.35083410199658555,"score_spread":0.31124686246376626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229070154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322123,0.00024958048,0.000014452983,0.010790661,0.0001734683,0.001933887,0.003380613,0.000033271685,0.00020282113],"genre_scores_gemma":[0.9953617,0.00013879535,0.00011894888,0.0015681471,0.00016699778,0.00028721406,0.00225289,0.00004916966,0.000056125504],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968109,0.00048124255,0.0009496135,0.000519804,0.00079184776,0.00044660838],"domain_scores_gemma":[0.9973861,0.00050713966,0.0009942004,0.0005960998,0.00042989,0.00008658692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057282974,0.00034724482,0.0009344042,0.00012391958,0.0001805544,0.0000074179025,0.00036221958,0.000111513866,0.0002078585],"category_scores_gemma":[0.00005291309,0.00020064496,0.000093560164,0.0006109144,0.00028394198,0.00018754232,0.00007246582,0.0004810395,8.358498e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8962827,0.0065047685,0.0271697,0.0000235827,0.00074471446,0.00011651935,0.0025010358,0.0064038765,0.0011175672,0.000088509056,0.00031783254,0.0587292],"study_design_scores_gemma":[0.45897886,0.04733578,0.47787562,0.00020310453,0.00044901323,0.00008333495,0.0011418005,0.00027622332,0.0008370213,0.00031581146,0.01208211,0.0004213229],"about_ca_topic_score_codex":0.010530325,"about_ca_topic_score_gemma":0.00584239,"teacher_disagreement_score":0.45070592,"about_ca_system_score_codex":0.0002389065,"about_ca_system_score_gemma":0.00034844797,"threshold_uncertainty_score":0.99605864},"labels":[],"label_agreement":null},{"id":"W4229082912","doi":"10.1016/j.annonc.2022.03.068","title":"53P ‘HER2-LOW’ breast cancer brain metastases: An opportunity for targeted systemic therapies in a high-need patient population","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Immunohistochemistry; Cancer; Metastatic breast cancer; Trastuzumab; Cohort; Population; Estrogen receptor; Targeted therapy","score_opus":0.07082120698224831,"score_gpt":0.3774135765735073,"score_spread":0.306592369591259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229082912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98083615,0.00094165356,0.000023597466,0.014744597,0.00022110349,0.001250805,0.0019224641,0.000026218131,0.000033402295],"genre_scores_gemma":[0.99354637,0.00011649104,0.000502538,0.0037095,0.000055363493,0.00085020036,0.0011499324,0.000025790465,0.000043819477],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99798185,0.00070171506,0.0005177846,0.0002823808,0.0002259188,0.00029032477],"domain_scores_gemma":[0.9988921,0.00020190024,0.00033172575,0.00026096826,0.00016277582,0.00015052555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089439686,0.00016442656,0.0006346068,0.0002176741,0.00009845764,0.000004490846,0.00008538257,0.00006868973,0.00054881215],"category_scores_gemma":[0.00007208239,0.0001403551,0.00013848724,0.00023217298,0.000043027234,0.00008755127,0.000049462178,0.0001410712,8.0370614e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016412076,0.017901812,0.09179902,0.001196263,0.0030319153,0.00068200653,0.011203242,0.0047848127,0.01283046,0.006399524,0.024610812,0.8091481],"study_design_scores_gemma":[0.04141714,0.07929589,0.7229122,0.00059472624,0.0011803885,0.001495739,0.039378025,0.0022479105,0.003972237,0.0054377243,0.10063892,0.001429119],"about_ca_topic_score_codex":0.006718467,"about_ca_topic_score_gemma":0.0007055923,"teacher_disagreement_score":0.80771893,"about_ca_system_score_codex":0.00021240796,"about_ca_system_score_gemma":0.00035292856,"threshold_uncertainty_score":0.9998959},"labels":[],"label_agreement":null},{"id":"W4231752673","doi":"10.1093/annonc/mdn217","title":"session 6 – extranodal lymphoma","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Session (web analytics); Lymphoma; Medical physics; Internal medicine; World Wide Web","score_opus":0.1252000018567793,"score_gpt":0.38811413738070877,"score_spread":0.2629141355239295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231752673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.886431,0.0006067867,0.00003430867,0.0035711324,0.00018287222,0.000102233265,0.00000546129,0.000022254038,0.10904395],"genre_scores_gemma":[0.98973674,0.0012045061,0.00061566697,0.0065055303,0.00013693151,0.0000054739644,0.000017295122,0.000009346511,0.0017685338],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993067,0.00003740347,0.00022073252,0.00013721308,0.000121044024,0.00017692267],"domain_scores_gemma":[0.999478,0.000067035224,0.00007749944,0.00016572067,0.00010566024,0.000106097206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010860291,0.0000750573,0.00031791805,0.00007450545,0.000044354056,6.48416e-7,0.000058584697,0.000116722375,0.0008488548],"category_scores_gemma":[0.000041006126,0.00006320147,0.00010180566,0.00008155975,0.00014744281,0.000055762353,0.000020191492,0.00006344574,0.00003966343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001997807,0.0008286258,0.023745254,0.00010009597,0.00012810975,0.0008868066,0.0010626564,0.000006134334,0.03986168,0.0002495254,0.13842188,0.79271144],"study_design_scores_gemma":[0.0034628913,0.0028290423,0.17648834,0.000026190815,0.000019778243,0.00072378526,0.00007457621,0.000056024062,0.029819341,0.0000704943,0.7863368,0.000092782095],"about_ca_topic_score_codex":0.00004819804,"about_ca_topic_score_gemma":0.0000057424286,"teacher_disagreement_score":0.79261863,"about_ca_system_score_codex":0.0000333509,"about_ca_system_score_gemma":0.0005800888,"threshold_uncertainty_score":0.92943645},"labels":[],"label_agreement":null},{"id":"W4232022766","doi":"10.1016/j.annonc.2021.08.1154","title":"641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Genentech; Astellas Pharma; Merck Sharp and Dohme; Eisai; Invitae; Advanced Accelerator Applications; Menarini Silicon Biosystems; Clovis Oncology; Sanofi Genzyme; Sierra Oncology; Taiho Pharmaceutical; Vertex Pharmaceuticals; Boston Scientific Corporation; Daiichi Sankyo Europe; Sanofi; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Docetaxel; Prostate cancer; Pembrolizumab; Oncology; Olaparib; Internal medicine; Enzalutamide; Cancer; Immunotherapy; Androgen receptor","score_opus":0.07525017458406637,"score_gpt":0.385290777884475,"score_spread":0.31004060330040867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232022766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992277,0.0020992283,0.0000022493232,0.0030805701,0.00022661895,0.0019583565,0.00016633794,0.000013566102,0.0001760291],"genre_scores_gemma":[0.98825544,0.010320634,0.000100070894,0.0005014896,0.00003335993,0.00024962908,0.00018425322,0.000032855867,0.0003222519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977214,0.000278932,0.0008755038,0.00042229038,0.00034756295,0.00035432808],"domain_scores_gemma":[0.998441,0.00013523725,0.00053529826,0.00029808568,0.0004777054,0.0001126755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017078959,0.00028622666,0.00094630796,0.00024776955,0.00007494843,0.000009463153,0.00006845547,0.000058441066,0.00020517656],"category_scores_gemma":[0.000062529194,0.00020653747,0.0001279032,0.00046527258,0.00020214762,0.00012278523,0.000027555734,0.00011757358,3.5743508e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70381874,0.014997484,0.014874527,0.00019856448,0.0010754301,0.00062472513,0.0013484806,0.000011893994,0.017609624,0.000032053642,0.0003357526,0.24507272],"study_design_scores_gemma":[0.5836476,0.18780337,0.14800517,0.00022438995,0.00043288263,0.00015916121,0.0004919524,0.00010652783,0.06894396,0.00003654944,0.0098256245,0.00032280915],"about_ca_topic_score_codex":0.0012819493,"about_ca_topic_score_gemma":0.0018719864,"teacher_disagreement_score":0.24474992,"about_ca_system_score_codex":0.00017085347,"about_ca_system_score_gemma":0.001118088,"threshold_uncertainty_score":0.8422353},"labels":[],"label_agreement":null},{"id":"W4233437943","doi":"10.1016/j.annonc.2021.07.011","title":"Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’","year":2021,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Oncology; Internal medicine; Cancer; Hormone receptor; Progression-free survival; Breast cancer; Metastatic breast cancer; Estrogen receptor; Epidermal growth factor receptor; Overall survival","score_opus":0.05281472117392018,"score_gpt":0.38073810267926245,"score_spread":0.3279233815053423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233437943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7840883,0.013654405,0.0013296513,0.07475217,0.029245682,0.0505024,0.03964064,0.0003725425,0.006414206],"genre_scores_gemma":[0.7423548,0.027159303,0.007761402,0.03174859,0.013995986,0.04743885,0.02967454,0.0018872367,0.097979285],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99254316,0.0016506985,0.0019952636,0.0013649088,0.0009360673,0.0015099029],"domain_scores_gemma":[0.993474,0.001330768,0.0018811745,0.00074911775,0.002068732,0.0004962119],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015432303,0.0011765147,0.005873055,0.00049790624,0.00022228844,0.000039604387,0.0006569717,0.00088177837,0.0012773297],"category_scores_gemma":[0.00047076333,0.0008351487,0.0004829239,0.00077764574,0.00079782883,0.0003149985,0.00012843756,0.0015996789,0.0000059956715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88276243,0.0019932506,0.0000045348092,0.0002471267,0.002999646,0.00014984986,0.006274825,0.000025350791,0.010171249,0.00020178982,0.07773694,0.017432997],"study_design_scores_gemma":[0.8634213,0.02883288,0.0011178409,0.0008930301,0.00055399095,0.000107059845,0.002640124,0.000016287355,0.002037138,0.00037359403,0.098887645,0.0011190702],"about_ca_topic_score_codex":0.0010576702,"about_ca_topic_score_gemma":0.00057327526,"teacher_disagreement_score":0.09156508,"about_ca_system_score_codex":0.001307658,"about_ca_system_score_gemma":0.0034420583,"threshold_uncertainty_score":0.99963564},"labels":[],"label_agreement":null},{"id":"W4234641050","doi":"10.1016/j.annonc.2020.10.435","title":"443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Ifosfamide; Etoposide; Internal medicine; Gastroenterology; Phases of clinical research; Surgery; Chemotherapy; Oncology","score_opus":0.06160958489256743,"score_gpt":0.3702902976727876,"score_spread":0.30868071278022013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234641050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584795,0.0016920198,0.0000033847334,0.005997133,0.000026775937,0.006317832,0.00003017946,0.000012345901,0.00007239318],"genre_scores_gemma":[0.99675775,0.0015662068,0.00042166963,0.0010076769,0.000014790175,0.00016768192,0.00003236021,0.000026452317,0.0000054142974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975239,0.00062831043,0.0007635158,0.000548134,0.0002513055,0.0002848274],"domain_scores_gemma":[0.99775606,0.0012226972,0.00037776027,0.00025505846,0.00016502396,0.00022338227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071842753,0.0003083978,0.0014407135,0.00017854068,0.000101901125,0.00002318136,0.00013286127,0.00007468545,0.00000434739],"category_scores_gemma":[0.00060638244,0.00018825241,0.000024014029,0.0002973726,0.00036526934,0.00014138516,0.0002823592,0.00028678955,3.413437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47663784,0.0115636615,0.4851372,0.000105165294,0.00035971467,0.00015872583,0.008639535,0.000002678915,0.00013127566,0.000030936182,0.00006582203,0.017167453],"study_design_scores_gemma":[0.47133127,0.027549766,0.49721456,0.0007353268,0.0002641546,0.000051009374,0.0023026585,0.00013849356,0.00025159246,0.000004474907,0.00003142573,0.00012528597],"about_ca_topic_score_codex":0.0013201496,"about_ca_topic_score_gemma":0.003942581,"teacher_disagreement_score":0.017042166,"about_ca_system_score_codex":0.000046844747,"about_ca_system_score_gemma":0.00012279513,"threshold_uncertainty_score":0.76767105},"labels":[],"label_agreement":null},{"id":"W4235822416","doi":"10.1093/annonc/mdv050.13","title":"Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (PTS) with Nsclc Harbouring EGFR Mutations (MUT): Subgroup Analyses by Race in Lux-Lung 3 (LL3) and Lux-Lung 6 (LL6)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Pemetrexed; Subgroup analysis; Lung cancer; Gemcitabine; Oncology; Gastroenterology; Chemotherapy; Cancer; Cisplatin; Gefitinib; Epidermal growth factor receptor; Confidence interval","score_opus":0.04781763379140514,"score_gpt":0.4072023918874924,"score_spread":0.3593847580960873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235822416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909556,0.0009274429,0.00010464557,0.0030336173,0.000068675334,0.00074781524,0.0000404407,0.000024818908,0.0040969574],"genre_scores_gemma":[0.9976531,0.00021108589,0.0007939191,0.0006921987,0.00004057102,0.00009102006,0.00018336302,0.00003862967,0.00029608965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983398,0.000130748,0.00043695248,0.00038792388,0.00032073155,0.000383845],"domain_scores_gemma":[0.9988924,0.00015688858,0.00021933067,0.0002343461,0.00029109453,0.00020591234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028385155,0.00024468006,0.00068016123,0.00028603277,0.000051803334,0.000017450435,0.000086753025,0.000091606744,0.000051462976],"category_scores_gemma":[0.000070690745,0.00018912865,0.00004626889,0.0003956809,0.00016023478,0.00025035234,0.000027346221,0.00020115638,0.0000023436905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027469678,0.0019034863,0.98241806,0.000089463974,0.00054067274,0.00012639946,0.0031766912,0.00050643075,0.00022651778,0.00012289843,0.0028606409,0.0052817767],"study_design_scores_gemma":[0.03925905,0.0067869094,0.9436228,0.00040344082,0.0004107529,0.000032526368,0.0013567442,0.0008436416,0.0014639564,0.00009529288,0.005324101,0.00040077427],"about_ca_topic_score_codex":0.0018274649,"about_ca_topic_score_gemma":0.0014895512,"teacher_disagreement_score":0.038795244,"about_ca_system_score_codex":0.00027129275,"about_ca_system_score_gemma":0.0004905568,"threshold_uncertainty_score":0.7712442},"labels":[],"label_agreement":null},{"id":"W4236139371","doi":"10.1093/annonc/mdw334.16","title":"Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Temsirolimus; Sunitinib; Pazopanib; Renal cell carcinoma; Internal medicine; Sorafenib; Bevacizumab; Oncology; Population; Urology; Gastroenterology; Chemotherapy; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors","score_opus":0.06123959229163349,"score_gpt":0.304829353636024,"score_spread":0.24358976134439048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236139371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756855,0.00023016066,0.00004077951,0.00026267808,0.000028639213,0.0005572438,0.0005930731,0.000021255437,0.0006976492],"genre_scores_gemma":[0.99781275,0.000017528826,0.0013396144,0.00016318542,0.000026621863,0.000026503258,0.00034833205,0.00003300238,0.00023247077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831325,0.00014486504,0.0005089427,0.00034618622,0.0003717199,0.0003150285],"domain_scores_gemma":[0.99818194,0.00026390815,0.00042566733,0.00044057737,0.00049217406,0.00019573636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001063494,0.00025505933,0.0008790356,0.00015677584,0.000025258088,0.0000020180587,0.00011254701,0.0001186484,0.00029590933],"category_scores_gemma":[0.0000632617,0.0001265147,0.00012876971,0.00015898551,0.00019405081,0.00006847485,0.00004037594,0.00007763339,0.00001531599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062867096,0.0015959594,0.9754721,0.00004414339,0.0004342359,0.00028160782,0.00009919527,0.0000037569328,0.012186131,0.0000020023872,0.0005979352,0.0029962235],"study_design_scores_gemma":[0.011251957,0.012554046,0.7066902,0.00004918992,0.00035118795,0.0000044426324,0.000024950523,0.0000035617193,0.2677865,0.0000051797047,0.0011722258,0.00010658102],"about_ca_topic_score_codex":0.0013542196,"about_ca_topic_score_gemma":0.0001336626,"teacher_disagreement_score":0.26878193,"about_ca_system_score_codex":0.000069016336,"about_ca_system_score_gemma":0.00012725093,"threshold_uncertainty_score":0.51591194},"labels":[],"label_agreement":null},{"id":"W4236537717","doi":"10.1093/annonc/mdw594.004","title":"440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Oncology; Internal medicine; Lung cancer; Epidermal growth factor receptor; Cancer","score_opus":0.05931508410021057,"score_gpt":0.40550290188048754,"score_spread":0.34618781778027696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236537717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704181,0.00018272168,0.00022308342,0.0081240535,0.00027964255,0.00075148564,0.0016701188,0.000030881885,0.018319942],"genre_scores_gemma":[0.99476784,0.0001376895,0.0009457841,0.001464191,0.00014547232,0.000051200073,0.0018815757,0.000031638512,0.0005746058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821264,0.00014517098,0.00046609732,0.0005020044,0.00032593452,0.00034816551],"domain_scores_gemma":[0.9980032,0.0005780326,0.00030468026,0.00056635845,0.00040118507,0.00014658501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020845259,0.00020761613,0.00056119886,0.00014102888,0.000052918986,0.000009321603,0.0002113324,0.00014561714,0.00045878705],"category_scores_gemma":[0.00020448757,0.00013660324,0.00005656163,0.0001565391,0.00014643259,0.00031775548,0.00010260901,0.00012416352,0.00005741062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007525804,0.0048226723,0.7965995,0.00008279847,0.001979916,0.0004259579,0.0029881906,0.000021472666,0.0006393078,0.0014382447,0.026746143,0.15672997],"study_design_scores_gemma":[0.020597529,0.0050641396,0.95856434,0.0004895781,0.000381434,0.000008352681,0.00022661418,0.00006378687,0.0008895876,0.00040285772,0.013065051,0.00024674897],"about_ca_topic_score_codex":0.0013970516,"about_ca_topic_score_gemma":0.00091633055,"teacher_disagreement_score":0.1619648,"about_ca_system_score_codex":0.00017512815,"about_ca_system_score_gemma":0.0005544433,"threshold_uncertainty_score":0.55705184},"labels":[],"label_agreement":null},{"id":"W4236738503","doi":"10.1016/j.annonc.2020.10.103","title":"83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bayer Yakuhin; Eli Lilly Japan; Chugai Pharmaceutical; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Genentech; Aptitude Health; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Daiichi-Sankyo; Array BioPharma; Ipsen; Peter MacCallum Cancer Centre; Sanofi K.K.; Clovis Oncology; University of Ulsan; Pfizer; Incyte; Taiho Pharmaceutical; MSD K.K.; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Servier; Gilead Sciences; Sanofi; Amgen; University of Michigan; Myriad Genetics; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; KRAS; Clinical endpoint; Adverse effect; Internal medicine; Gastroenterology; Colorectal cancer; Cancer; Anemia; Phases of clinical research; Oncology; Clinical trial","score_opus":0.10577231254624675,"score_gpt":0.37538011515654,"score_spread":0.26960780261029327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236738503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860924,0.00024383071,0.0002561472,0.008846878,0.0001423733,0.00165719,0.001628895,0.000018075594,0.001114219],"genre_scores_gemma":[0.99433666,0.000081962804,0.0029827813,0.0018889501,0.00031208817,0.00016068411,0.0001784763,0.000021185771,0.00003722493],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99859405,0.000042026542,0.0005341979,0.00034997397,0.00020447173,0.00027528283],"domain_scores_gemma":[0.99806595,0.0005716194,0.0004676485,0.00019381633,0.0005734478,0.00012751788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011360832,0.00020367611,0.0007210749,0.000029984645,0.000057533958,0.0000039299075,0.00012157563,0.00005495736,0.000017663477],"category_scores_gemma":[0.00078647037,0.00012575692,0.00015569513,0.00015483181,0.00020894558,0.000035304678,0.00005950002,0.00012378216,0.0000012530058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90118426,0.005016433,0.0019599418,0.00009176938,0.00082158606,0.000040713836,0.0033078576,0.000042958593,0.011230733,0.000029215147,0.013780536,0.06249402],"study_design_scores_gemma":[0.56326705,0.36849037,0.005961524,0.0006123037,0.00075791025,0.000015939228,0.0015029301,0.00054550654,0.025119206,0.000042825963,0.033357535,0.00032692918],"about_ca_topic_score_codex":0.00092909334,"about_ca_topic_score_gemma":0.0008227836,"teacher_disagreement_score":0.36347392,"about_ca_system_score_codex":0.00008650441,"about_ca_system_score_gemma":0.000514883,"threshold_uncertainty_score":0.51282185},"labels":[],"label_agreement":null},{"id":"W4237645952","doi":"10.1093/annonc/mdw594.010","title":"446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Squamous-cell carcinoma of the lung; Oncology; Internal medicine; Lung; Basal cell; Second line; First line; Epidermal growth factor receptor; Cancer","score_opus":0.020458390560395893,"score_gpt":0.3443730455752647,"score_spread":0.3239146550148688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237645952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996162,0.00025980017,0.00002522445,0.0011695937,0.000057403595,0.00075223565,0.00046932828,0.000003216608,0.0011012015],"genre_scores_gemma":[0.99920326,0.000012945609,0.00024282899,0.00020383539,0.000011015698,0.00004528949,0.00002916783,0.000011703155,0.00023992127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990619,0.00005447194,0.00040488126,0.0001839843,0.000119781515,0.00017500178],"domain_scores_gemma":[0.99872726,0.00028749456,0.00040497392,0.00021762608,0.0003076402,0.00005499421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516671,0.000107856205,0.0005309334,0.00023635842,0.00002320431,0.0000011631379,0.0000696601,0.00005903171,0.00008580999],"category_scores_gemma":[0.00006987737,0.000057397552,0.00012042123,0.0003678068,0.00015314721,0.000042874177,0.000028713383,0.00003534143,1.4042057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001179618,0.0007390302,0.9925627,0.00022196907,0.0007022514,0.0000032359949,0.0006516471,0.000010490993,0.00073420774,0.000031183015,0.0007246279,0.002439007],"study_design_scores_gemma":[0.0077852537,0.0036568756,0.977794,0.000059871556,0.0015538903,0.0000015051398,0.00018458409,0.00019767953,0.008331121,0.000014461784,0.00035654535,0.000064231455],"about_ca_topic_score_codex":0.00017527443,"about_ca_topic_score_gemma":0.0005751175,"teacher_disagreement_score":0.014768751,"about_ca_system_score_codex":0.000046068293,"about_ca_system_score_gemma":0.00023016908,"threshold_uncertainty_score":0.23406042},"labels":[],"label_agreement":null},{"id":"W4238575387","doi":"10.1093/annonc/mdy425.042","title":"KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Santé Montérégie","funders":"","keywords":"Medicine; Placebo; Carboplatin; Nausea; Internal medicine; Lung cancer; Pembrolizumab; Oncology; Cisplatin; Chemotherapy; Cancer; Pathology","score_opus":0.07705669747757675,"score_gpt":0.3994233666933724,"score_spread":0.32236666921579565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238575387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926052,0.0008726927,0.00013854828,0.000951817,0.00035301567,0.0033602396,0.00027409257,0.000045667803,0.0013987328],"genre_scores_gemma":[0.99673164,0.0001855375,0.0015419606,0.0004801005,0.0001417739,0.00014813065,0.000041178693,0.00006717937,0.00066251884],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99644506,0.00035993886,0.0014196931,0.0006754766,0.00047526692,0.00062456704],"domain_scores_gemma":[0.99421567,0.0031081582,0.0012282156,0.00060303515,0.00064037676,0.00020453744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011768247,0.0005284068,0.0023321146,0.0005133405,0.00015779054,0.00001724891,0.00024327035,0.00031046028,0.00018363791],"category_scores_gemma":[0.0008723158,0.00038596193,0.00028186338,0.00042313104,0.0008507568,0.00015464569,0.00015994611,0.00025793296,0.0000022034308],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48344314,0.008026351,0.19865635,0.005546135,0.013563362,0.00019991833,0.037026722,0.00007111298,0.087522194,0.00033145968,0.010472696,0.15514055],"study_design_scores_gemma":[0.29957408,0.15590298,0.437843,0.0009657993,0.003683088,0.00035288782,0.014176855,0.0030466702,0.07140449,0.000374074,0.011130695,0.0015454135],"about_ca_topic_score_codex":0.0021393618,"about_ca_topic_score_gemma":0.0032731362,"teacher_disagreement_score":0.23918663,"about_ca_system_score_codex":0.000120025274,"about_ca_system_score_gemma":0.0004999797,"threshold_uncertainty_score":0.9998592},"labels":[],"label_agreement":null},{"id":"W4239010921","doi":"10.1016/j.annonc.2020.10.228","title":"234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Ovarian cancer; Oncology; Progression-free survival; Cancer; Clinical endpoint; Maintenance therapy; Randomization; Gastroenterology; Chemotherapy; Surgery; Urology; Clinical trial","score_opus":0.05065239076537644,"score_gpt":0.35254642273326353,"score_spread":0.3018940319678871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239010921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734016,0.00059200975,0.00363496,0.019165386,0.00037825303,0.0013179904,0.0004721913,0.000056390334,0.0009811851],"genre_scores_gemma":[0.97827953,0.00078300585,0.006211548,0.013701984,0.00023182236,0.00043950454,0.00017526158,0.000043881704,0.00013347453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985188,0.000065044296,0.0004071388,0.0004532765,0.00021360075,0.00034211192],"domain_scores_gemma":[0.9982798,0.000376214,0.00036285393,0.00019308383,0.00056010025,0.00022796492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011284905,0.00020267967,0.00060680526,0.000064725275,0.00006538589,0.000009270331,0.00009915822,0.00016704875,0.00018185533],"category_scores_gemma":[0.00034561014,0.00017553417,0.00009129618,0.0001894983,0.00017394625,0.00016248487,0.000029087263,0.00016611312,0.000008349311],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08318003,0.0018893222,0.077359386,0.0006433129,0.0017569477,0.00022556617,0.012892581,0.00043624552,0.01895354,0.0042796885,0.14478429,0.6535991],"study_design_scores_gemma":[0.31226295,0.058067787,0.17710565,0.0014828604,0.0007579817,0.00003384955,0.0023758325,0.0018648043,0.028759,0.011315331,0.4045919,0.0013820571],"about_ca_topic_score_codex":0.0003924233,"about_ca_topic_score_gemma":0.00039960147,"teacher_disagreement_score":0.65221703,"about_ca_system_score_codex":0.00009133323,"about_ca_system_score_gemma":0.00035119383,"threshold_uncertainty_score":0.71580756},"labels":[],"label_agreement":null},{"id":"W4239051461","doi":"10.1093/annonc/mdy192","title":"4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Oncology; Consensus conference; Medical physics; Cancer; Family medicine; Internal medicine","score_opus":0.1732144412306442,"score_gpt":0.5044417495037564,"score_spread":0.3312273082731122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239051461","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42829055,0.0036831053,0.0043884674,0.5386152,0.0048503843,0.0014604903,0.0011334703,0.00019594963,0.017382389],"genre_scores_gemma":[0.9264634,0.00070455426,0.037585355,0.02789001,0.0035547926,0.0002300996,0.000053049178,0.000063657935,0.0034550305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987555,0.000024674284,0.00046328883,0.00027752935,0.00017629623,0.000302688],"domain_scores_gemma":[0.9957973,0.0001627991,0.00028808642,0.00022985782,0.0034166703,0.00010529627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021996052,0.00015511908,0.00044477012,0.000114963,0.0000537767,0.000003237762,0.00015657135,0.000120407836,0.0005638584],"category_scores_gemma":[0.00033413505,0.00013431528,0.00012288231,0.0001109935,0.00045818582,0.0000604044,0.00004703774,0.00008927345,0.000015609718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007613084,0.00027914692,0.0027441785,0.00005978198,0.00049474416,0.000015143754,0.00023787949,0.00007795763,0.020901538,0.0011611584,0.06715311,0.89926225],"study_design_scores_gemma":[0.0051958403,0.0020204545,0.008253811,0.00015897595,0.00006097885,0.00030131667,0.00027859156,0.0003031187,0.020321958,0.0022413689,0.9606933,0.00017028948],"about_ca_topic_score_codex":0.00012287141,"about_ca_topic_score_gemma":0.0001589154,"teacher_disagreement_score":0.89909196,"about_ca_system_score_codex":0.00008342386,"about_ca_system_score_gemma":0.00041013784,"threshold_uncertainty_score":0.61738545},"labels":[],"label_agreement":null},{"id":"W4241442457","doi":"10.1093/annonc/mdw589.007","title":"410P Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Ipilimumab; Metastatic melanoma; Oncology; Internal medicine; Melanoma; Safety profile; Adverse effect; Cancer research; Cancer; Immunotherapy","score_opus":0.08230944959589033,"score_gpt":0.40613393726275415,"score_spread":0.32382448766686384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241442457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97654665,0.00045403023,0.000008374836,0.013259042,0.00003807121,0.0006193606,0.000012339248,0.000010710293,0.009051429],"genre_scores_gemma":[0.9949755,0.00062423944,0.00046800368,0.00042885437,0.0000366237,0.000035815578,0.0000054896996,0.000017252694,0.0034082027],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985326,0.00025708985,0.00041600238,0.00025063343,0.00018032448,0.00036333568],"domain_scores_gemma":[0.99860024,0.0007980261,0.00007907337,0.00031979752,0.00008841091,0.000114443574],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010200822,0.000110841,0.0005579055,0.0002971559,0.000012226732,0.0000023822595,0.00012138927,0.000104729326,0.00196995],"category_scores_gemma":[0.00044297279,0.00007644503,0.000047625505,0.0002476129,0.0002163412,0.000053839925,0.000095787975,0.00017774188,0.00003215124],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059002535,0.0009037752,0.022693869,0.00010089722,0.000088954985,0.0002938234,0.0017820997,7.4751733e-7,0.14216585,0.00012081193,0.0013063648,0.82464254],"study_design_scores_gemma":[0.048351698,0.018113568,0.71001136,0.00064345193,0.00005756128,0.00027385628,0.0027644937,0.00007159901,0.09431571,0.002457305,0.12253301,0.00040639596],"about_ca_topic_score_codex":0.00030909042,"about_ca_topic_score_gemma":0.0016396382,"teacher_disagreement_score":0.82423615,"about_ca_system_score_codex":0.00008648447,"about_ca_system_score_gemma":0.0004269467,"threshold_uncertainty_score":0.9989424},"labels":[],"label_agreement":null},{"id":"W4241519036","doi":"10.1016/j.annonc.2020.01.049","title":"1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Population; Tolerability; Agonist; Oncology; Head and neck cancer; Gastroenterology; Cancer; Receptor; Adverse effect; Immunotherapy","score_opus":0.05711588904831182,"score_gpt":0.3158570011451614,"score_spread":0.2587411120968496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241519036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872644,0.0037240994,0.0000027396884,0.0055821054,0.00010164331,0.0007795957,0.00010188533,0.000031915435,0.0024116149],"genre_scores_gemma":[0.99617136,0.0008885411,0.00024133433,0.0021941562,0.00008621309,0.000024737585,0.0002602179,0.000035972775,0.00009745702],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99799216,0.00018692091,0.00063408696,0.00060604163,0.0002598189,0.0003209703],"domain_scores_gemma":[0.99866694,0.00029351594,0.00036659217,0.00029217178,0.0001487209,0.00023206323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003443151,0.00026277572,0.0007244339,0.0001747865,0.00007582673,0.0000142314475,0.00009698923,0.00036422597,0.000044159813],"category_scores_gemma":[0.000070336275,0.00023869099,0.000058371657,0.00025733717,0.0002705048,0.000141552,0.00006510721,0.0003662809,0.0000047561393],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3077824,0.0043803523,0.18010584,0.0008880041,0.00015758812,0.0007064392,0.017037444,0.00005838141,0.40926248,0.000011541667,0.03550191,0.044107627],"study_design_scores_gemma":[0.055144344,0.050241273,0.6692207,0.00022800795,0.000121357865,0.00005524743,0.0010372732,0.00051004527,0.21182762,0.00003400544,0.011147031,0.0004331127],"about_ca_topic_score_codex":0.00207564,"about_ca_topic_score_gemma":0.00014706378,"teacher_disagreement_score":0.48911485,"about_ca_system_score_codex":0.000080668964,"about_ca_system_score_gemma":0.00044483025,"threshold_uncertainty_score":0.9733536},"labels":[],"label_agreement":null},{"id":"W4241752191","doi":"10.1093/annonc/mdv338.01","title":"Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Hazard ratio; GiST; Randomization; Placebo; Gastroenterology; Randomized controlled trial; Response Evaluation Criteria in Solid Tumors; Sunitinib; Surrogate endpoint; Progression-free survival; Phases of clinical research; Surgery; Confidence interval; Cancer; Clinical trial; Colorectal cancer; Pathology; Chemotherapy; Stromal cell","score_opus":0.14019568591821685,"score_gpt":0.4138674545474313,"score_spread":0.27367176862921444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241752191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929881,0.00016358618,0.000035760604,0.0004840617,0.00003234489,0.005878286,0.00006659085,0.000019410576,0.0003318592],"genre_scores_gemma":[0.9845965,0.0000237451,0.0146047,0.00002634995,0.000074479256,0.00038582666,0.00010600864,0.00003505655,0.00014734217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99661845,0.0007089405,0.0009696719,0.00045617783,0.00059814565,0.00064859155],"domain_scores_gemma":[0.996887,0.0008637357,0.00081470393,0.00026585508,0.0006098453,0.00055881945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012560791,0.00038453753,0.0020304122,0.00032327446,0.000079628764,0.000026694735,0.000086435524,0.000034059485,0.000035649286],"category_scores_gemma":[0.001183799,0.00021927798,0.00011365671,0.00026282642,0.0010097834,0.00014773407,0.00008374393,0.00019953263,0.0000012728559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9672181,0.0098817,0.010650201,0.00015432898,0.00032502133,0.0017372982,0.00035565655,0.000004761912,0.00010822782,0.000018038107,0.00004597793,0.009500676],"study_design_scores_gemma":[0.7035771,0.29208884,0.0005507416,0.0005836145,0.00034631116,0.0014045035,0.0003571784,0.00017051914,0.00073909503,0.000015278018,0.0000562292,0.0001106115],"about_ca_topic_score_codex":0.00041771616,"about_ca_topic_score_gemma":0.00031381688,"teacher_disagreement_score":0.28220713,"about_ca_system_score_codex":0.00019667008,"about_ca_system_score_gemma":0.0012913379,"threshold_uncertainty_score":0.89418966},"labels":[],"label_agreement":null},{"id":"W4242642633","doi":"10.1093/annonc/mdw525.48","title":"KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Docetaxel; Regimen; Internal medicine; Oncology; Gemcitabine; Capecitabine; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Response Evaluation Criteria in Solid Tumors; Cancer; Immunotherapy; Colorectal cancer","score_opus":0.13726529517948816,"score_gpt":0.4518815340261645,"score_spread":0.31461623884667633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242642633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332076,0.0025028996,0.000003879696,0.0011765645,0.00023508871,0.0007737833,0.00014286634,0.000012196171,0.0018319456],"genre_scores_gemma":[0.9984586,0.0011411586,0.00013520794,0.00009127377,0.000047190275,0.000046728914,0.0000069540074,0.000020375173,0.00005248419],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9982277,0.00016666757,0.0007160943,0.00028066465,0.00031110365,0.00029774985],"domain_scores_gemma":[0.99832773,0.0005114345,0.00032912148,0.00029868548,0.00043885162,0.00009417483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025570067,0.00019644764,0.0014424872,0.00023141471,0.000023949136,0.0000011095763,0.00012074324,0.00008280113,0.00021779117],"category_scores_gemma":[0.00026657598,0.00012218044,0.00011775126,0.00028072885,0.00017624347,0.000052210657,0.000049755683,0.00011669395,0.0000021924595],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3446955,0.009321997,0.017861966,0.00065106637,0.00092506746,0.0003705021,0.015809033,0.0000011525293,0.0027872864,0.000043875745,0.0024023247,0.60513026],"study_design_scores_gemma":[0.36296618,0.5128974,0.03842203,0.0008466881,0.0004534971,0.00002665337,0.012039667,0.000015957568,0.063480176,0.000048562673,0.0084841205,0.0003190864],"about_ca_topic_score_codex":0.00013867601,"about_ca_topic_score_gemma":0.00072674244,"teacher_disagreement_score":0.60481113,"about_ca_system_score_codex":0.0001339471,"about_ca_system_score_gemma":0.0005475169,"threshold_uncertainty_score":0.4982374},"labels":[],"label_agreement":null},{"id":"W4242982914","doi":"10.1093/annonc/mdv341.13","title":"Era 223-A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapynaïve patients with bone-predominant metastatic Castration Resistant Prostate Cancer (Crpc)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Internal medicine; Denosumab; Prednisone; Clinical endpoint; Chemotherapy regimen; Placebo; Interim analysis; Progression-free survival; Asymptomatic; Gastroenterology; Prostate cancer; Surgery; Urology; Chemotherapy; Randomized controlled trial; Cancer; Osteoporosis; Androgen deprivation therapy; Pathology","score_opus":0.08184937363807175,"score_gpt":0.40479581516109653,"score_spread":0.32294644152302476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242982914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447453,0.00033363068,0.000023144128,0.002284846,0.000018966748,0.0027138726,0.00006989486,0.0000070361016,0.0000740522],"genre_scores_gemma":[0.998116,0.00050283765,0.0006104199,0.00007979666,0.000016185633,0.0005439347,0.000059817943,0.000016260647,0.000054751836],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998315,0.00016438372,0.0007499103,0.00022911176,0.00031777774,0.00022381831],"domain_scores_gemma":[0.998648,0.00023749743,0.00054770685,0.00023501064,0.00022750002,0.00010429237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045581808,0.0001941579,0.00074936345,0.00010687785,0.000024824112,0.000006702934,0.00007586138,0.00006458644,0.000010885206],"category_scores_gemma":[0.00005349382,0.000109516135,0.000037435646,0.00034117527,0.00027824676,0.00009585393,0.000006838801,0.00009462901,3.3874585e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68736994,0.09564565,0.015008555,0.0027135417,0.0014118549,0.00019549321,0.035226986,0.0003303688,0.071686395,0.00018555054,0.0002357349,0.08998991],"study_design_scores_gemma":[0.6578995,0.09287223,0.029904895,0.000836516,0.00092176604,0.000057247777,0.0018494839,0.003172407,0.21131738,0.00036759747,0.0004687917,0.0003322212],"about_ca_topic_score_codex":0.0002144887,"about_ca_topic_score_gemma":0.00023443128,"teacher_disagreement_score":0.13963097,"about_ca_system_score_codex":0.00012695762,"about_ca_system_score_gemma":0.000388693,"threshold_uncertainty_score":0.44659385},"labels":[],"label_agreement":null},{"id":"W4243637855","doi":"10.1016/j.annonc.2020.08.518","title":"407P Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for high-risk stage II colon cancer: ACHIEVE-2 as part of the IDEA collaboration","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; European Society for Medical Oncology; BeiGene; Genentech; Les Laboratories Pierre Fabre; FibroGen; Eli Lilly and Company; Servier; Instituto de Salud Carlos III; Amgen","keywords":"Medicine; Oxaliplatin; FOLFOX; Incidence (geometry); Colorectal cancer; Surgery; Stage (stratigraphy); Internal medicine; Cancer; Randomization; Gastroenterology; Randomized controlled trial","score_opus":0.04931255489397637,"score_gpt":0.3929471690141371,"score_spread":0.3436346141201608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243637855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98556834,0.0007915965,0.000011177102,0.010448087,0.0003773127,0.0018735845,0.00079467834,0.000014768483,0.00012045428],"genre_scores_gemma":[0.9956782,0.0010916262,0.00007051164,0.0024054921,0.00018623254,0.0001560708,0.000051926458,0.000029438954,0.00033053212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982718,0.00041639857,0.0006245152,0.0002574762,0.00021097009,0.00021882774],"domain_scores_gemma":[0.9976263,0.0006469525,0.0010150298,0.00022304684,0.00039855618,0.00009010723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030606982,0.00020616052,0.0010495876,0.000057338835,0.00006120633,0.0000017616453,0.00014260228,0.00016449187,0.000389174],"category_scores_gemma":[0.00019306848,0.00013873295,0.00021268653,0.000288071,0.0002703912,0.00003827738,0.000033774715,0.00014427358,4.9217766e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13043833,0.0021432727,0.18790352,0.0020556832,0.0012174346,0.000050209423,0.0034902631,0.0016131666,0.60340184,0.00006989528,0.008510512,0.05910591],"study_design_scores_gemma":[0.019063875,0.09012681,0.058798984,0.00011497061,0.00072234136,0.0000035083185,0.00007349176,0.0007437655,0.8213866,0.000010567106,0.008820181,0.0001349183],"about_ca_topic_score_codex":0.0005195358,"about_ca_topic_score_gemma":0.0006775585,"teacher_disagreement_score":0.21798477,"about_ca_system_score_codex":0.000060794744,"about_ca_system_score_gemma":0.0008516496,"threshold_uncertainty_score":0.56573653},"labels":[],"label_agreement":null},{"id":"W4243694231","doi":"10.1093/annonc/mdv050.06","title":"A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Veliparib; Carboplatin; Internal medicine; PARP inhibitor; Lung cancer; Neutropenia; Oncology; Clinical endpoint; Gastroenterology; Randomized controlled trial; Chemotherapy; Cisplatin","score_opus":0.1672549693496572,"score_gpt":0.46000483917913826,"score_spread":0.29274986982948104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243694231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987361,0.004039028,0.00017212251,0.0011004488,0.00015999597,0.004372486,0.00004686032,0.000016896855,0.0027311316],"genre_scores_gemma":[0.9937469,0.002241317,0.0018460088,0.00050746603,0.00009103512,0.0011159524,0.00003540768,0.000033511584,0.00038243775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997761,0.00035204247,0.0009476595,0.0003304018,0.0002618803,0.0003470021],"domain_scores_gemma":[0.99767095,0.0006052846,0.0007199841,0.00027179252,0.00050315645,0.00022883309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013426131,0.00024386818,0.0018152375,0.00028086497,0.000017524655,0.0000050261638,0.00008970271,0.00014266685,0.000088799265],"category_scores_gemma":[0.00018208746,0.00016912507,0.000106677355,0.0004111861,0.00032308992,0.000090268244,0.000026285798,0.00021824511,0.0000012003609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9847027,0.0014665249,0.00034751263,0.0003300069,0.00040802112,0.00010491086,0.0032210746,0.00023754715,0.0017083804,0.000025156172,0.0005448405,0.006903324],"study_design_scores_gemma":[0.96373403,0.0129957935,0.000022482025,0.00041194612,0.0005085026,0.00003341462,0.00043312044,0.0005378849,0.019972136,0.000071023765,0.001116504,0.00016314881],"about_ca_topic_score_codex":0.0012675765,"about_ca_topic_score_gemma":0.0010919166,"teacher_disagreement_score":0.020968657,"about_ca_system_score_codex":0.00011142501,"about_ca_system_score_gemma":0.0017531489,"threshold_uncertainty_score":0.689672},"labels":[],"label_agreement":null},{"id":"W4244716210","doi":"10.1093/annonc/mdr418","title":"The impact of the process of clinical research on health service outcomes","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; King's Health Partners; Universität Heidelberg; National Institute for Health and Care Research; University of Toronto; World Health Organization","keywords":"Medicine; Process (computing); Process management; Gerontology; Family medicine","score_opus":0.8752344519374818,"score_gpt":0.7573931407040145,"score_spread":0.1178413112334673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244716210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.828626,0.00021178088,7.9715704e-7,0.1549089,0.00009894946,0.0006275349,0.000011759007,0.0000039375886,0.015510355],"genre_scores_gemma":[0.98734707,0.0013927087,0.000023443268,0.010981622,0.00007010181,0.000012683128,0.0000011384557,0.000008652874,0.00016260539],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958017,0.0013247961,0.00095726654,0.00015035544,0.000915943,0.000849946],"domain_scores_gemma":[0.9897068,0.0052523455,0.00051287416,0.0006965661,0.0018856431,0.0019457688],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017215729,0.000080136335,0.0007099068,0.00010144432,0.00009102766,0.0000011233474,0.00041355303,0.00017525487,0.00009097113],"category_scores_gemma":[0.058530834,0.000032587734,0.00021845622,0.00051599595,0.0007514174,0.000023645163,0.000094359304,0.0008735268,0.000012236618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009772675,0.0053520305,0.29294458,0.0016269119,0.00039551675,0.000016603686,0.0049697864,0.0000021749308,0.00010863196,0.0014795598,0.17435497,0.5089766],"study_design_scores_gemma":[0.0017834015,0.030797856,0.94857967,0.00031025376,0.000007353008,0.000007392711,0.0008293225,0.000026784186,0.0014530766,0.0016046029,0.014567046,0.000033217577],"about_ca_topic_score_codex":0.0033743226,"about_ca_topic_score_gemma":0.00029470117,"teacher_disagreement_score":0.6556351,"about_ca_system_score_codex":0.00005131001,"about_ca_system_score_gemma":0.02054673,"threshold_uncertainty_score":0.98500586},"labels":[],"label_agreement":null},{"id":"W4245473243","doi":"10.1093/annonc/mdy483.002","title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Oncology; Internal medicine; Clinical endpoint; Ovarian cancer; Placebo; BRCA mutation; Hazard ratio; Progression-free survival; Chemotherapy; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.04305060990265014,"score_gpt":0.3968295337381739,"score_spread":0.3537789238355238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245473243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916055,0.0001729473,0.0007742129,0.0043505556,0.00041677523,0.0015328241,0.000034887635,0.000038810165,0.001073447],"genre_scores_gemma":[0.9902874,0.00017405143,0.0018429491,0.006897588,0.00026029363,0.00037714106,0.00005419895,0.00003947336,0.00006690777],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981112,0.00012909912,0.00061206915,0.0004400945,0.0002832232,0.00042432215],"domain_scores_gemma":[0.9985023,0.00027495684,0.00046648417,0.00025630477,0.00036073916,0.00013921285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039948957,0.00023582164,0.00073827576,0.00021838576,0.000073570096,0.000009684626,0.00009369526,0.00019954832,0.00018732689],"category_scores_gemma":[0.00016202491,0.00020507228,0.00008837688,0.0003675781,0.0002928259,0.00017331344,0.00001360122,0.000204612,0.0000032478772],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3122214,0.0038629519,0.014894521,0.00008304753,0.00036084454,0.0002018734,0.0039252727,0.00009495015,0.009361549,0.00011813426,0.0033209743,0.65155447],"study_design_scores_gemma":[0.90735966,0.034193106,0.018964352,0.0006646558,0.000076257726,0.000010516459,0.00023627398,0.00079097773,0.024511669,0.0002942486,0.012551247,0.00034701842],"about_ca_topic_score_codex":0.00044702302,"about_ca_topic_score_gemma":0.00077641616,"teacher_disagreement_score":0.65120745,"about_ca_system_score_codex":0.000193399,"about_ca_system_score_gemma":0.0006272193,"threshold_uncertainty_score":0.8362605},"labels":[],"label_agreement":null},{"id":"W4246209348","doi":"10.1093/annonc/mdz100.017","title":"Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Letrozole; Neutropenia; Internal medicine; Common Terminology Criteria for Adverse Events; QT interval; Fulvestrant; Breast cancer; Surgery; Tamoxifen; Cancer; Oncology; Chemotherapy","score_opus":0.04222964193277495,"score_gpt":0.40370793800425586,"score_spread":0.3614782960714809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246209348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744428,0.004508491,0.00017339516,0.017508848,0.00019960463,0.0007431111,0.00033793293,0.000041668085,0.0020441473],"genre_scores_gemma":[0.9864622,0.00910455,0.00057091203,0.0029523121,0.000078889956,0.00007698754,0.00009658195,0.000045421566,0.0006121541],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975478,0.00015579455,0.00094345916,0.00048624526,0.0003412557,0.0005254218],"domain_scores_gemma":[0.9976876,0.00038244834,0.0006117506,0.00062864996,0.0005539493,0.00013565137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004182792,0.00030632835,0.0018783879,0.00062350853,0.000027167824,0.0000027995468,0.00024790506,0.00016642948,0.0022056517],"category_scores_gemma":[0.00005970527,0.00026406487,0.00038788683,0.0014066598,0.00022096171,0.00018631485,0.00007770828,0.0003120284,0.000010370547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03438798,0.0020298741,0.29120705,0.0002836057,0.0067337314,0.0000947045,0.002163765,0.03921636,0.032612085,0.0007438734,0.00013999126,0.590387],"study_design_scores_gemma":[0.024151884,0.0037160038,0.8692198,0.00034411994,0.00071792427,0.00007604889,0.00054228486,0.0019327241,0.015705565,0.0004816766,0.08265498,0.00045697993],"about_ca_topic_score_codex":0.0014391403,"about_ca_topic_score_gemma":0.0029305553,"teacher_disagreement_score":0.58993,"about_ca_system_score_codex":0.00027331553,"about_ca_system_score_gemma":0.00045509895,"threshold_uncertainty_score":0.99998116},"labels":[],"label_agreement":null},{"id":"W4246797495","doi":"10.1016/j.annonc.2020.10.024","title":"3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"EMD Serono; Samsung; Genentech; PharmaMar; Chugai Pharmaceutical; Vifor Pharma; Astellas Pharma; Eisai; Bayer HealthCare; G1 Therapeutics; Silverback Therapeutics; OncoSec Medical; Mersana Therapeutics; Amgen; Radius Health; Syndax Pharmaceuticals; Queen Mary University of London; Clovis Oncology; Daiichi Sankyo Europe; Servier; Calithera Biosciences; Mylan; MacroGenics; Celldex Therapeutics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Ariad Pharmaceuticals; Exelixis; Sanofi; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Baxalta; Flatiron Health; Genomic Health; GlaxoSmithKline","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Breast cancer; Cyclophosphamide; Triple-negative breast cancer; Oncology; Placebo; Phases of clinical research; Neoadjuvant therapy; Gastroenterology; Chemotherapy; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Nivolumab","score_opus":0.11921368673131624,"score_gpt":0.4494909992734035,"score_spread":0.33027731254208725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246797495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754666,0.00045871225,0.000001763531,0.020045053,0.0002524827,0.001213487,0.0010677633,0.00002553076,0.0014685944],"genre_scores_gemma":[0.9968943,0.0005473163,0.00004842601,0.0017681904,0.0003277795,0.00013365736,0.000073768475,0.000023339462,0.00018319584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976885,0.00022054499,0.0009764919,0.0004941886,0.0002536824,0.00036664074],"domain_scores_gemma":[0.9982581,0.00036159757,0.00056976144,0.0002447183,0.0002974641,0.0002683696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019934776,0.00025271322,0.0012964768,0.00017178772,0.000032901924,0.0000033226067,0.000174501,0.00019798963,0.0007669186],"category_scores_gemma":[0.00011922003,0.00021030688,0.0001516631,0.00048795418,0.00015506413,0.00008638656,0.00010021246,0.00033780144,0.000012176141],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34958932,0.045860652,0.037079535,0.0001407904,0.0031874313,0.003002713,0.11106626,0.00009397476,0.06158196,0.000020185118,0.071334675,0.3170425],"study_design_scores_gemma":[0.41050848,0.09661481,0.4077489,0.00031408694,0.0011087464,0.0000548599,0.006377992,0.0006758978,0.063391745,0.0001719691,0.012486577,0.0005459048],"about_ca_topic_score_codex":0.02496044,"about_ca_topic_score_gemma":0.0021490406,"teacher_disagreement_score":0.3706694,"about_ca_system_score_codex":0.00014200846,"about_ca_system_score_gemma":0.00061898364,"threshold_uncertainty_score":0.98153245},"labels":[],"label_agreement":null},{"id":"W4247536710","doi":"10.1093/annonc/mdx805","title":"correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","year":2018,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation; Yale University; U.S. Department of Health and Human Services","keywords":"Medicine; Exome; Gene; Exome sequencing; Genetics; Oncology; Targeted therapy; Mutation; Bioinformatics; Cancer; Computational biology; Internal medicine; Biology","score_opus":0.06637428006091202,"score_gpt":0.35058617539828535,"score_spread":0.28421189533737334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247536710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492329,0.0029853662,0.00062931183,0.011917197,0.026021747,0.0023810193,0.0010101068,0.000013410918,0.0058089467],"genre_scores_gemma":[0.938501,0.002553687,0.0009016177,0.010288089,0.007576839,0.0013786663,0.0024910164,0.00013883728,0.036170255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979807,0.0006078251,0.0005309967,0.00042197888,0.0001471287,0.00031133648],"domain_scores_gemma":[0.9986235,0.00035339213,0.0002166696,0.00044779206,0.0002857038,0.00007296075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009271973,0.00023416559,0.00037513155,0.00027408832,0.000078047146,0.000036042446,0.00034811546,0.00046030388,0.000033190438],"category_scores_gemma":[0.001415223,0.0002053302,0.0001311786,0.00030361107,0.00010320751,0.0000045981787,0.00009793141,0.00024606904,0.000011341814],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015100151,0.00069367903,0.00009269078,0.000010127951,0.000074599506,0.000012203623,0.0029512423,0.00047689799,0.046463,0.0000151359845,0.9241738,0.009936526],"study_design_scores_gemma":[0.0031243882,0.011956454,0.0034073603,0.00006151913,0.000016987533,0.000008110478,0.0005728405,0.000030313635,0.011802474,0.00011984179,0.9686569,0.00024279795],"about_ca_topic_score_codex":0.0005473764,"about_ca_topic_score_gemma":0.024349129,"teacher_disagreement_score":0.04448317,"about_ca_system_score_codex":0.000064516054,"about_ca_system_score_gemma":0.0011525607,"threshold_uncertainty_score":0.993454},"labels":[],"label_agreement":null},{"id":"W4247542270","doi":"10.1016/j.annonc.2020.08.978","title":"839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; Eisai; Astellas Pharma; Amgen; Deciphera Pharmaceuticals; Agios Pharmaceuticals; Foundation Medicine; Sierra Oncology; Pfizer; Innovent Biologics; Symphogen; Incyte; Taiho Pharmaceutical; Jazz Pharmaceuticals; Ipsen; Five Prime Therapeutics; Plexxikon; Clovis Oncology; IFM Therapeutics; Valeant Pharmaceuticals International; Vertex Pharmaceuticals; Carrick Therapeutics; Bristol-Myers Squibb; AstraZeneca; Astex Pharmaceuticals","keywords":"Medicine; Internal medicine; Regimen; Paclitaxel; Carboplatin; Ovarian cancer; Oncology; Chemotherapy; Cancer; Metastatic breast cancer; Gastroenterology; Breast cancer; Urology; Surgery; Cisplatin","score_opus":0.12263221873016754,"score_gpt":0.43078950651568065,"score_spread":0.3081572877855131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247542270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549323,0.0024773343,0.000061575076,0.0011742391,0.0000469785,0.00035668953,0.00011215707,0.0000034182212,0.0002743596],"genre_scores_gemma":[0.997344,0.0008023398,0.00064252724,0.0009759569,0.000061736224,0.00007108776,0.000014360309,0.00001559504,0.000072353025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880487,0.00012446285,0.00045175155,0.00032118958,0.000098394295,0.0001993591],"domain_scores_gemma":[0.9993129,0.0000497844,0.00025790863,0.0001690311,0.00012137475,0.00008900422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021926436,0.0001379037,0.00044255564,0.000044514523,0.000033219625,0.0000025264062,0.00012633197,0.00008374741,0.00007655607],"category_scores_gemma":[0.00018398209,0.000113695714,0.000052985786,0.00016236513,0.00009025005,0.0000049900887,0.00012390187,0.0000615112,3.5128284e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011606553,0.0025584863,0.0045514023,0.00017529364,0.00045211488,0.000065927525,0.003062371,0.0002636835,0.86867565,0.00008814003,0.002914265,0.10558614],"study_design_scores_gemma":[0.05088332,0.22377923,0.031521432,0.00023992144,0.00044653178,0.00002635786,0.0150350435,0.0006143633,0.4081482,0.00022728344,0.2678549,0.0012234048],"about_ca_topic_score_codex":0.00022994269,"about_ca_topic_score_gemma":0.00089459674,"teacher_disagreement_score":0.46052742,"about_ca_system_score_codex":0.000007283874,"about_ca_system_score_gemma":0.0002166521,"threshold_uncertainty_score":0.46363765},"labels":[],"label_agreement":null},{"id":"W4247602503","doi":"10.1093/annonc/mdw585.005","title":"301O Exploring perceptions of cervical cancer in Dhaka, Bangladesh","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Toronto Metropolitan University; St. Michael's Hospital","funders":"","keywords":"Medicine; Cervical cancer; Cancer; Family medicine; Internal medicine","score_opus":0.3319224289429548,"score_gpt":0.46415436078624056,"score_spread":0.13223193184328574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247602503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808998,0.00046182814,0.000055261098,0.011056182,0.00011766262,0.000094772746,0.000017381428,0.000009814728,0.0072873067],"genre_scores_gemma":[0.9971328,0.0014738627,0.00024852582,0.00082224846,0.0001270643,0.000040510367,0.0000011475084,0.000006705177,0.00014716173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991267,0.000042856074,0.00031615648,0.00014215613,0.0001539423,0.00021821987],"domain_scores_gemma":[0.99938744,0.00010871156,0.00009172803,0.00014962407,0.00018101902,0.00008145395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022898059,0.0000695044,0.000348434,0.00011457076,0.000012682211,8.3560803e-7,0.000085868094,0.00009543251,0.001524132],"category_scores_gemma":[0.00011391415,0.00004946157,0.00008257264,0.000168364,0.00012201383,0.000105033265,0.000039537754,0.000089039306,0.000016953816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005315019,0.00021387082,0.60552627,0.000072543255,0.00005126008,0.00005626219,0.000984023,0.00001808576,0.047889743,0.0009170195,0.005046626,0.33869278],"study_design_scores_gemma":[0.0015294306,0.0015498743,0.9664781,0.0006105918,0.000031806987,0.000023932262,0.0011611233,0.000013573141,0.013569107,0.00042114174,0.014518327,0.000092953866],"about_ca_topic_score_codex":0.00082344265,"about_ca_topic_score_gemma":0.00084321434,"teacher_disagreement_score":0.36095184,"about_ca_system_score_codex":0.000057372457,"about_ca_system_score_gemma":0.00020415633,"threshold_uncertainty_score":0.99938864},"labels":[],"label_agreement":null},{"id":"W4247715549","doi":"10.1093/annonc/mdw587.036","title":"394TiP KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Oncology; Internal medicine; Platinum; Standard of care; Nasopharyngeal carcinoma; Phases of clinical research; Carcinoma; Radiation therapy; Cancer; Immunotherapy","score_opus":0.13968135926207415,"score_gpt":0.45143079712999923,"score_spread":0.3117494378679251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247715549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931736,0.0026308412,0.0000042480506,0.0011186793,0.00025058378,0.00082717976,0.00015130048,0.000013548475,0.0018300487],"genre_scores_gemma":[0.9984424,0.0011225694,0.00014097708,0.00010239979,0.000052129766,0.000051548726,0.000007833721,0.000022539818,0.00005758207],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99809474,0.000182514,0.00076246413,0.0003031946,0.00033421224,0.00032289035],"domain_scores_gemma":[0.99820054,0.0005590311,0.0003529399,0.00032139328,0.0004631018,0.000102975544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027873836,0.00021338683,0.0015237476,0.00024766877,0.00002643757,0.000001273171,0.00013172484,0.000090592504,0.0002263301],"category_scores_gemma":[0.0002866669,0.00013376425,0.0001275364,0.00030106673,0.00018706702,0.000056427933,0.000053714066,0.00012774888,0.0000024717822],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3537874,0.009769507,0.022749437,0.0007102083,0.0010051725,0.00040485262,0.016309336,0.0000013249178,0.0030258223,0.00004266669,0.0029347353,0.5892595],"study_design_scores_gemma":[0.36238876,0.5121563,0.0436489,0.00091403956,0.0004916233,0.000030151048,0.012189258,0.000017887309,0.058708943,0.000052961957,0.009047726,0.0003534512],"about_ca_topic_score_codex":0.00016061062,"about_ca_topic_score_gemma":0.00071662694,"teacher_disagreement_score":0.5889061,"about_ca_system_score_codex":0.0001450104,"about_ca_system_score_gemma":0.0005805757,"threshold_uncertainty_score":0.54547477},"labels":[],"label_agreement":null},{"id":"W4247733065","doi":"10.1093/annonc/mdw372.35","title":"Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Radium-223; Asymptomatic; Alkaline phosphatase; Oncology; Urology; Cancer; Confidence interval; Bone metastasis","score_opus":0.08434164852863081,"score_gpt":0.4334290861282512,"score_spread":0.3490874375996204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247733065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933734,0.00007200622,0.0000030603296,0.0052161,0.000021831573,0.00072582974,0.00036952953,0.000011797993,0.00020642782],"genre_scores_gemma":[0.9983417,0.0005464634,0.00016320916,0.00019814081,0.000022463097,0.0003539948,0.00028603373,0.000011657301,0.000076347394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989622,0.00006396189,0.00032858213,0.00026542874,0.00014978764,0.00023001105],"domain_scores_gemma":[0.99937195,0.0000992302,0.00013829044,0.00012068409,0.00015190603,0.00011794537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019247885,0.0001280186,0.0003144489,0.00011890178,0.000013651999,0.000013264652,0.00010928349,0.00006480449,0.000060180024],"category_scores_gemma":[0.000049138624,0.00009112476,0.000015700703,0.0002248798,0.00013949233,0.00022726762,0.000026174654,0.0001194344,6.273654e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003921685,0.0030647826,0.88998586,0.000095095704,0.00006773355,0.0001285078,0.00022236133,0.000024037763,0.0067497417,0.00035056123,0.000026082245,0.09536356],"study_design_scores_gemma":[0.010896434,0.0019744444,0.9678765,0.00019599356,0.000038506318,0.0000061262876,0.000048215745,0.0012228928,0.016358253,0.000100953344,0.0011262647,0.00015545153],"about_ca_topic_score_codex":0.0010826763,"about_ca_topic_score_gemma":0.013817344,"teacher_disagreement_score":0.09520811,"about_ca_system_score_codex":0.0001265656,"about_ca_system_score_gemma":0.00012128473,"threshold_uncertainty_score":0.77104026},"labels":[],"label_agreement":null},{"id":"W4250523013","doi":"10.1016/j.annonc.2020.08.1139","title":"1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacodynamics; Immunogenicity; Tolerability; Adverse effect; Pharmacology; Pharmacokinetics; Oncology; Internal medicine; Antibody; Immunology","score_opus":0.14229690519594798,"score_gpt":0.45291356441973685,"score_spread":0.3106166592237889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250523013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826853,0.0030302855,0.000034695935,0.013188017,0.00010446685,0.0005676815,0.000028640603,0.000030220961,0.00033063986],"genre_scores_gemma":[0.9897058,0.007971925,0.00028801142,0.0018217624,0.0000580022,0.00001445525,0.00006269613,0.000026340067,0.000051027313],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982356,0.000167295,0.00066923094,0.00037449555,0.00025281153,0.00030055866],"domain_scores_gemma":[0.9987088,0.00019580362,0.0004002069,0.00023797258,0.0003319293,0.0001253195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055377686,0.00022426056,0.0012017256,0.0002377226,0.00005049042,0.000006902329,0.00012939754,0.000162218,0.00008257504],"category_scores_gemma":[0.00015883401,0.0001669766,0.000080504644,0.00056389824,0.00058274507,0.00018650417,0.000063143874,0.00018095932,0.0000020532862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04474755,0.007245228,0.1041392,0.0021385266,0.0022683812,0.0009360677,0.007902158,0.000034962908,0.743052,0.00025668883,0.0041708043,0.08310841],"study_design_scores_gemma":[0.08972214,0.13219549,0.44154435,0.0018763418,0.0007580532,0.00056178146,0.010975547,0.0016719118,0.29968023,0.00016254779,0.01983139,0.0010202295],"about_ca_topic_score_codex":0.00017297668,"about_ca_topic_score_gemma":0.000112908645,"teacher_disagreement_score":0.4433718,"about_ca_system_score_codex":0.00003138691,"about_ca_system_score_gemma":0.0002784297,"threshold_uncertainty_score":0.6809108},"labels":[],"label_agreement":null},{"id":"W4250591910","doi":"10.1093/annonc/mdw594.008","title":"444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ceritinib; Anaplastic lymphoma kinase; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; ALK inhibitor; Lung cancer","score_opus":0.021542957625337634,"score_gpt":0.36154001526130375,"score_spread":0.3399970576359661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250591910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941886,0.00020082812,0.0000070936762,0.0005937039,0.0000355565,0.0044142352,0.000044843015,0.000025818597,0.00048928877],"genre_scores_gemma":[0.9987059,0.00023288516,0.00018341297,0.00021275306,0.000007233501,0.0005095584,0.00003947577,0.00004038384,0.000068370406],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99769515,0.00026078598,0.00092546036,0.00046454428,0.0002934332,0.0003606535],"domain_scores_gemma":[0.9980989,0.00040595824,0.0006716361,0.0003361041,0.00034382567,0.0001435926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002547171,0.00030810683,0.0016087672,0.00034577862,0.00003356571,0.0000049468103,0.00006834509,0.000047422865,0.000046146546],"category_scores_gemma":[0.0002763693,0.00017172523,0.00007999568,0.0003625188,0.00024598028,0.00014225362,0.000019996547,0.000073833886,7.848427e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27938765,0.015090026,0.50075257,0.000072679046,0.0008833772,0.0005749166,0.0019882054,0.000005010565,0.00016973836,0.0000056176964,0.00003146041,0.20103876],"study_design_scores_gemma":[0.6471728,0.052639984,0.29690212,0.00056840584,0.00042451028,0.000045909404,0.0007587139,0.000007263605,0.0010561286,0.000010218525,0.00023455662,0.00017936816],"about_ca_topic_score_codex":0.00091152237,"about_ca_topic_score_gemma":0.0010996734,"teacher_disagreement_score":0.36778516,"about_ca_system_score_codex":0.00013618541,"about_ca_system_score_gemma":0.00031193875,"threshold_uncertainty_score":0.7002752},"labels":[],"label_agreement":null},{"id":"W4251565026","doi":"10.1016/s0923-7534(21)00575-5","title":"417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Radionuclide therapy; Medicine; Capecitabine; Nuclear medicine; Neuroendocrine tumors; Internal medicine; Oncology; Cancer","score_opus":0.10643289759268099,"score_gpt":0.3886560436071487,"score_spread":0.28222314601446774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251565026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95676476,0.0006451975,0.000002354986,0.04202101,0.000046600588,0.000333699,0.000032839824,0.000003605517,0.000149946],"genre_scores_gemma":[0.996995,0.0015651856,0.0001009651,0.00076539244,0.000044498087,0.000008820367,0.0000054745774,0.000004878589,0.0005098261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988446,0.000274793,0.00028579918,0.00020280678,0.00020275934,0.00018922616],"domain_scores_gemma":[0.99862385,0.0007970503,0.00011704571,0.00016749292,0.00018165595,0.00011287924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050584436,0.000089341,0.00028529498,0.000056329332,0.000029719668,0.000005342405,0.000053973163,0.000012887368,0.00015370148],"category_scores_gemma":[0.0005146829,0.0000538318,0.000014753534,0.000119266,0.0003545484,0.00011353532,0.000031426083,0.00011359779,3.70772e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017589392,0.0001239516,0.8287812,0.00004998946,0.000024174484,0.000056624896,0.00021274095,3.2558822e-7,0.014324431,0.00004404824,0.107263796,0.0473598],"study_design_scores_gemma":[0.0024559835,0.0009653293,0.885172,0.000035996687,0.0000065611953,0.00016260751,0.000262735,0.000008928118,0.006089878,0.0007358585,0.10404952,0.000054618846],"about_ca_topic_score_codex":0.09683738,"about_ca_topic_score_gemma":0.23072492,"teacher_disagreement_score":0.13388753,"about_ca_system_score_codex":0.000027490709,"about_ca_system_score_gemma":0.0005241779,"threshold_uncertainty_score":0.9091769},"labels":[],"label_agreement":null},{"id":"W4251853166","doi":"10.1093/annonc/mdq399","title":"Misrepresentation","year":2010,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Park","funders":"","keywords":"Homeopathy; Medicine; Misrepresentation; Alternative medicine; Family medicine; Cancer; Scopus; Traditional medicine; Internal medicine; MEDLINE; Pathology; Law","score_opus":0.24818606228379628,"score_gpt":0.4964529131872663,"score_spread":0.24826685090347003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251853166","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024210652,0.00029357572,0.000014128964,0.9190787,0.0009338158,0.00027712027,0.000031777818,0.000016919048,0.055143278],"genre_scores_gemma":[0.014066403,0.0004615167,0.0003721213,0.96937186,0.009122087,0.000027663764,0.00053010473,0.00002192802,0.0060263486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989219,0.00006476535,0.0003379832,0.00022103668,0.0002395398,0.00021478302],"domain_scores_gemma":[0.998843,0.00033746936,0.00025396282,0.00024366601,0.0002843962,0.00003746959],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015424268,0.00015205769,0.0006343517,0.00016334337,0.000030172394,0.0000014877149,0.00010349809,0.00022867504,0.0012165868],"category_scores_gemma":[0.00019379656,0.000121869045,0.00015436887,0.000067644585,0.00023630368,0.00002085425,0.00006756175,0.0018548686,0.00003409547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060130613,0.00007444834,0.0022695784,0.00015635823,0.00028667174,0.0005674834,0.00014506977,3.587245e-8,0.00046862065,0.000021283919,0.9424362,0.053514127],"study_design_scores_gemma":[0.0007769566,0.0029049774,0.0036204585,0.00007042372,0.00013585098,0.000077406505,0.00007268434,0.0000012875237,0.0019461054,0.00041252535,0.98989785,0.00008345788],"about_ca_topic_score_codex":0.00011436758,"about_ca_topic_score_gemma":0.000023251338,"teacher_disagreement_score":0.05343067,"about_ca_system_score_codex":0.000011934722,"about_ca_system_score_gemma":0.00011435767,"threshold_uncertainty_score":0.99969643},"labels":[],"label_agreement":null},{"id":"W4253207701","doi":"10.1093/annonc/mdw576.001","title":"99O_PR Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Neoadjuvant therapy; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.025447014410178298,"score_gpt":0.346543612976686,"score_spread":0.32109659856650774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253207701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98019123,0.000076228614,0.00047053766,0.018097801,0.000027639151,0.0004585731,0.00014345857,0.00002196646,0.0005125865],"genre_scores_gemma":[0.9968506,0.0005495339,0.0016815595,0.00049776677,0.000022573113,0.00022860868,0.000010551083,0.000008671213,0.00015013493],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993182,0.000023558014,0.00026386563,0.00014397908,0.0001181908,0.00013219626],"domain_scores_gemma":[0.9993691,0.000042003063,0.00012285645,0.00018804273,0.00020118502,0.00007679945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007636754,0.000074885524,0.00026737363,0.000066830165,0.000006763133,4.5802273e-7,0.00004007149,0.000075196935,0.00014670353],"category_scores_gemma":[0.000019780415,0.000040424547,0.00003451739,0.00008914151,0.00013734795,0.00004142529,0.000015485697,0.00005083445,0.0000024077517],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002387559,0.00164562,0.43218106,0.000029108984,0.000049206836,0.000008989108,0.00008465263,0.0000015351059,0.0027278017,0.000085844615,0.001963076,0.5588355],"study_design_scores_gemma":[0.0056174067,0.0061328127,0.96270514,0.0006164321,0.00004837313,0.000007678007,0.0000103659695,0.000020543734,0.0056807525,0.00014083684,0.01896233,0.00005735154],"about_ca_topic_score_codex":0.000105904364,"about_ca_topic_score_gemma":0.00003444047,"teacher_disagreement_score":0.55877817,"about_ca_system_score_codex":0.00007734434,"about_ca_system_score_gemma":0.00015256622,"threshold_uncertainty_score":0.16484652},"labels":[],"label_agreement":null},{"id":"W4254889096","doi":"10.1093/annonc/mdw594.001","title":"437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04872773898541408,"score_gpt":0.35374730336662435,"score_spread":0.30501956438121025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254889096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96034414,0.0013206473,0.0037315576,0.030308086,0.00020812433,0.0026215815,0.00006346974,0.00012339646,0.001278983],"genre_scores_gemma":[0.9821324,0.0018283055,0.0024353478,0.011572393,0.00028768455,0.00047921584,0.000063235864,0.00010206403,0.001099388],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975145,0.00007132073,0.0007790111,0.0006086004,0.00040225426,0.0006243252],"domain_scores_gemma":[0.99753433,0.00036117062,0.00073249516,0.00058435404,0.0006158694,0.00017175889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052842573,0.00041719363,0.0009666395,0.00022191997,0.00012472784,0.000011473578,0.0002284255,0.0002752347,0.0006013115],"category_scores_gemma":[0.0001361968,0.0002583334,0.00036602493,0.0002932641,0.00044119827,0.0001569094,0.000017143184,0.00016731163,0.000016114485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43531093,0.0014182482,0.0027399866,0.00022909392,0.00048680662,0.000043864897,0.00025748953,0.000015248794,0.14664207,0.000076290286,0.002987445,0.4097925],"study_design_scores_gemma":[0.10519678,0.061569985,0.03641991,0.0010610401,0.0000970246,0.00022813497,0.00009262948,0.00013105132,0.49356022,0.0008028192,0.30020675,0.00063367526],"about_ca_topic_score_codex":0.00009884181,"about_ca_topic_score_gemma":0.00009586002,"teacher_disagreement_score":0.40915886,"about_ca_system_score_codex":0.00018408736,"about_ca_system_score_gemma":0.0011166363,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4255273450","doi":"10.1016/j.annonc.2020.10.349","title":"356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Chugai Pharmaceutical; Eli Lilly Japan; AstraZeneca; Eli Lilly and Company","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; Adjuvant; Hazard ratio; Discontinuation; Adenocarcinoma; Cancer; Confidence interval","score_opus":0.05058576355198821,"score_gpt":0.3667156560000392,"score_spread":0.316129892448051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255273450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825437,0.0010045391,0.000021228392,0.007559846,0.0001647587,0.0011652013,0.000121778794,0.00007145553,0.0016368476],"genre_scores_gemma":[0.9970327,0.00027475253,0.00010154163,0.002079052,0.000075472475,0.000088605564,0.00027167323,0.000028151222,0.00004807059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825764,0.00016145466,0.0004706221,0.0003842458,0.0002893243,0.00043670222],"domain_scores_gemma":[0.99860764,0.00007488051,0.00024917556,0.00024078488,0.0003889563,0.00043855587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007901529,0.00020837753,0.0005577463,0.00012567593,0.00005271159,0.0000081926,0.00012696178,0.000094184354,0.00006713693],"category_scores_gemma":[0.00011576542,0.00015091542,0.000085579704,0.000567492,0.00011254458,0.0000978509,0.000028589004,0.00018677021,0.000016657468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029871441,0.0044499757,0.6017961,0.0005290222,0.0009441378,0.0011397062,0.006197001,0.00031972834,0.0006310317,0.0002050397,0.009512015,0.34440482],"study_design_scores_gemma":[0.015475586,0.015223471,0.9560871,0.00053895864,0.00021706798,0.000008592,0.0005227877,0.00059332314,0.00097028964,0.000014383754,0.010109343,0.00023905902],"about_ca_topic_score_codex":0.00033479868,"about_ca_topic_score_gemma":0.00004997395,"teacher_disagreement_score":0.35429105,"about_ca_system_score_codex":0.00016924467,"about_ca_system_score_gemma":0.0007838293,"threshold_uncertainty_score":0.6154153},"labels":[],"label_agreement":null},{"id":"W4255513928","doi":"10.1093/annonc/mdx423.006","title":"Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Concomitant; Medicine; Denosumab; Prostate cancer; Internal medicine; Urology; Oncology; Bristol-Myers; Asymptomatic; Cancer; Osteoporosis","score_opus":0.1992204823832632,"score_gpt":0.50924769265856,"score_spread":0.3100272102752968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255513928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445736,0.000052355022,0.00000101306,0.0025822122,0.00004283554,0.00089400087,0.00007255908,0.000016307844,0.0018813653],"genre_scores_gemma":[0.99866253,0.00012405812,0.0003464286,0.0002084583,0.000039336664,0.00039643294,0.0001281467,0.000013967169,0.00008063166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987352,0.000056419452,0.00046756273,0.000279461,0.00019553202,0.0002658364],"domain_scores_gemma":[0.9989315,0.00005194262,0.00036303382,0.00023390047,0.0002748583,0.00014475953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021794197,0.00013584844,0.00035941982,0.000081720624,0.0000735221,0.000050219314,0.00025330615,0.00006869994,0.00006601425],"category_scores_gemma":[0.00012113462,0.00011206633,0.000037164562,0.00011866326,0.00019011158,0.0003625085,0.000039836603,0.00020380417,0.0000017919517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021011187,0.0027953463,0.95803344,0.000083534615,0.00010122662,0.00020070335,0.000379365,0.000051128194,0.008179404,0.00004746069,0.00012978539,0.027897505],"study_design_scores_gemma":[0.0062213866,0.0013342123,0.9696911,0.00013005291,0.000051766077,0.000005535102,0.000056715173,0.00072640576,0.018590633,0.00004695798,0.0030152176,0.00013002123],"about_ca_topic_score_codex":0.0009033181,"about_ca_topic_score_gemma":0.0007126759,"teacher_disagreement_score":0.027767483,"about_ca_system_score_codex":0.00009689629,"about_ca_system_score_gemma":0.00017830096,"threshold_uncertainty_score":0.45699322},"labels":[],"label_agreement":null},{"id":"W4256676562","doi":"10.1016/j.annonc.2021.03.068","title":"54P Overweight and prognosis in triple-negative breast cancer patients: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Region Midtjylland; Aarhus Universitet","keywords":"Medicine; Overweight; Meta-analysis; Hazard ratio; Observational study; Breast cancer; Internal medicine; Population; Triple-negative breast cancer; Body mass index; Oncology; Systematic review; Obesity; Publication bias; Cancer; Confidence interval; MEDLINE; Environmental health","score_opus":0.1929494852741038,"score_gpt":0.4707517987736567,"score_spread":0.27780231349955287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256676562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022554494,0.9942592,4.280301e-7,0.0013724745,0.00003274311,0.0034525467,0.000747531,0.000008294063,0.00010422933],"genre_scores_gemma":[0.000151083,0.9968848,0.000027511694,0.001181532,0.000020367908,0.0014506361,0.00008501158,0.000032728294,0.00016631129],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966513,0.00067584316,0.0016727039,0.0005225016,0.00023507592,0.00024258536],"domain_scores_gemma":[0.9972108,0.00046766718,0.0014396192,0.00030084956,0.00043299352,0.00014808877],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00066649023,0.0004037086,0.014840948,0.00043808488,0.000018557894,0.000010511836,0.00009244283,0.00029526197,0.0003847726],"category_scores_gemma":[0.00035017633,0.0002465388,0.0016630673,0.0011586995,0.000119470715,0.000058697646,0.00009247763,0.0003104902,0.0000010883368],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013077999,0.0003699977,0.0003262188,0.81704336,0.14251551,0.00003375274,0.00011876339,2.3821919e-8,6.0497674e-9,0.000016847154,0.0013146052,0.03824782],"study_design_scores_gemma":[0.00040368258,0.000449571,0.00035166336,0.066404454,0.85405004,0.000054166896,0.00002263969,5.269125e-7,2.429614e-7,0.000004567401,0.0780438,0.00021461939],"about_ca_topic_score_codex":0.0008814891,"about_ca_topic_score_gemma":0.00063693704,"teacher_disagreement_score":0.7506389,"about_ca_system_score_codex":0.000115313596,"about_ca_system_score_gemma":0.00047036295,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W4281630256","doi":"10.1016/j.annonc.2022.05.519","title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Amgen; Boehringer Ingelheim; Sanofi; Meso Scale Diagnostics; AbbVie; Novartis; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Daiichi-Sankyo","keywords":"Medicine; Microsatellite instability; Pembrolizumab; DNA mismatch repair; Oncology; Internal medicine; Microsatellite; Cancer; Genetics; Immunotherapy; Colorectal cancer","score_opus":0.08205419643992853,"score_gpt":0.39815905522167494,"score_spread":0.31610485878174643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281630256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341005,0.0010372866,0.0000053539643,0.0031531425,0.00040328896,0.001219569,0.00037400165,0.000049536713,0.0003477523],"genre_scores_gemma":[0.99682575,0.00009759186,0.00021455111,0.0021966381,0.000053409272,0.00018357878,0.00023512713,0.00002122563,0.00017215036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670553,0.00081719,0.00087230233,0.00065505924,0.00051127677,0.00043861236],"domain_scores_gemma":[0.9979187,0.00043704442,0.0003335425,0.00093416014,0.00026446304,0.000112089314],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012083391,0.00023138637,0.0009817337,0.0002647407,0.00019692113,0.0000067790443,0.00038637238,0.000116188465,0.0034071982],"category_scores_gemma":[0.0002529838,0.00016756964,0.00029038097,0.0019843974,0.00023187639,0.00003173553,0.0004676421,0.0005085695,0.000004713107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084586404,0.03824106,0.69990516,0.00009585871,0.007602677,0.0010174714,0.05588936,0.012884201,0.018269213,0.000033359738,0.027549064,0.053926148],"study_design_scores_gemma":[0.030258771,0.082280934,0.6905208,0.00004422331,0.0031370807,0.000046027442,0.021411987,0.002462963,0.012929922,0.00032479255,0.15589586,0.0006866001],"about_ca_topic_score_codex":0.017961962,"about_ca_topic_score_gemma":0.01613108,"teacher_disagreement_score":0.1283468,"about_ca_system_score_codex":0.0007970186,"about_ca_system_score_gemma":0.0012563331,"threshold_uncertainty_score":0.9975038},"labels":[],"label_agreement":null},{"id":"W4281845612","doi":"10.1016/j.annonc.2022.05.522","title":"Whole-genome and transcriptome analysis enhances precision cancer treatment options","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Simon Fraser University; Kelowna General Hospital; Pancreas Centre (Canada); University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"Canada Research Chairs; Genome British Columbia; Canada Foundation for Innovation; National Institutes of Health; BC Cancer Foundation; Genome Canada","keywords":"Medicine; Precision medicine; Transcriptome; Personalized medicine; Clinical trial; Genome; Computational biology; Bioinformatics; Gene; Oncology; Internal medicine; Gene expression; Genetics; Biology; Pathology","score_opus":0.041458771252957556,"score_gpt":0.3570804674799838,"score_spread":0.31562169622702624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281845612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98391277,0.012364236,0.0001813511,0.0018286182,0.00013221423,0.00013719893,0.0008443533,0.0000033620893,0.00059588975],"genre_scores_gemma":[0.98126227,0.01699757,0.00018285809,0.0004908195,0.00008669029,0.00014675497,0.00027140547,0.000008326414,0.0005533101],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992562,0.000067905996,0.0001933737,0.0002529735,0.00007428389,0.0001552451],"domain_scores_gemma":[0.9995605,0.000033183576,0.00009889091,0.00018207922,0.00006320348,0.00006216357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013769024,0.00009404886,0.00023886075,0.0001057979,0.000109778586,0.0000063499624,0.000105293795,0.000056640813,0.00015137119],"category_scores_gemma":[0.000013533739,0.00009235319,0.00013802249,0.00018160757,0.000069909984,0.000002066308,0.00008106046,0.000041732827,8.617543e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025501932,0.0003915759,0.0015176419,0.0000067307774,0.0008958353,0.0000045183197,0.0003821869,0.0070532495,0.94019395,0.00012513145,0.0012068638,0.04796731],"study_design_scores_gemma":[0.00065333775,0.0042069913,0.011726737,0.00000135397,0.00030953664,0.0000055695073,0.00022490563,0.00007890312,0.04128968,0.00016108456,0.94119257,0.00014933148],"about_ca_topic_score_codex":0.00025150258,"about_ca_topic_score_gemma":0.0006281803,"teacher_disagreement_score":0.9399857,"about_ca_system_score_codex":0.000032967026,"about_ca_system_score_gemma":0.00014919008,"threshold_uncertainty_score":0.3766054},"labels":[],"label_agreement":null},{"id":"W4282922206","doi":"10.1016/j.annonc.2022.05.517","title":"Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","year":2022,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Oncology; Phases of clinical research; Metastatic melanoma; Basal cell; Expanded access; Internal medicine; Clinical trial; Dermatology; Surgery; Immunotherapy; Cancer","score_opus":0.12182562326581722,"score_gpt":0.4326201249267309,"score_spread":0.3107945016609137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282922206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87752557,0.010727586,0.00011803495,0.0016972515,0.06493386,0.037424006,0.0025813056,0.000083761865,0.0049086194],"genre_scores_gemma":[0.8960558,0.002844341,0.002275233,0.0067853,0.0018204817,0.0058658067,0.0036211114,0.00039885475,0.080333024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948923,0.000785166,0.0017060024,0.0012289613,0.0005569585,0.0008306384],"domain_scores_gemma":[0.9963222,0.0005507198,0.0012017968,0.00091077416,0.0005454209,0.00046908122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012782308,0.0007286471,0.003066485,0.00048816935,0.00037216133,0.000050815914,0.0008455064,0.0004074728,0.0006639463],"category_scores_gemma":[0.0005510558,0.00067747734,0.00029836982,0.00034288006,0.00019606894,0.00013476124,0.0005494038,0.0008772227,0.0000035441035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.559448,0.025971092,0.000001701211,0.00032635205,0.00033841428,0.0004185521,0.0011592834,9.333766e-7,0.001021519,0.00000114642,0.22996208,0.18135092],"study_design_scores_gemma":[0.374851,0.29398176,0.000006560262,0.00006260478,0.00059321447,0.000102820886,0.0006021056,0.00012627068,0.00013540973,0.000006518183,0.32922077,0.00031096916],"about_ca_topic_score_codex":0.00073200243,"about_ca_topic_score_gemma":0.00071949,"teacher_disagreement_score":0.26801068,"about_ca_system_score_codex":0.00032824496,"about_ca_system_score_gemma":0.0020672309,"threshold_uncertainty_score":0.9995676},"labels":[],"label_agreement":null},{"id":"W4283072502","doi":"10.1016/j.annonc.2022.04.062","title":"44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Bevacizumab; Ovarian cancer; Paclitaxel; Oncology; Placebo; Internal medicine; Double blind; Chemotherapy; Cancer; Immunotherapy; Pathology","score_opus":0.1193212526315547,"score_gpt":0.42760210415333655,"score_spread":0.30828085152178186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283072502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97664183,0.001956057,0.00018352548,0.0088891,0.00046366954,0.009201745,0.00086958735,0.00003204626,0.0017624425],"genre_scores_gemma":[0.98830986,0.000386229,0.00073409674,0.00046756028,0.0002443542,0.009273883,0.00022886247,0.000048765425,0.00030638222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99654216,0.0003995827,0.0011958119,0.0006440525,0.00072453887,0.0004938588],"domain_scores_gemma":[0.99666876,0.0010936467,0.0009850812,0.0004984785,0.0005347175,0.00021929527],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013514805,0.00036753385,0.0020590257,0.00032539002,0.00024203156,0.00001166252,0.00021494707,0.00012441234,0.0013101257],"category_scores_gemma":[0.000094422954,0.0002884982,0.0003360911,0.00034175103,0.00021536121,0.00007840529,0.00012408268,0.00032682225,0.000001615005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94948643,0.016770799,0.00047668055,0.00017392007,0.0032293592,0.000109486275,0.0028744359,0.0009056841,0.00010110325,0.0025836653,0.004969219,0.01831919],"study_design_scores_gemma":[0.9177528,0.056857258,0.0008028808,0.00013121798,0.0016245415,0.000051327977,0.0016321947,0.0003336928,0.00067035534,0.00022899969,0.019647023,0.0002677355],"about_ca_topic_score_codex":0.0011747996,"about_ca_topic_score_gemma":0.00065997755,"teacher_disagreement_score":0.04008646,"about_ca_system_score_codex":0.00040822997,"about_ca_system_score_gemma":0.0014683193,"threshold_uncertainty_score":0.9999567},"labels":[],"label_agreement":null},{"id":"W4283512735","doi":"10.1016/j.annonc.2022.06.008","title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Genentech; Sirtex Medical; Eli Lilly and Company; Ono Pharmaceutical; Daiichi Sankyo Europe; Servier; Alberta Health Services; Alberta Cancer Foundation; Seagen; Pfizer; Incyte; Canadian Institutes of Health Research; Ipsen; BeiGene; Astellas Pharma; Mylan; Les Laboratories Pierre Fabre; Helsinn; Merck KGaA; Halozyme; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Amgen; Celgene","keywords":"Ipilimumab; Nivolumab; Medicine; Microsatellite instability; Colorectal cancer; Internal medicine; Oncology; Cancer; Gastroenterology; Immunotherapy","score_opus":0.028486911596228674,"score_gpt":0.3066975440504603,"score_spread":0.2782106324542316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283512735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993826,0.0023861716,0.0000014264482,0.0006660736,0.00040610827,0.0017203296,0.00064456725,0.00008024584,0.0002691024],"genre_scores_gemma":[0.9970066,0.0006763498,0.0002303706,0.0008379312,0.000025010318,0.000380269,0.00058322086,0.0000507815,0.00020950023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969522,0.00043940754,0.00090208877,0.00063425826,0.000485207,0.00058684143],"domain_scores_gemma":[0.99849117,0.00016526149,0.00047030204,0.00045896947,0.0002811553,0.00013316018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006672568,0.00031592973,0.0010847619,0.00024729423,0.00013577317,0.000010817949,0.00022215921,0.00011610625,0.0007406028],"category_scores_gemma":[0.000053624844,0.00027422296,0.00027815913,0.00075611146,0.00028532482,0.000092712056,0.00013762496,0.00036799008,0.000007658464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3205017,0.011507995,0.51984346,0.00076399714,0.0034915698,0.00049131585,0.019285884,0.00048796635,0.034204863,0.000035929726,0.005039389,0.08434594],"study_design_scores_gemma":[0.13487647,0.04240935,0.74229753,0.0007821022,0.00085844245,0.000049559974,0.0039553577,0.0004208886,0.034835946,0.00013710112,0.03825561,0.0011216657],"about_ca_topic_score_codex":0.014118855,"about_ca_topic_score_gemma":0.0041120197,"teacher_disagreement_score":0.22245403,"about_ca_system_score_codex":0.0009301303,"about_ca_system_score_gemma":0.001046781,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W4283772824","doi":"10.1016/j.annonc.2022.04.414","title":"SO-15 Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Systemic therapy; Liver transplantation; Malignancy; Liver disease; Cohort; Proportional hazards model; Oncology; Gastroenterology; Liver cancer; Sorafenib; Cancer; Transplantation","score_opus":0.04118041297309174,"score_gpt":0.3104862453501471,"score_spread":0.2693058323770554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283772824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986058,0.00012034618,0.00002305816,0.000035801848,0.00009331353,0.00026732616,0.0005431669,0.0000015559493,0.00030962098],"genre_scores_gemma":[0.9994918,0.00008234636,0.000043174005,0.000055178476,0.000017028227,0.000041845127,0.00020472359,0.000017662222,0.00004622573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990009,0.000099879864,0.0003341789,0.00020000519,0.00016511939,0.00019991747],"domain_scores_gemma":[0.99906576,0.00009745157,0.00034721955,0.0002852571,0.00014508414,0.000059236136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104203435,0.00016825741,0.00050791807,0.00007610766,0.000047001748,0.0000028679956,0.00013218496,0.00004477057,0.00003583137],"category_scores_gemma":[0.000034258126,0.00012609678,0.00021317397,0.000053060863,0.00014296388,0.0000021640344,0.00010364039,0.00005120344,1.8909604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059253996,0.0008685775,0.984016,0.000031931908,0.00042134576,0.000007874788,0.00035582075,0.0030411654,0.009438243,0.00006522454,0.00010047296,0.001060813],"study_design_scores_gemma":[0.0030258002,0.03986457,0.8566763,0.000012006654,0.000102861384,0.0000016445613,0.00047676472,0.0002704147,0.09901052,0.00012407474,0.00023357652,0.00020145751],"about_ca_topic_score_codex":0.0022238246,"about_ca_topic_score_gemma":0.00020970785,"teacher_disagreement_score":0.12733969,"about_ca_system_score_codex":0.00011159232,"about_ca_system_score_gemma":0.0003985199,"threshold_uncertainty_score":0.5142078},"labels":[],"label_agreement":null},{"id":"W4283775908","doi":"10.1016/j.annonc.2022.06.011","title":"Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Hazard ratio; Internal medicine; Placebo; Chemotherapy; Oncology; Ovarian cancer; Population; Cohort; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.1289920043521299,"score_gpt":0.4438730939755801,"score_spread":0.3148810896234502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283775908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754036,0.00031824398,0.000020712941,0.0070259464,0.0012200719,0.003037769,0.0005723064,0.000019428695,0.00024517765],"genre_scores_gemma":[0.99740106,0.00017081824,0.0003189157,0.0010904393,0.00020172341,0.00062249973,0.00010694481,0.000041173756,0.000046406905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975396,0.00035361337,0.0007654672,0.00035840343,0.0005801313,0.0004028284],"domain_scores_gemma":[0.99690723,0.0005277395,0.001227757,0.0004157188,0.00083621213,0.00008533982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262442,0.00022807368,0.00082908524,0.00017555623,0.00013803049,0.000004450422,0.0002592194,0.00011393829,0.000255665],"category_scores_gemma":[0.00023079362,0.00015606276,0.00031247115,0.00042448097,0.00039776767,0.00004092945,0.000054120137,0.0002983584,4.531437e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9072874,0.004177757,0.0008040537,0.00010689976,0.0010865256,0.000004144519,0.0012994711,0.0005034569,0.011188869,0.00013478426,0.0027237672,0.070682876],"study_design_scores_gemma":[0.6179365,0.13817665,0.014309518,0.0006615984,0.0005381283,0.000008072846,0.00048330732,0.00018906401,0.19474126,0.00013605302,0.032432083,0.00038774457],"about_ca_topic_score_codex":0.00014801692,"about_ca_topic_score_gemma":0.00004230331,"teacher_disagreement_score":0.28935087,"about_ca_system_score_codex":0.00035433282,"about_ca_system_score_gemma":0.0012383406,"threshold_uncertainty_score":0.6364054},"labels":[],"label_agreement":null},{"id":"W4283776238","doi":"10.1016/j.annonc.2022.04.252","title":"P-162 Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Liver transplantation; Hepatocellular carcinoma; Transplantation; Oncology; Cirrhosis; Internal medicine; Cancer research; Cancer; Immunotherapy; Chemotherapy; Nivolumab","score_opus":0.03240277524290608,"score_gpt":0.3159590780138492,"score_spread":0.2835563027709431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283776238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642235,0.00094604,0.00005149413,0.0009410877,0.00011400209,0.0007738061,0.00028200552,0.0000113664655,0.00045782232],"genre_scores_gemma":[0.9976289,0.00039531657,0.0003145753,0.0010252952,0.000030740823,0.00012948304,0.0003313088,0.000016674334,0.00012770506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991738,0.000065257984,0.00023014331,0.00019765038,0.00015253718,0.00018060434],"domain_scores_gemma":[0.99950796,0.00006440379,0.00012650348,0.00012341257,0.00012666629,0.000051078136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016210641,0.00010515685,0.00027421088,0.00008999647,0.00010661802,0.0000037723555,0.00005735047,0.000057173325,0.00019761635],"category_scores_gemma":[0.000006522801,0.00009122053,0.00006750705,0.000086163534,0.000094766685,0.000049378217,0.000017425671,0.00007493104,3.528658e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26636067,0.0029514523,0.4435874,0.001933107,0.0009836188,0.00041398904,0.013401461,0.0000061053415,0.016742304,0.0003086174,0.014204175,0.2391071],"study_design_scores_gemma":[0.027653882,0.046415072,0.8135474,0.000048251077,0.00035692923,0.00028374742,0.00035947203,0.00045739606,0.010509275,0.00018353359,0.09988931,0.0002957382],"about_ca_topic_score_codex":0.00018690513,"about_ca_topic_score_gemma":0.000029025254,"teacher_disagreement_score":0.36996,"about_ca_system_score_codex":0.000048508424,"about_ca_system_score_gemma":0.00012920928,"threshold_uncertainty_score":0.3719865},"labels":[],"label_agreement":null},{"id":"W4283779549","doi":"10.1016/j.annonc.2022.04.411","title":"SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Nivolumab; Cohort; Hepatocellular carcinoma; Sorafenib; Population; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.06950434111771035,"score_gpt":0.2843961183176281,"score_spread":0.21489177719991776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283779549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935116,0.00092547626,0.000004576549,0.001605515,0.00018705512,0.0015116364,0.00023300703,0.000051049876,0.001970037],"genre_scores_gemma":[0.99661916,0.00029720133,0.00031227327,0.00054802775,0.000043773212,0.00021451311,0.0016136344,0.00005328067,0.00029810306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734014,0.00037218738,0.0006845868,0.00056676724,0.0005648906,0.00047143287],"domain_scores_gemma":[0.99845153,0.0001774845,0.0004200715,0.00052241114,0.00028228218,0.00014624278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004608586,0.00029465766,0.00080941257,0.00030866874,0.0001652356,0.000011125471,0.00021246038,0.0001663672,0.0002864439],"category_scores_gemma":[0.000059515176,0.00026858167,0.00016469377,0.00040050826,0.00013789155,0.00013428314,0.00011720773,0.00036685652,0.000018003806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02217799,0.0027701173,0.931369,0.000025415662,0.00019018984,0.00028355495,0.0019347774,0.000021415564,0.00044862635,0.00007991223,0.0005762355,0.040122755],"study_design_scores_gemma":[0.086722195,0.03419708,0.836642,0.000074421696,0.000119879965,0.000008612023,0.0005774656,0.002447481,0.010579693,0.00027513152,0.027915454,0.00044054186],"about_ca_topic_score_codex":0.0011187126,"about_ca_topic_score_gemma":0.00007680583,"teacher_disagreement_score":0.094726965,"about_ca_system_score_codex":0.00034135033,"about_ca_system_score_gemma":0.0004987544,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W4283780125","doi":"10.1016/j.annonc.2022.04.412","title":"SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Oxaliplatin; Internal medicine; Hepatocellular carcinoma; Adverse effect; Oncology; Placebo; Open label; Cancer; Immunotherapy; Pathology; Alternative medicine; Colorectal cancer","score_opus":0.17662289679519239,"score_gpt":0.36422844760122236,"score_spread":0.18760555080602997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283780125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904433,0.0008778477,0.0000050557614,0.0012861026,0.000056417997,0.0061133076,0.0007305795,0.000049541257,0.0004378406],"genre_scores_gemma":[0.9916853,0.00004763819,0.00020538624,0.0008044171,0.000035394223,0.000633648,0.0063828067,0.00008088855,0.00012452986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612737,0.00092700875,0.00071849645,0.0009791292,0.0006342941,0.0006137305],"domain_scores_gemma":[0.9970053,0.00023972987,0.0004762729,0.0017651687,0.00031090408,0.00020262579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006731922,0.00043837624,0.0011745825,0.00018310807,0.00031740093,0.000042948246,0.0012348506,0.00011043096,0.00055686303],"category_scores_gemma":[0.00005837951,0.0002843382,0.00005360383,0.0008518527,0.00021118177,0.00030609404,0.0009810602,0.00050353934,0.0000136338485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03129488,0.021657297,0.925842,0.000017521363,0.00072647276,0.0015140864,0.0014172974,0.0000059590943,0.000113633956,0.000005088024,0.0020264105,0.015379382],"study_design_scores_gemma":[0.20130931,0.17137016,0.5945758,0.00010609988,0.0017701449,0.000047743062,0.0021452575,0.0037181547,0.0013921198,0.000028279383,0.022809237,0.0007276509],"about_ca_topic_score_codex":0.004049975,"about_ca_topic_score_gemma":0.0009260441,"teacher_disagreement_score":0.33126613,"about_ca_system_score_codex":0.00015923657,"about_ca_system_score_gemma":0.000827946,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W4283780799","doi":"10.1016/j.annonc.2022.04.117","title":"P-26 HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Antibody-dependent cell-mediated cytotoxicity; Chemotherapy; Cancer; Regimen; Cancer research; Oncology; Chemotherapy regimen; Combination chemotherapy; Internal medicine; Monoclonal antibody; Antibody; Immunology; Breast cancer","score_opus":0.0511468960694192,"score_gpt":0.3694295074956583,"score_spread":0.3182826114262391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283780799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994658,0.000119189084,0.00012642406,0.0024703324,0.000057907462,0.0022959623,0.000074455114,0.000030280202,0.00016743502],"genre_scores_gemma":[0.9976258,0.000058122194,0.0010400931,0.0005838699,0.000030007413,0.00027395086,0.00012634815,0.000056626737,0.00020516077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975101,0.0002896479,0.00075900415,0.0004774393,0.0005212344,0.00044259572],"domain_scores_gemma":[0.9986269,0.00017127921,0.0006084325,0.00031147726,0.00018496774,0.00009696198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038098881,0.00030320924,0.0011914248,0.00056203245,0.000085303815,0.000007124673,0.00022652766,0.000046360135,0.00064786087],"category_scores_gemma":[0.000046765705,0.00024130622,0.00006487557,0.0008657778,0.00014240829,0.00019754391,0.00010855837,0.0003673292,0.0000014763363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049588785,0.021513093,0.88325197,0.00036006287,0.00064197776,0.0014330231,0.008434973,0.00027555233,0.00052922074,0.00007426773,0.00062122615,0.03327588],"study_design_scores_gemma":[0.08783405,0.17879245,0.7244316,0.00012272953,0.0001554295,0.00010448951,0.0069006714,0.00019148388,0.00093636214,0.00003438147,0.00025656947,0.00023983495],"about_ca_topic_score_codex":0.0007645862,"about_ca_topic_score_gemma":0.0021231647,"teacher_disagreement_score":0.15882039,"about_ca_system_score_codex":0.00025329314,"about_ca_system_score_gemma":0.00024289516,"threshold_uncertainty_score":0.9840182},"labels":[],"label_agreement":null},{"id":"W4283784137","doi":"10.1016/j.annonc.2022.04.139","title":"P-49 GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – safety and preliminary response results","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech; Merck","keywords":"Oncolytic virus; Medicine; Atezolizumab; Immunotherapy; Microsatellite instability; Cancer research; Tumor microenvironment; Cancer; DNA mismatch repair; Biomarker; Immunology; Colorectal cancer; Internal medicine; Tumor cells; Biology; Microsatellite; Gene; Pembrolizumab","score_opus":0.04292710352985314,"score_gpt":0.3774572383823815,"score_spread":0.33453013485252836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283784137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980997,0.0006649862,0.000012081173,0.00035517657,0.0000051938205,0.00057269173,0.00021657949,0.0000055498676,0.00006807434],"genre_scores_gemma":[0.999309,0.0002464434,0.00011372555,0.000038339473,0.0000062689137,0.00010769076,0.0001259728,0.0000138849655,0.000038648966],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99868286,0.000366217,0.00022478723,0.0003836202,0.00011318641,0.00022933296],"domain_scores_gemma":[0.9994475,0.00012569506,0.00014739843,0.00013417349,0.00005329692,0.00009189283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004935135,0.000121428515,0.00019654812,0.00013619145,0.00010812575,0.000006919465,0.000060131337,0.00003468973,0.0000054112475],"category_scores_gemma":[0.00013222764,0.00011198944,0.00001540869,0.00014192199,0.00016249075,0.000008345396,0.00016162387,0.00010105539,8.643067e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5192987,0.0015134652,0.22253707,0.00003207607,0.00022480462,0.0005830037,0.0013146325,0.00030823768,0.14920703,0.0000016390405,0.00020701718,0.10477233],"study_design_scores_gemma":[0.047228027,0.1759112,0.7538244,0.00006474909,0.000048693764,0.0007622477,0.003290575,0.0008762185,0.014012678,0.000012553661,0.0036845764,0.00028404652],"about_ca_topic_score_codex":0.00097165664,"about_ca_topic_score_gemma":0.0015169207,"teacher_disagreement_score":0.5312874,"about_ca_system_score_codex":0.00008779148,"about_ca_system_score_gemma":0.00029012252,"threshold_uncertainty_score":0.45667967},"labels":[],"label_agreement":null},{"id":"W4283786270","doi":"10.1016/j.annonc.2022.04.162","title":"P-72 Real-world treatments and outcomes for biliary tract cancer patients using administrative databases in Ontario, Canada","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; AstraZeneca (Canada)","funders":"AstraZeneca Canada","keywords":"Medicine; Biliary tract cancer; Biliary tract; Internal medicine; Cancer; Oncology; Database; Gemcitabine","score_opus":0.2208694364989008,"score_gpt":0.4379322327933301,"score_spread":0.2170627962944293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283786270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950308,0.00042994914,2.8880214e-7,0.001892349,0.00020793696,0.00048650845,0.00064772513,0.0000034788288,0.0013009638],"genre_scores_gemma":[0.99740183,0.00010327527,0.00012049396,0.0013355969,0.000018745439,0.00016926572,0.00012624543,0.000009248344,0.00071529404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912095,0.00004347858,0.00026006147,0.00021303869,0.00014001217,0.00022248212],"domain_scores_gemma":[0.99941653,0.00020696818,0.00013433813,0.00010641734,0.0000748627,0.00006087311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009319028,0.00011591142,0.00046508102,0.00009493275,0.00009494521,0.0000015653964,0.0000413254,0.000014297989,0.00012566024],"category_scores_gemma":[0.000032160482,0.00010108666,0.000049944283,0.0000940838,0.00004837653,0.00004346363,0.000072270035,0.00011182514,3.634245e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004879929,0.00057499524,0.9869861,0.00002807945,0.00020415954,0.00006030834,0.00081415457,0.000005335312,0.000026495387,0.000016880153,0.0073798974,0.0034155964],"study_design_scores_gemma":[0.002471588,0.0014424982,0.96977204,0.0000189655,0.0001145011,0.0000045150045,0.0005638955,0.000008612838,0.00017803039,0.000013704791,0.025331056,0.00008057068],"about_ca_topic_score_codex":0.9820332,"about_ca_topic_score_gemma":0.9977712,"teacher_disagreement_score":0.017951157,"about_ca_system_score_codex":0.00066624116,"about_ca_system_score_gemma":0.0022655088,"threshold_uncertainty_score":0.41221943},"labels":[],"label_agreement":null},{"id":"W4283786624","doi":"10.1016/j.annonc.2022.04.199","title":"P-109 Care delivery impact of the COVID-19 pandemic on anal cancer care","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Coronavirus disease 2019 (COVID-19); Pandemic; Anal cancer; Retrospective cohort study; Demographics; Internal medicine; Demography; Disease","score_opus":0.2800465749391378,"score_gpt":0.5438553040889966,"score_spread":0.2638087291498588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283786624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776733,0.00476321,0.0000010672521,0.014914468,0.00028366907,0.0004401433,0.0005314693,0.000021082169,0.0013716106],"genre_scores_gemma":[0.9673353,0.0008096521,0.0000049005853,0.03154924,0.00013282988,0.00003890771,0.000034161167,0.000015194722,0.00007982689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984411,0.0002992215,0.00034220392,0.00022066868,0.00035966857,0.00033712602],"domain_scores_gemma":[0.9983313,0.00039046502,0.0002883013,0.00038545672,0.00031834145,0.00028610913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029170996,0.00013688242,0.0005066506,0.00017722281,0.00017631779,0.0000017375532,0.00021101664,0.00012413216,0.00079660764],"category_scores_gemma":[0.00039007276,0.0000963325,0.00033898474,0.00033188504,0.00013533469,0.000023109988,0.00014209287,0.00043643737,0.0000020021723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002541292,0.00022333303,0.87968767,0.00065200665,0.00021013527,0.000075224445,0.015038741,0.0028892285,0.0015718122,0.000063838255,0.036919273,0.060127437],"study_design_scores_gemma":[0.0031459336,0.016101584,0.69670683,0.00008444725,0.00015897,0.00011580344,0.007970496,0.00002170604,0.00062557193,0.00008418898,0.27481228,0.00017220776],"about_ca_topic_score_codex":0.022404578,"about_ca_topic_score_gemma":0.004452322,"teacher_disagreement_score":0.23789302,"about_ca_system_score_codex":0.0015573956,"about_ca_system_score_gemma":0.0090761585,"threshold_uncertainty_score":0.99654144},"labels":[],"label_agreement":null},{"id":"W4283787439","doi":"10.1016/j.annonc.2022.04.228","title":"P-138 Real-world delivery, toxicity and outcomes of perioperative FLOT chemotherapy in resectable gastric/gastroesophageal adenocarcinoma: A population-based study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Perioperative; Docetaxel; Regimen; Chemotherapy; Cancer; Population; Surgery; Oncology; Colorectal cancer","score_opus":0.05220692187934833,"score_gpt":0.3656978444483446,"score_spread":0.31349092256899624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283787439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946672,0.00017990272,0.0000067119418,0.0029952293,0.00007652731,0.00087593915,0.000022907754,0.000014854908,0.0011607815],"genre_scores_gemma":[0.99759245,0.000037503232,0.00034720325,0.0010834425,0.000029375227,0.00008514787,0.000023044164,0.000015374715,0.00078645436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983706,0.00022952803,0.0005199659,0.00028787326,0.00032257236,0.00026948613],"domain_scores_gemma":[0.99916726,0.00019234796,0.00023393681,0.00023000668,0.000109532186,0.000066918925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005734899,0.0001559069,0.00078360864,0.00053815794,0.00007977087,0.0000050629274,0.0001238553,0.000033716344,0.00035919817],"category_scores_gemma":[0.000055588636,0.0001446947,0.000092897615,0.00058253785,0.000055779175,0.000058691407,0.00012469455,0.00020766321,4.6348686e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013352932,0.0016164053,0.9922686,0.00004087541,0.00012689803,0.00007647633,0.0009615091,0.00027613586,0.000098212426,0.0000916036,0.00035912596,0.0027488335],"study_design_scores_gemma":[0.0074793682,0.0075893877,0.9824167,0.000008295964,0.000056401477,0.000003478742,0.0016826651,0.00024537815,0.00016573946,0.000016203181,0.0002628699,0.00007350444],"about_ca_topic_score_codex":0.005639888,"about_ca_topic_score_gemma":0.0031860655,"teacher_disagreement_score":0.009851923,"about_ca_system_score_codex":0.00016473234,"about_ca_system_score_gemma":0.00019430606,"threshold_uncertainty_score":0.8525861},"labels":[],"label_agreement":null},{"id":"W4283789080","doi":"10.1016/j.annonc.2022.04.119","title":"P-28 Real-world observational study of MVASI in metastatic colorectal cancer patients in Canada: Baseline patient characteristics","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Amgen (Canada); Centre Intégré de Santé et de Services Sociaux des Laurentides; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Southlake Regional Health Center; Grand River Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Amgen","keywords":"Biosimilar; Bevacizumab; Medicine; Colorectal cancer; Internal medicine; Oncology; Observational study; Real world evidence; Monoclonal antibody; Antibody; Cancer; Chemotherapy; Immunology","score_opus":0.13708244977754078,"score_gpt":0.3839199649749954,"score_spread":0.24683751519745464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283789080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971809,0.00013484799,6.968558e-7,0.00094773655,0.00048288846,0.0004063158,0.0006347217,0.00000260033,0.00020933693],"genre_scores_gemma":[0.9986392,0.00010214344,0.00008248922,0.00087570824,0.0000061712217,0.000107036016,0.00011977725,0.0000076595115,0.000059817055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973237,0.0011668995,0.0008981344,0.0002297028,0.00010283542,0.00027875337],"domain_scores_gemma":[0.9985998,0.0006507287,0.00042437937,0.00011439633,0.00018812524,0.000022514228],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007108321,0.00012513335,0.0006432875,0.00020599671,0.00004300908,8.9220566e-7,0.00017929156,0.000052304185,0.0010363664],"category_scores_gemma":[0.00022611002,0.00011606277,0.000045606143,0.00047756245,0.00008108448,0.000024977824,0.00017146878,0.00032234922,5.4347527e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008998208,0.004364761,0.9629686,0.000020054007,0.00015605356,0.00002810932,0.0005136328,0.00009768325,0.0016291126,0.000121595825,0.00289518,0.026305404],"study_design_scores_gemma":[0.0017667146,0.0035697643,0.98234093,0.000011422623,0.000035122383,0.0000010573577,0.00086097256,0.00006646896,0.0024270734,0.00005430756,0.008751736,0.000114400864],"about_ca_topic_score_codex":0.61546946,"about_ca_topic_score_gemma":0.8907795,"teacher_disagreement_score":0.27531007,"about_ca_system_score_codex":0.00031906797,"about_ca_system_score_gemma":0.0011995746,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W4286511961","doi":"10.1016/j.annonc.2022.05.065","title":"PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Oncology; Triple-negative breast cancer; Breast cancer; Internal medicine; Placebo; Cancer; Pathology; Immunotherapy; Alternative medicine","score_opus":0.04495780894443804,"score_gpt":0.3732214279464666,"score_spread":0.3282636190020286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286511961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73825264,0.0026987917,0.00020652403,0.24093091,0.0015510604,0.0042449054,0.0017138335,0.00015570351,0.0102456175],"genre_scores_gemma":[0.95689666,0.0029248206,0.00051691814,0.033529025,0.0005629359,0.0011692557,0.000103055565,0.00011250722,0.004184804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772495,0.00018001934,0.0006293428,0.00049374276,0.00037500987,0.00059691694],"domain_scores_gemma":[0.99840456,0.00023844159,0.0004884932,0.0004159064,0.00030236176,0.00015023378],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000719285,0.00031646056,0.00092543574,0.00024767168,0.0002445067,0.000010547252,0.00030998842,0.00020360219,0.0050537735],"category_scores_gemma":[0.000037939575,0.00029649917,0.00050455227,0.00046971205,0.0002917827,0.00008356762,0.00004715845,0.00033708895,0.0000047500303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28768906,0.0017339292,0.0022698357,0.00017867617,0.0017515562,0.00003070516,0.0043600644,0.00001889741,0.020833837,0.00020287011,0.15310447,0.5278261],"study_design_scores_gemma":[0.072134726,0.014299141,0.056569483,0.00008188106,0.00014635573,0.00044929018,0.0016013553,0.00022152481,0.035797365,0.0007375855,0.8173975,0.0005638033],"about_ca_topic_score_codex":0.0007176117,"about_ca_topic_score_gemma":0.0001811683,"teacher_disagreement_score":0.66429305,"about_ca_system_score_codex":0.00039185057,"about_ca_system_score_gemma":0.0010800288,"threshold_uncertainty_score":0.99994874},"labels":[],"label_agreement":null},{"id":"W4286512869","doi":"10.1016/j.annonc.2022.05.183","title":"MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Breast cancer","score_opus":0.05416364070373584,"score_gpt":0.41497815903784785,"score_spread":0.360814518334112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286512869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977796,0.00022136832,0.00001034456,0.00026254504,0.00007983373,0.00070797116,0.00024680534,0.0000027631158,0.00068875495],"genre_scores_gemma":[0.9985658,0.00025851463,0.00014822623,0.00029918452,0.000032528023,0.0002594512,0.00021575743,0.000020387575,0.00020013966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99858147,0.00020930117,0.00033391407,0.00027783655,0.00026840967,0.00032908752],"domain_scores_gemma":[0.9992432,0.000040270406,0.00023910092,0.00026452343,0.00012711376,0.00008577878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002290135,0.00013767999,0.0003725417,0.000110040026,0.00004546761,0.0000031191519,0.00021023315,0.000046050693,0.000258391],"category_scores_gemma":[0.000054304717,0.00011145131,0.000085625026,0.0002100121,0.00013095982,0.0000050341528,0.000081534294,0.00010981196,7.82959e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78482634,0.023095962,0.011100169,0.000100458856,0.0014135299,0.00006704099,0.0007692288,0.0004213945,0.005060552,0.000036375157,0.009159689,0.16394927],"study_design_scores_gemma":[0.5959043,0.25527626,0.0075385617,0.00002665711,0.00008042018,0.000016407115,0.00058350526,0.000034458048,0.05373983,0.0001517198,0.0862256,0.0004222503],"about_ca_topic_score_codex":0.0012108958,"about_ca_topic_score_gemma":0.0012325188,"teacher_disagreement_score":0.23218031,"about_ca_system_score_codex":0.00011748013,"about_ca_system_score_gemma":0.0012985258,"threshold_uncertainty_score":0.45448524},"labels":[],"label_agreement":null},{"id":"W4288737780","doi":"10.1016/j.annonc.2022.07.003","title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; FibroGen; Eisai; Astellas Pharma; Les Laboratories Pierre Fabre; European Organisation for Research and Treatment of Cancer; Daiichi-Sankyo; Sirtex Medical; Natera; Jiangsu Hengrui Medicine; Foundation Medicine; Sierra Oncology; Incyte; Sanofi; Royal Australian and New Zealand College of Radiologists; Ipsen; BeiGene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; INCLIVA Instituto de Investigación Sanitaria; GlaxoSmithKline; Amgen","keywords":"Medicine; Guideline; Cancer; Incidence (geometry); Scopus; Demography; Mortality rate; Disease; Family medicine; Internal medicine; MEDLINE; Pathology","score_opus":0.20213707542204665,"score_gpt":0.5457559216370017,"score_spread":0.3436188462149551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288737780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47100195,0.16410522,0.00007791438,0.3511722,0.0017248478,0.005020685,0.0012107554,0.000089154535,0.005597268],"genre_scores_gemma":[0.9374861,0.03493383,0.0047331154,0.016755441,0.00058903167,0.0037739489,0.0001901202,0.000035450546,0.001502928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814427,0.0002651185,0.0006271477,0.00036070298,0.00024554646,0.00035723657],"domain_scores_gemma":[0.99749136,0.001373418,0.00025644954,0.00024087871,0.0003612712,0.00027664128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010956777,0.00014703746,0.0006246948,0.00008980794,0.00015933259,0.0000051085844,0.000086088745,0.000079995814,0.0004701179],"category_scores_gemma":[0.000738814,0.000119370656,0.00022065535,0.00012046196,0.00012903486,0.00006020341,0.00011055309,0.00017932979,0.0000036633433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083316425,0.003676188,0.07340265,0.000056095196,0.0011902136,0.0005845969,0.00026912495,0.0000151333425,0.0000079108895,0.0004473916,0.24320932,0.6688097],"study_design_scores_gemma":[0.011166015,0.052268222,0.0064497804,0.000009876967,0.00036873395,0.00010255579,0.00024798512,0.00006211239,0.00088134804,0.00027038233,0.9280941,0.00007891782],"about_ca_topic_score_codex":0.001311605,"about_ca_topic_score_gemma":0.00019731159,"teacher_disagreement_score":0.6848847,"about_ca_system_score_codex":0.000235668,"about_ca_system_score_gemma":0.0010028945,"threshold_uncertainty_score":0.5147461},"labels":[],"label_agreement":null},{"id":"W4293581698","doi":"10.1016/j.annonc.2022.08.084","title":"Leveraging big data of immune checkpoint blockade response identifies novel potential targets","year":2022,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Public Health Ontario; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Université de Montréal; University of Toronto; University Health Network; Artificial Intelligence in Medicine (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune checkpoint; Medicine; Blockade; Oncology; Biomarker; Transcriptome; Immune system; Gene expression profiling; Immunotherapy; Gene signature; Cancer research; Computational biology; Gene; Bioinformatics; Internal medicine; Gene expression; Immunology; Biology; Genetics; Receptor","score_opus":0.3409202798145177,"score_gpt":0.4489994096355463,"score_spread":0.10807912982102857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293581698","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069524616,0.99461496,0.00004419612,0.0012915122,0.0016980362,0.0006718031,0.0005555764,0.000021827547,0.00040686261],"genre_scores_gemma":[0.0005762638,0.99669284,0.00017970179,0.00020142211,0.0003176398,0.00004545298,0.00087958924,0.000058150068,0.0010489229],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962598,0.0005029088,0.0018767267,0.000564573,0.0004234552,0.00037254312],"domain_scores_gemma":[0.9961169,0.00052787474,0.0016391602,0.0014970687,0.00014413084,0.00007486661],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036186473,0.0003555191,0.0027845837,0.0005429888,0.00008150965,0.000008189949,0.0008854373,0.00035751043,0.00094751245],"category_scores_gemma":[0.0005690414,0.00030876117,0.00097641296,0.00046536,0.00033611958,0.000060700873,0.00082797214,0.00056071836,0.0000065061495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006156549,0.0006599023,8.504012e-7,0.00726913,0.0020894392,0.0001477812,0.00021129493,5.380704e-7,0.011659535,0.0000015325185,0.0032426696,0.96856076],"study_design_scores_gemma":[0.001660771,0.0015185402,0.000101441234,0.0028505733,0.001055412,0.00052680884,0.00015955382,0.0000036047538,0.001376818,0.000008309096,0.99050593,0.00023221805],"about_ca_topic_score_codex":0.00037789866,"about_ca_topic_score_gemma":0.000009874633,"teacher_disagreement_score":0.98726326,"about_ca_system_score_codex":0.00012807263,"about_ca_system_score_gemma":0.0022540234,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W4295745145","doi":"10.1016/j.annonc.2022.07.037","title":"9P The role of ICAM1 in glioblastoma tumor associated macrophages under hypoxia","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Glioblastoma; Hypoxia (environmental); Cancer research; Tumor hypoxia; Oncology; Pathology; Internal medicine; Oxygen; Radiation therapy","score_opus":0.022395270145451743,"score_gpt":0.29882597039418096,"score_spread":0.27643070024872923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295745145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774294,0.013450447,0.0000012968457,0.0019015712,0.00072184595,0.0002157616,0.000071217386,0.00001862309,0.006189856],"genre_scores_gemma":[0.99731696,0.00015203691,0.000007621216,0.001288379,0.00001139511,0.000065107924,0.000014227709,0.000016874339,0.0011273872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979426,0.000916116,0.0004919434,0.00020550904,0.000061005554,0.00038278484],"domain_scores_gemma":[0.9985363,0.00060141925,0.00043484423,0.00031173052,0.00010635338,0.000009370332],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085899903,0.0001297853,0.000457877,0.00014929303,0.00012952343,0.0000017720864,0.00053858996,0.00015198663,0.0022746425],"category_scores_gemma":[0.0001432418,0.00010968783,0.00012477188,0.00034259676,0.00047025646,0.00003127819,0.000385533,0.0005358068,0.00005038551],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00148538,0.0015556953,0.0038406362,0.00001694192,0.00055897934,0.000036355603,0.001992234,0.0006493672,0.9362771,0.0031510135,0.023226617,0.027209695],"study_design_scores_gemma":[0.0023302978,0.0039511207,0.028091885,0.000017116743,0.0000428089,0.00009713735,0.004060042,0.000011506104,0.6459106,0.0048664683,0.31041405,0.0002069594],"about_ca_topic_score_codex":0.00032374126,"about_ca_topic_score_gemma":0.00016920283,"teacher_disagreement_score":0.29036647,"about_ca_system_score_codex":0.00009434313,"about_ca_system_score_gemma":0.00023739964,"threshold_uncertainty_score":0.99863744},"labels":[],"label_agreement":null},{"id":"W4295745317","doi":"10.1016/j.annonc.2022.07.064","title":"37P Breast cancer immunopeptidomes reveal a large number of targetable tumor antigens","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Antigen; Cancer research; Internal medicine; Immunology","score_opus":0.05852886662101639,"score_gpt":0.42768354870227776,"score_spread":0.36915468208126134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295745317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649871,0.002196491,0.0000013888127,0.012621291,0.00018324706,0.00023217109,0.0009346778,0.000011885432,0.018831722],"genre_scores_gemma":[0.98479277,0.0009923954,0.00023235034,0.002039738,0.00015556201,0.000058596266,0.000056374793,0.000018817494,0.011653426],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829346,0.00016734652,0.00041989467,0.00021111619,0.0004329926,0.0004751735],"domain_scores_gemma":[0.9989982,0.0001200625,0.00020367284,0.00021827566,0.0003383948,0.00012138842],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006148166,0.00012346616,0.0006376299,0.00010909544,0.00013319842,0.000002223428,0.00019669917,0.00004986284,0.012645323],"category_scores_gemma":[0.000036581416,0.000104254745,0.000204615,0.00030139738,0.00017689347,0.00004521062,0.00031766648,0.00033110764,0.00004058391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065507437,0.003502347,0.68056804,0.0006175765,0.00093055895,0.0005868358,0.0009879884,0.000026439215,0.10368932,0.0030525483,0.18258013,0.016907439],"study_design_scores_gemma":[0.0021124072,0.0017129622,0.26117292,0.000065052525,0.000060055383,0.0011599102,0.000536125,0.000059454196,0.013925315,0.000343107,0.7186737,0.00017897677],"about_ca_topic_score_codex":0.001720376,"about_ca_topic_score_gemma":0.000036196077,"teacher_disagreement_score":0.5360936,"about_ca_system_score_codex":0.000042102296,"about_ca_system_score_gemma":0.0005896752,"threshold_uncertainty_score":0.9882572},"labels":[],"label_agreement":null},{"id":"W4295747199","doi":"10.1016/j.annonc.2022.07.024","title":"3P Beyond first-line therapy in metastatic adrenal cortical cancer (ACC): Is it time to move on from chemotherapy?","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Chemotherapy; Capecitabine; Etoposide; Progression-free survival; Docetaxel; Pembrolizumab; Cancer; Chemotherapy regimen; Immunotherapy","score_opus":0.08679708867765197,"score_gpt":0.39904227776350143,"score_spread":0.3122451890858495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295747199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90237284,0.000615698,0.000013278708,0.092910886,0.000114031616,0.00040882156,0.00022354272,0.000013705722,0.0033272095],"genre_scores_gemma":[0.89725196,0.00018360993,0.00019450787,0.09841737,0.00016196215,0.00013992298,0.00005884838,0.000027212833,0.0035645706],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984716,0.00013988197,0.00043530692,0.00031414174,0.00031798656,0.0003210543],"domain_scores_gemma":[0.9990002,0.0003904073,0.00013380882,0.0002323758,0.000081103215,0.00016210358],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003129408,0.00016906628,0.0006308157,0.00017365607,0.00006143287,0.0000030339186,0.00016075165,0.00005995801,0.033327393],"category_scores_gemma":[0.000060051207,0.00014076466,0.00013017544,0.00034039558,0.00007247284,0.000026231259,0.000062590356,0.0003742813,0.0002054556],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03733237,0.008690994,0.004255452,0.00006423659,0.0015175107,0.0074524465,0.014777297,0.00304794,0.0046343124,0.00039345442,0.5097583,0.4080757],"study_design_scores_gemma":[0.022286825,0.04645881,0.14314622,0.00022872604,0.00020459625,0.0006496215,0.00096127175,0.003104246,0.050484464,0.004254751,0.72734237,0.00087810226],"about_ca_topic_score_codex":0.0005940929,"about_ca_topic_score_gemma":0.000092538256,"teacher_disagreement_score":0.40719756,"about_ca_system_score_codex":0.00008955593,"about_ca_system_score_gemma":0.00027858032,"threshold_uncertainty_score":0.9675563},"labels":[],"label_agreement":null},{"id":"W4295816704","doi":"10.1016/j.annonc.2022.07.901","title":"775P Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis","year":2022,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sarcoma; Meta-analysis; Oncology; Immune checkpoint; Immune system; Immunology; Internal medicine; Immunotherapy; Pathology","score_opus":0.22506570019955208,"score_gpt":0.4183905861172684,"score_spread":0.19332488591771635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295816704","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012359273,0.9940809,0.000001516238,0.0009958468,0.000027250328,0.003125478,0.00010189714,0.0000234279,0.0016313368],"genre_scores_gemma":[0.00016315462,0.99765396,0.000071924405,0.00047081805,0.000016770464,0.0010420935,0.00017748817,0.000060095033,0.00034372104],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99571514,0.00086405885,0.0022497512,0.00047608902,0.0003872761,0.00030767897],"domain_scores_gemma":[0.9952353,0.0004689255,0.0032160806,0.0007382505,0.00021408992,0.00012732616],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00091874297,0.00053483865,0.017277757,0.00048273895,0.000042374148,0.0000063300813,0.00015828024,0.0002633695,0.00048587786],"category_scores_gemma":[0.00021033488,0.00031098927,0.0046382574,0.0011355958,0.00016055682,0.0000348814,0.000068323105,0.0002119312,0.0000023994069],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006209489,0.0021435851,0.0000022363454,0.649076,0.3059068,0.00007312261,0.00017459622,6.8286e-7,9.2853475e-7,0.000018925875,0.00032353378,0.042217527],"study_design_scores_gemma":[0.0007099112,0.0132043585,4.1666533e-7,0.020981053,0.6635379,0.00008152954,0.00011253419,3.545769e-7,0.000007101309,0.000009225665,0.30117327,0.00018231318],"about_ca_topic_score_codex":0.0003487985,"about_ca_topic_score_gemma":0.00007837332,"teacher_disagreement_score":0.6280949,"about_ca_system_score_codex":0.0003525628,"about_ca_system_score_gemma":0.00065360696,"threshold_uncertainty_score":0.9999342},"labels":[],"label_agreement":null},{"id":"W4295816710","doi":"10.1016/j.annonc.2022.07.982","title":"856P Characterization of patients with brain metastases from metastatic uveal melanoma","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiplex ligation-dependent probe amplification; Melanoma; Monosomy; Internal medicine; Oncology; Progression-free survival; Retrospective cohort study; Brain metastasis; Gastroenterology; Pathology; Cancer; Overall survival; Metastasis; Cancer research; Karyotype; Chromosome","score_opus":0.04047531715974086,"score_gpt":0.3330514505451657,"score_spread":0.2925761333854249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295816710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995756,0.000083583494,0.000050592647,0.0022690215,0.00009940529,0.00036877664,0.0008183292,0.0000107590095,0.0005435488],"genre_scores_gemma":[0.99523485,0.000013112049,0.0007657218,0.0015266706,0.000016129188,0.00004876022,0.002247723,0.0000134772745,0.00013358604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880725,0.00032484252,0.00031309624,0.00017984056,0.0002224862,0.00015248348],"domain_scores_gemma":[0.99903476,0.00019910466,0.00036197234,0.0001884044,0.0001557315,0.00006000443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020679779,0.00010749123,0.0005344429,0.00012537291,0.00005707766,0.000001058897,0.00007410609,0.000042181873,0.00092845503],"category_scores_gemma":[0.00006630031,0.00008634915,0.000079283556,0.00016829236,0.000105301195,0.000057025576,0.00006139589,0.0001094694,0.0000065136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007975145,0.010904153,0.88616294,0.00009347737,0.0038971482,0.0004313242,0.0011832636,0.00001773649,0.011797953,0.0005816509,0.0018045522,0.07515066],"study_design_scores_gemma":[0.007860368,0.025116876,0.9164445,0.000016962695,0.00068519125,0.000017295219,0.00016255859,0.000016346823,0.011369498,0.00025629025,0.03794283,0.00011132404],"about_ca_topic_score_codex":0.00007600144,"about_ca_topic_score_gemma":0.000017102502,"teacher_disagreement_score":0.07503934,"about_ca_system_score_codex":0.00003474009,"about_ca_system_score_gemma":0.00020409256,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W4295816936","doi":"10.1016/j.annonc.2022.07.179","title":"144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Anastrozole; Palbociclib; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Stage (stratigraphy); Gynecology; Cancer; Urology; Gastroenterology; Metastatic breast cancer; Tamoxifen; Clinical trial","score_opus":0.023651441136603498,"score_gpt":0.3379894408180784,"score_spread":0.3143379996814749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295816936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181426,0.00033356692,0.000017726006,0.003760935,0.00010419424,0.0023040392,0.0014759661,0.000038681912,0.00015061702],"genre_scores_gemma":[0.9976474,0.00010143531,0.0001301342,0.00079178024,0.00004335237,0.00090689183,0.00010258628,0.00006870666,0.00020768943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555725,0.0011250229,0.0010563206,0.00072016363,0.0007267068,0.0008145503],"domain_scores_gemma":[0.99730563,0.00033002827,0.0008509262,0.00066161115,0.000605163,0.0002466389],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008443803,0.0004921917,0.00199681,0.00060424337,0.000282349,0.000011270257,0.000452392,0.00012448546,0.0014486429],"category_scores_gemma":[0.00004631377,0.00035042936,0.00024212559,0.0030595134,0.0006480937,0.00017630181,0.00024099059,0.0004995984,0.000001828073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4060334,0.018957105,0.407265,0.000066630244,0.019023094,0.00044547487,0.019199228,0.0042643263,0.055000145,0.000023630098,0.00021766221,0.06950428],"study_design_scores_gemma":[0.10028226,0.03883723,0.8428031,0.00011237874,0.0018805997,0.00010949112,0.007874341,0.00028679724,0.006128867,0.000021045553,0.001222922,0.00044092865],"about_ca_topic_score_codex":0.008705151,"about_ca_topic_score_gemma":0.0020205127,"teacher_disagreement_score":0.4355381,"about_ca_system_score_codex":0.0006072159,"about_ca_system_score_gemma":0.00081263675,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W4295817120","doi":"10.1016/j.annonc.2022.07.588","title":"459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Daiichi Sankyo Europe; Janssen Scientific Affairs; Genentech; Pharmacyclics; EMD Serono; Calithera Biosciences; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Celgene; Taiho Pharmaceutical; Daiichi-Sankyo; Pfizer","keywords":"Medicine; KRAS; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Colorectal cancer; Oncology; Cancer; Nausea; Adenocarcinoma; Pancreatic cancer; Phases of clinical research; Toxicity","score_opus":0.05754625226924613,"score_gpt":0.44073115375402466,"score_spread":0.3831849014847785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952001,0.000098412806,0.000004756766,0.0017823508,0.00005086239,0.0016906782,0.000025510351,0.000014211723,0.0011331395],"genre_scores_gemma":[0.997877,0.000011547547,0.000093672905,0.0012963191,0.000018281666,0.0005241885,0.000023446622,0.000018161203,0.00013740134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875253,0.00014120685,0.00027034286,0.00026441197,0.00034996946,0.00022154258],"domain_scores_gemma":[0.9993547,0.000051997667,0.00014667418,0.00015338695,0.00022373763,0.000069507674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002607344,0.00014512049,0.00052834593,0.0001919891,0.00008902328,0.0000031896502,0.000060956667,0.000015960575,0.00013560953],"category_scores_gemma":[0.000022278964,0.00010055343,0.00003379413,0.00035720872,0.00004587755,0.000037956626,0.0000374272,0.00011128744,0.0000030831227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07778888,0.028979028,0.7309039,0.000027149543,0.0011504346,0.0006278402,0.031096205,0.0009643306,0.00011046378,0.000012915709,0.0013793615,0.12695947],"study_design_scores_gemma":[0.03083456,0.23690327,0.72502947,0.000026632244,0.00012248805,0.000011396389,0.0044594426,0.000034624692,0.00025392877,0.000027954185,0.0021637895,0.0001324387],"about_ca_topic_score_codex":0.00041922095,"about_ca_topic_score_gemma":0.0010020579,"teacher_disagreement_score":0.20792423,"about_ca_system_score_codex":0.00017528415,"about_ca_system_score_gemma":0.00023269212,"threshold_uncertainty_score":0.410045},"labels":[],"label_agreement":null},{"id":"W4295817176","doi":"10.1016/j.annonc.2022.07.1038","title":"912P Metabolomic profiling for the early detection of lung cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta; St. Boniface Hospital; Université Laval","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Prostate cancer; Cancer; Univariate analysis; Stage (stratigraphy); Breast cancer; Survival rate; Multivariate analysis","score_opus":0.04133421493866845,"score_gpt":0.3608128117525038,"score_spread":0.31947859681383534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809734,0.015690235,0.00108035,0.00094168907,0.0004629241,0.00037152309,0.00010856379,0.0000031099778,0.0003682009],"genre_scores_gemma":[0.99626744,0.002468973,0.00027327557,0.00026118243,0.0001307301,0.0003382795,0.000010332958,0.0000106100215,0.00023917048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992909,0.00007476011,0.00022396115,0.00016726903,0.00007648307,0.00016662442],"domain_scores_gemma":[0.99936956,0.000065558124,0.00023160529,0.00017075495,0.00014543823,0.000017052018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004929443,0.00007656566,0.00022448241,0.000049646198,0.0001426275,0.0000019840184,0.00017474336,0.00005072951,0.000020693484],"category_scores_gemma":[0.00009319911,0.000060301918,0.00013877438,0.000107565415,0.00007543601,0.0000017246466,0.00016128612,0.00007549496,1.019052e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042634507,0.00007297478,0.0013805325,0.00002482783,0.00041319407,1.8895886e-7,0.00007114994,0.00021954153,0.9808758,0.00080916076,0.0013825364,0.014323764],"study_design_scores_gemma":[0.00044120415,0.0014407901,0.0031580417,0.0000010504223,0.00008650441,0.0000023512007,0.00017114788,0.00018165112,0.828813,0.00019255062,0.16543949,0.000072189745],"about_ca_topic_score_codex":0.000107938926,"about_ca_topic_score_gemma":0.000042826516,"teacher_disagreement_score":0.16405696,"about_ca_system_score_codex":0.000009265076,"about_ca_system_score_gemma":0.00011182691,"threshold_uncertainty_score":0.24590409},"labels":[],"label_agreement":null},{"id":"W4295817205","doi":"10.1016/j.annonc.2022.07.653","title":"525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Oncology; Internal medicine; Endometrial cancer; Gynecology; Family medicine; Medical physics; Cancer; Immunotherapy","score_opus":0.05058624724658811,"score_gpt":0.3731665568183526,"score_spread":0.3225803095717645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945922,0.0010259637,0.0000014892057,0.00043603175,0.00022062789,0.0023069666,0.00031065434,0.00001540007,0.0010906834],"genre_scores_gemma":[0.9982392,0.00072946417,0.00008184465,0.00027105008,0.00008152931,0.00033162598,0.00012764236,0.00003159036,0.00010602043],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972421,0.00036691097,0.0009326101,0.00048807898,0.0005873479,0.0003829624],"domain_scores_gemma":[0.9976621,0.00076376984,0.0007552312,0.00035941286,0.0003272891,0.00013216492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023827344,0.00030385453,0.0016761326,0.0005077522,0.000072398485,0.000002401228,0.0001556131,0.00008754408,0.00031325998],"category_scores_gemma":[0.00018787518,0.00023405513,0.00013874602,0.0014161684,0.00016114303,0.00008945188,0.00011928105,0.00018420898,0.0000010646011],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18548045,0.036108848,0.32137713,0.00013765108,0.0015598122,0.00004701349,0.0017923395,0.00051845907,0.00088713225,0.000030146792,0.00008154415,0.4519795],"study_design_scores_gemma":[0.18905944,0.13348152,0.66360754,0.00007386646,0.00045747455,0.0000024690085,0.00045112454,0.00000849284,0.005002189,0.000019812667,0.007644787,0.00019130968],"about_ca_topic_score_codex":0.0025826278,"about_ca_topic_score_gemma":0.00040870474,"teacher_disagreement_score":0.45178816,"about_ca_system_score_codex":0.0003832366,"about_ca_system_score_gemma":0.0003772693,"threshold_uncertainty_score":0.9544491},"labels":[],"label_agreement":null},{"id":"W4295817239","doi":"10.1016/j.annonc.2022.07.603","title":"475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Tolerability; Internal medicine; Gastroenterology; Asymptomatic; Oncology; Surgery","score_opus":0.03731267014780751,"score_gpt":0.36591195721428627,"score_spread":0.3285992870664788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104524,0.0006974986,0.000008865503,0.0020910776,0.00013944901,0.00048318782,0.00014471883,0.000011716888,0.005378264],"genre_scores_gemma":[0.99820805,0.0005907593,0.00009738669,0.0005865648,0.000060383536,0.000020404537,0.00013433675,0.000017018046,0.0002850949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843097,0.0001593543,0.0006173263,0.00025556216,0.00021837252,0.00031844492],"domain_scores_gemma":[0.99916637,0.00014522248,0.00028326848,0.00020107791,0.000071112496,0.00013291973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038758552,0.00015846817,0.00068381714,0.00017233024,0.000066420755,0.0000023812693,0.00010885336,0.0000762215,0.00088791124],"category_scores_gemma":[0.000045121185,0.00014027471,0.00013843838,0.0001963441,0.00014955486,0.000048969803,0.00020010814,0.00021551822,0.0000063845605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048492722,0.041389797,0.1528959,0.0016702636,0.00091566297,0.0045146756,0.0031230042,0.00010091952,0.051950403,0.0024078607,0.0026035847,0.6899352],"study_design_scores_gemma":[0.05623023,0.034682475,0.8385603,0.000123069,0.00029814357,0.0003892943,0.00047151564,0.000093262155,0.023520494,0.00022035971,0.044991735,0.00041911623],"about_ca_topic_score_codex":0.00034059983,"about_ca_topic_score_gemma":0.00005411927,"teacher_disagreement_score":0.68951607,"about_ca_system_score_codex":0.000053541648,"about_ca_system_score_gemma":0.00017496945,"threshold_uncertainty_score":0.9722006},"labels":[],"label_agreement":null},{"id":"W4295817242","doi":"10.1016/j.annonc.2022.07.676","title":"548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Microsatellite instability; Oncology; Cancer; Discontinuation; Progression-free survival; Endometrial cancer; Cohort; Population; Chemotherapy","score_opus":0.08234252386499086,"score_gpt":0.38700956025153277,"score_spread":0.3046670363865419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880625,0.0024857821,0.0000016394941,0.001512533,0.0008864863,0.0053408244,0.00033457702,0.00006254578,0.00056937605],"genre_scores_gemma":[0.9966087,0.0006460996,0.0003347273,0.00034733774,0.000085777145,0.0016047877,0.00008191156,0.00005700106,0.00023369971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937287,0.0016856039,0.0011925132,0.0011073408,0.0013154236,0.000970446],"domain_scores_gemma":[0.9963881,0.0015857872,0.00051452516,0.0009619596,0.00037555074,0.00017410339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035572147,0.00049376336,0.001428861,0.0005592976,0.00019321992,0.000030401266,0.00058960414,0.00017929365,0.00069054065],"category_scores_gemma":[0.0010212543,0.0003021282,0.0001294905,0.0021549393,0.0004089153,0.000115376104,0.0005939966,0.00087284954,0.0000014813378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12022414,0.013952059,0.821409,0.00041127013,0.00028131934,0.0008313768,0.01079698,0.001229714,0.0013554668,0.000049496735,0.001021985,0.028437225],"study_design_scores_gemma":[0.08598888,0.14672637,0.66119415,0.00069960207,0.00046740813,0.00029091293,0.03187585,0.00045891508,0.0041944757,0.00019996603,0.06651868,0.0013847747],"about_ca_topic_score_codex":0.0030194917,"about_ca_topic_score_gemma":0.020100031,"teacher_disagreement_score":0.1602148,"about_ca_system_score_codex":0.00062691653,"about_ca_system_score_gemma":0.0015863404,"threshold_uncertainty_score":0.9999431},"labels":[],"label_agreement":null},{"id":"W4295817295","doi":"10.1016/j.annonc.2022.07.663","title":"535P Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; F. Hoffmann-La Roche; Incyte; Astellas Pharma; Novocure; Springworks Therapeutics; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; American Society of Clinical Oncology; EMD Serono; Centre Léon Bérard; Mersana Therapeutics; Deciphera Pharmaceuticals; Institut Bergonié; Sociedad Española de Oncología Médica; Clovis Oncology; Takeda Oncology; Amgen","keywords":"Medicine; Anxiety; Quality of life (healthcare); Depression (economics); Ovarian cancer; Internal medicine; Chemotherapy; Germ cell tumors; Cog; Etoposide; Oncology; Cancer; Pediatrics; Psychiatry","score_opus":0.05797858506159117,"score_gpt":0.3837561868422294,"score_spread":0.32577760178063825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772501,0.001515611,0.000010515686,0.018569926,0.00040268767,0.0015361748,0.00037338622,0.000019292049,0.0003223207],"genre_scores_gemma":[0.99414325,0.00019419525,0.000016297663,0.0040572523,0.00029412497,0.0011219063,0.000009231065,0.000034031145,0.00012972616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739844,0.0008031177,0.0007200991,0.0003819761,0.00036308318,0.00033329963],"domain_scores_gemma":[0.9980875,0.0004468049,0.0005324903,0.0005737834,0.00021532393,0.00014405129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013095654,0.00022427895,0.0009537647,0.0001042762,0.00015816152,0.000008156401,0.00019423974,0.00008758853,0.002067854],"category_scores_gemma":[0.000072723284,0.00015955916,0.0002837722,0.0002488484,0.00021412215,0.000057361685,0.00009325581,0.00028794172,0.0000022358488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037648021,0.0040764227,0.9509754,0.00006985695,0.0013304339,0.001396764,0.0039310567,0.0000508957,0.000055895416,0.000030073112,0.00085258204,0.03346583],"study_design_scores_gemma":[0.008799567,0.004706364,0.98238564,0.000030360014,0.00032281235,0.00008238242,0.0023726881,0.000014137535,0.00028292811,0.000023216824,0.00084186235,0.00013806326],"about_ca_topic_score_codex":0.021252496,"about_ca_topic_score_gemma":0.01910972,"teacher_disagreement_score":0.033327766,"about_ca_system_score_codex":0.00014415837,"about_ca_system_score_gemma":0.00049532304,"threshold_uncertainty_score":0.9988444},"labels":[],"label_agreement":null},{"id":"W4295817391","doi":"10.1016/j.annonc.2022.07.782","title":"658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Docetaxel; Cetuximab; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Head and neck cancer; Radiation therapy; Cancer; Immunotherapy","score_opus":0.04529320590359399,"score_gpt":0.34223123775879116,"score_spread":0.2969380318551972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801026,0.015634932,0.0000024737026,0.0007448588,0.0002216243,0.0008874581,0.00028465307,0.000016038573,0.0021053893],"genre_scores_gemma":[0.9978314,0.0012225925,0.00020876809,0.00028151067,0.00002379569,0.00006497178,0.0000910353,0.000033951936,0.00024194288],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975565,0.00040001934,0.00089951535,0.0003639301,0.00038108625,0.00039894637],"domain_scores_gemma":[0.9984699,0.00024049338,0.00052649673,0.00037669626,0.00028063462,0.000105769934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005402602,0.00023651731,0.0011968695,0.00037446548,0.00006232202,0.0000038169305,0.0001823818,0.00011840594,0.00040452013],"category_scores_gemma":[0.00009723655,0.00022682008,0.00027338928,0.0005166623,0.00024614757,0.000052450803,0.00011534855,0.0002915421,0.0000011269532],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49497998,0.0039875004,0.2293313,0.006281492,0.0006102943,0.00047566486,0.025450263,0.000050749837,0.030346576,0.00014689825,0.01656831,0.19177099],"study_design_scores_gemma":[0.20629704,0.28826505,0.26319495,0.00083786104,0.0010636112,0.00035338278,0.014298904,0.0001467926,0.12123186,0.00033199982,0.102894545,0.0010840095],"about_ca_topic_score_codex":0.0011484738,"about_ca_topic_score_gemma":0.0006314498,"teacher_disagreement_score":0.28868294,"about_ca_system_score_codex":0.00021601922,"about_ca_system_score_gemma":0.0007383017,"threshold_uncertainty_score":0.9249454},"labels":[],"label_agreement":null},{"id":"W4295817408","doi":"10.1016/j.annonc.2022.07.729","title":"601P Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; University of the Fraser Valley; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Vulvar cancer; Vaginal cancer; Hazard ratio; Radiation therapy; Vulva; Cervical cancer; Cancer; Chemotherapy; Chemoradiotherapy; Internal medicine; Oncology; Surgery; Confidence interval","score_opus":0.035893220981311216,"score_gpt":0.3535934929014478,"score_spread":0.3177002719201366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977246,0.00038504272,0.0000020979924,0.0006121623,0.000080366386,0.00051406556,0.00045704038,0.000006377829,0.00021823726],"genre_scores_gemma":[0.99760455,0.0007667422,0.00008509688,0.0007165084,0.000012508572,0.00021917032,0.000038373924,0.000011583496,0.000545448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990317,0.000065280874,0.00029098926,0.00020498826,0.00021478004,0.00019225197],"domain_scores_gemma":[0.9994223,0.00011861025,0.00015598534,0.00010810272,0.00011224096,0.00008275054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006898707,0.000085531574,0.0006118989,0.00006621363,0.00003522444,0.0000039432057,0.000052170082,0.000037692454,0.0014128067],"category_scores_gemma":[0.000028080545,0.00008077678,0.000045343982,0.00022408504,0.00006754227,0.00003477965,0.0000504073,0.00007773819,2.9765178e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020308977,0.001663323,0.7328919,0.00004019355,0.0001815796,0.000113834634,0.00009868747,0.000017534732,0.0000066336297,9.828906e-7,0.000060474016,0.26289397],"study_design_scores_gemma":[0.017116463,0.024607005,0.95442814,0.000049154824,0.000086854874,0.000009956595,0.00015551833,0.0000020365605,0.00006419958,0.000021945947,0.0033876032,0.000071148264],"about_ca_topic_score_codex":0.043982908,"about_ca_topic_score_gemma":0.1474963,"teacher_disagreement_score":0.2628228,"about_ca_system_score_codex":0.00015872152,"about_ca_system_score_gemma":0.00024412536,"threshold_uncertainty_score":0.99950004},"labels":[],"label_agreement":null},{"id":"W4295817484","doi":"10.1016/j.annonc.2022.07.1070","title":"945P Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Stage (stratigraphy); Lung; Cancer; Respiratory system","score_opus":0.04894935660891992,"score_gpt":0.3957347785323185,"score_spread":0.34678542192339856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528694,0.034591205,0.000042302338,0.0052635176,0.0005504368,0.0004544101,0.0015930268,0.000017034276,0.0046186442],"genre_scores_gemma":[0.98895717,0.004519363,0.000043400352,0.0042741667,0.0002177145,0.00041780513,0.00011309872,0.000019051386,0.0014382156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986972,0.00016498032,0.00033297157,0.00031692302,0.00027212282,0.00021576087],"domain_scores_gemma":[0.9988658,0.00030204075,0.00027168455,0.00023821436,0.00022237883,0.000099881916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003429726,0.00015648859,0.0006057268,0.0002271918,0.00020213274,0.000020209975,0.00014164242,0.00005931418,0.00083990884],"category_scores_gemma":[0.000024260267,0.0001224908,0.00014318166,0.0003534311,0.00017743984,0.00005781721,0.00018497944,0.00019811113,3.2553808e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054926565,0.0002940244,0.95038366,0.000079094105,0.0146158375,0.00008220192,0.006922964,0.0008648189,0.0022160274,0.0002391267,0.014521525,0.009231451],"study_design_scores_gemma":[0.006436904,0.0005219529,0.75605047,0.000043730586,0.01184954,0.000005374879,0.0065368363,0.0020735273,0.001286389,0.000028508744,0.21489385,0.00027292178],"about_ca_topic_score_codex":0.022259941,"about_ca_topic_score_gemma":0.004095995,"teacher_disagreement_score":0.20037232,"about_ca_system_score_codex":0.00015788451,"about_ca_system_score_gemma":0.0007773134,"threshold_uncertainty_score":0.9842509},"labels":[],"label_agreement":null},{"id":"W4295817491","doi":"10.1016/j.annonc.2022.07.1086","title":"960P Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"China Scholarship Council","keywords":"Durvalumab; Medicine; Internal medicine; Chemoradiotherapy; Multivariate analysis; Proportional hazards model; Oncology; Cancer; Adjuvant; Hazard ratio; Stage (stratigraphy); Lung cancer; Immunotherapy; Confidence interval","score_opus":0.08226763748118476,"score_gpt":0.40132208972991773,"score_spread":0.31905445224873297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783687,0.0007650245,0.0000026817972,0.0086488165,0.00026065647,0.00045329743,0.00005862419,0.000017204447,0.0114249885],"genre_scores_gemma":[0.99439794,0.0017167267,0.0003846428,0.0010404753,0.00003536455,0.00008351959,0.000023114035,0.000015639676,0.0023025689],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99878895,0.00014148898,0.00042889788,0.00023804158,0.00019321442,0.00020942136],"domain_scores_gemma":[0.9991284,0.0002021109,0.00023750153,0.00026368228,0.000077340446,0.00009094014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039088662,0.00013544786,0.00066374097,0.00023751023,0.00008968267,0.0000026964883,0.00008123233,0.00005219199,0.00035468617],"category_scores_gemma":[0.000039125185,0.00010489657,0.00014670765,0.00022152497,0.00008454481,0.000034791832,0.00009475561,0.00008565603,0.0000014381267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018522494,0.00128697,0.16877507,0.00007637223,0.00060771493,0.00007495498,0.0038669512,0.000014199622,0.32317564,0.00006891615,0.010360571,0.47317016],"study_design_scores_gemma":[0.009224158,0.02260083,0.5236741,0.00011117496,0.00016864871,0.000054848344,0.008302247,0.000015460944,0.13435903,0.00020501718,0.3010258,0.00025868055],"about_ca_topic_score_codex":0.00074528466,"about_ca_topic_score_gemma":0.0001329215,"teacher_disagreement_score":0.47291148,"about_ca_system_score_codex":0.00014461801,"about_ca_system_score_gemma":0.00016539393,"threshold_uncertainty_score":0.4277558},"labels":[],"label_agreement":null},{"id":"W4295817497","doi":"10.1016/j.annonc.2022.07.677","title":"549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; University of British Columbia","funders":"GlaxoSmithKline; AstraZeneca","keywords":"Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Progression-free survival; Cohort; Interim analysis; Discontinuation; Cancer; Clinical trial; Phases of clinical research; Chemotherapy","score_opus":0.04262494270149251,"score_gpt":0.3438175202804933,"score_spread":0.30119257757900075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943792,0.00019708923,4.6805667e-7,0.0012642503,0.00012386814,0.0020725932,0.000041428364,0.00003072973,0.0018903757],"genre_scores_gemma":[0.99886525,0.00002466095,0.0001301093,0.0004810346,0.000021941298,0.0003491382,0.00003989213,0.000033476805,0.000054500448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654853,0.0008926834,0.0005543243,0.0005361636,0.00097133464,0.00049698347],"domain_scores_gemma":[0.9984484,0.00037413812,0.00027756116,0.0005916479,0.0002105754,0.00009770098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014789209,0.0002683918,0.0007770715,0.0002343345,0.000101047764,0.000009724432,0.00031157496,0.000081599246,0.00010849585],"category_scores_gemma":[0.000170976,0.00016804264,0.00005463878,0.0005658345,0.00021972194,0.00004176642,0.00029232,0.00049407274,9.865839e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010194455,0.005969561,0.97476786,0.000051987066,0.00009820613,0.0003988497,0.005148335,0.00032459552,0.0000425057,0.000014453558,0.001071148,0.0019180205],"study_design_scores_gemma":[0.01279826,0.056000773,0.9231585,0.00007325485,0.000065763874,0.00004663202,0.00625964,0.00009663201,0.000108589185,0.00003885254,0.0011564499,0.00019662634],"about_ca_topic_score_codex":0.001085152,"about_ca_topic_score_gemma":0.0040311846,"teacher_disagreement_score":0.051609356,"about_ca_system_score_codex":0.00019805349,"about_ca_system_score_gemma":0.00039852623,"threshold_uncertainty_score":0.685258},"labels":[],"label_agreement":null},{"id":"W4295817520","doi":"10.1016/j.annonc.2022.07.1202","title":"1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cachexia; Medicine; Gut flora; Internal medicine; Gastroenterology; Cancer; Lung cancer; Oncology; Immunology","score_opus":0.026051634660371623,"score_gpt":0.3596634768692644,"score_spread":0.3336118422088928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971192,0.0009029411,0.000011308099,0.0008439756,0.00011453533,0.00045973944,0.00037076714,0.0000035074966,0.00017404133],"genre_scores_gemma":[0.9945909,0.00085793925,0.0002411011,0.0033726117,0.000024374976,0.000063447114,0.00010377232,0.00002721974,0.00071866787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987546,0.00014145137,0.00037433126,0.0003268847,0.000087153145,0.0003155325],"domain_scores_gemma":[0.99900204,0.000040147857,0.00038182188,0.00022495176,0.00026434255,0.000086673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029203747,0.00015775663,0.00047867064,0.00005481608,0.00008884165,0.0000039657534,0.00018581949,0.00013831232,0.00008601002],"category_scores_gemma":[0.000013809909,0.00012646567,0.000070040056,0.0001228381,0.000114313065,0.0000028655102,0.00014574654,0.00015796493,2.980496e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009871925,0.00083077414,0.8755956,0.000037681682,0.00045446257,0.0000016875783,0.00023578617,0.00010571121,0.11334162,0.0000013855735,0.0071520046,0.0012560348],"study_design_scores_gemma":[0.0034309644,0.0064837947,0.95476675,0.000023600543,0.00006575557,8.731883e-7,0.00009007204,0.0000040635864,0.010285791,0.0000011742078,0.024650235,0.00019692033],"about_ca_topic_score_codex":0.0012998286,"about_ca_topic_score_gemma":0.002069365,"teacher_disagreement_score":0.103055835,"about_ca_system_score_codex":0.0000461305,"about_ca_system_score_gemma":0.00058525463,"threshold_uncertainty_score":0.5157121},"labels":[],"label_agreement":null},{"id":"W4295817534","doi":"10.1016/j.annonc.2022.07.633","title":"505P The impact of COVID-19 on the wellness and resilience of the Canadian medical oncology workforce: A Canadian Association of Medical Oncologists survey","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Medical Association; Dalhousie University; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Workforce; Workload; Pandemic; Family medicine; Psychological resilience; Nursing; Coronavirus disease 2019 (COVID-19); Gerontology; Internal medicine; Management; Disease; Psychology","score_opus":0.18594175766030363,"score_gpt":0.5014866737579504,"score_spread":0.3155449160976468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6143759,0.00022343452,0.0000014107271,0.38159725,0.00023098168,0.000544188,0.0002373378,0.0000036962897,0.0027858268],"genre_scores_gemma":[0.96563417,0.00045016236,0.0000021142812,0.0336442,0.00007178128,0.000031818734,0.000016749464,0.000011480092,0.00013750227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932682,0.0034752577,0.00082369323,0.00025004646,0.0015625394,0.0006202794],"domain_scores_gemma":[0.9861044,0.010450248,0.0009152666,0.00055137963,0.00048809915,0.0014905885],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01688449,0.00016070172,0.0008134213,0.0002759358,0.00042516584,0.00000399649,0.0008191376,0.00062169344,0.0018017853],"category_scores_gemma":[0.044090934,0.00008645438,0.00019078585,0.00082948006,0.001141066,0.000023069355,0.00019598518,0.0011399153,0.0000013709767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017279921,0.000687354,0.7222928,0.00020507337,0.00039412032,0.0002098382,0.007928179,0.00043720656,0.00004952299,0.005477163,0.21350585,0.04708493],"study_design_scores_gemma":[0.0015004419,0.0066751633,0.86321336,0.00008293777,0.00005267869,0.00012540566,0.001392935,0.00028893497,0.00009130646,0.00042825166,0.12605113,0.00009746236],"about_ca_topic_score_codex":0.9713589,"about_ca_topic_score_gemma":0.9933808,"teacher_disagreement_score":0.35125834,"about_ca_system_score_codex":0.0030871786,"about_ca_system_score_gemma":0.10352563,"threshold_uncertainty_score":0.9991107},"labels":[],"label_agreement":null},{"id":"W4295817538","doi":"10.1016/j.annonc.2022.07.1065","title":"940P Programmed death-ligand 1 (PDL1) expression and real-world outcomes in resected, early-stage non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Brampton Civic Hospital; London Health Sciences Centre; AstraZeneca (Canada); William Osler Health System; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Lung cancer; Cancer; Lung; Ligand (biochemistry); Pathology; Internal medicine; Cancer research; Receptor","score_opus":0.05707741825648091,"score_gpt":0.42636990270218567,"score_spread":0.3692924844457047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801778,0.0011352656,0.0000052737632,0.0031111673,0.00016386838,0.0009904603,0.00007231337,0.000025242107,0.014318577],"genre_scores_gemma":[0.98935276,0.0008145876,0.0004608845,0.00065388536,0.000042280844,0.00070801476,0.00004449444,0.000024331215,0.0078987805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987517,0.00009661848,0.0003369974,0.00030120177,0.00018396569,0.00032953286],"domain_scores_gemma":[0.99923533,0.00013876474,0.00018195862,0.0002179132,0.000096867036,0.00012916708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021256867,0.00014814205,0.0004718483,0.00025829286,0.000112767324,0.00000802852,0.000087078086,0.00007125193,0.00015333801],"category_scores_gemma":[0.000022991406,0.00012264203,0.0000711803,0.00026496992,0.00005619733,0.000054676417,0.00012809047,0.0002307595,0.0000011331553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005810965,0.0009920646,0.97616553,0.00015354132,0.0001421986,0.00023950115,0.0032491374,0.000036004494,0.0066574295,0.00006652185,0.0023029337,0.009414043],"study_design_scores_gemma":[0.008009918,0.0030479997,0.9267463,0.00013342705,0.00022458144,0.000009385539,0.00084785564,0.00008585464,0.015494072,0.000068045556,0.04513259,0.00019996102],"about_ca_topic_score_codex":0.009790494,"about_ca_topic_score_gemma":0.0032821866,"teacher_disagreement_score":0.04941922,"about_ca_system_score_codex":0.00017971377,"about_ca_system_score_gemma":0.00048922346,"threshold_uncertainty_score":0.9968034},"labels":[],"label_agreement":null},{"id":"W4295817546","doi":"10.1016/j.annonc.2022.07.960","title":"834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"EMD Serono; Regeneron Pharmaceuticals; Array BioPharma; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb; Symphogen; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; Melanoma; Proportional hazards model; Progression-free survival; Immunotherapy; Radiation therapy; Overall survival; Cancer; Gastroenterology; Surgery; Cancer research","score_opus":0.01477455985204754,"score_gpt":0.27712559915084634,"score_spread":0.26235103929879877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202996,0.0008616885,0.000010297527,0.005922387,0.000036023124,0.0007690074,0.00029084858,0.000011995699,0.00006780524],"genre_scores_gemma":[0.9988405,0.000049398797,0.00015250618,0.00053395657,0.000027202876,0.00008742644,0.00026729703,0.00001808619,0.00002359889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856406,0.0003820191,0.00033628242,0.00026785405,0.00023084779,0.00021890432],"domain_scores_gemma":[0.99916947,0.00023057134,0.00020807062,0.00014873265,0.00008032336,0.00016284848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004988197,0.00016893152,0.000562747,0.00016399227,0.00007245739,0.0000067411847,0.000033520304,0.000035521323,0.00006719521],"category_scores_gemma":[0.00008556253,0.00012014012,0.000045338893,0.00018139236,0.00014655296,0.00006730887,0.00003888384,0.0001371413,4.1355818e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024883863,0.002883056,0.8995181,0.00006606421,0.00070062996,0.0006259057,0.0003387673,0.00006821519,0.00016016368,0.00015821082,0.00019407948,0.07040299],"study_design_scores_gemma":[0.026433399,0.018050589,0.9528396,0.000027427533,0.00033153352,0.00003067465,0.00021550665,0.00009512774,0.00023527943,0.000048930728,0.001562733,0.0001292135],"about_ca_topic_score_codex":0.00047275473,"about_ca_topic_score_gemma":0.000094317315,"teacher_disagreement_score":0.07027378,"about_ca_system_score_codex":0.000056337893,"about_ca_system_score_gemma":0.00014599126,"threshold_uncertainty_score":0.4899172},"labels":[],"label_agreement":null},{"id":"W4295817547","doi":"10.1016/j.annonc.2022.07.779","title":"655MO Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cetuximab; Oncology; Cisplatin; Radiation therapy; Internal medicine; Quality of life (healthcare); Cancer; Chemotherapy; Colorectal cancer","score_opus":0.12666502659968518,"score_gpt":0.4182245135877886,"score_spread":0.2915594869881034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99296224,0.0011779016,0.000003525278,0.002980478,0.00006986491,0.0005684233,0.00005430739,0.000011910242,0.0021713458],"genre_scores_gemma":[0.9965219,0.00054521306,0.00023398742,0.0021525817,0.000043623128,0.00016480086,0.0000136954695,0.000030416304,0.00029382147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796057,0.00035463716,0.00066213147,0.0003065291,0.0003665169,0.0003496267],"domain_scores_gemma":[0.99884105,0.00023491417,0.0003828959,0.00021248282,0.00024400094,0.000084641666],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006048715,0.00017972595,0.0012859422,0.00021139026,0.00005166232,0.0000021646845,0.00012413602,0.00008002049,0.0015378803],"category_scores_gemma":[0.00010527965,0.00012245677,0.000042708107,0.00068122835,0.00014424155,0.00007188107,0.000057501195,0.00032820506,9.0864347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03420141,0.0019260301,0.92565495,0.00018129607,0.00026419223,0.000041520372,0.0035625962,0.00014813845,0.00062105944,0.000010295002,0.0025985723,0.030789936],"study_design_scores_gemma":[0.020364719,0.014780073,0.958081,0.00020863664,0.000021265269,0.000002505282,0.00065691007,0.000037204612,0.00053439493,0.000005512617,0.0051371804,0.00017058931],"about_ca_topic_score_codex":0.0037588938,"about_ca_topic_score_gemma":0.0077649816,"teacher_disagreement_score":0.032426056,"about_ca_system_score_codex":0.00023621702,"about_ca_system_score_gemma":0.0010704838,"threshold_uncertainty_score":0.99937487},"labels":[],"label_agreement":null},{"id":"W4295817549","doi":"10.1016/j.annonc.2022.07.647","title":"519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Adenocarcinoma; Cervical cancer; Population; Clinical endpoint; Oncology; Cancer; Randomized controlled trial","score_opus":0.1354505986576437,"score_gpt":0.4640827921681646,"score_spread":0.3286321935105209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988875,0.0025293096,0.000047243066,0.005788596,0.00089625485,0.0009847628,0.00025706686,0.00003031324,0.0005915093],"genre_scores_gemma":[0.99580204,0.002296045,0.000071940034,0.000984991,0.00016020273,0.00028851017,0.00016331546,0.000033734446,0.00019923715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960591,0.0007671195,0.0014936187,0.000501515,0.0006740111,0.0005045924],"domain_scores_gemma":[0.9978785,0.0005709426,0.0006630456,0.00050590525,0.00020877803,0.00017282536],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017532137,0.0002715131,0.0018802726,0.0007173473,0.00006854787,0.000006159758,0.0003469122,0.0001432949,0.0061463756],"category_scores_gemma":[0.00012213738,0.00022667168,0.00071619486,0.0019224739,0.0002548667,0.000058731173,0.00018575504,0.00049043086,0.0000021005187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7476295,0.014014639,0.010667243,0.00029458228,0.0055741174,0.0004354678,0.0015251534,0.00006253585,0.0027780612,0.00005045624,0.0018310273,0.21513718],"study_design_scores_gemma":[0.692633,0.1127739,0.09731158,0.00024210762,0.0068177613,0.00014658338,0.0026029225,0.00097508304,0.006398432,0.00012555857,0.07890181,0.0010712662],"about_ca_topic_score_codex":0.0016560669,"about_ca_topic_score_gemma":0.003921532,"teacher_disagreement_score":0.21406592,"about_ca_system_score_codex":0.0003021124,"about_ca_system_score_gemma":0.0011896278,"threshold_uncertainty_score":0.9947621},"labels":[],"label_agreement":null},{"id":"W4295817564","doi":"10.1016/j.annonc.2022.07.087","title":"59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Intrahepatic Cholangiocarcinoma; Mutation; Internal medicine; Cancer research; Genetics; Gene; Biology","score_opus":0.05514244635908472,"score_gpt":0.35811700969749016,"score_spread":0.30297456333840544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981945,0.0000863481,0.000071318944,0.00055080093,0.000036937083,0.00041555442,0.00013409731,0.000004712859,0.0005057046],"genre_scores_gemma":[0.99867827,0.000026176896,0.00049791165,0.0001292028,0.000016828568,0.00009691534,0.00045389088,0.000017809305,0.000083000974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986783,0.00024369439,0.00036002707,0.00025289145,0.00021746375,0.00024760174],"domain_scores_gemma":[0.99903005,0.00015533244,0.00019441791,0.00032508612,0.00023222486,0.00006289348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023973802,0.00010184067,0.00022169722,0.00019940443,0.00008757364,0.000003708032,0.00027685784,0.00007559997,0.00017656616],"category_scores_gemma":[0.0003399798,0.00008965718,0.000059369053,0.00038224485,0.00015912004,0.000005276753,0.00020790103,0.00016142747,0.000003344707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003339764,0.0049836203,0.77348894,0.0001095378,0.00022644551,0.000019350744,0.00096046185,0.0010205116,0.19572921,0.00050960673,0.004925259,0.014687271],"study_design_scores_gemma":[0.002816999,0.0068972795,0.943326,0.000017349916,0.000016705677,0.0000075097337,0.0003013875,0.000043657907,0.03348553,0.00006199688,0.01286089,0.00016470124],"about_ca_topic_score_codex":0.000101397985,"about_ca_topic_score_gemma":0.00016502252,"teacher_disagreement_score":0.16983703,"about_ca_system_score_codex":0.000017926655,"about_ca_system_score_gemma":0.00038366008,"threshold_uncertainty_score":0.36561134},"labels":[],"label_agreement":null},{"id":"W4295817566","doi":"10.1016/j.annonc.2022.07.585","title":"456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"Cilag; Army Research Office; Daiichi Sankyo Europe; National Cancer Institute; Ignyta; Institut National Du Cancer; University of Texas MD Anderson Cancer Center; Mereo BioPharma; Plexxikon; AstraZeneca; Genentech; MEI Pharma; Institut Gustave-Roussy; Basilea Pharmaceutica; Deciphera Pharmaceuticals; Astellas Pharma; Cancer Research UK; Springworks Therapeutics; Glenmark Pharmaceuticals; EMD Serono; Flatiron Health; Ascentage Pharma; Aminex Therapeutics; SK Life Science; Syndax Pharmaceuticals; Oregon Health and Science University; Mersana Therapeutics; Tizona Therapeutics; Amgen; Exelixis; Mirati Therapeutics; GlaxoSmithKline; Ribon Therapeutics; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Novocure; Ipsen; Jazz Pharmaceuticals; National Institutes of Health; Natera; Regeneron Pharmaceuticals; Sanofi; BeiGene; Memorial Sloan-Kettering Cancer Center; Merck KGaA; Gilead Sciences; Symphogen; Boston Biomedical; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Oncology; Population; Breast cancer; Anemia; Phases of clinical research; Renal cell carcinoma; Nausea; Cancer; Gastroenterology; Toxicity","score_opus":0.020260205089490613,"score_gpt":0.3406396318417041,"score_spread":0.3203794267522135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966195,0.0006710352,0.000016661466,0.0011267982,0.00011484143,0.0012857855,0.000060206225,0.0000025064833,0.00010264101],"genre_scores_gemma":[0.9995946,0.000060340008,0.00004118789,0.00009273729,0.000032392545,0.000085705986,0.00001172386,0.000014040221,0.00006726419],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982636,0.0005626391,0.0005562837,0.00026036985,0.00018999653,0.00016713195],"domain_scores_gemma":[0.9990585,0.000053442614,0.0003512146,0.0004003889,0.00010609659,0.000030353152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059005053,0.00012414262,0.00036166594,0.00006688451,0.00007239953,0.0000013575919,0.00025142264,0.00008377952,0.000019535917],"category_scores_gemma":[0.00016903543,0.00009160987,0.00011227969,0.00033814253,0.00016855488,0.0000040085715,0.00024373182,0.00018032517,6.7886376e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029650403,0.0017281764,0.00068290724,0.000027431468,0.000108374785,0.0000016571663,0.00077665556,0.00648816,0.9628917,0.00003168322,0.000074636046,0.024223577],"study_design_scores_gemma":[0.008215921,0.007841455,0.015491762,0.00002964667,0.00004578718,0.000009212447,0.0008332436,0.00008812506,0.96214235,0.00005812934,0.0051297247,0.00011462009],"about_ca_topic_score_codex":0.00008139443,"about_ca_topic_score_gemma":0.00020072739,"teacher_disagreement_score":0.024108957,"about_ca_system_score_codex":0.000024677835,"about_ca_system_score_gemma":0.00023556684,"threshold_uncertainty_score":0.37357423},"labels":[],"label_agreement":null},{"id":"W4295817567","doi":"10.1016/j.annonc.2022.07.861","title":"735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; CD8; Cancer; Adverse effect; Leukapheresis; Immunotherapy; Antigen; Immunology; CD34","score_opus":0.11352274174321512,"score_gpt":0.37618225927644733,"score_spread":0.2626595175332322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936997,0.0006706626,0.0000059611284,0.0010919238,0.00009918287,0.0036258993,0.00020817175,0.000021561824,0.0005768844],"genre_scores_gemma":[0.99611586,0.0010601804,0.00012829741,0.0003472141,0.000057299745,0.00020341294,0.0009822919,0.0000437707,0.0010616668],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960751,0.0016798249,0.00081678736,0.00042785174,0.00057122146,0.000429221],"domain_scores_gemma":[0.99770457,0.0009180135,0.000489499,0.00045411522,0.00030968006,0.00012409835],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013724355,0.00023954203,0.0009913403,0.00026573264,0.00012496757,0.00001472163,0.00025795394,0.000095268995,0.0032705707],"category_scores_gemma":[0.00018618499,0.00015143694,0.00010175964,0.00074984645,0.00025068794,0.00008715643,0.00011006609,0.00043951947,0.000002818932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65868324,0.0173646,0.0044122683,0.000060950337,0.0005217294,0.00011040861,0.002736709,0.00021969447,0.19548975,0.0000064895253,0.005927038,0.11446712],"study_design_scores_gemma":[0.5814768,0.2006162,0.005302669,0.000070319824,0.000311567,0.000022310582,0.0011387223,0.001864026,0.14100946,0.000025741214,0.06769648,0.00046567703],"about_ca_topic_score_codex":0.0017910243,"about_ca_topic_score_gemma":0.000394105,"teacher_disagreement_score":0.18325159,"about_ca_system_score_codex":0.00012765439,"about_ca_system_score_gemma":0.00082505314,"threshold_uncertainty_score":0.99764055},"labels":[],"label_agreement":null},{"id":"W4295817568","doi":"10.1016/j.annonc.2022.07.674","title":"546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Microsatellite instability; Internal medicine; Oncology; Cohort; DNA mismatch repair; Cancer; Clinical endpoint; Colorectal cancer; Lynch syndrome; Clinical trial; Immunotherapy","score_opus":0.09758012172234112,"score_gpt":0.38878552185522175,"score_spread":0.29120540013288065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98074424,0.003962459,0.000053464424,0.0032617352,0.005495319,0.0025004325,0.0032819498,0.0001318664,0.00056852086],"genre_scores_gemma":[0.99045366,0.0011154488,0.002783279,0.0019746954,0.000458386,0.0007335072,0.0006691112,0.00008093734,0.0017309939],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955056,0.00037008393,0.0014453596,0.0011285977,0.00069320446,0.0008571789],"domain_scores_gemma":[0.99518305,0.0021156867,0.0007617742,0.001000249,0.0006568619,0.00028240716],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010982588,0.0004170833,0.0014312157,0.00036076436,0.00023898155,0.000013446431,0.00047515563,0.00031124018,0.001253569],"category_scores_gemma":[0.0022748779,0.00038016832,0.00062555925,0.00079221703,0.00030050674,0.000069629765,0.00040643182,0.00052290765,0.000010024574],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5814157,0.0042368933,0.024223572,0.0008098195,0.0014568025,0.00039033737,0.0067733666,0.0017413625,0.107580796,0.00007018988,0.034237694,0.23706344],"study_design_scores_gemma":[0.11338858,0.060720287,0.07589465,0.00037843562,0.0009345329,0.00018109319,0.0013411916,0.00023836998,0.24596962,0.00080150977,0.49886647,0.001285271],"about_ca_topic_score_codex":0.0018360704,"about_ca_topic_score_gemma":0.001844845,"teacher_disagreement_score":0.46802714,"about_ca_system_score_codex":0.0006882235,"about_ca_system_score_gemma":0.001812404,"threshold_uncertainty_score":0.999865},"labels":[],"label_agreement":null},{"id":"W4295817612","doi":"10.1016/j.annonc.2022.07.645","title":"517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Ovarian cancer; Progression-free survival; Clinical endpoint; Oncology; Maintenance therapy; Cancer; Urology; Chemotherapy; Randomized controlled trial; Surgery; Gastroenterology; Gynecology","score_opus":0.04887063730822915,"score_gpt":0.3490527267444434,"score_spread":0.3001820894362142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670965,0.00024195119,0.000020733745,0.008752528,0.0006547748,0.0017927414,0.00010038851,0.000018999148,0.0017082547],"genre_scores_gemma":[0.9927871,0.0006178265,0.00016469386,0.0048146364,0.000110152316,0.0009911321,0.00009879414,0.00003414982,0.00038148332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719465,0.00072954834,0.00062204653,0.00047781548,0.0005071895,0.0004687655],"domain_scores_gemma":[0.99829215,0.0006270804,0.00045397555,0.00032431367,0.00021179933,0.00009066055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009867396,0.00022716918,0.0007316904,0.00022192253,0.00012438123,0.000010050562,0.0001955038,0.00013454595,0.00039115144],"category_scores_gemma":[0.00030332504,0.00018317449,0.000089092515,0.00046124755,0.00018370335,0.00014640583,0.00008519393,0.0004630272,0.0000030129431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65832204,0.004075224,0.20666282,0.00016631313,0.0004598992,0.0006215194,0.022576349,0.0036245084,0.0016472396,0.002272376,0.02731674,0.07225501],"study_design_scores_gemma":[0.56185055,0.021715919,0.37415272,0.00030689605,0.000082410384,0.000031574058,0.001975919,0.0002328594,0.00045750014,0.0021165833,0.03662232,0.00045472966],"about_ca_topic_score_codex":0.0015020801,"about_ca_topic_score_gemma":0.005978533,"teacher_disagreement_score":0.16748992,"about_ca_system_score_codex":0.00058980985,"about_ca_system_score_gemma":0.0005088486,"threshold_uncertainty_score":0.7469639},"labels":[],"label_agreement":null},{"id":"W4295817627","doi":"10.1016/j.annonc.2022.07.655","title":"527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Ovarian cancer; Disease; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.055474002945644904,"score_gpt":0.3812908630487363,"score_spread":0.32581686010309135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909786,0.00039957635,0.00005720299,0.0050656036,0.0003207692,0.002409054,0.0003983261,0.000034364613,0.0003364981],"genre_scores_gemma":[0.9923539,0.00019653648,0.000200746,0.0038713554,0.0000891816,0.0030917483,0.00004999098,0.000048341426,0.00009819359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974922,0.00039208983,0.0006233218,0.00055416534,0.00045313497,0.00048510512],"domain_scores_gemma":[0.99805456,0.00037162396,0.00052273896,0.0005782612,0.00020277068,0.00027002743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007536698,0.00028584836,0.00067782315,0.00023227751,0.00028648917,0.000014182999,0.00025384052,0.00004876822,0.00019013764],"category_scores_gemma":[0.000120223434,0.00020007197,0.00011291419,0.00060815335,0.000105138504,0.00009066582,0.000118413926,0.00034665357,0.000007826664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019332321,0.009059698,0.89077306,0.000014367679,0.0003816983,0.0002819604,0.01242182,0.008295971,0.000050533785,0.00043898192,0.0008396681,0.05810992],"study_design_scores_gemma":[0.10332094,0.07193032,0.78272194,0.00029271407,0.0005867682,0.000017249917,0.017273389,0.00057531125,0.00051075197,0.000676795,0.02144861,0.00064522226],"about_ca_topic_score_codex":0.005905607,"about_ca_topic_score_gemma":0.0029036014,"teacher_disagreement_score":0.10805113,"about_ca_system_score_codex":0.00087644375,"about_ca_system_score_gemma":0.0006775594,"threshold_uncertainty_score":0.89275503},"labels":[],"label_agreement":null},{"id":"W4295817665","doi":"10.1016/j.annonc.2022.07.675","title":"547P Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre","funders":"Merck Sharp and Dohme; ImmunoGen; Eisai; Deciphera Pharmaceuticals; Clovis Oncology; Genentech; PharmaMar; Mersana Therapeutics; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Medicine; Microsatellite instability; Internal medicine; Oncology; Population; Biomarker; Discontinuation; Endometrial cancer; Surrogate endpoint; Cohort; Cancer; Microsatellite; Genetics; Biology","score_opus":0.02482070273344385,"score_gpt":0.34354645082440044,"score_spread":0.3187257480909566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392337,0.0039118817,0.0000058463143,0.0004919694,0.00017100734,0.0003459832,0.0008861594,0.0000010928624,0.00026270826],"genre_scores_gemma":[0.99850535,0.0007763544,0.000016944516,0.00046416413,0.000027610375,0.00004897275,0.00012010329,0.000011516597,0.000028979193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986232,0.0002668719,0.0004697058,0.00025819303,0.00019457661,0.00018748014],"domain_scores_gemma":[0.99880797,0.00016680885,0.00040939584,0.00040439225,0.00017613082,0.000035313376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004713443,0.00010929466,0.00047640645,0.00022265126,0.000030737745,0.0000024758021,0.00037947253,0.00007868256,0.000108062595],"category_scores_gemma":[0.00035405273,0.00009900301,0.00025771637,0.00089953357,0.00011002059,0.0000013754974,0.00038516984,0.000112031215,1.5552503e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059320712,0.005193245,0.0958181,0.000026812539,0.0032729527,0.000018264453,0.0010577266,0.017620252,0.8512711,0.00014554447,0.0061306246,0.013513285],"study_design_scores_gemma":[0.021219589,0.043483835,0.22261468,0.000018164143,0.0025400168,0.00000677843,0.0029869515,0.00023686665,0.55676174,0.000105133135,0.14929327,0.0007329388],"about_ca_topic_score_codex":0.0020428144,"about_ca_topic_score_gemma":0.0016818147,"teacher_disagreement_score":0.29450935,"about_ca_system_score_codex":0.000031304302,"about_ca_system_score_gemma":0.00039571628,"threshold_uncertainty_score":0.40372255},"labels":[],"label_agreement":null},{"id":"W4295817741","doi":"10.1016/j.annonc.2022.07.925","title":"799P A pilot study of the neo-adjuvant use of vemurafenib plus cobimetinib in patients with BRAF mutant melanoma with palpable lymph node metastases","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Sunnybrook Health Science Centre; McGill University Health Centre; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Vemurafenib; Melanoma; Internal medicine; Surgery; Oncology; Metastatic melanoma; Cancer; Cancer research","score_opus":0.0520053171506117,"score_gpt":0.27798662691980586,"score_spread":0.22598130976919417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847984,0.00012723047,0.000012122152,0.00008307952,0.00007712522,0.00066005724,0.0002644786,0.0000033854246,0.0002926511],"genre_scores_gemma":[0.9993624,0.000013994447,0.0001485135,0.00022474877,0.000011867679,0.00007761182,0.00007248461,0.000021683509,0.00006670549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818975,0.00045679943,0.00046668897,0.000318945,0.00030085945,0.0002669387],"domain_scores_gemma":[0.99861735,0.000064474945,0.0005183632,0.00052977,0.00021935166,0.000050681978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003288473,0.0001789776,0.00053213397,0.00008863369,0.00006713839,0.0000035878315,0.0003364225,0.00004864953,0.000037276102],"category_scores_gemma":[0.000071289585,0.000118537086,0.000058839287,0.00026127006,0.00016231414,0.0000070370647,0.00033736203,0.00010698604,3.6448952e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01624595,0.014072799,0.8296011,0.000105887055,0.0008070684,0.00007682723,0.0011488657,0.005506421,0.129212,0.00015681724,0.00089661166,0.0021696305],"study_design_scores_gemma":[0.018154303,0.12621194,0.6944018,0.00005540691,0.00022649685,0.00004333151,0.002121687,0.000046528832,0.14857253,0.00002362492,0.009704835,0.00043751765],"about_ca_topic_score_codex":0.0009646094,"about_ca_topic_score_gemma":0.0007748719,"teacher_disagreement_score":0.13519931,"about_ca_system_score_codex":0.000021280948,"about_ca_system_score_gemma":0.00038334433,"threshold_uncertainty_score":0.4833802},"labels":[],"label_agreement":null},{"id":"W4295818061","doi":"10.1016/j.annonc.2022.07.1102","title":"974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Placebo; Internal medicine; Population; Pembrolizumab; Oncology; Lung cancer; Cancer; Alternative medicine","score_opus":0.030858326892885635,"score_gpt":0.33781582150594486,"score_spread":0.3069574946130592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295818061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731185,0.006748836,0.000025286496,0.011553326,0.000637915,0.0006277221,0.0001425032,0.00003223282,0.0071137217],"genre_scores_gemma":[0.97987455,0.0036778394,0.0002050858,0.014768473,0.0002212517,0.00017992317,0.00007566194,0.00004974807,0.00094744697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998148,0.00015398503,0.0005532756,0.00041146862,0.00027061356,0.000462606],"domain_scores_gemma":[0.9989624,0.00015339698,0.00029151115,0.0003997942,0.000091509406,0.000101390775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041160165,0.00022142695,0.00069893076,0.00022835653,0.00008327116,0.0000070184205,0.00029017523,0.00017482643,0.004339566],"category_scores_gemma":[0.000016632159,0.00022070363,0.00022971114,0.00037593892,0.00011569164,0.000046734174,0.00010880968,0.000438225,0.000011834789],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17940491,0.0053104353,0.06953608,0.0005918413,0.001478669,0.0010526155,0.017746605,0.0011080421,0.17855623,0.000103171245,0.2952871,0.24982427],"study_design_scores_gemma":[0.08171314,0.008711485,0.10073837,0.00019668572,0.00023476785,0.00006701236,0.0033774092,0.0020923095,0.06969087,0.00026529352,0.7320137,0.00089895865],"about_ca_topic_score_codex":0.008712432,"about_ca_topic_score_gemma":0.0007933062,"teacher_disagreement_score":0.43672657,"about_ca_system_score_codex":0.00043311922,"about_ca_system_score_gemma":0.0011268158,"threshold_uncertainty_score":0.9978886},"labels":[],"label_agreement":null},{"id":"W4295818074","doi":"10.1016/j.annonc.2022.07.665","title":"537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Alberta Health Services; Princess Margaret Cancer Centre; McGill University Health Centre; University Health Network; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Phases of clinical research; Ovarian cancer; Cancer; Chemotherapy","score_opus":0.05685263538688413,"score_gpt":0.4240513685658881,"score_spread":0.367198733179004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295818074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996073,0.000112661306,0.0000014989068,0.0013900783,0.0001331705,0.0020711708,0.000061527135,0.000009227455,0.0001476528],"genre_scores_gemma":[0.9983261,0.000031209373,0.00015071178,0.0005015783,0.000012642056,0.0007281858,0.000089739646,0.000020141033,0.00013964582],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984791,0.00023805836,0.00046855267,0.00026864329,0.00028839873,0.0002572074],"domain_scores_gemma":[0.9991396,0.000093347844,0.0003347295,0.00015473743,0.00021081248,0.00006678796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027172503,0.00016343474,0.0007392106,0.00040014496,0.000046391982,0.0000013261641,0.00008370286,0.00003338874,0.00057819195],"category_scores_gemma":[0.000024252106,0.000119891345,0.00002938158,0.00077196426,0.00008153388,0.00009449298,0.0000719487,0.00021200038,4.1992396e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20305716,0.19571722,0.46588936,0.00023477715,0.00095453614,0.00073037785,0.011519266,0.0014571598,0.0014508232,0.000053494354,0.0010553219,0.11788049],"study_design_scores_gemma":[0.251209,0.39720687,0.34457105,0.00010060592,0.00037295185,0.000010779141,0.00230766,0.00013553235,0.0012636122,0.000030343257,0.002587386,0.00020422778],"about_ca_topic_score_codex":0.0014704278,"about_ca_topic_score_gemma":0.0061963517,"teacher_disagreement_score":0.20148964,"about_ca_system_score_codex":0.00022826444,"about_ca_system_score_gemma":0.0006417645,"threshold_uncertainty_score":0.63307965},"labels":[],"label_agreement":null},{"id":"W4295818082","doi":"10.1016/j.annonc.2022.07.810","title":"686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck; Head and neck squamous-cell carcinoma; Immunotherapy; Oncology; Basal cell; Internal medicine; Head and neck cancer; Surgery; Cancer","score_opus":0.08298842479624616,"score_gpt":0.33221267001330756,"score_spread":0.2492242452170614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295818082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568415,0.0025635578,0.00004310283,0.0006357912,0.00029750835,0.00047256463,0.0001808513,0.0000036897404,0.00011881389],"genre_scores_gemma":[0.996172,0.00063791254,0.000499922,0.0021813957,0.00008076198,0.0001364283,0.00016088728,0.000023933924,0.000106772735],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984759,0.00034371272,0.00040504555,0.00036007274,0.00013689313,0.00027834525],"domain_scores_gemma":[0.999239,0.000116356394,0.00016905932,0.00026030897,0.00012189122,0.000093374816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049858744,0.00015378567,0.00026910336,0.00013646053,0.00009397726,0.000014714736,0.00016277417,0.0000725195,0.00005001163],"category_scores_gemma":[0.00023573532,0.00015778038,0.000059481456,0.00015294449,0.000042252937,0.0000062400286,0.00020239345,0.00011756829,0.0000015573818],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015887612,0.0012589745,0.010879526,0.000063924555,0.000048462312,0.000063752275,0.0024252508,0.0035030185,0.8958636,0.000022841523,0.014107258,0.055875804],"study_design_scores_gemma":[0.018447194,0.10628673,0.05677003,0.00003347693,0.000076538796,0.00007915259,0.0019685654,0.0024923754,0.35673434,0.00017233992,0.4558102,0.0011290825],"about_ca_topic_score_codex":0.00034447378,"about_ca_topic_score_gemma":0.0006835548,"teacher_disagreement_score":0.53912926,"about_ca_system_score_codex":0.0001287743,"about_ca_system_score_gemma":0.00053217413,"threshold_uncertainty_score":0.6434097},"labels":[],"label_agreement":null},{"id":"W4295819067","doi":"10.1016/j.annonc.2022.07.904","title":"778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Cancer research; Immunotherapy; T cell; Cancer; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.10486761897001701,"score_gpt":0.43402916207023273,"score_spread":0.3291615431002157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933143,0.00043997625,0.0000026151051,0.0025831468,0.0002093756,0.0010646975,0.000026954152,0.000027488139,0.002331426],"genre_scores_gemma":[0.9969969,0.00022658854,0.0005321607,0.00077617273,0.00015067254,0.00005403999,0.000030132307,0.000035863828,0.0011974847],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967409,0.00086752686,0.001111303,0.0003791629,0.00042133377,0.0004798218],"domain_scores_gemma":[0.9972442,0.0015591331,0.0005586849,0.00029902268,0.00014968973,0.00018931211],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029165577,0.0001753027,0.001082171,0.00037202603,0.00015109447,0.0000033976457,0.00019147295,0.00015988473,0.0017121648],"category_scores_gemma":[0.0023181168,0.00016070223,0.00012932242,0.00052584073,0.00042113545,0.00004116357,0.00032660417,0.00084551773,0.0000017454862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18278117,0.004796239,0.00031021083,0.00018097502,0.0001597026,0.0005869376,0.005226729,0.00020238411,0.6809663,0.00003945536,0.0030900626,0.12165981],"study_design_scores_gemma":[0.41096485,0.23884587,0.0016054304,0.00034551657,0.00013864941,0.00035747403,0.0055951225,0.003079735,0.17750518,0.00032743032,0.16061807,0.0006166966],"about_ca_topic_score_codex":0.0002496831,"about_ca_topic_score_gemma":0.000034850713,"teacher_disagreement_score":0.5034612,"about_ca_system_score_codex":0.0001459231,"about_ca_system_score_gemma":0.0011704967,"threshold_uncertainty_score":0.9992004},"labels":[],"label_agreement":null},{"id":"W4295819095","doi":"10.1016/j.annonc.2022.07.876","title":"750P Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Nausea; Pharmacokinetics; Gastroenterology; Cmax; Interim analysis; Oncology; Clinical trial","score_opus":0.061516848801112,"score_gpt":0.42093041683537075,"score_spread":0.3594135680342587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569255,0.000101350626,0.0000071168547,0.0017329138,0.000041804145,0.0015507286,0.000040300754,0.00000877955,0.0008244623],"genre_scores_gemma":[0.9982981,0.00010646231,0.0002499787,0.0004667356,0.000013408714,0.00017930279,0.000064023596,0.000026238193,0.0005957398],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99760836,0.0003600686,0.0005737865,0.00031667916,0.000744239,0.00039689065],"domain_scores_gemma":[0.9987589,0.0002752772,0.0002814872,0.00020117978,0.00036936728,0.000113758724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005502673,0.00018284447,0.00076943496,0.00050515996,0.00006101798,0.0000048739266,0.00017515349,0.000040599978,0.0003172554],"category_scores_gemma":[0.00008933605,0.00012784949,0.000041837116,0.00079193496,0.00015301387,0.00011628639,0.000085178406,0.00036846445,0.0000029033226],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2813694,0.097874045,0.47784746,0.00032239084,0.00065588433,0.0016445245,0.007705141,0.0031899612,0.005829214,0.00027477427,0.0012875693,0.12199963],"study_design_scores_gemma":[0.14572042,0.6152914,0.19842431,0.00030211467,0.00009578212,0.00008412909,0.009910655,0.0011087982,0.02104638,0.0003300495,0.0072109243,0.00047500856],"about_ca_topic_score_codex":0.0011354809,"about_ca_topic_score_gemma":0.0015195687,"teacher_disagreement_score":0.5174174,"about_ca_system_score_codex":0.000103385784,"about_ca_system_score_gemma":0.0006115019,"threshold_uncertainty_score":0.5213551},"labels":[],"label_agreement":null},{"id":"W4295819105","doi":"10.1016/j.annonc.2022.07.589","title":"460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Zymeworks (Canada); Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Antibody-drug conjugate; Phases of clinical research; Oncology; Gastroenterology; Toxicity; Antibody; Immunology; Monoclonal antibody","score_opus":0.15674332624624926,"score_gpt":0.4685276178053498,"score_spread":0.31178429155910053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858567,0.0009154443,0.0000050071526,0.008905081,0.00031215945,0.0011778338,0.00143545,0.000030020703,0.0013622782],"genre_scores_gemma":[0.99679935,0.00031380757,0.00014986044,0.0011667563,0.00040869837,0.000056440538,0.00063634827,0.000043018383,0.00042570752],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99523526,0.0012745946,0.0012265609,0.00069186353,0.0007656363,0.00080608594],"domain_scores_gemma":[0.9974275,0.001068247,0.00054032024,0.00048200527,0.0002746286,0.00020724941],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017826782,0.00031872684,0.0009818688,0.0003171321,0.0005713508,0.000021612794,0.00056095695,0.00009441001,0.0010137283],"category_scores_gemma":[0.00039389837,0.0002477137,0.00020481406,0.000490901,0.0003619038,0.00013275119,0.0007469942,0.0010854567,0.000011732518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13096651,0.03580046,0.18500711,0.00051105587,0.0028537174,0.015123342,0.07714525,0.0019227084,0.43611345,0.00046675757,0.07742534,0.036664315],"study_design_scores_gemma":[0.07662538,0.11387198,0.45952243,0.0005659699,0.0006370493,0.00056303927,0.08782139,0.016771838,0.09546526,0.00091773557,0.14490451,0.0023334257],"about_ca_topic_score_codex":0.030195568,"about_ca_topic_score_gemma":0.00075753545,"teacher_disagreement_score":0.34064817,"about_ca_system_score_codex":0.00023608391,"about_ca_system_score_gemma":0.0006544479,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W4295819107","doi":"10.1016/j.annonc.2022.07.1090","title":"964P PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Radiation therapy; Cancer; Oncology; Internal medicine; Immunotherapy","score_opus":0.15849579312623976,"score_gpt":0.4206691145799511,"score_spread":0.2621733214537113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94366556,0.0015155723,0.000006130504,0.05009321,0.0002623298,0.001809964,0.00022961549,0.000008893399,0.0024087117],"genre_scores_gemma":[0.9859996,0.0060881777,0.000064815744,0.0012533078,0.00006216442,0.006362723,0.0000226081,0.000016008207,0.00013060863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987271,0.0002519323,0.00032050637,0.00023702256,0.0002162887,0.00024717292],"domain_scores_gemma":[0.99746466,0.0018153349,0.00024250548,0.00031404558,0.00012578329,0.00003769615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045716335,0.00014169596,0.000466681,0.000076180564,0.00013921282,0.0000034383902,0.00012269795,0.00003420435,0.00014357262],"category_scores_gemma":[0.00009950326,0.00008165966,0.00014980472,0.00019334439,0.00010522795,0.00003268591,0.000027746435,0.00011189476,8.4353144e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015906192,0.018944465,0.114060864,0.00040940003,0.0027851404,0.00024915536,0.08052361,0.004950147,0.0016510992,0.010757472,0.028873289,0.72088915],"study_design_scores_gemma":[0.030953033,0.109146476,0.22477408,0.0014682283,0.0013305737,0.00007436577,0.07015738,0.0007904492,0.0660313,0.00052475923,0.49415272,0.0005966389],"about_ca_topic_score_codex":0.00061255944,"about_ca_topic_score_gemma":0.0010093844,"teacher_disagreement_score":0.7202925,"about_ca_system_score_codex":0.0005300777,"about_ca_system_score_gemma":0.0003762867,"threshold_uncertainty_score":0.33299842},"labels":[],"label_agreement":null},{"id":"W4295819112","doi":"10.1016/j.annonc.2022.07.783","title":"659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Eisai; Merck KGaA; Sanofi; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Chemotherapy; Population; Head and neck cancer; Immunotherapy; Cancer","score_opus":0.08290346032636627,"score_gpt":0.3642580752485326,"score_spread":0.28135461492216635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895809,0.0027045205,0.00002696394,0.0048683095,0.00013426188,0.0012449812,0.00090173865,0.000017192713,0.0005210731],"genre_scores_gemma":[0.9949805,0.0013343949,0.0016151344,0.00082503184,0.00008681448,0.00016946832,0.0002288754,0.000038877137,0.00072086713],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99841076,0.000099955185,0.00058687583,0.00038962162,0.00021890005,0.00029386164],"domain_scores_gemma":[0.99849546,0.0004414398,0.0004558767,0.00035979706,0.00014807578,0.000099349774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022596454,0.00023217667,0.00086878455,0.00013556336,0.00010021138,0.0000044753338,0.00010360818,0.00007265016,0.00023787496],"category_scores_gemma":[0.000034156797,0.00016560085,0.00016299088,0.00019891563,0.0001824272,0.000033419892,0.000026517204,0.00009540465,7.6479387e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8226843,0.006467447,0.013940599,0.00040181517,0.00070846785,0.00009918579,0.007853905,0.00003535054,0.0050417394,0.000012995684,0.0073859147,0.13536829],"study_design_scores_gemma":[0.2508012,0.35510853,0.032926537,0.00013272055,0.00064706313,0.00018818729,0.002757031,0.00074471283,0.04999079,0.00015547182,0.30604133,0.00050639827],"about_ca_topic_score_codex":0.0020703957,"about_ca_topic_score_gemma":0.0008343429,"teacher_disagreement_score":0.5718831,"about_ca_system_score_codex":0.00013517402,"about_ca_system_score_gemma":0.00045890396,"threshold_uncertainty_score":0.67530066},"labels":[],"label_agreement":null},{"id":"W4295819472","doi":"10.1016/j.annonc.2022.07.902","title":"776P Early mortality in patients with cancer treated with immunotherapy in routine practice","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Lung cancer; Retrospective cohort study; Bladder cancer; Cohort; Logistic regression; Head and neck cancer; Radiation therapy; Surgery","score_opus":0.0481672227730674,"score_gpt":0.37488362760163546,"score_spread":0.32671640482856806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010426,0.00030390386,0.0000011168773,0.0023798076,0.00003950291,0.0004900939,0.000042384123,0.000009650623,0.006629311],"genre_scores_gemma":[0.9944266,0.0002018207,0.00010077996,0.0049014385,0.000015153811,0.00012750959,0.000057779274,0.000016780541,0.00015214154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988027,0.00020285389,0.0003007909,0.00021826656,0.00024320703,0.00023217779],"domain_scores_gemma":[0.99927557,0.00009751037,0.00022116453,0.00020917671,0.00014975149,0.00004683143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033982232,0.000112012036,0.00043333074,0.00014935204,0.000030128249,0.000002275954,0.000081474005,0.000049547965,0.00071067945],"category_scores_gemma":[0.000026022915,0.000087609784,0.000028826322,0.00037606986,0.00007595404,0.00013160985,0.000026569813,0.0003120022,8.710371e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015715603,0.0014896828,0.964225,0.000017649576,0.00018494883,0.00012789405,0.0010321666,0.0002394647,0.00009367032,0.000016729371,0.0002731738,0.016584001],"study_design_scores_gemma":[0.011515897,0.010421542,0.95449483,0.000024007426,0.000029431758,0.0000065241675,0.00026026217,0.000019339855,0.00018924811,0.000004075662,0.022939341,0.000095475174],"about_ca_topic_score_codex":0.012469656,"about_ca_topic_score_gemma":0.0018649684,"teacher_disagreement_score":0.022666167,"about_ca_system_score_codex":0.00025362626,"about_ca_system_score_gemma":0.0005897421,"threshold_uncertainty_score":0.9941064},"labels":[],"label_agreement":null},{"id":"W4295819826","doi":"10.1016/j.annonc.2022.07.640","title":"512MO Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Stage (stratigraphy); Seminoma; Germ cell tumors; Progression-free survival; Surgery; Chemotherapy; Biology; Confidence interval","score_opus":0.1503574276528245,"score_gpt":0.4828708111131977,"score_spread":0.3325133834603732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961554,0.00051677896,0.000020787404,0.00078550057,0.00018614378,0.0003011573,0.0019673046,0.000007742999,0.000059205042],"genre_scores_gemma":[0.9979135,0.00012910408,0.0006626467,0.0008405931,0.000008425235,0.000042882864,0.000350895,0.000012262586,0.000039729683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811774,0.00046227605,0.00064303144,0.00023053681,0.00035357315,0.00019285078],"domain_scores_gemma":[0.99781334,0.00054516597,0.00065043254,0.00058598456,0.00026564804,0.00013943015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046122228,0.00011814446,0.0008089465,0.00014972265,0.00005145454,0.000001428694,0.0001944729,0.000036643625,0.0005273907],"category_scores_gemma":[0.0010741065,0.000081133636,0.0004430803,0.0005299714,0.00018729667,0.000043039003,0.0001695693,0.00013737896,9.0141793e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012798796,0.0071240943,0.9797347,0.000056774817,0.0064712726,0.00008361356,0.00010346218,0.0010874656,0.00008191984,0.00019777122,0.00019857942,0.0035804326],"study_design_scores_gemma":[0.006614836,0.005286167,0.973541,0.000015133086,0.0114669455,0.0000015533534,0.0002659392,0.000912608,0.00025644863,0.00002643443,0.001537185,0.000075731296],"about_ca_topic_score_codex":0.0008928392,"about_ca_topic_score_gemma":0.00022758958,"teacher_disagreement_score":0.006193716,"about_ca_system_score_codex":0.00006589666,"about_ca_system_score_gemma":0.00052901614,"threshold_uncertainty_score":0.5774558},"labels":[],"label_agreement":null},{"id":"W4295820891","doi":"10.1016/j.annonc.2022.07.939","title":"813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Vemurafenib; Placebo; Internal medicine; Oncology; Pembrolizumab; Pathology; Cancer; Immunotherapy; Metastatic melanoma","score_opus":0.03804869258544963,"score_gpt":0.3045034102998207,"score_spread":0.26645471771437107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295820891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559265,0.00009767574,0.00011501113,0.00040603656,0.00009506784,0.0014474574,0.0011668407,0.000023319533,0.0010559524],"genre_scores_gemma":[0.996517,0.000004983455,0.000985548,0.0003157165,0.000053550222,0.00019584082,0.0013923319,0.000033379496,0.0005016764],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997277,0.000634898,0.00074581656,0.000546279,0.0003560824,0.0004399133],"domain_scores_gemma":[0.9982668,0.00014689832,0.00055256503,0.0006340556,0.00024156022,0.00015809997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007729673,0.000284733,0.0006751197,0.00007500812,0.00022782065,0.000011096277,0.0005588421,0.00008351766,0.00018188167],"category_scores_gemma":[0.00007139434,0.00017720218,0.00007204228,0.00029910734,0.0001129137,0.0000049063906,0.0003792825,0.00014113256,0.000011231989],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5134033,0.0104668895,0.0007459639,0.000095834606,0.006012492,0.0009166075,0.008096732,0.0029244486,0.3213405,0.00009204002,0.08274317,0.05316202],"study_design_scores_gemma":[0.060462974,0.112056166,0.003026899,0.00008758236,0.00053728925,0.00018217658,0.010981713,0.0001444357,0.50995755,0.0000044943654,0.3017099,0.00084879185],"about_ca_topic_score_codex":0.00022524598,"about_ca_topic_score_gemma":0.00036016284,"teacher_disagreement_score":0.45294032,"about_ca_system_score_codex":0.00004272794,"about_ca_system_score_gemma":0.000862788,"threshold_uncertainty_score":0.7226095},"labels":[],"label_agreement":null},{"id":"W4295820897","doi":"10.1016/j.annonc.2022.07.1184","title":"1058P Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Incidence (geometry); Oncology; Internal medicine","score_opus":0.028747422765389247,"score_gpt":0.33891746401659306,"score_spread":0.31017004125120384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295820897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268514,0.0013531803,0.00006722891,0.0042353678,0.00013543012,0.00054026337,0.00005995606,0.00001428724,0.0009091616],"genre_scores_gemma":[0.99704593,0.0007162673,0.00042368128,0.0013142059,0.00004606003,0.00025457758,0.000026461175,0.0000132088635,0.00015963089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902475,0.00008212187,0.00032099994,0.00019965206,0.00019155728,0.00018093486],"domain_scores_gemma":[0.99921554,0.00012352735,0.0002552603,0.0001684819,0.00017549988,0.000061660496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002928697,0.00010734393,0.0003444104,0.00017039494,0.00014074429,0.0000043521895,0.00006848294,0.00005813431,0.00019591923],"category_scores_gemma":[0.000029605762,0.00009573841,0.00006698298,0.00028293623,0.0002346077,0.00006219096,0.00005126229,0.00015388851,2.8055524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011943052,0.002322872,0.7801418,0.000523178,0.0020246722,0.00016272931,0.0068213516,0.0013712444,0.08927327,0.00031172717,0.024188919,0.080915235],"study_design_scores_gemma":[0.01898927,0.07730783,0.6970757,0.00032549677,0.0009627047,0.0013466887,0.0045703365,0.0016661113,0.12806424,0.00015939081,0.06878236,0.0007498304],"about_ca_topic_score_codex":0.006733588,"about_ca_topic_score_gemma":0.0016225877,"teacher_disagreement_score":0.08306602,"about_ca_system_score_codex":0.00016867992,"about_ca_system_score_gemma":0.0007639237,"threshold_uncertainty_score":0.9998807},"labels":[],"label_agreement":null},{"id":"W4295827732","doi":"10.1016/j.annonc.2022.07.1268","title":"1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brain metastasis; Stage (stratigraphy); Oncology; Internal medicine; Metastasis; Cancer","score_opus":0.07787698650814676,"score_gpt":0.45925068328208735,"score_spread":0.3813736967739406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295827732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897946,0.0005605659,0.000011945652,0.004274023,0.0002549429,0.00060122495,0.0022809,0.000010315562,0.003026642],"genre_scores_gemma":[0.9960037,0.0003521388,0.00038027245,0.0005921757,0.000012597902,0.00011127573,0.0003047389,0.00001669938,0.0022264246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784344,0.00027144022,0.00095805107,0.00027240327,0.0004409355,0.00021371334],"domain_scores_gemma":[0.9957953,0.0023924583,0.0008677524,0.00036931655,0.0004640034,0.000111144174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041035388,0.00014080733,0.00087936217,0.00013629216,0.00007498167,0.0000014280752,0.00019904807,0.000079711725,0.0010132624],"category_scores_gemma":[0.0010386418,0.00012485556,0.000284222,0.00027270048,0.00038909056,0.000078459496,0.00018157724,0.00013602413,0.0000069500875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012338698,0.0055857943,0.88478786,0.00012669663,0.0018664568,0.000015417821,0.0016259609,0.00011669134,0.0003135975,0.0002850801,0.068907365,0.035135232],"study_design_scores_gemma":[0.013639887,0.019887028,0.8532104,0.00007770153,0.0009967491,0.0000038964204,0.0010190143,0.000057767433,0.0048320866,0.00008246392,0.105992004,0.00020101963],"about_ca_topic_score_codex":0.0005434686,"about_ca_topic_score_gemma":0.00008430668,"teacher_disagreement_score":0.037084643,"about_ca_system_score_codex":0.000097276774,"about_ca_system_score_gemma":0.0005074822,"threshold_uncertainty_score":0.9998999},"labels":[],"label_agreement":null},{"id":"W4295827736","doi":"10.1016/j.annonc.2022.07.1466","title":"1334P Objective response rates of placebo in randomized controlled trials of anticancer medicines: 2015 – 2019","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Placebo; Internal medicine; Clinical endpoint; Clinical trial; Subgroup analysis; Randomized controlled trial; Oncology; Radiation therapy; Meta-analysis; Surgery; Pathology; Alternative medicine","score_opus":0.040217483879689764,"score_gpt":0.4018093651912359,"score_spread":0.3615918813115461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295827736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796989,0.013834613,0.00007362314,0.0030329488,0.0003983915,0.0014093161,0.00030013072,0.0000017297663,0.0012503691],"genre_scores_gemma":[0.9935049,0.0052195503,0.00010651411,0.0006130717,0.00008176566,0.00022243499,0.000049136102,0.000012117999,0.00019052664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99503225,0.002891516,0.0014999988,0.00021752813,0.00017574344,0.00018295049],"domain_scores_gemma":[0.99195343,0.0061322413,0.0013112584,0.0002385108,0.00032210365,0.000042450185],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013328645,0.00013270826,0.00291079,0.00020463647,0.000021086382,0.0000015232667,0.00018845925,0.00011879343,0.00015410871],"category_scores_gemma":[0.015780283,0.000106629464,0.0004951437,0.00014129865,0.0003113179,0.000001976879,0.00014214253,0.00009689617,4.4942934e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7215784,0.0003449162,0.0004212845,0.000021546784,0.0005654503,0.000005989442,0.0003384006,0.0009784386,0.25652015,0.00022049813,0.01815142,0.00085346244],"study_design_scores_gemma":[0.5851306,0.00893027,0.0011741802,0.000053388667,0.00034314234,0.000010894228,0.0013769348,0.00018534988,0.37265605,0.0013354906,0.02855096,0.00025277503],"about_ca_topic_score_codex":0.0002656078,"about_ca_topic_score_gemma":0.0000913961,"teacher_disagreement_score":0.13644788,"about_ca_system_score_codex":0.000023896013,"about_ca_system_score_gemma":0.0010028493,"threshold_uncertainty_score":0.9925102},"labels":[],"label_agreement":null},{"id":"W4295827764","doi":"10.1016/j.annonc.2022.07.1312","title":"1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"TIGIT; Medicine; Lung cancer; non-small cell lung cancer (NSCLC); Cancer research; Atezolizumab; Internal medicine; Oncology; Cancer; Immunotherapy; A549 cell; Pembrolizumab","score_opus":0.05462985005233335,"score_gpt":0.3872184693149579,"score_spread":0.33258861926262456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295827764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98348004,0.005833233,0.000010387457,0.0033213496,0.0010039209,0.0022767573,0.00029030183,0.000054804594,0.003729236],"genre_scores_gemma":[0.9931229,0.003066538,0.00008558165,0.002502642,0.00019403889,0.00027785305,0.000076534285,0.00008944062,0.00058447546],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99514854,0.00046810723,0.0016803201,0.000887816,0.0007315399,0.00108368],"domain_scores_gemma":[0.9971891,0.00026253893,0.0010160608,0.00091148046,0.00038669902,0.000234142],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016849171,0.00053063006,0.0019791475,0.000824997,0.00029937553,0.000015356733,0.0006558523,0.0002813248,0.001640051],"category_scores_gemma":[0.00006763946,0.0005226757,0.0004425186,0.0013488968,0.00032894604,0.0001722712,0.00049473706,0.00079651974,0.0000055175115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022526035,0.059906557,0.37318417,0.001210129,0.0023993424,0.0016924869,0.022501355,0.0008104699,0.39298683,0.000022525384,0.03922819,0.083531916],"study_design_scores_gemma":[0.14661738,0.105763525,0.41596457,0.0007809589,0.0013310431,0.00027270746,0.022778887,0.0012142634,0.120722465,0.00004206048,0.18249138,0.0020207355],"about_ca_topic_score_codex":0.005940573,"about_ca_topic_score_gemma":0.0010105688,"teacher_disagreement_score":0.27226436,"about_ca_system_score_codex":0.00035365514,"about_ca_system_score_gemma":0.0014832292,"threshold_uncertainty_score":0.9997225},"labels":[],"label_agreement":null},{"id":"W4295827824","doi":"10.1016/j.annonc.2022.07.1459","title":"1326P Oncology under attack by predatory journals: A global survey","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Impact factor; Descriptive statistics; Citation; Family medicine; Publishing; Medical education; Library science; Political science","score_opus":0.17573406555172752,"score_gpt":0.5317821283083254,"score_spread":0.35604806275659784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295827824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84554046,0.032667726,0.0021094768,0.0481064,0.003965026,0.0009274456,0.0011099132,0.00011979827,0.065453775],"genre_scores_gemma":[0.9343855,0.00611832,0.001916987,0.05249709,0.00057553,0.0001146546,0.00020809515,0.00004971122,0.0041341307],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662036,0.0014495128,0.00067128515,0.0003827416,0.0003581316,0.0005179989],"domain_scores_gemma":[0.9976538,0.00091380294,0.0005286271,0.0003708945,0.00030141446,0.00023147764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023705089,0.00020380307,0.00094708236,0.00011543949,0.00023868788,0.0000036340878,0.00035075762,0.0003742667,0.0038483576],"category_scores_gemma":[0.00032625726,0.0001905944,0.00018787241,0.0004323399,0.0005650554,0.00009344612,0.00017896872,0.0007640831,0.000027891323],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046206573,0.0034319072,0.054941773,0.000034563087,0.000748856,0.0005798108,0.00027357828,0.0005165289,0.0012395931,0.0005073164,0.7885082,0.14459723],"study_design_scores_gemma":[0.0032068025,0.013245333,0.050726913,0.000009595588,0.00005001104,0.001392663,0.0003937673,0.00005860483,0.00013787282,0.0011180337,0.9294949,0.00016549423],"about_ca_topic_score_codex":0.00009546076,"about_ca_topic_score_gemma":0.00017492556,"teacher_disagreement_score":0.14443174,"about_ca_system_score_codex":0.00069708115,"about_ca_system_score_gemma":0.001554938,"threshold_uncertainty_score":0.99706227},"labels":[{"model":"gemma","categories":["metaresearch","research_integrity"],"domain":"evaluation","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch","scholarly_communication","research_integrity"],"domain":"evaluation","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4295828289","doi":"10.1016/j.annonc.2022.07.1314","title":"1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Oncology; Internal medicine; Chemotherapy; Lung cancer; Atlas (anatomy); Cancer; Immunotherapy","score_opus":0.045580937563633316,"score_gpt":0.3399214523671793,"score_spread":0.294340514803546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336165,0.0020183537,0.00017371748,0.000878726,0.000095545794,0.00047502873,0.000053808017,0.0000052289724,0.0029379523],"genre_scores_gemma":[0.99425316,0.0032986368,0.00030721808,0.0010227335,0.00006667411,0.00036439474,0.00011992199,0.000031464926,0.00053581875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987976,0.000082920116,0.0003353966,0.00038717204,0.000098001336,0.00029891878],"domain_scores_gemma":[0.99918383,0.00004616769,0.0002456273,0.0003083913,0.00014651474,0.000069494425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019046734,0.00018211656,0.00033349183,0.00009755715,0.00006804508,0.0000105749605,0.0001846708,0.000069470436,0.000089658504],"category_scores_gemma":[0.000019809855,0.00017662194,0.000082497616,0.00015281593,0.00006197677,0.0000036655647,0.0000876542,0.000105152016,0.0000018542743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005333522,0.0043735104,0.042010818,0.00024055556,0.001088274,0.00020308552,0.0033197217,0.11951783,0.7014214,0.00044226035,0.020109862,0.10193919],"study_design_scores_gemma":[0.016125048,0.028425409,0.014798182,0.000060791845,0.00028468482,0.0001351627,0.00393502,0.006581042,0.7828751,0.00036383336,0.1453729,0.0010428268],"about_ca_topic_score_codex":0.0033124331,"about_ca_topic_score_gemma":0.0030598114,"teacher_disagreement_score":0.12526304,"about_ca_system_score_codex":0.00016142338,"about_ca_system_score_gemma":0.0008678914,"threshold_uncertainty_score":0.72024333},"labels":[],"label_agreement":null},{"id":"W4295828333","doi":"10.1016/j.annonc.2022.07.1295","title":"1172P High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Exon; Lung cancer; Cancer research; Mutation; Cancer; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.042377125063117665,"score_gpt":0.40398834221574703,"score_spread":0.36161121715262934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872098,0.00046001226,0.000026004398,0.0049946923,0.00021658868,0.00063001446,0.00010329737,0.000009242695,0.006350378],"genre_scores_gemma":[0.99804854,0.00020619444,0.0002176593,0.00052842795,0.00003419598,0.00033282064,0.000076026205,0.000014668582,0.0005414371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998938,0.00013322968,0.00035387342,0.00021224572,0.00014952745,0.00021307846],"domain_scores_gemma":[0.9992998,0.00012376593,0.00024607166,0.00016168381,0.00011450332,0.000054138127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022606972,0.00010558622,0.0004105386,0.00030583618,0.00004696315,0.000001793316,0.00007473109,0.00007888392,0.000347179],"category_scores_gemma":[0.000027974167,0.000106890315,0.00007292202,0.0004430881,0.00005086432,0.00006885597,0.00005068441,0.00022225949,0.0000016312686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029675565,0.013804206,0.7218502,0.0008411385,0.00049423054,0.00034569408,0.018833993,0.01727656,0.0914737,0.00044497775,0.0059643434,0.1257034],"study_design_scores_gemma":[0.0073184483,0.003189122,0.9561826,0.00013177114,0.00020784252,0.000011262016,0.0013476813,0.0010848258,0.025232341,0.00020588099,0.0049253167,0.00016291327],"about_ca_topic_score_codex":0.011058672,"about_ca_topic_score_gemma":0.005000211,"teacher_disagreement_score":0.23433238,"about_ca_system_score_codex":0.00034259236,"about_ca_system_score_gemma":0.0008521634,"threshold_uncertainty_score":0.9955268},"labels":[],"label_agreement":null},{"id":"W4295828359","doi":"10.1016/j.annonc.2022.07.1275","title":"1151P Evolution of biomarker testing among non-squamous/non-small cell lung cancer (NSCLC) patients (Pts) and impact on turnaround times (TAT)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital; St Mary's Hospital Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Kingston Health Sciences Centre; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Cohort; ROS1; Internal medicine; Oncology; Biomarker; Cancer; Lung cancer; Stage (stratigraphy); Adenocarcinoma","score_opus":0.020865354335026825,"score_gpt":0.3086863282183802,"score_spread":0.28782097388335337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487984,0.001689892,0.00006371014,0.00007704669,0.00021308388,0.00029041155,0.0002570598,0.000003226289,0.0025257103],"genre_scores_gemma":[0.9990377,0.00030102296,0.00011832132,0.00022089874,0.000082250765,0.000048735266,0.00007227774,0.000023552047,0.00009528583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890494,0.00007791046,0.0003229651,0.0003020947,0.00011940409,0.0002726541],"domain_scores_gemma":[0.9989295,0.00016517963,0.00037433472,0.00021778129,0.00022535874,0.000087826294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026112387,0.00016554575,0.00027771224,0.00010003893,0.00009973217,0.0000073613537,0.00016251212,0.00012102506,0.000042747353],"category_scores_gemma":[0.00014002407,0.00016236691,0.000105599946,0.00013600924,0.00011411265,0.0000047046287,0.00024627848,0.00011553798,5.5515386e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090755726,0.0010155832,0.7578494,0.00014310733,0.00020009596,0.000008782214,0.00030133082,0.007369345,0.19241825,0.000021241382,0.019505607,0.020259697],"study_design_scores_gemma":[0.0034533169,0.01245748,0.9023252,0.000056434226,0.00012979792,0.000006402659,0.00025775138,0.004436632,0.0701976,0.0001343871,0.0060652504,0.0004797597],"about_ca_topic_score_codex":0.0015287006,"about_ca_topic_score_gemma":0.000116337374,"teacher_disagreement_score":0.14447579,"about_ca_system_score_codex":0.0001020053,"about_ca_system_score_gemma":0.00041050077,"threshold_uncertainty_score":0.662113},"labels":[],"label_agreement":null},{"id":"W4295828361","doi":"10.1016/j.annonc.2022.07.1441","title":"1309P CD8+ T cell infiltration is associated with improved survival in advanced pancreatic cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Nova Scotia Cancer Centre; Princess Margaret Cancer Centre; McGill University; Centre Hospitalier de l’Université de Montréal; University of Toronto; University Health Network","funders":"","keywords":"Medicine; CD8; Pancreatic cancer; Internal medicine; Immunohistochemistry; Pathology; Adenocarcinoma; Gastroenterology; Exact test; Immune system; Oncology; Cancer; Immunology","score_opus":0.04264593338123257,"score_gpt":0.3493253143852004,"score_spread":0.30667938100396785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990947,0.000948702,0.0000049554924,0.0042110095,0.00017670455,0.00037364315,0.000051209856,0.000016558113,0.004307773],"genre_scores_gemma":[0.99473524,0.00060778414,0.00005342968,0.00342934,0.000026236821,0.00014831644,0.000047072524,0.0000148930685,0.0009376685],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989717,0.00014061456,0.00030585963,0.00018084973,0.00017966487,0.00022131557],"domain_scores_gemma":[0.9993255,0.00012444773,0.00025279575,0.0001453463,0.00011352066,0.000038348247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042280264,0.00010155261,0.00039094055,0.00010900635,0.000050182105,0.0000024754079,0.000072819545,0.00006975193,0.0007588513],"category_scores_gemma":[0.000036675774,0.00008951902,0.00006642934,0.00038211842,0.0000649527,0.000049571274,0.000023763732,0.0001905776,8.1497404e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034471903,0.002538009,0.14603196,0.0001484231,0.00081010116,0.00012222475,0.0046614823,0.00025872578,0.6792182,0.000032882646,0.006780877,0.12492526],"study_design_scores_gemma":[0.043571647,0.043836538,0.56726927,0.0002803167,0.00032776193,0.00005080966,0.004777921,0.0011006456,0.19601575,0.00019471679,0.14182271,0.0007519048],"about_ca_topic_score_codex":0.0012279551,"about_ca_topic_score_gemma":0.0013738347,"teacher_disagreement_score":0.4832024,"about_ca_system_score_codex":0.00020365932,"about_ca_system_score_gemma":0.0005497775,"threshold_uncertainty_score":0.830889},"labels":[],"label_agreement":null},{"id":"W4295828376","doi":"10.1016/j.annonc.2022.07.1237","title":"1112P Real-world treatment (tx) patterns and outcomes based on PD-L1 status in tx-naive patients (pts) with METex14 advanced non-small cell lung cancer (aNSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.02826066290229761,"score_gpt":0.3871112570587321,"score_spread":0.3588505941564345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789716,0.00026677232,0.00001258151,0.0023782249,0.00016593319,0.0012752976,0.00053371396,0.000018130853,0.0074521783],"genre_scores_gemma":[0.99397606,0.00067966984,0.00035145835,0.0026652492,0.000018973766,0.00089649763,0.00024154784,0.000033647833,0.0011369154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985351,0.0001109921,0.00033425054,0.00039256498,0.00022997589,0.00039710102],"domain_scores_gemma":[0.99900126,0.000212338,0.0002420717,0.0002630035,0.0001246871,0.00015664437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085328815,0.0002406288,0.00063286547,0.0002529745,0.00009625618,0.0000049803125,0.00006322511,0.000046375666,0.0002534945],"category_scores_gemma":[0.000010546929,0.0001779511,0.00008748807,0.00022107438,0.00004788375,0.000049363607,0.000036908146,0.00014504009,0.0000014194482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013038731,0.0027297018,0.9578715,0.00007544963,0.0003016525,0.00010091337,0.0019935737,0.0019030053,0.000025871484,0.000015363068,0.0005981668,0.03308091],"study_design_scores_gemma":[0.016572786,0.015333127,0.9525955,0.00010072961,0.0004216528,0.0000010716176,0.0006022996,0.00031896096,0.0007233645,0.000007597796,0.013143812,0.00017914131],"about_ca_topic_score_codex":0.009557284,"about_ca_topic_score_gemma":0.00841847,"teacher_disagreement_score":0.032901768,"about_ca_system_score_codex":0.000857681,"about_ca_system_score_gemma":0.0006665376,"threshold_uncertainty_score":0.9970382},"labels":[],"label_agreement":null},{"id":"W4295828392","doi":"10.1016/j.annonc.2022.07.1236","title":"1111P Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Lung cancer; Oncology; Expanded access; Demographics; Demography","score_opus":0.05006063986485293,"score_gpt":0.4205134632515281,"score_spread":0.3704528233866752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97889936,0.00019214535,0.00007828696,0.0050188364,0.00014116828,0.0031915691,0.00011332287,0.000050829778,0.012314478],"genre_scores_gemma":[0.9940969,0.0002278015,0.00057734415,0.0006643351,0.000054014807,0.003398039,0.00052291213,0.000026994921,0.00043170812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983743,0.00015240887,0.0004523082,0.00037062835,0.00031059916,0.0003397577],"domain_scores_gemma":[0.9988196,0.00008010172,0.00044148296,0.00028441715,0.00029748416,0.00007694961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011437702,0.00022665925,0.0003974659,0.00011846335,0.00028846215,0.00002672243,0.00013879438,0.000057442143,0.0001124196],"category_scores_gemma":[0.000010948818,0.00014397677,0.00006974855,0.00083749346,0.000092567185,0.00024951543,0.000053894273,0.00015370065,0.00000112592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028247503,0.0051959576,0.93506,0.00007621587,0.00045812872,0.000036519774,0.005772516,0.006181236,0.00002808208,0.00006872104,0.0007325752,0.043565292],"study_design_scores_gemma":[0.01116482,0.011340933,0.96819466,0.00014285758,0.0006432597,0.000008024024,0.0012326903,0.0005357905,0.00062437734,0.000071092596,0.005840022,0.00020145353],"about_ca_topic_score_codex":0.012230718,"about_ca_topic_score_gemma":0.030583221,"teacher_disagreement_score":0.04336384,"about_ca_system_score_codex":0.0012710915,"about_ca_system_score_gemma":0.001155233,"threshold_uncertainty_score":0.9943469},"labels":[],"label_agreement":null},{"id":"W4295828435","doi":"10.1016/j.annonc.2022.07.1429","title":"1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic ductal adenocarcinoma; Adenocarcinoma; Oncology; Adjuvant; Clinical trial; Pancreatic cancer; Cancer","score_opus":0.03664091110392732,"score_gpt":0.3410152514717964,"score_spread":0.3043743403678691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963813,0.0011401954,5.586695e-7,0.00028245983,0.0002816652,0.0016135903,0.00012366723,0.0000033113454,0.00017325064],"genre_scores_gemma":[0.99861467,0.00009482696,0.000027708054,0.00095299736,0.00009058007,0.00010190804,0.00005740315,0.000020675496,0.00003920343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788725,0.00046759748,0.0005944131,0.0004886647,0.00029907416,0.0002630229],"domain_scores_gemma":[0.99860346,0.00011936841,0.0003839997,0.00055031077,0.00024845198,0.000094380586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006025706,0.00016960628,0.00047388,0.00007044129,0.00009270743,0.000006954389,0.00032732557,0.00012350186,0.000033430722],"category_scores_gemma":[0.00041699896,0.00012839615,0.000079924896,0.00020770219,0.00017101878,0.0000033591882,0.00050713273,0.0002814233,4.1857865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089294806,0.012923502,0.8834983,0.000047920275,0.0003250446,0.000062109444,0.001636274,0.001193408,0.0034637514,0.000035635036,0.003226636,0.004292593],"study_design_scores_gemma":[0.04426728,0.11923268,0.82636666,0.000018845572,0.00011783544,0.000013954569,0.0010613478,0.000085280095,0.0035757353,0.000066839515,0.0049352646,0.00025826984],"about_ca_topic_score_codex":0.0002302705,"about_ca_topic_score_gemma":0.00029775678,"teacher_disagreement_score":0.106309175,"about_ca_system_score_codex":0.000027790831,"about_ca_system_score_gemma":0.00058497617,"threshold_uncertainty_score":0.5235843},"labels":[],"label_agreement":null},{"id":"W4295828440","doi":"10.1016/j.annonc.2022.07.1492","title":"1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Cliniques Universitaires Saint-Luc; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Medical Research Council; Université Catholique de Louvain; Bayer HealthCare; University College London; Bayer","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Cumulative incidence; Incidence (geometry); Rash; Androgen deprivation therapy; Adverse effect; Clinical endpoint; Cancer; Randomized controlled trial; Cohort","score_opus":0.13070937859407863,"score_gpt":0.4640188743778277,"score_spread":0.333309495783749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917615,0.00055724377,9.0662604e-7,0.0053608436,0.00007100661,0.0007996972,0.00005517472,0.0000053815843,0.0013882247],"genre_scores_gemma":[0.9966895,0.000093326395,0.000019796315,0.0030091535,0.000023269447,0.00011042641,0.000014358706,0.00000651261,0.00003364795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984237,0.0005826044,0.0004294015,0.0001771775,0.00021848264,0.00016865865],"domain_scores_gemma":[0.99900264,0.00042362465,0.00026811563,0.00018131222,0.000064523956,0.000059803024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006657915,0.00009493766,0.0005238098,0.00010403607,0.000051085586,0.0000011642636,0.00007455332,0.000029147548,0.00024067034],"category_scores_gemma":[0.00005962718,0.00006315475,0.000044123775,0.00018168223,0.00014856322,0.000021672015,0.00006754949,0.00019029314,5.898712e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10413208,0.10084817,0.53358984,0.0002317351,0.0020741,0.001638436,0.09965383,0.00014437025,0.017605571,0.0005269693,0.02360634,0.11594859],"study_design_scores_gemma":[0.12316954,0.26282632,0.48286292,0.000031377287,0.0005875123,0.00023558586,0.06896773,0.00008112018,0.003902108,0.00037170306,0.05662166,0.00034240494],"about_ca_topic_score_codex":0.000697129,"about_ca_topic_score_gemma":0.00059570756,"teacher_disagreement_score":0.16197817,"about_ca_system_score_codex":0.000032485066,"about_ca_system_score_gemma":0.00025288746,"threshold_uncertainty_score":0.26351714},"labels":[],"label_agreement":null},{"id":"W4295828450","doi":"10.1016/j.annonc.2022.07.1262","title":"1138P Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 &gt;/= 50%: 3 weekly compared to 6 weekly dosing","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Dosing; Medicine; Pembrolizumab; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.05550377184018356,"score_gpt":0.36892179412118337,"score_spread":0.3134180222809998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719341,0.0011232353,0.00008516525,0.018755756,0.000480389,0.00058007654,0.000027352118,0.000044784443,0.006969164],"genre_scores_gemma":[0.99180216,0.000109741166,0.0009508066,0.0062056016,0.00009241445,0.00008938232,0.00002829903,0.00003913739,0.0006824678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978806,0.00020314545,0.0006327405,0.00041598472,0.00035704722,0.0005104819],"domain_scores_gemma":[0.9989687,0.00012348084,0.00029311382,0.000350215,0.00012715482,0.0001373008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056281866,0.0002262441,0.00075653667,0.0003933194,0.000117512885,0.000013098902,0.0002730518,0.000074805714,0.0003387272],"category_scores_gemma":[0.00003214088,0.00020903598,0.0001567164,0.0005136098,0.00014279205,0.000109191,0.00017051048,0.000370467,0.000008375504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26652136,0.002411964,0.012171377,0.00022375361,0.0007788393,0.00091027527,0.0060344846,0.0017707467,0.32361886,0.00016837758,0.014853593,0.37053636],"study_design_scores_gemma":[0.04761833,0.04431426,0.13950212,0.0012212438,0.00017258777,0.0014882341,0.004995416,0.0007822522,0.047582213,0.00026333093,0.7110595,0.001000512],"about_ca_topic_score_codex":0.00081676355,"about_ca_topic_score_gemma":0.00045657973,"teacher_disagreement_score":0.6962059,"about_ca_system_score_codex":0.00034616882,"about_ca_system_score_gemma":0.00036626888,"threshold_uncertainty_score":0.85242397},"labels":[],"label_agreement":null},{"id":"W4295828460","doi":"10.1016/j.annonc.2022.07.1235","title":"1110P Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.15306855910501577,"score_gpt":0.52759099597619,"score_spread":0.3745224368711742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95288855,0.00026227516,0.00011517047,0.034903273,0.0007532602,0.0008187005,0.00010396553,0.000046194255,0.010108601],"genre_scores_gemma":[0.98744226,0.000084440595,0.0008299227,0.008430122,0.00008436432,0.00028664828,0.0002230786,0.000017065304,0.0026020785],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989386,0.000093996816,0.00044426706,0.00019768722,0.00013375995,0.00019168593],"domain_scores_gemma":[0.9989832,0.00036660247,0.00018602767,0.00018216467,0.00018845378,0.00009352592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034388274,0.00008970023,0.00042887012,0.00008623677,0.00011426064,0.0000030475665,0.0000765441,0.00007175607,0.00045622396],"category_scores_gemma":[0.00018341493,0.00007496858,0.00023578765,0.00012529836,0.00006945817,0.0000458518,0.000043858785,0.00013176975,0.000010288184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036848988,0.007749879,0.51817614,0.000110459754,0.0028447309,0.00017773933,0.0022022903,0.00014233547,0.0008106224,0.0013635637,0.17729726,0.2854401],"study_design_scores_gemma":[0.008107457,0.01367844,0.3256823,0.000014592342,0.00045707283,0.00003902075,0.0011759193,0.00010666515,0.00029023105,0.000675659,0.6496428,0.00012979325],"about_ca_topic_score_codex":0.00017445805,"about_ca_topic_score_gemma":0.00008032524,"teacher_disagreement_score":0.4723456,"about_ca_system_score_codex":0.00008462631,"about_ca_system_score_gemma":0.00051470473,"threshold_uncertainty_score":0.49953324},"labels":[],"label_agreement":null},{"id":"W4295828577","doi":"10.1016/j.annonc.2022.07.1303","title":"1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"EMD Serono; Eisai; Merck KGaA; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Internal medicine; Oncology; Lung cancer; Progression-free survival; Pemetrexed; Real world data; Chemotherapy; Cancer; Immunotherapy","score_opus":0.08671700921615552,"score_gpt":0.5028440010374505,"score_spread":0.416126991821295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756716,0.0025517116,0.000013638961,0.0073349224,0.0006059859,0.001286254,0.00011169274,0.00001895826,0.012405221],"genre_scores_gemma":[0.98488474,0.00953135,0.002551387,0.0010718972,0.000118412274,0.0009580732,0.00007001726,0.000029544857,0.0007845855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978868,0.000406072,0.0006879372,0.00043795627,0.00023286352,0.00034836703],"domain_scores_gemma":[0.99819976,0.0008372071,0.0003823956,0.00032512782,0.00012309855,0.00013238563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079206814,0.00018440755,0.00069486396,0.0002671191,0.00007426816,0.0000061116866,0.00011351464,0.0000840734,0.00012622502],"category_scores_gemma":[0.00017002222,0.0001584704,0.00009715989,0.00032995568,0.000056195022,0.00010586415,0.0001487724,0.00029985578,7.965267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014365182,0.0038299004,0.79208475,0.00013902484,0.00028340053,0.00049650634,0.0023770034,0.00022627735,0.00012197936,0.00006651428,0.00069915445,0.198239],"study_design_scores_gemma":[0.020309491,0.012043848,0.870544,0.00034769464,0.0005214479,0.000029539671,0.0036750557,0.00032724856,0.00056399236,0.00008143663,0.091284096,0.0002721071],"about_ca_topic_score_codex":0.008038171,"about_ca_topic_score_gemma":0.013322317,"teacher_disagreement_score":0.19796689,"about_ca_system_score_codex":0.0004870223,"about_ca_system_score_gemma":0.00082864944,"threshold_uncertainty_score":0.9985674},"labels":[],"label_agreement":null},{"id":"W4295828587","doi":"10.1016/j.annonc.2022.07.1229","title":"1104P Health-related quality of life (HRQOL) in patients with ALK+ non-small cell lung cancer (NSCLC) in the phase III CROWN study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; non-small cell lung cancer (NSCLC); Quality of life (healthcare); Oncology; Internal medicine; Nursing; A549 cell","score_opus":0.06511884568022727,"score_gpt":0.44785721191884853,"score_spread":0.38273836623862123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143517,0.00092115026,0.0000022943125,0.0035956507,0.00009745836,0.0019554375,0.000087151566,0.0000055974897,0.0019000815],"genre_scores_gemma":[0.9970727,0.00005424287,0.000025023604,0.0022859185,0.000012323152,0.0003706373,0.00006476689,0.000011661296,0.000102705744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980898,0.00046414588,0.0007310497,0.00021390914,0.00026669767,0.00023443103],"domain_scores_gemma":[0.998907,0.00015149264,0.00048340502,0.00024787476,0.00013991861,0.00007026621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008266906,0.00011239513,0.00060574035,0.00015502263,0.0000711607,0.0000019120143,0.00012631301,0.00004136102,0.00016767261],"category_scores_gemma":[0.000030863655,0.00007748618,0.000051542953,0.00043180824,0.00005769962,0.000033597113,0.000047944795,0.00024100358,5.107272e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004572659,0.021543713,0.92686516,0.00012454607,0.00030388418,0.000030790856,0.036127694,0.00041244127,0.000027745129,0.000022549011,0.0024285375,0.0075402763],"study_design_scores_gemma":[0.038691185,0.015293302,0.93641293,0.000045684475,0.0001124845,8.669242e-7,0.008113743,0.000040753537,0.000033922894,0.000011507231,0.0011578847,0.00008572595],"about_ca_topic_score_codex":0.020223126,"about_ca_topic_score_gemma":0.004604088,"teacher_disagreement_score":0.034118526,"about_ca_system_score_codex":0.00020960851,"about_ca_system_score_gemma":0.0013880425,"threshold_uncertainty_score":0.9863013},"labels":[],"label_agreement":null},{"id":"W4295836711","doi":"10.1016/j.annonc.2022.07.1510","title":"1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Chugai Pharmaceutical; Genentech; Aptitude Health; European Society for Medical Oncology; Astellas Pharma; Eisai; Incyte; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Cumulative incidence; Subtyping; Biopsy; Basal (medicine); Proportional hazards model; Cancer; Cohort","score_opus":0.1135833553259525,"score_gpt":0.45110897388318094,"score_spread":0.33752561855722846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749858,0.004524769,0.000028042983,0.016972391,0.0003446019,0.0021580176,0.00051638315,0.000014033181,0.00045600595],"genre_scores_gemma":[0.9923715,0.004967979,0.00017005732,0.0008508068,0.000082325714,0.0008704334,0.00013526571,0.000021341275,0.00053028576],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940682,0.0030544596,0.0014573794,0.00045618007,0.0004767012,0.0004870599],"domain_scores_gemma":[0.994992,0.0028540154,0.0012963676,0.0003928249,0.0003157667,0.00014899834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008075851,0.00023589452,0.0030567793,0.000926901,0.00018882866,0.000007625668,0.00022117938,0.00017788778,0.00064277014],"category_scores_gemma":[0.0011931324,0.00015197748,0.0006332503,0.001769358,0.00089074677,0.000052138384,0.00018353933,0.0005763581,8.1494267e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74477905,0.0046156147,0.07977827,0.00025471946,0.009594527,0.00036887013,0.0033296184,0.0010289125,0.012232909,0.00025626103,0.0039595193,0.13980173],"study_design_scores_gemma":[0.8867961,0.009584194,0.031202683,0.0001853747,0.010694974,0.000020069168,0.0020179488,0.0066445894,0.021281326,0.0010826887,0.030084893,0.00040512456],"about_ca_topic_score_codex":0.0036219354,"about_ca_topic_score_gemma":0.00066414033,"teacher_disagreement_score":0.14201708,"about_ca_system_score_codex":0.00033528666,"about_ca_system_score_gemma":0.0018844265,"threshold_uncertainty_score":0.7037883},"labels":[],"label_agreement":null},{"id":"W4295836740","doi":"10.1016/j.annonc.2022.07.1838","title":"1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Bavarian Nordic; Astellas Pharma; Genentech; UroGen Pharma; Foundation Medicine; Silverback Therapeutics; Mirati Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; Exelixis; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Avelumab; Medicine; Metastatic Urothelial Carcinoma; Javelin; Internal medicine; Chemotherapy; Maintenance therapy; Oncology; Urology; Gastroenterology; Bladder cancer; Urothelial carcinoma; Immunotherapy; Cancer; Nivolumab","score_opus":0.05196338569092701,"score_gpt":0.32916951755272655,"score_spread":0.27720613186179954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891016,0.00029504398,0.00006688518,0.0023322466,0.00020986059,0.0020202235,0.0042358604,0.000017068409,0.0017211934],"genre_scores_gemma":[0.9956649,0.00017409143,0.0012993343,0.00074042444,0.000094471296,0.000598816,0.0005504524,0.000043546694,0.000833979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979674,0.000095418174,0.0007173106,0.00049443304,0.00027681162,0.00044862196],"domain_scores_gemma":[0.9985145,0.00030409495,0.00041282098,0.00037221063,0.00028349907,0.00011291874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001792049,0.00026287,0.0008622709,0.00017222307,0.00008300752,0.0000022414783,0.00015048565,0.00010315037,0.00016990372],"category_scores_gemma":[0.000109385306,0.00020635057,0.00016913512,0.00019196444,0.000120581746,0.000055107757,0.00007108416,0.00014154262,0.0000034178433],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32966712,0.02855353,0.22302419,0.00029613188,0.0027743194,0.00036464678,0.014214084,0.005425385,0.003079269,0.0002581291,0.009435917,0.38290727],"study_design_scores_gemma":[0.24806602,0.21478459,0.34400418,0.00028687777,0.0008142837,0.000027762266,0.0015746274,0.0008535309,0.030601824,0.0012673984,0.15691808,0.00080081896],"about_ca_topic_score_codex":0.0030192966,"about_ca_topic_score_gemma":0.0014561302,"teacher_disagreement_score":0.38210645,"about_ca_system_score_codex":0.00039407,"about_ca_system_score_gemma":0.00066168624,"threshold_uncertainty_score":0.8414732},"labels":[],"label_agreement":null},{"id":"W4295836765","doi":"10.1016/j.annonc.2022.07.1832","title":"1754P Association between body mass index (BMI) and anti-PD1/L1 immune checkpoint inhibitor (ICI) outcomes in patients with metastatic urothelial carcinoma (mUC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Toronto East General Hospital; University Health Network; Princess Margaret Cancer Centre; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Body mass index; Proportional hazards model; Cancer; Oncology; Cohort; Multivariate analysis; Retrospective cohort study","score_opus":0.03412157097411946,"score_gpt":0.31900852576909955,"score_spread":0.2848869547949801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952948,0.00012600327,0.0000070909305,0.0024372684,0.0001680606,0.00075588445,0.0002653109,0.000017512337,0.0009280844],"genre_scores_gemma":[0.9987623,0.00002300013,0.000106637985,0.00046799044,0.00006454462,0.00013404171,0.00009116033,0.000030398522,0.00031990258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980999,0.00024589078,0.00054885825,0.00029052168,0.0004627106,0.0003520959],"domain_scores_gemma":[0.99896556,0.00019327621,0.00039008903,0.00019743112,0.0001535521,0.00010011031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046432743,0.0002008328,0.00090003054,0.00023194228,0.00008338042,0.000006987215,0.00009228795,0.000089833615,0.00016489526],"category_scores_gemma":[0.00011426006,0.00016625978,0.000099226025,0.00022976696,0.00007508865,0.000085807515,0.00009284163,0.0003034356,0.0000044236194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008697809,0.0009198789,0.99424493,0.000047714922,0.0005268379,0.000039327457,0.00031907644,0.0000059684644,0.00035639125,0.0000100549605,0.00017740505,0.0024826345],"study_design_scores_gemma":[0.011119942,0.0056232037,0.97845685,0.000020780024,0.00027964002,0.0000035878336,0.00022860745,0.000009096571,0.0027218729,0.00009192555,0.0013035742,0.00014093671],"about_ca_topic_score_codex":0.00082737673,"about_ca_topic_score_gemma":0.000037851234,"teacher_disagreement_score":0.015788097,"about_ca_system_score_codex":0.00030111117,"about_ca_system_score_gemma":0.00035403643,"threshold_uncertainty_score":0.6779877},"labels":[],"label_agreement":null},{"id":"W4295836805","doi":"10.1016/j.annonc.2022.07.1766","title":"1687P Targeted metabolomics reveals dynamic changes and potential therapeutic targets in the serum metabolome of patients receiving adoptive cell therapy with tumor infiltrating lymphocytes","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Metabolome; Metabolomics; Medicine; Immunology; Cancer research; Bioinformatics; Biology","score_opus":0.04239882489301194,"score_gpt":0.32728600437881405,"score_spread":0.2848871794858021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98575306,0.01060031,0.000010723301,0.0016703788,0.00007853038,0.0010900002,0.00006833464,0.000010056617,0.00071863603],"genre_scores_gemma":[0.9958386,0.0019594969,0.00053675805,0.0013661974,0.000025766274,0.000120105076,0.00004727916,0.000028344632,0.00007744806],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970449,0.0010890249,0.00048396213,0.00032636613,0.0005938019,0.0004619402],"domain_scores_gemma":[0.99832505,0.0004922524,0.00049787166,0.00028251694,0.00032612786,0.00007618704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019119052,0.00020609371,0.00077272684,0.00030032863,0.00012876507,0.0000082458655,0.00027435037,0.00007745407,0.00019942725],"category_scores_gemma":[0.00011267484,0.00013795726,0.00007528692,0.00057504413,0.00023141906,0.00007121733,0.0001453132,0.00039423988,7.299822e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013620923,0.005504914,0.29699785,0.00072304124,0.0012202148,0.00037145137,0.023840185,0.0006428722,0.44234425,0.00027019638,0.00051408994,0.21395001],"study_design_scores_gemma":[0.011492562,0.02723776,0.8684481,0.00007383681,0.00019203001,0.0001297285,0.012779796,0.0014232646,0.06944091,0.0003526475,0.007982433,0.00044697264],"about_ca_topic_score_codex":0.0001039294,"about_ca_topic_score_gemma":0.00006310046,"teacher_disagreement_score":0.57145023,"about_ca_system_score_codex":0.000068592955,"about_ca_system_score_gemma":0.00031582825,"threshold_uncertainty_score":0.56257343},"labels":[],"label_agreement":null},{"id":"W4295836902","doi":"10.1016/j.annonc.2022.07.1521","title":"1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Abiraterone acetate; Abiraterone; Prednisone; Pembrolizumab; Prostate cancer; Oncology; Internal medicine; Cohort; Chemotherapy; Cancer; Gynecology; Androgen deprivation therapy; Androgen receptor; Immunotherapy","score_opus":0.04172470123149347,"score_gpt":0.35561525913190595,"score_spread":0.3138905579004125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937887,0.0009422404,0.000002193775,0.001995184,0.00008997321,0.0019881679,0.00035026085,0.000014340643,0.0008289426],"genre_scores_gemma":[0.996656,0.0009665395,0.00030365228,0.00024927346,0.000017321921,0.0004673631,0.00017229772,0.000040595733,0.0011269848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777406,0.00023442834,0.0005529174,0.0004144049,0.00055942417,0.00046475045],"domain_scores_gemma":[0.99873364,0.00009439333,0.00036311723,0.00026433272,0.00040298488,0.00014150552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000401762,0.0002359557,0.00086507364,0.0002663993,0.00009467422,0.000009028331,0.0001202804,0.000054614677,0.00028862458],"category_scores_gemma":[0.000025992273,0.00018518584,0.00007193592,0.0004024859,0.0003177261,0.00011764202,0.00009497474,0.00027811143,0.0000014232878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18900329,0.0035381278,0.7519393,0.0010828057,0.0029982955,0.00028362087,0.0114808595,0.0010800569,0.012883625,0.00021635965,0.0022062531,0.023287425],"study_design_scores_gemma":[0.12969263,0.029671405,0.8206724,0.00024046234,0.0004366824,0.000021898144,0.0019948427,0.00024114519,0.014186571,0.0002485559,0.002185024,0.000408422],"about_ca_topic_score_codex":0.0014112786,"about_ca_topic_score_gemma":0.0004502336,"teacher_disagreement_score":0.06873308,"about_ca_system_score_codex":0.00031038155,"about_ca_system_score_gemma":0.0010857882,"threshold_uncertainty_score":0.75516593},"labels":[],"label_agreement":null},{"id":"W4295836916","doi":"10.1016/j.annonc.2022.07.1508","title":"1376P Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer: Exploratory analysis of LATITUDE study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Hôpital Saint-Luc; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Prostate cancer; Internal medicine; Univariate; Univariate analysis; Brief Pain Inventory; Oncology; Cancer; Physical therapy; Multivariate analysis; Chronic pain; Multivariate statistics; Statistics","score_opus":0.10721131006997114,"score_gpt":0.4181923753401661,"score_spread":0.310981065270195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973492,0.00031046866,0.0000018328036,0.0008460274,0.000033728527,0.0012144014,0.0001855408,0.000004492162,0.000054295084],"genre_scores_gemma":[0.99898124,0.00030219278,0.000034033128,0.00007689763,0.0000033916506,0.00042027907,0.0001250356,0.0000104313585,0.000046475943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728113,0.0012086343,0.00057591667,0.00021850834,0.00047589335,0.0002399247],"domain_scores_gemma":[0.9984396,0.0002932362,0.0006727485,0.00014732426,0.00040360747,0.000043479304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002195306,0.00010691022,0.0008883636,0.00079280237,0.00002157967,0.0000013103046,0.00004521104,0.000032422962,0.000041500327],"category_scores_gemma":[0.000103535196,0.000089497174,0.00007095251,0.0017450986,0.000060491097,0.00006156524,0.00005025999,0.00018842553,1.1201242e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00317829,0.0029270158,0.9494414,0.00008423684,0.0035871007,0.00086824235,0.025477307,0.001363027,0.0010234251,0.0000026357918,0.000012488555,0.012034855],"study_design_scores_gemma":[0.0051339404,0.012911024,0.9523219,0.000053784497,0.0008806587,0.0000020116795,0.025284762,0.0023339915,0.00094554503,0.000012190554,0.000028218368,0.00009199416],"about_ca_topic_score_codex":0.005665933,"about_ca_topic_score_gemma":0.03762446,"teacher_disagreement_score":0.031958528,"about_ca_system_score_codex":0.0004661906,"about_ca_system_score_gemma":0.000573863,"threshold_uncertainty_score":0.97993636},"labels":[],"label_agreement":null},{"id":"W4295836924","doi":"10.1016/j.annonc.2022.07.1612","title":"1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.041199811624419616,"score_gpt":0.3602155427157212,"score_spread":0.3190157310913016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886906,0.00059288833,0.000004056296,0.0023968073,0.00013107309,0.0004820247,0.00008536217,0.000010821428,0.007606349],"genre_scores_gemma":[0.99856323,0.00033578722,0.0001495963,0.00045001705,0.00004695854,0.000026586646,0.000064894666,0.000013984485,0.00034891927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857765,0.0001458477,0.0005517316,0.00023079845,0.00022296706,0.0002709743],"domain_scores_gemma":[0.9992668,0.00013874282,0.00023503878,0.00017415038,0.00007151628,0.00011372051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038630128,0.00013874177,0.0006025252,0.00016117221,0.00010267203,0.0000012883369,0.00008277464,0.000076887554,0.00059362006],"category_scores_gemma":[0.000045678153,0.00012059624,0.000106969725,0.00019400743,0.000118181466,0.000042401873,0.00023673508,0.00019550677,0.000002504263],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028465604,0.042208537,0.010102603,0.00082113186,0.00038571595,0.0013891873,0.0062849666,0.0001112494,0.18475115,0.0018498342,0.005574744,0.71805525],"study_design_scores_gemma":[0.14169452,0.2276465,0.19278128,0.00036126055,0.00046753633,0.00077578233,0.0045999517,0.0004342375,0.11589546,0.00087685004,0.3135837,0.0008829188],"about_ca_topic_score_codex":0.00061730185,"about_ca_topic_score_gemma":0.000032291642,"teacher_disagreement_score":0.7171723,"about_ca_system_score_codex":0.00004640116,"about_ca_system_score_gemma":0.00017956455,"threshold_uncertainty_score":0.6499723},"labels":[],"label_agreement":null},{"id":"W4295836963","doi":"10.1016/j.annonc.2022.07.1567","title":"1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine","score_opus":0.09173054329450028,"score_gpt":0.3547854431976819,"score_spread":0.26305489990318165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987558,0.0010497321,0.00005569806,0.007397592,0.00028271505,0.0015141559,0.0009811991,0.000009396354,0.0011514996],"genre_scores_gemma":[0.99815243,0.00016052277,0.00006480251,0.00037226058,0.000043567074,0.00028726694,0.0008547164,0.000024296933,0.00004010647],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99374706,0.0038490207,0.0010961575,0.0003739308,0.0006415826,0.00029224873],"domain_scores_gemma":[0.9855269,0.012053028,0.001171894,0.0007610838,0.0004336876,0.000053374606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052639837,0.00027776917,0.0008553823,0.0002500248,0.00015977984,0.000008066864,0.00051014085,0.0000636992,0.0003249135],"category_scores_gemma":[0.00085435936,0.00014244263,0.00039340468,0.00045879473,0.00046839015,0.00008332219,0.00024038415,0.00048010715,0.000003196762],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30277574,0.025353866,0.07070663,0.00043421885,0.010739555,0.00078917545,0.017372623,0.02371011,0.50799716,0.0034100171,0.016407454,0.02030345],"study_design_scores_gemma":[0.023841938,0.050767172,0.76219827,0.00019032303,0.0010521936,0.00013826703,0.004259385,0.0031002292,0.14861545,0.0035012958,0.0020853134,0.00025017673],"about_ca_topic_score_codex":0.0056353095,"about_ca_topic_score_gemma":0.00041345033,"teacher_disagreement_score":0.6914916,"about_ca_system_score_codex":0.0004768031,"about_ca_system_score_gemma":0.00071762514,"threshold_uncertainty_score":0.851894},"labels":[],"label_agreement":null},{"id":"W4295836972","doi":"10.1016/j.annonc.2022.07.1813","title":"1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Immune system; Urothelial cancer; Dendritic cell; Cancer research; Cancer; Pathology; Oncology; Immunotherapy; Immunology; Internal medicine; Bladder cancer; Nivolumab","score_opus":0.023912725500981502,"score_gpt":0.304654174116137,"score_spread":0.2807414486151555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947996,0.0002764342,0.000009648912,0.0004741377,0.00007571713,0.0013809828,0.0019517392,0.000033887216,0.000997843],"genre_scores_gemma":[0.9971324,0.00016840626,0.00009514534,0.0012252277,0.000018365441,0.00036435892,0.00028565028,0.000086556975,0.00062385877],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974185,0.00035397816,0.0004258,0.0005869453,0.00064088264,0.0005738902],"domain_scores_gemma":[0.998579,0.00022928076,0.00041058796,0.00031219926,0.00027459985,0.00019429196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017756292,0.00043370927,0.0010878997,0.00018584094,0.00014989726,0.000016504922,0.00013521881,0.00010120892,0.0005071469],"category_scores_gemma":[0.000015162211,0.00027741064,0.000052519208,0.0003344942,0.00027129936,0.00009757045,0.00005178948,0.0003717014,0.000002476098],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40137935,0.027256055,0.4325084,0.0007590881,0.009258747,0.002339335,0.007224882,0.0016701714,0.08338412,0.000034106597,0.017361112,0.016824616],"study_design_scores_gemma":[0.1284683,0.15647227,0.16341497,0.0016618058,0.0021121595,0.000060690178,0.0011001386,0.00018349898,0.5405314,0.000035738114,0.0045828214,0.001376183],"about_ca_topic_score_codex":0.003910431,"about_ca_topic_score_gemma":0.0006729813,"teacher_disagreement_score":0.4571473,"about_ca_system_score_codex":0.0002917766,"about_ca_system_score_gemma":0.00068428105,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W4295836973","doi":"10.1016/j.annonc.2022.07.1551","title":"1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Cancer research; Immunotherapy; Cancer","score_opus":0.10989365781455002,"score_gpt":0.38303768861397725,"score_spread":0.27314403079942723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805016,0.0008235109,0.000024185647,0.0019557462,0.00026213552,0.0038935605,0.00026011321,0.000039624774,0.01223953],"genre_scores_gemma":[0.9923924,0.00022107679,0.00048843166,0.00050475687,0.00020276877,0.00074196473,0.000255887,0.00010134008,0.0050913277],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99606353,0.00031234164,0.0013083332,0.00086510787,0.00069250626,0.0007581688],"domain_scores_gemma":[0.9966824,0.00056603126,0.00092957733,0.0010144319,0.00046128995,0.0003462859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054231146,0.0005544498,0.0017204147,0.00045885958,0.0004230264,0.0000067538326,0.0003698044,0.00019573115,0.0008693337],"category_scores_gemma":[0.000071708404,0.00049380964,0.00061693153,0.00039375632,0.00015941898,0.00007229185,0.00036102012,0.00032892538,0.000022444761],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19066249,0.37936202,0.022285448,0.0021956915,0.0031239467,0.004954754,0.037139833,0.0034731084,0.23265564,0.00015232776,0.04884088,0.075153835],"study_design_scores_gemma":[0.08308608,0.5664391,0.0054102656,0.00002811547,0.0011194241,0.00014157493,0.0029882744,0.00054178515,0.29240578,0.000089810026,0.047347203,0.0004025649],"about_ca_topic_score_codex":0.0011643426,"about_ca_topic_score_gemma":0.00014682194,"teacher_disagreement_score":0.18707708,"about_ca_system_score_codex":0.00052022515,"about_ca_system_score_gemma":0.0009318055,"threshold_uncertainty_score":0.9997513},"labels":[],"label_agreement":null},{"id":"W4295836988","doi":"10.1016/j.annonc.2022.07.1641","title":"1547P Predictors of short-, medium-, and long-term survival with limited stage small cell lung cancer in the real-world","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AstraZeneca (Canada); University of Manitoba; CancerCare Manitoba","funders":"Daiichi Sankyo Europe; Shionogi; Astellas Pharma; Ono Pharmaceutical; Eisai; Chugai Pharmaceutical; Celltrion; Kissei; Taiho Pharmaceutical; Daiichi-Sankyo; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Kyowa Hakko Kirin","keywords":"Medicine; Prophylactic cranial irradiation; Internal medicine; Cohort; Proportional hazards model; Survival analysis; Radiation therapy; Cancer; Retrospective cohort study; Oncology; Stage (stratigraphy); Surgery; Conventional PCI; Myocardial infarction","score_opus":0.09098211067852403,"score_gpt":0.42048352447356657,"score_spread":0.32950141379504255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815543,0.002472378,0.0000016511589,0.006125965,0.00012982046,0.00074241625,0.000113976195,0.000011607779,0.008847831],"genre_scores_gemma":[0.9933793,0.0047353925,0.000016183303,0.00042474794,0.00009281961,0.00021940398,0.000018127806,0.000017550004,0.0010964855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998245,0.00034621233,0.0003302491,0.00024230174,0.00049782125,0.00033842397],"domain_scores_gemma":[0.99878204,0.0005334039,0.00014543196,0.00027343226,0.00018488517,0.00008080227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010242371,0.0001302347,0.00053859886,0.000244263,0.000068866735,0.0000033217877,0.00021292805,0.000042991192,0.0001858603],"category_scores_gemma":[0.000066413006,0.000085869186,0.000047864156,0.00048739216,0.00036311932,0.00003284707,0.00023755645,0.00039974894,1.3679528e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013859279,0.00039707654,0.9892826,0.0004923733,0.0002758284,0.0002396113,0.0033650247,0.000055859724,0.00093786203,0.000042473057,0.0020995487,0.0014258215],"study_design_scores_gemma":[0.001725257,0.0040193303,0.98616344,0.000080397556,0.00012231589,0.000006940104,0.0013437555,0.00003512855,0.001447074,0.000004757167,0.0049674315,0.00008415998],"about_ca_topic_score_codex":0.001883344,"about_ca_topic_score_gemma":0.022614397,"teacher_disagreement_score":0.020731052,"about_ca_system_score_codex":0.00012985307,"about_ca_system_score_gemma":0.00065272447,"threshold_uncertainty_score":0.99522036},"labels":[],"label_agreement":null},{"id":"W4295837015","doi":"10.1016/j.annonc.2022.07.1728","title":"1648P Deep learning identifies oncogenic genetic alterations in BRAF and NTRK in H&amp;E whole slide images from thyroid carcinomas","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Immunohistochemistry; Cancer research; Thyroid carcinoma; Targeted therapy; Sorafenib; Thyroid; Internal medicine; Oncology; Pathology; Cancer; Hepatocellular carcinoma","score_opus":0.045026604315786256,"score_gpt":0.34478064058100766,"score_spread":0.2997540362652214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96884245,0.024390431,0.000009650624,0.0058036055,0.00010464353,0.00027118664,0.000037403566,0.000012455046,0.0005281627],"genre_scores_gemma":[0.9960082,0.0021993825,0.00035922203,0.00074352755,0.000064620195,0.00021244118,0.00009363613,0.000015975533,0.00030300216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986852,0.00023775213,0.00038532563,0.000299262,0.00015141582,0.00024107749],"domain_scores_gemma":[0.99928373,0.00028657253,0.00012968873,0.00018196928,0.000047034697,0.00007103234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021688065,0.00012152572,0.0004248628,0.00022795425,0.000090340865,0.000011974908,0.000075734395,0.0000562854,0.00023750262],"category_scores_gemma":[0.00008215755,0.00012471517,0.000068744324,0.00019820462,0.0000843571,0.00005792717,0.00012643106,0.00026757387,0.00001117583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048916147,0.0015018926,0.87857413,0.00004398093,0.00020182136,0.0007154744,0.007750658,0.0029464038,0.055947993,0.000070930524,0.004577975,0.047179602],"study_design_scores_gemma":[0.0030893136,0.0021801747,0.96218675,0.000033156837,0.00007189563,0.00005382795,0.0015181558,0.00010051087,0.005168579,0.0006614101,0.024810655,0.00012554486],"about_ca_topic_score_codex":0.0034523865,"about_ca_topic_score_gemma":0.0062869415,"teacher_disagreement_score":0.083612666,"about_ca_system_score_codex":0.00013837536,"about_ca_system_score_gemma":0.00015344373,"threshold_uncertainty_score":0.5218999},"labels":[],"label_agreement":null},{"id":"W4295837070","doi":"10.1016/j.annonc.2022.07.1826","title":"1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Oncology; Internal medicine; Urinary system; Carcinoma; Urology; Cancer; Immunotherapy","score_opus":0.09783277607515922,"score_gpt":0.36873355237687655,"score_spread":0.2709007763017173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939991,0.0006860525,0.000011117062,0.0028057115,0.000042907413,0.00097332086,0.00027367813,0.000025096899,0.0011830156],"genre_scores_gemma":[0.9973742,0.000082782964,0.00027872925,0.0008373086,0.00001851458,0.00025743362,0.000028647324,0.000033834975,0.0010885658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982981,0.00033107094,0.00035257754,0.0003651449,0.00030028826,0.00035281913],"domain_scores_gemma":[0.99908453,0.0002261254,0.000110553054,0.000273841,0.00009288744,0.00021208328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004687198,0.00019977005,0.00067840394,0.00027578013,0.0000678235,0.0000043483633,0.00010082091,0.00005367108,0.00018038467],"category_scores_gemma":[0.000060836443,0.00016530084,0.000068979825,0.00029114334,0.000069191665,0.000063538966,0.0000829611,0.00020620097,0.000002215429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17404838,0.012466046,0.742927,0.00031890013,0.0009869633,0.006346095,0.014153568,0.0037586123,0.0030755182,0.00009266395,0.0013730025,0.040453233],"study_design_scores_gemma":[0.011544573,0.07934428,0.90209925,0.00005420938,0.0003064266,0.00094897964,0.0006816305,0.0011629784,0.0011274177,0.00014290238,0.0023498104,0.00023751521],"about_ca_topic_score_codex":0.0007763959,"about_ca_topic_score_gemma":0.00015743081,"teacher_disagreement_score":0.16250381,"about_ca_system_score_codex":0.00016506089,"about_ca_system_score_gemma":0.0006392347,"threshold_uncertainty_score":0.6740773},"labels":[],"label_agreement":null},{"id":"W4295837114","doi":"10.1016/j.annonc.2022.07.1631","title":"1536P Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Chemotherapy; Oncology; Internal medicine; Population; Proportional hazards model; Confidence interval","score_opus":0.02381458618281122,"score_gpt":0.3388116935326948,"score_spread":0.31499710734988356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927333,0.0012051371,0.000086259766,0.0023000904,0.000023644649,0.002232303,0.00081957085,0.000019913181,0.0005797645],"genre_scores_gemma":[0.9985802,0.00008612663,0.00014707712,0.0005142675,0.000017114193,0.00047208494,0.00007998639,0.000032417887,0.000070734364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977061,0.00029494945,0.0004969158,0.0003434646,0.00076453725,0.0003940122],"domain_scores_gemma":[0.9969178,0.00041264648,0.00057249377,0.00046453957,0.0015066154,0.00012594889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035850675,0.00022503563,0.0014673325,0.0003938604,0.000106863874,0.0000039965994,0.0002647088,0.000053086937,0.00030953268],"category_scores_gemma":[0.00007379864,0.00013701172,0.0001873353,0.0013248884,0.0003294851,0.000021284317,0.00006406524,0.0002291852,1.5103598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026607784,0.0008786224,0.9329778,0.00046285096,0.005544306,0.000015948757,0.0058853296,0.022255514,0.0003640257,0.0000022612473,0.0022539361,0.0027516088],"study_design_scores_gemma":[0.028903376,0.056168918,0.8770704,0.00051085494,0.0067662913,0.0000012247127,0.0034610103,0.003231244,0.01924593,0.000001314666,0.004272714,0.00036669613],"about_ca_topic_score_codex":0.0023490228,"about_ca_topic_score_gemma":0.005195163,"teacher_disagreement_score":0.055907387,"about_ca_system_score_codex":0.00037305927,"about_ca_system_score_gemma":0.0007896243,"threshold_uncertainty_score":0.5587176},"labels":[],"label_agreement":null},{"id":"W4295837169","doi":"10.1016/j.annonc.2022.07.1765","title":"1686P Evaluating the relationship between BRAF mutation class and patient demographics in an international cancer cohort","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Demographics; Cohort; Oncology; Cancer; Mutation; Internal medicine; Family medicine; Demography; Genetics; Gene","score_opus":0.15137463734243106,"score_gpt":0.4302997214824439,"score_spread":0.2789250841400128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713516,0.00028464608,0.000035691213,0.0015161622,0.0001559597,0.00017249702,0.000048417976,0.0000027024353,0.00064877066],"genre_scores_gemma":[0.9987876,0.00006899471,0.00009973895,0.00066335074,0.00007412285,0.00010495249,0.00017689752,0.000006198281,0.000018151066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907815,0.00030691657,0.00021060847,0.00016938406,0.0001331408,0.00010177647],"domain_scores_gemma":[0.9994994,0.00012325263,0.00014414998,0.00012102191,0.00008445489,0.000027759006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005749372,0.00005613233,0.000091732785,0.00006081182,0.00009853668,0.000005160971,0.00012259815,0.00006748182,0.000020075446],"category_scores_gemma":[0.00018073841,0.00005045895,0.000028114095,0.00008571634,0.00006129096,0.00000596404,0.00011175157,0.00012431193,2.3117893e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007192285,0.00005223836,0.9646033,0.0000033616109,0.000028898086,0.0000023423747,0.00030813404,0.0007298064,0.00554772,0.0007357701,0.0002581942,0.02765833],"study_design_scores_gemma":[0.00036089122,0.0027006092,0.9848619,0.0000035633907,0.000013995662,0.000010374746,0.00034855888,0.00050548185,0.0014579156,0.0009175888,0.008745524,0.00007356211],"about_ca_topic_score_codex":0.00006475799,"about_ca_topic_score_gemma":0.0002369963,"teacher_disagreement_score":0.027584769,"about_ca_system_score_codex":0.000013736434,"about_ca_system_score_gemma":0.00011363547,"threshold_uncertainty_score":0.20576563},"labels":[],"label_agreement":null},{"id":"W4295837182","doi":"10.1016/j.annonc.2022.07.1744","title":"1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Servier; Eisai; Seagen; Daiichi Sankyo Europe; Princess Margaret Cancer Foundation; Sanofi; Iterion Therapeutics; Karyopharm Therapeutics; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.05125988401333968,"score_gpt":0.3830134366659977,"score_spread":0.331753552652658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079967,0.0055041723,3.1106242e-7,0.002281648,0.00017072645,0.00029958037,0.000042710235,0.000009891836,0.0008912651],"genre_scores_gemma":[0.9965268,0.0012479695,0.000056060482,0.0017073437,0.000019562243,0.00014015476,0.00001125769,0.000012995247,0.00027785773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888116,0.00013914242,0.00034045763,0.00019344316,0.00020998769,0.00023579178],"domain_scores_gemma":[0.99951005,0.00008752933,0.00017135926,0.000115084134,0.000061772305,0.00005422942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000303066,0.000104593426,0.00041502222,0.00026363917,0.000062270105,0.000003160521,0.000073071606,0.000025337276,0.00074001035],"category_scores_gemma":[0.000036532667,0.000095863266,0.00007446978,0.00026860883,0.000093945986,0.000048473365,0.00009309058,0.00015878466,8.5686895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032576445,0.00411089,0.65221846,0.0009345176,0.0017478189,0.00052014494,0.009257802,0.00009602214,0.046593957,0.00020087432,0.005551547,0.24619153],"study_design_scores_gemma":[0.014372307,0.004946198,0.9269673,0.00007119605,0.00008788175,0.000064610045,0.0012727007,0.000028391405,0.012993112,0.0002157267,0.038795304,0.00018522657],"about_ca_topic_score_codex":0.00078255875,"about_ca_topic_score_gemma":0.00013353849,"teacher_disagreement_score":0.2747489,"about_ca_system_score_codex":0.00015152457,"about_ca_system_score_gemma":0.00019705266,"threshold_uncertainty_score":0.81025946},"labels":[],"label_agreement":null},{"id":"W4295837212","doi":"10.1016/j.annonc.2022.07.1558","title":"1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Carcinoma; Internal medicine; Database","score_opus":0.07915184960623357,"score_gpt":0.308049444028462,"score_spread":0.22889759442222846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97981054,0.00019134325,0.00028339602,0.009218151,0.00021181972,0.0013892788,0.008534375,0.000018474379,0.0003426392],"genre_scores_gemma":[0.9894669,0.000029341601,0.002149415,0.002198543,0.00007610096,0.00015820182,0.0055949125,0.00005323271,0.00027332045],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99557376,0.001120721,0.0012302607,0.00064422784,0.0010100513,0.00042097346],"domain_scores_gemma":[0.99518234,0.0018868875,0.0011801646,0.0008850514,0.0006511924,0.00021434219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001355064,0.00036831107,0.0008883452,0.00034064392,0.00021453701,0.00001748163,0.0005386033,0.00004641311,0.0004654405],"category_scores_gemma":[0.00032758873,0.00026549675,0.0001960295,0.00044068712,0.00020934906,0.00013850548,0.00040621267,0.0003663209,0.000012647382],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18238743,0.007169391,0.10240907,0.00027023294,0.0013350936,0.0010517238,0.014344086,0.001239645,0.68047976,0.000042198524,0.0055699362,0.0037014112],"study_design_scores_gemma":[0.018051507,0.022269588,0.81825304,0.000098130644,0.00084557344,0.00004489089,0.0011196737,0.0004511584,0.101535164,0.000022837648,0.03691712,0.00039134457],"about_ca_topic_score_codex":0.00069229555,"about_ca_topic_score_gemma":0.00011572392,"teacher_disagreement_score":0.7158439,"about_ca_system_score_codex":0.00023518123,"about_ca_system_score_gemma":0.0005603126,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W4295837229","doi":"10.1016/j.annonc.2022.07.1500","title":"1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Pharmaceuticals; Genentech; Sierra Oncology; Astellas Pharma; Menarini Silicon Biosystems; Vertex Pharmaceuticals; Merck Sharp and Dohme; Eisai; National Evidence-based Healthcare Collaborating Agency; Sanofi; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Taxane; Clinical endpoint; Olaparib; Primary tumor; Progression-free survival; Hormonal therapy; Population; Cancer; Breast cancer; Chemotherapy; Clinical trial; Genetics; Metastasis; Gene; Poly ADP ribose polymerase; Biology","score_opus":0.10781632104742811,"score_gpt":0.38532978992712075,"score_spread":0.27751346887969264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899511,0.0004548293,0.00008402573,0.0071344418,0.000057439516,0.0017063539,0.00043514825,0.000027735861,0.0001489695],"genre_scores_gemma":[0.9955749,0.00015884844,0.0010085836,0.00094385317,0.000023469604,0.0017905046,0.00019817981,0.000046743826,0.0002549492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753547,0.0005678896,0.0007387292,0.0003453086,0.0004980291,0.00031459314],"domain_scores_gemma":[0.9979228,0.00026644662,0.0008080359,0.00031896803,0.0005967849,0.000086977736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009816851,0.00021517948,0.00063291605,0.00035280085,0.00012989588,0.000011448041,0.000114823175,0.00005064705,0.00020852717],"category_scores_gemma":[0.000081062244,0.00018919667,0.000059305137,0.0007881496,0.00022802687,0.00021720468,0.00002488232,0.00027615484,7.083641e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12509924,0.005099539,0.02253826,0.00020785947,0.0012861689,0.00076450774,0.021044012,0.07931815,0.7381891,0.0006379382,0.0010865954,0.0047286036],"study_design_scores_gemma":[0.05141435,0.09612111,0.276809,0.00093081535,0.00060147245,0.000233673,0.008127634,0.0054387394,0.54784304,0.0021612481,0.009167934,0.0011509517],"about_ca_topic_score_codex":0.00019741447,"about_ca_topic_score_gemma":0.0027874212,"teacher_disagreement_score":0.25427073,"about_ca_system_score_codex":0.00031218232,"about_ca_system_score_gemma":0.0016026056,"threshold_uncertainty_score":0.7715216},"labels":[],"label_agreement":null},{"id":"W4295837241","doi":"10.1016/j.annonc.2022.07.1552","title":"1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Internal medicine","score_opus":0.0469790489166364,"score_gpt":0.322511109249764,"score_spread":0.2755320603331276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889475,0.00014680871,4.8731863e-7,0.00074459193,0.00006886425,0.002251462,0.000042677424,0.000014923207,0.0077826926],"genre_scores_gemma":[0.99862224,0.000017062443,0.000114525596,0.0006289614,0.000026767599,0.00020927125,0.00021217245,0.000043297376,0.00012571603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960256,0.0012171686,0.00097163976,0.0005003982,0.00075782504,0.00052736484],"domain_scores_gemma":[0.9978567,0.00049006374,0.000559492,0.00070144027,0.00029011918,0.00010219678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008544777,0.00030351052,0.0010014339,0.0004969728,0.00008314071,0.0000044507005,0.00041933774,0.00009624934,0.0002850892],"category_scores_gemma":[0.00009900496,0.00022369302,0.00013338226,0.00091735646,0.00017844557,0.000081878505,0.0002102743,0.0006302554,0.000007320153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08960079,0.04018934,0.8261421,0.00018069215,0.0002146705,0.0016270704,0.014965878,0.0012571731,0.0017533808,0.00010705388,0.0016098521,0.022352055],"study_design_scores_gemma":[0.03762586,0.08872915,0.8617583,0.000032386324,0.00010666675,0.000037041627,0.004560773,0.000024198249,0.0040124264,0.000014760141,0.002923338,0.00017509684],"about_ca_topic_score_codex":0.0007467638,"about_ca_topic_score_gemma":0.00035321517,"teacher_disagreement_score":0.051974926,"about_ca_system_score_codex":0.0002194975,"about_ca_system_score_gemma":0.00048439766,"threshold_uncertainty_score":0.91219366},"labels":[],"label_agreement":null},{"id":"W4295837261","doi":"10.1016/j.annonc.2022.07.1504","title":"1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Castration; Prostate-specific antigen; Prostate; Cancer; Urology; Hormone","score_opus":0.12480796055277366,"score_gpt":0.46891553046236173,"score_spread":0.3441075699095881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861293,0.00034369374,4.7512677e-7,0.010835245,0.00009760556,0.0022828025,0.00022505736,0.0000055975484,0.000080257945],"genre_scores_gemma":[0.997996,0.0009946957,0.00008570445,0.0003229271,0.000042649383,0.00024495294,0.00016159107,0.000012058632,0.00013942092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974787,0.00069314294,0.000695877,0.00026489323,0.00057343754,0.00029395218],"domain_scores_gemma":[0.99846065,0.00079645053,0.00034899544,0.00014894511,0.00018502442,0.000059911017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020382989,0.00012075698,0.0005763911,0.00017808792,0.000088970955,0.000014547646,0.000094164985,0.000057788664,0.00004942397],"category_scores_gemma":[0.00015432821,0.000072624396,0.00006313839,0.00035047144,0.00009776765,0.000084977895,0.00007189948,0.0003699793,9.87542e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04257614,0.0015255973,0.93192226,0.000021765609,0.00018744067,0.0000599207,0.00090474077,0.000014184845,0.000014907797,0.000007663535,0.000470085,0.02229532],"study_design_scores_gemma":[0.050589405,0.017561695,0.9275137,0.00002404758,0.000055687287,5.0621867e-7,0.0003764455,0.000008478335,0.000017471966,0.000115940624,0.003668678,0.00006794057],"about_ca_topic_score_codex":0.00042921485,"about_ca_topic_score_gemma":0.00085937715,"teacher_disagreement_score":0.02222738,"about_ca_system_score_codex":0.00022856749,"about_ca_system_score_gemma":0.0004603204,"threshold_uncertainty_score":0.2961537},"labels":[],"label_agreement":null},{"id":"W4295837302","doi":"10.1016/j.annonc.2022.07.1514","title":"1382P FDG-positive/PSMA-negative PET lesion prevalence in metastatic castration-resistant prostate cancer and its correlation with lines of systemic therapy: Results from the prospective 3TMPO imaging study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; McGill University; Hôpital Fleurimont; Jewish General Hospital; Hôpital Saint-Luc; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Pet imaging; Internal medicine; Correlation; Prospective cohort study; Positron emission tomography; Pathology; Radiology","score_opus":0.08628769088755937,"score_gpt":0.4044144203896574,"score_spread":0.318126729502098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853847,0.0073916125,0.0000024893016,0.0033480746,0.000043607473,0.0031133792,0.0006015539,0.0000074943127,0.00010706198],"genre_scores_gemma":[0.99669755,0.002376518,0.00005092921,0.00007412585,0.000020422156,0.0005113293,0.000048542996,0.000012477428,0.00020810499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982392,0.0005060389,0.00041397405,0.0003143556,0.0003499363,0.00017646355],"domain_scores_gemma":[0.9982371,0.00071533007,0.0003841753,0.00014532868,0.000479761,0.000038308528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071393733,0.0001317577,0.00037991643,0.00010788295,0.00012947837,0.000007246185,0.0000796417,0.000015035358,0.000017261991],"category_scores_gemma":[0.00012131827,0.00007944587,0.00002835014,0.00032626453,0.00014731303,0.00010848615,0.00005950138,0.00022522481,3.1201972e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07428976,0.0028854664,0.76199704,0.00032400075,0.0010359661,0.0006943482,0.10671352,0.002314726,0.037164513,0.00008167428,0.00021725033,0.01228175],"study_design_scores_gemma":[0.016752044,0.012634295,0.9191665,0.0007973018,0.00021009045,0.00006377201,0.033895668,0.0018786849,0.0142149655,0.00021758355,0.000023965944,0.00014510454],"about_ca_topic_score_codex":0.0026689295,"about_ca_topic_score_gemma":0.0005601551,"teacher_disagreement_score":0.15716949,"about_ca_system_score_codex":0.00015379145,"about_ca_system_score_gemma":0.00060914084,"threshold_uncertainty_score":0.4034641},"labels":[],"label_agreement":null},{"id":"W4295837309","doi":"10.1016/j.annonc.2022.07.1758","title":"1679P A comparative analysis of cancer NGS reporting practices between Europe and North America","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Natural Science Foundation of China; AstraZeneca","keywords":"Medicine; Family medicine; Cancer; Oncology; Internal medicine","score_opus":0.2853872928764236,"score_gpt":0.42315702641439634,"score_spread":0.13776973353797273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645309,0.0040288796,0.000054452663,0.0018488878,0.000101065365,0.00010755104,0.0006943968,0.0000067986634,0.028627057],"genre_scores_gemma":[0.9968933,0.0018732701,0.00017766481,0.000695294,0.00005576997,0.000028329569,0.000032885317,0.000007946613,0.00023554648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795234,0.00004967194,0.0014390793,0.00030832618,0.000035464647,0.00021511408],"domain_scores_gemma":[0.9872603,0.00023137804,0.012120799,0.00019682304,0.00012421072,0.00006653129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078229693,0.000105742634,0.001223341,0.00032693727,0.000098514756,0.000009679743,0.00017863406,0.000041596846,0.000494067],"category_scores_gemma":[0.0006675171,0.0001261964,0.00014251136,0.0008210059,0.00016862084,0.00018848282,0.00015801608,0.00017423801,0.000005440046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074809905,0.0001055837,0.9735668,0.000016309159,0.0013631243,0.0000050172357,0.0025131053,0.0016293343,0.000011902409,0.003103274,0.0016475138,0.015963243],"study_design_scores_gemma":[0.00018487753,0.00060691684,0.63919926,0.000002077113,0.00013714198,8.457707e-7,0.00033854198,0.0003983093,0.000034096585,0.00046563437,0.35851577,0.00011656554],"about_ca_topic_score_codex":0.004604722,"about_ca_topic_score_gemma":0.00075023447,"teacher_disagreement_score":0.35686824,"about_ca_system_score_codex":0.000047580823,"about_ca_system_score_gemma":0.000117677744,"threshold_uncertainty_score":0.6960993},"labels":[],"label_agreement":null},{"id":"W4295837313","doi":"10.1016/j.annonc.2022.07.1825","title":"1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Foundation Medicine; Merck Sharp and Dohme; EMD Serono; Genentech; Ipsen; Astellas Pharma; Calithera Biosciences; Sanofi Genzyme; Incyte; Exelixis; Merck KGaA; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Docetaxel; Cisplatin; Medicine; Exploratory analysis; Urothelial cancer; Pembrolizumab; Oncology; Cancer; Chemotherapy; Internal medicine","score_opus":0.08060300676111953,"score_gpt":0.44906555892392047,"score_spread":0.36846255216280094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959751,0.00041927732,0.0000025880324,0.0013873033,0.0001365129,0.0012007869,0.00038341718,0.000011166034,0.00048386568],"genre_scores_gemma":[0.9981699,0.00016969304,0.00001085062,0.0010514904,0.000046934667,0.00027427953,0.00001011264,0.00003239771,0.00023435905],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99718916,0.00086495304,0.0007499081,0.00035762557,0.0005297406,0.00030863017],"domain_scores_gemma":[0.99816316,0.0002968369,0.0005627877,0.00067777483,0.00020779538,0.000091669135],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092334463,0.0002371944,0.0012752808,0.00065155467,0.000074177326,0.0000022740014,0.0003072642,0.00009636729,0.0014374673],"category_scores_gemma":[0.00010705129,0.00016970064,0.00061328954,0.0014876247,0.00017369175,0.00004444484,0.00010233319,0.0003036391,0.0000010888882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5647185,0.040969644,0.19179587,0.000084181236,0.013961521,0.00016527281,0.0326391,0.004443084,0.092641525,0.000020773294,0.0023718204,0.0561887],"study_design_scores_gemma":[0.0764859,0.0701146,0.79590046,0.00006266592,0.002203078,0.000010933208,0.0030810123,0.00030637888,0.049727377,0.0000469234,0.0017904929,0.0002701655],"about_ca_topic_score_codex":0.002806848,"about_ca_topic_score_gemma":0.0003909151,"teacher_disagreement_score":0.6041046,"about_ca_system_score_codex":0.00043253673,"about_ca_system_score_gemma":0.0018488629,"threshold_uncertainty_score":0.99947536},"labels":[],"label_agreement":null},{"id":"W4295837322","doi":"10.1016/j.annonc.2022.07.1743","title":"1663MO DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice transplanted with human feces","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Dysbiosis; Fecal bacteriotherapy; Medicine; Feces; Antibiotics; Proof of concept; Human feces; Gut flora; Gastroenterology; Microbiology; Immunology; Clostridium difficile; Biology","score_opus":0.037798905220347956,"score_gpt":0.32924321549574875,"score_spread":0.2914443102754008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983076,0.0003389268,0.000025837555,0.00044349578,0.000051797862,0.00048529077,0.00009088802,0.0000073453684,0.00024885812],"genre_scores_gemma":[0.9989412,0.000048992235,0.00041817027,0.000362162,0.000029379997,0.000009472666,0.00013399964,0.000024689885,0.000031967535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983189,0.00025815,0.00046200273,0.00045801557,0.00009472436,0.000408187],"domain_scores_gemma":[0.99925274,0.000041241976,0.00031590182,0.00022883604,0.00007958622,0.0000817108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004090122,0.0002059442,0.00047460155,0.00015415836,0.0001317696,0.0000070169904,0.00027785022,0.00012021428,0.000020273985],"category_scores_gemma":[0.000029376532,0.00020183148,0.00007042855,0.00021494036,0.00021323553,0.0000065208797,0.00019214237,0.00026991576,2.800953e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003566995,0.0008494334,0.015749922,0.00019307852,0.000083997285,0.000046765585,0.00054683455,0.000049814607,0.9798505,0.00002933686,0.00016002372,0.0020836305],"study_design_scores_gemma":[0.002438795,0.00792381,0.070228666,0.0002110565,0.000041773954,0.00033613516,0.00046641225,0.000014479385,0.9168121,0.0000091691845,0.0012582025,0.00025937075],"about_ca_topic_score_codex":0.0003143075,"about_ca_topic_score_gemma":0.00027835052,"teacher_disagreement_score":0.063038334,"about_ca_system_score_codex":0.000025775278,"about_ca_system_score_gemma":0.00027236613,"threshold_uncertainty_score":0.8230449},"labels":[],"label_agreement":null},{"id":"W4295837323","doi":"10.1016/j.annonc.2022.07.1827","title":"1749P Association between immune-mediated adverse events (imAEs) and outcomes in metastatic urothelial cancer (mUC) treated with durvalumab (D) alone or in combination with tremelimumab (T) in the DANUBE study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada; Astellas Pharma Canada; Roche; Sanofi; Merck; Janssen Pharmaceuticals; Bayer; AstraZeneca; Pfizer","keywords":"Medicine; Durvalumab; Internal medicine; Hazard ratio; Cancer; Adverse effect; Oncology; Proportional hazards model; Immune system; Immunotherapy; Immunology; Confidence interval; Pembrolizumab","score_opus":0.057251954807823795,"score_gpt":0.3696447928145789,"score_spread":0.3123928380067551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329257,0.00015949101,7.6274864e-7,0.00475865,0.000033069722,0.0015997838,0.000067771274,0.0000094178395,0.000078506026],"genre_scores_gemma":[0.9984159,0.00017293336,0.000017640454,0.0005909304,0.000008318552,0.000577324,0.00006245228,0.00001653333,0.00013796691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975072,0.0009859354,0.0005755605,0.00023143625,0.0004490132,0.0002508489],"domain_scores_gemma":[0.998667,0.00066990097,0.00039387573,0.00015956209,0.000083863226,0.000025805173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019178862,0.0001577497,0.00070442626,0.00036690978,0.000057018537,0.0000031744885,0.00011646711,0.00005474677,0.00008936078],"category_scores_gemma":[0.00014154277,0.00009653021,0.00003938394,0.00083725725,0.000058800477,0.000088062334,0.00003194464,0.000283202,5.233965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018256892,0.0028028716,0.96718216,0.000023957,0.0005427294,0.00014168078,0.005144292,0.000043650292,0.00026833793,0.0000015316529,0.000041820484,0.0055500595],"study_design_scores_gemma":[0.036645576,0.011637244,0.9440871,0.00005310283,0.00016622376,0.00001022883,0.0068487194,0.000046537556,0.00012751693,0.0000101751075,0.0002606974,0.000106893305],"about_ca_topic_score_codex":0.009431079,"about_ca_topic_score_gemma":0.020836372,"teacher_disagreement_score":0.023095096,"about_ca_system_score_codex":0.000505041,"about_ca_system_score_gemma":0.00042141782,"threshold_uncertainty_score":0.9971652},"labels":[],"label_agreement":null},{"id":"W4295837344","doi":"10.1016/j.annonc.2022.07.1502","title":"1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ipsen; Astellas Pharma; Svenska Forskningsrådet Formas; Exelixis; Gilead Sciences; Merck; Genentech; Bristol-Myers Squibb; AstraZeneca; Pfizer; Merck Sharp and Dohme; Ono Pharmaceutical","keywords":"Medicine; Internal medicine; Prostate cancer; Cancer; Gastroenterology; Oncology","score_opus":0.033090003540048464,"score_gpt":0.32747645856948077,"score_spread":0.2943864550294323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977214,0.0007477092,0.000017709455,0.00022098594,0.000096094336,0.00095072045,0.0002029559,0.0000026594755,0.000039767103],"genre_scores_gemma":[0.99892277,0.00025133236,0.00012445837,0.000083716375,0.000024357043,0.0004002501,0.00017270207,0.000012616409,0.000007811851],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859375,0.00034171646,0.0004888972,0.00027575597,0.0001223943,0.0001774972],"domain_scores_gemma":[0.99926966,0.00010588101,0.00036053732,0.00012640873,0.0001126905,0.000024814255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005157797,0.00011356882,0.00027454196,0.0001366117,0.000052621148,0.0000074388786,0.000097312484,0.000052418574,0.000007202702],"category_scores_gemma":[0.00013615063,0.000100343364,0.000034323926,0.0002337291,0.00007741634,0.000008907985,0.000060800634,0.00012674452,8.423921e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023038521,0.0036861638,0.009504791,0.00009686683,0.00012657873,0.00017543891,0.0047527305,0.010181059,0.85953206,0.000046678677,0.00007099896,0.088788114],"study_design_scores_gemma":[0.17326742,0.060709022,0.14925219,0.00015991302,0.00026623515,0.00007096186,0.010074628,0.0034016902,0.5960091,0.0021693544,0.003722315,0.0008972056],"about_ca_topic_score_codex":0.004928942,"about_ca_topic_score_gemma":0.01815449,"teacher_disagreement_score":0.263523,"about_ca_system_score_codex":0.00006978123,"about_ca_system_score_gemma":0.0003106305,"threshold_uncertainty_score":0.99976164},"labels":[],"label_agreement":null},{"id":"W4295837361","doi":"10.1016/j.annonc.2022.07.1858","title":"274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Drug; Cancer; Gynecology; Pharmacology","score_opus":0.06520598839853473,"score_gpt":0.41253695573535093,"score_spread":0.34733096733681623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661043,0.0020843265,0.000010209858,0.02581558,0.00018268412,0.0028235563,0.001704584,0.000065590015,0.0012091412],"genre_scores_gemma":[0.98430014,0.0060972306,0.001252384,0.0055334647,0.0001950087,0.0010329167,0.00038182907,0.00015028639,0.0010567305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99283344,0.0021215298,0.001493929,0.0010372659,0.0012271792,0.0012866325],"domain_scores_gemma":[0.99579793,0.0010851681,0.0007844808,0.00089350506,0.0008705029,0.0005684339],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015706514,0.00062275183,0.0022272512,0.0007847137,0.00022380766,0.000030563842,0.0008948868,0.00021741507,0.0039509386],"category_scores_gemma":[0.0005055765,0.0005452758,0.00030123975,0.002296654,0.0009259878,0.0003158069,0.00029424776,0.0012608251,0.000028060882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05911284,0.0214047,0.36572447,0.0038418719,0.005023566,0.0028396887,0.031052928,0.00035115116,0.16920687,0.00069699617,0.20394926,0.13679567],"study_design_scores_gemma":[0.061923508,0.06270431,0.38296968,0.0026366322,0.0011300276,0.0035742172,0.012537634,0.0010666165,0.19320562,0.0009267658,0.27445692,0.0028680866],"about_ca_topic_score_codex":0.040911123,"about_ca_topic_score_gemma":0.0032576078,"teacher_disagreement_score":0.13392758,"about_ca_system_score_codex":0.0008838284,"about_ca_system_score_gemma":0.004260346,"threshold_uncertainty_score":0.9996999},"labels":[],"label_agreement":null},{"id":"W4295837466","doi":"10.1016/j.annonc.2022.08.072","title":"LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Perioperative; Randomized controlled trial; Oncology; Internal medicine; Nephrectomy; Clinical trial; Kidney cancer; Cancer; Surgery; Kidney; Immunotherapy","score_opus":0.30145614907350077,"score_gpt":0.4595597350834706,"score_spread":0.15810358600996982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728096,0.00023128251,0.00003458071,0.00035026527,0.00092035846,0.0078529585,0.000018958264,0.000030733834,0.0032799267],"genre_scores_gemma":[0.9966794,0.000039768725,0.00072643434,0.00034370925,0.0005222672,0.0011858216,0.00026790015,0.000043649266,0.00019099776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9885847,0.0062509854,0.002834849,0.00075254485,0.0010371249,0.00053980295],"domain_scores_gemma":[0.992384,0.0048981896,0.0015071519,0.00035125387,0.0006546039,0.00020477381],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010140796,0.00039821674,0.0034615167,0.00030942672,0.00027620356,0.000026363412,0.00022405977,0.00015889536,0.00030471635],"category_scores_gemma":[0.0016786628,0.00032825876,0.0005320311,0.00058478065,0.00018128818,0.00016383707,0.00021699819,0.00070186384,0.000006821764],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8837286,0.014704409,0.0931555,0.000026564405,0.0007562206,0.00016326229,0.0015269646,0.0022459552,0.00005581464,0.00007597197,0.0009078085,0.0026529254],"study_design_scores_gemma":[0.87534153,0.08598019,0.033790324,0.000035601566,0.0005590884,0.000007699667,0.0010197107,0.0019307615,0.00015450663,0.000029123348,0.0008971677,0.00025427487],"about_ca_topic_score_codex":0.00051400694,"about_ca_topic_score_gemma":0.0007212097,"teacher_disagreement_score":0.071275786,"about_ca_system_score_codex":0.0007902656,"about_ca_system_score_gemma":0.0019497364,"threshold_uncertainty_score":0.999917},"labels":[],"label_agreement":null},{"id":"W4295837529","doi":"10.1016/j.annonc.2022.08.070","title":"LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Clinical endpoint; Ipilimumab; Internal medicine; Nivolumab; Population; Cabozantinib; Placebo; Randomized controlled trial; Progression-free survival; Intention-to-treat analysis; Oncology; Phases of clinical research; Gastroenterology; Urology; Renal cell carcinoma; Cancer; Clinical trial; Chemotherapy; Immunotherapy; Pathology","score_opus":0.0515036698503485,"score_gpt":0.3865891785426204,"score_spread":0.33508550869227194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638134,0.0003271162,0.000007682974,0.00033368607,0.00003874836,0.0019343768,0.000056214776,0.000008593968,0.0009122289],"genre_scores_gemma":[0.998839,0.0004181133,0.00017315382,0.00008660547,0.00000999031,0.00018982371,0.00004346792,0.000020250623,0.00021959425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971344,0.00080727687,0.0009602142,0.0003634934,0.0003507896,0.00038384637],"domain_scores_gemma":[0.99806917,0.0005782015,0.00068112055,0.00028787035,0.00027462223,0.00010900672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012093715,0.00018172622,0.0013662633,0.00064049993,0.000052304396,0.0000017855664,0.00017499579,0.0001065347,0.0001626005],"category_scores_gemma":[0.00019919504,0.00014757908,0.00004874937,0.000584466,0.00033586295,0.0000733395,0.000179216,0.00047142128,7.0256374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09676272,0.024164764,0.8346957,0.0003803048,0.00023114437,0.00085777714,0.013086252,0.000075700664,0.0053638997,0.000025959169,0.00042798405,0.023927785],"study_design_scores_gemma":[0.20402917,0.18807314,0.5852791,0.00015177365,0.00033425118,0.00009795734,0.013904247,0.0021606067,0.0054363515,0.00008292047,0.00025136737,0.00019910754],"about_ca_topic_score_codex":0.0035211449,"about_ca_topic_score_gemma":0.00359439,"teacher_disagreement_score":0.2494166,"about_ca_system_score_codex":0.000118820164,"about_ca_system_score_gemma":0.0008901969,"threshold_uncertainty_score":0.60181},"labels":[],"label_agreement":null},{"id":"W4296006125","doi":"10.1016/j.annonc.2022.07.687","title":"559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; EMD Serono; Genentech; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; Sociedad Española de Oncología Médica; Silverback Therapeutics; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; AstraZeneca; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences","keywords":"Medicine; Neratinib; Bevacizumab; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Population; Cancer; Gastroenterology; Chemotherapy; Phases of clinical research; Trastuzumab; Breast cancer","score_opus":0.10091057117074319,"score_gpt":0.4716622743300022,"score_spread":0.370751703159259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296006125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96074814,0.0010014612,0.0000059252566,0.034135036,0.0007923481,0.0009308395,0.0010195951,0.000018734385,0.0013479065],"genre_scores_gemma":[0.9925855,0.00027498204,0.000114013856,0.005223719,0.00019936413,0.0004958734,0.0007510087,0.000019214585,0.0003363433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835205,0.0003454193,0.00048988685,0.00027839444,0.000257649,0.00027658994],"domain_scores_gemma":[0.99902886,0.00037454788,0.0001774815,0.00023498294,0.00009320582,0.000090927795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036247727,0.00014271266,0.0004828344,0.00009641752,0.00013642444,0.000009026791,0.00015811593,0.000054788303,0.004055411],"category_scores_gemma":[0.0001367643,0.00010302517,0.00011884897,0.0003936889,0.00009112585,0.000051965926,0.0000788759,0.00033847947,0.000010825748],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121921055,0.043234006,0.029369928,0.000087911874,0.0028159407,0.0011205627,0.012634678,0.00017739837,0.0020816186,0.0012674935,0.47457966,0.31070974],"study_design_scores_gemma":[0.27519986,0.014326301,0.007914333,0.00007332436,0.00078967796,0.000020791635,0.0026345376,0.00061289273,0.0010588611,0.0007813437,0.69633955,0.00024853137],"about_ca_topic_score_codex":0.0025635827,"about_ca_topic_score_gemma":0.0015888094,"teacher_disagreement_score":0.31046122,"about_ca_system_score_codex":0.0001829493,"about_ca_system_score_gemma":0.0008282021,"threshold_uncertainty_score":0.996855},"labels":[],"label_agreement":null},{"id":"W4296006449","doi":"10.1016/j.annonc.2022.07.659","title":"531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Oncology; Germline; Internal medicine; BRCA mutation; Germline mutation; Gynecology; Cancer; Mutation; Genetics; Poly ADP ribose polymerase","score_opus":0.07970447347517559,"score_gpt":0.37320506674236126,"score_spread":0.2935005932671857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296006449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773901,0.00013154278,0.00027760255,0.015966017,0.0013595925,0.002074845,0.0011735909,0.000039861286,0.0015868191],"genre_scores_gemma":[0.99052507,0.00033190998,0.00055485853,0.006218047,0.0006791459,0.0004603232,0.0008727613,0.0000587016,0.00029916273],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99613553,0.0008790785,0.0010773239,0.0006808546,0.0007295878,0.0004975945],"domain_scores_gemma":[0.996932,0.0008675404,0.0010650894,0.00052327005,0.0005000249,0.00011206201],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013564846,0.00032531458,0.0009014732,0.00018186067,0.00019744581,0.000014745236,0.0002413199,0.00020051163,0.0003024812],"category_scores_gemma":[0.00023610155,0.00025406058,0.00015456165,0.00044771703,0.00025187945,0.00015084785,0.000073746116,0.00078226515,0.000006366622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90730125,0.002703943,0.016908487,0.000026784859,0.0007329664,0.00014864345,0.011559582,0.004274571,0.0014563794,0.00034446563,0.023486042,0.031056914],"study_design_scores_gemma":[0.6122606,0.028408187,0.29571474,0.00056573364,0.000109425826,0.000041151743,0.0011810687,0.002524872,0.002369359,0.0011527713,0.055018254,0.000653884],"about_ca_topic_score_codex":0.0054379827,"about_ca_topic_score_gemma":0.0010558935,"teacher_disagreement_score":0.29504067,"about_ca_system_score_codex":0.0005978662,"about_ca_system_score_gemma":0.0010949088,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W4296007126","doi":"10.1016/j.annonc.2022.07.646","title":"518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; Chemotherapy; Ovarian carcinoma; Ovarian cancer; BRCA mutation; Gynecology; Cancer","score_opus":0.04698401234661571,"score_gpt":0.3723534837227811,"score_spread":0.3253694713761654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296007126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571186,0.00010626702,0.00009048125,0.002000702,0.00021466834,0.0011202232,0.00015878928,0.000028354067,0.00056867325],"genre_scores_gemma":[0.9964288,0.000028064833,0.0007946255,0.0021899743,0.000058606947,0.00013847784,0.0003001801,0.000033679775,0.000027620845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977839,0.000393216,0.0006555085,0.00048386445,0.00040275953,0.0002807447],"domain_scores_gemma":[0.99862057,0.0002677101,0.0004961763,0.00032033096,0.00019546418,0.00009976458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005665171,0.00019501898,0.00067181874,0.0002106142,0.00011927748,0.000015243383,0.00009695438,0.00008689702,0.000104695864],"category_scores_gemma":[0.00006922484,0.00019138615,0.00004552322,0.00027196432,0.000106076106,0.00017430917,0.00005097943,0.00034335916,6.1207606e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3420545,0.0218382,0.37749135,0.0000589444,0.0007652777,0.0011032649,0.043131012,0.0005388918,0.0067122425,0.0000933374,0.0012550446,0.20495793],"study_design_scores_gemma":[0.22709115,0.035697535,0.73010296,0.00006439089,0.0000613987,0.000024089863,0.002338405,0.00028812303,0.00090373534,0.0002924006,0.0028710745,0.00026471744],"about_ca_topic_score_codex":0.0010294857,"about_ca_topic_score_gemma":0.00017606407,"teacher_disagreement_score":0.3526116,"about_ca_system_score_codex":0.00021164892,"about_ca_system_score_gemma":0.0003701044,"threshold_uncertainty_score":0.7804501},"labels":[],"label_agreement":null},{"id":"W4296007234","doi":"10.1016/j.annonc.2022.07.1017","title":"891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Internal medicine; Population; Post-hoc analysis; Clinical endpoint; Neuroblastoma; Phases of clinical research; Clinical trial; Surgery; Oncology; Gastroenterology","score_opus":0.2353686009104677,"score_gpt":0.4422416962645087,"score_spread":0.206873095354041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296007234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831853,0.00022324134,0.0000043177306,0.012607481,0.0005588324,0.0021465842,0.0008829867,0.000021379727,0.0003699131],"genre_scores_gemma":[0.9964749,0.0002730336,0.00008641983,0.0007204756,0.00016886079,0.00052704115,0.000045657573,0.000031357264,0.0016722517],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974544,0.00072654255,0.0005811662,0.00036838013,0.00050209096,0.0003674372],"domain_scores_gemma":[0.9946917,0.00371661,0.0005594018,0.000768099,0.00015815081,0.000106012114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036073365,0.00022765413,0.00079533324,0.00010763897,0.00035120166,0.0000074826744,0.0003828267,0.00008470165,0.00050835294],"category_scores_gemma":[0.0008510488,0.00010798801,0.00056821696,0.00026292313,0.00025005254,0.00004716445,0.00023279182,0.0002902454,0.0000071026993],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.705702,0.0298105,0.020478375,0.00008715896,0.009400961,0.0005947523,0.0018951476,0.00030756285,0.010281816,0.00020215657,0.1438221,0.07741747],"study_design_scores_gemma":[0.21136804,0.2079606,0.32990965,0.000039270075,0.0016483059,0.000049816448,0.0005892941,0.00008912688,0.034632117,0.0005329225,0.2129186,0.00026225008],"about_ca_topic_score_codex":0.0014753728,"about_ca_topic_score_gemma":0.00070486654,"teacher_disagreement_score":0.49433395,"about_ca_system_score_codex":0.00013367638,"about_ca_system_score_gemma":0.0005750954,"threshold_uncertainty_score":0.5566108},"labels":[],"label_agreement":null},{"id":"W4296007697","doi":"10.1016/j.annonc.2022.07.775","title":"651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pembrolizumab; Carboplatin; Internal medicine; Clinical trial; Oncology; Head and neck squamous-cell carcinoma; Phases of clinical research; Surgery; Head and neck cancer; Radiation therapy; Cancer; Chemotherapy; Cisplatin; Adverse effect; Immunotherapy","score_opus":0.08756686997280383,"score_gpt":0.3949093965393589,"score_spread":0.3073425265665551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296007697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795117,0.011874669,0.0000031910938,0.0031742298,0.0004693328,0.0020758852,0.00014082037,0.000041873296,0.0027082947],"genre_scores_gemma":[0.99521834,0.001557805,0.00008307788,0.0022271848,0.00010717958,0.00030449827,0.00008666263,0.00006354068,0.00035172206],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962245,0.0007020574,0.001140358,0.00070194,0.00055662077,0.00067451893],"domain_scores_gemma":[0.9979291,0.00055818993,0.0005119875,0.0006147289,0.00016823648,0.00021774623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001208149,0.00043432557,0.00122379,0.0005230498,0.000207931,0.000016649998,0.0002758789,0.00014347935,0.0007222228],"category_scores_gemma":[0.00014109832,0.00040867802,0.00025865782,0.0007426814,0.00023569631,0.000093792136,0.00016957655,0.0006872037,0.000006298641],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2826896,0.06477817,0.10870454,0.0008338865,0.0009755962,0.0036905603,0.032049797,0.00017866516,0.02756795,0.00008016097,0.00966805,0.46878305],"study_design_scores_gemma":[0.29555926,0.39426452,0.19345908,0.00013821213,0.00044493235,0.0007719895,0.011363091,0.0013732451,0.008638634,0.0006322695,0.091995165,0.0013596406],"about_ca_topic_score_codex":0.005098838,"about_ca_topic_score_gemma":0.0015388734,"teacher_disagreement_score":0.4674234,"about_ca_system_score_codex":0.00025303493,"about_ca_system_score_gemma":0.0006193761,"threshold_uncertainty_score":0.9998365},"labels":[],"label_agreement":null},{"id":"W4296008380","doi":"10.1016/j.annonc.2022.07.500","title":"362P Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Jewish General Hospital","funders":"Seagen","keywords":"Medicine; KRAS; Colorectal cancer; Internal medicine; Oncology; Phases of clinical research; Mutation; Cancer; Chemotherapy; Genetics; Gene","score_opus":0.05725019530530146,"score_gpt":0.4376121223198598,"score_spread":0.38036192701455834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296008380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994254,0.00025349794,0.0000030328013,0.002149986,0.00010698716,0.0021158876,0.000058229554,0.000017216522,0.0010411503],"genre_scores_gemma":[0.99736756,0.000041243613,0.00007394916,0.0011323557,0.000029068773,0.0011701202,0.000029207073,0.000023066394,0.00013344914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985695,0.0001601968,0.00027767272,0.00032175033,0.00040901333,0.00026190403],"domain_scores_gemma":[0.99925965,0.00006695512,0.00016160948,0.00013212844,0.00029812817,0.00008151157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024107588,0.00017627586,0.00056092074,0.0001937439,0.00011120039,0.0000040104283,0.00007267226,0.000024995717,0.00033552627],"category_scores_gemma":[0.000019486755,0.00012403684,0.000039786362,0.00044653864,0.00006160016,0.000047262878,0.00004371023,0.00013986697,0.000002528571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06998819,0.01478428,0.78767455,0.000017480806,0.0010022325,0.00021582509,0.015648963,0.0008256908,0.00017789137,0.0000064158717,0.0012369081,0.10842161],"study_design_scores_gemma":[0.02903082,0.16960065,0.79484755,0.000022951936,0.00015949018,0.000005622052,0.0027565623,0.000036976948,0.00049471745,0.000015033081,0.0028839963,0.00014560117],"about_ca_topic_score_codex":0.0015324438,"about_ca_topic_score_gemma":0.0054073334,"teacher_disagreement_score":0.15481637,"about_ca_system_score_codex":0.0003303279,"about_ca_system_score_gemma":0.0003593725,"threshold_uncertainty_score":0.5058076},"labels":[],"label_agreement":null},{"id":"W4296008883","doi":"10.1016/j.annonc.2022.07.158","title":"126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Immunotherapy; Proportional hazards model; Oncology; Human leukocyte antigen; Tumor microenvironment; Internal medicine; Gene signature; Log-rank test; Immune system; Cancer; Progression-free survival; Gene expression; Immunology; Antigen; Overall survival; Gene; Confidence interval; Biology","score_opus":0.03864686665267729,"score_gpt":0.3063800342567599,"score_spread":0.2677331676040826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296008883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872814,0.002099649,0.000004488043,0.009050863,0.0000734105,0.001274811,0.000019436568,0.000013196337,0.0001827741],"genre_scores_gemma":[0.98933256,0.0007807602,0.00008126184,0.009205056,0.000031704178,0.00025571842,0.00006118186,0.000026979422,0.00022477291],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99848795,0.00030924144,0.00037428233,0.0002801537,0.000281262,0.00026712468],"domain_scores_gemma":[0.99924994,0.00012029987,0.0002292292,0.00029477256,0.00006065389,0.000045124845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004058133,0.0001904868,0.00036048243,0.00010945407,0.00029798396,0.000014321919,0.00018999325,0.000071748174,0.00021187509],"category_scores_gemma":[0.0000114759005,0.00010751679,0.0000856888,0.0003263422,0.00015809329,0.00005912924,0.00009663065,0.00035767735,0.0000025523711],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03757449,0.0013788121,0.075251974,0.000021543367,0.00031421284,0.000033599885,0.0060375324,0.00019818827,0.8284779,0.00000406906,0.0047230516,0.045984607],"study_design_scores_gemma":[0.0079758195,0.017159628,0.64014363,0.00013310493,0.00004991813,0.0001234307,0.0018214659,0.0000149118305,0.25196296,0.000016422746,0.08039697,0.00020172402],"about_ca_topic_score_codex":0.00026191722,"about_ca_topic_score_gemma":0.000037857153,"teacher_disagreement_score":0.57651496,"about_ca_system_score_codex":0.00018279947,"about_ca_system_score_gemma":0.00009654774,"threshold_uncertainty_score":0.43844074},"labels":[],"label_agreement":null},{"id":"W4296008893","doi":"10.1016/j.annonc.2022.07.1058","title":"932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Chemotherapy; Lung cancer; Quality of life (healthcare); Cancer; Nursing; Immunotherapy","score_opus":0.15537523018742835,"score_gpt":0.37430033848463307,"score_spread":0.2189251082972047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296008893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540618,0.013598481,0.00013489556,0.0072585335,0.0014019497,0.001325006,0.003079836,0.000035518762,0.019103983],"genre_scores_gemma":[0.9883343,0.0042615193,0.0005857419,0.002590725,0.00016579106,0.0005080506,0.00018077128,0.00008663408,0.0032864846],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959644,0.000077798104,0.0022946368,0.00075667584,0.000089434354,0.0008170655],"domain_scores_gemma":[0.9954743,0.00051093503,0.0029829685,0.0006306278,0.0001498184,0.00025138713],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001281477,0.0004034574,0.0025232558,0.00024318873,0.0002526032,0.000023716299,0.0005418955,0.00028725856,0.0023014357],"category_scores_gemma":[0.00018063895,0.00046311985,0.0005473375,0.00025038933,0.00013597941,0.00020039486,0.0001602188,0.00028029492,0.000030460234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10628923,0.011996284,0.35349903,0.0023716143,0.01254339,0.00004221492,0.048528865,0.023869302,0.0030206856,0.050061915,0.18667726,0.20110022],"study_design_scores_gemma":[0.18401155,0.027571285,0.17236914,0.00020693972,0.00023004483,0.0000060202487,0.0036159484,0.01143871,0.023852605,0.020414604,0.55250156,0.0037816116],"about_ca_topic_score_codex":0.06764817,"about_ca_topic_score_gemma":0.0018637761,"teacher_disagreement_score":0.36582428,"about_ca_system_score_codex":0.0014179716,"about_ca_system_score_gemma":0.0016019933,"threshold_uncertainty_score":0.999782},"labels":[],"label_agreement":null},{"id":"W4296009087","doi":"10.1016/j.annonc.2022.07.869","title":"743P A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Alberta Health Services; University Health Network; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; CD137; Cancer; Agonist; Oncology; Internal medicine; Immunotherapy; Receptor","score_opus":0.10462461641599974,"score_gpt":0.4779837997940729,"score_spread":0.37335918337807317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296009087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960261,0.00026826918,0.0000015331549,0.0017778121,0.000055993754,0.0011615963,0.00009832676,0.0000066836087,0.0006036783],"genre_scores_gemma":[0.997692,0.00022375926,0.00014808468,0.0007155268,0.000019480523,0.0002417686,0.00007577791,0.000017026829,0.0008665616],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983148,0.00025249962,0.00043666075,0.00023120879,0.0005060537,0.0002587934],"domain_scores_gemma":[0.999073,0.00017764865,0.00023972479,0.00017836603,0.00024370447,0.00008751599],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002991238,0.00012902565,0.0005680542,0.00022335825,0.00007057143,0.000002619492,0.00012149269,0.000029014676,0.0018639774],"category_scores_gemma":[0.000045775647,0.00009058755,0.00004901504,0.0003996282,0.00010162479,0.000057413512,0.00006998633,0.00022585466,0.000003332781],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18473977,0.054465752,0.20068406,0.00022951506,0.00087189884,0.00041634947,0.0050360933,0.0008392829,0.0021652102,0.00011294171,0.0014247184,0.54901445],"study_design_scores_gemma":[0.11533112,0.2784795,0.54726344,0.00010948362,0.00019136682,0.000030191506,0.0040293178,0.00060855405,0.0023302026,0.0002769676,0.05098356,0.00036631335],"about_ca_topic_score_codex":0.0023997573,"about_ca_topic_score_gemma":0.0008790901,"teacher_disagreement_score":0.5486481,"about_ca_system_score_codex":0.00007118328,"about_ca_system_score_gemma":0.00040321017,"threshold_uncertainty_score":0.9990485},"labels":[],"label_agreement":null},{"id":"W4296009454","doi":"10.1016/j.annonc.2022.07.1051","title":"926P Utility of point-of-care genomic profiling in the diagnosis and treatment of cancer of unknown primary","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Profiling (computer programming); Primary care; Point of care; Oncology; Computational biology; Internal medicine; Intensive care medicine; Bioinformatics; Family medicine; Pathology","score_opus":0.1113048858321758,"score_gpt":0.4081501297949416,"score_spread":0.2968452439627658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296009454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96851146,0.027232293,1.8765881e-7,0.0021736014,0.00005177073,0.00070751796,0.00023776406,0.0000016131416,0.001083802],"genre_scores_gemma":[0.98597133,0.0132757425,0.00011913352,0.00016044415,0.000016698516,0.00041749972,0.000024658388,0.00000643762,0.0000080446825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897325,0.0001320619,0.00047276067,0.00015612163,0.0001485557,0.00011725958],"domain_scores_gemma":[0.99890846,0.00035417447,0.00035845843,0.0002272994,0.00012580112,0.00002580972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022909665,0.00009135911,0.00068910775,0.00009598572,0.000017840563,4.1852553e-7,0.00006999054,0.00004226486,0.0001588255],"category_scores_gemma":[0.000022210523,0.000064259795,0.00013267528,0.00014276829,0.00016501396,0.000014225167,0.00005804383,0.000053337593,6.41191e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009757487,0.0034156623,0.81241465,0.0004917348,0.000297254,0.000013781005,0.0047755516,0.000030751264,0.0016933808,0.00012773769,0.00022093956,0.17554282],"study_design_scores_gemma":[0.0031794074,0.012679413,0.8827272,0.00010367337,0.00028944074,0.000005039552,0.002174152,0.0000106645,0.0925101,0.000075900585,0.0061955824,0.000049446167],"about_ca_topic_score_codex":0.0034300329,"about_ca_topic_score_gemma":0.00087800337,"teacher_disagreement_score":0.17549337,"about_ca_system_score_codex":0.00013330007,"about_ca_system_score_gemma":0.00038293606,"threshold_uncertainty_score":0.51852065},"labels":[],"label_agreement":null},{"id":"W4296010496","doi":"10.1016/j.annonc.2022.07.857","title":"731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Rash; Gastroenterology; Phases of clinical research; Expanded access; Oncology; Refractory (planetary science); Surgery; Adverse effect; Cancer; Clinical trial; Immunotherapy","score_opus":0.023206207790146014,"score_gpt":0.3092899193212572,"score_spread":0.2860837115311112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296010496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964611,0.000036646932,0.0000014653755,0.0017589419,0.000042985692,0.001176026,0.000012572835,0.000003684548,0.00050660595],"genre_scores_gemma":[0.9995179,0.0000042565334,0.00002630602,0.00017885097,0.000013713406,0.00013487275,0.000028217333,0.0000070409155,0.00008884311],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989951,0.00013913738,0.00028100915,0.0001579434,0.0002932568,0.00013355534],"domain_scores_gemma":[0.9994672,0.000049030255,0.00022502174,0.00009398908,0.00013004805,0.00003473865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023274175,0.00008412504,0.00034394336,0.00016571538,0.000044356893,0.0000011964603,0.00005269354,0.000034292818,0.00006416746],"category_scores_gemma":[0.00006554625,0.00005399905,0.000032164993,0.00036503354,0.00011248291,0.000048623246,0.000072693816,0.00019486967,1.7128542e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81651574,0.01284642,0.12245201,0.0001273308,0.000051855877,0.0000795247,0.00083580444,0.00019319933,0.009609292,0.00022021175,0.00011141324,0.036957163],"study_design_scores_gemma":[0.25924587,0.09685264,0.63917017,0.00014249625,0.000028721617,0.000040734336,0.0003463391,0.00020557825,0.0030028624,0.000252103,0.00060506817,0.00010742593],"about_ca_topic_score_codex":0.000097812066,"about_ca_topic_score_gemma":0.00023573104,"teacher_disagreement_score":0.5572699,"about_ca_system_score_codex":0.000064078704,"about_ca_system_score_gemma":0.00024729245,"threshold_uncertainty_score":0.22020173},"labels":[],"label_agreement":null},{"id":"W4296010994","doi":"10.1016/j.annonc.2022.07.1003","title":"877P Characteristics of malignant cutaneous adnexal tumors in a single-institution study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer and Skin Lesions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dermatology; Pathology","score_opus":0.09425711565974032,"score_gpt":0.38211129005264843,"score_spread":0.2878541743929081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296010994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948213,0.000079337566,0.000009062749,0.0011205549,0.00023266647,0.000368988,0.000048893035,0.000009503127,0.0033096964],"genre_scores_gemma":[0.9992397,0.00003931803,0.00004149678,0.0004490185,0.00005397238,0.00003479226,0.00001722025,0.0000074883196,0.000117031945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989243,0.000118273674,0.00044693766,0.0001493213,0.00019790087,0.00016325952],"domain_scores_gemma":[0.99941343,0.00008419921,0.00018208583,0.00017332636,0.00009581891,0.00005115103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028857985,0.00007369589,0.0004612173,0.00018889767,0.0000412163,0.0000010922558,0.00008160347,0.000038541715,0.00024718637],"category_scores_gemma":[0.00013789021,0.000071385904,0.00006571423,0.00022705863,0.00008888241,0.00001761511,0.00009015575,0.00017599962,0.0000022451097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01165225,0.043722153,0.5778164,0.00045913935,0.0003968635,0.022635946,0.01955068,0.0004393656,0.09704836,0.0027691568,0.007344444,0.21616521],"study_design_scores_gemma":[0.0077115726,0.08357269,0.81742424,0.00025406483,0.0002574446,0.0052056746,0.010145397,0.00027976697,0.007627829,0.00047443013,0.06665064,0.00039626454],"about_ca_topic_score_codex":0.0003162898,"about_ca_topic_score_gemma":0.00013271277,"teacher_disagreement_score":0.23960778,"about_ca_system_score_codex":0.000101605954,"about_ca_system_score_gemma":0.00038878783,"threshold_uncertainty_score":0.29110327},"labels":[],"label_agreement":null},{"id":"W4296011004","doi":"10.1016/j.annonc.2022.07.1021","title":"895P Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Staining; Gastroenterology; Immunohistochemistry; Pathology; Chromogranin A; Internal medicine; Neuroendocrine tumors; Ileum","score_opus":0.07880670757584018,"score_gpt":0.38832397915368155,"score_spread":0.30951727157784137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296011004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268144,0.00019883545,0.00012015049,0.003429559,0.00008845295,0.0008116867,0.000029657002,0.0000971738,0.00254302],"genre_scores_gemma":[0.988685,0.00007821298,0.008998812,0.0013982648,0.00010056067,0.00020502324,0.00005695209,0.000062331346,0.0004148437],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9957282,0.00083461916,0.0010504092,0.00073642866,0.00065732223,0.0009929999],"domain_scores_gemma":[0.99713844,0.0011477437,0.000681301,0.0005173921,0.00023470516,0.00028040292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080284884,0.00033008598,0.00096012634,0.00051041355,0.0002034751,0.000010946949,0.00035983862,0.0000104201945,0.00054771075],"category_scores_gemma":[0.0022702243,0.00028231594,0.000121792946,0.0007462305,0.00027364522,0.00019183109,0.0006469326,0.0013648793,0.00001113291],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0098654125,0.003193202,0.6655509,0.0003360933,0.00003123223,0.12204986,0.00019462501,0.018941443,0.1678171,0.00013068008,0.0036015594,0.008287921],"study_design_scores_gemma":[0.040971123,0.24455991,0.19765294,0.0037461172,0.00018579655,0.28792515,0.013269373,0.023382613,0.1622224,0.0013456431,0.022824647,0.0019142737],"about_ca_topic_score_codex":0.00016099279,"about_ca_topic_score_gemma":0.0000419564,"teacher_disagreement_score":0.46789795,"about_ca_system_score_codex":0.00010192317,"about_ca_system_score_gemma":0.0004628214,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W4296011058","doi":"10.1016/j.annonc.2022.07.957","title":"831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Western University; Princess Margaret Cancer Centre","funders":"Oncode Institute","keywords":"Medicine; Internal medicine; Progressive disease; Oncology; Melanoma; Progression-free survival; Log-rank test; Exact test; Proportional hazards model; Retrospective cohort study; Cohort; Gastroenterology; Disease; Overall survival; Cancer research","score_opus":0.0281237568491472,"score_gpt":0.32033574268287884,"score_spread":0.29221198583373165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296011058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960028,0.00015615577,0.0000011164052,0.0013416895,0.000052078296,0.00065021944,0.000041666324,0.000012485468,0.0017417767],"genre_scores_gemma":[0.9988864,0.000010580177,0.00034863668,0.00025431675,0.0000051897377,0.00008410198,0.00013421683,0.000020212281,0.00025632195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845165,0.00021674944,0.0005615019,0.00022611635,0.000284135,0.00025982957],"domain_scores_gemma":[0.9990033,0.000113224836,0.0004253499,0.00024749196,0.00014122589,0.000069410205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029056298,0.00017581951,0.00091470993,0.0002747474,0.000048881477,0.0000010201967,0.00008933297,0.00006387063,0.00024248846],"category_scores_gemma":[0.000039215654,0.00011884772,0.000114413095,0.00034067125,0.00018926653,0.000050666833,0.00007314839,0.00021269188,0.00000403398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004478553,0.005719704,0.9828438,0.000038999533,0.0010611777,0.00033529857,0.00036051634,0.000031565014,0.00012775445,0.000049759168,0.00008686851,0.0048659663],"study_design_scores_gemma":[0.015656678,0.037499435,0.9394423,0.00003176572,0.00031311717,0.000032732674,0.0003888301,0.000004529075,0.005532952,0.00003525321,0.0009607789,0.00010165602],"about_ca_topic_score_codex":0.0004447284,"about_ca_topic_score_gemma":0.00014569495,"teacher_disagreement_score":0.043401565,"about_ca_system_score_codex":0.000115591996,"about_ca_system_score_gemma":0.00025382036,"threshold_uncertainty_score":0.48464692},"labels":[],"label_agreement":null},{"id":"W4296011363","doi":"10.1016/j.annonc.2022.07.1055","title":"929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Durvalumab; Oncology; Pharmacodynamics; Stage (stratigraphy); Internal medicine; Lung cancer; Cancer; Pharmacokinetics; Immunotherapy","score_opus":0.04352965567501625,"score_gpt":0.369824625065871,"score_spread":0.3262949693908547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296011363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417615,0.00006745453,0.000009962464,0.00016136438,0.0000957318,0.004782754,0.00016596146,0.000009750124,0.0005308755],"genre_scores_gemma":[0.998896,0.000020547006,0.00004344793,0.0002242915,0.000009702875,0.00055900024,0.000072119605,0.000038571274,0.00013632906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980179,0.00016287065,0.0006045859,0.00038724454,0.00046345772,0.00036392067],"domain_scores_gemma":[0.99873155,0.00021346519,0.0005244469,0.0002744406,0.00018381319,0.00007225355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004712155,0.00024371865,0.00071296626,0.00028631257,0.00015427051,0.0000106367615,0.0001843585,0.0000400519,0.000041237956],"category_scores_gemma":[0.000018883778,0.00015761044,0.000032845055,0.0006673669,0.00007826929,0.00011014905,0.00014483849,0.00039345378,1.5974767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008127233,0.01760273,0.940663,0.00013411917,0.0005021962,0.0004776467,0.026483476,0.004719799,0.00008247901,0.0000057876728,0.00002671875,0.0011748067],"study_design_scores_gemma":[0.052254133,0.048090853,0.83162445,0.00015114393,0.00052389153,0.000022042377,0.046630006,0.020489272,0.000025908972,0.0000019086683,0.000011756461,0.000174609],"about_ca_topic_score_codex":0.011520683,"about_ca_topic_score_gemma":0.027012454,"teacher_disagreement_score":0.10903853,"about_ca_system_score_codex":0.000442678,"about_ca_system_score_gemma":0.00054072647,"threshold_uncertainty_score":0.9950617},"labels":[],"label_agreement":null},{"id":"W4296012068","doi":"10.1016/j.annonc.2022.07.660","title":"532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Chemotherapy; Oncology; Randomized controlled trial; Gynecology; Internal medicine; Cancer","score_opus":0.10741498964121081,"score_gpt":0.4599319288843317,"score_spread":0.3525169392431209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296012068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98132515,0.000997151,0.000012863586,0.0136515,0.00015506022,0.0031022804,0.00009008815,0.0000095636615,0.00065635337],"genre_scores_gemma":[0.9968604,0.00040451527,0.00015264307,0.0012768724,0.00002157644,0.0012029455,0.000034028428,0.000022984954,0.000024051044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997006,0.0006477418,0.0010606963,0.00036524716,0.0006151072,0.00030522578],"domain_scores_gemma":[0.9978685,0.0006631728,0.000721913,0.00045536988,0.0002287741,0.00006230248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014657547,0.00024105712,0.00198825,0.00033361497,0.00005970416,0.000006178661,0.00015499152,0.00006431577,0.00051389425],"category_scores_gemma":[0.0001235404,0.00014586392,0.0002387314,0.000710307,0.00016433501,0.00005138099,0.00004694016,0.00024441056,2.699466e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80280924,0.02248552,0.128284,0.000043869342,0.0048948242,0.00097480114,0.01199625,0.00034744033,0.00018169759,0.00013083634,0.0008868444,0.02696465],"study_design_scores_gemma":[0.9087656,0.03826972,0.038824722,0.000057490273,0.0011024353,0.000017682256,0.007546319,0.000044284447,0.0025903783,0.00009779991,0.002496012,0.00018756854],"about_ca_topic_score_codex":0.0058397125,"about_ca_topic_score_gemma":0.003446248,"teacher_disagreement_score":0.10595632,"about_ca_system_score_codex":0.00023887829,"about_ca_system_score_gemma":0.00072502793,"threshold_uncertainty_score":0.8827937},"labels":[],"label_agreement":null},{"id":"W4296012076","doi":"10.1016/j.annonc.2022.07.618","title":"490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemical Synthesis and Analysis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi","keywords":"Medicine; Internal medicine; Colorectal cancer; Carcinoembryonic antigen; Cohort; Adverse effect; Cancer; Gastroenterology; Oncology; Clinical endpoint; Clinical trial","score_opus":0.013631846942789506,"score_gpt":0.27238254398394957,"score_spread":0.25875069704116005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296012076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99803317,0.0013133048,0.000013376766,0.00011370572,0.000022157012,0.00014981972,0.000058759197,0.0000029640044,0.00029273605],"genre_scores_gemma":[0.9990577,0.00057951827,0.000094901116,0.00007857408,0.000012655457,0.000010302744,0.00009635462,0.000015515601,0.000054468368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987934,0.00014983978,0.00037476805,0.00030458174,0.00015198799,0.00022542675],"domain_scores_gemma":[0.9993575,0.00005773476,0.00027222277,0.00015351285,0.00010117237,0.00005780871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016274564,0.00013217896,0.00038442557,0.000090310714,0.00005905008,0.00000285211,0.0001326008,0.0001095115,0.00011777826],"category_scores_gemma":[0.000056117467,0.00010759527,0.00007769114,0.00029095475,0.000094545096,0.0000040554146,0.00018055807,0.0001224129,2.0071508e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004054211,0.0009802037,0.12753391,0.000032324766,0.0001113674,0.000008098818,0.0000953425,0.00067669555,0.85698736,0.0000025885017,0.00020144574,0.009316436],"study_design_scores_gemma":[0.0042755543,0.0038571802,0.30643377,0.000033372766,0.000064316126,0.000003944038,0.00010139587,0.00017010624,0.6827376,0.00000385883,0.0021180077,0.0002008679],"about_ca_topic_score_codex":0.00013539643,"about_ca_topic_score_gemma":0.00003400434,"teacher_disagreement_score":0.17889987,"about_ca_system_score_codex":0.000028224993,"about_ca_system_score_gemma":0.00013291287,"threshold_uncertainty_score":0.43876076},"labels":[],"label_agreement":null},{"id":"W4296012582","doi":"10.1016/j.annonc.2022.07.148","title":"116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University Medical Centre","funders":"","keywords":"Medicine; Oncology; Cancer; Internal medicine; Regression; Statistics","score_opus":0.028948718374145324,"score_gpt":0.344051997848164,"score_spread":0.31510327947401867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296012582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972584,0.0006116772,0.0000012889792,0.00095796,0.00011724285,0.0004433558,0.00006543912,0.000024342466,0.0005202452],"genre_scores_gemma":[0.9983772,0.00036790824,0.000037807455,0.0006764276,0.000031440224,0.00012382066,0.00016355186,0.000028972645,0.00019285886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977827,0.00028980497,0.00090864697,0.00034115167,0.00037291748,0.00030478463],"domain_scores_gemma":[0.9984834,0.000060278926,0.00077951065,0.00037550976,0.00021224485,0.00008904975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065509323,0.0002053571,0.0009619026,0.00068748504,0.000042854314,0.0000033859524,0.00016216829,0.00008203962,0.0009002875],"category_scores_gemma":[0.00004652238,0.00014935636,0.0003019602,0.0012168074,0.00022439021,0.00008673577,0.000100258454,0.0002617337,0.0000017494481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09085454,0.0066760397,0.7288805,0.00016589569,0.0029325255,0.00023173798,0.0037718771,0.000095024,0.06483557,0.0000097607135,0.001453742,0.100092776],"study_design_scores_gemma":[0.009565234,0.023980856,0.86140627,0.00020914467,0.00044284126,0.000011488178,0.0011147525,0.00010727408,0.09598679,0.000019171785,0.006956154,0.00020005049],"about_ca_topic_score_codex":0.0025710906,"about_ca_topic_score_gemma":0.0006106646,"teacher_disagreement_score":0.13252574,"about_ca_system_score_codex":0.00023748264,"about_ca_system_score_gemma":0.00032532567,"threshold_uncertainty_score":0.9857516},"labels":[],"label_agreement":null},{"id":"W4296012608","doi":"10.1016/j.annonc.2022.07.324","title":"CN12 Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Dietary fiber; Immune checkpoint; Oncology; Cancer; Immunotherapy; Food science","score_opus":0.0638778829407786,"score_gpt":0.4078346802023032,"score_spread":0.34395679726152456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296012608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891082,0.002237086,0.0000015149026,0.0033677162,0.0003473501,0.00029175176,0.00006595024,0.000036971192,0.0045434325],"genre_scores_gemma":[0.998639,0.00030350356,0.000041786578,0.0003005025,0.00005554366,0.000036184825,0.00008461754,0.000016577675,0.00052232505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986384,0.00019237239,0.0005829812,0.00017231469,0.00020641038,0.00020750986],"domain_scores_gemma":[0.9990598,0.00008726251,0.00040519866,0.0002761881,0.000121421,0.000050151728],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060244027,0.00012461367,0.0005108521,0.00019303239,0.00005010427,0.0000014926236,0.00012380554,0.000079257276,0.0023999708],"category_scores_gemma":[0.00006486373,0.00010587504,0.00069971976,0.0002854692,0.00013195995,0.000028370436,0.00004861931,0.00023307432,0.0000042561337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1084683,0.0067591253,0.0057053063,0.00018915505,0.0025363902,0.0000847046,0.0015226476,0.00008383106,0.5946361,0.000023599094,0.01861924,0.2613716],"study_design_scores_gemma":[0.010184053,0.14307375,0.65911674,0.0002519819,0.00019229183,0.00013579446,0.0009974522,0.0002233655,0.15165168,0.00020123106,0.033721704,0.00024996564],"about_ca_topic_score_codex":0.0010719572,"about_ca_topic_score_gemma":0.00002037989,"teacher_disagreement_score":0.65341145,"about_ca_system_score_codex":0.00015765154,"about_ca_system_score_gemma":0.00017410002,"threshold_uncertainty_score":0.99851197},"labels":[],"label_agreement":null},{"id":"W4296013560","doi":"10.1016/j.annonc.2022.07.719","title":"591P Feasibility of longitudinal monitoring of whole blood-based circulating tumour DNA (ctDNA) in patients with endometrial cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Takeda Oncology; EMD Serono; Genentech; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Mersana Therapeutics; Stryker; Mereo BioPharma; PTC Therapeutics","keywords":"Medicine; Endometrial cancer; Internal medicine; PTEN; Oncology; Hysterectomy; Cancer; Biopsy; Stage (stratigraphy); Endometrial biopsy; Uterine cancer; Liquid biopsy; Gastroenterology; Gynecology; Pathology; Biology","score_opus":0.058812608927063276,"score_gpt":0.3444007915983315,"score_spread":0.2855881826712682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296013560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986525,0.00047024686,0.000016546646,0.0000802056,0.0001954593,0.00022655919,0.00024497905,0.0000015176295,0.000111967456],"genre_scores_gemma":[0.9994987,0.000039274193,0.00023885988,0.000036762332,0.00008607264,0.00003259646,0.00005073383,0.000012062049,0.000004896065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998911,0.00009376581,0.00038562433,0.00024196753,0.00017944384,0.00018817106],"domain_scores_gemma":[0.99899703,0.00009896226,0.00041587613,0.00021287362,0.00023468955,0.000040569517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034564227,0.00009930014,0.00033241752,0.00011172561,0.000033624496,0.0000019581244,0.00016088155,0.000066402805,0.000021236036],"category_scores_gemma":[0.00024785197,0.00010420455,0.00008614644,0.00022113581,0.000091995076,0.0000027199203,0.00013406102,0.000096084936,7.192919e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010313181,0.00076856953,0.8640525,0.00004165983,0.000061817926,0.0000033739072,0.000036934227,0.006799397,0.12518452,0.0000070083165,0.000053329186,0.0019595686],"study_design_scores_gemma":[0.004798304,0.005312102,0.70509,0.000024161787,0.00004006282,8.9261715e-7,0.000069659814,0.000022487055,0.28391635,0.000019907598,0.0005886149,0.00011742491],"about_ca_topic_score_codex":0.00042048487,"about_ca_topic_score_gemma":0.00012859881,"teacher_disagreement_score":0.15896249,"about_ca_system_score_codex":0.000039278704,"about_ca_system_score_gemma":0.00042284653,"threshold_uncertainty_score":0.42493382},"labels":[],"label_agreement":null},{"id":"W4296013582","doi":"10.1016/j.annonc.2022.07.969","title":"843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Melanoma; Oncology; Metastatic melanoma; Term (time); Internal medicine; Surgery; Cancer research","score_opus":0.0558728683659256,"score_gpt":0.38177021289029117,"score_spread":0.3258973445243656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296013582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584883,0.00010713642,0.0000011829057,0.0004971465,0.00016356251,0.0016048461,0.00008474011,0.000013028597,0.0016794925],"genre_scores_gemma":[0.9987515,0.00003564249,0.000057822068,0.00033469778,0.000018614239,0.00016565285,0.00034727214,0.00001986908,0.00026888505],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9980376,0.00051030907,0.00056004885,0.0002836775,0.00030900448,0.00029940467],"domain_scores_gemma":[0.9988824,0.00020866982,0.0004179788,0.00027914406,0.00011476428,0.00009703051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042294798,0.00018290355,0.00090870814,0.00031257712,0.00007806811,0.0000011290552,0.00011558527,0.00008607893,0.00043823963],"category_scores_gemma":[0.00007809683,0.00014278946,0.00013076147,0.00031250776,0.00014304603,0.000043264554,0.000077026176,0.00022661485,0.0000050247236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20405275,0.061690547,0.6801278,0.00007921459,0.0010939407,0.0010594325,0.00078508543,0.000022178994,0.00006921436,0.00006584863,0.00028704232,0.050666966],"study_design_scores_gemma":[0.3240566,0.420239,0.25151736,0.00006851609,0.000612002,0.000037833204,0.00010634392,0.000009363816,0.0018374805,0.000048230395,0.0013006894,0.00016658852],"about_ca_topic_score_codex":0.00023969641,"about_ca_topic_score_gemma":0.00043785264,"teacher_disagreement_score":0.4286104,"about_ca_system_score_codex":0.00012084858,"about_ca_system_score_gemma":0.00028985203,"threshold_uncertainty_score":0.5822785},"labels":[],"label_agreement":null},{"id":"W4296017867","doi":"10.1016/j.annonc.2022.07.837","title":"713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Hepatocellular carcinoma; Placebo; Internal medicine; Oncology; Nuclear medicine; Urology; Immunotherapy; Pathology; Cancer","score_opus":0.1141393283507759,"score_gpt":0.33122606803070587,"score_spread":0.21708673967992997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296017867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402685,0.002610992,0.000040559145,0.003840501,0.0007198465,0.0034980457,0.0011827793,0.00015662918,0.0039238175],"genre_scores_gemma":[0.98388684,0.00030240725,0.0009782646,0.0014239133,0.00031247776,0.001972201,0.003034388,0.0001437655,0.007945763],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597627,0.00045860792,0.0010330469,0.0010442351,0.00051589636,0.00097197224],"domain_scores_gemma":[0.9969692,0.00069913105,0.0005483697,0.0009011638,0.0004103361,0.000471802],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044210325,0.0006826498,0.001828943,0.000400207,0.00038792178,0.00001951793,0.00034295063,0.0003753442,0.0045174495],"category_scores_gemma":[0.00014384063,0.0006393354,0.0010120907,0.00043971985,0.00016638688,0.00013604148,0.0001939193,0.00035707335,0.00012833874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18243578,0.008288828,0.6537689,0.00040541176,0.004201991,0.004253485,0.004482697,0.000055480315,0.05194173,0.0007065297,0.02194415,0.06751504],"study_design_scores_gemma":[0.100791276,0.08426882,0.006732931,0.000076173004,0.00212427,0.00026959306,0.0017132334,0.0047838246,0.35774896,0.0012086434,0.4392027,0.001079577],"about_ca_topic_score_codex":0.001899349,"about_ca_topic_score_gemma":0.00022605377,"teacher_disagreement_score":0.64703596,"about_ca_system_score_codex":0.0005744619,"about_ca_system_score_gemma":0.00097298186,"threshold_uncertainty_score":0.9996058},"labels":[],"label_agreement":null},{"id":"W4296020023","doi":"10.1016/j.annonc.2022.07.145","title":"113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Oncology; Internal medicine; DNA mismatch repair; Cancer; Immunotherapy; Colorectal cancer; Microsatellite","score_opus":0.05300824291177602,"score_gpt":0.3893450993631417,"score_spread":0.3363368564513657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296020023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928117,0.0009336411,0.00000377403,0.0023712975,0.001177732,0.001657586,0.00015676202,0.00004490931,0.0008425891],"genre_scores_gemma":[0.9972672,0.0001358121,0.0005395722,0.001547804,0.00009347098,0.00017027598,0.000057756974,0.000037240374,0.00015088957],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99630696,0.0007086669,0.0012633437,0.00059642503,0.0005677889,0.00055681076],"domain_scores_gemma":[0.9977058,0.00019821952,0.0006313161,0.0010134986,0.00030559752,0.00014553327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013617857,0.00026654324,0.0010609379,0.00022675107,0.00015916264,0.0000040400105,0.0004905711,0.00016581957,0.00064932974],"category_scores_gemma":[0.00045722537,0.00022240083,0.00034256917,0.0006888919,0.000445682,0.000069668145,0.0005770038,0.0006037136,0.0000031596362],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49076727,0.03599449,0.00678889,0.00069030025,0.00038349212,0.00026647563,0.016570885,0.007033611,0.29842538,0.00079404796,0.00415532,0.13812986],"study_design_scores_gemma":[0.20465657,0.16857615,0.02063525,0.0002841397,0.00025978527,0.0002963361,0.0031093198,0.0009335118,0.40315995,0.0032194438,0.1940296,0.0008399375],"about_ca_topic_score_codex":0.00028009524,"about_ca_topic_score_gemma":0.00029695715,"teacher_disagreement_score":0.2861107,"about_ca_system_score_codex":0.00027874013,"about_ca_system_score_gemma":0.0012238258,"threshold_uncertainty_score":0.9069243},"labels":[],"label_agreement":null},{"id":"W4297821370","doi":"10.1016/j.annonc.2022.07.1881","title":"1395P Real-world association between bone targeted agents and palliative bone radiation in prostate cancer decedents: A province-wide study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Internal medicine","score_opus":0.08308360903187328,"score_gpt":0.4247621991828738,"score_spread":0.3416785901510005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849206,0.0007772102,3.4697226e-7,0.011552298,0.00010066021,0.0020713795,0.00009765614,0.00002080849,0.00045902468],"genre_scores_gemma":[0.99458396,0.0015579788,0.00004417904,0.0013815319,0.00003371605,0.00058352255,0.00016303617,0.000017289853,0.0016348022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980086,0.00040781035,0.0005782386,0.00029415512,0.00035701317,0.00035416769],"domain_scores_gemma":[0.9987311,0.00025962605,0.00060806144,0.00012338388,0.00013659787,0.00014123187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080649456,0.00013364067,0.00059973414,0.00030021078,0.00011481482,0.0000045682064,0.000040421277,0.00006065666,0.00006756308],"category_scores_gemma":[0.00022141823,0.00013156599,0.00004002127,0.00041523622,0.000025398916,0.00008427586,0.000073517294,0.00025772062,0.0000032480675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008059219,0.0014976021,0.96831477,0.000051742318,0.00026273576,0.00013764961,0.0023793567,0.0000120925,0.000012923659,0.000009912677,0.0034861835,0.023029132],"study_design_scores_gemma":[0.006915531,0.004394823,0.97823775,0.00002698676,0.0001390346,0.0000012620173,0.0004024013,0.00003532205,0.00008871744,0.00016740109,0.009504556,0.000086236185],"about_ca_topic_score_codex":0.008824765,"about_ca_topic_score_gemma":0.011374563,"teacher_disagreement_score":0.022942895,"about_ca_system_score_codex":0.0010152214,"about_ca_system_score_gemma":0.0006000359,"threshold_uncertainty_score":0.99777555},"labels":[],"label_agreement":null},{"id":"W4297821381","doi":"10.1016/j.annonc.2022.07.1945","title":"1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Merck Sharp and Dohme; EMD Serono; Genentech; Unicancer; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Pfizer; Incyte; Ipsen; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; American Society of Clinical Oncology; Boston Scientific Corporation; Invitae; AstraZeneca; Advanced Accelerator Applications; Endocyte; Teva Pharmaceutical Industries; Merck; Yuhan; Gilead Sciences; Exelixis; Sanofi; Amgen","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Interim analysis; Biomarker; Randomization; Progression-free survival; Prednisone; Oncology; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.09282910501671691,"score_gpt":0.408646793756521,"score_spread":0.3158176887398041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840085,0.0016375243,0.000006357843,0.0072463197,0.00005987687,0.0036237396,0.003355908,0.000008616369,0.000053180367],"genre_scores_gemma":[0.99363184,0.0034556307,0.0002051912,0.0002885706,0.000032906795,0.0007262774,0.001307362,0.000020288733,0.00033192334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99808824,0.00026623427,0.00058891944,0.00042788105,0.0003443374,0.00028436395],"domain_scores_gemma":[0.9981663,0.0005065286,0.0004618967,0.00024239087,0.0004992281,0.00012364073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006675833,0.00020367022,0.00075024366,0.00018319782,0.00023862385,0.000021077705,0.000084491716,0.000056438777,0.00008799042],"category_scores_gemma":[0.0001252403,0.000117522206,0.00006889398,0.00046959738,0.00039790105,0.00008951563,0.00006850915,0.00014568017,2.5945084e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9244455,0.0027884748,0.0066571548,0.00008482805,0.004990108,0.000037815338,0.0035159206,0.000033763776,0.0036997611,0.000009158488,0.0027026492,0.051034845],"study_design_scores_gemma":[0.7956372,0.11249376,0.04049631,0.00010427637,0.0032085436,0.000009719946,0.001663328,0.0016078241,0.011273523,0.0002561181,0.032880776,0.00036863136],"about_ca_topic_score_codex":0.0025927494,"about_ca_topic_score_gemma":0.0013732379,"teacher_disagreement_score":0.12880833,"about_ca_system_score_codex":0.00005657125,"about_ca_system_score_gemma":0.0004282171,"threshold_uncertainty_score":0.47924164},"labels":[],"label_agreement":null},{"id":"W4297821452","doi":"10.1016/j.annonc.2022.07.1886","title":"1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; BC Cancer Agency; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Oncology; Internal medicine; Prostate-specific antigen; Cancer","score_opus":0.1391257395075549,"score_gpt":0.41543875423205257,"score_spread":0.27631301472449765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98242885,0.0062689134,9.976534e-7,0.0063033924,0.00015620695,0.0017363513,0.0019300062,0.000016114374,0.0011591875],"genre_scores_gemma":[0.96708,0.031366978,0.00023813406,0.00018448217,0.00007273986,0.00017582875,0.0005371713,0.000027770664,0.00031686976],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972923,0.00045126988,0.0008877199,0.00046535986,0.00048301672,0.00042033574],"domain_scores_gemma":[0.99846077,0.00047203572,0.00039617097,0.0002889887,0.00025544822,0.0001266035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009160529,0.0002073854,0.0007511962,0.00029800626,0.000118356824,0.0000100148,0.00012418383,0.00007733632,0.00030102173],"category_scores_gemma":[0.00008309633,0.00017337849,0.00007813016,0.0004769767,0.0003247806,0.00010385073,0.00009533354,0.00035605667,0.0000021482078],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35139954,0.0052003646,0.01518419,0.0003717152,0.0012952578,0.0019177473,0.025633369,0.00086560985,0.32554677,0.00020806919,0.0060929228,0.26628444],"study_design_scores_gemma":[0.10700575,0.040392015,0.37864408,0.00057932193,0.00017980124,0.00008947625,0.005078112,0.00027523164,0.32103503,0.0011318502,0.14488313,0.00070623023],"about_ca_topic_score_codex":0.0017929444,"about_ca_topic_score_gemma":0.00050023186,"teacher_disagreement_score":0.3634599,"about_ca_system_score_codex":0.00015808117,"about_ca_system_score_gemma":0.00083609106,"threshold_uncertainty_score":0.707017},"labels":[],"label_agreement":null},{"id":"W4297821473","doi":"10.1016/j.annonc.2022.08.025","title":"LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Takeda Oncology; EMD Serono; Eisai Canada; Ipsen; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Verastem Oncology; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; Clovis Oncology; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Meso Scale Diagnostics; Merck Sharp and Dohme; KU Leuven; Pfizer; Incyte; F. Hoffmann-La Roche; Seagen; Roche; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bevacizumab; Olaparib; Clinical endpoint; Population; Progression-free survival; Oncology; Ovarian cancer; BRCA mutation; Cancer; Chemotherapy; Gastroenterology; Randomized controlled trial","score_opus":0.13532923228084562,"score_gpt":0.42844639030923365,"score_spread":0.293117158028388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98148346,0.0004008346,0.00012579594,0.010874394,0.0014599646,0.0024655801,0.0014523224,0.000049262562,0.0016883693],"genre_scores_gemma":[0.9905376,0.00031460053,0.0006880214,0.005832017,0.00052296434,0.0011563412,0.00057479343,0.000059262788,0.0003144213],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947666,0.0011796234,0.0013316829,0.0008273499,0.0011237201,0.00077101024],"domain_scores_gemma":[0.9952212,0.0021055483,0.0011519418,0.0007765006,0.0005570188,0.00018781681],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020610222,0.00038310717,0.0011725134,0.00017238158,0.00030667795,0.00001844198,0.00045821033,0.00018231598,0.00095078285],"category_scores_gemma":[0.0011911399,0.00030426038,0.00019503648,0.00055814115,0.0002608033,0.00019415646,0.0001837038,0.0010182274,0.0000066251573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8569155,0.0029013003,0.0017314297,0.000021790074,0.00038565992,0.00019997757,0.0039357105,0.0060991882,0.000883302,0.00040474386,0.01777645,0.10874495],"study_design_scores_gemma":[0.90900654,0.03129384,0.016084563,0.0003170731,0.00015498674,0.000011619755,0.00082409335,0.0016620398,0.0005438137,0.0010416743,0.038616627,0.00044315076],"about_ca_topic_score_codex":0.004713854,"about_ca_topic_score_gemma":0.0022182711,"teacher_disagreement_score":0.108301796,"about_ca_system_score_codex":0.0010503198,"about_ca_system_score_gemma":0.0022704382,"threshold_uncertainty_score":0.9999625},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4297821517","doi":"10.1016/j.annonc.2022.07.1882","title":"1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; CTI Biopharma; Ipsen; Mirati Therapeutics; Institute for Clinical Evaluative Sciences; Calithera Biosciences; TG Therapeutics; Novocure; Eisai; Jazz Pharmaceuticals; Puma Biotechnology; Regeneron Pharmaceuticals; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Celgene; Boston Biomedical; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Nausea; Clinical endpoint; Internal medicine; Prostate cancer; Adverse effect; Cancer; Phases of clinical research; Oncology; Urology; Chemotherapy; Immunotherapy; Clinical trial; Pembrolizumab","score_opus":0.09520743144419953,"score_gpt":0.4310226322050076,"score_spread":0.33581520076080806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958047,0.00023282101,5.7840197e-7,0.0009888133,0.000038023674,0.0025407674,0.000111681424,0.00000781409,0.0002747745],"genre_scores_gemma":[0.99842894,0.00010370766,0.00005079127,0.0000838299,0.0000048186594,0.00077275175,0.0000870248,0.000023026148,0.00044512367],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9978791,0.00034600776,0.0005137038,0.0003090631,0.0005934777,0.0003586655],"domain_scores_gemma":[0.9989726,0.0000837763,0.0003075044,0.00020926424,0.00034656745,0.000080320184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049966836,0.00016589208,0.00067322573,0.0004431457,0.000084904495,0.000003725302,0.00011100538,0.000030581497,0.00020954332],"category_scores_gemma":[0.000030733554,0.000109595945,0.000028371573,0.00081508304,0.00014067511,0.00009065123,0.00008808398,0.00027276448,4.837299e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31729895,0.15144297,0.40449944,0.0007388314,0.0012751508,0.0032253806,0.030432953,0.001551633,0.0015756321,0.000064775115,0.0006469548,0.08724736],"study_design_scores_gemma":[0.20914494,0.5230556,0.24709748,0.0002881065,0.00025100677,0.000021880964,0.01526197,0.00023492637,0.0033671637,0.000071761,0.00093497563,0.0002701647],"about_ca_topic_score_codex":0.0029652119,"about_ca_topic_score_gemma":0.007830369,"teacher_disagreement_score":0.37161267,"about_ca_system_score_codex":0.00037431694,"about_ca_system_score_gemma":0.0012831423,"threshold_uncertainty_score":0.4482533},"labels":[],"label_agreement":null},{"id":"W4297981942","doi":"10.1016/j.annonc.2022.08.080","title":"LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Javelin; Avelumab; Urothelial carcinoma; Peripheral blood; Merkel cell carcinoma; Internal medicine; Oncology; Bladder cancer; Urology; Carcinoma; Immunotherapy; Cancer; Pembrolizumab","score_opus":0.039116989860089754,"score_gpt":0.32086810898857887,"score_spread":0.2817511191284891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923566,0.0006436812,0.0000033115903,0.002579817,0.00045069808,0.0021706,0.00033779256,0.000008437721,0.0014490364],"genre_scores_gemma":[0.99717647,0.00032625554,0.00018200737,0.0014212558,0.00012287882,0.00052960956,0.0001120787,0.00003553225,0.000093928196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969363,0.00056403264,0.0011019383,0.0004852881,0.0004119142,0.0005004842],"domain_scores_gemma":[0.9986669,0.00033287605,0.0003835885,0.00043511513,0.00010868061,0.0000728712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006739815,0.00027478702,0.0010069417,0.0003532135,0.000057317186,0.00000430109,0.0003700202,0.00015905945,0.0006174076],"category_scores_gemma":[0.0001985356,0.00022377426,0.00021652985,0.0005150356,0.00015857513,0.00006367266,0.00013836658,0.00041925162,0.0000042885276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4944173,0.02909702,0.3760599,0.00013736261,0.0012311457,0.0011083059,0.018082432,0.0011364871,0.0095805805,0.00007887912,0.0019147398,0.06715586],"study_design_scores_gemma":[0.4931593,0.03498643,0.45634136,0.00011453137,0.0002298697,0.000025583897,0.0020706577,0.00032837974,0.0028299328,0.00072861457,0.008764423,0.00042092183],"about_ca_topic_score_codex":0.0060496232,"about_ca_topic_score_gemma":0.003866699,"teacher_disagreement_score":0.08028149,"about_ca_system_score_codex":0.00029290383,"about_ca_system_score_gemma":0.0006753019,"threshold_uncertainty_score":0.9145261},"labels":[],"label_agreement":null},{"id":"W4297981952","doi":"10.1016/j.annonc.2022.08.079","title":"LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Cohort; Adverse effect; Clinical endpoint; Pembrolizumab; Cisplatin; Gastroenterology; Oncology; Urology; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy","score_opus":0.043784395096860544,"score_gpt":0.3740006686367162,"score_spread":0.33021627353985566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424034,0.000118923184,0.00003880872,0.00026878342,0.00006763881,0.004428788,0.00011647548,0.000024662324,0.000695568],"genre_scores_gemma":[0.99710304,0.0002973008,0.00018501842,0.0002502037,0.000011766124,0.0017591624,0.00004134521,0.000056344623,0.00029580086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730444,0.0005053281,0.00068853307,0.00048872666,0.0005927056,0.0004202646],"domain_scores_gemma":[0.99838924,0.00027824103,0.0005728177,0.0003288392,0.0003314554,0.00009937491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004545175,0.00032652257,0.0012374164,0.0004201432,0.000065967084,0.0000067997703,0.00017371672,0.00006672125,0.0004076722],"category_scores_gemma":[0.00008113432,0.00022149688,0.00006304437,0.00090847077,0.00014187004,0.00016829789,0.00003996644,0.00031156128,0.000001142724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14467725,0.017995339,0.76874566,0.00020888986,0.0007858043,0.00052870874,0.0024022132,0.0017880189,0.0005521962,0.000018849094,0.000079111545,0.06221796],"study_design_scores_gemma":[0.11327593,0.11487964,0.7591805,0.00033655818,0.0005115103,0.00007487439,0.00084293657,0.00041382873,0.009500648,0.000038694765,0.0005641579,0.00038072746],"about_ca_topic_score_codex":0.0065631187,"about_ca_topic_score_gemma":0.010493089,"teacher_disagreement_score":0.0968843,"about_ca_system_score_codex":0.000406198,"about_ca_system_score_gemma":0.0025914859,"threshold_uncertainty_score":0.9921516},"labels":[],"label_agreement":null},{"id":"W4297981953","doi":"10.1016/j.annonc.2022.08.075","title":"LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Oncology; Internal medicine; Pathology; Alternative medicine","score_opus":0.11769462462742171,"score_gpt":0.4509367312523494,"score_spread":0.3332421066249277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97702456,0.0035719846,0.00005103726,0.002904618,0.00101147,0.011986105,0.000043351734,0.000056518038,0.0033503545],"genre_scores_gemma":[0.99215066,0.00014023033,0.001311324,0.00028195008,0.00023121342,0.005352467,0.000039400882,0.00003483691,0.00045792718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99684006,0.0007102682,0.0012978746,0.0003111747,0.00041533107,0.00042530248],"domain_scores_gemma":[0.99141157,0.006604774,0.0011881891,0.00026703367,0.00041456692,0.00011387041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003334358,0.00023752844,0.0039913524,0.0002728254,0.00022133044,0.000005610787,0.00013869815,0.00007708992,0.00019734027],"category_scores_gemma":[0.0055694883,0.00019540428,0.0008428653,0.00024532928,0.00073255965,0.000043850927,0.00013310801,0.00021569195,0.0000015025638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97918594,0.0022758916,0.000015148537,0.00010929252,0.0015144066,0.00023545201,0.0013659995,0.000016612685,0.0007070383,0.0004003137,0.00380215,0.0103717465],"study_design_scores_gemma":[0.95274496,0.031581357,0.0000022479203,0.00005714645,0.0011895266,0.00009249979,0.0014355154,0.00026516474,0.0022043365,0.00020599179,0.010084757,0.00013652499],"about_ca_topic_score_codex":0.00004285522,"about_ca_topic_score_gemma":0.000012213922,"teacher_disagreement_score":0.029305466,"about_ca_system_score_codex":0.000088439345,"about_ca_system_score_gemma":0.00085364305,"threshold_uncertainty_score":0.79683554},"labels":[],"label_agreement":null},{"id":"W4297981956","doi":"10.1016/j.annonc.2022.08.050","title":"LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Lung cancer; Lymph node; Nivolumab; Chemotherapy; non-small cell lung cancer (NSCLC); Oncology; Gastroenterology; Cancer; Immunotherapy","score_opus":0.04156605645833943,"score_gpt":0.3631809270560452,"score_spread":0.32161487059770577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902864,0.0035953086,0.0000460396,0.004055274,0.00006793285,0.0009511901,0.00012702437,0.000013438855,0.00085739023],"genre_scores_gemma":[0.9947562,0.0013082738,0.0006758297,0.0020269654,0.000025464242,0.0002465287,0.00005055624,0.000024004314,0.000886174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845546,0.000101089274,0.0005011455,0.00037650255,0.00020777155,0.00035805377],"domain_scores_gemma":[0.99884933,0.00030699268,0.00037855105,0.00027088245,0.00012941915,0.00006481573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007016179,0.00019498366,0.0011725121,0.00038908742,0.000078269986,0.0000062010768,0.00016035716,0.00013979625,0.00029291064],"category_scores_gemma":[0.000028573852,0.00014450337,0.00023919865,0.0007038905,0.00016598128,0.0000353267,0.00007000356,0.0002419181,9.016437e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15030691,0.003364957,0.6417473,0.00083564525,0.0069832215,0.00023532323,0.0108310655,0.0034656243,0.0924723,0.000059236798,0.011545024,0.07815343],"study_design_scores_gemma":[0.03884302,0.01082501,0.920856,0.000110732566,0.0009645131,0.000038572092,0.0011440864,0.0016042951,0.016986277,0.000018629653,0.00827747,0.00033138585],"about_ca_topic_score_codex":0.0015751162,"about_ca_topic_score_gemma":0.001166495,"teacher_disagreement_score":0.27910873,"about_ca_system_score_codex":0.00013602176,"about_ca_system_score_gemma":0.00041328016,"threshold_uncertainty_score":0.5892676},"labels":[],"label_agreement":null},{"id":"W4297981965","doi":"10.1016/j.annonc.2022.08.052","title":"LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Genzyme; European Society for Medical Oncology; F. Hoffmann-La Roche; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Regimen; Gemcitabine; Taxane; Oncology; Clinical endpoint; Vinorelbine; Chemotherapy regimen; Phases of clinical research; Chemotherapy; Cancer; Clinical trial; Cisplatin; Breast cancer; Immunotherapy; Pembrolizumab","score_opus":0.08437136665025254,"score_gpt":0.36605979612960593,"score_spread":0.2816884294793534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939342,0.00022851075,0.000024540794,0.0025461835,0.00014356378,0.002284553,0.000348128,0.000026643711,0.00046365417],"genre_scores_gemma":[0.99735945,0.00008734147,0.0002906088,0.0013542295,0.000054576903,0.0002952412,0.00034306885,0.00004492032,0.00017058455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974614,0.0001319419,0.0011187678,0.0005081596,0.00038180797,0.0003979569],"domain_scores_gemma":[0.99798125,0.00036981076,0.0008624271,0.00046429085,0.000252121,0.00007011354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007274387,0.0002564722,0.0010119262,0.000274971,0.000112124275,0.0000061234177,0.0002232656,0.00011581603,0.00014219785],"category_scores_gemma":[0.00010153989,0.00022626357,0.00014650969,0.00041941955,0.000101916776,0.00007106291,0.00008365181,0.0002195125,6.881254e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7790445,0.026457962,0.011284903,0.00007396211,0.0013304536,0.000059541806,0.025283657,0.000173158,0.010179613,0.0000033436095,0.003717897,0.14239101],"study_design_scores_gemma":[0.5335095,0.3193872,0.016982485,0.00038657195,0.00025554173,0.000015813992,0.010481126,0.0004950199,0.065182514,0.000052320032,0.05272265,0.0005292735],"about_ca_topic_score_codex":0.003492354,"about_ca_topic_score_gemma":0.0010192532,"teacher_disagreement_score":0.29292923,"about_ca_system_score_codex":0.0003155259,"about_ca_system_score_gemma":0.00025348633,"threshold_uncertainty_score":0.922676},"labels":[],"label_agreement":null},{"id":"W4297981989","doi":"10.1016/j.annonc.2022.08.069","title":"LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bayer Fund; Ipsen Biopharmaceuticals; Janssen Pharmaceuticals; Sanofi Australia; AstraZeneca; Meso Scale Diagnostics; Merck; Astellas Pharma US; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Internal medicine; Oncology; Adjuvant; Nephrectomy; Placebo; Urology; Immunotherapy; Cancer; Kidney; Pathology","score_opus":0.0409074776014903,"score_gpt":0.31626374826913173,"score_spread":0.27535627066764146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297981989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996694,0.003734162,0.000103613405,0.0033964927,0.0010102411,0.007146111,0.0028941932,0.000052754658,0.0016954908],"genre_scores_gemma":[0.9905425,0.0005717501,0.0009705414,0.0009220645,0.00055074826,0.0022569152,0.0009048276,0.00009338635,0.003187299],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926526,0.0024348963,0.0023206403,0.00095477933,0.00084363,0.00079344923],"domain_scores_gemma":[0.9904005,0.0054901876,0.0020578317,0.0013078636,0.00044118636,0.00030244325],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036552835,0.0005819566,0.0033458127,0.0002516575,0.00031901227,0.000012057919,0.00049502635,0.00033777193,0.0010663674],"category_scores_gemma":[0.0009591383,0.00041095522,0.0013902957,0.00032931563,0.0006361967,0.00007822811,0.0005020101,0.0006557404,0.000021676837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96163714,0.0021784366,0.00011775733,0.00008225238,0.0010956138,0.00045239236,0.003073499,0.00023763387,0.0017015883,0.000026873126,0.025954489,0.0034423275],"study_design_scores_gemma":[0.8934855,0.02643699,0.00033611,0.000055468492,0.0027203774,0.00006218088,0.00039348588,0.0015368453,0.033223044,0.00041337725,0.04100768,0.00032892838],"about_ca_topic_score_codex":0.005831558,"about_ca_topic_score_gemma":0.0004235874,"teacher_disagreement_score":0.06815162,"about_ca_system_score_codex":0.00075674045,"about_ca_system_score_gemma":0.0012421958,"threshold_uncertainty_score":0.9998468},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4297982007","doi":"10.1016/j.annonc.2022.08.064","title":"LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Duration (music); Oncology; Androgen; Internal medicine; Cancer; Hormone","score_opus":0.07871350768273673,"score_gpt":0.41203610650731365,"score_spread":0.33332259882457693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297982007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96024835,0.0027857383,0.000022886632,0.03226308,0.0001472261,0.0038132542,0.0004784277,0.000008872073,0.00023215663],"genre_scores_gemma":[0.9924067,0.00509502,0.00021077138,0.000567623,0.00012471042,0.0008629753,0.0001654094,0.000021807151,0.00054497353],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983933,0.00023788505,0.0005496323,0.00023130143,0.0003737382,0.00021413407],"domain_scores_gemma":[0.99826485,0.00030230937,0.0005389613,0.00025906766,0.0005839518,0.00005085248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007132896,0.00012546402,0.00050171174,0.0001134836,0.00016770874,0.0000036754127,0.00015078296,0.000073445226,0.00007397934],"category_scores_gemma":[0.00009403005,0.00007373495,0.0001368947,0.0003086607,0.00028127653,0.000062657986,0.000034711626,0.00014672124,1.2621288e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8085598,0.0024791306,0.008771949,0.00018936624,0.0013723329,0.000011481146,0.010234758,0.0005371195,0.053369485,0.00034386592,0.0088062845,0.105324455],"study_design_scores_gemma":[0.2305059,0.1155403,0.012854258,0.00013648251,0.00012650939,0.000025442354,0.0011145351,0.0003372422,0.5057239,0.00023648258,0.13319668,0.00020224882],"about_ca_topic_score_codex":0.00048312242,"about_ca_topic_score_gemma":0.00017715326,"teacher_disagreement_score":0.5780539,"about_ca_system_score_codex":0.00014228081,"about_ca_system_score_gemma":0.001378829,"threshold_uncertainty_score":0.3006824},"labels":[],"label_agreement":null},{"id":"W4297982023","doi":"10.1016/j.annonc.2022.08.067","title":"LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Duration (music); Aggregate data; Androgen suppression; Oncology; Radiation therapy; Internal medicine; Androgen; Medical physics; Pathology; Hormone","score_opus":0.1771579412029137,"score_gpt":0.46265856988304876,"score_spread":0.28550062868013504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297982023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96752733,0.014957276,0.000053760967,0.012057483,0.000032882155,0.0011193282,0.0033312845,0.000008515805,0.0009121541],"genre_scores_gemma":[0.99448913,0.0015663271,0.0008077591,0.00036279723,0.000012273631,0.00009611218,0.0018510614,0.000012359604,0.00080219726],"study_design_codex":"meta_analysis","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829733,0.00037517108,0.00045765136,0.000289096,0.00042156546,0.00015920558],"domain_scores_gemma":[0.9977608,0.00016405268,0.0005464042,0.0005249512,0.0009388834,0.000064953405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006371423,0.00012226506,0.0012861325,0.0003796969,0.000067460096,0.00000269734,0.000197495,0.00005277952,0.0015436324],"category_scores_gemma":[0.000050324852,0.00007607905,0.00020688737,0.0011963912,0.00023245564,0.00011787535,0.00011582253,0.00012285242,3.8682802e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052893743,0.006187547,0.025047803,0.0002746297,0.68180674,0.0005920628,0.020282134,0.0022466616,0.17667517,0.00054914533,0.01789502,0.015549327],"study_design_scores_gemma":[0.014243132,0.07278574,0.013477703,0.00004056816,0.15996,0.00007814701,0.0103142755,0.0030940073,0.6681592,0.0000957743,0.057310123,0.00044136087],"about_ca_topic_score_codex":0.00018925323,"about_ca_topic_score_gemma":0.00010905845,"teacher_disagreement_score":0.5218468,"about_ca_system_score_codex":0.000046559533,"about_ca_system_score_gemma":0.0008904419,"threshold_uncertainty_score":0.9993691},"labels":[],"label_agreement":null},{"id":"W4297984664","doi":"10.1016/j.annonc.2022.08.046","title":"LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; European Research Council; Cancer Research UK; Lung Cancer Research Foundation","keywords":"Medicine; KRAS; Lung cancer; Lung; Carcinogenesis; Cancer; Internal medicine; Cancer research; Oncology; Pathology; Colorectal cancer","score_opus":0.092032215483481,"score_gpt":0.40984128336939774,"score_spread":0.31780906788591673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297984664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923874,0.00012671237,0.001880646,0.0042567714,0.00022399615,0.0005834938,0.000054242922,0.000011082999,0.00047563473],"genre_scores_gemma":[0.9967945,0.000322153,0.00055334886,0.0018272268,0.000038293758,0.00029159314,0.000011794469,0.000010019456,0.00015103281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894184,0.0001763694,0.00027705642,0.00020384711,0.00017384894,0.0002270423],"domain_scores_gemma":[0.9993741,0.00002348772,0.00035675796,0.000115178336,0.00003259608,0.000097915945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071615394,0.00008523211,0.00020000104,0.000060092916,0.00018081063,0.0000021923697,0.00009734283,0.00010994237,0.0004073308],"category_scores_gemma":[0.000016492477,0.000096388685,0.00004900777,0.00011709013,0.00004828093,0.0002040569,0.00009596544,0.0001235685,6.289473e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010456846,0.0010097133,0.003069214,0.0008420031,0.00008820484,0.000003414715,0.004683107,0.027244017,0.66032374,0.0017122148,0.0063846014,0.29359406],"study_design_scores_gemma":[0.0026585967,0.009537499,0.08456352,0.00005186726,0.00012660972,0.00000800856,0.0024833807,0.011974079,0.84042,0.008883355,0.038871117,0.00042196165],"about_ca_topic_score_codex":0.005182157,"about_ca_topic_score_gemma":0.0012678694,"teacher_disagreement_score":0.29317212,"about_ca_system_score_codex":0.00032296186,"about_ca_system_score_gemma":0.0003142262,"threshold_uncertainty_score":0.7833906},"labels":[],"label_agreement":null},{"id":"W4297986257","doi":"10.1016/j.annonc.2022.07.1943","title":"1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MaRS; Princess Margaret Cancer Centre; University Health Network","funders":"EMD Serono; AstraZeneca; Amgen","keywords":"Medicine; Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Oncology; Lung cancer; Tumor microenvironment; Immune system; Internal medicine; Cancer research; Cancer; Immunotherapy; Nivolumab; Immunology; Chemotherapy","score_opus":0.016327319268081907,"score_gpt":0.2506900521574491,"score_spread":0.2343627328893672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297986257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97444516,0.023633499,0.000014503884,0.00062531995,0.00003284544,0.0009651887,0.00008944408,0.000005183205,0.00018884096],"genre_scores_gemma":[0.99797046,0.0013296984,0.00008481498,0.00021015493,0.000012082334,0.00015047897,0.00001576461,0.000025062049,0.00020149801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986642,0.00017169114,0.0003825683,0.00031212298,0.00019549229,0.0002739172],"domain_scores_gemma":[0.99920976,0.00006382282,0.0003321542,0.0002728873,0.00006557826,0.00005580229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027169372,0.00021464084,0.0005873682,0.00014663476,0.00010046738,0.000004210669,0.00011586211,0.00005579158,0.00012353313],"category_scores_gemma":[0.000004439709,0.00013841964,0.00008122601,0.00028321313,0.0003702775,0.000034466997,0.000105177205,0.00022347242,1.9748843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030675793,0.0010568949,0.73709536,0.0005464202,0.00045134334,0.00043080348,0.0024025277,0.00011269515,0.21968274,0.0000065199506,0.00045777072,0.007081144],"study_design_scores_gemma":[0.014269078,0.010165018,0.77437615,0.000277827,0.00048707452,0.000395623,0.0021586693,0.0013244909,0.19511685,0.000003609135,0.0011797283,0.0002459028],"about_ca_topic_score_codex":0.012458884,"about_ca_topic_score_gemma":0.0008553646,"teacher_disagreement_score":0.03728078,"about_ca_system_score_codex":0.00032372662,"about_ca_system_score_gemma":0.0004367668,"threshold_uncertainty_score":0.99411726},"labels":[],"label_agreement":null},{"id":"W4297986259","doi":"10.1016/j.annonc.2022.08.029","title":"LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Placebo; Oncology; Head and neck; Head and neck cancer; Phases of clinical research; Basal cell; Internal medicine; Radiation therapy; Clinical trial; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.037661649349017924,"score_gpt":0.3400283840036157,"score_spread":0.30236673465459774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297986259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98882306,0.0022241224,0.00003411927,0.0033250314,0.00015516594,0.0028595005,0.00012530596,0.000021547421,0.0024321554],"genre_scores_gemma":[0.9964051,0.00026083528,0.00018667677,0.002118729,0.00006616078,0.0003221791,0.00006245683,0.000037594436,0.0005402571],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980097,0.00027916988,0.0006346397,0.00039779412,0.00036305943,0.00031563983],"domain_scores_gemma":[0.9981593,0.0004513849,0.0006097335,0.00046721098,0.00023422303,0.00007813985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007862427,0.00022961778,0.00073898135,0.00012684299,0.00018540052,0.000006899439,0.00022318066,0.0001097172,0.000033640634],"category_scores_gemma":[0.000053741704,0.00016692879,0.00016009425,0.0003013616,0.00026135438,0.000071289876,0.000082997125,0.0002470559,2.1214909e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.844639,0.0045082755,0.0025506099,0.00022597666,0.00024064143,0.00004382643,0.005148777,0.00029976896,0.03704038,0.000012976732,0.0049640574,0.10032569],"study_design_scores_gemma":[0.6014718,0.15438451,0.09701002,0.00006769221,0.00024326838,0.00020180768,0.0027712248,0.0005964002,0.0510033,0.000051796225,0.091765545,0.00043266412],"about_ca_topic_score_codex":0.00035963015,"about_ca_topic_score_gemma":0.00014319856,"teacher_disagreement_score":0.24316725,"about_ca_system_score_codex":0.00020187919,"about_ca_system_score_gemma":0.001231017,"threshold_uncertainty_score":0.6807158},"labels":[],"label_agreement":null},{"id":"W4297995279","doi":"10.1016/j.annonc.2022.07.1904","title":"1418P Extensive alteration of androgen precursor levels after castration in prostate cancer patients and their association with active androgen level: Importance for treatment intensification","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Androgen; Castration; Internal medicine; Endocrinology; Oncology; Cancer; Hormone","score_opus":0.10387857745286748,"score_gpt":0.3878932807247417,"score_spread":0.2840147032718742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297995279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994284,0.0006019686,0.000014767207,0.0021026258,0.000037659145,0.0019132966,0.0009847077,0.0000044815647,0.00005652734],"genre_scores_gemma":[0.99725676,0.00044380844,0.00011614723,0.0001490338,0.000017005714,0.0014328026,0.00034566227,0.000011966129,0.00022683122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910045,0.00009003005,0.00027048684,0.00021720755,0.00014737959,0.00017447806],"domain_scores_gemma":[0.998673,0.00009573657,0.00034437634,0.00008069424,0.00076588115,0.000040308496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019531176,0.000106977466,0.00032566136,0.000118834956,0.00004684214,0.0000037030982,0.000023656736,0.00004783465,0.000018076982],"category_scores_gemma":[0.00004575178,0.00007745259,0.000038821945,0.00014041968,0.000046553007,0.00010703907,0.000016087626,0.00005666329,1.3713223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021964584,0.0017542029,0.78795516,0.00014383502,0.00064848264,0.000017377955,0.016923234,0.00008647,0.011549513,0.00003924161,0.00039154806,0.15852633],"study_design_scores_gemma":[0.011412724,0.022923678,0.6370611,0.00007668064,0.00013097802,0.000012507603,0.0022523864,0.0003196436,0.32304212,0.00035451344,0.002258227,0.00015539645],"about_ca_topic_score_codex":0.00014680135,"about_ca_topic_score_gemma":0.00041691042,"teacher_disagreement_score":0.3114926,"about_ca_system_score_codex":0.0005111106,"about_ca_system_score_gemma":0.0005081868,"threshold_uncertainty_score":0.3158425},"labels":[],"label_agreement":null},{"id":"W4298007568","doi":"10.1016/j.annonc.2022.09.158","title":"Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022","year":2022,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"European Society for Medical Oncology; National Institute for Health and Care Research","keywords":"Medicine; Clinical trial; Clinical endpoint; Protocol (science); Randomization; Center of excellence; Clinical study design; Oncology; Medical physics; Phases of clinical research; Internal medicine; Alternative medicine; Pathology","score_opus":0.9812556986171592,"score_gpt":0.7770008680159786,"score_spread":0.20425483060118066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298007568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000016979882,0.96824366,0.013065699,0.0017433378,0.0026612536,0.011476295,0.0018209433,0.00007055567,0.00091654254],"genre_scores_gemma":[1.19674155e-8,0.6244099,0.36938405,0.00073406496,0.0013890162,0.0036354202,0.000046540856,0.00008136405,0.00031962016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.985186,0.008816279,0.0041195233,0.0008781712,0.00036919987,0.00063085277],"domain_scores_gemma":[0.7675969,0.22845262,0.0027693934,0.0005839238,0.00037567646,0.00022151365],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.023233186,0.0005940061,0.0081566395,0.00033458014,0.00012932696,0.000014057602,0.0007068315,0.0012714766,0.0035407238],"category_scores_gemma":[0.20784964,0.00048483405,0.0010258633,0.0003368041,0.00048808206,0.00005515272,0.0004646919,0.00076386955,0.000024200835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071516447,0.0011632775,3.2261824e-9,0.004170976,0.0005292455,0.00004642265,0.000045588207,3.012856e-8,9.575465e-7,0.0057349526,0.13694723,0.8442097],"study_design_scores_gemma":[0.01845959,0.026950361,2.5199647e-9,0.0005585913,0.0017796756,0.00005269588,0.000012094892,0.000036542628,0.0000026638954,0.19483836,0.75700045,0.00030895977],"about_ca_topic_score_codex":0.00000800082,"about_ca_topic_score_gemma":0.0000013295446,"teacher_disagreement_score":0.84390074,"about_ca_system_score_codex":0.00013602308,"about_ca_system_score_gemma":0.0014878268,"threshold_uncertainty_score":0.9997603},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"methods","study_design":"not_applicable","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"methods","study_design":"design_other","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4304084160","doi":"10.1016/j.annonc.2022.09.159","title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; University of Illinois at Urbana-Champaign; National Institutes of Health; Karolinska Institutet; Clovis Oncology; National Institute for Health and Care Research; Seagen; Cilag; Puma Biotechnology; NRG Oncology; Les Laboratories Pierre Fabre; Institut Bergonié; Amgen; Rush University; University of Pennsylvania; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; School of Medicine, Indiana University; European Commission; Sanofi; Genomic Health; Ochsner Health; MSD; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Placebo; Hazard ratio; Breast cancer; Confidence interval; Cancer; Pathology; Biology; Polymerase","score_opus":0.038108095548947445,"score_gpt":0.3551060294228056,"score_spread":0.31699793387385816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304084160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954574,0.00028571294,0.0000036273884,0.0022579536,0.00025172238,0.00096125336,0.00064087,0.0000047031735,0.00013675715],"genre_scores_gemma":[0.9982827,0.0004124288,0.00002421728,0.0008998717,0.00008193007,0.00021412219,0.000051741208,0.0000164003,0.000016592867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976158,0.00075564615,0.000676829,0.00027857334,0.00039149862,0.00028166818],"domain_scores_gemma":[0.99891293,0.00023691561,0.00043171196,0.00025195585,0.000112877235,0.00005360201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322768,0.00014571777,0.00072565017,0.00026351018,0.000033763103,0.0000030394071,0.00014488459,0.000090321875,0.0002654778],"category_scores_gemma":[0.000035597044,0.00011068839,0.00005070327,0.00042141118,0.00015640711,0.00007534803,0.00005925496,0.00040980417,3.9479076e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33054397,0.009670939,0.59435356,0.00004634524,0.00016636339,0.00017023501,0.0045269327,0.00023440753,0.0011748428,0.00027470544,0.00045372,0.058383975],"study_design_scores_gemma":[0.23461707,0.00885249,0.75557464,0.000057288675,0.000029721126,0.000011341309,0.000116215924,0.00003866259,0.00007931422,0.0001735447,0.00035968362,0.0000900234],"about_ca_topic_score_codex":0.008189053,"about_ca_topic_score_gemma":0.0022756273,"teacher_disagreement_score":0.16122109,"about_ca_system_score_codex":0.00013941465,"about_ca_system_score_gemma":0.00046149254,"threshold_uncertainty_score":0.9984155},"labels":[],"label_agreement":null},{"id":"W4306404824","doi":"10.1016/j.annonc.2022.09.002","title":"1MO Air pollution-induced non-small cell lung cancer: Towards molecular cancer prevention","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council","keywords":"Lung cancer; KRAS; Medicine; Lung; Cancer research; Carcinogenesis; Cancer; Malignancy; Oncology; Internal medicine; Pathology; Colorectal cancer","score_opus":0.0820064120425326,"score_gpt":0.4055701679064261,"score_spread":0.32356375586389347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306404824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456936,0.0005456001,0.00028663597,0.04066172,0.00037036263,0.00041099061,0.000054644137,0.000019623032,0.011956791],"genre_scores_gemma":[0.9776809,0.00037797508,0.0003109918,0.020506838,0.000051965962,0.00020521018,0.000008000115,0.000012628462,0.00084547553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984161,0.00028640474,0.0003293428,0.00026414896,0.00028408057,0.00041990503],"domain_scores_gemma":[0.99931324,0.000025843725,0.00028353208,0.00019339916,0.0000203944,0.00016357342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069573266,0.00011463647,0.00025532464,0.00004810414,0.00022596918,0.000002961137,0.00025868998,0.00009819782,0.0042785066],"category_scores_gemma":[0.000020557854,0.00012370774,0.00009402216,0.00025732451,0.00007390144,0.00009028105,0.00026931812,0.00023755229,0.000022510698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005113911,0.0022021004,0.02306008,0.00039029427,0.00014074432,0.00007362696,0.008266186,0.10298469,0.06643689,0.0005097535,0.2539757,0.54144853],"study_design_scores_gemma":[0.0029054908,0.007029924,0.28779355,0.00007052021,0.00014350515,0.000017068665,0.0014011704,0.0049227886,0.12439054,0.0022504434,0.56825787,0.0008171643],"about_ca_topic_score_codex":0.013434991,"about_ca_topic_score_gemma":0.0013707017,"teacher_disagreement_score":0.54063135,"about_ca_system_score_codex":0.00048192585,"about_ca_system_score_gemma":0.0004965247,"threshold_uncertainty_score":0.99663174},"labels":[],"label_agreement":null},{"id":"W4306404843","doi":"10.1016/j.annonc.2022.09.138","title":"137P Combining protein and mRNA spatial profiles to identify distinct cell population in metaplastic breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; Montreal General Hospital; University of Toronto; McGill University","funders":"","keywords":"Medicine; Breast cancer; Messenger RNA; Population; Oncology; Cancer research; Pathology; Internal medicine; Computational biology; Cancer; Genetics; Gene; Environmental health; Biology","score_opus":0.029638462175298134,"score_gpt":0.3514773056874485,"score_spread":0.32183884351215036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306404843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672395,0.00052631035,0.000028078723,0.0018597387,0.00011988774,0.00032232262,0.00020198687,0.000004856679,0.00021284886],"genre_scores_gemma":[0.9990184,0.000036033598,0.00009977742,0.00020275885,0.00006669255,0.00041718263,0.00008847132,0.000012566289,0.000058160334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910283,0.00012868954,0.00021060524,0.0002674936,0.00010256941,0.00018778574],"domain_scores_gemma":[0.9996423,0.000021357917,0.00012820584,0.00010915212,0.000055315286,0.000043682725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015876512,0.00011170936,0.00022682027,0.000070996066,0.00008662483,0.0000047235517,0.00008750197,0.000048232065,0.00005050065],"category_scores_gemma":[0.000030071706,0.00011250182,0.00003600381,0.00009908635,0.0000440634,0.000003732912,0.0002670629,0.000073084906,0.0000010176097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021382484,0.0009469993,0.74103254,0.00012742776,0.00023577455,0.000031897613,0.0007238623,0.00083540153,0.18351564,0.00008484022,0.0017263739,0.06860099],"study_design_scores_gemma":[0.001051681,0.0009693662,0.9748664,0.000017443133,0.000027842905,0.000018106177,0.00018131493,0.000024999992,0.020447416,0.00010687924,0.0021472976,0.00014128335],"about_ca_topic_score_codex":0.003172687,"about_ca_topic_score_gemma":0.0019770423,"teacher_disagreement_score":0.23383382,"about_ca_system_score_codex":0.000039246093,"about_ca_system_score_gemma":0.00007442018,"threshold_uncertainty_score":0.47961748},"labels":[],"label_agreement":null},{"id":"W4306404959","doi":"10.1016/j.annonc.2022.09.148","title":"147TiP Exactis-01 - Clinical utility of returning liquid biopsy NGS results in NSCL cancer patients: A Canadian trial through the Exactis Network","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital","funders":"EMD Serono; AstraZeneca; Amgen","keywords":"Medicine; Thymoma; Everolimus; Thymic carcinoma; Clinical trial; Internal medicine; Oncology; Refractory (planetary science); Chemotherapy; Biopsy; Cancer; Pathology","score_opus":0.14650795482414009,"score_gpt":0.42866207922127936,"score_spread":0.28215412439713927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306404959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738429,0.0006461652,0.0000011357297,0.013304508,0.0013258037,0.00081221556,0.00022792874,0.000009819073,0.0098295305],"genre_scores_gemma":[0.9955242,0.0004566723,0.00006340934,0.0031394504,0.00048560384,0.00009055498,0.00007049023,0.000018998111,0.00015058514],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.996441,0.0010016719,0.0013235628,0.00037744333,0.00033399402,0.00052232813],"domain_scores_gemma":[0.99757487,0.00084674166,0.00070301205,0.0004780569,0.00021849033,0.00017885483],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028017946,0.00015782489,0.00084958255,0.00010172574,0.00015159168,0.0000038931053,0.00027290962,0.0002167833,0.00095073145],"category_scores_gemma":[0.0010984988,0.00012202529,0.00023097928,0.00052038935,0.00027585082,0.00006109919,0.00014026513,0.00078272267,0.0000024524795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4268261,0.004200771,0.22652392,0.00011012529,0.0007095193,0.00042818475,0.00799838,0.00013424648,0.000070700735,0.0008876135,0.21206002,0.12005044],"study_design_scores_gemma":[0.04094556,0.023989432,0.26025668,0.00014345298,0.00011690877,0.000031843858,0.0009337308,0.00010844491,0.00010060852,0.0004913441,0.67266786,0.00021409377],"about_ca_topic_score_codex":0.21653295,"about_ca_topic_score_gemma":0.095261164,"teacher_disagreement_score":0.46060786,"about_ca_system_score_codex":0.00012420726,"about_ca_system_score_gemma":0.0014749524,"threshold_uncertainty_score":0.9999625},"labels":[],"label_agreement":null},{"id":"W4306934705","doi":"10.1016/j.annonc.2022.10.005","title":"Rules for the conduct of clinical trials need revision, but ‘good clinical practice’ requires much more","year":2022,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Clinical Practice; Medical physics; Intensive care medicine; Family medicine; Internal medicine","score_opus":0.8993752568839369,"score_gpt":0.7818661729441649,"score_spread":0.117509083939772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306934705","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019490472,0.008754324,0.00005563188,0.22450043,0.7522424,0.004719367,0.0020793402,0.00004771706,0.005651731],"genre_scores_gemma":[0.0008660234,0.14928244,0.0075663244,0.0065514264,0.82861,0.0003463562,0.00092699303,0.00016172402,0.005688737],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9467986,0.023316909,0.020094354,0.0021274413,0.0064353463,0.0012273343],"domain_scores_gemma":[0.01983666,0.95177436,0.010849109,0.002900176,0.0140469745,0.0005927463],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.3318845,0.00049733865,0.007806087,0.00028260396,0.00022977799,0.00002707188,0.0020408428,0.0074000414,0.001134844],"category_scores_gemma":[0.9568587,0.00032224852,0.003582766,0.00036761453,0.0037700066,0.00012708422,0.0013655289,0.014644991,0.000027118871],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020503767,0.0027059696,0.00013433018,0.0012317345,0.002705184,0.000097046446,0.00010882821,8.944321e-7,0.000023733257,0.0041581085,0.8949362,0.0733942],"study_design_scores_gemma":[0.007473432,0.028482232,0.000112238435,0.0005914282,0.0019395292,0.000012939006,0.0015869479,0.000023197432,0.00006594407,0.00798568,0.9514916,0.00023486375],"about_ca_topic_score_codex":0.00029679562,"about_ca_topic_score_gemma":0.000044185825,"teacher_disagreement_score":0.92845744,"about_ca_system_score_codex":0.000085717686,"about_ca_system_score_gemma":0.01989731,"threshold_uncertainty_score":0.99992293},"labels":[],"label_agreement":null},{"id":"W4310753211","doi":"10.1016/j.annonc.2022.10.469","title":"438P Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Metastatic melanoma; Melanoma; Internal medicine; Targeted therapy; Cancer; Cancer research","score_opus":0.059194602733875244,"score_gpt":0.3526533677524453,"score_spread":0.2934587650185701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542713,0.0006438592,0.00018922075,0.0018847098,0.00023906973,0.0013090655,0.0000613144,0.000026879328,0.00021877204],"genre_scores_gemma":[0.98458976,0.00010094561,0.011787315,0.0025158657,0.000055833076,0.00034336073,0.00016251982,0.00006445025,0.00037992792],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843436,0.00020046801,0.00050694065,0.00025132927,0.00026950045,0.00033742105],"domain_scores_gemma":[0.99879235,0.0004310068,0.00033951394,0.00022723647,0.00016616797,0.000043708944],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097543345,0.00017127804,0.00062781165,0.0002040779,0.00012020436,0.000006453887,0.00015148357,0.000051531835,0.0011511077],"category_scores_gemma":[0.00008602101,0.000126402,0.00012227507,0.00038293286,0.00008774761,0.000066763714,0.00002977094,0.00017480172,0.0000017987611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19768308,0.0038357438,0.099867515,0.0001407225,0.0018342605,0.00005472192,0.0028586856,0.0007006219,0.013708337,0.000017508484,0.0031925489,0.6761063],"study_design_scores_gemma":[0.11075365,0.13008931,0.64790857,0.00031086185,0.00013868028,0.000073057934,0.0010341799,0.0077141235,0.004355176,0.00033602593,0.09632778,0.0009585816],"about_ca_topic_score_codex":0.00021406333,"about_ca_topic_score_gemma":0.00008530422,"teacher_disagreement_score":0.67514765,"about_ca_system_score_codex":0.00012489867,"about_ca_system_score_gemma":0.00043204514,"threshold_uncertainty_score":0.999762},"labels":[],"label_agreement":null},{"id":"W4310753261","doi":"10.1016/j.annonc.2022.10.324","title":"296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Internal medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Chemotherapy; Stage (stratigraphy); Cancer; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.0326366005939003,"score_gpt":0.37178418750029063,"score_spread":0.33914758690639035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667216,0.00095009315,0.000004311403,0.0025547224,0.00025337687,0.0015724266,0.0015691557,0.000049968436,0.006373767],"genre_scores_gemma":[0.991318,0.00054910197,0.00017395506,0.0026848004,0.000052247302,0.00036872574,0.0029353434,0.000056034958,0.0018618051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752444,0.00026175648,0.0007143327,0.00057817117,0.0004170401,0.0005042349],"domain_scores_gemma":[0.9982048,0.00016679762,0.0005150001,0.0004511115,0.00048335656,0.00017893138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002376772,0.00027952148,0.00068844255,0.0002831573,0.00014813781,0.000009786123,0.00021019639,0.0001322334,0.0012310453],"category_scores_gemma":[0.000045632114,0.00022427918,0.00009019858,0.00069707044,0.00009501887,0.00008769036,0.000101000034,0.00042088103,0.000010821042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13672523,0.020081809,0.5628384,0.0001756945,0.0046943245,0.0020571828,0.039721847,0.0044753817,0.020988321,0.000039784616,0.088597834,0.11960424],"study_design_scores_gemma":[0.11167951,0.038499124,0.7147939,0.00032083812,0.0005888586,0.000008690725,0.002605722,0.0011331545,0.029379783,0.00006144351,0.10019402,0.00073494576],"about_ca_topic_score_codex":0.018674908,"about_ca_topic_score_gemma":0.0015440992,"teacher_disagreement_score":0.15195554,"about_ca_system_score_codex":0.0004124221,"about_ca_system_score_gemma":0.0016086763,"threshold_uncertainty_score":0.99968195},"labels":[],"label_agreement":null},{"id":"W4310753263","doi":"10.1016/j.annonc.2022.10.210","title":"173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Gynecology; Cancer","score_opus":0.23995173355578944,"score_gpt":0.5207115689632396,"score_spread":0.2807598354074501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804107,0.00061215885,4.1965174e-7,0.016453192,0.00007612465,0.0020125732,0.00005238217,0.0000053393705,0.0003771266],"genre_scores_gemma":[0.997085,0.001026105,0.000024160581,0.000895604,0.000018314344,0.00071709865,0.00004705689,0.000009930651,0.0001767739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704254,0.0013549532,0.00067307806,0.0002849268,0.00033299637,0.0003115362],"domain_scores_gemma":[0.9986663,0.00079851307,0.00016599493,0.00022973045,0.00009304553,0.000046433837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002768423,0.00011355527,0.0005920402,0.0002877888,0.000037614624,0.000005280803,0.00012397922,0.00003970882,0.000032348456],"category_scores_gemma":[0.00019618453,0.00007659208,0.00007427236,0.0005643679,0.00013932516,0.000052977877,0.00006212828,0.0005612332,0.0000032262246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035840073,0.0067252503,0.9552199,0.000020085025,0.0001560674,0.00146577,0.018091653,0.00012347673,0.00022219158,0.00008409806,0.0006215056,0.01368599],"study_design_scores_gemma":[0.0059480052,0.0065660765,0.96161246,0.000011199843,0.00003743842,0.000009521421,0.02469001,0.0001029696,0.00009389435,0.0003049426,0.00055613957,0.000067367764],"about_ca_topic_score_codex":0.002263581,"about_ca_topic_score_gemma":0.0075730495,"teacher_disagreement_score":0.016674273,"about_ca_system_score_codex":0.00017410083,"about_ca_system_score_gemma":0.0005745045,"threshold_uncertainty_score":0.42259392},"labels":[],"label_agreement":null},{"id":"W4310753331","doi":"10.1016/j.annonc.2022.10.396","title":"358P Intracranial metastatic disease (IMD) burden and management of patients with small cell lung cancer (SCLC): A population-based analysis of 8705 patients","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Cancer Care Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Disease; Lung cancer; Population; Disease burden","score_opus":0.03618631874369391,"score_gpt":0.37250374823269977,"score_spread":0.3363174294890059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965345,0.0007139701,0.000033688095,0.0010361699,0.00004044521,0.0009084155,0.00058511354,0.000005739568,0.00014193535],"genre_scores_gemma":[0.99847627,0.00024006245,0.0005538375,0.00018727592,0.000012189898,0.0001912441,0.0002618647,0.000013142333,0.00006409191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983935,0.00015529759,0.00042265287,0.00024235681,0.0005691231,0.00021707897],"domain_scores_gemma":[0.998692,0.00013325988,0.00039653995,0.00022458893,0.00043424458,0.00011940589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022723903,0.00012316399,0.00065029156,0.0004016948,0.000060815422,0.0000020183195,0.00010670436,0.000015638485,0.00021972919],"category_scores_gemma":[0.000042537515,0.000100741556,0.000110677356,0.00065082766,0.000109686975,0.00003053796,0.00015280022,0.0000951945,1.2092565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003669465,0.0011567039,0.97492206,0.0015412576,0.004211919,0.000031140135,0.00041744238,0.004089795,0.00000926873,0.000019498968,0.00034115053,0.009590303],"study_design_scores_gemma":[0.0045468207,0.0022419603,0.98547894,0.00007031218,0.004819751,5.262612e-8,0.00016756725,0.001986845,0.00003439008,0.00001352482,0.0005536483,0.00008616279],"about_ca_topic_score_codex":0.0013544918,"about_ca_topic_score_gemma":0.00027023838,"teacher_disagreement_score":0.010556909,"about_ca_system_score_codex":0.00012730928,"about_ca_system_score_gemma":0.00019421129,"threshold_uncertainty_score":0.41081214},"labels":[],"label_agreement":null},{"id":"W4310753448","doi":"10.1016/j.annonc.2022.10.194","title":"157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Abiraterone; Placebo; Internal medicine; Oncology; Biomarker; Prostate cancer; Pathology; Cancer; Alternative medicine; Nuclear magnetic resonance","score_opus":0.0927244702327429,"score_gpt":0.408633134894925,"score_spread":0.3159086646621821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836726,0.0016261066,0.0000064282845,0.0076672067,0.00005050535,0.0035695143,0.0033403276,0.000008667982,0.000058602025],"genre_scores_gemma":[0.99373996,0.0034056844,0.00021001935,0.00028120633,0.000028590732,0.0006980298,0.0012921732,0.000020053707,0.00032426137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809563,0.0002656986,0.00058639457,0.00042573514,0.0003436151,0.00028291537],"domain_scores_gemma":[0.9982885,0.0004983702,0.00045598813,0.0002409556,0.0003931765,0.00012297908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067892467,0.00020236072,0.0007460015,0.0001825175,0.0002363183,0.000021052003,0.000084064195,0.000056065674,0.000089696696],"category_scores_gemma":[0.00009876508,0.00011667544,0.00006837004,0.00046768878,0.00039626673,0.00008908247,0.00006804022,0.0001449862,2.6036025e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92290664,0.0028087585,0.0068591796,0.00008414112,0.004959192,0.00003868916,0.0036173032,0.000033390792,0.0038877241,0.000009847057,0.002256287,0.052538835],"study_design_scores_gemma":[0.7970817,0.11154165,0.041923165,0.00010360912,0.0032028998,0.000010891792,0.0016797367,0.0016711937,0.010842372,0.0002573149,0.03131823,0.0003672079],"about_ca_topic_score_codex":0.002663478,"about_ca_topic_score_gemma":0.0014044769,"teacher_disagreement_score":0.12582493,"about_ca_system_score_codex":0.00005611389,"about_ca_system_score_gemma":0.00042249978,"threshold_uncertainty_score":0.47578862},"labels":[],"label_agreement":null},{"id":"W4310753593","doi":"10.1016/j.annonc.2022.10.442","title":"411P Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Artificial Intelligence in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Medicine; Cancer; Cost analysis; Oncology; Internal medicine; Operations research","score_opus":0.43668439189272,"score_gpt":0.6330045482453318,"score_spread":0.1963201563526118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889182,0.0006949745,0.0015688284,0.0049368013,0.00026874084,0.0018357127,0.0013556989,0.0000060650186,0.0004149895],"genre_scores_gemma":[0.99471176,0.00015929328,0.001039697,0.0030912703,0.00002294759,0.00087236386,0.00005149412,0.000012786814,0.000038363025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97462976,0.02292146,0.001414206,0.00022798742,0.00043773587,0.00036884865],"domain_scores_gemma":[0.9825353,0.014116545,0.001609701,0.0010241306,0.00065063435,0.00006365939],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009591402,0.00013315717,0.0014068951,0.0010883141,0.00045537192,0.0000013419217,0.0010970421,0.00019310141,0.0011036034],"category_scores_gemma":[0.0015323359,0.00010141684,0.0004328339,0.006607952,0.00025412245,0.000035088662,0.00071985344,0.0014536979,0.0000010601848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006256819,0.00059689506,0.602854,0.000086596934,0.008319929,0.0000049014943,0.14983252,0.08969449,0.0024286732,0.00038238583,0.001425425,0.14374846],"study_design_scores_gemma":[0.00020439246,0.0008067227,0.8981533,0.000065672735,0.004252324,1.7013863e-7,0.0780532,0.01093851,0.0012171984,0.00089796924,0.005294095,0.00011644473],"about_ca_topic_score_codex":0.35568196,"about_ca_topic_score_gemma":0.22952521,"teacher_disagreement_score":0.29529926,"about_ca_system_score_codex":0.0002015839,"about_ca_system_score_gemma":0.00059807644,"threshold_uncertainty_score":0.9998095},"labels":[],"label_agreement":null},{"id":"W4310753897","doi":"10.1016/j.annonc.2022.10.500","title":"398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Medicine; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.02602173890808037,"score_gpt":0.3946457078920597,"score_spread":0.36862396898397937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996205,0.00090626074,0.00003049534,0.014202692,0.0001603146,0.0031405527,0.00006110041,0.000030767216,0.001505791],"genre_scores_gemma":[0.9926473,0.00042083117,0.000295364,0.0050674565,0.00006403755,0.0010007315,0.00006308638,0.00004597594,0.00039520275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99731886,0.0004251181,0.0010802022,0.0004057222,0.00039582048,0.00037429095],"domain_scores_gemma":[0.9984212,0.0003003521,0.0005440876,0.00043494787,0.0001873679,0.000112047885],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007925062,0.00026597237,0.0017606971,0.00033239674,0.00007187795,0.0000051276365,0.00017597541,0.00011004293,0.0018598359],"category_scores_gemma":[0.0000641382,0.0002195575,0.0002819035,0.00046547767,0.0001770722,0.00006844658,0.0000678352,0.00028873395,0.00000368132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.830016,0.032818325,0.005541618,0.00008161009,0.0029420767,0.00041283324,0.026155015,0.000050344268,0.008913657,0.000060676248,0.0030185124,0.089989305],"study_design_scores_gemma":[0.92778707,0.023339756,0.0052052927,0.00007421792,0.0006183409,0.00006312846,0.0046698796,0.00018123395,0.009405334,0.00018302212,0.028195497,0.00027722702],"about_ca_topic_score_codex":0.0008553668,"about_ca_topic_score_gemma":0.00018232457,"teacher_disagreement_score":0.09777104,"about_ca_system_score_codex":0.00014472767,"about_ca_system_score_gemma":0.00043822415,"threshold_uncertainty_score":0.9990526},"labels":[],"label_agreement":null},{"id":"W4310753899","doi":"10.1016/j.annonc.2022.10.356","title":"319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Crizotinib; Alectinib; Medicine; Refractory (planetary science); Randomized controlled trial; Internal medicine; Oncology; Lung cancer","score_opus":0.0517741438347148,"score_gpt":0.43679608422170196,"score_spread":0.38502194038698717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9289027,0.001263393,0.00002384758,0.007627596,0.0009742865,0.0031150584,0.00010576393,0.000038171456,0.057949204],"genre_scores_gemma":[0.99453837,0.0004303303,0.0006841319,0.0019005782,0.00013033701,0.00081808417,0.00012008971,0.00002994711,0.0013481162],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732006,0.0005944626,0.0010430054,0.0003354747,0.00036212846,0.00034486514],"domain_scores_gemma":[0.99750966,0.0011273262,0.0006915714,0.00032737083,0.00023046453,0.00011359476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010808051,0.0001913676,0.0015212577,0.00031613238,0.00008200016,0.000002945309,0.00014987076,0.000112276684,0.00093271065],"category_scores_gemma":[0.00083980535,0.0001691075,0.000382505,0.00041109594,0.00022669094,0.00008372545,0.0000851927,0.00033310716,0.0000063115904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90847546,0.00426005,0.00030406629,0.00008277361,0.000701784,0.00009654166,0.0029107204,0.00013670724,0.002347719,0.00070596824,0.005214191,0.07476403],"study_design_scores_gemma":[0.8470044,0.013859453,0.0006363248,0.000066265304,0.0003595411,0.000033478194,0.0007791538,0.000046733247,0.0022228584,0.0007599498,0.13408378,0.0001480431],"about_ca_topic_score_codex":0.0005404033,"about_ca_topic_score_gemma":0.00010109315,"teacher_disagreement_score":0.1288696,"about_ca_system_score_codex":0.00014095195,"about_ca_system_score_gemma":0.0011680818,"threshold_uncertainty_score":0.99998057},"labels":[],"label_agreement":null},{"id":"W4310753925","doi":"10.1016/j.annonc.2022.10.195","title":"158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Abiraterone; Oncology; Homologous recombination; Internal medicine; Gene; Cancer; Androgen deprivation therapy; Genetics; Biology; Androgen receptor","score_opus":0.0458447475444037,"score_gpt":0.346556760170719,"score_spread":0.3007120126263153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310356,0.0004544998,0.00003430404,0.0032047112,0.000051547555,0.0028100808,0.0002002678,0.000027890064,0.000113110254],"genre_scores_gemma":[0.99643415,0.0004720495,0.00071648485,0.00067316403,0.000012720621,0.0013441545,0.00015505767,0.000036284193,0.00015593169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970812,0.00070407934,0.00077289005,0.000514662,0.00062553235,0.0003015892],"domain_scores_gemma":[0.9977794,0.00012757619,0.00084282213,0.0004854306,0.0006839429,0.00008082612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008017134,0.0002746041,0.0008783689,0.0004995425,0.00022261922,0.000015606001,0.00014426779,0.000048767102,0.00016695018],"category_scores_gemma":[0.000030113033,0.00017920528,0.00008345306,0.0016361882,0.000306084,0.00016717825,0.00004832445,0.00027423454,3.5098455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038652346,0.011774819,0.88832104,0.00015125165,0.0074433694,0.00016821262,0.017395362,0.019378645,0.0028514916,0.00006948228,0.00016650699,0.013627477],"study_design_scores_gemma":[0.024935747,0.07200355,0.8941305,0.000103612074,0.0013614893,0.00004460909,0.0022572384,0.0005053578,0.0039964234,0.00011121166,0.00027656314,0.00027365],"about_ca_topic_score_codex":0.001674102,"about_ca_topic_score_gemma":0.013310473,"teacher_disagreement_score":0.060228735,"about_ca_system_score_codex":0.00023560024,"about_ca_system_score_gemma":0.0005385209,"threshold_uncertainty_score":0.74275565},"labels":[],"label_agreement":null},{"id":"W4310754059","doi":"10.1016/j.annonc.2022.10.320","title":"295TiP Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Palonosetron; Medicine; Chemotherapy-induced nausea and vomiting; Nausea; Vomiting; Chemotherapy; Oncology; Internal medicine; Anesthesia; Antiemetic","score_opus":0.05666539245958374,"score_gpt":0.3596057639673663,"score_spread":0.3029403715077826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310754059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706024,0.00019352556,0.000070437134,0.0010324653,0.00007903808,0.0012500196,0.000020022424,0.000013123104,0.00028114082],"genre_scores_gemma":[0.99828565,0.0001333972,0.0008422534,0.00051445985,0.000029949817,0.0000763911,0.000041923086,0.00003585693,0.00004013455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786586,0.0003414735,0.00085884705,0.00030181036,0.00031079308,0.00032120198],"domain_scores_gemma":[0.99739325,0.00078932574,0.0012208443,0.0002594302,0.00028825065,0.000048917515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024171555,0.00017245312,0.0006711222,0.00027793477,0.00020806593,0.000009998658,0.00016050285,0.00008702332,0.000042571945],"category_scores_gemma":[0.0004925959,0.00015691253,0.00014372602,0.00035045942,0.00007186621,0.0000931578,0.00015078826,0.00021412183,1.3875935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026295169,0.0018713707,0.82072985,0.0005325064,0.0005281939,0.0000024920262,0.0020395103,0.0002179581,0.03907893,0.00022457055,0.00018994014,0.13195518],"study_design_scores_gemma":[0.013118943,0.0046798326,0.9140671,0.0001754213,0.00017844675,0.0000033719537,0.00074241636,0.0065401555,0.059125744,0.000982522,0.00021469525,0.00017135087],"about_ca_topic_score_codex":0.0002857765,"about_ca_topic_score_gemma":0.000056547007,"teacher_disagreement_score":0.13178383,"about_ca_system_score_codex":0.00013906154,"about_ca_system_score_gemma":0.00010171624,"threshold_uncertainty_score":0.6398707},"labels":[],"label_agreement":null},{"id":"W4310754084","doi":"10.1016/j.annonc.2022.10.395","title":"357P Molecular stratification of small cell lung carcinoma subtypes by immunoexpression of ASCL1, NEUROD1, POU2F3 and YAP1 with clinicopathological correlation","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"YAP1; Medicine; Lung; Correlation; Cancer research; Pathology; Internal medicine; Biology; Genetics; Gene; Transcription factor","score_opus":0.052204182496479,"score_gpt":0.3770225237112079,"score_spread":0.3248183412147289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310754084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154484,0.004415283,0.00020381094,0.0015372917,0.000044040713,0.00045547646,0.000036591533,0.000008192956,0.0017544511],"genre_scores_gemma":[0.99863046,0.0005510368,0.000445059,0.00015195672,0.000010268892,0.000043501437,0.00004569012,0.000010374782,0.00011164462],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99862176,0.00032518865,0.00040435014,0.0002285336,0.00026641585,0.00015375315],"domain_scores_gemma":[0.99879616,0.00024930874,0.00039589754,0.00023045753,0.00027946357,0.000048733298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055140303,0.000093540235,0.00042175132,0.00009383563,0.00005337482,0.000001661244,0.00009822052,0.00007062126,0.00004780133],"category_scores_gemma":[0.0001580279,0.00007457325,0.00005235869,0.00015270134,0.00024764892,0.00003140349,0.00013667392,0.00023668133,3.1454513e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036062826,0.0010865605,0.28510454,0.0004437065,0.00007177903,0.00006747075,0.0009223608,0.00025117822,0.6969238,0.00024550848,0.0048819124,0.0063948845],"study_design_scores_gemma":[0.005102522,0.035066277,0.63374984,0.000110178036,0.00026710427,0.000078582954,0.0014923859,0.0016482238,0.3187142,0.00026434366,0.00329769,0.00020863065],"about_ca_topic_score_codex":0.00010511232,"about_ca_topic_score_gemma":0.0000038519174,"teacher_disagreement_score":0.3782096,"about_ca_system_score_codex":0.000029146164,"about_ca_system_score_gemma":0.00021603836,"threshold_uncertainty_score":0.30410087},"labels":[],"label_agreement":null},{"id":"W4310754340","doi":"10.1016/j.annonc.2022.10.287","title":"259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Immunotherapy; Gut flora; Cancer; Ecology; Oncology; Internal medicine; Immunology; Biology","score_opus":0.051516116497046245,"score_gpt":0.3926209245700886,"score_spread":0.3411048080730424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310754340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963121,0.0010563106,0.00003310126,0.0010769115,0.00008886377,0.0002045724,0.0008733841,0.0000050168424,0.00034973928],"genre_scores_gemma":[0.9966944,0.0006768531,0.00015162228,0.0021379932,0.000022990274,0.000042010888,0.00013724795,0.000013503949,0.00012339091],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985603,0.0004144492,0.00042698818,0.00027874557,0.00010447147,0.00021506553],"domain_scores_gemma":[0.9988727,0.00011112937,0.00043957983,0.0003287947,0.0002076806,0.000040140632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047908828,0.000119198274,0.0005199953,0.0002771693,0.000053193144,0.0000012181665,0.00025615274,0.0001627049,0.0003695267],"category_scores_gemma":[0.000061959996,0.00011035903,0.00029078426,0.0004045672,0.00021677426,0.0000013045384,0.00010552376,0.00012749707,2.9203994e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047106845,0.001011671,0.025458958,0.000026119105,0.00084993726,0.0000032341216,0.00012498052,0.0033596922,0.9592848,0.000029921648,0.0035160398,0.0016239658],"study_design_scores_gemma":[0.0016328575,0.019271819,0.66074526,0.000016351827,0.0002640813,0.0000033438782,0.00019432907,0.0002586281,0.26660267,0.000022136863,0.05081144,0.0001770628],"about_ca_topic_score_codex":0.00022741164,"about_ca_topic_score_gemma":0.00018916624,"teacher_disagreement_score":0.69268215,"about_ca_system_score_codex":0.000033762713,"about_ca_system_score_gemma":0.0006074128,"threshold_uncertainty_score":0.45003107},"labels":[],"label_agreement":null},{"id":"W4310755787","doi":"10.1016/j.annonc.2022.10.214","title":"178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Ovarian cancer; Internal medicine; Oncology; Disease; Gynecology; Cancer","score_opus":0.05208790311417248,"score_gpt":0.3768303549252736,"score_spread":0.3247424518111011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310755787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087954,0.00037423655,0.0000683631,0.005072329,0.00032327962,0.0025699656,0.000351494,0.000035225385,0.00032559672],"genre_scores_gemma":[0.9923037,0.00018306887,0.00019316598,0.003755494,0.00009072823,0.0032490634,0.000053791147,0.00004840788,0.0001225567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743,0.00037559326,0.0006669044,0.000568543,0.00046062647,0.0004983033],"domain_scores_gemma":[0.9980128,0.0003589428,0.0005617826,0.0005891723,0.0002004547,0.00027688223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007758649,0.000294615,0.0007298008,0.00023662871,0.00030876423,0.000014276427,0.00026023257,0.00005089908,0.00021089557],"category_scores_gemma":[0.000119709,0.00020688659,0.0001162643,0.00060701754,0.000109906294,0.00009361243,0.00012500123,0.00035491327,0.0000066206094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028827192,0.010304994,0.86653256,0.000015071255,0.0004871004,0.0003231807,0.016875353,0.009321511,0.00006823427,0.0005052426,0.00095696806,0.065782584],"study_design_scores_gemma":[0.15948562,0.07635671,0.71826005,0.00032990138,0.0006972327,0.000019668547,0.021726025,0.0007524682,0.00052527623,0.00079007127,0.020319482,0.000737494],"about_ca_topic_score_codex":0.0067151776,"about_ca_topic_score_gemma":0.0032637208,"teacher_disagreement_score":0.14827253,"about_ca_system_score_codex":0.0008877765,"about_ca_system_score_gemma":0.0006909143,"threshold_uncertainty_score":0.9998992},"labels":[],"label_agreement":null},{"id":"W4311025044","doi":"10.1016/j.annonc.2022.11.012","title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pharmacyclics; Merck Sharp and Dohme; EMD Serono; Genentech; Ipsen; Universidad de Navarra; Basilea Pharmaceutica; Astellas Pharma; Eisai; Seagen; Foundation Medicine; Flatiron Health; G1 Therapeutics; GlaxoSmithKline; UroGen Pharma; Bavarian Nordic; Silverback Therapeutics; Pfizer; Innovent Biologics; Incyte; BeiGene; Mirati Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Celldex Therapeutics; Advanced Accelerator Applications; National Institutes of Health; Natera; Regeneron Pharmaceuticals; Merck KGaA; Endocyte; Gilead Sciences; Exelixis; Sanofi; Amgen; Allergan; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Internal medicine; Expanded access; Cancer; Immunotherapy; Bladder cancer","score_opus":0.05259067387769641,"score_gpt":0.3455086135433258,"score_spread":0.2929179396656294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311025044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994575,0.0010820493,0.000006880392,0.0017883922,0.00019775094,0.0006320717,0.001060144,0.00000616192,0.0006515254],"genre_scores_gemma":[0.9982985,0.00019196211,0.00028273548,0.00083180174,0.000037961167,0.000049895472,0.00003909822,0.00002088159,0.0002471484],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983596,0.00020448877,0.0006174839,0.00033299933,0.0002547467,0.00023064378],"domain_scores_gemma":[0.998932,0.00038099068,0.00019693631,0.00027784772,0.00008551821,0.00012669932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031961137,0.00014823559,0.0007830549,0.00022011447,0.000024934228,0.0000021075903,0.00009415959,0.00006851227,0.00015497711],"category_scores_gemma":[0.00020230204,0.00014532763,0.000085662585,0.00021048136,0.00013857897,0.000036181857,0.00016485598,0.00016301512,0.0000020580082],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5760968,0.003520304,0.073246144,0.0004833569,0.0017169904,0.001124916,0.055055458,0.00014503878,0.021980356,0.00020351665,0.0064277663,0.25999936],"study_design_scores_gemma":[0.061179284,0.013139572,0.9024272,0.0000989462,0.0003971838,0.000045063356,0.001078499,0.000027053215,0.008194535,0.00038573172,0.01282762,0.00019929408],"about_ca_topic_score_codex":0.004059969,"about_ca_topic_score_gemma":0.00029523985,"teacher_disagreement_score":0.8291811,"about_ca_system_score_codex":0.000051173716,"about_ca_system_score_gemma":0.00031572368,"threshold_uncertainty_score":0.61374855},"labels":[],"label_agreement":null},{"id":"W4311917936","doi":"10.1016/j.annonc.2022.12.004","title":"Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Genentech; Ipsen; European Society for Medical Oncology; Chugai Pharmaceutical; Seagen; Regeneron Pharmaceuticals; Servier; G1 Therapeutics; Amgen; Pfizer; World Health Organization; Radius Health; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Checklist; Quality of life (healthcare); Clinical trial; Clinical endpoint; Scale (ratio); Test (biology); Medical physics; Intensive care medicine; Internal medicine; Nursing","score_opus":0.7311834190191645,"score_gpt":0.5746809436174326,"score_spread":0.1565024754017319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311917936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87228835,0.005554339,0.073510945,0.013529996,0.0018817128,0.0017295923,0.020301646,0.0000305962,0.011172848],"genre_scores_gemma":[0.8557453,0.00431486,0.13106517,0.006251064,0.0013638816,0.00031952333,0.00052525953,0.000081046805,0.0003338644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993164,0.0002038462,0.005372642,0.000709158,0.0001135073,0.00043683595],"domain_scores_gemma":[0.9859892,0.0056979423,0.007044166,0.00054832106,0.0005029658,0.00021737431],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.056916155,0.00016921201,0.0024511954,0.00009782738,0.00017869088,0.000009197715,0.00071649003,0.0003286055,0.00018252435],"category_scores_gemma":[0.035556648,0.00018313155,0.0007051299,0.00010273231,0.00049161457,0.00016109097,0.00064318365,0.0002899782,6.3367025e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084849475,0.0025912903,0.10957811,0.0016167737,0.0016875496,0.0000051441757,0.00156875,0.00027191022,0.00011703721,0.21204643,0.25103056,0.4110015],"study_design_scores_gemma":[0.0048995884,0.007109034,0.025786098,0.000021503878,0.000058051,0.000006674636,0.0005140417,0.0018245049,0.00010684091,0.045577846,0.9138249,0.00027090055],"about_ca_topic_score_codex":0.00017237118,"about_ca_topic_score_gemma":0.00010181186,"teacher_disagreement_score":0.66279435,"about_ca_system_score_codex":0.00007357797,"about_ca_system_score_gemma":0.0010200228,"threshold_uncertainty_score":0.97256726},"labels":[],"label_agreement":null},{"id":"W4312018944","doi":"10.1016/j.annonc.2022.12.007","title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of British Columbia","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Chemotherapy; Docetaxel; Population; Capecitabine; Gemcitabine; Cancer; Surgery; Immunotherapy; Colorectal cancer","score_opus":0.2366118768115211,"score_gpt":0.5025671330450882,"score_spread":0.2659552562335671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312018944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788854,0.005609783,0.0000086670325,0.0072307587,0.0012984178,0.0038740386,0.00014050583,0.000038301707,0.0029140923],"genre_scores_gemma":[0.9746123,0.015611526,0.00048449214,0.0046823355,0.00034674018,0.0033234246,0.00010502313,0.00007125312,0.0007629318],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662745,0.0009124696,0.0010091272,0.0005343251,0.0003971232,0.0005195304],"domain_scores_gemma":[0.99797726,0.00083892245,0.00046842464,0.00037097002,0.00015955095,0.00018486312],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001470759,0.00032046318,0.0026063581,0.00027695854,0.00017136334,0.000014492975,0.00038787664,0.00009698943,0.0024583372],"category_scores_gemma":[0.00020279843,0.00024999073,0.00014426731,0.0005183053,0.00022910729,0.00015811282,0.00015615871,0.00044939277,0.0000033627161],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7795122,0.009468825,0.000010950781,0.000035623725,0.0008045095,0.00017969706,0.0025002037,0.000013071562,0.00043895544,0.000078175275,0.005793383,0.20116438],"study_design_scores_gemma":[0.88994604,0.07577067,0.000018241151,0.0000534148,0.00019666665,0.00002223164,0.00050711335,0.0007553214,0.0006948264,0.00010800869,0.031710114,0.00021733611],"about_ca_topic_score_codex":0.0018531028,"about_ca_topic_score_gemma":0.0011134135,"teacher_disagreement_score":0.20094703,"about_ca_system_score_codex":0.00030713162,"about_ca_system_score_gemma":0.0013334076,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W4322505162","doi":"10.1016/j.annonc.2023.02.009","title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; St. Thomas Hospital","funders":"Cilag; Janssen Research and Development; BeiGene","keywords":"Medicine; Prostate cancer; Placebo; Androgen deprivation therapy; Hazard ratio; Prostate-specific antigen; Enzalutamide; Antiandrogen; Urology; Internal medicine; Proportional hazards model; Oncology; Cancer; Androgen receptor; Pathology; Confidence interval","score_opus":0.10048833024176645,"score_gpt":0.39972854692055465,"score_spread":0.2992402166787882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322505162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944902,0.0005187597,0.000012201352,0.002843267,0.00003320134,0.0019026002,0.00011417637,0.000027313767,0.000058265858],"genre_scores_gemma":[0.9909783,0.0077318107,0.0003351691,0.0003302805,0.000017878216,0.00013433989,0.0002650879,0.000036131758,0.00017102947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981356,0.0002084657,0.00046756465,0.0004400722,0.0003349203,0.00041337387],"domain_scores_gemma":[0.99832153,0.0004159071,0.0002943334,0.00016167935,0.00066093897,0.00014560374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060863467,0.00022757042,0.0007952089,0.00020324651,0.00008068481,0.000023116783,0.00004537091,0.000099527155,0.00001738551],"category_scores_gemma":[0.00007466861,0.00013487348,0.00003460057,0.0005072145,0.0003838003,0.00016409843,0.000035354686,0.0002072077,0.0000014061338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013865955,0.0004892044,0.96012515,0.000040899246,0.00094888883,0.00023907988,0.0018241801,0.00002757879,0.00019740066,0.0000042228608,0.00008386373,0.022153586],"study_design_scores_gemma":[0.020959133,0.009686901,0.96674854,0.000112509195,0.00006736233,0.000007392283,0.0007575819,0.0004532024,0.00084792264,0.000034461264,0.00016198143,0.00016299705],"about_ca_topic_score_codex":0.00037086985,"about_ca_topic_score_gemma":0.002038905,"teacher_disagreement_score":0.02199059,"about_ca_system_score_codex":0.0000868725,"about_ca_system_score_gemma":0.00050807395,"threshold_uncertainty_score":0.5499981},"labels":[],"label_agreement":null},{"id":"W4322615287","doi":"10.1016/j.annonc.2023.02.011","title":"First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Microbiome; Clinical trial; Oncology; Colorectal cancer; Cancer; Adverse effect; Bioinformatics; Biology","score_opus":0.021243876054727613,"score_gpt":0.31865653668229427,"score_spread":0.29741266062756666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322615287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979191,0.00021132918,0.0000028396971,0.00053635385,0.000087332795,0.0010153176,0.000027239494,0.0000069727153,0.00019352051],"genre_scores_gemma":[0.99923384,0.00022104105,0.000027489703,0.00005407597,0.00002289742,0.00018199874,0.00019574093,0.000022198094,0.00004071572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848944,0.00015861995,0.00044912726,0.00033058645,0.00016171108,0.0004105101],"domain_scores_gemma":[0.9993749,0.00003799184,0.00020221501,0.00021744122,0.00011332181,0.000054086715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037454834,0.00016272702,0.00040383608,0.00029390818,0.000027778438,0.000007594184,0.00014451887,0.00013333336,0.0000061407704],"category_scores_gemma":[0.000045804976,0.00013390623,0.00006047551,0.0004743257,0.000068951595,0.000012082128,0.00007044063,0.00012603987,0.000006240538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31508857,0.015957307,0.44378525,0.0006114945,0.0012639955,0.00063232984,0.0019014818,0.0061060996,0.11168153,0.00012048034,0.00077843486,0.10207302],"study_design_scores_gemma":[0.2286103,0.064807035,0.37873447,0.0005808513,0.000029590477,0.000011024913,0.00049629906,0.00015784476,0.31760415,0.00021169215,0.008081134,0.0006756056],"about_ca_topic_score_codex":0.0003838296,"about_ca_topic_score_gemma":0.013236553,"teacher_disagreement_score":0.20592262,"about_ca_system_score_codex":0.00011652102,"about_ca_system_score_gemma":0.0002540477,"threshold_uncertainty_score":0.7386307},"labels":[],"label_agreement":null},{"id":"W4360998472","doi":"10.1016/j.annonc.2023.02.008","title":"VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Population; Clinical endpoint; Placebo; Discontinuation; Paclitaxel; Phases of clinical research; Endometrial cancer; Oncology; Cancer; Chemotherapy; Randomized controlled trial; Cisplatin; Pathology","score_opus":0.12537693699103455,"score_gpt":0.44506532674029253,"score_spread":0.31968838974925795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360998472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93477845,0.016065942,0.00012477471,0.012687331,0.0047303643,0.028391045,0.0010717654,0.00014421754,0.0020061],"genre_scores_gemma":[0.74658674,0.19748761,0.0010772641,0.0044095963,0.0068739913,0.03389426,0.0009629824,0.00024408268,0.008463483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960349,0.000367685,0.0016552683,0.0006055952,0.00058823376,0.00074832124],"domain_scores_gemma":[0.9874377,0.010237339,0.0010228406,0.0005501491,0.00048097727,0.00027095235],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00130677,0.00049760105,0.0034074856,0.00061851274,0.0001507137,0.000012953393,0.00027989718,0.00030013607,0.0010633683],"category_scores_gemma":[0.00158944,0.0002738981,0.0014226013,0.0015093205,0.00024404877,0.00008249222,0.000041183655,0.0001792065,0.000012625244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5921866,0.0043356824,0.000011730597,0.00008837397,0.0024769073,0.00002653964,0.0005802925,0.000015977228,0.0021293664,0.000014716311,0.0025010877,0.3956327],"study_design_scores_gemma":[0.75307715,0.07106127,0.00006315538,0.000076383585,0.0011740263,0.0000044951535,0.00016792661,0.000111050314,0.008551789,0.00011089504,0.16541727,0.0001845771],"about_ca_topic_score_codex":0.00034131532,"about_ca_topic_score_gemma":0.00017218427,"teacher_disagreement_score":0.39544815,"about_ca_system_score_codex":0.00043703758,"about_ca_system_score_gemma":0.0013430757,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W4376272391","doi":"10.1016/j.annonc.2023.05.002","title":"A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; Princess Margaret Cancer Centre","funders":"Comprehensive Cancer Center, University of Chicago Medical Center; National Cancer Institute; Astellas Pharma; Celgene; AstraZeneca; University of Chicago; Pfizer","keywords":"Medicine; Lenalidomide; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Refractory (planetary science); Adverse effect; Progression-free survival; Thyroid cancer; Gastroenterology; Randomized controlled trial; Surgery; Clinical trial; Cancer; Chemotherapy; Multiple myeloma","score_opus":0.16842554019108977,"score_gpt":0.4695767661730993,"score_spread":0.3011512259820095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376272391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921043,0.0013953706,0.0000026811188,0.0021923361,0.00016424886,0.0036616514,0.000070128786,0.00003781889,0.00037147658],"genre_scores_gemma":[0.99229,0.005074199,0.00006804692,0.00050441385,0.000058349007,0.0012982473,0.0000497669,0.000039601848,0.00061734515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975902,0.00035819673,0.0008851718,0.00044078147,0.00032246936,0.00040320217],"domain_scores_gemma":[0.99808115,0.00050815014,0.0005648611,0.00039127574,0.00030232788,0.00015222446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006566378,0.00028738714,0.002224592,0.0003477917,0.000057971276,0.000008704892,0.00024249588,0.00011491231,0.0002698835],"category_scores_gemma":[0.00016635605,0.00017500459,0.000087523964,0.00057295465,0.00019683463,0.00010836485,0.00020626246,0.00020241826,0.000006635071],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.824761,0.08372847,0.040509842,0.00021779333,0.003064227,0.00066134025,0.0068542687,0.000041143277,0.009768819,0.000021373458,0.0062033804,0.024168396],"study_design_scores_gemma":[0.914788,0.0640458,0.008958756,0.00052952697,0.00085763953,0.00001012407,0.0015470501,0.0003308928,0.0069440515,0.0000126330115,0.0017736334,0.00020187316],"about_ca_topic_score_codex":0.0049271015,"about_ca_topic_score_gemma":0.008418587,"teacher_disagreement_score":0.09002707,"about_ca_system_score_codex":0.00010382239,"about_ca_system_score_gemma":0.0004216064,"threshold_uncertainty_score":0.74483365},"labels":[],"label_agreement":null},{"id":"W4377826643","doi":"10.1016/j.annonc.2023.05.006","title":"Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy","year":2023,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Clalit Health Services; Chugai Pharmaceutical; Pfizer; Daiichi Sankyo Europe; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Toxicity; Cancer therapy; Cancer; Clinical trial; Oncology; Medical physics; Intensive care medicine; Internal medicine","score_opus":0.08659278913106298,"score_gpt":0.4302291271481005,"score_spread":0.3436363380170375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377826643","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16823885,0.0023907206,0.000341978,0.004421552,0.8171755,0.0031439173,0.0035971326,0.00004084043,0.0006495167],"genre_scores_gemma":[0.037483454,0.1588191,0.0021626155,0.010870756,0.7839807,0.0022847746,0.0027350017,0.00040966037,0.0012539173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976028,0.00018883272,0.0007292194,0.0007484626,0.00025698752,0.00047366583],"domain_scores_gemma":[0.99748075,0.0005645217,0.000595482,0.00041167816,0.0006511402,0.00029640808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006926813,0.00034697965,0.00086406176,0.00018147504,0.00007202219,0.00010688323,0.00041434163,0.00089458143,0.000032746197],"category_scores_gemma":[0.0031416235,0.00034447858,0.00018467344,0.00019425162,0.000043906108,0.000009475495,0.0006632039,0.00020300392,0.000006798709],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025651348,0.00022401092,0.000021195754,0.000040621686,0.0003570606,0.000010425965,0.00016872783,0.0028964067,0.019606536,0.0000048682864,0.9340845,0.040020518],"study_design_scores_gemma":[0.001528,0.0055439915,0.000016020665,0.00008037073,0.00006148652,9.723808e-7,0.000026715084,0.00002256381,0.041781962,0.000028225446,0.9505585,0.00035122497],"about_ca_topic_score_codex":0.00065066846,"about_ca_topic_score_gemma":0.0005850712,"teacher_disagreement_score":0.15642837,"about_ca_system_score_codex":0.00011512582,"about_ca_system_score_gemma":0.0010354234,"threshold_uncertainty_score":0.9999007},"labels":[],"label_agreement":null},{"id":"W4380880376","doi":"10.1016/j.annonc.2023.06.001","title":"Fragmentomic analysis of circulating tumor DNA-targeted cancer panels","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Division of Graduate Education; Astellas Pharma; University of Wisconsin Carbone Cancer Center; Pfizer; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Medicine; Oncology; Cohort; Breast cancer; Cancer; Biomarker; Lung cancer; Internal medicine; Prostate cancer; Biology; Genetics","score_opus":0.0581449432716975,"score_gpt":0.37339761722755377,"score_spread":0.31525267395585627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380880376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743164,0.000744088,0.0000645538,0.0004256421,0.00016106233,0.00009010165,0.00022563596,0.0000076885735,0.0008495746],"genre_scores_gemma":[0.99736065,0.0015117512,0.00008227627,0.0006091609,0.000101806545,0.000022522512,0.00020594236,0.000013253676,0.00009265802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905246,0.00004369042,0.00034740972,0.000230918,0.000092304115,0.00023324137],"domain_scores_gemma":[0.9991604,0.0000759419,0.00026947976,0.00025222733,0.00018324582,0.000058709502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000249247,0.00009822618,0.00036708996,0.00021558024,0.000026359063,0.000003505834,0.00015412849,0.00010898281,0.00008191502],"category_scores_gemma":[0.00017049191,0.00010325135,0.00021072329,0.0005955069,0.00007881962,0.0000017002908,0.00011044477,0.000044952594,0.000004160248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086991386,0.000095950476,0.021927476,0.000033254135,0.0014459137,0.0000118492835,0.00019170383,0.010722486,0.9483702,0.00014437136,0.0045408485,0.012428928],"study_design_scores_gemma":[0.00080757955,0.0011009573,0.17192058,0.000020518199,0.00062292645,0.0000030088454,0.00027538542,0.0029526874,0.77628726,0.00029238997,0.045425005,0.00029170158],"about_ca_topic_score_codex":0.00034243896,"about_ca_topic_score_gemma":0.00024146319,"teacher_disagreement_score":0.17208298,"about_ca_system_score_codex":0.000013805972,"about_ca_system_score_gemma":0.00022384393,"threshold_uncertainty_score":0.42104676},"labels":[],"label_agreement":null},{"id":"W4381136693","doi":"10.1016/j.annonc.2023.06.002","title":"ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation; Queen's University","funders":"Genentech; Servier; European Society for Medical Oncology; Fondazione Beretta; Ipsen; BeiGene; Eisai; Jazz Pharmaceuticals; Gilead Sciences; European Federation of Pharmaceutical Industries and Associations; European Commission; Sanofi; Astellas Pharma; Celldex Therapeutics; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Seagen; Agios Pharmaceuticals","keywords":"Medicine; Clinical trial; Internal medicine; Oncology","score_opus":0.2509559698425497,"score_gpt":0.41505804551894077,"score_spread":0.16410207567639107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381136693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96833843,0.0006795034,0.00021620598,0.0038928473,0.0009632131,0.00028726403,0.0005100104,0.00003890481,0.02507365],"genre_scores_gemma":[0.99368334,0.0025801612,0.001193162,0.0010123017,0.00019928809,0.000040212544,0.000042311567,0.000022583477,0.0012266488],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750483,0.00002207721,0.0015930609,0.00040126572,0.000037130867,0.00044163526],"domain_scores_gemma":[0.9977477,0.0005746508,0.0010355447,0.00030550096,0.00021549714,0.00012106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017398641,0.00015684917,0.0013569104,0.00024159436,0.00006864236,0.000008944618,0.0003477531,0.00043278796,0.0002837377],"category_scores_gemma":[0.00085474836,0.0001689271,0.00045049514,0.0002272444,0.00033726988,0.00018040794,0.00012986384,0.00014573633,0.00039773594],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011181463,0.0008988649,0.5035782,0.00029608642,0.00025333656,0.00001968112,0.0005172972,0.00028901198,0.000094616305,0.32323468,0.13007388,0.039626215],"study_design_scores_gemma":[0.0019943605,0.0028451597,0.39262775,0.00004480415,0.000019579766,0.0000055068517,0.00015412038,0.0004275754,0.0017136789,0.11406572,0.48580125,0.0003004951],"about_ca_topic_score_codex":0.00017414875,"about_ca_topic_score_gemma":0.00007551638,"teacher_disagreement_score":0.3557274,"about_ca_system_score_codex":0.000025480023,"about_ca_system_score_gemma":0.000097994256,"threshold_uncertainty_score":0.6888647},"labels":[],"label_agreement":null},{"id":"W4382794886","doi":"10.1016/j.annonc.2023.06.009","title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development; National Cancer Institute; Genentech; Astellas Pharma; Ipsen; Clovis Oncology; Taiho Pharmaceutical; Gilead Sciences; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Takeda Oncology; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Abiraterone acetate; Interim analysis; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Progression-free survival; Urology; Oncology; Chemotherapy; Confidence interval; Gastroenterology; Androgen deprivation therapy; Randomized controlled trial; Cancer","score_opus":0.0673827402915172,"score_gpt":0.3994581347533062,"score_spread":0.332075394461789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382794886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486256,0.00039322968,0.000010199798,0.0012227135,0.000060664654,0.0031701485,0.00018672225,0.000017863,0.000075924734],"genre_scores_gemma":[0.99740195,0.00052572467,0.00023768753,0.00008132388,0.0000096075755,0.00070052827,0.00034778038,0.000013453466,0.0006819143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99820507,0.00038120124,0.00063444587,0.00027585917,0.00026997578,0.00023346505],"domain_scores_gemma":[0.99858665,0.00022414015,0.00043097377,0.00021662854,0.00048024743,0.00006134578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080772676,0.00015232446,0.0010384094,0.00048506475,0.00006198056,0.000011694305,0.00006417847,0.00005233069,0.000062329345],"category_scores_gemma":[0.000090269335,0.000084572785,0.00011347429,0.0010516661,0.0003850435,0.000113940056,0.000037015358,0.00012461098,4.2290796e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.976165,0.0016574905,0.0063430336,0.00018024333,0.005400755,0.000059060312,0.0034813108,0.0006426948,0.0018138618,0.000027540957,0.0001616837,0.0040673306],"study_design_scores_gemma":[0.92627704,0.014877748,0.04738759,0.00013373919,0.0020479134,0.0000034198963,0.00033316095,0.0021359117,0.0065408465,0.00008636175,0.000050434024,0.00012581308],"about_ca_topic_score_codex":0.000427061,"about_ca_topic_score_gemma":0.0025297394,"teacher_disagreement_score":0.04988793,"about_ca_system_score_codex":0.00009839766,"about_ca_system_score_gemma":0.0006179163,"threshold_uncertainty_score":0.3448778},"labels":[],"label_agreement":null},{"id":"W4382799053","doi":"10.1016/j.annonc.2023.04.171","title":"P-115 Cytoreductive surgery and HIPEC in the treatment of peritoneal carcinomatosis: The experience in a tertiary university hospital","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University Health Centre","keywords":"Medicine; Peritoneal carcinomatosis; Cytoreductive surgery; Tertiary care; Surgery; General surgery; Cancer; Internal medicine; Ovarian cancer; Colorectal cancer","score_opus":0.07116067532167664,"score_gpt":0.33817436135749074,"score_spread":0.2670136860358141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382799053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98794496,0.00048397496,7.671154e-8,0.010843184,0.00006981157,0.0002453712,0.000010899705,0.0000064582773,0.00039526782],"genre_scores_gemma":[0.9982541,0.0014550112,0.000006525864,0.00018119553,0.00004415614,0.00001636091,0.000004301749,0.000003420278,0.000034883305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992872,0.00012573911,0.00017859563,0.00013065351,0.000095448515,0.00018237953],"domain_scores_gemma":[0.99941516,0.00033099912,0.00007049002,0.00011907128,0.00003784821,0.000026420958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019683037,0.00007819043,0.00029444805,0.00011341338,0.000036059588,0.0000018690218,0.0000743785,0.00005949837,0.000007539848],"category_scores_gemma":[0.000026824991,0.000045598757,0.00006652479,0.0002769532,0.0004177694,0.000044592933,0.000023874885,0.00006126173,0.000001316332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072286295,0.001591241,0.8183488,0.00008148573,0.000067805464,0.001387498,0.15255381,0.0000036605413,0.0046191094,0.0009818136,0.0010408744,0.01860099],"study_design_scores_gemma":[0.00045277303,0.0017048576,0.9321614,0.000045589302,0.000015274009,0.000041270177,0.056430593,0.000020609687,0.0052982364,0.000058544676,0.0037219953,0.000048839698],"about_ca_topic_score_codex":0.0017404357,"about_ca_topic_score_gemma":0.00018263308,"teacher_disagreement_score":0.11381257,"about_ca_system_score_codex":0.000032481177,"about_ca_system_score_gemma":0.00011341242,"threshold_uncertainty_score":0.26310298},"labels":[],"label_agreement":null},{"id":"W4382799116","doi":"10.1016/j.annonc.2023.04.022","title":"O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"LEO Pharma; Ipsen; Astellas Pharma; Servier; Daiichi-Sankyo; Mirati Therapeutics; Merck KGaA; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Internal medicine; Hazard ratio; Oncology; Esophageal cancer; Placebo; Microsatellite instability; Chemoradiotherapy; Cancer; Biomarker; Gastroenterology; Confidence interval; Pathology; Immunotherapy; Gene; Allele","score_opus":0.19636179196239936,"score_gpt":0.4788410146094649,"score_spread":0.2824792226470655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382799116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868029,0.008149339,0.000021943362,0.00312383,0.00040999023,0.0008904944,0.00012921217,0.00008518483,0.0003871174],"genre_scores_gemma":[0.99525875,0.0022753505,0.00051920314,0.00032403416,0.00015965014,0.00021450708,0.00031943966,0.000051736468,0.0008773071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967553,0.00024087161,0.001024846,0.00061258284,0.0006561315,0.0007102795],"domain_scores_gemma":[0.99779445,0.00049999397,0.0005046293,0.00052527944,0.0004085847,0.00026707372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051783945,0.00032144616,0.0016137874,0.0006785876,0.00009376586,0.00000995056,0.00018329803,0.00023620065,0.0006854582],"category_scores_gemma":[0.00022171893,0.0002543392,0.00037781362,0.0013109958,0.00025010962,0.00012849862,0.000105831255,0.0003074198,0.000016940712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12686622,0.0043203956,0.42379627,0.0013063195,0.009775093,0.15131426,0.003318101,0.0014805947,0.096871145,0.000018294335,0.059286993,0.1216463],"study_design_scores_gemma":[0.02428887,0.008781716,0.8639014,0.0006570094,0.0003698724,0.000261518,0.0007001234,0.0024526466,0.096097566,0.00010015454,0.0021103835,0.00027873402],"about_ca_topic_score_codex":0.013635961,"about_ca_topic_score_gemma":0.003642427,"teacher_disagreement_score":0.44010514,"about_ca_system_score_codex":0.00038528666,"about_ca_system_score_gemma":0.00097569503,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W4382799163","doi":"10.1016/j.annonc.2023.04.182","title":"P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Loxo Oncology; Chugai Pharmaceutical; Pharmacyclics; Genentech; Aptitude Health; Servier; Eisai; Daiichi-Sankyo; AstraZeneca España; Silverback Therapeutics; Puma Biotechnology; F. Hoffmann-La Roche; Incyte; Mersana Therapeutics; Karyopharm Therapeutics; Sanofi; Spectrum Pharmaceuticals; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Oncology; Salvage therapy; Phases of clinical research; Solid tumor; Cancer; Chemotherapy","score_opus":0.046389210095218396,"score_gpt":0.401401696038203,"score_spread":0.3550124859429846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382799163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968485,0.0009900401,5.160507e-7,0.00042688055,0.000026738106,0.0016295412,0.00003246339,0.000009483865,0.000035842033],"genre_scores_gemma":[0.99577105,0.003792719,0.000047756253,0.000060408962,0.0000045860907,0.0002774775,0.000016253882,0.000017628457,0.000012131194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862003,0.00010621858,0.0004072249,0.000334067,0.00022625548,0.0003062288],"domain_scores_gemma":[0.9992729,0.00017301018,0.0002314783,0.000093681265,0.00017104582,0.00005788377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012546219,0.00020008012,0.00082234247,0.00045114543,0.00003623587,0.0000042301676,0.00004500632,0.00003287483,0.000013676772],"category_scores_gemma":[0.000064589185,0.00014662668,0.000017087877,0.0007517831,0.00015837203,0.00010088385,0.000047910133,0.000115869145,4.246052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014924406,0.006946297,0.9292317,0.00010431176,0.0002623331,0.00021258894,0.006966827,0.00008070667,0.000066291184,0.000002390221,0.000017511493,0.041184638],"study_design_scores_gemma":[0.05185169,0.027153531,0.9137673,0.0002941742,0.000090890746,0.0000052817045,0.0061955396,0.00025001564,0.0002354815,0.000024364896,0.000017123986,0.000114651004],"about_ca_topic_score_codex":0.0012296245,"about_ca_topic_score_gemma":0.019181661,"teacher_disagreement_score":0.041069984,"about_ca_system_score_codex":0.00012305182,"about_ca_system_score_gemma":0.0001681922,"threshold_uncertainty_score":0.9987157},"labels":[],"label_agreement":null},{"id":"W4382799231","doi":"10.1016/j.annonc.2023.04.200","title":"P-144 Characterisation of gastric tumour microbiota using isolation culture methodology and a novel gastric tumour bioreactor system","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"3D Printing in Biomedical Research","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Chinese Academy of Medical Sciences; National Natural Science Foundation of China; Wellcome Trust","keywords":"Medicine; Isolation (microbiology); Bioreactor; Microbiology; Biology","score_opus":0.19836297302981568,"score_gpt":0.39494097266833306,"score_spread":0.19657799963851738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382799231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98171645,0.00014438058,0.017027937,0.0002521751,0.00029546637,0.00020650828,0.000056309313,0.0001149604,0.00018583432],"genre_scores_gemma":[0.98674357,0.00020123592,0.012832371,0.00002060674,0.00011541692,0.000007693875,0.000036970843,0.000025182084,0.000016944652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99853903,0.00020339632,0.0005026866,0.00020995356,0.00017329406,0.00037161077],"domain_scores_gemma":[0.9988651,0.00046727565,0.00021468404,0.00014242121,0.00021343358,0.000097084216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013708989,0.00014258122,0.0004494392,0.00057522306,0.00003538131,0.00000938429,0.00016622944,0.0002738441,0.000017100534],"category_scores_gemma":[0.00053913554,0.00013581861,0.00006477363,0.0008049468,0.00012167466,0.00008277275,0.000110857,0.00024710558,0.000014116586],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003325308,0.00003498588,0.0011392583,0.00044341158,0.000053675227,0.0000068213003,0.00032623226,0.0002356028,0.9914707,0.00011079881,0.0004375081,0.005707735],"study_design_scores_gemma":[0.0023061829,0.001971149,0.44304225,0.0006168199,0.00013200397,0.00067315355,0.0013420334,0.18692887,0.35732767,0.00017144949,0.0048820074,0.0006064269],"about_ca_topic_score_codex":0.00006249974,"about_ca_topic_score_gemma":0.0000028844293,"teacher_disagreement_score":0.63414305,"about_ca_system_score_codex":0.00007727493,"about_ca_system_score_gemma":0.00008434708,"threshold_uncertainty_score":0.55385226},"labels":[],"label_agreement":null},{"id":"W4382806705","doi":"10.1016/j.annonc.2023.04.031","title":"PD-4 Deep learning of pancreatic cancer histopathology images predicts recurrence after surgery","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Natural Science Foundation of China","keywords":"Medicine; Histopathology; Pancreatic cancer; Cancer; General surgery; Surgery; Radiology; Oncology; Internal medicine; Pathology","score_opus":0.06465485342694925,"score_gpt":0.3504452867392094,"score_spread":0.2857904333122601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382806705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525207,0.0048695263,0.03263704,0.0046082777,0.002758444,0.00023030017,0.000013497449,0.00028552947,0.0020766417],"genre_scores_gemma":[0.99463725,0.0036083318,0.0010144002,0.00025657678,0.00009406694,0.00012083013,0.0000023077475,0.000010836263,0.00025541344],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99827975,0.0004088386,0.00042674696,0.0003423873,0.0001968109,0.000345476],"domain_scores_gemma":[0.9979954,0.00094652525,0.0003969354,0.00033134036,0.00027002406,0.000059782524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010542761,0.00011686286,0.0004440413,0.00031566934,0.000053126998,0.000006776963,0.0003727424,0.00013609223,0.000052900294],"category_scores_gemma":[0.00047473493,0.00011871226,0.00010549581,0.0007141794,0.0002158904,0.00023155588,0.00021835582,0.00023188909,0.000028614437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015604825,0.00009611184,0.08897242,0.00022124604,0.00004664734,0.00015227265,0.0025253121,0.0010812811,0.003802477,0.00027615603,0.012063852,0.89060616],"study_design_scores_gemma":[0.000610195,0.0030295586,0.8495319,0.0003805361,0.00006413793,0.00011757519,0.00017426338,0.017456282,0.043580983,0.0052292063,0.07925684,0.00056852814],"about_ca_topic_score_codex":0.00014684409,"about_ca_topic_score_gemma":0.00004703032,"teacher_disagreement_score":0.89003766,"about_ca_system_score_codex":0.00006212174,"about_ca_system_score_gemma":0.00026061427,"threshold_uncertainty_score":0.48409456},"labels":[],"label_agreement":null},{"id":"W4382806764","doi":"10.1016/j.annonc.2023.04.172","title":"P-116 Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University Health Centre","keywords":"Medicine; Internal medicine; Oncology; Stage (stratigraphy); Circulating tumor DNA; Adjuvant; Cohort; Clearance; Chemotherapy; Biliary tract cancer; Clinical endpoint; Cancer; Minimal residual disease; Multiplex; Gastroenterology; Clinical trial; Urology; Bioinformatics","score_opus":0.14430903000414308,"score_gpt":0.42473309953093025,"score_spread":0.28042406952678717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382806764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956443,0.00029382855,6.479821e-7,0.0014727748,0.00018061131,0.00038821826,0.000049318518,0.000030285488,0.0019400355],"genre_scores_gemma":[0.99923396,0.000117523836,0.000034852987,0.00041226074,0.000090730246,0.000031579886,0.00002396095,0.000016494343,0.000038632515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982939,0.0001499168,0.0006653341,0.0003075301,0.0002655538,0.00031776194],"domain_scores_gemma":[0.9985977,0.00039681606,0.00028957674,0.00026350498,0.00036229877,0.0000901358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058050896,0.0001334911,0.000793867,0.00017670137,0.000026955877,0.0000018079382,0.00009440925,0.00011834589,0.00008340501],"category_scores_gemma":[0.0004079499,0.00010474644,0.00014099841,0.00055837276,0.00025408986,0.000056703433,0.000074073956,0.00026731618,0.000004859517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011958384,0.0007647158,0.968342,0.0001287146,0.00016528371,0.00008194235,0.00065166096,0.0000023917291,0.00013833276,0.0000039516935,0.0028270513,0.025698131],"study_design_scores_gemma":[0.0035611957,0.0030110052,0.99176294,0.0001483676,0.00006157857,0.0000024928063,0.0001647691,0.00005393118,0.00039091118,0.00003721278,0.0007159295,0.0000896845],"about_ca_topic_score_codex":0.0009972106,"about_ca_topic_score_gemma":0.00060144824,"teacher_disagreement_score":0.025608446,"about_ca_system_score_codex":0.000029758892,"about_ca_system_score_gemma":0.00036604868,"threshold_uncertainty_score":0.4271436},"labels":[],"label_agreement":null},{"id":"W4382806783","doi":"10.1016/j.annonc.2023.04.025","title":"O-10 Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroesophageal Junction; Nivolumab; Esophageal adenocarcinoma; Internal medicine; Chemotherapy; Cancer; Esophageal cancer; Oncology; Adenocarcinoma; Gastroenterology; Quality of life (healthcare); Immunotherapy; Nursing","score_opus":0.08965549602491214,"score_gpt":0.40085627213617087,"score_spread":0.31120077611125874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382806783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904281,0.0035659159,0.0000034660618,0.0032718454,0.00018973336,0.0015513316,0.0003712029,0.00006529271,0.0005531359],"genre_scores_gemma":[0.9964132,0.0011276281,0.00033105887,0.00025106143,0.00006878438,0.00014945802,0.00036654912,0.000057880803,0.0012344259],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9952769,0.00036946117,0.0018484243,0.0006481704,0.00092643645,0.00093057606],"domain_scores_gemma":[0.9962403,0.0003930341,0.00138139,0.0006144861,0.00088676077,0.00048398867],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011263418,0.0003796302,0.0018783098,0.0005213625,0.00007030706,0.000004800357,0.00025393744,0.00024100272,0.0005360604],"category_scores_gemma":[0.0005750223,0.00029951354,0.0002049311,0.0015116702,0.00038349035,0.00015019558,0.00009167974,0.0004066839,0.00002348358],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67102283,0.004265468,0.232484,0.0015381771,0.0015424244,0.0003056665,0.0020783886,0.0007386878,0.00015815147,0.000028986486,0.0100506125,0.07578662],"study_design_scores_gemma":[0.089099646,0.045827758,0.8618565,0.00023837492,0.00005316964,0.00000420159,0.00026124224,0.00009623494,0.002172653,0.000017487344,0.00021536548,0.00015736056],"about_ca_topic_score_codex":0.004683348,"about_ca_topic_score_gemma":0.0015388113,"teacher_disagreement_score":0.62937254,"about_ca_system_score_codex":0.000688484,"about_ca_system_score_gemma":0.003071729,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W4382806888","doi":"10.1016/j.annonc.2023.04.256","title":"P-200 Clinical outcomes of T4 and/or N2 rectal cancer after neoadjuvant chemoradiotherapy: A retrospective study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Saint-Boniface; University of Manitoba; CancerCare Manitoba","funders":"Eli Lilly Japan; Astellas Pharma; Taiho Pharmaceutical; AstraZeneca; Daiichi Sankyo Europe; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Chugai Pharmaceutical; Daiichi-Sankyo; Amgen","keywords":"Medicine; Total mesorectal excision; Colorectal cancer; Retrospective cohort study; Internal medicine; Proportional hazards model; Neoadjuvant therapy; Cumulative incidence; Chemoradiotherapy; Oncology; Incidence (geometry); Cancer; Surgery; Cohort; Breast cancer","score_opus":0.16752569585909516,"score_gpt":0.510216482467664,"score_spread":0.3426907866085689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382806888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299634,0.00060502574,5.0541166e-7,0.003612113,0.00035977256,0.00074658945,0.000049362432,0.000045887467,0.0015844104],"genre_scores_gemma":[0.9953628,0.0020716898,0.00008468863,0.0008610592,0.0001261158,0.00019811052,0.000003556658,0.000023884157,0.001268065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832755,0.00015996181,0.00060655584,0.00037213616,0.00025732708,0.0002764396],"domain_scores_gemma":[0.99873936,0.00041471305,0.00022629571,0.00025547124,0.00022093958,0.00014324195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005514231,0.00017122246,0.0013702547,0.00013646034,0.000020726566,0.0000026208972,0.0000773039,0.0001650747,0.00052880956],"category_scores_gemma":[0.00033489632,0.000116434174,0.00021813631,0.00042139986,0.00024953895,0.000039527917,0.00008724712,0.00019572562,0.000011446977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007626853,0.0016345474,0.9348657,0.0000283573,0.0009419105,0.00051875797,0.0009695246,4.3455125e-7,0.000059537746,0.000006084289,0.0013373785,0.052010894],"study_design_scores_gemma":[0.0054447753,0.019583834,0.97046125,0.000041552372,0.00014308986,0.000018817507,0.00028564816,0.000014511279,0.0002463666,0.00007549076,0.0035889607,0.00009572172],"about_ca_topic_score_codex":0.0005047734,"about_ca_topic_score_gemma":0.0006112611,"teacher_disagreement_score":0.05191517,"about_ca_system_score_codex":0.00009926607,"about_ca_system_score_gemma":0.00028453462,"threshold_uncertainty_score":0.5790094},"labels":[],"label_agreement":null},{"id":"W4382806946","doi":"10.1016/j.annonc.2023.04.507","title":"P-418 Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Feeding tube; Dysphagia; Cohort; Gastrostomy; Surgery; Retrospective cohort study; Cancer; Internal medicine; Cohort study","score_opus":0.07661949738383628,"score_gpt":0.3481553814910956,"score_spread":0.2715358841072593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382806946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775285,0.00008586318,2.870738e-7,0.00061470916,0.000071111645,0.0012179578,0.000018107761,0.000018777577,0.00022033218],"genre_scores_gemma":[0.999493,0.00003259767,0.000057437785,0.00016423785,0.00002892796,0.0000563673,0.00001190395,0.000014892425,0.00014063025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988405,0.00012761053,0.00032089461,0.00027143332,0.00019110698,0.00024843944],"domain_scores_gemma":[0.9991027,0.0002371501,0.0001506728,0.00014105104,0.0002951292,0.0000733082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002646898,0.0001238647,0.0006160116,0.00025634735,0.000022688624,0.0000029198534,0.00004464873,0.00010314775,0.000016967906],"category_scores_gemma":[0.00023270216,0.000094968564,0.000029448584,0.0004016283,0.0001679469,0.00010067231,0.00006401225,0.00016567517,0.0000025614488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017085131,0.0021781262,0.98439586,0.00009504208,0.00012468238,0.0003469805,0.0018565538,0.0000066136236,0.00074073474,0.00001165911,0.00012286344,0.00841236],"study_design_scores_gemma":[0.003180784,0.0128783565,0.9818621,0.000068054396,0.00009823978,0.0000066106136,0.00048196927,0.000021132704,0.00125086,0.00001953227,0.00006582991,0.00006650261],"about_ca_topic_score_codex":0.00040434315,"about_ca_topic_score_gemma":0.00024153244,"teacher_disagreement_score":0.0107002305,"about_ca_system_score_codex":0.000042063526,"about_ca_system_score_gemma":0.00011477819,"threshold_uncertainty_score":0.38727057},"labels":[],"label_agreement":null},{"id":"W4382806959","doi":"10.1016/j.annonc.2023.04.073","title":"P-17 Impacts of patient-reported non-hormonal symptoms on outcomes of patients with neuroendocrine neoplasms (NENs)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Medicine; Nausea; Internal medicine; Proportional hazards model; Hazard ratio; Confidence interval","score_opus":0.0368021698249518,"score_gpt":0.37474898663250605,"score_spread":0.33794681680755423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382806959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99482745,0.000023506544,6.9151633e-7,0.0023126884,0.00013128216,0.0007116131,0.00008285981,0.000043227257,0.0018667094],"genre_scores_gemma":[0.9986989,0.00012580345,0.000073991854,0.0006354361,0.000021139871,0.000027214905,0.00007753988,0.000039895614,0.00030010886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972294,0.000093125724,0.0008429002,0.0003438426,0.00088134693,0.0006093663],"domain_scores_gemma":[0.9971767,0.0005784009,0.00073517725,0.0005200156,0.00073428504,0.0002553994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010979839,0.00024176697,0.0010213498,0.00055889424,0.000028106502,0.0000024763901,0.00018180287,0.000017428572,0.000083126746],"category_scores_gemma":[0.0009690113,0.00017350976,0.00017382158,0.000664597,0.00033035417,0.00010164116,0.00014610136,0.00026231396,0.000016050859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060310443,0.0023618066,0.96235114,0.00024566535,0.0004877647,0.003475069,0.000099179175,0.00015736606,0.0034632753,0.000047676687,0.01102847,0.010251544],"study_design_scores_gemma":[0.00466879,0.041181747,0.8934522,0.00009809408,0.000065275664,0.00012781438,0.00006381292,0.000024886629,0.055855826,0.00006613346,0.0042734286,0.00012194626],"about_ca_topic_score_codex":0.000086400294,"about_ca_topic_score_gemma":0.000026415066,"teacher_disagreement_score":0.068898894,"about_ca_system_score_codex":0.000024049206,"about_ca_system_score_gemma":0.00028568282,"threshold_uncertainty_score":0.70755225},"labels":[],"label_agreement":null},{"id":"W4382807504","doi":"10.1016/j.annonc.2023.04.017","title":"O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech; Genentech; Natera; National Institutes of Health; Daiichi Sankyo Europe; National Cancer Institute; Servier; Astellas Pharma; Eisai; Pfizer; Incyte; Seagen; Plexxikon; Array BioPharma; Parker Institute for Cancer Immunotherapy; Ipsen; Mirati Therapeutics; AstraZeneca; Novocure; Sanofi; Amgen; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Agios Pharmaceuticals","keywords":"Gemcitabine; Medicine; Gallbladder cancer; Cisplatin; Interim analysis; Internal medicine; Gallbladder; Biliary tract cancer; Phases of clinical research; Oncology; Population; Biliary tract; Clinical endpoint; Chemotherapy; Gastroenterology; Clinical trial","score_opus":0.09294583844716976,"score_gpt":0.41387321356330425,"score_spread":0.3209273751161345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382807504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419826,0.00091835565,0.00001177797,0.0015942825,0.0001703774,0.0023508868,0.0004766394,0.0000305184,0.00024891467],"genre_scores_gemma":[0.99769706,0.0009788009,0.00016652014,0.00012956577,0.00009800607,0.0005085173,0.00016962596,0.000035363562,0.00021656322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981329,0.000044673743,0.00079482264,0.00037720287,0.0002959468,0.00035444277],"domain_scores_gemma":[0.9978838,0.00045845707,0.0005626964,0.0003552911,0.00063898065,0.00010077559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017640085,0.0002663253,0.0013396614,0.00025871818,0.00006765722,0.0000017213227,0.00009980766,0.000098252814,0.00006938404],"category_scores_gemma":[0.00008569988,0.00019350277,0.00018498699,0.00046358185,0.00014033313,0.000071046896,0.000043509826,0.00007648541,0.0000014906923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044430368,0.04255761,0.6505883,0.00076584594,0.0025051816,0.00008640196,0.014025823,0.0003696519,0.0016814419,0.000017397297,0.005910158,0.23706183],"study_design_scores_gemma":[0.089461215,0.16179286,0.7348037,0.00017990542,0.0007985849,0.0000027327694,0.0015631281,0.00014460142,0.0054593156,0.000036476515,0.0055417535,0.00021577044],"about_ca_topic_score_codex":0.00048757758,"about_ca_topic_score_gemma":0.001427914,"teacher_disagreement_score":0.23684606,"about_ca_system_score_codex":0.00008597544,"about_ca_system_score_gemma":0.00020522247,"threshold_uncertainty_score":0.78908134},"labels":[],"label_agreement":null},{"id":"W4382807702","doi":"10.1016/j.annonc.2023.04.015","title":"LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; Astellas Pharma; Eisai; Foundation Medicine; MacroGenics; Array BioPharma; Ipsen; BeiGene; Halozyme; Mirati Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Incyte; Taiho Pharmaceutical; Ludwig Institute for Cancer Research; Exelixis; Sanofi; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Pembrolizumab; Medicine; Lenvatinib; Microsatellite instability; Colorectal cancer; Oncology; Internal medicine; Regorafenib; DNA mismatch repair; Standard of care; Cancer; Immunotherapy; Microsatellite","score_opus":0.16982140866177262,"score_gpt":0.48178814932813474,"score_spread":0.3119667406663621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382807702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020314,0.0017464128,0.000009065383,0.0014991219,0.0007320305,0.003886839,0.000593458,0.00006218644,0.0012677163],"genre_scores_gemma":[0.9976385,0.0005433663,0.00013472622,0.00014324402,0.000115601724,0.0010582212,0.000086181644,0.000049583174,0.00023054007],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9977101,0.00023990264,0.0006872868,0.0003920944,0.0004603582,0.0005102775],"domain_scores_gemma":[0.9968554,0.0011711323,0.00043721384,0.00039939236,0.001014839,0.00012206279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005954998,0.0002630401,0.0011977627,0.00019232761,0.000115244424,0.0000070593387,0.00028156655,0.00013214372,0.00022503747],"category_scores_gemma":[0.00079671445,0.00018889217,0.00026209943,0.0005684771,0.00034208442,0.0000384983,0.00010248676,0.00020487227,0.0000065217523],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48711967,0.0038791911,0.013294733,0.0029412017,0.007147272,0.00030063654,0.071287915,0.0018741394,0.021242319,0.00021689516,0.069420494,0.32127553],"study_design_scores_gemma":[0.14994255,0.5143068,0.017287271,0.0003641339,0.003982825,0.000043426404,0.039589375,0.0009464503,0.18241622,0.00024718902,0.090132535,0.00074123277],"about_ca_topic_score_codex":0.00040223298,"about_ca_topic_score_gemma":0.0033956587,"teacher_disagreement_score":0.5104276,"about_ca_system_score_codex":0.00030464883,"about_ca_system_score_gemma":0.0017011018,"threshold_uncertainty_score":0.77027994},"labels":[],"label_agreement":null},{"id":"W4382807727","doi":"10.1016/j.annonc.2023.04.087","title":"P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medac; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Ipsen; Servier; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; National Center for Global Health and Medicine; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celgene; MacroGenics; Sanofi; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Chimeric antigen receptor; Leukapheresis; Response Evaluation Criteria in Solid Tumors; T cell; Chemotherapy; Clinical trial; Internal medicine; Oncology; Immunotherapy; Phases of clinical research; Cancer research; Pharmacology; Cancer; Immunology; Immune system; CD34; Stem cell","score_opus":0.16540892445874333,"score_gpt":0.4750678984302584,"score_spread":0.30965897397151504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382807727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99007356,0.00016063679,0.0000011905269,0.0045388355,0.00014403535,0.000926082,0.000016465552,0.00005107469,0.004088136],"genre_scores_gemma":[0.99523634,0.00060056744,0.00020598382,0.00054926396,0.0001729684,0.000033527056,0.000031136162,0.000031607255,0.003138617],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99765265,0.00035627725,0.0009180728,0.00032241183,0.00029783483,0.00045274178],"domain_scores_gemma":[0.9973729,0.0015913912,0.0003447492,0.00032495044,0.00017164687,0.00019432757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019872494,0.00015623894,0.0010342586,0.000480763,0.000057693484,0.0000031201791,0.00014178784,0.0002687736,0.0004425713],"category_scores_gemma":[0.00394545,0.00013122545,0.000109240005,0.0007788385,0.0005319811,0.00004213909,0.00015794612,0.0004905922,0.000010014718],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21761854,0.0035292208,0.0006941139,0.0003062391,0.00024849494,0.0010284387,0.005314275,0.000037998303,0.33545092,0.00010735597,0.0077299247,0.4279345],"study_design_scores_gemma":[0.5129009,0.23142038,0.031429034,0.001029164,0.00015498468,0.00032496802,0.0024501446,0.0028081492,0.08275448,0.0008051441,0.1333152,0.00060745067],"about_ca_topic_score_codex":0.00019027466,"about_ca_topic_score_gemma":0.00010143081,"teacher_disagreement_score":0.42732704,"about_ca_system_score_codex":0.00007999289,"about_ca_system_score_gemma":0.0011182919,"threshold_uncertainty_score":0.53512186},"labels":[],"label_agreement":null},{"id":"W4382807783","doi":"10.1016/j.annonc.2023.04.170","title":"P-114 The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"McGill University Health Centre","keywords":"Cancer research; Medicine; Cancer; Hepatocellular carcinoma; Pathology; Internal medicine","score_opus":0.035884509567031625,"score_gpt":0.3059503312066361,"score_spread":0.27006582163960446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382807783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497193,0.0016810352,0.000025874775,0.0011293625,0.00016318363,0.00013222877,0.000009548487,0.000006827915,0.0018800114],"genre_scores_gemma":[0.9973375,0.0017251978,0.000042151478,0.0004694252,0.000105716026,0.000011910899,0.000042030388,0.000019252157,0.00024677633],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897087,0.00016959135,0.00030226976,0.00020738586,0.000116412935,0.00023348379],"domain_scores_gemma":[0.99937195,0.000032582473,0.00015454537,0.00029685342,0.000113557304,0.000030505755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047516715,0.000104334504,0.00021457767,0.000066369284,0.000035989244,0.0000035126573,0.00032942407,0.00021698751,0.000051854877],"category_scores_gemma":[0.00006772999,0.000081611295,0.000118938304,0.0002143499,0.0002376656,0.0000028957534,0.0001260218,0.00011187487,0.00002086635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020354382,0.00010856519,0.008676365,0.000062735126,0.000054520886,0.000016084383,0.00022135861,0.000088396206,0.9744738,0.00035523242,0.0059378548,0.00980155],"study_design_scores_gemma":[0.00079137174,0.0018573992,0.010645734,0.000018244487,0.000022871687,0.000017054881,0.00081813126,0.00054387725,0.7875019,0.0008372271,0.19675972,0.00018650874],"about_ca_topic_score_codex":0.00004480546,"about_ca_topic_score_gemma":0.0000065980134,"teacher_disagreement_score":0.19082186,"about_ca_system_score_codex":0.000006973408,"about_ca_system_score_gemma":0.00016199835,"threshold_uncertainty_score":0.3328012},"labels":[],"label_agreement":null},{"id":"W4382811312","doi":"10.1016/j.annonc.2023.04.055","title":"PD-28 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bayer Canada; Ono Pharmaceutical; Servier; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Astellas Pharma; Seagen; Incyte; Bayer HealthCare; Sanofi; Natera; GlaxoSmithKline; Amgen; Pfizer; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Trk receptor; Tropomyosin; Cancer; Receptor; Oncology; Internal medicine; Cancer research; Genetics; Neurotrophin; Biology","score_opus":0.037081233268342804,"score_gpt":0.35327252833645917,"score_spread":0.3161912950681164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382811312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997539,0.00004595762,0.000021938442,0.001617379,0.00005676024,0.00047032113,0.000034547065,0.00004627637,0.00016784017],"genre_scores_gemma":[0.99852467,0.00026146177,0.00036623955,0.00018407205,0.000037809557,0.000014221232,0.00040529374,0.000019028124,0.0001872127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859005,0.00010829298,0.00045859106,0.00030673904,0.00023763483,0.0002986956],"domain_scores_gemma":[0.9990206,0.000088497356,0.0003003813,0.00023632127,0.0002317944,0.0001224242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003040069,0.00015716227,0.00070481503,0.0006808627,0.00002837088,0.0000047064773,0.00009627091,0.00006117272,0.000323762],"category_scores_gemma":[0.00006606712,0.00012815675,0.00008031362,0.001520245,0.00013059647,0.00007726018,0.00007933191,0.00014076254,0.000002491874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005814933,0.00067823764,0.9382797,0.000065074375,0.00028124987,0.000038471324,0.00016664276,0.00008668521,0.00029279615,0.000008079246,0.0011742162,0.05311391],"study_design_scores_gemma":[0.0071293227,0.006094149,0.98503876,0.00013101372,0.000410722,0.000002307015,0.00009535156,0.00007701675,0.00028740495,0.0000025526772,0.00063724484,0.000094156065],"about_ca_topic_score_codex":0.0006415647,"about_ca_topic_score_gemma":0.0012672392,"teacher_disagreement_score":0.053019755,"about_ca_system_score_codex":0.000059652462,"about_ca_system_score_gemma":0.00010504695,"threshold_uncertainty_score":0.52260804},"labels":[],"label_agreement":null},{"id":"W4382811400","doi":"10.1016/j.annonc.2023.04.033","title":"PD-6 Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastroesophageal adenocarcinoma: A phase II trial. Correlation of response with molecular and imaging test results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"EMD Serono; Merck KGaA","keywords":"Medicine; Internal medicine; Docetaxel; Perioperative; Chemotherapy regimen; Adenocarcinoma; Gastroenterology; Clinical endpoint; Chemotherapy; Surrogate endpoint; Oncology; Surgery; Cancer; Clinical trial","score_opus":0.0275218340221768,"score_gpt":0.36023837789941193,"score_spread":0.33271654387723515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382811400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906211,0.0006180918,0.0002002566,0.0071486277,0.000054362867,0.0008178144,0.000024010353,0.000023326089,0.00049243076],"genre_scores_gemma":[0.9979224,0.00020929142,0.00069553405,0.0005039012,0.000022707256,0.00003769925,0.000039405673,0.000017200284,0.0005518562],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986917,0.00013031067,0.00049360754,0.0002615913,0.00018147545,0.00024131507],"domain_scores_gemma":[0.99895996,0.00033357964,0.00025673173,0.00020436473,0.000188893,0.00005645263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076172507,0.00014295317,0.00051650574,0.0003726661,0.000039202165,0.0000047841195,0.00006994162,0.000056030356,0.000015757232],"category_scores_gemma":[0.00048584165,0.00012305264,0.000056205125,0.0005191579,0.00018338779,0.00008885536,0.000054645217,0.00014742107,0.0000015097048],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80347836,0.0016258802,0.027323108,0.00010666323,0.00018709859,0.0011493646,0.0058414587,0.0003926127,0.0515681,0.00008801221,0.0009513965,0.10728796],"study_design_scores_gemma":[0.42055413,0.090116724,0.462848,0.00037020203,0.00013594942,0.00007843332,0.0030186547,0.0029725865,0.017446173,0.000056693545,0.0021524793,0.00024997036],"about_ca_topic_score_codex":0.000034649376,"about_ca_topic_score_gemma":0.000016766699,"teacher_disagreement_score":0.43552488,"about_ca_system_score_codex":0.000046708243,"about_ca_system_score_gemma":0.00024836732,"threshold_uncertainty_score":0.5017941},"labels":[],"label_agreement":null},{"id":"W4382811670","doi":"10.1016/j.annonc.2023.04.487","title":"SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; Chugai Pharmaceutical; University of California, San Francisco; Genentech; Humanitas Research Hospital; Sirtex Medical; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Humanitas University; Ludwig-Maximilians-Universität München; Universidad de Navarra; Khon Kaen University; FibroGen; Astellas Pharma; Eisai; Kanazawa University; BeiGene; University of Ulsan; Pfizer; Incyte; Agios Pharmaceuticals; Ipsen; Clinical Trial Center, China Medical University Hospital; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Boston Scientific Corporation; Eli Lilly and Company; Chinese University of Hong Kong; Helsinn; EA Pharma Co., Ltd.; National Cancer Institute; Servier; Gilead Sciences; AstraZeneca; Kindai University","keywords":"Durvalumab; Tremelimumab; Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab","score_opus":0.2225889435793515,"score_gpt":0.3668007661172619,"score_spread":0.14421182253791043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382811670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298286,0.0009830901,0.000003928411,0.002840373,0.0002562673,0.0014206624,0.0001132713,0.000051620624,0.0013479313],"genre_scores_gemma":[0.99848884,0.00038162665,0.000051642855,0.00026644452,0.00015698677,0.0001123887,0.00023922371,0.000047484165,0.00025536344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687725,0.0006941527,0.0008323492,0.0004839056,0.0005365444,0.00057577726],"domain_scores_gemma":[0.9978629,0.0007086857,0.00031185342,0.0007046292,0.00025910768,0.0001528392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011968549,0.00029278858,0.0011552495,0.00029685235,0.00009130452,0.00001382843,0.00032338867,0.00022021613,0.00043971927],"category_scores_gemma":[0.00023091157,0.00022325099,0.00026438135,0.0007242662,0.00016674341,0.00009307336,0.00019332579,0.0003156447,0.00010019581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003331584,0.0030479438,0.9750189,0.000053826094,0.00046340714,0.0017841058,0.003524904,0.000014313551,0.00275008,0.00008581318,0.0035404202,0.006384683],"study_design_scores_gemma":[0.095365725,0.035975646,0.7813341,0.00020965473,0.0011565213,0.000036992853,0.009717185,0.020699838,0.024769608,0.0010487897,0.0289414,0.00074455945],"about_ca_topic_score_codex":0.009262611,"about_ca_topic_score_gemma":0.0014183644,"teacher_disagreement_score":0.19368483,"about_ca_system_score_codex":0.00010057141,"about_ca_system_score_gemma":0.00057654525,"threshold_uncertainty_score":0.9973348},"labels":[],"label_agreement":null},{"id":"W4385989336","doi":"10.1016/j.annonc.2023.08.003","title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Principia Biopharma; ImmunoMedics; Sierra Oncology; Loxo Oncology; Chugai Pharmaceutical; AstraZeneca; Genentech; Amgen; Science Foundation Ireland; Seagen; G1 Therapeutics; Daiichi-Sankyo; MacroGenics; Silverback Therapeutics; FibroGen; Puma Biotechnology; Novartis Pharmaceuticals Corporation; F-star Therapeutics; Aminex Therapeutics; F. Hoffmann-La Roche; Genomic Health; Menarini Silicon Biosystems; BeiGene; University of Wisconsin Carbone Cancer Center; Sun Pharma; Five Prime Therapeutics; Array BioPharma; Merck KGaA; Memorial Sloan-Kettering Cancer Center; National Institutes of Health; Natera; BioMarin Pharmaceutical; Astellas Pharma; Eisai; Daiichi Sankyo Europe; University of Wisconsin-Madison; National Breast Cancer Foundation; Incyte; Servier; Gilead Sciences; Exelixis; Jounce Therapeutics; Breast Cancer Research Foundation; Apollomics; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer","keywords":"Fulvestrant; Neratinib; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Cancer; Gastroenterology; Progressive disease; Chemotherapy; Tamoxifen","score_opus":0.09886301706774538,"score_gpt":0.4203931923658902,"score_spread":0.3215301752981448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385989336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460942,0.00068729324,0.00075573404,0.047376875,0.00028228093,0.0014941402,0.0031379687,0.00006430534,0.000107204796],"genre_scores_gemma":[0.994646,0.0006848124,0.0013835597,0.002228401,0.00020000806,0.00043372292,0.00018455199,0.000041917952,0.00019702334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977917,0.0002876837,0.00067198643,0.0004858026,0.00029737508,0.00046542977],"domain_scores_gemma":[0.9961937,0.00257448,0.0003888832,0.00035111076,0.00033949394,0.00015230414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058535323,0.0003044948,0.0013340295,0.00023446504,0.00015144225,0.000020508738,0.00017738387,0.0001173522,0.00023391374],"category_scores_gemma":[0.00021164422,0.00019802351,0.00043490267,0.0009174792,0.00048148658,0.000114390525,0.0000534442,0.00017771643,0.0000051006637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13844086,0.0016490087,0.060437813,0.00018589337,0.03691323,0.00020032167,0.006295879,0.0003840712,0.009955742,0.00050935015,0.0041866666,0.74084115],"study_design_scores_gemma":[0.06414041,0.0043917843,0.90398335,0.00012781964,0.0050056167,0.00003570381,0.0033998657,0.0013301595,0.004241595,0.003174548,0.009728864,0.00044025524],"about_ca_topic_score_codex":0.0023312157,"about_ca_topic_score_gemma":0.0028457178,"teacher_disagreement_score":0.84354556,"about_ca_system_score_codex":0.00007405975,"about_ca_system_score_gemma":0.00035859874,"threshold_uncertainty_score":0.80751646},"labels":[],"label_agreement":null},{"id":"W4386445019","doi":"10.1016/j.annonc.2023.08.011","title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Medicine; Oncology; CDKN2A; Internal medicine; Breast cancer; Clinical trial; Cancer; Palbociclib; Biomarker; Progression-free survival; Placebo; Metastatic breast cancer; Pathology; Overall survival; Genetics; Biology","score_opus":0.14263278148074146,"score_gpt":0.499450519089931,"score_spread":0.35681773760918956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386445019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98069066,0.0021876819,0.00024314747,0.014229055,0.00027798864,0.00051460444,0.0008049851,0.00009322303,0.0009586388],"genre_scores_gemma":[0.9949136,0.002105489,0.00035449985,0.0014185632,0.0001799988,0.00012151399,0.00012750298,0.000029220942,0.00074962183],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997612,0.0002134636,0.0010944688,0.00034309283,0.00033816803,0.00039882088],"domain_scores_gemma":[0.9972306,0.0006535652,0.0008845429,0.000428665,0.0006409203,0.00016169764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011245506,0.00020553153,0.0023412374,0.0008847318,0.00003554488,0.000002226201,0.00016846547,0.00015975742,0.0013991562],"category_scores_gemma":[0.00030613033,0.00017365378,0.0006152865,0.0023235334,0.00024700732,0.00010551305,0.000058181893,0.00014887287,0.00001343416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012755961,0.00085969584,0.0023599167,0.00010086315,0.0098051615,0.00006356699,0.00070426444,0.002235409,0.15961307,0.0002517254,0.0015579914,0.8096924],"study_design_scores_gemma":[0.11044344,0.011792818,0.3226848,0.00079732586,0.026478792,0.00016755065,0.0038819897,0.005093062,0.2806086,0.0033003923,0.23339014,0.0013611006],"about_ca_topic_score_codex":0.00019515274,"about_ca_topic_score_gemma":0.000130931,"teacher_disagreement_score":0.80833125,"about_ca_system_score_codex":0.00007140097,"about_ca_system_score_gemma":0.00041179653,"threshold_uncertainty_score":0.9995137},"labels":[],"label_agreement":null},{"id":"W4386784388","doi":"10.1016/j.annonc.2023.08.007","title":"VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology","keywords":"Medicine; Internal medicine; Hospital Anxiety and Depression Scale; Quality of life (healthcare); Population; Anxiety; Aromatase inhibitor; Physical therapy; Breast cancer; Cancer; Psychiatry; Tamoxifen","score_opus":0.07369785635320222,"score_gpt":0.40994183603148554,"score_spread":0.33624397967828334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909701,0.0008989961,0.0000042003635,0.0046954188,0.00016425127,0.0021336975,0.001055798,0.000036051806,0.00004153483],"genre_scores_gemma":[0.9982123,0.00013500609,0.000040597657,0.0010473193,0.00005957481,0.00023845836,0.0001844914,0.000044381104,0.00003789452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995208,0.0008850989,0.0019820323,0.00052543666,0.000772844,0.00062657753],"domain_scores_gemma":[0.99686646,0.00043285525,0.0013917027,0.00065729883,0.00044990628,0.00020179976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016895203,0.00033735385,0.0019777776,0.00049145153,0.000054341544,0.000004756998,0.0003439924,0.00019694759,0.000050021823],"category_scores_gemma":[0.00015992968,0.0002506856,0.000116362,0.001473489,0.00047195624,0.00019565677,0.00013502616,0.0005327771,0.000008837269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14425719,0.031135326,0.6687716,0.0010693517,0.0013140513,0.0003872663,0.06493743,0.0008900916,0.0017138921,0.000048113074,0.0023064343,0.08316926],"study_design_scores_gemma":[0.07410918,0.018419068,0.89831525,0.00053919264,0.0000609196,0.000025152833,0.0076474748,0.00005411115,0.00029027465,0.000051691837,0.00025330216,0.00023440589],"about_ca_topic_score_codex":0.021560533,"about_ca_topic_score_gemma":0.013756418,"teacher_disagreement_score":0.22954363,"about_ca_system_score_codex":0.00023801436,"about_ca_system_score_gemma":0.0010701388,"threshold_uncertainty_score":0.9999945},"labels":[],"label_agreement":null},{"id":"W4387339999","doi":"10.1016/j.annonc.2023.09.3110","title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"MSD Italia; Eisai; Incyte; AstraZeneca; Les Laboratories Pierre Fabre; Gilead Sciences; Clovis Oncology; Servier; Pfizer","keywords":"Medicine; Olaparib; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Cancer; Poly ADP ribose polymerase; Polymerase; Genetics","score_opus":0.07819275097947659,"score_gpt":0.3885708198044928,"score_spread":0.31037806882501623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387339999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905146,0.000109288776,0.000033334454,0.005151385,0.00023435126,0.0028363306,0.00019120268,0.00013727622,0.0022553778],"genre_scores_gemma":[0.9959186,0.00060326286,0.00037552667,0.0013699591,0.00029134302,0.0008215135,0.00020758386,0.00007426316,0.0003379937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970337,0.00034167647,0.0007958008,0.000634626,0.00047120184,0.00072298443],"domain_scores_gemma":[0.9977306,0.00033928704,0.00059852743,0.00044340707,0.0006605024,0.00022766968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006843665,0.00035760688,0.0011424698,0.0004254834,0.00006964114,0.000008516406,0.000120670906,0.00030565544,0.00012329864],"category_scores_gemma":[0.00020171881,0.00026968823,0.000111574074,0.001093835,0.00032417045,0.00014893022,0.000037283506,0.00049272116,0.00002321066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86092806,0.006556646,0.028253512,0.00023106707,0.0011862846,0.0012805989,0.0074007353,0.00014605503,0.0031777069,0.0003119819,0.02296311,0.06756425],"study_design_scores_gemma":[0.8084946,0.08856959,0.0631471,0.0031041454,0.0002985123,0.00005528786,0.00079628173,0.00020275112,0.015822837,0.00018020795,0.018482083,0.0008465886],"about_ca_topic_score_codex":0.00040420707,"about_ca_topic_score_gemma":0.00075618044,"teacher_disagreement_score":0.082012944,"about_ca_system_score_codex":0.00034484122,"about_ca_system_score_gemma":0.00078223814,"threshold_uncertainty_score":0.9999755},"labels":[],"label_agreement":null},{"id":"W4387652542","doi":"10.1016/j.annonc.2023.10.001","title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; Queen's University; University Health Network","funders":"Foundation Medicine; Genentech; Gilead Sciences; Servier; European Society for Medical Oncology; Eisai; Astellas Pharma; Nordic Pharma Group; Clovis Oncology; National Institute for Health and Care Research; Sirtex Medical; Cancer Research UK; Seagen; Cilag; Puma Biotechnology; Pfizer; Incyte; Ipsen; AstraZeneca; Associazione Italiana di Oncologia Medica; European Commission; Sanofi; Amgen; Les Laboratories Pierre Fabre; Eli Lilly and Company","keywords":"Medicine; Real world evidence; Multidisciplinary approach; Expert opinion; Oncology; Medical education; Internal medicine; Intensive care medicine","score_opus":0.8580284612856468,"score_gpt":0.6253593534122207,"score_spread":0.2326691078734261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387652542","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.418147,0.0036079192,0.0028595885,0.4627894,0.0038092406,0.0025456152,0.00035221572,0.00034751967,0.10554151],"genre_scores_gemma":[0.92250115,0.0043919515,0.015355336,0.042437673,0.0018157911,0.0012025951,0.00009986955,0.000115969146,0.01207966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98812664,0.00044850347,0.00986093,0.000728326,0.00009530691,0.00074029557],"domain_scores_gemma":[0.9780837,0.007448182,0.013278594,0.0006614672,0.0003365226,0.0001915252],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.056237552,0.00019663262,0.0019022699,0.00065604754,0.00018993876,0.000020016974,0.0004423292,0.0002962327,0.00023360549],"category_scores_gemma":[0.04288564,0.00025696037,0.0002880641,0.000609757,0.00017337661,0.00039860109,0.0001234325,0.00019430701,0.0011667527],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001369505,0.00020881742,0.081635244,0.0009244826,0.00017686315,0.000021051876,0.0020474594,0.00046285984,0.00006627905,0.21195598,0.69163644,0.0107275965],"study_design_scores_gemma":[0.0007175168,0.0013353664,0.083579816,0.00022080076,0.000011101089,0.000011140171,0.0006061173,0.003010953,0.00015557722,0.059821066,0.85018677,0.00034378897],"about_ca_topic_score_codex":0.0021018265,"about_ca_topic_score_gemma":0.0017200668,"teacher_disagreement_score":0.5043542,"about_ca_system_score_codex":0.0004745397,"about_ca_system_score_gemma":0.000792103,"threshold_uncertainty_score":0.99998826},"labels":[],"label_agreement":null},{"id":"W4387807073","doi":"10.1016/j.annonc.2023.09.1014","title":"2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Seagen","keywords":"Medicine; Cystectomy; Bladder cancer; Urology; Internal medicine; Clinical endpoint; Cohort; Tolerability; Perioperative; Neoadjuvant therapy; Oncology; Gastroenterology; Cancer; Surgery; Adverse effect; Clinical trial","score_opus":0.09810588048068886,"score_gpt":0.4205012147464612,"score_spread":0.3223953342657723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875151,0.0004187997,0.0000019944014,0.0014927271,0.0003511923,0.0030778707,0.00014314397,0.000073712654,0.006925482],"genre_scores_gemma":[0.9909276,0.0035151776,0.0000492107,0.0013489148,0.00015734718,0.0014567232,0.00014285972,0.00006719502,0.0023349829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735814,0.00022008107,0.00076738774,0.00064766704,0.00039095455,0.0006157565],"domain_scores_gemma":[0.9985855,0.00022228045,0.0002551991,0.00044157662,0.00029394426,0.00020148171],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024228895,0.00041541824,0.0011177927,0.00041323368,0.000106150124,0.000015421954,0.00016025592,0.00020993053,0.0007256435],"category_scores_gemma":[0.0000690839,0.00033299386,0.00019413269,0.0006857319,0.00012769543,0.00013983432,0.000043617823,0.00020003565,0.000105708554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026706376,0.006742041,0.8800551,0.000040332998,0.0014660391,0.00030031148,0.0148559455,0.00021803849,0.0017066037,0.000025923882,0.0034672567,0.08845174],"study_design_scores_gemma":[0.023925405,0.029582113,0.9190105,0.00010780787,0.00029720477,0.0000052180867,0.0029542686,0.000091166294,0.012133526,0.00007183524,0.011470114,0.00035083925],"about_ca_topic_score_codex":0.00582849,"about_ca_topic_score_gemma":0.0044133924,"teacher_disagreement_score":0.0881009,"about_ca_system_score_codex":0.0003764643,"about_ca_system_score_gemma":0.0011868017,"threshold_uncertainty_score":0.9999122},"labels":[],"label_agreement":null},{"id":"W4387807077","doi":"10.1016/j.annonc.2023.09.1023","title":"2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Surrogate endpoint; Phases of clinical research; Progression-free survival; Oncology; Refractory (planetary science); Chemotherapy regimen; Gastroenterology; Cancer; Urology; Clinical trial; Surgery; Chemotherapy","score_opus":0.1815938663050468,"score_gpt":0.4683965966881169,"score_spread":0.2868027303830701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96743965,0.002833556,0.0009910312,0.0067431564,0.002150153,0.008323588,0.0024554038,0.00023889523,0.008824552],"genre_scores_gemma":[0.9831113,0.0041513722,0.0030976965,0.001409222,0.0005277965,0.0017221585,0.00019305937,0.00013158214,0.0056558014],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99740773,0.00012344275,0.0008604682,0.0005137774,0.00038904324,0.0007055306],"domain_scores_gemma":[0.9977003,0.0006311913,0.00045101225,0.0004183617,0.00056414324,0.00023500291],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039811066,0.00033515148,0.0013306784,0.00031764948,0.0000748485,0.000007825728,0.00020393549,0.00017878175,0.000588474],"category_scores_gemma":[0.00057638495,0.00025863893,0.00034291568,0.00069759926,0.00024715837,0.00015244428,0.000054790093,0.00016586733,0.000020664125],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40832204,0.010472453,0.000104314255,0.00077846134,0.0015431358,0.00022510307,0.00057099573,0.00036786246,0.04599229,0.00016111867,0.009466092,0.52199614],"study_design_scores_gemma":[0.32973117,0.19746321,0.000099392906,0.00051341066,0.0011754887,0.000047120186,0.00035901606,0.00045067776,0.28471497,0.0012923079,0.1837275,0.00042573427],"about_ca_topic_score_codex":0.0002827727,"about_ca_topic_score_gemma":0.00033400816,"teacher_disagreement_score":0.5215704,"about_ca_system_score_codex":0.00012407426,"about_ca_system_score_gemma":0.0014689183,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W4387807145","doi":"10.1016/j.annonc.2023.09.1020","title":"2371P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Gilead Sciences; Pfizer","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Progression-free survival; Adverse effect; Maintenance therapy; Chemotherapy; Oncology; Surgery; Urology; Randomized controlled trial; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.10137632114983085,"score_gpt":0.39086171173493095,"score_spread":0.2894853905851001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810166,0.00024896086,0.00007066043,0.012934217,0.001297844,0.0032174105,0.00063104206,0.000051994084,0.00053129235],"genre_scores_gemma":[0.9925144,0.0004277845,0.00013816147,0.0039656344,0.00049766485,0.00067514717,0.00035849932,0.000060373473,0.0013623658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997616,0.000117953896,0.00078482577,0.00051978335,0.00032997236,0.0006314527],"domain_scores_gemma":[0.9978622,0.00089813536,0.00028761968,0.00050796365,0.00031274345,0.00013130374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033625515,0.00031814227,0.0009321832,0.00015655474,0.000099641984,0.000010332939,0.00028642153,0.00025447112,0.00032392397],"category_scores_gemma":[0.00053538807,0.00021565724,0.0003415705,0.00030380097,0.00016425975,0.00008914721,0.00010145953,0.00023449004,0.00008169727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088388465,0.004124542,0.68352723,0.00013670004,0.0008219995,0.0001855178,0.0025634326,0.000045642137,0.00018765901,0.00007107234,0.026888574,0.19305916],"study_design_scores_gemma":[0.1551811,0.007223844,0.8268426,0.00011706963,0.00017790198,0.0000029894325,0.000108457934,0.00005829066,0.0010954062,0.00045296882,0.008517901,0.00022146548],"about_ca_topic_score_codex":0.000596617,"about_ca_topic_score_gemma":0.0011945772,"teacher_disagreement_score":0.1928377,"about_ca_system_score_codex":0.000120522156,"about_ca_system_score_gemma":0.0003925947,"threshold_uncertainty_score":0.8794247},"labels":[],"label_agreement":null},{"id":"W4387807199","doi":"10.1016/j.annonc.2023.09.1010","title":"2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Health Sciences Centre; London Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Ottawa; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"Astellas Pharma Canada; AstraZeneca","keywords":"Medicine; Positron emission tomography; Bladder cancer; Pet imaging; Nuclear medicine; Radiology; Preclinical imaging; Cancer; Internal medicine; In vivo","score_opus":0.055383504919857426,"score_gpt":0.4118716535591241,"score_spread":0.35648814863926664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892894,0.0006917917,0.000004646472,0.0021938174,0.00019929973,0.00037628782,0.00017222387,0.00004658643,0.00702596],"genre_scores_gemma":[0.9969974,0.0019477225,0.00007658705,0.00058233045,0.000108020606,0.000030798787,0.00004261412,0.000038349048,0.00017617669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833304,0.00009982411,0.00050490926,0.00031524216,0.00032834688,0.0004186413],"domain_scores_gemma":[0.99848485,0.0002546474,0.00037931124,0.00034750302,0.00036342943,0.00017028865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002456873,0.00022897836,0.0007456341,0.0005930853,0.000043765765,0.000003694939,0.00014221361,0.00006729192,0.00026214198],"category_scores_gemma":[0.00008816416,0.00018024795,0.00043277693,0.0006681435,0.00016611499,0.00008703192,0.0000654144,0.00017724604,0.0000072358516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033669353,0.001864393,0.45441052,0.00063419493,0.0024866124,0.00066655193,0.0029831047,0.00026637208,0.35352963,0.00006694371,0.04275342,0.1369713],"study_design_scores_gemma":[0.0057214717,0.010333107,0.6906152,0.001126358,0.00053774164,0.000049577517,0.00083139265,0.00011700356,0.28774613,0.00054169714,0.0020795302,0.00030082575],"about_ca_topic_score_codex":0.0028522615,"about_ca_topic_score_gemma":0.00005992073,"teacher_disagreement_score":0.23620464,"about_ca_system_score_codex":0.000100419835,"about_ca_system_score_gemma":0.000727814,"threshold_uncertainty_score":0.7350298},"labels":[],"label_agreement":null},{"id":"W4387807622","doi":"10.1016/j.annonc.2023.09.911","title":"2129P Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Lung function; Physical exercise; Physical therapy; Oncology; Lung; Internal medicine","score_opus":0.07001042844266572,"score_gpt":0.4532161222704635,"score_spread":0.3832056938277978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500924,0.000107408254,0.000028533499,0.0024916716,0.00040284108,0.001704339,0.00009630327,0.000036238067,0.00012343512],"genre_scores_gemma":[0.9982352,0.00008476688,0.00004567042,0.0005350369,0.00007757609,0.0008007029,0.00007980295,0.000013876275,0.00012734752],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99899685,0.000038323033,0.00031202298,0.00023932618,0.00017043597,0.00024302704],"domain_scores_gemma":[0.9990557,0.00012364368,0.000114112896,0.00016225594,0.00044413097,0.000100184276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024462765,0.00009678082,0.00049095094,0.00013021048,0.000014235727,0.0000014197866,0.00006249465,0.000086459295,0.000015559144],"category_scores_gemma":[0.0001799055,0.00008865049,0.00013274113,0.0004799349,0.000057954232,0.000043331893,0.000053186046,0.00008227414,0.0000023951307],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009603599,0.0020880867,0.13583711,0.00044776243,0.000051100786,0.0000032887358,0.0016773364,0.00017937591,0.0028342719,0.00005564315,0.0034403864,0.84378207],"study_design_scores_gemma":[0.011126282,0.034323163,0.90593624,0.0007182816,0.00022689009,5.091445e-7,0.0009136125,0.0023822454,0.018945903,0.00091306766,0.02422541,0.0002883995],"about_ca_topic_score_codex":0.00034532443,"about_ca_topic_score_gemma":0.002478333,"teacher_disagreement_score":0.84349364,"about_ca_system_score_codex":0.00006720752,"about_ca_system_score_gemma":0.00018344271,"threshold_uncertainty_score":0.3615062},"labels":[],"label_agreement":null},{"id":"W4387807931","doi":"10.1016/j.annonc.2023.09.742","title":"1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Oncology; Gene signature; Internal medicine; Distributed File System; Population; Atezolizumab; Breast cancer; Stage (stratigraphy); Adjuvant; Cancer; Database; Immunotherapy; Gene expression; Gene; Nivolumab; Biology","score_opus":0.026648757947546987,"score_gpt":0.3415231081374804,"score_spread":0.31487435018993337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966796,0.000359963,0.0000142109475,0.0011185925,0.00007200101,0.00054232636,0.00087731495,0.00007378597,0.00026219877],"genre_scores_gemma":[0.9960752,0.0004579846,0.00007728963,0.00020064741,0.000041219497,0.00007683615,0.0027528931,0.00006558293,0.00025234316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697745,0.0004171995,0.0006916401,0.00058058044,0.00073297706,0.00060015346],"domain_scores_gemma":[0.9971278,0.00033591202,0.00067620876,0.0005084366,0.00097535184,0.00037631718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003516025,0.0003403681,0.0013328707,0.0007955613,0.00007946765,0.000009558484,0.00029601963,0.00028979106,0.00014685834],"category_scores_gemma":[0.00067053374,0.00023181285,0.00016200193,0.0028178561,0.00031011118,0.000108544475,0.00013184297,0.00056137634,0.000002346874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03240049,0.0024196766,0.8977373,0.00042129704,0.0035003312,0.0009063514,0.003965495,0.0027732449,0.022723017,0.0000033608796,0.023674719,0.009474709],"study_design_scores_gemma":[0.027679762,0.021398453,0.9116403,0.002678185,0.0027112341,0.0000029506011,0.0045756698,0.0031239649,0.024543969,0.000017116117,0.00087019324,0.0007581926],"about_ca_topic_score_codex":0.0010310062,"about_ca_topic_score_gemma":0.0011634969,"teacher_disagreement_score":0.022804525,"about_ca_system_score_codex":0.0002263631,"about_ca_system_score_gemma":0.00073343224,"threshold_uncertainty_score":0.94530535},"labels":[],"label_agreement":null},{"id":"W4387808158","doi":"10.1016/j.annonc.2023.09.731","title":"1198P Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Adverse effect; Neuroendocrine tumors; Internal medicine; Nuclear medicine; Toxicity; Phases of clinical research; Gastroenterology; Radionuclide therapy; Oncology","score_opus":0.08680295144206697,"score_gpt":0.4498335621748774,"score_spread":0.36303061073281045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321294,0.00019574656,0.0000048457027,0.0046916986,0.00013927968,0.001577369,0.000063710664,0.000032766784,0.000081664446],"genre_scores_gemma":[0.9982365,0.0011388971,0.00008295089,0.00020261353,0.000074285526,0.000089888636,0.0000424774,0.000034435932,0.000097989396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969839,0.00048446373,0.0011056255,0.00037194334,0.00048118623,0.00057289517],"domain_scores_gemma":[0.99812686,0.00051738636,0.0006308203,0.00037831013,0.00019482704,0.00015181102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045303305,0.0002303578,0.0009258009,0.0005126432,0.00005507879,0.000008906196,0.00018322552,0.000018460758,0.00006401212],"category_scores_gemma":[0.0010743586,0.00017267987,0.00017758681,0.00075818563,0.0005471747,0.00017528597,0.00013439481,0.0003514701,0.0000025130682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48874757,0.014260816,0.14132853,0.0013479234,0.0003914894,0.007475725,0.0010465834,0.00010496387,0.17664,0.00005875082,0.0020656928,0.16653194],"study_design_scores_gemma":[0.3375321,0.071627274,0.32005507,0.0013447895,0.00018749291,0.0021127,0.0009828145,0.0007481619,0.2586799,0.0002464363,0.006132092,0.00035115992],"about_ca_topic_score_codex":0.00007039296,"about_ca_topic_score_gemma":0.00007642722,"teacher_disagreement_score":0.17872654,"about_ca_system_score_codex":0.000037139078,"about_ca_system_score_gemma":0.00024031353,"threshold_uncertainty_score":0.704168},"labels":[],"label_agreement":null},{"id":"W4387808212","doi":"10.1016/j.annonc.2023.09.657","title":"481P Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cochrane Library; Internal medicine; Oncology; Breast cancer; Meta-analysis; Adverse effect; Estrogen receptor; Nausea; Randomized controlled trial; Cancer","score_opus":0.6932043071277709,"score_gpt":0.6183950127801529,"score_spread":0.07480929434761807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045730398,0.99221134,0.000008498073,0.0019861204,0.00009933002,0.004255652,0.0013527453,0.000018453351,0.000022132725],"genre_scores_gemma":[0.000034233395,0.9963479,0.00032247746,0.0010478212,0.000120315446,0.0016007056,0.00023286766,0.000057344798,0.00023631428],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98698467,0.005917381,0.005797119,0.0006682166,0.00031375422,0.00031886564],"domain_scores_gemma":[0.99030703,0.0028220338,0.005526876,0.00054130115,0.0006392788,0.00016347134],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010486491,0.00049325137,0.033323452,0.0008099254,0.000021841339,0.0000052992077,0.00021112307,0.0005768617,0.0006332017],"category_scores_gemma":[0.0022134092,0.0003262053,0.0041754767,0.0019775755,0.00022416918,0.000081986975,0.0000613086,0.0005102847,0.0000072392186],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011682606,0.00018802947,0.00001825254,0.5338112,0.3478371,0.0000116976935,0.000073217736,0.0000035685043,0.0000030040017,0.000034112694,0.00096086564,0.11694213],"study_design_scores_gemma":[0.0006695303,0.00059114356,0.000022967914,0.027857676,0.92762405,0.000070808164,0.000047940823,0.000011091531,0.0000061883993,0.000019794108,0.042823855,0.00025494536],"about_ca_topic_score_codex":0.00017860488,"about_ca_topic_score_gemma":0.0006648495,"teacher_disagreement_score":0.57978696,"about_ca_system_score_codex":0.00016200508,"about_ca_system_score_gemma":0.0014891634,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W4387808477","doi":"10.1016/j.annonc.2023.09.528","title":"332P Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Washington University School of Medicine in St. Louis; Sidney Kimmel Comprehensive Cancer Center; University of California, San Francisco; University of North Carolina at Chapel Hill; University College Cork; University of Alberta; University of Washington; Translational Breast Cancer Research Consortium; Alvin J. Siteman Cancer Center; Johns Hopkins University; Vanderbilt University","keywords":"Medicine; Cohort; Breast cancer; Cancer; Radiomics; Receiver operating characteristic; Oncology; Internal medicine; Radiology","score_opus":0.03568004504754973,"score_gpt":0.39498891432643835,"score_spread":0.3593088692788886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642214,0.00014257716,0.000052514413,0.034287523,0.00021815056,0.00083920953,0.00007761443,0.00005051558,0.000110451816],"genre_scores_gemma":[0.9977005,0.0005104486,0.00013947536,0.0008675143,0.00021353005,0.00017352347,0.00003607444,0.00003548308,0.00032343506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981077,0.00018541097,0.0005436386,0.00038383878,0.00040171208,0.00037769924],"domain_scores_gemma":[0.99897486,0.00016590429,0.00022203317,0.00019763332,0.00026605016,0.00017353157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009805183,0.00016697613,0.0006541533,0.00033507886,0.00004171361,0.000006412187,0.0001388345,0.00012142314,0.00019153653],"category_scores_gemma":[0.00019905827,0.00014860774,0.00008017946,0.00046805936,0.00012422078,0.000048296755,0.00004886136,0.0004728667,0.000007978551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013958047,0.0007290419,0.939911,0.00006507359,0.0002300494,0.00006525222,0.001920054,0.005887527,0.010075341,9.586075e-7,0.0120181665,0.027701752],"study_design_scores_gemma":[0.0057419916,0.0022838446,0.9685389,0.00024529133,0.00008300298,0.000005559385,0.0004996734,0.01563347,0.00083408994,0.0000023991877,0.0060277428,0.000104077575],"about_ca_topic_score_codex":0.012437331,"about_ca_topic_score_gemma":0.00024064262,"teacher_disagreement_score":0.033479072,"about_ca_system_score_codex":0.000106455744,"about_ca_system_score_gemma":0.00024825992,"threshold_uncertainty_score":0.99413896},"labels":[],"label_agreement":null},{"id":"W4387808479","doi":"10.1016/j.annonc.2023.09.505","title":"309P Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Breast cancer; Oncology; Immune system; Internal medicine; Tumor microenvironment; Tissue microarray; CD8; Multiplex; Hazard ratio; Cancer; Immunology; Confidence interval; Bioinformatics; Biology","score_opus":0.024394042977783827,"score_gpt":0.31563212478390423,"score_spread":0.29123808180612043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953712,0.00012637813,0.00012793177,0.0021214958,0.00019806206,0.0020004322,0.000029655732,0.000016663895,0.000008180371],"genre_scores_gemma":[0.99913424,0.00031865123,0.0000143311445,0.00012277659,0.000072920775,0.00012559025,0.00010662016,0.000025221738,0.00007966253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997664,0.0006913246,0.0008126476,0.00026927557,0.00031817477,0.00024457762],"domain_scores_gemma":[0.9984823,0.00028555683,0.00085617823,0.00021826276,0.00008236492,0.00007537694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013558011,0.00017328668,0.0011343244,0.0002288518,0.00007155374,0.0000042348224,0.000107532476,0.00008161318,0.000029918212],"category_scores_gemma":[0.0003221145,0.000118667806,0.0001372382,0.00028220945,0.00040278505,0.00003208033,0.00009371737,0.00032958706,5.307105e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5706409,0.0017956526,0.18387978,0.00012096552,0.00023209056,0.000056810415,0.0015811482,0.0004076977,0.22638923,9.467359e-7,0.000008354533,0.014886424],"study_design_scores_gemma":[0.5518157,0.0040727383,0.42097342,0.00023770037,0.00020598967,0.000020429148,0.000035684985,0.017444296,0.005065891,0.0000011004557,0.000043238186,0.00008384545],"about_ca_topic_score_codex":0.003302952,"about_ca_topic_score_gemma":0.00072270154,"teacher_disagreement_score":0.23709364,"about_ca_system_score_codex":0.00006432694,"about_ca_system_score_gemma":0.00015423395,"threshold_uncertainty_score":0.49930975},"labels":[],"label_agreement":null},{"id":"W4387808506","doi":"10.1016/j.annonc.2023.09.572","title":"395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Interim analysis; Population; Breast cancer; Phases of clinical research; Cancer; Gastroenterology; Oncology; Toxicity; Clinical trial","score_opus":0.0466354699439815,"score_gpt":0.4023210216354885,"score_spread":0.355685551691507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574894,0.000082776125,0.000052000225,0.00086397975,0.000055943594,0.0019565981,0.0011493386,0.000016046513,0.000074363976],"genre_scores_gemma":[0.9985671,0.00014823167,0.00033805586,0.000078586956,0.000008371701,0.0006377746,0.00014245458,0.00003301962,0.000046414087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734837,0.00050147524,0.0009328025,0.00044176113,0.00039023702,0.00038534938],"domain_scores_gemma":[0.9977506,0.0003558519,0.00073848054,0.00045787822,0.00059438136,0.000102831844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029461016,0.00031665762,0.0012642083,0.0006291384,0.000055416553,0.0000033704443,0.00023372096,0.00008011975,0.00010624233],"category_scores_gemma":[0.000076071774,0.00022525196,0.00018790043,0.0023473536,0.00046006433,0.00014401623,0.000096940246,0.00020471204,0.0000016616249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028972417,0.08454085,0.52058446,0.00024671928,0.0076821316,0.00016993601,0.028928785,0.024181284,0.0037629595,0.00006718688,0.000044548357,0.30081874],"study_design_scores_gemma":[0.048170794,0.06987012,0.85146964,0.0008431876,0.0012272018,0.000013629363,0.011544143,0.00042011307,0.01586293,0.00019369878,0.00008721431,0.00029732846],"about_ca_topic_score_codex":0.00819593,"about_ca_topic_score_gemma":0.010886143,"teacher_disagreement_score":0.3308852,"about_ca_system_score_codex":0.00049084495,"about_ca_system_score_gemma":0.0005797366,"threshold_uncertainty_score":0.99840856},"labels":[],"label_agreement":null},{"id":"W4387809013","doi":"10.1016/j.annonc.2023.09.478","title":"281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: A meta-analysis of randomized clinical trials","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca; Amgen","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Hormonal therapy; Meta-analysis; Cancer","score_opus":0.22178342434744358,"score_gpt":0.48070566826926253,"score_spread":0.25892224392181895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96446365,0.0017543011,0.000514745,0.022771295,0.0003544198,0.0050966907,0.004806764,0.00011866387,0.00011946717],"genre_scores_gemma":[0.9919063,0.0024229886,0.0015057403,0.0011228953,0.0004514943,0.0017171531,0.0003796073,0.00008638862,0.00040746582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99052405,0.0039263335,0.003367387,0.00080997485,0.00071414106,0.00065811165],"domain_scores_gemma":[0.9804986,0.0134405745,0.0030814759,0.0004794074,0.0021673858,0.00033253862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007480951,0.0005568974,0.01017629,0.0008856165,0.000121876,0.000013065716,0.0002921616,0.0002949323,0.0013158836],"category_scores_gemma":[0.0023206568,0.00036462647,0.004544039,0.001247651,0.0011236218,0.00019803659,0.00008141921,0.0004308725,0.0000069862117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5799559,0.0018831907,0.00584862,0.000093888266,0.34727776,0.00003562132,0.0011197206,0.000077845485,0.021435248,0.0005850411,0.001410655,0.040276516],"study_design_scores_gemma":[0.51449096,0.02891238,0.100610584,0.0001282582,0.14944644,0.000028830545,0.0007588169,0.00013350866,0.20070013,0.001960806,0.001751858,0.0010774239],"about_ca_topic_score_codex":0.00093541184,"about_ca_topic_score_gemma":0.00015794863,"teacher_disagreement_score":0.19783132,"about_ca_system_score_codex":0.00010911908,"about_ca_system_score_gemma":0.0005377582,"threshold_uncertainty_score":0.99988055},"labels":[],"label_agreement":null},{"id":"W4387809545","doi":"10.1016/j.annonc.2023.10.060","title":"LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Lung cancer; Exon; Internal medicine; non-small cell lung cancer (NSCLC); Gene; A549 cell; Genetics","score_opus":0.029553060566340852,"score_gpt":0.41125183984126906,"score_spread":0.38169877927492823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97442853,0.0014537363,0.00004484741,0.01431656,0.00031595325,0.0058552097,0.00050660275,0.00012806548,0.0029504937],"genre_scores_gemma":[0.9779156,0.013734346,0.00030592666,0.0030179184,0.0001654564,0.0014193832,0.001334953,0.000060077746,0.0020463464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997018,0.00021522475,0.0011737896,0.00073964085,0.00030317204,0.0005502024],"domain_scores_gemma":[0.9979333,0.00051415653,0.00056514994,0.00049759954,0.0002803484,0.00020943888],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004061477,0.00045793352,0.001932845,0.0002383586,0.00010608479,0.00001386182,0.00016408094,0.00022441219,0.0001736938],"category_scores_gemma":[0.00007007602,0.00035811673,0.00030256732,0.0007780659,0.0001240324,0.00010990389,0.00003852156,0.00015655362,0.000022334541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8051337,0.019242223,0.008530708,0.00012783885,0.004198407,0.0011056187,0.023443794,0.002451872,0.005239594,0.000005440712,0.004981996,0.12553883],"study_design_scores_gemma":[0.94649583,0.01305259,0.021337032,0.00029025105,0.0008803392,0.00000830623,0.0012888935,0.0022416967,0.0074588875,0.00013032476,0.006450239,0.00036560683],"about_ca_topic_score_codex":0.013467958,"about_ca_topic_score_gemma":0.005142903,"teacher_disagreement_score":0.14136216,"about_ca_system_score_codex":0.0013702207,"about_ca_system_score_gemma":0.0017056246,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W4387809547","doi":"10.1016/j.annonc.2023.10.087","title":"LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; Astellas Pharma; National Evidence-based Healthcare Collaborating Agency; Sanofi; AstraZeneca; Pfizer","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Oncology; Abiraterone; Homologous recombination; Internal medicine; Cancer research; Gene; Cancer; Androgen deprivation therapy; Genetics; Androgen receptor; Biology","score_opus":0.0732502613041532,"score_gpt":0.36291371368569875,"score_spread":0.28966345238154556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396557,0.0009181713,0.00009234659,0.0034528838,0.000043242355,0.0012149863,0.00020825653,0.00005006842,0.00005445814],"genre_scores_gemma":[0.98889047,0.0072805164,0.0025102352,0.00041824073,0.000021361791,0.00038297614,0.0003546228,0.00003297795,0.00010857337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978938,0.00018990118,0.0007255186,0.0004901871,0.00037376073,0.0003268141],"domain_scores_gemma":[0.9981942,0.00013835741,0.00056697027,0.00030366046,0.0006882592,0.000108509106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005775243,0.000258959,0.00087053137,0.000621135,0.00009428835,0.000017805025,0.00007469227,0.00010048174,0.00009980227],"category_scores_gemma":[0.000044559943,0.00020592501,0.00006971754,0.0011355343,0.00034280666,0.00021116449,0.000030955507,0.00017451831,0.0000028807185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08029248,0.004936753,0.7601989,0.0012353213,0.010492877,0.00058434345,0.008605551,0.022797408,0.015062575,0.0006088285,0.0011817584,0.094003215],"study_design_scores_gemma":[0.039013784,0.037629277,0.8975377,0.0003785114,0.0010421647,0.000050054663,0.00034621038,0.0050527155,0.016555648,0.0013454038,0.000574015,0.0004745161],"about_ca_topic_score_codex":0.00069597067,"about_ca_topic_score_gemma":0.006091752,"teacher_disagreement_score":0.1373388,"about_ca_system_score_codex":0.00011380606,"about_ca_system_score_gemma":0.00040246078,"threshold_uncertainty_score":0.83973783},"labels":[],"label_agreement":null},{"id":"W4387809552","doi":"10.1016/j.annonc.2023.10.050","title":"LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Placebo; Nivolumab; Chemotherapy; Adjuvant; Neoadjuvant therapy; Internal medicine; Oncology; Cancer; Immunotherapy; Breast cancer; Pathology","score_opus":0.11740647008009243,"score_gpt":0.4261141496413201,"score_spread":0.3087076795612277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97847337,0.007409121,0.0000523216,0.004152952,0.00026248323,0.007904217,0.0002890639,0.00033390304,0.0011225826],"genre_scores_gemma":[0.97619283,0.004935836,0.00018715906,0.0007290284,0.0002122002,0.0015328741,0.0005497575,0.0001837588,0.015476532],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938334,0.00034801444,0.0014934035,0.0013481703,0.0009193745,0.0020576436],"domain_scores_gemma":[0.9954333,0.0014337788,0.00070976594,0.0009745435,0.0005510517,0.0008975631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025595154,0.00083464436,0.0034241837,0.000629925,0.00052733306,0.00006931446,0.0004228621,0.00040527195,0.00042673294],"category_scores_gemma":[0.00055057456,0.00068074104,0.00046173309,0.00097035605,0.00038327623,0.00028231356,0.0003993838,0.0005800034,0.00003623528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51963294,0.012362819,0.025765942,0.0025797721,0.0055616843,0.0069151768,0.01020033,0.00019302561,0.010780477,0.0000461595,0.29576737,0.11019435],"study_design_scores_gemma":[0.64281726,0.113249496,0.008022869,0.0020041196,0.0016449691,0.0006306762,0.008467634,0.016879017,0.12795487,0.00012647916,0.0757306,0.0024719995],"about_ca_topic_score_codex":0.002998204,"about_ca_topic_score_gemma":0.001564802,"teacher_disagreement_score":0.22003675,"about_ca_system_score_codex":0.00083298725,"about_ca_system_score_gemma":0.0023196763,"threshold_uncertainty_score":0.99956435},"labels":[],"label_agreement":null},{"id":"W4387809560","doi":"10.1016/j.annonc.2023.10.066","title":"LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Daiichi Sankyo Europe; MSD Italia; EMD Serono; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Astellas Pharma; MacroGenics; Pfizer; Incyte; BeiGene; Mirati Therapeutics; Spectrum Pharmaceuticals; Yuhan; Mersana Therapeutics; Les Laboratories Pierre Fabre; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Merck KGaA; Regeneron Pharmaceuticals; AstraZeneca; Associazione Italiana di Oncologia Medica; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; LAM Therapeutics; Celgene","keywords":"Medicine; Discontinuation; Pembrolizumab; Adverse effect; Internal medicine; Lung cancer; Nausea; Oncology; Cancer; Immunotherapy","score_opus":0.02248700678897033,"score_gpt":0.3272610444920983,"score_spread":0.304774037703128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969091,0.00069599116,0.00001580031,0.00039896823,0.000059247403,0.00094110565,0.000035397232,0.000020474297,0.0009239491],"genre_scores_gemma":[0.9976793,0.0016423526,0.00021968303,0.00011257445,0.000019462635,0.00007762983,0.00005161734,0.000025400854,0.00017195834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998908,0.000043903106,0.00035996144,0.00025944793,0.00015614218,0.0002725337],"domain_scores_gemma":[0.9991955,0.0001244379,0.00027243208,0.00017176323,0.00016972517,0.00006615443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012081614,0.00017298569,0.00050586654,0.00022921365,0.000032590764,0.000003108517,0.000051535957,0.00009246917,0.000024939029],"category_scores_gemma":[0.000011707932,0.0001252564,0.000048107522,0.00045705188,0.000116013915,0.00007216883,0.000017114473,0.00008282089,5.695107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10807779,0.0017244988,0.6427086,0.0006096885,0.00071745744,0.00011344234,0.0041869655,0.00058210676,0.013674386,0.000008189231,0.00017686689,0.22742002],"study_design_scores_gemma":[0.040887978,0.013215442,0.9311339,0.0005500938,0.00012926561,0.000004921241,0.00030671744,0.00011139752,0.012478638,0.000002220396,0.0010355872,0.00014382601],"about_ca_topic_score_codex":0.0007045263,"about_ca_topic_score_gemma":0.00075838895,"teacher_disagreement_score":0.28842533,"about_ca_system_score_codex":0.00013165188,"about_ca_system_score_gemma":0.00040606648,"threshold_uncertainty_score":0.5107808},"labels":[],"label_agreement":null},{"id":"W4387809564","doi":"10.1016/j.annonc.2023.10.063","title":"LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Chemotherapy regimen; Adenocarcinoma; Cancer","score_opus":0.030231741122535478,"score_gpt":0.45074689493994546,"score_spread":0.42051515381741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692833,0.00044226774,0.000057511315,0.013811101,0.0003075937,0.011762841,0.000035030578,0.00016997592,0.0041304193],"genre_scores_gemma":[0.98676944,0.0012816531,0.00059673033,0.0054880944,0.00014912491,0.0039724815,0.00011883202,0.000061150226,0.0015625055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970492,0.0003228715,0.0010963506,0.0005362096,0.00042578316,0.0005695691],"domain_scores_gemma":[0.99800706,0.0005289756,0.0006338524,0.00037011932,0.0002682508,0.00019175798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076573883,0.00040933356,0.0029595913,0.00027863373,0.000062272586,0.000016677446,0.00012903307,0.00025482837,0.00035711282],"category_scores_gemma":[0.00022976511,0.00023193109,0.00036564106,0.0007400336,0.0002684426,0.00010023797,0.000022034183,0.00021201349,0.00002389639],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8948345,0.0034323807,0.00036941044,0.00004173238,0.0013242259,0.0003524398,0.0011489292,0.000032716693,0.00027743625,0.000022887036,0.0011003963,0.09706295],"study_design_scores_gemma":[0.9645757,0.024899254,0.0004960928,0.0004719857,0.0004373154,0.000028752864,0.00022769248,0.0008881226,0.001607771,0.000091976115,0.0060405354,0.00023476413],"about_ca_topic_score_codex":0.00010067277,"about_ca_topic_score_gemma":0.00010315759,"teacher_disagreement_score":0.09682819,"about_ca_system_score_codex":0.00024473004,"about_ca_system_score_gemma":0.0011617397,"threshold_uncertainty_score":0.94578755},"labels":[],"label_agreement":null},{"id":"W4387809567","doi":"10.1016/j.annonc.2023.10.069","title":"LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Oncology; Discontinuation; Chemotherapy; Cisplatin","score_opus":0.05048217222669842,"score_gpt":0.434699390876069,"score_spread":0.3842172186493706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9506625,0.000800731,0.000022029122,0.03936847,0.00014403548,0.0004932216,0.00004920342,0.000036058973,0.008423776],"genre_scores_gemma":[0.99167377,0.0049670367,0.00031472795,0.001430452,0.0000309088,0.000034630786,0.000049602168,0.000018480407,0.001480377],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990065,0.000029580926,0.00043310353,0.00019301953,0.00011420894,0.00022355025],"domain_scores_gemma":[0.99918556,0.0002565796,0.00017094226,0.00019169462,0.00012140241,0.00007382434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018921564,0.0001222194,0.00059204665,0.00017823692,0.000032011165,0.0000015713655,0.00005738644,0.000102279046,0.00010219504],"category_scores_gemma":[0.00012209012,0.00009714459,0.0000829101,0.0003069337,0.00011013102,0.000052675616,0.000028675558,0.000084920364,0.00000870912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037065274,0.0017612693,0.39401567,0.0003093472,0.00096178945,0.00011712129,0.0050228634,0.00022517648,0.004707197,0.0006998809,0.0041597052,0.58431345],"study_design_scores_gemma":[0.012056848,0.0039335117,0.86345935,0.00015795353,0.00013099503,0.000013180034,0.00055066997,0.00014691192,0.0070274295,0.0005698496,0.111810714,0.00014260362],"about_ca_topic_score_codex":0.00016663979,"about_ca_topic_score_gemma":0.0003158146,"teacher_disagreement_score":0.5841708,"about_ca_system_score_codex":0.00004254607,"about_ca_system_score_gemma":0.00013373847,"threshold_uncertainty_score":0.39614415},"labels":[],"label_agreement":null},{"id":"W4387809590","doi":"10.1016/j.annonc.2023.10.074","title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Oxaliplatin; Internal medicine; Fluorouracil; Phases of clinical research; Cancer; Oncology; Gastroenterology; Chemotherapy; Colorectal cancer","score_opus":0.1384257662104756,"score_gpt":0.42903908938544427,"score_spread":0.2906133231749687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884022,0.00019580379,0.000030164463,0.009375085,0.00027904153,0.0011685888,0.00011589693,0.000034896395,0.00039832544],"genre_scores_gemma":[0.99793434,0.00021289184,0.0001249189,0.0008690714,0.00007417486,0.000088816865,0.00001273135,0.000012596421,0.0006704356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975104,0.00050493557,0.00076721836,0.00045278927,0.00033112,0.00043356477],"domain_scores_gemma":[0.9987803,0.00028871454,0.00030255003,0.0003514243,0.00014427621,0.00013269669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001786294,0.00021042448,0.0007810686,0.00038257203,0.00007703664,0.000015709173,0.0001712293,0.00009638151,0.00004163278],"category_scores_gemma":[0.0004887927,0.00015580036,0.00007699389,0.0012725116,0.00018270493,0.000083114166,0.0004472664,0.00022599805,0.0000043219297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14778271,0.00220938,0.6877802,0.0003041586,0.0003960118,0.0011421768,0.004454307,0.00054179627,0.0080496855,0.000067823385,0.050909672,0.09636207],"study_design_scores_gemma":[0.020670433,0.01218217,0.9599959,0.00010977813,0.00011222272,0.00007225052,0.0019078732,0.0002508675,0.00018481379,0.000047523223,0.004357697,0.00010842287],"about_ca_topic_score_codex":0.0013581985,"about_ca_topic_score_gemma":0.0010290545,"teacher_disagreement_score":0.27221572,"about_ca_system_score_codex":0.00018670222,"about_ca_system_score_gemma":0.00016904797,"threshold_uncertainty_score":0.63533545},"labels":[],"label_agreement":null},{"id":"W4387809597","doi":"10.1016/j.annonc.2023.10.052","title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Daiichi Sankyo Company; MSD Italia; Eli Lilly Japan; Sanofi Genzyme; Chugai Pharmaceutical; Ipsen; AstraZeneca Pharma Poland; Eli Lilly and Company; Ono Pharmaceutical; Otsuka Pharmaceutical; Seagen; Lunit; BeiGene; Mirati Therapeutics; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Regeneron Pharmaceuticals; AstraZeneca España; Helsinn; Daiichi Sankyo Europe; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Spectrum Pharmaceuticals; Medtronic Japan; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Placebo; Lung cancer; Interim; Interim analysis; Randomization; Stage (stratigraphy); Internal medicine; Pembrolizumab; Perioperative; Oncology; Tolerability; Cancer; Clinical trial; Surgery; Adverse effect; Pathology","score_opus":0.09338101173832299,"score_gpt":0.41300561536293673,"score_spread":0.31962460362461376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010855,0.0005545052,0.000012363729,0.0027218757,0.00028443715,0.0018612944,0.00006493979,0.000014151272,0.004377882],"genre_scores_gemma":[0.99562556,0.0008917159,0.00002391453,0.000960014,0.00011214535,0.00032213004,0.000014345102,0.000022806573,0.0020273677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848145,0.00020291028,0.000496758,0.00025856454,0.00022272574,0.00033761343],"domain_scores_gemma":[0.99880683,0.00041177144,0.00021556261,0.00029782188,0.00022758018,0.000040426366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009282418,0.00016341014,0.00059717643,0.0001756205,0.00005950818,0.00000771382,0.00022510898,0.00013169274,0.0001113233],"category_scores_gemma":[0.000051406114,0.00011597148,0.00017558517,0.00038014012,0.000112645226,0.00004833843,0.000048912832,0.00018225722,0.0000023040186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09972903,0.011786577,0.45425627,0.0018856362,0.0030740178,0.00042695788,0.24700533,0.0006686545,0.115702845,0.00044083892,0.021500044,0.0435238],"study_design_scores_gemma":[0.036984168,0.023926558,0.87969124,0.00018165982,0.00020414632,0.0000060775196,0.021204036,0.0007884092,0.0096863685,0.000019883533,0.027007991,0.0002994566],"about_ca_topic_score_codex":0.0051010353,"about_ca_topic_score_gemma":0.003480849,"teacher_disagreement_score":0.42543498,"about_ca_system_score_codex":0.00006284881,"about_ca_system_score_gemma":0.00047512059,"threshold_uncertainty_score":0.77112734},"labels":[],"label_agreement":null},{"id":"W4387809598","doi":"10.1016/j.annonc.2023.10.044","title":"LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Melanoma; Oncology; Metastatic melanoma; Internal medicine; Cancer research","score_opus":0.10358977352303528,"score_gpt":0.41862045268984155,"score_spread":0.31503067916680627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912746,0.0001436295,0.0000051746824,0.0020661617,0.00015401762,0.0014122085,0.00001868907,0.000043318607,0.0048822244],"genre_scores_gemma":[0.99873495,0.00015513747,0.0001872798,0.00021943907,0.000053184292,0.00014363855,0.00014066251,0.000022764234,0.00034292604],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981307,0.00031492597,0.0005514605,0.00032616442,0.00020290054,0.00047384953],"domain_scores_gemma":[0.999029,0.00033384844,0.00019078537,0.00024477733,0.00008144806,0.00012013103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080619997,0.00019292092,0.0010412607,0.00046738266,0.000027284828,0.0000031828918,0.00009885486,0.0001862044,0.00017767932],"category_scores_gemma":[0.00014771223,0.00014779602,0.00010072011,0.00080220104,0.00016449741,0.00006604767,0.000044163782,0.00025095645,0.00008836648],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38544273,0.017739123,0.4751928,0.0001888997,0.0020506703,0.02060799,0.0021783032,0.000056588487,0.00043707853,0.0009510848,0.0015891489,0.09356558],"study_design_scores_gemma":[0.76104826,0.10408429,0.12364002,0.00025733066,0.0006667261,0.00018439413,0.0009575015,0.00030704006,0.0013393426,0.0011607187,0.005999083,0.00035531432],"about_ca_topic_score_codex":0.0007349389,"about_ca_topic_score_gemma":0.007897056,"teacher_disagreement_score":0.3756055,"about_ca_system_score_codex":0.000090080015,"about_ca_system_score_gemma":0.0005349602,"threshold_uncertainty_score":0.6026947},"labels":[],"label_agreement":null},{"id":"W4387809599","doi":"10.1016/j.annonc.2023.10.090","title":"LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"EMD Serono; Genentech; Ipsen; Astellas Pharma; Eisai; Jounce Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Mylan; Arrowhead Pharmaceuticals; EUSA Pharma; AstraZeneca; Associazione Italiana di Oncologia Medica; European Association of Urology; Pfizer; Incyte; F. Hoffmann-La Roche; PTC Therapeutics; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Amgen; Seagen; Society for Immunotherapy of Cancer","keywords":"Medicine; Everolimus; Clear cell renal cell carcinoma; Renal cell carcinoma; Oncology; Internal medicine; Open label; Phases of clinical research; Randomized controlled trial; Clinical trial","score_opus":0.164115545599524,"score_gpt":0.4251918590171163,"score_spread":0.2610763134175923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816631,0.0009706943,0.0000032069406,0.0007587343,0.00015254837,0.00656708,0.000026063295,0.00009910184,0.009759443],"genre_scores_gemma":[0.99580103,0.00046625387,0.0002917929,0.000271558,0.000067929795,0.0009377863,0.00012900995,0.00009336319,0.0019412936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99466217,0.0011914056,0.0013658045,0.0009585518,0.00055465667,0.0012674325],"domain_scores_gemma":[0.9962919,0.0012430642,0.0006825972,0.0009148545,0.000325101,0.0005425349],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019796616,0.0005649785,0.0027772887,0.00054840726,0.00011284018,0.00002883849,0.00047055352,0.00024065062,0.00015601658],"category_scores_gemma":[0.00025925972,0.0004323193,0.00020066155,0.0011549948,0.0003046892,0.00020506782,0.00031171483,0.0004308305,0.00012312958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9276509,0.023728747,0.008967213,0.00015263166,0.00068971585,0.005946687,0.005234663,0.00020407628,0.010960822,0.000008971122,0.0017524037,0.014703145],"study_design_scores_gemma":[0.8503875,0.08857903,0.010170738,0.00013096264,0.001202949,0.0000291089,0.0016098825,0.0006355921,0.045864157,0.00001898418,0.00095606124,0.000415028],"about_ca_topic_score_codex":0.001079404,"about_ca_topic_score_gemma":0.0007650699,"teacher_disagreement_score":0.07726342,"about_ca_system_score_codex":0.00026028347,"about_ca_system_score_gemma":0.00069530687,"threshold_uncertainty_score":0.99981284},"labels":[],"label_agreement":null},{"id":"W4387809604","doi":"10.1016/j.annonc.2023.10.053","title":"LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health; European Society for Medical Oncology; BeiGene; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Chemotherapy; Complete response; Pathological; Clinical endpoint; Phases of clinical research; Neoadjuvant therapy; Immunotherapy; Clinical trial; Cancer","score_opus":0.07998844053475229,"score_gpt":0.4265823777995135,"score_spread":0.34659393726476123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97583663,0.0007324728,0.0000030454287,0.01895797,0.0002130693,0.0009998844,0.00005437083,0.000060881317,0.0031416768],"genre_scores_gemma":[0.9909233,0.0014413125,0.000019973055,0.0061642774,0.00012057392,0.00010272272,0.00007130253,0.000025723088,0.001130824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979472,0.00025717623,0.0007149186,0.00034596107,0.00032583566,0.00040887666],"domain_scores_gemma":[0.99880606,0.00023253201,0.0003026349,0.00049456785,0.00009728047,0.000066908906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018142629,0.00018901868,0.0005770187,0.00018812108,0.00007652856,0.000009704002,0.00028242203,0.00012450684,0.00013640673],"category_scores_gemma":[0.000100183875,0.00012643424,0.00014896983,0.0006315312,0.00015935002,0.00006792369,0.00004586294,0.00024133922,0.00002659051],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072810054,0.0054589547,0.0008307639,0.00005311436,0.0002120163,0.0004704958,0.0110579925,0.0000024472079,0.30614528,0.000005817094,0.42301166,0.1799414],"study_design_scores_gemma":[0.10993904,0.025625695,0.037639864,0.0003026361,0.000059377897,0.00009362222,0.009581725,0.00012998894,0.12958527,0.00011559899,0.68657815,0.000349039],"about_ca_topic_score_codex":0.00052582787,"about_ca_topic_score_gemma":0.000098437355,"teacher_disagreement_score":0.26356646,"about_ca_system_score_codex":0.00005316339,"about_ca_system_score_gemma":0.00018781408,"threshold_uncertainty_score":0.5155839},"labels":[],"label_agreement":null},{"id":"W4387809649","doi":"10.1016/j.annonc.2023.10.037","title":"LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; MLH1; Carboplatin; Endometrial cancer; Progression-free survival; Cancer; DNA mismatch repair; Chemotherapy; Immunotherapy; Colorectal cancer","score_opus":0.09975770371434342,"score_gpt":0.4136954993407552,"score_spread":0.3139377956264118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938502,0.00017547961,0.0000050125072,0.0011451794,0.0002425133,0.002628952,0.001698625,0.00003272639,0.0002213583],"genre_scores_gemma":[0.9984128,0.00012663846,0.00019077824,0.00013480679,0.00004088818,0.00021183818,0.00079796463,0.000030760828,0.000053539807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995209,0.0015042837,0.0012158256,0.0006713542,0.0009375135,0.0004620411],"domain_scores_gemma":[0.99544376,0.0021802462,0.0006794442,0.0011065105,0.00044161506,0.00014844903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030718532,0.0002957869,0.0018020559,0.0013000414,0.00003672476,0.000007324249,0.0006004285,0.00031016464,0.00010488255],"category_scores_gemma":[0.0030610145,0.0002121784,0.00013113134,0.0040235757,0.00027581034,0.00006574098,0.0004016395,0.00028137435,0.0000012899627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90111935,0.0011993533,0.074962296,0.00012173892,0.0016008785,0.00012990415,0.00486507,0.00052392506,0.0059412466,0.000014829955,0.007270719,0.0022506693],"study_design_scores_gemma":[0.4968349,0.07268784,0.37844357,0.0006968733,0.0031799793,0.000018508179,0.0038750053,0.011962598,0.028271466,0.00014858796,0.0030343216,0.00084634754],"about_ca_topic_score_codex":0.0069100587,"about_ca_topic_score_gemma":0.0077317995,"teacher_disagreement_score":0.40428448,"about_ca_system_score_codex":0.00027279585,"about_ca_system_score_gemma":0.0010598699,"threshold_uncertainty_score":0.999703},"labels":[],"label_agreement":null},{"id":"W4387809673","doi":"10.1016/j.annonc.2023.10.029","title":"LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"Ipsen; Astellas Pharma; Eisai; AstraZeneca; University College London; Boston Scientific Corporation; Seagen; Pfizer","keywords":"Medicine; Open label; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Open label study; Surgery; Randomized controlled trial","score_opus":0.3080902739800833,"score_gpt":0.5448928587729979,"score_spread":0.23680258479291455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322535,0.0008934624,0.000006074113,0.0092317145,0.00027680834,0.0052779214,0.00011740924,0.000037343274,0.00093389704],"genre_scores_gemma":[0.9894304,0.0042443317,0.00048589913,0.0028159872,0.00016116117,0.0011287357,0.0000581219,0.00008253026,0.0015928011],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943428,0.0013688143,0.0020525767,0.00065015873,0.00085299724,0.0007326589],"domain_scores_gemma":[0.9952242,0.0019436016,0.0008486073,0.0007511754,0.0008765862,0.00035585932],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040047527,0.00038443774,0.0034558645,0.0006031967,0.000045955418,0.000016259746,0.0008026914,0.00022242877,0.0035935207],"category_scores_gemma":[0.0029311008,0.00028063243,0.00015186195,0.0036459237,0.00068713113,0.00012979524,0.00040790107,0.00054273603,0.000015184556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6870807,0.024879755,0.0038671156,0.0009651425,0.0025575755,0.00042402634,0.0041038496,0.00001632316,0.021697382,0.00021792174,0.030682499,0.22350775],"study_design_scores_gemma":[0.8898019,0.051446598,0.0030656904,0.00066186,0.00037576183,0.000040365612,0.0019308642,0.00081304647,0.014135143,0.00047224606,0.036862187,0.00039432227],"about_ca_topic_score_codex":0.006909725,"about_ca_topic_score_gemma":0.0055705523,"teacher_disagreement_score":0.22311342,"about_ca_system_score_codex":0.00024269724,"about_ca_system_score_gemma":0.0034121433,"threshold_uncertainty_score":0.9999646},"labels":[],"label_agreement":null},{"id":"W4387809675","doi":"10.1016/j.annonc.2023.10.015","title":"LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Loxo Oncology; Jounce Therapeutics; Genentech; Gilead Sciences; Radius Health; MedImmune; Clovis Oncology; Eisai; Daiichi Sankyo Europe; Sanofi; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; HER2 negative; Internal medicine; Chemotherapy; Hormone receptor; Breast cancer; Cancer; Gynecology","score_opus":0.06623516967856484,"score_gpt":0.40216623548961317,"score_spread":0.3359310658110483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526737,0.00088010955,0.000005197725,0.0380148,0.00040611034,0.004726343,0.0019670047,0.00010100249,0.0012257685],"genre_scores_gemma":[0.9610164,0.02419934,0.00025628065,0.0061649815,0.00082400744,0.001655299,0.002424514,0.00010208149,0.0033570565],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99577975,0.0011179533,0.0012323163,0.00075067463,0.00035666997,0.0007626595],"domain_scores_gemma":[0.9955542,0.002713518,0.000626713,0.00050607085,0.00034941817,0.0002500636],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009332739,0.0004814187,0.0018406925,0.0002599282,0.00014916596,0.000021342214,0.0003217427,0.00025800642,0.0018075325],"category_scores_gemma":[0.00023766038,0.00031445376,0.00028341782,0.0011346439,0.00040488108,0.00017493141,0.00009072785,0.000491159,0.000050960847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8245586,0.0042895786,0.00041814955,0.000038410126,0.001989101,0.00032251954,0.0036685811,0.000016611433,0.008408664,0.0000047661056,0.086681895,0.06960311],"study_design_scores_gemma":[0.9148354,0.016624222,0.021304367,0.00029459156,0.000991794,0.000082542356,0.0006749023,0.00017833035,0.019342862,0.00011401495,0.025125373,0.00043159988],"about_ca_topic_score_codex":0.025138862,"about_ca_topic_score_gemma":0.0034645863,"teacher_disagreement_score":0.090276785,"about_ca_system_score_codex":0.000430304,"about_ca_system_score_gemma":0.0016047368,"threshold_uncertainty_score":0.99993074},"labels":[],"label_agreement":null},{"id":"W4387809682","doi":"10.1016/j.annonc.2023.10.011","title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Seagen; Genentech; Hope Foundation; AstraZeneca; Breast Cancer Research Foundation; Pfizer; Bristol-Myers Squibb; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Stage (stratigraphy); Adjuvant; Chemotherapy; Breast cancer; Adjuvant chemotherapy; Internal medicine; Gynecology; Cancer; Immunotherapy","score_opus":0.12724318332632856,"score_gpt":0.4865900282985598,"score_spread":0.35934684497223124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768841,0.001209723,0.00009652746,0.0115279555,0.0006028009,0.0066406876,0.0023166533,0.00023360064,0.0004879293],"genre_scores_gemma":[0.9620383,0.018059973,0.0002997702,0.002193984,0.00053643476,0.0021904712,0.00019974187,0.00029905967,0.014182303],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928911,0.0007513157,0.0018607206,0.0013217226,0.0013861682,0.0017889886],"domain_scores_gemma":[0.9937915,0.0017865811,0.0010936324,0.0014124019,0.0012868909,0.00062894356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020837341,0.0008316427,0.0029372422,0.00069688493,0.00022452355,0.00003853401,0.00090663956,0.00046232127,0.0038496135],"category_scores_gemma":[0.0005224079,0.000615599,0.0005262626,0.0014769594,0.00047366432,0.0002297792,0.00025723985,0.0009394621,0.000040060793],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33938563,0.015460821,0.008947152,0.00083691924,0.0036231473,0.0009974134,0.007394823,0.00011954382,0.06729037,0.000044434502,0.19438757,0.36151218],"study_design_scores_gemma":[0.4152745,0.1229393,0.042870447,0.00065929303,0.0007180333,0.00028357943,0.0056864386,0.0014307797,0.12355572,0.00012795311,0.28489733,0.0015566382],"about_ca_topic_score_codex":0.016763372,"about_ca_topic_score_gemma":0.0038579926,"teacher_disagreement_score":0.35995555,"about_ca_system_score_codex":0.00040718363,"about_ca_system_score_gemma":0.002969789,"threshold_uncertainty_score":0.99962956},"labels":[],"label_agreement":null},{"id":"W4387809745","doi":"10.1016/j.annonc.2023.09.2951","title":"228P Biomarker discovery via meta-analysis of immunotherapy clinical trials in cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Medicine; Cancer immunotherapy; Oncology; Clinical trial; Biomarker; Gene signature; Cancer; Gene expression profiling; Internal medicine; Computational biology; Bioinformatics; Gene; Gene expression; Biology; Genetics","score_opus":0.6018903158374248,"score_gpt":0.588874700187685,"score_spread":0.013015615649739853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959939,0.01872316,0.00012436812,0.018775577,0.0005036085,0.00065625156,0.00022226336,0.000030074429,0.0010256827],"genre_scores_gemma":[0.9674103,0.027318528,0.00009951493,0.0037273893,0.00007484232,0.0001115264,0.00006657759,0.000023208884,0.0011681019],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99502707,0.0015158823,0.002561082,0.0003283157,0.00027314122,0.00029454214],"domain_scores_gemma":[0.99544585,0.0027804654,0.0010580283,0.0004722556,0.00018279695,0.000060600094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0133847045,0.00017671341,0.004247312,0.0010010395,0.000017814675,0.000005220901,0.00017432105,0.00029137658,0.001749334],"category_scores_gemma":[0.0006092295,0.00012272513,0.003942751,0.0023885944,0.00031459786,0.00008568062,0.000039544404,0.00016436497,0.000007130714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023274947,0.0016009726,0.039496683,0.00008818048,0.49623683,0.00006700502,0.000466569,0.00006963467,0.08038191,0.000063832376,0.017572014,0.34068143],"study_design_scores_gemma":[0.010182663,0.0043634586,0.7614319,0.000050322764,0.10206859,0.0000065096856,0.00026824838,0.0005847697,0.015084211,0.0003804577,0.1052273,0.0003515692],"about_ca_topic_score_codex":0.0020969713,"about_ca_topic_score_gemma":0.0008701384,"teacher_disagreement_score":0.7219352,"about_ca_system_score_codex":0.00004031674,"about_ca_system_score_gemma":0.00039265867,"threshold_uncertainty_score":0.9991632},"labels":[],"label_agreement":null},{"id":"W4387809921","doi":"10.1016/j.annonc.2023.09.3000","title":"1259P Evolution of the diagnosis and management of CUP: A decade analysis","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09955530468430664,"score_gpt":0.418122760021357,"score_spread":0.3185674553370504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98839134,0.0018997502,0.000008680072,0.008086006,0.000047027104,0.00025772917,0.000019877283,0.00001002244,0.001279562],"genre_scores_gemma":[0.9860083,0.013585177,0.00008419946,0.00013356966,0.000012303028,0.000080191916,0.000004761046,0.000005293354,0.00008622179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993469,0.000038440787,0.00024805192,0.00012118749,0.00013979737,0.000105602754],"domain_scores_gemma":[0.99936986,0.00012625726,0.00017173022,0.00020775027,0.00009059022,0.000033798544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001859428,0.00005798927,0.00036564854,0.00018495659,0.000014326224,7.489208e-7,0.00005172063,0.000048465907,0.000031057993],"category_scores_gemma":[0.000024180154,0.000039211853,0.00018074045,0.0008038524,0.00010732082,0.000013916099,0.00007353721,0.000031080715,0.0000014628462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001149267,0.0007133884,0.9270554,0.0002845462,0.0033186167,0.000017058068,0.00027851635,0.00009835643,0.00015039898,0.0022518483,0.008342839,0.057374094],"study_design_scores_gemma":[0.00074397324,0.0008004235,0.9816822,0.0001014241,0.0016705317,0.0000014405834,0.00021932187,0.00006084509,0.0060784626,0.00028692017,0.0083262,0.00002825195],"about_ca_topic_score_codex":0.000504331,"about_ca_topic_score_gemma":0.00022681565,"teacher_disagreement_score":0.05734584,"about_ca_system_score_codex":0.0000385297,"about_ca_system_score_gemma":0.000039599046,"threshold_uncertainty_score":0.1599013},"labels":[],"label_agreement":null},{"id":"W4387809927","doi":"10.1016/j.annonc.2023.09.3100","title":"354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Seagen; Relay Therapeutics; Incyte; Daiichi-Sankyo; Pfizer; Genentech; Mersana Therapeutics; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adjuvant therapy; Oncology; Tamoxifen; Fulvestrant; Breast cancer; Adjuvant; Aromatase inhibitor; Hazard ratio; Cancer; Trastuzumab; Surgery; Confidence interval","score_opus":0.06015312760793879,"score_gpt":0.4174183995271137,"score_spread":0.3572652719191749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481696,0.00035768494,0.000026930944,0.0004298599,0.000086750915,0.0036346798,0.00060308626,0.000028067678,0.000015992258],"genre_scores_gemma":[0.99164736,0.007281641,0.00031035478,0.00018819899,0.00003448563,0.00041841317,0.00003757466,0.00005563058,0.000026324742],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972595,0.0005017153,0.00083696085,0.0005382043,0.00043121673,0.00043241165],"domain_scores_gemma":[0.99733776,0.00031552464,0.00093317963,0.00047725302,0.00076819153,0.00016807439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068025524,0.0003573945,0.0018074181,0.00030753482,0.000043722,0.000010863411,0.00030485837,0.0000783125,0.0000694326],"category_scores_gemma":[0.000044654975,0.00021762658,0.000039863797,0.0006100984,0.00047413853,0.00031938977,0.00007534281,0.00028763738,2.6092718e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54979396,0.00840446,0.07871648,0.000045715635,0.000739402,0.00007690472,0.004965319,0.000027027354,0.00051543704,0.000007427303,0.000011957983,0.3566959],"study_design_scores_gemma":[0.3848279,0.08824291,0.5238347,0.00033002178,0.00008091751,0.000012999927,0.0008725025,0.000023049563,0.0014806157,0.00005630392,0.00006995223,0.00016814304],"about_ca_topic_score_codex":0.00721411,"about_ca_topic_score_gemma":0.004055997,"teacher_disagreement_score":0.4451182,"about_ca_system_score_codex":0.00005967927,"about_ca_system_score_gemma":0.00071650924,"threshold_uncertainty_score":0.9993969},"labels":[],"label_agreement":null},{"id":"W4387809992","doi":"10.1016/j.annonc.2023.09.2915","title":"191P Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Queen Elizabeth II Health Sciences Centre; William Osler Health System; Brampton Civic Hospital","funders":"University of Texas MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas","keywords":"Medicine; Biomarker; Colorectal cancer; Oncology; Cancer; Quality (philosophy); Internal medicine; Medical physics; Genetics","score_opus":0.3914343460623405,"score_gpt":0.4995271716526005,"score_spread":0.10809282559026001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97704583,0.00061592687,0.00003781295,0.0069592637,0.00011069847,0.0014636469,0.00012803737,0.000041509353,0.013597279],"genre_scores_gemma":[0.9951752,0.0002209276,0.0018667122,0.00058883417,0.00004235833,0.0015722079,0.00003566597,0.00001300697,0.00048511947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880224,0.000038475966,0.0003719166,0.0003109268,0.000110016466,0.00036642497],"domain_scores_gemma":[0.998847,0.000623891,0.00011689613,0.000121779165,0.00020821355,0.00008219848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041030336,0.00014701385,0.0005554113,0.000171285,0.00006753957,0.000003796285,0.000054493088,0.000089708556,0.0000066988227],"category_scores_gemma":[0.0004841415,0.00010927304,0.000087679866,0.0006428443,0.000085655694,0.000025358253,0.000038877137,0.00004622101,0.0000033823464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035832713,0.005123924,0.6365964,0.0004241765,0.0005962314,0.000031848103,0.0034828125,0.00026834023,0.027590252,0.0004450522,0.007146643,0.31471103],"study_design_scores_gemma":[0.00397199,0.009889299,0.9613566,0.000102609425,0.00008702594,0.000007818496,0.0013338994,0.00072899304,0.0057242247,0.00015303816,0.01647268,0.00017186027],"about_ca_topic_score_codex":0.0020278662,"about_ca_topic_score_gemma":0.00146117,"teacher_disagreement_score":0.32476017,"about_ca_system_score_codex":0.00022498758,"about_ca_system_score_gemma":0.00040420282,"threshold_uncertainty_score":0.4456025},"labels":[],"label_agreement":null},{"id":"W4387810093","doi":"10.1016/j.annonc.2023.09.2783","title":"1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Université de Montréal; McGill University Health Centre; University of Calgary","funders":"Eisai; Exelixis; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; PALB2; Prostate cancer; CHEK2; Internal medicine; Oncology; Cancer; FANCA; Gene mutation; Germline mutation; DNA repair; Mutation; Gene; Fanconi anemia; Genetics","score_opus":0.05293878818306228,"score_gpt":0.4007037831249236,"score_spread":0.3477649949418613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945567,0.0001574362,0.0000011417417,0.0012933679,0.00009484793,0.0032657185,0.000048251808,0.000051178555,0.0005313504],"genre_scores_gemma":[0.99734807,0.00028864972,0.0000827504,0.0007935457,0.000029888552,0.0010046521,0.00000287415,0.000021436821,0.00042814208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851847,0.00015079592,0.00040916287,0.00032811964,0.0003088744,0.00028455828],"domain_scores_gemma":[0.9986104,0.00019549025,0.0002602923,0.00035648755,0.0005075645,0.00006979725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004712726,0.0001376137,0.00045033125,0.00018716637,0.000030748983,0.0000016473895,0.00012056075,0.00004247181,0.00004175915],"category_scores_gemma":[0.0001974821,0.00009225105,0.000059842092,0.0008293896,0.00014448064,0.000066709086,0.00006207859,0.0001408892,0.000007862556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007326892,0.0017923835,0.96311677,0.00031355128,0.00012911425,0.000041938823,0.009834594,0.0002347136,0.0018245938,0.000011386045,0.0011315296,0.0142425615],"study_design_scores_gemma":[0.0070667975,0.02752707,0.94828206,0.00038094207,0.000049793172,0.0000028191985,0.00062699296,0.000017155617,0.0147824865,0.000078999845,0.0010856373,0.00009922474],"about_ca_topic_score_codex":0.000101294274,"about_ca_topic_score_gemma":0.0005026109,"teacher_disagreement_score":0.025734687,"about_ca_system_score_codex":0.0001253125,"about_ca_system_score_gemma":0.0002924076,"threshold_uncertainty_score":0.37618887},"labels":[],"label_agreement":null},{"id":"W4387810156","doi":"10.1016/j.annonc.2023.09.2830","title":"375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Oncology; De-escalation; Solid tumor; Internal medicine; Nuclear medicine; Cancer","score_opus":0.034195459923182535,"score_gpt":0.4102452826055652,"score_spread":0.3760498226823827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977046,0.00004583731,0.0000058203204,0.00035778532,0.00003777346,0.0015706873,0.00002125418,0.000022554545,0.00023367099],"genre_scores_gemma":[0.9994237,0.000048959126,0.00014588193,0.00007161732,0.000013347725,0.00012799384,0.00010625999,0.000021960557,0.000040282768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867666,0.000067071865,0.00046931702,0.00030168777,0.00022847699,0.00025680178],"domain_scores_gemma":[0.99919933,0.00008142611,0.00025729297,0.00019133954,0.00018188031,0.0000887547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001434341,0.00016122244,0.00054369477,0.00036055688,0.000054342676,0.0000036005438,0.00004931919,0.00006000878,0.0000149544385],"category_scores_gemma":[0.000031971354,0.000119529665,0.000026005675,0.00043692873,0.00009366148,0.00012135137,0.000024849182,0.00010775163,0.0000010479068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008284145,0.018754164,0.89540267,0.00018877481,0.00027483774,0.00017707968,0.014513235,0.0016405006,0.00048154383,0.000010149171,0.00009901067,0.060173903],"study_design_scores_gemma":[0.052490663,0.038411416,0.90436625,0.00036497344,0.00013220502,0.0000029153425,0.003208195,0.00026311047,0.00045515795,0.000017913304,0.00017644916,0.00011075134],"about_ca_topic_score_codex":0.00043015555,"about_ca_topic_score_gemma":0.00396944,"teacher_disagreement_score":0.06006315,"about_ca_system_score_codex":0.00009831567,"about_ca_system_score_gemma":0.00014214321,"threshold_uncertainty_score":0.4874278},"labels":[],"label_agreement":null},{"id":"W4387810194","doi":"10.1016/j.annonc.2023.09.2818","title":"1869P First impressions: A prospective evaluation of patient comprehension and satisfaction in the communication of diagnosis, treatment, and prognosis following the initial medical oncology consultation","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Concordance; Family medicine; Prospective cohort study; Patient satisfaction; Internal medicine; Cancer; Oncology; Surgery","score_opus":0.44646197693996814,"score_gpt":0.5569994434071183,"score_spread":0.11053746646715013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715274,0.0034448293,0.000001920854,0.020914184,0.00015475045,0.00347088,0.000029592571,0.000017265937,0.00043916973],"genre_scores_gemma":[0.9886948,0.007368926,0.0001271166,0.00039813333,0.000015772228,0.0033201722,0.00006444725,0.000009417875,0.0000012125435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915426,0.006511704,0.0010665401,0.00019748519,0.00047206465,0.00020962332],"domain_scores_gemma":[0.98418707,0.013532927,0.0010445314,0.00043199206,0.0007506774,0.000052810337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025674046,0.00011810067,0.0004145643,0.00020557923,0.00048943906,0.0000027747296,0.00019589496,0.00029935,0.000026417794],"category_scores_gemma":[0.0040924926,0.00007675142,0.000051881645,0.0004776804,0.00038308217,0.00012524298,0.00022131263,0.00037256678,0.0000018205333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031483916,0.00048748363,0.5715546,0.00019461893,0.00008566701,0.0000011108741,0.15257517,0.000044063152,0.000081267084,0.00086887926,0.0007471246,0.27304518],"study_design_scores_gemma":[0.0048178574,0.00358483,0.86572284,0.00096470263,0.00015434959,0.0000047675153,0.11359626,0.004504824,0.00041695996,0.004056332,0.0020705084,0.000105791616],"about_ca_topic_score_codex":0.0041352795,"about_ca_topic_score_gemma":0.010030662,"teacher_disagreement_score":0.2941682,"about_ca_system_score_codex":0.00017119086,"about_ca_system_score_gemma":0.0007065534,"threshold_uncertainty_score":0.6251333},"labels":[],"label_agreement":null},{"id":"W4387810201","doi":"10.1016/j.annonc.2023.09.2861","title":"136P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Centre Léon Bérard; National Institute for Health and Care Research","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Internal medicine; Oncology; Clinical endpoint; Cohort; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical trial; Phases of clinical research; Immunotherapy; Microsatellite","score_opus":0.028498296209408823,"score_gpt":0.3441182922386782,"score_spread":0.3156199960292694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972965,0.00022825069,0.0000052254427,0.0005171275,0.00026296056,0.0009128429,0.000041803018,0.0000762116,0.0006590587],"genre_scores_gemma":[0.9982409,0.00019194544,0.0009688443,0.00034342537,0.000027547534,0.00004746495,0.0000756456,0.000038694507,0.000065517816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975039,0.00014308798,0.00088927336,0.00048386274,0.0004395589,0.000540344],"domain_scores_gemma":[0.99811375,0.00019751102,0.00037317688,0.000558558,0.00061049714,0.00014648047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004693307,0.0002614304,0.0009794183,0.0003397898,0.000027972479,0.0000028914385,0.00018320353,0.00018722525,0.000060255374],"category_scores_gemma":[0.00043233673,0.00020593924,0.00015886695,0.0009654051,0.00032254227,0.000053044703,0.00014981591,0.0002631367,0.000020054253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010685497,0.002336463,0.95099324,0.0006928128,0.000104646846,0.000073218645,0.0024806762,0.0014196335,0.014718058,0.00002194863,0.0003416062,0.016132198],"study_design_scores_gemma":[0.0057455148,0.011844532,0.94723904,0.00035309946,0.000026249872,0.000013048265,0.00018299646,0.00011420444,0.03297706,0.00025971825,0.0010535253,0.00019099275],"about_ca_topic_score_codex":0.00016935587,"about_ca_topic_score_gemma":0.00024202977,"teacher_disagreement_score":0.018259,"about_ca_system_score_codex":0.0001966126,"about_ca_system_score_gemma":0.0005188043,"threshold_uncertainty_score":0.8397958},"labels":[],"label_agreement":null},{"id":"W4387810206","doi":"10.1016/j.annonc.2023.09.2827","title":"2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; Loxo Oncology; Astellas Pharma; Seagen; Bayer Canada; G1 Therapeutics; Sanofi; Exelixis; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Merck KGaA; Gilead Sciences; Mirati Therapeutics; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Atezolizumab; Medicine; TIGIT; Internal medicine; Oncology; Clinical trial; Phases of clinical research; Cancer; Nivolumab; Immunotherapy","score_opus":0.11881336517725506,"score_gpt":0.4432796996802627,"score_spread":0.32446633450300766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863952,0.00008044787,0.000074679825,0.0012953734,0.00016145408,0.010173415,0.00092344027,0.00007324263,0.00082279154],"genre_scores_gemma":[0.9932882,0.00019986677,0.0017536186,0.0012591012,0.00008120297,0.0024139464,0.0003481282,0.000100574005,0.0005553354],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99682,0.00020762572,0.0010556949,0.0006685962,0.000510449,0.00073764427],"domain_scores_gemma":[0.997475,0.00038220506,0.0007851286,0.0004752696,0.0006466705,0.00023572159],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044296487,0.0005201403,0.0022099498,0.00030861533,0.00010734543,0.00002121485,0.0003405861,0.00020588402,0.00026350326],"category_scores_gemma":[0.00022760553,0.00034743204,0.00013824973,0.0011256862,0.00026001272,0.00016316847,0.00006946873,0.00016783336,0.00000638699],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9176721,0.01562615,0.009500107,0.0003104106,0.0013973257,0.000078782905,0.00070243474,0.00011969061,0.00042292502,0.0000075537137,0.00230979,0.051852718],"study_design_scores_gemma":[0.8759342,0.09805393,0.0009499258,0.00050557125,0.00081769907,0.0000082635415,0.00013199438,0.0018808478,0.01822705,0.000029693461,0.00310897,0.00035186164],"about_ca_topic_score_codex":0.003459754,"about_ca_topic_score_gemma":0.0023633002,"teacher_disagreement_score":0.082427785,"about_ca_system_score_codex":0.0003102652,"about_ca_system_score_gemma":0.0025100529,"threshold_uncertainty_score":0.9998978},"labels":[],"label_agreement":null},{"id":"W4387810225","doi":"10.1016/j.annonc.2023.09.2760","title":"1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; PharmaMar; Novartis Farmacéutica; Cilag; Astellas Pharma; Eisai; Ipsen; Clovis Oncology; Astellas Pharma Canada; Daiichi Sankyo Europe; Sanofi; Exelixis; F. Hoffmann-La Roche; Gilead Sciences; MacroGenics; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; CHEK2; Prostate cancer; Population; Internal medicine; Oncology; Enzalutamide; Cancer; Cancer research; Androgen receptor; Germline mutation; Genetics; Biology; Mutation; Gene","score_opus":0.11355469973697349,"score_gpt":0.39981697517091896,"score_spread":0.28626227543394545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922977,0.000055951496,0.00092142326,0.0057583,0.00012496136,0.00058507157,0.00012295182,0.00003533948,0.000098270844],"genre_scores_gemma":[0.99803865,0.00023594945,0.000933935,0.00015381756,0.00005883179,0.00008495584,0.00045995985,0.000010598177,0.000023328648],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856156,0.0003044981,0.0005214253,0.00019134935,0.00028541443,0.0001357676],"domain_scores_gemma":[0.9985669,0.0002724172,0.00059532805,0.00022025123,0.00031885767,0.000026245732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077073387,0.00009734589,0.00039823033,0.00029391542,0.000065262815,0.00000546993,0.000056198733,0.00010497617,0.000019984298],"category_scores_gemma":[0.00016807711,0.000078888086,0.00006787046,0.000564231,0.00010414053,0.00023234788,0.000017103956,0.000117951444,0.0000019097074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038465748,0.007716483,0.29737964,0.0006168538,0.00082949473,0.00016216443,0.016303528,0.013992499,0.62028,0.0063126013,0.004113585,0.02844656],"study_design_scores_gemma":[0.0029441253,0.002856017,0.934728,0.00012783923,0.00011366933,0.000022790005,0.00043225428,0.0058725527,0.048082076,0.004640155,0.00007095946,0.00010951465],"about_ca_topic_score_codex":0.0005668156,"about_ca_topic_score_gemma":0.00027061187,"teacher_disagreement_score":0.6373484,"about_ca_system_score_codex":0.00007231048,"about_ca_system_score_gemma":0.00015149043,"threshold_uncertainty_score":0.32169628},"labels":[],"label_agreement":null},{"id":"W4387810248","doi":"10.1016/j.annonc.2023.09.2753","title":"1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; AstraZeneca España; Genentech; UroGen Pharma; Advanced Accelerator Applications; Sanofi Genzyme; Pfizer; Incyte; Ipsen; BeiGene; Constellation Pharmaceuticals; Clovis Oncology; Sanofi; Exelixis; Boston Scientific Corporation; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Amgen","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Placebo; Internal medicine; Olaparib; BRCA mutation; Cancer; Urology; Gynecology; Ovarian cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.08187992572353721,"score_gpt":0.39519426297467053,"score_spread":0.31331433725113333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902447,0.0000858026,0.000017343376,0.0046371417,0.00016700357,0.004136545,0.00014388628,0.0000119523,0.0005556203],"genre_scores_gemma":[0.99773145,0.00019467609,0.00013258726,0.00064597436,0.00007310847,0.0009664181,0.0001541876,0.000028353974,0.00007324203],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968459,0.00065382785,0.0011412518,0.0003257857,0.0006520421,0.0003812073],"domain_scores_gemma":[0.99743253,0.0008079513,0.0008539112,0.00039929556,0.00045687854,0.00004942126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020303573,0.00022952308,0.000783705,0.00034579044,0.000053119235,0.000011356959,0.00025960876,0.00011155221,0.00005599287],"category_scores_gemma":[0.00021708364,0.00013833099,0.00010068306,0.0011121201,0.00036371071,0.000140771,0.000023489229,0.0003154606,0.0000069985126],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7024452,0.013880619,0.04013509,0.0023162419,0.0011662631,0.00042460047,0.12049919,0.007590222,0.055471927,0.00061409286,0.012761542,0.042695023],"study_design_scores_gemma":[0.2917446,0.047328204,0.6135502,0.0012329214,0.00040841126,0.00002534117,0.0075624078,0.0009609647,0.032287218,0.00062059757,0.0037839294,0.00049519347],"about_ca_topic_score_codex":0.0011987856,"about_ca_topic_score_gemma":0.0020246943,"teacher_disagreement_score":0.5734151,"about_ca_system_score_codex":0.00012697733,"about_ca_system_score_gemma":0.00091299065,"threshold_uncertainty_score":0.5640974},"labels":[],"label_agreement":null},{"id":"W4387810257","doi":"10.1016/j.annonc.2023.09.2714","title":"1764O Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Prostate-specific antigen; Surgery; Internal medicine; Cancer","score_opus":0.12425507802609304,"score_gpt":0.4441995365997397,"score_spread":0.3199444585736467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791783,0.0025619483,0.00001793016,0.008293535,0.00025874184,0.0050261426,0.00009208788,0.00004054652,0.004530775],"genre_scores_gemma":[0.9908294,0.004608849,0.00035830354,0.00030700525,0.00030269322,0.00063306536,0.00008120777,0.000031868116,0.0028475733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99702454,0.0003724027,0.001249852,0.00032186453,0.0005398933,0.0004914246],"domain_scores_gemma":[0.996975,0.0016622394,0.0004891077,0.00032488996,0.0003480697,0.00020067238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021935871,0.00019986255,0.0018503725,0.00042451252,0.00003519833,0.0000040438413,0.00015553815,0.00027122622,0.00035335615],"category_scores_gemma":[0.0010466059,0.00013733882,0.00049863703,0.00043143058,0.0006911002,0.00005095196,0.00004464147,0.00025264782,0.000009705434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94538975,0.0011462399,0.00023316154,0.0002079914,0.0009894624,0.00028070566,0.0007297841,0.0000064932005,0.011030346,0.000026027139,0.015433475,0.02452658],"study_design_scores_gemma":[0.93076265,0.013823197,0.0012515618,0.00019800209,0.00016844373,0.000016610522,0.00007364587,0.0002841415,0.039481618,0.00016880744,0.013658209,0.000113132155],"about_ca_topic_score_codex":0.00004621201,"about_ca_topic_score_gemma":0.0000030148399,"teacher_disagreement_score":0.028451271,"about_ca_system_score_codex":0.00006038138,"about_ca_system_score_gemma":0.001000102,"threshold_uncertainty_score":0.56005144},"labels":[],"label_agreement":null},{"id":"W4387810259","doi":"10.1016/j.annonc.2023.09.2734","title":"1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Cancer; Urology","score_opus":0.05247597282564745,"score_gpt":0.35081602817611146,"score_spread":0.29834005535046404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196273,0.0016229078,0.0000018997765,0.003988915,0.000036545578,0.002116259,0.00017712521,0.000034340323,0.000059271788],"genre_scores_gemma":[0.9789153,0.019935226,0.00017099742,0.00029767706,0.0000163363,0.00021820763,0.00019297683,0.000044585395,0.00020872238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978541,0.00016350682,0.00045089194,0.00054204336,0.00039912836,0.00059033476],"domain_scores_gemma":[0.99888355,0.00016327946,0.00022798289,0.00022458036,0.00033783566,0.00016275804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003466471,0.00029819913,0.0008848725,0.0005608141,0.00006382406,0.000022925247,0.000063513144,0.00009705818,0.000008811242],"category_scores_gemma":[0.000036748537,0.00019967297,0.000035261695,0.00079815334,0.000447988,0.00022617893,0.000058819158,0.00025951836,0.0000053173044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013879119,0.00072633923,0.9529665,0.00012323027,0.00037921654,0.000707833,0.0042009647,0.00008811835,0.002706669,0.000023609744,0.00034323568,0.023855157],"study_design_scores_gemma":[0.019274557,0.007928375,0.96622914,0.00019692804,0.000033611206,0.000012581746,0.00079245976,0.00011231862,0.0043152403,0.00014673908,0.00074001245,0.0002180127],"about_ca_topic_score_codex":0.0007938351,"about_ca_topic_score_gemma":0.00059029297,"teacher_disagreement_score":0.023637144,"about_ca_system_score_codex":0.00013217724,"about_ca_system_score_gemma":0.00036572816,"threshold_uncertainty_score":0.8142427},"labels":[],"label_agreement":null},{"id":"W4387810265","doi":"10.1016/j.annonc.2023.09.2748","title":"1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); BC Cancer Agency; University of Alberta; University of Calgary","funders":"Ipsen; Eisai; AstraZeneca; Amgen; Pfizer; Astellas Pharma; F. Hoffmann-La Roche","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; PARP inhibitor; Docetaxel; Cancer; Poly ADP ribose polymerase","score_opus":0.1348306269186467,"score_gpt":0.4325496976513883,"score_spread":0.2977190707327416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886433,0.00044339403,0.00002120469,0.008124955,0.00021065453,0.0013028702,0.00030921274,0.00013804832,0.00080634997],"genre_scores_gemma":[0.9937698,0.0018225427,0.0010333767,0.0013821408,0.00014888342,0.00069355173,0.00007260845,0.000052666535,0.0010244073],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979545,0.0001849727,0.000694684,0.000495826,0.0002352543,0.00043479397],"domain_scores_gemma":[0.99797934,0.00048499895,0.00056951004,0.00034594783,0.00041086038,0.00020934292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035661831,0.00026490516,0.00080856885,0.00055594696,0.000074827134,0.000010837461,0.000107099906,0.00007872092,0.00010513148],"category_scores_gemma":[0.00011685124,0.00022292088,0.000091691254,0.0007575179,0.0001450258,0.00014053786,0.00007304082,0.00012552021,0.0000077767645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0100165345,0.0020708663,0.1945833,0.0009730037,0.0016167588,0.00058610266,0.0064425254,0.00032074493,0.25341547,0.00008842326,0.0074477065,0.5224386],"study_design_scores_gemma":[0.008677038,0.017409418,0.28651726,0.00082255685,0.0003148722,0.00007262137,0.00040356038,0.0001384582,0.6830163,0.00030039306,0.0019701174,0.00035736474],"about_ca_topic_score_codex":0.004097497,"about_ca_topic_score_gemma":0.0021053255,"teacher_disagreement_score":0.5220812,"about_ca_system_score_codex":0.00029840562,"about_ca_system_score_gemma":0.00064627215,"threshold_uncertainty_score":0.909045},"labels":[],"label_agreement":null},{"id":"W4387810275","doi":"10.1016/j.annonc.2023.09.2761","title":"1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Astellas Pharma; AstraZeneca; Chugai Pharmaceutical; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Androgen receptor; Oncology; Pharmacology; Pharmacokinetics; Clinical endpoint; Androgen deprivation therapy; Antiandrogens; Clinical trial; Cancer","score_opus":0.2061185689696446,"score_gpt":0.5020156712325335,"score_spread":0.29589710226288896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877167,0.0007120587,0.0000063723974,0.0075647198,0.0001882702,0.0030242,0.00055667147,0.000025893974,0.00020511671],"genre_scores_gemma":[0.9971901,0.0010589589,0.00016262216,0.000093842995,0.000036084515,0.0005712793,0.0006454184,0.000022662158,0.00021902745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971733,0.00032714268,0.001042976,0.00040827531,0.0005121564,0.000536135],"domain_scores_gemma":[0.9983877,0.00030251846,0.00036909193,0.00026255994,0.0004891148,0.00018904886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013429557,0.00021869253,0.00097649905,0.0008571439,0.000052963947,0.0000089257,0.00012426106,0.000072645205,0.00003334526],"category_scores_gemma":[0.00035048937,0.00017257885,0.000076711935,0.0015040006,0.00019510732,0.00013287013,0.0000570384,0.00025970736,0.000006256372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7841515,0.023337321,0.0013430391,0.0005746918,0.00038065735,0.0009508625,0.010161728,0.00067663455,0.03760387,0.00014511307,0.00495669,0.1357179],"study_design_scores_gemma":[0.7942623,0.094476186,0.009665916,0.0011901577,0.00022606428,0.000012296477,0.0017688967,0.0015214515,0.0851167,0.0005191678,0.010852332,0.00038853727],"about_ca_topic_score_codex":0.0024450656,"about_ca_topic_score_gemma":0.007856668,"teacher_disagreement_score":0.13532937,"about_ca_system_score_codex":0.0002771427,"about_ca_system_score_gemma":0.0014700744,"threshold_uncertainty_score":0.7037561},"labels":[],"label_agreement":null},{"id":"W4387810278","doi":"10.1016/j.annonc.2023.09.2742","title":"1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of Ottawa","funders":"","keywords":"PTEN; Enzalutamide; Medicine; Oncology; Prostate cancer; Internal medicine; Proportional hazards model; Docetaxel; Multivariate analysis; Survival analysis; Overall survival; Cancer; Cancer research; Apoptosis; Androgen receptor; PI3K/AKT/mTOR pathway; Biology; Genetics","score_opus":0.2944132847888312,"score_gpt":0.4697874629469143,"score_spread":0.1753741781580831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941885,0.00013993785,0.0000016359539,0.0028474615,0.0005176907,0.0010233095,0.00004460839,0.000034690438,0.0012021745],"genre_scores_gemma":[0.9975971,0.00044902813,0.000021548984,0.00035798133,0.00009388148,0.00017993416,0.00003535688,0.000037367165,0.0012278305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689084,0.0005426248,0.00057824707,0.00046968999,0.0005135578,0.0010050285],"domain_scores_gemma":[0.99759316,0.0014549899,0.000149118,0.00039326047,0.00012644098,0.0002830201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011509105,0.00026485886,0.0010371873,0.00074319565,0.000033640055,0.000009775884,0.00023272063,0.0002485677,0.000059000904],"category_scores_gemma":[0.00080118066,0.00019638798,0.00014373365,0.0008133004,0.00019491749,0.00009273853,0.00015818732,0.00036866826,0.0000771799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12558655,0.0035491842,0.75326097,0.0013118876,0.001124954,0.0081821615,0.01755731,0.00030382906,0.053756442,0.000498193,0.005179555,0.029688993],"study_design_scores_gemma":[0.019859103,0.0220642,0.82360977,0.00055832876,0.00007190557,0.000003469114,0.000617154,0.000029330333,0.13220724,0.00023609203,0.000511615,0.00023176846],"about_ca_topic_score_codex":0.0022899953,"about_ca_topic_score_gemma":0.0033506546,"teacher_disagreement_score":0.10572744,"about_ca_system_score_codex":0.00018769086,"about_ca_system_score_gemma":0.00042347176,"threshold_uncertainty_score":0.80084693},"labels":[],"label_agreement":null},{"id":"W4387810283","doi":"10.1016/j.annonc.2023.09.2758","title":"1810P Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Medical Research Council","keywords":"Medicine; Prostate cancer; Imputation (statistics); Quality of life (healthcare); Progression-free survival; Log-rank test; Oncology; Internal medicine; Missing data; Urology; Gynecology; Cancer; Overall survival; Statistics","score_opus":0.15551892457803307,"score_gpt":0.48387834134422975,"score_spread":0.3283594167661967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928288,0.00017890587,3.8366431e-7,0.0050969245,0.000021643018,0.0017134162,0.00009649208,0.0000055984788,0.00005783606],"genre_scores_gemma":[0.999515,0.00014719457,0.000020658228,0.00006581315,0.0000023454593,0.00006670612,0.000068133886,0.000008142625,0.000106014966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997461,0.00069679983,0.00086999085,0.00014398864,0.0006322196,0.00019600608],"domain_scores_gemma":[0.9974199,0.0006785987,0.0010660068,0.00017635534,0.0006188597,0.000040294326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018648289,0.00009274311,0.0007951975,0.00018032941,0.000029703973,0.0000018383553,0.000072392155,0.00004008868,0.0000127525855],"category_scores_gemma":[0.00029083446,0.000048020804,0.000043060187,0.00065797666,0.000092479866,0.000047576515,0.000018312916,0.000115332485,5.191841e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062626204,0.004929884,0.9730032,0.00033197182,0.00066464045,0.0000060791535,0.010801055,0.00019215632,0.00018497577,0.000017015263,0.00021186331,0.0033945371],"study_design_scores_gemma":[0.011905881,0.018876579,0.96498793,0.00010960693,0.00006708487,8.736361e-8,0.0037378455,0.00000910611,0.00022589981,0.000022410224,0.000020150144,0.000037395403],"about_ca_topic_score_codex":0.004048802,"about_ca_topic_score_gemma":0.0033298356,"teacher_disagreement_score":0.013946694,"about_ca_system_score_codex":0.0000890345,"about_ca_system_score_gemma":0.0007559928,"threshold_uncertainty_score":0.6120604},"labels":[],"label_agreement":null},{"id":"W4387810297","doi":"10.1016/j.annonc.2023.09.2724","title":"1774P PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Sexual function; International Prostate Symptom Score; Internal medicine; Randomized controlled trial; Physical therapy; Cancer; Lower urinary tract symptoms; Prostate; Nursing","score_opus":0.07784553522504989,"score_gpt":0.440968325828364,"score_spread":0.3631227906033141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909037,0.0012085782,0.0000038841035,0.0008835075,0.00053945853,0.0056240247,0.00074850896,0.00006387441,0.000024464809],"genre_scores_gemma":[0.996117,0.0007523218,0.00002674825,0.00049433473,0.00008118313,0.0020491297,0.00040699815,0.000035046374,0.000037252],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954861,0.0011700077,0.0017153365,0.00057601655,0.0006576631,0.00039490324],"domain_scores_gemma":[0.9951237,0.0011898002,0.0017052505,0.00038072563,0.0012290754,0.0003714581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007930663,0.0003542059,0.0030554936,0.00022168667,0.000057967463,0.000010387431,0.00009978316,0.0001438778,0.000029878784],"category_scores_gemma":[0.0004218715,0.00024253465,0.0006487954,0.00047781158,0.0012918746,0.00011902821,0.00010983522,0.00027556092,4.1382935e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5379241,0.004119081,0.41315633,0.001021207,0.001248581,0.000015280171,0.00087451894,0.00007905436,0.000044201795,0.0000024161213,0.00026549413,0.041249756],"study_design_scores_gemma":[0.3359889,0.02052232,0.6404728,0.00026020067,0.00094546925,1.2813993e-7,0.0005682038,0.00041606912,0.00014018954,0.000049724444,0.00042487256,0.00021106322],"about_ca_topic_score_codex":0.0044330712,"about_ca_topic_score_gemma":0.000921643,"teacher_disagreement_score":0.22731653,"about_ca_system_score_codex":0.00005821713,"about_ca_system_score_gemma":0.0016139274,"threshold_uncertainty_score":0.98902756},"labels":[],"label_agreement":null},{"id":"W4387810308","doi":"10.1016/j.annonc.2023.09.2759","title":"1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Foundation Medicine; Pharmacyclics; Takeda Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; PharmaMar; Novartis Farmacéutica; Astellas Pharma; Eisai; Plexxikon; Seagen; UroGen Pharma; Pfizer; Incyte; Arog Pharmaceuticals; Exelixis; Karyopharm Therapeutics; MEI Pharma; Clovis Oncology; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Boston Scientific Corporation; Bayer Yakuhin; Novartis; Astellas Foundation for Research on Metabolic Disorders; Endocyte; Merck KGaA; Sanofi; Cilag; Puma Biotechnology; Advanced Accelerator Applications; Janssen Biotech; Teva Pharmaceutical Industries; Amgen; Myriad Genetics; ImmunoMedics; Eli Lilly and Company; Invitae; AstraZeneca; Lantheus Medical Imaging","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Placebo; Cancer; Androgen receptor; Pathology; Alternative medicine","score_opus":0.07905098879133958,"score_gpt":0.4067292390465667,"score_spread":0.3276782502552271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883337,0.00024304283,0.000011524676,0.00538208,0.00019705482,0.0036900362,0.0005870938,0.00022511138,0.00083071674],"genre_scores_gemma":[0.99566156,0.0003128839,0.00067412265,0.00043106102,0.000034598343,0.0016641229,0.0006169825,0.000055879445,0.0005487921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995763,0.00055020646,0.0017228696,0.000855914,0.00057718257,0.0005308236],"domain_scores_gemma":[0.99639696,0.0010853318,0.0012047477,0.0005101087,0.0006129789,0.00018989826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014768436,0.00037476126,0.0011303741,0.00064703374,0.00018202313,0.000029904984,0.00010520932,0.00015144146,0.00007327561],"category_scores_gemma":[0.00084673066,0.00033092123,0.000112478374,0.0010506284,0.0002839929,0.00031600715,0.00006478878,0.00037602693,0.0000061026044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17712219,0.02453113,0.41502258,0.00067989225,0.008794677,0.011445315,0.16029066,0.0045672925,0.069952175,0.00023806281,0.018846193,0.10850981],"study_design_scores_gemma":[0.19298579,0.03910686,0.7017781,0.0011259757,0.0012881408,0.00029739775,0.031189851,0.0038754954,0.022114052,0.0022693467,0.002734386,0.0012345919],"about_ca_topic_score_codex":0.0041784304,"about_ca_topic_score_gemma":0.00556803,"teacher_disagreement_score":0.28675553,"about_ca_system_score_codex":0.00032595472,"about_ca_system_score_gemma":0.00085580343,"threshold_uncertainty_score":0.9999143},"labels":[],"label_agreement":null},{"id":"W4387810341","doi":"10.1016/j.annonc.2023.09.2772","title":"1824P Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Hormonal therapy; Castration; Oncology; Internal medicine; Cancer; Hormone; Prostate; Gynecology","score_opus":0.13838977258649449,"score_gpt":0.4246881495505144,"score_spread":0.28629837696401994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961497,0.00033275588,0.000004245744,0.0016320532,0.0000694525,0.0011178363,0.0002813173,0.000038747894,0.00037387738],"genre_scores_gemma":[0.9950722,0.0024832748,0.000081995124,0.00015120485,0.000037441045,0.00065512495,0.00032908618,0.000024495886,0.001165188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858046,0.00004852794,0.0002863664,0.00029091857,0.00036796773,0.00042578843],"domain_scores_gemma":[0.99902034,0.00008840517,0.00015221449,0.00019394062,0.00038370362,0.00016138621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011732089,0.00019304885,0.00042718512,0.00017245003,0.00008519083,0.0000114888735,0.00007216911,0.00005366968,0.00015743518],"category_scores_gemma":[0.0000128692545,0.000112609734,0.000085425796,0.0003507267,0.00020987324,0.00010013229,0.000022088001,0.00008559204,0.000009932872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009928704,0.0035494128,0.85348123,0.000107176915,0.0015312883,0.00031783234,0.009838891,0.00008827319,0.012702319,0.000045237513,0.0008596065,0.10755002],"study_design_scores_gemma":[0.010648754,0.016840715,0.9502919,0.00008615357,0.000070604074,0.0000030163105,0.0010636052,0.000057133813,0.018391429,0.000024250983,0.0023876687,0.00013479852],"about_ca_topic_score_codex":0.0011604767,"about_ca_topic_score_gemma":0.00049420557,"teacher_disagreement_score":0.10741522,"about_ca_system_score_codex":0.00014371933,"about_ca_system_score_gemma":0.00064626086,"threshold_uncertainty_score":0.45920917},"labels":[],"label_agreement":null},{"id":"W4387810343","doi":"10.1016/j.annonc.2023.09.2731","title":"1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cancer; Quality of life (healthcare); Urology; Oncology; Gastroenterology","score_opus":0.11302744526953401,"score_gpt":0.4023910409696842,"score_spread":0.2893635957001502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825509,0.0025891308,0.0000069621237,0.008777564,0.00013805518,0.0021577037,0.0036400347,0.00006116974,0.00007845835],"genre_scores_gemma":[0.991258,0.003976722,0.00029487192,0.00028695888,0.00003052395,0.00020578018,0.0036444217,0.00005589999,0.0002467984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531424,0.00063515396,0.0017915927,0.0006282286,0.0008800089,0.00075076544],"domain_scores_gemma":[0.99674624,0.00049582694,0.0010071755,0.00057739014,0.00082528486,0.0003480961],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012296431,0.00035081117,0.0014474945,0.00038609232,0.000112433474,0.000021391115,0.00023929743,0.00019296372,0.00015926895],"category_scores_gemma":[0.00030056227,0.00027619887,0.00011585518,0.0012622497,0.0004186973,0.00019736002,0.00011481459,0.0003210459,0.000015497488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03408226,0.0024124943,0.8981369,0.0005385225,0.0009036458,0.00014078009,0.0031773963,0.00026594274,0.034849964,0.00002142508,0.006461239,0.01900943],"study_design_scores_gemma":[0.016819071,0.0076818615,0.9675951,0.00031693061,0.00004794827,9.22296e-7,0.0006283181,0.00013808717,0.0045713247,0.00033355047,0.0015915448,0.00027534773],"about_ca_topic_score_codex":0.019709246,"about_ca_topic_score_gemma":0.012008358,"teacher_disagreement_score":0.069458194,"about_ca_system_score_codex":0.0002763587,"about_ca_system_score_gemma":0.0017817265,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W4387810347","doi":"10.1016/j.annonc.2023.09.2728","title":"1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Clinical endpoint; Urology; Placebo; Internal medicine; Gynecology; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Pathology","score_opus":0.04619213243928624,"score_gpt":0.3734757764249406,"score_spread":0.32728364398565435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201155,0.0015822296,0.000003081387,0.003980043,0.0000664083,0.0010028926,0.00039623622,0.00003725282,0.0009203048],"genre_scores_gemma":[0.98649496,0.011646185,0.000329939,0.000087262415,0.00003414669,0.0003561861,0.0004294555,0.0000332418,0.00058861345],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982106,0.00019406895,0.00043464845,0.00040574078,0.0003338475,0.00042107512],"domain_scores_gemma":[0.9986765,0.0002878318,0.00033055776,0.0002701699,0.00029486167,0.00014008739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033011186,0.00023111604,0.0007209806,0.0003245311,0.000035937708,0.0000063476737,0.00010137067,0.00014061308,0.00008953227],"category_scores_gemma":[0.000045261415,0.00015022383,0.000072168215,0.00048937,0.0003415202,0.00008393573,0.0000491399,0.00026426036,0.000009990882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047127817,0.004113354,0.26640385,0.00051566097,0.0022681267,0.0011590652,0.0073282975,0.00020395285,0.03577818,0.00011888344,0.0025516553,0.63243115],"study_design_scores_gemma":[0.03116746,0.023057533,0.38673005,0.0008492055,0.0003033488,0.00002206141,0.00069774955,0.0001374849,0.550928,0.0015337368,0.004296004,0.00027739443],"about_ca_topic_score_codex":0.0033821634,"about_ca_topic_score_gemma":0.0017337472,"teacher_disagreement_score":0.63215375,"about_ca_system_score_codex":0.00025132805,"about_ca_system_score_gemma":0.001176128,"threshold_uncertainty_score":0.612595},"labels":[],"label_agreement":null},{"id":"W4387810358","doi":"10.1016/j.annonc.2023.09.2716","title":"1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Ipsen; Astellas Foundation for Research on Metabolic Disorders; Eisai; Sanofi; Clovis Oncology; PharmaMar; AstraZeneca; Pfizer","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Internal medicine; Prostatectomy; Biochemical recurrence; Placebo; Urology; Population; Oncology; Radiation therapy; Visual analogue scale; Gynecology; Cancer; Physical therapy; Pathology","score_opus":0.11017685590830867,"score_gpt":0.42880239856157587,"score_spread":0.3186255426532672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882647,0.0019473224,0.0000010333727,0.006941647,0.00009622776,0.0019067592,0.00076467916,0.00002180537,0.000055826087],"genre_scores_gemma":[0.99463665,0.004381014,0.000051900603,0.00035011824,0.000025617062,0.00017706947,0.00028738024,0.000020663509,0.00006955519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680096,0.0009281907,0.0008739388,0.00041296383,0.0005132222,0.00047072757],"domain_scores_gemma":[0.9974247,0.00095073535,0.0006228026,0.0003400138,0.00047744124,0.00018430648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013289264,0.00019326128,0.00097009254,0.00015583141,0.000069710535,0.000004627206,0.00014892666,0.0000980781,0.00002419255],"category_scores_gemma":[0.000612894,0.00011726686,0.00007285465,0.0009288597,0.0004079907,0.000056149587,0.000108470784,0.00043310394,0.000015220812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016116736,0.0037692273,0.91370165,0.000148771,0.0011289823,0.00008969342,0.020653836,0.00005487197,0.00070998055,0.000013474152,0.009719943,0.03389283],"study_design_scores_gemma":[0.010200582,0.010013036,0.9733612,0.00019010952,0.000078238045,6.0173625e-7,0.0041367607,0.000041872707,0.001553929,0.00020695412,0.00010085712,0.00011584119],"about_ca_topic_score_codex":0.025994666,"about_ca_topic_score_gemma":0.0019252046,"teacher_disagreement_score":0.05965956,"about_ca_system_score_codex":0.00014182915,"about_ca_system_score_gemma":0.001033672,"threshold_uncertainty_score":0.98049134},"labels":[],"label_agreement":null},{"id":"W4387810362","doi":"10.1016/j.annonc.2023.09.2764","title":"1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer; AstraZeneca; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Radium-223; Docetaxel; Internal medicine; Oncology; Cancer; Androgen receptor; Bone metastasis","score_opus":0.10025213596044721,"score_gpt":0.4213820801680757,"score_spread":0.3211299442076285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190366,0.000109101944,8.5918526e-7,0.0060909498,0.000008170282,0.0014069235,0.00003147389,0.000011690395,0.00043718488],"genre_scores_gemma":[0.99875224,0.0001867038,0.000038550632,0.00023625499,0.000010742452,0.0005852762,0.00005552423,0.000009451679,0.0001252864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990053,0.00012525827,0.00026176355,0.00021591899,0.0002022754,0.00018946327],"domain_scores_gemma":[0.99936604,0.00019815208,0.00011152757,0.00015667547,0.00010757044,0.000060002447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031691778,0.00012008646,0.00029598403,0.00008179037,0.000045811357,0.000007924296,0.000053909214,0.000034824512,0.000009245389],"category_scores_gemma":[0.000027055017,0.000071052724,0.000016732438,0.0004920162,0.000109007386,0.00004942173,0.000008468732,0.000120788514,0.0000015202918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075241467,0.017387252,0.9082527,0.00033498817,0.00055720325,0.0005553473,0.01256699,0.0005818,0.004070402,0.00034433015,0.0006759985,0.04714881],"study_design_scores_gemma":[0.014529051,0.011572753,0.96523684,0.000079829566,0.00020752686,0.000015534068,0.0027967943,0.00024350117,0.0028973308,0.00011687212,0.0021891813,0.0001147812],"about_ca_topic_score_codex":0.00039442233,"about_ca_topic_score_gemma":0.0012314601,"teacher_disagreement_score":0.05698411,"about_ca_system_score_codex":0.0000777928,"about_ca_system_score_gemma":0.00017514467,"threshold_uncertainty_score":0.28974462},"labels":[],"label_agreement":null},{"id":"W4387810382","doi":"10.1016/j.annonc.2023.09.2727","title":"1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Municipal Health Commission","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Biochemical recurrence; Internal medicine; Clinical endpoint; Cancer; Clinical trial; Androgen receptor","score_opus":0.08273213936567804,"score_gpt":0.41819373290201484,"score_spread":0.3354615935363368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980982,0.0070356037,0.0000117846375,0.009216541,0.00015082293,0.0016261906,0.0006342248,0.00003286177,0.0003099871],"genre_scores_gemma":[0.92367643,0.072176546,0.00033342335,0.00038089708,0.00015461599,0.001127154,0.00013491741,0.00003730226,0.0019786984],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860865,0.00007975209,0.00033341983,0.00031839282,0.0002265109,0.00043328851],"domain_scores_gemma":[0.99838316,0.0006179004,0.00023802038,0.00032736428,0.0003215338,0.00011200712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003539944,0.00018964443,0.0005325215,0.00013612723,0.00008469397,0.000005017929,0.00014079934,0.00011886126,0.00011542517],"category_scores_gemma":[0.00005348787,0.00010218587,0.00014648987,0.00034432372,0.00041331153,0.000042144053,0.000027754226,0.0001658348,0.0000076126053],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026699623,0.0016239007,0.03469882,0.0004222636,0.0027516335,0.00009313594,0.004783324,0.0000837776,0.02419036,0.00015531827,0.037990823,0.866507],"study_design_scores_gemma":[0.014693752,0.028449262,0.038886268,0.00026227097,0.000346283,0.00001513534,0.0007223989,0.00019905083,0.81707954,0.00108228,0.09805038,0.00021338057],"about_ca_topic_score_codex":0.0006680955,"about_ca_topic_score_gemma":0.00014294739,"teacher_disagreement_score":0.8662936,"about_ca_system_score_codex":0.0001168622,"about_ca_system_score_gemma":0.00089302904,"threshold_uncertainty_score":0.41670188},"labels":[],"label_agreement":null},{"id":"W4387810384","doi":"10.1016/j.annonc.2023.09.2689","title":"1735P Impact of revised US Preventive Services Task Force (USPSTF) 2021 lung cancer screening guideline on long-term cancer survivors in the United States","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cancer; Lung cancer; Guideline; Incidence (geometry); Lung cancer screening; Internal medicine; Pathology","score_opus":0.07998771578137884,"score_gpt":0.4707466220659761,"score_spread":0.3907589062845973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844533,0.0044589685,0.000010293836,0.009481807,0.00012889551,0.0005886122,0.00021292183,0.000017216127,0.0006479354],"genre_scores_gemma":[0.9682698,0.027799105,0.000026693593,0.0028545668,0.00017497783,0.00013449199,0.00025466105,0.000024437262,0.00046124385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980757,0.00028303656,0.0006591684,0.0002686414,0.00028381532,0.00042963473],"domain_scores_gemma":[0.99825084,0.0005060791,0.00037061973,0.00027188184,0.0005250707,0.00007552288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095974235,0.00020458364,0.00083817774,0.00034646306,0.000059805185,0.000004979241,0.00019957933,0.00011287779,0.00029143936],"category_scores_gemma":[0.00010521574,0.00013381112,0.00019151418,0.0011881845,0.000117676434,0.00006287856,0.000082423896,0.00022500366,0.000002782424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022140823,0.00039672892,0.9052036,0.0009893451,0.001283948,0.00015250167,0.008313181,0.0060633966,0.0017951045,0.000013695242,0.026643425,0.046931002],"study_design_scores_gemma":[0.002377413,0.0033976464,0.97783715,0.0023420618,0.0001982777,0.0000042829115,0.0012783824,0.0034314645,0.0014624486,0.000025281812,0.0074649397,0.00018066428],"about_ca_topic_score_codex":0.037016086,"about_ca_topic_score_gemma":0.026647402,"teacher_disagreement_score":0.07263355,"about_ca_system_score_codex":0.00009897432,"about_ca_system_score_gemma":0.0003273819,"threshold_uncertainty_score":0.9911137},"labels":[],"label_agreement":null},{"id":"W4387810435","doi":"10.1016/j.annonc.2023.09.2657","title":"1703P Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Cancer drugs; Oncology; Targeted therapy; Cancer; Personalized medicine; Internal medicine; Bioinformatics","score_opus":0.023542600351871158,"score_gpt":0.3332035968996864,"score_spread":0.30966099654781526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96901864,0.02693136,0.0001246655,0.0025187132,0.00020918541,0.00018657977,0.00023486764,0.000009305098,0.0007667119],"genre_scores_gemma":[0.97261417,0.02544309,0.00032840343,0.0011189478,0.000117781456,0.00004369064,0.00013744006,0.00002644169,0.00017002597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989952,0.00006504296,0.00028534644,0.000284685,0.0000995836,0.0002701378],"domain_scores_gemma":[0.9992195,0.000050468203,0.00019012229,0.00026656597,0.00019581307,0.00007753655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026887498,0.00014039222,0.00031046284,0.000088724155,0.000034842942,0.0000049749633,0.00017195487,0.0001861977,0.00003620708],"category_scores_gemma":[0.0001128921,0.00014058908,0.00009992739,0.00015000775,0.00018577476,0.0000028126335,0.0001890055,0.00007029778,0.0000032333069],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015908408,0.00008816167,0.0016063909,0.000049969152,0.0002517464,0.000010709332,0.0002222098,0.0006259893,0.9779812,0.0007357895,0.009439022,0.008829689],"study_design_scores_gemma":[0.0010837775,0.0022706245,0.017725648,0.000012456708,0.000052050582,0.0000068050767,0.00024158845,0.000120000055,0.6448552,0.003152383,0.33018255,0.00029689245],"about_ca_topic_score_codex":0.00018319383,"about_ca_topic_score_gemma":0.00010299596,"teacher_disagreement_score":0.333126,"about_ca_system_score_codex":0.000009262362,"about_ca_system_score_gemma":0.00020257031,"threshold_uncertainty_score":0.5733056},"labels":[],"label_agreement":null},{"id":"W4387810466","doi":"10.1016/j.annonc.2023.09.2645","title":"1691O Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre in a public healthcare system","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pandemic; Declaration; Cancer; Coronavirus disease 2019 (COVID-19); Public health; Logistic regression; Family medicine; Health care; Emergency medicine; Pediatrics; Internal medicine; Disease; Nursing; Infectious disease (medical specialty)","score_opus":0.3812513752166195,"score_gpt":0.5117998668380153,"score_spread":0.13054849162139576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70772284,0.001197602,6.5819637e-7,0.2901514,0.0001428119,0.00045302807,0.00008122099,0.00006423761,0.00018623294],"genre_scores_gemma":[0.97774386,0.0013569803,0.000006564349,0.020175435,0.00007588082,0.00006648652,0.000064525135,0.000015867228,0.000494419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785244,0.00039123252,0.00063409406,0.00028826602,0.00023496205,0.0005990276],"domain_scores_gemma":[0.99775636,0.0009461498,0.00025379108,0.0002555196,0.00025726852,0.0005309339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032873612,0.00014670927,0.00056966627,0.0007524038,0.000115591174,0.000005812082,0.00010465216,0.00019179887,0.00010586427],"category_scores_gemma":[0.00062557164,0.000114494396,0.00008428243,0.0015444567,0.00009876815,0.00004683854,0.00009689627,0.00032363698,0.000020389378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009967355,0.00016676012,0.8760503,0.001722439,0.00007489282,0.00052133674,0.026277592,0.00036741176,0.00036616207,0.0006668433,0.028102862,0.06468667],"study_design_scores_gemma":[0.0042859395,0.00072979473,0.7771465,0.00031344718,0.000017270095,0.00013834418,0.008741432,0.00019746252,0.00003299336,0.0000512224,0.20822312,0.0001224492],"about_ca_topic_score_codex":0.032393806,"about_ca_topic_score_gemma":0.18528703,"teacher_disagreement_score":0.27002102,"about_ca_system_score_codex":0.0019177682,"about_ca_system_score_gemma":0.00412017,"threshold_uncertainty_score":0.97404957},"labels":[],"label_agreement":null},{"id":"W4387810503","doi":"10.1016/j.annonc.2023.09.2567","title":"1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier; Eisai; Relay Therapeutics; Springworks Therapeutics; Revolution Medicines; Incyte; Novocure; Mersana Therapeutics; Eli Lilly and Company; AstraZeneca; Celgene; Ipsen; BeiGene; Sanofi; Pfizer","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Adenocarcinoma; Cancer research; Antibody; Oncology; Pancreatic cancer; Internal medicine; Cancer; Immunology","score_opus":0.07373313948172684,"score_gpt":0.4170988546425355,"score_spread":0.34336571516080866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97505546,0.002229778,0.000003505684,0.00863463,0.00017657573,0.00068547257,0.0000712562,0.0000455501,0.0130977845],"genre_scores_gemma":[0.99000984,0.0053251972,0.00032727048,0.0003956404,0.00015847248,0.000024764908,0.00022178418,0.000039952585,0.003497071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99709654,0.00022357928,0.0008222025,0.0005029433,0.0005861391,0.0007685908],"domain_scores_gemma":[0.99782014,0.0008721033,0.0002690287,0.00039812672,0.00040857098,0.00023202138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006642991,0.00027224424,0.0011374241,0.0006426291,0.00008452102,0.0000071998306,0.00028759416,0.00024666448,0.0004913371],"category_scores_gemma":[0.0003756555,0.0002319523,0.00027501752,0.0011930937,0.00040570032,0.00010812577,0.0002651073,0.00043639683,0.00020802062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017240731,0.0027463231,0.29294986,0.0010951249,0.00057661766,0.004444616,0.002966129,0.00012665667,0.6179066,0.0016687611,0.013075942,0.04520264],"study_design_scores_gemma":[0.0042120735,0.0074658277,0.9307894,0.00055840216,0.00006031469,0.0002839679,0.00089608954,0.00032415628,0.04506543,0.0005159911,0.0095781805,0.0002501752],"about_ca_topic_score_codex":0.001213736,"about_ca_topic_score_gemma":0.00014623774,"teacher_disagreement_score":0.63783956,"about_ca_system_score_codex":0.000092358714,"about_ca_system_score_gemma":0.00047360052,"threshold_uncertainty_score":0.94587404},"labels":[],"label_agreement":null},{"id":"W4387810529","doi":"10.1016/j.annonc.2023.09.2538","title":"1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Chemotherapy; Combination therapy; Phases of clinical research; non-small cell lung cancer (NSCLC); Lung cancer; Cisplatin","score_opus":0.08150752208758626,"score_gpt":0.4458721133865545,"score_spread":0.36436459129896825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417794,0.0009896689,0.000056430694,0.00026991326,0.000027075148,0.004342086,0.000075265845,0.000018802728,0.0000428225],"genre_scores_gemma":[0.9913488,0.005921415,0.0017089042,0.00014441914,0.000018237975,0.000597585,0.000018294575,0.00007671044,0.00016563678],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99775803,0.00019397704,0.0006881834,0.00050261983,0.00038472447,0.00047246792],"domain_scores_gemma":[0.9981603,0.00046594298,0.0004503371,0.0003851949,0.00036694857,0.00017124701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030603187,0.00034654912,0.0012676859,0.00034558531,0.000054135737,0.0000066178595,0.00012555468,0.000096559554,0.0001063217],"category_scores_gemma":[0.000042304855,0.00020518327,0.00004564541,0.0005321013,0.00026033644,0.00008313121,0.00004133424,0.00016569516,4.2269994e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14217606,0.0252567,0.55296767,0.0016811722,0.0007916452,0.00020914972,0.02253959,0.00033724253,0.011378564,2.0630186e-7,0.00010855934,0.24255347],"study_design_scores_gemma":[0.31561762,0.3649114,0.219398,0.003417923,0.0004933792,0.00002922746,0.007317201,0.005111426,0.08158801,0.000005282831,0.0015187435,0.00059175876],"about_ca_topic_score_codex":0.002438912,"about_ca_topic_score_gemma":0.0074188635,"teacher_disagreement_score":0.3396547,"about_ca_system_score_codex":0.00018571576,"about_ca_system_score_gemma":0.00066822907,"threshold_uncertainty_score":0.83671314},"labels":[],"label_agreement":null},{"id":"W4387810553","doi":"10.1016/j.annonc.2023.09.2572","title":"1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Progressive disease; Atezolizumab; Gemcitabine; Chemotherapy; Cancer; Gastroenterology; Immunotherapy; Nivolumab","score_opus":0.06656061876900553,"score_gpt":0.3792253383067788,"score_spread":0.31266471953777325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945635,0.0011089781,0.0000029154921,0.0027098767,0.00007135332,0.00091364334,0.0004438749,0.000011898716,0.00017394494],"genre_scores_gemma":[0.99374944,0.0047032614,0.00008187897,0.00038940492,0.000062878535,0.00015174609,0.00061651703,0.0000262609,0.00021859378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818206,0.00023915108,0.00044961236,0.0005046774,0.0002109523,0.0004135353],"domain_scores_gemma":[0.99887097,0.00026474788,0.0001827862,0.00044750932,0.00013846265,0.00009551988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034956273,0.00020733365,0.0004018638,0.00008323064,0.00008572593,0.00001514762,0.00024571037,0.00009137011,0.0000351309],"category_scores_gemma":[0.00046721997,0.00014105925,0.00006784633,0.00030729853,0.0001589145,0.000011205557,0.00018926279,0.00012394923,0.000013539522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05237934,0.0066238027,0.7665271,0.000109753346,0.0027918057,0.0009436382,0.005953811,0.00029845012,0.0044652764,0.000023923149,0.019549245,0.14033382],"study_design_scores_gemma":[0.028901242,0.02650024,0.9208195,0.000060336566,0.00009548535,0.000017223652,0.0018251613,0.000100924044,0.005631827,0.00057506777,0.015141018,0.0003319711],"about_ca_topic_score_codex":0.0018518377,"about_ca_topic_score_gemma":0.008116707,"teacher_disagreement_score":0.15429237,"about_ca_system_score_codex":0.000031334574,"about_ca_system_score_gemma":0.00016100683,"threshold_uncertainty_score":0.5752229},"labels":[],"label_agreement":null},{"id":"W4387810649","doi":"10.1016/j.annonc.2023.09.2456","title":"1425P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; AstraZeneca (Canada); McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Liquid biopsy; Internal medicine; Biopsy; Oncology; Epidermal growth factor receptor; KRAS; Lung; Pathology; Adenocarcinoma; Cancer; Stage (stratigraphy); Colorectal cancer","score_opus":0.0755076546906056,"score_gpt":0.43558565998203963,"score_spread":0.360078005291434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944044,0.0018942243,0.000063932646,0.0023433906,0.00031707072,0.0003850632,0.0004120958,0.0000046226487,0.00017523866],"genre_scores_gemma":[0.97410005,0.025046898,0.00017136724,0.0003481479,0.00014121842,0.00013463995,0.000025976608,0.000016481443,0.0000151887125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856126,0.0000992928,0.00072392996,0.0002692568,0.00008537354,0.00026087236],"domain_scores_gemma":[0.998019,0.0009580505,0.00041538538,0.00032597085,0.0002198466,0.0000617792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010568064,0.00010686143,0.00039874975,0.00005397704,0.000030156625,0.0000024102303,0.0002397716,0.000217757,0.000016672368],"category_scores_gemma":[0.0014346804,0.00009160243,0.0001993768,0.00018339336,0.00023171255,0.000003165531,0.00015929967,0.00009375171,5.0538864e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01150857,0.0011978298,0.5469601,0.00055657723,0.000841575,0.000015853422,0.00094717706,0.003154814,0.21778081,0.00067861285,0.018134173,0.1982239],"study_design_scores_gemma":[0.003644113,0.009387928,0.5824936,0.00016300508,0.00014569284,0.0000023502782,0.0006540687,0.0029989295,0.34552768,0.0002422821,0.05438248,0.00035783774],"about_ca_topic_score_codex":0.0005957129,"about_ca_topic_score_gemma":0.0006721866,"teacher_disagreement_score":0.19786607,"about_ca_system_score_codex":0.000010119625,"about_ca_system_score_gemma":0.00041734998,"threshold_uncertainty_score":0.37354386},"labels":[],"label_agreement":null},{"id":"W4387810683","doi":"10.1016/j.annonc.2023.09.2394","title":"1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Alectinib; Internal medicine; Cohort; Oncology; Population; Clinical endpoint; Biomarker; Crizotinib; Clinical trial; Lung cancer","score_opus":0.060788862811507575,"score_gpt":0.3755104978870426,"score_spread":0.314721635075535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971434,0.0006390191,0.00038182753,0.00037908368,0.00012256164,0.0005215022,0.0006340843,0.000022775035,0.00015573976],"genre_scores_gemma":[0.9956129,0.0004883628,0.0008962742,0.00032279326,0.000067268265,0.00009610488,0.0024343668,0.000038458016,0.00004343117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844486,0.00008322206,0.00052821834,0.0004843304,0.00009745733,0.00036192389],"domain_scores_gemma":[0.99844366,0.00037734123,0.0004026299,0.00029947687,0.00037112375,0.00010576411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019523235,0.00024688023,0.00064985716,0.00014983113,0.000071997834,0.00000980825,0.00013670344,0.00016162575,0.000018123299],"category_scores_gemma":[0.0003930843,0.00023634266,0.00019922931,0.0003202151,0.00012449785,0.0000050573035,0.00006807101,0.000041510088,0.0000014285035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046236956,0.00031427693,0.051731262,0.00002473344,0.001138849,0.000017566952,0.000045893445,0.00021653678,0.93230206,0.0000055018727,0.00093993294,0.012800998],"study_design_scores_gemma":[0.004565041,0.0028019657,0.13600218,0.000019999858,0.00037627041,0.0000099722265,0.000077213575,0.0014594262,0.8497588,0.00014929034,0.004498974,0.0002808345],"about_ca_topic_score_codex":0.00081304455,"about_ca_topic_score_gemma":0.0005365843,"teacher_disagreement_score":0.08427093,"about_ca_system_score_codex":0.000021891141,"about_ca_system_score_gemma":0.00029495056,"threshold_uncertainty_score":0.9637774},"labels":[],"label_agreement":null},{"id":"W4387810684","doi":"10.1016/j.annonc.2023.09.2398","title":"1365P Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Neurocognitive; Lung cancer; Adverse effect; Subgroup analysis; Mood; Cochrane Library; Population; Oncology; Cognition; Psychiatry","score_opus":0.18147104045251133,"score_gpt":0.4702237318090901,"score_spread":0.2887526913565788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057846846,0.98266965,0.0000036558615,0.0017256689,0.00010060522,0.013981178,0.00037071184,0.00006227165,0.0010284272],"genre_scores_gemma":[0.00009883671,0.988384,0.00003272259,0.0029270449,0.000020723994,0.0056080413,0.00009604511,0.00012123825,0.002711337],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99418354,0.0011331022,0.002802761,0.0009302537,0.0003701351,0.0005802184],"domain_scores_gemma":[0.99497426,0.0015029411,0.0020224038,0.0005163061,0.0007214645,0.00026261626],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0015661473,0.0007604659,0.017295223,0.001529584,0.000044827906,0.000003151461,0.00023133075,0.00045195306,0.00017703327],"category_scores_gemma":[0.0011726659,0.00056958356,0.0027722558,0.003733988,0.00009637752,0.00005300078,0.00031774613,0.000776152,0.00008604693],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003466015,0.00022369147,0.000047752925,0.8045674,0.18974818,0.00023591015,0.00030553012,0.0000054280913,7.734842e-8,0.0000015392807,0.0012411133,0.0035887084],"study_design_scores_gemma":[0.0006828334,0.0009127682,0.0000999045,0.14014955,0.8463087,0.00003385482,0.00010102084,0.000009635527,5.7398205e-7,0.0000066095545,0.0113233095,0.00037122695],"about_ca_topic_score_codex":0.00020516178,"about_ca_topic_score_gemma":0.0003720786,"teacher_disagreement_score":0.66441786,"about_ca_system_score_codex":0.00025078902,"about_ca_system_score_gemma":0.0006083994,"threshold_uncertainty_score":0.9996756},"labels":[],"label_agreement":null},{"id":"W4387810689","doi":"10.1016/j.annonc.2023.09.2386","title":"1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Lung cancer; Cohort; Proportional hazards model; Demographics; Targeted therapy; Cancer; Progression-free survival; Exact test; Overall survival; Confidence interval; Demography","score_opus":0.026993990122922862,"score_gpt":0.42107418582286066,"score_spread":0.3940801956999378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676234,0.00024473236,0.000070079645,0.0014429447,0.000083231054,0.000726777,0.000047991598,0.00002160422,0.010600287],"genre_scores_gemma":[0.9982545,0.00022269782,0.0002181045,0.0002052636,0.000032797558,0.0002188044,0.00014749612,0.000016519176,0.00068386225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992122,0.00006162459,0.00024973793,0.0001647871,0.0001233774,0.00018829563],"domain_scores_gemma":[0.99920917,0.00026004823,0.00016710296,0.00012659564,0.00017875148,0.00005835756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016369823,0.000104070874,0.0003660899,0.00025749984,0.000029712504,0.0000021038431,0.000045597353,0.000083605,0.000070537986],"category_scores_gemma":[0.000029188168,0.00007913937,0.000061245715,0.00044104602,0.000083296625,0.000050624218,0.000011263416,0.00008566425,0.000015091273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017526759,0.0010714997,0.8839899,0.0015157263,0.0009884911,0.000625042,0.01333631,0.00593051,0.016597364,0.00012884638,0.011412349,0.062651336],"study_design_scores_gemma":[0.014819831,0.011733346,0.8672017,0.0005970413,0.0011221006,0.00002603807,0.001098527,0.0015956883,0.09832836,0.000073126146,0.0031778296,0.00022644427],"about_ca_topic_score_codex":0.0007560654,"about_ca_topic_score_gemma":0.0003514751,"teacher_disagreement_score":0.08173099,"about_ca_system_score_codex":0.00008152832,"about_ca_system_score_gemma":0.00045383256,"threshold_uncertainty_score":0.32272097},"labels":[],"label_agreement":null},{"id":"W4387810720","doi":"10.1016/j.annonc.2023.09.2393","title":"1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Faculty of Medicine, Chulalongkorn University; Genentech; EMD Serono; Centre Léon Bérard; Centre Hospitalier Universitaire Vaudois; BeiGene; King Chulalongkorn Memorial Hospital; Amgen; Henry Ford Health System; F. Hoffmann-La Roche; Sanofi; Pfizer; Les Laboratories Pierre Fabre; Chulalongkorn University; National Cancer Centre of Singapore; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Post-hoc analysis; Neurocognitive; Clinical endpoint; Oncology; Cognition; Clinical trial; Psychiatry","score_opus":0.08028585454669245,"score_gpt":0.4161469821753147,"score_spread":0.33586112762862225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455285,0.0001600148,0.000012448974,0.0032160915,0.00010326533,0.0013729682,0.00047155243,0.000052097534,0.00005873278],"genre_scores_gemma":[0.99784744,0.000081270955,0.0001572825,0.000881684,0.000023979708,0.00008772727,0.00076878676,0.000024261197,0.00012756522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814385,0.00026088516,0.0006095064,0.00037759123,0.00028715536,0.00032101042],"domain_scores_gemma":[0.99852705,0.00043671537,0.00035286494,0.00030154124,0.0002325673,0.00014926617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002633514,0.0002341691,0.00074401643,0.00018212153,0.00010950303,0.0000069210178,0.00007101097,0.00007174223,0.000053533597],"category_scores_gemma":[0.0002992748,0.00012402389,0.000060447543,0.00047728402,0.00010458295,0.000101806254,0.00007904635,0.00010988631,0.0000028045692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021013494,0.0016583544,0.98073065,0.000040373117,0.001930019,0.00028656365,0.0022776853,0.00017130656,0.000011837282,0.0000027765434,0.0013568009,0.009432258],"study_design_scores_gemma":[0.011026925,0.0042657675,0.97636616,0.00012825959,0.001169014,0.000015152251,0.004771786,0.0002843094,0.00003807577,0.0000062243403,0.001803356,0.0001249764],"about_ca_topic_score_codex":0.0038973219,"about_ca_topic_score_gemma":0.004937561,"teacher_disagreement_score":0.009307282,"about_ca_system_score_codex":0.000063791886,"about_ca_system_score_gemma":0.00021104883,"threshold_uncertainty_score":0.5891611},"labels":[],"label_agreement":null},{"id":"W4387810740","doi":"10.1016/j.annonc.2023.09.2406","title":"1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Cilag; Chugai Pharmaceutical; BeiGene; Ipsen; Merck Sharp and Dohme; Eisai; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Daiichi-Sankyo; Amgen; Pfizer; Mesothelioma Applied Research Foundation","keywords":"ROS1; Medicine; Interim; Internal medicine; Interim analysis; Oncology; Lung cancer; Cancer; Clinical trial; Adenocarcinoma","score_opus":0.030367395179467675,"score_gpt":0.41128924309595116,"score_spread":0.3809218479164835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996041,0.000180135,0.000007124023,0.0003073643,0.00006802566,0.0007637591,0.0001717705,0.000009381882,0.002451453],"genre_scores_gemma":[0.9994669,0.000145155,0.00005850927,0.000075811164,0.000011995832,0.000043298132,0.000056352666,0.000009069496,0.00013294147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893296,0.000058114223,0.0004454385,0.00023210622,0.00015022942,0.00018117175],"domain_scores_gemma":[0.9991175,0.00008870894,0.00028851687,0.00018732931,0.00025151542,0.0000664257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001635225,0.00012116885,0.0007291336,0.00026094512,0.00002720572,0.0000016498711,0.00006638957,0.000067162255,0.00004716565],"category_scores_gemma":[0.00003398437,0.00009291204,0.00007831051,0.0012491136,0.00008438699,0.00003253013,0.000068329544,0.000066770575,5.229029e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001961264,0.0032992326,0.9678092,0.00009067587,0.0023997368,0.000016820039,0.0038719168,0.0003649403,0.000087812616,0.000004955576,0.0002665888,0.019826831],"study_design_scores_gemma":[0.009686226,0.010685641,0.9753434,0.00009903868,0.002275243,4.820134e-7,0.0011165966,0.00021286654,0.0003060894,0.0000018349705,0.00020449338,0.00006806412],"about_ca_topic_score_codex":0.002085226,"about_ca_topic_score_gemma":0.0033809815,"teacher_disagreement_score":0.019758767,"about_ca_system_score_codex":0.000109481065,"about_ca_system_score_gemma":0.00026982848,"threshold_uncertainty_score":0.37888432},"labels":[],"label_agreement":null},{"id":"W4387810758","doi":"10.1016/j.annonc.2023.09.2658","title":"1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical trial; Odds ratio; Internal medicine; Clinical Oncology; Food and drug administration; Clinical endpoint; Odds; Oncology; Cancer; Logistic regression; Pharmacology","score_opus":0.10037275379564192,"score_gpt":0.3489439568986116,"score_spread":0.24857120310296965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879489,0.0026002044,0.000012311759,0.0059961155,0.00019007655,0.00038432187,0.0008982187,0.000007817348,0.001962019],"genre_scores_gemma":[0.9959927,0.0020777383,0.000010992306,0.0015226182,0.000105147315,0.000062284955,0.000013497469,0.000014431588,0.00020055579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869466,0.000033497974,0.0007660776,0.00027040308,0.00003481257,0.00020053984],"domain_scores_gemma":[0.99842507,0.00036515557,0.00088011526,0.0001771148,0.000086641776,0.000065883265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011096587,0.00012220438,0.00070243096,0.00010839367,0.000035565194,0.000008189797,0.00013549553,0.0001721891,0.000058856906],"category_scores_gemma":[0.00014695097,0.00011083343,0.00009590588,0.00011990648,0.00018027736,0.0001112859,0.00003350014,0.000107799075,0.0000074641607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007241213,0.0031713818,0.40988147,0.0009957695,0.0014115692,0.000005586484,0.003928122,0.00094429817,0.0007743637,0.14539358,0.02555858,0.40069404],"study_design_scores_gemma":[0.011834943,0.011842355,0.819623,0.00014698715,0.000106686726,0.0000017128059,0.000145075,0.042023275,0.0057361308,0.017716244,0.09010181,0.00072179723],"about_ca_topic_score_codex":0.00040313695,"about_ca_topic_score_gemma":0.00012857196,"teacher_disagreement_score":0.40974152,"about_ca_system_score_codex":0.00001815741,"about_ca_system_score_gemma":0.00007951649,"threshold_uncertainty_score":0.45196563},"labels":[],"label_agreement":null},{"id":"W4387810829","doi":"10.1016/j.annonc.2023.09.2643","title":"1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Ipsen; Servier; F. Hoffmann-La Roche; Sanofi; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Real world data; Real world evidence; Work (physics); Working group; Medical physics; Oncology; Data science; Internal medicine","score_opus":0.2003312083554044,"score_gpt":0.460736168542475,"score_spread":0.2604049601870706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6960018,0.037932426,0.00019655477,0.25966078,0.00024243862,0.0016170563,0.00015776377,0.00016151999,0.0040296195],"genre_scores_gemma":[0.8738926,0.1146375,0.0033854856,0.0071897,0.00018523453,0.000037054153,0.00053492124,0.00003488007,0.000102592574],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99749404,0.00039029724,0.00094846246,0.00049260416,0.000301463,0.00037315596],"domain_scores_gemma":[0.9956376,0.0024700414,0.00084730313,0.00058806676,0.0002933689,0.0001636237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001487549,0.00018698239,0.00116777,0.0006483564,0.000091210815,0.000029828903,0.00029864538,0.000049529706,0.000019766278],"category_scores_gemma":[0.0019363915,0.00016714087,0.000056291232,0.0028876744,0.0003863303,0.00018879383,0.00026583404,0.00047875184,0.0000035177302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006381949,0.0005702666,0.27816725,0.00295687,0.0005288273,0.0001306178,0.0062980033,0.00006322418,0.00080485607,0.0018217235,0.057229415,0.65079075],"study_design_scores_gemma":[0.001404203,0.0011884165,0.8225064,0.073692754,0.00006203532,0.000008550076,0.00193688,0.0024207805,0.000057924393,0.0011114359,0.09530006,0.0003105274],"about_ca_topic_score_codex":0.0019220121,"about_ca_topic_score_gemma":0.0008618148,"teacher_disagreement_score":0.6504802,"about_ca_system_score_codex":0.00008832328,"about_ca_system_score_gemma":0.00048289687,"threshold_uncertainty_score":0.6815807},"labels":[],"label_agreement":null},{"id":"W4387810851","doi":"10.1016/j.annonc.2023.09.2652","title":"1698MO E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Cancer; Smoking cessation; Population; Cigarette smoking; Internal medicine; Environmental health; Pathology","score_opus":0.14354553893932756,"score_gpt":0.42882611097917317,"score_spread":0.2852805720398456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96739745,0.002261412,0.00000603307,0.028571537,0.00016374746,0.00026046098,0.00018835679,0.00004476623,0.001106223],"genre_scores_gemma":[0.9846672,0.010536014,0.000028059167,0.0037552824,0.00021502652,0.00015908873,0.000033093565,0.000017694847,0.0005885816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905604,0.00003639442,0.00022812623,0.00023571875,0.00015870355,0.00028499763],"domain_scores_gemma":[0.9990327,0.00034332645,0.00011928435,0.00011747898,0.00027897046,0.00010827292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019610737,0.00011162598,0.00032710863,0.00012254548,0.00014975046,0.000006908561,0.000054161002,0.0001083411,0.00009525351],"category_scores_gemma":[0.0001364662,0.00010164633,0.00006949387,0.00030409815,0.0000851865,0.00007715435,0.00007797245,0.0001532261,0.0000021355745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018164644,0.00009284887,0.9254312,0.00010558297,0.0003431196,0.000025144747,0.00014443831,0.00012953668,0.0004894625,0.0006871624,0.061274923,0.011094948],"study_design_scores_gemma":[0.00066178886,0.0003099961,0.934489,0.00021269833,0.00007631498,0.000003659268,0.00007011324,0.00024932748,0.0004731273,0.00007604112,0.06328579,0.000092147246],"about_ca_topic_score_codex":0.004236352,"about_ca_topic_score_gemma":0.0027919328,"teacher_disagreement_score":0.024816254,"about_ca_system_score_codex":0.00004514641,"about_ca_system_score_gemma":0.0000699517,"threshold_uncertainty_score":0.6404125},"labels":[],"label_agreement":null},{"id":"W4387811018","doi":"10.1016/j.annonc.2023.09.2265","title":"1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Premedication; Adverse effect; Oncology; Gastroenterology; Surgery","score_opus":0.060651446791656405,"score_gpt":0.36418821472110297,"score_spread":0.30353676792944656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850792,0.000520523,0.000001800075,0.0006813299,0.00041888238,0.00036316476,0.00004461539,0.000036594065,0.012853835],"genre_scores_gemma":[0.9942244,0.0013581731,0.00007090319,0.00032091653,0.000005796849,0.000043313616,0.00012386871,0.000019575311,0.0038330168],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979459,0.00060795364,0.00069063006,0.00024466126,0.00006191725,0.00044893238],"domain_scores_gemma":[0.998688,0.0005648591,0.00035536735,0.00029847614,0.00008023026,0.0000130845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008110493,0.00017316079,0.00057463686,0.0006252368,0.000054800825,0.0000026598661,0.00026769226,0.00012409713,0.00027735738],"category_scores_gemma":[0.000054847165,0.00015797636,0.00013701746,0.00056256884,0.00019300033,0.00005759396,0.0001216037,0.00020173135,0.00025069807],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013673037,0.0051840814,0.07310654,0.0005817835,0.0033713577,0.00023846785,0.0046855696,0.00015568385,0.09228682,0.012670937,0.032081064,0.7619647],"study_design_scores_gemma":[0.008690825,0.008105607,0.6673787,0.00042528188,0.00008763452,0.000008952939,0.001704888,0.000008749536,0.15522996,0.0009450771,0.15703651,0.00037781065],"about_ca_topic_score_codex":0.00036180607,"about_ca_topic_score_gemma":0.00011594323,"teacher_disagreement_score":0.76158684,"about_ca_system_score_codex":0.000038680737,"about_ca_system_score_gemma":0.00006459446,"threshold_uncertainty_score":0.6442089},"labels":[],"label_agreement":null},{"id":"W4387811021","doi":"10.1016/j.annonc.2023.09.2263","title":"1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck","keywords":"Medicine; Internal medicine; Ipilimumab; Oncology; Interim analysis; Proportional hazards model; Vemurafenib; Dacarbazine; Adjuvant therapy; Progression-free survival; Censoring (clinical trials); Hazard ratio; Survival analysis; Melanoma; Randomized controlled trial; Overall survival; Immunotherapy; Metastatic melanoma; Cancer; Chemotherapy; Confidence interval; Pathology; Cancer research","score_opus":0.06770739859690496,"score_gpt":0.37665951354072164,"score_spread":0.3089521149438167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920229,0.003738742,0.00000964934,0.00067833206,0.0014412076,0.0018874498,0.000041447485,0.000025872372,0.00015443211],"genre_scores_gemma":[0.99624735,0.0030558144,0.0000059740814,0.00005973476,0.00002717962,0.00020813447,0.00012267462,0.000028845638,0.00024430268],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99312943,0.0038989477,0.001975587,0.0003401334,0.00011989274,0.0005359887],"domain_scores_gemma":[0.9929071,0.005667857,0.0009784254,0.00032811207,0.00009758201,0.000020900574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006244293,0.0003531909,0.0028708326,0.00097148353,0.00006119755,0.0000043338723,0.00031876453,0.00034452658,0.00019554797],"category_scores_gemma":[0.0010923417,0.0002744131,0.0006478433,0.0005000265,0.0005975428,0.00009908466,0.00013074237,0.00039760544,0.000016669714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7691784,0.0017167184,0.0009524865,0.00013623848,0.0010311104,0.000048342918,0.0025941709,0.000039618906,0.2122154,0.00016814431,0.00007012887,0.01184925],"study_design_scores_gemma":[0.6188951,0.014751445,0.0013364429,0.00023160102,0.000077496814,0.000008232781,0.00012330861,0.000008393279,0.36402807,0.00015237756,0.00022751858,0.00016000179],"about_ca_topic_score_codex":0.0010237329,"about_ca_topic_score_gemma":0.0005067151,"teacher_disagreement_score":0.15181266,"about_ca_system_score_codex":0.00007558528,"about_ca_system_score_gemma":0.0002045965,"threshold_uncertainty_score":0.9999708},"labels":[],"label_agreement":null},{"id":"W4387811033","doi":"10.1016/j.annonc.2023.09.2232","title":"1098P Anti-PD1-based neoadjuvant therapy in resectable stage III or IV melanoma patients: A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Neoadjuvant therapy; Oncology; Melanoma; Cohort study; Cohort; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Cancer; Breast cancer","score_opus":0.28615253220467113,"score_gpt":0.45256243700830545,"score_spread":0.16640990480363432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031850104,0.99132264,0.000010430769,0.0008315067,0.000076028475,0.006908238,0.000114810915,0.00008075313,0.0006237539],"genre_scores_gemma":[0.0000704844,0.98779607,0.0000474936,0.002567545,0.000018902387,0.0011372949,0.00015624879,0.00008249157,0.008123446],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949947,0.0011741385,0.0023129722,0.00066309306,0.00042708416,0.00042802782],"domain_scores_gemma":[0.99618715,0.0008116466,0.0015934892,0.0009353854,0.00030882412,0.000163493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019851453,0.00054062676,0.014160708,0.0013814843,0.00004008682,0.000018126686,0.00025839292,0.00035147107,0.0008418318],"category_scores_gemma":[0.00058468414,0.00031848106,0.002073975,0.0021353748,0.00008227911,0.000041369745,0.00011348152,0.00036618812,0.000041851123],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013646338,0.0006313404,0.000005735586,0.85653305,0.11679194,0.00064979267,0.000039365732,0.0000023896848,1.4702378e-7,0.000022844037,0.0026168523,0.022570098],"study_design_scores_gemma":[0.0009881175,0.0030170404,0.000006056545,0.02256571,0.40223718,0.000040741605,0.00003174739,0.0000125482,9.902745e-7,0.0000030716553,0.570828,0.0002687429],"about_ca_topic_score_codex":0.00026469998,"about_ca_topic_score_gemma":0.00045445457,"teacher_disagreement_score":0.8339673,"about_ca_system_score_codex":0.00011553094,"about_ca_system_score_gemma":0.0003903751,"threshold_uncertainty_score":0.99992675},"labels":[],"label_agreement":null},{"id":"W4387811066","doi":"10.1016/j.annonc.2023.09.2184","title":"1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Reproductive System and Pregnancy","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Chugai Pharmaceutical; Seagen; Genentech; F-star Therapeutics; Sierra Oncology; Pfizer; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sociedad Española de Oncología Médica; BeiGene; Sanofi; Johns Hopkins University; Amgen; Celgene","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Cancer; Oncology; Renal cell carcinoma; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Progressive disease; Pharmacokinetics; Chemotherapy","score_opus":0.13266053955980525,"score_gpt":0.45582049714767203,"score_spread":0.32315995758786675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830688,0.013273235,0.00009463393,0.0009749311,0.0006476944,0.001098814,0.00038130916,0.000024414601,0.00043616802],"genre_scores_gemma":[0.9842262,0.014279308,0.000115061164,0.00003289561,0.00006243128,0.000053531487,0.00006385489,0.000017619659,0.0011490928],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99779594,0.0006360167,0.0007159548,0.00049403304,0.000038981358,0.00031904626],"domain_scores_gemma":[0.99674815,0.001833034,0.0006221865,0.0005395687,0.00022101546,0.000036072335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011068853,0.00019718455,0.0009938353,0.000111064684,0.000132661,0.0000027232354,0.00016837243,0.00024642615,0.00004018391],"category_scores_gemma":[0.00020915664,0.00013540426,0.00017629418,0.00014369108,0.00094334397,0.00010415257,0.00008868211,0.00011401771,0.0000056811978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013378505,0.0024324611,0.02406271,0.00039959332,0.001106653,0.000018308794,0.002946619,0.000045426423,0.37369466,0.0010833103,0.0008875976,0.5799442],"study_design_scores_gemma":[0.0053851753,0.04596305,0.61125916,0.00011893821,0.00017160014,0.00006355866,0.0015817687,0.000025285653,0.18010269,0.00038954953,0.15470223,0.00023699587],"about_ca_topic_score_codex":0.00007912017,"about_ca_topic_score_gemma":0.000045393084,"teacher_disagreement_score":0.58719647,"about_ca_system_score_codex":0.000012025873,"about_ca_system_score_gemma":0.0001231321,"threshold_uncertainty_score":0.5521626},"labels":[],"label_agreement":null},{"id":"W4387811078","doi":"10.1016/j.annonc.2023.09.2223","title":"1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Oncology; Adjuvant; Melanoma; Stage (stratigraphy); Adjuvant therapy; Immunotherapy; Cancer; Cancer research","score_opus":0.0882871583234907,"score_gpt":0.3801278779248938,"score_spread":0.29184071960140306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729794,0.0013591779,0.0000025003587,0.010734373,0.00051549525,0.0005076035,0.000395475,0.00013963213,0.013366312],"genre_scores_gemma":[0.98792034,0.002976412,0.00010840537,0.0014456538,0.00020415575,0.000039952683,0.00037689743,0.000040952986,0.006887227],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99726045,0.0002303219,0.0010215503,0.0005295207,0.00034259312,0.00061555195],"domain_scores_gemma":[0.9981813,0.00046828573,0.0003752121,0.0006288371,0.00021181644,0.00013456405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011515196,0.00024197195,0.00091910316,0.00045897753,0.0000599062,0.000009851717,0.00026072346,0.0003764404,0.00068438845],"category_scores_gemma":[0.00034262953,0.00022018315,0.00021359815,0.00096126564,0.00023997734,0.0000972293,0.00011960234,0.0003574697,0.00014024726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28201815,0.0021188438,0.007634564,0.00030024681,0.001442836,0.0031716009,0.009728946,0.000054513064,0.2354137,0.00016751989,0.2651968,0.19275227],"study_design_scores_gemma":[0.06531264,0.010567253,0.47771358,0.00056368543,0.00010374645,0.000036681282,0.0021859654,0.00085825473,0.055246666,0.0005109846,0.3863291,0.0005714472],"about_ca_topic_score_codex":0.0069614532,"about_ca_topic_score_gemma":0.0035204098,"teacher_disagreement_score":0.470079,"about_ca_system_score_codex":0.00016364871,"about_ca_system_score_gemma":0.0005390997,"threshold_uncertainty_score":0.99965125},"labels":[],"label_agreement":null},{"id":"W4387811089","doi":"10.1016/j.annonc.2023.09.2215","title":"1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Loxo Oncology; EMD Serono; Genentech; European Society for Medical Oncology; Eisai; PTC Therapeutics; Rakuten Medical; Seagen; MacroGenics; Pfizer; Symphogen; Moderna; Incyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Sun Pharma; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Sanofi; Castle Biosciences; Spectrum Pharmaceuticals; Amgen","keywords":"Medicine; Internal medicine; Adverse effect; Progressive disease; Peripheral edema; Population; Nausea; Gastroenterology; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Chemotherapy","score_opus":0.13350593380464454,"score_gpt":0.45443259320562585,"score_spread":0.3209266594009813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754007,0.00016902872,0.0000032580951,0.009528717,0.00044190066,0.00048141016,0.000007843384,0.000020080504,0.0018077157],"genre_scores_gemma":[0.9988729,0.00030166388,0.00022763979,0.00027524098,0.000039705832,0.000011742492,0.00003264698,0.000011235249,0.00022721976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829865,0.0004865423,0.0006274775,0.00023062393,0.00015658437,0.00020014365],"domain_scores_gemma":[0.9987068,0.0005582716,0.0002834674,0.00024862163,0.00013727657,0.00006552284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010315113,0.000108302345,0.0005803564,0.00018120032,0.00004132801,0.0000018800332,0.00008481486,0.00017933507,0.0000311142],"category_scores_gemma":[0.00065944,0.00007906841,0.00014761098,0.0003945889,0.00037722164,0.00005440127,0.00007096,0.00022246574,0.000017272914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035449304,0.008926844,0.6036011,0.00028418956,0.0014199916,0.00035856056,0.0015466474,0.000029068682,0.0037026329,0.0029078382,0.0062105823,0.36746764],"study_design_scores_gemma":[0.00822738,0.0075892154,0.9720718,0.000079442674,0.00033853704,0.00009908138,0.00033000964,0.00012532625,0.0057324823,0.0014643427,0.0038698837,0.00007245129],"about_ca_topic_score_codex":0.00007902251,"about_ca_topic_score_gemma":0.00006329964,"teacher_disagreement_score":0.36847076,"about_ca_system_score_codex":0.000028796392,"about_ca_system_score_gemma":0.00024373013,"threshold_uncertainty_score":0.32243162},"labels":[],"label_agreement":null},{"id":"W4387811091","doi":"10.1016/j.annonc.2023.09.2185","title":"1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"PharmaMar; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; European Society for Medical Oncology; American Society of Clinical Oncology; BeiGene; Sanofi","keywords":"Medicine; Cytokine release syndrome; Glypican 3; Pharmacokinetics; Oncology; Adverse effect; T cell; Internal medicine; Biomarker; Gastroenterology; Cancer; Cancer research; Immunotherapy; Immunology; Chimeric antigen receptor; Immune system","score_opus":0.1514363011465199,"score_gpt":0.47915271221053296,"score_spread":0.32771641106401306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990332,0.00003574811,9.884747e-7,0.0010460686,0.000094107716,0.0031743064,0.000060295195,0.000058956128,0.0051975227],"genre_scores_gemma":[0.9970495,0.00011298864,0.0001343796,0.00038729195,0.00006603946,0.00012409009,0.0003588006,0.00005519652,0.0017116837],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9968439,0.0006644472,0.0007120424,0.00062989374,0.00058207155,0.00056765415],"domain_scores_gemma":[0.9979386,0.00041210512,0.00029807485,0.0007109378,0.0004217366,0.00021856595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018763131,0.00024087405,0.0007832483,0.000569102,0.00012803002,0.000015955235,0.00035801396,0.00015452973,0.00010797895],"category_scores_gemma":[0.00034875004,0.0002052322,0.00003923809,0.0010055751,0.000120890654,0.00027339807,0.00026779933,0.0005479914,0.000044789962],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20827283,0.17611565,0.028958252,0.00014224624,0.00021522173,0.0012406918,0.01171881,0.0005466495,0.073085584,0.000011557131,0.006367386,0.49332514],"study_design_scores_gemma":[0.13601974,0.42902943,0.4085512,0.00022081273,0.000042178508,0.000004933295,0.0018734456,0.0006080876,0.019764919,0.000036699712,0.0035495362,0.00029902684],"about_ca_topic_score_codex":0.00009334109,"about_ca_topic_score_gemma":0.000056197965,"teacher_disagreement_score":0.4930261,"about_ca_system_score_codex":0.00009683282,"about_ca_system_score_gemma":0.00033190526,"threshold_uncertainty_score":0.8369126},"labels":[],"label_agreement":null},{"id":"W4387811212","doi":"10.1016/j.annonc.2023.09.2139","title":"995P Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Health Sciences Centre; Sunnybrook Health Science Centre; University of Ottawa","funders":"Sunnybrook Research Institute; University of Ottawa; AstraZeneca Canada","keywords":"Medicine; Hepatocellular carcinoma; Oncology; Internal medicine","score_opus":0.13008516638411152,"score_gpt":0.32764043945314925,"score_spread":0.19755527306903772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905737,0.0003254831,2.5425848e-7,0.0026033584,0.00016531748,0.00072583737,0.00003094535,0.000021940667,0.0055531496],"genre_scores_gemma":[0.9970446,0.0010032294,0.000036903653,0.00020246515,0.000029069144,0.00013079526,0.00023035967,0.000024611234,0.0012979375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982446,0.0001626267,0.00049332844,0.00038831853,0.00020888742,0.000502244],"domain_scores_gemma":[0.9991112,0.00025076538,0.0001126745,0.00026305692,0.00006874408,0.00019356239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030542695,0.0002387341,0.0008037109,0.00039812984,0.00002883486,0.0000044697467,0.00007084292,0.00012536033,0.00012652072],"category_scores_gemma":[0.00002802257,0.00021756359,0.00008141124,0.0004298309,0.00004900883,0.00005078587,0.000051428502,0.00017512354,0.0000066381153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040730095,0.00030715743,0.9657641,0.000044627108,0.000063535874,0.0051312223,0.0005012908,0.000002127066,0.00022180928,0.00006531194,0.00036570107,0.027125834],"study_design_scores_gemma":[0.0039647077,0.0020296976,0.97687405,0.000092209004,0.000042531676,0.000014261037,0.00034300255,0.00034851907,0.003812696,0.000026885831,0.012291816,0.0001596306],"about_ca_topic_score_codex":0.98941666,"about_ca_topic_score_gemma":0.99891317,"teacher_disagreement_score":0.026966203,"about_ca_system_score_codex":0.001164419,"about_ca_system_score_gemma":0.0015828328,"threshold_uncertainty_score":0.88719857},"labels":[],"label_agreement":null},{"id":"W4387811241","doi":"10.1016/j.annonc.2023.09.2158","title":"1019O Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Chugai Pharmaceutical; Astellas Pharma; Eisai; Daiichi-Sankyo; Svenska Forskningsrådet Formas; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; BeiGene; Pfizer; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Nivolumab; Internal medicine; Neutropenia; Oncology; CD8; Pembrolizumab; Cytokine release syndrome; Melanoma; Immunotherapy; Immunology; Antigen; Chimeric antigen receptor; Chemotherapy; Cancer; Cancer research","score_opus":0.3242130588186991,"score_gpt":0.5044721720448572,"score_spread":0.18025911322615806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853278,0.0003580803,0.000011331064,0.011506118,0.00017260453,0.0013546065,0.00037328503,0.000021497977,0.00087471114],"genre_scores_gemma":[0.99159247,0.0046324674,0.00032027188,0.00072633487,0.00035673936,0.000032089985,0.00084000337,0.00004122108,0.0014584069],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968837,0.0007934911,0.0009891486,0.0004661516,0.00050921156,0.00035832086],"domain_scores_gemma":[0.9948649,0.0037020058,0.00030493562,0.0007646178,0.00021925516,0.00014431027],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030469166,0.00017906289,0.0010377038,0.00015799416,0.00004268218,0.000008364159,0.00044835094,0.00022216754,0.002119915],"category_scores_gemma":[0.0002667927,0.000113219496,0.00010548059,0.0005176426,0.0006656356,0.000083418185,0.000107648026,0.00047398184,0.0000209544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.760273,0.008478294,0.016401831,0.000078542995,0.00041643975,0.00018903369,0.001489478,0.000009034358,0.05665092,0.000010108988,0.056322306,0.099681035],"study_design_scores_gemma":[0.66410774,0.106854334,0.03207642,0.00019175505,0.00014062041,0.00001995383,0.0012181554,0.002413458,0.056613863,0.0003686365,0.135576,0.00041909257],"about_ca_topic_score_codex":0.00045082884,"about_ca_topic_score_gemma":0.00056620076,"teacher_disagreement_score":0.09926195,"about_ca_system_score_codex":0.000011152469,"about_ca_system_score_gemma":0.001056575,"threshold_uncertainty_score":0.9987923},"labels":[],"label_agreement":null},{"id":"W4387811267","doi":"10.1016/j.annonc.2023.09.2157","title":"1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stephenson Cancer Center; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; Genentech; Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; Sun Pharma; PharmaMar; University of Toronto; European Society for Medical Oncology; FibroGen; Cytokinetics; Astellas Pharma; Eisai; Pfizer; Moderna; Incyte; BeiGene; Natera; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; Gilead Sciences; Ribon Therapeutics; Array BioPharma; Iterion Therapeutics; Sanofi; Amgen; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Rash; Mucositis; Gastroenterology; Internal medicine; Colorectal cancer; Phases of clinical research; Diarrhea; Toxicity; Adverse effect; Cancer; Oncology","score_opus":0.07137095289724445,"score_gpt":0.4252981760145111,"score_spread":0.35392722311726665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977435,0.00051409873,0.0000015082645,0.0005094378,0.0002516695,0.0004977349,0.000070880655,0.000018301023,0.0003928799],"genre_scores_gemma":[0.9990828,0.0004073648,0.000058226517,0.00024808192,0.000009202362,0.00005104102,0.000020340955,0.000010987894,0.00011196908],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986252,0.0003669797,0.00039026455,0.000249661,0.00005004617,0.00031782844],"domain_scores_gemma":[0.9991489,0.00025281956,0.00021043346,0.00015905757,0.00020661132,0.000022193815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037940603,0.00013792644,0.0005820573,0.00017909172,0.000032943546,0.0000012818513,0.00017564281,0.00022224618,0.00027538638],"category_scores_gemma":[0.00006255875,0.0000967992,0.000058992027,0.00049078313,0.00025277116,0.00003871096,0.000057908434,0.00019244257,0.0000074945574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014463621,0.0124404775,0.36941,0.000026374231,0.00086830935,0.000019975107,0.0020839255,0.00003500021,0.08688751,0.000070329246,0.0029576935,0.51073676],"study_design_scores_gemma":[0.02718424,0.059381444,0.77698326,0.000037978647,0.00005212384,0.0000013210173,0.0011650043,0.0000068445024,0.11894999,0.000106424624,0.015887477,0.00024391244],"about_ca_topic_score_codex":0.00022728095,"about_ca_topic_score_gemma":0.00035634797,"teacher_disagreement_score":0.51049286,"about_ca_system_score_codex":0.000017355987,"about_ca_system_score_gemma":0.000094853596,"threshold_uncertainty_score":0.3947357},"labels":[],"label_agreement":null},{"id":"W4387811279","doi":"10.1016/j.annonc.2023.09.2168","title":"1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Regeneron Pharmaceuticals; EMD Serono; Takeda Pharmaceuticals U.S.A.; Genentech; Amgen","keywords":"Medicine; Sting; Cytokine; Adverse effect; Pharmacology; Cytokine release syndrome; Internal medicine; Oncology; Cancer; Immunotherapy","score_opus":0.046951383831123114,"score_gpt":0.37843417556608816,"score_spread":0.33148279173496503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966651,0.00010581032,0.00004161273,0.0005533549,0.00006523553,0.002475163,0.000037733986,0.000028340663,0.000027656286],"genre_scores_gemma":[0.9991341,0.00010101065,0.00013496702,0.00008363504,0.0000027123472,0.00027761905,0.00017119411,0.000027663486,0.00006707225],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973086,0.0008879062,0.00077126344,0.00047139285,0.00006531981,0.0004955187],"domain_scores_gemma":[0.9981388,0.0009423096,0.0005381704,0.00019029486,0.00015936454,0.00003108923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011536761,0.00026485522,0.00090445933,0.00069385313,0.00009879655,0.000010364454,0.00010779109,0.00012162906,0.000018678526],"category_scores_gemma":[0.00051647995,0.00020945257,0.00003058156,0.00048038358,0.00015456823,0.00033852,0.00012777369,0.00028696426,0.000002460674],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.541673,0.020969598,0.06399483,0.00046556638,0.00026568913,0.00032924587,0.01070869,0.00018688155,0.11881675,0.000028817807,0.00013700503,0.24242394],"study_design_scores_gemma":[0.102593124,0.08882054,0.7732328,0.00051947794,0.000064261614,0.00010508036,0.0055088405,0.0008078147,0.027801607,0.000071924194,0.00010544647,0.00036904568],"about_ca_topic_score_codex":0.00018374475,"about_ca_topic_score_gemma":0.0010752536,"teacher_disagreement_score":0.709238,"about_ca_system_score_codex":0.000075249634,"about_ca_system_score_gemma":0.00019552775,"threshold_uncertainty_score":0.8541228},"labels":[],"label_agreement":null},{"id":"W4387811331","doi":"10.1016/j.annonc.2023.09.2048","title":"903P AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"G1 Therapeutics; Regeneron Pharmaceuticals; Sanofi; EMD Serono; Pfizer","keywords":"Medicine; Adenoid cystic carcinoma; Meta-analysis; Oncology; Internal medicine; Clinical trial; Carcinoma; Radiology","score_opus":0.42256104306265674,"score_gpt":0.49940928438235455,"score_spread":0.07684824131969781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950475,0.0005491245,6.0443034e-7,0.003027827,0.00009651958,0.0008595247,0.0002635686,0.0000116851525,0.00014362989],"genre_scores_gemma":[0.99838716,0.000526108,0.00015409355,0.0004563555,0.000022516964,0.000091723676,0.00029332875,0.000012335143,0.000056384288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971435,0.0004925531,0.0013760601,0.00039248995,0.00033808575,0.00025728147],"domain_scores_gemma":[0.99502957,0.0035508773,0.0006911796,0.00036968023,0.00023393436,0.00012473241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012573138,0.00020506894,0.0027081321,0.0005288325,0.000022812466,0.0000047711546,0.00009637364,0.0000908569,0.000099689285],"category_scores_gemma":[0.0012384623,0.00011881512,0.00069406617,0.00080455455,0.00014989305,0.00005332736,0.00004360454,0.0001568227,0.0000053448516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06005982,0.0038158195,0.88710463,0.000025453488,0.04157668,0.0001355382,0.0002295121,0.000013139314,2.1606957e-7,0.000026295764,0.0006539964,0.006358905],"study_design_scores_gemma":[0.06382574,0.023125645,0.8733077,0.0000062473064,0.039297283,0.0000014783324,0.000045637564,0.000032319826,0.000017558306,0.000056892684,0.00019833348,0.00008513999],"about_ca_topic_score_codex":0.0002773394,"about_ca_topic_score_gemma":0.00016424133,"teacher_disagreement_score":0.019309824,"about_ca_system_score_codex":0.000013491586,"about_ca_system_score_gemma":0.00017065184,"threshold_uncertainty_score":0.484514},"labels":[],"label_agreement":null},{"id":"W4387811339","doi":"10.1016/j.annonc.2023.09.2046","title":"901P Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Mucositis; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Toxicity; Gastroenterology; Head and neck cancer; Chemoradiotherapy; Tolerability; Adverse effect; Radiation therapy","score_opus":0.10240941998281085,"score_gpt":0.37197737599478675,"score_spread":0.2695679560119759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862381,0.0036932759,5.6287024e-7,0.008549073,0.00009329572,0.00020966298,0.000041006362,0.000017195754,0.0011577897],"genre_scores_gemma":[0.993961,0.003380474,0.00016214972,0.0022603387,0.00004782896,0.000011923929,0.000022871714,0.000010799138,0.00014262901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924797,0.000045987792,0.00024620138,0.00020416794,0.000056691733,0.0001989816],"domain_scores_gemma":[0.99948084,0.00021257644,0.00007936459,0.000116793264,0.000046250505,0.00006418773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002064377,0.00010964757,0.0005967031,0.0001410427,0.000031695086,0.000003850188,0.00003777439,0.000109468194,0.00001979089],"category_scores_gemma":[0.000048575523,0.00009280852,0.000043270942,0.00015501243,0.00008670866,0.00003519047,0.00004715556,0.000088183,0.0000062725285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045332155,0.00034182973,0.72736996,0.000097754324,0.00007099231,0.00006427235,0.004330554,0.0000021201338,0.21044433,0.000014498374,0.004392694,0.05241769],"study_design_scores_gemma":[0.003986667,0.0018433295,0.95454603,0.000008472499,0.000018321787,0.0000038931075,0.0002162296,0.00004375677,0.03163478,0.00011356935,0.0075019416,0.0000829991],"about_ca_topic_score_codex":0.0008121347,"about_ca_topic_score_gemma":0.00033466608,"teacher_disagreement_score":0.2271761,"about_ca_system_score_codex":0.00002853748,"about_ca_system_score_gemma":0.00007887132,"threshold_uncertainty_score":0.37846217},"labels":[],"label_agreement":null},{"id":"W4387811357","doi":"10.1016/j.annonc.2023.09.2043","title":"898P Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head &amp; neck cancer (LAHNC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Northeast Cancer Centre; Health Sciences North; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"AstraZeneca","keywords":"Medicine; Mucositis; Placebo; Renal function; Internal medicine; Creatinine; Adverse effect; Head and neck cancer; Kidney disease; Gastroenterology; Cancer; Surgery; Toxicity; Pathology","score_opus":0.23173593524680802,"score_gpt":0.47355100837644026,"score_spread":0.24181507312963224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889123,0.0042024995,0.000015882222,0.0038262843,0.00009804335,0.001276744,0.00023564386,0.000020505428,0.00141212],"genre_scores_gemma":[0.9963122,0.0013059449,0.0003372419,0.00076951075,0.0000370289,0.0003561242,0.00007410675,0.000023287517,0.00078455225],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99631333,0.00058397267,0.0018361446,0.00036170465,0.0005116608,0.00039317418],"domain_scores_gemma":[0.995728,0.0017057164,0.0012073289,0.0004232136,0.0008233835,0.00011234962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027003984,0.00025867796,0.008344681,0.0008803923,0.00002679469,0.0000018783171,0.00014323117,0.00012618839,0.00043955012],"category_scores_gemma":[0.0013241329,0.00016383805,0.0013193764,0.0015906509,0.00019826098,0.000059817397,0.00006383005,0.00016217805,0.0000070497013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14816625,0.0041438737,0.348422,0.0009235603,0.42735675,0.00010602029,0.0036693842,0.010155691,0.0031332877,0.0001462671,0.011458315,0.042318616],"study_design_scores_gemma":[0.19724911,0.02003275,0.47861686,0.00047390457,0.27641493,0.0000027060814,0.0006783355,0.00040324687,0.00669431,0.00022195648,0.018487317,0.0007245562],"about_ca_topic_score_codex":0.0013007926,"about_ca_topic_score_gemma":0.01416724,"teacher_disagreement_score":0.15094182,"about_ca_system_score_codex":0.000052799653,"about_ca_system_score_gemma":0.00041307448,"threshold_uncertainty_score":0.79056525},"labels":[],"label_agreement":null},{"id":"W4387811378","doi":"10.1016/j.annonc.2023.09.1927","title":"748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Institut Gustave-Roussy; Université Paris-Saclay; Seagen; Wilmot Cancer Institute, University of Rochester Medical Center; Università Cattolica del Sacro Cuore; Incyte; Clovis Oncology; PharmaMar; AstraZeneca","keywords":"Medicine; Lenvatinib; Pembrolizumab; Endometrial cancer; Oncology; Internal medicine; Gynecology; Cancer; Immunotherapy","score_opus":0.1202288141960582,"score_gpt":0.44560518613927597,"score_spread":0.3253763719432178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920041,0.00029707295,0.000012611215,0.0027477185,0.000282825,0.003713475,0.00024378396,0.00003813919,0.0006602682],"genre_scores_gemma":[0.99662787,0.00037117902,0.000077294746,0.0013699163,0.00012337115,0.0010315591,0.00013056886,0.000029110233,0.00023912126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977178,0.0002421389,0.00068566244,0.00042677156,0.00043725682,0.0004903453],"domain_scores_gemma":[0.9966404,0.002211547,0.0003620282,0.0002914282,0.00037034397,0.00012427733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059718767,0.00027198187,0.0013168185,0.00044878473,0.00010042303,0.0000122966,0.00018892444,0.000116720425,0.00007424617],"category_scores_gemma":[0.00091472315,0.00016357946,0.00013744457,0.0012500825,0.00015271075,0.00010074164,0.00006821442,0.00019586478,0.0000038222684],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092385635,0.010524706,0.39110348,0.00019515565,0.0012263532,0.00011358164,0.0036790376,0.000016232381,0.00025530442,0.00012152076,0.001705976,0.49867302],"study_design_scores_gemma":[0.36418778,0.052644007,0.5633748,0.00010413341,0.00040077462,0.0000043469086,0.001769928,0.000052282197,0.00028073989,0.00018294732,0.016750269,0.00024796976],"about_ca_topic_score_codex":0.0007292915,"about_ca_topic_score_gemma":0.0007048558,"teacher_disagreement_score":0.49842507,"about_ca_system_score_codex":0.00007312529,"about_ca_system_score_gemma":0.00016598546,"threshold_uncertainty_score":0.66705763},"labels":[],"label_agreement":null},{"id":"W4387811408","doi":"10.1016/j.annonc.2023.09.1902","title":"716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals UK Limited; EMD Serono; Servier; Cancer Research UK; Sierra Oncology; Incyte; Eisai; Merck KGaA; Alexion Pharmaceuticals; Celgene; CHILDREN with CANCER UK; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Translational research; Clinical trial; Precision medicine; Context (archaeology); Personalized medicine; Oncology; Cancer; Bioinformatics; Internal medicine; Pathology","score_opus":0.08508786063605718,"score_gpt":0.3961114500803129,"score_spread":0.31102358944425573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245286,0.0009385293,0.00067641836,0.002218277,0.0012508153,0.0005513623,0.00009928563,0.000012930331,0.0017995184],"genre_scores_gemma":[0.99397147,0.002778829,0.00030440034,0.0008906064,0.001206942,0.00014594078,0.00021280187,0.000021547554,0.00046743968],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991714,0.000021321963,0.0002783262,0.00022719543,0.000074635595,0.00022715273],"domain_scores_gemma":[0.9992493,0.00019251282,0.00012644025,0.00021160547,0.0001505007,0.00006964867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000316396,0.000098487966,0.00024470864,0.00007371448,0.000039730723,0.000003339122,0.00014860403,0.00015713232,0.00002494083],"category_scores_gemma":[0.0007605762,0.00009189963,0.00009585734,0.00010522304,0.000075096024,0.0000014348574,0.00006781482,0.000040083673,0.0000035843798],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024787465,0.00009402667,0.00027514796,0.00009668039,0.00017558181,0.000018002806,0.00034259245,0.0016440063,0.28489703,0.00030114662,0.47053325,0.21683507],"study_design_scores_gemma":[0.023272743,0.012601338,0.00046477327,0.00004192185,0.00003519618,0.000007418696,0.0001434417,0.00041029864,0.07804036,0.0007281063,0.8840583,0.00019610861],"about_ca_topic_score_codex":0.00007396285,"about_ca_topic_score_gemma":0.0001707151,"teacher_disagreement_score":0.41352504,"about_ca_system_score_codex":0.000019738218,"about_ca_system_score_gemma":0.00023908699,"threshold_uncertainty_score":0.37475583},"labels":[],"label_agreement":null},{"id":"W4387811428","doi":"10.1016/j.annonc.2023.09.1887","title":"701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Institut Gustave-Roussy; Genentech; BeiGene; Eisai Canada; Centre Léon Bérard; Daiichi Sankyo Europe; Servier; Basilea Pharmaceutica; Eisai; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Clovis Oncology; Boston Pharmaceuticals; F. Hoffmann-La Roche; Chugai Pharmaceutical; Agios Pharmaceuticals; Roche; Amgen","keywords":"Medicine; PTEN; Nivolumab; Internal medicine; Oncology; KRAS; Cancer research; Colorectal cancer; Cancer; PI3K/AKT/mTOR pathway; Immunotherapy","score_opus":0.017496026782408455,"score_gpt":0.3275702954259067,"score_spread":0.31007426864349824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987859,0.000092610426,0.000044718414,0.00019771901,0.00011479423,0.0005245483,0.00009164934,0.000005903002,0.00014215935],"genre_scores_gemma":[0.99886245,0.00028909495,0.00016708723,0.00014505126,0.000019987736,0.000034263503,0.0004376336,0.000018148838,0.000026296288],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989429,0.00007323546,0.00036774864,0.0002611766,0.00011192719,0.00024298887],"domain_scores_gemma":[0.9990807,0.000050122406,0.00025730205,0.00018333558,0.00036582976,0.00006270788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015948658,0.00012595825,0.00031357384,0.00013661302,0.000033371034,0.0000046389405,0.00010533235,0.00013063705,0.000005992869],"category_scores_gemma":[0.00027308083,0.00012534985,0.000044897846,0.00023878025,0.00012792235,0.0000071812024,0.00011911785,0.000061241946,9.249043e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14202446,0.010399467,0.055703823,0.00014949794,0.0005102598,0.000046656434,0.000687437,0.00055775495,0.689464,0.00014288945,0.004121776,0.09619199],"study_design_scores_gemma":[0.34178528,0.101722665,0.26228896,0.00012296143,0.00009104185,0.0000035212024,0.000182165,0.001565934,0.28263253,0.00015391511,0.008820637,0.00063039106],"about_ca_topic_score_codex":0.000040152943,"about_ca_topic_score_gemma":0.0001313472,"teacher_disagreement_score":0.40683147,"about_ca_system_score_codex":0.000016861939,"about_ca_system_score_gemma":0.00017496439,"threshold_uncertainty_score":0.51116186},"labels":[],"label_agreement":null},{"id":"W4387811434","doi":"10.1016/j.annonc.2023.09.1929","title":"750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Oncology; Clinical endpoint; Population; Chemotherapy; Carboplatin; Progression-free survival; Cancer; Immunotherapy; Clinical trial; Cisplatin","score_opus":0.10001557187261174,"score_gpt":0.3834242927997889,"score_spread":0.28340872092717717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882515,0.0012694271,0.000009450176,0.0024114307,0.0004926354,0.0072321896,0.0001750658,0.000030092511,0.00012820799],"genre_scores_gemma":[0.96978635,0.025687635,0.00053317053,0.0018349225,0.00025666534,0.0016123819,0.00009916905,0.000084707695,0.00010497728],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966628,0.00029830565,0.0009307433,0.00066318497,0.0007441661,0.0007007902],"domain_scores_gemma":[0.9970209,0.0013719437,0.00059957406,0.0004421019,0.0004407042,0.00012474916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001001293,0.00046029416,0.0016539871,0.00046939644,0.000041787007,0.000009842782,0.000271835,0.00025820252,0.0002072636],"category_scores_gemma":[0.00022860595,0.0002539511,0.00013209257,0.0012451662,0.00034708262,0.00009295371,0.00003825496,0.00031497463,6.3409624e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69886416,0.0022550684,0.019021915,0.00019831293,0.00046216373,0.000024309782,0.0024801828,0.000092436465,0.002149212,0.000007939992,0.0007844701,0.27365983],"study_design_scores_gemma":[0.48898235,0.14051278,0.34439605,0.00050037977,0.00012645077,0.000009968187,0.0005143141,0.000098914315,0.015202318,0.000045154244,0.009103049,0.0005082839],"about_ca_topic_score_codex":0.00088107033,"about_ca_topic_score_gemma":0.0029095153,"teacher_disagreement_score":0.32537413,"about_ca_system_score_codex":0.00059076375,"about_ca_system_score_gemma":0.0014970364,"threshold_uncertainty_score":0.9999913},"labels":[],"label_agreement":null},{"id":"W4387811438","doi":"10.1016/j.annonc.2023.09.1878","title":"692P First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Centre Léon Bérard; PharmaMar; Basilea Pharmaceutica; Eisai; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Memorial Sloan-Kettering Cancer Center; Genentech; Institut Gustave-Roussy; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Pfizer; Incyte; Boston Pharmaceuticals; F. Hoffmann-La Roche; Seagen; Agios Pharmaceuticals; Roche; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neutropenia; Folate receptor; Anemia; Internal medicine; Regimen; Adverse effect; Toxicity; Gastroenterology; Conjugate; Pharmacology; Cancer; Cancer cell","score_opus":0.09242421790982693,"score_gpt":0.432836990109584,"score_spread":0.3404127721997571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552554,0.00014684876,2.5157618e-7,0.0015018028,0.000071473216,0.00105809,0.000009805723,0.00004647137,0.0016396894],"genre_scores_gemma":[0.99914163,0.00008549867,0.000055214277,0.0001765577,0.00004551039,0.00012919126,0.00001057247,0.000041965068,0.00031385155],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972936,0.0003536199,0.0007710133,0.00040418413,0.00047954015,0.0006980566],"domain_scores_gemma":[0.9985532,0.00035704963,0.00025001675,0.0004080258,0.0002668558,0.0001648255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013761459,0.00017983452,0.00091901846,0.00054780766,0.000057460467,0.000008382309,0.0001872505,0.00010939955,0.00017499029],"category_scores_gemma":[0.0003473261,0.00015852568,0.000055762743,0.0012565664,0.00022430433,0.00010782364,0.00014446596,0.00038308057,0.000026386635],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004214496,0.005085363,0.48099953,0.0006965581,0.0002149325,0.0016094942,0.023275923,0.00074368675,0.46700254,0.000058047564,0.013253031,0.0028464163],"study_design_scores_gemma":[0.018884663,0.033313423,0.41273516,0.0018800128,0.000049911218,0.000036027457,0.011483751,0.000831357,0.5162466,0.00036779852,0.003731862,0.00043941516],"about_ca_topic_score_codex":0.0023100022,"about_ca_topic_score_gemma":0.005478575,"teacher_disagreement_score":0.06826436,"about_ca_system_score_codex":0.00013265567,"about_ca_system_score_gemma":0.0005076084,"threshold_uncertainty_score":0.64644897},"labels":[],"label_agreement":null},{"id":"W4387811450","doi":"10.1016/j.annonc.2023.09.1919","title":"740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Seagen; AstraZeneca","keywords":"Medicine; Internal medicine; Microsatellite instability; Oncology; Carboplatin; Endometrial cancer; Progression-free survival; Population; Cancer; Chemotherapy; Cisplatin; Gene; Biology; Genetics","score_opus":0.15212978952452494,"score_gpt":0.4537762290788031,"score_spread":0.30164643955427817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790659,0.0045325505,0.000049023492,0.011481484,0.00059921545,0.003401423,0.0006504628,0.000017796243,0.00020212053],"genre_scores_gemma":[0.9669374,0.030347958,0.00022726432,0.0004941707,0.00017446998,0.0012583754,0.00042089185,0.000029795227,0.00010967172],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973014,0.00042339985,0.00091715273,0.00039897146,0.00061641185,0.00034268392],"domain_scores_gemma":[0.9942281,0.004250363,0.0006844274,0.0005041233,0.00025326674,0.00007970203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012294598,0.00026275744,0.0015795494,0.0005060865,0.000056973986,0.000008116147,0.0002600007,0.00018283233,0.000075763324],"category_scores_gemma":[0.0007394624,0.00013200537,0.00050677126,0.0018509482,0.00018298252,0.00005553774,0.000041312225,0.000114479124,3.9182083e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21688552,0.005399191,0.017789347,0.00015895639,0.004794181,0.000011298857,0.0013416874,0.000031874337,0.006941033,0.00019995263,0.0007612733,0.7456857],"study_design_scores_gemma":[0.48109743,0.07601846,0.35492554,0.00015967854,0.005713465,0.0000020591995,0.0014983141,0.0006157595,0.020206314,0.0006056064,0.058676757,0.0004806069],"about_ca_topic_score_codex":0.0006807371,"about_ca_topic_score_gemma":0.0005823798,"teacher_disagreement_score":0.7452051,"about_ca_system_score_codex":0.00019170514,"about_ca_system_score_gemma":0.00028327163,"threshold_uncertainty_score":0.5383023},"labels":[],"label_agreement":null},{"id":"W4387811452","doi":"10.1016/j.annonc.2023.09.1928","title":"749P Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"PharmaMar; Eisai; Sumitomo Dainippon Pharma Oncology; Seagen; Clovis Oncology; Incyte; Novocure; Sanofi; Exelixis; Regeneron Pharmaceuticals; Mersana Therapeutics; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Endometrial cancer; Internal medicine; Quality of life (healthcare); Population; Placebo; Oncology; Urology; Gastroenterology; Cancer; Pathology","score_opus":0.08075554179485443,"score_gpt":0.3753753084850433,"score_spread":0.29461976669018886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885521,0.0006119813,0.0000016028464,0.0017997114,0.0026974564,0.005471398,0.00013529653,0.00011142894,0.00061900116],"genre_scores_gemma":[0.99548715,0.0007946378,0.00042512242,0.001602168,0.00013147133,0.0011796264,0.0002103538,0.00006038889,0.0001090546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941248,0.00076945365,0.0020099499,0.0009787603,0.0011360176,0.000980996],"domain_scores_gemma":[0.99577916,0.0015945063,0.00090447936,0.0009341329,0.00060443295,0.0001833021],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020339806,0.00050323096,0.0016378894,0.00080715073,0.000092067596,0.00001740731,0.00038473585,0.0003977349,0.00016889907],"category_scores_gemma":[0.0026171007,0.0003197,0.00030892258,0.002640715,0.00035618024,0.00011904164,0.00021678406,0.00074826763,0.000013255001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23771654,0.0067115044,0.5302375,0.00042893243,0.0003522864,0.00026828086,0.0065731294,0.00036643082,0.0007632834,0.000018888693,0.0029931683,0.21357004],"study_design_scores_gemma":[0.12912571,0.04691242,0.77335817,0.0005095088,0.00019105822,0.000020338648,0.0012798541,0.000033136184,0.0033226162,0.00012330996,0.044500515,0.0006233393],"about_ca_topic_score_codex":0.0011292766,"about_ca_topic_score_gemma":0.0027776205,"teacher_disagreement_score":0.24312069,"about_ca_system_score_codex":0.000826798,"about_ca_system_score_gemma":0.00154885,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W4387811453","doi":"10.1016/j.annonc.2023.09.1883","title":"697P Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Hackensack Meridian Health; National Cancer Center Japan; Sanofi; Boehringer Ingelheim","keywords":"Medicine; Internal medicine; Adverse effect; Clinical endpoint; Discontinuation; Gastroenterology; Peripheral edema; Clinical trial","score_opus":0.06275232884655985,"score_gpt":0.42106978766187136,"score_spread":0.3583174588153115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884918,0.00012717604,0.0000188694,0.008027868,0.0002646588,0.0028122338,0.00008959642,0.000022352158,0.00014546231],"genre_scores_gemma":[0.9978463,0.0005844537,0.00019143816,0.00071291236,0.0000472817,0.000066313245,0.00043863812,0.000036685935,0.000075964126],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99723643,0.00037128705,0.0009017748,0.0004318076,0.00060672755,0.00045199005],"domain_scores_gemma":[0.9979338,0.00033708542,0.0007865147,0.0004803299,0.0003955755,0.00006669114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011940236,0.00028381532,0.00095256144,0.0003706914,0.00013630326,0.000020749245,0.00044599388,0.00018690695,0.00004168759],"category_scores_gemma":[0.0001306353,0.00015431836,0.00008488454,0.0017180985,0.00044980203,0.00031173724,0.00015526099,0.00033034646,0.0000027699255],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61146694,0.021660333,0.1847561,0.00014698319,0.0004931388,0.00012497944,0.001412589,0.00033770048,0.11949278,0.000089513574,0.0016904824,0.05832849],"study_design_scores_gemma":[0.24979137,0.024156509,0.71494514,0.0004319802,0.00007204045,0.000012048113,0.0002762558,0.000634447,0.008770526,0.00004193393,0.00066749746,0.00020027919],"about_ca_topic_score_codex":0.00030424425,"about_ca_topic_score_gemma":0.00029783428,"teacher_disagreement_score":0.53018904,"about_ca_system_score_codex":0.000088960114,"about_ca_system_score_gemma":0.0008197647,"threshold_uncertainty_score":0.629292},"labels":[],"label_agreement":null},{"id":"W4387811469","doi":"10.1016/j.annonc.2023.09.1841","title":"655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Pfizer Japan; EMD Serono; AstraZeneca; Genentech; Array BioPharma; LG Chem; Loxo Oncology; Sierra Oncology; Eisai; Y-mAbs Therapeutics; Taiho Pharmaceutical; EQRx; Lunit; Seagen; Relay Therapeutics; Ribon Therapeutics; Syndax Pharmaceuticals; City of Hope; Astellas Pharma; Fondazione Beretta; Incyte; Servier; Eli Lilly and Company; Calithera Biosciences; OncoMed Pharmaceutical; Boehringer Ingelheim Japan; Yuhan; Mersana Therapeutics; Daiichi Sankyo Europe; Agios Pharmaceuticals; BeiGene; Helsinn; Mirati Therapeutics; Amgen; Tizona Therapeutics; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Jounce Therapeutics; Ono Pharmaceutical; Takeda Pharmaceutical Company; AbbVie; Revolution Medicines; Exelixis; Sanofi; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Neutropenia; Internal medicine; Carboplatin; Gastroenterology; Oncology; Chemotherapy; Cisplatin","score_opus":0.05459332157448155,"score_gpt":0.4176143013310369,"score_spread":0.36302097975655534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537474,0.00092967256,0.0000015915635,0.0003164544,0.00030223685,0.0015674677,0.0001022214,0.0000328204,0.0013728094],"genre_scores_gemma":[0.9985001,0.00088078517,0.00004904816,0.00013759252,0.00006223752,0.00011609722,0.00010426337,0.000033299028,0.00011657739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794626,0.00015123331,0.00064364215,0.00046951312,0.00033084257,0.0004585128],"domain_scores_gemma":[0.9984655,0.000119563985,0.00043265347,0.00031627403,0.000537003,0.00012902812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029981165,0.00027747962,0.0011046695,0.00030896792,0.00008787761,0.000007714247,0.00014280644,0.000086736414,0.000054201126],"category_scores_gemma":[0.000035733323,0.00021196895,0.00008051979,0.00053027255,0.00013738176,0.00010090795,0.00012388546,0.00020933028,0.0000027707688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005351093,0.0155557925,0.93847114,0.00042113665,0.0004531376,0.00017537674,0.012890667,0.000112660775,0.0015072922,0.0000016323356,0.0027016727,0.022358375],"study_design_scores_gemma":[0.029261641,0.031692408,0.92921627,0.0005418522,0.00033782664,0.0000016625187,0.0041066944,0.0003234417,0.0034709042,0.0000044694484,0.0007962821,0.00024654448],"about_ca_topic_score_codex":0.0016984788,"about_ca_topic_score_gemma":0.00211481,"teacher_disagreement_score":0.023910549,"about_ca_system_score_codex":0.000120774836,"about_ca_system_score_gemma":0.0003680159,"threshold_uncertainty_score":0.8643843},"labels":[],"label_agreement":null},{"id":"W4387811473","doi":"10.1016/j.annonc.2023.09.1846","title":"660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Loxo Oncology; Genentech; Seagen; Relay Therapeutics; Aileron Therapeutics; Jazz Pharmaceuticals; Exelixis; Daiichi Sankyo Europe; Eli Lilly and Company; Daiichi-Sankyo; Amgen","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Pharmacokinetics; Gastroenterology; Adverse effect; Oncology; Chemotherapy","score_opus":0.07154427690141917,"score_gpt":0.4382774052844848,"score_spread":0.3667331283830656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955739,0.00009359339,8.401967e-8,0.00064334966,0.00004968708,0.002599304,0.0001268211,0.000037508795,0.00087578816],"genre_scores_gemma":[0.9990131,0.00007479766,0.000045429733,0.000056150442,0.000034839482,0.00014143785,0.00014417282,0.000031150397,0.00045887532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963306,0.00041757312,0.0014044937,0.0005185508,0.0007474216,0.00058136333],"domain_scores_gemma":[0.99759287,0.0005967744,0.0005373457,0.00047629885,0.0006398942,0.0001568339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009911875,0.0002672668,0.0013971301,0.00090547366,0.00005479369,0.000002790741,0.0002912517,0.000116544674,0.000057178924],"category_scores_gemma":[0.00046296956,0.00021241908,0.000090347705,0.0013037301,0.0002328165,0.00008558295,0.00023258443,0.0003899736,0.000007845564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12091553,0.10251942,0.7386062,0.00058852736,0.00048789885,0.0013417773,0.014023607,0.00027212116,0.0015497582,0.000008265233,0.002162441,0.01752443],"study_design_scores_gemma":[0.04251981,0.18591052,0.7657862,0.0004132787,0.00004637799,0.0000040170175,0.0033895613,0.00018283271,0.0011302872,0.000018851422,0.0004467333,0.0001515349],"about_ca_topic_score_codex":0.0024059745,"about_ca_topic_score_gemma":0.0029137132,"teacher_disagreement_score":0.0833911,"about_ca_system_score_codex":0.000047159872,"about_ca_system_score_gemma":0.00020734589,"threshold_uncertainty_score":0.8662199},"labels":[],"label_agreement":null},{"id":"W4387811483","doi":"10.1016/j.annonc.2023.09.1852","title":"666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; National Evidence-based Healthcare Collaborating Agency; Mirati Therapeutics; Yuhan; F. Hoffmann-La Roche; AstraZeneca; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.04426788104364964,"score_gpt":0.41592201133084694,"score_spread":0.3716541302871973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448526,0.00014548197,0.000035493347,0.0021753048,0.00007540284,0.00073891896,0.0003670971,0.000019916866,0.0019571264],"genre_scores_gemma":[0.997002,0.00044951303,0.00064417755,0.00037255013,0.000012242171,0.000014067583,0.0013508175,0.00001502802,0.00013961722],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989071,0.000075663644,0.00035890157,0.00027483053,0.00016308555,0.0002204128],"domain_scores_gemma":[0.99892884,0.00024343001,0.00020946363,0.00028063226,0.00024848565,0.00008915032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017853909,0.00011818684,0.00045832538,0.00017590066,0.000034734534,0.0000024173937,0.00009345401,0.00004582354,0.000047711037],"category_scores_gemma":[0.00014614145,0.0000896802,0.000021657477,0.00041326784,0.00013408622,0.000096211916,0.000101943115,0.0000944481,0.000008233266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016913448,0.0068567363,0.21052697,0.00029088138,0.0016830699,0.00048225283,0.005926442,0.00090668286,0.0009461251,0.00024806673,0.011587671,0.74363166],"study_design_scores_gemma":[0.018343447,0.010596556,0.96371025,0.0004204347,0.00037824467,0.000016842267,0.0008656133,0.00024297167,0.0013667447,0.00009816636,0.0038248042,0.00013589943],"about_ca_topic_score_codex":0.0001155187,"about_ca_topic_score_gemma":0.00013824632,"teacher_disagreement_score":0.7531833,"about_ca_system_score_codex":0.00004109778,"about_ca_system_score_gemma":0.0003277148,"threshold_uncertainty_score":0.36570522},"labels":[],"label_agreement":null},{"id":"W4387811549","doi":"10.1016/j.annonc.2023.09.1853","title":"667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Trk receptor; Internal medicine; Cancer; Sarcoma; Surgery; Oncology; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Clinical trial; Phases of clinical research; Pathology; Receptor; Neurotrophin","score_opus":0.06584519936618642,"score_gpt":0.38593607923759804,"score_spread":0.3200908798714116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885309,0.0005898632,0.0000018813441,0.008714483,0.00012891651,0.0014628568,0.00020452416,0.000027199956,0.00033940776],"genre_scores_gemma":[0.9923282,0.0062426445,0.00024374892,0.00022491631,0.000074097385,0.00039330736,0.00023572147,0.000026172507,0.00023117999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887305,0.000048126545,0.00035756957,0.0002957674,0.00015838686,0.00026710864],"domain_scores_gemma":[0.9986696,0.0004475331,0.00023827041,0.0002032434,0.00030248915,0.00013881482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012760882,0.00018596115,0.00063002744,0.00016067999,0.000076427656,0.0000027988826,0.000043145927,0.00012217941,0.00015279469],"category_scores_gemma":[0.00013387765,0.00012503706,0.00010852309,0.00024938077,0.000098657554,0.000030468298,0.000033116892,0.00004643961,0.000010064337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01786658,0.015162907,0.1771988,0.00031115743,0.0012218809,0.00007461554,0.0015130403,0.0000880572,0.0036118522,0.00018648553,0.01124512,0.7715195],"study_design_scores_gemma":[0.07042796,0.13245048,0.32140625,0.0007735047,0.000865843,0.000012560754,0.00026472687,0.00008931463,0.13263795,0.00010086612,0.340652,0.0003185302],"about_ca_topic_score_codex":0.00062025833,"about_ca_topic_score_gemma":0.0005233399,"teacher_disagreement_score":0.77120095,"about_ca_system_score_codex":0.0001002719,"about_ca_system_score_gemma":0.00015306538,"threshold_uncertainty_score":0.50988626},"labels":[],"label_agreement":null},{"id":"W4387811718","doi":"10.1016/j.annonc.2023.09.1692","title":"498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Glioma; Hazard ratio; Internal medicine; Interim analysis; Oligodendroglioma; Randomization; Clinical endpoint; IDH1; Isocitrate dehydrogenase; Placebo; Randomized controlled trial; Surgery; Oncology; Astrocytoma; Confidence interval; Pathology","score_opus":0.1866518375911164,"score_gpt":0.46609472824104425,"score_spread":0.2794428906499279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167275,0.000321765,0.0000012576035,0.0027848529,0.0003931049,0.0036647755,0.000017830802,0.000051605544,0.0010920292],"genre_scores_gemma":[0.9985594,0.00031210505,0.00003685625,0.00013044685,0.00008610285,0.000742142,0.00003559287,0.000030426281,0.00006692439],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971959,0.00034627476,0.00112011,0.0004149387,0.0004367398,0.00048606293],"domain_scores_gemma":[0.99677795,0.0018799074,0.0004911674,0.00044957967,0.00021805808,0.00018330847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013183894,0.0002730109,0.001972347,0.0010836113,0.000044438748,0.000008298948,0.00018917111,0.00023294236,0.00017598018],"category_scores_gemma":[0.0004699946,0.00019976597,0.00028178844,0.0013580725,0.00020676984,0.000079880374,0.00011813462,0.00020950894,0.000047963204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9459755,0.023682695,0.0037508642,0.0001208356,0.0016791257,0.0050444873,0.00420285,0.00007746487,0.0025587387,0.00022473517,0.0034482828,0.009234456],"study_design_scores_gemma":[0.9536418,0.015319115,0.0020306162,0.00013497325,0.00050456304,0.00004429223,0.00338258,0.00008937759,0.023992237,0.000104094586,0.00059627934,0.00016007712],"about_ca_topic_score_codex":0.001033872,"about_ca_topic_score_gemma":0.0017987249,"teacher_disagreement_score":0.021433499,"about_ca_system_score_codex":0.00007337011,"about_ca_system_score_gemma":0.00039066377,"threshold_uncertainty_score":0.814622},"labels":[],"label_agreement":null},{"id":"W4387811970","doi":"10.1016/j.annonc.2023.09.1788","title":"597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Genentech; Ipsen; Parker Institute for Cancer Immunotherapy; Peking Union Medical College Hospital; Astellas Pharma; Eisai; Incyte; FibroGen; Exelixis; American Society of Clinical Oncology; American Association for Cancer Research; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; FOLFOX; Total mesorectal excision; Colorectal cancer; Clinical endpoint; Surgery; Capecitabine; Neoadjuvant therapy; Randomized controlled trial; Oxaliplatin; Internal medicine; Oncology; Cancer; Breast cancer","score_opus":0.07765653384090265,"score_gpt":0.4292452140986653,"score_spread":0.35158868025776263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882874,0.00028026212,0.00005311281,0.00595365,0.00020233785,0.0038510452,0.0003217956,0.00014649707,0.0009039273],"genre_scores_gemma":[0.99225986,0.0013296297,0.00097025634,0.0007937784,0.00022277106,0.0024518974,0.0006385442,0.00007375885,0.0012594744],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99767417,0.00007845942,0.0006293084,0.0006383171,0.00035628243,0.00062349177],"domain_scores_gemma":[0.99757165,0.000584651,0.00041854772,0.0002911609,0.0009153474,0.0002186236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004480881,0.0003093746,0.0011104966,0.0001001559,0.0000872951,0.000008742018,0.00012674247,0.0002535883,0.000099476776],"category_scores_gemma":[0.00023205396,0.00023932567,0.00028802178,0.00055695075,0.0001582707,0.00010805313,0.000027463297,0.00013294815,0.000009671093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12178629,0.0031723469,0.22068213,0.0005328976,0.00096328626,0.00008027676,0.00043735883,0.00012887284,0.0010606465,0.00016810563,0.005904464,0.6450833],"study_design_scores_gemma":[0.077680185,0.064722806,0.61117846,0.0003904652,0.00026469483,0.000019885465,0.000081809754,0.0011881631,0.039884266,0.0005131023,0.20340113,0.00067504996],"about_ca_topic_score_codex":0.00015679361,"about_ca_topic_score_gemma":0.00022359086,"teacher_disagreement_score":0.6444083,"about_ca_system_score_codex":0.00036961588,"about_ca_system_score_gemma":0.00047125923,"threshold_uncertainty_score":0.9759417},"labels":[],"label_agreement":null},{"id":"W4387811984","doi":"10.1016/j.annonc.2023.09.1543","title":"41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Servier; European Society for Medical Oncology; CRIS Cancer Foundation; Astellas Pharma; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Eisai; Sociedad Española de Oncología Médica; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene","keywords":"Enzalutamide; Medicine; Prostate cancer; Pharmacology; Drug; Cancer; Internal medicine","score_opus":0.39245533324299103,"score_gpt":0.526931954523353,"score_spread":0.13447662128036192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758596,0.00342005,0.000027122576,0.005021024,0.00015442395,0.0033723298,0.00019765485,0.000017724658,0.00020368083],"genre_scores_gemma":[0.9728509,0.025416788,0.00014854482,0.0002927245,0.00007977098,0.0008247981,0.00021164553,0.000025439756,0.00014934172],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99723506,0.00063624006,0.00083114894,0.0005510546,0.00024762758,0.0004988759],"domain_scores_gemma":[0.9980963,0.00072968984,0.00030400063,0.0001466835,0.00059844094,0.0001248982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022221068,0.00022549096,0.0009871579,0.00055568205,0.00005171996,0.00000823008,0.00005486175,0.00024376558,0.000012750688],"category_scores_gemma":[0.00015001434,0.00018995012,0.00008205888,0.0003759415,0.0004051742,0.00022855132,0.00006522808,0.00016538517,7.411946e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019047381,0.0020250203,0.027328992,0.0004919576,0.0007413718,0.00017487133,0.009565982,0.024260296,0.8201082,0.00046058017,0.0007634906,0.095031895],"study_design_scores_gemma":[0.030669298,0.008827057,0.029565664,0.00024204823,0.0005217968,0.000023775523,0.0011417913,0.74668294,0.17392623,0.007859493,0.00025668167,0.000283218],"about_ca_topic_score_codex":0.0009933616,"about_ca_topic_score_gemma":0.0021601622,"teacher_disagreement_score":0.72242266,"about_ca_system_score_codex":0.00023600564,"about_ca_system_score_gemma":0.0011509662,"threshold_uncertainty_score":0.7745941},"labels":[],"label_agreement":null},{"id":"W4387811997","doi":"10.1016/j.annonc.2023.09.1651","title":"CN57 Patients, informal caregivers and healthcare professionals experience in adoptive cell therapies: An experience-based co-design study (EBCD-ACT)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Context (archaeology); Medicine; Health care; Nursing; Focus group; Health professionals; Identification (biology)","score_opus":0.16388829770282384,"score_gpt":0.4628415664629118,"score_spread":0.298953268760088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284846,0.00011798262,0.000021961312,0.00566995,0.00013138723,0.00094408967,0.0000094187035,0.000028547767,0.00022820562],"genre_scores_gemma":[0.9979072,0.00016257238,0.00016868638,0.0014928776,0.00002930907,0.0001108597,0.00006808442,0.000010136076,0.0000502559],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9983859,0.0002862202,0.00039541474,0.0002531855,0.00039329563,0.00028598614],"domain_scores_gemma":[0.99893475,0.00020901431,0.0001857422,0.00017314234,0.00030391576,0.00019344437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000608067,0.00012767033,0.00036012675,0.00024646238,0.00009211202,0.0000054060433,0.00009930874,0.00026365774,0.000051930223],"category_scores_gemma":[0.00006204771,0.00009683025,0.000034026456,0.00039073118,0.0006027087,0.00014240934,0.000041703745,0.0002472985,0.0000028773886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027703373,0.0040694354,0.1802626,0.0002634557,0.00004454195,0.000096644195,0.64802116,0.000037490176,0.0009285016,0.0001682934,0.0011710731,0.16216649],"study_design_scores_gemma":[0.0063390625,0.021791803,0.71771514,0.00017114982,0.000011407042,0.0000019602155,0.24412805,0.0007902009,0.003214449,0.00011964839,0.005498417,0.00021872987],"about_ca_topic_score_codex":0.00023590047,"about_ca_topic_score_gemma":0.00006806677,"teacher_disagreement_score":0.5374525,"about_ca_system_score_codex":0.000035930374,"about_ca_system_score_gemma":0.0005711507,"threshold_uncertainty_score":0.3948623},"labels":[],"label_agreement":null},{"id":"W4387812143","doi":"10.1016/j.annonc.2023.09.1341","title":"2314P Quality and safety of research biopsies (RB) in oncology clinical trials","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; HORIZON EUROPE Framework Programme; Chugai Pharmaceutical; AstraZeneca; Genentech; INCLIVA Instituto de Investigación Sanitaria; Sun Pharma; EMD Serono; Mersana Therapeutics; Deutschen Konsortium für Translationale Krebsforschung; Incyte; Servier; Sociedad Española de Oncología Médica; Cancer Research UK; Seagen; Grifols; Fundación Científica Asociación Española Contra el Cáncer; MacroGenics; American Society of Clinical Oncology; Oncode Institute; Eisai Canada; BeiGene; Mirati Therapeutics; Amgen; Astellas Pharma; Deciphera Pharmaceuticals; Daiichi Sankyo Europe; Takeda Oncology; European Society for Medical Oncology; Agios Pharmaceuticals; Clovis Oncology; Les Laboratories Pierre Fabre; Novocure; Regeneron Pharmaceuticals; Ipsen; Takeda Pharmaceuticals International; Array BioPharma; Taiho Pharmaceutical; Merck KGaA; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; F. Hoffmann-La Roche; Loxo Oncology; European Association for Cancer Research; Pharmacyclics; Exelixis; Sanofi; PharmaMar; Novartis Farmacéutica; OncoMed Pharmaceutical; Pfizer; Celgene","keywords":"Medicine; Clinical trial; Context (archaeology); Internal medicine; Breast cancer; Oncology; Cancer; Surgery","score_opus":0.6642324169962353,"score_gpt":0.6911398944728597,"score_spread":0.026907477476624475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89988756,0.0005341828,0.000018633242,0.08894999,0.00029208564,0.00034705567,0.000009721693,0.00002418252,0.009936552],"genre_scores_gemma":[0.9874765,0.00940734,0.00070869405,0.0017085262,0.00027383392,0.000015471183,0.000019751287,0.0000146510165,0.0003751937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99154747,0.005377407,0.0020118165,0.00031260558,0.00034472102,0.0004059619],"domain_scores_gemma":[0.9817718,0.01692711,0.0004625744,0.0002720579,0.00035420863,0.00021224872],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07086925,0.00009363179,0.0016569879,0.00053061056,0.000040217314,0.0000030289618,0.00014178536,0.0003724533,0.000083237],"category_scores_gemma":[0.052107643,0.00007463111,0.00016611317,0.0006430802,0.0012672852,0.000031591517,0.00018518767,0.000990204,0.000014666559],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032766208,0.0008618595,0.18101019,0.0003747195,0.00019154475,0.00025347964,0.0010745451,0.000017548418,0.005367189,0.004708332,0.02605582,0.77680814],"study_design_scores_gemma":[0.0068002706,0.006170174,0.723856,0.00024615103,0.000042678028,0.000040765306,0.0012982632,0.0013591308,0.000692439,0.005509272,0.25387317,0.00011170273],"about_ca_topic_score_codex":0.00039435833,"about_ca_topic_score_gemma":0.00005481867,"teacher_disagreement_score":0.77669644,"about_ca_system_score_codex":0.000036103953,"about_ca_system_score_gemma":0.00063062966,"threshold_uncertainty_score":0.9567356},"labels":[],"label_agreement":null},{"id":"W4387812249","doi":"10.1016/j.annonc.2023.09.1544","title":"42P Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Servier; European Society for Medical Oncology; CRIS Cancer Foundation; Astellas Pharma; Fundação para a Ciência e a Tecnologia; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Eisai; Sociedad Española de Oncología Médica; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene","keywords":"Aldehyde dehydrogenase; Aldehyde; Endometrial cancer; Chlorin; Photodynamic therapy; Medicine; Pyridine; Chemistry; Combinatorial chemistry; Cancer; Enzyme; Biochemistry; Organic chemistry; Internal medicine","score_opus":0.1659000886124957,"score_gpt":0.45598435634097795,"score_spread":0.2900842677284823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878197,0.0012858551,0.000023902394,0.007849844,0.00045253354,0.0011549892,0.00009207028,0.00012369065,0.0011974217],"genre_scores_gemma":[0.98066264,0.014928376,0.00013627105,0.0021269617,0.00019732081,0.00030201554,0.000017801825,0.00004066472,0.0015879611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978836,0.00018059579,0.00046708732,0.0003664713,0.00040175038,0.0007004698],"domain_scores_gemma":[0.99846494,0.0004981937,0.0001461454,0.00027578766,0.00041525054,0.00019965906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008127752,0.00021019467,0.0008010593,0.0007415812,0.0000813957,0.000008989151,0.00023607898,0.00015565217,0.00021906146],"category_scores_gemma":[0.0001201302,0.00017405472,0.00015625909,0.0017017944,0.00016660304,0.000051200816,0.00012123085,0.000237503,0.00009831884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002764524,0.00016261805,0.00021211154,0.000068949295,0.0006890901,0.00013319174,0.0008446264,0.00012272301,0.79194206,0.000087704044,0.010517037,0.19245537],"study_design_scores_gemma":[0.007614536,0.009638394,0.017653644,0.0001655247,0.000031535914,0.000015957146,0.0010156377,0.00032061746,0.8269391,0.00042553077,0.13579847,0.00038103602],"about_ca_topic_score_codex":0.0004995074,"about_ca_topic_score_gemma":0.0002631945,"teacher_disagreement_score":0.19207433,"about_ca_system_score_codex":0.00018207468,"about_ca_system_score_gemma":0.0010199862,"threshold_uncertainty_score":0.70977455},"labels":[],"label_agreement":null},{"id":"W4387812289","doi":"10.1016/j.annonc.2023.09.1542","title":"40P Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Servier; European Society for Medical Oncology; CRIS Cancer Foundation; Astellas Pharma; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Eisai; Sociedad Española de Oncología Médica; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene","keywords":"Cancer research; CD8; Medicine; Prostate cancer; Cytotoxic T cell; T cell; Population; Immune system; Transcriptome; Cancer; Immunology; Biology; Internal medicine; Gene expression; Gene; In vitro; Genetics","score_opus":0.04737649435270452,"score_gpt":0.31328995400772364,"score_spread":0.2659134596550191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941882,0.004145115,0.0000048586858,0.00042216276,0.00014655435,0.000662785,0.000060430197,0.000015015344,0.00035490052],"genre_scores_gemma":[0.9986652,0.0008843082,0.00006226069,0.000045464727,0.0000020669672,0.000045577926,0.000030338604,0.000009938806,0.00025482418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981386,0.0007443669,0.0006707031,0.00012940499,0.000096525524,0.00022041712],"domain_scores_gemma":[0.9981865,0.00033502988,0.0007690896,0.00031924382,0.0003834457,0.0000066592834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013725511,0.00013628557,0.00053276913,0.00020066222,0.00006429937,0.0000014075554,0.00024652402,0.00019368119,0.00014565099],"category_scores_gemma":[0.00015502566,0.00008244892,0.000094742776,0.00032354196,0.0008758115,0.00010040688,0.0000671816,0.00014913888,0.0000070932515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028215435,0.0001801896,0.00097053574,0.00018424974,0.0002016156,3.63232e-7,0.0029287126,0.000054785585,0.9731299,0.00022265954,0.0003495895,0.018955851],"study_design_scores_gemma":[0.0025515507,0.00325514,0.063738585,0.00028000164,0.00006866277,0.000019479068,0.0012534375,0.000020809828,0.92770374,0.000325951,0.0007025749,0.00008004842],"about_ca_topic_score_codex":0.00009557703,"about_ca_topic_score_gemma":0.00000598828,"teacher_disagreement_score":0.06276805,"about_ca_system_score_codex":0.0000113586675,"about_ca_system_score_gemma":0.00031279464,"threshold_uncertainty_score":0.33621693},"labels":[],"label_agreement":null},{"id":"W4387812349","doi":"10.1016/j.annonc.2023.09.1394","title":"101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"Pharmacyclics; Genentech; European Society for Medical Oncology; Centre for Mathematical Cognition, Loughborough University; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Loxo Oncology; Astellas Pharma; Novocure; Eisai; Jazz Pharmaceuticals; Incyte; F. Hoffmann-La Roche; FibroGen; Celgene; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; Pfizer; Agios Pharmaceuticals","keywords":"Medicine; Biliary tract cancer; Internal medicine; Quality of life (healthcare); Biliary tract; Gastroenterology; Oncology; Cancer; Gemcitabine","score_opus":0.11823950711984818,"score_gpt":0.436515297590777,"score_spread":0.3182757904709288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918515,0.00038027638,4.7054345e-7,0.0049590934,0.00010860731,0.0014319712,0.00025589747,0.000028361073,0.0009838205],"genre_scores_gemma":[0.99785453,0.00025648356,0.0000086432765,0.0014175205,0.000048367314,0.00021104536,0.000099229044,0.0000260368,0.00007814767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972247,0.0005972659,0.0008595644,0.00043189293,0.0004644198,0.000422157],"domain_scores_gemma":[0.99807894,0.0006946804,0.00038494501,0.00045953513,0.0002902322,0.000091647256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095848565,0.00027557832,0.0012939499,0.0002688163,0.000051899126,0.0000064497854,0.00024126358,0.0001322109,0.00006135809],"category_scores_gemma":[0.00031891264,0.0001767621,0.00013733571,0.00092020177,0.00022235922,0.000108464235,0.00010139823,0.00032555222,0.0000075898906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040521394,0.011149854,0.9621617,0.0000975999,0.0005377483,0.00016727093,0.010528956,0.000007188012,0.00010237739,0.0000071628824,0.0022923562,0.008895635],"study_design_scores_gemma":[0.016618058,0.013109099,0.9598403,0.0000920131,0.00012594006,0.0000017739029,0.009379032,0.0000073961523,0.00026385003,0.000012465,0.00038767644,0.00016238073],"about_ca_topic_score_codex":0.015435353,"about_ca_topic_score_gemma":0.01431182,"teacher_disagreement_score":0.012565919,"about_ca_system_score_codex":0.000102823244,"about_ca_system_score_gemma":0.00034908488,"threshold_uncertainty_score":0.99112093},"labels":[],"label_agreement":null},{"id":"W4387812385","doi":"10.1016/j.annonc.2023.09.536","title":"357P Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; Simon Fraser University; Western University; Abbotsford Veterinary Clinic","funders":"National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Intas Pharmaceuticals; Hope Foundation; Seagen; Eisai; Daiichi Sankyo Europe; Sanofi; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Medicine; Breast cancer; Breast-conserving surgery; Palpation; Mammography; Lymph node; Radiology; Cancer; Chemotherapy; Neoadjuvant therapy; Ductal carcinoma; Nuclear medicine; Surgery; Mastectomy; Internal medicine","score_opus":0.022845037467660832,"score_gpt":0.3188221191028876,"score_spread":0.2959770816352268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952314,0.00012640512,0.00007011462,0.0032541647,0.00012062945,0.00040101673,0.000713639,0.000018533596,0.00006408291],"genre_scores_gemma":[0.99835694,0.00026556154,0.00044305247,0.00064232195,0.00006550287,0.000083804945,0.00007440072,0.000033392924,0.000035047688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984036,0.00014211077,0.00038721247,0.00045117066,0.00020333375,0.00041257724],"domain_scores_gemma":[0.9989421,0.000047249523,0.0001959174,0.00030967008,0.0004004644,0.00010459795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026763917,0.00023082225,0.00046004757,0.00017320279,0.00004437394,0.0000038469657,0.0001624619,0.00019198233,0.000013942136],"category_scores_gemma":[0.000051813608,0.00018933568,0.00007654305,0.00040603193,0.00022836955,0.000009745485,0.00013302638,0.00008811677,0.0000025894137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05995761,0.0023152723,0.61953676,0.000064255415,0.00043172436,0.000057289486,0.0006657557,0.005423857,0.16225775,0.0000147300625,0.0012236836,0.14805134],"study_design_scores_gemma":[0.005953248,0.0030036536,0.9790578,0.00011512505,0.000029685172,0.000031997868,0.00013486919,0.00004459125,0.010794625,0.000012576213,0.0006509973,0.0001708314],"about_ca_topic_score_codex":0.00021139173,"about_ca_topic_score_gemma":0.00019560664,"teacher_disagreement_score":0.35952106,"about_ca_system_score_codex":0.0000963258,"about_ca_system_score_gemma":0.00029206128,"threshold_uncertainty_score":0.7720885},"labels":[],"label_agreement":null},{"id":"W4387812409","doi":"10.1016/j.annonc.2023.09.1440","title":"1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Pneumonitis; Chimeric antigen receptor; Internal medicine; Oncology; Refractory (planetary science); Chemotherapy; Leukapheresis; Immunotherapy; Gastroenterology; Cancer; Stem cell; Lung","score_opus":0.1673751192360413,"score_gpt":0.47712884700499364,"score_spread":0.3097537277689524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908436,0.0001665162,0.0000014166877,0.00450704,0.00014817569,0.00090793805,0.00001645151,0.000052667914,0.0033561892],"genre_scores_gemma":[0.99591887,0.0005899666,0.00020021683,0.0005329769,0.00017268577,0.000031799154,0.000030177092,0.000033019547,0.0024903065],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755836,0.00041219665,0.0009302032,0.00032762182,0.00031107903,0.00046053543],"domain_scores_gemma":[0.997314,0.0016302776,0.00034631178,0.00033046267,0.00017765637,0.00020133631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020340558,0.00015896875,0.0010485001,0.00049439905,0.000058548965,0.0000032128282,0.0001452242,0.0002729409,0.0005751588],"category_scores_gemma":[0.0041000126,0.00013339325,0.00011099831,0.0007867631,0.0005401897,0.00004294137,0.00016045218,0.00049771846,0.000010266361],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21331583,0.0035012236,0.0007651795,0.00031038685,0.00024800532,0.0010001124,0.005509267,0.000038161063,0.31614983,0.00011077853,0.005322646,0.4537286],"study_design_scores_gemma":[0.520349,0.23628442,0.032379616,0.0010696393,0.00016057088,0.00033400106,0.0027068153,0.002939123,0.08566526,0.00082770735,0.11665938,0.0006244505],"about_ca_topic_score_codex":0.00020005209,"about_ca_topic_score_gemma":0.000108924985,"teacher_disagreement_score":0.45310414,"about_ca_system_score_codex":0.00006903207,"about_ca_system_score_gemma":0.0009978549,"threshold_uncertainty_score":0.62975854},"labels":[],"label_agreement":null},{"id":"W4387812459","doi":"10.1016/j.annonc.2023.09.1327","title":"2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Genentech; Aptitude Health; Sierra Oncology; Eisai; Astellas Pharma; Basilea Pharmaceutica; Daiichi Sankyo Europe; Servier; AstraZeneca; Institut National Du Cancer; Pfizer; Incyte; BeiGene; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Ipsen; Jazz Pharmaceuticals; Bayer HealthCare; Exelixis; Sanofi; Amgen; American Association for Cancer Research; Eli Lilly and Company; Bristol-Myers Squibb; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; PharmaMar; Celgene","keywords":"Medicine; Internal medicine; Oncology; Pembrolizumab; Lung cancer; Cancer; Immunotherapy","score_opus":0.02526084698264695,"score_gpt":0.366198722378926,"score_spread":0.340937875396279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972332,0.00012781245,0.00000130512,0.0011083226,0.000019420377,0.0011702208,0.00003598283,0.000016167705,0.00028754718],"genre_scores_gemma":[0.99947095,0.0001316182,0.00006084263,0.00005193451,0.000007320547,0.000096877164,0.000018911536,0.000021863038,0.00013971145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978605,0.00021188625,0.0006318213,0.00030183792,0.00066135096,0.0003326074],"domain_scores_gemma":[0.99819976,0.00014502375,0.000516004,0.0004761911,0.0006031906,0.00005981594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047771502,0.0001897316,0.0011587655,0.0006128052,0.00004310508,0.000002380341,0.00022422352,0.00008058416,0.00004459895],"category_scores_gemma":[0.00013140633,0.00011157807,0.00019922071,0.00229502,0.00040386734,0.000051917435,0.00013645587,0.0001900511,0.0000010274273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015156193,0.0023645235,0.9590853,0.00013799615,0.007313058,0.00005534019,0.0039371233,0.000582303,0.004258946,0.0000027416236,0.000060785667,0.007045732],"study_design_scores_gemma":[0.008552066,0.012893393,0.95102835,0.00016591127,0.00084124185,0.0000017445251,0.001978268,0.00011983913,0.024276394,0.0000127030635,0.000031443396,0.00009864134],"about_ca_topic_score_codex":0.0010694185,"about_ca_topic_score_gemma":0.00060027,"teacher_disagreement_score":0.020017447,"about_ca_system_score_codex":0.00008395796,"about_ca_system_score_gemma":0.00028584123,"threshold_uncertainty_score":0.45500216},"labels":[],"label_agreement":null},{"id":"W4387812500","doi":"10.1016/j.annonc.2023.09.1267","title":"2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Foundation Medicine; Takeda Pharmaceuticals International; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; European Society for Medical Oncology; Fundación Científica Asociación Española Contra el Cáncer; Cancer Research UK; Seagen; F-star Therapeutics; Genentech; Veracyte; BeiGene; Mirati Therapeutics; Les Laboratories Pierre Fabre; Natera; Regeneron Pharmaceuticals; Ribon Therapeutics; Ipsen; Array BioPharma; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Merck KGaA; Daiichi Sankyo Europe; Servier; Gilead Sciences; Astellas Pharma; FibroGen; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Celgene","keywords":"Medicine; CD19; Cancer; Tumor-infiltrating lymphocytes; Tumor microenvironment; Gene expression profiling; Gene signature; Pancreatic cancer; Colorectal cancer; Cancer research; Gene expression; Gene; Oncology; Internal medicine; Immunotherapy; Pathology; Immunology; Flow cytometry; Biology; Genetics","score_opus":0.051258496362040856,"score_gpt":0.39954416982533575,"score_spread":0.34828567346329486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574035,0.0020490678,0.0000029248736,0.001632753,0.00008364868,0.00024464246,0.000018906107,0.000031085023,0.00019661446],"genre_scores_gemma":[0.99680686,0.0016334344,0.00036422125,0.00092702237,0.00006867283,0.000039207003,0.000015423891,0.000015620133,0.00012952842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991489,0.000043198062,0.00022946991,0.00020568598,0.00011586118,0.00025685393],"domain_scores_gemma":[0.99960667,0.000042561664,0.00011177312,0.00012874238,0.000058136295,0.000052141673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000246738,0.00010726414,0.0003183751,0.000099107165,0.00004214819,0.0000048104102,0.000057221492,0.000099403645,0.00003052474],"category_scores_gemma":[0.000021863654,0.0000747383,0.000032236712,0.00021902738,0.00017978497,0.000049908354,0.00003275373,0.00008872746,0.0000010053453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043785535,0.000045944216,0.46360072,0.00010518545,0.000065356384,0.00005569402,0.0008482302,0.00002781162,0.48809248,0.0000036594934,0.00040338546,0.042372975],"study_design_scores_gemma":[0.0027155513,0.00083871436,0.41524643,0.00020499344,0.00001130311,0.00009085301,0.00043464956,0.00003540137,0.5789196,0.000067149,0.0013518889,0.00008345467],"about_ca_topic_score_codex":0.00048313566,"about_ca_topic_score_gemma":0.00026301877,"teacher_disagreement_score":0.09082714,"about_ca_system_score_codex":0.000033255703,"about_ca_system_score_gemma":0.00021870923,"threshold_uncertainty_score":0.30477396},"labels":[],"label_agreement":null},{"id":"W4387812581","doi":"10.1016/j.annonc.2023.09.1257","title":"2027P Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency; McMaster University; Western University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Meta-analysis; Cochrane Library; Adverse effect; Chemotherapy; Clinical endpoint; Confidence interval; Randomized controlled trial; Subgroup analysis","score_opus":0.33720105477581636,"score_gpt":0.5258642158560765,"score_spread":0.1886631610802601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000112532725,0.9888578,3.0488067e-7,0.003598133,0.000030692918,0.0070622275,0.00012424578,0.000012723195,0.00030264034],"genre_scores_gemma":[0.000019560626,0.9935691,0.000018412607,0.00020134222,0.000034882924,0.0051855044,0.000032232536,0.000039312516,0.0008997034],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99530286,0.0013147753,0.002254853,0.00040687434,0.0003730705,0.0003475856],"domain_scores_gemma":[0.9958889,0.0014015568,0.0015574642,0.00079506944,0.00028368007,0.000073352974],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0025505156,0.00042067285,0.01616506,0.000579505,0.000025295258,0.000005173394,0.00027408305,0.00019186756,0.00005424571],"category_scores_gemma":[0.0003529561,0.0001970038,0.0035073266,0.0016844941,0.00017805978,0.000016675825,0.0001093865,0.00025886294,0.00000419156],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008457134,0.00032106723,0.0000061807914,0.8235059,0.17049079,0.00006707153,0.00047728032,4.7036278e-7,2.2681657e-7,0.0000038870476,0.0007521062,0.004366562],"study_design_scores_gemma":[0.00029810725,0.0014947728,0.0000071972277,0.052735716,0.847236,0.000013254527,0.000120122786,0.0000017973533,0.0000072660355,0.0000037562427,0.09795689,0.0001251656],"about_ca_topic_score_codex":0.0018426221,"about_ca_topic_score_gemma":0.00085140025,"teacher_disagreement_score":0.7707702,"about_ca_system_score_codex":0.00029247743,"about_ca_system_score_gemma":0.00074061134,"threshold_uncertainty_score":0.998441},"labels":[],"label_agreement":null},{"id":"W4387812666","doi":"10.1016/j.annonc.2023.09.1322","title":"2295P Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Crizotinib; Cabozantinib; Cancer; Internal medicine; Colorectal cancer; Oncology; Lung cancer; C-Met; Targeted therapy; Receptor","score_opus":0.22079833348821043,"score_gpt":0.49875381198341584,"score_spread":0.2779554784952054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96994656,0.0076675653,0.0000035519515,0.021245861,0.00022483378,0.00034474116,0.00006343189,0.000029607578,0.00047386656],"genre_scores_gemma":[0.9672009,0.028788526,0.0003419157,0.002539864,0.00011902463,0.000051622534,0.0000032328562,0.000012416706,0.0009425425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998622,0.00026298233,0.0004555138,0.00026312532,0.00016968824,0.00022666856],"domain_scores_gemma":[0.9981793,0.0010112857,0.00014305569,0.00025718522,0.00028263507,0.00012651678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011703508,0.00010909132,0.0006020366,0.00017711194,0.000042392494,0.0000017344973,0.0000997996,0.000114910996,0.00015452903],"category_scores_gemma":[0.00081481546,0.000085210246,0.00014443278,0.0003970006,0.00023084818,0.000028673148,0.00012681581,0.00012955557,0.00001316185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014130882,0.0005358578,0.5798287,0.00022664717,0.00088479527,0.00007772113,0.0034477024,0.0000024392334,0.058642536,0.00006993419,0.07816414,0.26398864],"study_design_scores_gemma":[0.0015719292,0.007884047,0.9286424,0.00008054839,0.00008995701,0.0000057968728,0.00032590356,0.0000048717916,0.0055576563,0.00007877742,0.055684563,0.0000735827],"about_ca_topic_score_codex":0.000094191644,"about_ca_topic_score_gemma":0.000041867133,"teacher_disagreement_score":0.34881365,"about_ca_system_score_codex":0.000012884235,"about_ca_system_score_gemma":0.00023729485,"threshold_uncertainty_score":0.34747732},"labels":[],"label_agreement":null},{"id":"W4387824808","doi":"10.1016/j.annonc.2023.09.1967","title":"789P Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Eisai; BeiGene; Australian Government; American Society of Clinical Oncology; GlaxoSmithKline; Clovis Oncology; AstraZeneca; Pfizer","keywords":"Medicine; Epithelial ovarian cancer; Ovarian cancer; Oncology; Duration (music); Internal medicine; Cancer","score_opus":0.1456934424015971,"score_gpt":0.45004545396042467,"score_spread":0.3043520115588276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839,0.0002065516,0.000016832088,0.017843729,0.00031339758,0.0014323973,0.000099508856,0.000040835785,0.0016567856],"genre_scores_gemma":[0.98595387,0.010986972,0.00008435804,0.0008571387,0.00022241825,0.00071249803,0.000041267205,0.000031843094,0.0011096393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978573,0.00020580157,0.0009706293,0.00037318797,0.00021097131,0.00038211685],"domain_scores_gemma":[0.9987336,0.00022871654,0.00041290413,0.0003575223,0.0001924881,0.00007481105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073052075,0.00020921884,0.0008772792,0.0006894168,0.000029349143,0.0000030268866,0.000114504386,0.00014090422,0.00028746392],"category_scores_gemma":[0.000051160845,0.0001842676,0.00011314619,0.0010837921,0.00012287138,0.00007575135,0.000021687109,0.00016164387,0.000016221999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020833036,0.010316291,0.7141639,0.00023124894,0.0008212378,0.00062722433,0.026135417,0.0040511102,0.052449718,0.0011292178,0.007656053,0.16158555],"study_design_scores_gemma":[0.036974832,0.018639127,0.85136557,0.00051194587,0.00005988386,0.000010277666,0.0012027117,0.0012519642,0.04924497,0.0015197144,0.038890667,0.00032836187],"about_ca_topic_score_codex":0.014370581,"about_ca_topic_score_gemma":0.058622114,"teacher_disagreement_score":0.16125719,"about_ca_system_score_codex":0.0005613028,"about_ca_system_score_gemma":0.00052624627,"threshold_uncertainty_score":0.9921928},"labels":[],"label_agreement":null},{"id":"W4387824903","doi":"10.1016/j.annonc.2023.09.1436","title":"1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; INCLIVA Instituto de Investigación Sanitaria; Deutschen Konsortium für Translationale Krebsforschung; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Universidad de Navarra; Seoul National University Hospital; Fundación Científica Asociación Española Contra el Cáncer; Sanofi; Sungkyunkwan University; Pfizer; Incyte; Yonsei University; Seagen; BeiGene; University of Seoul; Cancer Research UK; Azərbaycan Milli Elmlər Akademiyası; Mirati Therapeutics; F. Hoffmann-La Roche; National Cancer Center Japan; Les Laboratories Pierre Fabre; Array BioPharma; Taiho Pharmaceutical; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncode Institute; American Society of Clinical Oncology; Merck; Universitat de Barcelona; Amgen; Celgene","keywords":"Ramucirumab; Medicine; Paclitaxel; Trastuzumab; Internal medicine; Oncology; Cancer; Breast cancer","score_opus":0.11399774585402783,"score_gpt":0.4384518013909765,"score_spread":0.32445405553694867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916081,0.00024614917,0.00033250486,0.005247062,0.00025430278,0.0014491882,0.0004534114,0.00005157736,0.00035772455],"genre_scores_gemma":[0.996333,0.00053580524,0.0010267182,0.00047368286,0.00021774949,0.00018534737,0.00029455996,0.000025970114,0.00090716797],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982679,0.00006879532,0.00071049586,0.00038157235,0.00023831193,0.00033293822],"domain_scores_gemma":[0.9985599,0.0003648964,0.00039232755,0.00029304417,0.00027265193,0.00011719948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005346219,0.00018353749,0.0007187451,0.00028329872,0.00007659391,0.000008923792,0.00012428466,0.00009875607,0.00006637418],"category_scores_gemma":[0.00026590654,0.0001667878,0.00010403668,0.0004135819,0.00009053851,0.00012644369,0.000105878345,0.000108179534,0.0000011489138],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05793228,0.027034126,0.059546646,0.0011945897,0.0048048976,0.00036342876,0.046357933,0.023978688,0.00297748,0.0005448021,0.17562221,0.59964293],"study_design_scores_gemma":[0.24806337,0.19607045,0.44286853,0.00045570877,0.0026810549,0.00001967562,0.036145624,0.029515186,0.002783612,0.00047893997,0.04006451,0.00085334113],"about_ca_topic_score_codex":0.001293568,"about_ca_topic_score_gemma":0.00035879854,"teacher_disagreement_score":0.5987896,"about_ca_system_score_codex":0.00005993608,"about_ca_system_score_gemma":0.00017995364,"threshold_uncertainty_score":0.68014085},"labels":[],"label_agreement":null},{"id":"W4387824924","doi":"10.1016/j.annonc.2023.09.2012","title":"866P Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Institut Gustave-Roussy; Institut National Du Cancer","keywords":"Medicine; DNA methylation; Cancer; Hazard ratio; Oncology; Internal medicine; Head and neck cancer; Stage (stratigraphy); Proportional hazards model; Confidence interval; Genetics; Biology; Gene","score_opus":0.04723140657621455,"score_gpt":0.3459804944821306,"score_spread":0.29874908790591603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953185,0.002971534,0.000005876011,0.00060542696,0.00010252219,0.00021053126,0.000048129998,0.000004098355,0.00073342863],"genre_scores_gemma":[0.97849053,0.020641178,0.00013828478,0.00045183333,0.00006169549,0.00006342409,0.000046803187,0.000011892777,0.000094363946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991216,0.000018969544,0.00031738335,0.00021245955,0.00007447797,0.0002550774],"domain_scores_gemma":[0.9994481,0.00009672184,0.00013840731,0.0001622035,0.00009518535,0.000059368514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026389997,0.00010438638,0.0002675871,0.0001136125,0.000019904393,0.0000031403374,0.00011489924,0.00012781667,0.000011463121],"category_scores_gemma":[0.00014491743,0.00010376512,0.00004534222,0.00018592665,0.0000974498,0.000003644509,0.00014978362,0.00006480221,0.0000028514837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008211114,0.00040320389,0.7351103,0.0003800752,0.00019639988,0.000023110446,0.0007306208,0.0032455993,0.18358387,0.00021260766,0.0030456022,0.07224754],"study_design_scores_gemma":[0.0015371846,0.005066746,0.82472104,0.00006237865,0.000025173365,0.0000061683063,0.00012680035,0.0003335583,0.08194069,0.00024870932,0.08570057,0.00023101507],"about_ca_topic_score_codex":0.00017432527,"about_ca_topic_score_gemma":0.00046231804,"teacher_disagreement_score":0.10164318,"about_ca_system_score_codex":0.000017035638,"about_ca_system_score_gemma":0.00022602346,"threshold_uncertainty_score":0.42314187},"labels":[],"label_agreement":null},{"id":"W4387824968","doi":"10.1016/j.annonc.2023.09.2005","title":"859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Adverse effect; Head and neck squamous-cell carcinoma; Refractory (planetary science); Phases of clinical research; Cohort; Surgery; Oncology; Clinical trial; Head and neck cancer; Cancer","score_opus":0.06312735777555628,"score_gpt":0.3723666057780799,"score_spread":0.3092392480025236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890461,0.00031841002,0.0000010041649,0.0042323857,0.00027624727,0.0016055949,0.00031104876,0.0000454742,0.0041637234],"genre_scores_gemma":[0.99588954,0.0003089136,0.00007786753,0.0008291502,0.0002672374,0.000079096746,0.00033406366,0.000052200445,0.0021619175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970215,0.00043353572,0.00074104534,0.000604175,0.0005590965,0.00064067583],"domain_scores_gemma":[0.9971561,0.00129058,0.00031448816,0.00073413877,0.00026991556,0.00023478731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007273694,0.00027496583,0.0008073375,0.00027691014,0.00012958581,0.000012581948,0.0002609663,0.00027983,0.00023003666],"category_scores_gemma":[0.00061920955,0.00019695642,0.00012058543,0.0006116297,0.00033983972,0.00010941293,0.00016687487,0.00068383076,0.000025664278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6686425,0.006538974,0.022134565,0.00008372469,0.0001145841,0.00045447037,0.0053055366,0.000028370117,0.0143224,0.00001867957,0.020069575,0.2622866],"study_design_scores_gemma":[0.55100214,0.13308117,0.14886814,0.00010075791,0.000079332385,0.000008022293,0.0007813151,0.00013601354,0.0064020357,0.000153165,0.15905589,0.00033202878],"about_ca_topic_score_codex":0.0013391445,"about_ca_topic_score_gemma":0.0010829556,"teacher_disagreement_score":0.26195458,"about_ca_system_score_codex":0.00018543765,"about_ca_system_score_gemma":0.0005704967,"threshold_uncertainty_score":0.80316496},"labels":[],"label_agreement":null},{"id":"W4387825043","doi":"10.1016/j.annonc.2023.09.1966","title":"788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of British Columbia; Sunnybrook Health Science Centre; Vancouver General Hospital","funders":"","keywords":"PTEN; Medicine; Oncology; Carcinosarcoma; Internal medicine; Cohort; Olaparib; Cancer; Retrospective cohort study; Endometrial cancer; Gene; Genetics; Carcinoma; Biology","score_opus":0.2228424938412327,"score_gpt":0.36763418911998214,"score_spread":0.14479169527874944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919182,0.0028343587,0.0016327611,0.0012500436,0.00016157985,0.00060291,0.0005300785,0.000010552022,0.0010595212],"genre_scores_gemma":[0.9958502,0.0022376147,0.0006980045,0.00034291457,0.00019020907,0.00025184086,0.00023134254,0.000032748012,0.00016512972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886507,0.000074091426,0.00033947095,0.00027553638,0.00015341514,0.0002923991],"domain_scores_gemma":[0.99887085,0.00020993962,0.0002931203,0.00022281182,0.00033501096,0.0000682747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005810392,0.0001555149,0.00041656476,0.00011329091,0.000042120584,0.000007009644,0.00017569536,0.00014945272,0.000013498289],"category_scores_gemma":[0.0002706777,0.00013401815,0.00016203301,0.00017584216,0.0002538313,0.0000029939304,0.00007080204,0.000053965403,3.8031328e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040396564,0.00029842803,0.0029728021,0.00037327365,0.000895857,0.000029727573,0.0002829418,0.00049897557,0.93595785,0.013099433,0.0017680359,0.03978303],"study_design_scores_gemma":[0.0038887719,0.00614521,0.00064841425,0.000051489096,0.00019038538,0.000013822576,0.0011877303,0.0002139064,0.9196367,0.0018555637,0.06581808,0.000349903],"about_ca_topic_score_codex":0.000045815177,"about_ca_topic_score_gemma":0.000053664928,"teacher_disagreement_score":0.06405005,"about_ca_system_score_codex":0.000017659824,"about_ca_system_score_gemma":0.0004983546,"threshold_uncertainty_score":0.5465101},"labels":[],"label_agreement":null},{"id":"W4387825061","doi":"10.1016/j.annonc.2023.09.1982","title":"806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Ambulatory; Gynecologic cancer; Oncology; Internal medicine; Cancer; Ovarian cancer","score_opus":0.06053957877141994,"score_gpt":0.36643351702809684,"score_spread":0.3058939382566769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965344,0.00019838207,4.8018137e-7,0.000350311,0.00035243863,0.0010004501,0.0000053023386,0.00013042873,0.0014277787],"genre_scores_gemma":[0.998898,0.00031867015,0.000089023255,0.00009236801,0.00006793782,0.00036210445,0.00002889161,0.000024087587,0.000118876276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983734,0.00007749873,0.00032699204,0.00033686392,0.00027044275,0.00061483943],"domain_scores_gemma":[0.999238,0.000113052774,0.00016962289,0.00019289415,0.00017203589,0.000114357455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020085141,0.00017224575,0.00046989383,0.00023530667,0.000039218554,0.000004138201,0.00008338814,0.00012636298,0.000054286993],"category_scores_gemma":[0.00006964956,0.00013649622,0.000066570465,0.00066881167,0.00011497078,0.0000731987,0.000047050282,0.00023254407,0.000022814464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002784524,0.000872219,0.88080436,0.0000506431,0.00015667453,0.00010714391,0.000098648554,0.00018752494,0.00012114401,0.00003132749,0.00012543725,0.11466032],"study_design_scores_gemma":[0.0039395215,0.032006443,0.95953244,0.00007449621,0.000043141164,0.0000047500953,0.000073494484,0.000043447744,0.0012367519,0.0001377374,0.0027903914,0.00011741561],"about_ca_topic_score_codex":0.00026426776,"about_ca_topic_score_gemma":0.00021871326,"teacher_disagreement_score":0.11454291,"about_ca_system_score_codex":0.00091758673,"about_ca_system_score_gemma":0.0004977005,"threshold_uncertainty_score":0.5566154},"labels":[],"label_agreement":null},{"id":"W4387825090","doi":"10.1016/j.annonc.2023.09.1970","title":"792P Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Serous fluid; Stage (stratigraphy); Multivariate analysis; Univariate analysis; Chemotherapy; Oncology; Gynecology; Gastroenterology","score_opus":0.22912457981258644,"score_gpt":0.3989477167335811,"score_spread":0.16982313692099466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835366,0.0030988636,0.0000026846851,0.010511066,0.00006195698,0.0008248735,0.0012608279,0.000019032237,0.00068412174],"genre_scores_gemma":[0.99797463,0.0006121003,0.00017433867,0.0006781891,0.000022859635,0.0001954998,0.00016986899,0.000018781893,0.00015371185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815404,0.000188779,0.0005599009,0.00044025003,0.0003488122,0.000308241],"domain_scores_gemma":[0.9982513,0.00029863653,0.0003474529,0.00085951725,0.00014071297,0.000102357226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005784633,0.0001752211,0.0011619466,0.0003383945,0.00005043835,0.00000792017,0.00026917303,0.00012314826,0.0001502361],"category_scores_gemma":[0.00017396147,0.00011577949,0.0002982733,0.0011945724,0.0001300756,0.00008005265,0.000442052,0.00015129632,0.000003015186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090688403,0.0039859125,0.6471854,0.0003084279,0.26492915,0.00032332196,0.018634506,0.007973579,0.0002861838,0.0014305046,0.01515267,0.03888351],"study_design_scores_gemma":[0.0035969925,0.0053285286,0.85933954,0.000055948083,0.10052113,0.0000069769144,0.0010631268,0.0048772544,0.001378047,0.00052139733,0.023060828,0.0002502049],"about_ca_topic_score_codex":0.0069405157,"about_ca_topic_score_gemma":0.0064167026,"teacher_disagreement_score":0.2121542,"about_ca_system_score_codex":0.00006396837,"about_ca_system_score_gemma":0.00055077166,"threshold_uncertainty_score":0.99967235},"labels":[],"label_agreement":null},{"id":"W4387825202","doi":"10.1016/j.annonc.2023.09.1578","title":"78P Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Narodowe Centrum Nauki","keywords":"Ponatinib; K562 cells; Dasatinib; Medicine; Myeloid leukemia; Propidium iodide; Cancer research; Imatinib mesylate; Viability assay; Molecular biology; Leukemia; Immunology; Biology; Apoptosis; Programmed cell death; Imatinib; Biochemistry","score_opus":0.036306211523819944,"score_gpt":0.31463759374362055,"score_spread":0.2783313822198006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927903,0.00016378799,0.000008317526,0.0038324709,0.00022679033,0.00091642444,0.000096261996,0.000062569736,0.0019030784],"genre_scores_gemma":[0.99737185,0.000338571,0.0003620549,0.00079688494,0.0001222367,0.00004013831,0.000021347738,0.000035188077,0.00091170624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981218,0.00019908453,0.0004628495,0.0004418996,0.00030644776,0.00046790074],"domain_scores_gemma":[0.9972781,0.0014574929,0.00027224008,0.0005034544,0.00025598574,0.0002327098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057700265,0.00028224758,0.00082024396,0.00015246672,0.00008404756,0.000006976222,0.00014400788,0.00020503635,0.000054109612],"category_scores_gemma":[0.00035914988,0.00019771917,0.00016952585,0.0005416948,0.00047964122,0.00005454241,0.00023777947,0.00017982317,0.00010133526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016651521,0.0007297306,0.0038488999,0.0005396119,0.00053217245,0.0004303875,0.004321206,0.00012601542,0.9245804,0.000069791764,0.029186329,0.033970285],"study_design_scores_gemma":[0.004963948,0.0041628624,0.029734356,0.00016589768,0.00032281768,0.00008420773,0.0006715853,0.00043689486,0.9550426,0.00015764305,0.0040760403,0.00018113981],"about_ca_topic_score_codex":0.00020152649,"about_ca_topic_score_gemma":0.000039235998,"teacher_disagreement_score":0.033789143,"about_ca_system_score_codex":0.00048622175,"about_ca_system_score_gemma":0.001009244,"threshold_uncertainty_score":0.8062754},"labels":[],"label_agreement":null},{"id":"W4387825294","doi":"10.1016/j.annonc.2023.09.2349","title":"1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Foundation Medicine; Takeda Pharmaceuticals International; Ignyta; Loxo Oncology; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Pfizer Japan; Novartis Pharma; EMD Serono; Grifols; Ipsen; PharmaMar; Sociedad Española de Oncología Médica; Japanese Society of Medical Oncology; Amgen Astellas Biopharma; Otsuka Pharmaceutical; Daiichi-Sankyo; Les Laboratories Pierre Fabre; Bayer HealthCare; Springworks Therapeutics; Relay Therapeutics; Sysmex Corporation; Helsinn; Mylan; Mirati Therapeutics; Daiichi Sankyo Europe; Takeda Oncology; European Society for Medical Oncology; Agios Pharmaceuticals; Jazz Pharmaceuticals; Kissei; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Teva Pharmaceutical Industries; Bayer Yakuhin; Verastem Oncology; Amgen; Ariad Pharmaceuticals; Ono Pharmaceutical; Takeda Pharmaceutical Company; FibroGen; Puma Biotechnology; Medpace; OncoMed Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; Celgene; Yuhan; Mersana Therapeutics; Merck Sharp and Dohme; Spectrum Pharmaceuticals; Barbara Ann Karmanos Cancer Institute; Eli Lilly and Company; Novocure; Genentech; International Association for the Study of Lung Cancer; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Company; BeiGene; Astellas Pharma; Eisai; Pharmacyclics; Pfizer Pharmaceuticals; Exelixis; Sanofi; Servier; Incyte; Pfizer","keywords":"Medicine; non-small cell lung cancer (NSCLC); Lung cancer; Oncology; Cancer research; Internal medicine","score_opus":0.03218767099273469,"score_gpt":0.416854446127853,"score_spread":0.3846667751351183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631916,0.0021173994,0.00003575292,0.0037571033,0.00037266922,0.0010576397,0.00011374014,0.00004553864,0.029308554],"genre_scores_gemma":[0.9899048,0.0055917306,0.00043586423,0.0005446125,0.000099526806,0.00011947019,0.00016105273,0.000043231877,0.0030996893],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982503,0.000076719334,0.0005822784,0.0004037282,0.00021185272,0.00047510205],"domain_scores_gemma":[0.99854285,0.00030843986,0.00031740917,0.00033307014,0.0003584766,0.00013975453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022191812,0.00021876539,0.000760787,0.0003907119,0.000067927365,0.000005250766,0.0001429272,0.00018224535,0.00027152535],"category_scores_gemma":[0.000058967085,0.0001928092,0.00017575758,0.0008845218,0.000125273,0.000086468666,0.00008054574,0.00020273152,0.00003849604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007974088,0.0097557,0.16512845,0.0023874845,0.002245215,0.0023087556,0.027861202,0.0065755076,0.44324198,0.0007092567,0.054246813,0.27756554],"study_design_scores_gemma":[0.028426412,0.0087282965,0.76571244,0.0024499577,0.000819223,0.000045946927,0.0037874195,0.0014001984,0.13675807,0.00024719952,0.050940793,0.00068403245],"about_ca_topic_score_codex":0.001870462,"about_ca_topic_score_gemma":0.00050725683,"teacher_disagreement_score":0.600584,"about_ca_system_score_codex":0.00022675206,"about_ca_system_score_gemma":0.0010005526,"threshold_uncertainty_score":0.7862531},"labels":[],"label_agreement":null},{"id":"W4387825362","doi":"10.1016/j.annonc.2023.09.2066","title":"922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Plexxikon; Eisai; EMD Serono; Rakuten Medical; MacroGenics; Genentech; Coherus Biosciences; Actuate Therapeutics; Regeneron Pharmaceuticals; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Conquer Cancer Foundation; Gilead Sciences; Astellas Pharma; Celldex Therapeutics; Gateway for Cancer Research; HCA Healthcare; Pfizer","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cohort; Expanded access; Progression-free survival; Progressive disease; Head and neck cancer; Gastroenterology; Surgery; Cancer; Chemotherapy; Immunotherapy; Clinical trial","score_opus":0.04322910080545783,"score_gpt":0.3161477198912267,"score_spread":0.27291861908576887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963743,0.00034900178,8.3164093e-7,0.0017936373,0.0001625992,0.0005071539,0.0000674257,0.00001082621,0.0007341914],"genre_scores_gemma":[0.9991853,0.00008276428,0.00008229023,0.00033903302,0.000029128856,0.000021027983,0.000055221368,0.000015155667,0.00019005175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998713,0.0001235682,0.0004099102,0.00023823562,0.00029407124,0.00022118902],"domain_scores_gemma":[0.99904966,0.0001708488,0.00028493235,0.00023589225,0.00020270556,0.000055982422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028904428,0.00013733548,0.0003714215,0.0001909417,0.000040203973,0.000003039773,0.00007029705,0.00007191142,0.00001776245],"category_scores_gemma":[0.000058690734,0.00007989263,0.000059647064,0.00055260904,0.0002319936,0.000057303623,0.00004170464,0.00014916334,0.0000018622783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32598796,0.003796698,0.58262604,0.0007787324,0.00022678023,0.00008757393,0.0037121633,0.00009488514,0.006332308,0.000023411558,0.019870216,0.05646321],"study_design_scores_gemma":[0.03194684,0.01836787,0.9416516,0.00018172305,0.000058156835,0.000014610016,0.00028286487,0.000031972922,0.003517262,0.000017291493,0.0038343072,0.000095539755],"about_ca_topic_score_codex":0.0004210515,"about_ca_topic_score_gemma":0.00045550303,"teacher_disagreement_score":0.35902548,"about_ca_system_score_codex":0.00004731281,"about_ca_system_score_gemma":0.0003480007,"threshold_uncertainty_score":0.3257927},"labels":[],"label_agreement":null},{"id":"W4387825383","doi":"10.1016/j.annonc.2023.09.2360","title":"1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Grand River Hospital; William Osler Health System; Ottawa Hospital; University Health Network; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Lakeridge Health; Princess Margaret Cancer Centre; Hamilton Health Sciences; Brampton Civic Hospital; London Health Sciences Centre","funders":"","keywords":"Osimertinib; Medicine; Pemetrexed; Lung cancer; Internal medicine; Clinical endpoint; Oncology; T790M; Interim analysis; Cohort; Population; Epidermal growth factor receptor; Cancer; Chemotherapy; Clinical trial; Erlotinib; Gefitinib","score_opus":0.052830336301056734,"score_gpt":0.4452087737739607,"score_spread":0.39237843747290396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447733,0.00007972452,0.000033343218,0.0033231238,0.00006119447,0.0010240058,0.000064529384,0.00008097069,0.0008557568],"genre_scores_gemma":[0.9984834,0.00004699568,0.00008062175,0.00035702126,0.00002043984,0.00031595226,0.00042292598,0.00003201369,0.00024058174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987056,0.00007072453,0.00040465748,0.00030200498,0.00023856173,0.00027845433],"domain_scores_gemma":[0.9989004,0.000118164295,0.00021875057,0.00024574035,0.00041614028,0.00010079422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013939808,0.00016874261,0.0005884472,0.00059840776,0.000058161626,0.000006939522,0.000079140074,0.00006183449,0.00010363706],"category_scores_gemma":[0.000032812837,0.00011647242,0.000066557106,0.0021617692,0.0000861249,0.000084811065,0.000032171774,0.00012771951,0.0000058267883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014521176,0.0031830948,0.9734314,0.00004057091,0.0037959663,0.0001167216,0.004128275,0.007995226,0.000007149482,0.000007937168,0.00057801564,0.0052635246],"study_design_scores_gemma":[0.008844187,0.009673806,0.97574687,0.00009520219,0.0024693045,0.0000012727913,0.0012176593,0.001001731,0.00010586445,0.000009966661,0.0007084664,0.00012565461],"about_ca_topic_score_codex":0.0023876198,"about_ca_topic_score_gemma":0.014397234,"teacher_disagreement_score":0.012009614,"about_ca_system_score_codex":0.00015155645,"about_ca_system_score_gemma":0.00033590023,"threshold_uncertainty_score":0.80339944},"labels":[],"label_agreement":null},{"id":"W4387825407","doi":"10.1016/j.annonc.2023.09.2438","title":"1406P Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Osimertinib; Pneumonitis; Internal medicine; Toxicity; Discontinuation; Lung cancer; Rash; Population; Oncology; Cancer; Erlotinib; Surgery; Lung; Epidermal growth factor receptor","score_opus":0.09334028529714586,"score_gpt":0.45506616304249475,"score_spread":0.3617258777453489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197954,0.00034033402,0.000083445004,0.00544669,0.0000947849,0.0005565423,0.00029136086,0.000022092256,0.0011852399],"genre_scores_gemma":[0.99838966,0.0003793559,0.00045269,0.00018198774,0.000013511521,0.00011406312,0.00010807095,0.00001633619,0.00034434602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989882,0.000027857039,0.0004653016,0.00015352594,0.0001900227,0.00017507319],"domain_scores_gemma":[0.99865526,0.00019493698,0.00037403128,0.00023542144,0.00047369418,0.000066663095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011205115,0.00010417796,0.00050969847,0.0001787143,0.00003973737,0.0000013366638,0.00006831469,0.000040893192,0.00010262595],"category_scores_gemma":[0.00011063061,0.000072917996,0.0000846189,0.00038268778,0.00012352367,0.000056721372,0.000026378377,0.000055924724,0.000003276208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000849112,0.002998502,0.95319206,0.00081063964,0.0036813212,0.000025200308,0.004148008,0.00269561,0.0012751727,0.0006130637,0.0026485415,0.027062766],"study_design_scores_gemma":[0.006227428,0.0028015613,0.97673595,0.0002609463,0.001426148,0.0000015533467,0.00035626048,0.0008594794,0.006921612,0.00011729951,0.004171067,0.000120689125],"about_ca_topic_score_codex":0.00041803808,"about_ca_topic_score_gemma":0.00019350457,"teacher_disagreement_score":0.026942076,"about_ca_system_score_codex":0.000050321793,"about_ca_system_score_gemma":0.00027574287,"threshold_uncertainty_score":0.29735094},"labels":[],"label_agreement":null},{"id":"W4387825459","doi":"10.1016/j.annonc.2023.09.2414","title":"1381P TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Sanofi; AstraZeneca; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Medicine; Internal medicine; Lung cancer; Oncology","score_opus":0.07791304895278989,"score_gpt":0.46156210773371886,"score_spread":0.383649058780929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918964,0.0013379317,0.000057132394,0.0020374504,0.000073192714,0.00043289867,0.00051317003,0.000029367153,0.0036224418],"genre_scores_gemma":[0.9959858,0.0007954329,0.0017162515,0.00025355423,0.000028527467,0.000017363396,0.0009892584,0.000019549288,0.0001942753],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988778,0.00007836202,0.0004776929,0.0002149335,0.00018184517,0.00016931456],"domain_scores_gemma":[0.99880475,0.00024112535,0.00040803532,0.00030932116,0.00017205064,0.00006474402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019567338,0.00012770631,0.00073012855,0.00019536994,0.00003346085,0.0000027471485,0.00006752475,0.00008425966,0.00010944342],"category_scores_gemma":[0.00003566092,0.00009527229,0.000058663038,0.00031117402,0.00015155767,0.00005784295,0.000038976446,0.00008859108,0.0000034305324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007819113,0.0028091837,0.14008884,0.00046100028,0.005642196,0.00010018672,0.010875492,0.0002230267,0.19248566,0.00041099574,0.0446718,0.5944125],"study_design_scores_gemma":[0.016134981,0.014099975,0.78255093,0.0010996745,0.0013728882,0.000014346879,0.003360124,0.0008962899,0.12504134,0.0003183741,0.054810986,0.0003000658],"about_ca_topic_score_codex":0.0038318897,"about_ca_topic_score_gemma":0.0011365447,"teacher_disagreement_score":0.64246213,"about_ca_system_score_codex":0.000039918123,"about_ca_system_score_gemma":0.00022750197,"threshold_uncertainty_score":0.57926965},"labels":[],"label_agreement":null},{"id":"W4387825535","doi":"10.1016/j.annonc.2023.09.2015","title":"869P Utilizing H&amp;E images and digital pathology to predict response to buparlisib in SCCHN","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Deutsche Forschungsgemeinschaft","keywords":"Medicine; Paclitaxel; Placebo; Internal medicine; Oncology; Clinical trial; Stromal cell; Pathology; Chemotherapy","score_opus":0.06425120721555985,"score_gpt":0.4208034776906016,"score_spread":0.3565522704750418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9282902,0.00014893802,0.00016442592,0.06806441,0.00013796204,0.00025320376,0.000016851409,0.000064006585,0.0028600444],"genre_scores_gemma":[0.99192697,0.00019449794,0.0012954028,0.00561615,0.00009356533,0.000023908871,0.000015669484,0.00002253374,0.0008112764],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986136,0.00014811897,0.00035824423,0.00031597723,0.00016145433,0.00040262853],"domain_scores_gemma":[0.99866325,0.00066679163,0.00006177564,0.00021920289,0.00008909278,0.00029989984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015576797,0.00011933525,0.00046396026,0.0005867701,0.000033217344,0.000014981662,0.00011292436,0.000118065895,0.000024710376],"category_scores_gemma":[0.005653401,0.0001092142,0.000048588532,0.0005114738,0.00015216786,0.00006553834,0.00020091621,0.00029312083,0.000065920176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005643289,0.0003699757,0.17020276,0.00012742479,0.00008304511,0.002633141,0.004440931,0.00021156557,0.08375919,0.00020319168,0.092469454,0.63985604],"study_design_scores_gemma":[0.0022220053,0.0043583964,0.5889158,0.00026691656,0.000024494806,0.00046167598,0.0007250154,0.0004801025,0.0013018941,0.0005685171,0.40046206,0.00021309571],"about_ca_topic_score_codex":0.00003934271,"about_ca_topic_score_gemma":0.000011770921,"teacher_disagreement_score":0.63964295,"about_ca_system_score_codex":0.000025873469,"about_ca_system_score_gemma":0.00013149012,"threshold_uncertainty_score":0.67680573},"labels":[],"label_agreement":null},{"id":"W4387825536","doi":"10.1016/j.annonc.2023.09.2347","title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Genentech; F. Hoffmann-La Roche; Grifols; Eisai; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Mirati Therapeutics; Regeneron Pharmaceuticals; Boston Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Amgen; Pfizer; Takeda Pharmaceuticals International; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Discontinuation; Gastroenterology; Adverse effect; Oncology; Pharmacokinetics; Antibody; Immunology","score_opus":0.027459478300683595,"score_gpt":0.3419865786908813,"score_spread":0.3145271003901977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960843,0.0010519668,0.0000385741,0.0009958008,0.000015718451,0.00074589835,0.000060711165,0.000029022407,0.0009780393],"genre_scores_gemma":[0.99173445,0.0071388893,0.00022454381,0.00034051767,0.000039391623,0.000021605509,0.00013789975,0.00003286602,0.00032985117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983276,0.00012199536,0.0005399154,0.00041761136,0.00023611546,0.00035674663],"domain_scores_gemma":[0.9987817,0.00019197329,0.00039124774,0.00022752948,0.0002701454,0.00013744319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041194275,0.00023079509,0.00082969293,0.00039793516,0.00006654827,0.0000082011275,0.00007851397,0.00014095995,0.000081052574],"category_scores_gemma":[0.000036372352,0.00016945986,0.000069680034,0.0006647126,0.00023978409,0.000083100014,0.00006556916,0.00021947564,0.000002354818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009317193,0.002143466,0.952048,0.00082500646,0.00042764665,0.00025040648,0.0027400292,0.0003281552,0.016798075,0.000009150036,0.0015122795,0.013600563],"study_design_scores_gemma":[0.016164934,0.008476102,0.96294147,0.0016140444,0.00014361349,0.000009874111,0.0006164391,0.0014871415,0.0064081345,0.0000022375089,0.0018657806,0.00027021964],"about_ca_topic_score_codex":0.00019965347,"about_ca_topic_score_gemma":0.00006411174,"teacher_disagreement_score":0.013330343,"about_ca_system_score_codex":0.000030859042,"about_ca_system_score_gemma":0.00021498742,"threshold_uncertainty_score":0.6910373},"labels":[],"label_agreement":null},{"id":"W4387825574","doi":"10.1016/j.annonc.2023.09.2000","title":"854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Head and neck squamous-cell carcinoma; Cetuximab; Clinical endpoint; Oncology; Interim analysis; Cancer; Progression-free survival; Head and neck cancer; Confidence interval; Phases of clinical research; Urology; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.06185240039931168,"score_gpt":0.3751156339257055,"score_spread":0.31326323352639385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950181,0.0019891795,0.0000013966868,0.00048169255,0.000023669441,0.0023716276,0.000035145054,0.000037263297,0.000041915795],"genre_scores_gemma":[0.9989851,0.00023460829,0.000094626885,0.00015667285,0.000024266508,0.00033328286,0.000054270553,0.00005597758,0.00006119421],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99763215,0.00022524163,0.000759036,0.0005517198,0.00034189477,0.0004899327],"domain_scores_gemma":[0.9986116,0.00010517476,0.0004577735,0.00040441763,0.00015988584,0.0002611454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041016584,0.00036487044,0.0009979658,0.00031928488,0.000050600913,0.000013540126,0.00009264632,0.00005477807,0.000035885954],"category_scores_gemma":[0.0000185336,0.00023055366,0.000057221798,0.0005268657,0.00041519926,0.00012525126,0.0000386088,0.00022089183,7.180189e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5919159,0.024800884,0.2483713,0.00094701763,0.00042493263,0.0023150458,0.013140104,0.000017488415,0.006142197,0.0000012459442,0.000060324575,0.11186352],"study_design_scores_gemma":[0.17087422,0.28614214,0.5187127,0.0016734521,0.000424471,0.00012519232,0.0046813786,0.0006673074,0.016136033,0.00001013462,0.00012681984,0.00042617452],"about_ca_topic_score_codex":0.00051466044,"about_ca_topic_score_gemma":0.0008737096,"teacher_disagreement_score":0.4210417,"about_ca_system_score_codex":0.00006568965,"about_ca_system_score_gemma":0.00028638667,"threshold_uncertainty_score":0.9401705},"labels":[],"label_agreement":null},{"id":"W4387825576","doi":"10.1016/j.annonc.2023.09.2003","title":"857O MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ipsen; Seagen; Sanofi; AstraZeneca","keywords":"Medicine; Cetuximab; Nimotuzumab; Panitumumab; Internal medicine; Oncology; Epidermal growth factor receptor; Head and neck cancer; EGFR inhibitors; Cancer; Colorectal cancer","score_opus":0.15290414028180183,"score_gpt":0.38827696799485717,"score_spread":0.23537282771305534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926719,0.003504095,0.0000051638067,0.0010913754,0.00004490444,0.00044722026,0.00086029863,0.000016666634,0.0013583796],"genre_scores_gemma":[0.9973117,0.0010569156,0.00074741675,0.000394837,0.000011200562,0.000022530481,0.00038904438,0.000021708523,0.000044619817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973855,0.00020738844,0.0009351941,0.0005333518,0.00053691305,0.00040164962],"domain_scores_gemma":[0.99770314,0.0005391296,0.0005609118,0.00063266547,0.00044610587,0.00011804738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057485723,0.0002677019,0.0026282114,0.0007016587,0.00004167426,0.000003895199,0.0002579445,0.00015076261,0.000039683564],"category_scores_gemma":[0.00020389122,0.00020031715,0.00025270175,0.0010963872,0.00043668016,0.00012548128,0.00043882054,0.00019873933,0.0000017212151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021735858,0.002510888,0.9412854,0.00061163213,0.021711934,0.00013438697,0.0035691478,0.0005094391,0.0007173536,0.00005480147,0.0033684531,0.023352979],"study_design_scores_gemma":[0.004994189,0.01241875,0.9557241,0.00005238475,0.018604996,0.0000039265838,0.0007391975,0.0003240699,0.003712559,0.000017711349,0.0031901156,0.00021800182],"about_ca_topic_score_codex":0.0006009061,"about_ca_topic_score_gemma":0.0010825376,"teacher_disagreement_score":0.023134977,"about_ca_system_score_codex":0.000026030233,"about_ca_system_score_gemma":0.00026491412,"threshold_uncertainty_score":0.8168697},"labels":[],"label_agreement":null},{"id":"W4387825621","doi":"10.1016/j.annonc.2023.09.1968","title":"790P Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centre Léon Bérard; Jikei University School of Medicine; BC Cancer Agency; Rigshospitalet; NHS Greater Glasgow and Clyde","keywords":"Medicine; PTEN; KRAS; Internal medicine; Oncology; Carcinoma; Immunohistochemistry; Adjuvant; Adjuvant therapy; Gynecology; Colorectal cancer; Cancer","score_opus":0.07318860230158364,"score_gpt":0.4115868454324562,"score_spread":0.3383982431308726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98220605,0.00018269884,0.000004959141,0.00085808034,0.00010960022,0.000869451,0.000046200505,0.000023877235,0.015699098],"genre_scores_gemma":[0.99916136,0.00015395129,0.00006452922,0.00027891723,0.000022264938,0.000051916522,0.00004625193,0.000009520543,0.0002113032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986463,0.00011675731,0.0003745315,0.0003057682,0.00032818152,0.00022843029],"domain_scores_gemma":[0.998663,0.000651246,0.00016295411,0.00028806765,0.00012285938,0.00011188311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006247725,0.00014758446,0.001085984,0.0012804214,0.000022837632,0.0000026633863,0.00007711511,0.00009784192,0.000066006105],"category_scores_gemma":[0.00036695035,0.00010490351,0.0003572744,0.0029453225,0.000103928694,0.000021217922,0.0001015617,0.00009133701,0.000009102836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005582233,0.0011935979,0.9394013,0.0002684416,0.0076243766,0.00032671288,0.00010241606,0.000027002701,0.000639679,0.002299769,0.00014546483,0.042388983],"study_design_scores_gemma":[0.011221978,0.015947808,0.9601458,0.000016666361,0.0024556841,0.0000017870254,0.000043016204,0.000020501138,0.009216713,0.00060167647,0.00025494918,0.00007344519],"about_ca_topic_score_codex":0.0001665641,"about_ca_topic_score_gemma":0.000023659468,"teacher_disagreement_score":0.042315535,"about_ca_system_score_codex":0.00009356186,"about_ca_system_score_gemma":0.000037183727,"threshold_uncertainty_score":0.42778412},"labels":[],"label_agreement":null},{"id":"W4387825797","doi":"10.1016/j.annonc.2023.09.506","title":"310P Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Royal Victoria Regional Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Seagen; Sanofi; Servier; Princess Margaret Cancer Foundation; Amgen; Pfizer; Genentech; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Cancer; Triple-negative breast cancer; Minimal residual disease; Perioperative; Gastroenterology; Surgery; Leukemia","score_opus":0.11679926496503722,"score_gpt":0.4048033611204578,"score_spread":0.28800409615542055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828446,0.00026711792,0.0002374189,0.00043023168,0.00015094869,0.00018069078,0.00011722753,0.0000041797684,0.0003277528],"genre_scores_gemma":[0.99938047,0.00009535833,0.00020289833,0.00008956131,0.000122032856,0.000021544553,0.000066603156,0.000014995138,0.0000065233558],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99882597,0.00017050082,0.0003612639,0.00023157644,0.00020182757,0.00020887433],"domain_scores_gemma":[0.99888146,0.00013656533,0.00027926278,0.00015484265,0.0005062073,0.000041675117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013015571,0.00010038199,0.00023288601,0.0001558972,0.000029514851,0.0000055185455,0.000100810365,0.00015080067,0.00002398038],"category_scores_gemma":[0.00035713092,0.00011202914,0.00008319624,0.00027893792,0.000064234955,0.000004593585,0.000052442243,0.00006398655,0.0000016270686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022004348,0.00013105634,0.18745165,0.000043729287,0.000080738435,0.000006482361,0.00011562343,0.174948,0.60428524,0.000068924324,0.000252395,0.0323961],"study_design_scores_gemma":[0.0020382507,0.000695164,0.6815098,0.000085587264,0.00010500261,0.00001411661,0.00009324419,0.11691508,0.19751135,0.00040056425,0.00039673387,0.0002351395],"about_ca_topic_score_codex":0.0010015854,"about_ca_topic_score_gemma":0.0010334728,"teacher_disagreement_score":0.49405813,"about_ca_system_score_codex":0.000055065266,"about_ca_system_score_gemma":0.0011432032,"threshold_uncertainty_score":0.4568416},"labels":[],"label_agreement":null},{"id":"W4387825816","doi":"10.1016/j.annonc.2023.09.675","title":"728P Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neuroblastoma RAS viral oncogene homolog; Thyroid cancer; Oncology; Internal medicine; Thyroid carcinoma; Medullary thyroid cancer; Cancer; Papillary thyroid cancer; Thyroid; KRAS; Colorectal cancer","score_opus":0.08041115359086191,"score_gpt":0.43537811579445407,"score_spread":0.35496696220359214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97131306,0.0022389719,0.0000024949902,0.025854949,0.000085232416,0.0002334804,0.000048092035,0.000017166178,0.00020655862],"genre_scores_gemma":[0.991867,0.004102902,0.00022517702,0.003639587,0.000024352552,0.000040165665,0.000031531563,0.00001169404,0.000057589514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989801,0.00010811197,0.00038926132,0.00023672139,0.00008739182,0.00019840387],"domain_scores_gemma":[0.9990039,0.0005652319,0.000106203035,0.00015841193,0.00005262468,0.00011361184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041690393,0.00011205213,0.000658433,0.000121981386,0.000015935508,0.0000035285468,0.000028795226,0.00008727381,0.000010383533],"category_scores_gemma":[0.0003999182,0.0000902265,0.000071931245,0.00012859421,0.00015803776,0.00003069168,0.000066354696,0.00010468834,0.0000044271615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022842776,0.00039731595,0.9119513,0.00004917419,0.00012368448,0.0008496899,0.000119891294,7.0967883e-7,0.0008630365,0.000543516,0.002732353,0.08214088],"study_design_scores_gemma":[0.003467777,0.0029944626,0.9820531,0.000026603488,0.00006696461,0.000024837334,0.00010409975,0.000018015855,0.0011084661,0.00025954415,0.0098050125,0.00007108866],"about_ca_topic_score_codex":0.000051665542,"about_ca_topic_score_gemma":0.00004417599,"teacher_disagreement_score":0.08206979,"about_ca_system_score_codex":0.000011952121,"about_ca_system_score_gemma":0.000083336265,"threshold_uncertainty_score":0.36793298},"labels":[],"label_agreement":null},{"id":"W4387825900","doi":"10.1016/j.annonc.2023.09.591","title":"414P Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer; Hope Foundation; Abbott Laboratories","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Brain metastasis; Observational study; Meta-analysis; Cochrane Library; Clinical trial; Hazard ratio; Population; Cancer; Metastasis; Confidence interval","score_opus":0.34145706322344893,"score_gpt":0.5177127106480852,"score_spread":0.17625564742463629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825900","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.8818314e-7,0.9686211,0.00009194199,0.014994977,0.00003610924,0.008325167,0.007828669,0.00005228863,0.00004948797],"genre_scores_gemma":[0.0000072366843,0.9857798,0.0005313176,0.0045571052,0.000049474536,0.0074356697,0.0005855109,0.00012462572,0.0009292448],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99493456,0.0014342272,0.00200739,0.0007986388,0.00032677435,0.00049841113],"domain_scores_gemma":[0.9943329,0.0023399827,0.0017804943,0.0007331168,0.0005361432,0.00027738005],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0026156094,0.0007381754,0.021196645,0.00058918475,0.00006331762,0.000015989803,0.00021335889,0.0003269411,0.00024037396],"category_scores_gemma":[0.0004161751,0.00044281327,0.0067666033,0.0012424582,0.0001489764,0.00004502566,0.00008884747,0.00026408886,0.000013375706],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017739772,0.00022485894,1.01189165e-7,0.52853745,0.41681626,0.00006319433,0.00002459022,2.2557772e-7,1.4066417e-8,0.00010386239,0.0032936719,0.050918035],"study_design_scores_gemma":[0.0003541692,0.001177227,0.0000025379297,0.036289547,0.81380147,0.00037556177,0.000037410467,0.0000011765769,4.9624606e-7,0.000039579023,0.14767866,0.00024215817],"about_ca_topic_score_codex":0.00033834035,"about_ca_topic_score_gemma":0.00034721242,"teacher_disagreement_score":0.49224788,"about_ca_system_score_codex":0.00015598859,"about_ca_system_score_gemma":0.00076510804,"threshold_uncertainty_score":0.99980235},"labels":[],"label_agreement":null},{"id":"W4387825903","doi":"10.1016/j.annonc.2023.09.507","title":"311P Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University Health Network; Seagen; Gilead Sciences; Sanofi; Servier; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Genetic counseling; Magenta; Genetic testing; Family medicine; Multinational corporation; Breast cancer; Oncology; Cancer; Medical physics; Gynecology; Clinical psychology; Internal medicine; Genetics","score_opus":0.09207940173868873,"score_gpt":0.37824802966478477,"score_spread":0.28616862792609604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846303,0.0001942081,0.00022014439,0.00022522044,0.000159694,0.00045325392,0.00015746386,0.000015231277,0.000111776215],"genre_scores_gemma":[0.9980962,0.0006561388,0.0005624462,0.0002868805,0.00011342505,0.00013973055,0.000059165945,0.000030814746,0.000055176868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981257,0.0003337155,0.00040488108,0.0005123032,0.0003150095,0.00030844295],"domain_scores_gemma":[0.9979129,0.00057374,0.00033661514,0.00029689545,0.00081712054,0.00006273479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007721321,0.00018607597,0.00019777278,0.00008501384,0.00026587734,0.00004471672,0.000227719,0.00010522322,0.000009210337],"category_scores_gemma":[0.000250433,0.00014560862,0.00002830397,0.00040470037,0.0003041268,0.00001136042,0.000045558907,0.00012689424,0.000002752494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035766614,0.00045684676,0.9303569,0.00001801439,0.00014612441,0.000013414239,0.0023248591,0.027347403,0.0051919143,0.0000017180308,0.0012044081,0.03258071],"study_design_scores_gemma":[0.000989104,0.0011651472,0.99128354,0.00004599528,0.000020743148,0.00000781941,0.0006943622,0.002606522,0.0025108308,0.000019266081,0.00047392468,0.00018275206],"about_ca_topic_score_codex":0.00045994055,"about_ca_topic_score_gemma":0.00083156035,"teacher_disagreement_score":0.060926612,"about_ca_system_score_codex":0.000035361954,"about_ca_system_score_gemma":0.00024289601,"threshold_uncertainty_score":0.59377474},"labels":[],"label_agreement":null},{"id":"W4387826084","doi":"10.1016/j.annonc.2023.09.974","title":"2192P Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mesothelioma; Quality of life (healthcare); Internal medicine; Oncology; Pathology; Nursing","score_opus":0.07978026206233513,"score_gpt":0.39675579707577036,"score_spread":0.31697553501343523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695635,0.00006060511,4.806242e-7,0.00066724117,0.000020640657,0.00026267982,0.000188197,0.000016502796,0.0018272772],"genre_scores_gemma":[0.9989963,0.00013478466,0.00014061625,0.00027068763,0.00001127485,0.00001936736,0.00021753501,0.000012208456,0.00019718998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986986,0.00011505014,0.00057257887,0.00017192354,0.00025496955,0.00018688184],"domain_scores_gemma":[0.9990642,0.00022888131,0.00036841875,0.00015520063,0.00009311891,0.00009015651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023907548,0.00010442342,0.00051728357,0.00021569336,0.000013848198,6.125858e-7,0.000062112464,0.00005171552,0.00008008216],"category_scores_gemma":[0.00016203281,0.00007957122,0.000078776415,0.00042547795,0.00014735188,0.000049186227,0.000042601692,0.00005413721,0.000006799218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045101405,0.0010367355,0.9809299,0.00023699814,0.000082196064,0.000014957272,0.00018894847,0.00013972324,0.00482016,0.00011116737,0.00037008477,0.007558963],"study_design_scores_gemma":[0.0029145563,0.0024997066,0.987157,0.0001426967,0.000030561594,4.7501823e-7,0.00020554615,0.000038917595,0.006563652,0.00009337927,0.00028316537,0.0000703596],"about_ca_topic_score_codex":0.0008396146,"about_ca_topic_score_gemma":0.00050091115,"teacher_disagreement_score":0.0074886032,"about_ca_system_score_codex":0.00003779856,"about_ca_system_score_gemma":0.00009426661,"threshold_uncertainty_score":0.32448202},"labels":[],"label_agreement":null},{"id":"W4387826135","doi":"10.1016/j.annonc.2023.09.1123","title":"1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Juravinski Cancer Centre; University of Manitoba; BC Cancer Agency; Hamilton Health Sciences; Dalhousie University","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Ipilimumab; Internal medicine; Adverse effect; Oncology; Odds ratio; Nephrectomy; Kidney cancer; Cohort; Urology; Gastroenterology; Cancer; Immunotherapy; Kidney","score_opus":0.10846761252191099,"score_gpt":0.3395749140781999,"score_spread":0.2311073015562889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97441334,0.0031725639,0.0000033368947,0.017892264,0.0002512186,0.00079639285,0.00032573577,0.00004666193,0.0030985142],"genre_scores_gemma":[0.9961936,0.00052219414,0.000103314145,0.0005142339,0.000048810783,0.000057511126,0.0019021721,0.000030132263,0.00062802737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974094,0.0004978188,0.0010620138,0.0003897034,0.00033617424,0.00030488663],"domain_scores_gemma":[0.9969264,0.0017349313,0.000530933,0.0005344142,0.00018455363,0.000088761495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008555077,0.00023889942,0.00072197727,0.00020702917,0.00007040615,0.0000032757225,0.00021513658,0.00016512697,0.00009950007],"category_scores_gemma":[0.00024534186,0.00016752651,0.00023670505,0.00047753923,0.00014710113,0.00009448591,0.00010375801,0.00030745525,0.00014393537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052390873,0.018007293,0.5763636,0.00040530035,0.006279232,0.012866827,0.08392313,0.002246042,0.10039418,0.00048369414,0.107304245,0.039335553],"study_design_scores_gemma":[0.019637538,0.0036993905,0.94050634,0.00015039677,0.00019048665,0.0000085396605,0.0015302575,0.0006480538,0.025736164,0.0035505497,0.0041653165,0.00017694023],"about_ca_topic_score_codex":0.007803908,"about_ca_topic_score_gemma":0.00042879154,"teacher_disagreement_score":0.36414275,"about_ca_system_score_codex":0.00010560809,"about_ca_system_score_gemma":0.00030391972,"threshold_uncertainty_score":0.9988032},"labels":[],"label_agreement":null},{"id":"W4387826320","doi":"10.1016/j.annonc.2023.09.739","title":"1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Chemotherapy; Internal medicine; Oncology; Phases of clinical research; Immunotherapy; Cancer","score_opus":0.11002207350618665,"score_gpt":0.4371958706070614,"score_spread":0.32717379710087474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614082,0.00056399574,0.000006045659,0.030690324,0.0005085637,0.0009838486,0.000015314175,0.000059309565,0.005764428],"genre_scores_gemma":[0.98415387,0.0035324222,0.000027185006,0.010495318,0.00037940094,0.00010826011,0.000043026717,0.000025833739,0.001234676],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824625,0.00017906915,0.0006220628,0.00026044546,0.00027052712,0.00042163985],"domain_scores_gemma":[0.99898356,0.00023810973,0.00022307012,0.00041049274,0.00008642134,0.00005831828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015705061,0.00016916574,0.0006259229,0.00023054588,0.000057901223,0.000009418057,0.00025202526,0.00020247315,0.00044133322],"category_scores_gemma":[0.00007191028,0.00011718178,0.00026209783,0.00068413303,0.00021783303,0.000058451864,0.000028817598,0.00023352946,0.00004898046],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50906855,0.0019139323,0.000080499856,0.000052458592,0.000253842,0.00020135495,0.0034085198,0.0000021163655,0.0150311,0.00011842603,0.061543576,0.4083256],"study_design_scores_gemma":[0.39355746,0.026552537,0.004708897,0.000100474026,0.000052048956,0.00008018162,0.0012059397,0.0001864305,0.008244423,0.00044633725,0.56465614,0.00020915108],"about_ca_topic_score_codex":0.00032316847,"about_ca_topic_score_gemma":0.00009421877,"teacher_disagreement_score":0.50311255,"about_ca_system_score_codex":0.000058696824,"about_ca_system_score_gemma":0.00034758647,"threshold_uncertainty_score":0.48322892},"labels":[],"label_agreement":null},{"id":"W4387826356","doi":"10.1016/j.annonc.2023.09.1132","title":"1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Genentech; Ipsen; PharmaMar; Servier; European Society for Medical Oncology; Associazione Italiana per la Ricerca sul Cancro; Cilag; Astellas Pharma; Merck Sharp and Dohme; Eisai; Pfizer; Ministero della Salute; Chugai Pharmaceutical; Seagen; Karyopharm Therapeutics; Sanofi; Exelixis; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Merck","keywords":"Medicine; Sunitinib; Internal medicine; Nivolumab; Ipilimumab; Proportional hazards model; Cabozantinib; Renal cell carcinoma; Hazard ratio; Oncology; Cancer; Immunotherapy; Confidence interval","score_opus":0.4345612815362631,"score_gpt":0.4358961580624438,"score_spread":0.001334876526180695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97556984,0.0006552008,0.002550949,0.0018296652,0.003350989,0.0008740787,0.011128885,0.000030642732,0.0040097446],"genre_scores_gemma":[0.9924282,0.00033942558,0.0025517954,0.00024182357,0.0007261552,0.000040696214,0.0033956387,0.00004821474,0.00022807215],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9967641,0.0000793225,0.0018676913,0.0006606376,0.00011697481,0.00051123253],"domain_scores_gemma":[0.9946837,0.0020580948,0.0020935896,0.00086953735,0.00018998346,0.00010513355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001767422,0.0002714293,0.00134483,0.00040202652,0.00019810778,0.00005186062,0.0010159146,0.0001285395,0.00024995446],"category_scores_gemma":[0.0010415775,0.00029200935,0.0003053806,0.00042120056,0.00022006512,0.0005906709,0.00041044428,0.00023793094,0.000038075417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3033587,0.0059426455,0.22211756,0.00086201285,0.006993038,0.00016853267,0.0104591865,0.07866713,0.0022296875,0.08763951,0.24983864,0.031723373],"study_design_scores_gemma":[0.13297509,0.0045125084,0.022924084,0.00014758139,0.00046606737,0.0000023445707,0.0015670495,0.48794547,0.0038097643,0.0073674642,0.337112,0.0011705736],"about_ca_topic_score_codex":0.011433316,"about_ca_topic_score_gemma":0.010967066,"teacher_disagreement_score":0.40927833,"about_ca_system_score_codex":0.0001711807,"about_ca_system_score_gemma":0.0005165671,"threshold_uncertainty_score":0.9999532},"labels":[],"label_agreement":null},{"id":"W4387826371","doi":"10.1016/j.annonc.2023.09.918","title":"2136P Prostate cancer supportive care (PCSC) program for patients and partners: A model for meeting an unmet need for PC patients","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; University of British Columbia","funders":"","keywords":"Medicine; Family medicine; Sexual health clinic; Prostate cancer; Physical therapy; Cancer; Internal medicine","score_opus":0.1091959900125954,"score_gpt":0.45990755554223345,"score_spread":0.35071156552963806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030375,0.0001836552,0.00006816281,0.0012875154,0.0003047281,0.005637073,0.0019534093,0.00007587319,0.00018584286],"genre_scores_gemma":[0.9890221,0.00015283217,0.0012119573,0.000964892,0.00011476535,0.0062874067,0.001932104,0.00004982635,0.00026411645],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856484,0.00003259849,0.00038340266,0.00037000835,0.00015442615,0.00049474655],"domain_scores_gemma":[0.99769205,0.00018931752,0.00025382452,0.00014425199,0.0015494376,0.00017110827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002382456,0.00017094535,0.00049693376,0.00012281793,0.0000955054,0.000010657067,0.0000726692,0.0001553858,0.0000028887287],"category_scores_gemma":[0.00025395394,0.00015459335,0.00015243742,0.00016311769,0.00008303933,0.00010100036,0.000041614087,0.00006304051,3.416834e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00931787,0.001312703,0.15782513,0.0029334582,0.00032871278,0.0000023683058,0.039552245,0.00019780536,0.000110952584,0.00013366893,0.028003326,0.76028174],"study_design_scores_gemma":[0.07422666,0.20792697,0.07369583,0.0012567014,0.002016027,0.000002796049,0.054022375,0.12259521,0.010536483,0.0053451443,0.44627595,0.0020998549],"about_ca_topic_score_codex":0.00023764315,"about_ca_topic_score_gemma":0.0016333679,"teacher_disagreement_score":0.7581819,"about_ca_system_score_codex":0.00006417492,"about_ca_system_score_gemma":0.0003245215,"threshold_uncertainty_score":0.6304134},"labels":[],"label_agreement":null},{"id":"W4387826437","doi":"10.1016/j.annonc.2023.09.766","title":"1288P Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Internal medicine; Chemotherapy; Randomized controlled trial; Oncology; Meta-analysis; Stage (stratigraphy); Neoadjuvant therapy; Cancer; Surgery; Breast cancer","score_opus":0.3831206968258392,"score_gpt":0.5308186288225758,"score_spread":0.1476979319967366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016573572,0.9688953,0.00019690774,0.001465855,0.0001405416,0.027829211,0.0011225641,0.000035484944,0.00014841261],"genre_scores_gemma":[0.000033426917,0.9864335,0.00044707587,0.002816374,0.00011115549,0.0061920434,0.00027479822,0.00013843848,0.0035532066],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98379016,0.0054953774,0.008587174,0.0010040691,0.0005232738,0.00059994246],"domain_scores_gemma":[0.9705171,0.01665194,0.010474634,0.0012691679,0.00086442253,0.00022271945],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.04081346,0.0009526495,0.061421722,0.0008677833,0.000107749394,0.00002136557,0.0004849781,0.0008334927,0.0006700795],"category_scores_gemma":[0.0018291197,0.0005073207,0.012953551,0.0017485835,0.00050283375,0.000056401164,0.00006440443,0.0005202481,9.797858e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054448508,0.0004130723,0.0000015554859,0.5097162,0.4199813,0.00002133706,0.0002113874,0.000003981643,0.000008790232,0.000006120911,0.0029408392,0.012246914],"study_design_scores_gemma":[0.110605404,0.0036433672,9.0351284e-7,0.054225083,0.77485025,0.000013735566,0.00006346589,0.00012964121,0.000056225334,0.0000038643802,0.055946346,0.00046171955],"about_ca_topic_score_codex":0.0008297948,"about_ca_topic_score_gemma":0.00021358929,"teacher_disagreement_score":0.4554911,"about_ca_system_score_codex":0.00013058567,"about_ca_system_score_gemma":0.0028437476,"threshold_uncertainty_score":0.99973786},"labels":[],"label_agreement":null},{"id":"W4387826531","doi":"10.1016/j.annonc.2023.09.1140","title":"1910P Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; DNA methylation; Genome; Oncology; Cancer research; Gene; Genetics; Gene expression; Biology","score_opus":0.09279231915420123,"score_gpt":0.3510396802693599,"score_spread":0.25824736111515867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776715,0.0008673856,0.00014691745,0.00015962307,0.00007033196,0.0005996347,0.00004045151,0.0000030359745,0.00034544882],"genre_scores_gemma":[0.99870384,0.0004067137,0.00034631044,0.00008559336,0.00005440778,0.0001547558,0.00022263189,0.000011860219,0.000013866946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99900556,0.00004356712,0.0003905366,0.00023745206,0.00012446613,0.00019839797],"domain_scores_gemma":[0.99906266,0.00018152202,0.00026192705,0.00016228182,0.0002935998,0.000037992504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012523491,0.0000921033,0.00020302463,0.00012421474,0.000032974025,0.000004579577,0.00008475967,0.00008917217,0.0000031024028],"category_scores_gemma":[0.00045058178,0.00009810427,0.00004880464,0.00014522571,0.00005463018,0.0000051488855,0.000062276675,0.000041389434,0.0000010136201],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028127563,0.00019784599,0.07303242,0.00031010198,0.00003918624,0.000002104909,0.0005199938,0.0069286767,0.88946265,0.00012275274,0.0002531573,0.028849855],"study_design_scores_gemma":[0.0018279825,0.0027425396,0.56638694,0.000024347386,0.00006783911,0.0000047833046,0.00024965362,0.013050713,0.41142944,0.00046016386,0.0035785278,0.00017704362],"about_ca_topic_score_codex":0.000028783103,"about_ca_topic_score_gemma":0.00006310469,"teacher_disagreement_score":0.49335453,"about_ca_system_score_codex":0.000028407963,"about_ca_system_score_gemma":0.00029750547,"threshold_uncertainty_score":0.4000576},"labels":[],"label_agreement":null},{"id":"W4387826569","doi":"10.1016/j.annonc.2023.09.983","title":"2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MaRS; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"DNA methylation; Methylated DNA immunoprecipitation; Differentially methylated regions; CpG site; Epigenetics; Methylation; Mesothelioma; Medicine; Cancer research; Molecular biology; Biology; Pathology; Oncology; Gene; Genetics; Gene expression","score_opus":0.1121775462494475,"score_gpt":0.3764245807385929,"score_spread":0.26424703448914544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829453,0.00012720987,0.0000050086855,0.00081505807,0.0001553325,0.00019135418,0.00009362511,0.000024004816,0.00029385797],"genre_scores_gemma":[0.99887764,0.00024083785,0.000058811587,0.0004095767,0.00005567015,0.000009588805,0.0002561922,0.000013929254,0.00007773113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903023,0.00006739587,0.00031051194,0.00017555656,0.0002076022,0.0002086843],"domain_scores_gemma":[0.9995712,0.00007601503,0.00011393423,0.000121762474,0.00004584798,0.000071212904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015041367,0.000100044075,0.00025371352,0.00026634498,0.000029236655,0.0000027888686,0.000053920117,0.00008196803,0.00019669342],"category_scores_gemma":[0.000036258156,0.00008644956,0.00007857254,0.00023309562,0.000070166934,0.000078699486,0.000054664146,0.00005603985,0.00008357547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017930516,0.0007605321,0.95633227,0.0000791257,0.000056470053,0.00007128575,0.00028938352,0.00021091958,0.0285245,0.0000790218,0.0010427488,0.010760692],"study_design_scores_gemma":[0.0009982368,0.0017798058,0.98097163,0.00006555913,0.00001931658,0.000003641843,0.00012190677,0.0001563227,0.013234504,0.00008935387,0.0024772882,0.00008240724],"about_ca_topic_score_codex":0.00006617179,"about_ca_topic_score_gemma":0.000012000671,"teacher_disagreement_score":0.024639387,"about_ca_system_score_codex":0.000057539546,"about_ca_system_score_gemma":0.000036518893,"threshold_uncertainty_score":0.35253108},"labels":[],"label_agreement":null},{"id":"W4387826635","doi":"10.1016/j.annonc.2023.09.1143","title":"1914MO The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders: Single-arm phase II clinical trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Ipsen; PharmaMar; Les Laboratories Pierre Fabre; AstraZeneca","keywords":"Medicine; Sorafenib; Radiological weapon; Fibromatosis; Aggressive fibromatosis; Oncology; Clinical trial; Internal medicine; Radiology; Surgery","score_opus":0.486750033343286,"score_gpt":0.5485222390582111,"score_spread":0.06177220571492509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774264,0.0008815534,0.0000012320079,0.019152924,0.00062542374,0.0011732646,0.000017465138,0.00005038983,0.0006713623],"genre_scores_gemma":[0.9973094,0.00062297686,0.0000828987,0.0009200931,0.00033950878,0.0001475959,0.0000120872055,0.000022158714,0.0005432707],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99641174,0.0009485886,0.0016053913,0.00036732567,0.0002355795,0.00043137211],"domain_scores_gemma":[0.9934763,0.0052698664,0.00047125455,0.0005585414,0.0001380983,0.00008594124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029417598,0.00022694356,0.0013727732,0.00016282739,0.000087916065,0.0000049284577,0.00021744205,0.00022935012,0.000108145214],"category_scores_gemma":[0.004128372,0.00011395755,0.0004811406,0.00054697786,0.0009819154,0.000039783998,0.00021833771,0.00032448408,0.000038072314],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45632824,0.028429737,0.29390767,0.00013807401,0.002123029,0.0029713889,0.01598201,0.000013527048,0.002779095,0.00047908735,0.01288079,0.18396738],"study_design_scores_gemma":[0.1989792,0.36573425,0.31392223,0.00032233947,0.0012543113,0.000248809,0.010378244,0.000099771816,0.0023661605,0.0012999446,0.10485439,0.0005403518],"about_ca_topic_score_codex":0.000066479566,"about_ca_topic_score_gemma":0.00013604472,"teacher_disagreement_score":0.3373045,"about_ca_system_score_codex":0.000059128037,"about_ca_system_score_gemma":0.00016946699,"threshold_uncertainty_score":0.4942345},"labels":[],"label_agreement":null},{"id":"W4387826920","doi":"10.1016/j.annonc.2023.09.1175","title":"1946P Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Germline; Oncology; Germline mutation; Internal medicine; Bladder cancer; Genetics; Cancer; Mutation; Biology; Gene","score_opus":0.1362513437820243,"score_gpt":0.45334160226715636,"score_spread":0.31709025848513206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826656,0.00055269484,0.0000011900265,0.004645889,0.00024418012,0.0005616928,0.000020843909,0.00006193158,0.011245952],"genre_scores_gemma":[0.99357986,0.0009656071,0.00009652646,0.003512573,0.00015752295,0.00003115473,0.000023927922,0.00002232302,0.0016104933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987134,0.00013462029,0.0004467823,0.00028841262,0.00015693517,0.00025988717],"domain_scores_gemma":[0.99906266,0.00034136252,0.00010814297,0.00026476718,0.00007786535,0.00014520595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004893022,0.00013928438,0.0007106957,0.00013313485,0.000045936227,0.000004798826,0.00008074064,0.000129732,0.00013836185],"category_scores_gemma":[0.000083719795,0.00010499993,0.00014679175,0.00015446839,0.0001304169,0.000033163135,0.00011519087,0.0001590285,0.00010913713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004890373,0.001385661,0.92785704,0.00002352201,0.0008931861,0.00022375274,0.0004398739,2.9754864e-7,0.00007212261,0.0000131269235,0.01446928,0.05413312],"study_design_scores_gemma":[0.005477795,0.007826464,0.9679037,0.000008329103,0.00025592223,0.000027503138,0.00043943748,0.000006580918,0.00002598724,0.00013917508,0.017806238,0.00008292281],"about_ca_topic_score_codex":0.00009253686,"about_ca_topic_score_gemma":0.00007146225,"teacher_disagreement_score":0.054050196,"about_ca_system_score_codex":0.00001655382,"about_ca_system_score_gemma":0.00024750695,"threshold_uncertainty_score":0.42817727},"labels":[],"label_agreement":null},{"id":"W4387826951","doi":"10.1016/j.annonc.2023.09.1027","title":"2378P Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Urothelial cancer; Pembrolizumab; Cancer; Internal medicine","score_opus":0.08085293338280829,"score_gpt":0.4097118803035344,"score_spread":0.3288589469207261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387826951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97911066,0.00046258824,0.000038962775,0.014678133,0.00015361526,0.0035755422,0.00055687706,0.000083156185,0.0013404865],"genre_scores_gemma":[0.9870817,0.0034140274,0.0019794179,0.0018429116,0.000097549164,0.0015998564,0.000092729126,0.000102762904,0.0037890498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99816394,0.00008239791,0.00039137353,0.0005355202,0.00029190435,0.0005348699],"domain_scores_gemma":[0.9983088,0.00050500303,0.00019001866,0.0003692075,0.00033673848,0.00029025372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015711124,0.0003571825,0.0010044753,0.00021067214,0.00013164156,0.000008146473,0.00010014674,0.00010987261,0.00006224435],"category_scores_gemma":[0.00009377916,0.00022892076,0.0001051187,0.00031732445,0.00012644642,0.00008287361,0.000037050308,0.000098561984,0.000015725951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20828305,0.006985403,0.095066026,0.00062996685,0.0042283623,0.00027764373,0.007212352,0.0005003239,0.00019728167,0.00025452903,0.0053869192,0.6709781],"study_design_scores_gemma":[0.10648794,0.15920068,0.58408064,0.0006392472,0.0013739706,0.000035199973,0.00056611776,0.000041721196,0.0016589223,0.00016153554,0.14519216,0.0005618514],"about_ca_topic_score_codex":0.00022718983,"about_ca_topic_score_gemma":0.0011683078,"teacher_disagreement_score":0.6704163,"about_ca_system_score_codex":0.00019918391,"about_ca_system_score_gemma":0.0006352551,"threshold_uncertainty_score":0.93351173},"labels":[],"label_agreement":null},{"id":"W4387836897","doi":"10.1016/j.annonc.2023.09.563","title":"386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"AstraZeneca","keywords":"Medicine; Trastuzumab; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Cancer","score_opus":0.215818782700106,"score_gpt":0.5112288047317133,"score_spread":0.29541002203160727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387836897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785149,0.00035542238,0.0000011316429,0.015628457,0.00043988632,0.0018165208,0.00078914675,0.00003483313,0.0024196838],"genre_scores_gemma":[0.9963064,0.0019233509,0.000015207838,0.0005583109,0.00037556936,0.00026207298,0.00008217659,0.000034845634,0.00044204303],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99695593,0.00066058175,0.00078933634,0.0004029241,0.0006188749,0.0005723776],"domain_scores_gemma":[0.9972645,0.0012583742,0.0003957017,0.0004558744,0.00049877836,0.00012678567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00104152,0.00022940879,0.00095595064,0.00027322033,0.00005617006,0.000006034567,0.00034127655,0.00013846773,0.00010264307],"category_scores_gemma":[0.00038269436,0.00016570426,0.00023851002,0.0015758667,0.00042829098,0.000074590964,0.000090223715,0.000467965,0.00001229746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5884726,0.0051287767,0.0006567332,0.00015003982,0.0010291093,0.00021586817,0.0031376604,0.00022979066,0.018837638,0.000031118205,0.026703022,0.35540763],"study_design_scores_gemma":[0.68703353,0.058522712,0.112307504,0.0008134126,0.00032122812,0.00003788327,0.00075269176,0.0010258517,0.1099832,0.0001098536,0.028708711,0.0003834427],"about_ca_topic_score_codex":0.007978094,"about_ca_topic_score_gemma":0.0014862345,"teacher_disagreement_score":0.3550242,"about_ca_system_score_codex":0.00025289544,"about_ca_system_score_gemma":0.0014804323,"threshold_uncertainty_score":0.99862784},"labels":[],"label_agreement":null},{"id":"W4387836902","doi":"10.1016/j.annonc.2023.09.556","title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Santé Montérégie; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; London Health Sciences Centre; Western University","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Tolerability; Oncology; Adverse effect; Gastroenterology","score_opus":0.1913055246931296,"score_gpt":0.5132972358923467,"score_spread":0.32199171119921705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387836902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9365632,0.0008141214,0.00013367826,0.039104324,0.00053723966,0.007322744,0.014073987,0.00023411524,0.001216604],"genre_scores_gemma":[0.98401684,0.0031215223,0.001046158,0.0012103989,0.00039808475,0.0027775594,0.0021711593,0.00015495419,0.0051033013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941622,0.00055458315,0.0015588197,0.0013702604,0.00095023523,0.0014039129],"domain_scores_gemma":[0.9941214,0.0018408715,0.0006252794,0.0012555375,0.0015145087,0.0006424098],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013981122,0.0006074297,0.0018929185,0.00063255976,0.00040140937,0.00003095384,0.0005578153,0.0002615973,0.0011531996],"category_scores_gemma":[0.0018299597,0.00052234804,0.00031730783,0.0017261097,0.0004106582,0.00023341771,0.0003219174,0.00048083256,0.00015470866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13089164,0.026312808,0.0019232286,0.00038962293,0.005821954,0.002833846,0.009422798,0.0012893084,0.0048116753,0.000060841397,0.11106996,0.7051723],"study_design_scores_gemma":[0.3280743,0.23584497,0.012435074,0.0013138058,0.0021440815,0.00029863886,0.00878179,0.010889167,0.05240064,0.0053216023,0.34083745,0.0016584612],"about_ca_topic_score_codex":0.01763586,"about_ca_topic_score_gemma":0.018528365,"teacher_disagreement_score":0.70351386,"about_ca_system_score_codex":0.0008445803,"about_ca_system_score_gemma":0.0038097203,"threshold_uncertainty_score":0.99975985},"labels":[],"label_agreement":null},{"id":"W4387837059","doi":"10.1016/j.annonc.2023.09.1133","title":"1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eisai Incorporated; Merck Sharp and Dohme","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Oncology; Post-hoc analysis; Internal medicine; Urology; Cancer; Immunotherapy","score_opus":0.045026071857746014,"score_gpt":0.31073095820562896,"score_spread":0.2657048863478829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387837059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955011,0.00013678864,0.0000014730647,0.0015230101,0.000035026147,0.0013835051,0.00079107814,0.000032269585,0.0005957503],"genre_scores_gemma":[0.99767286,0.000031083964,0.00009791939,0.0005874449,0.000028086642,0.000091845686,0.0009179118,0.000051492207,0.00052133325],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957599,0.0014965766,0.0009602056,0.00053125067,0.0007135726,0.0005384792],"domain_scores_gemma":[0.99638575,0.0011450583,0.0007696498,0.0007597624,0.0007468605,0.00019290627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012022441,0.00037643447,0.0015782288,0.0010307984,0.00007240056,0.0000078996245,0.00025916414,0.0001416718,0.00016664216],"category_scores_gemma":[0.0003863458,0.00022525321,0.00035274104,0.0029865098,0.0003665501,0.000071025446,0.00009973237,0.0002866508,0.000010178003],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9161999,0.0027886597,0.06903173,0.00008301745,0.0013911887,0.0006517287,0.00067989144,0.00042596975,0.0031647084,0.000005511052,0.0039848494,0.0015928224],"study_design_scores_gemma":[0.15765522,0.16294701,0.6082413,0.00011944088,0.004004037,0.000032113945,0.000855433,0.00038275885,0.06255628,0.0000020799785,0.002861782,0.00034252886],"about_ca_topic_score_codex":0.001550531,"about_ca_topic_score_gemma":0.00077678513,"teacher_disagreement_score":0.7585447,"about_ca_system_score_codex":0.000206675,"about_ca_system_score_gemma":0.00097054977,"threshold_uncertainty_score":0.918556},"labels":[],"label_agreement":null},{"id":"W4387882142","doi":"10.1016/j.annonc.2023.10.117","title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; American College of Radiology Imaging Network; Society for Immunotherapy of Cancer; Pfizer Japan; Genentech; Mirati Therapeutics; Jounce Therapeutics; Chugai Pharmaceutical; MSD K.K.; Jazz Pharmaceuticals; Eli Lilly Japan; ECOG-ACRIN Cancer Research Group; Janssen Biotech; Helsinn; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Janssen Research and Development; EMD Serono; International Association for the Study of Lung Cancer; Sanofi; Amgen; Pfizer","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Pemetrexed; Oncology; Chemotherapy regimen; Lung cancer; Hazard ratio; Osimertinib; Regimen; Progression-free survival; Phases of clinical research; Cancer; Cisplatin; Erlotinib; Epidermal growth factor receptor; Confidence interval","score_opus":0.036754216118626865,"score_gpt":0.4300967680827514,"score_spread":0.3933425519641245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387882142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130935,0.00046890165,0.0000027363874,0.015169809,0.00006185504,0.0018540553,0.00014016399,0.000048158072,0.00094498665],"genre_scores_gemma":[0.99537,0.00038570308,0.0001225526,0.0032899,0.000059546663,0.00035194104,0.00017304177,0.00002744081,0.00021991775],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986279,0.000109951536,0.0003811656,0.00038809102,0.00024238865,0.00025048832],"domain_scores_gemma":[0.99899465,0.00022335503,0.00019249332,0.00035014426,0.00008245584,0.00015689459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023083981,0.00017829935,0.0004392857,0.00009283267,0.000061734885,0.000008793139,0.00007516012,0.000057764984,0.00002090695],"category_scores_gemma":[0.00008521603,0.00009916975,0.000041456125,0.00025764533,0.00011525795,0.00006507428,0.00004142772,0.00014816503,0.000005389209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27442074,0.007906552,0.14777093,0.000053321935,0.0007548148,0.001069532,0.015301056,0.000046078003,0.0017084065,0.000012205145,0.0014746821,0.5494817],"study_design_scores_gemma":[0.09542955,0.014806293,0.8767246,0.0005896676,0.00032657423,0.0000064463075,0.0016607655,0.0001631833,0.00092340587,0.00007549482,0.009115864,0.00017814373],"about_ca_topic_score_codex":0.00014791824,"about_ca_topic_score_gemma":0.0001470017,"teacher_disagreement_score":0.72895366,"about_ca_system_score_codex":0.00007736996,"about_ca_system_score_gemma":0.00045444033,"threshold_uncertainty_score":0.40440252},"labels":[],"label_agreement":null},{"id":"W4388534086","doi":"10.1016/j.annonc.2023.10.129","title":"Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline","year":2023,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; INCLIVA Instituto de Investigación Sanitaria; Servier; European Society for Medical Oncology; Astellas Pharma; Sierra Oncology; Incyte; Sociedad Española de Oncología Médica; BeiGene; Natera; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Les Laboratories Pierre Fabre; Amgen","keywords":"Medicine; Colorectal cancer; Bevacizumab; Internal medicine; Oncology; Oxaliplatin; Irinotecan; Guideline; Cancer; Hazard ratio; Chemotherapy regimen; Chemotherapy; Confidence interval; Pathology","score_opus":0.13602767905111768,"score_gpt":0.44305599191451195,"score_spread":0.30702831286339427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388534086","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27405956,0.0044586994,0.000012132246,0.70804286,0.0017533433,0.0046421518,0.006264696,0.000109718596,0.0006568579],"genre_scores_gemma":[0.17959008,0.1352161,0.0034017067,0.5576154,0.012388901,0.056070235,0.041998383,0.0008075184,0.012911717],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996239,0.00034210004,0.0013660825,0.0009286373,0.00029672738,0.0008274695],"domain_scores_gemma":[0.99527967,0.002824462,0.00089265505,0.00031904833,0.0005879626,0.00009618955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037561663,0.00078888866,0.0023364876,0.00027841388,0.00019284342,0.00001936057,0.00020428612,0.000539572,0.00060079276],"category_scores_gemma":[0.0002643407,0.00049995445,0.00056971394,0.00047264257,0.0002028891,0.00008165882,0.00010340604,0.0004905366,0.000014251884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003799768,0.0011300788,0.004203159,0.00007891596,0.0056592603,0.00025595445,0.0020590087,0.00020819707,0.00031623992,0.0000028652196,0.70722777,0.27505878],"study_design_scores_gemma":[0.007324152,0.02064915,0.010727328,0.00042700343,0.0022929795,0.000012842052,0.00059630926,0.0007461054,0.0026841792,0.00013085302,0.9539459,0.00046323202],"about_ca_topic_score_codex":0.03260328,"about_ca_topic_score_gemma":0.09148731,"teacher_disagreement_score":0.27459556,"about_ca_system_score_codex":0.0023889397,"about_ca_system_score_gemma":0.0015623918,"threshold_uncertainty_score":0.9997452},"labels":[],"label_agreement":null},{"id":"W4388655064","doi":"10.1016/j.annonc.2023.09.134","title":"O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Antibody-drug conjugate; Epidermal growth factor receptor; Cohort; Cancer research; Cancer; Antibody; Monoclonal antibody; Immunology","score_opus":0.024903447188834357,"score_gpt":0.38965297613120514,"score_spread":0.3647495289423708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388655064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859763,0.0004665773,0.00003643768,0.0014754009,0.00014117004,0.00064422115,0.000039436633,0.000033847726,0.011186614],"genre_scores_gemma":[0.99630547,0.00047709874,0.0013501854,0.0007808314,0.000049320803,0.00016704085,0.00007731647,0.000033243035,0.00075946975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989946,0.000034344113,0.0002664184,0.00025134336,0.00014149558,0.00031180875],"domain_scores_gemma":[0.9993292,0.000060165,0.0001707159,0.00019048924,0.00016445895,0.00008493868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007808758,0.00014228307,0.00037907544,0.00020775045,0.000044125052,0.000005676781,0.00007235767,0.00009498637,0.00007689774],"category_scores_gemma":[0.000015307136,0.00011202333,0.000055699784,0.00037918097,0.000047740537,0.00008273153,0.000021625765,0.00011998052,0.000008740574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014732141,0.001349095,0.7123876,0.0002413707,0.00030648598,0.00011443971,0.0055836043,0.0015684662,0.0029007776,0.000025117253,0.004144706,0.26990512],"study_design_scores_gemma":[0.01954624,0.0046603032,0.9408583,0.00061985885,0.00017366509,0.000002124728,0.0009779999,0.00040736355,0.009127642,0.00006935099,0.023300128,0.00025703647],"about_ca_topic_score_codex":0.0004011551,"about_ca_topic_score_gemma":0.00026027075,"teacher_disagreement_score":0.26964808,"about_ca_system_score_codex":0.00015240666,"about_ca_system_score_gemma":0.000529317,"threshold_uncertainty_score":0.4568179},"labels":[],"label_agreement":null},{"id":"W4388673541","doi":"10.1016/j.annonc.2023.09.109","title":"PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Head and neck cancer; Radiation therapy; Immunotherapy; Cancer","score_opus":0.07269443490537662,"score_gpt":0.3856289528875479,"score_spread":0.31293451798217126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388673541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778905,0.004281797,0.000021772845,0.011560745,0.0002040939,0.00063893874,0.000020393236,0.000059483922,0.005322278],"genre_scores_gemma":[0.99223083,0.0035830718,0.00032037983,0.0026967004,0.00018916998,0.0001255846,0.00003570355,0.000026588841,0.0007919558],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988836,0.000034008124,0.00030733482,0.00027829394,0.00013068138,0.00036608466],"domain_scores_gemma":[0.99905723,0.00027206738,0.00012621663,0.00018200571,0.00024537087,0.00011712364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021756184,0.00015175916,0.00061242445,0.00013014232,0.000081640006,0.0000038956086,0.00006335953,0.00014451175,0.000019573667],"category_scores_gemma":[0.00012139932,0.00013344853,0.0001036648,0.00021857179,0.000101434474,0.000054467047,0.000032635733,0.0001036366,0.000013463132],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016409088,0.000936999,0.021454189,0.00078427134,0.00011228786,0.00009465475,0.005600257,0.00006041267,0.033829115,0.00026556884,0.06324935,0.8572038],"study_design_scores_gemma":[0.053108003,0.04974957,0.41028267,0.00009416148,0.00008791107,0.00004156206,0.0008637541,0.0012639624,0.08867967,0.0008423554,0.39454475,0.00044162682],"about_ca_topic_score_codex":0.00007280007,"about_ca_topic_score_gemma":0.00006515055,"teacher_disagreement_score":0.8567622,"about_ca_system_score_codex":0.00003859711,"about_ca_system_score_gemma":0.00028311837,"threshold_uncertainty_score":0.5441873},"labels":[],"label_agreement":null},{"id":"W4388673658","doi":"10.1016/j.annonc.2023.09.028","title":"PSY01-3 Financial toxicity of cancer treatment: From measurement to solutions","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Toxicity; Cancer; Cancer treatment; Quality of life (healthcare); Cardiac toxicity; Internal medicine; Oncology; Intensive care medicine; Finance; Economics; Nursing","score_opus":0.2913203846839613,"score_gpt":0.3686769677329427,"score_spread":0.07735658304898135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388673658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96185756,0.003385687,0.000409597,0.008503137,0.0009343403,0.0002871861,0.002013914,0.00003267813,0.022575881],"genre_scores_gemma":[0.9952654,0.0028183847,0.00015939088,0.0010356967,0.00024659684,0.00007948368,0.000013629027,0.00001532524,0.00036605203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853647,0.000015709187,0.0007161627,0.00029905493,0.000042821135,0.00038976505],"domain_scores_gemma":[0.9989723,0.0000619459,0.0004342777,0.0002651272,0.00014693465,0.00011939524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051023794,0.00013635399,0.00070016494,0.0002618992,0.000063202046,0.000006261625,0.00019860557,0.00015673978,0.00044202985],"category_scores_gemma":[0.0003054253,0.00015511719,0.00018404146,0.0003224305,0.00008334532,0.00010789781,0.00006381259,0.00006176434,0.0003682355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078173383,0.0017117963,0.10645906,0.00007546922,0.0008637628,0.000015076132,0.0047877594,0.0029899993,0.004809328,0.24328999,0.18590334,0.44831267],"study_design_scores_gemma":[0.0011198858,0.0017810878,0.29593274,0.000036677786,0.000019278918,2.8112314e-7,0.00005433925,0.00015625876,0.009534028,0.047317646,0.64377457,0.00027322175],"about_ca_topic_score_codex":0.0069165593,"about_ca_topic_score_gemma":0.004334616,"teacher_disagreement_score":0.4578712,"about_ca_system_score_codex":0.00022785878,"about_ca_system_score_gemma":0.00027124185,"threshold_uncertainty_score":0.9996965},"labels":[],"label_agreement":null},{"id":"W4388728839","doi":"10.1016/j.annonc.2023.10.790","title":"VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Amgen","keywords":"Medicine; Cmax; Internal medicine; Clinical endpoint; Gastroenterology; Pharmacokinetics; Confidence interval; Dosing; Randomized controlled trial","score_opus":0.16558930239500066,"score_gpt":0.4753252761831692,"score_spread":0.30973597378816853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388728839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497086,0.00050382316,0.0000026903501,0.0045661577,0.0005340041,0.00074162404,0.000022064125,0.00012827141,0.043792784],"genre_scores_gemma":[0.9928858,0.0012813073,0.00015062152,0.00048631325,0.00018054643,0.00011455206,0.000099807796,0.000045920293,0.0047551026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737,0.00018047176,0.0005786569,0.00048113786,0.00050587725,0.0008838387],"domain_scores_gemma":[0.9975655,0.0010407655,0.00015564811,0.00058577635,0.00039546995,0.00025681645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000781901,0.00022516724,0.0007907525,0.00055019354,0.000044308268,0.000007242726,0.00028396182,0.0003725321,0.00054231536],"category_scores_gemma":[0.0019210201,0.00020765427,0.00014475491,0.0016984185,0.00029053187,0.00010464246,0.00021891041,0.00039591588,0.000642797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06040785,0.003544243,0.011577869,0.0016551969,0.0015175907,0.0151311355,0.0052742194,0.0010030199,0.09257411,0.0016810995,0.33178055,0.4738531],"study_design_scores_gemma":[0.3302835,0.044913504,0.068203464,0.0015398714,0.0003310072,0.0004970633,0.004589845,0.019417724,0.081528634,0.002084034,0.44509944,0.0015118911],"about_ca_topic_score_codex":0.00095579383,"about_ca_topic_score_gemma":0.0006190998,"teacher_disagreement_score":0.4723412,"about_ca_system_score_codex":0.0031661964,"about_ca_system_score_gemma":0.0072455686,"threshold_uncertainty_score":0.99838245},"labels":[],"label_agreement":null},{"id":"W4389279747","doi":"10.1016/j.annonc.2023.10.294","title":"159P Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pancreatic cancer; Stroma; Histology; Pathology; Cancer; Artificial intelligence; Internal medicine; Immunohistochemistry","score_opus":0.029870291817855686,"score_gpt":0.40001903912378195,"score_spread":0.3701487473059263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525671,0.0009774826,0.0016628444,0.043835312,0.00019377605,0.00015286819,0.0000023831624,0.00004078821,0.0005674606],"genre_scores_gemma":[0.99243224,0.0014078865,0.0026038506,0.0029484672,0.00017811063,0.000016230622,0.000013127205,0.000019133393,0.00038094187],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99889714,0.0001462001,0.00028728205,0.00024145095,0.00016184285,0.00026609926],"domain_scores_gemma":[0.9988409,0.00060606404,0.00013291487,0.00013126268,0.00010191944,0.00018690739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037045262,0.0001115364,0.0006074595,0.00020655793,0.00004232208,0.0000037706602,0.00008164546,0.00013897923,0.00004351051],"category_scores_gemma":[0.0005276543,0.0000905023,0.00007066145,0.00017985735,0.00020985771,0.0000324422,0.00011737375,0.00035082555,0.0000051234456],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040225103,0.00019735268,0.038051214,0.00019765337,0.00015451299,0.00024371425,0.0013521027,0.0014949208,0.015050543,0.00079973886,0.028624354,0.91343164],"study_design_scores_gemma":[0.0026517266,0.009897532,0.68703914,0.0004587492,0.00019742048,0.00022957256,0.00016592394,0.17708108,0.001018977,0.00075217977,0.12027926,0.00022845378],"about_ca_topic_score_codex":0.00016524029,"about_ca_topic_score_gemma":0.000023881195,"teacher_disagreement_score":0.9132032,"about_ca_system_score_codex":0.000025073983,"about_ca_system_score_gemma":0.000076654025,"threshold_uncertainty_score":0.36905766},"labels":[],"label_agreement":null},{"id":"W4389279876","doi":"10.1016/j.annonc.2023.10.265","title":"129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Oxaliplatin; Internal medicine; Cancer; Oncology; Gastroesophageal Junction; Adenocarcinoma; Colorectal cancer","score_opus":0.13845696762718668,"score_gpt":0.42934313008501995,"score_spread":0.2908861624578333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988425,0.00019496809,0.000029798006,0.009356131,0.00027668185,0.0011617464,0.00011477634,0.00003452276,0.00040638857],"genre_scores_gemma":[0.9979327,0.00021882771,0.00012440764,0.00085383316,0.00007341908,0.000086281274,0.000012642543,0.000012452049,0.0006854677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975338,0.0005001566,0.00075997924,0.0004487343,0.00032782022,0.00042952126],"domain_scores_gemma":[0.99879414,0.000285293,0.0002993134,0.0003476176,0.00014306359,0.000130603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017701968,0.00020843663,0.00077359885,0.0003777214,0.00007656852,0.000015474181,0.00016944708,0.00009550093,0.000042398122],"category_scores_gemma":[0.00048796192,0.00015434521,0.00007580888,0.0012381225,0.00018076356,0.00008061415,0.00044338754,0.00022382398,0.0000042819356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14893176,0.002225827,0.6804485,0.00031082818,0.00040091752,0.0011452673,0.0046586925,0.00058358564,0.007974403,0.00006548124,0.052281473,0.10097331],"study_design_scores_gemma":[0.020681871,0.011874013,0.9600405,0.00010836847,0.000110629946,0.000069400405,0.0019365031,0.00025483116,0.00016951225,0.000046526107,0.004600512,0.000107304],"about_ca_topic_score_codex":0.0013845843,"about_ca_topic_score_gemma":0.0010533254,"teacher_disagreement_score":0.27959207,"about_ca_system_score_codex":0.00018293427,"about_ca_system_score_gemma":0.00016593497,"threshold_uncertainty_score":0.6294015},"labels":[],"label_agreement":null},{"id":"W4389279899","doi":"10.1016/j.annonc.2023.10.282","title":"147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Cancer Institute; Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Novartis Pharma; University of California, San Francisco; AstraZeneca; Genentech; F. Hoffmann-La Roche; Clinical Trial Center, China Medical University Hospital; Humanitas Research Hospital; Sirtex Medical; Teijin Pharma; Humanitas University; Eli Lilly and Company; EA Pharma Co., Ltd.; Ludwig-Maximilians-Universität München; Universidad de Navarra; Kyowa Hakko Kirin; Khon Kaen University; Bayer HealthCare; MacroGenics; Relay Therapeutics; Daiichi Sankyo Europe; Agios Pharmaceuticals; Kanazawa University; Regeneron Pharmaceuticals; Boston Scientific Corporation; Mylan; EMD Serono; Flatiron Health; Kindai University; Ipsen; Jazz Pharmaceuticals; Exelixis; Celgene; Yakult Honsha; Astellas Pharma; University of Ulsan; Chinese University of Hong Kong; BeiGene; Memorial Sloan-Kettering Cancer Center; Pfizer; Servier; Incyte; Gilead Sciences; Taiho Pharmaceutical; Eisai; FibroGen; Universitat de Barcelona; Amgen; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Jounce Therapeutics; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Durvalumab; Tremelimumab; Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab","score_opus":0.22210150407303664,"score_gpt":0.3656108423830158,"score_spread":0.14350933830997914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922418,0.0008007648,0.000005142128,0.002769642,0.00028658487,0.0016754546,0.00011029891,0.000059389888,0.0020509392],"genre_scores_gemma":[0.9982421,0.00043556586,0.00004957636,0.0002573075,0.00017550211,0.00013680488,0.00027212847,0.000053616604,0.00037744275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650216,0.0007284454,0.00096727256,0.000552668,0.0005981619,0.00065126177],"domain_scores_gemma":[0.99762154,0.0007529487,0.00035833986,0.00080515957,0.00028572345,0.00017631387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013635182,0.00033484175,0.0013510617,0.0003389909,0.00009346214,0.000012899229,0.00037720308,0.00025091312,0.00052570953],"category_scores_gemma":[0.00020956466,0.00025804262,0.00029991902,0.00082452263,0.00015668724,0.000109427245,0.000229969,0.00035885326,0.00009535334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055479547,0.0034914722,0.97132343,0.000059593924,0.00060779566,0.0020832801,0.0035408938,0.000017711269,0.0031615477,0.00013236763,0.004249241,0.0057846936],"study_design_scores_gemma":[0.16679978,0.038676836,0.70003355,0.0002813638,0.0015870861,0.000049710787,0.010971357,0.025157163,0.029935582,0.0012271175,0.024306092,0.0009743573],"about_ca_topic_score_codex":0.010521734,"about_ca_topic_score_gemma":0.0014162752,"teacher_disagreement_score":0.27128989,"about_ca_system_score_codex":0.000119048236,"about_ca_system_score_gemma":0.0005085956,"threshold_uncertainty_score":0.9999872},"labels":[],"label_agreement":null},{"id":"W4389279939","doi":"10.1016/j.annonc.2023.10.132","title":"LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Placebo; Oncology; Internal medicine; Breast cancer; Subgroup analysis; Adjuvant; Chemotherapy; Adjuvant chemotherapy; Stage (stratigraphy); Cancer; Meta-analysis; Immunotherapy; Pathology","score_opus":0.06947741953422655,"score_gpt":0.4134884706244978,"score_spread":0.34401105109027125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746675,0.00055061345,0.0002673661,0.003229027,0.00043129805,0.005280134,0.0022552372,0.00020333179,0.0003162452],"genre_scores_gemma":[0.98559004,0.0024573035,0.00009154365,0.0011170676,0.00020892468,0.0010743777,0.00028651932,0.00015606199,0.009018149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948662,0.00041158134,0.0018238138,0.001023138,0.0007879834,0.0010873083],"domain_scores_gemma":[0.9954424,0.00119383,0.0013821924,0.0009044751,0.0007253968,0.00035169604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001334095,0.0007015424,0.003126039,0.0010626003,0.00019565404,0.000026906093,0.00054606143,0.00045955315,0.001578334],"category_scores_gemma":[0.0002121211,0.0005178467,0.0010051347,0.0028378787,0.00045569477,0.00020222532,0.000109771594,0.00037967568,0.0000061564547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84681493,0.005888479,0.002619238,0.00031985153,0.014088994,0.0003585229,0.011762368,0.00017090655,0.016101222,0.00000818156,0.044248264,0.05761904],"study_design_scores_gemma":[0.75662696,0.09715769,0.04911158,0.00042293008,0.0064163734,0.00015011898,0.01890495,0.007059922,0.03147079,0.000036225534,0.03098866,0.0016537936],"about_ca_topic_score_codex":0.0095848115,"about_ca_topic_score_gemma":0.00795158,"teacher_disagreement_score":0.09126921,"about_ca_system_score_codex":0.0004642082,"about_ca_system_score_gemma":0.0016634237,"threshold_uncertainty_score":0.9997273},"labels":[],"label_agreement":null},{"id":"W4389280186","doi":"10.1016/j.annonc.2023.10.663","title":"585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Exon; Oncology; Mutation; Internal medicine; Cancer research; Genetics; Gene","score_opus":0.04064274358285673,"score_gpt":0.39660253448124827,"score_spread":0.3559597908983915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98451346,0.00005670309,0.000024425035,0.0055329134,0.00010246045,0.00078189303,0.00003649825,0.000048223083,0.008903418],"genre_scores_gemma":[0.9953276,0.00020569004,0.00057802367,0.00058058975,0.000028423325,0.00021330365,0.00023261398,0.000029294668,0.0028044498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989628,0.000037085632,0.00029208604,0.00024739327,0.00017533357,0.00028529717],"domain_scores_gemma":[0.9991315,0.00011352088,0.00020653979,0.00018246562,0.00027562643,0.000090332316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107378466,0.00014394095,0.00039342025,0.000296968,0.00006835111,0.000006012506,0.000057651425,0.00007061691,0.00009393344],"category_scores_gemma":[0.000020437168,0.00010512832,0.00004468466,0.0005794457,0.000058959362,0.00009682069,0.000020412019,0.00012374426,0.000014231685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004161164,0.00064867473,0.9858519,0.00009958968,0.0001950596,0.000031838117,0.002271526,0.00093281345,0.00007800691,0.000009517113,0.0018253188,0.0076396754],"study_design_scores_gemma":[0.005227968,0.0018264488,0.9900575,0.00022180352,0.00022590587,7.5167986e-7,0.00034651722,0.0002340498,0.00034031933,0.000023120425,0.0013819413,0.000113673304],"about_ca_topic_score_codex":0.0031738165,"about_ca_topic_score_gemma":0.01993431,"teacher_disagreement_score":0.016760493,"about_ca_system_score_codex":0.00017046942,"about_ca_system_score_gemma":0.00049266627,"threshold_uncertainty_score":0.99794936},"labels":[],"label_agreement":null},{"id":"W4389280230","doi":"10.1016/j.annonc.2023.10.462","title":"354O A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV+ solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Valganciclovir; Nasopharyngeal carcinoma; Oncology; Phases of clinical research; Internal medicine; Cancer research; Virology; Chemotherapy; Radiation therapy; Virus; Ganciclovir; Cancer; Immunotherapy","score_opus":0.06200147893821727,"score_gpt":0.4070001838657971,"score_spread":0.34499870492757984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974918,0.0007307655,0.0000039259517,0.00025717507,0.000069149246,0.0008605676,0.00007986072,0.000010386302,0.00049639354],"genre_scores_gemma":[0.99917805,0.00023903827,0.00007637504,0.000071901886,0.000037736405,0.00011815466,0.000100343554,0.000037443384,0.00014097978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971938,0.00049707,0.00075933564,0.0005885336,0.00035344486,0.0006077838],"domain_scores_gemma":[0.99881804,0.00012814494,0.00027284032,0.00038487278,0.00024398926,0.00015213409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000863693,0.00025697524,0.00075757003,0.0005986199,0.000062947,0.000006813674,0.0002726009,0.0001361307,0.000013788894],"category_scores_gemma":[0.00029772826,0.00024374323,0.00006701922,0.000770574,0.00032925777,0.000013663558,0.00031484076,0.00029443763,0.0000040018813],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03951011,0.018307013,0.05092836,0.0014304433,0.00073937204,0.008251354,0.037299354,0.0018333213,0.7103419,0.00011622586,0.016356807,0.114885785],"study_design_scores_gemma":[0.09472087,0.20539081,0.085455574,0.00044476843,0.00012841538,0.0005029974,0.01917659,0.0037275758,0.58356816,0.00019679981,0.0051333653,0.0015540863],"about_ca_topic_score_codex":0.00085474836,"about_ca_topic_score_gemma":0.0039394037,"teacher_disagreement_score":0.1870838,"about_ca_system_score_codex":0.00007119855,"about_ca_system_score_gemma":0.000783746,"threshold_uncertainty_score":0.993956},"labels":[],"label_agreement":null},{"id":"W4389280307","doi":"10.1016/j.annonc.2023.10.591","title":"512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Chemotherapy; Oncology; Internal medicine; Adenocarcinoma; Cancer","score_opus":0.05022058498647386,"score_gpt":0.43413890205650324,"score_spread":0.3839183170700294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531457,0.0007496664,0.000020179723,0.037763882,0.0001393456,0.00047754106,0.00004696396,0.000034439418,0.007622288],"genre_scores_gemma":[0.99173576,0.00493653,0.00029840175,0.0014118392,0.00003063455,0.00003564811,0.000048135862,0.000018243036,0.0014847842],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99900526,0.000029523375,0.0004324176,0.00019437072,0.00011405348,0.0002243859],"domain_scores_gemma":[0.99918264,0.00025851937,0.0001707932,0.00019288594,0.0001211024,0.0000740363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019010232,0.00012209373,0.0005906337,0.0001779165,0.00003196006,0.0000015705242,0.00005727775,0.00010213373,0.00009898641],"category_scores_gemma":[0.00012380481,0.00009705593,0.00008276785,0.00030616875,0.000109906374,0.000052603446,0.000028650367,0.00008465302,0.00000841667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037779834,0.0018090986,0.36032724,0.00032537009,0.0009971434,0.00011964405,0.0066342643,0.00023512638,0.0046777166,0.0006352039,0.0039898744,0.6164713],"study_design_scores_gemma":[0.012552273,0.0039524776,0.86026925,0.00016385363,0.00013744067,0.0000136462095,0.00074331806,0.00014693219,0.0083933165,0.0005923643,0.11288571,0.00014943513],"about_ca_topic_score_codex":0.00018386109,"about_ca_topic_score_gemma":0.00032261258,"teacher_disagreement_score":0.61632186,"about_ca_system_score_codex":0.000043024193,"about_ca_system_score_gemma":0.00013163626,"threshold_uncertainty_score":0.39578256},"labels":[],"label_agreement":null},{"id":"W4389280689","doi":"10.1016/j.annonc.2023.10.774","title":"195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Cluster analysis; Oncology; Translational research; Internal medicine; Pancreatic cancer; Pathology; Cancer; Artificial intelligence","score_opus":0.05851500818692625,"score_gpt":0.3311029235606874,"score_spread":0.27258791537376115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928862,0.0023022643,0.00001604039,0.003791949,0.00004448553,0.00028614784,0.000027363021,0.000035592842,0.0006099848],"genre_scores_gemma":[0.9984348,0.0009211469,0.00010706673,0.00036859946,0.000025942712,0.00007365614,0.000031570962,0.000020850457,0.000016371205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985998,0.00016137028,0.0004609853,0.00030336704,0.00017518883,0.00029926773],"domain_scores_gemma":[0.9993675,0.0002259817,0.00008740927,0.00015286062,0.00008098805,0.00008529088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036083412,0.00015580228,0.0007209245,0.0007758604,0.000021598586,0.000006388924,0.00007135786,0.00014100493,0.00007695894],"category_scores_gemma":[0.000049135633,0.00013016215,0.00015896258,0.0014022179,0.00007870989,0.00005897076,0.00004817912,0.00018170883,0.0000013828239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075876625,0.0004381064,0.937359,0.00012966669,0.00058407994,0.000075549244,0.007922001,0.0038229148,0.0074559553,0.000032020842,0.000088014276,0.04133393],"study_design_scores_gemma":[0.001418551,0.0010462365,0.9795555,0.000072497285,0.00013294251,0.000004637256,0.0019695847,0.012685194,0.0024119238,0.00017583813,0.00039839314,0.00012869127],"about_ca_topic_score_codex":0.0005878852,"about_ca_topic_score_gemma":0.0021900064,"teacher_disagreement_score":0.042196512,"about_ca_system_score_codex":0.000032393735,"about_ca_system_score_gemma":0.00010321621,"threshold_uncertainty_score":0.53078586},"labels":[],"label_agreement":null},{"id":"W4389280739","doi":"10.1016/j.annonc.2023.10.384","title":"258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prednisone; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.08289055712942077,"score_gpt":0.3990372821216814,"score_spread":0.3161467249922606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912784,0.00019509446,0.0000058145856,0.0047764024,0.000097544675,0.0029515105,0.00029561057,0.000017484655,0.000382115],"genre_scores_gemma":[0.99766606,0.0002044736,0.00005321221,0.00056389824,0.00002409891,0.000915905,0.00011125514,0.000028166087,0.00043293033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970162,0.0006473677,0.00099189,0.00042617501,0.0005041425,0.000414209],"domain_scores_gemma":[0.9982179,0.00022373967,0.00060730736,0.0005791485,0.0002990798,0.00007286238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084950594,0.0002944873,0.0010799655,0.00050243706,0.00007256746,0.000016240645,0.00025349826,0.00007617869,0.0002564784],"category_scores_gemma":[0.000051100677,0.00017118957,0.00016161667,0.0019790577,0.0002626634,0.0001119322,0.00005545621,0.00022052346,0.0000065503045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031124463,0.0126751,0.7893061,0.00051334966,0.008049515,0.0004891827,0.11643674,0.021115009,0.0024000846,0.000059559963,0.00081924803,0.017011669],"study_design_scores_gemma":[0.022510957,0.016991358,0.95069087,0.00016017821,0.0008519567,0.000005190138,0.0051780944,0.0003241825,0.0022677288,0.000097907236,0.0007413421,0.00018023895],"about_ca_topic_score_codex":0.004114424,"about_ca_topic_score_gemma":0.10823216,"teacher_disagreement_score":0.16138479,"about_ca_system_score_codex":0.00048792176,"about_ca_system_score_gemma":0.00068809284,"threshold_uncertainty_score":0.9080403},"labels":[],"label_agreement":null},{"id":"W4389286306","doi":"10.1016/j.annonc.2023.10.349","title":"213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; BC Cancer Agency","funders":"Cilag; Daiichi Sankyo Europe; Astellas Pharma; Genentech; AstraZeneca; LEO Pharma; Seagen; Pfizer","keywords":"Medicine; Renal cell carcinoma; Lymphocyte; Oncology; Internal medicine; First line; Immunotherapy; Cancer","score_opus":0.04678872414601174,"score_gpt":0.29577311872238576,"score_spread":0.24898439457637403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389286306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935276,0.0006806407,0.00006306744,0.0021554972,0.00011026125,0.0013341728,0.0017731574,0.00002558943,0.00033004727],"genre_scores_gemma":[0.995873,0.0004048119,0.0004895578,0.0005590756,0.000028295175,0.00012916476,0.00226503,0.000039971594,0.00021113406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972044,0.00025959744,0.001040767,0.0004868907,0.0006319631,0.0003763662],"domain_scores_gemma":[0.99634564,0.0014192885,0.0009688379,0.00055084494,0.00064022717,0.00007514453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008671863,0.0002999102,0.00070519676,0.00028742172,0.00007277308,0.000015473546,0.00032894468,0.00007281534,0.00009183147],"category_scores_gemma":[0.00015551226,0.00019700754,0.000110318644,0.0007318868,0.0004508359,0.0001435699,0.000056719666,0.00019368863,0.0000072236735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37903357,0.0127615705,0.4776154,0.00116947,0.004016265,0.0011294262,0.01182897,0.0018971934,0.079320304,0.000054101347,0.017358381,0.013815364],"study_design_scores_gemma":[0.056483924,0.013339573,0.8602261,0.00046305775,0.00047172516,0.000012597524,0.00074203196,0.0011428483,0.06324663,0.00003449494,0.0035159346,0.00032110215],"about_ca_topic_score_codex":0.0056003304,"about_ca_topic_score_gemma":0.0015388045,"teacher_disagreement_score":0.38261068,"about_ca_system_score_codex":0.0002123749,"about_ca_system_score_gemma":0.00090992195,"threshold_uncertainty_score":0.8466062},"labels":[],"label_agreement":null},{"id":"W4389286327","doi":"10.1016/j.annonc.2023.10.410","title":"288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Open label; Oncology; Internal medicine; Phases of clinical research; Chemotherapy; Randomized controlled trial","score_opus":0.2774718891999159,"score_gpt":0.5210854269679527,"score_spread":0.2436135377680368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389286327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857362,0.001394659,0.0000051693837,0.007629413,0.00040434298,0.0038543893,0.00018836238,0.000034095523,0.0007533806],"genre_scores_gemma":[0.99236333,0.00280705,0.0003652375,0.0030708383,0.00012539014,0.0008723867,0.000057698293,0.00003947201,0.0002986202],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956332,0.0007540326,0.00192075,0.0005636112,0.00059055944,0.0005378521],"domain_scores_gemma":[0.9961139,0.0015906981,0.0009398494,0.00048223094,0.0005507816,0.0003225646],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016591741,0.00036952808,0.0034389934,0.00046299765,0.00004057768,0.000010393457,0.0005135985,0.00018187783,0.0010997353],"category_scores_gemma":[0.002628254,0.00024449383,0.00015060148,0.0040612365,0.00036974653,0.00011950891,0.00026715524,0.0002960364,0.000012099393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74627566,0.03608707,0.0077686887,0.00096248294,0.003321289,0.0003705115,0.0021430852,0.00001253972,0.0011868533,0.00032195947,0.011490444,0.1900594],"study_design_scores_gemma":[0.93057334,0.04525183,0.008466668,0.0005767197,0.00078210345,0.000016409482,0.0008314699,0.00015678027,0.004302305,0.0007794664,0.007962715,0.00030017048],"about_ca_topic_score_codex":0.008603297,"about_ca_topic_score_gemma":0.0041404516,"teacher_disagreement_score":0.18975922,"about_ca_system_score_codex":0.00021603721,"about_ca_system_score_gemma":0.0018394706,"threshold_uncertainty_score":0.9998134},"labels":[],"label_agreement":null},{"id":"W4389286603","doi":"10.1016/j.annonc.2023.10.673","title":"595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Bispecific antibody; Antibody; Cancer research; Oncology; Immunology; Monoclonal antibody","score_opus":0.03239261749654995,"score_gpt":0.4176107955570832,"score_spread":0.38521817806053327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389286603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96496564,0.0021793928,0.000037610465,0.0036825424,0.00036974874,0.0010566665,0.000113140595,0.000045012333,0.027550243],"genre_scores_gemma":[0.99021184,0.0057145227,0.0004489723,0.00053551496,0.000096698925,0.00011922719,0.00016147726,0.000042812255,0.0026689256],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982736,0.00007609121,0.000574103,0.0003989053,0.00020841278,0.00046884795],"domain_scores_gemma":[0.9985556,0.0003111515,0.00031300462,0.0003286649,0.0003541186,0.00013746636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021659539,0.000215787,0.0007509434,0.00038508195,0.00006704285,0.000005115205,0.00014014362,0.00017768993,0.00026780317],"category_scores_gemma":[0.000058898164,0.00019011437,0.00017255815,0.000871858,0.0001231988,0.000086483225,0.00007929263,0.00019917695,0.000037391048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075065996,0.008985823,0.15253872,0.00223278,0.0020692039,0.002155613,0.025674809,0.0064414297,0.47839227,0.00066776015,0.04549248,0.2678425],"study_design_scores_gemma":[0.029422974,0.00890392,0.75766915,0.002486156,0.00083488174,0.000047558755,0.0039026632,0.0014127219,0.14170694,0.0002590155,0.05265504,0.000698953],"about_ca_topic_score_codex":0.0017808105,"about_ca_topic_score_gemma":0.0004979431,"teacher_disagreement_score":0.60513043,"about_ca_system_score_codex":0.00022415303,"about_ca_system_score_gemma":0.0009789789,"threshold_uncertainty_score":0.7752639},"labels":[],"label_agreement":null},{"id":"W4389287637","doi":"10.1016/j.annonc.2023.10.479","title":"372P Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Chemoradiotherapy; Radiation therapy; Oncology; Head and neck; Head and neck cancer; Basal cell; Internal medicine; Surgery","score_opus":0.041161104254754305,"score_gpt":0.3845829520983906,"score_spread":0.3434218478436363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389287637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925987,0.0057134903,0.000505927,0.00044178762,0.000041382635,0.00039242147,0.000078559715,0.000016458205,0.00021125193],"genre_scores_gemma":[0.9982943,0.00064426224,0.00044609408,0.00019066076,0.000023498169,0.000050662286,0.00032375875,0.000021562855,0.0000051805036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843,0.00019547952,0.00052586576,0.0005405765,0.00006591437,0.00024217874],"domain_scores_gemma":[0.9989015,0.000051356175,0.00040883868,0.00046224383,0.00010286626,0.00007321975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007962981,0.00017093522,0.0004472467,0.00009954845,0.00004405873,0.000010049546,0.00018433535,0.00019732089,9.4855153e-7],"category_scores_gemma":[0.00012313678,0.00017310785,0.000043344455,0.0001291308,0.00025016343,0.0000075431954,0.00032183423,0.00009803625,2.5628768e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013300944,0.000113053844,0.05649234,0.00052491465,0.000019261293,0.00004859908,0.00005412359,0.0000028580316,0.9342512,0.00014618812,0.00018710287,0.008027369],"study_design_scores_gemma":[0.002486497,0.0025508776,0.1944706,0.00018089816,0.0000398912,0.000240229,0.00014379284,0.00095322303,0.7931407,0.00010839018,0.0053588124,0.00032608176],"about_ca_topic_score_codex":0.00030670295,"about_ca_topic_score_gemma":0.000038253824,"teacher_disagreement_score":0.14111048,"about_ca_system_score_codex":0.000009511573,"about_ca_system_score_gemma":0.00008121854,"threshold_uncertainty_score":0.70591336},"labels":[],"label_agreement":null},{"id":"W4389328383","doi":"10.1016/j.annonc.2023.11.017","title":"Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Janssen Pharmaceuticals; National Cancer Institute; Genentech; Ipsen; European Society for Medical Oncology; Cilag; Sanofi Australia; Astellas Pharma; European School of Oncology; Advanced Accelerator Applications; Daiichi Sankyo Europe; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Sanofi; Exelixis; Prostate Cancer Foundation; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Astellas Pharma US; Takeda Oncology; Amgen; Pfizer","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Surrogate endpoint; Cancer; Metastasis; Prostate; Survival analysis; Clinical trial; Urology","score_opus":0.13930166921387518,"score_gpt":0.4525994068801056,"score_spread":0.31329773766623037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389328383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97426647,0.0012684559,0.0000118945145,0.018004555,0.00020580609,0.0036550832,0.002347178,0.00001220404,0.00022835698],"genre_scores_gemma":[0.99182427,0.0049683377,0.00019507225,0.000137043,0.000055354158,0.0019951367,0.0003512772,0.000029005612,0.00044451596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755764,0.00031459375,0.0008552154,0.00031929652,0.00044943285,0.0005038283],"domain_scores_gemma":[0.99755967,0.0008976762,0.000424684,0.00030910733,0.000741906,0.00006697034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025301187,0.00019049596,0.0008586319,0.0002808773,0.000041113326,0.000008721349,0.00020813289,0.000113531074,0.000053385324],"category_scores_gemma":[0.0004485968,0.00013309442,0.00019361182,0.000624142,0.0002123264,0.00010985078,0.000055240285,0.0001844454,8.286508e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25804627,0.00793108,0.15395431,0.014258184,0.004337089,0.00045040128,0.04946206,0.011805091,0.30969802,0.014520738,0.014005106,0.16153166],"study_design_scores_gemma":[0.09180528,0.021175519,0.21116793,0.001546046,0.0007175532,0.000009360727,0.008084083,0.0022062873,0.615335,0.024236284,0.023006804,0.0007098846],"about_ca_topic_score_codex":0.0060930396,"about_ca_topic_score_gemma":0.008573607,"teacher_disagreement_score":0.30563694,"about_ca_system_score_codex":0.00013377846,"about_ca_system_score_gemma":0.0015722963,"threshold_uncertainty_score":0.92108935},"labels":[],"label_agreement":null},{"id":"W4389503869","doi":"10.1016/j.annonc.2023.10.123","title":"Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Sanofi Genzyme; Genentech; Castle Biosciences; Incyte; Array BioPharma; Regeneron Pharmaceuticals; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Interquartile range; Clinical endpoint; Internal medicine; Gastroenterology; Phases of clinical research; Progression-free survival; Surgery; Oncology; Toxicity; Adverse effect; Overall survival; Clinical trial","score_opus":0.07055745788880101,"score_gpt":0.35058588262845886,"score_spread":0.28002842473965783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389503869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973665,0.0006163745,0.00004485581,0.0004177493,0.000062146086,0.00016899344,0.00036929257,0.000008518434,0.0009456012],"genre_scores_gemma":[0.99873304,0.00011189024,0.00030971848,0.00019563027,0.000049051036,0.000051349558,0.00026660343,0.000020048366,0.00026269112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814,0.00018815415,0.00065193686,0.0004446718,0.00018612204,0.00038911184],"domain_scores_gemma":[0.9988735,0.00010887639,0.00031142696,0.00037731766,0.000252975,0.00007591762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006987621,0.00020601414,0.00066708913,0.000528336,0.000042259166,0.000003194105,0.00017928382,0.00014493203,0.000012675646],"category_scores_gemma":[0.00017700938,0.00017887846,0.00021009754,0.0011712862,0.00023076974,0.000005050126,0.00020320714,0.00011276997,0.0000042669935],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012863891,0.0041801604,0.031234989,0.00031969315,0.0025056389,0.0009065496,0.0048414147,0.0036509116,0.91932,0.000024720552,0.0074552926,0.012696772],"study_design_scores_gemma":[0.007077154,0.01765824,0.032155417,0.00003865165,0.0004709972,0.000004810378,0.0009436343,0.00036380274,0.9310925,0.000041730207,0.009773949,0.00037913947],"about_ca_topic_score_codex":0.00008585038,"about_ca_topic_score_gemma":0.000449193,"teacher_disagreement_score":0.01347808,"about_ca_system_score_codex":0.000013855063,"about_ca_system_score_gemma":0.00027229197,"threshold_uncertainty_score":0.72944516},"labels":[],"label_agreement":null},{"id":"W4389516743","doi":"10.1016/j.annonc.2023.11.001","title":"Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?","year":2023,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Quality of life (healthcare); Testicular cancer; Population; Adverse effect; Cancer; Gerontology; Pediatrics; Internal medicine; Environmental health","score_opus":0.09512432013891256,"score_gpt":0.4479649202640521,"score_spread":0.3528406001251395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389516743","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37253204,0.08979537,0.000009116846,0.0044093975,0.5286826,0.0026866759,0.0013138127,0.00010837817,0.0004626167],"genre_scores_gemma":[0.5345032,0.35929525,0.0005930671,0.0008951555,0.08968771,0.0006346922,0.008934639,0.00048195617,0.0049743303],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99609816,0.00044415155,0.0017271086,0.00050549227,0.00074583845,0.000479227],"domain_scores_gemma":[0.9953415,0.001194726,0.001966132,0.00059856183,0.0006222525,0.00027686366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011313831,0.00032510032,0.0023432276,0.0003953028,0.000030368305,0.000008200172,0.00022116542,0.0006814271,0.0001133296],"category_scores_gemma":[0.0016802552,0.00029949174,0.0003476511,0.0005827232,0.00025056856,0.000087718814,0.0001397564,0.00039861794,0.000016474238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020484142,0.005413439,0.20250398,0.017146565,0.0042864243,0.00080892065,0.00037612754,0.00011358579,0.000024110494,0.00007753707,0.74491084,0.022290045],"study_design_scores_gemma":[0.01812041,0.008271223,0.88952214,0.013606541,0.0018444728,0.0000038463336,0.00041662675,0.000037496717,0.00008773638,0.0004738248,0.06690167,0.0007140183],"about_ca_topic_score_codex":0.016476963,"about_ca_topic_score_gemma":0.005633627,"teacher_disagreement_score":0.68701816,"about_ca_system_score_codex":0.00019118324,"about_ca_system_score_gemma":0.0025918232,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W4389516746","doi":"10.1016/j.annonc.2023.09.3104","title":"Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; Jewish General Hospital","funders":"Foundation Medicine; EMD Serono; Eisai; Sanofi; Seagen; Pfizer; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Fulvestrant; Medicine; Tolerability; Metastatic breast cancer; Internal medicine; Palbociclib; Oncology; Aromatase inhibitor; Breast cancer; Estrogen receptor; Pharmacology; Cancer; Adverse effect; Tamoxifen","score_opus":0.13297165779521494,"score_gpt":0.45270710836088984,"score_spread":0.3197354505656749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389516746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92613524,0.0007519596,0.0010795747,0.06452105,0.0008843799,0.0032272444,0.0029900668,0.00012206767,0.0002884397],"genre_scores_gemma":[0.9900022,0.00048778424,0.003822147,0.0017618653,0.0014198459,0.0011696751,0.0009229024,0.00006312066,0.000350437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797916,0.0002945456,0.0006539547,0.00038821396,0.00029835434,0.00038575023],"domain_scores_gemma":[0.995493,0.003034315,0.0004770991,0.00040568502,0.00044866235,0.00014126493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011777219,0.00022980948,0.001065759,0.00009516345,0.00015188614,0.000008863858,0.00017518418,0.00008919129,0.00014460625],"category_scores_gemma":[0.00048835133,0.00013875478,0.00020215212,0.00036612235,0.00047300986,0.00014890787,0.00002921986,0.00016889643,0.0000058389755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84356254,0.0006603628,0.0000014476074,0.000020868973,0.0011998876,0.00007924461,0.0017637811,0.00039206687,0.0003866178,0.00016604141,0.00093571295,0.15083143],"study_design_scores_gemma":[0.95641035,0.021139698,0.00013696248,0.000095760166,0.0008502646,0.00008118761,0.0012796264,0.00078203966,0.0012840043,0.0012867852,0.016486935,0.00016637743],"about_ca_topic_score_codex":0.00072671525,"about_ca_topic_score_gemma":0.0006478629,"teacher_disagreement_score":0.15066504,"about_ca_system_score_codex":0.000056221033,"about_ca_system_score_gemma":0.0006287525,"threshold_uncertainty_score":0.5658256},"labels":[],"label_agreement":null},{"id":"W4391070551","doi":"10.1016/j.annonc.2024.01.003","title":"Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Response Biomedical (Canada)","funders":"Cancer Research UK; National Centre for the Replacement, Refinement and Reduction of Animals in Research; Memorial Sloan-Kettering Cancer Center; Engineering and Physical Sciences Research Council; AstraZeneca","keywords":"Medicine; Breast cancer; PARP inhibitor; Cancer research; Cancer; Genetics; Gene; Internal medicine; Biology; Polymerase; Poly ADP ribose polymerase","score_opus":0.07608235447031829,"score_gpt":0.43704381216784643,"score_spread":0.36096145769752813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391070551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97823155,0.009504773,0.000050729774,0.009501132,0.0005423102,0.00043716523,0.00029783318,0.000070705064,0.0013638207],"genre_scores_gemma":[0.9955194,0.0027193276,0.00041584412,0.0007049733,0.00021834458,0.00013448598,0.000037239257,0.000024451658,0.00022595136],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984484,0.00009241953,0.0005271579,0.00039576326,0.00022563568,0.00031067844],"domain_scores_gemma":[0.9990925,0.00026948488,0.00013516554,0.0001786881,0.00020402372,0.00012014213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004433015,0.00016609089,0.0004452591,0.00035002705,0.00008174784,0.000021793225,0.000068640315,0.0001410366,0.00021784347],"category_scores_gemma":[0.00007773587,0.00015953167,0.000087747045,0.00038183085,0.00025661846,0.00023612751,0.00004019838,0.00030963973,0.000011735516],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057096044,0.0012767772,0.21228765,0.0039824094,0.000992609,0.0020623822,0.0058996584,0.0006009632,0.4761111,0.003800058,0.041213673,0.24606308],"study_design_scores_gemma":[0.013231556,0.003472311,0.41414338,0.011841269,0.00047014814,0.00131473,0.005792987,0.000977476,0.37346256,0.00595662,0.16809408,0.0012428636],"about_ca_topic_score_codex":0.00021473983,"about_ca_topic_score_gemma":0.0002096586,"teacher_disagreement_score":0.24482022,"about_ca_system_score_codex":0.00017798951,"about_ca_system_score_gemma":0.000507926,"threshold_uncertainty_score":0.65055126},"labels":[],"label_agreement":null},{"id":"W4391447886","doi":"10.1016/j.annonc.2023.11.015","title":"ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"PharmaMar; European Society for Medical Oncology; National Institute for Health and Care Research; Novocure; AstraZeneca","keywords":"Medicine; Consensus conference; Voting; Disease; Ovarian cancer; Stage (stratigraphy); Family medicine; MEDLINE; Oncology; Gynecology; Internal medicine; Cancer; Political science","score_opus":0.07204614253490907,"score_gpt":0.4331132394768885,"score_spread":0.36106709694197947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391447886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82322484,0.019367518,0.000046771238,0.15537702,0.0003564098,0.00040151153,0.00021697671,0.000027991222,0.000980988],"genre_scores_gemma":[0.9738629,0.023341341,0.0006798161,0.0018461975,0.000045616252,0.00013123272,0.000030495572,0.000013660956,0.000048773778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989131,0.00013202165,0.0002540614,0.000435678,0.00005095861,0.00021414658],"domain_scores_gemma":[0.9991126,0.00031186757,0.000080139595,0.00016516885,0.00009991621,0.00023031484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015452623,0.00015789169,0.00041969505,0.00013816687,0.000048852875,0.000012828736,0.00003062223,0.00011693929,0.00007866422],"category_scores_gemma":[0.00008922681,0.00013281038,0.00004166291,0.00008641531,0.00033649837,0.000024613553,0.000055368353,0.00015541277,0.0000025321801],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008225567,0.00040662207,0.02057239,0.0002037892,0.00034192647,0.00095561857,0.00044821092,0.0000014047948,0.0015361543,0.06591321,0.002696986,0.9061011],"study_design_scores_gemma":[0.009618791,0.023820704,0.4428294,0.0017386483,0.0011624983,0.00054026634,0.0002819992,0.00039003024,0.004090806,0.037936512,0.47692585,0.00066449214],"about_ca_topic_score_codex":0.00011833426,"about_ca_topic_score_gemma":0.000055376266,"teacher_disagreement_score":0.90543664,"about_ca_system_score_codex":0.00003279884,"about_ca_system_score_gemma":0.00026025163,"threshold_uncertainty_score":0.541585},"labels":[],"label_agreement":null},{"id":"W4391933719","doi":"10.1016/j.annonc.2024.02.005","title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AstraZeneca; AstraZeneca United States","keywords":"Durvalumab; Tremelimumab; Medicine; Sorafenib; Hepatocellular carcinoma; Oncology; Internal medicine; Confidence interval; Cancer; Immunotherapy; Nivolumab","score_opus":0.1856405556875463,"score_gpt":0.3639313170887483,"score_spread":0.178290761401202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391933719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845005,0.00456132,0.00001335327,0.0025061865,0.00036714357,0.0013644455,0.00009348393,0.000041804695,0.0026022366],"genre_scores_gemma":[0.99857455,0.0004185324,0.00006726886,0.00020608095,0.00019663773,0.00009380313,0.00013024225,0.00004596997,0.00026688754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719965,0.00054590194,0.0008263083,0.0005039022,0.0004648071,0.00045941063],"domain_scores_gemma":[0.99825156,0.000646563,0.00017768606,0.0005943755,0.0001954996,0.0001343369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009891754,0.00028817507,0.00108612,0.00024737237,0.000055325912,0.000019093804,0.00026796866,0.00020842312,0.00057951995],"category_scores_gemma":[0.00010350804,0.0002092531,0.0002819186,0.00047804316,0.00013186155,0.00011317641,0.00013945626,0.00036992715,0.00004244277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053835036,0.0042861463,0.95942235,0.00013741989,0.0009830174,0.003717398,0.0055469745,0.000008575412,0.0034656082,0.00039905516,0.0032222993,0.0134276785],"study_design_scores_gemma":[0.2213405,0.09702021,0.38862118,0.0013122383,0.004966016,0.00021251816,0.017488107,0.0835152,0.0672627,0.0030970231,0.11324242,0.0019218869],"about_ca_topic_score_codex":0.009642097,"about_ca_topic_score_gemma":0.0010074531,"teacher_disagreement_score":0.57080114,"about_ca_system_score_codex":0.00012715667,"about_ca_system_score_gemma":0.00060244557,"threshold_uncertainty_score":0.9969528},"labels":[],"label_agreement":null},{"id":"W4392126555","doi":"10.1016/j.annonc.2024.02.008","title":"Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Cancer Care Ontario; Public Health Ontario; University of Toronto","funders":"World Cancer Research Fund; Medical Research Council; National Cancer Institute; Institut National Du Cancer; Cancer Research UK; National Institute for Health and Care Research; NIHR Bristol Biomedical Research Centre; World Cancer Research Fund International; World Health Organization","keywords":"Mendelian randomization; Medicine; Genome-wide association study; Colorectal cancer; Mendelian inheritance; Cancer; Genetics; Oncology; Genome; Bioinformatics; Computational biology; Internal medicine; Single-nucleotide polymorphism; Gene; Genotype; Biology; Genetic variants","score_opus":0.1873812868257303,"score_gpt":0.482984723040963,"score_spread":0.2956034362152327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392126555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08350324,0.91306466,0.0000018408894,0.001286937,0.00050203304,0.0014181338,0.000038558308,0.000018318071,0.00016626627],"genre_scores_gemma":[0.050022867,0.94868666,0.00006253412,0.0002760871,0.00016939313,0.0004403376,0.000039722854,0.000039110713,0.00026329406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974249,0.0005725512,0.001025768,0.00038278542,0.00036017227,0.00023385129],"domain_scores_gemma":[0.994842,0.0029845324,0.0011363396,0.0002106951,0.0007565893,0.000069846334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007049883,0.00034549757,0.002750629,0.00037451094,0.000063573534,0.000011876513,0.00015002034,0.00043587084,0.000024916035],"category_scores_gemma":[0.0027223316,0.00019673073,0.00037657167,0.0005816948,0.00030836547,0.000042499454,0.00016054677,0.00036307058,0.000004778121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00220662,0.00033811718,0.008345729,0.06823316,0.029841667,0.000064199165,0.022884725,0.000046259156,0.00037535213,0.000024864486,0.02422001,0.8434193],"study_design_scores_gemma":[0.0015155327,0.003109027,0.0021743018,0.0063246014,0.011978922,0.000013759868,0.00045291035,0.000006326057,0.0009814438,0.0004605316,0.97268236,0.0003002883],"about_ca_topic_score_codex":0.00037723946,"about_ca_topic_score_gemma":0.0013944805,"teacher_disagreement_score":0.94846237,"about_ca_system_score_codex":0.0005043506,"about_ca_system_score_gemma":0.0015385277,"threshold_uncertainty_score":0.80224466},"labels":[],"label_agreement":null},{"id":"W4393970251","doi":"10.1016/j.annonc.2024.03.010","title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Queen's University; University Health Network","funders":"Medical Research Council; Canadian Cancer Society; National Institute for Health and Care Research; Cancer Research UK; UK Research and Innovation; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Prostatectomy; Radical; Urology; Radiation therapy; Term (time); Oncology; Prostate cancer; Internal medicine; Surgery; Cancer","score_opus":0.09636248618612947,"score_gpt":0.4377302419021084,"score_spread":0.34136775571597894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393970251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95881563,0.013721,0.00002932607,0.024453282,0.00043291674,0.0015971581,0.000036709884,0.000026888885,0.0008871079],"genre_scores_gemma":[0.9911758,0.0049836114,0.0002153127,0.0026881853,0.0002451275,0.00050929986,0.000022009819,0.00002728492,0.00013341825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981277,0.00020985113,0.0006709315,0.0003240992,0.00031615008,0.0003512933],"domain_scores_gemma":[0.9986862,0.00069959805,0.00012786356,0.000327011,0.00005960815,0.00009972647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007636173,0.00020266855,0.0008559641,0.00021483029,0.00002142684,0.000014819118,0.00015488894,0.00017881373,0.00042887387],"category_scores_gemma":[0.000087961045,0.00011954552,0.00030613714,0.00023340998,0.0003325802,0.00007069133,0.000031645304,0.00027882657,0.0000094849],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06937909,0.010234632,0.3229037,0.0015575966,0.002698779,0.0065452023,0.008463794,0.000008348395,0.001132592,0.001291435,0.020773932,0.5550109],"study_design_scores_gemma":[0.11610702,0.04144094,0.6873484,0.0017652287,0.0006970567,0.0003711744,0.00024396791,0.00015715192,0.014711046,0.0010156939,0.13559619,0.0005461409],"about_ca_topic_score_codex":0.000052349693,"about_ca_topic_score_gemma":0.00002594586,"teacher_disagreement_score":0.55446476,"about_ca_system_score_codex":0.00011855969,"about_ca_system_score_gemma":0.00043768907,"threshold_uncertainty_score":0.48749247},"labels":[],"label_agreement":null},{"id":"W4396732203","doi":"10.1016/j.annonc.2024.04.013","title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"Sanofi Genzyme; Gilead Sciences; Sanofi; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Nonsteroidal; Aromatase inhibitor; Aromatase; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.10355764462433985,"score_gpt":0.4507032766043178,"score_spread":0.34714563197997794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396732203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699497,0.006044035,0.00015426046,0.016609192,0.0010126946,0.0011089736,0.003995148,0.000096662916,0.0010292949],"genre_scores_gemma":[0.9940402,0.0015698968,0.0011853217,0.0012661426,0.00092602364,0.00026540647,0.0002316016,0.00006865562,0.00044675503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761707,0.00011418178,0.00082726707,0.0005368493,0.0003815709,0.00052306673],"domain_scores_gemma":[0.9980429,0.0005983115,0.00030365074,0.00038373054,0.0004929525,0.00017850245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045763326,0.00030619308,0.00097467296,0.00023674581,0.00005128216,0.000009920001,0.00020075748,0.00022502281,0.00015120069],"category_scores_gemma":[0.000094624316,0.0002667698,0.00029716163,0.00026371397,0.00039797803,0.00020993373,0.00006935806,0.0002962928,0.000014811579],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12974697,0.0009944886,0.0004032942,0.0007694232,0.0007908566,0.00030532226,0.0018215142,0.00025375804,0.05634258,0.00075923867,0.0033897758,0.8044228],"study_design_scores_gemma":[0.08314753,0.040765963,0.017282786,0.0030758132,0.00031995118,0.001933855,0.0012366142,0.001140657,0.25436413,0.008231947,0.58727336,0.0012273823],"about_ca_topic_score_codex":0.00040827345,"about_ca_topic_score_gemma":0.00010133577,"teacher_disagreement_score":0.8031954,"about_ca_system_score_codex":0.00013279184,"about_ca_system_score_gemma":0.0015382572,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W4396921377","doi":"10.1016/j.annonc.2024.04.001","title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; Daiichi Sankyo Europe; Gilead Sciences; Servier; Seagen; Genentech; Veracyte; Jazz Pharmaceuticals; Ipsen; Queen Mary University of London; Clovis Oncology; Eisai; Natera; Baxalta; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Amgen; Breast Cancer Research Foundation; Ariad Pharmaceuticals; Bayer HealthCare; Sanofi; Stryker; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Triple-negative breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Chemotherapy; Double blind; Breast cancer; Cancer; Immunotherapy; Placebo; Pathology","score_opus":0.09997999724582605,"score_gpt":0.4500273928235163,"score_spread":0.3500473955776902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396921377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799965,0.0019661675,0.0025256404,0.0057564448,0.0007359181,0.008034606,0.00024797785,0.00006328493,0.00067347905],"genre_scores_gemma":[0.98908395,0.0026423084,0.002110794,0.0006587532,0.00024171175,0.001188832,0.000029074794,0.000079557205,0.003965039],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99777,0.00012625319,0.0009354115,0.0004175327,0.0003207415,0.0004300482],"domain_scores_gemma":[0.9977302,0.00081056927,0.00051432115,0.00027408585,0.0005310642,0.00013978098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083002314,0.00029852698,0.001460096,0.00028249098,0.000075822405,0.00002089472,0.00014388694,0.00016174403,0.0008402985],"category_scores_gemma":[0.000083592786,0.00016850738,0.0003249732,0.00067958207,0.00035204296,0.00021242257,0.00001668013,0.00020785387,0.0000010126603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77873176,0.0010128669,0.000008121407,0.0003637357,0.002166163,0.000046499135,0.0012267035,0.000010936909,0.015528261,0.000015859676,0.0015265925,0.1993625],"study_design_scores_gemma":[0.89051795,0.04454109,0.000028505028,0.0012898422,0.0005448023,0.00013913114,0.00044426034,0.0005438744,0.05362711,0.00006422933,0.00804388,0.00021533323],"about_ca_topic_score_codex":0.0008285587,"about_ca_topic_score_gemma":0.0004939258,"teacher_disagreement_score":0.19914716,"about_ca_system_score_codex":0.0001499349,"about_ca_system_score_gemma":0.0032109544,"threshold_uncertainty_score":0.9200679},"labels":[],"label_agreement":null},{"id":"W4396946482","doi":"10.1016/j.annonc.2024.05.001","title":"Reply to ‘Letter to the Editor regarding “Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]”, by C. C. Parker et al.’","year":2024,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"Medical Research Council; Cancer Research UK","keywords":"Medicine; Prostatectomy; Radical; Term (time); Radiation therapy; Urology; Oncology; Internal medicine; Prostate cancer; Cancer","score_opus":0.05923096535786286,"score_gpt":0.39959865739715494,"score_spread":0.34036769203929207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396946482","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039691597,0.0042840713,0.000034556087,0.94577485,0.0043954104,0.0051612076,0.00032903327,0.00003516504,0.00029408885],"genre_scores_gemma":[0.009276965,0.001820048,0.0002606048,0.9732952,0.010852422,0.0034473666,0.00019430846,0.000129046,0.0007240153],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947528,0.0009059145,0.001437951,0.0010068843,0.0010144054,0.0008819921],"domain_scores_gemma":[0.9961871,0.0018332597,0.00043974607,0.0011799247,0.00017067385,0.00018932951],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023272068,0.0006454655,0.0020512438,0.00042426115,0.000057532015,0.00006439397,0.00061154756,0.00067088474,0.00027113312],"category_scores_gemma":[0.0003795166,0.00034810774,0.0006994151,0.00039842632,0.0003276242,0.00007991589,0.00017174911,0.0019920233,0.00003461891],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010800391,0.0006320661,0.0026914657,0.00026635412,0.0010674001,0.00185342,0.0014979606,0.0000019182223,0.000052839165,0.000003499258,0.9734633,0.0076693753],"study_design_scores_gemma":[0.01285484,0.00650942,0.0024559388,0.0009092347,0.00031695975,0.00006242991,0.000027788104,0.0000022677043,0.0005282657,0.000024716903,0.9759888,0.00031931425],"about_ca_topic_score_codex":0.00015655653,"about_ca_topic_score_gemma":0.000029614639,"teacher_disagreement_score":0.030414633,"about_ca_system_score_codex":0.0003392654,"about_ca_system_score_gemma":0.0005075714,"threshold_uncertainty_score":0.99989706},"labels":[],"label_agreement":null},{"id":"W4398194425","doi":"10.1016/j.annonc.2024.03.005","title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sirtex Medical; Ipsen; Boston Scientific Corporation; Incyte; Eisai; AstraZeneca; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Tolerability; Sorafenib; Internal medicine; Adverse effect; Hepatocellular carcinoma; Regimen; Oncology; Surgery; Gastroenterology; Immunotherapy; Cancer","score_opus":0.06001887754482442,"score_gpt":0.2881822019860163,"score_spread":0.22816332444119186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398194425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366325,0.0017316879,0.000009617548,0.00094796455,0.00006632359,0.001772096,0.00010314169,0.00010789791,0.0015980247],"genre_scores_gemma":[0.9973185,0.0005035309,0.00035633563,0.00013602817,0.000037932175,0.00012794769,0.0011620222,0.0000659986,0.0002917165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787813,0.00018120467,0.00055998197,0.00059199636,0.00036091363,0.00042776798],"domain_scores_gemma":[0.9987256,0.00016282528,0.0002013264,0.0004129847,0.00035098035,0.00014626756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026658984,0.00032533152,0.0007820011,0.00030150043,0.000045219105,0.00002067729,0.00011803115,0.00023107677,0.00006492582],"category_scores_gemma":[0.00003482957,0.00023234774,0.00011896427,0.00053549366,0.00013361387,0.00018354347,0.00002722824,0.00024812555,0.000031105228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023214918,0.0013867966,0.9273695,0.000091560345,0.00037818195,0.0006957904,0.0014126331,0.0000058445767,0.00032551456,0.000058791804,0.00020107033,0.044859447],"study_design_scores_gemma":[0.077360205,0.05414954,0.8260665,0.0008830903,0.00035990553,0.00001617008,0.00021086165,0.0046765446,0.029453399,0.00013857552,0.006133746,0.0005514863],"about_ca_topic_score_codex":0.0008935058,"about_ca_topic_score_gemma":0.000103032275,"teacher_disagreement_score":0.10130298,"about_ca_system_score_codex":0.00020750982,"about_ca_system_score_gemma":0.00044569,"threshold_uncertainty_score":0.9474866},"labels":[],"label_agreement":null},{"id":"W4399422624","doi":"10.1016/j.annonc.2024.06.001","title":"Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"KWF Kankerbestrijding; Roche; Roche Canada","keywords":"Medicine; Colorectal cancer; Danish; Resection; Oncology; Cancer; Internal medicine; Surgery","score_opus":0.027063546621783476,"score_gpt":0.3477407264470648,"score_spread":0.3206771798252813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399422624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97300875,0.01289826,0.0000024960932,0.0033480977,0.00189291,0.0077496716,0.00031344272,0.000033882476,0.00075246673],"genre_scores_gemma":[0.9913103,0.002853051,0.0000067774918,0.00032286855,0.00016950305,0.0051378096,0.000044561784,0.00004461294,0.00011051663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958104,0.001515016,0.00088413333,0.00060068036,0.00068784464,0.0005019209],"domain_scores_gemma":[0.9962863,0.0022588319,0.0005867104,0.00027576365,0.0005125342,0.00007987504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001647515,0.00043286613,0.0016007333,0.00012433481,0.00047584545,0.000042660056,0.00028360263,0.00011007099,0.00011952039],"category_scores_gemma":[0.0003260864,0.00018098952,0.0002623017,0.0008003795,0.0020015885,0.00015498124,0.00021372002,0.00064950733,7.87273e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92732257,0.0034669566,0.021905126,0.00024496738,0.0076930425,0.000046874793,0.013666578,0.000056646557,0.002486574,0.00008868008,0.0066449903,0.016377024],"study_design_scores_gemma":[0.6682403,0.06419224,0.2421754,0.00065546803,0.0061580706,0.000061436585,0.008898479,0.001357784,0.004499483,0.00008767238,0.0030903697,0.000583295],"about_ca_topic_score_codex":0.039436825,"about_ca_topic_score_gemma":0.10509035,"teacher_disagreement_score":0.25908223,"about_ca_system_score_codex":0.0009112704,"about_ca_system_score_gemma":0.0008246085,"threshold_uncertainty_score":0.96695966},"labels":[],"label_agreement":null},{"id":"W4399508081","doi":"10.1016/j.annonc.2024.05.546","title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University; McGill University Health Centre","funders":"GlaxoSmithKline","keywords":"Carboplatin; Medicine; Paclitaxel; Endometrial cancer; Interim analysis; Oncology; Internal medicine; Clinical endpoint; Placebo; Randomized controlled trial; Chemotherapy; Progression-free survival; Cancer; Cisplatin; Pathology","score_opus":0.0592321863011588,"score_gpt":0.3677798019540875,"score_spread":0.3085476156529287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399508081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98506004,0.0018933086,0.000004672616,0.0026147673,0.0005187427,0.003513962,0.00011443568,0.000033104065,0.0062469547],"genre_scores_gemma":[0.9973784,0.0006187076,0.00005566847,0.0006198307,0.00039854695,0.0006195605,0.00011342766,0.00003505782,0.00016080344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965968,0.0008661665,0.00083128666,0.00047821892,0.00071009225,0.00051742996],"domain_scores_gemma":[0.99586034,0.0032799589,0.00023541703,0.00029476848,0.00020624188,0.00012327752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014503727,0.00033586242,0.0018888158,0.0006735148,0.00003420313,0.000026487198,0.00017647655,0.00022499019,0.00025608423],"category_scores_gemma":[0.00070854835,0.00016941209,0.00025013924,0.0016385338,0.00023900106,0.00012361327,0.00003715183,0.00047860126,0.0000064161854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9594922,0.0015673338,0.01924688,0.000092527465,0.0008668563,0.00029901898,0.0012537036,0.00003744314,0.000014559897,0.0002593459,0.00019680659,0.016673326],"study_design_scores_gemma":[0.9505704,0.018481662,0.027205829,0.00026737072,0.00048326037,0.0000058550954,0.00015979119,0.0000552586,0.00013575761,0.00017041432,0.0022568647,0.00020755793],"about_ca_topic_score_codex":0.0084714675,"about_ca_topic_score_gemma":0.0023480796,"teacher_disagreement_score":0.016914329,"about_ca_system_score_codex":0.000336326,"about_ca_system_score_gemma":0.0007553786,"threshold_uncertainty_score":0.9981312},"labels":[],"label_agreement":null},{"id":"W4399795849","doi":"10.1016/j.annonc.2024.06.010","title":"Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia; Queen's University","funders":"Unicancer; Canceropôle Provence-Alpes-Côte d’Azur; National Cancer Institute; Institut National Du Cancer; Canceropôle PACA; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Fondation ARC pour la Recherche sur le Cancer; Fondation Aix-Marseille Universite","keywords":"Gemcitabine; FOLFIRINOX; Medicine; Pancreatic ductal adenocarcinoma; Oncology; Regimen; Chemotherapy; Internal medicine; Pancreatic cancer; Adenocarcinoma; Chemotherapy regimen; Adjuvant; Adjuvant chemotherapy; Cancer; Oxaliplatin; Breast cancer","score_opus":0.050352788328646425,"score_gpt":0.36630007902811496,"score_spread":0.31594729069946853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399795849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356854,0.0017746475,0.0000583606,0.0033620181,0.000037077087,0.00060170365,0.000010163184,0.000012606973,0.0005749033],"genre_scores_gemma":[0.9962924,0.000112578266,0.002687558,0.0006585629,0.000020170168,0.00004168761,0.00003222066,0.000016256792,0.00013856514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880946,0.0000863207,0.00037647685,0.00024370503,0.00025414597,0.00022986565],"domain_scores_gemma":[0.99939007,0.00014946345,0.000057441353,0.000110276,0.00018135252,0.00011140374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035203918,0.00012817413,0.0006406744,0.00031257438,0.000020056023,0.000004666532,0.00006111397,0.00014293658,0.00010264385],"category_scores_gemma":[0.00005337745,0.00009527819,0.00004055487,0.00026529998,0.00013846972,0.00005071988,0.000015857842,0.00018912036,0.0000038468174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041697747,0.00080837373,0.9464981,0.00058733666,0.00049374014,0.00009056774,0.008263357,0.0000019867834,0.0058564073,0.00023749794,0.00083855784,0.032154292],"study_design_scores_gemma":[0.0031089473,0.004237964,0.9832044,0.0003615483,0.000102178834,0.000020146403,0.00029954186,0.00006058397,0.006612242,0.000047706424,0.0018537152,0.00009098529],"about_ca_topic_score_codex":0.000058902708,"about_ca_topic_score_gemma":0.000039790822,"teacher_disagreement_score":0.036706332,"about_ca_system_score_codex":0.0000774464,"about_ca_system_score_gemma":0.00066882774,"threshold_uncertainty_score":0.3885332},"labels":[],"label_agreement":null},{"id":"W4399865048","doi":"10.1016/j.annonc.2024.06.009","title":"Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Health and Medical Research Council; Medical Research Council; European Society for Medical Oncology; National Breast Cancer Foundation; Peter MacCallum Cancer Centre; Associazione Italiana per la Ricerca sul Cancro; Korea Health Industry Development Institute; National Institutes of Health; Cancer Australia","keywords":"Medicine; Breast cancer; Hormone receptor; Oncology; Internal medicine; Hormone; Cancer; Receptor; Cancer research","score_opus":0.019215708912494845,"score_gpt":0.36121635729199847,"score_spread":0.3420006483795036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399865048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98178715,0.016440762,0.0000075739395,0.00034866255,0.00014616389,0.00009208331,0.0006627084,0.000002702867,0.00051220524],"genre_scores_gemma":[0.9943551,0.005329649,0.0001247945,0.000030568914,0.000060189417,0.000015581823,0.000024065912,0.00001311589,0.00004697053],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99925846,0.00005066625,0.00025921385,0.0001894559,0.00006553293,0.00017665827],"domain_scores_gemma":[0.99952096,0.000025038258,0.00010793058,0.00013687597,0.00016059732,0.0000485881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001622807,0.000088843444,0.00022772918,0.00010078375,0.000008541345,0.0000028639488,0.00007607659,0.000107683394,0.00005830327],"category_scores_gemma":[0.000040593615,0.00008086835,0.00007612422,0.00016272596,0.000211425,0.000005012476,0.000050231884,0.000065879445,4.8818674e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051445153,0.00008508373,0.102481015,0.00008124259,0.0003039733,0.000003404334,0.00060507626,0.00030138416,0.8671746,0.000060025184,0.0076679424,0.020721767],"study_design_scores_gemma":[0.0008636566,0.0029149763,0.73925835,0.00006714019,0.00004614397,0.000041838204,0.0003736324,0.000095027375,0.24860938,0.00016533372,0.007365471,0.00019906918],"about_ca_topic_score_codex":0.0016831027,"about_ca_topic_score_gemma":0.00075650157,"teacher_disagreement_score":0.63677734,"about_ca_system_score_codex":0.000056933102,"about_ca_system_score_gemma":0.0009029115,"threshold_uncertainty_score":0.32977155},"labels":[],"label_agreement":null},{"id":"W4400029468","doi":"10.1016/j.annonc.2024.05.541","title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; McGill University","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Genentech; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; MacroGenics; Plexxikon; BeiGene; Mirati Therapeutics; Yuhan; Mersana Therapeutics; PharmaMar; LAM Therapeutics; Astex Pharmaceuticals; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; LG Chem; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Osimertinib; Oncology; Lung cancer; Internal medicine; Mutant; Disease; Cancer research; Cancer; Epidermal growth factor receptor; Genetics; Gene","score_opus":0.020748794662583826,"score_gpt":0.36457837862506415,"score_spread":0.3438295839624803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400029468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790969,0.013127016,0.00026276734,0.0036684533,0.0003427613,0.00067143486,0.0014179401,0.00003589046,0.001376827],"genre_scores_gemma":[0.99381846,0.0040777707,0.00093793025,0.00023698689,0.00006785315,0.00017570992,0.000474117,0.00003465063,0.00017653254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982751,0.00007074852,0.0006057326,0.00049878657,0.00021880034,0.0003308485],"domain_scores_gemma":[0.99849886,0.00043846678,0.0003095436,0.00037110335,0.00018151429,0.00020049798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014203285,0.00024659952,0.00087938,0.00046565125,0.000043752072,0.000008926477,0.00012051692,0.00012625082,0.0005577916],"category_scores_gemma":[0.000046715228,0.00019043036,0.0002409027,0.0010521022,0.00013723124,0.000095065734,0.000051878647,0.0002168428,0.0000040430064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079843365,0.004727245,0.4889849,0.0029922833,0.066840656,0.004617609,0.009016537,0.028280687,0.0054892446,0.0001366936,0.004780819,0.30428994],"study_design_scores_gemma":[0.062363643,0.010827235,0.8057357,0.002110243,0.04532471,0.000009846237,0.0019495962,0.03401275,0.021038521,0.00023833306,0.015449554,0.0009398815],"about_ca_topic_score_codex":0.011281971,"about_ca_topic_score_gemma":0.009625205,"teacher_disagreement_score":0.31675076,"about_ca_system_score_codex":0.00028986606,"about_ca_system_score_gemma":0.0017393086,"threshold_uncertainty_score":0.99530196},"labels":[],"label_agreement":null},{"id":"W4400142788","doi":"10.1016/j.annonc.2024.05.217","title":"209P Setup of hepatocellular carcinoma (HCC) multidisciplinary teams (MDTs) demonstrate multi-faceted similarities and differences across US, Canada and Europe","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Multidisciplinary approach; Oncology; Internal medicine","score_opus":0.05074467196765786,"score_gpt":0.39090811561977823,"score_spread":0.34016344365212037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400142788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758528,0.020553354,0.000093559414,0.0022549983,0.00039074902,0.00026485397,0.00018207297,0.000024389057,0.0003832459],"genre_scores_gemma":[0.9897454,0.0071564,0.0016333438,0.00049206446,0.000091368864,0.000011375864,0.000018813289,0.000020902247,0.00083035935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986428,0.00014126458,0.00042238596,0.00033525104,0.00013430488,0.0003240014],"domain_scores_gemma":[0.9989637,0.00044007125,0.00013411704,0.00017504038,0.00014727426,0.00013976952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029417215,0.0002001708,0.0007146982,0.00007063257,0.000108961685,0.0000070847814,0.00009866525,0.00022294557,0.00004165322],"category_scores_gemma":[0.00008920332,0.00015686652,0.000050903724,0.00015314676,0.0011312327,0.00008367899,0.00009526253,0.0003000676,7.2036397e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004939123,0.00025645972,0.95594,0.00084297895,0.0003085007,0.0011199964,0.001894483,0.000006922679,0.009921092,0.0001223878,0.0018858425,0.02720742],"study_design_scores_gemma":[0.0032291682,0.0057528424,0.92284346,0.0004318113,0.00016969616,0.0008888435,0.0025857426,0.0101256175,0.015225808,0.00029095405,0.03805643,0.00039961765],"about_ca_topic_score_codex":0.019715063,"about_ca_topic_score_gemma":0.049957577,"teacher_disagreement_score":0.036170587,"about_ca_system_score_codex":0.000039788953,"about_ca_system_score_gemma":0.0008284756,"threshold_uncertainty_score":0.9868127},"labels":[],"label_agreement":null},{"id":"W4400142790","doi":"10.1016/j.annonc.2024.05.192","title":"183P Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Liver transplantation; Oncology; Internal medicine; Transplantation","score_opus":0.19918416431062932,"score_gpt":0.3632135857573097,"score_spread":0.1640294214466804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400142790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862941,0.008997027,0.0005110534,0.0011805415,0.00037003125,0.0007186463,0.00014400877,0.000028645369,0.0017559389],"genre_scores_gemma":[0.9961217,0.0017095468,0.0014298322,0.000107551044,0.000116147006,0.00017768465,0.00016407402,0.000021482016,0.00015196724],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989065,0.00006482073,0.00038792685,0.00026064354,0.00015366227,0.00022642969],"domain_scores_gemma":[0.9990434,0.00039139076,0.00009062313,0.00016937676,0.0002227418,0.00008248821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002839314,0.00014763791,0.0004156144,0.0001712464,0.000021061755,0.000005115255,0.00006640972,0.00017719377,0.0001744471],"category_scores_gemma":[0.000047081987,0.00012999617,0.0002804115,0.00018354038,0.000111942216,0.00008054871,0.000011831571,0.00010210947,0.000020817159],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019747905,0.0014288217,0.60937756,0.009501673,0.0011123919,0.0038815876,0.0067713335,0.0000010893297,0.012189906,0.0042045047,0.0053019715,0.32648125],"study_design_scores_gemma":[0.0150909275,0.042325605,0.061197065,0.0013362175,0.0034252354,0.00028639092,0.00042270156,0.015261889,0.6947461,0.001197092,0.16395369,0.0007571104],"about_ca_topic_score_codex":0.00008060641,"about_ca_topic_score_gemma":0.00001806307,"teacher_disagreement_score":0.68255615,"about_ca_system_score_codex":0.000026238931,"about_ca_system_score_gemma":0.000269617,"threshold_uncertainty_score":0.530109},"labels":[],"label_agreement":null},{"id":"W4400143109","doi":"10.1016/j.annonc.2024.05.185","title":"176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; National Natural Science Foundation of China; Sierra Oncology; Incyte; Ipsen; BeiGene; Eisai; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Astellas Pharma; Novocure; Boston Scientific Corporation; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Lenvatinib; Medicine; Hepatocellular carcinoma; Pharmacodynamics; Open label; Oncology; Pharmacology; Internal medicine; Sorafenib; Pharmacokinetics; Clinical trial","score_opus":0.23385400126100925,"score_gpt":0.4176022382086809,"score_spread":0.18374823694767167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400143109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993682,0.0017057888,0.000014304927,0.000998994,0.00009260402,0.002931015,0.000049498132,0.00002684474,0.0004989212],"genre_scores_gemma":[0.9985512,0.00024893932,0.00034519273,0.00017753508,0.00003072859,0.00023827334,0.0002770412,0.000051731164,0.00007938046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971525,0.00048358756,0.0009874249,0.0005877417,0.00032694812,0.0004617867],"domain_scores_gemma":[0.9988214,0.00021828042,0.00022575399,0.00036374776,0.0002228961,0.000147942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009672995,0.0003231821,0.0010602899,0.0009374632,0.000026646743,0.000023496546,0.0003009763,0.00018679781,0.000067044515],"category_scores_gemma":[0.000051783885,0.0002926451,0.000056486282,0.0010998513,0.0001280642,0.0004366569,0.00014455811,0.0004404688,0.0000061582477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034162325,0.026966786,0.91484904,0.00031887164,0.00014554989,0.005066281,0.0038286175,0.000010801906,0.009659829,0.00014762406,0.00007967926,0.035510685],"study_design_scores_gemma":[0.10107542,0.117319845,0.5441982,0.0008403378,0.0004805204,0.0001136929,0.0021945406,0.21070096,0.02131062,0.00025283775,0.00085568405,0.00065731304],"about_ca_topic_score_codex":0.0027414865,"about_ca_topic_score_gemma":0.002972517,"teacher_disagreement_score":0.3706508,"about_ca_system_score_codex":0.00018637873,"about_ca_system_score_gemma":0.0004474926,"threshold_uncertainty_score":0.99995255},"labels":[],"label_agreement":null},{"id":"W4400143131","doi":"10.1016/j.annonc.2024.05.176","title":"167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)","year":2024,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Sirtex Medical; Ipsen; Astellas Pharma; Eisai; Incyte; Boston Scientific Corporation; Gilead Sciences; Exelixis; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Durvalumab; Tremelimumab; Medicine; Hepatocellular carcinoma; Internal medicine; Carcinoma; Oncology; Gastroenterology; Immunotherapy; Cancer; Nivolumab","score_opus":0.12718031131586122,"score_gpt":0.3652423502696358,"score_spread":0.2380620389537746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400143131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337862,0.05438083,0.000020368465,0.0027479606,0.0021778112,0.0028766496,0.00013073222,0.000023538978,0.003855884],"genre_scores_gemma":[0.9951862,0.0014346838,0.000048577942,0.00013534309,0.00038410383,0.0001909358,0.00006407961,0.00007967812,0.0024763634],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9938036,0.0015731482,0.0021189752,0.0008248663,0.0005882023,0.0010911975],"domain_scores_gemma":[0.996779,0.0009025773,0.0006316906,0.001010037,0.0004475006,0.000229166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020924315,0.0005775809,0.0024196617,0.0007281981,0.00008689859,0.0000127673975,0.0006069164,0.0007476842,0.0008222275],"category_scores_gemma":[0.00023314556,0.00046648347,0.0007206171,0.0013642441,0.0008949363,0.0001832821,0.00036119073,0.00079665077,0.00004189503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005537551,0.01627124,0.8864636,0.0022369442,0.0017140924,0.0036980638,0.01598599,0.00005252406,0.019820167,0.0012876454,0.0027320383,0.044200163],"study_design_scores_gemma":[0.13831185,0.20134337,0.18787877,0.0044112117,0.0074584465,0.0006878583,0.017879216,0.14127825,0.25420514,0.0017131171,0.04300774,0.0018250322],"about_ca_topic_score_codex":0.013019422,"about_ca_topic_score_gemma":0.0013302293,"teacher_disagreement_score":0.6985848,"about_ca_system_score_codex":0.0003958232,"about_ca_system_score_gemma":0.002056094,"threshold_uncertainty_score":0.9997787},"labels":[],"label_agreement":null},{"id":"W4400143369","doi":"10.1016/j.annonc.2024.05.186","title":"177P Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A meta-analysis and systematic review","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; National Natural Science Foundation of China; Sierra Oncology; Incyte; Ipsen; BeiGene; Eisai; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Astellas Pharma; Novocure; Boston Scientific Corporation; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Sanming Project of Medicine in Shenzhen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Meta-analysis; Oncology; Radiology; Internal medicine","score_opus":0.15456416381730034,"score_gpt":0.33642400701898,"score_spread":0.18185984320167967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400143369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9027691,0.04856357,0.021091804,0.010101557,0.00035884103,0.015839368,0.00035686148,0.0002542076,0.00066472363],"genre_scores_gemma":[0.9951299,0.0010028266,0.00074448896,0.0003544522,0.00008040247,0.0013864236,0.0010697431,0.000069678725,0.00016211424],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972986,0.00030613202,0.00094695523,0.0006277046,0.0004043588,0.00041627622],"domain_scores_gemma":[0.99813116,0.00039004776,0.00031962185,0.00043969025,0.0005283663,0.00019110217],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008047489,0.0004627693,0.003497137,0.0003695639,0.00010306196,0.00005420235,0.00012329327,0.00023847348,0.00023135552],"category_scores_gemma":[0.000071485774,0.00030913186,0.00080019736,0.0011363765,0.00015973343,0.00019483533,0.00001260192,0.00013047128,0.0000038699363],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062823415,0.0031892622,0.010863964,0.55821264,0.3450139,0.00081789045,0.0039799633,0.000024791561,0.010120637,0.0027609074,0.0013795649,0.00081306824],"study_design_scores_gemma":[0.02665547,0.048498105,0.00031070094,0.0052676573,0.8267581,0.00013133102,0.00020840656,0.02620733,0.06416583,0.00011619465,0.000789758,0.00089112076],"about_ca_topic_score_codex":0.00006932204,"about_ca_topic_score_gemma":0.00008917677,"teacher_disagreement_score":0.552945,"about_ca_system_score_codex":0.000050984043,"about_ca_system_score_gemma":0.00036486395,"threshold_uncertainty_score":0.9999361},"labels":[],"label_agreement":null},{"id":"W4400143742","doi":"10.1016/j.annonc.2024.05.055","title":"44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; iCo Therapeutics (Canada); Innovative Targeting Solutions (Canada); McGill University; Princess Margaret Cancer Centre; University Health Network; Jewish General Hospital; McMaster University; Ottawa Regional Cancer Foundation; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Oncology; Phases of clinical research; Oxaliplatin; Colorectal cancer; Chemotherapy; Cancer","score_opus":0.051525430029275766,"score_gpt":0.42209046439000353,"score_spread":0.37056503436072774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400143742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496526,0.0007514267,0.000026476084,0.002605815,0.00015993175,0.0010061106,0.000008266609,0.000018109922,0.00045860317],"genre_scores_gemma":[0.9987083,0.00035427723,0.00023241637,0.00036877743,0.00003293546,0.000051720766,0.000042714273,0.00002858563,0.00018025261],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982634,0.00018307142,0.00064099516,0.00030946342,0.00035330091,0.00024977847],"domain_scores_gemma":[0.99891585,0.00024574788,0.00031565945,0.00021940228,0.00022603708,0.000077314275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006415649,0.00017357664,0.0007882059,0.00045476068,0.000030097302,0.000004290585,0.00012982338,0.00009152344,0.00005024812],"category_scores_gemma":[0.00020220492,0.00013169079,0.000066656656,0.0003372271,0.0001543157,0.00010631472,0.00007290696,0.0003399725,0.0000010711203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005509324,0.030948145,0.40127283,0.00030324105,0.00024347538,0.00020110386,0.010205099,0.00032469135,0.009157815,0.00009249267,0.00061550207,0.54112625],"study_design_scores_gemma":[0.18767841,0.21728076,0.5251937,0.0026721691,0.0002376852,0.000040488685,0.0050806203,0.023364171,0.01963377,0.00048003395,0.017715085,0.0006231062],"about_ca_topic_score_codex":0.0005133716,"about_ca_topic_score_gemma":0.00047689737,"teacher_disagreement_score":0.54050314,"about_ca_system_score_codex":0.00007163882,"about_ca_system_score_gemma":0.00015417548,"threshold_uncertainty_score":0.5370195},"labels":[],"label_agreement":null},{"id":"W4400143804","doi":"10.1016/j.annonc.2024.05.035","title":"24P Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Stress (linguistics); Adjuvant; Consensus conference; Colorectal cancer; Cancer; Family medicine; Oncology; Medical physics; Internal medicine; Linguistics","score_opus":0.43258664422632287,"score_gpt":0.5377907752487702,"score_spread":0.1052041310224473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400143804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95575786,0.016566189,0.000019260237,0.023837872,0.0011804148,0.0007107756,0.00065325835,0.00001699907,0.0012573953],"genre_scores_gemma":[0.9933287,0.0047767423,0.0004320467,0.0010051033,0.00022343991,0.00009071293,0.000071215814,0.000010601836,0.00006144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985518,0.000257914,0.00045132564,0.00032569963,0.00028308269,0.00013018791],"domain_scores_gemma":[0.9975025,0.0019738656,0.00013163601,0.00013071758,0.00022396207,0.000037305905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015276036,0.00010153122,0.00040309987,0.0001301758,0.000036900747,0.000026628873,0.000102392725,0.00010954881,0.0001376187],"category_scores_gemma":[0.0021238897,0.00007122723,0.000031703807,0.00015578783,0.0002082444,0.00004550972,0.00015599192,0.00015172569,4.42867e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009009331,0.00032557466,0.09498547,0.00017619248,0.0015786202,0.00019874942,0.007327508,0.000035453722,0.031157289,0.00045879424,0.5151797,0.33956736],"study_design_scores_gemma":[0.0074859015,0.002538839,0.11609023,0.0010493903,0.0003261344,0.00029027622,0.002641087,0.013717444,0.013062647,0.0017515727,0.84071386,0.0003326359],"about_ca_topic_score_codex":0.001550863,"about_ca_topic_score_gemma":0.0033370324,"teacher_disagreement_score":0.3392347,"about_ca_system_score_codex":0.00018353356,"about_ca_system_score_gemma":0.0015707252,"threshold_uncertainty_score":0.2904562},"labels":[],"label_agreement":null},{"id":"W4400143961","doi":"10.1016/j.annonc.2024.05.021","title":"10P A placebo-controlled study comparing doses and efficacy of lentinula edodes mycelia for chemotherapy-induced peripheral neuropathy in colorectal cancer: The LEMON trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Genentech; Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; European Society for Medical Oncology; PharmaMar; Daiichi Sankyo Europe; Gilead Sciences; Servier; FibroGen; Astellas Pharma; Eisai; Natera; F-star Therapeutics; Ribon Therapeutics; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Clovis Oncology; Merck KGaA; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lentinula; Placebo; Chemotherapy; Colorectal cancer; Peripheral neuropathy; Cancer; Internal medicine; Oncology; Chemotherapy-induced peripheral neuropathy; Food science; Pathology; Endocrinology","score_opus":0.10373159142677914,"score_gpt":0.4469295965515289,"score_spread":0.3431980051247498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400143961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940593,0.0023355593,0.000001324352,0.0030806134,0.0006498841,0.0040626265,0.000008879384,0.000020904074,0.0004342892],"genre_scores_gemma":[0.9981059,0.00054366235,0.000014323828,0.00025697958,0.00033746296,0.0006187591,0.0000043496684,0.000018042781,0.00010053753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987039,0.00021186919,0.0004751714,0.0002655346,0.00010843962,0.00023507097],"domain_scores_gemma":[0.9988095,0.0008261415,0.0001510467,0.000094315656,0.00007767239,0.00004131601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005564431,0.00016251148,0.00095149555,0.0001318646,0.000040647305,0.00001073306,0.00008705112,0.00008458569,0.000051330568],"category_scores_gemma":[0.00007334091,0.000109450804,0.00017364969,0.00015832904,0.000113160364,0.00003549592,0.00003339457,0.0001674478,3.7327803e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76301354,0.004816857,0.020435167,0.0001967161,0.001359726,0.00007387687,0.009669359,0.00004308065,0.06704009,0.000046441604,0.0019366458,0.13136847],"study_design_scores_gemma":[0.817608,0.07086947,0.0666562,0.00017933907,0.0012590591,0.00003829045,0.0022427456,0.0044244863,0.028920995,0.00006550188,0.0074837552,0.00025214299],"about_ca_topic_score_codex":0.00033905215,"about_ca_topic_score_gemma":0.0007791167,"teacher_disagreement_score":0.13111633,"about_ca_system_score_codex":0.00005183651,"about_ca_system_score_gemma":0.0002641923,"threshold_uncertainty_score":0.44632742},"labels":[],"label_agreement":null},{"id":"W4400144289","doi":"10.1016/j.annonc.2024.05.016","title":"5MO Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Queen's University","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Phases of clinical research","score_opus":0.4209689105584592,"score_gpt":0.5122414787343451,"score_spread":0.09127256817588592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400144289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8437815,0.12651467,0.0001850422,0.0037407943,0.00036571233,0.0039984756,0.020219421,0.000034578574,0.0011598525],"genre_scores_gemma":[0.98856395,0.0079954425,0.00081535935,0.00046889705,0.00010206972,0.00082164473,0.00095752266,0.000029534509,0.00024559352],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967164,0.0004188968,0.0015348404,0.0005483556,0.0004502957,0.00033125185],"domain_scores_gemma":[0.9951325,0.002819855,0.00085966336,0.00049806235,0.00058662286,0.000103290266],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002662359,0.00029077273,0.0049123033,0.0005373289,0.00005711991,0.000010559617,0.0002577469,0.00014285426,0.0020530752],"category_scores_gemma":[0.0007792011,0.00018908824,0.0018592537,0.00080937566,0.00027462863,0.000116713156,0.00015480662,0.000112824375,7.048341e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08813943,0.0031775907,0.00011620031,0.0004167977,0.69448674,0.0000638624,0.0030372203,0.000056883615,0.0061655333,0.0001447907,0.045560922,0.15863402],"study_design_scores_gemma":[0.07393681,0.024125218,0.00045327967,0.00006754588,0.6266754,0.0000111556465,0.00089994486,0.0010767495,0.15988322,0.00013017589,0.11240785,0.00033261388],"about_ca_topic_score_codex":0.0016586751,"about_ca_topic_score_gemma":0.0011458051,"teacher_disagreement_score":0.15830141,"about_ca_system_score_codex":0.000059339516,"about_ca_system_score_gemma":0.0006477802,"threshold_uncertainty_score":0.99885917},"labels":[],"label_agreement":null},{"id":"W4400144366","doi":"10.1016/j.annonc.2024.05.019","title":"8MO Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Genentech; Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; European Society for Medical Oncology; PharmaMar; Daiichi Sankyo Europe; Gilead Sciences; Servier; FibroGen; Astellas Pharma; Eisai; Natera; F-star Therapeutics; Ribon Therapeutics; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Clovis Oncology; Merck KGaA; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer","score_opus":0.1642273022822641,"score_gpt":0.4733978749761782,"score_spread":0.3091705726939141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400144366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691831,0.01507379,0.000009758565,0.0069511263,0.003296259,0.0019596447,0.000047306832,0.00013458512,0.0033444462],"genre_scores_gemma":[0.9939452,0.0030785964,0.00073382794,0.001021298,0.00046590387,0.00028918093,0.000014474108,0.000049044116,0.00040249806],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598444,0.00036769296,0.0014076281,0.0009555025,0.00052471086,0.0007600249],"domain_scores_gemma":[0.99767786,0.0010379506,0.0002203264,0.00040060002,0.00037269527,0.00029054855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022217787,0.00032360016,0.0013365678,0.00033336476,0.000060804403,0.000023517929,0.00017913463,0.00053796254,0.000211874],"category_scores_gemma":[0.0012154425,0.0002742467,0.0003445459,0.00066034775,0.0005510554,0.0000655488,0.000239917,0.0007611591,0.000020646263],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39286873,0.00811427,0.073870614,0.0032824888,0.0013435654,0.00471646,0.007539373,0.0015802024,0.03426858,0.0010777499,0.17339468,0.2979433],"study_design_scores_gemma":[0.18046746,0.16758715,0.19096228,0.0033024943,0.0012826486,0.0015774248,0.003792131,0.069462836,0.045670707,0.0013644793,0.33244428,0.0020861244],"about_ca_topic_score_codex":0.0008830077,"about_ca_topic_score_gemma":0.0009476484,"teacher_disagreement_score":0.29585716,"about_ca_system_score_codex":0.00047533598,"about_ca_system_score_gemma":0.0029069798,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W4400144484","doi":"10.1016/j.annonc.2024.05.023","title":"12P The prognostic significance of BRAF mutations in early-stage colon cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Fondation de l'Hôpital général juif; Canada Foundation for Innovation; AstraZeneca; Conquer Cancer Foundation","keywords":"Medicine; Stage (stratigraphy); Oncology; Colorectal cancer; Internal medicine; Cancer; Cancer research","score_opus":0.09476191324890507,"score_gpt":0.42691295411190305,"score_spread":0.33215104086299796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400144484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96753806,0.008489853,0.0000041932876,0.016291508,0.00017403015,0.00050573103,0.000053666154,0.000013171003,0.006929759],"genre_scores_gemma":[0.99660844,0.001520059,0.000044294942,0.00037184835,0.000046044603,0.0002576241,0.0000035402256,0.0000073309093,0.0011408308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993379,0.000044303244,0.000239987,0.00013354252,0.00010442018,0.00013985267],"domain_scores_gemma":[0.99925685,0.00041394308,0.00006554492,0.00009079711,0.00014776488,0.000025094392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001610352,0.000071503535,0.00027957346,0.000074688665,0.000025029289,0.0000032001992,0.000049930015,0.000048041737,0.00009500208],"category_scores_gemma":[0.00013225457,0.000045186312,0.0000649811,0.00027919852,0.00019459912,0.000027060009,0.000023692523,0.00010400341,0.0000043025448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019753177,0.0018072606,0.5315702,0.0013151388,0.0017632046,0.00079440634,0.024756027,0.00035710778,0.009029485,0.0058028116,0.018813886,0.40201518],"study_design_scores_gemma":[0.0010175284,0.005946482,0.8892829,0.0003963992,0.00020350501,0.000009905493,0.00091586163,0.00017750611,0.007016065,0.00064988364,0.09428896,0.000095002935],"about_ca_topic_score_codex":0.0017076428,"about_ca_topic_score_gemma":0.0026485876,"teacher_disagreement_score":0.40192017,"about_ca_system_score_codex":0.000053496544,"about_ca_system_score_gemma":0.0003772463,"threshold_uncertainty_score":0.25814566},"labels":[],"label_agreement":null},{"id":"W4400151179","doi":"10.1016/j.annonc.2024.05.447","title":"304P Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fibroblast growth factor receptor; Fibroblast growth factor receptor 2; Cancer research; Internal medicine; Intrahepatic Cholangiocarcinoma; Fibroblast growth factor; Fibroblast growth factor receptor 3; Oncology; Receptor","score_opus":0.07187510974608678,"score_gpt":0.3934198434067402,"score_spread":0.3215447336606534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415907,0.0012743855,0.000026167354,0.053885125,0.0005456635,0.000773466,0.000060621485,0.0000760442,0.0017678],"genre_scores_gemma":[0.9930098,0.00013126129,0.001636244,0.0035838839,0.00045417604,0.000109906214,0.0000111531235,0.000046556208,0.0010170098],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.997369,0.00031929967,0.00084059825,0.0006391611,0.0003264279,0.00050549663],"domain_scores_gemma":[0.9980399,0.0008129179,0.00010451467,0.0003813696,0.0002903805,0.00037089922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008955103,0.00026997208,0.00089805963,0.0005021901,0.00004247866,0.000021472644,0.00017978872,0.00020276199,0.00010021556],"category_scores_gemma":[0.0010703718,0.00021641281,0.00018587055,0.0010037466,0.00017475645,0.00010268441,0.00012672791,0.00027273447,0.00012589924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06309937,0.0011900992,0.39455137,0.0011559234,0.0008939129,0.0016149518,0.020298293,0.000006329667,0.030990172,0.0003634146,0.4314036,0.054432556],"study_design_scores_gemma":[0.0018907482,0.013191977,0.8641301,0.0014840068,0.00005544758,0.000026733771,0.000576423,0.000005303423,0.007086168,0.00005019433,0.1112017,0.00030118343],"about_ca_topic_score_codex":0.00008589407,"about_ca_topic_score_gemma":0.0007699013,"teacher_disagreement_score":0.46957874,"about_ca_system_score_codex":0.0001642806,"about_ca_system_score_gemma":0.0006027047,"threshold_uncertainty_score":0.88250583},"labels":[],"label_agreement":null},{"id":"W4400151238","doi":"10.1016/j.annonc.2024.05.516","title":"375P Landscape of pancreatic squamous cell carcinoma: A Polish multicenter study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multicenter study; Basal cell; Oncology; Pancreatic carcinoma; Internal medicine; Pancreatic cancer; Cancer","score_opus":0.0779562236416495,"score_gpt":0.4133299474330796,"score_spread":0.3353737237914301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391043,0.0031159706,0.000013472484,0.0015330251,0.00016382441,0.00075556233,0.000022382326,0.000031213753,0.055260252],"genre_scores_gemma":[0.99668884,0.00016271898,0.00023602381,0.0003051425,0.00015470728,0.000054610442,0.0000130108,0.000023937193,0.0023610066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981846,0.00024244984,0.00058068975,0.0002968487,0.00030147273,0.0003939202],"domain_scores_gemma":[0.99815977,0.00088577747,0.000117506694,0.00035704797,0.00030816137,0.00017171827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073544413,0.00015728806,0.0009812402,0.0003284067,0.00003050816,0.000006020293,0.00015112499,0.0001836261,0.00062710425],"category_scores_gemma":[0.00029542073,0.0001217804,0.00016802567,0.00030128294,0.00020761204,0.000051140058,0.00009531399,0.00029105373,0.00007216468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011929824,0.0047211596,0.9612848,0.0010979766,0.00031632907,0.0009238862,0.004802831,0.0000013984576,0.002891089,0.00015660793,0.018405171,0.004205777],"study_design_scores_gemma":[0.010939472,0.039852496,0.9144183,0.00018343596,0.0016996181,0.00013626758,0.0077179093,0.0020303424,0.0068010255,0.00023639444,0.01570941,0.00027534724],"about_ca_topic_score_codex":0.0005382081,"about_ca_topic_score_gemma":0.00006338789,"teacher_disagreement_score":0.057584543,"about_ca_system_score_codex":0.000039532402,"about_ca_system_score_gemma":0.00068172126,"threshold_uncertainty_score":0.6866352},"labels":[],"label_agreement":null},{"id":"W4400151297","doi":"10.1016/j.annonc.2024.05.506","title":"365P Pancreatic cancer in young patients under the age of 45 years old: A comparative study with older patients","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Sousse; Princess Margaret Cancer Foundation; AstraZeneca","keywords":"Medicine; Pancreatic cancer; Cancer; Gerontology; Internal medicine; Oncology","score_opus":0.10046458931284229,"score_gpt":0.45136081639285897,"score_spread":0.35089622708001666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917876,0.00042303844,0.000009773338,0.0006366488,0.000111448506,0.0014346438,0.0000291502,0.000011029794,0.0055566677],"genre_scores_gemma":[0.9985612,0.00019308148,0.000058131696,0.00028620602,0.00003200622,0.00018089601,0.000021466416,0.000016206324,0.00065082184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982245,0.00033189723,0.0004678911,0.0002622346,0.00040299163,0.00031050452],"domain_scores_gemma":[0.99869645,0.00052185386,0.00012861134,0.00026007317,0.00032309772,0.00006994017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004756187,0.00014559922,0.00085323304,0.00021851028,0.000029766365,0.000006042031,0.00014571565,0.000111104586,0.00019718589],"category_scores_gemma":[0.000060841805,0.000088126166,0.00006546621,0.00045519572,0.0003817551,0.000056793266,0.000070234746,0.0003146686,0.000013918717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086497754,0.002912295,0.98000467,0.00011209346,0.0006539238,0.00008640966,0.010910286,0.000015660364,0.000037108275,0.00013910158,0.0012751109,0.002988393],"study_design_scores_gemma":[0.0037301625,0.009691342,0.98202354,0.00029780867,0.00025871486,0.0000033312494,0.0031810005,0.00010786081,0.000044426914,0.00008987057,0.0004978187,0.00007413094],"about_ca_topic_score_codex":0.0017109668,"about_ca_topic_score_gemma":0.002903894,"teacher_disagreement_score":0.007729285,"about_ca_system_score_codex":0.00010701298,"about_ca_system_score_gemma":0.0005038735,"threshold_uncertainty_score":0.3593681},"labels":[],"label_agreement":null},{"id":"W4400151309","doi":"10.1016/j.annonc.2024.05.419","title":"504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; FOLFIRI; Gastrointestinal cancer; Internal medicine; Oncology; Cancer; Colorectal cancer; Irinotecan","score_opus":0.051749825533576294,"score_gpt":0.4110234841949122,"score_spread":0.35927365866133587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948487,0.0005807935,0.0000682841,0.002027052,0.00019368493,0.0018738697,0.00000879605,0.000027611746,0.00037117192],"genre_scores_gemma":[0.999179,0.00001712572,0.00024256352,0.00017003185,0.00005082561,0.00019505328,0.000003285092,0.00003072906,0.0001113681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980144,0.00023545552,0.00064076367,0.00038462583,0.0003917244,0.00033305582],"domain_scores_gemma":[0.9988208,0.00025430546,0.00023564388,0.00036169123,0.00026174146,0.00006585585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049087894,0.0002075237,0.000643504,0.0003542003,0.000027461529,0.0000053525737,0.00019411513,0.000051782106,0.000030411795],"category_scores_gemma":[0.00017115436,0.0001463163,0.0000613738,0.0009105533,0.00019554509,0.00016050588,0.00007571856,0.0003906191,0.000001430661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023300296,0.026533723,0.607747,0.0004201714,0.00038147857,0.0011783226,0.026311204,0.00289013,0.020882204,0.00015938572,0.00024464048,0.28995144],"study_design_scores_gemma":[0.07433026,0.14147808,0.7138572,0.003256435,0.00022509653,0.00032619687,0.049548686,0.0012440557,0.011851847,0.0005634695,0.002879985,0.00043873044],"about_ca_topic_score_codex":0.0010729011,"about_ca_topic_score_gemma":0.007083812,"teacher_disagreement_score":0.2895127,"about_ca_system_score_codex":0.00035087165,"about_ca_system_score_gemma":0.0007292664,"threshold_uncertainty_score":0.59666055},"labels":[],"label_agreement":null},{"id":"W4400151349","doi":"10.1016/j.annonc.2024.05.414","title":"502TiP Design and rationale of the PROSPECTive evaluation of nivolumab in adjuvant esophageal cancer/gastroesophageal junction cancer (EC/GEJC) (PROSPECT-ESO): A prospective, non-interventional, multicentre cohort study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Gastroesophageal Junction; Nivolumab; Esophageal cancer; Prospective cohort study; Cancer; Adjuvant; Internal medicine; Oncology; Surgery; Adenocarcinoma; Immunotherapy","score_opus":0.0791579838401902,"score_gpt":0.43100199647544607,"score_spread":0.3518440126352559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208095,0.018522656,0.00009597481,0.0008649557,0.00029017593,0.007783875,0.0000862498,0.000015218377,0.0002599675],"genre_scores_gemma":[0.99663764,0.0005225484,0.00018829419,0.00003159723,0.00010902151,0.0021173097,0.0000140210395,0.000022920927,0.00035663546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970613,0.00044633925,0.00067759765,0.0005136362,0.0010052052,0.0002959346],"domain_scores_gemma":[0.9979795,0.00020332777,0.00030840668,0.00024884279,0.0011659894,0.00009388951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016603428,0.00020987785,0.0006720891,0.00025927692,0.00006516964,0.000011365474,0.0001162792,0.000100630285,0.00032095105],"category_scores_gemma":[0.00018602089,0.00015437607,0.00016927806,0.0005523322,0.00027157948,0.00015859681,0.00008386908,0.0002952057,0.0000021484902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002475629,0.00326303,0.9731319,0.00032917468,0.0010131901,0.00006312708,0.001840351,0.0012351661,0.000486018,0.00011632116,0.00056602136,0.015480095],"study_design_scores_gemma":[0.007227202,0.00781265,0.9631284,0.0004462709,0.00053574645,0.000015591117,0.00040452788,0.0068046907,0.01279036,0.0007476457,0.000009767197,0.00007715574],"about_ca_topic_score_codex":0.0024072945,"about_ca_topic_score_gemma":0.002849976,"teacher_disagreement_score":0.024556724,"about_ca_system_score_codex":0.0008024596,"about_ca_system_score_gemma":0.0018533214,"threshold_uncertainty_score":0.62952733},"labels":[],"label_agreement":null},{"id":"W4400151375","doi":"10.1016/j.annonc.2024.05.505","title":"362P Impact of an interprofessional clinic on pancreatic cancer outcomes","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Cancer; Family medicine; Oncology; Internal medicine","score_opus":0.1382122429358347,"score_gpt":0.4476143157301435,"score_spread":0.30940207279430876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95377266,0.003451228,0.000040729585,0.0018074267,0.001126758,0.00013021646,0.00053065625,0.000020617646,0.039119706],"genre_scores_gemma":[0.995737,0.0013442257,0.00009918468,0.0008735975,0.0001638531,0.000024347706,0.000011711453,0.000024544162,0.0017215465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846464,0.00002787619,0.00088761747,0.00031232237,0.000029412842,0.0002781373],"domain_scores_gemma":[0.9988496,0.0002827324,0.00043489086,0.0002726377,0.000054760043,0.00010538746],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059646793,0.00016144446,0.0008736779,0.0002984627,0.000026040918,0.000013638357,0.00023649457,0.00019510268,0.00287731],"category_scores_gemma":[0.00015538666,0.00014158254,0.00038448503,0.00013682302,0.00013436966,0.00027226386,0.000043712924,0.00020119711,0.0003082929],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001339441,0.0013841493,0.55267733,0.00028858014,0.0016561516,0.000033743938,0.0019238861,0.0004056663,0.00017601681,0.16206078,0.038439628,0.23961459],"study_design_scores_gemma":[0.00092857453,0.0069216746,0.8649258,0.00027914625,0.000029184956,0.0000039825654,0.00008584611,0.0011856246,0.00040276433,0.078095146,0.046746578,0.00039565287],"about_ca_topic_score_codex":0.0016317052,"about_ca_topic_score_gemma":0.00012368176,"teacher_disagreement_score":0.31224847,"about_ca_system_score_codex":0.00012849408,"about_ca_system_score_gemma":0.00036946073,"threshold_uncertainty_score":0.9980342},"labels":[],"label_agreement":null},{"id":"W4400151400","doi":"10.1016/j.annonc.2024.05.508","title":"367P Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Princess Margaret Cancer Foundation; AstraZeneca","keywords":"PALB2; Medicine; Pancreatic cancer; Chemotherapy; Cancer research; Oncology; Internal medicine; Cancer; Mutation; Gene; Genetics; Germline mutation; Biology","score_opus":0.08039063100165937,"score_gpt":0.4238835149661108,"score_spread":0.34349288396445143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98512113,0.0016888301,0.00009508355,0.007889606,0.0000857208,0.001486969,0.00007714512,0.000040300725,0.0035152303],"genre_scores_gemma":[0.99443156,0.0031310616,0.00096705323,0.00036283387,0.00010700367,0.00025287175,0.000037353948,0.000036937647,0.0006733335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973318,0.00039160554,0.0008756531,0.00049122213,0.0004315797,0.00047811857],"domain_scores_gemma":[0.9965437,0.0022181035,0.00023703798,0.00045137585,0.00039308477,0.00015666393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016959067,0.00025230792,0.00148034,0.0004425052,0.000055256245,0.000009124093,0.00010762539,0.00022335381,0.0001497659],"category_scores_gemma":[0.0004737395,0.00018912925,0.00011365267,0.00082323264,0.00044413743,0.00008537407,0.000044584005,0.00037445655,0.00001719805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008138181,0.0035550848,0.954235,0.00085886434,0.001820452,0.00203825,0.009554274,0.0002552716,0.0024686442,0.00008818194,0.0019934287,0.014994336],"study_design_scores_gemma":[0.011215719,0.017320352,0.954441,0.0012077857,0.0007891447,0.00025469408,0.0025719395,0.004252229,0.0046489155,0.0002710071,0.0027622392,0.0002649432],"about_ca_topic_score_codex":0.0050053117,"about_ca_topic_score_gemma":0.008666567,"teacher_disagreement_score":0.014729393,"about_ca_system_score_codex":0.00015058617,"about_ca_system_score_gemma":0.0013956506,"threshold_uncertainty_score":0.7712467},"labels":[],"label_agreement":null},{"id":"W4400151466","doi":"10.1016/j.annonc.2024.05.375","title":"463P A real-world study to evaluate biomarker testing and treatment management in patients with locally advanced unresectable or metastatic G/GEJ adenocarcinoma in France, Germany, Italy, Spain, UK and Canada: Adelphi Real World G/GEJ cancer disease specific programme","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Toronto Public Health","funders":"","keywords":"Medicine; Biomarker; Oncology; Adenocarcinoma; Internal medicine; Cancer","score_opus":0.08284073563039081,"score_gpt":0.4049356520725289,"score_spread":0.3220949164421381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899418,0.0021952845,0.0000033259576,0.0019847981,0.00009716917,0.00422654,0.00009904498,0.000024188577,0.001427886],"genre_scores_gemma":[0.99460864,0.0006674865,0.0009129795,0.00028532645,0.00002479427,0.0013418128,0.000041513144,0.00003815029,0.0020792764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978663,0.00011978,0.00051689625,0.0006300333,0.0003463075,0.00052072405],"domain_scores_gemma":[0.9988806,0.00023489915,0.00011323106,0.00025599657,0.00018370048,0.0003315276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025941728,0.00029746533,0.00062615436,0.00060442224,0.00005765116,0.000027270113,0.00006714182,0.00002128612,0.000048038077],"category_scores_gemma":[0.000026486752,0.00020588584,0.000028507618,0.0011470411,0.000081356186,0.00009585332,0.00007101971,0.000101401754,0.0000011547058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031304276,0.001835481,0.8107734,0.00025408642,0.0009107383,0.0026578426,0.00087166,0.00020841447,0.000003342743,0.000031535765,0.00033222637,0.17899087],"study_design_scores_gemma":[0.008977074,0.005730737,0.97946936,0.00066364027,0.00067930954,0.0000031328748,0.00067202747,0.00031129972,0.000004587197,0.000028478595,0.0032615087,0.00019886371],"about_ca_topic_score_codex":0.320851,"about_ca_topic_score_gemma":0.86041445,"teacher_disagreement_score":0.5395635,"about_ca_system_score_codex":0.00090842665,"about_ca_system_score_gemma":0.001404761,"threshold_uncertainty_score":0.8395781},"labels":[],"label_agreement":null},{"id":"W4400151493","doi":"10.1016/j.annonc.2024.05.333","title":"419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Cancer; Gastroesophageal Junction; Internal medicine; Oncology; Chemotherapy; Esophageal adenocarcinoma; Esophageal cancer; Adenocarcinoma; Immunotherapy","score_opus":0.08238964688085516,"score_gpt":0.40254935799563096,"score_spread":0.3201597111147758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94980675,0.033589166,0.00046978664,0.006357937,0.0015819676,0.0015311594,0.00603702,0.00014692415,0.0004792968],"genre_scores_gemma":[0.9707504,0.018507859,0.0021551664,0.0013004724,0.0013188377,0.0009074639,0.001988408,0.000111307636,0.0029600952],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99694073,0.000077739314,0.0010381797,0.00081825873,0.0004680145,0.0006570649],"domain_scores_gemma":[0.9978482,0.00041532156,0.00056640717,0.00045626692,0.00050046947,0.00021332114],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024611314,0.00053442025,0.0013957852,0.0004242621,0.00013250846,0.000021870757,0.0002347882,0.0003712366,0.006953865],"category_scores_gemma":[0.00006880804,0.0004713435,0.0009152661,0.00071657076,0.0003125489,0.00020271278,0.000039168932,0.00023893233,0.00001845451],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098995246,0.002453728,0.005552453,0.0010506588,0.009147392,0.00028220148,0.001310716,0.0002825994,0.13166793,0.00008925751,0.098761894,0.65040594],"study_design_scores_gemma":[0.05313973,0.034959566,0.060676165,0.0015151048,0.00230899,0.00017271488,0.000459689,0.0026378173,0.66441596,0.0005727919,0.17828932,0.00085217255],"about_ca_topic_score_codex":0.0048623695,"about_ca_topic_score_gemma":0.0013405507,"teacher_disagreement_score":0.6495538,"about_ca_system_score_codex":0.0008883171,"about_ca_system_score_gemma":0.0015388564,"threshold_uncertainty_score":0.9997738},"labels":[],"label_agreement":null},{"id":"W4400151513","doi":"10.1016/j.annonc.2024.05.372","title":"460P Real-world study of ramucirumab and paclitaxel as ≥2nd-line therapy in patients with HER2-positive gastroesophageal cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Ramucirumab; Medicine; Paclitaxel; Internal medicine; Oncology; Cancer; Gastroenterology","score_opus":0.046375581311395325,"score_gpt":0.39510951767656743,"score_spread":0.34873393636517214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416596,0.00063129986,0.000001986436,0.0018264047,0.0000959771,0.00084892556,0.000016845006,0.000015909181,0.0023967095],"genre_scores_gemma":[0.9974825,0.0008500891,0.000038821658,0.0006783792,0.00006112265,0.00004402535,0.000013463714,0.000016957947,0.0008146338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887985,0.00007774106,0.0003425227,0.00025566097,0.00022484234,0.00021940726],"domain_scores_gemma":[0.9993969,0.00011656835,0.00011951143,0.00015350121,0.00015039601,0.00006310196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023014648,0.00013992954,0.0005419012,0.0003187956,0.000015386488,0.000006158983,0.0000615874,0.00004424084,0.00015384925],"category_scores_gemma":[0.000015237068,0.00010159559,0.000045112847,0.0003924657,0.00009475045,0.000066296976,0.000044950913,0.00014650037,0.0000014451914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031131725,0.0016261757,0.87506014,0.000096375734,0.00044893465,0.00013505125,0.0020461427,0.000011298191,0.000014215402,0.000112554226,0.0016758775,0.115660086],"study_design_scores_gemma":[0.0076452354,0.03233221,0.9578827,0.00014879646,0.00009011789,0.0000014149937,0.00052444986,0.0000124697035,0.00017020684,0.000059322836,0.0010698637,0.000063186875],"about_ca_topic_score_codex":0.0034235083,"about_ca_topic_score_gemma":0.0031333712,"teacher_disagreement_score":0.1155969,"about_ca_system_score_codex":0.00005822601,"about_ca_system_score_gemma":0.00013584588,"threshold_uncertainty_score":0.5175343},"labels":[],"label_agreement":null},{"id":"W4400151528","doi":"10.1016/j.annonc.2024.05.407","title":"495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Gastroesophageal Junction; Cancer; Drug; Internal medicine; Phases of clinical research; Conjugate; Gastroenterology; Oncology; Clinical trial; Pharmacology; Adenocarcinoma","score_opus":0.060759766501185475,"score_gpt":0.41251133515421873,"score_spread":0.35175156865303325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064976,0.0020573102,0.0002859558,0.0016266124,0.0012278229,0.003348566,0.00010413335,0.00013612815,0.0005637093],"genre_scores_gemma":[0.99153095,0.0017300122,0.00041045813,0.000880229,0.0003553586,0.000334954,0.00014730195,0.00006731828,0.0045433836],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99558187,0.00036697285,0.0018103792,0.00083617546,0.0005441548,0.00086046266],"domain_scores_gemma":[0.99768907,0.00054495863,0.0006501513,0.00050037395,0.000357037,0.00025843384],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011972537,0.00052852015,0.002142184,0.0015025861,0.000076784076,0.000028934179,0.000289334,0.0002369876,0.0026480025],"category_scores_gemma":[0.00027550457,0.00039683923,0.00033087563,0.002449926,0.00018452715,0.00031722424,0.00015700792,0.00072824344,0.000014012721],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47511888,0.022243364,0.08551013,0.004388039,0.005227046,0.009499862,0.007028667,0.0015906586,0.03868753,0.00006344616,0.04949176,0.30115062],"study_design_scores_gemma":[0.6858104,0.08577271,0.14785093,0.0018211033,0.003395736,0.00051390927,0.0078745885,0.006393217,0.007874078,0.0001460116,0.051269695,0.0012776409],"about_ca_topic_score_codex":0.00081243156,"about_ca_topic_score_gemma":0.0036745807,"teacher_disagreement_score":0.299873,"about_ca_system_score_codex":0.0002660281,"about_ca_system_score_gemma":0.0009734469,"threshold_uncertainty_score":0.99984837},"labels":[],"label_agreement":null},{"id":"W4400151534","doi":"10.1016/j.annonc.2024.05.285","title":"279MO Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Biliary tract cancer; Durvalumab; Chemotherapy; Term (time); Biliary tract; Topaz; Oncology; Cancer; Internal medicine; Gemcitabine; Immunotherapy","score_opus":0.0826210413554754,"score_gpt":0.4131257187769274,"score_spread":0.33050467742145195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752035,0.017543968,0.000033957953,0.005486104,0.00028924085,0.0007170124,0.00015260039,0.000024620045,0.0005489632],"genre_scores_gemma":[0.9918831,0.00727858,0.000013019107,0.000402598,0.00020262803,0.000051243078,0.000035496072,0.000023843399,0.000109473294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980196,0.00021709547,0.00067905645,0.0004891979,0.00031237662,0.0002827164],"domain_scores_gemma":[0.99840856,0.0007167622,0.00017856277,0.00045468003,0.00016099981,0.000080410086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077682885,0.0002331931,0.0012969245,0.00026041848,0.000055971355,0.000013135139,0.00017711577,0.00012815224,0.0003353828],"category_scores_gemma":[0.000052554373,0.00016018064,0.00024941887,0.0008211318,0.0002313112,0.000076754266,0.00008807709,0.00028245908,0.000001595528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058500245,0.0028619936,0.85908395,0.0001227319,0.005414643,0.00027428952,0.011211759,0.000017177175,0.0005050572,0.000023447603,0.00079218985,0.113842756],"study_design_scores_gemma":[0.010980019,0.0027893083,0.98098814,0.000093811104,0.0013387671,0.0000055607843,0.0022761875,0.00028481355,0.00023821459,0.00004938777,0.0008110882,0.00014471266],"about_ca_topic_score_codex":0.015808374,"about_ca_topic_score_gemma":0.06955446,"teacher_disagreement_score":0.121904194,"about_ca_system_score_codex":0.00008830563,"about_ca_system_score_gemma":0.00031624152,"threshold_uncertainty_score":0.9907454},"labels":[],"label_agreement":null},{"id":"W4400151542","doi":"10.1016/j.annonc.2024.05.232","title":"224P Genomic patterns and clinical implications in gastroenteropancreatic neuroendocrine neoplasms","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Oncology; Internal medicine","score_opus":0.0972250867063349,"score_gpt":0.4639051864604127,"score_spread":0.3666800997540778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621008,0.00054578116,0.000022465294,0.03585704,0.00013197168,0.00035403323,0.00002680357,0.00003943801,0.0009216641],"genre_scores_gemma":[0.99271137,0.005303731,0.00022676328,0.0012438733,0.00011261226,0.000037577032,0.000012291191,0.000023042927,0.00032873984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845666,0.00015745359,0.00053919223,0.00035461583,0.000106995445,0.00038509234],"domain_scores_gemma":[0.9988963,0.000526533,0.00006315329,0.00026125147,0.000059410857,0.00019335572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017305512,0.000117631746,0.00045644952,0.00026571326,0.000016518781,0.000011258724,0.00010676999,0.000009263215,0.00006238483],"category_scores_gemma":[0.00028889193,0.00010312866,0.0000950518,0.00016572904,0.00018549008,0.00008094554,0.0001283865,0.0003666176,0.000028491879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043601438,0.0005547502,0.91868246,0.00035245303,0.00008999047,0.006572364,0.00002683186,0.0000040058544,0.003433334,0.00086692057,0.0032238914,0.06575699],"study_design_scores_gemma":[0.0014884329,0.007117575,0.9444816,0.00016198186,0.00005132444,0.0055420003,0.000044177646,0.00025560614,0.0009879827,0.00077190757,0.03901671,0.00008069442],"about_ca_topic_score_codex":0.00009086701,"about_ca_topic_score_gemma":0.0002318112,"teacher_disagreement_score":0.065676294,"about_ca_system_score_codex":0.000026053687,"about_ca_system_score_gemma":0.00015083251,"threshold_uncertainty_score":0.42054647},"labels":[],"label_agreement":null},{"id":"W4400151570","doi":"10.1016/j.annonc.2024.05.294","title":"288P Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Biliary tract cancer; Meta-analysis; Systemic therapy; Cancer; Biliary tract; Oncology; Internal medicine; Intensive care medicine; Gemcitabine; Breast cancer","score_opus":0.25740831082815113,"score_gpt":0.5030595807559479,"score_spread":0.2456512699277968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022687188,0.98841596,0.0000032720707,0.003273318,0.00013888953,0.007654673,0.00031707258,0.000036611164,0.00015796574],"genre_scores_gemma":[0.000043071865,0.98924017,0.000049150538,0.0016086121,0.000055165696,0.008624345,0.00006306025,0.00006586542,0.00025055362],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963993,0.00041520403,0.0019180222,0.00070333673,0.00021922136,0.00034493583],"domain_scores_gemma":[0.99720526,0.0007465789,0.0010735085,0.00053877285,0.00033703656,0.00009886199],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0011699592,0.0005631666,0.017281044,0.0005986713,0.000024769799,0.000008507292,0.00019135851,0.0002677784,0.000041676984],"category_scores_gemma":[0.00023389135,0.00032035285,0.0031802042,0.0011735844,0.00009031657,0.00007764122,0.000054056163,0.00033219275,0.0000029522091],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000310358,0.00010453486,0.0000034100608,0.72935003,0.09007718,0.000030385625,0.00008528369,3.5266277e-7,1.15994524e-7,0.000011384283,0.001032922,0.17927337],"study_design_scores_gemma":[0.00023502341,0.00055563916,0.0000014271026,0.06184128,0.4810306,0.00007552751,0.000038220587,5.106757e-7,3.9533796e-7,0.000014883143,0.45605263,0.00015385514],"about_ca_topic_score_codex":0.00002843772,"about_ca_topic_score_gemma":0.00015669156,"teacher_disagreement_score":0.6675087,"about_ca_system_score_codex":0.000156901,"about_ca_system_score_gemma":0.0005724715,"threshold_uncertainty_score":0.99992484},"labels":[],"label_agreement":null},{"id":"W4400151721","doi":"10.1016/j.annonc.2024.05.269","title":"263P PET-CT and MRI correlation of tumour regression grading in rectal carcinoma post neoadjuvant treatment","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Key Research and Development Program of China; Basic Research Program of Jiangsu Province; Government of Jiangsu Province","keywords":"Medicine; Rectal carcinoma; Grading (engineering); Neoadjuvant therapy; Radiology; Correlation; Colorectal cancer; Nuclear medicine; Oncology; Internal medicine; Cancer","score_opus":0.03306485543786184,"score_gpt":0.375535373696433,"score_spread":0.3424705182585711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98267126,0.002902707,0.000051468403,0.011506363,0.00025852307,0.00014897552,0.0000037583318,0.000015268766,0.0024416621],"genre_scores_gemma":[0.99804693,0.0009464924,0.00050825474,0.00019951256,0.00006847547,0.0000044844123,0.000021631118,0.000012249177,0.00019195877],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991792,0.000086399676,0.00030056632,0.00018084742,0.000105422754,0.00014755073],"domain_scores_gemma":[0.99944896,0.0002507039,0.00009135816,0.000083812956,0.00004838831,0.000076757584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003691554,0.0000939589,0.0003708596,0.00023027665,0.000019979863,0.000004384738,0.000032305765,0.000027334598,0.000025478876],"category_scores_gemma":[0.00021953105,0.00006785293,0.00006505205,0.00012809192,0.000094900024,0.000044751363,0.000023358743,0.00022309177,0.0000022505924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006905882,0.00057561736,0.1982972,0.00050694816,0.00013785264,0.0074779377,0.0028483102,0.0001449731,0.07057148,0.0016258243,0.0032720612,0.7138512],"study_design_scores_gemma":[0.00674113,0.018664619,0.67214835,0.0036738385,0.00033033095,0.009109375,0.001499327,0.23222843,0.020330142,0.0014318537,0.033461776,0.0003808431],"about_ca_topic_score_codex":0.00049184385,"about_ca_topic_score_gemma":0.000020473011,"teacher_disagreement_score":0.71347034,"about_ca_system_score_codex":0.00006017178,"about_ca_system_score_gemma":0.00015887758,"threshold_uncertainty_score":0.2766962},"labels":[],"label_agreement":null},{"id":"W4400412596","doi":"10.1016/j.annonc.2024.07.244","title":"Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"NIHR Cambridge Biomedical Research Centre; Canadian Institutes of Health Research; National Institute for Health and Care Research; Foundation Medicine; Cancer Research UK; NIHR Leicester Biomedical Research Centre; AstraZeneca; Springworks Therapeutics; American Society of Clinical Oncology; NIHR Exeter Clinical Research Facility; Pfizer","keywords":"Medicine; Breast cancer; Germline; Oncology; Mainstream; Meta-analysis; Germline mutation; Population; Cancer; Gene; Internal medicine; Genetics; Mutation; Environmental health; Biology","score_opus":0.2350455018370315,"score_gpt":0.48703715598010644,"score_spread":0.25199165414307495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400412596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003584458,0.99466026,0.000036307316,0.0030523252,0.00015861457,0.00040580818,0.0012002775,0.00001246081,0.00011552317],"genre_scores_gemma":[0.0012011377,0.9924624,0.002474489,0.0015576937,0.0002762504,0.00051973335,0.0005912713,0.000044940294,0.0008721019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980927,0.00014980423,0.0007958111,0.00050503813,0.00019895095,0.0002576714],"domain_scores_gemma":[0.99781686,0.0002844225,0.00073592307,0.00032843562,0.0007572748,0.00007711071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006254974,0.00034285683,0.0022505305,0.00037104337,0.000070688024,0.00002107657,0.00016096665,0.00044137775,0.000040729632],"category_scores_gemma":[0.0005518595,0.00026557903,0.0008923793,0.0009856594,0.000043438646,0.000004806357,0.00016062749,0.00015139769,0.000007178657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001944146,0.00006876385,0.0003948143,0.0037374753,0.31116042,0.0000063886214,0.00006739609,0.0019844396,0.00003381676,0.000018054196,0.013970976,0.66853803],"study_design_scores_gemma":[0.00009280246,0.00021298364,0.00022539003,0.00009104435,0.26108402,0.000010901029,0.000015052347,0.000016364282,0.00007543378,0.00003331701,0.7378384,0.0003043094],"about_ca_topic_score_codex":0.00020942351,"about_ca_topic_score_gemma":0.00084630755,"teacher_disagreement_score":0.7238674,"about_ca_system_score_codex":0.00028951667,"about_ca_system_score_gemma":0.0009791563,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W4400429684","doi":"10.1016/j.annonc.2024.06.019","title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Unicancer; Ministère des Affaires Sociales et de la Santé; Ligue Contre le Cancer","keywords":"Medicine; Colorectal cancer; Neoadjuvant therapy; Internal medicine; Chemoradiotherapy; Clinical endpoint; Population; Surgery; Chemotherapy; Oncology; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.05252091223294044,"score_gpt":0.37678769331154993,"score_spread":0.3242667810786095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400429684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003845,0.0025385711,0.0000020446919,0.0018868499,0.00059633335,0.0025403362,0.000104832274,0.00002947689,0.00226308],"genre_scores_gemma":[0.997324,0.0016714276,0.00009640707,0.00017239961,0.000110276094,0.000288796,0.000030863655,0.000038252445,0.00026758516],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99798137,0.00016038245,0.0005396387,0.00050852716,0.00045769414,0.0003524164],"domain_scores_gemma":[0.9985772,0.00031011848,0.00026194067,0.00041470243,0.0003356499,0.00010038779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019619087,0.0002779234,0.0008765718,0.000108308486,0.000034324,0.000009106767,0.00018647307,0.00014754815,0.000068476984],"category_scores_gemma":[0.000056810153,0.00015201261,0.00014050181,0.00065711583,0.00040590044,0.00012227822,0.00004677011,0.00030838774,0.0000016020892],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71997297,0.0015441126,0.073967375,0.0000683528,0.00075604697,0.000108552864,0.0011478061,0.00019999979,0.0002049939,0.00001854956,0.000093273666,0.20191799],"study_design_scores_gemma":[0.25262558,0.10542793,0.62340873,0.0010189267,0.00009717744,0.000012469113,0.000052896572,0.000033238837,0.015737351,0.000008655279,0.001329511,0.00024751702],"about_ca_topic_score_codex":0.0003200062,"about_ca_topic_score_gemma":0.0014508286,"teacher_disagreement_score":0.54944134,"about_ca_system_score_codex":0.00041266571,"about_ca_system_score_gemma":0.0013979076,"threshold_uncertainty_score":0.61988944},"labels":[],"label_agreement":null},{"id":"W4400871285","doi":"10.1016/j.annonc.2024.05.004","title":"Reply to the Letter to the Editor ‘Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten’ (in regard to “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”) by Huguet et al.","year":2024,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Society for Medical Oncology; Indigenous Bar Association","keywords":"Medicine; Guideline; Pancreatic cancer; Clinical trial; Oncology; Clinical Practice; Radiation therapy; Internal medicine; Medical physics; Cancer; Family medicine; Pathology","score_opus":0.15175782772792795,"score_gpt":0.4900521706203447,"score_spread":0.3382943428924167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400871285","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011920261,0.008903676,0.0017233152,0.9598796,0.0024920069,0.014203217,0.00071253395,0.00004183966,0.00012360196],"genre_scores_gemma":[0.0033182295,0.022339178,0.0049020196,0.9318657,0.009781553,0.025062613,0.000594863,0.00014960133,0.001986249],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937225,0.0012044753,0.001977098,0.0013409535,0.00072279555,0.0010321729],"domain_scores_gemma":[0.9833017,0.013324349,0.00060890964,0.0011039057,0.0013615924,0.0002995621],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005714948,0.0006708849,0.0023117964,0.000361536,0.0001913449,0.00006636253,0.0005100207,0.00096057,0.000036703008],"category_scores_gemma":[0.0054325513,0.00039992935,0.00044225162,0.00053393614,0.00016448303,0.00012866205,0.0001290511,0.0012800659,0.000021034568],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009965182,0.0004457924,0.0028930402,0.00017519023,0.0015341298,0.000036891724,0.0010019483,0.000029112762,0.000053818447,0.000026795487,0.920968,0.06287012],"study_design_scores_gemma":[0.0062311376,0.028318377,0.0022315509,0.0004022801,0.0016618727,0.000033843346,0.00020640671,0.00057428324,0.0001405372,0.00009872968,0.9597421,0.00035887878],"about_ca_topic_score_codex":0.0016666474,"about_ca_topic_score_gemma":0.0012527859,"teacher_disagreement_score":0.06251124,"about_ca_system_score_codex":0.00049244077,"about_ca_system_score_gemma":0.0017475891,"threshold_uncertainty_score":0.99984527},"labels":[],"label_agreement":null},{"id":"W4401305210","doi":"10.1016/j.annonc.2024.07.728","title":"A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"American Regent; Fondation Gustave Roussy; Rising Tide Foundation for Clinical Cancer Research; Ipsen; Institut Gustave-Roussy; Vifor Pharma; Sierra Oncology; Fondation ARC pour la Recherche sur le Cancer; Astellas Pharma; Eisai; Agence Nationale de la Recherche; Abbott Laboratories; Clovis Oncology; Ionis Pharmaceuticals; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Susan G. Komen; Daiichi-Sankyo; Yuhan; Conquer Cancer Foundation; Daiichi Sankyo Europe; Rising Tide Foundation; Servier; Gilead Sciences; GlaxoSmithKline; Myriad Genetics; American Society of Clinical Oncology; AstraZeneca; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb; Puma Biotechnology; Regeneron Pharmaceuticals; Pfizer; Amgen; Breast Cancer Research Foundation","keywords":"Medicine; Systemic inflammation; Breast cancer; Inflammation; Cancer; Systemic therapy; Cancer-related fatigue; Inflammatory breast cancer; Oncology; Internal medicine","score_opus":0.18680036002614567,"score_gpt":0.46752703253930955,"score_spread":0.28072667251316386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401305210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417573,0.0034097037,0.000009446197,0.0015499403,0.00025763735,0.00017026132,0.00024056635,0.000011405115,0.00017529822],"genre_scores_gemma":[0.9951573,0.0044272724,0.000029948675,0.00010250091,0.00009550387,0.00006067718,0.000013371797,0.00001078686,0.00010266195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895954,0.000048873946,0.0005940937,0.00016268842,0.00012918339,0.0001056132],"domain_scores_gemma":[0.9993266,0.00009262566,0.00020391596,0.00014026812,0.00017587373,0.000060733895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032406204,0.00007282878,0.00048547742,0.00008220277,0.0000063468196,0.0000018181069,0.000043806773,0.00016514088,0.0000993768],"category_scores_gemma":[0.00001763861,0.000062586245,0.00011703546,0.00010267652,0.00013927817,0.000049058057,0.00003945787,0.00009610694,0.0000012087949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004863753,0.00012388009,0.86968416,0.0010341321,0.00012437304,0.000029826004,0.0021603247,0.00004853889,0.0050629745,0.00013540755,0.0027156114,0.11839441],"study_design_scores_gemma":[0.0031731955,0.0038294636,0.9458809,0.004180189,0.0009279322,0.00021174575,0.0009755453,0.005957525,0.028296595,0.00036435208,0.0058289836,0.0003736013],"about_ca_topic_score_codex":0.00067919254,"about_ca_topic_score_gemma":0.0015730889,"teacher_disagreement_score":0.11802081,"about_ca_system_score_codex":0.000031637523,"about_ca_system_score_gemma":0.00023457975,"threshold_uncertainty_score":0.25521928},"labels":[],"label_agreement":null},{"id":"W4401305294","doi":"10.1016/j.annonc.2024.07.727","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Genentech; Astellas Pharma; Eisai; European Society for Medical Oncology; European Association of Urology; Seagen; Advanced Accelerator Applications; National Institutes of Health; CVS Health; Amgen; Deciphera Pharmaceuticals; Jounce Therapeutics; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Merck KGaA; Endocyte; Nihon Pharmaceutical; PTC Therapeutics; BioCryst; Ipsen; Array BioPharma; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Revolution Medicines; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; EUSA Pharma; AstraZeneca; American Society of Clinical Oncology; Coherus Biosciences; Arrowhead Pharmaceuticals; GlaxoSmithKline; Dana-Farber Cancer Institute; Incyte; Pfizer","keywords":"Medicine; Sunitinib; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Oncology; Urology; Immunotherapy; Cancer","score_opus":0.11061446975755834,"score_gpt":0.3866629650592868,"score_spread":0.2760484953017285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401305294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98647946,0.004695525,0.00002764423,0.0019372972,0.00070883706,0.0026046133,0.0013297182,0.000028391734,0.0021884986],"genre_scores_gemma":[0.996089,0.0015483983,0.00050461135,0.00003217725,0.000335157,0.0001326543,0.0006321923,0.00003988686,0.00068594405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975674,0.00015753508,0.001114848,0.0005146683,0.00028032513,0.0003652306],"domain_scores_gemma":[0.99571615,0.0027759983,0.00046570567,0.00057926425,0.00030788127,0.0001549708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041310946,0.00032036655,0.0012727289,0.00013511657,0.00007685626,0.0000068680856,0.0001435024,0.00020686543,0.00005317498],"category_scores_gemma":[0.0002753168,0.0002173448,0.0004340228,0.00020029623,0.00029262304,0.000055750053,0.00006138807,0.00012745538,0.000003272761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8905522,0.003073503,0.000011354554,0.00021946488,0.0007690537,0.00015315699,0.0029947439,0.000051744777,0.010334711,0.00010847372,0.0012585954,0.09047296],"study_design_scores_gemma":[0.6892043,0.12387899,0.0010593596,0.0001698409,0.0014373744,0.000013223843,0.0006758595,0.00032793844,0.15847954,0.00010899072,0.024471045,0.00017356288],"about_ca_topic_score_codex":0.0005541436,"about_ca_topic_score_gemma":0.00025105666,"teacher_disagreement_score":0.20134798,"about_ca_system_score_codex":0.00021716836,"about_ca_system_score_gemma":0.00062948687,"threshold_uncertainty_score":0.8863064},"labels":[],"label_agreement":null},{"id":"W4402540651","doi":"10.1016/j.annonc.2024.08.2242","title":"ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Eisai; Natera; Seagen; Incyte; BeiGene; Clovis Oncology; Novocure; Exelixis; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Placebo; Chemotherapy; Adjuvant; Oncology; Radiation therapy; Internal medicine; Cancer; Immunotherapy; Alternative medicine","score_opus":0.06538704027016648,"score_gpt":0.4011213257799936,"score_spread":0.3357342855098271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402540651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98710036,0.0027114404,0.00014380371,0.00064758596,0.0004775432,0.008493023,0.0001299365,0.00007139054,0.00022494174],"genre_scores_gemma":[0.9921136,0.004345422,0.00037119177,0.00055190036,0.0005089582,0.0015401833,0.000055020875,0.000115453986,0.00039825315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99590224,0.00038126516,0.0012573712,0.00084581,0.00093689165,0.0006764157],"domain_scores_gemma":[0.99632907,0.0016868734,0.00066912535,0.00054367556,0.0004337523,0.00033749372],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006873789,0.00060278893,0.0029486152,0.0011138604,0.00007136955,0.000028050374,0.00029055172,0.0002943152,0.0013210151],"category_scores_gemma":[0.00018572334,0.00032631753,0.00022249015,0.002327106,0.0002531396,0.00019515489,0.00004576143,0.0005368433,0.0000042948504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8029513,0.010747729,0.0304549,0.00019400152,0.003393136,0.0004710508,0.0034547003,0.0002341426,0.00006031962,0.000007126687,0.00033321872,0.14769839],"study_design_scores_gemma":[0.8707504,0.11671407,0.0058564516,0.00043007758,0.00095957314,0.000020265796,0.00056319224,0.00009459969,0.0015540704,0.00000771531,0.0026991526,0.00035040174],"about_ca_topic_score_codex":0.00968926,"about_ca_topic_score_gemma":0.0052427147,"teacher_disagreement_score":0.14734797,"about_ca_system_score_codex":0.00047315948,"about_ca_system_score_gemma":0.0018506689,"threshold_uncertainty_score":0.9999189},"labels":[],"label_agreement":null},{"id":"W4402541957","doi":"10.1016/j.annonc.2024.08.2348","title":"Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Head and neck; Genome; DNA methylation; Computational biology; Head and neck cancer; Pathology; Genetics; Internal medicine; Gene; Surgery; Cancer; Biology","score_opus":0.1056900874443499,"score_gpt":0.4566918474981455,"score_spread":0.3510017600537956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402541957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95825964,0.021195667,0.00068288465,0.018415065,0.00021401039,0.0005558837,0.000061884486,0.000020806847,0.0005941708],"genre_scores_gemma":[0.99353343,0.0031579253,0.0014284084,0.001418133,0.00013131571,0.000059018286,0.00003375958,0.000014781275,0.00022320896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99870634,0.00013460832,0.00054136734,0.00026076753,0.00015648128,0.00020044178],"domain_scores_gemma":[0.99800223,0.0013818605,0.00009967118,0.00015519367,0.0002164428,0.0001445829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009562849,0.00010988351,0.0006245003,0.00010739582,0.000026662925,0.000005482183,0.000047560516,0.00009197563,0.000021323829],"category_scores_gemma":[0.0015632961,0.0000913112,0.0001123175,0.00011536161,0.00017059449,0.00004321143,0.0000560759,0.00008649033,0.0000037100801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009908814,0.0049057133,0.14852007,0.015535829,0.004913061,0.0021463798,0.0068844683,0.00012351725,0.18859267,0.012250136,0.096008874,0.51021045],"study_design_scores_gemma":[0.00410762,0.028131623,0.4388742,0.0011263081,0.0012843716,0.000022656443,0.00031857134,0.00009134587,0.091272905,0.0055597033,0.4288662,0.00034449092],"about_ca_topic_score_codex":0.000017892136,"about_ca_topic_score_gemma":0.0000053594886,"teacher_disagreement_score":0.509866,"about_ca_system_score_codex":0.000022111493,"about_ca_system_score_gemma":0.00034354412,"threshold_uncertainty_score":0.37235627},"labels":[],"label_agreement":null},{"id":"W4402552559","doi":"10.1016/j.annonc.2024.08.2330","title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Hexal AG; Pharmacyclics; Genentech; Eisai; Pfizer; Innovent Biologics; Incyte; Moderna; SkylineDx; BeiGene; Les Laboratories Pierre Fabre; Sun Pharma; Regeneron Pharmaceuticals; Array BioPharma; Qbiotics; NGM Biopharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Exelixis; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Ipilimumab; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.07706815044565193,"score_gpt":0.41984728697892937,"score_spread":0.3427791365332774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402552559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98544776,0.0027793609,0.000026321257,0.0030926417,0.0019193842,0.0012759943,0.00007636872,0.000034769808,0.005347376],"genre_scores_gemma":[0.9964216,0.00021894026,0.00007245052,0.00025659965,0.0001429798,0.00009582729,0.000015756394,0.000025621333,0.002750246],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869555,0.00008068111,0.00048870477,0.00026840207,0.00021112336,0.0002555508],"domain_scores_gemma":[0.9987817,0.00038930326,0.0001686063,0.0003894388,0.00022004747,0.000050915394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043713424,0.00015267803,0.00053736987,0.00011136405,0.000056015306,0.000005648382,0.0001941547,0.00012621598,0.00035088373],"category_scores_gemma":[0.00014857594,0.00010500513,0.00039791898,0.00028757472,0.00017800648,0.00005689032,0.00005268038,0.0001270633,0.0000068914524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48491842,0.0036799433,0.00023603147,0.0004292964,0.0028368984,0.00004920513,0.0034607071,0.0000063083085,0.052664425,0.00053763035,0.053895243,0.39728588],"study_design_scores_gemma":[0.2688699,0.08788957,0.0022915385,0.00027520285,0.0008842009,0.00003284321,0.003848188,0.00013630392,0.061225556,0.0002815464,0.5739687,0.00029643776],"about_ca_topic_score_codex":0.00007907221,"about_ca_topic_score_gemma":0.0001304891,"teacher_disagreement_score":0.5200735,"about_ca_system_score_codex":0.00007221654,"about_ca_system_score_gemma":0.00049183145,"threshold_uncertainty_score":0.4281985},"labels":[],"label_agreement":null},{"id":"W4402558258","doi":"10.1016/j.annonc.2024.08.430","title":"CN35 Screening recommendations for and outcomes of male patients (pts) with germline BRCA (gBRCA)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia Hospital; BC Cancer Agency; University of the Fraser Valley; Abbotsford Veterinary Clinic","funders":"AstraZeneca; Astellas Pharma US","keywords":"Medicine; Germline; Internal medicine; Oncology; Genetics","score_opus":0.05654253789954267,"score_gpt":0.3882641526118921,"score_spread":0.33172161471234946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805991,0.0012281981,0.0076308344,0.008218153,0.0002193437,0.0003164812,0.00033094018,0.00000865171,0.0014482917],"genre_scores_gemma":[0.9799953,0.00030110532,0.018140435,0.00056800176,0.00005853949,0.00005327331,0.00022804289,0.000017349597,0.0006379509],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939394,0.000027757309,0.00021384156,0.00019260851,0.000053467174,0.000118383476],"domain_scores_gemma":[0.999443,0.000075053336,0.0000925541,0.00013779316,0.0002213915,0.000030214156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015380961,0.00007965585,0.00016793064,0.00006358058,0.000030960215,0.0000054252955,0.0000740533,0.000093108974,0.00003310497],"category_scores_gemma":[0.00006990516,0.000068553076,0.000053135736,0.00007114115,0.00010224071,0.000005271608,0.00005037166,0.00004068764,6.6167433e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005715584,0.00053510716,0.08134562,0.00032885265,0.0011943878,0.0000031259485,0.00056341756,0.00018563753,0.027746655,0.0016729443,0.124863565,0.7609891],"study_design_scores_gemma":[0.0016727863,0.0045429803,0.026335977,0.00006289521,0.00009220925,0.000014695954,0.00016547854,0.00020455103,0.07241788,0.0003967211,0.89388734,0.00020651614],"about_ca_topic_score_codex":0.0000133171125,"about_ca_topic_score_gemma":0.000052935837,"teacher_disagreement_score":0.7690238,"about_ca_system_score_codex":0.000008971658,"about_ca_system_score_gemma":0.00012865588,"threshold_uncertainty_score":0.27955133},"labels":[],"label_agreement":null},{"id":"W4402558328","doi":"10.1016/j.annonc.2024.08.1417","title":"1362P Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Glycemic Index Laboratories; Princess Margaret Cancer Centre; Systems, Applications & Products in Data Processing (Canada); University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Computed tomography; Radiology; Nuclear medicine; Oncology","score_opus":0.0417545052990924,"score_gpt":0.40683021340407205,"score_spread":0.36507570810497963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7663727,0.003306268,0.2237264,0.0030680792,0.00035635312,0.0019935279,0.0000072114694,0.00006727623,0.0011021881],"genre_scores_gemma":[0.96746784,0.00003190247,0.031142414,0.0008546881,0.00014290505,0.00023979202,0.000068423666,0.000039795006,0.000012252075],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984555,0.00010006646,0.00047119276,0.0003598376,0.00031933602,0.00029401307],"domain_scores_gemma":[0.99833524,0.0004217584,0.0002306015,0.00016287316,0.00071995467,0.00012954541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001486191,0.0001552829,0.00044467163,0.00040927425,0.00006165117,0.0000132216965,0.000109544606,0.000060041395,0.000033971548],"category_scores_gemma":[0.00038273135,0.00014902471,0.0001454513,0.00047301897,0.000089869514,0.000044915178,0.000029099267,0.0002741181,0.0000011125184],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036121547,0.0003171801,0.020264074,0.001767084,0.00016609009,0.0000086744485,0.0009172654,0.18507518,0.15009902,0.0001348692,0.0005459806,0.64034337],"study_design_scores_gemma":[0.0020604366,0.0005747075,0.005730724,0.00058039685,0.00054053444,0.0000059982317,0.00011046484,0.95583236,0.03048205,0.00010406724,0.0038427925,0.00013548924],"about_ca_topic_score_codex":0.00007059163,"about_ca_topic_score_gemma":0.000008748996,"teacher_disagreement_score":0.77075714,"about_ca_system_score_codex":0.000092640075,"about_ca_system_score_gemma":0.0006270176,"threshold_uncertainty_score":0.6077051},"labels":[],"label_agreement":null},{"id":"W4402558343","doi":"10.1016/j.annonc.2024.08.1361","title":"1304P Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; AstraZeneca; EMD Serono; Pfizer; Amgen","keywords":"Crizotinib; Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine","score_opus":0.04988997537621109,"score_gpt":0.40813072264665934,"score_spread":0.35824074727044825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539065,0.00031726633,0.0000015734647,0.0003991413,0.00013639721,0.0011991153,0.00013293017,0.00001870074,0.0024042395],"genre_scores_gemma":[0.99882364,0.00005371246,0.00015880266,0.00046926664,0.000012469887,0.00023299347,0.000053689313,0.00002317394,0.0001722248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888307,0.00006268893,0.0003410392,0.0002791923,0.00015259284,0.00028142869],"domain_scores_gemma":[0.9990669,0.00007190579,0.00012836435,0.00019019666,0.00027495282,0.00026767314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007973816,0.0001477992,0.00042316687,0.0003260633,0.000031915377,0.000005444584,0.00007151541,0.000077263256,0.000095076786],"category_scores_gemma":[0.000048593192,0.00011695203,0.000032602144,0.0005511554,0.00007770827,0.00010585681,0.000018675884,0.00014481644,0.0000011860102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068475713,0.0023340136,0.95086753,0.00035647783,0.00055283215,0.0003397978,0.0333797,0.00028085074,0.0027548794,0.00002679596,0.00060735096,0.007815034],"study_design_scores_gemma":[0.016385088,0.023711221,0.90043795,0.0009660577,0.00053439656,0.000003052318,0.015023699,0.00021261215,0.03542725,0.000010993522,0.0069348454,0.00035281215],"about_ca_topic_score_codex":0.08804655,"about_ca_topic_score_gemma":0.07381097,"teacher_disagreement_score":0.050429538,"about_ca_system_score_codex":0.00024152816,"about_ca_system_score_gemma":0.0027682032,"threshold_uncertainty_score":0.94308954},"labels":[],"label_agreement":null},{"id":"W4402558349","doi":"10.1016/j.annonc.2024.08.1366","title":"1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"PARP inhibitor; Medicine; Homologous recombination; Cancer research; Poly ADP ribose polymerase; Olaparib; Phenotype; Lung cancer; Pathology; Genetics; Gene; Polymerase; Biology","score_opus":0.027569503970829617,"score_gpt":0.3603600992103541,"score_spread":0.3327905952395245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729568,0.011266977,0.0029532278,0.010034928,0.00081512623,0.0012681421,0.0002984499,0.000037321453,0.00036903072],"genre_scores_gemma":[0.9961866,0.0009787584,0.0006407018,0.001384908,0.00016549413,0.00021490143,0.00014275893,0.00003564304,0.00025019064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976891,0.00022763648,0.0008593976,0.00052023685,0.00036690483,0.00033667788],"domain_scores_gemma":[0.99745643,0.00038689433,0.00044878322,0.00043065686,0.0011520773,0.00012518217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000830943,0.00024550094,0.00078382343,0.001013019,0.00014220065,0.000031933396,0.00022701883,0.0002706841,0.0003752822],"category_scores_gemma":[0.00007281544,0.00020825976,0.0003255183,0.0015115885,0.00017985346,0.00012455307,0.00006960222,0.00032614835,0.000006171737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034998574,0.0027374418,0.0074656745,0.0017855347,0.00404793,0.00006280585,0.010603818,0.026608769,0.90109164,0.00039668757,0.024144618,0.017555244],"study_design_scores_gemma":[0.02217669,0.032523006,0.31689748,0.0029161444,0.025223969,0.000096288284,0.004031522,0.11379419,0.45343354,0.0011399792,0.02535437,0.0024128181],"about_ca_topic_score_codex":0.0009146002,"about_ca_topic_score_gemma":0.0013420957,"teacher_disagreement_score":0.44765806,"about_ca_system_score_codex":0.00022352257,"about_ca_system_score_gemma":0.0013930888,"threshold_uncertainty_score":0.84925866},"labels":[],"label_agreement":null},{"id":"W4402558380","doi":"10.1016/j.annonc.2024.08.1347","title":"1290P Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Oncology; Internal medicine; Cancer; Adenocarcinoma","score_opus":0.017995656564135962,"score_gpt":0.37439781244780723,"score_spread":0.35640215588367125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901576,0.0009992291,0.00011740547,0.0017993944,0.00010858881,0.00075331976,0.00009856028,0.000018586174,0.007089186],"genre_scores_gemma":[0.9981086,0.00037496877,0.00075902004,0.00034691495,0.000011748099,0.000019096542,0.00014658173,0.000014134239,0.0002188928],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991213,0.000055671033,0.00031471855,0.00021424054,0.00013080526,0.00016323222],"domain_scores_gemma":[0.9993015,0.0002034541,0.00010072477,0.000109720946,0.00021124733,0.0000733614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009891733,0.000112683374,0.00037651023,0.00015522484,0.000021963335,0.0000035006215,0.000032915632,0.00004990312,0.00008128435],"category_scores_gemma":[0.00005123163,0.0000809415,0.00003540113,0.00027487802,0.00011373346,0.00007006943,0.000024924182,0.000102577695,0.000005240837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008870186,0.003380299,0.027906153,0.00030176886,0.0011279025,0.00026321603,0.004558742,0.0002878683,0.00066486566,0.0005684309,0.0016752884,0.9503953],"study_design_scores_gemma":[0.038277067,0.04284525,0.877072,0.0028762317,0.0011526078,0.00007320918,0.0011666922,0.00031962636,0.005970002,0.00051194924,0.029378774,0.00035659358],"about_ca_topic_score_codex":0.00008517095,"about_ca_topic_score_gemma":0.000066791115,"teacher_disagreement_score":0.9500387,"about_ca_system_score_codex":0.00006315856,"about_ca_system_score_gemma":0.0003238849,"threshold_uncertainty_score":0.33006987},"labels":[],"label_agreement":null},{"id":"W4402558385","doi":"10.1016/j.annonc.2024.08.1362","title":"1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"Medicine; KRAS; Pooled analysis; Clinical trial; Oncology; Term (time); Internal medicine; Cancer; Meta-analysis","score_opus":0.29656837332955427,"score_gpt":0.5859161466639741,"score_spread":0.2893477733344198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257154,0.0035696772,0.00012738109,0.010077657,0.0008191085,0.0015314791,0.00016119458,0.0001233139,0.0010186401],"genre_scores_gemma":[0.99230564,0.003282386,0.00018878987,0.002378164,0.00044024928,0.00009891301,0.00033371025,0.0000519224,0.0009202574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888149,0.004593756,0.004110858,0.001018448,0.0007118838,0.0007501857],"domain_scores_gemma":[0.963316,0.034015663,0.0006256215,0.0011700159,0.0004671144,0.00040553915],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013806909,0.00038952372,0.00405573,0.0005182209,0.0000532417,0.00004519136,0.0005845691,0.00087553344,0.0010982454],"category_scores_gemma":[0.019230451,0.00023589349,0.0019728208,0.0018118792,0.0008351041,0.00012935589,0.0002661189,0.0012086695,0.00017546963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009710995,0.002101838,0.7458972,0.0000970922,0.018422915,0.0028400274,0.00040278607,0.000064685715,0.00030390383,0.000059383943,0.007711419,0.21238776],"study_design_scores_gemma":[0.03661515,0.0046225283,0.93795663,0.00041422207,0.005926259,0.000049239854,0.00015841777,0.009528394,0.00075695827,0.00031509416,0.0033282598,0.0003288263],"about_ca_topic_score_codex":0.0019564782,"about_ca_topic_score_gemma":0.0025470133,"teacher_disagreement_score":0.21205893,"about_ca_system_score_codex":0.0014605147,"about_ca_system_score_gemma":0.008965818,"threshold_uncertainty_score":0.99981487},"labels":[],"label_agreement":null},{"id":"W4402558405","doi":"10.1016/j.annonc.2024.08.1346","title":"1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ROS1; Oncology; Internal medicine; Lung cancer; Phases of clinical research; Clinical trial; Safety profile; Cancer; Adenocarcinoma; Adverse effect","score_opus":0.0491402154988023,"score_gpt":0.4385308151696402,"score_spread":0.3893905996708379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100906,0.004282392,0.00008306612,0.0009193808,0.00023987038,0.0014242104,0.0006711985,0.000017523605,0.0013532944],"genre_scores_gemma":[0.9966431,0.001020588,0.0013012983,0.00025173704,0.000051372557,0.00012276515,0.0001723641,0.000026399928,0.00041035248],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984576,0.00012802362,0.0007237696,0.00031948014,0.00015156093,0.00021957215],"domain_scores_gemma":[0.9985141,0.0007432486,0.0003082603,0.0001604931,0.00016665377,0.000107198655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030213513,0.00018365133,0.0010143728,0.00019129258,0.000037509406,0.0000059295644,0.000053806714,0.000073723815,0.0001862414],"category_scores_gemma":[0.00018062639,0.000119285054,0.00009248152,0.0002840874,0.00008666946,0.00008662883,0.000033867203,0.00013211597,0.0000011590122],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04085677,0.012655729,0.014981925,0.0011205744,0.00420848,0.00035712332,0.011124109,0.00025201138,0.009761407,0.000037009035,0.0025432534,0.90210164],"study_design_scores_gemma":[0.4462995,0.18678981,0.19342732,0.008452809,0.017449029,0.00003877186,0.0029919252,0.0019247216,0.08698326,0.00018485574,0.054152098,0.0013059037],"about_ca_topic_score_codex":0.0007740202,"about_ca_topic_score_gemma":0.0005431766,"teacher_disagreement_score":0.9007957,"about_ca_system_score_codex":0.00009860963,"about_ca_system_score_gemma":0.0008008653,"threshold_uncertainty_score":0.48643032},"labels":[],"label_agreement":null},{"id":"W4402558442","doi":"10.1016/j.annonc.2024.08.1369","title":"1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Docetaxel; Oncology; Lung cancer; Internal medicine; Chemotherapy; Cancer research","score_opus":0.019711067759654484,"score_gpt":0.3586001921693946,"score_spread":0.3388891244097401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935945,0.00415443,0.00031323274,0.0072274073,0.00029868304,0.001623932,0.0021633878,0.00008050557,0.004778969],"genre_scores_gemma":[0.9909611,0.00067925546,0.0041176416,0.0016826278,0.00011821868,0.000327761,0.0011195396,0.00008054199,0.0009133643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973553,0.00014419314,0.000703598,0.0008325998,0.00037602437,0.00058828184],"domain_scores_gemma":[0.9980368,0.0004863129,0.00031598276,0.0005591985,0.00035111158,0.00025059227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019593416,0.00041438948,0.00092551677,0.00037621128,0.00008376831,0.000031174728,0.00019718843,0.000172914,0.00014357403],"category_scores_gemma":[0.00008126629,0.00029156808,0.0001253322,0.0006443021,0.00017424978,0.00024464747,0.00006741135,0.00036101663,0.000017920105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06428229,0.016248588,0.22565599,0.0024289482,0.008634941,0.0057176086,0.02003425,0.0038713326,0.0033341858,0.0004462256,0.08965514,0.5596905],"study_design_scores_gemma":[0.16566709,0.06691023,0.36336026,0.00777092,0.008538558,0.00015430912,0.0035428014,0.0028767348,0.035669897,0.00033189802,0.3424292,0.0027481336],"about_ca_topic_score_codex":0.004337881,"about_ca_topic_score_gemma":0.0052030836,"teacher_disagreement_score":0.55694234,"about_ca_system_score_codex":0.00034218814,"about_ca_system_score_gemma":0.0017816391,"threshold_uncertainty_score":0.9999536},"labels":[],"label_agreement":null},{"id":"W4402558452","doi":"10.1016/j.annonc.2024.08.1351","title":"1294P Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adenocarcinoma; Histology; Lung cancer; Oncology; Pathology; Internal medicine; Cancer","score_opus":0.020745352884882304,"score_gpt":0.3733605415073323,"score_spread":0.35261518862244995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359457,0.0050418396,0.0000076675,0.05662244,0.0006712332,0.0005623546,0.00013500718,0.000021080574,0.0009927041],"genre_scores_gemma":[0.99678296,0.00015751195,0.00016523144,0.0016290625,0.00016719184,0.00009032422,0.000058308513,0.000024383662,0.000925056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987035,0.00017490839,0.00030882366,0.00037659227,0.00017802951,0.00025816238],"domain_scores_gemma":[0.9988113,0.0004992392,0.00009869966,0.00032598127,0.0001453393,0.00011944176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030604683,0.00015234278,0.00041788907,0.00012408044,0.00006004515,0.000010415033,0.000094521805,0.00015496311,0.000060097515],"category_scores_gemma":[0.00013486088,0.000100307734,0.00004760572,0.00023292848,0.00017586641,0.000057280104,0.000054819477,0.00022524416,0.0000055953224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007438569,0.00021817174,0.9001566,0.00009059393,0.0004081948,0.00034457323,0.004662482,0.00000810085,0.00023741605,0.00009235929,0.07585804,0.01048487],"study_design_scores_gemma":[0.0025566004,0.0031805658,0.90134764,0.00040548918,0.000256879,0.000008939142,0.00038545864,0.000026422427,0.00023963761,0.00006951251,0.09140408,0.000118798205],"about_ca_topic_score_codex":0.0030095587,"about_ca_topic_score_gemma":0.0013603502,"teacher_disagreement_score":0.060837258,"about_ca_system_score_codex":0.00028123683,"about_ca_system_score_gemma":0.00079474185,"threshold_uncertainty_score":0.45495725},"labels":[],"label_agreement":null},{"id":"W4402558483","doi":"10.1016/j.annonc.2024.08.1344","title":"1287P Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Predictive value; Lung cancer; Toxicity; Oncology; Internal medicine","score_opus":0.025320002150827758,"score_gpt":0.40755104750283544,"score_spread":0.3822310453520077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820071,0.005673166,0.000043045828,0.0015904276,0.00015366526,0.00030734093,0.00002794799,0.0000095652385,0.010187766],"genre_scores_gemma":[0.9977722,0.0014527771,0.00028889556,0.00014419132,0.00006164017,0.000053321506,0.000005937672,0.000011434958,0.0002095912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999239,0.00004374586,0.00027463885,0.00019492664,0.00007766516,0.00016997142],"domain_scores_gemma":[0.9996127,0.00011563873,0.00007572243,0.0000835286,0.00006251003,0.000049892704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015006437,0.00008853543,0.000329131,0.00021746088,0.000016424123,0.0000050639496,0.000033752767,0.00009958587,0.0000300591],"category_scores_gemma":[0.000020457352,0.00007563779,0.000041245454,0.00021145743,0.000060819584,0.00009339605,0.000031823412,0.00014114965,4.6420234e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042301754,0.0014006669,0.8622366,0.003157942,0.0005858794,0.00071513886,0.017851353,0.0008694104,0.072374314,0.0002831646,0.000880796,0.039221678],"study_design_scores_gemma":[0.0026497243,0.00085236295,0.93020886,0.0013919804,0.00024889,0.00001684436,0.00063080125,0.004039824,0.0587464,0.00017459708,0.0009382692,0.0001014524],"about_ca_topic_score_codex":0.0011990679,"about_ca_topic_score_gemma":0.00047401866,"teacher_disagreement_score":0.06797222,"about_ca_system_score_codex":0.00016633555,"about_ca_system_score_gemma":0.00046719713,"threshold_uncertainty_score":0.30844197},"labels":[],"label_agreement":null},{"id":"W4402558540","doi":"10.1016/j.annonc.2024.08.2251","title":"LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Loxo Oncology; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Genentech; Veracyte; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Eli Lilly and Company; National Comprehensive Cancer Network; Medac; Jazz Pharmaceuticals; Puma Biotechnology; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; Radius Health; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Celgene","keywords":"Medicine; Aromatase inhibitor; Breast cancer; Internal medicine; Nonsteroidal; Adjuvant; Oncology; Aromatase; Cancer; Gynecology","score_opus":0.03707574296529653,"score_gpt":0.3526388762594793,"score_spread":0.3155631332941828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828225,0.0016395081,0.000017913224,0.0110251,0.0010414018,0.0011075119,0.0020639,0.00007509697,0.00020711687],"genre_scores_gemma":[0.9963229,0.00012246885,0.00019992165,0.0020974353,0.0006431377,0.00019249372,0.00017128322,0.000066786044,0.00018360994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765116,0.00017290529,0.0006407839,0.00053071615,0.00049713376,0.0005072959],"domain_scores_gemma":[0.9984253,0.0004706433,0.00023564023,0.0004977246,0.00021178141,0.00015893033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029300753,0.00033657573,0.00093360746,0.00016140912,0.000057027155,0.00002806241,0.00027279474,0.00021645495,0.00035046096],"category_scores_gemma":[0.00006770218,0.00020968965,0.00017570343,0.0003445233,0.000412042,0.00027929872,0.000118916025,0.0005224523,0.00007053876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19278799,0.002315374,0.4338779,0.00022786866,0.0019665628,0.000708776,0.0068261093,0.00008050268,0.0006261596,0.0001948659,0.009541867,0.35084602],"study_design_scores_gemma":[0.09091541,0.006798746,0.87257886,0.00094815716,0.00024065818,0.000044591685,0.00074736075,0.00004051864,0.00074262364,0.0003070854,0.026213031,0.00042295328],"about_ca_topic_score_codex":0.0021408014,"about_ca_topic_score_gemma":0.0010738503,"teacher_disagreement_score":0.43870097,"about_ca_system_score_codex":0.0002584623,"about_ca_system_score_gemma":0.0007419027,"threshold_uncertainty_score":0.8550896},"labels":[],"label_agreement":null},{"id":"W4402558630","doi":"10.1016/j.annonc.2024.08.2153","title":"793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Endometrial cancer; Gynecology; Internal medicine; Cancer; Randomized controlled trial","score_opus":0.05917393748127625,"score_gpt":0.4080223914604927,"score_spread":0.34884845397921643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836557,0.0056765797,0.000023957808,0.0014237142,0.00022956003,0.008373213,0.0001472489,0.000030128718,0.00043989654],"genre_scores_gemma":[0.98420113,0.012907082,0.00024239,0.0011631565,0.0002069827,0.0008212224,0.00003785022,0.00010489368,0.000315283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996176,0.00048521775,0.0014504078,0.0008013578,0.00055597845,0.0005310555],"domain_scores_gemma":[0.99685526,0.0012279092,0.0008196699,0.00055017514,0.00036726284,0.00017972218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005960496,0.00061055896,0.0037213517,0.0007539134,0.00006155143,0.000034810284,0.0003079347,0.00024643954,0.00031127082],"category_scores_gemma":[0.00008113566,0.00041450965,0.00026697214,0.0009828992,0.00037425873,0.00023357329,0.00004802393,0.00023974071,0.000001252356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49585855,0.027354121,0.010651616,0.00011599011,0.0045304378,0.000020194064,0.0071073323,0.0000053731237,0.002011305,0.000007882193,0.00007512961,0.45226207],"study_design_scores_gemma":[0.878735,0.07617005,0.018500078,0.0005227724,0.0005046954,0.0000016033707,0.00043575696,0.00019593912,0.019067107,0.000045576588,0.0054809717,0.00034041313],"about_ca_topic_score_codex":0.0069056847,"about_ca_topic_score_gemma":0.00072441384,"teacher_disagreement_score":0.45192164,"about_ca_system_score_codex":0.0004380295,"about_ca_system_score_gemma":0.00043347818,"threshold_uncertainty_score":0.99983066},"labels":[],"label_agreement":null},{"id":"W4402558632","doi":"10.1016/j.annonc.2024.08.2167","title":"CN58 Canadian resources and strategies to build global oncology nursing excellence","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Interprofessional Education and Collaboration","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; CARE Canada","funders":"","keywords":"Medicine; Excellence; Oncology nursing; Nursing; Oncology; Internal medicine; Nurse education","score_opus":0.09963788259419705,"score_gpt":0.5586593556382037,"score_spread":0.45902147304400664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52397215,0.0016350427,0.00013588823,0.190755,0.002997714,0.00037945333,0.000056073473,0.00004516573,0.28002352],"genre_scores_gemma":[0.9870018,0.00015525681,0.0006975805,0.009387134,0.00033541652,0.00006806213,0.000009179102,0.000008990386,0.0023366187],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984936,0.00042281012,0.00036505703,0.00023384785,0.000107075386,0.00037759045],"domain_scores_gemma":[0.9988129,0.00036089972,0.00008292895,0.00011968924,0.00033766762,0.00028588943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054682506,0.00009873254,0.00022457492,0.00018584229,0.00031054585,0.000016414255,0.00012583617,0.00029049776,0.00050027645],"category_scores_gemma":[0.00014200386,0.00008902651,0.000026123851,0.00038444964,0.000119731776,0.00012753876,0.00003544787,0.0002942186,0.00019222638],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027332018,0.00010778447,0.0016154805,0.00015530895,0.000038095506,0.0000332791,0.04120281,0.000013698694,0.00060072023,0.1880412,0.5272259,0.2406924],"study_design_scores_gemma":[0.00012384028,0.0007953403,0.010984997,0.0004982075,0.000009866424,0.000008120723,0.038605936,0.000117346455,0.00003252019,0.011071069,0.93765897,0.000093792885],"about_ca_topic_score_codex":0.03438232,"about_ca_topic_score_gemma":0.16782416,"teacher_disagreement_score":0.46302962,"about_ca_system_score_codex":0.0005015396,"about_ca_system_score_gemma":0.010650547,"threshold_uncertainty_score":0.99495816},"labels":[],"label_agreement":null},{"id":"W4402558664","doi":"10.1016/j.annonc.2024.08.2144","title":"987TiP First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Glypican 3; Chimeric antigen receptor; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer research; Immunotherapy; Cancer","score_opus":0.06382615843562044,"score_gpt":0.35002115545629187,"score_spread":0.2861949970206714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500024,0.0005937074,0.000025430283,0.00092285365,0.00021368395,0.0020691955,0.000025335552,0.000017876295,0.0011316696],"genre_scores_gemma":[0.9982202,0.00052135816,0.00019100728,0.00012289797,0.00026529472,0.000071333736,0.00027284515,0.00004469675,0.00029038647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775684,0.00034197484,0.0006507304,0.00041968198,0.0004709397,0.00035985437],"domain_scores_gemma":[0.9989112,0.000174367,0.00019904479,0.00030698246,0.00030805686,0.00010036076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064119394,0.00020881824,0.00068705506,0.00056456355,0.00003923999,0.000012365977,0.00012732926,0.00022867901,0.00051849737],"category_scores_gemma":[0.000036346577,0.00017627237,0.00014091893,0.00064889906,0.00015782009,0.00011863142,0.000034237095,0.00032076458,0.000008166382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06820361,0.0040271264,0.50522226,0.00018287916,0.00023315767,0.000102252605,0.003456269,0.00009624261,0.3549847,0.00006769586,0.0007206053,0.06270318],"study_design_scores_gemma":[0.08435105,0.054928828,0.5674145,0.000248225,0.00005092402,0.0000047522826,0.00014407326,0.0038041377,0.28133333,0.00007244302,0.007281222,0.00036649988],"about_ca_topic_score_codex":0.00088884664,"about_ca_topic_score_gemma":0.0002494783,"teacher_disagreement_score":0.07365136,"about_ca_system_score_codex":0.00017109142,"about_ca_system_score_gemma":0.00038829978,"threshold_uncertainty_score":0.71881783},"labels":[],"label_agreement":null},{"id":"W4402558698","doi":"10.1016/j.annonc.2024.08.2142","title":"1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Crizotinib; Melanoma; Oncology; Second-line therapy; Internal medicine; Metastatic melanoma; Second line; Dermatology; First line; Cancer research; Chemotherapy; Lung cancer","score_opus":0.13007298190412508,"score_gpt":0.4199939671503539,"score_spread":0.28992098524622884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860248,0.0014501243,0.0000046825,0.008911435,0.00018293611,0.0008348309,0.00001905808,0.000022808967,0.0025493419],"genre_scores_gemma":[0.9977894,0.0008043282,0.00049516547,0.0005296741,0.000026905365,0.00012676152,0.00006660383,0.00002322485,0.00013793747],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984431,0.00026772954,0.00052132295,0.00032792863,0.00016919778,0.00027068311],"domain_scores_gemma":[0.9981804,0.0011508568,0.00018395133,0.00021445526,0.00014401018,0.00012632823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003045528,0.0002271023,0.00079530803,0.00040795837,0.000025590278,0.000004222637,0.00007844693,0.00015981967,0.00009783966],"category_scores_gemma":[0.00037863498,0.0001660663,0.00010862237,0.00051715487,0.00027276052,0.000117789394,0.000019440027,0.00019042211,0.000021365675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047613274,0.02913435,0.5718809,0.0010231258,0.010285309,0.008554623,0.019073566,0.00060138537,0.0033048769,0.009900135,0.0013829245,0.29724556],"study_design_scores_gemma":[0.10691369,0.40046698,0.35221326,0.0011103692,0.001088445,0.00016074559,0.0015308954,0.0011429809,0.107592516,0.008736696,0.018489005,0.0005544077],"about_ca_topic_score_codex":0.002042102,"about_ca_topic_score_gemma":0.004056495,"teacher_disagreement_score":0.37133262,"about_ca_system_score_codex":0.00028843078,"about_ca_system_score_gemma":0.00110019,"threshold_uncertainty_score":0.6771987},"labels":[],"label_agreement":null},{"id":"W4402558709","doi":"10.1016/j.annonc.2024.08.2094","title":"2008P Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial carcinoma; Oncology; Multicenter study; Carcinoma; Internal medicine; Cancer; Bladder cancer; Immunotherapy","score_opus":0.05517249742119814,"score_gpt":0.3924936933833818,"score_spread":0.3373211959621837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651015,0.001225923,0.0001699228,0.0008726824,0.00014927943,0.00036668553,0.00021018817,0.000015762682,0.00047941876],"genre_scores_gemma":[0.9988462,0.0001564135,0.00064185396,0.00013843246,0.000044947235,0.000046505666,0.000010925078,0.0000187386,0.000096005984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986195,0.00031790332,0.0004327823,0.00029333492,0.0001426173,0.00019383803],"domain_scores_gemma":[0.99910814,0.00038379346,0.0001016889,0.00019098521,0.00014409424,0.00007131979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062798976,0.00013569053,0.00045962166,0.00017961132,0.000016409653,0.000007712268,0.00003977874,0.00012554754,0.0001078899],"category_scores_gemma":[0.00024148262,0.00011528024,0.000091586895,0.00013492529,0.00012220035,0.00015647255,0.0000360074,0.00018089234,0.000002275555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17394151,0.0037198642,0.60467356,0.0019777757,0.0005244526,0.0006601981,0.013896058,0.0009753266,0.09982073,0.00007515513,0.00018827607,0.09954709],"study_design_scores_gemma":[0.011885449,0.0033643718,0.91725224,0.00027272178,0.00023949043,0.000040564384,0.00029866557,0.011155634,0.053927526,0.000821596,0.00055966043,0.0001820895],"about_ca_topic_score_codex":0.00019620934,"about_ca_topic_score_gemma":0.0001853098,"teacher_disagreement_score":0.31257865,"about_ca_system_score_codex":0.00007573725,"about_ca_system_score_gemma":0.00049919897,"threshold_uncertainty_score":0.47009918},"labels":[],"label_agreement":null},{"id":"W4402558712","doi":"10.1016/j.annonc.2024.08.2123","title":"1905P Impact of proactive callback in patients with solid tumors receiving systemic therapy: A meta-analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Systemic therapy; Callback; Meta-analysis; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.1488304167108582,"score_gpt":0.4629236299410243,"score_spread":0.31409321323016615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935412,0.0041082767,0.000005503586,0.00060383993,0.000042353393,0.00062587345,0.000050828887,0.000021089156,0.0010010647],"genre_scores_gemma":[0.99921453,0.00027677426,0.00004570892,0.00014923807,0.000025343541,0.0000821554,0.00003269005,0.000020915812,0.00015264815],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9987546,0.00017988421,0.0004306016,0.0002519744,0.00015979113,0.00022312849],"domain_scores_gemma":[0.99910444,0.0002242143,0.00019977818,0.0001694029,0.00023252866,0.000069627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030014114,0.00016315616,0.001511087,0.00048171813,0.000008976154,0.000003242243,0.00006560269,0.000093391274,0.00039881532],"category_scores_gemma":[0.000019258641,0.000096447606,0.0007087933,0.0007786124,0.00008696338,0.00006396369,0.000017319651,0.00015512337,0.000003255818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008036134,0.003881248,0.44132733,0.000260859,0.52515477,0.0001974141,0.0045138462,0.00072018005,0.0022485629,0.00003261635,0.00182115,0.011805912],"study_design_scores_gemma":[0.0063266666,0.03953941,0.83836985,0.000101020356,0.10761558,0.00003781043,0.00018665384,0.0002799975,0.006541531,0.00007627875,0.0006575442,0.00026766854],"about_ca_topic_score_codex":0.0008728259,"about_ca_topic_score_gemma":0.00018729891,"teacher_disagreement_score":0.41753915,"about_ca_system_score_codex":0.00015506393,"about_ca_system_score_gemma":0.000481658,"threshold_uncertainty_score":0.4366748},"labels":[],"label_agreement":null},{"id":"W4402558718","doi":"10.1016/j.annonc.2024.08.2121","title":"1902P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Hôpital Maisonneuve-Rosemont; University Health Network; CancerCare Manitoba; Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre; University of British Columbia; Sunnybrook Health Science Centre; McGill University Health Centre; University of British Columbia Hospital; University of Saskatchewan; Centre Hospitalier de l’Université de Montréal; Université Laval; Dalhousie University","funders":"","keywords":"Medicine; Psychological intervention; Perspective (graphical); Delphi; Breast cancer; Family medicine; Delphi method; Medical physics; Dermatology; Cancer; Internal medicine; Nursing; Artificial intelligence","score_opus":0.09436969967300946,"score_gpt":0.4983854578413114,"score_spread":0.40401575816830193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558718","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1569638,0.051117014,0.0017647072,0.75997347,0.0034038112,0.0021787481,0.0012039766,0.000103074126,0.023291385],"genre_scores_gemma":[0.9831455,0.006079066,0.00069348817,0.009154894,0.00035934724,0.00024763623,0.000027369028,0.000017862525,0.00027485332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991459,0.0000720163,0.00028581772,0.00020248735,0.000056998055,0.00023676058],"domain_scores_gemma":[0.99913234,0.00042275837,0.00006639011,0.0001053143,0.00016390858,0.00010926832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017191673,0.0000978068,0.00033469233,0.0004078914,0.00004960468,0.0000038354196,0.000057311066,0.00018471133,0.00016573188],"category_scores_gemma":[0.00010623406,0.00008941153,0.00015852092,0.00017866904,0.0001575814,0.000039377785,0.00000509085,0.0001730422,0.0000052780506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016357034,0.0008777597,0.0015819623,0.0004298911,0.0007967422,0.0005492933,0.010454271,0.0009312322,0.0005780919,0.06995808,0.23298466,0.6792223],"study_design_scores_gemma":[0.009458996,0.009528547,0.060706675,0.003032684,0.00018460111,0.001349622,0.0056283195,0.013687708,0.001302236,0.018234605,0.8763199,0.0005660967],"about_ca_topic_score_codex":0.023428055,"about_ca_topic_score_gemma":0.0725661,"teacher_disagreement_score":0.8261817,"about_ca_system_score_codex":0.00069795584,"about_ca_system_score_gemma":0.0010677885,"threshold_uncertainty_score":0.983075},"labels":[],"label_agreement":null},{"id":"W4402559791","doi":"10.1016/j.annonc.2024.08.408","title":"CN21 Descriptive and content analysis of breast cancer vlogs on YouTube","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia; McGill University","funders":"","keywords":"Medicine; Descriptive statistics; Content analysis; Gynecology; Oncology; Statistics","score_opus":0.4908825991523964,"score_gpt":0.5360081680159761,"score_spread":0.04512556886357966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953818,0.0019593844,0.0000045407583,0.037897967,0.0020512117,0.00026712546,0.00007507394,0.00001571786,0.003910956],"genre_scores_gemma":[0.9960532,0.0027454663,0.00003338007,0.0007327511,0.00027045168,0.0001010266,0.0000033148735,0.0000043537125,0.000056040455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989884,0.0002544895,0.000239692,0.00015436442,0.00017896734,0.00018411179],"domain_scores_gemma":[0.9980266,0.0013629979,0.00011951793,0.0000686133,0.00032717458,0.00009509189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073634746,0.000054464137,0.00030026806,0.00025196868,0.00007183258,0.00000775555,0.000082414066,0.00012515445,0.00020388972],"category_scores_gemma":[0.0006574414,0.000050088544,0.000078017176,0.0007708218,0.00041796363,0.00007100575,0.000013651922,0.00008963959,0.0000035063924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013662211,0.00028522397,0.10397925,0.00008971728,0.0010943719,0.0000048974207,0.19709583,0.0000110625015,0.0004314575,0.048372567,0.0042471327,0.6442519],"study_design_scores_gemma":[0.00017012516,0.00067830645,0.89862174,0.0001110029,0.00057439186,5.9683504e-7,0.03257643,0.0001046157,0.0003452516,0.0011049603,0.06559036,0.00012221816],"about_ca_topic_score_codex":0.04739316,"about_ca_topic_score_gemma":0.011975252,"teacher_disagreement_score":0.7946425,"about_ca_system_score_codex":0.00013125842,"about_ca_system_score_gemma":0.0007094101,"threshold_uncertainty_score":0.95895034},"labels":[],"label_agreement":null},{"id":"W4402559843","doi":"10.1016/j.annonc.2024.08.893","title":"842P Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment: An analysis of the lymphoma coalition’s 2022 global patient survey","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Depression (economics); Lymphoma; Association (psychology); Leukemia; Internal medicine; Oncology; Psychotherapist","score_opus":0.042999884448597085,"score_gpt":0.2797143815461439,"score_spread":0.23671449709754683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614984,0.001039647,0.00003711069,0.00008754239,0.00017495987,0.00033382443,0.00055210735,0.000005775234,0.0016191821],"genre_scores_gemma":[0.999164,0.00054370647,0.000009586388,0.000088351306,0.000020689124,0.000061990955,0.00005235304,0.000011964208,0.000047388046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986388,0.0001476941,0.00061478233,0.0002915163,0.000073539486,0.0002336724],"domain_scores_gemma":[0.998346,0.0003296392,0.0008327824,0.0003176091,0.0001336006,0.00004037465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005650479,0.00014465963,0.00069478905,0.00019036738,0.000049221067,0.000016497323,0.00017431709,0.00010574408,0.00001602429],"category_scores_gemma":[0.00014141892,0.00009559173,0.00013487953,0.00061442226,0.00008788204,0.00028619703,0.000039041508,0.00005399521,0.0000021628668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036811864,0.00013475257,0.960108,0.000031582542,0.0006732196,0.0000011827346,0.00076980796,0.012119363,0.0000015434773,0.0007525424,0.00007721213,0.024962667],"study_design_scores_gemma":[0.00150504,0.002085225,0.990391,0.00008578569,0.00011186479,2.0417129e-7,0.000052536376,0.0043756603,0.00031286443,0.0003728142,0.00060157996,0.00010540945],"about_ca_topic_score_codex":0.01186885,"about_ca_topic_score_gemma":0.019735117,"teacher_disagreement_score":0.030283008,"about_ca_system_score_codex":0.0055556195,"about_ca_system_score_gemma":0.00071701716,"threshold_uncertainty_score":0.99826187},"labels":[],"label_agreement":null},{"id":"W4402559844","doi":"10.1016/j.annonc.2024.08.825","title":"764P How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Duration (music); Term (time); Ovarian cancer; Oncology; Intensive care medicine; Internal medicine; Cancer","score_opus":0.2136544856485848,"score_gpt":0.42551418100671445,"score_spread":0.21185969535812965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8321915,0.00036328766,0.0001382923,0.1658111,0.0005265473,0.0005572054,0.0001075554,0.000012709328,0.00029175708],"genre_scores_gemma":[0.99279124,0.0052318973,0.00018156826,0.0013505103,0.00011752557,0.00018449743,0.00007086303,0.00001768193,0.00005421165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866647,0.0002922993,0.00033814073,0.00031346717,0.0002187924,0.00017082023],"domain_scores_gemma":[0.99781126,0.0012989666,0.00028131166,0.00019078386,0.00036242034,0.000055250814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008134551,0.0001582553,0.00034820932,0.00015508424,0.000043499975,0.000033584267,0.000060075523,0.00007468179,0.000046306188],"category_scores_gemma":[0.00025191953,0.00010059476,0.000048838236,0.00021800488,0.00006623125,0.00037489235,0.000024201592,0.00020762206,9.280392e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020823805,0.0014229203,0.7725291,0.000055543387,0.0012448531,0.00022608992,0.0070034075,0.000026606544,0.00007083823,0.00207791,0.0007985108,0.21246181],"study_design_scores_gemma":[0.001723605,0.002362764,0.99045366,0.00059225556,0.00006743856,0.000026653874,0.0003960685,0.00016148963,0.003107857,0.0000361551,0.00097411004,0.00009794467],"about_ca_topic_score_codex":0.00074309757,"about_ca_topic_score_gemma":0.0038076735,"teacher_disagreement_score":0.21792454,"about_ca_system_score_codex":0.00017163175,"about_ca_system_score_gemma":0.00025434914,"threshold_uncertainty_score":0.41021356},"labels":[],"label_agreement":null},{"id":"W4402559856","doi":"10.1016/j.annonc.2024.08.824","title":"763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Poly ADP ribose polymerase; Gynecology; Cancer; Genetics; DNA; Polymerase; Biology","score_opus":0.05025327819796144,"score_gpt":0.41482749380043477,"score_spread":0.36457421560247333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96981215,0.0017497968,0.000013896534,0.021612564,0.00016849517,0.0021881894,0.00014277275,0.00004735111,0.0042647948],"genre_scores_gemma":[0.9896856,0.00064257695,0.006925896,0.0003058343,0.0002717013,0.0013721886,0.00003282397,0.0000544631,0.00070892274],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99780333,0.00012586627,0.0006444917,0.0005930544,0.0003266971,0.0005065653],"domain_scores_gemma":[0.99859923,0.00018007409,0.0002811785,0.0003935913,0.00030946758,0.00023646865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041187007,0.00030518766,0.0010740767,0.00034195327,0.00006573453,0.000025248744,0.000091754206,0.00012802983,0.00038908786],"category_scores_gemma":[0.000023021286,0.00020870552,0.00008822281,0.0005083677,0.00011355788,0.00010780789,0.000042933876,0.00013654817,0.0000029812197],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4587784,0.026102724,0.0059316023,0.0011570733,0.006129367,0.0046937265,0.01633744,0.00033488477,0.048542093,0.0006045347,0.013867023,0.41752112],"study_design_scores_gemma":[0.29713383,0.49133435,0.073589124,0.0111746015,0.0017051456,0.00007342495,0.0018188828,0.0008559249,0.01803356,0.00011504175,0.10310306,0.0010630427],"about_ca_topic_score_codex":0.0011010589,"about_ca_topic_score_gemma":0.0016257039,"teacher_disagreement_score":0.46523163,"about_ca_system_score_codex":0.0016216475,"about_ca_system_score_gemma":0.0031599407,"threshold_uncertainty_score":0.8510764},"labels":[],"label_agreement":null},{"id":"W4402559864","doi":"10.1016/j.annonc.2024.08.812","title":"751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Bevacizumab; Carboplatin; Paclitaxel; Oncology; Internal medicine; Ovarian cancer; Chemotherapy; Cancer; Adverse effect; Cisplatin","score_opus":0.02996050006913973,"score_gpt":0.37450741893861755,"score_spread":0.3445469188694778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881659,0.0011092522,0.0003481787,0.005526539,0.00038348456,0.003143131,0.0003432069,0.000030634048,0.0009496791],"genre_scores_gemma":[0.997123,0.0005124565,0.0003267235,0.0011201854,0.000087843466,0.0005787707,0.00013135812,0.00004307111,0.00007660538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963011,0.00054237794,0.0014133737,0.0006881501,0.0005426135,0.0005123497],"domain_scores_gemma":[0.99756914,0.0008781431,0.0005835046,0.0004493733,0.0003880543,0.00013177386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001533289,0.00035389693,0.0013177012,0.00027497803,0.00006289064,0.000018049008,0.0001977036,0.00025701761,0.00009327617],"category_scores_gemma":[0.00047880507,0.00026596052,0.00014499763,0.0007538087,0.00039897897,0.00027344486,0.00004003585,0.00054003,0.0000015092851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7222874,0.010061695,0.033947356,0.001136544,0.00079608214,0.00055083405,0.02594181,0.0010449273,0.013797302,0.0009791916,0.0077615553,0.18169527],"study_design_scores_gemma":[0.84884465,0.034749374,0.09211045,0.0026468828,0.0003383106,0.000069026515,0.0022747773,0.0030371968,0.006589432,0.0018549983,0.0066964286,0.0007884745],"about_ca_topic_score_codex":0.0023757215,"about_ca_topic_score_gemma":0.002786439,"teacher_disagreement_score":0.18090679,"about_ca_system_score_codex":0.0005064347,"about_ca_system_score_gemma":0.0010832029,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W4402559885","doi":"10.1016/j.annonc.2024.08.813","title":"752P Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of Calgary","funders":"National Health and Medical Research Council; Medical Research Council; Marshfield Clinic Research Foundation; BeiGene; Cancer Institute NSW; Ovarian Cancer Australia; National Cancer Institute; National Institutes of Health; Cancer Australia; Medical Research and Materiel Command; Genentech; AstraZeneca","keywords":"Medicine; Ovarian carcinoma; Serous fluid; Internal medicine; Oncology; Serous carcinoma; Carcinoma; Overall survival; Gynecology; Ovarian cancer; Cancer","score_opus":0.06389431438586542,"score_gpt":0.3790001159869204,"score_spread":0.315105801601055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400085,0.0005815225,0.000009280767,0.004583948,0.0002159572,0.0002719781,0.00006423879,0.000008546359,0.00026367744],"genre_scores_gemma":[0.99903566,0.00019219054,0.0003236881,0.00030482528,0.00006498083,0.000015616846,0.000032371117,0.000013248185,0.00001740303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888957,0.00009222341,0.00043554333,0.00026387512,0.0001732707,0.00014554632],"domain_scores_gemma":[0.99941576,0.00018836255,0.00007805568,0.0001294933,0.000081980346,0.00010633437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002657378,0.000111707806,0.000519932,0.00011472697,0.000009941499,0.0000042515876,0.000032011252,0.00012378627,0.00003485112],"category_scores_gemma":[0.000039274993,0.000082873354,0.000051530726,0.00010925193,0.00021781912,0.000038028025,0.000037773134,0.00013228541,0.0000011107225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004127445,0.000852797,0.9856257,0.00012744476,0.00026425146,0.00017259571,0.000119163,0.0000022331083,0.000009647389,0.0012895975,0.00021867377,0.010905164],"study_design_scores_gemma":[0.0046163592,0.0061782957,0.9876827,0.00010406354,0.00013356996,0.00000993859,0.000024252273,0.000013418842,0.000078959274,0.00019230817,0.00090365973,0.00006249375],"about_ca_topic_score_codex":0.00028612436,"about_ca_topic_score_gemma":0.00007495661,"teacher_disagreement_score":0.010842671,"about_ca_system_score_codex":0.000023993794,"about_ca_system_score_gemma":0.00013695733,"threshold_uncertainty_score":0.33794773},"labels":[],"label_agreement":null},{"id":"W4402559898","doi":"10.1016/j.annonc.2024.08.859","title":"808MO Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Wellcome Trust","keywords":"Medicine; Chimeric antigen receptor; Lymphoma; Antigen; Diffuse large B-cell lymphoma; B cell; Nuclear medicine; Cancer research; Oncology; Immunotherapy; Pathology; Internal medicine; Immunology; Cancer; Antibody","score_opus":0.04343359763471496,"score_gpt":0.3659126109900065,"score_spread":0.32247901335529155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98454976,0.004065498,0.0000015460735,0.00096505333,0.0003557734,0.000909254,0.00007730854,0.00003973195,0.009036103],"genre_scores_gemma":[0.9815819,0.0139623005,0.00018107393,0.0004018827,0.000100104735,0.000048824506,0.000081484766,0.000069070615,0.0035733518],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750924,0.00036414943,0.00062594283,0.00046227404,0.00042326504,0.00061512185],"domain_scores_gemma":[0.9984835,0.0004206141,0.00017755646,0.0004581026,0.0002877829,0.00017247112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005857133,0.00026950447,0.0008017201,0.00050714053,0.000037074173,0.000013740599,0.00021405703,0.00007244746,0.0010769772],"category_scores_gemma":[0.000064305896,0.0002204193,0.0002984299,0.0005727009,0.0001297716,0.000094818155,0.000081780316,0.00019751862,0.000110854795],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042386497,0.04315372,0.16171333,0.00041572662,0.00053428015,0.00096655,0.005453689,0.000002846639,0.35351145,0.00004557759,0.0024073622,0.4275568],"study_design_scores_gemma":[0.035242546,0.0428463,0.24482198,0.00034132603,0.00006251851,0.00006949189,0.00051408244,0.00017599874,0.39788935,0.00006853189,0.27754468,0.00042320063],"about_ca_topic_score_codex":0.0011583692,"about_ca_topic_score_gemma":0.000074201394,"teacher_disagreement_score":0.4271336,"about_ca_system_score_codex":0.000235848,"about_ca_system_score_gemma":0.0006328319,"threshold_uncertainty_score":0.99983615},"labels":[],"label_agreement":null},{"id":"W4402559915","doi":"10.1016/j.annonc.2024.08.1207","title":"1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Foundation Medicine; Genentech; Servier; Eisai; Natera; Advanced Accelerator Applications; Sanofi; Halozyme; Exelixis; Boston Scientific Corporation; Ipsen; Amryt Pharma; BeiGene; Handok; Amgen; Pfizer; Recordati Rare Diseases; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Multivariate analysis; DOTA; Multivariate statistics; Nuclear medicine; Internal medicine; Oncology; Statistics; Genetics","score_opus":0.1456131318391659,"score_gpt":0.500614329831278,"score_spread":0.35500119799211205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9371457,0.0001612503,0.00056893897,0.05891309,0.00003365469,0.00057888083,0.000011207152,0.000039170623,0.0025481025],"genre_scores_gemma":[0.9952752,0.00008132783,0.0009770562,0.003403694,0.000044451594,0.000080248894,0.00001660148,0.0000077855075,0.00011363097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988471,0.00016325859,0.00044071733,0.00020130379,0.00018858413,0.00015902288],"domain_scores_gemma":[0.9988695,0.00054447993,0.00008868724,0.00036575063,0.00008418916,0.000047415928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010338384,0.000084076244,0.0004723793,0.00033502793,0.000015513257,0.000005647484,0.00017790333,0.00006071523,0.00016240965],"category_scores_gemma":[0.00016658263,0.00005177984,0.0001674497,0.001147926,0.00012413014,0.000022112781,0.0000478764,0.00024242054,0.0000082960405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088102225,0.028853748,0.06625086,0.00059814216,0.01127673,0.002128241,0.041253127,0.00024194088,0.03802088,0.013713873,0.3251624,0.47161904],"study_design_scores_gemma":[0.0030260931,0.005660221,0.6618543,0.0002689923,0.005079472,0.000047585563,0.002259098,0.026745036,0.0030216551,0.0015829972,0.29017514,0.00027936758],"about_ca_topic_score_codex":0.0004108208,"about_ca_topic_score_gemma":0.00004796402,"teacher_disagreement_score":0.59560347,"about_ca_system_score_codex":0.000011795158,"about_ca_system_score_gemma":0.00007662273,"threshold_uncertainty_score":0.21115206},"labels":[],"label_agreement":null},{"id":"W4402559918","doi":"10.1016/j.annonc.2024.08.1310","title":"1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Cancer research; Internal medicine; Lung cancer","score_opus":0.06455710799785216,"score_gpt":0.508165654786099,"score_spread":0.4436085467882468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589912,0.0014671576,0.00001042511,0.0054281345,0.00025740516,0.00066711224,0.000068180496,0.00002289402,0.033087455],"genre_scores_gemma":[0.9979154,0.00018373827,0.00007262489,0.0005622867,0.000085422624,0.000066716486,0.00003965678,0.00001682886,0.0010573468],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989203,0.00007199729,0.00039969975,0.00024255579,0.00015418864,0.0002112331],"domain_scores_gemma":[0.9993341,0.00014133604,0.00010076107,0.0001765913,0.00016637583,0.00008083374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019909423,0.0001219339,0.00049064984,0.00025538856,0.00003229035,0.00000385764,0.00006579431,0.000080212405,0.00012075035],"category_scores_gemma":[0.000051089417,0.000099900026,0.00008930957,0.00027923763,0.000084435014,0.000075415424,0.000043460226,0.00012543167,0.000010435126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042547453,0.08374812,0.027063169,0.0006274965,0.0052775843,0.006049567,0.1194248,0.00022818656,0.023740636,0.0037343185,0.06667547,0.65917593],"study_design_scores_gemma":[0.07633879,0.38011563,0.14698206,0.002262362,0.005082285,0.00048544662,0.041359298,0.0011410597,0.09226747,0.003494182,0.24944784,0.0010235789],"about_ca_topic_score_codex":0.00059818395,"about_ca_topic_score_gemma":0.0004124091,"teacher_disagreement_score":0.65815234,"about_ca_system_score_codex":0.00008746887,"about_ca_system_score_gemma":0.0004660502,"threshold_uncertainty_score":0.4073805},"labels":[],"label_agreement":null},{"id":"W4402559933","doi":"10.1016/j.annonc.2024.08.792","title":"730P Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Randomized controlled trial; Oncology; Internal medicine; Carcinoma","score_opus":0.08142761417320024,"score_gpt":0.38244181013730705,"score_spread":0.30101419596410683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239486,0.0041225473,0.0006412865,0.00061356084,0.00056153664,0.0012049498,0.00038924854,0.0000035851713,0.000068399044],"genre_scores_gemma":[0.9973374,0.000528799,0.001038745,0.000040839896,0.00059675396,0.00014887498,0.00029216334,0.000011799699,0.000004607588],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987482,0.00016905961,0.0006161892,0.00024856933,0.00008133089,0.00013669101],"domain_scores_gemma":[0.996717,0.0026980876,0.0002597598,0.00015538912,0.00013983558,0.000029946726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014620038,0.00009895867,0.000391564,0.00008139384,0.000039035764,0.000014613549,0.0000852485,0.000070572765,0.0000014342413],"category_scores_gemma":[0.0066088513,0.00007980682,0.000120617995,0.00012419268,0.00009275647,0.0000062991207,0.00006147886,0.000057988666,1.278863e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46056363,0.0007421427,0.00041968309,0.00016098257,0.0004666373,0.000016507127,0.0014210315,0.00040101158,0.46429092,0.00070896203,0.0008767173,0.06993177],"study_design_scores_gemma":[0.50030935,0.0056245653,0.00030340027,0.000091337446,0.00028856818,0.000007686952,0.0001913149,0.0024174212,0.48359036,0.0014454161,0.005552839,0.00017773954],"about_ca_topic_score_codex":0.00016865616,"about_ca_topic_score_gemma":0.000018360019,"teacher_disagreement_score":0.06975403,"about_ca_system_score_codex":0.000013741959,"about_ca_system_score_gemma":0.00026752296,"threshold_uncertainty_score":0.791189},"labels":[],"label_agreement":null},{"id":"W4402559945","doi":"10.1016/j.annonc.2024.08.776","title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Yakult Honsha; Servier; Kyowa Hakko Kirin; Ipsen; BeiGene; Clovis Oncology; Minderoo Foundation; Ono Pharmaceutical; Eisai; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Endometrial cancer; Ovarian cancer; Gynecology; Oncology; Internal medicine; Cancer","score_opus":0.09096058962015123,"score_gpt":0.4112799389509216,"score_spread":0.32031934933077033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871523,0.0010459854,0.000006242817,0.007036777,0.0009062328,0.0016528871,0.0012162223,0.00004448042,0.00093889213],"genre_scores_gemma":[0.9972438,0.00033321118,0.000089439534,0.0009775624,0.0006050009,0.0001782442,0.0002592366,0.000034010925,0.00027945024],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99728984,0.00031172342,0.00081099937,0.0006074451,0.0005424888,0.00043748133],"domain_scores_gemma":[0.9974043,0.0014828003,0.00022202823,0.00050118426,0.00020628178,0.00018344996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048222116,0.0002760277,0.00088991405,0.00036008132,0.00010137272,0.00002324412,0.00025881754,0.00013897617,0.0007356033],"category_scores_gemma":[0.00088093494,0.00014343749,0.00012438247,0.0015834385,0.00013817758,0.00011814809,0.00013941065,0.00038610757,0.000019224839],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19317073,0.024129553,0.095659025,0.00007334999,0.0027066648,0.0016162152,0.0044253026,0.0000068580916,0.00012889112,0.00012453822,0.008350654,0.66960824],"study_design_scores_gemma":[0.29709956,0.13984604,0.42457888,0.0006213265,0.0013121393,0.000017515697,0.0013878699,0.000051988773,0.0012160545,0.00040563534,0.13297586,0.00048711308],"about_ca_topic_score_codex":0.007341557,"about_ca_topic_score_gemma":0.003453826,"teacher_disagreement_score":0.6691211,"about_ca_system_score_codex":0.00018488948,"about_ca_system_score_gemma":0.00082981813,"threshold_uncertainty_score":0.99926865},"labels":[],"label_agreement":null},{"id":"W4402559951","doi":"10.1016/j.annonc.2024.08.799","title":"737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Internal medicine; Cancer; Immunotherapy; Thyroid cancer","score_opus":0.06545529475976408,"score_gpt":0.38070123633921205,"score_spread":0.31524594157944796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035627,0.0004744457,0.0000078912835,0.0069600497,0.00012996119,0.00085103343,0.000026210915,0.000022695556,0.0011714557],"genre_scores_gemma":[0.9976709,0.0002067609,0.000019304473,0.0014543806,0.00008054046,0.00007932549,0.000028492386,0.000019235073,0.00044107225],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99837506,0.0004642085,0.00047933563,0.00022344924,0.00025609924,0.00020183122],"domain_scores_gemma":[0.9989522,0.00040644995,0.00017431425,0.00030100415,0.00013566343,0.000030335937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015083819,0.00013496817,0.00043494123,0.0002517363,0.00002806656,0.000010085688,0.00015595277,0.000077927456,0.0001481649],"category_scores_gemma":[0.00009609467,0.00008480638,0.00007693663,0.0005016055,0.00016070147,0.00008206881,0.000024340243,0.0002046089,0.00000651294],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35802913,0.0050209225,0.012026118,0.0006814739,0.0010337674,0.001224218,0.037666924,0.00000775074,0.47731557,0.0002615131,0.0032810457,0.10345158],"study_design_scores_gemma":[0.0145017905,0.030836673,0.8415105,0.00044354497,0.00014868482,0.00032332778,0.004380159,0.00013154415,0.011018234,0.000025035075,0.096487924,0.00019259604],"about_ca_topic_score_codex":0.0002026659,"about_ca_topic_score_gemma":0.00016186033,"teacher_disagreement_score":0.82948434,"about_ca_system_score_codex":0.00006216461,"about_ca_system_score_gemma":0.0006449936,"threshold_uncertainty_score":0.34583038},"labels":[],"label_agreement":null},{"id":"W4402559952","doi":"10.1016/j.annonc.2024.08.796","title":"734P Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Genentech; Eisai; Seagen; MacroGenics; Moderna; Clovis Oncology; Incyte; Astellas Pharma; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; EMD Serono; Mersana Therapeutics; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Endometrial cancer; Overall survival; Oncology; Internal medicine; Cancer","score_opus":0.11826150507289113,"score_gpt":0.43741776708606095,"score_spread":0.3191562620131698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167097,0.0011868707,9.734532e-7,0.0025288956,0.0010759528,0.0020075315,0.00021422646,0.000021623011,0.0012929764],"genre_scores_gemma":[0.99686974,0.0012591834,0.0000638641,0.0009949326,0.00033282637,0.00029607047,0.00007375282,0.000033930613,0.00007571787],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959837,0.0013190226,0.00094721763,0.00049433927,0.00076051254,0.0004951657],"domain_scores_gemma":[0.9938857,0.004943056,0.00034008216,0.00037915146,0.00022662888,0.00022539095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019450878,0.00033322859,0.0012843738,0.0009064327,0.00002696863,0.000014367417,0.00025091373,0.00023588256,0.00022445517],"category_scores_gemma":[0.0035471318,0.00018025101,0.00029037,0.002017979,0.00017521474,0.00014276487,0.000056323795,0.0005348037,0.000006063166],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8391017,0.0050124195,0.031873308,0.00021823132,0.00045879142,0.00020107096,0.0007262741,0.0000767692,0.0006364352,0.0000846421,0.001154801,0.12045557],"study_design_scores_gemma":[0.28158695,0.17075148,0.5293294,0.001101002,0.00022334896,0.0000059445283,0.00012290623,0.00001938249,0.0017684535,0.00023039295,0.014528329,0.0003324232],"about_ca_topic_score_codex":0.0019971079,"about_ca_topic_score_gemma":0.0007161221,"teacher_disagreement_score":0.5575147,"about_ca_system_score_codex":0.0007905164,"about_ca_system_score_gemma":0.003087836,"threshold_uncertainty_score":0.7350423},"labels":[],"label_agreement":null},{"id":"W4402559962","doi":"10.1016/j.annonc.2024.08.778","title":"716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Cervical cancer; Internal medicine; Cancer; Immunotherapy","score_opus":0.06881142453976026,"score_gpt":0.39088560832348224,"score_spread":0.322074183783722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909262,0.0039970493,0.000017667104,0.0023552678,0.00022187589,0.00074500847,0.00013463528,0.000021013047,0.0015812801],"genre_scores_gemma":[0.9979636,0.0012587904,0.00018514655,0.00031902015,0.000050382838,0.00004338562,0.00003641057,0.000020960759,0.00012231425],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984381,0.000105061285,0.0005325806,0.000321423,0.00031178907,0.00029104375],"domain_scores_gemma":[0.9989667,0.00040303753,0.00012830574,0.0001729281,0.00016536766,0.00016367515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018115228,0.00018597419,0.00085458526,0.0002788707,0.000019607545,0.0000053346716,0.00007865253,0.000096630574,0.00048549144],"category_scores_gemma":[0.00012394645,0.00011450803,0.000077265846,0.00064282684,0.00016579445,0.000060010683,0.000056531433,0.00021546378,0.0000052470255],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08463452,0.0026436662,0.017520009,0.0017384149,0.001187222,0.00026060143,0.0010858345,0.000042122276,0.00006347005,0.0006052399,0.00062034634,0.88959855],"study_design_scores_gemma":[0.069836445,0.05249925,0.84905803,0.0021740522,0.0010105046,0.000047711274,0.00016335188,0.0002469216,0.0011858906,0.00045487826,0.02294725,0.00037572766],"about_ca_topic_score_codex":0.00057841185,"about_ca_topic_score_gemma":0.00058960874,"teacher_disagreement_score":0.8892228,"about_ca_system_score_codex":0.00022488146,"about_ca_system_score_gemma":0.0006960422,"threshold_uncertainty_score":0.5315791},"labels":[],"label_agreement":null},{"id":"W4402559972","doi":"10.1016/j.annonc.2024.08.761","title":"698P Outcomes of patients with testicular germ cell tumors in Latin-America","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Germ cell tumors; Germ cell; Latin Americans; Testicular cancer; Oncology; Cancer research; Gynecology; Internal medicine; Cancer; Genetics; Chemotherapy","score_opus":0.028695589365900685,"score_gpt":0.34122669826277957,"score_spread":0.3125311088968789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583447,0.001143789,0.000011409576,0.000640093,0.00004239537,0.000257831,0.000038462756,0.000019002704,0.0020125746],"genre_scores_gemma":[0.99872774,0.00003444697,0.00073161855,0.00032009627,0.000009106462,0.000014022161,0.000039075756,0.000014778987,0.00010914269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992085,0.000032185588,0.00026729133,0.00016553667,0.0001642133,0.00016227571],"domain_scores_gemma":[0.99933195,0.00019269095,0.00011694454,0.00016111598,0.00011348065,0.000083835024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047234385,0.00010853838,0.00042999242,0.00012869634,0.000007679291,0.000002261803,0.000042959222,0.00004740783,0.00007441849],"category_scores_gemma":[0.00013300679,0.000071816154,0.00009113086,0.00021162137,0.00009349369,0.000028568975,0.000023480563,0.00007202932,0.000015952757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012938434,0.0018230841,0.9776353,0.00021251623,0.0001460138,0.0004326295,0.00011678088,0.000023084305,0.000039574126,0.00004394112,0.00025437505,0.019143276],"study_design_scores_gemma":[0.001528945,0.0035019384,0.9921994,0.0001414646,0.00016034712,0.0000031517027,0.000035664067,0.00006404238,0.00036907755,0.00009613717,0.0018376902,0.00006210911],"about_ca_topic_score_codex":0.00010469632,"about_ca_topic_score_gemma":0.0000069104976,"teacher_disagreement_score":0.019081166,"about_ca_system_score_codex":0.000022486203,"about_ca_system_score_gemma":0.0002156602,"threshold_uncertainty_score":0.29285777},"labels":[],"label_agreement":null},{"id":"W4402559978","doi":"10.1016/j.annonc.2024.08.804","title":"743P Immunotherapy plus chemotherapy in the first-line treatment for primary advanced or recurrent endometrial cancer: An extracted individual patient data and trial-level meta-analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Meta-analysis; Endometrial cancer; Oncology; Chemotherapy; Immunotherapy; Internal medicine; Cancer; Gynecology","score_opus":0.4390870775415397,"score_gpt":0.49242783619903335,"score_spread":0.05334075865749366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8342178,0.11810232,0.0002801676,0.031006005,0.0009485094,0.008609295,0.0065428405,0.00009302287,0.00020005967],"genre_scores_gemma":[0.9309775,0.0547106,0.0021246052,0.0058972607,0.0006512587,0.0030607453,0.0023209066,0.00007499579,0.0001820726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752116,0.00024431798,0.0008602086,0.00064257573,0.00039509832,0.00033661973],"domain_scores_gemma":[0.9967286,0.0020739564,0.00027958857,0.00068456447,0.00012800527,0.00010530285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009973896,0.00030760022,0.0019000904,0.0006018018,0.000055809654,0.00003491197,0.0003176701,0.00016549333,0.00030786512],"category_scores_gemma":[0.00019477589,0.00015683746,0.0006042027,0.0015056526,0.00009235326,0.00016496018,0.000055117394,0.00015734087,6.8099376e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13916664,0.0028434973,0.00007207133,0.00006872302,0.054265734,0.0000420807,0.0011960487,0.00001957605,0.00006356856,0.000020512389,0.00032802217,0.8019135],"study_design_scores_gemma":[0.23411323,0.12441491,0.0067211483,0.000048221802,0.08910559,0.000027279057,0.00037636087,0.0004193264,0.0013034912,0.00032994009,0.542701,0.00043949278],"about_ca_topic_score_codex":0.000585383,"about_ca_topic_score_gemma":0.0016620824,"teacher_disagreement_score":0.80147403,"about_ca_system_score_codex":0.0002180285,"about_ca_system_score_gemma":0.0006018364,"threshold_uncertainty_score":0.6395646},"labels":[],"label_agreement":null},{"id":"W4402559996","doi":"10.1016/j.annonc.2024.08.794","title":"732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Paclitaxel; Olaparib; Carboplatin; Oncology; Endometrial cancer; Internal medicine; Progression-free survival; Cancer; Overall survival; Chemotherapy; Cisplatin; Nivolumab; Immunotherapy","score_opus":0.16801789610162463,"score_gpt":0.4963520012881549,"score_spread":0.3283341051865303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.931711,0.021097695,0.0000244582,0.03519801,0.0036808548,0.0035574434,0.0028637112,0.000113959846,0.0017528383],"genre_scores_gemma":[0.9824683,0.012113848,0.00030782033,0.0004718169,0.00096955517,0.0018346981,0.000597043,0.00009718313,0.0011397391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560994,0.0003524706,0.0015919763,0.0010484799,0.0005897743,0.0008073563],"domain_scores_gemma":[0.9940428,0.0041957977,0.00041184033,0.00067496096,0.00024569355,0.00042888487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012888776,0.00055002095,0.002062645,0.00034857937,0.00010434665,0.000037948146,0.0002625339,0.00061357534,0.000487995],"category_scores_gemma":[0.0016614308,0.00040821516,0.00085753103,0.00061084406,0.00023874432,0.00012248103,0.000110518726,0.00035258126,0.00001945187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014872421,0.015856031,0.26856926,0.00059441663,0.0056888596,0.00065239123,0.0013793581,0.000022068734,0.0006892864,0.00073761545,0.2765678,0.4143705],"study_design_scores_gemma":[0.07140849,0.06543563,0.021765044,0.001006286,0.0015944765,0.000027342188,0.00027287245,0.0003325302,0.012078417,0.0007386147,0.8246292,0.0007110955],"about_ca_topic_score_codex":0.004190495,"about_ca_topic_score_gemma":0.0032610726,"teacher_disagreement_score":0.54806143,"about_ca_system_score_codex":0.00077948614,"about_ca_system_score_gemma":0.0015699887,"threshold_uncertainty_score":0.999837},"labels":[],"label_agreement":null},{"id":"W4402559997","doi":"10.1016/j.annonc.2024.08.686","title":"619MO Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Loss function; Oncology; Internal medicine; Cancer research; Phenotype; Genetics","score_opus":0.041243936472599455,"score_gpt":0.3258487570872658,"score_spread":0.28460482061466635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973866,0.00048170844,0.00033197488,0.0003211247,0.00043091676,0.00017041081,0.000030335816,0.000032555905,0.0008144236],"genre_scores_gemma":[0.9989528,0.00020425135,0.0004870022,0.00025041186,0.000029403032,0.00002299388,0.000007809592,0.000013802729,0.000031498363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900633,0.0000806556,0.00030862802,0.00023616209,0.00016202786,0.0002061706],"domain_scores_gemma":[0.9995133,0.00008336653,0.000103349026,0.00014039749,0.00012004793,0.000039501196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022283103,0.0001088959,0.000293021,0.00012588919,0.000026619764,0.000008612608,0.00010994631,0.000061402534,0.00021470788],"category_scores_gemma":[0.000011926849,0.00008548025,0.000048578215,0.00023851621,0.00011093653,0.00024712773,0.000014215448,0.00007808898,0.00001983641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007589924,0.00076865044,0.050034333,0.0005109037,0.00018249378,0.0000761427,0.0022989786,0.0046418975,0.85200965,0.005031878,0.00049712375,0.076358035],"study_design_scores_gemma":[0.0044668177,0.012698662,0.13908358,0.0005675853,0.00007179455,0.0000073475867,0.0002117399,0.00039590217,0.81820846,0.0037197045,0.020087928,0.00048047997],"about_ca_topic_score_codex":0.00066421577,"about_ca_topic_score_gemma":0.00058208423,"teacher_disagreement_score":0.08904924,"about_ca_system_score_codex":0.000051084302,"about_ca_system_score_gemma":0.00016268565,"threshold_uncertainty_score":0.34857833},"labels":[],"label_agreement":null},{"id":"W4402559998","doi":"10.1016/j.annonc.2024.08.724","title":"658P First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncolytic virus; Pembrolizumab; Virology; Herpes simplex virus; Oncology; Cancer research; Internal medicine; Virus; Immunotherapy; Cancer","score_opus":0.05677139824352929,"score_gpt":0.4353904370972907,"score_spread":0.3786190388537614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969606,0.0006900505,0.000014469078,0.0008924693,0.00006909038,0.00083355495,0.000030909134,0.000008818916,0.0005000637],"genre_scores_gemma":[0.9986227,0.0006705887,0.00005511228,0.0001723118,0.000066827604,0.00014539309,0.000083023835,0.000034164274,0.00014983342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978871,0.0003058669,0.00071950996,0.00042824188,0.00023290298,0.00042641305],"domain_scores_gemma":[0.99916846,0.00014980465,0.00017562721,0.00031151887,0.00012405784,0.00007055016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085205777,0.00019624889,0.00060587045,0.00042739257,0.00002537968,0.0000093892095,0.0002700755,0.00022629031,0.00007128641],"category_scores_gemma":[0.00015872774,0.00017264094,0.00008584494,0.00050024,0.0002099746,0.000015194847,0.00007784403,0.00020239437,0.0000031458032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3652814,0.0056809615,0.00014980468,0.00026937353,0.00013498949,0.00045722947,0.0006034439,0.0016535331,0.47185805,0.00010722706,0.0005518854,0.15325211],"study_design_scores_gemma":[0.108817406,0.119646914,0.0005443877,0.00023654083,0.0000142261315,0.000018119701,0.00020537215,0.00073554175,0.75577927,0.00047384418,0.013226384,0.00030198338],"about_ca_topic_score_codex":0.00033121076,"about_ca_topic_score_gemma":0.023631599,"teacher_disagreement_score":0.28392124,"about_ca_system_score_codex":0.000095571115,"about_ca_system_score_gemma":0.00078461645,"threshold_uncertainty_score":0.99418455},"labels":[],"label_agreement":null},{"id":"W4402560004","doi":"10.1016/j.annonc.2024.08.781","title":"719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation","funders":"","keywords":"Medicine; Endometrial cancer; Ovarian cancer; Gynecology; Oncology; Internal medicine; Cancer","score_opus":0.07695685094731747,"score_gpt":0.44070883043770515,"score_spread":0.3637519794903877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994634,0.0007770558,0.0000034120185,0.0016691405,0.0003875959,0.0013619328,0.00012173541,0.000020189884,0.0010249679],"genre_scores_gemma":[0.9986682,0.00037482282,0.00019696972,0.0001801918,0.000092551185,0.00031022565,0.000018819788,0.000022604521,0.00013560647],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985595,0.00007676898,0.0004751679,0.0003553167,0.00027549645,0.00025775534],"domain_scores_gemma":[0.9990579,0.00020839991,0.00015451541,0.00026875452,0.00020944196,0.00010097188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022198877,0.00016940017,0.00073897,0.00043270257,0.000025443316,0.0000043179507,0.00008088026,0.00007633639,0.00044475053],"category_scores_gemma":[0.00009282616,0.00011368769,0.00007006851,0.00078301446,0.000065310436,0.00008909944,0.000057009445,0.00014905579,0.000002766828],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029900828,0.04344572,0.13694078,0.00029568194,0.0014575816,0.001132825,0.0026089232,0.0000488802,0.00009405132,0.00022163565,0.0016138792,0.7822392],"study_design_scores_gemma":[0.15178782,0.38320726,0.37579045,0.0010189583,0.00071886246,0.000020028441,0.00080908835,0.000033524113,0.0031149576,0.00004607543,0.083143376,0.0003096203],"about_ca_topic_score_codex":0.0009768246,"about_ca_topic_score_gemma":0.0013581633,"teacher_disagreement_score":0.7819296,"about_ca_system_score_codex":0.00014393395,"about_ca_system_score_gemma":0.0006270753,"threshold_uncertainty_score":0.48697066},"labels":[],"label_agreement":null},{"id":"W4402560049","doi":"10.1016/j.annonc.2024.08.667","title":"598TiP PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine","score_opus":0.16860824868837135,"score_gpt":0.46266007634948775,"score_spread":0.29405182766111637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97308135,0.006436006,0.00008494356,0.011901703,0.0001299561,0.0073045474,0.000050462837,0.00002808365,0.0009829706],"genre_scores_gemma":[0.9931464,0.0012580928,0.0028085432,0.00038064076,0.00010237994,0.001506908,0.000033583696,0.00003195069,0.00073149794],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99660075,0.0007784103,0.0010094099,0.0005470214,0.0004433931,0.00062099216],"domain_scores_gemma":[0.9970433,0.0017533184,0.00019772047,0.00044759593,0.000256985,0.0003010735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019124133,0.00035642873,0.0016554919,0.0004173362,0.00006579549,0.000020350166,0.00018690433,0.00006274007,0.00011201562],"category_scores_gemma":[0.0011554584,0.00019132278,0.00036046992,0.0004341189,0.00035232762,0.00006938574,0.00007649333,0.00019036906,0.000017707634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7971602,0.008907761,0.00012725867,0.00029316347,0.00080511364,0.0032583585,0.0023144688,0.000016198599,0.0012038422,0.00030868122,0.00047264356,0.1851323],"study_design_scores_gemma":[0.74521935,0.23925641,0.0007429305,0.0004032265,0.0009046798,0.00058179896,0.00045627618,0.0004689892,0.0061856997,0.0007452983,0.004870701,0.00016461081],"about_ca_topic_score_codex":0.00026377567,"about_ca_topic_score_gemma":0.00029842684,"teacher_disagreement_score":0.23034865,"about_ca_system_score_codex":0.00014405942,"about_ca_system_score_gemma":0.0009813525,"threshold_uncertainty_score":0.78019166},"labels":[],"label_agreement":null},{"id":"W4402560059","doi":"10.1016/j.annonc.2024.08.695","title":"628P Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Medicine; Trk receptor; Cancer; Oncology; Internal medicine; Neurotrophin","score_opus":0.06330915017653069,"score_gpt":0.39784758646836627,"score_spread":0.33453843629183555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99146706,0.003153504,0.000024313415,0.0038729717,0.00008968645,0.00062268873,0.00014577687,0.000034323435,0.0005896852],"genre_scores_gemma":[0.99556047,0.0034947628,0.00014599417,0.00021538399,0.00008357899,0.000071185255,0.00022649608,0.00001873306,0.00018340202],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990844,0.00003296987,0.00029734563,0.00029414528,0.000117440875,0.00017369537],"domain_scores_gemma":[0.9991992,0.00015832743,0.0001122093,0.00017293297,0.00026794535,0.00008936989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010659647,0.00014548562,0.0006711594,0.00020538107,0.00004812541,0.000004326224,0.00003984776,0.0000812335,0.000071817274],"category_scores_gemma":[0.000025619895,0.00009767448,0.00013522783,0.00039618262,0.00009336094,0.000043586493,0.000024450388,0.00005275184,6.793505e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017018361,0.0033631932,0.32479936,0.00034145988,0.010134835,0.00004955444,0.0055733407,0.00013862003,0.0003629626,0.00009193069,0.00441388,0.63371253],"study_design_scores_gemma":[0.015103715,0.07439547,0.69926643,0.00023943014,0.00647378,0.000013068544,0.0003796346,0.0005986384,0.0050087045,0.000057749054,0.19821717,0.00024620723],"about_ca_topic_score_codex":0.0012274106,"about_ca_topic_score_gemma":0.0031073014,"teacher_disagreement_score":0.6334663,"about_ca_system_score_codex":0.00006478201,"about_ca_system_score_gemma":0.00015950247,"threshold_uncertainty_score":0.39830497},"labels":[],"label_agreement":null},{"id":"W4402560060","doi":"10.1016/j.annonc.2024.08.674","title":"607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital","funders":"Seagen; Pfizer","keywords":"Medicine; Interim; Solid tumor; Phase (matter); Internal medicine; Oncology; Nuclear medicine; Cancer","score_opus":0.09569989157081261,"score_gpt":0.4662667078971952,"score_spread":0.3705668163263826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955215,0.00030126199,0.000008937052,0.00034671804,0.00010714827,0.00084174203,0.000045685898,0.000020162892,0.0028068821],"genre_scores_gemma":[0.9994719,0.000037724934,0.00013719009,0.00008083839,0.00004749524,0.000027313456,0.000022465789,0.000030562802,0.00014452904],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973506,0.00020796517,0.0010682746,0.00039670424,0.0005765054,0.00039996015],"domain_scores_gemma":[0.9981764,0.00044252633,0.00030850575,0.00049508613,0.00045535766,0.00012214122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008523394,0.00017831035,0.00094727625,0.0005424015,0.000016174696,0.0000067069377,0.00022630439,0.00012772255,0.000054708886],"category_scores_gemma":[0.0005613021,0.00013628432,0.00008548261,0.0005681774,0.000314681,0.00010881245,0.00019415241,0.00030364897,0.000006121222],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17876025,0.10560401,0.02955795,0.008538871,0.0035797036,0.006910377,0.0856728,0.00076298293,0.03687056,0.00018094557,0.030114587,0.513447],"study_design_scores_gemma":[0.4379981,0.3426369,0.03695355,0.011077815,0.00052025326,0.00019731525,0.011228645,0.012621234,0.13863906,0.00024554494,0.0070939814,0.00078758947],"about_ca_topic_score_codex":0.0012029916,"about_ca_topic_score_gemma":0.00017559214,"teacher_disagreement_score":0.5126594,"about_ca_system_score_codex":0.0010727046,"about_ca_system_score_gemma":0.004445894,"threshold_uncertainty_score":0.7886826},"labels":[],"label_agreement":null},{"id":"W4402560067","doi":"10.1016/j.annonc.2024.08.681","title":"614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Cancer research; Melanoma; Solid tumor; Oncology; Internal medicine; Cancer","score_opus":0.06356548457946962,"score_gpt":0.3571273992258349,"score_spread":0.2935619146463653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99315023,0.0021057276,0.0000847381,0.0010801441,0.00037738922,0.00029551738,0.00004836061,0.000022666269,0.002835239],"genre_scores_gemma":[0.9956193,0.0010333576,0.0003511514,0.0004881834,0.00029315785,0.0000448261,0.000089241505,0.000030687017,0.0020501013],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987633,0.0001124425,0.00034997604,0.0004026871,0.0000991692,0.0002724129],"domain_scores_gemma":[0.9993299,0.00006501529,0.00011914628,0.0002680241,0.00011809769,0.000099770645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028738283,0.0001795931,0.00030542625,0.00013519349,0.000059770762,0.000013182771,0.0001390652,0.00025287535,0.00017121267],"category_scores_gemma":[0.00012898096,0.00012472057,0.000049750757,0.00021031672,0.00013420546,0.0000108635895,0.0001165634,0.00015588917,0.000016787306],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064484044,0.00095337105,0.0012367518,0.00025365915,0.00018521922,0.00020687564,0.0012281904,0.000013005076,0.8448162,0.0010392598,0.032586876,0.11103218],"study_design_scores_gemma":[0.0013784743,0.01596828,0.0024700442,0.00021284053,0.000035938447,0.00015067501,0.00032617577,0.00007679564,0.1637474,0.00016399739,0.81511235,0.00035705103],"about_ca_topic_score_codex":0.000037137925,"about_ca_topic_score_gemma":0.00049172767,"teacher_disagreement_score":0.7825255,"about_ca_system_score_codex":0.000015831994,"about_ca_system_score_gemma":0.00047918278,"threshold_uncertainty_score":0.5085957},"labels":[],"label_agreement":null},{"id":"W4402560080","doi":"10.1016/j.annonc.2024.08.793","title":"731P Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Oncology; Overall survival; Internal medicine; Immunotherapy; Progression-free survival; Cancer; Surgery","score_opus":0.07872055122836827,"score_gpt":0.41649626949202534,"score_spread":0.33777571826365704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969157,0.0052047437,0.0000025956847,0.006187586,0.0039207987,0.0030661153,0.00014791814,0.00004395754,0.001734747],"genre_scores_gemma":[0.9876355,0.0076750424,0.00016824385,0.0022664848,0.0005455317,0.00092204293,0.00020427734,0.000061811676,0.0005210899],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961879,0.00073370116,0.0010320966,0.00059998763,0.0008411053,0.0006051552],"domain_scores_gemma":[0.9966666,0.002142107,0.0003372588,0.00040179247,0.00031982735,0.0001323746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001195939,0.0003972493,0.0015878876,0.00071937224,0.00006121094,0.000027485343,0.00032001326,0.00028726243,0.00040017848],"category_scores_gemma":[0.00097422086,0.00020752642,0.0003147836,0.001773271,0.00014412263,0.0001911758,0.000071673414,0.00060008315,0.000010925671],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3523606,0.0026695079,0.029427528,0.00013074564,0.00042365692,0.000117163836,0.0012329816,0.0000027259778,0.00017626774,0.000024732548,0.00045890172,0.6129752],"study_design_scores_gemma":[0.49588853,0.10191588,0.32449442,0.0014427608,0.00028696295,0.000009353543,0.00059263624,0.000011483545,0.00092831283,0.00018681843,0.07369603,0.00054680184],"about_ca_topic_score_codex":0.0008511263,"about_ca_topic_score_gemma":0.0015957317,"teacher_disagreement_score":0.61242837,"about_ca_system_score_codex":0.00047359685,"about_ca_system_score_gemma":0.0008904829,"threshold_uncertainty_score":0.8462682},"labels":[],"label_agreement":null},{"id":"W4402560083","doi":"10.1016/j.annonc.2024.08.691","title":"624P Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.026726967471272407,"score_gpt":0.32412004431273234,"score_spread":0.29739307684145994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541056,0.00021342772,0.00007473683,0.0005019798,0.00022245824,0.00043832508,0.00005501755,0.000012025198,0.0030714427],"genre_scores_gemma":[0.9980726,0.000043765758,0.000085837775,0.00047408222,0.0001562027,0.00005683409,0.00018606927,0.000020001951,0.00090456393],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875224,0.00013253333,0.00031815114,0.00040130244,0.00013744114,0.0002583443],"domain_scores_gemma":[0.99940085,0.000039104347,0.000092897346,0.00023221233,0.00016391685,0.00007098963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002222566,0.00016826589,0.00027552558,0.000091068956,0.00005986185,0.000015363295,0.00015943254,0.0001697651,0.000043940403],"category_scores_gemma":[0.00004465169,0.00012912563,0.000055113018,0.00014947468,0.00008032778,0.000010133026,0.0001241512,0.0001380604,0.000009227472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020782394,0.030218843,0.41771838,0.0006171746,0.002765752,0.0029236642,0.015651157,0.00061980967,0.24503636,0.004162175,0.11135878,0.14814553],"study_design_scores_gemma":[0.016481983,0.19728711,0.30069798,0.00041201914,0.00021260566,0.00014958036,0.0025617662,0.00024932556,0.35086313,0.0002718926,0.1293694,0.0014432031],"about_ca_topic_score_codex":0.00006598122,"about_ca_topic_score_gemma":0.00053946034,"teacher_disagreement_score":0.16706826,"about_ca_system_score_codex":0.00001984571,"about_ca_system_score_gemma":0.00032081432,"threshold_uncertainty_score":0.52655905},"labels":[],"label_agreement":null},{"id":"W4402560097","doi":"10.1016/j.annonc.2024.08.698","title":"631P Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Mutation; Cancer research; Oncology; Genetics; Gene; Biology","score_opus":0.025992759140914843,"score_gpt":0.362124663246008,"score_spread":0.33613190410509314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985008,0.0009108336,0.00002215262,0.00014077677,0.00006964617,0.00024045949,0.000034004883,0.0000021430212,0.00007914845],"genre_scores_gemma":[0.9990121,0.0006889477,0.00006604521,0.00012261533,0.000031428863,0.000013013191,0.00004254525,0.000009638237,0.000013666681],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99939877,0.000035929555,0.00019941725,0.00020160527,0.00005951004,0.00010475089],"domain_scores_gemma":[0.9996563,0.000046896625,0.00007206358,0.000098975484,0.00008729544,0.00003846084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011764545,0.00007923919,0.00017748118,0.000057544923,0.000014311256,0.0000065437707,0.000040384017,0.00007201158,0.0000043539803],"category_scores_gemma":[0.000056511228,0.000063869404,0.000014849371,0.00006627229,0.000064191576,0.0000039839397,0.000053063308,0.000044146505,2.3907998e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01226284,0.011608146,0.32479304,0.0005265156,0.0005595598,0.00026405745,0.008458425,0.0005587534,0.0902424,0.0002295228,0.004993053,0.5455037],"study_design_scores_gemma":[0.027036574,0.17172699,0.6455154,0.00027874758,0.00023460218,0.000041027113,0.004602719,0.00068494456,0.13607503,0.0004974785,0.012595161,0.00071135384],"about_ca_topic_score_codex":0.00009031535,"about_ca_topic_score_gemma":0.0004954787,"teacher_disagreement_score":0.5447923,"about_ca_system_score_codex":0.0000061155934,"about_ca_system_score_gemma":0.00010554796,"threshold_uncertainty_score":0.26045185},"labels":[],"label_agreement":null},{"id":"W4402560107","doi":"10.1016/j.annonc.2024.08.687","title":"620P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Microsatellite instability; Antibody; Cancer research; Oncology; Microsatellite; Genetics; Immunology; Gene; Allele","score_opus":0.019729019020304182,"score_gpt":0.3282027910193738,"score_spread":0.3084737719990696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942362,0.0014819839,0.0000058924365,0.0023440812,0.0001867076,0.0008340835,0.0007771985,0.000020242102,0.00011366084],"genre_scores_gemma":[0.9963868,0.0019687042,0.0003212186,0.00040582547,0.00006315266,0.000013197398,0.00078285363,0.000025737969,0.000032459728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770755,0.00015734868,0.0009293127,0.0006080425,0.0002926763,0.00030509403],"domain_scores_gemma":[0.9985967,0.0005522881,0.00025016637,0.00029236986,0.00020100916,0.00010743427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067056244,0.00023752841,0.0008293258,0.000298898,0.000043397988,0.000014990706,0.00009922371,0.00018672486,0.0000837791],"category_scores_gemma":[0.00011425345,0.00018084039,0.000058843456,0.0004511713,0.0005217122,0.00018683141,0.00005270223,0.0002329438,0.0000010571255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22349542,0.0028432775,0.6422626,0.00087209715,0.0008543722,0.00057990494,0.008500878,0.00028767416,0.016228702,0.00010463512,0.00037118755,0.103599265],"study_design_scores_gemma":[0.015647372,0.005853973,0.9674438,0.0013159075,0.0000676184,0.00002014242,0.00027659917,0.00021776158,0.0026054669,0.000059928654,0.006292559,0.00019884444],"about_ca_topic_score_codex":0.016788088,"about_ca_topic_score_gemma":0.005314083,"teacher_disagreement_score":0.32518125,"about_ca_system_score_codex":0.00016507703,"about_ca_system_score_gemma":0.00068824785,"threshold_uncertainty_score":0.9897592},"labels":[],"label_agreement":null},{"id":"W4402560108","doi":"10.1016/j.annonc.2024.08.683","title":"616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Term (time); KRAS; Surgery; Oncology; Internal medicine; Cancer","score_opus":0.05881352604461389,"score_gpt":0.39886128802742493,"score_spread":0.34004776198281106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940696,0.00047389825,0.0000137469815,0.0018266519,0.00020821855,0.0006819617,0.000037111247,0.000028764827,0.0026600421],"genre_scores_gemma":[0.9988502,0.00009962103,0.000104354505,0.00033935808,0.000054165343,0.000029957608,0.00003870067,0.0000341414,0.00044945834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805045,0.0001402814,0.0004984432,0.00035951962,0.00046462467,0.0004866749],"domain_scores_gemma":[0.9987724,0.00029765378,0.00015172819,0.0002618955,0.00034991998,0.00016643493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016440057,0.0001884332,0.00069389987,0.0004110814,0.000019530466,0.00000772442,0.00015952806,0.000023978117,0.00010081878],"category_scores_gemma":[0.00027126848,0.00014534035,0.000115636576,0.00042357383,0.0003055254,0.00014429286,0.00011761578,0.00028916547,0.000022164535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065406165,0.0039533433,0.9088468,0.0011288022,0.00043582072,0.013985768,0.0007784371,0.000024982985,0.013982694,0.00023959747,0.0018109478,0.0482722],"study_design_scores_gemma":[0.004821362,0.0284957,0.8402196,0.001223496,0.00007310413,0.0001977004,0.000096401796,0.000013094647,0.123624824,0.0001816162,0.0008721449,0.0001809521],"about_ca_topic_score_codex":0.000054490083,"about_ca_topic_score_gemma":0.000108632405,"teacher_disagreement_score":0.10964213,"about_ca_system_score_codex":0.00008953064,"about_ca_system_score_gemma":0.00030543504,"threshold_uncertainty_score":0.59268075},"labels":[],"label_agreement":null},{"id":"W4402560117","doi":"10.1016/j.annonc.2024.08.671","title":"604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Maximum tolerated dose; Pharmacology; Nuclear medicine; Adverse effect","score_opus":0.02474736697317593,"score_gpt":0.35497132541297166,"score_spread":0.33022395843979574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998056,0.00049500796,0.00009421295,0.00038743956,0.00013880654,0.0004267352,0.00010371026,0.000010068478,0.00028799628],"genre_scores_gemma":[0.9987734,0.0001986715,0.00013622295,0.00008014882,0.00012135522,0.000024664194,0.0006001919,0.000020675634,0.000044649183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856055,0.00015635618,0.0005417372,0.0003909539,0.00015449701,0.00019593173],"domain_scores_gemma":[0.99918425,0.000040035302,0.00021595975,0.00018307396,0.000314796,0.00006187426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002660239,0.00016392984,0.0003065157,0.0001713345,0.000028549357,0.000009751311,0.000063831765,0.0002676872,0.0000057289744],"category_scores_gemma":[0.00011767534,0.00014553004,0.00004969948,0.00025767944,0.00017538026,0.000021094393,0.0000633587,0.00012740475,0.0000015608417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018921122,0.0017560672,0.0010360626,0.00017251531,0.000249214,0.0000365278,0.0022167799,0.0050859475,0.7721171,0.000054654287,0.003740753,0.19461326],"study_design_scores_gemma":[0.018807013,0.02989953,0.026136853,0.0005048912,0.00007323697,0.00002244323,0.00020810658,0.0040853913,0.9128912,0.00010451726,0.0068318825,0.00043494842],"about_ca_topic_score_codex":0.00008962105,"about_ca_topic_score_gemma":0.00029984745,"teacher_disagreement_score":0.19417831,"about_ca_system_score_codex":0.00003394481,"about_ca_system_score_gemma":0.00034454415,"threshold_uncertainty_score":0.59345424},"labels":[],"label_agreement":null},{"id":"W4402560121","doi":"10.1016/j.annonc.2024.08.685","title":"618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","score_opus":0.08902763781321484,"score_gpt":0.39765652122498907,"score_spread":0.30862888341177425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853114,0.00425516,0.0006065369,0.00696268,0.00070610305,0.0018555722,0.00016515197,0.00003879381,0.000098587385],"genre_scores_gemma":[0.9958478,0.0012534604,0.0009618109,0.00046533076,0.00073547004,0.00047789284,0.00011180226,0.00005992764,0.00008649903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720854,0.00019456969,0.0010646369,0.0007133288,0.00036182572,0.00045710083],"domain_scores_gemma":[0.99827087,0.00029190964,0.0004778974,0.00019708744,0.0006209196,0.00014131263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060044683,0.00038189124,0.0011179266,0.0006860185,0.00010973271,0.000033633325,0.000079164376,0.00022497741,0.00003639981],"category_scores_gemma":[0.00021627184,0.0003735927,0.000103115846,0.0008475415,0.00032411452,0.0010118029,0.0000655746,0.0004248228,0.0000013472134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02716007,0.0033477903,0.00033803072,0.00045553848,0.00038389786,0.00006280436,0.006150781,0.0014109198,0.6196131,0.0008009996,0.00041703452,0.33985904],"study_design_scores_gemma":[0.22801189,0.038954157,0.009412819,0.0022757726,0.00064199814,0.00064345903,0.0025492816,0.10253969,0.6038931,0.0022608684,0.007417349,0.0013995913],"about_ca_topic_score_codex":0.000612414,"about_ca_topic_score_gemma":0.0028512413,"teacher_disagreement_score":0.33845943,"about_ca_system_score_codex":0.00055192393,"about_ca_system_score_gemma":0.0007983365,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W4402560186","doi":"10.1016/j.annonc.2024.08.1645","title":"1583P Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Blockade; Immune checkpoint; Adjuvant; Oncology; Surrogate endpoint; Internal medicine; Neoadjuvant therapy; Cancer","score_opus":0.2130049803754344,"score_gpt":0.4213249497223415,"score_spread":0.20831996934690714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907993,0.0044853175,0.000016415268,0.0025313206,0.0008907759,0.00065887754,0.00011558414,0.00002113806,0.00048125745],"genre_scores_gemma":[0.9934981,0.0048741302,0.00028248178,0.00027459543,0.00010343717,0.000028669509,0.000025405707,0.000027507744,0.0008857065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973756,0.00016077422,0.0016174157,0.00028001206,0.0002465116,0.00031968276],"domain_scores_gemma":[0.99831426,0.000593749,0.00044611088,0.0003782411,0.00019176585,0.00007586756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011986725,0.00019568107,0.0011638146,0.0004778851,0.000010222163,0.000005624022,0.00016735497,0.00022986202,0.0005506962],"category_scores_gemma":[0.0005279461,0.00014417787,0.0004262181,0.00046841823,0.00037210638,0.00011525409,0.0000892025,0.00025929083,0.000007607545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23779835,0.0019468926,0.0011641071,0.001015093,0.0008909317,0.00051461277,0.002589173,0.0000050068024,0.44982243,0.00006919337,0.0021431795,0.30204102],"study_design_scores_gemma":[0.055036683,0.021131624,0.06710034,0.0024825253,0.00019617744,0.00014139317,0.000632051,0.00018983612,0.78869927,0.0001488266,0.063968636,0.00027264914],"about_ca_topic_score_codex":0.001098992,"about_ca_topic_score_gemma":0.00038084763,"teacher_disagreement_score":0.3388768,"about_ca_system_score_codex":0.000076657314,"about_ca_system_score_gemma":0.0008341151,"threshold_uncertainty_score":0.60297376},"labels":[],"label_agreement":null},{"id":"W4402560192","doi":"10.1016/j.annonc.2024.08.1688","title":"1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Biomarker; Internal medicine; Oncology; Clinical trial; Genetics","score_opus":0.07214308806424065,"score_gpt":0.420935868887728,"score_spread":0.34879278082348736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97826636,0.0027841183,0.000010608615,0.0077780276,0.009007323,0.00034561483,0.000042771153,0.0000038594453,0.0017612907],"genre_scores_gemma":[0.98649764,0.0054847263,0.000056117315,0.0020866445,0.004609985,0.00003225034,0.0000147243745,0.000011868262,0.0012060669],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857414,0.00048092412,0.00045539203,0.00020387479,0.000128614,0.00015705098],"domain_scores_gemma":[0.99909425,0.00037174425,0.00019430932,0.00024058222,0.00007462166,0.00002450591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002055278,0.000088995665,0.00031059483,0.0000404585,0.000024063782,0.0000099449235,0.00020719782,0.00027322778,0.000010754018],"category_scores_gemma":[0.00097155455,0.000052402615,0.00023506954,0.00011500568,0.00014367512,0.000003967609,0.00009275085,0.00013986115,0.0000013134419],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005680607,0.0010388603,0.105252385,0.00009975975,0.00089484,7.1649026e-7,0.0006935804,0.000002600203,0.030335547,0.001270338,0.6157707,0.23896007],"study_design_scores_gemma":[0.003986633,0.0009217407,0.085250326,0.00001096362,0.00005812531,0.0000027825638,0.00008258078,0.000009199428,0.001398548,0.00025403083,0.90795875,0.00006631721],"about_ca_topic_score_codex":0.00007348828,"about_ca_topic_score_gemma":0.00036381572,"teacher_disagreement_score":0.29218808,"about_ca_system_score_codex":0.000009131688,"about_ca_system_score_gemma":0.00022158933,"threshold_uncertainty_score":0.21369165},"labels":[],"label_agreement":null},{"id":"W4402560194","doi":"10.1016/j.annonc.2024.08.1640","title":"1578P Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Cancer drugs; Clinical trial; Oncology; Intensive care medicine; Internal medicine","score_opus":0.09905824199885628,"score_gpt":0.3822298951514053,"score_spread":0.28317165315254905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95523524,0.009164476,0.000041584964,0.0024643326,0.0015023602,0.00029890504,0.00043250693,0.000014910867,0.030845694],"genre_scores_gemma":[0.9841464,0.014264111,0.00010253797,0.0005294867,0.00032760843,0.000051778254,0.000004973631,0.000022479187,0.0005506196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829173,0.000035137207,0.0009855265,0.00037754135,0.000045325345,0.00026474937],"domain_scores_gemma":[0.99871767,0.00021270115,0.0007075955,0.00019934386,0.00008952694,0.00007318307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079577556,0.00016369126,0.0009037814,0.00031319915,0.000028877987,0.000011514164,0.00017391723,0.00025760473,0.00064774894],"category_scores_gemma":[0.00015197031,0.00017234424,0.00018638888,0.00016043254,0.0002822952,0.00018547846,0.000053879525,0.00017971123,0.000028511016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01225272,0.00085781346,0.016655726,0.0008846697,0.0008321743,0.000011625811,0.008635413,0.0008543383,0.0019128403,0.38665244,0.01780871,0.5526415],"study_design_scores_gemma":[0.036244236,0.024532497,0.18213236,0.0014961527,0.00024645275,0.0000112296375,0.0014841427,0.004728295,0.01463014,0.13745807,0.595424,0.0016124146],"about_ca_topic_score_codex":0.0040852404,"about_ca_topic_score_gemma":0.0002792805,"teacher_disagreement_score":0.5776153,"about_ca_system_score_codex":0.00018234522,"about_ca_system_score_gemma":0.000271625,"threshold_uncertainty_score":0.7092397},"labels":[],"label_agreement":null},{"id":"W4402560244","doi":"10.1016/j.annonc.2024.08.1699","title":"1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa","funders":"National Health and Medical Research Council; Astellas Pharma US","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Cancer","score_opus":0.14052973065755486,"score_gpt":0.46424179152199413,"score_spread":0.32371206086443927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97703934,0.007900554,0.0000075018256,0.012963723,0.00036732602,0.0012164275,0.00019677645,0.000027037937,0.00028130287],"genre_scores_gemma":[0.9936868,0.004095832,0.00017207673,0.00042621166,0.00009058265,0.00013038152,0.000069204885,0.000030642706,0.001298301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975608,0.00041526227,0.0008381206,0.0003844012,0.0003813654,0.00042004563],"domain_scores_gemma":[0.9975836,0.0014256253,0.00023483032,0.0002628185,0.00035218455,0.0001409121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001596619,0.00020356609,0.0008894624,0.00023461398,0.000031472337,0.000012910124,0.00013985534,0.00013591151,0.00006690086],"category_scores_gemma":[0.0006027255,0.00011789184,0.0001935985,0.000571878,0.0007299504,0.00009479776,0.00009208225,0.0005629109,0.000017827171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018930756,0.0061673834,0.6990286,0.0029002563,0.007852202,0.005936874,0.042641982,0.00020016404,0.022458969,0.0029888505,0.049497314,0.14139667],"study_design_scores_gemma":[0.007977327,0.026173485,0.8830269,0.0012805306,0.0012471086,0.000097684206,0.005320538,0.0018244543,0.05102779,0.0033171729,0.0182411,0.00046593876],"about_ca_topic_score_codex":0.0018726118,"about_ca_topic_score_gemma":0.0004952845,"teacher_disagreement_score":0.18399829,"about_ca_system_score_codex":0.000111083566,"about_ca_system_score_gemma":0.0013878031,"threshold_uncertainty_score":0.48074895},"labels":[],"label_agreement":null},{"id":"W4402560269","doi":"10.1016/j.annonc.2024.08.1680","title":"1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Oncology; Internal medicine; Quality of life (healthcare); Castration; Phases of clinical research; Clinical trial; Cancer; Hormone; Nursing","score_opus":0.07814622430017823,"score_gpt":0.44859140634268474,"score_spread":0.37044518204250654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330485,0.0028427842,0.000008659229,0.0008555726,0.000030646854,0.0022516637,0.0006644678,0.000007931966,0.000033451874],"genre_scores_gemma":[0.9989109,0.00048523894,0.00006788966,0.000053129945,0.0000039578226,0.00016218206,0.00027226197,0.000015362746,0.000029081682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601096,0.0010897974,0.0017544662,0.0003655066,0.00046117086,0.0003181258],"domain_scores_gemma":[0.9977449,0.0005361194,0.00089865946,0.00022039124,0.00045929514,0.00014060459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020140698,0.00021298282,0.0018196417,0.000989703,0.000025627003,0.0000045163442,0.00009161979,0.0000766646,0.000031493877],"category_scores_gemma":[0.00021759038,0.00015533596,0.00012435201,0.0015735814,0.0002732249,0.00011163753,0.000051937117,0.00023197204,1.7968e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031550948,0.023093307,0.7815728,0.0059219184,0.015981354,0.00024228357,0.07719839,0.0004108096,0.0019186352,0.00011485048,0.0001436025,0.06185108],"study_design_scores_gemma":[0.035434496,0.063670106,0.8716679,0.0021142066,0.0013218446,0.0000025918082,0.022176202,0.002239652,0.0009907521,0.0001455729,0.000007640457,0.00022903233],"about_ca_topic_score_codex":0.015561238,"about_ca_topic_score_gemma":0.01523846,"teacher_disagreement_score":0.09009509,"about_ca_system_score_codex":0.00019300838,"about_ca_system_score_gemma":0.0011893607,"threshold_uncertainty_score":0.9909942},"labels":[],"label_agreement":null},{"id":"W4402560272","doi":"10.1016/j.annonc.2024.08.1692","title":"1611P Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; American Society of Clinical Oncology; Amgen; Stand Up To Cancer; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Castration; Cancer; Hormone","score_opus":0.1697050343098413,"score_gpt":0.4788614098846602,"score_spread":0.3091563755748189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918636,0.0040358766,3.5618166e-7,0.0020633284,0.00011380772,0.0011528424,0.00024582364,0.00001274421,0.00051161804],"genre_scores_gemma":[0.9983524,0.0010608762,0.00006815058,0.000048886996,0.000021574995,0.00024083746,0.000101282334,0.000018610219,0.000087347085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855983,0.00009525592,0.00041594342,0.0002637238,0.00026621853,0.00039900013],"domain_scores_gemma":[0.99922764,0.00015597057,0.00013035235,0.00016733295,0.00022380818,0.00009491719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026936104,0.00017125279,0.0006283316,0.000423533,0.000016431282,0.000007400813,0.0000761218,0.00008572891,0.00016097892],"category_scores_gemma":[0.000051564788,0.00010712341,0.000095352174,0.00052876497,0.0001864185,0.0001378572,0.000029875613,0.00021146832,0.000004695243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04015546,0.0023739336,0.8712369,0.0018502248,0.0011986024,0.0020411038,0.0069696554,0.00015097075,0.00079236296,0.0003848015,0.00091632234,0.07192963],"study_design_scores_gemma":[0.013453685,0.021785296,0.96044016,0.00096860895,0.0001304345,0.000009835844,0.00043684326,0.0002456708,0.0017561164,0.00031641382,0.00029266498,0.00016424946],"about_ca_topic_score_codex":0.002916684,"about_ca_topic_score_gemma":0.0035165206,"teacher_disagreement_score":0.08920325,"about_ca_system_score_codex":0.00027452552,"about_ca_system_score_gemma":0.000980506,"threshold_uncertainty_score":0.4409173},"labels":[],"label_agreement":null},{"id":"W4402560286","doi":"10.1016/j.annonc.2024.08.1559","title":"1494P Prognostic features in NSCLC patients with ECOG-PS 2-4: A prospective cohort study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cohort; Prospective cohort study; Oncology; Internal medicine","score_opus":0.024725848833969055,"score_gpt":0.35017321021668457,"score_spread":0.3254473613827155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768556,0.0006593937,0.000002523381,0.00095626636,0.00018649768,0.0023308762,0.000019814235,0.000039202034,0.018949823],"genre_scores_gemma":[0.9983329,0.000058373713,0.00008501853,0.0007871257,0.00006884672,0.00020554969,0.000035482735,0.000021074744,0.00040559235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998804,0.00007829586,0.00027926834,0.00036045376,0.00022768369,0.00025032394],"domain_scores_gemma":[0.9993034,0.00017088432,0.00006498169,0.00018670526,0.00019298635,0.00008103375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002710715,0.00014613842,0.00049653533,0.00021701465,0.000022263182,0.0000091472175,0.00007522412,0.00009612633,0.00017525423],"category_scores_gemma":[0.000115245944,0.000105682855,0.000057034853,0.00029386696,0.00009961139,0.00009579267,0.000035505505,0.00030825476,0.00001612447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014054271,0.00154101,0.9637259,0.00010990417,0.00035946743,0.00031115112,0.001657243,0.0000065620325,0.000020394935,0.000053381926,0.003782694,0.027026864],"study_design_scores_gemma":[0.0030512721,0.011807237,0.98008573,0.00013290255,0.00010829637,0.000014293021,0.00030722792,0.000021280059,0.00011198645,0.00005101483,0.0042030998,0.000105678584],"about_ca_topic_score_codex":0.00016303816,"about_ca_topic_score_gemma":0.00061471,"teacher_disagreement_score":0.026921187,"about_ca_system_score_codex":0.000121770994,"about_ca_system_score_gemma":0.0005823278,"threshold_uncertainty_score":0.43096218},"labels":[],"label_agreement":null},{"id":"W4402560337","doi":"10.1016/j.annonc.2024.08.1489","title":"1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Ipsen; Cilag; Astellas Pharma; Eisai; National Institute for Health and Care Research; Servier; Moderna; Incyte; EUSA Pharma; Seagen; Gilead Sciences; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gastro-; Chemotherapy; Internal medicine; Adenocarcinoma; Metastatic adenocarcinoma; Oncology; Esophageal adenocarcinoma; Cancer; Disease; Reflux","score_opus":0.1966977244664351,"score_gpt":0.45611713817048444,"score_spread":0.2594194137040493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624584,0.008790713,0.0024935147,0.01992689,0.00061492657,0.002932514,0.0025947622,0.00006800404,0.00012029608],"genre_scores_gemma":[0.9706453,0.0051684235,0.013730392,0.0011731217,0.0008272284,0.00011672528,0.0043836236,0.0000623582,0.0038928206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983816,0.000038718314,0.00061405613,0.00050136214,0.00017010789,0.0002941415],"domain_scores_gemma":[0.99860394,0.00037624012,0.00021884957,0.0005778035,0.00007247663,0.0001507067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019921805,0.00024119092,0.0010108093,0.000180315,0.000043071504,0.000012347984,0.00020373498,0.00007506204,0.00076097844],"category_scores_gemma":[0.000092741575,0.00017364413,0.00014384261,0.0002498596,0.00009567155,0.0001598282,0.000110409266,0.00006808048,0.000003430642],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15118328,0.0036405467,0.00036337832,0.00029582696,0.0024440472,0.00029265694,0.0006933182,0.000006213935,0.0005335682,0.00008936327,0.071721405,0.76873636],"study_design_scores_gemma":[0.31687263,0.175513,0.0017676833,0.00014679469,0.0022139526,0.000037018268,0.0003306134,0.0029220385,0.003813829,0.00054704,0.49561155,0.00022385217],"about_ca_topic_score_codex":0.00036135572,"about_ca_topic_score_gemma":0.00029250738,"teacher_disagreement_score":0.76851255,"about_ca_system_score_codex":0.0000527985,"about_ca_system_score_gemma":0.00039660407,"threshold_uncertainty_score":0.83321804},"labels":[],"label_agreement":null},{"id":"W4402560372","doi":"10.1016/j.annonc.2024.08.1494","title":"1428P Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Internal medicine; Neoadjuvant therapy; Cohort; Adenocarcinoma; General surgery; Cancer","score_opus":0.06110019792146209,"score_gpt":0.40632501539433796,"score_spread":0.34522481747287587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465127,0.0007064859,0.000021102624,0.0062355534,0.0008183628,0.00060997467,0.000005498305,0.00004945605,0.006902285],"genre_scores_gemma":[0.99687845,0.00026222615,0.00011607822,0.00092627027,0.0003411464,0.000040134666,0.000023151366,0.000017495742,0.0013950509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879915,0.00005110474,0.0003583664,0.00031311996,0.0002605696,0.0002176719],"domain_scores_gemma":[0.9995206,0.00005893649,0.000058605397,0.00021044677,0.00007720714,0.00007421163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046055732,0.00012548054,0.00039828825,0.00046047746,0.000013259631,0.000015157597,0.00014585422,0.00006720106,0.0005419171],"category_scores_gemma":[0.000033722077,0.00010954838,0.000090459376,0.00034928753,0.000045774235,0.00014012182,0.00005943213,0.00017639573,0.00002668748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034712983,0.0010369053,0.90117055,0.000027249323,0.00029299408,0.0006625293,0.0006518254,0.000015795511,0.000064348904,0.00023070088,0.0035116351,0.091988325],"study_design_scores_gemma":[0.0022764588,0.004301522,0.9823765,0.000022575543,0.000062064864,0.000055651646,0.0004860455,0.00046431477,0.00007699831,0.00006097223,0.009745798,0.000071071525],"about_ca_topic_score_codex":0.00024898598,"about_ca_topic_score_gemma":0.00007408649,"teacher_disagreement_score":0.091917254,"about_ca_system_score_codex":0.000096380536,"about_ca_system_score_gemma":0.00013766422,"threshold_uncertainty_score":0.59336126},"labels":[],"label_agreement":null},{"id":"W4402560613","doi":"10.1016/j.annonc.2024.08.1467","title":"1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Trastuzumab; Gastroesophageal Junction; Esophageal adenocarcinoma; Internal medicine; Oncology; Adenocarcinoma; Gastroenterology; Cancer","score_opus":0.03240448846183839,"score_gpt":0.33111372308727255,"score_spread":0.29870923462543414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920876,0.0016617032,0.0016078105,0.0021460766,0.00026123447,0.0013104449,0.000043537642,0.00008841104,0.0007931667],"genre_scores_gemma":[0.9939621,0.0005657343,0.0035727238,0.0008165641,0.0000704249,0.00012513164,0.00009234025,0.000055978708,0.000739],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976759,0.00016079184,0.0006295118,0.00057533686,0.00039275427,0.0005656977],"domain_scores_gemma":[0.9987494,0.00032723977,0.00023223399,0.00024280424,0.00024893333,0.00019938707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003111404,0.00036000193,0.0007651552,0.0008962453,0.000090740956,0.000040878444,0.00013181065,0.00010374701,0.00014144962],"category_scores_gemma":[0.000092543494,0.0002874463,0.000108590284,0.0012805999,0.00023269915,0.00030393497,0.000056078385,0.00037195004,0.0000147463425],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004628873,0.002811828,0.40947732,0.0005261759,0.0006160814,0.0012266759,0.00135507,0.00021116335,0.00004769053,0.00037716748,0.00360075,0.5751212],"study_design_scores_gemma":[0.011751876,0.027646307,0.9569096,0.0003313151,0.00033244255,0.00021969553,0.0006205514,0.00047496383,0.00016729507,0.00034318533,0.000979573,0.0002231833],"about_ca_topic_score_codex":0.00016918124,"about_ca_topic_score_gemma":0.00017678423,"teacher_disagreement_score":0.574898,"about_ca_system_score_codex":0.00029759828,"about_ca_system_score_gemma":0.00039882842,"threshold_uncertainty_score":0.99995774},"labels":[],"label_agreement":null},{"id":"W4402560614","doi":"10.1016/j.annonc.2024.08.1481","title":"1415P Real-world data on the use of nivolumab plus chemotherapy for patients with metastatic GC/GEJC/EAC: A Canadian perspective","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Bristol-Myers Squibb (Canada); Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; Capital District Health Authority; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Nivolumab; Oncology; Chemotherapy; Perspective (graphical); Internal medicine; Cancer; Immunotherapy; Artificial intelligence","score_opus":0.19213163807173256,"score_gpt":0.41356165648760523,"score_spread":0.22143001841587268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9099945,0.00091380556,0.000066045126,0.07969277,0.00034987723,0.0025042242,0.0018443485,0.0000350288,0.0045993854],"genre_scores_gemma":[0.9910248,0.0006796423,0.0008070866,0.006187259,0.000068418296,0.000051435192,0.00016048153,0.00003770187,0.0009831726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898213,0.00006803072,0.00025965084,0.00027640694,0.00016777229,0.0002460113],"domain_scores_gemma":[0.9983449,0.0005949038,0.0001359627,0.0005357501,0.00030753165,0.00008092632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034420536,0.0001301278,0.00039772352,0.00023150853,0.00004556706,0.000012004361,0.00019659878,0.000041981362,0.00013018133],"category_scores_gemma":[0.000118519,0.0000794507,0.00009374613,0.00035982468,0.00027983572,0.00008583356,0.000018835106,0.00011838439,0.0000025104239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06273467,0.0018812708,0.0058077797,0.00050689356,0.008757014,0.000107229986,0.009896794,0.000023684725,0.0006901183,0.014258089,0.58053917,0.31479728],"study_design_scores_gemma":[0.0079244105,0.018446714,0.03595185,0.00049504463,0.00038042897,0.000011333091,0.0013917572,0.0008672019,0.001186896,0.00049182185,0.93260944,0.00024310588],"about_ca_topic_score_codex":0.1475653,"about_ca_topic_score_gemma":0.24019574,"teacher_disagreement_score":0.35207027,"about_ca_system_score_codex":0.0002792914,"about_ca_system_score_gemma":0.0014469667,"threshold_uncertainty_score":0.85811114},"labels":[],"label_agreement":null},{"id":"W4402560620","doi":"10.1016/j.annonc.2024.08.1444","title":"1389P Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Association of Medical Oncologists; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Disease; Autoimmune disease; Immunotherapy; Cancer; Immunology; Oncology; Immune system; Internal medicine","score_opus":0.022144275947253687,"score_gpt":0.3535493462548458,"score_spread":0.3314050703075921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96255136,0.035709053,0.000008432997,0.00081230665,0.0001234877,0.00059884985,0.00003203927,0.000013057758,0.00015143288],"genre_scores_gemma":[0.99355245,0.0062062074,0.000031282587,0.00008579188,0.000023853263,0.000035523495,0.00001549074,0.00001619869,0.000033198696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905634,0.00010172338,0.0003713068,0.00020554382,0.00011293104,0.00015215432],"domain_scores_gemma":[0.9994,0.00020585592,0.00011769536,0.00012337243,0.00010342045,0.00004962043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005774659,0.0001213927,0.00043532657,0.000119211814,0.000023487206,0.000005142529,0.000034966542,0.00007284432,0.000022474018],"category_scores_gemma":[0.00003419368,0.00008762293,0.000057678317,0.00019069582,0.000224943,0.000067170215,0.000031117375,0.00012102952,7.638781e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092751004,0.0006435602,0.61819154,0.0029199454,0.0007108706,0.000027975948,0.0012680321,0.000010690454,0.035884436,0.000075043245,0.00003181487,0.24748506],"study_design_scores_gemma":[0.006103993,0.002943154,0.9798754,0.0022574808,0.00004722985,0.0000022544577,0.000024543178,0.00012165172,0.006974489,0.0000220509,0.0015384624,0.00008930438],"about_ca_topic_score_codex":0.00051849394,"about_ca_topic_score_gemma":0.000022408069,"teacher_disagreement_score":0.36168382,"about_ca_system_score_codex":0.00006089838,"about_ca_system_score_gemma":0.00024528886,"threshold_uncertainty_score":0.35731593},"labels":[],"label_agreement":null},{"id":"W4402560674","doi":"10.1016/j.annonc.2024.08.1238","title":"1178P EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cancer; Computational biology; Internal medicine","score_opus":0.0657672189633323,"score_gpt":0.44652901930207667,"score_spread":0.38076180033874435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8977964,0.0014426913,0.08782058,0.007013083,0.0002062041,0.00052925927,0.0000031504565,0.000036788162,0.0051518497],"genre_scores_gemma":[0.9925387,0.00016999367,0.0052108197,0.0017241464,0.00014726994,0.00009703083,0.000038895087,0.00002299001,0.000050187402],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984112,0.00019287037,0.00043920396,0.00039655832,0.00029313393,0.00026704674],"domain_scores_gemma":[0.9992391,0.00009695584,0.000074142365,0.0002360706,0.00017828729,0.00017548191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018668886,0.00012005761,0.0004442421,0.00061853946,0.0000189456,0.000019766338,0.00014810082,0.00012212228,0.000065156826],"category_scores_gemma":[0.0002290232,0.000110011955,0.00013456757,0.00109375,0.000059637907,0.000049795846,0.000042086653,0.00036670404,0.0000041713347],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002021324,0.00092422543,0.0072203027,0.00042484183,0.0005095212,0.0001161985,0.006041876,0.15237638,0.022956721,0.0013454477,0.00087361946,0.80700874],"study_design_scores_gemma":[0.00015275257,0.0006707316,0.006661139,0.00009383566,0.0007901947,0.000006948983,0.0002796777,0.980963,0.008024576,0.0006111278,0.0016244218,0.00012160501],"about_ca_topic_score_codex":0.0009315477,"about_ca_topic_score_gemma":0.00013136641,"teacher_disagreement_score":0.8285866,"about_ca_system_score_codex":0.000109249864,"about_ca_system_score_gemma":0.00040991502,"threshold_uncertainty_score":0.44861573},"labels":[],"label_agreement":null},{"id":"W4402560691","doi":"10.1016/j.annonc.2024.08.1111","title":"1053P The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Population; Oncology; Value (mathematics); Immunology; Statistics","score_opus":0.024932605650777723,"score_gpt":0.31985794587829397,"score_spread":0.29492534022751626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994116,0.0020750714,0.000005905647,0.0007452056,0.0007196539,0.0018868892,0.000008657536,0.000045552762,0.00039708219],"genre_scores_gemma":[0.9994232,0.00007346651,0.000017620228,0.0001344257,0.000080128804,0.00015202747,0.000023904002,0.000028488885,0.00006672887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977371,0.00033162037,0.0011157247,0.00024481185,0.00034412506,0.00022660288],"domain_scores_gemma":[0.9983957,0.0005547792,0.00043056268,0.0003308524,0.00023811922,0.000049981496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016018848,0.00017030802,0.0004880957,0.00023461772,0.000057740446,0.000011285674,0.00014289832,0.00014244457,0.00004776581],"category_scores_gemma":[0.00033946056,0.000117779025,0.00029452387,0.0003977125,0.0001497622,0.00007237501,0.000042312502,0.00021350363,0.000003297293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021102678,0.00070669025,0.9532528,0.00080134574,0.00068432535,0.000026999329,0.0016151032,0.000076997734,0.0030008012,0.000012950339,0.0004826017,0.03722913],"study_design_scores_gemma":[0.00188966,0.0034920336,0.9892166,0.0015727616,0.00018663943,0.0000067981923,0.0010724739,0.00032196217,0.0017842834,0.000017396545,0.00033010298,0.00010926948],"about_ca_topic_score_codex":0.00082578225,"about_ca_topic_score_gemma":0.000093228125,"teacher_disagreement_score":0.037119858,"about_ca_system_score_codex":0.00013750183,"about_ca_system_score_gemma":0.00034232927,"threshold_uncertainty_score":0.48028895},"labels":[],"label_agreement":null},{"id":"W4402560719","doi":"10.1016/j.annonc.2024.08.1025","title":"965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Lenvatinib; Nivolumab; Ipilimumab; Hepatocellular carcinoma; Sorafenib; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.375544513528456,"score_gpt":0.43278756887779224,"score_spread":0.057243055349336214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971906,0.014152235,0.00038081355,0.0060314895,0.0005818229,0.0026883318,0.00054222456,0.00027022677,0.0034468756],"genre_scores_gemma":[0.98215675,0.003988536,0.0014780413,0.0005807137,0.00072537304,0.0009758763,0.0013969545,0.00015241941,0.008545352],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956709,0.00023798966,0.0012451569,0.0011874285,0.0005063029,0.0011522206],"domain_scores_gemma":[0.99653983,0.00124118,0.0003507189,0.00091800204,0.00047759802,0.0004726652],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053370063,0.0007826564,0.0021391332,0.0006058344,0.00027067232,0.00007340632,0.00032343873,0.0006291427,0.001916505],"category_scores_gemma":[0.00026568113,0.0005913516,0.0010522336,0.0007584152,0.00023914356,0.0002599919,0.0001400115,0.00029052643,0.0002471268],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112145565,0.0154431285,0.3855349,0.005728604,0.02371117,0.023056695,0.01432733,0.00016875741,0.07586006,0.0018419299,0.047801573,0.29438028],"study_design_scores_gemma":[0.029575387,0.05041259,0.002628493,0.00074429973,0.0043479134,0.00027870838,0.0007380724,0.04872501,0.52775455,0.0015974327,0.3320748,0.0011227387],"about_ca_topic_score_codex":0.006821831,"about_ca_topic_score_gemma":0.0012571415,"teacher_disagreement_score":0.4518945,"about_ca_system_score_codex":0.00056960306,"about_ca_system_score_gemma":0.0019077741,"threshold_uncertainty_score":0.9997918},"labels":[],"label_agreement":null},{"id":"W4402560723","doi":"10.1016/j.annonc.2024.08.1022","title":"962P Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Discipline; Carcinoma; Oncology; Internal medicine; Intensive care medicine; Medical physics; Social science","score_opus":0.10892759565607038,"score_gpt":0.49238322297496373,"score_spread":0.3834556273188934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639171,0.029699836,0.000043471635,0.0012057155,0.00033165677,0.0003726279,0.00010166501,0.000025437412,0.004302486],"genre_scores_gemma":[0.99323666,0.0046553505,0.0012766708,0.0002123224,0.00027678438,0.000020055799,0.000042672455,0.000015260066,0.0002642021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998931,0.00009081652,0.00033390356,0.00033476422,0.00011143878,0.00019809803],"domain_scores_gemma":[0.99876285,0.00050517573,0.00028826832,0.0002443619,0.000075621814,0.0001237089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009271961,0.00019970242,0.00066370884,0.00010372525,0.000049433966,0.0000042874262,0.000077427736,0.0002909169,0.00006175836],"category_scores_gemma":[0.00007219785,0.00013033005,0.00019354322,0.00015986295,0.00038114178,0.00011718088,0.000033243232,0.00016010602,0.000013001754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005766695,0.005114238,0.7968748,0.00019805631,0.002275039,0.0029128965,0.0028448862,0.000048880203,0.009817928,0.0007991565,0.0012674519,0.17207992],"study_design_scores_gemma":[0.015960349,0.2281293,0.58304656,0.0009871759,0.001567392,0.0014831355,0.0020788072,0.014534628,0.020188453,0.0065178005,0.12478315,0.0007232415],"about_ca_topic_score_codex":0.0010351272,"about_ca_topic_score_gemma":0.00013013215,"teacher_disagreement_score":0.22301506,"about_ca_system_score_codex":0.00022599877,"about_ca_system_score_gemma":0.0005671051,"threshold_uncertainty_score":0.53147054},"labels":[],"label_agreement":null},{"id":"W4402560725","doi":"10.1016/j.annonc.2024.08.1045","title":"985P Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; Ipsen; Sociedad Española de Oncología Médica; Sierra Oncology; Fondation ARC pour la Recherche sur le Cancer; Pfizer; Incyte; NuCana; Moderna; BeiGene; Seagen; Pharmacyclics; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Institut National Du Cancer; AstraZeneca; Novocure; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Astellas Pharma; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; PharmaMar; European Society for Medical Oncology; OncoMed Pharmaceutical; Celgene","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Oncology","score_opus":0.11700182009689444,"score_gpt":0.38528196101175133,"score_spread":0.26828014091485686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98630834,0.009421134,0.0000117613135,0.0011062354,0.00017028641,0.0018347537,0.0000892846,0.000025074954,0.0010331471],"genre_scores_gemma":[0.998968,0.000446227,0.000047022506,0.00010947434,0.00004912166,0.00012479181,0.00007980408,0.000038798127,0.00013672636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963531,0.00050116924,0.0013691445,0.00062090275,0.000590513,0.00056519895],"domain_scores_gemma":[0.997963,0.0005593598,0.00026010512,0.0007012685,0.00036342023,0.00015283698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011053581,0.0003657269,0.002011699,0.0020430838,0.000058310085,0.000015496262,0.00032302807,0.00022475849,0.00014182023],"category_scores_gemma":[0.0001587652,0.0002749845,0.0004924986,0.00362094,0.00020297417,0.000117251664,0.00017003951,0.00037856237,0.000005827855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026213804,0.0051754965,0.9555683,0.00034597196,0.0021753076,0.0027337675,0.015733227,0.00013721314,0.009232132,0.000113025344,0.0007137193,0.0054504494],"study_design_scores_gemma":[0.03635104,0.054149885,0.66327876,0.00093215564,0.009260409,0.0001206731,0.021149145,0.061269175,0.14874218,0.00013858489,0.0035646688,0.001043324],"about_ca_topic_score_codex":0.02008192,"about_ca_topic_score_gemma":0.008086523,"teacher_disagreement_score":0.29228956,"about_ca_system_score_codex":0.00014136058,"about_ca_system_score_gemma":0.0005453205,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W4402560732","doi":"10.1016/j.annonc.2024.08.1240","title":"1180P An integrated metabolomics-based platform for early-stage detection of multiple cancers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Medicine; Metabolomics; Stage (stratigraphy); Oncology; Computational biology; Bioinformatics","score_opus":0.05212204333005058,"score_gpt":0.35396784324731106,"score_spread":0.30184579991726046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987213,0.0026741982,0.008590154,0.000098940094,0.0004072758,0.00027396082,0.00059150363,0.000015626321,0.00013533168],"genre_scores_gemma":[0.99738556,0.0005580727,0.0011534262,0.00022939304,0.0001670119,0.00005856441,0.0003338376,0.000019945237,0.000094185336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992103,0.000038805905,0.0002610714,0.00025038197,0.000060838698,0.00017860305],"domain_scores_gemma":[0.9993029,0.00004316309,0.00009567412,0.00019416925,0.00027665112,0.000087406035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019750309,0.00011053394,0.00020077176,0.00009381147,0.000031633186,0.000007789249,0.00011113638,0.00018938069,0.000015170775],"category_scores_gemma":[0.0001139755,0.00010901414,0.00015217808,0.00008705957,0.00012462106,0.0000066570983,0.000017310542,0.00005107396,9.417705e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020230315,0.00026384142,0.00083367986,0.0002301387,0.00015232271,0.0000021881103,0.000086633256,0.000619489,0.95169973,0.00010569923,0.0013324604,0.042650774],"study_design_scores_gemma":[0.0009376429,0.00313363,0.0008636612,0.000015103725,0.000033612778,0.0000010209386,0.00012453769,0.0021418356,0.79631,0.00019769497,0.19613382,0.000107450964],"about_ca_topic_score_codex":0.00032554913,"about_ca_topic_score_gemma":0.0007452882,"teacher_disagreement_score":0.19480136,"about_ca_system_score_codex":0.00001895059,"about_ca_system_score_gemma":0.00042951913,"threshold_uncertainty_score":0.44454676},"labels":[],"label_agreement":null},{"id":"W4402560756","doi":"10.1016/j.annonc.2024.08.1149","title":"1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Melanoma; Dermatology; Phase (matter); Oncology; Internal medicine; Cancer research","score_opus":0.05754284482523902,"score_gpt":0.4079441693441884,"score_spread":0.3504013245189494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470246,0.000104117105,0.0000026874072,0.0005224523,0.00003990838,0.0010407806,0.000006329101,0.000011627162,0.0035696647],"genre_scores_gemma":[0.99944305,0.000028821602,0.000026584425,0.000055539673,0.000012395632,0.00003454285,0.000023176053,0.000019754829,0.00035610836],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99872977,0.00014012882,0.00033336802,0.00021977286,0.00036553378,0.00021141574],"domain_scores_gemma":[0.9992959,0.00016045687,0.00007610478,0.00020026526,0.00021331347,0.00005394186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028277354,0.00010303299,0.0004511883,0.00046403354,0.000008207538,0.000004232872,0.00007772206,0.000076193384,0.0003293505],"category_scores_gemma":[0.000038595197,0.000076268974,0.000024793686,0.0005372165,0.000099323675,0.00005295395,0.000026114918,0.00021034526,0.0000047071508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03398264,0.037818644,0.66350406,0.0003632254,0.00047047428,0.0033484318,0.008625919,0.00007193116,0.0020613486,0.00022976898,0.0005298935,0.24899368],"study_design_scores_gemma":[0.08180632,0.46800137,0.42889243,0.0007586022,0.00013320273,0.00019195139,0.0029296319,0.00075706013,0.0076956926,0.0002430811,0.0082743745,0.00031629126],"about_ca_topic_score_codex":0.0004066408,"about_ca_topic_score_gemma":0.0012956243,"teacher_disagreement_score":0.43018273,"about_ca_system_score_codex":0.00008611721,"about_ca_system_score_gemma":0.00024563583,"threshold_uncertainty_score":0.36061573},"labels":[],"label_agreement":null},{"id":"W4402560803","doi":"10.1016/j.annonc.2024.08.968","title":"907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Docetaxel; Pembrolizumab; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Pemetrexed; Head and neck cancer; Radiation therapy; Cancer; Chemotherapy; Cisplatin; Immunotherapy","score_opus":0.18422490648783385,"score_gpt":0.46312683146676853,"score_spread":0.2789019249789347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851776,0.009581642,0.000044964705,0.0012836059,0.00053468056,0.0013240097,0.00027631302,0.000021902006,0.0017553321],"genre_scores_gemma":[0.9982646,0.00056063297,0.00041465822,0.00017090276,0.00004982142,0.00011664394,0.000023139903,0.000031112977,0.00036845668],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9973167,0.0003566162,0.0010371966,0.0005189987,0.00035003136,0.0004204585],"domain_scores_gemma":[0.99667037,0.0017740622,0.00043410197,0.00051527563,0.00047305605,0.00013311747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079381594,0.00030396448,0.0020400155,0.0005906348,0.000095082636,0.000008598623,0.00020756648,0.000121839395,0.000092241105],"category_scores_gemma":[0.00045353608,0.00019435168,0.000496669,0.0015542284,0.00031438022,0.00006985091,0.0001524222,0.00020318464,0.0000010524817],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30727947,0.042306125,0.014060612,0.011840409,0.0318851,0.00055225077,0.041468404,0.00009053006,0.024570502,0.0003251859,0.057523247,0.46809816],"study_design_scores_gemma":[0.33005804,0.34272808,0.11622222,0.00082754635,0.06103298,0.00010034178,0.020268649,0.015270358,0.041279677,0.00024321112,0.07064511,0.0013237946],"about_ca_topic_score_codex":0.0005081259,"about_ca_topic_score_gemma":0.001154354,"teacher_disagreement_score":0.46677437,"about_ca_system_score_codex":0.00006535562,"about_ca_system_score_gemma":0.00052260136,"threshold_uncertainty_score":0.7925432},"labels":[],"label_agreement":null},{"id":"W4402560830","doi":"10.1016/j.annonc.2024.08.917","title":"855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; Northeast Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; TIGIT; Head and neck; Head and neck cancer; Oncology; Immunotherapy; Cancer research; Internal medicine; Cancer; Surgery","score_opus":0.03000376623706928,"score_gpt":0.3450944541369353,"score_spread":0.315090687899866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841198,0.010417181,0.0000023591788,0.0022798108,0.00008673238,0.001744025,0.0002481516,0.000043447435,0.0010584984],"genre_scores_gemma":[0.99717385,0.0020723334,0.0000650851,0.00034662124,0.000040188504,0.000021451897,0.00012637615,0.00003702227,0.000117092066],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976675,0.0002033528,0.00093645044,0.0005569003,0.00023673399,0.00039905607],"domain_scores_gemma":[0.99817145,0.00080813136,0.0002970647,0.000463379,0.0001462939,0.00011369037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047315113,0.00031091148,0.0009546427,0.00020307674,0.00009778328,0.000015313834,0.00014613448,0.00018205127,0.000030890656],"category_scores_gemma":[0.000104259816,0.00020252845,0.00009688155,0.00056781457,0.0003611571,0.000112268615,0.00009362755,0.0003069118,0.0000012183489],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5841632,0.012395926,0.035489783,0.0005911011,0.0010902087,0.0013006919,0.02661639,0.00010512026,0.049375642,0.00003213485,0.0013165018,0.28752333],"study_design_scores_gemma":[0.26986384,0.100189626,0.5817933,0.0009179688,0.0006946524,0.00026799814,0.0020455392,0.0008527411,0.02063358,0.000024683588,0.022216348,0.0004996936],"about_ca_topic_score_codex":0.0030697118,"about_ca_topic_score_gemma":0.0016701544,"teacher_disagreement_score":0.5463035,"about_ca_system_score_codex":0.0000779085,"about_ca_system_score_gemma":0.00044823586,"threshold_uncertainty_score":0.825887},"labels":[],"label_agreement":null},{"id":"W4402560834","doi":"10.1016/j.annonc.2024.08.1295","title":"1236P ctDNA-Lung-Detect: Profiling of non-shedding ctDNA early stage resected non-small cell lung cancers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto East General Hospital; Princess Margaret Cancer Centre; St Joseph's Health Centre; University Health Network","funders":"","keywords":"Medicine; Lung; Stage (stratigraphy); Oncology; Lung cancer; Profiling (computer programming); Pathology; Internal medicine; Biology","score_opus":0.023086031114638278,"score_gpt":0.3271290544703725,"score_spread":0.3040430233557342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98351216,0.005838918,0.0019329544,0.00019332021,0.00067154947,0.000420957,0.00024918304,0.000015490454,0.007165436],"genre_scores_gemma":[0.9932878,0.0034252545,0.001841162,0.00024502704,0.00037953834,0.00004925589,0.000087570486,0.000053074687,0.0006313299],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832445,0.000056198038,0.0005203302,0.0004995802,0.00013846245,0.00046099536],"domain_scores_gemma":[0.9988065,0.00013486191,0.00023045891,0.00041244688,0.00028804378,0.00012771536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040037543,0.00022818419,0.00041670326,0.0001599375,0.00005445201,0.000025006375,0.00032107503,0.0003490414,0.00003779365],"category_scores_gemma":[0.00012625521,0.00023863405,0.00020772697,0.00023740412,0.0001389806,0.0000072003845,0.00022080718,0.00022579583,0.000005374681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026676242,0.00007495004,0.0024938541,0.0005739969,0.00020054737,0.000040331524,0.00036228116,0.0010768569,0.9806694,0.00007627251,0.008131239,0.006033553],"study_design_scores_gemma":[0.00065779156,0.0021806015,0.0017522787,0.00011526892,0.00006820006,0.0000047961175,0.00014732181,0.0023470756,0.9566715,0.000050848736,0.035733283,0.00027103059],"about_ca_topic_score_codex":0.0009432952,"about_ca_topic_score_gemma":0.0004066604,"teacher_disagreement_score":0.027602045,"about_ca_system_score_codex":0.00007916828,"about_ca_system_score_gemma":0.0011195065,"threshold_uncertainty_score":0.9731214},"labels":[],"label_agreement":null},{"id":"W4402560836","doi":"10.1016/j.annonc.2024.08.1269","title":"1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Adjuvant; Placebo; Stage (stratigraphy); Oncology; Internal medicine; Cancer; Alternative medicine; Pathology; Immunotherapy","score_opus":0.13863269686914514,"score_gpt":0.5114329727693283,"score_spread":0.37280027590018316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756623,0.0028715574,0.00035838078,0.003906371,0.00038763808,0.0030997891,0.00030832982,0.000058759866,0.0014429174],"genre_scores_gemma":[0.9882923,0.00081741123,0.0003475731,0.0008493319,0.00016601346,0.00029907812,0.00003710505,0.00005691288,0.009134281],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978697,0.00014008272,0.0007444039,0.00050611387,0.00032509986,0.00041462085],"domain_scores_gemma":[0.998059,0.00065351627,0.00031383318,0.0004946225,0.00031366062,0.0001654159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039536724,0.00032016353,0.0010946261,0.00023974397,0.00013720541,0.000028939998,0.00020254165,0.00016621679,0.00036627933],"category_scores_gemma":[0.000152508,0.00017494963,0.0002801151,0.00043135646,0.00026108185,0.00013724992,0.00007534895,0.00020192402,0.000003637143],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2516502,0.018946903,0.0068479627,0.002809021,0.01846179,0.0014937103,0.06439251,0.00021024093,0.04350756,0.0012672553,0.032875832,0.557537],"study_design_scores_gemma":[0.39601755,0.18244067,0.08466302,0.0018968297,0.012089624,0.0005714066,0.024828227,0.006213494,0.053858016,0.00061441143,0.23526506,0.001541695],"about_ca_topic_score_codex":0.0013140348,"about_ca_topic_score_gemma":0.00078215636,"teacher_disagreement_score":0.5559953,"about_ca_system_score_codex":0.00014561252,"about_ca_system_score_gemma":0.0014928152,"threshold_uncertainty_score":0.7134239},"labels":[],"label_agreement":null},{"id":"W4402560869","doi":"10.1016/j.annonc.2024.08.634","title":"565P Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; St. Boniface Hospital; Queen's University; CancerCare Manitoba; Ottawa Regional Cancer Foundation; Ottawa Hospital; BC Cancer Agency; Health Sciences North; University of Ottawa; Canadian Cancer Society; University of British Columbia Hospital; NOSM University; University of British Columbia","funders":"Ipsen; EMD Serono; Cook Medical; Seagen; Gilead Sciences; Genentech; AstraZeneca; Incyte; Pfizer; Intuitive Surgical; Servier; Amgen","keywords":"Medicine; Chemotherapy; Oncology; Colorectal cancer; Internal medicine; Cancer; Surgery","score_opus":0.13101385377810948,"score_gpt":0.44802150929432716,"score_spread":0.3170076555162177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729705,0.0028270877,0.000011968205,0.02057305,0.001215665,0.0015098493,0.0002283268,0.000040429215,0.0006231459],"genre_scores_gemma":[0.9930015,0.0014911306,0.00016195042,0.0013732783,0.00061688665,0.0005359996,0.00005087239,0.000030610652,0.002737729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857295,0.00008119499,0.00046780446,0.00037932428,0.00022326996,0.00027548173],"domain_scores_gemma":[0.99869573,0.00066671014,0.00013344288,0.00022217068,0.0001701223,0.000111844136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005037515,0.00016744276,0.00049193087,0.00008932858,0.00006419961,0.000019918007,0.00008739597,0.00018669339,0.000116780575],"category_scores_gemma":[0.00023125368,0.00011501068,0.00020976628,0.00022541334,0.00014093977,0.000091591035,0.000042040334,0.00015294482,0.0000056412878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29708874,0.0005807386,0.0004508922,0.000053734464,0.00039265616,0.00013178265,0.0026599467,7.1642233e-7,0.0010982413,0.000026468388,0.034926485,0.6625896],"study_design_scores_gemma":[0.12945302,0.054792646,0.028273152,0.00024484642,0.00025395636,0.00003495414,0.00009635819,0.00034768868,0.003445916,0.00071696326,0.7821365,0.00020402626],"about_ca_topic_score_codex":0.00021839578,"about_ca_topic_score_gemma":0.00011787785,"teacher_disagreement_score":0.74720997,"about_ca_system_score_codex":0.00009220662,"about_ca_system_score_gemma":0.0003212472,"threshold_uncertainty_score":0.46899992},"labels":[],"label_agreement":null},{"id":"W4402560899","doi":"10.1016/j.annonc.2024.08.552","title":"483P The use of steroids associated with PD1/PDL-1 blockage in patients with brain metastasis: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health","funders":"","keywords":"Medicine; Meta-analysis; Brain metastasis; Oncology; Metastasis; Internal medicine; Cancer","score_opus":0.3009395843857577,"score_gpt":0.4287907860484836,"score_spread":0.1278512016627259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013361333,0.99225,0.000004703213,0.0018227344,0.000010568875,0.004960355,0.0007812622,0.0000149172365,0.000021821545],"genre_scores_gemma":[0.00048690964,0.9959442,0.00021256176,0.001807222,0.00000458379,0.0007131381,0.00034510603,0.00006932798,0.0004169231],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945961,0.0023546906,0.0017409121,0.00050850166,0.000498248,0.00030153108],"domain_scores_gemma":[0.9950789,0.001679033,0.0018639333,0.00087890826,0.0003915613,0.00010767164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021821465,0.00057664636,0.0141245965,0.0005152336,0.000021626513,0.000017404798,0.00018024046,0.00020430448,0.00005739758],"category_scores_gemma":[0.00064997474,0.00022420865,0.0017876409,0.0017490954,0.00019735999,0.000055682412,0.0000926179,0.00037933973,0.000003067756],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042023417,0.0008375215,0.000041031133,0.471992,0.5196102,0.00011999158,0.000064976906,0.0000011127438,3.1162393e-9,0.000032003507,0.0012176585,0.0060414383],"study_design_scores_gemma":[0.0006464308,0.0035017165,0.00007165187,0.05259321,0.9047159,0.000027361704,0.00001552461,0.0000011684889,1.1712515e-7,0.0000034015386,0.038259063,0.0001644476],"about_ca_topic_score_codex":0.00008965979,"about_ca_topic_score_gemma":0.00030396623,"teacher_disagreement_score":0.41939878,"about_ca_system_score_codex":0.00007453903,"about_ca_system_score_gemma":0.00031459497,"threshold_uncertainty_score":0.9655292},"labels":[],"label_agreement":null},{"id":"W4402560917","doi":"10.1016/j.annonc.2024.08.1129","title":"1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Bispecific antibody; Melanoma; Antibody; Cancer research; Oncology; Immunology; Monoclonal antibody","score_opus":0.12503701716567664,"score_gpt":0.4862943189360423,"score_spread":0.36125730177036564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98978597,0.0022439687,0.000004285656,0.004776857,0.00016780959,0.0006884918,0.00006995881,0.000016742284,0.0022459123],"genre_scores_gemma":[0.99805444,0.00023131579,0.00010311834,0.0009121753,0.000121198376,0.000019181523,0.000013060487,0.000023139495,0.00052238913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792665,0.0002594361,0.00066899543,0.00035877147,0.00045153176,0.00033459323],"domain_scores_gemma":[0.9986725,0.00060124847,0.00012340843,0.00026418,0.0001778833,0.00016079562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066711166,0.0001841625,0.00063849613,0.0002951327,0.000058200476,0.000010172056,0.00018334891,0.00012275782,0.00021484683],"category_scores_gemma":[0.0002447251,0.00012388571,0.00011036131,0.0004711721,0.0006795096,0.000068840585,0.00014705306,0.00040159014,0.00001653983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005445735,0.0095383655,0.7181203,0.0012558592,0.000795113,0.0011025409,0.0053005097,0.00026038682,0.17206578,0.009029583,0.005481404,0.07160448],"study_design_scores_gemma":[0.014287454,0.024947194,0.7601697,0.0016545657,0.00018908335,0.00038539676,0.0024845758,0.008066469,0.048312195,0.003860976,0.13506335,0.00057906745],"about_ca_topic_score_codex":0.0001905974,"about_ca_topic_score_gemma":0.00008341135,"teacher_disagreement_score":0.12958194,"about_ca_system_score_codex":0.000029346598,"about_ca_system_score_gemma":0.00041869155,"threshold_uncertainty_score":0.5051912},"labels":[],"label_agreement":null},{"id":"W4402560938","doi":"10.1016/j.annonc.2024.08.1268","title":"1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Oncology; Internal medicine; Lung cancer; Neoadjuvant therapy; Cancer; Immunotherapy","score_opus":0.031859783692050475,"score_gpt":0.3459355386364147,"score_spread":0.31407575494436424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96688586,0.027927548,0.00001008228,0.0029830383,0.00021248058,0.00037740407,0.00020391868,0.000020645626,0.0013790454],"genre_scores_gemma":[0.9872052,0.011351402,0.0002070027,0.00050682534,0.000037455986,0.000025418105,0.000052479707,0.000024319925,0.0005898762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828017,0.00009752207,0.0006469271,0.0004322307,0.00018668234,0.00035648147],"domain_scores_gemma":[0.99886084,0.00040050398,0.00018249387,0.00031472428,0.0001288345,0.0001125963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047409977,0.00020813507,0.0011883964,0.0006490263,0.000036502006,0.000016191903,0.00011602082,0.0002260086,0.00032549028],"category_scores_gemma":[0.000037125727,0.0001823416,0.0002172632,0.0007925237,0.00023186274,0.00008121514,0.00008620578,0.00023358302,0.0000010972213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010092708,0.0008295701,0.83271927,0.0011806476,0.007422696,0.0002891968,0.006073961,0.000060292707,0.05803295,0.00006569994,0.011134151,0.07209886],"study_design_scores_gemma":[0.016207792,0.005110312,0.93279505,0.0007265964,0.002852604,0.000008301904,0.0018612666,0.010106994,0.018943055,0.000155989,0.010790346,0.00044167822],"about_ca_topic_score_codex":0.030588994,"about_ca_topic_score_gemma":0.011769976,"teacher_disagreement_score":0.100075796,"about_ca_system_score_codex":0.000117219075,"about_ca_system_score_gemma":0.00046013045,"threshold_uncertainty_score":0.9758664},"labels":[],"label_agreement":null},{"id":"W4402561053","doi":"10.1016/j.annonc.2024.08.1060","title":"1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Ipsen; Oncolytics Biotech; Swedish Orphan Biovitrum; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Sanofi; Servier; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pharmacokinetics; T-cell receptor; Pharmacology; Oncology; Immunology; T cell","score_opus":0.2060912645721676,"score_gpt":0.5038702914157137,"score_spread":0.2977790268435461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97936475,0.0014781578,0.00031287558,0.012096354,0.00013008762,0.0004934402,0.00041977226,0.00007461129,0.0056299227],"genre_scores_gemma":[0.9972929,0.0013583478,0.00042886767,0.00037671122,0.00022325633,0.000018881668,0.0002197797,0.000017776569,0.00006352012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985628,0.00010113678,0.0005182734,0.00041832076,0.000170878,0.00022858451],"domain_scores_gemma":[0.9988008,0.00037098242,0.00013206743,0.00037610732,0.00012659433,0.00019342282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045091473,0.00015226874,0.0005127833,0.00013980338,0.000028541075,0.00000944236,0.00015827906,0.0001247492,0.0004367468],"category_scores_gemma":[0.0002836935,0.00014441865,0.000055809753,0.0003955723,0.00031748274,0.00015481323,0.00012820933,0.0003401389,0.000007312493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023322264,0.0025401448,0.00024363611,0.0005866818,0.00016357788,0.00024408125,0.00012522274,0.000007657469,0.8123432,0.00030251182,0.0060677244,0.17504334],"study_design_scores_gemma":[0.011149919,0.0010823526,0.029206654,0.00028551128,0.0004483648,0.00024601788,0.00008523444,0.052146118,0.74950033,0.00041679753,0.15509658,0.00033612363],"about_ca_topic_score_codex":0.000038948474,"about_ca_topic_score_gemma":0.0000061750884,"teacher_disagreement_score":0.17470722,"about_ca_system_score_codex":0.000027603759,"about_ca_system_score_gemma":0.000289684,"threshold_uncertainty_score":0.58892214},"labels":[],"label_agreement":null},{"id":"W4402561058","doi":"10.1016/j.annonc.2024.08.1064","title":"1005P Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immune system; Pharmacology; Immunology","score_opus":0.051608571652888215,"score_gpt":0.33943059212143134,"score_spread":0.2878220204685431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930984,0.0018989611,0.000001854805,0.0038019135,0.00015436062,0.00062009954,0.000071053786,0.000046116824,0.00030723534],"genre_scores_gemma":[0.99832517,0.00073111407,0.000055157092,0.00040910777,0.000057528818,0.000053685704,0.00012076074,0.000028125656,0.00021937597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854845,0.00023428845,0.00055708544,0.00025245608,0.0001395073,0.00026823825],"domain_scores_gemma":[0.99934494,0.00015586197,0.00013939866,0.00019041203,0.00011889847,0.000050475428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004912766,0.0001956885,0.00051884307,0.0003205915,0.00002666756,0.000011651013,0.00004529811,0.00016811452,0.00008952397],"category_scores_gemma":[0.000012656478,0.00013384447,0.00016442094,0.00035495398,0.000103421655,0.00006168707,0.000013979549,0.000113315764,0.000014191818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27013707,0.004365137,0.025987454,0.00034326923,0.0019599474,0.00067969016,0.0052547483,0.000008137674,0.5717373,0.000026078818,0.0005844144,0.118916765],"study_design_scores_gemma":[0.022896415,0.082050845,0.23453344,0.0012572801,0.00032369036,0.00013784204,0.00049395184,0.00010616176,0.60289073,0.00003213141,0.054919925,0.0003575881],"about_ca_topic_score_codex":0.00027317714,"about_ca_topic_score_gemma":0.00028837755,"teacher_disagreement_score":0.24724065,"about_ca_system_score_codex":0.0003941342,"about_ca_system_score_gemma":0.00039228663,"threshold_uncertainty_score":0.54580194},"labels":[],"label_agreement":null},{"id":"W4402561069","doi":"10.1016/j.annonc.2024.08.1055","title":"996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Solid tumor; Phase (matter); Oncology; Nuclear medicine; Internal medicine; Cancer; Immunotherapy","score_opus":0.06164670606560626,"score_gpt":0.3922550541486538,"score_spread":0.33060834808304757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995673,0.00141207,0.00012914829,0.0015463411,0.00006946765,0.00063164823,0.00014328804,0.00002184427,0.00037319874],"genre_scores_gemma":[0.9972342,0.0004501581,0.0008062583,0.00036855476,0.000020541947,0.00002910327,0.0010357376,0.000022833854,0.00003259636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986152,0.000100901605,0.0004496928,0.00040024932,0.00021479915,0.00021913585],"domain_scores_gemma":[0.999161,0.00019561267,0.0001637538,0.00031764168,0.0001035159,0.000058487007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033478145,0.0001614509,0.00047482466,0.00028611175,0.000021305405,0.000014839521,0.00010748932,0.000068282236,0.000056507964],"category_scores_gemma":[0.00006819942,0.00012400639,0.000020504755,0.0004306225,0.00015903886,0.00035161915,0.0000494045,0.00018273373,0.0000031138354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10822943,0.0070790565,0.061588854,0.0006261285,0.00045182678,0.0006322208,0.0019316652,0.000085666084,0.006946282,0.00006729377,0.0014565578,0.81090504],"study_design_scores_gemma":[0.11799198,0.03807082,0.8185046,0.0032653082,0.00022784078,0.00009932813,0.00057410885,0.01121471,0.0034977633,0.0006673004,0.0054221116,0.00046416355],"about_ca_topic_score_codex":0.00042805675,"about_ca_topic_score_gemma":0.00084477384,"teacher_disagreement_score":0.81044084,"about_ca_system_score_codex":0.00008512429,"about_ca_system_score_gemma":0.00025510378,"threshold_uncertainty_score":0.50568336},"labels":[],"label_agreement":null},{"id":"W4402561075","doi":"10.1016/j.annonc.2024.08.1046","title":"986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; OncoMed Pharmaceutical; European Society for Medical Oncology; AstraZeneca; Novocure; Institut National Du Cancer; FibroGen; Astellas Pharma; Eisai; Sociedad Española de Oncología Médica; BeiGene; Sierra Oncology; Fondation ARC pour la Recherche sur le Cancer; Pharmacyclics; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Celgene","keywords":"Medicine; Lenvatinib; Hepatocellular carcinoma; Oncology; Internal medicine; Immunotherapy; Phases of clinical research; Sorafenib; Chemotherapy; Cancer","score_opus":0.071613809024952,"score_gpt":0.4218901432045754,"score_spread":0.3502763341796234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918346,0.00111699,0.00015453923,0.0016890098,0.00017997182,0.0039736433,0.0007403262,0.0000612014,0.00024971698],"genre_scores_gemma":[0.9955822,0.000082034196,0.0016496206,0.00043177503,0.00002365665,0.00055445667,0.001122194,0.000055824537,0.0004982142],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99767697,0.00020110518,0.00077806896,0.00056551665,0.00038407007,0.00039428327],"domain_scores_gemma":[0.9984488,0.00035521618,0.00024563647,0.00043295592,0.00040138062,0.00011600057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002479067,0.0003045829,0.00077184185,0.0003504536,0.000070582166,0.00002810574,0.00013879147,0.00007991786,0.000075237804],"category_scores_gemma":[0.00014772489,0.00020961784,0.0000917741,0.00052748696,0.00011311475,0.00021074079,0.00003569251,0.00025193483,0.0000136451745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14585595,0.1666912,0.4374848,0.0004974416,0.005780411,0.0032359455,0.019399408,0.00038378694,0.00093375746,0.0001558666,0.0018207717,0.21776065],"study_design_scores_gemma":[0.51445913,0.16365618,0.29532298,0.0016931385,0.0007834023,0.000011843458,0.002805656,0.007182658,0.002603386,0.00013089046,0.01073469,0.00061601924],"about_ca_topic_score_codex":0.0005362987,"about_ca_topic_score_gemma":0.00031873802,"teacher_disagreement_score":0.3686032,"about_ca_system_score_codex":0.00028356162,"about_ca_system_score_gemma":0.00084624236,"threshold_uncertainty_score":0.85479677},"labels":[],"label_agreement":null},{"id":"W4402561078","doi":"10.1016/j.annonc.2024.08.995","title":"934P Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Oncology; Head and neck cancer; Internal medicine; Surgery; Radiation therapy","score_opus":0.14749092931448096,"score_gpt":0.44252316828667027,"score_spread":0.29503223897218933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262453,0.00027355936,0.000098841214,0.013708691,0.0004917402,0.00056676375,0.000014997351,0.000022797953,0.0021981047],"genre_scores_gemma":[0.99775875,0.000086015905,0.00022465178,0.0016156076,0.00017941017,0.000016711534,0.000022693734,0.00001806625,0.000078085686],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982818,0.00023979045,0.00046732294,0.00047083927,0.00025763107,0.00028263268],"domain_scores_gemma":[0.9983728,0.00082450284,0.00010102628,0.000488666,0.00007690137,0.00013613662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012358858,0.00013940566,0.0003682396,0.00026879695,0.00006507385,0.000038412672,0.00029066764,0.00004537622,0.000017081105],"category_scores_gemma":[0.0011599571,0.00009824594,0.000028982948,0.0005009411,0.0001729657,0.00009053743,0.00022305745,0.00063667534,0.000013141105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005761484,0.0017399531,0.27837664,0.00017990576,0.000022155915,0.00027808335,0.0036435146,0.00010203712,0.000096802454,0.00031719566,0.0051388047,0.70952874],"study_design_scores_gemma":[0.0009612434,0.016240573,0.90650284,0.00067883346,0.00015568292,0.000025192461,0.0018880323,0.043089967,0.00041675582,0.0007077094,0.029047629,0.00028551643],"about_ca_topic_score_codex":0.0012699006,"about_ca_topic_score_gemma":0.0007680104,"teacher_disagreement_score":0.70924324,"about_ca_system_score_codex":0.000048898135,"about_ca_system_score_gemma":0.00019717401,"threshold_uncertainty_score":0.4006353},"labels":[],"label_agreement":null},{"id":"W4402561160","doi":"10.1016/j.annonc.2024.08.371","title":"423P Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Western University","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Cancer; Oncology; Internal medicine; Demography; Gynecology","score_opus":0.0551422711436541,"score_gpt":0.276197002092646,"score_spread":0.22105473094899192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659544,0.00037646882,0.00004518128,0.00026356644,0.00012763902,0.00018200593,0.0006363859,0.0000081052385,0.0017652194],"genre_scores_gemma":[0.9993903,0.00012904678,0.000011102364,0.00023490797,0.0000112327725,0.000027531389,0.000031964155,0.00001790946,0.00014598914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990166,0.000020445877,0.0003805482,0.00025745702,0.0000373756,0.00028757626],"domain_scores_gemma":[0.99937356,0.00009650133,0.0002739088,0.00009353679,0.00007289143,0.00008959837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023753097,0.00013761237,0.0004582712,0.0001309506,0.00002951232,0.00002937205,0.000076864,0.00007567802,0.00023306983],"category_scores_gemma":[0.000046530717,0.0001273482,0.000026049769,0.0001733703,0.00009906157,0.00030395488,0.000016344027,0.00014816209,8.075778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046544526,0.000087239685,0.996103,0.000023882563,0.00018087715,0.000028200035,0.0008871182,0.00028365315,2.901627e-7,0.0013190343,0.00027526147,0.0007649185],"study_design_scores_gemma":[0.0007024713,0.000345813,0.9964295,0.000083561,0.00002034009,9.632705e-7,0.000046438778,0.00017809872,0.000007507161,0.0006292956,0.0013967375,0.00015924675],"about_ca_topic_score_codex":0.9656648,"about_ca_topic_score_gemma":0.9968045,"teacher_disagreement_score":0.031139681,"about_ca_system_score_codex":0.00072113745,"about_ca_system_score_gemma":0.00093349244,"threshold_uncertainty_score":0.5193109},"labels":[],"label_agreement":null},{"id":"W4402561187","doi":"10.1016/j.annonc.2024.08.1126","title":"1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Royal Victoria Hospital; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Fecal bacteriotherapy; Melanoma; Immune checkpoint; Cancer; Transplantation; Internal medicine; Oncology; Lung cancer; Immunotherapy; Cancer research","score_opus":0.02559648026178742,"score_gpt":0.35027308941468865,"score_spread":0.32467660915290125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868083,0.008770934,0.00005032848,0.0019794619,0.00048128664,0.000972476,0.00010160088,0.000018788165,0.0008167953],"genre_scores_gemma":[0.98809606,0.01095881,0.00015244848,0.00018856031,0.00009815432,0.000061345185,0.00009612123,0.000022455803,0.00032605918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853176,0.000066499924,0.00074619893,0.0002945057,0.00011169762,0.00024936287],"domain_scores_gemma":[0.99938977,0.00011478576,0.00021056403,0.00013718099,0.00009293804,0.000054735974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037323756,0.00017877684,0.00059842394,0.00025871096,0.000034755743,0.00000621749,0.00005625089,0.00023684533,0.00010696297],"category_scores_gemma":[0.000013185661,0.00016383873,0.0001698294,0.00025014364,0.00016027474,0.00007273105,0.000022005475,0.00021048899,0.0000010955662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12721841,0.0008418205,0.00004067198,0.0011420747,0.00013546107,0.0003738968,0.0032323352,0.000013668642,0.7981698,0.000008680032,0.00018496429,0.06863821],"study_design_scores_gemma":[0.10053504,0.021617547,0.00070815923,0.0012827836,0.0002558212,0.00037546144,0.0003587808,0.00079659704,0.8699051,0.000024795128,0.0039274995,0.00021241436],"about_ca_topic_score_codex":0.0008082099,"about_ca_topic_score_gemma":0.00042335427,"teacher_disagreement_score":0.071735285,"about_ca_system_score_codex":0.00015092736,"about_ca_system_score_gemma":0.0004685812,"threshold_uncertainty_score":0.66811496},"labels":[],"label_agreement":null},{"id":"W4402561191","doi":"10.1016/j.annonc.2024.08.1077","title":"1018P Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Innate immune system; Acquired immune system; Cancer; Immunity; Immunology; Oncology; Immunotherapy; Internal medicine; Immune system; Nivolumab","score_opus":0.09142715196903854,"score_gpt":0.3835679807072185,"score_spread":0.2921408287381799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96535075,0.029158676,0.00003395198,0.0039274027,0.00006261608,0.00019494635,0.0000132040705,0.0000142197305,0.0012442414],"genre_scores_gemma":[0.9906873,0.008080877,0.00030076923,0.00071191415,0.000019759449,0.000020693062,0.0000030773904,0.0000116092115,0.00016396368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992889,0.00007859925,0.0001988659,0.00017087656,0.000082677594,0.00018003854],"domain_scores_gemma":[0.9996224,0.00013084162,0.000054733606,0.00008541092,0.000059703743,0.00004689141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032040037,0.000104264145,0.00032001772,0.00022405779,0.000024564602,0.000008863015,0.000032139975,0.000045871333,0.00006318906],"category_scores_gemma":[0.000014992187,0.00007688769,0.000028326562,0.0003201577,0.00020759233,0.00007552516,0.000028527718,0.00018209801,7.5838767e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010880691,0.00023974774,0.010001942,0.00056247925,0.0011271491,0.00060340547,0.007398876,0.000012984636,0.009865066,0.00027561173,0.0011506319,0.9578814],"study_design_scores_gemma":[0.022416674,0.031039959,0.80990416,0.0043286546,0.00083027425,0.0028867775,0.010684798,0.0033914375,0.015114811,0.0019630059,0.09657727,0.00086217234],"about_ca_topic_score_codex":0.002268033,"about_ca_topic_score_gemma":0.00058759085,"teacher_disagreement_score":0.95701927,"about_ca_system_score_codex":0.000055101962,"about_ca_system_score_gemma":0.0003164092,"threshold_uncertainty_score":0.34286028},"labels":[],"label_agreement":null},{"id":"W4402561249","doi":"10.1016/j.annonc.2024.08.1005","title":"944TiP Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Oncolytics Biotech; Coherus Biosciences; Celgene; Rakuten Medical; Pfizer; Incyte; Break Through Cancer; Relay Therapeutics; Seagen; Agios Pharmaceuticals; BeiGene; Tizona Therapeutics; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; Sanofi; Exelixis; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; AbbVie; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Open label; Head and neck; Head and neck cancer; Immunotherapy; Randomized controlled trial; Cancer; Surgery","score_opus":0.10361793668828055,"score_gpt":0.41855865730273056,"score_spread":0.31494072061445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497259,0.03402924,0.00018924601,0.004814763,0.0008816429,0.008035898,0.00069992687,0.00004089894,0.0015824311],"genre_scores_gemma":[0.9893983,0.0066198255,0.00056894217,0.00050611177,0.00031983218,0.0010773275,0.0003545314,0.00007038642,0.0010847637],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643326,0.00038411445,0.0015352594,0.00073287217,0.0003102482,0.0006042246],"domain_scores_gemma":[0.99635434,0.0019908622,0.00059371063,0.00045239212,0.0003672324,0.00024143621],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008941889,0.00051939173,0.003094041,0.00040162035,0.00013632546,0.000045332803,0.0002400368,0.00024361895,0.00017353134],"category_scores_gemma":[0.00019047108,0.00040278825,0.0005950039,0.00036576384,0.00056452147,0.00016564899,0.000092915485,0.0001867191,0.000005401442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9021807,0.00805424,0.000005871255,0.00094824,0.0011509409,0.0002533984,0.0024164324,0.0000034941097,0.0021425146,0.00014875094,0.0036556798,0.07903976],"study_design_scores_gemma":[0.8311668,0.1318666,0.00003944016,0.0002924083,0.0016685768,0.00026525863,0.00015337043,0.002059632,0.013201222,0.00023742343,0.018753413,0.00029582714],"about_ca_topic_score_codex":0.0014122832,"about_ca_topic_score_gemma":0.0003574168,"teacher_disagreement_score":0.12381236,"about_ca_system_score_codex":0.00035592326,"about_ca_system_score_gemma":0.0014088036,"threshold_uncertainty_score":0.9998424},"labels":[],"label_agreement":null},{"id":"W4402561251","doi":"10.1016/j.annonc.2024.08.582","title":"513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"FOLFOX; FOLFIRI; Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Oxaliplatin","score_opus":0.2492686992421674,"score_gpt":0.5171064460490095,"score_spread":0.267837746806842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276496,0.0045808763,0.000002983669,0.0050301757,0.00075092196,0.0020998155,0.0009109802,0.00006970973,0.0037895786],"genre_scores_gemma":[0.9948523,0.0020356276,0.00035914095,0.0006590438,0.0001846486,0.0005456649,0.00014087919,0.0000418303,0.0011808496],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972854,0.00024248773,0.00088937284,0.00078712404,0.0003178689,0.0004777007],"domain_scores_gemma":[0.9984331,0.0006324969,0.00019769892,0.00034483866,0.00020357718,0.00018828016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053888984,0.0003330675,0.0014196906,0.00025726252,0.00013255775,0.000041247084,0.00031646667,0.00011301297,0.00032297053],"category_scores_gemma":[0.0002626905,0.00023521806,0.00007207826,0.000637162,0.00016751257,0.00025311732,0.00036725125,0.00029079535,0.000014656293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13843688,0.04773146,0.002778328,0.00018399865,0.0067574126,0.013956466,0.04639012,0.00003354775,0.0051941616,0.0002774857,0.035418514,0.70284164],"study_design_scores_gemma":[0.20637667,0.5518815,0.030515937,0.0011034416,0.0032385283,0.00017386735,0.016680803,0.003406736,0.008542421,0.0016557736,0.17525934,0.0011649674],"about_ca_topic_score_codex":0.014484852,"about_ca_topic_score_gemma":0.053934775,"teacher_disagreement_score":0.70167667,"about_ca_system_score_codex":0.0004207621,"about_ca_system_score_gemma":0.0015633103,"threshold_uncertainty_score":0.99207777},"labels":[],"label_agreement":null},{"id":"W4402561305","doi":"10.1016/j.annonc.2024.08.384","title":"437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Antibody-drug conjugate; Open label; Conjugate; Trastuzumab; Drug; Oncology; Pharmacology; Phases of clinical research; Internal medicine; Antibody; Clinical trial; Monoclonal antibody; Adverse effect; Cancer; Immunology; Breast cancer","score_opus":0.14514835074140064,"score_gpt":0.5117613860980696,"score_spread":0.366613035356669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865478,0.00072781154,0.000016324742,0.0042775013,0.00011778902,0.007631412,0.000421825,0.00003797508,0.00022154035],"genre_scores_gemma":[0.9961147,0.0009927232,0.00040571656,0.00071213127,0.00006281639,0.00042204926,0.00007712618,0.000096760705,0.0011159991],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99513024,0.0011459091,0.0011643101,0.0008975409,0.00079312903,0.0008688765],"domain_scores_gemma":[0.9967186,0.001026508,0.0002704715,0.00062100106,0.00096844765,0.0003949862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036524558,0.00042329013,0.0014211716,0.00033723714,0.00017326135,0.00007458315,0.00061109033,0.000087475215,0.0009079719],"category_scores_gemma":[0.0006431367,0.0002384095,0.00004968462,0.0013398885,0.00033898925,0.00031827093,0.00046610952,0.0005267853,0.0000123051],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33983976,0.15484309,0.051589157,0.0042513288,0.004479103,0.0017612292,0.04363914,0.00080813165,0.023024872,0.000019848218,0.0074472395,0.36829713],"study_design_scores_gemma":[0.30793434,0.50183624,0.0915696,0.013069325,0.0025901587,0.00027853777,0.01261283,0.02599089,0.013237269,0.000019120844,0.02914628,0.001715399],"about_ca_topic_score_codex":0.021909436,"about_ca_topic_score_gemma":0.015181151,"teacher_disagreement_score":0.3665817,"about_ca_system_score_codex":0.0002711965,"about_ca_system_score_gemma":0.0016889743,"threshold_uncertainty_score":0.99416554},"labels":[],"label_agreement":null},{"id":"W4402561311","doi":"10.1016/j.annonc.2024.08.569","title":"500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Glioblastoma; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Cancer research","score_opus":0.10118891103444745,"score_gpt":0.425779293027831,"score_spread":0.3245903819933836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839254,0.0018563782,0.0000046889845,0.016113985,0.0006146509,0.0017897013,0.00013270356,0.000049003,0.0010463393],"genre_scores_gemma":[0.99664986,0.0008952516,0.00018127396,0.0016216082,0.00017985493,0.0003768701,0.000035563524,0.000020456113,0.000039279694],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805135,0.000097083976,0.00055342313,0.0005500383,0.0003066819,0.0004414508],"domain_scores_gemma":[0.9986198,0.0005168508,0.00012691467,0.0002840518,0.00014314355,0.00030922846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005114797,0.00027703942,0.0007655156,0.00033415732,0.000057924186,0.000017449636,0.00008940511,0.00018270922,0.00010690186],"category_scores_gemma":[0.0003609126,0.0002026665,0.00015693626,0.0004988753,0.000092231116,0.000087347435,0.00011358081,0.00019835387,0.000054720287],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18297042,0.011869195,0.0004211522,0.00006522155,0.000641752,0.0032799065,0.0014931432,0.000060433667,0.0006179877,0.0018437159,0.09121661,0.70552045],"study_design_scores_gemma":[0.35874033,0.35867846,0.0045257695,0.0016661026,0.000591487,0.00015058916,0.0005898654,0.0028995331,0.013721897,0.0012911637,0.2565776,0.0005671772],"about_ca_topic_score_codex":0.0002166835,"about_ca_topic_score_gemma":0.0010223135,"teacher_disagreement_score":0.7049533,"about_ca_system_score_codex":0.00023219339,"about_ca_system_score_gemma":0.00030170774,"threshold_uncertainty_score":0.82645005},"labels":[],"label_agreement":null},{"id":"W4402561315","doi":"10.1016/j.annonc.2024.08.970","title":"909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Nivolumab; Head and neck cancer; Salvage surgery; Oncology; Adjuvant; Head and neck squamous-cell carcinoma; Basal cell; Squamous cell cancer; Salvage therapy; Internal medicine; Head and neck; Surgery; Cancer; Immunotherapy; Radiation therapy; Chemotherapy","score_opus":0.05736057747459269,"score_gpt":0.3652727655285547,"score_spread":0.30791218805396203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89362603,0.096835844,3.8296116e-7,0.00616277,0.001008608,0.0009525985,0.00004645325,0.000029832127,0.0013374472],"genre_scores_gemma":[0.9890334,0.007973431,0.000006594037,0.0013274127,0.00035722114,0.00029401606,0.000020837653,0.000031866108,0.0009551973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826497,0.00018447726,0.000585288,0.00037144817,0.00019168686,0.0004021037],"domain_scores_gemma":[0.99867666,0.00072932645,0.00011926028,0.00032845765,0.000055962344,0.00009033932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004562482,0.00023999326,0.0007104953,0.00021255575,0.000045568228,0.000019354935,0.00008774084,0.00019992942,0.00031457038],"category_scores_gemma":[0.000051943614,0.00015511175,0.00029328154,0.0002891863,0.00025808573,0.00006429253,0.000041541272,0.00021442251,0.000013189862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38843834,0.0035426975,0.03652952,0.00058306084,0.00058781455,0.0023636508,0.007461785,0.0000052092187,0.007621559,0.000018563649,0.021333102,0.5315147],"study_design_scores_gemma":[0.095514126,0.02970228,0.643413,0.0006102393,0.00047054683,0.00021385284,0.000443115,0.00007688734,0.0144787,0.00006306409,0.21460216,0.00041199982],"about_ca_topic_score_codex":0.006593576,"about_ca_topic_score_gemma":0.0014095287,"teacher_disagreement_score":0.6068835,"about_ca_system_score_codex":0.00023514128,"about_ca_system_score_gemma":0.0011423599,"threshold_uncertainty_score":0.99675584},"labels":[],"label_agreement":null},{"id":"W4402561335","doi":"10.1016/j.annonc.2024.08.372","title":"425P The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Max Bell Foundation","funders":"","keywords":"Pact; Medicine; Stakeholder; Low and middle income countries; Breast cancer; Cancer; Economic growth; Public relations; Developing country; Internal medicine; Political science; Law","score_opus":0.13160667614520175,"score_gpt":0.37524879402129396,"score_spread":0.24364211787609222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402978,0.0049654874,0.00057258003,0.04726197,0.0009499542,0.0016758635,0.0033144548,0.000019576722,0.00094233843],"genre_scores_gemma":[0.9942287,0.0016515112,0.00024692953,0.0025111667,0.00017697977,0.00066457695,0.0000075622356,0.000024410192,0.00048812214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873656,0.000012161904,0.0005365432,0.00037641413,0.000019080711,0.0003192472],"domain_scores_gemma":[0.99927676,0.00015563772,0.00017785814,0.00018776648,0.000105692336,0.00009627114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003577105,0.00016056187,0.00048868253,0.00024840867,0.000077431025,0.0001368216,0.00017875108,0.00010580789,0.000055228855],"category_scores_gemma":[0.00008195005,0.00014189072,0.00006167487,0.00023873402,0.00006169913,0.00045308308,0.000048885428,0.00006381234,0.00002369601],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005314542,0.0013472228,0.13256885,0.0020751473,0.0010953884,0.000051812247,0.040715206,0.0076089287,0.0003920109,0.36787626,0.0074699773,0.43348464],"study_design_scores_gemma":[0.0039177523,0.004422019,0.3266705,0.0005704358,0.000034307006,0.000007372066,0.0008712361,0.0018744167,0.0011923658,0.013176871,0.6465414,0.0007213252],"about_ca_topic_score_codex":0.0018199944,"about_ca_topic_score_gemma":0.017534213,"teacher_disagreement_score":0.6390714,"about_ca_system_score_codex":0.00033939024,"about_ca_system_score_gemma":0.00024798463,"threshold_uncertainty_score":0.9784503},"labels":[],"label_agreement":null},{"id":"W4402561493","doi":"10.1016/j.annonc.2024.08.184","title":"241P Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Association of Schools and Colleges of Optometry; Chugai Pharmaceutical; Samsung; European Society for Medical Oncology; Astellas Pharma; Eisai; Genentech; Veracyte; Sociedad Española de Oncología Médica; BeiGene; Mylan; Japanese Breast Cancer Society; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; F. Hoffmann-La Roche; Relay Therapeutics; Seagen; Roche; Celgene; Novartis; Amgen; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Palbociclib; Placebo; Oncology; Internal medicine; Breast cancer; Disease; Overall survival; Cancer; Surgery; Metastatic breast cancer; Pathology; Alternative medicine","score_opus":0.036486052286007,"score_gpt":0.32645242039347855,"score_spread":0.28996636810747156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552502,0.0017760277,0.000013625067,0.0255366,0.000516859,0.0016190265,0.015202154,0.00005463149,0.000030862935],"genre_scores_gemma":[0.99513394,0.00064294256,0.00043630644,0.0014714613,0.0009241898,0.00034099523,0.00086028024,0.00007210569,0.00011780847],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975679,0.00035604503,0.0005353261,0.00070311053,0.00041509976,0.00042255578],"domain_scores_gemma":[0.99593574,0.00241002,0.00032238747,0.000471406,0.00037407503,0.00048637483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050423807,0.00034400827,0.0006620839,0.00007557203,0.00013927126,0.000051339506,0.00017454034,0.00012457756,0.000053649845],"category_scores_gemma":[0.0011282302,0.0002267357,0.000087619366,0.00016360695,0.0006195271,0.00025873812,0.0001800977,0.00031141244,0.0000015898817],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7308762,0.00039277683,0.24179155,0.00023824809,0.0011184603,0.00012821234,0.0014658581,0.0000471629,0.0000634207,0.00025045383,0.0046263332,0.019001331],"study_design_scores_gemma":[0.08409897,0.0024729248,0.902609,0.00064075174,0.0007124688,0.0000028759528,0.00021592586,0.000056703848,0.00006531156,0.004348808,0.0044589024,0.00031737864],"about_ca_topic_score_codex":0.002105439,"about_ca_topic_score_gemma":0.002196226,"teacher_disagreement_score":0.66081744,"about_ca_system_score_codex":0.00007769461,"about_ca_system_score_gemma":0.0010261156,"threshold_uncertainty_score":0.9246014},"labels":[],"label_agreement":null},{"id":"W4402561515","doi":"10.1016/j.annonc.2024.08.227","title":"286P Impact of adjuvant endocrine therapy on survival outcomes in female breast cancer patients over 50","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Ontario Institute for Cancer Research; Alberta Health; University of Alberta","funders":"","keywords":"Medicine; Oncology; Breast cancer; Adjuvant; Internal medicine; Endocrine system; Adjuvant therapy; Cancer; Overall survival; Gynecology; Hormone","score_opus":0.09601065234537197,"score_gpt":0.491891860198112,"score_spread":0.39588120785274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915922,0.001717149,1.9754805e-7,0.0030553367,0.0006382538,0.00032403177,0.0003433125,0.000015413909,0.002314087],"genre_scores_gemma":[0.99537796,0.0032374777,0.0000049942414,0.0006718253,0.000115425115,0.00004056734,0.00003431084,0.00001814864,0.0004993045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989761,0.00007888134,0.00032987344,0.00020282801,0.00015325575,0.0002590786],"domain_scores_gemma":[0.99936366,0.00023632922,0.00009550831,0.00012750819,0.00010127846,0.00007570729],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000114567534,0.00015696153,0.0006888349,0.00022683704,0.000009410115,0.0000021370151,0.000064746964,0.00007987427,0.0017912599],"category_scores_gemma":[0.000012385262,0.00010513835,0.00023853478,0.00017362363,0.000078824225,0.000044585475,0.000023487797,0.00015052511,0.000011073214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030914324,0.0032139132,0.90843266,0.00006162566,0.00070859265,0.00008678288,0.000420969,0.00002014934,0.0026991104,0.00007056291,0.0046360325,0.07655818],"study_design_scores_gemma":[0.00514461,0.009203828,0.9748571,0.00007845607,0.000053583102,0.000007966355,0.000011886589,0.000017312406,0.0026291327,0.000062176434,0.007856825,0.00007713758],"about_ca_topic_score_codex":0.0043417327,"about_ca_topic_score_gemma":0.00044621818,"teacher_disagreement_score":0.07648104,"about_ca_system_score_codex":0.00015712075,"about_ca_system_score_gemma":0.00035339792,"threshold_uncertainty_score":0.99912125},"labels":[],"label_agreement":null},{"id":"W4402561603","doi":"10.1016/j.annonc.2024.08.533","title":"463P Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Retrospective cohort study; Oncology; Lung cancer; Cohort; Internal medicine; Disease","score_opus":0.02090518596534157,"score_gpt":0.35326712717444253,"score_spread":0.33236194120910095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959801,0.0008665106,0.00024963685,0.0010756003,0.000044924633,0.0007946937,0.00034944832,0.000024386301,0.00061471463],"genre_scores_gemma":[0.9965252,0.00045714024,0.0022555895,0.00021761926,0.000021996168,0.00009637243,0.00008172152,0.00003167673,0.00031262857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870276,0.00007693104,0.00033348272,0.000369627,0.00029154296,0.0002256528],"domain_scores_gemma":[0.99891746,0.00013013853,0.00020661902,0.0002470825,0.00031616338,0.00018254822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002275002,0.00020744507,0.001090908,0.00033047763,0.000025037129,0.000008716699,0.00004948644,0.000030226704,0.00009273307],"category_scores_gemma":[0.00001935993,0.00012308902,0.000145081,0.00063402887,0.00018554667,0.00005425093,0.00002833618,0.00012562811,5.466821e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015784326,0.0008140965,0.9837353,0.00038164348,0.0107138045,0.00019661935,0.00025292387,0.000048255373,0.0000059880786,0.000106857224,0.00020952683,0.001956553],"study_design_scores_gemma":[0.0025563808,0.002783714,0.97816086,0.00012233925,0.015347521,0.00000224546,0.000045191977,0.0005449411,0.00008754117,0.000031949843,0.00020139613,0.000115915456],"about_ca_topic_score_codex":0.0015270037,"about_ca_topic_score_gemma":0.0025465805,"teacher_disagreement_score":0.005574436,"about_ca_system_score_codex":0.000084878,"about_ca_system_score_gemma":0.00035150294,"threshold_uncertainty_score":0.50194246},"labels":[],"label_agreement":null},{"id":"W4402561655","doi":"10.1016/j.annonc.2024.08.095","title":"87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Genome British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Profiling (computer programming); Clinical decision making; DNA sequencing; Computational biology; DNA; Intensive care medicine; Genetics; Computer science","score_opus":0.2398657865723113,"score_gpt":0.49142795215672264,"score_spread":0.25156216558441136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98022974,0.0048375535,0.013538665,0.0005558081,0.00011130115,0.00067122065,0.0000327195,0.0000040927757,0.000018897703],"genre_scores_gemma":[0.9853428,0.0009106431,0.013305591,0.00015497545,0.0001215466,0.00010357204,0.000047292415,0.0000119658025,0.0000016256103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989721,0.000073838324,0.0005255042,0.00026139495,0.000052047406,0.0001151036],"domain_scores_gemma":[0.9988721,0.00047204483,0.00023184418,0.00020410492,0.00020350084,0.000016393133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005232639,0.00008983502,0.0002598975,0.00009522988,0.000027406651,0.000005243383,0.00009317605,0.00020265073,7.074445e-7],"category_scores_gemma":[0.00026875865,0.00007405489,0.00006610442,0.00009592043,0.00014362506,0.000002748125,0.00005745883,0.000052623407,2.3002845e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033118817,0.000057400754,0.00052192854,0.000052869753,0.000036490277,6.6971336e-7,0.000057269084,0.005381379,0.7967033,0.0010921794,0.000033488603,0.19573183],"study_design_scores_gemma":[0.00085002504,0.011885593,0.0005251994,0.00006554038,0.000061742554,0.000006783969,0.00015256579,0.116362005,0.86454713,0.0012482582,0.004201245,0.000093912735],"about_ca_topic_score_codex":0.000045929864,"about_ca_topic_score_gemma":0.00008986145,"teacher_disagreement_score":0.19563793,"about_ca_system_score_codex":0.000042440093,"about_ca_system_score_gemma":0.00047655843,"threshold_uncertainty_score":0.30198708},"labels":[],"label_agreement":null},{"id":"W4402561660","doi":"10.1016/j.annonc.2024.08.378","title":"431P Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Incidence (geometry); Adverse effect; Internal medicine; Chemotherapy; Oncology; Family medicine","score_opus":0.055316604342201675,"score_gpt":0.3768241193797079,"score_spread":0.3215075150375062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945379,0.0012115453,0.000001961046,0.0019416,0.00021206235,0.0015318173,0.00048090098,0.000019597814,0.00006262452],"genre_scores_gemma":[0.9982913,0.0006569653,0.00008885797,0.00053037715,0.000061484876,0.00016545731,0.00008814364,0.00004243612,0.00007497056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972418,0.0004979666,0.0009866974,0.00048307178,0.0004445867,0.0003458812],"domain_scores_gemma":[0.9976003,0.0006242897,0.00059811457,0.00046838965,0.00054615235,0.0001627276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027195635,0.00034033702,0.0011989351,0.00027057092,0.000035476296,0.000002671395,0.00031859498,0.00014093678,0.0005118034],"category_scores_gemma":[0.00009647596,0.0002280308,0.000118386226,0.0008620094,0.00038137028,0.0001861982,0.00008319684,0.00030545323,0.0000035274606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006628013,0.006310453,0.9632122,0.00036568614,0.0017600697,0.00004968954,0.0066919513,0.0001539797,0.0020451301,0.000007003491,0.0010440975,0.011731749],"study_design_scores_gemma":[0.016347421,0.014196584,0.95285815,0.00095399946,0.00083424663,0.000015006653,0.0019993656,0.00016143547,0.012047631,0.000042481824,0.00035623074,0.00018746033],"about_ca_topic_score_codex":0.03965985,"about_ca_topic_score_gemma":0.009463166,"teacher_disagreement_score":0.030196685,"about_ca_system_score_codex":0.00016983045,"about_ca_system_score_gemma":0.0012124686,"threshold_uncertainty_score":0.9667351},"labels":[],"label_agreement":null},{"id":"W4402561714","doi":"10.1016/j.annonc.2024.08.376","title":"429P Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Cancer; Breast cancer; Internal medicine; Radiology","score_opus":0.05707386712719624,"score_gpt":0.4350356522901061,"score_spread":0.37796178516290985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91945344,0.014010887,0.00003052639,0.06282909,0.00021919484,0.0003068503,0.00009729546,0.000031495056,0.0030212114],"genre_scores_gemma":[0.99494374,0.0012960418,0.00019275135,0.0030113573,0.00013985245,0.000047423222,0.000017125769,0.000017753448,0.00033396328],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991136,0.00008529236,0.00020690479,0.00026261844,0.00009350236,0.00023805998],"domain_scores_gemma":[0.99947864,0.00023247434,0.000060115057,0.00006779421,0.0001027455,0.000058257097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016350899,0.00012437071,0.0003787611,0.00022423956,0.000024729366,0.000008183109,0.000039300896,0.00003534878,0.00025987483],"category_scores_gemma":[0.000021172447,0.00011007346,0.00007357302,0.00023594564,0.00015726942,0.00011869732,0.00003425351,0.00016279385,0.0000032749526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009715203,0.0015740232,0.12945732,0.00030948207,0.00069728674,0.0003488374,0.0097264685,0.000016870308,0.0061851465,0.0007772985,0.034319773,0.81561595],"study_design_scores_gemma":[0.010228307,0.00413727,0.8621462,0.000886662,0.0007336524,0.00019967384,0.006481345,0.0019201578,0.0024804133,0.0007696329,0.10958007,0.00043663348],"about_ca_topic_score_codex":0.0008047731,"about_ca_topic_score_gemma":0.00023736479,"teacher_disagreement_score":0.81517935,"about_ca_system_score_codex":0.00008515857,"about_ca_system_score_gemma":0.00018184194,"threshold_uncertainty_score":0.44886655},"labels":[],"label_agreement":null},{"id":"W4402561754","doi":"10.1016/j.annonc.2024.08.038","title":"29P Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Complete response; Oncology; Internal medicine; Chemotherapy","score_opus":0.8990191969399026,"score_gpt":0.7285280157833078,"score_spread":0.17049118115659478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85807943,0.00038017883,0.103988394,0.029531697,0.0021948488,0.003819737,0.0007304553,0.00012344372,0.0011517876],"genre_scores_gemma":[0.5538869,0.0005445519,0.44456995,0.00028326456,0.00026778004,0.00039147874,0.000003021636,0.000031583117,0.000021485228],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97999424,0.015743889,0.0032879824,0.00056497654,0.000102223414,0.00030668927],"domain_scores_gemma":[0.3869614,0.6120467,0.00034798455,0.00036624618,0.00014360166,0.00013401988],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0655444,0.00016665479,0.0016964343,0.00011290197,0.00003535178,0.000019628811,0.00010801066,0.00032869843,0.000060528608],"category_scores_gemma":[0.58829886,0.0001298125,0.00028113046,0.00016817755,0.00035845753,0.000033686898,0.00007628938,0.0001726204,0.000003146591],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047005587,0.001453616,0.0007134643,0.00013487926,0.00024539747,0.000010346208,0.000351839,0.000002143826,0.00037448975,0.16273113,0.0010441616,0.82823795],"study_design_scores_gemma":[0.0027371286,0.0059518185,0.009369371,0.00008747027,0.00017539633,0.0000066205657,0.000055367553,0.00027877517,0.0006025769,0.9604087,0.020191088,0.00013571176],"about_ca_topic_score_codex":0.000013665732,"about_ca_topic_score_gemma":0.000023493787,"teacher_disagreement_score":0.8281023,"about_ca_system_score_codex":0.00007462191,"about_ca_system_score_gemma":0.00042796016,"threshold_uncertainty_score":0.9622187},"labels":[],"label_agreement":null},{"id":"W4402561793","doi":"10.1016/j.annonc.2024.08.247","title":"306P Patient-reported symptoms in early breast cancer and future cardiovascular events: A province-wide administrative database study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Alberta Health Services; Alberta Health; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Database; Cancer; Internal medicine","score_opus":0.03387567202114927,"score_gpt":0.3415087065546949,"score_spread":0.3076330345335456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795,0.017010882,0.0000059992585,0.001961965,0.00026049235,0.00055887597,0.0004499586,0.000012943013,0.00023890304],"genre_scores_gemma":[0.9968551,0.0023214684,0.000027360325,0.00019580184,0.00023789138,0.00024433338,0.00006239167,0.000020344318,0.000035347075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857825,0.0001408321,0.00032346393,0.00054223114,0.00016393267,0.000251297],"domain_scores_gemma":[0.9993365,0.00003206686,0.00009460339,0.00033132354,0.0001358562,0.00006964025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019741355,0.00020716248,0.00039413382,0.00007866533,0.000039452658,0.000009729636,0.00009479757,0.00012234079,0.000009709764],"category_scores_gemma":[0.000024947318,0.00017567564,0.00012767053,0.000152448,0.00010973905,0.000014029819,0.0001568836,0.00011522685,0.0000011398844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015346372,0.0021271345,0.6529233,0.00018879089,0.009064307,0.0011048819,0.0032631946,0.000019546118,0.0014663172,0.00006517972,0.002720849,0.3255219],"study_design_scores_gemma":[0.0025695923,0.0043355213,0.9117508,0.00013570939,0.0004391504,0.00019241824,0.0022872929,0.00000471474,0.0032390177,0.000042272186,0.07463609,0.0003674419],"about_ca_topic_score_codex":0.0010229776,"about_ca_topic_score_gemma":0.0013675069,"teacher_disagreement_score":0.32515445,"about_ca_system_score_codex":0.000039029823,"about_ca_system_score_gemma":0.00042755037,"threshold_uncertainty_score":0.7163845},"labels":[],"label_agreement":null},{"id":"W4402561806","doi":"10.1016/j.annonc.2024.08.064","title":"55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"FUJIFILM Toyama Chemical; Foundation Medicine; Genentech; Sirtex Medical; Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University; Astellas Pharma; Eisai; Seagen; MacroGenics; Revolution Medicines; Chugai Pharmaceutical; NGM Biopharmaceuticals; EMD Serono; XBiotech; BeiGene; Halozyme; Mirati Therapeutics; Agios Pharmaceuticals; Vertex Pharmaceuticals; Moderna; Pfizer; HCA Healthcare; NuCana; Incyte; Handok; Ipsen; Array BioPharma; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Mylan; LG Chem; Myriad Genetics; TG Therapeutics; Amgen; Jounce Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Durvalumab; Biliary tract cancer; Cisplatin; Topaz; Internal medicine; Oncology; Cancer; Chemotherapy; Nivolumab","score_opus":0.09577148927491659,"score_gpt":0.41006077034112676,"score_spread":0.3142892810662102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748194,0.021001281,0.0000043249183,0.002750424,0.00029371984,0.0006398605,0.00014054762,0.000010606191,0.00033981397],"genre_scores_gemma":[0.99502057,0.004394784,0.000022713699,0.00025018957,0.00009523092,0.000063576415,0.000013544483,0.000016478389,0.00012292432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827135,0.00016196107,0.00066866627,0.00036526436,0.00031173325,0.00022101065],"domain_scores_gemma":[0.9988433,0.00032352557,0.00021841661,0.00037023678,0.00018693387,0.000057604135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040432066,0.00018388586,0.001148131,0.00029763445,0.000030986055,0.000005342371,0.00013810862,0.000100290985,0.00021041239],"category_scores_gemma":[0.00006038397,0.00012245815,0.00026989967,0.00088097743,0.00022389549,0.000060390506,0.000080803686,0.00021309093,5.443761e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005111095,0.0024610956,0.90263575,0.00016803679,0.0057448917,0.00013186951,0.023599736,0.000089453155,0.011285118,0.00003998696,0.0015517733,0.047181178],"study_design_scores_gemma":[0.017934693,0.0037971858,0.9667557,0.00015492136,0.0015483939,0.0000040441264,0.0036816935,0.0004595392,0.004365805,0.0000810144,0.0010821088,0.0001348842],"about_ca_topic_score_codex":0.010382014,"about_ca_topic_score_gemma":0.009861217,"teacher_disagreement_score":0.06411995,"about_ca_system_score_codex":0.000088068475,"about_ca_system_score_gemma":0.00038497357,"threshold_uncertainty_score":0.99620795},"labels":[],"label_agreement":null},{"id":"W4402561834","doi":"10.1016/j.annonc.2024.08.074","title":"66O Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Signature (topology); Association (psychology); Gene signature; Gene; Genetics; Gene expression","score_opus":0.0764100759833467,"score_gpt":0.40310973652532617,"score_spread":0.32669966054197946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712988,0.0067835385,0.000012355976,0.008130603,0.0003007422,0.00023831893,0.0002646366,0.000025679396,0.012945312],"genre_scores_gemma":[0.9840626,0.004983093,0.0008680908,0.0005539236,0.00052585115,0.000010282857,0.00015287376,0.000026450289,0.008816812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980105,0.00020919577,0.0005943511,0.00036356764,0.0004849495,0.0003374366],"domain_scores_gemma":[0.99721193,0.0017132772,0.00024036615,0.00022997851,0.00043746232,0.0001669719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009266328,0.00016451818,0.00070021773,0.00015328424,0.000042369764,0.000009695585,0.00016464193,0.00043054915,0.0005466763],"category_scores_gemma":[0.00009934356,0.000119515535,0.00026583727,0.00029122917,0.00015563569,0.000051017367,0.00007172258,0.0008148113,0.000052092455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008514189,0.0069410075,0.18681814,0.0018885892,0.003489234,0.002317118,0.0026078154,0.0001096751,0.6221564,0.0006542236,0.109421775,0.05508189],"study_design_scores_gemma":[0.0047186036,0.012617185,0.08799095,0.0003915429,0.0008706305,0.00003733958,0.00038199077,0.0003528828,0.61851287,0.0007365338,0.27300912,0.00038036017],"about_ca_topic_score_codex":0.00023368435,"about_ca_topic_score_gemma":0.000049697945,"teacher_disagreement_score":0.16358736,"about_ca_system_score_codex":0.000029790775,"about_ca_system_score_gemma":0.00041308053,"threshold_uncertainty_score":0.5985722},"labels":[],"label_agreement":null},{"id":"W4402561837","doi":"10.1016/j.annonc.2024.08.158","title":"150P Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Dutch Colorectal Cancer Group; PharmaMar; Government of the United Kingdom; European Society for Medical Oncology; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; National Institute for Health and Care Research; Seagen; Pfizer; NuCana; Incyte; BeiGene; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sarcoma UK; Sanofi; Exelixis; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; Gilead Sciences; Amgen; Celgene","keywords":"Medicine; Exploratory analysis; Computational biology; Oncology; Pharmacology; Internal medicine; Data science","score_opus":0.10346893173334729,"score_gpt":0.43476854580594054,"score_spread":0.33129961407259323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889099,0.009189512,0.00038135672,0.0004766939,0.0002314157,0.00030160663,0.00009675633,0.000008330507,0.0004044289],"genre_scores_gemma":[0.9980384,0.0007933354,0.00066922547,0.0001425035,0.00021841338,0.00001941552,0.000046994704,0.000019513538,0.000052194424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874204,0.00014235229,0.0005007939,0.00030251397,0.00012364904,0.00018862545],"domain_scores_gemma":[0.9992266,0.000058717753,0.00020453504,0.0002636888,0.00016630959,0.0000801024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028074905,0.00015264978,0.0003999297,0.00017258001,0.00002140051,0.000006598113,0.00013061902,0.000228755,0.00004717876],"category_scores_gemma":[0.00011592491,0.00013630698,0.00015714619,0.00018255197,0.00033837795,0.000005707987,0.00006899637,0.00005992315,0.0000017852893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054530613,0.0005237317,0.000048545724,0.00017143339,0.0002652822,0.000023414144,0.00004482098,0.000017881348,0.95038426,0.00003111761,0.0035758596,0.039460607],"study_design_scores_gemma":[0.008860772,0.011693529,0.00008388516,0.000053465006,0.00007766208,0.0000052669875,0.00007123147,0.000088052,0.93346256,0.000076141914,0.045399893,0.00012753869],"about_ca_topic_score_codex":0.000047478985,"about_ca_topic_score_gemma":0.000020167738,"teacher_disagreement_score":0.041824035,"about_ca_system_score_codex":0.0000049376235,"about_ca_system_score_gemma":0.00033345373,"threshold_uncertainty_score":0.5558437},"labels":[],"label_agreement":null},{"id":"W4402561845","doi":"10.1016/j.annonc.2024.08.072","title":"64O Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay for MRD in head and neck cancers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Head and neck; Genome; DNA methylation; Head and neck cancer; Computational biology; Genetics; Internal medicine; Gene; Cancer; Surgery; Biology; Gene expression","score_opus":0.08165127544807266,"score_gpt":0.47331035586020564,"score_spread":0.391659080412133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699162,0.0040341527,0.0033776562,0.020956984,0.00039926392,0.00042915993,0.000007705012,0.000013706581,0.0008651267],"genre_scores_gemma":[0.9923776,0.0018152371,0.004054049,0.0013464437,0.00016524563,0.00003081083,0.000025819916,0.000014127614,0.00017068078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987434,0.00014542986,0.0005805476,0.00022317845,0.000121974794,0.00018547002],"domain_scores_gemma":[0.9974575,0.0021212946,0.00011985565,0.000109704655,0.00008705649,0.000104561186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002118149,0.000083638835,0.00051376363,0.00017459529,0.000013405264,0.000005955878,0.000057357844,0.000116389994,0.00003383098],"category_scores_gemma":[0.0026119596,0.00007180613,0.000074859214,0.00014774672,0.00014273565,0.000040881605,0.000032003973,0.00025147686,0.000002148591],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008374738,0.0006607232,0.111676395,0.001860525,0.0005079268,0.00021875977,0.0018911465,0.0011252512,0.013703116,0.0018594771,0.010969853,0.85468936],"study_design_scores_gemma":[0.006272169,0.014593426,0.21964897,0.0010473831,0.00041802163,0.00007375665,0.00024300955,0.021136906,0.0075762775,0.0054371683,0.7232534,0.0002994725],"about_ca_topic_score_codex":0.00024832622,"about_ca_topic_score_gemma":0.000018548339,"teacher_disagreement_score":0.8543899,"about_ca_system_score_codex":0.000057358386,"about_ca_system_score_gemma":0.00032679518,"threshold_uncertainty_score":0.31269485},"labels":[],"label_agreement":null},{"id":"W4402561908","doi":"10.1016/j.annonc.2024.08.075","title":"67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Legend Biotech; Genentech; Esperion Therapeutics; EMD Serono; Centre Hospitalier Universitaire Vaudois; Seagen; Incyte; Institut des maladies génétiques Imagine; BioCryst; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Novavax; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; National Science Foundation; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Amgen; Université de Lausanne; Pfizer","keywords":"Medicine; Polygenic risk score; Endocrine system; Toxicity; Oncology; Internal medicine; Bioinformatics; Genetics; Gene; Hormone; Single-nucleotide polymorphism; Genotype; Biology","score_opus":0.027698486610285646,"score_gpt":0.35493135236735607,"score_spread":0.32723286575707045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95222193,0.0029222032,0.00018779315,0.03367061,0.0004138262,0.00021947057,0.000017869892,0.0001263575,0.010219929],"genre_scores_gemma":[0.9961605,0.0010077645,0.0007711156,0.0006255797,0.00020145129,0.000010885143,0.000049389193,0.000030880776,0.0011424305],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985298,0.00012683311,0.00054073974,0.00025440723,0.00023677359,0.0003114697],"domain_scores_gemma":[0.99898934,0.00028225873,0.00022683278,0.00020977251,0.0001431422,0.00014862148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008405527,0.00013978919,0.0004787193,0.00020059706,0.000075190736,0.000013192411,0.00008921092,0.00012713646,0.00019042604],"category_scores_gemma":[0.000961453,0.000105174484,0.0001958831,0.00040414056,0.00019761242,0.00006702586,0.000052578962,0.0008621049,0.000035823512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000925183,0.0024023245,0.20574579,0.0007624582,0.0049729366,0.0027952706,0.00512492,0.0006079329,0.11472724,0.008142854,0.041201167,0.6125919],"study_design_scores_gemma":[0.009872978,0.016966503,0.5568948,0.0023832712,0.0019807452,0.002424767,0.00072904775,0.025228238,0.090620965,0.00712999,0.2847213,0.0010474519],"about_ca_topic_score_codex":0.00039452178,"about_ca_topic_score_gemma":0.000021606376,"teacher_disagreement_score":0.6115445,"about_ca_system_score_codex":0.000084025545,"about_ca_system_score_gemma":0.0003678989,"threshold_uncertainty_score":0.4288891},"labels":[],"label_agreement":null},{"id":"W4402561928","doi":"10.1016/j.annonc.2024.08.012","title":"2P Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; University of Calgary; Sanofi (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"T-cell receptor; Medicine; Phenotype; Adenocarcinoma; Repertoire; Immune system; Cancer research; Immunology; T cell; Genetics; Biology; Cancer; Gene; Internal medicine","score_opus":0.020375704908916922,"score_gpt":0.3052211643625127,"score_spread":0.28484545945359574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97099406,0.027190046,0.00012771443,0.00049319083,0.00006459677,0.00014605075,0.00005062462,0.0000059638633,0.0009277513],"genre_scores_gemma":[0.997789,0.0012828447,0.00038104985,0.00021912904,0.00003834695,0.000015496322,0.00014912477,0.0000123751715,0.00011260648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990807,0.00008900269,0.0003070616,0.00030978673,0.000052867686,0.000160551],"domain_scores_gemma":[0.9994611,0.00013809178,0.0001233954,0.000116395044,0.000119720666,0.000041308882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003227144,0.00011736533,0.00030685903,0.00015435174,0.000030468394,0.000023041333,0.00005818972,0.00013802508,0.0000051167785],"category_scores_gemma":[0.00029695543,0.00011049502,0.00007134112,0.0002515571,0.000092182294,0.000006087018,0.00007692342,0.00009662208,3.9866472e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002681939,0.00029561098,0.065133035,0.00019675755,0.00086433545,0.00011972067,0.0015903574,0.00025923483,0.91153157,0.0006967577,0.00095146685,0.01809298],"study_design_scores_gemma":[0.0019358776,0.005576345,0.12678148,0.0002568218,0.0009597505,0.00005295487,0.0022913557,0.009274233,0.8457513,0.0032466005,0.0031280308,0.0007452552],"about_ca_topic_score_codex":0.00019114929,"about_ca_topic_score_gemma":0.00043031288,"teacher_disagreement_score":0.06578026,"about_ca_system_score_codex":0.000033674598,"about_ca_system_score_gemma":0.00011727582,"threshold_uncertainty_score":0.4505856},"labels":[],"label_agreement":null},{"id":"W4402565431","doi":"10.1016/j.annonc.2024.08.2226","title":"222P Artificial intelligence (AI) based prognostication from baseline computed tomography (CT) scans in a phase III advanced non-small cell lung cancer (aNSCLC) trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Glycemic Index Laboratories; Systems, Applications & Products in Data Processing (Canada); Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Lung cancer; Baseline (sea); Computed tomography; Nuclear medicine; Radiology; Oncology","score_opus":0.04412376791264384,"score_gpt":0.4101424405171835,"score_spread":0.3660186726045397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7938952,0.0024848056,0.18359774,0.01706214,0.0010906952,0.001288756,0.00006992649,0.00008583274,0.00042492736],"genre_scores_gemma":[0.9902924,0.00036794526,0.005517586,0.0027981224,0.00057871605,0.00015401552,0.0002367568,0.000031640113,0.00002284944],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979417,0.00018343037,0.0008152537,0.0004789548,0.00022624168,0.00035447234],"domain_scores_gemma":[0.998341,0.00085978035,0.00017570265,0.00023420829,0.00020036114,0.00018893022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009006816,0.00019819174,0.0006229737,0.00044645648,0.00004045352,0.00002256683,0.00016797935,0.000116690375,0.00020930357],"category_scores_gemma":[0.00034722878,0.0001818469,0.00016373103,0.0007517528,0.00016902192,0.00007139667,0.000027421393,0.0006395852,0.000005098046],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016158158,0.0031086719,0.002487717,0.00045403096,0.00017078836,0.00047342858,0.00102084,0.005509611,0.019641945,0.00025549863,0.003023077,0.9476962],"study_design_scores_gemma":[0.015470145,0.0023845895,0.00048670065,0.0008903779,0.00022102761,0.0000058018277,0.00009058128,0.9482183,0.021861782,0.0004435969,0.009721468,0.00020565111],"about_ca_topic_score_codex":0.0009960502,"about_ca_topic_score_gemma":0.00021423024,"teacher_disagreement_score":0.9474906,"about_ca_system_score_codex":0.00005919504,"about_ca_system_score_gemma":0.0008402617,"threshold_uncertainty_score":0.74155015},"labels":[],"label_agreement":null},{"id":"W4402565436","doi":"10.1016/j.annonc.2024.08.2272","title":"LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Stand Up To Cancer; PharmaMar; Vifor Pharma; Eisai; Cancer Australia; European Commission; Canadian Cancer Society; Seagen; Aldeyra Therapeutics; MacroGenics; Veracyte; Austrian Science Fund; Amgen; Deciphera Pharmaceuticals; Clovis Oncology; Les Laboratories Pierre Fabre; National Health and Medical Research Council; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Mersana Therapeutics; Stryker; Pfizer; Incyte; EQRx; F. Hoffmann-La Roche; Verastem Oncology; Array BioPharma; Hexal AG; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Internal medicine; Randomized controlled trial; Maintenance therapy; Cancer; Chemotherapy","score_opus":0.04611177208356617,"score_gpt":0.40641699276092813,"score_spread":0.360305220677362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774116,0.00014376848,0.00073548954,0.015613496,0.0002835404,0.0054914956,0.00008823801,0.000038917326,0.00019345227],"genre_scores_gemma":[0.9923073,0.000064010615,0.00088095356,0.0058646174,0.00008175838,0.00058590533,0.000021555807,0.00005798012,0.00013589425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966433,0.0008429926,0.0008874798,0.0005800793,0.0006804462,0.00036568326],"domain_scores_gemma":[0.9958543,0.0027217371,0.00028340405,0.00037707426,0.0006090278,0.00015445657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030710122,0.0003371741,0.0013986798,0.00045801103,0.00006535227,0.000024917488,0.00018439561,0.0001051665,0.00015080921],"category_scores_gemma":[0.00053733226,0.00019082353,0.00014194688,0.0007740812,0.00026653666,0.000106082625,0.000033418626,0.00032344126,0.000002403328],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9480841,0.0027557882,0.0042027733,0.000022406562,0.0017508526,0.00016346341,0.018437868,0.0005054529,0.0068403194,0.000030343064,0.00058467087,0.016621934],"study_design_scores_gemma":[0.90013367,0.03085492,0.04933237,0.0016573442,0.0002267101,0.000016217627,0.0011951964,0.0011955138,0.012945382,0.000034612483,0.0020632467,0.00034480979],"about_ca_topic_score_codex":0.000387328,"about_ca_topic_score_gemma":0.0003269814,"teacher_disagreement_score":0.047950447,"about_ca_system_score_codex":0.0002077445,"about_ca_system_score_gemma":0.00096791936,"threshold_uncertainty_score":0.77815574},"labels":[],"label_agreement":null},{"id":"W4402565458","doi":"10.1016/j.annonc.2024.08.2267","title":"LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; PharmaMar; Eisai; Natera; Chugai Pharmaceutical; Seagen; Incyte; BeiGene; Clovis Oncology; Novocure; Daiichi Sankyo Europe; Sanofi; Exelixis; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Placebo; Pembrolizumab; Radiation therapy; Chemotherapy; Adjuvant; Oncology; Internal medicine; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.04039741290159089,"score_gpt":0.38199739676752886,"score_spread":0.341599983865938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993559,0.0009802664,0.00013883554,0.00066915166,0.00019910022,0.004208927,0.00009083841,0.000042476444,0.00011142225],"genre_scores_gemma":[0.9962163,0.0018915107,0.0004032912,0.00039187496,0.00015308091,0.00068328064,0.000045146047,0.000077457385,0.00013805764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969968,0.00033065316,0.0008321529,0.0006292881,0.0007346086,0.00047647915],"domain_scores_gemma":[0.9976215,0.0010462966,0.0004735183,0.0003502608,0.00033149062,0.00017696328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045227355,0.0004200054,0.00180462,0.001106293,0.00003957207,0.000016682394,0.00017608602,0.0001919437,0.00048063236],"category_scores_gemma":[0.00015593477,0.00022600645,0.00007633921,0.0024616937,0.00018465046,0.00018399357,0.000025244999,0.0004135374,0.0000014917249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49342358,0.018423222,0.2738588,0.00016793779,0.0013483756,0.00047551552,0.0039382153,0.00017946625,0.00005535936,0.000014525081,0.0001289964,0.20798603],"study_design_scores_gemma":[0.6093598,0.23743093,0.14836246,0.0007266001,0.00044606955,0.00001698638,0.0008370475,0.00015587643,0.0011041667,0.00002065347,0.0012132496,0.00032616063],"about_ca_topic_score_codex":0.010119671,"about_ca_topic_score_gemma":0.012950392,"teacher_disagreement_score":0.21900772,"about_ca_system_score_codex":0.00041538946,"about_ca_system_score_gemma":0.001063479,"threshold_uncertainty_score":0.996472},"labels":[],"label_agreement":null},{"id":"W4402565510","doi":"10.1016/j.annonc.2024.08.2291","title":"LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Novartis Pharma; University of Texas MD Anderson Cancer Center; EMD Serono; Bristol-Myers Squibb; Samsung; Genentech; European Society for Medical Oncology; Seagen; Pfizer; Moderna; Mirati Therapeutics; Les Laboratories Pierre Fabre; Eli Lilly and Company; Ono Pharmaceutical; Jazz Pharmaceuticals; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Regeneron Pharmaceuticals; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Spectrum Pharmaceuticals; Amgen; Takeda Pharmaceutical Company","keywords":"Medicine; Nivolumab; Internal medicine; Perioperative; Placebo; Oncology; Phases of clinical research; Clinical trial; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.0800987718462758,"score_gpt":0.44196014387362176,"score_spread":0.361861372027346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877048,0.0014524775,0.000008629839,0.0058872174,0.00046027807,0.0013241037,0.000072331204,0.00003446521,0.003055661],"genre_scores_gemma":[0.9957154,0.0006929882,0.000059939113,0.0024608648,0.00018084722,0.00008683126,0.00006221846,0.000028737051,0.0007121701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976882,0.00047282944,0.0007616962,0.00045409775,0.00028835333,0.0003348286],"domain_scores_gemma":[0.99867344,0.00048073335,0.00015945859,0.0004033755,0.00020071883,0.00008226388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012305103,0.00020296838,0.0006928745,0.00010511197,0.00008018165,0.000029123326,0.00021033143,0.00016743103,0.0006589789],"category_scores_gemma":[0.000120692755,0.00012207571,0.00013787801,0.00039419753,0.00033702044,0.00012914439,0.000077983386,0.000491187,0.000037406116],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30123362,0.016358607,0.15179226,0.00008641701,0.003888652,0.0007302275,0.020527756,0.00000854518,0.0016672417,0.00009456264,0.061976038,0.4416361],"study_design_scores_gemma":[0.18768452,0.09993023,0.2800829,0.0010355831,0.00052825303,0.000028357981,0.010435665,0.0005747787,0.0027509192,0.000077231896,0.416262,0.00060955225],"about_ca_topic_score_codex":0.0018145465,"about_ca_topic_score_gemma":0.0020997496,"teacher_disagreement_score":0.4410265,"about_ca_system_score_codex":0.0000967955,"about_ca_system_score_gemma":0.0006301419,"threshold_uncertainty_score":0.7215357},"labels":[],"label_agreement":null},{"id":"W4402565535","doi":"10.1016/j.annonc.2024.08.2222","title":"218P Exploiting a unique glycosaminoglycan for novel pan-cancer therapies and diagnostics","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China; Canadian Institutes of Health Research; Carlsbergfondet; Fundamental Research Funds for the Central Universities; Department of Education of Guizhou Province; Natural Science Foundation of Guizhou Province; National Institutes of Health; Lundbeckfonden; Novo Nordisk Fonden; National Natural Science Foundation of China; Innovationsfonden","keywords":"Medicine; Glycosaminoglycan; Cancer; Cancer research; Computational biology; Internal medicine; Anatomy","score_opus":0.11283124149790069,"score_gpt":0.442069798899404,"score_spread":0.3292385574015033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602232,0.032884743,0.0015671648,0.0038751292,0.00014931572,0.00035115666,0.000336637,0.000012822423,0.00059982034],"genre_scores_gemma":[0.97262996,0.025401616,0.0007185636,0.0004585856,0.00021307239,0.0002592791,0.000061846804,0.000018289515,0.00023879076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935174,0.000022692659,0.00012935336,0.00022133085,0.000055498662,0.00021936945],"domain_scores_gemma":[0.99956554,0.00013618333,0.00003671779,0.0001049751,0.000098735414,0.000057817397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012949301,0.00009351787,0.00014532484,0.000044126195,0.000038549115,0.000016240276,0.000072219795,0.00009907938,0.000010346619],"category_scores_gemma":[0.000109486864,0.00008049902,0.00006442005,0.00005045492,0.00011004264,0.00000433719,0.000060961047,0.000051103463,8.426644e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005692544,0.0003190866,0.0027840023,0.000253938,0.00083274016,0.000023366374,0.00046490633,0.0000054053844,0.33826026,0.0027089848,0.01779425,0.63598377],"study_design_scores_gemma":[0.0011049266,0.0039890353,0.0017747129,0.000085950975,0.000036291698,0.000020684009,0.00018728124,0.00007641892,0.27974164,0.0013374882,0.71148604,0.0001595295],"about_ca_topic_score_codex":0.00021427847,"about_ca_topic_score_gemma":0.0004378159,"teacher_disagreement_score":0.6936918,"about_ca_system_score_codex":0.0000114532895,"about_ca_system_score_gemma":0.00020753765,"threshold_uncertainty_score":0.32826546},"labels":[],"label_agreement":null},{"id":"W4402565567","doi":"10.1016/j.annonc.2024.08.2317","title":"LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Merck Sharp and Dohme; EMD Serono; Genentech; Ipsen; European Association of Urology; European Society for Medical Oncology; Eisai; Astellas Pharma; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; Jounce Therapeutics; Aptitude Health; Arrowhead Pharmaceuticals; Seagen; Society for Immunotherapy of Cancer; EUSA Pharma; Invitae; AstraZeneca; Associazione Italiana di Oncologia Medica; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Dana-Farber Cancer Institute","keywords":"Medicine; Everolimus; Renal cell carcinoma; Clear cell renal cell carcinoma; Oncology; Internal medicine; Urology","score_opus":0.11800073331204684,"score_gpt":0.3930948423803325,"score_spread":0.27509410906828563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379873,0.0020849386,0.0000029926177,0.00024767494,0.000080416416,0.0012296394,0.000042391002,0.000019565437,0.0024936555],"genre_scores_gemma":[0.99919814,0.00013518034,0.00007365365,0.000052314805,0.000027553617,0.00007816655,0.000031116288,0.000033467433,0.00037042977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694604,0.00043061236,0.0010286439,0.0005491322,0.00049572095,0.0005498764],"domain_scores_gemma":[0.99783176,0.00046663813,0.0004983743,0.000758281,0.00025961315,0.00018534035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005191715,0.00031732646,0.0014625007,0.0006422046,0.000038939994,0.0000061524297,0.00025182203,0.00014846101,0.0001234414],"category_scores_gemma":[0.000060573762,0.00020868564,0.00036505182,0.001928893,0.00022690858,0.00007521265,0.00010478844,0.00030091975,0.000004247702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2092859,0.06570828,0.47862652,0.0016218532,0.012973548,0.005179704,0.03907305,0.012534221,0.117444,0.000045714416,0.0011863651,0.056320846],"study_design_scores_gemma":[0.06714716,0.15539174,0.44672915,0.00036966248,0.016307523,0.000026767057,0.0036433898,0.0031905072,0.305807,0.000010903694,0.0009533528,0.00042284452],"about_ca_topic_score_codex":0.0010942513,"about_ca_topic_score_gemma":0.0018531686,"teacher_disagreement_score":0.18836299,"about_ca_system_score_codex":0.00016503698,"about_ca_system_score_gemma":0.00049644394,"threshold_uncertainty_score":0.85099536},"labels":[],"label_agreement":null},{"id":"W4402565585","doi":"10.1016/j.annonc.2024.08.2311","title":"LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Bayer HealthCare; Exelixis; American Society of Clinical Oncology; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.06839710869532524,"score_gpt":0.4041756379512355,"score_spread":0.3357785292559103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871797,0.007089583,0.000015372198,0.0030699288,0.00007880618,0.0021740338,0.00029752436,0.000011519267,0.000083548824],"genre_scores_gemma":[0.9912651,0.008074631,0.000058278805,0.00022382171,0.00005279501,0.000085336695,0.00017007043,0.000017708204,0.000052230498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870104,0.00017379907,0.00038044743,0.00025919545,0.00026180703,0.00022373878],"domain_scores_gemma":[0.998911,0.000516946,0.00014062686,0.0001650051,0.00020370758,0.00006271809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036831,0.00014117821,0.0005290619,0.00011612749,0.00003448907,0.00000872558,0.00005678622,0.00006048651,0.000020034386],"category_scores_gemma":[0.000058078207,0.00007849576,0.000052534626,0.0002843318,0.00028257968,0.00008796109,0.000029961539,0.00018038656,0.0000011555745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.669998,0.0013577482,0.0037194532,0.000059303682,0.0013691499,0.0001445873,0.009248777,0.00004147101,0.002941135,0.00004349378,0.00044177374,0.3106351],"study_design_scores_gemma":[0.70544523,0.04163317,0.21784227,0.00067648286,0.000472837,0.000007848014,0.0007372472,0.00088206906,0.023722159,0.0005081134,0.0077934097,0.00027919674],"about_ca_topic_score_codex":0.0007426474,"about_ca_topic_score_gemma":0.000095113195,"teacher_disagreement_score":0.3103559,"about_ca_system_score_codex":0.000089313,"about_ca_system_score_gemma":0.0006213148,"threshold_uncertainty_score":0.32009643},"labels":[],"label_agreement":null},{"id":"W4402565608","doi":"10.1016/j.annonc.2024.08.2310","title":"LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Movember Foundation","keywords":"Medicine; Atezolizumab; Cabozantinib; Prostate cancer; Oncology; Hormonal therapy; Internal medicine; Randomized controlled trial; Cancer; Immunotherapy; Nivolumab","score_opus":0.15150180573280111,"score_gpt":0.43960817400768887,"score_spread":0.2881063682748878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893174,0.0021128438,0.000004004803,0.0022441028,0.00039545272,0.0039763493,0.00063027354,0.000015382842,0.0013041546],"genre_scores_gemma":[0.9971044,0.0014786004,0.000044474767,0.00008266514,0.00004746152,0.000345665,0.000117559735,0.000028740216,0.0007504073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704224,0.00039394587,0.00092447083,0.0004437536,0.0007408943,0.000454697],"domain_scores_gemma":[0.99784905,0.00081623456,0.0003644842,0.00031346778,0.0005442656,0.00011248652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011135121,0.00028526236,0.0012254878,0.00022105315,0.00007144936,0.000023639092,0.00017454427,0.00008422741,0.00008525389],"category_scores_gemma":[0.00015076365,0.00015781086,0.0001974977,0.00042722482,0.0003551236,0.0001377326,0.000056105073,0.00035460934,0.0000017259299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97076356,0.0053036893,0.0019520724,0.00014348685,0.0021889654,0.00027930402,0.005165958,0.00011484631,0.0017817013,0.00018713126,0.0008102077,0.011309058],"study_design_scores_gemma":[0.9363436,0.02905769,0.026613161,0.0003576036,0.00038839455,0.0000068383756,0.0009568481,0.00045068367,0.002843547,0.000038967653,0.0027391058,0.00020356681],"about_ca_topic_score_codex":0.0048263976,"about_ca_topic_score_gemma":0.003298173,"teacher_disagreement_score":0.034419987,"about_ca_system_score_codex":0.0002255475,"about_ca_system_score_gemma":0.0023939135,"threshold_uncertainty_score":0.7296102},"labels":[],"label_agreement":null},{"id":"W4402565617","doi":"10.1016/j.annonc.2024.08.2297","title":"LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Chugai Pharmaceutical; Amgen; Pfizer; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Mesothelioma Applied Research Foundation","keywords":"Osimertinib; Medicine; Mutant; Acquired resistance; Lung cancer; Oncology; Cancer research; Internal medicine; Cancer; Epidermal growth factor receptor; Genetics; Biology; Gene","score_opus":0.028635943468299348,"score_gpt":0.3866559773268554,"score_spread":0.3580200338585561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936391,0.00078202033,0.0005902972,0.001966842,0.0002590364,0.0019303946,0.0004832345,0.000028249995,0.00032083257],"genre_scores_gemma":[0.9979967,0.00011729375,0.00076710375,0.00039036723,0.000043091924,0.0002752094,0.00018721687,0.00003267388,0.00019034525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980338,0.00010683682,0.00066694885,0.0005279638,0.0003322865,0.00033211746],"domain_scores_gemma":[0.99838793,0.00030147965,0.0002805158,0.0005243673,0.00032816164,0.0001775324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021169557,0.00024439083,0.0008559793,0.00026531308,0.000072605704,0.000014734553,0.00021903738,0.00009318193,0.000110112276],"category_scores_gemma":[0.000044208246,0.00016527898,0.0001334077,0.0011129393,0.000054546857,0.000115310286,0.00006231427,0.000107243024,0.0000021710282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2523636,0.03844775,0.44013077,0.00071591133,0.033799566,0.0012034577,0.10415795,0.013247845,0.0129549,0.00030367097,0.0018097119,0.10086487],"study_design_scores_gemma":[0.17023127,0.08848688,0.66800785,0.0012495983,0.022519896,8.2969217e-7,0.00856956,0.004142228,0.03228617,0.00016986203,0.0033790467,0.0009568182],"about_ca_topic_score_codex":0.004046182,"about_ca_topic_score_gemma":0.02121077,"teacher_disagreement_score":0.22787708,"about_ca_system_score_codex":0.00025787274,"about_ca_system_score_gemma":0.0006358757,"threshold_uncertainty_score":0.99664956},"labels":[],"label_agreement":null},{"id":"W4402565641","doi":"10.1016/j.annonc.2024.08.2230","title":"226TiP CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Disease; Oncology; Internal medicine; Melanoma; Interception; Cancer research","score_opus":0.018549659980161223,"score_gpt":0.308266031979694,"score_spread":0.28971637199953276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961003,0.00010546539,0.00011424612,0.0020598916,0.00025705254,0.000805868,0.000013282475,0.000044016746,0.00049986615],"genre_scores_gemma":[0.9985028,0.00009104281,0.0003292215,0.0007369646,0.00009123524,0.000030350504,0.000013314046,0.000021259228,0.00018383024],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99897534,0.00011825249,0.00025888873,0.00028540348,0.00018230679,0.00017979663],"domain_scores_gemma":[0.9994906,0.000050461844,0.000056213947,0.00017074324,0.000063908185,0.00016806409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000231213,0.00011315699,0.0002710785,0.0003022965,0.000021227543,0.0000146424645,0.000045832705,0.00007703076,0.00009812744],"category_scores_gemma":[0.00012348665,0.00009353436,0.000046948033,0.00018800104,0.00005233914,0.000039263323,0.00006431543,0.00016517873,0.000040397026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36816195,0.0006903302,0.010517912,0.00028831468,0.00036952482,0.001426164,0.0008439164,0.00010523264,0.00076006283,0.0003854264,0.0070118955,0.60943925],"study_design_scores_gemma":[0.06031309,0.14879139,0.6823118,0.0005577822,0.00061049283,0.000044706714,0.00038809894,0.00027685895,0.0018263077,0.0010718054,0.103276834,0.0005308615],"about_ca_topic_score_codex":0.00016021669,"about_ca_topic_score_gemma":0.00014282177,"teacher_disagreement_score":0.6717939,"about_ca_system_score_codex":0.000053370943,"about_ca_system_score_gemma":0.000061368206,"threshold_uncertainty_score":0.38142207},"labels":[],"label_agreement":null},{"id":"W4402565645","doi":"10.1016/j.annonc.2024.08.2285","title":"LBA44 Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Ipilimumab; Oncology; Melanoma; Internal medicine; Phases of clinical research; Immunotherapy; Cancer research; Chemotherapy; Cancer","score_opus":0.047359941220065,"score_gpt":0.39199009921779376,"score_spread":0.3446301579977288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98451656,0.0029410687,0.0000035620956,0.003410596,0.00075558637,0.00081253354,0.00002757127,0.000027741507,0.007504755],"genre_scores_gemma":[0.99618375,0.000376941,0.00002731121,0.00048572037,0.000080109545,0.000048123027,0.000008426279,0.000023146013,0.0027664953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837136,0.00016489695,0.00063377497,0.00029502352,0.00025712364,0.00027784347],"domain_scores_gemma":[0.9990204,0.00019945072,0.00016658056,0.00042919343,0.00013374309,0.00005064615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005845426,0.00016544989,0.0006439754,0.0002013663,0.000033521563,0.0000055416203,0.00021839143,0.00014358725,0.00059048785],"category_scores_gemma":[0.00009782741,0.00011490479,0.00027589628,0.0005329609,0.00019241024,0.000069992675,0.000074650445,0.00022487949,0.000015057528],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2888442,0.011419751,0.010312871,0.00071521435,0.0023510803,0.00054516684,0.01294975,0.00001920403,0.11012305,0.0005174463,0.06373679,0.49846548],"study_design_scores_gemma":[0.25842094,0.08479277,0.088899866,0.0011537861,0.0006617111,0.00017521212,0.007562038,0.000225002,0.09053717,0.0006907311,0.4662353,0.00064547325],"about_ca_topic_score_codex":0.0003091084,"about_ca_topic_score_gemma":0.00047795865,"teacher_disagreement_score":0.49782002,"about_ca_system_score_codex":0.00009232125,"about_ca_system_score_gemma":0.0005165167,"threshold_uncertainty_score":0.6465428},"labels":[],"label_agreement":null},{"id":"W4402565651","doi":"10.1016/j.annonc.2024.08.2321","title":"LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Physical therapy","score_opus":0.03331599505332596,"score_gpt":0.3259019813757941,"score_spread":0.2925859863224682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948785,0.00019786293,0.000016628237,0.0010990946,0.0003304535,0.0012512666,0.00023617619,0.000019740695,0.0019702844],"genre_scores_gemma":[0.99886924,0.00011075011,0.00009436661,0.0002302526,0.00015673759,0.000021413944,0.00036554274,0.000020292866,0.00013142473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99844915,0.00015127832,0.00059428945,0.0002935171,0.00025968006,0.0002520707],"domain_scores_gemma":[0.99909467,0.00025532706,0.00020607772,0.00021851511,0.00012801217,0.00009742314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029569294,0.0001778512,0.0006235733,0.00009687826,0.000042750857,0.000008888915,0.00008738948,0.00011790606,0.0002739469],"category_scores_gemma":[0.00006757389,0.00011029083,0.00011221909,0.00022303376,0.00016686876,0.00008185597,0.000059224036,0.00019132238,0.000010491573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64464664,0.02076316,0.024994332,0.00045967105,0.0018977022,0.00028553954,0.0039455746,0.000009825489,0.003006183,0.0009868409,0.004093431,0.2949111],"study_design_scores_gemma":[0.7236528,0.069973856,0.17315802,0.0007205686,0.00096606463,0.000009956775,0.0005996209,0.0001652239,0.007588571,0.00030344364,0.02247308,0.00038879254],"about_ca_topic_score_codex":0.0015163843,"about_ca_topic_score_gemma":0.000181962,"teacher_disagreement_score":0.2945223,"about_ca_system_score_codex":0.00004399012,"about_ca_system_score_gemma":0.00017575039,"threshold_uncertainty_score":0.44975296},"labels":[],"label_agreement":null},{"id":"W4402565676","doi":"10.1016/j.annonc.2024.08.2289","title":"LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Ottawa Hospital; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Medicine; Placebo; Internal medicine; Oncology; Lung cancer; Adjuvant; Double blind; non-small cell lung cancer (NSCLC); Cancer; Pathology; Immunotherapy; A549 cell","score_opus":0.0812384853944997,"score_gpt":0.4632508735200075,"score_spread":0.3820123881255078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578059,0.009965737,0.00007926732,0.0020132207,0.0005020166,0.008271647,0.0001318669,0.000043187876,0.02118721],"genre_scores_gemma":[0.9958414,0.00086743274,0.000119724784,0.00026028385,0.00012248415,0.0016052081,0.00006867413,0.000028704257,0.0010861123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99720526,0.0003319033,0.0012364606,0.00047920636,0.00032103338,0.00042613343],"domain_scores_gemma":[0.9979615,0.0006779556,0.00039701612,0.00034519687,0.00045855812,0.00015972625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009576083,0.00029274178,0.0023766048,0.0003728532,0.000055967623,0.000016991036,0.00016595745,0.0001801772,0.00022584164],"category_scores_gemma":[0.00009335075,0.00021878618,0.00034528086,0.0006453344,0.00016190135,0.00008124642,0.00006746032,0.0002592088,0.000007493104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96171415,0.009866374,0.0009678161,0.00046260792,0.003936528,0.00057349465,0.006897008,0.00027623048,0.0013696837,0.00013356256,0.0061572692,0.007645289],"study_design_scores_gemma":[0.98224527,0.0064717657,0.00049534,0.00045717158,0.0027763085,0.000020484094,0.0013430155,0.0036666351,0.00067078444,0.000054862023,0.0016229649,0.00017538601],"about_ca_topic_score_codex":0.010028277,"about_ca_topic_score_gemma":0.004781913,"teacher_disagreement_score":0.03803553,"about_ca_system_score_codex":0.0003267081,"about_ca_system_score_gemma":0.0021185493,"threshold_uncertainty_score":0.99656403},"labels":[],"label_agreement":null},{"id":"W4402565677","doi":"10.1016/j.annonc.2024.08.2296","title":"LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; Chemotherapy; Oncology; Interim; Lung cancer; Internal medicine; Chemotherapy regimen; Cancer research; Cancer; Adenocarcinoma; ROS1","score_opus":0.022275084750157815,"score_gpt":0.4032019958116301,"score_spread":0.38092691106147225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776355,0.007067244,0.00004158212,0.009319155,0.00078532426,0.0011508747,0.00026393146,0.000068508234,0.003667868],"genre_scores_gemma":[0.98825616,0.0026447726,0.00041065997,0.006019105,0.00022859382,0.00046538992,0.00018345953,0.0000811404,0.0017106979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982282,0.000075448406,0.00048770447,0.0005806892,0.00021330734,0.00041467178],"domain_scores_gemma":[0.99904317,0.00014460881,0.00015652458,0.00032229835,0.00010952446,0.0002238655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000119064964,0.00032106953,0.0006545366,0.00020212673,0.000032433596,0.000024356828,0.0001262493,0.00018008387,0.0015658487],"category_scores_gemma":[0.00001188027,0.00025625777,0.00019387815,0.00019732764,0.00008574884,0.00012315331,0.000038670973,0.0002954404,0.000021184174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09851261,0.008180784,0.14236675,0.0027713657,0.0033096245,0.0039508766,0.01907595,0.00043644715,0.04859354,0.00010989686,0.021340642,0.6513515],"study_design_scores_gemma":[0.043941546,0.010140504,0.67062545,0.0055039576,0.0008316693,0.000013576975,0.0005058696,0.005646319,0.089655906,0.0006394715,0.17138584,0.001109908],"about_ca_topic_score_codex":0.00041340635,"about_ca_topic_score_gemma":0.00032077354,"teacher_disagreement_score":0.6502416,"about_ca_system_score_codex":0.0004278431,"about_ca_system_score_gemma":0.0009514288,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4402565679","doi":"10.1016/j.annonc.2024.08.2307","title":"LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Radium-223; Asymptomatic; Open label; Prostate cancer; Internal medicine; Oncology; Phases of clinical research; Urology; Randomized controlled trial; Clinical trial; Bone metastasis; Cancer; Androgen receptor","score_opus":0.09570365100150162,"score_gpt":0.42806967115118466,"score_spread":0.33236602014968303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741335,0.0023855066,0.000015723806,0.0016049565,0.00013681277,0.007901132,0.00027247527,0.000022155606,0.00024787386],"genre_scores_gemma":[0.9965269,0.0012555416,0.0007404825,0.000083111736,0.000020038884,0.0007894849,0.00022240586,0.000036868838,0.00032519334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961259,0.00056044076,0.0018547924,0.00046029093,0.0005650664,0.00043352236],"domain_scores_gemma":[0.99638337,0.0018200452,0.00083129515,0.00029177513,0.0005075539,0.00016595343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002030418,0.0003134285,0.0021805975,0.00055039645,0.00006531131,0.00004299485,0.00018115886,0.00010481887,0.000037873073],"category_scores_gemma":[0.00060825516,0.00020521971,0.00011161028,0.000586657,0.0005046794,0.00032033108,0.00012090054,0.00023067211,0.0000014419221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96884733,0.00755442,0.0019566047,0.0031181618,0.0015711236,0.00018693846,0.006593485,0.00004423233,0.0015760474,0.00009177767,0.0003939389,0.008065932],"study_design_scores_gemma":[0.9585831,0.015281785,0.0029679227,0.0041724527,0.0008588,0.000011212287,0.00043411908,0.011918319,0.005252065,0.00011753216,0.00019206395,0.00021058474],"about_ca_topic_score_codex":0.002113691,"about_ca_topic_score_gemma":0.0021704796,"teacher_disagreement_score":0.011874087,"about_ca_system_score_codex":0.00021658189,"about_ca_system_score_gemma":0.0010314949,"threshold_uncertainty_score":0.83686167},"labels":[],"label_agreement":null},{"id":"W4402565731","doi":"10.1016/j.annonc.2024.08.2284","title":"LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.09439874432614945,"score_gpt":0.4237533734174347,"score_spread":0.3293546290912852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97854316,0.0043489323,0.000011311621,0.009351766,0.0012942608,0.00062140485,0.00010479567,0.000030543342,0.005693811],"genre_scores_gemma":[0.9965186,0.0011685384,0.00006341286,0.0007230716,0.00019105613,0.000041220126,0.000046203542,0.000020245394,0.0012276174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983563,0.00016886035,0.0007330763,0.0002564617,0.00023150095,0.0002538155],"domain_scores_gemma":[0.9985706,0.0007502846,0.00019573329,0.00034774444,0.0000887679,0.0000468452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078207627,0.00016155338,0.00085992157,0.00011928724,0.000025378518,0.000006848468,0.00019098379,0.00017047368,0.00085305236],"category_scores_gemma":[0.00014308917,0.000107402615,0.00030151897,0.00027392147,0.00022661759,0.00006895565,0.000048561054,0.00019171415,0.000013708101],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5101073,0.001477329,0.00077050674,0.00011993158,0.0012253718,0.00017364544,0.0022979989,0.0000062760373,0.027274895,0.0002325025,0.009869128,0.44644514],"study_design_scores_gemma":[0.5512246,0.023478867,0.01702151,0.0004903271,0.00029956343,0.0000221098,0.0017336432,0.00033816314,0.030604994,0.0006343339,0.37379807,0.0003538334],"about_ca_topic_score_codex":0.0012679714,"about_ca_topic_score_gemma":0.0006285516,"teacher_disagreement_score":0.4460913,"about_ca_system_score_codex":0.00009169126,"about_ca_system_score_gemma":0.0005745297,"threshold_uncertainty_score":0.9340325},"labels":[],"label_agreement":null},{"id":"W4402565732","doi":"10.1016/j.annonc.2024.08.2300","title":"LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Mount Sinai Hospital; Canadian Cancer Society; Dalhousie University; Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Medical Research Council; Canadian Institutes of Health Research; Servier; Astellas Pharma; Amarin Corporation; Monash University; BeiGene; Cancer Australia; Health Research Council of New Zealand; Incyte; National Health and Medical Research Council; Boston Scientific Corporation; Canadian Cancer Society Research Institute; Novavax; Gilead Sciences; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Perioperative; Chemoradiotherapy; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Internal medicine; Oncology","score_opus":0.07945648658238787,"score_gpt":0.4315538954699322,"score_spread":0.35209740888754437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546207,0.0014243214,0.0007036398,0.004048104,0.000517538,0.006541537,0.00031067204,0.000037196827,0.00095494994],"genre_scores_gemma":[0.9864237,0.0037223003,0.0026701812,0.0006312074,0.0008021065,0.0009790288,0.00011906771,0.000058550908,0.004593868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970305,0.0003086182,0.0012691433,0.00064958003,0.00036098436,0.00038116844],"domain_scores_gemma":[0.9976115,0.0007981311,0.00059565395,0.0003791624,0.00046754445,0.0001479948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012252823,0.00037941468,0.0028104107,0.00033582762,0.000061324565,0.000042763495,0.0001937339,0.0001385043,0.0003923484],"category_scores_gemma":[0.00037558857,0.00024444866,0.00032870725,0.00044507123,0.00059339346,0.0002649212,0.00004100661,0.00024327231,3.3263112e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9502428,0.0015787277,0.00012298503,0.00021093368,0.0020014644,0.00004327005,0.008098928,0.000008726708,0.0022482674,0.0001352032,0.0019250991,0.033383574],"study_design_scores_gemma":[0.9116552,0.0666846,0.00008606082,0.00038581743,0.00064725755,0.00002169306,0.0012917354,0.0024389925,0.00960236,0.00003953221,0.006938175,0.00020857704],"about_ca_topic_score_codex":0.0019146845,"about_ca_topic_score_gemma":0.00076706754,"teacher_disagreement_score":0.06510588,"about_ca_system_score_codex":0.000100159305,"about_ca_system_score_gemma":0.0011108688,"threshold_uncertainty_score":0.9968327},"labels":[],"label_agreement":null},{"id":"W4402565751","doi":"10.1016/j.annonc.2024.08.2065","title":"1980P Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Skin Protection and Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Janssen Biotech; Allergan; EMD Serono; Ipsen; Cilag; Astellas Pharma; Dendreon Pharmaceuticals; Sanofi; Bayer HealthCare; Incyte; Pfizer; Intuitive Surgical; Boston Scientific Corporation; Seagen; Gilead Sciences; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; tar (computing); Clinical trial; Sunrise; Internal medicine; Oncology; Meteorology","score_opus":0.1644573915756166,"score_gpt":0.5318877724822731,"score_spread":0.3674303809066566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96915454,0.000108761364,0.00010984386,0.02788878,0.00039309482,0.00061022805,0.0000059258773,0.000018515277,0.0017103137],"genre_scores_gemma":[0.9965914,0.000046579924,0.00021991061,0.0021679597,0.00028821346,0.000043325836,0.000003987097,0.000007989295,0.00063065987],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818546,0.0007992442,0.00047694187,0.00016533402,0.00023161828,0.00014142774],"domain_scores_gemma":[0.9979214,0.0016020885,0.00015248258,0.00015550136,0.000115174895,0.00005333321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046219965,0.00006706193,0.0003283785,0.00017532049,0.00002052325,0.000005513609,0.000072205534,0.00015168164,0.000100872254],"category_scores_gemma":[0.002224053,0.000040991323,0.000093462186,0.00031696504,0.000040017705,0.0000390091,0.000020430745,0.00028911853,0.000012454676],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7712119,0.0039509423,0.0070008463,0.00011001501,0.00021534222,0.00043823145,0.0054220036,0.000021400372,0.038635857,0.00024975705,0.08666329,0.086080424],"study_design_scores_gemma":[0.12161638,0.063961156,0.038449243,0.0011579929,0.00019015376,0.00008183699,0.0024260643,0.00026955758,0.03135116,0.00045175062,0.73981595,0.00022874297],"about_ca_topic_score_codex":0.00003647405,"about_ca_topic_score_gemma":0.0000255705,"teacher_disagreement_score":0.65315264,"about_ca_system_score_codex":0.000050656578,"about_ca_system_score_gemma":0.00028922118,"threshold_uncertainty_score":0.266256},"labels":[],"label_agreement":null},{"id":"W4402565762","doi":"10.1016/j.annonc.2024.08.2029","title":"1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Neoadjuvant therapy; Complete response; Joint (building); Oncology; Surgery; Internal medicine; Cancer; Chemotherapy","score_opus":0.1451970655772216,"score_gpt":0.45844714486034166,"score_spread":0.3132500792831201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95376086,0.0035595663,0.00138243,0.040159833,0.0003387695,0.00033570404,0.000016642034,0.000053608157,0.0003925676],"genre_scores_gemma":[0.98287654,0.00052309636,0.01190926,0.004086309,0.00019742714,0.000024674431,0.000023399924,0.000025214098,0.000334079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860394,0.00008526908,0.00064500206,0.00026968753,0.00014369051,0.00025243164],"domain_scores_gemma":[0.99879956,0.00038495805,0.00016329101,0.00017745582,0.00036719663,0.000107530956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022806607,0.0001308956,0.0006191704,0.00023272392,0.000034850626,0.000008728403,0.000076185424,0.00010318528,0.000027535229],"category_scores_gemma":[0.00300545,0.000097863005,0.00012929046,0.00016002568,0.00021900293,0.000042489584,0.000078269375,0.0002489435,0.000002516526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035845693,0.0003179691,0.0049911705,0.0013948192,0.00033135113,0.0016064122,0.0009531914,0.00008588186,0.33838162,0.0017527492,0.0788916,0.5677087],"study_design_scores_gemma":[0.0064723752,0.018735334,0.060653497,0.0027351466,0.00057192316,0.0032849482,0.0007686871,0.06620776,0.052974388,0.0055177817,0.7815341,0.0005440963],"about_ca_topic_score_codex":0.00004546927,"about_ca_topic_score_gemma":0.0000022150684,"teacher_disagreement_score":0.70264244,"about_ca_system_score_codex":0.000019236944,"about_ca_system_score_gemma":0.00027294512,"threshold_uncertainty_score":0.39907375},"labels":[],"label_agreement":null},{"id":"W4402565779","doi":"10.1016/j.annonc.2024.08.1971","title":"1877P Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Trastuzumab; Adverse effect; Oncology; Meta-analysis; Internal medicine; Cancer; Breast cancer","score_opus":0.09088546132920396,"score_gpt":0.47424189706307723,"score_spread":0.3833564357338733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95442843,0.018646913,0.00034575348,0.011366304,0.00023626142,0.0009296626,0.00010264245,0.000090223475,0.0138538005],"genre_scores_gemma":[0.99810696,0.00021694957,0.0005227156,0.0005251641,0.000029928482,0.00009309584,0.000029457886,0.000018003233,0.00045772883],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99886674,0.000101913574,0.00041923634,0.00024180533,0.00016412325,0.00020618134],"domain_scores_gemma":[0.9991682,0.00028344957,0.00011587523,0.00021977843,0.00013015402,0.00008255099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027031425,0.00013175151,0.0011843916,0.0005810377,0.00001252935,0.0000028808713,0.000066795285,0.00009689798,0.00022384367],"category_scores_gemma":[0.00007847973,0.00009663323,0.00080520415,0.00081287895,0.00009166257,0.000060183538,0.000020541656,0.00011656269,0.000011232743],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011714625,0.0074715377,0.017236955,0.0024927729,0.79176545,0.003909914,0.016967468,0.0023113908,0.009331616,0.0060332036,0.012095655,0.12921256],"study_design_scores_gemma":[0.0062072114,0.014816276,0.0961884,0.00022675697,0.78019404,0.000120244375,0.0017843063,0.0012162233,0.05653009,0.0031140887,0.039120525,0.00048180323],"about_ca_topic_score_codex":0.00050768605,"about_ca_topic_score_gemma":0.0006138658,"teacher_disagreement_score":0.12873076,"about_ca_system_score_codex":0.000082885446,"about_ca_system_score_gemma":0.00046616822,"threshold_uncertainty_score":0.39405888},"labels":[],"label_agreement":null},{"id":"W4402565813","doi":"10.1016/j.annonc.2024.08.2052","title":"1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Cohort; Urothelial carcinoma; Expanded access; Safety profile; Adverse effect; Immunotherapy; Cancer; Bladder cancer","score_opus":0.03841236257424397,"score_gpt":0.3611249404934512,"score_spread":0.3227125779192072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98392123,0.007100493,0.00013770832,0.0014042066,0.00011196455,0.0018349679,0.00014664562,0.000042766394,0.0052999924],"genre_scores_gemma":[0.99604756,0.0018560458,0.00095629116,0.0001638564,0.00005951313,0.00025388814,0.000035223544,0.000054926506,0.0005727087],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979323,0.0002566607,0.00063009973,0.0005259758,0.0002711208,0.00038379882],"domain_scores_gemma":[0.99847114,0.00071305106,0.00017893895,0.00032640982,0.00013488418,0.0001755671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024684554,0.0003461847,0.0011519452,0.00022794634,0.000040773466,0.000011359096,0.000099132914,0.00013591765,0.00018812313],"category_scores_gemma":[0.00009196598,0.00022542084,0.0001242455,0.00025759923,0.00037873525,0.00010550362,0.000054325606,0.00018297973,0.0000073293386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17505446,0.0094650015,0.08870501,0.002035249,0.0040605213,0.007980058,0.008706572,0.00037579375,0.0038811797,0.0007915022,0.0010744998,0.69787014],"study_design_scores_gemma":[0.07201074,0.17466988,0.6769867,0.0040020673,0.0039599165,0.0022620203,0.0013698718,0.0007345974,0.03505437,0.00028884134,0.027814396,0.0008466419],"about_ca_topic_score_codex":0.00059651537,"about_ca_topic_score_gemma":0.00015178038,"teacher_disagreement_score":0.6970235,"about_ca_system_score_codex":0.00016948486,"about_ca_system_score_gemma":0.0014052775,"threshold_uncertainty_score":0.9192395},"labels":[],"label_agreement":null},{"id":"W4402565842","doi":"10.1016/j.annonc.2024.08.2269","title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Ovarian cancer; Maintenance therapy; Cancer; Chemotherapy; Immunotherapy","score_opus":0.06469292880486023,"score_gpt":0.40063125342927786,"score_spread":0.33593832462441764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97895604,0.0021843205,0.00050028757,0.008213368,0.0010559019,0.005692085,0.00004464049,0.00012569063,0.0032276826],"genre_scores_gemma":[0.98517215,0.0079821395,0.00028359197,0.0027996781,0.0003025136,0.0025355965,0.00012286927,0.00008539458,0.0007160497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964334,0.0005924436,0.0011927794,0.00068587845,0.0004900039,0.00060553825],"domain_scores_gemma":[0.9976056,0.00079172925,0.00054971786,0.00046733517,0.000390263,0.00019531375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093507115,0.000480217,0.0022407414,0.00051311863,0.00009347239,0.000044165958,0.00020004953,0.00028162674,0.000545465],"category_scores_gemma":[0.00008036766,0.0003594941,0.000393553,0.0005666529,0.00040194934,0.00022359665,0.000019605888,0.00035073937,0.000017970318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8712304,0.0073440475,0.0016204949,0.00004688776,0.0011310397,0.00013071034,0.004880616,0.00009390689,0.0004288376,0.0023269614,0.0024823511,0.108283706],"study_design_scores_gemma":[0.938386,0.026755435,0.0009084858,0.0006218937,0.00014110708,0.000015174024,0.00012989025,0.0017961843,0.0033051781,0.001772077,0.025830153,0.00033837755],"about_ca_topic_score_codex":0.004814446,"about_ca_topic_score_gemma":0.00061541464,"teacher_disagreement_score":0.10794533,"about_ca_system_score_codex":0.0009287415,"about_ca_system_score_gemma":0.0012668567,"threshold_uncertainty_score":0.9998857},"labels":[],"label_agreement":null},{"id":"W4402565845","doi":"10.1016/j.annonc.2024.08.2325","title":"LBA82 Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"GDF15 and Related Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Monoclonal antibody; Cachexia; Placebo; Oncology; Cancer cachexia; Internal medicine; Monoclonal; Randomized controlled trial; Phases of clinical research; Cancer; Antibody; Clinical trial; Immunology; Pathology; Alternative medicine","score_opus":0.017706699492297053,"score_gpt":0.33924489068110397,"score_spread":0.32153819118880694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939696,0.0014404587,0.0000074936333,0.0012638149,0.00016170018,0.0029119982,0.000075481534,0.000011380817,0.00015803997],"genre_scores_gemma":[0.99916196,0.000578264,0.000023498997,0.000032778484,0.000025818483,0.00007447187,0.000042770193,0.000017438853,0.00004301856],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979847,0.00030609735,0.00091286085,0.0002962237,0.00027352347,0.0002265702],"domain_scores_gemma":[0.9984757,0.0007781962,0.0003326642,0.00012669683,0.00020815537,0.00007861072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059088995,0.00020541644,0.0015686571,0.00048239512,0.000027076127,0.0000035184953,0.00006125342,0.0002213594,0.000052238087],"category_scores_gemma":[0.0002732925,0.00013194965,0.00014400532,0.0003390239,0.0002260267,0.000068117864,0.000049520368,0.000246006,4.3804653e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80235827,0.009296051,0.17606676,0.0003769552,0.0019012544,0.00006339215,0.0031332446,0.000012078252,0.0021701355,0.000026754282,0.00015096112,0.0044441167],"study_design_scores_gemma":[0.6442495,0.01268055,0.33996952,0.000694161,0.00047966704,0.000003832798,0.0002048932,0.0006362377,0.00091011333,0.000014402074,0.000041008145,0.000116122086],"about_ca_topic_score_codex":0.0005412128,"about_ca_topic_score_gemma":0.00036664476,"teacher_disagreement_score":0.16390276,"about_ca_system_score_codex":0.00006102383,"about_ca_system_score_gemma":0.00027652486,"threshold_uncertainty_score":0.5380751},"labels":[],"label_agreement":null},{"id":"W4402565848","doi":"10.1016/j.annonc.2024.08.2308","title":"LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Jewish General Hospital; Canadian Cancer Society; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Splash; Androgen receptor; Pharmacology; Androgen; Oncology; Cancer research; Internal medicine; Cancer; Prostate cancer; Hormone","score_opus":0.0703037373994569,"score_gpt":0.43976374096153664,"score_spread":0.36946000356207975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879274,0.003973032,0.000002430864,0.0029400145,0.00045606744,0.00078922376,0.000061389306,0.000041917374,0.00380853],"genre_scores_gemma":[0.9982407,0.000481599,0.00021404967,0.00017014651,0.0002528012,0.0000616759,0.00011244427,0.000031491727,0.00043510788],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982154,0.00019526356,0.00043442348,0.00039099774,0.00035973868,0.00040420098],"domain_scores_gemma":[0.9990223,0.0003431449,0.000092723596,0.0002239987,0.00013854241,0.00017929295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005327803,0.0001856671,0.00057228113,0.00039320285,0.000039665247,0.000010377542,0.00010615069,0.00023638284,0.00010170345],"category_scores_gemma":[0.00011728569,0.00013545204,0.00020436602,0.00043289913,0.00016141757,0.00012570538,0.00005976187,0.00031977793,0.000045039083],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010499079,0.0077764774,0.0136587415,0.00072052353,0.0008158472,0.0026125594,0.0059060357,0.000016401154,0.2534504,0.0008212589,0.008101475,0.6956212],"study_design_scores_gemma":[0.0074787447,0.031570245,0.011012983,0.0029670717,0.000090328766,0.000033206594,0.0004441489,0.00016981717,0.91984415,0.00020726449,0.025939044,0.00024297832],"about_ca_topic_score_codex":0.00004247874,"about_ca_topic_score_gemma":0.00001929074,"teacher_disagreement_score":0.69537824,"about_ca_system_score_codex":0.00013104443,"about_ca_system_score_gemma":0.0005490541,"threshold_uncertainty_score":0.5523574},"labels":[],"label_agreement":null},{"id":"W4402565873","doi":"10.1016/j.annonc.2024.08.2007","title":"1926MO Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: Real-world treatment patterns and clinical outcomes in Europe and Canada","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Medicine; Thyroid cancer; Refractory (planetary science); Oncology; Internal medicine; Cancer","score_opus":0.05826697059684817,"score_gpt":0.3807579671329032,"score_spread":0.32249099653605506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921797,0.0022848775,3.9157104e-7,0.0040772916,0.00016090731,0.000566697,0.00026307022,0.000028830622,0.0004382386],"genre_scores_gemma":[0.95635325,0.041916206,0.000013290697,0.00086902146,0.00005608943,0.00012002199,0.00009259595,0.000037277157,0.000542264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983937,0.00013667817,0.0005422516,0.00046381334,0.00016912863,0.00029440416],"domain_scores_gemma":[0.9989341,0.00039374008,0.00015309846,0.00020547459,0.0001221159,0.00019147589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008876809,0.00028732905,0.00089831604,0.00016806576,0.0000312601,0.0000137725365,0.000047515983,0.00009180883,0.000069596215],"category_scores_gemma":[0.000016026255,0.00018054008,0.00006514745,0.00019055394,0.00010896974,0.000052828364,0.000024366112,0.00015447396,8.428939e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079783297,0.0014134607,0.9300476,0.0000540924,0.0012147084,0.00027576453,0.0001694314,0.0000012456688,0.000016805641,0.000017412782,0.0015939411,0.06439773],"study_design_scores_gemma":[0.008775791,0.008585466,0.966681,0.00021761436,0.00031906716,0.0000046503355,0.000024762958,0.000024070552,0.00030215026,0.0000028386046,0.014910184,0.00015240212],"about_ca_topic_score_codex":0.7008881,"about_ca_topic_score_gemma":0.885882,"teacher_disagreement_score":0.18499392,"about_ca_system_score_codex":0.00030792993,"about_ca_system_score_gemma":0.00068252586,"threshold_uncertainty_score":0.73622113},"labels":[],"label_agreement":null},{"id":"W4402565877","doi":"10.1016/j.annonc.2024.08.2276","title":"LBA37 Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Synthesis of Organic Compounds","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; McMaster University; London Health Sciences Centre; Occupational Cancer Research Centre; Juravinski Cancer Centre; Western University","funders":"European Network for Rare Adult Solid Cancers; Associazione Italiana di Oncologia Medica; AstraZeneca","keywords":"Medicine; Cisplatin; Ototoxicity; Dosing; Oncology; Head and neck squamous-cell carcinoma; Internal medicine; Head and neck cancer; Confidence interval; Chemotherapy; Radiation therapy","score_opus":0.07439209884229325,"score_gpt":0.38257254205226954,"score_spread":0.3081804432099763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161185,0.00029323052,0.0076549626,0.004755878,0.00028731007,0.0044162706,0.00007416134,0.000022123731,0.00088422204],"genre_scores_gemma":[0.98071814,0.000008936877,0.018567348,0.00016526229,0.00015453594,0.0002294003,0.000019463048,0.000036513273,0.00010039063],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975534,0.00018956796,0.0012433401,0.00041016482,0.00030641796,0.0002971024],"domain_scores_gemma":[0.9949279,0.0035714733,0.00066139636,0.00034912222,0.00038726532,0.00010288437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018063062,0.00023633307,0.0016186284,0.00019966623,0.000060473776,0.000015517304,0.00019765233,0.00015265045,0.0000071093896],"category_scores_gemma":[0.0014680675,0.0001704807,0.00032730095,0.00024495134,0.00021787571,0.0000886317,0.00008687905,0.00018804158,2.4420908e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9058589,0.0010454935,0.0019478742,0.0015557817,0.00028030478,0.0000070174106,0.0013076328,0.00053515047,0.061295677,0.00039854282,0.0015955209,0.024172135],"study_design_scores_gemma":[0.67452353,0.02898023,0.020102756,0.0012543253,0.00070918805,0.000049927403,0.00033428284,0.049058974,0.22323051,0.0002581537,0.0012059284,0.00029216966],"about_ca_topic_score_codex":0.000090532245,"about_ca_topic_score_gemma":0.00012590678,"teacher_disagreement_score":0.23133531,"about_ca_system_score_codex":0.00013237077,"about_ca_system_score_gemma":0.0007460932,"threshold_uncertainty_score":0.6952001},"labels":[],"label_agreement":null},{"id":"W4402565893","doi":"10.1016/j.annonc.2024.08.1990","title":"1896P Importance of prompt medical oncologist (MO) consultation at the Emergency Department (ED): A prospective study in a tertiary hospital on 10,896 admissions in the first quarter of 2024","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quarter (Canadian coin); Emergency department; Tertiary care; Emergency medicine; Family medicine; Medical emergency; Nursing","score_opus":0.03366702119650909,"score_gpt":0.3989838584851639,"score_spread":0.36531683728865477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636402,0.00084719073,0.0000011988616,0.028788373,0.00031919242,0.0020476647,0.000027182114,0.000009849035,0.004319125],"genre_scores_gemma":[0.9979288,0.00029956788,0.0000049932464,0.00062618096,0.000055329405,0.0007819638,0.000008488915,0.00000897735,0.0002856988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983067,0.00019599238,0.00068659894,0.00026839325,0.00035612754,0.00018616875],"domain_scores_gemma":[0.9989301,0.00044768266,0.00018700835,0.00022892404,0.00014321195,0.00006308045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076876767,0.00012591576,0.00037968458,0.00012759739,0.00004716971,0.0000027286212,0.00014891339,0.00010856955,0.0013779189],"category_scores_gemma":[0.00038436794,0.00006927083,0.00010863672,0.0004522027,0.00020920734,0.000041751642,0.000054325377,0.00030980358,0.000013961452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012274472,0.008753563,0.8556828,0.0001982411,0.00027829086,0.00037011245,0.014334007,0.000014924844,0.00021583233,0.0005825661,0.114880554,0.0034617018],"study_design_scores_gemma":[0.0021471565,0.018289192,0.9561258,0.00028602057,0.00011949618,0.00004536117,0.0038608047,0.000052060124,0.0006297623,0.0003768404,0.0179746,0.00009289796],"about_ca_topic_score_codex":0.0002359812,"about_ca_topic_score_gemma":0.007361415,"teacher_disagreement_score":0.10044305,"about_ca_system_score_codex":0.00013252441,"about_ca_system_score_gemma":0.00059407286,"threshold_uncertainty_score":0.99953496},"labels":[],"label_agreement":null},{"id":"W4402565894","doi":"10.1016/j.annonc.2024.08.2067","title":"1982P Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Janssen Research and Development","keywords":"Atezolizumab; Medicine; Oncology; Post-hoc analysis; Cisplatin; Internal medicine; Post hoc; Platinum; Chemotherapy; Cancer; Immunotherapy; Nivolumab","score_opus":0.08971721828821749,"score_gpt":0.43127055176608836,"score_spread":0.34155333347787087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905212,0.00052165793,0.000008572849,0.007687363,0.00009968755,0.0008472281,0.000124915,0.0000063142347,0.00018305362],"genre_scores_gemma":[0.9988613,0.00008089999,0.00009009348,0.000736128,0.000028551487,0.00007532375,0.000015041708,0.000012572673,0.00010009759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989055,0.000109819164,0.00043036183,0.00021662994,0.00020135919,0.00013636965],"domain_scores_gemma":[0.9988249,0.0007046371,0.000117285555,0.00018695225,0.00012629104,0.000039939918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058224925,0.00011832565,0.0005904225,0.0005301443,0.000019405546,0.000006352702,0.00013622954,0.00004291983,0.000044417902],"category_scores_gemma":[0.00010800322,0.0000795653,0.00017254344,0.0003573146,0.000038895138,0.000043289238,0.00003612438,0.00007477292,5.6254873e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03322376,0.0060537537,0.837549,0.00015865939,0.0049552447,0.00043084836,0.022832979,0.000051849613,0.005497649,0.000052389747,0.0005361582,0.08865772],"study_design_scores_gemma":[0.003930685,0.022573618,0.9643564,0.0000406277,0.00065693085,0.00003932891,0.0052610226,0.00013498831,0.0013666637,0.00002935732,0.0015462486,0.00006413311],"about_ca_topic_score_codex":0.0006473808,"about_ca_topic_score_gemma":0.00019983744,"teacher_disagreement_score":0.1268074,"about_ca_system_score_codex":0.000060714014,"about_ca_system_score_gemma":0.00018526833,"threshold_uncertainty_score":0.3244579},"labels":[],"label_agreement":null},{"id":"W4402565907","doi":"10.1016/j.annonc.2024.08.1984","title":"1890P End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; University of Ottawa; McMaster University; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Institute for Work & Health; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Internal medicine; Disease","score_opus":0.15654208584623303,"score_gpt":0.3773825870090762,"score_spread":0.22084050116284315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416026,0.04895476,0.00004822001,0.007878341,0.00026438,0.00028299628,0.00036089576,0.000023264634,0.00058452686],"genre_scores_gemma":[0.9620184,0.03448419,0.000035427704,0.003064457,0.00011688233,0.000023406592,0.000005387425,0.00001715557,0.00023472075],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986304,0.000029001463,0.00070074806,0.0003279021,0.00002361399,0.00028833572],"domain_scores_gemma":[0.99891925,0.00020315027,0.000445213,0.00021106839,0.000026118118,0.00019521032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064778066,0.00015463262,0.0007017447,0.00016058964,0.00009947565,0.000043597483,0.000119719145,0.00012395052,0.00006070236],"category_scores_gemma":[0.000049144604,0.00012621642,0.000083753446,0.00010511622,0.00023258329,0.0002617762,0.000059302,0.00009835052,0.000010380096],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015383377,0.00008628855,0.891493,0.00205623,0.0003348987,0.000010483359,0.007453027,0.00008878933,0.00002903358,0.06451894,0.0006712191,0.033104256],"study_design_scores_gemma":[0.0021082317,0.0026106194,0.4668453,0.00025573722,0.000039717215,0.00018894408,0.0008678503,0.0008819873,0.00005327815,0.013680887,0.5120937,0.00037371521],"about_ca_topic_score_codex":0.0075302,"about_ca_topic_score_gemma":0.003209563,"teacher_disagreement_score":0.5114225,"about_ca_system_score_codex":0.00024025135,"about_ca_system_score_gemma":0.00038550474,"threshold_uncertainty_score":0.99907875},"labels":[],"label_agreement":null},{"id":"W4402565926","doi":"10.1016/j.annonc.2024.08.1986","title":"1892P Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Exelixis; Peterborough K. M. Hunter Charitable Foundation; Canadian Institutes of Health Research; Ipsen; Eli Lilly and Company","keywords":"Medicine; Cardiotoxicity; Anthracycline; Hematologic Neoplasms; Internal medicine; Oncology; Cancer; Chemotherapy; Breast cancer","score_opus":0.06535165115290559,"score_gpt":0.37911630396920454,"score_spread":0.31376465281629895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98556465,0.0031657447,0.000032297285,0.005425868,0.00026431523,0.0003476507,0.000021193015,0.00008341538,0.005094878],"genre_scores_gemma":[0.9948992,0.0026480812,0.0001524939,0.0017959077,0.000085506006,0.000025811509,0.000030558724,0.000019846922,0.00034257813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859947,0.00013205463,0.00043555407,0.0003333487,0.00018222396,0.00031733856],"domain_scores_gemma":[0.9992146,0.00027562943,0.000103891616,0.0001824002,0.000125263,0.00009822583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000700188,0.00017073724,0.00076649524,0.0002087705,0.00004120232,0.000015563695,0.00006555478,0.00034923552,0.000028555349],"category_scores_gemma":[0.00026387916,0.00015563024,0.00018762925,0.00033911396,0.00024904092,0.00009895401,0.00004351657,0.000299027,0.0000099753415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041736697,0.00077650597,0.017430225,0.00085247937,0.00066207733,0.0013816189,0.0026571134,0.000019307165,0.9264877,0.0017083174,0.010721767,0.036885552],"study_design_scores_gemma":[0.002777235,0.0023520933,0.08755814,0.0010580857,0.00015414793,0.00085745874,0.0007303687,0.0004005156,0.8617607,0.002836278,0.03913535,0.00037965062],"about_ca_topic_score_codex":0.000165236,"about_ca_topic_score_gemma":0.00017029149,"teacher_disagreement_score":0.07012791,"about_ca_system_score_codex":0.00009965579,"about_ca_system_score_gemma":0.00027415107,"threshold_uncertainty_score":0.6346417},"labels":[],"label_agreement":null},{"id":"W4402565956","doi":"10.1016/j.annonc.2024.08.1913","title":"1817MO Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the breast cancer weight loss (BWEL) trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Sinai Health System","funders":"","keywords":"Medicine; Weight loss; Cancer; Breast cancer; Intervention (counseling); Oncology; Physical therapy; Randomized controlled trial; Internal medicine; Obesity; Nursing","score_opus":0.020952201828089368,"score_gpt":0.35449595458101363,"score_spread":0.33354375275292425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785571,0.0028107918,0.0000024719777,0.013192379,0.0016179034,0.00088827685,0.0025290549,0.00003450683,0.00036749087],"genre_scores_gemma":[0.9945044,0.0034777767,0.0000022994316,0.000347003,0.00072241394,0.0005894927,0.00006932404,0.00003992332,0.00024735066],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99762046,0.00034981364,0.0006972322,0.0005027003,0.00041297398,0.00041684468],"domain_scores_gemma":[0.9984298,0.0004976484,0.00028910322,0.00043732807,0.00020738764,0.00013877459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093172444,0.0002827956,0.0009440817,0.00021008324,0.000035015844,0.0000136569315,0.00023672689,0.0002434011,0.00060548855],"category_scores_gemma":[0.000027678967,0.00017174403,0.00024231282,0.0005393679,0.0002877193,0.000102405415,0.00006699503,0.00046075988,0.000008801035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47820568,0.0009281686,0.032642312,0.00046127354,0.0004502236,0.00045764688,0.0064043035,0.000018105278,0.0002429634,0.00003600446,0.0068163867,0.47333694],"study_design_scores_gemma":[0.18757267,0.03859296,0.68043524,0.024179187,0.0020421492,0.00038354174,0.0017571183,0.000106038875,0.017366106,0.00037655464,0.046172015,0.0010163797],"about_ca_topic_score_codex":0.036243875,"about_ca_topic_score_gemma":0.02052752,"teacher_disagreement_score":0.64779294,"about_ca_system_score_codex":0.0003814937,"about_ca_system_score_gemma":0.00048500736,"threshold_uncertainty_score":0.9973453},"labels":[],"label_agreement":null},{"id":"W4402565972","doi":"10.1016/j.annonc.2024.08.1889","title":"1798P Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; CancerCare Manitoba; St. Michael's Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Systemic therapy; Refractory (planetary science); Lung cancer; Oncology; Internal medicine; Database; Cancer","score_opus":0.1196713710788802,"score_gpt":0.45891073948268385,"score_spread":0.33923936840380364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.866349,0.059875622,6.578022e-7,0.049326792,0.00034764182,0.0010074661,0.00012651217,0.000029347848,0.022936981],"genre_scores_gemma":[0.94705594,0.046826053,0.000025404406,0.0032872048,0.0001388938,0.00017912599,0.0000157765,0.00002186929,0.0024497283],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847317,0.00024872308,0.00031703766,0.00029569023,0.00023657214,0.00042881307],"domain_scores_gemma":[0.9986248,0.00068766956,0.00006597106,0.00033856023,0.00012240255,0.00016058153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010854282,0.00015101329,0.0004819879,0.0004242482,0.00007808161,0.000018994137,0.00017774208,0.000106193685,0.000066607536],"category_scores_gemma":[0.000113238355,0.00009326484,0.00006730549,0.00034810268,0.00018599672,0.0000683592,0.000052635096,0.0005136916,0.00000572284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008413531,0.000445755,0.6300592,0.0038761282,0.0012011745,0.003335807,0.017257532,0.000008627256,0.005615334,0.001726107,0.2904337,0.0451993],"study_design_scores_gemma":[0.0040024007,0.0022839904,0.39313218,0.0017409294,0.00021049335,0.0001038731,0.0020962534,0.00026493656,0.0016896313,0.00013604407,0.5939651,0.00037416114],"about_ca_topic_score_codex":0.41495737,"about_ca_topic_score_gemma":0.7701746,"teacher_disagreement_score":0.35521728,"about_ca_system_score_codex":0.00044258797,"about_ca_system_score_gemma":0.0019950164,"threshold_uncertainty_score":0.5889385},"labels":[],"label_agreement":null},{"id":"W4402565993","doi":"10.1016/j.annonc.2024.08.1910","title":"1814O Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"ETOP IBCSG Partners Foundation; Fonds Baillet Latour; National Cancer Institute; KWF Kankerbestrijding; Swiss Cancer Foundation; National Institutes of Health; Krebsliga Schweiz; Canadian Cancer Society; Canada Foundation for Innovation; Korea Breast Cancer Foundation; Breast Cancer Research Foundation; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Korean Breast Cancer Society","keywords":"Medicine; Breastfeeding; Endocrine system; Breast cancer; Oncology; Hormone receptor; Hormone; Cancer; Internal medicine; Gynecology; Oestrogen receptor; Obstetrics; Pediatrics","score_opus":0.05470321828382248,"score_gpt":0.3708803747852534,"score_spread":0.3161771565014309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695064,0.0034747839,0.0000056802796,0.023212539,0.00025894016,0.0006736325,0.0018559078,0.000017537532,0.0009946156],"genre_scores_gemma":[0.99360526,0.0042761215,0.000015816266,0.0012467531,0.0005096117,0.00014701241,0.00007488633,0.000022970507,0.00010159139],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985666,0.00015138258,0.0005006004,0.00031909556,0.00020266885,0.00025964802],"domain_scores_gemma":[0.9988979,0.00042225907,0.00021652259,0.00017106431,0.00021370815,0.000078508856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000331128,0.00017513163,0.00059204997,0.00012688455,0.00002032562,0.000011468623,0.000093405455,0.00010744978,0.00017886709],"category_scores_gemma":[0.000025575107,0.000107647014,0.00008822547,0.00028127237,0.00027767394,0.00013908221,0.00004229059,0.00030780182,0.0000024572305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67909604,0.00043100058,0.0053342604,0.000024028344,0.0009352814,0.0001546713,0.020373112,0.000005167625,0.015375404,0.000023780764,0.006136812,0.2721104],"study_design_scores_gemma":[0.04978634,0.015510607,0.91203773,0.0017625357,0.00009636196,0.00005871452,0.003059829,0.000045418496,0.006398228,0.000083494866,0.010926827,0.00023391197],"about_ca_topic_score_codex":0.011696543,"about_ca_topic_score_gemma":0.00041664025,"teacher_disagreement_score":0.9067035,"about_ca_system_score_codex":0.0001828042,"about_ca_system_score_gemma":0.00044495246,"threshold_uncertainty_score":0.99488467},"labels":[],"label_agreement":null},{"id":"W4402566002","doi":"10.1016/j.annonc.2024.08.1884","title":"1793P Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Jewish General Hospital; Western University; Capital District Health Authority; AstraZeneca (Canada); Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Oncology; Disease; Internal medicine; Cascade","score_opus":0.10322854119174955,"score_gpt":0.43619415135617623,"score_spread":0.33296561016442666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402566002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84797454,0.10196992,0.0000027209337,0.043909956,0.00025671264,0.0013863266,0.0010049449,0.000020123636,0.0034747825],"genre_scores_gemma":[0.96346784,0.031315845,0.00006569688,0.0025021806,0.00014919034,0.0005302945,0.00005853212,0.000033979046,0.0018764387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803686,0.00021122335,0.00042663136,0.00044257447,0.0002495233,0.00063320546],"domain_scores_gemma":[0.99825156,0.00058713293,0.00010943223,0.00042864555,0.00019769558,0.00042554157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004786007,0.00026656035,0.00069386134,0.00040563117,0.0000886478,0.000019562074,0.0002151618,0.000118447024,0.00014514904],"category_scores_gemma":[0.00012201329,0.00017228957,0.00014345006,0.00038437016,0.00026221882,0.00006438608,0.000109619046,0.0003168539,0.000002374737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076381024,0.0009284844,0.9087304,0.0046419348,0.0012548324,0.0017364495,0.00948307,0.00009928706,0.0012448914,0.00016079392,0.05235894,0.018597143],"study_design_scores_gemma":[0.0066621588,0.0026727878,0.78851295,0.0014834668,0.002300459,0.000016310574,0.0014464937,0.00461465,0.0065496275,0.000060400693,0.18509932,0.00058138894],"about_ca_topic_score_codex":0.42720956,"about_ca_topic_score_gemma":0.7209061,"teacher_disagreement_score":0.29369652,"about_ca_system_score_codex":0.00075394637,"about_ca_system_score_gemma":0.0039170566,"threshold_uncertainty_score":0.70257646},"labels":[],"label_agreement":null},{"id":"W4402566013","doi":"10.1016/j.annonc.2024.08.1940","title":"1845P The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University Health Network","funders":"Sanofi; AstraZeneca; Ipsen; Pfizer","keywords":"Medicine; Body mass index; Adverse effect; Immune system; Population; Oncology; Internal medicine; Immunology; Environmental health","score_opus":0.025331950189818757,"score_gpt":0.35034321842931576,"score_spread":0.325011268239497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402566013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970436,0.0006312117,0.0000018210185,0.00028908244,0.0004113155,0.0013856323,0.000048703434,0.000033483633,0.00015512716],"genre_scores_gemma":[0.999489,0.00013227599,0.000008630966,0.00007547725,0.000029257086,0.000048463393,0.000106839194,0.000035619836,0.00007440524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978143,0.00025045272,0.0010410558,0.00030661383,0.0003178504,0.00026971684],"domain_scores_gemma":[0.9985631,0.0002461295,0.0004788911,0.0003886961,0.00025328825,0.000069906586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060536177,0.00024700185,0.0005938606,0.0003151049,0.00008362557,0.0000099715335,0.00012459836,0.00021237493,0.000058729005],"category_scores_gemma":[0.00013314222,0.00016409374,0.00048836134,0.0004493021,0.00012728326,0.00014852338,0.000051641146,0.00032700208,0.0000021548533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054487097,0.0008238548,0.97003484,0.000101485464,0.0018636645,0.000036329395,0.001706591,0.00019035292,0.0045156246,0.0000016138625,0.00012747105,0.015149464],"study_design_scores_gemma":[0.004687179,0.007859264,0.98315215,0.000557534,0.00023529973,0.0000034163115,0.0008576755,0.00031903372,0.0021141386,0.000014509425,0.00005782637,0.00014198302],"about_ca_topic_score_codex":0.0053271563,"about_ca_topic_score_gemma":0.00015832386,"teacher_disagreement_score":0.015007481,"about_ca_system_score_codex":0.00024062755,"about_ca_system_score_gemma":0.00022179441,"threshold_uncertainty_score":0.8053102},"labels":[],"label_agreement":null},{"id":"W4402566053","doi":"10.1016/j.annonc.2024.08.1861","title":"1770P Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Surgery; Oncology; Internal medicine","score_opus":0.0370907144734042,"score_gpt":0.3505285809775074,"score_spread":0.3134378665041032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402566053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439913,0.00023256095,0.0000045412226,0.00065951317,0.00015435617,0.003497128,0.00007755869,0.00008101315,0.0008942252],"genre_scores_gemma":[0.9988956,0.00007977898,0.00025068468,0.0003630177,0.000044836514,0.00008422097,0.00006215731,0.000069450434,0.00015026132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969811,0.00018697379,0.0010153236,0.00071147416,0.00051600585,0.0005891278],"domain_scores_gemma":[0.9983036,0.00035739449,0.00047673707,0.0003532513,0.0002814596,0.00022755218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027470355,0.00047080297,0.0013043283,0.00029983572,0.00019306678,0.000033867396,0.00010686744,0.00013876389,0.00011228239],"category_scores_gemma":[0.00011537761,0.0002969585,0.000117971795,0.00040499476,0.00017308108,0.0002004807,0.000132371,0.0003481966,0.00000418225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008863022,0.014489444,0.7750633,0.00021887264,0.0009938573,0.0011083034,0.00592658,0.000029945424,0.0007159563,0.0000058851883,0.000055120305,0.19252974],"study_design_scores_gemma":[0.039554216,0.11411199,0.8418071,0.00044887414,0.00020482503,0.000030421012,0.00067691325,0.00013791853,0.0008481674,0.0000053010126,0.0018316611,0.00034260316],"about_ca_topic_score_codex":0.0008077896,"about_ca_topic_score_gemma":0.0002305357,"teacher_disagreement_score":0.19218713,"about_ca_system_score_codex":0.000113478214,"about_ca_system_score_gemma":0.0003477242,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W4402566097","doi":"10.1016/j.annonc.2024.08.1846","title":"1755P Multimodal therapy in first line treatment of very high risk Ewing sarcoma patients: Results of the French prospective multicenter COMBINAIR3 phase II trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Sarcoma; Oncology; Ewing's sarcoma; Multimodal therapy; Internal medicine; Chemotherapy; Pathology","score_opus":0.05550877138569128,"score_gpt":0.37316789026378633,"score_spread":0.31765911887809506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402566097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925187,0.0019233004,0.0000011435945,0.0024147835,0.00054095144,0.001993876,0.00034322118,0.000014045655,0.00024992687],"genre_scores_gemma":[0.9967889,0.0026294813,0.000109224005,0.00007995494,0.00009657378,0.00017949169,0.000057939928,0.000017920305,0.000040505554],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982723,0.00017984494,0.00078126095,0.00031286868,0.00022743194,0.00022631702],"domain_scores_gemma":[0.9982936,0.00073020125,0.00034159253,0.00035365016,0.00022625968,0.000054721244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022869994,0.00020203358,0.000755624,0.0001711124,0.000051187282,0.0000034764307,0.00009753438,0.00013778973,0.000030745337],"category_scores_gemma":[0.00022501311,0.00012004596,0.00031728615,0.00025708307,0.00016476272,0.000052580253,0.000052572734,0.00012804518,0.0000023408995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081533164,0.13635556,0.31886533,0.00010695484,0.0015695802,0.00013115042,0.008930646,0.000046276902,0.00028952057,0.0000779031,0.0011564808,0.45093745],"study_design_scores_gemma":[0.31047112,0.11442441,0.53704643,0.00040384772,0.00022520532,0.0000025788868,0.000100114994,0.00030038928,0.03273022,0.00020486518,0.003983059,0.00010775074],"about_ca_topic_score_codex":0.003752768,"about_ca_topic_score_gemma":0.00054545474,"teacher_disagreement_score":0.45082968,"about_ca_system_score_codex":0.00018082841,"about_ca_system_score_gemma":0.00015650799,"threshold_uncertainty_score":0.5673088},"labels":[],"label_agreement":null},{"id":"W4402661363","doi":"10.1016/j.annonc.2024.08.2339","title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Loxo Oncology; University of Texas MD Anderson Cancer Center; Amgen; Pfizer; Symphogen; GlaxoSmithKline","keywords":"Protein arginine methyltransferase 5; Medicine; Maximum tolerated dose; Cancer research; Arginine; Pharmacology; Methyltransferase; Biochemistry; Pharmacokinetics; Amino acid; Biology; Methylation; Gene","score_opus":0.04062427101121577,"score_gpt":0.36532275548836995,"score_spread":0.3246984844771542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402661363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849254,0.00018054854,0.000033508863,0.00022939022,0.000112096255,0.00071242463,0.00014699776,0.0000101609585,0.00008236351],"genre_scores_gemma":[0.99837273,0.000043191372,0.00005076133,0.000036934292,0.00012396932,0.00005648531,0.0012693364,0.00002284528,0.000023735442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982811,0.00022050935,0.00066483376,0.00047851136,0.00016574697,0.00018928798],"domain_scores_gemma":[0.99910563,0.000032128046,0.00023179527,0.00030765898,0.0002724861,0.000050328817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026408568,0.00016759246,0.00034364455,0.00018366403,0.000030916297,0.000011543446,0.000115917945,0.00019733899,0.000009700567],"category_scores_gemma":[0.00006784872,0.00015507432,0.000037395344,0.00029148613,0.00007999481,0.000037051737,0.00005271712,0.00013116046,0.0000013027811],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03495428,0.033901867,0.019677639,0.0001706111,0.0009956906,0.00014065435,0.03655773,0.11303909,0.698687,0.000072094306,0.0043254616,0.057477888],"study_design_scores_gemma":[0.054166302,0.14294147,0.16754656,0.0007281334,0.00013248387,0.0000030272938,0.004055269,0.0060306024,0.618159,0.00033482202,0.004921672,0.0009806582],"about_ca_topic_score_codex":0.00090409175,"about_ca_topic_score_gemma":0.0107223615,"teacher_disagreement_score":0.14786892,"about_ca_system_score_codex":0.000048575333,"about_ca_system_score_gemma":0.00020039555,"threshold_uncertainty_score":0.6323747},"labels":[],"label_agreement":null},{"id":"W4402704826","doi":"10.1016/j.annonc.2024.08.1799","title":"1706P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Antibody; Oncology; Center (category theory); Cancer research; Internal medicine; Immunology","score_opus":0.038363272036108204,"score_gpt":0.34463062368850683,"score_spread":0.3062673516523986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947452,0.0013196341,0.000076155804,0.00036552208,0.00018072904,0.0020503462,0.00084994873,0.00003117473,0.0003813184],"genre_scores_gemma":[0.9938304,0.000961869,0.0037593711,0.00016867054,0.000028656495,0.000034795554,0.0009585822,0.000071268274,0.00018638384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962008,0.00028881565,0.0014391145,0.0009669505,0.0004963825,0.0006079599],"domain_scores_gemma":[0.9976573,0.00076408824,0.0004701642,0.0005858498,0.00027080893,0.00025181507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005310033,0.000484989,0.0015566442,0.00052159757,0.00004604749,0.000013475049,0.00017062231,0.00023649844,0.000048467442],"category_scores_gemma":[0.00016398237,0.00035117572,0.00015350521,0.00054233545,0.0002902227,0.00018182238,0.000138746,0.000437121,0.000012595129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18520825,0.060878027,0.67975295,0.0022451,0.00079899165,0.00785011,0.005810509,0.00059921585,0.036163352,0.0000061651335,0.0009899822,0.019697323],"study_design_scores_gemma":[0.13547888,0.020144988,0.81310225,0.0011879129,0.00041851422,0.000029785831,0.00027572564,0.0043692105,0.021694457,0.0000021534718,0.00291007,0.00038603356],"about_ca_topic_score_codex":0.0012842396,"about_ca_topic_score_gemma":0.0009353158,"teacher_disagreement_score":0.13334928,"about_ca_system_score_codex":0.00020519485,"about_ca_system_score_gemma":0.00044693335,"threshold_uncertainty_score":0.999894},"labels":[],"label_agreement":null},{"id":"W4402704878","doi":"10.1016/j.annonc.2024.08.1797","title":"1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Surrogate endpoint; Immunotherapy; Oncology; Internal medicine; Cancer","score_opus":0.11283027433729874,"score_gpt":0.4021011426745032,"score_spread":0.28927086833720445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288887,0.0010728976,0.00026320154,0.0011135816,0.0007597,0.0020650048,0.0005802939,0.00005759407,0.0011988797],"genre_scores_gemma":[0.99554205,0.00022575415,0.0017479005,0.00032891615,0.0001337342,0.0002465006,0.0010205725,0.000075671625,0.0006788822],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963198,0.00068060047,0.0011004853,0.0007808013,0.00054563914,0.0005727153],"domain_scores_gemma":[0.9979277,0.00058683933,0.00028371095,0.0005938869,0.00038188056,0.00022596135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014799455,0.0004169061,0.0011020021,0.0006655344,0.000052083135,0.0000451979,0.00031099116,0.000091224356,0.00053135835],"category_scores_gemma":[0.00010680449,0.00035494898,0.00033456148,0.00028261088,0.00015630726,0.00034639132,0.00009584548,0.0003113607,0.000035405723],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06142566,0.05879145,0.14647752,0.0025711518,0.013514842,0.056793567,0.011393113,0.0010754544,0.57089555,0.0020552208,0.0075297356,0.06747675],"study_design_scores_gemma":[0.088500224,0.089901164,0.4805376,0.0005267806,0.00447082,0.0014657688,0.005424765,0.01612311,0.28918344,0.0017437997,0.020188726,0.0019338013],"about_ca_topic_score_codex":0.0012911112,"about_ca_topic_score_gemma":0.0004768519,"teacher_disagreement_score":0.33406007,"about_ca_system_score_codex":0.00022332127,"about_ca_system_score_gemma":0.000595983,"threshold_uncertainty_score":0.99989027},"labels":[],"label_agreement":null},{"id":"W4402704898","doi":"10.1016/j.annonc.2024.08.1707","title":"1626P Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Germline; Somatic cell; Incidence (geometry); Homologous recombination; Cancer research; Gene; Oncology; Genetics; Biology","score_opus":0.04936451172287829,"score_gpt":0.36329275357948987,"score_spread":0.31392824185661156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932184,0.0006466657,0.00019416363,0.0047152257,0.00025229526,0.0007920257,0.00003457904,0.000016384105,0.00013022427],"genre_scores_gemma":[0.9991022,0.0002379142,0.00027142998,0.00019768969,0.00005311114,0.000067157445,0.000028027232,0.0000074151067,0.00003508808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983278,0.00040303293,0.00071805,0.00015552493,0.0002777008,0.000117921176],"domain_scores_gemma":[0.998326,0.0005039251,0.00065538555,0.00020864532,0.00029157253,0.000014458379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012757813,0.000099544806,0.0004471872,0.00017878108,0.00003906087,0.000005062511,0.000088304514,0.0001334694,0.000019275165],"category_scores_gemma":[0.00026344843,0.000056841654,0.00011075267,0.00037233828,0.00016689769,0.00008439742,0.00002273957,0.00014346212,2.7628826e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04583298,0.010875731,0.29386652,0.006171792,0.002264257,0.00012392637,0.057369974,0.007985932,0.4912469,0.052397925,0.00737201,0.02449204],"study_design_scores_gemma":[0.03489181,0.028318224,0.3909555,0.0025245268,0.00059313513,0.0006943305,0.0037955982,0.01476924,0.4846139,0.037974913,0.00042330337,0.00044551294],"about_ca_topic_score_codex":0.00017686076,"about_ca_topic_score_gemma":0.00009907024,"teacher_disagreement_score":0.097088985,"about_ca_system_score_codex":0.00010176534,"about_ca_system_score_gemma":0.00021220416,"threshold_uncertainty_score":0.23179355},"labels":[],"label_agreement":null},{"id":"W4402704903","doi":"10.1016/j.annonc.2024.08.1709","title":"1628P Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.21844748114473406,"score_gpt":0.5138100927976443,"score_spread":0.2953626116529103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656534,0.00022080174,0.0000058386627,0.0021904323,0.00002736594,0.00045108204,0.000014365963,0.00006787584,0.00045687318],"genre_scores_gemma":[0.9989524,0.00013751908,0.000093941824,0.0006204241,0.00004503865,0.000059866055,0.000021410324,0.000010931626,0.00005845791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877644,0.00013845193,0.0004127513,0.00033074315,0.00010606127,0.00023553091],"domain_scores_gemma":[0.9988896,0.0006122639,0.00006768852,0.0001506741,0.00009963916,0.00018013445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036857475,0.00013227602,0.00040279992,0.00007311573,0.000030321635,0.000019046183,0.00009859348,0.00026592304,0.000039827006],"category_scores_gemma":[0.00019750869,0.00008752645,0.000061613995,0.00033589263,0.00047188348,0.00008298256,0.0000461146,0.00038539132,0.000004027197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032920665,0.0008808956,0.96825796,0.00005902631,0.00008675669,0.000048518134,0.00012491137,0.0000029647795,0.0009677317,0.000052131694,0.00013475916,0.026092289],"study_design_scores_gemma":[0.0015871242,0.0050668735,0.9813592,0.00009716032,0.000039577328,0.0000081848775,0.000054987195,0.00004252135,0.0035679515,0.0000935837,0.007987798,0.0000950553],"about_ca_topic_score_codex":0.000027416881,"about_ca_topic_score_gemma":0.000002307883,"teacher_disagreement_score":0.025997233,"about_ca_system_score_codex":0.000021137945,"about_ca_system_score_gemma":0.00014553385,"threshold_uncertainty_score":0.3569225},"labels":[],"label_agreement":null},{"id":"W4402704907","doi":"10.1016/j.annonc.2024.08.1685","title":"1604P PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Radioligand; Internal medicine; Chemotherapy; Urology; Androgen receptor; Cancer; Receptor","score_opus":0.07466563848155026,"score_gpt":0.3938245005664609,"score_spread":0.3191588620849106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97345245,0.013452608,0.000007913836,0.008097918,0.00031594982,0.0036714058,0.0003773438,0.00011542139,0.0005090032],"genre_scores_gemma":[0.98604155,0.008872265,0.00044212682,0.0016193906,0.00015941971,0.0011047573,0.00039653172,0.00014713104,0.0012168591],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955849,0.00036243015,0.0010029868,0.0009911482,0.00090615795,0.0011523794],"domain_scores_gemma":[0.99778974,0.00034111127,0.0003635126,0.00052338943,0.0005984806,0.0003837603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069519714,0.00066160894,0.0014526581,0.00065130746,0.00014700255,0.000091834445,0.00025201074,0.00023836504,0.00036454567],"category_scores_gemma":[0.000063662425,0.00045829578,0.00019643895,0.0009817638,0.0005445479,0.00032236587,0.00004320433,0.0006577027,0.000032158325],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26266104,0.0152847795,0.07278562,0.004351978,0.008896072,0.0072348933,0.034513604,0.0012223424,0.19469935,0.00022586551,0.032376803,0.36574766],"study_design_scores_gemma":[0.09247048,0.08603698,0.13864063,0.004259539,0.0005990355,0.00011830633,0.0014409341,0.0013660033,0.6148589,0.0006303695,0.057835884,0.0017429049],"about_ca_topic_score_codex":0.000969064,"about_ca_topic_score_gemma":0.001100799,"teacher_disagreement_score":0.42015958,"about_ca_system_score_codex":0.0007683076,"about_ca_system_score_gemma":0.002399358,"threshold_uncertainty_score":0.99978685},"labels":[],"label_agreement":null},{"id":"W4402704908","doi":"10.1016/j.annonc.2024.08.1741","title":"1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EMD Serono; Genentech; Astellas Pharma; Moderna; Jounce Therapeutics; SK Life Science; Incyte; MacroGenics; Aptitude Health; AbbVie; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Antibody-drug conjugate; Conjugate; Internal medicine; Antibody; Cancer; Monoclonal antibody; Immunology","score_opus":0.05999168936279459,"score_gpt":0.41973923162184845,"score_spread":0.35974754225905387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941017,0.0013495814,0.0000011914246,0.001312497,0.00010484831,0.0018606383,0.00013147632,0.000017371423,0.0011206941],"genre_scores_gemma":[0.998083,0.00050472515,0.00009455096,0.00007666318,0.000025731451,0.0002430517,0.00010406734,0.000028830222,0.0008393954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978865,0.00017186732,0.00067082635,0.00040272644,0.00042117518,0.00044690463],"domain_scores_gemma":[0.99897,0.00017590262,0.00016726235,0.0002331366,0.0003460048,0.00010772649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058236095,0.00020659526,0.00073857466,0.0004356562,0.000049446702,0.000016273467,0.00009219912,0.00006000534,0.00015830285],"category_scores_gemma":[0.00003892461,0.00014772947,0.000049819326,0.00068913127,0.00015129698,0.00015258121,0.00005022046,0.00027280895,0.0000041425506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019038215,0.022634609,0.88938785,0.0044982675,0.0025936696,0.0044676503,0.030548116,0.0016032662,0.0108115375,0.0009153934,0.003921532,0.009579884],"study_design_scores_gemma":[0.057332214,0.07502158,0.8326052,0.004015326,0.000797898,0.000030237894,0.0075666234,0.0007973275,0.011014956,0.0009116574,0.009219953,0.0006870449],"about_ca_topic_score_codex":0.0070209503,"about_ca_topic_score_gemma":0.008774845,"teacher_disagreement_score":0.056782678,"about_ca_system_score_codex":0.00018735882,"about_ca_system_score_gemma":0.0009213887,"threshold_uncertainty_score":0.9995914},"labels":[],"label_agreement":null},{"id":"W4402704916","doi":"10.1016/j.annonc.2024.08.1732","title":"1651P Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Gerontology; Demography; Family medicine; Oncology","score_opus":0.07012401704931298,"score_gpt":0.4274231976884535,"score_spread":0.3572991806391405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982447,0.00023206575,0.000008436491,0.00025196062,0.00004076843,0.00067046547,0.00012267039,0.000030414092,0.00039854544],"genre_scores_gemma":[0.9992664,0.00020314152,0.000060693335,0.0000747444,0.000051740688,0.00014620186,0.000066814566,0.000016152404,0.00011412079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908507,0.00006199166,0.0003005655,0.0002391304,0.00014574925,0.00016747185],"domain_scores_gemma":[0.9991016,0.00025632815,0.00014401795,0.00017994698,0.00021331217,0.00010481033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015636382,0.00012404981,0.0005249221,0.0000450379,0.000020059193,0.000008568837,0.00010852139,0.00012341735,0.000029660652],"category_scores_gemma":[0.00006633405,0.00009227699,0.000054500608,0.0002527318,0.00037881595,0.00006799034,0.00003053995,0.00016604281,0.0000013139804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008279936,0.0031839553,0.75381505,0.005371685,0.0006370284,0.00017560791,0.00071191386,0.000005624843,0.027145365,0.0001280188,0.00027665458,0.20026913],"study_design_scores_gemma":[0.0015677641,0.0025909604,0.872032,0.00062793476,0.00013879221,0.00001150914,0.000030982468,0.00004229345,0.11950224,0.00002522496,0.0033416864,0.00008864476],"about_ca_topic_score_codex":0.00005451063,"about_ca_topic_score_gemma":0.0000020469013,"teacher_disagreement_score":0.20018049,"about_ca_system_score_codex":0.00001129288,"about_ca_system_score_gemma":0.00010884013,"threshold_uncertainty_score":0.37629464},"labels":[],"label_agreement":null},{"id":"W4402704918","doi":"10.1016/j.annonc.2024.08.1722","title":"1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Abiraterone; Urology; Cancer; Androgen receptor","score_opus":0.1336092074318502,"score_gpt":0.4620167032676954,"score_spread":0.32840749583584516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876314,0.0015737598,0.000010076298,0.0076652584,0.00014619275,0.002279102,0.0001491863,0.000019914927,0.0005251212],"genre_scores_gemma":[0.9978678,0.00046191702,0.000391113,0.00017227362,0.000030870815,0.000401913,0.000157307,0.000024268451,0.000492504],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99799466,0.00021657375,0.0006607667,0.00033421195,0.00039183276,0.00040194855],"domain_scores_gemma":[0.9989923,0.00023337734,0.00014584485,0.00018186019,0.00030968475,0.0001369263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007707154,0.00018601703,0.0007909868,0.0006896222,0.00003239728,0.0000134651245,0.00009377722,0.00007800879,0.00009342755],"category_scores_gemma":[0.00010855927,0.00014117938,0.00006850424,0.00096030853,0.00015705547,0.00014075957,0.00004079205,0.00023242536,0.000004517485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66074705,0.01934635,0.0063925707,0.0021616158,0.001398626,0.004142016,0.0213371,0.00088667247,0.14810775,0.0013886939,0.004002083,0.13008946],"study_design_scores_gemma":[0.5539202,0.16047025,0.030155212,0.0034997908,0.0006948819,0.00008108243,0.0036424443,0.003051323,0.22325754,0.0022243073,0.018190615,0.0008123093],"about_ca_topic_score_codex":0.003491159,"about_ca_topic_score_gemma":0.010151672,"teacher_disagreement_score":0.1411239,"about_ca_system_score_codex":0.0002648721,"about_ca_system_score_gemma":0.0014672097,"threshold_uncertainty_score":0.5757128},"labels":[],"label_agreement":null},{"id":"W4402704931","doi":"10.1016/j.annonc.2024.08.1697","title":"1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; U.S. Army; EMD Serono; Genentech; National Institutes of Health; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cilag; Astellas Pharma; Eisai; Prostate Cancer Foundation; Bristol-Myers Squibb; Eli Lilly and Company; UK Research and Innovation; AstraZeneca; American Society of Clinical Oncology; Ipsen; Peter MacCallum Cancer Centre; University of New South Wales; BeiGene; Sanofi; Amgen; Pfizer; Prostate Cancer UK","keywords":"Medicine; Prostate cancer; Lutetium; Oncology; Cancer; Nuclear medicine; Prostate; Cancer research; Internal medicine","score_opus":0.1693996611291912,"score_gpt":0.4659190459110379,"score_spread":0.2965193847818467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866534,0.0025298728,0.000011443577,0.0055092988,0.00010387095,0.002489496,0.00012132321,0.000033908145,0.00053544325],"genre_scores_gemma":[0.9983009,0.0003218436,0.00030861192,0.00012071209,0.000053379656,0.00039511753,0.000037667633,0.00004414222,0.00041762678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968222,0.0005764618,0.00077334314,0.00055128266,0.00071605423,0.00056065124],"domain_scores_gemma":[0.9983815,0.0003357925,0.00023561246,0.0002535685,0.00054654223,0.00024700342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020668795,0.00028867176,0.00089339213,0.00064350304,0.00007569858,0.00003698111,0.00010357566,0.00005046902,0.00007591497],"category_scores_gemma":[0.00034156945,0.0002174212,0.00009809826,0.00070330227,0.00022072787,0.00016467705,0.0000579955,0.0002468567,0.0000033341273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6071837,0.001237583,0.0031366146,0.0010175536,0.0009220087,0.003943122,0.0053343647,0.00047968322,0.3431744,0.000021791906,0.00024872695,0.033300474],"study_design_scores_gemma":[0.58986735,0.08235638,0.052657764,0.007501961,0.0025024088,0.000981924,0.004299011,0.01517004,0.23977995,0.00033464708,0.0033012764,0.0012473039],"about_ca_topic_score_codex":0.00091349875,"about_ca_topic_score_gemma":0.0005595055,"teacher_disagreement_score":0.10339445,"about_ca_system_score_codex":0.0004898853,"about_ca_system_score_gemma":0.003033057,"threshold_uncertainty_score":0.88661796},"labels":[],"label_agreement":null},{"id":"W4402704938","doi":"10.1016/j.annonc.2024.08.1719","title":"1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of British Columbia","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Post-hoc analysis; Internal medicine; Cancer; Gynecology","score_opus":0.030439442080964475,"score_gpt":0.37673672785490003,"score_spread":0.34629728577393554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895913,0.004988506,0.00001383917,0.003106336,0.00008602417,0.0011805246,0.0005750607,0.000056870194,0.00040153356],"genre_scores_gemma":[0.9899846,0.006345313,0.000362849,0.00051698595,0.00006469738,0.00033845287,0.00062476704,0.00005613598,0.0017062288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732393,0.00015872126,0.00053114805,0.0007131931,0.0005862249,0.00068680523],"domain_scores_gemma":[0.99848,0.00014977097,0.00022224033,0.00037390794,0.00049237086,0.0002817126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036656164,0.00034768923,0.0010441116,0.00060038,0.00005762083,0.000032886608,0.0001762956,0.0001920081,0.000169363],"category_scores_gemma":[0.00006280763,0.00019918996,0.00013799517,0.0016018718,0.00054828177,0.00013256645,0.000075217344,0.000519327,0.000012023715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073078476,0.002815467,0.7307641,0.0007777824,0.0062235417,0.0012170384,0.0026494234,0.000059137175,0.003185495,0.000023475885,0.013301825,0.16590427],"study_design_scores_gemma":[0.078281924,0.25603098,0.3767712,0.006165306,0.0120970905,0.00009588684,0.0019326329,0.0011025176,0.158484,0.00038720897,0.10579733,0.0028539165],"about_ca_topic_score_codex":0.0016536806,"about_ca_topic_score_gemma":0.0031347345,"teacher_disagreement_score":0.35399285,"about_ca_system_score_codex":0.0003598354,"about_ca_system_score_gemma":0.001146157,"threshold_uncertainty_score":0.8122731},"labels":[],"label_agreement":null},{"id":"W4402704941","doi":"10.1016/j.annonc.2024.08.1714","title":"1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Bavarian Nordic; Merck KGaA; Pfizer; CMC Microsystems; National Cancer Institute; National Institutes of Health","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Pathology; Alternative medicine; Androgen receptor","score_opus":0.056709507383788174,"score_gpt":0.4136443889298662,"score_spread":0.35693488154607805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986924,0.0011909417,0.000013771124,0.0019195135,0.00028601085,0.004995258,0.00043972436,0.00006162535,0.0012239474],"genre_scores_gemma":[0.9958949,0.0007978113,0.00013227024,0.0003331816,0.00008515317,0.0018120847,0.0002071322,0.000069081245,0.0006683911],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99648213,0.00026074186,0.001310475,0.00071992545,0.00069721317,0.0005295321],"domain_scores_gemma":[0.9980539,0.00027227763,0.00055580516,0.00049148616,0.0004124892,0.00021402678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005872595,0.00046507956,0.0013907144,0.00047678404,0.00008442792,0.000020412033,0.00014322587,0.0001305769,0.0004490283],"category_scores_gemma":[0.00007111927,0.0003619623,0.00015229864,0.00069375767,0.00027660237,0.00021326954,0.000040868596,0.00029955484,0.0000133509375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27373272,0.12399195,0.33149648,0.0032024751,0.014518792,0.005337562,0.06313686,0.010130857,0.026286565,0.0007673361,0.0075466363,0.13985178],"study_design_scores_gemma":[0.26892954,0.36122513,0.23387557,0.0031392418,0.0031553584,0.0001979318,0.00406398,0.0017161652,0.08491526,0.0006534488,0.036612947,0.0015154207],"about_ca_topic_score_codex":0.0047615273,"about_ca_topic_score_gemma":0.007430956,"teacher_disagreement_score":0.23723318,"about_ca_system_score_codex":0.0006802953,"about_ca_system_score_gemma":0.0013409898,"threshold_uncertainty_score":0.99988323},"labels":[],"label_agreement":null},{"id":"W4402704946","doi":"10.1016/j.annonc.2024.08.1698","title":"1617P Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Merck Sharp and Dohme; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia; Genentech; AstraZeneca; National Health and Medical Research Council; Amgen; Pfizer; Astellas Pharma; Peter MacCallum Cancer Centre","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Cancer","score_opus":0.24638739276222485,"score_gpt":0.4860402514209991,"score_spread":0.23965285865877425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869765,0.005240407,0.00007870486,0.0023475345,0.00019740104,0.0014707127,0.0018957034,0.0000194547,0.000052441348],"genre_scores_gemma":[0.97874635,0.018619914,0.000869629,0.00003187468,0.000040076528,0.00040913705,0.0001166064,0.000024134128,0.0011422575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850696,0.00032647874,0.00047514393,0.00028194452,0.0001541197,0.0002553478],"domain_scores_gemma":[0.998817,0.00057899294,0.00016265603,0.00013815075,0.00022544796,0.00007774993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010354266,0.00015093174,0.00052477064,0.00019534428,0.0000368524,0.000009215461,0.00003477592,0.00009076461,0.00004205722],"category_scores_gemma":[0.00010045416,0.00010521366,0.000094089715,0.00023500399,0.00012608434,0.000081230915,0.00001211664,0.000105716244,0.000001172709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11303781,0.0016240182,0.67221403,0.00082893786,0.0020738272,0.00033789442,0.009267222,0.00007782806,0.120909475,0.00012426129,0.00037325095,0.07913147],"study_design_scores_gemma":[0.02123653,0.017441014,0.8759121,0.00025505034,0.00037946578,0.00002648403,0.0006192109,0.0024680689,0.07633776,0.0005280688,0.0046399445,0.0001563015],"about_ca_topic_score_codex":0.0013319372,"about_ca_topic_score_gemma":0.0003954348,"teacher_disagreement_score":0.20369808,"about_ca_system_score_codex":0.0001803391,"about_ca_system_score_gemma":0.0006951857,"threshold_uncertainty_score":0.42904884},"labels":[],"label_agreement":null},{"id":"W4402748292","doi":"10.1016/j.annonc.2024.09.010","title":"Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Endocrine system; Oncology; Internal medicine; Genetic enhancement; Endocrinology; Gene; Hormone; Genetics","score_opus":0.20248340160230427,"score_gpt":0.425786403148013,"score_spread":0.22330300154570876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402748292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868577,0.009674806,0.000091548005,0.001782653,0.000039351162,0.0013671808,0.00014036796,0.00002098868,0.000025373132],"genre_scores_gemma":[0.9930303,0.003712984,0.0023058986,0.000536933,0.00011399189,0.00014080499,0.00010865798,0.000034068136,0.00001635015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785197,0.00049744756,0.00079721137,0.00035724894,0.00018750632,0.000308634],"domain_scores_gemma":[0.99783754,0.0014591205,0.00026819317,0.0002259068,0.00014724208,0.000062002124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062246074,0.0002672406,0.0010549887,0.00030252867,0.00005012461,0.000015488096,0.00006845716,0.000046681555,0.000056409233],"category_scores_gemma":[0.00015083191,0.00014878892,0.00007418193,0.00040571205,0.00022944354,0.00013548204,0.000021936774,0.00009247946,1.8301985e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025497584,0.0019728956,0.13778643,0.00016900511,0.0011654398,0.0007164853,0.0067541087,0.0006780623,0.12973228,0.00016547859,0.000013769806,0.69534844],"study_design_scores_gemma":[0.14809765,0.061592955,0.43297228,0.0020898504,0.0006333649,0.002760687,0.0039624716,0.010380643,0.31595954,0.0013386715,0.019018201,0.0011936643],"about_ca_topic_score_codex":0.0011868487,"about_ca_topic_score_gemma":0.00042660724,"teacher_disagreement_score":0.6941548,"about_ca_system_score_codex":0.00014556483,"about_ca_system_score_gemma":0.0004022712,"threshold_uncertainty_score":0.6067436},"labels":[],"label_agreement":null},{"id":"W4403312202","doi":"10.1016/j.annonc.2024.10.002","title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Bevacizumab; Pembrolizumab; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Immunotherapy; Confidence interval","score_opus":0.13767327379298985,"score_gpt":0.4595266413385656,"score_spread":0.3218533675455757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403312202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97921616,0.00392378,0.00027420974,0.013432107,0.00022112807,0.002670375,0.000046618556,0.000022060678,0.00019356093],"genre_scores_gemma":[0.9945837,0.0017294282,0.00031351772,0.0020589514,0.0001452288,0.0010386619,0.000019218378,0.000016250477,0.00009504652],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982115,0.00027218144,0.0005407045,0.00041472868,0.00025520072,0.00030570076],"domain_scores_gemma":[0.99720937,0.0022135926,0.000096261865,0.00022178951,0.00014466484,0.000114328366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091221125,0.00019162253,0.0013717061,0.00048883853,0.000047337206,0.0000302957,0.00013240233,0.000094185096,0.000074857046],"category_scores_gemma":[0.00045473612,0.000116319694,0.00036943,0.0013034221,0.00006878807,0.0000784016,0.000044942888,0.00017974606,0.0000019175538],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43285415,0.0014344268,0.009189987,0.0002082401,0.0035103527,0.00010122107,0.0042566964,0.00017866823,0.00010177936,0.00027751358,0.0003800119,0.547507],"study_design_scores_gemma":[0.8372587,0.030262,0.08991333,0.00040040002,0.0076001505,0.000040334344,0.0041912077,0.004398299,0.00076199445,0.0014748325,0.023141306,0.0005574334],"about_ca_topic_score_codex":0.0008967696,"about_ca_topic_score_gemma":0.0012601421,"teacher_disagreement_score":0.5469495,"about_ca_system_score_codex":0.00015956057,"about_ca_system_score_gemma":0.00021798613,"threshold_uncertainty_score":0.47433797},"labels":[],"label_agreement":null},{"id":"W4403432450","doi":"10.1016/j.annonc.2024.10.006","title":"Lung cancer research and treatment: global perspectives and strategic calls to action","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Action (physics); Call to action; Cancer; Intensive care medicine; Oncology; Internal medicine; Marketing","score_opus":0.4288030712226979,"score_gpt":0.6514425563294657,"score_spread":0.2226394851067678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403432450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022958084,0.9821031,3.2377437e-7,0.002647002,0.0001275082,0.0010664087,0.00025225125,0.000014785866,0.011492776],"genre_scores_gemma":[0.001695988,0.9956611,0.000044977984,0.000046461828,0.0002196503,0.0003530551,0.00003378309,0.000017737557,0.0019272594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894017,0.00009381701,0.00022463643,0.00038787417,0.00012537182,0.00022815734],"domain_scores_gemma":[0.99931276,0.00009515853,0.00006927897,0.00013635548,0.00021545206,0.00017096825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013039215,0.00019202329,0.00093603466,0.00020107004,0.000058546153,0.00001986407,0.000034504552,0.00020972779,0.00004491595],"category_scores_gemma":[0.000016629263,0.00012506818,0.00010313026,0.00032803998,0.00014053105,0.000029042867,0.000040838335,0.00016046259,0.000009510659],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063834195,0.00026436843,0.000032230757,0.0046411282,0.0017082515,0.0000950206,0.00085035287,9.9547464e-8,0.0000012916075,0.0030283274,0.0024110968,0.986904],"study_design_scores_gemma":[0.000463161,0.0048852814,0.0000779643,0.0036918307,0.00305585,0.00013380978,0.0011163753,0.0000016211994,0.0000016080734,0.00053815154,0.9859337,0.00010063763],"about_ca_topic_score_codex":0.0012214202,"about_ca_topic_score_gemma":0.0005874445,"teacher_disagreement_score":0.98680335,"about_ca_system_score_codex":0.00078845135,"about_ca_system_score_gemma":0.0015955655,"threshold_uncertainty_score":0.5100132},"labels":[],"label_agreement":null},{"id":"W4403797757","doi":"10.1016/j.annonc.2024.07.638","title":"O5-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Daiichi-Sankyo; Kanazawa University","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Consensus conference; Clinical Oncology; Family medicine; Cancer; Gynecology","score_opus":0.07591772040298896,"score_gpt":0.4249526068402364,"score_spread":0.34903488643724745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403797757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71413386,0.037896615,0.00012561327,0.18254332,0.0035828764,0.0009222498,0.0004831222,0.00044387605,0.059868496],"genre_scores_gemma":[0.989284,0.0014473563,0.0012115459,0.00514893,0.0012504809,0.000119002405,0.000030403253,0.000073170864,0.0014351454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978468,0.00016490158,0.00061037665,0.000507667,0.0002500126,0.0006202864],"domain_scores_gemma":[0.99818057,0.0006701571,0.00022339723,0.00032986625,0.00036521355,0.00023081196],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047558366,0.00027075908,0.0008773978,0.00026274114,0.000071915216,0.000010845533,0.00016866604,0.00033377833,0.0011611962],"category_scores_gemma":[0.0001113939,0.00023941026,0.00020879814,0.0004428892,0.00057418837,0.000079652644,0.00010080772,0.00048305583,0.0001846733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017705283,0.00044587583,0.0034533103,0.00043004888,0.00079645327,0.0007040534,0.0011084062,0.0000686522,0.04596696,0.0019390637,0.012875117,0.93044156],"study_design_scores_gemma":[0.0024540364,0.0035457124,0.031279642,0.0007406476,0.0002648697,0.0031901489,0.0012983414,0.00025530634,0.0036021208,0.0014228071,0.9515885,0.00035787403],"about_ca_topic_score_codex":0.0009877436,"about_ca_topic_score_gemma":0.00088245526,"teacher_disagreement_score":0.9387134,"about_ca_system_score_codex":0.0003153081,"about_ca_system_score_gemma":0.0009795391,"threshold_uncertainty_score":0.99975187},"labels":[],"label_agreement":null},{"id":"W4403797847","doi":"10.1016/j.annonc.2024.07.648","title":"O10-4 Current status and future of patient and public involvement in pancreatic cancer clinical practice guidelines revision","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Pancreatic cancer; Cancer; Clinical Practice; Oncology; Family medicine; Internal medicine; Intensive care medicine","score_opus":0.1995314735182915,"score_gpt":0.4475051724952671,"score_spread":0.2479736989769756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403797847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6440278,0.33474,0.000025529385,0.018065091,0.0009325556,0.00018114499,0.00009515107,0.0000058443015,0.0019268716],"genre_scores_gemma":[0.5616634,0.43589908,0.0006528984,0.0014552114,0.0002824407,0.000015230665,0.0000053102194,0.000010449587,0.000015987744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979298,0.0000427566,0.0014245298,0.0003243818,0.000032098596,0.00024640476],"domain_scores_gemma":[0.99872005,0.0002457661,0.00056247745,0.00015010622,0.0002109716,0.00011064529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012114221,0.00011573274,0.0006374179,0.00021933476,0.000018688695,0.000024804624,0.00007137722,0.00013425124,0.000074075135],"category_scores_gemma":[0.000837369,0.00011342476,0.00006815466,0.00015532775,0.00012555302,0.00036916984,0.00008911178,0.00018057473,0.0000057451716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006854673,0.00017202085,0.081497565,0.00021319833,0.0000618824,0.0000033193428,0.000601212,0.000004426064,0.000001323859,0.06615585,0.008918644,0.842302],"study_design_scores_gemma":[0.00037849302,0.00077968906,0.02955454,0.00013697793,0.00001217392,0.0000017757366,0.00038228606,0.00026192726,0.0000074359104,0.0072327238,0.96114117,0.00011079385],"about_ca_topic_score_codex":0.00082945335,"about_ca_topic_score_gemma":0.000225515,"teacher_disagreement_score":0.9522225,"about_ca_system_score_codex":0.00006126453,"about_ca_system_score_gemma":0.00021016414,"threshold_uncertainty_score":0.46253273},"labels":[],"label_agreement":null},{"id":"W4405134544","doi":"10.1016/j.annonc.2024.10.567","title":"540P Topical steroids for the prevention of radiation dermatitis in breast cancer: A systematic review and network meta-analyses of randomised controlled trials","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Beijing Xisike Clinical Oncology Research Foundation","keywords":"Medicine; Meta-analysis; Systematic review; Breast cancer; Randomized controlled trial; Oncology; Dermatology; Cancer; MEDLINE; Internal medicine","score_opus":0.26998481920884543,"score_gpt":0.5216740800586899,"score_spread":0.25168926084984444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405134544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000057779025,0.97782075,0.00012544282,0.0037983079,0.00013925276,0.017922485,0.00015100854,0.0000054904363,0.000031474316],"genre_scores_gemma":[0.0003798012,0.9937754,0.0000885211,0.00044915781,0.00014497298,0.0049832677,0.000053348784,0.000019936446,0.00010554452],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99055713,0.0045479857,0.0042911633,0.0002175433,0.00023076563,0.00015539864],"domain_scores_gemma":[0.98287696,0.012011916,0.0044244365,0.0003194085,0.00032044944,0.00004683662],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009193168,0.00027920274,0.020265346,0.00023195671,0.000015392097,0.0000060507905,0.00013549863,0.0002912934,0.000069732996],"category_scores_gemma":[0.005752649,0.00013094103,0.003202706,0.00032444383,0.00007566248,0.000043088316,0.000024288174,0.0001782603,6.5136544e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057526486,0.00008938155,0.0000018612927,0.8402655,0.03271757,0.0000020685081,0.00003161402,0.000007970517,0.0000013628386,0.00010819083,0.005142736,0.121056475],"study_design_scores_gemma":[0.02448941,0.0012297599,0.000023324576,0.26579285,0.68784994,0.00008584617,0.000010959191,0.00013520641,0.0000074405198,0.00013484663,0.02009478,0.00014560425],"about_ca_topic_score_codex":0.000036693295,"about_ca_topic_score_gemma":0.00002835375,"teacher_disagreement_score":0.6551324,"about_ca_system_score_codex":0.000048290884,"about_ca_system_score_gemma":0.0005380402,"threshold_uncertainty_score":0.99427986},"labels":[],"label_agreement":null},{"id":"W4405134823","doi":"10.1016/j.annonc.2024.10.277","title":"259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nanoplatforms for cancer theranostics","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Irinotecan; Observational study; Regimen; Center (category theory); Oncology; Internal medicine; Pancreatic cancer; Cancer; Colorectal cancer","score_opus":0.042193193107854604,"score_gpt":0.3446164915814062,"score_spread":0.30242329847355165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405134823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996653,0.0005686102,0.00012864708,0.0001564891,0.00039647607,0.0011111301,0.00011136586,0.0001690333,0.00070524967],"genre_scores_gemma":[0.998194,0.00023947335,0.00085757463,0.000088737055,0.000050912575,0.00036468066,0.000045208675,0.00006417787,0.00009527351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986772,0.000031066767,0.00043203394,0.00029072733,0.00023708038,0.00033190582],"domain_scores_gemma":[0.9992702,0.00017163578,0.00008220129,0.00024253168,0.00016423024,0.00006920037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013405754,0.000246377,0.0004748244,0.0003242207,0.000026696021,0.000014768784,0.00017726654,0.00007200345,0.000025467996],"category_scores_gemma":[0.000030700714,0.00020294618,0.000056054785,0.0008130742,0.000056202098,0.00022750975,0.000027282631,0.00023693148,0.0000049793953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006275573,0.0019966802,0.9564053,0.00025416014,0.0002833815,0.000039308412,0.00089908094,0.01890374,0.00041920785,0.000052057112,0.00013079523,0.019988758],"study_design_scores_gemma":[0.009118576,0.0032104373,0.9728351,0.000429431,0.000045169567,6.500609e-7,0.000054836153,0.010362097,0.0007117606,0.00017193229,0.0027220745,0.0003379277],"about_ca_topic_score_codex":0.00048519834,"about_ca_topic_score_gemma":0.007719495,"teacher_disagreement_score":0.01965083,"about_ca_system_score_codex":0.0003872834,"about_ca_system_score_gemma":0.00023223655,"threshold_uncertainty_score":0.82759047},"labels":[],"label_agreement":null},{"id":"W4405134861","doi":"10.1016/j.annonc.2024.10.160","title":"135P Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; LG Chem; Kaohsiung Medical University; Eisai; Astellas Pharma; University of Manchester; Servier; Moderna; National Health Research Institutes; Yuhan; Tokyo Cooperative Oncology Group; Halozyme; Ipsen; Kaohsiung Medical University Chung-Ho Memorial Hospital; BeiGene; Mirati Therapeutics; Handok; Eli Lilly and Company; AstraZeneca; Celgene; Pfizer","keywords":"Medicine; Durvalumab; Chemotherapy; Biliary tract cancer; Topaz; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Gemcitabine; Astronomy; Geology","score_opus":0.06933144540916644,"score_gpt":0.4118499747647386,"score_spread":0.34251852935557214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405134861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97373915,0.020284146,0.000042876658,0.0041750334,0.00030274127,0.0008162602,0.0001530413,0.000026895415,0.0004598469],"genre_scores_gemma":[0.9899953,0.009214264,0.000023133822,0.00037370954,0.00016085841,0.00006651932,0.00003834793,0.000025864041,0.00010201192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796486,0.00020147845,0.00070086936,0.00052430574,0.0003117651,0.0002967239],"domain_scores_gemma":[0.99832284,0.0007416741,0.0001994242,0.0004733385,0.00018015518,0.000082557395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006606686,0.0002472696,0.0013474283,0.00025342798,0.00005790701,0.000011395562,0.00017899368,0.000121196375,0.00025647075],"category_scores_gemma":[0.00006280325,0.00017249928,0.00024684973,0.0008498025,0.00022034948,0.0000965037,0.000086449945,0.00028421642,0.0000013461888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009270295,0.0030278622,0.75599205,0.0001440973,0.005136966,0.00028493325,0.011007694,0.000048086076,0.0011222655,0.000024159308,0.0004160533,0.21352552],"study_design_scores_gemma":[0.013810975,0.0031933764,0.9775897,0.00011498999,0.0011546366,0.0000049869795,0.0023650124,0.00027140664,0.00037560007,0.000052027528,0.00090844574,0.00015880965],"about_ca_topic_score_codex":0.008442209,"about_ca_topic_score_gemma":0.054066893,"teacher_disagreement_score":0.22159767,"about_ca_system_score_codex":0.00009575452,"about_ca_system_score_gemma":0.00029872236,"threshold_uncertainty_score":0.99816066},"labels":[],"label_agreement":null},{"id":"W4405134893","doi":"10.1016/j.annonc.2024.10.365","title":"346P High genomic risk is associated with clinically significant prostate cancer (csPCa) recurrences following focal therapy (FT)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"Association of Schools and Colleges of Optometry","keywords":"Medicine; Prostate cancer; Oncology; Prostate; Internal medicine; Cancer; Urology","score_opus":0.11955148465602199,"score_gpt":0.45380816955871633,"score_spread":0.33425668490269433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405134893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731311,0.011199563,0.0000071090153,0.0129162,0.00044903893,0.00073974545,0.0001990517,0.0000800673,0.001278108],"genre_scores_gemma":[0.9557795,0.040986147,0.00011074626,0.00084613985,0.00016234077,0.0001531964,0.000057949503,0.000034680947,0.001869291],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979651,0.00022029967,0.0004907197,0.00046576138,0.00035780398,0.0005002912],"domain_scores_gemma":[0.9985719,0.0005878773,0.00019478396,0.00020893433,0.00026013455,0.000176413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009690624,0.00020359858,0.0006657674,0.0001442698,0.00008836898,0.0000266425,0.00014185955,0.00020176824,0.00028166588],"category_scores_gemma":[0.000119606346,0.00012686214,0.00022687994,0.00037407508,0.00027843355,0.000081144426,0.000040015442,0.0004676064,0.0000268681],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008861272,0.0011775292,0.24654375,0.00013504218,0.005368607,0.0013640876,0.0042356323,0.000016355625,0.0041182954,0.00006559882,0.027556956,0.7005569],"study_design_scores_gemma":[0.030482063,0.13229172,0.55273736,0.0038961892,0.0015613912,0.000036904137,0.0018486627,0.0011574295,0.041569326,0.006785644,0.22618403,0.0014493264],"about_ca_topic_score_codex":0.00068418763,"about_ca_topic_score_gemma":0.000094180235,"teacher_disagreement_score":0.6991075,"about_ca_system_score_codex":0.00015709458,"about_ca_system_score_gemma":0.0018054505,"threshold_uncertainty_score":0.5173288},"labels":[],"label_agreement":null},{"id":"W4405134957","doi":"10.1016/j.annonc.2024.10.152","title":"133O Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"College of Medicine, Seoul National University; Seoul National University Hospital; Fudan University; Yonsei University; Seoul St. Mary's Hospital, Catholic University of Korea; AstraZeneca; University of Ulsan; Seoul National University; Seoul National University Bundang Hospital; Cancer Research Institute","keywords":"Medicine; Gemcitabine; Chemotherapy; Internal medicine; Biliary tract cancer; Oncology","score_opus":0.044404432855636305,"score_gpt":0.3603843039205552,"score_spread":0.31597987106491887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405134957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98214054,0.0057731727,0.000015366266,0.010559118,0.00008355383,0.00069007964,0.00016169835,0.000010991792,0.0005654758],"genre_scores_gemma":[0.9941519,0.005154869,0.0002709744,0.00014720176,0.000033773664,0.000055969198,0.0000632865,0.000019164718,0.00010289508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99831724,0.000076320575,0.00090825045,0.0002712895,0.0002313931,0.00019551581],"domain_scores_gemma":[0.99873775,0.00035329125,0.0003381192,0.0002323035,0.00029690977,0.000041633633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038548012,0.00018158404,0.0008939379,0.0003872993,0.000011703148,0.0000011459355,0.00007072414,0.00012502634,0.000058436726],"category_scores_gemma":[0.000078063575,0.0001370225,0.00012142875,0.0005111595,0.0001686667,0.00006723086,0.000018437424,0.00012347309,4.100717e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06216974,0.010379498,0.32383066,0.0022938894,0.0006765877,0.000240142,0.011962259,0.0032799463,0.034340013,0.00009047391,0.00073213794,0.55000466],"study_design_scores_gemma":[0.02750273,0.022521205,0.87023455,0.0014903992,0.00008926349,0.0000048828683,0.00024717886,0.00072752713,0.07380884,0.000043909287,0.003203523,0.00012599313],"about_ca_topic_score_codex":0.0038009025,"about_ca_topic_score_gemma":0.004615424,"teacher_disagreement_score":0.54987866,"about_ca_system_score_codex":0.00017280233,"about_ca_system_score_gemma":0.00044663978,"threshold_uncertainty_score":0.5745853},"labels":[],"label_agreement":null},{"id":"W4405135012","doi":"10.1016/j.annonc.2024.10.404","title":"383P Next-generation sequencing-based assay for detection of human papillomavirus in clinical samples","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Human papillomavirus; Hybrid capture; DNA sequencing; Computational biology; Virology; Oncology; Genetics; Internal medicine; DNA; Cancer; Cervical cancer; Cervical intraepithelial neoplasia; Biology","score_opus":0.259314132068324,"score_gpt":0.4597562004208395,"score_spread":0.2004420683525155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405135012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92905855,0.0008485518,0.06871059,0.00054650253,0.00010276906,0.0003625202,0.000048835896,0.000016636477,0.000305027],"genre_scores_gemma":[0.9962772,0.00022327492,0.002486074,0.00041930444,0.00015547122,0.00014159342,0.00025426116,0.000013037151,0.000029785308],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989101,0.00015903158,0.00047653628,0.00027791885,0.000041816318,0.00013458799],"domain_scores_gemma":[0.9994341,0.00007312314,0.00013143384,0.00020960673,0.00012242633,0.000029276263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009167054,0.00008764285,0.0002124096,0.00008123003,0.00003013149,0.0000050563312,0.00010892505,0.00034426295,0.0000060389416],"category_scores_gemma":[0.00014642961,0.0000847486,0.00016468894,0.000091651105,0.00013031474,0.0000029338105,0.000027831227,0.00008441789,7.251405e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042005544,0.00008802606,0.00033802356,0.000031947155,0.000027942182,0.0000010102143,0.000007782321,0.0000308757,0.9458489,0.0013255209,0.000831791,0.051426217],"study_design_scores_gemma":[0.0002451984,0.002506954,0.00055592146,0.000015387712,0.000014713824,0.0000025526979,0.000010669266,0.0011714335,0.9396364,0.0008586732,0.054900113,0.00008196814],"about_ca_topic_score_codex":0.000070521935,"about_ca_topic_score_gemma":0.00040533513,"teacher_disagreement_score":0.06721863,"about_ca_system_score_codex":0.000013315574,"about_ca_system_score_gemma":0.00018532891,"threshold_uncertainty_score":0.34559476},"labels":[],"label_agreement":null},{"id":"W4405165478","doi":"10.1016/j.annonc.2024.10.645","title":"615P Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chemoradiotherapy; Oncology; Internal medicine; Overall survival","score_opus":0.0729573448425896,"score_gpt":0.4939715026471867,"score_spread":0.4210141578045971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943794,0.00044984944,0.00005366349,0.0018427558,0.00004766121,0.0009379573,0.00026627007,0.000026251095,0.0019961766],"genre_scores_gemma":[0.998047,0.0007069701,0.00017312072,0.00021817423,0.000031112904,0.00006337093,0.00016453743,0.000015291065,0.00058042014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835086,0.00017619453,0.0006285953,0.00041868474,0.0001953508,0.00023033505],"domain_scores_gemma":[0.99893355,0.00036411354,0.00019439496,0.00022032092,0.00018113789,0.00010646186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023251909,0.00021394978,0.0012146153,0.00038197622,0.00003245854,0.000012841393,0.00005102005,0.00009507887,0.000079130805],"category_scores_gemma":[0.000018384775,0.00014416272,0.00021147927,0.0010588735,0.000115904004,0.00008287956,0.000015691763,0.00009184036,0.0000011294026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021653492,0.0046225996,0.9372675,0.00002937576,0.013065465,0.00059147837,0.00178014,0.000066218294,0.000016350341,0.000098159355,0.00006447471,0.04023288],"study_design_scores_gemma":[0.009046068,0.021144234,0.9623777,0.00009541443,0.0054126256,0.000015439433,0.0010572795,0.00046298606,0.00015365898,0.000026753607,0.000100720645,0.00010708229],"about_ca_topic_score_codex":0.021789392,"about_ca_topic_score_gemma":0.041108232,"teacher_disagreement_score":0.040125795,"about_ca_system_score_codex":0.00045527256,"about_ca_system_score_gemma":0.00047221463,"threshold_uncertainty_score":0.9847246},"labels":[],"label_agreement":null},{"id":"W4405165483","doi":"10.1016/j.annonc.2024.10.670","title":"637P Taletrectinib vs repotrectinib in ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ROS1; Lung cancer; Matching (statistics); Internal medicine; Oncology; Cancer; Adenocarcinoma; Pathology","score_opus":0.05405829193496321,"score_gpt":0.4310774231623228,"score_spread":0.3770191312273596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9210202,0.009631273,0.00015527608,0.0057027405,0.0012054663,0.0011706225,0.00013540812,0.00012805895,0.060850915],"genre_scores_gemma":[0.9926172,0.00067933305,0.00055720535,0.0011517355,0.00023822168,0.0002760411,0.00010978313,0.000055654582,0.004314814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.00014593558,0.0006836631,0.0005532982,0.00021129723,0.00048115972],"domain_scores_gemma":[0.9986888,0.00040263167,0.0002584457,0.00026763757,0.0002171118,0.00016536859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034608465,0.00028169178,0.00093612936,0.00045714734,0.000078731246,0.00002750296,0.00011386366,0.00026764398,0.00024275483],"category_scores_gemma":[0.000061875944,0.00024792505,0.000213745,0.0007024082,0.000098996585,0.000105715124,0.000058901063,0.0005062,0.000029653249],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004593017,0.007584261,0.33660498,0.0032449951,0.004536679,0.004783165,0.08673579,0.0010248075,0.021994026,0.00039629283,0.12557773,0.40292427],"study_design_scores_gemma":[0.021119349,0.018677903,0.58872944,0.008424272,0.005255525,0.00075092557,0.008976592,0.009610936,0.18949665,0.00063730363,0.146427,0.0018941023],"about_ca_topic_score_codex":0.004556725,"about_ca_topic_score_gemma":0.0030336995,"teacher_disagreement_score":0.40103015,"about_ca_system_score_codex":0.00041323432,"about_ca_system_score_gemma":0.0012134648,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4405165604","doi":"10.1016/j.annonc.2024.10.580","title":"554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Supine position; Meta-analysis; Radiation therapy; Prone position; Oncology; Medical physics; Surgery; Internal medicine","score_opus":0.18378457511548976,"score_gpt":0.5009385971650505,"score_spread":0.3171540220495608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012720285,0.9946726,0.000025873705,0.0007935964,0.00002961585,0.003077664,0.0012532497,0.0000049968608,0.000015223026],"genre_scores_gemma":[0.0009845827,0.9961584,0.0005207017,0.0005074964,0.000023051693,0.0012850075,0.00043917607,0.00003504909,0.00004653774],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99710804,0.0004922663,0.0016568879,0.00046688566,0.000099097146,0.00017684407],"domain_scores_gemma":[0.99823916,0.00022768401,0.00088165636,0.00035037892,0.00024674257,0.000054375298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071007136,0.0003360481,0.008240617,0.00020554561,0.000013916566,0.000004428704,0.00014906425,0.0002177281,0.000006111726],"category_scores_gemma":[0.00018603518,0.00021209335,0.0020125064,0.00031335538,0.00006942071,0.0000025770528,0.000093117815,0.000071530114,6.5116734e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085400454,0.0007819215,0.00081238436,0.62659895,0.3450903,0.0000023956975,0.000052825268,0.0000012772424,8.183788e-7,0.000012217634,0.0009510157,0.02561045],"study_design_scores_gemma":[0.0007994619,0.0018233701,0.0013750391,0.015054252,0.96638983,0.000019187059,0.000013760845,0.0000017075441,0.0000031472914,0.000008249067,0.014181384,0.00033059018],"about_ca_topic_score_codex":0.000056584384,"about_ca_topic_score_gemma":0.00016198227,"teacher_disagreement_score":0.62129956,"about_ca_system_score_codex":0.00003414907,"about_ca_system_score_gemma":0.0001064377,"threshold_uncertainty_score":0.8648916},"labels":[],"label_agreement":null},{"id":"W4405165611","doi":"10.1016/j.annonc.2024.10.674","title":"641P METRIX: International real-world study of c-Met protein overexpression in patients with non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Aptitude Health; AbbVie","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine; Lung; Cancer research; Pathology","score_opus":0.01963518923088559,"score_gpt":0.33948843169807186,"score_spread":0.31985324246718627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99399054,0.0007979914,0.00001668127,0.00006985598,0.00039266548,0.000573767,0.00006319942,0.000004296621,0.004091031],"genre_scores_gemma":[0.9978327,0.0007226828,0.000170861,0.00006479615,0.0002827356,0.000103213875,0.000047503905,0.000017644259,0.00075785554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990029,0.000070915215,0.0002990787,0.00029545743,0.00016204231,0.00016960359],"domain_scores_gemma":[0.99939674,0.000017147462,0.00015401175,0.00019160613,0.00019675524,0.000043727654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001862025,0.00012163346,0.00026025958,0.00021177439,0.000012939933,0.0000062136382,0.00018475618,0.00010180946,0.000043369626],"category_scores_gemma":[0.000020420774,0.00010026599,0.000055803437,0.00021069274,0.00003932661,0.0000071395098,0.00011483534,0.00010640789,6.357902e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028423767,0.0044984566,0.2829409,0.00043076053,0.00055769493,0.000009704195,0.0014325519,0.00045245164,0.62740093,0.00006632821,0.014618066,0.06474979],"study_design_scores_gemma":[0.0072853426,0.007608565,0.2952442,0.0006009465,0.000089295194,7.451622e-7,0.00033780176,0.00009295834,0.48709583,0.000028646593,0.2012218,0.00039385958],"about_ca_topic_score_codex":0.0011589109,"about_ca_topic_score_gemma":0.0015204735,"teacher_disagreement_score":0.18660372,"about_ca_system_score_codex":0.00002294989,"about_ca_system_score_gemma":0.00024317425,"threshold_uncertainty_score":0.40887284},"labels":[],"label_agreement":null},{"id":"W4405165722","doi":"10.1016/j.annonc.2024.10.596","title":"570P NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Balanced scorecard; Nano-; Medical physics; Radiology; Nuclear medicine","score_opus":0.15775853789446237,"score_gpt":0.4980222459106157,"score_spread":0.34026370801615335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991194,0.00070974464,0.0009738447,0.0044057807,0.00038872752,0.0011322593,0.0005498696,0.000030645075,0.0006151463],"genre_scores_gemma":[0.98960745,0.00013756679,0.008656298,0.0007460703,0.00010245279,0.00007614771,0.00057054026,0.000022560254,0.00008090886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985061,0.00022028905,0.00053478207,0.00027622338,0.00023926406,0.0002233282],"domain_scores_gemma":[0.9982759,0.0007482908,0.00019048361,0.00031576637,0.00035965003,0.000109945744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011267486,0.00014388177,0.0006337126,0.000087529515,0.00004278542,0.000008475529,0.0001040352,0.00008453714,0.00018105253],"category_scores_gemma":[0.000059197722,0.00007534976,0.00023135684,0.00016953802,0.00024093218,0.00006632282,0.000038594615,0.00013488637,0.0000021956932],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005294669,0.009137527,0.16625752,0.00039944216,0.009888062,0.00013162447,0.00035507875,0.00007707394,0.00020796376,0.00794555,0.06074632,0.7395592],"study_design_scores_gemma":[0.009785906,0.09032403,0.37481266,0.00018400783,0.0037495429,0.000026381022,0.0003817431,0.00087796606,0.0027388239,0.00039321327,0.516482,0.00024375525],"about_ca_topic_score_codex":0.000035605684,"about_ca_topic_score_gemma":0.000024240924,"teacher_disagreement_score":0.7393154,"about_ca_system_score_codex":0.000025237247,"about_ca_system_score_gemma":0.00048651014,"threshold_uncertainty_score":0.3072674},"labels":[],"label_agreement":null},{"id":"W4405287327","doi":"10.1016/j.annonc.2024.12.003","title":"Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai Incorporated; EMD Serono; Genentech; Institut Servier; Ipsen; Eisai; Incyte; Deciphera Pharmaceuticals; Harvard Medical School; Gilead Sciences; Exelixis; Servier; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Dana-Farber Cancer Institute; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Biomarker; Oncology; Internal medicine; Kidney cancer; Cancer; Immunotherapy; Sorafenib; Hepatocellular carcinoma","score_opus":0.23151620533878947,"score_gpt":0.45991423637376444,"score_spread":0.22839803103497497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405287327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96206856,0.009995644,0.000028719036,0.0037058669,0.0007534166,0.0018565534,0.00008538864,0.000051874587,0.02145398],"genre_scores_gemma":[0.99723285,0.0006369642,0.00027450826,0.00047962324,0.0002660399,0.0002235842,0.00031631463,0.000046503752,0.000523599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965575,0.000957564,0.0011205341,0.00052765134,0.00038199153,0.00045477902],"domain_scores_gemma":[0.99398977,0.004789716,0.00031292043,0.0005630356,0.00018311979,0.00016141927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011152806,0.00033238137,0.0017171974,0.00033239834,0.00006667808,0.00002310912,0.00022653225,0.00023293376,0.0006221954],"category_scores_gemma":[0.0005321233,0.00021187593,0.00065958744,0.00054337725,0.00043525157,0.00010085415,0.00009105767,0.00038953248,0.000046461988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9499759,0.00080606906,0.000024904464,0.00005546661,0.0006232169,0.0011980766,0.001018967,0.00002815907,0.012424167,0.0001053525,0.0042290217,0.029510705],"study_design_scores_gemma":[0.9333586,0.010272285,0.00073924084,0.000121195466,0.00095218344,0.000026067024,0.0008229437,0.0010517553,0.03915396,0.00017104899,0.01313183,0.00019890422],"about_ca_topic_score_codex":0.0024817502,"about_ca_topic_score_gemma":0.0002486132,"teacher_disagreement_score":0.035164308,"about_ca_system_score_codex":0.00019463406,"about_ca_system_score_gemma":0.0008697519,"threshold_uncertainty_score":0.86400497},"labels":[],"label_agreement":null},{"id":"W4405386896","doi":"10.1016/j.annonc.2024.12.007","title":"Reply to Letter to the Editor regarding “Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies” by C. Zhang","year":2024,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.0710247705036185,"score_gpt":0.4095296044433488,"score_spread":0.3385048339397303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405386896","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033897877,0.005637175,0.00051649887,0.9548698,0.002519564,0.001937167,0.0003898016,0.000022665574,0.00020945749],"genre_scores_gemma":[0.00877881,0.0005481963,0.0010371585,0.9703851,0.016755588,0.0004848619,0.0002473942,0.00007083565,0.0016921052],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969615,0.00037860047,0.0009984811,0.0006996807,0.00047360166,0.00048814426],"domain_scores_gemma":[0.9961032,0.0023956622,0.00029036976,0.0005378102,0.00044804506,0.00022490569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018330903,0.00031103627,0.0013531909,0.00021820943,0.00006583546,0.000019661376,0.00020122594,0.00039051616,0.000017483344],"category_scores_gemma":[0.0039556995,0.00022808385,0.00024415113,0.00021476291,0.00013725342,0.00003825802,0.00024500888,0.00058637274,0.000017680764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051221874,0.00008536329,0.00017321696,0.0008866474,0.00046783258,0.00025925878,0.0004021344,0.000005047658,0.0024156389,0.0000053099093,0.9924029,0.0023844026],"study_design_scores_gemma":[0.00070620124,0.0055728415,0.0008542377,0.0006650647,0.000642764,0.0000052112828,0.000033507662,0.0000013268067,0.0053459792,0.000090737725,0.9858758,0.00020634788],"about_ca_topic_score_codex":0.00006175662,"about_ca_topic_score_gemma":0.0000058575974,"teacher_disagreement_score":0.025119066,"about_ca_system_score_codex":0.000089438436,"about_ca_system_score_gemma":0.00033434987,"threshold_uncertainty_score":0.93009895},"labels":[],"label_agreement":null},{"id":"W4405506971","doi":"10.1016/j.annonc.2024.12.010","title":"Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; Lombardi Comprehensive Cancer Center, Georgetown University; Campbell Family Mental Health Research Institute; Samsung; National Institutes of Health; Fondation contre le Cancer; Fondation Rose et Jean Hoguet; Stichting Tegen Kanker; Celltrion; Eisai; Fonds De La Recherche Scientifique - FNRS; Fonds National de la Recherche Luxembourg; Genentech; Veracyte; Seagen; Les Laboratories Pierre Fabre; NSABP Foundation; Queen Mary University of London; Clovis Oncology; Susan G. Komen; Baxalta; Breast Cancer Research Foundation; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Bayer HealthCare; European Commission; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company; AstraZeneca; GlaxoSmithKline","keywords":"Medicine; Breast cancer; Neoadjuvant therapy; Oncology; Minimal residual disease; Internal medicine; Disease; Cancer","score_opus":0.013255413651988795,"score_gpt":0.3053748758639135,"score_spread":0.2921194622119247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405506971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898395,0.006252054,0.00000277417,0.002783654,0.00006286761,0.000371364,0.0006545767,0.0000052996493,0.000027923796],"genre_scores_gemma":[0.9976809,0.0018160574,0.000042206346,0.000074714015,0.000094812705,0.00018552088,0.00006628523,0.000015226865,0.000024253957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991336,0.00011918492,0.00015516805,0.00031399075,0.00006959658,0.00020846356],"domain_scores_gemma":[0.99955374,0.000056004363,0.000087714136,0.00015334821,0.00009748458,0.0000517188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056068024,0.00015988734,0.00024182629,0.000057189565,0.000044017088,0.0000045477623,0.00007009159,0.00007921055,0.000004822425],"category_scores_gemma":[0.0000128562415,0.00009427744,0.000035610778,0.00007462127,0.00024423326,0.000004783366,0.0000993771,0.00004485015,3.49291e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026707202,0.0005384638,0.9555554,0.00007317644,0.0004068646,0.000024148954,0.0007484388,0.000033384407,0.021215139,0.000030987372,0.00006456599,0.018638754],"study_design_scores_gemma":[0.0011551919,0.0024022,0.94439644,0.00015438488,0.00007624832,0.0000053914814,0.0000507573,0.0000022281185,0.051409245,0.000030965934,0.0002253351,0.00009162129],"about_ca_topic_score_codex":0.00065693643,"about_ca_topic_score_gemma":0.0004209961,"teacher_disagreement_score":0.030194106,"about_ca_system_score_codex":0.000034288347,"about_ca_system_score_gemma":0.00012547294,"threshold_uncertainty_score":0.38445225},"labels":[],"label_agreement":null},{"id":"W4406410185","doi":"10.1016/j.annonc.2024.12.005","title":"ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Society for Medical Oncology","keywords":"Medicine; Cancer; Cancer drugs; Environmental health; Internal medicine","score_opus":0.10725535700326713,"score_gpt":0.4019771745821707,"score_spread":0.2947218175789036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406410185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93178904,0.0045983014,0.000032656975,0.009615204,0.0007855419,0.00047770428,0.0005381299,0.0000057670254,0.05215768],"genre_scores_gemma":[0.9951338,0.0017975827,0.000015094799,0.0027974192,0.000044527224,0.000033941687,0.0000026034993,0.000005551294,0.00016946325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816513,0.00006752184,0.0011358191,0.0003661125,0.00003856266,0.0002268348],"domain_scores_gemma":[0.9980263,0.00037045035,0.0008934419,0.00047211803,0.00018328073,0.000054382443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015888575,0.00014760895,0.0009216624,0.000101744285,0.00004681609,0.000008671225,0.00035942864,0.00014360515,0.0005109698],"category_scores_gemma":[0.00076951104,0.00012363816,0.00009979723,0.00022743232,0.0005875239,0.00010552573,0.00015759563,0.00013628668,0.000015427011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031973372,0.0006032954,0.90791583,0.0000708926,0.00024425908,0.0000010098275,0.0002911184,0.000006562541,0.000008196461,0.056882072,0.015880229,0.017776784],"study_design_scores_gemma":[0.0010783082,0.0010730113,0.92733043,0.000048686685,0.000030915646,1.9036138e-7,0.0005553716,0.000030345873,0.0003501922,0.037218418,0.03216639,0.000117704214],"about_ca_topic_score_codex":0.0025079693,"about_ca_topic_score_gemma":0.002166048,"teacher_disagreement_score":0.06334481,"about_ca_system_score_codex":0.00011111132,"about_ca_system_score_gemma":0.0002378871,"threshold_uncertainty_score":0.5594761},"labels":[],"label_agreement":null},{"id":"W4407393534","doi":"10.1016/j.annonc.2025.01.009","title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis; Pfizer","keywords":"Medicine; Metastatic breast cancer; Chemotherapy; Oncology; Breast cancer; Internal medicine; Hormone receptor; Cancer; HER2 negative; Mammary gland","score_opus":0.0593424706167068,"score_gpt":0.39717629210244715,"score_spread":0.33783382148574037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407393534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562943,0.003057479,0.0003345624,0.034593422,0.0005614388,0.0031345778,0.0011128363,0.000090726986,0.00082065235],"genre_scores_gemma":[0.9812277,0.006471612,0.0013372825,0.006195905,0.0005680977,0.0008319481,0.00039883278,0.000105160696,0.0028634844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954457,0.0009889703,0.0012404973,0.0009207588,0.00048773768,0.00091629516],"domain_scores_gemma":[0.9962773,0.0014819285,0.00063178374,0.0007826153,0.0006002907,0.00022610032],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065568753,0.00064858585,0.0020342658,0.0002749673,0.00018665279,0.000036358862,0.0005446753,0.00021324445,0.0028085562],"category_scores_gemma":[0.00025412597,0.0004574171,0.00029350907,0.001010145,0.0006332976,0.00033463322,0.00014367337,0.0007715566,0.000019980685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6060981,0.00575943,0.0036125523,0.000115381445,0.0033433188,0.00030997305,0.0025945723,0.000106732106,0.0063042217,0.0003287418,0.011513049,0.35991395],"study_design_scores_gemma":[0.7029072,0.020715771,0.098038,0.0023997729,0.0015012175,0.0003500876,0.0037012915,0.0005402474,0.037069324,0.003379797,0.12777662,0.001620676],"about_ca_topic_score_codex":0.03199148,"about_ca_topic_score_gemma":0.0064133657,"teacher_disagreement_score":0.35829327,"about_ca_system_score_codex":0.00065398886,"about_ca_system_score_gemma":0.0021988736,"threshold_uncertainty_score":0.99978775},"labels":[],"label_agreement":null},{"id":"W4407484999","doi":"10.1016/j.annonc.2025.01.017","title":"Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; University of Alberta; University Health Network; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; NRG Oncology; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; U.S. Department of Defense","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Internal medicine; Oncology; Randomized controlled trial; Androgen suppression; Prostate; Cancer","score_opus":0.05801730156321392,"score_gpt":0.4455645348332371,"score_spread":0.38754723327002316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407484999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94576186,0.012878117,0.000058458478,0.037458364,0.00013517622,0.003387777,0.00009270486,0.000009431607,0.00021809342],"genre_scores_gemma":[0.9860045,0.010277587,0.00013410441,0.0023810838,0.00006886303,0.0009160211,0.00003489812,0.000008709767,0.00017428906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971532,0.0015263429,0.00078239327,0.00021407566,0.00015532598,0.0001686538],"domain_scores_gemma":[0.99592394,0.003238073,0.00044658926,0.00017731739,0.00016348642,0.000050606242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058199577,0.00012965863,0.001124957,0.00027263514,0.000035463552,0.000008802512,0.00006234072,0.00012430114,0.00005062233],"category_scores_gemma":[0.001924737,0.00008207163,0.00012749479,0.00035641523,0.000094934025,0.000060049024,0.000016444314,0.00011454603,1.9830597e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68419796,0.0011158733,0.0040094,0.00014363886,0.00068117405,0.00002290903,0.009272602,0.0003214271,0.023322806,0.00012208708,0.0056470674,0.27114305],"study_design_scores_gemma":[0.7788167,0.008693702,0.010847582,0.00092958525,0.0008769715,0.000008325561,0.000842549,0.0005921319,0.16494773,0.0005495084,0.032715935,0.00017929472],"about_ca_topic_score_codex":0.00034526145,"about_ca_topic_score_gemma":0.000039128205,"teacher_disagreement_score":0.27096376,"about_ca_system_score_codex":0.00010583628,"about_ca_system_score_gemma":0.00048160323,"threshold_uncertainty_score":0.3346784},"labels":[],"label_agreement":null},{"id":"W4407793214","doi":"10.1016/j.annonc.2025.02.006","title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology; Kasturba Medical College, Manipal","keywords":"Medicine; Hepatocellular carcinoma; Guideline; Clinical Practice; Carcinoma; Oncology; Internal medicine; Pathology; Family medicine","score_opus":0.22324385887817588,"score_gpt":0.4491684928225428,"score_spread":0.2259246339443669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407793214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9230446,0.011998891,0.00034426188,0.05533365,0.0005326665,0.0018179948,0.00004550229,0.000040408242,0.0068419836],"genre_scores_gemma":[0.9750509,0.0061165043,0.0095777875,0.0070771077,0.00021453203,0.00054520316,0.00015100381,0.000023126875,0.0012438259],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780864,0.00022832848,0.0010304855,0.00046413124,0.00011882819,0.00034958444],"domain_scores_gemma":[0.9966504,0.0018387948,0.00028514094,0.00037847905,0.00064663857,0.00020055189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011112362,0.0002458833,0.0009718385,0.0001711923,0.000088757944,0.000009764887,0.00008401316,0.00034232574,0.000047225058],"category_scores_gemma":[0.0013936628,0.00019956044,0.00043031553,0.00018407629,0.00017008882,0.000079063626,0.000060720446,0.00012225665,0.000008777691],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015576242,0.001655886,0.77672017,0.000085478714,0.00071242056,0.00017101083,0.000112611015,7.567678e-8,0.000055631772,0.000875076,0.057120424,0.1609336],"study_design_scores_gemma":[0.009311871,0.012238125,0.017198898,0.0000511574,0.0015544209,0.000042140153,0.00015518823,0.0007480094,0.009956073,0.00040818617,0.9481939,0.00014203395],"about_ca_topic_score_codex":0.0003575539,"about_ca_topic_score_gemma":0.000028623646,"teacher_disagreement_score":0.89107347,"about_ca_system_score_codex":0.00007173711,"about_ca_system_score_gemma":0.0006011535,"threshold_uncertainty_score":0.8137838},"labels":[],"label_agreement":null},{"id":"W4408803504","doi":"10.1016/j.annonc.2025.03.010","title":"Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Gilead Sciences; Novartis","keywords":"Medicine; Breast cancer; Chemotherapy; Oncology; Palbociclib; Internal medicine; Cancer; Placebo; Gynecology; Pathology; Metastatic breast cancer","score_opus":0.052464791902858084,"score_gpt":0.3622241662839321,"score_spread":0.30975937438107404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408803504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96250653,0.00065634283,0.00004191774,0.03239397,0.00054347346,0.0013862124,0.0023736833,0.000025889596,0.000071976065],"genre_scores_gemma":[0.99362606,0.00035833658,0.0015185653,0.002995033,0.00066831487,0.00040122194,0.00019816046,0.000036485148,0.0001978264],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99832517,0.00017251467,0.00045626203,0.00045008873,0.00025450022,0.00034148386],"domain_scores_gemma":[0.9970931,0.0016442505,0.00038012554,0.00035174756,0.00037253127,0.00015824389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036704002,0.00024051231,0.0005562315,0.0000551279,0.00012896389,0.000014986124,0.00014413543,0.00011881427,0.000035772646],"category_scores_gemma":[0.00047347386,0.00015841884,0.00007716071,0.00015587609,0.0004536812,0.00009868414,0.000063122156,0.0002270214,9.0009684e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77822053,0.00031041657,0.0748503,0.000036988484,0.00054265367,0.000007338609,0.0006625138,0.000035981353,0.000025717432,0.000058470916,0.0014630076,0.14378606],"study_design_scores_gemma":[0.24615195,0.0034102874,0.73736936,0.0003013081,0.00031349063,7.1735724e-7,0.00022201258,0.00002575995,0.00017472552,0.0008961927,0.010956667,0.00017750001],"about_ca_topic_score_codex":0.0012526431,"about_ca_topic_score_gemma":0.00093088875,"teacher_disagreement_score":0.6625191,"about_ca_system_score_codex":0.000075225704,"about_ca_system_score_gemma":0.000763886,"threshold_uncertainty_score":0.6460133},"labels":[],"label_agreement":null},{"id":"W4409095915","doi":"10.1016/j.annonc.2025.02.008","title":"Lessons from TROPiCS-04: ‘safety-first’ for success in late-stage clinical trials","year":2025,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Tropics; Clinical trial; Stage (stratigraphy); Intensive care medicine; Internal medicine; Ecology","score_opus":0.8155101084363119,"score_gpt":0.7205218029517918,"score_spread":0.09498830548452009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409095915","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023355192,0.00039437323,0.04366511,0.011299312,0.9118225,0.0033136331,0.025016004,0.0000927467,0.0041627926],"genre_scores_gemma":[0.00007032909,0.006509478,0.37034255,0.000671135,0.61751026,0.00055527233,0.00042229143,0.00014471401,0.0037739528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9688917,0.015940214,0.011690546,0.0015993909,0.0009022523,0.00097593106],"domain_scores_gemma":[0.26099437,0.731816,0.004566077,0.0012426487,0.0011173751,0.00026352657],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.06432695,0.0007037894,0.010267493,0.00039518872,0.00009819847,0.000044035238,0.0016540466,0.006632822,0.00063469046],"category_scores_gemma":[0.85966486,0.0006262877,0.0018911667,0.00037583822,0.00064213364,0.00007206612,0.000530316,0.002701517,0.00001908764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005289094,0.001425873,0.000050901413,0.0008935389,0.0008762203,0.00004736477,0.000071037044,0.000011822468,0.000002179143,0.032976627,0.8934742,0.06488114],"study_design_scores_gemma":[0.0051291077,0.0013400753,0.00004108208,0.0005001354,0.00044285718,3.121752e-8,0.000013822705,0.00006706883,0.000045666584,0.4450306,0.5471,0.0002895218],"about_ca_topic_score_codex":0.0004000526,"about_ca_topic_score_gemma":0.001400717,"teacher_disagreement_score":0.79533786,"about_ca_system_score_codex":0.00016775691,"about_ca_system_score_gemma":0.002600208,"threshold_uncertainty_score":0.9996188},"labels":[],"label_agreement":null},{"id":"W4409188114","doi":"10.1016/j.annonc.2025.03.019","title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ministero dell’Istruzione, dell’Università e della Ricerca; European Commission","keywords":"Medicine; Meta-analysis; Biomarker; Oncology; Immune checkpoint; Internal medicine; Immune system; Complete response; Cancer research; Immunotherapy; Chemotherapy; Immunology; Cancer","score_opus":0.05169435931246081,"score_gpt":0.3473046035091251,"score_spread":0.2956102441966643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409188114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023045301,0.9734992,0.000018003275,0.000063464286,0.000010400681,0.0026937497,0.00060759595,0.000006428832,0.000055848715],"genre_scores_gemma":[0.07690234,0.92170215,0.00012790466,0.0002975547,0.000007657523,0.0005622911,0.0003305191,0.000046735408,0.000022865492],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99593395,0.0011202691,0.0018081946,0.0006630003,0.00018160159,0.00029297735],"domain_scores_gemma":[0.99598825,0.000387902,0.002373423,0.0006955438,0.00048125186,0.00007364082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012697199,0.00048572256,0.006912728,0.0003621955,0.000029285146,0.000009416749,0.00025078942,0.00023623378,0.000006418571],"category_scores_gemma":[0.0009935015,0.00031423572,0.0009409845,0.00078149204,0.00025181184,0.000005083076,0.00019017085,0.00017185394,5.163329e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067482484,0.0013758015,0.0002967834,0.84054554,0.14533186,0.00045137337,0.00015078098,0.00013808293,0.00029837247,0.000014850265,0.000076721735,0.004571583],"study_design_scores_gemma":[0.0034732474,0.030740837,0.0032508783,0.15644738,0.7986153,0.00027010968,0.000120971206,0.000029612447,0.0005454565,0.000023016826,0.004881789,0.0016014096],"about_ca_topic_score_codex":0.00008443961,"about_ca_topic_score_gemma":0.00003763041,"teacher_disagreement_score":0.6840982,"about_ca_system_score_codex":0.00004718745,"about_ca_system_score_gemma":0.0006252897,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W4410118358","doi":"10.1016/j.annonc.2025.04.011","title":"Long-term development of 12- and 15-year-old offspring after maternal cancer diagnosis during pregnancy: a prospective multicentre cohort study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Kom op tegen Kanker; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; KWF Kankerbestrijding; Stichting Tegen Kanker; Fonds Wetenschappelijk Onderzoek; Univerzita Karlova v Praze","keywords":"Medicine; Offspring; Pregnancy; Prospective cohort study; Cohort; Obstetrics; Cancer; Cohort study; Term (time); Gynecology; Internal medicine","score_opus":0.031272801376980235,"score_gpt":0.3647938506359066,"score_spread":0.33352104925892634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410118358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996527,0.0016274513,0.000004309239,0.00021089916,0.00014777067,0.0011243031,0.000013771837,0.000012596891,0.0003319039],"genre_scores_gemma":[0.99737084,0.0012618636,0.00011678433,0.0000661165,0.000029657713,0.0006688355,0.0000011814169,0.000011335798,0.0004734127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895346,0.000028269586,0.00038587584,0.00026986384,0.00015072932,0.00021178371],"domain_scores_gemma":[0.9994243,0.00004350835,0.00015607983,0.00015281864,0.0001566975,0.00006664007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092095535,0.00013135397,0.0005013734,0.00013048483,0.000036241792,0.000005191352,0.00005897846,0.00007542349,0.00017568306],"category_scores_gemma":[0.000028083257,0.00011313619,0.0000510751,0.00009591479,0.00007427157,0.00004528232,0.00011971647,0.00011264181,0.0000010712215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009325447,0.0007245432,0.97191745,0.00044912935,0.00062098325,0.000081974555,0.0028802713,0.0000010830793,0.00033842554,0.0000037448922,0.000027998662,0.022021867],"study_design_scores_gemma":[0.002557806,0.00041879332,0.96505255,0.0011397523,0.00016192149,0.0000032661421,0.00022378613,0.0000017673489,0.030230727,0.0000038537223,0.00012233967,0.0000834386],"about_ca_topic_score_codex":0.00069994957,"about_ca_topic_score_gemma":0.003873759,"teacher_disagreement_score":0.029892301,"about_ca_system_score_codex":0.000124029,"about_ca_system_score_gemma":0.00021632377,"threshold_uncertainty_score":0.461356},"labels":[],"label_agreement":null},{"id":"W4410541480","doi":"10.1016/j.annonc.2025.05.529","title":"Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; State Government of Victoria; Cancer Australia; National Health and Medical Research Council; Astellas Pharma US","keywords":"Medicine; Prostate cancer; Oncology; Post-hoc analysis; Internal medicine; Clinical trial; Cancer; Post hoc; Prostate; Gynecology","score_opus":0.04490853584119963,"score_gpt":0.39619170830278094,"score_spread":0.3512831724615813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410541480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949401,0.0006235577,0.000041580588,0.0016730067,0.0013362824,0.000980689,0.00021483788,0.0000022792149,0.00018766192],"genre_scores_gemma":[0.99703276,0.0012391262,0.000067566034,0.0008230601,0.00033238382,0.00007508665,0.000034772613,0.000008595296,0.00038667253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99747825,0.00086020934,0.0009715491,0.0002738127,0.00020107612,0.00021508461],"domain_scores_gemma":[0.99734944,0.00046973414,0.0012756172,0.0003605933,0.00051312085,0.000031467323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016689239,0.00014732557,0.0011147807,0.000125086,0.000047070876,0.000004824032,0.00021247656,0.00016605858,0.000005587941],"category_scores_gemma":[0.0013451822,0.000088765235,0.00058134657,0.00058479985,0.00021916331,0.000006169955,0.00009848835,0.00016020464,7.1807776e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42717054,0.00376749,0.13902107,0.00014656165,0.028300203,0.0000011433017,0.0030538389,0.0028539593,0.3089331,0.000159081,0.010309656,0.076283336],"study_design_scores_gemma":[0.51194555,0.0070840246,0.3661968,0.00012877869,0.010256189,0.0000022128204,0.0018765153,0.0006037534,0.06657468,0.00010754263,0.03471334,0.00051063177],"about_ca_topic_score_codex":0.0006260599,"about_ca_topic_score_gemma":0.002497683,"teacher_disagreement_score":0.24235843,"about_ca_system_score_codex":0.000032936394,"about_ca_system_score_gemma":0.0007875987,"threshold_uncertainty_score":0.36197412},"labels":[],"label_agreement":null},{"id":"W4410586923","doi":"10.1016/j.annonc.2025.05.528","title":"Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Genentech; Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; Nordic Pharma Group; Daiichi Sankyo Europe; Gilead Sciences; Servier; Deutsche Krebshilfe; European Society for Medical Oncology; FibroGen; Astellas Pharma; Aptitude Health; Natera; Seagen; Actuate Therapeutics; F-star Therapeutics; Boston Scientific Corporation; Ribon Therapeutics; BeiGene; Sanofi; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Guideline; Colorectal cancer; Clinical Practice; Cancer; General surgery; Oncology; Intensive care medicine; Internal medicine; Family medicine; Pathology","score_opus":0.16771526345676546,"score_gpt":0.5441843588012119,"score_spread":0.3764690953444464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410586923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7708293,0.015629364,0.00023056942,0.17977954,0.0021929718,0.002770731,0.00017888783,0.00007928084,0.02830933],"genre_scores_gemma":[0.90833205,0.04691836,0.008980722,0.029915093,0.0005321687,0.0021718417,0.00011116318,0.000037868536,0.0030007425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982151,0.00016665325,0.000819065,0.00040549634,0.00011296167,0.00028072533],"domain_scores_gemma":[0.9959379,0.0028130382,0.00025978475,0.0002351128,0.0005830464,0.00017111318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006234119,0.00018282094,0.00088345475,0.000094427654,0.000053449497,0.000005656489,0.00006588253,0.00024409224,0.00009623694],"category_scores_gemma":[0.0022109828,0.00014278463,0.00027071952,0.00019571315,0.00018097112,0.00006170024,0.000056836623,0.00010964399,0.0000033451063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01204979,0.002178862,0.06876684,0.000063527,0.0013739163,0.000083540726,0.000087096625,0.0000030961864,0.000022285987,0.0003229445,0.12289162,0.79215646],"study_design_scores_gemma":[0.012205384,0.01508555,0.011233007,0.00009293481,0.00078266754,0.000021589807,0.00007901707,0.0001107336,0.0023462896,0.00031043054,0.9576348,0.00009758189],"about_ca_topic_score_codex":0.00094412104,"about_ca_topic_score_gemma":0.00045442703,"teacher_disagreement_score":0.8347432,"about_ca_system_score_codex":0.00019837375,"about_ca_system_score_gemma":0.00079781585,"threshold_uncertainty_score":0.5822588},"labels":[],"label_agreement":null},{"id":"W4410592778","doi":"10.1016/j.annonc.2025.04.006","title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Unicancer; Grifols; Ipsen; Japanese Society of Medical Oncology; PharmaMar; European Society for Medical Oncology; Amgen; Koninklijke Nederlandse Akademie van Wetenschappen; Relay Therapeutics; Seagen; Genentech; Veracyte; Astellas Pharma; Fondazione Beretta; Mersana Therapeutics; Medical Research Council; Les Laboratories Pierre Fabre; Celldex Therapeutics; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Natera; AstraZeneca; Associazione Italiana di Oncologia Medica; Daiichi Sankyo Europe; LEO Pharma; Servier; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; NeraCare; World Health Organization; Sanofi; Pfizer","keywords":"Medicine; Identification (biology); Scale (ratio); Medical physics","score_opus":0.12051507393250943,"score_gpt":0.40112584736255896,"score_spread":0.28061077343004953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410592778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7237756,0.0017752107,0.00017154506,0.0036282232,0.0011607403,0.00013545259,0.00014279135,0.000012865202,0.26919755],"genre_scores_gemma":[0.9903123,0.003261246,0.0007900766,0.0025035823,0.00015325453,0.000008952765,0.000012367085,0.000013401559,0.0029448208],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761987,0.000025672693,0.0016372005,0.0003701262,0.000028897837,0.0003182104],"domain_scores_gemma":[0.99806464,0.00028472155,0.00097122707,0.00039145324,0.00019123056,0.000096750664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309294,0.00014588694,0.0011632269,0.00028572703,0.0000513032,0.000008621305,0.00037246846,0.00039045725,0.00056606287],"category_scores_gemma":[0.00046384317,0.00017217075,0.00034790538,0.00021363229,0.000292378,0.00019645714,0.00013831502,0.00022364994,0.00023971795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005954021,0.00090800103,0.57964003,0.000113647424,0.000276675,0.0000050307226,0.00022505794,0.00011844653,0.000033021322,0.24044932,0.06260647,0.11502888],"study_design_scores_gemma":[0.0013173597,0.0009489324,0.40149042,0.000040581086,0.00001562429,8.893724e-7,0.000047857007,0.0001006229,0.0010149654,0.05267709,0.542187,0.00015869872],"about_ca_topic_score_codex":0.0007156992,"about_ca_topic_score_gemma":0.00019513998,"teacher_disagreement_score":0.4795805,"about_ca_system_score_codex":0.00004447169,"about_ca_system_score_gemma":0.00017888368,"threshold_uncertainty_score":0.70209193},"labels":[],"label_agreement":null},{"id":"W4410884998","doi":"10.1016/j.annonc.2025.05.011","title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma Europe; Astellas Pharma; Bayer HealthCare; Bayer; Astellas Pharma US","keywords":"Medicine; Enzalutamide; Prostate cancer; Radium-223; Oncology; Internal medicine; Cancer; Radium; Urology; Radiochemistry; Bone metastasis","score_opus":0.11903641848419842,"score_gpt":0.4541410662425793,"score_spread":0.3351046477583809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410884998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959024,0.004674592,0.000002173006,0.02504957,0.0003867949,0.0019853492,0.00018995807,0.000010282157,0.008677294],"genre_scores_gemma":[0.9905156,0.0030260799,0.0000847287,0.00040733424,0.00005081213,0.00018636925,0.000029657223,0.000009690458,0.0056897225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981109,0.0002814253,0.00074503134,0.00024965857,0.00028599266,0.00032702243],"domain_scores_gemma":[0.99866676,0.00037061385,0.00029020425,0.00032472133,0.00028256312,0.00006511518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085413834,0.00013498735,0.00061562087,0.0002211606,0.000049323167,0.0000055130686,0.00016274827,0.00009057681,0.000030603434],"category_scores_gemma":[0.00043321965,0.000085981264,0.00014260634,0.0005964008,0.00031171716,0.00005000383,0.0000660158,0.0002372474,0.0000017941194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7381074,0.0043489174,0.0069327727,0.0014926695,0.0018747383,0.00050298916,0.00710113,0.00072160916,0.059200883,0.00345097,0.047797777,0.12846819],"study_design_scores_gemma":[0.4727734,0.017044755,0.07321792,0.0017304352,0.0007021416,0.000020856078,0.0025621834,0.0003641329,0.29961196,0.0043226825,0.12726858,0.00038094516],"about_ca_topic_score_codex":0.002603347,"about_ca_topic_score_gemma":0.0029185074,"teacher_disagreement_score":0.26533395,"about_ca_system_score_codex":0.00023541908,"about_ca_system_score_gemma":0.003344409,"threshold_uncertainty_score":0.5932838},"labels":[],"label_agreement":null},{"id":"W4410935761","doi":"10.1016/j.annonc.2025.05.010","title":"Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"EMD Serono; Genentech; Foundation Medicine; LEO Pharma; Medac; Ipsen; Ono Pharmaceutical; Genesis Pharma; Cilag; Astellas Pharma; Seagen; Teva Pharmaceutical Industries; Gilead Sciences; Daiichi Sankyo Europe; Exelixis; Sanofi; Merck; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Merck Healthcare KGaA","keywords":"Javelin; Avelumab; Medicine; Urothelial carcinoma; Interim analysis; Interim; Oncology; Internal medicine; Urology; First line treatment; Metastatic Urothelial Carcinoma; Urothelial cancer; Bladder cancer; Chemotherapy; Immunotherapy; Cancer; Clinical trial; Pembrolizumab","score_opus":0.03714372364506753,"score_gpt":0.35750115043469394,"score_spread":0.3203574267896264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410935761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868722,0.0005830202,0.0005060784,0.0032264935,0.000356178,0.0015427482,0.00016362626,0.00006563991,0.0066840374],"genre_scores_gemma":[0.9956829,0.00068134966,0.00044041287,0.0014105813,0.000065004424,0.0003004559,0.00013945298,0.000057779103,0.0012220478],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99741817,0.00012426708,0.00076889404,0.0007258924,0.0003391384,0.0006236713],"domain_scores_gemma":[0.99823064,0.00019109988,0.0003116552,0.0006618455,0.0004221456,0.00018259788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014193844,0.00048176706,0.0014946364,0.0007053873,0.000070456554,0.00001248816,0.00021865153,0.00025376515,0.00027222416],"category_scores_gemma":[0.00008183254,0.00036908113,0.00035869374,0.0010646785,0.00023373502,0.000105716455,0.00005685355,0.00022385869,0.00001686621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27401105,0.014268206,0.2774421,0.000234204,0.01936527,0.00058941613,0.0057073263,0.0026720173,0.00025319617,0.0007030316,0.0014039825,0.4033502],"study_design_scores_gemma":[0.254522,0.104489885,0.58011556,0.00042910335,0.0043689376,0.000014616963,0.0008969969,0.0009904602,0.011724006,0.0004887478,0.040928226,0.0010314808],"about_ca_topic_score_codex":0.003415432,"about_ca_topic_score_gemma":0.0057235635,"teacher_disagreement_score":0.40231872,"about_ca_system_score_codex":0.0012296836,"about_ca_system_score_gemma":0.0013848412,"threshold_uncertainty_score":0.99987614},"labels":[],"label_agreement":null},{"id":"W4410958726","doi":"10.1016/j.annonc.2025.04.003","title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"Genentech; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Daiichi-Sankyo; Gilead Sciences; Servier; Pfizer; Yonsei University; Regeneron Pharmaceuticals; Natera; Seagen; Sanofi; Apollomics; International Association for the Study of Lung Cancer; BeiGene; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Samsung; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Yuhan; Amgen; Celgene","keywords":"Osimertinib; Medicine; Epidermal growth factor receptor; Cancer research; Lung cancer; Oncology; Internal medicine; Receptor; Erlotinib","score_opus":0.04496678258221625,"score_gpt":0.4243055604986285,"score_spread":0.37933877791641224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410958726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881331,0.001629742,0.000052189935,0.005457716,0.00018953694,0.0033606358,0.0005277329,0.000047519763,0.0006018249],"genre_scores_gemma":[0.9953723,0.00031692258,0.00063472555,0.0018878672,0.0000680754,0.0007424158,0.0005757858,0.00003250972,0.00036937377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763596,0.00028926297,0.00074408617,0.0006667193,0.0002868417,0.00037714074],"domain_scores_gemma":[0.9978505,0.00081721693,0.00047660206,0.00042973537,0.00022337191,0.0002025713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002725101,0.00030763182,0.00066402496,0.00016918949,0.00023972943,0.00001625114,0.00015239265,0.00012011244,0.000033901528],"category_scores_gemma":[0.00034413298,0.00018087163,0.00009766794,0.00037970417,0.00008960264,0.00015808335,0.0001000781,0.00026705556,0.0000014020903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24124634,0.029778231,0.3273267,0.00075374136,0.002517474,0.00042700223,0.036850713,0.0005158929,0.054603074,0.00004346551,0.010923474,0.29501393],"study_design_scores_gemma":[0.11465489,0.028077764,0.79019284,0.00655434,0.0019980436,0.0000019648526,0.0048451177,0.0009357276,0.04655576,0.00006968313,0.005467989,0.0006458831],"about_ca_topic_score_codex":0.00071413093,"about_ca_topic_score_gemma":0.00009583117,"teacher_disagreement_score":0.46286616,"about_ca_system_score_codex":0.0002695215,"about_ca_system_score_gemma":0.0013579198,"threshold_uncertainty_score":0.73757315},"labels":[],"label_agreement":null},{"id":"W4410958737","doi":"10.1016/j.annonc.2025.05.009","title":"Dostarlimab and niraparib in primary advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"PharmaMar; Genesis Pharma; Astellas Pharma; Eisai; Seagen; Verastem Oncology; Pfizer; Incyte; Ipsen; Clovis Oncology; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Intuitive Surgical; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline; Amgen","keywords":"Medicine; Ovarian cancer; Oncology; Primary (astronomy); Gynecology; Internal medicine; Cancer","score_opus":0.05532924224225995,"score_gpt":0.4313976606856236,"score_spread":0.37606841844336364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410958737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85577416,0.007284055,0.000066604814,0.04972969,0.0002995029,0.00037993674,0.000020822936,0.00002418959,0.08642106],"genre_scores_gemma":[0.97125065,0.0061055254,0.0009380617,0.020794125,0.000049507118,0.00009792005,0.000010407807,0.000008782176,0.0007450387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921125,0.000051955638,0.0002841915,0.00018869454,0.000078869416,0.00018501037],"domain_scores_gemma":[0.9994833,0.00011605575,0.00008645771,0.0001563221,0.00011059212,0.000047256435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021467898,0.000084299034,0.0003902641,0.00019472073,0.000018520372,0.0000020661175,0.000049045182,0.00011851798,0.00012689136],"category_scores_gemma":[0.00004063403,0.00008158323,0.00003723913,0.00025129312,0.00013987091,0.000054007443,0.00003165582,0.00015251948,0.0000020083733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004272039,0.00065218855,0.06684876,0.00035613382,0.00018424816,0.00007484587,0.00067751686,0.000034662913,0.05606237,0.004489439,0.018892854,0.84745497],"study_design_scores_gemma":[0.014010965,0.0016409897,0.46248683,0.00054599345,0.000041826308,0.000022734583,0.00016121872,0.000033590648,0.035170767,0.0047934004,0.48093426,0.00015742832],"about_ca_topic_score_codex":0.00016161514,"about_ca_topic_score_gemma":0.00013015192,"teacher_disagreement_score":0.8472975,"about_ca_system_score_codex":0.00010639403,"about_ca_system_score_gemma":0.0005370036,"threshold_uncertainty_score":0.33268675},"labels":[],"label_agreement":null},{"id":"W4411021324","doi":"10.1016/j.annonc.2025.05.540","title":"What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study","year":2025,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Kidney cancer; Cancer; Neoadjuvant therapy; Delphi; Delphi method; Oncology; Internal medicine; Breast cancer","score_opus":0.3724895310634243,"score_gpt":0.5932161042350984,"score_spread":0.2207265731716741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411021324","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049460633,0.00082114775,0.000043750915,0.97371197,0.007473255,0.0041316384,0.00089698675,0.00011849159,0.00785671],"genre_scores_gemma":[0.010490267,0.023849858,0.0006863816,0.950548,0.004890405,0.0025293329,0.0001651742,0.000083235944,0.006757369],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98510104,0.0072607542,0.002399908,0.001389578,0.0022133144,0.0016353815],"domain_scores_gemma":[0.98916334,0.004565491,0.0017534022,0.0008856867,0.0029710752,0.0006610216],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.019571811,0.0005478236,0.0022626757,0.0024993734,0.00031152097,0.00036520156,0.002615888,0.0015979867,0.002020628],"category_scores_gemma":[0.025670689,0.00056337763,0.00038160547,0.001554797,0.0005347041,0.0017427884,0.0008334676,0.0020795558,0.000035376364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005782521,0.00058608723,0.0005410926,0.000077108816,0.00052109035,0.00096513884,0.024945667,0.000024469213,0.00008310482,0.00013019702,0.8719605,0.099587254],"study_design_scores_gemma":[0.0011858726,0.0010938076,0.000113408576,0.0013576844,0.00016090652,0.000004440959,0.017405553,0.00004395977,0.00025255876,0.00045062177,0.97742516,0.00050603686],"about_ca_topic_score_codex":0.076255664,"about_ca_topic_score_gemma":0.013250451,"teacher_disagreement_score":0.105464615,"about_ca_system_score_codex":0.0014509585,"about_ca_system_score_gemma":0.008696876,"threshold_uncertainty_score":0.99969816},"labels":[],"label_agreement":null},{"id":"W4411319185","doi":"10.1016/j.annonc.2025.04.012","title":"Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"European Society for Medical Oncology; Cancer Research UK","keywords":"CHEK2; Medicine; PALB2; Oncology; Breast cancer; Internal medicine; Cancer; PTEN; Genetic testing; Germline mutation; Genetics; Gene; Biology; Mutation","score_opus":0.2826800938487806,"score_gpt":0.48984177175187454,"score_spread":0.20716167790309392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411319185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7047104,0.00475026,0.007958464,0.25748307,0.005340861,0.0021048824,0.00048328016,0.00010165202,0.017067146],"genre_scores_gemma":[0.9566113,0.0041667013,0.017874628,0.020178756,0.00037250345,0.00029447884,0.0003229934,0.0000345365,0.00014412763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948043,0.0017709312,0.0016405635,0.00091793144,0.00016200512,0.00070423575],"domain_scores_gemma":[0.99589664,0.0016965856,0.00088558614,0.0006958338,0.0006292544,0.000196097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00425851,0.00029560018,0.0008991664,0.0004766429,0.00017053173,0.000012527925,0.00047157423,0.0007821104,0.00008653318],"category_scores_gemma":[0.0016692755,0.00030497182,0.00019750354,0.0008672419,0.0004167445,0.000011329269,0.00026162752,0.0005561984,0.0000051557477],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056644256,0.0020017377,0.023639014,0.000045310888,0.00016342226,0.000009689551,0.00011759927,0.0010397299,0.0022237683,0.00009065486,0.014385748,0.9557169],"study_design_scores_gemma":[0.005092261,0.0073069637,0.07987409,0.000410411,0.00004488338,0.00003885754,0.0006198789,0.008459624,0.0021283715,0.00054420263,0.89506227,0.0004181993],"about_ca_topic_score_codex":0.000452676,"about_ca_topic_score_gemma":0.005698119,"teacher_disagreement_score":0.95529866,"about_ca_system_score_codex":0.00077451876,"about_ca_system_score_gemma":0.006317724,"threshold_uncertainty_score":0.9999402},"labels":[],"label_agreement":null},{"id":"W4412479810","doi":"10.1016/j.annonc.2025.05.510","title":"493P Young-onset gastrointestinal cancer patients enrolled in phase I clinical trials: The experience from Gustave Roussy Cancer Center","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Cancer; Clinical trial; Internal medicine; Oncology; Surgery","score_opus":0.22138315873761663,"score_gpt":0.5538600302799473,"score_spread":0.33247687154233074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984441,0.0023764113,0.000012184772,0.00857584,0.00087949506,0.00079039624,0.00030646275,0.000012609807,0.0026056105],"genre_scores_gemma":[0.99292547,0.0023857164,0.00006996397,0.0033716052,0.00017939074,0.00048558204,0.0000298256,0.000008872836,0.00054355705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974938,0.0005570222,0.0010859065,0.0003534843,0.0001851048,0.00032467477],"domain_scores_gemma":[0.99775213,0.0012383094,0.00038288353,0.00022773026,0.00031783374,0.00008111822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081492995,0.0001870892,0.0011554863,0.00009180311,0.000072084935,0.000007688088,0.00015217843,0.00009140334,0.00038915686],"category_scores_gemma":[0.0015794149,0.000113092516,0.00025060328,0.00021558139,0.00029918912,0.000041868134,0.00010816844,0.00026336286,0.0000033775234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010562773,0.0028578422,0.8653314,0.000013262594,0.00035198173,0.000046864723,0.0017544446,0.0000024273488,0.000049588438,0.000008618871,0.023569513,0.095451266],"study_design_scores_gemma":[0.028697172,0.006664565,0.92514336,0.00048607375,0.00026617365,0.000006750879,0.0016814468,0.000113629496,0.00046119903,0.00014993447,0.03618814,0.00014153185],"about_ca_topic_score_codex":0.0053682663,"about_ca_topic_score_gemma":0.006707902,"teacher_disagreement_score":0.095309734,"about_ca_system_score_codex":0.00017580221,"about_ca_system_score_gemma":0.0005719286,"threshold_uncertainty_score":0.8115248},"labels":[],"label_agreement":null},{"id":"W4412479820","doi":"10.1016/j.annonc.2025.05.055","title":"43P A canadian real-world evidence study of panitumumab with encorafenib in BRAF V600E mutated metastatic colorectal cancer (mCRC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); University of Calgary","funders":"","keywords":"Medicine; Panitumumab; Colorectal cancer; Oncology; Internal medicine; Cancer; KRAS","score_opus":0.1116932154794989,"score_gpt":0.4407895172977952,"score_spread":0.3290963018182963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822182,0.0015175168,6.171556e-7,0.0031686495,0.00011375604,0.0011912473,0.000031502997,0.000013487699,0.011744991],"genre_scores_gemma":[0.9974437,0.0010017025,0.000059388338,0.00052404974,0.000013433217,0.0003192959,0.0000056259464,0.000012008621,0.0006208107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844253,0.00015768531,0.00051260483,0.00031879355,0.00020287267,0.00036549187],"domain_scores_gemma":[0.9986609,0.0003829733,0.00020749039,0.00019030977,0.000433043,0.00012527466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027923798,0.0001939192,0.0009724159,0.00062165124,0.00005831519,0.000004296563,0.0001179245,0.00005226832,0.00012342846],"category_scores_gemma":[0.00015342684,0.00014682554,0.00007466873,0.0011633112,0.00019261384,0.00006585413,0.00004774094,0.00017010438,0.0000015703883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069371164,0.0028134692,0.93957675,0.00024182728,0.002317984,0.0009545252,0.0069413087,0.00012402236,0.00053366367,0.00015255238,0.0020883717,0.03731843],"study_design_scores_gemma":[0.0052280626,0.017590567,0.9682264,0.0006188009,0.00058792596,0.000009012245,0.004420067,0.00005453888,0.0016380481,0.00008509361,0.0014009591,0.00014056271],"about_ca_topic_score_codex":0.6555675,"about_ca_topic_score_gemma":0.97718996,"teacher_disagreement_score":0.32162246,"about_ca_system_score_codex":0.00047818854,"about_ca_system_score_gemma":0.0028044228,"threshold_uncertainty_score":0.5987372},"labels":[],"label_agreement":null},{"id":"W4412479857","doi":"10.1016/j.annonc.2025.05.493","title":"477TiP A randomised phase II study of zimberelimab ± domvanalimab immunotherapy in resectable mismatch repair deficient (dMMR) gastric and gastroesophageal junctional (G/GOJ) adenocarcinoma (ZODIAC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Gastroesophageal Junction; Immunotherapy; Internal medicine; Cancer; Gastric adenocarcinoma; Adenocarcinoma; Oncology; Cancer research","score_opus":0.044396117199982155,"score_gpt":0.38134510508231834,"score_spread":0.3369489878823362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870158,0.007196392,0.00004611243,0.00085126155,0.00034902367,0.0016359433,0.000019482497,0.00002949613,0.0028564932],"genre_scores_gemma":[0.99765116,0.00035726835,0.0008133449,0.0004974264,0.00004657094,0.00019407952,0.000012304718,0.000021351225,0.0004064683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971947,0.00038461376,0.0010491186,0.00050916633,0.00039444913,0.0004679563],"domain_scores_gemma":[0.9981814,0.0005649818,0.00033007908,0.00044925069,0.00036821657,0.00010609805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011558488,0.00025723144,0.001161457,0.0008488629,0.00008840073,0.000005302862,0.00016245109,0.0001950105,0.0002434376],"category_scores_gemma":[0.000374761,0.00023495876,0.0002063653,0.00095880445,0.00025040048,0.000044290064,0.0001455401,0.00034267487,0.0000014296346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29908267,0.046189915,0.50095105,0.0008561841,0.0023826729,0.0005195525,0.007867442,0.00065024063,0.060643405,0.00022257051,0.021958139,0.058676153],"study_design_scores_gemma":[0.3390337,0.12452387,0.51155466,0.00031161655,0.0005309929,0.00022963657,0.0037977968,0.0007914577,0.013801887,0.00043093803,0.0046261484,0.00036729604],"about_ca_topic_score_codex":0.00038113276,"about_ca_topic_score_gemma":0.00017821758,"teacher_disagreement_score":0.07833395,"about_ca_system_score_codex":0.00016479727,"about_ca_system_score_gemma":0.00073665334,"threshold_uncertainty_score":0.958134},"labels":[],"label_agreement":null},{"id":"W4412479874","doi":"10.1016/j.annonc.2025.05.496","title":"479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Antibody; T-cell receptor; Antigen; Bispecific antibody; BETA (programming language); Oncology; Immunology; Cancer research; T cell; Immune system; Monoclonal antibody","score_opus":0.06488600984547917,"score_gpt":0.4213885211849206,"score_spread":0.35650251133944144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862331,0.0006598498,0.000026713476,0.009646978,0.00013413411,0.00093981606,0.00007001911,0.000017526349,0.0022718662],"genre_scores_gemma":[0.99569684,0.0014513053,0.00077294215,0.0013919023,0.00007314978,0.000026007845,0.00018440194,0.000026609292,0.00037682548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645174,0.00036147825,0.0013967361,0.0005891184,0.0005399892,0.00066096254],"domain_scores_gemma":[0.9976384,0.00057235337,0.0005081012,0.00039504768,0.00065121124,0.0002348752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010188884,0.00031626437,0.0012903694,0.0008572639,0.00009346837,0.000008212161,0.0003004095,0.00022114578,0.00014962115],"category_scores_gemma":[0.00029957044,0.000261902,0.00017324364,0.001261961,0.00089765963,0.000110611734,0.00011998051,0.0006014275,0.0000070810515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015376937,0.0026853017,0.959924,0.00025056282,0.00019109946,0.00016064192,0.0003103587,0.000042616084,0.010261404,0.00047528566,0.002253739,0.008068079],"study_design_scores_gemma":[0.014515672,0.02033826,0.9480932,0.000995428,0.00003094365,0.000011095347,0.00012570526,0.00042691297,0.0075109685,0.0001972047,0.007547207,0.00020741031],"about_ca_topic_score_codex":0.002203633,"about_ca_topic_score_gemma":0.0014061783,"teacher_disagreement_score":0.017652959,"about_ca_system_score_codex":0.00014241556,"about_ca_system_score_gemma":0.0015414149,"threshold_uncertainty_score":0.9999833},"labels":[],"label_agreement":null},{"id":"W4412479885","doi":"10.1016/j.annonc.2025.05.048","title":"36P BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Sunnybrook Health Science Centre","funders":"Cilag; MSD K.K.; Chugai Pharmaceutical; EMD Serono; Nordic Pharma Group; Novocure; Menarini Group; American Association for Cancer Research; Incyte; Servier; Pfizer Japan; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Astellas Pharma; Eisai; Miyarisan Pharmaceutical; Daiichi-Sankyo; AstraZeneca; Genentech; University of Oxford; Sirtex Medical; Cancer Research UK; Springworks Therapeutics; Seagen; Sysmex Corporation; BeiGene; Mirati Therapeutics; Takeda Pharmaceutical Company; Ono Pharmaceutical; Eli Lilly and Company; Les Laboratories Pierre Fabre; Pfizer; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Natera; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Amgen; Bristol-Myers Squibb; American Society of Clinical Oncology; Revolution Medicines; Exelixis; Sanofi; Celgene","keywords":"Medicine; Bevacizumab; Cetuximab; Oncology; Post-hoc analysis; Internal medicine; Chemotherapy; Post hoc; Cancer; Colorectal cancer","score_opus":0.08269816231793721,"score_gpt":0.46742718925177834,"score_spread":0.38472902693384115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9135136,0.005813805,0.000042185187,0.058948796,0.00053373683,0.0007483366,0.00009092325,0.000104990075,0.020203656],"genre_scores_gemma":[0.9649504,0.004202761,0.00027481464,0.019024447,0.00020179029,0.0000582113,0.0002822299,0.00003578271,0.010969555],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792963,0.00017435299,0.00061159435,0.00051104283,0.00020855827,0.0005648417],"domain_scores_gemma":[0.99833053,0.00038266237,0.00027412816,0.00045764798,0.00037334816,0.0001816807],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026022468,0.0003316842,0.0012102628,0.00035558047,0.000094309944,0.000011057033,0.00024530257,0.0003430271,0.0010190122],"category_scores_gemma":[0.000051540035,0.00028395432,0.00036004643,0.00048621066,0.00029275139,0.00008121843,0.0000756024,0.00027791798,0.000057741196],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03745692,0.0070520323,0.0023651812,0.00024240068,0.0034953787,0.00031256708,0.0017084007,0.000016637467,0.17214352,0.0004263246,0.6154996,0.159281],"study_design_scores_gemma":[0.03049179,0.02091411,0.0074380133,0.00009905385,0.00093519955,0.000107100765,0.00018394335,0.00006319322,0.17384183,0.00028357963,0.76530915,0.00033300402],"about_ca_topic_score_codex":0.00061389926,"about_ca_topic_score_gemma":0.000120919845,"teacher_disagreement_score":0.158948,"about_ca_system_score_codex":0.00025110153,"about_ca_system_score_gemma":0.0007541648,"threshold_uncertainty_score":0.99996126},"labels":[],"label_agreement":null},{"id":"W4412479911","doi":"10.1016/j.annonc.2025.05.104","title":"92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cohort; Minimal residual disease; Cancer; Disease","score_opus":0.04788415837012499,"score_gpt":0.3841068125979542,"score_spread":0.3362226542278292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365526,0.0031597156,0.000013594651,0.0012783774,0.00018472376,0.00033939985,0.00030665778,0.000006547241,0.0010557075],"genre_scores_gemma":[0.9969372,0.0008849556,0.0007308392,0.0009799276,0.00017990645,0.00008814285,0.00013371931,0.000016076798,0.00004923476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850255,0.00014909993,0.00050541654,0.0004509342,0.00012808356,0.00026392375],"domain_scores_gemma":[0.9984245,0.00044990864,0.00026618186,0.00043375092,0.0002826999,0.00014299282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021303765,0.00017179367,0.0004004564,0.00019414084,0.000039824692,0.0000092530545,0.0004077341,0.0001847799,0.000018368342],"category_scores_gemma":[0.0012455244,0.00018484009,0.00006171358,0.00031854858,0.00023516189,0.00000889768,0.0002055186,0.00011597948,6.4316936e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028452517,0.00057684456,0.6043212,0.00012598067,0.000118011616,0.00009464122,0.0001736486,0.0011360763,0.3731465,0.00021640987,0.0050664954,0.0121789845],"study_design_scores_gemma":[0.0010586759,0.0018288129,0.6416675,0.00026498077,0.00006373783,4.1919657e-7,0.000044469383,0.00016820249,0.3502477,0.00066032604,0.0038011025,0.00019407237],"about_ca_topic_score_codex":0.0137418555,"about_ca_topic_score_gemma":0.0737876,"teacher_disagreement_score":0.06004574,"about_ca_system_score_codex":0.000055647386,"about_ca_system_score_gemma":0.0020445685,"threshold_uncertainty_score":0.99282575},"labels":[],"label_agreement":null},{"id":"W4412479961","doi":"10.1016/j.annonc.2025.05.133","title":"121P Deep learning can predict MSI/MMR status from primary and metastatic colorectal tissue slides","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Commission; Seerave Foundation; Canadian Institute for Advanced Research; Israel Cancer Research Fund","keywords":"Medicine; Oncology; Internal medicine; Primary (astronomy); Colorectal cancer; Cancer","score_opus":0.021273015231605408,"score_gpt":0.3606876896887121,"score_spread":0.3394146744571067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412479961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625433,0.004366729,0.001375142,0.012259974,0.000274374,0.0002803132,0.000017063905,0.000059866525,0.01882323],"genre_scores_gemma":[0.98697233,0.0019298508,0.0058812383,0.0041033207,0.00010328906,0.000018252907,0.00010672172,0.000020535657,0.0008644532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985406,0.0002207882,0.0003940358,0.00029380672,0.00018351366,0.00036725117],"domain_scores_gemma":[0.9985481,0.0008108569,0.00016852366,0.00014167542,0.00012216168,0.00020871963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050156174,0.0001536557,0.00066797424,0.00018822664,0.00008611671,0.000013843853,0.00009093256,0.00010867938,0.00014354012],"category_scores_gemma":[0.0013409175,0.00013620852,0.000062910454,0.00017500167,0.00031283457,0.000046519428,0.000106854146,0.0005662703,0.0000036416002],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005656356,0.00030240492,0.08244654,0.00029632827,0.00064637157,0.00029051863,0.0015981632,0.00012705095,0.017600214,0.0005850942,0.006892026,0.88864964],"study_design_scores_gemma":[0.006242602,0.0059855487,0.43729636,0.00048560055,0.0007974888,0.00013253634,0.0012657167,0.013092301,0.007307685,0.0032632765,0.5237734,0.0003574942],"about_ca_topic_score_codex":0.0009462174,"about_ca_topic_score_gemma":0.0000856256,"teacher_disagreement_score":0.8882922,"about_ca_system_score_codex":0.000054482607,"about_ca_system_score_gemma":0.00036173713,"threshold_uncertainty_score":0.5554422},"labels":[],"label_agreement":null},{"id":"W4412480006","doi":"10.1016/j.annonc.2025.05.470","title":"454P Global physician and patient-reported symptom concordance in association with quality of life in HER2-negative advanced gastric, gastroesophageal or esophageal adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Servier; Deutsche Krebshilfe; Astellas Pharma; Eisai; Incyte; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre","keywords":"Medicine; Concordance; Esophageal adenocarcinoma; Internal medicine; Gastroesophageal Junction; Gastroenterology; Quality of life (healthcare); Adenocarcinoma; Oncology; Cancer","score_opus":0.0336975898894371,"score_gpt":0.36110317161580613,"score_spread":0.327405581726369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939266,0.00046482068,0.000056755096,0.0023943675,0.00008905393,0.00059246836,0.00002246014,0.000013391449,0.0024400817],"genre_scores_gemma":[0.9969882,0.00011120782,0.00071324554,0.0019600075,0.0000208561,0.000034086963,0.000010152299,0.000006448044,0.00015580787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980975,0.000189724,0.00082317396,0.00030076067,0.00027216505,0.0003166858],"domain_scores_gemma":[0.99840224,0.00030446224,0.0007941414,0.00017515867,0.00025232334,0.00007165366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038170532,0.00016502227,0.00093133724,0.00019583388,0.000017940056,0.000004230938,0.000078566845,0.00010237382,0.000013281784],"category_scores_gemma":[0.00059990515,0.00013995498,0.00006193961,0.00086066464,0.000121594836,0.0001080647,0.00006727854,0.0001704027,4.6841842e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004399009,0.00041500415,0.9632018,0.00016037005,0.00018700986,0.00009759479,0.00032659664,0.00004785786,0.000048184138,0.00022149559,0.0004664113,0.030428644],"study_design_scores_gemma":[0.008051214,0.0030345859,0.9869662,0.00015617552,0.000055263536,0.0000029442695,0.0009658784,0.000033448716,0.00036515904,0.00019461312,0.00010322045,0.00007132994],"about_ca_topic_score_codex":0.0011999129,"about_ca_topic_score_gemma":0.0019100332,"teacher_disagreement_score":0.030357314,"about_ca_system_score_codex":0.0003057892,"about_ca_system_score_gemma":0.00049570424,"threshold_uncertainty_score":0.5707199},"labels":[],"label_agreement":null},{"id":"W4412480030","doi":"10.1016/j.annonc.2025.05.429","title":"413P Mismatch repair deficiency (MMRd) in esophagogastric adenocarcinoma (ADC) following chemotherapy for resectable disease: Correlation with survival and recurrence patterns from ST03 and OE05 trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Esophagogastric junction; Adenocarcinoma; Internal medicine; Chemotherapy; Oncology; Cancer","score_opus":0.08540453436478425,"score_gpt":0.39531862151454156,"score_spread":0.3099140871497573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984069,0.010877935,0.0010204004,0.00213374,0.0003901447,0.0010943615,0.000064989625,0.0000229765,0.00032648334],"genre_scores_gemma":[0.99679416,0.0007602671,0.0017488917,0.00033845106,0.000062110164,0.00011102578,0.000033379136,0.000015485295,0.0001362507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983192,0.00023764072,0.0005261333,0.0004432715,0.00019179677,0.00028195148],"domain_scores_gemma":[0.9977931,0.001518978,0.00021252777,0.00023050905,0.00013793743,0.000106997664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011227863,0.00016982867,0.00076970196,0.00021051998,0.00005211483,0.000010368302,0.00008178289,0.00015514824,0.000041992338],"category_scores_gemma":[0.001038903,0.00014380072,0.00009733498,0.00027520896,0.000095994976,0.00006356668,0.000043785378,0.00015212237,3.3739013e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004873025,0.0001998827,0.9692039,0.00019956919,0.00010649213,0.000026324817,0.000423691,0.000024346014,0.00059734896,0.00007995381,0.0008908203,0.023374628],"study_design_scores_gemma":[0.006695848,0.0028043792,0.9846303,0.0003972614,0.00018890717,0.000004281266,0.0003639495,0.0006892767,0.0016313934,0.0015428441,0.0009167817,0.00013478426],"about_ca_topic_score_codex":0.00036855615,"about_ca_topic_score_gemma":0.00026087213,"teacher_disagreement_score":0.023239844,"about_ca_system_score_codex":0.000070980925,"about_ca_system_score_gemma":0.0004671443,"threshold_uncertainty_score":0.5864023},"labels":[],"label_agreement":null},{"id":"W4412480038","doi":"10.1016/j.annonc.2025.05.400","title":"385TiP AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Biliary tract cancer; CLARITY; Internal medicine; Oncology; Cancer; Gemcitabine","score_opus":0.05054774186181461,"score_gpt":0.3812779612181729,"score_spread":0.3307302193563583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97976816,0.0072827577,0.000018255452,0.005787664,0.00028997977,0.00076027506,0.000025484513,0.0000402398,0.006027206],"genre_scores_gemma":[0.9926818,0.0025298796,0.00027137177,0.0039202087,0.00007734616,0.00016534797,0.000018552762,0.000029399249,0.0003060702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998058,0.00012890396,0.00056050165,0.0004953372,0.0002631434,0.0004940886],"domain_scores_gemma":[0.99872303,0.00019901326,0.00024957542,0.00038013933,0.00035162517,0.00009664269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002693762,0.0002824364,0.0009652453,0.00035307804,0.00009251947,0.000009867988,0.00017265878,0.00019864386,0.00006725598],"category_scores_gemma":[0.00007959964,0.00022842643,0.00013582606,0.0005397945,0.00021676687,0.00015664253,0.0000651906,0.0004324329,0.0000028490135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003841899,0.0019841439,0.8562156,0.00014075564,0.0002911219,0.00006626038,0.00130543,0.000027902763,0.0013406872,0.000034445042,0.004794922,0.12995684],"study_design_scores_gemma":[0.010636585,0.0033911483,0.96354735,0.00046945165,0.000114378294,0.000004357233,0.0005851805,0.000019960708,0.0040270877,0.00013157564,0.016862728,0.00021020725],"about_ca_topic_score_codex":0.0007283136,"about_ca_topic_score_gemma":0.0009925871,"teacher_disagreement_score":0.12974663,"about_ca_system_score_codex":0.00017503454,"about_ca_system_score_gemma":0.00047904637,"threshold_uncertainty_score":0.93149596},"labels":[],"label_agreement":null},{"id":"W4412480159","doi":"10.1016/j.annonc.2025.05.345","title":"330P Real-world treatment (tx) outcomes of durvalumab (D)-based regimens in advanced biliary tract cancer (aBTC): LIVER-R interim analysis (IA)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biliary tract cancer; Interim analysis; Durvalumab; Internal medicine; Interim; Oncology; Cancer; Clinical trial; Gemcitabine","score_opus":0.09807169671387607,"score_gpt":0.4564170640920828,"score_spread":0.35834536737820677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718756,0.0042498345,0.000021787357,0.011592456,0.00020186818,0.0005803774,0.000073270894,0.000022669887,0.011382124],"genre_scores_gemma":[0.99322563,0.0031849644,0.00029247705,0.0011182947,0.000026917745,0.00020186766,0.000031230127,0.000012644083,0.0019059826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983177,0.00014044551,0.0006763403,0.00038438215,0.0001725511,0.00030853355],"domain_scores_gemma":[0.99850255,0.00042536468,0.00030389518,0.00045500655,0.0002421879,0.000071012524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024454173,0.000234115,0.0015371959,0.0010021235,0.000031287596,0.0000025754857,0.0001244325,0.00011189526,0.00015060442],"category_scores_gemma":[0.00008452986,0.00018889495,0.00052451965,0.0011161872,0.00019133836,0.000049105995,0.000050770686,0.00013370317,0.0000019382628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013272804,0.00177809,0.9483682,0.00017112147,0.002905794,0.00013066488,0.00073036895,0.00018470187,0.0013506673,0.00007437525,0.0014739103,0.041504834],"study_design_scores_gemma":[0.0039233505,0.0024479048,0.973249,0.00015697812,0.0014747294,0.0000012757649,0.00034224993,0.00010949258,0.012725393,0.000033925447,0.0054113385,0.00012436538],"about_ca_topic_score_codex":0.010947043,"about_ca_topic_score_gemma":0.030464346,"teacher_disagreement_score":0.04138047,"about_ca_system_score_codex":0.00036840411,"about_ca_system_score_gemma":0.00060568575,"threshold_uncertainty_score":0.99563915},"labels":[],"label_agreement":null},{"id":"W4412480301","doi":"10.1016/j.annonc.2025.05.079","title":"67P Physicians’ preferences for later-line treatment of metastatic colorectal cancer in Germany and the UK","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute of Mining, Metallurgy and Petroleum; EVRAZ (Canada)","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Family medicine","score_opus":0.0847725012837717,"score_gpt":0.42498451750936905,"score_spread":0.3402120162255974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98051715,0.008430298,0.000004307808,0.0071565304,0.000091804366,0.00078243983,0.00006917125,0.0000033714193,0.002944954],"genre_scores_gemma":[0.99219596,0.0064998404,0.00007454828,0.00031080798,0.000021632663,0.00045718942,0.000004240097,0.000003205811,0.00043260131],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994163,0.000045048146,0.00023952092,0.00012405554,0.000049644605,0.00012542761],"domain_scores_gemma":[0.9992958,0.00041103706,0.0001086181,0.00006429872,0.00010658955,0.000013663671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010135069,0.00009211607,0.00061114656,0.00006474499,0.000027411035,0.0000016347582,0.00003181046,0.00003053756,0.000020039943],"category_scores_gemma":[0.000028735465,0.000050481194,0.00008383131,0.000109248576,0.00024819767,0.0000131776815,0.000018595414,0.00002615289,1.4044282e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01903544,0.002345275,0.08012249,0.00039477585,0.0033523175,0.000016195767,0.008356474,0.00003682946,0.0025412603,0.0023261444,0.0010407665,0.880432],"study_design_scores_gemma":[0.033327643,0.030980553,0.85397226,0.0003752356,0.0015568594,0.00000617411,0.0019232923,0.0004887109,0.051129945,0.008297464,0.01776754,0.00017432241],"about_ca_topic_score_codex":0.0008424719,"about_ca_topic_score_gemma":0.004306896,"teacher_disagreement_score":0.8802577,"about_ca_system_score_codex":0.000046526533,"about_ca_system_score_gemma":0.00014007918,"threshold_uncertainty_score":0.24033491},"labels":[],"label_agreement":null},{"id":"W4412480304","doi":"10.1016/j.annonc.2025.05.068","title":"56eP Liver transplantation or hepatic arterial infusion for unresectable colorectal liver metastases: A meta-analysis of reconstructed single-arm survival data","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Liver transplantation; Internal medicine; Colorectal cancer; Oncology; Transplantation; Gastroenterology; Surgery; Cancer","score_opus":0.38230182326241885,"score_gpt":0.3965111451073814,"score_spread":0.014209321844962541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923902,0.00125746,0.0011288875,0.0006859752,0.0001791785,0.0011650813,0.0021418012,0.000021505486,0.0010299025],"genre_scores_gemma":[0.9919266,0.00081643485,0.003682152,0.00017910956,0.000031962973,0.00009466937,0.0030851765,0.000012033967,0.00017188006],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9980749,0.00039170586,0.00070669845,0.00038746797,0.00019654675,0.00024269384],"domain_scores_gemma":[0.99738497,0.0013345005,0.00033439923,0.00042842273,0.00044247904,0.00007522273],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008064651,0.0001936277,0.0017211732,0.000569083,0.000054159995,0.000009373255,0.00019221472,0.00018618297,0.0013434482],"category_scores_gemma":[0.00032354842,0.00014257937,0.0006742841,0.00085711264,0.00014204529,0.0001356027,0.00006283343,0.00007836066,0.0000023708985],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07159749,0.013479889,0.06065731,0.0042008488,0.6591748,0.0012849615,0.002873192,0.00003264875,0.074414164,0.0012583988,0.005517415,0.10550887],"study_design_scores_gemma":[0.00896482,0.018345343,0.009806713,0.00007310188,0.7826861,0.00006221329,0.00031261917,0.02408299,0.14543453,0.00013563088,0.009729492,0.00036640718],"about_ca_topic_score_codex":0.0007360943,"about_ca_topic_score_gemma":0.003445202,"teacher_disagreement_score":0.12351134,"about_ca_system_score_codex":0.000031096686,"about_ca_system_score_gemma":0.00039803612,"threshold_uncertainty_score":0.9995695},"labels":[],"label_agreement":null},{"id":"W4412480317","doi":"10.1016/j.annonc.2025.05.131","title":"119P Results of colorectal cancer screening in the Republic of Kazakhstan over 14 years (2011-2024)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Seerave Foundation; Canadian Institute for Advanced Research; Israel Cancer Research Fund","keywords":"Medicine; Colorectal cancer; Cancer; Family medicine; Oncology; Internal medicine","score_opus":0.06241861125835578,"score_gpt":0.392810470841967,"score_spread":0.3303918595836112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412480317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708321,0.00093730306,0.000038265614,0.004189156,0.00030607876,0.00026349863,0.000036295933,0.000012268784,0.023385018],"genre_scores_gemma":[0.99823105,0.0002439265,0.00022179805,0.00058990874,0.00005032983,0.000028697705,0.000007061228,0.0000067191945,0.00062050525],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986894,0.0001502945,0.0005430628,0.00020282886,0.00022330735,0.00019110831],"domain_scores_gemma":[0.99876124,0.0003907753,0.00030613982,0.00023446945,0.00027436877,0.0000330031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010136405,0.000090212896,0.00045438897,0.00033585547,0.000019385096,0.0000027738986,0.00013962804,0.00016098963,0.000102042846],"category_scores_gemma":[0.00047899823,0.00007276475,0.00011978693,0.0006078239,0.0001757077,0.0000456583,0.00005609269,0.00024500495,7.69038e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07211842,0.0011773258,0.09245875,0.0004474692,0.00067375397,0.00009538164,0.0055295364,0.00032055023,0.01827608,0.0011878596,0.15996173,0.6477532],"study_design_scores_gemma":[0.0041485573,0.008415672,0.9045674,0.0003334097,0.00008929226,0.000017969254,0.0007913953,0.0003306113,0.025878659,0.0002756458,0.055054832,0.00009650692],"about_ca_topic_score_codex":0.004318623,"about_ca_topic_score_gemma":0.0026026617,"teacher_disagreement_score":0.8121087,"about_ca_system_score_codex":0.000039062816,"about_ca_system_score_gemma":0.00039004904,"threshold_uncertainty_score":0.65284944},"labels":[],"label_agreement":null},{"id":"W4412521280","doi":"10.1016/j.annonc.2025.07.003","title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; EMD Serono; Genentech; Sierra Oncology; Amgen; Siemens Healthineers; Astellas Pharma; Eisai; AstraZeneca; Invitae; MacroGenics; Y-mAbs Therapeutics; UroGen Pharma; Ipsen; BeiGene; National Institutes of Health; Menarini Silicon Biosystems; Vertex Pharmaceuticals; Boston Scientific Corporation; Sanofi; Endocyte; Novartis; Cardinal Health; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Progression-free survival; Abiraterone acetate; Taxane; Adverse effect; Oncology; Randomized controlled trial; Urology; Androgen receptor; Confidence interval; Androgen deprivation therapy; Chemotherapy; Cancer; Breast cancer","score_opus":0.19551776687375252,"score_gpt":0.4526475834852379,"score_spread":0.2571298166114854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412521280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486274,0.0010842982,9.4554474e-7,0.00090391864,0.00019641059,0.0017245443,0.0009073962,0.0000025093243,0.00031723187],"genre_scores_gemma":[0.9985258,0.0009749587,0.00006422811,0.000031649055,0.000031824275,0.0001129419,0.000106068524,0.000008359086,0.00014419829],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984023,0.00021798305,0.00062055595,0.00020817813,0.00033067414,0.00022029007],"domain_scores_gemma":[0.99843967,0.00024665997,0.0005215278,0.00019208447,0.00054197176,0.00005810939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036567866,0.00014776136,0.00076972356,0.00019865778,0.000035447298,0.0000025315019,0.00008681922,0.00007404816,0.00003811351],"category_scores_gemma":[0.00013249154,0.00008958139,0.000098023775,0.00039946806,0.0003911546,0.00007537442,0.000056777495,0.00012573965,8.889373e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87145483,0.004616208,0.053104237,0.0010476714,0.0018177317,0.00002898192,0.0033543417,0.000028062046,0.018819982,0.00021815156,0.0004321688,0.045077614],"study_design_scores_gemma":[0.58597696,0.04954887,0.08648209,0.0013297542,0.0008419832,0.0000010998012,0.002178023,0.000046135425,0.27127853,0.00012103937,0.001955133,0.0002404001],"about_ca_topic_score_codex":0.0020990279,"about_ca_topic_score_gemma":0.0014657445,"teacher_disagreement_score":0.2854779,"about_ca_system_score_codex":0.00008056797,"about_ca_system_score_gemma":0.0013021976,"threshold_uncertainty_score":0.3653023},"labels":[],"label_agreement":null},{"id":"W4412595186","doi":"10.1016/j.annonc.2025.07.009","title":"From epigenetic alterations to clinical impact: the role of DNMT3A in modulating immunotherapy response","year":2025,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Epigenetics; Immunotherapy; Oncology; Immunology; Immune system; Genetics; Gene","score_opus":0.05085911907880081,"score_gpt":0.4710971843933706,"score_spread":0.4202380653145698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412595186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68630624,0.012386562,0.00004930994,0.009646028,0.28830153,0.0013691954,0.00087201234,0.000019633808,0.0010494716],"genre_scores_gemma":[0.56161755,0.011283017,0.001228809,0.0033974466,0.41995192,0.00022393219,0.00055396045,0.000102577564,0.00164079],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967415,0.0008903089,0.0014340366,0.00033981673,0.0003250257,0.0002693474],"domain_scores_gemma":[0.99175245,0.0065118256,0.00056624954,0.0006846193,0.00041947683,0.00006536177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026214796,0.0002234546,0.0011279209,0.00029290363,0.000041106065,0.000008771312,0.00033207404,0.0008414932,0.00018871126],"category_scores_gemma":[0.002177062,0.00016107039,0.00049977755,0.00037144765,0.00020182518,0.00002429504,0.00007219263,0.00064695167,0.0000037992766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06176946,0.0007048651,0.0020319885,0.000035106044,0.0010966131,0.000012994268,0.0020250527,0.0000661569,0.026795767,0.0000046287005,0.65858227,0.24687509],"study_design_scores_gemma":[0.003245264,0.0066243364,0.030653885,0.0004975567,0.000073980336,0.0000010741087,0.00023342695,0.000057225243,0.0032896379,0.00042649676,0.95475364,0.00014349405],"about_ca_topic_score_codex":0.004047996,"about_ca_topic_score_gemma":0.00046564324,"teacher_disagreement_score":0.29617134,"about_ca_system_score_codex":0.00012698521,"about_ca_system_score_gemma":0.0028325447,"threshold_uncertainty_score":0.656826},"labels":[],"label_agreement":null},{"id":"W4413092431","doi":"10.1016/j.annonc.2025.05.216","title":"203eP Cell-free DNA (cfDNA) biomarkers and AI models for early detection of liver cancer: A systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Medicine; Meta-analysis; Cell-free fetal DNA; Cancer; Oncology; Computational biology; Internal medicine; Genetics; Biology","score_opus":0.052096261350931226,"score_gpt":0.3445567333520513,"score_spread":0.2924604720011201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092431","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12134264,0.8591631,0.011999447,0.004351979,0.00007475918,0.001958496,0.00061266596,0.000007686666,0.0004892204],"genre_scores_gemma":[0.9194723,0.077640615,0.00030970958,0.002157504,0.0000106259695,0.00023499184,0.000011649588,0.000009882291,0.00015274445],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99916685,0.0000734441,0.0003653066,0.00022994756,0.000046915877,0.00011751443],"domain_scores_gemma":[0.9990189,0.00010736374,0.00026492076,0.00030124062,0.00026785897,0.000039684925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034689158,0.00010987909,0.00095867185,0.00009876101,0.000024623965,0.0000060831303,0.00011505713,0.00012329577,0.0000034630386],"category_scores_gemma":[0.00014073442,0.000094652474,0.0003273032,0.00014794678,0.00008305559,0.000004087004,0.00009848714,0.000029501794,5.225348e-8],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001184095,0.00078092964,0.0005245195,0.34692466,0.35135424,0.0000068891145,0.00037791542,0.0010351205,0.26168847,0.0019691284,0.028823005,0.0053310306],"study_design_scores_gemma":[0.0021370135,0.0038692893,0.00056106935,0.0006790912,0.64858204,0.000007857409,0.00008842749,0.0024932509,0.33232218,0.0031695259,0.005530351,0.0005598865],"about_ca_topic_score_codex":0.0003970531,"about_ca_topic_score_gemma":0.00077251677,"teacher_disagreement_score":0.7981296,"about_ca_system_score_codex":0.00000789039,"about_ca_system_score_gemma":0.000091541,"threshold_uncertainty_score":0.3859816},"labels":[],"label_agreement":null},{"id":"W4413092498","doi":"10.1016/j.annonc.2025.05.206","title":"193P Multidisciplinary teams (MDTs) for hepatocellular carcinoma (HCC): Maturity and optimal practices in Europe and Canada (EUCAN)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Multidisciplinary approach; Maturity (psychological); Multidisciplinary team; Cabozantinib; Oncology; Internal medicine; Cancer; Nursing","score_opus":0.026483804100833966,"score_gpt":0.3306168730083889,"score_spread":0.3041330689075549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909575,0.004549381,0.000048614358,0.0029397518,0.0001441517,0.00025509344,0.000098498494,0.0000016049652,0.0010053867],"genre_scores_gemma":[0.9956006,0.0024443842,0.0008856878,0.0007103258,0.000062052306,0.000028937007,0.000052719108,0.000009110396,0.00020622229],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921626,0.000047900703,0.00021507434,0.0002853638,0.00004057409,0.00019482954],"domain_scores_gemma":[0.99932724,0.00013559399,0.00017036733,0.00016018967,0.00014601745,0.00006056829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023332237,0.00010726045,0.00022375489,0.000043799064,0.000049304217,0.0000095539945,0.00009990687,0.00012356637,0.0000017751962],"category_scores_gemma":[0.00044299357,0.00011149887,0.000022823717,0.00006116988,0.000098774086,0.000004067367,0.00021119548,0.00007604761,9.0812776e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026183624,0.00064272207,0.77761036,0.0006443922,0.00023600768,0.00014839886,0.000361494,0.00022790306,0.13431144,0.0024997613,0.055661127,0.025038011],"study_design_scores_gemma":[0.003205201,0.003044349,0.18319984,0.000054462296,0.000080546924,0.000044684268,0.0007080709,0.0026982417,0.11646084,0.00042795393,0.6896359,0.00043991936],"about_ca_topic_score_codex":0.07926523,"about_ca_topic_score_gemma":0.2605996,"teacher_disagreement_score":0.6339748,"about_ca_system_score_codex":0.00001894676,"about_ca_system_score_gemma":0.0010365353,"threshold_uncertainty_score":0.926866},"labels":[],"label_agreement":null},{"id":"W4413092567","doi":"10.1016/j.annonc.2025.05.277","title":"262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hotel Dieu Hospital","funders":"","keywords":"Medicine; IDH1; Oncology; Internal medicine; Mutation; Gene; Genetics","score_opus":0.05826841621763065,"score_gpt":0.40012524710518754,"score_spread":0.3418568308875569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886516,0.0007680482,0.0000025839024,0.00611083,0.00020586229,0.0019850216,0.0001895558,0.000026826528,0.0020597046],"genre_scores_gemma":[0.99829966,0.000026608433,0.000048491787,0.0012350561,0.000062129715,0.000084571606,0.00013301463,0.000019340492,0.00009111846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766994,0.00026839878,0.0009072253,0.00045327534,0.00036099687,0.0003401931],"domain_scores_gemma":[0.99739724,0.0010999417,0.00038406157,0.00061099563,0.0004376916,0.00007003954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040755112,0.0002680609,0.0010373387,0.0002454719,0.00007412769,0.000008089129,0.00028476838,0.00013421306,0.000015722206],"category_scores_gemma":[0.000671005,0.00016888554,0.00015465713,0.00052241696,0.00029491194,0.00008769174,0.00020177902,0.0003266657,0.0000032670987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031552,0.008716132,0.92531997,0.00004140503,0.0011074455,0.00013342823,0.007432965,0.0000062015356,0.00008934581,0.000011682879,0.005638265,0.019951185],"study_design_scores_gemma":[0.047980748,0.01736212,0.92989,0.00016648095,0.00041228696,0.0000016804531,0.0019571346,0.000007116225,0.0013782659,0.000029184814,0.00068508,0.0001298997],"about_ca_topic_score_codex":0.0016616582,"about_ca_topic_score_gemma":0.000600822,"teacher_disagreement_score":0.019821286,"about_ca_system_score_codex":0.000059802034,"about_ca_system_score_gemma":0.0004084909,"threshold_uncertainty_score":0.68869525},"labels":[],"label_agreement":null},{"id":"W4413092579","doi":"10.1016/j.annonc.2025.05.013","title":"1O Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Health-related quality of life (HRQoL) analyses from CheckMate 8HW","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Sanofi K.K.; MSD K.K.; Chugai Pharmaceutical; Genentech; Aptitude Health; Nordic Pharma Group; Menarini Group; Pfizer Japan; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; G1 Therapeutics; Sysmex Corporation; BeiGene; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Takeda Pharmaceutical Company; Amgen; American Association for Cancer Research; Samsung; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; Servier; Gilead Sciences; Exelixis; Sanofi; Bayer Yakuhin; Celgene","keywords":"Medicine; Nivolumab; Ipilimumab; Microsatellite instability; Colorectal cancer; Internal medicine; Oncology; Cancer; Immunotherapy; Microsatellite; Gene; Genetics","score_opus":0.16965210488774107,"score_gpt":0.4646958506887479,"score_spread":0.29504374580100684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675631,0.019989504,0.00052072416,0.0063260337,0.0012347589,0.002598974,0.0011214073,0.00015124663,0.00049425225],"genre_scores_gemma":[0.9864245,0.0027121645,0.0061812736,0.0033393174,0.000076135344,0.0004087297,0.00024967032,0.00007475562,0.0005334524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931713,0.0009807593,0.0031794165,0.0011320787,0.0005994956,0.0009369908],"domain_scores_gemma":[0.9939662,0.0016450178,0.0017536181,0.00097396004,0.0013068059,0.00035435834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002206243,0.0005864486,0.003427468,0.00047445804,0.00017798276,0.000016820433,0.00045533985,0.0005042937,0.0005710468],"category_scores_gemma":[0.0010224979,0.00054803997,0.0008946413,0.0010690994,0.0008052258,0.00009656004,0.00017252291,0.00048897124,0.0000070217825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1521747,0.010453207,0.07461715,0.009699906,0.016947556,0.000045400884,0.019651294,0.0069600064,0.601822,0.0016576984,0.032665744,0.0733053],"study_design_scores_gemma":[0.05234865,0.027094757,0.30192825,0.0018930719,0.0020188054,0.00002127181,0.0040760827,0.005360842,0.5574515,0.008347518,0.037664223,0.0017950175],"about_ca_topic_score_codex":0.029065132,"about_ca_topic_score_gemma":0.0068822177,"teacher_disagreement_score":0.2273111,"about_ca_system_score_codex":0.0010167009,"about_ca_system_score_gemma":0.005141732,"threshold_uncertainty_score":0.9996971},"labels":[],"label_agreement":null},{"id":"W4413092593","doi":"10.1016/j.annonc.2025.05.265","title":"251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Kelowna General Hospital; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Medicine; Rectal carcinoma; Basal cell; Oncology; Internal medicine; Colorectal cancer; General surgery; Cancer","score_opus":0.04616777165913098,"score_gpt":0.35513813632561675,"score_spread":0.30897036466648575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689223,0.0005955127,4.2831468e-7,0.002369661,0.00036041028,0.00020658216,0.000031756346,0.0000065788677,0.027506728],"genre_scores_gemma":[0.9934802,0.00005000157,0.000034529297,0.0025207591,0.000040427723,0.000008438165,0.000010331064,0.000007141251,0.003848142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984853,0.00012316283,0.0007568963,0.00022721637,0.0001559252,0.00025147197],"domain_scores_gemma":[0.9987733,0.00056312926,0.00016723557,0.0001736478,0.00022150685,0.00010121163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037196733,0.00007747194,0.0008540536,0.000071571536,0.000020848767,0.000004286022,0.00012114507,0.00017235131,0.00014348768],"category_scores_gemma":[0.00050219323,0.00010589261,0.0001939073,0.0002612961,0.00015827343,0.000020053127,0.00008381348,0.00025364838,0.0000011418678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014645049,0.0005844533,0.9479632,0.00012072284,0.000025612337,0.00049212965,0.000029274466,7.634826e-7,0.00012307649,0.0000106982425,0.02900331,0.021500347],"study_design_scores_gemma":[0.002036191,0.0022696715,0.98413587,0.000032821874,0.000044320466,0.000026705899,0.00023032934,0.000017115379,0.0005802149,0.00011045672,0.01044151,0.00007479315],"about_ca_topic_score_codex":0.91976535,"about_ca_topic_score_gemma":0.9931069,"teacher_disagreement_score":0.073341526,"about_ca_system_score_codex":0.000071907605,"about_ca_system_score_gemma":0.0022669965,"threshold_uncertainty_score":0.4318175},"labels":[],"label_agreement":null},{"id":"W4413092622","doi":"10.1016/j.annonc.2025.05.189","title":"176P Tegavivint, a downstream Wnt/β-catenin inhibitor: Interim results from a phase I/II trial in advanced hepatocellular carcinoma (aHCC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Interim; Interim analysis; Internal medicine; Wnt signaling pathway; Regorafenib; Oncology; Clinical trial; Cancer; Colorectal cancer; Cell biology","score_opus":0.1335508853952117,"score_gpt":0.38042630661164606,"score_spread":0.24687542121643435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805095,0.0016056797,0.000016750088,0.0061580497,0.0005936509,0.0017566122,0.0002644671,0.00006742342,0.009027834],"genre_scores_gemma":[0.9964712,0.00026323352,0.00051754457,0.00065949495,0.0002396495,0.0002325219,0.000684691,0.000030612144,0.0009010436],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968114,0.0003041103,0.0013197329,0.00073945126,0.000254235,0.00057106424],"domain_scores_gemma":[0.99821967,0.00042453015,0.00036823572,0.0005270791,0.00024628857,0.00021419192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061174575,0.00038674945,0.0013113722,0.000597002,0.00007910749,0.000013042788,0.00023592744,0.00045616383,0.00013843575],"category_scores_gemma":[0.0005212653,0.0003492913,0.0004090533,0.00062602555,0.00020779761,0.00012819622,0.0002031081,0.0004229755,0.000030452276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36123282,0.02110657,0.1629511,0.00016634853,0.00083312776,0.003448968,0.003517805,0.0000017260414,0.10284305,0.0003322517,0.013631662,0.32993457],"study_design_scores_gemma":[0.35828334,0.049351215,0.0052518127,0.00069545483,0.0005084089,0.000028588473,0.00056932354,0.001413181,0.5151344,0.00096728734,0.067263156,0.00053382124],"about_ca_topic_score_codex":0.0020262653,"about_ca_topic_score_gemma":0.00028029465,"teacher_disagreement_score":0.41229135,"about_ca_system_score_codex":0.00017377907,"about_ca_system_score_gemma":0.000749869,"threshold_uncertainty_score":0.99989593},"labels":[],"label_agreement":null},{"id":"W4413092759","doi":"10.1016/j.annonc.2025.05.190","title":"177P Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Oncology; Alpha-fetoprotein; Gastroenterology","score_opus":0.04966078919795928,"score_gpt":0.3210906622515927,"score_spread":0.2714298730536334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949249,0.00040534567,0.00001050843,0.0017008176,0.000056768313,0.001507289,0.0000401134,0.0000220504,0.0013322049],"genre_scores_gemma":[0.9982799,0.00013292099,0.00029983371,0.00031229158,0.000019380683,0.00007664258,0.00012844833,0.000026833392,0.0007237386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997542,0.0003684359,0.00083748414,0.000446428,0.0003884248,0.00041721473],"domain_scores_gemma":[0.99792385,0.00045927486,0.00048262332,0.00034904064,0.0006495769,0.00013560988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006690251,0.0002881845,0.0013920872,0.00035973088,0.00005348303,0.00001022403,0.00011876649,0.0003969988,0.000049902483],"category_scores_gemma":[0.00022817547,0.00020816918,0.00016855709,0.00045977382,0.00016935157,0.00010400376,0.00006130647,0.0002895067,0.00000348544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062390612,0.0020250066,0.9858028,0.0001656866,0.0007810692,0.00016384291,0.00014106423,8.0489184e-7,0.00010056444,0.000057630292,0.0003989771,0.0041234377],"study_design_scores_gemma":[0.017005961,0.013754478,0.9591427,0.00017570582,0.00050187396,0.0000030763567,0.00005664229,0.0002511085,0.008057173,0.000043301952,0.0008373639,0.0001706084],"about_ca_topic_score_codex":0.0023188319,"about_ca_topic_score_gemma":0.00082023354,"teacher_disagreement_score":0.02666015,"about_ca_system_score_codex":0.000174811,"about_ca_system_score_gemma":0.00047700005,"threshold_uncertainty_score":0.84888923},"labels":[],"label_agreement":null},{"id":"W4413116457","doi":"10.1016/j.annonc.2025.07.012","title":"Imatinib’s last lessons? A roadmap to cure","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"GlaxoSmithKline; MSD","keywords":"Medicine; Imatinib; Imatinib mesylate; Oncology; Internal medicine","score_opus":0.14318647574565213,"score_gpt":0.5069355149283589,"score_spread":0.36374903918270673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413116457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6495906,0.00033935832,0.00029073667,0.23533739,0.00009165457,0.00056370615,0.000016849383,0.000038416485,0.11373126],"genre_scores_gemma":[0.9890106,0.000053456297,0.004778106,0.0036704326,0.00003979711,0.00005028636,0.000009609146,0.0000066692473,0.0023810416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991407,0.00005172314,0.00020752312,0.00017121258,0.00013576049,0.00029311999],"domain_scores_gemma":[0.9991602,0.00013611566,0.000047073067,0.000207274,0.00025964298,0.0001897467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020321658,0.00008827327,0.00033041224,0.00018552484,0.000029702629,0.000004137554,0.000086063344,0.00003947948,0.00012895734],"category_scores_gemma":[0.00047524046,0.00007003209,0.00008694289,0.00024335911,0.000066798224,0.000018974948,0.00007911248,0.00013226214,0.00013176732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046075447,0.0047949813,0.09920711,0.00044646522,0.00057256094,0.0018110999,0.0003889086,0.000022667988,0.013212664,0.020229558,0.4143913,0.44031513],"study_design_scores_gemma":[0.006241159,0.040358875,0.29964885,0.0008663784,0.0001372007,0.00059033214,0.0006614169,0.00007578483,0.032707088,0.0034799534,0.6150384,0.00019459553],"about_ca_topic_score_codex":0.000055316406,"about_ca_topic_score_gemma":0.00006627286,"teacher_disagreement_score":0.44012052,"about_ca_system_score_codex":0.000038918162,"about_ca_system_score_gemma":0.0003871408,"threshold_uncertainty_score":0.28558257},"labels":[],"label_agreement":null},{"id":"W4413796114","doi":"10.1016/j.annonc.2025.08.003","title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; Chugai Pharmaceutical; Genentech; Nordic Pharma Group; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Eisai; Array BioPharma; European School of Oncology; Sanofi; Apollomics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Regeneron Pharmaceuticals; International Association for the Study of Lung Cancer; BeiGene; F. Hoffmann-La Roche; Varian Medical Systems; Kasturba Medical College, Manipal; Pfizer; Incyte; Daiichi Sankyo Europe; Gilead Sciences; Roche; Novartis; GlaxoSmithKline; Amgen; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Guideline; Lung cancer; Clinical Practice; Cancer; Oncology; Intensive care medicine; Medical physics; Internal medicine; Family medicine; Pathology","score_opus":0.05507737742056936,"score_gpt":0.46630432602353195,"score_spread":0.4112269486029626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413796114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8853748,0.031655576,0.00033672331,0.07601226,0.000688249,0.0022801273,0.00007251217,0.00002515401,0.0035546084],"genre_scores_gemma":[0.7766087,0.18419135,0.016025195,0.019104717,0.0002737517,0.002353336,0.000045183482,0.000035074932,0.0013626921],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983224,0.0000774488,0.00075018033,0.00047068862,0.00008675379,0.00029251477],"domain_scores_gemma":[0.9970443,0.001690128,0.0003037524,0.00026213113,0.0005201923,0.00017945454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046497118,0.00021435793,0.00082839344,0.000087073335,0.00007116495,0.000011116695,0.000060645445,0.0002062984,0.000016970327],"category_scores_gemma":[0.00037505288,0.00016831522,0.00016596932,0.000107510234,0.000118122756,0.00007664125,0.000059665286,0.00010231709,0.0000010421778],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033344456,0.0028799293,0.3308362,0.0003678945,0.0015426327,0.000060413815,0.0003167464,0.000011134204,0.000046827558,0.0002921639,0.073913544,0.58639807],"study_design_scores_gemma":[0.026524788,0.019353442,0.06345371,0.00047077338,0.0024854443,0.000012382654,0.00018475617,0.0002548284,0.003918085,0.00013129562,0.88302284,0.00018763557],"about_ca_topic_score_codex":0.0010651222,"about_ca_topic_score_gemma":0.0005585114,"teacher_disagreement_score":0.80910933,"about_ca_system_score_codex":0.00017060163,"about_ca_system_score_gemma":0.0007771136,"threshold_uncertainty_score":0.68636954},"labels":[],"label_agreement":null},{"id":"W4413801718","doi":"10.1016/j.annonc.2025.08.008","title":"Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Eisai Canada","keywords":"Pembrolizumab; Medicine; Lenvatinib; Placebo; Oncology; Internal medicine; Double blind; Phases of clinical research; Metastatic melanoma; Immunotherapy; Clinical trial; Cancer; Pathology","score_opus":0.19559295964400839,"score_gpt":0.4627367715875191,"score_spread":0.26714381194351067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413801718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97285205,0.003112957,0.00087297754,0.0034613,0.0011056891,0.010011822,0.000103901126,0.000058623515,0.008420696],"genre_scores_gemma":[0.99168575,0.0010772193,0.0003094747,0.00055737223,0.00013110219,0.001491869,0.00010790387,0.000047146204,0.004592137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962081,0.00037981238,0.0017905702,0.00057021267,0.000421455,0.0006298675],"domain_scores_gemma":[0.99426556,0.0033729144,0.00088954985,0.00067773904,0.000654612,0.00013965683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001985939,0.00043101882,0.0029682368,0.00061813986,0.00017398768,0.000016890703,0.00037946072,0.0002551454,0.00055301277],"category_scores_gemma":[0.0007422862,0.0003270959,0.00060199416,0.0007759813,0.00045028926,0.00013049174,0.00011733707,0.00028581833,0.0000038414914],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9664676,0.0044590514,0.000024757046,0.0007245907,0.005644785,0.00006982342,0.0018275513,0.00022295344,0.0003805258,0.00034662412,0.007089798,0.01274194],"study_design_scores_gemma":[0.9288563,0.03602507,0.000017625958,0.00019637984,0.0017599397,0.00003253652,0.0024998847,0.0015631983,0.00606309,0.00010072998,0.022634909,0.00025032324],"about_ca_topic_score_codex":0.001723098,"about_ca_topic_score_gemma":0.0028415634,"teacher_disagreement_score":0.037611287,"about_ca_system_score_codex":0.00027294792,"about_ca_system_score_gemma":0.0021367474,"threshold_uncertainty_score":0.9999181},"labels":[],"label_agreement":null},{"id":"W4414094800","doi":"10.1016/j.annonc.2025.08.3757","title":"Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Ipsen; Gilead Sciences; Bayer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; GlaxoSmithKline; Amgen","keywords":"Pembrolizumab; Adenoid cystic carcinoma; Phases of clinical research; Carcinoma; Melanoma","score_opus":0.009787600156352473,"score_gpt":0.3268003003395209,"score_spread":0.3170127001831684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414094800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99858236,0.00045143664,0.000019086661,0.00016147004,0.000028806477,0.0006628876,0.0000041328894,0.0000021048138,0.00008773345],"genre_scores_gemma":[0.9994677,0.0002990726,0.00006737529,0.00006728814,0.0000057333723,0.000041031042,0.000023800767,0.000007981718,0.000020034428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992937,0.000071433475,0.00021998535,0.00023022323,0.00007932057,0.00010534057],"domain_scores_gemma":[0.9995598,0.000014922674,0.00015116348,0.00011882476,0.00013350378,0.000021740927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091825576,0.00009487158,0.00021876964,0.00014892616,0.000015373198,0.0000019279544,0.000037985374,0.00010501737,0.0000011399741],"category_scores_gemma":[0.000015181165,0.00008325624,0.00000942886,0.00018446178,0.000079257894,0.000009249028,0.000024699852,0.00005552414,2.8615815e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06902845,0.008611752,0.45530707,0.000141766,0.00027356567,0.000006073437,0.002439269,0.0068706158,0.12726626,0.000050774874,0.00012222391,0.32988217],"study_design_scores_gemma":[0.08456781,0.06733524,0.7637867,0.00019174916,0.000032093427,0.000002056785,0.000724938,0.00028578893,0.082053,0.0000971948,0.0007084093,0.00021503681],"about_ca_topic_score_codex":0.0002726683,"about_ca_topic_score_gemma":0.0023990383,"teacher_disagreement_score":0.32966712,"about_ca_system_score_codex":0.000038150687,"about_ca_system_score_gemma":0.00019750431,"threshold_uncertainty_score":0.33950907},"labels":[],"label_agreement":null},{"id":"W4414687149","doi":"10.1016/j.annonc.2025.09.011","title":"Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Intuitive","keywords":"Opera; Process (computing); MEDLINE; Plan (archaeology)","score_opus":0.3684872002894267,"score_gpt":0.6450354795276336,"score_spread":0.2765482792382069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414687149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8128206,0.00033014838,0.000019120647,0.18336672,0.00016356847,0.00092672626,0.0000044275967,0.0000029159055,0.0023657782],"genre_scores_gemma":[0.95103,0.00024467692,0.00008449085,0.048523303,0.00005441901,0.00004852623,0.0000019590007,0.000005287134,0.000007302858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651533,0.0017187274,0.0011372437,0.00018382576,0.00029825725,0.0001465961],"domain_scores_gemma":[0.9663395,0.03251258,0.0005063154,0.00034887623,0.00027153653,0.000021185022],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0073671634,0.00008286934,0.00034298628,0.00003872205,0.00008114259,0.000009706862,0.00027971106,0.00009985316,0.00002482599],"category_scores_gemma":[0.01701809,0.00003203087,0.000117154035,0.00027772237,0.00031912286,0.00006167886,0.00019350303,0.0006509878,6.612862e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03702985,0.0012825711,0.030741058,0.000018193155,0.00020182213,0.000021736274,0.007916533,0.00015489353,0.000032872962,0.0012972524,0.01933236,0.90197086],"study_design_scores_gemma":[0.02780182,0.0060725515,0.27180666,0.0006100016,0.00030488917,0.00007576375,0.048618324,0.0012055519,0.00026311213,0.016213221,0.62689865,0.00012948208],"about_ca_topic_score_codex":0.00007771232,"about_ca_topic_score_gemma":0.0001274067,"teacher_disagreement_score":0.9018414,"about_ca_system_score_codex":0.000013241883,"about_ca_system_score_gemma":0.00048657483,"threshold_uncertainty_score":0.99126196},"labels":[],"label_agreement":null},{"id":"W4415279920","doi":"10.1016/j.annonc.2025.07.002","title":"Corrigendum to “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3”","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Aromatase inhibitor; Nonsteroidal; Aromatase; Overall survival; Letrozole","score_opus":0.10947747122385279,"score_gpt":0.4493020162833795,"score_spread":0.33982454505952675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415279920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722037,0.0013653834,0.0004285139,0.022736492,0.0016111229,0.0017648374,0.003176933,0.000055942433,0.0016403828],"genre_scores_gemma":[0.9899212,0.00050799735,0.0019243314,0.00499633,0.00044901166,0.00040633345,0.00017431905,0.000044951634,0.0015755191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997564,0.00012765198,0.00088136486,0.0005338618,0.00033088643,0.00056222675],"domain_scores_gemma":[0.997794,0.00032780814,0.00040121685,0.00048195405,0.0007901809,0.00020484401],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040827476,0.0003081655,0.0011084528,0.00030616278,0.000071365874,0.000005861422,0.00026848607,0.00021990393,0.000095333155],"category_scores_gemma":[0.00017237927,0.00028559047,0.00023757407,0.00036293882,0.00029494776,0.000121124875,0.00010971771,0.0002351077,0.000008775626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24876848,0.0015758375,0.0020202957,0.00040114365,0.00065414415,0.000091366026,0.001422191,0.0003132982,0.06000042,0.00077240105,0.01049848,0.67348194],"study_design_scores_gemma":[0.09166903,0.030778699,0.05571725,0.0017655157,0.00020854076,0.00031754255,0.001372352,0.000220042,0.3008392,0.0039555086,0.51224697,0.000909359],"about_ca_topic_score_codex":0.00068349554,"about_ca_topic_score_gemma":0.0002717424,"teacher_disagreement_score":0.6725726,"about_ca_system_score_codex":0.00015942293,"about_ca_system_score_gemma":0.0017066426,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W4415281009","doi":"10.1016/j.annonc.2025.09.017","title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Unicancer; Roche","keywords":"Atezolizumab; Bladder cancer; Bacillus (shape); BCG vaccine; Clinical trial; Phases of clinical research","score_opus":0.06096434800192671,"score_gpt":0.4136386297376899,"score_spread":0.3526742817357632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415281009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768502,0.0013301607,0.00013269654,0.0065572304,0.0018420309,0.003320431,0.00036731854,0.000016845175,0.009583066],"genre_scores_gemma":[0.988169,0.008589638,0.00041530037,0.0011626763,0.00039278175,0.0005826298,0.000093937706,0.000033175354,0.00056086836],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99671715,0.00043153827,0.00128745,0.0006535543,0.00039304924,0.0005172716],"domain_scores_gemma":[0.9969731,0.0013277719,0.0006078987,0.00038867167,0.00048116493,0.00022142434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008014048,0.00040368605,0.0023444938,0.000409312,0.00007695833,0.0000248097,0.0004120312,0.0003944186,0.00048634288],"category_scores_gemma":[0.0007187025,0.00034563284,0.0001967767,0.00038156973,0.00068836863,0.00016974121,0.00029965272,0.0005154549,0.000008429146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76056236,0.006578446,0.00015189678,0.00008649417,0.0032114522,0.00029554043,0.0016131696,0.000013382247,0.001303369,0.0006008981,0.0030190917,0.22256388],"study_design_scores_gemma":[0.96528363,0.017239261,0.0008647331,0.00033161978,0.0011537584,0.000023436536,0.0003917137,0.000188069,0.010751318,0.0010029926,0.002496863,0.0002726071],"about_ca_topic_score_codex":0.017593494,"about_ca_topic_score_gemma":0.0029890947,"teacher_disagreement_score":0.22229128,"about_ca_system_score_codex":0.00029685674,"about_ca_system_score_gemma":0.0018246693,"threshold_uncertainty_score":0.99989957},"labels":[],"label_agreement":null},{"id":"W4415295431","doi":"10.1016/j.annonc.2025.10.017","title":"Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"Helsinn","keywords":"Antiemetic; Nausea; Vomiting; Regimen; Chemotherapy-induced nausea and vomiting","score_opus":0.042063422483322496,"score_gpt":0.3329288610674196,"score_spread":0.2908654385840971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415295431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143726,0.000121783116,0.0001827562,0.00443729,0.0001428487,0.0031093345,0.000169363,0.000019440835,0.00037995115],"genre_scores_gemma":[0.9954713,0.00033135107,0.0025248814,0.0010095286,0.00015441222,0.00012344886,0.000096855096,0.000026479034,0.00026173843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980003,0.00028154216,0.0007291802,0.0004176408,0.00030144257,0.00026984548],"domain_scores_gemma":[0.9956644,0.002577695,0.00078638806,0.00028627788,0.00062788,0.000057314286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013645947,0.00021221738,0.00073724694,0.00014166436,0.00018366262,0.0000143882635,0.00014227863,0.0001579373,0.00002069096],"category_scores_gemma":[0.0017518183,0.00014303335,0.00018078503,0.00023280333,0.0001538707,0.00005255997,0.00005979723,0.00017131107,4.7004906e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8300841,0.0014786932,0.02715985,0.00021537245,0.0025280335,0.0000033238048,0.0021933587,0.00002808172,0.0049188645,0.000087015665,0.0026739463,0.12862937],"study_design_scores_gemma":[0.73724526,0.012844719,0.19810109,0.00035280598,0.00066873484,0.0000013364162,0.0003560061,0.002022765,0.045427546,0.0006141158,0.0021028642,0.00026276291],"about_ca_topic_score_codex":0.00040873542,"about_ca_topic_score_gemma":0.00006399599,"teacher_disagreement_score":0.17094125,"about_ca_system_score_codex":0.00006123535,"about_ca_system_score_gemma":0.00019901768,"threshold_uncertainty_score":0.5832731},"labels":[],"label_agreement":null},{"id":"W4415295624","doi":"10.1016/j.annonc.2025.09.018","title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Foundation Medicine; Genentech; Ipsen; BeiGene; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Incyte; F. Hoffmann-La Roche; Roche; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alectinib; Crizotinib; Overall survival; Lung; Phases of clinical research; Standard of care","score_opus":0.04998713965319557,"score_gpt":0.4563106273006205,"score_spread":0.40632348764742493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415295624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97819036,0.0009322868,0.000029463632,0.0013311631,0.00034177833,0.0015611544,0.00010569706,0.000011578398,0.017496502],"genre_scores_gemma":[0.9973122,0.00039991058,0.00006754874,0.0003369825,0.000022879436,0.00016701664,0.00006506559,0.000010950596,0.0016174699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984469,0.00019696078,0.0005606976,0.0003364179,0.00016834417,0.00029071007],"domain_scores_gemma":[0.9984781,0.00038906618,0.00034224615,0.0003387162,0.0003890233,0.00006282025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022826555,0.00018516801,0.00091219303,0.0003713678,0.000065695116,0.000004286461,0.00015582025,0.00009848309,0.00009908253],"category_scores_gemma":[0.000076764765,0.0001394067,0.00025246784,0.0013054903,0.00008813187,0.000045846646,0.000065702916,0.00017238646,5.2213704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021983711,0.02168931,0.8380963,0.00030865349,0.024146508,0.00016974617,0.019458687,0.00627343,0.004069437,0.00018298846,0.0024878462,0.06113335],"study_design_scores_gemma":[0.10205259,0.013887615,0.84358716,0.00035700286,0.020399032,0.0000016103846,0.0036979998,0.0017750775,0.011988669,0.000022848071,0.001963522,0.00026689703],"about_ca_topic_score_codex":0.005199294,"about_ca_topic_score_gemma":0.009635893,"teacher_disagreement_score":0.08006889,"about_ca_system_score_codex":0.00022948267,"about_ca_system_score_gemma":0.0010983294,"threshold_uncertainty_score":0.7859812},"labels":[],"label_agreement":null},{"id":"W4415321365","doi":"10.1016/j.annonc.2025.10.007","title":"Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Clovis Oncology","keywords":"Interim; Ovarian cancer; Interim analysis; Olaparib; Maintenance therapy; Phases of clinical research","score_opus":0.07431117249813045,"score_gpt":0.43318192299261105,"score_spread":0.3588707504944806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415321365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740563,0.0030097843,0.0008623491,0.015112466,0.0017947532,0.0030716422,0.0009255998,0.000049900173,0.0011171843],"genre_scores_gemma":[0.9900003,0.0048302715,0.000933133,0.002414558,0.00020047031,0.000807232,0.00009182153,0.00004688945,0.0006752873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719,0.0003682367,0.0009996477,0.0006037902,0.00036067844,0.00047762963],"domain_scores_gemma":[0.9950471,0.0026592296,0.0006798582,0.0009473345,0.00051929645,0.00014717906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011267619,0.00030820235,0.0013002318,0.0001190387,0.00014899505,0.0000125126,0.00048039874,0.00021470418,0.00024767802],"category_scores_gemma":[0.0009096546,0.0002448262,0.00024498167,0.00028372311,0.00045595347,0.000110268855,0.0003032496,0.00027224762,0.0000016325715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13490297,0.007497142,0.039030686,0.00038110587,0.0038799488,0.00012420825,0.012105292,0.00007258955,0.040159464,0.007328412,0.15508996,0.59942824],"study_design_scores_gemma":[0.34417745,0.02297666,0.13803044,0.0028678954,0.0009688906,0.00001215024,0.0062699644,0.00031588387,0.018233346,0.01594013,0.44929537,0.0009117834],"about_ca_topic_score_codex":0.0016222489,"about_ca_topic_score_gemma":0.0024477795,"teacher_disagreement_score":0.59851646,"about_ca_system_score_codex":0.0002083201,"about_ca_system_score_gemma":0.0006025928,"threshold_uncertainty_score":0.99837226},"labels":[],"label_agreement":null},{"id":"W4415321954","doi":"10.1016/j.annonc.2025.10.013","title":"Antibody–drug conjugates in combination therapy: defining the next chapter","year":2025,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Conjugate; Cancer","score_opus":0.1082992593934442,"score_gpt":0.4806774783455847,"score_spread":0.3723782189521405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415321954","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012901598,0.031945936,0.000011270484,0.07280208,0.76677775,0.0022266877,0.00017374038,0.00007156721,0.113089345],"genre_scores_gemma":[0.1579418,0.21062844,0.0002692393,0.010388853,0.60206264,0.00054624316,0.002848158,0.00023503753,0.015079553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759436,0.00033967535,0.00059165107,0.0003679641,0.000694609,0.0004117472],"domain_scores_gemma":[0.99497736,0.0033539599,0.00028871026,0.00045420782,0.00085884286,0.00006694819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183925,0.00022543165,0.00086809235,0.00040411289,0.00005876785,0.000021637574,0.00039825344,0.00069375837,0.00029822526],"category_scores_gemma":[0.0018704634,0.00016337325,0.00015489609,0.00028990654,0.0003327554,0.000057271183,0.00014105262,0.001478422,0.00004101524],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069023477,0.00030640158,0.0007422465,0.0002588387,0.00015290458,0.00006747018,0.00063866377,0.0000014719873,0.00032702694,0.002303877,0.9160692,0.07844163],"study_design_scores_gemma":[0.002114255,0.0018524078,0.0005833654,0.0006768075,0.00002478479,0.0000029080156,0.00013166416,0.000028424194,0.0008247797,0.0010730274,0.9925714,0.0001161902],"about_ca_topic_score_codex":0.0010628408,"about_ca_topic_score_gemma":0.00024950868,"teacher_disagreement_score":0.1786825,"about_ca_system_score_codex":0.000116010386,"about_ca_system_score_gemma":0.0020086311,"threshold_uncertainty_score":0.6662168},"labels":[],"label_agreement":null},{"id":"W4415322256","doi":"10.1016/j.annonc.2025.10.010","title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Memorial Sloan-Kettering Cancer Center; Merck","keywords":"Clinical trial; Phase (matter); Phases of clinical research; Cell; Safety profile","score_opus":0.1515518232999306,"score_gpt":0.41865348601268293,"score_spread":0.2671016627127523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415322256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96426034,0.0017778714,0.000011705698,0.0022225883,0.00034572344,0.0041775494,0.00006499921,0.000018418352,0.027120817],"genre_scores_gemma":[0.9925734,0.00043567386,0.00041405013,0.0010694795,0.000056344245,0.00030055942,0.000064591084,0.000045482193,0.0050404514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99687964,0.00020749809,0.0012268781,0.0006603138,0.00043902392,0.0005866583],"domain_scores_gemma":[0.9972603,0.00052374863,0.0006919006,0.001004545,0.00035117823,0.00016834046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005344893,0.0004689571,0.0014397049,0.00034608535,0.00016983559,0.000012448518,0.0006452346,0.00033548998,0.00017084298],"category_scores_gemma":[0.00011812204,0.000329231,0.0003100837,0.00075831404,0.0002646943,0.00010572187,0.00027914724,0.00038679046,0.00001272269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5967011,0.13818781,0.00651816,0.00036765495,0.00066796347,0.00043444984,0.0012369445,0.00044514108,0.2097019,0.0001852941,0.0035072097,0.042046383],"study_design_scores_gemma":[0.4687156,0.11358923,0.011273631,0.00014726396,0.00029777957,0.000017900054,0.00013237985,0.0001956857,0.39743716,0.000098728204,0.0078771785,0.00021745301],"about_ca_topic_score_codex":0.0010521604,"about_ca_topic_score_gemma":0.00028828968,"teacher_disagreement_score":0.18773526,"about_ca_system_score_codex":0.00033627005,"about_ca_system_score_gemma":0.0017022728,"threshold_uncertainty_score":0.99991596},"labels":[],"label_agreement":null},{"id":"W4415368586","doi":"10.1016/j.annonc.2025.10.006","title":"Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; Chugai Pharmaceutical; Weill Cornell Medical College; Daiichi Sankyo Company; Pfizer Japan; Unicancer; Ipsen; Eisai; Relay Therapeutics; Seagen; European Social Fund; Puma Biotechnology; Pfizer; Fondazione Internazionale Menarini; Genentech; Lilly Deutschland; Veracyte; Mersana Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Menarini Silicon Biosystems; Friedrich-Alexander-Universität Erlangen-Nürnberg; Eisai Korea; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Novartis Foundation; Gilead Sciences; Sanofi; Celgene; Universität Ulm; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Emory University","keywords":"Clinical trial; Disease; Breast cancer; Safety profile; MEDLINE","score_opus":0.02773852152055462,"score_gpt":0.35713053667040384,"score_spread":0.3293920151498492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415368586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899072,0.00040781003,0.000015866983,0.007776432,0.00016500063,0.0015871119,0.0000804707,0.000011726212,0.000048371985],"genre_scores_gemma":[0.99859726,0.0002897129,0.0001472525,0.00055804825,0.00002304235,0.00032785296,0.000025836203,0.000014919416,0.000016043212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984225,0.00009177727,0.00072985596,0.00025351992,0.00024378113,0.00025855942],"domain_scores_gemma":[0.9988239,0.00020207331,0.00038470625,0.00025355094,0.00029256364,0.000043203538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012467256,0.00019005695,0.00067934976,0.0002779287,0.000038622686,0.0000025496097,0.000079950994,0.00006496008,0.000027610138],"category_scores_gemma":[0.00006705748,0.00012391225,0.00007060023,0.0004115408,0.00017272659,0.000077378994,0.000020953894,0.00017383312,1.0393381e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1909062,0.0039545074,0.687544,0.00023224649,0.00041774346,0.00007602242,0.0019760546,0.005445114,0.000921569,0.000028324477,0.000012905918,0.10848535],"study_design_scores_gemma":[0.14923157,0.0035294811,0.8419832,0.00031240954,0.000043778196,0.0000066272405,0.00039705128,0.00003689259,0.0039296965,0.00006715967,0.00034783324,0.000114320916],"about_ca_topic_score_codex":0.00057432987,"about_ca_topic_score_gemma":0.0012718571,"teacher_disagreement_score":0.15443923,"about_ca_system_score_codex":0.00010399493,"about_ca_system_score_gemma":0.00045934969,"threshold_uncertainty_score":0.50529945},"labels":[],"label_agreement":null},{"id":"W4415390112","doi":"10.1016/j.annonc.2025.10.019","title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Daiichi Sankyo Europe; Allergan; Genentech; Servier; Astellas Pharma; Seagen; Eisai; Jazz Pharmaceuticals; Taiho Pharmaceutical; Gilead Sciences; Relay Therapeutics; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Les Laboratories Pierre Fabre; Nipro","keywords":"Pertuzumab; Trastuzumab; Neoadjuvant therapy; Breast cancer; Clinical trial; Chemotherapy","score_opus":0.08287070357006318,"score_gpt":0.4633421922553893,"score_spread":0.3804714886853261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415390112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95586133,0.0035691375,0.0007778614,0.020569539,0.00067708385,0.013548837,0.0038930168,0.00007922802,0.0010239902],"genre_scores_gemma":[0.9854166,0.0036224297,0.0015179515,0.0023474249,0.00039111768,0.0030724488,0.00019292823,0.000108701315,0.0033304219],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99440944,0.00088128564,0.0015721635,0.0011929839,0.00063018454,0.0013139682],"domain_scores_gemma":[0.99375683,0.0030770255,0.0006902111,0.00063892367,0.0011495398,0.00068745005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020400386,0.00063271594,0.0026532924,0.00039231917,0.0003805885,0.00010762125,0.0006338826,0.0005385898,0.00046459775],"category_scores_gemma":[0.0015047278,0.0005115619,0.00024854808,0.00067769206,0.0007286714,0.00027652245,0.00030436568,0.00073959905,0.000008281486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5913251,0.0064632795,0.00034308078,0.00024402226,0.0013972024,0.00015707374,0.001028046,0.0000018398621,0.0038673403,0.000060575185,0.050928693,0.3441837],"study_design_scores_gemma":[0.92172605,0.04816916,0.0021070768,0.0009365706,0.0014468768,0.00017200848,0.000924173,0.00042972484,0.0063396194,0.0002640444,0.016903883,0.0005807981],"about_ca_topic_score_codex":0.014121786,"about_ca_topic_score_gemma":0.0021074482,"teacher_disagreement_score":0.34360293,"about_ca_system_score_codex":0.0007241469,"about_ca_system_score_gemma":0.004325539,"threshold_uncertainty_score":0.9997336},"labels":[],"label_agreement":null},{"id":"W4415595419","doi":"10.1016/j.annonc.2025.10.1236","title":"Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Queen's University; Hamilton Health Sciences; Occupational Cancer Research Centre; Ottawa Hospital; Health Sciences Centre; University Health Network; Abbotsford Veterinary Clinic; Jewish General Hospital; Sunnybrook Health Science Centre; Surrey Place Centre; Juravinski Cancer Centre; Canadian Centre for Applied Research in Cancer Control; Princess Margaret Cancer Centre; London Health Sciences Centre; Interior Health; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Genentech; BC Cancer Foundation; Ipsen; Syöpäsäätiö; Radboud Universitair Medisch Centrum; Astellas Pharma; Institute of Cancer Research; Terry Fox Research Institute; Michael Smith Health Research BC; Suomen Kulttuurirahasto; Academy of Finland; Eisai; EMD Serono; Jane ja Aatos Erkon Säätiö; Radboud Universiteit; Canadian Cancer Society; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Prostate Cancer Foundation","keywords":"Repertoire; Prostate cancer; Locus (genetics); Somatic cell; Hierarchy; Clinical significance","score_opus":0.11491517348765343,"score_gpt":0.5037442646344384,"score_spread":0.388829091146785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415595419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659778,0.0040586,0.0000028343297,0.024577973,0.00007797041,0.00041149816,0.000033676857,0.000004822889,0.004854819],"genre_scores_gemma":[0.9896031,0.0074496013,0.00015637497,0.00037746326,0.000027595268,0.000048328257,0.000016588918,0.0000040854243,0.002316873],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990488,0.000095745745,0.0004491989,0.00016556047,0.00009033969,0.0001503183],"domain_scores_gemma":[0.9992966,0.00019109708,0.00008818154,0.00013168914,0.00023576031,0.000056653495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034748335,0.000062850486,0.00034103103,0.00016222087,0.00002805789,0.0000030650551,0.000036854537,0.000087982065,0.000033146258],"category_scores_gemma":[0.00014015174,0.000048184454,0.00004909269,0.00020962066,0.00029232728,0.00003877968,0.000028925535,0.00014172446,5.7000244e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011055876,0.0025306758,0.45972213,0.0007480545,0.0006888065,0.00034409235,0.0021389406,0.000031236734,0.03347655,0.004203884,0.011856799,0.47320294],"study_design_scores_gemma":[0.01748364,0.013558596,0.8219799,0.0014088074,0.00023652188,0.000021184014,0.0012035652,0.0004252725,0.06836742,0.005060195,0.07001396,0.00024096937],"about_ca_topic_score_codex":0.00062059244,"about_ca_topic_score_gemma":0.0013431165,"teacher_disagreement_score":0.472962,"about_ca_system_score_codex":0.000039811664,"about_ca_system_score_gemma":0.0010169946,"threshold_uncertainty_score":0.19649051},"labels":[],"label_agreement":null},{"id":"W4415877393","doi":"10.1016/j.annonc.2025.10.018","title":"Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Queen's University","funders":"Cancer Moonshot; Melanoma Centre of Research Excellence; National Cancer Institute; Faculty of Medicine and Health, University of Sydney; University of Texas MD Anderson Cancer Center; Johns Hopkins University; University of Sydney; Mark Foundation For Cancer Research; National Institutes of Health; LUNGevity Foundation; Ontario Institute for Cancer Research; Foundation for the National Institutes of Health; National Health and Medical Research Council; Bloomberg Family Foundation","keywords":"Clinical trial; Standardization; Neoadjuvant therapy; Surrogate endpoint; Clinical endpoint; MEDLINE; Risk stratification","score_opus":0.2176632095438715,"score_gpt":0.46936142705588196,"score_spread":0.2516982175120105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415877393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98190236,0.0024350216,0.000107222884,0.013698768,0.0001807836,0.00052702986,0.000039314848,0.000018957291,0.0010905414],"genre_scores_gemma":[0.99165136,0.00042907242,0.002922081,0.0043580686,0.000059263926,0.0000603506,0.000020461555,0.000007655542,0.0004916638],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988512,0.000066273744,0.0005823128,0.00020725613,0.000097696044,0.000195259],"domain_scores_gemma":[0.99861276,0.00033722102,0.00020039846,0.00017147193,0.0006154723,0.000062696294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076806295,0.0001127709,0.00069202046,0.00023539792,0.000029325369,0.0000021765595,0.00005872525,0.000101004654,0.000031939402],"category_scores_gemma":[0.0018038441,0.000080989455,0.000119844175,0.00029700753,0.00010784969,0.000025121797,0.00007365507,0.000070986476,0.0000012615475],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06449446,0.001989967,0.03963724,0.0012183851,0.0010241674,0.00049784646,0.000341543,0.000019731373,0.199717,0.0018488184,0.028972093,0.66023874],"study_design_scores_gemma":[0.030480511,0.037893146,0.44944373,0.00095550634,0.00078903505,0.00018298149,0.000587081,0.00017246214,0.33206934,0.008084491,0.1390144,0.00032730945],"about_ca_topic_score_codex":0.000082293904,"about_ca_topic_score_gemma":0.000013487391,"teacher_disagreement_score":0.65991145,"about_ca_system_score_codex":0.00003030777,"about_ca_system_score_gemma":0.0002481427,"threshold_uncertainty_score":0.3302654},"labels":[],"label_agreement":null},{"id":"W4415939652","doi":"10.1016/j.annonc.2025.08.2684","title":"2063eP Real-world treatment patterns and outcomes in stage IV NSCLC: A retrospective study from Southwestern Ontario","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"MD Precision (Canada); London Health Sciences Centre; Western University","funders":"","keywords":"Retrospective cohort study; Stage (stratigraphy); MEDLINE; Medical record","score_opus":0.05379844394685784,"score_gpt":0.4340419835925989,"score_spread":0.38024353964574104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098075,0.000075017175,0.000006107893,0.0022630321,0.00012558392,0.0008462012,0.00013906023,0.000015763235,0.0155484555],"genre_scores_gemma":[0.98178464,0.000114949435,0.00006213698,0.00051475124,0.000018679788,0.00011695436,0.00004192457,0.000008535621,0.017337443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990583,0.000059337952,0.00031150997,0.00030039047,0.000094146424,0.0001763215],"domain_scores_gemma":[0.99941677,0.00010143126,0.000104869425,0.0002419863,0.00007414302,0.000060772483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007819859,0.00015002512,0.00062940276,0.00022285769,0.00003320544,0.0000072976145,0.000042458036,0.000060281433,0.00012932452],"category_scores_gemma":[0.000014635535,0.00011261579,0.00006615785,0.00012304039,0.000041995536,0.000043835378,0.000038099122,0.00009527505,0.000003439121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030151499,0.0026789946,0.97404563,0.000008803643,0.0009381791,0.00018364722,0.012597974,0.0000013732898,0.000011649806,0.00011364033,0.00007121775,0.009047346],"study_design_scores_gemma":[0.0068252487,0.004104638,0.9832832,0.000054322703,0.000321716,7.528631e-7,0.0025787938,0.000002174085,0.000061833816,0.0001998511,0.002500005,0.0000674505],"about_ca_topic_score_codex":0.48930392,"about_ca_topic_score_gemma":0.8929393,"teacher_disagreement_score":0.40363538,"about_ca_system_score_codex":0.0006450926,"about_ca_system_score_gemma":0.0004777203,"threshold_uncertainty_score":0.51409686},"labels":[],"label_agreement":null},{"id":"W4415939659","doi":"10.1016/j.annonc.2025.08.3535","title":"2923eP Exploring physician practices in cancer rehabilitation in under-resourced settings: The first survey-based study across the MENA Region and Africa","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton University","funders":"","keywords":"Viewpoints; Cancer; Rehabilitation; Health care; Mental healthcare; Mental health","score_opus":0.21039731962426547,"score_gpt":0.45162648144482354,"score_spread":0.24122916182055806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9045991,0.00086704426,0.0000044722556,0.09292438,0.00013086115,0.00059650315,0.0000047358612,0.0000084493795,0.0008645019],"genre_scores_gemma":[0.9956705,0.00011534881,0.000004741836,0.003763371,0.000033627155,0.0003505172,0.0000026382188,0.000007496273,0.00005175192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985345,0.00060544524,0.0002876374,0.00022746543,0.00013886599,0.00020607734],"domain_scores_gemma":[0.99627,0.0030403663,0.0002663007,0.0002592915,0.00014415536,0.00001988992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020735278,0.00009611394,0.000288601,0.00009108975,0.00009312807,0.000013212722,0.00011343909,0.00005910163,0.0000020873113],"category_scores_gemma":[0.0008073422,0.00006209577,0.000038095062,0.0006106909,0.00013353815,0.00007890783,0.000055625187,0.00023700313,3.9918163e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020430654,0.0010334514,0.84607315,0.00022778318,0.00009509575,0.000014289014,0.10312945,0.00055424095,0.0000847114,0.00007822757,0.0032510355,0.043415498],"study_design_scores_gemma":[0.0014368574,0.0012214809,0.88729703,0.00021191695,0.000028279872,4.0248509e-7,0.077303745,0.00012749553,0.00010681665,0.00014654419,0.03205989,0.00005956795],"about_ca_topic_score_codex":0.012122088,"about_ca_topic_score_gemma":0.25196135,"teacher_disagreement_score":0.23983926,"about_ca_system_score_codex":0.00009947677,"about_ca_system_score_gemma":0.00018507577,"threshold_uncertainty_score":0.9944563},"labels":[],"label_agreement":null},{"id":"W4415939673","doi":"10.1016/j.annonc.2025.08.543","title":"109O Capturing clonal evolution through histology","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Histology; Somatic evolution in cancer; Disease; Gene deletion; Anatomical pathology; Genetic diagnosis","score_opus":0.03376252231962767,"score_gpt":0.3519495181937567,"score_spread":0.318186995874129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8816948,0.010336147,0.008800029,0.0066290284,0.0012923472,0.00019136065,0.000048381393,0.000012808554,0.09099509],"genre_scores_gemma":[0.9943629,0.0011046199,0.00083590666,0.002714597,0.00017211096,0.000014712163,0.000045493605,0.0000075227586,0.0007421439],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992464,0.000043742322,0.00023296477,0.00022570869,0.000044513778,0.00020665771],"domain_scores_gemma":[0.99945086,0.00004828237,0.00010306757,0.0002227428,0.00014528703,0.000029741752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012773645,0.0000924508,0.0001955152,0.000047940128,0.000044245535,0.0000030651756,0.00015110463,0.00021998103,0.000020728796],"category_scores_gemma":[0.00017082505,0.000100108315,0.00009228894,0.0000715515,0.00014738007,0.0000021389237,0.00012704228,0.00007266044,0.0000062097733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010951542,0.00077067065,0.013669754,0.00012961164,0.0004932948,0.000029285316,0.0002891791,0.0011854965,0.4265219,0.15304263,0.34177426,0.060998775],"study_design_scores_gemma":[0.00060479605,0.0008840454,0.0050401296,0.000010806225,0.000023562661,0.000012986076,0.00006373877,0.00002284263,0.08751079,0.00785625,0.897853,0.00011704727],"about_ca_topic_score_codex":0.00019442114,"about_ca_topic_score_gemma":0.0002434787,"teacher_disagreement_score":0.55607873,"about_ca_system_score_codex":0.000036271165,"about_ca_system_score_gemma":0.00038273563,"threshold_uncertainty_score":0.40822986},"labels":[],"label_agreement":null},{"id":"W4415939711","doi":"10.1016/j.annonc.2025.08.3070","title":"2455P Prevalence and severity of hot flashes and their association with prostate-specific antigen (PSA) response: results from the initial treatment phase of LIBERTAS, a phase 3 study in metastatic hormone-sensitive prostate cancer (mHSPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Johnson and Johnson","keywords":"Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Phases of clinical research; Androgen suppression; Antiandrogen; Hot flash","score_opus":0.11067709328636673,"score_gpt":0.44231026580445554,"score_spread":0.3316331725180888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984513,0.0066930605,0.0000015932618,0.0035748922,0.000027427193,0.0024663866,0.0026385242,0.000006814355,0.00007830343],"genre_scores_gemma":[0.98208016,0.01724836,0.00006537207,0.00007006308,0.000013557175,0.00015961062,0.0000810076,0.000010369751,0.0002714709],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979119,0.00073589786,0.0005271381,0.00034914515,0.00022294422,0.00025300033],"domain_scores_gemma":[0.9971411,0.0017502633,0.0004075361,0.00022559759,0.00041149443,0.00006396542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010279241,0.0001915675,0.00073643844,0.00014050503,0.000052217532,0.000009338363,0.00006276423,0.00006783063,0.0000039519564],"category_scores_gemma":[0.00027033951,0.00010950591,0.000043786473,0.00035477406,0.00035872715,0.000094614916,0.000052230913,0.00014599989,1.8104417e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6137997,0.010767279,0.1119161,0.00022724744,0.0027639754,0.00030400068,0.09275925,0.000008947533,0.0430494,0.000006065271,0.0007207185,0.123677336],"study_design_scores_gemma":[0.06833265,0.052793328,0.6997458,0.00052793935,0.0003909665,0.000005866771,0.008865843,0.000098386845,0.16719119,0.00011873269,0.0017779287,0.00015140699],"about_ca_topic_score_codex":0.0018376001,"about_ca_topic_score_gemma":0.000886185,"teacher_disagreement_score":0.58782965,"about_ca_system_score_codex":0.00016312323,"about_ca_system_score_gemma":0.00081957626,"threshold_uncertainty_score":0.44655216},"labels":[],"label_agreement":null},{"id":"W4415939716","doi":"10.1016/j.annonc.2025.08.675","title":"245eP Assessment of the diagnostic accuracy of urine biomarkers for the detection of bladder cancer from an international multicentric study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Cystoscopy; Bladder cancer; Diagnostic accuracy; Gold standard (test); Biomarker; Cancer; Diagnostic test; Urothelial cancer","score_opus":0.06477506658228259,"score_gpt":0.4663409624708745,"score_spread":0.4015658958885919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300367,0.00075669534,0.00042517466,0.0030534854,0.00071319076,0.0013507752,0.00018783739,0.0000038108776,0.0005053728],"genre_scores_gemma":[0.9986921,0.0006297655,0.0000915964,0.0003035408,0.000058235695,0.00016351619,0.000007769073,0.0000061103465,0.000047385354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991245,0.00009800001,0.000378765,0.00013468921,0.00017290551,0.000091090355],"domain_scores_gemma":[0.99734896,0.0016134954,0.00035301436,0.00025594918,0.00040733593,0.00002122212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020351337,0.00007964864,0.00029648648,0.00008555025,0.000028750092,0.0000017013805,0.0001830767,0.000051739764,0.000112174224],"category_scores_gemma":[0.0005408685,0.00004640962,0.00011232648,0.00017881916,0.000109430664,0.000044091328,0.000055825632,0.000061637744,1.2704464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021046242,0.005811202,0.7204934,0.0001151978,0.005612818,0.0000020002162,0.0009486986,0.00019857299,0.016822556,0.000070433445,0.0005251396,0.24729536],"study_design_scores_gemma":[0.004064214,0.0022383675,0.9421468,0.00006640205,0.0007757715,5.148492e-7,0.0006777874,0.0005726737,0.047819484,0.000105151244,0.001502018,0.00003084696],"about_ca_topic_score_codex":0.0041705985,"about_ca_topic_score_gemma":0.0009937242,"teacher_disagreement_score":0.24726452,"about_ca_system_score_codex":0.000051629915,"about_ca_system_score_gemma":0.00037274612,"threshold_uncertainty_score":0.6304725},"labels":[],"label_agreement":null},{"id":"W4415939749","doi":"10.1016/j.annonc.2025.08.3517","title":"2905P PROPEL: Patient-reported outcomes of people experiencing lung cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northwestern Polytechnic; Alberta Health Services; University of Calgary","funders":"","keywords":"Lung cancer; Quality of life (healthcare); Outcome (game theory); Cancer; MEDLINE; Data collection","score_opus":0.048901408590862436,"score_gpt":0.41454126122387863,"score_spread":0.3656398526330162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97560537,0.002147291,0.000042491367,0.004087269,0.0007287071,0.00030624217,0.000008991602,0.000022053266,0.01705158],"genre_scores_gemma":[0.9966007,0.0002501502,0.000044023578,0.002024335,0.000027784974,0.00008543398,0.000005998452,0.000008886049,0.0009527213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896514,0.00004482899,0.0004577271,0.00017681564,0.00016499177,0.00019050033],"domain_scores_gemma":[0.9989295,0.00008925318,0.00024103445,0.00025379803,0.00043095273,0.000055454388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014226079,0.000098998345,0.00057851564,0.00013547367,0.00002416165,0.0000017738703,0.000072788665,0.00010535128,0.00021724874],"category_scores_gemma":[0.00016902472,0.000080049045,0.00013430853,0.00029829872,0.00007344285,0.000038421105,0.000059138678,0.00009837247,6.5728216e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004942621,0.00038519836,0.8629582,0.0004531603,0.0004980103,0.00003301766,0.016935043,0.000014690547,0.0051183742,0.00034308239,0.010906813,0.101860166],"study_design_scores_gemma":[0.0033937767,0.0026934894,0.70442986,0.0005854146,0.0004886907,0.000021282483,0.0152355265,0.00014111586,0.14998326,0.00015709054,0.12257433,0.00029616815],"about_ca_topic_score_codex":0.0044953316,"about_ca_topic_score_gemma":0.0032223316,"teacher_disagreement_score":0.15852833,"about_ca_system_score_codex":0.000054519223,"about_ca_system_score_gemma":0.0006413419,"threshold_uncertainty_score":0.6795627},"labels":[],"label_agreement":null},{"id":"W4415939780","doi":"10.1016/j.annonc.2025.08.2506","title":"1882P Glans-look lung cancer research study (GLR): A population-level real-world evidence database","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Lung cancer; Clinical trial; Real world evidence; Clinical research; MEDLINE; Cancer; Evidence-based medicine; Personalization; Evidence-based practice","score_opus":0.31764986044598575,"score_gpt":0.6132934011239383,"score_spread":0.2956435406779525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94113725,0.0035754372,0.00004731688,0.023088465,0.0004126304,0.0019390481,0.00013761334,0.000041854863,0.02962036],"genre_scores_gemma":[0.981895,0.0015210524,0.0003474031,0.0010655671,0.00012998689,0.00039215767,0.000074491196,0.000012826162,0.01456149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983123,0.0002503945,0.00040577812,0.000353113,0.00035324116,0.00032517329],"domain_scores_gemma":[0.9979975,0.0006023638,0.0001092817,0.00047764342,0.0007045744,0.000108603774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008754349,0.0001177897,0.0004057723,0.00047506051,0.00015834226,0.000010723224,0.000148915,0.00006648932,0.00028737434],"category_scores_gemma":[0.00037369502,0.00009883159,0.00006444318,0.00083871215,0.0001060166,0.00014093037,0.00011056423,0.00023520853,0.000010942606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007193188,0.001819738,0.8797644,0.00025537956,0.00078216015,0.00013029158,0.0012811964,0.000025579626,0.00047778993,0.0022923213,0.07977366,0.032678198],"study_design_scores_gemma":[0.0025059765,0.001663124,0.9745672,0.0008520898,0.00052674196,0.0000035764551,0.00092097966,0.00011134298,0.00051548437,0.00030452418,0.017924415,0.00010456176],"about_ca_topic_score_codex":0.044539012,"about_ca_topic_score_gemma":0.024575008,"teacher_disagreement_score":0.09480282,"about_ca_system_score_codex":0.00034835425,"about_ca_system_score_gemma":0.00163175,"threshold_uncertainty_score":0.99322397},"labels":[],"label_agreement":null},{"id":"W4415939788","doi":"10.1016/j.annonc.2025.08.3072","title":"2457P CDK12 as a prostate cancer predisposition gene","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University; University of British Columbia","funders":"Canadian Cancer Society; Michael Smith Health Research BC; Prostate Cancer Canada; AstraZeneca; BC Cancer Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Gene; Genetic predisposition; Cancer; Prostate","score_opus":0.034659880763349527,"score_gpt":0.40076857280061284,"score_spread":0.3661086920372633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9136906,0.0051539866,0.00019733519,0.031828854,0.0006545929,0.0007584667,0.000053740263,0.00006463011,0.047597755],"genre_scores_gemma":[0.98691446,0.002066022,0.00042880067,0.007179495,0.00011489374,0.00014726698,0.000052116397,0.000017609427,0.0030793487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990637,0.00005445221,0.00028338504,0.00022555485,0.0001343545,0.0002385578],"domain_scores_gemma":[0.9992336,0.00003805666,0.000120388206,0.00023371613,0.0002936447,0.00008057181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016410375,0.0001067048,0.00033608952,0.00016537728,0.000033040917,0.000003322083,0.00006818534,0.00018947857,0.00017330695],"category_scores_gemma":[0.00009360584,0.000103096376,0.00010630437,0.00028049777,0.000101713544,0.000035558784,0.000047042093,0.00018045104,0.000029680677],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036699348,0.0010075694,0.0027591547,0.0003908498,0.00087816746,0.00038892627,0.00094662607,0.00023491337,0.620117,0.00510148,0.091812976,0.27269238],"study_design_scores_gemma":[0.003702823,0.0039961003,0.0132997455,0.00042090475,0.0002997446,0.00010459147,0.00006587197,0.00016671048,0.6200159,0.0022878493,0.35548374,0.00015600429],"about_ca_topic_score_codex":0.00038099484,"about_ca_topic_score_gemma":0.0001021782,"teacher_disagreement_score":0.27253637,"about_ca_system_score_codex":0.00010955803,"about_ca_system_score_gemma":0.0012139681,"threshold_uncertainty_score":0.4204148},"labels":[],"label_agreement":null},{"id":"W4415939801","doi":"10.1016/j.annonc.2025.08.1862","title":"1227eP Real-world (rw) outcomes in patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib: Final results from the 1NSPIRE chart review study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Epithelial ovarian cancer; Chemotherapy; Placebo; Chart; Ovarian cancer; Maintenance therapy","score_opus":0.10244560087867295,"score_gpt":0.41625983669040517,"score_spread":0.31381423581173223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7997537,0.0028651266,0.000014595108,0.18447699,0.0006871163,0.0032577247,0.00089974294,0.00005396626,0.0079909945],"genre_scores_gemma":[0.9178771,0.038182616,0.00016342165,0.03869491,0.0002825486,0.00067970075,0.00016605327,0.000041048,0.0039126193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678993,0.0004509965,0.0012305978,0.00063127227,0.000425721,0.00047147775],"domain_scores_gemma":[0.99692327,0.00080220687,0.0006710936,0.00085833255,0.0006433613,0.00010170988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011383762,0.00033168786,0.0014122047,0.0001865605,0.00011611363,0.000008831437,0.00036458203,0.00014208014,0.00024377306],"category_scores_gemma":[0.0005552917,0.00021271277,0.0001540388,0.0007796337,0.00026479756,0.00009042748,0.00008858673,0.0005064835,0.00001644683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017847663,0.003727094,0.7540536,0.00030115887,0.00086416304,0.00009358872,0.0016780464,0.000059264265,0.00003729435,0.00014579369,0.14992124,0.071271114],"study_design_scores_gemma":[0.025364911,0.0038610022,0.8001111,0.005369522,0.00019553122,0.0000012040358,0.00012581627,0.000015752616,0.00023200297,0.00021877246,0.16430482,0.00019955472],"about_ca_topic_score_codex":0.010053714,"about_ca_topic_score_gemma":0.03131395,"teacher_disagreement_score":0.14578208,"about_ca_system_score_codex":0.00029314702,"about_ca_system_score_gemma":0.00066412747,"threshold_uncertainty_score":0.9965384},"labels":[],"label_agreement":null},{"id":"W4415939802","doi":"10.1016/j.annonc.2025.08.3399","title":"2788P Real-world third-line treatment patterns and outcomes for recurrent or extensive stage small cell lung cancer (SCLC) in the Canadian small cell lung cancer database (CASCADE)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Capital District Health Authority; London Health Sciences Centre; Western University; Atlantic School of Theology; Atlantic Cancer Research Institute; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network; Jewish General Hospital; Ottawa Regional Cancer Foundation; CancerCare Manitoba","funders":"","keywords":"Lung cancer; Small Cell Lung Carcinoma; Cancer; Small-cell carcinoma; Stage (stratigraphy)","score_opus":0.14396334498684643,"score_gpt":0.4763903635046531,"score_spread":0.33242701851780665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88614196,0.018168401,0.000028221308,0.07964442,0.0006622588,0.0054463507,0.0033666403,0.000027679307,0.00651407],"genre_scores_gemma":[0.86241144,0.088257015,0.00040141033,0.015074343,0.00035422284,0.0026721708,0.00022758638,0.00006429405,0.030537492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997542,0.00022528095,0.00056466646,0.0005802223,0.0002275049,0.00086027995],"domain_scores_gemma":[0.9974224,0.0010804724,0.00022505884,0.00051648275,0.00048613822,0.00026946136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006443631,0.000350592,0.00097518263,0.00048969773,0.000170352,0.000022447472,0.00026778923,0.00014165844,0.00011281989],"category_scores_gemma":[0.0001943679,0.00021560008,0.00014612297,0.00036305963,0.00017372984,0.000055143886,0.00014610209,0.0003720258,0.0000010062957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003090294,0.0011167043,0.86266375,0.004364646,0.0011888703,0.0006976592,0.007457796,0.00007465693,0.00029045128,0.00024714155,0.090403736,0.028404327],"study_design_scores_gemma":[0.018276941,0.0070235757,0.60105395,0.001964154,0.001783439,0.000008473432,0.0044811554,0.001864956,0.01159864,0.000054867964,0.3511492,0.00074064604],"about_ca_topic_score_codex":0.6753426,"about_ca_topic_score_gemma":0.98763466,"teacher_disagreement_score":0.31229204,"about_ca_system_score_codex":0.0014429562,"about_ca_system_score_gemma":0.004126548,"threshold_uncertainty_score":0.87919164},"labels":[],"label_agreement":null},{"id":"W4415939819","doi":"10.1016/j.annonc.2025.08.540","title":"107eP Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto","funders":"","keywords":"Isocitrate dehydrogenase; Phase (matter); Phases of clinical research; Safety profile","score_opus":0.044862992435662656,"score_gpt":0.371219291320809,"score_spread":0.32635629888514633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828457,0.00056703744,0.0000029940713,0.008928427,0.000112759604,0.001123462,0.0001584804,0.000011465062,0.0062496383],"genre_scores_gemma":[0.99831605,0.000056997163,0.000044984405,0.0012047454,0.000036594363,0.000029714678,0.00010029294,0.000008069373,0.00020257846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985757,0.0001526347,0.0005936013,0.00027558868,0.00020541008,0.00019707438],"domain_scores_gemma":[0.99859554,0.00035033375,0.00024011488,0.0004067349,0.00037041627,0.000036835714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033476783,0.00013748741,0.00061233726,0.00011004175,0.000043701602,0.0000028247314,0.00015767624,0.000076909804,0.000027397835],"category_scores_gemma":[0.00026141273,0.00008385554,0.00006345123,0.00039199452,0.00017809428,0.000041658514,0.00010587295,0.0001806429,0.0000019434485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03151873,0.005922528,0.90281874,0.000029183318,0.00083906634,0.00004076965,0.005401936,0.0000042958827,0.00011723197,0.000031188865,0.032826584,0.020449763],"study_design_scores_gemma":[0.033288896,0.0075867493,0.9440868,0.00012078199,0.00017785959,4.4027618e-7,0.0018574576,0.0000046471355,0.00078160316,0.000045187437,0.011980025,0.000069570815],"about_ca_topic_score_codex":0.0015247578,"about_ca_topic_score_gemma":0.00203928,"teacher_disagreement_score":0.04126806,"about_ca_system_score_codex":0.00004316554,"about_ca_system_score_gemma":0.00029307994,"threshold_uncertainty_score":0.34195298},"labels":[],"label_agreement":null},{"id":"W4415939841","doi":"10.1016/j.annonc.2025.08.1740","title":"1102P Contribution of bevacizumab (bev) use to safety outcomes in FIRST/ENGOT-OV44","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Bevacizumab; Ovarian cancer; Chemotherapy; Stage (stratigraphy); Safety profile; MEDLINE","score_opus":0.07945393653273285,"score_gpt":0.43881939463913633,"score_spread":0.35936545810640347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337621,0.00031538933,0.000558008,0.059757236,0.00034541162,0.0006603269,0.00009336926,0.000025427255,0.004482753],"genre_scores_gemma":[0.9908544,0.00045621835,0.00042582353,0.007504983,0.00003278538,0.00005023994,0.000024870682,0.000008076472,0.0006426394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861914,0.00010692802,0.00066672155,0.00020400179,0.00015630873,0.0002468816],"domain_scores_gemma":[0.9984003,0.0006108784,0.00018089577,0.00030528492,0.00042751367,0.000075178934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046725431,0.000117962205,0.00074373046,0.00035108693,0.000026447191,0.0000023914108,0.00010057953,0.00019044675,0.000155417],"category_scores_gemma":[0.00082475215,0.00011063149,0.00012525229,0.00041523264,0.0001071991,0.00007017518,0.00004749312,0.00015496368,0.000014498749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01869828,0.003536478,0.7407133,0.000402024,0.0009103571,0.00011178225,0.001948186,0.00042546925,0.032152206,0.037973426,0.07153706,0.09159142],"study_design_scores_gemma":[0.010282408,0.0025164622,0.5608189,0.0003855249,0.000048842518,0.000009280128,0.000095370335,0.000027725233,0.066680305,0.0018338853,0.35717118,0.00013012593],"about_ca_topic_score_codex":0.0002845196,"about_ca_topic_score_gemma":0.0006058031,"teacher_disagreement_score":0.2856341,"about_ca_system_score_codex":0.0001997889,"about_ca_system_score_gemma":0.00031272287,"threshold_uncertainty_score":0.4511421},"labels":[],"label_agreement":null},{"id":"W4415939861","doi":"10.1016/j.annonc.2025.08.2637","title":"2013P Repotrectinib in adult and pediatric patients with NTRK+ advanced solid tumors: Updated results from the TRIDENT-1 and CARE trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Micropalaeontological Society; Bamfield Marine Sciences Centre","keywords":"Standard of care; Clinical trial; Solid tumor; MEDLINE; Tyrosine kinase","score_opus":0.030687893561948426,"score_gpt":0.40925444022155,"score_spread":0.37856654665960154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943996,0.00219598,0.0000023793398,0.0054550106,0.00011922881,0.0008022507,0.0002469985,0.00001131132,0.0017269001],"genre_scores_gemma":[0.9973863,0.0009888374,0.00018150317,0.00088472373,0.00005768449,0.000047964724,0.0002728911,0.000006934966,0.00017318576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988338,0.00015191938,0.0005277026,0.0002491318,0.000095914584,0.0001415264],"domain_scores_gemma":[0.99848926,0.00061526854,0.0003089058,0.00018016444,0.0003564628,0.000049908467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022753028,0.00010640154,0.00052736286,0.00011085046,0.000050904844,0.000007663151,0.000041511663,0.00007492914,0.000008762496],"category_scores_gemma":[0.0010180922,0.000062581974,0.00003279518,0.00022499567,0.00006272886,0.000057560846,0.000028706514,0.00010047347,7.999927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01582088,0.0008712097,0.70071125,0.00010211949,0.000636792,0.00008356868,0.00945639,0.000028545146,0.00008376504,0.00007769105,0.02158957,0.25053823],"study_design_scores_gemma":[0.032892395,0.002975301,0.953732,0.00021856681,0.0006603357,0.0000030975395,0.0028446694,0.000009562052,0.0007083845,0.00017205182,0.0056785676,0.00010507178],"about_ca_topic_score_codex":0.0008511769,"about_ca_topic_score_gemma":0.00066658854,"teacher_disagreement_score":0.25302073,"about_ca_system_score_codex":0.00003861996,"about_ca_system_score_gemma":0.00031548968,"threshold_uncertainty_score":0.25520188},"labels":[],"label_agreement":null},{"id":"W4415939879","doi":"10.1016/j.annonc.2025.08.3702","title":"3088P Association of molecular markers with clinical response to TAR-200 in the phase IIb SunRISe-1 trial in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Johnson and Johnson; Astellas Pharma; Merck KGaA; Eisai; Else Kröner-Fresenius-Stiftung; AstraZeneca","keywords":"Bladder cancer; Carcinoma in situ; In situ; Carcinoma; Phases of clinical research","score_opus":0.03733582358958509,"score_gpt":0.4027620757087445,"score_spread":0.3654262521191594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990993,0.00013443567,0.00001567318,0.0042503187,0.00006465297,0.003920205,0.000109374916,0.000007873505,0.0005044702],"genre_scores_gemma":[0.9950123,0.000074367796,0.00016956207,0.0039146217,0.00003454997,0.0005759632,0.00003929739,0.000035050536,0.0001443232],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9963529,0.0012780362,0.0007588235,0.00054951775,0.00059841655,0.00046227372],"domain_scores_gemma":[0.99707526,0.001227204,0.0004591128,0.00047509265,0.00057018036,0.00019316554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012234355,0.00032113498,0.0011018553,0.0004825637,0.00003773524,0.000009494952,0.00019844554,0.00019789589,0.000035996738],"category_scores_gemma":[0.00069961883,0.00018112893,0.00008361789,0.0011584975,0.00021807302,0.00011186558,0.000045988923,0.00037245834,0.0000012019889],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49882704,0.0022581406,0.49539047,0.000042739746,0.00032708395,0.0005619228,0.0011302414,0.00008797423,0.000059884485,0.0000020984821,0.00025162907,0.0010607635],"study_design_scores_gemma":[0.15282227,0.056305867,0.78809047,0.00058118056,0.00040801681,0.0000021684637,0.0009472594,0.00001180874,0.00040300912,0.000010120813,0.00023705888,0.0001807449],"about_ca_topic_score_codex":0.0013812233,"about_ca_topic_score_gemma":0.015533872,"teacher_disagreement_score":0.34600478,"about_ca_system_score_codex":0.00041610276,"about_ca_system_score_gemma":0.0052622757,"threshold_uncertainty_score":0.9335051},"labels":[],"label_agreement":null},{"id":"W4415939886","doi":"10.1016/j.annonc.2025.08.3074","title":"2459P Darolutamide efficacy, quality of life, and safety outcomes by age subgroup: ARANOTE post hoc analyses","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare","keywords":"Prostate cancer; Placebo; Post-hoc analysis; Post hoc; Radiological weapon; Clinical trial","score_opus":0.16459982559444677,"score_gpt":0.5096159244262625,"score_spread":0.3450160988318157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657059,0.00744504,0.000025919937,0.020086415,0.000069356334,0.00035264454,0.00015173301,0.000017666265,0.0061453595],"genre_scores_gemma":[0.99109274,0.0040265624,0.0001257543,0.0022550162,0.000016607839,0.000009082186,0.00011449648,0.000008409177,0.0023513164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984646,0.0002148303,0.00058128964,0.00024902978,0.00021381288,0.00027644387],"domain_scores_gemma":[0.99834096,0.0007946135,0.0001896509,0.0002915899,0.00024589038,0.00013726538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006021583,0.00014325071,0.0009707841,0.00019894131,0.000050722472,0.000004698531,0.00011267924,0.00015550577,0.0000585986],"category_scores_gemma":[0.00058292603,0.00010349328,0.00017277048,0.00026301364,0.00045474674,0.00004459222,0.00009869801,0.00016176913,0.0000027155322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028646294,0.003688705,0.6634983,0.0012467499,0.004163124,0.00014363481,0.0009998243,0.000007798263,0.11969796,0.001505011,0.032872237,0.14353035],"study_design_scores_gemma":[0.008417928,0.0029476138,0.94828767,0.00007717139,0.00014696369,0.0000023976295,0.0002470757,0.0000075034186,0.01626265,0.00030390365,0.02318741,0.000111728456],"about_ca_topic_score_codex":0.00077362027,"about_ca_topic_score_gemma":0.00017491958,"teacher_disagreement_score":0.28478935,"about_ca_system_score_codex":0.00004160002,"about_ca_system_score_gemma":0.0004076121,"threshold_uncertainty_score":0.42203334},"labels":[],"label_agreement":null},{"id":"W4415939895","doi":"10.1016/j.annonc.2025.08.2941","title":"2325P A Retrospective study demonstrating higher completion rates of parallel germline testing vs. sequential ordering after tumor BRCA1/2 mutation detection","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; BC Cancer Agency","funders":"","keywords":"Germline; Germline mutation; Genetic testing; Retrospective cohort study; Hereditary Cancer; Cancer","score_opus":0.05477221513985032,"score_gpt":0.37756116899101033,"score_spread":0.32278895385116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844737,0.0002616632,0.009476376,0.00023574416,0.0002790185,0.00037050716,0.000013802343,0.00001290095,0.00090259896],"genre_scores_gemma":[0.9940441,0.0000120628,0.0054081017,0.00020084853,0.0001249556,0.00011403798,0.00002382278,0.000013351901,0.000058669357],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987627,0.00016824763,0.00047339924,0.00031342517,0.00010951046,0.00017269987],"domain_scores_gemma":[0.9987736,0.000052368257,0.0003397638,0.00018587138,0.0006253255,0.000023083232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037237623,0.00013058078,0.00026903418,0.00011598859,0.000073328476,0.000009430157,0.00009943708,0.0001145838,0.00002153452],"category_scores_gemma":[0.00030205477,0.00014217886,0.000066576344,0.00029440768,0.00012365119,0.000009623409,0.00008245103,0.00010803929,0.0000010192357],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090664194,0.00053661386,0.0930512,0.00009004989,0.00034590086,0.000015850674,0.0003074344,0.003565697,0.8757817,0.00006578957,0.00019029425,0.025142796],"study_design_scores_gemma":[0.0017694404,0.004100682,0.5036314,0.00006038706,0.000095375835,0.000021574673,0.00049413106,0.0009491033,0.487036,0.000583793,0.0010479005,0.00021019751],"about_ca_topic_score_codex":0.00015017232,"about_ca_topic_score_gemma":0.00043340205,"teacher_disagreement_score":0.41058022,"about_ca_system_score_codex":0.00006736323,"about_ca_system_score_gemma":0.00024539404,"threshold_uncertainty_score":0.57978857},"labels":[],"label_agreement":null},{"id":"W4415939936","doi":"10.1016/j.annonc.2025.08.3355","title":"2745eP Isocitrate dehydrogenase 1 (IDH1) mutation testing in the phase III study of ivosidenib vs placebo in IDH1-mutant conventional chondrosarcoma (CHONQUER)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier","keywords":"Isocitrate dehydrogenase; Chondrosarcoma; IDH1; Placebo; Phases of clinical research; Mutant","score_opus":0.09453919579035619,"score_gpt":0.42601140849285224,"score_spread":0.33147221270249605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940388,0.00042246756,0.0000054923435,0.0026798411,0.000086456785,0.0013135084,0.0000195805,0.000010799603,0.0014230075],"genre_scores_gemma":[0.9985882,0.000048566635,0.00010480836,0.0009118298,0.000020848887,0.00024001913,0.00003633624,0.000009902466,0.000039458744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980539,0.00035619474,0.000827457,0.00026737392,0.00023882758,0.00025624188],"domain_scores_gemma":[0.9982855,0.0009115133,0.0003346233,0.00022438617,0.00019690594,0.000047086825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008504666,0.0001585024,0.0006243457,0.00031752835,0.00004704852,0.0000064699066,0.0001303834,0.00009664599,0.000047546986],"category_scores_gemma":[0.00038796113,0.00012379701,0.00009194348,0.0006464928,0.0001116353,0.000073006966,0.00003938159,0.00022678258,0.0000049435607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096205175,0.07095282,0.81991845,0.0003424986,0.00086908997,0.0050172694,0.0077362233,0.00032991785,0.05325233,0.001904952,0.0023750183,0.027680937],"study_design_scores_gemma":[0.17732733,0.035761435,0.6796797,0.0012660511,0.00076832157,0.00041291866,0.013263259,0.0025828504,0.08283338,0.004495744,0.0011666112,0.0004424025],"about_ca_topic_score_codex":0.0009922081,"about_ca_topic_score_gemma":0.0012759736,"teacher_disagreement_score":0.16770682,"about_ca_system_score_codex":0.0000751463,"about_ca_system_score_gemma":0.00033903032,"threshold_uncertainty_score":0.5048295},"labels":[],"label_agreement":null},{"id":"W4415939974","doi":"10.1016/j.annonc.2025.08.720","title":"291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Trastuzumab; Paclitaxel; Breast cancer; Chemotherapy","score_opus":0.06240779686711495,"score_gpt":0.42127854042782764,"score_spread":0.3588707435607127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9117401,0.0053639323,0.003116545,0.066199794,0.0013467616,0.0048457575,0.004089475,0.00032213997,0.0029754858],"genre_scores_gemma":[0.97907186,0.0031726714,0.002484374,0.003963175,0.0005976013,0.0015542799,0.00020476495,0.00020371003,0.008747592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275357,0.0006594136,0.0017610088,0.0015205853,0.001109844,0.0021956097],"domain_scores_gemma":[0.99374413,0.0018571217,0.00071501674,0.0012348081,0.0016014146,0.0008475307],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018162584,0.00088343787,0.0027330501,0.0007080644,0.00044879754,0.00007307354,0.0009465427,0.00094416854,0.0015007816],"category_scores_gemma":[0.001198446,0.0007505361,0.00070878665,0.0013207692,0.000926244,0.00027031644,0.0002735472,0.0012768432,0.000069415255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025630826,0.0037152157,0.01957833,0.0012087395,0.0022737945,0.00044186343,0.0017670394,0.000041419826,0.00786904,0.00048555838,0.31982005,0.6171681],"study_design_scores_gemma":[0.07464466,0.07860511,0.29908487,0.0041535776,0.004107665,0.0018165032,0.0036253089,0.0015763467,0.04638869,0.0065399623,0.47593015,0.0035271603],"about_ca_topic_score_codex":0.01830935,"about_ca_topic_score_gemma":0.005211411,"teacher_disagreement_score":0.61364096,"about_ca_system_score_codex":0.0015701618,"about_ca_system_score_gemma":0.0071071936,"threshold_uncertainty_score":0.99949455},"labels":[],"label_agreement":null},{"id":"W4415940025","doi":"10.1016/j.annonc.2025.08.1923","title":"1289P Prognostic value of FDG PET/CT in multiple myeloma patients at the time of initial diagnosis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Value (mathematics); Overall survival; Infiltration (HVAC); Bone marrow; Predictive value of tests","score_opus":0.06354901922538532,"score_gpt":0.4090645909389949,"score_spread":0.3455155717136096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180967,0.00032566575,0.0000010987045,0.0019175793,0.000067452675,0.0009673179,0.00010510466,0.000006801791,0.004799341],"genre_scores_gemma":[0.99877423,0.00021542361,0.0001151221,0.00029487401,0.000015609008,0.00014948816,0.000080606565,0.000009997596,0.00034464308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984074,0.0002635801,0.000536977,0.00020032279,0.00028788592,0.0003038384],"domain_scores_gemma":[0.9972437,0.001840499,0.00021177075,0.00029176104,0.00033470744,0.000077568686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003318085,0.00012709151,0.00057528284,0.00024470262,0.00003580283,0.0000016237422,0.00015984473,0.000035808935,0.00016101931],"category_scores_gemma":[0.0023947074,0.00008807141,0.0001410344,0.00032804723,0.00033226894,0.00003628557,0.00018236238,0.00013592145,0.000024047908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015182743,0.002831695,0.94424754,0.00019792859,0.0002846412,0.0002321866,0.00014777402,0.00000995765,0.0005337442,0.00005327964,0.002914627,0.047028363],"study_design_scores_gemma":[0.005927821,0.0036434436,0.94071096,0.00024349566,0.00006393056,0.000014119618,0.000051943774,0.00026590927,0.046786282,0.0001294899,0.002106428,0.00005614851],"about_ca_topic_score_codex":0.00060173805,"about_ca_topic_score_gemma":0.00029336495,"teacher_disagreement_score":0.04697221,"about_ca_system_score_codex":0.00006859242,"about_ca_system_score_gemma":0.00031242732,"threshold_uncertainty_score":0.35914478},"labels":[],"label_agreement":null},{"id":"W4415940047","doi":"10.1016/j.annonc.2025.08.3098","title":"2483P PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"State Government of Victoria; Cancer Australia; National Health and Medical Research Council; Astellas Pharma US","keywords":"Prostate cancer; Clinical trial; Chemotherapy; Prostate disease; MEDLINE","score_opus":0.17817083031105194,"score_gpt":0.5360375030362083,"score_spread":0.3578666727251564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867636,0.0016434821,0.00003626519,0.0062717875,0.0030555718,0.00144593,0.00026817934,0.000003488816,0.00051170576],"genre_scores_gemma":[0.9848305,0.0077051567,0.0004722155,0.0033938617,0.0023767927,0.0006947627,0.00022213995,0.000018068504,0.0002865118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963172,0.001675218,0.00080988876,0.00050726463,0.00023007907,0.00046033302],"domain_scores_gemma":[0.9985749,0.00054115016,0.00017181973,0.00035192037,0.0002887574,0.00007142849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038128304,0.00015552578,0.0004950612,0.00027792307,0.000047150974,0.000018350725,0.00030856623,0.0001838798,0.000020973239],"category_scores_gemma":[0.00070696976,0.00012826233,0.00012982343,0.000539422,0.00021551199,0.00000930951,0.00017924084,0.00027671963,0.0000056223375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065457195,0.00097168604,0.0029964854,0.00003051992,0.00036578762,0.0000056514896,0.003218277,0.000044491928,0.09802847,0.00019090693,0.3808475,0.447843],"study_design_scores_gemma":[0.023412852,0.0033662491,0.061756086,0.000032859865,0.000047821886,0.0000015427219,0.0037602459,0.000031158685,0.014394497,0.00051506324,0.8924969,0.00018474775],"about_ca_topic_score_codex":0.004556738,"about_ca_topic_score_gemma":0.018081116,"teacher_disagreement_score":0.51164937,"about_ca_system_score_codex":0.00004079487,"about_ca_system_score_gemma":0.0009104054,"threshold_uncertainty_score":0.9998363},"labels":[],"label_agreement":null},{"id":"W4415940065","doi":"10.1016/j.annonc.2025.08.1488","title":"919O A first-in-human study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumours","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hippo pathway signaling and YAP/TAZ","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis","keywords":"Mesothelioma; Hippo signaling pathway; Hyperactivation; Cancer","score_opus":0.018608824037828924,"score_gpt":0.342033474233771,"score_spread":0.3234246501959421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984766,0.00013841275,0.0000073489427,0.00013551199,0.00002828365,0.00028538035,0.000017422435,0.0000030249905,0.0009080018],"genre_scores_gemma":[0.99944675,0.000028070948,0.000087795306,0.00031992665,0.0000074794266,0.000027573222,0.000010737687,0.000010504094,0.00006115217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990878,0.00009992539,0.00030364082,0.00024797433,0.0000743807,0.00018624286],"domain_scores_gemma":[0.9994888,0.000022224996,0.0001311282,0.000181993,0.00014509645,0.000030801733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018283747,0.000114665185,0.00031788435,0.00015135475,0.000022953436,0.0000023862156,0.000118067175,0.00011296928,0.0000052053847],"category_scores_gemma":[0.00006036865,0.00009919007,0.0000283066,0.0001544878,0.000091537324,0.0000030226336,0.00005737835,0.00007178895,3.1798723e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013496449,0.0034971803,0.86567086,0.000072737814,0.00012023647,0.000015626634,0.0013234289,0.00036687474,0.11908322,0.000108593245,0.00012517285,0.008266411],"study_design_scores_gemma":[0.026016206,0.043797407,0.54105747,0.0004174746,0.00007301615,0.0000043368004,0.0032023345,0.000059823564,0.3747777,0.00047726303,0.009512916,0.000604036],"about_ca_topic_score_codex":0.00027451094,"about_ca_topic_score_gemma":0.0040554036,"teacher_disagreement_score":0.3246134,"about_ca_system_score_codex":0.000006879444,"about_ca_system_score_gemma":0.00006617223,"threshold_uncertainty_score":0.40448537},"labels":[],"label_agreement":null},{"id":"W4415940075","doi":"10.1016/j.annonc.2025.08.971","title":"548P Phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Palbociclib; Fulvestrant; Chemotherapy; Cohort; Breast cancer; Clinical trial","score_opus":0.0452135782774123,"score_gpt":0.44670831638304226,"score_spread":0.40149473810562997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95557785,0.0036893848,0.0036287368,0.025109109,0.0014104482,0.0043164683,0.0017645381,0.00013081661,0.0043726717],"genre_scores_gemma":[0.9927827,0.0009302416,0.0017892807,0.0021138063,0.00037375843,0.0007449671,0.0001469196,0.00007288426,0.001045449],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697024,0.00018577324,0.0011334502,0.0006539897,0.0003416054,0.0007149266],"domain_scores_gemma":[0.9963877,0.0006647699,0.0007335742,0.00053733133,0.0014823601,0.00019421647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037028798,0.00044647753,0.0017557653,0.000402166,0.000119401506,0.00000792345,0.00031720012,0.00036866608,0.00024121249],"category_scores_gemma":[0.00027178245,0.00041189493,0.00046646313,0.00066024,0.00063225854,0.00023261523,0.00008318984,0.00035304733,0.0000034462464],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31497318,0.005267613,0.00010598406,0.00045969116,0.0012241396,0.000054130203,0.0013440818,0.00015675115,0.022743197,0.0009799962,0.001906768,0.6507845],"study_design_scores_gemma":[0.6013374,0.063949816,0.005891231,0.0023757091,0.0014881374,0.00041137348,0.003171988,0.0007841747,0.17305133,0.004720155,0.14172477,0.0010939531],"about_ca_topic_score_codex":0.00050005707,"about_ca_topic_score_gemma":0.0001560314,"teacher_disagreement_score":0.6496905,"about_ca_system_score_codex":0.0005085304,"about_ca_system_score_gemma":0.0018771644,"threshold_uncertainty_score":0.9998333},"labels":[],"label_agreement":null},{"id":"W4415940076","doi":"10.1016/j.annonc.2025.08.3151","title":"2537eTiP PSMACare trial-in-progress: a phase II trial of [177Lu]Lu-PSMA-617 with or without ARPI in patients with PSMA-positive non-metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal General Hospital","funders":"Novartis","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Androgen receptor; Androgen deprivation therapy; Radioligand; Androgen; Phases of clinical research; Prostate-specific antigen","score_opus":0.0617472521708245,"score_gpt":0.45189649003081417,"score_spread":0.3901492378599897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908323,0.0005687444,0.0000054338702,0.0026087891,0.00013769181,0.0065062866,0.00028158806,0.000011990503,0.0007962442],"genre_scores_gemma":[0.99681735,0.00034256288,0.0004293339,0.00018952898,0.000046425204,0.001165395,0.00016885824,0.000028111615,0.000812416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973752,0.00023941035,0.00085190934,0.00048049993,0.00050814234,0.00054487045],"domain_scores_gemma":[0.99803627,0.00021506846,0.00047167786,0.0003189951,0.0008200236,0.00013797487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004772219,0.00030153187,0.0012722217,0.0005717586,0.00007352709,0.000012112183,0.00014398589,0.00013063951,0.0000611903],"category_scores_gemma":[0.00010807091,0.00018538593,0.00008961755,0.0009694503,0.0004997936,0.00013701069,0.000057601592,0.00031540665,9.211392e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9056148,0.009724769,0.044366598,0.00042451706,0.0006212449,0.00032369193,0.0026578067,0.000019155088,0.00021621406,0.000021683945,0.00029984728,0.035709653],"study_design_scores_gemma":[0.7938722,0.16696699,0.028342664,0.0018988058,0.0003449654,0.0000035768776,0.0015562988,0.00006427789,0.006249581,0.000057918583,0.00041735437,0.00022541493],"about_ca_topic_score_codex":0.0010090274,"about_ca_topic_score_gemma":0.003946032,"teacher_disagreement_score":0.15724222,"about_ca_system_score_codex":0.00024262573,"about_ca_system_score_gemma":0.0036064486,"threshold_uncertainty_score":0.75598186},"labels":[],"label_agreement":null},{"id":"W4415940078","doi":"10.1016/j.annonc.2025.08.3223","title":"2607P Belzutifan for advanced clear cell renal cell carcinoma (ccRCC) after a PD-(L)1 inhibitor and ≥2 VEGFR-TKIs in LITESPARK-005","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clear cell renal cell carcinoma; Clear cell; Discovery and development of mTOR inhibitors; Kidney cancer; Phases of clinical research; Renal cell carcinoma","score_opus":0.03004724296364463,"score_gpt":0.33437555714878353,"score_spread":0.3043283141851389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759572,0.0065114354,0.000022712611,0.004092257,0.0001654953,0.0010594071,0.00003427523,0.00002024159,0.012136981],"genre_scores_gemma":[0.9928062,0.00032253884,0.0021625112,0.001687114,0.000115393086,0.00025737606,0.000029089404,0.000031893713,0.0025878919],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809164,0.00011685553,0.00059727894,0.00051929126,0.00015783292,0.00051712495],"domain_scores_gemma":[0.9986805,0.0003734966,0.00018676829,0.0003810415,0.00019162294,0.00018661395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003365809,0.00027073658,0.0007827529,0.00039446016,0.00004375121,0.000009153856,0.00010808678,0.00027195163,0.0000486262],"category_scores_gemma":[0.00009276368,0.0002471781,0.00019096269,0.00027715074,0.00016466074,0.000075803524,0.00011943958,0.00024398978,0.000010584375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05813488,0.008552477,0.2931383,0.00554918,0.00039721114,0.0024510515,0.0060510603,0.00008249229,0.4028245,0.00044029448,0.035341952,0.18703663],"study_design_scores_gemma":[0.015473763,0.019213485,0.2999791,0.00036082973,0.0002959573,0.000045510904,0.0004777077,0.00013408487,0.5353071,0.00064178463,0.12768178,0.00038889542],"about_ca_topic_score_codex":0.00008962049,"about_ca_topic_score_gemma":0.00012677447,"teacher_disagreement_score":0.18664773,"about_ca_system_score_codex":0.00013897644,"about_ca_system_score_gemma":0.0003645236,"threshold_uncertainty_score":0.99999803},"labels":[],"label_agreement":null},{"id":"W4415940094","doi":"10.1016/j.annonc.2025.08.2492","title":"1868P Evaluating prognostic associations of longitudinal changes in body composition by sex using AI-based quantifications of skeletal muscle volume (SMV) and subcutaneous fat volume (SFV) in computed tomography (CT) imaging of advanced NSCLC (aNSCLC) patients","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Glycemic Index Laboratories; University of Calgary; Princess Margaret Cancer Centre; Occupational Cancer Research Centre","funders":"","keywords":"Skeletal muscle; Subcutaneous fat; Computed tomography; Volume (thermodynamics); Composition (language); Adipose tissue; Body mass index","score_opus":0.06950933626755723,"score_gpt":0.4181974332204759,"score_spread":0.3486880969529187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531376,0.0005728443,0.0006267257,0.0023697445,0.00008145946,0.00080552965,0.00013749592,0.0000133787125,0.00007906446],"genre_scores_gemma":[0.9966205,0.000039491748,0.002752588,0.00028025196,0.000010016338,0.00002470811,0.00025631383,0.000010505726,0.000005618515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981198,0.00026882338,0.00089562504,0.00024280332,0.00022787976,0.0002450892],"domain_scores_gemma":[0.9980067,0.00039632636,0.00065456826,0.0001476509,0.00074149104,0.000053242366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005609554,0.00012311905,0.0006469945,0.0007685723,0.00006141044,0.0000038733565,0.0000725075,0.00007491672,0.000011136589],"category_scores_gemma":[0.00023363302,0.00014615107,0.00007187511,0.0007663525,0.00020548559,0.00006986736,0.000031757118,0.0001852298,1.7294869e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001539807,0.0018024355,0.9274691,0.0008206604,0.00003967409,0.0000066814187,0.0003691401,0.00032467773,0.056195445,0.000051965795,0.00012186791,0.012644412],"study_design_scores_gemma":[0.0034662015,0.0014528135,0.93293345,0.001293891,0.00009609253,0.000004407868,0.00025418747,0.052137714,0.008106356,0.000101838305,0.00005674334,0.00009629796],"about_ca_topic_score_codex":0.00036595672,"about_ca_topic_score_gemma":0.00020216501,"teacher_disagreement_score":0.051813036,"about_ca_system_score_codex":0.00008906666,"about_ca_system_score_gemma":0.00020242798,"threshold_uncertainty_score":0.5959868},"labels":[],"label_agreement":null},{"id":"W4415940101","doi":"10.1016/j.annonc.2025.08.2627","title":"2003P Real-world (RW) characteristics and outcomes of ERBB2-altered (HER2+) metastatic non-small cell lung cancer (mNSCLC) in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Lung cancer; MEDLINE; Clinical trial; Cancer; Expanded access","score_opus":0.029002719480758256,"score_gpt":0.3957886970125683,"score_spread":0.36678597753181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662552,0.00067637465,0.000010011739,0.0082219215,0.00029666218,0.00049889134,0.00013782314,0.0000037379516,0.0238994],"genre_scores_gemma":[0.98812795,0.0011981814,0.00035008055,0.0019290976,0.00001860248,0.00007034503,0.000043641616,0.000011353965,0.008250775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989859,0.000045345405,0.0004723624,0.00018430728,0.00009177107,0.0002203534],"domain_scores_gemma":[0.99905276,0.0002985441,0.00022641385,0.00017889592,0.00016356051,0.00007981227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000989847,0.00013509148,0.00069872366,0.00017707066,0.000023604121,0.0000027123458,0.00006270218,0.00004802561,0.0000824591],"category_scores_gemma":[0.00005501001,0.000113029084,0.000048246227,0.00022531938,0.000059940667,0.00002668538,0.000030632465,0.00010024147,4.085739e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016709308,0.00047931162,0.97515684,0.0006881061,0.0007048721,0.000057400463,0.00084445206,0.000013767779,0.0003329459,0.0003168103,0.010318766,0.010919651],"study_design_scores_gemma":[0.002591988,0.00027763215,0.9760286,0.00019379158,0.0006069752,0.0000018493224,0.00020269629,0.00016237548,0.0016354449,0.00005364395,0.018150428,0.0000945352],"about_ca_topic_score_codex":0.8275289,"about_ca_topic_score_gemma":0.9207377,"teacher_disagreement_score":0.09320878,"about_ca_system_score_codex":0.00018607036,"about_ca_system_score_gemma":0.0025815682,"threshold_uncertainty_score":0.46091923},"labels":[],"label_agreement":null},{"id":"W4415940105","doi":"10.1016/j.annonc.2025.08.654","title":"222eP Characterizing MTAP deletions in a pan tumor convenience cohort analyzed by whole genome sequencing","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"Genome British Columbia; Canada Foundation for Innovation; Genome Canada","keywords":"Whole genome sequencing; Genome; Cohort; DNA sequencing; Genomics","score_opus":0.027807221877881032,"score_gpt":0.3349965413871346,"score_spread":0.30718931950925354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941253,0.0011627123,0.00086824334,0.0010576398,0.000071198745,0.000141137,0.000049182345,0.000008305635,0.0025162706],"genre_scores_gemma":[0.9963712,0.00043942756,0.00031320707,0.002276454,0.000040306884,0.000038369166,0.00013058864,0.000008015959,0.00038242366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898666,0.00008218028,0.000339541,0.0002848389,0.000065965156,0.00024080348],"domain_scores_gemma":[0.9994937,0.000021014781,0.00013377515,0.0001921476,0.000118819946,0.00004052404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035100227,0.00010564018,0.0002645442,0.0000795111,0.0000449638,0.000006613434,0.00016257675,0.000119906974,0.000015728923],"category_scores_gemma":[0.00009005037,0.00011159747,0.0000766857,0.00017000396,0.00009896061,0.0000044529543,0.00007407598,0.000100564255,0.000003849931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004375412,0.00006115378,0.003954356,0.00002422078,0.00004589724,0.000006286215,0.00005974652,0.00010133462,0.9915259,0.000032966163,0.0011055288,0.0030388625],"study_design_scores_gemma":[0.0019379697,0.0011496309,0.042200662,0.0001808438,0.00006489443,0.000051250732,0.00055506086,0.002246871,0.65835696,0.0003215325,0.2924094,0.0005248971],"about_ca_topic_score_codex":0.00019425433,"about_ca_topic_score_gemma":0.00008331054,"teacher_disagreement_score":0.33316892,"about_ca_system_score_codex":0.000046204637,"about_ca_system_score_gemma":0.00032944078,"threshold_uncertainty_score":0.45508125},"labels":[],"label_agreement":null},{"id":"W4415940213","doi":"10.1016/j.annonc.2025.08.3066","title":"2451P Real-world (RW) genomic landscape, PARP inhibitor (PARPi) treatment (tx) patterns and adverse events (AE) in advanced prostate cancer (PCa): the national CanaDNA Study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia Hospital; University of Alberta; University of Calgary","funders":"","keywords":"PARP inhibitor; Adverse effect; Prostate cancer; Discovery and development of mTOR inhibitors; MEDLINE; Cancer","score_opus":0.0677070143827827,"score_gpt":0.43207682311160883,"score_spread":0.36436980872882613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98127514,0.0009769902,1.959572e-7,0.011821396,0.0001629018,0.0017942409,0.00018095615,0.000012072344,0.0037761347],"genre_scores_gemma":[0.9863206,0.0063953428,0.000013002744,0.0007565718,0.00007986982,0.0006343379,0.00006386981,0.000013410916,0.0057229893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998527,0.00015374989,0.0003787742,0.0003330049,0.00024373495,0.00036373184],"domain_scores_gemma":[0.9991872,0.00020551993,0.00012480344,0.00016963937,0.00021192667,0.000100930905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030248318,0.00017999383,0.00044304912,0.00029011522,0.00008731822,0.0000036427018,0.000093367424,0.00006387011,0.000089047295],"category_scores_gemma":[0.000040078943,0.000116001305,0.000060739992,0.00030377356,0.00008890971,0.000056255074,0.000076704266,0.00015765273,0.0000032158032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027212037,0.001332922,0.95031226,0.000061632476,0.00045052898,0.00009360609,0.0017555803,0.00006671629,0.0003038742,0.000033443233,0.0028289228,0.040039334],"study_design_scores_gemma":[0.010250845,0.002634216,0.96853536,0.000155631,0.00008618391,0.0000031295237,0.0015094995,0.000049905993,0.001264047,0.00012827381,0.015283759,0.00009914267],"about_ca_topic_score_codex":0.012058041,"about_ca_topic_score_gemma":0.10572687,"teacher_disagreement_score":0.093668826,"about_ca_system_score_codex":0.0005370983,"about_ca_system_score_gemma":0.0013213343,"threshold_uncertainty_score":0.9945207},"labels":[],"label_agreement":null},{"id":"W4415940216","doi":"10.1016/j.annonc.2025.08.2325","title":"1698eP Incidence of chronic immune related adverse events (irAEs) in patients with advanced melanoma treated with immune checkpoint inhibitors in British Columbia","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; BC Cancer Agency","funders":"","keywords":"Adverse effect; Incidence (geometry); Immune system; Melanoma; Pembrolizumab; Immune checkpoint; Clinical trial","score_opus":0.00811521122977008,"score_gpt":0.2754361221465436,"score_spread":0.2673209109167735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995535,0.0022698084,0.000001336491,0.0002960499,0.000092899325,0.0010070604,0.00001591886,0.00001739108,0.00076454587],"genre_scores_gemma":[0.9984654,0.0007591996,0.00008642562,0.00010977839,0.0000059272456,0.00005722967,0.000060634804,0.000020253898,0.00043513966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783057,0.000128453,0.0011485829,0.00032375587,0.00022538997,0.00034325058],"domain_scores_gemma":[0.99872094,0.000071109505,0.00055657496,0.00032151464,0.00028434742,0.000045509096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043949994,0.0001584822,0.0008594392,0.00025556513,0.000029493649,0.0000031575196,0.00014900017,0.00022276823,0.00012365532],"category_scores_gemma":[0.000078458375,0.00017958155,0.00012139986,0.0011315244,0.00029435309,0.00013609415,0.000054136177,0.0002656314,0.000001361341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010681364,0.0017019977,0.9053813,0.00018424785,0.0003159996,0.00010871356,0.00020567724,0.000048550974,0.0076482785,0.0000015351673,0.000064004256,0.07365833],"study_design_scores_gemma":[0.024267644,0.011049193,0.9524224,0.0031707305,0.000050537692,0.000016411408,0.00020206161,0.000017943965,0.00825478,0.000018790002,0.00037587297,0.00015367642],"about_ca_topic_score_codex":0.031078655,"about_ca_topic_score_gemma":0.064561434,"teacher_disagreement_score":0.07350466,"about_ca_system_score_codex":0.00039145042,"about_ca_system_score_gemma":0.00071570935,"threshold_uncertainty_score":0.97537345},"labels":[],"label_agreement":null},{"id":"W4415940242","doi":"10.1016/j.annonc.2025.08.3346","title":"WITHDRAWN: 2736P Targeting SS18::SSX biology in synovial sarcomagenesis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Epigenomics; Synovial sarcoma; Cancer; Sarcoma; Genomics; Epigenetics","score_opus":0.059946982156359074,"score_gpt":0.41509617021254785,"score_spread":0.3551491880561888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95158714,0.0059165834,0.000030339983,0.018511618,0.00027688395,0.00033093133,0.000009313374,0.000027559972,0.02330964],"genre_scores_gemma":[0.99408823,0.000830516,0.0010051421,0.0036794154,0.000080856735,0.00006833838,0.000029316761,0.000010622567,0.00020756178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869275,0.00014426891,0.00046464565,0.00028564685,0.00007414218,0.00033857324],"domain_scores_gemma":[0.9990481,0.00041287314,0.00012230373,0.0002249563,0.00012507987,0.00006668506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036825376,0.00014655467,0.0006497908,0.00033459943,0.000037043763,0.0000032768785,0.00010259885,0.00020774863,0.00014849838],"category_scores_gemma":[0.00027273528,0.00012189436,0.00013351953,0.00032194462,0.0001517743,0.000029168465,0.000079074685,0.000133844,0.000026194768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005071158,0.0025011015,0.7626644,0.00008294289,0.00027959677,0.00032914357,0.00017096623,0.000006165269,0.006112379,0.005262742,0.01395269,0.20813079],"study_design_scores_gemma":[0.0067386786,0.004268796,0.69348174,0.00025389495,0.00019942837,0.000049803853,0.00038067222,0.0000779908,0.047844794,0.0038752253,0.24258466,0.0002443108],"about_ca_topic_score_codex":0.00044722384,"about_ca_topic_score_gemma":0.0001414061,"teacher_disagreement_score":0.22863197,"about_ca_system_score_codex":0.00006746247,"about_ca_system_score_gemma":0.00030193318,"threshold_uncertainty_score":0.4970708},"labels":[],"label_agreement":null},{"id":"W4415940248","doi":"10.1016/j.annonc.2025.08.3216","title":"2600MO Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Ipsen; European Society for Medical Oncology; Astellas Pharma; Eisai; European Association of Urology; Micropalaeontological Society; National Cancer Institute; Aptitude Health; Bamfield Marine Sciences Centre; Cleveland Clinic; Daiichi Sankyo Europe; Exelixis; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Institut Gustave-Roussy; Invitae; Gilead Sciences; Amgen; Dana-Farber Cancer Institute; Pfizer; Society for Immunotherapy of Cancer","keywords":"Standard of care; Nephrectomy; Renal cell carcinoma; Clinical trial; Immunotherapy; Kidney cancer; Cell; MEDLINE","score_opus":0.062029697455792454,"score_gpt":0.3550135299256223,"score_spread":0.29298383246982984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982,0.003590004,0.0000010153552,0.00077997684,0.0002501539,0.0010728311,0.00002872495,0.0000033705103,0.01227396],"genre_scores_gemma":[0.9990665,0.00049917743,0.000096515665,0.00013930388,0.000043324722,0.000049582883,0.0000048444763,0.000011334656,0.00008944314],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984008,0.00022281334,0.00059727806,0.00024962993,0.0002700023,0.00025947168],"domain_scores_gemma":[0.99855393,0.00048572643,0.00034107472,0.0003713098,0.0002098857,0.00003805022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041652247,0.00016176718,0.00081977766,0.00017167469,0.000033594566,0.000003920279,0.00022167945,0.000103268605,0.000017527373],"category_scores_gemma":[0.00009636148,0.00010545042,0.00013643867,0.00041809294,0.00028744334,0.00003546414,0.0001123243,0.0003141563,4.7147975e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7346644,0.0018798086,0.20004368,0.0029155686,0.00024578534,0.00028165258,0.012229972,0.0010857764,0.017277189,0.00018173453,0.003603011,0.025591418],"study_design_scores_gemma":[0.24723443,0.050207622,0.29539257,0.0021750277,0.000528575,0.000016523372,0.00893873,0.00041516812,0.3826169,0.00014906758,0.011990595,0.00033476192],"about_ca_topic_score_codex":0.0014498015,"about_ca_topic_score_gemma":0.006896054,"teacher_disagreement_score":0.48742998,"about_ca_system_score_codex":0.0002040624,"about_ca_system_score_gemma":0.0007185809,"threshold_uncertainty_score":0.43001434},"labels":[],"label_agreement":null},{"id":"W4415940260","doi":"10.1016/j.annonc.2025.08.2932","title":"2316P Global distribution and characteristics of research facilities recruiting for phase III oncology trials: Cross-sectional analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Phase (matter); Distribution (mathematics); Precision oncology; Clinical Oncology; Radiation oncology","score_opus":0.8461598576821593,"score_gpt":0.7528051343609544,"score_spread":0.09335472332120487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785754,0.0004126204,0.004805715,0.00871428,0.00027257056,0.0008810545,0.0022581941,0.00002328235,0.0040568537],"genre_scores_gemma":[0.99543947,0.0014638718,0.0006698466,0.00023266363,0.00019597309,0.00010988709,0.00040656922,0.000006417001,0.0014753212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954421,0.0011625779,0.0018810256,0.00042982696,0.0006286257,0.00045582574],"domain_scores_gemma":[0.94212925,0.051208887,0.00055879616,0.00034167067,0.00559599,0.00016539975],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0367021,0.000114556155,0.0015221465,0.00034803018,0.00015157083,0.000019408171,0.00019405181,0.0008584201,0.00009418411],"category_scores_gemma":[0.14169824,0.00010371663,0.00039438644,0.00097398186,0.001976188,0.00005034882,0.00022273745,0.0009331147,0.0000011601335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044409785,0.0037591953,0.3946224,0.0031416402,0.005736902,0.00004743526,0.0005645957,0.00001516912,0.0034427068,0.199643,0.004987401,0.33962977],"study_design_scores_gemma":[0.025059117,0.029338073,0.5353838,0.00039144073,0.0012053213,0.000025545385,0.0022181894,0.0017717406,0.007460219,0.1992684,0.19760787,0.0002702773],"about_ca_topic_score_codex":0.00028890063,"about_ca_topic_score_gemma":0.00024387779,"teacher_disagreement_score":0.3393595,"about_ca_system_score_codex":0.00027997908,"about_ca_system_score_gemma":0.002503713,"threshold_uncertainty_score":0.9919179},"labels":[],"label_agreement":null},{"id":"W4415940266","doi":"10.1016/j.annonc.2025.08.2184","title":"1554P Enhanced safety profile of IMC-002, an affinity-optimized anti-CD47 antibody: Preclinical and phase Ia/Ib findings","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Safety profile; Toxicity; In vitro; Phase (matter); Phases of clinical research; In vivo; Animal model","score_opus":0.05718265524750983,"score_gpt":0.43747640643667574,"score_spread":0.3802937511891659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903713,0.0022345118,0.0005785874,0.00136435,0.0007856515,0.00043301965,0.000102352584,0.000037345286,0.0040929182],"genre_scores_gemma":[0.9964287,0.0017668498,0.000569192,0.0002796747,0.000023030938,0.000017326965,0.00035095567,0.000012605973,0.00055165356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761826,0.0005886944,0.00096796895,0.00040524534,0.000042888707,0.00037696387],"domain_scores_gemma":[0.99810386,0.0007560782,0.00044601393,0.0003774346,0.00028080516,0.000035802004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010234674,0.00021113559,0.0010418065,0.00022566406,0.00013617692,0.0000066967937,0.00026274662,0.00059324625,0.00042508592],"category_scores_gemma":[0.0005093971,0.00019322368,0.00017023018,0.00023881256,0.0006313907,0.00019804937,0.00016312125,0.00030121277,0.000018342695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030714215,0.0024638544,0.00077681436,0.00007403857,0.00042503828,0.0000015835246,0.0003499697,0.000011874639,0.9406776,0.0013028097,0.0028328719,0.048012134],"study_design_scores_gemma":[0.010059908,0.0048353025,0.02689687,0.00012012002,0.00014169324,0.000010060282,0.00014880944,0.0000715958,0.931214,0.00034294077,0.025954956,0.00020378461],"about_ca_topic_score_codex":0.000050652292,"about_ca_topic_score_gemma":0.000008738222,"teacher_disagreement_score":0.04780835,"about_ca_system_score_codex":0.000017526572,"about_ca_system_score_gemma":0.00025996455,"threshold_uncertainty_score":0.7879433},"labels":[],"label_agreement":null},{"id":"W4415940293","doi":"10.1016/j.annonc.2025.08.2935","title":"2319P Landscape of phase III clinical trials in cancer: A cross-sectional analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Clinical trial; Phase (matter); Phases of clinical research; MEDLINE","score_opus":0.8638329969577937,"score_gpt":0.768263488987001,"score_spread":0.09556950797079267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95000833,0.00041659566,0.037938327,0.0019482299,0.0015847965,0.000730584,0.00045161124,0.000045846395,0.0068756505],"genre_scores_gemma":[0.8816368,0.0009692962,0.11572249,0.00083037344,0.0003456279,0.00010789351,0.0000067454102,0.000019337063,0.0003614176],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98609924,0.0067312974,0.0061683957,0.0004307536,0.00028208378,0.00028824547],"domain_scores_gemma":[0.80333173,0.19387954,0.0018061084,0.0003939487,0.00049670483,0.000091944916],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05098938,0.00015247603,0.003791072,0.00053231895,0.000022284585,0.000009325622,0.00033843526,0.00055007904,0.001021895],"category_scores_gemma":[0.29627177,0.0001276307,0.0010710666,0.0012615079,0.0004517733,0.000035575333,0.00012022442,0.00038374268,0.0000021279045],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009266528,0.00785077,0.6538387,0.0003095528,0.006020845,0.000026190353,0.00010395651,0.00011331732,0.0002853121,0.10889335,0.015815474,0.197476],"study_design_scores_gemma":[0.016173214,0.002032463,0.14623395,0.00008454722,0.0013002065,7.8081007e-7,0.000039885777,0.0012203588,0.0015267106,0.82693195,0.0042805355,0.0001753924],"about_ca_topic_score_codex":0.00013015144,"about_ca_topic_score_gemma":0.00020644642,"teacher_disagreement_score":0.7180386,"about_ca_system_score_codex":0.00002919749,"about_ca_system_score_gemma":0.0005352869,"threshold_uncertainty_score":0.9998913},"labels":[],"label_agreement":null},{"id":"W4415940303","doi":"10.1016/j.annonc.2025.08.3087","title":"2472P Initial management of newly diagnosed non-metastatic prostate cancer according to age-group: A RADICAL-PC substudy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Population Health Research Institute; Université Laval; Centre Hospitalier de l’Université de Montréal; University of British Columbia; McMaster University Medical Centre; McMaster Children's Hospital; McMaster University","funders":"Canadian Cancer Society; Movember Foundation; Hamilton Health Sciences","keywords":"Prostate cancer; Management of prostate cancer; MEDLINE; Prostatectomy; Radiation therapy","score_opus":0.10241004265832686,"score_gpt":0.4712479070483219,"score_spread":0.36883786438999505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97472805,0.001551172,0.00009958004,0.008818632,0.00028901544,0.0020717066,0.000044817752,0.000021964697,0.012375048],"genre_scores_gemma":[0.9912349,0.003074179,0.0010507234,0.0016402097,0.00004763486,0.0005756364,0.000042571002,0.000018240049,0.0023158942],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983094,0.00010078825,0.0005084394,0.00032468198,0.0003004423,0.00045629594],"domain_scores_gemma":[0.9989743,0.0002287339,0.00013985006,0.0002807109,0.0002049997,0.00017139333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044582994,0.00017269964,0.00071878993,0.00037889116,0.00005619364,0.000008432597,0.0001797315,0.0000708213,0.00012105027],"category_scores_gemma":[0.00006387653,0.00013867629,0.00013111238,0.0006942649,0.00021173622,0.000056415356,0.00014448217,0.0001741677,0.000015535494],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0140116615,0.005852299,0.07348248,0.0037695258,0.004970927,0.0061472696,0.0044394066,0.000102769685,0.010939367,0.0012293019,0.044764925,0.8302901],"study_design_scores_gemma":[0.08621038,0.041113194,0.5377338,0.007438177,0.0029529692,0.000038178663,0.02256945,0.00030208283,0.11411773,0.0033686997,0.18302953,0.0011258407],"about_ca_topic_score_codex":0.00071351713,"about_ca_topic_score_gemma":0.000119437536,"teacher_disagreement_score":0.8291642,"about_ca_system_score_codex":0.00012638974,"about_ca_system_score_gemma":0.00035641633,"threshold_uncertainty_score":0.5655055},"labels":[],"label_agreement":null},{"id":"W4415940359","doi":"10.1016/j.annonc.2025.08.1371","title":"798P Impact of metastatic colorectal cancer on patients' subjective well-being: Results of a patient survey in Europe and Canada","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institute of Mining, Metallurgy and Petroleum; BC Cancer Agency","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Colorectal cancer; MEDLINE; Cancer; Colonic disease","score_opus":0.02971694724873125,"score_gpt":0.3563101036174078,"score_spread":0.32659315636867653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920364,0.000255763,4.4328414e-7,0.00029211896,0.00020437254,0.00029784883,0.00032493926,0.0000020856437,0.0065860096],"genre_scores_gemma":[0.99931157,0.00023028116,0.0000034675054,0.0003409027,0.000005531611,0.000013080257,0.000044565306,0.0000071730733,0.000043428943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986755,0.00031748408,0.0004728788,0.000185,0.00017522181,0.00017389299],"domain_scores_gemma":[0.99815124,0.00061934756,0.0002733424,0.00012765358,0.00076659035,0.00006183113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003245885,0.000111777365,0.0005887708,0.000181475,0.000010642004,9.802947e-7,0.000055184773,0.000051399074,0.00002052803],"category_scores_gemma":[0.0006977743,0.000091322305,0.000053751475,0.00046400804,0.000098484335,0.000018494076,0.00003881938,0.0001232623,1.3483962e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010571978,0.00058245024,0.96755785,0.00012278346,0.00029051187,0.000021227983,0.0025846586,0.00010465792,0.00020151988,0.000038265916,0.0031987561,0.014725326],"study_design_scores_gemma":[0.0024051957,0.0073166154,0.981501,0.0001669974,0.000041769228,7.7800007e-7,0.00025032475,0.000016598393,0.0074919844,0.000023644941,0.00072288373,0.00006223621],"about_ca_topic_score_codex":0.9218957,"about_ca_topic_score_gemma":0.9642406,"teacher_disagreement_score":0.04234491,"about_ca_system_score_codex":0.00017754312,"about_ca_system_score_gemma":0.0019930506,"threshold_uncertainty_score":0.37240154},"labels":[],"label_agreement":null},{"id":"W4415940413","doi":"10.1016/j.annonc.2025.08.3697","title":"3083P JAVELIN bladder medley phase II trial of avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Subgroup analyses based on metastatic sites","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Merck","keywords":"Javelin; Avelumab; Interim analysis; Bladder cancer; Chemotherapy; Urothelial carcinoma; Subgroup analysis; Merkel cell carcinoma","score_opus":0.12129978985561646,"score_gpt":0.4482988970148013,"score_spread":0.32699910715918484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97021013,0.001439168,0.006006986,0.010477482,0.00065208547,0.006625803,0.0018317868,0.00008819065,0.0026683782],"genre_scores_gemma":[0.9884474,0.001022565,0.0027372076,0.003603813,0.00025177468,0.0013051686,0.0003932543,0.00009356219,0.002145256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958677,0.0002748631,0.0015454706,0.00097479805,0.00050990796,0.0008272173],"domain_scores_gemma":[0.9960342,0.0011568161,0.0008349511,0.0009562329,0.00073413673,0.0002836841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044352404,0.0007676596,0.0024823446,0.0006944934,0.00023408902,0.000016007556,0.00031795085,0.00031170575,0.00040571674],"category_scores_gemma":[0.0005021092,0.00060987996,0.0010085679,0.00058318215,0.0003703319,0.00011699884,0.000051515162,0.00023390696,0.000011484455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74223024,0.03263396,0.00046700545,0.00052626117,0.0058557233,0.00024940757,0.0019970331,0.0015368655,0.0248019,0.00084806053,0.003893646,0.18495989],"study_design_scores_gemma":[0.42724296,0.21511872,0.00046298254,0.00035273164,0.0024527758,0.000021116586,0.0003503175,0.006374986,0.3264444,0.0020100607,0.018596288,0.00057267846],"about_ca_topic_score_codex":0.0012614838,"about_ca_topic_score_gemma":0.0007090788,"teacher_disagreement_score":0.31498727,"about_ca_system_score_codex":0.00059610116,"about_ca_system_score_gemma":0.0020428067,"threshold_uncertainty_score":0.9996353},"labels":[],"label_agreement":null},{"id":"W4415940440","doi":"10.1016/j.annonc.2025.08.3520","title":"2908P Moderate penetrance breast and ovarian cancer susceptibility genes: A 10-year retrospective analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ovarian cancer; Penetrance; Breast cancer; Retrospective cohort study; Gene; Genetic testing; Genetic predisposition","score_opus":0.02440110438983508,"score_gpt":0.35934122724685524,"score_spread":0.3349401228570202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671365,0.0028409988,0.001996061,0.0030773736,0.00014026789,0.00019134514,0.00021596908,0.000014665408,0.004809687],"genre_scores_gemma":[0.9957962,0.0016508556,0.00081861863,0.0006341533,0.00008762114,0.000053878717,0.000040335497,0.000012533702,0.00090577296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998817,0.00011798948,0.00026975834,0.0004936977,0.00008478129,0.00021672313],"domain_scores_gemma":[0.9989304,0.00002235881,0.00013126599,0.00038792664,0.0004754188,0.000052630166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003035137,0.00013652185,0.0003442622,0.00013162979,0.00006120017,0.000012057334,0.0001586202,0.00021502556,0.00014491168],"category_scores_gemma":[0.000056163262,0.00014058514,0.00012892378,0.00047074846,0.0002453923,0.000005442247,0.00010314952,0.00008216675,0.0000013397217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022927565,0.0005849918,0.6084792,0.00014295227,0.00639804,0.000007821092,0.0004482237,0.0061785826,0.25722212,0.0019791957,0.023293015,0.09297311],"study_design_scores_gemma":[0.0017154166,0.00088275777,0.81781447,0.00002263109,0.0005854756,0.000009672353,0.00021259312,0.0010420644,0.13945968,0.0020190596,0.03585492,0.00038122782],"about_ca_topic_score_codex":0.0003087311,"about_ca_topic_score_gemma":0.0025230877,"teacher_disagreement_score":0.2093353,"about_ca_system_score_codex":0.000069548165,"about_ca_system_score_gemma":0.00051637983,"threshold_uncertainty_score":0.5732896},"labels":[],"label_agreement":null},{"id":"W4415940442","doi":"10.1016/j.annonc.2025.08.537","title":"104eP A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Durvalumab; Gemcitabine; Biliary tract cancer; Index (typography); Biliary tract","score_opus":0.02961697510261584,"score_gpt":0.3453662783580814,"score_spread":0.3157493032554656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891249,0.0027262354,0.000081558755,0.0048984415,0.00005200252,0.001244771,0.00004038831,0.000026006146,0.0018057099],"genre_scores_gemma":[0.9971187,0.0003379402,0.0005392615,0.0010431893,0.000045377452,0.00021579544,0.000035394412,0.00001750733,0.00064683985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990773,0.000020836556,0.00023658642,0.00028903078,0.00012222432,0.0002539737],"domain_scores_gemma":[0.99896574,0.00022704466,0.00013755738,0.00015307452,0.00042385506,0.000092746086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006295111,0.00017323525,0.00055320957,0.00013306997,0.000054687906,0.0000045149827,0.000047731668,0.0000856774,0.000018753506],"category_scores_gemma":[0.00011117161,0.00011525645,0.000047513953,0.0002534329,0.00013676552,0.00006921172,0.000025853695,0.0001010733,3.3285755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005852478,0.00047382075,0.8473322,0.0002055843,0.00041808613,0.000012776969,0.0002529598,0.000006599449,0.000053768414,0.000026067351,0.004114583,0.14125107],"study_design_scores_gemma":[0.012746524,0.0108616715,0.9646883,0.00032153307,0.0003849449,0.00000734201,0.00010333813,0.000033270782,0.00031191015,0.00005742589,0.010364239,0.00011949433],"about_ca_topic_score_codex":0.000272558,"about_ca_topic_score_gemma":0.0004880018,"teacher_disagreement_score":0.14113158,"about_ca_system_score_codex":0.000040664196,"about_ca_system_score_gemma":0.00047313518,"threshold_uncertainty_score":0.47000217},"labels":[],"label_agreement":null},{"id":"W4415940472","doi":"10.1016/j.annonc.2025.08.2443","title":"1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Stage (stratigraphy); Disease; Minimal residual disease; Residual","score_opus":0.0398736530682345,"score_gpt":0.4313741866833378,"score_spread":0.39150053361510334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399836,0.0019921495,0.00006448805,0.007776936,0.00006986147,0.00083508494,0.00016150005,0.000016278478,0.005085329],"genre_scores_gemma":[0.99698627,0.00012256061,0.00005796709,0.0016173947,0.000018331979,0.0000986361,0.00017961356,0.0000113779515,0.0009078444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982905,0.00029755518,0.0005878995,0.000321615,0.00024924116,0.00025322358],"domain_scores_gemma":[0.9984598,0.0003987648,0.00023351681,0.0005327056,0.00027553272,0.00009967059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030794772,0.00015312861,0.0006824728,0.00035154048,0.00006080683,0.000008018929,0.00018306458,0.00008141704,0.00024322537],"category_scores_gemma":[0.00022556706,0.00010934096,0.00016010001,0.0013749019,0.000114215,0.000051408722,0.00008563709,0.00016045508,0.000003012628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008371688,0.015108533,0.90045774,0.00012028681,0.021462707,0.0011692009,0.01055113,0.006467642,0.006845988,0.0012622023,0.012534358,0.01564852],"study_design_scores_gemma":[0.014405158,0.0031898415,0.9521344,0.00015900334,0.0078087235,6.209557e-7,0.009182588,0.0006666206,0.0049206577,0.0005715291,0.006776887,0.00018400027],"about_ca_topic_score_codex":0.011089688,"about_ca_topic_score_gemma":0.0034455885,"teacher_disagreement_score":0.051676624,"about_ca_system_score_codex":0.00007909349,"about_ca_system_score_gemma":0.00070393627,"threshold_uncertainty_score":0.99549556},"labels":[],"label_agreement":null},{"id":"W4415940506","doi":"10.1016/j.annonc.2025.08.705","title":"277eP Feasibility of gut microbiome collection in metastatic renal cell carcinoma (mRCC) treated with first-line immune checkpoint blockade (ICB)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Gut microbiome; Renal cell carcinoma; Blockade; Microbiome; Immune checkpoint; Kidney cancer; Immune system","score_opus":0.04241225713837637,"score_gpt":0.33806057870674416,"score_spread":0.2956483215683678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995536,0.0013631934,0.00009749708,0.0012478628,0.000054421624,0.00047145062,0.000048078677,0.0000051013035,0.0011763854],"genre_scores_gemma":[0.99760795,0.00045682956,0.0007415046,0.00017742034,0.000016851953,0.000021040278,0.00013897517,0.000011972907,0.00082743604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984245,0.0001846386,0.00066694105,0.00036148532,0.000055972312,0.00030651412],"domain_scores_gemma":[0.99896634,0.0000454701,0.00032076566,0.00035451603,0.00026050708,0.00005242657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004393685,0.00018022371,0.0005382415,0.00021315752,0.000050820003,0.0000033322797,0.00016521015,0.00020820346,0.000028650513],"category_scores_gemma":[0.00005809428,0.0001596212,0.00012739953,0.00044664572,0.00019082395,0.0000036696183,0.00008310867,0.00013045857,0.0000016503162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014086425,0.0009560513,0.016091071,0.00033101442,0.000071379945,0.000009566408,0.00009061353,0.000063012936,0.97967756,0.0000065848867,0.00094995194,0.00034456654],"study_design_scores_gemma":[0.0028637056,0.0042029056,0.10304015,0.000053369764,0.00004985233,0.000018563916,0.00007180425,0.000021888069,0.8863455,0.00004001287,0.0031687515,0.00012348754],"about_ca_topic_score_codex":0.0013004843,"about_ca_topic_score_gemma":0.00328756,"teacher_disagreement_score":0.09333204,"about_ca_system_score_codex":0.000057911027,"about_ca_system_score_gemma":0.0006868342,"threshold_uncertainty_score":0.65091634},"labels":[],"label_agreement":null},{"id":"W4415940507","doi":"10.1016/j.annonc.2025.08.2928","title":"2312P Recent trends in utilization of outpatient medical oncology services in patients with breast and pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Pancreatic cancer; Breast cancer; Incidence (geometry); Disease; MEDLINE; Cancer; Outpatient clinic","score_opus":0.05145847200714541,"score_gpt":0.3335590170485039,"score_spread":0.28210054504135845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747617,0.002153023,0.000019584033,0.0035603622,0.00018404282,0.00014644105,0.000110207024,0.0000034539812,0.01906115],"genre_scores_gemma":[0.99441105,0.004408245,0.00004550343,0.0009822408,0.000014900517,0.000027437098,0.00002347472,0.000007383693,0.000079792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998654,0.0000350235,0.0008041571,0.00024779228,0.000036305173,0.00022273506],"domain_scores_gemma":[0.9991442,0.00007362789,0.00049148616,0.000130091,0.00010148936,0.00005912127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043216595,0.00010940179,0.0007151978,0.0005553979,0.000013930491,0.000003838819,0.00013253799,0.00023557157,0.00030407662],"category_scores_gemma":[0.000059609978,0.00010962134,0.000029519093,0.00039770274,0.00012654811,0.00013907775,0.000055999353,0.00012692835,0.0000019744848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038837755,0.00048652696,0.7195429,0.000056305635,0.00003114503,0.0000011472225,0.0004613163,0.000048940547,2.7049091e-7,0.0064216363,0.00016235039,0.2723991],"study_design_scores_gemma":[0.0024726433,0.0010201926,0.97173333,0.0001265276,0.00000612365,4.6459704e-7,0.00007210784,0.00029727904,0.000014906682,0.0019453435,0.02221864,0.00009242487],"about_ca_topic_score_codex":0.003188519,"about_ca_topic_score_gemma":0.009977173,"teacher_disagreement_score":0.27230665,"about_ca_system_score_codex":0.00018560402,"about_ca_system_score_gemma":0.00018634614,"threshold_uncertainty_score":0.5567497},"labels":[],"label_agreement":null},{"id":"W4415940509","doi":"10.1016/j.annonc.2025.08.1858","title":"1223TiP A randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Genentech; National Institutes of Health; PharmaMar; Sociedad Española de Oncología Médica; Eisai; Seagen; NRG Oncology; Incyte; Novocure; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Amgen; Intuitive Surgical; Pfizer; Minnesota Ovarian Cancer Alliance; Gilead Sciences","keywords":"Pembrolizumab; Trastuzumab; Chemotherapy; Endometrial cancer; Phases of clinical research; Immunotherapy","score_opus":0.054917554073010945,"score_gpt":0.39043662606839896,"score_spread":0.335519071995388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98425025,0.0024806662,0.0001748809,0.000568519,0.00079149095,0.010123866,0.00017786284,0.00011043882,0.0013220523],"genre_scores_gemma":[0.99406326,0.0012618101,0.0013883235,0.0003780217,0.00018568737,0.0020362197,0.00012676913,0.00007721777,0.00048271523],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927762,0.0010492734,0.002686222,0.0012105593,0.0013134858,0.00096426986],"domain_scores_gemma":[0.99123025,0.0045787124,0.0016752576,0.0008609088,0.0012696525,0.00038524016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017285841,0.00080132094,0.0050376137,0.0021885033,0.00017230272,0.000021454665,0.00042338303,0.00033604834,0.00042755084],"category_scores_gemma":[0.0036256972,0.00047069302,0.0004797102,0.0051172925,0.00053530413,0.00019214941,0.0002018987,0.00064211886,0.0000019656243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8088653,0.033191815,0.023026336,0.0006758584,0.002330678,0.0002070739,0.0011759136,0.00015976382,0.00007964117,0.000009729909,0.00025353467,0.13002436],"study_design_scores_gemma":[0.8705835,0.10769747,0.011923308,0.0016393199,0.0019596315,0.000014189141,0.000710303,0.00007627334,0.0021780813,0.000027225904,0.002732102,0.0004586013],"about_ca_topic_score_codex":0.0021791535,"about_ca_topic_score_gemma":0.0035792973,"teacher_disagreement_score":0.12956575,"about_ca_system_score_codex":0.00083063677,"about_ca_system_score_gemma":0.002283636,"threshold_uncertainty_score":0.99977446},"labels":[],"label_agreement":null},{"id":"W4415940516","doi":"10.1016/j.annonc.2025.08.1798","title":"1162P Identifying druggable targets and prognostic biomarkers in vulvar squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Druggability; Immunohistochemistry; Malignancy; Basal cell; Antibody; Immunotherapy; Immune system; Vulvar neoplasm","score_opus":0.05611039455424389,"score_gpt":0.36989444027331125,"score_spread":0.3137840457190674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534534,0.009573123,0.000012677448,0.002250843,0.00020146107,0.00041758208,0.0000069158586,0.000013989309,0.034069996],"genre_scores_gemma":[0.9978634,0.00026765835,0.00025138643,0.000959383,0.000028863582,0.000039301776,0.000011759345,0.000007510064,0.0005707271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999014,0.0000734735,0.00031218055,0.00023291136,0.000104830106,0.00026255677],"domain_scores_gemma":[0.99922717,0.00038189098,0.00008362871,0.00012858323,0.00009000425,0.000088735214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002547974,0.00010913886,0.00042298934,0.00033427504,0.000030839536,0.0000050838707,0.000061930004,0.000118121614,0.000088009074],"category_scores_gemma":[0.00027910105,0.000093626506,0.000060665214,0.00050846447,0.00008614203,0.000043524065,0.00006498009,0.00010760526,0.000007764977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001964284,0.0017307352,0.9172306,0.0010882358,0.00018202316,0.0005041177,0.00045192472,0.0000031852571,0.0070581567,0.00030522965,0.0044825333,0.06499895],"study_design_scores_gemma":[0.013760657,0.0043678437,0.92197317,0.00014936145,0.0002531817,0.000023576635,0.00049824355,0.00005760504,0.044081163,0.0020690137,0.012591886,0.00017427806],"about_ca_topic_score_codex":0.00084346224,"about_ca_topic_score_gemma":0.0001426646,"teacher_disagreement_score":0.06482467,"about_ca_system_score_codex":0.000057894867,"about_ca_system_score_gemma":0.00019026407,"threshold_uncertainty_score":0.38179782},"labels":[],"label_agreement":null},{"id":"W4415940538","doi":"10.1016/j.annonc.2025.08.978","title":"555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); McGill University Health Centre; Santé Montérégie","funders":"AstraZeneca","keywords":"Durvalumab; Begonia; Breast cancer; Cancer","score_opus":0.18474838880903363,"score_gpt":0.5169851682150306,"score_spread":0.33223677940599694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8830128,0.003115108,0.00044312136,0.092675894,0.00072531786,0.008663471,0.008358606,0.00008800075,0.0029176993],"genre_scores_gemma":[0.98421717,0.0023342818,0.0011132973,0.0024300267,0.0003635961,0.0024252024,0.00038240236,0.00007202687,0.0066620144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514437,0.00063377357,0.0013436495,0.0010975641,0.0007297047,0.0010509485],"domain_scores_gemma":[0.9928008,0.0037360664,0.00051772245,0.0012642458,0.0013502305,0.0003309341],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001376874,0.00052888936,0.0014910552,0.00029783102,0.0005439719,0.000035767516,0.00068418874,0.00020721162,0.0006600624],"category_scores_gemma":[0.0024158496,0.00037734353,0.00030915378,0.00093041087,0.0005428499,0.00016541012,0.0003105604,0.00054485846,0.000029184623],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10908505,0.021798775,0.0033889215,0.00031169155,0.0044654827,0.0006230704,0.0058918674,0.00070729345,0.0010612375,0.00028222162,0.07134992,0.78103447],"study_design_scores_gemma":[0.28924578,0.16377187,0.026924552,0.0021907045,0.0029869722,0.00021855695,0.010814853,0.0043333485,0.036550503,0.009994742,0.45175135,0.0012167513],"about_ca_topic_score_codex":0.01885821,"about_ca_topic_score_gemma":0.026426198,"teacher_disagreement_score":0.7798177,"about_ca_system_score_codex":0.00089264463,"about_ca_system_score_gemma":0.0052904105,"threshold_uncertainty_score":0.99986786},"labels":[],"label_agreement":null},{"id":"W4415940560","doi":"10.1016/j.annonc.2025.08.1739","title":"1101P FIRST/ENGOT-OV44 trial: Does the addition of dostarlimab (dost) impact niraparib (nira) tolerability, exposure, or dose modification?","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Bevacizumab; Ovarian cancer; Chemotherapy; Platelet; Cyclophosphamide","score_opus":0.15337787001863273,"score_gpt":0.48502219057507223,"score_spread":0.3316443205564395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.939986,0.0009570871,0.00017282733,0.047170922,0.00075883215,0.0020783145,0.0003889802,0.00007047352,0.008416589],"genre_scores_gemma":[0.99449897,0.0012402158,0.00022562504,0.0027300892,0.000246736,0.0003400516,0.000105954554,0.000019439898,0.00059292326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756384,0.0003581364,0.0010561753,0.0003652348,0.00033333118,0.00032328736],"domain_scores_gemma":[0.99630374,0.0013935011,0.0005929492,0.00088647875,0.0007272756,0.00009604902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011629686,0.00022363654,0.0008411528,0.00025178486,0.00011553938,0.000011550887,0.0002838104,0.00028030926,0.0014075444],"category_scores_gemma":[0.00069789554,0.00012777602,0.00034684272,0.0005950935,0.0005117295,0.00012817373,0.00006135824,0.000286364,0.000012786905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3491053,0.011221799,0.014370455,0.0011581818,0.0026630245,0.000042850614,0.005154892,0.00046580777,0.029131658,0.008471994,0.35109657,0.22711748],"study_design_scores_gemma":[0.15754756,0.039575055,0.16037944,0.0009847359,0.0006860094,0.000076574455,0.0015676949,0.000367154,0.17067182,0.025508372,0.44195876,0.00067681755],"about_ca_topic_score_codex":0.00027955,"about_ca_topic_score_gemma":0.00019770223,"teacher_disagreement_score":0.22644065,"about_ca_system_score_codex":0.00017900638,"about_ca_system_score_gemma":0.0010676752,"threshold_uncertainty_score":0.9995053},"labels":[],"label_agreement":null},{"id":"W4415940566","doi":"10.1016/j.annonc.2025.08.2579","title":"1955P SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"AstraZeneca","keywords":"Osimertinib; Tolerability; Disease; Safety profile; Adverse effect","score_opus":0.045052076973173046,"score_gpt":0.44228154625093946,"score_spread":0.3972294692777664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935044,0.0010610252,0.0001482342,0.0038540657,0.00006780327,0.0011636189,0.000065052234,0.000022112758,0.004267629],"genre_scores_gemma":[0.9967699,0.00037911636,0.0017033998,0.000632347,0.000015811325,0.00009600599,0.00009450594,0.000012584147,0.00029632088],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985415,0.00012706578,0.0005217964,0.00039993945,0.00018985543,0.00021985306],"domain_scores_gemma":[0.998744,0.00037366105,0.00026611236,0.00032321308,0.0001476085,0.00014539789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002722002,0.00017425549,0.0005746322,0.00016499491,0.00007394231,0.0000057604893,0.000055925047,0.00010554881,0.000025079864],"category_scores_gemma":[0.0003572723,0.00011894769,0.00006939536,0.00023232154,0.00015026476,0.00012761616,0.000049489256,0.00012806866,5.9081174e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07059606,0.0049311817,0.24006845,0.0012604229,0.0005075296,0.000047770227,0.0026968182,0.00012105462,0.01993131,0.0043168114,0.0005289512,0.65499365],"study_design_scores_gemma":[0.016462633,0.008777857,0.9215578,0.005806466,0.0004992427,0.0000067477727,0.0009823263,0.00011384095,0.015363772,0.0014632114,0.028680697,0.0002854242],"about_ca_topic_score_codex":0.00007174815,"about_ca_topic_score_gemma":0.000049405946,"teacher_disagreement_score":0.68148935,"about_ca_system_score_codex":0.000091480506,"about_ca_system_score_gemma":0.0005159441,"threshold_uncertainty_score":0.4850546},"labels":[],"label_agreement":null},{"id":"W4415940695","doi":"10.1016/j.annonc.2025.08.716","title":"288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"FGF19; Hepatocellular carcinoma; Fibroblast growth factor receptor 4; Fibroblast growth factor receptor; Head and neck squamous-cell carcinoma; Cancer; Hepatocellular cancer; Carcinoma","score_opus":0.0670707278049033,"score_gpt":0.39478941470550444,"score_spread":0.32771868690060113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997242,0.00021451774,0.000019969337,0.00021883647,0.000021939359,0.001020039,0.0000165491,0.0000034677305,0.0012427118],"genre_scores_gemma":[0.99928194,0.000021115075,0.00027087439,0.0001145573,0.000010480061,0.00012439712,0.0000135580585,0.000020667938,0.00014239528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841934,0.00023812003,0.00048071012,0.0004167634,0.00012325103,0.00032182175],"domain_scores_gemma":[0.99914515,0.00008739546,0.00020608361,0.00034057235,0.00016554765,0.00005524644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039339016,0.00016774608,0.00043861303,0.0002026357,0.00006551068,0.000013108942,0.00032976887,0.00013477498,0.000010594573],"category_scores_gemma":[0.00015615879,0.0001575095,0.000022452321,0.00026880848,0.00015178366,0.000015701833,0.0003698737,0.00018232173,4.0752084e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080240594,0.0021320425,0.4887948,0.00010033171,0.0000650985,0.000024303303,0.0008097363,0.00010714195,0.50593245,0.00006637541,0.000052735122,0.0011125779],"study_design_scores_gemma":[0.015736002,0.017053777,0.22977898,0.00036806663,0.000014239355,0.0000065482127,0.0036238215,0.0008489282,0.7292977,0.00008922038,0.0028313128,0.0003514045],"about_ca_topic_score_codex":0.0011235223,"about_ca_topic_score_gemma":0.0061382195,"teacher_disagreement_score":0.25901586,"about_ca_system_score_codex":0.000026007474,"about_ca_system_score_gemma":0.00022023168,"threshold_uncertainty_score":0.6423051},"labels":[],"label_agreement":null},{"id":"W4415940698","doi":"10.1016/j.annonc.2025.08.2791","title":"2172P Pathological complete response in gastroesophageal cancer trials: A reliable surrogate for overall survival?","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Complete response; Pathological; Cancer; Surrogate endpoint; Drug response","score_opus":0.2830464592434614,"score_gpt":0.5156410703034147,"score_spread":0.23259461105995327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9461041,0.011715445,0.00011865866,0.03622865,0.00035445258,0.0019577064,0.00032956628,0.000036512338,0.0031548755],"genre_scores_gemma":[0.99226755,0.0024687697,0.00090054603,0.0022313702,0.00009125411,0.0005877894,0.000042401636,0.000013043056,0.0013972886],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973298,0.0008848402,0.00067644176,0.00035106493,0.00020536035,0.00055249274],"domain_scores_gemma":[0.99675286,0.00235946,0.0001761545,0.00025950596,0.0003014034,0.00015063335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044802926,0.00016466624,0.0012081449,0.0002709007,0.000048675214,0.000007096032,0.00013009283,0.00016980521,0.00018656919],"category_scores_gemma":[0.0022292517,0.00012546818,0.00026194463,0.0002496824,0.00015572507,0.00005035975,0.000070052425,0.0002348734,0.0000060986013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5500829,0.0067425724,0.23076966,0.0012270536,0.0015754843,0.004455815,0.00069162995,0.00039203203,0.017530091,0.009168681,0.050863244,0.12650084],"study_design_scores_gemma":[0.056515116,0.051752638,0.73104745,0.0007772229,0.0003165362,0.000042461095,0.00021751726,0.0004761002,0.016226823,0.009750982,0.13256206,0.00031507286],"about_ca_topic_score_codex":0.000377165,"about_ca_topic_score_gemma":0.0002428833,"teacher_disagreement_score":0.5002778,"about_ca_system_score_codex":0.00021674242,"about_ca_system_score_gemma":0.001091184,"threshold_uncertainty_score":0.5116444},"labels":[],"label_agreement":null},{"id":"W4415940700","doi":"10.1016/j.annonc.2025.08.2608","title":"1984P Real-world efficacy and outcomes in older adults with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A Canadian multicenter experience","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Brampton Civic Hospital; Queen Elizabeth II Health Sciences Centre; Hôpital du Sacré-Cœur de Montréal; McGill University; BC Cancer Agency; Northeast Cancer Centre; Institute of Cancer Research; Juravinski Cancer Centre; Western University; University Health Network; Ottawa Regional Cancer Foundation; Hôpital Fleurimont; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Anaplastic lymphoma kinase; Clinical trial; Lymphoma; MEDLINE; Multicenter study","score_opus":0.013906956313904331,"score_gpt":0.3705956109970542,"score_spread":0.35668865468314986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98385423,0.00093758106,0.00001163287,0.0027129848,0.00015664949,0.0010917721,0.00004151813,0.000014120834,0.0111795105],"genre_scores_gemma":[0.9956365,0.00056505325,0.00042382604,0.001856909,0.000016617018,0.00033738103,0.000021508808,0.000016449738,0.0011257328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886644,0.00003559656,0.00028828718,0.0003388444,0.000090933245,0.00037990787],"domain_scores_gemma":[0.9991313,0.00016870532,0.00010414358,0.00021329512,0.00015669563,0.00022586406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052908017,0.00018548481,0.00047809433,0.0003889793,0.000064112966,0.0000075394796,0.00007585472,0.0000817114,0.00005037284],"category_scores_gemma":[0.000040076808,0.00014445251,0.00004193508,0.0003337833,0.00011105118,0.00006834986,0.000022937946,0.00008525608,0.0000014308016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024827681,0.001250172,0.8961671,0.0003657169,0.00027870908,0.00039218002,0.012094259,0.00007798329,0.00032841155,0.0000370421,0.0007068257,0.08581881],"study_design_scores_gemma":[0.020077446,0.00092148467,0.971362,0.0009977013,0.00019998587,0.0000031063933,0.0013675438,0.00032057022,0.0011631049,0.0000018051106,0.003440222,0.00014500535],"about_ca_topic_score_codex":0.14301257,"about_ca_topic_score_gemma":0.55169725,"teacher_disagreement_score":0.40868467,"about_ca_system_score_codex":0.00029643628,"about_ca_system_score_gemma":0.0012683786,"threshold_uncertainty_score":0.8626942},"labels":[],"label_agreement":null},{"id":"W4415940703","doi":"10.1016/j.annonc.2025.08.3333","title":"2723P Reverse fragility index (RFI) of systemic therapy trials in soft tissue sarcoma (STS)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Systemic therapy; Soft tissue sarcoma; Clinical trial; Fragility; Randomized controlled trial; Sarcoma","score_opus":0.7358110313541325,"score_gpt":0.661529090089907,"score_spread":0.07428194126422549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6521668,0.004164283,0.3117882,0.009795216,0.0033039548,0.005026811,0.0003138176,0.00013399938,0.0133069195],"genre_scores_gemma":[0.88721544,0.0014547139,0.109651566,0.001190261,0.000126466,0.000061815765,0.0000016562698,0.000022848559,0.00027525768],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9882158,0.0074437093,0.0033434404,0.00039094777,0.00027010153,0.0003359951],"domain_scores_gemma":[0.8576032,0.13973577,0.0014213952,0.00072976446,0.00042915047,0.00008070674],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029399388,0.00020393525,0.0031742638,0.00021451578,0.000026181322,0.0000053857116,0.0004757359,0.00059780135,0.0006103054],"category_scores_gemma":[0.23404649,0.00017371998,0.00030980527,0.00041525456,0.00039186398,0.00004045493,0.00013663688,0.00037652635,0.000011270827],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004720222,0.0041859304,0.010462436,0.0016793589,0.0007365414,0.000068735375,0.0009275414,0.000043463548,0.009307227,0.1061292,0.03982666,0.8219127],"study_design_scores_gemma":[0.0041339947,0.0012437522,0.0058064233,0.0005359417,0.00006630737,0.0000040864925,0.00020932124,0.00013348208,0.009003729,0.97263956,0.0060633845,0.00015999876],"about_ca_topic_score_codex":0.00021479127,"about_ca_topic_score_gemma":0.000057420606,"teacher_disagreement_score":0.8665104,"about_ca_system_score_codex":0.000047743593,"about_ca_system_score_gemma":0.0003522149,"threshold_uncertainty_score":0.9994376},"labels":[],"label_agreement":null},{"id":"W4415940713","doi":"10.1016/j.annonc.2025.08.3140","title":"2526eP Population-based analysis of lifetime use of prostate cancer therapies","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Standard of care; Prostate; Cancer; Overall survival; MEDLINE","score_opus":0.10223193071508699,"score_gpt":0.4567891000637131,"score_spread":0.35455716934862613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882852,0.0028596472,0.0000131423285,0.007779464,0.000043023643,0.00030171068,0.00011814234,0.000007677788,0.0005920204],"genre_scores_gemma":[0.99563956,0.0016649102,0.00022986432,0.00051479205,0.000010099911,0.000034534954,0.00010375684,0.0000054785814,0.0017969726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912137,0.00008004598,0.0003566109,0.0001336464,0.0001599091,0.00014841264],"domain_scores_gemma":[0.9987568,0.00028332483,0.00019975014,0.00020407794,0.00051635795,0.00003968602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018402723,0.000077383826,0.0006029939,0.0005836048,0.00001859823,0.000001975901,0.000057056262,0.00008116731,0.00022483875],"category_scores_gemma":[0.00009154488,0.000056928402,0.00018438124,0.00092207256,0.00014567505,0.00003645138,0.000019650017,0.000064008724,5.357388e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019244063,0.00053122686,0.9513186,0.00020884095,0.0037824633,0.000005596546,0.00036545604,0.00083526626,0.0035844129,0.00019281356,0.0015229239,0.035727955],"study_design_scores_gemma":[0.0017444565,0.001252674,0.952115,0.00013514013,0.0010555066,1.3061384e-7,0.000071395676,0.0010035733,0.03462544,0.00014510183,0.0077992883,0.000052316544],"about_ca_topic_score_codex":0.0028394891,"about_ca_topic_score_gemma":0.00033256641,"teacher_disagreement_score":0.03567564,"about_ca_system_score_codex":0.000041570936,"about_ca_system_score_gemma":0.00054292474,"threshold_uncertainty_score":0.4292477},"labels":[],"label_agreement":null},{"id":"W4415940731","doi":"10.1016/j.annonc.2025.08.3688","title":"3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Astellas Pharma; Pfizer","keywords":"Pembrolizumab; Urothelial cancer; Cohort; Cisplatin; Metastatic Urothelial Carcinoma; Expanded access; Chemotherapy","score_opus":0.0360325907053891,"score_gpt":0.3754102315221576,"score_spread":0.33937764081676847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888231,0.0011721068,0.0004659047,0.00090635876,0.00006866215,0.0036378077,0.00015143401,0.000039734772,0.0047348887],"genre_scores_gemma":[0.99310094,0.0022607879,0.0023434742,0.00038547485,0.000024478555,0.00048725004,0.000036193655,0.00006453314,0.0012968518],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99713254,0.00022618027,0.001004313,0.0005985886,0.0004820081,0.00055639714],"domain_scores_gemma":[0.9974571,0.0006275274,0.0006297886,0.00047528217,0.0006001668,0.0002101558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039697942,0.00048369757,0.002117202,0.00041746814,0.000051449453,0.000008127411,0.00019157979,0.00018491279,0.00017032192],"category_scores_gemma":[0.00020441679,0.0002783794,0.000084132516,0.0009590035,0.00062452315,0.00013116018,0.000040771327,0.00028079373,0.0000010793361],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6026923,0.002880583,0.25763604,0.002614882,0.0048166793,0.0009601508,0.0032722848,0.000613466,0.002032195,0.00023876395,0.0003684932,0.121874146],"study_design_scores_gemma":[0.39204946,0.17327058,0.28464702,0.017230093,0.010164127,0.0014058675,0.0020644928,0.0011087683,0.10992367,0.00018556773,0.006293611,0.0016567574],"about_ca_topic_score_codex":0.004493302,"about_ca_topic_score_gemma":0.026319616,"teacher_disagreement_score":0.21064286,"about_ca_system_score_codex":0.00014719441,"about_ca_system_score_gemma":0.0056643044,"threshold_uncertainty_score":0.99997264},"labels":[],"label_agreement":null},{"id":"W4415940747","doi":"10.1016/j.annonc.2025.08.1727","title":"1089P Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Stand Up To Cancer; Cancer Australia; Canadian Cancer Society","keywords":"Olaparib; Chemotherapy; Ovarian cancer; Quality of life (healthcare); Epithelial ovarian cancer; Chemotherapy regimen","score_opus":0.08929534852264863,"score_gpt":0.44509291900957476,"score_spread":0.3557975704869261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8727593,0.0001949639,0.00019139562,0.12304927,0.0001286409,0.00057879934,0.000048878275,0.000021467482,0.0030272983],"genre_scores_gemma":[0.9262816,0.00018527596,0.0005373364,0.071798295,0.000022644268,0.00006354937,0.000004578993,0.00002120716,0.0010855385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976384,0.00047214696,0.00086365826,0.00038444682,0.0002916793,0.00034963957],"domain_scores_gemma":[0.9968921,0.0018249057,0.00044950494,0.00027096405,0.00043707958,0.00012546947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022561282,0.00020938867,0.0011971341,0.00030687044,0.00004673191,0.000005753103,0.00009519844,0.00026059823,0.00007733186],"category_scores_gemma":[0.002126605,0.00018359034,0.0001338265,0.00062769,0.0001652778,0.000054916778,0.000029755336,0.0002847062,0.0000019567217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22973514,0.0022630785,0.4698674,0.000408388,0.005187236,0.0003143793,0.050644957,0.00042876313,0.19066934,0.0013034793,0.035342824,0.013835006],"study_design_scores_gemma":[0.05087068,0.007020635,0.83306116,0.0050548115,0.00016904203,0.00001061252,0.0063502956,0.00024013563,0.0775407,0.0012673497,0.01782776,0.0005868222],"about_ca_topic_score_codex":0.0010382544,"about_ca_topic_score_gemma":0.0009059162,"teacher_disagreement_score":0.36319375,"about_ca_system_score_codex":0.00023858385,"about_ca_system_score_gemma":0.0011299618,"threshold_uncertainty_score":0.7486597},"labels":[],"label_agreement":null},{"id":"W4415940751","doi":"10.1016/j.annonc.2025.08.1252","title":"677P EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hellenic Society of Medical Oncology; Sjöbergstiftelsen; European Society for Medical Oncology; University of Crete; Cancerfonden; Canadian Cancer Society","keywords":"Brain metastasis; Metastasis; MEDLINE; Cancer; Neoplasm staging","score_opus":0.05569170123665718,"score_gpt":0.44329145867720104,"score_spread":0.38759975744054387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79973984,0.0022265406,0.021124551,0.13498612,0.00045609847,0.005712363,0.0007809688,0.00017594206,0.03479757],"genre_scores_gemma":[0.9782898,0.00004170894,0.008571862,0.00843453,0.000058238154,0.0005424882,0.00026880216,0.00002140041,0.003771191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990706,0.000031881973,0.0002886805,0.00024158199,0.00010485659,0.0002623903],"domain_scores_gemma":[0.9986105,0.0005743952,0.00012960813,0.00019561638,0.00042386944,0.000065987144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017975268,0.00014082705,0.00044806916,0.00016321757,0.00006467062,0.000007640993,0.00006721268,0.00008425899,0.0000512358],"category_scores_gemma":[0.00041997558,0.000101255515,0.00010363282,0.00028817775,0.00011798445,0.000059049347,0.000021349411,0.000073560645,0.0000053064073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013828867,0.014725537,0.04359234,0.0020339505,0.015283954,0.00040769385,0.0030497452,0.0003309314,0.025547685,0.04831697,0.33788088,0.49500144],"study_design_scores_gemma":[0.034309145,0.027555728,0.077192985,0.00094751903,0.0045250864,0.00018530429,0.0010874806,0.00035522765,0.020978145,0.0021376342,0.8302569,0.0004688523],"about_ca_topic_score_codex":0.00010047031,"about_ca_topic_score_gemma":0.00008812446,"teacher_disagreement_score":0.4945326,"about_ca_system_score_codex":0.000057540426,"about_ca_system_score_gemma":0.0010826039,"threshold_uncertainty_score":0.412908},"labels":[],"label_agreement":null},{"id":"W4415940758","doi":"10.1016/j.annonc.2025.08.1715","title":"1077P How long is long enough? An international GCIG collaboration investigating long term outcomes of exceptional responders with platinum sensitive recurrent ovarian cancer treated with PARP inhibitors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Syndax Pharmaceuticals","keywords":"Myeloid leukemia; Ovarian cancer; Disease; Myelodysplastic syndromes; Chemotherapy; Cancer","score_opus":0.08283893316557171,"score_gpt":0.4167267100380951,"score_spread":0.33388777687252336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96513,0.00010707734,0.00049840513,0.031940836,0.0002880262,0.00064031547,0.00017719062,0.000042676926,0.0011755077],"genre_scores_gemma":[0.9951834,0.00014414333,0.0010439442,0.002371565,0.00018996552,0.00009981397,0.00028536565,0.000027847142,0.0006539534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979521,0.00024316832,0.0005604351,0.00045056094,0.0005153571,0.0002784041],"domain_scores_gemma":[0.99704325,0.00025520645,0.0007209024,0.00027125847,0.0015728393,0.00013652256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037945123,0.00026894885,0.00066052366,0.00045622792,0.00009240546,0.000025163321,0.00011779562,0.00020890502,0.00014583801],"category_scores_gemma":[0.00012975546,0.00022017863,0.00007749932,0.00068729545,0.0005222621,0.00038813739,0.000034170745,0.00026623832,0.0000012025616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049714376,0.00048571374,0.9596353,0.00011987999,0.0011565072,0.00008969568,0.0032643576,0.00024418303,0.010232864,0.00034934387,0.0018709357,0.017579744],"study_design_scores_gemma":[0.005977131,0.003179927,0.8811811,0.0011535019,0.00016164439,0.000039833983,0.0011784678,0.00016269468,0.10614178,0.00006424337,0.00053445954,0.00022519105],"about_ca_topic_score_codex":0.00020155663,"about_ca_topic_score_gemma":0.0014308657,"teacher_disagreement_score":0.09590892,"about_ca_system_score_codex":0.00035004152,"about_ca_system_score_gemma":0.0014455628,"threshold_uncertainty_score":0.8978624},"labels":[],"label_agreement":null},{"id":"W4415940764","doi":"10.1016/j.annonc.2025.08.2037","title":"1405P AI informed virtual immunocyte profiling from H&amp;E images predicts immunotherapy response (VIPER) in head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Dental and Craniofacial Research; Institute of Aging; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Immunotherapy; Head and neck squamous-cell carcinoma; Head and neck; Immunohistochemistry; CD68; Immune system; Head and neck cancer; Basal cell; Monoclonal antibody","score_opus":0.038570153056316406,"score_gpt":0.36590476161951335,"score_spread":0.32733460856319696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742024,0.015507137,0.00003023359,0.0054318276,0.00030693755,0.0006501146,0.000064376516,0.000037958354,0.0037690361],"genre_scores_gemma":[0.9880027,0.0022741247,0.0006228107,0.007597958,0.00005420122,0.000056884757,0.000057643076,0.000023683475,0.0013099853],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99801373,0.00026013504,0.0007824022,0.00034521212,0.00018086156,0.00041764393],"domain_scores_gemma":[0.9982773,0.00081201777,0.0002150546,0.00044542225,0.00017561209,0.00007458779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075138576,0.000251306,0.00071260147,0.00043743703,0.000069559916,0.000018529756,0.00018115918,0.0003267534,0.00009491108],"category_scores_gemma":[0.0002594415,0.00022910173,0.00015461238,0.0003831738,0.00034709094,0.00015200804,0.0000826412,0.0003651052,0.000006210735],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17803289,0.00088770676,0.08266651,0.00018838933,0.00021977993,0.000097422075,0.002751189,0.0000080457185,0.6404655,0.000052069987,0.0062247324,0.08840577],"study_design_scores_gemma":[0.022356788,0.0072239223,0.6161487,0.00025379827,0.00004886486,0.000029336106,0.00081325497,0.000044703153,0.22113305,0.0001896182,0.13150226,0.00025570596],"about_ca_topic_score_codex":0.0018465683,"about_ca_topic_score_gemma":0.00030025252,"teacher_disagreement_score":0.5334822,"about_ca_system_score_codex":0.00015559822,"about_ca_system_score_gemma":0.0012959177,"threshold_uncertainty_score":0.93424976},"labels":[],"label_agreement":null},{"id":"W4415940767","doi":"10.1016/j.annonc.2025.08.2926","title":"2310P Global contribution and representation on pivotal clinical trials in hematology/oncology","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clinical trial; Representation (politics); MEDLINE; Clinical Practice","score_opus":0.8250238855526464,"score_gpt":0.7769338959604901,"score_spread":0.04808998959215627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82401496,0.00068318803,0.00021576256,0.13639311,0.0006544843,0.0008692073,0.000020187768,0.000022079392,0.037126992],"genre_scores_gemma":[0.9879478,0.0032130561,0.00044591507,0.007909871,0.00012784067,0.00004307187,0.000022741135,0.0000050919584,0.00028458968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99160177,0.0046168496,0.002523423,0.0005399017,0.00033937665,0.00037867946],"domain_scores_gemma":[0.9138438,0.08389644,0.00065955915,0.00044227543,0.0009524678,0.00020545266],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03630969,0.000119864446,0.0018446399,0.00021074193,0.00003795676,0.000005814858,0.0001424454,0.0014490858,0.000056342524],"category_scores_gemma":[0.24482481,0.000102802485,0.00024063654,0.00041010554,0.0008910135,0.000039549952,0.00017095149,0.0013904286,0.00002108007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011547983,0.002312527,0.4202138,0.00014223786,0.00026072795,0.0002844365,0.0000562076,0.0000032606433,0.00030120494,0.38233566,0.011569897,0.17097205],"study_design_scores_gemma":[0.017768044,0.020405095,0.5793466,0.0005435361,0.000153586,0.000098081146,0.00035458675,0.00026690916,0.0034125936,0.3379886,0.039508946,0.00015344334],"about_ca_topic_score_codex":0.000112386886,"about_ca_topic_score_gemma":0.0006079558,"teacher_disagreement_score":0.20851512,"about_ca_system_score_codex":0.00014717798,"about_ca_system_score_gemma":0.0015400922,"threshold_uncertainty_score":0.99984723},"labels":[],"label_agreement":null},{"id":"W4415940769","doi":"10.1016/j.annonc.2025.08.2572","title":"1948P Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Phases of clinical research; Conjugate; Wild type; Overall survival; Adverse effect; Clinical trial","score_opus":0.09948266861913178,"score_gpt":0.44885699711055543,"score_spread":0.34937432849142364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97924006,0.0004865789,0.00001627912,0.007719784,0.00019130054,0.0028126321,0.00005115539,0.000024175657,0.009458018],"genre_scores_gemma":[0.9964387,0.00038441826,0.00042793865,0.00160759,0.000058833735,0.0005042369,0.000045666766,0.000023519842,0.0005091047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997075,0.00058838807,0.0007690235,0.0005125485,0.00046612532,0.00058887445],"domain_scores_gemma":[0.9976078,0.0009129811,0.00025173457,0.00081551255,0.00030367557,0.00010825587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000776213,0.00027929398,0.0009615146,0.00049398246,0.00011746757,0.000024729587,0.00038601694,0.00023796174,0.00005304736],"category_scores_gemma":[0.00070683245,0.00018957921,0.00014460161,0.0007365647,0.0003120845,0.00013304087,0.00009622991,0.0004809997,0.000013166263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06738844,0.018130714,0.5655941,0.0002459953,0.00035830747,0.00015204297,0.0046578837,0.00052778824,0.0007163963,0.00064084015,0.009512483,0.33207506],"study_design_scores_gemma":[0.13487118,0.029948,0.7741405,0.0008730981,0.00016112022,0.0000074078134,0.0011634218,0.00024016155,0.0024990672,0.00031028077,0.055401407,0.0003843932],"about_ca_topic_score_codex":0.0024170533,"about_ca_topic_score_gemma":0.0023517439,"teacher_disagreement_score":0.33169064,"about_ca_system_score_codex":0.0007467772,"about_ca_system_score_gemma":0.0014933483,"threshold_uncertainty_score":0.77308154},"labels":[],"label_agreement":null},{"id":"W4415940781","doi":"10.1016/j.annonc.2025.08.3043","title":"2428P Time to response with talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Enzalutamide; Prostate cancer; Placebo; Post-hoc analysis; Overall survival; Prostate-specific antigen","score_opus":0.040792322447850804,"score_gpt":0.38909276318279906,"score_spread":0.34830044073494826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841904,0.0003949454,0.0000027143356,0.011275909,0.000029288563,0.0019155319,0.000091076734,0.000015843707,0.0020842834],"genre_scores_gemma":[0.9913765,0.000089525245,0.0003941303,0.0009611838,0.000009233739,0.00053603854,0.000060036356,0.000023301396,0.006550008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796784,0.0002682974,0.00047009502,0.00040998863,0.00035842785,0.0005253539],"domain_scores_gemma":[0.99879396,0.0002387917,0.00013788111,0.00027173862,0.00040564057,0.00015199653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006424929,0.00021839327,0.0006493203,0.00065711624,0.00004158751,0.000013109845,0.000112898735,0.000081294456,0.00012950142],"category_scores_gemma":[0.0001605253,0.00015212811,0.000041377425,0.0010707343,0.0001965655,0.000116785806,0.000053815773,0.00024236547,0.00002307109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41761655,0.005625902,0.4860873,0.0006661139,0.0008402633,0.0018799846,0.0039355024,0.0011565365,0.0242692,0.00013152878,0.0063621867,0.05142896],"study_design_scores_gemma":[0.021532774,0.02337142,0.91964954,0.0012470027,0.00011894114,0.000009879894,0.00045541808,0.000088505905,0.020945925,0.000108313565,0.012193469,0.00027880268],"about_ca_topic_score_codex":0.00068322226,"about_ca_topic_score_gemma":0.002802709,"teacher_disagreement_score":0.43356228,"about_ca_system_score_codex":0.0004155546,"about_ca_system_score_gemma":0.0020620888,"threshold_uncertainty_score":0.62036043},"labels":[],"label_agreement":null},{"id":"W4415940823","doi":"10.1016/j.annonc.2025.08.2612","title":"1988P Real-world treatment patterns and survival in patients (pts) with ROS1-positive (ROS1+) locally advanced or metastatic (LAM) non-small cell lung cancer (NSCLC) in Canada and Europe","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Bristol-Myers Squibb","keywords":"Lung cancer; Respiratory disease; Chemotherapy; Cancer; Overall survival; MEDLINE","score_opus":0.02030350977072649,"score_gpt":0.35482434904905485,"score_spread":0.3345208392783284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275887,0.0003859667,0.000025071175,0.0011676839,0.00009919021,0.0010075385,0.00017163676,0.00000465271,0.0043794187],"genre_scores_gemma":[0.99514335,0.0020161609,0.00022390552,0.0008187269,0.000008954862,0.00016715116,0.00005992769,0.000016714923,0.0015451248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988861,0.000088580084,0.0003248354,0.00031400527,0.000110210116,0.0002762644],"domain_scores_gemma":[0.9992641,0.00019011604,0.00013306814,0.0001337843,0.0001758762,0.00010303947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006758009,0.00019166312,0.0005686016,0.00017564846,0.000032241118,0.000005748098,0.000041273026,0.000031448424,0.000022130664],"category_scores_gemma":[0.000013597635,0.00013350515,0.000019258214,0.00029896857,0.00005450285,0.00005018954,0.000031822317,0.00009146571,2.2100068e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017670792,0.00072325655,0.9513495,0.00018735572,0.0002980266,0.00030191077,0.0008880215,0.00014671835,0.000029552575,0.000022628737,0.00013094817,0.044154983],"study_design_scores_gemma":[0.013187018,0.003540638,0.98000157,0.0005125408,0.0003266395,0.0000019393708,0.00040361713,0.00012225946,0.00092498446,0.0000050375907,0.0008502694,0.0001234573],"about_ca_topic_score_codex":0.81928754,"about_ca_topic_score_gemma":0.990479,"teacher_disagreement_score":0.17119151,"about_ca_system_score_codex":0.0007105991,"about_ca_system_score_gemma":0.0032653068,"threshold_uncertainty_score":0.5792514},"labels":[],"label_agreement":null},{"id":"W4415940864","doi":"10.1016/j.annonc.2025.08.2307","title":"1679P Circulating metabolic profiling for predicting tebentafusp efficacy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Princess Margaret Cancer Centre","funders":"","keywords":"Metabolome; Immune checkpoint; Blockade; Immune system; Melanoma; Cancer; Cell; Metabolomics; Immunotherapy","score_opus":0.08641315390919703,"score_gpt":0.4388150737059903,"score_spread":0.3524019197967933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696487,0.0016802349,0.000491105,0.0036370656,0.00037971957,0.0010195991,0.000011962832,0.000057985057,0.023073636],"genre_scores_gemma":[0.99197173,0.00008224236,0.0056527434,0.0014882954,0.00012731788,0.00009249029,0.000046610643,0.00001367813,0.00052489986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988633,0.000077046876,0.00041003007,0.00025636275,0.00008755561,0.0003057428],"domain_scores_gemma":[0.9988039,0.0005097559,0.00018595136,0.00020897262,0.00022525832,0.00006616598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046194144,0.00012836648,0.0005802865,0.00017763813,0.00011284177,0.0000033587187,0.00007741232,0.00022027647,0.000024583147],"category_scores_gemma":[0.00076788606,0.00011403009,0.00020949982,0.00021160909,0.00009331296,0.000045927725,0.00004816326,0.00015052318,0.0000067065243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011992401,0.0024991867,0.60438704,0.0004275932,0.0023244182,0.00010431665,0.0004120638,0.000063012994,0.0114841135,0.014929681,0.0013371183,0.36083218],"study_design_scores_gemma":[0.032489672,0.010788062,0.42357537,0.0007550282,0.0033411242,0.0002175002,0.0010507312,0.0030707908,0.30550337,0.0065531614,0.21216811,0.00048709597],"about_ca_topic_score_codex":0.00001816986,"about_ca_topic_score_gemma":0.0000069743164,"teacher_disagreement_score":0.3603451,"about_ca_system_score_codex":0.000032667645,"about_ca_system_score_gemma":0.00037058693,"threshold_uncertainty_score":0.46500123},"labels":[],"label_agreement":null},{"id":"W4415940884","doi":"10.1016/j.annonc.2025.08.2130","title":"1500P SOLARIS: A phase-II open-label Study of pembrOlizumab and Lenvatinib in patients with Advanced stage hepatocellular carcinoma who are Refractory to atezolizumab and bevacizumab/ IO-baSed therapy (IKF t-037 trial)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutsche Forschungsgemeinschaft","keywords":"Lenvatinib; Pembrolizumab; Atezolizumab; Refractory (planetary science); Nivolumab; Regorafenib; Concomitant; Hepatocellular carcinoma","score_opus":0.13863993907139968,"score_gpt":0.38162182503401243,"score_spread":0.24298188596261275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897165,0.0019331862,0.000008603742,0.0009293628,0.00006160055,0.006855374,0.00007923684,0.000018324306,0.00039785382],"genre_scores_gemma":[0.99795836,0.00023701155,0.0002766805,0.00077737565,0.000016111991,0.00044567176,0.000059693153,0.00004053647,0.000188583],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99722755,0.00040178277,0.00089664385,0.00069648435,0.00034194163,0.0004355884],"domain_scores_gemma":[0.99797326,0.00024047082,0.00051608274,0.00058639765,0.00047600636,0.0002077722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005136697,0.00040029894,0.0016589387,0.00057448936,0.00013088537,0.000020971158,0.00024223456,0.0002403148,0.000031541447],"category_scores_gemma":[0.00013588868,0.00032754292,0.00006314301,0.0005755875,0.00015221213,0.00017786761,0.0002153576,0.0002718315,9.0453125e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16719368,0.024520783,0.7454907,0.00018671232,0.00032668398,0.00015345622,0.0017926298,0.0000010354182,0.0005095947,0.00001897114,0.0001372772,0.059668526],"study_design_scores_gemma":[0.5029724,0.20226242,0.284442,0.00042018763,0.0002215049,0.0000017720683,0.0010285093,0.00033800688,0.0046991394,0.000023261991,0.003277425,0.00031335573],"about_ca_topic_score_codex":0.00055950397,"about_ca_topic_score_gemma":0.0002411016,"teacher_disagreement_score":0.46104863,"about_ca_system_score_codex":0.000102365746,"about_ca_system_score_gemma":0.0005655982,"threshold_uncertainty_score":0.9999177},"labels":[],"label_agreement":null},{"id":"W4415940923","doi":"10.1016/j.annonc.2025.08.3158","title":"2543MO Imposter syndrome, burnout, and maladaptive perfectionism among oncology professionals: A global cross-sectional study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Perfectionism, Procrastination, Anxiety Studies","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bank of Canada","funders":"","keywords":"Perfectionism (psychology); MEDLINE; Clinical Oncology; Young adult","score_opus":0.0587317146006874,"score_gpt":0.4580577993143414,"score_spread":0.399326084713654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94690657,0.00074510666,0.00015517964,0.0026933528,0.0027970762,0.0011097373,0.000052396546,0.000112598434,0.045427997],"genre_scores_gemma":[0.9918955,0.00008743007,0.000108018474,0.00088869623,0.00014985623,0.0005623808,0.000010685257,0.000019494424,0.006277955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964694,0.00090175675,0.00093835546,0.0008605286,0.00025920098,0.0005708001],"domain_scores_gemma":[0.99744415,0.00066668796,0.0004962152,0.00033702425,0.00093316514,0.00012273471],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014719864,0.00034282458,0.00076807314,0.00031750888,0.00070752116,0.000045259305,0.00026791217,0.0006028097,0.00042496523],"category_scores_gemma":[0.00032212352,0.00033196967,0.0001767186,0.0006133581,0.00093790214,0.00024767287,0.00035233455,0.0005136762,0.00005884051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068767485,0.003446513,0.9754365,0.000043802884,0.0010955249,0.00008712093,0.0023968709,0.000011284737,0.00004457917,0.0043047504,0.0065565137,0.005888849],"study_design_scores_gemma":[0.0028471823,0.006010114,0.97436905,0.000031809177,0.00008982406,0.00040459455,0.005634382,0.000016506303,0.000026362426,0.0027575442,0.0075765974,0.00023602083],"about_ca_topic_score_codex":0.00082547177,"about_ca_topic_score_gemma":0.0010659047,"teacher_disagreement_score":0.044988927,"about_ca_system_score_codex":0.0003195594,"about_ca_system_score_gemma":0.0004318277,"threshold_uncertainty_score":0.9999132},"labels":[],"label_agreement":null},{"id":"W4415940927","doi":"10.1016/j.annonc.2025.08.3749","title":"3207eP Accelerating eSource data collection for accurate clinical research","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Electronic Health Records Systems","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Electronic data capture; Data collection; Electronic medical record; Data quality; Clinical trial; Quality (philosophy); Medical record; Electronic data","score_opus":0.8986521079377753,"score_gpt":0.7701624445116991,"score_spread":0.12848966342607615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46014318,0.0030965153,0.010102855,0.19703588,0.0108954655,0.013390312,0.00021165714,0.000280912,0.30484325],"genre_scores_gemma":[0.92395693,0.0025444126,0.0054503498,0.0167301,0.003285513,0.0020090186,0.0002633457,0.00007880472,0.04568154],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903216,0.00581408,0.0019159565,0.0005693197,0.00022976779,0.0011493242],"domain_scores_gemma":[0.9776181,0.01913498,0.0006009976,0.00096413825,0.0015301522,0.00015165901],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029222652,0.000117724194,0.0007013014,0.00031848747,0.0011820641,0.000007815284,0.00080985704,0.00069300353,0.00010573092],"category_scores_gemma":[0.013100806,0.00010991174,0.00007505999,0.00080691726,0.0001535554,0.00013495352,0.0005571179,0.0015930346,0.00007468741],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006073959,0.0002293361,0.015186846,0.0007402447,0.0000861418,0.0000014695069,0.0005456821,0.0000025935412,0.00011193353,0.0060081286,0.85329235,0.12318787],"study_design_scores_gemma":[0.0015712242,0.002036011,0.0043141507,0.0002726336,0.0000129915625,0.0000010959607,0.0014339397,0.004572074,0.000062424675,0.0021944384,0.98344946,0.0000795341],"about_ca_topic_score_codex":0.0011220777,"about_ca_topic_score_gemma":0.002866599,"teacher_disagreement_score":0.46381375,"about_ca_system_score_codex":0.0002503523,"about_ca_system_score_gemma":0.008306513,"threshold_uncertainty_score":0.99961954},"labels":[],"label_agreement":null},{"id":"W4415940937","doi":"10.1016/j.annonc.2025.08.2610","title":"1986P TRUST-II global study: Efficacy and safety of taletrectinib after prior entrectinib exposure in patients with advanced ROS1+ non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Lung cancer; Tyrosine kinase; Tyrosine-kinase inhibitor; Clinical trial; Cancer; Cell; Clinical Practice","score_opus":0.010248784556993082,"score_gpt":0.3588284323872693,"score_spread":0.34857964783027623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921119,0.001261815,0.000007466458,0.0006759454,0.00017674752,0.0017213126,0.00008687647,0.000010642504,0.003947292],"genre_scores_gemma":[0.9985015,0.00019253661,0.00030094667,0.00031809774,0.00001812088,0.0001589573,0.000017324748,0.000010113186,0.00048243362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989002,0.000058434933,0.00039694418,0.00029434438,0.00012581001,0.00022431952],"domain_scores_gemma":[0.9992024,0.000086391534,0.0001938781,0.00019411078,0.0002536264,0.00006963112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010081447,0.00016104124,0.0005426463,0.000111225374,0.00004431879,0.0000028247202,0.0000579066,0.000093047616,0.00004765079],"category_scores_gemma":[0.000037836893,0.00012422535,0.00004614233,0.00033698624,0.000071914794,0.000050044262,0.00006012561,0.00010675948,3.7274228e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065592085,0.003949302,0.9043683,0.00014218298,0.00035251325,0.000017997883,0.0023727904,0.000049730475,0.00002387694,0.0000048874736,0.0001697404,0.0819895],"study_design_scores_gemma":[0.02383362,0.0074363425,0.9645601,0.0002660092,0.00039408996,8.5976484e-7,0.0005611544,0.0000067813226,0.0004058,0.000004808732,0.0024407993,0.00008963824],"about_ca_topic_score_codex":0.00038858497,"about_ca_topic_score_gemma":0.0013561369,"teacher_disagreement_score":0.08189986,"about_ca_system_score_codex":0.00014654914,"about_ca_system_score_gemma":0.0004974576,"threshold_uncertainty_score":0.5065763},"labels":[],"label_agreement":null},{"id":"W4415940939","doi":"10.1016/j.annonc.2025.08.2913","title":"2297P Higher termination rates and survival trade-offs: A 10-year review of NICE appraisals of oncology combination therapies","year":2025,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Nice; Overall survival; Valuation (finance); Cost–benefit analysis; MEDLINE","score_opus":0.5512544572431582,"score_gpt":0.5652767323781224,"score_spread":0.014022275134964124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074036594,0.9621469,0.000024552146,0.017836438,0.0006993074,0.0015177298,0.00061391667,0.000014128011,0.017072987],"genre_scores_gemma":[0.00026080798,0.9957654,0.00041506684,0.002182777,0.00012262941,0.0002146324,0.00023567441,0.000032207474,0.00077081716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.988972,0.0024067713,0.0076042204,0.0005786653,0.00012797966,0.0003103711],"domain_scores_gemma":[0.98026466,0.007845838,0.0109444,0.00052673573,0.00032964488,0.00008873461],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.021039564,0.00035176243,0.006944712,0.00074115605,0.000053518354,0.000009956293,0.00043986173,0.00072965765,0.000560113],"category_scores_gemma":[0.0051438464,0.0003864252,0.0004779628,0.00044366182,0.00030979,0.0002204053,0.00010441601,0.00026225578,0.00005299855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030440422,0.00070588477,0.00022327255,0.32746878,0.0007166665,0.0000011191287,0.00049868686,4.149712e-7,4.1574057e-7,0.11232357,0.054762408,0.50326836],"study_design_scores_gemma":[0.0006119775,0.0010123914,0.00059079303,0.02080531,0.00014828394,0.000003834611,0.000113127855,0.0000061991773,0.0000018026936,0.0030483806,0.9734125,0.00024538115],"about_ca_topic_score_codex":0.00014979838,"about_ca_topic_score_gemma":0.000030218689,"teacher_disagreement_score":0.9186501,"about_ca_system_score_codex":0.00021243388,"about_ca_system_score_gemma":0.0011107363,"threshold_uncertainty_score":0.99985874},"labels":[],"label_agreement":null},{"id":"W4415940943","doi":"10.1016/j.annonc.2025.08.1239","title":"664MO Long-term efficacy and safety of larotrectinib in TRK fusion primary central nervous system tumours: An updated analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Trk receptor; Central nervous system; Nervous system; Fusion; Neurotrophin","score_opus":0.020674499688767927,"score_gpt":0.31606979547465125,"score_spread":0.2953952957858833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615514,0.000665994,0.0002676113,0.00015558403,0.000117565636,0.00023008583,0.000035308884,0.000012689332,0.0023599928],"genre_scores_gemma":[0.9988545,0.00027643013,0.000119879776,0.00016475984,0.000044209202,0.000006829889,0.00044069297,0.00000951266,0.00008316375],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986042,0.00029902463,0.0004507966,0.00031983972,0.000073129166,0.0002530257],"domain_scores_gemma":[0.9992769,0.000035551682,0.00020183783,0.00029961785,0.00010944335,0.00007665276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041168847,0.00013268167,0.0005057661,0.00021497325,0.00002732326,0.0000045271127,0.00016412279,0.00025038296,0.0000094156085],"category_scores_gemma":[0.000039478567,0.00012562425,0.00010738457,0.00033064946,0.000089956106,0.0000051146467,0.00012025394,0.00008498181,3.5191573e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030760267,0.0011041334,0.3612319,0.00030530678,0.0007651115,0.000072480034,0.00026356595,0.0002469976,0.5478304,0.00043442313,0.00076372316,0.08390595],"study_design_scores_gemma":[0.0014880048,0.0014291193,0.8992057,0.00004825829,0.00017952266,0.0000117918635,0.00009735412,0.00006317653,0.09581314,0.000007833228,0.0015367244,0.000119374214],"about_ca_topic_score_codex":0.00011898802,"about_ca_topic_score_gemma":0.00045789755,"teacher_disagreement_score":0.5379738,"about_ca_system_score_codex":0.000018469838,"about_ca_system_score_gemma":0.00017502041,"threshold_uncertainty_score":0.5122808},"labels":[],"label_agreement":null},{"id":"W4415940953","doi":"10.1016/j.annonc.2025.08.2914","title":"2298P Uncertain promises: FDA accelerated approval for malignant hematology and oncology - Withdrawals scope and trends","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Scope (computer science); Hematology; Drug approval; MEDLINE; Clinical Oncology","score_opus":0.12267224141864314,"score_gpt":0.3721061548380944,"score_spread":0.24943391341945126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7372535,0.02610608,0.0017831709,0.024662808,0.0009838197,0.0011276561,0.00044641402,0.00005462165,0.20758192],"genre_scores_gemma":[0.987794,0.0038529655,0.0017464528,0.003229006,0.00009085623,0.00019911928,0.000026699086,0.000025110683,0.0030358175],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792963,0.00004769983,0.00096060365,0.0005630684,0.000016761473,0.00048225006],"domain_scores_gemma":[0.9985404,0.00033693603,0.0006371351,0.00023554343,0.00012977622,0.00012019307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097465434,0.00022485793,0.0012929459,0.00047692138,0.00013188235,0.000032750064,0.00020531962,0.0004274282,0.00010701588],"category_scores_gemma":[0.0003475775,0.0002400109,0.00010131389,0.000247879,0.0004419652,0.00021951996,0.00011606341,0.00017122418,0.000008964811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009732815,0.0003799017,0.010833996,0.00028422254,0.0003485802,0.000013086997,0.0006035473,0.000020255817,0.00019332883,0.71440923,0.028500896,0.24343967],"study_design_scores_gemma":[0.0050752778,0.004211876,0.016750574,0.00007944587,0.000044257245,0.000050339542,0.00027350296,0.00071754795,0.0019887653,0.12011375,0.8502145,0.0004801543],"about_ca_topic_score_codex":0.0003681245,"about_ca_topic_score_gemma":0.00026720625,"teacher_disagreement_score":0.8217136,"about_ca_system_score_codex":0.000088946006,"about_ca_system_score_gemma":0.00026305974,"threshold_uncertainty_score":0.97873604},"labels":[],"label_agreement":null},{"id":"W4415940977","doi":"10.1016/j.annonc.2025.08.2574","title":"1950P Ocular surface disorders in patients with c-Met protein–overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Antibody-drug conjugate; Phases of clinical research; Conjugate; Adverse effect; Clinical trial; Brentuximab vedotin","score_opus":0.04071054316473132,"score_gpt":0.38936537763969814,"score_spread":0.3486548344749668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889049,0.00014125914,0.0000072599564,0.0021443302,0.00001624829,0.0033829692,0.000007704812,0.0000145439135,0.0053807655],"genre_scores_gemma":[0.9992132,0.000016757784,0.00017395572,0.00029538336,0.000009431201,0.0001375344,0.000013575578,0.000017589977,0.00012253645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757296,0.00072614703,0.00037179515,0.00037726006,0.0005176758,0.00043417787],"domain_scores_gemma":[0.9988855,0.00021472543,0.00012605451,0.0004863577,0.00023117379,0.00005620443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001026861,0.00018292246,0.0005561195,0.0002371801,0.00005771834,0.000014417454,0.00027609267,0.000121224664,0.000029228964],"category_scores_gemma":[0.00020481688,0.00011406664,0.000038214373,0.0009649384,0.0002533788,0.00007715666,0.0000833662,0.0005013146,0.0000029219673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037966843,0.004319725,0.97716814,0.000111931295,0.00010176244,0.00007858709,0.0016094184,0.00010605725,0.00018693769,0.000014384445,0.0003306934,0.0121757025],"study_design_scores_gemma":[0.00922896,0.013364263,0.97189647,0.0005367493,0.00003706609,0.0000012674992,0.0019676809,0.00003050176,0.0012864148,0.000031392254,0.0015041886,0.000115039584],"about_ca_topic_score_codex":0.00391954,"about_ca_topic_score_gemma":0.0044624656,"teacher_disagreement_score":0.012060663,"about_ca_system_score_codex":0.00017018522,"about_ca_system_score_gemma":0.0006939337,"threshold_uncertainty_score":0.5925198},"labels":[],"label_agreement":null},{"id":"W4415941010","doi":"10.1016/j.annonc.2025.08.3640","title":"3025eP LINC01929 mediates breast cancer immunosuppression and is a target to increase antigen presentation","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Prince Edward Island; Acadia University; Dalhousie University","funders":"","keywords":"Immunosuppression; Presentation (obstetrics); Breast cancer; Antigen presentation; Antigen; Tumor associated antigen","score_opus":0.030296408452998844,"score_gpt":0.4052150594016355,"score_spread":0.37491865094863663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93998337,0.006513375,0.000025929932,0.049880713,0.00024799298,0.00038055077,0.00011066109,0.00001803018,0.0028393741],"genre_scores_gemma":[0.9784009,0.00810548,0.00035444467,0.011963622,0.000099373625,0.00005321584,0.000028351224,0.000009449045,0.0009851631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916136,0.00006527838,0.00028454335,0.00019768305,0.0001135865,0.00017756724],"domain_scores_gemma":[0.99934965,0.000106011306,0.000099432684,0.00016440933,0.00019729645,0.00008322326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023559468,0.00010334646,0.0003129077,0.00017632305,0.00004825971,0.000006760236,0.00007374483,0.00012642375,0.00048875576],"category_scores_gemma":[0.00005297227,0.00008473581,0.00006687959,0.00023596021,0.000102701444,0.000062451065,0.00006518638,0.00008244727,0.000003984379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015808173,0.0005282248,0.16245301,0.00025265053,0.0006562375,0.000022621545,0.0019425831,0.000003746828,0.25721034,0.00005090659,0.18295877,0.37811273],"study_design_scores_gemma":[0.003314519,0.0010753772,0.6825693,0.00036954126,0.000070776754,0.000028546885,0.00035267673,0.00007242244,0.11404377,0.0002710047,0.19770819,0.0001238516],"about_ca_topic_score_codex":0.002824365,"about_ca_topic_score_gemma":0.00007714395,"teacher_disagreement_score":0.5201163,"about_ca_system_score_codex":0.000037247362,"about_ca_system_score_gemma":0.0003370103,"threshold_uncertainty_score":0.5351533},"labels":[],"label_agreement":null},{"id":"W4415941029","doi":"10.1016/j.annonc.2025.08.3617","title":"3003P Thyroid cancer mortality in the United States: A CDC analysis from 1999 to 2020","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Thyroid cancer; Incidence (geometry); Cancer; Retrospective cohort study; Thyroid; Cancer incidence; Endocrine system","score_opus":0.07102030141316593,"score_gpt":0.43637391756689553,"score_spread":0.36535361615372963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93133813,0.0036421816,0.000030817453,0.062303144,0.00008529526,0.00036680623,0.00019996188,0.000011308589,0.0020223642],"genre_scores_gemma":[0.9634252,0.0056653847,0.000068645364,0.030185701,0.000053415402,0.00025394754,0.0002285384,0.0000054936763,0.00011367916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879014,0.00017183337,0.00036512563,0.00027643886,0.00016931785,0.00022713256],"domain_scores_gemma":[0.99891627,0.00035252274,0.00010274121,0.00040600862,0.00014572896,0.00007671761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030400988,0.0001268467,0.00059117726,0.00032778064,0.000028905784,0.000007023859,0.00015866506,0.00008745642,0.00022635159],"category_scores_gemma":[0.00006946394,0.0000850843,0.00017152911,0.002090596,0.00005977135,0.000020807342,0.00004663247,0.00013263892,0.00000862401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062711997,0.0018052818,0.8331119,0.00003454109,0.004873522,0.00018385764,0.0034623016,0.0020841472,0.00022024613,0.00040338084,0.1346702,0.018523514],"study_design_scores_gemma":[0.0013230265,0.0008430404,0.86191136,0.000052556385,0.0012618749,4.5294686e-7,0.0008543718,0.0001599714,0.0010000463,0.00047476546,0.13204902,0.000069493166],"about_ca_topic_score_codex":0.066842355,"about_ca_topic_score_gemma":0.029166514,"teacher_disagreement_score":0.03767584,"about_ca_system_score_codex":0.00011545056,"about_ca_system_score_gemma":0.00025301118,"threshold_uncertainty_score":0.98854864},"labels":[],"label_agreement":null},{"id":"W4415941031","doi":"10.1016/j.annonc.2025.08.1525","title":"956P Encouraging antitumor activity of PDL1V (PF-08046054) monotherapy, an ADC targeting PD-L1, correlates with antigen expression in patients with NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Seagen; Pfizer","keywords":"Antigen; Tumor associated antigen; Cancer; Tumor antigen; Over expression","score_opus":0.021225442824662086,"score_gpt":0.33215999920335976,"score_spread":0.31093455637869766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622416,0.0007200297,0.00021184159,0.0007159858,0.000113457514,0.0004859501,0.000010727552,0.000021314494,0.0014965314],"genre_scores_gemma":[0.9980618,0.00043256686,0.0008463657,0.0005133825,0.000022371014,0.0000151939685,0.000020814685,0.000019260577,0.00006826024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986523,0.00013961966,0.00040100544,0.000301817,0.00021329535,0.0002920124],"domain_scores_gemma":[0.9989157,0.000121990786,0.00038858905,0.0002735318,0.0002443192,0.0000558955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042625994,0.0001844462,0.0006083299,0.0002837443,0.000054503882,0.000005790558,0.00013374245,0.00014280782,0.00006614598],"category_scores_gemma":[0.000035853405,0.00013216611,0.0000701263,0.00040339955,0.00021906734,0.00019308152,0.000032511674,0.00020917425,5.7254425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035459064,0.0016296471,0.7369183,0.00013419871,0.00022899124,0.000021337948,0.0010152663,0.000047582434,0.1101731,0.000009195754,0.00059092924,0.113772444],"study_design_scores_gemma":[0.008749858,0.0066536474,0.80081373,0.0011305353,0.000036294565,0.0000035020241,0.0003599568,0.000111148314,0.1796898,0.000023626679,0.0022599238,0.0001679507],"about_ca_topic_score_codex":0.00037389493,"about_ca_topic_score_gemma":0.00010947596,"teacher_disagreement_score":0.11360449,"about_ca_system_score_codex":0.000054074113,"about_ca_system_score_gemma":0.00036015845,"threshold_uncertainty_score":0.5389578},"labels":[],"label_agreement":null},{"id":"W4415941038","doi":"10.1016/j.annonc.2025.08.3042","title":"WITHDRAWN: 2427P Association between metformin use in individuals with prostate cancer and mortality: An analysis of the RADICAL-PC study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; McMaster University; Queen's University; Centre Hospitalier de l’Université de Montréal; McMaster University Medical Centre","funders":"Canadian Cancer Society; Movember Foundation; Population Health Research Institute","keywords":"Metformin; Prostate cancer; Prospective cohort study; Diabetes mellitus; Association (psychology)","score_opus":0.04164718880400974,"score_gpt":0.37503446155345344,"score_spread":0.3333872727494437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991545,0.007704966,0.0000059021477,0.00013475251,0.000036615646,0.0003425497,0.0001437848,0.0000020229293,0.00008438823],"genre_scores_gemma":[0.99439555,0.0048258593,0.00003997324,0.0004594598,0.000028839071,0.00006211701,0.00004298241,0.000006095662,0.00013912634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876475,0.0002887174,0.00034344796,0.00025365726,0.00016747345,0.00018194827],"domain_scores_gemma":[0.99911207,0.00005984717,0.0003361508,0.00028147394,0.00017192375,0.00003850586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088467,0.00010595186,0.00049786584,0.00014807502,0.000032444175,0.000010375684,0.00015394877,0.000145672,0.0000073138985],"category_scores_gemma":[0.00012966858,0.00007430304,0.000065383174,0.00054919475,0.000119752534,0.000012292386,0.00008187897,0.00008770587,4.536918e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055285636,0.0002253794,0.9659317,0.000013860922,0.0024845535,4.144095e-7,0.00041684732,0.00011237538,0.00070008734,0.000022771288,0.00014853248,0.029888205],"study_design_scores_gemma":[0.00090119964,0.0006285199,0.96246904,0.000012869057,0.0012160301,6.496037e-8,0.00029548883,0.000013622112,0.017577898,0.00006643072,0.016738225,0.00008059749],"about_ca_topic_score_codex":0.0011505513,"about_ca_topic_score_gemma":0.0102194,"teacher_disagreement_score":0.029807607,"about_ca_system_score_codex":0.000021245834,"about_ca_system_score_gemma":0.00026454893,"threshold_uncertainty_score":0.5702665},"labels":[],"label_agreement":null},{"id":"W4415941040","doi":"10.1016/j.annonc.2025.08.3149","title":"2535eP Incidence of incidental primary lung malignancies vs. solitary prostate cancer lung metastasis detected on PSMA-PET CT scans for prostate cancer staging and surveillance","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Prostate cancer; Incidence (geometry); Lung; Prostate; Lung cancer; Metastasis; Stage (stratigraphy)","score_opus":0.03588269843316088,"score_gpt":0.3979777260730109,"score_spread":0.36209502763985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97027344,0.019276634,0.000023001643,0.006171071,0.0002453491,0.002208918,0.0013108617,0.000039710936,0.00045101298],"genre_scores_gemma":[0.97619635,0.019886194,0.00033556423,0.0011462106,0.00005027271,0.000866604,0.00012272914,0.000035112153,0.0013609459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755055,0.0001768503,0.00066652166,0.0005465801,0.00037503467,0.0006844667],"domain_scores_gemma":[0.9978594,0.00048418334,0.00035841897,0.0003076757,0.00083439716,0.00015593515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078268547,0.0003062088,0.0010026322,0.0004132857,0.00014837799,0.000014971154,0.00017901209,0.000059597944,0.000039282135],"category_scores_gemma":[0.00019795095,0.00025150247,0.00014187314,0.0005345578,0.0005133417,0.0001695418,0.00017897334,0.0002526303,4.7015797e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012264299,0.00049853086,0.8841317,0.005156847,0.0015027502,0.000395264,0.0013086781,0.00019165422,0.019202018,0.000117154326,0.010364828,0.06486623],"study_design_scores_gemma":[0.011569167,0.0052421875,0.7980129,0.0027112241,0.000526538,0.000101672995,0.0008773793,0.001947637,0.1732265,0.00045033192,0.004770822,0.00056365196],"about_ca_topic_score_codex":0.002879202,"about_ca_topic_score_gemma":0.0014132616,"teacher_disagreement_score":0.15402448,"about_ca_system_score_codex":0.00045655813,"about_ca_system_score_gemma":0.0021072158,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W4415941064","doi":"10.1016/j.annonc.2025.08.1403","title":"830P Liver fat in relation to clinical outcomes in stage I-III colon or rectal cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek; KWF Kankerbestrijding; ZonMw","keywords":"Colorectal cancer; Stage (stratigraphy); Visceral fat; Disease; Cancer; Overall survival; Survival rate; Liver disease","score_opus":0.0818263088948358,"score_gpt":0.4515140538292143,"score_spread":0.3696877449343785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99008703,0.0011034823,0.000053760865,0.00207973,0.0038926317,0.00029576445,0.000027282436,0.0000045253796,0.0024558099],"genre_scores_gemma":[0.97906345,0.0061929487,0.00024043501,0.0046290155,0.0012839906,0.00008602231,0.000021632071,0.000010335482,0.00847214],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877775,0.00017198364,0.0004793593,0.00029040902,0.000062184234,0.00021830147],"domain_scores_gemma":[0.99946654,0.00009633576,0.00010791307,0.00018832946,0.00008911479,0.00005175842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046923422,0.00010220212,0.00040430113,0.00013494614,0.000015859207,0.0000033729739,0.0001338647,0.0003136403,0.000058829217],"category_scores_gemma":[0.00039873156,0.0000911683,0.0000936439,0.00018685598,0.00006984531,0.0000046491323,0.00010484804,0.00013911948,0.000003879403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006192851,0.0010041756,0.6189078,0.000071947274,0.00018713783,0.000006176953,0.0006515987,0.00040912104,0.039680295,0.0007953176,0.16285159,0.16924202],"study_design_scores_gemma":[0.0014241243,0.000695376,0.3451103,0.00002229273,0.00000890587,5.0206904e-7,0.00007446525,0.000012744836,0.003676432,0.00003211772,0.64885616,0.000086610744],"about_ca_topic_score_codex":0.0014130356,"about_ca_topic_score_gemma":0.027178075,"teacher_disagreement_score":0.48600456,"about_ca_system_score_codex":0.000031770658,"about_ca_system_score_gemma":0.00038816207,"threshold_uncertainty_score":0.9905734},"labels":[],"label_agreement":null},{"id":"W4415941094","doi":"10.1016/j.annonc.2025.08.1524","title":"955P Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered in combination with pembrolizumab in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Barbara Ann Karmanos Cancer Institute; Institut Gustave-Roussy; McGill University Health Centre; McGill University; Boehringer Ingelheim; Institut National Du Cancer; Wayne State University; Case Western Reserve University; Cleveland Clinic; University of Texas MD Anderson Cancer Center; Pfizer; Bristol-Myers Squibb","keywords":"Oncolytic virus; Pembrolizumab; Virus; Vaccinia; Immunotherapy; Solid tumor","score_opus":0.049496907237051135,"score_gpt":0.4242128900780724,"score_spread":0.37471598284102126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998461,0.00007669005,0.000013376408,0.00019134488,0.000046475514,0.0005582906,0.00006263725,0.000008096536,0.0005820567],"genre_scores_gemma":[0.9985085,0.00009725254,0.00030691535,0.00032006716,0.000017466386,0.000029157669,0.00064618734,0.000025578018,0.000048866455],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99718153,0.0007325578,0.00090782146,0.00055682304,0.00023099402,0.00039027113],"domain_scores_gemma":[0.99832183,0.00006874971,0.00044130077,0.0005888522,0.00047142955,0.000107843036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087905285,0.00020207363,0.0006184051,0.0002984673,0.000036369493,0.000010327167,0.00036270384,0.00027522445,0.0000105838335],"category_scores_gemma":[0.00015729507,0.00018002915,0.000046832592,0.00035630452,0.0002925563,0.000030274217,0.00009779411,0.00023791585,7.968543e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34480792,0.021627596,0.15560658,0.00014487591,0.0002856382,0.0000947081,0.00048921595,0.0023242326,0.30168122,0.000061462284,0.00041951082,0.17245704],"study_design_scores_gemma":[0.05001285,0.14543758,0.38167953,0.00026401575,0.000024309682,0.0000036845568,0.00024035643,0.00044432672,0.42005685,0.00011203966,0.0013358995,0.00038856326],"about_ca_topic_score_codex":0.000105760526,"about_ca_topic_score_gemma":0.0025957471,"teacher_disagreement_score":0.29479507,"about_ca_system_score_codex":0.00004053731,"about_ca_system_score_gemma":0.0007858075,"threshold_uncertainty_score":0.7341376},"labels":[],"label_agreement":null},{"id":"W4415941096","doi":"10.1016/j.annonc.2025.08.2723","title":"2102P Quality of life in people with stomach/gastroesophageal junction (GOJ) cancers in TOPGEAR","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Quality of life (healthcare); MEDLINE; Cancer; Quality (philosophy)","score_opus":0.07068129245982138,"score_gpt":0.4399556349675961,"score_spread":0.3692743425077747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870814,0.002266251,0.000023711029,0.004431536,0.000059999224,0.00040441475,0.000010571325,0.000008416251,0.0057137106],"genre_scores_gemma":[0.998381,0.00033319488,0.0001704514,0.00070224016,0.000025100302,0.000067114575,0.000011996428,0.0000061505266,0.00030274084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866915,0.00018267735,0.00043095904,0.000205558,0.00022914376,0.00028251694],"domain_scores_gemma":[0.99925303,0.0001559225,0.00013260558,0.00019491359,0.00016080296,0.00010274806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005524818,0.00009978132,0.00061582203,0.00031308155,0.000013894968,0.0000017008238,0.000071298135,0.000088853834,0.00009041761],"category_scores_gemma":[0.00018414069,0.00008104607,0.000059792506,0.00052086916,0.00012102957,0.000049110145,0.0000330414,0.00020392676,0.0000023773464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006159563,0.0007391759,0.9759752,0.00030616275,0.00013055076,0.00012170005,0.00037759676,0.00016617989,0.00019029417,0.0004904477,0.000907531,0.014435559],"study_design_scores_gemma":[0.005617389,0.005064457,0.985811,0.00010607509,0.000016224296,0.0000035447374,0.00034509317,0.00003547619,0.0025542201,0.00013974064,0.0002672298,0.000039557166],"about_ca_topic_score_codex":0.015951231,"about_ca_topic_score_gemma":0.030213475,"teacher_disagreement_score":0.014396001,"about_ca_system_score_codex":0.00033262963,"about_ca_system_score_gemma":0.001823261,"threshold_uncertainty_score":0.99060166},"labels":[],"label_agreement":null},{"id":"W4415941108","doi":"10.1016/j.annonc.2025.08.1360","title":"787P Real-world outcomes of organ preservation approach in patients with locally advanced rectal cancer in Canada: Results from the CHORD Consortium","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Regional Cancer Foundation; University of Alberta; University of Calgary; Ottawa Hospital","funders":"","keywords":"Colorectal cancer; Chord (peer-to-peer); Rectum; Neoplasm staging; MEDLINE","score_opus":0.03954347293956681,"score_gpt":0.3442402716742603,"score_spread":0.30469679873469346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821686,0.000121339064,0.0000020962414,0.0050976747,0.000115561226,0.000828884,0.00017792975,0.000005960523,0.01148196],"genre_scores_gemma":[0.99843514,0.00014065349,0.00016085024,0.00079077523,0.000009831963,0.00009792036,0.00009164811,0.000008857177,0.0002642958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851894,0.00013717517,0.00059872045,0.00027377994,0.00025283176,0.00021857137],"domain_scores_gemma":[0.9984917,0.0006438847,0.00027350616,0.00027242425,0.0002721926,0.000046314784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018352894,0.00013208149,0.0006396251,0.000112255315,0.000014733592,0.0000014882261,0.00013387809,0.00006975006,0.000028532966],"category_scores_gemma":[0.00029676096,0.00008527712,0.00003542731,0.0006787096,0.000096501026,0.000058888585,0.00005877984,0.00018290343,1.994062e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010458729,0.00050886924,0.9669107,0.000023639705,0.00016296674,0.000012662183,0.00020363323,0.00035787714,0.00001847785,0.000030995485,0.0005448637,0.020766545],"study_design_scores_gemma":[0.008582237,0.0007770912,0.9884776,0.0001649998,0.00003714453,1.10620725e-7,0.00011087411,0.00007145489,0.0006395874,0.00004506671,0.0010298037,0.00006401958],"about_ca_topic_score_codex":0.8404512,"about_ca_topic_score_gemma":0.97182655,"teacher_disagreement_score":0.13137537,"about_ca_system_score_codex":0.00064400816,"about_ca_system_score_gemma":0.002662266,"threshold_uncertainty_score":0.4722745},"labels":[],"label_agreement":null},{"id":"W4415941110","doi":"10.1016/j.annonc.2025.08.2866","title":"2249P Baseline methylthioadenosine (MTA) levels as potential prognostic markers in metastatic pancreatic ductal adenocarcinoma (mPDAC): An exploratory analysis of CCTG PA.7 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Dalhousie University; Jewish General Hospital; St. Michael's Hospital; Moncton Hospital; Bausch Health (Canada); Nova Scotia Cancer Centre; Centre Hospitalier Universitaire de Sherbrooke; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; BC Cancer Agency; Ottawa Regional Cancer Foundation","funders":"Pfizer","keywords":"Pancreatic ductal adenocarcinoma; Exploratory analysis; Methionine; Pancreatic cancer; Arginine; Gemcitabine","score_opus":0.04551727781309674,"score_gpt":0.36468450832094373,"score_spread":0.319167230507847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204934,0.004224912,0.0016811191,0.00084102096,0.00029623217,0.00066187093,0.00008293801,0.00000972592,0.00015283906],"genre_scores_gemma":[0.99790066,0.00037054546,0.00064814236,0.00023766537,0.0001188551,0.0000823035,0.00048158035,0.00002105026,0.00013921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969751,0.00096488063,0.0009566956,0.0005341506,0.00023645272,0.00033268545],"domain_scores_gemma":[0.9983906,0.0001640482,0.00047829835,0.0005004782,0.00037171342,0.00009484335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013106337,0.00023939247,0.00086102204,0.00076986756,0.00003845334,0.000008524146,0.00026053053,0.0003128037,0.00010226844],"category_scores_gemma":[0.00077237166,0.00024987076,0.00032069083,0.0011748645,0.0002198457,0.000018314324,0.0001102199,0.0001539813,0.0000021820026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066738315,0.004203833,0.02184456,0.0004134604,0.014891948,0.00016106438,0.0007952974,0.029711587,0.817211,0.00036492277,0.0039358395,0.039728187],"study_design_scores_gemma":[0.06661002,0.031480134,0.38662463,0.00025727422,0.015241598,0.000059938924,0.002776114,0.017257055,0.47284436,0.0016240821,0.0037205482,0.0015042468],"about_ca_topic_score_codex":0.00018012122,"about_ca_topic_score_gemma":0.0005309811,"teacher_disagreement_score":0.36478007,"about_ca_system_score_codex":0.00004651103,"about_ca_system_score_gemma":0.00078757765,"threshold_uncertainty_score":0.99999535},"labels":[],"label_agreement":null},{"id":"W4415941146","doi":"10.1016/j.annonc.2025.08.690","title":"262eP Comprehensive HER2 isoform expression analysis reveals subgroup-specific profiles and implications for ADC resistance","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Gene isoform; Expression (computer science); Gene expression; Focus (optics)","score_opus":0.16175002698525984,"score_gpt":0.48723935820992287,"score_spread":0.32548933122466306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.828606,0.025179083,0.0063350284,0.1068595,0.0002116316,0.003815042,0.0004843106,0.00009459862,0.028414803],"genre_scores_gemma":[0.9788714,0.0053545204,0.0083563365,0.001982964,0.00012375084,0.00062584813,0.00011682126,0.000020193178,0.0045481334],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852353,0.0001063186,0.00047946224,0.00039586143,0.00015034493,0.00034448568],"domain_scores_gemma":[0.9974124,0.00081706094,0.00017931605,0.0005219791,0.00094570685,0.00012356525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043603545,0.00013030569,0.0006818664,0.0004215499,0.00012582989,0.000011075324,0.00016563165,0.00018344012,0.00009149468],"category_scores_gemma":[0.00022459372,0.00011516949,0.00016705913,0.00082698755,0.00027190216,0.000053244396,0.00009559676,0.00016988625,0.000003433199],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020648683,0.00069113384,0.089221016,0.0015168415,0.0011691136,0.000011669325,0.00058621337,0.000010350038,0.19773751,0.016935416,0.59280646,0.097249396],"study_design_scores_gemma":[0.0012807782,0.0009601834,0.366116,0.0002506404,0.00022055989,0.0000035014207,0.00041746235,0.000024019286,0.027094206,0.005769067,0.5977405,0.00012312664],"about_ca_topic_score_codex":0.000047175527,"about_ca_topic_score_gemma":0.000115783565,"teacher_disagreement_score":0.276895,"about_ca_system_score_codex":0.000085862666,"about_ca_system_score_gemma":0.00026302633,"threshold_uncertainty_score":0.46964753},"labels":[],"label_agreement":null},{"id":"W4415941164","doi":"10.1016/j.annonc.2025.08.687","title":"258eP Effective biomarker testing rates in advanced non-small cell lung cancer (NSCLC) patients in U.S. community oncology practices","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Biomarker; Lung cancer; Precision oncology; Profiling (computer programming); Standard of care; Cancer","score_opus":0.05814192484491954,"score_gpt":0.4745007925859957,"score_spread":0.41635886774107617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92637295,0.0010646561,0.000013450417,0.0029151947,0.00026769683,0.0012593188,0.000017444643,0.000013426758,0.068075866],"genre_scores_gemma":[0.99552554,0.0004947598,0.00095357577,0.0022745517,0.000012664758,0.0004928201,0.00003970011,0.000012504176,0.0001938781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840677,0.0006045366,0.00041860715,0.00021540294,0.00007452987,0.0002801398],"domain_scores_gemma":[0.99647766,0.0023808167,0.00049735844,0.00020079283,0.00038875762,0.00005461777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061694265,0.00015233959,0.0005359356,0.00032914834,0.00006657944,0.0000049997666,0.00010758285,0.0001688326,0.000020632737],"category_scores_gemma":[0.0010684669,0.00013494407,0.000051314673,0.00059900526,0.00008693158,0.00012904305,0.00009006184,0.0004259383,0.0000026581336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007293879,0.0032738906,0.8179293,0.0003169823,0.00015802869,0.00003507106,0.0024490792,0.00011739429,0.001984483,0.000017137783,0.0005972693,0.17239197],"study_design_scores_gemma":[0.007993889,0.002770313,0.97785026,0.00061334734,0.00015949609,0.0000013660488,0.0010017775,0.0003274848,0.0032628386,0.00010642283,0.0058121197,0.000100667574],"about_ca_topic_score_codex":0.012200952,"about_ca_topic_score_gemma":0.009623404,"teacher_disagreement_score":0.1722913,"about_ca_system_score_codex":0.0004723305,"about_ca_system_score_gemma":0.001341239,"threshold_uncertainty_score":0.9943769},"labels":[],"label_agreement":null},{"id":"W4415941182","doi":"10.1016/j.annonc.2025.08.766","title":"337P Non-enrichment-based circulating tumor cells (CTCs) as predictors of late recurrence in ER/PgR-positive breast cancer (BC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Sinai Health System; Sunnybrook Health Science Centre; Western University; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Circulating tumor cell; Breast cancer; CA15-3; Circulating tumor DNA; Cancer; Tumor cells","score_opus":0.02889337447648775,"score_gpt":0.36598433322601465,"score_spread":0.3370909587495269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97775006,0.0007999445,0.000056807115,0.0038028841,0.0006319962,0.00053688715,0.00026846188,0.000013642068,0.016139284],"genre_scores_gemma":[0.99669373,0.000506297,0.00026354595,0.0020838443,0.00007187427,0.00004986534,0.00002195227,0.000012717061,0.00029617653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984325,0.00010054379,0.0005915896,0.0003244337,0.00020995548,0.00034093347],"domain_scores_gemma":[0.99872124,0.00022213945,0.00035510003,0.00023968692,0.0003549619,0.000106877276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004120167,0.00017129672,0.0007260548,0.00030830866,0.000028878823,0.000003694171,0.00012663078,0.00011395269,0.00025612218],"category_scores_gemma":[0.00006497625,0.00016205486,0.00015605272,0.0005878142,0.00017669139,0.00005240164,0.00005867602,0.00023485743,0.0000058774044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055402946,0.0039699837,0.41315427,0.0028068067,0.0012031754,0.0005898568,0.002693943,0.0043998808,0.24692321,0.00039906878,0.018370057,0.29994944],"study_design_scores_gemma":[0.0075967517,0.003106532,0.5263218,0.0032294116,0.0005326491,0.00002963178,0.0004904169,0.0011992466,0.44397983,0.00023291307,0.012904499,0.00037626943],"about_ca_topic_score_codex":0.005959464,"about_ca_topic_score_gemma":0.00048793823,"teacher_disagreement_score":0.29957318,"about_ca_system_score_codex":0.00014946017,"about_ca_system_score_gemma":0.0013395422,"threshold_uncertainty_score":0.9008966},"labels":[],"label_agreement":null},{"id":"W4415941189","doi":"10.1016/j.annonc.2025.08.2420","title":"1794P Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Interprofessional Education and Collaboration","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Institut Gustave-Roussy; Université Paris-Saclay; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; AstraZeneca","keywords":"Multidisciplinary approach; Multidisciplinary team; MEDLINE; Risk assessment; Palliative care","score_opus":0.09857977018265042,"score_gpt":0.5996730060897759,"score_spread":0.5010932359071255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82424587,0.0002976717,0.00020961808,0.006106895,0.0012175831,0.0006179521,0.00010449358,0.000012680179,0.16718724],"genre_scores_gemma":[0.9934917,0.000052403902,0.0023506617,0.0008986961,0.000028769164,0.00014679847,0.00004511979,0.0000053903645,0.002980474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781024,0.0008683401,0.00072611304,0.0001971658,0.00015338448,0.0002447495],"domain_scores_gemma":[0.99778837,0.0005497829,0.00041134085,0.00019476429,0.0010099813,0.000045738696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005890358,0.00010355149,0.00037475498,0.00018714306,0.00014903878,0.0000016422882,0.00016742753,0.00025560134,0.0001777873],"category_scores_gemma":[0.00025077935,0.00009452207,0.00005989471,0.00057099795,0.000097915974,0.00009515884,0.00014154204,0.00033090907,0.000019777644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012758969,0.0010194425,0.6319355,0.0005703162,0.00007058695,0.0000047414387,0.02699976,0.00011471799,0.0008395325,0.3128406,0.016189067,0.008139839],"study_design_scores_gemma":[0.0011994231,0.0011599837,0.8871004,0.0005495375,0.000010496566,9.919598e-8,0.08826887,0.00025310478,0.00017503978,0.0020740828,0.019123428,0.000085516345],"about_ca_topic_score_codex":0.0011056248,"about_ca_topic_score_gemma":0.005117587,"teacher_disagreement_score":0.31076652,"about_ca_system_score_codex":0.0003143407,"about_ca_system_score_gemma":0.005613036,"threshold_uncertainty_score":0.9957285},"labels":[],"label_agreement":null},{"id":"W4415941228","doi":"10.1016/j.annonc.2025.08.642","title":"209eP Genome and transcriptome analysis on 235 patients treated with immune checkpoint inhibitors: Leveraging multi-omics data in the quest for biomarkers","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Transcriptome; Genome; Immune checkpoint; Immune system; Nivolumab; Immunotherapy","score_opus":0.07195616759296611,"score_gpt":0.36691651554819377,"score_spread":0.29496034795522763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907308,0.0014362489,0.00019267653,0.0062370375,0.000059177102,0.0008197269,0.00015921946,0.0000111552445,0.00035390686],"genre_scores_gemma":[0.9963673,0.000711046,0.0004437342,0.0018288784,0.000018683724,0.000044627017,0.0005097679,0.00001074962,0.0000652427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987398,0.0001066386,0.00048434574,0.000333377,0.000114054295,0.00022178842],"domain_scores_gemma":[0.99901456,0.00018340605,0.000165806,0.00048697132,0.00011783698,0.000031428408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008789142,0.00015221859,0.0005105557,0.00045601756,0.00005553282,0.000011531931,0.00020837484,0.00011082038,0.000007957193],"category_scores_gemma":[0.000059806596,0.00009956083,0.00012500364,0.0007606062,0.00018186127,0.00006746088,0.000030177873,0.00011415229,2.6880502e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07951498,0.007557014,0.5303477,0.0007752577,0.019279312,0.00007232453,0.0072274134,0.00004010287,0.11617359,0.000077181845,0.002107386,0.23682773],"study_design_scores_gemma":[0.015639815,0.004525671,0.9417497,0.00019350594,0.0010376644,0.0000049553723,0.0009805858,0.0007202031,0.0071118358,0.000013935875,0.027832298,0.00018985574],"about_ca_topic_score_codex":0.0009976439,"about_ca_topic_score_gemma":0.00046967916,"teacher_disagreement_score":0.41140196,"about_ca_system_score_codex":0.000066191074,"about_ca_system_score_gemma":0.00012872409,"threshold_uncertainty_score":0.40599728},"labels":[],"label_agreement":null},{"id":"W4415941232","doi":"10.1016/j.annonc.2025.08.3322","title":"2712P Determinants of diagnostic intervals in sarcoma: Results from the global diagnosis pathway survey","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Sarcoma; Care pathway; Diagnostic test; MEDLINE; Diagnosis code; Interval (graph theory)","score_opus":0.10930550335898177,"score_gpt":0.4099600043748295,"score_spread":0.30065450101584773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98315734,0.0050800424,0.0000020943205,0.007993955,0.00026332214,0.0004895992,0.0010342342,0.0000099077115,0.0019694942],"genre_scores_gemma":[0.9949901,0.002766987,0.00007990618,0.0018961853,0.00003247671,0.00012406682,0.000080656384,0.000007689566,0.000021931282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775046,0.0005606541,0.0009110472,0.0003189413,0.00017547923,0.00028339654],"domain_scores_gemma":[0.98382044,0.015054943,0.00031508945,0.0005143546,0.0002275718,0.00006762106],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010190662,0.00017397688,0.00085125177,0.00008910986,0.00002727811,0.0000051389566,0.00024743075,0.00017531635,0.00003865671],"category_scores_gemma":[0.009196153,0.00011786482,0.00018083976,0.0004365898,0.00019792066,0.00003566864,0.00016131483,0.00012583034,0.000012126591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006863078,0.002378798,0.8221424,0.000021868427,0.00014292146,0.00020353367,0.00018065602,0.0000020799043,0.00000902859,0.000108204316,0.0067097973,0.16741441],"study_design_scores_gemma":[0.003865141,0.0012988977,0.97874725,0.00060493976,0.00008689452,0.0000057938914,0.00010711203,0.000012962305,0.007439385,0.00091945,0.006838055,0.000074128395],"about_ca_topic_score_codex":0.014172024,"about_ca_topic_score_gemma":0.021239888,"teacher_disagreement_score":0.16734028,"about_ca_system_score_codex":0.00009419316,"about_ca_system_score_gemma":0.0003101162,"threshold_uncertainty_score":0.9991498},"labels":[],"label_agreement":null},{"id":"W4415941235","doi":"10.1016/j.annonc.2025.08.2591","title":"1967P MET testing and treatment (tx) sequencing after progression on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real-world (rw) study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Interim analysis; Interim; C-Met; Clinical trial","score_opus":0.07704972867911013,"score_gpt":0.4562838769249002,"score_spread":0.37923414824579005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975068,0.00020987174,0.00002258785,0.00028391217,0.000023976145,0.0012486789,0.00007438441,0.0000150035285,0.0006147813],"genre_scores_gemma":[0.99684006,0.00016174224,0.002460804,0.00013561617,0.000008221853,0.00025493835,0.00006529803,0.000009398395,0.000063945845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986288,0.00010506559,0.00049442466,0.00042265886,0.0001661061,0.00018292536],"domain_scores_gemma":[0.9988352,0.00028211536,0.0003511266,0.00024021037,0.00020903736,0.000082331135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015178492,0.00020367219,0.0006900464,0.0003213236,0.00006570833,0.000009598961,0.00003843854,0.000069736205,0.00001181299],"category_scores_gemma":[0.00014509153,0.00013053679,0.000043074666,0.0007678134,0.00009400752,0.00009627643,0.000059337122,0.000047090612,1.6330084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010198101,0.0026944084,0.8104249,0.000085258725,0.0011733873,0.000014693615,0.0016879467,0.00007340682,0.0007585858,0.000024648734,0.000010353425,0.1728543],"study_design_scores_gemma":[0.009541975,0.024179788,0.960825,0.0012198138,0.0018239155,0.000001871216,0.000782529,0.00021247304,0.0011200293,0.000036318394,0.00014243943,0.00011380377],"about_ca_topic_score_codex":0.001144208,"about_ca_topic_score_gemma":0.0035774051,"teacher_disagreement_score":0.17274049,"about_ca_system_score_codex":0.000338691,"about_ca_system_score_gemma":0.000160388,"threshold_uncertainty_score":0.5323136},"labels":[],"label_agreement":null},{"id":"W4415941244","doi":"10.1016/j.annonc.2025.08.2724","title":"2103P 5-year results of perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastro-esophageal adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Perioperative; Adenocarcinoma; Cohort; Chemotherapy; Overall survival; Complete response","score_opus":0.0369482805667986,"score_gpt":0.40081305870268696,"score_spread":0.36386477813588836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484109,0.013245428,0.000043642165,0.0073397118,0.000090799775,0.00090102403,0.00007438528,0.00001805067,0.029876022],"genre_scores_gemma":[0.9940068,0.0014008544,0.0013620347,0.00078348187,0.00003278905,0.000059945647,0.00003366347,0.00001367572,0.0023067477],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982913,0.00015673284,0.00060310005,0.00032078312,0.00023794276,0.00039015446],"domain_scores_gemma":[0.9987953,0.000180426,0.00015738083,0.0003535543,0.00040733127,0.000106008905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003936507,0.00016930306,0.00071220874,0.00029894232,0.000031128504,0.000003869468,0.00016247631,0.00013917817,0.00011353884],"category_scores_gemma":[0.00021727716,0.00014585111,0.00013340927,0.00039901154,0.00028379803,0.00006411985,0.00006349622,0.0002800731,0.000010552871],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1375369,0.007814087,0.27714002,0.00096767565,0.0019334481,0.0025106939,0.0077966126,0.0002160329,0.039205957,0.009342305,0.0053863632,0.5101499],"study_design_scores_gemma":[0.04359777,0.031030122,0.67973197,0.00058218994,0.00005381096,0.00003518307,0.0013417951,0.00008240251,0.23744015,0.00041158823,0.0055155684,0.00017746503],"about_ca_topic_score_codex":0.0003399892,"about_ca_topic_score_gemma":0.00015538087,"teacher_disagreement_score":0.50997245,"about_ca_system_score_codex":0.00015588565,"about_ca_system_score_gemma":0.0011107719,"threshold_uncertainty_score":0.5947636},"labels":[],"label_agreement":null},{"id":"W4415941245","doi":"10.1016/j.annonc.2025.08.2561","title":"1937P A large multicentre study assessing the effectiveness of upfront brain stereotactic radiation therapy with chemo-immunotherapy for patients with metastatic NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Stereotactic radiation therapy; Stereotactic radiotherapy; Radiosurgery; Radiation therapy; Lung cancer; Brain metastasis","score_opus":0.03387899146639953,"score_gpt":0.3994387592011444,"score_spread":0.36555976773474486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916248,0.0007677125,0.0017725787,0.0013285597,0.0000638327,0.004223525,0.00003131514,0.000010276621,0.00017742426],"genre_scores_gemma":[0.9978686,0.000051103958,0.00086325046,0.0008205281,0.000011696496,0.00027452846,0.00005283775,0.000019647594,0.000037787224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827236,0.0007762842,0.0003072063,0.00022528101,0.00019419457,0.00022466038],"domain_scores_gemma":[0.99664307,0.0022970382,0.0003277708,0.0003112355,0.00038822068,0.000032684384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012759309,0.00017444408,0.0006295348,0.00010402067,0.000082419145,0.000010900204,0.000083905354,0.000040010214,0.00001538855],"category_scores_gemma":[0.00014438828,0.000090831505,0.00009604955,0.00022123067,0.000077692275,0.00008209627,0.000014137943,0.00008914847,3.62245e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037719578,0.02888702,0.6092073,0.0005566118,0.009107781,0.000023715582,0.0029054554,0.000044534343,0.0006078755,0.00034789497,0.00026752814,0.31032476],"study_design_scores_gemma":[0.052904487,0.028800381,0.909382,0.0002605946,0.00056540634,0.0000029605999,0.0015293476,0.00010742109,0.0026078757,0.0000842065,0.0036469882,0.00010834527],"about_ca_topic_score_codex":0.000087819324,"about_ca_topic_score_gemma":0.000044331817,"teacher_disagreement_score":0.31021643,"about_ca_system_score_codex":0.000062139836,"about_ca_system_score_gemma":0.000282078,"threshold_uncertainty_score":0.37040013},"labels":[],"label_agreement":null},{"id":"W4415941250","doi":"10.1016/j.annonc.2025.08.1587","title":"1018eTiP A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"MYB; Colorectal cancer; Adenoid cystic carcinoma; Carcinogenesis; Transcription factor; Messenger RNA; Cancer; Transcriptome","score_opus":0.05634999147510498,"score_gpt":0.38137928907211444,"score_spread":0.32502929759700944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581033,0.00080558023,0.000017144337,0.00061461434,0.00043522444,0.0017053925,0.00038771026,0.000016532727,0.00020748902],"genre_scores_gemma":[0.99868435,0.00018776918,0.00016932563,0.00026501023,0.00010992966,0.00032727886,0.00018293696,0.000018833836,0.000054596905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986961,0.00010933328,0.0004684392,0.00031166172,0.00017044223,0.000244021],"domain_scores_gemma":[0.99886703,0.0002639404,0.0002384229,0.0001569904,0.00034083254,0.0001327877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014097423,0.00019743598,0.00072837545,0.00018732893,0.0000529396,0.0000054960115,0.000059168684,0.00017340516,0.000051781863],"category_scores_gemma":[0.000093020484,0.00014587113,0.000117864074,0.00013474152,0.00015333379,0.000105456355,0.000014089486,0.00011222686,4.6781798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41543823,0.027426003,0.47664317,0.0005692529,0.0008544896,0.000053587137,0.0013816316,0.0000023789398,0.0048706327,0.00029047756,0.0025616616,0.06990848],"study_design_scores_gemma":[0.25811473,0.1600562,0.5551635,0.00024824074,0.0008128514,0.0000066634493,0.00016509718,0.000041144678,0.020393422,0.00009020972,0.004707665,0.00020026504],"about_ca_topic_score_codex":0.00036096992,"about_ca_topic_score_gemma":0.00020067129,"teacher_disagreement_score":0.15732351,"about_ca_system_score_codex":0.00007461466,"about_ca_system_score_gemma":0.00039083685,"threshold_uncertainty_score":0.59484524},"labels":[],"label_agreement":null},{"id":"W4415941260","doi":"10.1016/j.annonc.2025.08.2129","title":"1499P Interim analysis of the REFINE-IO study of systemic therapies in patients (pts) with unresectable hepatocellular carcinoma (uHCC) following first-line (1L) immune checkpoint inhibitor (ICI) combination therapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Interim analysis; Combination therapy; Hepatocellular carcinoma; Interim; Nivolumab; Immune checkpoint; Systemic therapy","score_opus":0.08281440848941347,"score_gpt":0.32105226101185486,"score_spread":0.2382378525224414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431056,0.0027788032,0.00001084127,0.0006824522,0.00014127645,0.0017667777,0.000011809811,0.000012483829,0.00028500552],"genre_scores_gemma":[0.9993644,0.00021575877,0.000021360303,0.000070319074,0.000010969063,0.00013006334,0.00005215742,0.000020106347,0.00011489842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974839,0.00041867743,0.0011193026,0.00032595033,0.00040242166,0.00024974605],"domain_scores_gemma":[0.99800605,0.00020715439,0.0006279466,0.0006055747,0.00051270647,0.000040571013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082241435,0.0002492356,0.0014002837,0.00079082104,0.000063429005,0.0000060561556,0.00025413965,0.00016607885,0.000022628223],"category_scores_gemma":[0.000090697824,0.00016273969,0.00044544035,0.0018956792,0.0001254079,0.000083137245,0.000108407155,0.00018662818,5.42832e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020381543,0.006368256,0.97243667,0.00020161796,0.0036274733,0.000026187145,0.0052540954,0.000025694766,0.007944059,0.000042749078,0.000013630862,0.0020214082],"study_design_scores_gemma":[0.014061352,0.016584473,0.8820358,0.00066603196,0.001542103,0.0000014616367,0.002883816,0.0013163598,0.08064702,0.0000307285,0.00008259356,0.00014825477],"about_ca_topic_score_codex":0.0025161514,"about_ca_topic_score_gemma":0.00063072075,"teacher_disagreement_score":0.090400875,"about_ca_system_score_codex":0.00013199174,"about_ca_system_score_gemma":0.00020199941,"threshold_uncertainty_score":0.6636332},"labels":[],"label_agreement":null},{"id":"W4415941336","doi":"10.1016/j.annonc.2025.08.1892","title":"1258P ULBP2 drives a non-canonical NK cell cytotoxicity in B-ALL: A novel mechanism associated with improved patient survival","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; National Research Council Canada; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Research Council Canada; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Cytotoxicity; Immunotherapy; Cytotoxic T cell; Mechanism (biology); Leukemia; Cell; Cell survival; Cell culture","score_opus":0.034214938788527285,"score_gpt":0.3039542507682866,"score_spread":0.2697393119797593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96807307,0.00021628116,0.0010412043,0.0012183986,0.0020868175,0.00046156952,0.00001599216,0.000043890792,0.026842758],"genre_scores_gemma":[0.99352825,0.00011184109,0.00006161039,0.0018482446,0.000008536064,0.000050112598,0.000085503234,0.0000131447,0.0042927507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983372,0.0003114631,0.00055332563,0.0003357199,0.000040468814,0.0004218375],"domain_scores_gemma":[0.99877757,0.00038970058,0.00034123572,0.00022796026,0.00024081448,0.000022694054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039794378,0.0002029955,0.00056658656,0.00025505002,0.00007439221,0.0000069058297,0.0001816832,0.0005211566,0.0003271776],"category_scores_gemma":[0.00019751892,0.00017678204,0.00015410958,0.00025507723,0.00016382169,0.00009042755,0.000109699955,0.0005334181,0.000045470344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016211821,0.002376411,0.00056190987,0.00001975524,0.00040039216,0.0000064188857,0.0005189178,0.0000124395065,0.98834187,0.0010447135,0.003527114,0.0015688967],"study_design_scores_gemma":[0.006458142,0.0068954607,0.010423034,0.00012418325,0.00007804737,0.0000130623885,0.000978541,0.00013713926,0.9329086,0.000171417,0.04151861,0.00029379452],"about_ca_topic_score_codex":0.0004384794,"about_ca_topic_score_gemma":0.00075538084,"teacher_disagreement_score":0.05543328,"about_ca_system_score_codex":0.00011317515,"about_ca_system_score_gemma":0.00035855747,"threshold_uncertainty_score":0.7208962},"labels":[],"label_agreement":null},{"id":"W4415941338","doi":"10.1016/j.annonc.2025.08.1355","title":"WITHDRAWN: 782P Optimizing neoadjuvant therapy for locally advanced rectal cancer: A prospective comparative two arm study of total neoadjuvant therapy vs standard chemoradiation","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Neoadjuvant therapy; Colorectal cancer; Rectal carcinoma; Prospective cohort study; Chemotherapy","score_opus":0.07498268310002126,"score_gpt":0.44593444079747835,"score_spread":0.3709517576974571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98418343,0.0042819213,0.00035868943,0.0016640613,0.00036815237,0.005404473,0.000094449686,0.000048500675,0.0035963082],"genre_scores_gemma":[0.99474496,0.0017244067,0.0014106854,0.00046831847,0.00008795516,0.00132187,0.000022172288,0.000026314097,0.00019332531],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978495,0.00016007201,0.00071237807,0.0005441314,0.0003430819,0.00039082378],"domain_scores_gemma":[0.997624,0.00042648742,0.0005248467,0.00029346705,0.0010192356,0.00011196636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033978125,0.00032461766,0.0016064929,0.00020431704,0.0000990939,0.000009758308,0.00012842033,0.00013027285,0.00006584589],"category_scores_gemma":[0.00007035959,0.0002604806,0.00023107092,0.00053052127,0.00020519066,0.00011866962,0.000049561808,0.00022136769,7.575025e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18079852,0.0092517305,0.02635716,0.000083670806,0.0028414566,0.000056487188,0.011085549,0.003394498,0.0073386566,0.00018450544,0.000396896,0.7582109],"study_design_scores_gemma":[0.16401958,0.33277014,0.13999803,0.00088141236,0.00041609284,0.00003886508,0.008070777,0.0025676107,0.3404983,0.001186953,0.008792733,0.0007594977],"about_ca_topic_score_codex":0.00041142473,"about_ca_topic_score_gemma":0.00036083846,"teacher_disagreement_score":0.75745136,"about_ca_system_score_codex":0.0004494619,"about_ca_system_score_gemma":0.001088801,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W4415941346","doi":"10.1016/j.annonc.2025.08.1897","title":"1263P Assessing ABC-DLBCL therapeutic targets using transcriptomics and AI-predicted networks","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Business Development Bank of Canada","funders":"","keywords":"Transcriptome; Disease; Germinal center; Therapeutic approach; Cell","score_opus":0.0927124827836775,"score_gpt":0.42114349769963727,"score_spread":0.3284310149159598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9255033,0.024198378,0.021227216,0.019095073,0.00083446805,0.00048821425,0.000011722081,0.0000748005,0.008566789],"genre_scores_gemma":[0.9837427,0.002765979,0.0008801496,0.012411287,0.00010978549,0.000011706983,0.000011507198,0.000015872058,0.00005101561],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989221,0.00009308237,0.0003545562,0.0002349395,0.00010306912,0.000292266],"domain_scores_gemma":[0.9993419,0.000091288486,0.000108883476,0.00016940701,0.00020433044,0.00008418519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029531194,0.00013968765,0.0005237362,0.0001423319,0.00008753474,0.000017736002,0.00007562308,0.00024379298,0.00005198041],"category_scores_gemma":[0.00002948899,0.00012468752,0.00010444747,0.00026187746,0.00019494639,0.00009514609,0.000031148236,0.0002525029,3.161136e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011462637,0.001503373,0.093415946,0.00044792873,0.001271307,0.000048416718,0.0009035092,0.00041346034,0.035606824,0.0021827186,0.010685424,0.85237485],"study_design_scores_gemma":[0.016949942,0.0066393483,0.36195502,0.0019516965,0.0022130557,0.0001781857,0.002064043,0.20598117,0.03754108,0.0039798794,0.35961288,0.0009336963],"about_ca_topic_score_codex":0.000052325715,"about_ca_topic_score_gemma":0.000012208442,"teacher_disagreement_score":0.85144114,"about_ca_system_score_codex":0.00004199816,"about_ca_system_score_gemma":0.00030691002,"threshold_uncertainty_score":0.50846094},"labels":[],"label_agreement":null},{"id":"W4415941381","doi":"10.1016/j.annonc.2025.08.2552","title":"1928P Multi-omic profiling of circulating extracellular vesicles to identify biomarkers of response and resistance to immune checkpoint inhibitors in NSCLC patients","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Atlantic Cancer Research Institute","funders":"Canadian Cancer Society","keywords":"Extracellular vesicles; Lung cancer; Immune system; Immune checkpoint; Liquid biopsy; Microvesicles; Extracellular; Biomarker","score_opus":0.025833259364301264,"score_gpt":0.3529471977711199,"score_spread":0.3271139384068186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943534,0.003895097,0.00043276974,0.00048847316,0.000100975514,0.00055186945,0.00003394887,0.000004246888,0.00013917629],"genre_scores_gemma":[0.992952,0.000055945296,0.0067485995,0.00009875497,0.000011979508,0.000026105687,0.000019200623,0.000016976559,0.00007047702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798506,0.00032155644,0.0009219049,0.0003886233,0.00012827037,0.000254587],"domain_scores_gemma":[0.9987921,0.00010799122,0.00035086606,0.00039672747,0.0002605538,0.000091746624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012489981,0.00015493181,0.00037888956,0.00028918733,0.000028791437,0.000004671263,0.00023289953,0.00018820736,0.0000023923324],"category_scores_gemma":[0.001640355,0.00017693224,0.00011456564,0.0003340995,0.00017369763,0.000007491117,0.00028288475,0.000078206795,8.050445e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030763443,0.00039671827,0.039098524,0.00019552172,0.00007285039,0.000007958903,0.00023995285,0.000071388604,0.9520255,0.000040062427,0.000097804565,0.0046774163],"study_design_scores_gemma":[0.0010460346,0.00044063528,0.17797522,0.0002358232,0.000015063828,4.826713e-7,0.0002278292,0.000022300197,0.8193834,0.00007690961,0.00046037478,0.00011591886],"about_ca_topic_score_codex":0.00004309018,"about_ca_topic_score_gemma":0.000051992876,"teacher_disagreement_score":0.1388767,"about_ca_system_score_codex":0.000028142285,"about_ca_system_score_gemma":0.00019519751,"threshold_uncertainty_score":0.7215087},"labels":[],"label_agreement":null},{"id":"W4415941410","doi":"10.1016/j.annonc.2025.08.2567","title":"1943P Impact of chemo-immunotherapy as first-line treatment for non-small cell lung cancer with brain metastases","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lung cancer; Immunotherapy; Brain metastasis; Cancer; Cell; Respiratory disease","score_opus":0.05365839788369902,"score_gpt":0.42569476854613036,"score_spread":0.37203637066243134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492915,0.007061815,0.0007620402,0.012230965,0.00008401135,0.0018057487,0.00047042666,0.000016247945,0.002639569],"genre_scores_gemma":[0.9873851,0.0032616602,0.0036750396,0.0019716655,0.000064156724,0.00044210922,0.00014448533,0.000031368465,0.0030244237],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884576,0.000058748694,0.00040194122,0.0002736484,0.00010154782,0.0003183347],"domain_scores_gemma":[0.99843585,0.00056144374,0.00028108608,0.00035468486,0.0002755033,0.00009140669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025557852,0.00025589028,0.00097095635,0.00016802561,0.00004915079,0.000004063757,0.00008734495,0.00010414069,0.00027758416],"category_scores_gemma":[0.000039320952,0.00015960091,0.0004421171,0.0002122812,0.00010624206,0.000027475293,0.000018868603,0.000062252315,0.0000014849498],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04608148,0.028382706,0.08776915,0.0026366876,0.03428981,0.00035624267,0.0030667116,0.0026278947,0.029402034,0.001052044,0.09257527,0.67175996],"study_design_scores_gemma":[0.06508498,0.15297443,0.03396874,0.00087613164,0.003748434,0.00006979815,0.00037472753,0.00076241425,0.5156794,0.0004915204,0.22544657,0.0005228504],"about_ca_topic_score_codex":0.0032992698,"about_ca_topic_score_gemma":0.0006096514,"teacher_disagreement_score":0.6712371,"about_ca_system_score_codex":0.00019548363,"about_ca_system_score_gemma":0.0011245598,"threshold_uncertainty_score":0.6508336},"labels":[],"label_agreement":null},{"id":"W4415941414","doi":"10.1016/j.annonc.2025.08.2126","title":"1496P Clinical benefit of camrelizumab (cam) + rivoceranib (rivo) in unresectable hepatocellular carcinoma (uHCC) patients with macrovascular invasion (MVI) and extrahepatic spread (EHS), CARES-310","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Overall survival; Complete response; Disease; Survival rate","score_opus":0.08359350873281653,"score_gpt":0.3355124208049663,"score_spread":0.2519189120721498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908848,0.005071914,0.000028413655,0.00058930105,0.00015819163,0.0014704779,0.00003419213,0.00001928978,0.0017434205],"genre_scores_gemma":[0.9973322,0.0012966793,0.000568508,0.00030256965,0.000037989117,0.000081519414,0.00015292721,0.000037409125,0.00019018384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968842,0.00033121568,0.0011920388,0.0006498686,0.00041075036,0.0005319295],"domain_scores_gemma":[0.9977034,0.00045711032,0.0003572396,0.0006456994,0.0006098884,0.00022669391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007684867,0.00036608515,0.0015409936,0.00050491304,0.00006944501,0.00001075125,0.00020275285,0.0004717897,0.00010307043],"category_scores_gemma":[0.00021685788,0.00030117165,0.00030834912,0.000628679,0.00035095264,0.00011765529,0.00015851122,0.0003839694,0.0000066663615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022643616,0.0018417557,0.95565236,0.00053140696,0.00039511838,0.0002966095,0.00031369782,0.0000021369392,0.00063639594,0.0001657285,0.00031707078,0.037583355],"study_design_scores_gemma":[0.01563371,0.010785326,0.93722785,0.00074292405,0.0006970467,0.000022561951,0.0001433978,0.0014034449,0.02981039,0.00037901278,0.0028302467,0.0003241052],"about_ca_topic_score_codex":0.0031157574,"about_ca_topic_score_gemma":0.0010600918,"teacher_disagreement_score":0.03725925,"about_ca_system_score_codex":0.00009769246,"about_ca_system_score_gemma":0.0005557716,"threshold_uncertainty_score":0.99994403},"labels":[],"label_agreement":null},{"id":"W4415941425","doi":"10.1016/j.annonc.2025.08.3329","title":"WITHDRAWN: 2719P Revealing a novel role for YB-1 on mitochondrial function in Ewing sarcoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; BC Cancer Agency","funders":"","keywords":"Sarcoma; Cancer; Translation (biology); Metastasis; Function (biology); Pediatric cancer; Oxidative stress; Mitochondrion","score_opus":0.03402561992390928,"score_gpt":0.34185250335570244,"score_spread":0.30782688343179315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96842027,0.0049921363,0.009881581,0.0023234854,0.004733269,0.0007509271,0.000059971313,0.000015242491,0.008823112],"genre_scores_gemma":[0.9899159,0.0005439133,0.001695791,0.0039219344,0.0021927925,0.00014085603,0.000088389126,0.000021211079,0.0014791796],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904287,0.000045184162,0.00029110073,0.0003027272,0.00006452723,0.00025357024],"domain_scores_gemma":[0.99945194,0.000051746607,0.00011566137,0.00021476665,0.00012841063,0.00003746978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024374633,0.00011896892,0.00028072487,0.00012521021,0.000047128084,0.0000068309705,0.00012462995,0.00024594582,0.0000050938056],"category_scores_gemma":[0.0002035333,0.0001225803,0.00012865559,0.00012226895,0.000052232015,0.000004168679,0.00005109217,0.00009491407,0.000001251958],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022210865,0.00027257856,0.00012898316,0.000037597307,0.00007737997,3.7311318e-7,0.000068896785,0.00021847522,0.91843385,0.001228377,0.01325311,0.06405931],"study_design_scores_gemma":[0.00259504,0.0014968677,0.0015245432,0.00004514167,0.000028118782,0.0000024837816,0.00009639556,0.000058955273,0.19566359,0.0007033871,0.7976688,0.00011667586],"about_ca_topic_score_codex":0.000078473175,"about_ca_topic_score_gemma":0.00027967323,"teacher_disagreement_score":0.7844157,"about_ca_system_score_codex":0.000015383377,"about_ca_system_score_gemma":0.0002499075,"threshold_uncertainty_score":0.49986792},"labels":[],"label_agreement":null},{"id":"W4415941435","doi":"10.1016/j.annonc.2025.08.2433","title":"1808eP Bronchoalveolar lavage (BAL) to accelerate time to molecular (AToM-001) diagnosis in early-stage lung cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Bronchoalveolar lavage; Liquid biopsy; Lung cancer; Concordance; Genotyping; Biopsy; Lung tumor","score_opus":0.027671680429813814,"score_gpt":0.4355999144893546,"score_spread":0.40792823405954076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93223596,0.0016994585,0.00008036041,0.03653723,0.00015466717,0.0010769564,0.00011799769,0.00003135026,0.028065996],"genre_scores_gemma":[0.9558404,0.0004748926,0.00068422663,0.02684255,0.00005551857,0.000916167,0.000042074967,0.0000269097,0.015117258],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878037,0.00006723023,0.00033870374,0.00032291425,0.00014019341,0.00035060203],"domain_scores_gemma":[0.99915653,0.00009549615,0.00007082401,0.0002778414,0.00021267564,0.00018664436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015847052,0.00015785798,0.0004844817,0.00035442412,0.000039579947,0.000011804806,0.00013291086,0.00012674491,0.0011292706],"category_scores_gemma":[0.00007984528,0.00014774123,0.000085547974,0.00049108925,0.000032660806,0.00006602815,0.00008860295,0.00013154904,0.00013869438],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013655685,0.003636763,0.3329174,0.00049418694,0.0022005485,0.001236636,0.005201872,0.001823919,0.022579286,0.0020186496,0.4403389,0.18618625],"study_design_scores_gemma":[0.0031162654,0.00164179,0.14835617,0.00035925134,0.00028147709,0.000001944083,0.00007100059,0.0000607227,0.036016073,0.000073878604,0.8098196,0.00020187492],"about_ca_topic_score_codex":0.0033705698,"about_ca_topic_score_gemma":0.000607629,"teacher_disagreement_score":0.36948064,"about_ca_system_score_codex":0.00025009352,"about_ca_system_score_gemma":0.0005211869,"threshold_uncertainty_score":0.9997838},"labels":[],"label_agreement":null},{"id":"W4415941452","doi":"10.1016/j.annonc.2025.08.2862","title":"2245P Evaluation of a cell-free DNA (cfDNA)-based blood test for early detection of pancreatic cancer in high-risk individuals with family history and genetic predisposition","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada); Royal Victoria Hospital","funders":"","keywords":"Pancreatic cancer; Family history; Genetic predisposition; Genetic testing; Cancer; Adenocarcinoma; Pancreatic ductal adenocarcinoma","score_opus":0.01817539398035335,"score_gpt":0.28541164834446137,"score_spread":0.26723625436410803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250513,0.0056118695,0.00076006405,0.00007687474,0.00007529817,0.00053489255,0.00030296863,0.0000017149465,0.00013115747],"genre_scores_gemma":[0.99728316,0.0014259801,0.0009147619,0.00009967925,0.000029800396,0.00019227131,0.00003307653,0.000009371576,0.000011891095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991964,0.00008557769,0.00029839107,0.00020013256,0.0001049757,0.00011451883],"domain_scores_gemma":[0.99889266,0.00016556752,0.00033350973,0.00020394649,0.0003804599,0.000023842815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032986217,0.00009234899,0.00024051279,0.00012688368,0.000015863221,0.0000018978649,0.00008710348,0.00014715859,0.0000027145627],"category_scores_gemma":[0.00025465782,0.000094046816,0.000040537514,0.00008162107,0.00011097586,0.0000031308343,0.00003126736,0.000041659845,3.161555e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005130906,0.00044984889,0.0970246,0.0001996107,0.00011625318,4.2895215e-7,0.0000871841,0.0018316957,0.8834281,0.000013739389,0.00022668643,0.016108762],"study_design_scores_gemma":[0.0039896998,0.0048422194,0.39023843,0.00006591811,0.000458524,5.024139e-7,0.000026260703,0.00048522407,0.5991508,0.0003131268,0.00035024234,0.000079070174],"about_ca_topic_score_codex":0.00093137374,"about_ca_topic_score_gemma":0.0014147162,"teacher_disagreement_score":0.2932138,"about_ca_system_score_codex":0.000045325134,"about_ca_system_score_gemma":0.0006529354,"threshold_uncertainty_score":0.38351178},"labels":[],"label_agreement":null},{"id":"W4415941460","doi":"10.1016/j.annonc.2025.08.2581","title":"1957P Day-7 ctDNA response as a prognostic marker in EGFR-mutant NSCLC under osimertinib: The MELROSE study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Osimertinib; Circulating tumor DNA; Prospective cohort study; Multicenter study; Chemotherapy","score_opus":0.05093655239407268,"score_gpt":0.4587565328063985,"score_spread":0.4078199804123258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9311739,0.000828911,0.000014354148,0.047784597,0.00019270611,0.0015067759,0.000008976193,0.000022784268,0.018466972],"genre_scores_gemma":[0.99031764,0.000078240904,0.00003734604,0.0060309027,0.000026758453,0.00026304022,0.000007179199,0.000012843481,0.003226062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837714,0.0005365596,0.00040787456,0.00025305012,0.00016469497,0.0002606938],"domain_scores_gemma":[0.9981132,0.0011966832,0.00011359472,0.00035326113,0.00016115484,0.00006209794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001026336,0.00013522503,0.00038008098,0.00019961769,0.00007291286,0.000008374667,0.00012255421,0.00009309425,0.0001296909],"category_scores_gemma":[0.00083044404,0.00008683531,0.000081671,0.00044767538,0.00013524441,0.000039343344,0.0000683865,0.00017723114,0.000029841132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04482508,0.030799609,0.5732049,0.00020167035,0.0059297187,0.0024195428,0.030286262,0.0001583042,0.011784971,0.0072921207,0.0362145,0.25688332],"study_design_scores_gemma":[0.0060974737,0.0056610866,0.9248423,0.0001642258,0.000558479,0.000028839308,0.0055557764,0.00003683399,0.0009948062,0.0012467812,0.054707833,0.00010555598],"about_ca_topic_score_codex":0.00036887344,"about_ca_topic_score_gemma":0.00029901203,"teacher_disagreement_score":0.35163742,"about_ca_system_score_codex":0.00011809365,"about_ca_system_score_gemma":0.0011996819,"threshold_uncertainty_score":0.3541041},"labels":[],"label_agreement":null},{"id":"W4415941465","doi":"10.1016/j.annonc.2025.08.3036","title":"2421P Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab (Pembro) in metastatic castration-resistant prostate cancer (mCRPC): Results from phase II MK-2870-002/SKB264-II-06 Study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Prostate cancer; Cohort; Cancer; Phases of clinical research","score_opus":0.10738357577069794,"score_gpt":0.46260576440841994,"score_spread":0.355222188637722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720447,0.0033153263,0.0000074278328,0.014746319,0.00028608408,0.0027800319,0.0014439848,0.000059760943,0.0053163376],"genre_scores_gemma":[0.98647654,0.0013888748,0.0002065543,0.00063165603,0.00010073464,0.0004615165,0.0005427178,0.000039381746,0.0101520065],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995845,0.00044901256,0.0013629502,0.0008796321,0.0006025321,0.00086087134],"domain_scores_gemma":[0.99758357,0.00042836327,0.00042399214,0.0007127934,0.0005876991,0.00026360253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090636814,0.00042924384,0.0013116735,0.00070078956,0.00029910298,0.000028217715,0.0003103376,0.00019667369,0.00027842508],"category_scores_gemma":[0.00036804823,0.00035446518,0.00019153894,0.001008666,0.00033299602,0.00019175166,0.00023901246,0.00057867164,0.00001740663],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24565066,0.065873325,0.015308318,0.0011502987,0.008056651,0.008123469,0.044600513,0.00053029973,0.09944769,0.0009677467,0.09854324,0.41174778],"study_design_scores_gemma":[0.40129334,0.13592762,0.11537435,0.0026311926,0.002617266,0.00006476887,0.016255373,0.0017720113,0.097312815,0.0057073804,0.21924685,0.0017970263],"about_ca_topic_score_codex":0.0110499635,"about_ca_topic_score_gemma":0.012460813,"teacher_disagreement_score":0.40995076,"about_ca_system_score_codex":0.0006417985,"about_ca_system_score_gemma":0.0034031551,"threshold_uncertainty_score":0.99989074},"labels":[],"label_agreement":null},{"id":"W4415941485","doi":"10.1016/j.annonc.2025.08.1705","title":"1065MO First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Ovarian cancer; Conjugate; Folate receptor; Phases of clinical research; Topoisomerase; Chemotherapy","score_opus":0.05104004993616807,"score_gpt":0.4325312644285181,"score_spread":0.38149121449235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195933,0.00057659595,0.0000015184938,0.0022837443,0.0002572298,0.0021755851,0.00007813707,0.000017717493,0.0026501107],"genre_scores_gemma":[0.99877536,0.0002540311,0.00009996433,0.00024155273,0.000034306508,0.00019571568,0.000054697302,0.000028834285,0.00031555936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699265,0.00037616614,0.001022866,0.000511023,0.0005294747,0.0005678516],"domain_scores_gemma":[0.99812376,0.00025337376,0.0003550182,0.00048761585,0.0006485713,0.00013166509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093736674,0.00024153406,0.0010997633,0.00069448235,0.000056736244,0.0000068921318,0.0002781541,0.00016860195,0.00039170112],"category_scores_gemma":[0.00024819645,0.00020498251,0.000062686915,0.001035266,0.00019345134,0.00007133731,0.00014280324,0.00052885636,0.0000042451456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009591782,0.007908115,0.95659435,0.0006480133,0.0003679527,0.00007902066,0.0033880686,0.000055595083,0.002554067,0.00013377555,0.0060194745,0.012659802],"study_design_scores_gemma":[0.018020354,0.022162892,0.9413706,0.0017663559,0.00006547004,4.7132357e-7,0.0007962565,0.000048376183,0.0026437605,0.000105555446,0.01280605,0.00021386506],"about_ca_topic_score_codex":0.008410817,"about_ca_topic_score_gemma":0.026934728,"teacher_disagreement_score":0.018523911,"about_ca_system_score_codex":0.00034613235,"about_ca_system_score_gemma":0.0009746576,"threshold_uncertainty_score":0.99819225},"labels":[],"label_agreement":null},{"id":"W4415941497","doi":"10.1016/j.annonc.2025.08.2714","title":"3208P 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Clinical trial; Lung cancer; Immunotherapy; Cancer; Chemotherapy","score_opus":0.19313410227825825,"score_gpt":0.51311728074028,"score_spread":0.31998317846202173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95123845,0.014546714,0.007659979,0.014304785,0.0018466727,0.00462333,0.00081832346,0.00005293038,0.004908835],"genre_scores_gemma":[0.90063727,0.030616986,0.024545016,0.025555523,0.00048024827,0.0011106788,0.00016462902,0.00013248873,0.01675717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961349,0.00051808386,0.002355436,0.00043910154,0.00018492395,0.0003675681],"domain_scores_gemma":[0.9929258,0.004832931,0.0011579846,0.00047852047,0.00049769203,0.000107059976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028364768,0.00027500058,0.0025737442,0.00021542663,0.00004198612,0.000006788366,0.0002772639,0.00029059814,0.00133307],"category_scores_gemma":[0.0010472113,0.00019471048,0.0010146738,0.0002651547,0.00023588823,0.000054884295,0.000041319214,0.00018577899,0.0000030601557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25037813,0.0023799746,0.013430451,0.00097092445,0.006293665,0.000021116226,0.00048008448,0.000042973854,0.038383372,0.00008592447,0.062571146,0.6249623],"study_design_scores_gemma":[0.24334334,0.029207442,0.084277205,0.0020599344,0.0037283336,0.0000047727535,0.0012913534,0.0013662844,0.1873273,0.000990524,0.44552463,0.00087888876],"about_ca_topic_score_codex":0.0004695379,"about_ca_topic_score_gemma":0.00031650715,"teacher_disagreement_score":0.62408334,"about_ca_system_score_codex":0.00007648016,"about_ca_system_score_gemma":0.0022776513,"threshold_uncertainty_score":0.99957985},"labels":[],"label_agreement":null},{"id":"W4415941514","doi":"10.1016/j.annonc.2025.08.3571","title":"2959eP EGFR-targeted monoclonal antibodies administered to patients with colon cancer can increase the risk of bone fracture","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Monoclonal antibody; Colorectal cancer; Monoclonal; Risk factor; Antibody; Pathologic fracture; Cancer","score_opus":0.050522614143201895,"score_gpt":0.4299389961492394,"score_spread":0.3794163820060375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635245,0.0013494745,0.000009406759,0.03076435,0.00012237209,0.00090284616,0.00039256632,0.000013701993,0.0029207827],"genre_scores_gemma":[0.9909823,0.00091512565,0.00031872335,0.006887487,0.000068433925,0.00011412494,0.000044276017,0.000018013634,0.00065154815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982038,0.0002733754,0.00044222292,0.0002811662,0.00042164166,0.00037775352],"domain_scores_gemma":[0.99770343,0.0004069933,0.00028345163,0.00044159067,0.0009865069,0.00017801963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000513209,0.00016908991,0.0006795779,0.00022296341,0.00008281371,0.0000056483914,0.00021214734,0.00017039047,0.00026547274],"category_scores_gemma":[0.0007379304,0.00010628657,0.0000943856,0.0004639067,0.00033565646,0.000027706383,0.00013018175,0.00038949077,0.000004042946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074617844,0.0008136144,0.87678653,0.00027270135,0.0006485138,0.00003481743,0.0010092594,0.00007711281,0.0010409526,0.00004227603,0.07466471,0.03714771],"study_design_scores_gemma":[0.0023944627,0.0051821554,0.8241619,0.00030896874,0.00017407977,0.0000029236157,0.00016266365,0.000024443167,0.0144002475,0.00008843497,0.1529942,0.000105558596],"about_ca_topic_score_codex":0.011361928,"about_ca_topic_score_gemma":0.0059175347,"teacher_disagreement_score":0.07832949,"about_ca_system_score_codex":0.000116311436,"about_ca_system_score_gemma":0.0017691419,"threshold_uncertainty_score":0.9952215},"labels":[],"label_agreement":null},{"id":"W4415941544","doi":"10.1016/j.annonc.2025.08.1957","title":"1325MO Retifanlimab (Anti–PD-1 mAb) alone or in combination with Anti-LAG3 ± Anti-TIM3 mAbs In previously untreated, recurrent and/or metastatic (R/M) PD-L1+ HNSCC: A double-blind randomised controlled phase II trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Incyte","keywords":"Blockade; Phases of clinical research; Clinical trial; Immunotherapy; Immune checkpoint; Chemotherapy","score_opus":0.0900878328807049,"score_gpt":0.4193750796481191,"score_spread":0.32928724676741417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745836,0.0029862395,0.000033272558,0.009869499,0.0003334351,0.008349968,0.000024426794,0.00003023182,0.0009145878],"genre_scores_gemma":[0.9904668,0.0067256344,0.00023599375,0.0010603404,0.000044102948,0.0006142463,0.00011782381,0.000025853096,0.0007092207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965158,0.00062861777,0.0015357047,0.0005222178,0.00030423424,0.0004934002],"domain_scores_gemma":[0.99770546,0.00089462835,0.00066051877,0.00033383336,0.00030200547,0.000103574166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023627684,0.00035664553,0.0024488806,0.0008864338,0.00008586776,0.000023751354,0.00015338788,0.00024317145,0.00031239726],"category_scores_gemma":[0.00044611134,0.00023294122,0.00020901128,0.0010937144,0.00030773046,0.00014502674,0.000053394735,0.00032440305,0.0000021540395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93696725,0.008577154,0.0003779406,0.0003012141,0.0009993652,0.0004005079,0.0006646668,0.0000064733567,0.0033682382,0.000061917715,0.0010877588,0.047187526],"study_design_scores_gemma":[0.95350266,0.03633551,0.0012600189,0.0010068254,0.000598333,0.00010199985,0.00028016442,0.00036510578,0.0036951813,0.00006282843,0.002560332,0.00023105893],"about_ca_topic_score_codex":0.000423578,"about_ca_topic_score_gemma":0.0010096962,"teacher_disagreement_score":0.04695647,"about_ca_system_score_codex":0.00014680419,"about_ca_system_score_gemma":0.0011954815,"threshold_uncertainty_score":0.9499067},"labels":[],"label_agreement":null},{"id":"W4415941564","doi":"10.1016/j.annonc.2025.08.1210","title":"CN136 Disease perceptions of adult patients with acute myeloid leukemia (AML) during diagnosis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Myeloid leukemia; Disease; Leukemia; Myeloid; MEDLINE","score_opus":0.020883960256373037,"score_gpt":0.3491355264644909,"score_spread":0.3282515662081179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756135,0.00010186419,0.000037062397,0.006657011,0.00006907503,0.00061159406,0.00013632917,0.000032250726,0.0047934977],"genre_scores_gemma":[0.9948474,0.0014779083,0.0005485605,0.0013487951,0.000053520376,0.00016435998,0.00010442305,0.000023583398,0.0014314522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833614,0.00010422022,0.0004604657,0.00032951756,0.00035906813,0.00041057589],"domain_scores_gemma":[0.9976787,0.0002317569,0.00017821528,0.0004996551,0.001146143,0.0002655484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012899503,0.00018015108,0.0006000121,0.00040631156,0.00008307507,0.0000045714187,0.00022583055,0.00016163867,0.0003086355],"category_scores_gemma":[0.00044387483,0.00014615712,0.00016092989,0.00052309706,0.00040139395,0.00010368395,0.00017507187,0.00032414732,0.000026036661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005118001,0.0012312202,0.9492062,0.0005379158,0.0008326498,0.00016509586,0.00036555773,0.000030449935,0.002388829,0.00037259003,0.019976443,0.019775093],"study_design_scores_gemma":[0.0051566777,0.0019275969,0.98145,0.0003199633,0.00028528494,0.0000058525407,0.00019892873,0.00003627408,0.006966607,0.000104858555,0.0034223676,0.0001255389],"about_ca_topic_score_codex":0.00018968737,"about_ca_topic_score_gemma":0.00005490467,"teacher_disagreement_score":0.032243893,"about_ca_system_score_codex":0.00038186062,"about_ca_system_score_gemma":0.0017107282,"threshold_uncertainty_score":0.59601146},"labels":[],"label_agreement":null},{"id":"W4415941573","doi":"10.1016/j.annonc.2025.08.930","title":"507P Real-world outcomes of patients with advanced or metastatic HR+/HER2- breast cancer treated with CDK4/6 inhibitors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; London Health Sciences Centre; Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research","keywords":"Palbociclib; Metastatic breast cancer; Breast cancer; Clinical trial; Randomized controlled trial; Endocrine system; Hormone receptor; Cancer","score_opus":0.032758316782611825,"score_gpt":0.3870564967107744,"score_spread":0.3542981799281626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910362,0.00027709175,0.000067298184,0.0047907443,0.00011009094,0.0008904539,0.0002400027,0.000055582877,0.002532557],"genre_scores_gemma":[0.9932923,0.00023539035,0.0023796994,0.0013840825,0.000026545376,0.00015591699,0.000040948165,0.000043841064,0.0024412978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827224,0.000088689594,0.0005787033,0.000360075,0.00031625893,0.00038404795],"domain_scores_gemma":[0.99779683,0.0002527196,0.0005342883,0.0003999389,0.00089923653,0.00011701139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116575495,0.00030348264,0.0012553321,0.00037312057,0.00004239985,0.0000029957155,0.0001371606,0.00007314287,0.000259493],"category_scores_gemma":[0.0000425792,0.00018039386,0.00009569879,0.0008901995,0.00043040857,0.00014717777,0.000041459716,0.00017254411,0.000001894077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024281241,0.0013534735,0.7940135,0.00031851232,0.0016976146,0.000041246323,0.00026360794,0.0001784971,0.00046086675,0.00017078266,0.00041830252,0.17680234],"study_design_scores_gemma":[0.011584634,0.0053642066,0.96296924,0.0006978676,0.0004919943,0.000011446971,0.00031631222,0.0000056010485,0.009034057,0.0000868932,0.009221453,0.0002162658],"about_ca_topic_score_codex":0.0010546471,"about_ca_topic_score_gemma":0.0028465237,"teacher_disagreement_score":0.17658608,"about_ca_system_score_codex":0.0001539892,"about_ca_system_score_gemma":0.00072441075,"threshold_uncertainty_score":0.73562485},"labels":[],"label_agreement":null},{"id":"W4415941585","doi":"10.1016/j.annonc.2025.08.1651","title":"WITHDRAWN: 3180eP Oncologist attitudes and practices on liquid biopsy (LB)– Global survey by the International Society of Liquid Biopsy (ISLB)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Liquid biopsy; Transformative learning; Biopsy; Radiation oncologist; MEDLINE","score_opus":0.05010843868650542,"score_gpt":0.3998404446869529,"score_spread":0.34973200600044746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909313,0.0026884186,0.00013237951,0.010666169,0.00041694127,0.00017273983,0.0005780981,0.0000051205975,0.006247015],"genre_scores_gemma":[0.9898189,0.005342006,0.0004107097,0.0038368113,0.00012995047,0.00001881391,0.00018114761,0.000007713499,0.0002539948],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988989,0.000113934475,0.0003412344,0.00032877683,0.000121693716,0.00019543464],"domain_scores_gemma":[0.99842554,0.00036583788,0.0005240914,0.00028724154,0.0003490046,0.000048309223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007459046,0.00015179242,0.00026782253,0.000024287701,0.00007271085,0.000020653322,0.0003915617,0.0002533239,0.00001175946],"category_scores_gemma":[0.0007682698,0.00012177119,0.000111828274,0.0001242651,0.000527162,0.000005851188,0.00031067288,0.00010776403,0.0000014992389],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009497836,0.0019032579,0.081684805,0.00013331832,0.0015541149,0.000008486102,0.00013611432,0.00012135612,0.3914473,0.003817269,0.50098014,0.008716003],"study_design_scores_gemma":[0.0021163595,0.014265814,0.09433941,0.0000758782,0.00009464735,0.000054094162,0.00033676458,0.00005038755,0.24646595,0.00023966219,0.6415746,0.0003864095],"about_ca_topic_score_codex":0.0010484533,"about_ca_topic_score_gemma":0.0007994151,"teacher_disagreement_score":0.14498135,"about_ca_system_score_codex":0.00003983341,"about_ca_system_score_gemma":0.00053261634,"threshold_uncertainty_score":0.4965685},"labels":[],"label_agreement":null},{"id":"W4415941623","doi":"10.1016/j.annonc.2025.08.942","title":"519P Real-world effectiveness of 1st line palbociclib + endocrine therapy and subsequent treatments in patients with HR+/HER2- advanced breast cancer: Interim results from the PERFORM study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Palbociclib; Interim; Second line; Endocrine system; Interim analysis; Line (geometry)","score_opus":0.0453364453890282,"score_gpt":0.3955320625878051,"score_spread":0.3501956171987769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945478,0.0008835594,0.0000035067592,0.0018794718,0.00012402193,0.0017815925,0.00035542663,0.000017807528,0.00040682688],"genre_scores_gemma":[0.99725515,0.0018725684,0.00009752494,0.000319532,0.00003803727,0.0002356827,0.00007407139,0.000024252402,0.000083174724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998189,0.0003178291,0.00056776893,0.00042662537,0.00021348405,0.00028532738],"domain_scores_gemma":[0.9980567,0.00070501235,0.00035020921,0.00044846846,0.00037885696,0.000060729835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003463984,0.0002615898,0.0008984289,0.0001675555,0.000045420038,0.0000041492317,0.00015958409,0.000056930232,0.00003426912],"category_scores_gemma":[0.000042984317,0.00016045345,0.00006097651,0.000431357,0.0002777802,0.00010032596,0.000077457385,0.00020126245,3.937901e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06314666,0.0024379718,0.661246,0.00004664003,0.0006557159,0.000014299445,0.00094496406,0.000041372637,0.0007202688,0.00001634898,0.000008143929,0.27072158],"study_design_scores_gemma":[0.035520654,0.008864855,0.9464706,0.00072332786,0.00009697179,0.0000024469055,0.00057404715,0.0000069423772,0.006947947,0.00011371406,0.00056805875,0.00011042717],"about_ca_topic_score_codex":0.006132513,"about_ca_topic_score_gemma":0.0042850813,"teacher_disagreement_score":0.2852246,"about_ca_system_score_codex":0.00021735068,"about_ca_system_score_gemma":0.00024300133,"threshold_uncertainty_score":0.92705655},"labels":[],"label_agreement":null},{"id":"W4415941668","doi":"10.1016/j.annonc.2025.08.2237","title":"1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Italfarmaco; Sun Pharma; Istituto Oncologico Veneto; Medizinische Universität Wien; Pfizer; Incyte; Odense Universitetshospital; Novo Nordisk; Astellas Pharma; Eisai; American Society of Clinical Oncology; Universität Wien; BeiGene; Regeneron Pharmaceuticals; Mylan; Helsinn; Les Laboratories Pierre Fabre; Society for Immunotherapy of Cancer; Daiichi Sankyo Europe; Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu; Hospices Civils de Lyon; Gilead Sciences; Univerzita Karlova v Praze; Melanoma Research Alliance; AstraZeneca; Associazione Italiana di Oncologia Medica; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Sanofi; Johns Hopkins University; Melanoma Institute Australia; Amgen","keywords":"Ipilimumab; Nivolumab; Adjuvant; Melanoma; Stage (stratigraphy); Phases of clinical research","score_opus":0.11395194068233609,"score_gpt":0.42176272067913306,"score_spread":0.30781077999679696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97900367,0.0010710022,0.0000061199053,0.011367482,0.0005135416,0.0010106727,0.00045009286,0.000022725879,0.0065546785],"genre_scores_gemma":[0.9905727,0.0021754429,0.000105468214,0.0015681911,0.0001618869,0.000043724955,0.00012242293,0.00001570841,0.0052344473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755514,0.00034126538,0.0011754396,0.00034471112,0.00025201033,0.00033144778],"domain_scores_gemma":[0.9976415,0.00096061965,0.0004898145,0.0006295128,0.00022531452,0.000053254833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012722122,0.00018397416,0.0009268123,0.00021119561,0.000054004206,0.0000068761797,0.00030339166,0.00027173382,0.0005746379],"category_scores_gemma":[0.0007987412,0.00012207298,0.00021196579,0.000607435,0.00033452432,0.000055593722,0.00008778326,0.00029920178,0.00000559787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8748996,0.0017735442,0.0001617371,0.00005576692,0.00045567728,0.00010068421,0.0010876742,0.0000018957692,0.02112079,0.000055146535,0.058250148,0.042037304],"study_design_scores_gemma":[0.63962567,0.026821716,0.012721812,0.00059373333,0.00016243303,0.00000639257,0.0014605358,0.00013222829,0.052676033,0.00016381947,0.2654398,0.00019582466],"about_ca_topic_score_codex":0.0042528026,"about_ca_topic_score_gemma":0.0027392462,"teacher_disagreement_score":0.23527397,"about_ca_system_score_codex":0.0000956466,"about_ca_system_score_gemma":0.0011685643,"threshold_uncertainty_score":0.64289933},"labels":[],"label_agreement":null},{"id":"W4415941713","doi":"10.1016/j.annonc.2025.08.2230","title":"1602O Enucleation prevention and vision preservation in primary uveal melanoma (UM): Preliminary results from a phase II study of neoadjuvant darovasertib","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Enucleation; Melanoma; Eye Enucleation; Brachytherapy; Phases of clinical research; Uvea; Choroidal melanoma","score_opus":0.048114660660655714,"score_gpt":0.41954253110132994,"score_spread":0.3714278704406742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936547,0.00046293417,0.000032259497,0.0023991673,0.00009179011,0.0010901318,0.00003327462,0.000013122561,0.0022226202],"genre_scores_gemma":[0.99840224,0.00015801284,0.0005224171,0.00020335188,0.000020483283,0.000028063321,0.00037369432,0.000006968373,0.00028474646],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984948,0.00028169403,0.00064957305,0.00030142532,0.00014018995,0.00013229843],"domain_scores_gemma":[0.9989956,0.00024185136,0.00032029234,0.00025798348,0.00014462731,0.000039629496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048004978,0.00011527751,0.0004996075,0.000256511,0.000053671276,0.000002126492,0.00006302199,0.00021366568,0.0000142241925],"category_scores_gemma":[0.00021454833,0.00010555253,0.000051361123,0.00021046035,0.00007231792,0.00017267774,0.00011655297,0.00013109007,0.0000010787745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060690884,0.04069438,0.09415073,0.00016980838,0.00062842114,0.00020118708,0.0049243486,0.00003793505,0.010853047,0.00009614513,0.001534321,0.7860188],"study_design_scores_gemma":[0.038675085,0.19151866,0.7589846,0.0003428868,0.00034241588,0.0000061593105,0.0005720229,0.0005365185,0.006189695,0.0011949105,0.001559748,0.00007728331],"about_ca_topic_score_codex":0.00045667842,"about_ca_topic_score_gemma":0.00030396908,"teacher_disagreement_score":0.78594154,"about_ca_system_score_codex":0.000062538966,"about_ca_system_score_gemma":0.00022978285,"threshold_uncertainty_score":0.4304307},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4415941717","doi":"10.1016/j.annonc.2025.08.499","title":"64eP Translating tumor biology into clinical practice using patient-derived organoids in renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Occupational Cancer Research Centre; McGill Genome Centre","funders":"","keywords":"Organoid; Chromophobe cell; Renal cell carcinoma; Clinical Practice; Precision oncology; Ex vivo; Clear cell; Clear cell renal cell carcinoma","score_opus":0.11389469240157536,"score_gpt":0.4444231149248281,"score_spread":0.33052842252325276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755914,0.0018336067,0.00018138681,0.005081127,0.0002911186,0.0005058069,0.000004473006,0.000019321737,0.016491715],"genre_scores_gemma":[0.9791927,0.000071251576,0.017238472,0.0033226176,0.000087010325,0.000016715416,0.000018588842,0.000020052417,0.00003264459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99706435,0.00071072293,0.0012116058,0.0004605106,0.0001406403,0.0004121613],"domain_scores_gemma":[0.99770415,0.001005639,0.0004339062,0.00034592117,0.00037478848,0.00013558057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008226893,0.00021577122,0.0009030309,0.00033264756,0.000052215284,0.0000047157628,0.0001271648,0.00029959538,0.000059172628],"category_scores_gemma":[0.0009196295,0.00019201479,0.0002039282,0.00043278787,0.0002508604,0.00008637741,0.00009302501,0.0004555571,0.000010070825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039070267,0.003335888,0.22108471,0.00031000818,0.0002559313,0.0017373891,0.0025914027,0.000046513902,0.62012124,0.00031082475,0.0007353826,0.1455637],"study_design_scores_gemma":[0.014107312,0.028905248,0.13677025,0.00033611764,0.0008209716,0.00042606934,0.0033145358,0.0009797815,0.77981293,0.0013830449,0.032616608,0.0005271261],"about_ca_topic_score_codex":0.0008954797,"about_ca_topic_score_gemma":0.00011136546,"teacher_disagreement_score":0.15969172,"about_ca_system_score_codex":0.00016052103,"about_ca_system_score_gemma":0.0011076088,"threshold_uncertainty_score":0.78301364},"labels":[],"label_agreement":null},{"id":"W4415941719","doi":"10.1016/j.annonc.2025.08.933","title":"510P Clinical and molecular characteristics of cancers that switch phenotype from ER+ primary to triple negative in metastatic disease","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Phenotype; Disease; Breast cancer; Clinical phenotype; Cancer; Metastasis","score_opus":0.053523999403280266,"score_gpt":0.3713198270787527,"score_spread":0.31779582767547243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956583,0.0010262156,0.0005848155,0.00090827653,0.00020707081,0.0002510718,0.00019972706,0.0000023645794,0.001162187],"genre_scores_gemma":[0.99519956,0.0006562096,0.001036673,0.002862154,0.000033871453,0.000023125882,0.00010050658,0.000007859575,0.000080054786],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99891275,0.00018134741,0.00039651853,0.00028010612,0.00006985772,0.0001594269],"domain_scores_gemma":[0.99928963,0.000105205516,0.00015838761,0.0002352769,0.00010096674,0.000110507615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027011515,0.00011040272,0.0004334346,0.000067871326,0.000012919118,0.0000030312206,0.00013475372,0.00009104658,0.000011319485],"category_scores_gemma":[0.000411722,0.0001070443,0.00007626161,0.000095246665,0.00013671868,0.00000305291,0.00013697793,0.00007981022,0.0000011182203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077804183,0.0010539067,0.24508002,0.00036269764,0.00082284614,0.00018482636,0.00045818128,0.000032777152,0.5567911,0.0016007096,0.00938433,0.17644818],"study_design_scores_gemma":[0.00300227,0.0027289365,0.76858944,0.000118343,0.00016100818,0.0000011396809,0.000181009,0.00005467311,0.18879816,0.0035296015,0.03254601,0.00028942234],"about_ca_topic_score_codex":0.0002337209,"about_ca_topic_score_gemma":0.0001400133,"teacher_disagreement_score":0.5235094,"about_ca_system_score_codex":0.000011251922,"about_ca_system_score_gemma":0.0005373882,"threshold_uncertainty_score":0.436514},"labels":[],"label_agreement":null},{"id":"W4415941744","doi":"10.1016/j.annonc.2025.08.2111","title":"1481P PROACTIF: Final results from the largest, prospective HCC real-world study using Yttrium-90 (Y90) glass microspheres","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Glass microsphere; Microsphere; Hepatocellular carcinoma; Prospective cohort study; Liver cancer","score_opus":0.24520449282371024,"score_gpt":0.40572702510261355,"score_spread":0.1605225322789033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669071,0.00094229827,0.000010094091,0.007665784,0.00024061745,0.0019968941,0.00011467527,0.000046716632,0.022075811],"genre_scores_gemma":[0.9943457,0.00015098604,0.000713845,0.000810598,0.00022883488,0.00010160293,0.0000650137,0.000021365493,0.003562022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978717,0.00037721056,0.0006132781,0.00051084254,0.0002381174,0.00038883896],"domain_scores_gemma":[0.9979193,0.000771543,0.00029518825,0.0005462726,0.00037966843,0.000088030305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070211606,0.00025087883,0.0007355738,0.0001179806,0.00018385418,0.000023328299,0.00020832685,0.00016884916,0.00008778781],"category_scores_gemma":[0.0002979401,0.00017396169,0.00020608907,0.0005891506,0.000185734,0.00007393906,0.00013340436,0.00033340993,0.000018292876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004006566,0.002646614,0.9677837,0.00002708609,0.0010074086,0.00030021873,0.0018257485,0.0000015671127,0.0020269623,0.00017299727,0.011120261,0.009080906],"study_design_scores_gemma":[0.008718364,0.004138772,0.9222531,0.00017736448,0.0008994161,0.00001130314,0.0014666844,0.00027108815,0.031169588,0.0005499746,0.03014145,0.00020294696],"about_ca_topic_score_codex":0.008392879,"about_ca_topic_score_gemma":0.0031611687,"teacher_disagreement_score":0.045530617,"about_ca_system_score_codex":0.00014936253,"about_ca_system_score_gemma":0.0006632492,"threshold_uncertainty_score":0.9982103},"labels":[],"label_agreement":null},{"id":"W4415941750","doi":"10.1016/j.annonc.2025.08.2899","title":"2283MO PFMG2025: Integrating genomic medicine into the national healthcare system in France","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Calgary Arts Development; Agence Nationale de la Recherche","keywords":"Healthcare system; Personalized medicine; Genomic medicine; Precision medicine; Profiling (computer programming); Health care; Genomics; Systems medicine","score_opus":0.03946043837151778,"score_gpt":0.4050219350393389,"score_spread":0.3655614966678211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87970036,0.016152784,0.0011298782,0.07115959,0.0009956103,0.00045932256,0.00001990644,0.0000144389505,0.030368138],"genre_scores_gemma":[0.99269766,0.00036635576,0.00054803776,0.0056909793,0.00021667441,0.00007359438,0.000024260531,0.0000067553724,0.00037567315],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902374,0.00015590475,0.00035902284,0.0002161803,0.000101115744,0.00014406675],"domain_scores_gemma":[0.99924207,0.000091083246,0.00013603947,0.00017017497,0.00034016048,0.000020476778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000693117,0.000087034256,0.00018707721,0.00009725727,0.00006383877,0.0000029196103,0.00024885795,0.00014878319,0.000009034237],"category_scores_gemma":[0.00027898222,0.00006666646,0.00004120782,0.00022584367,0.00018263188,0.0000020882565,0.00008550865,0.00013070564,0.0000027849892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035915792,0.00025311037,0.03055365,0.0007910332,0.00048276407,0.000013019004,0.006694577,0.0029010319,0.43201342,0.06824218,0.12679623,0.3308998],"study_design_scores_gemma":[0.00181813,0.0014557787,0.030669581,0.00037983214,0.000023248109,0.000028190834,0.005203697,0.00094932155,0.060429227,0.0044556153,0.894331,0.00025639517],"about_ca_topic_score_codex":0.00033585442,"about_ca_topic_score_gemma":0.0007310025,"teacher_disagreement_score":0.76753473,"about_ca_system_score_codex":0.00011907377,"about_ca_system_score_gemma":0.0007219091,"threshold_uncertainty_score":0.27185792},"labels":[],"label_agreement":null},{"id":"W4415941756","doi":"10.1016/j.annonc.2025.08.2362","title":"1734TiP CELEBRATE study (JCOG2107E): A multicenter, open-label, phase III trial of etoposide, carboplatin, and durvalumab in first-line treatment of unresectable or recurrent digestive NEC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Winship Cancer Institute; Novartis Pharma; Deutschen Konsortium für Translationale Krebsforschung; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Novartis Institutes for BioMedical Research; Universität Duisburg-Essen; Emory University; University of Toronto; Yale University; AstraZeneca","keywords":"Durvalumab; Phases of clinical research; Clinical trial; Digestive tract","score_opus":0.15623460969269456,"score_gpt":0.46939490057409655,"score_spread":0.31316029088140196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98992866,0.0010023866,0.000009108024,0.00204718,0.0003155132,0.0039227046,0.00003203629,0.000008009204,0.0027344215],"genre_scores_gemma":[0.99554425,0.0021296488,0.00015335299,0.00013769642,0.0000387217,0.00018793062,0.000019471909,0.000010123725,0.0017787785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99813676,0.00017409574,0.0009249955,0.00032706896,0.00017645322,0.00026063444],"domain_scores_gemma":[0.99846107,0.00051638496,0.00044626114,0.0002906094,0.00021436973,0.00007132077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045884532,0.0001999507,0.0013121893,0.00037424217,0.00003382479,0.000007636811,0.00015597773,0.00008642686,0.000063984015],"category_scores_gemma":[0.00029930714,0.00015028653,0.00006326076,0.0005126462,0.000119444405,0.000080091886,0.00019911,0.00009669205,4.6478485e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50752074,0.06351173,0.072903104,0.0004852469,0.0014617775,0.00023674237,0.003822137,0.00003464145,0.0004179061,0.00012342451,0.0018795113,0.34760302],"study_design_scores_gemma":[0.78208554,0.17007783,0.032202967,0.00041712457,0.0008056481,0.000002753169,0.0018886323,0.00074791216,0.003880884,0.00007027834,0.0076548834,0.00016555873],"about_ca_topic_score_codex":0.0043721865,"about_ca_topic_score_gemma":0.0060211765,"teacher_disagreement_score":0.34743747,"about_ca_system_score_codex":0.00011285657,"about_ca_system_score_gemma":0.00037519704,"threshold_uncertainty_score":0.6609467},"labels":[],"label_agreement":null},{"id":"W4415941783","doi":"10.1016/j.annonc.2025.08.1767","title":"1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; Cancer Research UK; National Institute for Health and Care Research; Target Ovarian Cancer","keywords":"Ovarian cancer; Performance status; Karnofsky Performance Status; MEDLINE","score_opus":0.061236882447625346,"score_gpt":0.3932023316732281,"score_spread":0.3319654492256028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969165,0.0038905602,0.0000018819111,0.013635204,0.0005064073,0.0004012181,0.000021947391,0.0000084430985,0.012369337],"genre_scores_gemma":[0.9747313,0.023429407,0.00012741469,0.0011921254,0.00006567658,0.00014572659,0.000008085514,0.000008790641,0.00029144165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872965,0.00006461739,0.0004937858,0.00022118965,0.00014197126,0.00034879002],"domain_scores_gemma":[0.99907184,0.00018716912,0.00021869337,0.00029638095,0.00016589103,0.00006001149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039582877,0.00013701752,0.00050834264,0.00019326956,0.000050460276,0.0000038298763,0.00012453864,0.000099616715,0.00018215165],"category_scores_gemma":[0.000049358834,0.000095707954,0.00009309221,0.00041509522,0.0001377476,0.00006575531,0.000056078028,0.00020393741,0.0000052781243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006021843,0.00068414095,0.552421,0.00032600865,0.0002147762,0.000008632724,0.00060747407,0.00013261392,0.000116323565,0.000730237,0.0042054555,0.43995118],"study_design_scores_gemma":[0.0027635784,0.0028468377,0.8793767,0.0007823374,0.0001132791,0.000005355718,0.00012616935,0.00096543174,0.011969268,0.00006537536,0.100895956,0.000089707435],"about_ca_topic_score_codex":0.00055348413,"about_ca_topic_score_gemma":0.00041616624,"teacher_disagreement_score":0.43986148,"about_ca_system_score_codex":0.0001767518,"about_ca_system_score_gemma":0.0007855779,"threshold_uncertainty_score":0.39028573},"labels":[],"label_agreement":null},{"id":"W4415941792","doi":"10.1016/j.annonc.2025.08.2363","title":"1735TiP NETTER-3: A phase III study of [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, grade 1 and grade 2 (Ki-67&lt;10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Novartis","keywords":"Neuroendocrine tumors; Somatostatin; Somatostatin receptor; Disease; Phases of clinical research; Prospective cohort study; Progressive disease","score_opus":0.02369705343896458,"score_gpt":0.3585467326253535,"score_spread":0.33484967918638897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185735,0.00045757927,0.0000047416065,0.0051125577,0.00006043613,0.0023549395,0.00006155508,0.00003097186,0.000059850983],"genre_scores_gemma":[0.99806994,0.0005043985,0.00017817157,0.00073714607,0.00003356903,0.00017392825,0.00003927449,0.000039527622,0.00022402983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686307,0.00038270603,0.0008444153,0.0007017682,0.0004706525,0.0007373904],"domain_scores_gemma":[0.9979843,0.00043513475,0.00037846877,0.00052426005,0.00024198972,0.0004358821],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012282224,0.00037718276,0.0012574429,0.0006303849,0.00005882653,0.000013908235,0.00021989249,0.000010449993,0.000030959498],"category_scores_gemma":[0.0005297634,0.00031467972,0.00006430136,0.0004947406,0.00047263686,0.00023091055,0.0002764204,0.0003480239,9.634502e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04038805,0.014288979,0.89633507,0.0008895266,0.0003406782,0.019302897,0.00037044627,0.00022188544,0.0014236138,0.000047910165,0.0014038018,0.024987172],"study_design_scores_gemma":[0.0931453,0.049214777,0.8529378,0.000563989,0.0002738485,0.00013198868,0.0008227288,0.00012281562,0.0013492359,0.00020465348,0.0010002159,0.00023264524],"about_ca_topic_score_codex":0.0004621124,"about_ca_topic_score_gemma":0.00028990154,"teacher_disagreement_score":0.052757252,"about_ca_system_score_codex":0.00004124689,"about_ca_system_score_gemma":0.00015690485,"threshold_uncertainty_score":0.9999305},"labels":[],"label_agreement":null},{"id":"W4415941821","doi":"10.1016/j.annonc.2025.08.2832","title":"2215O HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: A phase Ib/II study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Gemcitabine; Mutant; Pancreatic cancer; Phases of clinical research; Mutation","score_opus":0.06342722265722689,"score_gpt":0.4641270690155586,"score_spread":0.4006998463583317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97366434,0.0021194685,0.000019456927,0.011184375,0.00006891109,0.0020957103,0.000026036334,0.000034174933,0.0107874945],"genre_scores_gemma":[0.99077123,0.0025914465,0.00055376656,0.0013712072,0.000038459813,0.0005195558,0.00001457071,0.000021793652,0.004117979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975309,0.00032846548,0.0007274551,0.0005064595,0.00029977533,0.0006069817],"domain_scores_gemma":[0.9980737,0.0006770632,0.00019090348,0.00044669874,0.00039772285,0.00021389384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009782265,0.00027564596,0.0017403469,0.00039595022,0.00012338291,0.0000067815495,0.00017068112,0.0002059908,0.00034987478],"category_scores_gemma":[0.00047157987,0.00021074532,0.00006618192,0.0007099046,0.0005049696,0.00009062098,0.00013167577,0.00044483985,0.0000060038856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032075237,0.015301181,0.7656301,0.00060997234,0.0016064026,0.0012374851,0.0038813164,0.000013278424,0.005267017,0.0008079395,0.0021120547,0.17145798],"study_design_scores_gemma":[0.1250879,0.18582849,0.65091264,0.0014606841,0.0016052213,0.00015381824,0.008066341,0.0017418705,0.0021169186,0.001452597,0.020980004,0.00059352873],"about_ca_topic_score_codex":0.0011723433,"about_ca_topic_score_gemma":0.0019424062,"teacher_disagreement_score":0.17086445,"about_ca_system_score_codex":0.00015612369,"about_ca_system_score_gemma":0.0012235697,"threshold_uncertainty_score":0.85939443},"labels":[],"label_agreement":null},{"id":"W4415941824","doi":"10.1016/j.annonc.2025.08.1826","title":"1191P Clinical outcome of vulvar cancer after surgery: Experience of the Centre Hospitalier de l’Université de Montréal (CHUM)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Berlin Institute of Health","keywords":"Vulvar cancer; Outcome (game theory); Cancer; MEDLINE; Vulvar Carcinoma","score_opus":0.06740710431552208,"score_gpt":0.4038468541998288,"score_spread":0.3364397498843067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698723,0.0022898896,0.000004210199,0.0076663806,0.0002706478,0.00015184954,0.000034579945,0.0000047715066,0.0025904414],"genre_scores_gemma":[0.9943045,0.001648532,0.00007446325,0.0022267567,0.0000406341,0.000012049139,0.0000014689875,0.0000048859224,0.0016867367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988993,0.000137884,0.00046678144,0.00014527749,0.00014080458,0.0002099783],"domain_scores_gemma":[0.99881256,0.0004878512,0.00022574088,0.00022533364,0.00016296208,0.00008555914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028669916,0.000085612024,0.00058871537,0.00007170274,0.000022929975,7.056952e-7,0.00012390706,0.00013999245,0.0005264469],"category_scores_gemma":[0.0003348733,0.000057142213,0.0003112936,0.00029396964,0.00024572844,0.000021003934,0.00011592414,0.00009811602,0.0000016497008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017252036,0.00048434842,0.9704237,0.0000694374,0.00021078011,0.00003052894,0.0006203361,0.0000021831274,0.00026477274,0.000060349597,0.0053726765,0.0207357],"study_design_scores_gemma":[0.0015962394,0.0003973955,0.96530944,0.000089232686,0.00015545484,0.0000026863477,0.0002670263,0.0000042880274,0.010636418,0.00009280023,0.021406343,0.000042654043],"about_ca_topic_score_codex":0.0023349081,"about_ca_topic_score_gemma":0.0011069061,"teacher_disagreement_score":0.020693045,"about_ca_system_score_codex":0.00013456019,"about_ca_system_score_gemma":0.00030819725,"threshold_uncertainty_score":0.57642245},"labels":[],"label_agreement":null},{"id":"W4415941839","doi":"10.1016/j.annonc.2025.08.3301","title":"2690MO Extended efficacy and safety from the phase III MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour (TGCT)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Placebo; Phases of clinical research; Clinical trial; Cell; Giant Cell Tumors","score_opus":0.02228688797440259,"score_gpt":0.3314282913446074,"score_spread":0.3091414033702048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99024683,0.00013983954,0.000007766691,0.0016875989,0.00017471005,0.0011821863,0.00009615609,0.000007560113,0.006457356],"genre_scores_gemma":[0.998726,0.000130078,0.000090863934,0.00064367603,0.000063279265,0.000017232755,0.000091493624,0.000009874282,0.00022750301],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99863553,0.0001332661,0.00056274096,0.00024149167,0.00018916624,0.00023781398],"domain_scores_gemma":[0.9989475,0.00036694633,0.00024895024,0.00024142333,0.00012519017,0.00006998524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021256851,0.00016467305,0.00066532416,0.00008565319,0.000044840537,0.0000037445652,0.00010499892,0.0001208643,0.00010602559],"category_scores_gemma":[0.00007650356,0.00009854516,0.0000901252,0.00016018297,0.00020752467,0.000044172164,0.000081540275,0.00016121159,0.000002142491],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6880356,0.02933413,0.053149156,0.000261574,0.001009936,0.00012371388,0.0013002768,0.000007105824,0.0015240237,0.0011410362,0.002864223,0.22124924],"study_design_scores_gemma":[0.3813362,0.019402973,0.58910424,0.00017996957,0.00026804715,0.0000016857849,0.00017871353,0.000011688868,0.0026808218,0.00019936077,0.006516576,0.00011971809],"about_ca_topic_score_codex":0.0012699619,"about_ca_topic_score_gemma":0.00016113262,"teacher_disagreement_score":0.5359551,"about_ca_system_score_codex":0.00003127849,"about_ca_system_score_gemma":0.00020041046,"threshold_uncertainty_score":0.4018555},"labels":[],"label_agreement":null},{"id":"W4415941875","doi":"10.1016/j.annonc.2025.08.1681","title":"1040P Outcomes of male patients with relapsed/refractory germ cell tumors treated with tandem high-dose chemotherapy and autologous stem cell transplantation: Princess Margaret Cancer Centre 16 year experience","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Germ cell tumors; Chemotherapy; Stem cell; Salvage therapy; Germ cell; Autologous stem-cell transplantation","score_opus":0.014297083793025335,"score_gpt":0.29598742610109846,"score_spread":0.2816903423080731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972857,0.0007228988,0.000012775066,0.000352715,0.000028402677,0.00047447946,0.000081166705,0.000022423277,0.0010193896],"genre_scores_gemma":[0.9975578,0.0005554221,0.00019301675,0.00029730264,0.000005431084,0.00003148834,0.00004727918,0.00001540609,0.001296857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908346,0.00004964324,0.00025119068,0.0002579478,0.0001669444,0.00019083366],"domain_scores_gemma":[0.9991857,0.00008349213,0.0002714495,0.00018028758,0.00018228235,0.00009677796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030595875,0.00017372801,0.00050323515,0.000076235076,0.000034195928,0.000003603833,0.000064455766,0.000089821144,0.00010691969],"category_scores_gemma":[0.0000035135213,0.000114120274,0.00004567161,0.00013784044,0.00017092681,0.000052719843,0.000010808153,0.00006950161,8.777536e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002115845,0.0014615313,0.9870623,0.0002760793,0.0002094036,0.00013131644,0.00066477584,0.0000071409245,0.00007130572,0.000020301246,0.00012075024,0.007859288],"study_design_scores_gemma":[0.009750793,0.002429143,0.97865564,0.00019404881,0.00027246578,0.000005932484,0.00032177276,0.000003103191,0.007856706,0.000005965452,0.00040270365,0.00010172569],"about_ca_topic_score_codex":0.0003293401,"about_ca_topic_score_gemma":0.00008714613,"teacher_disagreement_score":0.008406622,"about_ca_system_score_codex":0.000053229713,"about_ca_system_score_gemma":0.00026496052,"threshold_uncertainty_score":0.465369},"labels":[],"label_agreement":null},{"id":"W4415941891","doi":"10.1016/j.annonc.2025.08.2101","title":"1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Atezolizumab; Ipilimumab; Bevacizumab; Systemic therapy; Hepatocellular carcinoma; Nivolumab; Immunotherapy","score_opus":0.08403274616397495,"score_gpt":0.3161995178664331,"score_spread":0.23216677170245814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850431,0.003087938,0.000033495497,0.0031355994,0.00022037607,0.004667285,0.00007156023,0.000076240365,0.0036643737],"genre_scores_gemma":[0.99611634,0.00061647,0.00021326367,0.00092513365,0.000083588275,0.00085783616,0.00027792418,0.00008063355,0.0008288217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953821,0.00043251918,0.0013897772,0.0010137066,0.000603671,0.0011782493],"domain_scores_gemma":[0.9975729,0.000328164,0.0003736238,0.0008568404,0.00056005194,0.000308393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092224014,0.0006367948,0.001973352,0.0014331803,0.0001457368,0.00003195003,0.00045635857,0.00053630135,0.0001547413],"category_scores_gemma":[0.0002217925,0.0005364309,0.0002574733,0.0020251537,0.00014301366,0.00020930755,0.00018652124,0.00055207615,0.000052983396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016698891,0.0023876869,0.9553304,0.000751946,0.00030880596,0.0008763859,0.0016403304,0.0000929396,0.00051084126,0.00013710435,0.0012078339,0.020056859],"study_design_scores_gemma":[0.1787687,0.06826163,0.5996716,0.008040512,0.0005993713,0.0002200172,0.0014550486,0.010836208,0.06832793,0.00038421547,0.061076444,0.0023583486],"about_ca_topic_score_codex":0.0019803508,"about_ca_topic_score_gemma":0.0011152508,"teacher_disagreement_score":0.3556588,"about_ca_system_score_codex":0.0010571217,"about_ca_system_score_gemma":0.0012227629,"threshold_uncertainty_score":0.9997087},"labels":[],"label_agreement":null},{"id":"W4415941907","doi":"10.1016/j.annonc.2025.08.1699","title":"1060P Efficacy and safety of immune checkpoint blockade (ICB) in locally advanced or metastatic penile cancer (la/mPC): A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blockade; Penile cancer; Immune checkpoint; Chemotherapy; Malignancy; Immunotherapy; Nivolumab","score_opus":0.1656660338999495,"score_gpt":0.49484148804310196,"score_spread":0.32917545414315247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026874643,0.99222964,0.000007406845,0.0013368707,0.00002055145,0.0057936576,0.00026112454,0.00001220984,0.00031163925],"genre_scores_gemma":[0.0010747914,0.9956006,0.0003021926,0.0009016471,0.0000067264937,0.0011671928,0.00006960565,0.00002884308,0.00084844267],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99424607,0.0012210805,0.0034078555,0.00050711195,0.00025716634,0.00036073235],"domain_scores_gemma":[0.99474955,0.0021454147,0.0018099587,0.00062929845,0.00034230182,0.00032346454],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020011724,0.00047431895,0.016331842,0.000629602,0.000024249168,0.000004284705,0.00018305097,0.00023149593,0.00025698036],"category_scores_gemma":[0.0023172665,0.0002884114,0.0016756346,0.0013187552,0.00018567656,0.00003951579,0.00013197264,0.00034451723,0.0000024203098],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038330822,0.0003963075,0.0000011686699,0.94473696,0.024314934,0.000089459536,0.00004548375,0.000002177746,4.1049628e-7,0.000015688795,0.00004550753,0.029968621],"study_design_scores_gemma":[0.0017461882,0.001165506,0.000034749522,0.07862387,0.8906128,0.00008740711,0.00004169367,0.0000055072574,0.0000028039526,0.000018044148,0.02742859,0.00023287626],"about_ca_topic_score_codex":0.0001984428,"about_ca_topic_score_gemma":0.00021430558,"teacher_disagreement_score":0.86629784,"about_ca_system_score_codex":0.0000667699,"about_ca_system_score_gemma":0.0025890225,"threshold_uncertainty_score":0.9999568},"labels":[],"label_agreement":null},{"id":"W4415941912","doi":"10.1016/j.annonc.2025.08.2361","title":"1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seneca Polytechnic","funders":"","keywords":"Nivolumab; Ipilimumab; Oncolytic virus; Neuroendocrine tumors; Neuroendocrine carcinoma; Immunotherapy; Virus","score_opus":0.026847573356151986,"score_gpt":0.3319454593582296,"score_spread":0.3050978860020776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743956,0.000107230764,0.000003895742,0.00082287745,0.00008874869,0.0014049087,0.000050319097,0.000007430842,0.00007505232],"genre_scores_gemma":[0.9990793,0.0001701262,0.000007981242,0.00024574916,0.000013647709,0.00007788751,0.00015607695,0.000028223458,0.00022101],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976393,0.0006112734,0.0005782283,0.00046084705,0.00027422886,0.00043613146],"domain_scores_gemma":[0.9988672,0.00008790905,0.00029677246,0.00044804876,0.0002289719,0.00007108259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013975943,0.00026111543,0.00056573696,0.00033362518,0.000050837232,0.000011592503,0.0003364707,0.000061438994,0.000021162323],"category_scores_gemma":[0.000119134595,0.00017611108,0.000063131265,0.00063962105,0.0003150852,0.000011713013,0.00018412665,0.00027612597,4.5236342e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7480256,0.018923981,0.10733129,0.00020388242,0.0002995246,0.0001619044,0.00010142079,0.00010498357,0.11141825,0.000032533968,0.0007294127,0.012667249],"study_design_scores_gemma":[0.31060255,0.110607766,0.23441891,0.0001231447,0.0000748174,0.00001868999,0.000050472976,0.00032724193,0.34279606,0.00005772806,0.0006432149,0.00027939],"about_ca_topic_score_codex":0.00039776298,"about_ca_topic_score_gemma":0.0053437897,"teacher_disagreement_score":0.43742302,"about_ca_system_score_codex":0.000039579132,"about_ca_system_score_gemma":0.00039722156,"threshold_uncertainty_score":0.7181601},"labels":[],"label_agreement":null},{"id":"W4415941930","doi":"10.1016/j.annonc.2025.08.2895","title":"2279MO Discontinuation and attrition rates in phase II or phase III first-line randomized clinical trials (RCTs) of solid tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Discontinuation; Attrition; Randomized controlled trial; Clinical trial; Phases of clinical research; Cancer","score_opus":0.768843418923632,"score_gpt":0.7129977182229175,"score_spread":0.055845700700714485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8395521,0.0004563254,0.14149305,0.011742777,0.0010300825,0.0042291246,0.00043528643,0.000041887917,0.0010193367],"genre_scores_gemma":[0.84962076,0.002764267,0.14579742,0.00077335985,0.00032215813,0.00027040037,0.000022501838,0.000025120256,0.00040402147],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.979111,0.012554857,0.0073652887,0.00044351723,0.00022649896,0.00029881689],"domain_scores_gemma":[0.6390716,0.35734105,0.002671039,0.0003526798,0.00044469358,0.00011893284],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07251871,0.00022455925,0.005616134,0.00028888325,0.00005739608,0.000008224742,0.00020040316,0.00042871956,0.0003027393],"category_scores_gemma":[0.61204827,0.0001600627,0.00046697204,0.0003740276,0.00085354043,0.000086760054,0.00014957647,0.00032265592,0.0000014315161],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42553484,0.01681389,0.000076869306,0.0005072787,0.00063445646,0.00003778383,0.000346082,0.000005277081,0.0010643329,0.05244207,0.0072549796,0.49528214],"study_design_scores_gemma":[0.3863232,0.0064726556,0.0000345883,0.0005198001,0.00039971588,0.0000019293316,0.000081501545,0.001829619,0.008951723,0.59465367,0.00060040894,0.00013118524],"about_ca_topic_score_codex":0.000031046122,"about_ca_topic_score_gemma":0.00007892846,"teacher_disagreement_score":0.5422116,"about_ca_system_score_codex":0.000019968173,"about_ca_system_score_gemma":0.00028084972,"threshold_uncertainty_score":0.9550372},"labels":[],"label_agreement":null},{"id":"W4415941950","doi":"10.1016/j.annonc.2025.08.2900","title":"2284MO The human crisis in oncology education: Insights from a global survey","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"MEDLINE; Clinical Oncology; Radiation oncology","score_opus":0.07331270014582228,"score_gpt":0.5165162564276123,"score_spread":0.4432035562817901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8272927,0.00895387,0.00019417383,0.056964755,0.0018443431,0.0004652622,0.000028191635,0.000025107509,0.10423162],"genre_scores_gemma":[0.9591029,0.0014092445,0.00081723696,0.037514437,0.00031191882,0.000061517596,0.00006356571,0.000007504838,0.0007116569],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817413,0.00069241243,0.00050913455,0.0002952827,0.00009936653,0.00022967563],"domain_scores_gemma":[0.99797994,0.0010901517,0.00020320431,0.00040941898,0.00025501376,0.00006228141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005107249,0.00014135358,0.00065747637,0.00013158543,0.00009918685,0.000003143045,0.0002792465,0.00041973963,0.00019595277],"category_scores_gemma":[0.00032206508,0.00009990311,0.00009441277,0.0005437767,0.00045346917,0.000052946118,0.000062753876,0.0003389306,0.00001483123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018030226,0.00459001,0.36029002,0.000038701688,0.00051371177,0.00009998638,0.0013653063,0.000020990885,0.0006399864,0.035662986,0.3055779,0.28939736],"study_design_scores_gemma":[0.0015049151,0.001437931,0.4727158,0.000037521007,0.00003578769,0.000016673615,0.0006278643,0.0000062472986,0.00020771,0.024204222,0.49913505,0.000070267946],"about_ca_topic_score_codex":0.0017620039,"about_ca_topic_score_gemma":0.0077100047,"teacher_disagreement_score":0.28932709,"about_ca_system_score_codex":0.00030226444,"about_ca_system_score_gemma":0.0020554443,"threshold_uncertainty_score":0.43023637},"labels":[],"label_agreement":null},{"id":"W4415941962","doi":"10.1016/j.annonc.2025.08.2834","title":"2217P Randomized phase II study of NaliCap compared to NAPOLI-1 in gemcitabine-pretreated advanced pancreatic cancer: PC-NaliCap study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; Micropalaeontological Society; American Society of Clinical Oncology; Bamfield Marine Sciences Centre","keywords":"Capecitabine; Gemcitabine; Irinotecan; Pancreatic cancer; Phases of clinical research; Fluorouracil; Pancreatic disease; Randomized controlled trial","score_opus":0.10041806440490636,"score_gpt":0.5045507359280952,"score_spread":0.4041326715231888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790615,0.0009831721,0.000033557477,0.0036797025,0.00013785643,0.0075763,0.00003308079,0.00003760078,0.008457246],"genre_scores_gemma":[0.9950137,0.00045053355,0.0002782228,0.0008797077,0.00004195573,0.0015850045,0.000019221347,0.000023290553,0.0017083779],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99492294,0.0015284836,0.0018016289,0.00059947424,0.000497731,0.0006497729],"domain_scores_gemma":[0.99603516,0.0016328486,0.00045938234,0.00074395037,0.0008560805,0.00027257754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002356324,0.00033965157,0.004476204,0.0010337573,0.0001049416,0.00000498425,0.00038709445,0.00020939237,0.00040414016],"category_scores_gemma":[0.0019393031,0.00027637457,0.00021709212,0.0015047108,0.00037674836,0.000062391286,0.00026653957,0.0003961323,0.000008912534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46758738,0.073537216,0.3888868,0.00046118847,0.0054920367,0.00034059852,0.018778984,0.00015968752,0.0112160975,0.00028958867,0.0050917435,0.028158683],"study_design_scores_gemma":[0.77935266,0.071435,0.12613907,0.000680499,0.002294624,0.000012899336,0.013132769,0.001752178,0.002796109,0.0003036136,0.0017347566,0.00036579056],"about_ca_topic_score_codex":0.0064084437,"about_ca_topic_score_gemma":0.002398159,"teacher_disagreement_score":0.3117653,"about_ca_system_score_codex":0.00019457853,"about_ca_system_score_gemma":0.0010548057,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W4415941986","doi":"10.1016/j.annonc.2025.08.1065","title":"643eP The association of circulating tumor cells with body mass index, body composition and blood biomarkers in patients with newly diagnosed metastatic breast cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Cancer Care South East; Mount Sinai Hospital; Princess Margaret Cancer Centre; Western University; University of Toronto; Hôpital Charles-Le Moyne; Kingston Health Sciences Centre; McGill University Health Centre; Northeast Cancer Centre; Sunnybrook Health Science Centre; Royal Victoria Regional Health Centre; Occupational Cancer Research Centre","funders":"Breast Cancer Society of Canada","keywords":"Metastatic breast cancer; Circulating tumor cell; Body mass index; Breast cancer; CA15-3; Cancer","score_opus":0.013060702960973069,"score_gpt":0.3057853490896522,"score_spread":0.29272464612867916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972521,0.000111171954,0.000031906886,0.0017072891,0.000049377024,0.00047391368,0.00008727629,0.0000052892055,0.00028167054],"genre_scores_gemma":[0.99927527,0.000066485976,0.00009068304,0.00048709827,0.00001166802,0.000028497769,0.000022157541,0.000008124985,0.000010019361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991251,0.00009829974,0.00028129166,0.00014819727,0.0001866475,0.00016042686],"domain_scores_gemma":[0.9990046,0.00024355017,0.0003799024,0.0001041252,0.00023192188,0.00003592105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024054539,0.000098684504,0.00038204822,0.0001325876,0.000031310447,0.0000053679923,0.00004234708,0.000048310263,0.000014697168],"category_scores_gemma":[0.000021866417,0.00006383873,0.000031187683,0.00028960247,0.00008650133,0.00005266933,0.000015226191,0.00011411383,1.2288949e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012016591,0.00049547164,0.9895352,0.00011210957,0.000668191,0.000013430573,0.00022620056,0.00012999112,0.0039554155,0.000021679723,0.00016281116,0.0034778109],"study_design_scores_gemma":[0.006668568,0.0011013446,0.9891023,0.0002709068,0.0003518051,0.0000029381167,0.00020687537,0.00020349679,0.0019400346,0.000021296928,0.000068282505,0.00006215868],"about_ca_topic_score_codex":0.0025678165,"about_ca_topic_score_gemma":0.00066137273,"teacher_disagreement_score":0.005466909,"about_ca_system_score_codex":0.00009081891,"about_ca_system_score_gemma":0.00023550852,"threshold_uncertainty_score":0.38817877},"labels":[],"label_agreement":null},{"id":"W4415941999","doi":"10.1016/j.annonc.2025.08.2366","title":"1738eTiP IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy (domvanalimab + zimberelimab) in patients with advanced rare cancers: The neuroendocrine tumors cohort","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pembrolizumab; University hospital; Immunotherapy; Phases of clinical research; Clinical trial; ABX test","score_opus":0.034081067964845904,"score_gpt":0.38446607638903485,"score_spread":0.35038500842418896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96819454,0.0009622769,0.000008867509,0.026672399,0.0001013484,0.0032332884,0.00023955922,0.000009202004,0.0005784867],"genre_scores_gemma":[0.9968356,0.0017448411,0.000017179753,0.0010780201,0.000014022171,0.000037474747,0.000028053868,0.000015180769,0.00022965425],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99711674,0.00083710474,0.0008070345,0.0002945135,0.00059079536,0.0003538275],"domain_scores_gemma":[0.9946657,0.0033774162,0.00072948984,0.00044242732,0.0007311706,0.00005381269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011618183,0.00021428474,0.0009710387,0.00017282946,0.00021150569,0.0000056526364,0.0006906216,0.000023061519,0.00002415929],"category_scores_gemma":[0.002599695,0.00009899809,0.0001578889,0.0010226478,0.0011388374,0.00014607883,0.00032526665,0.0006197177,2.2699565e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6149984,0.007850002,0.21771996,0.0004738883,0.0037676962,0.00023444988,0.0027836964,0.002387486,0.013565412,0.0073799207,0.02236845,0.106470674],"study_design_scores_gemma":[0.16752149,0.026026234,0.6959658,0.00096907903,0.0004209401,0.000080014666,0.0030087926,0.00016798734,0.031366635,0.00058768207,0.07349734,0.00038799236],"about_ca_topic_score_codex":0.00037880856,"about_ca_topic_score_gemma":0.000071726856,"teacher_disagreement_score":0.47824585,"about_ca_system_score_codex":0.00016627027,"about_ca_system_score_gemma":0.00079137116,"threshold_uncertainty_score":0.4196094},"labels":[],"label_agreement":null},{"id":"W4415942041","doi":"10.1016/j.annonc.2025.08.2073","title":"1442TiP Peri-radiotherapy immunotherapy in undifferentiated sinonasal cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for Oil Sands Innovation, University of Alberta; Cliniques Universitaires Saint-Luc; Humanitas Research Hospital; Universitätsspital Zürich; Universitair Ziekenhuis Gent; Humanitas University; Associazione Italiana di Oncologia Medica; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Université Catholique de Louvain; Pfizer","keywords":"Immunotherapy; Cancer immunotherapy; Cancer; Chemotherapy; Radiation therapy","score_opus":0.0690414009109452,"score_gpt":0.4472896040622778,"score_spread":0.3782482031513326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753704,0.00530757,0.000072381976,0.007976064,0.0002949111,0.00022366502,0.000021172327,0.000023499406,0.0107103465],"genre_scores_gemma":[0.9893472,0.0024496762,0.00013131826,0.006264744,0.000060562183,0.000041497144,0.000021821132,0.0000117006375,0.0016714463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991855,0.000074466436,0.00029285587,0.0001582912,0.000082393846,0.00020649817],"domain_scores_gemma":[0.9994839,0.00010267342,0.000075120646,0.00016733204,0.00013177673,0.00003923743],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012834811,0.00009979914,0.0004173009,0.0002953279,0.00003129516,0.000004155628,0.00007786586,0.0001525344,0.0013962864],"category_scores_gemma":[0.000023876433,0.0000898586,0.00010056197,0.00035950198,0.000113338596,0.000033993034,0.000012671216,0.00015662736,0.000004057949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00298303,0.0027405233,0.5180235,0.00013522217,0.0010305188,0.0001869409,0.0011725856,0.000021566591,0.18659489,0.010263995,0.044660687,0.23218653],"study_design_scores_gemma":[0.003689993,0.001175639,0.9240395,0.00013673899,0.000024349194,0.000011550383,0.00007315585,0.000067418965,0.0072128237,0.000426815,0.063052006,0.000090018824],"about_ca_topic_score_codex":0.000574768,"about_ca_topic_score_gemma":0.00035984945,"teacher_disagreement_score":0.406016,"about_ca_system_score_codex":0.00007913982,"about_ca_system_score_gemma":0.0004276883,"threshold_uncertainty_score":0.99951655},"labels":[],"label_agreement":null},{"id":"W4415942047","doi":"10.1016/j.annonc.2025.08.1517","title":"948P Cancer Research UK first-in-human (FIH) phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 (HTL) as monotherapy and in combination with immunotherapy in patients with advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development","funders":"","keywords":"Antagonist; Immunotherapy; Blockade; Prostaglandin E2; Immune system; Receptor; Receptor antagonist; Cancer immunotherapy","score_opus":0.028430566526316692,"score_gpt":0.41442178721213385,"score_spread":0.38599122068581715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932692,0.00024700523,0.0000010360426,0.0031325745,0.00017174198,0.0027973286,0.0000134547145,0.0000058970477,0.00036174743],"genre_scores_gemma":[0.9984171,0.0007260897,0.000026669146,0.00033602753,0.000030801348,0.00031346286,0.000018489138,0.00002067705,0.000110696245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981121,0.00038697143,0.00052119186,0.00027887616,0.0003441001,0.0003567671],"domain_scores_gemma":[0.99880934,0.00026264714,0.00026715378,0.00026146282,0.00034881322,0.000050612107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011184133,0.00016849804,0.0006540373,0.0004604105,0.00008072796,0.000007285021,0.00013520733,0.00015671279,0.000036240614],"category_scores_gemma":[0.00013833701,0.00011108984,0.000037958413,0.00064071355,0.00037182576,0.00007578935,0.000029156363,0.00037763442,4.6415101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26964396,0.0045632254,0.6964986,0.0002400801,0.00009844572,0.000025155834,0.0026438872,0.000031859618,0.0106345555,0.0005413554,0.0004260877,0.014652788],"study_design_scores_gemma":[0.304047,0.0356703,0.59599674,0.0013231529,0.000018520957,0.0000014116026,0.00034764037,0.00003543228,0.060052097,0.0003147491,0.0020069373,0.00018604926],"about_ca_topic_score_codex":0.0011402433,"about_ca_topic_score_gemma":0.003993234,"teacher_disagreement_score":0.100501865,"about_ca_system_score_codex":0.00019313152,"about_ca_system_score_gemma":0.0006011516,"threshold_uncertainty_score":0.4530112},"labels":[],"label_agreement":null},{"id":"W4415942060","doi":"10.1016/j.annonc.2025.08.797","title":"372P A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Aromatase inhibitor; Breast cancer; Adjuvant; Aromatase; Cancer; Letrozole","score_opus":0.048406500609201604,"score_gpt":0.39043368077632307,"score_spread":0.34202718016712147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905254,0.0010377561,0.0005449462,0.0039411946,0.00017039187,0.0018603025,0.0011159447,0.00008393623,0.000720102],"genre_scores_gemma":[0.9960627,0.00046447737,0.0011526969,0.0008163023,0.00009127141,0.0004482715,0.0002683436,0.000056901317,0.000639055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724865,0.00025913632,0.00060339714,0.0009167801,0.0003799486,0.0005920871],"domain_scores_gemma":[0.9980991,0.00029715008,0.0003300412,0.00071382156,0.0002970374,0.00026284938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042460824,0.00046322637,0.0011174995,0.00046191155,0.00010168845,0.000017816796,0.0002742287,0.00014521331,0.00003321885],"category_scores_gemma":[0.00009980267,0.0003507585,0.00006750954,0.0006590261,0.00029374316,0.0002531003,0.00019566489,0.00042868534,0.000002930412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021304777,0.0010655669,0.7344514,0.00029818586,0.00036688783,0.00006844962,0.0008055411,0.002246943,0.00066228415,0.00003136734,0.00025815514,0.23844044],"study_design_scores_gemma":[0.038584106,0.032031767,0.8649472,0.0056333626,0.0006704915,0.000037278092,0.000163986,0.035688404,0.0043371343,0.00017148432,0.016753323,0.0009814353],"about_ca_topic_score_codex":0.0057699503,"about_ca_topic_score_gemma":0.01237186,"teacher_disagreement_score":0.237459,"about_ca_system_score_codex":0.0005730047,"about_ca_system_score_gemma":0.00077180495,"threshold_uncertainty_score":0.99989444},"labels":[],"label_agreement":null},{"id":"W4415942079","doi":"10.1016/j.annonc.2025.08.2701","title":"2080eTiP A phase I/IIa, open-label, dose-finding study of the safety, pharmacokinetics, and preliminary efficacy of iza-bren (BL-B01D1) combinations in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Lung cancer; Conjugate; Solid tumor; Phases of clinical research; Monoclonal antibody; Response Evaluation Criteria in Solid Tumors; Antibody; Cancer","score_opus":0.1152148650888674,"score_gpt":0.5120847254551094,"score_spread":0.396869860366242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103296,0.00027301227,0.0000045336783,0.0030927083,0.00009637133,0.0030203278,0.00004259436,0.0000064433843,0.0024310448],"genre_scores_gemma":[0.9990988,0.00020784378,0.00013856252,0.00025363849,0.000009149861,0.00008577386,0.000013847579,0.000017557495,0.00017485583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800223,0.00033103552,0.00071515,0.00029491945,0.0003701906,0.00028649755],"domain_scores_gemma":[0.99806666,0.0005334409,0.00035212422,0.0004139855,0.0005530318,0.00008074339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066024304,0.00014738232,0.0007181404,0.0003427414,0.00006429161,0.0000053231124,0.00044894769,0.000075855525,0.00003949536],"category_scores_gemma":[0.0004984924,0.00011138336,0.000028660983,0.0007872551,0.00034713998,0.0000763857,0.0005361489,0.00030598903,5.9191126e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04371827,0.10908404,0.48739463,0.0010942648,0.00089124934,0.00006813891,0.0076941852,0.0003904246,0.0069754007,0.00045772537,0.0049302313,0.33730146],"study_design_scores_gemma":[0.10118171,0.05226992,0.83186597,0.0010502478,0.00017589086,0.0000034784582,0.0010234631,0.0001882229,0.010460791,0.000110183,0.0015357283,0.00013441606],"about_ca_topic_score_codex":0.00020254105,"about_ca_topic_score_gemma":0.00008728536,"teacher_disagreement_score":0.34447134,"about_ca_system_score_codex":0.000077951234,"about_ca_system_score_gemma":0.00060257065,"threshold_uncertainty_score":0.45420814},"labels":[],"label_agreement":null},{"id":"W4415942084","doi":"10.1016/j.annonc.2025.08.571","title":"137P OST: An immune-related adverse event (irAE) grading tool and its prognostic value in cancer patients","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Grading (engineering); Cancer; Value (mathematics); Event (particle physics); Adverse effect","score_opus":0.03860606023844163,"score_gpt":0.3777800509033372,"score_spread":0.33917399066489556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894837,0.006151338,0.0000011543387,0.002167986,0.00035754172,0.0006964847,0.000013672534,0.000015730133,0.0011123931],"genre_scores_gemma":[0.9959746,0.0024337955,0.00002055607,0.0011568969,0.000017284694,0.000060721293,0.00002398967,0.00000968992,0.00030245126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987588,0.000109463894,0.00057647895,0.00021507451,0.00010670615,0.00023345875],"domain_scores_gemma":[0.99940944,0.000105358915,0.00017348363,0.00012879768,0.00013567509,0.000047220197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041393618,0.000119297,0.0003645907,0.00021129868,0.000037203747,0.0000027559613,0.00007272289,0.00015808131,0.00008608835],"category_scores_gemma":[0.00014609264,0.00010722171,0.00009142058,0.0003128057,0.000079227255,0.000086742104,0.000038417787,0.00014952806,0.0000020734883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009766146,0.002950949,0.48663774,0.0005131949,0.00083431485,0.00007888904,0.0023943079,0.000077733304,0.0366672,0.001059611,0.0012928735,0.45772702],"study_design_scores_gemma":[0.011682449,0.004255554,0.958836,0.00076850253,0.00011766637,0.000008156907,0.00020195763,0.00058748125,0.009429067,0.00023167416,0.013715733,0.00016571312],"about_ca_topic_score_codex":0.000499019,"about_ca_topic_score_gemma":0.00010298996,"teacher_disagreement_score":0.47219828,"about_ca_system_score_codex":0.00010590172,"about_ca_system_score_gemma":0.0003089055,"threshold_uncertainty_score":0.43723744},"labels":[],"label_agreement":null},{"id":"W4415942102","doi":"10.1016/j.annonc.2025.08.3292","title":"2681eP Real-world comparison of immunotherapy (IO)-based combinations in intermediate/poor-(int/poor-) risk patients (pts) with non-clear cell Renal Cell Carcinoma (nccRCC): The ARON-1 multicenter experience","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Renal cell carcinoma; Immunotherapy; Kidney cancer; Multicenter study; Carcinoma; Kidney disease","score_opus":0.0312523321001368,"score_gpt":0.3467426834120145,"score_spread":0.3154903513118777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98419625,0.0004382504,0.000069352005,0.0009384078,0.0001912391,0.001209418,0.000032772463,0.000016347116,0.01290797],"genre_scores_gemma":[0.99780774,0.00026671932,0.0003911731,0.00073649496,0.000020481817,0.00015616148,0.000067270346,0.000031606876,0.00052234845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973544,0.00037650185,0.0009910754,0.00043705947,0.00039576416,0.00044521882],"domain_scores_gemma":[0.99739134,0.00061197137,0.00075695023,0.00064638053,0.00048418163,0.00010920222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034728748,0.00032084988,0.0009250965,0.00049919635,0.00009580852,0.00001028795,0.00037818844,0.00015771427,0.00009308686],"category_scores_gemma":[0.000052389623,0.00022270661,0.00020520348,0.00056394003,0.00053725444,0.00007355808,0.000094822215,0.0004640194,0.000013786256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050801095,0.008314348,0.96433806,0.00018544027,0.0001135859,0.000047032805,0.0048377616,0.00021658206,0.006396373,0.0000226193,0.0030186335,0.0074294745],"study_design_scores_gemma":[0.01478235,0.00911223,0.74717164,0.00022968996,0.00012799441,8.264166e-7,0.0012640939,0.001970411,0.22306186,0.000018171278,0.0020916092,0.00016912745],"about_ca_topic_score_codex":0.0028397723,"about_ca_topic_score_gemma":0.0013230976,"teacher_disagreement_score":0.2171664,"about_ca_system_score_codex":0.00025493946,"about_ca_system_score_gemma":0.00040820535,"threshold_uncertainty_score":0.90817124},"labels":[],"label_agreement":null},{"id":"W4415942115","doi":"10.1016/j.annonc.2025.08.2705","title":"2084eTiP A phase III study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard of care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Università degli Studi di Perugia; Istituto Oncologico Veneto; Sapienza Università di Roma; Università degli Studi di Padova","keywords":"Standard of care; Chemotherapy; Chemotherapy regimen; Immunotherapy; Immune checkpoint; Clinical trial","score_opus":0.058893868294680976,"score_gpt":0.4324994319029268,"score_spread":0.3736055636082458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908854,0.002169968,0.0000053084177,0.002094514,0.00018039801,0.0051665865,0.000068771464,0.000023481418,0.0012024423],"genre_scores_gemma":[0.9984674,0.0004403227,0.000499367,0.00006079207,0.000039837632,0.00032043108,0.00006654898,0.00003400786,0.0000713009],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962277,0.00038065965,0.0015132963,0.00054913573,0.000720847,0.0006083553],"domain_scores_gemma":[0.99733233,0.00033962072,0.0006200471,0.00061028963,0.0009532182,0.00014451859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007314429,0.00036948523,0.0020031887,0.00074940093,0.000047706264,0.0000072879106,0.00026682008,0.00025806346,0.000056662906],"category_scores_gemma":[0.00037736824,0.000288196,0.00018246408,0.0011256109,0.00051102997,0.000112209585,0.00010302018,0.00044153936,8.2442995e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8657895,0.014360773,0.004110852,0.00058281,0.0007803953,0.00057005015,0.0055458266,0.000020580032,0.058521718,0.00008629647,0.000038804155,0.04959241],"study_design_scores_gemma":[0.51478416,0.15111768,0.009398299,0.0011566284,0.00012000374,0.0000036451952,0.00673386,0.000027637747,0.31606787,0.000035444747,0.0003727762,0.00018202046],"about_ca_topic_score_codex":0.00094364194,"about_ca_topic_score_gemma":0.002444865,"teacher_disagreement_score":0.35100535,"about_ca_system_score_codex":0.00040206403,"about_ca_system_score_gemma":0.0017111233,"threshold_uncertainty_score":0.999957},"labels":[],"label_agreement":null},{"id":"W4415942153","doi":"10.1016/j.annonc.2025.08.3374","title":"2763P Treatment patterns and outcomes of clinical stage I small cell lung cancer (SCLC) in the Canadian SCLC database (CASCADE)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Ottawa Regional Cancer Foundation; CancerCare Manitoba; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Ottawa","funders":"","keywords":"Stage (stratigraphy); Radiation therapy; Small Cell Lung Carcinoma; Chemotherapy; Prophylactic cranial irradiation; Modalities; Stereotactic radiotherapy","score_opus":0.21553980894216113,"score_gpt":0.5431567617882272,"score_spread":0.3276169528460661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546331,0.003386877,0.000002712316,0.033438377,0.00013625529,0.00069421023,0.00033167205,0.0000041397225,0.007372657],"genre_scores_gemma":[0.9859868,0.008516134,0.000059164595,0.0037510006,0.000048817346,0.00009814013,0.000017214084,0.0000070656833,0.0015156543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847394,0.00025548594,0.0005368125,0.00023944429,0.0001600387,0.00033428264],"domain_scores_gemma":[0.9984192,0.0008323347,0.0001361836,0.00033594403,0.0001409045,0.00013539386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094724423,0.00012328084,0.0007329828,0.00020870658,0.000049890885,0.0000046774967,0.0001538747,0.00011158062,0.000066465494],"category_scores_gemma":[0.0003075296,0.000075524884,0.00009466126,0.00015653239,0.00024179039,0.000027248314,0.00009045426,0.00024062555,8.4377007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018886133,0.00040723,0.9709046,0.00032142785,0.00032995795,0.0001253196,0.0011990167,0.000002445829,0.000040507646,0.00012479769,0.005629266,0.020726608],"study_design_scores_gemma":[0.002815292,0.0014328817,0.93765885,0.00013805396,0.00013723262,0.0000012975119,0.00092979474,0.000046130936,0.0012970174,0.0000120506875,0.055471387,0.000060009126],"about_ca_topic_score_codex":0.50091076,"about_ca_topic_score_gemma":0.8948456,"teacher_disagreement_score":0.39393482,"about_ca_system_score_codex":0.00019558653,"about_ca_system_score_gemma":0.002134429,"threshold_uncertainty_score":0.5024127},"labels":[],"label_agreement":null},{"id":"W4415942157","doi":"10.1016/j.annonc.2025.08.2890","title":"2274O Dissecting four decades of phase III randomised pharmacological interventions for primary cancer prevention to guide future developments: ESMO early detection and prevention task force","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Task force; Primary prevention; Psychological intervention; Cancer prevention; Phase (matter); Task (project management); MEDLINE","score_opus":0.10187781475284098,"score_gpt":0.49915074305878426,"score_spread":0.3972729283059433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236939,0.0011694625,0.06911179,0.0022316016,0.00063286023,0.0023854685,0.00002702452,0.00003291915,0.00071501295],"genre_scores_gemma":[0.98902535,0.0009632977,0.005432932,0.0009460873,0.00023545428,0.001421412,0.000032954318,0.000014966182,0.0019275142],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831164,0.00019053515,0.0008550006,0.00029184687,0.000133939,0.00021703512],"domain_scores_gemma":[0.99848723,0.0002711536,0.00045355185,0.00010392281,0.0005976532,0.0000864922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010006671,0.00014666645,0.00058514444,0.0002939803,0.00010476738,0.0000068000995,0.000079567624,0.000186816,0.00007359511],"category_scores_gemma":[0.00026369016,0.00013796471,0.00028574603,0.00029727464,0.00007365312,0.00012484839,0.00004564165,0.00014071491,4.6800835e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030380443,0.00092103356,0.00086268544,0.0008077121,0.00093552086,0.0000026809714,0.00051452586,0.000018909122,0.39139578,0.00009174547,0.0029271678,0.5711418],"study_design_scores_gemma":[0.14772783,0.013988173,0.030526184,0.003473341,0.0013101657,0.000030195111,0.0007624762,0.00017472834,0.7619464,0.0035068812,0.0361915,0.00036211812],"about_ca_topic_score_codex":0.00003186822,"about_ca_topic_score_gemma":0.00009280506,"teacher_disagreement_score":0.5707797,"about_ca_system_score_codex":0.00018510451,"about_ca_system_score_gemma":0.00033836561,"threshold_uncertainty_score":0.5626038},"labels":[],"label_agreement":null},{"id":"W4415942170","doi":"10.1016/j.annonc.2025.08.1339","title":"766P Performance of a tissue-agnostic approach based on whole-genome methylation and fragmentomics features for detecting minimal residual disease (MRD) in colorectal cancer (CRC) and its comparison with a clinically validated, tissue-informed MRD assay","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Ministry of Science and ICT, South Korea; National Research Foundation","keywords":"Minimal residual disease; Colorectal cancer; DNA methylation; Methylation; Cancer","score_opus":0.037259880844619626,"score_gpt":0.37523384267399196,"score_spread":0.33797396182937234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995797,0.0016938597,0.00065647817,0.00059555256,0.000056752462,0.00069812645,0.00027142884,0.000003915949,0.00022691731],"genre_scores_gemma":[0.99613214,0.00084317755,0.0021639562,0.00040189896,0.000057450638,0.00013802672,0.00021732227,0.000014414404,0.00003160298],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879277,0.00007576253,0.00046726802,0.00033556574,0.000095858435,0.00023278919],"domain_scores_gemma":[0.9987132,0.0005389007,0.00029867253,0.00012938752,0.00023462645,0.00008520353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004706694,0.00016542013,0.0004036102,0.00013226006,0.00005410424,0.00001383397,0.00010920804,0.0002079836,0.0000015984889],"category_scores_gemma":[0.0008205665,0.00015572377,0.00003321378,0.00012675177,0.000119627395,0.000007829625,0.00007747555,0.00011936838,1.0161822e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05527343,0.0015069244,0.09927287,0.0020834685,0.00043341963,0.000010754551,0.00082471815,0.06096387,0.7034867,0.00017885484,0.0016137973,0.07435121],"study_design_scores_gemma":[0.008839195,0.028174799,0.20356229,0.00034812285,0.00032241872,0.000004622713,0.0003389644,0.038708135,0.7077727,0.00007015811,0.011254388,0.00060425873],"about_ca_topic_score_codex":0.0000516352,"about_ca_topic_score_gemma":0.0002903772,"teacher_disagreement_score":0.10428942,"about_ca_system_score_codex":0.00003060727,"about_ca_system_score_gemma":0.0005702386,"threshold_uncertainty_score":0.6350231},"labels":[],"label_agreement":null},{"id":"W4415942181","doi":"10.1016/j.annonc.2025.08.3601","title":"2987O Efficacy and safety of dabrafenib plus trametinib (D+T) in patients with radioactive iodine (RAI)-refractory BRAF V600-mutant differentiated thyroid cancer (DTC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Dabrafenib; Trametinib; Thyroid cancer; Radioactive iodine; Thyroid","score_opus":0.02546129162047945,"score_gpt":0.34046152154084863,"score_spread":0.3150002299203692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161965,0.003336227,0.0000113533615,0.0026110671,0.0001359038,0.0009626995,0.00015440259,0.00001647475,0.001152237],"genre_scores_gemma":[0.9958869,0.0032060952,0.000080745245,0.0005563635,0.000025526648,0.00007827585,0.000062569154,0.000018774157,0.0000847052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838877,0.0001264325,0.00056802673,0.00038762207,0.00021551273,0.0003136243],"domain_scores_gemma":[0.99858385,0.00041268894,0.00034043874,0.00027511147,0.00027099316,0.00011689619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014491811,0.00024467372,0.0010570888,0.00026807626,0.000037663856,0.0000040755763,0.000095770454,0.00017289595,0.00009928052],"category_scores_gemma":[0.00008983016,0.00017882773,0.00008756829,0.00034154425,0.00026351598,0.000063467225,0.00005569164,0.00022860462,9.672875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0433882,0.015538668,0.743478,0.00045759248,0.0028927487,0.000082540784,0.0021650046,0.0001469616,0.0054512187,0.00049162185,0.0017881644,0.1841193],"study_design_scores_gemma":[0.035915975,0.0072336686,0.93860257,0.00051474536,0.0003248201,0.000002314583,0.00011400939,0.000016381626,0.014419762,0.000035677996,0.0026789121,0.0001411393],"about_ca_topic_score_codex":0.0006027083,"about_ca_topic_score_gemma":0.00044833653,"teacher_disagreement_score":0.19512461,"about_ca_system_score_codex":0.00025604886,"about_ca_system_score_gemma":0.0005227985,"threshold_uncertainty_score":0.7292383},"labels":[],"label_agreement":null},{"id":"W4415942202","doi":"10.1016/j.annonc.2025.08.2840","title":"2223P First-line (1L) AZD0171 + durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): Phase II study results","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Royal Victoria Regional Health Centre","funders":"AstraZeneca","keywords":"Chemotherapy; Durvalumab; Pancreatic ductal adenocarcinoma; Phases of clinical research; Gemcitabine; Adenocarcinoma","score_opus":0.07829122726750101,"score_gpt":0.4275496093810707,"score_spread":0.34925838211356974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98265487,0.00075504475,0.000038013615,0.0063986667,0.000112927875,0.002721975,0.000056958605,0.000038454884,0.0072230734],"genre_scores_gemma":[0.99453866,0.00044816235,0.0006257392,0.0010520689,0.00005969182,0.00022764206,0.00010575813,0.000036147285,0.0029061362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962355,0.00049227837,0.0012668225,0.0006872091,0.0005739687,0.00074423477],"domain_scores_gemma":[0.99717236,0.00083715713,0.00039539096,0.0007668182,0.00059930974,0.00022899122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014771587,0.00037690328,0.0019457698,0.0006938894,0.00017632669,0.00000931333,0.0003184112,0.00014189791,0.0002616278],"category_scores_gemma":[0.001014606,0.0002927243,0.00014179522,0.0009456873,0.00045264556,0.00011481651,0.0001564574,0.00051729527,0.00002499896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034426253,0.037596874,0.8903036,0.00030144173,0.0019286918,0.0012312805,0.0026046406,0.00001680358,0.000055528624,0.00014976625,0.0067720627,0.02461305],"study_design_scores_gemma":[0.106583714,0.11196232,0.7732088,0.00034356216,0.00082928676,0.00007248381,0.0013021134,0.00061532296,0.00028811753,0.00029440116,0.0042212773,0.00027863117],"about_ca_topic_score_codex":0.00079091056,"about_ca_topic_score_gemma":0.0008171608,"teacher_disagreement_score":0.11709484,"about_ca_system_score_codex":0.00024075636,"about_ca_system_score_gemma":0.0011709989,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W4415942215","doi":"10.1016/j.annonc.2025.08.2107","title":"1477P Overall survival among 4913 patients with hepatocellular carcinoma treated with external beam radiation therapy: Individual patient data outcomes from a multinational cohort","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Cohort; Overall survival; External beam radiation; External beam radiotherapy; Radiation therapy; Retrospective cohort study","score_opus":0.09386105800167989,"score_gpt":0.3072159203288688,"score_spread":0.21335486232718892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959171,0.00068693276,0.00007960602,0.0005015249,0.000100779536,0.0014996008,0.0006109953,0.000041241805,0.0005622489],"genre_scores_gemma":[0.992155,0.00011895766,0.0006608321,0.00061050634,0.000046929108,0.000114793,0.006181281,0.000030636398,0.00008104317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977178,0.00020702828,0.0005197352,0.0005840751,0.00063407636,0.00033729954],"domain_scores_gemma":[0.9980719,0.00031250354,0.00036769605,0.00062760053,0.0004727861,0.000147494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027004676,0.00032634215,0.0007650816,0.0002528321,0.000092997056,0.000023509896,0.0002638818,0.00020684095,0.00015652248],"category_scores_gemma":[0.000068068046,0.00022721876,0.0001063282,0.00024359126,0.00017305012,0.00022377764,0.00012362211,0.00019549661,0.000005188955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019485377,0.0019038823,0.9634703,0.00001769527,0.0015909177,0.00012631582,0.00024594614,0.000002669442,0.000068318615,0.00001782817,0.00051800214,0.030089578],"study_design_scores_gemma":[0.0098538855,0.004160165,0.97858125,0.000084238156,0.00048358866,0.00000196436,0.000031904572,0.000990004,0.004206366,0.000022560887,0.0013819654,0.00020212197],"about_ca_topic_score_codex":0.0021867892,"about_ca_topic_score_gemma":0.000086968335,"teacher_disagreement_score":0.029887456,"about_ca_system_score_codex":0.000084794236,"about_ca_system_score_gemma":0.0003887356,"threshold_uncertainty_score":0.9265712},"labels":[],"label_agreement":null},{"id":"W4415942231","doi":"10.1016/j.annonc.2025.08.3305","title":"2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Placebo; Clinical trial; Phases of clinical research; Disease; Circulating tumor cell; Neoplasm","score_opus":0.027960304621858424,"score_gpt":0.3379943246076695,"score_spread":0.31003401998581104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336725,0.00009857071,0.000014230322,0.0012031764,0.00018679374,0.0013390041,0.0002400758,0.0000087556955,0.0035421383],"genre_scores_gemma":[0.9989474,0.0001383541,0.00007136184,0.00030967008,0.00009709161,0.000017071494,0.00026870272,0.000009797133,0.0001405518],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9984294,0.00015967168,0.0007183289,0.00028022975,0.00018061242,0.0002317284],"domain_scores_gemma":[0.99871165,0.0004117232,0.00036673734,0.00027713453,0.00015949974,0.00007323793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032510216,0.00016391034,0.000611935,0.00009355019,0.000050578856,0.000004931123,0.000099788085,0.00011326577,0.000051712934],"category_scores_gemma":[0.00017710356,0.00010162345,0.00008790103,0.00018691411,0.0002001575,0.00005411403,0.00007302533,0.00015995785,0.000002717201],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7044495,0.014511387,0.099474795,0.00018273715,0.00051928783,0.00009007177,0.0010723057,0.0000071424233,0.0004544967,0.00021071627,0.00096708146,0.17806049],"study_design_scores_gemma":[0.3711494,0.016686527,0.6084416,0.0002548738,0.000185863,0.0000017372374,0.00010584719,0.0000099241915,0.0018171644,0.00003723348,0.0012154006,0.00009444679],"about_ca_topic_score_codex":0.0012083962,"about_ca_topic_score_gemma":0.00020885411,"teacher_disagreement_score":0.5089668,"about_ca_system_score_codex":0.000040810173,"about_ca_system_score_gemma":0.00016857716,"threshold_uncertainty_score":0.41440842},"labels":[],"label_agreement":null},{"id":"W4415942258","doi":"10.1016/j.annonc.2025.08.3412","title":"2800O A randomised trial of continuing or de-escalating bone modifying agents (BMA) after more than 2 years of treatment in patients with bone metastases from breast or castration-resistant prostate cancer: REaCT-Hold BMA","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; McMaster University; Brampton Civic Hospital; Western University; Southlake Regional Health Center; Ottawa Hospital","funders":"","keywords":"Prostate; Prostate cancer; Dosing; Bone metastasis; Randomized controlled trial","score_opus":0.05243896513122367,"score_gpt":0.3794276494235274,"score_spread":0.32698868429230377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589115,0.00034716932,0.0000035589073,0.0004863153,0.00006807664,0.0023698,0.00075193355,0.0000093960525,0.00007260177],"genre_scores_gemma":[0.998182,0.00022706234,0.0006808485,0.00013837601,0.000019517845,0.00040191924,0.00013978078,0.000018444032,0.00019206238],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980039,0.00018975227,0.00095792284,0.00028175005,0.0002253636,0.00034129585],"domain_scores_gemma":[0.9984132,0.00035763584,0.0006596207,0.00022723193,0.00021673435,0.00012558936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029199666,0.0002009753,0.0012123752,0.00022653963,0.00002394157,0.000004737021,0.000043787273,0.00012014226,0.000049461305],"category_scores_gemma":[0.00014273816,0.00013738684,0.00012035104,0.00026469587,0.00010351159,0.00007472813,0.000023784763,0.00010156907,3.8020718e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70360065,0.0028461574,0.17840008,0.00022006095,0.00065477815,0.00029183493,0.0021261526,0.000026172527,0.0008098042,0.0000015671628,0.000047626694,0.11097511],"study_design_scores_gemma":[0.3575315,0.010883952,0.62700856,0.0013161246,0.00063079194,0.0000067707224,0.00033857606,0.000094026684,0.0019169616,0.000013743405,0.00014556355,0.0001134614],"about_ca_topic_score_codex":0.011865179,"about_ca_topic_score_gemma":0.0052471193,"teacher_disagreement_score":0.44860843,"about_ca_system_score_codex":0.00021023826,"about_ca_system_score_gemma":0.001075338,"threshold_uncertainty_score":0.9947149},"labels":[],"label_agreement":null},{"id":"W4415942260","doi":"10.1016/j.annonc.2025.08.791","title":"366P Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2− EBC: A subgroup analysis from the phase 3 NATALEE trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Subgroup analysis; Chemotherapy; Clinical trial; Population; Complete response; Phases of clinical research; Chinese population","score_opus":0.09594002647997328,"score_gpt":0.5289163602019209,"score_spread":0.4329763337219476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331165,0.0005648226,0.00025379672,0.014471881,0.00014182391,0.00081594626,0.00017062193,0.000023650155,0.0002457909],"genre_scores_gemma":[0.99412805,0.00025918538,0.00040588982,0.004769334,0.0001100039,0.00004941011,0.00004302894,0.000024250096,0.00021082621],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99695116,0.0008253453,0.001107393,0.00044156634,0.00031479774,0.00035976127],"domain_scores_gemma":[0.99334586,0.004839475,0.000633256,0.0008324766,0.00024083011,0.00010809837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018353498,0.0002808887,0.001878953,0.00042537312,0.000036512058,0.000005892753,0.0003152323,0.0002642561,0.00027629174],"category_scores_gemma":[0.0009118224,0.0001625078,0.00081676367,0.001068331,0.0005321596,0.000072948846,0.000045019762,0.00047848484,0.0000030173153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65278506,0.0035552725,0.24394979,0.000010905872,0.0062237214,0.00007888077,0.0007292552,0.000110294735,0.00081925176,0.000047598125,0.0006850239,0.09100495],"study_design_scores_gemma":[0.14656477,0.027678885,0.8174947,0.00013482328,0.00072526926,0.0000045717934,0.00034049677,0.00011804419,0.0015358613,0.00039651507,0.004844297,0.00016181362],"about_ca_topic_score_codex":0.0014136554,"about_ca_topic_score_gemma":0.00070096133,"teacher_disagreement_score":0.57354486,"about_ca_system_score_codex":0.00019209637,"about_ca_system_score_gemma":0.0010357358,"threshold_uncertainty_score":0.6626876},"labels":[],"label_agreement":null},{"id":"W4415942300","doi":"10.1016/j.annonc.2025.08.3413","title":"2801O Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"Helsinn","keywords":"Antiemetic; Clinical trial; MEDLINE; Cisapride; Randomized controlled trial","score_opus":0.07243638129630496,"score_gpt":0.38083970365744935,"score_spread":0.30840332236114437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841216,0.00029468018,0.00008000912,0.009617453,0.00085394166,0.0018317119,0.00022512284,0.000025029305,0.002950428],"genre_scores_gemma":[0.99480635,0.00027891734,0.0008270124,0.0017221323,0.00030046384,0.00008639329,0.00013012848,0.000013525998,0.0018350858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836415,0.00023145524,0.0005609418,0.00033455808,0.0002225882,0.00028631036],"domain_scores_gemma":[0.99718875,0.0016868991,0.0003736678,0.0003823275,0.0003154269,0.00005294807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009297984,0.00013903024,0.00047337078,0.000112019916,0.00016902121,0.000009276392,0.0001641602,0.00013685641,0.000037358583],"category_scores_gemma":[0.0031440207,0.00009496384,0.00020590455,0.00021298682,0.00012760184,0.00002544236,0.0001402377,0.00016239639,0.000013482433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21058813,0.00317783,0.04378082,0.000306603,0.0017336262,0.00002210713,0.0020311966,0.00001104914,0.00045057046,0.0013625021,0.36283812,0.37369746],"study_design_scores_gemma":[0.19027694,0.032618113,0.20149748,0.0003476186,0.001308204,8.5029194e-7,0.00061739434,0.00017779742,0.004466241,0.0046791416,0.5637174,0.0002928027],"about_ca_topic_score_codex":0.00063182425,"about_ca_topic_score_gemma":0.000057917518,"teacher_disagreement_score":0.37340465,"about_ca_system_score_codex":0.000066614535,"about_ca_system_score_gemma":0.00012644395,"threshold_uncertainty_score":0.38725132},"labels":[],"label_agreement":null},{"id":"W4415942417","doi":"10.1016/j.annonc.2025.08.1754","title":"1117P Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Clinical trial; Endometrial cancer; MEDLINE","score_opus":0.15223815650260536,"score_gpt":0.4728840045935657,"score_spread":0.32064584809096036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710593,0.004372165,0.00034512943,0.016921986,0.0022036089,0.0027273116,0.0011436419,0.000048940132,0.0011779214],"genre_scores_gemma":[0.9935127,0.00040087884,0.00042108443,0.0013025368,0.0017985596,0.0005525039,0.0012263133,0.00002706663,0.00075837784],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99703795,0.00038449492,0.0010486434,0.0005297728,0.0005682804,0.00043084245],"domain_scores_gemma":[0.99281853,0.005582316,0.00056702207,0.00034300762,0.00054311054,0.00014602307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069042586,0.0003044992,0.0012862015,0.00032882564,0.00020579407,0.000026142081,0.00025945084,0.00029407602,0.00041592828],"category_scores_gemma":[0.003968153,0.00021766315,0.0006114229,0.0011347004,0.00016441563,0.0000899466,0.00006782288,0.00023677773,0.000008371652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6519987,0.0039153765,0.007334641,0.00022171537,0.00946132,0.00007394896,0.001091241,0.0015558482,0.026322382,0.0021957338,0.09971798,0.19611111],"study_design_scores_gemma":[0.7880237,0.018385913,0.09706315,0.0003061817,0.0053596976,0.000009017769,0.0006456787,0.0009935576,0.03278046,0.0077661457,0.04800082,0.0006656704],"about_ca_topic_score_codex":0.014942444,"about_ca_topic_score_gemma":0.000667855,"teacher_disagreement_score":0.19544543,"about_ca_system_score_codex":0.00034836898,"about_ca_system_score_gemma":0.0011496041,"threshold_uncertainty_score":0.99161714},"labels":[],"label_agreement":null},{"id":"W4415942438","doi":"10.1016/j.annonc.2025.08.749","title":"320P Phase 3 study of neoadjuvant pembrolizumab (Pembro) plus chemotherapy (Chemo) followed by adjuvant pembro for early-stage TNBC: KEYNOTE-522 magnetic resonance imaging (MRI) subgroup analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Adjuvant; Exploratory analysis; Neoadjuvant therapy; Magnetic resonance imaging; Subgroup analysis; Adjuvant chemotherapy","score_opus":0.03766017846796767,"score_gpt":0.4088319717736823,"score_spread":0.37117179330571465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96606517,0.01555053,0.0015348837,0.011010278,0.00037941235,0.003065737,0.0003370048,0.00012502672,0.001931985],"genre_scores_gemma":[0.9880211,0.0038102341,0.0012328133,0.0031263484,0.000109793174,0.00062491035,0.00009411562,0.000104859115,0.0028758629],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954436,0.0002798131,0.0016506166,0.0010925558,0.00062863546,0.00090476807],"domain_scores_gemma":[0.9957318,0.0009938256,0.00083182106,0.001319752,0.0008727313,0.0002501264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010171062,0.0005536177,0.0026967507,0.0009490831,0.00011355856,0.000022842476,0.0006278648,0.00029580333,0.00043542363],"category_scores_gemma":[0.00024415294,0.00054729223,0.0007959943,0.0018265791,0.0003505828,0.000151843,0.00016533311,0.00039241827,0.0000042823413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047538627,0.024176573,0.21891731,0.0014545689,0.005024534,0.0004440711,0.007453038,0.0003345296,0.030977529,0.0002486761,0.279266,0.38416457],"study_design_scores_gemma":[0.17641014,0.041506164,0.17617874,0.0006506164,0.007900965,0.00002268688,0.0041698036,0.012278766,0.06420196,0.00031049195,0.51498467,0.001385022],"about_ca_topic_score_codex":0.0021885154,"about_ca_topic_score_gemma":0.0006018331,"teacher_disagreement_score":0.38277954,"about_ca_system_score_codex":0.00034422672,"about_ca_system_score_gemma":0.0007565698,"threshold_uncertainty_score":0.99969786},"labels":[],"label_agreement":null},{"id":"W4415942465","doi":"10.1016/j.annonc.2025.08.3732","title":"3119eP Real-world use of Bacillus Calmette Guérin (BCG) in patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Johnson and Johnson","keywords":"Bladder cancer; Bacillus (shape); Urinary bladder; Cancer; Bladder Neoplasm","score_opus":0.04215214399027526,"score_gpt":0.3440201172759157,"score_spread":0.3018679732856404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895469,0.00017308274,0.000011543392,0.0018675049,0.0002431498,0.00080026337,0.0002533695,0.000015068619,0.0070891506],"genre_scores_gemma":[0.9946399,0.0012170584,0.0003559357,0.0021462385,0.000052260864,0.00010931245,0.000047631067,0.000025792573,0.001405887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830306,0.0001284178,0.0005569179,0.0003740395,0.00026459654,0.00037300008],"domain_scores_gemma":[0.9983573,0.00029162833,0.00032924494,0.0004202102,0.00048868655,0.00011294198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001469027,0.00023284864,0.0008636122,0.0004182791,0.000036515703,0.00000485395,0.00012805924,0.00016603782,0.00025239127],"category_scores_gemma":[0.00011861017,0.00018337251,0.000105045365,0.0006473498,0.00021177037,0.00011902335,0.00007893215,0.00024516397,0.000007873942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002634933,0.0015996197,0.91714376,0.00014255031,0.00082432944,0.000051807263,0.0004249456,0.00011991084,0.00023604861,0.000120818586,0.010649698,0.06605158],"study_design_scores_gemma":[0.00849217,0.00500264,0.9693308,0.00032523056,0.00032942145,5.710491e-7,0.000052347033,0.000007866797,0.007782604,0.00017068128,0.008363685,0.00014198777],"about_ca_topic_score_codex":0.041096326,"about_ca_topic_score_gemma":0.029405788,"teacher_disagreement_score":0.065909594,"about_ca_system_score_codex":0.00017292296,"about_ca_system_score_gemma":0.0009912828,"threshold_uncertainty_score":0.98830503},"labels":[],"label_agreement":null},{"id":"W4415942484","doi":"10.1016/j.annonc.2025.08.3420","title":"2808MO Impact of proton pump inhibitors use and potency on Immunotherapy (ICI) outcomes and gut microbiome in advanced NSCLC and RCC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Horizon 2020 Framework Programme; Agence Nationale de la Recherche","keywords":"Potency; Microbiome; Gut microbiome; Immunotherapy; Gut flora","score_opus":0.027293701868148636,"score_gpt":0.38215173015630594,"score_spread":0.3548580282881573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626315,0.0019456838,0.0000043496575,0.0010038541,0.00004528073,0.0005086453,0.0000354258,0.000002793319,0.0001908187],"genre_scores_gemma":[0.9942289,0.0046953834,0.00016269214,0.0007171472,0.000009705952,0.000015370719,0.000016864722,0.000009336706,0.00014462475],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99908864,0.000083652616,0.0003269334,0.0002593456,0.000030177594,0.00021124],"domain_scores_gemma":[0.9995059,0.00004769621,0.00014702884,0.00017580291,0.000079727324,0.00004384268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020735666,0.00014668042,0.00037636678,0.00016610273,0.000029963652,0.0000072616963,0.000064728476,0.0002194034,0.0000033645642],"category_scores_gemma":[0.000060716753,0.000121469064,0.000060658072,0.000091361435,0.00018022266,0.000008456881,0.00007198889,0.000091094436,1.9603505e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064463227,0.0001732548,0.11411683,0.00008562113,0.00006488956,0.0000018120293,0.00011166321,0.0000022329518,0.86843085,0.00003900408,0.0002249021,0.0161043],"study_design_scores_gemma":[0.0025885294,0.004308415,0.73848283,0.000098804245,0.0000079564525,0.000011116697,0.000057291214,0.0000020609857,0.24817379,0.0001302588,0.0060043912,0.00013456529],"about_ca_topic_score_codex":0.00035951735,"about_ca_topic_score_gemma":0.00010599897,"teacher_disagreement_score":0.624366,"about_ca_system_score_codex":0.000013568685,"about_ca_system_score_gemma":0.00015842228,"threshold_uncertainty_score":0.49533647},"labels":[],"label_agreement":null},{"id":"W4415942489","doi":"10.1016/j.annonc.2025.08.2535","title":"1911P Evaluation of an AI-based imaging endpoint as a surrogate endpoint for overall survival (OS) in a phase III advanced non-small cell lung cancer (aNSCLC) randomized controlled trial (RCT)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Glycemic Index Laboratories; University of Calgary; Princess Margaret Cancer Centre; Occupational Cancer Research Centre","funders":"","keywords":"Surrogate endpoint; Clinical endpoint; Randomized controlled trial; Overall survival; Lung cancer; Survival rate; Progression-free survival; Survival analysis","score_opus":0.030202384002716482,"score_gpt":0.4442721274187099,"score_spread":0.41406974341599345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96658427,0.0012307285,0.008820979,0.009968247,0.0009780582,0.00913151,0.000029184674,0.000025207633,0.0032318197],"genre_scores_gemma":[0.99260896,0.00020494637,0.0017803658,0.0030797692,0.0001638993,0.0018158827,0.00013812444,0.000030605544,0.00017746376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995662,0.0013182464,0.0016210887,0.00046291458,0.00047775285,0.0004580139],"domain_scores_gemma":[0.9953562,0.002330634,0.0009054529,0.00032130384,0.0009277253,0.000158706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01168477,0.00027784676,0.0029770145,0.0005275634,0.000052867035,0.000012447764,0.0001823995,0.00015163433,0.00016661298],"category_scores_gemma":[0.0043209926,0.00023185999,0.0006381029,0.00021358485,0.0002054484,0.000097432385,0.000037974856,0.00042420294,4.325815e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9307599,0.0020265025,0.00020076723,0.00032151013,0.00035256732,0.000023657609,0.0005401165,0.0058404086,0.011323092,0.0002422729,0.0002855538,0.048083644],"study_design_scores_gemma":[0.5872821,0.0010676421,0.00008308325,0.00022357906,0.00072976795,9.681355e-7,0.000076981465,0.404139,0.005167317,0.00055258156,0.00057439937,0.000102558726],"about_ca_topic_score_codex":0.0009775967,"about_ca_topic_score_gemma":0.00016591803,"teacher_disagreement_score":0.39829862,"about_ca_system_score_codex":0.00018548705,"about_ca_system_score_gemma":0.0028759441,"threshold_uncertainty_score":0.9454976},"labels":[],"label_agreement":null},{"id":"W4415942490","doi":"10.1016/j.annonc.2025.08.3246","title":"2631P Unmet needs &amp; disparities in kidney cancer (KC): International kidney cancer coalition (IKCC) global patient survey (GPS)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kidney Foundation of Canada; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Kidney cancer; Incidence (geometry); Cancer; Kidney disease; Cancer incidence; Healthcare system; Health care","score_opus":0.09275938904004867,"score_gpt":0.417859287127138,"score_spread":0.32509989808708933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238392,0.0016831157,0.00005472398,0.046513386,0.0017695323,0.0005370086,0.0017314686,0.000028758437,0.023842799],"genre_scores_gemma":[0.97844267,0.002068442,0.00013586541,0.016082766,0.00012008836,0.00023740513,0.00079491065,0.0000131704455,0.0021046572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998054,0.00029698154,0.00061997963,0.00031284857,0.00034408865,0.00037209352],"domain_scores_gemma":[0.99852616,0.00017552073,0.00022519578,0.00026937132,0.00052171474,0.00028203934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041462164,0.00021934134,0.0006200374,0.00031461593,0.00003673973,0.000012752549,0.00016626206,0.00021249912,0.00070187723],"category_scores_gemma":[0.0006046042,0.00019953189,0.0001371821,0.00054065854,0.00017352261,0.00008888578,0.00012121226,0.00018996232,0.000014539571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015704455,0.00079840166,0.7652626,0.00016239745,0.00043128544,0.00004410052,0.00026358303,0.0000673105,0.0003648611,0.001299042,0.2158386,0.013897386],"study_design_scores_gemma":[0.0029429677,0.0007890797,0.77562857,0.0005793723,0.00010997073,0.000013332888,0.00010784651,0.000070404465,0.0027248468,0.0006428608,0.2162184,0.00017237331],"about_ca_topic_score_codex":0.045374375,"about_ca_topic_score_gemma":0.01156871,"teacher_disagreement_score":0.054603487,"about_ca_system_score_codex":0.0009637159,"about_ca_system_score_gemma":0.0019483874,"threshold_uncertainty_score":0.96098256},"labels":[],"label_agreement":null},{"id":"W4415942492","doi":"10.1016/j.annonc.2025.08.2355","title":"1727P Outcomes of CAPTEM chemotherapy used in neuroendocrine and endocrine tumours: A real-world comparison of evidence in Alberta, Canada, 2011-2021","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Chemotherapy; Endocrine system; Neuroendocrine tumors; Chemotherapy regimen; Neuroendocrine tumour","score_opus":0.13028799427264462,"score_gpt":0.45844233813514473,"score_spread":0.3281543438625001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94358987,0.00095106533,7.6853627e-7,0.05301119,0.000086926244,0.0006026288,0.000013710524,0.000004708053,0.001739119],"genre_scores_gemma":[0.99463326,0.002324076,0.0001390398,0.000723254,0.000013975021,0.000033598808,0.000004841196,0.00001658936,0.0021113947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974023,0.00026051997,0.0010835491,0.00036961178,0.00037293692,0.0005110979],"domain_scores_gemma":[0.99656653,0.0023004862,0.00036485467,0.00040871845,0.00023399918,0.00012542668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021062215,0.00021244196,0.0015745383,0.00075551134,0.0000132683745,0.0000025256072,0.00024342272,0.000011518024,0.00011312629],"category_scores_gemma":[0.0011145746,0.00017894876,0.00007917624,0.0006212422,0.00028952234,0.00010421948,0.00013898622,0.0003538646,8.206943e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00117316,0.0007126671,0.9787719,0.00044222415,0.000060097693,0.0011628121,0.00010141924,0.00004023999,0.005769288,0.0003049604,0.003979347,0.00748183],"study_design_scores_gemma":[0.0035655969,0.001780316,0.85285646,0.00044711703,0.000025258187,0.00006672237,0.00025934045,0.00013605537,0.13359891,0.00015563847,0.007002136,0.00010645346],"about_ca_topic_score_codex":0.7196242,"about_ca_topic_score_gemma":0.93388677,"teacher_disagreement_score":0.21426255,"about_ca_system_score_codex":0.00010057124,"about_ca_system_score_gemma":0.0011993211,"threshold_uncertainty_score":0.72973186},"labels":[],"label_agreement":null},{"id":"W4415942529","doi":"10.1016/j.annonc.2025.08.3244","title":"2629P Durability of Complete Response (CR) to first-line (1L) in metastatic renal cell carcinoma (mRCC) in the real world","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Renal cell carcinoma; Complete response; Real world data; Carcinoma; Metastasis; Kidney cancer","score_opus":0.1380209231022706,"score_gpt":0.3995283480690519,"score_spread":0.2615074249667813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96205133,0.00035770185,0.0000116464935,0.024907097,0.00006350661,0.001033972,0.000038134654,0.0000072802804,0.011529329],"genre_scores_gemma":[0.9968027,0.000056715155,0.0006655839,0.0017082518,0.000019284593,0.000096351316,0.000018713994,0.000011055856,0.0006213611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693483,0.0010823465,0.00097365124,0.00036151003,0.00027620184,0.00037148077],"domain_scores_gemma":[0.99642986,0.002380517,0.00021484471,0.0006712882,0.00021017004,0.000093323506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023679615,0.00020003296,0.0009371785,0.00070616155,0.0000280249,0.0000034095356,0.00026446924,0.000081485494,0.00006352511],"category_scores_gemma":[0.0005483168,0.0001441188,0.00017053571,0.0010964168,0.00020087832,0.000026629239,0.00010861571,0.00027897774,0.0000096614895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081276745,0.010903944,0.77060497,0.0017439103,0.00031035463,0.003353537,0.009603295,0.0011739228,0.0905046,0.0017373672,0.008925655,0.019861685],"study_design_scores_gemma":[0.0034754886,0.0060607423,0.9513346,0.00012452876,0.00009875324,0.00001459444,0.0003526299,0.000079135505,0.02936434,0.0006761407,0.008323776,0.00009526012],"about_ca_topic_score_codex":0.003615636,"about_ca_topic_score_gemma":0.01613632,"teacher_disagreement_score":0.18072963,"about_ca_system_score_codex":0.00023477935,"about_ca_system_score_gemma":0.00053212827,"threshold_uncertainty_score":0.9004445},"labels":[],"label_agreement":null},{"id":"W4415942556","doi":"10.1016/j.annonc.2025.08.1750","title":"1113P Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Post-hoc analysis; Post hoc; Endometrial cancer; Immunotherapy; Overall survival; Clinical trial; Chemotherapy; DNA mismatch repair","score_opus":0.07563375287738103,"score_gpt":0.398080559091951,"score_spread":0.32244680621457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871966,0.00094837695,0.000002730563,0.0035902476,0.0010152459,0.0047120503,0.00032794094,0.000035890585,0.0021709013],"genre_scores_gemma":[0.99351376,0.0014579613,0.00021016058,0.002952068,0.00015546904,0.0010852524,0.00029318596,0.000031021413,0.00030112415],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99623024,0.0007181244,0.0010404922,0.00070767984,0.000641467,0.0006619667],"domain_scores_gemma":[0.99679965,0.0019098893,0.00037968974,0.00047022782,0.00028885098,0.00015168382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000969112,0.00045849185,0.0015900509,0.0007949583,0.000094498595,0.000023191034,0.000200431,0.000232553,0.0001023532],"category_scores_gemma":[0.0005761598,0.0002564983,0.0002477867,0.0014583285,0.00019585773,0.00010459197,0.000066207336,0.00034239716,0.0000030424349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6347049,0.014130419,0.1594344,0.00029010992,0.00044992092,0.0002239303,0.00094207295,0.00006117363,0.00009385685,0.00007108297,0.00015989426,0.18943825],"study_design_scores_gemma":[0.49940124,0.14592437,0.32450306,0.0006574274,0.00047539157,0.0000044748253,0.00064642465,0.000044030483,0.0028910881,0.000063964115,0.024898086,0.00049040467],"about_ca_topic_score_codex":0.001850085,"about_ca_topic_score_gemma":0.0031486347,"teacher_disagreement_score":0.18894784,"about_ca_system_score_codex":0.0009728259,"about_ca_system_score_gemma":0.0014387709,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W4415942559","doi":"10.1016/j.annonc.2025.08.607","title":"173TiP DyNAMIc trial: Circulating tumour DNA guided adaptive BRAF and MEK inhibitor therapy - A phase II randomised proof of concept study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; St. Thomas Hospital","funders":"","keywords":"MEK inhibitor; Population; Mutation; Acquired resistance; Mutant; Phases of clinical research","score_opus":0.06634267648748954,"score_gpt":0.38295494382005774,"score_spread":0.3166122673325682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940539,0.0016513473,0.00041225387,0.000279415,0.00020515894,0.0018240253,0.000032291548,0.000008006853,0.0015336204],"genre_scores_gemma":[0.9990084,0.000098642886,0.0001487446,0.00028622293,0.00008119409,0.000116884265,0.000035071967,0.000013723927,0.00021108033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833554,0.00036229118,0.0006236278,0.0003558214,0.00010531066,0.00021738012],"domain_scores_gemma":[0.9989406,0.00010587206,0.00038512136,0.00025411465,0.00025519167,0.000059138674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006359467,0.00018007908,0.0006079751,0.000091386195,0.000077520766,0.0000049877544,0.00015600758,0.00018783739,0.00001250085],"category_scores_gemma":[0.00030509068,0.00015889914,0.00014105186,0.000114725844,0.00017785943,0.0000052051837,0.00013266935,0.00008488125,1.5796476e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048751596,0.0025847366,0.00007612447,0.000026463022,0.0004372593,0.000015189535,0.0008513233,0.000016753385,0.8869218,0.0000990091,0.0014722878,0.058747455],"study_design_scores_gemma":[0.21855915,0.036227252,0.00018652136,0.000033158725,0.000060385417,0.000008608985,0.00081266527,0.00017584252,0.74076194,0.00027167896,0.0027323863,0.00017042198],"about_ca_topic_score_codex":0.000033586944,"about_ca_topic_score_gemma":0.000032167885,"teacher_disagreement_score":0.16980754,"about_ca_system_score_codex":0.000008669665,"about_ca_system_score_gemma":0.0003265251,"threshold_uncertainty_score":0.64797187},"labels":[],"label_agreement":null},{"id":"W4415942560","doi":"10.1016/j.annonc.2025.08.3104","title":"2489P Association of race and survival in apalutamide treated patients from the TITAN and SPARTAN phase III trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital","funders":"","keywords":"Race (biology); Spartan; Clinical trial; Titan (rocket family); Phases of clinical research","score_opus":0.11229912228663791,"score_gpt":0.46215984439495983,"score_spread":0.3498607221083219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98822755,0.0014372573,0.0000013759487,0.007530429,0.00006997118,0.00044593945,0.000086007974,0.0000035798873,0.0021979124],"genre_scores_gemma":[0.9961248,0.0026193315,0.0000131257175,0.00019027227,0.000023461354,0.000014129328,0.000066739354,0.0000032955622,0.0009448362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989947,0.00029611395,0.00034454052,0.00011941681,0.00011902214,0.00012620405],"domain_scores_gemma":[0.99815106,0.0013779138,0.00019000136,0.0000881973,0.00015877478,0.000034074903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010763375,0.000063392086,0.0005532579,0.00007974509,0.000023293887,0.0000035011715,0.00003417727,0.00009890015,0.000025672078],"category_scores_gemma":[0.0008395717,0.000039698454,0.00003587882,0.00014845893,0.00008151696,0.00002851545,0.00002961681,0.000083295185,4.842853e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049572494,0.0007761602,0.92563945,0.000030774132,0.00039226972,0.000007843327,0.00071432843,2.998937e-7,0.0030307686,0.00012230013,0.0040589334,0.060269635],"study_design_scores_gemma":[0.039863076,0.0028425388,0.9302678,0.00014183445,0.00021336699,2.589207e-7,0.00041899367,0.0000497297,0.017217163,0.001204806,0.0077233906,0.00005704317],"about_ca_topic_score_codex":0.00078105094,"about_ca_topic_score_gemma":0.00049298874,"teacher_disagreement_score":0.06021259,"about_ca_system_score_codex":0.00006185198,"about_ca_system_score_gemma":0.00011593645,"threshold_uncertainty_score":0.16188559},"labels":[],"label_agreement":null},{"id":"W4415942564","doi":"10.1016/j.annonc.2025.08.3363","title":"WITHDRAWN: 2753eP Investigating mechanistic roles of a novel oncofusion-driven transcript isoform, named DLG2η3, in Ewing sarcoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia; BC Cancer Agency; University of British Columbia; Dalhousie University; University of British Columbia Hospital","funders":"","keywords":"Sarcoma; Enhancer; Fusion gene; Gene; Oncogene Proteins; Fusion protein; Function (biology); Cancer","score_opus":0.08442227450680694,"score_gpt":0.37920942634532,"score_spread":0.29478715183851306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829372,0.0013360981,0.00035032353,0.009473485,0.00013068171,0.00051837496,0.000020453457,0.000023132314,0.005210225],"genre_scores_gemma":[0.9909014,0.0002386091,0.0062689018,0.0023898203,0.000028837774,0.00007596818,0.000019983912,0.000015996486,0.00006044503],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983627,0.00008214351,0.00073210214,0.0002823804,0.000210469,0.00033017402],"domain_scores_gemma":[0.9987237,0.00046979517,0.0002472448,0.00026473202,0.00018964012,0.000104917344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003565228,0.00019029563,0.0008806801,0.00038661357,0.000048712867,0.000004570307,0.00014055733,0.00019125461,0.000039290426],"category_scores_gemma":[0.00039149806,0.00016364014,0.00017492523,0.0004426692,0.00017958847,0.000057285604,0.00006381788,0.00019878805,0.000002568785],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011133592,0.013056947,0.25425553,0.0011802174,0.0010545332,0.00040008398,0.0070239697,0.00023735617,0.39801702,0.033221744,0.0018486555,0.28859058],"study_design_scores_gemma":[0.03641722,0.013989507,0.4485513,0.008096877,0.0011415362,0.0002077642,0.0062127905,0.0115505,0.4408675,0.0127568375,0.019418994,0.0007891473],"about_ca_topic_score_codex":0.00045058422,"about_ca_topic_score_gemma":0.0007148625,"teacher_disagreement_score":0.28780144,"about_ca_system_score_codex":0.00009150453,"about_ca_system_score_gemma":0.00050032994,"threshold_uncertainty_score":0.6673051},"labels":[],"label_agreement":null},{"id":"W4415942575","doi":"10.1016/j.annonc.2025.08.1043","title":"621TiP BNT323-03: A phase I/II trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 x VEGF-A) in patients (pts) with advanced breast cancer (BC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Tolerability; Breast cancer; Limiting; Phases of clinical research; Cancer; Topoisomerase; Clinical trial","score_opus":0.07087206971817465,"score_gpt":0.4770906131229302,"score_spread":0.40621854340475555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747737,0.00048765063,0.000018835643,0.008353276,0.00036734415,0.0023676313,0.00020573064,0.00003814811,0.013387683],"genre_scores_gemma":[0.9953624,0.00072537945,0.0004496828,0.0014603776,0.00017617554,0.0005610887,0.000050391685,0.0000612027,0.0011533207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99616146,0.00031143412,0.001013091,0.0007146596,0.00090645713,0.00089291984],"domain_scores_gemma":[0.9968467,0.00031935587,0.0004986133,0.0007815936,0.0012633919,0.0002903743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078315684,0.00039149428,0.001534744,0.00067665346,0.00007848074,0.000009096263,0.00041835583,0.00034956337,0.0006258243],"category_scores_gemma":[0.00028288312,0.0003053196,0.00015682627,0.0013880106,0.0006382319,0.00017443311,0.0001876887,0.0007101487,0.000012938572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4818868,0.016275385,0.077489994,0.00097349304,0.0007697932,0.00023134648,0.0012247984,0.00012621404,0.00128435,0.0002139547,0.014582863,0.40494102],"study_design_scores_gemma":[0.49469844,0.18774524,0.16260232,0.0044374773,0.00043073425,0.000050055118,0.0007413022,0.00013599281,0.014534544,0.0002341999,0.13358338,0.0008063347],"about_ca_topic_score_codex":0.0027773944,"about_ca_topic_score_gemma":0.0032798867,"teacher_disagreement_score":0.4041347,"about_ca_system_score_codex":0.00043519592,"about_ca_system_score_gemma":0.003652208,"threshold_uncertainty_score":0.9999399},"labels":[],"label_agreement":null},{"id":"W4415942591","doi":"10.1016/j.annonc.2025.08.1181","title":"CN104 Impact of fecal microbial transplantation on quality of life in patients with non-small cell lung cancer or melanoma undergoing immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Melanoma; Fecal bacteriotherapy; Lung cancer; Programmed cell death 1; Nivolumab; Immune system; Immunotherapy; Pembrolizumab","score_opus":0.02628693939479588,"score_gpt":0.37351339472306744,"score_spread":0.34722645532827157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986152,0.0003155755,0.000032779884,0.00008602793,0.000042397114,0.00030641054,0.0001507879,0.0000011747281,0.00044965392],"genre_scores_gemma":[0.99915934,0.0005609783,0.0000510929,0.00004348848,0.000015477674,0.000019528887,0.00010228791,0.0000073462215,0.00004046762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990257,0.00010495081,0.0004131529,0.00018134351,0.00008859324,0.00018626283],"domain_scores_gemma":[0.9993726,0.000053909862,0.00023991102,0.0001414812,0.00014729542,0.00004477614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016737745,0.00010932868,0.00032785386,0.00010028327,0.000015300375,0.000002051991,0.00009141717,0.00012339192,0.000015568692],"category_scores_gemma":[0.000041322804,0.0000818881,0.00011942184,0.00012614543,0.00007497859,0.0000038971457,0.000029677149,0.00007061066,2.1050738e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01846984,0.0012032306,0.7377135,0.00049724226,0.00039070228,0.0000034871634,0.00016309948,0.00040028366,0.23897713,0.000004226792,0.00019735278,0.0019798845],"study_design_scores_gemma":[0.0051763514,0.004910548,0.5210335,0.00011951569,0.00001851124,1.6548724e-7,0.000018348985,0.0000040442087,0.46864077,0.0000039641477,0.000015942775,0.000058303474],"about_ca_topic_score_codex":0.0057909978,"about_ca_topic_score_gemma":0.0075985147,"teacher_disagreement_score":0.22966366,"about_ca_system_score_codex":0.00006075069,"about_ca_system_score_gemma":0.0011102317,"threshold_uncertainty_score":0.8754295},"labels":[],"label_agreement":null},{"id":"W4415942593","doi":"10.1016/j.annonc.2025.08.1808","title":"1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Cervix; Cancer; Toxicity; Clinical trial; Cervical cancer","score_opus":0.23168125478454707,"score_gpt":0.4805219076226978,"score_spread":0.24884065283815074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97373146,0.00049302017,0.000004768727,0.022724729,0.00013474356,0.0012134833,0.000015968042,0.000008744405,0.0016730699],"genre_scores_gemma":[0.99554664,0.00014756924,0.000025670533,0.0038970318,0.000038291306,0.0002143405,0.0000098357405,0.000006314845,0.00011428704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816555,0.00038751622,0.0007398992,0.0002274652,0.00019915859,0.0002804109],"domain_scores_gemma":[0.9963542,0.002955494,0.00026976794,0.00024469403,0.00012036933,0.000055448887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077198097,0.00013260457,0.0006194658,0.00013963472,0.000049807277,0.0000062444797,0.00010716648,0.00013838145,0.000031482294],"category_scores_gemma":[0.0016035205,0.00006535092,0.00006337394,0.0008683365,0.00016242902,0.00005003599,0.00003771092,0.00029637487,0.0000014473171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017894603,0.0004991472,0.9262041,0.00002349999,0.00015858818,0.00002987944,0.00055373803,0.000025982621,0.000006818116,0.00012112971,0.000084685234,0.05439784],"study_design_scores_gemma":[0.04020736,0.0035409082,0.95355517,0.000120574354,0.00015840789,0.0000010240435,0.0004792914,0.0000073254155,0.00014654378,0.00093339215,0.0007904459,0.00005953299],"about_ca_topic_score_codex":0.00092510885,"about_ca_topic_score_gemma":0.00507986,"teacher_disagreement_score":0.054338306,"about_ca_system_score_codex":0.00006289494,"about_ca_system_score_gemma":0.00039481214,"threshold_uncertainty_score":0.2834681},"labels":[],"label_agreement":null},{"id":"W4415942594","doi":"10.1016/j.annonc.2025.08.3234","title":"2619P How clinicians decide – analyzing real-world practice patterns in metastatic renal cell carcinoma (mRCC) with machine learning: Results from the international metastatic renal cell carcinoma database consortium (IMDC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Juravinski Cancer Centre; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Renal cell carcinoma; Carcinoma; MEDLINE; Metastasis; Kidney cancer; Clear cell renal cell carcinoma","score_opus":0.08858054876424672,"score_gpt":0.37312418436637157,"score_spread":0.28454363560212487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94386035,0.0013353422,0.0005768919,0.03440145,0.00026307008,0.0009930492,0.00085115456,0.000038219052,0.017680489],"genre_scores_gemma":[0.9853432,0.00065907266,0.0058447467,0.0033276407,0.00014905863,0.00009066414,0.001758908,0.000060039885,0.0027666478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99415535,0.0016375086,0.0015962826,0.0010778148,0.00080251775,0.0007305259],"domain_scores_gemma":[0.9890782,0.007301649,0.0015401128,0.0010960776,0.00071599893,0.00026796182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024987743,0.0005647012,0.0013765207,0.0007618499,0.00015031855,0.00006540869,0.0006364861,0.00012428132,0.00015353937],"category_scores_gemma":[0.0014932061,0.00040243275,0.0003157981,0.0008638972,0.00031220843,0.0003143651,0.00032962652,0.0012361757,0.000019439067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030393729,0.004881166,0.89841837,0.00038743753,0.0022485158,0.014931572,0.0029640703,0.0013094,0.014222355,0.000212189,0.020269336,0.009761857],"study_design_scores_gemma":[0.03549821,0.010846019,0.7282916,0.00082141865,0.0058266697,0.00034508386,0.0072092167,0.0044415137,0.13341172,0.00015460205,0.07217773,0.0009762807],"about_ca_topic_score_codex":0.023176437,"about_ca_topic_score_gemma":0.021753779,"teacher_disagreement_score":0.17012683,"about_ca_system_score_codex":0.00037004912,"about_ca_system_score_gemma":0.001451726,"threshold_uncertainty_score":0.99984276},"labels":[],"label_agreement":null},{"id":"W4415942595","doi":"10.1016/j.annonc.2025.08.3674","title":"3061eP Transcriptomically inferred communications between immune cells &amp; endothelial cells (ECs) via the TIGIT pathway in non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Roche; Eli Lilly and Company","keywords":"TIGIT; Immune system; Downregulation and upregulation; Immune checkpoint; Receptor; Endothelial stem cell; Transcriptome; Lung cancer","score_opus":0.050762098319055884,"score_gpt":0.3568711593010113,"score_spread":0.30610906098195545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93198925,0.012793381,0.00069661747,0.025996165,0.00082506397,0.0017974306,0.00038038514,0.000047626116,0.0254741],"genre_scores_gemma":[0.9886041,0.0054646004,0.00047467943,0.00282692,0.000102129125,0.00015869905,0.00005309802,0.000027062648,0.002288682],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979122,0.00028775563,0.0009295825,0.00028705632,0.00015625687,0.00042709545],"domain_scores_gemma":[0.99778014,0.0006338965,0.000283323,0.0010320763,0.00019470036,0.000075859134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077630737,0.00023686954,0.00073567225,0.00023234397,0.00010872523,0.000014753888,0.0007415358,0.0003092717,0.00018684582],"category_scores_gemma":[0.000018087212,0.00018709495,0.00032781807,0.00047899786,0.00043562922,0.000054839224,0.00012592302,0.00053059426,0.00001659228],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016281715,0.000681109,0.006082963,0.00017644808,0.000402305,0.000005402002,0.002105951,0.000012778764,0.9114445,0.00003330073,0.00530521,0.07212187],"study_design_scores_gemma":[0.0058268276,0.00058131776,0.02233767,0.00031831226,0.00017352366,0.0000024419685,0.00017219313,0.000119164644,0.48308462,0.000114060604,0.48705158,0.0002182936],"about_ca_topic_score_codex":0.0027913777,"about_ca_topic_score_gemma":0.0016690397,"teacher_disagreement_score":0.48174638,"about_ca_system_score_codex":0.00013876808,"about_ca_system_score_gemma":0.0009659265,"threshold_uncertainty_score":0.762951},"labels":[],"label_agreement":null},{"id":"W4415942596","doi":"10.1016/j.annonc.2025.08.3005","title":"2389P Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Prostate cancer; Expanded access; Overall survival; MEDLINE; Prostate","score_opus":0.09703122849621203,"score_gpt":0.4644545704678482,"score_spread":0.3674233419716362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575865,0.00095343374,0.0000014286685,0.0010530999,0.000021713666,0.0014679135,0.00011226867,0.000008555852,0.0006229395],"genre_scores_gemma":[0.9978535,0.000679952,0.00013400285,0.0001081545,0.000004392884,0.00060240366,0.00013783007,0.0000095842315,0.0004701823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819124,0.00016553246,0.00065206457,0.00032800445,0.00027008227,0.0003930808],"domain_scores_gemma":[0.99897057,0.0001301061,0.00023236327,0.00020370573,0.00040037674,0.000062898616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029812235,0.00016619504,0.0008976747,0.0013658986,0.000018713623,0.000011439771,0.0001415758,0.00008961441,0.000041068964],"category_scores_gemma":[0.00006264372,0.00012362306,0.00008230944,0.0035460184,0.00019941045,0.00014514882,0.00003871975,0.00022207847,4.832312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005402334,0.0026158495,0.9461459,0.00025594427,0.0007612449,0.00020836346,0.0009141041,0.00046007853,0.00023135527,0.00001970913,0.000050797433,0.042934347],"study_design_scores_gemma":[0.007774823,0.0034775198,0.9844272,0.000333694,0.00030510005,2.806509e-7,0.00014169353,0.00035943487,0.0027900173,0.000048805745,0.00025177572,0.00008963871],"about_ca_topic_score_codex":0.009163844,"about_ca_topic_score_gemma":0.023057448,"teacher_disagreement_score":0.04284471,"about_ca_system_score_codex":0.0001736371,"about_ca_system_score_gemma":0.0008979267,"threshold_uncertainty_score":0.9974342},"labels":[],"label_agreement":null},{"id":"W4415942597","doi":"10.1016/j.annonc.2025.08.555","title":"121P Using AI-generated molecular digital twins to predict chemotherapy response in cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nanoplatforms for cancer theranostics","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas","keywords":"Cancer; Chemotherapy; Complete response; Chemotherapy regimen; MEDLINE","score_opus":0.035904211932516465,"score_gpt":0.3550266061557359,"score_spread":0.3191223942232194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140686,0.0007212256,0.0047246204,0.0013754725,0.00038187223,0.00023048655,0.00006218119,0.00006561976,0.0010316628],"genre_scores_gemma":[0.9969426,0.00012395706,0.00036875068,0.0023913104,0.000031321324,0.000023803714,0.0000046887044,0.000030162018,0.000083415674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991398,0.000023990118,0.0003054888,0.00014904785,0.00008967017,0.0002919993],"domain_scores_gemma":[0.99955064,0.000076619384,0.00003147305,0.00018712906,0.00009497632,0.000059176673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016997007,0.00013850165,0.0003010125,0.00023967162,0.000014353235,0.000014017456,0.00016024544,0.00015171088,0.000029563997],"category_scores_gemma":[0.00006606455,0.00014863299,0.000055519547,0.00058088935,0.000036424717,0.00010805464,0.000029972593,0.0001325479,0.000003711718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015522167,0.00009762559,0.0020628693,0.00004747128,0.00018230929,0.000046985395,0.00040391713,0.21142603,0.7443454,0.000084886735,0.0026353686,0.037114915],"study_design_scores_gemma":[0.0023647917,0.0010788018,0.004965543,0.00021885164,0.000024281659,0.000005311627,0.000063686886,0.029373731,0.82590055,0.00097552146,0.13465197,0.00037698],"about_ca_topic_score_codex":0.00006701405,"about_ca_topic_score_gemma":0.000051450414,"teacher_disagreement_score":0.1820523,"about_ca_system_score_codex":0.00020927966,"about_ca_system_score_gemma":0.00028321502,"threshold_uncertainty_score":0.6061077},"labels":[],"label_agreement":null},{"id":"W4415942628","doi":"10.1016/j.annonc.2025.08.1277","title":"703P Impact of dexamethasone on outcomes in pembrolizumab-treated CNS tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Pembrolizumab; Dexamethasone; Concomitant; Overall survival; Chemotherapy; Glioma","score_opus":0.06907549939427375,"score_gpt":0.4395022519836616,"score_spread":0.37042675258938784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816831,0.00031221588,6.5642655e-7,0.0039497917,0.000045538145,0.00030898757,0.000022947424,0.000012487957,0.013664287],"genre_scores_gemma":[0.99901724,0.00014297728,0.000053548916,0.00055549113,0.0000080410555,0.000031780695,0.000014820561,0.0000085426855,0.00016755663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989668,0.0000876055,0.0004130267,0.00018403253,0.00011397659,0.00023454646],"domain_scores_gemma":[0.9988852,0.0004857253,0.0001553713,0.00026855164,0.00013489483,0.00007026153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017503323,0.00014555329,0.0008696491,0.00049230026,0.000012257196,0.0000016089966,0.00007291598,0.00010641715,0.00011979308],"category_scores_gemma":[0.00031165805,0.00010156761,0.00026297127,0.00036732547,0.00008829932,0.000021180591,0.000030092046,0.00010760779,0.000009740467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000907451,0.004176895,0.9714078,0.00004444345,0.0005454476,0.0002466321,0.00009789329,0.00006424289,0.0029387858,0.0007030045,0.0027056532,0.016161788],"study_design_scores_gemma":[0.0050802864,0.006332787,0.950531,0.0001678957,0.00008151641,0.000008988434,0.000041198233,0.000021645297,0.037010953,0.00031825338,0.00035021015,0.000055257937],"about_ca_topic_score_codex":0.0013711449,"about_ca_topic_score_gemma":0.00015626584,"teacher_disagreement_score":0.03407217,"about_ca_system_score_codex":0.00011643674,"about_ca_system_score_gemma":0.00026743853,"threshold_uncertainty_score":0.4141807},"labels":[],"label_agreement":null},{"id":"W4415942630","doi":"10.1016/j.annonc.2025.08.2069","title":"1438P Laryngeal cancer mortality trends in the United States: A 21-year retrospective analysis (1999–2020)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Retrospective cohort study; Cancer; Laryngeal Neoplasm; MEDLINE; Larynx","score_opus":0.08717493199745122,"score_gpt":0.45846425480754655,"score_spread":0.3712893228100953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93228847,0.001211706,0.000008190396,0.038410384,0.00010605922,0.0001332632,0.00008473573,0.000017075994,0.027740104],"genre_scores_gemma":[0.9877941,0.003967206,0.000022412458,0.007218284,0.00006774279,0.00006175776,0.00007912089,0.0000052776163,0.00078412105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987325,0.00019244172,0.00035689864,0.0002527216,0.00019237788,0.0002730236],"domain_scores_gemma":[0.9991649,0.00015887673,0.00011049555,0.0002722725,0.00024847168,0.0000450192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058869174,0.00012347907,0.00080531504,0.00058369746,0.00005337681,0.0000042602364,0.00012804569,0.000110476765,0.00021590614],"category_scores_gemma":[0.00010091079,0.00008486287,0.0001946136,0.003585694,0.00017785418,0.000028607852,0.000049517163,0.00026161547,0.000002252319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004743622,0.0005851531,0.9100838,0.000059668164,0.0030962375,0.00012223076,0.004375922,0.00009259043,0.000053557233,0.0008632052,0.06882192,0.011371374],"study_design_scores_gemma":[0.0011148609,0.0010491352,0.94386995,0.00003984636,0.00075588335,0.0000012960584,0.001639731,0.00022461933,0.00012752682,0.00038913268,0.0507193,0.000068721936],"about_ca_topic_score_codex":0.009681164,"about_ca_topic_score_gemma":0.018145189,"teacher_disagreement_score":0.0555056,"about_ca_system_score_codex":0.00012179539,"about_ca_system_score_gemma":0.00020673379,"threshold_uncertainty_score":0.9997711},"labels":[],"label_agreement":null},{"id":"W4415942647","doi":"10.1016/j.annonc.2025.08.2475","title":"1851MO Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase III, randomized trial (PAULIEN)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pembrolizumab; Chemotherapy; Randomized controlled trial; Phases of clinical research; Chemotherapy regimen","score_opus":0.08929967220707699,"score_gpt":0.4317234721105517,"score_spread":0.3424237999034747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95203686,0.0057984274,0.0014219885,0.014405461,0.0014955229,0.017461382,0.00006607321,0.0001351735,0.00717912],"genre_scores_gemma":[0.96975595,0.010686969,0.0016932283,0.00978819,0.0005323018,0.003830467,0.00031870147,0.00012444181,0.0032697616],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99571526,0.00031487143,0.0017126906,0.00093590235,0.0005059056,0.00081539626],"domain_scores_gemma":[0.99581414,0.0010177324,0.0013005954,0.0008314796,0.00082334026,0.00021270291],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017997957,0.0006424964,0.0029714317,0.00040568702,0.00032004257,0.000065296306,0.0006192621,0.0002756514,0.0004748004],"category_scores_gemma":[0.00044422617,0.00047977982,0.00054087216,0.0006823701,0.0008001743,0.0003403371,0.00008550095,0.00037920842,0.0000070891992],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78163326,0.0041005868,0.0000038748954,0.00015611533,0.0018923824,0.000070733746,0.00030215227,0.000018177458,0.0036789335,0.00036475094,0.0036533528,0.20412567],"study_design_scores_gemma":[0.7775152,0.05530007,0.00002927526,0.00036465694,0.00034065518,0.00009267919,0.00014071928,0.0003584897,0.019003266,0.0004483743,0.14602698,0.0003796587],"about_ca_topic_score_codex":0.00040762895,"about_ca_topic_score_gemma":0.00017927442,"teacher_disagreement_score":0.20374602,"about_ca_system_score_codex":0.00039069387,"about_ca_system_score_gemma":0.0035035997,"threshold_uncertainty_score":0.9997654},"labels":[],"label_agreement":null},{"id":"W4415942648","doi":"10.1016/j.annonc.2025.08.912","title":"489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Estrogen receptor; Breast cancer; Clinical trial; Gene; Epidermal growth factor receptor; Cancer","score_opus":0.0215413814384618,"score_gpt":0.32627467992751,"score_spread":0.30473329848904823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477655,0.0001713105,0.00002055305,0.0023568163,0.0002894017,0.0017701705,0.00039780364,0.000018423741,0.00019898212],"genre_scores_gemma":[0.9973143,0.00019345141,0.00029202635,0.00094814255,0.000068955895,0.00040817712,0.00068719924,0.0000329821,0.000054805376],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971287,0.0004037829,0.0009650227,0.00064218644,0.00031841567,0.0005418635],"domain_scores_gemma":[0.99842155,0.00005596615,0.0005644462,0.0004479521,0.00039720064,0.000112908245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025929042,0.00039660034,0.0006708396,0.00020097995,0.000102066326,0.000022403008,0.0003594217,0.00030972503,0.000101641795],"category_scores_gemma":[0.00013422778,0.00027404423,0.00013775524,0.00044059978,0.00026838784,0.000038761187,0.000064860025,0.0003041248,0.0000024391973],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19938812,0.015282316,0.32759172,0.000232142,0.0014648361,0.00015223457,0.0015971832,0.0001923421,0.31868693,0.00019123103,0.0049432595,0.13027771],"study_design_scores_gemma":[0.14708185,0.035538025,0.20176972,0.00026460926,0.00012938732,0.000029939903,0.00058432174,0.000013643491,0.60070664,0.00006046593,0.0127834,0.0010380076],"about_ca_topic_score_codex":0.0004927347,"about_ca_topic_score_gemma":0.0004989052,"teacher_disagreement_score":0.2820197,"about_ca_system_score_codex":0.000079957834,"about_ca_system_score_gemma":0.0005693957,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W4415942662","doi":"10.1016/j.annonc.2025.08.1806","title":"1170P Pembrolizumab (Pembro) + concurrent chemoradiotherapy (CCRT) for high-risk locally advanced cervical cancer (LACC): Post hoc subgroup analyses from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Chemoradiotherapy; Cervical cancer; Phases of clinical research; Post-hoc analysis; Post hoc","score_opus":0.0890417153072301,"score_gpt":0.47127129372095006,"score_spread":0.38222957841371996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96547836,0.016414307,0.0011712058,0.0112619065,0.0011385893,0.0029144683,0.0008865494,0.00007783345,0.00065676885],"genre_scores_gemma":[0.985251,0.0052008727,0.00033308848,0.0070735095,0.0006828731,0.00078337634,0.0002677173,0.000047512207,0.00036002687],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965703,0.00039634938,0.0010814809,0.0008108443,0.00047854864,0.0006624864],"domain_scores_gemma":[0.9953736,0.0022386292,0.0005678113,0.0007109767,0.00083917764,0.000269788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048397048,0.0004934463,0.0019190537,0.00023685193,0.00022732042,0.00002725847,0.0005058813,0.00029104995,0.00082349963],"category_scores_gemma":[0.00041054914,0.000327742,0.00051722914,0.00088614406,0.00028675873,0.00010628043,0.00012515244,0.0004468685,0.000010123685],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065474905,0.009183925,0.009410465,0.000130461,0.0046678795,0.0000592303,0.001076292,0.000055225893,0.0041827406,0.00036870202,0.0051021706,0.900288],"study_design_scores_gemma":[0.5115279,0.10421768,0.15085895,0.0005975174,0.0076670577,0.00001337604,0.0040225517,0.0007619552,0.048269454,0.0024103837,0.16836248,0.0012906967],"about_ca_topic_score_codex":0.008803982,"about_ca_topic_score_gemma":0.0040260307,"teacher_disagreement_score":0.8989973,"about_ca_system_score_codex":0.00032954966,"about_ca_system_score_gemma":0.0009164857,"threshold_uncertainty_score":0.99991745},"labels":[],"label_agreement":null},{"id":"W4415942672","doi":"10.1016/j.annonc.2025.08.3008","title":"2392P PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): A randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia; Prostate Cancer Foundation of Australia; Australian Nuclear Science and Technology Organisation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Prostate cancer; Androgen receptor; Biomarker; Progression-free survival; Overall survival; Abiraterone; Androgen","score_opus":0.09464686932957608,"score_gpt":0.4401653355578007,"score_spread":0.3455184662282246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781652,0.0027846554,0.0000038324933,0.009402054,0.00033959106,0.0060036806,0.00007971844,0.000017563289,0.0032036905],"genre_scores_gemma":[0.9926389,0.0032396524,0.00018731962,0.00026216632,0.000045062196,0.0017379577,0.000066310364,0.0000269336,0.0017957147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966599,0.00064370834,0.0012275472,0.00047877396,0.000389633,0.00060048985],"domain_scores_gemma":[0.99781007,0.0009283971,0.00043372952,0.0003269986,0.0003793501,0.00012145009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640469,0.00028691159,0.0013285683,0.0008888681,0.000047535603,0.000014779178,0.00017107849,0.00020707096,0.000115419636],"category_scores_gemma":[0.00086859264,0.00022236943,0.00021489509,0.0009389168,0.00035683898,0.00012029212,0.00005841267,0.00033411203,0.000005501917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87325513,0.0031334953,0.007301683,0.00095571595,0.00091574003,0.0004510826,0.0025617837,0.00004265615,0.048028603,0.0001983236,0.0017320843,0.06142371],"study_design_scores_gemma":[0.86504817,0.018657396,0.05114653,0.0020911787,0.0005324394,0.000028774553,0.0018211501,0.00093516364,0.051902305,0.0020263249,0.005410203,0.0004003593],"about_ca_topic_score_codex":0.002368943,"about_ca_topic_score_gemma":0.0036566583,"teacher_disagreement_score":0.061023355,"about_ca_system_score_codex":0.00029733407,"about_ca_system_score_gemma":0.0036520108,"threshold_uncertainty_score":0.9067963},"labels":[],"label_agreement":null},{"id":"W4415942674","doi":"10.1016/j.annonc.2025.08.2211","title":"1581P Results from a phase I dose escalation study of BA3182, a dual-conditionally active biologic (CAB) EpCAM x CD3 bispecific T cell engager in patients with treatment refractory metastatic adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Micropalaeontological Society; Bamfield Marine Sciences Centre","keywords":"Epithelial cell adhesion molecule; CD3; T cell; Colorectal cancer; Metastatic breast cancer; Cell; Antibody; Receptor","score_opus":0.10499511973511554,"score_gpt":0.4142335141531862,"score_spread":0.30923839441807066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330056,0.00030668962,0.0000032863948,0.00092424534,0.00006207522,0.0013092526,0.0009622595,0.000009862201,0.0031217586],"genre_scores_gemma":[0.9976346,0.00016111214,0.00022972871,0.00017899353,0.000034480407,0.00007878795,0.0010532197,0.000011239252,0.00061783165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975871,0.0005953401,0.0007333703,0.0004454988,0.00034903007,0.00028964906],"domain_scores_gemma":[0.99750155,0.0012926871,0.0003664039,0.00029998223,0.00043746305,0.00010190658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034732884,0.00022310835,0.0007930166,0.00048690476,0.000060246537,0.000004439444,0.00009958377,0.00011730291,0.0001911767],"category_scores_gemma":[0.00017593033,0.00015155676,0.00010552517,0.00040575073,0.00019492554,0.00008080849,0.00006121882,0.00028112286,0.000012330065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19034307,0.15008716,0.5198164,0.00024177281,0.0032127001,0.0010047938,0.011809589,0.00012043801,0.01699903,0.00018235388,0.0029768692,0.1032058],"study_design_scores_gemma":[0.030483808,0.04801601,0.91195893,0.000086332046,0.00016844372,0.0000016808536,0.0013581743,0.00003980761,0.0056969463,0.00017597954,0.0018959484,0.000117951415],"about_ca_topic_score_codex":0.0011645525,"about_ca_topic_score_gemma":0.0003421339,"teacher_disagreement_score":0.39214247,"about_ca_system_score_codex":0.0001377936,"about_ca_system_score_gemma":0.00043009262,"threshold_uncertainty_score":0.61803055},"labels":[],"label_agreement":null},{"id":"W4415942701","doi":"10.1016/j.annonc.2025.08.1752","title":"1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Metastatic breast cancer; Endometrial cancer; Phases of clinical research; Clinical trial; Randomized controlled trial","score_opus":0.1684586252757167,"score_gpt":0.43680370448520456,"score_spread":0.26834507920948786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857443,0.003911107,0.0002009243,0.002776044,0.0005341191,0.005054414,0.00006472436,0.00007955075,0.0016347948],"genre_scores_gemma":[0.99408835,0.0013813035,0.00066311855,0.001611425,0.00014765952,0.0016898719,0.000026527541,0.000060542916,0.0003311802],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945441,0.0012161703,0.0015926376,0.00094660185,0.0007715624,0.0009289665],"domain_scores_gemma":[0.99622184,0.001420489,0.00080326415,0.00058164017,0.00060335046,0.0003693976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029381544,0.0006039913,0.003559028,0.0011545463,0.00022037844,0.00004146177,0.00027040183,0.00015896953,0.00040561048],"category_scores_gemma":[0.00067128043,0.000425936,0.00023495476,0.0015804714,0.0007617237,0.00021916452,0.00014660737,0.0006087374,0.0000030795056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9138292,0.016307585,0.004108572,0.0005243927,0.005288215,0.00037076275,0.013237812,0.0002708963,0.0030313146,0.000081482416,0.0012110617,0.041738674],"study_design_scores_gemma":[0.8955778,0.07832478,0.0016486411,0.0015732158,0.0019150901,0.00013238552,0.00895427,0.00079989317,0.0028543891,0.00009681595,0.0075184936,0.00060421746],"about_ca_topic_score_codex":0.0007869508,"about_ca_topic_score_gemma":0.0017849285,"teacher_disagreement_score":0.062017195,"about_ca_system_score_codex":0.0007985483,"about_ca_system_score_gemma":0.0014342476,"threshold_uncertainty_score":0.9998192},"labels":[],"label_agreement":null},{"id":"W4415942707","doi":"10.1016/j.annonc.2025.08.3007","title":"2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Radiosensitizer; Prostate cancer; Radiation therapy; PARP inhibitor; Clinical trial","score_opus":0.08780623247322457,"score_gpt":0.45483488395187227,"score_spread":0.3670286514786477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919136,0.0010809738,0.0000044890767,0.0031599253,0.00011787317,0.001661573,0.00011457039,0.000007831262,0.0019391231],"genre_scores_gemma":[0.99708486,0.001337481,0.00018432736,0.00017428113,0.000022627879,0.00019177247,0.00008372503,0.000011310677,0.00090959755],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99847746,0.00015654847,0.00051920215,0.00027349746,0.00026948063,0.0003038017],"domain_scores_gemma":[0.9989361,0.00013924761,0.00024098925,0.00019017373,0.00040076466,0.0000926975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042999632,0.00015020795,0.0006467917,0.0003039745,0.000038933966,0.00000721467,0.00006399464,0.000083049155,0.0000342807],"category_scores_gemma":[0.00010960228,0.000107800006,0.000050285595,0.00038867546,0.00027098542,0.000092601964,0.00003590998,0.00016889298,7.142777e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67701,0.009791161,0.06538465,0.0013502492,0.0011108636,0.00022484502,0.0026843802,0.000026268834,0.006825646,0.0005704763,0.003951038,0.23107043],"study_design_scores_gemma":[0.70850945,0.09768028,0.113817096,0.0013954679,0.00079208816,0.000008751346,0.0016011392,0.00017659998,0.06154045,0.0012500362,0.012853221,0.00037540315],"about_ca_topic_score_codex":0.00068632804,"about_ca_topic_score_gemma":0.00096839503,"teacher_disagreement_score":0.23069502,"about_ca_system_score_codex":0.0001104661,"about_ca_system_score_gemma":0.0011037119,"threshold_uncertainty_score":0.43959567},"labels":[],"label_agreement":null},{"id":"W4415942720","doi":"10.1016/j.annonc.2025.08.1755","title":"1118P Time to quality of life (QoL) deterioration in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/rEC) and by population subgroups in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Quality of life (healthcare); Population; Chemotherapy; Endometrial cancer; Clinical trial; Immunotherapy; Post-hoc analysis; DNA mismatch repair","score_opus":0.057828702283717344,"score_gpt":0.38607980184591534,"score_spread":0.328251099562198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993554,0.0009984575,0.000009568947,0.001335011,0.00025360205,0.0032971436,0.00014604199,0.00001746806,0.00038868203],"genre_scores_gemma":[0.9969946,0.00048254378,0.0003233762,0.0012392849,0.000075767566,0.00038007752,0.00027126036,0.000014026776,0.0002190252],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970056,0.00062644924,0.0011682023,0.0004357303,0.00043249197,0.00033156795],"domain_scores_gemma":[0.99807596,0.0007473579,0.00050732074,0.00027455323,0.00028899338,0.000105838575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014575622,0.0002151997,0.0010592219,0.00043041722,0.000047368976,0.000011549854,0.00012647032,0.00017153237,0.00007620019],"category_scores_gemma":[0.0011428278,0.00013999005,0.000094792056,0.0015902173,0.00007476077,0.00013959949,0.000061123676,0.00019506448,0.000002325079],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54993165,0.0050442014,0.21925128,0.0006345816,0.00020718196,0.00000621481,0.0012626528,0.000025806856,0.0034080485,0.000030754265,0.0012358784,0.21896175],"study_design_scores_gemma":[0.20997263,0.041174576,0.730026,0.0006041371,0.00019670786,0.0000012832904,0.00033031826,0.000033569577,0.0041952096,0.00012921398,0.012973778,0.00036255713],"about_ca_topic_score_codex":0.0024670402,"about_ca_topic_score_gemma":0.0013541182,"teacher_disagreement_score":0.51077473,"about_ca_system_score_codex":0.0003286838,"about_ca_system_score_gemma":0.00041689086,"threshold_uncertainty_score":0.5708628},"labels":[],"label_agreement":null},{"id":"W4415942731","doi":"10.1016/j.annonc.2025.08.3006","title":"2390P Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novartis","keywords":"Baseline (sea); Androgen receptor; Androgen; Phases of clinical research; Clinical trial; Disease","score_opus":0.2127818758607951,"score_gpt":0.5083710103296752,"score_spread":0.29558913446888013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646811,0.00063418923,0.000013591572,0.031093543,0.00006360626,0.0011855313,0.0000959685,0.000013623577,0.0022188695],"genre_scores_gemma":[0.99751943,0.00037177326,0.00029236192,0.0009789246,0.000035407116,0.00007820882,0.000118839554,0.000008549667,0.00059648097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982158,0.0005792941,0.00040209809,0.00025990387,0.00023230587,0.0003106285],"domain_scores_gemma":[0.9968029,0.0025344414,0.00013106238,0.00023712903,0.0002290289,0.000065429624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016894595,0.00013546059,0.00055535045,0.00027388035,0.00010414896,0.0000132953655,0.0001479918,0.00006731554,0.000018435747],"category_scores_gemma":[0.0009321178,0.000089180416,0.000080181235,0.0005294857,0.00021510989,0.000054324428,0.00007082203,0.00028235585,0.000006332729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077776733,0.0039882003,0.9442677,0.0000701704,0.0008496248,0.00032435646,0.007594603,0.000012891899,0.0000619762,0.0010994095,0.013515812,0.027437486],"study_design_scores_gemma":[0.0062051928,0.0054135136,0.97315496,0.00007198779,0.00023418579,0.000005562879,0.0069496543,0.0000527658,0.00038579022,0.0007507024,0.006683736,0.00009194036],"about_ca_topic_score_codex":0.00062280294,"about_ca_topic_score_gemma":0.00082180573,"teacher_disagreement_score":0.032838378,"about_ca_system_score_codex":0.00007224855,"about_ca_system_score_gemma":0.00034919335,"threshold_uncertainty_score":0.3636672},"labels":[],"label_agreement":null},{"id":"W4415942743","doi":"10.1016/j.annonc.2025.08.1751","title":"1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; Endometrial cancer; Exploratory analysis; Progression-free survival","score_opus":0.09508130975977898,"score_gpt":0.409851283042694,"score_spread":0.31476997328291506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7441141,0.0107979085,0.00039675133,0.10195418,0.013442525,0.008753749,0.089279674,0.00036563198,0.030895498],"genre_scores_gemma":[0.9378191,0.016567703,0.0039114296,0.0098221935,0.0038292585,0.0025093053,0.010494706,0.00010016581,0.014946129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997217,0.0001061147,0.0010574074,0.0006765336,0.0004047593,0.0005382141],"domain_scores_gemma":[0.99375445,0.004485658,0.00050200644,0.00040948906,0.0006320721,0.0002163565],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034243806,0.00034688474,0.0012928243,0.00042560048,0.00012902294,0.000011673076,0.00024921529,0.00022802205,0.008848213],"category_scores_gemma":[0.0037136339,0.00026919285,0.00043669454,0.00093634485,0.00014465439,0.000097558055,0.00006974345,0.00028270233,0.000029416924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30451018,0.0022180094,0.00018925157,0.00015169077,0.0011828764,0.000034032633,0.00011941936,0.00001906873,0.000292021,0.00032843387,0.20693532,0.4840197],"study_design_scores_gemma":[0.15492438,0.011804429,0.0025929352,0.00037041036,0.00022677811,0.0000048808233,0.000048329315,0.000035741326,0.0073211016,0.0013370536,0.8211146,0.0002193419],"about_ca_topic_score_codex":0.0006368622,"about_ca_topic_score_gemma":0.0009703198,"teacher_disagreement_score":0.6141793,"about_ca_system_score_codex":0.00028277654,"about_ca_system_score_gemma":0.00094971136,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W4415942750","doi":"10.1016/j.annonc.2025.08.3710","title":"3096P Impact of time of infusion of immunotherapy on efficacy in metastatic urothelial cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Urothelial cancer; Immunotherapy; Cancer; Cancer immunotherapy; Bladder cancer; Chemotherapy","score_opus":0.058975160825329186,"score_gpt":0.45157997907242453,"score_spread":0.39260481824709537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920343,0.001422286,0.000006430731,0.0006729293,0.00007048434,0.00043548504,0.00010249939,0.000004074391,0.0052514826],"genre_scores_gemma":[0.9974721,0.0017332569,0.00008008558,0.00035720033,0.000015704823,0.000017310327,0.0000072052526,0.000010493535,0.00030661872],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989377,0.00010549465,0.00053510244,0.00012803743,0.00014464461,0.0001490204],"domain_scores_gemma":[0.99904627,0.000230319,0.00028484515,0.00022379139,0.00018402036,0.000030730407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020822436,0.0001176214,0.0008158825,0.00029849287,0.0000071968384,5.075225e-7,0.00009181567,0.00008305854,0.000574595],"category_scores_gemma":[0.000074798336,0.000087382956,0.00021800226,0.00029697505,0.0001321762,0.00002180158,0.000020105745,0.00008946122,0.0000029469081],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024375562,0.00908439,0.05632639,0.00046685146,0.0025001192,0.000022771957,0.0024807234,0.00058024476,0.56967896,0.00022281245,0.0030901546,0.331171],"study_design_scores_gemma":[0.018088233,0.024688527,0.48362958,0.0010517023,0.00023876657,0.0000036799133,0.00006187075,0.00006338272,0.47001526,0.000488736,0.0015597825,0.000110475106],"about_ca_topic_score_codex":0.0037011264,"about_ca_topic_score_gemma":0.00006244474,"teacher_disagreement_score":0.4273032,"about_ca_system_score_codex":0.0000644864,"about_ca_system_score_gemma":0.00092150713,"threshold_uncertainty_score":0.6291413},"labels":[],"label_agreement":null},{"id":"W4415942765","doi":"10.1016/j.annonc.2025.08.1495","title":"926MO MK-1084 monotherapy in participants (Pts) with KRAS G12C–mutated advanced solid tumors: Activity and safety in the phase I KANDLELIT-001 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Merck Sharp and Dohme","keywords":"KRAS; Phases of clinical research; Combination therapy; Solid tumor; Adverse effect; Maximum tolerated dose","score_opus":0.041032931380026554,"score_gpt":0.39989048204104566,"score_spread":0.3588575506610191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690163,0.0006210934,0.00020556923,0.0010732455,0.000019817477,0.00070891564,0.000010811213,0.0000054173383,0.00045349062],"genre_scores_gemma":[0.99879616,0.0002487959,0.00006169835,0.0007062491,0.000018893052,0.00010032832,0.000020291878,0.000008309946,0.00003927332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986103,0.00040831475,0.00031754037,0.00030067685,0.00009007891,0.00027304492],"domain_scores_gemma":[0.99943733,0.000067770794,0.00013800008,0.00023943679,0.00007692544,0.000040509236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007699258,0.0001455384,0.00033205684,0.00010073535,0.000049953524,0.000009233446,0.00013090609,0.00010604181,0.000011103548],"category_scores_gemma":[0.00008217232,0.000106416606,0.000031878724,0.00023700309,0.000118739044,0.000009172597,0.000046182282,0.00012818532,6.096089e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020273073,0.009143732,0.024014084,0.00007748845,0.00029733803,0.0001599828,0.00200825,0.0018842865,0.6665937,0.00025744826,0.0001861879,0.27510446],"study_design_scores_gemma":[0.04633325,0.020640574,0.14855966,0.00024877055,0.000069566115,0.00002508596,0.002933999,0.0014905088,0.7574544,0.0007101086,0.020922078,0.0006120348],"about_ca_topic_score_codex":0.00014577346,"about_ca_topic_score_gemma":0.0016571479,"teacher_disagreement_score":0.2744924,"about_ca_system_score_codex":0.000011772527,"about_ca_system_score_gemma":0.00016598032,"threshold_uncertainty_score":0.43395433},"labels":[],"label_agreement":null},{"id":"W4415942864","doi":"10.1016/j.annonc.2025.08.1760","title":"1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; Endometrial cancer; Phases of clinical research; Subgroup analysis; Clinical trial","score_opus":0.14156110764722712,"score_gpt":0.4622116491794812,"score_spread":0.3206505415322541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438203,0.0059439563,0.0000036054319,0.0053351307,0.00060651725,0.0022544037,0.00008378025,0.000040316187,0.0013502464],"genre_scores_gemma":[0.98919785,0.006773458,0.000110496985,0.0024081336,0.00011549797,0.00067038013,0.0000246502,0.00002950512,0.0006700505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99696195,0.00033970203,0.00091868686,0.0006354506,0.0004400583,0.00070415344],"domain_scores_gemma":[0.99724346,0.0013728867,0.000343596,0.0004020614,0.0004017458,0.00023622962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005762519,0.00039547725,0.0017626622,0.00068859494,0.00008036305,0.000015192584,0.00019518142,0.00018753132,0.00049795123],"category_scores_gemma":[0.0010158496,0.00024292772,0.00012878499,0.0013018,0.00018721161,0.00012754125,0.00010839155,0.00036876797,0.000006486946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07371629,0.007406352,0.23194192,0.00011260599,0.0010780868,0.00022654634,0.0010271635,0.000012516912,0.00044721673,0.000059517042,0.0001890433,0.68378276],"study_design_scores_gemma":[0.1546677,0.060322437,0.76084197,0.0003444609,0.00042474485,0.000014618531,0.0015025346,0.00001650847,0.0032808902,0.00013962091,0.018066043,0.0003784381],"about_ca_topic_score_codex":0.0018928391,"about_ca_topic_score_gemma":0.0041459054,"teacher_disagreement_score":0.6834043,"about_ca_system_score_codex":0.00019065871,"about_ca_system_score_gemma":0.00075256405,"threshold_uncertainty_score":0.9906305},"labels":[],"label_agreement":null},{"id":"W4415942887","doi":"10.1016/j.annonc.2025.08.3418","title":"2806MO Effect of a multidisciplinary intervention on fatigue in lymphoma survivors with chronic fatigue- a randomized controlled trial (REFUEL)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Randomized controlled trial; Quality of life (healthcare); Coping (psychology); Psychological intervention; Multidisciplinary approach; Intervention (counseling); Cancer-related fatigue","score_opus":0.03391452918357484,"score_gpt":0.39174050028179397,"score_spread":0.3578259710982191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833573,0.0021171803,0.00020553269,0.0011744634,0.00089376135,0.0049644015,0.000007785043,0.000022078244,0.0072575104],"genre_scores_gemma":[0.9979634,0.0002836937,0.00001542065,0.00011290851,0.000092251306,0.0010594947,0.00002703815,0.000015273428,0.00043051288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965704,0.0015790878,0.0010301766,0.00030236878,0.00025538568,0.00026259015],"domain_scores_gemma":[0.9962414,0.002655546,0.0005268767,0.00030488404,0.00020982536,0.000061457984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026730327,0.0002367427,0.003041209,0.00053347246,0.000023043889,0.0000033083518,0.00012591682,0.00023312808,0.00006566276],"category_scores_gemma":[0.00076895824,0.00015428284,0.0007437011,0.00041700876,0.00026890688,0.000042680203,0.000051876115,0.00016652718,0.0000016007759],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94817895,0.0011508235,0.001790216,0.00067981984,0.0007137362,0.00003089512,0.0005313858,0.000065722554,0.0002280096,0.0003297716,0.00010391422,0.04619677],"study_design_scores_gemma":[0.9606746,0.028278107,0.002876489,0.0015279282,0.00038086108,0.0000039515344,0.00016393315,0.00045175917,0.005230327,0.00011593188,0.00018590897,0.00011024506],"about_ca_topic_score_codex":0.002577263,"about_ca_topic_score_gemma":0.0110709,"teacher_disagreement_score":0.046086524,"about_ca_system_score_codex":0.00016418828,"about_ca_system_score_gemma":0.00049452204,"threshold_uncertainty_score":0.6291472},"labels":[],"label_agreement":null},{"id":"W4416266598","doi":"10.1016/j.annonc.2025.08.011","title":"AJS-2 Unlocking undraggable targets: from mission impossible to mission achievable","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Spacecraft Dynamics and Control","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"MEDLINE; Set (abstract data type); Key (lock)","score_opus":0.023666258158634244,"score_gpt":0.3264646040222165,"score_spread":0.30279834586358223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416266598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7522731,0.010777752,0.060884286,0.023229165,0.0028762717,0.0008358107,0.0000959282,0.0005164881,0.1485112],"genre_scores_gemma":[0.99358994,0.00033917066,0.0021418766,0.0013084076,0.00008319838,0.000009458079,0.00001878418,0.00002670053,0.0024824669],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898285,0.000036190617,0.0003098865,0.00021362698,0.00010309812,0.00035432694],"domain_scores_gemma":[0.9993135,0.0001489994,0.000049490038,0.0002734162,0.00008663814,0.0001279669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018935718,0.00015457578,0.00037445562,0.00019318282,0.000069056776,0.00001906351,0.00022878914,0.00019929859,0.00014354044],"category_scores_gemma":[0.00007254237,0.00014943762,0.00008758634,0.00029201002,0.000015799715,0.00007444212,0.00007994988,0.00016041077,0.000034729288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031046337,0.00026993925,0.0024398004,0.00012221783,0.00033042315,0.000033668206,0.00049025624,0.08108455,0.6709894,0.0019153699,0.11782388,0.12419001],"study_design_scores_gemma":[0.0010623087,0.0004802131,0.0014300164,0.00022837162,0.00003809223,0.0000014237389,0.00016116472,0.2323082,0.05384434,0.0059593953,0.704208,0.00027847025],"about_ca_topic_score_codex":0.000340548,"about_ca_topic_score_gemma":0.000075192685,"teacher_disagreement_score":0.61714506,"about_ca_system_score_codex":0.000083724815,"about_ca_system_score_gemma":0.00010045125,"threshold_uncertainty_score":0.60938895},"labels":[],"label_agreement":null},{"id":"W4416387684","doi":"10.1016/j.annonc.2025.09.054","title":"LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Institute of Cancer Research; Seoul St. Mary's Hospital, Catholic University of Korea; Instituto de Salud Carlos III; Amgen; lékařská fakulta Univerzity Karlovy; Yonsei University College of Medicine; Taipei Veterans General Hospital; Saitama Medical University; Catholic University of Korea; Yonsei University; Univerzita Karlova v Praze; Mersana Therapeutics; AstraZeneca; Merck; Daiichi-Sankyo","keywords":"Ovarian cancer; Phases of clinical research; Primary (astronomy); Cancer; Ovary","score_opus":0.04016149790392913,"score_gpt":0.37707460921462554,"score_spread":0.3369131113106964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845903,0.0004109039,0.0008370456,0.005027057,0.0002185791,0.00093991123,0.00028797705,0.000016916629,0.0076713264],"genre_scores_gemma":[0.9955983,0.00024384906,0.0014347085,0.0021250672,0.00003243049,0.00010524724,0.000117159965,0.000016761682,0.00032646063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978541,0.00023598524,0.0009688262,0.00031602447,0.00036847353,0.00025658766],"domain_scores_gemma":[0.9976643,0.00017121524,0.0008911827,0.0005056627,0.00070719275,0.000060451723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048733214,0.00018054587,0.000987739,0.0005932678,0.000063304935,0.0000028622198,0.00018653751,0.00017643133,0.0003339011],"category_scores_gemma":[0.00011481781,0.00013368082,0.0001630898,0.0018757791,0.00028466698,0.00007895256,0.00006677279,0.00019621252,2.455858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08613835,0.02338477,0.4528469,0.0018179074,0.015565494,0.000039680635,0.0064138104,0.13064165,0.044051223,0.0043843356,0.017107375,0.2176085],"study_design_scores_gemma":[0.07475103,0.020577462,0.80565625,0.002703166,0.0051395604,0.0000038920125,0.00043023098,0.0068270825,0.05185408,0.00068104884,0.030765397,0.00061078515],"about_ca_topic_score_codex":0.00058658863,"about_ca_topic_score_gemma":0.00083128945,"teacher_disagreement_score":0.35280937,"about_ca_system_score_codex":0.00021646258,"about_ca_system_score_gemma":0.0010929331,"threshold_uncertainty_score":0.54513454},"labels":[],"label_agreement":null},{"id":"W4416387689","doi":"10.1016/j.annonc.2025.09.040","title":"LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Colorectal cancer; Metastatic melanoma; Chemotherapy; Phases of clinical research","score_opus":0.05744008029439762,"score_gpt":0.37715881685172103,"score_spread":0.3197187365573234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646294,0.014291718,0.00040075937,0.014125988,0.0014602013,0.0023243143,0.0013076193,0.00019700674,0.0012629912],"genre_scores_gemma":[0.96453345,0.009113557,0.007060222,0.008560035,0.0003637702,0.00044193075,0.0006673649,0.000115376344,0.009144274],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957977,0.0002584938,0.0017103715,0.0010408731,0.0003638013,0.00082879176],"domain_scores_gemma":[0.9968588,0.00076705427,0.00071264943,0.00085265416,0.0005875637,0.00022130707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011659883,0.00050254865,0.0016611806,0.00032575548,0.0001964407,0.000034417684,0.00037577437,0.00041068674,0.0003988598],"category_scores_gemma":[0.00027642748,0.0004648854,0.0007818337,0.000657646,0.00048324026,0.00013956991,0.00009903472,0.00034668285,0.000016293647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37650082,0.0029253957,0.0016603499,0.00085509144,0.0055793063,0.0000780525,0.008675622,0.00022312076,0.1588329,0.0004208882,0.11604104,0.32820743],"study_design_scores_gemma":[0.076009504,0.010988189,0.018404743,0.0010508753,0.0008583637,0.0000315442,0.0013380637,0.0014181614,0.17270537,0.0023279607,0.71404797,0.0008192738],"about_ca_topic_score_codex":0.023637902,"about_ca_topic_score_gemma":0.0051975166,"teacher_disagreement_score":0.5980069,"about_ca_system_score_codex":0.00076343905,"about_ca_system_score_gemma":0.0032330703,"threshold_uncertainty_score":0.9997803},"labels":[],"label_agreement":null},{"id":"W4416387692","doi":"10.1016/j.annonc.2025.09.056","title":"LBA44 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Defence and Security Accelerator; Humanitas University; Institute of Cancer Research; Yonsei University; University of Pittsburgh; Knight Cancer Institute, Oregon Health and Science University; Oregon Health and Science University; Università degli Studi di Milano; Debreceni Egyetem; AstraZeneca","keywords":"Bevacizumab; Durvalumab; Olaparib; Overall survival; Epithelial ovarian cancer; Survival analysis","score_opus":0.025898421506752027,"score_gpt":0.3407779570062561,"score_spread":0.3148795354995041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781634,0.001200955,0.00047017928,0.009795829,0.0012735389,0.0023451967,0.001477179,0.00014338038,0.005130294],"genre_scores_gemma":[0.98970443,0.0011444082,0.0016917061,0.00432974,0.00016488206,0.0006815106,0.00097518123,0.00011700705,0.0011911521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99370545,0.0006293315,0.0018518417,0.0014370593,0.0009929988,0.0013833125],"domain_scores_gemma":[0.995048,0.0012317002,0.0010557239,0.0011612059,0.0011152297,0.00038817103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007728552,0.0008564207,0.0024108165,0.00057169725,0.00019153324,0.000038876457,0.0005864957,0.00070251076,0.0006476375],"category_scores_gemma":[0.00066902477,0.0008185299,0.00035953752,0.0011990062,0.00047996303,0.0004066511,0.00016995025,0.001050366,0.000030516054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15022743,0.011544669,0.53326046,0.000768049,0.004422158,0.0011390614,0.004357556,0.0027409222,0.023022082,0.0015702866,0.10125029,0.16569705],"study_design_scores_gemma":[0.20003694,0.009599838,0.73287475,0.0029034787,0.0004252461,0.00000908071,0.0004646639,0.00082435226,0.012193134,0.0018630439,0.037426136,0.0013793261],"about_ca_topic_score_codex":0.0058289045,"about_ca_topic_score_gemma":0.0032870902,"teacher_disagreement_score":0.1996143,"about_ca_system_score_codex":0.0012632352,"about_ca_system_score_gemma":0.002312058,"threshold_uncertainty_score":0.99942654},"labels":[],"label_agreement":null},{"id":"W4416387716","doi":"10.1016/j.annonc.2025.09.047","title":"LBA36 Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms ≤2 cm: A prospective international observational multicentric cohort study (ASPEN study)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Asymptomatic; Observational study; Cohort study; Prospective cohort study; Cohort; Neuroendocrine carcinoma; Neuroendocrine tumors","score_opus":0.062095432303132296,"score_gpt":0.4168782477018111,"score_spread":0.3547828153986788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800074,0.00009057705,0.000053624,0.0026767296,0.000408948,0.0046154563,0.000009409942,0.000049893388,0.012087971],"genre_scores_gemma":[0.99509454,0.00018845001,0.000775148,0.0002799979,0.0000529012,0.00047616212,0.000022284932,0.000020993326,0.0030895195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712217,0.00024306771,0.00091087044,0.00051355606,0.0008309871,0.0003793361],"domain_scores_gemma":[0.9978749,0.00044810894,0.00041044934,0.00044026336,0.00072039873,0.00010584225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004137483,0.00022477607,0.0008154925,0.00063007383,0.00007292407,0.000013826927,0.00033098774,0.0000102273725,0.00021226483],"category_scores_gemma":[0.0005857847,0.0002073187,0.00012093472,0.00089584576,0.00018920189,0.00017492255,0.00030667658,0.00027298965,0.00001568309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016024018,0.008186091,0.97922176,0.00027239925,0.0020019272,0.0029809612,0.0001461885,0.00017032148,0.00012268759,0.00078271836,0.0007019115,0.0038106581],"study_design_scores_gemma":[0.0065981564,0.007104242,0.98010045,0.00015003976,0.00046302401,0.00015043237,0.0026156914,0.000615019,0.0008158176,0.00027468495,0.0010074612,0.00010499949],"about_ca_topic_score_codex":0.00021423744,"about_ca_topic_score_gemma":0.00006194889,"teacher_disagreement_score":0.015087152,"about_ca_system_score_codex":0.00015132119,"about_ca_system_score_gemma":0.0002500741,"threshold_uncertainty_score":0.84542114},"labels":[],"label_agreement":null},{"id":"W4416387737","doi":"10.1016/j.annonc.2025.09.126","title":"LBA107 ALBAN: A phase III, randomized, open-label, international study of intravenous (iv) atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naïve high-risk, non-muscle-invasive bladder cancer (NMIBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Tsukuba; Medizinische Universität Wien; Astellas Pharma; St. Antonius Ziekenhuis; Universität Wien; Russian Academy of Sciences; Cancer Research UK; Queen Mary University of London; Université Laval; Gilead Sciences; Merck KGaA; Sanofi; AstraZeneca; Pfizer","keywords":"Atezolizumab; Bladder cancer; Bacillus (shape); Bladder tumor; Standard of care; Resection","score_opus":0.050700726460933994,"score_gpt":0.40621506218727943,"score_spread":0.35551433572634544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848356,0.0011285207,0.0000990767,0.0057865065,0.0006473978,0.0035735238,0.0002248409,0.000018885095,0.0036856316],"genre_scores_gemma":[0.9922135,0.00413966,0.00024804642,0.0019890694,0.00018824483,0.00068204984,0.00005830598,0.000035435507,0.00044567455],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99649185,0.0004993374,0.0013553924,0.00071968115,0.00041773304,0.000516006],"domain_scores_gemma":[0.9973352,0.00090298697,0.0005734182,0.00044777602,0.00052590796,0.00021469739],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008668518,0.00042204387,0.0025287345,0.0005234185,0.00008576058,0.000026700087,0.00045385756,0.0003107193,0.00041569176],"category_scores_gemma":[0.0004070806,0.00035380374,0.00013064258,0.00046104475,0.00050195534,0.00017151359,0.0003791534,0.0005319749,0.0000067728693],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43094072,0.043458685,0.00936006,0.00031736444,0.010366174,0.0015694211,0.014128265,0.000076804354,0.0040818593,0.0007576547,0.007921778,0.47702122],"study_design_scores_gemma":[0.927118,0.028052324,0.026026713,0.00053390284,0.0018038775,0.00007506724,0.001985713,0.0004018807,0.010392456,0.0013296658,0.0018103386,0.00047008166],"about_ca_topic_score_codex":0.029561829,"about_ca_topic_score_gemma":0.0070924847,"teacher_disagreement_score":0.49617726,"about_ca_system_score_codex":0.0002461076,"about_ca_system_score_gemma":0.0012456155,"threshold_uncertainty_score":0.9998914},"labels":[],"label_agreement":null},{"id":"W4416387748","doi":"10.1016/j.annonc.2025.09.048","title":"LBA37 A phase II study of avelumab in locally advanced or metastatic penile cancer patients unfit for platinum-based chemotherapy or progressed on or after platinum-based chemotherapy (ALPACA)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Avelumab; Chemotherapy; Penile cancer; Chemotherapy regimen; Phases of clinical research","score_opus":0.06850458171728806,"score_gpt":0.4611741257478917,"score_spread":0.3926695440306036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938406,0.00017570658,0.00011365126,0.002615735,0.00013524698,0.0070119137,0.0003494883,0.000034299926,0.00017990965],"genre_scores_gemma":[0.9821165,0.000014621149,0.0018459054,0.012391026,0.000032812128,0.0026882514,0.00009237831,0.000051858777,0.0007666465],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99716693,0.00015486866,0.0011390463,0.00053973426,0.00039515374,0.0006042739],"domain_scores_gemma":[0.99736637,0.00076222647,0.00054344675,0.00041983117,0.0006288755,0.00027924922],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003462514,0.00037460096,0.0012621571,0.00045123178,0.00007423835,0.0000061290375,0.0001871769,0.0001721267,0.0010193761],"category_scores_gemma":[0.00053751393,0.00025768796,0.00016755004,0.0006990721,0.00013572274,0.00007100192,0.000022681714,0.0002007936,0.000002277526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6331034,0.06217177,0.014096289,0.0028127683,0.00021697766,0.0001477765,0.0014124728,0.00029691303,0.00045293264,0.000008141622,0.0019035307,0.28337708],"study_design_scores_gemma":[0.47348595,0.42828327,0.050018515,0.0013416127,0.00049583486,0.000002528203,0.0015140864,0.006156537,0.029159829,0.00017673423,0.00866159,0.00070351013],"about_ca_topic_score_codex":0.000118398566,"about_ca_topic_score_gemma":0.0011848841,"teacher_disagreement_score":0.36611152,"about_ca_system_score_codex":0.00015836878,"about_ca_system_score_gemma":0.0036880637,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W4416387758","doi":"10.1016/j.annonc.2025.09.049","title":"LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Southwest Medical University; University of Science and Technology of China; Tongji Medical College, Huazhong University of Science and Technology; Fourth Military Medical University; Hebei Medical University; Tongji University; Huazhong University of Science and Technology; Chongqing University; Jiangsu Hengrui Medicine","keywords":"Pembrolizumab; Bevacizumab; Placebo; Phases of clinical research; Paclitaxel; Randomized controlled trial","score_opus":0.09908739646318673,"score_gpt":0.4280868963601682,"score_spread":0.3289994998969815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8975099,0.006212549,0.000052270098,0.07225075,0.0012426643,0.008914852,0.0008114492,0.00006143387,0.012944169],"genre_scores_gemma":[0.99186695,0.002876158,0.0001588466,0.0015967656,0.0003419124,0.0022465037,0.00022727986,0.000036085,0.00064952264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946224,0.0011157128,0.002049359,0.0009830181,0.00054473226,0.0006847854],"domain_scores_gemma":[0.9932608,0.0042225923,0.0008303084,0.0010777939,0.00039186573,0.00021662586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002480731,0.00052118255,0.0026681714,0.00036582668,0.00018870419,0.000043503012,0.00042257467,0.0003436947,0.00027933187],"category_scores_gemma":[0.00075711077,0.0003583596,0.0003996521,0.0006906716,0.00031512228,0.00010097244,0.00019925302,0.00066163955,0.000013357483],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9133827,0.006778352,0.0007867706,0.000055385666,0.0023848,0.0003175355,0.0059200963,0.00009540514,0.00004384231,0.0015477691,0.0125847785,0.056102548],"study_design_scores_gemma":[0.9536353,0.007280668,0.008112081,0.0007108157,0.0013777239,0.0000042511815,0.0016364068,0.0003229311,0.0005231981,0.0007066121,0.025404925,0.00028508512],"about_ca_topic_score_codex":0.021305159,"about_ca_topic_score_gemma":0.013227576,"teacher_disagreement_score":0.094357066,"about_ca_system_score_codex":0.00075946876,"about_ca_system_score_gemma":0.002420601,"threshold_uncertainty_score":0.9998868},"labels":[],"label_agreement":null},{"id":"W4416387766","doi":"10.1016/j.annonc.2025.09.127","title":"LBA108 Durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Final analysis of the phase III, open-label, randomised POTOMAC trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Cilag; Institut National Du Cancer; Sanofi; AstraZeneca; Pfizer","keywords":"Durvalumab; Bladder cancer; Bacillus (shape); Phases of clinical research; Cancer; Clinical trial","score_opus":0.08227437248820987,"score_gpt":0.4244943737016463,"score_spread":0.34222000121343643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858133,0.00035825395,0.00033669005,0.0046366807,0.00039167193,0.005597367,0.00047436863,0.000011452071,0.0023801841],"genre_scores_gemma":[0.99495804,0.0005181666,0.00025082077,0.0015513458,0.000072216455,0.0014632179,0.00011062068,0.00002211976,0.0010534344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997612,0.00033846314,0.00088837824,0.00047013955,0.0003203099,0.00037069494],"domain_scores_gemma":[0.9972481,0.000843248,0.00069306564,0.00049029256,0.0006340032,0.00009128651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007436314,0.00027616243,0.0016543732,0.0005206534,0.00011623958,0.000013995314,0.0003632995,0.00022922225,0.00022288345],"category_scores_gemma":[0.00036714083,0.00018795834,0.00028753912,0.0014354469,0.00024919308,0.00010897278,0.00010630207,0.00023400808,9.532861e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74970603,0.014517797,0.007779718,0.00023098936,0.016216928,0.000059182912,0.0011565462,0.0004863866,0.003172447,0.0004196124,0.009643354,0.196611],"study_design_scores_gemma":[0.9225783,0.020981269,0.02772706,0.00022157365,0.008283996,0.0000024675314,0.00021154218,0.0009411854,0.016372332,0.00051770866,0.0019448695,0.00021771216],"about_ca_topic_score_codex":0.00903271,"about_ca_topic_score_gemma":0.008352093,"teacher_disagreement_score":0.1963933,"about_ca_system_score_codex":0.00019495792,"about_ca_system_score_gemma":0.0020558452,"threshold_uncertainty_score":0.9975662},"labels":[],"label_agreement":null},{"id":"W4416391581","doi":"10.1016/j.annonc.2025.09.031","title":"LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Astellas Pharma; Eisai; Jazz Pharmaceuticals; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; G1 Therapeutics; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Metastatic breast cancer; Chemotherapy; Immunotherapy; Breast cancer; Cancer; Chemotherapy regimen","score_opus":0.08251542603776353,"score_gpt":0.4295659143172496,"score_spread":0.3470504882794861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93668437,0.00073493214,0.0012132614,0.046756323,0.0005670104,0.010869197,0.002978333,0.00003956342,0.0001570138],"genre_scores_gemma":[0.974842,0.005145589,0.0025764694,0.010950193,0.0006520426,0.003471055,0.0014229192,0.000114609655,0.0008251006],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955805,0.00078001374,0.0014794826,0.0008081479,0.00065832847,0.0006935184],"domain_scores_gemma":[0.9948268,0.0023755624,0.00058485236,0.0008790703,0.0011289585,0.00020477122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015522899,0.0004343787,0.001672604,0.00028012876,0.00024272925,0.00005393025,0.00054542685,0.00022585779,0.0004490366],"category_scores_gemma":[0.00057915016,0.00026749415,0.0002083367,0.00075686304,0.00050931016,0.00023864229,0.00007415809,0.00059820595,0.0000028881188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67921376,0.004501706,0.00034114544,0.00009500472,0.0008112621,0.000016531158,0.0014349398,0.000060341525,0.00015422919,0.000015996668,0.0034508577,0.3099042],"study_design_scores_gemma":[0.9172048,0.03003153,0.012630693,0.00090582954,0.0002579251,0.000009459805,0.0003661803,0.0009521572,0.0027975482,0.00023016958,0.034279473,0.0003342184],"about_ca_topic_score_codex":0.003916827,"about_ca_topic_score_gemma":0.0052352175,"teacher_disagreement_score":0.30956998,"about_ca_system_score_codex":0.00058030325,"about_ca_system_score_gemma":0.004472716,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W4416391584","doi":"10.1016/j.annonc.2025.09.032","title":"LBA22 Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Eisai; Gilead Sciences; AstraZeneca; Gilead UK and Ireland Corporate Contributions; Pfizer","keywords":"Pembrolizumab; Metastatic breast cancer; Chemotherapy; Breast cancer; Phases of clinical research; Chemotherapy regimen","score_opus":0.027596952817562605,"score_gpt":0.36601590485305335,"score_spread":0.33841895203549077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872939,0.0003628099,0.00001738273,0.0048350706,0.00015734689,0.006382287,0.00014785102,0.00005232727,0.0007509993],"genre_scores_gemma":[0.9933976,0.0003026532,0.00008942907,0.0048085083,0.000022658323,0.00082409737,0.000102852435,0.00006453407,0.00038764934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511105,0.0007126739,0.001616205,0.00088862324,0.00080203835,0.00086942286],"domain_scores_gemma":[0.99681413,0.00041766712,0.001099866,0.000881965,0.00064645347,0.0001399196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083714625,0.0006966988,0.001984965,0.00070677436,0.00013243142,0.000036713165,0.0004092928,0.00020689526,0.00024132778],"category_scores_gemma":[0.00012380547,0.00042678203,0.00024464872,0.0020752246,0.0004647818,0.0002207571,0.00006190872,0.00059447915,0.0000021604947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32335654,0.022013212,0.5144186,0.0002473533,0.004074095,0.00037359708,0.013675945,0.0000387432,0.00033148605,0.000014185716,0.0014119571,0.12004426],"study_design_scores_gemma":[0.21612296,0.02565881,0.7483878,0.00061283016,0.000669632,0.00007943407,0.0050824108,0.000073227995,0.0016220768,0.00003094794,0.001193873,0.0004659913],"about_ca_topic_score_codex":0.012537387,"about_ca_topic_score_gemma":0.012434019,"teacher_disagreement_score":0.2339692,"about_ca_system_score_codex":0.00079461193,"about_ca_system_score_gemma":0.0016739941,"threshold_uncertainty_score":0.9998184},"labels":[],"label_agreement":null},{"id":"W4416391612","doi":"10.1016/j.annonc.2025.09.103","title":"LBA87 EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SAIT Polytechnic; University of British Columbia","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Bristol-Myers Squibb; AstraZeneca; Movember Foundation; University of California, San Francisco; Comprehensive Cancer Center, City of Hope; Exelixis; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; NorthShore University HealthSystem; Genentech; University of Pittsburgh; University of Texas MD Anderson Cancer Center; Pfizer; Cancer Institute, University of Pittsburgh; Roswell Park Cancer Institute","keywords":"Enzalutamide; Overall survival; Prostate cancer; Recurrent prostate cancer; Survival analysis; Progression-free survival","score_opus":0.06934023701720003,"score_gpt":0.4391255060900267,"score_spread":0.36978526907282666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958035,0.0049700155,0.000003150249,0.01973005,0.00015026232,0.0005427272,0.000026718519,0.00001654604,0.01652553],"genre_scores_gemma":[0.98824936,0.006960573,0.00014710179,0.0009443875,0.000047433045,0.00014705442,0.000036860674,0.000012173169,0.0034550366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882555,0.00007339369,0.00027758846,0.00026231303,0.0001888798,0.00037227897],"domain_scores_gemma":[0.999278,0.00010660917,0.00007715118,0.00018272732,0.0002644373,0.00009106537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027966496,0.00012818177,0.00044173546,0.00020555375,0.000021504375,0.0000046214755,0.00009188022,0.00011035828,0.000089857],"category_scores_gemma":[0.00006670062,0.00008968177,0.00005721534,0.00032723657,0.00018345888,0.00003840205,0.00006056368,0.00023823744,0.000004370084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033474356,0.0033044794,0.5168182,0.0010793627,0.0010116408,0.00066384533,0.0014713025,0.000041260293,0.055693455,0.001932767,0.028412748,0.35609657],"study_design_scores_gemma":[0.029663196,0.011960188,0.42193118,0.002574033,0.0002252262,0.000026886368,0.000533408,0.00013155592,0.3301867,0.0031193001,0.1991285,0.0005198304],"about_ca_topic_score_codex":0.00040560425,"about_ca_topic_score_gemma":0.00043954173,"teacher_disagreement_score":0.35557672,"about_ca_system_score_codex":0.0001592146,"about_ca_system_score_gemma":0.0012872573,"threshold_uncertainty_score":0.36571166},"labels":[],"label_agreement":null},{"id":"W4416391634","doi":"10.1016/j.annonc.2025.09.130","title":"LBA111 Randomized comparison of upfront magnetic resonance imaging versus transurethral resection for staging new bladder cancers: Final survival analysis from the BladderPath trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Assistance publique-Hôpitaux de Paris; Medac; University College London; Weston Park Cancer Charity; National Institute for Health and Care Research; Cancer Research UK; Seoul National University Hospital; UroGen Pharma; AstraZeneca; Queen Elizabeth Hospital Birmingham Charity; Astellas Pharma; Elekta; Université de Paris; Queen Mary University of London; University of Washington; Gilead Sciences; Seoul National University; Sanofi; Pfizer","keywords":"Cystoscopy; Bladder cancer; Magnetic resonance imaging; Stage (stratigraphy); Clinical trial; Resection","score_opus":0.12984180004286444,"score_gpt":0.43859941479951153,"score_spread":0.3087576147566471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8306668,0.08093416,0.021315783,0.04379494,0.0052932715,0.0071270624,0.00074764085,0.000089886504,0.0100304475],"genre_scores_gemma":[0.99671304,0.0006637718,0.00088821,0.00062148593,0.00038900232,0.0001596947,0.0000899308,0.000017071865,0.00045777406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99771845,0.0004350528,0.0008404838,0.00037327604,0.0003060845,0.00032667755],"domain_scores_gemma":[0.99681395,0.0020998435,0.00032952643,0.0003569475,0.00032037287,0.000079383266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008643804,0.00021161047,0.0016431994,0.00020690415,0.00009649318,0.000011657018,0.00018326905,0.00012899232,0.00019955351],"category_scores_gemma":[0.00039177603,0.00015558816,0.0006905575,0.0005320074,0.00028631318,0.00005876371,0.000027220998,0.00021064146,6.865428e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8560533,0.0003676136,0.0072118365,0.000030175908,0.002737629,0.0000033020347,0.001706798,0.00014882532,0.00018211786,0.00015951399,0.00949301,0.12190591],"study_design_scores_gemma":[0.9367276,0.008042512,0.013198092,0.0001419085,0.0099251885,5.5644614e-7,0.0015699201,0.004644911,0.003969275,0.0011821393,0.02039916,0.00019875297],"about_ca_topic_score_codex":0.013020797,"about_ca_topic_score_gemma":0.0056784456,"teacher_disagreement_score":0.16604625,"about_ca_system_score_codex":0.000120926576,"about_ca_system_score_gemma":0.0011088287,"threshold_uncertainty_score":0.9935516},"labels":[],"label_agreement":null},{"id":"W4416391641","doi":"10.1016/j.annonc.2025.09.064","title":"LBA52 Nofazinlimab combined with lenvatinib versus placebo plus lenvatinib as first-line therapy for unresectable or metastatic hepatocellular carcinoma: A phase III, randomized, double-blind, multiregional study (CS1003-305)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; European Association for the Study of the Liver; Servier; Gilead Sciences; Hospices Civils de Lyon; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; Les Laboratories Pierre Fabre; Eisai; Ipsen; Jazz Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Oncolytics Biotech; Boston Scientific Corporation; American Association for the Study of Liver Diseases; Bayer HealthCare; Kowa Company; Sanofi; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Placebo; Hepatocellular carcinoma; Phases of clinical research; Clinical trial; Monoclonal","score_opus":0.2859654360450613,"score_gpt":0.425820200287502,"score_spread":0.1398547642424407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688114,0.0019687947,0.0007704143,0.005590869,0.00034241343,0.020360993,0.00007080134,0.000098102755,0.001986242],"genre_scores_gemma":[0.9868737,0.00050892314,0.0015869909,0.00085600786,0.00012851246,0.0065711937,0.0005447272,0.0000841902,0.0028457565],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956651,0.0005281311,0.0014494093,0.00090258947,0.00059529586,0.00085947773],"domain_scores_gemma":[0.99315137,0.0040836204,0.00069461885,0.0007472571,0.0010246855,0.000298422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019603171,0.00071354234,0.0031852033,0.00061814964,0.00033182214,0.000038553535,0.0003533825,0.00028473494,0.0004040917],"category_scores_gemma":[0.0004975612,0.00048881,0.0006382597,0.00089674984,0.00048792385,0.00017079248,0.0001059356,0.00037535955,0.000017923929],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9465458,0.012918657,0.024888635,0.00031769508,0.005423425,0.00084192044,0.0015578029,0.00002007411,0.00012363505,0.00057617953,0.0017946947,0.004991517],"study_design_scores_gemma":[0.89412266,0.074417084,0.00010503412,0.00014479805,0.0021729942,0.0000360235,0.0011204609,0.009345721,0.009255712,0.00011164022,0.008761937,0.0004059671],"about_ca_topic_score_codex":0.0010615503,"about_ca_topic_score_gemma":0.0005695746,"teacher_disagreement_score":0.061498426,"about_ca_system_score_codex":0.0001770929,"about_ca_system_score_gemma":0.0024134999,"threshold_uncertainty_score":0.99975634},"labels":[],"label_agreement":null},{"id":"W4416391671","doi":"10.1016/j.annonc.2025.09.100","title":"LBA85 Results of a randomized phase III trial of short-course versus long-course pre-operative chemotherapy for stage I-III pancreatic ductal adenocarcinoma (PDAC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Pancreatic ductal adenocarcinoma; Chemotherapy; Stage (stratigraphy); Adenocarcinoma; Pancreatic carcinoma; Phases of clinical research","score_opus":0.09589621341850306,"score_gpt":0.48449964360584,"score_spread":0.38860343018733695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746459,0.0020199984,0.00096880057,0.0049105003,0.00040783608,0.006508441,0.00021569124,0.000021933616,0.010300893],"genre_scores_gemma":[0.99058264,0.0016122935,0.0014883787,0.00025987066,0.00022165517,0.0005848957,0.00012285402,0.00002707517,0.00510032],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99593776,0.0006509681,0.0019426898,0.00048239692,0.000433375,0.0005527852],"domain_scores_gemma":[0.9927337,0.0044847224,0.00073909,0.00063847867,0.0012180277,0.00018596437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036192327,0.00031212947,0.004039082,0.00032057567,0.00007567897,0.0000051038987,0.00028957808,0.00044423217,0.00021617493],"category_scores_gemma":[0.0026065358,0.000248407,0.0006897004,0.0003772062,0.0014423915,0.0000824289,0.00007378421,0.000307459,0.0000017952334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9658892,0.006643275,0.0016068975,0.00032653677,0.0052468977,0.00006404954,0.0021629632,0.0000051552797,0.0028472247,0.001085611,0.005573749,0.00854841],"study_design_scores_gemma":[0.93561935,0.040565874,0.0028998915,0.00023803071,0.0026949774,0.000011020489,0.0010359953,0.0011116294,0.014666784,0.0002307961,0.00076262275,0.00016305064],"about_ca_topic_score_codex":0.0003782516,"about_ca_topic_score_gemma":0.000113109694,"teacher_disagreement_score":0.033922598,"about_ca_system_score_codex":0.00007797501,"about_ca_system_score_gemma":0.003037341,"threshold_uncertainty_score":0.99999684},"labels":[],"label_agreement":null},{"id":"W4416391673","doi":"10.1016/j.annonc.2025.09.067","title":"LBA55 START-001: Initial phase II clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bispecific antibody; Blockade; Immune checkpoint; Antibody; T cell; Immune system; Immunotherapy","score_opus":0.060706116302489614,"score_gpt":0.43227839584045974,"score_spread":0.3715722795379701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837602,0.0005020706,0.000008139837,0.010624881,0.00023625293,0.0015186468,0.00016533061,0.000019442321,0.00316508],"genre_scores_gemma":[0.9958519,0.0013795658,0.00030672195,0.00082146534,0.00010227459,0.000050032155,0.0001465647,0.00003860001,0.0013028817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956733,0.00036766758,0.0017624983,0.0007115613,0.000639099,0.0008458798],"domain_scores_gemma":[0.9973165,0.00063580176,0.00053989806,0.0005608482,0.0006375538,0.00030942375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014671921,0.00039375195,0.0018441394,0.0009544632,0.00011812014,0.0000113661745,0.00037144468,0.00036416517,0.00041032524],"category_scores_gemma":[0.00038243976,0.0003260643,0.0002547662,0.0011871228,0.00050624757,0.00011837615,0.0002659108,0.0008332433,0.000021824875],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20657182,0.052980535,0.24985783,0.000721025,0.00073672744,0.00058294326,0.0019309847,0.0000502698,0.43727058,0.00014168964,0.003783895,0.045371708],"study_design_scores_gemma":[0.032209683,0.060406562,0.4698369,0.000757955,0.0000419403,0.0000043282866,0.000252049,0.00014427,0.37635195,0.00011389809,0.05941335,0.0004671123],"about_ca_topic_score_codex":0.0016928772,"about_ca_topic_score_gemma":0.00082796445,"teacher_disagreement_score":0.21997906,"about_ca_system_score_codex":0.00013799155,"about_ca_system_score_gemma":0.0010294613,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W4416391683","doi":"10.1016/j.annonc.2025.09.074","title":"LBA62 Phase I trial of camu camu prebiotic plus immunotherapy in patients with melanoma and non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; Hôpital Charles-Le Moyne; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Melanoma; Prebiotic; Immunotherapy; Lung cancer; Clinical trial; Cancer immunotherapy","score_opus":0.024511910266033186,"score_gpt":0.31948579224085044,"score_spread":0.2949738819748173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956695,0.00042357342,0.0000030743568,0.00085097377,0.000044352106,0.00060714094,0.000079253754,0.0000048252605,0.0023173187],"genre_scores_gemma":[0.9993402,0.00021842752,0.000028551016,0.00018395904,0.000036705667,0.00005749754,0.000037233734,6.554276e-7,0.00009677509],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992851,0.000037596128,0.00026219827,0.00017580208,0.00008223049,0.00015708724],"domain_scores_gemma":[0.99942046,0.00020540672,0.00018098167,0.000058040052,0.00009719172,0.0000379068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013133377,0.000092281014,0.00029926334,0.000019538871,0.000029714565,0.0000031658362,0.00015579017,0.00010212107,0.000035911555],"category_scores_gemma":[0.000015857311,0.00004036017,0.000029957375,0.0002150192,0.000097930904,0.00002716075,0.000028903065,0.000087791435,2.9530605e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060104586,0.005539011,0.22406496,0.00026642386,0.00021730493,0.000008764727,0.0007713093,0.00002631581,0.48094845,0.00008688219,0.0031981184,0.22476788],"study_design_scores_gemma":[0.088231705,0.014605979,0.74089545,0.00037853964,0.000104632476,0.0000017569436,0.0003801116,0.00017090989,0.14618577,0.00021235205,0.008441136,0.00039163826],"about_ca_topic_score_codex":0.0007252066,"about_ca_topic_score_gemma":0.0005584067,"teacher_disagreement_score":0.5168305,"about_ca_system_score_codex":0.000023845292,"about_ca_system_score_gemma":0.000093784285,"threshold_uncertainty_score":0.164584},"labels":[],"label_agreement":null},{"id":"W4416391722","doi":"10.1016/j.annonc.2025.09.101","title":"LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Phases of clinical research; Clinical trial; Chemotherapy; Phase (matter)","score_opus":0.04062675798568513,"score_gpt":0.39697898191817627,"score_spread":0.3563522239324911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892123,0.00035182203,0.000022399137,0.0034291418,0.00009940054,0.0033060396,0.00058857125,0.000016231184,0.00297413],"genre_scores_gemma":[0.99678695,0.0005573913,0.00020816454,0.0005173114,0.00003025713,0.00041306514,0.00056841155,0.000022795948,0.00089565094],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979604,0.00023202448,0.0005702552,0.00037793478,0.0004094758,0.0004499084],"domain_scores_gemma":[0.99780667,0.00030272483,0.00037933004,0.0002503922,0.0011279617,0.00013289755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003151115,0.00025284383,0.0010985708,0.000438897,0.00006067629,0.000006733075,0.000092738446,0.00010229486,0.000055642802],"category_scores_gemma":[0.00007680182,0.00016994111,0.000092625196,0.0006940479,0.00053563376,0.00013785416,0.000050436647,0.00028329625,0.000002855342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93657947,0.010620491,0.0075347456,0.00022641911,0.0022528518,0.0003765953,0.002242398,0.00002899748,0.0006439403,0.00028818753,0.0036787253,0.0355272],"study_design_scores_gemma":[0.7133725,0.14790457,0.09342173,0.0011370135,0.00087111874,0.0000070093597,0.0015842204,0.00007442216,0.03985185,0.0003674218,0.0010690945,0.00033900334],"about_ca_topic_score_codex":0.00053702475,"about_ca_topic_score_gemma":0.0003709325,"teacher_disagreement_score":0.22320691,"about_ca_system_score_codex":0.00019114988,"about_ca_system_score_gemma":0.0014805198,"threshold_uncertainty_score":0.6929997},"labels":[],"label_agreement":null},{"id":"W4416391724","doi":"10.1016/j.annonc.2025.09.076","title":"LBA64 Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: Initial results from the registrational PATHFINDER II study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pathfinder; Test (biology); Test site","score_opus":0.6448445048999395,"score_gpt":0.6030298954929485,"score_spread":0.041814609406991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555904,0.000018522667,0.0022166884,0.0009316077,0.00021956018,0.0005662087,0.00030980032,0.000013575194,0.00016498615],"genre_scores_gemma":[0.96536636,0.00005484801,0.03418508,0.00020627838,0.00009193108,0.00003629426,0.0000055237415,0.0000076579745,0.000046026904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972117,0.00091638975,0.0012717168,0.00028325917,0.00017982401,0.0001371225],"domain_scores_gemma":[0.9683989,0.030426417,0.0005106033,0.00030776006,0.0003216336,0.000034680048],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002654003,0.000114269824,0.00050954416,0.0000717951,0.00008575395,0.0000111518975,0.00016129125,0.00018449941,0.00002217751],"category_scores_gemma":[0.045862924,0.000087136286,0.000044016324,0.00021879743,0.00021402935,0.00013435408,0.00010921436,0.00027421175,3.4081583e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017672585,0.0067542987,0.5210181,0.00010563667,0.0002911151,0.00001399588,0.0045912885,0.000089696194,0.00075707346,0.011150386,0.0003245837,0.43723127],"study_design_scores_gemma":[0.0036546998,0.004146077,0.9274267,0.00010380748,0.00005520053,6.6860787e-7,0.000273866,0.0017439529,0.00054056535,0.061896794,0.00007418866,0.00008346236],"about_ca_topic_score_codex":0.0009527961,"about_ca_topic_score_gemma":0.003735879,"teacher_disagreement_score":0.4371478,"about_ca_system_score_codex":0.000030338619,"about_ca_system_score_gemma":0.00011197514,"threshold_uncertainty_score":0.9621742},"labels":[],"label_agreement":null},{"id":"W4416391725","doi":"10.1016/j.annonc.2025.09.105","title":"LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University of Alberta; Sunnybrook Health Science Centre; Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Université Laval; University of British Columbia Hospital; Juravinski Cancer Centre; Western University; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Prostate cancer; Randomized controlled trial; Clinical trial; Phases of clinical research","score_opus":0.0752403058241683,"score_gpt":0.4500744677641108,"score_spread":0.3748341619399425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97953165,0.00385542,0.0000018764836,0.0028553968,0.00011829091,0.012529987,0.0009372565,0.000009237306,0.00016086026],"genre_scores_gemma":[0.99545336,0.0009396429,0.00003331697,0.00023835365,0.000025593412,0.0026370017,0.00012211838,0.000022732274,0.00052790524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959271,0.0013802447,0.0011611676,0.00052846293,0.0004769098,0.00052613736],"domain_scores_gemma":[0.9973291,0.00064126187,0.0005482112,0.0002969456,0.0008035629,0.00038090366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019159862,0.00031774113,0.0023025488,0.0006924579,0.00016138125,0.000019517654,0.00012377805,0.00006896638,0.000088296816],"category_scores_gemma":[0.00047439072,0.00021155382,0.00011971645,0.00065471506,0.0003485175,0.00013730499,0.00006550437,0.00022946576,3.6727002e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6977854,0.023918275,0.23460384,0.000449042,0.0056105214,0.0005081333,0.012270953,0.00004767653,0.00017666852,0.00007146263,0.0006235555,0.023934474],"study_design_scores_gemma":[0.58509487,0.036091667,0.3709267,0.0005755558,0.00254583,7.9551774e-7,0.0038235679,0.000051308238,0.00031922347,0.00011827076,0.00023049008,0.00022171621],"about_ca_topic_score_codex":0.15033408,"about_ca_topic_score_gemma":0.33327767,"teacher_disagreement_score":0.18294361,"about_ca_system_score_codex":0.00034224844,"about_ca_system_score_gemma":0.0036615024,"threshold_uncertainty_score":0.86269146},"labels":[],"label_agreement":null},{"id":"W4416391729","doi":"10.1016/j.annonc.2025.09.079","title":"LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lung cancer; Perioperative; Respiratory disease; Cancer","score_opus":0.032199601494794144,"score_gpt":0.35926907952241294,"score_spread":0.32706947802761877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954295,0.0042866217,0.00005114159,0.0048056114,0.00070876774,0.00063142576,0.00008892042,0.000021878646,0.03511068],"genre_scores_gemma":[0.9792007,0.0025839882,0.0001940667,0.0045785327,0.00012261374,0.000110575325,0.000026501635,0.000023736879,0.013159249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984056,0.00012410889,0.0005257269,0.00039306606,0.00015655802,0.0003949867],"domain_scores_gemma":[0.99903667,0.00016649738,0.00016921728,0.00034291265,0.00020258148,0.000082124054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026669988,0.00022291942,0.000712939,0.00025001052,0.000058766294,0.0000137714,0.00019948081,0.00030381797,0.00088120543],"category_scores_gemma":[0.000044913217,0.00020199237,0.00022895132,0.00038679744,0.00017077928,0.00007491142,0.000074732045,0.00032928016,0.000013265482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10005285,0.0023692206,0.44333053,0.0008886558,0.0026925784,0.0005238049,0.033138957,0.00009100497,0.265068,0.00040336399,0.050068446,0.1013726],"study_design_scores_gemma":[0.054943033,0.0046779,0.5815893,0.0011970262,0.00032520815,0.000004657266,0.0049071386,0.00049914914,0.21045688,0.000074160635,0.1407032,0.00062236877],"about_ca_topic_score_codex":0.022993246,"about_ca_topic_score_gemma":0.005282841,"teacher_disagreement_score":0.13825876,"about_ca_system_score_codex":0.00020623504,"about_ca_system_score_gemma":0.0012623656,"threshold_uncertainty_score":0.9835127},"labels":[],"label_agreement":null},{"id":"W4416391742","doi":"10.1016/j.annonc.2025.09.077","title":"LBA65 Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; AstraZeneca (Canada); Kingston General Hospital","funders":"Jiangsu Cancer Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; University of Chicago Medicine; Betta Pharmaceuticals; State Key Laboratory of Molecular Oncology; Guangxi Medical University; Xiamen University; School of Medicine, Stanford University; Tianjin Medical University; Weill Cornell Medical College; Peking University; Directorate for Biological Sciences; Universidad de Las Palmas de Gran Canaria; Université de Montréal; University of Chinese Academy of Sciences; Zhejiang University; Chinese Academy of Medical Sciences; Tongji University; Peking Union Medical College; Huazhong University of Science and Technology; Dalian University of Technology; Shandong University; Sichuan University; Sun Yat-sen University; McGill University; McGill University Health Centre; Chinese Academy of Sciences; West China Hospital, Sichuan University; Lanzhou University; Stanford Cancer Institute; Harbin Medical University; Memorial Sloan-Kettering Cancer Center; Deutsches Zentrum für Lungenforschung; AstraZeneca","keywords":"Durvalumab; Interim; Neoadjuvant therapy; Chemotherapy; Adjuvant; Stage (stratigraphy)","score_opus":0.05451174183621708,"score_gpt":0.40424994759058586,"score_spread":0.34973820575436876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945737,0.0013741177,0.000034992077,0.0019639793,0.00009579672,0.0015607745,0.00010582149,0.0000121689245,0.00027866545],"genre_scores_gemma":[0.99522275,0.0011695295,0.00004172109,0.0008325314,0.000012979939,0.00008864931,0.00005539452,0.000023384606,0.002553047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976597,0.0003883558,0.0008629167,0.00044372847,0.00030207686,0.0003432258],"domain_scores_gemma":[0.99820554,0.00042710756,0.0004964653,0.00048103178,0.00032042098,0.000069413734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013076963,0.0002496782,0.001236771,0.0004965357,0.000116769144,0.000015115187,0.00014772436,0.00010930143,0.00034712185],"category_scores_gemma":[0.0002594262,0.00014965357,0.00013408846,0.001456378,0.00034322953,0.0001259591,0.00010751446,0.00019433364,1.7651365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21993667,0.014332372,0.5892256,0.00032445038,0.0051747574,0.00007820138,0.0027697582,0.000010258514,0.022529766,0.000005725554,0.017805083,0.12780736],"study_design_scores_gemma":[0.10375405,0.05793654,0.7449174,0.000994279,0.00139319,0.00002376726,0.0035340046,0.00039676658,0.049804714,0.000013187931,0.036676437,0.0005556362],"about_ca_topic_score_codex":0.0025052465,"about_ca_topic_score_gemma":0.00457959,"teacher_disagreement_score":0.15569182,"about_ca_system_score_codex":0.0000873492,"about_ca_system_score_gemma":0.00060895586,"threshold_uncertainty_score":0.61026955},"labels":[],"label_agreement":null},{"id":"W4416391774","doi":"10.1016/j.annonc.2025.09.060","title":"LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Paclitaxel; Head and neck; Immunotherapy; Head and neck squamous-cell carcinoma; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.03394894241334596,"score_gpt":0.3529242206495555,"score_spread":0.3189752782362095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529576,0.0023145063,0.00003864374,0.00012096952,0.00016871866,0.0009896671,0.00012603623,0.000008785011,0.00093690364],"genre_scores_gemma":[0.9991335,0.000081257844,0.00016389448,0.00022645334,0.000028491491,0.00008076089,0.00011877315,0.000026939868,0.00013991578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977165,0.00031389433,0.0007205291,0.00060340494,0.00022172401,0.00042397203],"domain_scores_gemma":[0.99842286,0.00011255128,0.00041307337,0.00052355655,0.00041815243,0.0001098338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032092608,0.00031158124,0.00077298126,0.00024527,0.00005025582,0.000010007813,0.00028401436,0.00020636174,0.000020700845],"category_scores_gemma":[0.000139033,0.00028318603,0.00008537126,0.00039179221,0.00022334185,0.00001165159,0.00016802881,0.00019826528,9.783682e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04988494,0.026502583,0.8249127,0.001026478,0.00087769073,0.00015356674,0.00416589,0.0006869191,0.05294331,0.000044106375,0.008937116,0.029864693],"study_design_scores_gemma":[0.19948804,0.19900182,0.40974686,0.00042071677,0.0007636719,0.000015693131,0.003003416,0.00040809828,0.17740038,0.00020221525,0.008035894,0.0015131873],"about_ca_topic_score_codex":0.00070034614,"about_ca_topic_score_gemma":0.00067231077,"teacher_disagreement_score":0.41516584,"about_ca_system_score_codex":0.00005650974,"about_ca_system_score_gemma":0.00042446514,"threshold_uncertainty_score":0.99996203},"labels":[],"label_agreement":null},{"id":"W4416391787","doi":"10.1016/j.annonc.2025.09.028","title":"LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Taxane; Trastuzumab; Breast cancer; Chemotherapy","score_opus":0.147782217334356,"score_gpt":0.4590405512808375,"score_spread":0.3112583339464815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843241,0.0007837109,0.0006479549,0.0037687698,0.0001905117,0.0021426245,0.006755221,0.00003762482,0.0013494611],"genre_scores_gemma":[0.9922989,0.0005116193,0.004596087,0.000566057,0.00007782936,0.00086052786,0.0006782775,0.000081452774,0.00032926226],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952645,0.00037937707,0.0017419175,0.00085438084,0.00078149,0.0009783709],"domain_scores_gemma":[0.9938845,0.0017144101,0.0009263893,0.00066429016,0.002497711,0.0003126758],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064839085,0.0005505865,0.002157871,0.0012509581,0.00009153637,0.000012598267,0.0005708182,0.00028015836,0.0018769044],"category_scores_gemma":[0.0010108161,0.00047148005,0.00040101932,0.0014837496,0.0010273956,0.00023928208,0.00014828255,0.0005762929,0.0000043885752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06138777,0.024708446,0.12732305,0.009195983,0.00395757,0.00032012022,0.0022893697,0.0011141424,0.013726315,0.0013366248,0.030823782,0.7238168],"study_design_scores_gemma":[0.05265128,0.083165735,0.7699033,0.013638526,0.0018360883,0.00071944343,0.0045535956,0.0022140208,0.045385957,0.0024860508,0.021742115,0.0017038684],"about_ca_topic_score_codex":0.002535484,"about_ca_topic_score_gemma":0.0055519,"teacher_disagreement_score":0.72211295,"about_ca_system_score_codex":0.0011278442,"about_ca_system_score_gemma":0.0043774447,"threshold_uncertainty_score":0.9997737},"labels":[],"label_agreement":null},{"id":"W4416391803","doi":"10.1016/j.annonc.2025.09.024","title":"LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aromatase inhibitor; Adjuvant; Aromatase; Breast cancer; Nonsteroidal; Cancer","score_opus":0.019907205644584276,"score_gpt":0.3489278082874372,"score_spread":0.32902060264285293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961663,0.0005789933,0.000042371143,0.006846926,0.00040695656,0.0007617522,0.00065475807,0.000059851645,0.0010317762],"genre_scores_gemma":[0.9950118,0.00009334379,0.0004649974,0.0034283737,0.00010163775,0.00013912964,0.00009128371,0.00004494971,0.0006244511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977515,0.00011102813,0.00065555633,0.00050926395,0.000380263,0.0005924259],"domain_scores_gemma":[0.99842924,0.00015644307,0.00032362094,0.00050064473,0.00041623675,0.00017383033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021264039,0.00034576716,0.0011133797,0.0003748552,0.000055809778,0.000010940676,0.00023998936,0.00023674042,0.00015426868],"category_scores_gemma":[0.000059139937,0.0002761471,0.0001326995,0.00047209382,0.00039720576,0.0002519661,0.00013776672,0.0004023678,0.000028779039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009716051,0.0012290265,0.89339614,0.00019763884,0.00044699284,0.00013176224,0.0006640401,0.000054562435,0.00036741397,0.00017049232,0.001852785,0.091773115],"study_design_scores_gemma":[0.016548451,0.002682672,0.9680874,0.00061670324,0.00009343669,0.000022250559,0.00029916715,0.000012319385,0.0014590377,0.00016227578,0.009748507,0.000267786],"about_ca_topic_score_codex":0.0008646026,"about_ca_topic_score_gemma":0.00077951455,"teacher_disagreement_score":0.091505334,"about_ca_system_score_codex":0.0003384932,"about_ca_system_score_gemma":0.00079871947,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W4416391806","doi":"10.1016/j.annonc.2025.09.113","title":"LBA96 First-line pembrolizumab-based regimens for advanced clear cell renal cell carcinoma: KEYMAKER-U03 substudy 03A","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Genentech; European Association of Urology","keywords":"Clear cell renal cell carcinoma; Pembrolizumab; Clear cell; Renal cell carcinoma; Cell","score_opus":0.060103354560220396,"score_gpt":0.35542522841092666,"score_spread":0.2953218738507063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9361919,0.0029668375,0.00037444656,0.008588312,0.00032827738,0.0019575998,0.00006774553,0.000070376525,0.049454503],"genre_scores_gemma":[0.98422796,0.0001587416,0.0025865245,0.0019123731,0.00012288398,0.0002914781,0.0001357332,0.00005588703,0.010508452],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973249,0.00014482727,0.0008216164,0.00069111906,0.00030422656,0.0007133167],"domain_scores_gemma":[0.99709475,0.0007371069,0.00039787756,0.0008336447,0.0006821961,0.0002544203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042226329,0.0004046586,0.0011327118,0.00037478656,0.00015226132,0.000008857208,0.00025105977,0.0003271128,0.00013578733],"category_scores_gemma":[0.0001487123,0.0003629822,0.0004968083,0.00040117427,0.00020316953,0.000057525733,0.0000882072,0.0002979814,0.00004120599],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121210895,0.03693331,0.057374075,0.0088967,0.0015747364,0.0031819802,0.0025178648,0.006509664,0.25727654,0.0019208693,0.45570722,0.046896122],"study_design_scores_gemma":[0.032663327,0.038031325,0.032688312,0.00016408696,0.0008610215,0.000031830667,0.00027267315,0.00077326247,0.6763104,0.000346623,0.21742132,0.00043581042],"about_ca_topic_score_codex":0.0001223101,"about_ca_topic_score_gemma":0.00014717701,"teacher_disagreement_score":0.41903386,"about_ca_system_score_codex":0.00025259162,"about_ca_system_score_gemma":0.0009216245,"threshold_uncertainty_score":0.9998822},"labels":[],"label_agreement":null},{"id":"W4416391810","doi":"10.1016/j.annonc.2025.09.022","title":"LBA12 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Outcome (game theory); Endocrine system; Clinical trial; Breast cancer; MEDLINE","score_opus":0.07181994454982062,"score_gpt":0.41324274535544986,"score_spread":0.34142280080562926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760387,0.00080168067,0.00003259752,0.018961124,0.00029922248,0.0011750252,0.0015726263,0.000008927008,0.0011100841],"genre_scores_gemma":[0.99608207,0.0017015946,0.00009439437,0.0012151465,0.00013046479,0.00011353974,0.000023983423,0.00001169079,0.0006271307],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9988265,0.0001044912,0.00049821514,0.0002376658,0.00010566802,0.00022747602],"domain_scores_gemma":[0.9977388,0.0013190787,0.00032771114,0.00022140902,0.0003393801,0.00005366384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031667578,0.0001295505,0.00062739925,0.00007511633,0.000053569973,0.000004398056,0.000098348806,0.00007562631,0.000033313754],"category_scores_gemma":[0.00026552076,0.000077902805,0.00009090426,0.0001411854,0.00018309664,0.000038026243,0.000049082377,0.00014279498,1.8796617e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7818486,0.00018713503,0.023659434,0.000034124172,0.0007062344,0.0000099502195,0.00473622,0.0000019136903,0.0009989921,0.00019528427,0.0011546839,0.1864674],"study_design_scores_gemma":[0.27975288,0.021872466,0.6578635,0.0013995594,0.00021027253,0.000016074311,0.006772012,0.0000134604115,0.0044927825,0.00047972728,0.026926575,0.00020068773],"about_ca_topic_score_codex":0.001922176,"about_ca_topic_score_gemma":0.0007364662,"teacher_disagreement_score":0.6342041,"about_ca_system_score_codex":0.00007527503,"about_ca_system_score_gemma":0.00039704694,"threshold_uncertainty_score":0.31767842},"labels":[],"label_agreement":null},{"id":"W4416391839","doi":"10.1016/j.annonc.2025.09.080","title":"LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Dalhousie University; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Chinese Society of Clinical Oncology; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; Boehringer Ingelheim Japan; International Association for the Study of Lung Cancer; BeiGene; AstraZeneca; Associazione Italiana di Oncologia Medica; Novocure; Pfizer; Incyte; Ono Pharmaceutical; Eli Lilly and Company; European SocieTy for Radiotherapy and Oncology; Bristol-Myers Squibb; American Society of Clinical Oncology; Regeneron Pharmaceuticals; Sanofi; Amgen","keywords":"Durvalumab; Overall survival; Adjuvant; Lung cancer; Disease; Survival analysis; Proportional hazards model; Lung","score_opus":0.09800486052716045,"score_gpt":0.4299573125928187,"score_spread":0.33195245206565827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684644,0.015041649,0.000012047462,0.008987258,0.00032172995,0.0005490137,0.00011107153,0.000022570988,0.0064903037],"genre_scores_gemma":[0.9883937,0.005475637,0.00013719853,0.0021124282,0.00015968688,0.0000712419,0.00005371077,0.0000210671,0.0035752815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978447,0.00023806051,0.0006828451,0.0004907225,0.00025012688,0.0004935334],"domain_scores_gemma":[0.9986537,0.0003450858,0.00022793568,0.00034951235,0.00024656072,0.00017717411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060951675,0.00025792426,0.0008291364,0.00044424992,0.00007188759,0.000015412154,0.00018033053,0.00022350077,0.00026020646],"category_scores_gemma":[0.0001700421,0.0002320568,0.00018510393,0.00049590424,0.0002788431,0.00007934339,0.0001176563,0.00030507203,0.0000018804458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14409085,0.003730187,0.44926098,0.0022443288,0.0021780103,0.0013535476,0.0015693167,0.00008989117,0.19171551,0.00014265717,0.13796405,0.06566067],"study_design_scores_gemma":[0.015309502,0.0018755934,0.9586679,0.00066063716,0.00039465073,0.000008880226,0.00025579362,0.00052768586,0.009978125,0.00007852625,0.011970507,0.00027221686],"about_ca_topic_score_codex":0.0043848506,"about_ca_topic_score_gemma":0.0038010045,"teacher_disagreement_score":0.50940686,"about_ca_system_score_codex":0.0001535049,"about_ca_system_score_gemma":0.0021170264,"threshold_uncertainty_score":0.9463002},"labels":[],"label_agreement":null},{"id":"W4416391849","doi":"10.1016/j.annonc.2025.09.038","title":"LBA9 ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Canadian Cancer Society; BC Cancer Agency","funders":"National Health and Medical Research Council; Canadian Cancer Society; Sol Goldman Charitable Trust; Commonwealth of Virginia; Lustgarten Foundation; Canadian Institutes of Health Research; Conrad N. Hilton Foundation","keywords":"Cohort; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Colorectal cancer; Cohort study; Randomized controlled trial","score_opus":0.017310213297740608,"score_gpt":0.34781237312166835,"score_spread":0.3305021598239277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947685,0.0013810995,0.00021609824,0.0012184856,0.00019105706,0.00161602,0.00019323375,0.0000022052018,0.00041327593],"genre_scores_gemma":[0.9939074,0.0047872323,0.000054269123,0.00084971206,0.00003927843,0.0001456398,0.00007241638,0.000009865719,0.00013420511],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805236,0.00051539956,0.0008031005,0.00032111935,0.00013429821,0.00017371862],"domain_scores_gemma":[0.9978406,0.00080699864,0.00067190133,0.000407408,0.00024323903,0.000029870318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010453345,0.00016303782,0.0010636485,0.00011467755,0.00004574668,0.000008252153,0.00029001033,0.00018490011,0.000019164858],"category_scores_gemma":[0.00040972256,0.000114180395,0.0002631825,0.00036542804,0.0003404053,0.0000045473025,0.0001840319,0.00011762476,4.1226794e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55463445,0.0043795207,0.18717316,0.00008301473,0.017301202,0.0000065292375,0.007883648,0.0064389175,0.18186222,0.00030387793,0.0043480885,0.03558536],"study_design_scores_gemma":[0.48994705,0.003882385,0.42989996,0.00010106126,0.0027397564,6.396217e-7,0.002099831,0.0037073568,0.064851515,0.0007983416,0.0016435598,0.0003285396],"about_ca_topic_score_codex":0.009354759,"about_ca_topic_score_gemma":0.020846108,"teacher_disagreement_score":0.2427268,"about_ca_system_score_codex":0.00007099086,"about_ca_system_score_gemma":0.00042977423,"threshold_uncertainty_score":0.99724203},"labels":[],"label_agreement":null},{"id":"W4416391851","doi":"10.1016/j.annonc.2025.09.096","title":"LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Durvalumab; Docetaxel; Overall survival; Oxaliplatin; Pathological; Phases of clinical research","score_opus":0.05429311914018962,"score_gpt":0.3765634884471452,"score_spread":0.3222703693069556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368453,0.001807312,0.00004282442,0.0020473448,0.00006957417,0.0018934399,0.000029642426,0.00000779033,0.00041755807],"genre_scores_gemma":[0.9989506,0.00032151598,0.00008781874,0.0000980031,0.000027399532,0.00018081297,0.000016175081,0.000010291229,0.00030736992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654126,0.001223595,0.0008714824,0.00037209576,0.0005785398,0.00041301636],"domain_scores_gemma":[0.9975542,0.0013042492,0.00046093544,0.0003210574,0.00027097762,0.000088592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030240167,0.00022248087,0.001437443,0.0003641971,0.00005446186,0.000011387528,0.00015149299,0.00013936778,0.000031367996],"category_scores_gemma":[0.0008373561,0.00014361527,0.00009736179,0.0004069717,0.00021491491,0.00010862778,0.00017420115,0.0003897496,3.7817873e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112430274,0.0026669754,0.8809012,0.00016029768,0.00036559033,0.00035360295,0.00079455297,0.000074131975,0.00008325246,0.00014683131,0.0001538038,0.0018694596],"study_design_scores_gemma":[0.24918492,0.01065905,0.7384479,0.00006900558,0.00015313472,0.000025486494,0.00084329006,0.00015126838,0.00014735959,0.00025704157,0.000004040414,0.000057477453],"about_ca_topic_score_codex":0.0025837934,"about_ca_topic_score_gemma":0.0033848307,"teacher_disagreement_score":0.1424533,"about_ca_system_score_codex":0.00024285633,"about_ca_system_score_gemma":0.00041154152,"threshold_uncertainty_score":0.5856461},"labels":[],"label_agreement":null},{"id":"W4416391857","doi":"10.1016/j.annonc.2025.09.087","title":"LBA73 Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Foundation Medicine; Genentech; PharmaMar; AstraZeneca Korea; Ipsen; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; LG Chem; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Pfizer; Incyte; F. Hoffmann-La Roche; Chugai Pharmaceutical; Celltrion; Roche; Relay Therapeutics; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alectinib; Crizotinib; Overall survival; Lung cancer; Phases of clinical research; Survival analysis","score_opus":0.019633282549771185,"score_gpt":0.3854270002300882,"score_spread":0.365793717680317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915202,0.00044968413,0.000032566804,0.00045340462,0.00008157683,0.0018226231,0.00020583505,0.0000055239575,0.0054285624],"genre_scores_gemma":[0.99868643,0.00028009442,0.00008774414,0.00026378944,0.000009261975,0.00008712535,0.00007427386,0.000011515874,0.0004997463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848,0.00016795496,0.00058847165,0.00032840497,0.00019771872,0.00023741958],"domain_scores_gemma":[0.9984257,0.00023430049,0.00046157526,0.0002899438,0.00052760576,0.000060835424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017531188,0.00018967415,0.00097355817,0.0003053017,0.000059706865,0.0000030691174,0.00010763444,0.00008367604,0.00005007161],"category_scores_gemma":[0.000036146106,0.00012885657,0.000119735865,0.0008424445,0.000120808145,0.00005839582,0.000063068146,0.0001385264,9.4637954e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011328869,0.007828656,0.95558697,0.00015753435,0.0047230115,0.000011491726,0.0061980532,0.0010717417,0.00018352916,0.000026933443,0.00015266283,0.012730551],"study_design_scores_gemma":[0.044926345,0.008704051,0.9377503,0.00030924418,0.0056987717,4.4857165e-7,0.00085929036,0.00018225008,0.0012363946,0.000005425012,0.0002240829,0.0001034075],"about_ca_topic_score_codex":0.0038183955,"about_ca_topic_score_gemma":0.0065920656,"teacher_disagreement_score":0.033597477,"about_ca_system_score_codex":0.00012338636,"about_ca_system_score_gemma":0.000602639,"threshold_uncertainty_score":0.57722974},"labels":[],"label_agreement":null},{"id":"W4416391865","doi":"10.1016/j.annonc.2025.09.095","title":"LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"David Geffen School of Medicine, University of California, Los Angeles; Ono Pharmaceutical; Yonsei University College of Medicine; Seoul National University; European Society for Medical Oncology; College of Medicine, Seoul National University; Genentech; Seoul National University Hospital; KU Leuven; Weill Cornell Medical College; National Institute for Health and Care Research; Pfizer; Yonsei University; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute; AstraZeneca; American Society of Clinical Oncology; Université de Montréal; University of Victoria; Daiichi Sankyo Europe; Gilead Sciences; Hospital de Câncer de Barretos; Amgen; Ipsen; BeiGene","keywords":"Nivolumab; Regorafenib; Refractory (planetary science); Chemotherapy; Gastroesophageal Junction; Phases of clinical research; Ramucirumab","score_opus":0.06575530322274843,"score_gpt":0.42386207741232146,"score_spread":0.35810677418957304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98454314,0.0017451786,0.00017874817,0.0069141067,0.0004063945,0.004509468,0.000026174483,0.00008695908,0.0015898399],"genre_scores_gemma":[0.98790157,0.0023880156,0.0004000705,0.0036450343,0.0001482713,0.0006419209,0.000043015018,0.000048426802,0.004783653],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99559414,0.0007025944,0.0018423836,0.0007102858,0.00040237483,0.0007481893],"domain_scores_gemma":[0.99684834,0.0007732663,0.00097193586,0.00066159817,0.000466049,0.00027882756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014525631,0.00053735246,0.0033956415,0.0012965668,0.000054929234,0.00002194399,0.0005233234,0.00023458949,0.0004523057],"category_scores_gemma":[0.0014498138,0.00041066224,0.00046977907,0.001949671,0.00054242933,0.00017919061,0.00018775857,0.0005235827,0.000004638369],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54737616,0.009553167,0.19598114,0.0011682764,0.0043928856,0.0007701297,0.0053650737,0.000097968565,0.001296272,0.00016608731,0.061055865,0.17277698],"study_design_scores_gemma":[0.9090538,0.023971647,0.043406013,0.0013490355,0.0019270096,0.000028615985,0.0023556286,0.0013588461,0.0037467643,0.00018278084,0.012128775,0.00049109873],"about_ca_topic_score_codex":0.005362158,"about_ca_topic_score_gemma":0.0040324107,"teacher_disagreement_score":0.36167765,"about_ca_system_score_codex":0.00049789896,"about_ca_system_score_gemma":0.0016903523,"threshold_uncertainty_score":0.99983454},"labels":[],"label_agreement":null},{"id":"W4416391869","doi":"10.1016/j.annonc.2025.09.119","title":"LBA102 Efficacy and safety of ponsegromab in patients with cancer-associated cachexia: Results from the open-label extension of a randomized, placebo-controlled, phase II study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"Pfizer","keywords":"Extension (predicate logic); Phase (matter); Phases of clinical research; Clinical trial","score_opus":0.08611860185181648,"score_gpt":0.44292162187023754,"score_spread":0.35680302001842107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813039,0.0010137181,0.000003590932,0.0116506675,0.000084102176,0.0048959274,0.00016086838,0.0000063862285,0.00088088244],"genre_scores_gemma":[0.9976461,0.00052074314,0.00011578593,0.0014398441,0.0000119189235,0.00011060235,0.000043935237,0.000007525112,0.00010355039],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99729633,0.000915718,0.001157142,0.0002482013,0.00019952013,0.00018307565],"domain_scores_gemma":[0.99526,0.0031310953,0.00075482903,0.00025422702,0.0005420258,0.00005782284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028322828,0.00012653782,0.0018745335,0.00015270042,0.00008180473,0.000003007553,0.00013351465,0.00011359501,0.0000150913265],"category_scores_gemma":[0.0024020039,0.000077933735,0.00004872442,0.0002945611,0.00020584444,0.000038131693,0.00012086417,0.00021832726,1.4404462e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9564193,0.017241422,0.011093871,0.00004542407,0.00062579394,0.000009296421,0.0019470645,0.000004474046,0.00017072356,0.00005001467,0.0019729242,0.010419719],"study_design_scores_gemma":[0.885891,0.0104373135,0.101336844,0.0008725529,0.0003521742,3.8751966e-7,0.0004636008,0.00011816247,0.00015046394,0.00008522504,0.00023869137,0.00005356235],"about_ca_topic_score_codex":0.0033289744,"about_ca_topic_score_gemma":0.00094002206,"teacher_disagreement_score":0.090242974,"about_ca_system_score_codex":0.00005405614,"about_ca_system_score_gemma":0.00044978238,"threshold_uncertainty_score":0.50324357},"labels":[],"label_agreement":null},{"id":"W4416391870","doi":"10.1016/j.annonc.2025.09.107","title":"LBA91 Patient (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Calgary","funders":"Johnson and Johnson","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Homologous chromosome; Abiraterone; Phases of clinical research","score_opus":0.049314117480779254,"score_gpt":0.4007666378702927,"score_spread":0.35145252038951347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98231286,0.0026372806,0.00013216642,0.0039165393,0.00016252059,0.010129488,0.00018887411,0.000050655155,0.00046959677],"genre_scores_gemma":[0.9921275,0.002425769,0.0009332483,0.00023970095,0.000012998406,0.0029765267,0.00030124554,0.00002508787,0.0009579582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961337,0.0008753486,0.0016271047,0.00056087156,0.00038015895,0.00042282778],"domain_scores_gemma":[0.99606603,0.0015226711,0.0011168605,0.00033829812,0.00083171873,0.00012440796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001488018,0.00032385104,0.0030597113,0.00059906335,0.00007374561,0.000015345728,0.000071827024,0.000154341,0.000020411793],"category_scores_gemma":[0.00089078315,0.00022016144,0.00027097823,0.000489754,0.0006471594,0.00014083982,0.000066394416,0.00028001418,7.4831166e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9690649,0.0029570223,0.00069465034,0.00012944748,0.004947633,0.00045398241,0.005905195,0.00009787888,0.0022586924,0.00007328487,0.00023735619,0.013179987],"study_design_scores_gemma":[0.97266847,0.011506937,0.0032308728,0.0002557683,0.0015806906,0.000015248686,0.0010930417,0.0015298214,0.0066644247,0.0011918964,0.000081507635,0.00018130984],"about_ca_topic_score_codex":0.0028162415,"about_ca_topic_score_gemma":0.0007670559,"teacher_disagreement_score":0.012998677,"about_ca_system_score_codex":0.00024637877,"about_ca_system_score_gemma":0.0014446967,"threshold_uncertainty_score":0.89779234},"labels":[],"label_agreement":null},{"id":"W4416391872","doi":"10.1016/j.annonc.2025.09.121","title":"LBA104 Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma: A phase III randomised trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Bayer","keywords":"Durvalumab; Chemotherapy; Phases of clinical research; Chemotherapy regimen; Clinical trial; Intention-to-treat analysis","score_opus":0.03289495058979891,"score_gpt":0.38579497017193587,"score_spread":0.35290001958213696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344,0.0005412916,0.000008408147,0.007162219,0.00007319458,0.0016190247,0.00009871114,0.000014986971,0.0070421924],"genre_scores_gemma":[0.99538743,0.0010996349,0.00023127232,0.0014552419,0.000057035988,0.00018030638,0.00024038876,0.000012857005,0.0013358205],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985954,0.000079639394,0.0006459168,0.0002663104,0.00021454527,0.00019818703],"domain_scores_gemma":[0.99897856,0.00037591072,0.0002668223,0.00023110332,0.000058776925,0.000088848166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020870597,0.00017886111,0.0008380897,0.00019187586,0.000027392261,0.0000015881548,0.00007488769,0.000100098376,0.00010128814],"category_scores_gemma":[0.00011328686,0.00012642333,0.00016389231,0.00021643126,0.00020346094,0.00005157209,0.000020184672,0.00006671317,0.0000036327924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9302911,0.0102363415,0.0012048496,0.00008634609,0.00035346363,0.00008190531,0.00029343902,0.00015655122,0.0026653444,0.000049009555,0.00072373607,0.053857893],"study_design_scores_gemma":[0.9139895,0.03765137,0.018439585,0.00019006972,0.00019245672,0.000011674374,0.000096851974,0.00006447784,0.017783025,0.00030430054,0.011161353,0.00011535123],"about_ca_topic_score_codex":0.0002738805,"about_ca_topic_score_gemma":0.00009817675,"teacher_disagreement_score":0.053742543,"about_ca_system_score_codex":0.00014953155,"about_ca_system_score_gemma":0.00046856175,"threshold_uncertainty_score":0.5155394},"labels":[],"label_agreement":null},{"id":"W4416391890","doi":"10.1016/j.annonc.2025.09.039","title":"LBA28 Predictors of adherence to the structured exercise program and physical activity target in the Canadian Cancer Trials Group CO.21 CHALLENGE trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of British Columbia; University of British Columbia Hospital; Saint John Regional Hospital; Saskatchewan Cancer Agency; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; BC Cancer Agency; Canadian Cancer Society; Alberta Health Services; Queen's University","funders":"Canadian Institutes of Health Research; National Institutes of Health; Queen's University Belfast; University of Alberta; University of British Columbia; National Health and Medical Research Council; Queen's University; Alberta Health Services","keywords":"Physical activity; Randomized controlled trial; Cancer; Colorectal cancer; Clinical trial; Alternative medicine; Physical exercise; Physical activity level","score_opus":0.12075088319517234,"score_gpt":0.4515505264777432,"score_spread":0.33079964328257083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751338,0.0010097666,0.000002728624,0.018774932,0.00067192246,0.0025930984,0.0001782866,0.000008397673,0.0016271078],"genre_scores_gemma":[0.99785256,0.00046739995,0.000011815622,0.00068127003,0.0003130742,0.00061457127,0.000010900905,0.000006121774,0.000042306576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857605,0.00046918614,0.00028860246,0.00021088336,0.00020350194,0.00025179068],"domain_scores_gemma":[0.99891394,0.00042602303,0.00016093475,0.0002624182,0.00012709503,0.00010959204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011971754,0.00012384648,0.0007736085,0.0001245779,0.000052994805,0.000008466775,0.0001887757,0.00015488084,0.000030325797],"category_scores_gemma":[0.00036877717,0.000071294635,0.00012226416,0.00032387505,0.00016230425,0.000030245952,0.000031271884,0.00025276362,3.6723944e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030444365,0.0009863982,0.0049869088,0.00023498114,0.00023244601,0.000018883671,0.015810419,0.000007880458,0.0004054654,0.00070109917,0.013038002,0.9331331],"study_design_scores_gemma":[0.05820845,0.043380704,0.3293424,0.0009612112,0.0009975957,0.000008492459,0.010706879,0.00019107088,0.009029066,0.0041280645,0.54248756,0.00055851246],"about_ca_topic_score_codex":0.13179356,"about_ca_topic_score_gemma":0.71802807,"teacher_disagreement_score":0.9325746,"about_ca_system_score_codex":0.000067508336,"about_ca_system_score_gemma":0.0010693638,"threshold_uncertainty_score":0.8739879},"labels":[],"label_agreement":null},{"id":"W4416410310","doi":"10.1016/j.annonc.2025.11.004","title":"Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Cancer Council Queensland; Medical Research Council; Arts South Australia; Associazione Italiana per la Ricerca sul Cancro; National Institutes of Health; Cancer Australia; European Society for Medical Oncology; National Breast Cancer Foundation; National Health and Medical Research Council; Breast Cancer Research Foundation","keywords":"Germline; Breast cancer; Phenotype; Cohort study; Cohort; Germline mutation; Clinical phenotype; Cancer","score_opus":0.018356896000580075,"score_gpt":0.33027230918518696,"score_spread":0.3119154131846069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416410310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981395,0.0001559905,0.000043547054,0.00047741763,0.000088213346,0.0004715862,0.0005445733,0.0000034616542,0.00007568396],"genre_scores_gemma":[0.99856323,0.0003383135,0.00037358832,0.00006872023,0.00005647378,0.00005123165,0.0004984079,0.000010345108,0.000039680213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989397,0.0001281399,0.00033019087,0.0003436478,0.00014409165,0.000114239105],"domain_scores_gemma":[0.9981578,0.000050158764,0.00033323868,0.0001589841,0.0012697562,0.000030076013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033063843,0.00010491592,0.00023151314,0.00008601301,0.00002614285,0.000008579936,0.00010635896,0.00013509794,0.0000053985277],"category_scores_gemma":[0.00014889632,0.000086540196,0.000008539437,0.0003416327,0.00006565874,0.000017967624,0.00006123625,0.00006564017,1.2921625e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021462718,0.00045518167,0.9779887,0.000012378604,0.00057748304,0.000001082012,0.0002664628,0.00006234387,0.0016957179,0.0000030223296,0.000056360394,0.016735],"study_design_scores_gemma":[0.0028952293,0.002177569,0.9934668,0.000044136126,0.00014880436,9.739049e-7,0.00008955402,0.00003880118,0.0009614033,0.000017141183,0.00007411348,0.00008547149],"about_ca_topic_score_codex":0.0008094256,"about_ca_topic_score_gemma":0.005940278,"teacher_disagreement_score":0.01664953,"about_ca_system_score_codex":0.00007300402,"about_ca_system_score_gemma":0.0005571324,"threshold_uncertainty_score":0.35290068},"labels":[],"label_agreement":null},{"id":"W4416410316","doi":"10.1016/j.annonc.2025.11.005","title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Alberta","funders":"Seagen; Gilead Sciences; Roche; Novartis; Daiichi-Sankyo; Pfizer; Bristol-Myers Squibb","keywords":"Metastatic breast cancer; Trastuzumab emtansine; Trastuzumab; Phases of clinical research; Randomized controlled trial; Clinical endpoint","score_opus":0.033511208488277475,"score_gpt":0.4264416677257516,"score_spread":0.3929304592374741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416410316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654586,0.0015693182,0.0002459185,0.0045735743,0.0000636238,0.005903848,0.00053277495,0.000010186209,0.00055489084],"genre_scores_gemma":[0.9958367,0.0017670628,0.0005105461,0.000800506,0.000022263795,0.00067186455,0.00010933838,0.000019381827,0.00026238628],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977209,0.0005238836,0.0007630999,0.00037075114,0.00030548754,0.00031588224],"domain_scores_gemma":[0.99630505,0.0018169425,0.00046182278,0.00029067232,0.0010041976,0.00012130198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093928777,0.00020981173,0.0020889693,0.0003187254,0.000070284885,0.000007938263,0.0001227935,0.00009586921,0.000046034536],"category_scores_gemma":[0.00047881485,0.00012772878,0.0002476276,0.0009286379,0.0007451971,0.000058276146,0.000057837766,0.00016410195,7.2084546e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8280082,0.0026118024,0.0035719238,0.0004747046,0.00675123,0.0000058826195,0.00069683784,0.000028235747,0.00025114836,0.00003745035,0.00039564288,0.15716697],"study_design_scores_gemma":[0.9428375,0.01427941,0.030981742,0.00064644567,0.008623587,0.0000063601788,0.00019762824,0.0005793138,0.0012027766,0.00006559189,0.00043199374,0.00014765734],"about_ca_topic_score_codex":0.0005193472,"about_ca_topic_score_gemma":0.0005770871,"teacher_disagreement_score":0.15701932,"about_ca_system_score_codex":0.00013004095,"about_ca_system_score_gemma":0.0013797509,"threshold_uncertainty_score":0.5208628},"labels":[],"label_agreement":null},{"id":"W4416410553","doi":"10.1016/j.annonc.2025.11.008","title":"Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Rexanna's Foundation; University of Texas at Austin; Cancer Prevention and Research Institute of Texas","keywords":"Immunotherapy; Lung cancer; Immune system; Carcinoma; Immune checkpoint; Nivolumab; Tumor microenvironment","score_opus":0.023821984828242136,"score_gpt":0.37509629284134677,"score_spread":0.3512743080131046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416410553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428684,0.032818027,0.00018068514,0.014713026,0.00027421478,0.00052147475,0.000011361091,0.00001428734,0.0085985055],"genre_scores_gemma":[0.99186826,0.0049853413,0.0008821301,0.0016003526,0.00007443743,0.00007229964,0.000011968519,0.000009328794,0.00049586804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99929684,0.000033338514,0.00028125066,0.00015828872,0.00004565987,0.00018464767],"domain_scores_gemma":[0.9995454,0.00011581492,0.00008556883,0.0001381486,0.00009298739,0.000022106718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021418619,0.000097075674,0.00030180396,0.0001870443,0.000045231653,0.0000057843113,0.000056515117,0.00012068561,0.000038662223],"category_scores_gemma":[0.000009700602,0.000088300694,0.00008863265,0.00019219842,0.00009433041,0.00007054479,0.00001240479,0.000094706076,1.7875129e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017831795,0.00092049845,0.011390509,0.0009301921,0.00019337308,0.000022053015,0.0027720092,0.00004227966,0.31463856,0.008616483,0.008606958,0.6340353],"study_design_scores_gemma":[0.02590125,0.0056352387,0.19280446,0.00013572007,0.00008032658,0.000021500315,0.01117854,0.00034667237,0.035267618,0.0020975515,0.7262417,0.00028944225],"about_ca_topic_score_codex":0.000092319504,"about_ca_topic_score_gemma":0.00009533838,"teacher_disagreement_score":0.71763474,"about_ca_system_score_codex":0.00003789662,"about_ca_system_score_gemma":0.00029868577,"threshold_uncertainty_score":0.3600798},"labels":[],"label_agreement":null},{"id":"W4417148749","doi":"10.1016/j.annonc.2025.11.020","title":"Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Bevacizumab; Durvalumab; Olaparib; Ovarian cancer; Prostate cancer; Cancer","score_opus":0.025408448384387324,"score_gpt":0.3711802441592098,"score_spread":0.3457717957748225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417148749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97974426,0.0025732988,0.00037027686,0.0110870125,0.00016688331,0.0018516955,0.00015225982,0.00007372044,0.003980626],"genre_scores_gemma":[0.9886373,0.0028759008,0.0024882338,0.0035695015,0.00004706671,0.00067185675,0.00005150798,0.00007065222,0.0015879568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686867,0.00022216744,0.0008342169,0.00091069005,0.00039471083,0.0007695226],"domain_scores_gemma":[0.99768424,0.000473613,0.0005003539,0.00053918455,0.00053020695,0.00027237798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005031846,0.0005187846,0.0016167646,0.00038876125,0.00013187173,0.000027049284,0.00017813723,0.0003466072,0.00010085059],"category_scores_gemma":[0.0002074405,0.00038868753,0.00007060354,0.0009181195,0.00072903343,0.00025631508,0.000076878954,0.0005337752,0.0000019325662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21622409,0.0033274044,0.45109716,0.001994087,0.003317726,0.002445299,0.009879314,0.00055249187,0.050303943,0.00091178966,0.028983023,0.23096366],"study_design_scores_gemma":[0.40741795,0.04658903,0.41044292,0.010382041,0.0013065797,0.0012614965,0.0061838077,0.0040768124,0.049793743,0.0011977605,0.05862909,0.0027187585],"about_ca_topic_score_codex":0.0023134847,"about_ca_topic_score_gemma":0.0073998114,"teacher_disagreement_score":0.22824492,"about_ca_system_score_codex":0.00036990838,"about_ca_system_score_gemma":0.001840591,"threshold_uncertainty_score":0.99985653},"labels":[],"label_agreement":null},{"id":"W4417467139","doi":"10.1016/j.annonc.2025.12.009","title":"Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ipsen; European Society for Medical Oncology; Kasturba Medical College, Manipal; European Association of Urology; Sanofi; Bristol-Myers Squibb; AstraZeneca; Bayer; Astellas Pharma; Astellas Pharma US; Veracyte; Pfizer","keywords":"Prostate; Prostate cancer; Guideline; Clinical Practice; Rectal examination; Prostate-specific antigen","score_opus":0.11142746436545234,"score_gpt":0.49365164855508736,"score_spread":0.382224184189635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417467139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46761918,0.066141844,0.00068192184,0.45818263,0.00096858235,0.0037909523,0.0003679162,0.000044713746,0.0022022696],"genre_scores_gemma":[0.67606753,0.2815227,0.0060667987,0.032214966,0.00020446595,0.0028598732,0.00014144772,0.000026359845,0.0008958613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851847,0.00007848395,0.0006678539,0.00039445286,0.000086745364,0.0002539949],"domain_scores_gemma":[0.99754626,0.0013712355,0.00024287894,0.00017337089,0.0005023614,0.00016390865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004725618,0.00017660634,0.00067930215,0.00007899608,0.00006452409,0.000007891074,0.000037615828,0.00015202427,0.000017463006],"category_scores_gemma":[0.00041292244,0.0001329037,0.0001298094,0.00009142711,0.00032724277,0.00006863732,0.000049979913,0.00008315562,9.690808e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033553704,0.0015413818,0.12258521,0.00010767589,0.00090055197,0.00004839762,0.00014824895,0.0000051961124,0.000005116422,0.001279621,0.14261615,0.7274071],"study_design_scores_gemma":[0.011076582,0.012816612,0.019421734,0.00017428363,0.0007262519,0.000029410177,0.00021408124,0.00012818673,0.001611814,0.00080194196,0.9529014,0.00009768129],"about_ca_topic_score_codex":0.0006047532,"about_ca_topic_score_gemma":0.0002793799,"teacher_disagreement_score":0.8102853,"about_ca_system_score_codex":0.000118671545,"about_ca_system_score_gemma":0.0007624047,"threshold_uncertainty_score":0.5419656},"labels":[],"label_agreement":null},{"id":"W7104176868","doi":"10.1016/j.annonc.2025.08.2547","title":"1923P METRIX: International real-world (RW) study of c-Met protein overexpression (OE) in patients (pts) with locally advanced (LA)/metastatic NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Institute for Biodiagnostics; Dalhousie University","funders":"AbbVie","keywords":"Concordance; Reproducibility; Cancer; Gene","score_opus":0.03504139402169926,"score_gpt":0.39080164260924527,"score_spread":0.355760248587546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104176868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935855,0.000037922153,0.000033473432,0.00033831844,0.000095726755,0.0010423927,0.000014496104,0.000011588018,0.019067507],"genre_scores_gemma":[0.99795914,0.00005655956,0.0009610068,0.00047520903,0.000015368449,0.00008345541,0.000039517956,0.000009527092,0.00040020308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983335,0.00045698506,0.0005353884,0.00029748908,0.0001771337,0.00019947463],"domain_scores_gemma":[0.99863046,0.00035356943,0.0003353845,0.00026778592,0.00036651647,0.000046262565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040686422,0.00014598301,0.0006627399,0.0005882843,0.000021567887,0.0000014090933,0.00018216079,0.000109183755,0.00007116103],"category_scores_gemma":[0.00025060534,0.00011257309,0.00005372366,0.0004659366,0.00018422499,0.00007827563,0.000118693104,0.00026772855,0.0000037178345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03247201,0.022376982,0.76939464,0.0004115925,0.00096044544,0.00019226021,0.0021712703,0.00024305221,0.0272981,0.002174119,0.0017445498,0.14056101],"study_design_scores_gemma":[0.018648757,0.025422975,0.94118404,0.0009526184,0.00009159616,0.000003953112,0.00064243353,0.000027621603,0.008769568,0.0008094024,0.0033106417,0.00013636917],"about_ca_topic_score_codex":0.0002284328,"about_ca_topic_score_gemma":0.00027451268,"teacher_disagreement_score":0.17178945,"about_ca_system_score_codex":0.000044813747,"about_ca_system_score_gemma":0.00026204178,"threshold_uncertainty_score":0.45905975},"labels":[],"label_agreement":null},{"id":"W7104177074","doi":"10.1016/j.annonc.2025.08.2675","title":"2053eP ESMO treatment (tx) guideline adherence in patients (pts) with lung cancer (LC) with EGFR or ALK (EGFR/ALK) alterations: A WAYFIND-R registry-based study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Lung cancer; Guideline; MEDLINE; Erlotinib; Chemotherapy","score_opus":0.05267926010928427,"score_gpt":0.4611828682689936,"score_spread":0.4085036081597093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104177074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97583246,0.0006839403,0.00032695415,0.012585594,0.00016595001,0.0033153137,0.00012280123,0.000041707,0.006925265],"genre_scores_gemma":[0.990389,0.0001461566,0.0018110852,0.0025012533,0.000045201963,0.0012618649,0.00020234945,0.00002201171,0.003621086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831104,0.000099875164,0.00059296214,0.00044274752,0.0002398192,0.0003135393],"domain_scores_gemma":[0.9984101,0.00014026587,0.00027958507,0.00044255354,0.00062389334,0.00010358356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012808111,0.00026198677,0.00062195875,0.00023838916,0.00009162808,0.0000134526945,0.00010661541,0.00009926978,0.00022422252],"category_scores_gemma":[0.00006845273,0.00015865013,0.000057170844,0.00048622375,0.00010106499,0.000086260414,0.000021362503,0.00011538146,0.0000032761604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008414524,0.0142281,0.8853627,0.00015737955,0.0019366714,0.0003992071,0.0023824554,0.0018199963,0.000024191211,0.000107697,0.014252036,0.070915066],"study_design_scores_gemma":[0.11949886,0.13716526,0.6105903,0.0025062265,0.0040531447,0.000016499629,0.0033265164,0.0016183346,0.0017887327,0.00006578169,0.11860685,0.0007634892],"about_ca_topic_score_codex":0.0059184455,"about_ca_topic_score_gemma":0.026814217,"teacher_disagreement_score":0.27477238,"about_ca_system_score_codex":0.0006381506,"about_ca_system_score_gemma":0.003430415,"threshold_uncertainty_score":0.9909439},"labels":[],"label_agreement":null},{"id":"W7104177269","doi":"10.1016/j.annonc.2025.08.751","title":"322P Immune profiling across blood, tumour and lymph nodes to guide patient stratification for neoadjuvant immunotherapy in early-stage TNBC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Lymph; Profiling (computer programming); Stratification (seeds); Risk stratification; Immune system","score_opus":0.04273266134237628,"score_gpt":0.40000602601828655,"score_spread":0.35727336467591025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104177269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886089,0.0035062549,0.00027582454,0.0054363823,0.00016942763,0.0010900183,0.000049724767,0.000018095543,0.00084537413],"genre_scores_gemma":[0.9932918,0.0011564557,0.0023141105,0.0022450516,0.000028053782,0.0002021672,0.000026012518,0.000015311034,0.0007210513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857277,0.000057712736,0.00069271337,0.00027467718,0.000099149096,0.00030298645],"domain_scores_gemma":[0.9991393,0.00015303493,0.00019940453,0.00024966424,0.000214275,0.000044304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006409372,0.00014215708,0.0004447578,0.00015525326,0.00006742651,0.000015566553,0.0001016938,0.000139253,0.000013094782],"category_scores_gemma":[0.00010803801,0.00012829925,0.00010484019,0.00024622004,0.0001051446,0.00005906789,0.000034477176,0.00008188619,0.0000010237526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066424916,0.00050508353,0.016472407,0.00015904882,0.00021355429,0.000013293792,0.002519589,0.0000128799875,0.7128147,0.00045370017,0.00023492785,0.25995833],"study_design_scores_gemma":[0.008698129,0.0039280243,0.32610965,0.00035991892,0.000036450016,0.000013108454,0.002503915,0.00011354719,0.6235511,0.00023980808,0.03424667,0.0001996809],"about_ca_topic_score_codex":0.0009744754,"about_ca_topic_score_gemma":0.000097829696,"teacher_disagreement_score":0.30963725,"about_ca_system_score_codex":0.00006868977,"about_ca_system_score_gemma":0.00031033432,"threshold_uncertainty_score":0.5231891},"labels":[],"label_agreement":null},{"id":"W7104179308","doi":"10.1016/j.annonc.2025.08.2109","title":"1479P Safety and efficacy of radiotherapy combined with lenvatinib and sintilimab as neoadjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: Interim results of an open-label, single-arm, multicenter, prospective phase I clinical trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Object Research Systems (Canada)","funders":"","keywords":"Lenvatinib; Hepatocellular carcinoma; Radiation therapy; Interim; Portal vein; Neoadjuvant therapy; Interim analysis","score_opus":0.1949464068817133,"score_gpt":0.434977104181802,"score_spread":0.24003069730008872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104179308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902261,0.0014383022,0.00008873743,0.0012679381,0.0000947167,0.006270339,0.00013412045,0.000018436247,0.00046129452],"genre_scores_gemma":[0.994457,0.0005963919,0.004189704,0.0003667685,0.000050099745,0.000094921605,0.00014921294,0.00003745681,0.000058430967],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972815,0.00033084434,0.0012710127,0.0006272577,0.00019273184,0.00029665526],"domain_scores_gemma":[0.9972425,0.00078962935,0.00082718814,0.00043026777,0.0005442183,0.0001662089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010314994,0.00032280636,0.0017499799,0.00017201583,0.000067556895,0.000017872633,0.0001919419,0.00018717884,0.000016803906],"category_scores_gemma":[0.00025251828,0.00022609618,0.000102003854,0.0002261911,0.00077368465,0.00014882184,0.00006928881,0.00018907188,1.2759057e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7750659,0.03677589,0.11514307,0.00015766604,0.0012872174,0.00019641023,0.001164468,1.6941662e-7,0.009961644,0.00017314163,0.00008859417,0.059985854],"study_design_scores_gemma":[0.47779956,0.42876402,0.017254563,0.00031984734,0.000355478,0.00004238796,0.0003296905,0.0012054992,0.07249351,0.00004433196,0.001215043,0.00017606099],"about_ca_topic_score_codex":0.00019994771,"about_ca_topic_score_gemma":0.000041340154,"teacher_disagreement_score":0.39198813,"about_ca_system_score_codex":0.00003214342,"about_ca_system_score_gemma":0.0005880772,"threshold_uncertainty_score":0.9219935},"labels":[],"label_agreement":null},{"id":"W7104179491","doi":"10.1016/j.annonc.2025.08.1083","title":"CN7 Development of an AI-based emotional tone classifier to support psychosocial triage in digital cancer nursing tools","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Mental Health via Writing","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal; Royal Victoria Hospital; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Psychosocial; Empathy; Distress; Triage; Breast cancer; Oncology nursing; Emotional distress; Nursing assessment","score_opus":0.22379395083301343,"score_gpt":0.5606983684136552,"score_spread":0.3369044175806417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104179491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262229,0.000057380545,0.0005356752,0.00822909,0.001037025,0.00051445834,0.00008574042,0.000017265524,0.06330043],"genre_scores_gemma":[0.9910933,0.0000023378877,0.00177809,0.0062106075,0.000111332054,0.00013366641,0.00006996223,0.000014045702,0.00058669905],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978372,0.00015563222,0.0009871331,0.00035266584,0.00020160303,0.00046579144],"domain_scores_gemma":[0.9989736,0.00026757314,0.00025114833,0.00019738836,0.00018078445,0.00012948958],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074602885,0.00014324626,0.0004952435,0.00037203418,0.00006188613,0.000010738343,0.00021919845,0.0002453812,0.0010057077],"category_scores_gemma":[0.00010492463,0.00016125107,0.000068223795,0.00041639296,0.00012259612,0.00013524208,0.00003173692,0.0002115363,0.00002862402],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001661848,0.0023981768,0.015528929,0.00008937069,0.000055133474,0.000021416341,0.0037106988,0.000022457092,0.00087331305,0.0033248302,0.013235455,0.9590784],"study_design_scores_gemma":[0.010975684,0.0069416068,0.8491871,0.0013202885,0.00003091864,0.0000109876455,0.0058253207,0.00007534649,0.015441328,0.0037258703,0.10585605,0.00060951564],"about_ca_topic_score_codex":0.00007690445,"about_ca_topic_score_gemma":0.00033268443,"teacher_disagreement_score":0.95846885,"about_ca_system_score_codex":0.00028209315,"about_ca_system_score_gemma":0.0014259795,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W7104179723","doi":"10.1016/j.annonc.2025.08.1382","title":"809P Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ± mFOLFOX6 and chemotherapy (chemo) ± bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Cetuximab; Bevacizumab; Colorectal cancer; Safety profile; Chemotherapy; Chemotherapy regimen","score_opus":0.0246460616700586,"score_gpt":0.3245464942917242,"score_spread":0.2999004326216656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104179723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838013,0.0008565921,0.000012140681,0.0057765245,0.00010410184,0.001602499,0.00028896137,0.00004246538,0.002936557],"genre_scores_gemma":[0.99635255,0.0012354316,0.00022870103,0.0011837247,0.000023408546,0.0003409898,0.00015040899,0.000035720474,0.00044908025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979106,0.000101136204,0.00059397623,0.00053322816,0.00032525085,0.00053578784],"domain_scores_gemma":[0.9984629,0.00034126246,0.00035270545,0.00020410558,0.00052554795,0.00011349292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023435376,0.00039104963,0.0014063696,0.00023502237,0.00013341362,0.000012241174,0.000111038564,0.00015988076,0.00014195473],"category_scores_gemma":[0.00013803689,0.00026262816,0.00008044488,0.000667202,0.0003493633,0.0001013818,0.00008270449,0.00025060234,0.000001558987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08183979,0.007866607,0.78747606,0.00058222195,0.005956458,0.00029372057,0.004524171,0.000093980074,0.0002869869,0.00010322981,0.0021697008,0.108807094],"study_design_scores_gemma":[0.050202206,0.02249154,0.91510874,0.0008340981,0.0005992014,0.000015781456,0.00032600993,0.00019029257,0.004455953,0.000109349574,0.0052877595,0.0003790878],"about_ca_topic_score_codex":0.0010705643,"about_ca_topic_score_gemma":0.015271762,"teacher_disagreement_score":0.12763268,"about_ca_system_score_codex":0.00064428936,"about_ca_system_score_gemma":0.000980138,"threshold_uncertainty_score":0.9999826},"labels":[],"label_agreement":null},{"id":"W7104180020","doi":"10.1016/j.annonc.2025.08.2580","title":"1956P Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT-cohort A interim analysis)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Lakeridge Health; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Western University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Brampton Civic Hospital; Lions Gate Hospital; London Health Sciences Centre","funders":"","keywords":"Osimertinib; Interim; Lung cancer; Chemotherapy; Interim analysis","score_opus":0.051855382793633435,"score_gpt":0.4608945026276346,"score_spread":0.40903911983400115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104180020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93153346,0.005237057,0.0003368301,0.03831933,0.00015299961,0.0011447808,0.000030747466,0.00010541103,0.023139378],"genre_scores_gemma":[0.98840714,0.003680401,0.0004159176,0.005571532,0.00004790745,0.00031277674,0.0000704805,0.000032750395,0.0014610857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983454,0.00010372658,0.0005928714,0.00042662775,0.00017548271,0.00035593827],"domain_scores_gemma":[0.9988164,0.00013306577,0.00025811276,0.00037126878,0.0003255497,0.00009563419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033155386,0.00023076896,0.0009372587,0.0005541611,0.000039420243,0.0000075212165,0.00014019017,0.00018396117,0.00023582268],"category_scores_gemma":[0.000045237284,0.00017006209,0.0001795303,0.001214396,0.00012932913,0.000070956485,0.00003445378,0.00023335156,0.0000028801646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009052542,0.005235326,0.7755989,0.00041770536,0.034991477,0.00022839653,0.009111616,0.0014057204,0.004766519,0.0007537993,0.011832336,0.1466057],"study_design_scores_gemma":[0.019110061,0.006616126,0.87651956,0.0010589598,0.009151843,0.00002056189,0.0015244369,0.003247327,0.028076066,0.00031577193,0.053785574,0.00057368644],"about_ca_topic_score_codex":0.0017011372,"about_ca_topic_score_gemma":0.0014117057,"teacher_disagreement_score":0.14603202,"about_ca_system_score_codex":0.00022203139,"about_ca_system_score_gemma":0.0008481059,"threshold_uncertainty_score":0.6934931},"labels":[],"label_agreement":null},{"id":"W7104180031","doi":"10.1016/j.annonc.2025.08.2540","title":"1916P AI-powered multimodal prediction of response in 1L non-mutated mNSCLC using routine pre-treatment data (DEEP Lung-IV)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"MEDLINE; Clinical trial; Real world data; Response Evaluation Criteria in Solid Tumors","score_opus":0.07306891384026383,"score_gpt":0.4429110944146122,"score_spread":0.36984218057434837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104180031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989737,0.0012554908,0.0001959124,0.0063862074,0.0003067644,0.0010039372,0.00028712154,0.00002424939,0.000803336],"genre_scores_gemma":[0.9973232,0.0008421289,0.00079141575,0.00043028794,0.00005001779,0.00006065305,0.0003345833,0.00001582815,0.0001518561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981917,0.00021913373,0.00068372587,0.00044281298,0.00017178549,0.00029082937],"domain_scores_gemma":[0.9983302,0.00035229218,0.00025236246,0.00074905955,0.00023172879,0.00008436332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055196544,0.00019802942,0.00075765565,0.00033524036,0.00003376627,0.000004423472,0.00015509219,0.00020347154,0.000058064103],"category_scores_gemma":[0.00022787397,0.0001645622,0.0000999382,0.00039023388,0.00011593671,0.00010364616,0.00013442893,0.00011916576,0.0000020688967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056691527,0.017119655,0.8157254,0.00069967756,0.0034453822,0.00057014433,0.0031531,0.002385263,0.027750341,0.00010320254,0.006272848,0.06608347],"study_design_scores_gemma":[0.01926665,0.010772594,0.859456,0.001032728,0.0008945175,0.000032754426,0.00021883608,0.06560572,0.035904314,0.00006956553,0.0065842685,0.00016206944],"about_ca_topic_score_codex":0.0018737566,"about_ca_topic_score_gemma":0.00039859058,"teacher_disagreement_score":0.0659214,"about_ca_system_score_codex":0.0006165595,"about_ca_system_score_gemma":0.0009327949,"threshold_uncertainty_score":0.67106515},"labels":[],"label_agreement":null},{"id":"W7116836130","doi":"10.1016/j.annonc.2025.10.357","title":"1165P Safety profile of dabrafenib plus trametinib (D+T) in previously treated Chinese Mainland subgroup (CMS) population with radioactive iodine (RAI)–refractory BRAF V600E mutation–positive differentiated thyroid cancer (DTC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Dabrafenib; Trametinib; Thyroid cancer; Thyroid; Safety profile; Population","score_opus":0.02032554499753216,"score_gpt":0.3506057895090531,"score_spread":0.33028024451152094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116836130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903464,0.0030473191,0.00007743089,0.002183923,0.00009999693,0.0018328596,0.0003063152,0.00003390872,0.0020718826],"genre_scores_gemma":[0.9961836,0.0017229851,0.00021067867,0.00031648806,0.000048652662,0.0003591403,0.0007769562,0.00002824696,0.00035326276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978642,0.0002825468,0.00075960625,0.00047451473,0.00025584386,0.00036332177],"domain_scores_gemma":[0.99819803,0.0004657914,0.00054193015,0.00028945997,0.0003908391,0.000113943424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023856634,0.00032703474,0.0012238642,0.00040943123,0.000055918517,0.000007316246,0.00010609624,0.00022698623,0.00016569888],"category_scores_gemma":[0.00010667038,0.00023547166,0.0001579305,0.00073346007,0.00016835246,0.0001380817,0.000032759894,0.00024351163,0.000001877822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029406222,0.0065343664,0.8852901,0.0005425442,0.0026779936,0.00026797183,0.0037729735,0.00091746624,0.0063706017,0.00039471843,0.0009858182,0.06283925],"study_design_scores_gemma":[0.016465569,0.005541006,0.9631691,0.0005978405,0.000459101,0.000021215317,0.00019816175,0.00031862882,0.012729144,0.00012308432,0.00018800881,0.00018916308],"about_ca_topic_score_codex":0.0056595006,"about_ca_topic_score_gemma":0.004317706,"teacher_disagreement_score":0.077879,"about_ca_system_score_codex":0.0005733524,"about_ca_system_score_gemma":0.0005290466,"threshold_uncertainty_score":0.9602255},"labels":[],"label_agreement":null},{"id":"W7116845963","doi":"10.1016/j.annonc.2025.10.386","title":"491MO Combinatorial multimodal AI (MMAI) pathology and decipher genomic classifier (GC) enhance NCCN prognostication in localized prostate cancer (PCa)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emera (Canada)","funders":"","keywords":"DECIPHER; Prostate cancer; Classifier (UML); Metastasis; Distant metastasis; Cancer; Biochemical recurrence","score_opus":0.03246221028383829,"score_gpt":0.3903979476516034,"score_spread":0.3579357373677651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116845963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97099274,0.004671684,0.0000576115,0.020710927,0.0006398962,0.0012544409,0.000037704827,0.0000205662,0.0016144003],"genre_scores_gemma":[0.9889286,0.006491068,0.00035324114,0.0030421065,0.000074173244,0.0007921259,0.000034137727,0.000015770886,0.00026873493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851406,0.00013691747,0.00048377147,0.00041709456,0.000104015824,0.00034413906],"domain_scores_gemma":[0.9990167,0.0002342049,0.00017519937,0.00021933508,0.00025997713,0.00009458337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002834396,0.00017760502,0.000623106,0.0001572583,0.000039494815,0.000007887312,0.000072195915,0.00023065542,0.00006319346],"category_scores_gemma":[0.00015044099,0.00015629259,0.000060453385,0.00020904106,0.00027272868,0.000061827894,0.000072261995,0.00020737624,0.000006440264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043451153,0.0029958715,0.5300747,0.0003801455,0.00037742066,0.00037905216,0.001220392,0.000036855894,0.013509088,0.0055934126,0.007378382,0.43370953],"study_design_scores_gemma":[0.02189777,0.0064662364,0.7459478,0.0007064835,0.00034282194,0.000038808004,0.00019932508,0.00070868863,0.08183904,0.010295244,0.13117473,0.00038307675],"about_ca_topic_score_codex":0.00032887238,"about_ca_topic_score_gemma":0.00029145213,"teacher_disagreement_score":0.43332645,"about_ca_system_score_codex":0.00020366529,"about_ca_system_score_gemma":0.00069856725,"threshold_uncertainty_score":0.6373427},"labels":[],"label_agreement":null},{"id":"W7116849223","doi":"10.1016/j.annonc.2025.10.1226","title":"811eP Distribution of tumor-associated antigen targets in solid Tumors: Findings from the prospective DUST study in India","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Distribution (mathematics); Antigen; Prospective cohort study; Antibody","score_opus":0.021573162004440267,"score_gpt":0.32810731324172976,"score_spread":0.3065341512372895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116849223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936603,0.004117417,0.0000056662084,0.00061336777,0.00027441053,0.0007330235,0.00014464043,0.00001334509,0.0004378813],"genre_scores_gemma":[0.9990844,0.00025110182,0.000002220691,0.00027543306,0.000005583246,0.000059153193,0.00014163312,0.000007863301,0.00017257564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745274,0.0011253589,0.00075527263,0.00025762888,0.000041283074,0.00036771168],"domain_scores_gemma":[0.9982761,0.00097349694,0.00033073593,0.00025352766,0.00015966361,0.0000064524734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011626984,0.00016944943,0.00072071387,0.00019910622,0.00009012316,0.000004873058,0.0003715015,0.00026351094,0.00010191405],"category_scores_gemma":[0.000881878,0.00013537351,0.00009787154,0.00059665047,0.00034781708,0.00007858316,0.00012475552,0.00045410925,0.000014150391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003338751,0.0034777208,0.87697375,0.000008168918,0.0005851709,0.000027831951,0.0061827954,0.000005649642,0.10480311,0.00045144965,0.0018244516,0.0023211392],"study_design_scores_gemma":[0.0029917264,0.0015710637,0.8569016,0.00011735622,0.000015211043,0.0000020861662,0.002627166,0.0000011489826,0.13359097,0.0005793246,0.0015089745,0.000093394156],"about_ca_topic_score_codex":0.0024348039,"about_ca_topic_score_gemma":0.0006365578,"teacher_disagreement_score":0.02878786,"about_ca_system_score_codex":0.00010875714,"about_ca_system_score_gemma":0.0003516064,"threshold_uncertainty_score":0.5520371},"labels":[],"label_agreement":null},{"id":"W7116850254","doi":"10.1016/j.annonc.2025.10.318","title":"1126P Unveiling toxicity patterns of cellular therapies across malignancies: A multi-centre Indian experience","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Toxicity; MEDLINE; Clinical trial","score_opus":0.08298021439577435,"score_gpt":0.42224556989204437,"score_spread":0.33926535549627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116850254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98230577,0.00065846415,0.0021774224,0.014309837,0.00018854764,0.00017011406,0.000019995427,0.000012775056,0.00015710016],"genre_scores_gemma":[0.99675566,0.0003817133,0.00041580864,0.0019878487,0.000035194247,0.000005474408,0.000012064792,0.0000053587146,0.00040087264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990099,0.00006542218,0.0003691071,0.00016939561,0.00016768549,0.0002184695],"domain_scores_gemma":[0.9992051,0.00011432539,0.00016694203,0.00018830312,0.000255223,0.000070109956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003812721,0.000088213856,0.00035759612,0.00007752136,0.000048139587,0.0000030599308,0.000104723724,0.00030059795,0.00006734588],"category_scores_gemma":[0.00011257488,0.00006855533,0.00009882699,0.00018617841,0.0005985035,0.000030314804,0.00006375041,0.00016255547,0.0000013838106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000398062,0.0023667011,0.11168151,0.0013370753,0.0003295345,0.000101446894,0.08710263,0.000011726469,0.6164741,0.0038433003,0.0003453751,0.17600854],"study_design_scores_gemma":[0.003492908,0.0012579672,0.13578203,0.0010605806,0.00004023508,0.000009315632,0.024261154,0.0005773119,0.80618703,0.0010282974,0.026115984,0.0001871644],"about_ca_topic_score_codex":0.00018179796,"about_ca_topic_score_gemma":0.00016561939,"teacher_disagreement_score":0.18971294,"about_ca_system_score_codex":0.000018600536,"about_ca_system_score_gemma":0.00020615589,"threshold_uncertainty_score":0.2795605},"labels":[],"label_agreement":null},{"id":"W7116856447","doi":"10.1016/j.annonc.2025.10.1100","title":"663TiP BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre","funders":"","keywords":"Chemotherapy; Trastuzumab; Endometrial cancer; Phases of clinical research; Chemotherapy regimen","score_opus":0.08636840016573863,"score_gpt":0.4216284111288951,"score_spread":0.3352600109631565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116856447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928355,0.0011790957,0.0000070229476,0.0008615628,0.00082168775,0.0016815929,0.00013299739,0.000018396446,0.0024621256],"genre_scores_gemma":[0.9982827,0.0007527992,0.00014859476,0.0003160361,0.00016328887,0.00017978721,0.000068863876,0.000023820905,0.00006414278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99737793,0.00025382283,0.0010952732,0.00041372702,0.0004702531,0.0003889929],"domain_scores_gemma":[0.9973357,0.0009343929,0.00076082384,0.0003276988,0.00042654277,0.00021485011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034535615,0.00028892473,0.0015556143,0.0007182832,0.000030623967,0.000004651803,0.00018840376,0.00025876448,0.00021327859],"category_scores_gemma":[0.0012473033,0.00022326705,0.00021489168,0.0018599876,0.00032805197,0.00008229049,0.000045746343,0.00025951437,5.4835704e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6468251,0.011797966,0.029626768,0.00030495683,0.0012882284,0.000011177931,0.0005244807,0.000008403559,0.0015323608,0.000030060355,0.0008527683,0.30719775],"study_design_scores_gemma":[0.8275794,0.06992739,0.038256884,0.0010725136,0.00051926955,4.171038e-7,0.00010858912,0.000017971603,0.055320006,0.000070224836,0.0069076996,0.00021963239],"about_ca_topic_score_codex":0.0030048885,"about_ca_topic_score_gemma":0.0005754275,"teacher_disagreement_score":0.3069781,"about_ca_system_score_codex":0.00028686476,"about_ca_system_score_gemma":0.0013249533,"threshold_uncertainty_score":0.9104566},"labels":[],"label_agreement":null},{"id":"W7116872897","doi":"10.1016/j.annonc.2025.10.100","title":"273MO Safety results in Asian participants (pts) from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for pts with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Carcinoma; Hepatocellular cancer","score_opus":0.1659568706614315,"score_gpt":0.3774655174604004,"score_spread":0.2115086467989689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116872897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807136,0.0028820587,0.000010758095,0.010417112,0.000047735593,0.004887579,0.00025808776,0.000020689205,0.00076234614],"genre_scores_gemma":[0.9975743,0.0007441557,0.00019849784,0.00023992456,0.000049375187,0.0008290851,0.00014802528,0.000030511948,0.000186099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722147,0.00034464963,0.0009431494,0.0006703454,0.0002663622,0.00055401865],"domain_scores_gemma":[0.9977528,0.0009834663,0.0003367185,0.00046536405,0.00026694516,0.00019472945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077336835,0.0003750581,0.0012394497,0.00023642334,0.00016913902,0.000017414905,0.00014615202,0.00020769073,0.000024992363],"category_scores_gemma":[0.00032534776,0.00024475518,0.0001320059,0.00043937415,0.00023982654,0.00008180023,0.00009267834,0.00015036034,0.0000011690661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032477573,0.0116971005,0.8798353,0.0001640937,0.0012853278,0.0004012009,0.007244186,0.000003493176,0.0005912789,0.00004231502,0.0002829389,0.06597516],"study_design_scores_gemma":[0.21036048,0.20243676,0.48893213,0.000900345,0.004656598,0.00005377519,0.010196284,0.010509742,0.05725298,0.0004845404,0.013586683,0.00062968145],"about_ca_topic_score_codex":0.0070461067,"about_ca_topic_score_gemma":0.008629566,"teacher_disagreement_score":0.3909032,"about_ca_system_score_codex":0.00012287968,"about_ca_system_score_gemma":0.0004776644,"threshold_uncertainty_score":0.9995661},"labels":[],"label_agreement":null},{"id":"W7116872912","doi":"10.1016/j.annonc.2025.10.1030","title":"193eP Transcriptomic analysis of umbilical cord blood NK cells informs CXCR3-armored NK design to boost functionality for cancer therapies","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Transcriptome; Cancer; Umbilical cord; Umbilical vein; Blood cancer","score_opus":0.06760311513167001,"score_gpt":0.3596942985055174,"score_spread":0.2920911833738474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116872912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94376844,0.0045590773,0.035885,0.005059964,0.0062719514,0.0013716092,0.00024028802,0.000073554045,0.0027701424],"genre_scores_gemma":[0.9864955,0.00081277173,0.00024588502,0.0038619735,0.00002506361,0.00019973952,0.00017570352,0.000010930987,0.008172429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839884,0.00023447123,0.00073432137,0.00028856695,0.000042696116,0.00030111],"domain_scores_gemma":[0.99828947,0.00060592423,0.00028491527,0.00027190844,0.0005223379,0.000025477006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057236286,0.00017912142,0.0007575129,0.00053704047,0.00010795633,0.000006170141,0.00020851227,0.00035263636,0.0018313488],"category_scores_gemma":[0.000115299066,0.00015679511,0.00044689164,0.0005832106,0.00021707737,0.00009141383,0.000032639386,0.00019050328,0.000026282592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011234641,0.0008196758,0.0009831977,0.000068425106,0.007822057,3.7709478e-7,0.00065514684,0.00042720817,0.87325394,0.0010016165,0.062408406,0.0413253],"study_design_scores_gemma":[0.001851532,0.0029060105,0.013377841,0.000028326695,0.0012581346,0.0000024059138,0.00040805354,0.000063899446,0.6376799,0.0001618752,0.34210905,0.00015296618],"about_ca_topic_score_codex":0.00061764586,"about_ca_topic_score_gemma":0.0003199964,"teacher_disagreement_score":0.27970067,"about_ca_system_score_codex":0.000046537854,"about_ca_system_score_gemma":0.00026124733,"threshold_uncertainty_score":0.99908113},"labels":[],"label_agreement":null},{"id":"W7116880392","doi":"10.1016/j.annonc.2025.10.345","title":"1153P Enhanced pan-cancer early detection: A multi-feature AI model on whole-genome methylation data expands detection to 12 Solid tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Machine Learning in Healthcare","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Cancer; Cancer detection; DNA methylation; Cancer cell; Solid tumor","score_opus":0.11324727825828546,"score_gpt":0.4487375618628052,"score_spread":0.33549028360451977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116880392","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.111661404,0.00021957504,0.86627644,0.019747926,0.0007957445,0.0005118914,0.000044317436,0.00016396419,0.0005787499],"genre_scores_gemma":[0.98347473,0.000052177813,0.01031107,0.00505092,0.00015510008,0.00013341433,0.000017493443,0.00001614052,0.00078894425],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976622,0.00035647815,0.0004578908,0.00082244375,0.00027750773,0.0004234644],"domain_scores_gemma":[0.99776375,0.00021224703,0.00028878084,0.0012007186,0.00041030737,0.00012417052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078534667,0.00021806205,0.00044167144,0.00045371626,0.0002093749,0.00005346521,0.0011965882,0.00028573087,0.0000069734356],"category_scores_gemma":[0.00038545573,0.00021895887,0.000075665586,0.00077214563,0.000044014774,0.00046164525,0.0005388271,0.00063011807,0.000024869716],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025710356,0.0001664994,0.00022183615,0.0000904794,0.00006207332,0.0000056043405,0.0018575173,0.06527921,0.1331496,0.0002628965,0.0004644192,0.7981828],"study_design_scores_gemma":[0.00092971924,0.002865983,0.03497276,0.00014409273,0.00002246648,0.00000541672,0.000051277235,0.84359264,0.09799714,0.0012307377,0.017814381,0.00037336576],"about_ca_topic_score_codex":0.00051735673,"about_ca_topic_score_gemma":0.0015557772,"teacher_disagreement_score":0.87181336,"about_ca_system_score_codex":0.0001483724,"about_ca_system_score_gemma":0.0003847146,"threshold_uncertainty_score":0.89288837},"labels":[],"label_agreement":null},{"id":"W7116881267","doi":"10.1016/j.annonc.2025.10.1207","title":"793P Real-world landscape of homologous recombination repair (HRR) gene alterations across solid tumors: Single-institution experience using comprehensive genomic profiling (CGP) from India","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Homologous recombination; Gene; Homologous chromosome; Profiling (computer programming); Genome; Gene deletion","score_opus":0.12288818312396775,"score_gpt":0.44734180711187016,"score_spread":0.3244536239879024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116881267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353874,0.00053469493,0.0011710083,0.0005767232,0.0005890624,0.00055432116,0.000105000625,0.000076647055,0.002853803],"genre_scores_gemma":[0.9910797,0.00030237148,0.007270784,0.0008540481,0.00016378034,0.00006361675,0.00017987598,0.000014658586,0.000071180526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818075,0.00016767472,0.00084003137,0.00036674572,0.00016298547,0.0002818205],"domain_scores_gemma":[0.9981203,0.00021523591,0.00055904133,0.00035738826,0.000682548,0.00006547612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465973,0.00016645476,0.000639766,0.00030772237,0.00015292548,0.000009839956,0.00011819783,0.00017068122,0.000055284963],"category_scores_gemma":[0.00010754168,0.00017799881,0.00014210197,0.00046284986,0.00034927204,0.00015142624,0.00006844232,0.00018697107,0.0000038096612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008261654,0.0007345239,0.03783052,0.00011940462,0.00023191044,0.000047614685,0.0037529457,0.0015153894,0.94898564,0.00092747196,0.00039660343,0.0046318113],"study_design_scores_gemma":[0.0028842855,0.0013322579,0.08717739,0.00046143107,0.00007288047,0.00004787807,0.0012742138,0.0025999043,0.9016901,0.0013368704,0.00093769416,0.00018508134],"about_ca_topic_score_codex":0.0005384432,"about_ca_topic_score_gemma":0.00013549728,"teacher_disagreement_score":0.049346868,"about_ca_system_score_codex":0.00026722453,"about_ca_system_score_gemma":0.00059387024,"threshold_uncertainty_score":0.7258581},"labels":[],"label_agreement":null},{"id":"W7116896088","doi":"10.1016/j.annonc.2025.10.099","title":"272O TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC): early safety and efficacy results in participants (pts) from Asia","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Durvalumab; Gemcitabine; Chemotherapy; Biliary tract cancer; Phases of clinical research; Clinical trial","score_opus":0.05354938172002125,"score_gpt":0.3858304287697283,"score_spread":0.332281047049707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116896088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98765457,0.0015004074,0.000003733379,0.009319296,0.0000570938,0.0009903722,0.000035052155,0.000008855325,0.0004306219],"genre_scores_gemma":[0.99872833,0.0005797658,0.00007526637,0.00045505166,0.000015275647,0.00007464978,0.000019945883,0.000011254237,0.00004044983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983086,0.00017820476,0.0007433135,0.0003413415,0.00016900619,0.00025951344],"domain_scores_gemma":[0.9989309,0.0004345791,0.00021691842,0.0002248027,0.00014824948,0.000044581982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051402964,0.00015821583,0.0008329009,0.00035455162,0.000016444734,0.000002494176,0.00007588129,0.00009951095,0.000011901804],"category_scores_gemma":[0.00018472869,0.00013414105,0.000034377666,0.00056819717,0.00010647643,0.00007001091,0.000027809809,0.00021049491,1.9978738e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030078601,0.0063809697,0.8800786,0.000072699666,0.00013397024,0.000091563496,0.005534884,0.00037153615,0.0011578159,0.000008710327,0.00007778927,0.076012865],"study_design_scores_gemma":[0.060350213,0.0060417117,0.9290451,0.00041802565,0.000046157405,5.5338387e-7,0.001221451,0.00023733654,0.00226427,0.000027468319,0.0002534271,0.00009427746],"about_ca_topic_score_codex":0.008465244,"about_ca_topic_score_gemma":0.027484829,"teacher_disagreement_score":0.07591859,"about_ca_system_score_codex":0.0001063146,"about_ca_system_score_gemma":0.00028713644,"threshold_uncertainty_score":0.9981375},"labels":[],"label_agreement":null},{"id":"W7116896438","doi":"10.1016/j.annonc.2025.10.021","title":"198MO MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Colorectal cancer; KRAS; Colonic disease; MEDLINE; Cancer","score_opus":0.047358189136086325,"score_gpt":0.4094244649414065,"score_spread":0.3620662758053202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116896438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980421,0.0019564172,0.00008980346,0.007358951,0.0016832115,0.0013533889,0.0005201297,0.00009827597,0.006518838],"genre_scores_gemma":[0.9902281,0.0006695606,0.0016141654,0.0041731773,0.00015887304,0.00043427103,0.0005258584,0.00004375843,0.002152214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977481,0.00009214188,0.0007051995,0.00059537997,0.00024308113,0.000616121],"domain_scores_gemma":[0.99764484,0.00078846613,0.00025390016,0.00032115864,0.0008135331,0.00017808922],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028041954,0.00032184256,0.0010406662,0.00026039864,0.00009658249,0.000010353929,0.00027082223,0.00046466175,0.0017065329],"category_scores_gemma":[0.00065378274,0.00029765605,0.00022674093,0.0005250353,0.0002963716,0.00006475277,0.00011700698,0.00031416677,0.000028002327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01878229,0.0015514953,0.04602167,0.0003619359,0.002009305,0.0000590646,0.00090521865,0.0002402922,0.48545468,0.00045656395,0.2885544,0.15560307],"study_design_scores_gemma":[0.010343425,0.0057406444,0.06649296,0.0002658985,0.00041731482,0.000009684021,0.00019418882,0.00045889066,0.5318884,0.0019925635,0.381825,0.00037100795],"about_ca_topic_score_codex":0.00079298083,"about_ca_topic_score_gemma":0.0009009228,"teacher_disagreement_score":0.15523206,"about_ca_system_score_codex":0.00027495564,"about_ca_system_score_gemma":0.0011640972,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W7116910451","doi":"10.1016/j.annonc.2025.10.607","title":"LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lung cancer; Subgroup analysis; Perioperative; MEDLINE","score_opus":0.030612822902916614,"score_gpt":0.3650202672501153,"score_spread":0.3344074443471987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116910451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97448957,0.0042531025,0.000018295472,0.007861178,0.00042081473,0.0011892327,0.00009867724,0.000015024383,0.011654117],"genre_scores_gemma":[0.99404633,0.0011661681,0.00004714058,0.0025112866,0.00008910641,0.00010751057,0.0000102316335,0.000013387924,0.002008826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984448,0.00023422173,0.00043821023,0.00038688493,0.00016532691,0.00033055944],"domain_scores_gemma":[0.9991657,0.0001521031,0.00013921174,0.00033768272,0.00013713392,0.000068161055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039581978,0.00021418829,0.00059431914,0.0000816206,0.00009811868,0.000024935889,0.00020870988,0.00018702827,0.00019847487],"category_scores_gemma":[0.000046105364,0.00015661208,0.00012841524,0.0003937982,0.00021464886,0.000063840744,0.000110798435,0.0002667917,0.0000028984146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016018648,0.001033812,0.9217279,0.00007868362,0.00095515244,0.00012309762,0.013521977,0.0000031662096,0.0035902313,0.00010504941,0.0041544638,0.03868784],"study_design_scores_gemma":[0.020620756,0.0031182938,0.9531775,0.0001827382,0.00019226769,0.0000031469895,0.008555739,0.000067249726,0.0013024166,0.00002755514,0.012587817,0.00016449788],"about_ca_topic_score_codex":0.019179521,"about_ca_topic_score_gemma":0.025729919,"teacher_disagreement_score":0.038523342,"about_ca_system_score_codex":0.00018158476,"about_ca_system_score_gemma":0.00074344175,"threshold_uncertainty_score":0.99204797},"labels":[],"label_agreement":null},{"id":"W7116917451","doi":"10.1016/j.annonc.2025.10.716","title":"1005P MET testing and treatment (tx) sequencing after progression of disease (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Final analysis of a global real-world (rw) study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Disease; C-Met; MEDLINE; Respiratory disease","score_opus":0.07739625107389356,"score_gpt":0.44608546161368484,"score_spread":0.3686892105397913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116917451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978136,0.00025285312,0.00001850262,0.00026397253,0.000015401241,0.0012231577,0.00014578729,0.000009936543,0.00025679893],"genre_scores_gemma":[0.9974478,0.00015981535,0.0019494997,0.00007946431,0.0000068197264,0.00021576893,0.00008003684,0.000008101623,0.000052724907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986375,0.00010344922,0.0005083818,0.00038478267,0.0001982599,0.0001676208],"domain_scores_gemma":[0.99869514,0.00030434987,0.0004087692,0.00024450687,0.00023903437,0.00010820666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013894746,0.00018868256,0.00066985696,0.00029958342,0.000057270474,0.0000055992,0.00003682406,0.00005372237,0.000010882959],"category_scores_gemma":[0.00018272926,0.00012274797,0.000049345155,0.00073501957,0.00010863901,0.000088966,0.00004850819,0.000038481343,8.4240284e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020074574,0.0034254347,0.86945224,0.00014717256,0.00095483055,0.000015663796,0.0009186278,0.00019777234,0.00043677105,0.000030680363,0.000007763123,0.10433846],"study_design_scores_gemma":[0.00923401,0.017267153,0.9687986,0.0011123209,0.002289559,6.74991e-7,0.0003572907,0.00023596344,0.00051578006,0.000048196882,0.000049693528,0.00009080509],"about_ca_topic_score_codex":0.0008159456,"about_ca_topic_score_gemma":0.0017170578,"teacher_disagreement_score":0.10424765,"about_ca_system_score_codex":0.00023896321,"about_ca_system_score_gemma":0.000247738,"threshold_uncertainty_score":0.5005517},"labels":[],"label_agreement":null},{"id":"W7116923068","doi":"10.1016/j.annonc.2025.10.140","title":"313P Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Chemotherapy; Nivolumab; Chemotherapy regimen; Chemoimmunotherapy; Cyclophosphamide","score_opus":0.026630085028864887,"score_gpt":0.33765457265372445,"score_spread":0.31102448762485957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116923068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622376,0.00052920164,0.00005380327,0.03586135,0.00011265863,0.00065604504,0.000083946274,0.000023895753,0.0004414756],"genre_scores_gemma":[0.9728445,0.01605212,0.00007960131,0.00879562,0.000027913387,0.00007135793,0.00011680062,0.000025340332,0.0019867732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987802,0.00004259021,0.00046318356,0.00030540282,0.00012050307,0.00028811727],"domain_scores_gemma":[0.9992011,0.00010952647,0.00022511737,0.0002837948,0.00011254306,0.000067893234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012869164,0.0002410077,0.0008027474,0.00016525335,0.000048702164,0.000008881686,0.00008617541,0.00016817306,0.00008100065],"category_scores_gemma":[0.000019629348,0.00017700353,0.000100132595,0.00017049727,0.00016951335,0.00004682525,0.00001713387,0.00009852895,0.0000012399282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014846338,0.0018059181,0.8194282,0.00016263676,0.00062498735,0.000017419434,0.00073246815,3.4045823e-7,0.00025345696,0.0000136381905,0.006896131,0.15521844],"study_design_scores_gemma":[0.025131928,0.0069304644,0.85911983,0.00028641056,0.00004839909,0.0000060742614,0.000089559784,0.00001995979,0.0033172406,0.000024976878,0.104868285,0.00015688637],"about_ca_topic_score_codex":0.0014247276,"about_ca_topic_score_gemma":0.0010865501,"teacher_disagreement_score":0.15506154,"about_ca_system_score_codex":0.00021215326,"about_ca_system_score_gemma":0.00024447936,"threshold_uncertainty_score":0.7217995},"labels":[],"label_agreement":null},{"id":"W7116924793","doi":"10.1016/j.annonc.2025.10.442","title":"546MO Knowledge gaps and shared decision making (SDM) disparities in kidney cancer (KC) across Asia: Results from the international kidney cancer coalition (IKCC) global patient survey (GPS)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca","keywords":"Kidney cancer; Cancer; Healthcare system; Global Positioning System; Global health; MEDLINE; Health care; Health equity","score_opus":0.09568904143616246,"score_gpt":0.4350608041268182,"score_spread":0.3393717626906557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116924793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95845675,0.0060562664,0.000027886885,0.020598842,0.0011486773,0.00050182606,0.007849622,0.000016769844,0.0053433473],"genre_scores_gemma":[0.9910005,0.00271394,0.00014886171,0.004981444,0.00013384168,0.00013338625,0.00065586285,0.000011172203,0.00022100766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979431,0.00029655223,0.00067817623,0.00045670485,0.00029076403,0.0003346717],"domain_scores_gemma":[0.9977462,0.0010265827,0.00026347797,0.00029307362,0.00050640095,0.00016426411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068881985,0.00020828006,0.0005134208,0.00007976725,0.000088528745,0.000036216865,0.00020666486,0.00020440326,0.00010971468],"category_scores_gemma":[0.001953738,0.00015446365,0.00009140442,0.00028928387,0.00018920598,0.00009437229,0.00028240692,0.00020476972,0.000004694357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076333806,0.00058206765,0.666109,0.00008493249,0.00038667605,0.00008724423,0.0016915381,0.000032495696,0.00027729766,0.00019731377,0.21101217,0.11190584],"study_design_scores_gemma":[0.004242418,0.00045197865,0.95039815,0.0019872359,0.00006587599,0.000008753146,0.00034187536,0.00028223672,0.0012242537,0.00063403486,0.04024364,0.00011954285],"about_ca_topic_score_codex":0.028923748,"about_ca_topic_score_gemma":0.039860588,"teacher_disagreement_score":0.28428912,"about_ca_system_score_codex":0.0006635283,"about_ca_system_score_gemma":0.0011000492,"threshold_uncertainty_score":0.97765946},"labels":[],"label_agreement":null},{"id":"W7116929023","doi":"10.1016/j.annonc.2025.10.1044","title":"607MO Iparomlimab and tuvonralimab (QL1706) vs zimberelimab for previously treated recurrent/metastatic cervical cancer (r/mCC): An unanchored matching-adjusted indirect comparison (MAIC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Cervical cancer; MEDLINE; Cancer; Cervical carcinoma","score_opus":0.1243475234793026,"score_gpt":0.44135235047077476,"score_spread":0.31700482699147214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116929023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760515,0.009903244,0.00013852183,0.007978272,0.00050575496,0.0021342,0.00029150385,0.000111524125,0.0028854639],"genre_scores_gemma":[0.9919329,0.0024637412,0.0016165974,0.0023310622,0.00013846312,0.0005499974,0.00038890928,0.000041282692,0.00053704233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971078,0.00031527548,0.0009538388,0.00066947105,0.0002780862,0.0006755404],"domain_scores_gemma":[0.9977173,0.00074501836,0.00039700567,0.0003858662,0.0004285732,0.0003262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004696199,0.0003915985,0.0018795418,0.00043006314,0.00012689778,0.000023273922,0.00020057686,0.00027589325,0.0002095566],"category_scores_gemma":[0.00028697998,0.0003189669,0.00025585073,0.0008415876,0.000198375,0.00012739479,0.00009518798,0.00030670362,0.000006767572],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03862865,0.007830744,0.07881921,0.0026710762,0.0032945892,0.00008907227,0.0019652776,0.000030739964,0.0017664692,0.0012591023,0.012317575,0.8513275],"study_design_scores_gemma":[0.108348124,0.07869615,0.6361743,0.0027579188,0.008919012,0.00013299417,0.0015415599,0.0021907128,0.030673584,0.013004568,0.115945496,0.0016155663],"about_ca_topic_score_codex":0.0014202606,"about_ca_topic_score_gemma":0.0015354711,"teacher_disagreement_score":0.84971195,"about_ca_system_score_codex":0.00017714308,"about_ca_system_score_gemma":0.0005147581,"threshold_uncertainty_score":0.99992627},"labels":[],"label_agreement":null},{"id":"W7116938074","doi":"10.1016/j.annonc.2025.10.727","title":"1016P Patient (pt) characteristics, HER2 testing, and treatment (Tx) patterns in advanced HER2 (ERBB2)-mutant (HER2m) NSCLC in real-world clinical practice","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Clinical Practice; Mutation; Chemotherapy; Clinical trial; MEDLINE","score_opus":0.20592206771403104,"score_gpt":0.5385735729854448,"score_spread":0.3326515052714138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116938074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563652,0.0004937996,0.000007068756,0.017716192,0.00034889113,0.0011903611,0.000043713022,0.000030718304,0.023804002],"genre_scores_gemma":[0.9860883,0.006975127,0.0016239679,0.004217805,0.00013479311,0.00019829402,0.000021492444,0.000032211832,0.0007080263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964322,0.00057857914,0.0014319512,0.0006240418,0.0003182869,0.00061498175],"domain_scores_gemma":[0.99494815,0.003429945,0.00042587382,0.0005094417,0.00046077804,0.0002258067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014798356,0.00025880785,0.0011053518,0.00044863598,0.00003639906,0.000013629071,0.00015107659,0.00025702544,0.00010337106],"category_scores_gemma":[0.0048470614,0.00022843677,0.000092697584,0.000603751,0.00023042117,0.00010418442,0.00016668065,0.0006222267,0.00001687371],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015984967,0.0023195816,0.49052927,0.00012290606,0.00007889164,0.0009052398,0.00036647537,0.0000026175117,0.00025911396,0.00008855831,0.0006757296,0.5030531],"study_design_scores_gemma":[0.004471123,0.01223505,0.8264913,0.0009934758,0.000057664067,0.000034748235,0.00048609785,0.0001441306,0.00095390156,0.000187105,0.15377015,0.00017527574],"about_ca_topic_score_codex":0.005938646,"about_ca_topic_score_gemma":0.00869066,"teacher_disagreement_score":0.50287783,"about_ca_system_score_codex":0.00056629226,"about_ca_system_score_gemma":0.0012586694,"threshold_uncertainty_score":0.9315381},"labels":[],"label_agreement":null},{"id":"W7116948267","doi":"10.1016/j.annonc.2025.10.758","title":"1047P Pembrolizumab (Pembro) monotherapy for locally advanced or metastatic non–small-cell lung cancer (NSCLC): 10-year outcomes from clinical trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Clinical trial; Lung cancer; Cancer; Immunotherapy; Respiratory disease","score_opus":0.20408833573306595,"score_gpt":0.5220085272068498,"score_spread":0.3179201914737838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116948267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142394,0.020269884,0.011879318,0.034142368,0.0033206376,0.0074364166,0.00077320647,0.00013140115,0.007807338],"genre_scores_gemma":[0.76388776,0.05407966,0.03523722,0.08457204,0.0012800056,0.0032083236,0.00033193242,0.00027082107,0.057132214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602425,0.00062047533,0.002097019,0.0005700904,0.00020561434,0.00048256057],"domain_scores_gemma":[0.9929369,0.0050395965,0.00087045314,0.0005455288,0.00045793044,0.00014956597],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002981068,0.00033967535,0.0024787413,0.00022220178,0.00007539728,0.00001568023,0.000313493,0.00034588366,0.0019682364],"category_scores_gemma":[0.0011838116,0.0002405021,0.0010355084,0.0002982203,0.00022635695,0.0000733243,0.000049466118,0.00024626698,0.000009547089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21407537,0.001893016,0.007669554,0.0004918611,0.005990579,0.00003558141,0.00033147485,0.000027954518,0.015156598,0.00007867595,0.085845225,0.6684041],"study_design_scores_gemma":[0.2170058,0.020524679,0.04527727,0.0012892069,0.0033761223,0.0000069576317,0.00092916,0.0015273816,0.05021569,0.0008798992,0.65807515,0.000892665],"about_ca_topic_score_codex":0.00046298347,"about_ca_topic_score_gemma":0.0004330753,"teacher_disagreement_score":0.66751146,"about_ca_system_score_codex":0.00011755628,"about_ca_system_score_gemma":0.0025452129,"threshold_uncertainty_score":0.9989441},"labels":[],"label_agreement":null},{"id":"W7116952014","doi":"10.1016/j.annonc.2025.10.923","title":"88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): A DESTINY-Breast09 analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Taxane; Trastuzumab; Breast cancer; Chemotherapy","score_opus":0.06237122466736459,"score_gpt":0.4233950909921288,"score_spread":0.3610238663247642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116952014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644886,0.002209926,0.0040347143,0.01940622,0.00030309753,0.004964741,0.0023894086,0.00016602142,0.002037263],"genre_scores_gemma":[0.98907316,0.0019886398,0.0047735674,0.00071025104,0.0001336253,0.0017178035,0.0003542137,0.00015066128,0.001098073],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99423987,0.0003340198,0.0016812002,0.0012904552,0.0010255161,0.0014289438],"domain_scores_gemma":[0.9940116,0.00090577034,0.0009076357,0.001176639,0.0024091823,0.0005892019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000533005,0.00084421283,0.0031926997,0.0015165042,0.00022847884,0.000026722539,0.0005422724,0.0003481189,0.0005155709],"category_scores_gemma":[0.00037923479,0.0006686156,0.00090041704,0.0027182968,0.0007715009,0.00019771398,0.0001041212,0.0003813646,0.000006757913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022529453,0.014096766,0.074268416,0.0019667172,0.009523396,0.00019332336,0.0019331734,0.0019437688,0.0004451563,0.0001494073,0.0019356447,0.8710148],"study_design_scores_gemma":[0.08642462,0.21392356,0.5492282,0.0037653043,0.020103443,0.0006239379,0.004138251,0.0076199947,0.015758418,0.0009797453,0.09497569,0.0024588655],"about_ca_topic_score_codex":0.0038664495,"about_ca_topic_score_gemma":0.010728626,"teacher_disagreement_score":0.8685559,"about_ca_system_score_codex":0.0026085714,"about_ca_system_score_gemma":0.0042487285,"threshold_uncertainty_score":0.9995765},"labels":[],"label_agreement":null},{"id":"W7116953272","doi":"10.1016/j.annonc.2025.10.905","title":"71P Diffuse optical breast (DOB) scanner as a non-invasive approach for predicting pathologic response to neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Optical Imaging and Spectroscopy Techniques","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Richmond Hospital; Simon Fraser University; Abbotsford Veterinary Clinic","funders":"","keywords":"Chemotherapy; Breast cancer; Scanner; Cancer; Neoadjuvant therapy","score_opus":0.022749308997816013,"score_gpt":0.39440649852360643,"score_spread":0.3716571895257904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116953272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90763074,0.00020100971,0.011977464,0.07287971,0.00010620662,0.0016629152,0.00009191878,0.00013420433,0.0053158044],"genre_scores_gemma":[0.9429449,0.00029810434,0.04154355,0.01369827,0.00009917548,0.0006318602,0.000015089573,0.00003786553,0.0007311797],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978107,0.00013313965,0.0005961639,0.0006013026,0.00019718081,0.0006615056],"domain_scores_gemma":[0.9981815,0.00056810264,0.00013340026,0.00039278693,0.0004893475,0.00023482341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009196534,0.00027855625,0.00093078957,0.00037615787,0.000060618277,0.000014970154,0.00022999852,0.0003081762,0.000023416405],"category_scores_gemma":[0.0007983204,0.00023215888,0.00017205115,0.0004800589,0.00028920048,0.000079740996,0.00010123416,0.0003967946,0.000003009163],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103150375,0.008138138,0.029305976,0.00069588557,0.0003676234,0.00064704736,0.0017787308,0.00032588822,0.52317786,0.0016853287,0.009743379,0.32098377],"study_design_scores_gemma":[0.04951049,0.042961296,0.4647734,0.005398922,0.00053597183,0.0029164364,0.0034685542,0.0146763185,0.39779752,0.0046841805,0.0114262225,0.001850679],"about_ca_topic_score_codex":0.00016456237,"about_ca_topic_score_gemma":0.000028773233,"teacher_disagreement_score":0.43546742,"about_ca_system_score_codex":0.0002290679,"about_ca_system_score_gemma":0.00097571564,"threshold_uncertainty_score":0.9467164},"labels":[],"label_agreement":null},{"id":"W7116955310","doi":"10.1016/j.annonc.2025.12.017","title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; AstraZeneca","keywords":"Clinical endpoint; Chemotherapy; Overall survival; Phases of clinical research; Chemotherapy regimen; Hormone therapy; Hormone","score_opus":0.09547552410677164,"score_gpt":0.4617903217570697,"score_spread":0.36631479765029806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116955310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688,0.0005658037,0.000016684638,0.008584193,0.00015933256,0.0018067467,0.00034439558,0.000016879623,0.0016259715],"genre_scores_gemma":[0.9965951,0.0019156616,0.000081137936,0.0004984538,0.000042943535,0.00021462802,0.000049626728,0.000024868265,0.0005776205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625427,0.0011775796,0.0009050821,0.00054330536,0.0005680901,0.0005517014],"domain_scores_gemma":[0.9972806,0.0007569146,0.0003715875,0.0006592017,0.00079237967,0.0001393021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010650064,0.0002951972,0.0016025921,0.00072301854,0.00008395645,0.000012229626,0.00043140785,0.00013984281,0.0006385411],"category_scores_gemma":[0.000255387,0.00022238013,0.00029596593,0.0031477034,0.00042173485,0.00008560872,0.00013527085,0.0005006977,0.000002202965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13600661,0.0292058,0.387873,0.00036640617,0.026912438,0.00019219308,0.011186005,0.0007375984,0.013380061,0.00026430597,0.008127395,0.38574818],"study_design_scores_gemma":[0.066681236,0.012955296,0.9022874,0.0003594827,0.0022756397,0.000008986481,0.002765394,0.0008100326,0.010036287,0.000055132994,0.0014794939,0.0002856099],"about_ca_topic_score_codex":0.029659597,"about_ca_topic_score_gemma":0.011069649,"teacher_disagreement_score":0.5144144,"about_ca_system_score_codex":0.00056518475,"about_ca_system_score_gemma":0.0018623925,"threshold_uncertainty_score":0.976802},"labels":[],"label_agreement":null},{"id":"W7116956468","doi":"10.1016/j.annonc.2025.10.107","title":"280P Efficacy and safety of ivosidenib in Australian and South Korean patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Global Affairs Canada","funders":"","keywords":"IDH1; Phases of clinical research; Maximum tolerated dose; Chemotherapy; Phase (matter)","score_opus":0.055841785947004875,"score_gpt":0.37680862982479496,"score_spread":0.32096684387779006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116956468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925774,0.0005492405,0.0000012399189,0.004097526,0.00007019771,0.0013933724,0.00026888563,0.00001372308,0.001028411],"genre_scores_gemma":[0.999191,0.000053511478,0.00003525236,0.00047898892,0.000051082574,0.00002749784,0.00009092549,0.000012339541,0.00005944019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983256,0.00019454735,0.00062297774,0.00039758757,0.0002004457,0.00025885287],"domain_scores_gemma":[0.99863243,0.0004745427,0.00025412033,0.00032351603,0.00023368254,0.000081699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036145234,0.00020661068,0.0007011742,0.00016407474,0.00007598949,0.000009961531,0.00011923901,0.00010746375,0.000007309623],"category_scores_gemma":[0.0002972333,0.00013546717,0.00004939024,0.00032293488,0.00040343756,0.00006396685,0.0001341885,0.0002506731,5.358009e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031840734,0.0024382903,0.9151957,0.00006038647,0.0006701854,0.000106249616,0.02072378,0.000001768275,0.00015990828,0.000016990989,0.0015901785,0.027195815],"study_design_scores_gemma":[0.05934052,0.007534807,0.9263547,0.00019626267,0.00029681274,0.0000035548667,0.0045829965,0.0000045960946,0.0008853668,0.000028165008,0.0006639588,0.000108261185],"about_ca_topic_score_codex":0.0019270377,"about_ca_topic_score_gemma":0.0012395936,"teacher_disagreement_score":0.027499788,"about_ca_system_score_codex":0.000028371573,"about_ca_system_score_gemma":0.00019771491,"threshold_uncertainty_score":0.5524191},"labels":[],"label_agreement":null},{"id":"W7116956731","doi":"10.1016/j.annonc.2025.10.1041","title":"604MO Prognostic value of progression free status at 6 months on overall survival (OS) in platinum resistant ovarian cancer (PROC): Landmark analysis from the GCIG Symptom Benefit Study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; Cancer Research UK; National Institute for Health and Care Research; Target Ovarian Cancer","keywords":"Surrogate endpoint; Progression-free survival; Overall survival; Ovarian cancer; Immunotherapy; Clinical trial; Survival analysis","score_opus":0.0382349403986068,"score_gpt":0.381974377686269,"score_spread":0.3437394372876622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116956731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832229,0.0023770833,0.0000036020422,0.009183351,0.00021784376,0.0015431622,0.0004442445,0.000015944657,0.0029918905],"genre_scores_gemma":[0.9978796,0.00067291816,0.00012756712,0.00055836426,0.000072228875,0.00039161387,0.000096189266,0.000016366339,0.00018515407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976411,0.00029748413,0.0007197739,0.0005037329,0.00045243613,0.00038547677],"domain_scores_gemma":[0.9971278,0.0014202361,0.00039960904,0.00073311053,0.000220517,0.000098741286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005525852,0.00023878508,0.001067767,0.00027458408,0.00007504221,0.000009960098,0.00022284762,0.00016433388,0.00023314497],"category_scores_gemma":[0.000300354,0.00015497302,0.00019027718,0.00073399825,0.00009062204,0.000034539396,0.00017955116,0.00020236873,0.0000020592963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053769024,0.0043467376,0.9614405,0.00005451131,0.003726463,0.00010374261,0.0012255945,0.000580739,0.000114295624,0.00097461423,0.0018619834,0.02019392],"study_design_scores_gemma":[0.0073217605,0.005048604,0.98090446,0.00048771707,0.0018585008,2.7575663e-7,0.0003311584,0.00024746463,0.00056930655,0.00070529745,0.0024127385,0.00011270278],"about_ca_topic_score_codex":0.018363656,"about_ca_topic_score_gemma":0.04077611,"teacher_disagreement_score":0.022412457,"about_ca_system_score_codex":0.0003382355,"about_ca_system_score_gemma":0.0004725499,"threshold_uncertainty_score":0.9881731},"labels":[],"label_agreement":null},{"id":"W7116961433","doi":"10.1016/j.annonc.2025.10.694","title":"981P Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with HER2 Exon 20 mutant NSCLC: Randomized dose optimization","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi-Sankyo","keywords":"Penetrant (biochemical); Mutant; Exon; Mutation; Randomized controlled trial","score_opus":0.01277304934096056,"score_gpt":0.3394166619055724,"score_spread":0.32664361256461183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116961433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710496,0.000671844,0.0006532977,0.011579381,0.00018564978,0.0022508241,0.000028522232,0.000034530425,0.01354634],"genre_scores_gemma":[0.99555355,0.0002629068,0.0015379477,0.0017834252,0.00003168979,0.00016000516,0.000103836304,0.000017613509,0.000549042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99859124,0.0002110702,0.00047513086,0.00030880445,0.00016406579,0.00024971305],"domain_scores_gemma":[0.99887294,0.00035408608,0.00020407345,0.0001518964,0.00033346814,0.00008353183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003183631,0.00017939623,0.0007694178,0.00028934557,0.00005504422,0.000009598277,0.00004844379,0.00014553174,0.000034671048],"category_scores_gemma":[0.00021209155,0.00013094337,0.0000702862,0.00039732183,0.0001414343,0.000102757826,0.000025218178,0.00013632147,0.0000013669378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5349455,0.016686127,0.22401972,0.00079280254,0.0049590394,0.00030789446,0.013625036,0.006263866,0.0020123534,0.0030638613,0.01321378,0.18011002],"study_design_scores_gemma":[0.77492404,0.013177587,0.18992737,0.0009524092,0.0012388078,0.000020150264,0.00032879354,0.002026346,0.0043050298,0.0007805992,0.0118275285,0.0004913306],"about_ca_topic_score_codex":0.0005616368,"about_ca_topic_score_gemma":0.00031354115,"teacher_disagreement_score":0.23997857,"about_ca_system_score_codex":0.00014046022,"about_ca_system_score_gemma":0.0005732442,"threshold_uncertainty_score":0.53397155},"labels":[],"label_agreement":null},{"id":"W7116964997","doi":"10.1016/j.annonc.2025.10.1154","title":"717P Molecular landscape of locally advanced and metastatic head and neck squamous cell carcinoma from India","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; ASTER","funders":"","keywords":"Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Epidermoid carcinoma; Head and neck cancer; Squamous cell cancer","score_opus":0.029347129253750395,"score_gpt":0.35173574971400484,"score_spread":0.32238862046025446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116964997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589869,0.028357154,0.00004318902,0.0019688269,0.000057422007,0.00018976802,0.000025607615,0.000006836743,0.010364338],"genre_scores_gemma":[0.99563015,0.0011593313,0.0012813895,0.0017937955,0.000011199386,0.000011293157,0.00000800628,0.0000068652603,0.00009794711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925154,0.00005052444,0.0002910244,0.0001655821,0.00008116555,0.0001601531],"domain_scores_gemma":[0.99935627,0.00021213121,0.00010218168,0.0001376289,0.00012230485,0.00006945754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010614995,0.00010382214,0.0006583054,0.000101266356,0.000021610118,0.0000012830186,0.000041032657,0.00006694208,0.000019345924],"category_scores_gemma":[0.000082112136,0.000088936424,0.00004313715,0.000119754186,0.00013745042,0.0000224964,0.00006445803,0.00009248157,8.335108e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053903,0.0018397071,0.51018727,0.0028803963,0.0007417333,0.0006893126,0.0062824925,0.000024463798,0.13425669,0.00091396633,0.014856105,0.3219376],"study_design_scores_gemma":[0.015431892,0.014361624,0.8088506,0.00031036005,0.00048500174,0.000021738299,0.0018467751,0.0001365241,0.13474312,0.0014486092,0.02213157,0.00023220509],"about_ca_topic_score_codex":0.00018839199,"about_ca_topic_score_gemma":0.000077435936,"teacher_disagreement_score":0.32170537,"about_ca_system_score_codex":0.00000775344,"about_ca_system_score_gemma":0.00018963187,"threshold_uncertainty_score":0.3626722},"labels":[],"label_agreement":null},{"id":"W7116977830","doi":"10.1016/j.annonc.2025.10.1101","title":"664TiP BEHOLD-2: A phase I/II randomised study evaluating GSK5733584, a B7-H4-targeted antibody-drug conjugate, in combination with anti-cancer agents in patients with advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Abbotsford Veterinary Clinic; McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Phases of clinical research; Phase (matter); Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Cancer","score_opus":0.09961585291141915,"score_gpt":0.517144164483099,"score_spread":0.4175283115716798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116977830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912828,0.00024250508,0.000015356016,0.0017710014,0.0001361416,0.0056454204,0.00003162665,0.000031529176,0.0008435973],"genre_scores_gemma":[0.9978919,0.0001444683,0.0001994051,0.0007666914,0.00001929601,0.00064839056,0.00009895509,0.000040541643,0.00019036274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99620837,0.0007372875,0.0009267326,0.00062364375,0.00083009683,0.0006738686],"domain_scores_gemma":[0.997656,0.00030878032,0.00042729775,0.00040944244,0.0010543357,0.0001441392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020259866,0.0003023236,0.0012842229,0.00088301575,0.000099323115,0.000013513862,0.00024904657,0.00013033624,0.00012033434],"category_scores_gemma":[0.00060467183,0.00024695628,0.00006910976,0.0013830543,0.00022996454,0.00018979558,0.000119691525,0.0005568119,0.0000027116175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060021255,0.01753058,0.88251776,0.00025708933,0.00033290352,0.00015300034,0.002774808,0.0006813178,0.004973748,0.000008756685,0.00056381786,0.030185],"study_design_scores_gemma":[0.31634778,0.03851592,0.6316991,0.0011936482,0.0001258782,0.0000017994946,0.0010825392,0.0012974004,0.009288825,0.000031444935,0.00016312003,0.00025255323],"about_ca_topic_score_codex":0.0006064737,"about_ca_topic_score_gemma":0.00080417056,"teacher_disagreement_score":0.25632653,"about_ca_system_score_codex":0.00031406627,"about_ca_system_score_gemma":0.00135926,"threshold_uncertainty_score":0.9999983},"labels":[],"label_agreement":null},{"id":"W7116981447","doi":"10.1016/j.annonc.2025.10.609","title":"903MO Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in patients (pts) with resectable epidermal growth factor receptor-mutated (EGFRm) stage II–IIIB non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from NeoADAURA","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Lung cancer; Chemotherapy; Neoadjuvant therapy; Stage (stratigraphy); Epidermal growth factor receptor","score_opus":0.021858885541620753,"score_gpt":0.34920376093870376,"score_spread":0.327344875397083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116981447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894716,0.0010642274,0.00004821675,0.003734772,0.00050148304,0.0025908884,0.0005976779,0.00007892469,0.0019122075],"genre_scores_gemma":[0.99007696,0.00069525035,0.0007854731,0.0042084395,0.00004490415,0.00041860028,0.0006693168,0.00007907144,0.0030219923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642164,0.00016802186,0.0012970113,0.0008464341,0.0004386996,0.00082820916],"domain_scores_gemma":[0.9971697,0.0003377925,0.00085689203,0.00060049625,0.0007770432,0.000258079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016555733,0.00054805074,0.0015128588,0.0004202138,0.00019137353,0.000029064362,0.00022261462,0.00017794456,0.0007178056],"category_scores_gemma":[0.00014278603,0.00042570097,0.00021526772,0.0007146569,0.000163679,0.00027816746,0.00011713777,0.00043986505,0.000007738158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004262905,0.0035856331,0.9544038,0.00018904518,0.0017491756,0.00029954562,0.0018898936,0.00011565571,0.0029877122,0.000012115863,0.009297775,0.021206697],"study_design_scores_gemma":[0.040267635,0.0070372103,0.8480694,0.00089888705,0.0007524779,0.0000073918495,0.00038046172,0.00026136683,0.08054921,0.00003536072,0.021074664,0.00066589925],"about_ca_topic_score_codex":0.024459423,"about_ca_topic_score_gemma":0.0012146283,"teacher_disagreement_score":0.10633441,"about_ca_system_score_codex":0.00051792536,"about_ca_system_score_gemma":0.001510011,"threshold_uncertainty_score":0.99981946},"labels":[],"label_agreement":null},{"id":"W7117002553","doi":"10.1016/j.annonc.2025.10.681","title":"LBA13 Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in EGFR Exon 20 mutant NSCLC: Randomized dose optimization and CNS activity","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi-Sankyo","keywords":"Penetrant (biochemical); Mutant; Exon; Mutation; Dose dependence","score_opus":0.022452845484421897,"score_gpt":0.37923110418426537,"score_spread":0.3567782586998435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117002553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95595837,0.0018752438,0.0010249136,0.028443301,0.00018932813,0.0016058092,0.000025920092,0.00003372589,0.010843405],"genre_scores_gemma":[0.99525905,0.0015083319,0.0010243958,0.0013544193,0.00004426128,0.00014727475,0.000027264381,0.0000138774785,0.00062111084],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985955,0.00029410844,0.0004018049,0.00033992724,0.000118224016,0.00025048474],"domain_scores_gemma":[0.99870706,0.0006994781,0.0001798494,0.00014122609,0.00017595942,0.00009645634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052083604,0.00017945218,0.00083562935,0.0003014244,0.0000698489,0.000012804602,0.00004074494,0.00018650747,0.000025752717],"category_scores_gemma":[0.0003526738,0.00014675714,0.00007984904,0.00033319424,0.00019082357,0.00012754985,0.00003982672,0.00016973919,8.200385e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29076728,0.011582132,0.02678058,0.0013723022,0.004696504,0.00064967957,0.021557396,0.0029529957,0.10812764,0.0063791205,0.013270881,0.51186347],"study_design_scores_gemma":[0.7676778,0.0108131,0.10134304,0.0012571707,0.0022035989,0.00020658593,0.0009800775,0.015452285,0.063102655,0.003379274,0.03268072,0.00090373185],"about_ca_topic_score_codex":0.00090922945,"about_ca_topic_score_gemma":0.00051485276,"teacher_disagreement_score":0.51095974,"about_ca_system_score_codex":0.00013745844,"about_ca_system_score_gemma":0.0005808911,"threshold_uncertainty_score":0.59845823},"labels":[],"label_agreement":null}]}